Serotonin B
receptor O
2A O
( O
HTR2A O
) O
gene O
polymorphism O
predicts O
treatment O
response O
to O
venlafaxine O
XR O
in O
generalized O
anxiety O
disorder O
. O

Several O
studies O
in O
major O
depression O
have O
implicated O
a O
role O
of O
the O
serotonin B
receptor O
gene O
( O
HTR2A O
) O
in O
treatment O
response O
to O
antidepressants O
. O

We O
analyzed O
the O
concentrations O
of O
104 O
congeners O
of O
persistent O
organic O
pollutants O
, O
seven O
organotin O
compounds O
, O
five O
heavy O
metals O
, O
and O
methylmercury B
in O
130 O
randomly O
selected O
placentas O
. O

Moreover O
, O
dichlorodiphenyldich B
( O
p B
, I
p I
' I
- I
DDE I
) O
was O
found O
in O
all O
placentas O
. O

The O
data O
indicates O
that O
fetal O
exposure O
to O
dioxins O
and O
furans O
( O
PCDD O
/ O
Fs O
) O
, O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
p B
, I
p I
' I
- I
DDE I
, O
and O
methylmercury B
depends O
on O
the O
mother O
' O
s O
parity O
, O
and O
age O
. O

We O
also O
conclude O
that O
sources O
of O
the O
above O
four O
pollutants O
are O
similar O
but O
differ O
from O
the O
sources O
of O
polybrominated B
diphenyl I
ethers I
. O

The O
fish O
ingredient O
N3 O
- O
docosahexaenoic O
acid O
22 O
: O
6 O
n O
- O
3 O
( O
DHA B
) O
stimulates O
brain O
development O
. O

On O
the O
other O
hand O
methylmercury B
( O
MeHg B
) O
in O
fish O
disturbs O
the O
developing O
central O
nervous O
system O
. O

To O
determine O
the O
effect O
of O
DHA B
exposure O
on O
prenatal O
neurodevelopment O
the O
maternal O
DHA B
intake O
during O
pregnancy O
was O
compared O
with O
its O
epidemiologically O
observed O
effect O
on O
the O
IQ O
score O
of O
children O
. O

For O
MeHg B
the O
maternal O
intake O
was O
converted O
into O
its O
accumulation O
in O
the O
maternal O
body O
. O

Taking O
the O
MeHg B
and O
DHA B
content O
of O
33 O
fish O
species O
the O
net O
effect O
of O
these O
compounds O
on O
the O
IQ O
score O
was O
quantified O
. O

For O
most O
fish O
species O
the O
adverse O
effect O
of O
MeHg B
on O
the O
IQ O
score O
exceeded O
the O
beneficial O
effect O
of O
DHA B
. O

The O
results O
of O
this O
study O
indicate O
that O
food O
interventions O
aiming O
at O
the O
beneficial O
effects O
of O
fish O
consumption O
should O
focus O
on O
fish O
species O
with O
a O
high O
DHA B
content O
, O
while O
avoiding O
fish O
species O
with O
a O
high O
MeHg B
content O
. O

Analysis O
of O
heavy O
metal O
concentrations O
in O
BLCO O
showed O
that O
Zn B
> O
Fe B
> O
Pb B
> O
Cu B
> O
Ni B
. O

The O
trend O
of O
accumulation O
of O
the O
metals O
in O
the O
tissues O
is O
blood O
- O
Fe B
> O
Pb B
> O
Zn B
whereas O
Cu B
and O
Ni B
levels O
were O
not O
affected O
; O
Liver O
- O
Ni B
> O
Zn B
> O
Fe B
> O
Cu B
> O
Pb B
and O
Testes O
- O
Ni B
> O
Cu B
> O
Pb B
> O
Zn B
> O
Fe B
. O

The O
order O
of O
concentration O
of O
the O
metals O
in O
the O
tissues O
is O
as O
follows O
: O
iron B
- O
blood O
> O
liver O
> O
testes O
; O
zinc B
- O
liver O
> O
blood O
> O
testes O
; O
lead O
- O
blood O
> O
liver O
> O
testes O
; O
copper B
- O
testes O
> O
liver O
> O
blood O
; O
nickel B
- O
liver O
> O
testes O
> O
blood O
. O

Activities O
of O
the O
antioxidant O
enzymes O
of O
erythrocytes O
such O
as O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
S B
- O
transferase O
and O
glutathione B
peroxidase O
increased O
significantly O
in O
a O
dose O
- O
dependent O
manner O
with O
significant O
elevation O
in O
hydrogen B
peroxide I
and O
malondialdehyde B
levels O
, O
whereas O
glutathione B
level O
was O
not O
significantly O
decreased O
in O
BLCO O
- O
treated O
animals O
. O

Twelve O
FVCs O
were O
identified O
in O
the O
pink O
- O
yellow O
cultivar O
, O
with O
linalool B
as O
the O
major O
compound O
; O
30 O
FVCs O
were O
identified O
in O
the O
yellow O
cultivar O
, O
with O
linalool B
and O
terpineol O
as O
the O
two O
major O
compounds O
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic O
acids O
, O
viridicatic O
acid O
and O
terrestric O
acid O
, O
found O
in O
ethyl B
acetate I
and O
n B
- I
butanol I
extracts O
. O

A O
total O
of O
18 O
substances O
were O
identified O
, O
consisting O
of O
a O
complex O
mixture O
of O
sesquiterpenes B
( O
83 O
. O
52 O
% O
) O
, O
monoterpenes O
( O
5 O
. O
46 O
% O
) O
and O
triterpenes B
( O
4 O
. O
56 O
% O
) O
. O

The O
main O
components O
in O
the O
oil O
were O
beta O
- O
caryophyllene O
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S O
, O
13 O
- O
cedran O
- O
diol O
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta O
- O
eudesmol O
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene O
oxide O
( O
2 O
. O
51 O
% O
) O
and O
ethyl O
iso O
- O
allocholate O
( O
2 O
. O
03 O
% O
) O
along O
with O
beta O
- O
cubebene O
, O
gamma O
- O
cadinene O
, O
cubenol O
, O
1 O
, O
8 O
- O

cineol O
, O
o O
- O
cymene O
, O
curcumenol O
, O
spathulenol O
, O
friedeline O
and O
beta B
- I
sitosterol I
as O
minor O
constituents O
. O

An O
antioxidant O
property O
was O
tested O
with O
the O
oil O
obtained O
by O
means O
of O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
assay O
; O
the O
oil O
presented O
interesting O
radical O
scavenging O
activity O
. O

Green O
tea O
extract O
alleviates O
arsenic B
- O
induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
in O
rats O
. O

The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
( O
GT O
, O
Camellia O
sinensis O
) O
leaves O
against O
arsenic B
( O
NaAsO2 O
) O
- O
induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O

The O
treatment O
with O
arsenic B
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
( O
alanine B
aminotransferase O
, O
aspartate B
aminotransferase O
, O
alkaline O
phosphatase O
, O
total O
protein O
, O
albumin O
, O
bilirubin B
, O
cholesterol B
, O
urea B
and O
creatinine B
) O
. O

Exposure O
of O
rats O
to O
arsenic B
caused O
also O
a O
significant O
increase O
in O
liver O
, O
kidney O
and O
testicular O
thiobarbituric B
acid I
reactive O
substances O
compared O
to O
control O
. O

To O
conclude O
, O
our O
data O
suggest O
that O
arsenic B
exposure O
enhanced O
an O
oxidative O
stress O
by O
disturbing O
the O
tissue O
antioxidant O
defense O
system O
, O
but O
the O
GT O
co O
- O
administration O
alleviates O
the O
toxicity O
induced O
by O
arsenic B
exposure O
. O

Changes O
in O
carbohydrate B
metabolism O
, O
oxidative O
stress O
and O
loss O
of O
cortisol B
secretion O
in O
adrenocortica O
l O
cells O
of O
Oreochromis O
niloticus O
exposed O
in O
vitro O
to O
endosulfan B
. O

The O
effects O
of O
endosulfan B
, O
an O
organochlorine B
pesticide O
regularly O
used O
in O
Niger O
Delta O
ecological O
zone O
, O
were O
examined O
and O
also O
its O
effects O
on O
various O
biochemical O
parameters O
in O
the O
serum O
of O
Oreochromis O
niloticus O
, O
a O
dominant O
fish O
species O
in O
Nigeria O
. O

From O
the O
result O
of O
the O
LC50 O
determination O
, O
lower O
concentrations O
of O
endosulfan B
were O
prepared O
for O
sublethal O
test O
. O

Five O
fish O
per O
test O
concentration O
in O
three O
replicates O
were O
exposed O
to O
varying O
concentrations O
of O
endosulfan B
. O

Glucose B
level O
and O
the O
enzyme O
activities O
were O
measured O
spectrophotometrical O
at O
the O
end O
of O
28 O
days O
of O
exposure O
. O

Glucose B
levels O
and O
glutathione B
- O
S B
- O
transferase O
activities O
were O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
than O
the O
control O
and O
the O
concentrations O
increased O
with O
increasing O
concentration O
of O
the O
toxicant O
and O
exposure O
duration O
. O

Cortisol B
secretion O
was O
significantly O
( O
p O
= O
0 O
. O
05 O
) O
lower O
in O
the O
treated O
fish O
than O
the O
control O
. O

These O
findings O
indicated O
that O
endosulfan B
altered O
all O
the O
investigated O
parameters O
, O
which O
is O
an O
indication O
of O
their O
suitability O
as O
markers O
for O
fish O
and O
other O
aquatic O
organism O
toxicity O
study O
. O

CNS O
distribution O
of O
metabotropic O
glutamate B
2 O
and O
3 O
receptors O
: O
transgenic O
mice O
and O
[ O
( O
3 O
) O
H O
] O
LY459477 O
autoradiography O
. O

Group O
II O
metabotropic O
glutamate B
( O
mGlu O
) O
receptor O
agonists O
were O
efficacious O
in O
randomized O
clinical O
research O
trials O
for O
schizophrenia O
and O
generalized O
anxiety O
disorder O
. O

The O
functional O
selectivity O
of O
LY459477 O
was O
demonstrated O
by O
over O
640 O
- O
fold O
selectivity O
and O
the O
displacement O
binding O
selectivity O
was O
greater O
than O
320 O
- O
fold O
for O
all O
glutamate B
receptors O
except O
mGlu O
( O
6 O
) O
( O
~ O
230 O
- O
fold O
) O
. O

More O
than O
1000 O
- O
fold O
selectivity O
was O
demonstrated O
for O
all O
non O
- O
glutamate B
receptors O
known O
to O
be O
targeted O
by O
antipsychotic O
drugs O
. O

Like O
atypical O
antipsychotic O
drugs O
, O
LY459477 O
reversed O
in O
vitro O
electrophysiological O
effects O
of O
a O
serotonergic O
hallucinogen O
and O
behavioral O
effects O
of O
phencyclidine B
or O
amphetamine B
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Formulation O
, O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
transdermal O
patches O
containing O
risperidone B
. O

The O
efficacy O
of O
oral O
risperidone B
treatment O
in O
prevention O
of O
schizophrenia O
is O
well O
known O
. O

In O
this O
study O
, O
risperidone B
was O
formulated O
into O
matrix O
transdermal O
patches O
to O
overcome O
these O
problems O
. O

The O
transdermal O
patches O
containing O
risperidone B
were O
prepared O
by O
solvent O
casting O
method O
and O
characterized O
for O
physicochemical O
and O
in O
vitro O
permeation O
studies O
through O
excised O
rat O
skin O
. O

Among O
the O
tested O
preparations O
, O
formulations O
with O
20 O
% O
risperidone B
, O
3 O
: O
2 O
ERL O
100 O
and O
ERS O
100 O
as O
polymers O
, O
mixture O
of O
olive O
oil O
and O
jojoba O
oil O
as O
enhancer O
, O
exhibited O
greatest O
cumulative O
amount O
of O
drug O
permeated O
( O
1 O
. O
87 O
+ O
/ O
- O
0 O
. O
09 O
mg O
/ O
cm O
( O
2 O
) O
) O
in O
72 O
h O
, O
so O
batch O
ROJ O
was O
concluded O
as O
optimized O
formulation O
and O
assessed O
for O
pharmacokinetic O
, O
pharmacodynamic O
and O
skin O
irritation O
potential O
. O

The O
pharmacokinetic O
characteristics O
of O
the O
optimized O
risperidone B
patch O
were O
determined O
using O
rabbits O
, O
while O
orally O
administered O
risperidone B
in O
solution O
was O
used O
for O
comparison O
. O

The O
calculated O
relative O
bioavailability O
of O
risperidone B
transdermal O
patch O
was O
115 O
. O
20 O
% O
with O
prolonged O
release O
of O
drug O
. O

This O
suggests O
the O
transdermal O
application O
of O
risperidone B
holds O
promise O
for O
improved O
bioavailability O
and O
better O
management O
of O
schizophrenia O
in O
long O
- O
term O
basis O
. O

Trans O
- O
3 O
( O
10 O
) O
- O
caren O
- O
4 O
- O
ol O
( O
22 O
. O
3 O
% O
) O
, O
artemisia B
ketone I
( O
18 O
. O
6 O
% O
) O
, O
1 O
, O
8 O
- O
cineole O
( O
14 O
. O
9 O
% O
) O
, O
delta O
- O
selinene O
( O
13 O
. O
0 O
% O
) O
and O
alpha B
- I
pinene I
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

In O
both O
sediment O
types O
, O
oxygen B
radical O
absorbance O
capacity O
( O
ORAC O
) O
and O
antioxidant O
enzyme O
activities O
[ O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
] O
increased O
during O
hypoxia O
, O
suggesting O
that O
M O
. O
affinis O
has O
a O
strategy O
of O
preparation O
for O
oxidative O
stress O
that O
facilitates O
recovery O
after O
a O
hypoxic O
episode O
. O

This O
coincided O
with O
significantly O
elevated O
oxidative O
damage O
evidenced O
by O
a O
marked O
reduction O
in O
glutathione B
redox O
status O
( O
ratio O
of O
reduced B
GSH I
/ O
oxidized O
GSSG O
) O
and O
an O
increase O
in O
lipid O
peroxidation O
( O
TBARS O
levels O
) O
. O

By O
contrast O
, O
co O
- O
exposure O
to O
contaminants O
caused O
greater O
increase O
in O
antioxidants O
, O
lipid O
peroxidation O
, O
and O
slowed O
recovery O
from O
hypoxia O
as O
indicated O
by O
CAT O
, O
GSH B
/ O
GSSG B
, O
TBARS O
and O
AChE O
responses O
. O

Simultaneous O
determination O
of O
glucoraphanin O
and O
sulforaphane B
in O
Brassica O
oleracea O
seeds O
by O
high O
- O
performance O
liquid O
chromatography O
with O
evaporative O
light O
- O
scattering O
detector O
. O

In O
this O
article O
, O
a O
novel O
and O
efficient O
analysis O
method O
is O
described O
to O
simultaneously O
and O
quantitatively O
determine O
glucoraphanin O
and O
its O
major O
degradation O
product O
sulforaphane B
by O
reversed O
- O
phase O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
coupled O
with O
an O
evaporative O
light O
- O
scattering O
detector O
( O
ELSD O
) O
. O

The O
HPLC O
- O
ELSD O
method O
was O
successfully O
used O
to O
assess O
the O
contents O
of O
glucoraphanin O
and O
sulforaphane B
in O
varieties O
of O
Brassica O
oleracea O
seeds O
. O

Ser B
/ O
Thr B
protein O
phosphatase O
1 O
( O
PP1 O
) O
is O
a O
single O
- O
domain O
hub O
protein O
with O
nearly O
200 O
validated O
interactors O
in O
vertebrates O
. O

When O
cultures O
of O
Serratia O
marcescens O
, O
an O
enterobacteria O
isolated O
from O
the O
microflora O
associated O
with O
banana O
plantations O
incubated O
at O
27 O
degrees O
C O
in O
a O
yeast O
- O
calcium B
carbonate I
- O
dextrose O
solid O
medium O
( O
10 O
g O
of O
yeast O
extract O
, O
20 O
g O
dextrose O
, O
15 O
g O
bacteriological O
agar O
, O
20 O
g O
calcium B
carbonate I
and O
1000 O
mL O
distilled O
water O
) O
were O
extracted O
with O
chloroform B
and O
purified O
by O
column O
chromatography O
, O
we O
obtained O
a O
new O
colourless O
bacterial O
metabolite O
which O
according O
to O
spectroscopic O
data O
proved O
to O
be O
serratin O
. O

In O
particular O
, O
we O
have O
isolated O
and O
identified O
harpagide O
, O
7 O
- O
beta O
- O
hydroxy O
- O
harpagide O
, O
ajugol O
, O
5 O
- O
allosyloxy O
- O
aucubin O
, O
verbascoside B
and O
, O
for O
the O
first O
time O
in O
this O
genus O
, O
arbutin B
. O

Metformin O
hydrochloride O
( O
MH O
) O
, O
a O
biguanide B
antidiabetic O
, O
is O
the O
drug O
of O
choice O
in O
obese O
patients O
. O

Oral O
glucose B
tolerance O
test O
( O
OGTT O
) O
was O
analyzed O
by O
one O
- O
way O
analysis O
of O
variance O
followed O
by O
Dunnet O
multiple O
comparison O
test O
, O
a O
significant O
decrease O
( O
p O
< O
0 O
. O
05 O
) O
in O
the O
blood O
glucose B
levels O
was O
observed O
when O
formulations O
were O
compared O
with O
control O
rats O
. O

Pharmacological O
evidence O
of O
functional O
inhibitory O
metabotrophic O
glutamate B
receptors O
on O
mouse O
arousal O
- O
related O
cholinergic O
laterodorsal O
tegmental O
neurons O
. O

Glutamate B
mediates O
the O
vast O
majority O
of O
excitatory O
synaptic O
transmission O
in O
the O
vertebrate O
CNS O
and O
while O
presence O
of O
glutamate B
input O
in O
the O
LDT O
has O
been O
shown O
and O
ionotropic O
responses O
to O
glutamate B
have O
been O
reported O
in O
the O
LDT O
, O
characterization O
of O
metabotropic O
responses O
is O
lacking O
. O

Therefore O
, O
electrophysiological O
responses O
and O
changes O
in O
levels O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
in O
mouse O
cholinergic O
LDT O
neurons O
following O
application O
of O
specific O
mGluR O
agonists O
and O
antagonists O
were O
examined O
. O

Unexpectedly O
, O
both O
the O
mGluR O
( O
5 O
) O
specific O
agonist O
, O
CHPG O
, O
and O
the O
group O
II O
mGluR O
( O
mGlu O
( O
2 O
/ O
3 O
) O
) O
agonist O
, O
LY379268 B
( O
LY O
) O
, O
induced O
a O
TTX B
- O
insensitive O
outward O
current O
/ O
hyperpolarization O
. O

Both O
outward O
currents O
were O
significantly O
reduced O
by O
the O
mGluR O
antagonist O
MCPG O
and O
the O
CHPG O
- O
induced O
current O
was O
blocked O
by O
the O
specific O
mGluR O
( O
5 O
) O
antagonist O
MTEP B
. O

Concurrent O
Ca B
( I
2 I
+ I
) I
imaging O
revealed O
that O
while O
CHPG O
actions O
did O
include O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
CPA B
/ O
thapsigargin B
- O
sensitive O
intracellular O
stores O
, O
actions O
of O
LY O
did O
not O
. O

Both O
CHPG O
- O
and O
LY O
- O
induced O
outward O
currents O
were O
mediated O
by O
a O
TEA B
- O
sensitive O
potassium B
conductance O
. O

The O
large O
- O
conductance O
, O
Ca B
( I
2 I
+ I
) I
- O
dependent O
potassium B
( O
BK O
) O
channel O
blocker O
, O
iberiotoxin O
, O
attenuated O
CHPG O
actions O
. O

Effects O
of O
glutamatergic O
input O
would O
be O
, O
thus O
, O
expected O
not O
only O
to O
be O
excitation O
via O
stimulation O
of O
ionotropic O
glutamate B
receptors O
and O
mGluR O
( O
1 O
) O
, O
but O
also O
inhibition O
via O
actions O
at O
mGluR O
( O
5 O
) O
and O
mGluR O
( O
2 O
/ O
3 O
) O
on O
these O
neurons O
. O

As O
these O
two O
processes O
counteract O
each O
other O
, O
these O
surprising O
findings O
necessitate O
revision O
of O
predictions O
regarding O
the O
net O
level O
of O
excitation O
generated O
by O
glutamate B
input O
to O
cholinergic O
LDT O
cells O
and O
, O
by O
extension O
, O
the O
functional O
outcome O
of O
glutamate B
transmission O
on O
processes O
which O
these O
neurons O
regulate O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Ten O
known O
compounds O
including O
two O
steroids B
( O
1 O
- O
2 O
) O
, O
six O
bibenzyls O
( O
3 O
, O
5 O
- O
9 O
) O
, O
a O
flavonoid B
( O
10 O
) O
, O
and O
a O
terpenoid B
( O
4 O
) O
were O
isolated O
from O
these O
calluses O
. O

Preparation O
and O
in O
vitro O
/ O
in O
vivo O
evaluation O
of O
a O
ketoprofen B
orally O
disintegrating O
/ O
sustained O
release O
tablet O
. O

Ketoprofen B
, O
one O
of O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
is O
an O
ideal O
model O
drug O
for O
ODSRTs O
. O

Methods O
: O
We O
designed O
a O
simple O
two O
- O
step O
process O
to O
develop O
novel O
ketoprofen B
orally O
disintegrating O
/ O
sustained O
release O
tablets O
( O
KODSRTs O
) O
. O

Firstly O
, O
sustained O
release O
ketoprofen B
fine O
granules O
were O
developed O
by O
spray O
drying O
the O
aqueous O
dispersions O
composed O
of O
Eudragit O
RS O
- O
30D O
, O
Starch O
1500 O
and O
PEG O
6000 O
. O

Subsequently O
, O
the O
obtained O
granules O
were O
directly O
compressed O
into O
KODSRTs O
after O
mixing O
with O
lactose B
, O
mannitol B
and O
a O
superdisintegrant O
, O
crosslinked O
polyvinylpyrrolidone B
( O
PVPP O
) O
. O

Results O
: O
Results O
of O
an O
in O
vitro O
release O
test O
demonstrated O
that O
KODSRTs O
could O
slowly O
release O
ketoprofen B
for O
24 O
h O
after O
disintegrating O
within O
30 O
s O
. O

Extended O
release O
properties O
of O
KODSRTs O
were O
decided O
by O
the O
ketoprofen B
sustained O
release O
fine O
granules O
in O
tablets O
. O

In O
vivo O
pharmacokinetic O
studies O
in O
beagles O
also O
showed O
that O
KODSRTs O
possessed O
a O
significantly O
extended O
release O
profile O
compared O
with O
ketoprofen B
normal O
capsules O
. O

The O
receptor O
tyrosine B
kinase O
Axl O
is O
an O
essential O
regulator O
of O
prostate O
cancer O
proliferation O
and O
tumor O
growth O
and O
represents O
a O
new O
therapeutic O
target O
. O

Deregulation O
of O
the O
receptor O
tyrosine B
kinase O
Axl O
has O
been O
implicated O
in O
the O
progression O
of O
several O
human O
cancers O
. O

Oncogenic O
K O
- O
ras O
expression O
is O
associated O
with O
derangement O
of O
the O
cAMP B
/ O
PKA O
pathway O
and O
forskolin B
- O
reversible O
alterations O
of O
mitochondrial O
dynamics O
and O
respiration O
. O

In O
previous O
papers O
, O
it O
has O
been O
shown O
that O
K O
- O
ras O
transformed O
mouse O
cells O
are O
much O
more O
sensitive O
as O
compared O
with O
normal O
cells O
to O
glucose B
withdrawal O
( O
undergoing O
apoptosis O
) O
and O
present O
a O
high O
glycolytic O
rate O
and O
a O
strong O
reduction O
of O
mitochondrial O
complex O
I O
. O

Recent O
observations O
suggest O
that O
transformed O
cells O
have O
a O
derangement O
in O
the O
cyclic O
adenosine O
monophosphate O
/ O
cAMP B
- O
dependent O
protein O
kinase O
( O
cAMP B
/ O
PKA O
) O
pathway O
, O
which O
is O
known O
to O
regulate O
several O
mitochondrial O
functions O
. O

Herein O
, O
the O
derangement O
of O
the O
cAMP B
/ O
PKA O
pathway O
and O
its O
impact O
on O
transformation O
- O
linked O
changes O
of O
mitochondrial O
functions O
is O
investigated O
. O

Exogenous O
stimulation O
of O
PKA O
activity O
, O
achieved O
by O
forskolin B
treatment O
, O
protected O
K O
- O
ras O
- O
transformed O
cells O
from O
apoptosis O
induced O
by O
glucose B
deprivation O
, O
enhanced O
complex O
I O
activity O
, O
intracellular O
adenosine B
triphosphate I
( O
ATP B
) O
levels O
, O
mitochondrial O
fusion O
and O
decreased O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
levels O
. O

These O
findings O
support O
the O
notion O
that O
glucose B
shortage O
- O
induced O
apoptosis O
, O
specific O
of O
K O
- O
ras O
- O
transformed O
cells O
, O
is O
associated O
to O
a O
derangement O
of O
PKA O
signaling O
that O
leads O
to O
mitochondrial O
complex O
I O
decrease O
, O
reduction O
of O
ATP B
formation O
, O
prevalence O
of O
mitochondrial O
fission O
over O
fusion O
, O
and O
thereby O
opening O
new O
approaches O
for O
development O
of O
anticancer O
drugs O
. O

A O
new O
chromone B
from O
the O
leaves O
of O
Melaleuca O
cajuputi O
Powell O
. O

A O
new O
chromone B
, O
5 O
, O
7 O
- O
dihydroxy O
- O
2 O
- O
( O
hydroxymethyl O
) O
- O
6 O
, O
8 O
- O
dimethyl O
- O
chromen O
- O
4 O
- O
one O
, O
named O
melachromone O
, O
together O
with O
12 O
known O
compounds O
, O
including O
chromones O
, O
anthraquinone B
, O
flavonoids B
, O
flavonoid O
glycosides O
, O
benzene B
derivatives O
, O
ellagic O
acids O
and O
terpenes B
, O
were O
isolated O
from O
the O
leaves O
of O
Melaleuca O
cajuputi O
Powell O
. O

Metabotropic O
glutamate B
receptors O
( O
mGlus O
) O
are O
a O
group O
of O
Family O
C O
Seven O
Transmembrane O
Spanning O
Receptors O
( O
7TMRs O
) O
that O
play O
important O
roles O
in O
modulating O
signaling O
transduction O
, O
particularly O
within O
the O
central O
nervous O
system O
. O

We O
now O
report O
that O
the O
ubiquitous O
autacoid O
and O
neuromodulator O
, O
histamine B
, O
induces O
substantial O
glutamate B
- O
activated O
calcium B
mobilization O
in O
mGlu O
( O
4 O
) O
- O
expressing O
cells O
, O
an O
effect O
which O
is O
observed O
in O
the O
absence O
of O
co O
- O
expressed O
chimeric O
G O
proteins O
. O

This O
strong O
induction O
of O
calcium B
signaling O
downstream O
of O
glutamate B
activation O
of O
mGlu O
( O
4 O
) O
depends O
upon O
the O
presence O
of O
H O
( O
1 O
) O
histamine B
receptors O
. O

Interestingly O
, O
the O
potentiating O
effect O
of O
histamine B
activation O
does O
not O
extend O
to O
other O
mGlu O
( O
4 O
) O
- O
mediated O
signaling O
events O
downstream O
of O
G O
( O
i O
/ O
o O
) O
G O
proteins O
, O
such O
as O
cAMP B
inhibition O
, O
suggesting O
that O
the O
presence O
of O
G O
( O
q O
) O
coupled O
receptors O
such O
as O
H O
( O
1 O
) O
may O
bias O
normal O
mGlu O
( O
4 O
) O
- O
mediated O
G O
( O
i O
/ O
o O
) O
signaling O
events O
. O

When O
the O
activity O
induced O
by O
small O
molecule O
positive O
allosteric O
modulators O
of O
mGlu O
( O
4 O
) O
is O
assessed O
, O
the O
potentiated O
signaling O
of O
mGlu O
( O
4 O
) O
is O
further O
biased O
by O
histamine B
toward O
calcium B
- O
dependent O
pathways O
. O

These O
results O
suggest O
that O
G O
( O
i O
/ O
o O
) O
- O
coupled O
mGlus O
may O
induce O
substantial O
, O
and O
potentially O
unexpected O
, O
calcium B
- O
mediated O
signaling O
events O
if O
stimulation O
occurs O
concomitantly O
with O
activation O
of O
G O
( O
q O
) O
receptors O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Two O
new O
triterpenoid B
saponins I
from O
the O
husks O
of O
Xanthoceras O
sorbifolia O
. O

Two O
new O
oleanane B
triterpenoid B
saponins I
, O
xanthohuskisides O
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
husks O
of O
Xanthoceras O
sorbifolia O
. O

To O
better O
understand O
SFK O
- O
mediated O
nuclear O
translocation O
of O
EGFR O
, O
we O
investigated O
which O
SFK O
member O
( O
s O
) O
controlled O
this O
process O
as O
well O
as O
the O
EGFR O
tyrosine B
residues O
that O
are O
involved O
. O

Sinensetin O
decreased O
the O
expression O
of O
sterol B
regulatory O
element O
- O
binding O
protein O
1c O
( O
SREBP1c O
) O
, O
suggesting O
its O
antiadipogeneic O
property O
via O
downreguation O
of O
SREBP1c O
. O

Also O
, O
sinensetin O
increased O
the O
phosphorylation O
of O
protein O
kinase O
A O
and O
hormone O
- O
sensitive O
lipase O
, O
indicating O
its O
lipolytic O
property O
via O
a O
cAMP B
- O
mediated O
signaling O
pathway O
. O

Moreover O
, O
sinensetin O
inhibited O
insulin O
- O
stimulated O
glucose B
uptake O
by O
decreasing O
the O
phosphorylation O
of O
insulin O
receptor O
substrate O
and O
Akt O
. O

Furthermore O
, O
sinensetin O
increased O
the O
phosphorylation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl B
- I
CoA I
carboxylase O
. O

It O
also O
upregulated O
mRNA O
expression O
of O
carnitine B
palmitoyltransferase O
- O
1a O
, O
suggesting O
that O
sinensetin O
enhances O
fatty O
acid O
beta O
- O
oxidation O
through O
the O
AMPK O
pathway O
. O

Of O
the O
22 O
seaweed O
species O
examined O
, O
ethanol B
extracts O
of O
Gelidium O
amansii O
( O
GAE O
) O
exhibited O
potent O
neuritogenic O
activity O
, O
followed O
by O
Undaria O
pinnatifida O
and O
Sargassum O
fulvellum O
extracts O
. O

Aceton O
: O
chloroform B
( O
1 O
: O
2 O
) O
extracts O
of O
the O
aerial O
parts O
of O
Euphorbia O
kopetdaghi O
Prokh O
. O

( O
Euphorbiaceae O
) O
were O
investigated O
for O
its O
diterpenoids B
and O
afforded O
three O
new O
five O
- O
membered O
ring O
, O
pentacyclic O
myrisinane O
polyester O
comprised O
of O
3 O
, O
5 O
, O
10 O
- O
O O
- O
triacetyl O
- O
8 O
- O
O O
- O
isobutanoyl O
- O
14 O
- O
O O
- O
benzoylcyclomyrsinol O
( O
1 O
) O
, O
3 O
, O
5 O
, O
10 O
, O
14 O
- O
O O
- O
tetraacetyl O
- O
8 O
- O
O O
- O
( O
2 O
' O
- O
methyl O
butanoyl O
) O
- O
cyclomyrsinol O
( O
2 O
) O
and O
3 O
, O

The O
structures O
were O
elucidated O
based O
on O
( O
13 O
) O
C O
- O
and O
( B
1 I
) I
H I
- O
NMR O
as O
well O
as O
2D O
- O
NMR O
, O
IR O
and O
different O
MS O
spectra O
and O
the O
immunomodulation O
activity O
for O
compound O
1 O
was O
evaluated O
through O
lymphocyte O
proliferation O
assay O
, O
IL O
- O
2 O
assay O
, O
oxidative O
burst O
of O
phagocytic O
leukocytes O
and O
through O
their O
cytotoxicity O
on O
two O
cell O
lines O
. O

The O
two O
stressors O
were O
the O
myxozoan O
parasite O
, O
Tetracapsuloides O
bryosalmonae O
, O
which O
is O
the O
etiological O
agent O
of O
proliferative O
kidney O
disease O
( O
PKD O
) O
and O
a O
natural O
stressor O
to O
salmonid O
populations O
, O
and O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
as O
prototype O
of O
estrogen B
- O
active O
chemical O
stressors O
in O
the O
aquatic O
environment O
. O

Using O
a O
microarray O
approach O
contrasting O
parasite O
- O
infected O
and O
non O
- O
infected O
rainbow O
trout O
at O
low O
or O
high O
estrogen B
levels O
, O
it O
was O
observed O
that O
molecular O
response O
patterns O
under O
joint O
exposure O
differed O
from O
those O
to O
the O
single O
stressors O
. O

Monoterpene B
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene O
hydrocarbons O
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha B
- I
pinene I
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene O
D O
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta O
- O
3 O
- O
carene O
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma O
- O
cadinene O
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

These O
oils O
were O
differentiated O
by O
the O
content O
of O
the O
major O
constituents O
( O
alpha B
- I
pinene I
, O
germacrene O
D O
, O
delta O
- O
3 O
- O
carene O
and O
gamma O
- O
cadinene O
) O
, O
geographical O
location O
and O
climatic O
characteristics O
. O

Protein O
phosphatase O
type O
2A O
( O
PP2A O
) O
enzymes O
constitute O
a O
large O
family O
of O
Ser B
/ O
Thr B
phosphatases O
with O
multiple O
functions O
in O
cellular O
signaling O
and O
physiology O
. O

In O
this O
review O
, O
we O
highlight O
how O
PP2A O
holoenzyme O
biogenesis O
and O
enzymatic O
activity O
are O
controlled O
by O
a O
sophisticatedly O
coordinated O
network O
of O
five O
PP2A O
modulators O
, O
consisting O
of O
alpha O
4 O
, O
phosphatase O
2A O
phosphatase O
activator O
( O
PTPA O
) O
, O
leucine O
carboxyl O
methyl O
transferase O
1 O
( O
LCMT1 O
) O
, O
PP2A O
methyl B
esterase O
1 O
( O
PME O
- O
1 O
) O
and O
, O
potentially O
, O
target O
of O
rapamycin B
signaling O
pathway O
regulator O
- O
like O
1 O
( O
TIPRL1 O
) O
, O
which O
serve O
to O
prevent O

Ascorbic B
acid I
( O
100 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
was O
used O
as O
a O
standard O
drug O
. O

The O
MKA O
improved O
the O
level O
of O
protective O
antioxidants O
such O
as O
glutathione B
peroxidase O
( O
GPx O
) O
, O
reduced B
glutathione I
( O
GSH B
) O
, O
glutathione B
reductase O
( O
GRD O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
in O
brain O
homogenate O
at O
higher O
doses O
( O
20 O
and O
40 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
. O

Moreover O
, O
a O
dose O
dependent O
decline O
was O
noted O
in O
lipid O
peroxidation O
( O
LPO O
) O
and O
the O
nitric B
oxide I
assay O
( O
NO O
) O
at O
all O
doses O
of O
MKA O
( O
10 O
, O
20 O
and O
40 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
. O

Interestingly O
, O
significant O
progress O
was O
noted O
with O
the O
supplementation O
of O
MKA O
by O
an O
improvement O
of O
the O
acetylcholine B
( O
ACh B
) O
levels O
and O
a O
reduction O
in O
the O
acetylcholinesterase O
( O
AChE O
) O
activity O
in O
aged O
mouse O
brain O
. O

In O
addition O
, O
a O
significant O
elevation O
of O
serum O
albumin O
( O
ALBU O
) O
, O
alkaline O
phosphatase O
( O
ALP O
) O
, O
alanine B
transaminase O
( O
ALT O
) O
, O
aspartate B
transaminase O
( O
AST O
) O
and O
total O
protein O
as O
well O
as O
a O
decline O
in O
creatinine B
, O
total O
cholesterol B
, O
urea O
nitrogen O
and O
glucose B
levels O
with O
MKA O
also O
ameliorated O
the O
hepatic O
and O
renal O
functions O
in O
normal O
ageing O
process O
. O

Quercetin B
reduces O
high O
- O
fat O
diet O
- O
induced O
fat O
accumulation O
in O
the O
liver O
by O
regulating O
lipid O
metabolism O
genes O
. O

To O
understand O
the O
molecular O
mechanisms O
underlying O
the O
influence O
of O
quercetin B
on O
the O
physiological O
effects O
of O
hyperlipidemia O
, O
we O
investigated O
its O
role O
in O
the O
prevention O
of O
high O
- O
fat O
diet O
( O
HFD O
) O
- O
induced O
obesity O
and O
found O
that O
it O
regulated O
hepatic O
gene O
expression O
related O
to O
lipid O
metabolism O
. O

Quercetin B
supplementation O
in O
mice O
significantly O
reduced O
the O
HFD O
- O
induced O
gains O
in O
body O
weight O
, O
liver O
weight O
, O
and O
white O
adipose O
tissue O
weight O
compared O
with O
the O
mice O
fed O
only O
with O
HFD O
. O

It O
also O
significantly O
reduced O
HFD O
- O
induced O
increases O
in O
serum O
lipids O
, O
including O
cholesterol B
, O
triglyceride B
, O
and O
thiobarbituric B
acid I
- O
reactive O
substance O
( O
TBARS O
) O
. O

Consistent O
with O
the O
reduced O
liver O
weight O
and O
white O
adipose O
tissue O
weight O
, O
hepatic O
lipid O
accumulation O
and O
the O
size O
of O
lipid O
droplets O
in O
the O
epididymal O
fat O
pads O
were O
also O
reduced O
by O
quercetin B
supplementation O
. O

To O
further O
investigate O
how O
quercetin B
may O
reduce O
obesity O
, O
we O
analyzed O
lipid O
metabolism O
- O
related O
genes O
in O
the O
liver O
. O

Quercetin B
supplementation O
altered O
expression O
profiles O
of O
several O
lipid O
metabolism O
- O
related O
genes O
, O
including O
Fnta O
, O
Pon1 O
, O
Pparg O
, O
Aldh1b1 O
, O
Apoa4 O
, O
Abcg5 O
, O
Gpam O
, O
Acaca O
, O
Cd36 O
, O
Fdft1 O
, O
and O
Fasn O
, O
relative O
to O
those O
in O
HFD O
control O
mice O
. O

Collectively O
, O
our O
results O
indicate O
that O
quercetin B
prevents O
HFD O
- O
induced O
obesity O
in O
C57B1 O
/ O
6 O
mice O
, O
and O
its O
anti O
- O
obesity O
effects O
may O
be O
related O
to O
the O
regulation O
of O
lipogenesis O
at O
the O
level O
of O
transcription O
. O

The O
present O
study O
investigated O
the O
effects O
of O
the O
aqueous O
extract O
from O
Bixa O
orellana O
seeds O
( O
AEBO O
) O
in O
mice O
with O
hyperlipidemia O
induced O
by O
tyloxapol O
, O
fructose B
and O
ethanol B
. O

In O
hyperlipidemia O
induced O
by O
Triton O
WR1339 O
, O
400 O
and O
800 O
mg O
/ O
kg O
AEBO O
reduced O
triglycerides B
( O
TG O
) O
serum O
levels O
at O
24 O
h O
and O
48 O
h O
. O

In O
the O
study O
of O
hypertriglyceridemia O
induced O
by O
fructose B
, O
AEBO O
in O
doses O
of O
400 O
mg O
/ O
kg O
and O
800 O
mg O
/ O
kg O
reduced O
TG O
levels O
by O
48 O
. O
2 O
% O
and O
48 O
. O
7 O
% O
, O
respectively O
. O

Finally O
, O
the O
ethanol B
experimental O
model O
with O
400 O
mg O
/ O
kg O
AEBO O
promoted O
a O
reduction O
of O
33 O
. O
6 O
% O
of O
TG O
levels O
, O
while O
the O
800 O
mg O
/ O
kg O
concentration O
reduced O
hypertriglyceridemia O
in O
62 O
. O
2 O
% O
. O

In O
conclusion O
, O
the O
aqueous O
extract O
of O
the O
seeds O
of O
Bixa O
orellana O
was O
capable O
of O
reversing O
the O
hypertriglyceridemia O
induced O
by O
Triton O
, O
fructose B
and O
ethanol B
, O
demonstrating O
a O
hypolipidemic O
effect O
. O

The O
analysed O
feeds O
, O
containing O
non O
- O
genetically O
modified O
( O
GM O
) O
soybean O
and O
Roundup O
Ready O
soybean O
, O
showed O
a O
different O
polyphenolic B
content O
and O
lipophilic O
composition O
. O

Non O
- O
GM O
soybean O
extract O
possessed O
twice O
the O
polyphenolic B
content O
of O
GM O
soybean O
and O
the O
highest O
number O
of O
sterols B
. O

Methanolic O
extract O
of O
non O
- O
GM O
soybean O
extract O
was O
more O
potent O
than O
GM O
soybean O
extract O
against O
colon O
carcinoma O
cell O
line O
LoVo O
using O
MTT B
assay O
, O
while O
the O
second O
one O
showed O
a O
slightly O
higher O
anti O
- O
inflammatory O
activity O
. O

Because O
both O
glutamate B
and O
dopamine B
are O
required O
to O
induce O
and O
sustain O
MSNs O
plasticity O
, O
the O
particular O
molecular O
mechanisms O
involved O
at O
this O
synaptic O
triad O
are O
difficult O
to O
understand O
. O

We O
focused O
on O
long O
- O
term O
depression O
involving O
group O
I O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
. O

Thus O
the O
dependence O
on O
glutamate B
and O
dopamine B
balance O
of O
the O
corticostriatal O
synapse O
responsiveness O
validates O
the O
accuracy O
of O
this O
manageable O
in O
vitro O
model O
to O
depict O
the O
molecular O
pathways O
involved O
in O
the O
plasticity O
at O
corticostriatal O
synapses O
and O
to O
test O
restorative O
therapeutic O
approaches O
in O
Parkinson O
' O
s O
disease O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

In O
this O
study O
copper B
, O
nickel B
, O
lead O
, O
cadmium B
, O
arsenic B
, O
chromium B
and O
vanadium B
content O
was O
measured O
in O
the O
muscles O
and O
gills O
of O
24 O
fishes O
( O
Sarda O
sarda O
, O
Sardinella O
aurita O
and O
Lepidopus O
caudatus O
) O
caught O
in O
the O
Strait O
of O
Messina O
, O
by O
inductively O
coupled O
plasma O
- O
optical O
emission O
spectroscopy O
with O
microwave O
digestion O
techniques O
. O

In O
general O
, O
it O
was O
found O
that O
arsenic B
was O
higher O
than O
other O
analytes O
in O
all O
fish O
species O
, O
particularly O
its O
content O
was O
much O
higher O
in O
S O
. O
aurita O
than O
in O
the O
other O
two O
exemplary O
species O
. O

Lead O
and O
cadmium B
were O
always O
detected O
with O
values O
below O
the O
legal O
limits O
( O
CE O
no O
. O
1881 O
/ O
2006 O
and O
subsequent O
modification O
CE O
no O
. O
629 O
/ O
2008 O
) O
. O

From O
the O
chloroform B
extract O
of O
aerial O
part O
of O
Salvia O
xanthocheila O
Boiss O
. O
one O
new O
abietane O
diterpenoid O
, O
xantoquinone O
( O
5 O
alpha O
, O
6 O
alpha O
- O
dimethoxy O
- O
7 O
, O
11 O
, O
14 O
- O
trioxoabieta O
- O
8 O
, O
12 O
- O
diene O
) O
and O
one O
known O
oleanene O
triterpenoid O
namely O
1 O
beta O
, O
3 O
beta O
- O
dihydroxy O
- O
12 O
- O
oleanene O
were O
isolated O
. O

The O
structure O
of O
the O
new O
terpenoid B
was O
elucidated O
by O
comprehensive O
spectroscopic O
analysis O
including O
electron O
ionisation O
- O
mass O
spectra O
, O
( B
1 I
) I
H I
NMR O
, O
( B
13 I
) I
C I
NMR O
, O
distortionless O
enchancement O
by O
polarisation O
transfer O
, O
H B
, O
H B
correlation O
spectroscopy O
, O
heteronuclear O
multiple O
- O
quantum O
coherence O
and O
heteronuclear O
multiple O
- O
bond O
correlation O
. O

A O
new O
amide B
and O
a O
new O
monoterpene B
from O
the O
seeds O
of O
Clausena O
lansium O
. O

A O
new O
amide B
( O
2 O
) O
and O
a O
new O
monoterpene B
( O
6 O
) O
were O
isolated O
from O
the O
seeds O
of O
Clausena O
lansium O
together O
with O
four O
known O
ones O
( O
1 O
, O
3 O
- O
5 O
) O
. O

New O
triterpenoids B
from O
Morus O
alba O
L O
. O
stem O
bark O
. O

Two O
lupeol B
- O
type O
pentacyclic O
triterpenoids O
characterised O
as O
lup O
- O
20 O
( O
29 O
) O
- O
en O
- O
3 O
beta O
- O
ol O
- O
27 O
- O
oic O
acid O
( O
moruslupenoic O
acid O
A O
) O
and O
lup O
- O
12 O
, O
20 O
( O
29 O
) O
- O
dien O
- O
3 O
beta O
- O
ol O
- O
26 O
- O
oic O
acid O
( O
moruslupenoic O
acid O
B O
) O
and O
lanst O
- O
5 O
, O
24 O
- O
dien O
- O
3 O
beta O
- O
yl O
acetate O
( O
moruslanosteryl O
acetate O
) O
along O
with O
the O
known O
triterpenoidal O

phytoconstituents O
alpha O
- O
amyrin O
acetate O
, O
beta O
- O
amyrin O
- O
beta O
- O
D O
- O
glucopyranoside O
and O
betulinic B
acid I
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Morus O
alba O
L O
. O

Synergy O
between O
L O
- O
DOPA O
and O
a O
novel O
positive O
allosteric O
modulator O
of O
metabotropic O
glutamate B
receptor O
4 O
: O
implications O
for O
Parkinson O
' O
s O
disease O
treatment O
and O
dyskinesia O
. O

Group O
III O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
are O
localized O
in O
presynaptic O
terminals O
within O
basal O
ganglia O
( O
BG O
) O
circuitry O
that O
become O
hyperactive O
due O
to O
dopamine B
depletion O
in O
Parkinson O
' O
s O
disease O
( O
PD O
) O
. O

In O
na O
i O
ve O
rats O
, O
Lu O
AF21934 O
dose O
- O
dependently O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
alleviated O
haloperidol B
- O
induced O
catalepsy O
. O

In O
hemiparkinsonian O
rats O
( O
unilateral O
6 B
- I
hydroxydopamine I
lesion O
of O
the O
substantia O
nigra O
pars O
compacta O
) O
, O
Lu O
AF21934 O
alone O
did O
not O
affect O
akinesia O
at O
the O
doses O
tested O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
. O

Interestingly O
, O
these O
effects O
occurred O
at O
Lu O
AF21934 O
brain O
free O
concentrations O
that O
showed O
functional O
activity O
in O
in O
vitro O
screens O
( O
calcium B
flux O
and O
electrophysiology O
assays O
) O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

New O
triterpenoids B
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri O
. O

A O
new O
pentacyclic O
triterpenoid O
and O
three O
new O
derivatives O
based O
on O
the O
taraxer O
- O
14 O
- O
ene O
skeleton O
with O
a O
C O
- O
28 O
attached O
a O
carboxylic B
acid I
group O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri O
, O
together O
with O
six O
known O
compounds O
. O

Kinghorn O
, O
A O
. O
D O
. O
( O
1995 O
) O
. O
Isolation O
and O
structural O
elucidation O
of O
pentacyclic O
triterpenoids O
from O
Maprounea O
africana O
. O
Journal O
of O
Natural O
Products O
, O
58 O
, O
1 O
- O
9 O
) O
, O
3 O
- O
oxo O
- O
taraxer O
- O
14 O
- O
ene O
or O
taraxerone O
( O
8 O
) O
beta B
- I
sitosterol I
( O
9 O
) O
and O
stigmasterol B
( O
10 O
) O
( O
Kamboj O
& O
Saluja O
, O
2011 O
) O
, O
together O
with O
fatty O
acids O
. O

A O
new O
flavonol B
from O
Oxytropis O
ochrocephala O
Bunge O
. O

A O
new O
acylated O
flavonoid O
, O
3 O
- O
O O
- O
rhamnocitrin O
- O
6 O
- O
O O
- O
benzoyl O
- O
beta O
- O
D O
- O
glucopyranoside O
( O
1 O
) O
, O
together O
with O
five O
known O
flavonoids B
, O
rhamnocitrin O
( O
2 O
) O
, O
pratensein O
( O
3 O
) O
, O
( O
3R O
) O
- O
7 O
, O
3 O
' O
- O
dihydroxy O
- O
2 O
' O
, O
4 O
' O
- O
dimethoxyisoflavan O
( O
4 O
) O
, O
( O
3R O
) O
- O
7 O
, O
2 O
' O
- O
dihydroxy O
- O
3 O
' O
, O
4 O
' O
- O

Antihyperglycemic O
and O
antihyperlipidemic O
activities O
of O
ethanolic O
extract O
of O
Zygophyllum O
album O
in O
streptozotocin B
- O
induced O
diabetic O
mice O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
possible O
antihyperglycemic O
effects O
of O
ethanolic O
extracts O
of O
the O
whole O
plant O
of O
Z O
. O
album O
on O
blood O
glucose B
, O
plasma O
insulin O
, O
serum O
lipids O
and O
hepatic O
glycogen O
and O
metabolism O
enzymes O
of O
carbohydrate B
in O
streptozotocin B
( O
STZ B
) O
- O
induced O
diabetic O
mice O
. O

Administration O
of O
the O
ethanolic O
extract O
from O
plant O
( O
100 O
and O
300 O
mg O
/ O
kg O
body O
weight O
) O
for O
14 O
days O
resulted O
in O
significant O
reduction O
in O
plasma O
glucose B
, O
cholesterol B
, O
triglycerides B
, O
low O
- O
density O
lipoprotein O
, O
very O
- O
low O
- O
density O
liprotein O
, O
hepatic O
glucokinase O
and O
glycogen O
in O
STZ B
diabetic O
mice O
. O

In O
addition O
to O
that O
, O
significant O
increase O
in O
plasma O
high O
- O
density O
lipoprotein O
, O
hepatic O
phosphofructokinase O
and O
glucose B
- I
6 I
phosphate I
dehydrogenase O
was O
observed O
in O
STZ B
diabetic O
mice O
. O

Griseofulvin O
and O
Naproxen B
were O
milled O
in O
both O
recirculation O
mode O
and O
multi O
- O
pass O
continuous O
mode O
to O
study O
the O
breakage O
dynamics O
and O
to O
determine O
the O
effects O
of O
suspension O
flow O
rate O
. O

The O
latter O
part O
of O
this O
study O
focused O
on O
the O
roles O
of O
stabilizers O
( O
hydroxypropyl B
cellulose O
and O
sodium B
lauryl I
sulfate I
) O
and O
elucidation O
of O
the O
so O
- O
called O
Rehbinder O
effect O
( O
reduction O
in O
particle O
strength O
due O
to O
adsorbed O
stabilizers O
such O
as O
polymers O
and O
surfactants O
) O
. O

Using O
laser O
diffraction O
, O
BET O
nitrogen B
adsorption O
, O
scanning O
electron O
microscopy O
imaging O
, O
and O
a O
microhydrodynamic O
analysis O
of O
milling O
, O
this O
study O
, O
for O
the O
first O
time O
, O
provides O
sufficient O
evidence O
for O
the O
existence O
of O
the O
Rehbinder O
effect O
during O
the O
milling O
of O
drugs O
. O

We O
have O
previously O
shown O
that O
epidermal O
growth O
factor O
( O
EGF O
) O
downregulates O
E O
- O
cadherin O
and O
induces O
ovarian O
cancer O
cell O
invasion O
through O
the O
H B
( I
2 I
) I
O I
( I
2 I
) I
/ O
p38 O
MAPK O
- O
mediated O
upregulation O
of O
the O
E O
- O
cadherin O
transcriptional O
repressor O
Snail O
. O

EGF O
- O
induced O
Egr O
- O
1 O
expression O
required O
the O
activation O
of O
the O
ERK1 O
/ O
2 O
and O
PI3K O
/ O
Akt O
signaling O
pathways O
and O
was O
unrelated O
to O
EGF O
- O
induced O
H B
( I
2 I
) I
O I
( I
2 I
) I
production O
and O
activation O
of O
the O
p38 O
MAPK O
pathway O
. O

Our O
results O
also O
demonstrate O
that O
EGF O
activates O
two O
independent O
signaling O
pathways O
, O
which O
are O
the O
H B
( I
2 I
) I
O I
( I
2 I
) I
/ O
p38 O
MAPK O
- O
mediated O
upregulation O
of O
Snail O
expression O
and O
the O
Egr O
- O
1 O
- O
mediated O
upregulation O
of O
Slug O
expression O
. O

Phagocytotic O
assay O
by O
fluorescein B
isothiocyanate I
- O
dextran O
internalization O
showed O
that O
PSG O
- O
1 O
stimulated O
the O
phagocytosis O
of O
macrophages O
. O

G O
. O
atrum O
polysaccharide O
increased O
the O
production O
of O
NO B
, O
and O
the O
level O
of O
mRNA O
expression O
of O
inducible O
nitric B
oxide I
synthase O
in O
a O
dose O
- O
response O
manner O
. O

Generation O
of O
reactive O
oxygen B
species O
was O
promoted O
by O
PSG O
- O
1 O
, O
as O
determined O
by O
flow O
cytometry O
. O

Prevention O
of O
hydrogen B
peroxide I
- O
induced O
red O
blood O
cells O
lysis O
by O
Ilex O
paraguariensis O
aqueous O
extract O
: O
participation O
of O
phenolic B
and O
xanthine B
compounds O
. O

The O
presence O
of O
polyphenols B
and O
xanthines B
, O
which O
present O
antioxidant O
activity O
, O
has O
been O
described O
in O
I O
. O
paraguariensis O
. O

In O
living O
organism O
, O
reactive O
oxygen B
species O
can O
cause O
tissue O
damage O
affecting O
erythrocyte O
membranes O
leading O
to O
hemolysis O
. O

The O
aim O
of O
this O
work O
was O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
I O
. O
paraguariensis O
( O
green O
leaves O
) O
on O
the O
hemolysis O
of O
red O
blood O
cells O
induced O
by O
hydrogen B
peroxide I
and O
to O
correlate O
this O
activity O
with O
the O
enzymatic O
activity O
related O
to O
hydrogen B
peroxide I
metabolism O
. O

The O
antioxidant O
activity O
of O
chlorogenic B
acid I
and O
caffeine B
was O
also O
analysed O
to O
evaluate O
their O
contribution O
to O
the O
activity O
of O
the O
crude O
extract O
. O

Potential O
anti O
- O
diabetic O
mechanisms O
were O
investigated O
with O
blood O
glucose O
, O
serum O
insulin O
, O
serum O
adiponectin O
, O
hemoglobin O
A1c O
( O
HbA1c O
) O
, O
glucose B
tolerance O
, O
insulin O
secretion O
assay O
, O
quantitative O
real O
- O
time O
polymerase O
chain O
reaction O
, O
and O
hematoxylin B
- O
eosin B
staining O
. O

Compared O
with O
the O
control O
group O
, O
the O
FGE O
group O
had O
lower O
levels O
of O
blood O
glucose B
after O
6 O
and O
9 O
h O
fasting O
, O
HbA1c O
, O
and O
the O
area O
under O
the O
curve O
in O
an O
oral O
glucose B
tolerance O
test O
and O
higher O
levels O
of O
adiponectin O
and O
serum O
insulin O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
FGE O
group O
had O
higher O
levels O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
2 O
and O
glucose B
transporter O
protein O
2 O
mRNAs O
, O
a O
lower O
level O
of O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
less O
lymphocytes O
in O
pancreas O
than O
the O
control O
group O
had O
. O

Model O
drug O
rhodamine B
B I
was O
encapsulated O
in O
the O
range O
of O
50 O
micro O
g O
to O
450 O
micro O
g O
per O
microneedle O
array O
. O

The O
fabricated O
microneedles O
containing O
rhodamine B
B I
increased O
the O
permeability O
by O
four O
times O
than O
the O
control O
. O

Effects O
of O
estradiol B
in O
adult O
neurogenesis O
and O
brain O
repair O
in O
zebrafish O
. O

Remarkably O
, O
the O
brain O
estrogen B
- O
synthesizing O
enzyme O
, O
aromatase O
B O
, O
is O
strongly O
expressed O
, O
particularly O
in O
adult O
fishes O
, O
in O
radial O
glial O
cells O
, O
which O
act O
as O
progenitors O
. O

Using O
zebrafish O
, O
we O
tested O
the O
hypothesis O
that O
estrogens B
affect O
adult O
neurogenesis O
and O
brain O
regeneration O
by O
modulating O
the O
neurogenic O
activity O
of O
radial O
glial O
cells O
. O

To O
investigate O
this O
, O
the O
estrogenic O
environment O
was O
modified O
through O
inhibition O
of O
aromatase O
activity O
, O
blockade O
of O
nuclear O
estrogen B
receptors O
, O
or O
estrogenic O
treatments O
. O

We O
also O
developed O
a O
model O
of O
telencephalic O
lesion O
to O
assess O
the O
role O
of O
aromatase O
and O
estrogens B
in O
brain O
repair O
. O

Altogether O
these O
data O
suggest O
that O
estrogens B
modulate O
adult O
, O
but O
not O
reparative O
neurogenesis O
, O
in O
zebrafish O
. O

The O
objective O
of O
this O
study O
was O
to O
improve O
the O
dissolution O
rate O
and O
to O
enhance O
the O
stability O
of O
a O
poorly O
water O
- O
soluble O
and O
low O
glass O
- O
trasition O
temperature O
( O
T O
( O
g O
) O
) O
model O
drug O
, O
fenofibrate B
, O
in O
low O
molecular O
weight O
grades O
of O
hydroxypropylcellulo O
matrices O
produced O
by O
hot O
- O
melt O
extrusion O
( O
HME O
) O
. O

Dissolution O
rate O
of O
fenofibrate B
from O
melt O
extruded O
pellets O
was O
faster O
than O
that O
of O
the O
pure O
drug O
( O
p O
< O
0 O
. O
05 O
) O
. O

Incorporation O
of O
sugars B
within O
the O
formulation O
further O
increased O
the O
fenofibrate B
release O
rates O
. O

Fenofibrate B
is O
prone O
to O
recrystallization O
due O
to O
its O
low O
T O
( O
g O
) O
. O

Various O
polymers O
were O
evaluated O
as O
stabilizing O
agents O
among O
which O
polyvinylpyrrolidone B
17PF O
and O
amino O
methacrylate O
copolymer O
exhibited O
a O
significant O
inhibitory O
effect O
on O
fenofibrate B
recrystallization O
in O
the O
hot O
- O
melt O
extrudates O
. O

Subsequently O
immediate O
- O
release O
fenofibrate B
tablets O
were O
successfully O
developed O
and O
complete O
drug O
release O
was O
achieved O
within O
5 O
min O
. O

The O
hot O
- O
melt O
extruded O
fenofibrate B
tablets O
were O
stable O
, O
and O
exhibited O
an O
unchanged O
drug O
release O
profile O
after O
3 O
- O
month O
storage O
at O
40 O
degrees O
C O
/ O
75 O
% O
RH O
. O

Here O
, O
we O
report O
a O
novel O
regulatory O
mechanism O
for O
the O
YAP O
oncogenic O
function O
via O
direct O
interaction O
with O
non O
- O
receptor O
tyrosine B
phosphatase O
14 O
( O
PTPN14 O
) O
through O
the O
WW O
domain O
of O
YAP O
and O
the O
PPxY O
domain O
of O
PTPN14 O
. O

This O
was O
associated O
with O
alterations O
of O
energy O
metabolism O
, O
in O
particular O
reduced O
ATP B
and O
lactate B
levels O
. O

Group O
II O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
are O
known O
to O
induce O
a O
long O
- O
term O
depression O
( O
LTD O
) O
of O
synaptic O
transmission O
in O
many O
brain O
regions O
including O
the O
amygdala O
. O

To O
address O
whether O
mGlu2 O
activation O
alone O
is O
also O
sufficient O
to O
induce O
LTD O
at O
this O
synapse O
we O
used O
LY541850 B
( O
the O
active O
enantiomer O
of O
LY395756 O
) O
in O
wild O
- O
type O
mice O
. O

LY541850 B
induced O
a O
substantial O
LTD O
showing O
that O
either O
receptor O
alone O
is O
capable O
of O
inducing O
LTD O
in O
this O
pathway O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

This O
study O
investigated O
the O
glucose B
uptake O
activity O
of O
the O
water O
extracts O
from O
the O
leaves O
and O
fruit O
of O
edible O
Myrtaceae O
plants O
, O
including O
guava O
( O
Psidium O
guajava O
Linn O
. O
) O
, O
wax O
apples O
[ O
Syzygium O
samarangense O
( O
Blume O
) O
Merr O
. O
and O
L O
. O
M O
. O
Perry O
] O
, O
Pu O
- O
Tau O
[ O
Syzygium O
jambo O
( O
L O
. O
) O
Alston O
] O
, O
and O
Kan O
- O
Shi O
Pu O
- O
Tau O
( O
Syzygium O
cumini O
Linn O
. O
) O
in O
FL83B O
mouse O
hepatocytes O
. O

Glucose B
uptake O
test O
showed O
that O
pink O
wax O
apple O
fruit O
extract O
( O
PWFE O
) O
exhibits O
the O
highest O
glucose B
uptake O
activity O
, O
at O
an O
increment O
of O
21 O
% O
in O
the O
insulin O
- O
resistant O
FL83B O
mouse O
hepatocytes O
as O
compared O
with O
the O
TNF O
- O
alpha O
- O
treated O
control O
group O
. O

Vescalagin B
was O
isolated O
using O
column O
chromatography O
of O
PWFE O
. O

This O
compound O
, O
at O
the O
concentration O
of O
6 O
. O
25 O
micro O
g O
/ O
mL O
, O
exhibits O
the O
same O
glucose B
uptake O
improvement O
in O
insulin O
- O
resistant O
cells O
as O
PWFE O
at O
a O
100 O
- O
micro O
g O
/ O
mL O
dose O
. O

We O
postulate O
that O
vescalagin B
is O
an O
active O
component O
in O
PWFE O
that O
may O
alleviate O
the O
insulin O
resistance O
in O
mouse O
hepatocytes O
. O

Antioxidant O
activity O
of O
the O
isolated O
compounds O
was O
tested O
using O
DPPH B
free O
radical O
scavenging O
assay O
and O
some O
exhibited O
remarkable O
effects O
with O
IC50 O
of O
13 O
. O
63 O
- O
17 O
. O
46 O
micro O
g O
mL O
( O
- O
1 O
) O
. O

The O
poor O
solubility O
of O
itraconazole B
( O
ITR O
) O
results O
in O
its O
variable O
oral O
absorption O
and O
bioavailability O
and O
has O
also O
proven O
to O
be O
a O
major O
setback O
in O
developing O
an O
efficient O
oral O
delivery O
system O
. O

To O
further O
improve O
dissolution O
characteristics O
, O
the O
physical O
mixtures O
of O
ITR O
and O
ITRDNT O
with O
two O
cyclodextrins O
, O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
and O
HP O
- O
beta O
- O
cyclodextrin O
( O
HP B
- I
beta I
- I
CD I
) O
were O
prepared O
and O
their O
molar O
ratios O
were O
optimized O
. O

It O
was O
observed O
that O
about O
75 O
% O
of O
drug O
was O
released O
in O
30 O
min O
from O
1 O
: O
3 O
molar O
ratio O
of O
ITRDNT O
and O
HP B
- I
beta I
- I
CD I
physical O
mixture O
, O
which O
was O
distinctly O
higher O
than O
ITR O
commercial O
capsules O
( O
70 O
% O
) O
. O

" O
Vitamin B
E I
" O
fortified O
parenteral O
lipid O
emulsions O
: O
Plackett O
- O
Burman O
screening O
of O
primary O
process O
and O
composition O
parameters O
. O

The O
objective O
of O
this O
study O
was O
to O
screen O
the O
effect O
of O
eight O
formulations O
and O
process O
parameters O
on O
the O
physical O
attributes O
and O
stability O
of O
" O
Vitamin B
E I
" O
- O
rich O
parenteral O
lipid O
emulsions O
. O

This O
design O
was O
employed O
to O
construct O
polynomial O
equations O
that O
identified O
the O
magnitude O
and O
direction O
of O
the O
linear O
effect O
of O
homogenization O
pressure O
, O
number O
of O
homogenization O
cycles O
, O
primary O
and O
secondary O
emulsifiers O
, O
pre O
- O
homogenization O
temperature O
, O
oil O
loading O
, O
and O
ratio O
of O
vitamin B
E I
to O
medium O
- O
chain O
triglycerides B
( O
MCT O
) O
in O
the O
oil O
phase O
on O
particle O
size O
, O
polydispersity O
index O
, O
short O
- O
term O
stability O
, O
and O
outlet O
temperature O
of O
manufactured O
emulsions O
. O

The O
viscosity O
of O
vitamin B
E I
was O
reduced O
from O
3700 O
( O
100 O
% O
) O
to O
64 O
mPa O
. O
s O
( O
30 O
% O
) O
by O
MCT O
addition O
. O

Recently O
, O
a O
downregulation O
in O
the O
expression O
of O
GABAergic O
genes O
( O
i O
. O
e O
. O
, O
glutamic B
acid I
decarboxylase O
67 O
and O
reelin O
) O
associated O
with O
DNA O
methyltransferase O
( O
DNMT O
) O
overexpression O
in O
GABAergic O
neurons O
has O
been O
regarded O
as O
a O
characteristic O
phenotypic O
component O
of O
the O
neuropathology O
of O
psychotic O
disorders O
( O
Guidotti O
et O
al O
. O
, O
2011 O
) O
. O

PRS O
mice O
also O
showed O
an O
increased O
binding O
of O
DNMT1 O
and O
MeCP2 O
, O
and O
an O
increase O
in O
5 B
- I
methylcytosine I
and O
5 B
- I
hydroxymethylcytosin I
in O
specific O
CpG B
- O
rich O
regions O
of O
the O
reelin O
and O
GAD67 O
promoters O
. O

Behaviorally O
, O
adult O
PRS O
mice O
showed O
hyperactivity O
and O
deficits O
in O
social O
interaction O
, O
prepulse O
inhibition O
, O
and O
fear O
conditioning O
that O
were O
corrected O
by O
administration O
of O
valproic B
acid I
( O
a O
histone O
deacetylase O
inhibitor O
) O
or O
clozapine B
( O
an O
atypical O
antipsychotic O
with O
DNA O
- O
demethylation O
activity O
) O
. O

Presynaptic O
mGlu7 O
receptors O
control O
GABA B
release O
in O
mouse O
hippocampus O
. O

The O
functional O
role O
of O
presynaptic O
release O
- O
regulating O
metabotropic O
glutamate B
type O
7 O
( O
mGlu7 O
) O
receptors O
in O
hippocampal O
GABAergic O
terminals O
was O
investigated O
. O

Mouse O
hippocampal O
synaptosomes O
were O
preloaded O
with O
[ O
( O
3 O
) O
H O
] O
D O
- O
gamma O
- O
aminobutyric O
acid O
( O
[ B
( I
3 I
) I
H I
] I
GABA I
) O
and O
then O
exposed O
in O
superfusion O
to O
12 O
mM O
KCl B
. O

The O
K B
( I
+ I
) I
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
inhibited O
by O
the O
mGlu7 O
allosteric O
agonist O
N O
, O
N O
' O
- O
dibenzyhydryl O
- O
ethane O
- O
1 O
, O
2 O
- O
diamine O
dihydrochloride O
( O
AMN082 B
, O
0 O
. O
001 O
- O
10 O
mu O
M O
) O
, O
as O
well O
as O
by O
the O
group O
III O
mGlu O
receptor O
agonist O
l O
- O
( O
+ O
) O
- O
2 O
- O
amino O
- O
4 O
- O
phosphonobutyric O
acid O
[ O
( B
l I
) I
- I
AP4 I
, O
0 O
. O
01 O
- O
1 O
mM O
] O
. O

The O
mGlu8 O
receptor O
agonist O
( B
S I
) I
- I
3 I
, I
4 I
- I
dicarboxyphenylglyci I
[ O
( B
S I
) I
- I
3 I
, I
4 I
- I
DCPG I
, O
10 O
- O
100 O
nM O
] O
was O
ineffective O
. O

AMN082 B
and O
( B
l I
) I
- I
AP4 I
- O
induced O
effects O
were O
recovered O
by O
the O
mGlu7 O
negative O
allosteric O
modulator O
( O
NAM O
) O
6 O
- O
( O
4 O
- O
methoxyphenyl O
) O
- O
5 O
- O
methyl O
- O
3 O
- O
( O
4 O
- O
pyridinyl O
) O
- O
isoxazolo O
[ O
4 O
, O
5 O
- O
c O
] O
pyridin O
- O
4 O
( O
5H O
) O
- O
one O
hydrochloride O
( O
MMPIP O
) O
. O

AMN082 B
also O
inhibited O
in O
a O
MMPIP O
- O
sensitive O
manner O
the O
K B
( I
+ I
) I
- O
evoked O
release O
of O
endogenous O
GABA B
. O

AMN082 B
and O
the O
adenylyl O
cyclase O
( O
AC O
) O
inhibitor O
MDL O
- O
12 O
, O
330A O
reduced O
[ B
( I
3 I
) I
H I
] I
GABA I
exocytosis O
in O
a O
8 O
- O
Br O
- O
cAMP O
- O
sensitive O
. O

AMN082 B
- O
inhibitory O
effect O
was O
additive O
to O
that O
caused O
by O
( B
- I
) I
baclofen I
, O
but O
insensitive O
to O
the O
GABA B
( O
B O
) O
antagonist O
3 O
- O
[ O
[ O
( O
3 O
, O
4 O
- O
Dichlorophenyl O
) O
methyl O
] O
amino O
] O
propyl O
] O
diethoxymethyl O
) O
phosphinic O
acid O
( O
CGP52432 O
) O
. O

Conversely O
, O
( B
- I
) I
baclofen I
- O
induced O
inhibition O
of O
GABA B
exocytosis O
was O
insensitive O
to O
MMPIP O
. O

Finally O
, O
the O
forskolin B
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
reduced O
by O
AMN082 B
or O
( B
- I
) I
baclofen I
but O
abolished O
when O
the O
two O
agonists O
were O
added O
concomitantly O
. O

Mouse O
hippocampal O
synaptosomal O
plasmamembranes O
posses O
mGlu7 O
receptor O
proteins O
; O
confocal O
microscopy O
analysis O
unveiled O
that O
mGlu7 O
proteins O
colocalize O
with O
syntaxin O
- O
1A O
( O
Stx O
- O
1A O
) O
, O
with O
vesicular O
GABA B
transporter O
( O
VGAT O
) O
- O
proteins O
and O
with O
GABA B
( O
B O
) O
receptor O
subunit O
proteins O
. O

We O
propose O
that O
presynaptic O
inhibitory O
mGlu7 O
heteroreceptors O
, O
negatively O
coupled O
to O
AC O
- O
dependent O
intraterminal O
pathway O
, O
exist O
in O
mouse O
hippocampal O
GABA B
- O
containing O
terminals O
, O
where O
they O
colocalize O
, O
but O
do O
not O
functionally O
cross O
- O
talk O
, O
with O
GABA B
( O
B O
) O
autoreceptors O
. O

The O
optimal O
conditions O
of O
MAE O
employed O
were O
extraction O
with O
absolute O
ethanol B
as O
solvent O
, O
an O
irradiation O
power O
of O
600 O
W O
, O
at O
75 O
degrees O
C O
, O
four O
irradiation O
cycles O
and O
four O
extraction O
times O
. O

The O
method O
involved O
a O
macroporous O
resin O
( O
Diaion O
( O
R O
) O
HP O
- O
20 O
) O
column O
eluted O
with O
ethanol B
and O
a O
decolourisation O
step O
with O
activated O
charcoal O
. O

The O
interplay O
between O
cardiac O
sarcoplasmic O
Ca B
( I
2 I
+ I
) I
ATPase O
and O
phospholamban O
is O
a O
key O
regulating O
factor O
of O
contraction O
and O
relaxation O
in O
the O
cardiac O
muscle O
. O

In O
heart O
failure O
, O
aberrations O
in O
the O
inhibition O
of O
sarcoplasmic O
Ca B
( I
2 I
+ I
) I
ATPase O
by O
phospholamban O
are O
associated O
with O
anomalies O
in O
cardiac O
functions O
. O

The O
aim O
of O
our O
research O
was O
to O
find O
molecules O
able O
to O
interfere O
with O
the O
inhibitory O
activity O
of O
phospholamban O
on O
sarcoplasmic O
Ca B
( I
2 I
+ I
) I
ATPase O
. O

Its O
functional O
activity O
was O
tested O
in O
Ca B
( I
2 I
+ I
) I
uptake O
assays O
utilizing O
preparations O
from O
cardiac O
sarcoplasmic O
reticulum O
. O

By O
synthesizing O
and O
testing O
a O
series O
of O
alanine B
point O
- O
mutated O
cyclic O
peptides O
, O
we O
identified O
which O
amino B
acid I
was O
important O
for O
the O
inhibition O
of O
the O
phospholamban O
function O
. O

The O
structures O
of O
active O
and O
inactive O
alanine B
- O
mutated O
cyclic O
peptides O
, O
and O
of O
phospholamban O
( O
1 O
- O
36 O
) O
, O
were O
determined O
by O
NMR O
. O

Sm O
. O
: O
alpha B
- I
pinene I
, O
p O
- O
cymene O
, O
1 O
, O
8 O
- O
cineole O
, O
and O
limonene B
. O

The O
results O
indicated O
that O
the O
amount O
of O
alpha B
- I
pinene I
in O
the O
brain O
and O
liver O
was O
twofold O
greater O
after O
mixed O
- O
component O
inhalation O
than O
that O
after O
single O
- O
component O
inhalation O
. O

In O
a O
comparison O
of O
the O
components O
of O
the O
mixed O
inhalation O
, O
the O
ratio O
of O
alpha B
- I
pinene I
increased O
to O
about O
three O
times O
that O
of O
1 O
, O
8 O
- O
cineole O
. O

Antiangiogenic O
effects O
of O
p B
- I
coumaric I
acid I
in O
human O
endothelial O
cells O
. O

p B
- I
Coumaric I
acid I
, O
a O
hydroxy B
derivative O
of O
cinnamic B
acid I
, O
has O
been O
known O
to O
possess O
antioxidant O
and O
anticancer O
activities O
. O

Despite O
its O
potential O
contribution O
to O
chemopreventive O
effects O
, O
the O
mechanism O
by O
which O
p B
- I
coumaric I
acid I
exerts O
its O
antiangiogenic O
actions O
remains O
elusive O
. O

In O
this O
study O
, O
we O
revealed O
that O
p B
- I
coumaric I
acid I
inhibited O
the O
sprouting O
of O
endothelial O
cells O
in O
rat O
aortic O
rings O
and O
inhibited O
the O
tube O
formation O
and O
migration O
of O
endothelial O
cells O
. O

We O
observed O
that O
p B
- I
coumaric I
acid I
could O
downregulate O
mRNA O
expression O
levels O
of O
the O
key O
angiogenic O
factors O
vascular O
endothelial O
growth O
factor O
and O
basic O
fibroblast O
growth O
factor O
. O

Also O
, O
we O
demonstrated O
that O
p B
- I
coumaric I
acid I
inhibited O
both O
the O
AKT O
and O
ERK O
signaling O
pathways O
, O
which O
are O
known O
to O
be O
crucial O
for O
angiogenesis O
. O

Using O
a O
mouse O
model O
, O
we O
also O
showed O
that O
p B
- I
coumaric I
acid I
effectively O
suppressed O
tumor O
growth O
in O
vivo O
by O
lowering O
hemoglobin O
contents O
. O

Collectively O
, O
these O
findings O
indicate O
that O
p B
- I
coumaric I
acid I
possesses O
potent O
anticancer O
properties O
due O
to O
the O
inhibition O
of O
angiogenesis O
in O
vivo O
. O

Fatty B
acid I
composition O
of O
selected O
macrophytes O
. O

The O
content O
of O
total O
lipids O
and O
the O
fatty B
acid I
( O
FA O
) O
profile O
were O
determined O
for O
eight O
macroalgae O
( O
Cystoseira O
abies O
- O
marina O
, O
Fucus O
spiralis O
, O
Chaetomorpha O
pachynema O
, O
Codium O
elisabethae O
, O
Porphyra O
sp O
. O
, O
Osmundea O
pinnatifida O
, O
Pterocladiella O
capillacea O
and O
Sphaeroccoccus O
coronopifolius O
) O
. O

Total O
lipids O
were O
extracted O
using O
a O
solvent O
mixture O
of O
methanol B
/ O
chloroform B
( O
2 O
/ O
1 O
, O
v O
/ O
v O
) O
and O
further O
derivatised O
to O
FA O
methyl O
esters O
( O
FAME O
) O
. O

The O
most O
abundant O
saturated O
FA O
were O
palmitic B
( O
C16 O
: O
0 O
) O
and O
myristic O
( O
C14 O
: O
0 O
) O
, O
while O
oleic B
( O
C18 O
: O
1 O
n O
- O
9 O
) O
was O
the O
dominant O
monounsaturated O
acid O
. O

The O
alpha O
- O
linolenic O
( O
C18 O
: O
3 O
n O
- O
3 O
) O
and O
eicosapentaenoic B
( O
20 O
: O
5 O
n O
- O
3 O
) O
acids O
were O
present O
only O
in O
Porphyra O
sp O
. O

The O
n O
- O
6 O
/ O
n O
- O
3 O
and O
h O
/ O
H B
ratios O
were O
low O
, O
suggesting O
a O
high O
nutritional O
value O
of O
the O
algae O
studied O
. O

Improvement O
in O
solubility O
and O
bioavailability O
of O
puerarin B
by O
mechanochemical O
preparation O
. O

An O
efficient O
and O
solvent O
- O
free O
procedure O
was O
developed O
to O
improve O
the O
solubility O
and O
bioavailability O
of O
the O
poorly O
water O
- O
soluble O
drug O
puerarin B
by O
mechanochemical O
technology O
. O

The O
stable O
inclusion O
complex O
of O
puerarin B
and O
2 O
- O
hydroxypropyl O
- O
beta O
- O
cyclodextrin O
( O
HPCD O
) O
was O
prepared O
by O
a O
ball O
mill O
under O
the O
following O
conditions O
: O
equimolar O
ratio O
of O
puerarin O
to O
HPCD O
; O
rotational O
speed O
of O
250 O
rpm O
; O
milling O
time O
of O
90 O
min O
; O
steel O
balls O
of O
22 O
mm O
diameter O
. O

In O
comparison O
to O
puerarin B
, O
a O
1 O
. O
64 O
- O
fold O
increase O
in O
absolute O
bioavailability O
was O
obtained O
. O

Design O
and O
evaluation O
of O
a O
self O
- O
microemulsifying O
drug O
delivery O
system O
for O
apigenin B
. O

Objective O
of O
this O
study O
was O
to O
prepare O
, O
characterize O
and O
evaluate O
a O
self O
- O
microemulsifying O
drug O
delivery O
system O
( O
SMEDDS O
) O
with O
the O
aim O
to O
improve O
the O
solubility O
and O
dissolution O
of O
apigenin B
. O

Ternary O
phase O
diagrams O
were O
constructed O
in O
order O
to O
obtain O
the O
most O
efficient O
self O
- O
emulsification O
region O
, O
and O
the O
formulation O
of O
apigenin B
loaded O
SMEDDS O
was O
optimized O
by O
a O
simplex O
lattice O
experiment O
design O
. O

The O
equilibrium O
solubility O
of O
apigenin B
in O
SMEDDS O
was O
about O
15 O
mg O
/ O
g O
, O
and O
it O
could O
increase O
the O
solubility O
of O
apigenin B
in O
water O
for O
about O
7500 O
folds O
. O

Apigenin B
loaded O
SMEDDS O
could O
turn O
into O
microemulsion O
when O
diluted O
with O
distilled O
water O
and O
the O
droplets O
were O
spherical O
under O
transmission O
electron O
microscope O
( O
TEM O
) O
, O
the O
average O
particle O
size O
was O
17 O
. O
1 O
nm O
and O
zeta O
potential O
- O
5 O
. O
18 O
mV O
. O

In O
vitro O
dissolution O
studies O
showed O
about O
95 O
% O
of O
apigenin B
was O
released O
within O
10 O
min O
. O

All O
of O
the O
results O
showed O
that O
SMEDDS O
could O
enhance O
the O
solubility O
and O
dissolution O
of O
apigenin B
, O
and O
would O
be O
a O
potential O
carrier O
to O
improve O
the O
oral O
absorption O
of O
apigenin B
, O
a O
poorly O
water O
soluble O
drug O
. O

The O
study O
was O
focused O
on O
the O
potential O
effects O
of O
a O
mixture O
of O
Schisandra O
fruit O
extract O
and O
sesamin O
( O
hereinafter O
called O
' O
SCH O
' O
) O
in O
the O
subjects O
with O
borderline O
high O
levels O
( O
40 O
- O
60 O
U O
/ O
L O
) O
of O
alanine B
aminotransferase O
( O
ALT O
) O
or O
aspartate B
aminotransferase O
( O
AST O
) O
. O

The O
effects O
of O
SCH O
on O
ALT O
, O
AST O
, O
total O
bilirubin B
, O
direct O
bilirubin B
, O
free O
radical O
levels O
, O
total O
antioxidant O
status O
, O
glutathione B
peroxidase O
, O
glutathione B
reductase O
, O
and O
the O
lag O
time O
for O
low O
- O
density O
lipoprotein O
oxidation O
were O
determined O
. O

Intervention O
of O
SCH O
clearly O
reduced O
the O
levels O
of O
ALT O
and O
AST O
, O
but O
it O
made O
no O
change O
in O
the O
total O
bilirubin B
and O
direct O
bilirubin B
. O

Intake O
of O
SCH O
also O
greatly O
increased O
the O
antioxidant O
capacity O
and O
decreased O
the O
values O
of O
thiobarbituric B
acid I
reactive O
substances O
, O
total O
free O
radicals O
, O
and O
superoxide B
anion O
radicals O
in O
the O
plasma O
. O

The O
activities O
of O
glutathione B
peroxidase O
and O
reductase O
in O
the O
erythrocytes O
were O
significantly O
increased O
. O

Most O
solid O
tumors O
are O
characterized O
by O
a O
metabolic O
shift O
from O
glucose B
oxidation O
to O
glycolysis O
, O
in O
part O
due O
to O
actively O
suppressed O
mitochondrial O
function O
, O
a O
state O
that O
favors O
resistance O
to O
apoptosis O
. O

We O
have O
previously O
shown O
that O
the O
inhibitor O
of O
pyruvate B
dehydrogenase O
kinase O
( O
PDK O
) O
dichloroacetate O
( O
DCA O
) O
activates O
glucose B
oxidation O
and O
induces O
apoptosis O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O

Using O
pharmacologic O
and O
molecular O
approaches O
that O
suppress O
the O
prolyl B
- O
hydroxylase O
( O
PHD O
) O
- O
mediated O
inhibition O
of O
HIF1 O
alpha O
, O
we O
show O
that O
DCA O
inhibits O
HIF1 O
alpha O
by O
both O
a O
PHD O
- O
dependent O
mechanism O
( O
that O
involves O
a O
DCA O
- O
induced O
increase O
in O
the O
production O
of O
mitochondria O
- O
derived O
alpha B
- I
ketoglutarate I
) O
and O
a O
PHD O
- O
independent O
mechanism O
, O
involving O
activation O
of O
p53 O
via O
mitochondrial O
- O
derived O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
as O
well O
as O
activation O
of O
GSK3 O
beta O
. O

This O
work O
suggests O
that O
mitochondria O
- O
targeting O
metabolic O
modulators O
that O
increase O
pyruvate B
dehydrogenase O
activity O
, O
in O
addition O
to O
the O
recently O
described O
pro O
- O
apoptotic O
and O
anti O
- O
proliferative O
effects O
, O
suppress O
angiogenesis O
as O
well O
, O
normalizing O
the O
pseudo O
- O
hypoxic O
signals O
that O
lead O
to O
normoxic O
HIF1 O
alpha O
activation O
in O
solid O
tumors O
. O

BMMs O
are O
the O
major O
source O
of O
inflammatory O
factors O
and O
proteases O
, O
including O
cysteine B
protease O
cathepsin O
K O
( O
CTSK O
) O
. O

Self O
- O
nanoemulsifying O
capacity O
of O
Cremophor O
RH O
40 O
, O
Cremophor O
EL O
, O
Tween O
20 O
, O
Tween O
60 O
, O
Tween B
80 I
and O
Labrasol O
were O
tested O
for O
the O
selected O
oil O
. O

Capmul O
MCM O
was O
found O
to O
be O
better O
nanoemulsified O
in O
decreasing O
order O
of O
Cremophor O
RH O
40 O
> O
Cremophor O
EL O
> O
Tween O
20 O
> O
Tween O
60 O
> O
Tween B
80 I
. O

Does O
the O
light O
influence O
astaxanthin B
production O
in O
Xanthophyllomyces O
dendrorhous O
? O

Astaxanthin B
( O
C40H52O4 O
) O
is O
an O
important O
natural O
pigment O
that O
has O
considerable O
promising O
applications O
in O
human O
health O
. O

The O
extraction O
of O
natural O
astaxanthin B
from O
the O
yeast O
Xanthophyllomyces O
dendrorhous O
till O
now O
seems O
to O
be O
rather O
expensive O
if O
compared O
with O
chemically O
synthesized O
astaxanthin B
. O

In O
this O
article O
, O
astaxanthin B
production O
by O
Xanthophyllomyces O
dendrorhous O
under O
two O
different O
conditions O
was O
studied O
: O
a O
first O
effort O
was O
made O
using O
a O
conventional O
reactor O
while O
a O
second O
using O
an O
enlightened O
one O
. O

This O
research O
was O
aimed O
also O
to O
optimise O
astaxanthin B
production O
by O
testing O
the O
influence O
of O
the O
light O
and O
of O
some O
nutrient O
sources O
. O

From O
fermentation O
tests O
, O
an O
astaxanthin B
yield O
ranging O
about O
970 O
micro O
g O
g O
( O
- O
1 O
) O
was O
obtained O
after O
fed O
batch O
cultivation O
in O
the O
conventional O
reactor O
. O

Silibinin O
, O
a O
flavonoid B
compound O
, O
has O
shown O
to O
be O
of O
chemopreventive O
potential O
against O
many O
cancers O
. O

The O
determined O
structures O
were O
characterized O
with O
a O
unit O
of O
galactose B
which O
is O
rarely O
seen O
in O
the O
previously O
isolated O
pyrrole B
and O
pyridinol O
compounds O
. O

This O
review O
focuses O
on O
the O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
and O
their O
potential O
for O
drug O
targets O
for O
the O
treatment O
of O
depression O
. O

Moreover O
, O
their O
potential O
in O
clinic O
will O
be O
discussed O
in O
the O
context O
of O
neuronal O
mechanisms O
of O
ketamine B
, O
an O
agent O
recently O
demonstrated O
a O
robust O
effect O
for O
patients O
with O
treatment O
- O
resistant O
depression O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Glucagon O
- O
like O
peptide O
- O
1 O
receptor O
agonists O
( O
GLP O
- O
1RAs O
) O
increase O
insulin O
release O
and O
suppress O
glucagon O
secretion O
in O
a O
glucose B
- O
dependent O
manner O
, O
thus O
conferring O
glycaemic O
control O
with O
a O
low O
incidence O
of O
hypoglycaemia O
. O

The O
combination O
of O
a O
GLP O
- O
1RA O
and O
insulin O
might O
thus O
be O
highly O
effective O
for O
optimal O
glucose B
control O
, O
ameliorating O
the O
adverse O
effects O
typically O
associated O
with O
insulin O
. O

Group O
III O
and O
subtype O
4 O
metabotropic O
glutamate B
receptor O
agonists O
: O
discovery O
and O
pathophysiological O
applications O
in O
Parkinson O
' O
s O
disease O
. O

Reducing O
the O
excitatory O
action O
of O
glutamate B
, O
the O
major O
excitatory O
neurotransmitter O
in O
the O
basal O
ganglia O
, O
should O
lead O
to O
symptomatic O
improvement O
for O
PD O
patients O
and O
may O
promote O
the O
survival O
of O
DA O
neurons O
. O

Recent O
studies O
have O
focused O
on O
the O
modulatory O
action O
of O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
on O
neurodegenerative O
diseases O
including O
PD O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

The O
present O
study O
was O
aimed O
at O
developing O
colloidal O
formulations O
like O
solid O
lipid O
nanoparticles O
( O
SLN O
) O
and O
nanosuspension O
( O
NS O
) O
for O
improving O
bioavailability O
of O
adefovir O
dipivoxil O
( O
AD O
) O
, O
a O
nucleoside B
reverse O
transcriptase O
inhibitor O
which O
displays O
poor O
oral O
bioavailability O
. O

A O
new O
bromophenol O
, O
2 O
, O
3 O
, O
6 O
- O
tribromo O
- O
4 O
, O
5 O
- O
dihydroxybenzyl O
methyl O
sulphoxide O
, O
was O
isolated O
from O
the O
EtOH B
extract O
of O
the O
marine O
alga O
Symphyocladia O
latiuscula O
. O

Aromadendrine O
, O
a O
new O
component O
of O
the O
flavonoid B
pattern O
of O
Olea O
europaea O
L O
. O
and O
its O
anti O
- O
inflammatory O
activity O
. O

Leaves O
of O
Olea O
europaea O
, O
cultivar O
Nocellara O
del O
Belice O
, O
were O
examined O
with O
respect O
to O
the O
medium O
- O
polar O
fraction O
, O
obtained O
by O
an O
ethyl B
acetate I
extraction O
of O
the O
whole O
extract O
. O

In O
the O
medium O
polar O
fraction O
, O
we O
isolated O
the O
two O
hydroxy O
- O
phenyl O
- O
ethyl O
alcohols O
( O
hydroxyl O
- O
tyrosol O
and O
tyrosol B
) O
that O
are O
the O
main O
component O
of O
olives O
. O

Ibuprofen B
ion O
- O
exchange O
fiber O
complex O
: O
improved O
dissolution O
and O
gastric O
tolerance O
based O
on O
ion O
exchange O
. O

The O
purpose O
of O
the O
present O
study O
is O
to O
develop O
a O
novel O
method O
to O
improve O
the O
dissolution O
of O
water O
- O
insoluble O
drug O
ibuprofen B
and O
the O
gastric O
tolerance O
of O
this O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
which O
has O
potentially O
serious O
gastrointestinal O
side O
effects O
. O

Water O
- O
insoluble O
drug O
ibuprofen B
was O
dispersed O
in O
deionized O
water O
, O
and O
then O
the O
ion O
- O
exchange O
fibers O
in O
OH B
( I
- I
) I
type O
was O
immersed O
in O
it O
. O

Ibuprofen B
and O
the O
active O
groups O
of O
the O
ion O
- O
exchange O
fibers O
combined O
into O
ion O
pairs O
based O
on O
the O
acid O
- O
base O
reaction O
. O

Confirmed O
by O
the O
X O
- O
ray O
diffraction O
and O
the O
scanning O
electron O
microscopy O
, O
the O
ibuprofen B
combined O
onto O
the O
ion O
- O
exchange O
fibers O
was O
in O
a O
highly O
molecular O
level O
dispersed O
state O
. O

The O
improved O
dissolution O
of O
ibuprofen B
ion O
- O
exchange O
fiber O
complexes O
is O
likely O
to O
originate O
from O
this O
ibuprofen B
' O
s O
highly O
dispersed O
state O
. O

Due O
to O
this O
, O
ibuprofen B
' O
s O
highly O
dispersed O
state O
, O
ibuprofen B
ion O
- O
exchange O
fiber O
complexes O
significantly O
decreases O
the O
gastrointestinal O
side O
effects O
of O
ibuprofen B
by O
avoiding O
the O
solid O
ibuprofen B
' O
s O
educing O
. O

The O
present O
study O
showed O
that O
ibuprofen B
ion O
- O
exchange O
fiber O
complexes O
have O
the O
two O
- O
fold O
advantages O
. O

One O
is O
to O
improve O
the O
dissolution O
of O
ibuprofen B
. O

The O
other O
is O
to O
decrease O
the O
ibuprofen B
' O
s O
gastrointestinal O
toxicity O
. O

This O
study O
aimed O
to O
evaluate O
the O
antimicrobial O
effects O
, O
the O
radical O
scavenging O
activity O
( O
by O
DPPH B
and O
ABTS B
tests O
) O
and O
the O
antioxidant O
capacity O
( O
by O
beta B
- I
carotene I
bleaching O
test O
) O
of O
Betula O
aetnensis O
leaves O
extract O
. O

Betula O
aetnensis O
showed O
also O
an O
interesting O
reducing O
power O
with O
TEAC O
values O
of O
9 O
. O
7 O
and O
a O
good O
inhibition O
of O
linoleic B
acid I
oxidation O
with O
an O
IC50 O
value O
of O
22 O
. O
0 O
micro O
g O
mL O
( O
- O
1 O
) O
after O
30 O
min O
of O
incubation O
. O

The O
total O
phenol B
and O
flavonoid B
contents O
were O
determined O
with O
the O
purpose O
to O
evaluate O
the O
relationship O
with O
the O
observed O
bioactivities O
. O

Of O
triterpenoids B
examined O
, O
feroniellides O
D O
and O
E O
revealed O
anticancer O
activity O
against O
KB O
and O
HeLa O
cells O
with O
IC50 O
values O
in O
range O
of O
3 O
. O
4 O
- O
14 O
. O
2 O
micro O
g O
mL O
( O
- O
1 O
) O
, O
which O
are O
significantly O
more O
potent O
than O
feroniellides O
A O
- O
C O
( O
IC50 O
25 O
. O
5 O
- O
60 O
. O
0 O
micro O
g O
mL O
( O
- O
1 O
) O
) O
. O

Cation O
- O
chloride B
cotransporters O
NKCC1 O
and O
KCC2 O
as O
potential O
targets O
for O
novel O
antiepileptic O
and O
antiepileptogenic O
treatments O
. O

In O
cortical O
and O
hippocampal O
neurons O
, O
cation O
- O
chloride B
cotransporters O
( O
CCCs O
) O
control O
the O
reversal O
potential O
( O
EGABA O
) O
of O
GABAA O
receptor O
- O
mediated O
current O
and O
voltage O
responses O
and O
, O
consequently O
, O
they O
modulate O
the O
efficacy O
of O
GABAergic O
inhibition O
. O

The O
antioxidant O
properties O
of O
six O
flavones B
from O
Teucrium O
polium O
L O
. O
, O
one O
of O
them O
isolated O
for O
the O
first O
time O
, O
have O
been O
established O
through O
the O
determination O
of O
their O
abilities O
to O
inhibit O
free O
radicals O
using O
DPPH B
, O
ABTS B
radicals O
and O
ORAC O
test O
. O

The O
structure O
of O
the O
new O
metabolite O
has O
been O
elucidated O
by O
1 O
- O
D O
( O
1H B
, O
13C B
and O
DEPT O
) O
and O
2 O
- O
D O
( O
COSY O
, O
TOCSY O
, O
HSQC O
, O
CIGAR O
) O
NMR O
experiments O
and O
by O
ESI O
Q O
- O
TOF O
HRMS O
analysis O
. O

Flavones B
1 O
- O
3 O
presented O
an O
efficacious O
activity O
towards O
the O
stable O
DPPH B
radical O
. O

Analogously O
, O
compounds O
2 O
and O
3 O
resulted O
significantly O
active O
also O
versus O
ABTS B
cation O
radical O
. O

On O
the O
basis O
of O
the O
comparable O
bioactivity O
of O
luteolin B
- O
based O
compounds O
, O
the O
presence O
of O
an O
ortho O
- O
dihydroxy O
substitution O
in O
the O
flavone B
B O
- O
ring O
is O
supposed O
to O
be O
the O
structural O
feature O
responsible O
for O
the O
antioxidant O
activity O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol O
( O
12 O
. O
66 O
% O
) O
, O
alpha O
- O
caryophyllene O
( O
11 O
. O
84 O
% O
) O
, O
delta O
- O
elemene O
( O
10 O
. O
65 O
% O
) O
, O
beta O
- O
caryophyllene O
( O
7 O
. O
82 O
% O
) O
, O
gamma O
- O
elemene O
( O
4 O
. O
24 O
% O
) O
and O
germacrene O
D O
( O
2 O
. O
82 O
% O
) O
. O

The O
antioxidant O
activity O
of O
the O
oil O
was O
evaluated O
in O
terms O
of O
their O
free O
- O
radical O
scavenging O
activity O
against O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
. O

BHT B
( O
36 O
. O
30 O
% O
) O
was O
also O
determined O
by O
HPLC O
- O
DAD O
in O
the O
hexane B
fraction O
from O
the O
leaves O
. O

The O
results O
showed O
that O
the O
extract O
inhibited O
the O
contraction O
induced O
by O
a O
submaximal O
dose O
of O
acetylcholine B
( O
2 O
. O
04 O
x O
10 O
( O
- O
4 O
) O
mg O
mL O
( O
- O
1 O
) O
) O
, O
oxytocin B
( O
1 O
. O
54 O
x O
10 O
( O
- O
4 O
) O
mg O
mL O
( O
- O
1 O
) O
) O
and O
prostaglandin B
E2 I
( O
PGE2 B
) O
( O
6 O
. O
00 O
x O
10 O
( O
- O
4 O
) O
mg O
mL O
( O
- O
1 O
) O
) O
. O

The O
IC50 O
of O
Prasaplai O
extracts O
expressed O
as O
milligram O
of O
powdered O
preparation O
per O
millilitre O
of O
perfusion O
solution O
for O
acetylcholine B
, O
oxytocin B
and O
PGE2 B
were O
11 O
. O
70 O
, O
10 O
. O
00 O
and O
5 O
. O
75 O
mg O
mL O
( O
- O
1 O
) O
, O
respectively O
. O

The O
13C B
- O
NMR O
data O
of O
compound O
2 O
are O
reported O
for O
the O
first O
time O
. O

The O
new O
siderophore O
tsukubachelin O
B O
( O
1 O
) O
was O
isolated O
from O
the O
iron B
- O
deficient O
culture O
medium O
of O
the O
newly O
isolated O
strain O
Streptomyces O
sp O
. O

The O
structure O
of O
tsukubachelin O
B O
( O
1 O
) O
comprises O
6 O
mol O
of O
amino B
acids I
, O
including O
2 O
mol O
of O
serine B
and O
1 O
mol O
each O
of O
ornithine B
, O
N O
- O
alpha O
- O
methyl O
- O
N O
- O
delta O
- O
hydroxy O
- O
N O
- O
delta O
- O
formylornithine O
, O
N O
- O
alpha O
- O
methyl O
- O
N O
- O
delta O
- O
hydroxyornithine O
, O
and O
cyclic O
N O
- O
hydroxyornithine O
. O

Primary O
objectives O
were O
to O
assess O
the O
long O
- O
term O
safety O
of O
alipogene O
tiparvovec O
and O
achieve O
a O
< O
E2F6 O
> O
40 O
% O
reduction O
in O
fasting O
median O
plasma O
triglyceride B
( O
TG O
) O
at O
3 O
- O
12 O
weeks O
compared O
with O
baseline O
. O

Anti O
- O
diabetic O
Activity O
of O
Swertiamarin B
is O
due O
to O
an O
Active O
Metabolite O
, O
Gentianine O
, O
that O
Upregulates O
PPAR O
- O
gamma O
Gene O
Expression O
in O
3T3 O
- O
L1 O
cells O
. O

We O
have O
previously O
shown O
the O
anti O
- O
diabetic O
effects O
of O
swertiamarin B
; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin B
had O
a O
plasma O
half O
- O
life O
of O
1 O
. O
3 O
h O
. O

Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin B
that O
possesses O
a O
pharmacophoric O
moiety O
. O

The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti O
- O
diabetic O
effect O
of O
swertiamarin B
is O
due O
to O
gentianine O
. O

Swertiamarin B
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR O
- O
gamma O
and O
GLUT O
- O
4 O
; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O

These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti O
- O
diabetic O
effect O
of O
swertiamarin B
is O
due O
to O
gentianine O
, O
an O
active O
metabolite O
of O
swertiamarin B
. O

Selective O
I O
( O
2 O
) O
- O
imidazoline O
receptor O
ligands O
induce O
neuroprotection O
through O
various O
molecular O
mechanisms O
including O
blockade O
of O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptors O
. O

Similar O
chronic O
treatments O
with O
LSL O
60101 O
( O
the O
imidazole B
analogue O
of O
2 O
- O
BFI O
) O
and O
idazoxan O
( O
a O
mixed O
I O
( O
2 O
) O
/ O
alpha O
( O
2 O
) O
- O
ligand O
) O
did O
not O
induce O
significant O
alterations O
of O
pro O
- O
or O
anti O
- O
apoptotic O
proteins O
. O

A O
new O
furolactone O
- O
type O
lignan B
from O
Lycium O
chinense O
. O

Its O
structure O
and O
absolute O
configurations O
were O
established O
on O
the O
basis O
of O
spectral O
data O
, O
particularly O
by O
the O
use O
of O
1D O
NMR O
, O
2D O
shift O
- O
correlated O
NMR O
pulse O
sequences O
( O
( B
1 I
) I
H I
- O
( B
1 I
) I
H I
COSY O
, O
HSQC O
, O
HMBC O
and O
ROESY O
) O
and O
CD O
spectra O
. O

Stimulation O
of O
serotonin B
2A O
receptors O
facilitates O
consolidation O
and O
extinction O
of O
fear O
memory O
in O
C57BL O
/ O
6J O
mice O
. O

Serotonin B
modulates O
the O
acquisition O
and O
retention O
of O
conditioned O
emotional O
memory O
, O
and O
the O
serotonin B
2A O
receptor O
( O
5HT2AR O
) O
may O
be O
one O
of O
the O
postsynaptic O
targets O
mediating O
such O
effects O
. O

Rescue O
of O
both O
impaired O
extinction O
acquisition O
and O
deficient O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
prior O
extinction O
training O
administration O
of O
valproic B
acid I
( O
a O
GABAergic O
enhancer O
and O
HDAC O
inhibitor O
) O
or O
AMN082 B
[ O
metabotropic O
glutamate B
receptor O
7 O
( O
mGlu7 O
) O
agonist O
] O
, O
while O
MS O
- O
275 O
or O
PEPA O
( O
AMPA B
receptor O
potentiator O
) O
failed O
to O
affect O
extinction O
acquisition O
in O
S1 O
mice O
. O

Alleviation O
of O
high O
salt O
toxicity O
- O
induced O
oxidative O
damage O
by O
salicylic B
acid I
pretreatment O
in O
two O
wheat O
cultivars O
. O

Role O
of O
exogenous O
salicylic B
acid I
( O
SA O
) O
in O
the O
antioxidative O
response O
to O
salt O
toxicity O
of O
two O
wheat O
( O
Triticum O
aestivum O
) O
cultivars O
( O
Gerek O
- O
79 O
and O
Bezostaya O
) O
was O
investigated O
. O

Hydroponic O
growth O
environment O
of O
10 O
- O
day O
wheat O
seedlings O
grown O
under O
normal O
conditions O
( O
22 O
/ O
20 O
degrees O
C O
) O
was O
adjusted O
to O
0 O
. O
0 O
, O
0 O
. O
25 O
, O
0 O
. O
50 O
and O
0 O
. O
75 O
M O
of O
salt O
( O
NaCl B
) O
, O
and O
then O
freshly O
prepared O
SA O
solutions O
( O
0 O
. O
0 O
, O
0 O
. O
01 O
and O
0 O
. O
1 O
mM O
) O
were O
once O
sprayed O
on O
leaves O
of O
the O
same O
seedlings O
. O

Activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
, O
peroxidase O
( O
POX O
) O
and O
catalase O
( O
CAT O
) O
were O
determined O
in O
fresh O
leaves O
obtained O
from O
15 O
- O
day O
seedlings O
. O

In O
plants O
under O
saline O
conditions O
, O
except O
0 O
. O
75 O
M O
NaCl B
, O
treatments O
with O
SA O
increased O
the O
activities O
of O
CAT O
, O
POX O
and O
SOD O
in O
both O
the O
varieties O
compared O
with O
plants O
applied O
salt O
alone O
. O

In O
plants O
applied O
with O
0 O
. O
75 O
M O
NaCl B
, O
however O
, O
treatments O
with O
SA O
decreased O
CAT O
activity O
. O

Possibility O
for O
the O
development O
of O
cosmetics O
with O
PLGA B
nanospheres O
. O

The O
optimized O
preparation O
of O
Poly O
- O
( O
lactide O
- O
co O
- O
glycolic O
acid O
) O
( O
PLGA B
) O
nanospheres O
containing O
ubiquinone O
( O
UQ O
) O
for O
cosmetic O
products O
was O
pursued O
. O

By O
investigating O
various O
conditions O
for O
the O
preparation O
of O
UQ O
/ O
PLGA B
nanospheres O
such O
as O
the O
molecular O
weight O
of O
PLGA B
, O
PLGA B
concentration O
, O
and O
UQ O
concentration O
, O
UQ O
/ O
PLGA B
nanospheres O
with O
increased O
stability O
and O
slower O
drug O
release O
at O
a O
higher O
drug O
loading O
efficiency O
were O
prepared O
. O

Therefore O
, O
the O
prepared O
UQ O
/ O
PLGA B
nanospheres O
and O
the O
established O
iontophoresis O
technique O
with O
the O
PLGA B
nanospheres O
in O
the O
present O
study O
can O
be O
applied O
to O
the O
future O
development O
of O
cosmetics O
. O

Melamine B
in O
prenatal O
and O
postnatal O
organs O
in O
rats O
. O

Melamine B
can O
be O
transferred O
to O
fetus O
in O
utero O
through O
placenta O
and O
to O
infant O
ex O
utero O
by O
breast O
feeding O
. O

In O
this O
study O
, O
we O
characterized O
the O
pharmacokinetics O
of O
melamine B
in O
prenatal O
and O
postnatal O
organs O
in O
rats O
. O

Single O
bolus O
of O
melamine B
was O
administered O
to O
pregnant O
rats O
at O
different O
gestational O
stages O
and O
to O
infants O
at O
different O
postnatal O
stages O
. O

Distribution O
of O
melamine B
in O
maternal O
serum O
was O
about O
30 O
% O
higher O
in O
late O
pregnancy O
than O
that O
in O
early O
pregnancy O
; O
and O
it O
was O
2 O
folds O
higher O
in O
postnatal O
serum O
in O
early O
infants O
in O
young O
adulthood O
. O

Distribution O
of O
melamine B
in O
all O
postnatal O
organs O
was O
higher O
than O
that O
in O
prenatal O
organs O
. O

Postnatal O
kidneys O
in O
early O
infants O
had O
the O
highest O
maximum O
concentration O
and O
the O
lowest O
clearance O
of O
melamine B
than O
the O
other O
postnatal O
organs O
. O

It O
may O
relate O
to O
the O
high O
vulnerability O
to O
the O
toxicity O
of O
melamine B
in O
this O
population O
. O

Selective O
GABA B
( O
A O
) O
alpha O
5 O
positive O
allosteric O
modulators O
improve O
cognitive O
function O
in O
aged O
rats O
with O
memory O
impairment O
. O

Compounds O
that O
act O
as O
positive O
allosteric O
modulators O
at O
GABA B
( O
A O
) O
alpha O
5 O
receptors O
might O
be O
useful O
in O
targeting O
this O
condition O
because O
GABA B
( O
A O
) O
alpha O
5 O
receptors O
mediate O
tonic O
inhibition O
of O
principal O
neurons O
in O
the O
affected O
network O
. O

While O
agents O
to O
improve O
cognitive O
function O
in O
the O
past O
focused O
on O
inverse O
agonists O
, O
which O
are O
negative O
allosteric O
modulators O
at O
GABA B
( O
A O
) O
alpha O
5 O
receptors O
, O
research O
supporting O
that O
approach O
used O
only O
young O
animals O
and O
predated O
current O
evidence O
for O
excessive O
hippocampal O
activity O
in O
age O
- O
related O
conditions O
of O
cognitive O
impairment O
. O

Here O
, O
we O
used O
two O
compounds O
, O
Compound O
44 O
[ O
6 O
, O
6 O
- O
dimethyl O
- O
3 O
- O
( O
3 O
- O
hydroxypropyl O
) O
thio O
- O
1 O
- O
( O
thiazol O
- O
2 O
- O
yl O
) O
- O
6 O
, O
7 O
- O
dihydro O
- O
2 O
- O
benzothiophen O
- O
4 O
( O
5H O
) O
- O
one O
] O
and O
Compound O
6 O
[ O
methyl O
3 O
, O
5 O
- O
diphenylpyridazine O
- O
4 O
- O
carboxylate O
] O
, O
with O
functional O
activity O
as O
potentiators O
of O
gamma B
- I
aminobutyric I
acid I
at O
GABA B
( O
A O
) O
alpha O
5 O
receptors O
, O
to O

While O
litter O
size O
significantly O
decreased O
( O
p O
< O
0 O
. O
05 O
) O
at O
100 O
mg O
/ O
kg O
EAA O
, O
maternal O
estrogen B
levels O
decreased O
in O
all O
the O
EAA O
- O
treated O
groups O
. O

Nicotine B
facilitates O
memory O
consolidation O
in O
perceptual O
learning O
. O

In O
particular O
, O
reduced O
levels O
or O
efficacy O
of O
the O
neurotransmitter O
acetylcholine B
were O
found O
to O
facilitate O
declarative O
memory O
consolidation O
. O

One O
group O
received O
chewing O
tobacco O
containing O
nicotine B
for O
1 O
h O
directly O
following O
the O
TDT O
training O
. O

The O
other O
group O
received O
a O
similar O
tasting O
control O
substance O
without O
nicotine B
. O

Electroencephalograp O
recordings O
during O
substance O
consumption O
showed O
reduced O
alpha O
activity O
and O
P300 O
latencies O
in O
the O
nicotine B
group O
compared O
to O
the O
control O
group O
. O

A O
group O
comparison O
showed O
that O
learning O
effects O
were O
more O
pronounced O
in O
the O
nicotine B
group O
than O
in O
the O
control O
group O
. O

These O
findings O
suggest O
that O
oral O
consumption O
of O
nicotine B
enhances O
the O
efficacy O
of O
nicotinic O
acetylcholine B
receptors O
. O

In O
that O
regard O
acetylcholine B
seems O
to O
affect O
consolidation O
processes O
in O
perceptual O
learning O
in O
a O
different O
manner O
than O
in O
declarative O
learning O
. O

Geraniol B
, O
alpha O
- O
cedrene O
and O
p O
- O
cymene O
were O
determined O
as O
the O
main O
components O
. O

Geraniol B
was O
detected O
as O
a O
major O
component O
in O
C O
. O
cilicica O
( O
14 O
. O
64 O
% O
) O
, O
and O
alpha O
- O
cedrene O
was O
detected O
as O
a O
major O
component O
with O
26 O
. O
03 O
% O
for O
C O
. O
lycica O
, O
16 O
. O
93 O
% O
for O
C O
. O
scoparia O
, O
13 O
. O
01 O
% O
for O
C O
. O
davisiana O
and O
10 O
. O
94 O
% O
for O
C O
. O
paphlagonica O
. O

The O
reduction O
in O
the O
growth O
and O
colonospheres O
formation O
in O
FOLFOX O
- O
resistant O
HT O
- O
29 O
was O
also O
associated O
with O
a O
concomitant O
decrease O
in O
phospho B
- O
epidermal O
growth O
factor O
receptor O
. O

Dried O
ground O
parts O
of O
Z O
. O
usambarense O
were O
extracted O
by O
maceration O
using O
methanol B
( O
MeOH B
) O
at O
room O
temperature O
, O
extract O
was O
dried O
and O
reconstituted O
in O
70 O
% O
aq O
. O

MeOH B
and O
partitioned O
against O
n B
- I
hexane I
and O
chloroform B
( O
CHCl3 B
) O
to O
obtain O
MeOH B
, O
n B
- I
hexane I
and O
CHCl3 B
extracts O
. O

All O
extracts O
were O
assessed O
for O
cytotoxicity O
against O
two O
breast O
cancer O
cell O
lines O
, O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
, O
and O
the O
brain O
tumour O
cell O
line O
U251 O
by O
the O
MTT B
assay O
. O

The O
free O
- O
radical O
scavenging O
activity O
of O
the O
extracts O
was O
also O
determined O
by O
the O
2 O
, O
2 O
- O
diphenyl O
- O
1 O
- O
picryhydrazyl O
( O
DPPH B
) O
assay O
. O

In O
the O
DPPH B
assay O
, O
the O
MeOH B
extract O
was O
found O
to O
be O
the O
most O
active O
free O
- O
radical O
scavenger O
with O
a O
RC50 O
value O
of O
41 O
. O
1 O
x O
10 O
( O
- O
3 O
) O
mg O
/ O
mL O
. O

Thioxodipeptides O
Gly O
- O
thio O
- O
Lys O
( O
GtK O
) O
, O
Ala O
- O
thio O
- O
Lys O
( O
AtK O
) O
, O
and O
Ala O
- O
thio O
- O
Arg O
( O
AtR B
) O
in O
which O
the O
amide B
group O
has O
been O
modified O
to O
a O
thioxoamide O
were O
made O
into O
dications O
by O
electrospray O
ionization O
and O
converted O
to O
cation O
- O
radicals O
, O
( O
GtK O
+ O
2H B
) O
( O
+ O
* O
) O
, O
( O
AtK O
+ O
2H B
) O
( O
+ O
* O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
+ O
* O
) O
, O
by O
electron O
transfer O

The O
common O
and O
dominant O
dissociation O
of O
these O
cation O
- O
radicals O
was O
the O
loss O
of O
a O
hydrogen B
atom O
. O

The O
ground O
electronic O
states O
of O
several O
( O
GtK O
+ O
2H B
) O
( O
+ O
* O
) O
, O
( O
AtK O
+ O
2H B
) O
( O
+ O
* O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
+ O
* O
) O
conformers O
were O
explored O
by O
extensive O
ab O
initio O
and O
density O
functional O
theory O
calculations O
of O
the O
potential O
energy O
surface O
. O

In O
silico O
electron O
transfer O
to O
the O
precursor O
dications O
, O
( O
GtK O
+ O
2H B
) O
( O
2 O
+ O
) O
, O
( O
AtK O
+ O
2H B
) O
( O
2 O
+ O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
2 O
+ O
) O
, O
formed O
zwitterionic O
intermediates O
containing O
thioenol O
anion O
- O
radical O
and O
ammonium O
cation O
groups O
that O
were O
local O
energy O
minima O
on O
the O
potential O
energy O
surface O
of O
the O
ground O
electronic O
state O
. O

The O
zwitterions O
underwent O
facile O
isomerization O
by O
N B
- O
terminal O
ammonium O
proton O
migration O
to O
the O
thioenol O
anion O
- O
radical O
group O
forming O
aminothioketyl O
intermediates O
. O

This O
discrepancy O
is O
interpreted O
as O
being O
due O
to O
the O
population O
upon O
electron O
transfer O
of O
low O
- O
lying O
excited O
electronic O
states O
that O
promote O
loss O
of O
hydrogen B
atoms O
. O

For O
( O
GtK O
+ O
2H B
) O
( O
+ O
* O
) O
, O
these O
excited O
states O
were O
characterized O
by O
time O
- O
dependent O
density O
functional O
theory O
as O
A O
- O
C O
states O
that O
had O
large O
components O
of O
Rydberg O
- O
like O
3s O
molecular O
orbitals O
at O
the O
N B
- O
terminal O
and O
lysine B
ammonium O
groups O
that O
are O
conducive O
to O
hydrogen B
atom O
loss O
. O

In O
this O
multicenter O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
randomized O
, O
four O
way O
cross O
- O
over O
proof O
- O
of O
- O
mechanism O
study O
, O
we O
tested O
the O
effect O
of O
the O
positive O
allosteric O
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
modulator O
JNJ O
- O
39393406 O
in O
a O
key O
translational O
assay O
( O
sensory O
P50 O
gating O
) O
in O
39 O
regularly O
smoking O
male O
patients O
with O
schizophrenia O
. O

Effects O
of O
collisional O
and O
vibrational O
velocity O
on O
proton O
and O
deuteron O
transfer O
in O
the O
reaction O
of O
HOD O
+ O
with O
CO B
. O

Reaction O
of O
HOD O
( O
+ O
) O
with O
CO B
was O
studied O
over O
the O
collision O
energy O
( O
E O
( O
col O
) O
) O
range O
between O
0 O
. O
18 O
and O
2 O
. O
87 O
eV O
, O
for O
HOD O
( O
+ O
) O
in O
its O
ground O
state O
and O
with O
one O
quantum O
in O
each O
of O
its O
vibrational O
modes O
: O
( O
001 O
) O
- O
- O
predominantly O
OH B
stretch O
; O
( O
010 O
) O
- O
- O
bend O
, O
and O
( O
100 O
) O
- O
- O
predominately O
OD B
stretch O
. O

The O
dominant O
reactions O
are O
near O
- O
thermoneutral O
proton O
and O
deuteron O
transfer O
, O
generating O
HCO B
( I
+ I
) I
and O
DCO O
( O
+ O
) O
product O
ions O
by O
a O
predominantly O
direct O
mechanism O
. O

The O
HCO B
( I
+ I
) I
and O
DCO O
( O
+ O
) O
channels O
occur O
with O
a O
combined O
efficiency O
of O
76 O
% O
for O
ground O
state O
HOD O
( O
+ O
) O
at O
our O
lowest O
E O
( O
col O
) O
, O
increasing O
to O
94 O
% O
for O
E O
( O
col O
) O
around O
0 O
. O
33 O
eV O
, O
then O
falling O
at O
high O
E O
( O
col O
) O
to O
~ O
40 O
% O
. O

The O
HCO B
( I
+ I
) I
and O
DCO O
( O
+ O
) O
channels O
have O
a O
complicated O
dependence O
on O
the O
HOD O
( O
+ O
) O
vibrational O
state O
. O

Excitation O
of O
the O
OH B
or O
OD B
stretch O
modes O
enhances O
H B
( I
+ I
) I
or O
D B
( I
+ I
) I
transfer O
, O
respectively O
, O
and O
inhibits O
D B
( I
+ I
) I
or O
H B
( I
+ I
) I
transfer O
. O

Bend O
excitation O
preferentially O
enhances O
H B
( I
+ I
) I
transfer O
, O
with O
no O
effect O
on O
D B
( I
+ I
) I
transfer O
. O

The O
results O
suggest O
that O
transfer O
of O
H B
or O
D B
atoms O
is O
enhanced O
if O
the O
atom O
in O
question O
has O
a O
high O
vibrational O
velocity O
, O
and O
that O
this O
effect O
offsets O
what O
is O
otherwise O
a O
general O
inhibition O
of O
reactivity O
by O
added O
energy O
. O

HOCO B
( I
+ I
) I
+ O
D B
and O
DOCO O
( O
+ O
) O
+ O
H B
products O
are O
also O
observed O
, O
but O
as O
minor O
channels O
despite O
being O
barrierless O
and O
exoergic O
. O

Density O
functional O
theory O
study O
on O
the O
reaction O
mechanism O
of O
synthesizing O
1 O
, O
3 O
- O
dimethyl O
- O
2 O
- O
imidazolidinone O
by O
urea B
method O
. O

We O
report O
a O
first O
- O
principles O
density O
functional O
theory O
investigation O
on O
tailoring O
the O
fundamental O
reaction O
mechanism O
of O
synthesizing O
1 O
, O
3 O
- O
dimethyl O
- O
2 O
- O
imidazolidinone O
( O
DMI O
) O
through O
the O
urea B
method O
with O
water O
serving O
as O
both O
solvent O
and O
catalyst O
. O

The O
nucleophilic O
cyclization O
reaction O
is O
implemented O
by O
two O
ammonia B
removal O
steps O
. O

One O
- O
NH B
group O
of O
dimethylethylenediam O
( O
DMEDA O
) O
first O
attacks O
the O
carbon B
atom O
of O
urea B
, O
eliminating O
one O
- O
NH3 B
group O
and O
forming O
an O
intermediate O
state O
CH3NHC2H4N O
( O
CH3 O
) O
CONH2 O
( O
IMI O
) O
. O

Without O
water O
, O
the O
two O
ammonia B
removal O
steps O
are O
both O
slightly O
exothermic O
with O
high O
activation O
barriers O
( O
~ O
50 O
kcal O
mol O
( O
- O
1 O
) O
) O
. O

Due O
to O
the O
spatial O
configuration O
, O
the O
direct O
proton O
migration O
from O
the O
N B
atoms O
of O
ethylenediamine O
to O
urea B
is O
difficult O
to O
occur O
. O

The O
current O
computational O
understanding O
on O
the O
prototypical O
reaction O
to O
DMI O
can O
be O
extended O
to O
guide O
developing O
more O
efficient O
routes O
to O
synthesize O
imidazolidinone B
derivatives O
through O
the O
urea B
method O
. O

Here O
we O
discuss O
the O
role O
of O
the O
cortical O
cholinergic O
system O
in O
mediating O
cue O
detection O
and O
attentional O
control O
and O
propose O
two O
target O
mechanisms O
for O
cognition O
enhancers O
: O
stimulation O
of O
prefrontal O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine B
receptors O
( O
nAChR O
) O
for O
the O
enhancement O
of O
cue O
detection O
and O
augmentation O
of O
tonic O
acetylcholine B
levels O
for O
the O
enhancement O
of O
attentional O
control O
. O

A O
selective O
dopamine B
reuptake O
inhibitor O
improves O
prefrontal O
cortex O
- O
dependent O
cognitive O
function O
: O
potential O
relevance O
to O
attention O
deficit O
hyperactivity O
disorder O
. O

The O
majority O
of O
ADHD O
- O
related O
treatments O
act O
either O
as O
dual O
norepinephrine B
( O
NE O
) O
and O
dopamine B
( O
DA O
) O
reuptake O
inhibitors O
( O
psychostimulants O
) O
or O
selective O
NE O
reuptake O
inhibitors O
( O
SNRIs O
) O
. O

The O
NMDA B
receptor O
as O
a O
target O
for O
cognitive O
enhancement O
. O

NMDA B
receptors O
( O
NMDARs O
) O
play O
an O
important O
role O
in O
neural O
plasticity O
including O
long O
- O
term O
potentiation O
and O
long O
- O
term O
depression O
, O
which O
are O
likely O
to O
explain O
their O
importance O
for O
learning O
and O
memory O
. O

Urinary O
Smad1 O
, O
fasting O
plasma O
glucose B
( O
FPG O
) O
, O
fasting O
serum O
C O
- O
Peptide O
( O
C O
- O
P O
) O
, O
hemoglobin O
A1C O
( O
HbA1c O
) O
, O
cystatin O
C O
, O
and O
other O
chemistry O
laboratory O
parameters O
of O
T2DM O
participants O
and O
controls O
were O
measured O
. O

Metastability O
in O
Pressure O
- O
Induced O
Structural O
Transformations O
of O
CdSe B
/ O
ZnS B
Core O
/ O
Shell O
Nanocrystals O
. O

Here O
, O
we O
show O
with O
molecular O
dynamics O
computer O
simulation O
that O
in O
a O
model O
of O
CdSe B
/ O
ZnS B
core O
/ O
shell O
nanocrystals O
the O
core O
high O
- O
pressure O
structure O
can O
be O
made O
metastable O
under O
ambient O
conditions O
by O
tuning O
the O
thickness O
of O
the O
shell O
. O

In O
nanocrystals O
with O
thick O
shells O
, O
we O
furthermore O
observe O
a O
wurtzite B
to O
NiAs O
transformation O
, O
which O
does O
not O
occur O
in O
the O
pure O
bulk O
materials O
. O

Serotonergic O
involvement O
in O
the O
amelioration O
of O
behavioral O
abnormalities O
in O
dopamine B
transporter O
knockout O
mice O
by O
nicotine B
. O

Dopamine B
transporter O
knockout O
( O
DAT O
KO O
) O
mice O
exhibit O
elevated O
extracellular O
dopamine B
levels O
in O
brain O
regions O
that O
include O
the O
striatum O
and O
the O
nucleus O
accumbens O
, O
but O
not O
the O
prefrontal O
cortex O
. O

We O
report O
nicotine B
- O
induced O
normalization O
of O
effects O
on O
locomotion O
and O
prepulse O
inhibition O
of O
acoustic O
startle O
( O
PPI O
) O
in O
DAT O
KO O
mice O
that O
require O
intact O
serotonin B
5 O
- O
HT1A O
systems O
. O

First O
, O
we O
observed O
that O
the O
marked O
hyperactivity O
displayed O
by O
DAT O
KO O
mice O
was O
reduced O
by O
administration O
of O
nicotine B
. O

This O
nicotine B
effect O
was O
blocked O
by O
pretreatment O
with O
the O
non O
- O
specific O
nicotinic O
acetylcholine B
( O
nACh O
) O
receptor O
antagonist O
mecamylamine B
, O
or O
the O
5 O
- O
HT1A O
antagonist O
WAY100635 O
. O

Secondly O
, O
we O
examined O
the O
effects O
of O
nicotine B
on O
PPI O
in O
DAT O
KO O
mice O
. O

Treatment O
with O
nicotine B
significantly O
ameliorated O
the O
PPI O
deficits O
observed O
in O
DAT O
KO O
mice O
. O

The O
ameliorating O
action O
of O
nicotine B
on O
PPI O
deficits O
in O
DAT O
KO O
mice O
was O
blocked O
by O
mecamylamine B
, O
the O
alpha O
7 O
nACh O
receptor O
antagonist O
methyllycaconitine B
or O
WAY100635 O
, O
while O
the O
alpha O
4 O
beta O
2 O
nACh O
receptor O
antagonist O
dihydro O
- O
beta O
- O
erythroidinehydrobro O
( O
DH B
beta I
E I
) O
produced O
only O
a O
non O
- O
significant O
trend O
toward O
attenuation O
of O
nicotine B
effects O
. O

Finally O
, O
we O
observed O
that O
administration O
of O
the O
5 O
- O
HT1A O
receptor O
agonist O
8 B
- I
OH I
- I
DPAT I
also O
ameliorated O
the O
deficit O
in O
PPI O
observed O
in O
DAT O
KO O
mice O
. O

These O
data O
support O
the O
idea O
that O
nicotine B
might O
ameliorate O
some O
of O
the O
cognitive O
dysfunctions O
found O
in O
schizophrenia O
in O
a O
5 O
- O
HT1A O
- O
dependent O
fashion O
. O

Two O
new O
diterpenes B
from O
Caesalpinia O
minax O
Hance O
. O

Two O
new O
cassane O
- O
type O
diterpenes B
, O
Caesalpinolide O
F O
( O
1 O
) O
and O
Caesalpinolide O
G O
( O
2 O
) O
were O
isolated O
from O
Caesalpinia O
minax O
Hance O
. O

Pregnant O
Sprague O
- O
Dawley O
rats O
received O
50 O
, O
250 O
, O
and O
500 O
mg O
/ O
kg O
/ O
day O
diisononyl O
phthalate O
( O
DiNP B
) O
from O
GD O
12 O
to O
19 O
via O
corn O
oil O
gavage O
to O
study O
the O
dose O
response O
for O
effects O
on O
fetal O
male O
rat O
sexual O
development O
as O
well O
as O
metabolite O
disposition O
in O
the O
dam O
and O
fetus O
. O

Testosterone B
concentration O
in O
the O
fetal O
testes O
was O
reduced O
at O
250 O
and O
750 O
mg O
/ O
kg O
/ O
day O
. O

The O
no O
observed O
effect O
level O
( O
NOEL O
) O
for O
this O
study O
was O
50 O
mg O
/ O
kg O
/ O
day O
based O
on O
increased O
MNGs O
and O
reduced O
testes O
testosterone B
concentration O
in O
the O
fetal O
rat O
. O

Quantitative O
prediction O
of O
CYP2B6 O
induction O
by O
estradiol B
during O
pregnancy O
: O
potential O
explanation O
for O
increased O
methadone O
clearance O
during O
pregnancy O
. O

In O
rodent O
models O
and O
in O
HepG2 O
cells O
, O
CYP2B O
enzymes O
have O
been O
shown O
to O
be O
regulated O
by O
estradiol B
. O

Because O
estradiol B
concentrations O
increase O
by O
~ O
50 O
- O
fold O
during O
human O
pregnancy O
, O
it O
was O
hypothesized O
that O
the O
increasing O
estradiol B
concentrations O
during O
human O
pregnancy O
would O
result O
in O
induction O
of O
CYP2B6 O
activity O
. O

Hepatocytes O
from O
three O
female O
donors O
were O
treated O
with O
estradiol B
, O
and O
the O
EC O
( O
50 O
) O
and O
E O
( O
max O
) O
were O
measured O
for O
CYP2B6 O
mRNA O
and O
bupropion B
hydroxylation O
activity O
. O

At O
100 O
nM O
total O
estradiol B
, O
a O
concentration O
achievable O
during O
the O
third O
trimester O
of O
pregnancy O
, O
CYP2B6 O
activity O
was O
predicted O
to O
increase O
by O
1 O
. O
5 O
- O
3 O
- O
fold O
, O
based O
on O
increased O
CYP2B6 O
activity O
and O
mRNA O
. O

When O
the O
E O
( O
max O
) O
and O
EC O
( O
50 O
) O
values O
were O
compared O
with O
those O
for O
carbamazepine B
and O
rifampin O
, O
estradiol B
was O
found O
to O
be O
as O
potent O
an O
inducer O
of O
CYP2B6 O
as O
rifampin O
and O
carbamazepine B
. O

These O
data O
suggest O
that O
, O
during O
human O
pregnancy O
, O
the O
increasing O
estradiol B
concentrations O
will O
result O
in O
increased O
clearance O
of O
drugs O
that O
have O
CYP2B6 O
- O
mediated O
clearance O
pathways O
. O

Cholesterol B
- O
rich O
membrane O
domains O
, O
or O
lipid O
rafts O
, O
form O
an O
organized O
portion O
of O
the O
membrane O
that O
is O
thought O
to O
concentrate O
signaling O
molecules O
. O

Effects O
of O
clopidogrel B
and O
clarithromycin B
on O
the O
disposition O
of O
sibutramine B
and O
its O
active O
metabolites O
M1 O
and O
M2 O
in O
relation O
to O
CYP2B6 O
* O
6 O
polymorphism O
. O

Plasma O
concentrations O
of O
sibutramine B
and O
its O
two O
active O
metabolites O
after O
single O
oral O
dose O
of O
sibutramine B
were O
determined O
in O
Korean O
healthy O
male O
subjects O
with O
different O
CYP2B6 O
genotypes O
( O
CYP2B6 O
* O
1 O
/ O
* O
1 O
, O
* O
1 O
/ O
* O
6 O
and O
* O
6 O
/ O
* O
6 O
) O
, O
either O
alone O
or O
after O
four O
- O
day O
pretreatment O
with O
clopidogrel B
or O
clarithromycin B
. O

The O
pretreatment O
with O
clopidogrel B
and O
clarithromycin B
raised O
the O
mean O
area O
under O
the O
concentration O
- O
time O
curve O
( O
AUC O
) O
of O
sibutramine B
by O
163 O
% O
and O
255 O
% O
, O
respectively O
. O

Co O
- O
administration O
of O
clarithromycin B
, O
combined O
with O
CYP2B6 O
* O
6 O
/ O
* O
6 O
genotype O
, O
led O
to O
highest O
concentration O
of O
sibutramine B
. O

The O
molar O
sum O
AUC O
( O
M1 O
+ O
M2 O
) O
was O
raised O
by O
35 O
% O
in O
the O
clopidogrel B
phase O
but O
not O
significantly O
affected O
by O
clarithromycin B
or O
CYP2B6 O
genotype O
. O

The O
CYP2B6 O
* O
6 O
/ O
* O
6 O
subjects O
in O
the O
clopidogrel B
phase O
showed O
the O
highest O
molar O
AUC O
( O
M1 O
+ O
M2 O
) O
among O
three O
genotype O
groups O
throughout O
the O
three O
phases O
. O

The O
exposure O
of O
sibutramine B
and O
its O
metabolites O
seemed O
to O
be O
associated O
with O
the O
CYP2B6 O
genotype O
. O

The O
treatment O
of O
clopidogrel B
significantly O
altered O
the O
disposition O
of O
active O
metabolites O
as O
well O
as O
sibutramine B
, O
but O
clarithromycin B
only O
affects O
the O
disposition O
of O
sibutramine B
. O

These O
results O
suggest O
that O
the O
perturbation O
of O
CYP2B6 O
activity O
may O
contribute O
to O
the O
inter O
- O
individual O
variation O
of O
sibutramine B
drug O
responses O
although O
the O
clinical O
relevance O
is O
remained O
to O
be O
established O
. O

We O
present O
two O
cases O
in O
which O
patients O
had O
increased O
blood O
levels O
of O
testosterone B
and O
frank O
hirsutism O
. O

An O
androgen B
producing O
tumour O
should O
be O
excluded O
in O
every O
woman O
with O
evidence O
of O
hirsutism O
or O
frank O
virilization O
and O
markedly O
elevated O
testosterone B
levels O
. O

Adrenal O
disease O
with O
androgen B
hypersecretion O
can O
be O
suspected O
by O
detailed O
clinical O
, O
laboratory O
and O
radiologic O
imaging O
. O

As O
these O
clinical O
entities O
represent O
a O
diagnostic O
and O
therapeutic O
challenge O
, O
oophorectomy O
should O
be O
considered O
in O
postmenopausal O
women O
with O
hirsutism O
and O
elevated O
testosterone B
levels O
, O
after O
the O
exclusion O
of O
adrenal O
causes O
. O

Isoform O
- O
specific O
regulation O
of O
cytochromes O
P450 O
expression O
by O
estradiol B
and O
progesterone B
. O

The O
objective O
of O
this O
study O
was O
to O
comprehensively O
characterize O
the O
effects O
of O
estrogen B
and O
progesterone B
on O
the O
expression O
and O
activity O
of O
major O
drug O
- O
metabolizing O
P450s O
. O

To O
this O
end O
, O
primary O
human O
hepatocytes O
were O
treated O
with O
estradiol B
and O
progesterone B
, O
and O
mRNA O
expression O
and O
activity O
levels O
of O
10 O
different O
P450 O
isoforms O
were O
determined O
. O

The O
results O
showed O
that O
estradiol B
enhances O
CYP2A6 O
, O
CYP2B6 O
, O
and O
CYP3A4 O
expression O
, O
whereas O
progesterone B
induces O
CYP2A6 O
, O
CYP2B6 O
, O
CYP2C8 O
, O
CYP3A4 O
, O
and O
CYP3A5 O
expression O
. O

Estradiol B
also O
increased O
enzyme O
activities O
of O
CYP2C9 O
and O
CYP2E1 O
without O
affecting O
the O
mRNA O
expression O
levels O
by O
unknown O
mechanisms O
. O

Taken O
together O
, O
our O
results O
show O
differential O
effects O
of O
estrogen B
and O
progesterone B
on O
P450 O
expression O
, O
suggesting O
involvement O
of O
different O
regulatory O
mechanisms O
in O
female O
hormone O
- O
mediated O
P450 O
regulation O
. O

Naringin B
induces O
death O
receptor O
and O
mitochondria O
- O
mediated O
apoptosis O
in O
human O
cervical O
cancer O
( O
SiHa O
) O
cells O
. O

Fruit O
- O
based O
cancer O
prevention O
entities O
, O
such O
as O
flavonoid B
and O
their O
derivatives O
, O
have O
demonstrated O
a O
marked O
ability O
to O
inhibit O
preclinical O
models O
of O
epithelial O
cancer O
cell O
growth O
and O
tumor O
formation O
. O

Here O
, O
we O
extend O
the O
role O
of O
naringin B
- O
mediated O
chemoprevention O
to O
that O
of O
cervical O
carcinogenesis O
. O

The O
present O
study O
sought O
to O
investigate O
the O
therapeutic O
potential O
effect O
of O
naringin B
on O
apoptosis O
in O
human O
cervical O
SiHa O
cancer O
cells O
. O

Viability O
of O
SiHa O
cells O
was O
evaluated O
by O
the O
MTT B
assay O
, O
apoptosis O
and O
mitochondrial O
transmembrane O
potential O
by O
flow O
cytometry O
, O
and O
pro O
- O
apoptotic O
related O
genes O
by O
Real O
- O
time O
quantitative O
PCR O
. O

Naringin B
showed O
a O
50 O
% O
inhibition O
of O
SiHa O
human O
cervical O
cancer O
cells O
at O
a O
concentration O
of O
750 O
mu O
M O
. O

In O
addition O
, O
administration O
of O
naringin B
increased O
the O
expression O
of O
caspases O
, O
p53 O
and O
Bax O
, O
Fas O
death O
receptor O
and O
its O
adaptor O
protein O
FADD O
. O

These O
results O
suggest O
that O
the O
induction O
of O
apoptosis O
by O
naringin B
is O
through O
both O
death O
- O
receptor O
and O
mitochondrial O
pathways O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
naringin B
might O
be O
an O
effective O
agent O
to O
treat O
human O
cervical O
cancer O
. O

Using O
neuroblastoma O
- O
derived O
Neuro O
- O
2a O
cells O
to O
investigate O
the O
function O
of O
ARIP1 O
, O
we O
found O
that O
overexpression O
of O
ARIP1 O
down O
- O
regulated O
the O
activin O
A O
- O
induced O
signal O
transduction O
and O
significantly O
decreased O
the O
voltage O
- O
gated O
Na B
( I
+ I
) I
current O
( O
I O
( O
Na B
) O
) O
. O

Coronary O
flow O
velocity O
in O
the O
left O
anterior O
descending O
coronary O
artery O
was O
investigated O
by O
transthoracic O
Doppler O
echocardiography O
at O
rest O
and O
during O
adenosine B
infusion O
. O

CFR O
was O
inversely O
related O
to O
urinary O
cortisol B
in O
patients O
with O
endogenous O
hypercortisolism O
( O
Spearman O
' O
s O
rho O
= O
- O
0 O
. O
57 O
, O
P O
= O
0 O
. O
03 O
) O
, O
while O
no O
correlation O
was O
found O
in O
controls O
. O

Whether O
urinary O
cortisol B
may O
be O
a O
predictor O
of O
coronary O
microvascular O
function O
in O
the O
setting O
of O
patients O
with O
Cushing O
' O
s O
syndrome O
, O
needs O
further O
investigation O
. O

A O
rosette O
cooling O
cell O
: O
more O
effective O
container O
for O
solubilization O
of O
single O
- O
walled O
carbon B
nanotubes O
under O
probe O
- O
type O
ultrasonic O
irradiation O
. O

Probe O
- O
type O
ultrasonication O
has O
been O
employed O
for O
surfactant O
- O
aided O
solubilization O
, O
or O
individualization O
, O
of O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
. O

Density O
functional O
study O
on O
the O
adsorption O
of O
the O
drug O
isoniazid B
onto O
pristine O
and O
B B
- O
doped O
single O
wall O
carbon B
nanotubes O
. O

The O
current O
study O
explores O
a O
new O
strategy O
to O
incorporate O
single O
wall O
carbon B
nanotubes O
( O
SWNTs O
) O
/ O
doped O
SWNTs O
as O
carrier O
modules O
in O
target O
- O
specific O
administration O
of O
antitubercular O
chemotherapeutics O
through O
covalent O
and O
noncovalent O
functionalization O
onto O
the O
nanotube O
sidewall O
. O

Density O
functional O
studies O
illustrate O
that O
noncovalent O
functionalization O
of O
isoniazid B
( O
INH O
) O
is O
preferred O
over O
covalent O
attachment O
, O
exhibiting O
low O
adsorption O
energy O
values O
, O
HOMO O
- O
LUMO O
gap O
and O
comparison O
of O
quantum O
molecular O
descriptors O
performed O
in O
( O
5 O
, O
5 O
) O
and O
( O
9 O
, O
0 O
) O
SWNT O
systems O
. O

Substitution O
doping O
of O
boron B
facilitates O
the O
adsorption O
of O
INH O
onto O
the O
otherwise O
inert O
nanotube O
. O

The O
charge O
transfer O
is O
significant O
in O
covalent O
functionalization O
of O
INH O
via O
the O
B B
- O
dopant O
atom O
, O
whereas O
in O
noncovalent O
functionalization O
a O
small O
amount O
of O
charge O
transfer O
is O
noted O
. O

Solvation O
studies O
demonstrate O
the O
dissolution O
of O
INH O
in O
B B
- O
doped O
( O
5 O
, O
5 O
) O
and O
( O
9 O
, O
0 O
) O
SWNTs O
to O
be O
higher O
compared O
to O
pristine O
nanotube O
- O
INH O
complexes O
. O

Protection O
by O
chrysin B
, O
apigenin B
, O
and O
luteolin B
against O
oxidative O
stress O
is O
mediated O
by O
the O
Nrf2 O
- O
dependent O
up O
- O
regulation O
of O
heme B
oxygenase O
1 O
and O
glutamate B
cysteine B
ligase O
in O
rat O
primary O
hepatocytes O
. O

Chrysin B
, O
apigenin B
, O
and O
luteolin B
are O
flavones B
that O
differ O
in O
their O
number O
of O
hydroxyl B
groups O
in O
the O
B O
ring O
. O

In O
this O
study O
, O
we O
investigated O
the O
protection O
by O
chrysin B
, O
apigenin B
, O
and O
luteolin B
against O
tert B
- I
butyl I
hydroperoxide I
( O
tBHP O
) O
- O
induced O
oxidative O
stress O
and O
the O
possible O
mechanisms O
involved O
in O
rat O
primary O
hepatocytes O
. O

Chrysin B
, O
apigenin B
, O
and O
luteolin B
dose O
- O
dependently O
up O
- O
regulated O
the O
protein O
expression O
of O
heme B
oxygenase O
1 O
( O
HO O
- O
1 O
) O
and O
glutamate B
cysteine B
ligase O
( O
GCL O
) O
catalytic O
( O
GCLC O
) O
and O
modifier O
subunit O
( O
GCLM O
) O
and O
increased O
the O
intracellular O
glutathione B
( O
GSH B
) O
content O
and O
the O
ratio O
of O
GSH B
to O
oxidized O
GSH O
. O

Among O
the O
flavones O
studied O
, O
chrysin B
showed O
the O
greatest O
induction O
of O
HO O
- O
1 O
, O
GCLC O
, O
and O
GCLM O
protein O
expression O
and O
GSH B
content O
. O

Cellular O
reactive O
oxygen B
species O
production O
induced O
by O
tBHP O
was O
attenuated O
by O
pretreatment O
with O
chrysin B
, O
apigenin B
, O
and O
luteolin B
( O
P O
< O
. O
05 O
) O
, O
and O
this O
protection O
was O
reversed O
by O
the O
GCL O
inhibitor O
l O
- O
buthionine O
- O
S O
- O
sulfoximine O
and O
the O
HO O
- O
1 O
inhibitor O
zinc B
protoporphyrin I
. O

Chrysin B
, O
apigenin B
, O
and O
luteolin B
activated O
extracellular O
signal O
- O
regulated O
protein O
kinase O
2 O
( O
ERK2 O
) O
, O
nuclear O
factor O
erythroid O
2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
nuclear O
translocation O
, O
nuclear O
Nrf2 O
- O
antioxidant O
responsive O
element O
( O
ARE O
) O
binding O
activity O
, O
and O
ARE O
- O
dependent O
luciferase O
activity O
. O

Both O
ERK2 O
and O
Nrf2 O
siRNAs O
attenuated O
chrysin B
- O
induced O
HO O
- O
1 O
, O
GCLC O
, O
and O
GCLM O
protein O
expression O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
chrysin B
, O
apigenin B
, O
and O
luteolin B
inhibit O
tBHP O
- O
induced O
oxidative O
stress O
by O
up O
- O
regulating O
HO O
- O
1 O
, O
GCLC O
, O
and O
GCLM O
gene O
transcription O
via O
the O
ERK2 O
/ O
Nrf2 O
/ O
ARE O
signaling O
pathways O
in O
rat O
primary O
hepatocytes O
. O

Alteration O
in O
plasma O
protein O
binding O
properties O
of O
propranolol B
and O
flurbiprofen O
during O
development O
of O
adjuvant O
- O
induced O
arthritis O
in O
rats O
. O

We O
choose O
propranolol B
( O
PL O
) O
and O
flurbiprofen O
( O
FP O
) O
as O
model O
basic O
and O
acidic O
drugs O
, O
respectively O
, O
and O
investigated O
the O
effect O
of O
AA O
induction O
on O
their O
plasma O
protein O
binding O
at O
each O
developing O
stage O
of O
inflammation O
. O

Determination O
of O
10 O
ginsenosides B
in O
Panax O
ginseng O
of O
different O
harvest O
times O
based O
on O
HPLC O
fingerprints O
and O
principal O
component O
analysis O
. O

A O
combinative O
method O
of O
HPLC O
fingerprinting O
and O
quantitative O
determination O
was O
successfully O
applied O
to O
monitor O
dynamic O
accumulation O
of O
ginsenosides B
in O
five O
- O
year O
- O
old O
Panax O
ginseng O
roots O
from O
different O
harvest O
times O
. O

The O
result O
indicated O
that O
the O
contents O
of O
total O
ginsenosides B
showed O
significant O
variations O
, O
and O
a O
decrease O
tendency O
appeared O
in O
the O
growth O
period O
of O
the O
fifth O
year O
. O

A O
large O
proportion O
of O
the O
population O
carries O
restorative O
dental O
fillings O
containing O
either O
classic O
Hg B
- O
based O
amalgams O
and O
/ O
or O
the O
more O
frequently O
used O
methacrylates O
. O

Both O
Hg B
- O
and O
resin O
- O
based O
materials O
have O
been O
shown O
to O
be O
released O
into O
the O
buccal O
cavity O
and O
to O
be O
spread O
systemically O
. O

Lifestyle O
variables O
, O
also O
including O
alcohol B
intake O
and O
smoking O
habits O
, O
did O
not O
affect O
the O
genotoxic O
response O
and O
did O
not O
act O
as O
confounding O
factors O
. O

Increase O
in O
malondialdehyde B
levels O
and O
histological O
damage O
caused O
by O
E O
. O
coli O
were O
improved O
markedly O
with O
TQ O
treatment O
. O

TQ O
treatment O
particularly O
increased O
the O
activity O
of O
glutathione B
peroxidase O
and O
decreased O
the O
activities O
of O
catalase O
and O
superoxide B
dismutase O
. O

Toxicokinetics O
of O
methyleugenol B
in O
F344 O
rats O
and O
B6C3F O
1 O
mice O
. O

1 O
. O
Methyleugenol B
( O
MEG B
) O
has O
been O
used O
as O
a O
flavouring O
agent O
in O
food O
, O
as O
a O
fragrance O
in O
cosmetic O
products O
, O
and O
as O
an O
insect O
attractant O
. O

MEG B
was O
carcinogenic O
in O
both O
rats O
and O
mice O
following O
gavage O
administration O
. O

In O
this O
study O
we O
investigated O
plasma O
toxicokinetics O
of O
MEG B
in O
F344 O
rats O
and O
B6C3F O
1 O
mice O
of O
both O
sexes O
following O
single O
gavage O
( O
37 O
, O
75 O
, O
or O
150 O
mg O
/ O
kg O
) O
and O
intravenous O
( O
IV O
) O
( O
37 O
mg O
/ O
kg O
) O
administration O
. O

2 O
. O
Following O
IV O
administration O
, O
MEG B
was O
rapidly O
distributed O
and O
cleared O
from O
the O
systemic O
circulation O
in O
both O
species O
and O
sexes O
. O

Absorption O
of O
MEG B
was O
rapid O
following O
gavage O
administration O
with O
secondary O
peaks O
in O
the O
plasma O
MEG B
concentration O
- O
versus O
- O
time O
profiles O
. O

In O
general O
, O
rats O
had O
higher O
internal O
exposure O
to O
MEG B
than O
mice O
. O

3 O
. O
The O
results O
for O
AUC O
( O
T O
) O
and O
clearance O
suggest O
that O
perhaps O
the O
metabolism O
of O
MEG B
is O
saturated O
at O
higher O
doses O
tested O
in O
this O
study O
. O

There O
was O
no O
sex O
difference O
in O
plasma O
toxicokinetics O
of O
MEG B
following O
gavage O
administration O
both O
in O
rats O
and O
mice O
. O

Chalcones B
( O
1 O
, O
3 O
- O
Diphenyl O
- O
2 O
- O
propen O
- O
1 O
- O
one O
) O
are O
constituted O
by O
a O
three O
carbon B
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
system O
. O

The O
biosynthesis O
of O
flavonoids B
and O
isoflavonoids B
is O
initiated O
by O
chalcones B
. O

Notable O
pharmacological O
activities O
of O
chalcones B
and O
its O
derivatives O
include O
anti O
- O
inflammatory O
, O
antifungal O
, O
antibacterial O
, O
antimalarial O
, O
antituberculosis O
, O
antitumor O
, O
antimicrobial O
and O
antiviral O
effects O
respectively O
. O

Owing O
to O
simplicity O
of O
the O
chemical O
structures O
and O
a O
huge O
variety O
of O
pharmacological O
actions O
exhibited O
, O
the O
entities O
derived O
from O
chalcones B
are O
subjected O
to O
extensive O
consideration O
. O

This O
review O
article O
is O
an O
effort O
to O
sum O
up O
the O
anti O
- O
inflammatory O
activities O
of O
chalcone B
derived O
chemical O
entities O
. O

Effect O
of O
chalcones B
on O
lipid O
peroxidation O
, O
heme B
oxygenase O
1 O
( O
HO O
- O
1 O
) O
, O
cyclooxygenase O
( O
COX O
) O
, O
interleukin O
5 O
( O
IL O
- O
5 O
) O
, O
nitric B
oxide I
( O
NO B
) O
and O
expression O
of O
cell O
adhesion O
molecules O
( O
CAM O
) O
is O
summarized O
stepwise O
. O

Chalcones B
in O
Cancer O
: O
Understanding O
their O
Role O
in O
Terms O
of O
QSAR O
. O

Chalcones B
are O
a O
group O
of O
plant O
- O
derived O
polyphenolic B
compounds O
belonging O
to O
the O
flavonoids B
family O
and O
possess O
a O
wide O
variety O
of O
cytoprotective O
and O
modulatory O
functions O
. O

In O
this O
research O
we O
tried O
to O
review O
the O
anticancer O
effect O
of O
chalcones B
derivatives O
and O
to O
evaluate O
new O
QSARs O
which O
will O
help O
in O
the O
understanding O
of O
the O
role O
of O
chalcones B
and O
of O
their O
analogs O
on O
cancer O
. O

These O
results O
compared O
to O
our O
previous O
findings O
on O
the O
QSAR O
of O
anti O
- O
proliferative O
chalcones B
support O
primarily O
the O
role O
of O
bulk O
. O

Silent O
information O
regulator O
2 O
( O
Sir2 O
) O
enzymes O
or O
sirtuins O
are O
a O
family O
of O
evolutionarily O
conserved O
intracellular O
protein O
deacetylases O
that O
can O
catalyze O
the O
acetyl B
group O
removal O
from O
the O
specific O
N O
epsilon O
- O
acetyl O
- O
lysine O
( O
AcK O
) O
side O
chains O
on O
a O
variety O
of O
proteins O
from O
all O
kingdoms O
of O
life O
. O

Specifically O
, O
the O
sirtuin O
- O
catalyzed O
AcK O
side O
chain O
deacetylation O
is O
not O
merely O
an O
amide B
hydrolysis O
reaction O
, O
instead O
is O
coupled O
to O
the O
nicotinamide B
cleavage O
from O
beta O
- O
nicotinamide O
adenine O
dinucleotide O
( O
beta O
- O
NAD O
+ O
or O
NAD B
+ O
) O
with O
the O
generation O
of O
three O
enzymatic O
products O
, O
i O
. O
e O
. O
the O
deacetylated O
protein O
species O
, O
nicotinamide O
, O
and O
2 O
' O
- O
O O
- O
acetyl O
- O
ADP O
- O
ribose O
( O
2 O
' O
- O
O O
- O
AADPR O
) O
. O

Thiazolidinediones B
( O
TZDs O
) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD B
effects O
on O
aromatase O
. O

Thiazolidinediones B
( O
TZDs O
) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O

We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen B
synthesis O
by O
inhibiting O
aromatase O
activity O
in O
human O
granulosa O
cells O
( O
HGC O
) O
. O

We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co O
- O
culture O
with O
HGC O
to O
determine O
whether O
TZD B
inhibition O
of O
aromatase O
plays O
a O
role O
in O
their O
effects O
on O
bone O
metabolism O
. O

Mouse O
osteoblasts O
were O
cultured O
with O
and O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone B
, O
pioglitazone B
or O
rosiglitazone B
. O

TZDs O
inhibited O
estradiol B
production O
by O
up O
to O
84 O
% O
in O
HGC O
/ O
mouse O
osteoblast O
co O
- O
cultures O
. O

TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic B
acid I
uptake O
. O

TZD B
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O
aromatase O
. O

We O
synthesized O
18 O
alloferon O
analogues O
: O
12 O
peptides O
with O
sequences O
shortened O
from O
N B
- O
or O
C B
- O
terminus O
and O
6 O
N B
- O
terminally O
modified O
analogues O
H O
- O
X O
( O
1 O
) O
- O
Gly O
- O
Val O
- O
Ser O
- O
Gly O
- O
His O
- O
Gly O
- O
Gln O
- O
His O
- O
Gly O
- O
Val O
- O
His O
- O
Gly O
- O
OH O
, O
where O
X O
( O
1 O
) O
= O
Phe B
( O
13 O
) O
, O
Tyr B
( O
14 O
) O
, O
Trp B
( O
15 O
) O
, O
Phg O
( O
16 O
) O
, O
Phe O
( O
p O
- O
Cl O
) O
( O
17 O
) O
, O
and O
Phe O
( O
p O
- O
OMe O
) O
( O
18 O
) O

Sonochemical O
synthesis O
of O
hierarchical O
ZnO B
nanostructures O
. O

This O
work O
is O
about O
fabrication O
of O
ZnO B
nanostructures O
( O
ZnO B
- O
NS O
) O
via O
a O
simple O
sonochemical O
method O
. O

The O
chemicals O
used O
for O
the O
synthesis O
of O
various O
shaped O
ZnO B
are O
Zn B
salt O
, O
sodium B
hydroxide I
and O
ammonia O
solution O
without O
other O
structure O
directing O
agent O
or O
surfactant O
needed O
. O

The O
shape O
of O
the O
ZnO B
- O
NS O
can O
be O
tuned O
by O
adjusting O
the O
ultrasound O
energy O
dissipated O
via O
varying O
the O
ultrasonication O
time O
from O
5 O
to O
60 O
min O
. O

It O
was O
found O
that O
uniform O
ZnO B
nanorods O
with O
diameter O
around O
50 O
nm O
were O
formed O
after O
15 O
min O
of O
ultrasonication O
while O
flowerlike O
ZnO B
- O
NS O
was O
formed O
after O
30 O
min O
. O

This O
method O
produces O
high O
quality O
ZnO B
- O
NS O
with O
controllable O
shapes O
, O
uniformity O
, O
and O
purity O
. O

Objective O
and O
subjective O
cognitive O
enhancing O
effects O
of O
mixed O
amphetamine B
salts O
in O
healthy O
people O
. O

Psychostimulants O
such O
as O
mixed O
amphetamine B
salts O
( O
MAS O
, O
brand O
name O
Adderall O
) O
are O
widely O
used O
for O
cognitive O
enhancement O
by O
healthy O
young O
people O
, O
yet O
laboratory O
research O
on O
effectiveness O
has O
yielded O
variable O
results O
. O

Vitamin B
D I
binding O
protein O
is O
a O
key O
determinant O
of O
25 B
- I
hydroxyvitamin I
D I
levels O
in O
infants O
and O
toddlers O
. O

Circulating O
25 B
- I
hydroxyvitamin I
D I
( O
25 B
- I
OHD I
) O
levels O
vary O
among O
human O
populations O
. O

Only O
limited O
information O
regarding O
determinants O
of O
these O
measures O
is O
available O
for O
infants O
and O
children O
, O
particularly O
in O
minority O
groups O
at O
greatest O
risk O
for O
vitamin B
D I
deficiency O
. O

We O
identified O
demographic O
determinants O
of O
circulating O
25 B
- I
OHD I
in O
a O
large O
cohort O
of O
minority O
children O
, O
and O
now O
extend O
our O
studies O
to O
examine O
potential O
roles O
of O
vitamin B
D I
binding O
protein O
( O
DBP O
) O
as O
a O
determinant O
of O
25 B
- I
OHD I
levels O
. O

Serum O
DBP O
level O
and O
common O
single O
nucleotide B
polymorphisms O
( O
SNPs O
) O
at O
positions O
432 O
and O
436 O
in O
the O
GC O
gene O
, O
encoding O
DBP O
, O
were O
examined O
. O

The O
multivariate O
model O
incorporated O
previously O
identified O
demographic O
and O
nutritional O
determinants O
of O
25 B
- I
OHD I
in O
this O
cohort O
, O
as O
well O
as O
GC O
SNPs O
and O
circulating O
DBP O
. O

Circulating O
DBP O
was O
significantly O
correlated O
with O
25 B
- I
OHD I
. O

GC O
SNPs O
were O
associated O
with O
both O
circulating O
DBP O
and O
25 B
- I
OHD I
. O

It O
appears O
that O
progressive O
substitution O
of O
lysine B
for O
threonine B
at O
the O
436 O
position O
results O
in O
lower O
circulating O
25 B
- I
OHD I
. O

Multivariate O
analysis O
revealed O
that O
genetic O
variance O
in O
GC O
significantly O
contributes O
to O
circulating O
DBP O
as O
well O
as O
25 B
- I
OHD I
. O

Moreover O
, O
the O
effect O
of O
GC O
SNPs O
on O
25 B
- I
OHD I
are O
evident O
after O
adjusting O
for O
their O
effects O
on O
circulating O
DBP O
. O

Thus O
in O
young O
children O
genetic O
variance O
of O
the O
common O
GC O
T436K O
SNP O
affects O
circulating O
levels O
of O
the O
DBP O
protein O
, O
which O
in O
turn O
affects O
circulating O
25 B
- I
OHD I
. O

However O
, O
the O
GC O
genotype O
also O
affects O
circulating O
25 B
- I
OHD I
independently O
of O
its O
effect O
on O
circulating O
DBP O
. O

In O
this O
article O
we O
report O
calculations O
of O
the O
activation O
free O
energy O
for O
a O
chemical O
reaction O
between O
propylene O
oxide O
and O
DNA O
, O
in O
particular O
with O
the O
guanine B
at O
the O
N7 O
position O
. O

Moreover O
, O
the O
reactivities O
of O
a O
series O
of O
ultimate O
carcinogens O
of O
the O
epoxy B
type O
toward O
DNA O
are O
shown O
to O
be O
related O
to O
their O
carcinogenicities O
. O

The O
present O
work O
explores O
the O
effect O
of O
dietary O
omega O
- O
3 O
polyunsaturated O
fatty O
acids O
( O
PUFAs B
) O
intake O
on O
lipid O
peroxidation O
among O
mild O
cognitive O
impairment O
( O
MCI O
) O
patients O
. O

The O
plasma O
lipid O
hydroperoxide B
( O
LPO O
) O
levels O
in O
67 O
MCI O
patients O
were O
compared O
to O
those O
of O
134 O
healthy O
elderly O
controls O
. O

Omega B
- I
3 I
PUFA I
intake O
was O
assessed O
using O
an O
interviewer O
- O
administered O
food O
frequency O
questionnaire O
. O

The O
influence O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
eicosapentaenoic B
acid I
( O
EPA B
) O
intake O
on O
LPO O
level O
was O
investigated O
. O

Inverse O
correlations O
were O
found O
between O
DHA B
and O
EPA B
intake O
and O
LPO O
level O
among O
the O
MCI O
group O
. O

LPO O
levels O
decreased O
significantly O
with O
increasing O
DHA B
and O
EPA B
intake O
. O

In O
summary O
, O
the O
findings O
revealed O
that O
DHA B
and O
EPA B
can O
play O
a O
role O
in O
alleviating O
oxidative O
stress O
and O
reducing O
the O
risk O
of O
neurodegenerative O
diseases O
. O

Multidrug O
resistance O
- O
associated O
proteins O
are O
involved O
in O
the O
transport O
of O
the O
glutathione B
conjugates O
of O
the O
ultimate O
carcinogen O
of O
benzo B
[ I
a I
] I
pyrene I
in O
human O
Caco O
- O
2 O
cells O
. O

A O
wide O
variety O
of O
contaminants O
are O
ingested O
through O
food O
, O
among O
them O
the O
pro O
- O
carcinogenic O
polycyclic O
aromatic O
hydrocarbon O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
that O
is O
resorbed O
and O
partially O
metabolized O
in O
the O
enterocytes O
of O
the O
small O
intestine O
. O

Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP O
phenols O
are O
excreted O
as O
Phase O
II O
metabolites O
including O
glucuronides O
and O
sulfates B
. O

The O
ultimate O
carcinogenic O
Phase O
I O
BP O
metabolite O
anti O
- O
BP O
- O
7 O
, O
8 O
- O
dihydrodiol O
- O
9 O
, O
10 O
- O
epoxide O
( O
BPDE O
) O
can O
be O
detoxified O
by O
glutathione B
conjugate O
formation O
catalyzed O
by O
glutathione B
S B
- O
transferases O
. O

In O
the O
present O
study O
, O
differentiated O
human O
intestinal O
Caco O
- O
2 O
cells O
were O
used O
as O
a O
model O
for O
the O
human O
small O
intestine O
to O
investigate O
the O
detoxification O
of O
BPDE O
and O
excretion O
of O
stereoisomeric O
glutathione B
conjugates O
in O
the O
presence O
of O
an O
inhibitor O
of O
the O
glutathione B
- O
cleaving O
enzyme O
gamma O
- O
glutamyl O
transpeptidase O
at O
the O
cell O
surface O
. O

The O
results O
indicate O
that O
the O
glutathione B
conjugates O
of O
BPDE O
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco O
- O
2 O
monolayers O
. O

In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione B
conjugation O
and O
subsequently O
excreted O
by O
Caco O
- O
2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O

Oleuropein O
supplementation O
increases O
urinary O
noradrenaline B
and O
testicular O
testosterone B
levels O
and O
decreases O
plasma O
corticosterone B
level O
in O
rats O
fed O
high O
- O
protein O
diet O
. O

The O
effects O
of O
oleuropein O
, O
a O
phenolic B
compound O
in O
extra O
virgin O
olive O
oil O
, O
on O
protein O
metabolism O
were O
investigated O
by O
measuring O
testicular O
testosterone B
and O
plasma O
corticosterone B
levels O
in O
rats O
fed O
diets O
with O
different O
protein O
levels O
. O

After O
28 O
days O
of O
feeding O
, O
the O
testosterone B
level O
in O
the O
testis O
was O
significantly O
higher O
and O
the O
plasma O
corticosterone B
level O
was O
significantly O
lower O
in O
rats O
fed O
the O
40 O
% O
casein O
diet O
with O
oleuropein O
than O
in O
those O
fed O
the O
same O
diet O
without O
oleuropein O
. O

The O
urinary O
noradrenaline B
level O
, O
nitrogen B
balance O
and O
hepatic O
arginase O
activity O
were O
significantly O
higher O
in O
rats O
fed O
the O
40 O
% O
casein O
diet O
with O
oleuropein O
supplementation O
than O
in O
those O
fed O
the O
40 O
% O
casein O
diet O
without O
oleuropein O
supplementation O
. O

In O
Experiment O
2 O
, O
the O
effects O
of O
oleuropein O
aglycone O
( O
a O
major O
phenolic B
compound O
in O
extra O
virgin O
olive O
oil O
and O
the O
absorbed O
form O
of O
oleuropein O
ingested O
in O
the O
gastrointestinal O
tracts O
) O
on O
the O
secretion O
of O
luteinizing O
hormone O
( O
LH O
) O
from O
the O
pituitary O
gland O
, O
which O
regulates O
testosterone B
production O
in O
the O
testis O
, O
were O
investigated O
in O
anesthetized O
rats O
. O

These O
findings O
suggest O
that O
dietary O
supplementation O
with O
0 O
. O
1 O
g O
/ O
100 O
g O
oleuropein O
alters O
the O
levels O
of O
hormones O
associated O
with O
protein O
anabolism O
by O
increasing O
urinary O
noradrenaline B
and O
testicular O
testosterone B
levels O
and O
decreasing O
plasma O
corticosterone B
level O
in O
rats O
fed O
a O
high O
- O
protein O
diet O
. O

The O
choice O
of O
digestion O
enzymes O
used O
in O
this O
study O
does O
not O
affect O
uptake O
of O
either O
pravastatin B
( O
an O
organic O
anion O
probe O
substrate O
for O
Oatp O
transporter O
) O
or O
metformin B
( O
an O
organic O
cation O
probe O
substrate O
for O
Oct O
transporter O
) O
. O

Materials O
and O
methods O
: O
Three O
modified O
- O
release O
formulations O
of O
aminophylline O
consisted O
of O
Carbopol B
( O
R O
) O
971P O
/ O
HPMC O
K4M O
( O
F O
- O
I O
) O
, O
and O
HPMC O
K100M O
( O
F O
- O
II O
) O
or O
HPMC O
K4M O
( O
F O
- O
III O
) O
were O
used O
. O

Mercury B
and O
lead O
are O
widespread O
in O
the O
environment O
, O
causing O
chronic O
exposure O
of O
a O
large O
population O
to O
low O
concentrations O
of O
these O
metals O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
mercuric O
( O
Hg B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
on O
T O
cells O
. O

Up O
to O
100 O
mu O
M O
Pb B
( I
NO I
( I
3 I
) I
) I
( I
2 I
) I
had O
no O
effect O
on O
cellular O
viability O
and O
proliferation O
. O

Additionally O
, O
Hg B
( I
2 I
+ I
) I
induced O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
accompanied O
by O
the O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
measured O
by O
Dihydrorhodamine O
and O
Rhodamine O
- O
123 O
, O
respectively O
. O

The O
antioxidant O
N B
- I
acetylcysteine I
partially O
reversed O
the O
toxic O
effects O
of O
Hg B
( I
2 I
+ I
) I
, O
pointing O
to O
an O
involvement O
of O
ROS O
. O

Hg B
( I
2 I
+ I
) I
had O
no O
effect O
on O
the O
secretion O
of O
IL O
- O
2 O
, O
but O
on O
IL O
- O
2 O
mediated O
signal O
transduction O
pathways O
, O
reducing O
phosphorylation O
of O
the O
downstream O
kinases O
ERK1 O
/ O
2 O
and O
AKT O
. O

Moreover O
, O
Hg B
( I
2 I
+ I
) I
led O
to O
an O
arrest O
of O
the O
cells O
in O
the O
S O
phase O
of O
the O
cell O
cycle O
. O

Taken O
together O
, O
these O
data O
fit O
a O
model O
in O
which O
Hg B
( I
2 I
+ I
) I
disrupts O
mitochondria O
, O
and O
the O
resulting O
release O
of O
ROS O
inhibits O
IL O
- O
2 O
- O
dependent O
signal O
transduction O
, O
reducing O
proliferation O
and O
survival O
of O
T O
cells O
. O

Both O
colombienases O
present O
fibrino O
( O
geno O
) O
lytic O
activity O
, O
but O
did O
not O
show O
any O
hemorrhagic O
, O
amidolytic O
, O
plasminogen O
activator O
or O
coagulant O
activities O
, O
and O
no O
effect O
on O
platelet O
aggregation O
induced O
by O
collagen O
or O
ADP B
. O

The O
homology O
demonstrated O
by O
the O
comparison O
of O
sequences O
, O
with O
zinc B
- O
dependent O
metalloproteinases O
, O
as O
well O
as O
the O
metal O
chelant O
effects O
on O
, O
confirmed O
that O
the O
colombienases O
were O
metalloproteinases O
, O
particularly O
to O
alpha O
- O
fibrinogenases O
belonging O
to O
the O
P O
- O
I O
class O
of O
SVPMs O
( O
20 O
- O
30 O
kDa O
) O
, O
which O
contain O
only O
the O
single O
- O
domain O
proteins O
. O

Organophosphorus B
nerve O
agents O
irreversibly O
inhibit O
cholinesterases O
. O

Phosphylation O
of O
the O
catalytic O
serine B
can O
be O
reversed O
by O
the O
mean O
of O
powerful O
nucleophiles O
like O
oximes B
. O

But O
the O
phosphyl O
adduct O
can O
undergo O
a O
rapid O
spontaneous O
reaction O
leading O
to O
an O
aged O
enzyme O
, O
i O
. O
e O
. O
, O
a O
conjugated O
enzyme O
that O
is O
no O
longer O
reactivable O
by O
oximes B
. O

Specific O
alkylating O
molecules O
were O
synthesized O
and O
the O
crystal O
structures O
of O
the O
complexes O
they O
form O
with O
soman B
- O
aged O
human O
butyrylcholinesteras O
were O
solved O
. O

The O
anticholinesterase O
( O
antiChE O
) O
organophosphorus B
( O
OP O
) O
and O
methylcarbamate O
( O
MC O
) O
insecticides O
have O
been O
used O
very O
effectively O
as O
contact O
and O
systemic O
plant O
protectants O
for O
seven O
decades O
. O

In O
both O
insects O
and O
mammals O
, O
AChE O
inhibition O
and O
acetylcholine B
accumulation O
leads O
to O
excitation O
and O
death O
. O

Structural O
differences O
between O
insect O
and O
mammalian O
AChE O
are O
also O
evident O
in O
their O
genomics O
, O
amino B
acid I
sequences O
and O
active O
site O
conformations O
. O

Much O
of O
the O
success O
of O
antiChE O
insecticides O
results O
from O
a O
suitable O
balance O
of O
bioactivation O
and O
detoxification O
by O
families O
of O
CYP450 O
oxidases O
, O
hydrolases O
, O
glutathione B
S B
- O
transferases O
and O
others O
. O

Postpartum O
corticosterone B
administration O
reduces O
dendritic O
complexity O
and O
increases O
the O
density O
of O
mushroom O
spines O
of O
hippocampal O
CA3 O
arbours O
in O
dams O
. O

To O
model O
these O
components O
in O
rats O
, O
we O
administered O
high O
corticosterone B
( O
CORT B
) O
postpartum O
, O
which O
increases O
immobility O
in O
the O
forced O
swim O
test O
( O
FST O
) O
, O
and O
reduces O
maternal O
care O
, O
body O
weight O
and O
hippocampal O
cell O
proliferation O
in O
dams O
. O

In O
the O
present O
study O
, O
we O
examined O
whether O
high O
CORT B
reduced O
dendritic O
complexity O
and O
spines O
in O
the O
CA3 O
region O
of O
the O
hippocampus O
. O

Dams O
received O
40 O
mg O
/ O
kg O
/ O
day O
of O
CORT B
or O
oil O
starting O
on O
day O
2 O
postpartum O
for O
23 O
days O
. O

As O
previously O
established O
, O
high O
CORT B
postpartum O
reduced O
maternal O
care O
and O
increased O
immobility O
in O
the O
FST O
, O
which O
is O
a O
measure O
of O
depressive O
- O
like O
behaviour O
. O

High O
CORT B
postpartum O
reduced O
the O
complexity O
of O
basal O
arbours O
and O
increased O
mushroom O
spines O
on O
both O
apical O
and O
basal O
dendrites O
. O

These O
data O
show O
that O
chronic O
high O
CORT B
in O
postpartum O
females O
alters O
hippocampal O
morphology O
and O
may O
provide O
insight O
regarding O
the O
neurobiological O
consequences O
of O
high O
stress O
or O
CORT B
during O
the O
postpartum O
period O
, O
as O
well O
as O
be O
relevant O
for O
postpartum O
stress O
or O
depression O
. O

Effects O
of O
anti O
- O
cocaine B
vaccine O
and O
viral O
gene O
transfer O
of O
cocaine B
hydrolase O
in O
mice O
on O
cocaine B
toxicity O
including O
motor O
strength O
and O
liver O
damage O
. O

In O
developing O
an O
vivo O
drug O
- O
interception O
therapy O
to O
treat O
cocaine B
abuse O
and O
hinder O
relapse O
into O
drug O
seeking O
provoked O
by O
re O
- O
encounter O
with O
cocaine B
, O
two O
promising O
agents O
are O
: O
( O
1 O
) O
a O
cocaine B
hydrolase O
enzyme O
( O
CocH O
) O
derived O
from O
human O
butyrylcholinesteras O
and O
delivered O
by O
gene O
transfer O
; O
( O
2 O
) O
an O
anti O
- O
cocaine B
antibody O
elicited O
by O
vaccination O
. O

Recent O
behavioral O
experiments O
showed O
that O
antibody O
and O
enzyme O
work O
in O
a O
complementary O
fashion O
to O
reduce O
cocaine B
- O
stimulated O
locomotor O
activity O
in O
rats O
and O
mice O
. O

Our O
present O
goal O
was O
to O
test O
protection O
against O
liver O
damage O
and O
muscle O
weakness O
in O
mice O
challenged O
with O
massive O
doses O
of O
cocaine B
at O
or O
near O
the O
LD50 O
level O
( O
100 O
- O
120mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

The O
prolyl B
- O
isomerase O
Pin1 O
activates O
the O
mitochondrial O
death O
program O
of O
p53 O
. O

Here O
we O
have O
explored O
the O
role O
had O
in O
this O
pathway O
by O
the O
prolyl B
- O
isomerase O
Pin1 O
( O
peptidylprolyl O
cis O
/ O
trans O
isomerase O
, O
NIMA O
- O
interacting O
1 O
) O
, O
a O
crucial O
transducer O
of O
p53 O
' O
s O
phosphorylation O
into O
conformational O
changes O
unleashing O
its O
pro O
- O
apoptotic O
activity O
. O

Carbon B
nanotube O
functionalization O
with O
carboxylic B
derivatives O
: O
a O
DFT O
study O
. O

Chemical O
functionalization O
of O
a O
single O
- O
walled O
carbon B
nanotube O
( O
CNT O
) O
with O
different O
carboxylic B
derivatives O
including O
- O
COOX O
( O
X O
= O
H B
, O
CH3 B
, O
CH2NH2 O
, O
CH3Ph O
, O
CH2NO2 O
, O
and O
CH2CN O
) O
has O
been O
theoretically O
investigated O
in O
terms O
of O
geometric O
, O
energetic O
, O
and O
electronic O
properties O
. O

The O
results O
reveal O
that O
the O
reaction O
energy O
is O
increased O
by O
increasing O
the O
electron O
withdrawing O
character O
of O
the O
functional O
groups O
so O
that O
the O
relative O
magnitude O
order O
is O
- O
CH2NO2 O
> O
- O
CH2CN O
> O
- O
H B
> O
- O
CH2Ph O
> O
- O
CH3 B
> O
- O
CH2NH2 O
. O

The O
chemical O
functionalization O
leads O
to O
an O
increase O
in O
HOMO O
/ O
LUMO O
energy O
gap O
of O
CNT O
by O
about O
0 O
. O
32 O
to O
0 O
. O
35 O
eV O
( O
except O
for O
- O
H B
) O
. O

A O
green O
and O
simple O
approach O
to O
assembling O
of O
2 O
- O
amino O
- O
4 O
, O
8 O
- O
dihydropyrano O
[ O
3 O
, O
2 O
- O
b O
] O
pyran O
- O
3 O
- O
carbonitrile O
scaffolds O
via O
three O
- O
component O
reaction O
of O
kojic B
acid I
, O
malononitrile B
, O
and O
aromatic B
aldehydes I
in O
aqueous O
media O
under O
ultrasound O
irradiation O
is O
described O
. O

In O
comparison O
to O
conventional O
methods O
, O
experimental O
simplicity O
, O
good O
functional O
group O
tolerance O
, O
excellent O
yields O
, O
short O
routine O
, O
and O
selectivity O
without O
the O
need O
for O
a O
transition B
metal I
or O
base O
catalyst O
are O
prominent O
features O
of O
this O
green O
procedure O
. O

Adenosine B
and O
autism O
: O
a O
spectrum O
of O
opportunities O
. O

In O
rodents O
, O
insufficient O
adenosine B
produces O
behavioral O
and O
physiological O
symptoms O
consistent O
with O
several O
comorbidities O
of O
autism O
. O

In O
rodents O
and O
humans O
, O
stimuli O
postulated O
to O
increase O
adenosine B
can O
ameliorate O
these O
comorbidities O
. O

Because O
adenosine B
is O
a O
broad O
homeostatic O
regulator O
of O
cell O
function O
and O
nervous O
system O
activity O
, O
increasing O
adenosine B
' O
s O
influence O
might O
be O
a O
new O
therapeutic O
target O
for O
autism O
with O
multiple O
beneficial O
effects O
. O

Mutations O
in O
the O
gene O
encoding O
methyl B
- O
CpG B
- O
binding O
protein O
2 O
( O
MECP2 O
) O
have O
been O
identified O
as O
clear O
etiological O
factors O
in O
more O
than O
90 O
% O
of O
classical O
RTT O
cases O
. O

These O
animal O
models O
are O
based O
on O
chemical O
interventions O
( O
e O
. O
g O
. O
pentylenetetrazol B
, O
kainic O
acid O
, O
pilocarpine B
) O
, O
electrical O
stimulations O
( O
e O
. O
g O
. O
kindling O
, O
electroshock O
) O
, O
and O
genetic O
/ O
selective O
breeding O
paradigms O
( O
e O
. O
g O
. O
genetically O
epilepsy O
- O
prone O
rats O
( O
GEPRs O
) O
, O
genetic O
absence O
epilepsy O
rat O
from O
Strasbourg O
( O
GAERS O
) O
, O
WAG O
/ O
Rij O
rats O
, O
swim O
lo O
- O
active O
rats O
( O
SwLo O
) O
) O
. O

Body O
weight O
, O
serum O
high O
sensitivity O
C O
- O
reactive O
protein O
( O
hs O
- O
CRP O
) O
, O
interleukin O
( O
IL O
) O
- O
6 O
, O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
, O
fasting O
glucose B
, O
and O
insulin O
were O
measured O
. O

The O
number O
of O
branches O
containing O
Gal O
beta O
1 O
- O
4Gal O
on O
N B
- O
glycans O
did O
not O
significantly O
affect O
K O
( O
d O
) O
of O
mAbs O
of O
IgG1 O
subclasses O
, O
but O
those O
of O
IgM O
mAbs O
were O
decreased O
by O
~ O
1 O
order O
of O
magnitude O
, O
in O
increments O
of O
the O
number O
of O
branches O
present O
. O

Diethyldithiocarbama O
induces O
apoptosis O
in O
neuroblastoma O
cells O
by O
raising O
the O
intracellular O
copper B
level O
, O
triggering O
cytochrome O
c O
release O
and O
caspase O
activation O
. O

Dithiocarbamates O
are O
nitrogen B
- O
and O
sulfur B
- O
containing O
compounds O
commonly O
used O
in O
pharmacology O
, O
medicine O
and O
agriculture O
. O

The O
molecular O
effects O
of O
dithiocarbamates O
on O
neuronal O
cell O
systems O
are O
not O
fully O
understood O
, O
especially O
in O
terms O
of O
their O
ability O
to O
accumulate O
copper B
ions O
inside O
the O
cell O
. O

In O
this O
work O
, O
the O
molecular O
effects O
of O
N O
, O
N O
- O
diethyldithiocarbama O
( O
DEDTC O
) O
were O
studied O
in O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
to O
determine O
the O
role O
of O
copper B
in O
the O
DEDTC O
toxicity O
and O
the O
pathway O
trigged O
in O
cell O
by O
the O
complex O
Cu O
- O
DEDTC O
. O

From O
concentration O
- O
dependent O
studies O
, O
we O
found O
that O
5 O
mu O
M O
of O
this O
compound O
induced O
a O
drastic O
decrease O
in O
viable O
cells O
with O
a O
concomitant O
accumulation O
in O
intracellular O
copper B
resulted O
from O
complexation O
with O
DEDTC O
, O
measured O
by O
atomic O
absorption O
spectroscopy O
. O

This O
pathway O
is O
induced O
by O
the O
cytotoxic O
effects O
that O
occur O
when O
DEDTC O
forms O
a O
complex O
with O
the O
copper B
ions O
present O
in O
the O
culture O
medium O
and O
transports O
them O
into O
the O
cell O
, O
suggesting O
that O
the O
DEDTC O
by O
itself O
was O
not O
able O
to O
cause O
cell O
death O
and O
the O
major O
effect O
is O
from O
its O
copper B
- O
complex O
in O
neuroblastoma O
cells O
. O

The O
present O
study O
suggests O
a O
role O
for O
the O
influence O
of O
copper B
by O
low O
concentrations O
of O
DEDTC O
in O
the O
extracellular O
media O
, O
the O
absorption O
and O
accumulation O
of O
copper B
in O
the O
cell O
and O
apoptotic O
events O
, O
induced O
by O
the O
cytotoxic O
effects O
that O
occur O
when O
DEDTC O
forms O
a O
complex O
with O
the O
copper B
ions O
. O

Silver B
nanoparticle O
- O
induced O
cytotoxicity O
in O
rat O
brain O
endothelial O
cell O
culture O
. O

Silver B
nanoparticles O
( O
AgNPs O
) O
are O
among O
the O
most O
widely O
commercialised O
engineered O
nanomaterials O
, O
because O
of O
their O
antimicrobial O
properties O
. O

The O
present O
study O
examined O
the O
cytotoxic O
effects O
of O
spherical O
, O
citrate B
- O
coated O
AgNPs O
( O
10 O
, O
50 O
and O
100 O
nm O
) O
in O
rat O
brain O
endothelial O
( O
RBE4 O
) O
cells O
and O
investigated O
whether O
the O
observed O
effects O
can O
be O
explained O
by O
the O
intrinsic O
toxicity O
of O
the O
particles O
or O
the O
silver B
ions O
released O
from O
the O
particles O
. O

The O
results O
indicated O
that O
exposure O
of O
RBE4 O
cells O
to O
AgNPs O
lead O
to O
significant O
reduction O
in O
dye O
uptake O
as O
measured O
with O
the O
Neutral B
red I
( O
NR O
) O
assay O
. O

In O
contrast O
, O
silver B
ions O
increased O
NR O
uptake O
( O
ca O
. O
10 O
% O
) O
in O
RBE4 O
cells O
after O
1h O
, O
while O
a O
reduction O
in O
NR O
uptake O
was O
observed O
after O
24h O
exposure O
at O
high O
concentrations O
( O
20 O
- O
30 O
mu O
M O
) O
. O

Silver B
ions O
had O
less O
effect O
on O
the O
colony O
formation O
of O
RBE4 O
cells O
than O
AgNPs O
. O

Delayed O
temporal O
increase O
of O
hepatic O
Hsp70 O
in O
ApoE O
knockout O
mice O
after O
prenatal O
arsenic B
exposure O
. O

Prenatal O
arsenic B
exposure O
accelerates O
atherosclerosis O
in O
ApoE O
( O
- O
/ O
- O
) O
mice O
by O
unknown O
mechanism O
. O

Arsenic B
is O
a O
hepatotoxicant O
, O
and O
liver O
disease O
increases O
atherosclerosis O
risk O
. O

Prenatal O
arsenic B
exposure O
may O
predispose O
to O
liver O
disease O
by O
priming O
for O
susceptibility O
to O
other O
environmental O
insults O
. O

Earlier O
microarray O
analyses O
showed O
prenatal O
arsenic B
exposure O
increased O
Hsc70 O
( O
HspA8 O
) O
and O
Hsp70 O
( O
HspA1a O
) O
mRNAs O
in O
livers O
of O
10 O
- O
week O
- O
old O
mice O
. O

We O
determined O
effects O
of O
prenatal O
arsenic B
exposure O
on O
hepatic O
Hsp70 O
and O
Hsc70 O
expression O
by O
Western O
blot O
and O
on O
DNA O
methylation O
by O
methyl B
acceptance O
assay O
during O
prenatal O
and O
postnatal O
development O
. O

Pregnant O
ApoE O
( O
- O
/ O
- O
) O
mice O
were O
given O
drinking O
water O
containing O
85 O
mg O
/ O
l O
NaAsO O
( O
2 O
) O
( O
49 O
ppm O
arsenic B
) O
from O
gestation O
day O
( O
GD O
) O
8 O
to O
18 O
. O

Global O
DNA O
methylation O
increased O
with O
age O
; O
arsenic B
had O
no O
effects O
. O

Bisulfite B
sequencing O
of O
DNA O
from O
livers O
of O
10 O
- O
week O
- O
old O
mice O
showed O
Hsp70 O
promoter O
region O
methylation O
was O
unchanged O
, O
but O
methylation O
was O
increased O
within O
the O
transcribed O
region O
. O

Putative O
binding O
sites O
were O
identified O
in O
HSP70 O
for O
in O
utero O
arsenic B
exposure O
- O
suppressed O
microRNAs O
suggesting O
a O
possible O
mechanism O
. O

Thus O
, O
prenatal O
arsenic B
exposure O
causes O
delayed O
temporal O
hepatic O
Hsp70 O
induction O
, O
suggesting O
a O
transient O
state O
of O
stress O
in O
livers O
which O
can O
predispose O
the O
mice O
to O
developing O
liver O
disease O
. O

Involvement O
of O
interleukin O
- O
6 O
- O
regulated O
nitric B
oxide I
synthase O
in O
hemorrhagic O
cystitis O
and O
impaired O
bladder O
contractions O
in O
young O
rats O
induced O
by O
acrolein B
, O
a O
urinary O
metabolite O
of O
cyclophosphamide B
. O

Hemorrhagic O
cystitis O
is O
a O
common O
complication O
in O
children O
receiving O
cyclophosphamide B
, O
a O
chemotherapeutic O
alkylating O
agent O
. O

Acrolein B
is O
a O
urinary O
metabolite O
from O
cyclophosphamide B
and O
can O
induce O
hemorrhagic O
cystitis O
. O

Here O
, O
we O
investigated O
the O
effects O
and O
mechanisms O
of O
acrolein B
by O
intravesical O
instillation O
on O
urinary O
bladder O
muscle O
contractions O
and O
pathological O
alterations O
in O
rats O
. O

Acrolein B
instillation O
significantly O
increased O
the O
muscle O
contractions O
of O
rat O
bladder O
detrusor O
after O
1 O
and O
6 O
h O
but O
markedly O
decreased O
detrusor O
contractions O
after O
24 O
h O
. O

Acrolein B
increased O
phosphorylated O
protein O
kinase O
C O
( O
pan O
- O
PKC O
) O
expressions O
in O
bladders O
after O
1 O
and O
6 O
h O
but O
inhibited O
it O
after O
24 O
h O
. O

Inducible O
nitric B
oxide I
( O
NO B
) O
synthase O
( O
iNOS O
) O
protein O
expressions O
were O
markedly O
induced O
in O
bladders O
24 O
h O
after O
acrolein B
treatment O
. O

Twenty O
- O
four O
- O
hour O
acrolein B
instillation O
increased O
the O
levels O
of O
nitrite B
/ O
nitrate B
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
the O
urinary O
bladder O
. O

The O
iNOS O
inhibitors O
significantly O
inhibited O
the O
acrolein B
- O
increased O
nitrite B
/ O
nitrate B
levels O
, O
but O
not O
IL O
- O
6 O
levels O
. O

IL O
- O
6 O
- O
neutralizing O
antibodies O
effectively O
inhibited O
the O
acrolein B
- O
increased O
NOx O
levels O
. O

The O
increased O
detrusor O
contractions O
by O
1 O
- O
h O
acrolein B
treatment O
were O
significantly O
reversed O
by O
the O
PKC O
inhibitor O
RO32 O
- O
0432 O
, O
and O
the O
decreased O
detrusor O
contractions O
by O
24 O
- O
h O
acrolein B
treatment O
were O
significantly O
reversed O
by O
the O
iNOS O
inhibitor O
and O
IL O
- O
6 O
- O
neutralizing O
antibody O
. O

Both O
the O
iNOS O
inhibitor O
and O
IL O
- O
6 O
- O
neutralizing O
antibody O
effectively O
reversed O
the O
increased O
iNOS O
expression O
, O
decreased O
PKC O
phosphorylation O
, O
increased O
bladder O
weight O
, O
and O
hemorrhagic O
cystitis O
in O
rats O
24 O
h O
after O
acrolein B
treatment O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
an O
IL O
- O
6 O
- O
regulated O
iNOS O
/ O
NO B
signaling O
pathway O
participates O
in O
the O
acrolein B
- O
triggered O
detrusor O
contraction O
inhibition O
and O
hemorrhagic O
cystitis O
. O

These O
findings O
may O
help O
us O
to O
find O
a O
new O
strategy O
to O
treat O
cyclophosphamide B
- O
induced O
hemorrhagic O
cystitis O
. O

Robust O
and O
aligned O
carbon B
nanotube O
/ O
titania O
core O
/ O
shell O
films O
for O
flexible O
TCO O
- O
free O
photoelectrodes O
. O

Carbon B
nanotube O
( O
CNT O
) O
/ O
semiconducting O
oxide B
hybrids O
are O
an O
ideal O
architecture O
for O
light O
- O
harvesting O
devices O
, O
in O
which O
the O
CNTs O
are O
expected O
to O
not O
only O
act O
as O
a O
scaffold O
but O
also O
provide O
fast O
transport O
paths O
for O
photogenerated O
charges O
in O
the O
oxide B
. O

However O
, O
the O
current O
potential O
of O
CNTs O
for O
charge O
transport O
is O
largely O
suppressed O
due O
to O
the O
nanotubes O
not O
being O
interconnected O
but O
isolated O
by O
the O
low O
conductive O
oxide B
coatings O
. O

Herein O
, O
a O
flexible O
and O
conductive O
CNT O
/ O
TiO B
( I
2 I
) I
core O
/ O
shell O
heterostructure O
film O
is O
reported O
, O
with O
aligned O
and O
interconnected O
CNTs O
wrapped O
in O
a O
continuous O
TiO B
( I
2 I
) I
coating O
. O

Without O
using O
additional O
transparent O
conducting O
oxide B
( O
TCO O
) O
substrates O
, O
this O
unique O
feature O
of O
the O
film O
boosts O
the O
incident O
photon O
- O
to O
- O
electron O
conversion O
efficiency O
to O
32 O
% O
, O
outperforming O
TiO B
( I
2 I
) I
nanoparticle O
electrodes O
fabricated O
on O
TCO O
substrates O
. O

The O
core O
cysteines B
, O
( O
C909 O
) O
of O
islet O
antigen O
- O
2 O
and O
( O
C945 O
) O
of O
islet O
antigen O
- O
2 O
beta O
, O
are O
crucial O
to O
autoantibody O
binding O
in O
type O
1 O
diabetes O
. O

Cysteines B
are O
thought O
integral O
to O
conformational O
epitopes O
of O
islet O
antigen O
- O
2 O
( O
IA O
- O
2 O
) O
autoantibodies O
( O
IA O
- O
2A O
) O
, O
possibly O
through O
disulfide B
bond O
formation O
. O

We O
therefore O
investigated O
which O
cysteines B
are O
critical O
to O
IA O
- O
2A O
binding O
in O
patients O
with O
newly O
diagnosed O
type O
1 O
diabetes O
. O

All O
10 O
cysteines B
in O
the O
intracellular O
domain O
of O
IA O
- O
2 O
were O
modified O
to O
serine B
by O
site O
- O
directed O
mutagenesis O
, O
and O
the O
effects O
of O
these O
changes O
on O
autoantibody O
binding O
in O
comparison O
with O
wild O
- O
type O
control O
were O
investigated O
by O
radiobinding O
assay O
. O

Mutation O
of O
the O
protein O
tyrosine B
phosphatase O
( O
PTP O
) O
core O
cysteine B
( O
C909 O
) O
in O
IA O
- O
2 O
caused O
large O
reductions O
in O
autoantibody O
binding O
. O

In O
contrast O
, O
little O
or O
no O
reduction O
in O
binding O
was O
seen O
following O
substitution O
of O
the O
other O
cysteines B
. O

Modification O
of O
the O
core O
cysteine B
( O
C945 O
) O
in O
IA O
- O
2 O
beta O
also O
greatly O
reduced O
autoantibody O
binding O
. O

Lysine B
substitution O
of O
glutamate B
- O
836 O
in O
IA O
- O
2 O
or O
glutamate B
- O
872 O
in O
IA O
- O
2 O
beta O
resulted O
in O
modest O
reductions O
in O
binding O
and O
identified O
a O
second O
epitope O
region O
. O

Binding O
to O
IA O
- O
2 O
PTP O
and O
IA O
- O
2 O
beta O
PTP O
was O
almost O
abolished O
by O
mutation O
of O
both O
the O
core O
cysteine B
and O
these O
glutamates B
. O

The O
core O
cysteine B
is O
key O
to O
the O
major O
PTP O
conformational O
epitope O
, O
but O
disulfide O
bonding O
contributes O
little O
to O
IA O
- O
2A O
epitope O
integrity O
. O

Role O
of O
oestrogen B
receptors O
on O
the O
modulation O
of O
NADPH B
- O
diaphorase O
- O
positive O
cell O
number O
in O
supraoptic O
and O
paraventricular O
nuclei O
of O
ovariectomised O
female O
rats O
. O

Modulation O
of O
the O
nitric B
oxide I
producing O
system O
( O
demonstrated O
via O
the O
NADPH B
- O
diaphorase O
histochemical O
reaction O
) O
by O
oestradiol B
has O
been O
established O
in O
several O
structures O
of O
the O
rat O
brain O
. O

The O
present O
study O
aimed O
to O
explore O
the O
possible O
regulation O
of O
NADPH B
- O
diaphorase O
activity O
by O
oestradiol B
in O
neurones O
of O
the O
supraoptic O
( O
SON O
) O
and O
paraventricular O
( O
PVN O
) O
nuclei O
and O
the O
role O
of O
oestrogen B
receptors O
( O
ER O
alpha O
and O
ER O
beta O
) O
in O
this O
regulation O
. O

Adult O
ovariectomised O
rats O
were O
divided O
into O
six O
groups O
and O
injected O
either O
with O
vehicle O
or O
a O
single O
dose O
of O
oestradiol B
, O
a O
selective O
ER O
alpha O
agonist O
- O
PPT B
[ O
4 O
, O
4 O
' O
, O
4 O
' O
' O
- O
( O
4 O
- O
propyl O
- O
[ O
1H O
] O
- O
pyrazole O
- O
1 O
, O
3 O
, O
5 O
- O
triyl O
) O
trisphenol O
] O
, O
a O
selective O
ER O
beta O
agonist O
- O
DPN B
[ O
2 B
, I
3 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
propionitrile I
] O
, O
a O
selective O
ER O
alpha O
antagonist O
- O
MPP B
[ O
1 O
, O

The O
number O
of O
NADPH B
- O
diaphorase O
positive O
elements O
in O
the O
SON O
and O
the O
PVN O
was O
modulated O
by O
both O
ERs O
but O
, O
depending O
on O
the O
nucleus O
, O
ER O
alpha O
and O
ER O
beta O
ligands O
induced O
different O
effects O
. O

These O
results O
suggest O
that O
the O
regulation O
of O
nitrergic O
system O
by O
ERs O
may O
play O
a O
role O
in O
the O
control O
of O
oestrogen B
- O
dependent O
physiological O
mechanisms O
regulated O
by O
the O
SON O
and O
the O
PVN O
. O

In O
the O
present O
studies O
, O
dose O
- O
response O
curves O
for O
d B
- I
amphetamine I
( O
AMPH O
) O
- O
induced O
hyperlocomotion O
were O
similar O
in O
standard O
B6 O
mice O
and O
in O
the O
BTBR O
mouse O
model O
of O
autism O
. O

Estrogen B
receptor O
- O
alpha O
is O
required O
for O
the O
osteogenic O
response O
to O
mechanical O
loading O
in O
a O
ligand O
- O
independent O
manner O
involving O
its O
activation O
function O
1 O
but O
not O
2 O
. O

Estrogen B
receptor O
- O
alpha O
( O
ER O
alpha O
) O
is O
crucial O
for O
the O
adaptive O
response O
of O
bone O
to O
loading O
but O
the O
role O
of O
endogenous O
estradiol B
( O
E2 O
) O
for O
this O
response O
is O
unclear O
. O

Mechanical O
loading O
of O
transgenic O
estrogen B
response O
element O
( O
ERE O
) O
- O
luciferase O
reporter O
mice O
did O
not O
increase O
luciferase O
expression O
in O
cortical O
bone O
, O
suggesting O
that O
the O
loading O
response O
does O
not O
involve O
classical O
genomic O
ERE O
- O
mediated O
pathways O
. O

Serum O
total O
cholesterol B
and O
low O
- O
density O
lipoprotein O
cholesterol B
levels O
in O
mice O
fed O
GTE O
were O
modestly O
reduced O
, O
and O
liver O
total O
cholesterol B
level O
was O
strongly O
decreased O
in O
HFD O
plus O
GTE O
- O
fed O
mice O
compared O
to O
that O
in O
HFD O
- O
fed O
mice O
. O

Adenosine B
- I
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl B
- I
CoA I
carboxylase O
phosphorylation O
in O
liver O
from O
HFD O
plus O
GTE O
- O
fed O
mice O
was O
significantly O
elevated O
, O
and O
HMG B
- I
CoA I
reductase O
expression O
was O
also O
significantly O
decreased O
. O

Nephrogenic O
systemic O
fibrosis O
- O
like O
effects O
of O
magnetic O
resonance O
imaging O
contrast O
agents O
in O
rats O
with O
adenine B
- O
induced O
renal O
failure O
. O

Nephrogenic O
systemic O
fibrosis O
( O
NSF O
) O
is O
a O
scleroderma O
- O
like O
disease O
associated O
with O
prior O
administration O
of O
certain O
gadolinium B
chelates O
( O
GCs O
) O
. O

Firstly O
, O
after O
characterization O
of O
the O
model O
, O
male O
Wistar O
rats O
received O
a O
0 O
. O
75 O
% O
adenine B
- O
enriched O
diet O
for O
8 O
, O
14 O
, O
or O
16 O
days O
to O
obtain O
various O
degrees O
of O
renal O
failure O
. O

Secondly O
, O
the O
safety O
profile O
and O
in O
vivo O
propensity O
to O
dissociate O
of O
all O
categories O
of O
marketed O
GCs O
( O
gadoterate O
, O
gadobutrol O
, O
gadobenate O
, O
gadopentetate O
, O
and O
gadodiamide O
) O
were O
compared O
in O
rats O
receiving O
adenine B
- O
enriched O
diet O
for O
16 O
days O
. O

Total O
Gd B
concentration O
in O
tissues O
was O
measured O
by O
Inductively O
Coupled O
Plasma O
Mass O
Spectrometry O
. O

Relaxometry O
was O
used O
to O
evaluate O
the O
presence O
of O
dissociated O
Gd B
in O
skin O
and O
bone O
. O

Gadodiamide O
- O
induced O
high O
mortality O
and O
skin O
lesions O
( O
dermal O
fibrosis O
, O
calcification O
, O
and O
inflammation O
) O
were O
related O
to O
adenine B
diet O
duration O
. O

Unlike O
macrocyclic O
GCs O
, O
gadodiamide O
, O
gadopentetate O
, O
and O
gadobenate O
gradually O
increased O
the O
r O
( O
1 O
) O
relaxivity O
value O
, O
consistent O
with O
in O
vivo O
dissociation O
and O
release O
of O
soluble O
Gd B
( O
or O
, O
in O
the O
case O
of O
gadobenate O
, O
the O
consequence O
of O
protein O
binding O
) O
. O

Effects O
of O
ozone B
and O
particulate O
matter O
on O
cardiac O
mechanics O
: O
role O
of O
the O
atrial O
natriuretic O
peptide O
gene O
. O

We O
address O
these O
hypotheses O
by O
initially O
examining O
the O
exposure O
effects O
of O
ozone B
( O
O B
( I
3 I
) I
) O
and O
/ O
or O
particulate O
matter O
( O
PM O
) O
on O
cardiac O
function O
in O
C57Bl O
/ O
6J O
( O
B6 O
) O
mice O
. O

Separate O
groups O
of O
mice O
underwent O
3 O
consecutive O
days O
of O
the O
same O
exposure O
sequence O
for O
3h O
each O
consisting O
of O
the O
following O
: O
( O
1 O
) O
6h O
of O
filtered O
air O
( O
FAFA O
) O
, O
( O
2 O
) O
O B
( I
3 I
) I
then O
FA O
( O
O B
( I
3 I
) I
FA O
) O
, O
( O
3 O
) O
FA O
then O
carbon B
black I
( O
FACB O
) O
, O
or O
( O
4 O
) O
O B
( I
3 I
) I
then O
CB O
. O

For O
example O
, O
O B
( I
3 I
) I
FA O
exposure O
led O
to O
reductions O
in O
both O
end O
- O
systolic O
and O
end O
- O
diastolic O
left O
ventricular O
( O
LV O
) O
volumes O
, O
whereas O
FACB O
exposure O
led O
an O
increase O
in O
end O
- O
diastolic O
LV O
volume O
. O

These O
same O
cardiac O
compensatory O
changes O
were O
largely O
abolished O
in O
Nppa O
KO O
mice O
following O
O B
( I
3 I
) I
FA O
or O
FACB O
exposure O
. O

These O
results O
suggest O
that O
cardiac O
functional O
changes O
in O
response O
to O
air O
pollution O
exposure O
are O
strongly O
dependent O
on O
the O
pollutant O
constituents O
, O
especially O
related O
to O
O B
( I
3 I
) I
and O
/ O
or O
PM O
. O

The O
residence O
time O
of O
a O
stoichiometric O
bioscavenger O
, O
human O
butyrylcholinesteras O
( O
huBuChE O
) O
, O
in O
the O
plasma O
more O
closely O
matches O
that O
of O
VX O
than O
do O
the O
residence O
times O
of O
conventional O
therapy O
drugs O
( O
oxime B
, O
anti O
- O
muscarinic O
, O
anticonvulsant O
) O
. O

A O
combination O
of O
nerve O
agent O
therapy O
drugs O
( O
oxime B
, O
anti O
- O
muscarinic O
, O
anticonvulsant O
) O
with O
huBuChE O
( O
i O
. O
m O
. O
) O
protected O
100 O
% O
( O
8 O
/ O
8 O
) O
of O
guinea O
- O
pigs O
from O
a O
lethal O
dose O
of O
VX O
( O
0 O
. O
74mg O
/ O
kg O
) O
to O
48h O
, O
even O
when O
administered O
on O
signs O
of O
poisoning O
. O

Plasma O
concentrations O
of O
intramuscularly O
- O
administered O
atropine O
, O
diazepam B
and O
HI B
- I
6 I
reached O
a O
peak O
within O
15min O
and O
were O
eliminated O
rapidly O
within O
4h O
. O

We O
sequentially O
exposed O
cells O
to O
air O
- O
delivered O
copper B
( O
Cu B
) O
NPs O
in O
vitro O
to O
compare O
toxicity O
results O
to O
our O
prior O
in O
vivo O
inhalation O
studies O
. O

The O
evaluation O
of O
cellular O
dosimetry O
indicated O
that O
a O
large O
amount O
of O
Cu B
was O
taken O
up O
, O
dissolved O
and O
released O
into O
the O
basolateral O
medium O
( O
62 O
% O
of O
total O
mass O
) O
. O

Exposure O
to O
Cu B
NPs O
decreased O
cell O
viability O
to O
73 O
% O
( O
p O
< O
0 O
. O
01 O
) O
and O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
elevated O
levels O
of O
lactate B
dehydrogenase O
, O
intracellular O
reactive O
oxygen B
species O
and O
interleukin O
- O
8 O
that O
mirrored O
our O
findings O
from O
subacute O
in O
vivo O
inhalation O
studies O
in O
mice O
. O

The O
PARP O
inhibitor O
PJ34 B
modifies O
proliferation O
, O
NIS O
expression O
and O
epigenetic O
marks O
in O
thyroid O
cancer O
cell O
lines O
. O

Since O
PARP O
- O
1 O
is O
supposed O
to O
be O
part O
of O
a O
multimeric O
repressor O
of O
sodium B
iodide I
symporter O
( O
NIS O
) O
expression O
, O
in O
this O
study O
the O
effect O
of O
the O
PARP O
inhibitor O
PJ34 B
on O
several O
properties O
of O
thyroid O
cancer O
cell O
lines O
was O
investigated O
. O

In O
TPC1 O
, O
BCPAP O
, O
FRO O
, O
WRO O
cell O
lines O
PJ34 B
induced O
a O
strong O
increase O
in O
NIS O
mRNA O
levels O
. O

Accordingly O
, O
in O
transfection O
experiments O
performed O
in O
TPC1 O
cells O
, O
treatment O
with O
PJ34 B
increased O
NIS O
promoter O
activity O
without O
affecting O
PARP O
- O
1 O
binding O
to O
the O
promoter O
sequence O
. O

We O
also O
investigated O
the O
epigenetic O
status O
of O
NIS O
promoter O
after O
PJ34 B
treatment O
in O
TPC1 O
cell O
line O
: O
in O
addition O
to O
an O
increase O
of O
histone O
modification O
activation O
marks O
( O
H3K9K14ac O
, O
H3K4me3 O
) O
, O
surprisingly O
we O
observed O
also O
an O
increase O
of O
H3K27me3 O
, O
a O
classical O
repressive O
mark O
. O

NMDA B
receptor O
signaling O
mediates O
the O
expression O
of O
protein O
inhibitor O
of O
activated O
STAT1 O
( O
PIAS1 O
) O
in O
rat O
hippocampus O
. O

Our O
results O
revealed O
that O
pias1 O
gene O
expression O
is O
rapidly O
induced O
upon O
NMDA B
receptor O
activation O
in O
rat O
hippocampus O
, O
but O
this O
effect O
is O
blocked O
by O
transfection O
of O
sub O
- O
threshold O
concentrations O
of O
ERK1 O
siRNA O
/ O
ERK2 O
siRNA O
or O
CREB O
siRNA O
. O

But O
NMDA B
and O
MK B
- I
801 I
do O
not O
affect O
the O
expression O
of O
IL O
- O
6 O
and O
TNF O
alpha O
. O

NMDA B
also O
did O
not O
affect O
the O
expression O
of O
PIAS2 O
, O
PIAS3 O
and O
PIAS4 O
. O

These O
results O
together O
suggest O
that O
pias1 O
may O
function O
as O
an O
immediate O
early O
gene O
in O
an O
activity O
- O
dependent O
manner O
and O
PIAS1 O
expression O
is O
regulated O
by O
the O
NMDA B
- O
MAPK O
/ O
ERK O
- O
CREB O
signaling O
pathway O
implicated O
in O
neuronal O
plasticity O
. O

Thus O
, O
administration O
of O
alpha O
2 O
- O
adrenoceptor O
antagonists O
augments O
noradrenaline B
levels O
and O
provides O
an O
effective O
therapeutic O
approach O
for O
the O
treatment O
of O
depressive O
disorders O
. O

In O
previous O
studies O
, O
we O
have O
characterized O
three O
new O
synthesized O
guanidine B
and O
2 O
- O
aminoimidazoline O
aromatic O
derivatives O
( O
8b O
, O
17b O
and O
20b O
) O
as O
alpha O
2 O
- O
adrenoceptor O
antagonists O
that O
are O
able O
to O
increase O
extracellular O
concentration O
of O
noradrenaline B
in O
rat O
brain O
. O

As O
drugs O
of O
reference O
, O
fluoxetine B
induced O
a O
significant O
antidepressant O
- O
like O
effect O
in O
both O
TST O
and O
FST O
, O
while O
mirtazapine B
induced O
a O
significant O
antidepressant O
- O
like O
effect O
only O
in O
the O
FST O
. O

Tyrosine B
hydroxylase O
was O
measured O
in O
hypothalamus O
and O
VTA O
along O
with O
brown O
adipose O
tissue O
uncoupling O
protein O
1 O
. O

Human O
liver O
prolidase O
, O
a O
metal O
- O
dependent O
dipeptidase O
, O
is O
being O
tested O
as O
a O
potential O
catalytic O
bioscavenger O
against O
organophosphorus B
( O
OP O
) O
chemical O
warfare O
nerve O
agents O
. O

Here O
, O
we O
report O
that O
a O
single O
intravenous O
injection O
of O
Ad O
containing O
the O
prolidase O
gene O
with O
a O
6 O
x O
histidine B
- O
tag O
( O
Ad O
- O
prolidase O
) O
introduced O
high O
- O
levels O
of O
rHu O
prolidase O
in O
the O
circulation O
of O
mice O
which O
peaked O
on O
days O
5 O
- O
7 O
at O
159 O
+ O
/ O
- O
129U O
/ O
mL O
. O

Di O
- O
2 O
- O
ethyl O
hexyl O
phthalate O
( O
DEHP B
) O
, O
an O
industrial O
plasticizer O
and O
a O
ubiquitous O
environmental O
contaminant O
, O
is O
an O
established O
endocrine O
disruptor O
( O
ED O
) O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effects O
of O
DEHP B
on O
the O
expression O
of O
cell O
cycle O
proteins O
, O
differentiation O
markers O
, O
Runx2 O
and O
its O
co O
- O
activator O
TAZ O
in O
osteoblasts O
derived O
from O
neonatal O
rat O
calvaria O
. O

A O
significant O
decrease O
in O
protein O
levels O
of O
cyclin O
D1 O
and O
CDK O
- O
2 O
was O
found O
at O
high O
dosage O
of O
DEHP B
( O
100 O
mu O
M O
) O
after O
24h O
treatment O
. O

DEHP B
treatment O
caused O
a O
significant O
decrease O
in O
ALP O
mRNA O
. O

While O
DEHP B
treatment O
significantly O
decreased O
the O
TAZ O
at O
mRNA O
and O
protein O
levels O
, O
it O
decreased O
only O
the O
Runx2protein O
levels O
. O

Histochemical O
localization O
of O
ALP O
, O
collagen O
and O
mineralized O
nodules O
studied O
from O
cells O
treated O
with O
DEHP B
( O
10 O
and O
100 O
mu O
M O
) O
for O
21 O
days O
revealed O
a O
drastic O
decrease O
in O
collagen O
, O
ALP O
and O
mineralization O
. O

In O
conclusion O
, O
DEHP B
affected O
differentiation O
of O
neonatal O
rat O
calvarial O
osteoblasts O
and O
mineralization O
of O
matrix O
secreted O
by O
these O
cells O
. O

Fibroblast O
growth O
factor O
23 O
( O
FGF O
- O
23 O
) O
is O
known O
as O
a O
phosphaturic O
factor O
regulating O
phosphate B
homeostasis O
. O

Several O
studies O
suggest O
that O
dietary O
phosphate B
, O
serum O
phosphate B
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
[ O
1 O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
] O
are O
candidate O
regulators O
of O
FGF O
- O
23 O
. O

While O
the O
human O
studies O
, O
which O
modulated O
the O
dietary O
or O
serum O
phosphate B
showed O
in O
rather O
controversial O
results O
, O
manipulation O
of O
the O
active O
vitamin B
D I
definitely O
affected O
FGF O
- O
23 O
in O
animals O
. O

This O
study O
was O
conducted O
to O
elucidate O
the O
relationship O
between O
active O
vitamin B
D I
directly O
stimulated O
by O
ultraviolet O
B O
( O
UVB O
) O
exposure O
and O
FGF O
- O
23 O
level O
in O
human O
. O

Serum O
calcium B
, O
phosphate B
, O
mineral O
- O
related O
hormones O
and O
bone O
turnover O
markers O
were O
analyzed O
before O
and O
after O
the O
UVB O
exposure O
every O
4 O
week O
for O
12 O
whole O
weeks O
. O

Purinergic O
receptor O
antagonist O
a438079 O
protects O
against O
acetaminophen B
- O
induced O
liver O
injury O
by O
inhibiting O
p450 O
isoenzymes O
, O
not O
by O
inflammasome O
activation O
. O

Acetaminophen B
( O
APAP B
) O
overdose O
is O
the O
most O
frequent O
cause O
of O
acute O
liver O
failure O
in O
the O
western O
world O
. O

A O
recent O
study O
suggested O
that O
the O
purinergic O
receptor O
antagonist O
A438079 O
protects O
against O
APAP B
- O
induced O
liver O
injury O
by O
preventing O
the O
activation O
of O
the O
Nalp3 O
inflammasome O
in O
Kupffer O
cells O
and O
thereby O
preventing O
inflammatory O
injury O
. O

To O
test O
the O
hypothesis O
that O
A438079 O
actually O
affects O
the O
intracellular O
signaling O
events O
in O
hepatocytes O
, O
C57Bl O
/ O
6 O
mice O
were O
treated O
with O
APAP B
( O
300 O
mg O
/ O
kg O
) O
and O
A438079 O
( O
80 O
mg O
/ O
kg O
) O
or O
saline O
and O
GSH B
depletion O
, O
protein O
adduct O
formation O
, O
c O
- O
jun O
- O
N B
- O
terminal O
kinase O
( O
JNK O
) O
activation O
, O
oxidant O
stress O
, O
and O
liver O
cell O
necrosis O
were O
determined O
between O
0 O
and O
6 O
h O
after O
APAP B
administration O
. O

APAP B
caused O
rapid O
GSH B
depletion O
, O
extensive O
protein O
adduct O
formation O
in O
liver O
homogenates O
and O
in O
mitochondria O
, O
JNK O
phosphorylation O
and O
mitochondrial O
translocation O
of O
phospho O
- O
JNK O
within O
2 O
h O
, O
oxidant O
stress O
, O
and O
extensive O
centrilobular O
necrosis O
at O
6 O
h O
. O

A438079 O
significantly O
attenuated O
GSH B
depletion O
, O
which O
resulted O
in O
a O
50 O
% O
reduction O
of O
total O
liver O
and O
mitochondrial O
protein O
adducts O
and O
substantial O
reduction O
of O
JNK O
activation O
, O
mitochondrial O
P O
- O
JNK O
translocation O
, O
oxidant O
stress O
, O
and O
liver O
injury O
. O

A438079 O
did O
not O
directly O
affect O
JNK O
activation O
induced O
by O
tert B
- I
butyl I
hydroperoxide I
and O
GSH B
depletion O
. O

Thus O
, O
the O
protective O
effect O
of O
A438079 O
against O
APAP B
hepatotoxicity O
in O
vivo O
can O
be O
explained O
by O
its O
effect O
on O
metabolic O
activation O
and O
cell O
death O
pathways O
in O
hepatocytes O
without O
involvement O
of O
the O
Nalp3 O
inflammasome O
. O

Protective O
roles O
of O
single O
- O
wall O
carbon B
nanotubes O
in O
ultrasonication O
- O
induced O
DNA O
base O
damage O
. O

The O
overall O
level O
of O
ultrasonication O
- O
induced O
DNA O
damage O
is O
reduced O
in O
the O
presence O
of O
single O
- O
wall O
carbon B
nanotubes O
( O
SWCNTs O
) O
, O
particularly O
for O
DNA O
lesions O
formed O
by O
one O
- O
electron O
reduction O
of O
intermediate O
radicals O
. O

The O
protective O
role O
of O
SWCNTs O
observed O
in O
this O
work O
suggests O
a O
contrary O
view O
to O
the O
general O
idea O
that O
carbon B
nanotubes O
have O
damaging O
effects O
on O
biomolecules O
. O

Polymer O
grafting O
to O
single O
- O
walled O
carbon B
nanotubes O
: O
effect O
of O
chain O
length O
on O
solubility O
, O
graft O
density O
and O
mechanical O
properties O
of O
macroscopic O
structures O
. O

Single O
- O
walled O
carbon B
nanotubes O
are O
grafted O
with O
polystyrene B
chains O
employing O
a O
graft O
- O
to O
protocol O
. O

Withaferin O
A O
- O
stimulated O
Ca2 B
+ I
entry O
, O
ceramide O
formation O
and O
suicidal O
death O
of O
erythrocytes O
. O

Withaferin O
A O
, O
a O
triterpenoid B
component O
from O
Withania O
somnifera O
, O
counteracts O
malignancy O
, O
an O
effect O
attributed O
to O
stimulation O
of O
apoptosis O
. O

Erythrocytes O
lack O
mitochondria O
and O
nuclei O
but O
may O
enter O
apoptosis O
- O
like O
eryptosis O
, O
a O
suicidal O
cell O
death O
characterized O
by O
cell O
shrinkage O
and O
cell O
membrane O
scrambling O
with O
phosphatidylserine B
exposure O
at O
the O
cell O
surface O
. O

Triggers O
of O
eryptosis O
include O
increase O
of O
cytosolic O
Ca B
( I
2 I
+ I
) I
- O
activity O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
following O
activation O
of O
oxidant O
- O
sensitive O
Ca B
( I
2 I
+ I
) I
- O
permeable O
cation O
channels O
, O
ceramide O
formation O
and O
/ O
or O
ATP B
- O
depletion O
. O

To O
this O
end O
, O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
was O
estimated O
from O
Fluo3 O
- O
fluorescence O
, O
cell O
volume O
from O
forward O
scatter O
, O
phosphatidylserine B
exposure O
from O
annexin O
- O
V O
- O
binding O
, O
hemolysis O
from O
hemoglobin O
release O
, O
oxidative O
stress O
from O
DCFDA O
- O
fluorescence O
and O
ceramide O
abundance O
utilizing O
antibodies O
. O

A O
48 O
h O
exposure O
to O
withaferin O
A O
significantly O
decreased O
forward O
scatter O
( O
at O
> O
= O
10 O
mu O
M O
withaferin O
concentration O
) O
and O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
( O
> O
= O
5 O
mu O
M O
) O
, O
ROS O
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
ceramide O
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
as O
well O
as O
annexin O
- O
V O
- O
binding O
( O
> O
= O
5 O
mu O
M O
) O
. O

Extracellular O
Ca B
( I
2 I
+ I
) I
removal O
, O
amiloride B
, O
and O
the O
antioxidant O
N B
- I
acetyl I
- I
l I
- I
cysteine I
significantly O
blunted O
withaferin O
A O
- O
triggered O
annexin O
- O
V O
- O
binding O
. O

Eco O
- O
biological O
treatments O
, O
with O
plant O
- O
derived O
substances O
, O
or O
phytochemicals O
, O
e O
. O
g O
. O
curcumin B
and O
resveratrol B
, O
and O
pre O
- O
, O
pro O
- O
and O
syn O
- O
biotics O
offers O
similar O
effects O
as O
use O
of O
biologicals O
, O
although O
milder O
but O
also O
free O
from O
adverse O
effects O
. O

Aryl O
methylcarbamates O
: O
Potency O
and O
selectivity O
towards O
wild O
- O
type O
and O
carbamate B
- O
insensitive O
( O
G119S O
) O
Anopheles O
gambiae O
acetylcholinesterase O
, O
and O
toxicity O
to O
G3 O
strain O
An O
. O
gambiae O
. O

New O
carbamates B
that O
are O
highly O
selective O
for O
inhibition O
of O
Anopheles O
gambiae O
acetylcholinesterase O
( O
AChE O
) O
over O
the O
human O
enzyme O
might O
be O
useful O
in O
continuing O
efforts O
to O
limit O
malaria O
transmission O
. O

In O
this O
report O
we O
assessed O
34 O
synthesized O
and O
commercial O
carbamates B
for O
their O
selectivity O
to O
inhibit O
the O
AChEs O
found O
in O
carbamate B
- O
susceptible O
( O
G3 O
) O
and O
carbamate B
- O
resistant O
( O
Akron O
) O
An O
. O
gambiae O
, O
relative O
to O
human O
AChE O
. O

Excellent O
correspondence O
is O
seen O
between O
inhibition O
potencies O
measured O
with O
carbamate B
- O
susceptible O
mosquito O
homogenate O
and O
purified O
recombinant O
wild O
- O
type O
( O
WT O
) O
An O
. O
gambiae O
AChE O
( O
AgAChE O
) O
. O

Similarly O
, O
excellent O
correspondence O
is O
seen O
between O
inhibition O
potencies O
measured O
with O
carbamate B
- O
resistant O
mosquito O
homogenate O
and O
purified O
recombinant O
G119S O
AgAChE O
, O
consistent O
with O
our O
earlier O
finding O
that O
the O
Akron O
strain O
carries O
the O
G119S O
mutation O
. O

Although O
high O
( O
100 O
- O
to O
500 O
- O
fold O
) O
WT O
An O
. O
gambiae O
vs O
human O
selectivity O
is O
observed O
for O
several O
compounds O
, O
none O
of O
the O
carbamates B
tested O
potently O
inhibits O
the O
G119S O
mutant O
enzyme O
. O

Finally O
, O
we O
describe O
a O
predictive O
model O
for O
WT O
An O
. O
gambiae O
tarsal O
contact O
toxicity O
of O
the O
carbamates B
that O
relies O
on O
inhibition O
potency O
, O
molecular O
volume O
, O
and O
polar O
surface O
area O
. O

X O
- O
linked O
hypophosphatemia O
( O
XLH O
/ O
HYP O
) O
- O
with O
renal O
phosphate B
wasting O
, O
hypophosphatemia O
, O
osteomalacia O
, O
and O
tooth O
abscesses O
- O
is O
caused O
by O
mutations O
in O
the O
zinc B
- O
metallopeptidase O
PHEX O
gene O
( O
phosphate B
- O
regulating O
gene O
with O
homologies O
to O
endopeptidase O
on O
the O
X O
chromosome O
) O
. O

Inactivating O
mutations O
in O
PHEX O
lead O
to O
distal O
renal O
effects O
( O
implying O
accumulation O
of O
a O
secreted O
, O
circulating O
phosphaturic O
factor O
) O
and O
accumulation O
in O
bone O
and O
teeth O
of O
mineralization O
- O
inhibiting O
, O
acidic O
serine B
- O
and O
aspartate B
- O
rich O
motif O
( O
ASARM O
) O
- O
containing O
peptides O
, O
which O
are O
proteolytically O
derived O
from O
the O
mineral O
- O
binding O
matrix O
proteins O
of O
the O
SIBLING O
family O
( O
small O
, O
integrin O
- O
binding O
ligand O
N B
- O
linked O
glycoproteins O
) O
. O

Valproic B
acid I
but O
not O
D O
- O
cycloserine O
facilitates O
sleep O
- O
dependent O
offline O
learning O
of O
extinction O
and O
habituation O
of O
conditioned O
fear O
in O
humans O
. O

The O
effectiveness O
of O
D O
- O
cycloserine O
( O
DCS O
) O
, O
an O
N O
- O
methyl O
- O
D O
- O
aspartate O
glutamate O
receptor O
partial O
agonist O
, O
and O
valproic B
acid I
( O
VPA B
) O
, O
a O
histone O
deacetylase O
inhibitor O
, O
in O
facilitating O
the O
extinction O
of O
fear O
- O
conditioned O
memory O
has O
been O
explored O
in O
humans O
and O
animals O
. O

Here O
, O
we O
confirmed O
whether O
DCS O
( O
100 O
mg O
) O
and O
VPA B
( O
400 O
mg O
) O
act O
in O
off O
- O
line O
learning O
processes O
during O
sleep O
or O
waking O
, O
for O
further O
clinical O
application O
to O
anxiety O
disorders O
and O
posttraumatic O
stress O
disorder O
( O
PTSD O
) O
. O

Newly O
acquired O
conditioned O
fear O
was O
also O
eliminated O
or O
habituated O
by O
DCS O
and O
VPA B
administration O
, O
in O
line O
with O
previous O
findings O
. O

Furthermore O
, O
VPA B
facilitated O
the O
off O
- O
line O
learning O
process O
of O
conditioned O
fear O
extinction O
and O
habituation O
during O
sleep O
, O
while O
DCS O
facilitated O
this O
process O
during O
waking O
. O

These O
novel O
findings O
suggest O
that O
DCS O
and O
VPA B
might O
enhance O
exposure O
- O
based O
cognitive O
therapy O
for O
anxiety O
disorders O
and O
PTSD O
by O
reducing O
the O
vulnerability O
to O
reinstatement O
and O
preventing O
relapses O
of O
fear O
- O
conditioned O
responses O
, O
and O
provide O
evidence O
for O
a O
peculiarity O
of O
the O
sleep O
- O
dependent O
off O
- O
line O
learning O
process O
for O
conditioned O
fear O
extinction O
. O

Acute O
effects O
of O
caffeine B
on O
attention O
: O
a O
comparison O
of O
non O
- O
consumers O
and O
withdrawn O
consumers O
. O

Despite O
the O
large O
number O
of O
studies O
on O
caffeine B
and O
attention O
, O
interpretation O
is O
often O
difficult O
because O
of O
methodological O
weaknesses O
. O

This O
methodology O
was O
used O
to O
examine O
whether O
effects O
of O
caffeine B
( O
a O
dose O
of O
2 O
mg O
/ O
kg O
) O
could O
be O
explained O
in O
terms O
of O
reversal O
of O
the O
effects O
of O
caffeine B
withdrawal O
. O

In O
contrast O
, O
the O
caffeine B
challenge O
carried O
out O
on O
Day O
8 O
showed O
that O
ingestion O
of O
caffeine B
was O
associated O
with O
faster O
simple O
reaction O
time O
, O
fewer O
long O
responses O
, O
greater O
detection O
of O
targets O
in O
the O
cognitive O
vigilance O
task O
, O
and O
faster O
encoding O
of O
new O
information O
. O

These O
results O
suggest O
that O
it O
is O
important O
to O
continue O
to O
investigate O
mechanisms O
underlying O
these O
effects O
of O
caffeine B
and O
to O
further O
evaluate O
the O
practical O
implications O
of O
such O
effects O
. O

Neurotoxic O
potential O
of O
iron B
oxide I
nanoparticles O
in O
the O
rat O
brain O
striatum O
and O
hippocampus O
. O

It O
has O
recently O
been O
reported O
that O
iron B
oxide I
nanoparticles O
( O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
, O
30 O
nm O
) O
have O
the O
ability O
to O
translocate O
directly O
from O
the O
olfactory O
nerve O
to O
the O
brain O
. O

Therefore O
, O
it O
is O
critical O
to O
evaluate O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
and O
their O
potential O
to O
confer O
striatum O
and O
hippocampus O
neurotoxicity O
. O

This O
study O
focuses O
on O
the O
effects O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
on O
the O
striatum O
and O
hippocampus O
, O
including O
oxidative O
injury O
and O
the O
accumulation O
and O
retention O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
. O

This O
study O
also O
explores O
the O
molecular O
mechanism O
of O
oxidative O
damage O
in O
dopaminergic O
neurons O
; O
we O
were O
able O
to O
assess O
the O
neurotoxic O
effects O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
by O
incubating O
dopaminergic O
neurons O
with O
radioactive O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
. O

A O
regional O
distribution O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
was O
observed O
in O
rat O
brains O
after O
the O
particles O
were O
intranasally O
instilled O
for O
seven O
days O
. O

Over O
half O
of O
the O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
were O
retained O
in O
the O
striata O
for O
a O
minimum O
of O
14 O
days O
, O
and O
may O
have O
induced O
oxidative O
damage O
to O
the O
region O
. O

These O
in O
vitro O
studies O
demonstrate O
that O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
may O
decrease O
neuron O
viability O
, O
trigger O
oxidative O
stress O
, O
and O
activate O
JNK O
- O
and O
p53 O
- O
mediated O
pathways O
to O
regulate O
the O
cell O
cycle O
and O
apoptosis O
. O

These O
results O
also O
suggest O
that O
environmental O
exposure O
to O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
may O
play O
a O
role O
in O
the O
development O
of O
neurodegenerative O
diseases O
. O

Epothilones O
are O
a O
new O
group O
of O
compounds O
with O
action O
mechanisms O
similar O
to O
taxanes B
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
epothilone O
A O
( O
Epo O
A O
) O
and O
epothilone O
B O
( O
Epo O
B O
) O
on O
ovarian O
cancer O
cell O
line O
SKOV O
- O
3 O
with O
those O
of O
paclitaxel B
( O
PTX B
) O
, O
a O
classic O
taxane B
. O

Apoptotic O
and O
necrotic O
cell O
levels O
were O
measured O
by O
double O
staining O
with O
Hoechst B
33258 I
and O
propidium B
iodide I
( O
PI O
) O
as O
well O
as O
Annexin O
V O
staining O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo O
A O
, O
Epo O
B O
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH O
( O
2 O
) O
- O
DA O
( O
2 O
' O
, O
7 O
' O
- O
dichlorodihydrofluor O
diacetate O
) O
and O
JC O
- O
1 O
( O
5 O
, O
5 O
' O
, O
6 O
, O
6 O
' O
- O
tetrachloro O
- O
1 O
, O
1 O
' O
, O
3 O
, O
3 O
' O
- O
tetraethylbenzimidaz O
) O
. O

The O
cytotoxic O
activity O
of O
the O
drugs O
was O
determined O
by O
the O
MTT B
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
diphenyltetrazolium I
bromide I
) O
test O
. O

All O
probes O
were O
analyzed O
in O
both O
the O
presence O
and O
absence O
of O
the O
antioxidant O
N B
- I
acetylcysteine I
( O
NAC B
) O
. O

The O
results O
obtained O
demonstrated O
that O
the O
antiproliferative O
capacity O
of O
Epo O
A O
and O
Epo O
B O
in O
SKOV O
- O
3 O
cell O
line O
( O
measured O
as O
IC O
( O
50 O
) O
after O
72 O
h O
continuous O
treatment O
) O
was O
six O
and O
five O
times O
greater O
than O
that O
of O
PTX B
' O
s O
respectively O
. O

Apoptotic O
and O
necrotic O
events O
were O
partially O
blocked O
by O
NAC B
, O
indicating O
ROS O
played O
a O
substantial O
role O
in O
epothilone O
- O
induced O
apoptosis O
. O

Cell O
death O
was O
also O
associated O
with O
a O
decrease O
in O
mitochondrial O
membrane O
potential O
, O
which O
was O
more O
pronounced O
after O
treatment O
with O
epothilones O
as O
compared O
to O
paclitaxel B
. O

Proniosomes O
were O
prepared O
by O
film O
deposition O
on O
carrier O
' O
s O
method O
using O
various O
molar O
ratios O
of O
nonionic O
surfactants O
such O
as O
span20 O
, O
span40 O
, O
span60 O
, O
and O
span80 O
with O
cholesterol B
as O
membrane O
stabilizing O
agent O
and O
dicetylphosphate O
as O
a O
charge O
inducer O
. O

Combination O
of O
beta B
- I
cyclodextrin I
inclusion O
complex O
and O
self O
- O
microemulsifying O
drug O
delivery O
system O
for O
photostability O
and O
enhanced O
oral O
bioavailability O
of O
methotrexate B
: O
novel O
technique O
. O

In O
the O
present O
study O
, O
we O
prepared O
an O
inclusion O
complex O
of O
methotrexate B
( O
MTX B
) O
with O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
in O
order O
to O
decrease O
its O
photosensitivity O
and O
enhance O
its O
aqueous O
solubility O
. O

The O
proper O
molecular O
ratio O
of O
MTX B
/ O
beta B
- I
CD I
was O
found O
to O
be O
of O
1 O
: O
7 O
, O
and O
the O
water O
- O
solubility O
of O
MTX B
was O
increased O
in O
an O
average O
of O
10 O
- O
fold O
. O

The O
photostability O
studies O
showed O
that O
the O
MTX B
became O
stable O
on O
exposure O
to O
light O
. O

Construction O
of O
pseudoternary O
diagrams O
were O
investigated O
to O
prepare O
a O
MTX B
/ O
beta B
- I
CD I
inclusion O
complex O
loaded O
SMEDDS O
which O
was O
characterized O
by O
measuring O
the O
particle O
size O
and O
the O
zeta O
- O
potential O
. O

The O
optimum O
formulation O
of O
SMEDDS O
was O
a O
system O
consisting O
of O
ethyl O
oleate O
, O
tween B
80 I
, O
and O
propylene B
glycol I
with O
a O
mean O
droplet O
size O
of O
39 O
. O
42 O
nm O
. O

In O
vitro O
drug O
release O
in O
different O
pH O
media O
showed O
that O
the O
release O
profile O
of O
MTX B
from O
the O
MTX B
/ O
beta B
- I
CD I
loaded O
SMEDDS O
was O
influenced O
by O
the O
pH O
of O
the O
release O
medium O
and O
presented O
the O
characteristics O
of O
a O
sustained O
release O
profile O
. O

Finally O
, O
in O
- O
vivo O
studies O
showed O
an O
enhancement O
of O
the O
bioavailability O
of O
MTX B
from O
the O
MTX B
/ O
beta B
- I
CD I
loaded O
SMEDDS O
form O
of O
1 O
. O
57 O
- O
fold O
. O

We O
concluded O
that O
the O
beta B
- I
CD I
inclusion O
complex O
loaded O
SMEDDS O
improved O
the O
chemical O
and O
physiological O
properties O
of O
MTX B
and O
could O
be O
a O
promising O
means O
for O
the O
delivery O
of O
MTX B
and O
other O
unstable O
and O
lipophilic O
drugs O
by O
oral O
route O
. O

proteinase O
, O
disintegrin O
- O
like O
and O
cysteine B
- O
rich O
domain O
structure O
. O

The O
active O
site O
of O
the O
metalloproteinase O
domain O
has O
a O
consensus O
HEXXHXXGXXHD O
sequence O
and O
a O
Met B
- O
turn O
. O

The O
" O
Met B
- O
turn O
" O
structure O
contains O
a O
conserved O
Met B
residue O
that O
forms O
a O
hydrophobic O
basement O
for O
the O
three O
zinc B
- O
binding O
histidines O
in O
the O
consensus O
sequence O
. O

Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid B
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti O
- O
inflammatory O
and O
anti O
- O
angiogenic O
activities O
. O

Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
and O
p70 O
- O
S6 O
kinase O
( O
p70S6K O
) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK1 O
/ O
2 O
) O
and O
p38 O
involved O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
signaling O
pathway O
. O

In O
this O
study O
, O
we O
investigated O
the O
potential O
of O
water O
extracts O
from O
three O
Hypericum O
sps O
. O
and O
some O
of O
their O
main O
phenolic B
compounds O
to O
prevent O
and O
repair O
oxidative O
and O
alkylating O
DNA O
damage O
in O
colon O
cells O
. O

The O
results O
showed O
that O
water O
extracts O
of O
Hypericum O
perforatum O
, O
Hypericum O
androsaemum O
, O
Hypericum O
undulatum O
, O
quercetin B
and O
rutin B
have O
protective O
effect O
against O
oxidative O
DNA O
damage O
in O
HT29 O
cells O
. O

Protective O
effect O
was O
also O
observed O
against O
alkylating O
DNA O
damage O
induced O
by O
methyl B
- I
methanesulfonate I
, O
except O
for O
H O
. O
androsaemum O
. O

With O
regard O
to O
alkylating O
damage O
repair O
H O
. O
perforatum O
, O
H O
. O
androsaemum O
and O
chlorogenic B
acid I
increased O
repair O
of O
alkylating O
DNA O
damage O
by O
base O
excision O
repair O
pathway O
. O

No O
effect O
was O
observed O
on O
nucleotide B
excision O
repair O
pathway O
. O

Antigenotoxic O
effects O
of O
Hypericum O
sps O
. O
may O
contribute O
to O
colon O
cancer O
prevention O
and O
the O
high O
amount O
of O
phenolic B
compounds O
present O
in O
Hypericum O
sps O
. O
play O
an O
important O
role O
in O
DNA O
protective O
effects O
. O

Ion O
disturbance O
and O
clustering O
in O
the O
NaCl B
water O
solutions O
. O

Ion O
clustering O
and O
the O
solvation O
properties O
in O
the O
NaCl B
solutions O
are O
explored O
by O
molecular O
dynamics O
simulations O
with O
several O
popular O
force O
fields O
. O

The O
existence O
of O
ions O
has O
a O
negligible O
disturbance O
to O
the O
hydrogen B
bond O
structures O
and O
rotational O
mobility O
of O
water O
beyond O
the O
first O
ion O
solvation O
shells O
, O
which O
is O
suggested O
by O
the O
local O
hydrogen B
bond O
structures O
and O
the O
rotation O
times O
of O
water O
. O

The O
effect O
of O
varying O
the O
surfactant O
and O
solvent O
medium O
on O
the O
dynamics O
of O
spin O
- O
lattice O
relaxation O
in O
photoexcited O
Fe3O4 B
nanocrystals O
has O
been O
investigated O
by O
measuring O
the O
time O
- O
dependent O
magnetization O
employing O
pump O
- O
probe O
transient O
Faraday O
rotation O
technique O
. O

The O
variation O
of O
the O
surfactants O
having O
surface O
- O
binding O
functional O
groups O
modified O
not O
only O
the O
static O
magnetization O
but O
also O
the O
dynamics O
of O
the O
recovery O
of O
the O
magnetization O
occurring O
via O
spin O
- O
lattice O
relaxation O
in O
the O
photoexcited O
Fe3O4 B
nanocrystals O
. O

A O
novel O
, O
potent O
, O
and O
selective O
inhibitor O
of O
cardiac O
late O
sodium B
current O
suppresses O
experimental O
arrhythmias O
. O

Inhibition O
of O
cardiac O
late O
sodium B
current O
( O
late O
I O
( O
Na B
) O
) O
is O
a O
strategy O
to O
suppress O
arrhythmias O
and O
sodium B
- O
dependent O
calcium B
overload O
associated O
with O
myocardial O
ischemia O
and O
heart O
failure O
. O

Current O
inhibitors O
of O
late O
I O
( O
Na B
) O
are O
unselective O
and O
can O
be O
proarrhythmic O
. O

This O
study O
introduces O
GS967 O
( O
6 O
- O
[ O
4 O
- O
( O
trifluoromethoxy O
) O
phenyl O
] O
- O
3 O
- O
( O
trifluoromethyl O
) O
- O
[ O
1 O
, O
2 O
, O
4 O
] O
triazolo O
[ O
4 O
, O
3 O
- O
a O
] O
pyridine O
) O
, O
a O
potent O
and O
selective O
inhibitor O
of O
late O
I O
( O
Na B
) O
, O
and O
demonstrates O
its O
effectiveness O
to O
suppress O
ventricular O
arrhythmias O
. O

GS967 O
inhibited O
Anemonia O
sulcata O
toxin O
II O
( O
ATX O
- O
II O
) O
- O
induced O
late O
I O
( O
Na B
) O
in O
ventricular O
myocytes O
and O
isolated O
hearts O
with O
IC O
( O
50 O
) O
values O
of O
0 O
. O
13 O
and O
0 O
. O
21 O
micro O
M O
, O
respectively O
. O

Reduction O
of O
peak O
I O
( O
Na B
) O
by O
GS967 O
was O
minimal O
at O
a O
holding O
potential O
of O
- O
120 O
mV O
but O
increased O
at O
- O
80 O
mV O
. O

GS967 O
prevented O
and O
reversed O
proarrhythmic O
effects O
( O
afterdepolarizations O
and O
torsades O
de O
pointes O
) O
of O
the O
late O
I O
( O
Na B
) O
enhancer O
ATX O
- O
II O
and O
the O
I O
( O
Kr O
) O
inhibitor O
E O
- O
4031 O
in O
isolated O
ventricular O
myocytes O
and O
hearts O
. O

GS967 O
was O
more O
potent O
and O
effective O
to O
reduce O
late O
I O
( O
Na B
) O
and O
arrhythmias O
than O
either O
flecainide O
or O
ranolazine O
. O

Results O
of O
all O
studies O
and O
assays O
of O
binding O
and O
activity O
of O
GS967 O
at O
numerous O
receptors O
, O
transporters O
, O
and O
enzymes O
indicated O
that O
GS967 O
selectively O
inhibited O
late O
I O
( O
Na B
) O
. O

In O
summary O
, O
GS967 O
selectively O
suppressed O
late O
I O
( O
Na B
) O
and O
prevented O
and O
/ O
or O
reduced O
the O
incidence O
of O
experimentally O
induced O
arrhythmias O
in O
rabbit O
myocytes O
and O
hearts O
. O

The O
cationic O
polymer O
polyethylenimine B
( O
PEI B
) O
or O
the O
cationic O
lipid O
oleylamine B
( O
OAM O
) O
were O
added O
to O
monoolein O
( O
MO O
) O
- O
based O
systems O
in O
different O
concentrations O
, O
and O
after O
dispersion O
in O
aqueous O
medium O
, O
liquid O
crystalline O
phase O
nanodispersions O
were O
obtained O
and O
characterized O
by O
their O
physicochemical O
properties O
. O

Then O
, O
in O
vitro O
penetration O
studies O
using O
diffusion O
cell O
and O
pig O
ear O
skin O
were O
carried O
out O
to O
evaluate O
the O
effect O
of O
the O
nanodispersions O
on O
the O
skin O
penetration O
of O
siRNA O
; O
based O
on O
these O
results O
, O
the O
nanodispersions O
containing O
MO O
/ O
OA O
/ O
PEI B
/ O
aqueous O
phase O
( O
8 O
: O
2 O
: O
5 O
: O
85 O
, O
w O
/ O
w O
/ O
w O
/ O
w O
) O
and O
MO O
/ O
OA O
/ O
OAM O
/ O
aqueous O
phase O
( O
8 O
: O
2 O
: O
2 O
: O
88 O
, O
w O
/ O
w O
/ O
w O
/ O
w O
) O
were O
selected O
. O

The O
in O
vivo O
liver O
toxicity O
of O
Artemisia O
dracunculus O
was O
assessed O
in O
the O
blood O
of O
mice O
treated O
orally O
with O
the O
extract O
of O
the O
herb O
, O
using O
alanine B
aminotransferase O
( O
ALT O
) O
and O
aspartate B
aminotransferase O
( O
AST O
) O
as O
liver O
function O
indicators O
. O

Liver O
morphology O
was O
assessed O
using O
hematoxylin B
and O
eosin B
( O
HE O
) O
staining O
of O
liver O
tissue O
. O

Transgenic O
mice O
lacking O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
and O
breast O
cancer O
resistance O
protein O
( O
Bcrp O
) O
were O
used O
to O
study O
efflux O
of O
erlotinib B
at O
the O
BBB O
. O

A O
U87 O
rat O
xenograft O
model O
of O
GBM O
was O
used O
to O
investigate O
the O
regional O
distribution O
of O
erlotinib B
to O
the O
tumor O
, O
and O
brain O
regions O
surrounding O
the O
tumor O
. O

The O
effect O
of O
concurrent O
administration O
of O
elacridar O
on O
regional O
tumor O
distribution O
of O
erlotinib B
was O
evaluated O
. O

We O
show O
that O
erlotinib B
transport O
across O
an O
intact O
BBB O
is O
significantly O
restricted O
due O
to O
P O
- O
gp O
- O
and O
Bcrp O
- O
mediated O
efflux O
transport O
. O

We O
then O
show O
that O
the O
BBB O
is O
sufficiently O
intact O
in O
areas O
of O
brain O
adjacent O
to O
the O
tumor O
core O
to O
significantly O
restrict O
erlotinib B
delivery O
. O

Inhibition O
of O
P O
- O
gp O
and O
Bcrp O
by O
the O
dual O
inhibitor O
elacridar O
dramatically O
increased O
erlotinib B
delivery O
to O
the O
tumor O
core O
, O
rim O
, O
and O
normal O
brain O
. O

Phenolics B
profiles O
of O
olive O
fruits O
( O
Olea O
europaea O
L O
. O
) O
and O
oils O
from O
Ayval O
i O
k O
, O
Domat O
and O
Gemlik O
varieties O
at O
different O
ripening O
stages O
. O

Phenolic B
compounds O
in O
olive O
fruit O
and O
oils O
obtained O
from O
Ayval O
i O
k O
, O
Domat O
and O
Gemlik O
olive O
varieties O
collected O
at O
different O
ripening O
periods O
were O
evaluated O
by O
High O
Performance O
Liquid O
Chromatography O
( O
HPLC O
) O
. O

Gallic B
acid I
and O
p O
- O
cumaric O
acid O
were O
identified O
for O
Ayval O
i O
k O
and O
Domat O
at O
each O
period O
of O
ripening O
, O
respectively O
. O

In O
addition O
, O
gallic B
acid I
, O
p O
- O
cumaric O
acid O
, O
sinapinic O
and O
apigenin O
acids O
were O
detected O
in O
Gemlik O
olive O
fruit O
. O

Hydroxytyrosol B
, O
rutin B
, O
oleoropein O
, O
luteolin B
, O
tyrosol B
, O
vanilic O
acid O
and O
gallic B
acid I
in O
Ayval O
i O
k O
olive O
fruit O
in O
all O
ripening O
periods O
were O
determined O
. O

Luteolin B
contents O
of O
olive O
oils O
ranged O
at O
the O
levels O
between O
0 O
. O
12 O
to O
2 O
. O
28mg O
/ O
kg O
. O

Vanillic B
acid I
contents O
of O
oils O
ranged O
between O
0 O
. O
08 O
to O
2 O
. O
38mg O
/ O
kg O
. O

The O
total O
solids O
, O
a O
( O
w O
) O
value O
, O
total O
phenolics B
, O
vitamin B
C I
, O
antioxidant O
activity O
, O
anthocyanin B
content O
, O
total O
colour O
change O
and O
firmness O
were O
used O
as O
quality O
indicators O
of O
dried O
sour O
cherry O
. O

Under O
these O
optimal O
conditions O
, O
the O
predicted O
amount O
of O
total O
phenolics B
was O
744mg O
CAE O
/ O
100 O
dw O
, O
vitamin B
C I
1 O
. O
44mg O
/ O
100g O
per O
dry O
weight O
( O
g O
dw O
) O
, O
anthocyanin B
content O
125mg O
/ O
100g O
dw O
, O
IC O
( O
50 O
) O
3 O
. O
23mg O
/ O
ml O
, O
total O
solids O
70 O
. O
72 O
% O
, O
a O
( O
w O
) O
value O
0 O
. O
646 O
, O
total O
colour O
change O
52 O
. O
61 O
and O
firmness O
3395 O
. O
4g O
. O

Occurrence O
of O
ochratoxin B
A I
in O
cocoa O
by O
- O
products O
and O
determination O
of O
its O
reduction O
during O
chocolate O
manufacture O
. O

This O
work O
reports O
an O
investigation O
carried O
out O
to O
assess O
the O
natural O
occurrence O
of O
ochratoxin B
A I
in O
168 O
samples O
from O
different O
fractions O
obtained O
during O
the O
technological O
processing O
of O
cocoa O
( O
shell O
, O
nibs O
, O
liquor O
, O
butter O
, O
cake O
and O
cocoa O
powder O
) O
and O
the O
reduction O
of O
ochratoxin B
A I
during O
chocolate O
manufacture O
. O

Ochratoxin B
A I
analyses O
were O
performed O
with O
immunoaffinity O
columns O
and O
detection O
by O
high O
performance O
liquid O
chromatography O
. O

Concerning O
the O
natural O
ochratoxin B
A I
contamination O
in O
cocoa O
by O
- O
products O
, O
the O
highest O
levels O
of O
ochratoxin B
A I
were O
found O
in O
the O
shell O
, O
cocoa O
powder O
and O
cocoa O
cake O
. O

The O
cocoa O
butter O
was O
the O
least O
contaminated O
, O
showing O
that O
ochratoxin B
A I
seems O
to O
remain O
in O
the O
defatted O
cocoa O
solids O
. O

Under O
the O
technological O
conditions O
applied O
during O
the O
manufacture O
of O
chocolate O
in O
this O
study O
and O
the O
level O
of O
contamination O
present O
in O
the O
cocoa O
beans O
, O
this O
experiment O
demonstrated O
that O
93 O
. O
6 O
% O
of O
ochratoxin B
A I
present O
in O
the O
beans O
was O
reduced O
during O
the O
chocolate O
producing O
. O

The O
bitter O
amino B
acids I
were O
significantly O
decreased O
and O
the O
umami O
acids O
were O
markedly O
increased O
in O
MSPC O
. O

Green O
and O
gold O
kiwifruit O
peel O
ethanol B
extracts O
potentiate O
pentobarbital B
- O
induced O
sleep O
in O
mice O
via O
a O
GABAergic O
mechanism O
. O

The O
peel O
of O
kiwifruit O
, O
which O
is O
a O
by O
- O
product O
of O
processing O
, O
is O
a O
good O
source O
of O
flavonoids B
; O
however O
, O
its O
bioactivity O
has O
not O
been O
widely O
investigated O
. O

In O
this O
study O
, O
we O
evaluated O
the O
hypnotic O
effects O
of O
green O
( O
GRPE O
, O
Actinidia O
deliciosa O
) O
and O
gold O
( O
GOPE O
, O
Actinidia O
chinensis O
) O
kiwifruit O
peel O
ethanol B
extracts O
and O
their O
solvent O
fractions O
, O
and O
the O
possible O
underlying O
mechanisms O
. O

Oral O
GRPE O
and O
GOPE O
administration O
( O
125 O
- O
1000mg O
/ O
kg O
) O
produced O
a O
dose O
- O
dependent O
decrease O
in O
sleep O
latency O
and O
an O
increase O
in O
sleep O
duration O
in O
pentobarbital B
- O
treated O
mice O
. O

Among O
three O
different O
solvent O
fractions O
of O
GRPE O
and O
GOPE O
, O
ethyl B
acetate I
( O
EA O
) O
fractions O
had O
the O
greatest O
effect O
on O
sleep O
duration O
at O
250mg O
/ O
kg O
. O

The O
total O
flavonoid B
contents O
of O
solvent O
fractions O
were O
proportional O
to O
sleep O
duration O
. O

Like O
diazepam O
( O
a O
GABA B
( O
A O
) O
- O
benzodiazepine B
( O
BZD O
) O
receptor O
agonist O
) O
, O
the O
hypnotic O
effects O
of O
GRPE O
, O
GOPE O
, O
and O
their O
EA O
fractions O
were O
fully O
inhibited O
by O
flumazenil B
( O
a O
GABA B
( O
A O
) O
- O
BZD O
receptor O
antagonist O
) O
. O

These O
results O
suggest O
that O
potentiation O
effects O
of O
GRPE O
and O
GOPE O
on O
pentobarbital B
- O
induced O
sleep O
in O
mice O
may O
be O
modulated O
by O
a O
GABAergic O
mechanism O
. O

An O
investigation O
into O
the O
supramolecular O
structure O
, O
solubility O
, O
stability O
and O
antioxidant O
activity O
of O
rutin B
/ O
cyclodextrin O
inclusion O
complex O
. O

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( O
2 O
- O
hydroxypropyl O
) O
- O
alpha O
- O
cyclodextrin O
( O
HP O
- O
alpha O
- O
CD O
) O
, O
( O
2 O
- O
hydroxypropyl O
) O
- O
beta O
- O
cyclodextrin O
( O
HP B
- I
beta I
- I
CD I
) O
and O
( O
2 O
- O
hydroxypropyl O
) O
- O
gamma O
- O
cyclodextrin O
( O
HP O
- O
gamma O
- O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP O
- O
alpha O
- O
CD O
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP O
- O
gamma O
- O
CD O
; O
the O
complexes O
formed O
with O
HP O
- O
gamma O
- O
CD O
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP O
- O
alpha O
- O
CD O
. O

Thermodynamic O
studies O
demonstrate O
that O
the O
inclusion O
of O
rutin B
into O
HP B
- I
beta I
- I
CD I
was O
an O
exothermic O
process O
which O
occurred O
spontaneously O
. O

Two O
- O
dimensional O
rotating O
- O
frame O
nuclear O
Overhauser O
effect O
spectroscopy O
( O
2D O
ROESY O
) O
( B
1 I
) I
H I
NMR O
analyses O
show O
that O
the O
A O
ring O
of O
rutin B
was O
the O
part O
of O
the O
molecule O
that O
most O
likely O
inserted O
into O
the O
cavity O
of O
HP B
- I
beta I
- I
CD I
, O
thus O
forming O
a O
supramolecular O
inclusion O
complex O
. O

Formation O
of O
such O
an O
inclusion O
complex O
conferred O
moderate O
degrees O
of O
protection O
to O
rutin B
from O
degradation O
by O
heat O
and O
UV O
radiation O
during O
storage O
, O
and O
significantly O
enhanced O
its O
antioxidant O
capacity O
as O
determined O
by O
three O
different O
procedures O
. O

A O
nanosised O
oxygen B
scavenger O
: O
preparation O
and O
antioxidant O
application O
to O
roasted O
sunflower O
seeds O
and O
walnuts O
. O

A O
novel O
oxygen B
scavenger O
using O
iron O
nanoparticle O
was O
produced O
and O
evaluated O
as O
a O
potential O
oxygen B
scavenger O
. O

The O
absorption O
capacity O
of O
different O
kinds O
of O
oxygen B
scavengers O
was O
measured O
as O
a O
function O
of O
time O
, O
and O
the O
absorption O
rate O
constant O
was O
evaluated O
at O
25 O
degrees O
C O
. O

The O
absorption O
rate O
constant O
of O
nanosised O
and O
conventional O
oxygen B
scavenger O
were O
0 O
. O
45 O
+ O
/ O
- O
0 O
. O
044h O
( O
- O
1 O
) O
and O
0 O
. O
05 O
+ O
/ O
- O
0 O
. O
006h O
( O
- O
1 O
) O
, O
respectively O
. O

Successful O
application O
of O
the O
nanosised O
oxygen B
scavenger O
on O
roasted O
sunflower O
seed O
and O
walnut O
demonstrated O
its O
ability O
to O
inhibit O
lipid O
oxidation O
in O
lipid O
- O
containing O
food O
. O

Roasted O
nut O
treated O
with O
nanosised O
oxygen B
scavenger O
possessed O
the O
lowest O
PV O
and O
AnV O
in O
all O
treatments O
after O
120 O
days O
of O
storage O
. O

Therefore O
, O
it O
has O
the O
potential O
for O
broad O
application O
as O
an O
active O
packaging O
in O
a O
variety O
of O
oxygen B
- O
sensitive O
foods O
. O

Metabolite O
accumulation O
levels O
along O
the O
time O
course O
suggest O
that O
flavanones B
, O
flavones B
, O
polymethoxylated B
flavones I
and O
scoparone B
are O
induced O
in O
citrus O
fruit O
in O
response O
to O
P O
. O
digitatum O
infection O
, O
although O
with O
different O
trends O
depending O
on O
the O
tissue O
. O

Direct O
- O
acting O
CB1 O
agonists O
, O
including O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
, O
WIN O
55 O
, O
212 O
[ O
R O
- O
( O
1 O
) O
- O
[ O
2 O
, O
3 O
- O
dihydro O
- O
5 O
- O
methyl O
- O
3 O
- O
[ O
( O
morpholinyl O
) O
methyl O
] O
pyrrolo O
[ O
1 O
, O
2 O
, O
3 O
- O
de O
] O
- O
1 O
, O
4 O
- O
benzoxazinyl O
] O
- O
( O
1 O
- O
naphthalenyl O
) O
methanone O
mesylate O
] O
, O
AM2389 O
[ O
9 O
beta O
- O
hydroxy O
- O
3 O
- O
( O
1 O
- O
hexyl O

The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26 O
- O
32 O
g O
/ O
kg O
urine O
; O
comparable O
effects O
were O
obtained O
with O
10 O
mg O
/ O
kg O
furosemide B
and O
3 O
. O
0 O
mg O
/ O
kg O
trans O
- O
( O
- O
) O
- O
3 O
, O
4 O
- O
dichloro O
- O
N O
- O
methyl O
- O
N O
- O
[ O
2 O
- O
( O
1 O
- O
pyrrolidinyl O
) O
cyclohexyl O
] O
benzeneacetamide O
( O
U50 B
- I
488 I
) O
. O

Methanandamide O
( O
10 O
. O
0 O
mg O
/ O
kg O
) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 O
agonist O
AM1241 O
[ O
1 O
- O
( O
methylpiperidin O
- O
2 O
- O
ylmethyl O
) O
- O
3 O
- O
( O
2 O
- O
iodo O
- O
5 O
- O
nitrobenzoyl O
) O
indole O
] O
, O
the O
anandamide B
transport O
inhibitor O
AM404 O
, O
and O
the O
CB O
antagonist O
rimonabant B
did O
not O
have O
diuretic O
effects O
. O

In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 B
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose O
- O
dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant B
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine B
, O
nor O
were O
the O
effects O
of O
WIN O
55 O
, O
212 O
antagonized O
by O
the O
CB2 O
antagonist O
AM630 O
[ O
( O
6 O
- O
iodo O
- O
2 O
- O
methyl O
- O
1 O
- O
[ O
2 O
- O
( O
4 O
- O
morpholinyl O
) O
ethyl O
] O
- O

One O
important O
biotransformation O
pathway O
is O
carbonyl B
reduction O
, O
which O
leads O
to O
the O
phase O
I O
metabolite O
, O
reduced O
nabumetone O
. O

The O
aim O
of O
this O
study O
is O
the O
determination O
of O
the O
role O
of O
a O
particular O
human O
liver O
subcellular O
fraction O
in O
the O
nabumetone O
reduction O
and O
the O
identification O
of O
participating O
carbonyl B
reducing O
enzymes O
along O
with O
their O
stereospecificities O
. O

Both O
subcellular O
fractions O
take O
part O
in O
the O
carbonyl B
reduction O
of O
nabumetone O
and O
the O
reduction O
is O
at O
least O
in O
vitro O
the O
main O
biotransformation O
pathway O
. O

The O
activities O
of O
eight O
cytosolic O
carbonyl B
reducing O
enzymes O
- O
- O
CBR1 O
, O
CBR3 O
, O
AKR1B1 O
, O
AKR1B10 O
, O
AKR1C1 O
- O
4 O
- O
- O
toward O
nabumetone O
were O
tested O
. O

This O
project O
provides O
for O
the O
first O
time O
evidence O
that O
seven O
specific O
carbonyl B
reducing O
enzymes O
participate O
in O
nabumetone O
metabolism O
. O

Transport O
of O
gemifloxacin O
, O
a O
4th O
generation O
quinolone B
antibiotic O
, O
in O
the O
Caco O
- O
2 O
and O
engineered O
MDCKII O
cells O
, O
and O
potential O
involvement O
of O
efflux O
transporters O
in O
the O
intestinal O
absorption O
of O
the O
drug O
. O

The O
secretory O
transport O
in O
Caco O
- O
2 O
cells O
was O
significantly O
decreased O
by O
MRP2 O
( O
MK571 B
) O
and O
BCRP O
( O
Ko143 B
) O
inhibitors O
. O

The O
efflux O
was O
significantly O
decreased O
by O
verapamil B
and O
Ko143 B
, O
but O
not O
significantly O
by O
MK571 B
. O

The O
comparative O
po O
bioavailability O
in O
rats O
was O
increased O
by O
the O
preadministration O
of O
Ko143 B
( O
four O
- O
fold O
) O
, O
MK571 B
( O
two O
- O
fold O
) O
and O
verapamil B
( O
two O
- O
fold O
) O
. O

Inhibition O
of O
GABA B
synthesis O
in O
the O
prefrontal O
cortex O
increases O
locomotor O
activity O
but O
does O
not O
affect O
attention O
in O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
. O

Attention O
is O
regulated O
, O
at O
least O
in O
part O
, O
by O
the O
prefrontal O
cortex O
( O
PFC O
) O
, O
a O
brain O
area O
in O
which O
pathology O
of O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
neurons O
has O
been O
consistently O
observed O
in O
post O
- O
mortem O
analysis O
of O
the O
brains O
of O
people O
with O
schizophrenia O
. O

Specifically O
, O
expression O
of O
the O
67 O
- O
kD O
isoform O
of O
the O
GABA B
synthesis O
enzyme O
glutamic B
acid I
decarboxylase O
( O
GAD67 O
) O
is O
reduced O
in O
parvalbumin O
- O
containing O
fast O
- O
spiking O
GABA B
interneurons O
. O

Thus O
it O
is O
hypothesized O
that O
reduced O
cortical O
GABA B
synthesis O
and O
release O
may O
contribute O
to O
the O
attention O
deficits O
in O
schizophrenia O
. O

Here O
the O
effect O
of O
reducing O
cortical O
GABA B
synthesis O
with O
l O
- O
allylglycine O
( O
LAG O
) O
on O
attention O
was O
tested O
using O
three O
different O
versions O
of O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
( O
5CSRTT O
) O
. O

Finally O
, O
the O
expression O
of O
Fos O
protein O
was O
used O
as O
an O
indirect O
measure O
of O
reduced O
GABA B
synthesis O
. O

These O
results O
suggest O
that O
a O
general O
decrease O
in O
GABA B
synthesis O
is O
not O
sufficient O
to O
cause O
attention O
deficits O
. O

It O
remains O
to O
be O
tested O
whether O
a O
selective O
decrease O
in O
GABA B
synthesis O
in O
parvalbumin O
- O
containing O
GABA B
neurons O
could O
cause O
attention O
deficits O
. O

Decreased O
cortical O
GABA B
synthesis O
did O
increase O
locomotor O
activity O
; O
this O
may O
reflect O
the O
positive O
symptoms O
of O
schizophrenia O
. O

Cytisine O
confers O
neuronal O
protection O
against O
excitotoxic O
injury O
by O
down O
- O
regulating O
GluN2B O
- O
containing O
NMDA B
receptors O
. O

The O
present O
study O
investigated O
the O
protective O
effect O
of O
CYT O
on O
cultured O
cortical O
neural O
injury O
induced O
by O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
. O

Our O
data O
showed O
that O
CYT O
conferred O
protective O
effect O
against O
loss O
of O
cellular O
viability O
induced O
by O
brief O
exposure O
to O
200 O
mu O
M O
NMDA B
in O
a O
concentration O
- O
dependent O
manner O
. O

CYT O
significantly O
inhibited O
the O
neuronal O
apoptosis O
induced O
by O
NMDA B
exposure O
by O
reversing O
intracellular O
Ca B
( I
2 I
+ I
) I
overload O
and O
balancing O
Bcl O
- O
2 O
and O
Bax O
expression O
levels O
. O

Furthermore O
, O
CYT O
significantly O
reversed O
the O
up O
- O
regulation O
of O
GluN2B O
- O
containing O
NMDA B
receptors O
by O
exposure O
to O
NMDA B
, O
but O
it O
did O
not O
affect O
the O
level O
of O
GluN2A O
- O
containing O
NMDA B
receptors O
. O

These O
findings O
suggest O
that O
CYT O
protects O
cortical O
neurons O
, O
at O
least O
partially O
, O
by O
inhibiting O
the O
level O
of O
GluN2B O
- O
containing O
NMDA B
receptors O
and O
regulating O
Bcl O
- O
2 O
family O
. O

Inhibition O
of O
neurite O
outgrowth O
and O
alteration O
of O
cytoskeletal O
gene O
expression O
by O
sodium B
arsenite I
. O

Arsenic B
compounds O
that O
are O
often O
found O
in O
drinking O
water O
increase O
the O
risk O
of O
developmental O
brain O
disorders O
. O

In O
this O
study O
, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro O
- O
2a O
cells O
expressing O
SCAT3 O
, O
a O
caspase O
- O
3 O
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins O
; O
enhanced O
cyan O
fluorescence O
protein O
( O
ECFP O
) O
and O
Venus O
, O
to O
determine O
whether O
sodium B
arsenite I
( O
NaAsO O
( O
2 O
) O
; O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
mu O
M O
) O
affects O
both O
neurite O
outgrowth O
and O
/ O
or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O

Metabolism O
of O
triethylenetetramine O
and O
1 O
, O
12 O
- O
diamino O
- O
3 O
, O
6 O
, O
9 O
- O
triazadodecane O
by O
the O
spermidine B
/ O
spermine B
- O
N O
( O
1 O
) O
- O
acetyltransferase O
and O
thialysine B
acetyltransferase O
. O

Triethylenetetramine O
( O
TETA O
; O
Syprine O
; O
Merck O
Rahway O
, O
NJ O
) O
, O
a O
drug O
for O
Wilson O
' O
s O
disease O
, O
is O
a O
copper B
chelator O
and O
a O
charge O
- O
deficient O
analog O
of O
polyamine B
spermidine B
. O

We O
recently O
showed O
that O
TETA O
is O
metabolized O
in O
vitro O
by O
polyamine B
catabolic O
enzyme O
spermidine B
/ O
spermine B
- O
N O
( O
1 O
) O
- O
acetyltransferase O
( O
SSAT1 O
) O
and O
by O
thialysine B
acetyltransferase O
( O
SSAT2 O
) O
to O
its O
monoacetylated O
derivative O
( O
MAT O
) O
. O

By O
contrast O
, O
1 O
, O
12 O
- O
diamino O
- O
3 O
, O
6 O
, O
9 O
- O
triazadodecane O
( O
SpmTrien O
) O
, O
a O
charge O
- O
deficient O
spermine B
analog O
, O
was O
an O
extremely O
poor O
substrate O
of O
human O
recombinant O
SSAT2 O
and O
was O
metabolized O
by O
SSAT1 O
in O
HEPG2 O
cells O
and O
in O
wild O
- O
type O
primary O
hepatocytes O
. O

Coupling O
between O
excitons O
of O
CdSe B
nanocrystal O
quantum O
dots O
( O
NQDs O
) O
and O
surface O
plasmon O
polaritons O
( O
SPPs O
) O
of O
an O
Ag B
film O
attached O
to O
a O
prism O
have O
been O
studied O
by O
steady O
- O
state O
and O
transient O
reflectivity O
measurements O
in O
the O
Kretschmann O
geometry O
. O

In O
contrast O
, O
at O
probe O
wavevectors O
where O
the O
lower O
hybrid O
state O
is O
predominantly O
excitonic O
, O
the O
dynamics O
are O
similar O
to O
that O
measured O
for O
CdSe B
NQDs O
on O
glass O
. O

Methamphetamine B
regulation O
of O
sulfotransferase O
1A1 O
and O
2A1 O
expression O
in O
rat O
brain O
sections O
. O

Rat O
sulfotransferase O
rSULT1A1 O
catalyzes O
the O
sulfation O
of O
neurotransmitters O
and O
xenobiotic O
phenolic B
compounds O
. O

rSULT2A1 O
catalyzes O
the O
sulfation O
of O
hydroxysteroids O
and O
xenobiotic O
alcoholic B
compounds O
. O

In O
this O
work O
, O
Western O
blot O
and O
real O
- O
time O
RT O
- O
PCR O
were O
used O
to O
investigate O
the O
effect O
of O
methamphetamine B
on O
rSULT1A1 O
and O
rSULT2A1 O
protein O
and O
mRNA O
expression O
in O
rat O
cerebellum O
, O
frontal O
cortex O
, O
hippocampus O
, O
and O
striatum O
. O

rSULT1A1 O
and O
rSULT2A1are O
inducible O
by O
methamphetamine B
in O
rat O
brain O
sections O
in O
a O
time O
dependable O
manner O
. O

rSULT2A1 O
is O
more O
inducible O
than O
rSULT1A1 O
by O
methamphetamine B
in O
rat O
brain O
sections O
. O

Induction O
activity O
of O
methamphetamine B
is O
in O
the O
order O
of O
cerebellum O
> O
frontal O
cortex O
, O
hippocampus O
> O
striatum O
. O

These O
results O
suggest O
that O
the O
physiological O
functions O
of O
rSULT1A1 O
and O
rSULT2A1 O
in O
different O
brain O
regions O
can O
be O
affected O
by O
methamphetamine B
. O

3 O
. O
A O
compilation O
of O
research O
applications O
in O
the O
fields O
of O
vascular O
and O
airway O
reactivity O
, O
mucociliary O
transport O
, O
polyamine B
transport O
, O
xenobiotic O
biotransformation O
, O
chemicals O
toxicology O
and O
complex O
aerosols O
supports O
the O
concept O
that O
precision O
cut O
lung O
slices O
are O
a O
very O
efficient O
tool O
maintaining O
highly O
differentiated O
functions O
similar O
to O
in O
vivo O
lung O
organ O
when O
kept O
under O
dynamic O
organ O
culture O
. O

Several O
series O
of O
45 O
acetophenone O
derivatives O
bearing O
various O
alkyl B
or O
benzyl B
substituents O
were O
conveniently O
synthesized O
and O
their O
structures O
characterized O
by O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectroscopy O
, O
HRMS O
and O
single O
- O
crystal O
X O
- O
ray O
analysis O
. O

It O
is O
a O
cell O
surface O
receptor O
tyrosine B
kinase O
and O
a O
proto O
- O
oncogene O
. O

Here O
we O
present O
a O
study O
which O
investigates O
whether O
ddPCR O
can O
be O
used O
to O
assess O
HER2 O
transcript O
levels O
in O
formalin B
- O
fixed O
paraffin O
embedded O
( O
FFPE O
) O
human O
breast O
tumors O
and O
whether O
these O
ddPCR O
measurements O
agree O
with O
prior O
assessments O
of O
these O
same O
samples O
by O
pathologists O
using O
immunohistochemistry O
( O
IHC O
) O
and O
in O
some O
cases O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O

Apo O
( O
a O
) O
interferes O
with O
plasminogen O
binding O
to O
C B
- O
terminal O
lysines O
of O
cell O
surface O
and O
extracellular O
matrix O
proteins O
. O

Identification O
and O
characterization O
of O
novel O
catalytic O
bioscavengers O
of O
organophosphorus B
nerve O
agents O
. O

In O
an O
effort O
to O
discover O
novel O
catalytic O
bioscavengers O
of O
organophosphorus B
( O
OP O
) O
nerve O
agents O
, O
cell O
lysates O
from O
a O
diverse O
set O
of O
bacterial O
strains O
were O
screened O
for O
their O
capacity O
to O
hydrolyze O
the O
OP O
nerve O
agents O
VX O
, O
VR O
, O
and O
soman B
( O
GD O
) O
. O

For O
the O
rational O
approach O
, O
the O
protein O
sequence O
of O
organophosphorus B
hydrolase O
( O
OPH O
) O
from O
Brevundimonas O
diminuta O
was O
searched O
against O
a O
non O
- O
redundant O
protein O
database O
using O
the O
Basic O
Local O
Alignment O
Search O
Tool O
to O
find O
regions O
of O
local O
similarity O
between O
sequences O
. O

Peroxisome O
proliferator O
- O
activated O
receptor O
- O
beta O
/ O
delta O
( O
PPAR O
delta O
) O
is O
a O
ubiquitously O
expressed O
, O
ligand O
- O
activated O
transcriptional O
factor O
that O
performs O
diverse O
critical O
functions O
in O
normal O
cells O
( O
e O
. O
g O
. O
, O
fatty B
acid I
metabolism O
, O
obesity O
, O
apoptosis O
, O
and O
inflammation O
) O
. O

Differential O
cell O
- O
protective O
function O
of O
two O
resveratrol B
( O
trans O
- O
3 O
, O
5 O
, O
4 O
' O
- O
trihydroxystilbene O
) O
glucosides O
against O
oxidative O
stress O
. O

Resveratrol B
( O
trans B
- I
3 I
, I
5 I
, I
4 I
' I
- I
trihydroxystilbene I
; O
RSV O
) O
, O
a O
natural O
polyphenol B
, O
exerts O
a O
beneficial O
effect O
on O
health O
and O
diseases O
. O

RSV O
targets O
and O
activates O
the O
NAD B
( I
+ I
) I
- O
dependent O
protein O
deacetylase O
SIRT1 O
; O
in O
turn O
, O
SIRT1 O
induces O
an O
intracellular O
antioxidative O
mechanism O
by O
inducing O
mitochondrial O
superoxide B
dismutase O
( O
SOD2 O
) O
. O

In O
oxygen O
radical O
absorbance O
capacity O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
assays O
, O
the O
antioxidant O
activity O
of O
3G O
- O
RSV O
was O
comparable O
to O
that O
of O
RSV O
, O
whereas O
the O
radical O
- O
scavenging O
efficiency O
of O
4 O
' O
G O
- O
RSV O
was O
less O
than O
50 O
% O
of O
that O
of O
RSV O
. O

The O
primary O
route O
of O
excretion O
of O
drug O
- O
related O
material O
was O
via O
O B
- O
dealkylation O
to O
metabolites O
, O
which O
were O
mainly O
excreted O
in O
urine O
. O

Circulating O
metabolites O
resulted O
mainly O
from O
O B
- O
dealkylation O
and O
exhibited O
negligible O
pharmacologic O
activity O
. O

Then O
, O
the O
effect O
of O
UVA O
- O
irradiation O
over O
NCTC2544 O
cells O
treated O
with O
increasing O
concentrations O
of O
15 O
compounds O
including O
photoallergens O
( O
benzophenone B
, O
4 O
- O
ter O
- O
butyl O
- O
4 O
- O
methoxy O
- O
dibenzoylmethane O
, O
2 O
- O
ethylexyl O
- O
p O
- O
methoxycinnamate O
, O
ketoprofen B
, O
6 O
- O
methylcumarin O
) O
; O
photoirritant O
and O
photoallergen O
( O
4 O
- O
aminobenzoic O
acid O
, O
chlorpromazine B
, O
promethazine O
) O
; O
photoirritants O
( O
acridine B
, O

ibuprofen B
, O
8 B
- I
methoxypsoralen I
, O
retinoic B
acid I
) O
; O
and O
negative O
compounds O
( O
lactic B
acid I
, O
SDS B
and O
p O
- O
phenilendiamine O
) O
was O
investigated O
. O

Twenty O
- O
four O
hours O
after O
exposure O
, O
cytotoxicity O
was O
evaluated O
by O
the O
MTT B
assay O
or O
LDH O
leakage O
, O
while O
ELISA O
was O
used O
to O
measure O
the O
production O
of O
IL O
- O
18 O
. O

Histomorphometric O
analysis O
demonstrated O
that O
tartrate B
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
( O
+ O
) O
osteoclast O
number O
and O
area O
were O
significantly O
increased O
in O
CD74 O
KO O
by O
35 O
% O
and O
43 O
% O
, O
respectively O
compared O
to O
WT O
. O

Immunohistochemical O
analysis O
also O
revealed O
that O
LPS O
- O
induced O
lipocalin O
- O
2 O
is O
expressed O
by O
brain O
endothelial O
cells O
and O
is O
partly O
co O
- O
localised O
with O
cyclooxygenase O
- O
2 O
( O
Cox O
- O
2 O
) O
, O
the O
rate O
- O
limiting O
enzyme O
for O
the O
production O
of O
inflammatory O
induced O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
, O
which O
is O
the O
key O
mediator O
of O
fever O
. O

Our O
findings O
suggest O
that O
IL O
- O
6 O
influences O
the O
expression O
of O
lipocalin O
- O
2 O
, O
which O
in O
turn O
may O
be O
involved O
in O
the O
control O
of O
the O
formation O
of O
Cox O
- O
2 O
, O
and O
hence O
central O
PGE B
( I
2 I
) I
- O
production O
. O

Interspecies O
variation O
in O
the O
metabolism O
of O
zoniporide O
by O
aldehyde B
oxidase O
. O

1 O
. O
Aldehyde B
oxidase O
( O
AO O
) O
is O
a O
cytosolic O
enzyme O
that O
contributes O
to O
the O
Phase O
I O
metabolism O
of O
xenobiotics O
in O
human O
and O
preclinical O
species O
. O

Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis O
: O
a O
case O
study O
with O
paraoxon B
. O

Using O
paraoxon B
as O
a O
reference O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
( O
AOP O
) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O

We O
then O
showed O
that O
static O
exposure O
of O
embryos O
to O
paraoxon B
( O
31 O
. O
2 O
- O
500 O
nM O
) O
from O
5 O
to O
96 O
hpf O
resulted O
in O
significant O
stage O
- O
and O
concentration O
- O
dependent O
AChE O
inhibition O
, O
albeit O
these O
effects O
were O
fully O
reversible O
within O
48 O
h O
following O
transfer O
to O
clean O
water O
. O

However O
, O
even O
in O
the O
presence O
of O
significant O
AChE O
inhibition O
, O
exposure O
to O
non O
- O
teratogenic O
paraoxon B
concentrations O
( O
< O
= O
250 O
nM O
) O
did O
not O
adversely O
impact O
secondary O
motoneuron O
development O
at O
96 O
hpf O
. O

Therefore O
, O
we O
investigated O
the O
potential O
effects O
of O
paraoxon B
exposure O
on O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
( O
not O
secondary O
) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O

Based O
on O
these O
studies O
, O
the O
frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE O
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon B
concentrations O
as O
low O
as O
31 O
. O
2 O
nM O
. O

Overall O
, O
our O
data O
suggest O
that O
( O
1 O
) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
( O
2 O
) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon B
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O

Hierarchical O
rutile O
TiO2 B
flower O
cluster O
- O
based O
high O
efficiency O
dye O
- O
sensitized O
solar O
cells O
via O
direct O
hydrothermal O
growth O
on O
conducting O
substrates O
. O

Dye O
- O
sensitized O
solar O
cells O
( O
DSSCs O
) O
based O
on O
hierarchical O
rutile O
TiO B
( I
2 I
) I
flower O
clusters O
prepared O
by O
a O
facile O
, O
one O
- O
pot O
hydrothermal O
process O
exhibit O
a O
high O
efficiency O
. O

Complex O
yet O
appealing O
rutile O
TiO B
( I
2 I
) I
flower O
films O
are O
, O
for O
the O
first O
time O
, O
directly O
hydrothermally O
grown O
on O
a O
transparent O
conducting O
fluorine O
- O
doped O
tin O
oxide O
( O
FTO B
) O
substrate O
. O

Notably O
, O
the O
small O
lattice O
mismatch O
between O
the O
FTO B
substrate O
and O
rutile O
TiO B
( I
2 I
) I
renders O
the O
epitaxial O
growth O
of O
a O
compact O
rutile O
TiO B
( I
2 I
) I
layer O
on O
the O
FTO B
glass O
. O

Intriguingly O
, O
these O
TiO B
( I
2 I
) I
flower O
clusters O
can O
then O
be O
exploited O
as O
photoanodes O
to O
produce O
DSSCs O
, O
yielding O
a O
power O
conversion O
efficiency O
of O
2 O
. O
94 O
% O
despite O
their O
rutile O
nature O
, O
which O
is O
further O
increased O
to O
4 O
. O
07 O
% O
upon O
the O
TiCl B
( I
4 I
) I
treatment O
. O

Circulating O
very O
- O
low O
- O
density O
lipoprotein O
from O
subjects O
with O
impaired O
glucose B
tolerance O
accelerates O
adrenocortical O
cortisol B
and O
aldosterone B
synthesis O
. O

Apart O
from O
their O
role O
in O
cardiovascular O
homeostasis O
and O
immunomodulation O
, O
aldosterone B
and O
cortisol B
are O
also O
implicated O
in O
the O
pathogenesis O
of O
insulin O
resistance O
and O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
. O

The O
causative O
relationship O
between O
in O
vivo O
lipoprotein O
modifications O
and O
steroidogenesis O
in O
subjects O
with O
impaired O
glucose B
tolerance O
( O
IGT O
) O
, O
however O
, O
is O
not O
well O
defined O
. O

Therefore O
, O
we O
aimed O
to O
investigate O
the O
impact O
of O
in O
vivo O
modified O
lipoproteins O
on O
aldosterone B
and O
cortisol B
release O
from O
human O
adrenocortical O
H295R O
cells O
. O

Following O
an O
oral O
glucose B
tolerance O
test O
, O
20 O
individuals O
with O
normal O
glucose B
tolerance O
( O
NGT O
) O
and O
20 O
IGT O
subjects O
were O
randomly O
selected O
from O
the O
ongoing O
PRAEDIAS O
prevention O
study O
in O
our O
department O
. O

Cells O
were O
incubated O
for O
24 O
h O
with O
lipoproteins O
isolated O
from O
NGT O
and O
IGT O
individuals O
and O
aldosterone B
and O
cortisol B
release O
was O
measured O
in O
the O
supernatants O
. O

VLDL O
induced O
a O
greater O
stimulating O
effect O
on O
adrenocortical O
aldosterone B
and O
cortisol B
release O
compared O
to O
HDL O
and O
LDL O
. O

Consistent O
with O
weight O
loss O
, O
these O
animals O
significantly O
decreased O
adiposity O
and O
improved O
glucose B
tolerance O
. O

Adipocyte O
fatty B
acid I
binding O
protein O
: O
a O
novel O
adipokine O
involved O
in O
the O
pathogenesis O
of O
metabolic O
and O
vascular O
disease O
? O

Adipocyte O
fatty B
acid I
binding O
protein O
( O
AFABP O
, O
also O
known O
as O
aP2 O
and O
FABP4 O
) O
has O
recently O
been O
introduced O
as O
a O
novel O
fat O
- O
derived O
circulating O
protein O
. O

Magnesium O
sulfate O
treatment O
against O
sarin B
poisoning O
: O
dissociation O
between O
overt O
convulsions O
and O
recorded O
cortical O
seizure O
activity O
. O

Sarin B
, O
a O
potent O
organophosphate B
cholinesterase O
inhibitor O
, O
induces O
an O
array O
of O
toxic O
effects O
including O
convulsions O
. O

Magnesium O
sulfate O
( O
MGS O
) O
is O
used O
to O
suppress O
eclamptic O
seizures O
in O
pregnant O
women O
with O
hypertension O
and O
was O
shown O
to O
block O
kainate B
- O
induced O
convulsions O
. O

Magnesium O
sulfate O
was O
evaluated O
herein O
as O
an O
anticonvulsant O
against O
sarin O
poisoning O
and O
its O
efficacy O
was O
compared O
with O
the O
potent O
anticonvulsants O
midazolam B
( O
MDZ B
) O
and O
caramiphen B
( O
CRM O
) O
. O

Rats O
were O
exposed O
to O
a O
convulsant O
dose O
of O
sarin B
( O
96 O
mu O
g O
/ O
kg O
, O
im O
) O
and O
1 O
min O
later O
treated O
with O
the O
oxime B
TMB4 O
and O
atropine O
to O
increase O
survival O
. O

Five O
minutes O
after O
initiation O
of O
convulsions O
, O
MGS O
, O
CRM O
, O
or O
MDZ B
were O
administered O
. O

However O
, O
radio O
- O
telemetric O
electro O
- O
corticography O
( O
ECoG O
) O
monitoring O
demonstrated O
sustained O
seizure O
activity O
in O
MGS O
- O
injected O
animals O
while O
this O
activity O
was O
completely O
blocked O
by O
MDZ B
and O
CRM O
. O

Additionally O
, O
histopathological O
analyses O
of O
MGS O
- O
treated O
group O
showed O
typical O
sarin B
- O
induced O
brain O
injury O
excluding O
the O
hippocampus O
that O
was O
partially O
protected O
. O

Our O
results O
clearly O
show O
that O
MGS O
demonstrated O
misleading O
features O
as O
an O
anticonvulsant O
against O
sarin B
- O
induced O
seizures O
. O

Repeat O
oral O
dose O
toxicity O
studies O
of O
melamine B
in O
rats O
and O
monkeys O
. O

Melamine B
is O
an O
important O
and O
widely O
used O
organic O
industrial O
chemical O
. O

Recently O
, O
clinical O
findings O
of O
renal O
failure O
and O
kidney O
stones O
in O
infants O
have O
been O
associated O
with O
ingestion O
of O
melamine B
- O
contaminated O
infant O
formula O
. O

To O
understand O
the O
toxicity O
and O
clinical O
outcome O
of O
melamine B
exposure O
, O
repeated O
oral O
dose O
studies O
in O
rats O
and O
monkeys O
were O
performed O
to O
characterize O
the O
subchronic O
toxicity O
of O
melamine B
. O

Oral O
administration O
of O
melamine B
at O
700 O
mg O
/ O
kg O
/ O
day O
for O
14 O
consecutive O
days O
in O
rats O
produced O
compound O
- O
related O
clinical O
signs O
( O
red O
urine O
) O
, O
decreased O
body O
weights O
, O
and O
changes O
in O
clinical O
pathology O
( O
increased O
serum O
urea B
nitrogen B
and O
creatinine B
) O
and O
anatomical O
pathology O
( O
renal O
tubular O
cell O
debris O
, O
crystal O
deposition O
, O
and O
hyperactive O
regeneration O
of O
renal O
tubular O
epithelium O
) O
. O

These O
results O
indicated O
that O
genomic O
markers O
could O
sensitively O
diagnose O
melamine B
- O
induced O
kidney O
injury O
. O

In O
this O
monkey O
study O
, O
the O
animals O
were O
treated O
with O
melamine B
at O
doses O
of O
60 O
, O
200 O
, O
or O
700 O
mg O
/ O
kg O
/ O
day O
. O

The O
administration O
of O
700 O
mg O
/ O
kg O
/ O
day O
melamine B
by O
nasal O
- O
gastric O
gavage O
to O
monkeys O
resulted O
in O
test O
article O
- O
related O
clinical O
signs O
including O
turbid O
and O
whitish O
urine O
, O
urine O
crystals O
, O
red O
blood O
cell O
changes O
, O
increased O
serum O
alanine B
aminotransferase O
and O
kidney O
and O
/ O
or O
liver O
weights O
, O
and O
microscopic O
findings O
including O
nephrotoxicity O
, O
pericarditis O
, O
and O
increased O
hematopoiesis O
. O

Claudin O
- O
3 O
and O
claudin O
- O
4 O
regulate O
sensitivity O
to O
cisplatin B
by O
controlling O
expression O
of O
the O
copper B
and O
cisplatin B
influx O
transporter O
CTR1 O
. O

We O
found O
that O
knockdown O
of O
the O
expression O
of O
either O
CLDN3 O
or O
CLDN4 O
produced O
marked O
changes O
in O
the O
phenotype O
of O
ovarian O
cancer O
cells O
, O
including O
an O
increase O
in O
resistance O
to O
cisplatin B
( O
cDDP O
) O
. O

The O
net O
accumulation O
of O
platinum B
( O
Pt B
) O
and O
the O
Pt B
- O
DNA O
adduct O
levels O
were O
reduced O
in O
CLDN3KD O
and O
CLDN4KD O
cells O
. O

The O
endogenous O
mRNA O
levels O
of O
copper B
influx O
transporter O
CTR1 O
were O
found O
to O
be O
significantly O
reduced O
in O
the O
knockdown O
cells O
, O
and O
exogenous O
expression O
of O
CTR1 O
restored O
their O
sensitivity O
to O
cDDP O
. O

Baseline O
copper B
( O
Cu B
) O
level O
, O
Cu B
uptake O
, O
and O
Cu B
cytotoxicity O
were O
also O
reduced O
in O
CLDN3KD O
and O
CLDN4KD O
cells O
. O

Cu B
- O
dependent O
tyrosinase O
activity O
was O
also O
markedly O
reduced O
in O
both O
types O
of O
CLDN O
knockdown O
cells O
when O
incubated O
with O
the O
substrate O
l O
- O
DOPA O
. O

These O
results O
indicate O
that O
CLDN3 O
and O
CLDN4 O
affect O
sensitivity O
of O
the O
ovarian O
cancer O
cells O
to O
the O
cytotoxic O
effect O
of O
cDDP O
by O
regulating O
expression O
of O
the O
Cu B
transporter O
CTR1 O
. O

Parallel O
changes O
in O
serotonin B
levels O
in O
brain O
and O
blood O
following O
acute O
administration O
of O
MDMA B
. O

Recent O
studies O
have O
demonstrated O
a O
similar O
acute O
effect O
of O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
) O
in O
blood O
platelets O
and O
brain O
tissue O
via O
action O
on O
the O
serotonin B
transporter O
. O

To O
investigate O
the O
validity O
of O
blood O
serotonin B
as O
a O
peripheral O
marker O
for O
central O
serotonin B
in O
this O
regard O
, O
we O
administered O
MDMA B
( O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
to O
rats O
and O
observed O
a O
parallel O
decrease O
in O
serotonin B
levels O
in O
the O
frontal O
cortex O
and O
blood O
at O
2 O
h O
( O
63 O
% O
and O
46 O
% O
respectively O
) O
with O
some O
recovery O
evident O
at O
8 O
h O
( O
42 O
% O
and O
38 O
% O
) O
and O
more O
so O
at O
18 O
h O
( O
19 O
% O
and O
24 O
% O
below O
control O
levels O
) O
. O

Administration O
of O
a O
tryptophan B
supplement O
( O
82 O
. O
5 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
to O
na O
i O
ve O
rats O
produced O
parallel O
increases O
in O
serotonin B
levels O
2 O
h O
later O
in O
the O
frontal O
cortex O
( O
39 O
% O
) O
and O
blood O
( O
26 O
% O
) O
. O

Following O
MDMA B
administration O
, O
the O
same O
dose O
of O
tryptophan B
caused O
a O
smaller O
( O
26 O
% O
) O
rise O
in O
brain O
serotonin B
whereas O
in O
blood O
it O
had O
no O
effect O
. O

We O
conclude O
that O
blood O
serotonin B
is O
a O
useful O
marker O
for O
brain O
serotonin B
levels O
in O
the O
rat O
following O
acute O
administration O
of O
MDMA B
and O
this O
finding O
highlights O
the O
possible O
use O
of O
platelet O
serotonin B
as O
a O
marker O
for O
brain O
serotonin B
in O
human O
studies O
involving O
MDMA B
. O

The O
new O
Al B
/ O
Pd B
Janus O
microspheres O
- O
prepared O
by O
depositing O
a O
Pd B
layer O
on O
one O
side O
of O
Al B
microparticles O
- O
are O
propelled O
efficiently O
by O
the O
thrust O
of O
hydrogen B
bubbles O
generated O
from O
different O
reactions O
of O
Al B
in O
strong O
acidic O
and O
alkaline O
environments O
, O
and O
by O
an O
oxygen B
bubble O
thrust O
produced O
at O
their O
partial O
Pd B
coating O
in O
hydrogen B
peroxide I
media O
. O

INO O
- O
8875 O
, O
a O
highly O
selective O
A1 O
adenosine B
receptor O
agonist O
: O
evaluation O
of O
chronotropic O
, O
dromotropic O
, O
and O
hemodynamic O
effects O
in O
rats O
. O

Selective O
pharmacological O
activation O
of O
the O
adenosine B
1 O
receptor O
( O
A O
( O
1 O
) O
R O
) O
is O
a O
promising O
new O
approach O
to O
achieve O
a O
potent O
block O
of O
atrioventricular O
( O
A O
- O
V O
) O
- O
nodal O
conduction O
without O
significant O
cardiovascular O
side O
effects O
. O

Molecular O
mechanisms O
associated O
with O
increased O
tolerance O
to O
the O
neonicotinoid O
insecticide O
imidacloprid B
in O
the O
dengue O
vector O
Aedes O
aegypti O
. O

Resistance O
of O
mosquitoes O
to O
organochlorines O
, O
organophosphates B
, O
carbamates B
and O
pyrethroids B
led O
to O
a O
regain O
of O
interest O
for O
the O
use O
of O
neonicotinoid O
insecticides O
in O
vector O
control O
. O

A O
strain O
susceptible O
to O
insecticides O
was O
selected O
at O
the O
larval O
stage O
with O
imidacloprid B
. O

After O
eight O
generations O
of O
selection O
, O
larvae O
of O
the O
selected O
strain O
( O
Imida O
- O
R O
) O
showed O
a O
5 O
. O
4 O
- O
fold O
increased O
tolerance O
to O
imidacloprid B
while O
adult O
tolerance O
level O
remained O
low O
. O

Imida O
- O
R O
larvae O
showed O
significant O
cross O
- O
tolerance O
to O
other O
neonicotinoids O
but O
not O
to O
pyrethroids B
, O
organophosphates B
and O
carbamates B
. O

Bioassays O
with O
enzyme O
inhibitors O
and O
biochemical O
assays O
confirmed O
the O
contribution O
of O
P450s O
with O
an O
increased O
capacity O
of O
the O
Imida O
- O
R O
microsomes O
to O
metabolize O
imidacloprid B
in O
presence O
of O
NADPH B
. O

Comparison O
of O
substrate O
recognition O
sites O
and O
imidacloprid B
docking O
models O
of O
six O
CYP6s O
over O
- O
transcribed O
in O
the O
Imida O
- O
R O
strain O
together O
with O
Bemisia O
tabaci O
CYP6CM1vQ O
and O
Drosophila O
melanogaster O
CYP6G1 O
, O
both O
able O
to O
metabolize O
imidacloprid B
, O
suggested O
that O
CYP6BB2 O
and O
CYP6N12 O
are O
good O
candidates O
for O
imidacloprid B
metabolism O
in O
Ae O
. O
aegypti O
. O

The O
present O
study O
revealed O
that O
imidacloprid B
tolerance O
in O
mosquitoes O
can O
arise O
after O
few O
generations O
of O
selection O
at O
the O
larval O
stage O
but O
does O
not O
lead O
to O
a O
significant O
tolerance O
of O
adults O
. O

As O
in O
other O
insects O
, O
P450 O
- O
mediated O
insecticide O
metabolism O
appears O
to O
play O
a O
major O
role O
in O
imidacloprid B
tolerance O
in O
mosquitoes O
. O

Aluminum B
( O
Al B
) O
is O
a O
low O
toxicological O
metal O
and O
can O
accumulate O
in O
the O
liver O
. O

It O
is O
not O
clear O
if O
the O
CYPS O
is O
affected O
by O
Al B
exposure O
. O

The O
body O
weight O
( O
BW O
) O
of O
rats O
, O
hepatosomatic O
index O
( O
HSI O
) O
, O
hepatic O
Al B
content O
, O
the O
concentrations O
of O
cytochrome O
P450 O
( O
CYP450 O
) O
, O
cytochrome O
B5 O
( O
B5 O
) O
, O
microsomal O
protein O
and O
the O
activities O
of O
NADPH B
- O
cytochrome O
c O
reductase O
( O
CR O
) O
, O
aminopyrin O
N B
- O
demethylase O
( O
AND O
) O
, O
erythromycin O
N B
- O
demethylase O
( O
ERND O
) O
and O
aniline B
- O
4 O
- O
hydeoxylase O
( O
AH O
) O
were O
assessed O

The O
results O
showed O
that O
the O
increase O
in O
Al B
concentration O
decreased O
BW O
, O
HIS O
, O
concentrations O
of O
CYP450 O
, O
B5 O
, O
microsomal O
protein O
and O
the O
activity O
of O
CR O
, O
AND O
, O
ERND O
and O
AH O
in O
hepatic O
microsomes O
. O

Metal O
distribution O
in O
tissues O
of O
free O
- O
range O
chickens O
near O
a O
lead O
- O
zinc B
mine O
in O
Kabwe O
, O
Zambia O
. O

Concentrations O
of O
Pb B
, O
Cd B
, O
and O
other O
metals O
in O
tissues O
of O
17 O
free O
- O
range O
and O
32 O
commercial O
broiler O
chickens O
from O
the O
Kabwe O
mining O
town O
in O
Zambia O
were O
determined O
. O

Mean O
concentrations O
of O
Pb B
and O
Cd B
exceeded O
maximum O
levels O
for O
human O
consumption O
in O
some O
organs O
including O
muscle O
( O
Pb B
only O
) O
in O
free O
- O
range O
chickens O
, O
in O
contrast O
to O
low O
levels O
in O
broiler O
chickens O
. O

Human O
consumers O
in O
Kabwe O
could O
be O
exposed O
to O
Pb B
and O
Cd B
in O
free O
- O
range O
chickens O
. O

These O
biochemical O
variations O
include O
the O
degree O
and O
positioning O
of O
d O
- O
alanyl O
and O
glycosyl B
substitution O
in O
lipoteichoic O
acids O
, O
and O
acetylation O
of O
peptidoglycan O
. O

Nano O
- O
graphene B
in O
biomedicine O
: O
theranostic O
applications O
. O

Owing O
to O
their O
unique O
physical O
and O
chemical O
properties O
, O
graphene B
and O
its O
derivatives O
such O
as O
graphene B
oxide I
( O
GO O
) O
, O
reduced O
graphene O
oxide O
( O
RGO O
) O
and O
GO O
- O
nanocomposites O
have O
attracted O
tremendous O
interest O
in O
many O
different O
fields O
including O
biomedicine O
in O
recent O
years O
. O

With O
every O
atom O
exposed O
on O
its O
surface O
, O
single O
- O
layered O
graphene B
shows O
ultra O
- O
high O
surface O
area O
available O
for O
efficient O
molecular O
loading O
and O
bioconjugation O
, O
and O
has O
been O
widely O
explored O
as O
novel O
nano O
- O
carriers O
for O
drug O
and O
gene O
delivery O
. O

Utilizing O
the O
intrinsic O
near O
- O
infrared O
( O
NIR O
) O
optical O
absorbance O
, O
in O
vivo O
graphene B
- O
based O
photothermal O
therapy O
has O
been O
realized O
, O
achieving O
excellent O
anti O
- O
tumor O
therapeutic O
efficacy O
in O
animal O
experiments O
. O

A O
variety O
of O
inorganic O
nanoparticles O
can O
be O
grown O
on O
the O
surface O
of O
nano O
- O
graphene B
, O
obtaining O
functional O
graphene B
- O
based O
nanocomposites O
with O
interesting O
optical O
and O
magnetic O
properties O
useful O
for O
multi O
- O
modal O
imaging O
and O
imaging O
- O
guided O
cancer O
therapy O
. O

Moreover O
, O
significant O
efforts O
have O
also O
been O
devoted O
to O
study O
the O
behaviors O
and O
toxicology O
of O
functionalized O
nano O
- O
graphene B
in O
animals O
. O

It O
has O
been O
uncovered O
that O
both O
surface O
chemistry O
and O
sizes O
play O
key O
roles O
in O
controlling O
the O
biodistribution O
, O
excretion O
, O
and O
toxicity O
of O
nano O
- O
graphene B
. O

Biocompatibly O
coated O
nano O
- O
graphene B
with O
ultra O
- O
small O
sizes O
can O
be O
cleared O
out O
from O
body O
after O
systemic O
administration O
, O
without O
rendering O
noticeable O
toxicity O
to O
the O
treated O
mice O
. O

In O
this O
review O
article O
, O
we O
will O
summarize O
the O
latest O
progress O
in O
this O
rapidly O
growing O
field O
, O
and O
discuss O
future O
prospects O
and O
challenges O
of O
using O
graphene B
- O
based O
materials O
for O
theranostic O
applications O
. O

Chronic O
PFOS B
exposures O
induce O
life O
stage O
- O
specific O
behavioral O
deficits O
in O
adult O
zebrafish O
and O
produce O
malformation O
and O
behavioral O
deficits O
in O
F1 O
offspring O
. O

Perfluorooctane B
sulfonic I
acid I
( O
PFOS B
) O
is O
an O
organic O
contaminant O
that O
is O
ubiquitous O
in O
the O
environment O
. O

Few O
studies O
have O
assessed O
the O
behavioral O
effects O
of O
chronic O
PFOS B
exposure O
in O
aquatic O
organisms O
. O

The O
present O
study O
defined O
the O
behavioral O
effects O
of O
varying O
life O
span O
chronic O
exposures O
to O
PFOS B
in O
zebrafish O
. O

Specifically O
, O
zebrafish O
were O
exposed O
to O
control O
or O
0 O
. O
5 O
micro O
M O
PFOS B
during O
1 O
to O
20 O
, O
21 O
to O
120 O
, O
or O
1 O
to O
120 O
d O
postfertilization O
( O
dpf O
) O
. O

Exposure O
to O
PFOS B
impaired O
the O
adult O
zebrafish O
behavior O
mode O
under O
the O
tapping O
stimulus O
. O

Residues O
of O
PFOS B
in O
F1 O
embryos O
derived O
from O
parental O
exposure O
for O
1 O
to O
120 O
and O
21 O
to O
120 O
dpf O
were O
significantly O
higher O
than O
control O
, O
and O
F1 O
embryos O
in O
these O
two O
groups O
also O
showed O
high O
malformation O
and O
mortality O
. O

The O
F1 O
larvae O
of O
parental O
fish O
exposed O
to O
PFOS B
for O
1 O
to O
20 O
or O
21 O
to O
120 O
dpf O
exhibited O
a O
higher O
swimming O
speed O
than O
control O
larvae O
in O
a O
light O
- O
to O
- O
dark O
behavior O
assessment O
test O
. O

The O
F1 O
larvae O
derived O
from O
parental O
fish O
exposed O
to O
PFOS B
for O
1 O
to O
120 O
dpf O
showed O
a O
significantly O
lower O
speed O
in O
the O
light O
period O
and O
a O
higher O
speed O
in O
the O
dark O
period O
compared O
with O
controls O
. O

Although O
there O
was O
little O
PFOS B
residue O
in O
embryos O
derived O
from O
the O
1 O
- O
to O
20 O
- O
dpf O
parental O
PFOS B
- O
exposed O
group O
, O
the O
adverse O
behavioral O
effects O
on O
both O
adult O
and O
F1 O
larvae O
indicate O
that O
exposure O
during O
the O
first O
21 O
dpf O
induces O
long O
- O
term O
neurobehaviorial O
toxicity O
. O

The O
authors O
' O
findings O
demonstrate O
that O
chronic O
PFOS B
exposure O
during O
different O
life O
stages O
adversely O
affects O
adult O
behavior O
and O
F1 O
offspring O
morphology O
, O
behavior O
, O
and O
survival O
. O

In O
the O
present O
study O
, O
ESB O
values O
are O
reported O
for O
34 O
polycyclic O
aromatic O
hydrocarbon O
, O
32 O
other O
organic O
contaminants O
, O
and O
seven O
metals O
( O
cadmium B
, O
chromium B
, O
copper B
, O
nickel B
, O
lead O
, O
silver B
, O
zinc B
) O
. O

It O
should O
be O
noted O
that O
the O
adverse O
clinical O
effects O
may O
be O
due O
to O
other O
ingredients O
in O
the O
DMAA O
- O
containing O
products O
, O
such O
as O
caffeine B
. O

Emergency O
do O
not O
consume O
/ O
do O
not O
use O
concentrations O
for O
blended O
phosphates B
in O
drinking O
water O
. O

The O
present O
evaluation O
concerns O
the O
concentrations O
of O
the O
blended O
phosphates B
( O
also O
known O
as O
polyphosphates B
, O
condensed O
complex O
phosphates B
, O
polyphosphate O
glassy O
balls O
, O
and O
pyrophosphates O
) O
intended O
to O
aid O
regulatory O
agencies O
in O
decisions O
to O
avoid O
contact O
with O
affected O
water O
. O

Polyphosphates B
are O
direct O
food O
additives O
and O
they O
are O
used O
to O
treat O
municipal O
drinking O
water O
, O
but O
depending O
upon O
the O
concentration O
and O
duration O
of O
exposure O
these O
substances O
can O
induce O
chemical O
burns O
. O

Ingested O
polyphosphates B
are O
degraded O
by O
phosphatase O
enzymes O
to O
monophosphates O
, O
substances O
that O
are O
over O
- O
the O
- O
counter O
bowel O
purgatives O
. O

High O
oral O
doses O
of O
the O
monophosphates O
can O
induce O
transient O
hyperphosphatemia O
in O
older O
and O
susceptible O
young O
people O
, O
which O
can O
lead O
to O
acute O
phosphate B
nephropathy O
. O

In O
this O
study O
, O
we O
determined O
the O
effect O
of O
Rhodobacter O
sphaeroides O
lipopolysaccharide O
( O
Rs O
- O
LPS O
) O
, O
an O
established O
TLR4 O
antagonist O
, O
on O
early O
- O
stage O
atherosclerosis O
in O
nondiabetic O
and O
streptozotocin B
- O
induced O
diabetic O
apolipoprotein O
E O
- O
deficient O
( O
Apoe O
( O
- O
/ O
- O
) O
) O
mice O
. O

Metabolic O
study O
showed O
that O
Rs O
- O
LPS O
significantly O
lowered O
serum O
levels O
of O
cholesterol B
and O
triglycerides B
in O
nondiabetic O
mice O
but O
not O
in O
diabetic O
mice O
. O

Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
TLR4 O
antagonist O
inhibited O
vascular O
inflammation O
and O
atherogenesis O
in O
diabetic O
Apoe O
( O
- O
/ O
- O
) O
mice O
and O
lowered O
serum O
cholesterol B
and O
triglyceride B
levels O
in O
nondiabetic O
Apoe O
( O
- O
/ O
- O
) O
mice O
. O

Progress O
in O
synthesis O
and O
antitumor O
activities O
of O
estradiol B
- O
linked O
platinum B
complex O
. O

Platinum B
complexes O
such O
as O
cisplatin B
and O
caboplatin O
are O
widely O
used O
in O
cancer O
chemotherapy O
. O

In O
this O
review O
, O
we O
discuss O
the O
current O
progress O
on O
the O
design O
and O
synthesis O
of O
estradiol B
- O
linked O
platinum B
complexes O
as O
the O
targeted O
antitumor O
drugs O
. O

The O
estradiol B
- O
linked O
platinum B
complexes O
could O
be O
used O
as O
target O
therapeutics O
for O
breast O
cancer O
. O

Most O
studies O
were O
carried O
out O
with O
naturally O
occurring O
heterocyclic O
compounds O
such O
as O
plant O
polyphenols B
: O
flavonoids B
, O
xanthones B
, O
coumarins B
, O
and O
ellagitannins O
, O
or O
plant O
derived O
products O
( O
juices O
, O
extracts O
, O
supplements O
) O
rich O
in O
bioactive O
heterocyclic O
compounds O
. O

FoxA1 O
corrupts O
the O
antiandrogenic O
effect O
of O
bicalutamide B
but O
only O
weakly O
attenuates O
the O
effect O
of O
MDV3100 O
( O
Enzalutamide B
( O
TM O
) O
) O
. O

Prostate O
cancer O
growth O
depends O
on O
androgens B
. O

However O
, O
antiandrogens O
, O
such O
as O
bicalutamide B
( O
BIC B
) O
, O
have O
a O
mixed O
agonist O
/ O
antagonist O
activity O
. O

Here O
we O
compare O
the O
antiandrogenic O
capacity O
of O
BIC B
to O
a O
new O
antiandrogen O
, O
MDV3100 O
( O
MDV O
) O
or O
Enzalutamide B
( O
TM O
) O
. O

By O
reconstitution O
of O
a O
hormone O
- O
regulated O
enhancer O
in O
Xenopus O
oocytes O
we O
show O
that O
both O
antagonists O
trigger O
the O
androgen B
receptor O
( O
AR O
) O
translocation O
to O
the O
nucleus O
, O
albeit O
with O
a O
reduced O
efficiency O
for O
MDV O
. O

In O
this O
context O
the O
BIC B
- O
AR O
antiandrogenic O
effect O
is O
seriously O
compromised O
as O
demonstrated O
by O
a O
significant O
chromatin O
remodeling O
and O
induction O
of O
a O
robust O
MMTV O
transcription O
whereas O
the O
MDV O
- O
AR O
complex O
displays O
a O
more O
persistent O
antagonistic O
character O
. O

Global O
slowing O
of O
network O
oscillations O
in O
mouse O
neocortex O
by O
diazepam B
. O

Benzodiazepines B
have O
a O
broad O
spectrum O
of O
clinical O
applications O
including O
sedation O
, O
anti O
- O
anxiety O
, O
and O
anticonvulsive O
therapy O
. O

At O
the O
cellular O
level O
, O
benzodiazepines B
are O
allosteric O
modulators O
of O
GABA O
( O
A O
) O
receptors O
; O
they O
increase O
the O
efficacy O
of O
inhibition O
in O
neuronal O
networks O
by O
prolonging O
the O
duration O
of O
inhibitory O
postsynaptic O
potentials O
. O

This O
mechanism O
of O
action O
predicts O
that O
benzodiazepines B
reduce O
the O
frequency O
of O
inhibition O
- O
driven O
network O
oscillations O
, O
consistent O
with O
observations O
from O
human O
and O
animal O
EEG O
. O

We O
therefore O
analyzed O
diazepam B
effects O
on O
a O
large O
range O
of O
cortical O
network O
oscillations O
in O
freely O
moving O
mice O
, O
including O
theta O
( O
4 O
- O
12 O
Hz O
) O
, O
gamma O
( O
40 O
- O
100 O
Hz O
) O
and O
fast O
gamma O
( O
120 O
- O
160 O
Hz O
) O
oscillations O
. O

We O
also O
investigated O
diazepam B
effects O
over O
the O
coupling O
between O
theta O
phase O
and O
the O
amplitude O
fast O
oscillations O
. O

We O
report O
that O
diazepam B
causes O
a O
global O
slowing O
of O
oscillatory O
activity O
in O
all O
frequency O
domains O
. O

Cross O
- O
frequency O
coupling O
strength O
, O
in O
contrast O
, O
was O
mostly O
unaffected O
by O
diazepam B
. O

Such O
state O
- O
and O
frequency O
- O
dependent O
actions O
of O
benzodiazepines B
on O
cortical O
network O
oscillations O
may O
be O
relevant O
for O
their O
specific O
cognitive O
effects O
. O

The O
role O
of O
oxygen B
during O
fracture O
healing O
. O

Oxygen B
affects O
the O
activity O
of O
multiple O
skeletogenic O
cells O
and O
is O
involved O
in O
many O
processes O
that O
are O
important O
for O
fracture O
healing O
. O

However O
, O
the O
role O
of O
oxygen B
in O
fracture O
healing O
has O
not O
been O
fully O
studied O
. O

Here O
we O
systematically O
examine O
the O
effects O
of O
oxygen B
tension O
on O
fracture O
healing O
and O
test O
the O
ability O
of O
hyperoxia O
to O
rescue O
healing O
defects O
in O
a O
mouse O
model O
of O
ischemic O
fracture O
healing O
. O

Mice O
with O
tibia O
fracture O
were O
housed O
in O
custom O
- O
built O
gas O
chambers O
and O
groups O
breathed O
a O
constant O
atmosphere O
of O
13 O
% O
oxygen B
( O
hypoxia O
) O
, O
21 O
% O
oxygen B
( O
normoxia O
) O
, O
or O
50 O
% O
oxygen B
( O
hyperoxia O
) O
. O

In O
addition O
, O
the O
efficacy O
of O
hyperoxia O
( O
50 O
% O
oxygen B
) O
as O
a O
treatment O
regimen O
for O
fracture O
nonunion O
was O
tested O
. O

However O
, O
neither O
hypoxia O
nor O
hyperoxia O
significantly O
altered O
chondrogenesis O
or O
osteogenesis O
during O
early O
stages O
of O
fracture O
healing O
, O
and O
infiltration O
of O
macrophages O
and O
neutrophils O
was O
not O
affected O
by O
environmental O
oxygen B
after O
bone O
injury O
. O

In O
conclusion O
, O
our O
results O
indicate O
that O
environmental O
oxygen B
levels O
affect O
tissue O
vascularization O
and O
fracture O
healing O
, O
and O
that O
providing O
oxygen B
when O
fractures O
are O
accompanied O
by O
ischemia O
may O
be O
beneficial O
. O

Inhalable O
highly O
concentrated O
itraconazole B
nanosuspension O
for O
the O
treatment O
of O
bronchopulmonary O
aspergillosis O
. O

While O
current O
standard O
of O
treatment O
of O
ABPA O
in O
CF O
patients O
is O
to O
suppress O
the O
allergy O
related O
symptoms O
by O
administration O
of O
glucocorticoids O
, O
itraconazole B
( O
ITRA O
) O
, O
administered O
orally O
at O
high O
doses O
, O
can O
alleviate O
the O
symptoms O
of O
ABPA O
. O

Regulation O
of O
adenosine B
levels O
during O
cerebral O
ischemia O
. O

Adenosine B
is O
a O
neuromodulator O
with O
its O
level O
increasing O
up O
to O
100 O
- O
fold O
during O
ischemic O
events O
, O
and O
attenuates O
the O
excitotoxic O
neuronal O
injury O
. O

Adenosine B
is O
produced O
both O
intracellularly O
and O
extracellularly O
, O
and O
nucleoside B
transport O
proteins O
transfer O
adenosine B
across O
plasma O
membranes O
. O

Adenosine B
levels O
and O
receptor O
- O
mediated O
effects O
of O
adenosine B
are O
regulated O
by O
intracellular O
ATP B
consumption O
, O
cellular O
release O
of O
ATP B
, O
metabolism O
of O
extracellular O
ATP B
( O
and O
other O
adenine O
nucleotides O
) O
, O
adenosine B
influx O
, O
adenosine B
efflux O
and O
adenosine B
metabolism O
. O

Recent O
studies O
have O
used O
genetically O
modified O
mice O
to O
investigate O
the O
relative O
contributions O
of O
intra O
- O
and O
extracellular O
pathways O
for O
adenosine B
formation O
. O

The O
importance O
of O
cortical O
or O
hippocampal O
neurons O
as O
a O
source O
or O
a O
sink O
of O
adenosine B
under O
basal O
and O
hypoxic O
/ O
ischemic O
conditions O
was O
addressed O
through O
the O
use O
of O
transgenic O
mice O
expressing O
human O
equilibrative O
nucleoside B
transporter O
1 O
( O
hENT1 O
) O
under O
the O
control O
of O
a O
promoter O
for O
neuron O
- O
specific O
enolase O
. O

From O
these O
studies O
, O
we O
conclude O
that O
ATP B
consumption O
within O
neurons O
is O
the O
primary O
source O
of O
adenosine B
in O
neuronal O
cultures O
, O
but O
not O
in O
hippocampal O
slices O
or O
in O
vivo O
mice O
exposed O
to O
ischemic O
conditions O
. O

The O
toxicity O
of O
the O
N O
- O
hydroxy O
and O
6 O
- O
hydroxy O
metabolites O
of O
3 O
, O
4 O
- O
dichloropropionanili O
does O
not O
depend O
on O
calcium B
release O
- O
activated O
calcium B
channel O
inhibition O
. O

In O
addition O
, O
fluorine B
analogs O
of O
DCPA O
and O
DCA O
were O
investigated O
to O
determine O
the O
relative O
role O
of O
chlorine B
substituents O
on O
T O
- O
cell O
immunotoxicity O
. O

Here O
we O
report O
that O
exposure O
of O
Jurkat O
T O
cells O
to O
DCPA O
and O
DCA O
alters O
IL O
- O
2 O
secretion O
, O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NFAT O
) O
activity O
, O
and O
calcium B
influx O
. O

However O
, O
exposure O
to O
6OH O
- O
DCA O
and O
NOH O
- O
DCA O
reduces O
IL O
- O
2 O
secretion O
and O
NFAT O
activity O
but O
has O
no O
effect O
on O
calcium B
flux O
. O

Rat O
microsomal O
incubations O
and O
analyses O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
identified O
seven O
metabolites O
, O
characterized O
as O
O O
- O
deethyl O
, O
hydroxyl B
, O
and O
N O
- O
deethyl O
derivatives O
of O
nonradioactive O
DPA O
- O
714 O
, O
two O
of O
them O
having O
the O
same O
retention O
times O
than O
those O
detected O
in O
rat O
and O
baboon O
plasma O
. O

The O
third O
plasma O
radiometabolite O
was O
suggested O
to O
be O
a O
carboxylic B
acid I
compound O
that O
accounted O
for O
15 O
% O
of O
the O
rat O
brain O
radioactivity O
. O

O B
- O
deethylation O
led O
to O
a O
nonradioactive O
compound O
and O
[ O
( O
18 O
) O
F O
] O
fluoroacetic O
acid O
. O

Polymorphisms O
in O
the O
vitamin B
D I
receptor O
gene O
and O
risk O
of O
autoimmune O
thyroid O
diseases O
: O
a O
meta O
- O
analysis O
. O

Polymorphisms O
of O
vitamin B
D I
receptor O
( O
VDR O
) O
were O
implicated O
in O
AITDs O
risk O
. O

Optimization O
of O
CD4 O
/ O
gp120 O
inhibitors O
by O
thermodynamic O
- O
guided O
alanine B
- O
scanning O
mutagenesis O
. O

In O
this O
study O
, O
we O
show O
that O
in O
some O
situations O
the O
blueprint O
can O
be O
constructed O
by O
combining O
the O
standard O
technique O
of O
alanine B
- O
scanning O
mutagenesis O
with O
isothermal O
titration O
calorimetry O
( O
ITC O
) O
. O

Alanine B
scan O
of O
an O
immunosuppressive O
peptide O
( O
CP O
) O
: O
analysis O
of O
structure O
- O
function O
relationships O
. O

Here O
, O
we O
report O
the O
role O
each O
constituent O
amino B
acid I
plays O
within O
core O
peptide O
using O
an O
alanine B
scan O
and O
the O
amino B
acid I
effect O
on O
function O
using O
a O
biological O
antigen O
presentation O
assay O
. O

Removal O
of O
any O
single O
hydrophobic O
amino B
acid I
between O
the O
two O
charged O
amino B
acids I
in O
core O
peptide O
( O
R O
, O
K O
) O
resulted O
in O
lower O
binding O
. O

As O
a O
proof O
of O
concept O
, O
we O
employed O
a O
Protein O
Kinase O
A O
( O
PKA O
) O
- O
dependent O
switch O
and O
coupled O
it O
to O
a O
lipid O
phosphatase O
to O
manipulate O
the O
level O
of O
phosphatidylinositol B
4 I
, I
5 I
- I
bisphosphate I
( O
PI O
( O
4 O
, O
5 O
) O
P O
( O
2 O
) O
) O
in O
living O
cells O
. O

Design O
, O
synthesis O
, O
and O
in O
vitro O
evaluation O
of O
new O
amphiphilic O
cyclodextrin O
- O
based O
nanoparticles O
for O
the O
incorporation O
and O
controlled O
release O
of O
acyclovir B
. O

Acyclovir B
possesses O
low O
solubility O
in O
water O
and O
in O
lipid O
bilayers O
, O
so O
that O
its O
dosage O
forms O
do O
not O
allow O
suitable O
drug O
levels O
at O
target O
sites O
following O
oral O
, O
local O
, O
or O
parenteral O
administration O
. O

The O
capacity O
of O
these O
molecules O
to O
form O
nanoparticles O
in O
water O
and O
to O
encapsulate O
acyclovir B
has O
then O
been O
studied O
. O

The O
nanoparticles O
prepared O
from O
the O
new O
beta B
- I
cyclodextrin I
derivatives O
have O
been O
characterized O
by O
dynamic O
light O
scattering O
and O
have O
an O
average O
size O
of O
120nm O
for O
the O
fluorinated O
derivatives O
and O
220nm O
for O
the O
hydrogenated O
analogs O
. O

They O
all O
allowed O
high O
loading O
and O
sustained O
release O
of O
acyclovir B
. O

Fingolimod B
protects O
cultured O
cortical O
neurons O
against O
excitotoxic O
death O
. O

Fingolimod B
( O
FTY720 O
) O
, O
a O
novel O
drug O
approved O
for O
the O
treatment O
of O
relapsing O
- O
remitting O
multiple O
sclerosis O
, O
activates O
different O
sphingosine B
- I
1 I
- I
phosphate I
receptor O
( O
S1PR O
) O
subtypes O
. O

Here O
, O
we O
examined O
the O
effect O
of O
FTY720 O
, O
its O
active O
metabolite O
, O
FTY720 O
- O
P O
, O
and O
sphingosine B
- I
1 I
- I
phosphate I
( O
S1P B
) O
on O
neuronal O
viability O
using O
a O
classical O
in O
vitro O
model O
of O
excitotoxic O
neuronal O
death O
. O

Mixed O
cultures O
of O
mouse O
cortical O
cells O
were O
challenged O
with O
toxic O
concentrations O
of O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
for O
10 O
min O
, O
and O
neuronal O
death O
was O
assessed O
20 O
h O
later O
. O

FTY720 O
, O
FTY720 O
- O
P O
, O
and O
S1P B
were O
all O
neuroprotective O
when O
applied O
18 O
- O
20 O
h O
prior O
to O
the O
NMDA B
pulse O
. O

Neuroprotection O
was O
attenuated O
by O
pertussis O
toxin O
, O
and O
inhibited O
by O
the O
selective O
type O
- O
1 O
S1PR O
( O
S1P1R O
) O
antagonist O
, O
W146 O
, O
and O
by O
inhibitors O
of O
the O
mitogen O
associated O
protein O
kinase O
( O
MAPK O
) O
and O
the O
phosphatidylinositol B
- O
3 O
- O
kinase O
( O
PtdIns O
- O
3 O
- O
K O
) O
pathways O
. O

To O
afford O
the O
user O
additional O
control O
over O
the O
presentation O
of O
microtopographic O
cues O
to O
cell O
populations O
, O
a O
photolabile O
, O
PEG B
- O
based O
hydrogel O
system O
is O
presented O
in O
which O
precisely O
engineered O
topographic O
cues O
can O
be O
formed O
in O
situ O
by O
controlled O
erosion O
. O

Hyaluronic O
acid O
modified O
mesoporous O
silica B
nanoparticles O
for O
targeted O
drug O
delivery O
to O
CD44 O
- O
overexpressing O
cancer O
cells O
. O

In O
this O
paper O
, O
a O
targeted O
drug O
delivery O
system O
has O
been O
developed O
based O
on O
hyaluronic O
acid O
( O
HA O
) O
modified O
mesoporous O
silica B
nanoparticles O
( O
MSNs O
) O
. O

An O
anticancer O
drug O
, O
doxorubicin O
hydrochloride O
( O
Dox B
) O
, O
has O
been O
loaded O
into O
MSNs O
and O
HA O
- O
MSNs O
as O
drug O
delivery O
vehicles O
. O

Dox B
loaded O
HA O
- O
MSNs O
show O
greater O
cytotoxicity O
to O
HCT O
- O
116 O
cells O
than O
free O
Dox B
and O
Dox B
- O
MSNs O
due O
to O
the O
enhanced O
cell O
internalization O
behavior O
of O
HA O
- O
MSNs O
. O

Active O
carbon B
and O
bentonite O
were O
used O
in O
the O
efficacy O
and O
drug O
interaction O
trials O
, O
respectively O
, O
to O
validate O
the O
developed O
model O
. O

The O
evaluated O
parameters O
were O
passage O
of O
DON B
and O
tylosin O
through O
the O
epithelial O
monolayer O
, O
the O
integrity O
of O
the O
monolayer O
by O
measurements O
of O
the O
trans O
- O
epithelial O
electrical O
resistance O
and O
the O
viability O
of O
the O
monolayer O
using O
the O
neutral B
red I
assay O
. O

In O
the O
efficacy O
model O
it O
was O
shown O
that O
active O
carbon B
effectively O
bound O
DON B
at O
both O
non O
- O
cytotoxic O
and O
cytotoxic O
concentrations O
of O
DON B
, O
respectively O
0 O
. O
5 O
and O
1 O
mu O
g O
/ O
mL O
. O

Moreover O
, O
the O
negative O
effects O
of O
DON B
at O
cytotoxic O
concentrations O
on O
cellular O
viability O
and O
integrity O
were O
completely O
offset O
. O

Moreover O
, O
it O
reduced O
the O
transepithelial O
passage O
of O
DON B
with O
37 O
% O
to O
57 O
% O
compared O
to O
active O
carbon B
, O
at O
both O
cytotoxic O
and O
non O
- O
cytotoxic O
concentrations O
of O
DON B
. O

In O
our O
drug O
interaction O
model O
, O
the O
interaction O
between O
tylosin O
and O
mycotoxin O
binders O
was O
investigated O
as O
some O
authors O
suggest O
binding O
of O
macrolide B
antibiotics O
to O
bentonite O
clays O
. O

The O
arginine B
and O
GHRP O
- O
2 O
tests O
as O
alternatives O
to O
the O
insulin O
tolerance O
test O
for O
the O
diagnosis O
of O
adult O
GH O
deficiency O
in O
Japanese O
patients O
: O
a O
comparison O
. O

The O
arginine B
+ O
GHRH O
test O
has O
been O
established O
as O
an O
alternative O
to O
the O
insulin O
tolerance O
test O
( O
ITT O
) O
for O
the O
diagnosis O
of O
adult O
GH O
deficiency O
( O
AGHD O
) O
. O

However O
, O
the O
glucagon O
, O
arginine B
, O
and O
GH O
releasing O
peptide O
- O
2 O
( O
GHRP O
- O
2 O
) O
test O
are O
recommended O
as O
alternatives O
in O
Japan O
. O

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
arginine B
and O
GHRP O
- O
2 O
tests O
as O
alternatives O
to O
the O
ITT O
for O
the O
diagnosis O
of O
AGHD O
in O
a O
Japanese O
population O
. O

Three O
stimulation O
tests O
( O
ITT O
, O
arginine B
test O
, O
and O
GHRP O
- O
2 O
test O
) O
were O
conducted O
in O
71 O
pre O
- O
operative O
adult O
patients O
with O
pituitary O
tumors O
( O
age O
, O
18 O
- O
65 O
years O
) O
. O

The O
arginine B
and O
GHRP O
- O
2 O
stimulation O
tests O
are O
acceptable O
alternatives O
to O
the O
ITT O
for O
the O
diagnosis O
of O
AGHD O
in O
Japanese O
patients O
. O

H B
- O
TiO B
( I
2 I
) I
@ O
MnO B
( I
2 I
) I
/ O
/ O
H B
- O
TiO B
( I
2 I
) I
@ O
C B
core O
- O
shell O
nanowires O
for O
high O
performance O
and O
flexible O
asymmetric O
supercapacitors O
. O

A O
flexible O
solid O
- O
state O
asymmetric O
supercapacitor O
device O
with O
H B
- O
TiO B
( I
2 I
) I
@ O
MnO B
( I
2 I
) I
core O
- O
shell O
NWs O
as O
the O
positive O
electrode O
and O
H B
- O
TiO B
( I
2 I
) I
@ O
C B
core O
- O
shell O
NWs O
as O
the O
negative O
electrode O
is O
developed O
. O

Sub O
- O
lethal O
effects O
of O
titanium B
dioxide I
nanoparticles O
on O
the O
physiology O
and O
reproduction O
of O
zebrafish O
. O

There O
are O
limited O
data O
on O
the O
sub O
- O
lethal O
physiological O
effects O
of O
titanium B
dioxide I
nanoparticles O
( O
TiO B
( I
2 I
) I
NPs O
) O
in O
adult O
fishes O
, O
and O
the O
consequences O
of O
TiO B
( I
2 I
) I
NP O
exposure O
on O
reproductive O
success O
are O
also O
unclear O
. O

This O
study O
aimed O
to O
examine O
the O
sub O
- O
lethal O
effects O
of O
a O
14 O
- O
d O
aqueous O
TiO B
( I
2 I
) I
( O
TiO B
( I
2 I
) I
NP O
, O
0 O
. O
1 O
or O
1 O
. O
0 O
mg O
l O
( O
- O
1 O
) O
; O
TiO B
( I
2 I
) I
bulk O
, O
1 O
. O
0 O
mg O
l O
( O
- O
1 O
) O
) O
exposure O
on O
the O
physiology O
and O
reproductive O
health O
of O
zebrafish O
. O

Then O
, O
during O
a O
21 O
- O
d O
post O
exposure O
recovery O
period O
, O
effects O
of O
the O
TiO B
( I
2 I
) I
exposure O
on O
reproductive O
success O
were O
evaluated O
. O

Whole O
body O
Ti B
concentrations O
increased O
significantly O
in O
fish O
exposed O
to O
both O
the O
1 O
. O
0 O
mg O
l O
( O
- O
1 O
) O
TiO B
( I
2 I
) I
NP O
and O
bulk O
TiO B
( I
2 I
) I
compared O
to O
controls O
, O
but O
concentrations O
returned O
to O
control O
levels O
by O
the O
end O
of O
the O
recovery O
period O
. O

No O
change O
in O
erythrocyte O
counts O
were O
observed O
, O
but O
there O
was O
a O
two O
- O
fold O
decline O
in O
leukocyte O
counts O
in O
all O
TiO B
( I
2 I
) I
treatment O
groups O
relative O
to O
time O
- O
matched O
controls O
. O

Whole O
body O
electrolyte O
and O
trace O
metal O
profiles O
were O
not O
affected O
by O
exposure O
to O
TiO B
( I
2 I
) I
, O
and O
there O
were O
no O
changes O
in O
Na B
( I
+ I
) I
K B
( I
+ I
) I
- O
ATPase O
activity O
in O
brain O
, O
gill O
or O
liver O
tissues O
. O

Total O
glutathione B
( O
GSH B
) O
levels O
in O
brain O
, O
gill O
and O
liver O
tissues O
were O
higher O
in O
fish O
exposed O
to O
TiO B
( I
2 I
) I
NP O
( O
both O
0 O
. O
1 O
and O
1 O
. O
0 O
mg O
l O
( O
- O
1 O
) O
) O
compared O
to O
bulk O
TiO B
( I
2 I
) I
and O
control O
fish O
. O

At O
the O
end O
of O
the O
14 O
- O
d O
exposure O
adult O
zebrafish O
were O
able O
to O
reproduce O
; O
however O
, O
the O
cumulative O
number O
of O
viable O
embryos O
produced O
was O
lower O
in O
fish O
exposed O
to O
1 O
. O
0 O
mg O
l O
( O
- O
1 O
) O
TiO B
( I
2 I
) I
( O
both O
NP O
and O
bulk O
) O
by O
the O
end O
of O
the O
21 O
- O
d O
recovery O
period O
. O

Overall O
, O
this O
study O
showed O
limited O
toxicity O
of O
bulk O
or O
nano O
scale O
TiO B
( I
2 I
) I
during O
the O
exposure O
; O
however O
reproduction O
was O
affected O
in O
both O
bulk O
and O
NP O
1 O
. O
0 O
mg O
l O
( O
- O
1 O
) O
groups O
. O

Moreover O
, O
the O
same O
dosage O
of O
MC O
- O
LR O
increased O
reactive O
oxygen B
species O
production O
and O
malondialdehyde B
content O
. O

At O
the O
same O
time O
, O
antioxidant O
enzyme O
( O
catalase O
and O
glutathione B
S B
- O
transferase O
) O
activity O
and O
glutathione B
reduced O
content O
rapidly O
increased O
, O
whereas O
antioxidant O
enzyme O
superoxide B
dismutase O
activity O
significantly O
decreased O
. O

The O
exposure O
of O
highly O
toxic O
aconitine B
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome O
P450 O
3A O
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O
liquid O
chromatography O
- O
tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone O
. O

The O
herbs O
are O
always O
used O
with O
drugs O
such O
as O
paclitaxel B
. O

Aconitine B
( O
AC O
) O
is O
one O
of O
the O
main O
bioactive O
/ O
high O
- O
toxic O
alkaloids O
of O
Aconitum O
roots O
. O

This O
approach O
has O
not O
only O
contributed O
to O
a O
fundamental O
understanding O
of O
structure O
and O
function O
of O
a O
large O
family O
of O
hydrolase O
- O
like O
proteins O
possessing O
functions O
other O
than O
catalysis O
, O
but O
also O
has O
been O
used O
to O
develop O
new O
practical O
strategies O
for O
scavenging O
and O
antidotal O
activity O
in O
cases O
of O
organophosphate B
insecticide O
or O
nerve O
agent O
exposure O
. O

The O
pharmacokinetics O
of O
drugs O
such O
as O
oximes B
, O
atropine O
and O
diazepam B
, O
are O
not O
aligned O
with O
the O
variable O
and O
persistent O
toxicokinetics O
of O
the O
agent O
. O

Because O
of O
the O
effectiveness O
of O
continuous O
treatment O
, O
it O
was O
investigated O
to O
what O
extent O
a O
subchronic O
pretreatment O
with O
carbamate B
( O
pyridostigmine O
or O
physostigmine B
combined O
with O
either O
procyclidine B
or O
scopolamine B
) O
would O
protect O
against O
percutaneous O
VX O
exposure O
. O

Inclusion O
of O
scopolamine B
in O
the O
pretreatment O
prevented O
seizures O
in O
all O
animals O
, O
but O
none O
of O
the O
pretreatments O
affected O
survival O
time O
or O
the O
onset O
time O
of O
cholinergic O
signs O
. O

Furthermore O
, O
antibodies O
to O
DNA O
show O
localized O
binding O
to O
these O
microstructures O
, O
which O
also O
react O
positively O
with O
DNA O
intercalating O
stains O
propidium B
iodide I
( O
PI O
) O
and O
4 O
' O
, O
6 O
' O
- O
diamidino O
- O
2 O
- O
phenylindole O
dihydrochloride O
( O
DAPI B
) O
. O

Effect O
of O
amorphization O
method O
on O
telmisartan B
solubility O
and O
the O
tableting O
process O
. O

Telmisartan B
( O
TLM O
) O
, O
a O
poorly O
water O
- O
soluble O
angiotensin O
II O
receptor O
antagonist O
in O
crystalline O
form O
, O
was O
transformed O
into O
the O
amorphous O
state O
by O
the O
melt O
quench O
technique O
, O
as O
well O
as O
a O
cryogenic O
grinding O
method O
, O
in O
order O
to O
improve O
its O
physiochemical O
properties O
. O

In O
the O
next O
stage O
, O
the O
solubility O
of O
TLM O
in O
0 O
. O
1M O
HCl B
, O
phosphate O
buffer O
, O
pH O
= O
6 O
. O
8 O
, O
and O
water O
( O
25 O
degrees O
C O
and O
37 O
degrees O
C O
) O
was O
determined O
. O

Measurements O
of O
the O
physical O
properties O
and O
dissolution O
tests O
of O
G4 O
formulations O
tablets O
with O
telmisartan B
in O
crystalline O
and O
amorphous O
form O
after O
different O
storage O
periods O
were O
also O
performed O
. O

What O
is O
behind O
the O
non O
- O
antibiotic O
properties O
of O
minocycline B
? O

Minocycline B
is O
a O
second O
- O
generation O
, O
semi O
- O
synthetic O
tetracycline B
that O
has O
been O
in O
use O
in O
therapy O
for O
over O
30 O
years O
for O
its O
antibiotic O
properties O
against O
both O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacteria O
. O

There O
are O
also O
many O
studies O
that O
have O
focused O
on O
the O
mechanisms O
involved O
in O
these O
non O
- O
antibiotic O
properties O
of O
minocycline B
, O
including O
anti O
- O
oxidant O
activity O
, O
inhibition O
of O
several O
enzyme O
activities O
, O
inhibition O
of O
apoptosis O
and O
regulation O
of O
immune O
cell O
activation O
and O
proliferation O
. O

This O
review O
summarizes O
the O
current O
findings O
in O
this O
topic O
, O
mainly O
focusing O
on O
the O
mechanisms O
underlying O
the O
immunomodulatory O
and O
anti O
- O
inflammatory O
activities O
of O
minocycline B
. O

Twice O
daily O
injection O
of O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
in O
normal O
mice O
transferred O
to O
a O
high O
fat O
diet O
reduced O
energy O
intake O
( O
p O
< O
0 O
. O
001 O
) O
, O
body O
weight O
( O
p O
< O
0 O
. O
01 O
) O
, O
circulating O
insulin O
and O
LDL O
- O
cholesterol B
( O
p O
< O
0 O
. O
001 O
) O
and O
improved O
insulin O
sensitivity O
( O
p O
< O
0 O
. O
001 O
) O
as O
well O
as O
oral O
and O
intraperitoneal O
( O
p O
< O
0 O
. O
001 O
) O
glucose B
tolerance O
. O

Energy O
intake O
, O
body O
weight O
, O
circulating O
insulin O
and O
glucose B
tolerance O
of O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
mice O
were O
similar O
to O
lean O
controls O
. O

In O
addition O
, O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
prevented O
the O
effect O
of O
high O
fat O
feeding O
on O
triacylglycerol B
accumulation O
in O
liver O
and O
muscle O
. O

Beneficial O
metabolic O
effects O
were O
observed O
similarly O
in O
ob O
/ O
ob O
mice O
treated O
twice O
daily O
with O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
for O
18 O
days O
, O
including O
significantly O
reduced O
energy O
intake O
( O
p O
< O
0 O
. O
05 O
) O
, O
body O
weight O
( O
p O
< O
0 O
. O
05 O
to O
p O
< O
0 O
. O
01 O
) O
, O
circulating O
glucose B
( O
p O
< O
0 O
. O
05 O
to O
p O
< O
0 O
. O
01 O
) O
and O
insulin O
( O
p O
< O
0 O
. O
05 O
to O
p O
< O
0 O
. O
001 O
) O
and O
improved O
glucose B
tolerance O
( O
p O
< O
0 O
. O
05 O
) O
and O
insulin O
sensitivity O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
whether O
lactational O
exposure O
to O
polychlorinated O
biphenyl O
- O
153 O
( O
PCB O
- O
153 O
) O
, O
dichlorodiphenyldich B
( O
DDE B
) O
, O
or O
hexachlorobenzene O
( O
HCB O
) O
as O
estimated O
with O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
, O
is O
associated O
with O
decrements O
in O
mental O
and O
psychomotor O
development O
scores O
of O
the O
Bayley O
Scales O
of O
Infant O
Development O
( O
BSID O
) O
test O
in O
children O
aged O
around O
14 O
- O
months O
of O
a O
subsample O
( O
N O
= O

Although O
in O
the O
present O
study O
population O
PCB O
- O
153 O
, O
DDE B
and O
HCB O
exposure O
increased O
within O
the O
first O
months O
of O
postnatal O
life O
, O
no O
associations O
were O
found O
between O
different O
periods O
of O
postnatal O
exposure O
to O
these O
compounds O
and O
mental O
or O
psychomotor O
scores O
. O

Despite O
the O
recent O
attention O
focused O
on O
the O
roles O
of O
the O
nucleotide B
binding O
and O
oligomerization O
domain O
- O
like O
receptor O
family O
pyrin O
domain O
- O
containing O
3 O
( O
NLRP3 O
) O
inflammasome O
in O
the O
pathogenesis O
of O
type O
2 O
diabetes O
, O
little O
is O
known O
about O
the O
ex O
vivo O
profile O
of O
inflammasome O
activation O
in O
type O
2 O
diabetic O
patients O
. O

Upregulated O
interleukin O
( O
IL O
) O
- O
1 O
beta O
maturation O
, O
IL O
- O
18 O
secretion O
, O
and O
caspase O
- O
1 O
cleavage O
were O
observed O
in O
MDMs O
from O
type O
2 O
diabetic O
patients O
after O
stimulation O
with O
various O
danger O
molecules O
( O
ATP B
, O
high O
- O
mobility O
group O
protein O
B1 O
, O
free O
fatty B
acids I
, O
islet O
amyloid O
polypeptide O
, O
and O
monosodium O
uric O
acid O
crystals O
) O
. O

Mitochondrial O
reactive O
oxygen B
species O
and O
NLRP3 O
were O
required O
for O
IL O
- O
1 O
beta O
synthesis O
in O
MDMs O
. O

Finally O
, O
2 O
months O
of O
therapy O
with O
the O
antidiabetic O
drug O
metformin B
significantly O
inhibited O
the O
maturation O
of O
IL O
- O
1 O
beta O
in O
MDMs O
from O
patients O
with O
type O
2 O
diabetes O
through O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
activation O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
NLRP3 O
inflammasome O
activation O
is O
elevated O
in O
myeloid O
cells O
from O
type O
2 O
diabetic O
patients O
and O
that O
antidiabetic O
treatment O
with O
metformin B
contributes O
to O
modulation O
of O
inflammasome O
activation O
in O
type O
2 O
diabetes O
. O

To O
understand O
the O
physiological O
role O
of O
APJ O
in O
regulation O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
, O
we O
measured O
ACTH O
and O
corticosterone B
( O
CORT B
) O
plasma O
levels O
in O
male O
and O
female O
mice O
lacking O
APJ O
( O
APJ O
knockout O
, O
APJ O
KO O
) O
and O
in O
wild O
- O
type O
controls O
, O
in O
response O
to O
a O
variety O
of O
acute O
stressors O
. O

Exposure O
to O
mild O
restraint O
, O
systemic O
injection O
of O
lipopolysaccharide O
( O
LPS O
) O
, O
insulin O
- O
induced O
hypoglycaemia O
and O
forced O
swim O
( O
FS O
) O
stressors O
, O
elevated O
plasma O
ACTH O
and O
CORT B
levels O
in O
wild O
- O
type O
mice O
. O

Acute O
mild O
restraint O
significantly O
increased O
plasma O
ACTH O
and O
CORT B
to O
a O
similar O
level O
in O
APJ O
KO O
mice O
as O
in O
wild O
- O
type O
mice O
. O

However O
, O
an O
intact O
APJ O
was O
required O
for O
a O
conventional O
ACTH O
, O
but O
not O
CORT B
, O
response O
to O
LPS O
administration O
in O
male O
mice O
and O
to O
insulin O
- O
induced O
hypoglycaemia O
in O
male O
and O
female O
mice O
. O

In O
contrast O
, O
APJ O
KO O
mice O
displayed O
an O
impaired O
CORT B
response O
to O
acute O
FS O
stress O
, O
regardless O
of O
gender O
. O

Assessing O
bioavailability O
and O
toxicity O
of O
permethrin B
and O
DDT B
in O
sediment O
using O
matrix O
solid O
phase O
microextraction O
. O

Matrix O
solid O
phase O
microextraction O
( O
matrix O
- O
SPME O
) O
was O
evaluated O
as O
a O
surrogate O
for O
the O
absorbed O
dose O
in O
organisms O
to O
estimate O
bioavailability O
and O
toxicity O
of O
permethrin B
and O
dichlorodiphenyltric B
( O
DDT B
) O
in O
laboratory O
- O
spiked O
sediment O
. O

Disposable O
polydimethylsiloxane B
fibers O
were O
used O
to O
estimate O
the O
absorbed O
dose O
in O
organisms O
and O
to O
examine O
bioavailability O
and O
toxicity O
. O

Based O
on O
median O
lethal O
fiber O
concentrations O
( O
fiber O
LC50 O
) O
, O
toxicity O
of O
permethrin B
was O
not O
significantly O
different O
among O
the O
different O
aging O
times O
. O

Due O
to O
the O
substantial O
degradation O
of O
DDT B
to O
dichlorodiphenyldich B
( O
DDD O
) O
in O
sediment O
, O
sediment O
toxicity O
to O
C O
. O
dilutus O
increased O
, O
while O
it O
decreased O
for O
H O
. O
azteca O
with O
extended O
aging O
times O
. O

A O
toxic O
unit O
- O
based O
fiber O
LC50 O
value O
represented O
the O
DDT B
mixture O
( O
DDT B
and O
DDD O
) O
toxicity O
for O
both O
species O
. O

Effects O
of O
DMSA O
- O
coated O
Fe3O4 B
nanoparticles O
on O
the O
transcription O
of O
genes O
related O
to O
iron B
and O
osmosis O
homeostasis O
. O

In O
this O
article O
, O
we O
checked O
the O
effect O
of O
2 O
, O
3 O
- O
dimercaptosuccinic O
acid O
- O
coated O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
nanoparticles O
on O
gene O
expression O
of O
mouse O
macrophage O
RAW264 O
. O
7 O
cells O
and O
found O
that O
the O
transcription O
of O
several O
important O
genes O
related O
to O
intracellular O
iron B
homeostasis O
were O
significantly O
changed O
. O

We O
thus O
speculated O
that O
the O
cellular O
iron B
homeostasis O
might O
be O
disturbed O
by O
this O
nanoparticle O
through O
releasing O
iron B
ion O
in O
cells O
. O

To O
verify O
this O
speculation O
, O
we O
first O
confirmed O
the O
transcriptional O
changes O
of O
several O
key O
iron B
homeostasis O
- O
related O
genes O
, O
such O
as O
Tfrc O
, O
Trf O
, O
and O
Lcn2 O
, O
using O
quantitative O
PCR O
, O
and O
found O
that O
an O
iron B
ion O
chelator O
, O
desferrioxamine B
, O
could O
alleviate O
the O
transcriptional O
alterations O
of O
two O
typical O
genes O
, O
Tfrc O
and O
Lcn2 O
. O

After O
extensive O
measures O
of O
intracellular O
iron B
in O
two O
forms O
and O
total O
iron B
, O
we O
found O
that O
the O
intracellular O
iron B
ion O
significantly O
increased O
with O
intracellular O
total O
iron B
and O
nanoparticle O
iron B
, O
demonstrating O
degradation O
of O
this O
nanoparticle O
into O
iron B
ion O
in O
cells O
. O

We O
next O
mimicked O
the O
intralysosomal O
environment O
in O
vitro O
and O
verified O
that O
the O
internalized O
iron O
nanoparticle O
could O
release O
iron B
ion O
in O
lysosome O
. O

We O
found O
that O
as O
another O
important O
compensatory O
response O
to O
intracellular O
overload O
of O
iron B
ion O
, O
cells O
significantly O
downregulated O
the O
expressions O
of O
genes O
belonging O
to O
solute O
carrier O
family O
which O
are O
responsible O
for O
transferring O
many O
organic O
solutes O
into O
cells O
, O
such O
as O
Slc5a3 O
and O
Slc44a1 O
, O
in O
order O
to O
prevent O
more O
organic O
solutes O
into O
cells O
and O
thus O
lower O
the O
intracellular O
osmosis O
. O

Based O
on O
these O
findings O
, O
we O
profiled O
a O
map O
of O
gene O
effects O
after O
cells O
were O
treated O
with O
this O
iron B
nanoparticle O
and O
concluded O
that O
the O
iron B
nanoparticles O
might O
be O
more O
detrimental O
to O
cell O
than O
iron B
ion O
due O
to O
its O
intracellular O
internalization O
fashion O
, O
nonspecific O
endocytosis O
. O

The O
anchoring O
of O
AChE O
at O
the O
synapse O
requires O
the O
interaction O
of O
ColQ O
with O
MuSK O
( O
Muscle O
- O
Specific O
Kinase O
) O
, O
a O
tyrosine B
kinase O
expressed O
on O
the O
muscle O
membrane O
that O
is O
necessary O
for O
the O
formation O
and O
the O
maintenance O
of O
the O
NMJ O
. O

A O
number O
of O
human O
teratogens O
elicit O
their O
deleterious O
effects O
through O
mechanisms O
involving O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
oxidative O
stress O
. O

Newer O
definitions O
of O
oxidative O
stress O
focus O
on O
the O
targeted O
redox O
modification O
of O
cysteine B
/ O
thiol B
functional O
groups O
found O
in O
the O
regulatory O
domains O
of O
critical O
signaling O
pathway O
proteins O
, O
suggesting O
that O
the O
targeted O
disruption O
of O
signaling O
through O
specific O
redox O
couples O
may O
account O
for O
the O
specificity O
of O
teratogen O
- O
induced O
malformations O
which O
previously O
could O
not O
be O
rationalized O
. O

Cholesterol B
ester I
droplets O
and O
steroidogenesis O
. O

Cholesteryl O
ester O
( O
CE O
) O
- O
rich O
LDs O
normally O
accumulate O
in O
steroidogenic O
cells O
and O
their O
mobilization O
is O
the O
preferred O
initial O
source O
of O
cholesterol B
for O
steroidogenesis O
. O

Plin1a O
, O
1b O
and O
5 O
were O
found O
to O
preferentially O
associate O
with O
triacylglycerol B
- O
rich O
LDs O
and O
Plin1c O
and O
Plin4 O
to O
associate O
with O
CE O
- O
rich O
LDs O
, O
but O
the O
biological O
significance O
of O
this O
remains O
unanswered O
. O

Vimentin O
null O
mice O
were O
found O
to O
have O
decreased O
ACTH O
- O
stimulated O
corticosterone B
levels O
, O
and O
decreased O
progesterone B
levels O
in O
females O
, O
but O
normal O
hCG O
- O
stimulated O
testosterone B
levels O
in O
males O
. O

Lipoprotein O
cholesterol B
delivery O
to O
adrenals O
and O
ovary O
was O
normal O
, O
as O
was O
the O
expression O
of O
steroidogenic O
genes O
; O
however O
, O
the O
movement O
of O
cholesterol B
to O
mitochondria O
was O
reduced O
in O
vimentin O
null O
mice O
. O

These O
results O
suggest O
that O
vimentin O
is O
important O
in O
the O
maintenance O
of O
CE O
- O
rich O
LDs O
and O
in O
the O
movement O
of O
cholesterol B
for O
steroidogenesis O
. O

The O
interactive O
effects O
of O
selenomethionine B
and O
methylmercury B
on O
their O
absorption O
, O
disposition O
, O
and O
elimination O
in O
juvenile O
white O
sturgeon O
. O

Selenium B
( O
Se B
) O
and O
mercury B
( O
Hg B
) O
are O
prevalent O
pollutants O
of O
industrialized O
watersheds O
. O

However O
, O
when O
co O
- O
administered O
, O
Se B
has O
protective O
effects O
on O
organisms O
from O
Hg B
. O

The O
mechanism O
is O
not O
fully O
understood O
, O
but O
it O
is O
thought O
that O
Se B
reduces O
Hg B
availability O
, O
either O
by O
forming O
biologically O
inert O
complexes O
and O
/ O
or O
associating O
with O
selenoproteins O
. O

In O
the O
present O
study O
, O
the O
interactive O
effects O
of O
Se B
and O
Hg B
on O
their O
absorption O
, O
disposition O
, O
and O
elimination O
were O
examined O
in O
juvenile O
white O
sturgeon O
, O
a O
benthic O
fish O
species O
at O
high O
risk O
to O
exposures O
of O
both O
contaminants O
. O

Selenium B
and O
Hg B
were O
provided O
as O
L O
- O
selenomethionine O
( O
SeMet B
) O
and O
methylmercury B
( O
MeHg B
) O
, O
respectively O
. O

Groups O
of O
10 O
sturgeon O
were O
orally O
intubated O
with O
a O
single O
dose O
of O
either O
0 O
( O
control O
) O
, O
SeMet B
( O
500 O
mu O
g O
Se B
/ O
kg O
body O
weight O
; O
BW O
) O
, O
MeHg B
( O
850 O
mu O
g O
Hg B
/ O
kg O
BW O
) O
, O
or O
their O
combination O
( O
Se B
/ O
Hg B
; O
500 O
mu O
g O
Se B
/ O
kg O
and O
850 O
mu O
g O
Hg O
/ O
kg O
BW O
) O
. O

At O
48 O
h O
, O
the O
fish O
were O
sacrificed O
for O
Se B
and O
Hg B
tissue O
concentration O
and O
distribution O
. O

The O
co O
- O
administration O
of O
SeMet B
and O
MeHg B
significantly O
( O
p O
< O
0 O
. O
05 O
) O
lowered O
blood O
concentrations O
of O
both O
Se B
and O
Hg B
and O
tissue O
Se B
concentrations O
. O

Similarly O
, O
assimilation O
of O
Se B
and O
Hg B
was O
also O
reduced O
significantly O
. O

The O
interaction O
has O
a O
more O
quantitative O
effect O
on O
Se B
metabolism O
because O
the O
reduction O
in O
the O
overall O
tissue O
Se B
is O
a O
consequence O
of O
reduced O
Se B
absorption O
at O
the O
gut O
and O
not O
from O
the O
metabolic O
effects O
after O
absorption O
. O

In O
contrast O
, O
given O
the O
pulse O
increase O
in O
blood O
Hg B
concentration O
, O
tissue O
redistribution O
, O
and O
increased O
urinary O
elimination O
, O
the O
interactive O
effect O
on O
tissue O
Hg B
concentration O
is O
likely O
to O
be O
post O
- O
absorption O
. O

Even O
in O
the O
absence O
of O
exogenous O
SeMet B
, O
Se B
and O
Hg B
co O
- O
accumulated O
in O
tissue O
at O
a O
Se B
: O
Hg B
molar O
ratio O
greater O
than O
1 O
. O

Thus O
, O
similar O
to O
mammals O
, O
maintaining O
at O
least O
a O
1 O
: O
1 O
molar O
ratio O
of O
Se B
and O
Hg B
is O
of O
great O
physiological O
importance O
in O
the O
white O
sturgeon O
. O

Interestingly O
, O
SeMet B
did O
not O
divert O
Hg B
from O
the O
brain O
. O

Allocation O
of O
Se B
from O
the O
kidneys O
may O
have O
occurred O
in O
order O
to O
maintain O
the O
high O
Se B
: O
Hg B
molar O
ratios O
in O
the O
brain O
of O
white O
sturgeon O
. O

In O
the O
current O
study O
, O
the O
combined O
use O
of O
kinetic O
analysis O
and O
that O
of O
the O
conventional O
approach O
of O
measuring O
tissue O
concentration O
changes O
provided O
a O
comprehensive O
understanding O
of O
the O
interactive O
effect O
of O
SeMet B
and O
MeHg B
on O
their O
respective O
metabolic O
processes O
in O
juvenile O
white O
sturgeon O
. O

Adsorption O
of O
multimeric O
T O
cell O
antigens O
on O
carbon B
nanotubes O
: O
effect O
on O
protein O
structure O
and O
antigen O
- O
specific O
T O
cell O
stimulation O
. O

Antigen O
- O
specific O
activation O
of O
cytotoxic O
T O
cells O
can O
be O
enhanced O
up O
to O
three O
- O
fold O
more O
than O
soluble O
controls O
when O
using O
functionalized O
bundled O
carbon B
nanotube O
substrates O
( O
( O
b O
) O
CNTs O
) O
. O

To O
overcome O
the O
denaturing O
effects O
of O
direct O
adsorption O
on O
( O
b O
) O
CNTs O
, O
a O
simple O
but O
robust O
method O
is O
demonstrated O
to O
stabilize O
the O
T O
cell O
stimulus O
on O
carbon B
nanotube O
substrates O
through O
non O
- O
covalent O
attachment O
of O
the O
linker O
neutravidin O
. O

Based O
on O
recent O
insights O
from O
experimental O
models O
, O
including O
genetics O
and O
pharmacology O
in O
rodents O
typically O
exposed O
to O
diclofenac B
, O
indomethacin B
, O
or O
naproxen B
, O
we O
propose O
a O
multiple O
- O
hit O
pathogenesis O
of O
NSAID O
enteropathy O
. O

Combination O
lopinavir O
and O
ritonavir B
alter O
exogenous O
and O
endogenous O
bile B
acid I
disposition O
in O
sandwich O
- O
cultured O
rat O
hepatocytes O
. O

Inhibition O
of O
the O
bile B
salt I
export O
pump O
( O
BSEP O
) O
can O
cause O
intracellular O
accumulation O
of O
bile B
acids I
and O
is O
a O
risk O
factor O
for O
drug O
- O
induced O
liver O
injury O
in O
humans O
. O

Antiretroviral O
protease O
inhibitors O
lopinavir O
( O
LPV O
) O
and O
ritonavir B
( O
RTV O
) O
are O
reported O
BSEP O
inhibitors O
. O

However O
, O
the O
consequences O
of O
LPV O
and O
RTV O
, O
alone O
and O
combined O
( O
LPV O
/ O
r O
) O
, O
on O
hepatocyte O
viability O
, O
bile B
acid I
transport O
, O
and O
endogenous O
bile B
acid I
disposition O
in O
rat O
hepatocytes O
have O
not O
been O
examined O
. O

Lactate B
dehydrogenase O
and O
ATP B
assays O
revealed O
a O
concentration O
- O
dependent O
effect O
of O
LPV O
and O
RTV O
on O
cellular O
viability O
. O

LPV O
( O
50 O
micro O
M O
) O
, O
RTV O
( O
5 O
micro O
M O
) O
, O
and O
LPV O
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile B
acids I
( O
TCA O
, O
glycocholic O
acid O
, O
taurochenodeoxycholi O
acid O
, O
glycochenodeoxycholi O
acid O
, O
and O
alpha O
/ O
beta O
- O
tauromuricholic O
acid O
) O
in O
SCRH O
. O

Quantification O
of O
endogenous O
bile B
acids I
in O
SCRH O
may O
reveal O
important O
adaptive O
responses O
associated O
with O
exposure O
to O
known O
BSEP O
inhibitors O
. O

The O
theoretical O
calculation O
successfully O
predicted O
the O
experimental O
observation O
that O
the O
monomodal O
- O
poly O
( O
dimethyl O
siloxane O
) O
( O
PDMS B
) O
- O
brush O
- O
grafted O
TiO B
( I
2 I
) I
nanoparticles O
can O
only O
be O
well O
dispersed O
within O
a O
small O
molecular O
weight O
silicone B
matrix O
. O

We O
further O
extended O
the O
parametric O
phase O
diagram O
to O
analyze O
the O
dispersion O
behavior O
of O
bimodal O
- O
PDMS B
- O
brush O
- O
grafted O
particles O
, O
which O
is O
also O
in O
good O
agreement O
with O
experimental O
results O
. O

Utilizing O
a O
bimodal O
grafted O
polymer O
brush O
design O
, O
with O
densely O
grafted O
short O
brushes O
to O
shield O
particle O
surfaces O
and O
sparsely O
grafted O
long O
brushes O
that O
favor O
the O
entanglement O
with O
matrix O
chains O
, O
we O
dispersed O
TiO B
( I
2 I
) I
nanoparticles O
in O
high O
molecular O
weight O
commercial O
silicone B
matrices O
and O
successfully O
prepared O
thick O
( O
about O
5 O
mm O
) O
transparent O
high O
- O
refractive O
- O
index O
TiO B
( I
2 I
) I
/ O
silicone B
nanocomposites O
. O

The O
complete O
and O
reversible O
charge O
- O
selective O
sequestration O
of O
fluorophores O
by O
a O
weak O
polyelectrolyte O
brush O
, O
poly O
( O
2 O
- O
( O
dimethylamino O
) O
ethylmethacrylate O
) O
( O
PDMAEMA B
) O
was O
demonstrated O
using O
fluorescence O
correlation O
spectroscopy O
( O
FCS O
) O
. O

The O
chemistry O
and O
thickness O
of O
the O
weak O
polyelectrolyte O
PDMAEMA B
was O
tuned O
reversibly O
between O
neutral O
and O
cationic O
polymer O
forms O
. O

These O
results O
, O
which O
quantify O
the O
selective O
sequestration O
properties O
of O
the O
PDMAEMA B
brush O
, O
are O
important O
because O
they O
enable O
a O
better O
understanding O
of O
transport O
in O
polymers O
and O
establish O
a O
spectroscopic O
means O
of O
evaluating O
materials O
with O
proposed O
applications O
in O
separations O
science O
, O
charge O
storage O
/ O
release O
, O
and O
environmental O
remediation O
. O

Regulated O
associated O
protein O
of O
mTOR O
( O
Raptor O
) O
and O
rapamycin B
- O
insensitive O
companion O
of O
mTOR O
( O
rictor O
) O
are O
two O
proteins O
that O
delineate O
two O
different O
mTOR O
complexes O
, O
mTORC1 O
and O
mTORC2 O
respectively O
. O

However O
, O
most O
of O
the O
studies O
evaluating O
its O
role O
used O
either O
drug O
treatment O
( O
i O
. O
e O
. O
rapamycin B
) O
or O
modification O
of O
expression O
of O
proteins O
known O
to O
modulate O
its O
activity O
, O
and O
the O
direct O
role O
of O
raptor O
in O
insulin O
secretion O
is O
unclear O
. O

Reduced O
expression O
of O
raptor O
is O
associated O
with O
increased O
glucose B
- O
stimulated O
insulin O
secretion O
and O
intracellular O
insulin O
content O
. O

Our O
finding O
shed O
new O
light O
on O
the O
mechanism O
of O
control O
of O
insulin O
secretion O
and O
production O
by O
the O
mTOR O
, O
and O
they O
provide O
evidence O
for O
antagonistic O
effect O
of O
raptor O
and O
rictor O
on O
insulin O
secretion O
in O
response O
to O
glucose B
by O
modulating O
the O
activity O
of O
Akt O
, O
whereas O
only O
raptor O
is O
able O
to O
control O
insulin O
biosynthesis O
. O

Male O
Sprague O
- O
Dawley O
rats O
were O
exposed O
to O
either O
sham O
or O
IH O
( O
cycles O
between O
21 O
% O
O B
( I
2 I
) I
/ O
0 O
% O
CO B
( I
2 I
) I
and O
5 O
% O
O B
( I
2 I
) I
/ O
5 O
% O
CO B
( I
2 I
) I
) O
conditions O
for O
7 O
h O
/ O
day O
for O
14 O
or O
21 O
days O
. O

Mouse O
liver O
protein O
sulfhydryl B
depletion O
after O
acetaminophen B
exposure O
. O

Acetaminophen B
( O
APAP B
) O
- O
induced O
liver O
injury O
is O
the O
leading O
cause O
of O
acute O
liver O
failure O
in O
many O
countries O
. O

This O
study O
determined O
the O
extent O
of O
liver O
protein O
sulfhydryl B
depletion O
not O
only O
in O
whole O
liver O
homogenate O
but O
also O
in O
the O
zonal O
pattern O
of O
sulfhydryl B
depletion O
within O
the O
liver O
lobule O
. O

A O
single O
oral O
gavage O
dose O
of O
150 O
or O
300 O
mg O
/ O
kg O
APAP B
in O
B6C3F1 O
mice O
produced O
increased O
serum O
alanine B
aminotransferase O
levels O
, O
liver O
necrosis O
, O
and O
glutathione B
depletion O
in O
a O
dose O
- O
dependent O
manner O
. O

Free O
protein O
sulfhydryls B
were O
measured O
in O
liver O
protein O
homogenates O
by O
labeling O
with O
maleimide B
linked O
to O
a O
near O
infrared O
fluorescent O
dye O
followed O
by O
SDS B
- O
polyacrylamide B
gel O
electrophoresis O
. O

Global O
protein O
sulfhydryl B
levels O
were O
decreased O
significantly O
( O
48 O
. O
4 O
% O
) O
starting O
at O
1 O
hour O
after O
the O
APAP B
dose O
and O
maintained O
at O
this O
reduced O
level O
through O
24 O
hours O
. O

To O
visualize O
the O
specific O
hepatocytes O
that O
had O
reduced O
protein O
sulfhydryl B
levels O
, O
frozen O
liver O
sections O
were O
labeled O
with O
maleimide B
linked O
to O
horseradish O
peroxidase O
. O

The O
centrilobular O
areas O
exhibited O
dramatic O
decreases O
in O
free O
protein O
sulfhydryls B
while O
the O
periportal O
regions O
were O
essentially O
spared O
. O

These O
protein O
sulfhydryl B
- O
depleted O
regions O
correlated O
with O
areas O
exhibiting O
histopathologic O
injury O
and O
APAP B
binding O
to O
protein O
. O

The O
majority O
of O
protein O
sulfhydryl B
depletion O
was O
due O
to O
reversible O
oxidation O
since O
the O
global O
- O
and O
lobule O
- O
specific O
effects O
were O
essentially O
reversed O
when O
the O
samples O
were O
reduced O
with O
tris O
( O
2 O
- O
carboxyethy O
) O
phosphine O
before O
maleimide B
labeling O
. O

These O
temporal O
and O
zonal O
pattern O
changes O
in O
protein O
sulfhydryl B
oxidation O
shed O
new O
light O
on O
the O
importance O
that O
changes O
in O
protein O
redox O
status O
might O
play O
in O
the O
pathogenesis O
of O
APAP B
hepatotoxicity O
. O

Distinct O
sensitivity O
of O
slo1 O
channel O
proteins O
to O
ethanol B
. O

Ethanol B
levels O
reached O
in O
circulation O
during O
moderate O
- O
to O
- O
heavy O
alcohol B
intoxication O
( O
50 O
- O
100 O
mM O
) O
modify O
Ca B
( I
2 I
+ I
) I
- O
and O
voltage O
- O
gated O
K B
( I
+ I
) I
( O
BK O
) O
channel O
steady O
- O
state O
activity O
, O
eventually O
altering O
both O
physiology O
and O
behavior O
. O

Ethanol B
action O
on O
BK O
steady O
- O
state O
activity O
solely O
requires O
the O
channel O
- O
forming O
subunit O
slo1 O
within O
a O
bare O
lipid O
environment O
. O

To O
identify O
the O
protein O
regions O
that O
confer O
ethanol B
sensitivity O
to O
slo1 O
, O
we O
tested O
the O
ethanol B
sensitivity O
of O
heterologously O
expressed O
slo1 O
and O
structurally O
related O
channels O
. O

Ethanol B
( O
50 O
mM O
) O
increased O
the O
steady O
- O
state O
activities O
of O
mslo1 O
and O
Ca B
( I
2 I
+ I
) I
- O
gated O
MthK O
, O
the O
latter O
after O
channel O
reconstitution O
into O
phospholipid O
bilayers O
. O

In O
contrast O
, O
50 O
- O
100 O
mM O
ethanol B
failed O
to O
alter O
the O
steady O
- O
state O
activities O
of O
Na B
( I
+ I
) I
/ O
Cl B
( I
- I
) I
- O
gated O
rslo2 O
, O
H B
( I
+ I
) I
- O
gated O
mslo3 O
, O
and O
an O
mslo1 O
/ O
3 O
chimera O
engineered O
by O
joining O
the O
mslo1 O
region O
encompassing O
the O
N B
terminus O
to O
S6 O
with O
the O
mslo3 O
cytosolic O
tail O
domain O
( O
CTD O
) O
. O

Collectively O
, O
data O
indicate O
that O
the O
slo O
family O
canonical O
design O
, O
which O
combines O
a O
transmembrane O
6 O
( O
TM6 O
) O
voltage O
- O
gated O
K B
( I
+ I
) I
channel O
( O
K B
( O
V O
) O
) O
core O
with O
CTDs O
that O
empower O
the O
channel O
with O
ion O
- O
sensing O
, O
does O
not O
necessarily O
render O
ethanol B
sensitivity O
. O

In O
addition O
, O
the O
region O
encompassing O
the O
N B
terminus O
to O
the O
S0 O
- O
S1 O
cytosolic O
loop O
( O
missing O
in O
MthK O
) O
is O
not O
necessary O
for O
ethanol B
action O
. O

Moreover O
, O
incorporation O
of O
both O
this O
region O
and O
an O
ion O
- O
sensing O
CTD O
to O
TM6 O
K B
( O
V O
) O
cores O
( O
a O
design O
common O
to O
mslo1 O
, O
mslo3 O
, O
and O
the O
mslo1 O
/ O
mslo3 O
chimera O
) O
is O
not O
sufficient O
for O
ethanol B
sensitivity O
. O

Rather O
, O
a O
CTD O
containing O
Ca B
( I
2 I
+ I
) I
- O
sensing O
regulator O
of O
conductance O
for O
K B
( I
+ I
) I
domains O
seems O
to O
be O
critical O
to O
bestow O
K B
( O
V O
) O
structures O
, O
whether O
of O
TM2 O
( O
MthK O
) O
or O
TM6 O
( O
slo1 O
) O
, O
with O
sensitivity O
to O
intoxicating O
ethanol B
levels O
. O

Identification O
of O
determinants O
required O
for O
agonistic O
and O
inverse O
agonistic O
ligand O
properties O
at O
the O
ADP B
receptor O
P2Y12 O
. O

The O
ADP B
receptor O
P2Y O
( O
12 O
) O
belongs O
to O
the O
superfamily O
of O
G O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
, O
and O
its O
activation O
triggers O
platelet O
aggregation O
. O

Therefore O
, O
potent O
antagonists O
, O
such O
as O
clopidogrel B
, O
are O
of O
high O
clinical O
relevance O
in O
prophylaxis O
and O
treatment O
of O
thromboembolic O
events O
. O

To O
expand O
this O
limited O
chemical O
space O
and O
improve O
understanding O
of O
structural O
determinants O
of O
inverse O
agonist O
- O
receptor O
interaction O
, O
this O
study O
screened O
a O
purine B
compound O
library O
for O
lead O
structures O
using O
wild O
- O
type O
( O
WT O
) O
human O
P2Y O
( O
12 O
) O
and O
28 O
constitutively O
active O
mutants O
. O

Results O
showed O
that O
ATP B
and O
ATP B
derivatives O
are O
agonists O
at O
P2Y O
( O
12 O
) O
. O

The O
potency O
at O
P2Y O
( O
12 O
) O
was O
2 O
- O
( O
methylthio O
) O
- O
ADP O
> O
2 O
- O
( O
methylthio O
) O
- O
ATP O
> O
ADP B
> O
ATP B
. O

Molecular O
docking O
studies O
revealed O
a O
binding O
pocket O
for O
the O
ATP B
derivatives O
that O
is O
bordered O
by O
transmembrane O
helices O
3 O
, O
5 O
, O
6 O
, O
and O
7 O
in O
human O
P2Y O
( O
12 O
, O
) O
with O
Y O
( O
105 O
) O
, O
E O
( O
188 O
) O
, O
R O
( O
256 O
) O
, O
Y O
( O
259 O
) O
, O
and O
K O
( O
280 O
) O
playing O
a O
particularly O
important O
role O
in O
ligand O
interaction O
. O

N O
- O
Methyl O
- O
anthraniloyl O
modification O
at O
the O
3 O
' O
- O
OH O
of O
the O
2 O
' O
- O
deoxyribose O
leads O
to O
ligands O
( O
mant O
- O
deoxy O
- O
ATP B
[ O
dATP O
] O
, O
mant O
- O
deoxy O
- O
ADP B
) O
with O
inverse O
agonist O
activity O
. O

This O
study O
showed O
that O
, O
in O
addition O
to O
ADP B
and O
ATP B
, O
other O
ATP B
derivatives O
are O
not O
only O
ligands O
of O
P2Y O
( O
12 O
) O
but O
also O
agonists O
. O

Modification O
of O
the O
ribose O
within O
ATP B
can O
result O
in O
inverse O
activity O
of O
ATP B
- O
derived O
ligands O
. O

Over O
12 O
months O
, O
we O
followed O
- O
up O
75 O
schizophrenia O
patients O
who O
were O
classified O
into O
two O
groups O
according O
to O
antipsychotic O
treatment O
: O
clozapine B
or O
olanzapine B
( O
group O
I O
) O
versus O
aripiprazole O
or O
amisulpride B
( O
group O
II O
) O
. O

Interestingly O
, O
ICAM2 O
was O
found O
to O
associate O
with O
beta O
1 O
- O
integrin O
, O
nectin O
- O
3 O
, O
afadin O
, O
Src O
, O
proline O
- O
rich O
tyrosine B
kinase O
2 O
, O
annexin O
II O
, O
and O
actin O
. O

Two O
new O
anthraquinone B
dimers O
from O
the O
fruit O
bodies O
of O
Bulgaria O
inquinans O
. O

Two O
new O
dimeric O
anthraquinone B
derivatives O
, O
bulgareone O
A O
( O
1 O
) O
and O
bulgareone O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
fruit O
bodies O
of O
Bulgaria O
inquinans O
. O

Sex O
differences O
in O
effects O
of O
low O
level O
domoic B
acid I
exposure O
. O

Consumption O
of O
seafood O
containing O
the O
phytoplankton O
- O
derived O
toxin O
domoic B
acid I
( O
DOM O
) O
causes O
neurotoxicity O
in O
humans O
and O
in O
animals O
. O

Toxicokinetic O
study O
and O
absolute O
oral O
bioavailability O
of O
deoxynivalenol B
, O
T O
- O
2 O
toxin O
and O
zearalenone B
in O
broiler O
chickens O
. O

Little O
information O
is O
available O
on O
the O
absolute O
oral O
bioavailability O
and O
the O
toxicokinetic O
parameters O
of O
deoxynivalenol B
, O
T O
- O
2 O
and O
zearalenone B
in O
broilers O
. O

For O
deoxynivalenol B
a O
bolus O
of O
0 O
. O
75mg O
/ O
kg O
BW O
was O
administered O
, O
for O
T O
- O
2 O
toxin O
0 O
. O
02mg O
/ O
kg O
BW O
and O
for O
zearalenone B
0 O
. O
3mg O
/ O
kg O
BW O
. O

Deoxynivalenol B
has O
a O
low O
absolute O
oral O
bioavailability O
( O
19 O
. O
3 O
% O
) O
. O

For O
zearalenone B
and O
T O
- O
2 O
no O
plasma O
levels O
above O
the O
limit O
of O
quantification O
were O
observed O
after O
an O
oral O
bolus O
. O

Volumes O
of O
distribution O
were O
recorded O
, O
i O
. O
e O
. O
4 O
. O
99 O
, O
0 O
. O
14 O
and O
22 O
. O
26L O
/ O
kg O
for O
deoxynivalenol B
, O
T O
- O
2 O
toxin O
and O
zearalenone B
, O
respectively O
. O

Total O
body O
clearance O
was O
0 O
. O
12 O
, O
0 O
. O
03 O
and O
0 O
. O
48L O
/ O
minkg O
for O
deoxynivalenol B
, O
T O
- O
2 O
toxin O
and O
zearalenone B
, O
respectively O
. O

After O
IV O
administration O
, O
T O
- O
2 O
toxin O
had O
the O
shortest O
elimination O
half O
- O
life O
( O
3 O
. O
9min O
) O
, O
followed O
by O
deoxynivalenol B
( O
27 O
. O
9min O
) O
and O
zearalenone B
( O
31 O
. O
8min O
) O
. O

Citrus O
peel O
polymethoxylated B
flavones I
extract O
modulates O
liver O
and O
heart O
function O
parameters O
in O
diet O
induced O
hypercholesterolemic O
rats O
. O

The O
primary O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
Ortanique O
peel O
polymethoxylated B
flavones I
extract O
( O
PMF O
( O
ort O
) O
) O
on O
organ O
function O
parameters O
in O
the O
serum O
of O
hypercholesterolemic O
and O
normal O
rats O
. O

Thirty O
Sprague O
- O
Dawley O
rats O
were O
fed O
high O
cholesterol B
diets O
supplemented O
with O
1 O
. O
5 O
% O
PMF O
( O
ort O
) O
and O
niacin O
respectively O
for O
49days O
. O

Hypercholesterolemic O
rats O
fed O
PMF O
( O
ort O
) O
had O
significant O
reductions O
in O
the O
activities O
of O
aspartate B
aminotransferase O
and O
alkaline O
phosphatase O
( O
69 O
. O
12 O
+ O
/ O
- O
3 O
. O
34 O
and O
87 O
. O
22 O
+ O
/ O
- O
8 O
. O
42U O
/ O
L O
respectively O
) O
compared O
to O
the O
untreated O
hypercholesterolemic O
group O
( O
118 O
. O
61 O
+ O
/ O
- O
4 O
. O
85 O
and O
132 O
. O
62 O
+ O
/ O
- O
10 O
. O
62U O
/ O
L O
respectively O
, O
p O
< O
0 O
. O
05 O
) O
. O

Supplementation O
of O
the O
diet O
with O
niacin O
or O
PMF O
( O
ort O
) O
resulted O
in O
no O
significant O
differences O
in O
the O
serum O
levels O
of O
creatinine B
or O
urea B
in O
any O
of O
the O
groups O
. O

Total O
bilirubin B
was O
highest O
in O
the O
untreated O
hypercholesterolemic O
group O
. O

Supplementation O
of O
the O
diets O
of O
hypercholesterolemic O
rats O
with O
PMF O
( O
ort O
) O
resulted O
in O
significant O
reductions O
in O
the O
activities O
of O
serum O
creatine B
kinase O
and O
lactate B
dehydrogenase O
( O
119 O
. O
3 O
+ O
/ O
- O
25 O
. O
3 O
; O
222 O
. O
5 O
+ O
/ O
- O
50 O
. O
3U O
/ O
L O
, O
p O
< O
0 O
. O
05 O
) O
respectively O
relative O
to O
the O
untreated O
hypercholesterolemic O
group O
( O
257 O
. O
2 O
+ O
/ O
- O
48 O
. O
3 O
; O
648 O
. O
8 O
+ O
/ O
- O
103U O
/ O
L O
, O
p O
< O
0 O
. O
05 O
) O
. O

Assessment O
of O
immunotoxicity O
and O
genotoxicity O
in O
workers O
exposed O
to O
low O
concentrations O
of O
formaldehyde B
. O

Formaldehyde B
( O
FA O
) O
, O
which O
is O
an O
important O
chemical O
with O
a O
wide O
commercial O
use O
, O
has O
been O
classified O
as O
carcinogenic O
to O
humans O
by O
International O
Research O
on O
Cancer O
( O
IARC O
) O
. O

Mitochondrial O
fusion O
: O
a O
mechanism O
of O
cisplatin B
- O
induced O
resistance O
in O
neuroblastoma O
cells O
? O

Cisplatin B
induces O
apoptosis O
through O
different O
pathways O
. O

The O
intrinsic O
apoptotic O
pathway O
is O
mediated O
by O
mitochondria O
, O
which O
, O
as O
a O
result O
of O
cisplatin B
treatment O
, O
undergo O
morphological O
alterations O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
cisplatin B
- O
induced O
mitochondrial O
functional O
and O
morphological O
long O
- O
term O
effects O
in O
neuroblastoma O
B50 O
rat O
cells O
. O

We O
applied O
different O
treatment O
protocols O
based O
on O
the O
incubation O
of O
the O
neuroblastoma O
B50 O
rat O
cells O
with O
40 O
mu O
M O
cisplatin B
: O
( O
i O
) O
for O
48 O
h O
and O
harvesting O
of O
the O
cells O
at O
the O
end O
of O
the O
treatment O
; O
( O
ii O
) O
further O
recovery O
in O
drug O
- O
free O
medium O
for O
7 O
days O
post O
- O
treatment O
; O
( O
iii O
) O
conditions O
as O
in O
( O
ii O
) O
followed O
by O
re O
- O
seeding O
in O
normal O
medium O
and O
growth O
for O
a O
further O
4 O
days O
. O

HBM O
cases O
had O
substantially O
greater O
trabecular O
density O
at O
the O
distal O
tibia O
( O
340 O
[ O
320 O
, O
359 O
] O
mg O
/ O
cm O
( O
3 O
) O
) O
, O
compared O
to O
both O
family O
( O
294 O
[ O
276 O
, O
312 O
] O
) O
and O
population O
controls O
( O
290 O
[ O
281 O
, O
299 O
] O
) O
( O
p O
< O
0 O
. O
001 O
for O
both O
, O
adjusted O
for O
age O
, O
gender O
, O
weight O
, O
height O
, O
alcohol O
, O
smoking O
, O
malignancy O
, O
menopause O
, O
steroid B
and O
estrogen B
replacement O
use O
) O
. O

Intestinal O
metabolism O
was O
studied O
using O
testosterone B
and O
midazolam B
as O
probe O
substrates O
. O

Regional O
permeability O
data O
showed O
a O
tendency O
for O
highly O
permeable O
compounds O
to O
have O
higher O
or O
similar O
P O
( O
app O
) O
in O
colon O
as O
in O
the O
small O
intestinal O
segments O
, O
while O
the O
colonic O
regions O
showed O
a O
lower O
P O
( O
app O
) O
for O
more O
polar O
compounds O
as O
well O
as O
for O
d B
- I
glucose I
and O
l B
- I
leucine I
. O

Intestinal O
metabolic O
extraction O
during O
transport O
across O
jejunum O
segments O
was O
found O
for O
both O
testosterone B
and O
midazolam B
. O

Can O
P O
- O
glycoprotein O
mediate O
resistance O
to O
nilotinib B
in O
human O
leukaemia O
cells O
? O

The O
effect O
of O
P O
- O
glycoprotein O
( O
P O
- O
gp O
, O
ABCB1 O
, O
MDR1 O
) O
expression O
on O
cell O
resistance O
to O
nilotinib B
was O
studied O
in O
human O
leukaemia O
cells O
. O

We O
used O
K562 O
/ O
Dox B
cells O
overexpressing O
P O
- O
gp O
and O
their O
variants O
( O
subclones O
) O
with O
a O
gradually O
decreased O
P O
- O
gp O
expression O
. O

These O
subclones O
were O
established O
by O
stable O
transfection O
of O
K562 O
/ O
Dox B
cells O
with O
a O
plasmid O
vector O
expressing O
shRNA O
targeting O
the O
ABCB1 O
gene O
. O

We O
observed O
that O
K562 O
/ O
Dox B
cells O
overexpressing O
P O
- O
gp O
contained O
a O
significantly O
reduced O
intracellular O
level O
of O
nilotinib B
when O
compared O
to O
their O
counter O
partner O
K562 O
cells O
, O
which O
do O
not O
express O
P O
- O
gp O
. O

This O
effect O
was O
accompanied O
by O
a O
decreased O
sensitivity O
of O
the O
K562 O
/ O
Dox B
cells O
to O
nilotinib B
. O

Importantly O
, O
cells O
with O
downregulated O
expression O
of O
P O
- O
gp O
gradually O
lost O
their O
ability O
to O
decrease O
the O
intracellular O
level O
of O
nilotinib B
although O
they O
still O
significantly O
decreased O
the O
intracellular O
level O
of O
daunorubicin O
( O
DNR O
) O
. O

Accordingly O
, O
cells O
with O
the O
reduced O
expression O
of O
P O
- O
gp O
concomitantly O
failed O
to O
provide O
resistance O
to O
nilotinib B
, O
however O
, O
they O
exhibited O
a O
significant O
resistance O
to O
DNR O
. O

Taken O
together O
, O
we O
demonstrated O
that O
the O
conclusion O
as O
to O
whether O
P O
- O
gp O
is O
involved O
in O
nilotinib B
resistance O
or O
not O
strongly O
depends O
on O
its O
expression O
at O
protein O
level O
. O

Peroxisome O
- O
proliferator O
activated O
receptor O
( O
PPAR O
) O
- O
delta O
agonists O
have O
never O
been O
tested O
in O
models O
of O
sugar B
- O
induced O
metabolic O
abnormalities O
. O

In O
the O
kidney O
, O
HFCS O
- O
55 O
enhanced O
the O
expression O
of O
the O
NLRP3 O
( O
nucleotide B
- O
binding O
domain O
and O
leucine B
- O
rich O
- O
repeat O
- O
protein O
3 O
) O
inflammasome O
complex O
, O
resulting O
in O
caspase O
- O
1 O
activation O
and O
interleukin O
- O
1 O
beta O
production O
. O

Biology O
and O
therapeutic O
potential O
of O
hydrogen B
sulfide I
and O
hydrogen B
sulfide I
- O
releasing O
chimeras O
. O

Hydrogen B
sulfide I
, O
H2S O
, O
is O
a O
colorless O
gas O
with O
a O
strong O
odor O
that O
until O
recently O
was O
only O
considered O
to O
be O
a O
toxic O
environmental O
pollutant O
with O
little O
or O
no O
physiological O
significance O
. O

However O
, O
the O
past O
few O
years O
have O
demonstrated O
its O
role O
in O
many O
biological O
systems O
and O
it O
is O
becoming O
increasingly O
clear O
that O
H2S O
is O
likely O
to O
join O
nitric B
oxide I
( O
NO B
) O
and O
carbon B
monoxide I
( O
CO B
) O
as O
a O
major O
player O
in O
mammalian O
biology O
. O

The O
naturally O
occurring O
compounds O
discussed O
include O
, O
garlic O
, O
sulforaphane B
, O
erucin O
, O
and O
iberin O
. O

The O
synthetic O
H2S O
donors O
reviewed O
include O
, O
GYY4137 O
; O
cysteine B
analogs O
; O
S O
- O
propyl O
cysteine O
, O
S O
- O
allyl O
cysteine O
, O
S O
- O
propargyl O
cysteine O
, O
and O
N B
- I
acetyl I
cysteine I
. O

Dithiolethione O
and O
its O
NSAID O
and O
other O
chimeras O
such O
as O
, O
L O
- O
DOPA O
, O
sildenafil B
, O
aspirin B
, O
diclofenac B
, O
naproxen B
, O
ibuprofen B
, O
indomethacin B
, O
and O
mesalamine O
have O
also O
been O
reviewed O
in O
detail O
. O

The O
newly O
reported O
NOSH O
- O
aspirin O
that O
releases O
both O
NO B
and O
H2S O
has O
also O
been O
discussed O
. O

Nearly O
half O
of O
the O
AKRs O
are O
expected O
to O
be O
monomeric O
, O
but O
there O
are O
examples O
of O
dimeric O
, O
trimeric O
and O
octameric O
enzymes O
, O
as O
well O
as O
diversity O
in O
specificity O
for O
NAD B
as O
well O
as O
NADP B
as O
a O
cofactor O
. O

Dietary O
exposure O
to O
inorganic O
arsenic B
of O
the O
Hong O
Kong O
population O
: O
results O
of O
the O
first O
Hong O
Kong O
total O
diet O
study O
. O

Inorganic O
arsenic B
, O
a O
human O
carcinogen O
, O
can O
be O
found O
in O
the O
environment O
and O
food O
. O

In O
the O
first O
Hong O
Kong O
Total O
Diet O
Study O
, O
the O
dietary O
exposure O
of O
the O
Hong O
Kong O
people O
, O
including O
various O
age O
- O
gender O
subgroups O
, O
to O
inorganic O
arsenic B
was O
estimated O
for O
assessing O
the O
associated O
health O
risk O
. O

Concentrations O
of O
inorganic O
arsenic B
, O
as O
sum O
of O
arsenite B
( O
As B
( I
III I
) I
) O
and O
arsenate B
( O
As B
( I
V I
) I
) O
were O
determined O
in O
600 O
composite O
samples O
by O
using O
inductively O
coupled O
plasma O
mass O
spectrometry O
. O

The O
mean O
and O
95th O
percentile O
of O
inorganic O
arsenic B
exposures O
of O
the O
Hong O
Kong O
people O
were O
0 O
. O
22 O
and O
0 O
. O
38 O
mu O
g O
/ O
kg O
body O
weight O
( O
bw O
) O
/ O
day O
, O
respectively O
. O

The O
main O
food O
category O
that O
contributed O
inorganic O
arsenic B
was O
" O
cereals O
and O
their O
products O
" O
( O
53 O
. O
5 O
% O
of O
the O
total O
exposure O
) O
, O
particularly O
rice O
. O

Having O
considered O
the O
carcinogenic O
risk O
of O
inorganic O
arsenic B
to O
humans O
, O
it O
is O
suggested O
that O
efforts O
should O
be O
made O
to O
reduce O
the O
inorganic O
arsenic B
exposure O
of O
the O
Hong O
Kong O
population O
. O

The O
two O
- O
component O
system O
AfsQ1 O
/ O
Q2 O
of O
Streptomyces O
coelicolor O
was O
identified O
in O
our O
previous O
work O
as O
a O
pleiotropic O
regulator O
for O
antibiotic O
biosynthesis O
and O
morphological O
differentiation O
under O
the O
condition O
of O
a O
minimal O
medium O
supplemented O
with O
75 O
mM O
glutamate B
. O

By O
computational O
prediction O
and O
functional O
analysis O
, O
at O
least O
17 O
new O
AfsQ1 O
targets O
were O
identified O
, O
including O
pstS O
gene O
encoding O
a O
high O
- O
affinity O
phosphate B
- O
binding O
protein O
and O
two O
developmental O
genes O
whiD O
, O
bldM O
. O

Interestingly O
, O
we O
found O
from O
electrophoretic O
mobility O
shift O
assays O
and O
transcriptional O
analysis O
that O
AfsQ1 O
/ O
Q2 O
can O
also O
function O
as O
a O
repressor O
for O
nitrogen B
assimilation O
, O
and O
AfsQ1 O
can O
compete O
with O
GlnR O
for O
the O
promoter O
regions O
of O
glnA O
and O
nirB O
, O
suggesting O
the O
cross O
- O
regulation O
between O
AfsQ1 O
/ O
Q2 O
and O
GlnR O
in O
nitrogen B
metabolism O
. O

These O
findings O
suggested O
that O
AfsQ1 O
/ O
Q2 O
is O
important O
not O
only O
for O
antibiotic O
biosynthesis O
but O
also O
in O
maintaining O
the O
metabolic O
homeostasis O
of O
nutrient O
utilization O
under O
the O
stress O
of O
high O
concentration O
of O
glutamate B
in O
S O
. O
coelicolor O
. O

Autophagy O
upregulation O
promotes O
survival O
and O
attenuates O
doxorubicin B
- O
induced O
cardiotoxicity O
. O

This O
study O
evaluated O
whether O
the O
manipulation O
of O
autophagy O
could O
attenuate O
the O
cardiotoxic O
effects O
of O
doxorubicin B
( O
DXR B
) O
in O
vitro O
as O
well O
as O
in O
a O
tumour O
- O
bearing O
mouse O
model O
of O
acute O
doxorubicin B
- O
induced O
cardiotoxicity O
. O

We O
examined O
the O
effect O
of O
an O
increase O
or O
inhibition O
of O
autophagy O
in O
combination O
with O
DXR B
on O
apoptosis O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
mitochondrial O
function O
. O

H9C2 O
rat O
cardiac O
myoblasts O
were O
pre O
- O
treated O
with O
bafilomycin B
A1 I
( O
autophagy O
inhibitor O
, O
10 O
nM O
) O
or O
rapamycin B
( O
autophagy O
inducer O
, O
50 O
mu O
M O
) O
followed O
by O
DXR B
treatment O
( O
3 O
mu O
M O
) O
. O

The O
augmentation O
of O
autophagy O
with O
rapamycin B
in O
the O
presence O
of O
DXR B
substantially O
ameliorated O
the O
detrimental O
effects O
induced O
by O
DXR B
. O

Following O
the O
appearance O
of O
tumours O
, O
animals O
were O
either O
treated O
with O
one O
injection O
of O
rapamycin B
( O
4 O
mg O
/ O
kg O
) O
followed O
by O
two O
injections O
of O
DXR B
( O
10 O
mg O
/ O
kg O
) O
. O

These O
results O
strongly O
indicate O
that O
the O
co O
- O
treatment O
strategy O
with O
rapamycin B
can O
attenuate O
the O
cardiotoxic O
effects O
of O
DXR B
in O
a O
tumour O
- O
bearing O
mouse O
model O
. O

Arsenic B
inhibits O
the O
adipogenic O
differentiation O
of O
mesenchymal O
stem O
cells O
by O
down O
- O
regulating O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
and O
CCAAT O
enhancer O
- O
binding O
proteins O
. O

Arsenic B
remains O
a O
top O
environmental O
concern O
in O
the O
United O
States O
as O
well O
as O
worldwide O
because O
of O
its O
global O
existence O
and O
serious O
health O
impacts O
. O

Apoptotic O
effect O
of O
arsenic B
in O
human O
mesenchymal O
stem O
cells O
( O
hMSCs O
) O
has O
been O
identified O
in O
our O
previous O
study O
; O
the O
effects O
of O
arsenic B
on O
hMSCs O
remain O
largely O
unknown O
. O

Here O
, O
we O
report O
that O
arsenic B
inhibits O
the O
adipogenic O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
( O
hMSCs O
) O
. O

Arsenic B
reduced O
the O
formation O
of O
lipid O
droplets O
and O
the O
expression O
of O
adipogenesis O
- O
related O
proteins O
, O
such O
as O
CCAAT O
enhancer O
binding O
protein O
- O
( O
C O
/ O
EBPs O
) O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
( O
PPAR O
- O
gamma O
) O
, O
and O
adipocyte O
fatty B
acid I
- O
binding O
protein O
aP2 O
( O
aP2 O
) O
. O

Arsenic B
mediates O
this O
process O
by O
sustaining O
PPAR O
- O
gamma O
activity O
. O

In O
addition O
, O
inhibition O
of O
PPAR O
- O
gamma O
activity O
with O
T0070907 O
and O
up O
- O
regulation O
with O
its O
agonist O
troglitazone B
, O
showed O
the O
direct O
association O
of O
PPAR O
- O
gamma O
and O
arsenic B
- O
mediated O
inhibition O
of O
differentiating O
hMSCs O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
arsenic B
inhibits O
adipogenic O
differentiation O
through O
PPAR O
- O
gamma O
pathway O
and O
suggest O
a O
novel O
inhibitory O
effect O
of O
arsenic B
on O
adipogenic O
differentiation O
in O
hMSCs O
. O

Ethyl B
acetate I
: O
X O
- O
ray O
, O
solvent O
and O
computed O
structures O
. O

Ethyl B
acetate I
( O
ethyl O
ethanoate O
) O
was O
crystallized O
in O
situ O
and O
the O
crystal O
structure O
was O
determined O
. O

The O
geometric O
details O
of O
ethyl B
acetate I
as O
a O
solvate O
are O
analyzed O
statistically O
using O
the O
Cambridge O
Structural O
Database O
, O
uncovering O
a O
high O
degree O
of O
hidden O
disorder O
. O

H2AX O
is O
thought O
to O
operate O
primarily O
through O
its O
C B
- O
terminal O
S139 O
phosphorylation O
, O
which O
mediates O
the O
recruitment O
of O
DNA O
damage O
response O
( O
DDR O
) O
factors O
to O
chromatin O
at O
DSB O
sites O
. O

In O
search O
of O
a O
next O
generation O
molecule O
to O
the O
novel O
wake O
- O
promoting O
agent O
modafinil B
, O
a O
series O
of O
aryl O
- O
heteroayl O
- O
derived O
wakefulness O
enhancing O
agents O
( O
in O
rats O
) O
was O
developed O
. O

The O
participating O
laboratories O
received O
two O
identical O
blood O
specimens O
: O
in O
an O
EDTA B
tubes O
( O
unstabilized O
blood O
; O
n O
= O
67 O
) O
or O
in O
tubes O
designed O
specifically O
for O
the O
stabilization O
of O
intracellular O
RNA O
in O
blood O
( O
PAXgene O
( O
R O
) O
Blood O
RNA O
tubes O
; O
n O
= O
35 O
) O
. O

Reversal O
of O
efflux O
mediated O
antifungal O
resistance O
underlies O
synergistic O
activity O
of O
two O
monoterpenes O
with O
fluconazole B
. O

Thymol B
( O
THY O
) O
and O
carvacrol B
( O
CARV O
) O
, O
the O
principal O
chemical O
components O
of O
thyme O
oil O
have O
long O
been O
known O
for O
their O
wide O
use O
in O
medicine O
due O
to O
antimicrobial O
and O
disinfectant O
properties O
. O

This O
study O
, O
however O
, O
draws O
attention O
to O
a O
possible O
synergistic O
antifungal O
effect O
of O
these O
monoterpenes O
with O
azole B
antimycotic O
- O
fluconazole B
. O

Resistance O
to O
azoles B
in O
Candida O
albicans O
involves O
over O
- O
expression O
of O
efflux O
- O
pump O
genes O
MDR1 O
, O
CDR1 O
, O
CDR2 O
or O
mutations O
and O
over O
- O
expression O
of O
target O
gene O
ERG11 O
. O

The O
drug O
efflux O
activity O
was O
determined O
using O
two O
dyes O
, O
Rhodamine6G O
( O
R6G O
) O
and O
fluorescent O
Hoechst B
33342 I
. O

No O
significant O
differences O
were O
observed O
in O
dye O
uptakes O
between O
FLC O
- O
susceptible O
and O
resistant O
isolates O
, O
incubated O
in O
glucose B
free O
buffer O
. O

However O
, O
a O
significantly O
higher O
efflux O
was O
recorded O
in O
FLC O
- O
resistant O
isolates O
when O
glucose B
was O
added O
. O

Experimental O
exposure O
of O
red O
- O
legged O
partridges O
( O
Alectoris O
rufa O
) O
to O
seeds O
coated O
with O
imidacloprid B
, O
thiram O
and O
difenoconazole O
. O

One O
year O
- O
old O
partridges O
( O
n O
= O
42 O
pairs O
) O
were O
fed O
for O
10 O
days O
in O
spring O
( O
prior O
to O
breeding O
) O
with O
wheat O
treated O
with O
difenoconazole O
( O
fungicide O
) O
, O
thiram O
( O
fungicide O
) O
or O
imidacloprid B
( O
insecticide O
) O
, O
using O
two O
doses O
for O
each O
pesticide O
( O
the O
one O
recommended O
, O
and O
its O
double O
to O
represent O
potential O
cases O
of O
abuse O
of O
pesticides O
) O
. O

Thiram O
and O
imidacloprid B
at O
high O
exposure O
doses O
produced O
mortalities O
of O
41 O
. O
6 O
and O
58 O
. O
3 O
% O
, O
respectively O
. O

The O
first O
death O
was O
observed O
at O
day O
3 O
for O
imidacloprid B
and O
at O
day O
7 O
for O
thiram O
. O

The O
high O
exposure O
doses O
of O
imidacloprid B
and O
thiram O
also O
produced O
a O
decrease O
in O
cellular O
immune O
response O
measured O
by O
the O
phytohemagglutinin O
test O
in O
males O
. O

Bearing O
in O
mind O
the O
limitation O
of O
the O
small O
number O
of O
surviving O
pairs O
in O
some O
treatments O
, O
we O
found O
that O
the O
three O
pesticides O
reduced O
the O
size O
of O
eggs O
and O
imidacloprid B
and O
difenoconazole O
also O
reduced O
the O
fertilization O
rate O
. O

In O
addition O
, O
both O
thiram O
and O
imidacloprid B
reduced O
chick O
survival O
. O

The O
role O
of O
adenosine B
receptors O
on O
amitriptyline B
- O
induced O
electrophysiological O
changes O
on O
rat O
atrium O
. O

We O
investigated O
the O
role O
of O
adenosine B
receptors O
in O
amitriptyline B
- O
induced O
cardiac O
action O
potential O
( O
AP O
) O
changes O
in O
isolated O
rat O
atria O
. O

In O
the O
first O
group O
, O
APs O
were O
recorded O
after O
cumulative O
addition O
of O
amitriptyline B
( O
1 O
mu O
M O
, O
10 O
mu O
M O
and O
50 O
mu O
M O
) O
. O

In O
other O
groups O
, O
each O
atrium O
was O
incubated O
with O
selective O
adenosine B
A O
( O
1 O
) O
antagonist O
( O
8 O
- O
cyclopentyl O
- O
1 O
, O
3 O
- O
dipropylxanthine O
( O
DPCPX O
) O
, O
10 O
( O
- O
4 O
) O
M O
) O
or O
selective O
adenosine B
A O
( O
2a O
) O
receptor O
antagonist O
( O
8 O
- O
( O
3 O
- O
chlorostyryl O
) O
caffeine O
, O
10 O
( O
- O
5 O
) O
M O
) O
before O
amitriptyline B
administration O
. O

Amitriptyline B
( O
50 O
mu O
M O
) O
prolonged O
the O
APD O
( O
50 O
) O
and O
APD O
( O
80 O
) O
( O
p O
< O
0 O
. O
001 O
) O
and O
the O
maximum O
rise O
slope O
of O
AP O
was O
reduced O
by O
amitriptyline B
( O
p O
< O
0 O
. O
0001 O
) O
. O

Amitriptyline B
reduced O
maximum O
decay O
slope O
of O
AP O
only O
at O
50 O
mu O
M O
( O
p O
< O
0 O
. O
01 O
) O
. O

DPCPX O
significantly O
decreased O
the O
50 O
- O
mu O
M O
amitriptyline B
- O
induced O
APD O
( O
50 O
) O
and O
APD O
( O
80 O
) O
prolongation O
( O
p O
< O
0 O
. O
001 O
) O
. O

DPCPX O
significantly O
prevented O
the O
effects O
of O
amitriptyline B
( O
1 O
mu O
M O
and O
50 O
mu O
M O
) O
on O
maximum O
rise O
slope O
of O
AP O
( O
p O
< O
0 O
. O
05 O
) O
. O

DPCPX O
significantly O
prevented O
the O
amitriptyline B
- O
induced O
( O
50 O
mu O
M O
) O
reduction O
in O
maximum O
decay O
slope O
of O
AP O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
selective O
adenosine B
A O
( O
1 O
) O
receptor O
antagonist O
prevented O
the O
electrophysiological O
effects O
of O
amitriptyline B
on O
atrial O
AP O
. O

A O
( O
1 O
) O
receptor O
stimulation O
may O
be O
responsible O
for O
the O
cardiovascular O
toxic O
effects O
produced O
by O
amitriptyline B
. O

Single O
- O
agent O
duloxetine B
ingestions O
. O

Duloxetine B
is O
a O
serotonin B
and O
norepinephrine B
reuptake O
inhibitor O
, O
which O
is O
mainly O
used O
to O
treat O
depression O
. O

This O
retrospective O
study O
describes O
the O
demographic O
and O
clinical O
effects O
of O
duloxetine B
ingestions O
reported O
to O
the O
National O
Poison O
Data O
System O
( O
NPDS O
) O
. O

NPDS O
data O
were O
searched O
for O
duloxetine B
exposures O
between O
2004 O
and O
2010 O
. O

The O
protective O
effect O
of O
recombinant O
human O
erythropoietin O
against O
cisplatin B
- O
induced O
renal O
and O
hepatic O
dysfunctions O
in O
Wistar O
rats O
. O

Cisplatin B
( O
Cisp O
) O
is O
one O
of O
the O
most O
effective O
chemotherapeutic O
drugs O
. O

Our O
results O
showed O
that O
Cisp O
- O
induced O
a O
marked O
renal O
and O
liver O
failure O
characterized O
by O
a O
significant O
decrease O
in O
body O
weight O
, O
organ O
weight O
and O
organ O
ratio O
and O
a O
significant O
increase O
in O
creatinine B
, O
blood O
urea B
nitrogen B
, O
alanine B
aminotransferase O
, O
aspartate B
aminotransferase O
, O
G O
- O
glutamyl O
transferase O
, O
alkaline O
phosphatase O
, O
bilirubin B
conjugated O
and O
bilirubin B
total O
levels O
in O
serum O
. O

Effects O
of O
increasing O
supplementation O
of O
magnesium B
in O
diets O
on O
productive O
performance O
and O
eggshell O
quality O
of O
aged O
laying O
hens O
. O

Magnesium B
( O
Mg B
) O
concentrations O
in O
diets O
have O
been O
associated O
with O
performance O
and O
eggshell O
quality O
of O
laying O
hens O
, O
but O
the O
results O
have O
been O
inconclusive O
. O

In O
this O
experiment O
, O
the O
effects O
of O
increasing O
concentrations O
of O
dietary O
Mg B
on O
productive O
performance O
and O
eggshell O
quality O
of O
aged O
laying O
hens O
were O
evaluated O
. O

A O
commercial O
- O
type O
basal O
diet O
containing O
1 O
. O
6 O
g O
/ O
kg O
Mg B
was O
prepared O
, O
and O
three O
additional O
diets O
were O
prepared O
to O
contain O
2 O
. O
3 O
, O
2 O
. O
6 O
, O
or O
3 O
. O
0 O
g O
/ O
kg O
Mg B
in O
diets O
by O
adding O
1 O
. O
0 O
, O
1 O
. O
5 O
, O
or O
2 O
. O
0 O
g O
of O
MgO B
to O
the O
basal O
diet O
. O

Results O
indicated O
that O
Mg B
concentrations O
in O
eggshells O
were O
increased O
( O
linear O
, O
P O
< O
0 O
. O
01 O
) O
with O
increasing O
concentrations O
of O
Mg B
in O
diets O
. O

Increasing O
concentrations O
of O
Mg B
in O
diets O
decreased O
( O
linear O
and O
quadratic O
, O
P O
< O
0 O
. O
01 O
) O
broken O
and O
shell O
- O
less O
egg O
production O
, O
but O
improved O
( O
linear O
, O
P O
< O
0 O
. O
05 O
) O
eggshell O
strength O
. O

Feed O
intake O
was O
decreased O
( O
linear O
, O
P O
< O
0 O
. O
05 O
) O
with O
the O
concentrations O
of O
Mg B
in O
diets O
, O
but O
hen O
- O
day O
egg O
production O
, O
egg O
weight O
, O
feed O
conversion O
ratio O
, O
and O
Haugh O
unit O
were O
not O
affected O
by O
increasing O
concentrations O
of O
Mg B
in O
diets O
. O

Hunter O
L O
* O
and O
a O
* O
values O
of O
eggshell O
were O
decreased O
( O
linear O
, O
P O
< O
0 O
. O
05 O
) O
as O
the O
concentrations O
of O
Mg B
in O
diets O
increased O
. O

In O
conclusion O
, O
feeding O
aged O
laying O
hens O
with O
diets O
containing O
increasing O
concentrations O
of O
Mg B
up O
to O
3 O
. O
0 O
g O
/ O
kg O
improves O
eggshell O
strength O
, O
but O
has O
no O
detrimental O
effects O
on O
laying O
performance O
. O

Novel O
insights O
on O
the O
effect O
of O
nicotine B
in O
a O
murine O
colitis O
model O
. O

Studies O
showed O
that O
nicotine B
has O
a O
positive O
influence O
on O
symptoms O
of O
ulcerative O
colitis O
. O

In O
the O
present O
study O
, O
we O
explored O
the O
effect O
of O
nicotine B
treatment O
using O
different O
routes O
of O
administration O
in O
the O
dextran O
sodium O
sulfate O
( O
DSS O
) O
colitis O
mouse O
model O
. O

We O
also O
investigated O
the O
effects O
of O
cotinine B
, O
a O
major O
metabolite O
of O
nicotine B
, O
in O
the O
model O
. O

The O
effect O
of O
nicotine B
and O
cotinine B
treatments O
via O
various O
different O
routes O
of O
administration O
were O
examined O
the O
DSS O
model O
. O

In O
addition O
, O
we O
measured O
the O
plasma O
levels O
of O
nicotine B
and O
cotinine B
in O
our O
treatment O
protocols O
. O

Administration O
of O
low O
, O
but O
not O
high O
, O
doses O
of O
oral O
nicotine B
in O
DSS O
- O
treated O
mice O
resulted O
in O
a O
significant O
decrease O
in O
disease O
severity O
, O
histologic O
damage O
scores O
, O
as O
well O
as O
colonic O
level O
of O
tumor O
necrosis O
factor O
- O
alpha O
. O

However O
, O
the O
anti O
- O
inflammatory O
effect O
of O
nicotine B
was O
not O
seen O
after O
chronic O
s O
. O
c O
. O
or O
minipump O
infusion O
of O
the O
drug O
. O

Differences O
in O
plasma O
levels O
of O
nicotine B
and O
cotinine B
do O
not O
seem O
to O
account O
for O
this O
lack O
of O
effect O
. O

Finally O
, O
oral O
cotinine B
alone O
failed O
to O
show O
a O
significant O
effect O
in O
the O
DSS O
model O
of O
colitis O
. O

These O
results O
highlight O
that O
dose O
and O
route O
of O
administration O
play O
a O
critical O
role O
in O
the O
protective O
effect O
of O
nicotine B
in O
the O
DSS O
mouse O
colitis O
model O
. O

Androgen B
receptor O
CAG O
repeat O
length O
modifies O
the O
effect O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
on O
receptor O
activity O
in O
human O
prostate O
cells O
. O

Increased O
incidence O
of O
prostate O
cancer O
has O
been O
reported O
in O
men O
exposed O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

TCDD B
acts O
through O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
which O
interacts O
with O
the O
androgen B
receptor O
( O
AR O
) O
. O

We O
investigated O
the O
influence O
of O
TCDD B
on O
prostate O
cancer O
cells O
( O
PC O
- O
3 O
) O
and O
non O
- O
tumor O
prostate O
cells O
( O
PNT1A O
) O
on O
5 B
alpha I
- I
dihydrotestosterone I
- O
activated O
ARs O
containing O
CAG O
repeats O
within O
normal O
length O
range O
( O
16 O
, O
22 O
, O
and O
28 O
) O
. O

The O
AhR O
target O
gene O
CYP1A1 O
mRNA O
expression O
was O
induced O
by O
TCDD B
, O
but O
was O
not O
affected O
by O
the O
AR O
CAG O
length O
. O

TCDD B
had O
no O
effect O
on O
AR O
activity O
in O
PC O
- O
3 O
cells O
, O
whereas O
the O
shortest O
AR O
variant O
was O
induced O
by O
TCDD B
in O
PNT1A O
cells O
. O

In O
conclusion O
, O
the O
CAG O
length O
dependent O
effect O
of O
TCDD B
on O
AR O
activity O
in O
PNT1A O
, O
but O
not O
in O
PC O
- O
3 O
cells O
, O
indicates O
as O
a O
cell O
- O
specific O
effect O
of O
TCDD B
on O
AR O
activity O
. O

Keap1 O
is O
expressed O
in O
differentiating O
osteoclast O
- O
like O
cells O
and O
the O
S349T O
mutation O
selectively O
impairs O
the O
SQSTM1 O
- O
Keap1 O
interaction O
in O
co O
- O
immunoprecipitations O
, O
which O
molecular O
modelling O
indicates O
results O
from O
effects O
on O
critical O
hydrogen B
bonds O
required O
to O
stabilise O
the O
KIR O
- O
Keap1 O
complex O
. O

RuvC O
dimer O
and O
HJ O
- O
DNA O
, O
as O
well O
as O
positions O
of O
sulfate B
ions O
bound O
on O
the O
protein O
surface O
. O

In O
the O
present O
study O
, O
the O
potential O
influences O
of O
prey O
composition O
on O
the O
trophic O
transfer O
, O
accumulation O
, O
subcellular O
distribution O
and O
metallothionein O
induction O
of O
six O
metals O
( O
Ag B
, O
As B
, O
Cd B
, O
Cu B
, O
Pb B
and O
Zn B
) O
in O
a O
predator O
Nassarius O
siquijorensis O
were O
investigated O
. O

All O
the O
studied O
metals O
except O
Pb B
were O
enriched O
during O
transfer O
to O
the O
snails O
. O

The O
extract O
inhibited O
elevation O
of O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
concentration O
caused O
by O
stimulation O
by O
antigen O
, O
while O
not O
suppressing O
degranulation O
induced O
by O
a O
calcium B
ionophore O
A23187 O
. O

Immunoblot O
analysis O
revealed O
that O
the O
inhibitory O
effect O
results O
from O
downregulation O
of O
phosphorylation O
of O
both O
Syk O
kinase O
and O
phosphatidylinositol B
3 O
- O
kinase O
in O
the O
signalling O
pathways O
involved O
in O
degranulation O
caused O
by O
the O
antigen O
- O
antibody O
interaction O
. O

Anthraquinone B
profile O
, O
antioxidant O
and O
antimicrobial O
activity O
of O
bark O
extracts O
of O
Rhamnus O
alaternus O
, O
R O
. O
fallax O
, O
R O
. O
intermedia O
and O
R O
. O
pumila O
. O

The O
quantity O
of O
phenols B
, O
as O
well O
as O
antioxidant O
and O
antimicrobial O
activities O
, O
were O
investigated O
in O
bark O
of O
Rhamnus O
alaternus O
L O
. O
, O
R O
. O
fallax O
Boiss O
. O
, O
R O
. O
intermedia O
Steud O
. O

The O
most O
abundant O
anthraquinones B
in O
the O
investigated O
extracts O
were O
chrysophanol O
in O
R O
. O
alaternus O
( O
3 O
. O
14 O
mg O
/ O
g O
) O
, O
emodin B
in O
R O
. O
pumila O
( O
0 O
. O
339 O
mg O
/ O
g O
) O
, O
and O
physcion O
in O
R O
. O
fallax O
( O
2 O
. O
70 O
mg O
/ O
g O
) O
and O
R O
. O
intermedia O
( O
0 O
. O
285 O
mg O
/ O
g O
) O
. O

A O
positive O
correlation O
was O
observed O
between O
total O
phenolic B
and O
flavonoid B
levels O
of O
the O
extracts O
and O
antioxidant O
activity O
in O
some O
of O
the O
assays O
. O

The O
results O
indicate O
that O
the O
investigated O
Rhamnus O
species O
are O
a O
source O
of O
anthraquinones B
and O
other O
phenols B
, O
which O
act O
as O
multifunctional O
antioxidants O
with O
antimicrobial O
activity O
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 O
- O
hydroxybenzaldehyde O
, O
myricetin O
- O
3 O
- O
O O
- O
rhamnoside O
, O
europetin O
- O
3 O
- O
O O
- O
rhamnoside O
, O
phloretin B
, O
myrigalone O
- O
G O
and O
myrigalone O
- O
B O
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

We O
observed O
that O
, O
S O
. O
aqueum O
leaf O
extract O
( O
0 O
. O
04 O
- O
5 O
mu O
g O
/ O
ml O
) O
and O
its O
six O
bioactive O
compounds O
( O
0 O
. O
08 O
- O
10 O
mu O
M O
) O
at O
non O
- O
cytotoxic O
concentrations O
were O
effectively O
enhance O
adipogenesis O
, O
stimulate O
glucose B
uptake O
and O
increase O
adiponectin O
secretion O
in O
3T3 O
- O
L1 O
adipocytes O
. O

These O
compounds O
were O
far O
better O
than O
rosiglitazone B
and O
the O
other O
isolated O
compounds O
in O
enhancing O
adipogenesis O
, O
stimulating O
2 O
- O
NBDG O
uptake O
and O
increasing O
adiponectin O
secretion O
at O
all O
the O
concentrations O
tested O
. O

An O
improved O
mass O
spectrometric O
method O
for O
identification O
and O
quantification O
of O
phenolic B
compounds O
in O
apple O
fruits O
. O

Thirty O
- O
nine O
phenolic B
compounds O
were O
analysed O
using O
ultra O
high O
performance O
liquid O
chromatography O
( O
UHPLC O
) O
coupled O
with O
diode O
array O
and O
accurate O
mass O
spectrometry O
detection O
using O
electrospray O
ionisation O
( O
DAD O
/ O
ESI O
- O
am O
- O
MS O
) O
. O

The O
mass O
accuracy O
of O
each O
selected O
phenolic B
compound O
was O
below O
1 O
. O
5 O
ppm O
. O

The O
results O
confirmed O
that O
the O
UHPLC O
- O
DAD O
/ O
ESI O
- O
am O
- O
MS O
method O
developed O
here O
was O
convenient O
and O
reliable O
for O
the O
determination O
of O
phenolic B
compounds O
in O
apple O
extracts O
. O

Phillyrin O
attenuates O
high O
glucose B
- O
induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
through O
the O
activation O
of O
LKB1 O
/ O
AMP B
- O
activated O
protein O
kinase O
- O
dependent O
signalling O
. O

The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism O
( O
s O
) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose B
- O
induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O

We O
found O
that O
phillyrin O
suppressed O
high O
glucose B
- O
induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O

Phillyrin O
strongly O
inhibited O
high O
glucose B
- O
induced O
fatty B
acid I
synthase O
( O
FAS O
) O
expression O
by O
modulating O
sterol B
regulatory O
element O
- O
binding O
protein O
- O
1c O
( O
SREBP O
- O
1c O
) O
activation O
. O

Moreover O
, O
use O
of O
the O
pharmacological O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP O
- O
1c O
expression O
in O
phillyrin O
- O
treated O
cells O
. O

When O
oil O
/ O
tomato O
ratio O
was O
between O
0 O
. O
11 O
and O
1 O
, O
extraction O
of O
lycopene B
was O
limited O
by O
the O
saturation O
of O
the O
oil O
phase O
. O

With O
a O
large O
excess O
of O
oil O
, O
diffusion O
was O
also O
limited O
, O
as O
only O
31 O
+ O
/ O
- O
1 O
% O
of O
lycopene B
could O
be O
extracted O
from O
the O
juice O
. O

When O
the O
juice O
was O
mixed O
in O
an O
emulsion O
stabilised O
with O
bovine O
serum O
albumin O
or O
phospholipids O
the O
maximum O
extraction O
decreased O
to O
14 O
. O
5 O
+ O
/ O
- O
0 O
. O
2 O
% O
and O
18 O
. O
5 O
+ O
/ O
- O
1 O
. O
5 O
% O
respectively O
, O
indicating O
that O
in O
addition O
to O
the O
saturation O
of O
the O
oil O
phase O
at O
low O
oil O
/ O
tomato O
ratio O
and O
in O
addition O
to O
intrinsic O
properties O
of O
the O
tomato O
juice O
in O
non O
- O
saturating O
conditions O
, O
lycopene B
diffusion O
was O
limited O
by O
the O
structure O
of O
the O
interface O
in O
emulsions O
. O

The O
principal O
constituents O
of O
the O
oils O
were O
similar O
except O
for O
the O
minor O
compounds O
, O
including O
linalool B
, O
terpinen B
- I
4 I
- I
ol I
and O
alpha B
- I
terpineol I
, O
the O
levels O
of O
which O
increased O
after O
steam O
distillation O
. O

Salicylic B
acid I
- O
induced O
elicitation O
of O
folates O
in O
coriander O
( O
Coriandrum O
sativum O
L O
. O
) O
improves O
bioaccessibility O
and O
reduces O
pro O
- O
oxidant O
status O
. O

Foliage O
of O
Coriandrum O
sativum O
is O
a O
rich O
source O
of O
natural O
folates O
amenable O
for O
enhancement O
through O
salicylic B
acid I
- O
mediated O
elicitation O
, O
thereby O
holding O
a O
great O
promise O
for O
natural O
- O
mode O
alleviation O
of O
this O
vitamin O
( O
B O
( O
9 O
) O
) O
deficiency O
. O

In O
the O
present O
study O
we O
report O
salicylic B
acid I
- O
mediated O
differential O
elicitation O
of O
different O
forms O
of O
folates B
- O
5 O
- O
methyltetrahydrofola O
, O
5 O
- O
formyltetrahydrofola O
and O
10 O
- O
formyltetrahydrofola O
- O
their O
stabilities O
during O
microwave O
- O
drying O
and O
bioaccessibilities O
from O
fresh O
and O
dried O
foliage O
. O

Short O
- O
term O
comparative O
study O
of O
the O
influence O
of O
fried O
edible O
oils O
intake O
on O
the O
metabolism O
of O
essential O
fatty B
acids I
in O
obese O
individuals O
. O

The O
effect O
of O
breakfast O
intake O
of O
fried O
oils O
containing O
natural O
antioxidants O
or O
a O
synthetic O
autooxidation O
inhibitor O
on O
the O
metabolism O
of O
essential O
fatty B
acids I
focused O
on O
obese O
individuals O
. O

Twenty O
- O
three O
compounds O
, O
including O
various O
phenolic B
glycosides I
, O
a O
new O
dimeric O
phenylpropanoid O
glucoside O
, O
saponins B
, O
and O
fatty B
acids I
were O
identified O
online O
, O
or O
after O
targeted O
isolation O
. O

In O
addition O
, O
substances O
relevant O
for O
nutrition O
, O
such O
as O
beta B
- I
carotene I
, O
fatty B
acids I
, O
ascorbic B
acid I
and O
minerals O
were O
quantified O
in O
leaves O
and O
flowers O
. O

The O
antioxidant O
capacity O
was O
determined O
with O
an O
ORAC O
assay O
, O
and O
total O
phenolic B
compounds O
were O
quantified O
. O

Neferine O
induces O
reactive O
oxygen B
species O
mediated O
intrinsic O
pathway O
of O
apoptosis O
in O
HepG2 O
cells O
. O

We O
evaluated O
its O
anticancer O
potential O
by O
studying O
its O
effect O
on O
mitochondrial O
membrane O
potential O
, O
intracellular O
calcium B
levels O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
, O
cell O
membrane O
integrity O
, O
apoptotic O
body O
formation O
and O
DNA O
fragmentation O
in O
cultured O
HepG2 O
cells O
. O

The O
reactive O
oxygen B
species O
level O
has O
been O
increased O
upon O
neferine O
treatment O
with O
concomitant O
decrease O
in O
reduced O
glutathione B
. O

Our O
data O
further O
indicate O
reduction O
of O
Delta O
psi O
M O
and O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
during O
apoptosis O
induction O
by O
neferine O
with O
increased O
expression O
of O
apoptotic O
proteins O
such O
as O
Bax O
, O
Bad O
, O
cleaved O
forms O
of O
caspase O
3 O
, O
caspase O
9 O
and O
PARP O
, O
with O
the O
downregulation O
of O
anti O
- O
apoptotic O
protein O
Bcl2 O
in O
HepG2 O
cells O
. O

Batch O
and O
continuous O
synthesis O
of O
lactulose B
from O
whey O
lactose B
by O
immobilized O
beta O
- O
galactosidase O
. O

In O
this O
study O
, O
lactulose B
synthesis O
from O
whey O
lactose B
was O
investigated O
in O
batch O
and O
continuous O
systems O
using O
immobilized O
beta O
- O
galactosidase O
. O

In O
the O
batch O
system O
, O
the O
optimal O
concentration O
of O
fructose B
for O
lactulose B
synthesis O
was O
20 O
% O
, O
and O
the O
effect O
of O
galactose B
, O
glucose B
and O
fructose B
on O
beta O
- O
galactosidase O
activity O
was O
determined O
for O
hydrolysis O
of O
whey O
lactose B
and O
the O
transgalactosylation O
reaction O
for O
lactulose B
synthesis O
. O

Galactose B
and O
fructose B
were O
competitive O
inhibitors O
, O
and O
glucose B
acted O
as O
a O
noncompetitive O
inhibitor O
. O

The O
inhibitory O
effects O
of O
galactose B
and O
glucose B
were O
stronger O
in O
the O
transgalactosylation O
reaction O
than O
they O
were O
in O
the O
hydrolysis O
reaction O
. O

In O
addition O
, O
when O
immobilized O
beta O
- O
galactosidase O
was O
reused O
for O
lactulose B
synthesis O
, O
its O
catalytic O
activity O
was O
retained O
to O
the O
extent O
of O
52 O
. O
9 O
% O
after O
10 O
reuses O
. O

Lactulose B
was O
synthesized O
continuously O
in O
a O
packed O
- O
bed O
reactor O
. O

We O
synthesized O
19 O
. O
1g O
/ O
l O
lactulose B
during O
the O
continuous O
flow O
reaction O
at O
a O
flow O
rate O
of O
0 O
. O
5 O
ml O
/ O
min O
. O

Gangliosides O
and O
sialic B
acid I
effects O
upon O
newborn O
pathogenic O
bacteria O
adhesion O
: O
an O
in O
vitro O
study O
. O

The O
effect O
of O
the O
main O
gangliosides O
( O
GM O
( O
1 O
) O
, O
GM O
( O
3 O
) O
, O
GD O
( O
3 O
) O
) O
and O
free O
sialic B
acid I
( O
Neu5Ac O
) O
upon O
the O
adhesion O
of O
pathogenic O
bacteria O
implicated O
in O
infant O
diarrhoea O
is O
assessed O
in O
vitro O
using O
the O
Caco O
- O
2 O
cell O
line O
. O

Remarkable O
quantities O
of O
corosolic O
acid O
were O
found O
in O
dried O
extracts O
from O
aerial O
parts O
of O
Lagerstroemia O
speciosa O
and O
Ortosiphon O
stamineus O
( O
14233 O
and O
1132 O
mg O
/ O
kg O
, O
respectively O
) O
, O
while O
oleanolic B
acid I
was O
abundant O
in O
O O
. O
stamineus O
and O
Crataegus O
monogyna O
flowers O
( O
2774 O
and O
2339 O
mg O
/ O
kg O
) O
; O
ursolic O
was O
identified O
in O
O O
. O
stamineus O
, O
C O
. O
monogyna O
, O
L O
. O
speciosa O
and O
Arctostaphylos O
uva O
- O
ursi O
leaves O
( O
7773 O
, O
4165 O

Only O
L O
. O
speciosa O
was O
rich O
in O
maslinic O
acid O
( O
4958 O
mg O
/ O
kg O
) O
, O
while O
minor O
amounts O
of O
betulinic B
acid I
( O
257 O
and O
80 O
mg O
/ O
kg O
) O
were O
detected O
in O
L O
. O
speciosa O
and O
C O
. O
monogyna O
extracts O
. O

The O
presence O
of O
egg O
yolk O
slightly O
increased O
the O
susceptibility O
to O
hydrolysis O
of O
egg O
white O
proteins O
and O
abrogated O
bile B
salt I
- O
induced O
precipitation O
of O
LYS O
in O
the O
duodenal O
medium O
. O

Changes O
in O
the O
oil O
were O
assessed O
by O
the O
free O
fatty B
acid I
( O
FFA O
) O
content O
, O
p B
- I
anisidine I
value O
( O
AnV O
) O
, O
colour O
, O
viscosity O
, O
fatty B
acid I
profile O
and O
concentration O
of O
tocols O
. O

There O
was O
a O
reduction O
in O
the O
loss O
of O
polyunsaturated B
fatty I
acids I
in O
the O
case O
of O
vacuum O
drainage O
after O
5 O
days O
of O
frying O
but O
differences O
in O
retention O
of O
tocols O
were O
only O
evident O
in O
the O
first O
two O
days O
of O
frying O
. O

Non O
- O
targeted O
metabolomic O
approach O
reveals O
urinary O
metabolites O
linked O
to O
steroid B
biosynthesis O
pathway O
after O
ingestion O
of O
citrus O
juice O
. O

This O
approach O
allowed O
the O
identification O
of O
four O
endocrine O
compounds O
( O
tetrahydroaldosteron O
- O
3 O
- O
glucuronide O
, O
cortolone O
- O
3 O
- O
glucuronide O
, O
testosterone O
- O
glucuronide O
and O
17 B
- I
hydroxyprogesterone I
) O
, O
which O
belonged O
to O
the O
steroid B
biosynthesis O
pathway O
as O
significant O
metabolites O
upregulated O
by O
citrus O
juice O
intake O
. O

Identification O
of O
flavonoids B
and O
flavonoid O
rhamnosides O
from O
Rhododendron O
mucronulatum O
for O
. O
albiflorum O
and O
their O
inhibitory O
activities O
against O
aldose B
reductase O
. O

To O
investigate O
the O
therapeutic O
potential O
of O
compounds O
from O
natural O
sources O
, O
Rhododendron O
mucronulatum O
for O
. O
albiflorum O
flowers O
( O
RMAF O
) O
and O
R O
. O
mucronulatum O
flowers O
( O
RMF O
) O
were O
tested O
for O
inhibition O
of O
aldose B
reductase O
( O
AR O
) O
. O

The O
methanol B
extracts O
of O
RMAF O
and O
RMF O
exhibited O
AR O
inhibitory O
activities O
( O
IC O
( O
50 O
) O
values O
1 O
. O
07 O
and O
1 O
. O
29 O
mu O
g O
/ O
mL O
, O
respectively O
) O
. O

Of O
these O
, O
the O
ethyl B
acetate I
( O
EtOAc B
) O
fraction O
exhibited O
AR O
inhibitory O
activity O
( O
IC O
( O
50 O
) O
0 O
. O
15 O
mu O
g O
/ O
mL O
) O
. O

A O
chromatography O
of O
the O
active O
EtOAc B
fraction O
of O
RMAF O
led O
to O
the O
isolation O
of O
six O
flavonoids B
, O
which O
were O
identified O
by O
spectroscopic O
analysis O
as O
kaempferol B
( O
1 O
) O
, O
afzelin O
( O
2 O
) O
, O
quercetin B
( O
3 O
) O
, O
quercitrin O
( O
4 O
) O
, O
myricetin B
( O
5 O
) O
and O
myricitrin O
( O
6 O
) O
. O

HPLC O
/ O
UV O
analysis O
revealed O
that O
the O
major O
flavonoids B
of O
RMAF O
and O
RMF O
are O
quercitrin O
( O
4 O
) O
and O
myricitrin O
( O
6 O
) O
. O

Our O
results O
suggest O
that O
RMAF O
containing O
these O
six O
flavonoids B
could O
be O
a O
useful O
natural O
source O
in O
the O
development O
of O
a O
novel O
AR O
inhibitory O
agent O
against O
diabetic O
complications O
. O

Encapsulation O
of O
food O
grade O
antioxidant O
in O
natural O
biopolymer O
by O
electrospinning O
technique O
: O
a O
physicochemical O
study O
based O
on O
zein O
- O
gallic B
acid I
system O
. O

Gallic B
acid I
was O
successfully O
incorporated O
into O
zein O
ultra O
- O
fine O
fibres O
at O
different O
loading O
amount O
( O
5 O
% O
, O
10 O
% O
and O
20 O
% O
) O
in O
order O
to O
develop O
an O
encapsulating O
technology O
for O
functional O
ingredient O
delivery O
using O
electrospinning O
. O

The O
physical O
and O
thermal O
properties O
of O
encapsulated O
gallic B
acid I
were O
determined O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
and O
differential O
scanning O
calorimetry O
( O
DSC O
) O
; O
and O
the O
interaction O
between O
gallic B
acid I
and O
zein O
was O
attested O
by O
attenuated O
total O
reflection O
- O
Fourier O
transform O
infrared O
( O
ATR O
- O
FTIR O
) O
. O

Thermogravimetric O
analysis O
( O
TGA O
) O
demonstrated O
a O
different O
thermal O
stability O
of O
the O
fabricated O
complex O
before O
and O
after O
the O
gallic B
acid I
incorporation O
. O

Lastly O
, O
the O
1 B
, I
1 I
' I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
assay O
showed O
that O
the O
gallic B
acid I
had O
retained O
its O
antioxidant O
activity O
after O
incorporation O
in O
zein O
electrospun O
fibres O
. O

Therefore O
, O
in O
this O
study O
, O
the O
effects O
of O
rosemary O
on O
the O
activation O
of O
nuclear O
factor O
kappa O
beta O
( O
NF O
- O
kB O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
, O
the O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
and O
the O
production O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
, O
and O
cytokine O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O

A O
methanol B
extract O
of O
rosemary O
and O
its O
hexane B
fraction O
reduced O
NO B
generation O
with O
an O
IC O
( O
50 O
) O
of O
2 O
. O
75 O
and O
2 O
. O
83 O
mu O
g O
/ O
ml O
, O
respectively O
. O

Also O
, O
the O
methanol B
extract O
and O
the O
hexane B
fraction O
inhibited O
LPS O
- O
induced O
MAPKs O
and O
NF O
- O
kB O
activation O
associated O
with O
the O
inhibition O
of O
iNOS O
or O
COX O
- O
2 O
expression O
. O

LPS O
- O
induced O
production O
of O
PGE B
( I
2 I
) I
and O
tumour O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
were O
blocked O
by O
rosemary O
. O

Rosemary O
extract O
and O
its O
hexane B
fraction O
are O
important O
for O
the O
prevention O
of O
phosphorylation O
of O
MAPKs O
, O
thereby O
blocking O
NF O
- O
kB O
activation O
, O
which O
in O
turn O
leads O
to O
decreased O
expression O
of O
iNOS O
and O
COX O
- O
2 O
, O
thus O
preventing O
inflammation O
. O

This O
study O
examines O
the O
effects O
of O
Cassia O
seed O
ethanol B
extract O
( O
CSEE O
) O
upon O
lipid O
accumulation O
in O
white O
adipose O
tissue O
( O
WAT O
) O
. O

CSEE O
enhanced O
the O
phosphorylation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
primary O
downstream O
targeting O
enzyme O
, O
acetyl B
- I
CoA I
carboxylase O
, O
up O
- O
regulated O
gene O
expression O
of O
carnitine B
palmitoyl B
transferase O
1 O
, O
and O
down O
- O
regulated O
sterol O
regulatory O
element O
- O
binding O
protein O
1 O
and O
fatty B
acid I
synthase O
protein O
levels O
in O
epididymal O
WAT O
of O
HFD O
- O
fed O
rats O
. O

NMR O
structure O
and O
dynamics O
of O
the O
C B
- O
terminal O
domain O
of O
R O
- O
type O
lectin O
from O
the O
earthworm O
Lumbricus O
terrestris O
. O

The O
C B
- O
terminal O
domain O
( O
Ch O
; O
C O
- O
half O
) O
of O
the O
R O
- O
type O
earthworm O
29 O
- O
kDa O
lectin O
( O
EW29 O
) O
, O
isolated O
from O
the O
earthworm O
Lumbricus O
terrestris O
, O
has O
two O
sugar B
- O
binding O
sites O
, O
in O
subdomains O
alpha O
and O
gamma O
, O
and O
the O
protein O
uses O
the O
two O
sugar B
- O
binding O
sites O
for O
its O
function O
as O
a O
single O
domain O
- O
type O
haemagglutinin O
. O

Our O
previous O
NMR O
titration O
experiments O
showed O
that O
the O
alpha O
sugar B
- O
binding O
site O
is O
a O
high O
- O
affinity O
site O
and O
the O
gamma O
sugar B
- O
binding O
site O
is O
a O
low O
- O
affinity O
site O
. O

However O
, O
it O
remains O
unclear O
why O
the O
alpha O
sugar B
- O
binding O
site O
of O
EW29Ch O
binds O
to O
lactose O
much O
more O
strongly O
because O
the O
crystal O
structure O
of O
lactose B
- O
bound O
EW29Ch O
showed O
that O
the O
interaction O
between O
the O
alpha O
sugar B
- O
binding O
site O
and O
lactose B
was O
almost O
same O
as O
that O
between O
the O
gamma O
sugar B
- O
binding O
site O
and O
lactose B
. O

In O
the O
present O
study O
, O
we O
have O
determined O
the O
NMR O
structure O
of O
EW29Ch O
in O
the O
sugar B
- O
free O
state O
and O
performed O
( B
15 I
) I
N I
relaxation O
experiments O
for O
EW29Ch O
in O
both O
the O
sugar B
- O
free O
state O
and O
the O
lactose B
- O
bound O
states O
. O

The O
conformation O
of O
EW29Ch O
in O
the O
sugar B
- O
free O
state O
was O
similar O
to O
that O
of O
EW29Ch O
in O
complex O
with O
lactose O
. O

By O
contrast O
, O
the O
( B
15 I
) I
N I
relaxation O
experiments O
revealed O
a O
conformational O
exchange O
at O
the O
alpha O
sugar B
- O
binding O
site O
in O
the O
sugar B
- O
free O
state O
, O
which O
was O
suppressed O
in O
the O
lactose B
- O
bound O
state O
. O

The O
conformational O
exchange O
phenomenon O
observed O
for O
the O
alpha O
sugar B
- O
binding O
site O
was O
not O
observed O
for O
the O
gamma O
sugar B
- O
binding O
site O
. O

Differences O
in O
the O
conformational O
change O
and O
the O
backbone O
dynamics O
between O
subdomains O
alpha O
and O
gamma O
may O
be O
associated O
with O
the O
difference O
of O
the O
sugar B
- O
binding O
modes O
between O
the O
two O
sugar B
- O
binding O
sites O
. O

DATABASE O
: O
Structural O
data O
for O
the O
NMR O
structure O
of O
EW29Ch O
in O
the O
sugar B
- O
free O
state O
have O
been O
deposited O
in O
the O
Protein O
Data O
Bank O
database O
under O
accession O
number O
2RST O
. O

In O
this O
present O
study O
, O
we O
aimed O
to O
compare O
the O
protective O
effect O
of O
ethanol B
extract O
of O
Cortex O
Phellodendri O
chinensis O
( O
ECPC O
) O
and O
Cortex O
Phellodendri O
Amurensis O
( O
ECPA O
) O
against O
beta O
- O
amyloid O
( O
A O
beta O
) O
- O
induced O
neurotoxicity O
in O
PC12 O
cells O
, O
a O
typical O
model O
of O
Alzheimer O
' O
s O
disease O
. O

The O
results O
showed O
that O
ECPC O
and O
ECPA O
contain O
four O
common O
chemical O
markers O
such O
as O
berberine B
, O
but O
palmatine B
and O
jatrorrhizin O
were O
not O
found O
in O
CPC O
in O
contrast O
to O
the O
presence O
in O
CPA O
. O

beta B
- I
Asarone I
, O
an O
active O
principle O
of O
Acorus O
calamus O
rhizome O
, O
inhibits O
morphogenesis O
, O
biofilm O
formation O
and O
ergosterol B
biosynthesis O
in O
Candida O
albicans O
. O

Anti O
- O
Candida O
potential O
of O
Acorus O
calamus O
rhizome O
and O
its O
active O
principle O
, O
beta B
- I
asarone I
, O
was O
evaluated O
against O
the O
human O
fungal O
pathogen O
, O
Candida O
albicans O
. O

beta B
- I
Asarone I
exhibited O
promising O
growth O
inhibitory O
activity O
at O
0 O
. O
5mg O
/ O
ml O
and O
it O
was O
fungicidal O
at O
8 O
mg O
/ O
ml O
. O

Time O
dependant O
kill O
curve O
assay O
showed O
that O
MFC O
of O
beta B
- I
asarone I
was O
highly O
toxic O
to O
C O
. O
albicans O
, O
killing O
99 O
. O
9 O
% O
inoculum O
within O
120 O
min O
of O
exposure O
. O

beta B
- I
Asarone I
caused O
significant O
inhibition O
of O
C O
. O
albicans O
morphogenesis O
and O
biofilm O
development O
at O
sub O
- O
inhibitory O
concentrations O
. O

Our O
data O
indicate O
that O
the O
growth O
inhibitory O
activity O
of O
beta B
- I
asarone I
might O
be O
through O
inhibition O
of O
ergosterol B
biosynthesis O
. O

Hemolytic O
assay O
showed O
that O
beta B
- I
asarone I
is O
non O
- O
toxic O
, O
even O
at O
concentrations O
approaching O
MIC O
value O
. O

Our O
results O
suggest O
that O
beta B
- I
asarone I
may O
be O
safe O
as O
a O
topical O
antifungal O
agent O
. O

Testing O
of O
novel O
brain O
- O
penetrating O
oxime B
reactivators O
of O
acetylcholinesterase O
inhibited O
by O
nerve O
agent O
surrogates O
. O

A O
critical O
need O
for O
combating O
the O
effects O
of O
organophosphate B
( O
OP O
) O
anticholinesterases O
, O
such O
as O
nerve O
agents O
, O
is O
the O
current O
lack O
of O
an O
effective O
oxime B
reactivator O
which O
can O
penetrate O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
, O
and O
therefore O
reactivate O
inhibited O
acetylcholinesterase O
( O
AChE O
) O
in O
the O
brain O
. O

Our O
laboratories O
have O
synthesized O
and O
have O
initiated O
testing O
of O
novel O
phenoxyalkyl O
pyridinium O
oximes O
( O
patent O
pending O
) O
that O
are O
more O
lipophilic O
than O
currently O
approved O
oximes B
. O

This O
is O
a O
preliminary O
report O
on O
these O
novel O
oximes B
which O
have O
been O
tested O
in O
vitro O
in O
rat O
brain O
homogenates O
with O
highly O
relevant O
surrogates O
for O
sarin B
( O
phthalimidyl O
isopropyl O
methylphosphonate O
; O
PIMP O
) O
and O
VX O
( O
nitrophenyl O
ethyl O
methylphosphonate O
; O
NEMP O
) O
. O

The O
oximes B
demonstrated O
a O
range O
of O
14 O
- O
76 O
% O
reactivation O
of O
rat O
brain O
AChE O
in O
vitro O
. O

An O
in O
vivo O
testing O
paradigm O
was O
developed O
in O
which O
the O
novel O
oxime B
was O
administered O
at O
the O
time O
of O
maximal O
brain O
AChE O
inhibition O
( O
about O
80 O
% O
) O
( O
1h O
) O
elicited O
by O
nitrophenyl O
isopropyl O
methylphosphonate O
( O
NIMP O
; O
sarin B
surrogate O
) O
. O

This O
paradigm O
, O
with O
delayed O
administration O
of O
oxime B
to O
a O
time O
when O
brain O
AChE O
was O
starting O
to O
recover O
, O
was O
designed O
to O
minimize O
reactivation O
/ O
reinhibition O
of O
peripheral O
AChE O
during O
the O
reactivation O
period O
which O
would O
decrease O
the O
availability O
of O
the O
surrogate O
for O
entry O
into O
the O
brain O
; O
this O
paradigm O
will O
allow O
proof O
of O
concept O
of O
BBB O
penetrability O
. O

The O
initial O
studies O
of O
these O
oximes B
in O
vivo O
with O
the O
sarin B
surrogate O
NIMP O
have O
indicated O
reactivation O
of O
up O
to O
about O
25 O
% O
at O
30min O
after O
oxime B
administration O
and O
substantial O
attenuation O
of O
seizure O
behavior O
from O
some O
of O
the O
oximes B
. O

Therefore O
these O
novel O
oximes B
have O
considerable O
potential O
as O
brain O
- O
protecting O
therapeutics O
for O
anticholinesterases O
. O

Contributions O
of O
rat O
Ctr1 O
to O
the O
uptake O
and O
toxicity O
of O
copper B
and O
platinum B
anticancer O
drugs O
in O
dorsal O
root O
ganglion O
neurons O
. O

Dorsal O
root O
ganglion O
( O
DRG O
) O
neurons O
are O
affected O
by O
platinum B
- O
induced O
neurotoxicity O
and O
neurodegenerative O
processes O
associated O
with O
disturbed O
copper B
homeostasis O
and O
transport O
. O

This O
study O
aimed O
to O
understand O
the O
role O
of O
copper B
transporter O
1 O
( O
Ctr1 O
) O
in O
the O
uptake O
and O
toxicity O
of O
copper B
and O
platinum B
drugs O
in O
cultured O
rat O
DRG O
neurons O
, O
and O
the O
functional O
activities O
of O
rat O
Ctr1 O
( O
rCtr1 O
) O
as O
a O
membrane O
transporter O
of O
copper B
and O
platinum B
drugs O
. O

Heterologous O
expression O
of O
rCtr1 O
in O
HEK293 O
cells O
( O
HEK O
/ O
rCtr1 O
cells O
) O
increased O
the O
uptake O
and O
cytotoxicity O
of O
copper B
, O
oxaliplatin O
, O
cisplatin B
and O
carboplatin O
, O
in O
comparison O
to O
isogenic O
vector O
- O
transfected O
control O
cells O
. O

Cultured O
rat O
DRG O
neurons O
endogenously O
expressed O
rCtr1 O
protein O
on O
their O
neuronal O
cell O
body O
plasma O
membranes O
and O
cytoplasm O
, O
and O
displayed O
substantial O
capacity O
for O
taking O
up O
copper B
, O
but O
were O
resistant O
to O
copper B
toxicity O
. O

The O
uptake O
of O
copper B
by O
both O
cultured O
rat O
DRG O
neurons O
and O
HEK O
/ O
rCtr1 O
cells O
was O
saturable O
and O
inhibited O
by O
cold O
temperature O
, O
silver B
and O
zinc B
, O
consistent O
with O
it O
being O
mediated O
by O
rCtr1 O
. O

Cultured O
rat O
DRG O
neurons O
accumulated O
platinum B
during O
their O
exposure O
to O
oxaliplatin O
and O
were O
sensitive O
to O
oxaliplatin O
cytotoxicity O
. O

The O
accumulation O
of O
platinum B
by O
both O
cultured O
rat O
DRG O
neurons O
and O
HEK O
/ O
rCtr1 O
cells O
, O
during O
oxaliplatin O
exposure O
, O
was O
saturable O
and O
temperature O
dependent O
, O
but O
was O
inhibited O
by O
copper B
only O
in O
HEK O
/ O
rCtr1 O
cells O
. O

In O
conclusion O
, O
rCtr1 O
can O
transport O
copper B
and O
platinum B
drugs O
, O
and O
sensitizes O
cells O
to O
their O
cytotoxicities O
. O

DRG O
neurons O
display O
substantial O
capacity O
for O
accumulating O
copper B
via O
a O
transport O
process O
mediated O
by O
rCtr1 O
, O
but O
appear O
able O
to O
resist O
copper B
toxicity O
and O
use O
alternative O
mechanisms O
to O
take O
up O
oxaliplatin O
. O

Elevation O
of O
cysteine B
consumption O
in O
tamoxifen B
- O
resistant O
MCF O
- O
7 O
cells O
. O

Tamoxifen B
( O
TAM B
) O
resistance O
is O
a O
main O
cause O
of O
therapeutic O
failure O
in O
breast O
cancers O
. O

Although O
methionine B
dependency O
is O
a O
phenotypic O
characteristic O
of O
tumor O
cells O
, O
the O
role O
of O
sulfur B
amino B
acid I
metabolism O
in O
chemotherapy O
resistance O
remains O
to O
be O
elucidated O
. O

This O
study O
compared O
metabolite O
profiles O
of O
sulfur B
amino B
acid I
metabolism O
from O
methionine B
to O
taurine B
or O
glutathione B
( O
GSH B
) O
between O
normal O
MCF O
- O
7 O
and O
TAM B
- O
resistant O
MCF O
- O
7 O
( O
TAMR O
- O
MCF O
- O
7 O
) O
cells O
. O

TAMR O
- O
MCF O
- O
7 O
cells O
showed O
elevated O
levels O
and O
activities O
of O
enzymes O
involved O
in O
both O
transsulfuration O
from O
methionine B
to O
cysteine B
and O
metabolism O
of O
cysteine B
to O
GSH B
and O
taurine B
. O

Cysteine B
concentrations O
in O
TAMR O
- O
MCF O
- O
7 O
cells O
and O
medium O
conditioned O
by O
cell O
culture O
for O
42h O
were O
markedly O
decreased O
, O
while O
GSH B
, O
hypotaurine O
, O
and O
taurine B
concentrations O
in O
the O
medium O
were O
increased O
. O

These O
results O
show O
that O
TAMR O
- O
MCF O
- O
7 O
cells O
display O
enhanced O
cysteine B
utilization O
. O

The O
addition O
of O
propargylglycine O
, O
a O
specific O
cystathionine B
gamma O
- O
lyase O
inhibitor O
, O
and O
buthionine B
sulfoximine I
, O
a O
specific O
gamma B
- I
glutamylcysteine I
ligase O
inhibitor O
, O
to O
TAMR O
- O
MCF O
- O
7 O
cells O
, O
but O
not O
to O
MCF O
- O
7 O
cells O
, O
resulted O
in O
cytotoxicity O
after O
sulfur B
amino B
acid I
deprivation O
. O

These O
results O
suggest O
that O
cell O
viability O
of O
TAMR O
- O
MCF O
- O
7 O
cells O
is O
affected O
by O
inhibition O
of O
sulfur B
amino B
acid I
metabolism O
, O
particularly O
cysteine B
synthesis O
from O
homocysteine B
and O
GSH B
synthesis O
from O
cysteine B
. O

Additionally O
, O
the O
S B
- I
adenosylmethionine I
/ O
S B
- I
adenosylhomocysteine I
ratio O
, O
an O
index O
of O
transmethylation O
potential O
, O
in O
TAMR O
- O
MCF O
- O
7 O
cells O
increased O
to O
~ O
3 O
. O
6 O
- O
fold O
relative O
to O
that O
in O
MCF O
- O
7 O
cells O
, O
a O
finding O
that O
may O
result O
from O
upregulation O
of O
methionine B
adenosyltransferase O
IIa O
and O
S B
- I
adenosylhomocysteine I
hydrolase O
. O

In O
conclusion O
, O
this O
study O
suggests O
that O
TAMR O
- O
MCF O
- O
7 O
cells O
display O
enhanced O
cysteine B
utilization O
for O
synthesis O
of O
GSH B
and O
taurine B
, O
and O
are O
sensitive O
to O
inhibition O
of O
cysteine B
metabolism O
. O

They O
are O
homozygous O
for O
a O
point O
mutation O
at O
codon O
307 O
( O
CTT O
- O
- O
> O
CCT O
) O
resulting O
in O
the O
substitution O
of O
leucine B
307 O
by O
proline B
. O

The O
distance O
between O
delta O
nitrogen B
of O
His438 O
to O
epsilon O
oxygen B
of O
Glu325 O
and O
epsilon O
nitrogen B
of O
His438 O
to O
gamma O
oxygen B
of O
Ser198 O
were O
highly O
altered O
in O
L307P O
mutant O
than O
the O
wild O
and O
other O
three O
variants O
throughout O
the O
simulation O
. O

The O
mitochondrial O
respiratory O
chain O
complex O
IV O
( O
cytochrome O
c O
oxidase O
) O
is O
a O
multi O
- O
subunit O
enzyme O
that O
transfers O
electrons O
from O
cytochrome O
c O
to O
molecular O
oxygen B
, O
yielding O
water O
. O

The O
dichloromethane B
extract O
of O
the O
aerial O
parts O
of O
Salvia O
chrysophylla O
Stapf O
( O
Lamiaceae O
) O
, O
which O
is O
an O
endemic O
species O
to O
south O
- O
western O
Anatolia O
, O
was O
studied O
for O
non O
- O
volatile O
secondary O
metabolites O
for O
the O
first O
time O
in O
this O
study O
. O

Structures O
of O
the O
isolated O
compounds O
were O
elucidated O
as O
sclareol O
, O
beta B
- I
sitosterol I
, O
salvigenin O
, O
oleanolic B
acid I
and O
ursolic B
acid I
. O

The O
lipid O
peroxidation O
inhibitory O
activity O
and O
the O
DPPH B
free O
radical O
scavenging O
activity O
of O
the O
pure O
isolates O
were O
investigated O
to O
establish O
their O
antioxidant O
potential O
. O

Down O
- O
regulation O
of O
8 B
- I
oxoguanine I
DNA O
glycosylase O
1 O
expression O
in O
the O
airway O
epithelium O
ameliorates O
allergic O
lung O
inflammation O
. O

Our O
goal O
was O
to O
establish O
the O
role O
of O
8 B
- I
oxoguanine I
( O
8 B
- I
oxoG I
) O
, O
a O
common O
oxidatively O
damaged O
base O
, O
and O
its O
repair O
by O
8 B
- I
oxoguanine I
DNA O
glycosylase O
1 O
( O
Ogg1 O
) O
in O
allergic O
airway O
inflammatory O
processes O
. O

We O
utilized O
siRNA O
technology O
to O
deplete O
Ogg1 O
from O
airway O
epithelium O
; O
8 B
- I
oxoG I
and O
DNA O
strand O
break O
levels O
were O
quantified O
by O
Comet O
assays O
. O

Decreased O
Ogg1 O
expression O
and O
thereby O
8 B
- I
oxoG I
repair O
in O
the O
airway O
epithelium O
conveyed O
a O
lower O
inflammatory O
response O
after O
RWPE O
challenge O
of O
sensitized O
mice O
, O
as O
determined O
by O
expression O
of O
Th2 O
cytokines O
, O
eosinophilia O
, O
epithelial O
methaplasia O
, O
and O
airway O
hyperresponsiveness O
. O

In O
contrast O
, O
8 B
- I
oxoG I
repair O
in O
Ogg1 O
- O
proficient O
airway O
epithelium O
was O
coupled O
to O
an O
increase O
in O
DNA O
single O
- O
strand O
break O
( O
SSB O
) O
levels O
and O
exacerbation O
of O
allergen O
challenge O
- O
dependent O
inflammation O
. O

These O
results O
show O
that O
DNA O
SSBs O
formed O
during O
Ogg1 O
- O
mediated O
repair O
of O
8 B
- I
oxoG I
augment O
antigen O
- O
driven O
allergic O
immune O
responses O
. O

Sulfur B
fumigation O
, O
a O
better O
or O
worse O
choice O
in O
preservation O
of O
Traditional O
Chinese O
Medicine O
? O

Sulfur B
fumigation O
( O
SF O
) O
in O
Traditional O
Chinese O
Medicine O
( O
TCM O
) O
is O
a O
highly O
efficient O
and O
important O
traditional O
preservation O
method O
in O
China O
. O

In O
addition O
, O
a O
quantification O
- O
operation O
sulfur B
fumigation O
device O
( O
QOSFD O
) O
, O
which O
can O
maintain O
the O
quality O
of O
TCMs O
by O
controlling O
the O
SF O
processing O
parameters O
, O
has O
been O
designed O
and O
introduced O
. O

The O
key O
technologies O
of O
this O
device O
involve O
controlling O
the O
O B
( I
2 I
) I
content O
and O
the O
temperature O
of O
SO O
( O
2 O
) O
as O
well O
as O
the O
quantification O
of O
sulfur B
in O
SF O
. O

This O
device O
can O
reduce O
the O
possibility O
of O
reaction O
between O
bioactive O
compounds O
and O
sulfur B
/ O
sulfurous O
acid O
, O
as O
well O
as O
control O
the O
limitation O
of O
SO O
( O
2 O
) O
residues O
. O

This O
is O
in O
contrast O
to O
treatment O
with O
AZT B
, O
a O
potent O
inhibitor O
of O
HIV O
replication O
that O
has O
been O
shown O
to O
significantly O
reduce O
virus O
production O
. O

Protective O
effect O
of O
cinnamon O
polyphenols B
against O
STZ B
- O
diabetic O
mice O
fed O
high O
- O
sugar O
, O
high O
- O
fat O
diet O
and O
its O
underlying O
mechanism O
. O

This O
study O
was O
designed O
to O
investigate O
the O
potential O
effects O
of O
14days O
' O
intragastrically O
given O
of O
cinnamon O
polyphenols B
( O
CPS O
) O
in O
treating O
diabetic O
mice O
induced O
by O
intraperitoneal O
injection O
of O
streptozotocin B
( O
150mgkg O
( O
- O
1 O
) O
) O
and O
fed O
high O
- O
sugar B
, O
high O
- O
fat O
diet O
. O

The O
diabetic O
mice O
model O
was O
successfully O
established O
through O
determining O
on O
fasting O
blood O
- O
glucose B
( O
FBG O
) O
test O
. O

As O
revealed O
by O
glucose B
oxidase O
( O
GOD O
) O
and O
radioimmunoassay O
( O
RIA O
) O
, O
both O
dimethyldiguanide O
( O
DC O
, O
0 O
. O
6gkg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
and O
CPS O
( O
0 O
. O
3 O
, O
0 O
. O
6 O
, O
1 O
. O
2gkg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
treatments O
significantly O
resulted O
in O
down O
- O
regulation O
of O
blood O
glucose B
and O
insulin O
levels O
in O
serum O
, O
while O
the O
levels O
of O
oxidative O
stress O
markers O
were O
markedly O
lowered O
through O
ELISA O
assay O
. O

These O
findings O
demonstrate O
that O
cinnamon O
polyphenols B
can O
exert O
the O
hypoglycemic O
and O
hypolipidemic O
effects O
through O
the O
mechanisms O
that O
may O
be O
associated O
with O
repairing O
pancreatic O
beta O
cells O
in O
diabetic O
mice O
and O
improving O
its O
anti O
- O
oxidative O
capacity O
, O
as O
well O
as O
attenuating O
cytotoxicity O
via O
inhibition O
of O
iNOS O
, O
NF O
- O
kappa O
B O
activation O
. O

Nine O
new O
steroidal B
glycosides I
from O
the O
roots O
of O
Cynanchum O
stauntonii O
. O

Nine O
new O
steroidal B
glycosides I
, O
named O
as O
stauntosides O
C O
- O
K O
( O
2 O
, O
5 O
, O
7 O
- O
10 O
, O
13 O
, O
14 O
, O
and O
16 O
) O
, O
along O
with O
seven O
known O
compounds O
( O
1 O
, O
3 O
, O
4 O
, O
6 O
, O
11 O
, O
12 O
, O
and O
15 O
) O
were O
isolated O
from O
the O
95 O
% O
ethanol B
extract O
of O
the O
roots O
of O
Cynanchum O
stauntonii O
. O

Polymorphisms O
in O
OCTN1 O
and O
OCTN2 O
transporters O
genes O
are O
associated O
with O
prolonged O
time O
to O
progression O
in O
unresectable O
gastrointestinal O
stromal O
tumours O
treated O
with O
imatinib B
therapy O
. O

The O
two O
basic O
mainstays O
of O
gastrointestinal O
stromal O
tumours O
( O
GIST O
) O
treatment O
are O
surgery O
and O
imatinib B
, O
a O
selective O
tyrosine B
kinase O
inhibitor O
that O
allows O
achieving O
a O
stable O
or O
responding O
disease O
in O
about O
80 O
% O
of O
patients O
with O
unresectable O
/ O
metastatic O
GIST O
. O

Response O
to O
imatinib B
mainly O
depends O
from O
KIT O
and O
PDGFR O
alpha O
mutational O
status O
. O

Nevertheless O
, O
some O
patients O
with O
a O
potentially O
responsive O
genotype O
do O
not O
respond O
, O
and O
others O
develop O
a O
pattern O
of O
resistance O
to O
imatinib B
which O
is O
not O
associated O
with O
secondary O
mutations O
. O

We O
investigated O
a O
panel O
of O
31 O
polymorphisms O
in O
11 O
genes O
, O
potentially O
associated O
with O
the O
pharmacogenetics O
of O
imatinib B
, O
in O
a O
group O
of O
54 O
unresectable O
/ O
metastatic O
GISTs O
treated O
with O
imatinib B
400mg O
daily O
as O
first O
line O
therapy O
. O

In O
conclusion O
, O
in O
this O
study O
we O
showed O
that O
SLC22A4 O
and O
SLC22A5 O
genotypes O
may O
be O
an O
important O
predictor O
of O
time O
to O
progression O
in O
GIST O
patients O
receiving O
imatinib B
therapy O
. O

Postexposure O
application O
of O
Fas O
receptor O
small O
- O
interfering O
RNA O
to O
suppress O
sulfur B
mustard O
- O
induced O
apoptosis O
in O
human O
airway O
epithelial O
cells O
: O
implication O
for O
a O
therapeutic O
approach O
. O

Sulfur B
mustard O
( O
SM O
) O
is O
a O
vesicant O
chemical O
warfare O
and O
terrorism O
agent O
. O

Results O
using O
annexin O
V O
/ O
propidium B
iodide I
- O
stained O
cells O
showed O
that O
both O
apoptosis O
and O
necrosis O
were O
involved O
in O
cell O
death O
due O
to O
SM O
; O
FasR O
siRNA O
decreased O
both O
apoptotic O
and O
necrotic O
cell O
populations O
. O

Sir2 O
is O
an O
evolutionarily O
conserved O
NAD B
( I
+ I
) I
- O
dependent O
deacetylase O
which O
has O
been O
shown O
to O
play O
a O
critical O
role O
in O
glucose B
and O
fat O
metabolism O
. O

We O
report O
that O
dSir2 O
plays O
a O
critical O
role O
in O
insulin O
signaling O
, O
glucose B
homeostasis O
, O
and O
mitochondrial O
functions O
. O

By O
genetic O
perturbations O
and O
metabolic O
rescue O
, O
we O
provide O
evidence O
to O
illustrate O
that O
fat O
body O
dSir2 O
mediates O
its O
effects O
on O
the O
muscles O
via O
free O
fatty B
acids I
( O
FFA O
) O
and O
dILPs O
( O
from O
the O
insulin O
- O
producing O
cells O
[ O
IPCs O
] O
) O
. O

For O
example O
, O
the O
extent O
of O
phosphorylation O
of O
tyrosine B
residues O
reflects O
the O
balance O
of O
a O
kinase O
and O
a O
phosphatase O
enzyme O
. O

Alternatively O
, O
tissue O
damage O
associated O
with O
systemic O
inflammation O
might O
be O
attenuated O
by O
an O
AP O
- O
mediated O
effect O
on O
adenosine B
metabolism O
. O

Adenosine B
is O
a O
signaling O
molecule O
that O
has O
been O
shown O
to O
protect O
the O
body O
from O
inflammation O
- O
induced O
tissue O
injury O
, O
which O
is O
derived O
through O
dephosphorylation O
of O
ATP B
. O

The O
use O
of O
2D O
INADEQUATE O
and O
( B
15 I
) I
N I
NMR O
for O
the O
unambiguous O
structure O
elucidation O
of O
the O
reaction O
products O
is O
discussed O
in O
this O
manuscript O
. O

p21 O
- O
Activated O
kinase O
6 O
( O
PAK6 O
) O
inhibits O
prostate O
cancer O
growth O
via O
phosphorylation O
of O
androgen B
receptor O
and O
tumorigenic O
E3 O
ligase O
murine O
double O
minute O
- O
2 O
( O
Mdm2 O
) O
. O

The O
androgen B
receptor O
( O
AR O
) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
the O
development O
and O
growth O
of O
prostate O
malignancies O
. O

Furthermore O
, O
AR O
phosphorylation O
at O
Ser B
- O
578 O
by O
PAK6 O
promotes O
AR O
- O
E3 O
ligase O
murine O
double O
minute O
- O
2 O
( O
Mdm2 O
) O
association O
, O
causing O
AR O
degradation O
upon O
androgen B
stimuli O
. O

We O
also O
showed O
that O
PAK6 O
phosphorylates O
Mdm2 O
on O
Thr B
- O
158 O
and O
Ser B
- O
186 O
, O
which O
is O
critical O
for O
AR O
ubiquitin O
- O
mediated O
degradation O
. O

Moreover O
, O
we O
found O
that O
Thr B
- O
158 O
collaborates O
with O
Ser B
- O
186 O
for O
AR O
- O
Mdm2 O
association O
and O
AR O
ubiquitin O
- O
mediated O
degradation O
as O
it O
facilitates O
PAK6 O
- O
mediated O
AR O
homeostasis O
. O

These O
observations O
indicate O
that O
PAK6 O
may O
be O
important O
for O
the O
maintenance O
of O
androgen B
- O
induced O
AR O
signaling O
homeostasis O
and O
in O
prostate O
malignancy O
, O
as O
well O
as O
being O
a O
possible O
new O
therapeutic O
target O
for O
AR O
- O
positive O
and O
hormone O
- O
sensitive O
prostate O
cancer O
. O

Gene O
transfer O
of O
apoA O
- O
IV O
in O
apoA O
- O
I O
( O
- O
/ O
- O
) O
x O
apoE O
( O
- O
/ O
- O
) O
mice O
increased O
plasma O
cholesterol B
and O
triglyceride B
levels O
, O
and O
80 O
% O
of O
the O
protein O
was O
distributed O
in O
the O
VLDL O
/ O
IDL O
/ O
LDL O
region O
. O

Lipid O
- O
free O
apoA O
- O
IV O
and O
reconstituted O
HDL O
- O
A O
- O
IV O
promoted O
ABCA1 O
and O
scavenger O
receptor O
BI O
( O
SR O
- O
BI O
) O
- O
mediated O
cholesterol B
efflux O
, O
respectively O
, O
as O
efficiently O
as O
apoA O
- O
I O
and O
apoE O
. O

Investigating O
the O
roles O
of O
different O
monoamine B
transmitters O
and O
impulse O
control O
using O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
. O

Previous O
studies O
have O
shown O
that O
drugs O
which O
block O
the O
reuptake O
of O
catecholamine B
neurotransmitters O
improve O
impulse O
control O
in O
diseases O
such O
as O
attention O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
. O

Serotonin B
- O
specific O
reuptake O
inhibitors O
( O
SSRI O
) O
lack O
efficacy O
in O
ADHD O
and O
have O
been O
linked O
to O
increased O
suicide O
risk O
. O

The O
present O
study O
investigated O
drugs O
with O
affinity O
for O
one O
or O
more O
of O
the O
monoamine B
reuptake O
transporters O
using O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
, O
a O
model O
of O
attention O
and O
impulsivity O
in O
rodents O
. O

We O
also O
tested O
the O
effects O
of O
the O
alpha O
( O
2 O
) O
- O
adreoceptor O
antagonist O
, O
idazoxan O
and O
novel O
antidepressant O
, O
agomelatine B
, O
which O
both O
increase O
cortical O
noradrenaline B
concentrations O
through O
non O
- O
reuptake O
mechanisms O
. O

Improvements O
in O
impulse O
control O
were O
observed O
with O
venlafaxine B
, O
a O
serotonin B
and O
noradrenaline B
re O
- O
uptake O
inhibitor O
( O
SNRI O
) O
but O
not O
bupropion B
( O
dopamine B
and O
noradrenaline B
re O
- O
uptake O
inhibitor O
) O
. O

Sibutramine B
( O
SNRI O
) O
reduced O
premature O
responses O
by O
~ O
50 O
% O
at O
the O
highest O
dose O
tested O
but O
this O
was O
not O
significant O
. O

Neither O
idazoxan O
nor O
agomelatine B
significantly O
reduced O
premature O
responding O
, O
suggesting O
a O
lack O
of O
efficacy O
at O
the O
doses O
tested O
. O

None O
of O
the O
drugs O
tested O
improved O
attention O
in O
this O
task O
but O
sibutramine B
( O
SNRI O
) O
, O
fluoxetine B
( O
SSRI O
) O
and O
paroxetine B
( O
SSRI O
) O
all O
increased O
omissions O
at O
the O
highest O
dose O
tested O
. O

These O
data O
suggest O
that O
the O
SNRIs O
and O
SSRIs O
reduce O
premature O
responding O
but O
tend O
to O
be O
less O
specific O
than O
noradrenaline B
specific O
reuptake O
inhibitors O
in O
this O
model O
. O

The O
metallohormone O
cadmium B
modulates O
AhR O
- O
associated O
gene O
expression O
in O
the O
small O
intestine O
of O
rats O
similar O
to O
ethinyl B
- I
estradiol I
. O

Cadmium B
( O
Cd B
) O
affects O
the O
expression O
of O
estrogen B
receptor O
( O
ER O
) O
and O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
associated O
genes O
in O
rat O
uterus O
and O
elicits O
estrogen B
- O
like O
activity O
in O
vitro O
. O

The O
small O
intestine O
is O
highly O
exposed O
to O
dietary O
Cd B
which O
may O
mimic O
or O
antagonize O
estrogen B
action O
in O
this O
tissue O
. O

We O
investigated O
the O
effects O
of O
Cd B
and O
17 B
- I
alpha I
- I
ethinylestradiol I
( O
EE O
2 O
) O
on O
AhR O
- O
associated O
gene O
expression O
after O
oral O
exposure O
of O
ovariectomized O
female O
Wistar O
rats O
, O
and O
metallothionein O
( O
Mt1a O
) O
expression O
as O
a O
typical O
metal O
- O
response O
marker O
. O

Mt1a O
in O
the O
small O
intestine O
was O
strongly O
induced O
by O
co O
- O
treatment O
with O
CdCl O
2 O
at O
2 O
mg O
/ O
kg O
b O
. O
wt O
( O
Cd B
2 O
) O
and O
0 O
. O
1 O
mg O
/ O
kg O
b O
. O
wt O
EE2 B
than O
by O
the O
single O
compound O
( O
3 O
- O
day O
gavage O
) O
. O

The O
Cd B
2 O
- O
induced O
down O
- O
regulation O
of O
Cyp1a1 O
, O
Gsta2 O
, O
and O
Nqo1 O
mRNA O
was O
not O
antagonized O
by O
pure O
anti O
- O
estrogen B
( O
2 O
. O
5 O
mg O
/ O
kg O
b O
. O
wt O
ZK191703 O
s O
. O
c O
. O
, O
ZK O
) O
. O

Interestingly O
, O
the O
EE O
2 O
- O
induced O
down O
- O
regulation O
of O
Cyp1a1 O
, O
Gsta2 O
, O
and O
Nqo1 O
mRNA O
was O
antagonized O
by O
Cd B
2 O
in O
vivo O
and O
in O
colon O
cancer O
cell O
lines O
( O
HT O
- O
29 O
and O
CaCo O
- O
2 O
, O
treated O
5 O
days O
with O
Cd B
1 O
micro O
M O
and O
/ O
or O
E O
2 O
0 O
. O
01 O
micro O
M O
) O
with O
low O
or O
no O
ER O
- O
beta O
expression O
. O

Dose O
dependency O
was O
studied O
after O
Cd B
exposure O
with O
drinking O
water O
( O
5 O
and O
50 O
ppm O
CdCl O
2 O
equivalent O
to O
0 O
. O
4 O
and O
4 O
mg O
/ O
kg O
b O
. O
wt O
; O
Cd B
0 O
. O
4 O
, O
Cd B
4 O
) O
for O
28 O
days O
and O
EE O
2 O
as O
reference O
. O

Intestinal O
Mt1a O
expression O
was O
dose O
dependently O
induced O
, O
while O
AhR O
target O
genes O
were O
down O
- O
regulated O
by O
Cd B
0 O
. O
4 O
similar O
to O
EE O
2 O
and O
more O
pronounced O
than O
by O
Cd B
4 O
. O

We O
propose O
that O
Cd B
modulates O
intestinal O
AhR O
- O
associated O
gene O
expression O
similar O
to O
estrogens B
, O
but O
( O
contrary O
to O
its O
effects O
in O
uterus O
) O
via O
ER O
- O
independent O
and O
/ O
or O
ER O
- O
beta O
- O
mediated O
mechanisms O
. O

Our O
new O
data O
suggest O
interference O
of O
Cd B
with O
estrogen B
and O
AhR O
signaling O
in O
the O
small O
intestine O
. O

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn O
( O
IV O
) O
on O
incorporation O
of O
( O
68 O
) O
Ga O
( O
3 O
+ O
) O
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( O
68 O
) O
Ga O
labeling O
of O
1 O
, O
4 O
, O
7 O
- O
triazacyclononane O
- O
1 O
, O
4 O
, O
7 O
- O
triacetic O
acid O
( O
NOTA O
) O
, O
1 O
, O
4 O
, O
7 O
, O
10 O
- O
tetraazacyclododecan O
- O

The O
( O
68 O
) O
Ga O
labeling O
yield O
for O
carboxylate B
- O
type O
chelators O
NOTA O
and O
DOTA B
is O
decreased O
at O
lower O
metal O
ion O
contaminant O
concentrations O
compared O
with O
phosphinate O
- O
type O
chelators O
TRAP O
and O
NOPO O
. O

The O
latter O
are O
able O
to O
rapidly O
exchange O
coordinated O
Zn B
( I
II I
) I
with O
( O
68 O
) O
Ga O
( O
3 O
+ O
) O
, O
as O
confirmed O
by O
mass O
spectrometry O
and O
( B
31 I
) I
P I
NMR O
spectroscopy O
. O

( O
68 O
) O
Ga O
labeling O
of O
Zn B
( I
II I
) I
complexes O
of O
TRAP O
and O
NOPO O
proceeds O
as O
efficient O
as O
labeling O
of O
neat O
NOTA O
; O
this O
applies O
also O
to O
the O
corresponding O
peptide O
conjugates O
of O
these O
chelators O
. O

Single O
nucleotide B
polymorphisms O
in O
the O
TMEM106B O
gene O
were O
recently O
discovered O
as O
a O
risk O
factor O
for O
FTLD O
- O
U O
, O
especially O
in O
patients O
with O
PGRN O
mutations O
. O

High O
- O
dose O
sodium B
selenite I
toxicity O
cannot O
be O
prevented O
by O
the O
co O
- O
administration O
of O
pharmacological O
levels O
of O
epigallocatechin B
- I
3 I
- I
gallate I
which O
in O
turn O
aggravates O
the O
toxicity O
. O

Selenium B
, O
an O
essential O
trace O
element O
, O
can O
also O
be O
toxic O
at O
higher O
levels O
of O
exposure O
. O

Several O
lines O
of O
evidence O
show O
epigallocatechin B
- I
3 I
- I
gallate I
( O
EGCG B
) O
, O
a O
predominant O
component O
of O
green O
tea O
catechins B
with O
numerous O
health O
benefits O
, O
can O
ameliorate O
the O
toxicity O
of O
many O
agents O
. O

A O
proof O
- O
in O
- O
principle O
experiment O
was O
conducted O
to O
determine O
if O
EGCG B
would O
ameliorate O
sodium B
selenite I
- O
induced O
growth O
suppression O
. O

Mice O
were O
intraperitioneally O
injected O
with O
selenite O
once O
daily O
for O
five O
days O
at O
a O
dose O
of O
3 O
mg O
Se B
/ O
kg O
, O
which O
fully O
suppressed O
animal O
growth O
but O
did O
not O
cause O
death O
. O

Surprisingly O
the O
co O
- O
administration O
of O
the O
selenite O
and O
nontoxic O
doses O
of O
EGCG B
( O
10 O
, O
20 O
and O
40 O
mg O
/ O
kg O
, O
intraperitioneally O
) O
resulted O
in O
the O
mortality O
of O
treated O
mice O
in O
a O
dose O
and O
time O
- O
dependent O
manner O
( O
33 O
. O
3 O
% O
, O
100 O
% O
and O
100 O
% O
, O
respectively O
) O
. O

EGCG B
- O
selenite O
induced O
lethality O
did O
not O
result O
from O
enhanced O
selenium B
accumulation O
but O
appeared O
to O
involve O
the O
suppression O
of O
a O
selenite O
- O
induced O
adaptive O
response O
as O
evidenced O
by O
hepatic O
glutathione B
S B
- O
transferase O
activity O
. O

While O
EGCG B
has O
been O
reported O
to O
ameliorate O
the O
toxicity O
of O
some O
agents O
, O
the O
induction O
of O
mortality O
by O
combined O
treatment O
with O
pharmacological O
doses O
of O
selenium B
and O
EGCG B
is O
a O
previously O
unrecognized O
synergism O
that O
must O
be O
considered O
not O
only O
in O
the O
remediation O
of O
high O
environmental O
selenium B
exposures O
but O
also O
in O
the O
development O
of O
pharmaceuticals O
and O
nutriceuticals O
. O

Hoechst B
33258 I
staining O
and O
Western O
blot O
analysis O
of O
apoptosis O
- O
related O
proteins O
showed O
that O
WK O
induced O
SGC O
- O
7901 O
cell O
death O
was O
not O
through O
apoptosis O
. O

Relieving O
visceral O
hyperalgesia O
effect O
of O
Kangtai O
capsule O
and O
its O
potential O
mechanisms O
via O
modulating O
the O
5 B
- I
HT I
and O
NO B
level O
in O
vivo O
. O

The O
neonatal O
maternal O
separation O
( O
NMS O
) O
on O
Sprague O
- O
Dawley O
pups O
was O
employed O
to O
evaluate O
the O
therapeutic O
effect O
of O
KT O
by O
virtue O
of O
various O
parameters O
including O
visceral O
hyperalgesia O
, O
serum O
nitric B
oxide I
( O
NO B
) O
level O
, O
and O
tissue O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
level O
. O

Consequently O
, O
a O
chromatographic O
condition O
, O
which O
was O
carried O
at O
30 O
degrees O
C O
with O
a O
flow O
rate O
of O
0 O
. O
5 O
ml O
/ O
min O
on O
AQUA O
3 O
mu O
C18 O
column O
with O
mobile O
phase O
of O
acetonitrile B
and O
water O
- O
phosphoric B
acid I
( O
100 O
: O
0 O
. O
1 O
, O
v O
/ O
v O
) O
, O
was O
established O
to O
give O
a O
common O
fingerprint O
chromatography O
under O
254 O
nm O
with O
a O
similarity O
index O
of O
0 O
. O
963 O
within O
ten O
batches O
of O
KT O
samples O
. O

Furthermore O
, O
KT O
at O
three O
doses O
significantly O
decreased O
5 B
- I
HT I
content O
from O
distal O
colon O
of O
visceral O
hyperalgesia O
rats O
induced O
by O
NMS O
, O
while O
the O
significant O
decrease O
of O
5 B
- I
HT I
content O
in O
serum O
was O
only O
observed O
in O
the O
group O
with O
KT O
at O
high O
dose O
. O

However O
, O
compared O
with O
that O
in O
NMS O
rats O
without O
KT O
, O
there O
was O
no O
apparent O
difference O
of O
5 B
- I
HT I
level O
from O
brain O
issue O
in O
the O
rats O
with O
various O
doses O
. O

Besides O
, O
KT O
could O
substantially O
elevate O
the O
concentration O
of O
NO B
in O
the O
serum O
. O

Data O
from O
the O
pharmacological O
investigation O
suggested O
that O
the O
curative O
effect O
of O
KT O
to O
the O
visceral O
hypersensitivity O
may O
be O
concerned O
with O
the O
level O
of O
5 B
- I
HT I
and O
NO B
in O
vivo O
, O
promising O
its O
potential O
in O
irritable O
bowel O
syndrome O
treatment O
. O

First O
report O
of O
the O
use O
of O
a O
saxitoxin B
- O
protein O
conjugate O
to O
develop O
a O
DNA O
aptamer O
to O
a O
small O
molecule O
toxin O
. O

Saxitoxin B
( O
STX O
) O
is O
a O
low O
molecular O
weight O
neurotoxin O
mainly O
produced O
by O
certain O
marine O
dinoflagellates O
that O
, O
along O
with O
its O
family O
of O
similarly O
related O
paralytic O
shellfish O
toxins O
, O
may O
cause O
the O
potentially O
fatal O
intoxication O
known O
as O
paralytic O
shellfish O
poisoning O
. O

Reactive O
oxygen B
species O
are O
formed O
in O
the O
eyes O
following O
a O
wide O
variety O
of O
stressors O
, O
and O
are O
largely O
implicated O
in O
glaucoma O
pathogenesis O
. O

This O
article O
reviews O
the O
early O
evidence O
suggesting O
that O
reactive O
oxygen B
species O
, O
immune O
inflammatory O
response O
mediators O
, O
and O
apoptogenic O
molecules O
are O
engaged O
in O
glaucoma O
disease O
. O

Divergence O
in O
androgen B
sensitivity O
contributes O
to O
population O
differences O
in O
sexual O
dimorphism O
of O
electrocommunication O
behavior O
. O

Gonadal O
steroid O
hormones O
can O
modulate O
EODs O
, O
and O
differences O
in O
androgen B
sensitivity O
are O
hypothesized O
to O
underlie O
variation O
in O
the O
degree O
of O
sexual O
dimorphism O
across O
species O
. O

In O
this O
study O
, O
we O
asked O
whether O
variation O
in O
androgen B
sensitivity O
explained O
variation O
in O
sexual O
dimorphism O
of O
EODs O
within O
species O
, O
at O
the O
population O
level O
. O

11 B
- I
Ketotestosterone I
( O
11 B
- I
kT I
) O
was O
administered O
over O
a O
two O
- O
week O
period O
to O
assess O
population O
differences O
in O
sensitivity O
to O
androgens B
. O

11 B
- I
kT I
masculinized O
EODf O
significantly O
more O
in O
the O
population O
with O
the O
greater O
degree O
of O
sexual O
dimorphism O
. O

11 B
- I
kT I
had O
no O
effect O
on O
the O
sexually O
monomorphic O
chirping O
rates O
. O

We O
conclude O
that O
population O
divergence O
in O
androgen B
sensitivity O
contributes O
to O
variation O
in O
sexual O
dimorphism O
of O
EODf O
in O
A O
. O
albifrons O
. O

Plasma O
concentrations O
of O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
PGE2 B
were O
elevated O
by O
both O
phospholipase O
A O
( O
2 O
) O
( O
PLA O
( O
2 O
) O
) O
and O
metalloprotease O
( O
MP O
) O
fractions O
. O

The O
plasma O
level O
of O
nitric B
oxide I
was O
increased O
after O
PLA O
( O
2 O
) O
fraction O
injection O
but O
not O
with O
MP O
fraction O
injection O
. O

The O
nucleotide B
sequence O
of O
HmTx O
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino B
acid I
residues O
- O
104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O

The O
beta O
- O
sheet O
consisted O
of O
a O
single O
stranded O
anti O
- O
parallel O
beta O
- O
sheet O
( O
b1 O
. O
1 O
at O
Glu43 O
- O
Lys45 O
and O
b1 O
. O
2 O
at O
Lys48 B
- O
Asn50 O
) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
( O
- O
CGXG O
- O
, O
- O
CCXXHDXC O
- O
and O
CXCEXXXXXC O
- O
) O
of O
Apis O
mellifera O
( O
bee O
) O
phospholipases O
. O

Rev1 O
stably O
interacts O
with O
Rad5 O
( O
a O
central O
component O
of O
the O
template O
switching O
pathway O
) O
via O
the O
C B
- O
terminal O
region O
of O
Rev1 O
and O
the O
N B
- O
terminal O
region O
of O
Rad5 O
. O

Deletion O
analysis O
revealed O
that O
the O
C B
- O
terminal O
21 O
- O
amino B
acid I
sequence O
of O
Rev1 O
is O
uniquely O
required O
for O
its O
interaction O
with O
Rad5 O
and O
is O
essential O
for O
its O
non O
- O
catalytic O
function O
. O

Deletion O
analysis O
additionally O
implicated O
a O
C B
- O
terminal O
region O
of O
Rev1 O
in O
its O
negative O
regulation O
. O

CXCL8 O
and O
acetylcholine B
( O
ACh B
) O
concentrations O
were O
measured O
using O
ELISA O
and O
LC O
- O
MS O
/ O
MS O
, O
respectively O
. O

In O
A549 O
cells O
, O
TNF O
- O
alpha O
increased O
the O
release O
of O
CXCL8 O
and O
ACh B
and O
the O
expression O
of O
the O
subtype O
3 O
MR O
( O
M3R O
) O
. O

Furthermore O
, O
TNF O
- O
alpha O
- O
induced O
CXCL8 O
secretion O
was O
( O
i O
) O
inhibited O
by O
the O
MR O
antagonist O
tiotropium B
and O
the O
M3R O
antagonist O
4 O
- O
DAMP O
and O
( O
ii O
) O
enhanced O
by O
the O
M1 O
/ O
M3R O
agonist O
pilocarpine B
and O
the O
cholinesterase O
inhibitor O
physostigmine B
. O

Taken O
as O
a O
whole O
, O
these O
results O
suggest O
that O
ACh B
release O
by O
A549 O
cells O
enhances O
TNF O
- O
alpha O
- O
induced O
CXCL8 O
secretion O
through O
activation O
of O
the O
M3R O
. O

Western O
blot O
analysis O
revealed O
that O
pilocarpine B
and O
physostigmine B
enhanced O
the O
TNF O
- O
alpha O
- O
induced O
phosphorylation O
of O
ERK1 O
/ O
2 O
and O
p38 O
MAPK O
and O
the O
degradation O
of O
I O
kappa O
B O
alpha O
. O

Inhibition O
of O
these O
pathways O
with O
specific O
inhibitors O
abrogated O
the O
pilocarpine B
- O
induced O
CXCL8 O
release O
. O

Our O
results O
suggest O
that O
the O
TNF O
- O
alpha O
- O
induced O
secretion O
of O
CXCL8 O
in O
A549 O
cells O
is O
regulated O
by O
the O
release O
of O
ACh B
, O
the O
latter O
' O
s O
binding O
to O
the O
M3R O
and O
the O
downstream O
activation O
of O
NF O
- O
kappa O
B O
and O
the O
ERK1 O
/ O
2 O
and O
p38 O
MAPK O
signaling O
pathways O
. O

Our O
findings O
suggest O
that O
MR O
antagonists O
may O
have O
anti O
- O
inflammatory O
effects O
by O
preventing O
pro O
- O
inflammatory O
events O
driven O
by O
endogenous O
, O
non O
- O
neuronal O
ACh B
. O

Inhibition O
of O
vitellogenin O
gene O
induction O
by O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
is O
mediated O
by O
aryl B
hydrocarbon I
receptor O
2 O
( O
AHR2 O
) O
in O
zebrafish O
( O
Danio O
rerio O
) O
. O

To O
better O
understand O
chemical O
effects O
on O
vitellogenin O
gene O
regulation O
, O
we O
tested O
the O
hypothesis O
that O
activation O
of O
the O
aryl B
hydrocarbon I
receptor O
2 O
( O
AHR2 O
) O
by O
dioxin B
inhibits O
the O
estrogen B
receptor O
pathway O
regulation O
of O
3 O
vitellogenin O
genes O
( O
vtg1 O
- O
3 O
) O
in O
vivo O
, O
using O
zebrafish O
( O
Danio O
rerio O
) O
as O
a O
model O
teleost O
. O

Using O
an O
embryo O
- O
larval O
bioassay O
, O
embryos O
were O
either O
treated O
with O
1000 O
pptr O
( O
parts O
- O
per O
- O
trillion O
, O
pg O
/ O
mL O
) O
17 O
alpha O
- O
ethynylestradiol O
( O
EE2 B
) O
alone O
from O
6h O
post O
fertilization O
( O
hpf O
) O
to O
4 O
days O
post O
fertilization O
( O
dpf O
) O
, O
or O
pre O
- O
treated O
with O
dioxin O
( O
4 O
- O
5 O
hpf O
) O
prior O
to O
EE2 B
. O

Pre O
- O
treatment O
with O
400 O
pptr O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
TCDD O
) O
or O
1 O
, O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
pentachlorodibenzo O
- O
p O
- O
dioxin O
inhibited O
the O
EE2 B
induction O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
> O
95 O
% O
( O
p O
< O
= O
0 O
. O
05 O
) O
. O

Effects O
of O
octylphenol O
and O
bisphenol B
A I
on O
the O
expression O
of O
calcium B
transport O
genes O
in O
the O
mouse O
duodenum O
and O
kidney O
during O
pregnancy O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
organic O
compound O
with O
two O
functional O
phenol B
groups O
, O
and O
used O
for O
manufacturing O
polycarbonate B
plastic O
and O
epoxy B
resins O
, O
as O
well O
as O
other O
applications O
. O

OP O
and O
BPA B
are O
known O
as O
endocrine O
disruptors O
( O
EDs O
) O
with O
estrogenic O
activities O
, O
and O
may O
disturb O
natural O
calcium B
( O
Ca B
) O
metabolism O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
OP O
and O
BPA B
on O
Ca B
levels O
in O
the O
serum O
and O
expression O
of O
Ca B
transport O
genes O
in O
the O
duodenum O
, O
and O
kidney O
were O
investigated O
in O
pregnant O
mice O
. O

Calbindin O
refers O
to O
several O
Ca B
- O
binding O
proteins O
originally O
described O
as O
vitamin B
D I
- O
dependent O
Ca B
- O
binding O
factors O
in O
the O
intestine O
, O
and O
kidney O
of O
birds O
and O
mammals O
. O

Transient O
receptor O
potential O
cation O
channel O
, O
subfamily O
V O
, O
member O
6 O
( O
TRPV6 O
) O
and O
transient O
receptor O
potential O
cation O
channel O
, O
subfamily O
V O
, O
member O
5 O
( O
TRPV5 O
) O
are O
Ca B
entry O
channels O
responsible O
for O
Ca B
absorption O
in O
the O
kidney O
and O
intestine O
, O
respectively O
. O

From O
6 O
. O
5 O
to O
16 O
. O
5 O
day O
post O
coitus O
( O
dpc O
) O
, O
pregnant O
mice O
were O
given O
oral O
doses O
of O
17 O
alpha O
- O
ethynylestradiol O
( O
EE O
, O
0 O
. O
2mg O
/ O
kg O
/ O
day O
) O
, O
BPA B
( O
5 O
or O
50mg O
/ O
kg O
/ O
day O
) O
, O
or O
OP O
( O
3 O
, O
12 O
, O
or O
48 O
mg O
/ O
kg O
/ O
day O
) O
dissolved O
in O
corn O
oil O
. O

Serum O
Ca B
levels O
were O
decreased O
in O
the O
groups O
treated O
with O
OP O
and O
BPA B
. O

The O
expression O
levels O
of O
Ca B
transport O
genes O
, O
TRPV5 O
and O
calbindin O
- O
D9k O
( O
CaBP O
- O
9k O
) O
, O
in O
the O
kidney O
were O
decreased O
after O
treatment O
with O
OP O
and O
BPA B
. O

Duodenal O
expression O
of O
TRPV6 O
was O
also O
reduced O
by O
BPA B
and O
OP O
administration O
. O

CaBP O
- O
9k O
expression O
was O
differentially O
regulated O
by O
BPA B
and O
OP O
. O

Transcriptional O
and O
translational O
levels O
of O
CaBP O
- O
9k O
were O
decreased O
by O
EE O
and O
BPA B
but O
increased O
by O
a O
high O
dose O
of O
OP O
. O

Taken O
together O
, O
our O
findings O
demonstrate O
that O
OP O
and O
BPA B
regulated O
the O
expression O
of O
genes O
associated O
with O
Ca B
transport O
in O
the O
pregnant O
mice O
, O
which O
may O
result O
in O
the O
decreased O
serum O
Ca B
levels O
. O

Liposomes O
prepared O
with O
an O
equimolar O
mixture O
of O
POPC B
, O
sphingomyelin B
and O
cholesterol B
, O
were O
chosen O
as O
models O
for O
lipid O
rafts O
. O

The O
interactions O
of O
these O
liposomes O
with O
two O
local O
anesthetics O
, O
tetracaine O
and O
lidocaine B
, O
and O
one O
general O
anesthetic O
, O
propofol B
, O
were O
studied O
. O

The O
effect O
of O
cholesterol B
was O
investigated O
by O
comparing O
anesthetic O
interactions O
with O
POPC B
/ O
SM O
liposomes O
and O
POPC B
/ O
SM O
/ O
CHOL O
liposomes O
. O

The O
following O
experimental O
techniques O
were O
used O
: O
quartz B
crystal O
microbalance O
with O
dissipation O
, O
differential O
scanning O
calorimetry O
and O
phosphorus B
nuclear O
magnetic O
resonance O
. O

Tetracaine O
interacts O
more O
with O
raftlike O
domains O
, O
lidocaine B
induces O
stronger O
modifications O
on O
POPC B
/ O
SM O
liposomes O
and O
the O
results O
for O
propofol B
are O
not O
fully O
conclusive O
but O
it O
seems O
to O
be O
the O
least O
prone O
to O
lipid O
interactions O
. O

The O
results O
were O
compared O
with O
those O
obtained O
with O
DMPC B
- O
containing O
liposomes O
, O
reported O
in O
a O
previous O
work O
. O

Gene O
transcription O
and O
biomarker O
responses O
in O
the O
clam O
Ruditapes O
philippinarum O
after O
exposure O
to O
ibuprofen B
. O

We O
investigated O
the O
effects O
of O
ibuprofen B
( O
IBU B
) O
on O
the O
clam O
Ruditapes O
philippinarum O
. O

Clams O
were O
exposed O
for O
1 O
, O
3 O
, O
5 O
and O
7 O
days O
to O
0 O
, O
100 O
and O
1000 O
mu O
gIBU O
/ O
L O
, O
and O
established O
biomarker O
responses O
( O
haemolymph O
lysozyme O
, O
gill O
acetylcholinesterase O
and O
digestive O
gland O
superoxide B
dismutase O
activities O
) O
as O
well O
as O
digestive O
gland O
transcriptome O
were O
evaluated O
. O

A O
two O
- O
way O
ANOVA O
revealed O
significant O
effects O
of O
both O
" O
IBU B
concentration O
" O
and O
" O
exposure O
duration O
" O
on O
biomarker O
responses O
. O

Overall O
, O
the O
enzyme O
activities O
were O
generally O
lower O
in O
IBU B
- O
exposed O
clams O
than O
in O
controls O
. O

Although O
limited O
knowledge O
of O
the O
mollusc O
transcriptome O
makes O
it O
difficult O
to O
interpret O
the O
effects O
of O
IBU B
on O
clams O
, O
the O
gene O
transcription O
analysis O
using O
DNA O
microarrays O
enabled O
the O
identification O
of O
the O
putative O
molecular O
mode O
of O
action O
of O
the O
IBU B
. O

The O
functional O
analysis O
of O
differentially O
transcribed O
genes O
suggests O
that O
IBU B
can O
interfere O
with O
various O
signalling O
pathways O
in O
clams O
, O
such O
as O
arachidonic B
acid I
metabolism O
, O
apoptosis O
, O
peroxisomal O
proliferator O
- O
activated O
receptors O
, O
and O
nuclear O
factor O
- O
kappa O
B O
. O

In O
addition O
, O
several O
genes O
involved O
in O
the O
metabolism O
of O
xenobiotics O
( O
e O
. O
g O
. O
, O
glutathione B
S B
- O
transferase O
, O
sulfotransferase O
, O
cytochrome O
P450 O
) O
were O
also O
found O
to O
be O
significantly O
affected O
by O
IBU B
exposure O
. O

In O
summary O
, O
the O
integrated O
approach O
of O
gene O
transcription O
analysis O
and O
biomarker O
responses O
facilitated O
the O
elucidation O
of O
the O
putative O
mechanisms O
of O
action O
of O
IBU B
in O
non O
- O
target O
species O
. O

O2 B
- O
independent O
formation O
of O
the O
inactive O
states O
of O
NiFe O
hydrogenase O
. O

They O
suggest O
that O
, O
contrary O
to O
the O
commonly O
accepted O
mechanism O
, O
the O
attacking O
O B
( I
2 I
) I
is O
not O
incorporated O
as O
an O
active O
site O
ligand O
but O
, O
rather O
, O
acts O
as O
an O
electron O
acceptor O
. O

Our O
findings O
offer O
new O
ways O
toward O
the O
understanding O
of O
O B
( I
2 I
) I
inactivation O
and O
O B
( I
2 I
) I
tolerance O
in O
NiFe O
hydrogenases O
. O

Liver O
microtissues O
were O
stable O
and O
functional O
for O
5 O
weeks O
in O
culture O
enabling O
, O
for O
example O
, O
long O
- O
term O
toxicity O
testing O
of O
acetaminophen B
and O
diclofenac B
. O

Thyroid O
and O
male O
gonad O
morphology O
and O
functionality O
, O
and O
testosterone B
levels O
were O
investigated O
through O
histological O
, O
immunohistochemical O
and O
biochemical O
techniques O
. O

Effects O
of O
pyrene B
exposure O
and O
temperature O
on O
early O
development O
of O
two O
co O
- O
existing O
Arctic O
copepods O
. O

We O
investigated O
the O
effects O
of O
the O
oil O
compound O
pyrene B
, O
on O
egg O
hatching O
and O
naupliar O
development O
of O
the O
calanoid O
copepods O
Calanus O
glacialis O
and O
C O
. O
finmarchicus O
, O
two O
key O
species O
in O
the O
Disko O
Bay O
, O
Western O
Greenland O
. O

At O
low O
temperature O
the O
nauplii O
of O
C O
. O
glacialis O
experienced O
reduced O
growth O
when O
exposed O
to O
pyrene B
, O
and O
survival O
in O
both O
species O
decreased O
. O

Naupliar O
mortality O
increased O
with O
temperature O
at O
high O
pyrene B
concentration O
in O
C O
. O
finmarchicus O
. O

Both O
Calanus O
species O
were O
affected O
by O
pyrene B
exposure O
but O
C O
. O
finmarchicus O
was O
more O
sensitive O
compared O
to O
C O
. O
glacialis O
. O

Exposure O
to O
pyrene B
from O
an O
oil O
spill O
may O
reduce O
the O
standing O
stock O
of O
Calanus O
, O
which O
can O
lead O
to O
less O
energy O
available O
to O
higher O
trophic O
levels O
in O
the O
Arctic O
marine O
food O
web O
. O

Metal O
- O
supported O
aluminosilicate B
ultrathin O
films O
as O
a O
versatile O
tool O
for O
studying O
the O
surface O
chemistry O
of O
zeolites B
. O

The O
application O
of O
a O
variety O
of O
" O
surface O
- O
science O
" O
techniques O
to O
elucidate O
surface O
structures O
and O
mechanisms O
of O
chemical O
reactions O
at O
zeolite B
surfaces O
has O
long O
been O
considered O
as O
almost O
impossible O
because O
of O
the O
poor O
electrical O
and O
thermal O
conductivity O
of O
those O
materials O
. O

Here O
, O
we O
show O
that O
the O
growth O
of O
a O
thin O
aluminosilicate B
film O
on O
a O
metal O
single O
crystal O
under O
controlled O
conditions O
results O
in O
adequate O
and O
well O
- O
defined O
model O
systems O
for O
zeolite B
surfaces O
. O

In O
principle O
, O
silicate B
films O
that O
contain O
metals O
other O
than O
Al B
( O
e O
. O
g O
. O
Ti B
, O
Fe B
, O
etc O
) O
may O
be O
prepared O
in O
a O
similar O
way O
. O

We O
believe O
that O
this O
approach O
opens O
up O
a O
new O
playground O
for O
experimental O
and O
theoretical O
modeling O
of O
zeolites B
, O
aimed O
at O
a O
fundamental O
understanding O
of O
structure O
- O
reactivity O
relationships O
in O
such O
materials O
. O

Emodin B
- I
6 I
- I
O I
- I
beta I
- I
D I
- I
glucoside I
inhibits O
HMGB1 O
- O
induced O
inflammatory O
responses O
in O
vitro O
and O
in O
vivo O
. O

Emodin B
- I
6 I
- I
O I
- I
beta I
- I
D I
- I
glucoside I
( O
EG O
) O
is O
a O
new O
active O
compound O
from O
Reynoutria O
japonica O
, O
and O
its O
biologic O
activities O
have O
not O
been O
previously O
investigated O
. O

Puerarin B
mediates O
hepatoprotection O
against O
CCl4 B
- O
induced O
hepatic O
fibrosis O
rats O
through O
attenuation O
of O
inflammation O
response O
and O
amelioration O
of O
metabolic O
function O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
potential O
effects O
of O
puerarin B
( O
PR O
) O
, O
an O
effective O
isoflavonoid O
compound O
purified O
from O
Pueraria O
lobata O
, O
in O
treating O
hepatic O
fibrosis O
( O
HF O
) O
rats O
induced O
by O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
, O
2 O
mL O
kg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
. O

Compared O
to O
model O
control O
, O
PR O
treatment O
effectively O
lowered O
the O
serum O
levels O
of O
alanine B
aminotransferase O
( O
ALT O
) O
, O
aspartate B
aminotransferase O
( O
AST O
) O
, O
albumin O
( O
Alb O
) O
, O
total O
protein O
( O
TP O
) O
in O
HF O
rats O
. O

Additionally O
, O
the O
activity O
of O
superoxide B
dismutase O
( O
SOD O
) O
was O
elevated O
, O
while O
the O
content O
of O
malondialdehyde B
( O
MDA B
) O
was O
lessened O
in O
liver O
tissue O
. O

Moreover O
, O
it O
also O
was O
attributed O
to O
decreased O
mRNA O
level O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
using O
RT O
- O
PCR O
analysis O
. O

These O
findings O
demonstrate O
that O
puerarin B
successfully O
reverses O
hepatotoxicity O
in O
CCl B
( I
4 I
) I
- O
induced O
HF O
rats O
via O
the O
underlying O
mechanisms O
of O
regulating O
serum O
enzymes O
and O
attenuating O
TNF O
- O
alpha O
/ O
NF O
- O
kappa O
B O
pathway O
for O
anti O
- O
inflammation O
response O
, O
as O
well O
as O
improving O
metabolic O
function O
in O
liver O
tissue O
. O

Hepatoprotective O
effects O
of O
Gentiana O
asclepiadea O
L O
. O
extracts O
against O
carbon B
tetrachloride I
induced O
liver O
injury O
in O
rats O
. O

This O
study O
is O
an O
attempt O
to O
evaluate O
the O
hepatoprotective O
activity O
of O
Gentiana O
asclepiadea O
L O
. O
against O
carbon B
tetrachloride I
- O
induced O
liver O
injury O
in O
rats O
. O

Methanol B
extracts O
of O
aerial O
parts O
( O
GAA O
) O
and O
roots O
( O
GAR O
) O
of O
G O
. O
asclepiadea O
at O
doses O
of O
100 O
, O
200 O
, O
and O
400mg O
/ O
kg O
b O
. O
w O
. O
were O
orally O
administered O
to O
Wistar O
rats O
once O
daily O
for O
7 O
days O
before O
they O
were O
treated O
with O
CCl B
( I
4 I
) I
. O

In O
CCl B
( I
4 I
) I
treated O
animals O
, O
GAA O
and O
GAR O
significantly O
decreased O
levels O
of O
serum O
transaminases O
, O
alkaline O
phosphatase O
and O
total O
bilirubin B
, O
and O
increased O
the O
level O
of O
total O
protein O
. O

Treatment O
with O
the O
extracts O
resulted O
in O
a O
significant O
increase O
in O
the O
levels O
of O
catalase O
, O
superoxide B
dismutase O
and O
reduced B
glutathione I
, O
accompanied O
with O
a O
marked O
reduction O
in O
the O
levels O
of O
malondialdehyde B
, O
as O
compared O
to O
CCl B
( I
4 I
) I
treated O
group O
. O

The O
histopathological O
studies O
confirmed O
protective O
effects O
of O
extracts O
against O
CCl B
( I
4 I
) I
- O
induced O
liver O
injuries O
. O

Phytochemical O
analysis O
revealed O
the O
presence O
of O
sweroside B
, O
swertiamarin B
and O
gentiopicrin O
in O
high O
concentrations O
in O
both O
extracts O
. O

PBMCs O
, O
isolated O
from O
blood O
samples O
of O
four O
male O
and O
four O
female O
healthy O
individuals O
, O
were O
exposed O
in O
vitro O
for O
18h O
to O
either O
a O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB126 B
, O
1 O
mu O
M O
) O
, O
a O
non O
- O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB153 O
, O
10 O
mu O
M O
) O
, O
a O
brominated O
flame O
retardant O
( O
BDE47 O
, O
10 O
mu O
M O
) O
, O
a O
perfluorinated O
alkyl O
acid O
( O
PFOA B
, O
10 O
mu O
M O
) O
or O

bisphenol O
( O
BPA B
, O
10 O
mu O
M O
) O
. O

Hierarchical O
cluster O
analysis O
created O
three O
groups O
and O
clustered O
: O
( O
1 O
) O
PCB126 B
- O
exposed O
samples O
, O
( O
2 O
) O
PCB153 O
and O
BDE47 O
, O
( O
3 O
) O
PFOA B
and O
BPA B
. O

Exposure O
to O
PCB126 B
induced O
the O
AhR O
signaling O
pathway O
. O

BPA B
and O
PFOA B
did O
not O
induce O
significant O
changes O
in O
the O
expression O
of O
known O
nuclear O
receptors O
. O

The O
mechanism O
of O
carvacrol B
- O
evoked O
[ O
Ca2 B
+ I
] O
i O
rises O
and O
non O
- O
Ca2 B
+ I
- O
triggered O
cell O
death O
in O
OC2 O
human O
oral O
cancer O
cells O
. O

Carvacrol B
is O
one O
of O
the O
main O
substances O
of O
essential O
oil O
which O
triggers O
intracellular O
Ca B
( I
2 I
+ I
) I
mobilization O
and O
causes O
cytotoxicity O
in O
diverse O
cell O
models O
. O

However O
, O
the O
mechanism O
of O
carvacrol B
- O
induced O
Ca B
( I
2 I
+ I
) I
movement O
and O
cytotoxicity O
is O
not O
fully O
understood O
. O

This O
study O
examined O
the O
effect O
of O
carvacrol B
on O
cytosolic O
free O
Ca B
( I
2 I
+ I
) I
concentrations O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
) O
, O
cell O
viability O
and O
apoptosis O
in O
OC2 O
human O
oral O
cancer O
cells O
. O

Carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
and O
the O
signal O
was O
reduced O
by O
removal O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
. O

Carvacrol B
- O
induced O
Ca B
( I
2 I
+ I
) I
entry O
was O
not O
altered O
by O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channel O
inhibitors O
and O
protein O
kinase O
C O
( O
PKC O
) O
activator O
, O
but O
was O
inhibited O
by O
a O
PKC O
inhibitor O
. O

In O
Ca B
( I
2 I
+ I
) I
- O
free O
medium O
, O
treatment O
with O
the O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
pump O
inhibitor O
thapsigargin B
( O
TG O
) O
or O
2 O
, O
5 O
- O
di O
- O
tert O
- O
butylhydroquinone O
( O
BHQ O
) O
inhibited O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Conversely O
, O
incubation O
with O
carvacrol B
inhibited O
TG O
or O
BHQ O
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Inhibition O
of O
phospholipase O
C O
( O
PLC O
) O
with O
U73122 O
abolished O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Carvacrol B
decreased O
cell O
viability O
, O
which O
was O
not O
reversed O
when O
cytosolic O
Ca B
( I
2 I
+ I
) I
was O
chelated O
with O
BAPTA B
- I
AM I
( O
1 O
, O
2 O
- O
bis O
( O
2 O
- O
aminophenoxy O
) O
ethane O
- O
N O
, O
N O
, O
N O
' O
, O
N O
' O
- O
tetraacetic O
acid O
- O
acetoxymethyl O
ester O
) O
. O

Carvacrol B
- O
induced O
apoptosis O
and O
activation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
caspase O
- O
3 O
. O

Together O
, O
carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
by O
inducing O
PLC O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
from O
the O
endoplasmic O
reticulum O
and O
Ca B
( I
2 I
+ I
) I
entry O
via O
PKC O
- O
sensitive O
, O
non O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channels O
. O

Carvacrol B
- O
induced O
ROS O
- O
and O
caspase O
- O
3 O
- O
associated O
apoptosis O
. O

The O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
hydroxylated O
metabolites O
5 O
- O
OH O
- O
BDE O
- O
47 O
and O
6 O
- O
OH O
- O
BDE O
- O
47 O
stimulate O
estradiol B
secretion O
in O
the O
ovary O
by O
activating O
aromatase O
expression O
. O

Both O
metabolites O
failed O
to O
affect O
the O
production O
of O
androstenedione B
and O
testosterone B
but O
increased O
the O
secretion O
of O
estradiol B
at O
all O
concentrations O
tested O
. O

The O
increased O
secretion O
of O
estradiol B
was O
due O
to O
the O
stimulation O
of O
aromatase O
gene O
and O
protein O
expression O
. O

Direct O
assessment O
of O
aromatase O
activity O
by O
dibenzylfluorescein O
assay O
and O
indirect O
assessment O
of O
aromatase O
activity O
by O
measurement O
of O
the O
conversion O
of O
testosterone B
to O
estradiol B
confirmed O
that O
5 O
- O
OH O
- O
BDE O
- O
47 O
and O
6 O
- O
OH O
- O
BDE O
- O
47 O
stimulate O
aromatase O
activity O
. O

The O
aromatase O
inhibitor O
CGS O
16949A O
abolished O
this O
stimulatory O
activity O
and O
reduced O
estradiol B
levels O
in O
the O
control O
and O
treatment O
groups O
. O

Cholestatic O
effect O
of O
epigallocatechin B
gallate I
in O
rats O
is O
mediated O
via O
decreased O
expression O
of O
Mrp2 O
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
has O
been O
shown O
to O
be O
protective O
in O
various O
experimental O
models O
of O
liver O
injury O
, O
although O
opposite O
effects O
have O
also O
been O
reported O
. O

Since O
its O
effect O
on O
biliary O
physiology O
has O
not O
been O
thoroughly O
investigated O
, O
the O
present O
study O
evaluated O
effect O
of O
EGCG B
on O
bile O
flow O
and O
bile B
acid I
homeostasis O
in O
rats O
. O

Compared O
to O
controls O
, O
EGCG B
treatment O
decreased O
bile O
flow O
by O
23 O
% O
. O

Hepatic O
paracellular O
permeability O
and O
biliary O
bile B
acid I
excretion O
were O
not O
altered O
by O
EGCG B
administration O
, O
but O
biliary O
glutathione B
excretion O
was O
reduced O
by O
70 O
% O
. O

Accordingly O
, O
the O
main O
glutathione B
transporter O
on O
the O
hepatocyte O
canalicular O
membrane O
, O
multidrug O
resistance O
- O
associated O
protein O
2 O
( O
Mrp2 O
) O
, O
was O
significantly O
decreased O
at O
the O
protein O
level O
. O

EGCG B
administration O
also O
doubled O
plasma O
bile B
acid I
levels O
compared O
to O
controls O
. O

While O
protein O
levels O
of O
the O
main O
hepatic O
bile B
acid I
transporters O
were O
unchanged O
, O
the O
rate O
- O
limiting O
enzyme O
in O
the O
bile B
acid I
synthesis O
, O
Cyp7a1 O
, O
was O
significantly O
increased O
by O
EGCG B
. O

Enhanced O
bile B
acid I
synthesis O
in O
these O
animals O
was O
also O
confirmed O
by O
a O
2 O
- O
fold O
increase O
in O
plasma O
marker O
7 O
alpha O
- O
hydroxy O
- O
4 O
- O
cholesten O
- O
3 O
- O
one O
. O

In O
contrast O
, O
EGCG B
markedly O
downregulated O
major O
bile B
acid I
transporters O
( O
Asbt O
and O
Ost O
alpha O
) O
and O
regulatory O
molecules O
( O
Shp O
and O
Fgf15 O
) O
in O
the O
ileum O
. O

When O
EGCG B
was O
coadministered O
with O
ethinylestradiol B
, O
a O
potent O
cholestatic O
agent O
, O
it O
did O
not O
show O
any O
additional O
effect O
on O
the O
induced O
cholestasis O
. O

This O
study O
shows O
ability O
of O
EGCG B
to O
raise O
plasma O
bile B
acid I
concentrations O
, O
mainly O
through O
Cyp7a1 O
upregulation O
, O
and O
to O
decrease O
bile O
production O
through O
reduction O
in O
Mrp2 O
- O
mediated O
bile B
acid I
- O
independent O
bile O
flow O
. O

In O
conclusion O
, O
our O
data O
demonstrate O
that O
under O
certain O
conditions O
EGCG B
may O
induce O
cholestasis O
. O

Organization O
of O
the O
BcgI O
restriction O
- O
modification O
protein O
for O
the O
transfer O
of O
one O
methyl B
group O
to O
DNA O
. O

Like O
almost O
all O
Type O
IIB O
systems O
, O
BcgI O
needs O
two O
unmethylated O
sites O
for O
nuclease O
activity O
; O
it O
cuts O
both O
sites O
upstream O
and O
downstream O
of O
the O
recognition O
sequence O
, O
hydrolyzing O
eight O
phosphodiester B
bonds O
in O
a O
single O
synaptic O
complex O
. O

The O
BcgI O
recognition O
sequence O
contains O
one O
adenine B
in O
each O
strand O
that O
can O
be O
N O
( O
6 O
) O
- O
methylated O
. O

Though O
it O
transfers O
one O
methyl B
group O
at O
a O
time O
, O
presumably O
through O
a O
single O
A O
subunit O
, O
BcgI O
methyltransferase O
can O
be O
activated O
by O
adding O
extra O
A O
subunits O
, O
either O
individually O
or O
as O
part O
of O
A O
( O
2 O
) O
B O
protomers O
, O
which O
indicates O
that O
it O
requires O
an O
assembly O
containing O
at O
least O
two O
A O
( O
2 O
) O
B O
units O
. O

The O
amount O
, O
type O
and O
balance O
of O
the O
main O
dietary O
macronutrients O
( O
carbohydrates B
, O
proteins O
and O
fats O
) O
have O
a O
great O
impact O
on O
the O
large O
intestinal O
microbiota O
. O

Microbial O
metabolism O
of O
dietary O
carbohydrates B
results O
mainly O
in O
the O
formation O
of O
short O
chain O
fatty B
acids I
and O
gases O
. O

The O
major O
bacterial O
fermentation O
products O
are O
acetate B
, O
propionate O
and O
butyrate O
; O
and O
the O
production O
of O
these O
tends O
to O
lower O
the O
colonic O
pH O
. O

Certain O
bacterial O
species O
in O
the O
colon O
survive O
by O
cross O
- O
feeding O
, O
using O
either O
the O
breakdown O
products O
of O
complex O
carbohydrate B
degradation O
or O
fermentation O
products O
such O
as O
lactic B
acid I
for O
growth O
. O

Effects O
- O
based O
marine O
ecological O
risk O
assessment O
at O
a O
polychlorinated B
biphenyl I
- O
contaminated O
site O
in O
Saglek O
, O
Labrador O
, O
Canada O
. O

Although O
the O
presence O
and O
distribution O
of O
polychlorinated B
biphenyls I
( O
PCBs B
) O
in O
Arctic O
marine O
environments O
has O
been O
well O
documented O
, O
the O
implications O
for O
the O
health O
of O
biota O
are O
poorly O
understood O
. O

In O
the O
present O
study O
, O
multiple O
lines O
of O
evidence O
, O
including O
site O
- O
specific O
effects O
data O
, O
were O
used O
to O
assess O
PCB B
- O
related O
risks O
to O
marine O
biota O
at O
a O
contaminated O
military O
site O
in O
Saglek O
Bay O
, O
Labrador O
, O
Canada O
, O
from O
1997 O
to O
1999 O
. O

Average O
sediment O
PCB B
concentrations O
exceeded O
the O
Canadian O
interim O
sediment O
quality O
guideline O
level O
by O
41 O
- O
fold O
. O

In O
contrast O
, O
shorthorn O
sculpin O
and O
black O
guillemot O
PCB B
exposures O
( O
measured O
as O
sum O
of O
55 O
congeners O
) O
were O
elevated O
enough O
to O
pose O
risks O
to O
survival O
or O
reproduction O
. O

Based O
on O
the O
collective O
evidence O
, O
the O
authors O
estimated O
that O
risks O
were O
posed O
by O
sediment O
PCB B
concentrations O
greater O
than O
77 O
ng O
/ O
g O
dry O
weight O
for O
black O
guillemots O
and O
750 O
ng O
/ O
g O
dry O
weight O
for O
shorthorn O
sculpins O
. O

This O
ecological O
risk O
assessment O
describes O
the O
steps O
and O
rationale O
taken O
to O
evaluate O
the O
risk O
posed O
by O
an O
area O
of O
PCB B
- O
contaminated O
marine O
sediments O
in O
an O
otherwise O
relatively O
pristine O
northern O
coastal O
environment O
. O

Metabolically O
competent O
human O
skin O
models O
: O
activation O
and O
genotoxicity O
of O
benzo B
[ I
a I
] I
pyrene I
. O

The O
polycyclic O
aromatic O
hydrocarbon O
( O
PAH B
) O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
is O
metabolized O
into O
a O
complex O
pattern O
of O
BP O
derivatives O
, O
among O
which O
the O
ultimate O
carcinogen O
( O
+ O
) O
- O
anti O
- O
BP O
- O
7 O
, O
8 O
- O
diol O
- O
9 O
, O
10 O
- O
epoxide O
( O
BPDE O
) O
is O
formed O
to O
certain O
extents O
. O

Skin O
is O
frequently O
in O
contact O
with O
PAHs B
and O
data O
on O
the O
metabolic O
capacity O
of O
skin O
tissue O
toward O
these O
compounds O
are O
inconclusive O
. O

Response O
to O
variable O
light O
intensity O
in O
photoacclimated O
algae O
and O
cyanobacteria O
exposed O
to O
atrazine B
. O

Atrazine B
is O
frequently O
detected O
in O
freshwater O
ecosystems O
exposed O
to O
agricultural O
waste O
waters O
and O
runoffs O
worldwide O
and O
it O
can O
affect O
non O
- O
target O
organisms O
( O
mainly O
photoautotrophic O
) O
and O
modify O
community O
structure O
. O

Meanwhile O
, O
light O
environment O
is O
known O
to O
vary O
between O
aquatic O
ecosystems O
, O
but O
also O
before O
and O
during O
the O
exposure O
to O
atrazine B
and O
these O
variations O
may O
modify O
the O
sensitivity O
to O
atrazine B
of O
photoautotroph O
organisms O
. O

In O
this O
study O
, O
10 O
species O
of O
phytoplankton O
( O
chlorophytes O
, O
baccilariophytes O
and O
cyanophytes O
) O
acclimated O
to O
low O
or O
high O
light O
intensities O
were O
exposed O
to O
atrazine B
and O
light O
of O
different O
intensities O
to O
compare O
their O
combined O
effect O
. O

Our O
data O
showed O
that O
chlorophytes O
and O
baccilariophytes O
were O
more O
resistant O
to O
atrazine B
compared O
to O
cyanophytes O
for O
all O
light O
conditions O
. O

Atrazine B
was O
found O
to O
inhibit O
Phi O
' O
( O
M O
) O
, O
Psi O
( O
0 O
) O
, O
P O
( O
M O
) O
and O
non O
- O
photochemical O
quenching O
for O
all O
species O
indicating O
an O
effect O
on O
electron O
transport O
, O
primary O
production O
and O
photoregulation O
processes O
. O

These O
data O
also O
indicate O
a O
higher O
sensitivity O
of O
Psi O
( O
0 O
) O
( O
average O
Psi O
( O
0 O
) O
- O
EC O
( O
50 O
) O
of O
91 O
+ O
/ O
- O
11 O
nM O
or O
19 O
. O
6 O
+ O
/ O
- O
0 O
. O
9 O
mu O
gL O
( O
- O
1 O
) O
) O
compared O
to O
Phi O
' O
( O
M O
) O
( O
average O
Phi O
' O
( O
M O
) O
- O
EC O
( O
50 O
) O
of O
217 O
+ O
/ O
- O
19 O
nM O
or O
46 O
. O
8 O
+ O
/ O
- O
4 O
. O
1 O
mu O
gL O
( O
- O
1 O
) O
) O
and O
suggest O
that O
photoregulation O
processes O
activated O
in O
presence O
of O
light O
decrease O
the O
effect O
of O
atrazine B
. O

Despite O
this O
similarity O
, O
most O
species O
acclimated O
to O
high O
light O
were O
found O
to O
have O
higher O
or O
similar O
Phi O
' O
( O
M O
) O
- O
EC O
( O
50 O
) O
compared O
to O
low O
light O
acclimated O
cells O
and O
thus O
, O
were O
less O
sensitive O
to O
atrazine B
in O
low O
light O
and O
high O
light O
environments O
. O

We O
concluded O
that O
an O
increase O
in O
the O
plastoquinone B
pool O
induced O
by O
acclimation O
to O
high O
light O
decreased O
the O
sensitivity O
to O
atrazine B
in O
phytoplankton O
and O
we O
hypothesized O
that O
the O
effect O
observed O
was O
the O
result O
of O
a O
dilution O
of O
atrazine B
toxicity O
through O
increased O
binding O
site O
availability O
( O
quinones B
) O
combined O
with O
increased O
photoregulation O
processes O
capacity O
. O

Short O
duration O
of O
diabetes O
and O
disuse O
of O
sulfonylurea B
have O
any O
association O
with O
insulin O
cessation O
of O
the O
patients O
with O
type O
2 O
diabetes O
in O
a O
clinical O
setting O
in O
Japan O
( O
JDDM O
30 O
) O
. O

Data O
regarding O
age O
, O
sex O
, O
body O
mass O
index O
, O
duration O
of O
diabetes O
, O
HbA1c O
, O
postprandial O
plasma O
glucose B
, O
plasma O
fasting O
C O
- O
peptide O
immunoreactivity O
and O
treatment O
modality O
were O
compared O
between O
patients O
who O
were O
able O
to O
stop O
insulin O
therapy O
and O
those O
who O
continued O
with O
insulin O
. O

In O
the O
patients O
who O
stopped O
insulin O
therapy O
, O
the O
duration O
of O
diabetes O
was O
significantly O
shorter O
and O
the O
daily O
insulin O
dosage O
at O
initiation O
and O
the O
prevalence O
of O
sulfonylurea B
pretreatment O
significantly O
lower O
compared O
with O
patients O
who O
continued O
on O
insulin O
. O

Shorter O
duration O
of O
diabetes O
and O
disuse O
of O
sulfonylureas B
prior O
to O
insulin O
may O
associate O
with O
stopping O
insulin O
therapy O
as O
a O
near O
- O
normoglycemic O
remission O
in O
outpatients O
with O
T2DM O
in O
Japan O
. O

a O
, O
j O
] O
xanthenes O
- O
3 O
, O
11 O
- O
dicarboxylic O
acid O
, O
were O
synthesized O
, O
and O
the O
structures O
of O
which O
were O
characterized O
by O
( O
1 O
) O
H O
- O
NMR O
, O
( B
13 I
) I
C I
- O
NMR O
, O
high O
resolution O
( O
HR O
) O
- O
MS O
, O
and O
IR O
spectra O
. O

The O
carboxamide B
derivatives O
6c O
and O
6e O
exhibitted O
good O
inhibition O
on O
NB4 O
cancer O
cells O
, O
and O
the O
IC O
( O
50 O
) O
values O
of O
which O
were O
0 O
. O
82 O
micro O
M O
and O
0 O
. O
96 O
micro O
M O
, O
respectively O
, O
much O
lower O
than O
5 O
. O
01 O
micro O
M O
of O
the O
positive O
control O
As B
( I
2 I
) I
O I
( I
3 I
) I
. O

In O
a O
previous O
work O
we O
showed O
that O
a O
new O
class O
of O
compounds O
derived O
from O
XR9576 O
( O
tariquidar B
) O
selectively O
inhibits O
BCRP O
. O

The O
inhibitory O
activities O
against O
BCRP O
and O
P O
- O
gp O
were O
assayed O
using O
a O
Hoechst B
33342 I
assay O
for O
BCRP O
and O
a O
calcein O
AM O
assay O
for O
P O
- O
gp O
. O

Reduction O
of O
helical O
content O
by O
insertion O
of O
a O
disulfide B
bond O
leads O
to O
an O
antimicrobial O
peptide O
with O
decreased O
hemolytic O
activity O
. O

CAPs O
off O
to O
the O
S O
- O
S O
bond O
: O
Application O
of O
a O
strategy O
involving O
the O
introduction O
of O
intramolecular O
disulfide B
bonds O
to O
amphipathic O
cationic O
antimicrobial O
peptides O
( O
CAPs O
) O
led O
to O
decreased O
alpha O
- O
helicity O
and O
hydrophobicity O
. O

In O
agreement O
with O
the O
increased O
Cyp2d O
mRNA O
, O
Cyp2d O
- O
mediated O
dextrorphan B
formation O
from O
dextromethorphan B
was O
increased O
2 O
. O
7 O
- O
fold O
( O
P O
< O
0 O
. O
05 O
) O
on O
GD19 O
( O
56 O
. O
8 O
+ O
/ O
- O
39 O
. O
4 O
pmol O
/ O
min O
/ O
mg O
protein O
) O
when O
compared O
with O
the O
non O
- O
pregnant O
controls O
( O
20 O
. O
8 O
+ O
/ O
- O
11 O
. O
2 O
pmol O
/ O
min O
/ O
mg O
protein O
) O
. O

An O
increase O
in O
Cyp26a1 O
mRNA O
( O
10 O
- O
fold O
) O
and O
retinoic B
acid I
receptor O
( O
Rar O
) O
beta O
mRNA O
( O
2 O
. O
8 O
- O
fold O
) O
was O
also O
observed O
during O
pregnancy O
. O

The O
increase O
in O
Cyp26a1 O
and O
Rar O
beta O
mRNA O
during O
pregnancy O
indicates O
increased O
retinoic B
acid I
signaling O
in O
the O
liver O
during O
pregnancy O
. O

A O
putative O
retinoic B
acid I
response O
element O
was O
identified O
within O
the O
Cyp2d40 O
promoter O
and O
the O
mRNA O
of O
Cyp2d40 O
correlated O
( O
P O
< O
0 O
. O
05 O
) O
with O
Cyp26a1 O
and O
Rar O
beta O
. O

Our O
findings O
also O
suggest O
that O
retinoic B
acid I
signaling O
in O
the O
liver O
is O
increased O
during O
pregnancy O
, O
which O
may O
have O
broader O
implications O
to O
energy O
homeostasis O
in O
the O
liver O
during O
pregnancy O
. O

Susceptibility O
to O
fatty B
acid I
- O
induced O
beta O
- O
cell O
dysfunction O
is O
enhanced O
in O
prediabetic O
diabetes O
- O
prone O
biobreeding O
rats O
: O
a O
potential O
link O
between O
beta O
- O
cell O
lipotoxicity O
and O
islet O
inflammation O
. O

To O
determine O
this O
, O
we O
examined O
the O
effects O
of O
prolonged O
free O
fatty B
acids I
elevation O
on O
beta O
- O
cell O
secretory O
function O
in O
the O
prediabetic O
diabetes O
- O
prone O
BioBreeding O
( O
dp O
- O
BB O
) O
rat O
, O
its O
diabetes O
- O
resistant O
BioBreeding O
( O
dr O
- O
BB O
) O
control O
, O
and O
normal O
Wistar O
- O
Furth O
( O
WF O
) O
rats O
. O

Rats O
received O
a O
48 O
- O
h O
iv O
infusion O
of O
saline O
or O
Intralipid O
plus O
heparin O
( O
IH O
) O
( O
to O
elevate O
free O
fatty B
acid I
levels O
~ O
2 O
- O
fold O
) O
followed O
by O
hyperglycemic O
clamp O
or O
islet O
secretion O
studies O
ex O
vivo O
. O

IH O
significantly O
decreased O
beta O
- O
cell O
function O
, O
assessed O
both O
by O
the O
disposition O
index O
( O
insulin O
secretion O
corrected O
for O
IH O
- O
induced O
insulin O
resistance O
) O
and O
in O
isolated O
islets O
, O
in O
dp O
- O
BB O
, O
but O
not O
in O
dr O
- O
BB O
or O
WF O
, O
rats O
, O
and O
the O
effect O
of O
IH O
was O
inhibited O
by O
the O
antioxidant O
N B
- I
acetylcysteine I
. O

Consistent O
with O
an O
adult O
- O
onset O
isolated O
GHD O
model O
, O
mutant O
animals O
are O
hypoglycemic O
and O
display O
increased O
insulin O
sensitivity O
and O
glucose B
clearance O
. O

This O
latter O
phenotype O
is O
in O
contrast O
to O
the O
glucose B
intolerance O
observed O
in O
another O
early O
- O
onset O
GHD O
model O
. O

Surprisingly O
, O
increased O
insulin O
sensitivity O
is O
not O
accompanied O
by O
a O
modified O
balance O
between O
fat O
and O
lean O
tissues O
, O
but O
by O
reduced O
metabolic O
adaptability O
between O
glucose B
and O
lipid O
oxidation O
conditions O
. O

In O
conclusion O
, O
our O
mutant O
may O
be O
a O
valuable O
genetic O
model O
with O
which O
to O
study O
the O
effects O
of O
long O
- O
term O
GH O
deficiency O
, O
in O
conditions O
of O
normal O
pancreatic O
function O
and O
unaffected O
balance O
between O
fat O
and O
glucose B
metabolism O
. O

Lipid O
rafts O
were O
originally O
defined O
as O
membrane O
domains O
, O
i O
. O
e O
. O
, O
ordered O
structures O
created O
as O
a O
consequence O
of O
the O
lateral O
segregation O
of O
sphingolipids B
and O
differing O
from O
the O
surrounding O
membrane O
in O
their O
molecular O
composition O
and O
properties O
. O

This O
definition O
was O
subsequently O
modified O
to O
introduce O
the O
notion O
that O
lipid O
rafts O
correspond O
to O
membrane O
areas O
stabilized O
by O
the O
presence O
of O
cholesterol B
within O
a O
liquid O
- O
ordered O
phase O
. O

G O
protein O
coupled O
- O
receptor O
( O
GPCR O
) O
kinases O
( O
GRKs O
) O
initiate O
the O
deactivation O
of O
GPCRs O
by O
phosphorylating O
their O
cytoplasmic O
loops O
and O
C B
- O
terminal O
tails O
. O

Membrane O
lipids O
in O
the O
function O
of O
serotonin B
and O
adrenergic O
receptors O
. O

Since O
GPCRs O
are O
integral O
membrane O
proteins O
, O
interaction O
of O
membrane O
lipids O
such O
as O
cholesterol B
and O
sphingolipids B
with O
GPCRs O
constitutes O
an O
emerging O
area O
of O
research O
in O
contemporary O
biology O
. O

Cholesterol B
and O
sphingolipids B
represent O
important O
lipid O
components O
of O
eukaryotic O
membranes O
and O
play O
a O
crucial O
role O
in O
a O
variety O
of O
cellular O
functions O
. O

In O
this O
review O
, O
we O
highlight O
the O
role O
of O
these O
vital O
lipids O
in O
the O
function O
of O
two O
representative O
GPCRs O
, O
the O
serotonin B
( O
1A O
) O
receptor O
and O
the O
adrenergic O
receptor O
. O

A O
number O
of O
integral O
membrane O
G O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
share O
common O
structural O
features O
( O
including O
palmytoilated O
aminoacid O
residues O
and O
consensus O
sequences O
specific O
for O
interaction O
with O
cholesterol B
) O
that O
allow O
them O
to O
interact O
with O
lipid O
rafts O
, O
membrane O
cholesterol B
- O
rich O
microdomains O
able O
to O
regulate O
GPCR O
signalling O
and O
functions O
. O

We O
shall O
also O
outline O
the O
structural O
features O
that O
allow O
GPR55 O
to O
interact O
with O
cholesterol B
and O
to O
associate O
with O
lipid O
rafts O
; O
how O
the O
latter O
lipid O
microdomains O
impact O
the O
biological O
activity O
of O
GPR55 O
is O
also O
addressed O
, O
as O
well O
as O
their O
potential O
for O
the O
discovery O
of O
new O
therapeutics O
useful O
for O
the O
treatment O
of O
those O
human O
diseases O
that O
might O
be O
associated O
with O
alterations O
of O
GPR55 O
activity O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
- O
mediated O
production O
of O
reactive O
oxygen B
species O
is O
an O
essential O
step O
in O
the O
mechanism O
of O
action O
to O
accelerate O
human O
keratinocyte O
differentiation O
. O

Chloracne O
is O
commonly O
observed O
in O
humans O
exposed O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
; O
yet O
, O
the O
mechanism O
of O
toxicity O
is O
not O
well O
understood O
. O

Using O
normal O
human O
epidermal O
keratinocytes O
, O
we O
investigated O
the O
mechanism O
of O
TCDD B
- O
mediated O
enhancement O
of O
epidermal O
differentiation O
by O
integrating O
functional O
genomic O
, O
metabolomic O
, O
and O
biochemical O
analyses O
. O

TCDD B
increased O
the O
expression O
of O
40 O
% O
of O
the O
genes O
of O
the O
epidermal O
differentiation O
complex O
found O
on O
chromosome O
1q21 O
and O
75 O
% O
of O
the O
genes O
required O
for O
de O
novo O
ceramide O
biosynthesis O
. O

Lipid O
analysis O
demonstrated O
that O
eight O
of O
the O
nine O
classes O
of O
ceramides B
were O
increased O
by O
TCDD B
, O
altering O
the O
ratio O
of O
ceramides B
to O
free O
fatty B
acids I
. O

TCDD B
decreased O
the O
expression O
of O
the O
glucose B
transporter O
, O
SLC2A1 O
, O
and O
most O
of O
the O
glycolytic O
transcripts O
, O
followed O
by O
decreases O
in O
glycolytic O
intermediates O
, O
including O
pyruvate B
. O

NADH B
and O
Krebs O
cycle O
intermediates O
were O
decreased O
, O
whereas O
NAD B
( I
+ I
) I
was O
increased O
. O

Mitochondrial O
glutathione B
( O
GSH B
) O
reductase O
activity O
and O
the O
GSH B
/ O
glutathione B
disulfide I
ratio O
were O
decreased O
by O
TCDD B
, O
ultimately O
leading O
to O
mitochondrial O
dysfunction O
, O
characterized O
by O
decreased O
inner O
mitochondrial O
membrane O
potential O
and O
ATP B
production O
, O
and O
increased O
production O
of O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
hydrogen B
peroxide I
. O

Aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
antagonists O
blocked O
the O
response O
of O
many O
transcripts O
to O
TCDD B
, O
and O
the O
endpoints O
of O
decreased O
ATP B
production O
and O
differentiation O
, O
suggesting O
regulation O
by O
the O
AHR O
. O

Cotreatment O
of O
cells O
with O
chemical O
antioxidants O
or O
the O
enzyme O
catalase O
blocked O
the O
TCDD B
- O
mediated O
acceleration O
of O
keratinocyte O
cornified O
envelope O
formation O
, O
an O
endpoint O
of O
terminal O
differentiation O
. O

Thus O
, O
TCDD B
- O
mediated O
ROS O
production O
is O
a O
critical O
step O
in O
the O
mechanism O
of O
this O
chemical O
to O
accelerate O
keratinocyte O
differentiation O
. O

Delta B
9 I
- I
tetrahydrocannabinol I
impairs O
the O
inflammatory O
response O
to O
influenza O
infection O
: O
role O
of O
antigen O
- O
presenting O
cells O
and O
the O
cannabinoid O
receptors O
1 O
and O
2 O
. O

Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta O
( O
9 O
) O
- O
THC O
) O
has O
potent O
immune O
modulatory O
properties O
and O
can O
impair O
pathogen O
- O
induced O
immune O
defenses O
, O
which O
in O
part O
have O
been O
attributed O
to O
ligation O
of O
the O
cannabinoid O
receptors O
1 O
( O
CB O
( O
1 O
) O
) O
and O
2 O
( O
CB O
( O
2 O
) O
) O
. O

The O
severe O
hypocalcaemia O
is O
believed O
to O
be O
due O
to O
increased O
influx O
of O
calcium B
into O
bone O
, O
due O
to O
the O
sudden O
removal O
of O
the O
effect O
of O
high O
circulating O
levels O
of O
PTH O
on O
osteoclastic O
resorption O
, O
leading O
to O
a O
decrease O
in O
the O
activation O
frequency O
of O
new O
remodelling O
sites O
and O
to O
a O
decrease O
in O
remodelling O
space O
, O
although O
there O
is O
no O
good O
documentation O
for O
this O
. O

Various O
risk O
factors O
have O
been O
suggested O
for O
the O
development O
of O
HBS O
, O
including O
older O
age O
, O
weight O
/ O
volume O
of O
the O
resected O
parathyroid O
glands O
, O
radiological O
evidence O
of O
bone O
disease O
and O
vitamin B
D I
deficiency O
. O

Treatment O
is O
aimed O
at O
replenishing O
the O
severe O
calcium B
deficit O
by O
using O
high O
doses O
of O
calcium B
supplemented O
by O
high O
doses O
of O
active O
metabolites O
of O
vitamin B
D I
. O

Adequate O
correction O
of O
magnesium B
deficiency O
and O
normalisation O
of O
bone O
turnover O
are O
required O
for O
resolution O
of O
the O
hypocalcaemia O
which O
may O
last O
for O
a O
number O
of O
months O
after O
successful O
surgery O
. O

Preoperative O
treatment O
with O
bisphosphonates B
has O
been O
suggested O
to O
reduce O
post O
- O
operative O
hypocalcaemia O
, O
but O
there O
are O
to O
date O
no O
prospective O
studies O
addressing O
this O
issue O
. O

Hot O
isotropic O
mixture O
of O
stearic B
acid I
, O
poloxamer B
and O
polyethylene B
glycol I
was O
spontaneously O
self O
nano O
- O
emulsify O
in O
hot O
water O
and O
SLNs O
were O
formed O
with O
subsequent O
rapid O
cooling O
. O

Self O
nano O
- O
emulsification O
ability O
of O
stearic B
acid I
, O
poloxamer B
and O
polyethylene B
glycol I
mixture O
was O
assessed O
by O
ternary O
phase O
diagram O
study O
. O

Results O
indicate O
that O
SLNs O
of O
higher O
fatty B
acids I
can O
be O
successfully O
prepared O
by O
hot O
SNE O
technique O
. O

Retinal O
drug O
delivery O
using O
eyedrop O
preparations O
of O
poly B
- I
L I
- I
lysine I
- O
modified O
liposomes O
. O

Various O
molecular O
weights O
and O
concentrations O
of O
the O
water O
- O
soluble O
cationic O
polymer O
poly B
- I
L I
- I
lysine I
( O
PLL B
) O
were O
used O
to O
modify O
the O
surface O
of O
submicronized O
( O
100 O
nm O
) O
liposomes O
. O

Using O
coumarin O
- O
6 O
as O
a O
model O
drug O
and O
fluorescent O
marker O
, O
we O
show O
that O
liposome O
surface O
modification O
by O
PLL B
dramatically O
increased O
delivery O
to O
mouse O
retina O
segments O
after O
eye O
drop O
administration O
. O

However O
, O
when O
PLL B
of O
high O
molecular O
weight O
( O
> O
30 O
, O
000 O
) O
was O
used O
at O
higher O
concentrations O
( O
> O
0 O
. O
05 O
% O
) O
, O
aggregation O
of O
surface O
- O
modified O
liposomes O
increased O
particle O
size O
and O
hampered O
distribution O
to O
inner O
ocular O
tissues O
. O

The O
optimal O
molecular O
weight O
and O
concentration O
of O
PLL B
in O
drug O
- O
delivering O
liposomes O
were O
15 O
, O
000 O
- O
30 O
, O
000 O
and O
0 O
. O
005 O
% O
, O
respectively O
. O

Under O
these O
conditions O
, O
PLL B
- O
modified O
liposomes O
were O
not O
cytotoxic O
in O
corneal O
or O
conjunctival O
cells O
. O

Amino B
acid I
derivatives O
as O
transdermal O
permeation O
enhancers O
. O

In O
this O
study O
, O
we O
investigated O
enhancers O
with O
amino B
acids I
( O
proline B
, O
sarcosine B
, O
alanine B
, O
beta O
- O
alanine O
, O
and O
glycine B
) O
attached O
to O
hydrophobic O
chain O
( O
s O
) O
via O
a O
biodegradable O
ester B
link O
. O

The O
proline B
derivative O
l O
- O
Pro2 O
reached O
enhancement O
ratios O
of O
up O
to O
40 O
at O
1 O
% O
concentration O
, O
which O
is O
higher O
than O
that O
of O
the O
well O
- O
established O
and O
standard O
enhancers O
Azone O
, O
DDAIP O
, O
DDAK O
, O
and O
Transkarbam O
12 O
. O

l O
- O
Pro2 O
acted O
synergistically O
with O
propylene B
glycol I
. O

The O
onset O
of O
antineutrophil O
cytoplasmic O
antibody O
- O
associated O
vasculitis O
immediately O
after O
methimazole B
was O
switched O
to O
propylthiouracil O
in O
a O
woman O
with O
Graves O
' O
disease O
who O
wished O
to O
become O
pregnant O
. O

Propylthiouracil O
( O
PTU B
) O
is O
recommended O
as O
a O
first O
- O
line O
antithyroid O
drug O
( O
ATD O
) O
during O
first O
trimester O
organogenesis O
in O
pregnancy O
because O
recent O
evidence O
suggests O
that O
methimazole B
( O
MMI O
) O
may O
be O
associated O
with O
congenital O
anomalies O
. O

However O
, O
PTU B
more O
commonly O
causes O
myeloperoxidase O
( O
MPO O
) O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
ANCA O
) O
- O
associated O
vasculitis O
, O
which O
usually O
occurs O
during O
prolonged O
treatment O
, O
compared O
with O
MMI O
. O

Although O
her O
thyroid O
function O
could O
be O
maintained O
euthyroid O
by O
MMI O
, O
her O
ATD O
was O
switched O
to O
PTU B
because O
she O
wished O
to O
become O
pregnant O
. O

The O
patient O
presented O
with O
flu O
- O
like O
symptoms O
8 O
days O
after O
starting O
PTU B
and O
developed O
hemoptysis O
and O
dyspnea O
at O
22 O
days O
. O

Her O
MPO O
- O
ANCA O
titer O
was O
21 O
ELISA O
units O
( O
EUs O
) O
before O
PTU B
treatment O
but O
increased O
to O
259 O
EUs O
at O
22 O
days O
after O
PTU B
treatment O
. O

Her O
clinical O
condition O
improved O
with O
the O
discontinuation O
of O
PTU B
and O
with O
immunosuppressive O
therapy O
. O

This O
case O
indicated O
that O
MPO O
- O
ANCA O
vasculitis O
occurred O
within O
several O
weeks O
after O
the O
initiation O
of O
PTU B
and O
that O
this O
side O
effect O
could O
be O
caused O
by O
the O
change O
from O
MMI O
to O
PTU B
. O

Thus O
, O
our O
clinical O
observation O
suggests O
that O
patients O
treated O
with O
PTU B
should O
be O
carefully O
monitored O
for O
MPO O
- O
ANCA O
titers O
and O
variable O
manifestations O
of O
MPO O
- O
ANCA O
- O
associated O
vasculitis O
regardless O
of O
the O
period O
of O
administration O
. O

Two O
alginate O
- O
mAb1 O
sustained O
release O
formulations O
were O
developed O
by O
an O
internal O
gelation O
technique O
using O
CaCO B
( I
3 I
) I
and O
CaHPO O
( O
4 O
) O
as O
calcium B
sources O
for O
physical O
cross O
- O
linking O
. O

The O
CaCO B
( I
3 I
) I
formulation O
provided O
a O
stable O
pH O
- O
environment O
, O
optimally O
suited O
for O
pH O
- O
sensitive O
proteins O
. O

BDNF O
is O
also O
believed O
to O
interact O
with O
other O
neurotransmitter O
systems O
implicated O
in O
schizophrenia O
, O
such O
as O
dopamine B
, O
glutamate B
, O
serotonin B
and O
GABA B
. O

A O
cross O
- O
sectional O
survey O
revealed O
that O
serum O
BDNF O
levels O
in O
chronic O
schizophrenic O
patients O
treated O
with O
clozapine B
exceeded O
those O
of O
patients O
treated O
with O
risperidone B
or O
with O
typical O
antipsychotics O
. O

Facilitative O
effect O
of O
serotonin B
( O
1A O
) O
receptor O
agonists O
on O
cognition O
in O
patients O
with O
schizophrenia O
. O

There O
is O
much O
attention O
to O
the O
role O
of O
psychotropic O
compounds O
acting O
on O
serotonin B
( O
5 B
- I
HT I
) O
receptors O
in O
ameliorating O
cognitive O
deficits O
of O
the O
disease O
. O

Among O
the O
5 B
- I
HT I
receptor O
subtypes O
, O
the O
5 B
- I
HT I
( O
1A O
) O
receptor O
is O
attracting O
particular O
interests O
as O
a O
potential O
target O
for O
enhancing O
cognition O
, O
based O
on O
preclinical O
and O
clinical O
evidence O
. O

The O
neural O
network O
underlying O
the O
ability O
of O
5 B
- I
HT I
( O
1A O
) O
agonists O
to O
treat O
cognitive O
impairments O
of O
schizophrenia O
likely O
includes O
dopamine B
, O
glutamate B
, O
and O
gamma B
- I
aminobutyric I
acid I
neurons O
. O

Recent O
advances O
of O
electrophysiological O
measures O
, O
such O
as O
event O
- O
related O
potentials O
, O
have O
provided O
insights O
into O
facilitative O
effects O
on O
cognition O
of O
some O
atypical O
antipsychotic O
drugs O
or O
related O
compounds O
acting O
directly O
or O
indirectly O
on O
5 B
- I
HT I
( O
1A O
) O
receptors O
. O

Abnormal O
striatal O
dopamine B
transmission O
in O
schizophrenia O
. O

Despite O
numerous O
revisions O
and O
reformulations O
, O
dopamine B
( O
DA O
) O
hypothesis O
of O
schizophrenia O
remains O
a O
pivotal O
neurochemical O
hypothesis O
of O
this O
illness O
. O

DA O
function O
was O
studied O
at O
several O
levels O
: O
i O
) O
at O
a O
presynaptic O
level O
where O
neuroimaging O
studies O
investigating O
DOPA B
uptake O
capacity O
clearly O
show O
an O
increase O
of O
DA O
synthesis O
in O
patients O
with O
schizophrenia O
; O
ii O
) O
at O
a O
synaptic O
level O
where O
neuroimaging O
studies O
investigating O
dopamine B
transporter O
availability O
( O
DAT O
) O
does O
not O
bring O
any O
evidence O
of O
dysfunction O
; O
iii O
) O
and O
finally O
, O
neuroimaging O
studies O
investigating O
DA O
receptor O
density O
show O
a O
mild O
increase O
of O
D2 O
receptor O
density O
in O
basic O
condition O
and O
, O
an O
hyperreactivity O
of O
DA O
system O
in O
dynamic O
condition O
. O

Proton O
magnetic O
resonance O
spectroscopy O
( O
( B
1 I
) I
H I
MRS O
) O
enables O
the O
observation O
of O
brain O
function O
in O
vivo O
. O

Several O
brain O
metabolites O
can O
be O
measured O
by O
the O
means O
of O
( O
1 O
) O
H O
MRS O
: O
N O
- O
acetylaspartate O
( O
NAA O
) O
, O
choline B
containing O
compounds O
( O
Cho O
) O
, O
myo B
- I
inositol I
( O
mI O
) O
and O
glutamate B
( O
Glu B
) O
, O
glutamine B
( O
Gln B
) O
and O
GABA B
( O
together O
as O
Glx O
complex O
or O
separately O
) O
. O

( B
1 I
) I
H I
MRS O
measures O
have O
been O
found O
to O
be O
abnormal O
in O
psychotic O
disorders O
such O
as O
schizophrenia O
. O

Here O
we O
specifically O
review O
the O
influence O
exerted O
by O
antipsychotic O
drugs O
on O
brain O
metabolism O
, O
as O
detected O
by O
( B
1 I
) I
H I
MRS O
. O

Other O
studies O
indicated O
that O
glutamate B
measures O
are O
decreasing O
along O
with O
the O
duration O
of O
the O
disease O
, O
suggesting O
both O
a O
neurodegenerative O
process O
present O
in O
schizophrenic O
brain O
as O
well O
as O
an O
influence O
of O
antipsychotics O
. O

Behavioural O
and O
EEG O
effects O
of O
chronic O
rapamycin B
treatment O
in O
a O
mouse O
model O
of O
Tuberous O
Sclerosis O
Complex O
. O

Rapamycin B
is O
a O
potent O
inhibitor O
of O
mTOR O
and O
its O
efficacy O
in O
treating O
epilepsy O
and O
neurological O
symptoms O
remains O
elusive O
. O

In O
a O
mouse O
model O
in O
which O
Tsc1 O
has O
been O
deleted O
in O
embryonic O
telencephalic O
neural O
stem O
cells O
, O
we O
analyzed O
anxiety O
- O
and O
depression O
- O
like O
behaviour O
by O
elevated O
- O
plus O
maze O
( O
EPM O
) O
, O
open O
- O
field O
test O
( O
OFT O
) O
, O
forced O
- O
swim O
test O
( O
FST O
) O
and O
tail O
- O
suspension O
test O
( O
TST O
) O
, O
after O
chronic O
administration O
of O
rapamycin B
. O

Rapamycin B
- O
treated O
mutant O
mice O
displayed O
a O
reduction O
in O
anxiety O
- O
and O
depression O
- O
like O
phenotype O
, O
as O
shown O
by O
the O
EPM O
/ O
OFT O
and O
FST O
, O
respectively O
. O

The O
same O
effects O
of O
rapamycin B
were O
observed O
in O
wild O
- O
type O
mice O
. O

Notably O
, O
in O
heterozygous O
animals O
we O
did O
not O
observe O
any O
EEG O
and O
/ O
or O
behavioural O
variation O
after O
rapamycin B
treatment O
. O

Together O
these O
results O
suggest O
that O
both O
TSC1 O
deletion O
and O
chronic O
rapamycin B
treatment O
might O
have O
a O
role O
in O
modulating O
behaviour O
and O
brain O
activity O
, O
and O
point O
out O
to O
the O
potential O
usefulness O
of O
background O
EEG O
analysis O
in O
tracking O
brain O
dysfunction O
in O
parallel O
with O
behavioural O
testing O
. O

All O
the O
winter O
fractions O
increased O
within O
1h O
the O
level O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
while O
only O
summer O
PM2 O
. O
5 O
had O
this O
effect O
on O
A549 O
cells O
. O

Films O
of O
ethyl B
cellulose O
( O
EC O
) O
and O
water O
- O
soluble O
hydroxypropyl B
cellulose O
( O
HPC O
) O
can O
be O
used O
for O
extended O
release O
coatings O
in O
oral O
formulations O
. O

Aldehyde B
dehydrogenases O
: O
from O
eye O
crystallins O
to O
metabolic O
disease O
and O
cancer O
stem O
cells O
. O

The O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
is O
composed O
of O
nicotinamide B
adenine I
dinucleotide I
( I
phosphate I
) I
( O
NAD O
( O
P O
) O
( O
+ O
) O
) O
- O
dependent O
enzymes O
that O
catalyze O
the O
oxidation O
of O
aldehydes B
to O
their O
corresponding O
carboxylic B
acids I
. O

In O
addition O
to O
aldehyde B
metabolizing O
capacity O
, O
ALDHs O
have O
additional O
catalytic O
( O
e O
. O
g O
. O
esterase O
and O
reductase O
) O
and O
non O
- O
catalytic O
activities O
. O

Mutations O
in O
human O
ALDH O
genes O
and O
subsequent O
inborn O
errors O
in O
aldehyde B
metabolism O
are O
the O
molecular O
basis O
of O
several O
diseases O
. O

Aldehyde B
dehydrogenase O
enzymes O
also O
play O
important O
roles O
in O
embryogenesis O
and O
development O
, O
neurotransmission O
, O
oxidative O
stress O
and O
cancer O
. O

Biochemical O
and O
molecular O
mechanisms O
of O
N B
- I
acetyl I
cysteine I
and O
silymarin O
- O
mediated O
protection O
against O
maneb O
- O
and O
paraquat B
- O
induced O
hepatotoxicity O
in O
rats O
. O

Oxidative O
stress O
is O
one O
of O
the O
major O
players O
in O
the O
pathogenesis O
of O
maneb O
( O
MB O
) O
and O
paraquat B
( O
PQ O
) O
- O
induced O
disorders O
. O

N B
- I
acetyl I
cysteine I
( O
NAC B
) O
, O
a O
glutathione B
( O
GSH B
) O
precursor O
and O
silymarin O
( O
SIL O
) O
, O
a O
naturally O
occurring O
antioxidant O
, O
encounter O
oxidative O
stress O
- O
mediated O
cellular O
damage O
. O

The O
present O
study O
was O
aimed O
to O
investigate O
the O
effects O
of O
NAC B
and O
SIL O
against O
MB O
and O
/ O
or O
PQ O
- O
induced O
hepatotoxicity O
in O
rats O
. O

The O
levels O
of O
hepatotoxicity O
markers O
- O
alanine B
aminotransaminase O
( O
ALT O
) O
, O
aspartate B
aminotransaminase O
( O
AST O
) O
and O
total O
bilirubin B
, O
histological O
changes O
, O
oxidative O
stress O
indices O
, O
phase O
I O
and O
phase O
II O
xenobiotic O
metabolizing O
enzymes O
- O
cytochrome O
P450 O
( O
CYP O
) O
and O
glutathione B
S B
- O
transferase O
( O
GST O
) O
and O
pro O
- O
inflammatory O
molecules O
- O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O

- O
alpha O
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
were O
measured O
in O
animals O
treated O
with O
MB O
and O
/ O
or O
PQ O
in O
the O
presence O
or O
absence O
of O
NAC B
and O
SIL O
. O

MB O
and O
/ O
or O
PQ O
augmented O
ALT O
, O
AST O
, O
total O
bilirubin B
, O
lipid O
peroxidation O
and O
nitrite B
contents O
and O
catalytic O
activities O
of O
superoxide B
dismutase O
and O
glutathione B
peroxidase O
however O
, O
the O
GSH B
content O
was O
attenuated O
. O

NAC B
and O
SIL O
restored O
the O
above O
- O
mentioned O
alterations O
towards O
basal O
levels O
but O
the O
restorations O
were O
more O
pronounced O
in O
SIL O
treated O
groups O
. O

Similarly O
, O
MB O
and O
/ O
or O
PQ O
- O
mediated O
histopathological O
symptoms O
and O
changes O
in O
the O
catalytic O
activities O
/ O
expressions O
of O
CYP1A2 O
, O
CYP2E1 O
, O
iNOS O
, O
TNF O
- O
alpha O
, O
and O
IL O
- O
1 O
beta O
were O
alleviated O
by O
NAC B
and O
SIL O
. O

Conversely O
, O
MB O
and O
/ O
or O
PQ O
- O
induced O
GSTA4 O
- O
4 O
expression O
/ O
activity O
was O
further O
increased O
by O
NAC B
/ O
SIL O
and O
glutathione B
reductase O
activity O
was O
also O
increased O
. O

The O
results O
obtained O
thus O
suggest O
that O
NAC B
and O
SIL O
protect O
MB O
and O
/ O
or O
PQ O
- O
induced O
hepatotoxicity O
by O
reducing O
oxidative O
stress O
, O
inflammation O
and O
by O
modulating O
xenobitic O
metabolizing O
machinery O
and O
SIL O
seems O
to O
be O
more O
effective O
. O

Rats O
were O
dosed O
orally O
for O
7 O
days O
to O
determine O
( O
1 O
) O
if O
HDN O
( O
induced O
by O
2 B
- I
propanol I
or O
D O
- O
limonene O
) O
altered O
the O
newer O
renal O
biomarkers O
and O
not O
BUN O
or O
creatinine B
, O
( O
2 O
) O
if O
renal O
biomarkers O
could O
distinguish O
between O
HDN O
and O
oxidative O
stress O
- O
induced O
kidney O
injury O
( O
induced O
by O
potassium O
bromate O
) O
, O
( O
3 O
) O
sensitivity O
of O
HDN O
- O
induced O
renal O
biomarker O
changes O
relative O
to O
D O
- O
limonene O
dose O
, O
and O
( O
4 O
) O
reversibility O
of O
HDN O
and O
renal O
biomarkers O
, O
using O

HDN O
- O
induced O
renal O
biomarker O
changes O
in O
male O
rats O
were O
potentially O
compound O
specific O
: O
( O
1 O
) O
2 B
- I
propanol I
induced O
mild O
HDN O
without O
increased O
renal O
biomarkers O
, O
( O
2 O
) O
potassium O
bromate O
induced O
moderate O
HDN O
with O
increased O
clusterin O
, O
and O
( O
3 O
) O
D O
- O
limonene O
induced O
marked O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
. O

The O
compound O
D O
- O
limonene O
induced O
a O
dose O
dependent O
increase O
in O
HDN O
severity O
and O
renal O
biomarker O
changes O
without O
altering O
BUN O
, O
creatinine B
or O
NAG O
: O
( O
1 O
) O
minimal O
induction O
of O
HDN O
and O
no O
altered O
biomarkers O
at O
10 O
mg O
/ O
kg O
/ O
day O
, O
( O
2 O
) O
mild O
induction O
of O
HDN O
with O
increased O
alpha O
GST O
and O
mu O
GST O
at O
50 O
mg O
/ O
kg O
/ O
day O
and O
( O
3 O
) O
marked O
induction O
of O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
at O
300 O
mg O
/ O
kg O
/ O
day O
. O

The O
first O
genetic O
defect O
in O
human O
signal O
transducer O
and O
activator O
of O
transcription O
( O
STAT O
) O
5b O
was O
identified O
in O
an O
individual O
with O
profound O
short O
stature O
and O
GH O
insensitivity O
, O
immune O
dysfunction O
, O
and O
severe O
pulmonary O
disease O
, O
and O
was O
caused O
by O
an O
alanine B
to O
proline B
substitution O
( O
A630P O
) O
within O
the O
Src O
homology O
- O
2 O
( O
SH2 O
) O
domain O
. O

Here O
we O
have O
characterized O
the O
second O
human O
STAT5b O
amino B
acid I
substitution O
mutation O
in O
an O
individual O
with O
similar O
pathophysiological O
features O
. O

This O
single O
nucleotide B
transition O
, O
predicted O
to O
change O
phenyalanine O
646 O
to O
serine B
( O
F646S O
) O
, O
also O
maps O
to O
the O
SH2 O
domain O
. O

Unlike O
STAT5b O
( O
A630P O
) O
, O
which O
showed O
minimal O
GH O
- O
induced O
tyrosine B
phosphorylation O
and O
no O
transcriptional O
activity O
, O
STAT5b O
( O
F646S O
) O
became O
tyrosine B
phosphorylated O
after O
GH O
treatment O
and O
could O
function O
as O
a O
GH O
- O
activated O
transcription O
factor O
, O
although O
to O
a O
substantially O
lesser O
extent O
than O
STAT5b O
( O
WT O
) O
. O

TSH O
and O
insulin O
/ O
IGF O
- O
I O
synergistically O
induce O
the O
proliferation O
of O
thyroid O
cells O
mainly O
through O
the O
cAMP B
and O
phosphatidylinositol B
3 O
- O
kinase O
( O
PI3K O
) O
pathways O
. O

In O
differentiated O
cells O
, O
TSH O
/ O
cAMP B
treatment O
decreases O
FoxO1 O
mRNA O
and O
protein O
levels O
through O
proteasome O
activation O
, O
whereas O
both O
TSH O
and O
IGF O
- O
I O
control O
FoxO1 O
localization O
by O
promoting O
a O
rapid O
exclusion O
from O
the O
nucleus O
in O
an O
Akt O
- O
dependent O
manner O
. O

Gliotransmission O
and O
brain O
glucose B
sensing O
: O
critical O
role O
of O
endozepines O
. O

Hypothalamic O
glucose B
sensing O
is O
involved O
in O
the O
control O
of O
feeding O
behavior O
and O
peripheral O
glucose B
homeostasis O
, O
and O
glial O
cells O
are O
suggested O
to O
play O
an O
important O
role O
in O
this O
process O
. O

Diazepam B
- O
binding O
inhibitor O
( O
DBI O
) O
and O
its O
processing O
product O
the O
octadecaneuropeptide O
( O
ODN O
) O
, O
collectively O
named O
endozepines O
, O
are O
secreted O
by O
astroglia O
, O
and O
ODN O
is O
a O
potent O
anorexigenic O
factor O
. O

Therefore O
, O
we O
investigated O
the O
involvement O
of O
endozepines O
in O
brain O
glucose B
sensing O
. O

First O
, O
we O
showed O
that O
intracerebroventricu O
administration O
of O
glucose B
in O
rats O
increases O
DBI O
expression O
in O
hypothalamic O
glial O
- O
like O
tanycytes O
. O

We O
then O
demonstrated O
that O
glucose B
stimulates O
endozepine O
secretion O
from O
hypothalamic O
explants O
. O

Feeding O
experiments O
indicate O
that O
the O
anorexigenic O
effect O
of O
central O
administration O
of O
glucose B
was O
blunted O
by O
coinjection O
of O
an O
ODN O
antagonist O
. O

The O
anorexigenic O
effects O
of O
centrally O
injected O
glucose B
or O
ODN O
agonist O
were O
suppressed O
by O
blockade O
of O
the O
melanocortin O
- O
3 O
/ O
4 O
receptors O
, O
suggesting O
that O
glucose B
sensing O
involves O
endozepinergic O
control O
of O
the O
melanocortin O
pathway O
. O

Finally O
, O
we O
found O
that O
brain O
endozepines O
modulate O
blood O
glucose B
levels O
, O
suggesting O
their O
involvement O
in O
a O
feedback O
loop O
controlling O
whole O
- O
body O
glucose B
homeostasis O
. O

Collectively O
, O
these O
data O
indicate O
that O
endozepines O
are O
a O
critical O
relay O
in O
brain O
glucose B
sensing O
and O
potentially O
new O
targets O
in O
treatment O
of O
metabolic O
disorders O
. O

Nuclear O
anchorage O
appears O
mediated O
through O
a O
specialized O
transmembrane O
domain O
located O
in O
the O
carboxyl B
terminus O
. O

Twelve O
potential O
confounders O
were O
evaluated O
: O
habitat O
, O
organic O
enrichment O
, O
nutrients O
, O
deposited O
sediments O
, O
pH O
, O
selenium B
, O
temperature O
, O
lack O
of O
headwaters O
, O
catchment O
area O
, O
settling O
ponds O
, O
dissolved O
oxygen B
, O
and O
metals O
. O

An O
eight O
- O
orders O
of O
magnitude O
enhancement O
in O
current O
across O
Hg B
/ O
X O
- O
styrene B
- O
Si B
junctions O
is O
caused O
by O
merely O
altering O
a O
substituent O
, O
X O
. O

Interface O
states O
are O
passivated O
and O
, O
depending O
on O
X O
, O
the O
Si B
Schottky O
junction O
encompasses O
the O
full O
range O
from O
Ohmic O
to O
strongly O
rectifying O
. O

Influence O
of O
silver B
doping O
on O
electron O
transport O
in O
thin O
films O
of O
PbSe B
nanocrystals O
. O

Changes O
in O
the O
Fermi O
level O
and O
transport O
parameters O
indicate O
that O
Ag B
is O
acting O
as O
a O
p O
- O
type O
dopant O
( O
acceptor O
) O
. O

New O
horizons O
for O
diagnostics O
and O
therapeutic O
applications O
of O
graphene B
and O
graphene B
oxide I
. O

Graphene B
, O
a O
one O
- O
atom O
- O
thick O
two O
- O
dimensional O
( O
2D O
) O
layer O
of O
sp O
( O
2 O
) O
- O
bonded O
carbon B
, O
has O
received O
worldwide O
attention O
owing O
to O
its O
extraordinary O
physical O
and O
chemical O
properties O
. O

Recently O
, O
great O
efforts O
have O
been O
devoted O
to O
explore O
potential O
applications O
of O
graphene B
and O
its O
oxide O
in O
life O
science O
, O
especially O
in O
disease O
- O
related O
diagnostics O
, O
near O
- O
Infrared O
( O
NIR O
) O
phototherapy O
and O
imaging O
. O

Here O
we O
will O
introduce O
recent O
advances O
and O
new O
horizons O
in O
this O
area O
, O
and O
focus O
on O
the O
rising O
progress O
on O
NIR O
photothermal O
therapy O
for O
cancer O
and O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
, O
human O
telomerase O
detection O
, O
stem O
cell O
proliferation O
and O
differentiation O
on O
graphene B
substrate O
, O
diagnosis O
of O
cancer O
cell O
and O
related O
biomarkers O
, O
drug O
/ O
nucleotide B
/ O
peptide O
delivery O
and O
cell O
imaging O
, O
which O
have O
not O
been O
comprehensively O
reviewed O
. O

We O
hope O
to O
provide O
an O
outlook O
to O
the O
applications O
of O
graphene B
and O
its O
oxide O
, O
especially O
on O
the O
new O
horizons O
in O
this O
field O
, O
and O
inspire O
broader O
interests O
across O
various O
disciplines O
. O

SAR O
beyond O
protein O
- O
ligand O
interactions O
: O
By O
combining O
structure O
- O
affinity O
relationships O
, O
protein O
- O
ligand O
modeling O
studies O
, O
and O
quantum O
mechanical O
calculations O
, O
we O
show O
that O
ligand O
conformational O
energies O
and O
basicity O
play O
critical O
roles O
in O
ligand O
binding O
to O
the O
histamine B
H4 O
receptor O
, O
a O
GPCR O
that O
plays O
a O
key O
role O
in O
inflammation O
. O

A O
reporter O
construct O
driven O
by O
4 O
kb O
of O
the O
chicken O
ras O
- O
dva O
5 O
' O
- O
flanking O
region O
, O
containing O
six O
putative O
pituitary O
- O
specific O
transcription O
factor O
- O
1 O
( O
Pit O
- O
1 O
) O
binding O
sites O
and O
two O
potential O
glucocorticoid O
receptor O
( O
GR O
) O
binding O
sites O
, O
was O
highly O
activated O
in O
embryonic O
pituitary O
cells O
and O
up O
- O
regulated O
by O
corticosterone B
. O

However O
, O
mutating O
putative O
GR O
binding O
sites O
did O
not O
substantially O
reduce O
induction O
of O
ras O
- O
dva O
promoter O
activity O
by O
corticosterone B
, O
suggesting O
additional O
DNA O
elements O
within O
the O
5 O
' O
- O
flanking O
region O
are O
responsible O
for O
glucocorticoid O
regulation O
. O

The O
role O
of O
the O
carbohydrate B
response O
element O
- O
binding O
protein O
in O
male O
fructose B
- O
fed O
rats O
. O

In O
part O
, O
this O
epidemic O
is O
fueled O
by O
the O
increasing O
consumption O
of O
caloric O
sweeteners O
coupled O
with O
an O
innate O
capacity O
to O
convert O
sugar B
into O
fat O
via O
hepatic O
de O
novo O
lipogenesis O
. O

In O
addition O
to O
serving O
as O
substrates O
, O
monosaccharides B
also O
increase O
the O
expression O
of O
key O
enzymes O
involved O
in O
de O
novo O
lipogenesis O
via O
the O
carbohydrate B
response O
element O
- O
binding O
protein O
( O
ChREBP O
) O
. O

To O
determine O
whether O
ChREBP O
is O
a O
potential O
therapeutic O
target O
, O
we O
decreased O
hepatic O
expression O
of O
ChREBP O
with O
a O
specific O
antisense O
oligonucleotide O
( O
ASO O
) O
in O
male O
Sprague O
- O
Dawley O
rats O
fed O
either O
a O
high O
- O
fructose B
or O
high O
- O
fat O
diet O
. O

ChREBP O
ASO O
treatment O
decreased O
plasma O
triglyceride B
concentrations O
compared O
with O
control O
ASO O
treatment O
in O
both O
diet O
groups O
. O

The O
reduction O
was O
more O
pronounced O
in O
the O
fructose B
- O
fed O
group O
and O
attributed O
to O
decreased O
hepatic O
expression O
of O
ACC2 O
, O
FAS O
, O
SCD1 O
, O
and O
MTTP O
and O
a O
decrease O
in O
the O
rate O
of O
hepatic O
triglyceride B
secretion O
. O

This O
was O
associated O
with O
an O
increase O
in O
insulin O
- O
stimulated O
peripheral O
glucose B
uptake O
, O
as O
assessed O
by O
the O
hyperinsulinemic O
- O
euglycemic O
clamp O
. O

Interestingly O
, O
fructose B
- O
fed O
rats O
treated O
with O
ChREBP O
ASO O
had O
increased O
plasma O
uric B
acid I
, O
alanine B
transaminase O
, O
and O
aspartate B
aminotransferase O
concentrations O
. O

This O
was O
associated O
with O
decreased O
expression O
of O
fructose B
aldolase O
and O
fructokinase O
, O
reminiscent O
of O
inherited O
disorders O
of O
fructose B
metabolism O
. O

In O
summary O
, O
these O
studies O
suggest O
that O
targeting O
ChREBP O
may O
prevent O
fructose B
- O
induced O
hypertriglyceridemia O
but O
without O
the O
improvements O
in O
hepatic O
steatosis O
and O
hepatic O
insulin O
responsiveness O
. O

Genetic O
requirements O
for O
Moraxella O
catarrhalis O
growth O
under O
iron B
- O
limiting O
conditions O
. O

Iron B
sequestration O
by O
the O
human O
host O
is O
a O
first O
line O
defence O
against O
respiratory O
pathogens O
like O
Moraxella O
catarrhalis O
, O
which O
consequently O
experiences O
a O
period O
of O
iron B
starvation O
during O
colonization O
. O

We O
determined O
the O
genetic O
requirements O
for O
M O
. O
catarrhalis O
BBH18 O
growth O
during O
iron B
starvation O
using O
the O
high O
- O
throughput O
genome O
- O
wide O
screening O
technology O
genomic O
array O
footprinting O
( O
GAF O
) O
. O

By O
subjecting O
a O
large O
random O
transposon O
mutant O
library O
to O
growth O
under O
iron B
- O
limiting O
conditions O
, O
mutants O
of O
the O
MCR O
_ O
0996 O
- O
rhlB O
- O
yggW O
operon O
, O
rnd O
, O
and O
MCR O
_ O
0457 O
were O
negatively O
selected O
. O

Growth O
experiments O
using O
directed O
mutants O
confirmed O
the O
GAF O
phenotypes O
with O
Delta O
yggW O
( O
putative O
haem O
- O
shuttling O
protein O
) O
and O
Delta O
MCR O
_ O
0457 O
( O
hypothetical O
protein O
) O
most O
severely O
attenuated O
during O
iron B
starvation O
, O
phenotypes O
which O
were O
restored O
upon O
genetic O
complementation O
of O
the O
deleted O
genes O
. O

In O
all O
five O
mutants O
, O
expression O
of O
nitrate B
reductase O
genes O
was O
increased O
and O
of O
nitrite B
reductase O
decreased O
, O
suggesting O
an O
impaired O
aerobic O
respiration O
. O

Alteration O
of O
iron B
metabolism O
may O
affect O
nasopharyngeal O
colonization O
as O
adherence O
of O
all O
mutants O
to O
respiratory O
tract O
epithelial O
cells O
was O
attenuated O
. O

In O
conclusion O
, O
we O
elucidated O
the O
genetic O
requirements O
for O
M O
. O
catarrhalis O
growth O
during O
iron B
starvation O
and O
characterized O
the O
roles O
of O
the O
identified O
genes O
in O
bacterial O
growth O
and O
host O
interaction O
. O

Synaptic O
plasticity O
in O
the O
hippocampus O
shows O
resistance O
to O
acute O
ethanol B
exposure O
in O
transgenic O
mice O
with O
astrocyte O
- O
targeted O
enhanced O
CCL2 O
expression O
. O

The O
role O
of O
these O
neuroimmune O
factors O
in O
the O
effects O
of O
ethanol B
on O
the O
central O
nervous O
system O
has O
yet O
to O
be O
elucidated O
. O

To O
address O
this O
question O
, O
we O
investigated O
the O
effects O
of O
ethanol B
on O
synaptic O
transmission O
and O
plasticity O
in O
the O
hippocampus O
from O
mice O
that O
express O
elevated O
levels O
of O
CCL2 O
in O
the O
brain O
and O
their O
non O
- O
transgenic O
littermate O
controls O
. O

We O
used O
extracellular O
field O
potential O
recordings O
in O
acutely O
isolated O
hippocampal O
slices O
to O
identify O
neuroadaptive O
changes O
produced O
by O
elevated O
levels O
of O
CCL2 O
and O
how O
these O
neuroadaptive O
changes O
affect O
the O
actions O
of O
acute O
ethanol B
. O

Results O
showed O
that O
synaptic O
transmission O
and O
the O
effects O
of O
ethanol B
on O
synaptic O
transmission O
were O
similar O
in O
the O
CCL2 O
- O
transgenic O
and O
non O
- O
transgenic O
hippocampus O
. O

However O
, O
long O
- O
term O
potentiation O
( O
LTP O
) O
, O
a O
cellular O
mechanism O
thought O
to O
underlie O
learning O
and O
memory O
, O
in O
the O
CCL2 O
- O
transgenic O
hippocampus O
was O
resistant O
to O
the O
ethanol B
- O
induced O
depression O
of O
LTP O
observed O
in O
the O
non O
- O
transgenic O
hippocampus O
. O

Consistent O
with O
these O
results O
, O
ethanol B
pretreatment O
significantly O
impaired O
cued O
and O
contextual O
fear O
conditioning O
in O
non O
- O
transgenic O
mice O
, O
but O
had O
no O
effect O
in O
CCL2 O
- O
transgenic O
mice O
. O

These O
data O
show O
that O
chronically O
elevated O
levels O
of O
CCL2 O
in O
the O
hippocampus O
produce O
neuroadaptive O
changes O
that O
block O
the O
depressing O
effects O
of O
ethanol B
on O
hippocampal O
synaptic O
plasticity O
and O
support O
the O
hypothesis O
that O
CCL2 O
may O
provide O
a O
neuroprotective O
effect O
against O
the O
devastating O
actions O
of O
ethanol B
on O
hippocampal O
function O
. O

Supra O
- O
normal O
stimulation O
of O
dopamine B
D1 O
receptors O
in O
the O
prelimbic O
cortex O
blocks O
behavioral O
expression O
of O
both O
aversive O
and O
rewarding O
associative O
memories O
through O
a O
cyclic B
- I
AMP I
- O
dependent O
signaling O
pathway O
. O

Dopamine B
( O
DA O
) O
receptor O
transmission O
through O
either O
D O
( O
1 O
) O
or O
D O
( O
2 O
) O
- O
like O
subtypes O
is O
involved O
critically O
in O
the O
processing O
of O
emotional O
information O
within O
the O
medial O
prefrontal O
cortex O
( O
mPFC O
) O
. O

Furthermore O
, O
using O
an O
unbiased O
place O
conditioning O
procedure O
( O
CPP O
) O
, O
intra O
- O
PLC O
D O
( O
1 O
) O
receptor O
activation O
blocks O
the O
spontaneous O
expression O
of O
an O
associative O
morphine B
( O
5 O
mg O
/ O
kg O
; O
i O
. O
p O
. O
) O
reward O
memory O
, O
while O
leaving O
morphine B
- O
primed O
memory O
expression O
intact O
. O

Interestingly O
, O
both O
intra O
- O
PLC O
D O
( O
1 O
) O
- O
receptor O
mediated O
block O
of O
either O
fear O
- O
related O
or O
reward O
- O
related O
associative O
memories O
were O
dependent O
upon O
downstream O
cyclic B
- I
AMP I
( O
cAMP B
) O
signaling O
as O
both O
effects O
were O
rescued O
by O
co O
- O
administration O
of O
a O
cAMP B
signaling O
inhibitor O
. O

Glucose B
attenuates O
impairments O
in O
memory O
and O
CREB O
activation O
produced O
by O
an O
alpha O
4 O
beta O
2 O
but O
not O
an O
alpha O
7 O
nicotinic O
receptor O
antagonist O
. O

Glucose B
improves O
memory O
for O
a O
variety O
of O
tasks O
when O
administered O
to O
rats O
and O
mice O
near O
the O
time O
of O
training O
. O

Prior O
work O
indicates O
glucose B
may O
enhance O
memory O
by O
increasing O
the O
synthesis O
and O
release O
of O
the O
neurotransmitter O
acetylcholine B
in O
the O
brain O
. O

To O
investigate O
if O
specific O
acetylcholine B
receptor O
subtypes O
may O
mediate O
some O
of O
the O
memory O
- O
enhancing O
actions O
of O
glucose B
, O
we O
examined O
the O
effects O
of O
subtype O
- O
specific O
nicotinic O
acetylcholine B
receptor O
antagonists O
on O
memory O
in O
Fischer O
- O
344 O
rats O
and O
also O
examined O
the O
ability O
of O
glucose B
to O
reverse O
drug O
- O
induced O
impairments O
. O

Pre O
- O
training O
peripheral O
injections O
of O
methyllycaconitine B
( O
MLA B
) O
or O
dihydro O
- O
beta O
- O
erythroidine O
( O
DH B
beta I
E I
) O
, O
which O
are O
specific O
alpha O
7 O
and O
alpha O
4 O
beta O
2 O
nicotinic O
receptor O
antagonists O
, O
respectively O
, O
dose O
- O
dependently O
impaired O
retention O
latencies O
in O
an O
inhibitory O
avoidance O
task O
when O
tested O
7 O
- O
days O
but O
not O
1 O
h O
after O
training O
. O

Immediate O
post O
- O
training O
glucose B
injections O
attenuated O
the O
impairments O
, O
but O
were O
more O
effective O
in O
attenuating O
the O
DH B
beta I
E I
- O
induced O
impairments O
. O

Likewise O
, O
peripheral O
or O
direct O
intrahippocampal O
injections O
of O
MLA B
or O
DH B
beta I
E I
dose O
- O
dependently O
impaired O
spatial O
working O
memory O
scores O
on O
a O
spontaneous O
alternation O
task O
. O

Concurrent O
administration O
of O
glucose B
reversed O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
impairments O
. O

Both O
MLA B
and O
DH B
beta I
E I
impaired O
hippocampal O
CREB O
phosphorylation O
; O
glucose B
reversed O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
deficits O
. O

The O
effectiveness O
of O
glucose B
in O
reversing O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
impairments O
in O
behavioral O
performance O
and O
CREB O
phosphorylation O
suggests O
that O
activation O
of O
alpha O
7 O
receptors O
may O
play O
an O
important O
role O
in O
memory O
enhancement O
by O
glucose B
. O

Biochemical O
analyses O
showed O
that O
NO B
and O
ROS O
production O
and O
iNOS O
activity O
were O
significantly O
reduced O
by O
catalpol O
. O

Korean O
red O
ginseng O
ameliorates O
acute O
3 B
- I
nitropropionic I
acid I
- O
induced O
cochlear O
damage O
in O
mice O
. O

3 B
- I
Nitropropionic I
acid I
( O
3 O
- O
NP O
) O
, O
a O
mitochondrial O
toxin O
, O
has O
been O
reported O
to O
induce O
an O
acute O
cochlear O
damage O
. O

Rotigotine O
is O
a O
non O
- O
ergoline O
D O
( O
3 O
) O
/ O
D O
( O
2 O
) O
/ O
D O
( O
1 O
) O
dopamine B
receptor O
agonist O
for O
treating O
PD O
. O

As O
a O
new O
treatment O
option O
for O
CDS O
, O
rotigotine O
- O
loaded O
microspheres O
( O
RoMS O
) O
, O
long O
- O
acting O
sustained O
- O
release O
microspheres O
with O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
as O
drug O
carrier O
, O
are O
now O
being O
evaluated O
in O
clinical O
trial O
. O

The O
major O
toxicological O
effects O
were O
associated O
with O
dopamine B
agonist O
- O
related O
pharmacodynamic O
properties O
of O
rotigotine O
( O
e O
. O
g O
. O
, O
hyperactivity O
and O
stereotype O
, O
decreased O
serum O
prolactin O
level O
) O
and O
foreign O
body O
removal O
reaction O
induced O
by O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
and O
carboxymethycellulos O
sodium B
( O
e O
. O
g O
. O
, O
increased O
mononuclear O
cells O
and O
neutrophils O
, O
thymus O
atrophy O
and O
vacuolar O
degeneration O
of O
adrenal O
cortex O
, O
foreign O
body O
granuloma O
with O
foam O
cells O
accumulation O
at O

To O
investigate O
the O
combined O
toxic O
effects O
of O
pesticide O
cocktails O
previously O
identified O
in O
the O
French O
diet O
, O
we O
first O
studied O
the O
cytotoxicity O
induced O
by O
seven O
cocktails O
composed O
of O
two O
to O
six O
pesticides O
on O
human O
hepatic O
( O
HepG2 O
) O
and O
colon O
( O
Caco O
- O
2 O
) O
cell O
lines O
using O
the O
MTT B
and O
neutral B
red I
uptake O
assays O
. O

For O
the O
cocktail O
composed O
of O
dichlorodiphenyltric B
( O
DDT B
) O
and O
dieldrin B
, O
the O
cytotoxicity O
of O
the O
equimolar O
cocktail O
proved O
greater O
than O
the O
additive O
effect O
estimated O
by O
the O
two O
concepts O
. O

Furthermore O
, O
apoptosis O
induction O
was O
higher O
in O
equimolar O
cocktail O
than O
predicted O
by O
summing O
the O
effects O
of O
DDT B
and O
dieldrin B
. O

Thus O
, O
some O
supra O
- O
additive O
toxicity O
was O
found O
in O
the O
DDT B
- O
dieldrin B
cocktail O
. O

SS O
phages O
are O
genetically O
enginnered O
by O
replacing O
2 O
N B
- O
terminal O
amino B
acids I
of O
the O
p8 O
coat O
protein O
of O
the O
fd O
phage O
. O

Bundles O
induced O
by O
CoCl2 B
and O
CaCl2 B
are O
either O
metallized O
by O
chemical O
reduction O
or O
biomineralized O
for O
apatite O
- O
like O
material O
formation O
. O

EDX O
spectroscopy O
confirms O
the O
presence O
of O
Co B
, O
P B
and O
Ca B
peaks O
in O
mineralized O
samples O
. O

Dunaliella O
bardawil O
was O
employed O
in O
the O
present O
research O
to O
test O
the O
toxic O
effects O
of O
SDBS O
, O
CTAC O
, O
and O
their O
mixture O
on O
cell O
growth O
, O
cellular O
morphology O
, O
beta B
- I
carotene I
accumulation O
, O
and O
enzymatic O
activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
. O

The O
results O
showed O
that O
SDBS O
at O
200 O
, O
550 O
, O
900 O
, O
1 O
, O
350 O
, O
1 O
, O
800 O
, O
and O
2 O
, O
400 O
mg O
/ O
L O
and O
CTAC O
at O
0 O
. O
4 O
, O
0 O
. O
7 O
, O
1 O
. O
0 O
, O
1 O
. O
3 O
, O
2 O
. O
8 O
, O
and O
3 O
. O
5 O
mg O
/ O
L O
inhibited O
algal O
growth O
and O
beta B
- I
carotene I
accumulation O
, O
both O
of O
which O
declined O
and O
then O
increased O
. O

Garcinia O
xanthones B
as O
orally O
active O
antitumor O
agents O
. O

Using O
a O
newly O
developed O
strategy O
whose O
key O
step O
is O
the O
regioselective O
propargylation O
of O
hydroxyxanthone O
substrates O
, O
99 O
structurally O
diverse O
Garcinia O
natural O
- O
product O
- O
like O
xanthones B
based O
on O
gambogic O
acid O
were O
designed O
and O
synthesized O
and O
their O
in O
vitro O
antitumor O
activity O
was O
evaluated O
. O

5 O
. O
These O
findings O
suggested O
that O
, O
following O
oral O
administration O
of O
darexaban O
in O
humans O
, O
M1 O
is O
quickly O
formed O
during O
first O
- O
pass O
metabolism O
via O
UDP B
- O
glucuronosyltransfer O
, O
exerting O
its O
pharmacological O
activity O
in O
blood O
before O
being O
excreted O
into O
urine O
and O
faeces O
. O

Using O
an O
exemplar O
poly B
( I
ethylene I
glycol I
) I
- O
based O
resin O
, O
the O
control O
of O
features O
in O
the O
X O
, O
Y O
, O
and O
Z O
planes O
is O
demonstrated O
such O
that O
complex O
structures O
can O
be O
manufactured O
. O

Human O
mesenchymal O
stem O
cells O
cultured O
on O
the O
manufactured O
scaffolds O
remained O
viable O
during O
the O
7 O
day O
assessment O
period O
, O
with O
proliferation O
rates O
comparable O
to O
those O
observed O
on O
tissue O
culture O
polystyrene B
. O

Stiripentol B
is O
anticonvulsant O
by O
potentiating O
GABAergic O
transmission O
in O
a O
model O
of O
benzodiazepine B
- O
refractory O
status O
epilepticus O
. O

Benzodiazepines B
( O
BZDs O
) O
are O
first O
- O
line O
therapy O
for O
treatment O
of O
status O
epilepticus O
( O
SE O
) O
. O

Stiripentol B
( O
STP O
) O
is O
an O
anticonvulsant O
that O
is O
used O
as O
add O
- O
on O
treatment O
for O
Dravet O
Syndrome O
. O

We O
tested O
this O
possibility O
by O
comparing O
the O
ability O
of O
STP O
and O
diazepam B
( O
DZP O
) O
, O
a O
commonly O
used O
BZD O
, O
to O
terminate O
behavioral O
convulsions O
in O
a O
rodent O
model O
of O
pharmacoresistant O
SE O
. O

Regulation O
of O
serotonin B
( O
5 B
- I
HT I
) O
function O
by O
a O
VGLUT1 O
dependent O
glutamate B
pathway O
. O

Unraveling O
the O
mechanisms O
of O
5 B
- I
HT I
neuron O
control O
might O
provide O
new O
insights O
into O
depression O
pathophysiology O
. O

In O
addition O
to O
the O
inhibitory O
5 O
- O
HT1A O
autoreceptors O
, O
cortico O
- O
raphe O
glutamatergic O
descending O
pathways O
are O
suggested O
to O
modulate O
5 B
- I
HT I
activity O
in O
the O
DRN O
. O

Here O
we O
studied O
how O
decreased O
VGLUT1 O
levels O
in O
the O
brain O
stem O
affect O
glutamate B
regulation O
of O
5 B
- I
HT I
function O
. O

VGLUT1 O
expression O
in O
the O
DRN O
, O
5 B
- I
HT I
turnover O
and O
immuno O
histochemical O
analysis O
of O
neuronal O
activity O
in O
different O
areas O
was O
studied O
. O

VGLUT1 O
immunoreactivity O
was O
markedly O
lower O
in O
the O
DRN O
of O
the O
VGLUT1 O
+ O
/ O
- O
mice O
and O
specifically O
, O
in O
the O
surroundings O
of O
GABA B
and O
5 B
- I
HT I
cell O
bodies O
. O

These O
mice O
showed O
decreased O
induced O
neuronal O
activity O
in O
5 B
- I
HT I
cells O
bodies O
and O
in O
different O
forebrain O
areas O
, O
as O
well O
as O
decreased O
hippocampal O
cell O
proliferation O
and O
5 B
- I
HT I
turnover O
. O

This O
study O
shows O
first O
time O
that O
VGLUT1 O
dependent O
glutamate B
innervation O
of O
the O
DRN O
could O
modulate O
5 B
- I
HT I
function O
. O

Metabolism O
and O
pharmacokinetics O
of O
3 O
- O
n O
- O
butylphthalide O
( O
NBP O
) O
in O
humans O
: O
the O
role O
of O
cytochrome O
P450s O
and O
alcohol B
dehydrogenase O
in O
biotransformation O
. O

Principal O
metabolic O
pathways O
included O
hydroxylation O
on O
alkyl B
side O
chain O
, O
particularly O
at O
3 O
- O
, O
omega O
- O
1 O
- O
, O
and O
omega O
- O
carbons O
, O
and O
further O
oxidation O
and O
conjugation O
. O

Using O
M3 O
- O
2 O
and O
11 O
- O
hydroxy O
- O
NBP O
as O
substrates O
, O
human O
subcellular O
fractions O
experiments O
revealed O
that O
P450 O
, O
alcohol B
dehydrogenase O
, O
and O
aldehyde B
dehydrogenase O
catalyzed O
the O
generation O
of O
M2 O
and O
M5 O
- O
2 O
. O

The O
disposition O
of O
ertugliflozin O
( O
PF O
- O
04971729 O
) O
, O
an O
orally O
active O
selective O
inhibitor O
of O
the O
sodium B
- O
dependent O
glucose B
cotransporter O
2 O
, O
was O
studied O
after O
a O
single O
25 O
- O
mg O
oral O
dose O
of O
[ O
( O
14 O
) O
C O
] O
- O
ertugliflozin O
to O
healthy O
human O
subjects O
. O

The O
principal O
biotransformation O
pathway O
involved O
glucuronidation O
of O
the O
glycoside O
hydroxyl B
groups O
to O
yield O
three O
regioisomeric O
metabolites O
, O
M4a O
, O
M4b O
, O
and O
M4c O
( O
~ O
39 O
. O
3 O
% O
of O
the O
dose O
in O
urine O
) O
, O
of O
which O
M4c O
was O
the O
major O
regioisomer O
( O
~ O
31 O
. O
7 O
% O
of O
the O
dose O
) O
. O

The O
role O
of O
cytochrome O
P450 O
- O
dependent O
metabolism O
in O
the O
regulation O
of O
mouse O
hepatic O
growth O
hormone O
signaling O
components O
and O
target O
genes O
by O
3 B
- I
methylcholanthrene I
. O

3 B
- I
Methylcholanthrene I
( O
MC O
) O
is O
a O
readily O
metabolized O
aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
agonist O
. O

To O
determine O
if O
these O
effects O
of O
MC O
depend O
on O
hepatic O
microsomal O
P450 O
- O
mediated O
activity O
, O
we O
examined O
biologic O
responses O
to O
MC O
treatment O
in O
liver O
Cpr O
- O
null O
( O
LCN O
) O
mice O
with O
hepatocyte O
- O
specific O
conditional O
deletion O
of O
NADPH B
- O
cytochrome O
P450 O
oxidoreductase O
( O
POR O
) O
. O

Although O
aspirin B
and O
thienopyridines O
have O
proved O
their O
efficacy O
in O
the O
prevention O
of O
arterial O
thrombotic O
events O
, O
limited O
efficacy O
, O
increased O
risk O
of O
bleeding O
, O
significant O
inter O
- O
individual O
variability O
in O
the O
response O
and O
extended O
duration O
of O
action O
that O
cannot O
be O
reversed O
if O
the O
need O
for O
haemostasis O
or O
emergency O
surgery O
arises O
represent O
major O
limitations O
of O
these O
drugs O
. O

At O
variance O
with O
newer O
anticoagulant O
drugs O
, O
which O
showed O
a O
series O
of O
advantages O
as O
compared O
with O
the O
traditional O
warfarin B
treatment O
, O
newer O
antiplatelet O
drugs O
have O
only O
partially O
overcome O
these O
limitations O
. O

Although O
ad O
hoc O
studies O
on O
their O
efficacy O
in O
the O
stroke O
prevention O
are O
currently O
lacking O
, O
newer O
antiplatelet O
agents O
( O
mainly O
ticagrelor O
and O
prasugrel O
) O
do O
not O
provide O
a O
significant O
better O
protection O
over O
and O
above O
aspirin B
and O
/ O
or O
clopidogrel B
in O
the O
prevention O
of O
atherothrombotic O
stroke O
. O

Spo0A O
links O
de O
novo O
fatty B
acid I
synthesis O
to O
sporulation O
and O
biofilm O
development O
in O
Bacillus O
subtilis O
. O

Spo0A O
reactivates O
the O
accDA O
operon O
that O
encodes O
the O
carboxylase O
component O
of O
the O
acetyl B
- I
CoA I
carboxylase O
enzyme O
, O
which O
catalyses O
the O
first O
and O
rate O
- O
limiting O
step O
in O
de O
novo O
lipid O
biosynthesis O
, O
malonyl O
- O
CoA O
formation O
. O

Exogenous O
fatty B
acid I
supplementation O
to O
accDA O
( O
0A O
) O
cells O
overcomes O
their O
inability O
to O
synthesize O
lipids O
during O
development O
and O
restores O
sporulation O
and O
biofilm O
proficiencies O
. O

The O
mycobacterial O
binuclear O
iron B
monooxygenases O
require O
a O
specific O
chaperonin O
- O
like O
protein O
for O
functional O
expression O
in O
a O
heterologous O
host O
. O

The O
mimABCD O
gene O
clusters O
in O
Mycobacterium O
smegmatis O
strain O
mc O
( O
2 O
) O
155 O
and O
Mycobacterium O
goodii O
strain O
12523 O
encode O
binuclear O
iron B
monooxygenases O
that O
oxidize O
propane B
and O
phenol B
. O

Although O
whole O
- O
cell O
assays O
were O
performed O
with O
phenol B
as O
a O
substrate O
, O
the O
transformed O
R O
. O
opacus O
cells O
did O
not O
oxidize O
this O
substrate O
. O

SDS B
/ O
PAGE O
analysis O
revealed O
that O
the O
oxygenase O
large O
subunit O
MimA O
was O
expressed O
in O
the O
insoluble O
fraction O
of O
R O
. O
opacus O
cells O
. O

We O
found O
that O
a O
gene O
designated O
mimG O
, O
which O
lies O
downstream O
of O
mimABCD O
, O
exhibits O
similarity O
in O
the O
amino B
acid I
sequence O
of O
its O
product O
with O
the O
products O
of O
genes O
encoding O
the O
chaperonin O
GroEL O
. O

When O
the O
mimG O
gene O
was O
cloned O
and O
coexpressed O
with O
each O
mimABCD O
gene O
cluster O
in O
R O
. O
opacus O
strain O
B O
- O
4 O
, O
this O
host O
successfully O
acquired O
oxidation O
activity O
towards O
phenol B
. O

SDS B
/ O
PAGE O
and O
western O
blotting O
analyses O
demonstrated O
that O
MimA O
was O
clearly O
soluble O
when O
in O
the O
presence O
of O
MimG O
. O

High O
electrochemical O
performance O
based O
on O
ultrathin O
porous O
CuO B
nanobelts O
grown O
on O
Cu B
substrate O
as O
integrated O
electrode O
. O

A O
facile O
and O
low O
- O
cost O
approach O
has O
been O
developed O
to O
fabricate O
porous O
CuO B
nanobelts O
directly O
grown O
on O
a O
Cu B
substrate O
. O

The O
as O
- O
prepared O
CuO B
samples O
can O
be O
directly O
used O
as O
integrated O
electrodes O
for O
lithium B
- O
ion O
batteries O
and O
pseudo O
- O
supercapacitors O
without O
the O
addition O
of O
other O
ancillary O
materials O
such O
as O
carbon B
black I
or O
a O
binder O
to O
enhance O
electrode O
conductivity O
and O
cycling O
stability O
. O

Monte O
Carlo O
simulations O
show O
that O
charge O
- O
regulation O
alone O
can O
cause O
highly O
charged O
zirconium B
nanoparticles O
to O
adsorb O
to O
a O
similarly O
charged O
or O
neutral O
silica B
particle O
and O
thereby O
stabilizing O
the O
latter O
. O

The O
charge O
- O
regulation O
mechanism O
also O
turns O
the O
silica B
surface O
from O
positively O
charged O
, O
without O
nanoparticles O
, O
to O
negatively O
charged O
in O
the O
presence O
of O
nanoparticles O
. O

Name O
your O
splice O
: O
FR901464 B
analogues O
and O
herboxidiene O
inhibit O
constitutive O
splicing O
, O
most O
likely O
by O
inhibiting O
spliceosomal O
subunit O
SF3b O
. O

Contaminant O
- O
mobilizing O
capability O
of O
fullerene B
nanoparticles O
( O
nC60 O
) O
: O
Effect O
of O
solvent O
- O
exchange O
process O
in O
nC60 O
formation O
. O

Fullerene B
nanoparticles O
( O
nC O
( O
60 O
) O
) O
in O
aqueous O
environments O
can O
significantly O
enhance O
the O
transport O
of O
hydrophobic O
organic O
contaminants O
by O
serving O
as O
a O
contaminant O
carrier O
. O

A O
series O
of O
nC O
( O
60 O
) O
samples O
were O
prepared O
using O
a O
modified O
toluene B
- O
water O
solvent O
- O
exchange O
method O
through O
the O
inclusion O
of O
a O
secondary O
organic O
solvent O
in O
the O
phase O
transfer O
of O
molecular O
C B
( I
60 I
) I
in O
toluene B
to O
nC O
( O
60 O
) O
in O
water O
. O

The O
involvement O
of O
a O
secondary O
solvent O
in O
the O
phase O
transfer O
process O
had O
only O
small O
effects O
on O
the O
particle O
size O
and O
distribution O
, O
zeta O
potential O
, O
and O
mobility O
of O
the O
nC O
( O
60 O
) O
products O
but O
significantly O
influenced O
the O
capability O
of O
nC O
( O
60 O
) O
to O
enhance O
the O
transport O
of O
2 O
, O
2 O
' O
, O
5 O
, O
5 O
' O
- O
polychlorinated O
biphenyl O
( O
PCB B
) O
in O
a O
saturated O
sandy O
soil O
column O
, O
regardless O
of O
whether O
the O
secondary O
solvent O
was O
water O
- O
miscible O
or O
non O
- O
water O
- O
miscible O
. O

In O
general O
, O
nC O
( O
60 O
) O
products O
made O
with O
a O
secondary O
water O
- O
miscible O
solvent O
have O
stronger O
capabilities O
to O
enhance O
PCB B
transport O
. O

The O
nuclear O
receptors O
pregnane O
X O
receptor O
, O
constitutive O
androstane B
receptor O
, O
and O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
have O
important O
endogenous O
functions O
and O
are O
also O
involved O
in O
the O
induction O
of O
drug O
- O
metabolizing O
enzymes O
and O
transporters O
in O
response O
to O
exogenous O
xenobiotics O
. O

Though O
not O
belonging O
to O
the O
same O
protein O
family O
, O
the O
Per O
- O
Sim O
- O
ARNT O
domain O
receptor O
aryl B
hydrocarbon I
receptor O
functionally O
overlaps O
with O
the O
three O
nuclear O
receptors O
in O
many O
aspects O
and O
is O
therefore O
included O
in O
this O
review O
. O

The O
relationship O
between O
carotid O
intima O
- O
media O
thickness O
and O
endogenous O
androgens B
in O
young O
women O
with O
polycystic O
ovary O
syndrome O
in O
Taiwan O
. O

Our O
objective O
was O
to O
investigate O
the O
relationship O
between O
carotid O
intima O
- O
media O
thickness O
( O
CIMT O
) O
and O
endogenous O
androgens B
in O
young O
Taiwanese O
- O
Chinese O
women O
with O
PCOS O
. O

Furthermore O
, O
androstenedione B
appears O
to O
be O
inversely O
associated O
with O
CIMT O
. O

Histopathological O
effects O
of O
waterborne O
copper B
nanoparticles O
and O
copper O
sulphate O
on O
the O
organs O
of O
rainbow O
trout O
( O
Oncorhynchus O
mykiss O
) O
. O

It O
is O
unclear O
whether O
copper B
nanoparticles O
are O
more O
toxic O
than O
traditional O
forms O
of O
dissolved O
copper B
. O

This O
study O
aimed O
to O
describe O
the O
pathologies O
in O
gill O
, O
gut O
, O
liver O
, O
kidney O
, O
brain O
and O
muscle O
of O
juvenile O
rainbow O
trout O
, O
Oncorhynchus O
mykiss O
, O
exposed O
in O
triplicate O
to O
either O
a O
control O
( O
no O
added O
Cu B
) O
, O
20 O
or O
100 O
mu O
g O
l O
( O
- O
1 O
) O
of O
either O
dissolved O
Cu B
( O
as O
CuSO O
( O
4 O
) O
) O
or O
Cu B
- O
NPs O
( O
mean O
primary O
particle O
size O
of O
87 O
+ O
/ O
- O
27 O
nm O
) O
in O
a O
semi O
- O
static O
waterborne O
exposure O
regime O
. O

All O
treatments O
caused O
organ O
injuries O
, O
and O
the O
kinds O
of O
pathologies O
observed O
with O
Cu B
- O
NPs O
were O
broadly O
of O
the O
same O
type O
as O
CuSO O
( O
4 O
) O
including O
: O
hyperplasia O
, O
aneurisms O
, O
and O
necrosis O
in O
the O
secondary O
lamellae O
of O
the O
gills O
; O
swelling O
of O
goblet O
cells O
, O
necrosis O
in O
the O
mucosa O
layer O
and O
vacuole O
formation O
in O
the O
gut O
; O
hepatitis O
- O
like O
injury O
and O
cells O
with O
pyknotic O
nuclei O
in O
the O
liver O
; O
damage O
to O
the O
epithelium O
of O
some O
renal O
tubules O
and O
increased O
Bowman O
' O
s O
space O
in O
the O
kidney O
. O

Overall O
the O
data O
showed O
that O
pathology O
from O
CuSO O
( O
4 O
) O
and O
Cu B
- O
NPs O
were O
of O
similar O
types O
, O
but O
there O
were O
some O
material O
- O
type O
effects O
in O
the O
severity O
or O
incidence O
of O
injuries O
with O
Cu B
- O
NPs O
causing O
more O
injury O
in O
the O
intestine O
, O
liver O
and O
brain O
than O
the O
equivalent O
concentration O
of O
CuSO O
( O
4 O
) O
by O
the O
end O
of O
the O
experiment O
, O
but O
in O
the O
gill O
and O
muscle O
CuSO O
( O
4 O
) O
caused O
more O
pathology O
. O

BMS O
- O
763534 O
is O
a O
potent O
( O
CRF O
( O
1 O
) O
IC O
( O
50 O
) O
= O
0 O
. O
4 O
nM O
) O
and O
selective O
( O
> O
1000 O
- O
fold O
selectivity O
vs O
. O
all O
other O
sites O
tested O
) O
CRF O
( O
1 O
) O
receptor O
antagonist O
( O
pA2 O
= O
9 O
. O
47 O
vs O
. O
CRF O
( O
1 O
) O
- O
mediated O
cAMP B
production O
in O
Y79 O
cells O
) O
. O

BMS O
- O
763534 O
accelerated O
the O
dissociation O
of O
( B
125 I
) I
I I
- O
o O
- O
CRF O
from O
rat O
frontal O
cortex O
membrane O
CRF O
( O
1 O
) O
receptors O
consistent O
with O
a O
negative O
allosteric O
modulation O
of O
CRF O
binding O
. O

At O
doses O
of O
5 O
- O
to O
18 O
- O
fold O
higher O
than O
the O
lowest O
efficacious O
dose O
in O
the O
anxiety O
assay O
, O
BMS O
- O
763534 O
shared O
subjective O
effects O
with O
the O
benzodiazepine O
chlordiazepoxide B
. O

Interestingly O
BMS O
- O
790318 O
, O
the O
O B
- O
demethylated O
metabolite O
of O
BMS O
- O
763534 O
, O
showed O
weak O
affinity O
for O
the O
TBOB O
site O
of O
the O
GABA B
( O
A O
) O
receptor O
( O
67 O
% O
inhibition O
at O
10 O
mu O
M O
) O
and O
augmented O
GABA B
evoked O
currents O
( O
EC O
( O
50 O
) O
= O
1 O
. O
6 O
mu O
M O
) O
. O

Thus O
, O
the O
unanticipated O
signal O
in O
the O
drug O
discrimination O
assay O
may O
have O
resulted O
from O
an O
interaction O
of O
the O
metabolite O
BMS O
- O
790318 O
with O
the O
TBOB O
site O
on O
the O
GABA B
( O
A O
) O
channel O
where O
it O
appears O
to O
behave O
as O
an O
allosteric O
potentiator O
of O
GABA B
evoked O
currents O
. O

Hydroalcoholic O
extracts O
, O
obtained O
from O
the O
red O
propolis O
, O
revealed O
polyphenol B
content O
, O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
scavenging O
potential O
and O
enzymatic O
activities O
for O
catalase O
- O
like O
and O
superoxide B
dismutase O
- O
like O
. O

Anti O
- O
inflammatory O
properties O
of O
anthraquinones B
and O
their O
relationship O
with O
the O
regulation O
of O
P O
- O
glycoprotein O
function O
and O
expression O
. O

In O
this O
report O
, O
we O
assessed O
the O
effects O
of O
anthraquinone B
derivatives O
from O
rhubarb O
on O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
to O
determine O
their O
anti O
- O
inflammatory O
potential O
. O

Five O
anthraquinones B
were O
tested O
to O
determine O
their O
inhibitory O
activities O
on O
NO B
production O
and O
the O
protein O
and O
mRNA O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
. O

Furthermore O
, O
the O
level O
of O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
was O
determined O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
macrophages O
. O

Emodin B
was O
found O
to O
be O
the O
most O
potent O
inhibitor O
, O
and O
it O
also O
reduced O
paw O
swelling O
in O
the O
mouse O
model O
of O
carrageenan O
- O
induced O
paw O
edema O
. O

Structure O
sensitivity O
of O
CO B
oxidation O
on O
Co3O4 B
: O
a O
DFT O
study O
. O

The O
reaction O
mechanism O
of O
CO B
oxidation O
on O
the O
Co O
( O
3 O
) O
O O
( O
4 O
) O
( O
110 O
) O
and O
Co O
( O
3 O
) O
O O
( O
4 O
) O
( O
111 O
) O
surfaces O
is O
investigated O
by O
means O
of O
spin O
- O
polarized O
density O
functional O
theory O
( O
DFT O
) O
within O
the O
GGA O
+ O
U O
framework O
. O

Adsorption O
situation O
and O
complete O
reaction O
cycles O
for O
CO B
oxidation O
are O
clarified O
. O

The O
results O
indicate O
that O
1 O
) O
the O
U O
value O
can O
affect O
the O
calculated O
energetic O
result O
significantly O
, O
not O
only O
the O
absolute O
adsorption O
energy O
but O
also O
the O
trend O
in O
adsorption O
energy O
; O
2 O
) O
CO B
can O
directly O
react O
with O
surface O
lattice O
oxygen B
atoms O
( O
O B
( O
2f O
) O
/ O
O B
( O
3f O
) O
) O
to O
form O
CO B
( I
2 I
) I
via O
the O
Mars O
- O
van O
Krevelen O
reaction O
mechanism O
on O
both O
( O
110 O
) O
- O
B O
and O
( O
111 O
) O
- O
B O
; O
3 O
) O
pre O
- O
adsorbed O
molecular O
O B
( I
2 I
) I
can O
enhance O
CO B
oxidation O
through O
the O
channel O
in O
which O
it O
directly O
reacts O
with O
molecular O
CO B
to O
form O
CO B
( I
2 I
) I
[ O
O O

( O
2 O
) O
( O
a O
) O
+ O
CO O
( O
g O
) O
- O
- O
> O
CO B
( I
2 I
) I
( O
g O
) O
+ O
O B
( O
a O
) O
] O
on O
( O
110 O
) O
- O
A O
/ O
( O
111 O
) O
- O
A O
; O
4 O
) O
CO B
oxidation O
is O
a O
structure O
- O
sensitive O
reaction O
, O
and O
the O
activation O
energy O
of O
CO B
oxidation O
follows O
the O
order O
of O
Co O
( O
3 O
) O
O O
( O
4 O
) O
( O
111 O
) O
- O
A O
( O
0 O
. O
78 O
eV O
) O
> O
Co O
( O
3 O
) O
O O
( O
4 O
) O
( O
111 O
) O
- O
B O
( O
0 O
. O
68 O
eV O
) O
> O
Co O
( O
3 O
) O
O O
( O
4 O
) O
( O
110 O
) O
- O
A O
( O
0 O
. O
51 O
eV O
) O
> O
Co O

( O
3 O
) O
O O
( O
4 O
) O
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO O
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co O
( O
3 O
+ O
) O
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co O
( O
3 O
+ O
) O
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co O
( O
3 O
) O
O O
( O
4 O
) O
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co O
( O
3 O
+ O
) O
or O
O B
( O

Which O
were O
in O
turn O
reflected O
in O
the O
levels O
of O
serotonin B
and O
acetylcholine B
esterase O
. O

The O
conjunctive O
treatment O
also O
showed O
significant O
decrease O
in O
oxidative O
stress O
as O
assessed O
by O
MDA B
levels O
and O
the O
antioxidant O
enzymes O
( O
GSH B
, O
GSSH O
, O
GPX O
, O
total O
glutathione B
, O
Catalase O
and O
Superoxide B
dismutase O
) O
which O
were O
depressed O
by O
TMT O
treatment O
was O
significantly O
improved O
by O
GBE O
. O

Seizure O
control O
by O
ketogenic O
diet O
- O
associated O
medium O
chain O
fatty B
acids I
. O

The O
medium O
chain O
triglyceride B
( O
MCT O
) O
ketogenic O
diet O
is O
used O
extensively O
for O
treating O
refractory O
childhood O
epilepsy O
. O

This O
diet O
increases O
the O
plasma O
levels O
of O
medium O
straight O
chain O
fatty B
acids I
. O

A O
role O
for O
these O
and O
related O
fatty B
acids I
in O
seizure O
control O
has O
not O
been O
established O
. O

We O
compared O
the O
potency O
of O
an O
established O
epilepsy O
treatment O
, O
Valproate B
( O
VPA B
) O
, O
with O
a O
range O
of O
MCT O
diet O
- O
associated O
fatty B
acids I
( O
and O
related O
branched O
compounds O
) O
, O
using O
in O
vitro O
seizure O
and O
in O
vivo O
epilepsy O
models O
, O
and O
assessed O
side O
effect O
potential O
in O
vitro O
for O
one O
aspect O
of O
teratogenicity O
, O
for O
liver O
toxicology O
and O
in O
vivo O
for O
sedation O
, O
and O
for O
a O
neuroprotective O
effect O
. O

We O
identify O
specific O
medium O
chain O
fatty B
acids I
( O
both O
prescribed O
in O
the O
MCT O
diet O
, O
and O
related O
compounds O
branched O
on O
the O
fourth O
carbon O
) O
that O
provide O
significantly O
enhanced O
in O
vitro O
seizure O
control O
compared O
to O
VPA B
. O

The O
activity O
of O
these O
compounds O
on O
seizure O
control O
is O
independent O
of O
histone O
deacetylase O
inhibitory O
activity O
( O
associated O
with O
the O
teratogenicity O
of O
VPA B
) O
, O
and O
does O
not O
correlate O
with O
liver O
cell O
toxicity O
. O

In O
vivo O
, O
these O
compounds O
were O
more O
potent O
in O
epilepsy O
control O
( O
perforant O
pathway O
stimulation O
induced O
status O
epilepticus O
) O
, O
showed O
less O
sedation O
and O
enhanced O
neuroprotection O
compared O
to O
VPA B
. O

Our O
data O
therefore O
implicates O
medium O
chain O
fatty B
acids I
in O
the O
mechanism O
of O
the O
MCT O
ketogenic O
diet O
, O
and O
highlights O
a O
related O
new O
family O
of O
compounds O
that O
are O
more O
potent O
than O
VPA B
in O
seizure O
control O
with O
a O
reduced O
potential O
for O
side O
effects O
. O

Vitamin B
D I
receptor O
signaling O
mechanisms O
: O
integrated O
actions O
of O
a O
well O
- O
defined O
transcription O
factor O
. O

The O
main O
physiological O
actions O
of O
the O
biologically O
most O
active O
metabolite O
of O
vitamin B
D I
, O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 O
alpha O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
( O
3 O
) O
) O
, O
are O
calcium B
and O
phosphorus B
uptake O
and O
transport O
and O
thereby O
controlling O
bone O
formation O
. O

All O
genomic O
actions O
of O
1 O
alpha O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
( O
3 O
) O
are O
mediated O
by O
the O
transcription O
factor O
vitamin B
D I
receptor O
( O
VDR O
) O
that O
has O
been O
the O
subject O
of O
intense O
study O
since O
the O
1980 O
' O
s O
. O

Thus O
, O
vitamin B
D I
signaling O
primarily O
implies O
the O
molecular O
actions O
of O
the O
VDR O
. O

By O
comparing O
the O
actions O
of O
the O
VDR O
, O
a O
relatively O
well O
- O
understood O
and O
characterized O
protein O
, O
with O
those O
of O
other O
transcription O
factors O
, O
we O
aim O
to O
build O
a O
realistic O
positioning O
of O
vitamin B
D I
signaling O
in O
the O
context O
of O
other O
intracellular O
signaling O
systems O
. O

Biochemical O
and O
biological O
characterization O
of O
two O
serine B
proteinases O
from O
Colombian O
Crotalus O
durissus O
cumanensis O
snake O
venom O
. O

Two O
clotting O
serine B
proteinases O
, O
named O
Cdc O
SI O
and O
Cdc O
SII O
, O
were O
isolated O
and O
characterized O
for O
the O
first O
time O
from O
Colombian O
Crotalus O
durissus O
cumanensis O
snake O
venom O
. O

The O
serine B
proteinases O
hydrolyzed O
specific O
chromogenic O
substrate O
( O
BaPNA O
) O
and O
exhibited O
a O
Michaelis O
- O
Menten O
behavior O
. O

N B
- O
terminal O
sequences O
were O
VIGGDEXNIN O
and O
VIGGDICNINEHNFLVALYE O
for O
Cdc O
SI O
and O
Cdc O
SII O
, O
respectively O
. O

Molecular O
masses O
, O
N B
- O
terminal O
sequences O
, O
inhibition O
assays O
, O
and O
enzymatic O
profile O
suggest O
that O
Cdc O
SI O
and O
Cdc O
SII O
belong O
to O
the O
family O
of O
snake O
venom O
thrombin O
- O
like O
enzymes O
. O

These O
serine B
proteinases O
differed O
in O
their O
clotting O
activity O
on O
human O
plasma O
, O
showing O
a O
minimum O
coagulant O
dose O
of O
25 O
mu O
g O
and O
0 O
. O
571 O
mu O
g O
for O
Cdc O
SI O
and O
Cdc O
SII O
, O
respectively O
. O

These O
serine B
proteinases O
may O
contribute O
indirectly O
to O
the O
local O
hemorrhage O
induced O
by O
metalloproteinases O
, O
by O
causing O
blood O
clotting O
disturbances O
, O
and O
might O
also O
contribute O
to O
cardiovascular O
alterations O
characteristic O
of O
patients O
envenomed O
by O
C O
. O

In O
other O
cases O
, O
the O
observed O
deviations O
are O
independent O
of O
the O
buffers O
used O
since O
they O
are O
caused O
by O
the O
formation O
of O
new O
species O
such O
as O
drug O
aggregates O
( O
cefadroxil O
) O
or O
the O
precipitation O
of O
a O
salt O
from O
a O
cationic O
species O
of O
the O
analyzed O
compound O
( O
quetiapine B
) O
. O

Herb O
- O
drug O
interaction O
of O
Fucus O
vesiculosus O
extract O
and O
amiodarone B
in O
rats O
: O
a O
potential O
risk O
for O
reduced O
bioavailability O
of O
amiodarone B
in O
clinical O
practice O
. O

Therefore O
, O
considering O
the O
relationship O
between O
obesity O
and O
cardiovascular O
diseases O
, O
this O
work O
aimed O
to O
assess O
the O
potential O
for O
an O
herb O
- O
drug O
interaction O
among O
a O
standardized O
F O
. O
vesiculosus O
extract O
( O
GMP O
certificate O
) O
and O
amiodarone B
( O
a O
narrow O
therapeutic O
index O
drug O
) O
in O
rats O
. O

In O
a O
first O
pharmacokinetic O
study O
, O
rats O
were O
simultaneously O
co O
- O
administered O
with O
a O
single O
- O
dose O
of O
F O
. O
vesiculosus O
( O
575 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
and O
amiodarone B
( O
50 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
; O
in O
a O
second O
study O
, O
rats O
were O
pre O
- O
treated O
during O
14 O
days O
with O
F O
. O
vesiculosus O
( O
575 O
mg O
/ O
kg O
/ O
day O
, O
p O
. O
o O
. O
) O
and O
received O
amiodarone B
( O
50 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
on O
the O
15th O
day O
. O

After O
analysis O
of O
the O
pharmacokinetic O
data O
it O
deserves O
to O
be O
highlighted O
the O
significant O
decrease O
in O
the O
peak O
plasma O
concentration O
of O
amiodarone B
( O
55 O
. O
4 O
% O
) O
as O
well O
as O
the O
reduction O
of O
systemic O
exposure O
to O
the O
parent O
drug O
( O
~ O
30 O
% O
) O
following O
the O
simultaneous O
co O
- O
administration O
of O
F O
. O
vesiculosus O
extract O
and O
amiodarone B
. O

This O
paper O
reports O
, O
for O
the O
first O
time O
, O
the O
herb O
- O
drug O
interaction O
between O
F O
. O
vesiculosus O
and O
amiodarone B
, O
which O
determined O
a O
considerable O
decrease O
on O
amiodarone B
bioavailability O
in O
rats O
. O

Therefore O
, O
the O
therapeutic O
efficacy O
of O
amiodarone B
may O
be O
compromised O
by O
the O
concurrent O
administration O
of O
herbal O
slimming O
medicines O
/ O
dietary O
supplements O
containing O
F O
. O
vesiculosus O
. O

The O
aim O
of O
this O
study O
was O
to O
in O
vitro O
investigate O
whether O
HA O
is O
able O
to O
reduce O
reactive O
oxygen B
species O
( O
ROS O
) O
- O
induced O
heart O
ischemia O
- O
reperfusion O
injury O
and O
activate O
the O
cardiomyocyte O
' O
s O
damage O
surveillance O
systems O
. O

Accordingly O
, O
rattus O
cardiomyocyte O
line O
, O
H9C2 O
, O
was O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
as O
a O
heart O
ischemia O
- O
reperfusion O
model O
followed O
by O
incubation O
with O
low O
molecular O
weight O
hyaluronan O
( O
LMW O
- O
HA O
, O
100 O
kDa O
) O
or O
high O
molecular O
weight O
hyaluronan O
( O
HMW O
- O
HA O
, O
1000 O
kDa O
) O
and O
proteomic O
analysis O
was O
performed O
to O
investigate O
the O
physiologic O
protection O
of O
HA O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
induced O
ischemia O
- O
reperfusion O
in O

Combination O
chemotherapy O
using O
core O
- O
shell O
nanoparticles O
through O
the O
self O
- O
assembly O
of O
HPMA B
- O
based O
copolymers O
and O
degradable O
polyester B
. O

The O
preparation O
of O
core O
- O
shell O
polymeric O
nanoparticles O
simultaneously O
loaded O
with O
docetaxel B
( O
DTXL O
) O
and O
doxorubicin B
( O
DOX B
) O
is O
reported O
herein O
. O

The O
self O
- O
assembly O
of O
the O
aliphatic O
biodegradable O
copolyester O
PBS B
/ O
PBDL O
( O
poly O
( O
butylene O
succinate O
- O
co O
- O
butylene O
dilinoleate O
) O
) O
and O
HPMA B
- O
based O
copolymers O
( O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
- O
based O
copolymers O
) O
hydrophobically O
modified O
by O
the O
incorporation O
of O
cholesterol B
led O
to O
the O
formation O
of O
narrow O
- O
size O
- O
distributed O
( O
PDI O
< O
0 O
. O
10 O
) O
sub O
- O
200 O
- O
nm O
polymeric O
nanoparticles O
suitable O
for O
passive O
tumor O
- O

The O
highly O
hydrophobic O
drug O
docetaxel B
( O
DTXL O
) O
was O
physically O
entrapped O
within O
the O
PBS B
/ O
PBDL O
copolyester O
core O
and O
the O
hydrophilic O
drug O
doxorubicin O
hydrochloride O
( O
DOX O
. O
HCl O
) O
was O
chemically O
conjugated O
to O
the O
reactive O
PHPMA O
copolymer O
shell O
via O
hydrazone B
bonding O
that O
allowed O
its O
pH O
- O
sensitive O
release O
. O

This O
strategy O
enabled O
the O
combination O
chemotherapy O
by O
the O
simultaneous O
DOX B
and O
DTXL O
drug O
delivery O
. O

The O
use O
of O
nanoparticles O
simultaneously O
loaded O
with O
DTXL O
and O
DOX B
provided O
a O
more O
efficient O
suppression O
of O
tumor O
- O
cell O
growth O
in O
mice O
bearing O
EL O
- O
4 O
T O
cell O
lymphoma O
when O
compared O
to O
the O
effect O
of O
nanoparticles O
loaded O
with O
either O
DTXL O
or O
DOX B
separately O
. O

Additionally O
, O
the O
obtained O
self O
- O
assembled O
nanoparticles O
enable O
further O
development O
of O
targeting O
strategies O
based O
on O
the O
use O
of O
multiple O
ligands O
attached O
to O
an O
HPMA B
copolymer O
on O
the O
particle O
surface O
for O
simultaneous O
passive O
and O
active O
targeting O
and O
different O
combination O
therapies O
. O

Iron B
excess O
disturbs O
metabolic O
status O
and O
relative O
gonad O
mass O
in O
rats O
on O
high O
fat O
, O
fructose B
, O
and O
salt O
diets O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
metabolic O
and O
physiological O
changes O
in O
rats O
fed O
a O
diet O
high O
in O
fat O
, O
fructose B
, O
and O
salt O
, O
and O
with O
excess O
iron B
level O
. O

Wistar O
rats O
were O
assigned O
to O
groups O
fed O
either O
a O
standard O
control O
diet O
( O
C O
) O
or O
a O
diet O
high O
in O
fat O
, O
fructose B
, O
and O
salt O
. O

The O
noncontrol O
diets O
contained O
either O
normal O
( O
M O
) O
or O
high O
level O
( O
MFe O
) O
of O
iron B
. O

Serum O
levels O
of O
insulin O
, O
nitric B
oxide I
, O
and O
iron B
were O
measured O
. O

The O
iron B
, O
zinc B
, O
copper B
, O
and O
calcium B
concentrations O
of O
tissues O
were O
determined O
. O

Among O
the O
rats O
fed O
the O
M O
diet O
, O
markedly O
higher O
serum O
level O
of O
iron B
and O
lower O
levels O
of O
zinc B
and O
copper B
were O
observed O
in O
tissues O
, O
while O
significantly O
higher O
calcium B
levels O
were O
found O
in O
the O
gonads O
. O

The O
MFe O
diet O
resulted O
in O
decreased O
obesity O
index O
, O
insulin O
level O
, O
and O
nitric B
oxide I
serum O
concentration O
in O
the O
rats O
, O
when O
compared O
with O
both O
the O
M O
and O
C O
diets O
. O

The O
high O
iron B
level O
in O
the O
modified O
diet O
increased O
the O
relative O
mass O
of O
the O
gonads O
. O

The O
excess O
iron B
level O
in O
the O
diet O
disturbed O
the O
zinc B
, O
copper B
, O
and O
calcium B
status O
of O
tissues O
. O

The O
decrease O
in O
insulin O
and O
nitric B
oxide I
in O
rats O
fed O
the O
diet O
high O
in O
iron B
, O
fat O
, O
fructose B
, O
and O
salt O
was O
associated O
with O
disorders O
of O
zinc B
, O
copper B
, O
and O
calcium B
status O
, O
as O
well O
as O
with O
an O
increase O
in O
the O
relative O
mass O
of O
the O
gonads O
. O

Periphyton O
responses O
to O
nutrient O
and O
atrazine B
mixtures O
introduced O
through O
agricultural O
runoff O
. O

The O
individual O
influence O
of O
nutrients O
and O
atrazine B
on O
periphyton O
has O
been O
extensively O
studied O
, O
but O
their O
impact O
when O
introduced O
together O
and O
with O
multiple O
agricultural O
pollutants O
is O
less O
clear O
. O

Additionally O
, O
laboratory O
chamber O
assays O
were O
used O
to O
identify O
potential O
periphyton O
changes O
due O
to O
nutrients O
, O
atrazine B
, O
and O
their O
interactions O
. O

Generally O
, O
nutrients O
stimulated O
, O
and O
atrazine B
reduced O
chlorophyll B
a I
( O
Chl B
a I
) O
in O
chambers O
. O

In O
the O
wetland O
, O
nutrient O
and O
atrazine B
relationships O
with O
periphyton O
were O
weaker O
, O
and O
when O
found O
, O
were O
often O
opposite O
of O
trends O
in O
chambers O
. O

Total O
nitrogen B
( O
TN O
) O
was O
inversely O
related O
to O
Chl B
a I
, O
and O
total O
phosphorus B
was O
inversely O
related O
to O
respiration O
( O
R O
) O
rates O
. O

Atrazine B
( O
10 O
- O
20 O
mu O
g O
L O
( O
- O
1 O
) O
in O
the O
wetland O
) O
had O
a O
positive O
relationship O
with O
ash O
- O
free O
dry O
mass O
( O
AFDM O
) O
, O
and O
weakened O
the O
relationship O
between O
TN O
and O
AFDM O
. O

Wetland O
periphyton O
biomass O
was O
better O
correlated O
to O
total O
suspended O
solids O
than O
nutrients O
or O
atrazine B
. O

The O
individual O
and O
combined O
impacts O
of O
nutrients O
and O
atrazine B
in O
complex O
pollutant O
mixtures O
can O
vary O
substantially O
from O
their O
influence O
when O
introduced O
separately O
, O
and O
non O
- O
linear O
impacts O
can O
occur O
with O
distance O
downstream O
of O
the O
pollutant O
introduction O
point O
. O

Valproic B
acid I
( O
VPA B
) O
and O
methylmercury B
( O
MeHg B
) O
were O
used O
as O
positive O
control O
compounds O
to O
address O
the O
following O
fundamental O
questions O
: O
( O
1 O
) O
Does O
transcriptome O
analysis O
allow O
discrimination O
of O
the O
two O
compounds O
? O

VPA O
triggered O
vast O
transcriptional O
changes O
, O
whereas O
MeHg B
altered O
fewer O
transcripts O
. O

However O
, O
using O
TFBS O
enrichment O
, O
a O
relatively O
large O
' O
common O
response O
' O
to O
VPA B
and O
MeHg B
could O
be O
distinguished O
from O
' O
compound O
- O
specific O
' O
responses O
. O

Adrenal O
insufficiency O
may O
be O
caused O
by O
the O
destruction O
or O
altered O
function O
of O
the O
adrenal O
gland O
with O
a O
primary O
deficit O
in O
cortisol B
secretion O
( O
primary O
adrenal O
insufficiency O
) O
or O
by O
hypothalamic O
- O
pituitary O
pathologies O
determining O
a O
deficit O
of O
ACTH O
( O
secondary O
adrenal O
insufficiency O
) O
. O

The O
clinical O
picture O
is O
determined O
by O
the O
glucocorticoid O
deficit O
, O
which O
may O
in O
some O
conditions O
be O
accompanied O
by O
a O
deficit O
of O
mineralcorticoids O
and O
adrenal O
androgens B
. O

The O
oral O
substitutive O
treatment O
should O
attempt O
at O
mimicking O
the O
normal O
circadian O
profile O
of O
cortisol B
secretion O
, O
by O
using O
the O
lower O
possible O
doses O
able O
to O
guarantee O
an O
adequate O
quality O
of O
life O
to O
patients O
. O

The O
currently O
available O
hydrocortisone B
or O
cortisone O
acetate O
preparations O
do O
not O
allow O
an O
accurate O
reproduction O
of O
the O
physiological O
secretion O
pattern O
of O
cortisol B
. O

A O
novel O
dual O
- O
release O
formulation O
of O
hydrocortisone B
, O
recently O
approved O
by O
EMEA O
, O
represents O
an O
advancement O
in O
the O
optimization O
of O
the O
clinical O
management O
of O
patients O
with O
adrenal O
insufficiency O
. O

One O
new O
compound O
named O
amauroamoienin O
( O
1 O
) O
, O
together O
with O
thirteen O
known O
compounds O
( O
2 O
- O
14 O
) O
, O
was O
isolated O
from O
the O
EtOAc B
extract O
of O
Amauroderma O
amoiensis O
. O

Highly O
flexible O
stacked O
and O
in O
- O
plane O
all O
- O
solid O
- O
state O
supercapacitors O
are O
fabricated O
on O
3D O
hierarchical O
GeSe2 O
nanostructures O
with O
high O
performance O
, O
and O
, O
when O
configured O
as O
a O
self O
- O
powered O
photodetector O
nanosystem O
, O
can O
be O
used O
to O
power O
CdSe B
nanowire O
photodetectors O
. O

Bottom O
- O
up O
nutrient O
and O
top O
- O
down O
fish O
impacts O
on O
insect O
- O
mediated O
mercury B
flux O
from O
aquatic O
ecosystems O
. O

Methyl B
mercury I
( O
MeHg B
) O
is O
one O
of O
the O
most O
hazardous O
contaminants O
in O
the O
environment O
, O
adversely O
affecting O
the O
health O
of O
wildlife O
and O
humans O
. O

Recent O
studies O
have O
demonstrated O
that O
aquatic O
insects O
biotransport O
MeHg B
and O
other O
contaminants O
to O
terrestrial O
consumers O
, O
but O
the O
factors O
that O
regulate O
the O
flux O
of O
MeHg B
out O
of O
aquatic O
ecosystems O
via O
emergent O
insects O
have O
not O
been O
studied O
. O

The O
authors O
used O
experimental O
mesocosms O
to O
test O
the O
hypothesis O
that O
insect O
emergence O
and O
the O
associated O
flux O
of O
MeHg B
from O
aquatic O
to O
terrestrial O
ecosystems O
is O
affected O
by O
both O
bottom O
- O
up O
nutrient O
effects O
and O
top O
- O
down O
fish O
consumer O
effects O
. O

In O
the O
present O
study O
, O
nutrient O
addition O
led O
to O
an O
increase O
in O
MeHg B
flux O
primarily O
by O
enhancing O
the O
biomass O
of O
emerging O
insects O
whose O
tissues O
were O
contaminated O
with O
MeHg B
, O
whereas O
fish O
decreased O
MeHg B
flux O
primarily O
by O
reducing O
the O
biomass O
of O
emerging O
insects O
. O

The O
present O
study O
is O
the O
first O
to O
demonstrate O
that O
the O
flux O
of O
MeHg B
from O
aquatic O
to O
terrestrial O
ecosystems O
is O
strongly O
enhanced O
by O
bottom O
- O
up O
nutrient O
effects O
and O
diminished O
by O
top O
- O
down O
consumer O
effects O
. O

This O
system O
is O
used O
to O
investigate O
the O
lateral O
diffusion O
of O
40 O
nm O
gold O
spheres O
tethered O
to O
biotinylated O
lipids O
through O
antibody O
- O
functionalized O
ligands O
( O
single O
- O
stranded O
DNA O
or O
polyethylene B
glycol I
) O
. O

A O
new O
class O
of O
room O
- O
temperature O
multiferroic O
thin O
films O
with O
bismuth B
- O
based O
supercell O
structure O
. O

These O
results O
open O
up O
a O
new O
avenue O
for O
exploring O
room O
- O
temperature O
single O
- O
phase O
multiferroic O
thin O
films O
by O
controlling O
the O
phase O
mixing O
of O
two O
perovskite B
BiRO O
( O
3 O
) O
( O
R O
= O
Cr B
, O
Mn B
, O
Fe B
, O
Co B
, O
Ni B
) O
materials O
. O

Synthesis O
and O
anti O
- O
angiogenic O
activity O
of O
benzothiazole B
, O
benzimidazole B
containing O
phthalimide B
derivatives O
. O

Benzothiazole B
and O
benzimidazole B
containing O
phthalimide B
derivatives O
( O
NK037 O
, O
NK041 O
, O
NK042 O
, O
NK0139A O
and O
NK0148 O
) O
have O
been O
synthesized O
and O
their O
anti O
- O
angiogenic O
activity O
was O
evaluated O
using O
ex O
vivo O
egg O
yolk O
angiogenesis O
model O
. O

A O
comparative O
study O
with O
pure O
thalidomide B
( O
NKTA O
) O
has O
also O
been O
performed O
to O
describe O
the O
efficacy O
of O
these O
derivatives O
in O
blocking O
angiogenesis O
. O

Its O
polar O
extracts O
consist O
of O
phenolic B
acids I
, O
tannins B
and O
flavonoids B
. O

Additionally O
, O
because O
M O
. O
purpurea O
contains O
phenolic B
compounds O
, O
the O
antioxidative O
properties O
of O
this O
plant O
extracts O
were O
also O
studied O
and O
compared O
. O

Control O
of O
hypercholesterolemia O
and O
atherosclerosis O
using O
the O
cholesterol B
recognition O
/ O
interaction O
amino B
acid I
sequence O
of O
the O
translocator O
protein O
TSPO O
. O

The O
translocator O
protein O
( O
18 O
- O
kDa O
) O
TSPO O
is O
an O
ubiquitous O
high O
affinity O
cholesterol B
- O
binding O
protein O
reported O
to O
be O
present O
in O
the O
endothelial O
and O
smooth O
muscle O
cells O
of O
the O
blood O
vessels O
; O
its O
expression O
dramatically O
increased O
in O
macrophages O
found O
in O
atherosclerotic O
plaques O
. O

A O
domain O
in O
the O
carboxy B
- O
terminus O
of O
TSPO O
was O
identified O
and O
characterized O
as O
the O
cholesterol B
recognition O
/ O
interaction O
amino B
acid I
consensus O
( O
CRAC O
) O
. O

The O
ability O
of O
the O
CRAC O
domain O
to O
bind O
to O
cholesterol B
led O
us O
to O
hypothesize O
that O
this O
peptide O
could O
be O
used O
as O
an O
hypocholesterolemic O
, O
with O
potential O
anti O
- O
atherogenic O
properties O
, O
agent O
. O

We O
report O
herein O
the O
therapeutic O
benefit O
that O
resulted O
for O
the O
administration O
of O
the O
VLNYYVWR O
human O
CRAC O
sequence O
to O
guinea O
pigs O
fed O
with O
a O
high O
cholesterol B
diet O
and O
ApoE O
knock O
- O
out O
B6 O
. O
129P2 O
- O
Apoetm1Unc O
/ O
J O
mice O
. O

CRAC O
treatment O
( O
3 O
and O
30mg O
/ O
kg O
once O
daily O
for O
6 O
weeks O
) O
resulted O
in O
reduced O
circulating O
cholesterol B
levels O
in O
guinea O
pigs O
fed O
with O
2 O
% O
high O
cholesterol B
diet O
and O
ApoE O
knock O
- O
out O
B6 O
. O
129P2 O
- O
Apoetm1Unc O
/ O
J O
mice O
. O

In O
high O
cholesterol B
fed O
guinea O
pigs O
, O
CRAC O
treatment O
administered O
once O
daily O
induced O
an O
increase O
in O
circulating O
HDL O
, O
decreased O
total O
, O
free O
and O
LDL O
cholesterol B
, O
and O
removed O
atheroma O
deposits O
in O
the O
aorta O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
treatment O
also O
prevented O
the O
high O
cholesterol B
diet O
- O
induced O
increase O
in O
serum O
creatine B
kinase O
, O
total O
and O
isoforms O
, O
markers O
of O
neurological O
, O
cardiac O
and O
muscular O
damage O
. O

Disrupted O
cytoskeletal O
homeostasis O
, O
astrogliosis O
and O
apoptotic O
cell O
death O
in O
the O
cerebellum O
of O
preweaning O
rats O
injected O
with O
diphenyl B
ditelluride I
. O

In O
the O
present O
report O
15 O
day O
- O
old O
rats O
were O
injected O
with O
0 O
. O
3 O
mu O
mol O
of O
diphenyl B
ditelluride I
( B
PhTe I
) I
( I
2 I
) I
/ O
kg O
body O
weight O
and O
parameters O
of O
neurodegeneration O
were O
analyzed O
in O
slices O
from O
cerebellum O
3 O
and O
6 O
days O
afterwards O
. O

The O
earlier O
responses O
, O
at O
day O
3 O
after O
injection O
, O
included O
hyperphosphorylation O
of O
intermediate O
filament O
( O
IF O
) O
proteins O
from O
astrocyte O
( O
glial O
fibrillary O
acidic O
protein O
- O
GFAP O
- O
and O
vimentin O
) O
and O
neuron O
( O
low O
- O
, O
medium O
- O
and O
high O
molecular O
weight O
neurofilament O
subunits O
: O
NF O
- O
L O
, O
NF O
- O
M O
and O
NF O
- O
H O
) O
; O
increased O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
( O
Erk O
and O
p38MAPK O
) O
and O
cAMP B
- O
dependent O
protein O
kinase O
( O
PKA O
) O
activities O
. O

Also O
, O
reactive O
astrogliosis O
takes O
part O
of O
the O
early O
responses O
to O
the O
insult O
with O
( B
PhTe I
) I
( I
2 I
) I
, O
evidenced O
by O
upregulated O
GFAP O
in O
Western O
blot O
, O
PCR O
and O
immunofluorescence O
analysis O
. O

Six O
days O
after O
( B
PhTe I
) I
( I
2 I
) I
injection O
we O
found O
persistent O
astrogliosis O
, O
increased O
propidium B
iodide I
( O
PI O
) O
positive O
cells O
in O
NeuN O
positive O
population O
evidenced O
by O
flow O
cytometry O
and O
reduced O
immunofluorescence O
for O
NeuN O
, O
suggesting O
that O
the O
in O
vivo O
exposure O
to O
( B
PhTe I
) I
( I
2 I
) I
progressed O
to O
neuronal O
death O
. O

Neurodegeneration O
was O
related O
with O
decreased O
[ O
( O
3 O
) O
H O
] O
glutamate O
uptake O
and O
decreased O
Akt O
immunoreactivity O
, O
however O
phospho O
- O
GSK O
- O
3 O
- O
beta O
( O
Ser9 O
) O
was O
not O
altered O
in O
( B
PhTe I
) I
( I
2 I
) I
injected O
rat O
. O

Therefore O
, O
the O
present O
results O
show O
that O
the O
earlier O
cerebellar O
responses O
to O
( B
PhTe I
) I
( I
2 I
) I
include O
disruption O
of O
cytoskeletal O
homeostasis O
that O
could O
be O
related O
with O
MAPK O
and O
PKA O
activation O
and O
reactive O
astrogliosis O
. O

The O
later O
events O
of O
the O
neurodegenerative O
process O
are O
characterized O
by O
persistent O
astrogliosis O
and O
activation O
of O
apoptotic O
neuronal O
death O
through O
caspase O
3 O
mediated O
mechanisms O
, O
which O
could O
be O
related O
with O
glutamate B
excitotoxicity O
. O

The O
progression O
of O
these O
responses O
are O
therefore O
likely O
to O
be O
critical O
for O
the O
outcome O
of O
the O
neurodegeneration O
provoked O
by O
( B
PhTe I
) I
( I
2 I
) I
in O
rat O
cerebellum O
. O

The O
microsomal O
enzyme O
17 B
beta I
- I
hydroxysteroid I
dehydrogenase O
3 O
faces O
the O
cytoplasm O
and O
uses O
NADPH B
generated O
by O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

Recent O
studies O
proposed O
a O
functional O
coupling O
between O
17 B
beta I
- I
hydroxysteroid I
dehydrogenase O
3 O
( O
17 O
beta O
- O
HSD3 O
) O
- O
dependent O
testosterone O
formation O
and O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
1 O
( O
11 O
beta O
- O
HSD1 O
) O
- O
mediated O
interconversion O
of O
glucocorticoids O
through O
competition O
for O
the O
luminal O
pyridine O
nucleotide O
pool O
. O

To O
test O
this O
hypothesis O
, O
we O
used O
human O
embryonic O
kidney O
- O
293 O
cells O
transfected O
with O
17 O
beta O
- O
HSD3 O
and O
/ O
or O
11 O
beta O
- O
HSD1 O
, O
in O
the O
absence O
or O
presence O
of O
hexose O
- O
6 O
- O
phosphate O
dehydrogenase O
that O
generates O
reduced O
nicotinamide B
adenine I
dinucleotide I
phosphate I
( O
NADPH B
) O
in O
the O
endoplasmic O
reticulum O
and O
determined O
enzyme O
activities O
. O

In O
contrast O
, O
knockdown O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
decreased O
17 O
beta O
- O
HSD3 O
activity O
, O
indicating O
dependence O
on O
cytoplasmic O
NADPH B
. O

Upon O
selective O
permeabilization O
of O
the O
plasma O
membrane O
by O
digitonin O
, O
17 O
beta O
- O
HSD3 O
but O
not O
11 O
beta O
- O
HSD1 O
was O
detected O
by O
antibodies O
against O
C B
- O
terminal O
epitope O
tags O
, O
suggesting O
a O
cytoplasmic O
orientation O
of O
17 O
beta O
- O
HSD3 O
. O

The O
cytoplasmic O
orientation O
was O
confirmed O
using O
proteinase O
K O
digestion O
of O
microsomal O
preparations O
and O
by O
analysis O
of O
glycosylation O
of O
wild O
- O
type O
17 O
beta O
- O
HSD3 O
and O
chimera O
in O
which O
the O
N B
- O
terminal O
anchor O
sequences O
between O
17 O
beta O
- O
HSD3 O
and O
11 O
beta O
- O
HSD1 O
were O
exchanged O
. O

In O
conclusion O
, O
the O
results O
demonstrate O
a O
cytoplasmic O
orientation O
of O
17 O
beta O
- O
HSD3 O
and O
dependence O
on O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
- O
generated O
NADPH B
, O
explaining O
the O
lack O
of O
a O
direct O
functional O
coupling O
with O
the O
luminal O
11 O
beta O
- O
HSD1 O
- O
mediated O
glucocorticoid O
metabolism O
. O

A O
combined O
nuclear O
and O
nucleolar O
localization O
motif O
in O
activation O
- O
induced O
cytidine B
deaminase O
( O
AID O
) O
controls O
immunoglobulin O
class O
switching O
. O

Activation O
- O
induced O
cytidine B
deaminase O
( O
AID O
) O
is O
a O
DNA O
mutator O
enzyme O
essential O
for O
adaptive O
immunity O
. O

AID O
initiates O
somatic O
hypermutation O
and O
class O
switch O
recombination O
( O
CSR O
) O
by O
deaminating O
cytosine B
to O
uracil B
in O
specific O
immunoglobulin O
( O
Ig O
) O
gene O
regions O
. O

Moreover O
, O
we O
demonstrate O
that O
release O
of O
AID O
from O
nucleoli O
is O
dependent O
on O
its O
C B
- O
terminal O
motif O
. O

Our O
findings O
suggest O
that O
directional O
nucleolar O
transit O
is O
important O
for O
the O
physiological O
function O
of O
AID O
and O
demonstrate O
that O
nuclear O
/ O
nucleolar O
import O
and O
DNA O
cytosine B
deamination O
together O
define O
the O
biological O
activity O
of O
AID O
. O

One O
pot O
synthesis O
and O
biological O
activity O
evaluation O
of O
novel O
Schiff B
bases I
derived O
from O
2 O
- O
hydrazinyl O
- O
1 O
, O
3 O
, O
4 O
- O
thiadiazole O
. O

Considering O
the O
structural O
features O
of O
a O
group O
of O
known O
potent O
inhibitors O
of O
human O
platelet O
aggregation O
containing O
hydrazone B
structural O
backbone O
, O
a O
series O
of O
novel O
hydrazone B
derivatives O
of O
2 O
- O
hydrazinyl O
- O
1 O
, O
3 O
, O
4 O
- O
thiadiazole O
were O
synthesized O
using O
a O
one O
- O
pot O
process O
and O
tested O
for O
their O
inhibitory O
activity O
against O
platelet O
aggregation O
induced O
by O
arachidonic B
acid I
and O
ADP B
. O

We O
have O
cycled O
supercooling O
to O
freezing O
and O
then O
thawing O
of O
deionized O
water O
in O
hydrophilic O
( O
untreated O
aluminum B
) O
, O
hydrophobic O
, O
superhydrophobic O
, O
and O
SLIPS O
- O
treated O
DSC O
pans O
multiple O
times O
to O
determine O
the O
effects O
of O
surface O
treatment O
on O
the O
nucleation O
and O
subsequent O
growth O
of O
ice O
. O

X O
- O
linked O
dystonia O
parkinsonism O
syndrome O
( O
XDP O
, O
lubag O
) O
: O
disease O
- O
specific O
sequence O
change O
DSC3 O
in O
TAF1 O
/ O
DYT3 O
affects O
genes O
in O
vesicular O
transport O
and O
dopamine B
metabolism O
. O

Although O
most O
sequence O
changes O
are O
intronic O
, O
one O
, O
disease O
- O
specific O
single O
- O
nucleotide B
change O
3 O
( O
DSC3 O
) O
, O
is O
located O
within O
an O
exon O
( O
d4 O
) O
. O

Annotation O
clustering O
revealed O
enrichment O
of O
genes O
related O
to O
vesicular O
transport O
, O
dopamine B
metabolism O
, O
synapse O
function O
, O
Ca B
( I
2 I
+ I
) I
metabolism O
and O
oxidative O
stress O
. O

Disturbance O
of O
dopamine O
function O
and O
of O
Ca B
( I
2 I
+ I
) I
metabolism O
can O
explain O
abnormal O
movement O
; O
loss O
of O
protection O
against O
reactive O
oxygen B
species O
may O
account O
for O
the O
neurodegenerative O
changes O
in O
XDP O
. O

The O
latest O
version O
of O
SCOPE O
produces O
a O
hydrogen B
bond O
profile O
that O
is O
substantially O
more O
informative O
than O
a O
single O
hydrogen B
bond O
energy O
value O
. O

Electronic O
transition O
moments O
of O
6 O
- O
methyl O
isoxanthopterin O
- O
- O
a O
fluorescent O
analogue O
of O
the O
nucleic O
acid O
base O
guanine B
. O

We O
studied O
the O
orientations O
and O
magnitudes O
of O
the O
electric O
dipole O
transition O
moments O
( O
EDTMs O
) O
of O
6 O
- O
methyl O
isoxanthopterin O
( O
6 O
- O
MI O
) O
, O
a O
fluorescent O
analogue O
of O
guanine B
that O
has O
been O
particularly O
useful O
in O
biological O
studies O
. O

Evaluation O
of O
romidepsin B
for O
clinical O
activity O
and O
radioactive B
iodine I
reuptake O
in O
radioactive B
iodine I
- O
refractory O
thyroid O
carcinoma O
. O

Background O
: O
Historically O
, O
systemic O
therapy O
for O
radioactive B
iodine I
( O
RAI B
) O
- O
refractory O
thyroid O
cancer O
has O
been O
understudied O
. O

Romidepsin B
is O
a O
histone O
deacetylase O
inhibitor O
with O
potent O
antitumor O
effects O
both O
in O
vitro O
and O
in O
vivo O
. O

In O
thyroid O
cancer O
cell O
lines O
, O
romidepsin O
increases O
expression O
of O
both O
thyroglobulin O
and O
the O
sodium B
iodide I
symporter O
messenger O
RNAs O
, O
suggesting O
the O
possibility O
of O
improved O
iodine B
concentrating O
ability O
of O
RAI B
- O
resistant O
tumors O
. O

Eligible O
patients O
had O
progressive O
, O
RAI B
- O
refractory O
, O
recurrent O
/ O
metastatic O
, O
nonmedullary O
, O
nonanaplastic O
thyroid O
cancer O
. O

Romidepsin B
13 O
mg O
/ O
m O
( O
2 O
) O
was O
administered O
intravenously O
on O
days O
1 O
, O
8 O
, O
and O
15 O
, O
in O
cycles O
of O
28 O
days O
. O

The O
primary O
endpoint O
was O
the O
response O
rate O
by O
RECIST O
; O
change O
in O
RAI B
avidity O
was O
a O
secondary O
endpoint O
. O

Restoration O
of O
RAI B
avidity O
was O
documented O
in O
two O
patients O
. O

Conclusions O
: O
We O
observed O
preliminary O
signs O
of O
in O
vivo O
reversal O
of O
RAI B
resistance O
after O
treatment O
with O
romidepsin B
. O

Neuronal O
P2X3 O
receptor O
activation O
is O
essential O
to O
the O
hyperalgesia O
induced O
by O
prostaglandins B
and O
sympathomimetic O
amines B
released O
during O
inflammation O
. O

We O
have O
demonstrated O
that O
the O
activation O
of O
P2X3 O
receptor O
on O
peripheral O
afferent O
neurons O
is O
critical O
to O
development O
of O
inflammatory O
hyperalgesia O
in O
peripheral O
tissue O
, O
although O
pharmacological O
administration O
of O
prostaglandin B
E I
( I
2 I
) I
or O
sympathomimetic O
amines B
is O
enough O
to O
sensitize O
primary O
afferent O
neurons O
by O
acting O
directly O
in O
neuronal O
receptors O
. O

Therefore O
, O
to O
clarify O
this O
ambiguity O
this O
study O
verifies O
whether O
P2X3 O
receptor O
activation O
on O
primary O
afferent O
neurons O
enables O
the O
sensitization O
induced O
by O
prostaglandin B
E I
( I
2 I
) I
or O
sympathomimetic O
amine B
. O

Initially O
, O
this O
study O
confirmed O
that O
co O
- O
administration O
of O
A317491 O
( O
60 O
mu O
g O
/ O
paw O
) O
, O
a O
selective O
P2X3 O
receptor O
antagonist O
, O
or O
pre O
- O
treatment O
with O
dexamethasone B
( O
1 O
mg O
/ O
mL O
/ O
kg O
) O
prevents O
the O
mechanical O
hyperalgesia O
induced O
by O
carrageenan O
( O
300 O
mu O
g O
/ O
paw O
) O
in O
the O
rat O
' O
s O
hind O
paw O
. O

Sub O
- O
threshold O
doses O
of O
PGE B
( I
2 I
) I
( O
4 O
ng O
/ O
paw O
) O
or O
dopamine B
( O
0 O
. O
4 O
mu O
g O
/ O
paw O
) O
, O
that O
do O
not O
induce O
hyperalgesia O
by O
themselves O
, O
when O
injected O
just O
following O
alpha O
beta O
meATP O
or O
carrageenan O
in O
rats O
treated O
with O
dexamethasone B
induced O
hyperalgesia O
, O
which O
is O
prevented O
by O
A317491 O
or O
treatment O
with O
periganglionar O
( O
DRG O
- O
L5 O
) O
injections O
of O
ODN O
- O
antisense O
, O
against O
P2X3 O
receptor O
. O

Furthermore O
, O
because O
PKC O
epsilon O
translocation O
induces O
an O
increase O
of O
neuronal O
susceptibility O
to O
inflammatory O
mediators O
, O
this O
study O
demonstrates O
that O
alpha O
beta O
meATP O
in O
peripheral O
tissue O
increases O
the O
expression O
of O
PKC O
epsilon O
in O
cell O
membranes O
of O
DRG O
- O
L5 O
, O
and O
in O
contrast O
, O
the O
administration O
of O
PKC O
epsilon O
translocation O
inhibitor O
( O
1 O
mu O
g O
/ O
paw O
) O
in O
peripheral O
tissue O
45 O
min O
before O
alpha O
beta O
meATP O
, O
prevented O
the O
hyperalgesia O
induced O
by O
sub O
- O
threshold O
dose O
of O
PGE B
( I
2 I
) I
( O
4 O
ng O
/ O
paw O
) O
. O

Quantification O
of O
silanol B
sites O
for O
the O
most O
common O
mesoporous O
ordered O
silicas B
and O
organosilicas O
: O
total O
versus O
accessible O
silanols O
. O

IR O
and O
NMR O
spectroscopy O
were O
used O
to O
determine O
the O
silanol B
content O
in O
the O
most O
common O
mesoporous O
ordered O
silicas B
: O
MCM B
- I
41 I
, O
MCM O
- O
48 O
, O
SBA B
- I
15 I
and O
SBA O
- O
16 O
. O

In O
addition O
, O
a O
spray O
dried O
MCM B
- I
41 I
and O
an O
ethene O
bridged O
PMO O
are O
investigated O
. O

The O
results O
are O
compared O
with O
a O
commercial O
chromatographic O
silica B
( O
Nucleosil O
) O
. O

A O
distinction O
is O
made O
between O
the O
total O
silanol B
number O
and O
the O
reachable O
or O
surface O
silanol B
content O
. O

The O
latter O
is O
determined O
by O
controlled O
reactions O
with O
simple O
silanes B
. O

All O
mesoporous O
ordered O
silicas B
, O
and O
especially O
the O
thick O
walled O
SBA O
- O
type O
materials O
and O
the O
PMO O
contain O
a O
surprisingly O
high O
amount O
of O
total O
silanol B
sites O
, O
albeit O
that O
up O
to O
90 O
% O
of O
these O
silanols O
are O
buried O
inside O
the O
walls O
and O
are O
not O
reachable O
for O
small O
silanes O
. O

Due O
to O
its O
unique O
mechanical O
properties O
, O
graphene B
can O
be O
applied O
for O
reinforcement O
in O
nanocomposites O
. O

We O
analyse O
the O
Young O
' O
s O
modulus O
of O
graphene B
at O
the O
semi O
- O
empirical O
PM6 O
level O
of O
theory O
. O

The O
internal O
forces O
are O
calculated O
and O
the O
Young O
' O
s O
modulus O
is O
predicted O
for O
a O
finite O
graphene B
sheet O
when O
external O
strain O
is O
applied O
on O
the O
system O
. O

In O
addition O
, O
the O
influence O
of O
the O
presence O
of O
a O
single O
vacancy O
, O
as O
well O
as O
for O
oxygenation O
of O
a O
vacancy O
, O
on O
the O
mechanical O
properties O
of O
graphene B
has O
been O
analysed O
. O

The O
incretin O
hormones O
glucagon O
- O
like O
peptide O
- O
1 O
and O
glucose B
- O
dependent O
insulinotropic O
peptide O
are O
secreted O
by O
enteroendocrine O
cells O
and O
augment O
glucose B
- O
induced O
insulin O
secretion O
in O
response O
to O
food O
ingestion O
in O
a O
glucose B
- O
dependent O
manner O
. O

In O
animal O
models O
of O
diabetes O
, O
the O
authors O
show O
that O
co O
- O
administration O
of O
a O
lipid O
- O
lowering O
drug O
with O
a O
dipeptidyl O
peptidase O
- O
4 O
inhibitor O
or O
a O
glucagon O
- O
like O
peptide O
- O
1 O
agonist O
improved O
glucose B
tolerance O
and O
beta O
cell O
mass O
. O

Insulin O
- O
degrading O
enzyme O
( O
IDE O
) O
is O
a O
highly O
conserved O
zinc B
metallopeptidase O
that O
is O
ubiquitously O
distributed O
in O
human O
tissues O
, O
and O
particularly O
abundant O
in O
the O
brain O
, O
liver O
, O
and O
muscles O
. O

Mangiferin O
is O
a O
plant O
natural O
polyphenol B
of O
C O
- O
glycosylxanthone O
structure O
and O
various O
pharmacological O
activities O
. O

Mangiferin O
is O
also O
an O
efficient O
iron B
chelator O
, O
therefore O
preventing O
the O
generation O
of O
hydroxyl B
radical O
in O
Fenton O
- O
type O
reactions O
. O

Phenolic B
compounds O
as O
antioxidants O
: O
carbonic O
anhydrase O
isoenzymes O
inhibitors O
. O

The O
major O
antioxidant O
compounds O
are O
especially O
phenolics B
and O
flavonoids B
, O
which O
are O
responsible O
for O
their O
health O
benefits O
. O

It O
catalyzes O
the O
hydration O
of O
carbon B
dioxide I
( O
CO B
( I
2 I
) I
) O
to O
bicarbonate B
( O
HCO B
( I
3 I
) I
- I
) O
and O
the O
corresponding O
dehydration O
of O
HCO B
( I
3 I
) I
- I
in O
acidic O
medium O
with O
regeneration O
of O
CO B
( I
2 I
) I
. O

Also O
, O
CA O
isoforms O
are O
found O
in O
a O
variety O
of O
tissues O
where O
they O
participate O
in O
several O
important O
biological O
processes O
such O
as O
acid O
- O
base O
balance O
, O
respiration O
, O
carbon B
dioxide I
and O
ion O
transport O
, O
bone O
resorption O
, O
ureagenesis O
, O
gluconeogenesis O
, O
lipogenesis O
and O
electrolyte O
secretion O
. O

On O
the O
other O
hand O
, O
the O
phenyl B
moiety O
of O
phenol B
was O
found O
to O
lay O
in O
the O
hydrophobic O
part O
of O
the O
CA O
active O
site O
, O
where O
CO B
( I
2 I
) I
, O
the O
physiologic O
substrate O
of O
the O
CAs O
, O
binds O
in O
the O
precatalytic O
complex O
, O
explaining O
thus O
the O
behavior O
of O
phenol B
as O
a O
unique O
CO B
( I
2 I
) I
competitive O
inhibitor O
. O

The O
first O
section O
is O
devoted O
to O
main O
phenolic B
antioxidant O
compounds O
in O
the O
foodstuffs O
and O
beverages O
. O

The O
second O
general O
section O
is O
about O
some O
definitions O
of O
CA O
inhibitory O
effects O
of O
the O
main O
phenolic B
compounds O
used O
for O
antioxidant O
activity O
. O

The O
phenolic B
compounds O
and O
acids O
had O
marked O
especially O
CA O
I O
and O
CA O
II O
inhibitory O
effects O
and O
might O
be O
used O
as O
leads O
for O
generating O
CA O
isoenzyme O
inhibitors O
. O

In O
addition O
, O
there O
are O
given O
some O
chemical O
and O
kinetic O
basis O
and O
technical O
details O
related O
to O
phenolic B
antioxidant O
compounds O
and O
carbonic O
anhydrase O
isoenzymes O
. O

Recent O
studies O
of O
antioxidant O
quinoline B
derivatives O
. O

Quinoline B
derivatives O
constitute O
an O
important O
class O
of O
compounds O
for O
new O
drug O
development O
. O

As O
a O
large O
number O
of O
experimental O
and O
theoretical O
studies O
have O
shown O
that O
the O
quinoline B
ring O
system O
is O
an O
important O
structural O
unit O
widely O
existing O
in O
alkaloids O
, O
therapeutics O
and O
synthetic O
analogues O
with O
exciting O
biological O
activities O
. O

Novel O
block O
copolymers O
comprising O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
and O
an O
oligo O
( O
tyrosine O
) O
block O
were O
synthesized O
in O
different O
compositions O
by O
N O
- O
carboxyanhydride O
( O
NCA O
) O
polymerization O
. O

Circular O
dichroism O
( O
CD O
) O
results O
suggest O
that O
better O
packing O
of O
the O
beta O
- O
sheet O
tyrosine B
block O
at O
increasing O
temperature O
induces O
the O
reverse O
thermogelation O
. O

1 O
. O
When O
benzophenone O
- O
3 O
( O
2 O
- O
hydroxy O
- O
4 O
- O
methoxybenzophenone O
; O
BP O
- O
3 O
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 O
, O
5 O
- O
dihydroxy O
- O
4 O
- O
methoxybenzophenone O
( O
5 O
- O
OH O
- O
BP O
- O
3 O
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP O
- O
3 O
. O

The O
4 O
- O
desmethylated O
metabolite O
, O
2 B
, I
4 I
- I
dihydroxybenzophenon I
( O
2 O
, O
4 O
- O
diOH O
- O
BP O
) O
, O
previously O
reported O
as O
the O
major O
in O
vivo O
metabolite O
of O
BP O
- O
3 O
, O
was O
also O
detected O
. O

2 O
. O
The O
oxidase O
activity O
affording O
5 O
- O
OH O
- O
BP O
- O
3 O
was O
inhibited O
by O
SKF O
525 O
- O
A O
and O
ketoconazole B
, O
and O
partly O
by O
quinidine B
and O
sulfaphenazole O
. O

The O
oxidase O
activity O
affording O
2 O
, O
4 O
- O
diOH O
- O
BP O
was O
inhibited O
by O
SKF O
525 O
- O
A O
, O
ketoconazole B
and O
alpha O
- O
naphthoflavone O
, O
and O
partly O
by O
sulfaphenazole O
. O

3 O
. O
The O
oxidase O
activity O
affording O
5 O
- O
OH O
- O
BP O
- O
3 O
was O
enhanced O
in O
liver O
microsomes O
of O
dexamethasone B
- O
, O
phenobarbital B
- O
and O
3 B
- I
methylcholanthrene I
- O
treated O
rats O
. O

The O
activity O
affording O
2 O
, O
4 O
- O
diOH O
- O
BP O
was O
enhanced O
in O
liver O
microsomes O
of O
3 B
- I
methylcholanthrene I
- O
and O
phenobarbital B
- O
treated O
rats O
. O

GIP O
potentiates O
glucose B
- O
stimulated O
insulin O
secretion O
and O
induces O
energy O
accumulation O
into O
adipose O
tissue O
, O
resulting O
in O
obesity O
. O

The O
crystal O
structure O
of O
the O
protein O
- O
disulfide B
isomerase O
family O
member O
ERp27 O
provides O
insights O
into O
its O
substrate O
binding O
capabilities O
. O

Protein O
- O
disulfide B
isomerase O
( O
PDI O
) O
and O
related O
members O
of O
the O
PDI O
family O
assist O
in O
the O
folding O
of O
substrates O
by O
catalyzing O
the O
oxidation O
of O
two O
cysteines B
and O
isomerization O
of O
disulfide B
bonds O
as O
well O
as O
by O
acting O
as O
chaperones O
. O

Leukocyte O
adhesion O
during O
inflammation O
is O
initiated O
by O
the O
binding O
of O
sialofucosylated O
carbohydrates B
expressed O
on O
leukocytes O
to O
endothelial O
E O
/ O
P O
- O
selectin O
. O

Results O
demonstrate O
that O
predominantly O
FUT7 O
, O
and O
to O
a O
lesser O
extent O
FUT4 O
, O
forms O
the O
selectin O
- O
ligand O
at O
the O
N B
terminus O
of O
leukocyte O
P O
- O
selectin O
glycoprotein O
ligand O
- O
1 O
( O
PSGL O
- O
1 O
) O
in O
humans O
and O
mice O
. O

A O
family O
of O
cheap O
and O
easily O
accessible O
beta O
- O
amino O
alcohols O
, O
obtained O
in O
one O
step O
from O
naturally O
occurring O
amino B
acids I
, O
was O
shown O
to O
successfully O
catalyze O
the O
asymmetric O
aldol O
reaction O
between O
a O
series O
of O
ketones B
and O
aromatic B
aldehydes I
. O

Diet O
, O
physical O
exercise O
and O
Orlistat B
administration O
increase O
serum O
Anti O
- O
M O
u O
llerian O
Hormone O
( O
AMH O
) O
levels O
in O
women O
with O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
. O

The O
present O
study O
investigates O
the O
combined O
effect O
of O
diet O
, O
physical O
exercise O
and O
Orlistat B
for O
24 O
weeks O
, O
on O
serum O
Anti O
- O
M O
u O
llerian O
Hormone O
( O
AMH O
) O
levels O
in O
overweight O
and O
obese O
women O
with O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
and O
in O
overweight O
and O
obese O
controls O
. O

Sixty O
- O
one O
( O
61 O
) O
selected O
women O
with O
PCOS O
and O
20 O
overweight O
and O
obese O
controls O
followed O
an O
energy O
- O
restricted O
diet O
, O
physical O
exercise O
plus O
Orlistat B
administration O
( O
120 O
mg O
, O
3 O
times O
per O
day O
) O
for O
24 O
weeks O
. O

At O
baseline O
, O
week O
12 O
and O
week O
24 O
, O
serum O
levels O
of O
AMH O
, O
FSH O
, O
LH O
, O
PRL O
, O
androgens B
, O
sex O
hormone O
- O
binding O
globulin O
( O
SHBG O
) O
, O
glucose B
, O
and O
insulin O
were O
measured O
and O
Free O
Androgen B
Index O
( O
FAI O
) O
and O
Insulin O
Resistance O
( O
IR O
) O
indices O
were O
calculated O
. O

After O
12 O
weeks O
LH O
and O
SHBG O
were O
increased O
, O
while O
Testosterone B
decreased O
. O

We O
concluded O
that O
in O
overweight O
and O
obese O
women O
with O
PCOS O
Orlistat B
administration O
, O
combined O
with O
diet O
and O
physical O
exercise O
, O
for O
24 O
weeks O
, O
resulted O
in O
significant O
weight O
loss O
, O
improvement O
of O
hyperandrogenism O
and O
insulin O
sensitivity O
, O
and O
increased O
serum O
AMH O
levels O
. O

For O
this O
purpose O
, O
sulfonate B
, O
carboxylate B
, O
and O
hydroxyl B
groups O
were O
incorporated O
on O
self O
- O
assembled O
peptide O
nanofibers O
. O

Experimentally O
engineering O
the O
edge O
termination O
of O
graphene B
nanoribbons O
. O

The O
edges O
of O
graphene B
nanoribbons O
( O
GNRs O
) O
have O
attracted O
much O
interest O
due O
to O
their O
potentially O
strong O
influence O
on O
GNR O
electronic O
and O
magnetic O
properties O
. O

Here O
we O
report O
the O
ability O
to O
engineer O
the O
microscopic O
edge O
termination O
of O
high O
- O
quality O
GNRs O
via O
hydrogen B
plasma O
etching O
. O

We O
find O
that O
the O
edges O
of O
hydrogen B
- O
plasma O
- O
etched O
GNRs O
are O
generally O
flat O
, O
free O
of O
structural O
reconstructions O
, O
and O
terminated O
by O
hydrogen B
atoms O
with O
no O
rehybridization O
of O
the O
outermost O
carbon B
edge O
atoms O
. O

Mice O
fed O
ad O
lib O
. O
on O
any O
of O
the O
palatable O
diets O
were O
heavier O
, O
fatter O
and O
had O
higher O
blood O
leptin O
than O
controls O
, O
and O
had O
reduced O
NPY O
and O
increased O
cocaine B
- O
and O
- O
amphetamine B
- O
regulated O
transcript O
mRNA O
in O
the O
ARC O
. O

However O
, O
assessment O
of O
opioid O
and O
dopamine B
receptor O
gene O
expression O
in O
the O
NAcc O
did O
not O
reveal O
evidence O
of O
the O
involvement O
of O
these O
genes O
in O
driving O
large O
meals O
, O
at O
least O
at O
the O
investigated O
time O
point O
. O

Alteration O
in O
structure O
of O
Ara O
h O
6 O
was O
characterised O
by O
circular O
dichroism O
( O
CD O
) O
spectroscopy O
, O
ultraviolet O
( O
UV O
) O
absorption O
spectroscopy O
, O
fluorescence O
spectroscopy O
and O
SDS B
- O
PAGE O
, O
and O
antigenicity O
was O
evaluated O
by O
immunoblotting O
and O
indirect O
ELISA O
with O
anti O
- O
Ara O
h O
6 O
polyclonal O
antibody O
. O

Analysis O
of O
total O
polyphenols B
in O
wines O
by O
FIA O
with O
highly O
stable O
amperometric O
detection O
using O
carbon B
nanotube O
- O
modified O
electrodes O
. O

The O
use O
of O
glassy O
carbon B
electrodes O
( O
GCEs O
) O
modified O
with O
multi O
- O
walled O
carbon B
nanotube O
( O
CNT O
) O
films O
for O
the O
continuous O
monitoring O
of O
polyphenols B
in O
flow O
systems O
has O
been O
examined O
. O

The O
performance O
of O
these O
modified O
electrodes O
was O
evaluated O
and O
compared O
to O
bare O
GCE O
by O
cyclic O
voltammetry O
experiments O
and O
by O
flow O
injection O
analysis O
( O
FIA O
) O
with O
amperometric O
detection O
monitoring O
the O
response O
of O
gallic O
, O
caffeic O
, O
ferulic O
and O
p O
- O
coumaric O
acids O
in O
0 O
. O
050 O
M O
acetate B
buffer O
pH O
4 O
. O
5 O
containing O
100 O
mM O
NaCl B
. O

The O
GCE O
modified O
with O
CNT O
dispersions O
in O
polyethyleneimine B
( O
PEI B
) O
provided O
lower O
overpotentials O
, O
higher O
sensitivity O
and O
much O
higher O
signal O
stability O
under O
a O
dynamic O
regime O
than O
bare O
GCEs O
. O

These O
properties O
allowed O
the O
estimation O
of O
the O
total O
polyphenol B
content O
in O
red O
and O
white O
wines O
with O
a O
remarkable O
long O
- O
term O
stability O
in O
the O
measurements O
despite O
the O
presence O
of O
potential O
fouling O
substances O
in O
the O
wine O
matrix O
. O

In O
addition O
, O
the O
versatility O
of O
the O
electrochemical O
methodology O
allowed O
the O
selective O
estimation O
of O
the O
easily O
oxidisable O
polyphenol B
fraction O
as O
well O
as O
the O
total O
polyphenol B
content O
just O
by O
tuning O
the O
detection O
potential O
at O
+ O
0 O
. O
30 O
or O
0 O
. O
70 O
V O
, O
respectively O
. O

The O
significance O
of O
the O
electrochemical O
results O
was O
demonstrated O
through O
correlation O
studies O
with O
the O
results O
obtained O
with O
conventional O
spectrophotometric O
assays O
for O
polyphenols B
( O
Folin O
- O
Ciocalteu O
, O
absorbance O
at O
280 O
nm O
index O
and O
colour O
intensity O
index O
) O
. O

The O
heat O
treatment O
and O
the O
gelation O
are O
strong O
determinants O
of O
the O
kinetics O
of O
milk O
proteins O
digestion O
and O
of O
the O
peripheral O
availability O
of O
amino B
acids I
. O

This O
study O
aimed O
to O
determine O
the O
kinetics O
of O
milk O
protein O
digestion O
and O
amino B
acid I
absorption O
after O
ingestion O
of O
four O
dairy O
matrices O
by O
six O
minipigs O
: O
unheated O
or O
heated O
skim O
milk O
and O
corresponding O
rennet O
gels O
. O

Gelation O
of O
milk O
slowed O
down O
the O
outflow O
of O
the O
meal O
from O
the O
stomach O
and O
the O
subsequent O
absorption O
of O
amino B
acids I
, O
and O
decreased O
their O
bioavailability O
in O
peripheral O
blood O
. O

The O
in O
vivo O
antioxidant O
and O
antifibrotic O
properties O
of O
green O
tea O
( O
Camellia O
sinensis O
, O
Theaceae O
) O
were O
investigated O
with O
a O
study O
of O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
) O
- O
induced O
oxidative O
stress O
and O
hepatic O
fibrosis O
in O
male O
ICR O
mice O
. O

Oral O
administration O
of O
green O
tea O
extract O
at O
doses O
of O
125 O
, O
625 O
and O
1250 O
mg O
/ O
kg O
for O
8 O
weeks O
significantly O
reduced O
( O
p O
< O
0 O
. O
05 O
) O
the O
levels O
of O
thiobarbituric B
acid I
- O
reactive O
substances O
( O
TBARS O
) O
and O
protein O
carbonyls B
in O
the O
liver O
by O
at O
least O
28 O
% O
compared O
with O
that O
was O
induced O
by O
CCl B
( I
4 I
) I
( O
1 O
mL O
/ O
kg O
) O
in O
mice O
. O

Moreover O
, O
green O
tea O
extract O
administration O
significantly O
increased O
( O
p O
< O
0 O
. O
05 O
) O
the O
activities O
of O
catalase O
, O
glutathione B
peroxidase O
( O
GSH B
- O
Px O
) O
and O
glutathione B
reductase O
( O
GSH B
- O
Rd O
) O
in O
the O
liver O
. O

Our O
study O
found O
that O
oral O
administration O
of O
green O
tea O
extract O
prevented O
CCl B
( I
4 I
) I
- O
induced O
hepatic O
fibrosis O
, O
as O
evidenced O
by O
a O
decreased O
hydroxyproline B
level O
in O
the O
liver O
and O
a O
reduced O
incidence O
of O
hepatic O
fibrosis O
by O
histological O
observations O
. O

These O
results O
indicate O
that O
green O
tea O
exhibits O
potent O
protective O
effects O
against O
CCl B
( I
4 I
) I
- O
induced O
oxidative O
stress O
and O
hepatic O
fibrosis O
in O
mice O
by O
inhibiting O
oxidative O
damage O
and O
increasing O
antioxidant O
enzyme O
activities O
. O

Protein O
carbonyls B
were O
lower O
in O
the O
group O
that O
consumed O
WPH O
. O

Information O
concerning O
the O
C B
- O
terminal O
pentapeptide O
is O
considered O
to O
describe O
the O
peptide O
structure O
in O
the O
model O
. O

The O
whole O
C B
- O
terminal O
pentapeptide O
information O
is O
a O
determinant O
for O
modelling O
the O
ACE O
inhibition O
activity O
of O
oligopeptides O
. O

Starting O
from O
the O
C B
- O
terminus O
, O
the O
C O
- O
1 O
position O
is O
the O
most O
relevant O
position O
in O
the O
model O
; O
this O
is O
followed O
by O
position O
C O
- O
4 O
. O

However O
, O
in O
the O
C O
- O
4 O
position O
, O
the O
model O
indicates O
a O
clear O
preference O
for O
bulky O
hydrophobic O
amino B
acids I
and O
for O
sulphur O
- O
containing O
amino B
acids I
. O

Total O
polyphenols B
, O
catechin B
profiles O
and O
antioxidant O
activity O
of O
tea O
products O
from O
purple O
leaf O
coloured O
tea O
cultivars O
. O

Black O
( O
aerated O
) O
and O
green O
( O
unaerated O
) O
tea O
products O
, O
processed O
from O
10 O
green O
and O
18 O
purple O
leaf O
coloured O
cultivars O
of O
Kenyan O
origin O
, O
and O
two O
tea O
products O
, O
from O
the O
Japanese O
cultivars O
, O
Yabukita O
and O
Yutakamidori O
, O
were O
assayed O
for O
total O
polyphenols B
( O
TP O
) O
content O
, O
individual O
catechin B
profiles O
and O
in O
vitro O
antioxidant O
capacity O
( O
AA O
) O
. O

In O
addition O
, O
the O
phenolic B
content O
of O
the O
tea O
products O
was O
determined O
using O
the O
Folin O
- O
Ciocalteu O
phenol O
reagent O
. O

Catechin B
fractions O
were O
identified O
using O
reverse O
phase O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
a O
binary O
gradient O
elution O
system O
. O

The O
AA O
% O
of O
the O
tea O
products O
was O
determined O
using O
a O
2 O
, O
2 O
' O
- O
diphenyl O
picrylhydrazyl O
( O
DPPH B
) O
radical O
assay O
method O
. O

The O
results O
showed O
that O
TPs O
, O
catechin B
profiles O
and O
antioxidant O
activities O
were O
significantly O
( O
p O
< O
= O
0 O
. O
05 O
) O
higher O
in O
unaerated O
than O
in O
aerated O
teas O
. O

Tea O
products O
from O
the O
purple O
leaf O
coloured O
tea O
cultivars O
had O
levels O
of O
TPs O
, O
total O
catechin B
( O
TC O
) O
and O
antioxidant O
activities O
similar O
to O
those O
from O
the O
green O
leaf O
coloured O
cultivars O
, O
except O
for O
teas O
from O
the O
Japanese O
cultivars O
that O
were O
very O
low O
in O
the O
assayed O
parameters O
. O

Caffeine B
content O
was O
significantly O
( O
p O
< O
= O
0 O
. O
05 O
) O
lower O
in O
products O
from O
the O
purple O
leaf O
coloured O
cultivars O
than O
in O
those O
from O
the O
green O
leaf O
coloured O
tea O
cultivars O
. O

Antioxidant O
potency O
of O
tea O
products O
was O
significantly O
( O
r O
= O
0 O
. O
789 O
( O
* O
* O
) O
, O
p O
< O
= O
0 O
. O
01 O
) O
influenced O
by O
the O
total O
anthocyanin B
content O
of O
the O
purple O
leaf O
coloured O
cultivars O
. O

Cyanidin O
- O
3 O
- O
O O
- O
glucoside O
was O
the O
anthocyanin B
most O
highly O
correlated O
with O
AA O
% O
( O
r O
= O
0 O
. O
843 O
( O
* O
* O
) O
, O
p O
< O
= O
0 O
. O
01 O
in O
unaerated O
tea O
) O
. O

Total O
catechins B
in O
the O
unaerated O
products O
from O
the O
green O
leaf O
coloured O
tea O
cultivars O
were O
also O
significantly O
correlated O
with O
antioxidant O
capacity O
( O
r O
= O
0 O
. O
818 O
( O
* O
* O
) O
, O
p O
< O
= O
0 O
. O
01 O
) O
. O

Results O
from O
this O
study O
suggest O
that O
the O
antioxidant O
potency O
of O
teas O
is O
dependent O
on O
the O
predominant O
flavonoid B
compound O
, O
the O
type O
of O
tea O
cultivar O
and O
the O
processing O
method O
. O

The O
samples O
were O
extracted O
with O
acetonitrile B
followed O
by O
partitioning O
at O
- O
80 O
degrees O
C O
for O
5 O
- O
10 O
min O
. O

A O
Cyclocarya O
paliurus O
( O
Batal O
. O
) O
Iljinskaja O
polysaccharide O
( O
CPP O
) O
was O
isolated O
and O
purified O
by O
hot O
water O
extraction O
, O
ethanol B
precipitation O
, O
deproteinisation O
and O
anion O
- O
exchange O
chromatography O
. O

The O
anticancer O
effect O
of O
CPP O
in O
human O
gastric O
cancer O
HeLa O
cells O
was O
also O
evaluated O
by O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
. O

The O
results O
showed O
that O
the O
molecular O
weight O
of O
CPP O
was O
900 O
kDa O
, O
and O
it O
contained O
64 O
. O
8 O
% O
total O
sugar O
, O
23 O
. O
5 O
% O
uronic O
acid O
, O
9 O
. O
26 O
% O
protein O
, O
and O
six O
kinds O
of O
monosaccharides B
, O
including O
glucose B
, O
rhamnose O
, O
arabinose B
, O
xylose B
, O
mannose B
and O
galactose B
, O
with O
molar O
percentages O
of O
32 O
. O
7 O
% O
, O
9 O
. O
33 O
% O
, O
30 O
. O
6 O
% O
, O
3 O
. O
48 O
% O
, O
10 O
. O
4 O
% O
, O
and O
13 O
. O
5 O
% O
, O
respectively O
. O

Long O
term O
compulsivity O
on O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
after O
acute O
Chlorpyrifos B
exposure O
. O

In O
the O
present O
study O
, O
we O
investigated O
whether O
acute O
exposure O
to O
organophosphate B
( O
OP O
) O
chlorpyrifos B
( O
CPF O
) O
is O
related O
to O
long O
- O
term O
lack O
of O
inhibitory O
control O
; O
we O
also O
examined O
the O
possible O
neurochemical O
basis O
of O
this O
association O
. O

We O
manipulated O
the O
baseline O
conditions O
of O
this O
task O
and O
also O
systemically O
pre O
- O
administered O
d B
- I
amphetamine I
, O
quinpirole B
, O
dizocilpine O
( O
MK B
- I
801 I
) O
or O
ketanserin O
. O

We O
also O
analysed O
the O
post O
- O
mortem O
baseline O
levels O
of O
monoamines B
and O
amino B
acids I
in O
different O
brain O
regions O
. O

Only O
D B
- I
amphetamine I
induced O
a O
dose O
- O
dependent O
amelioration O
of O
the O
increased O
perseverative O
responses O
in O
the O
CPF O
group O
. O

The O
CPF O
group O
also O
exhibited O
increased O
levels O
of O
dopamine B
metabolism O
in O
the O
hippocampus O
and O
decreased O
levels O
of O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
and O
glutamate B
in O
the O
striatum O
compared O
to O
the O
vehicle O
group O
. O

These O
findings O
suggest O
that O
CPF O
induced O
a O
long O
- O
term O
compulsivity O
that O
was O
apparent O
in O
the O
5 O
- O
CSRT O
task O
and O
associated O
with O
changes O
in O
monoaminergic O
and O
amino B
acid I
brain O
systems O
of O
inhibitory O
control O
function O
. O

A O
variety O
of O
5 O
- O
, O
6 O
- O
and O
8 O
- O
( O
4 O
- O
aminobutyloxy O
) O
quinolines O
as O
novel O
oxygen B
analogues O
of O
known O
4 O
- O
and O
8 O
- O
( O
4 O
- O
aminobutylamino O
) O
quinoline O
antimalarial O
drugs O
was O
generated O
from O
hydroxyquinolines O
through O
a O
three O
- O
step O
approach O
with O
a O
rhodium O
- O
catalyzed O
hydroformylation O
as O
the O
key O
step O
. O

Antiplasmodial O
assays O
of O
these O
new O
quinolines B
revealed O
micromolar O
potency O
for O
all O
representatives O
against O
a O
chloroquine B
- O
sensitive O
strain O
of O
Plasmodium O
falciparum O
, O
and O
three O
compounds O
showed O
submicromolar O
activity O
against O
a O
chloroquine B
- O
resistant O
strain O
of O
P O
. O
falciparum O
with O
IC O
( O
50 O
) O
- O
values O
ranging O
between O
150 O
and O
680 O
nM O
. O

Reproductive O
experience O
modifies O
the O
effects O
of O
estradiol B
on O
learning O
and O
memory O
bias O
in O
female O
rats O
. O

Previous O
studies O
have O
shown O
that O
estrogen B
affects O
whether O
a O
hippocampus O
- O
mediated O
place O
( O
allocentric O
) O
or O
a O
striatum O
- O
mediated O
response O
( O
egocentric O
) O
memory O
system O
is O
employed O
by O
female O
rats O
when O
searching O
for O
a O
food O
reward O
in O
a O
maze O
. O

All O
rats O
were O
exposed O
to O
no O
, O
chronic O
low O
or O
chronic O
low O
with O
pulsatile O
high O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
replacement O
. O

Ubiquitin O
- O
dependent O
regulation O
of O
phospho B
- O
AKT O
dynamics O
by O
the O
ubiquitin O
E3 O
ligase O
, O
NEDD4 O
- O
1 O
, O
in O
the O
insulin O
- O
like O
growth O
factor O
- O
1 O
response O
. O

Mechanisms O
underlying O
activated O
phospho B
- O
AKT O
( O
pAKT O
) O
translocation O
to O
its O
action O
sites O
remain O
unclear O
. O

Although O
the O
tumor O
- O
promoting O
effects O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
coplanar O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
and O
related O
compounds O
in O
liver O
tissue O
are O
primarily O
attributed O
to O
the O
activation O
of O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
the O
underlying O
molecular O
mechanisms O
are O
still O
unclear O
. O

AhR O
- O
and O
ARNT O
- O
dependent O
regulation O
of O
selected O
target O
genes O
of O
interest O
was O
then O
confirmed O
using O
TCDD B
as O
a O
model O
AhR O
agonist O
, O
together O
with O
pharmacological O
inhibition O
of O
the O
AhR O
and O
by O
RNA O
- O
interference O
techniques O
. O

Photochemical O
properties O
and O
activity O
of O
water O
- O
soluble O
polymer O
/ O
c B
( I
60 I
) I
nanohybrids O
for O
photodynamic O
therapy O
. O

Water O
- O
soluble O
star O
- O
like O
poly B
( I
vinyl I
alcohol I
) I
/ O
C B
( I
60 I
) I
and O
poly O
{ O
[ O
poly O
( O
ethylene O
glycol O
) O
acrylate O
] O
- O
co O
- O
( O
vinyl O
acetate O
) O
} O
/ O
C B
( I
60 I
) I
nanohybrids O
are O
prepared O
by O
grafting O
macroradicals O
onto O
C B
( I
60 I
) I
and O
are O
assessed O
as O
photosensitizers O
for O
photodynamic O
therapy O
. O

The O
macromolecular O
structure O
( O
linear O
/ O
graft O
) O
and O
nature O
( O
presence O
/ O
absence O
of O
hydroxyl B
groups O
) O
of O
the O
polymeric O
arms O
respectively O
impact O
the O
photodynamic O
activity O
and O
the O
stealthiness O
of O
the O
nanohybrids O
. O

The O
advantages O
of O
both O
nanohybrids O
are O
encountered O
in O
a O
third O
one O
, O
poly O
[ O
( O
N O
- O
vinylpyrrolidone O
) O
- O
co O
- O
( O
vinyl O
acetate O
) O
] O
/ O
C B
( I
60 I
) I
, O
which O
has O
linear O
grafts O
without O
hydroxyl B
groups O
, O
and O
shows O
a O
better O
photodynamic O
activity O
. O

Identification O
of O
transporters O
associated O
with O
Etoposide B
sensitivity O
of O
stomach O
cancer O
cell O
lines O
and O
methotrexate B
sensitivity O
of O
breast O
cancer O
cell O
lines O
by O
quantitative O
targeted O
absolute O
proteomics O
. O

In O
stomach O
cancer O
cell O
lines O
, O
the O
protein O
expression O
level O
of O
multidrug O
resistance O
- O
associated O
protein O
1 O
( O
MRP1 O
) O
was O
inversely O
correlated O
with O
etoposide B
sensitivity O
. O

MK571 B
, O
an O
MRP O
inhibitor O
, O
increased O
both O
the O
cell O
- O
to O
- O
medium O
ratio O
of O
etoposide O
and O
the O
etoposide O
sensitivity O
of O
MRP1 O
- O
expressing O
stomach O
cancer O
cell O
lines O
. O

In O
breast O
cancer O
cell O
lines O
, O
the O
protein O
expression O
level O
of O
reduced O
folate O
carrier O
1 O
( O
RFC1 O
) O
was O
directly O
correlated O
with O
methotrexate B
( O
MTX B
) O
sensitivity O
. O

Initial O
uptake O
rate O
and O
steady O
- O
state O
cell O
- O
to O
- O
medium O
ratio O
of O
[ O
( O
3 O
) O
H O
] O
MTX O
were O
correlated O
with O
both O
RFC1 O
expression O
level O
and O
MTX B
sensitivity O
. O

These O
results O
suggest O
that O
MRP1 O
modulates O
the O
etoposide B
sensitivity O
of O
stomach O
cancer O
cell O
lines O
and O
RFC1 O
modulates O
the O
MTX B
sensitivity O
of O
breast O
cancer O
cell O
lines O
. O

In O
the O
present O
studies O
, O
the O
effects O
of O
CB O
( O
1 O
) O
agonists O
[ O
( O
6aR O
, O
10aR O
) O
- O
3 O
- O
( O
1 O
- O
adamantyl O
) O
- O
6 O
, O
6 O
, O
9 O
- O
trimethyl O
- O
6a O
, O
7 O
, O
10 O
, O
10a O
- O
tetrahydrobenzo O
[ O
c O
] O
chromen O
- O
1 O
- O
ol O
( O
AM411 O
) O
, O
9 O
beta O
- O
( O
hydroxymethyl O
) O
- O
3 O
- O
( O
1 O
- O
adamantyl O
) O
- O
hexahydrocannabinol O
( O
AM4054 B
) O
, O
R O
- O
( O
+ O
) O
- O
[ O
2 O

, O
3 O
- O
dihydro O
- O
5 O
- O
methyl O
- O
3 O
- O
[ O
( O
morpholinyl O
) O
methyl O
] O
pyrrolo O
[ O
1 O
, O
2 O
, O
3 O
- O
de O
] O
- O
1 O
, O
4 O
- O
benzoxazinyl O
] O
- O
( O
1 O
- O
naphthalenyl O
) O
methanone O
mesylate O
( O
WIN55 O
, O
212 O
. O
2 O
) O
, O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta O
( O
9 O
) O
- O
THC O
) O
, O
( O
R O
) O
- O
( O
+ O
) O
- O
arachidonyl O
- O
1 O
' O
- O
hydroxy O
- O
2 O
' O
- O

propylamide O
( O
methanandamide O
) O
] O
, O
CB O
( O
1 O
) O
antagonists O
[ O
5 O
- O
( O
4 O
- O
chlorophenyl O
) O
- O
1 O
- O
( O
2 O
, O
4 O
- O
dichloro O
- O
phenyl O
) O
- O
4 O
- O
methyl O
- O
N O
- O
( O
piperidin O
- O
1 O
- O
yl O
) O
- O
1H O
- O
pyrazole O
- O
3 O
- O
carboxamide O
( O
SR141716A B
) O
, O
5 O
- O
( O
4 O
- O
alkylphenyl O
) O
- O
1 O
- O
( O
2 O
, O
4 O
- O
dichlorophenyl O
) O
- O
4 O
- O
methyl O
- O
N O
- O
( O

piperidin O
- O
1 O
- O
yl O
) O
- O
1H O
- O
pyrazole O
- O
3 O
- O
carboxamide O
( O
AM4113 O
) O
] O
, O
and O
dopamine B
( O
DA O
) O
- O
related O
[ O
methamphetamine B
, O
( O
+ O
/ O
- O
) O
- O
6 O
- O
chloro O
- O
7 O
, O
8 O
- O
dihydroxy O
- O
3 O
- O
allyl O
- O
1 O
- O
phenyl O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrahydro O
- O
1H O
- O
3 O
- O
benzazepine O
hydrobromide O
( O
SKF82958 O
) O
, O
( O
R O
) O
- O
( O
+ O
) O
- O
7 O

- O
chloro O
- O
8 O
- O
hydroxy O
- O
3 O
- O
methyl O
- O
1 O
- O
phenyl O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrahydro O
- O
1H O
- O
3 O
- O
benzazepine O
hydrochloride O
( O
SCH23390 O
) O
, O
( O
6aR O
) O
- O
5 O
, O
6 O
, O
6a O
, O
7 O
- O
tetrahydro O
- O
6 O
- O
propyl O
- O
4H O
- O
dibenzo O
[ O
de O
, O
g O
] O
quinoline O
- O
10 O
, O
11 O
- O
diol O
( O
R O
- O
( O
- O
) O
- O
NPA O
) O
, O
haloperidol B
] O
and O

opioid O
( O
morphine B
, O
naltrexone O
) O
drugs O
on O
scheduled O
- O
controlled O
responding O
under O
a O
30 O
- O
response O
fixed O
ratio O
schedule O
of O
stimulus O
- O
shock O
termination O
in O
squirrel O
monkeys O
were O
compared O
before O
and O
during O
chronic O
treatment O
with O
the O
long O
- O
acting O
CB O
( O
1 O
) O
agonist O
AM411 O
( O
1 O
. O
0 O
mg O
/ O
kg O
per O
day O
, O
i O
. O
m O
. O
) O
. O

Dose O
- O
response O
re O
- O
determinations O
during O
chronic O
treatment O
revealed O
the O
following O
: O
1 O
) O
> O
250 O
- O
fold O
( O
AM411 O
, O
methanandamide O
) O
and O
> O
45 O
- O
fold O
( O
AM4054 B
, O
WIN55 B
, I
212 I
. I
2 I
, O
Delta O
( O
9 O
) O
- O
THC O
) O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
CB O
( O
1 O
) O
agonists O
; O
2 O
) O
> O
100 O
- O
fold O
and O
> O
20 O
- O
fold O
leftward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
SR141716A B
and O
AM4113 B
, O
respectively O
; O
and O
3 O
) O
approximately O
4 O
. O
8 O
- O
fold O
and O
10 O
- O

fold O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
methamphetamine B
and O
the O
DA O
D O
( O
2 O
) O
agonist O
R O
- O
( O
- O
) O
- O
NPA O
, O
respectively O
. O

Finally O
, O
the O
development O
of O
cross O
- O
tolerance O
to O
methamphetamine B
and O
R O
- O
( O
- O
) O
- O
NPA O
bolsters O
previous O
evidence O
of O
interplay O
between O
CB O
( O
1 O
) O
and O
DA O
D O
( O
2 O
) O
signaling O
mechanisms O
. O

Amylose O
, O
a O
linear O
polymer O
of O
alpha O
( O
1 O
, O
4 O
) O
- O
linked O
glucosyl O
units O
and O
a O
major O
constituent O
of O
starch O
granules O
, O
can O
also O
be O
enzymatically O
synthesized O
in O
vitro O
from O
sucrose B
by O
bacterial O
amylosucrases O
. O

Depending O
on O
the O
initial O
sucrose B
concentration O
and O
the O
enzyme O
used O
, O
amylose O
oligomers O
( O
or O
polymers O
) O
are O
formed O
and O
self O
- O
associate O
during O
synthesis O
into O
various O
semicrystalline O
morphologies O
. O

At O
75 O
degrees O
C O
, O
maximum O
activity O
decreased O
to O
non O
detectable O
values O
of O
7 O
. O
9 O
% O
for O
free O
laccase O
, O
manganese B
peroxidase O
( O
MnP O
) O
, O
lignin O
peroxidase O
( O
LiP O
) O
, O
respectively O
; O
to O
94 O
% O
, O
97 O
% O
, O
93 O
% O
for O
laccase O
, O
MnP O
and O
LiP O
entrapped O
into O
Polyacrylamide B
/ O
pectin O
, O
94 O
% O
, O
98 O
% O
, O
88 O
% O
for O
laccase O
, O
MnP O
and O
LiP O
encapsulated O
respectively O
into O
polyacrylamide B
/ O
gelatine O
and O
to O
87 O
% O
, O
91 O

% O
, O
87 O
% O
for O
laccase O
, O
MnP O
and O
LiP O
entrapped O
, O
respectively O
into O
polyacrylamide B
/ O
carboxymethylcellulo O
( O
CMC O
) O
. O

Effect O
of O
high O
- O
pressure O
treatment O
on O
biogenic O
amines B
formation O
in O
vacuum O
- O
packed O
trout O
flesh O
( O
Oncorhynchus O
mykiss O
) O
. O

The O
content O
of O
eight O
biogenic O
amines B
( O
putrescine B
, O
cadaverine O
, O
spermidine B
, O
spermine B
, O
histamine B
, O
tyramine B
, O
tryptamine B
and O
phenylethylamine O
) O
were O
determined O
. O

Putrescine B
, O
cadaverine O
and O
tyramine B
showed O
very O
good O
correspondence O
with O
the O
level O
of O
applied O
pressure O
and O
organoleptic O
properties O
. O

Samples O
of O
very O
good O
quality O
contained O
less O
than O
10 O
mg O
/ O
kg O
of O
each O
of O
these O
amines B
. O

Polyamines B
spermidine B
and O
spermine B
did O
not O
show O
statistically O
significant O
changes O
with O
the O
level O
of O
applied O
pressure O
and O
the O
time O
of O
storage O
. O

Tryptamine B
, O
phenylethylamine O
and O
histamine B
( O
with O
the O
single O
exception O
of O
a O
sample O
stored O
for O
70 O
days O
) O
were O
not O
detected O
in O
pressure O
- O
treated O
samples O
kept O
at O
3 O
. O
5 O
degrees O
C O
. O

GC O
- O
olfactometry O
analysis O
of O
the O
hydrolysates O
of O
ripe O
' O
Hayward O
' O
and O
' O
Hort16A O
' O
revealed O
the O
presence O
of O
2 O
- O
phenylethanol O
, O
beta O
- O
damascenone O
, O
vanillin B
and O
2 O
, O
5 O
- O
dimethyl O
- O
4 O
- O
hydroxy O
- O
3 O
( O
2H O
) O
- O
furanone O
( O
DMHF O
) O
. O

Proximate O
composition O
, O
fatty B
acid I
profile O
, O
cholesterol B
, O
alpha O
- O
tocoferol O
content O
and O
essential O
( O
K B
, O
Na B
, O
Cl B
, O
S B
, O
Mg B
, O
Ca B
, O
Zn B
, O
Cu B
, O
Fe B
, O
Mn B
, O
and O
Se B
) O
and O
contaminant O
element O
( O
Hg B
/ O
MeHg B
, O
Cd B
, O
Pb B
, O
and O
As B
) O
levels O
in O
silver B
scabbardfish O
( O
Lepidopus O
caudatus O
) O
, O
hake O
( O
Merluccius O
merluccius O
) O
, O
and O
ray O
( O
Raja O
spp O
. O
) O
were O
investigated O
. O

Results O
showed O
that O
these O
species O
contain O
high O
protein O
, O
low O
cholesterol B
and O
energy O
levels O
, O
being O
its O
consumption O
recommended O
. O

Polyunsaturated B
fatty I
acids I
( O
PUFA B
) O
were O
the O
dominant O
group O
of O
the O
fatty B
acids I
, O
being O
80 O
% O
of O
the O
n O
- O
3 O
family O
. O

Attending O
to O
the O
dietary O
reference O
intakes O
( O
DRIs O
) O
, O
these O
fish O
species O
are O
a O
good O
source O
of O
Se B
and O
the O
other O
minerals O
can O
give O
a O
relevant O
contribution O
to O
the O
DRIs O
in O
a O
balanced O
diet O
. O

More O
than O
one O
weekly O
meal O
of O
silver B
scabbardfish O
has O
to O
be O
avoided O
due O
to O
the O
organic O
mercury B
concentration O
. O

The O
toxins O
were O
extracted O
with O
acetonitrile B
/ O
water O
( O
90 O
: O
10 O
, O
v O
/ O
v O
) O
containing O
0 O
. O
1 O
% O
formic B
acid I
and O
cleaned O
by O
HLB O
and O
GCB O
sorbents O
. O

Qualitative O
and O
quantitative O
detection O
for O
the O
analytes O
were O
carried O
out O
under O
the O
multiple O
reaction O
monitoring O
( O
MRM O
) O
in O
positive O
ionization O
mode O
after O
chromatography O
separation O
on O
a O
TSK O
- O
gel O
Amide B
- O
80 O
( O
R O
) O
column O
( O
150 O
mm O
x O
2 O
. O
0 O
mm O
x O
3 O
mu O
m O
) O
. O

N B
- O
alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O

Addition O
of O
a O
6 O
- O
aryl O
- O
4 O
, O
5 O
- O
dihydropyridazin O
- O
3 O
( O
2H O
) O
- O
one O
extension O
to O
the O
N B
- O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4 O
- O
inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O

In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3 O
/ O
4 O
inhibitors O
that O
suppress O
histamine B
- O
induced O
bronchoconstriction O
in O
vivo O
and O
exhibit O
promising O
anti O
- O
inflammatory O
activity O
via O
intratracheal O
administration O
. O

Lessons O
from O
the O
dissection O
of O
the O
activation O
functions O
( O
AF O
- O
1 O
and O
AF O
- O
2 O
) O
of O
the O
estrogen B
receptor O
alpha O
in O
vivo O
. O

Estrogens B
influence O
most O
of O
the O
physiological O
processes O
in O
mammals O
, O
including O
but O
not O
limited O
to O
reproduction O
, O
cognition O
, O
behavior O
, O
vascular O
system O
, O
metabolism O
and O
bone O
integrity O
. O

Given O
this O
widespread O
role O
for O
estrogen B
in O
human O
physiology O
, O
it O
is O
not O
surprising O
that O
estrogen B
influence O
the O
pathophysiology O
of O
numerous O
diseases O
, O
including O
cancer O
( O
of O
the O
reproductive O
tract O
as O
breast O
, O
endometrial O
but O
also O
colorectal O
, O
prostate O
, O
. O
. O
. O
) O
, O
as O
well O
as O
neurodegenerative O
, O
inflammatory O
- O
immune O
, O
cardiovascular O
and O
metabolic O
diseases O
, O
and O
osteoporosis O
. O

These O
actions O
are O
mediated O
by O
the O
activation O
of O
estrogen B
receptors O
( O
ER O
) O
alpha O
( O
ER O
alpha O
) O
and O
beta O
( O
ER O
beta O
) O
, O
which O
regulate O
target O
gene O
transcription O
( O
genomic O
action O
) O
through O
two O
independent O
activation O
functions O
( O
AF O
) O
- O
1 O
and O
AF O
- O
2 O
, O
but O
can O
also O
elicit O
rapid O
membrane O
initiated O
steroid B
signals O
( O
MISS O
) O
. O

However O
, O
the O
use O
of O
these O
estrogens B
or O
selective O
estrogen B
receptors O
modulators O
( O
SERMs O
) O
have O
also O
induced O
undesired O
effects O
. O

Effects O
of O
quercetin B
on O
mRNA O
expression O
of O
steroidogenesis O
genes O
in O
primary O
cultures O
of O
Leydig O
cells O
treated O
with O
atrazine B
. O

The O
effect O
of O
the O
phytoestrogen O
, O
quercetin B
( O
QT O
) O
on O
the O
reproductive O
toxicity O
of O
atrazine B
( O
ATZ O
) O
was O
explored O
in O
interstitial O
Leydig O
cells O
( O
ILCs O
) O
. O

We O
measured O
the O
mRNA O
expressions O
of O
steroidogenesis O
genes O
: O
steroidogenic O
acute O
regulatory O
protein O
( O
StAR O
) O
, O
3 B
beta I
- I
hydroxysteroid I
dehydrogenase O
( O
3 O
beta O
- O
HSD O
) O
, O
cytochrome O
- O
P450 O
( O
CYP O
) O
11A1 O
, O
insulin O
- O
like O
factor O
3 O
( O
INSL O
- O
3 O
) O
, O
CYP17A1 O
, O
inhibin O
- O
alpha O
( O
INH O
- O
alpha O
) O
, O
androgen B
receptor O
( O
AR O
) O
, O
estrogen B
receptor O
- O
alpha O
( O
ER O
- O
alpha O
) O
, O
and O
luteinising O
hormone O
receptor O
( O
LHR O
) O
in O
isolated O
ILCs O

The O
mRNA O
expression O
of O
tested O
genes O
increased O
with O
ATZ O
treatment O
and O
was O
normalized O
by O
quercetin B
except O
AR O
and O
ER O
- O
alpha O
expression O
. O

We O
also O
found O
that O
QT O
( O
50 O
mu O
M O
) O
increased O
the O
expressions O
of O
AR O
and O
ER O
- O
alpha O
in O
the O
presence O
of O
a O
sub O
- O
threshold O
level O
of O
cyclic B
- I
AMP I
at O
1h O
culture O
period O
to O
the O
levels O
seen O
with O
maximal O
stimulation O
of O
cyclic B
- I
AMP I
. O

Furthermore O
, O
the O
expressions O
of O
tested O
genes O
were O
unaffected O
by O
cyclic B
- I
AMP I
at O
6h O
when O
the O
stimulatory O
effects O
of O
ATZ O
on O
tested O
genes O
were O
sustained O
. O

These O
findings O
suggest O
that O
ATZ O
may O
stimulate O
the O
expression O
of O
tested O
steroidogenesis O
genes O
in O
ILCs O
via O
a O
mechanism O
independent O
of O
cyclic B
- I
AMP I
which O
was O
partially O
antagonize O
by O
QT O
. O

Effects O
of O
pubertal O
exposure O
to O
thiazole B
- O
Zn B
on O
thyroid O
function O
and O
development O
in O
female O
rats O
. O

Thiazole B
- O
Zn B
is O
a O
newly O
Chinese O
- O
created O
systemic O
fungicide O
, O
and O
belongs O
to O
the O
sort O
of O
thiadiazole O
compounds O
, O
some O
of O
which O
have O
been O
found O
to O
be O
thyroid O
disrupters O
. O

To O
determine O
the O
probable O
adverse O
effects O
of O
thiazole B
- O
Zn B
on O
thyroid O
gland O
and O
development O
function O
, O
the O
rodent O
20 O
- O
day O
Pubertal O
Female O
Assay O
in O
this O
study O
was O
used O
. O

Postnatal O
days O
( O
PND O
) O
22 O
- O
old O
Sprague O
- O
Dawley O
rats O
were O
administered O
with O
thiazole B
- O
Zn B
daily O
by O
oral O
gavage O
at O
doses O
0 O
, O
40 O
, O
100 O
, O
200 O
mg O
/ O
kg O
/ O
day O
for O
20 O
days O
. O

The O
results O
indicated O
that O
serum O
TT4 O
and O
TSH O
levels O
were O
significantly O
increased O
at O
all O
concentrations O
, O
serum O
TT3 O
levels O
were O
significantly O
reduced O
only O
at O
40 O
mg O
/ O
kg O
thiazole B
- O
Zn B
, O
but O
had O
no O
difference O
from O
controls O
at O
the O
other O
doses O
. O

These O
results O
demonstrate O
that O
thiazole B
- O
Zn B
is O
likely O
a O
thyroid O
disrupter O
, O
but O
did O
not O
demonstrate O
that O
it O
has O
estrogenic O
/ O
anti O
- O
estrogenic O
activity O
. O

A O
10 O
- O
minute O
point O
- O
of O
- O
care O
assay O
for O
detection O
of O
blood O
protein O
adducts O
resulting O
from O
low O
level O
exposure O
to O
organophosphate B
nerve O
agents O
. O

The O
OrganoTox O
test O
is O
a O
rapid O
, O
point O
- O
of O
- O
care O
assay O
capable O
of O
detecting O
clinically O
relevant O
organophosphate B
( O
OP O
) O
poisoning O
after O
low O
- O
level O
exposure O
to O
sarin B
, O
soman B
, O
tabun B
, O
or O
VX O
chemical O
nerve O
agents O
. O

For O
performance O
testing O
, O
40 O
plasma O
samples O
were O
spiked O
with O
sarin B
, O
soman B
, O
tabun B
, O
or O
VX O
and O
10 O
normal O
plasma O
samples O
were O
used O
as O
the O
negative O
control O
. O

At O
the O
clinically O
relevant O
low O
- O
level O
exposure O
of O
10ng O
/ O
ml O
, O
the O
OrganoTox O
test O
demonstrated O
100 O
% O
sensitivity O
for O
soman B
, O
tabun B
, O
and O
VX O
and O
80 O
% O
sensitivity O
for O
sarin B
. O

Altered O
expression O
of O
genes O
involved O
in O
progesterone B
biosynthesis O
, O
metabolism O
and O
action O
in O
endometrial O
cancer O
. O

It O
is O
associated O
with O
prolonged O
exposure O
to O
estrogens O
that O
is O
unopposed O
by O
the O
protective O
effects O
of O
progesterone B
, O
which O
suggests O
that O
altered O
progesterone B
biosynthesis O
, O
metabolism O
and O
actions O
might O
be O
implicated O
in O
the O
development O
of O
EC O
. O

First O
, O
we O
examined O
the O
expression O
of O
genes O
encoding O
proteins O
associated O
with O
progesterone B
biosynthesis O
: O
steroidogenic O
acute O
regulatory O
protein O
( O
STAR O
) O
; O
a O
side O
chain O
cleavage O
enzyme O
( O
CYP11A1 O
) O
; O
and O
3 B
beta I
- I
hydroxysteroid I
dehydrogenase O
/ O
ketosteroid B
isomerase O
( O
HSD3B O
) O
. O

Next O
, O
we O
examined O
expression O
of O
genes O
encoding O
five O
progesterone B
metabolizing O
enzymes O
: O
the O
3 O
- O
keto O
and O
20 O
- O
ketosteroid O
reductases O
( O
AKR1C1 O
- O
AKR1C3 O
) O
and O
5 O
alpha O
- O
reductases O
( O
SRD5A1 O
and O
SRD5A2 O
) O
; O
and O
the O
opposing O
20 O
alpha O
- O
hydroxysteroid O
dehydrogenase O
( O
HSD17B2 O
) O
. O

We O
also O
examined O
mRNA O
levels O
of O
progesterone B
receptors O
A O
and O
B O
( O
PGR O
) O
, O
and O
separately O
the O
expression O
of O
progesterone B
receptor O
B O
( O
PR O
- O
B O
) O
. O

This O
down O
- O
regulation O
of O
STAR O
, O
CYP11A1 O
and O
PGR O
in O
endometrial O
cancer O
may O
lead O
to O
decreased O
progesterone B
biosynthesis O
and O
actions O
although O
the O
effects O
on O
progesterone B
levels O
should O
be O
further O
studied O
. O

Origin O
and O
evolution O
of O
medium O
chain O
alcohol B
dehydrogenases O
. O

Different O
lines O
of O
alcohol B
dehydrogenases O
( O
ADHs O
) O
have O
separate O
superfamily O
origins O
, O
already O
recognized O
but O
now O
extended O
and O
re O
- O
evaluated O
by O
re O
- O
screening O
of O
the O
latest O
databank O
update O
. O

The O
Zn B
- O
MDR O
origin O
constitutes O
a O
third O
stage O
, O
possibly O
compatible O
with O
the O
transition O
to O
oxidative O
conditions O
on O
earth O
. O

Stearoyl O
- O
PEG O
- O
polySDM O
was O
synthesised O
using O
a O
multi O
- O
step O
procedure O
that O
includes O
pH O
- O
sensitive O
sulfadimethoxine O
methacrylate O
polymerisation O
by O
AGET O
- O
ATRP O
at O
the O
amino B
terminal O
side O
of O
stearoyl O
- O
PEG O
- O
NH2 O
. O

Fluorescence O
spectroscopic O
and O
cytofluorimetric O
studies O
showed O
that O
the O
incubation O
of O
MCF O
- O
7 O
tumour O
cells O
with O
fluorescein B
- O
labelled O
stearoyl O
- O
PEG O
- O
polySDM O
at O
pH O
6 O
. O
5 O
resulted O
in O
massive O
time O
- O
dependent O
cell O
association O
, O
while O
the O
incubation O
at O
pH O
7 O
. O
4 O
showed O
significantly O
lower O
cell O
interaction O
. O

Confocal O
microscopy O
confirmed O
that O
at O
pH O
6 O
. O
5 O
, O
the O
micelles O
are O
taken O
up O
by O
cells O
and O
that O
the O
fluorescein B
- O
labelled O
stearoyl O
- O
PEG O
- O
polySDM O
is O
distributed O
into O
the O
cytosol O
. O

At O
pH O
6 O
. O
5 O
, O
paclitaxel B
- O
loaded O
stearoyl O
- O
PEG O
- O
polySDM O
micelles O
had O
a O
higher O
cytotoxic O
effect O
than O
the O
micelles O
incubated O
at O
pH O
7 O
. O
4 O
. O

The O
former O
displayed O
similar O
cytotoxic O
activity O
to O
free O
paclitaxel B
. O

Activity O
within O
the O
social O
behavior O
neural O
network O
is O
modulated O
by O
the O
neuropeptide O
arginine O
vasotocin O
( O
AVT O
) O
and O
its O
mammalian O
homologue O
arginine B
vasopressin I
( O
AVP O
) O
. O

Fenamiphos O
( O
ethyl O
4 O
- O
methylthio O
- O
m O
- O
tolyl O
isopropylphosphorami O
) O
is O
a O
racemic O
organophosphorus B
nematicide O
widely O
used O
in O
agriculture O
around O
the O
world O
. O

The O
paraoxonase O
1 O
from O
human O
serum O
( O
PON1 O
) O
is O
a O
phosphotriesterase O
( O
PTE O
) O
that O
hydrolyses O
several O
xenobiotics O
including O
drugs O
and O
organophosphorus B
compounds O
( O
OPs O
) O
. O

In O
this O
work O
, O
the O
separation O
of O
the O
enantiomers O
of O
fenamiphos O
by O
HPLC O
using O
the O
column O
CHIRALCEL O
OJ O
and O
a O
mobile O
phase O
of O
hexane B
/ O
ethanol B
( O
99 O
/ O
1 O
) O
is O
presented O
. O

The O
levels O
of O
the O
Ca B
( I
2 I
+ I
) I
- O
dependent O
hydrolysis O
( O
residual O
concentration O
[ O
mu O
M O
] O
) O
quantified O
during O
30min O
of O
reaction O
were O
only O
just O
4 O
- O
14 O
% O
for O
both O
fenamiphos O
enantiomers O
with O
the O
three O
alloforms O
of O
PON1 O
Q192R O
of O
the O
two O
groups O
of O
serum O
studied O
. O

These O
results O
demonstrate O
that O
human O
serum O
PON1 O
is O
could O
be O
involved O
in O
the O
detoxification O
of O
a O
limited O
number O
of O
organophosphorus B
insecticides O
. O

Reduced O
plasma O
oxytocin B
levels O
in O
female O
patients O
with O
borderline O
personality O
disorder O
. O

The O
neuropeptide O
oxytocin B
is O
involved O
in O
social O
cognition O
and O
interaction O
across O
species O
and O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
affiliative O
behaviors O
. O

Oxytocin B
levels O
in O
cerebrospinal O
fluid O
( O
CSF O
) O
, O
but O
also O
in O
plasma O
or O
urine O
, O
have O
been O
shown O
to O
be O
negatively O
associated O
with O
childhood O
traumata O
, O
aggressive O
behavior O
, O
and O
suicide O
attempts O
. O

Recently O
, O
an O
altered O
activity O
of O
the O
oxytocin B
system O
has O
been O
discussed O
to O
play O
a O
prominent O
role O
in O
borderline O
personality O
disorder O
( O
BPD O
) O
, O
which O
is O
thought O
to O
be O
closely O
related O
to O
traumatic O
experiences O
in O
childhood O
and O
is O
characterized O
by O
( O
para O
) O
suicidal O
behaviors O
as O
well O
as O
aggressive O
outbursts O
. O

In O
the O
present O
study O
, O
we O
compared O
plasma O
oxytocin B
levels O
of O
women O
with O
and O
without O
BPD O
in O
the O
follicular O
phase O
and O
assessed O
the O
relationship O
between O
oxytocin B
concentrations O
and O
childhood O
traumata O
. O

Women O
diagnosed O
with O
BPD O
had O
significantly O
reduced O
oxytocin B
concentrations O
, O
even O
after O
controlling O
for O
estrogen B
, O
progesterone B
, O
and O
contraceptive O
intake O
. O

In O
addition O
, O
plasma O
oxytocin B
correlated O
negatively O
with O
experiences O
of O
childhood O
traumata O
, O
in O
particular O
with O
emotional O
neglect O
and O
abuse O
. O

The O
results O
of O
mediation O
analyses O
do O
not O
support O
a O
model O
of O
oxytocin B
being O
a O
prominent O
mediator O
in O
the O
link O
between O
childhood O
trauma O
and O
BPD O
. O

Thus O
, O
the O
findings O
indicate O
dysregulations O
in O
the O
oxytocin B
system O
of O
patients O
diagnosed O
with O
BPD O
with O
more O
longitudinal O
research O
being O
necessary O
to O
disentangle O
the O
relationship O
between O
childhood O
adversities O
, O
oxytocin B
system O
, O
and O
psychopathology O
. O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl O
- O
N O
- O
nitro O
- O
N O
- O
nitrosoguanidine O
( O
MNNG O
) O
, O
ethyl O
- O
N O
- O
nitro O
- O
N O
' O
- O
nitrosoguanidine O
( O
ENNG O
) O
, O
frameshift O
mutagens O
2 O
- O
aminoanthracene O
( O
2AA O
) O
and O
2 O
- O
acetyl O
- O
amino O
- O
fluorene O
( O
2AF O
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic O
acid O
( O
NLX O
) O
, O
using O

In O
vivo O
antimutagenesis O
studies O
were O
performed O
against O
urinary O
mutagens O
induced O
by O
NOR B
( O
70 O
mg O
/ O
kg O
) O
or O
NLX O
( O
100 O
mg O
/ O
kg O
) O
in O
CD1 O
mice O
. O

All O
of O
them O
reduced O
mutagenesis O
of O
NOR B
or O
NLX O
( O
P O
< O
0 O
. O
001 O
) O
. O

In O
vivo O
studies O
showed O
that O
vitamins O
B1 O
and O
B6 O
( O
10 O
or O
100 O
mg O
/ O
kg O
) O
reduced O
urinary O
mutagens O
from O
NOR B
( O
P O
< O
0 O
. O
001 O
) O
or O
NLX O
( O
P O
< O
0 O
. O
02 O
) O
either O
free O
or O
beta O
- O
glucoronidase O
- O
conjugates O
. O

Vitamin B
B12 I
( O
4 O
mg O
/ O
kg O
) O
reduced O
urinary O
mutagens O
of O
NOR B
or O
NLX O
( O
P O
< O
0 O
. O
02 O
) O
. O

Vitamins B
B I
inhibited O
DNA O
mutations O
induced O
by O
ROS O
generated O
by O
NLX O
or O
NOR B
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Based O
on O
the O
observations O
, O
employment O
of O
vitamins B
B I
in O
vivo O
can O
be O
a O
promising O
alternative O
to O
reduce O
genotoxic O
risk O
exposure O
to O
ROS O
. O

Effect O
of O
body O
- O
weight O
loading O
onto O
the O
articular O
cartilage O
on O
the O
occurrence O
of O
quinolone B
- O
induced O
chondrotoxicity O
in O
juvenile O
rats O
. O

Animals O
were O
sacrificed O
at O
8h O
post O
- O
dose O
, O
and O
then O
the O
distal O
femoral O
articular O
cartilage O
was O
subjected O
to O
a O
histological O
examination O
and O
an O
investigation O
for O
gene O
expression O
of O
tumor O
necrosis O
factor O
receptor O
superfamily O
, O
member O
12a O
( O
Tnfrsf12a O
) O
; O
prostaglandin B
- O
endoperoxide O
synthase O
2 O
( O
Ptgs2 O
) O
; O
plasminogen O
activator O
, O
urokinase O
receptor O
( O
Plaur O
) O
; O
and O
matrix O
metalloproteinase O
3 O
( O
Mmp3 O
) O
by O
qRT O
- O
PCR O
analysis O
. O

The O
present O
investigation O
was O
carried O
out O
to O
evaluate O
the O
safety O
of O
hydro O
- O
ethanol B
extract O
of O
Bridelia O
ferruginea O
Benth O
( O
Euphorbiaceae O
) O
root O
bark O
. O

High O
levels O
of O
ephrinB2 O
over O
- O
expression O
increases O
the O
osteogenic O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
and O
promotes O
enhanced O
cell O
mediated O
mineralisation O
in O
a O
polyethyleneimine B
- O
ephrinB2 O
gene O
- O
activated O
matrix O
. O

Polyethyleneimine B
( O
PEI B
) O
, O
a O
non O
- O
viral O
vector O
, O
has O
previously O
been O
optimised O
for O
high O
efficiency O
gene O
transfer O
in O
rat O
mesenchymal O
stem O
cells O
( O
rMSCs O
) O
. O

The O
use O
of O
PEI B
to O
transfect O
human O
MSCs O
( O
hMSCs O
) O
with O
ephrinB2 O
is O
assessed O
here O
. O

This O
select O
interaction O
, O
coupled O
with O
the O
transient O
gene O
expression O
profile O
of O
PEI B
, O
makes O
the O
PEI B
- O
ephrinB2 O
GAM O
an O
ideal O
candidate O
matrix O
for O
a O
bone O
targeted O
GAM O
. O

Cardioprotective O
effect O
of O
salvianolic B
acid I
B I
against O
arsenic B
trioxide I
- O
induced O
injury O
in O
cardiac O
H9c2 O
cells O
via O
the O
PI3K O
/ O
Akt O
signal O
pathway O
. O

The O
clinical O
use O
of O
arsenic B
trioxide I
( O
ATO B
) O
, O
a O
potent O
anti O
- O
neoplastic O
agent O
, O
is O
often O
limited O
because O
of O
its O
severe O
cardiotoxicity O
. O

One O
of O
the O
most O
abundant O
ingredients O
of O
S O
. O
miltiorrhiza O
is O
salvianolic B
acid I
B I
( O
Sal B
B I
) O
. O

The O
present O
study O
was O
designed O
to O
evaluate O
whether O
Sal B
B I
protects O
against O
ATO B
- O
induced O
cardiac O
cell O
injury O
in O
vitro O
. O

With O
MTT B
cell O
viability O
assay O
, O
LDH O
release O
, O
ROS O
generation O
, O
caspase O
- O
3 O
activity O
assay O
and O
Hoechst B
33342 I
/ O
PI O
staining O
, O
we O
found O
that O
Sal B
B I
pretreatment O
provided O
significantly O
protection O
against O
ATO B
- O
induced O
cell O
death O
. O

Conversely O
, O
blocking O
Akt O
activation O
with O
the O
PI3K O
inhibitor O
LY294002 B
effectively O
suppressed O
the O
protective O
effect O
of O
Sal B
B I
against O
ATO B
- O
induced O
cell O
apoptosis O
. O

In O
addition O
, O
the O
PI3K O
inhibitor O
partially O
blocked O
the O
effects O
of O
Sal B
B I
on O
the O
upregulation O
of O
Bcl O
- O
2 O
and O
Bcl O
- O
xl O
protein O
expression O
, O
and O
downregulation O
of O
Bax O
protein O
expression O
. O

Collectively O
, O
the O
results O
showed O
that O
Sal B
B I
decreased O
the O
apoptosis O
and O
necrosis O
of O
H9c2 O
cardiomyocytes O
caused O
by O
ATO B
treatment O
, O
and O
PI3K O
played O
a O
crucial O
role O
in O
enhancing O
cell O
survival O
during O
this O
process O
. O

These O
observations O
indicate O
that O
Sal B
B I
has O
the O
potential O
to O
exert O
cardioprotective O
effects O
against O
ATO B
toxicity O
. O

The O
effects O
of O
short O
- O
term O
( O
1 O
day O
) O
and O
long O
- O
term O
( O
49 O
days O
) O
of O
lead O
( O
Pb B
) O
stress O
on O
growth O
and O
physiological O
responses O
in O
the O
leaves O
and O
roots O
of O
two O
mangrove O
plants O
, O
Kandelia O
obovata O
and O
Acanthus O
ilicifolius O
, O
were O
compared O
. O

The O
growth O
of O
both O
species O
was O
affected O
by O
Pb B
at O
Day O
49 O
, O
whereas O
the O
root O
to O
shoot O
ratio O
of O
K O
. O
obovata O
remained O
unchanged O
. O

Compared O
with O
A O
. O
ilicifolius O
, O
less O
Pb B
accumulated O
in O
leaves O
of O
K O
. O
obovata O
, O
which O
indicates O
that O
this O
species O
is O
a O
typical O
Pb B
- O
excluder O
. O

Significant O
linear O
relationships O
were O
observed O
between O
the O
Pb B
concentrations O
in O
the O
roots O
and O
leaves O
and O
the O
Pb B
treatment O
concentrations O
in O
the O
sediments O
in O
A O
. O
ilicifolius O
but O
not O
in O
K O
. O
obovata O
. O

The O
tolerant O
species O
K O
. O
obovata O
tended O
to O
acclimate O
to O
metal O
stress O
by O
restricting O
the O
translocation O
of O
toxic O
metals O
and O
by O
increasing O
and O
/ O
or O
maintaining O
high O
superoxide B
dismutase O
( O
SOD O
) O
activity O
, O
minimizing O
lipid O
peroxidation O
, O
and O
exhibiting O
prolonged O
unaltered O
growth O
( O
49 O
days O
) O
under O
Pb B
treatment O
. O

The O
non O
- O
tolerant O
species O
, O
A O
. O
ilicifolius O
, O
did O
not O
acclimate O
to O
metal O
stress O
, O
its O
leaves O
were O
seriously O
damaged O
with O
significant O
increased O
MDA B
content O
, O
and O
its O
SOD O
activity O
was O
decreased O
. O

Tightly O
bound O
trions O
in O
monolayer O
MoS2 B
. O

Two O
- O
dimensional O
( O
2D O
) O
atomic O
crystals O
, O
such O
as O
graphene B
and O
transition O
- O
metal O
dichalcogenides O
, O
have O
emerged O
as O
a O
new O
class O
of O
materials O
with O
remarkable O
physical O
properties O
. O

In O
contrast O
to O
graphene B
, O
monolayer O
MoS B
( I
2 I
) I
is O
a O
non O
- O
centrosymmetric O
material O
with O
a O
direct O
energy O
gap O
. O

Here O
we O
report O
the O
spectroscopic O
identification O
in O
a O
monolayer O
MoS B
( I
2 I
) I
field O
- O
effect O
transistor O
of O
tightly O
bound O
negative O
trions O
, O
a O
quasiparticle O
composed O
of O
two O
electrons O
and O
a O
hole O
. O

In O
the O
search O
for O
room O
- O
temperature O
batteries O
with O
high O
energy O
densities O
, O
rechargeable O
metal O
- O
air O
( O
more O
precisely O
metal O
- O
oxygen B
) O
batteries O
are O
considered O
as O
particularly O
attractive O
owing O
to O
the O
simplicity O
of O
the O
underlying O
cell O
reaction O
at O
first O
glance O
. O

Atmospheric O
oxygen B
is O
used O
to O
form O
oxides B
during O
discharging O
, O
which O
- O
ideally O
- O
decompose O
reversibly O
during O
charging O
. O

Much O
work O
has O
been O
focused O
on O
aprotic O
Li O
- O
O O
( O
2 O
) O
cells O
( O
mostly O
with O
carbonate B
- O
based O
electrolytes O
and O
Li O
( O
2 O
) O
O O
( O
2 O
) O
as O
a O
potential O
discharge O
product O
) O
, O
where O
large O
overpotentials O
are O
observed O
and O
a O
complex O
cell O
chemistry O
is O
found O
. O

Here O
we O
report O
on O
a O
Na O
- O
O O
( O
2 O
) O
cell O
reversibly O
discharging O
/ O
charging O
at O
very O
low O
overpotentials O
( O
< O
200 O
mV O
) O
and O
current O
densities O
as O
high O
as O
0 O
. O
2 O
mA O
cm O
( O
- O
2 O
) O
using O
a O
pure O
carbon B
cathode O
without O
an O
added O
catalyst O
. O

This O
work O
demonstrates O
that O
substitution O
of O
lithium B
by O
sodium B
may O
offer O
an O
unexpected O
route O
towards O
rechargeable O
metal O
- O
air O
batteries O
. O

High O
- O
resolution O
solid O
- O
state O
13C B
NMR O
spectroscopy O
of O
the O
paramagnetic O
metal O
- O
organic O
frameworks O
, O
STAM O
- O
1 O
and O
HKUST O
- O
1 O
. O

Solid O
- O
state O
( B
13 I
) I
C I
magic O
- O
angle O
spinning O
( O
MAS O
) O
NMR O
spectroscopy O
is O
used O
to O
investigate O
the O
structure O
of O
the O
Cu B
( I
II I
) I
- O
based O
metal O
- O
organic O
frameworks O
( O
MOFs O
) O
, O
HKUST O
- O
1 O
and O
STAM O
- O
1 O
, O
and O
the O
structural O
changes O
occurring O
within O
these O
MOFs O
upon O
activation O
( O
dehydration O
) O
. O

However O
, O
interactions O
between O
nuclei O
and O
unpaired O
electrons O
in O
paramagnetic O
systems O
( O
e O
. O
g O
. O
, O
Cu B
( I
II I
) I
- O
based O
MOFs O
) O
pose O
a O
considerable O
challenge O
, O
not O
only O
for O
spectral O
acquisition O
, O
but O
also O
in O
the O
assignment O
and O
interpretation O
of O
the O
spectral O
resonances O
. O

Here O
, O
we O
exploit O
the O
rapid O
T O
( O
1 O
) O
relaxation O
of O
these O
materials O
to O
obtain O
( B
13 I
) I
C I
NMR O
spectra O
using O
a O
spin O
- O
echo O
pulse O
sequence O
at O
natural O
abundance O
levels O
, O
and O
employ O
frequency O
- O
stepped O
acquisition O
to O
ensure O
uniform O
excitation O
of O
resonances O
over O
a O
wide O
frequency O
range O
. O

We O
then O
utilise O
selective O
( B
13 I
) I
C I
isotopic O
labelling O
of O
the O
organic O
linker O
molecules O
to O
enable O
an O
unambiguous O
assignment O
of O
NMR O
spectra O
of O
both O
MOFs O
for O
the O
first O
time O
. O

Design O
, O
synthesis O
and O
crystallographic O
analysis O
of O
nitrile B
- O
based O
broad O
- O
spectrum O
peptidomimetic O
inhibitors O
for O
coronavirus O
3C O
- O
like O
proteases O
. O

We O
designed O
and O
synthesized O
four O
nitrile B
- O
based O
peptidomimetic O
inhibitors O
with O
different O
N B
- O
terminal O
protective O
groups O
and O
different O
peptide O
length O
, O
and O
examined O
their O
inhibitory O
effect O
on O
the O
in O
- O
vitro O
enzymatic O
activity O
of O
3CL O
( O
pro O
) O
of O
severe O
- O
acute O
- O
respiratory O
- O
syndrome O
- O
coronavirus O
. O

The O
IC O
( O
50 O
) O
values O
of O
the O
inhibitors O
were O
in O
the O
range O
of O
4 O
. O
6 O
- O
49 O
mu O
M O
, O
demonstrating O
that O
the O
nitrile B
warhead O
can O
effectively O
inactivate O
the O
3CL O
( O
pro O
) O
autocleavage O
process O
. O

The O
best O
inhibitor O
, O
Cbz B
- O
AVLQ O
- O
CN O
with O
an O
N B
- O
terminal O
carbobenzyloxy O
group O
, O
was O
~ O
10x O
more O
potent O
than O
the O
other O
inhibitors O
tested O
. O

Crystal O
structures O
of O
the O
enzyme O
- O
inhibitor O
complexes O
showed O
that O
the O
nitrile B
warhead O
inhibits O
3CL O
( O
pro O
) O
by O
forming O
a O
covalent O
bond O
with O
the O
catalytic O
Cys145 O
residue O
, O
while O
the O
AVLQ O
peptide O
forms O
a O
number O
of O
favourable O
interactions O
with O
the O
S1 O
- O
S4 O
substrate O
- O
binding O
pockets O
. O

We O
have O
further O
showed O
that O
the O
peptidomimetic O
inhibitor O
, O
Cbz B
- O
AVLQ O
- O
CN O
, O
has O
broad O
- O
spectrum O
inhibition O
against O
3CL O
( O
pro O
) O
from O
human O
coronavirus O
strains O
229E O
, O
NL63 O
, O
OC43 O
, O
HKU1 O
, O
and O
infectious O
bronchitis O
virus O
, O
with O
IC O
( O
50 O
) O
values O
ranging O
from O
1 O
. O
3 O
to O
3 O
. O
7 O
mu O
M O
, O
but O
no O
detectable O
inhibition O
against O
caspase O
- O
3 O
. O

In O
summary O
, O
we O
have O
shown O
that O
the O
nitrile B
- O
based O
peptidomimetic O
inhibitors O
are O
effective O
against O
3CL O
( O
pro O
) O
, O
and O
they O
inhibit O
3CL O
( O
pro O
) O
from O
a O
broad O
range O
of O
coronaviruses O
. O

Synthesis O
and O
antibacterial O
and O
antifungal O
evaluation O
of O
some O
chalcone B
based O
sulfones O
and O
bisulfones O
. O

Two O
series O
of O
chalcone B
based O
sulfone B
and O
bisulfone O
derivatives O
were O
synthesized O
using O
chalcone B
, O
thiophenol B
and O
sodium B
metal O
at O
room O
temperature O
, O
followed O
by O
oxidation O
of O
chalcone O
sulfides O
with O
m O
- O
CPBA O
at O
0 O
degrees O
C O
in O
a O
novel O
method O
. O

Amphotericin B
- I
B I
and O
Nystatin O
. O

Compound O
1c O
has O
shown O
slightly O
better O
antibacterial O
activity O
against O
B O
. O
subtilis O
and O
compounds O
5c O
, O
6c O
and O
7c O
have O
shown O
excellent O
antibacterial O
activity O
against O
S O
. O
typhimurium O
in O
compare O
to O
reference O
drugs O
Ampicillin B
and O
Kanamycin O
. O

Propenone O
analogs O
4 O
possess O
some O
of O
the O
structurally O
important O
characteristics O
of O
isoflavone B
2 O
and O
chalcone B
3 O
previously O
known O
as O
potent O
IL O
- O
5 O
inhibitor O
. O

This O
enhanced O
activity O
of O
5 O
compared O
to O
4 O
could O
be O
due O
to O
the O
effective O
location O
of O
hydroxyl B
group O
of O
allylic O
alcohol O
moiety O
of O
5 O
in O
the O
3D O
structure O
. O

The O
electron O
withdrawing O
substituents O
at O
position O
4 O
of O
phenyl B
ring O
of O
5 O
enhances O
the O
activity O
possibly O
due O
to O
an O
increase O
in O
the O
strength O
of O
hydrogen B
bonding O
property O
of O
hydroxyl B
group O
of O
allylic O
alcohol O
moiety O
. O

Among O
8 O
, O
8b O
- O
8d O
, O
and O
8h O
- O
8l O
displayed O
dramatically O
improved O
potency O
against O
inducibly O
MLS O
( O
B O
) O
- O
resistant O
and O
efflux O
- O
resistant O
pathogens O
as O
compared O
to O
clarithromycin B
and O
azithromycin B
. O

Especially O
, O
8i O
( O
Ar O
= O
4 O
- O
isoquinolyl O
) O
possessed O
an O
MIC O
of O
0 O
. O
064 O
mu O
g O
/ O
mL O
against O
constitutively O
MLS O
( O
B O
) O
- O
resistant O
Streptococcus O
pneumoniae O
, O
and O
MICs O
of O
0 O
. O
032 O
- O
0 O
. O
064 O
mu O
g O
/ O
mL O
against O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
and O
methicillin B
- O
resistant O
Staphylococcus O
hominis O
. O

The O
analog O
10 O
with O
a O
propyl B
linker O
was O
less O
effective O
than O
both O
the O
corresponding O
8 O
and O
9 O
containing O
propynyl O
and O
propenyl O
linkers O
. O

Hybrid O
compound O
N O
' O
- O
( O
4 O
- O
phenyl O
- O
3 O
- O
furoxanylmethylidene O
) O
isoniazide O
9 O
showed O
the O
best O
antibacterial O
profile O
with O
MIC O
value O
4 O
. O
5 O
lesser O
than O
the O
value O
for O
the O
reference O
isoniazid B
against O
MDR O
strain O
. O

The O
protein O
amide O
( O
1 O
) O
H O
( O
N O
) O
chemical O
shift O
temperature O
coefficient O
reflects O
thermal O
expansion O
of O
the O
N B
- I
H I
. O
. O
. O
O B
= I
C I
hydrogen B
bond O
. O

In O
this O
work O
, O
we O
find O
that O
this O
coefficient O
strongly O
correlates O
with O
the O
temperature O
coefficient O
of O
the O
through O
- O
hydrogen B
- O
bond O
coupling O
, O
( O
3h O
) O
J O
( O
NC O
' O
) O
, O
based O
on O
NMR O
measurements O
of O
protein O
GB3 O
. O

Parallel O
tempering O
molecular O
dynamics O
simulation O
suggests O
that O
the O
hydrogen B
bond O
distance O
variation O
at O
different O
temperatures O
/ O
replicas O
is O
largely O
responsible O
for O
the O
( O
1 O
) O
H O
( O
N O
) O
chemical O
shift O
temperature O
dependence O
, O
from O
which O
an O
empirical O
equation O
is O
proposed O
to O
predict O
the O
hydrogen B
bond O
thermal O
expansion O
coefficient O
, O
revealing O
responses O
of O
individual O
hydrogen B
bonds O
to O
temperature O
changes O
. O

TCDD B
inhibits O
heart O
regeneration O
in O
adult O
zebrafish O
. O

We O
report O
that O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
significantly O
impairs O
this O
regeneration O
. O

Adult O
male O
zebrafish O
were O
injected O
with O
vehicle O
( O
control O
) O
or O
TCDD B
( O
70ng O
/ O
g O
, O
ip O
) O
1 O
day O
prior O
to O
partial O
amputation O
of O
the O
ventricle O
apex O
. O

Gross O
observation O
and O
histological O
analysis O
of O
the O
amputated O
heart O
at O
21 O
days O
postamputation O
revealed O
that O
TCDD B
- O
exposed O
fish O
had O
not O
progressed O
beyond O
the O
initial O
clot O
formation O
stage O
, O
whereas O
the O
vehicle O
control O
fish O
showed O
substantial O
recovery O
and O
almost O
complete O
resolution O
of O
the O
formed O
clot O
. O

In O
contrast O
, O
hearts O
that O
were O
not O
surgically O
wounded O
showed O
no O
signs O
of O
TCDD B
toxicity O
. O

Striking O
features O
in O
the O
TCDD B
- O
exposed O
hearts O
were O
the O
absence O
of O
the O
normal O
sheath O
of O
new O
tissue O
enveloping O
the O
wound O
and O
the O
absence O
of O
intense O
cell O
proliferation O
at O
the O
site O
of O
the O
wound O
. O

In O
addition O
, O
the O
patterns O
of O
collagen O
deposition O
at O
the O
wound O
site O
were O
different O
between O
the O
TCDD B
and O
vehicle O
groups O
. O

Because O
the O
receptor O
for O
TCDD B
is O
the O
aryl B
hydrocarbon I
receptor O
ligand O
- O
activated O
transcriptional O
regulator O
, O
we O
examined O
the O
effects O
of O
TCDD B
exposure O
on O
gene O
expression O
in O
the O
ventricle O
using O
DNA O
microarrays O
. O

TCDD B
- O
pretreated O
hearts O
had O
dysregulated O
expression O
of O
genes O
involved O
in O
heart O
function O
, O
tissue O
regeneration O
, O
cell O
growth O
, O
and O
extracellular O
matrix O
. O

Because O
embryonic O
, O
but O
not O
adult O
, O
hearts O
are O
major O
targets O
for O
TCDD B
- O
induced O
cardiotoxicity O
, O
we O
speculate O
that O
the O
need O
for O
embryonic O
- O
like O
cells O
in O
regeneration O
is O
connected O
with O
the O
effects O
of O
TCDD B
in O
inhibiting O
the O
response O
to O
wounding O
. O

The O
calmodulin O
regulator O
protein O
, O
PEP O
- O
19 O
, O
sensitizes O
ATP B
- O
induced O
Ca2 B
+ I
release O
. O

PEP O
- O
19 O
is O
a O
small O
, O
intrinsically O
disordered O
protein O
that O
binds O
to O
the O
C O
- O
domain O
of O
calmodulin O
( O
CaM O
) O
via O
an O
IQ O
motif O
and O
tunes O
its O
Ca B
( I
2 I
+ I
) I
binding O
properties O
via O
an O
acidic O
sequence O
. O

We O
show O
here O
that O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
has O
intrinsic O
Ca B
( I
2 I
+ I
) I
binding O
activity O
, O
which O
may O
modulate O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
by O
stabilizing O
an O
initial O
Ca B
( I
2 I
+ I
) I
- O
CaM O
complex O
or O
by O
electrostatically O
steering O
Ca B
( I
2 I
+ I
) I
to O
and O
from O
CaM O
. O

Because O
PEP O
- O
19 O
is O
expressed O
in O
cells O
that O
exhibit O
highly O
active O
Ca B
( I
2 I
+ I
) I
dynamics O
, O
we O
tested O
the O
hypothesis O
that O
it O
influences O
ligand O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
. O

We O
show O
that O
PEP O
- O
19 O
increases O
the O
sensitivity O
of O
HeLa O
cells O
to O
ATP B
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
to O
greatly O
increase O
the O
percentage O
of O
cells O
responding O
to O
sub O
- O
saturating O
doses O
of O
ATP B
and O
increases O
the O
frequency O
of O
Ca B
( I
2 I
+ I
) I
oscillations O
. O

Mutations O
in O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
that O
inhibit O
or O
prevent O
it O
from O
modulating O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
greatly O
inhibit O
its O
effect O
on O
ATP B
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
. O

Tuning O
the O
activities O
of O
Ca B
( I
2 I
+ I
) I
mobilization O
pathways O
places O
PEP O
- O
19 O
at O
the O
top O
of O
CaM O
signaling O
cascades O
, O
with O
great O
potential O
to O
exert O
broad O
effects O
on O
downstream O
CaM O
targets O
, O
thus O
expanding O
the O
biological O
significance O
of O
this O
small O
regulator O
of O
CaM O
signaling O
. O

Effects O
of O
single O
or O
repeated O
silymarin O
administration O
on O
pharmacokinetics O
of O
risperidone B
and O
its O
major O
metabolite O
, O
9 O
- O
hydroxyrisperidone O
in O
rats O
. O

2 O
. O
The O
objective O
of O
this O
article O
is O
to O
examine O
the O
effects O
of O
single O
and O
repeated O
administrations O
of O
silymarin O
on O
pharmacokinetics O
of O
a O
P O
- O
gp O
substrate O
, O
risperidone B
, O
and O
its O
major O
metabolite O
, O
9 O
- O
hydroxyrisperidone O
, O
in O
rats O
. O

3 O
. O
To O
determine O
the O
plasma O
levels O
of O
risperidone B
and O
9 O
- O
hydroxyrisperidone O
in O
rats O
, O
a O
HPLC O
method O
was O
developed O
using O
a O
liquid O
- O
liquid O
acid O
back O
extraction O
. O

When O
risperidone B
( O
6 O
mg O
/ O
kg O
) O
was O
co O
- O
administered O
with O
silymarin O
( O
40 O
mg O
/ O
kg O
) O
to O
rats O
orally O
, O
the O
C O
( O
max O
) O
of O
9 O
- O
hydroxyrisperidone O
was O
significantly O
increased O
to1 O
. O
3 O
- O
fold O
( O
p O
< O
0 O
. O
05 O
) O
, O
while O
the O
other O
pharmacokinetic O
parameters O
did O
not O
show O
any O
significant O
differences O
. O

Expanding O
the O
experiment O
where O
rats O
were O
repeatedly O
administered O
with O
silymarin O
for O
5 O
days O
prior O
to O
giving O
risperidone B
, O
the O
C O
( O
max O
) O
of O
risperidone B
and O
9 O
- O
hydroxyrisperidone O
were O
significantly O
increased O
to O
2 O
. O
4 O
- O
fold O
( O
p O
< O
0 O
. O
001 O
) O
and O
1 O
. O
7 O
- O
fold O
( O
p O
< O
0 O
. O
001 O
) O
, O
respectively O
, O
and O
the O
AUC O
( O
0 O
- O
t O
) O
, O
as O
well O
to O
1 O
. O
7 O
- O
fold O
( O
p O
< O
0 O
. O
05 O
) O
and O
2 O
. O
1 O
- O
fold O
( O
p O
< O
0 O
. O
01 O
) O
, O
respectively O
. O

4 O
. O
The O
repeated O
exposures O
of O
silymarin O
, O
compared O
to O
single O
administration O
of O
silymarin O
, O
increased O
oral O
bioavailability O
and O
affected O
the O
pharmacokinetics O
of O
risperidone B
and O
9 O
- O
hydroxyrisperidone O
, O
by O
inhibiting O
P O
- O
gp O
. O

The O
Fraction O
of O
Exhaled O
Nitric B
Oxide I
( O
FeNO O
) O
was O
calculated O
, O
dynamic O
flow O
volumes O
were O
assessed O
through O
spirometry O
; O
while O
airway O
impedance O
( O
Z O
) O
, O
resistance O
( O
R O
) O
, O
and O
reactance O
( O
X O
) O
was O
assessed O
through O
impulse O
oscillometry O
before O
and O
after O
exposure O
. O

Effects O
of O
the O
lipid O
environment O
, O
cholesterol B
and O
bile B
acids I
on O
the O
function O
of O
the O
purified O
and O
reconstituted O
human O
ABCG2 O
protein O
. O

By O
using O
the O
purified O
and O
reconstituted O
protein O
we O
demonstrate O
that O
cholesterol B
is O
an O
essential O
activator O
, O
whereas O
bile B
acids I
are O
important O
modulators O
of O
ABCG2 O
activity O
. O

Both O
wild O
- O
type O
ABCG2 O
and O
its O
R482G O
mutant O
variant O
require O
cholesterol B
for O
full O
activity O
, O
although O
they O
exhibit O
different O
cholesterol B
sensitivities O
. O

Bile B
acids I
strongly O
decrease O
the O
basal O
ABCG2 O
- O
ATPase O
activity O
both O
in O
the O
wild O
- O
type O
ABCG2 O
and O
in O
the O
mutant O
variant O
. O

These O
data O
reinforce O
the O
results O
for O
the O
modulatory O
effects O
of O
cholesterol B
and O
bile B
acids I
of O
ABCG2 O
investigated O
in O
a O
complex O
cell O
membrane O
environment O
. O

Spontaneous O
periodic O
diameter O
oscillations O
in O
InP B
nanowires O
: O
the O
role O
of O
interface O
instabilities O
. O

We O
have O
observed O
that O
thin O
InP B
nanowires O
generated O
by O
vapor O
- O
liquid O
- O
solid O
growth O
display O
spontaneous O
periodic O
diameter O
oscillations O
when O
large O
group O
III O
supersaturations O
are O
used O
. O

Diameter O
variations O
are O
associated O
with O
a O
large O
number O
of O
stacking O
faults O
and O
crystallographic O
phase O
changes O
( O
wurtzite B
/ O
zinc B
- I
blende I
) O
; O
also O
the O
axial O
distance O
between O
oscillations O
depends O
on O
the O
indium B
precursor O
flow O
used O
during O
the O
run O
. O

Interactions O
of O
sarin B
with O
polyelectrolyte O
membranes O
: O
a O
molecular O
dynamics O
simulation O
study O
. O

Nanostructured O
polyelectrolyte O
membranes O
( O
PEMs O
) O
, O
which O
are O
widely O
used O
as O
permselective O
diffusion O
barriers O
in O
fuel O
cell O
technologies O
and O
electrochemical O
processing O
, O
are O
considered O
as O
protective O
membranes O
suitable O
for O
blocking O
warfare O
toxins O
, O
including O
water O
- O
soluble O
nerve O
agents O
such O
as O
sarin B
. O

In O
this O
article O
, O
we O
examine O
the O
mechanisms O
of O
sorption O
and O
diffusion O
of O
sarin B
in O
hydrated O
PEMs O
by O
means O
of O
atomistic O
molecular O
dynamics O
simulations O
. O

Three O
PEMs O
are O
considered O
: O
Nafion B
, O
sulfonated O
polystyrene O
( O
sPS B
) O
that O
forms O
the O
hydrophilic O
subphase O
of O
segregated O
sPS B
- O
polyolefin O
block O
copolymers O
, O
and O
random O
sPS B
- O
polyethylene B
copolymer O
. O

We O
found O
that O
sarin B
concentrates O
at O
the O
interface O
between O
the O
hydrophilic O
and O
hydrophobic O
subphases O
of O
hydrated O
Nafion O
acting O
as O
a O
surfactant O
. O

In O
hydrated O
sPS O
, O
where O
the O
scale O
of O
water O
- O
polymer O
segregation O
is O
much O
smaller O
( O
1 O
- O
2 O
nm O
) O
, O
sarin B
also O
interacts O
favorably O
with O
hydrophobic O
and O
hydrophilic O
components O
. O

Water O
diffusion O
slows O
as O
the O
sarin B
content O
increases O
despite O
the O
overall O
increase O
in O
solvent O
content O
, O
which O
suggests O
that O
sarin B
and O
water O
have O
somewhat O
different O
pathways O
through O
the O
segregated O
membrane O
. O

Upon O
replacement O
of O
counterions O
of O
monovalent O
potassium B
with O
those O
of O
divalent O
calcium B
, O
sarin B
diffusion O
slows O
but O
remains O
substantial O
in O
all O
ionomers O
considered O
, O
especially O
at O
high O
sarin B
concentrations O
. O

The O
behavior O
of O
sarin B
is O
similar O
to O
that O
of O
its O
common O
simulant O
, O
dimethyl B
methylphosphonate I
. O

Multifunctional O
Fe3O4 B
@ O
Ag B
/ O
SiO2 B
/ O
Au B
core O
- O
shell O
microspheres O
as O
a O
novel O
SERS O
- O
activity O
label O
via O
long O
- O
range O
plasmon O
coupling O
. O

Due O
to O
their O
wide O
accessible O
potential O
range O
in O
aqueous O
solutions O
and O
the O
high O
biocompatibility O
, O
Au B
supports O
are O
preferred O
for O
spectro O
- O
electrochemical O
investigations O
. O

However O
, O
the O
optical O
range O
in O
SERS O
spectroscopy O
is O
restricted O
to O
excitation O
lines O
above O
600 O
nm O
, O
which O
is O
shorter O
than O
the O
Ag B
supports O
. O

Herein O
, O
the O
present O
article O
reports O
the O
novel O
multifunctional O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
/ O
SiO B
( I
2 I
) I
/ O
Au B
core O
- O
shell O
microspheres O
that O
display O
long O
- O
range O
plasmon O
transfer O
of O
Ag B
to O
Au B
leading O
to O
enhanced O
Raman O
scattering O
. O

As O
a O
result O
, O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
/ O
SiO B
( I
2 I
) I
/ O
Au B
microspheres O
have O
the O
best O
enhancement O
effect O
in O
the O
Raman O
active O
research O
by O
using O
Rhodamine B
- I
b I
( O
RdB O
) O
as O
a O
probe O
molecule O
. O

The O
enhancement O
factor O
is O
estimated O
to O
be O
2 O
. O
2 O
x O
10 O
( O
4 O
) O
for O
RdB O
from O
the O
long O
- O
range O
plasmon O
transfer O
of O
Ag B
to O
Au B
, O
corresponding O
to O
an O
attenuation O
of O
the O
enhancement O
by O
a O
factor O
of O
only O
0 O
. O
672 O
x O
10 O
( O
4 O
) O
compared O
to O
RdB O
adsorbed O
directly O
on O
the O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
microspheres O
. O

Belatacept O
combined O
with O
corticosteroids B
and O
a O
mycophenolic B
acid I
is O
indicated O
for O
prophylaxis O
of O
graft O
rejection O
in O
adults O
receiving O
renal O
transplant O
. O

We O
report O
the O
design O
, O
synthesis O
and O
photophysical O
properties O
of O
highly O
solvatochromic O
donor O
/ O
acceptor O
substituted O
naphthalimide B
based O
fluorophores O
. O

The O
solid O
state O
photophysical O
property O
of O
donor O
substituted O
naphthalimide B
1 O
showed O
promising O
for O
future O
application O
in O
material O
sciences O
. O

Furthermore O
, O
both O
the O
donor O
/ O
acceptor O
substituted O
naphthalimide B
fluorophores O
1 O
- O
2 O
were O
exploited O
in O
sensing O
calf O
- O
thymus O
DNA O
via O
switch O
- O
on O
fluorescence O
response O
. O

A O
comprehensive O
study O
of O
the O
sonochemical O
degradation O
of O
dimethyl O
phthalate O
( O
DMP B
) O
was O
carried O
out O
using O
high O
- O
frequency O
ultrasonic O
processes O
. O

The O
effects O
of O
various O
operating O
parameters O
were O
investigated O
, O
including O
ultrasonic O
frequency O
, O
power O
density O
, O
initial O
DMP B
concentration O
, O
solution O
pH O
and O
the O
presence O
of O
hydrogen B
peroxide I
. O

In O
general O
, O
a O
frequency O
of O
400kHz O
was O
the O
optimum O
for O
achieving O
the O
highest O
DMP B
degradation O
rate O
. O

The O
degradation O
rate O
was O
directly O
proportional O
to O
the O
power O
density O
and O
inversely O
related O
to O
the O
initial O
DMP B
concentration O
. O

The O
addition O
of O
hydrogen B
peroxide I
can O
increase O
the O
radical O
generation O
to O
some O
extent O
. O

Furthermore O
, O
both O
hydroxylation O
of O
the O
aromatic O
ring O
and O
oxidation O
of O
the O
aliphatic O
chain O
appear O
to O
be O
the O
major O
mechanism O
of O
DMP B
degradation O
by O
sonolysis O
based O
on O
LC O
/ O
ESI O
- O
MS O
analysis O
. O

Among O
the O
principle O
reaction O
intermediates O
identified O
, O
tri O
- O
and O
tetra O
- O
hydroxylated O
derivatives O
of O
DMP B
, O
as O
well O
as O
hydroxylated O
monomethyl O
phthalates O
and O
hydroxylated O
phthalic O
acid O
were O
reported O
for O
the O
first O
time O
in O
this O
study O
. O

Comparison O
of O
hydroxyl B
radical O
formation O
in O
aqueous O
solutions O
at O
different O
ultrasound O
frequencies O
and O
powers O
using O
the O
salicylic B
acid I
dosimeter O
. O

Ultrasonic O
frequencies O
of O
20kHz O
, O
382kHz O
, O
584kHz O
, O
862kHz O
( O
and O
998kHz O
) O
have O
been O
compared O
with O
regard O
to O
energy O
output O
and O
hydroxyl B
radical O
formation O
utilising O
the O
salicylic B
acid I
dosimeter O
. O

Using O
the O
salicylic B
acid I
dosimeter O
and O
inputting O
virtually O
the O
same O
Wattages O
it O
is O
established O
that O
862kHz O
is O
around O
10 O
% O
more O
efficient O
at O
generating O
hydroxyl B
radicals O
than O
the O
382kHz O
but O
both O
of O
these O
are O
far O
more O
effective O
than O
the O
other O
frequencies O
. O

Also O
, O
it O
is O
found O
that O
as O
temperature O
increases O
to O
42 O
degrees O
C O
then O
the O
total O
dihydroxybenzoic B
acid I
( O
Total O
DHBA O
) O
produced O
is O
virtually O
identical O
for O
382kHz O
and O
862kHz O
, O
though O
582kHz O
is O
substantially O
lower O
, O
when O
the O
power O
levels O
are O
set O
at O
approximately O
9W O
for O
all O
systems O
. O

Ion O
- O
exchange O
and O
iontophoresis O
- O
controlled O
delivery O
of O
apomorphine B
. O

The O
objective O
of O
this O
study O
was O
to O
test O
a O
drug O
delivery O
system O
that O
combines O
iontophoresis O
and O
cation O
- O
exchange O
fibers O
as O
drug O
matrices O
for O
the O
controlled O
transdermal O
delivery O
of O
antiparkinsonian O
drug O
apomorphine B
. O

Positively O
charged O
apomorphine B
was O
bound O
to O
the O
ion O
- O
exchange O
groups O
of O
the O
cation O
- O
exchange O
fibers O
until O
it O
was O
released O
by O
mobile O
counter O
- O
ions O
in O
the O
external O
solution O
. O

Due O
to O
high O
affinity O
of O
apomorphine B
toward O
the O
ion O
- O
exchanger O
, O
a O
clear O
reduction O
in O
the O
in O
vitro O
transdermal O
fluxes O
from O
the O
fibers O
was O
observed O
compared O
to O
the O
respective O
fluxes O
from O
apomorphine B
solutions O
. O

Overall O
, O
the O
present O
study O
has O
demonstrated O
a O
promising O
approach O
using O
ion O
- O
exchange O
fibers O
for O
controlling O
the O
release O
and O
iontophoretic O
transdermal O
delivery O
of O
apomorphine B
. O

The O
first O
step O
was O
the O
selection O
of O
a O
suitable O
dataset O
of O
heterocyclic O
compounds O
that O
include O
chromones O
, O
coumarins B
, O
chalcones B
, O
thiazolylhydrazones O
, O
etc O
. O

The O
final O
models O
exhibit O
significant O
statistics O
, O
interpretability O
, O
as O
well O
as O
displaying O
predictive O
power O
on O
an O
external O
validation O
set O
made O
up O
of O
chromone O
derivatives O
with O
unknown O
activity O
( O
that O
are O
being O
reported O
here O
for O
first O
time O
) O
synthesized O
by O
our O
group O
, O
and O
coumarins B
recently O
reported O
in O
the O
literature O
. O

Some O
of O
the O
saponins B
( O
2 O
, O
3 O
, O
9 O
) O
were O
revealed O
as O
hyaluronidase O
inhibitors O
similar O
to O
epicatechin B
( O
17 O
) O
. O

Simple O
colorimetric O
bacterial O
detection O
and O
high O
- O
throughput O
drug O
screening O
based O
on O
a O
graphene B
- O
enzyme O
complex O
. O

A O
simple O
, O
colorimetric O
, O
sensitive O
, O
cost O
- O
effective O
and O
high O
- O
throughput O
system O
based O
on O
a O
positively O
charged O
graphene B
oxide I
- O
enzyme O
complex O
was O
developed O
for O
bacterial O
detection O
and O
drug O
screening O
. O

PET O
probe O
discovery O
using O
in O
situ O
click O
chemistry O
uses O
( B
19 I
) I
F I
- O
bearing O
fragments O
as O
( B
18 I
) I
F I
surrogates O
. O

Total O
synthesis O
of O
the O
polyhydroxy O
caprolactam O
amide O
natural O
product O
, O
bengamide O
E O
, O
is O
accomplished O
starting O
from O
tartaric B
acid I
. O

Key O
reactions O
in O
the O
synthesis O
include O
desymmetrization O
of O
the O
bis O
( O
dimethylamide O
) O
unit O
of O
tartaric B
acid I
, O
Zn O
( O
BH O
( O
4 O
) O
) O
( O
2 O
) O
- O
mediated O
anti O
- O
selective O
reduction O
, O
and O
a O
Horner O
- O
Wadsworth O
- O
Emmons O
olefination O
. O

The O
Ypt O
- O
DNA O
hybrid O
molecules O
described O
here O
are O
used O
for O
DNA O
- O
directed O
immobilization O
on O
glass O
- O
and O
silica B
- O
based O
microarrays O
. O

Methods O
for O
the O
detection O
of O
protein O
- O
DNA O
conjugates O
, O
as O
well O
as O
approaches O
for O
nucleotide B
exchange O
and O
distinguishing O
between O
GDP B
- O
and O
GTP B
- O
bound O
Ypts O
on O
microarrays O
, O
are O
reported O
. O

The O
high O
specificity O
of O
different O
Rab O
/ O
Ypt O
- O
effector O
interactions O
, O
which O
also O
depends O
on O
the O
bound O
nucleotide B
, O
is O
shown O
by O
fluorescence O
readout O
of O
microarrays O
. O

Self O
- O
assembly O
process O
of O
soft O
ferritin O
- O
PNIPAAm B
conjugate O
bionanoparticles O
at O
polar O
- O
apolar O
interfaces O
. O

We O
describe O
an O
in O
- O
depth O
investigation O
on O
the O
dynamics O
and O
assembly O
behavior O
at O
polar O
- O
apolar O
interfaces O
of O
ferritin O
- O
PNIPAAm B
conjugates O
( O
poly B
- I
N I
- I
isopropylacrylamide I
) O
. O

The O
difference O
in O
interfacial O
stabilization O
was O
also O
shown O
by O
cryo O
- O
scanning O
electron O
microscopy O
and O
scanning O
force O
microscopy O
, O
which O
displayed O
very O
different O
morphologies O
at O
the O
polar O
- O
apolar O
interface O
for O
the O
unmodified O
ferritin O
, O
pure O
PNIPAAm B
, O
and O
the O
ferritin O
- O
PNIPAAm B
conjugate O
, O
respectively O
. O

The O
self O
- O
assembly O
of O
the O
ferritin O
- O
PNIPAAm B
was O
further O
analyzed O
by O
cryo O
- O
transmission O
electron O
microscopy O
and O
fluorescence O
microscopy O
, O
for O
which O
a O
fluorescently O
labeled O
polymer O
was O
used O
. O

This O
smart O
fluid O
is O
an O
aqueous O
solution O
of O
cationic O
surfactant O
oleyl O
bis O
( O
2 O
- O
hydroxyethyl O
) O
methyl O
ammonium O
chloride O
( O
OHAC O
, O
3 O
. O
4 O
mM O
) O
and O
the O
sodium B
salt O
of O
4 O
- O
phenylazo O
benzoic O
acid O
( O
ACA O
, O
2 O
mM O
) O
. O

These O
nanostructural O
changes O
are O
confirmed O
by O
cryo O
- O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
, O
and O
the O
photoisomerization O
of O
trans O
- O
ACA O
and O
cis O
- O
ACA O
is O
verified O
by O
( B
1 I
) I
H I
NMR O
. O

In O
the O
last O
decade O
, O
several O
inhibitors O
of O
CK2 O
, O
have O
been O
discovered O
and O
characterized O
to O
be O
ATP B
- O
competitive O
compounds O
. O

In O
this O
review O
, O
we O
report O
all O
chemical O
classes O
of O
CK2 O
inhibitors O
available O
in O
literature O
, O
focusing O
our O
attention O
on O
conventional O
ATP B
- O
competitive O
and O
on O
non O
ATP B
- O
competitive O
inhibitors O
, O
which O
could O
represent O
a O
new O
frontier O
in O
CK2 O
inhibition O
and O
, O
consequently O
, O
a O
promising O
field O
of O
study O
in O
discovering O
new O
drug O
candidates O
. O

Bioprocessing O
of O
plant O
in O
vitro O
systems O
for O
the O
mass O
production O
of O
pharmaceutically O
important O
metabolites O
: O
paclitaxel B
and O
its O
derivatives O
. O

Taxol B
( O
paclitaxel B
) O
and O
its O
derivatives O
are O
microtubule O
- O
stabilizing O
drugs O
widely O
used O
in O
the O
treatment O
of O
several O
types O
of O
cancer O
, O
including O
mammary O
, O
prostate O
, O
ovarian O
and O
non O
- O
small O
- O
cell O
lung O
carcinoma O
, O
as O
well O
as O
AIDS O
- O
associated O
Kaposi O
' O
s O
sarcoma O
and O
other O
types O
of O
tumor O
. O

Taxanes B
stabilize O
microtubules O
by O
enhancing O
their O
polymerization O
and O
inhibiting O
depolymerization O
. O

Microtubule O
dynamics O
are O
crucial O
to O
mitotic O
spindle O
formation O
and O
function O
; O
therefore O
, O
cells O
exposed O
to O
taxanes B
are O
unable O
to O
undergo O
chromosomal O
separation O
during O
mitosis O
, O
become O
arrested O
in O
the O
G2 O
/ O
M O
phases O
of O
the O
cell O
cycle O
, O
and O
are O
subsequently O
targeted O
for O
apoptosis O
. O

Plant O
cell O
cultures O
are O
used O
for O
industrial O
- O
scale O
biotechnological O
production O
of O
important O
bioactive O
plant O
secondary O
metabolites O
, O
including O
the O
anticancer O
agent O
paclitaxel B
. O

In O
the O
last O
two O
decades O
, O
there O
have O
been O
numerous O
empirical O
approaches O
to O
improve O
the O
biotechnological O
production O
of O
taxanes B
, O
leading O
to O
the O
conclusion O
that O
treatment O
of O
Taxus O
sp O
. O
cells O
with O
methyl O
jasmonate O
or O
other O
elicitors O
is O
the O
most O
effective O
strategy O
. O

However O
, O
little O
insight O
has O
been O
gained O
into O
how O
the O
elicitors O
increase O
taxane B
biosynthesis O
or O
how O
this O
process O
is O
regulated O
. O

In O
recent O
years O
, O
with O
the O
help O
of O
" O
omics O
" O
tools O
, O
a O
rational O
approach O
has O
provided O
new O
information O
about O
taxane B
metabolism O
and O
its O
control O
. O

Once O
pathway O
bottlenecks O
have O
been O
identified O
, O
it O
will O
be O
possible O
to O
engineer O
Taxus O
sp O
. O
cell O
lines O
with O
overexpression O
of O
genes O
that O
control O
the O
flux O
- O
limiting O
steps O
, O
thus O
boosting O
taxane B
productivity O
. O

This O
review O
describes O
the O
chemical O
and O
biological O
characterization O
of O
paclitaxel B
and O
its O
derivatives O
and O
discusses O
future O
prospects O
for O
their O
biotechnological O
production O
. O

Pentacyclic O
triterpenoids O
including O
the O
oleanane B
, O
ursane O
and O
lupane O
groups O
are O
widely O
distributed O
in O
many O
medicinal O
plants O
, O
such O
as O
Glycyrrhiza O
species O
, O
Gymnema O
species O
, O
Centella O
asiatica O
, O
Camellia O
sinensis O
, O
Crataegus O
species O
and O
Olea O
europaea O
, O
which O
are O
commonly O
used O
in O
traditional O
medicine O
for O
the O
treatment O
of O
diabetes O
and O
diabetic O
complications O
. O

A O
large O
number O
of O
bioactive O
pentacyclic O
triterpenoids O
, O
such O
as O
oleanolic B
acid I
, O
glycyrrhizin B
, O
glycyrrhetinic B
acid I
, O
ursolic B
acid I
, O
betulin O
, O
betulinic B
acid I
and O
lupeol B
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose B
absorption O
, O
glucose B
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

For O
example O
, O
resveratrol B
and O
thymoquinone O
are O
hitherto O
known O
compounds O
to O
possess O
proapoptotic O
effects O
on O
platelets O
. O

In O
contrast O
, O
cinnamtannin O
B1 O
and O
crocin B
exhibit O
antiapoptotic O
effects O
. O

Synthesis O
and O
HIV O
- O
1 O
inhibitory O
activities O
of O
dicaffeoyl O
and O
digalloyl O
esters O
of O
quinic B
acid I
derivatives O
. O

Twenty O
analogues O
of O
the O
anti O
- O
HIV O
- O
1 O
integrase O
( O
IN O
) O
inhibitors O
dicaffeoylquinic B
acids I
( O
DCQAs O
) O
were O
prepared O
. O

Although O
post O
- O
translational O
addition O
of O
methyl B
groups O
to O
the O
histone O
lysine B
has O
been O
discovered O
three O
decades O
ago O
, O
the O
importance O
of O
this O
epigenetic O
modification O
has O
emerged O
only O
in O
the O
last O
few O
years O
. O

Effects O
of O
dopamine B
D2 O
/ O
D3 O
receptor O
ligands O
on O
food O
- O
cocaine B
choice O
in O
socially O
housed O
male O
cynomolgus O
monkeys O
. O

Dopamine B
D2 O
/ O
D3 O
receptor O
partial O
agonists O
have O
been O
suggested O
as O
medications O
for O
cocaine B
dependence O
. O

The O
present O
experiments O
examined O
the O
effect O
of O
acute O
and O
repeated O
administration O
of O
drugs O
with O
varying O
intrinsic O
efficacy O
at O
D2 O
/ O
D3 O
receptors O
on O
the O
relative O
reinforcing O
strength O
of O
cocaine B
. O

The O
high O
- O
efficacy O
agonist O
R O
( O
- O
) O
- O
norpropylapomorphine O
[ O
( O
- O
) O
- O
NPA O
] O
, O
low O
- O
efficacy O
agonist O
aripiprazole O
( O
ARI O
) O
, O
and O
antagonist O
eticlopride O
( O
ETIC O
) O
were O
administered O
acutely O
to O
monkeys O
self O
- O
administering O
cocaine B
under O
a O
food O
- O
cocaine B
choice O
procedure O
in O
which O
a O
cocaine B
self O
- O
administration O
dose O
- O
effect O
curve O
was O
determined O
daily O
. O

The O
effects O
of O
5 O
- O
day O
treatment O
with O
ARI O
and O
( O
- O
) O
- O
NPA O
were O
characterized O
under O
conditions O
in O
which O
monkeys O
did O
( O
ARI O
) O
or O
did O
not O
[ O
ARI O
and O
( O
- O
) O
- O
NPA O
] O
self O
- O
administer O
cocaine B
during O
treatment O
. O

When O
administered O
acutely O
, O
ARI O
and O
ETIC O
increased O
the O
choice O
of O
low O
cocaine B
doses O
, O
and O
only O
( O
- O
) O
- O
NPA O
decreased O
the O
choice O
of O
higher O
cocaine B
doses O
and O
cocaine B
intake O
; O
effects O
were O
similar O
across O
social O
ranks O
. O

When O
administered O
repeatedly O
while O
self O
administration O
occurred O
only O
on O
days O
1 O
and O
5 O
of O
treatment O
, O
ARI O
, O
but O
not O
( O
- O
) O
- O
NPA O
, O
decreased O
cocaine B
choice O
in O
dominant O
monkeys O
, O
whereas O
( O
- O
) O
- O
NPA O
, O
but O
not O
ARI O
, O
did O
so O
in O
subordinates O
. O

When O
dominant O
monkeys O
self O
- O
administered O
cocaine B
on O
all O
five O
days O
of O
ARI O
treatment O
, O
however O
, O
these O
effects O
were O
not O
observed O
. O

Moreover O
, O
these O
results O
suggest O
that O
exposure O
to O
cocaine B
during O
treatment O
can O
counteract O
treatment O
- O
induced O
reductions O
in O
the O
reinforcing O
effects O
of O
cocaine B
. O

Protective O
effect O
of O
70 O
% O
ethanolic O
extract O
of O
Lindera O
obtusiloba O
Blume O
on O
tert B
- I
butyl I
hydroperoxide I
- O
induced O
oxidative O
hepatotoxicity O
in O
rats O
. O

LOE O
prevented O
tert B
- I
butyl I
hydroperoxide I
( O
t O
- O
BHP O
) O
- O
induced O
oxidative O
damage O
in O
HepG2 O
cells O
. O

Along O
with O
its O
high O
antioxidant O
potency O
in O
vitro O
, O
our O
animal O
study O
confirmed O
that O
pretreatment O
with O
LOE O
( O
500 O
or O
2000 O
mg O
/ O
kg O
) O
for O
7 O
days O
prior O
to O
a O
single O
dose O
of O
t O
- O
BHP O
( O
i O
. O
p O
. O
: O
0 O
. O
5 O
mmol O
/ O
kg O
) O
significantly O
lowered O
the O
serum O
levels O
of O
alanine B
and O
aspartate B
aminotransferases O
. O

In O
addition O
, O
glutathione B
levels O
were O
increased O
in O
the O
liver O
, O
and O
lipid O
peroxidation O
levels O
were O
decreased O
in O
a O
dose O
- O
dependent O
manner O
. O

Steroid B
receptor O
coactivator O
- O
1 O
mediates O
estrogenic O
actions O
to O
prevent O
body O
weight O
gain O
in O
female O
mice O
. O

Estrogen B
receptor O
- O
alpha O
( O
ER O
alpha O
) O
expressed O
by O
hypothalamic O
proopiomelanocortin O
and O
steroidogenic O
factor O
- O
1 O
neurons O
largely O
mediates O
the O
antiobesity O
effects O
of O
estrogens B
in O
females O
. O

In O
the O
current O
study O
, O
we O
demonstrated O
that O
steroid B
receptor O
coactivator O
- O
1 O
( O
SRC1 O
) O
, O
a O
nuclear O
receptor O
coactivator O
, O
is O
abundantly O
expressed O
by O
both O
proopiomelanocortin O
and O
steroidogenic O
factor O
- O
1 O
neurons O
. O

Finally O
, O
we O
demonstrated O
that O
the O
effects O
of O
estrogens B
on O
energy O
homeostasis O
are O
significantly O
blunted O
in O
female O
mice O
lacking O
SRC1 O
globally O
. O

Collectively O
our O
results O
indicate O
that O
SRC1 O
is O
functionally O
required O
to O
mediate O
the O
antiobesity O
effects O
of O
estrogen B
- O
ER O
alpha O
signals O
. O

ADP B
- O
ribosylation O
of O
guanosine B
by O
SCO5461 O
protein O
secreted O
from O
Streptomyces O
coelicolor O
. O

The O
Streptomyces O
coelicolor O
A3 O
( O
2 O
) O
genome O
encodes O
a O
possible O
secretion O
protein O
, O
SCO5461 O
, O
that O
shares O
a O
30 O
% O
homology O
with O
the O
activity O
domains O
of O
two O
toxic O
ADP B
- O
ribosyltransferases O
, O
pierisins O
and O
mosquitocidal O
toxin O
. O

We O
found O
ADP B
- O
ribosylating O
activity O
for O
the O
SCO5461 O
protein O
product O
through O
its O
co O
- O
incubation O
with O
guanosine B
and O
NAD B
( I
+ I
) I
, O
which O
resulted O
in O
the O
formation O
of O
N O
( O
2 O
) O
- O
( O
ADP O
- O
ribos O
- O
1 O
- O
yl O
) O
- O
guanosine O
( O
( O
ar2 O
) O
Guo O
) O
, O
with O
a O
K O
( O
m O
) O
value O
of O
110 O
mu O
M O
. O

SCO5461 O
was O
further O
found O
to O
ADP B
- O
ribosylate O
deoxyguanosine O
, O
GMP O
, O
dGMP O
, O
GTP B
, O
dGTP O
, O
and O
cyclic O
GMP O
with O
k O
( O
cat O
) O
values O
of O
150 O
- O
370 O
s O
( O
- O
1 O
) O
. O

Oligo O
( O
dG O
) O
, O
oligo O
( O
G O
) O
, O
and O
yeast O
tRNA O
were O
also O
ADP B
- O
ribosylated O
by O
this O
protein O
, O
although O
with O
much O
lower O
k O
( O
cat O
) O
values O
of O
0 O
. O
2 O
s O
( O
- O
1 O
) O
or O
less O
. O

SCO5461 O
showed O
maximum O
ADP B
- O
ribosylation O
activity O
towards O
guanosine O
at O
30 O
degrees O
C O
, O
and O
maintained O
20 O
% O
of O
these O
maximum O
activity O
levels O
even O
at O
0 O
degrees O
C O
. O

This O
is O
the O
first O
report O
of O
the O
ADP B
- O
ribosylation O
of O
guanosine B
and O
guanine O
mononucleotides O
among O
the O
family O
members O
of O
various O
ADP B
- O
ribosylating O
enzymes O
. O

We O
thus O
designated O
the O
SCO5461 O
protein O
product O
as O
S O
. O
coelicolor O
ADP B
- O
ribosylating O
protein O
, O
ScARP O
. O

Our O
current O
results O
could O
offer O
new O
insights O
into O
not O
only O
the O
ADP B
- O
ribosylation O
of O
small O
molecules O
but O
also O
signal O
transduction O
events O
via O
enzymatic O
nucleoside B
modification O
by O
toxin O
- O
related O
enzymes O
. O

Vitamin B
K I
antagonists O
( O
VKAs O
) O
were O
, O
until O
recently O
, O
the O
only O
option O
for O
chronic O
anticoagulation O
in O
patients O
with O
atrial O
fibrillation O
. O

Three O
new O
oral O
anticoagulants O
have O
been O
tested O
for O
this O
indication O
in O
recent O
randomized O
trials O
: O
dabigatran B
, O
rivaroxaban B
, O
and O
apixaban B
. O

Overall O
, O
efficacy O
and O
safety O
appear O
to O
be O
noninferior O
, O
and O
in O
some O
instances O
superior O
, O
to O
warfarin B
. O

However O
, O
the O
new O
drugs O
have O
their O
downsides O
, O
and O
switching O
from O
warfarin B
is O
not O
recommended O
for O
all O
patients O
. O

Theoretical O
study O
of O
the O
reaction O
of O
CH2XO O
( O
X O
= O
F B
, O
Cl B
, O
Br B
) O
radicals O
with O
the O
NO B
radical O
. O

In O
this O
paper O
, O
we O
focus O
on O
the O
multiple O
- O
channel O
reactions O
of O
CH O
( O
2 O
) O
XO O
( O
X O
= O
F B
, O
Cl B
, O
Br B
) O
radicals O
with O
the O
NO B
radical O
by O
means O
of O
direct O
dynamic O
methods O
. O

The O
rate O
constants O
for O
the O
three O
hydrogen B
abstraction O
reaction O
channels O
over O
the O
temperature O
range O
200 O
- O
1 O
, O
500 O
K O
were O
calculated O
by O
the O
improved O
canonical O
variational O
transition O
state O
theory O
( O
ICVT O
) O
with O
a O
correction O
for O
small O
- O
curvature O
tunneling O
( O
SCT O
) O
. O

Furthermore O
, O
mutagenesis O
studies O
suggest O
that O
Val B
- O
499 O
is O
the O
primary O
site O
responsible O
for O
these O
changes O
. O

Adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 O
- O
naphthylamine O
to O
colloidal O
oxidized O
multiwalled O
carbon B
nanotubes O
: O
effects O
of O
humic O
acid O
and O
surfactant O
modification O
. O

Carbon B
nanotubes O
( O
CNTs O
) O
can O
exist O
in O
the O
form O
of O
colloidal O
suspension O
in O
aquatic O
environments O
, O
particularly O
in O
the O
presence O
of O
natural O
organic O
matter O
or O
surfactants O
, O
and O
may O
significantly O
affect O
the O
fate O
and O
transport O
of O
organic O
contaminants O
. O

In O
the O
present O
study O
, O
the O
authors O
examined O
the O
adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 O
- O
naphthylamine O
to O
three O
colloidal O
CNTs O
, O
including O
a O
stable O
suspension O
of O
oxidized O
multiwalled O
carbon B
nanotubes O
( O
O O
- O
MWNT O
) O
, O
a O
humic O
acid O
( O
HA O
) O
- O
modified O
colloidal O
O O
- O
MWNT O
, O
and O
a O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
- O
modified O
colloidal O
O O
- O
MWNT O
. O

All O
three O
colloidal O
O O
- O
MWNTs O
exhibit O
strong O
adsorption O
affinities O
to O
the O
three O
test O
compounds O
( O
with O
K O
( O
OC O
) O
values O
orders O
of O
magnitude O
greater O
than O
those O
of O
natural O
organic O
matter O
) O
, O
likely O
resulting O
from O
strong O
nonhydrophobic O
interactions O
such O
as O
pi O
- O
pi O
electron O
donor O
- O
acceptor O
interactions O
and O
Lewis B
acid I
- O
base O
interactions O
. O

When O
thoroughly O
mixed O
, O
HA O
( O
at O
~ O
310 O
mg O
HA O
/ O
g O
CNT O
) O
and O
SDS B
( O
at O
~ O
750 O
mg O
SDS B
/ O
g O
CNT O
) O
significantly O
affected O
the O
aggregation O
properties O
of O
O O
- O
MWNT O
, O
causing O
individually O
dispersed O
tubes O
to O
form O
a O
loosely O
entangled O
network O
. O

The O
effects O
of O
HA O
or O
SDS B
modification O
on O
adsorption O
are O
twofold O
. O

Adsorption O
of O
HA O
/ O
SDS B
significantly O
reduces O
surface O
areas O
of O
O O
- O
MWNT O
; O
however O
, O
the O
entangled O
network O
allows O
adsorbate O
molecules O
to O
interact O
simultaneously O
with O
multiple O
tubes O
. O

An O
important O
implication O
is O
that O
humic O
substances O
and O
surfactant O
- O
like O
materials O
not O
only O
facilitate O
the O
formation O
of O
colloidal O
carbon B
nanoparticles O
but O
also O
affect O
how O
these O
colloidal O
carbon B
nanoparticles O
adsorb O
organic O
contaminants O
. O

Previous O
studies O
have O
shown O
inexplicable O
declines O
in O
breeding O
waterbirds O
within O
western O
New O
York O
/ O
New O
Jersey O
Harbor O
between O
1996 O
and O
2002 O
and O
elevated O
polychlorinated O
dibenzo O
- O
p O
- O
dioxins O
and O
polychlorinated B
biphenyls I
( O
PCBs B
) O
in O
double O
- O
crested O
cormorant O
( O
Phalacrocorax O
auritus O
) O
eggs O
. O

The O
present O
study O
assessed O
associations O
between O
immune O
function O
, O
prefledgling O
survival O
, O
and O
selected O
organochlorine B
compounds O
and O
metals O
in O
herring O
gulls O
( O
Larus O
argentatus O
) O
and O
black O
- O
crowned O
night O
herons O
( O
Nycticorax O
nycticorax O
) O
in O
lower O
New O
York O
Harbor O
during O
2003 O
. O

Strong O
negative O
correlations O
( O
r O
= O
- O
0 O
. O
95 O
to O
- O
0 O
. O
98 O
) O
between O
the O
PHA O
response O
and O
dioxins O
and O
PCBs B
in O
gull O
livers O
was O
strong O
evidence O
suggesting O
that O
these O
chemicals O
contribute O
significantly O
to O
immunosuppression O
in O
New O
York O
Harbor O
waterbirds O
. O

Estradiol B
exerts O
antiapoptotic O
effects O
in O
skeletal O
myoblasts O
via O
mitochondrial O
PTP O
and O
MnSOD O
. O

17 B
beta I
- I
Estradiol I
( O
E O
( O
2 O
) O
) O
protects O
several O
non O
- O
reproductive O
tissues O
from O
apoptosis O
, O
including O
skeletal O
muscle O
. O

We O
have O
shown O
that O
E O
( O
2 O
) O
at O
physiological O
concentrations O
prevented O
apoptosis O
induced O
by O
H B
( I
2 I
) I
O I
( I
2 I
) I
in O
C2C12 O
skeletal O
myoblasts O
. O

As O
we O
also O
demonstrated O
the O
presence O
of O
estrogen B
receptors O
in O
mitochondria O
, O
the O
present O
work O
was O
focused O
on O
the O
effects O
of O
E O
( O
2 O
) O
on O
this O
organelle O
. O

Specifically O
, O
we O
evaluated O
the O
actions O
of O
E O
( O
2 O
) O
on O
the O
mitochondrial O
permeability O
transition O
pore O
( O
MPTP O
) O
by O
the O
calcein B
- O
acetoxymethylester O
/ O
cobalt B
method O
using O
fluorescence O
microscopy O
and O
flow O
cytometry O
. O

Pretreatment O
with O
E O
( O
2 O
) O
prevented O
MPTP O
opening O
induced O
by O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
which O
preceded O
loss O
of O
mitochondrial O
membrane O
potential O
. O

In O
addition O
, O
it O
was O
observed O
that O
H B
( I
2 I
) I
O I
( I
2 I
) I
induced O
translocation O
of O
Bax O
to O
mitochondria O
; O
however O
, O
in O
the O
presence O
of O
the O
steroid B
this O
effect O
was O
abrogated O
suggesting O
that O
members O
of O
the O
Bcl O
- O
2 O
family O
may O
be O
regulated O
by O
E O
( O
2 O
) O
to O
exert O
an O
antiapoptotic O
effect O
. O

Moreover O
, O
E O
( O
2 O
) O
increased O
mitochondrial O
manganese O
superoxide B
dismutase O
protein O
expression O
and O
activity O
, O
as O
part O
of O
a O
mechanism O
activated O
by O
E O
( O
2 O
) O
that O
improved O
mitochondrial O
performance O
. O

Functionalized O
alkynyl O
polyvinyl O
alcohol O
magnetic O
microspheres O
( O
PVA B
MMs O
) O
were O
developed O
for O
the O
specific O
enrichment O
of O
sialic B
acid I
- O
rich O
glycoproteins O
by O
click O
chemistry O
. O

The O
PVA B
MM O
parameters O
, O
including O
the O
size O
and O
coverage O
of O
functionalized O
groups O
, O
were O
optimized O
by O
response O
surface O
methodology O
. O

Then O
, O
the O
optimal O
PVA B
MMs O
were O
synthesized O
, O
and O
the O
morphology O
and O
surface O
chemical O
properties O
were O
characterized O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
scanning O
electron O
microscopy O
( O
SEM O
) O
, O
and O
Fourier O
transform O
infrared O
spectroscopy O
( O
FT O
- O
IR O
) O
. O

To O
capture O
glycoproteins O
from O
the O
cell O
surface O
, O
a O
bioorthogonal O
chemical O
method O
was O
applied O
to O
metabolically O
label O
them O
with O
an O
azide B
group O
. O

Legumain O
is O
a O
lysosomal O
cysteine B
protease O
whose O
biological O
function O
remains O
poorly O
defined O
. O

Optical O
pumping O
of O
a O
single O
electron O
spin O
bound O
to O
a O
fluorine B
donor O
in O
a O
ZnSe O
nanostructure O
. O

Here O
we O
demonstrate O
optical O
pumping O
of O
a O
single O
electron O
within O
a O
semiconductor O
nanostructure O
comprised O
of O
a O
single O
fluorine B
donor O
located O
within O
a O
ZnSe O
/ O
ZnMgSe O
quantum O
well O
. O

This O
study O
sought O
to O
investigate O
the O
inhibitory O
effect O
of O
aqueous O
extracts O
of O
two O
varieties O
( O
red O
and O
white O
) O
of O
Hibiscus O
sabdariffa O
( O
Roselle O
) O
calyces O
on O
carbohydrate B
hydrolyzing O
enzymes O
( O
alpha O
- O
amylase O
and O
alpha O
- O
glucosidase O
) O
, O
with O
the O
aim O
of O
providing O
the O
possible O
mechanism O
for O
their O
antidiabetes O
properties O
. O

In O
addition O
, O
the O
red O
variety O
possessed O
higher O
antioxidant O
capacity O
as O
exemplified O
by O
the O
( B
* I
) I
OH I
scavenging O
abilities O
, O
Fe B
( I
2 I
+ I
) I
chelating O
ability O
, O
and O
inhibition O
of O
Fe B
( I
2 I
+ I
) I
- O
induced O
pancreatic O
lipid O
peroxidation O
in O
vitro O
. O

The O
enzyme O
inhibitory O
activities O
and O
antioxidant O
properties O
of O
the O
roselle O
extracts O
agreed O
with O
their O
phenolic B
content O
. O

Rooibos O
is O
rich O
in O
antioxidant O
polyphenols B
, O
with O
the O
dihydrochalcone O
, O
aspalathin O
, O
as O
a O
major O
active O
ingredient O
. O

In O
a O
high O
glucose B
environment O
, O
C O
. O
elegans O
treated O
with O
rooibos O
extract O
exhibited O
an O
extended O
lifespan O
. O

In O
addition O
, O
rooibos O
decreased O
acute O
oxidative O
damage O
caused O
by O
the O
superoxide B
anion O
radical O
generator O
, O
juglone B
, O
with O
aspalathin O
playing O
a O
major O
role O
in O
improving O
the O
survival O
rate O
of O
C O
. O
elegans O
. O

Synthesis O
, O
antimalarial O
activity O
and O
cytotoxic O
potential O
of O
new O
monocarbonyl O
analogues O
of O
curcumin B
. O

A O
series O
of O
novel O
monocarbonyl O
analogues O
of O
curcumin B
have O
been O
designed O
, O
synthesized O
and O
tested O
for O
their O
activity O
against O
Molt4 O
, O
HeLa O
, O
PC3 O
, O
DU145 O
and O
KB O
cancer O
cell O
lines O
. O

Six O
of O
the O
analogues O
showed O
potent O
cytotoxicity O
towards O
these O
cell O
lines O
with O
IC O
( O
50 O
) O
values O
below O
1 O
mu O
M O
, O
which O
is O
better O
than O
doxorubicin B
, O
a O
US O
FDA O
approved O
drug O
. O

Inhibitory O
effects O
of O
metachromins O
L O
- O
Q O
and O
its O
related O
analogs O
against O
receptor O
tyrosine B
kinases O
EGFR O
and O
HER2 O
. O

Inhibitory O
effects O
of O
metachromins O
L O
- O
Q O
( O
1 O
- O
6 O
) O
, O
sesquiterpenoid O
quinones O
with O
an O
amino B
acid I
residue O
, O
and O
their O
related O
analogs O
( O
7 O
- O
18 O
) O
prepared O
from O
metachromins O
A O
( O
19 O
) O
and O
C O
( O
20 O
) O
against O
receptor O
tyrosine B
kinases O
EGFR O
and O
HER2 O
were O
investigated O
. O

Anti O
- O
diabetic O
activities O
of O
Gegen O
Qinlian O
Decoction O
in O
high O
- O
fat O
diet O
combined O
with O
streptozotocin B
- O
induced O
diabetic O
rats O
and O
in O
3T3 O
- O
L1 O
adipocytes O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
anti O
- O
diabetic O
effects O
of O
GGQLD O
in O
high O
- O
fat O
diet O
combined O
with O
streptozotocin B
- O
induced O
diabetic O
rats O
and O
in O
3T3 O
- O
L1 O
adipocytes O
. O

The O
present O
results O
suggested O
GGQLD O
( O
4 O
. O
95 O
, O
11 O
. O
55 O
and O
18 O
. O
15 O
g O
/ O
kg O
) O
decreased O
significantly O
fasting O
blood O
glucose B
, O
glycosylated O
serum O
protein O
, O
and O
glycosylated O
hemoglobin O
of O
diabetic O
rats O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
GGQLD O
( O
4 O
. O
95 O
and O
18 O
. O
15 O
g O
/ O
kg O
) O
decreased O
significantly O
fasting O
serum O
insulin O
levels O
of O
diabetic O
rats O
( O
p O
< O
0 O
. O
05 O
) O
; O
in O
3T3 O
- O
L1 O
adipocytes O
, O
Gegen O
Qinlian O
Decoction O
- O
containing O
serum O
( O
GGQLD O

- O
CS O
) O
( O
4 O
% O
, O
8 O
% O
and O
16 O
% O
) O
enhanced O
glucose B
consumption O
, O
triglyceride B
( O
TG O
) O
content O
, O
adiponectin O
protein O
concentration O
and O
the O
mRNA O
expression O
of O
adiponectin O
. O

Adiponectin O
contributes O
to O
the O
regulation O
of O
lipid O
and O
glucose B
metabolism O
, O
and O
can O
play O
a O
critical O
role O
in O
the O
development O
of O
diabetes O
mellitus O
; O
the O
mechanisms O
of O
action O
of O
GGQLD O
might O
be O
related O
to O
augmentation O
of O
adiponectin O
protein O
concentration O
and O
up O
- O
regulation O
of O
the O
mRNA O
expression O
of O
adiponectin O
. O

4 O
- O
tert O
- O
Octylphenol O
stimulates O
the O
expression O
of O
cathepsins O
in O
human O
breast O
cancer O
cells O
and O
xenografted O
breast O
tumors O
of O
a O
mouse O
model O
via O
an O
estrogen B
receptor O
- O
mediated O
signaling O
pathway O
. O

Endocrine O
disrupting O
chemicals O
( O
EDCs O
) O
are O
defined O
as O
environmental O
compounds O
that O
modulate O
steroid B
hormone O
receptor O
- O
dependent O
responses O
an O
abnormal O
manner O
, O
resulting O
in O
adverse O
health O
problems O
for O
humans O
such O
as O
cancer O
growth O
and O
metastasis O
. O

Treatment O
with O
OP O
significantly O
induced O
the O
proliferation O
MCF O
- O
7 O
cells O
in O
an O
MTT B
assay O
. O

The O
relation O
between O
lead O
( O
Pb B
) O
and O
iron B
( O
Fe B
) O
becomes O
increasingly O
concerned O
because O
they O
are O
both O
divalent O
metals O
that O
are O
absorbed O
by O
the O
same O
intestinal O
mechanism O
, O
and O
Pb B
exposure O
and O
Fe B
deficiency O
in O
the O
developmental O
brain O
, O
as O
well O
as O
Fe B
overload O
in O
the O
aged O
brain O
, O
can O
cause O
cognitive O
deficits O
. O

However O
, O
the O
interaction O
between O
Pb B
exposure O
and O
Fe B
status O
in O
the O
brain O
has O
not O
been O
established O
. O

Therefore O
, O
in O
the O
current O
study O
, O
we O
examined O
the O
effects O
of O
maternal O
ingestion O
of O
Pb B
in O
drinking O
water O
during O
gestation O
and O
lactation O
on O
the O
Fe B
status O
and O
the O
expression O
of O
divalent O
metal O
transporter O
1 O
( O
DMT1 O
) O
and O
ferroportin O
1 O
( O
FP1 O
) O
in O
the O
brain O
of O
offspring O
. O

Pb B
exposure O
increases O
the O
Fe B
content O
in O
the O
old O
- O
aged O
rats O
' O
brain O
, O
which O
might O
be O
not O
subjected O
to O
DMT1 O
mediating O
, O
but O
may O
be O
associated O
with O
the O
decrease O
expression O
of O
FP1 O
. O

Furthermore O
, O
the O
effect O
of O
Pb B
on O
FP1 O
expression O
is O
regulated O
at O
transcriptional O
and O
posttranscriptional O
levels O
. O

The O
perturbation O
in O
Fe B
homeostasis O
may O
contribute O
to O
the O
neurotoxicology O
consequences O
induced O
by O
Pb B
exposure O
, O
and O
FP1 O
may O
play O
a O
role O
in O
Pb B
- O
induced O
Fe B
cumulation O
in O
the O
brain O
. O

The O
tryptophan B
conversion O
into O
several O
other O
metabolites O
through O
this O
pathway O
provides O
neuronal O
and O
redox O
modulators O
useful O
for O
maintenance O
of O
major O
functions O
in O
the O
brain O
. O

In O
this O
review O
, O
we O
explored O
most O
of O
literature O
favoring O
one O
or O
the O
other O
concept O
, O
in O
order O
to O
provide O
an O
accurate O
vision O
on O
the O
real O
participation O
of O
this O
tryptophan B
metabolite O
in O
both O
experimental O
paradigms O
and O
human O
brain O
pathologies O
. O

Unlike O
previously O
reported O
6 O
- O
methyl O
- O
2 O
, O
4 O
- O
disubstituted O
pyridazin O
- O
3 O
( O
2H O
) O
- O
ones O
, O
whose O
R O
- O
forms O
preferentially O
activated O
FPR1 O
/ O
FPR2 O
, O
we O
found O
that O
four O
S O
- O
enantiomers O
in O
the O
seven O
ureidopropanamide O
pairs O
tested O
preferentially O
activated O
intracellular O
Ca B
( I
2 I
+ I
) I
flux O
in O
FPR2 O
- O
transfected O
cells O
, O
while O
the O
R O
- O
counterpart O
was O
more O
active O
in O
two O
enantiomer O
pairs O
. O

Biological O
impact O
of O
phthalates B
. O

Esters B
of O
phthalic O
acid O
are O
chemical O
agents O
used O
to O
improve O
the O
plasticity O
of O
industrial O
polymers O
. O

This O
study O
investigated O
cytotoxicity O
, O
endocrine O
disruption O
, O
effects O
mediated O
via O
AhR O
, O
lipid O
peroxidation O
and O
effects O
on O
expression O
of O
enzymes O
of O
xenobiotic O
metabolism O
caused O
by O
di O
- O
( O
2 O
- O
ethy O
hexyl O
) O
phthalate O
( O
DEHP B
) O
, O
diethyl O
phthalate O
( O
DEP O
) O
, O
dibutyl B
phthalate I
( O
DBP O
) O
and O
benzyl O
butyl O
phthalate O
( O
BBP O
) O
in O
developing O
fish O
embryos O
. O

Oxidative O
stress O
was O
identified O
as O
the O
critical O
mechanism O
of O
toxicity O
( O
CMTA O
) O
in O
the O
case O
of O
DEHP B
and O
DEP O
, O
while O
the O
efficient O
removal O
of O
DBP O
and O
BBP O
by O
phase O
1 O
enzymes O
resulted O
in O
lesser O
toxicity O
. O

DEHP B
and O
DEP O
did O
not O
mimic O
estradiol B
( O
E O
( O
2 O
) O
) O
in O
transactivation O
studies O
, O
but O
at O
concentrations O
of O
10mg O
/ O
L O
synthesis O
of O
sex O
steroid B
hormones O
was O
affected O
. O

Exposure O
to O
10mg O
BBP O
/ O
L O
resulted O
in O
weak O
transactivation O
of O
the O
estrogen B
receptor O
( O
ER O
) O
. O

All O
phthalates B
exhibited O
weak O
potency O
as O
agonists O
of O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
. O

The O
order O
of O
potency O
of O
the O
4 O
phthalates B
studied O
was O
; O
DEHP B
> O
DEP O
> O
BBP O
> O
DBP O
. O

The O
study O
highlights O
the O
need O
for O
simultaneous O
assessment O
of O
: O
( O
1 O
) O
multiple O
cellular O
targets O
affected O
by O
phthalates B
and O
( O
2 O
) O
phthalate B
mixtures O
to O
account O
for O
additive O
effects O
when O
multiple O
phthalates B
modulate O
the O
same O
pathway O
. O

Doxorubicin B
decreases O
paraquat B
accumulation O
and O
toxicity O
in O
Caco O
- O
2 O
cells O
. O

P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
is O
an O
efflux O
pump O
belonging O
to O
the O
ATP B
- O
binding O
cassette O
transporter O
superfamily O
expressed O
in O
several O
organs O
. O

The O
herbicide O
paraquat B
( O
PQ O
) O
is O
a O
P O
- O
gp O
substrate O
responsible O
for O
thousands O
of O
fatal O
intoxications O
worldwide O
that O
still O
lacks O
an O
effective O
antidote O
. O

The O
aim O
of O
the O
present O
work O
was O
to O
evaluate O
the O
effectiveness O
of O
such O
an O
antidote O
by O
testing O
whether O
doxorubicin B
( O
DOX B
) O
, O
a O
known O
P O
- O
gp O
inducer O
, O
could O
efficiently O
protect O
Caco O
- O
2 O
cells O
against O
PQ O
cytotoxicity O
, O
6 O
h O
after O
the O
incubation O
with O
the O
herbicide O
, O
reflecting O
a O
real O
- O
life O
intoxication O
scenario O
. O

Cytotoxicity O
was O
evaluated O
by O
the O
MTT B
assay O
and O
PQ O
intracellular O
concentrations O
were O
measured O
by O
gas O
chromatography O
- O
ion O
trap O
- O
mass O
spectrometry O
( O
GC O
- O
IT O
- O
MS O
) O
. O

Also O
, O
the O
DOX B
modulatory O
effect O
on O
choline B
uptake O
transport O
system O
was O
assessed O
by O
measuring O
the O
uptake O
of O
[ O
( O
3 O
) O
H O
] O
- O
choline O
. O

The O
results O
show O
that O
DOX B
exerts O
protective O
effects O
against O
PQ O
cytotoxicity O
, O
preventing O
the O
intracellular O
accumulation O
of O
the O
herbicide O
. O

In O
fact O
, O
DOX B
also O
efficiently O
inhibited O
the O
choline B
transport O
system O
that O
influences O
PQ O
cellular O
uptake O
. O

In O
conclusion O
, O
in O
this O
cellular O
model O
, O
DOX B
effectively O
protects O
against O
PQ O
toxicity O
by O
inducing O
P O
- O
gp O
and O
through O
the O
interaction O
with O
the O
choline B
transporter O
, O
suggesting O
that O
compounds O
presenting O
this O
double O
feature O
of O
promoting O
the O
efflux O
and O
limiting O
the O
uptake O
of O
PQ O
could O
be O
used O
as O
effective O
antidotes O
to O
treat O
intoxications O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
chemical O
composition O
of O
acetone B
extracts O
of O
the O
lichens O
Evernia O
prunastri O
and O
Pseudoevernia O
furfuraceae O
and O
in O
vitro O
antioxidant O
, O
antimicrobial O
, O
and O
anticancer O
activities O
of O
these O
extracts O
and O
some O
their O
major O
metabolites O
. O

Antioxidant O
activity O
was O
evaluated O
by O
free O
radical O
scavenging O
, O
superoxide B
anion O
radical O
scavenging O
, O
reducing O
power O
and O
determination O
of O
total O
phenolic B
compounds O
. O

Total O
content O
of O
phenol B
in O
extracts O
was O
determined O
as O
pyrocatechol O
equivalent O
. O

Anticancer O
activity O
was O
tested O
against O
FemX O
( O
human O
melanoma O
) O
and O
LS174 O
( O
human O
colon O
carcinoma O
) O
cell O
lines O
using O
MTT B
method O
. O

Lecithin O
in O
mixed O
micelles O
attenuates O
the O
cytotoxicity O
of O
bile B
salts I
in O
Caco O
- O
2 O
cells O
. O

This O
study O
was O
designed O
to O
investigate O
the O
cytotoxicity O
of O
bile B
salt I
- O
lecithin O
mixed O
micelles O
on O
the O
Caco O
- O
2 O
cell O
model O
. O

Cell O
viability O
and O
proliferation O
after O
mixed O
micelles O
treatments O
were O
evaluated O
with O
the O
MTT B
assay O
, O
and O
the O
integrity O
of O
Caco O
- O
2 O
cell O
monolayer O
was O
determined O
by O
quantitating O
the O
transepithelial O
electrical O
resistance O
and O
the O
flux O
of O
tracer O
, O
FITC B
- O
dextran O
4400 O
. O

The O
mixed O
micelles O
with O
lower O
than O
0 O
. O
2mM O
sodium B
deoxycholate I
( O
SDC O
) O
had O
no O
significant O
effects O
on O
cell O
viability O
and O
proliferation O
. O

These O
results O
demonstrate O
that O
relatively O
higher O
concentrations O
of O
mixed O
micelles O
are O
toxic O
to O
Caco O
- O
2 O
cells O
, O
while O
phospholipids O
can O
attenuate O
the O
toxicity O
of O
the O
bile B
salts I
. O

Six O
biodegradable O
polymers O
have O
been O
investigated O
as O
drug O
carriers O
using O
molecular O
simulations O
: O
l O
- O
polylactide O
, O
d O
- O
polylactide O
, O
chitosan O
, O
polyglycolic O
acid O
, O
polyethylene B
glycol I
and O
cellulose O
. O

Cyclosporine B
A I
has O
been O
chosen O
as O
a O
model O
drug O
substance O
. O

Single O
and O
repeated O
injections O
both O
demonstrated O
a O
statistically O
significant O
reduction O
in O
dyspareunia O
by O
VAS O
scores O
from O
54 O
to O
30 O
in O
the O
single O
injection O
group O
and O
from O
51 O
to O
23 O
in O
the O
multiple O
injection O
group O
( O
p O
= O
. O
001 O
) O
, O
non O
- O
menstrual O
pelvic O
pain O
VAS O
from O
37 O
to O
25 O
( O
p O
= O
. O
04 O
) O
, O
as O
well O
as O
vaginal O
pressures O
; O
40 O
versus O
34 O
cm O
H B
( I
2 I
) I
O I
( O
p O
= O
. O
02 O
) O
. O

A O
polyacetylene B
- O
rich O
extract O
from O
Gymnaster O
koraiensis O
strongly O
inhibits O
colitis O
- O
associated O
colon O
cancer O
in O
mice O
. O

Because O
GK O
contains O
polyacetylenes O
and O
because O
other O
polyacetylenes O
have O
been O
found O
to O
exhibit O
anti O
- O
inflammatory O
and O
anti O
- O
cancer O
activities O
, O
we O
hypothesized O
that O
the O
polyacetylene B
gymnasterkoreayne O
B O
( O
GKB O
) O
, O
known O
to O
increase O
hepatic O
detoxification O
enzymes O
, O
may O
also O
exert O
anti O
- O
inflammatory O
and O
anti O
- O
cancer O
activities O
. O

We O
fed O
male O
C57BL O
/ O
6 O
mice O
purified O
AIN93G O
diets O
containing O
no O
additions O
, O
GKB O
or O
the O
GKB O
- O
rich O
fraction O
of O
an O
ethanol B
extract O
( O
GE O
) O
from O
GK O
to O
determine O
if O
these O
diets O
would O
slow O
or O
prevent O
either O
inflammation O
or O
inflammation O
- O
enhanced O
colon O
cancer O
, O
using O
the O
dextran O
sulfate O
sodium B
/ O
azoxymethane O
mouse O
model O
. O

The O
estrogenic O
effects O
of O
benzylparaben B
at O
low O
doses O
based O
on O
uterotrophic O
assay O
in O
immature O
SD O
rats O
. O

Benzylparaben B
( O
BzP O
) O
, O
a O
type O
of O
parabens O
being O
used O
as O
a O
preservative O
agent O
in O
cosmetics O
, O
food O
, O
and O
pharmaceutical O
products O
, O
may O
be O
ingested O
by O
humans O
. O

The O
in O
vivo O
estrogenicity O
of O
BzP O
was O
supported O
by O
in O
vitro O
results O
from O
the O
human O
estrogen B
receptor O
alpha O
( O
hER O
alpha O
) O
- O
coactivator O
recruiting O
assay O
and O
in O
silico O
molecular O
docking O
analysis O
performed O
in O
this O
study O
. O

The O
lowest O
observed O
effect O
dose O
( O
LOED O
) O
( O
0 O
. O
16 O
mg O
/ O
kg O
/ O
day O
) O
of O
BzP O
is O
much O
lower O
than O
the O
documented O
LOEDs O
of O
other O
parabens B
. O

In O
addition O
, O
we O
tested O
the O
sensitivity O
of O
Wistar O
rats O
to O
17 B
beta I
- I
estradiol I
by O
immature O
uterotrophic O
assay O
, O
and O
no O
obvious O
uterotrophic O
response O
was O
observed O
in O
the O
rats O
given O
doses O
up O
to O
100 O
mu O
g O
/ O
kg O
body O
weight O
. O

Isoorientin O
( O
ISO B
) O
( O
CAS O
RN O
: O
4261 O
- O
42 O
- O
1 O
) O
is O
a O
flavonoid B
compound O
that O
can O
be O
extracted O
from O
several O
plant O
species O
, O
such O
as O
Phyllostachys O
pubescens O
, O
Patrinia O
, O
and O
Drosophyllum O
lusitanicum O
. O

ISO B
is O
able O
to O
induce O
apoptosis O
through O
mitochondrial O
dysfunction O
and O
inhibition O
of O
PI3K O
/ O
Akt O
signaling O
pathway O
in O
HepG2 O
cells O
, O
however O
, O
the O
effects O
of O
ISO B
on O
MAPK O
signaling O
pathways O
remain O
unknown O
. O

The O
present O
study O
investigated O
the O
effects O
of O
ISO B
on O
this O
pathway O
, O
and O
the O
roles O
of O
MAPK O
kinases O
on O
mitochondrial O
- O
mediated O
apoptosis O
in O
HepG2 O
cells O
. O

The O
results O
showed O
that O
ISO B
induced O
cell O
death O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
, O
and O
induction O
apoptosis O
is O
main O
cause O
for O
ISO B
- O
induced O
cytotoxicity O
in O
HepG2 O
cells O
. O

ISO B
significantly O
inhibited O
the O
levels O
of O
ERK1 O
/ O
2 O
kinase O
and O
increased O
the O
expression O
of O
JNK O
and O
p38 O
kinases O
. O

Furthermore O
, O
U0126 B
( O
an O
ERK1 O
/ O
2 O
inhibitor O
) O
significantly O
enhanced O
the O
ISO B
- O
induced O
the O
Bax O
/ O
Bcl O
- O
2 O
ratio O
, O
the O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
fraction O
, O
and O
the O
levels O
of O
cleaved O
caspase O
- O
3 O
. O

While O
SP600125 B
( O
a O
JNK O
inhibitor O
) O
and O
SB203580 B
( O
a O
p38 O
inhibitor O
) O
markedly O
prevented O
the O
expression O
of O
these O
proteins O
induced O
by O
ISO B
. O

Furthermore O
, O
the O
ROS O
inhibitor O
( O
NAC B
) O
notably O
promoted O
the O
inhibited O
effect O
of O
ISO B
on O
the O
ERK1 O
/ O
2 O
kinase O
. O

NAC B
also O
suppressed O
the O
p O
- O
JNK O
and O
p O
- O
p38 O
, O
but O
failed O
to O
reverse O
the O
effects O
of O
ISO B
. O

These O
results O
demonstrated O
for O
the O
first O
time O
that O
ISO B
induces O
apoptosis O
in O
HepG2 O
cells O
through O
inactivating O
ERK1 O
/ O
2 O
kinase O
and O
activating O
JNK O
and O
p38 O
kinases O
, O
and O
ROS O
stimulated O
by O
ISO B
is O
able O
to O
activate O
the O
MAPK O
singaling O
pathway O
as O
the O
upstream O
signaling O
molecules O
. O

Initiating O
event O
of O
the O
mitochondrial O
- O
mediated O
apoptosis O
induced O
by O
ISO B
is O
MAPK O
signals O
. O

Hepatic O
methionine B
was O
markedly O
decreased O
in O
db O
/ O
db O
mice O
, O
although O
the O
hepatic O
activity O
of O
betaine O
homocysteine B
methyltransferase O
was O
increased O
. O

The O
decrease O
in O
hepatic O
methionine B
was O
reflected O
by O
decreased O
sulfur B
- O
containing O
methionine B
metabolites O
, O
including O
S B
- I
adenosylmethionine I
, O
homocysteine B
, O
cysteine B
, O
and O
hypotaurine O
in O
liver O
and O
plasma O
. O

In O
contrast O
, O
S B
- I
adenosylhomocysteine I
, O
putrescine B
, O
and O
spermidine B
were O
increased O
in O
db O
/ O
db O
mice O
. O

The O
hepatic O
level O
and O
activity O
of O
methionine B
adenosyltransferase O
I O
/ O
III O
, O
an O
S B
- I
adenosylmethionine I
synthesizing O
enzyme O
, O
were O
significantly O
increased O
. O

These O
results O
suggest O
that O
increased O
polyamine B
synthesis O
, O
in O
conjunction O
with O
decreased O
hepatic O
methionine B
levels O
, O
is O
partly O
responsible O
for O
the O
reduction O
in O
hepatic O
S B
- I
adenosylmethionine I
. O

Decreased O
homocysteine B
in O
liver O
and O
plasma O
may O
be O
attributable O
to O
the O
decrease O
in O
hepatic O
methionine B
and O
upregulation O
of O
hepatic O
betaine O
homocysteine B
methyltransferase O
. O

Glutathione B
in O
liver O
and O
plasma O
did O
not O
change O
despite O
decreased O
gamma B
- I
glutamylcysteine I
ligase O
activity O
. O

The O
decreased O
hepatic O
hypotaurine O
may O
be O
attributable O
to O
the O
downregulation O
of O
cysteine B
dioxygenase O
. O

Antithrombotic O
and O
profibrinolytic O
activities O
of O
isorhamnetin O
- O
3 O
- O
O O
- O
galactoside O
and O
hyperoside B
. O

The O
potential O
anticoagulant O
activities O
of O
two O
single O
compounds O
, O
isorhamnetin O
- O
3 O
- O
O O
- O
galactoside O
( O
IMG O
) O
and O
hyperoside B
, O
from O
Oenanthe O
javanica O
, O
were O
tested O
. O

Treatment O
with O
IMG O
and O
hyperoside B
resulted O
in O
significantly O
prolonged O
aPTT O
and O
PT O
and O
inhibition O
of O
the O
activities O
of O
thrombin O
and O
FXa O
, O
and O
IMG O
or O
hyperoside B
inhibited O
production O
of O
thrombin O
and O
FXa O
in O
HUVECs O
. O

In O
addition O
, O
treatment O
with O
IMG O
and O
hyperoside B
resulted O
in O
inhibition O
of O
TNF O
- O
alpha O
- O
induced O
production O
of O
PAI O
- O
1 O
, O
and O
treatment O
with O
IMG O
resulted O
in O
significant O
reduction O
of O
the O
PAI O
- O
1 O
to O
t O
- O
PA O
ratio O
. O

The O
anticoagulant O
and O
profibrinolytic O
effects O
of O
IMG O
were O
greater O
than O
those O
of O
hyperoside B
, O
indicating O
positive O
regulation O
of O
its O
anticoagulant O
function O
by O
the O
methoxy B
group O
of O
IMG O
. O

IMG O
and O
hyperoside B
possess O
antithrombotic O
activities O
and O
offer O
bases O
for O
development O
of O
a O
novel O
anticoagulant O
. O

Silent O
information O
regulator O
2 O
( O
Sir2 O
) O
enzymes O
or O
sirtuins O
are O
a O
family O
of O
NAD B
( I
+ I
) I
- O
dependent O
protein O
N O
( O
epsilon O
) O
- O
acetyl O
- O
lysine O
( O
AcK O
) O
deacetylases O
. O

Hepatic O
glucose B
metabolism O
in O
late O
pregnancy O
: O
normal O
versus O
high O
- O
fat O
and O
- O
fructose B
diet O
. O

Net O
hepatic O
glucose B
uptake O
( O
NHGU O
) O
is O
an O
important O
contributor O
to O
postprandial O
glycemic O
control O
. O

We O
hypothesized O
that O
NHGU O
is O
reduced O
during O
normal O
pregnancy O
and O
in O
a O
pregnant O
diet O
- O
induced O
model O
of O
impaired O
glucose B
intolerance O
/ O
gestational O
diabetes O
mellitus O
( O
IGT O
/ O
GDM O
) O
. O

Dogs O
( O
n O
= O
7 O
per O
group O
) O
that O
were O
nonpregnant O
( O
N O
) O
, O
normal O
pregnant O
( O
P O
) O
, O
or O
pregnant O
with O
IGT O
/ O
GDM O
( O
pregnant O
dogs O
fed O
a O
high O
- O
fat O
and O
- O
fructose B
diet O
[ O
P O
- O
HFF O
] O
) O
underwent O
a O
hyperinsulinemic O
- O
hyperglycemic O
clamp O
with O
intraportal O
glucose B
infusion O
. O

Clamp O
period O
insulin O
, O
glucagon O
, O
and O
glucose B
concentrations O
and O
hepatic O
glucose B
loads O
did O
not O
differ O
among O
groups O
. O

Here O
we O
provide O
a O
real O
- O
time O
view O
of O
hot O
CT O
exciton O
formation O
and O
relaxation O
using O
femtosecond O
nonlinear O
optical O
spectroscopies O
and O
non O
- O
adiabatic O
mixed O
quantum O
mechanics O
/ O
molecular O
mechanics O
simulations O
in O
the O
phthalocyanine B
- O
fullerene B
model O
OPV O
system O
. O

For O
initial O
excitation O
on O
phthalocyanine B
, O
hot O
CT O
excitons O
are O
formed O
in O
10 O
( O
- O
13 O
) O
s O
, O
followed O
by O
relaxation O
to O
lower O
energies O
and O
shorter O
electron O
- O
hole O
distances O
on O
a O
10 O
( O
- O
12 O
) O
s O
timescale O
. O

Diabetic O
cardiomyopathy O
is O
associated O
with O
suppression O
of O
cardiac O
autophagy O
, O
and O
activation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
restores O
cardiac O
autophagy O
and O
prevents O
cardiomyopathy O
in O
diabetic O
mice O
, O
albeit O
by O
an O
unknown O
mechanism O
. O

We O
hypothesized O
that O
AMPK O
- O
induced O
autophagy O
ameliorates O
diabetic O
cardiomyopathy O
by O
inhibiting O
cardiomyocyte O
apoptosis O
and O
examined O
the O
effects O
of O
AMPK O
on O
the O
interaction O
between O
Beclin1 O
and O
Bcl O
- O
2 O
, O
a O
switch O
between O
autophagy O
and O
apoptosis O
, O
in O
diabetic O
mice O
and O
high O
glucose B
- O
treated O
H9c2 O
cardiac O
myoblast O
cells O
. O

Exposure O
of O
H9c2 O
cells O
to O
high O
glucose B
reduced O
AMPK O
activity O
, O
inhibited O
Jun O
NH2 B
- O
terminal O
kinase O
1 O
( O
JNK1 O
) O
- O
B O
- O
cell O
lymphoma O
2 O
( O
Bcl O
- O
2 O
) O
signaling O
, O
and O
promoted O
Beclin1 O
binding O
to O
Bcl O
- O
2 O
. O

Activation O
of O
AMPK O
, O
which O
normalized O
cardiac O
autophagy O
, O
attenuated O
high O
glucose B
- O
induced O
apoptosis O
in O
cultured O
H9c2 O
cells O
. O

Finally O
, O
chronic O
administration O
of O
metformin B
in O
diabetic O
mice O
restored O
cardiac O
autophagy O
by O
activating O
JNK1 O
- O
Bcl O
- O
2 O
pathways O
and O
dissociating O
Beclin1 O
and O
Bcl O
- O
2 O
. O

Placental O
growth O
hormone O
( O
PGH O
) O
, O
estrogens B
( O
primarily O
17 B
beta I
- I
estradiol I
) O
, O
cortisol B
, O
and O
progesterone B
have O
the O
potential O
to O
modulate O
CYP3A O
activity O
. O

We O
incubated O
sandwich O
- O
cultured O
human O
hepatocytes O
( O
SCHH O
) O
from O
premenopausal O
female O
donors O
( O
n O
= O
2 O
) O
with O
the O
physiologic O
( O
unbound O
, O
1 O
x O
total O
) O
and O
the O
10 O
x O
total O
third O
trimester O
hormone O
plasma O
concentrations O
( O
individually O
and O
in O
combination O
) O
and O
determined O
their O
effect O
on O
CYP3A O
activity O
and O
the O
transcripts O
of O
CYP3A4 O
, O
CYP3A5 O
, O
and O
the O
respective O
hormone O
receptors O
( O
growth O
hormone O
receptor O
, O
glucocorticoid O
receptor O
, O
and O
estrogen B
receptor O
alpha O
) O
. O

Of O
all O
the O
hormones O
, O
cortisol B
was O
the O
most O
potent O
inducer O
of O
CYP3A O
activity O
and O
CYP3A4 O
, O
CYP3A5 O
mRNA O
expression O
. O

The O
combination O
of O
PGH O
/ O
growth O
hormone O
and O
cortisol B
induced O
CYP3A O
activity O
and O
expression O
significantly O
more O
than O
did O
cortisol B
alone O
. O

Aqueous O
phase O
synthesis O
of O
copper B
nanoparticles O
: O
a O
link O
between O
heavy O
metal O
resistance O
and O
nanoparticle O
synthesis O
ability O
in O
bacterial O
systems O
. O

We O
demonstrate O
aqueous O
phase O
biosynthesis O
of O
phase O
- O
pure O
metallic O
copper B
nanoparticles O
( O
CuNPs O
) O
using O
a O
silver B
resistant O
bacterium O
Morganella O
morganii O
. O

Electrochemical O
analysis O
of O
bacterial O
cells O
exposed O
to O
Cu B
( I
2 I
+ I
) I
ions O
provides O
new O
insights O
into O
the O
mechanistic O
aspect O
of O
Cu B
( I
2 I
+ I
) I
ion O
reduction O
within O
the O
bacterial O
cell O
and O
indicates O
a O
strong O
link O
between O
the O
silver B
and O
copper B
resistance O
machinery O
of O
bacteria O
in O
the O
context O
of O
metal O
ion O
reduction O
. O

2 O
- O
Phenoxy O
- O
nicotinamides O
are O
potent O
agonists O
at O
the O
bile B
acid I
receptor O
GPBAR1 O
( O
TGR5 O
) O
. O

Effect O
of O
ganglioside B
GM3 O
synthase O
gene O
knockout O
on O
the O
glycoprotein O
N O
- O
glycan O
profile O
of O
mouse O
embryonic O
fibroblast O
. O

Organotins B
: O
A O
review O
of O
their O
reproductive O
toxicity O
, O
biochemistry O
, O
and O
environmental O
fate O
. O

The O
review O
purposes O
are O
to O
( O
1 O
) O
evaluate O
the O
experimental O
evidence O
for O
adverse O
effects O
on O
reproduction O
and O
metabolism O
and O
( O
2 O
) O
identify O
the O
current O
knowledge O
of O
analytical O
procedures O
, O
biochemistry O
and O
environmental O
aspects O
relating O
to O
organotins B
. O

Organotins B
are O
pollutants O
that O
are O
used O
as O
biocides O
in O
antifouling O
paints O
. O

In O
rodents O
, O
organotin B
exposure O
induces O
developmental O
and O
reproductive O
toxicity O
as O
well O
as O
alteration O
of O
metabolic O
homeostasis O
through O
its O
action O
as O
an O
obesogen O
. O

The O
adverse O
effects O
that O
appear O
in O
rodents O
have O
raised O
concerns O
about O
organotins B
' O
potential O
health O
risk O
to O
humans O
in O
relation O
to O
organotin B
exposure O
. O

At O
present O
, O
triorganotin O
, O
such O
as O
tributyltin B
, O
have O
been O
demonstrated O
to O
produce O
imposex O
, O
and O
mammalian O
reproductive O
and O
metabolic O
toxicity O
. O

With O
these O
risks O
in O
mind O
, O
it O
is O
important O
to O
improve O
our O
knowledge O
of O
organotins B
' O
effects O
on O
environmental O
health O
. O

Multiple O
microRNAs O
may O
regulate O
the O
DNA O
repair O
enzyme O
uracil B
- O
DNA O
glycosylase O
. O

Human O
nuclear O
uracil B
- O
DNA O
glycosylase O
UNG2 O
is O
essential O
for O
post O
- O
replicative O
repair O
of O
uracil B
in O
DNA O
, O
and O
UNG2 O
protein O
and O
mRNA O
levels O
rapidly O
decline O
in O
G2 O
/ O
M O
phase O
. O

Oxidative O
modification O
of O
neurofilament O
- O
L O
and O
neuronal O
cell O
death O
induced O
by O
the O
catechol B
neurotoxin O
, O
tetrahydropapaveroli O
. O

The O
formation O
of O
carbonyl B
compounds O
and O
dityrosine O
were O
observed O
in O
the O
THP O
- O
mediated O
NF O
- O
L O
aggregates O
. O

These O
results O
suggest O
that O
the O
modification O
of O
NF O
- O
L O
by O
THP O
may O
be O
due O
to O
oxidative O
damage O
resulting O
from O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

When O
THP O
exposed O
NF O
- O
L O
was O
subjected O
to O
amino B
acid I
analysis O
, O
glutamate B
, O
proline B
and O
lysine B
residues O
were O
found O
to O
be O
particularly O
sensitive O
. O

We O
also O
investigated O
the O
effects O
of O
copper B
ions O
on O
THP O
- O
mediated O
NF O
- O
L O
modification O
. O

At O
a O
low O
concentration O
of O
THP O
, O
copper B
ions O
enhanced O
the O
modification O
of O
NF O
- O
L O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
novel O
11 O
, O
4 O
' O
' O
- O
disubstituted O
azithromycin O
analogs O
with O
greatly O
improved O
activity O
against O
erythromycin B
- O
resistant O
bacteria O
. O

All O
the O
11 O
, O
4 O
' O
' O
- O
disubstituted O
analogs O
exhibited O
excellent O
activity O
( O
0 O
. O
03 O
- O
0 O
. O
12 O
mu O
g O
/ O
ml O
) O
against O
erythromycin B
- O
susceptible O
Streptococcus O
pneumoniae O
, O
and O
significantly O
improved O
activity O
against O
three O
phenotypes O
of O
erythromycin B
- O
resistant O
S O
. O
pneumoniae O
compared O
with O
erythromycin O
A O
, O
clarithromycin B
or O
azithromycin B
. O

In O
addition O
, O
compound O
28 O
was O
the O
most O
effective O
( O
0 O
. O
03 O
and O
0 O
. O
12 O
mu O
g O
/ O
ml O
) O
against O
erythromycin B
- O
susceptible O
S O
. O
pneumoniae O
and O
Staphylococcus O
aureus O
as O
well O
. O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ O
Cu O
( O
CH O
( O
3 O
) O
CN O
) O
( O
4 O
) O
] O
BF O
( O
4 O
) O
, O
CuCl O
) O
with O
a O
panel O
of O
bis O
( O
azolyl O
) O
borates O
or O
poly O
( O
pyrazolyl O
) O
methanes O
and O
a O
tertiary O
monodentate O
phosphine O
( O
PTA O
= O
1 O
, O
3 O
, O
5 O
- O
triaza O
- O
7 O
- O
phosphaadamantane O
, O
PCN O
= O
tris O
( O
cyanoethyl O
) O
phosphine O
) O
produced O
two O
series O
of O
heteroleptic O
, O

either O
' O
2 O
+ O
1 O
+ O
1 O
' O
- O
or O
' O
3 O
+ O
1 O
' O
- O
type O
complexes O
, O
which O
have O
been O
characterized O
by O
elemental O
analysis O
, O
FT O
- O
IR O
, O
ESI O
- O
MS O
and O
multinuclear O
( B
31 I
) I
P I
and O
( B
1 I
) I
H I
NMR O
. O

' O
2 O
+ O
1 O
+ O
1 O
' O
- O
type O
complexes O
include O
a O
N B
, O
N B
- O
bidentate O
chelate O
and O
two O
monodentate O
phosphines B
( O
1 O
- O
8 O
) O
and O
' O
3 O
+ O
1 O
' O
- O
type O
complexes O
comprise O
a O
N B
, O
N B
, O
O B
- O
or O
N B
, O
N B
, O
N B
- O
tridentate O
chelate O
and O
one O
monodentate O
phosphine O
( O
9 O
- O
12 O
) O
. O

Cytotoxic O
activity O
of O
all O
compounds O
has O
been O
evaluated O
by O
MTT B
test O
against O
a O
panel O
of O
several O
human O
tumor O
cell O
lines O
including O
examples O
of O
breast O
( O
MCF O
- O
7 O
) O
, O
colon O
( O
HCT O
- O
15 O
and O
LoVo O
) O
, O
lung O
( O
A549 O
) O
, O
cervix O
( O
A431 O
) O
and O
ovarian O
( O
2008 O
and O
its O
cisplatin B
resistant O
variant O
, O
C13 O
* O
) O
carcinoma O
, O
melanoma O
( O
A375 O
) O
and O
promyelocytic O
leukemia O
( O
HL60 O
) O
. O

Copper B
complexes O
generally O
show O
in O
vitro O
antitumour O
activity O
comparable O
to O
that O
of O
cisplatin B
. O

Utilizing O
Eisenia O
andrei O
to O
assess O
the O
ecotoxicity O
of O
platinum B
mine O
tailings O
disposal O
facilities O
. O

South O
Africa O
is O
an O
important O
platinum B
mining O
country O
which O
results O
in O
environmental O
impacts O
due O
to O
the O
construction O
of O
tailing O
disposal O
facilities O
( O
TDFs O
) O
. O

This O
might O
be O
ascribed O
to O
the O
elevated O
levels O
of O
Cr B
( O
+ O
/ O
- O
200 O
to O
1 O
, O
166 O
mu O
g O
g O
( O
- O
1 O
) O
) O
and O
Ni B
( O
+ O
/ O
- O
100 O
to O
316 O
mu O
g O
g O
( O
- O
1 O
) O
) O
in O
all O
of O
the O
sites O
. O

Studies O
like O
these O
could O
be O
useful O
when O
establishing O
a O
ranking O
of O
TDFs O
in O
the O
future O
to O
provide O
legislative O
institutions O
with O
an O
indication O
of O
the O
environmental O
liabilities O
of O
platinum B
mines O
. O

Oxidative O
folding O
of O
peptides O
with O
cystine B
- O
knot O
architectures O
: O
kinetic O
studies O
and O
optimization O
of O
folding O
conditions O
. O

Bioactive O
peptides O
often O
contain O
several O
disulfide B
bonds O
that O
provide O
the O
main O
contribution O
to O
conformational O
rigidity O
and O
structural O
, O
thermal O
, O
or O
biological O
stability O
. O

Among O
them O
, O
cystine B
- O
knot O
peptides O
- O
commonly O
named O
" O
knottins O
" O
- O
make O
up O
a O
subclass O
with O
several O
thousand O
natural O
members O
. O

Although O
cystine B
- O
knot O
peptides O
are O
available O
through O
chemical O
and O
recombinant O
synthetic O
routes O
, O
oxidative O
folding O
to O
afford O
the O
bioactive O
isomers O
still O
remains O
a O
crucial O
step O
. O

An O
important O
effector O
of O
the O
ISR O
is O
activating O
transcription O
factor O
4 O
( O
ATF4 O
) O
, O
a O
transcription O
factor O
that O
regulates O
genes O
involved O
in O
redox O
homeostasis O
and O
amino B
acid I
metabolism O
and O
transport O
. O

Understanding O
how O
noncatalytic O
carbohydrate B
binding O
modules O
can O
display O
specificity O
for O
xyloglucan O
. O

Plant O
biomass O
is O
central O
to O
the O
carbon B
cycle O
and O
to O
environmentally O
sustainable O
industries O
exemplified O
by O
the O
biofuel O
sector O
. O

Plant O
cell O
wall O
degrading O
enzymes O
generally O
contain O
noncatalytic O
carbohydrate B
binding O
modules O
( O
CBMs O
) O
that O
fulfil O
a O
targeting O
function O
, O
which O
enhances O
catalysis O
. O

Binding O
to O
the O
backbone O
chains O
of O
beta O
- O
glucans O
is O
mediated O
primarily O
by O
five O
aromatic O
residues O
that O
also O
make O
hydrophobic O
interactions O
with O
the O
xylose B
side O
chains O
of O
xyloglucan O
, O
conferring O
the O
distinctive O
specificity O
of O
the O
CBMs O
for O
the O
decorated O
polysaccharide O
. O

Thus O
, O
Gln B
( O
106 O
) O
is O
central O
to O
cellulose O
recognition O
, O
but O
is O
not O
required O
for O
binding O
to O
mixed O
linked O
glucans O
. O

The O
bovine O
ATP B
- O
binding O
cassette O
transporter O
ABCG2 O
Tyr581Ser O
single O
- O
nucleotide O
polymorphism O
increases O
milk O
secretion O
of O
the O
fluoroquinolone O
danofloxacin O
. O

The O
bovine O
adenosine B
triphosphate I
- O
binding O
cassette O
transporter O
G2 O
( O
ABCG2 O
/ O
breast O
cancer O
resistance O
protein O
) O
polymorphism O
Tyr581Ser O
( O
Y581S O
) O
has O
recently O
been O
shown O
to O
increase O
in O
vitro O
transepithelial O
transport O
of O
antibiotics O
. O

Herein O
, O
a O
new O
concept O
is O
presented O
to O
assemble O
equilibrium O
Au B
nanoclusters O
of O
controlled O
size O
by O
tuning O
the O
colloidal O
interactions O
with O
a O
polymeric O
stabilizer O
, O
PLA B
( O
1k O
) O
- O
b O
- O
PEG B
( O
10k O
) O
- O
b O
- O
PLA B
( O
1k O
) O
. O

The O
nanoclusters O
form O
upon O
mixing O
a O
dispersion O
of O
~ O
5 O
nm O
Au B
nanospheres O
with O
a O
polymer O
solution O
followed O
by O
partial O
solvent O
evaporation O
. O

Nanocluster O
size O
is O
tuned O
from O
~ O
20 O
to O
~ O
40 O
nm O
by O
experimentally O
varying O
the O
final O
Au B
nanoparticle O
concentration O
and O
the O
polymer O
/ O
Au B
ratio O
, O
along O
with O
the O
charge O
on O
the O
initial O
Au B
nanoparticle O
surface O
. O

Equilibrium O
cluster O
size O
is O
predicted O
semiquantitatively O
with O
a O
free O
energy O
model O
that O
balances O
short O
- O
ranged O
depletion O
and O
van O
der O
Waals O
attractions O
with O
longer O
- O
ranged O
electrostatic O
repulsion O
, O
as O
a O
function O
of O
the O
Au B
and O
polymer O
concentrations O
. O

The O
close O
spacings O
of O
the O
Au B
nanoparticles O
in O
the O
clusters O
produce O
strong O
NIR O
extinction O
over O
a O
broad O
range O
of O
wavelengths O
from O
650 O
to O
900 O
nm O
, O
which O
is O
of O
practical O
interest O
in O
biomedical O
imaging O
. O

Porphyrin B
metabolisms O
in O
human O
skin O
commensal O
Propionibacterium O
acnes O
bacteria O
: O
potential O
application O
to O
monitor O
human O
radiation O
risk O
. O

Like O
human O
cells O
, O
the O
bacteria O
produce O
porphyrins B
, O
which O
exhibit O
fluorescence O
properties O
and O
make O
bacteria O
visible O
with O
a O
Wood O
' O
s O
lamp O
. O

In O
this O
review O
, O
we O
compare O
the O
porphyrin B
biosynthesis O
in O
humans O
and O
P O
. O
acnes O
. O

Also O
, O
since O
P O
. O
acnes O
living O
on O
the O
surface O
of O
skin O
receive O
the O
same O
radiation O
exposure O
as O
humans O
, O
we O
envision O
that O
the O
changes O
in O
porphyrin B
profiles O
( O
the O
absorption O
spectra O
and O
/ O
or O
metabolism O
) O
of O
P O
. O
acnes O
by O
radiation O
may O
mirror O
the O
response O
of O
human O
cells O
to O
radiation O
. O

The O
porphyrin B
profiles O
of O
P O
. O
acnes O
may O
be O
a O
more O
accurate O
reflection O
of O
radiation O
risk O
to O
the O
patient O
than O
other O
biodosimeters O
/ O
biomarkers O
such O
as O
gene O
up O
- O
/ O
down O
- O
regulation O
, O
which O
may O
be O
non O
- O
specific O
due O
to O
patient O
related O
factors O
such O
as O
autoimmune O
diseases O
. O

We O
present O
an O
ab O
initio O
molecular O
dynamics O
study O
of O
proton O
dynamics O
at O
sulfonic B
- I
acid I
terminated O
surface O
groups O
. O

Results O
furnish O
a O
highly O
efficient O
collective O
mechanism O
of O
hydronium B
ion O
translocations O
at O
a O
critical O
surface O
group O
separation O
of O
~ O
6 O
. O
5 O
A O
. O

Orientational O
fluctuations O
of O
SG O
trigger O
hydrogen B
bond O
breaking O
that O
sets O
off O
the O
hydronium B
ion O
motion O
. O

The O
soliton O
- O
like O
nature O
of O
this O
mechanism O
is O
owed O
to O
the O
trigonal O
symmetry O
of O
sulfonate B
anions O
and O
exceptionally O
strong O
interfacial O
hydrogen B
bonding O
. O

These O
insights O
should O
stimulate O
surface O
conductance O
studies O
at O
SG O
monolayers O
with O
sulfonic B
acid I
groups O
, O
and O
they O
bolster O
efforts O
in O
designing O
proton O
conducting O
polymers O
conducive O
to O
fuel O
cell O
operation O
above O
~ O
100 O
degrees O
C O
. O

Synthesis O
of O
polystyrene B
/ O
polysilsesquioxane O
core O
/ O
shell O
composite O
particles O
via O
emulsion O
polymerization O
in O
the O
existence O
of O
poly O
( O
gamma O
- O
methacryloxypropyl O
trimethoxysilane O
) O
sol O
. O

Here O
, O
we O
synthesized O
the O
polystyrene B
/ O
polysilsesquioxane O
( O
PS O
/ O
PSQ O
) O
core O
/ O
shell O
latex O
particles O
via O
emulsion O
polymerization O
, O
which O
behave O
as O
an O
amusing O
morphology O
. O

First O
, O
the O
nanosized O
PSQ O
particles O
were O
prepared O
by O
the O
hydrolysis O
- O
condensation O
reaction O
of O
gamma O
- O
methacryloxypropyl O
trimethoxysilane O
( O
MPTS O
) O
in O
ethanol B
medium O
. O

Subsequently O
, O
the O
as O
- O
obtained O
methacryloxypropylen O
functionalized O
PSQ O
( O
PMPTS O
) O
sol O
was O
directly O
added O
into O
the O
emulsion O
system O
of O
styrene B
( O
St O
) O
monomer O
, O
and O
PS O
/ O
PSQ O
composite O
particles O
with O
core O
/ O
shell O
structure O
were O
obtained O
through O
emulsion O
polymerization O
. O

Citalopram B
at O
the O
recommended O
human O
doses O
after O
long O
- O
term O
treatment O
is O
genotoxic O
for O
male O
germ O
cell O
. O

The O
present O
study O
was O
aimed O
to O
examine O
if O
multiple O
oral O
administration O
of O
citalopram B
, O
an O
antidepressant O
drug O
, O
has O
any O
genotoxic O
potential O
on O
germ O
cells O
of O
male O
mice O
. O

Mice O
were O
treated O
with O
citalopram B
for O
4 O
or O
8 O
weeks O
at O
the O
doses O
of O
6 O
, O
12 O
and O
24 O
mg O
/ O
kg O
/ O
day O
and O
were O
sacrificed O
24 O
h O
after O
the O
last O
dose O
. O

Multiple O
exposures O
to O
12 O
and O
24 O
mg O
/ O
kg O
/ O
day O
citalopram B
significantly O
increased O
sperm O
DNA O
strand O
breaks O
( O
14 O
. O
0 O
and O
16 O
. O
0 O
, O
respectively O
, O
compared O
to O
the O
concurrent O
control O
of O
6 O
. O
8 O
at O
week O
4 O
and O
15 O
. O
2 O
and O
20 O
. O
7 O
, O
respectively O
, O
compared O
to O
the O
concurrent O
control O
of O
7 O
. O
2 O
at O
week O
8 O
) O
and O
aberrant O
primary O
spermatocytes O
( O
6 O
. O
6 O
% O
and O
7 O
. O
6 O
% O
, O
respectively O
, O
compared O
to O
the O
control O
of O
2 O
. O
8 O
% O
at O
week O
4 O
and O
7 O
. O
4 O
% O
and O
8 O
. O
4 O
% O
, O
respectively O
, O
compared O
to O
the O
control O
of O
3 O
. O
2 O
% O
at O

Overall O
, O
this O
study O
provides O
that O
citalopram B
at O
the O
recommended O
human O
doses O
after O
long O
- O
term O
treatment O
is O
genotoxic O
for O
mouse O
germ O
cells O
. O

Thus O
, O
male O
patients O
receiving O
citalopram B
may O
stand O
at O
higher O
risk O
for O
abnormal O
reproductive O
outcomes O
, O
particularly O
in O
the O
reproductive O
ages O
. O

In O
contrast O
, O
mutation O
c O
. O
1244T O
> O
C O
results O
in O
an O
amino B
acid I
substitution O
( O
Ile415Thr O
) O
, O
which O
abolishes O
signal O
transduction O
due O
to O
structural O
changes O
. O

pi O
- O
Extended O
isomeric O
and O
expanded O
porphyrins B
. O

The O
phenomenon O
of O
pi O
- O
extension O
has O
been O
widely O
applied O
to O
, O
and O
exploited O
within O
, O
the O
field O
porphyrin B
chemistry O
. O

The O
chemical O
resemblance O
between O
porphyrins B
and O
expanded O
and O
isomeric O
porphyrins B
, O
as O
well O
as O
the O
increasing O
accessibility O
of O
the O
requisite O
starting O
materials O
is O
giving O
birth O
to O
the O
hybrid O
field O
of O
pi O
- O
extended O
expanded O
and O
isomeric O
porphyrins B
. O

This O
tutorial O
review O
is O
intended O
to O
provide O
an O
overview O
of O
up O
- O
to O
- O
date O
published O
synthetic O
efforts O
and O
to O
summarize O
the O
effect O
of O
annulation O
on O
the O
properties O
of O
expanded O
and O
isomeric O
porphyrins B
. O

Optimization O
of O
carbamate B
analogues O
of O
the O
diazatricylic O
compounds O
led O
to O
the O
identification O
of O
32i O
as O
a O
potent O
agonist O
of O
the O
GPR119 O
receptor O
with O
low O
unbound O
human O
liver O
microsomal O
clearance O
. O

Functionalization O
of O
monodisperse O
iron B
oxide I
NPs O
and O
their O
properties O
as O
magnetically O
recoverable O
catalysts O
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron B
oxide I
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic O
( O
LLA O
) O
and O
linoleic O
( O
LEA O
) O
acids O
or O
pyridine B
moieties O
such O
as O
6 O
- O
methylpyridine O
- O
2 O
- O
carboxylic O
acid O
, O
isonicotinic O
acid O
, O
3 O
- O
hydroxypicolinic O
acid O
, O
and O
6 O
- O
( O
1 O
- O
piperidinyl O
) O
pyridine O
- O
3 O
- O
carboxlic O
acid O
( O
PPCA O
) O
. O

We O
determined O
that O
both O
LLA O
and O
LEA O
stabilize O
magnetic O
iron B
oxide I
NPs O
, O
allowing O
the O
formation O
of O
pi O
- O
complexes O
with O
bis O
( O
acetonitrile O
) O
dichloropalladium O
( O
II O
) O
in O
the O
NP O
shells O
. O

In O
the O
case O
of O
pyridine B
- O
containing O
ligands O
, O
only O
PPCA O
with O
two O
N B
- O
containing O
rings O
is O
able O
to O
provide O
NP O
stabilization O
and O
functionalization O
whereas O
other O
pyridine B
- O
containing O
acids O
did O
now O
allow O
sufficient O
steric O
stabilization O
. O

We O
recently O
showed O
that O
the O
developmentally O
important O
family O
of O
SOX O
( O
SRY O
( O
sex O
determining O
region O
on O
the O
Y O
chromosome O
) O
- O
related O
high O
mobility O
group O
( O
HMG O
) O
box O
) O
proteins O
require O
the O
calcium B
- O
binding O
protein O
calmodulin O
( O
CaM O
) O
for O
optimal O
nuclear O
accumulation O
, O
with O
clinical O
mutations O
in O
SRY O
that O
specifically O
impair O
nuclear O
accumulation O
via O
this O
pathway O
resulting O
in O
XY O
sex O
reversal O
. O

Finally O
, O
we O
demonstrate O
direct O
binding O
of O
hsc70 O
to O
the O
SRY O
. O
CaM O
complex O
, O
with O
immunoprecipitation O
experiments O
from O
cell O
extracts O
showing O
association O
of O
hsc70 O
with O
wild O
type O
SRY O
, O
but O
not O
with O
a O
mutant O
derivative O
with O
impaired O
CaM O
binding O
, O
dependent O
on O
Ca B
( I
2 I
+ I
) I
. O

Effect O
of O
multilayer O
structure O
on O
cyclic O
performance O
of O
Si B
/ O
Fe B
anode O
electrode O
in O
lithium B
- O
ion O
secondary O
batteries O
. O

A O
buffer O
- O
strengthened O
Si B
/ O
Fe B
multilayer O
film O
, O
consisting O
of O
amorphous O
silicon B
layers O
and O
polycrystalline O
Fe B
layers O
, O
is O
investigated O
as O
the O
anode O
for O
Li B
- O
ion O
batteries O
. O

Decreasing O
the O
thickness O
of O
the O
Fe B
layer O
can O
lead O
to O
a O
higher O
capacity O
, O
which O
is O
related O
to O
the O
fast O
transport O
of O
the O
Li B
ion O
, O
but O
the O
cyclic O
performance O
deteriorates O
with O
repeated O
cycling O
. O

In O
contrast O
, O
increasing O
the O
thickness O
of O
the O
Fe B
buffer O
layers O
and O
the O
number O
of O
deposit O
stacks O
improves O
the O
cycle O
life O
with O
high O
reversibility O
. O

Because O
of O
the O
strain O
in O
the O
Si B
layers O
suppressed O
by O
the O
primary O
multilayer O
structure O
, O
the O
long O
- O
term O
strength O
is O
preserved O
and O
the O
substantial O
fracture O
toughness O
is O
enhanced O
by O
the O
increasing O
numbers O
of O
effective O
grain O
boundaries O
and O
interfacial O
layers O
. O

In O
addition O
, O
we O
demonstrate O
that O
the O
Ti B
underlayer O
promotes O
the O
electrochemical O
properties O
in O
the O
Si B
/ O
Fe B
multilayer O
for O
various O
Fe B
layer O
thicknesses O
because O
of O
the O
enhanced O
adhesion O
of O
the O
interfacial O
electrode O
and O
current O
collector O
. O

The O
mechanically O
optimized O
Si B
/ O
Fe B
multilayer O
films O
can O
have O
superior O
cycle O
- O
life O
performances O
and O
higher O
capacities O
. O

The O
AT1R O
is O
connected O
to O
the O
adrenal O
potassium B
sensory O
system O
and O
regulates O
calcium B
influx O
as O
well O
as O
phospholipase O
C O
- O
beta O
( O
PLC O
- O
beta O
) O
and O
thus O
calmodulin O
kinase O
- O
dependent O
transcription O
of O
steroidogenic O
enzymes O
. O

Sulfonylureas B
have O
antifungal O
activity O
and O
are O
potent O
inhibitors O
of O
Candida O
albicans O
acetohydroxyacid O
synthase O
. O

The O
sulfonylurea B
herbicides O
exert O
their O
activity O
by O
inhibiting O
plant O
acetohydroxyacid O
synthase O
( O
AHAS O
) O
, O
the O
first O
enzyme O
in O
the O
branched O
- O
chain O
amino B
acid I
biosynthesis O
pathway O
. O

Herein O
, O
we O
have O
cloned O
, O
expressed O
, O
and O
purified O
C O
. O
albicans O
AHAS O
and O
shown O
that O
several O
sulfonylureas B
are O
inhibitors O
of O
this O
enzyme O
and O
possess O
antifungal O
activity O
. O

For O
the O
sulfonylureas B
tested O
there O
was O
a O
strong O
correlation O
between O
inhibitory O
activity O
toward O
C O
. O
albicans O
AHAS O
and O
fungicidal O
activity O
, O
supporting O
the O
hypothesis O
that O
AHAS O
is O
the O
target O
for O
their O
inhibitory O
activity O
within O
the O
cell O
. O

Calcium B
- O
dependent O
ligand O
binding O
and O
G O
- O
protein O
signaling O
of O
family O
B O
GPCR O
parathyroid O
hormone O
1 O
receptor O
purified O
in O
nanodiscs O
. O

Using O
this O
approach O
, O
we O
purified O
a O
family O
B O
GPCR O
, O
parathyroid O
hormone O
1 O
receptor O
( O
PTH1R O
) O
, O
which O
regulates O
calcium B
and O
phosphate B
homeostasis O
and O
is O
a O
drug O
target O
for O
osteoporosis O
. O

We O
also O
observed O
that O
Ca B
( I
2 I
+ I
) I
is O
a O
weak O
agonist O
of O
PTH1R O
, O
and O
Ca B
( I
2 I
+ I
) I
in O
millimolar O
concentration O
can O
switch O
PTH O
( O
1 O
- O
34 O
) O
from O
an O
inverse O
agonist O
to O
an O
agonist O
. O

Isoliquiritigenin O
showed O
strong O
inhibitory O
effects O
towards O
multiple O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
isoform O
- O
catalyzed O
4 O
- O
methylumbelliferone O
( O
4 O
- O
MU O
) O
glucuronidation O
. O

Isoliquiritigenin O
, O
a O
herbal O
ingredient O
with O
chalcone B
structure O
, O
has O
been O
speculated O
to O
be O
able O
to O
inhibit O
one O
of O
the O
most O
drug O
- O
metabolizing O
enzymes O
( O
DMEs O
) O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
piperidine B
- O
derived O
non O
- O
urea B
soluble O
epoxide B
hydrolase O
inhibitors O
. O

A O
series O
of O
potent O
amide B
non O
- O
urea B
inhibitors O
of O
soluble O
epoxide B
hydrolase O
( O
sEH O
) O
is O
disclosed O
. O

The O
inhibition O
of O
soluble O
epoxide B
hydrolase O
leads O
to O
elevated O
levels O
of O
epoxyeicosatrienoic B
acids I
( O
EETs B
) O
, O
and O
thus O
inhibitors O
of O
sEH O
represent O
one O
of O
a O
novel O
approach O
to O
the O
development O
of O
vasodilatory O
and O
anti O
- O
inflammatory O
drugs O
. O

Catalytic O
properties O
of O
a O
bacterial O
acylating O
acetaldehyde B
dehydrogenase O
: O
evidence O
for O
several O
active O
oligomeric O
states O
and O
coenzyme O
A O
activation O
upon O
binding O
. O

Until O
the O
last O
decade O
, O
two O
unrelated O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamilies O
, O
i O
. O
e O
. O
the O
phosphorylating O
and O
non O
- O
phosphorylating O
superfamilies O
, O
were O
known O
to O
catalyze O
the O
oxidation O
of O
aldehydes B
to O
activated O
or O
non O
- O
activated O
acids O
. O

However O
, O
a O
third O
one O
was O
discovered O
by O
the O
crystal O
structure O
of O
a O
bifunctional O
enzyme O
4 O
- O
hydroxy O
- O
2 O
- O
ketovalerate O
aldolase O
/ O
acylating O
acetaldehyde B
dehydrogenase O
( O
DmpFG O
) O
from O
Pseudomonas O
sp O
. O
strain O
CF600 O
( O
Manjasetty O
et O
al O
. O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
100 O
( O
2003 O
) O
6992 O
- O
6997 O
) O
. O

Indeed O
, O
DmpF O
exhibits O
a O
non O
- O
phosphorylating O
CoA B
- O
dependent O
ALDH O
activity O
, O
but O
is O
structurally O
related O
to O
the O
phosphorylating O
superfamily O
. O

In O
this O
study O
, O
we O
undertook O
the O
characterization O
of O
the O
catalytic O
and O
structural O
properties O
of O
MhpEF O
from O
Escherichia O
coli O
, O
an O
ortholog O
of O
DmpFG O
in O
which O
MhpF O
converts O
acetaldehyde B
, O
produced O
by O
the O
cleavage O
of O
4 O
- O
hydroxy O
- O
2 O
- O
ketovalerate O
by O
MhpE O
, O
into O
acetyl B
- I
CoA I
. O

The O
kinetic O
data O
obtained O
under O
steady O
- O
state O
and O
pre O
- O
steady O
- O
state O
conditions O
show O
that O
the O
aldehyde B
dehydrogenase O
, O
MhpF O
, O
is O
active O
as O
a O
monomer O
, O
a O
unique O
feature O
relative O
to O
the O
phosphorylating O
and O
non O
- O
phosphorylating O
ALDH O
superfamilies O
. O

Therefore O
, O
CoA B
binding O
to O
MhpF O
increases O
its O
reactivity O
and O
optimizes O
its O
positioning O
relative O
to O
the O
thioacylenzyme O
intermediate O
, O
thus O
enabling O
the O
formation O
of O
an O
efficient O
deacylation O
complex O
. O

Age O
dependent O
differences O
in O
the O
regulation O
of O
hippocampal O
steroid B
hormones O
and O
receptor O
genes O
: O
relations O
to O
motivation O
and O
cognition O
in O
male O
rats O
. O

Estrogen B
and O
estrogenic O
functions O
are O
age O
- O
dependently O
involved O
in O
the O
modulation O
of O
learning O
, O
memory O
and O
mood O
in O
female O
humans O
and O
animals O
. O

Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen B
receptors O
alpha O
and O
beta O
( O
ER O
alpha O
, O
beta O
) O
in O
8 O
- O
week O
- O
old O
, O
12 O
- O
week O
- O
old O
and O
24 O
- O
week O
- O
old O
male O
rats O
. O

To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen B
receptor O
genes O
and O
other O
learning O
- O
related O
steroid B
receptors O
, O
androgen B
receptors O
( O
AR O
) O
, O
corticosterone B
- O
binding O
glucocorticoid O
receptors O
( O
GR O
) O
and O
mineralocorticoid O
receptors O
( O
MR O
) O
were O
also O
measured O
. O

Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17 B
beta I
- I
estradiol I
, O
testosterone B
and O
corticosterone B
were O
measured O
. O

The O
concentrations O
of O
estradiol B
and O
testosterone B
, O
however O
, O
were O
generally O
higher O
in O
the O
24 O
- O
week O
- O
old O
rats O
than O
in O
the O
8 O
- O
week O
- O
old O
and O
12 O
- O
week O
- O
old O
rats O
. O

Thus O
, O
estrogen B
and O
estrogenic O
functions O
may O
play O
a O
more O
prominent O
role O
in O
young O
male O
behavior O
and O
development O
than O
has O
been O
previously O
assumed O
. O

Directional O
scrolling O
of O
SiGe O
/ O
Si B
/ O
Cr B
nanoribbon O
on O
Si B
( O
111 O
) O
surfaces O
controlled O
by O
two O
- O
fold O
rotational O
symmetry O
underetching O
. O

The O
controllable O
fabrication O
of O
self O
- O
scrolling O
SiGe O
/ O
Si B
/ O
Cr B
helical O
nanoribbons O
on O
Si B
( O
111 O
) O
substrates O
is O
investigated O
. O

The O
initial O
lateral O
etching O
profile O
of O
the O
Si B
( O
111 O
) O
substrates O
shows O
a O
2 O
- O
fold O
rotational O
symmetry O
using O
4 O
% O
ammonia B
solution O
, O
which O
provides O
guidance O
for O
initial O
scrolling O
of O
one O
- O
end O
- O
fixed O
nanoribbons O
to O
form O
helical O
structures O
. O

The O
chirality O
of O
the O
SiGe O
/ O
Si B
/ O
Cr B
helices O
with O
isotropic O
Young O
' O
s O
moduli O
is O
governed O
by O
the O
anisotropic O
underetching O
in O
the O
initial O
stage O
, O
which O
can O
be O
precisely O
judged O
, O
as O
the O
orientation O
of O
the O
ribbon O
is O
predesigned O
. O

Furthermore O
, O
the O
helicity O
angle O
and O
radius O
of O
the O
formed O
helices O
are O
investigated O
by O
the O
lateral O
etching O
behavior O
and O
Cosserat O
curve O
theory O
of O
the O
Si B
( O
111 O
) O
substrates O
, O
respectively O
, O
which O
are O
consistent O
with O
the O
experimental O
data O
. O

Chelidonine O
and O
the O
alkaloid O
extract O
inhibited O
P O
- O
gp O
/ O
MDR1 O
activity O
in O
a O
concentration O
- O
dependent O
manner O
in O
Caco O
- O
2 O
and O
CEM O
/ O
ADR5000 O
and O
reversed O
their O
doxorubicin B
resistance O
. O

Characterization O
of O
arsenic B
resistant O
bacteria O
from O
arsenic B
rich O
groundwater O
of O
West O
Bengal O
, O
India O
. O

Sixty O
- O
four O
arsenic B
( O
As B
) O
resistant O
bacteria O
isolated O
from O
an O
arsenic B
rich O
groundwater O
sample O
of O
West O
Bengal O
were O
characterized O
to O
investigate O
their O
potential O
role O
in O
subsurface O
arsenic B
mobilization O
. O

Among O
the O
isolated O
strains O
predominance O
of O
genera O
Agrobacterium O
/ O
Rhizobium O
, O
Ochrobactrum O
and O
Achromobacter O
which O
could O
grow O
chemolitrophically O
and O
utilize O
arsenic B
as O
electron O
donor O
were O
detected O
. O

Higher O
tolerance O
to O
As O
( O
3 O
+ O
) O
[ O
maximum O
tolerable O
concentration O
( O
MTC O
) O
: O
> O
= O
10 O
mM O
] O
, O
As B
( O
5 O
+ O
) O
( O
MTC O
: O
> O
= O
100 O
mM O
) O
and O
other O
heavy O
metals O
like O
Cu B
( I
2 I
+ I
) I
, O
Cr O
( O
2 O
+ O
) O
, O
Ni B
( I
2 I
+ I
) I
etc O
. O

( O
MTC O
: O
> O
= O
10 O
mM O
) O
, O
presence O
of O
arsenate B
reductase O
and O
siderophore O
was O
frequently O
observed O
among O
the O
isolates O
. O

Ability O
to O
produce O
arsenite B
oxidase O
and O
phosphatase O
enzyme O
was O
detected O
in O
50 O
and O
34 O
% O
of O
the O
isolates O
, O
respectively O
. O

Although O
no O
direct O
correlation O
among O
taxonomic O
identity O
of O
bacterial O
strains O
and O
their O
metabolic O
abilities O
as O
mentioned O
above O
was O
apparent O
, O
several O
isolates O
affiliated O
to O
genera O
Ochrobactrum O
, O
Achromobacter O
and O
unclassified O
Rhizobiaceae O
members O
were O
found O
to O
be O
highly O
resistant O
to O
As O
( O
3 O
+ O
) O
and O
As B
( I
5 I
+ I
) I
and O
positive O
for O
all O
the O
test O
properties O
. O

Arsenate B
reductase O
activity O
was O
found O
to O
be O
conferred O
by O
arsC O
gene O
, O
which O
in O
many O
strains O
was O
coupled O
with O
arsenite B
efflux O
gene O
arsB O
as O
well O
. O

Based O
on O
the O
results O
we O
propose O
that O
under O
the O
prevailing O
low O
nutrient O
condition O
inhabitant O
bacteria O
capable O
of O
using O
inorganic O
electron O
donors O
play O
a O
synergistic O
role O
wherein O
siderophores O
and O
phosphatase O
activities O
facilitate O
the O
release O
of O
sediment O
bound O
As B
( I
5 I
+ I
) I
, O
which O
is O
subsequently O
reduced O
by O
arsenate B
reductase O
resulting O
into O
the O
mobilization O
of O
As O
( O
3 O
+ O
) O
in O
groundwater O
. O

Phase O
1 O
and O
phase O
2 O
drug O
metabolism O
and O
bile B
acid I
production O
of O
HepaRG O
cells O
in O
a O
bioartificial O
liver O
in O
absence O
of O
dimethyl B
sulfoxide I
. O

However O
, O
currently O
the O
hepatic O
differentiation O
of O
these O
cells O
relies O
on O
exposure O
to O
dimethylsulfoxide B
( O
DMSO B
) O
, O
which O
, O
as O
a O
side O
effect O
, O
has O
a O
cytotoxic O
effect O
and O
represses O
an O
all O
- O
round O
hepatic O
functionality O
. O

We O
therefore O
cultured O
HepaRG O
cells O
in O
the O
AMC O
- O
BAL O
without O
DMSO B
and O
characterized O
the O
drug O
metabolism O
. O

We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26 O
% O
( O
UDP B
- O
glucuronosyltransfer O
1A1 O
) O
, O
47 O
% O
( O
CYP3A4 O
) O
, O
to O
240 O
% O
( O
CYP2C9 O
) O
of O
primary O
human O
hepatocytes O
. O

The O
CYP3A4 O
activity O
could O
be O
induced O
2 O
- O
fold O
by O
rifampicin B
, O
whereas O
CYP2C9 O
activity O
remained O
equally O
high O
. O

The O
HepaRG O
- O
AMC O
- O
BAL O
secreted O
bile B
acids I
at O
43 O
% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile B
salts I
. O

Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O
AMC O
- O
BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism O
, O
while O
maintaining O
high O
viability O
, O
rendering O
DMSO B
addition O
superfluous O
for O
the O
promotion O
of O
drug O
metabolism O
. O

Moreover O
, O
addition O
of O
water O
to O
a O
tetrahydrofuran B
( O
THF B
) O
solution O
of O
this O
compound O
leads O
to O
quenching O
of O
the O
yellow O
fluorescence O
owing O
to O
an O
increase O
in O
the O
solvent O
polarity O
. O

This O
observation O
suggests O
the O
occurrence O
of O
a O
crystallization O
- O
induced O
emission O
( O
CIE O
) O
phenomenon O
in O
highly O
aqueous O
THF B
. O

The O
double O
- O
wall O
FePO4 O
nanotubes O
show O
interesting O
cathode O
performance O
in O
Li B
ion O
batteries O
. O

On O
the O
morphological O
scale O
, O
Gram O
- O
negative O
E O
. O
coli O
cells O
exposed O
to O
CPE O
and O
OPE B
compounds O
in O
the O
dark O
show O
damage O
to O
the O
cell O
envelope O
, O
plasma O
membrane O
, O
and O
in O
some O
cases O
the O
cytoplasm O
, O
while O
with O
UV O
- O
irradiation O
, O
E O
. O
coli O
sustained O
catastrophic O
damages O
to O
both O
the O
cell O
envelope O
and O
cytoplasm O
. O

In O
contrast O
, O
the O
Gram O
- O
positive O
S O
. O
epi O
bacteria O
appeared O
intact O
when O
exposed O
to O
CPE O
and O
OPE B
compounds O
in O
the O
dark O
but O
showed O
damages O
to O
the O
cell O
envelope O
with O
UV O
- O
irradiation O
. O

To O
better O
understand O
the O
molecular O
basis O
of O
CPE O
- O
and O
OPE B
- O
induced O
morphological O
changes O
and O
damages O
to O
bacteria O
, O
we O
investigated O
the O
effect O
of O
these O
compounds O
on O
model O
bacterial O
plasma O
membrane O
and O
bacterial O
proteins O
and O
plasmid O
DNA O
. O

Under O
UV O
- O
irradiation O
, O
E O
. O
coli O
bacteria O
exposed O
to O
CPEs O
and O
OPEs O
showed O
covalent O
modifications O
and O
damages O
to O
both O
cellular O
protein O
and O
plasmid O
DNA O
, O
likely O
through O
oxidative O
pathways O
mediated O
by O
singlet O
oxygen B
and O
subsequent O
reactive O
oxygen B
species O
sensitized O
by O
the O
CPE O
and O
OPE B
compounds O
. O

Unconventional O
growth O
mechanism O
for O
monolithic O
integration O
of O
III O
- O
V O
on O
silicon B
. O

The O
heterogeneous O
integration O
of O
III O
- O
V O
optoelectronic O
devices O
with O
Si B
electronic O
circuits O
is O
highly O
desirable O
because O
it O
will O
enable O
many O
otherwise O
unattainable O
capabilities O
. O

However O
, O
direct O
growth O
of O
III O
- O
V O
thin O
film O
on O
silicon B
substrates O
has O
been O
very O
challenging O
because O
of O
large O
mismatches O
in O
lattice O
constants O
and O
thermal O
coefficients O
. O

Here O
, O
we O
present O
a O
detailed O
studies O
on O
a O
novel O
growth O
mode O
which O
yields O
a O
catalyst O
- O
free O
( O
Al B
, O
In B
) O
GaAs B
nanopillar O
laser O
on O
a O
silicon B
substrate O
by O
metal O
- O
organic O
chemical O
vapor O
deposition O
at O
the O
low O
temperature O
of O
400 O
degrees O
C O
. O

We O
study O
the O
growth O
and O
misfit O
stress O
relaxation O
mechanism O
by O
cutting O
through O
the O
center O
of O
the O
InGaAs O
/ O
GaAs B
nanopillars O
using O
focused O
ion O
beam O
and O
inspecting O
with O
high O
- O
resolution O
transmission O
electron O
microscopy O
. O

The O
bulk O
material O
of O
the O
nanopillar O
is O
in O
pure O
wurtzite B
crystal O
phase O
, O
despite O
the O
6 O
% O
lattice O
mismatch O
with O
the O
substrate O
, O
with O
all O
stacking O
disorders O
well O
confined O
in O
the O
bottom O
- O
most O
transition O
region O
and O
terminated O
horizontally O
. O

Furthermore O
, O
InGaAs O
was O
found O
to O
be O
in O
direct O
contact O
with O
silicon B
, O
in O
agreement O
with O
the O
observed O
crystal O
orientation O
alignment O
and O
good O
electrical O
conduction O
across O
the O
interface O
. O

This O
is O
in O
sharp O
contrast O
to O
many O
III O
- O
V O
nanowires O
on O
silicon B
which O
are O
observed O
to O
stem O
from O
thin O
SiN O
( O
x O
) O
, O
SiO B
( I
2 I
) I
, O
or O
SiO B
( I
2 I
) I
/ O
Si B
openings O
. O

In O
addition O
, O
GaAs B
was O
found O
to O
grow O
perfectly O
as O
a O
shell O
layer O
on O
In O
( O
0 O
. O
2 O
) O
Ga O
( O
0 O
. O
8 O
) O
As O
with O
an O
extraordinary O
thickness O
, O
which O
is O
15 O
times O
greater O
than O
the O
theoretical O
thin O
- O
film O
critical O
thickness O
for O
a O
1 O
. O
5 O
% O
lattice O
mismatch O
. O

A O
comparative O
study O
of O
the O
rotational O
dynamics O
of O
PF6 B
( I
- I
) I
anions O
in O
the O
crystals O
and O
liquid O
states O
of O
1 O
- O
butyl O
- O
3 O
- O
methylimidazolium O
hexafluorophosphate O
: O
results O
from O
31P B
NMR O
spectroscopy O
. O

The O
rotational O
dynamics O
of O
the O
hexafluorophosphate O
anion O
( O
PF O
( O
6 O
) O
( O
- O
) O
) O
in O
the O
crystalline O
and O
liquid O
states O
of O
the O
archetypal O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
1 O
- O
butyl O
- O
3 O
- O
methylimidazolium O
hexafluorophosphate O
( O
[ O
C O
( O
4 O
) O
mim O
] O
PF O
( O
6 O
) O
) O
are O
investigated O
using O
( B
31 I
) I
P I
NMR O
spectroscopy O
line O
shape O
analyses O
and O
spin O
- O
lattice O
relaxation O
time O
measurements O
. O

Interestingly O
, O
compound O
- O
induced O
gene O
expression O
changes O
were O
generally O
model O
specific O
, O
especially O
for O
methylmercury B
and O
flusilazole B
, O
which O
were O
predicted O
better O
in O
ESTn O
and O
ESTc O
, O
respectively O
. O

Valproic B
acid I
- O
induced O
gene O
expression O
changes O
were O
most O
comparable O
out O
of O
the O
six O
developmental O
toxicants O
between O
the O
ESTn O
and O
ESTc O
. O

Hydrophobic O
carbon B
nanotubes O
( O
CNTs O
) O
and O
hydrophilic O
nanofilaments O
such O
as O
oxidized O
CNTs O
, O
Pd B
nanowires O
( O
NWs O
) O
, O
and O
MnO B
( I
2 I
) I
NWs O
are O
transformed O
from O
wires O
to O
rings O
by O
a O
general O
methodology O
. O

Preparation O
of O
raspberry O
- O
like O
polymer O
particles O
by O
a O
heterocoagulation O
technique O
utilizing O
hydrogen B
bonding O
interactions O
between O
steric O
stabilizers O
. O

Large O
polystyrene B
particles O
stabilized O
by O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
( O
L O
- O
PS O
( O
PAA O
) O
) O
( O
as O
the O
core O
) O
and O
small O
polystyrene B
particles O
stabilized O
by O
poly O
( O
vinyl O
pyrrolidone O
) O
( O
PVP B
) O
( O
S O
- O
PS O
( O
PVP O
) O
) O
( O
as O
the O
corona O
) O
were O
successfully O
used O
to O
prepare O
raspberry O
- O
like O
particles O
by O
a O
heterocoagulation O
technique O
utilizing O
the O
hydrogen B
bonding O
interaction O
between O
PAA B
and O
PVP B
. O

The O
coverage O
of O
L O
- O
PS O
( O
PAA O
) O
by O
S O
- O
PS O
( O
PVP O
) O
could O
be O
controlled O
by O
adding O
PVP B
homopolymer O
to O
the O
L O
- O
PS O
( O
PAA O
) O
dispersion O
and O
by O
changing O
the O
molecular O
weight O
of O
the O
stabilizers O
. O

Moreover O
, O
the O
heterocoagulation O
of O
large O
poly B
( I
methyl I
methacrylate I
) I
particles O
stabilized O
by O
PAA B
( O
L O
- O
PMMA O
( O
PAA O
) O
) O
and O
S O
- O
PS O
( O
PVP O
) O
particles O
was O
also O
accomplished O
, O
resulting O
in O
the O
formation O
of O
L O
- O
PMMA O
( O
PAA O
) O
- O
core O
/ O
S O
- O
PS O
( O
PVP O
) O
- O
corona O
raspberry O
- O
like O
composite O
particles O
. O

These O
results O
suggested O
that O
the O
raspberry O
- O
like O
particles O
composed O
of O
various O
polymer O
particles O
could O
be O
formed O
by O
the O
heterocoagulation O
technique O
utilizing O
the O
hydrogen B
bonding O
interaction O
. O

Chemically O
modified O
graphene B
( O
CMG O
) O
nanoplatelets O
have O
shown O
great O
promise O
in O
various O
applications O
due O
to O
their O
electrical O
properties O
and O
high O
surface O
area O
. O

Chemical O
doping O
is O
one O
of O
the O
most O
effective O
methods O
to O
tune O
the O
electronic O
properties O
of O
graphene B
materials O
. O

In O
this O
work O
, O
novel O
B B
- O
doped O
nanoplatelets O
( O
borane B
- O
reduced O
graphene B
oxide I
, O
B B
- O
rG O
- O
O B
) O
were O
produced O
on O
a O
large O
scale O
via O
the O
reduction O
of O
graphene B
oxide I
by O
a O
borane B
- O
tetrahydrofuran B
adduct O
under O
reflux O
, O
and O
their O
use O
for O
supercapacitor O
electrodes O
was O
studied O
. O

The O
B B
- O
rG O
- O
O B
had O
a O
high O
specific O
surface O
area O
of O
466 O
m O
( O
2 O
) O
/ O
g O
and O
showed O
excellent O
supercapacitor O
performance O
including O
a O
high O
specific O
capacitance O
of O
200 O
F O
/ O
g O
in O
aqueous O
electrolyte O
as O
well O
as O
superior O
surface O
area O
- O
normalized O
capacitance O
to O
typical O
carbon B
- O
based O
supercapacitor O
materials O
and O
good O
stability O
after O
4500 O
cycles O
. O

Two O
- O
and O
three O
- O
electrode O
cell O
measurements O
showed O
that O
energy O
storage O
in O
the O
B B
- O
rG O
- O
O B
supercapacitors O
was O
contributed O
by O
ion O
adsorption O
on O
the O
surface O
of O
the O
nanoplatelets O
in O
addition O
to O
electrochemical O
redox O
reactions O
. O

Unique O
aggregation O
behavior O
of O
a O
carboxylate B
gemini O
surfactant O
with O
a O
long O
rigid O
spacer O
in O
aqueous O
solution O
. O

The O
homologue O
O O
, O
O O
' O
- O
bis O
( O
sodium O
2 O
- O
dodecylcarboxylate O
) O
- O
p O
- O
benzenediol O
( O
C O
( O
12 O
) O
phi O
C O
( O
12 O
) O
) O
whose O
spacer O
only O
contains O
a O
single O
phenyl B
group O
was O
also O
examined O
for O
comparison O
. O

This O
behavior O
was O
attributed O
to O
an O
extending O
configuration O
of O
C O
( O
12 O
) O
phi O
( O
2 O
) O
C O
( O
12 O
) O
with O
the O
two O
alkyl B
tails O
stretching O
toward O
the O
solution O
due O
to O
the O
rigidity O
of O
the O
long O
spacer O
. O

Freeze O
- O
fracture O
transmission O
electron O
microscopy O
( O
FF O
- O
TEM O
) O
images O
and O
( B
1 I
) I
H I
NMR O
measurements O
supported O
this O
speculation O
. O

The O
cationic O
polymer O
nanobrush O
was O
synthesized O
on O
a O
gold O
substrate O
by O
AIBN O
photoinitiated O
polymerization O
, O
using O
a O
70 O
: O
30 O
ratio O
of O
2 O
- O
aminoethyl O
methacrylate O
hydrochloride O
( O
AEMA O
) O
: O
N B
- I
isopropylacrylamide I
( O
NIPAAM O
) O
. O

Direct O
measurement O
of O
Dirac O
point O
energy O
at O
the O
graphene B
/ O
oxide B
interface O
. O

We O
report O
the O
direct O
measurement O
of O
the O
Dirac O
point O
, O
the O
Fermi O
level O
, O
and O
the O
work O
function O
of O
graphene B
by O
performing O
internal O
photoemission O
measurements O
on O
a O
graphene B
/ O
SiO B
( I
2 I
) I
/ O
Si B
structure O
with O
a O
unique O
optical O
- O
cavity O
enhanced O
test O
structure O
. O

A O
complete O
electronic O
band O
alignment O
at O
the O
graphene B
/ O
SiO B
( I
2 I
) I
/ O
Si B
interfaces O
is O
accurately O
established O
. O

The O
observation O
of O
enhanced O
photoemission O
from O
a O
one O
- O
atom O
thick O
graphene B
layer O
was O
possible O
by O
taking O
advantage O
of O
the O
constructive O
optical O
interference O
in O
the O
SiO B
( I
2 I
) I
cavity O
. O

At O
the O
flat O
band O
condition O
, O
the O
Fermi O
level O
was O
extracted O
and O
found O
to O
reside O
3 O
. O
3 O
eV O
+ O
/ O
- O
0 O
. O
05 O
eV O
below O
the O
bottom O
of O
the O
SiO B
( I
2 I
) I
conduction O
band O
. O

When O
combined O
with O
the O
shift O
of O
the O
Fermi O
level O
from O
the O
Dirac O
point O
, O
we O
are O
able O
to O
ascertain O
the O
position O
of O
the O
Dirac O
point O
at O
3 O
. O
6 O
eV O
+ O
/ O
- O
0 O
. O
05 O
eV O
with O
respect O
to O
the O
bottom O
of O
the O
SiO B
( I
2 I
) I
conduction O
band O
edge O
, O
yielding O
a O
work O
function O
of O
4 O
. O
5 O
eV O
+ O
/ O
- O
0 O
. O
05 O
eV O
which O
is O
in O
an O
excellent O
agreement O
with O
theory O
. O

The O
accurate O
determination O
of O
the O
work O
function O
of O
graphene B
is O
of O
significant O
importance O
to O
the O
engineering O
of O
graphene B
- O
based O
devices O
, O
and O
the O
measurement O
technique O
we O
have O
advanced O
in O
this O
Letter O
will O
have O
significant O
impact O
on O
numerous O
applications O
for O
emerging O
graphene B
- O
like O
2 O
- O
dimensional O
material O
systems O
. O

Despite O
the O
fully O
complementary O
hydrogen B
bonding O
groups O
to O
guanine B
, O
MCND O
did O
not O
bind O
to O
guanine B
- O
guanine B
mismatch O
but O
did O
to O
adenine B
- O
adenine B
mismatch O
. O

Naphthyridinone O
( O
NTD O
) O
integrase O
inhibitors O
: O
N1 O
protio O
and O
methyl B
combination O
substituent O
effects O
with O
C3 O
amide B
groups O
. O

The O
effects O
of O
combinations O
of O
the O
N1 O
substituent O
and O
C3 O
amide B
groups O
was O
extensively O
studied O
to O
compare O
enzyme O
inhibition O
, O
antiviral O
activity O
and O
protein O
binding O
effects O
on O
potency O
. O

Overexpression O
of O
Escherichia O
coli O
nucleotide B
excision O
repair O
genes O
after O
cisplatin B
- O
induced O
damage O
. O

Cisplatin B
is O
currently O
used O
in O
tumor O
chemotherapy O
to O
induce O
the O
death O
of O
malignant O
cells O
through O
blockage O
of O
DNA O
replication O
. O

Escherichia O
coli O
K12 O
mutant O
strains O
deficient O
in O
nucleotide B
excision O
repair O
( O
NER O
) O
were O
submitted O
to O
increasing O
concentrations O
of O
cisplatin B
, O
and O
the O
results O
revealed O
that O
uvrA O
and O
uvrB O
mutants O
are O
sensitive O
to O
this O
agent O
, O
while O
uvrC O
and O
cho O
mutants O
remain O
as O
the O
wild O
type O
strain O
. O

The O
time O
required O
for O
both O
gene O
expression O
turn O
- O
off O
and O
return O
to O
normal O
weight O
DNA O
in O
wild O
- O
type O
E O
. O
coli O
was O
not O
accomplished O
even O
after O
4 O
h O
post O
- O
treatment O
with O
cisplatin B
, O
while O
the O
same O
process O
takes O
place O
within O
1 O
. O
5 O
h O
after O
ultraviolet O
radiation O
( O
UV O
) O
. O

Besides O
, O
a O
heavily O
damaging O
action O
of O
cisplatin B
can O
be O
seen O
not O
only O
by O
persistent O
nicks O
on O
genomic O
DNA O
, O
but O
also O
by O
NER O
gene O
expression O
exceeding O
manifold O
that O
seen O
after O
equivalent O
lethal O
doses O
of O
UV O
. O

Moreover O
, O
cisplatin B
caused O
an O
increase O
in O
uvrB O
gene O
expression O
from O
its O
putative O
upstream O
promoter O
P3 O
in O
an O
SOS O
- O
independent O
manner O
. O

Non O
- O
ionic O
Gd B
- O
based O
MRI O
contrast O
agents O
are O
optimal O
for O
encapsulation O
into O
phosphatidyldiglycer O
- O
based O
thermosensitive O
liposomes O
. O

CAs O
were O
passively O
encapsulated O
with O
323 O
mOs O
kg O
( O
- O
1 O
) O
into O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 O
, O
2 O
- O
distearoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
/ O
1 O
, O
2 O
- O
dipalmitoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphodiglycerol O
50 O
/ O
20 O
/ O
30 O
( O
mol O
/ O
mol O
) O
TSL O
( O
DPPG O
( O
2 O
) O
- O
TSL O
) O

Wogonin O
inhibits O
H2O2 B
- O
induced O
vascular O
permeability O
through O
suppressing O
the O
phosphorylation O
of O
caveolin O
- O
1 O
. O

In O
this O
study O
, O
we O
evaluated O
the O
effects O
of O
wogonin O
on O
H2O2 B
- O
induced O
vascular O
permeability O
in O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
. O

We O
found O
that O
wogonin O
can O
suppress O
the O
H2O2 B
- O
stimulated O
actin O
remodeling O
and O
albumin O
uptake O
of O
HUVECs O
, O
as O
well O
as O
transendothelial O
cell O
migration O
of O
the O
human O
breast O
carcinoma O
cell O
MDA O
- O
MB O
- O
231 O
. O

The O
mechanism O
revealed O
that O
wogonin O
inhibited O
H2O2 B
- O
induced O
phosphorylation O
of O
caveolin O
- O
1 O
( O
cav O
- O
1 O
) O
associating O
with O
the O
suppression O
of O
stabilization O
of O
VE O
- O
cadherin O
and O
beta O
- O
catenin O
. O

Moreover O
, O
wogonin O
repressed O
anisomycin B
- O
induced O
phosphorylation O
of O
p38 O
, O
cav O
- O
1 O
and O
vascular O
permeability O
. O

These O
results O
suggested O
that O
wogonin O
could O
inhibit O
H2O2 B
- O
induced O
vascular O
permeability O
by O
downregulating O
the O
phosphorylation O
of O
cav O
- O
1 O
, O
and O
that O
it O
might O
have O
a O
therapeutic O
potential O
for O
the O
diseases O
associated O
with O
the O
development O
of O
both O
oxidant O
and O
vascular O
permeability O
. O

While O
studying O
possible O
mechanisms O
involved O
in O
this O
inhibition O
, O
we O
observed O
that O
pre O
- O
treatment O
with O
dexamethasone B
, O
zileuton B
or O
Boc2 O
( O
a O
selective O
antagonist O
of O
formyl O
peptide O
receptors O
) O
, O
but O
not O
with O
indomethacin B
, O
canceled O
out O
the O
inhibitory O
effect O
of O
Cdt O
venom O
on O
the O
edema O
induced O
by O
BCG O
. O

Evaluation O
of O
genotoxicity O
in O
leukocytes O
and O
testis O
following O
intra O
- O
vasal O
contraception O
with O
RISUG O
and O
its O
reversal O
by O
DMSO B
and O
NaHCO3 O
in O
Wistar O
albino O
rats O
. O

Animals O
were O
allotted O
into O
groups O
of O
sham O
operated O
control O
, O
vas O
occlusion O
with O
RISUG O
( O
5 O
- O
7 O
mu O
l O
) O
for O
360 O
days O
and O
reversal O
by O
DMSO B
( O
250 O
- O
500 O
mu O
l O
) O
and O
5 O
% O
NaHCO3 O
( O
500 O
mu O
l O
) O
. O

Hydrogen B
peroxide I
induced O
samples O
were O
used O
as O
positive O
control O
. O

When O
compared O
with O
positive O
control O
the O
variation O
was O
highly O
significant O
for O
both O
20 O
mu O
M O
and O
50 O
mu O
M O
H2O2 B
( O
p O
< O
0 O
. O
001 O
) O
. O

Developmental O
exposure O
to O
lead O
( O
Pb B
) O
has O
adverse O
effects O
on O
cognitive O
functioning O
and O
behavior O
that O
can O
persist O
into O
adulthood O
. O

Since O
DNA O
methylation O
is O
regulated O
by O
DNA O
methyltransferases O
and O
methyl O
cytosine O
- O
binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb B
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O

Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb B
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
( O
early O
postnatal O
exposure O
group O
) O
. O

Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb B
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 O
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb B
exposure O
. O

These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb B
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

New O
formulation O
approaches O
to O
improve O
solubility O
and O
drug O
release O
from O
fixed O
dose O
combinations O
: O
Case O
examples O
pioglitazone B
/ O
glimepiride O
and O
ezetimibe O
/ O
simvastatin B
. O

The O
first O
FDC O
contained O
a O
weak O
acid O
( O
glimepiride O
) O
and O
a O
weak O
base O
( O
pioglitazone B
) O
, O
while O
the O
second O
FDC O
contained O
two O
compounds O
( O
simvastatin B
and O
ezetimibe O
) O
that O
are O
essentially O
non O
- O
ionised O
over O
the O
physiological O
pH O
range O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

The O
FDCs O
of O
the O
pure O
drugs O
and O
the O
marketed O
products O
showed O
very O
poor O
( O
and O
especially O
for O
pioglitazone B
, O
strongly O
pH O
- O
dependent O
) O
dissolution O
. O

For O
example O
, O
in O
pH O
conditions O
of O
the O
fasted O
small O
intestine O
after O
a O
test O
duration O
of O
240min O
, O
we O
observed O
100 O
% O
dissolution O
of O
both O
drugs O
from O
the O
ternary O
pioglitazone B
/ O
glimepiride O
( O
30mg O
/ O
4mg O
) O
complex O
formulation O
, O
whereas O
from O
the O
marketed O
formulation O
less O
than O
5 O
% O
pioglitazone B
, O
and O
only O
25 O
% O
glimepiride O
dissolved O
. O

Using O
the O
same O
conditions O
, O
60 O
% O
ezetimibe O
and O
85 O
% O
simvastatin B
dissolved O
from O
the O
ternary O
ezetimibe O
/ O
simvastatin B
( O
10mg O
/ O
40mg O
) O
complex O
formulation O
, O
whereas O
with O
less O
than O
5 O
% O
ezetimibe O
and O
10 O
% O
simvastatin B
dissolved O
after O
240min O
, O
the O
marketed O
FDC O
formulation O
showed O
poor O
dissolution O
. O

Based O
on O
the O
results O
of O
the O
present O
study O
, O
the O
bioavailability O
of O
both O
drugs O
in O
the O
fixed O
dose O
combination O
is O
likely O
to O
be O
increased O
after O
oral O
administration O
of O
the O
new O
formulations O
, O
especially O
when O
the O
fixed O
dose O
combination O
is O
formulated O
as O
a O
ternary O
complex O
consisting O
of O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

Preparation O
of O
highly O
porous O
gastroretentive O
metformin B
tablets O
using O
a O
sublimation O
method O
. O

The O
present O
investigation O
is O
aimed O
to O
formulate O
floating O
gastroretentive O
tablets O
containing O
metformin B
using O
a O
sublimation O
material O
. O

The O
effect O
of O
the O
amount O
of O
PEO B
on O
swelling O
and O
eroding O
of O
the O
tablets O
was O
determined O
. O

The O
water O
- O
uptake O
and O
erosion O
behavior O
of O
the O
gastroretentive O
( O
GR O
) O
tablets O
were O
highly O
dependent O
on O
the O
amount O
of O
PEO B
. O

The O
water O
- O
uptake O
increased O
with O
increasing O
PEO B
concentration O
in O
the O
tablet O
matrix O
. O

The O
weight O
loss O
from O
tablets O
decreased O
with O
increasing O
amounts O
of O
PEO B
. O

Camphor B
was O
used O
as O
the O
sublimation O
material O
to O
prepare O
GR O
tablets O
that O
are O
low O
- O
density O
and O
easily O
floatable O
. O

Camphor B
was O
changed O
to O
pores O
in O
the O
tablet O
during O
the O
sublimation O
process O
. O

Floating O
properties O
of O
tablets O
and O
tablet O
density O
were O
affected O
by O
the O
sublimation O
of O
camphor B
. O

However O
, O
as O
the O
amount O
of O
camphor B
in O
the O
tablet O
matrix O
increased O
, O
the O
crushing O
strength O
of O
the O
tablet O
decreased O
after O
sublimation O
. O

Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde B
and O
other O
biological O
aldehydes B
in O
the O
body O
. O

Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72 O
% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde B
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O

Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino B
acid I
sequences O
. O

A O
retrospective O
test O
also O
showed O
that O
nine O
mineralocorticoid O
ligands O
were O
ranked O
among O
the O
top O
ten O
molecules O
in O
a O
search O
of O
a O
database O
of O
approved O
drugs O
for O
molecules O
similar O
to O
aldosterone B
. O

Observation O
of O
direct O
vibrational O
excitation O
in O
gas O
- O
surface O
collisions O
of O
CO B
with O
Au B
( O
111 O
) O
: O
a O
new O
model O
system O
for O
surface O
dynamics O
. O

We O
report O
vibrational O
excitation O
of O
CO B
from O
its O
ground O
( O
v O
= O
0 O
) O
to O
first O
excited O
( O
v O
= O
1 O
) O
vibrational O
state O
in O
collision O
with O
Au B
( O
111 O
) O
at O
an O
incidence O
energy O
of O
translation O
of O
E O
( O
I O
) O
= O
0 O
. O
45 O
eV O
. O

The O
angular O
distributions O
of O
the O
scattered O
CO B
molecules O
are O
narrow O
, O
consistent O
with O
direct O
scattering O
occurring O
on O
a O
sub O
- O
ps O
time O
scale O
. O

Our O
measurements O
are O
consistent O
with O
a O
vibrational O
excitation O
mechanism O
involving O
coupling O
of O
thermally O
excited O
electron O
- O
hole O
pairs O
of O
the O
solid O
to O
CO B
vibration O
. O

Selective O
focused O
- O
ion O
- O
beam O
sculpting O
of O
TiO2 B
nanotubes O
and O
mechanism O
understanding O
. O

Anodic O
TiO B
( I
2 I
) I
nanotubes O
with O
different O
structures O
, O
doping O
agents O
, O
and O
decorations O
have O
been O
studied O
in O
order O
to O
improve O
energy O
conversion O
and O
storage O
efficiencies O
such O
as O
in O
dye O
sensitized O
solar O
cells O
, O
solar O
fuels O
, O
and O
electrochemical O
supercapacitors O
. O

However O
, O
the O
top O
surface O
modification O
of O
TiO B
( I
2 I
) I
nanotubes O
has O
never O
been O
addressed O
. O

In O
this O
study O
, O
anodic O
TiO B
( I
2 I
) I
nanotubes O
have O
been O
selectively O
closed O
by O
high O
energy O
focused O
ion O
beams O
and O
re O
- O
opened O
by O
low O
energy O
focused O
ion O
beams O
. O

Under O
a O
30 O
kV O
Ga B
( I
+ I
) I
beam O
, O
TiO B
( I
2 I
) I
nanotubes O
are O
closed O
with O
a O
65 O
nm O
shield O
layer O
covering O
the O
top O
entrance O
when O
the O
ion O
dose O
is O
larger O
than O
1 O
. O
2 O
x O
10 O
( O
17 O
) O
ions O
per O
cm O
( O
2 O
) O
; O
under O
a O
5 O
kV O
Ga B
( I
+ I
) I
beam O
, O
the O
shield O
layer O
is O
removed O
and O
the O
closed O
tubes O
are O
re O
- O
opened O
. O

An O
ion O
- O
induced O
viscous O
flow O
model O
has O
been O
proposed O
to O
explain O
the O
influence O
of O
Ga B
( I
+ I
) I
ion O
beam O
flux O
, O
substrate O
temperature O
, O
initial O
tube O
diameter O
, O
ion O
beam O
dwell O
time O
, O
and O
the O
incidence O
angle O
of O
the O
ion O
beam O
. O

We O
investigated O
the O
relationship O
between O
muscular O
bioaccumulation O
levels O
of O
metals O
( O
Hg B
, O
Cd B
, O
Pb B
, O
Cu B
, O
Zn B
, O
Ni B
, O
Cr B
, O
As B
and O
Se B
) O
, O
PCBs B
and O
organochlorine O
pesticides O
( O
DDTs O
) O
, O
the O
health O
status O
( O
condition O
factor O
and O
lipid O
reserves O
) O
and O
the O
associated O
transcriptional O
response O
in O
liver O
and O
gill O
tissues O
for O
genes O
involved O
in O
metal O
detoxification O
( O
metallothionein O
, O
MT O
) O
and O
oxidative O
metabolism O
( O
cytochrome O
P4501A O
, O
CYP1A O
) O
of O
xenobiotic O
compounds O
. O

A O
comparative O
VCD O
study O
of O
methyl O
mandelate O
in O
methanol B
, O
dimethyl B
sulfoxide I
, O
and O
chloroform B
: O
explicit O
and O
implicit O
solvation O
models O
. O

Vibrational O
absorption O
( O
VA O
) O
and O
vibrational O
circular O
dichroism O
( O
VCD O
) O
spectra O
of O
methyl O
mandelate O
, O
a O
prototype O
chiral O
molecule O
, O
in O
a O
series O
of O
organic O
solvents O
, O
namely O
methanol B
( O
MeOH O
- O
d O
( O
4 O
) O
) O
, O
dimethyl B
sulfoxide I
( O
DMSO B
- I
d I
( I
6 I
) I
) O
, O
and O
chloroform B
( O
CDCl O
( O
3 O
) O
) O
, O
have O
been O
measured O
in O
the O
finger O
print O
region O
from O
1800 O
to O
1150 O
cm O
( O
- O
1 O
) O
. O

Initial O
geometry O
searches O
have O
been O
carried O
out O
at O
the O
B3LYP O
/ O
6 O
- O
31G O
( O
d O
) O
level O
for O
the O
methyl O
mandelate O
monomer O
and O
its O
explicit O
1 O
: O
1 O
and O
1 O
: O
2 O
solute O
- O
solvent O
hydrogen B
- O
bonded O
complexes O
. O

The O
results O
show O
that O
inclusion O
of O
solvent O
explicitly O
and O
implicitly O
at O
the O
same O
time O
has O
significant O
impacts O
on O
the O
appearance O
of O
the O
VA O
and O
VCD O
spectra O
, O
and O
is O
crucial O
for O
reliable O
spectral O
assignments O
when O
solvents O
are O
capable O
of O
hydrogen B
- O
bonding O
interactions O
with O
solutes O
. O

When O
no O
strong O
solvent O
- O
solute O
hydrogen B
- O
bonding O
interactions O
in O
the O
case O
of O
chloroform B
are O
expected O
, O
the O
gas O
phase O
monomer O
model O
is O
adequate O
for O
spectral O
interpretation O
, O
while O
inclusion O
of O
implicit O
solvation O
improves O
the O
frequency O
agreement O
with O
experiment O
. O

Canonical O
microdomain O
association O
of O
Stx O
GSL O
receptors O
, O
sphingomyelin B
, O
and O
cholesterol B
in O
membranes O
of O
Raji O
and O
THP O
- O
1 O
cells O
was O
assessed O
by O
comparative O
analysis O
of O
detergent O
- O
resistant O
membrane O
( O
DRM O
) O
and O
nonDRM O
fractions O
obtained O
by O
density O
gradient O
centrifugation O
and O
showed O
high O
correlation O
based O
on O
nonparametric O
statistical O
analysis O
. O

Extremely O
flexible O
nanoscale O
ultrathin O
body O
silicon B
integrated O
circuits O
on O
plastic O
. O

In O
recent O
years O
, O
flexible O
devices O
based O
on O
nanoscale O
materials O
and O
structures O
have O
begun O
to O
emerge O
, O
exploiting O
semiconductor O
nanowires O
, O
graphene B
, O
and O
carbon B
nanotubes O
. O

Here O
, O
we O
show O
nanoscale O
flexible O
circuits O
on O
60 O
A O
thick O
silicon B
, O
including O
functional O
ring O
oscillators O
and O
memory O
cells O
. O

The O
mechanical O
flexibility O
is O
achieved O
by O
employing O
the O
controlled O
spalling O
technology O
, O
enabling O
the O
large O
- O
area O
transfer O
of O
the O
ultrathin O
body O
silicon B
devices O
to O
a O
plastic O
substrate O
at O
room O
temperature O
. O

These O
results O
provide O
a O
simple O
and O
cost O
- O
effective O
pathway O
to O
enable O
ultralight O
flexible O
nanoelectronics O
with O
unprecedented O
level O
of O
system O
complexity O
based O
on O
mainstream O
silicon B
technology O
. O

The O
spectral O
changes O
evident O
in O
the O
vibrational O
spectra O
of O
the O
3M O
membranes O
can O
be O
associated O
with O
two O
major O
phenomena O
: O
( O
1 O
) O
dissociation O
of O
the O
proton O
from O
the O
sulfonic B
acid I
groups O
even O
in O
the O
presence O
of O
small O
amounts O
of O
water O
; O
and O
( O
2 O
) O
changes O
in O
the O
conformation O
or O
the O
degree O
of O
crystallinity O
of O
the O
poly O
( O
tetrafluoroethylene O
) O
hydrophobic O
domains O
both O
as O
a O
function O
of O
EW O
and O
membrane O
water O
content O
. O

Here O
, O
for O
the O
first O
time O
, O
we O
show O
that O
with O
addition O
of O
a O
biological O
buffer O
, O
4 O
- O
( O
2 O
- O
hydroxyethyl O
) O
piperazine O
- O
1 O
- O
ethanesulfonic O
acid O
( O
HEPES O
) O
, O
into O
aqueous O
solutions O
of O
tetrahydrofuran B
( O
THF B
) O
, O
1 O
, O
3 O
- O
dioxolane O
, O
1 O
, O
4 O
- O
dioxane O
, O
1 O
- O
propanol O
, O
2 B
- I
propanol I
, O
tert O
- O
butanol O
, O
acetonitrile B
, O
or O
acetone B
, O
the O
organic O
solvent O
can O
be O
excluded O
from O
water O
to O
form O
a O
new O
liquid O
phase O
. O

In O
order O
to O
understand O
why O
and O
how O
a O
zwitterion O
solute O
( O
HEPES O
) O
induced O
phase O
separation O
of O
the O
investigated O
systems O
, O
molecular O
dynamics O
( O
MD O
) O
simulation O
studies O
are O
performed O
for O
HEPES O
+ O
water O
+ O
THF B
system O
. O

The O
simulation O
results O
of O
HEPES O
in O
pure O
THF B
and O
in O
a O
composition O
inside O
the O
phase O
separation O
region O
were O
justified O
qualitatively O
. O

Interestingly O
, O
all O
HEPES O
molecules O
entirely O
aggregated O
in O
pure O
THF B
. O

This O
reveals O
that O
HEPES O
is O
insoluble O
in O
pure O
THF B
, O
which O
is O
consistent O
with O
the O
experimental O
results O
. O

The O
THF B
molecules O
are O
squeezed O
out O
from O
the O
water O
network O
into O
a O
new O
liquid O
phase O
. O

Receptor O
function O
is O
also O
influenced O
by O
amino B
acid I
substitutions O
in O
the O
protein O
sequence O
. O

Mechanisms O
limiting O
distribution O
of O
the O
threonine B
- O
protein O
kinase O
B O
- O
RaF O
( O
V600E O
) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases O
. O

Dabrafenib O
is O
a O
BRAF O
( O
gene O
encoding O
serine B
/ O
threonine B
- O
protein O
kinase O
B O
- O
Raf O
) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine B
600 O
to O
glutamic B
acid I
substitution O
( O
BRAF O
( O
V600E O
) O
) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O

Further O
, O
compared O
with O
vemurafenib B
, O
another O
BRAF O
( O
V600E O
) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O

Pharmacological O
inhibition O
of O
mitochondrial O
carbonic O
anhydrases O
protects O
mouse O
cerebral O
pericytes O
from O
high O
glucose B
- O
induced O
oxidative O
stress O
and O
apoptosis O
. O

Diabetes O
- O
associated O
complications O
in O
the O
microvasculature O
of O
the O
brain O
are O
caused O
by O
oxidative O
stress O
, O
generated O
by O
overproduction O
of O
reactive O
oxygen B
species O
from O
hyperglycemia O
- O
induced O
accelerated O
oxidative O
metabolism O
of O
glucose B
. O

Mitochondrial O
carbonic O
anhydrases O
, O
regulators O
of O
the O
oxidative O
metabolism O
of O
glucose B
, O
determine O
the O
rate O
of O
reactive O
oxygen B
species O
production O
and O
inhibition O
of O
mitochondrial O
carbonic O
anhydrases O
rescues O
glucose B
- O
induced O
pericyte O
loss O
in O
the O
diabetic O
mouse O
brain O
. O

We O
hypothesized O
that O
high O
glucose B
induces O
intracellular O
oxidative O
stress O
and O
pericyte O
apoptosis O
and O
that O
inhibition O
of O
mitochondrial O
carbonic O
anhydrases O
protects O
pericytes O
from O
oxidative O
stress O
- O
induced O
apoptosis O
. O

To O
validate O
our O
hypothesis O
, O
conditionally O
immortalized O
cerebral O
pericyte O
( O
IPC O
) O
cultures O
were O
established O
from O
Immortomice O
to O
investigate O
the O
effect O
of O
high O
glucose B
on O
oxidative O
stress O
and O
pericyte O
apoptosis O
. O

High O
glucose B
caused O
oxidative O
stress O
and O
apoptosis O
of O
these O
cells O
, O
with O
both O
oxidative O
stress O
and O
apoptosis O
significantly O
reduced O
after O
mitochondrial O
carbonic O
anhydrase O
inhibition O
. O

These O
results O
provide O
the O
first O
evidence O
that O
pharmacological O
inhibition O
of O
mitochondrial O
carbonic O
anhydrases O
attenuates O
pericyte O
apoptosis O
caused O
by O
high O
glucose B
- O
induced O
oxidative O
stress O
. O

Here O
, O
we O
leveraged O
protein O
engineering O
to O
modify O
the O
PK O
characteristics O
of O
the O
native O
molecule O
by O
fusing O
FST315 O
to O
a O
murine O
IgG O
( O
1 O
) O
Fc O
and O
removing O
the O
intrinsic O
heparan O
sulfate B
- O
binding O
activity O
of O
follistatin O
. O

Evaluation O
of O
percutaneous O
absorption O
of O
esculetin B
: O
effect O
of O
chemical O
enhancers O
. O

Percutaneous O
transdermal O
absorption O
of O
esculetin B
( O
6 O
, O
7 O
- O
dihydroxycoumarin O
) O
, O
an O
oxidative O
damage O
inhibitor O
, O
was O
evaluated O
by O
means O
of O
in O
vitro O
permeation O
studies O
in O
which O
vertical O
Franz O
- O
type O
diffusion O
cells O
and O
pig O
ear O
skin O
were O
employed O
. O

To O
determine O
the O
absorption O
of O
esculetin B
, O
we O
validated O
a O
simple O
, O
accurate O
, O
precise O
, O
and O
rapid O
HPLC O
- O
UV O
method O
. O

Pretreatment O
of O
porcine O
skin O
was O
performed O
with O
ethanol B
( O
control O
vehicle O
) O
, O
decenoic O
acid O
, O
oleic B
acid I
, O
R O
- O
( O
+ O
) O
- O
limonene O
, O
and O
laurocapram O
( O
Azone O
( O
R O
) O
) O
( O
5 O
% O
in O
ethanol B
, O
w O
/ O
w O
, O
respectively O
) O
. O

Pretreatment O
of O
skin O
with O
oleic B
acid I
or O
laurocapram O
led O
to O
statistically O
significant O
differences O
in O
the O
transdermal O
flux O
of O
esculetin B
with O
respect O
to O
controls O
. O

Of O
the O
two O
enhancers O
, O
laurocapram O
showed O
the O
greatest O
capacity O
to O
enhance O
the O
flux O
of O
esculetin B
across O
pig O
skin O
. O

Design O
and O
exploration O
of O
novel O
boronic O
acid O
inhibitors O
reveals O
important O
interactions O
with O
a O
clavulanic O
acid O
- O
resistant O
sulfhydryl B
- O
variable O
( O
SHV O
) O
beta O
- O
lactamase O
. O

The O
K234R O
substitution O
in O
the O
SHV O
beta O
- O
lactamase O
, O
from O
Klebsiella O
pneumoniae O
, O
results O
in O
resistance O
to O
ampicillin B
/ O
clavulanate O
. O

After O
site O
- O
saturation O
mutagenesis O
of O
Lys B
- O
234 O
in O
SHV O
, O
microbiological O
and O
biochemical O
characterization O
of O
the O
resulting O
beta O
- O
lactamases O
revealed O
that O
only O
- O
Arg O
conferred O
resistance O
to O
ampicillin B
/ O
clavulanate O
. O

X O
- O
ray O
crystallography O
revealed O
two O
conformations O
of O
Arg O
- O
234 O
and O
Ser B
- O
130 O
in O
SHV O
K234R O
. O

The O
movement O
of O
Ser B
- O
130 O
is O
the O
principal O
cause O
of O
the O
observed O
clavulanate O
resistance O
. O

A O
chiral O
ampicillin B
analogue O
was O
discovered O
to O
have O
a O
2 O
. O
4 O
+ O
/ O
- O
0 O
. O
2 O
nM O
K O
( O
i O
) O
for O
SHV O
K234R O
; O
the O
chiral O
ampicillin B
analogue O
formed O
a O
more O
complex O
hydrogen B
- O
bonding O
network O
in O
SHV O
K234R O
vs O
SHV O
- O
1 O
. O

Consideration O
of O
the O
spatial O
position O
of O
Ser B
- O
130 O
and O
Lys B
- O
234 O
and O
this O
hydrogen B
- O
bonding O
network O
will O
be O
important O
in O
the O
design O
of O
novel O
antibiotics O
targeting O
IR O
beta O
- O
lactamases O
. O

Architecturing O
hierarchical O
function O
layers O
on O
self O
- O
assembled O
viral O
templates O
as O
3D O
nano O
- O
array O
electrodes O
for O
integrated O
Li B
- O
ion O
microbatteries O
. O

The O
resultant O
microbattery O
based O
on O
self O
- O
aligned O
LiFePO B
( I
4 I
) I
nanoforests O
of O
shell O
- O
core O
- O
shell O
structure O
, O
with O
precise O
arrangement O
of O
various O
auxiliary O
material O
layers O
including O
a O
central O
nanometric O
metal O
core O
as O
direct O
electronic O
pathway O
to O
current O
collector O
, O
delivers O
excellent O
energy O
density O
and O
stable O
cycling O
stability O
only O
rivaled O
by O
the O
best O
Li B
- O
ion O
batteries O
of O
conventional O
configurations O
, O
while O
providing O
rate O
performance O
per O
foot O
- O
print O
and O
on O
- O
site O
manufacturability O
unavailable O
from O
the O
latter O
. O

The O
GBJs O
are O
shunted O
by O
a O
thin O
Au B
layer O
to O
provide O
nonhysteretic O
current O
voltage O
characteristics O
, O
and O
the O
SQUID O
incorporates O
a O
90 O
nm O
wide O
constriction O
which O
is O
used O
for O
on O
- O
chip O
modulation O
of O
the O
magnetic O
flux O
through O
the O
SQUID O
loop O
. O

Role O
of O
pharmacogenetics O
in O
busulfan O
/ O
cyclophosphamide B
conditioning O
therapy O
prior O
to O
hematopoietic O
stem O
cell O
transplantation O
. O

Busulfan O
( O
Bu O
) O
and O
cyclophosphamide B
( O
Cy O
) O
are O
the O
most O
commonly O
used O
alkylators O
in O
high O
- O
dose O
pretransplant O
conditioning O
for O
HSCT O
; O
a O
treatment O
that O
is O
correlated O
with O
drug O
- O
related O
toxicity O
and O
relapse O
. O

Pharmacogenetic O
investigations O
have O
shown O
that O
CYP450 O
, O
as O
well O
as O
aldehyde B
dehydrogenase O
, O
are O
clearly O
involved O
with O
Cy O
metabolism O
and O
are O
associated O
with O
altered O
treatment O
response O
, O
Cy O
metabolism O
and O
the O
unique O
stem O
- O
cell O
sparing O
capacity O
. O

Moreover O
, O
glutathione B
- O
S B
- O
transferase O
isoenzymes O
have O
been O
associated O
with O
cellular O
outward O
transport O
of O
various O
alkylating O
agents O
, O
including O
Cy O
metabolites O
, O
melphalan O
, O
Bu O
and O
chlorambucil O
. O

Vasorelaxing O
effects O
and O
inhibition O
of O
nitric B
oxide I
in O
macrophages O
by O
new O
iron B
- O
containing O
carbon B
monoxide I
- O
releasing O
molecules O
( O
CO O
- O
RMs O
) O
. O

Carbon B
monoxide I
- O
releasing O
molecules O
( O
CO B
- O
RMs O
) O
are O
a O
class O
of O
organometallo O
carbonyl O
complexes O
capable O
of O
delivering O
controlled O
quantities O
of O
CO B
gas O
to O
cells O
and O
tissues O
thus O
exerting O
a O
broad O
spectrum O
of O
pharmacological O
effects O
. O

Here O
we O
report O
on O
the O
chemical O
synthesis O
, O
CO B
releasing O
properties O
, O
cytotoxicity O
profile O
and O
pharmacological O
activities O
of O
four O
novel O
structurally O
related O
iron O
- O
allyl O
carbonyls O
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM O
- O
307 O
, O
CORM O
- O
308 O
and O
CORM O
- O
314 O
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM O
- O
319 O
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron O
- O
carbonyl O
with O
hydrogen O
tetrafluoroborate O
. O

We O
found O
that O
despite O
the O
fact O
all O
compounds O
liberated O
CO B
, O
CO B
- O
RMs O
soluble O
in O
DMSO B
caused O
a O
more O
pronounced O
toxic O
effect O
both O
in O
vascular O
and O
inflammatory O
cells O
as O
well O
as O
in O
isolated O
vessels O
. O

More O
specifically O
, O
iron O
carbonyls O
soluble O
in O
DMSO B
released O
CO B
with O
a O
fast O
kinetic O
and O
displayed O
a O
marked O
cytotoxic O
effect O
in O
smooth O
muscle O
cells O
and O
RAW O
247 O
. O
6 O
macrophages O
despite O
exerting O
a O
rapid O
and O
pronounced O
vasorelaxation O
ex O
vivo O
. O

In O
contrast O
, O
CORM O
- O
319 O
that O
is O
soluble O
in O
water O
and O
liberated O
CO B
with O
a O
slower O
rate O
, O
preserved O
smooth O
muscle O
cell O
viability O
, O
relaxed O
aortic O
tissue O
and O
exerted O
a O
significant O
anti O
- O
inflammatory O
effect O
in O
macrophages O
challenged O
with O
endotoxin O
. O

These O
data O
suggest O
that O
iron O
carbonyls O
can O
be O
used O
as O
scaffolds O
for O
the O
design O
and O
synthesis O
of O
pharmacologically O
active O
CO B
- O
RMs O
and O
indicate O
that O
increasing O
water O
solubility O
and O
controlling O
the O
rate O
of O
CO B
release O
are O
important O
parameters O
for O
limiting O
their O
potential O
toxic O
effects O
. O

Estradiol B
negative O
and O
positive O
feedback O
in O
a O
prenatal O
androgen B
- O
induced O
mouse O
model O
of O
polycystic O
ovarian O
syndrome O
. O

Gonadal O
steroid B
hormone O
feedback O
is O
impaired O
in O
polycystic O
ovarian O
syndrome O
( O
PCOS O
) O
, O
a O
common O
endocrine O
disorder O
characterized O
by O
hyperandrogenism O
and O
an O
associated O
increase O
in O
LH O
pulse O
frequency O
. O

Using O
a O
prenatal O
androgen B
( O
PNA O
) O
- O
treated O
mouse O
model O
of O
PCOS O
, O
we O
aimed O
to O
investigate O
negative O
and O
positive O
feedback O
effects O
of O
estrogens B
on O
the O
hypothalamic O
- O
pituitary O
axis O
regulation O
of O
LH O
. O

To O
assess O
the O
negative O
feedback O
effects O
of O
estrogens B
, O
LH O
was O
measured O
before O
and O
after O
ovariectomy O
and O
after O
estradiol B
( O
E2 O
) O
administration O
. O

Inhibitory O
effects O
of O
a O
bazedoxifene B
/ O
conjugated O
equine O
estrogen B
combination O
on O
human O
breast O
cancer O
cells O
in O
vitro O
. O

Breast O
cancer O
incidence O
is O
increased O
in O
women O
receiving O
menopausal O
hormone O
therapy O
with O
estrogen B
plus O
progestin O
but O
not O
with O
estrogen B
alone O
. O

The O
use O
of O
a O
tissue O
- O
selective O
estrogen B
complex O
( O
TSEC O
) O
has O
been O
proposed O
as O
a O
novel O
menopausal O
hormone O
therapy O
strategy O
to O
eliminate O
the O
requirement O
for O
a O
progestogen O
. O

Combination O
of O
bazedoxifene B
( O
BZA O
) O
with O
conjugated O
estrogens B
( O
CEs O
) O
, O
the O
first O
TSEC O
, O
has O
shown O
beneficial O
effects O
. O

To O
address O
this O
issue O
, O
we O
compared O
estradiol B
( O
E O
( O
2 O
) O
) O
and O
CE O
alone O
on O
proliferation O
and O
apoptosis O
in O
MCF O
- O
7 O
breast O
cancer O
cells O
. O

Gene O
expression O
studies O
demonstrated O
that O
CE O
and O
E O
( O
2 O
) O
were O
equally O
potent O
on O
expression O
of O
cMyc O
, O
pS2 O
, O
and O
WNT1 O
inducible O
signaling O
pathway O
protein O
2 O
, O
whereas O
the O
stimulatory O
effects O
of O
CE O
on O
progesterone B
receptor O
and O
amphiregulin O
expression O
were O
weaker O
than O
E O
( O
2 O
) O
. O

BZA O
effectively O
blocked O
each O
of O
these O
effects O
and O
showed O
no O
estrogen B
agonistic O
effects O
when O
used O
alone O
. O

Synthesis O
and O
characterization O
of O
self O
- O
bridged O
silver O
vanadium O
oxide O
/ O
CNTs O
composite O
and O
its O
enhanced O
lithium B
storage O
performance O
. O

The O
improvement O
of O
the O
electrochemical O
properties O
of O
electrode O
materials O
with O
large O
capacity O
and O
good O
capacity O
retention O
is O
becoming O
an O
important O
task O
in O
the O
field O
of O
lithium B
ion O
batteries O
( O
LIBs O
) O
. O

We O
designed O
a O
function O
- O
oriented O
hybrid O
material O
consisting O
of O
silver O
vanadium O
oxide O
( O
beta O
- O
AgVO O
( O
3 O
) O
) O
nanowires O
modified O
with O
uniform O
Ag B
nanoparticles O
and O
multi O
- O
walled O
carbon B
nanotubes O
( O
CNTs O
) O
as O
a O
high O
- O
performance O
cathode O
material O
for O
LIBs O
. O

The O
Ag B
nanoparticles O
which O
precipitated O
automatically O
in O
the O
synthetic O
process O
act O
as O
a O
bridge O
between O
the O
beta O
- O
AgVO O
( O
3 O
) O
nanowires O
and O
CNTs O
, O
creating O
a O
self O
- O
bridged O
network O
structure O
. O

The O
Ag B
particles O
at O
the O
junction O
of O
the O
nanowires O
and O
CNTs O
facilitate O
electron O
transport O
from O
the O
CNTs O
to O
the O
nanowires O
, O
and O
thereby O
improve O
the O
electrical O
conductivity O
of O
the O
beta O
- O
AgVO O
( O
3 O
) O
nanowires O
and O
the O
composite O
. O

The O
improved O
performance O
of O
the O
composite O
arises O
from O
its O
unique O
nanosized O
beta O
- O
AgVO O
( O
3 O
) O
nanowires O
with O
short O
diffusion O
pathway O
for O
lithium B
ions O
, O
efficient O
electron O
collection O
and O
transfer O
in O
the O
presence O
of O
Ag B
nanoparticles O
, O
together O
with O
excellent O
electrical O
conductivity O
of O
CNTs O
. O

WNT O
- O
5A O
engages O
noncanonical O
WNT O
signaling O
pathways O
, O
as O
inhibition O
of O
Ca B
( I
2 I
+ I
) I
and O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
signaling O
attenuated O
this O
TGF O
- O
beta O
response O
, O
whereas O
the O
canonical O
WNT O
antagonist O
Dickkopf O
1 O
( O
DKK O
- O
1 O
) O
did O
not O
. O

The O
photophysics O
of O
7 O
- O
( O
N O
, O
N O
' O
- O
diethylamino O
) O
coumarin O
- O
3 O
- O
carboxylic O
acid O
in O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
: O
an O
excitation O
wavelength O
dependent O
study O
. O

In O
this O
manuscript O
we O
have O
studied O
the O
photophysics O
of O
7 O
- O
( O
N O
, O
N O
' O
- O
diethylamino O
) O
coumarin O
- O
3 O
- O
carboxylic O
acid O
( O
7 O
- O
DCCA O
) O
in O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
. O

We O
have O
studied O
the O
spectral O
behaviour O
of O
7 O
- O
DCCA O
inside O
the O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
with O
variation O
of O
excitation O
wavelength O
. O

Capture O
and O
stimulated O
release O
of O
circulating O
tumor O
cells O
on O
polymer O
- O
grafted O
silicon B
nanostructures O
. O

A O
platform O
for O
capture O
and O
release O
of O
circulating O
tumor O
cells O
is O
demonstrated O
by O
utilizing O
polymer O
grafted O
silicon B
nanowires O
. O

Characterization O
of O
disease O
- O
associated O
N B
- O
linked O
glycoproteins O
. O

N B
- O
linked O
glycoproteins O
play O
important O
roles O
in O
biological O
processes O
, O
including O
cell O
- O
to O
- O
cell O
recognition O
, O
growth O
, O
differentiation O
, O
and O
programmed O
cell O
death O
. O

Specific O
N B
- O
linked O
glycoprotein O
changes O
are O
associated O
with O
disease O
progression O
and O
identification O
of O
these O
N B
- O
linked O
glycoproteins O
has O
potential O
for O
use O
in O
disease O
diagnosis O
, O
prognosis O
, O
and O
prediction O
of O
treatments O
. O

In O
this O
review O
, O
we O
summarize O
common O
strategies O
for O
N B
- O
linked O
glycoprotein O
characterization O
and O
applications O
of O
these O
strategies O
to O
identification O
of O
glycoprotein O
changes O
associated O
with O
disease O
states O
. O

We O
also O
review O
the O
N B
- O
linked O
glycoproteins O
altered O
in O
diseases O
such O
as O
breast O
cancer O
, O
lung O
cancer O
, O
and O
prostate O
cancer O
. O

The O
effect O
of O
converting O
ammonium O
into O
guanidine B
moieties O
, O
compared O
to O
other O
factors O
such O
as O
molecular O
weight O
or O
hydrophobicity O
, O
on O
the O
antibacterial O
activity O
is O
investigated O
for O
homo O
- O
and O
copolymers O
of O
2 O
- O
aminoethylmethacryla O
in O
solution O
or O
coatings O
. O

Polymers O
are O
obtained O
by O
free O
radical O
polymerization O
, O
polymer O
- O
analogous O
guanidinylation O
is O
conducted O
with O
cyanamide B
; O
non O
- O
leaching O
immobilization O
is O
achieved O
by O
LBL O
assembly O
of O
homopolymers O
or O
crosslinking O
of O
functional O
sidegroups O
in O
copolymers O
. O

To O
find O
out O
which O
metabolites O
in O
serum O
are O
effective O
for O
the O
diagnosis O
of O
MS O
, O
we O
utilized O
metabolic O
profiling O
using O
proton O
nuclear O
magnetic O
resonance O
spectroscopy O
( O
( B
1 I
) I
H I
- O
NMR O
) O
. O

Atomic O
absorption O
spectroscopy O
was O
used O
to O
measure O
the O
serum O
levels O
of O
selenium B
. O

The O
results O
showed O
that O
the O
levels O
of O
selenium B
were O
lower O
in O
the O
MS O
group O
, O
when O
compared O
with O
the O
control O
group O
. O

RF O
was O
used O
to O
identify O
the O
metabolites O
that O
caused O
selenium B
changes O
in O
people O
with O
MS O
by O
building O
a O
correlation O
model O
between O
these O
metabolites O
and O
serum O
levels O
of O
selenium B
. O

The O
regression O
model O
of O
levels O
of O
selenium B
and O
metabolites O
showed O
the O
correlation O
( O
R O
( O
2 O
) O
) O
value O
of O
0 O
. O
88 O
for O
the O
external O
test O
set O
. O

A O
novel O
model O
with O
good O
prediction O
outcomes O
was O
constructed O
between O
serum O
levels O
of O
selenium B
and O
NMR O
data O
. O

The O
coating O
consists O
of O
a O
several O
nanometer O
thin O
plasma O
- O
polymerized O
norbornene B
layer O
. O

The O
layer O
transforms O
a O
weakly O
performing O
polystyrene B
film O
into O
a O
highly O
wear O
- O
resistive O
system O
, O
ideal O
for O
high O
- O
density O
and O
low O
- O
power O
data O
storage O
applications O
. O

We O
show O
that O
the O
plastic O
deformation O
is O
governed O
by O
yielding O
in O
the O
polystyrene B
sublayer O
, O
which O
renders O
the O
overall O
system O
soft O
for O
plastic O
deformation O
. O

Thus O
, O
we O
find O
softening O
temperatures O
of O
more O
than O
100 O
degrees O
C O
above O
the O
polystyrene B
glass O
transition O
, O
which O
implies O
that O
for O
the O
short O
interaction O
time O
scales O
the O
glassy O
state O
of O
the O
polymer O
is O
preserved O
up O
to O
this O
temperature O
. O

The O
electronic O
circular O
dichroism O
( O
CD O
) O
spectra O
of O
a O
methyl O
- O
thiol O
adsorbed O
at O
different O
sites O
on O
an O
icosahedral O
silver B
nanoparticle O
is O
studied O
by O
using O
time O
- O
perturbed O
density O
functional O
theory O
. O

It O
is O
found O
that O
chirality O
is O
favored O
when O
the O
thiol B
is O
adsorbed O
between O
two O
atoms O
of O
different O
coordination O
number O
. O

Surfactant O
- O
Assisted O
Assembly O
of O
Fullerene B
( O
C B
( I
60 I
) I
) O
Nanorods O
and O
Nanotubes O
Formed O
at O
a O
Liquid O
- O
Liquid O
Interface O
. O

Herein O
we O
report O
the O
surfactant O
- O
triggered O
assembly O
of O
fullerene B
( O
C B
( I
60 I
) I
) O
into O
3D O
flowerlike O
microcrystals O
at O
the O
liquid O
- O
liquid O
interface O
. O

C B
( I
60 I
) I
crystals O
were O
grown O
using O
a O
liquid O
- O
liquid O
interfacial O
precipitation O
( O
LLIP O
) O
method O
by O
layering O
surfactant O
solution O
in O
butanol B
with O
a O
saturated O
solution O
of O
C B
( I
60 I
) I
in O
benzene B
. O

In O
the O
LLIP O
method O
, O
it O
is O
suggested O
that O
the O
crystal O
formation O
mechanism O
is O
driven O
by O
supersaturation O
related O
to O
the O
low O
C B
( I
60 I
) I
solubility O
in O
alcohol O
. O

We O
found O
that O
the O
dimensions O
of O
the O
synthesized O
C B
( I
60 I
) I
flowers O
depend O
on O
the O
concentration O
and O
surfactant O
type O
. O

In O
the O
absence O
of O
surfactant O
( O
i O
. O
e O
. O
, O
in O
the O
butanol B
/ O
benzene B
system O
) O
, O
1D O
C B
( I
60 I
) I
nanowhiskers O
( O
nanorods O
) O
and O
C B
( I
60 I
) I
nanotubes O
( O
diameter O
400 O
nm O
- O
2 O
mu O
m O
and O
length O
5 O
- O
20 O
mu O
m O
) O
are O
obtained O
. O

However O
, O
when O
surfactants O
are O
incorporated O
into O
the O
system O
flowerlike O
microcrystals O
consisting O
of O
C B
( I
60 I
) I
nanotubes O
are O
observed O
. O

For O
instance O
, O
crystals O
grown O
at O
the O
interface O
of O
a O
0 O
. O
01 O
% O
diglycerol O
monolaurate O
( O
C O
( O
12 O
) O
G O
( O
2 O
) O
) O
nonionic O
surfactant O
in O
butanol B
with O
benzene B
lead O
to O
the O
formation O
of O
flower O
- O
shaped O
microcrystals O
of O
average O
sizes O
in O
the O
range O
of O
10 O
- O
35 O
mu O
m O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
example O
of O
the O
surfactant O
- O
assisted O
assembly O
of O
C B
( I
60 I
) I
crystals O
. O

X O
- O
ray O
diffraction O
( O
XRD O
) O
and O
transmission O
electron O
microscopy O
( O
TEM O
) O
measurements O
have O
shown O
that O
fullerene B
flowers O
have O
a O
hexagonal O
structure O
with O
cell O
dimensions O
of O
a O
= O
2 O
. O
539 O
nm O
and O
c O
= O
1 O
. O
021 O
nm O
, O
which O
differ O
from O
that O
of O
pristine O
C B
( I
60 I
) I
. O

Mixtures O
of O
flower O
- O
shaped O
C B
( I
60 I
) I
crystals O
and O
free O
- O
standing O
C B
( I
60 I
) I
nanotubes O
are O
found O
in O
the O
0 O
. O
1 O
% O
C O
( O
12 O
) O
G O
( O
2 O
) O
/ O
butanol B
system O
. O

Flower O
- O
shaped O
C B
( I
60 I
) I
microcrystals O
are O
also O
observed O
with O
anionic O
surfactants O
cetyltrimethylammoni O
bromide O
( O
CTAB B
) O
and O
cetyltrimethylammoni O
chloride O
( O
CTAC O
) O
. O

C B
( I
60 I
) I
flowers O
obtained O
from O
0 O
. O
01 O
% O
CTAB B
and O
0 O
. O
01 O
% O
CTAC O
also O
exhibit O
hexagonal O
structures O
with O
cell O
dimensions O
of O
a O
= O
2 O
. O
329 O
nm O
and O
c O
= O
1 O
. O
273 O
nm O
, O
a O
= O
2 O
. O
459 O
nm O
and O
c O
= O
0 O
. O
938 O
nm O
, O
respectively O
. O

Our O
C B
( I
60 I
) I
flowers O
exhibit O
intense O
photoluminescence O
( O
PL O
) O
and O
a O
blue O
- O
shifted O
PL O
intensity O
maximum O
compared O
to O
the O
same O
parameters O
for O
pristine O
C B
( I
60 I
) I
, O
demonstrating O
the O
potential O
to O
control O
the O
optoelectronic O
properties O
of O
fullerene B
- O
based O
nanostructures O
. O

1 O
. O
This O
work O
investigated O
the O
drug O
interaction O
potential O
of O
GSK1292263 O
, O
a O
novel O
GPR119 O
agonist O
, O
with O
the O
HMG O
- O
coA O
reductase O
inhibitors O
simvastatin B
and O
rosuvastatin B
. O

2 O
. O
In O
vitro O
experiments O
assessed O
the O
inhibition O
of O
transporters O
and O
CYP O
enzymes O
by O
GSK1292263 O
, O
and O
a O
clinical O
drug O
interaction O
study O
investigated O
the O
effect O
of O
GSK1292263 O
( O
300 O
mg O
BID O
) O
on O
the O
pharmacokinetic O
profile O
of O
simvastatin B
( O
40 O
mg O
single O
dose O
) O
and O
rosuvastatin B
( O
10 O
mg O
single O
dose O
) O
. O

4 O
. O
In O
the O
clinical O
study O
, O
small O
increases O
in O
the O
AUC O
( O
0 O
- O
inf O
) O
of O
simvastatin B
[ O
mean O
ratio O
( O
90 O
% O
CI O
) O
of O
1 O
. O
34 O
( O
1 O
. O
22 O
, O
1 O
. O
48 O
) O
] O
and O
rosuvastatin B
[ O
mean O
ratio O
( O
90 O
% O
CI O
) O
of O
1 O
. O
39 O
( O
1 O
. O
30 O
, O
1 O
. O
49 O
) O
] O
were O
observed O
when O
co O
- O
administered O
with O
GSK1292263 O
, O
which O
is O
consistent O
with O
an O
inhibitory O
effect O
on O
intestinal O
BCRP O
and O
CYP3A4 O
. O

In O
contrast O
, O
GSK1292263 O
did O
not O
inhibit O
OATP1B1 O
based O
on O
the O
lack O
of O
changes O
in O
simvastatin B
acid O
exposure O
[ O
mean O
AUC O
( O
0 O
- O
inf O
) O
ratio O
( O
90 O
% O
CI O
) O
of O
1 O
. O
05 O
( O
0 O
. O
91 O
, O
1 O
. O
21 O
) O
] O
. O

5 O
. O
GSK1292263 O
has O
a O
weak O
drug O
interaction O
with O
simvastatin B
and O
rosuvastain O
. O

The O
first O
example O
of O
Ir B
- O
catalyzed O
asymmetric O
substitution O
reaction O
with O
vinyl O
trifluoroborates O
is O
described O
. O

Steroid B
toxicity O
and O
detoxification O
in O
ascomycetous O
fungi O
. O

A O
major O
interest O
into O
fungal O
steroid B
action O
has O
been O
provoked O
since O
research O
has O
proven O
that O
steroid B
hormones O
are O
toxic O
to O
fungi O
and O
affect O
the O
host O
/ O
fungus O
relationship O
. O

Steroid B
hormones O
were O
found O
to O
differ O
in O
their O
antifungal O
activity O
in O
ascomycetous O
fungi O
Hortaea O
werneckii O
, O
Saccharomyces O
cerevisiae O
and O
Aspergillus O
oryzae O
. O

Dehydroepiandrostero O
was O
shown O
to O
be O
the O
strongest O
inhibitor O
of O
growth O
in O
all O
three O
varieties O
of O
fungi O
followed O
by O
androstenedione B
and O
testosterone B
. O

For O
their O
protection O
, O
fungi O
use O
several O
mechanisms O
to O
lower O
the O
toxic O
effects O
of O
steroids B
. O

The O
efficiency O
of O
biotransformation O
in O
detoxification O
depended O
on O
the O
microorganism O
and O
steroid B
substrate O
used O
. O

In O
addition O
to O
biotransformation O
, O
steroid B
extrusion O
out O
of O
the O
cells O
contributed O
to O
the O
lowering O
of O
the O
active O
intracellular O
steroid B
concentration O
. O

Proteins O
Aus1 O
and O
Dan1 O
were O
not O
found O
to O
be O
involved O
in O
steroid B
import O
. O

The O
research O
of O
possible O
targets O
of O
steroid B
hormone O
action O
in O
fungi O
suggests O
that O
steroid B
hormones O
inhibit O
ergosterol B
biosynthesis O
in O
S O
. O
cerevisiae O
and O
H O
. O
werneckii O
. O

Results O
of O
this O
inhibition O
caused O
changes O
in O
the O
sterol B
content O
of O
the O
cellular O
membrane O
. O

The O
presence O
of O
steroid B
hormones O
most O
probably O
causes O
the O
degradation O
of O
the O
Tat2 O
permease O
and O
impairment O
of O
tryptophan B
import O
. O

ADX71743 O
, O
a O
potent O
and O
selective O
negative O
allosteric O
modulator O
of O
metabotropic O
glutamate B
receptor O
7 O
: O
in O
vitro O
and O
in O
vivo O
characterization O
. O

Metabotropic O
glutamate B
receptor O
7 O
( O
mGlu O
( O
7 O
) O
) O
has O
been O
suggested O
to O
be O
a O
promising O
novel O
target O
for O
treatment O
of O
a O
range O
of O
disorders O
, O
including O
anxiety O
, O
post O
- O
traumatic O
stress O
disorder O
, O
depression O
, O
drug O
abuse O
, O
and O
schizophrenia O
. O

Whereas O
ADX71743 O
caused O
a O
small O
reduction O
in O
amphetamine B
- O
induced O
hyperactivity O
in O
mice O
, O
it O
was O
inactive O
in O
the O
mouse O
2 O
, O
5 O
- O
dimethoxy O
- O
4 O
- O
iodoamphetamine O
- O
induced O
head O
twitch O
and O
the O
rat O
conditioned O
avoidance O
response O
tests O
. O

Among O
them O
, O
the O
most O
potent O
compound O
8a O
was O
evaluated O
for O
its O
antileukopenia O
activity O
in O
cyclophosphamide B
( O
CTX O
) O
treated O
mice O
. O

Characterization O
of O
steroidogenic O
enzyme O
expression O
in O
aldosterone B
- O
producing O
adenoma O
: O
a O
comparison O
with O
various O
human O
adrenal O
tumors O
. O

We O
analyzed O
the O
expression O
profiles O
of O
several O
steroidogenic O
enzymes O
in O
normal O
adrenals O
, O
aldosterone B
- O
producing O
adenomas O
( O
APA O
) O
, O
cortisol B
- O
producing O
adenomas O
combined O
with O
Cushing O
' O
s O
syndrome O
( O
CPA O
) O
or O
with O
subclinical O
Cushing O
' O
s O
syndrome O
( O
SCPA O
) O
, O
and O
nonfunctioning O
adrenal O
adenomas O
( O
NFA O
) O
to O
clarify O
the O
nature O
and O
characteristics O
of O
steroidogenesis O
in O
APA O
. O

A O
theoretical O
analysis O
of O
the O
effect O
of O
the O
hydrogenation O
of O
graphene B
to O
graphane B
on O
its O
mechanical O
properties O
. O

We O
investigated O
the O
effect O
of O
the O
hydrogenation O
of O
graphene B
to O
graphane B
on O
its O
mechanical O
properties O
using O
first O
- O
principles O
calculations O
based O
on O
density O
- O
functional O
theory O
. O

Our O
results O
indicate O
that O
graphene B
- O
graphane B
systems O
could O
be O
used O
for O
hydrogen B
storage O
with O
high O
speed O
of O
charge O
- O
discharge O
of O
hydrogen B
. O

Special O
attention O
is O
paid O
to O
the O
floppy O
strongly O
anharmonic O
degree O
of O
freedom O
of O
44BPY O
, O
which O
is O
related O
to O
the O
most O
salient O
structural O
feature O
, O
namely O
the O
twist O
angle O
theta O
between O
the O
two O
pyridine B
rings O
. O

We O
previously O
reported O
that O
a O
cholesterol B
metabolite O
, O
5 O
- O
cholesten O
- O
3 O
beta O
, O
25 O
- O
diol O
3 O
- O
sulfate O
( O
25HC3S O
) O
, O
inhibits O
the O
LXR O
alpha O
signaling O
and O
reduces O
lipogenesis O
by O
decreasing O
SREBP O
- O
1c O
expression O
in O
primary O
hepatocytes O
. O

Gene O
expression O
analysis O
showed O
that O
25HC3S O
significantly O
suppressed O
the O
SREBP O
- O
1c O
signaling O
pathway O
that O
was O
associated O
with O
the O
suppression O
of O
the O
key O
enzymes O
involved O
in O
lipogenesis O
: O
fatty B
acid I
synthase O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
and O
glycerol O
- O
3 O
- O
phosphate O
acyltransferase O
. O

A O
glucose B
tolerance O
test O
and O
insulin O
tolerance O
test O
showed O
that O
25HC3S O
administration O
improved O
HFD O
- O
induced O
insulin O
resistance O
. O

Oxygen B
tracer O
diffusion O
along O
interfaces O
of O
strained O
Y2O3 B
/ O
YSZ O
multilayers O
. O

In O
recent O
studies O
an O
enhancement O
of O
the O
ionic O
conductivity O
was O
indeed O
observed O
in O
micro O
- O
/ O
nanoscaled O
Y O
( O
2 O
) O
O O
( O
3 O
) O
- O
stabilised O
ZrO B
( I
2 I
) I
( O
YSZ O
) O
composites O
and O
hetero O
multilayers O
of O
thin O
films O
. O

Multilayer O
samples O
were O
prepared O
by O
Pulsed O
Laser O
Deposition O
( O
PLD O
) O
on O
( O
0001 O
) O
Al B
( I
2 I
) I
O I
( I
3 I
) I
substrates O
and O
characterised O
by O
X O
- O
Ray O
Diffraction O
( O
XRD O
) O
, O
Scanning O
Electron O
Microscopy O
( O
HRSEM O
) O
and O
Time O
- O
of O
- O
Flight O
Secondary O
Ion O
Mass O
Spectrometry O
( O
ToF O
- O
SIMS O
) O
. O

To O
separate O
interface O
and O
bulk O
transport O
from O
the O
total O
oxygen B
diffusivity O
of O
the O
multilayer O
system O
, O
the O
( O
average O
) O
thickness O
of O
the O
YSZ O
- O
layers O
in O
the O
multilayers O
was O
varied O
from O
45 O
nm O
to O
12 O
nm O
. O

Iron B
L O
- O
edge O
X O
- O
ray O
absorption O
spectroscopy O
of O
oxy O
- O
picket O
fence O
porphyrin B
: O
experimental O
insight O
into O
Fe B
- O
O2 B
bonding O
. O

The O
electronic O
structure O
of O
the O
Fe B
- O
O B
( I
2 I
) I
center O
in O
oxy O
- O
hemoglobin O
and O
oxy O
- O
myoglobin O
is O
a O
long O
- O
standing O
issue O
in O
the O
field O
of O
bioinorganic O
chemistry O
. O

Spectroscopic O
studies O
have O
been O
complicated O
by O
the O
highly O
delocalized O
nature O
of O
the O
porphyrin B
, O
and O
calculations O
require O
interpretation O
of O
multideterminant O
wave O
functions O
for O
a O
highly O
covalent O
metal O
site O
. O

Here O
, O
iron B
L O
- O
edge O
X O
- O
ray O
absorption O
spectroscopy O
, O
interpreted O
using O
a O
valence O
bond O
configuration O
interaction O
multiplet O
model O
, O
is O
applied O
to O
directly O
probe O
the O
electronic O
structure O
of O
the O
iron B
in O
the O
biomimetic O
Fe B
- O
O B
( I
2 I
) I
heme B
complex O
[ O
Fe O
( O
pfp O
) O
( O
1 O
- O
MeIm O
) O
O O
( O
2 O
) O
] O
( O
pfp O
( O
" O
picket O
fence O
porphyrin O
" O
) O
= O
meso O
- O
tetra O
( O
alpha O
, O
alpha O
, O
alpha O
, O
alpha O
- O
o O
- O
pivalamidophenyl O
) O
porphyrin O
or O
TpivPP O
) O
. O

The O
L O
- O
edge O
spectrum O
of O
[ O
Fe O
( O
pfp O
) O
( O
1 O
- O
MeIm O
) O
O O
( O
2 O
) O
] O
is O
further O
compared O
to O
those O
of O
[ O
Fe O
( O
II O
) O
( O
pfp O
) O
( O
1 O
- O
MeIm O
) O
( O
2 O
) O
] O
, O
[ O
Fe O
( O
II O
) O
( O
pfp O
) O
] O
, O
and O
[ O
Fe O
( O
III O
) O
( O
tpp O
) O
( O
ImH O
) O
( O
2 O
) O
] O
Cl O
( O
tpp B
= O
meso O
- O
tetraphenylporphyrin O
) O
which O
have O
Fe B
( I
II I
) I
S O
= O
0 O
, O
Fe B
( I
II I
) I
S O
= O
1 O
, O
and O
Fe B
( I
III I
) I
S O

The O
Fe B
- O
O B
( I
2 I
) I
pfp O
site O
is O
experimentally O
determined O
to O
have O
both O
significant O
sigma O
- O
donation O
and O
a O
strong O
pi O
- O
interaction O
of O
the O
O B
( I
2 I
) I
with O
the O
iron B
, O
with O
the O
latter O
having O
implications O
with O
respect O
to O
the O
spin O
polarization O
of O
the O
ground O
state O
. O

Probing O
the O
Bonding O
and O
Electronic O
Structure O
of O
Single O
Atom O
Dopants O
in O
Graphene B
with O
Electron O
Energy O
Loss O
Spectroscopy O
. O

A O
combination O
of O
scanning O
transmission O
electron O
microscopy O
, O
electron O
energy O
loss O
spectroscopy O
, O
and O
ab O
initio O
calculations O
reveal O
striking O
electronic O
structure O
differences O
between O
two O
distinct O
single O
substitutional O
Si B
defect O
geometries O
in O
graphene B
. O

The O
near O
- O
edge O
fine O
structure O
can O
be O
compared O
with O
great O
accuracy O
to O
simulations O
and O
reveal O
either O
an O
sp O
( O
3 O
) O
- O
like O
configuration O
for O
a O
trivalent O
Si B
or O
a O
more O
complicated O
hybridized O
structure O
for O
a O
tetravalent O
Si B
impurity O
. O

Controlling O
the O
pulsed O
- O
laser O
- O
induced O
size O
reduction O
of O
Au B
and O
Ag B
nanoparticles O
via O
changes O
in O
the O
external O
pressure O
, O
laser O
intensity O
, O
and O
excitation O
wavelength O
. O

More O
complicated O
results O
were O
obtained O
for O
100 O
nm O
silver B
nanoparticles O
, O
possibly O
because O
of O
the O
different O
size O
- O
dependent O
light O
- O
absorbing O
nature O
of O
these O
particles O
. O

Based O
on O
our O
extensive O
experimental O
studies O
, O
a O
detailed O
picture O
was O
developed O
for O
the O
nanosecond O
laser O
- O
induced O
fabrication O
of O
gold O
and O
silver B
nanoparticles O
, O
leading O
to O
unprecedented O
size O
control O
. O

Novel O
strategy O
for O
preparation O
of O
graphene B
- O
Pd B
, O
Pt B
composite O
, O
and O
its O
enhanced O
electrocatalytic O
activity O
for O
alcohol B
oxidation O
. O

As O
advanced O
electrodes O
for O
direct O
alcohol B
fuel O
cells O
, O
graphene B
- O
Pd B
and O
graphene B
- O
Pt B
composites O
with O
a O
trace O
of O
SnO B
( I
2 I
) I
have O
been O
successfully O
synthesized O
by O
a O
modified O
electroless O
plating O
technique O
. O

The O
surface O
of O
graphene B
oxide I
is O
first O
sensitized O
by O
Sn O
( O
2 O
+ O
) O
ions O
, O
and O
subsequently O
, O
Pd B
or O
Pt B
nanoparticles O
are O
deposited O
on O
the O
surface O
of O
graphene B
oxide I
. O

Finally O
, O
graphene B
oxide I
was O
reduced O
to O
graphene B
by O
further O
adding O
NaBH O
( O
4 O
) O
. O

Compared O
to O
other O
carbon B
- O
( O
e O
. O
g O
. O
, O
Vulcan O
XC O
- O
72R O
) O
supported O
Pd B
and O
Pt B
, O
the O
resultant O
graphene B
- O
Pd B
and O
Pt B
composites O
exhibit O
better O
electrocatalytic O
activity O
and O
long O
- O
term O
stability O
toward O
alcohol B
electrooxidation O
. O

Additionally O
, O
a O
trace O
amount O
of O
SnO B
( I
2 I
) I
formed O
around O
active O
catalysts O
may O
also O
be O
beneficial O
to O
the O
enhancement O
of O
electrochemical O
activity O
. O

In O
this O
work O
, O
a O
facile O
photoinduced O
one O
- O
step O
method O
was O
first O
developed O
for O
the O
covalent O
immobilization O
of O
ATRP O
initiators O
on O
the O
C B
- I
H I
group O
- O
containing O
substrates O
such O
as O
biaxially O
oriented O
polypropylene B
( O
BOPP O
) O
. O

The O
C B
- I
H I
bonds O
of O
precise O
location O
of O
inert O
polymer O
surfaces O
were O
readily O
transferred O
to O
bromoalkyl O
initiator O
, O
followed O
by O
ATRP O
of O
2 B
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
( O
DMAEMA B
) O
and O
glycidyl O
methacrylate O
( O
GMA O
) O
, O
respectively O
, O
to O
produce O
the O
resultant O
patterned O
BOPP O
- O
g O
- O
P O
( O
DMAEMA O
) O
and O
BOPP O
- O
g O
- O
P O
( O
GMA O
) O
films O
. O

The O
epoxy B
groups O
of O
the O
P O
( O
GMA O
) O
microdomains O
can O
be O
aminated O
for O
covalently O
coupling O
IgG O
, O
while O
the O
P O
( O
DMAEMA O
) O
microdomains O
were O
used O
for O
immobilizing O
IgG O
via O
electronic O
interactions O
. O

The O
selectivity O
that O
darapladib O
and O
other O
Lp O
- O
PLA O
( O
2 O
) O
inhibitors O
display O
across O
the O
larger O
serine B
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O

We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate B
inhibitors O
inactivate O
Lp O
- O
PLA O
( O
2 O
) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O

Identification O
of O
benzofuran B
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A O
( O
4 O
) O
hydrolase O
. O

This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans B
as O
LTH O
( O
4 O
) O
H O
inhibitors O
. O

The O
benzofuran B
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB O
( O
4 O
) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O

Benzofuran B
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA O
( O
4 O
) O
H O
inhibitor O
for O
the O
treatment O
of O
inflammatory O
diseases O
, O
such O
as O
asthma O
and O
inflammatory O
bowel O
disease O
( O
IBD O
) O
. O

Disruption O
of O
the O
cell O
- O
cycle O
boxes O
also O
affected O
growth O
in O
a O
DNA O
polymerase O
- O
defective O
strain O
background O
where O
mismatch O
repair O
is O
essential O
, O
particularly O
in O
the O
presence O
of O
the O
DNA O
damaging O
agent O
methyl O
methane O
sulfonate O
( O
MMS B
) O
. O

Promoter O
replacements O
conferring O
constitutive O
expression O
of O
MSH2 O
revealed O
that O
the O
transcriptional O
induction O
in O
response O
to O
MMS B
is O
required O
to O
maintain O
induced O
levels O
of O
Msh2 O
. O

Turnover O
experiments O
confirmed O
an O
elevated O
rate O
of O
degradation O
in O
the O
presence O
of O
MMS B
. O

3 O
, O
4 O
- O
Methylenedioxy O
- O
methamphetamine O
induces O
in O
vivo O
regional O
up O
- O
regulation O
of O
central O
nicotinic O
receptors O
in O
rats O
and O
potentiates O
the O
regulatory O
effects O
of O
nicotine B
on O
these O
receptors O
. O

Nicotine B
( O
NIC B
) O
, O
the O
main O
psychostimulant O
compound O
of O
smoked O
tobacco O
, O
exerts O
its O
effects O
through O
activation O
of O
central O
nicotinic O
acetylcholine B
receptors O
( O
nAChR O
) O
, O
which O
become O
up O
- O
regulated O
after O
chronic O
administration O
. O

Recent O
work O
has O
demonstrated O
that O
the O
recreational O
drug O
3 O
, O
4 O
- O
methylenedioxy O
- O
methamphetamine O
( O
MDMA B
) O
has O
affinity O
for O
nAChR O
and O
also O
induces O
up O
- O
regulation O
of O
nAChR O
in O
PC O
12 O
cells O
. O

Tobacco O
and O
MDMA B
are O
often O
consumed O
together O
. O

In O
the O
present O
work O
we O
studied O
the O
in O
vivo O
effect O
of O
a O
classic O
chronic O
dosing O
schedule O
of O
MDMA B
in O
rats O
, O
alone O
or O
combined O
with O
a O
chronic O
schedule O
of O
NIC B
, O
on O
the O
density O
of O
nAChR O
and O
on O
serotonin B
reuptake O
transporters O
. O

MDMA B
induced O
significant O
decreases O
in O
[ B
( I
3 I
) I
H I
] I
paroxetine I
binding O
in O
the O
cortex O
and O
hippocampus O
measured O
24h O
after O
the O
last O
dose O
and O
these O
decreases O
were O
not O
modified O
by O
the O
association O
with O
NIC B
. O

In O
the O
prefrontal O
cortex O
, O
NIC B
and O
MDMA B
each O
induced O
significant O
increases O
in O
[ O
( O
3 O
) O
H O
] O
epibatidine O
binding O
( O
29 O
. O
5 O
and O
34 O
. O
6 O
% O
, O
respectively O
) O
with O
respect O
to O
saline O
- O
treated O
rats O
, O
and O
these O
increases O
were O
significantly O
potentiated O
( O
up O
to O
72 O
. O
1 O
% O
) O
when O
the O
two O
drugs O
were O
associated O
. O

Also O
in O
this O
area O
, O
[ O
( O
3 O
) O
H O
] O
methyllycaconitine O
binding O
was O
increased O
a O
42 O
. O
1 O
% O
with O
NIC B
+ O
MDMA B
but O
not O
when O
they O
were O
given O
alone O
. O

In O
the O
hippocampus O
, O
MDMA B
potentiated O
the O
alpha O
7 O
regulatory O
effects O
of O
NIC B
( O
raising O
a O
25 O
. O
5 O
% O
increase O
to O
52 O
. O
5 O
% O
) O
but O
alone O
was O
devoid O
of O
effect O
. O

MDMA B
had O
no O
effect O
on O
heteromeric O
nAChR O
in O
striatum O
and O
a O
coronal O
section O
of O
the O
midbrain O
containing O
superior O
colliculi O
, O
geniculate O
nuclei O
, O
substantia O
nigra O
and O
ventral O
tegmental O
area O
. O

Western O
blots O
with O
specific O
alpha O
4 O
and O
alpha O
7 O
antibodies O
showed O
no O
significant O
differences O
between O
the O
groups O
, O
indicating O
that O
, O
as O
reported O
for O
nicotine B
, O
up O
- O
regulation O
caused O
by O
MDMA B
is O
due O
to O
post O
- O
translational O
events O
rather O
than O
increased O
receptor O
synthesis O
. O

Cloning O
, O
expression O
and O
analysis O
of O
the O
olfactory O
glutathione B
S B
- O
transferases O
in O
coho O
salmon O
. O

The O
glutathione B
S B
- O
transferases O
( O
GSTs O
) O
provide O
cellular O
protection O
by O
detoxifying O
xenobiotics O
, O
maintaining O
redox O
status O
, O
and O
modulating O
secondary O
messengers O
, O
all O
of O
which O
are O
critical O
to O
maintaining O
olfaction O
in O
salmonids O
. O

OlfGST O
omega O
contained O
an O
open O
reading O
frame O
of O
720bp O
and O
encoded O
a O
protein O
of O
239 O
amino B
acids I
. O

OlfGST O
pi O
and O
OlfGST O
rho O
contained O
open O
reading O
frames O
of O
627 O
and O
681nt O
, O
respectively O
, O
and O
encoded O
proteins O
of O
208 O
and O
226 O
amino B
acids I
. O

OlfGST O
pi O
and O
rho O
exhibited O
thiol B
oxidoreductase O
activity O
toward O
2 O
- O
hydroxyethyl O
disulfide O
( O
2 O
- O
HEDS O
) O
and O
conjugated O
4 B
- I
hydroxynonenal I
( O
HNE O
) O
, O
a O
toxic O
aldehyde B
with O
neurodegenerative O
properties O
. O

Salsolinol O
( O
SAL O
) O
, O
a O
catechol O
isoquinoline O
has O
invited O
considerable O
attention O
due O
to O
its O
structural O
similarity O
with O
dopaminergic O
neurotoxin O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
. O

This O
was O
confirmed O
on O
adding O
LY294002 B
the O
PI3K O
inhibitor O
which O
abolished O
the O
protection O
. O

The O
classic O
Neutral B
Red I
Uptake O
( O
NRU O
) O
assay O
proved O
to O
be O
robust O
and O
reliable O
to O
be O
applied O
as O
viability O
assay O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium O
lauryl O
sulphate O
, O
atropine O
sulphate O
monohydrate O
, O
acetylsalicylic B
acid I
) O
. O

Monotropein O
isolated O
from O
the O
roots O
of O
Morinda O
officinalis O
ameliorates O
proinflammatory O
mediators O
in O
RAW O
264 O
. O
7 O
macrophages O
and O
dextran O
sulfate O
sodium B
( O
DSS O
) O
- O
induced O
colitis O
via O
NF O
- O
kappa O
B O
inactivation O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
molecular O
mechanisms O
underlying O
the O
anti O
- O
inflammatory O
effects O
of O
monotropein O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
and O
dextran O
sulfate O
sodium B
( O
DSS O
) O
- O
induced O
colitis O
mouse O
model O
. O

Monotropein O
was O
found O
to O
inhibit O
the O
expressions O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
mRNA O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
. O

Increased O
urinary O
excretion O
of O
albumin O
, O
hemopexin O
, O
transferrin O
and O
VDBP O
correlates O
with O
chronic O
sensitization O
to O
gentamicin B
nephrotoxicity O
in O
rats O
. O

To O
this O
end O
, O
rats O
were O
treated O
with O
a O
subtoxic O
dosage O
of O
the O
experimental O
nephrotoxin O
uranyl O
nitrate B
( O
UN O
) O
in O
the O
drinking O
water O
for O
21 O
weeks O
, O
or O
plain O
water O
( O
as O
control O
) O
, O
and O
then O
with O
low O
- O
dose O
gentamicin B
for O
7 O
days O
. O

The O
mild O
renal O
damage O
caused O
by O
gentamicin B
was O
markedly O
magnified O
in O
rats O
having O
received O
UN O
chronically O
, O
which O
was O
evident O
both O
at O
the O
functional O
and O
histological O
level O
. O

Four O
proteins O
, O
namely O
albumin O
, O
hemopexin O
, O
transferrin O
and O
vitamin B
D I
binding O
protein O
were O
increased O
in O
the O
urine O
in O
temporal O
association O
with O
the O
appearance O
of O
chronic O
predisposition O
. O

Although O
further O
studies O
are O
necessary O
, O
our O
results O
suggest O
that O
these O
proteins O
might O
be O
potentially O
used O
as O
markers O
of O
hidden O
, O
chronic O
predisposition O
to O
gentamicin B
nephrotoxicity O
, O
in O
order O
to O
appropriately O
and O
pre O
- O
emptively O
stratify O
and O
handle O
individuals O
according O
to O
their O
specific O
risk O
in O
the O
long O
term O
, O
and O
to O
conveniently O
optimize O
their O
life O
conditions O
or O
additional O
clinical O
procedures O
or O
treatments O
that O
might O
trigger O
the O
disease O
. O

Fracture O
of O
the O
femur O
was O
performed O
in O
streptozotocin B
- O
induced O
diabetic O
and O
matched O
normoglycemic O
control O
mice O
. O

A O
novel O
series O
of O
substituted O
( O
E O
) O
- O
3 O
- O
( O
Benzo O
[ O
d O
] O
thiazol O
- O
2 O
- O
ylamino O
) O
phenylprop O
- O
2 O
- O
en O
- O
1 O
- O
onewere O
synthesized O
starting O
from O
2 O
- O
aminobenzothiazole O
and O
1 O
- O
aryl O
- O
3 O
, O
3 O
- O
bis O
- O
( O
methylsulfanyl O
) O
- O
2 O
- O
propen O
- O
1 O
- O
onesin O
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium O
hydride O
in O
THF B
. O

The O
synthesised O
compounds O
' O
structures O
were O
confirmed O
by O
IR O
, O
Mass O
spectrometry O
, O
( B
1 I
) I
H I
NMR O
, O
( B
13 I
) I
C I
NMR O
and O
HRMS O
spectral O
data O
. O

This O
research O
investigates O
the O
release O
of O
DS O
- O
SILY O
from O
fast O
- O
dissolving O
polymer O
films O
composed O
of O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
and O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
. O

Synthesis O
and O
evaluation O
of O
a O
backbone O
biodegradable O
multiblock O
HPMA B
copolymer O
nanocarrier O
for O
the O
systemic O
delivery O
of O
paclitaxel B
. O

For O
example O
, O
the O
currently O
widely O
used O
Cremophor O
EL O
( O
R O
) O
- O
based O
paclitaxel B
( O
PTX B
) O
formulation O
exhibits O
pharmacokinetic O
concerns O
and O
severe O
side O
effects O
. O

The O
present O
work O
aims O
to O
develop O
a O
new O
- O
generation O
of O
long O
- O
circulating O
, O
biodegradable O
carriers O
for O
effective O
delivery O
of O
PTX B
. O

First O
, O
a O
multiblock O
backbone O
biodegradable O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
- O
PTX B
conjugate O
( O
mP O
- O
PTX B
) O
with O
molecular O
weight O
( O
Mw O
) O
of O
335 O
kDa O
was O
synthesized O
by O
RAFT O
( O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
) O
copolymerization O
, O
followed O
by O
chain O
extension O
. O

In O
vitro O
studies O
on O
human O
ovarian O
carcinoma O
A2780 O
cells O
were O
carried O
out O
to O
investigate O
the O
cytotoxicity O
of O
free O
PTX B
, O
HPMA B
copolymer O
- O
PTX B
conjugate O
with O
Mw O
of O
48 O
kDa O
( O
P O
- O
PTX B
) O
, O
and O
mP O
- O
PTX B
. O

The O
experiments O
demonstrated O
that O
mP O
- O
PTX B
has O
a O
similar O
cytotoxic O
effect O
against O
A2780 O
cells O
as O
free O
PTX B
and O
P O
- O
PTX B
. O

To O
further O
compare O
the O
behavior O
of O
this O
new O
biodegradable O
conjugate O
( O
mP O
- O
PTX B
) O
with O
free O
PTX B
and O
P O
- O
PTX B
in O
vivo O
evaluation O
was O
performed O
using O
female O
nu O
/ O
nu O
mice O
bearing O
orthotopic O
A2780 O
ovarian O
tumors O
. O

Pharmacokinetics O
study O
showed O
that O
high O
Mw O
mP O
- O
PTX B
was O
cleared O
more O
slowly O
from O
the O
blood O
than O
commercial O
PTX B
formulation O
and O
low O
Mw O
P O
- O
PTX B
. O

SPECT O
/ O
CT O
imaging O
and O
biodistribution O
studies O
demonstrated O
biodegradability O
as O
well O
as O
elimination O
of O
mP O
- O
PTX B
from O
the O
body O
. O

The O
tumors O
in O
the O
mP O
- O
PTX B
treated O
group O
grew O
more O
slowly O
than O
those O
treated O
with O
saline O
, O
free O
PTX B
, O
and O
P O
- O
PTX B
( O
single O
dose O
at O
20 O
mg O
PTX B
/ O
kg O
equivalent O
) O
. O

Moreover O
, O
mice O
treated O
with O
mP O
- O
PTX B
had O
no O
obvious O
ascites O
and O
body O
- O
weight O
loss O
. O

Histological O
analysis O
indicated O
that O
mP O
- O
PTX B
had O
no O
toxicity O
in O
liver O
and O
spleen O
, O
but O
induced O
massive O
cell O
death O
in O
the O
tumor O
. O

Caffeine B
- O
induced O
inhibition O
of O
the O
activity O
of O
glutamate B
transporter O
type O
3 O
expressed O
in O
Xenopus O
oocytes O
. O

Caffeine B
has O
been O
known O
to O
trigger O
seizures O
, O
however O
, O
the O
precise O
mechanism O
about O
the O
proconvulsive O
effect O
of O
caffeine B
remains O
unclear O
. O

Glutamate B
transporters O
play O
an O
important O
role O
to O
maintain O
the O
homeostasis O
of O
glutamate B
concentration O
in O
the O
brain O
tissue O
. O

Especially O
, O
dysfunction O
of O
excitatory O
amino B
acid I
transporter O
type O
3 O
( O
EAAT3 O
) O
can O
lead O
to O
seizures O
. O

We O
investigated O
the O
effects O
of O
caffeine B
on O
the O
activity O
of O
EAAT3 O
and O
the O
involvement O
of O
protein O
kinase O
C O
( O
PKC O
) O
and O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3K O
) O
. O

Caffeine B
decreased O
EAAT3 O
activity O
in O
a O
dose O
- O
dependent O
manner O
. O

Caffeine B
( O
30 O
mu O
M O
for O
3min O
) O
significantly O
reduced O
V O
( O
max O
) O
, O
but O
did O
not O
alter O
K O
( O
m O
) O
value O
of O
EAAT3 O
for O
glutamate B
. O

When O
preincubated O
oocytes O
with O
phorbol B
- I
12 I
- I
myristate I
- I
13 I
- I
acetate I
( O
PMA B
, O
a O
PKC O
activator O
) O
were O
exposed O
to O
caffeine B
, O
PMA B
- O
induced O
increase O
in O
EAAT3 O
activity O
was O
abolished O
. O

Two O
PKC O
inhibitors O
( O
chelerythrine B
and O
staurosporine B
) O
significantly O
reduced O
basal O
EAAT3 O
activity O
. O

Whereas O
, O
there O
were O
no O
significant O
differences O
among O
the O
PKC O
inhibitors O
, O
caffeine B
, O
and O
PKC O
inhibitors O
+ O
caffeine B
groups O
. O

In O
similarly O
fashion O
, O
wortmannin B
( O
a O
PI3K O
inhibitor O
) O
significantly O
decreased O
EAAT3 O
activity O
, O
however O
no O
statistical O
differences O
were O
observed O
among O
the O
wortmannin B
, O
caffeine B
, O
and O
wortmannin B
+ O
caffeine B
groups O
. O

Our O
results O
demonstrate O
that O
caffeine B
attenuates O
EAAT3 O
activity O
and O
this O
reducing O
effect O
of O
caffeine B
seems O
to O
be O
mediated O
by O
PKC O
and O
PI3K O
. O

The O
electroreduction O
of O
benzoic B
acid I
: O
voltammetric O
observation O
of O
adsorbed O
hydrogen B
at O
a O
platinum B
microelectrode O
in O
room O
temperature O
ionic O
liquids O
. O

The O
electrochemical O
reduction O
of O
benzoic B
acid I
in O
the O
presence O
and O
absence O
of O
hydrogen B
( O
H B
( I
2 I
) I
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum B
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ O
C O
( O
4 O
) O
mim O
] O
[ O
NTf O
( O
2 O
) O
] O
, O
[ O
C O
( O
4 O
) O
mpyrr O
] O
[ O
NTf O
( O
2 O
) O
] O
, O
[ O
C O
( O
4 O
) O
mim O
] O
[ O
OTf O
] O
and O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
BF I
( I
4 I
) I
] I
, O
versus O
Ag B
/ O
Ag O
( O

In O
all O
cases O
, O
reductive O
voltammetry O
is O
observed O
, O
and O
is O
suggested O
to O
occur O
via O
a O
CE O
mechanism O
in O
which O
dissociation O
of O
benzoic O
acid O
is O
followed O
by O
electron O
transfer O
to O
H B
( I
+ I
) I
ultimately O
forming O
adsorbed O
hydrogen B
. O

Furthermore O
, O
the O
adsorbed O
H B
atoms O
, O
formed O
from O
the O
reduction O
of O
benzoic B
acid I
, O
could O
be O
used O
to O
achieve O
the O
rapid O
hydrogenolysis O
of O
the O
organic O
compound O
( O
bis O
( O
benzyloxycarbonyl O
) O
- O
l O
- O
lysine O
) O
on O
the O
timescale O
of O
the O
voltammetric O
technique O
under O
moderate O
conditions O
( O
25 O
degrees O
C O
) O
. O

The O
electron O
delocalization O
pattern O
for O
all O
the O
clusters O
and O
the O
nature O
of O
bonding O
between O
Fe B
and O
S B
atoms O
were O
studied O
by O
analyzing O
molecular O
orbitals O
. O

Natural O
population O
analysis O
demonstrates O
that O
Fe B
atoms O
act O
as O
an O
electron O
donor O
in O
all O
clusters O
, O
and O
the O
electron O
density O
difference O
map O
clearly O
shows O
the O
direction O
of O
the O
electron O
flow O
over O
the O
whole O
complex O
. O

Furthermore O
, O
the O
investigated O
magnetism O
shows O
that O
the O
Fe B
atoms O
carried O
most O
of O
the O
magnetic O
moments O
, O
which O
is O
due O
mainly O
to O
the O
3d O
state O
, O
while O
only O
very O
small O
magnetic O
moments O
are O
found O
on O
S B
atoms O
. O

It O
is O
anchored O
in O
the O
mitochondrial O
inner O
membrane O
with O
the O
C B
- O
terminal O
J O
domain O
facing O
the O
matrix O
space O
. O

The O
yeast O
eukaryotic O
translation O
initiation O
factor O
2B O
translation O
initiation O
complex O
interacts O
with O
the O
fatty B
acid I
synthesis O
enzyme O
YBR159W O
and O
endoplasmic O
reticulum O
membranes O
. O

Using O
affinity O
purifications O
coupled O
with O
mass O
spectrometry O
and O
yeast O
two O
- O
hybrid O
assays O
, O
we O
show O
the O
Saccharomyces O
cerevisiae O
translation O
initiation O
factor O
complex O
eukaryotic O
translation O
initiation O
factor O
2B O
( O
eIF2B O
) O
and O
the O
very O
- O
long O
- O
chain O
fatty B
acid I
( O
VLCFA O
) O
synthesis O
keto O
- O
reductase O
enzyme O
YBR159W O
physically O
interact O
. O

A O
ybr159w O
Delta O
null O
strain O
has O
a O
slow O
- O
growth O
phenotype O
and O
a O
reduced O
translation O
rate O
but O
a O
normal O
GCN4 O
response O
to O
amino B
acid I
starvation O
. O

The O
purpose O
of O
this O
study O
was O
to O
quantitatively O
determine O
the O
contribution O
of O
PepT1 O
[ O
peptide O
transporter O
1 O
( O
SLC15A1 O
) O
] O
to O
the O
intestinal O
permeability O
of O
valacyclovir O
, O
an O
ester O
prodrug O
of O
the O
antiviral O
drug O
acyclovir B
. O

Acyclovir B
pharmacokinetics O
was O
also O
evaluated O
after O
oral O
administration O
of O
25 O
nmol O
/ O
g O
valacyclovir O
. O

Valacyclovir O
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine O
and O
the O
aminocephalosporin O
cefadroxil O
, O
but O
not O
by O
the O
amino B
acids I
l O
- O
valine O
or O
l O
- O
histidine O
, O
the O
organic O
acid O
p O
- O
aminohippurate O
, O
or O
the O
organic O
base O
tetraethylammonium B
( O
all O
at O
25 O
mM O
) O
. O

Mammalian O
frataxin O
controls O
sulfur B
production O
and O
iron B
entry O
during O
de O
novo O
Fe4S4 O
cluster O
assembly O
. O

In O
the O
mammalian O
ISC O
machinery O
, O
preassembly O
of O
the O
Fe O
- O
S O
cluster O
on O
the O
scaffold O
protein O
( O
ISCU O
) O
involves O
a O
cysteine B
desulfurase O
complex O
( O
NFS1 O
/ O
ISD11 O
) O
and O
frataxin O
( O
FXN O
) O
, O
the O
protein O
deficient O
in O
Friedreich O
' O
s O
ataxia O
. O

Here O
, O
by O
comparing O
the O
biochemical O
and O
spectroscopic O
properties O
of O
quaternary O
( O
ISCU O
/ O
NFS1 O
/ O
ISD11 O
/ O
FXN O
) O
and O
ternary O
( O
ISCU O
/ O
NFS1 O
/ O
ISD11 O
) O
complexes O
, O
we O
show O
that O
FXN O
stabilizes O
the O
quaternary O
complex O
and O
controls O
iron B
entry O
to O
the O
complex O
through O
activation O
of O
cysteine B
desulfurization O
. O

Furthermore O
, O
we O
show O
for O
the O
first O
time O
that O
in O
the O
presence O
of O
iron B
and O
L O
- O
cysteine O
, O
an O
[ O
Fe O
( O
4 O
) O
S O
( O
4 O
) O
] O
cluster O
is O
formed O
within O
the O
quaternary O
complex O
that O
can O
be O
transferred O
to O
mammalian O
aconitase O
( O
mACO2 O
) O
to O
generate O
an O
active O
enzyme O
. O

Textured O
silicon B
surfaces O
decorated O
by O
square O
arrays O
of O
pillars O
with O
adjustable O
pitch O
were O
fabricated O
. O

The O
wetting O
behavior O
, O
especially O
for O
direction O
- O
dependent O
water O
contact O
angles O
on O
textured O
silicon B
surfaces O
after O
silanization O
, O
was O
investigated O
by O
incorporating O
the O
contact O
line O
fraction O
into O
a O
modified O
Wenzel O
model O
. O

This O
work O
studies O
the O
effect O
of O
packing O
cracked O
seasoned O
olives O
with O
NaCl B
, O
KCl B
, O
and O
CaCl B
( I
2 I
) I
mixture O
brines O
on O
their O
mineral O
nutrients O
and O
sensory O
attributes O
, O
using O
RSM O
methodology O
. O

The O
Na B
, O
K B
, O
Ca B
, O
and O
residual O
natural O
Mn B
contents O
in O
flesh O
as O
well O
as O
saltiness O
, O
bitterness O
and O
fibrousness O
were O
significantly O
related O
to O
the O
initial O
concentrations O
of O
salts O
in O
the O
packing O
solution O
. O

This O
new O
process O
led O
to O
table O
olives O
with O
a O
significantly O
lower O
sodium B
content O
( O
about O
31 O
% O
) O
than O
the O
traditional O
product O
but O
fortified O
in O
K B
and O
Ca B
. O

High O
levels O
of O
Na B
and O
Ca B
in O
the O
flesh O
led O
to O
high O
scores O
of O
acidity O
and O
saltiness O
( O
the O
first O
descriptor O
) O
and O
bitterness O
( O
the O
second O
) O
while O
the O
K B
content O
was O
unrelated O
to O
any O
sensory O
descriptor O
. O

Direct O
potentiometric O
determination O
of O
starch O
using O
a O
platinum B
redox O
sensor O
. O

Here O
, O
we O
describe O
the O
development O
of O
a O
platinum B
redox O
sensor O
for O
the O
direct O
potentiometric O
quantification O
of O
starch O
in O
solution O
. O

The O
sensor O
measures O
the O
decrease O
in O
free O
triiodide B
ion O
after O
it O
complexes O
with O
starch O
to O
form O
a O
starch O
- O
triiodide B
complex O
. O

The O
starch O
- O
triiodide B
complex O
was O
characterized O
potentiometrically O
at O
variable O
starch O
and O
triiodide B
concentrations O
. O

We O
also O
propose O
a O
response O
mechanism O
for O
the O
platinum B
redox O
sensor O
towards O
starch O
and O
an O
appropriate O
theoretical O
model O
. O

Milk O
samples O
were O
purchased O
from O
local O
grocery O
stores O
( O
Columbus O
, O
OH O
, O
USA O
) O
and O
spiked O
at O
different O
concentrations O
of O
whey O
, O
hydrogen B
peroxide I
, O
synthetic O
urine O
, O
urea B
and O
synthetic O
milk O
. O

Partial O
Least O
Squares O
Regression O
( O
PLSR O
) O
showed O
standard O
error O
of O
prediction O
( O
SEP O
) O
~ O
2 O
. O
33 O
, O
0 O
. O
06 O
, O
0 O
. O
41 O
, O
0 O
. O
30 O
and O
0 O
. O
014 O
g O
/ O
L O
for O
estimation O
of O
levels O
of O
adulteration O
with O
whey O
, O
synthetic O
milk O
, O
synthetic O
urine O
, O
urea B
and O
hydrogen B
peroxide I
, O
respectively O
. O

Auroxanthin O
and O
beta B
- I
cryptoxanthin I
represented O
around O
50 O
% O
of O
total O
carotenoids O
. O

Concentration O
of O
the O
extract O
by O
microfiltration O
led O
to O
epoxy B
- O
furanoxy O
rearrangement O
of O
violaxanthin O
and O
antheraxanthin O
. O

Inhibition O
effects O
and O
induction O
of O
apoptosis O
of O
flavonoids B
on O
the O
prostate O
cancer O
cell O
line O
PC O
- O
3 O
in O
vitro O
. O

Myricetin B
and O
myricitrin O
are O
naturally O
occurring O
flavonoids B
have O
been O
suggested O
to O
play O
a O
role O
in O
inhibition O
of O
proliferation O
and O
transformation O
of O
carcinogenic O
cell O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
clarify O
the O
molecular O
mechanisms O
of O
apoptosis O
cell O
on O
the O
prostate O
cancer O
induced O
by O
myricetin B
, O
myricitrin O
, O
quercetin B
and O
quercitrin O
. O

The O
MTT B
assay O
confirmed O
that O
myricetin B
had O
the O
strongest O
inhibitory O
effect O
on O
human O
prostate O
cancer O
cell O
line O
PC O
- O
3 O
, O
myricitrin O
was O
second O
, O
and O
quercitrin O
was O
the O
weakest O
. O

A O
noticeable O
synergistic O
effect O
was O
observed O
with O
the O
inhibition O
of O
cell O
proliferation O
when O
myricetin B
was O
used O
in O
combination O
with O
myricitrin O
. O

In O
the O
concentration O
range O
of O
37 O
. O
5 O
- O
300 O
mu O
mol O
/ O
L O
, O
the O
inhibitory O
effects O
of O
these O
flavonoids B
were O
enhanced O
with O
increasing O
dose O
and O
treatment O
time O
. O

The O
acridine O
orange O
analysis O
and O
annexin O
V O
- O
FITC B
/ O
PI O
double O
- O
staining O
results O
confirmed O
that O
myricetin B
and O
myricitrin O
were O
effective O
in O
inducing O
PC O
- O
3 O
cell O
apoptosis O
. O

The O
results O
showed O
that O
myricetin B
was O
more O
effective O
than O
myricitrin O
in O
inducing O
cell O
apoptosis O
. O

The O
apoptosis O
rate O
increased O
with O
increasing O
flavonoid B
concentration O
in O
a O
dose O
dependent O
manner O
. O

A O
synergistic O
effect O
was O
observed O
on O
the O
apoptosis O
rate O
when O
myricetin B
was O
used O
in O
combination O
with O
myricitrin O
. O

A O
gas O
chromatographic O
method O
for O
the O
determination O
of O
endocrine O
disruptor O
pesticides O
( O
Chlorpyrifos B
, O
Penconazole O
, O
Procymidone B
, O
Iprodione B
, O
Bromopropylate O
and O
Lambda B
- I
Cyhalothrin I
) O
in O
wine O
samples O
is O
described O
. O

The O
pesticides O
were O
extracted O
from O
the O
sample O
by O
cyclohexane B
- O
ethyl B
acetate I
mixture O
( O
1 O
: O
1 O
v O
/ O
v O
) O
and O
cleaned O
up O
by O
florosil O
column O
. O

White O
bread O
contained O
the O
lowest O
amounts O
of O
free O
umami O
amino B
acids I
and O
umami O
5 O
' O
- O
nucleotides B
and O
showed O
the O
lowest O
EUC O
value O
. O

After O
baking O
, O
mycelium O
- O
supplemented O
bread O
still O
contained O
substantial O
amounts O
of O
gamma B
- I
aminobutyric I
acid I
and O
ergothioneine O
( O
0 O
. O
23 O
- O
0 O
. O
86 O
and O
0 O
. O
79 O
- O
2 O
. O
10 O
mg O
/ O
g O
dry O
matter O
, O
respectively O
) O
. O

Natural O
occurrence O
of O
deoxynivalenol B
in O
wheat O
from O
Paran O
a O
State O
, O
Brazil O
and O
estimated O
daily O
intake O
by O
wheat O
products O
. O

The O
occurrence O
of O
deoxynivalenol B
( O
DON B
) O
was O
evaluated O
in O
113 O
wheat O
samples O
from O
the O
northern O
and O
central O
/ O
southwestern O
regions O
of O
Paran O
a O
State O
, O
Brazil O
during O
the O
2008 O
and O
2009 O
growing O
seasons O
, O
and O
this O
rate O
of O
occurrence O
was O
used O
to O
estimate O
the O
DON B
dietary O
exposure O
. O

The O
DON B
determination O
was O
carried O
out O
by O
an O
indirect O
competitive O
enzyme O
- O
linked O
immunosorbent O
assay O
. O

DON B
was O
detected O
in O
66 O
. O
4 O
% O
samples O
at O
levels O
ranging O
from O
206 O
. O
3 O
to O
4732 O
. O
3 O
mu O
g O
/ O
kg O
( O
mean O
1894 O
. O
9 O
mu O
g O
/ O
kg O
) O
. O

The O
estimated O
daily O
intake O
( O
EDI O
) O
of O
DON B
through O
bread O
and O
pasta O
was O
evaluated O
in O
the O
inhabitants O
of O
Londrina O
City O
in O
northern O
Paran O
a O
State O
, O
Brazil O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
on O
natural O
DON B
occurrence O
in O
wheat O
and O
DON B
dietary O
exposure O
estimation O
from O
Paran O
a O
, O
Brazil O
. O

Hepatoprotective O
effect O
of O
2 O
, O
3 O
- O
dehydrosilybin O
on O
carbon B
tetrachloride I
- O
induced O
liver O
injury O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
2 O
, O
3 O
- O
dehydrosilybin O
( O
DHS O
) O
against O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
) O
- O
induced O
liver O
injury O
in O
rats O
. O

Administration O
of O
DHS O
significantly O
attenuated O
the O
levels O
of O
serum O
aspartate B
aminotransferase O
, O
alanine B
aminotransferase O
, O
and O
liver O
lipid O
peroxidation O
in O
CCl B
( I
4 I
) I
- O
treated O
rats O
. O

Moreover O
, O
we O
showed O
that O
DHS O
prevented O
DNA O
damage O
and O
decreased O
the O
protein O
levels O
of O
gamma O
- O
H2AX O
, O
which O
is O
a O
specific O
DNA O
damage O
marker O
, O
in O
CCl B
( I
4 I
) I
- O
treated O
rat O
livers O
. O

DHS O
also O
markedly O
increased O
the O
activity O
of O
antioxidant O
enzymes O
, O
such O
as O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
peroxidase O
, O
and O
glutathione O
reductase O
in O
CCl B
( I
4 I
) I
- O
treated O
rat O
livers O
. O

Furthermore O
, O
we O
found O
that O
DHS O
significantly O
inhibited O
the O
production O
of O
serum O
nitric B
oxide I
as O
well O
as O
the O
levels O
of O
serum O
IL O
- O
6 O
, O
IFN O
- O
gamma O
, O
and O
TNF O
- O
alpha O
in O
CCl B
( I
4 I
) I
- O
treated O
rats O
. O

Additionally O
, O
DHS O
significantly O
suppressed O
iNOS O
expression O
on O
the O
protein O
levels O
in O
CCl B
( I
4 I
) I
- O
treated O
rat O
livers O
. O

Collectively O
, O
the O
present O
study O
suggests O
that O
DHS O
protects O
the O
liver O
from O
CCl B
( I
4 I
) I
- O
induced O
hepatic O
damage O
via O
antioxidant O
and O
anti O
- O
inflammatory O
mechanisms O
. O

The O
method O
explores O
the O
ABTS B
radical O
( O
2 O
, O
2 O
' O
- O
azinobis O
( O
3 O
- O
ethylbenzothiazoline O
- O
6 O
- O
sulphonic O
acid O
) O
) O
assay O
as O
a O
redox O
probe O
and O
it O
relays O
on O
measuring O
catalytic O
voltammetric O
currents O
. O

The O
electrocatalysis O
comprises O
redox O
regeneration O
of O
the O
electrochemically O
created O
ABTS B
( I
+ I
) I
radical O
either O
by O
Trolox B
( O
6 O
- O
hydroxy O
- O
2 O
, O
5 O
, O
7 O
, O
8 O
- O
tetramethychroman O
- O
2 O
- O
carboxylic O
acid O
) O
or O
by O
antioxidants O
present O
in O
studied O
oils O
. O

The O
detection O
limit O
of O
the O
method O
is O
determined O
to O
be O
0 O
. O
5 O
mg O
/ O
L O
of O
Trolox B
equivalent O
, O
being O
a O
slightly O
lower O
than O
the O
corresponding O
UV O
- O
VIS O
spectrophotometric O
method O
. O

Potent O
antioxidant O
capacity O
of O
studied O
oils O
was O
also O
confirmed O
by O
electron O
paramagnetic O
resonance O
spectroscopy O
of O
superoxide B
anion O
produced O
by O
macrophages O
. O

Effect O
of O
the O
genistein B
metabolite O
on O
leptin O
secretion O
in O
murine O
adipocytes O
in O
vitro O
. O

Soy O
isoflavonoids B
have O
many O
useful O
properties O
. O

The O
effect O
of O
the O
metabolism O
of O
soy O
isoflavonoids B
on O
their O
properties O
is O
not O
fully O
understood O
. O

We O
have O
isolated O
the O
bacterial O
strain O
SY8519 O
, O
which O
has O
been O
shown O
to O
metabolize O
daidzein B
to O
O O
- O
desmethylangolensin O
and O
to O
produce O
2 O
- O
( O
4 O
- O
hydroxyphenyl O
) O
propionic O
acid O
from O
genistein B
. O

We O
also O
applied O
the O
metabolite O
to O
mouse O
adipocytes O
and O
found O
that O
2 O
- O
HPPA O
was O
less O
effective O
at O
reducing O
leptin O
secretion O
than O
the O
parent O
compound O
genistein B
. O

Our O
results O
suggested O
that O
' O
O O
- O
desmethylangolensin O
- O
production O
' O
attenuates O
the O
effect O
of O
soy O
isoflavonoids B
by O
reducing O
not O
only O
the O
activity O
of O
daidzein B
but O
also O
that O
of O
genistein B
. O

Simultaneous O
detection O
of O
flavonoids B
and O
phenolic B
acids I
in O
Herba O
Lysimachiae O
and O
Herba O
Desmodii O
Styracifolii O
using O
liquid O
chromatography O
tandem O
mass O
spectrometry O
. O

A O
sensitive O
liquid O
chromatography O
and O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
and O
validated O
for O
the O
simultaneous O
analysis O
of O
15 O
flavonoids B
and O
3 O
phenolic B
acids I
in O
Herba O
Lysimachiae O
and O
Herba O
Desmodii O
Styracifolii O
. O

Separation O
was O
performed O
using O
a O
Diamonsil O
C O
( O
18 O
) O
column O
, O
which O
was O
eluted O
with O
methanol B
( O
A O
) O
and O
0 O
. O
1 O
/ O
1000 O
acetic B
acid I
( O
B O
) O
. O

Exploration O
of O
Vanilla O
pompona O
from O
the O
Peruvian O
Amazon O
as O
a O
potential O
source O
of O
vanilla O
essence O
: O
quantification O
of O
phenolics B
by O
HPLC O
- O
DAD O
. O

LC O
- O
ESI O
- O
MS O
studies O
corroborated O
the O
identities O
of O
four O
glucosides O
and O
seven O
aglycones O
, O
among O
them O
vanillin B
( O
5 O
. O
7 O
/ O
100 O
g O
) O
, O
4 O
- O
hydroxybenzyl O
alcohol O
( O
3 O
. O
6 O
/ O
100 O
g O
) O
, O
and O
anisyl O
alcohol O
( O
7 O
. O
1 O
/ O
100 O
g O
) O
were O
found O
in O
high O
concentrations O
. O

Crude O
protein O
per O
100g O
edible O
portion O
of O
dry O
weight O
ranged O
between O
7 O
. O
9 O
+ O
/ O
- O
0 O
. O
0 O
and O
8 O
. O
7 O
+ O
/ O
- O
0 O
. O
0 O
g O
, O
crude O
fat O
from O
0 O
. O
8 O
+ O
/ O
- O
0 O
. O
0 O
to O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
0 O
g O
, O
crude O
fibre O
from O
4 O
. O
9 O
+ O
/ O
- O
0 O
. O
0 O
to O
7 O
. O
3 O
+ O
/ O
- O
0 O
. O
0 O
g O
, O
ash O
between O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
0 O
and O
4 O
. O
3 O
+ O
/ O
- O
0 O
. O
0 O
g O
and O
carbohydrate B
between O
79 O
. O
5 O
+ O
/ O
- O
0 O
. O
0 O
and O
83 O
. O
2 O
+ O

The O
fruits O
were O
rich O
in O
vitamin B
C I
( O
15 O
. O
0 O
+ O
/ O
- O
0 O
. O
0 O
- O
43 O
. O
8 O
+ O
/ O
- O
0 O
. O
02 O
mg O
100 O
g O
( O
- O
1 O
) O
) O
and O
the O
energy O
values O
ranged O
between O
1516 O
. O
0 O
+ O
/ O
- O
1 O
. O
73 O
and O
1575 O
. O
0 O
+ O
/ O
- O
2 O
. O
3 O
kJ O
100 O
g O
( O
- O
1 O
) O
. O

Furthermore O
, O
the O
fruits O
contained O
( O
mg O
100 O
g O
( O
- O
1 O
) O
of O
dry O
weight O
) O
potassium B
from O
1865 O
. O
0 O
+ O
/ O
- O
1 O
. O
3 O
to O
2441 O
. O
0 O
+ O
/ O
- O
1 O
. O
1 O
, O
calcium B
from O
160 O
. O
0 O
+ O
/ O
- O
0 O
. O
3 O
to O
254 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
, O
sodium B
between O
185 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
and O
223 O
. O
0 O
+ O
/ O
- O
0 O
. O
2 O
, O
magnesium B
between O
83 O
. O
0 O
+ O
/ O
- O
0 O
. O
0 O
and O
150 O
. O
0 O
+ O
/ O
- O
0 O
. O
13 O
and O
phosphorous B
from O
87 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
to O
148 O
. O
0 O
+ O

Manganese B
and O
copper B
contents O
ranged O
between O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
03 O
and O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
03 O
, O
while O
iron B
and O
zinc B
ranged O
between O
2 O
. O
1 O
+ O
/ O
- O
0 O
. O
43 O
and O
4 O
. O
3 O
+ O
/ O
- O
0 O
. O
1 O
, O
and O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
0 O
- O
0 O
. O
9 O
+ O
/ O
- O
0 O
. O
0 O
mg O
100 O
g O
( O
- O
1 O
) O
of O
dry O
weight O
, O
respectively O
. O

The O
masau O
fruit O
is O
therefore O
a O
good O
potential O
source O
of O
carbohydrates B
, O
proteins O
and O
micronutrients O
, O
such O
as O
calcium B
, O
potassium B
, O
sodium B
, O
phosphorous B
, O
copper B
, O
iron B
, O
Vitamin B
C I
and O
zinc B
. O

Comparative O
formation O
of O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
in O
creatinine B
/ O
phenylalanine B
and O
creatinine B
/ O
phenylalanine B
/ O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
reaction O
mixtures O
. O

The O
comparative O
formation O
of O
the O
heterocyclic O
aromatic O
amine O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
in O
both O
creatinine B
/ O
phenylalanine B
( O
CRN O
/ O
Phe B
) O
and O
creatinine B
/ O
phenylalanine B
/ O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
( O
CRN O
/ O
Phe B
/ O
ON O
) O
systems O
was O
studied O
to O
analyse O
the O
ability O
of O
lipid O
- O
derived O
reactive O
carbonyls B
to O
promote O
PhIP B
formation O
. O

Although O
PhIP B
was O
produced O
to O
some O
extent O
in O
the O
CRN O
/ O
Phe B
system O
, O
the O
presence O
of O
the O
oxidized O
lipid O
increased O
considerably O
the O
amount O
of O
PhIP B
produced O
. O

On O
the O
other O
hand O
, O
the O
addition O
of O
the O
lipid O
did O
not O
seem O
to O
produce O
PhIP B
by O
an O
alternative O
mechanism O
because O
PhIP B
was O
formed O
analogously O
in O
both O
CRN O
/ O
Phe B
and O
CRN O
/ O
Phe B
/ O
ON O
systems O
as O
a O
function O
of O
pH O
, O
creatinine B
concentration O
, O
phenylalanine B
concentration O
, O
time O
, O
temperature O
, O
oxygen B
concentration O
in O
the O
reaction O
atmosphere O
, O
and O
the O
addition O
of O
different O
amounts O
of O
ammonia B
. O

All O
these O
results O
suggest O
that O
the O
ability O
of O
lipid O
oxidation O
products O
to O
produce O
PhIP B
is O
related O
to O
their O
capacity O
to O
induce O
the O
Strecker O
degradation O
of O
phenylalanine B
to O
phenylacetaldehyde O
. O

Therefore O
, O
any O
other O
reactive O
carbonyl B
compound O
that O
can O
produce O
the O
Strecker O
degradation O
of O
phenylalanine B
should O
also O
be O
considered O
as O
a O
potential O
inducer O
of O
PhIP B
formation O
under O
appropriate O
conditions O
. O

E B
- I
beta I
- I
ocimene I
( O
53 O
. O
81 O
% O
) O
, O
R O
- O
D O
- O
decalactone O
( O
12 O
. O
75 O
% O
) O
, O
alpha B
- I
pinene I
( O
6 O
. O
43 O
% O
) O
, O
n O
- O
heptanol O
( O
6 O
. O
27 O
% O
) O
, O
beta O
- O
phellanderne O
( O
2 O
. O
70 O
% O
) O
and O
linalool B
( O
1 O
. O
89 O
% O
) O
were O
the O
major O
constituents O
. O

Separation O
was O
performed O
on O
C O
( O
18 O
) O
column O
utilising O
5 O
% O
( O
v O
/ O
v O
) O
acetic B
acid I
in O
water O
and O
acetonitrile B
at O
330 O
nm O
. O

Subsequently O
the O
methods O
were O
applied O
for O
the O
identification O
and O
quantification O
of O
chlorogenic B
acid I
( O
5 O
- O
CQA O
) O
and O
1 B
, I
5 I
- I
dicaffeoylquinic I
acid I
( O
1 O
, O
5 O
- O
DCQA O
) O
as O
main O
compounds O
in O
samples O
. O

The O
antioxidant O
assessment O
was O
carried O
out O
using O
DPPH B
and O
total O
phenolic O
content O
( O
Folin O
- O
Ciocalteu O
) O
assays O
. O

The O
chromatographic O
and O
spectral O
data O
revealed O
the O
presence O
of O
several O
simple O
phenolic B
acids I
, O
derivatives O
of O
both O
caffeic O
and O
benzoic O
acids O
, O
and O
flavonoids B
in O
the O
produced O
extracts O
. O

The O
most O
beneficial O
conditions O
were O
calculated O
for O
methanol B
and O
water O
: O
ethanol B
( O
50 O
: O
50 O
) O
extracts O
derived O
from O
the O
combination O
of O
SFE O
and O
ASE O
methodologies O
. O

The O
optimal O
mobile O
phase O
consisted O
of O
5 O
% O
methanol B
and O
0 O
. O
1 O
% O
( O
v O
/ O
v O
) O
TFA B
in O
water O
, O
and O
the O
optimal O
loading O
amount O
and O
flow O
rate O
were O
1 O
. O
0 O
g O
and O
80 O
ml O
/ O
min O
, O
respectively O
. O

59 O
. O
7 O
mg O
of O
78 O
. O
0 O
% O
gallic B
acid I
could O
be O
separated O
simultaneously O
. O

Binding O
of O
vitamin B
A I
with O
milk O
alpha O
- O
and O
beta O
- O
caseins O
. O

The O
binding O
sites O
of O
retinol B
and O
retinoic B
acid I
with O
milk O
alpha O
- O
and O
beta O
- O
caseins O
were O
determined O
, O
using O
constant O
protein O
concentration O
and O
various O
retinoid O
contents O
. O

FTIR O
, O
UV O
- O
visible O
and O
fluorescence O
spectroscopic O
methods O
as O
well O
as O
molecular O
modelling O
were O
used O
to O
analyse O
retinol B
and O
retinoic B
acid I
binding O
sites O
, O
the O
binding O
constant O
and O
the O
effect O
of O
retinoid B
complexation O
on O
the O
stability O
and O
conformation O
of O
caseins O
. O

Structural O
analysis O
showed O
that O
retinoids B
bind O
caseins O
via O
both O
hydrophilic O
and O
hydrophobic O
contacts O
with O
overall O
binding O
constants O
of O
K O
( O
retinol B
- O
) O
( O
alpha O
) O
( O
- O
caseins O
) O
= O
1 O
. O
21 O
( O
+ O
/ O
- O
0 O
. O
4 O
) O
x O
10 O
( O
5 O
) O
M O
( O
- O
1 O
) O
and O
K O
( O
retinol B
- O
) O
( O
beta O
) O
( O
- O
caseins O
) O
= O
1 O
. O
11 O
( O
+ O
/ O
- O
0 O
. O
5 O
) O
x O
10 O
( O
5 O
) O
M O
( O
- O
1 O
) O
and O
K O
( O
retinoic B
acid I
- O
) O
( O
alpha O
) O
( O
- O
caseins O
) O
= O
6 O
. O
2 O
( O
+ O

/ O
- O
0 O
. O
6 O
) O
x O
10 O
( O
4 O
) O
M O
( O
- O
1 O
) O
and O
K O
( O
retinoic B
acid I
- O
) O
( O
beta O
) O
( O
- O
caseins O
) O
= O
6 O
. O
3 O
( O
+ O
/ O
- O
0 O
. O
6 O
) O
x O
10 O
( O
4 O
) O
M O
( O
- O
1 O
) O
. O

The O
number O
of O
bound O
retinol B
molecules O
per O
protein O
( O
n O
) O
was O
1 O
. O
5 O
( O
+ O
/ O
- O
0 O
. O
1 O
) O
for O
alpha O
- O
casein O
and O
1 O
. O
0 O
( O
+ O
/ O
- O
0 O
. O
1 O
) O
for O
beta O
- O
casein O
, O
while O
1 O
molecule O
of O
retinoic B
acid I
was O
bound O
in O
the O
alpha O
- O
and O
beta O
- O
casein O
complexes O
. O

Molecular O
modelling O
showed O
different O
binding O
sites O
for O
retinol B
and O
retinoic B
acid I
on O
alpha O
- O
and O
beta O
- O
caseins O
with O
more O
stable O
complexes O
formed O
with O
alpha O
- O
casein O
. O

Retinoid B
- O
casein O
complexation O
induced O
minor O
alterations O
of O
protein O
conformation O
. O

Caseins O
might O
act O
as O
carriers O
for O
transportation O
of O
retinoids B
to O
target O
molecules O
. O

Lutein B
content O
of O
wheat O
flour O
ranged O
from O
0 O
. O
10 O
to O
0 O
. O
69 O
mu O
g O
/ O
g O
, O
and O
alpha B
- I
tocopherol I
ranged O
from O
0 O
. O
12 O
to O
0 O
. O
83 O
mu O
g O
/ O
g O
. O

Total O
carotenoids O
were O
primarily O
affected O
by O
E O
( O
45 O
. O
7 O
% O
) O
, O
while O
G O
x O
E O
interaction O
had O
a O
larger O
effect O
on O
the O
level O
of O
total O
tocopherols B
( O
71 O
. O
6 O
% O
) O
. O

E O
had O
the O
largest O
effect O
on O
antioxidant O
activity O
against O
oxygen B
, O
hydroxyl B
, O
and O
ABTS B
( I
. I
+ I
) I
radicals O
. O

ABTS B
( I
. I
+ I
) I
radical O
scavenging O
capacity O
had O
a O
positive O
correlation O
with O
average O
air O
temperature O
( O
r O
= O
0 O
. O
705 O
, O
p O
< O
0 O
. O
01 O
) O
, O
while O
hydroxyl B
radical O
scavenging O
capacity O
had O
a O
negative O
correlation O
with O
temperature O
( O
r O
= O
- O
0 O
. O
269 O
. O
p O
< O
0 O
. O
01 O
) O
. O

Arsenic B
speciation O
analysis O
in O
mono O
- O
varietal O
wines O
by O
on O
- O
line O
ionic O
liquid O
- O
based O
dispersive O
liquid O
- O
liquid O
microextraction O
. O

A O
highly O
efficient O
separation O
and O
pre O
- O
concentration O
method O
for O
arsenic B
species O
determination O
, O
based O
on O
ionic O
liquid O
( O
IL O
) O
dispersive O
microextraction O
technique O
implemented O
in O
a O
flow O
analysis O
system O
, O
is O
proposed O
. O

Highly O
selective O
separation O
of O
arsenite B
species O
[ O
As B
( I
III I
) I
] O
was O
achieved O
by O
chelation O
with O
sodium O
diethyldithiocarbama O
( O
DDTC O
) O
followed O
by O
dispersion O
with O
40 O
mg O
of O
1 O
- O
octyl O
- O
3 O
- O
methylimidazolium O
hexafluorophosphate O
( O
[ O
C O
( O
8 O
) O
mim O
] O
[ O
PF O
( O
6 O
) O
] O
) O
IL O
. O

Analyte O
extraction O
, O
retention O
and O
separation O
of O
IL O
phase O
were O
achieved O
with O
a O
packed O
microcolumn O
and O
As B
( I
III I
) I
was O
determined O
in O
eluent O
solution O
by O
electrothermal O
atomic O
absorption O
spectrometry O
( O
ETAAS O
) O
. O

Concentration O
of O
As B
( I
V I
) I
was O
deduced O
by O
the O
difference O
between O
total O
inorganic O
arsenic B
and O
As B
( I
III I
) I
. O

Thus O
, O
determination O
of O
total O
arsenic B
was O
performed O
by O
previous O
degradation O
of O
organo O
- O
arsenic O
species O
, O
followed O
by O
a O
reduction O
. O

Under O
optimal O
conditions O
, O
As B
( I
III I
) I
extraction O
efficiency O
was O
100 O
% O
and O
a O
sensitivity O
enhancement O
factor O
of O
46 O
was O
obtained O
with O
only O
4 O
. O
0 O
ml O
of O
sample O
The O
method O
was O
successfully O
applied O
for O
arsenic B
speciation O
studies O
in O
mono O
- O
varietal O
wines O
. O

Stabilization O
of O
anthocyanin B
and O
skullcap O
flavone B
complexes O
- O
- O
investigations O
with O
computer O
simulation O
and O
experimental O
methods O
. O

We O
examined O
the O
stabilization O
of O
anthocyanins B
with O
flavones B
from O
the O
practical O
and O
theoretical O
perspective O
. O

The O
influence O
of O
addition O
of O
skullcap O
flavones B
, O
heating O
to O
50 O
degrees O
C O
, O
and O
12 O
day O
storage O
time O
( O
in O
the O
presence O
and O
absence O
of O
light O
) O
on O
the O
stability O
of O
anthocyanins B
in O
honeysuckle O
concentrates O
was O
investigated O
experimentally O
. O

By O
the O
methods O
of O
the O
computer O
simulation O
of O
the O
copigmentation O
process O
we O
determined O
the O
sites O
responsible O
for O
the O
stabilization O
of O
a O
cyanidin O
quinoidal O
base O
- O
baicalin B
complex O
. O

We O
revealed O
both O
direct O
and O
water O
- O
mediated O
hydrogen B
bondings O
that O
keep O
the O
lamellar O
stacking O
structure O
of O
these O
molecules O
in O
the O
bounded O
form O
in O
water O
medium O
. O

The O
experimental O
part O
of O
the O
study O
confirmed O
the O
effectiveness O
of O
anthocyanins B
stabilization O
in O
a O
concentrate O
of O
honeysuckle O
with O
the O
use O
of O
skullcap O
flavones B
. O

Burdock O
fructooligosaccharid O
induces O
fungal O
resistance O
in O
postharvest O
Kyoho O
grapes O
by O
activating O
the O
salicylic B
acid I
- O
dependent O
pathway O
and O
inhibiting O
browning O
. O

BFO O
treatment O
induced O
upregulation O
of O
the O
npr1 O
, O
pr1 O
, O
pal O
, O
and O
sts O
genes O
, O
and O
inhibited O
the O
total O
phenol B
content O
decrease O
, O
which O
activated O
chitinase O
and O
beta O
- O
1 O
, O
3 O
- O
glucanase O
. O

These O
results O
indicated O
that O
the O
salicylic B
acid I
- O
dependent O
signalling O
pathway O
was O
induced O
. O

The O
aim O
of O
this O
work O
was O
to O
study O
the O
influence O
of O
processes O
( O
boiling O
or O
germination O
) O
on O
the O
phenolic B
composition O
of O
dark O
beans O
( O
Phaseolus O
vulgaris O
L O
. O
c O
. O
v O
. O
Tolosana O
) O
and O
their O
effect O
on O
their O
antioxidant O
, O
neuroprotective O
and O
anticancer O
ability O
. O

Phenolic B
composition O
of O
raw O
and O
processed O
dark O
beans O
was O
analysed O
by O
HPLC O
- O
PAD O
and O
HPLC O
- O
ESI O
/ O
MS O
. O

Anticancer O
activities O
were O
evaluated O
on O
three O
different O
cell O
lines O
( O
renal O
adenocarcinoma O
( O
TK O
- O
10 O
) O
, O
breast O
adenocarcinoma O
( O
MCF O
- O
7 O
) O
and O
melanoma O
( O
UACC O
- O
62 O
) O
) O
by O
sulphorhodamine B
B I
method O
. O

Qualitative O
and O
quantitative O
differences O
in O
phenolic B
composition O
have O
been O
observed O
between O
raw O
and O
processed O
dark O
beans O
that O
influence O
the O
antioxidant O
activity O
, O
mainly O
for O
germinated O
samples O
which O
show O
a O
decrease O
of O
antioxidant O
capacity O
. O

Although O
every O
assayed O
extracts O
decreased O
reactive O
oxygen B
species O
release O
and O
exhibited O
cytotoxicity O
activities O
on O
cancer O
cell O
lines O
, O
raw O
beans O
proved O
to O
be O
the O
most O
active O
in O
neuroprotective O
and O
antitumoral O
effects O
; O
this O
sample O
is O
especially O
rich O
in O
phenolic B
compounds O
, O
mainly O
anthocyanins B
. O

This O
study O
further O
demonstrated O
that O
phenolic B
composition O
of O
dark O
beans O
is O
related O
with O
cooking O
process O
and O
so O
with O
their O
neuroprotective O
and O
anticancer O
activity O
; O
cooking O
of O
dark O
beans O
improves O
their O
digestion O
and O
absorption O
at O
intestinal O
level O
, O
while O
maintaining O
its O
protective O
ability O
on O
oxidative O
process O
at O
cellular O
level O
. O

Glucose B
, O
fructose B
and O
sucrose B
increase O
the O
solubility O
of O
protein O
- O
tannin O
complexes O
and O
at O
high O
concentration O
, O
glucose B
and O
sucrose B
interfere O
with O
bisulphite O
bleaching O
of O
wine O
pigments O
. O

Wines O
were O
modified O
with O
increasing O
sugar B
concentrations O
and O
decreasing O
tannin O
concentrations O
and O
analysed O
by O
a O
combination O
of O
protein O
precipitation O
and O
bisulphite O
bleaching O
. O

Increasing O
sugar B
concentration O
decreased O
the O
precipitation O
of O
tannin O
and O
protein O
- O
precipitable O
polymeric O
pigments O
( O
PPP O
) O
. O

The O
use O
of O
a O
hydrogen B
bond O
disruptor O
( O
urea B
) O
to O
reduce O
protein O
- O
tannin O
and O
protein O
- O
pigment O
complex O
formation O
showed O
that O
the O
effect O
of O
sugar B
concentration O
occurred O
by O
increasing O
the O
solubility O
of O
the O
tannin O
- O
protein O
complex O
, O
not O
by O
interfering O
with O
protein O
- O
tannin O
complex O
formation O
. O

There O
was O
also O
an O
increase O
in O
total O
polymeric O
pigments O
at O
each O
tannin O
concentration O
with O
increasing O
glucose B
and O
sucrose B
concentration O
, O
indicating O
that O
sugar B
concentration O
might O
also O
affect O
bisulphite O
bleaching O
of O
wine O
pigments O
. O

While O
a O
significant O
effect O
of O
sugar B
concentration O
on O
tannin O
- O
protein O
complex O
solubility O
was O
observed O
, O
these O
effects O
were O
greatest O
at O
sugar B
concentrations O
far O
in O
excess O
of O
normal O
wine O
making O
conditions O
. O

Under O
normal O
wine O
making O
conditions O
, O
sugar B
concentration O
will O
have O
a O
negligible O
effect O
on O
protein O
- O
precipitable O
tannin O
, O
PPP O
and O
nPPP O
concentrations O
. O

BLG O
was O
sonicated O
in O
the O
presence O
of O
glucose B
, O
galactose B
, O
lactose B
, O
fructose B
, O
ribose B
and O
arabinose B
. O

Ultrasound O
treatment O
resulted O
in O
formation O
of O
MRPs O
with O
all O
tested O
carbohydrates B
. O

Ribose B
induced O
the O
highest O
degree O
of O
modification O
resulting O
in O
76 O
% O
of O
BLG O
modified O
and O
an O
average O
of O
three O
anhydroribose O
units O
attached O
. O

MRP O
obtained O
by O
ultrasound O
exhibited O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
scavenging O
activity O
and O
possessed O
increased O
iron B
- O
chelating O
activity O
and O
reducing O
power O
. O

A O
new O
strawberry O
spread O
formulated O
with O
fructose B
and O
isomaltulose O
( O
replacing O
sucrose B
partially O
or O
totally O
) O
and O
a O
high O
percentage O
of O
fruit O
was O
developed O
in O
line O
with O
the O
new O
trend O
of O
healthier O
products O
. O

This O
work O
studies O
the O
influence O
of O
some O
process O
variables O
( O
percentage O
of O
sugar B
, O
pectin O
and O
citric B
acid I
, O
and O
time O
of O
thermal O
treatment O
) O
on O
the O
volatile O
profile O
of O
these O
spreads O
with O
different O
formulations O
. O

Most O
of O
the O
esters B
and O
alcohols B
decreased O
whereas O
13 O
new O
compounds O
appear O
, O
mostly O
furans O
( O
furfural B
, O
2 O
- O
acetylfurane O
, O
5 O
- O
methyl O
furfural O
, O
mesifurane O
) O
and O
aldehydes B
( O
octanal B
, O
nonanal O
, O
decanal O
and O
benzaldeyhde O
) O
. O

In O
general O
, O
the O
spreads O
formulated O
with O
sucrose B
- O
isomaltulose O
that O
contained O
higher O
levels O
of O
pectin O
and O
citric B
acid I
gave O
better O
results O
in O
the O
preservation O
of O
the O
original O
aromatic O
compounds O
in O
raw O
strawberries O
. O

The O
original O
ABTS B
method O
was O
thus O
improved O
, O
and O
in O
particular O
the O
procedures O
of O
cell O
disruption O
and O
storage O
were O
optimized O
. O

The O
best O
solvent O
found O
was O
ethanol B
/ O
water O
( O
1 O
: O
1 O
, O
v O
/ O
v O
) O
. O

The O
reaction O
to O
form O
ABTS B
( I
+ I
) I
in O
said O
solvent O
was O
essentially O
complete O
by O
eight O
hours O
, O
and O
this O
radical O
cation O
was O
stable O
for O
at O
least O
6 O
days O
; O
at O
room O
temperature O
, O
the O
ABTS B
( I
+ I
) I
solution O
remained O
within O
an O
allowable O
analytical O
range O
for O
up O
to O
13 O
h O
. O

Biogenic O
amines B
formation O
in O
Streptococcus O
thermophilus O
isolated O
from O
home O
- O
made O
natural O
yogurt O
. O

Twelve O
different O
biogenic O
amines B
formation O
in O
58 O
isolates O
of O
Streptococcus O
thermophilus O
from O
home O
- O
made O
natural O
yogurt O
were O
investigated O
in O
histidine B
( O
HDB O
) O
and O
lysine B
decarboxylase O
broth O
( O
LDB O
) O
. O

All O
S O
. O
thermophilus O
isolates O
had O
an O
ability O
to O
produce O
twelve O
different O
biogenic O
amines B
in O
HDB O
and O
LDB O
. O

Most O
of O
the O
S O
. O
thermophilus O
isolates O
formed O
low O
amounts O
of O
histamine B
( O
1 O
- O
50 O
mg O
/ O
L O
) O
from O
histidine B
. O

Apart O
from O
one O
isolate O
, O
S O
. O
thermophilus O
produced O
tyramine B
at O
low O
( O
47 O
isolates O
) O
and O
medium O
( O
10 O
isolates O
) O
levels O
. O

The O
amount O
of O
each O
specific O
biogenic O
amine B
produced O
by O
S O
. O
thermophilus O
was O
generally O
lower O
than O
100 O
mg O
L O
( O
- O
1 O
) O
. O

Also O
, O
the O
presence O
of O
hdcA O
gene O
was O
investigated O
using O
PCR O
technique O
and O
relation O
between O
gene O
and O
histamine B
production O
was O
conducted O
in O
S O
. O
thermophilus O
isolates O
. O

This O
study O
showed O
that O
most O
of O
the O
S O
. O
thermophilus O
isolates O
have O
the O
ability O
to O
form O
biogenic O
amines B
, O
especially O
histamine B
, O
and O
tyramine B
, O
which O
is O
an O
important O
consideration O
when O
selecting O
strains O
as O
starter O
cultures O
. O

Shelf O
- O
life O
of O
the O
roasted O
almonds O
was O
determined O
by O
measuring O
the O
changes O
in O
colour O
, O
peroxide B
value O
, O
moisture O
content O
, O
water O
activity O
, O
volatile O
components O
and O
sensory O
quality O
. O

GC O
/ O
MS O
analysis O
showed O
that O
aldehydes B
, O
alcohols B
, O
and O
pyrazines O
were O
the O
main O
volatile O
components O
of O
almonds O
. O

Aliphatic B
aldehydes I
such O
as O
hexanal O
, O
( O
E O
) O
- O
2 O
- O
octenal O
, O
and O
nonanal O
were O
produced O
as O
off O
- O
odours O
during O
storage O
. O

Although O
the O
overall O
quality O
of O
roasted O
almonds O
produced O
with O
SIRHA O
and O
HA O
heating O
was O
similar O
during O
the O
first O
three O
months O
of O
storage O
, O
their O
peroxide B
value O
and O
concentration O
of O
aliphatic B
aldehydes I
differed O
significantly O
for O
different O
roasting O
methods O
and O
increased O
significantly O
in O
all O
roasted O
samples O
during O
storage O
. O

We O
postulate O
that O
hexanal O
and O
nonanal O
might O
be O
better O
indicators O
of O
the O
shelf O
life O
of O
roasted O
almonds O
than O
the O
current O
standard O
, O
peroxide B
value O
. O

Novel O
limonene B
and O
citral B
based O
2 O
, O
5 O
- O
disubstituted O
- O
1 O
, O
3 O
, O
4 O
- O
oxadiazoles O
: O
a O
natural O
product O
coupled O
approach O
to O
semicarbazones O
for O
antiepileptic O
activity O
. O

The O
anticonvulsant O
activities O
of O
the O
compounds O
were O
investigated O
using O
maximal O
electroshock O
seizure O
( O
MES O
) O
, O
subcutaneous O
pentylenetrtrazole O
( O
scPTZ O
) O
and O
subcutaneous O
strychnine B
( O
scSTY O
) O
models O
. O

Some O
of O
the O
selected O
active O
compounds O
were O
subjected O
to O
GABA B
assay O
to O
confirm O
their O
mode O
of O
action O
. O

Lead O
optimization O
of O
isocytosine O
- O
derived O
xanthine B
oxidase O
inhibitors O
. O

We O
report O
our O
attempts O
at O
improving O
the O
oral O
efficacy O
of O
low O
- O
nanomolar O
inhibitors O
of O
xanthine B
oxidase O
from O
isocytosine O
series O
through O
chemical O
modifications O
. O

Preliminary O
structure O
- O
activity O
relationship O
investigation O
identified O
essentiality O
of O
the O
spermine B
polyamine B
core O
and O
the O
requirement O
for O
1 O
, O
14 O
- O
disubstitution O
for O
potent O
activity O
. O

Our O
lead O
compound O
for O
a O
phosphoinositide O
3 O
- O
kinase O
( O
PI3K O
) O
inhibitor O
( O
1 O
) O
was O
metabolically O
unstable O
because O
of O
rapid O
glucuronidation O
of O
the O
phenol B
moiety O
. O

Based O
on O
structure O
- O
activity O
relationship O
( O
SAR O
) O
information O
and O
a O
FlexSIS O
docking O
simulation O
score O
, O
aminopyrimidine O
was O
identified O
as O
a O
bioisostere O
of O
phenol B
. O

An O
X O
- O
ray O
structure O
study O
revealed O
a O
hydrogen B
bonding O
pattern O
of O
aminopyrimidine O
derivatives O
. O

We O
describe O
here O
the O
design O
and O
development O
of O
a O
new O
heterobivalent O
peptide O
ligand O
, O
truncated O
bombesin B
( O
t O
- O
BBN O
) O
/ O
BVD15 O
- O
DO3A O
, O
for O
dual O
- O
targeting O
of O
GRPR O
and O
Y1 O
, O
and O
validation O
of O
its O
dual O
binding O
capability O
. O

Competitive O
displacement O
binding O
assays O
using O
t O
- O
BBN O
/ O
BVD15 O
- O
DO3A O
against O
( B
125 I
) I
I I
- O
Tyr B
( O
4 O
) O
- O
BBN O
yielded O
an O
IC O
( O
50 O
) O
value O
of O
18 O
+ O
/ O
- O
0 O
. O
7 O
nM O
for O
GRPR O
in O
T O
- O
47D O
cells O
, O
a O
human O
breast O
cancer O
cell O
line O
. O

A O
similar O
assay O
using O
t O
- O
BBN O
/ O
BVD15 O
- O
DO3A O
against O
porcine O
( B
125 I
) I
I I
- O
NPY O
showed O
IC O
( O
50 O
) O
values O
of O
80 O
+ O
/ O
- O
11 O
nM O
for O
Y1 O
receptor O
in O
MCF7 O
cells O
, O
another O
human O
breast O
cancer O
cell O
line O
. O

Discovery O
and O
optimization O
of O
potent O
broad O
- O
spectrum O
arenavirus O
inhibitors O
derived O
from O
benzimidazole B
. O

High O
- O
throughput O
screening O
resulted O
in O
discovery O
of O
a O
hit O
compound O
( O
ST O
- O
37 O
) O
possessing O
a O
benzimidazole B
core O
which O
led O
to O
a O
potent O
compound O
series O
. O

Herein O
, O
we O
report O
SAR O
studies O
which O
involved O
structural O
modifications O
to O
the O
phenyl B
rings O
and O
methylamino O
linker O
portion O
attached O
to O
the O
benzimidazole B
core O
. O

Compounds O
in O
this O
benzimidazole B
series O
also O
exhibited O
nanomolar O
antiviral O
activity O
against O
pseudotypes O
generated O
from O
other O
arenavirus O
envelopes O
indicating O
the O
potential O
for O
development O
of O
a O
broad O
- O
spectrum O
inhibitor O
. O

These O
neurotoxins O
display O
different O
biochemical O
activities O
, O
but O
similarly O
alter O
the O
presynaptic O
membrane O
permeability O
causing O
Ca B
( I
2 I
+ I
) I
overload O
within O
the O
nerve O
terminals O
, O
which O
in O
turn O
induces O
nerve O
degeneration O
. O

Using O
different O
methods O
, O
here O
we O
show O
that O
the O
calcium B
- O
activated O
proteases O
calpains O
are O
involved O
in O
the O
cytoskeletal O
rearrangements O
that O
we O
have O
previously O
documented O
in O
neurons O
exposed O
to O
alpha O
- O
latrotoxin O
or O
to O
snake O
presynaptic O
phospholipases O
A2 O
neurotoxins O
. O

These O
results O
indicate O
that O
calpains O
, O
activated O
by O
the O
massive O
calcium B
influx O
from O
the O
extracellular O
medium O
, O
target O
fundamental O
components O
of O
neuronal O
cytoskeleton O
such O
as O
spectrin O
and O
neurofilaments O
, O
whose O
cleavage O
is O
functional O
to O
the O
ensuing O
nerve O
terminal O
fragmentation O
. O

The O
picrate O
paper O
procedure O
detected O
no O
cyanide B
in O
the O
plant O
roots O
, O
but O
the O
reaction O
used O
for O
nitrate B
detection O
gave O
a O
strongly O
positive O
response O
. O

Retinol B
deprivation O
partially O
rescues O
the O
skeletal O
mineralization O
defects O
of O
Phex O
- O
deficient O
Hyp O
mice O
. O

Since O
several O
experiments O
involving O
Phex O
- O
deficient O
Hyp O
mice O
have O
demonstrated O
that O
an O
increased O
expression O
of O
Fgf23 O
in O
osteoblasts O
is O
causative O
for O
the O
renal O
phosphate B
loss O
characteristic O
of O
XLH O
, O
we O
performed O
genome O
- O
wide O
expression O
analysis O
to O
compare O
differentiated O
osteoblasts O
from O
wildtype O
and O
Hyp O
mice O
. O

Here O
we O
did O
not O
only O
observe O
the O
expected O
increase O
of O
Fgf23 O
expression O
in O
the O
latter O
ones O
, O
but O
also O
a O
differential O
expression O
of O
genes O
that O
are O
either O
induced O
by O
or O
involved O
in O
retinoic B
acid I
signaling O
, O
which O
led O
us O
to O
analyze O
whether O
dietary O
retinol B
deprivation O
would O
influence O
the O
phenotype O
of O
Hyp O
mice O
. O

When O
we O
fed O
the O
same O
diet O
for O
24 O
weeks O
the O
amount O
of O
non O
- O
mineralized O
bone O
matrix O
( O
osteoid O
) O
was O
reduced O
by O
more O
than O
70 O
% O
, O
although O
phosphate B
homeostasis O
was O
unaffected O
. O

In O
contrast O
, O
a O
dietary O
normalization O
of O
serum O
phosphate B
levels O
in O
Hyp O
mice O
reduced O
the O
osteoid O
amount O
by O
less O
than O
30 O
% O
, O
thereby O
demonstrating O
a O
previously O
unknown O
impact O
of O
retinol O
on O
the O
cell O
- O
autonomous O
mineralization O
defect O
of O
Phex O
- O
deficient O
osteoblasts O
. O

Effects O
of O
baicalein B
on O
apoptosis O
, O
cell O
cycle O
arrest O
, O
migration O
and O
invasion O
of O
osteosarcoma O
cells O
. O

Baicalein B
is O
a O
bioactive O
flavonoid B
that O
is O
widely O
used O
in O
ancient O
China O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effects O
of O
baicalein B
in O
osteosarcoma O
cells O
. O

Our O
results O
indicate O
baicalein B
might O
be O
an O
efficacious O
anti O
- O
osteosarcoma O
drug O
. O

We O
found O
that O
baicalein B
could O
inhibit O
cell O
proliferation O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

Additionally O
, O
we O
demonstrated O
that O
baicalein B
promotes O
osteosarcoma O
cell O
apoptosis O
, O
and O
our O
mechanistic O
studies O
suggest O
that O
this O
is O
mediated O
by O
caspase O
activation O
, O
especially O
caspase O
- O
3 O
. O

We O
also O
showed O
that O
the O
down O
- O
regulation O
of O
Bcl O
- O
2 O
and O
concurrent O
increase O
in O
Bax O
and O
Bim O
levels O
contribute O
to O
the O
apoptosis O
induced O
by O
baicalein B
. O

In O
addition O
, O
we O
observed O
that O
baicalein B
induces O
G1 O
cell O
cycle O
arrest O
by O
decreasing O
cyclin O
D1 O
and O
cyclin O
- O
dependent O
kinase O
4 O
( O
CDK4 O
) O
. O

Furthermore O
, O
our O
data O
verifies O
that O
baicalein B
can O
reduce O
osteosarcoma O
cell O
adhesion O
, O
migration O
and O
invasion O
in O
vitro O
, O
which O
indicates O
its O
potential O
to O
inhibit O
osteosarcoma O
metastasis O
. O

The O
decrease O
in O
expression O
of O
matrix O
metalloproteinases O
( O
MMP O
) O
- O
2 O
and O
MMP O
- O
9 O
may O
contribute O
to O
the O
effects O
of O
baicalein B
. O

Taken O
together O
, O
our O
results O
provide O
evidence O
that O
baicalein B
plays O
important O
roles O
in O
anti O
- O
osteosarcoma O
therapy O
, O
and O
thus O
may O
serve O
as O
a O
novel O
and O
efficient O
candidate O
agent O
for O
osteosarcoma O
treatment O
. O

Tri O
- O
and O
diorganotin O
( O
IV O
) O
orotates O
of O
general O
formula O
, O
R O
( O
n O
) O
Sn O
( O
H O
( O
2 O
) O
Or O
) O
( O
m O
) O
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n O
- O
Bu O
, O
n O
- O
Oct O
and O
Ph B
; O
H O
( O
2 O
) O
Or O
( O
- O
) O
= O
monoanion O
of O
orotic O
acid O
( O
H O
( O
3 O
) O
Or O
) O
] O
( O
n O
- O
Bu O
( O
2 O
) O
Sn O
( O
HOr O
) O
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Determination O
of O
bioactive O
, O
free O
isothiocyanates B
from O
a O
glucosinolate O
- O
containing O
phytotherapeutic O
agent O
: O
a O
pilot O
study O
with O
in O
vitro O
models O
and O
human O
intervention O
. O

Isothiocyanates B
( O
ITCs O
) O
derived O
from O
plants O
of O
the O
order O
Brassicales O
are O
known O
for O
their O
antibacterial O
, O
anti O
- O
inflammatory O
or O
anticarcinogenic O
potential O
. O

Furthermore O
, O
in O
human O
urine O
conversion O
of O
the O
ultimate O
, O
inactive O
mercapturic B
acid I
conjugate O
back O
into O
its O
corresponding O
bioactive O
form O
is O
increased O
at O
alkaline O
as O
compared O
to O
neutral O
pH O
. O

We O
observed O
that O
cytarabine B
promotes O
multiple O
myeloma O
( O
MM O
) O
cell O
escape O
and O
that O
the O
number O
of O
cells O
in O
the O
lower O
chamber O
increased O
with O
increasing O
clinical O
disease O
stage O
in O
in O
vitro O
model O
which O
was O
constructed O
by O
a O
Boyden O
chamber O
, O
matrigel O
glue O
and O
serum O
from O
MM O
patients O
in O
different O
disease O
stages O
. O

The O
mechanism O
of O
cytarabine B
that O
promotes O
MM O
cell O
escape O
is O
closely O
associated O
with O
the O
up O
- O
regulation O
of O
CXCR4 O
. O

Fucoidan O
, O
a O
sulfated O
polysaccharide O
in O
the O
cell O
wall O
matrix O
of O
brown O
algae O
, O
has O
attracted O
much O
attention O
for O
its O
multiple O
biological O
activities O
, O
and O
we O
further O
explored O
the O
effects O
and O
possible O
underlying O
mechanisms O
of O
fucoidan O
on O
MM O
cell O
escape O
from O
cytarabine B
cytotoxicity O
. O

The O
results O
show O
that O
fucoidan O
may O
decrease O
MM O
cell O
escape O
from O
cytarabine B
cytotoxicity O
, O
and O
that O
fucoidan O
can O
down O
- O
regulate O
CXCR4 O
, O
MMP9 O
and O
RHoC O
expression O
. O

Fourteen O
sterols B
( O
1 O
- O
14 O
) O
, O
including O
two O
new O
sterols B
, O
trihydroxysitosterol O
( O
2 O
) O
and O
5 O
alpha O
, O
6 O
beta O
, O
7 O
alpha O
- O
7 O
alpha O
- O
acetoxysitosterol O
( O
3 O
) O
, O
were O
isolated O
from O
the O
branches O
and O
leaves O
of O
Phyllanthus O
emblica O
L O
. O

The O
isolated O
compounds O
and O
a O
structurally O
related O
sterol B
15 O
from O
Aphanamixis O
grandifolia O
were O
screened O
for O
cytotoxicity O
in O
two O
tumor O
cell O
lines O
( O
HL O
- O
60 O
and O
SMMC O
- O
7721 O
) O
and O
a O
non O
- O
tumor O
cell O
line O
( O
HL O
- O
7702 O
) O
using O
RSB O
assay O
. O

HTS O
of O
2560 O
small O
molecules O
to O
search O
for O
inhibitory O
compounds O
yielded O
several O
hits O
, O
including O
suramin B
, O
doxorubicin B
and O
ellagic B
acid I
. O

Both O
suramin B
and O
doxorubicin B
are O
potent O
( O
low O
- O
micro O
M O
) O
DNA O
- O
and O
nucleotide O
triphosphate O
- O
competitive O
priming O
inhibitors O
that O
interact O
with O
more O
than O
one O
site O
on O
Mtb O
DnaG O
. O

A O
series O
of O
substituted O
ortho O
- O
carboranylphenoxyace O
were O
synthesized O
and O
evaluated O
for O
their O
ability O
to O
inhibit O
hypoxia O
- O
induced O
HIF O
- O
1 O
transcriptional O
activity O
using O
a O
cell O
- O
based O
reporter O
assay O
in O
HeLa O
cells O
expressing O
the O
HRE O
- O
dependent O
firefly O
luciferase O
reporter O
construct O
( O
HRE O
- O
Luc O
) O
and O
constitutively O
expressing O
CMV O
- O
driven O
Renilla O
luciferase O
reporter O
, O
and O
their O
ability O
to O
inhibit O
cell O
growth O
( O
GI O
( O
50 O
) O
) O
using O
the O
MTT B
assay O
. O

The O
porcine O
heart O
malate B
dehydrogenase O
( O
MDH O
) O
refolding O
assay O
revealed O
that O
compound O
1l O
inhibited O
human O
Hsp60 O
chaperone O
activity O
( O
IC O
( O
50 O
) O
: O
6 O
. O
80 O
+ O
/ O
- O
0 O
. O
25 O
mu O
M O
) O
and O
this O
inhibition O
activity O
was O
higher O
than O
that O
of O
ETB O
( O
IC O
( O
50 O
) O
: O
10 O
. O
9 O
+ O
/ O
- O
0 O
. O
63 O
mu O
M O
) O
. O

NMDA B
and O
AMPA B
receptor O
mediated O
excitotoxicity O
in O
cerebral O
cortex O
of O
streptozotocin B
induced O
diabetic O
rat O
: O
ameliorating O
effects O
of O
curcumin B
. O

We O
evaluated O
the O
neuroprotective O
effect O
of O
curcumin B
in O
glutamate B
mediated O
excitotoxicity O
in O
cerebral O
cortex O
of O
streptozotocin B
induced O
diabetic O
rats O
. O

Gene O
expression O
studies O
in O
diabetic O
rats O
showed O
a O
down O
regulation O
of O
glutamate B
decarboxylase O
mRNA O
leading O
to O
accumulation O
of O
glutamate B
. O

Radioreceptor O
binding O
assays O
showed O
a O
significant O
increase O
in O
alpha O
- O
amino O
- O
3 O
- O
hydroxy O
- O
5 O
- O
methyl O
- O
4 O
- O
isoxazole O
propionate O
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
density O
which O
was O
confirmed O
by O
immunohistochemical O
studies O
. O

Decreased O
glutathione B
peroxidases O
gene O
expression O
indicates O
enhanced O
oxidative O
stress O
in O
diabetic O
rats O
. O

This O
leads O
to O
decreased O
expression O
of O
glutamate B
aspartate B
transporter O
, O
which O
in O
turn O
reduces O
glutamate B
transport O
. O

Curcumin B
and O
insulin O
treatment O
reversed O
these O
altered O
parameters O
to O
near O
control O
. O

We O
establish O
, O
a O
novel O
therapeutic O
role O
of O
curcumin B
by O
reducing O
the O
glutamate B
mediated O
excitotoxicity O
in O
cerebral O
cortex O
of O
diabetes O
through O
modulating O
the O
altered O
neurochemical O
parameters O
. O

Neu2000 O
[ O
2 O
- O
hydroxy O
- O
5 O
- O
( O
2 O
, O
3 O
, O
5 O
, O
6 O
- O
tetrafluoro O
- O
4 O
trifluoromethylbenzy O
) O
benzoic O
acid O
] O
is O
a O
dual O
- O
acting O
neuroprotective O
agent O
that O
functions O
both O
as O
a O
noncompetitive O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA O
) O
receptor O
antagonist O
and O
a O
free O
radical O
scavenger O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
scavenging O
activity O
of O
Neu2000 O
on O
various O
classes O
of O
reactive O
oxygen B
species O
and O
reactive O
nitrogen B
species O
( O
ROS O
/ O
RNS O
) O
as O
well O
as O
its O
efficacy O
for O
reducing O
free O
radicals O
and O
oxidative O
stress O
/ O
damage O
induced O
in O
spinal O
cord O
mitochondrial O
preparations O
. O

Neu2000 O
exerted O
scavenging O
activity O
against O
superoxide B
, O
nitric B
oxide I
, O
and O
hydroxyl B
radicals O
, O
and O
efficiently O
scavenged O
peroxynitrite B
. O

In O
the O
mitochondrial O
studies O
, O
Neu2000 O
markedly O
inhibited O
ROS O
/ O
RNS O
and O
hydrogen B
peroxide I
levels O
following O
antimycin O
treatment O
. O

In O
addition O
, O
Neu2000 O
effectively O
scavenged O
hydroxyl B
radicals O
generated O
by O
iron O
( O
III O
) O
- O
ascorbate O
, O
reduced O
protein O
carbonyl B
formation O
mediated O
by O
hydroxyl B
radicals O
and O
peroxynitrite B
, O
and O
prevented O
glutathione B
oxidation O
caused O
by O
tert B
- I
butyl I
hydroperoxide I
in O
isolated O
mitochondria O
. O

The O
results O
of O
the O
present O
study O
demonstrate O
that O
Neu2000 O
possesses O
potent O
in O
vitro O
antioxidant O
activity O
due O
, O
most O
likely O
, O
to O
its O
active O
phenoxy B
group O
. O

GBSA O
: O
a O
comprehensive O
software O
for O
analysing O
whole O
genome O
bisulfite B
sequencing O
data O
. O

High O
- O
throughput O
sequencing O
is O
increasingly O
being O
used O
in O
combination O
with O
bisulfite B
( O
BS O
) O
assays O
to O
study O
DNA O
methylation O
at O
nucleotide B
resolution O
. O

Here O
, O
we O
present O
Genome O
Bisulfite B
Sequencing O
Analyser O
( O
GBSA O
- O
http O
: O
/ O
/ O
ctrad O
- O
csi O
. O
nus O
. O
edu O
. O
sg O
/ O
gbsa O
) O
, O
a O
free O
open O
- O
source O
software O
capable O
of O
analysing O
whole O
- O
genome O
bisulfite B
sequencing O
data O
with O
either O
a O
gene O
- O
centric O
or O
gene O
- O
independent O
focus O
. O

Mitochondrial O
Permeability O
Transition O
Pore O
Inhibitors O
Prevent O
Ethanol B
- O
Induced O
Neuronal O
Death O
in O
Mice O
. O

Ethanol B
induces O
brain O
injury O
by O
a O
mechanism O
that O
remains O
partly O
unknown O
. O

Here O
, O
we O
tested O
the O
effect O
of O
ethanol B
and O
PTP O
inhibitors O
on O
mitochondrial O
physiology O
and O
cell O
viability O
both O
in O
vitro O
and O
in O
vivo O
. O

Direct O
addition O
of O
ethanol B
up O
to O
100 O
mM O
on O
isolated O
mouse O
brain O
mitochondria O
slightly O
decreased O
oxygen B
consumption O
but O
did O
not O
affect O
PTP O
regulation O
. O

In O
comparison O
, O
when O
isolated O
from O
ethanol B
- O
treated O
( O
two O
doses O
of O
2 O
g O
/ O
kg O
, O
2 O
h O
apart O
) O
7 O
- O
day O
- O
old O
mouse O
pups O
, O
brain O
mitochondria O
displayed O
a O
transient O
decrease O
in O
oxygen B
consumption O
but O
no O
change O
in O
PTP O
regulation O
or O
H B
( I
2 I
) I
O I
( I
2 I
) I
production O
. O

Conversely O
, O
exposure O
of O
primary O
cultured O
astrocytes O
and O
neurons O
to O
20 O
mM O
ethanol B
for O
3 O
days O
led O
to O
a O
transient O
PTP O
opening O
in O
astrocytes O
without O
affecting O
cell O
viability O
and O
to O
a O
permanent O
PTP O
opening O
in O
10 O
to O
20 O
% O
neurons O
with O
the O
same O
percentage O
of O
cell O
death O
. O

Ethanol B
- O
treated O
mouse O
pups O
displayed O
a O
widespread O
caspase O
- O
3 O
activation O
in O
neurons O
but O
not O
in O
astrocytes O
and O
dramatic O
behavioral O
alterations O
. O

Interestingly O
, O
two O
different O
PTP O
inhibitors O
( O
namely O
, O
cyclosporin O
A O
and O
nortriptyline B
) O
prevented O
both O
ethanol B
- O
induced O
neuronal O
death O
in O
vivo O
and O
ethanol B
- O
induced O
behavioral O
modifications O
. O

We O
conclude O
that O
PTP O
opening O
is O
involved O
in O
ethanol B
- O
induced O
neurotoxicity O
in O
the O
mouse O
. O

The O
selective O
metabotropic O
glutamate B
2 O
/ O
3 O
receptor O
agonist O
MGS0028 O
reverses O
psychomotor O
abnormalities O
and O
recognition O
memory O
deficits O
in O
mice O
lacking O
the O
pituitary O
adenylate O
cyclase O
- O
activating O
polypeptide O
. O

Previous O
studies O
suggest O
that O
metabotropic O
glutamate B
2 O
/ O
3 O
receptors O
are O
involved O
in O
psychiatric O
disorders O
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
the O
selective O
metabotropic O
glutamate B
2 O
/ O
3 O
( O
mGlu2 O
/ O
3 O
) O
receptor O
agonist O
MGS0028 O
on O
behavioral O
abnormalities O
in O
mice O
lacking O
the O
pituitary O
adenylate O
cyclase O
- O
activating O
polypeptide O
( O
PACAP O
) O
, O
an O
experimental O
model O
of O
psychiatric O
disorders O
such O
as O
schizophrenia O
and O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

Differential O
Effects O
of O
Crambescins O
and O
Crambescidin O
816 O
in O
Voltage O
- O
Gated O
Sodium B
, O
Potassium B
and O
Calcium B
Channels O
in O
Neurons O
. O

Although O
very O
little O
information O
about O
their O
biological O
effect O
has O
been O
reported O
, O
it O
is O
known O
that O
crambescidin O
816 O
( O
Cramb816 O
) O
blocks O
calcium B
channels O
in O
a O
neuroblastoma O
X O
glioma O
cell O
line O
. O

Taking O
this O
into O
account O
, O
and O
the O
fact O
that O
ion O
channels O
are O
frequent O
targets O
for O
natural O
toxins O
, O
we O
examined O
the O
effect O
of O
Cramb816 O
and O
three O
compounds O
from O
the O
crambescin O
family O
, O
norcrambescin O
A2 O
( O
NcrambA2 O
) O
, O
crambescin O
A2 O
( O
CrambA2 O
) O
, O
and O
crambescin O
C1 O
( O
CrambC1 O
) O
, O
in O
the O
main O
voltage O
- O
dependent O
ion O
channels O
in O
neurons O
: O
sodium B
, O
potassium B
, O
and O
calcium B
channels O
. O

Electrophysiological O
recordings O
of O
voltage O
gated O
sodium B
, O
potassium B
, O
and O
calcium B
currents O
, O
in O
the O
presence O
of O
these O
guanidine O
alkaloids O
, O
were O
performed O
in O
cortical O
neurons O
from O
embryonic O
mice O
. O

Different O
effects O
were O
discovered O
: O
crambescins O
inhibited O
K B
( I
+ I
) I
currents O
with O
the O
following O
potency O
: O
NcrambA2 O
> O
CrambC1 O
> O
CrambA2 O
, O
while O
Cramb816 O
lacked O
an O
effect O
. O

Only O
CrambC1 O
and O
Cramb816 O
partially O
blocked O
Na B
( I
+ I
) I
total O
current O
. O

However O
, O
Cramb816 O
partially O
blocked O
Ca B
( I
2 I
+ I
) I
, O
while O
NcrambA2 O
did O
not O
. O

Since O
the O
blocking O
effect O
of O
Cramb816 O
on O
calcium B
currents O
has O
not O
been O
previously O
reported O
in O
detail O
, O
we O
further O
pharmacologically O
isolated O
the O
two O
main O
fractions O
of O
HVA O
Ca B
( I
2 I
+ I
) I
channels O
in O
neurons O
and O
investigated O
the O
Cramb816 O
effect O
on O
them O
. O

Here O
, O
we O
revealed O
that O
Cav1 O
or O
L O
- O
type O
calcium B
channels O
are O
the O
main O
target O
for O
Cramb816 O
. O

These O
two O
families O
of O
guanidine O
alkaloids O
clearly O
showed O
a O
structure O
- O
activity O
relationship O
with O
the O
crambescins O
acting O
on O
voltage O
- O
gated O
potassium B
channels O
, O
while O
Cramb816 O
blocks O
the O
voltage O
- O
gated O
calcium B
channel O
Cav1 O
with O
higher O
potency O
than O
nifedipine B
. O

The O
novel O
evidence O
that O
Cramb816 O
partially O
blocked O
Ca B
( O
V O
) O
and O
Na B
( O
V O
) O
channels O
in O
neurons O
suggests O
that O
this O
compound O
might O
be O
involved O
in O
decreasing O
the O
neurotransmitter O
release O
and O
synaptic O
transmission O
in O
the O
central O
nervous O
system O
. O

The O
findings O
presented O
here O
provide O
the O
first O
detailed O
approach O
on O
the O
different O
effects O
of O
crambescin O
and O
crambescidin O
compounds O
in O
voltage O
- O
gated O
sodium B
, O
potassium B
, O
and O
calcium B
channels O
in O
neurons O
and O
thus O
provide O
a O
basis O
for O
future O
studies O
. O

This O
toxin O
has O
been O
shown O
to O
induce O
protein O
synthesis O
inhibition O
as O
well O
as O
inhibition O
of O
glutathione B
synthesis O
. O

The O
involvement O
of O
reactive O
oxygen B
species O
in O
toxin O
induced O
cell O
death O
, O
the O
relationship O
between O
protein O
synthesis O
inhibition O
and O
toxicity O
, O
and O
the O
cell O
endogenous O
antioxidant O
response O
regulation O
were O
studied O
. O

Since O
the O
bulky O
mesityl B
groups O
of O
the O
ligand O
hang O
over O
the O
cage O
cavity O
, O
the O
effective O
cavity O
volume O
is O
reduced O
. O

Synthesis O
and O
insight O
into O
the O
structure O
- O
activity O
relationships O
of O
chalcones B
as O
antimalarial O
agents O
. O

In O
continuation O
of O
our O
drug O
discovery O
program O
, O
we O
isolated O
two O
similar O
chalcones B
, O
medicagenin O
( O
II O
) O
and O
munchiwarin O
( O
III O
) O
, O
from O
Crotalaria O
medicagenia O
, O
which O
exhibited O
antimalarial O
activity O
against O
Plasmodium O
falciparum O
. O

A O
library O
of O
88 O
chalcones B
were O
synthesized O
and O
evaluated O
for O
their O
in O
vitro O
antimalarial O
activity O
. O

These O
chalcones B
also O
showed O
reduction O
in O
parasitemia O
and O
increased O
survival O
time O
of O
Swiss O
mice O
infected O
with O
Plasmodium O
yoelii O
( O
strain O
N O
- O
67 O
) O
. O

We O
hypothesized O
that O
conformational O
resemblance O
of O
semirigid O
scaffolds O
expressing O
amino B
acid I
side O
- O
chains O
to O
PPI O
- O
interface O
regions O
could O
guide O
this O
process O
. O

Conformations O
of O
one O
such O
chemotype O
( O
1aaa O
; O
all O
methyl B
side O
- O
chains O
) O
matched O
several O
biomedically O
significant O
PPIs O
, O
including O
the O
dimerization O
interface O
of O
HIV O
- O
1 O
protease O
. O

Coming O
full O
circle O
: O
contributions O
of O
central O
and O
peripheral O
oxytocin B
actions O
to O
energy O
balance O
. O

The O
neuropeptide O
oxytocin B
has O
emerged O
as O
an O
important O
anorexigen O
in O
the O
regulation O
of O
energy O
balance O
. O

Pharmacologic O
and O
pair O
- O
feeding O
studies O
indicate O
that O
its O
ability O
to O
reduce O
body O
mass O
extends O
beyond O
that O
of O
food O
intake O
, O
affecting O
multiple O
factors O
that O
determine O
energy O
balance O
such O
as O
energy O
expenditure O
, O
lipolysis O
, O
and O
glucose B
regulation O
. O

Systemic O
administration O
of O
oxytocin B
recapitulates O
many O
of O
its O
effects O
when O
administered O
centrally O
, O
raising O
the O
questions O
of O
whether O
and O
to O
what O
extent O
circulating O
oxytocin B
contributes O
to O
energy O
regulation O
. O

Its O
therapeutic O
potential O
to O
treat O
metabolic O
conditions O
remains O
to O
be O
determined O
, O
but O
data O
from O
diet O
- O
induced O
and O
genetically O
obese O
rodent O
models O
as O
well O
as O
application O
of O
oxytocin B
in O
humans O
in O
other O
areas O
of O
research O
have O
revealed O
promising O
results O
thus O
far O
. O

The O
interactions O
of O
apamin O
and O
tetraethylammonium B
are O
differentially O
affected O
by O
single O
mutations O
in O
the O
pore O
mouth O
of O
small O
conductance O
calcium B
- O
activated O
potassium B
( O
SK O
) O
channels O
. O

Valine B
residues O
in O
the O
pore O
region O
of O
SK2 O
( O
V366 O
) O
and O
SK3 O
( O
V520 O
) O
were O
replaced O
by O
either O
an O
alanine B
or O
a O
phenylalanine B
to O
evaluate O
the O
impact O
on O
the O
interactions O
with O
the O
allosteric O
blocker O
apamin O
. O

Unlike O
TEA B
which O
showed O
high O
sensitivity O
to O
phenylalanine B
mutated O
channels O
, O
the O
binding O
affinity O
of O
apamin O
to O
the O
phenylalanine B
mutants O
was O
strongly O
reduced O
. O

In O
addition O
, O
currents O
from O
phenylalanine B
mutants O
were O
largely O
resistant O
to O
block O
by O
apamin O
. O

On O
the O
other O
hand O
, O
when O
the O
valine B
residue O
was O
replaced O
by O
an O
alanine B
residue O
, O
an O
increase O
of O
the O
binding O
affinity O
and O
the O
amount O
of O
block O
by O
apamin O
was O
observed O
for O
alanine B
mutated O
SK2 O
channels O
, O
but O
not O
for O
mutated O
SK3 O
channels O
. O

Interestingly O
, O
the O
VA O
mutation O
reduced O
the O
sensitivity O
to O
TEA B
. O

Curcumin B
reverses O
glomerular O
hemodynamic O
alterations O
and O
oxidant O
stress O
in O
5 O
/ O
6 O
nephrectomized O
rats O
. O

The O
administration O
of O
curcumin B
before O
and O
throughout O
the O
study O
attenuates O
oxidant O
stress O
and O
glomerular O
hemodynamic O
alterations O
induced O
by O
5 O
/ O
6 O
nephrectomy O
( O
5 O
/ O
6NX O
) O
. O

The O
purpose O
of O
this O
work O
was O
to O
study O
if O
curcumin B
is O
able O
to O
reverse O
established O
glomerular O
hemodynamic O
alterations O
( O
e O
. O
g O
. O
hyperfiltration O
and O
glomerular O
hypertension O
) O
and O
oxidant O
stress O
in O
rats O
with O
5 O
/ O
6NX O
. O

Curcumin B
( O
120 O
mg O
/ O
kg O
) O
was O
given O
to O
rats O
with O
established O
renal O
injury O
( O
30 O
days O
after O
surgery O
) O
and O
continued O
for O
30 O
days O
( O
days O
31 O
- O
60 O
of O
the O
study O
) O
. O

Curcumin B
was O
able O
( O
a O
) O
to O
reverse O
5 O
/ O
6NX O
- O
induced O
glomerular O
hypertension O
and O
hyperfiltration O
, O
( O
b O
) O
to O
induce O
cell O
proliferation O
and O
nuclear O
translocation O
of O
Nrf2 O
and O
( O
c O
) O
to O
reverse O
5 O
/ O
6NX O
- O
induced O
oxidant O
stress O
and O
decrease O
in O
antioxidant O
enzymes O
. O

These O
beneficial O
effects O
of O
curcumin B
were O
associated O
with O
the O
ability O
of O
this O
antioxidant O
to O
reverse O
renal O
structural O
alterations O
, O
proteinuria O
, O
hypertension O
, O
interstitial O
fibrosis O
, O
fibrotic O
glomeruli O
, O
tubular O
atrophy O
and O
mesangial O
expansion O
. O

It O
has O
been O
shown O
for O
the O
first O
time O
that O
curcumin B
is O
able O
to O
reverse O
established O
oxidants O
stress O
glomerular O
hypertension O
and O
hyperfiltration O
in O
rats O
with O
5 O
/ O
6NX O
. O

These O
data O
suggest O
that O
curcumin B
may O
be O
useful O
to O
reverse O
established O
hemodynamic O
alterations O
and O
renal O
injury O
in O
patients O
with O
chronic O
renal O
failure O
. O

CAN O
significantly O
inhibited O
the O
production O
of O
NO B
and O
the O
release O
of O
TNF O
- O
alpha O
induced O
by O
LPS O
in O
macrophage O
RAW O
264 O
. O
7 O
. O

Bioavailability O
of O
stabilised O
ferrous O
gluconate O
with O
glycine B
in O
fresh O
cheese O
matrix O
: O
a O
novel O
iron B
compound O
for O
food O
fortification O
. O

Iron B
fortification O
of O
foods O
continues O
to O
be O
one O
of O
the O
preferred O
ways O
of O
improving O
the O
iron B
status O
of O
the O
population O
. O

Dairy O
product O
is O
a O
common O
product O
in O
the O
diet O
; O
therefore O
, O
it O
is O
a O
plausible O
vehicle O
for O
iron B
fortification O
. O

This O
study O
aims O
to O
investigate O
the O
bioavailability O
of O
ferrous O
gluconate O
stabilised O
with O
glycine B
( O
FGSG O
) O
in O
a O
fresh O
cheese O
fortified O
with O
zinc B
. O

The O
iron B
bioavailability O
of O
fresh O
cheese O
fortified O
with O
either O
FGSG O
and O
with O
or O
without O
zinc B
and O
FGSG O
in O
aqueous O
solution O
and O
a O
water O
solution O
of O
ferrous O
ascorbate O
( O
reference O
dose O
) O
was O
studied O
using O
double O
radio O
iron O
( O
( O
55 O
) O
Fe O
and O
( B
59 I
) I
Fe I
) O
erythrocyte O
incorporation O
in O
15 O
male O
subjects O
. O

All O
subjects O
presented O
with O
normal O
values O
for O
iron B
status O
parameters O
. O

The O
geometric O
mean O
of O
iron B
bioavailability O
for O
the O
water O
solution O
of O
FGSG O
was O
38 O
. O
2 O
% O
, O
adjusted O
to O
40 O
% O
from O
reference O
doses O
( O
N O
. O
S O
. O
) O
. O

Iron B
bioavailability O
in O
fresh O
cheese O
fortified O
with O
Ca B
and O
Zn B
was O
15 O
. O
4 O
% O
and O
was O
23 O
. O
1 O
% O
without O
Zn B
, O
adjusted O
to O
40 O
% O
from O
reference O
doses O
( O
N O
. O
S O
. O
) O
. O

The O
results O
of O
the O
present O
study O
show O
that O
the O
novel O
iron B
compound O
ferrous O
gluconate O
stabilised O
with O
glycine B
in O
a O
fresh O
cheese O
matrix O
is O
a O
good O
source O
of O
iron B
and O
can O
be O
used O
in O
iron B
fortification O
programmes O
. O

Interaction O
of O
cisplatin B
with O
adenine B
and O
guanine B
: O
a O
combined O
IRMPD O
, O
MS O
/ O
MS O
, O
and O
theoretical O
study O
. O

Infrared O
multiple O
photon O
dissociation O
( O
IRMPD O
) O
spectroscopy O
of O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
G O
) O
Cl O
] O
( O
+ O
) O
and O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
A O
) O
Cl O
] O
( O
+ O
) O
ions O
( O
where O
A O
is O
adenine B
and O
G O
is O
guanine B
) O
has O
been O
performed O
in O
two O
spectral O
regions O
, O
950 O
- O
1900 O
and O
2900 O
- O
3700 O
cm O
( O
- O
1 O
) O
. O

Quantum O
chemical O
calculations O
at O
the O
B3LYP O
/ O
LACV3P O
/ O
6 O
- O
311G O
* O
* O
level O
yield O
the O
optimized O
geometries O
and O
IR O
spectra O
for O
the O
conceivable O
isomers O
of O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
G O
) O
Cl O
] O
( O
+ O
) O
and O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
A O
) O
Cl O
] O
( O
+ O
) O
, O
whereby O
the O
cisplatin B
residue O
is O
attached O
to O
the O
N7 O
, O
N3 O
, O
or O
carbonyl O
oxygen O
atom O
, O
( O
O6 O
) O
, O

of O
guanine B
and O
to O
the O
N7 O
, O
N3 O
, O
or O
N1 O
position O
of O
adenine B
, O
respectively O
. O

In O
addition O
to O
the O
conventional O
binding O
sites O
of O
native O
adenine B
, O
complexes O
with O
N7 O
- O
H O
tautomers O
have O
also O
been O
considered O
. O

In O
agreement O
with O
computational O
results O
, O
the O
IR O
characterization O
of O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
G O
) O
Cl O
] O
( O
+ O
) O
points O
to O
a O
covalent O
structure O
where O
Pt B
is O
bound O
to O
the O
N7 O
atom O
of O
guanine B
. O

The O
characterized O
conformer O
has O
a O
hydrogen B
- O
bonding O
interaction O
between O
a O
hydrogen B
atom O
of O
one O
NH B
( I
3 I
) I
ligand O
and O
the O
carbonyl B
group O
of O
guanine B
. O

The O
experimental O
C B
= I
O I
stretching O
feature O
of O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
G O
) O
Cl O
] O
( O
+ O
) O
at O
1718 O
cm O
( O
- O
1 O
) O
, O
remarkably O
red O
- O
shifted O
with O
respect O
to O
an O
unperturbed O
C B
= I
O I
stretching O
mode O
, O
is O
indicative O
of O
a O
lengthened O
CO B
bond O
in O
guanine B
, O
a O
signature O
that O
this O
group O
is O
involved O
in O
hydrogen B
bonding O
. O

The O
IRMPD O
spectra O
of O
cis O
- O
[ O
Pt O
( O
NH O
( O
3 O
) O
) O
( O
2 O
) O
( O
A O
) O
Cl O
] O
( O
+ O
) O
are O
consistent O
with O
the O
presence O
of O
two O
major O
isomers O
, O
PtAN3 O
and O
PtAN1 O
, O
where O
Pt B
is O
bound O
to O
the O
N3 O
and O
N1 O
positions O
of O
native O
adenine B
, O
respectively O
. O

We O
tested O
our O
structural O
predictions O
by O
mutational O
analysis O
of O
base O
excision O
and O
found O
a O
single O
amino B
acid I
responsible O
at O
least O
in O
part O
for O
Mag2 O
' O
s O
lack O
of O
activity O
. O

Substitution O
of O
Mag2 O
Asp56 O
, O
which O
caps O
the O
helix O
at O
the O
base O
of O
the O
DNA O
intercalation O
loop O
, O
with O
the O
corresponding O
serine B
residue O
in O
Mag1 O
endows O
Mag2 O
with O
epsilon O
A O
excision O
activity O
comparable O
to O
Mag1 O
. O

The O
coupling O
distance O
between O
presynaptic O
Ca B
( I
2 I
+ I
) I
influx O
and O
the O
sensor O
for O
vesicular O
transmitter O
release O
determines O
speed O
and O
reliability O
of O
synaptic O
transmission O
. O

We O
quantified O
the O
coupling O
distance O
by O
combining O
multiprobability O
fluctuation O
analyses O
, O
presynaptic O
Ca B
( I
2 I
+ I
) I
imaging O
, O
and O
reaction O
- O
diffusion O
simulations O
in O
wild O
- O
type O
and O
calretinin O
- O
deficient O
mice O
. O

The O
most O
intensive O
stimulating O
DOAs O
were O
further O
investigated O
and O
compared O
with O
the O
known O
P O
- O
gp O
model O
substrates O
sertraline O
and O
verapamil B
. O

ATPase O
stimulation O
kinetics O
could O
be O
modeled O
for O
the O
entactogen O
3 O
, O
4 O
- O
methylenedioxy O
- O
alpha O
- O
ethylphenethylamine O
( O
3 O
, O
4 O
- O
BDB O
) O
, O
the O
hallucinogen O
2 O
, O
5 O
- O
dimethoxy O
- O
4 O
- O
iodoamphetamine O
( O
DOI B
) O
, O
the O
abused O
alkaloid O
glaucine B
, O
the O
opioid O
- O
like O
drugs O
N O
- O
iso O
- O
propyl O
- O
1 O
, O
2 O
- O
diphenylethylamine O
( O
NPDPA O
) O
, O
and O
N O
- O
( O
1 O
- O
phenylcyclohexyl O
) O
- O

3 O
- O
ethoxypropanamine O
( O
PCEPA O
) O
, O
with O
K O
( O
m O
) O
and O
V O
( O
max O
) O
values O
within O
the O
same O
range O
as O
for O
verapamil B
or O
sertraline O
. O

6 B
- I
OHDA I
- O
induced O
apoptosis O
and O
mitochondrial O
dysfunction O
are O
mediated O
by O
early O
modulation O
of O
intracellular O
signals O
and O
interaction O
of O
Nrf2 O
and O
NF O
- O
kappa O
B O
factors O
. O

6 B
- I
Hydroxydopamine I
( O
6 B
- I
OHDA I
) O
is O
a O
neurotoxin O
that O
generates O
an O
experimental O
model O
of O
Parkinson O
' O
s O
disease O
in O
rodents O
and O
is O
commonly O
employed O
to O
induce O
a O
lesion O
in O
dopaminergic O
pathways O
. O

The O
characterization O
of O
those O
molecular O
mechanisms O
linked O
to O
6 B
- I
OHDA I
- O
induced O
early O
toxicity O
is O
needed O
to O
better O
understand O
the O
cellular O
events O
further O
leading O
to O
neurodegeneration O
. O

The O
present O
work O
explored O
how O
6 B
- I
OHDA I
triggers O
early O
downstream O
signaling O
pathways O
that O
activate O
neurotoxicity O
in O
the O
rat O
striatum O
. O

We O
found O
that O
6 B
- I
OHDA I
initiates O
cell O
damage O
via O
mitochondrial O
complex O
I O
inhibition O
, O
cytochrome O
c O
and O
apoptosis O
- O
inducing O
factor O
( O
AIF O
) O
release O
, O
as O
well O
as O
activation O
of O
caspases O
9 O
and O
3 O
to O
induce O
apoptosis O
, O
kinase O
signaling O
modulation O
and O
NF O
- O
kappa O
B O
- O
mediated O
inflammatory O
responses O
, O
accompanied O
by O
inhibition O
of O
antioxidant O
systems O
regulated O
by O
the O
Nrf2 O
pathway O
. O

Our O
results O
suggest O
that O
kinases O
SAP O
/ O
JNK O
and O
p38 O
up O
- O
regulation O
may O
play O
a O
role O
in O
the O
early O
stages O
of O
6 B
- I
OHDA I
toxicity O
to O
trigger O
intrinsic O
pathways O
for O
apoptosis O
and O
enhanced O
NF O
- O
kappa O
B O
activation O
. O

The O
use O
of O
Reamer O
Irrigator O
Aspirator O
( O
RIA O
) O
autograft O
harvest O
in O
the O
treatment O
of O
critical O
- O
sized O
iliac O
wing O
defects O
in O
sheep O
: O
investigation O
of O
dexamethasone B
and O
beta O
- O
tricalcium O
phosphate O
augmentation O
. O

A O
reamer O
bone O
graft O
alone O
, O
or O
after O
short O
term O
incubation O
in O
a O
dexamethasone B
enriched O
solution O
, O
and O
a O
reamer O
graft O
collected O
using O
beta O
- O
tricalcium O
phosphate O
( O
beta O
- O
TCP O
) O
granules O
in O
the O
filter O
of O
the O
RIA O
collection O
device O
were O
compared O
to O
autologous O
iliac O
wing O
graft O
. O

In O
addition O
, O
reamer O
graft O
was O
combined O
with O
the O
cellular O
fraction O
collected O
from O
the O
irrigation O
fluid O
with O
and O
without O
short O
- O
term O
incubation O
in O
a O
dexamethasone B
enriched O
solution O
. O

The O
current O
model O
does O
not O
support O
the O
use O
of O
short O
- O
term O
high O
concentration O
dexamethasone B
for O
augmentation O
of O
a O
graft O
volume O
. O

These O
include O
the O
regulation O
of O
expression O
and O
intracellular O
positioning O
of O
nucleoporin O
and O
nucleophosmin O
; O
downregulation O
of O
steroid B
receptor O
coactivator O
- O
3 O
( O
SRC O
- O
3 O
) O
and O
its O
downstream O
proteins O
; O
upregulation O
of O
death O
inducer O
- O
obliterator O
( O
DIO O
- O
1 O
) O
; O
downregulation O
of O
HERG O
potassium B
channel O
; O
as O
well O
as O
induction O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
accumulation O
. O

Synthesis O
of O
spirolactone O
- O
type O
diterpenoid B
derivatives O
from O
kaurene O
- O
type O
oridonin O
with O
improved O
antiproliferative O
effects O
and O
their O
apoptosis O
- O
inducing O
activity O
in O
human O
hepatoma O
Bel O
- O
7402 O
cells O
. O

A O
series O
of O
novel O
spirolactone O
- O
type O
diterpenoid B
derivatives O
of O
oridonin O
( O
12a O
- O
j O
) O
were O
designed O
and O
synthesized O
. O

These O
results O
demonstrate O
that O
the O
spirolactone O
- O
type O
diterpenoid B
derivatives O
of O
oridonin O
have O
optimized O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
interesting O
apoptosis O
- O
inducing O
ability O
. O

We O
examined O
( O
1 O
) O
reproductive O
physiology O
, O
( O
2 O
) O
pair O
- O
maintenance O
behaviors O
in O
several O
contexts O
, O
and O
( O
3 O
) O
circulating O
and O
brain O
steroid B
levels O
. O

In O
males O
, O
water O
restriction O
had O
no O
effect O
on O
testes O
size O
but O
decreased O
systemic O
testosterone B
levels O
. O

However O
, O
in O
the O
hypothalamus O
, O
local O
testosterone B
and O
estradiol B
levels O
were O
unaffected O
by O
water O
restriction O
in O
both O
sexes O
. O

Systemic O
and O
local O
levels O
of O
the O
androgen B
precursor O
dehydroepiandrostero B
( O
DHEA B
) O
were O
also O
unaffected O
by O
water O
restriction O
. O

Taken O
together O
, O
these O
correlational O
data O
are O
consistent O
with O
the O
hypothesis O
that O
local O
production O
of O
sex O
steroids B
in O
the O
brain O
promotes O
the O
expression O
of O
pair O
- O
maintenance O
behaviors O
in O
non O
- O
breeding O
zebra O
finches O
. O

Trichothecene B
toxicity O
in O
eukaryotes O
: O
cellular O
and O
molecular O
mechanisms O
in O
plants O
and O
animals O
. O

Trichothecenes B
are O
sesquiterpenoid O
mycotoxins O
commonly O
found O
as O
contaminants O
in O
cereal O
grains O
and O
are O
a O
major O
health O
and O
food O
safety O
concern O
due O
to O
their O
toxicity O
to O
humans O
and O
farm O
animals O
. O

Trichothecenes B
are O
predominantly O
produced O
by O
the O
phytopathogenic O
Fusarium O
fungus O
, O
and O
in O
plants O
they O
act O
as O
a O
virulence O
factor O
aiding O
the O
spread O
of O
the O
fungus O
during O
disease O
development O
. O

Known O
for O
their O
inhibitory O
effect O
on O
eukaryotic O
protein O
synthesis O
, O
trichothecenes B
also O
induce O
oxidative O
stress O
, O
DNA O
damage O
and O
cell O
cycle O
arrest O
and O
affect O
cell O
membrane O
integrity O
and O
function O
in O
eukaryotic O
cells O
. O

In O
animals O
, O
trichothecenes B
can O
be O
either O
immunostimulatory O
or O
immunosuppressive O
and O
induce O
apoptosis O
via O
mitochondria O
- O
mediated O
or O
- O
independent O
pathway O
. O

In O
plants O
, O
trichothecenes B
induce O
programmed O
cell O
death O
via O
production O
of O
reactive O
oxygen O
species O
. O

Recent O
advances O
in O
molecular O
techniques O
have O
led O
to O
the O
elucidation O
of O
signal O
transduction O
pathways O
that O
manifest O
trichothecene B
toxicity O
in O
eukaryotes O
. O

In O
animals O
, O
trichothecenes B
induce O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
signalling O
cascades O
via O
ribotoxic O
stress O
response O
and O
/ O
or O
endoplasmic O
reticulum O
stress O
response O
. O

The O
upstream O
signalling O
events O
that O
lead O
to O
the O
activation O
trichothecene B
- O
induced O
ribotoxic O
stress O
response O
are O
discussed O
. O

In O
plants O
, O
trichothecenes B
exhibit O
elicitor O
- O
like O
activity O
leading O
to O
the O
inductions O
MAPKs O
and O
genes O
involved O
in O
oxidative O
stress O
, O
cell O
death O
and O
plant O
defence O
response O
. O

Trichothecenes B
might O
also O
modulate O
hormone O
- O
mediated O
defence O
signalling O
and O
abiotic O
stress O
signalling O
in O
plants O
. O

Cationic O
nanoparticles O
disrupt O
cellular O
signaling O
in O
a O
cholesterol B
dependent O
manner O
. O

In O
this O
study O
, O
we O
investigate O
the O
interaction O
of O
charged O
polystyrene B
particles O
with O
respiratory O
epithelial O
cells O
. O

A549 O
cells O
, O
containing O
a O
stably O
transfected O
Interleukin O
- O
8 O
( O
IL O
- O
8 O
) O
Luciferase O
promoter O
construct O
, O
were O
cultured O
in O
the O
presence O
of O
the O
proinflammatory O
cytokine O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
polystyrene B
particles O
for O
4 O
. O
5h O
. O

However O
, O
the O
activity O
of O
the O
cationic O
nanoparticles O
on O
the O
IL O
- O
8 O
promoter O
and O
NF O
- O
kappa O
B O
translocation O
is O
lost O
when O
cholesterol B
is O
depleted O
from O
A549 O
cells O
before O
particle O
exposure O
, O
which O
suggests O
that O
cationic O
nanoparticles O
rely O
on O
membrane O
cholesterol B
integrity O
to O
disrupt O
cellular O
signaling O
. O

Principal O
component O
analysis O
indicated O
that O
a O
low O
abundance O
of O
lactate B
- O
producing O
and O
butyrate O
- O
producing O
species O
was O
associated O
with O
beta O
- O
cell O
autoimmunity O
. O

EphA5 O
- O
EphrinA5 O
interactions O
within O
the O
ventromedial O
hypothalamus O
influence O
counterregulatory O
hormone O
release O
and O
local O
glutamine B
/ O
glutamate B
balance O
during O
hypoglycemia O
. O

Given O
the O
similarities O
between O
islet O
and O
ventromedial O
hypothalamus O
( O
VMH O
) O
glucose B
sensing O
, O
we O
tested O
the O
hypothesis O
that O
the O
EphA5 O
/ O
ephrinA5 O
system O
might O
function O
within O
the O
VMH O
during O
hypoglycemia O
to O
stimulate O
counterregulatory O
hormone O
release O
as O
well O
. O

Counterregulatory O
responses O
and O
glutamine B
/ O
glutamate B
concentrations O
in O
the O
VMH O
were O
assessed O
during O
a O
hyperinsulinemic O
- O
hypoglycemic O
glucose B
clamp O
study O
in O
chronically O
catheterized O
awake O
male O
Sprague O
- O
Dawley O
rats O
that O
received O
an O
acute O
VMH O
microinjection O
of O
ephrinA5 O
- O
Fc O
, O
chronic O
VMH O
knockdown O
, O
or O
overexpression O
of O
ephrinA5 O
using O
an O
adenoassociated O
viral O
construct O
. O

Overexpression O
of O
VMH O
ephrinA5 O
transiently O
increased O
local O
glutamate B
concentrations O
, O
whereas O
ephrinA5 O
knockdown O
produced O
profound O
suppression O
of O
VMH O
interstitial O
fluid O
glutamine B
concentrations O
in O
the O
basal O
state O
and O
during O
hypoglycemia O
. O

Changes O
in O
ephrinA5 O
/ O
EphA5 O
interactions O
within O
the O
VMH O
, O
a O
key O
brain O
glucose B
- O
sensing O
region O
, O
act O
in O
concert O
with O
islets O
to O
restore O
glucose B
homeostasis O
during O
acute O
hypoglycemia O
, O
and O
its O
effect O
on O
counterregulation O
may O
be O
mediated O
by O
changes O
in O
glutamate B
/ O
glutamine B
cycling O
. O

Electrical O
Stimuli O
Release O
ATP B
to O
Increase O
GLUT4 O
Translocation O
and O
Glucose B
Uptake O
via O
PI3K O
gamma O
- O
Akt O
- O
AS160 O
in O
Skeletal O
Muscle O
Cells O
. O

Skeletal O
muscle O
glucose B
uptake O
in O
response O
to O
exercise O
is O
preserved O
in O
insulin O
- O
resistant O
conditions O
, O
but O
the O
signals O
involved O
are O
debated O
. O

ATP B
is O
released O
from O
skeletal O
muscle O
by O
contractile O
activity O
and O
can O
autocrinely O
signal O
through O
purinergic O
receptors O
, O
and O
we O
hypothesized O
it O
may O
influence O
glucose B
uptake O
. O

Electrical O
stimulation O
, O
ATP B
, O
and O
insulin O
each O
increased O
fluorescent O
2 O
- O
NBD O
- O
Glucose O
( O
2 O
- O
NBDG O
) O
uptake O
in O
primary O
myotubes O
, O
but O
only O
electrical O
stimulation O
and O
ATP B
- O
dependent O
2 O
- O
NBDG O
uptake O
were O
inhibited O
by O
adenosine O
- O
phosphate O
phosphatase O
and O
by O
purinergic O
receptor O
blockade O
( O
suramin B
) O
. O

Electrical O
stimulation O
transiently O
elevated O
extracellular O
ATP B
and O
caused O
Akt O
phosphorylation O
that O
was O
additive O
to O
insulin O
and O
inhibited O
by O
suramin B
. O

Exogenous O
ATP B
transiently O
activated O
Akt O
and O
, O
inhibiting O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3K O
) O
or O
Akt O
as O
well O
as O
dominant O
- O
negative O
Akt O
mutant O
, O
reduced O
ATP B
- O
dependent O
2 O
- O
NBDG O
uptake O
and O
Akt O
phosphorylation O
. O

ATP B
- O
dependent O
2 O
- O
NBDG O
uptake O
was O
also O
inhibited O
by O
the O
G O
protein O
beta O
gamma O
subunit O
- O
interacting O
peptide O
beta O
ark O
- O
ct O
and O
by O
the O
phosphatidylinositol O
3 O
- O
kinase O
- O
gamma O
( O
PI3K O
gamma O
) O
inhibitor O
AS605240 O
. O

ATP B
caused O
translocation O
of O
GLUT4myc O
- O
eGFP O
to O
the O
cell O
surface O
, O
mechanistically O
mediated O
by O
increased O
exocytosis O
involving O
AS160 O
/ O
Rab8A O
reduced O
by O
dominant O
- O
negative O
Akt O
or O
PI3K O
gamma O
kinase O
- O
dead O
mutants O
, O
and O
potentiated O
by O
myristoylated O
PI3K O
gamma O
. O

ATP B
stimulated O
2 O
- O
NBDG O
uptake O
in O
normal O
and O
insulin O
- O
resistant O
adult O
muscle O
fibers O
, O
resembling O
the O
reported O
effect O
of O
exercise O
. O

Hence O
, O
the O
ATP B
- O
induced O
pathway O
may O
be O
tapped O
to O
bypass O
insulin O
resistance O
. O

A O
line O
expressing O
high O
levels O
of O
INS O
( O
C94Y O
) O
mRNA O
( O
70 O
- O
86 O
% O
of O
wild O
- O
type O
INS O
transcripts O
) O
exhibited O
elevated O
blood O
glucose B
soon O
after O
birth O
but O
unaltered O
beta O
- O
cell O
mass O
at O
the O
age O
of O
8 O
days O
. O

T2D O
patients O
are O
routinely O
treated O
with O
oral O
antidiabetic O
agents O
such O
as O
sulfonylureas B
or O
dipeptidyl O
peptidase O
- O
4 O
antagonists O
, O
which O
promote O
glucose B
- O
and O
incretin O
- O
dependent O
insulin O
secretion O
, O
respectively O
. O

We O
observed O
that O
Nogo O
- O
A O
- O
deficient O
mice O
display O
improved O
insulin O
secretion O
and O
glucose B
clearance O
. O

This O
was O
associated O
with O
a O
stronger O
parasympathetic O
input O
and O
higher O
sensitivity O
of O
beta O
- O
cells O
to O
the O
cholinergic O
analog O
carbachol B
. O

In O
vitro O
cytotoxicity O
and O
genotoxicity O
studies O
of O
titanium B
dioxide I
( O
TiO2 B
) O
nanoparticles O
in O
Chinese O
hamster O
lung O
fibroblast O
cells O
. O

The O
unique O
physical O
and O
chemical O
characteristics O
of O
titanium B
dioxide I
( O
TiO2 B
) O
nanoparticles O
result O
in O
different O
chemical O
and O
biological O
activities O
compared O
to O
their O
larger O
micron O
- O
sized O
counterparts O
, O
and O
can O
subsequently O
play O
an O
important O
role O
in O
influencing O
toxicity O
. O

Therefore O
, O
our O
objective O
was O
to O
investigate O
the O
cytotoxicity O
and O
genotoxicity O
of O
commercially O
available O
TiO2 B
nanoparticles O
with O
respect O
to O
their O
selected O
physicochemical O
properties O
, O
as O
well O
as O
the O
role O
of O
surface O
coating O
of O
these O
nanoparticles O
. O

While O
all O
types O
of O
tested O
TiO2 B
samples O
decrease O
cell O
viability O
in O
a O
mass O
- O
based O
concentration O
- O
and O
size O
- O
dependent O
manner O
, O
the O
polyacrylate O
- O
coated O
nano O
- O
TiO2 B
product O
was O
only O
cytotoxic O
at O
higher O
concentrations O
. O

A O
similar O
pattern O
of O
response O
was O
observed O
for O
induction O
of O
apoptosis O
/ O
necrosis O
, O
and O
no O
DNA O
damage O
was O
detected O
in O
the O
polyacrylate O
- O
coated O
nano O
- O
TiO2 B
model O
. O

Given O
the O
increasing O
production O
of O
TiO2 B
nanoparticles O
, O
toxicological O
studies O
should O
take O
into O
account O
the O
physiochemical O
properties O
of O
these O
nanoparticles O
that O
may O
help O
researchers O
to O
develop O
new O
nanoparticles O
with O
minimum O
toxicity O
. O

GABA B
( O
B O
) O
receptor O
- O
positive O
modulators O
are O
thought O
to O
have O
advantages O
as O
potential O
medications O
for O
anxiety O
, O
depression O
, O
and O
drug O
addiction O
. O

They O
may O
have O
fewer O
side O
effects O
than O
GABA B
( O
B O
) O
receptor O
agonists O
, O
because O
selective O
enhancement O
of O
activated O
receptors O
could O
have O
effects O
different O
from O
nonselective O
activation O
of O
all O
receptors O
. O

To O
examine O
this O
, O
pigeons O
were O
trained O
to O
discriminate O
the O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
( O
R O
, O
S O
) O
- O
5 O
, O
7 O
- O
di O
- O
tert O
- O
butyl O
- O
3 O
- O
hydroxy O
- O
3 O
- O
trifluoromethyl O
- O
3H O
- O
benzofuran O
- O
2 O
- O
one O
( O
rac O
- O
BHFF O
) O
from O
its O
vehicle O
. O

The O
discriminative O
stimulus O
effects O
of O
rac O
- O
BHFF O
were O
not O
mimicked O
by O
the O
GABA B
( O
B O
) O
receptor O
agonists O
baclofen B
and O
gamma B
- I
hydroxybutyrate I
( O
GHB B
) O
, O
not O
by O
diazepam B
, O
and O
not O
by O
alcohol B
, O
cocaine B
, O
and O
nicotine B
, O
whose O
self O
- O
administration O
has O
been O
reported O
to O
be O
attenuated O
by O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulators O
. O

The O
discriminative O
stimulus O
effects O
of O
rac O
- O
BHFF O
were O
not O
antagonized O
by O
the O
GABA B
( O
B O
) O
receptor O
antagonist O
3 O
- O
aminopropyl O
( O
diethoxymethyl O
) O
phosphinic O
acid O
( O
CGP35348 O
) O
but O
were O
attenuated O
by O
the O
less O
efficacious O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
2 O
, O
6 O
- O
di O
- O
tert O
- O
butyl O
- O
4 O
- O
( O
3 O
- O
hydroxy O
- O
2 O
, O
2 O
- O
dimethylpropyl O
) O
phenol O
( O
CGP7930 O
) O
, O
suggesting O
the O
possibility O
that O
rac O
- O

BHFF O
produces O
its O
discriminative O
stimulus O
effects O
by O
directly O
activating O
GABA O
( O
B2 O
) O
subunits O
of O
GABA B
( O
B O
) O
receptors O
. O

At O
a O
dose O
10 O
- O
fold O
lower O
than O
the O
training O
dose O
, O
rac O
- O
BHFF O
enhanced O
the O
discriminative O
stimulus O
effects O
of O
baclofen B
, O
but O
not O
of O
GHB B
. O

This O
study O
provides O
evidence O
that O
the O
effects O
of O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulators O
are O
not O
identical O
to O
those O
of O
GABA B
( O
B O
) O
receptor O
agonists O
. O

In O
addition O
, O
the O
results O
suggest O
that O
positive O
modulation O
of O
GABA B
( O
B O
) O
receptors O
does O
not O
produce O
discriminative O
stimulus O
effects O
similar O
to O
those O
of O
benzodiazepines B
, O
alcohol B
, O
cocaine B
, O
and O
nicotine B
. O

Finally O
, O
the O
finding O
that O
rac O
- O
BHFF O
enhanced O
effects O
of O
baclofen B
but O
not O
of O
GHB B
is O
consistent O
with O
converging O
evidence O
that O
the O
populations O
of O
GABA B
( O
B O
) O
receptors O
mediating O
the O
effects O
of O
baclofen B
and O
GHB B
are O
not O
identical O
. O

Surfactant O
- O
free O
( O
calcined O
) O
and O
surfactant O
- O
templated O
( O
non O
- O
calcined O
) O
mesoporous O
silica B
have O
been O
used O
as O
IP O
and O
OP O
starting O
matrices O
, O
respectively O
. O

However O
, O
non O
- O
calcined O
matrices O
induce O
on O
fibroblasts O
a O
significant O
proliferation O
delay O
with O
morphological O
alterations O
and O
dose O
- O
dependent O
increases O
in O
fibroblast O
size O
, O
internal O
complexity O
, O
and O
intracellular O
calcium B
content O
but O
without O
cell O
lysis O
and O
apoptosis O
. O

Residual O
ethanol B
and O
the O
surface O
silanol B
groups O
in O
these O
non O
- O
calcined O
matrices O
are O
involved O
in O
the O
observed O
fibroblast O
changes O
. O

The O
CSN O
/ O
IRF5 O
interaction O
occurred O
on O
the O
carboxyl B
and O
amino B
termini O
of O
IRF5 O
; O
a O
single O
internal O
deletion O
from O
amino B
acids I
455 O
to O
466 O
( O
Delta O
455 O
- O
466 O
) O
was O
found O
to O
significantly O
reduce O
IRF5 O
protein O
stability O
. O

At O
3 O
months O
, O
Osx O
- O
Cre O
; O
Rosa O
( O
Notch O
) O
and O
Dmp1 O
- O
Cre O
; O
Rosa O
( O
Notch O
) O
mice O
displayed O
increased O
bone O
volume O
, O
and O
increased O
osteoblasts O
although O
calcein B
- O
demeclocycline O
labels O
were O
diffuse O
and O
fragmented O
, O
indicating O
abnormal O
bone O
formation O
. O

We O
also O
show O
that O
loop O
- O
loop O
kissing O
complex O
formation O
becomes O
more O
efficient O
at O
physiological O
temperature O
and O
in O
the O
presence O
of O
magnesium B
. O

The O
first O
part O
of O
the O
review O
is O
related O
to O
compounds O
with O
ring O
fused O
to O
the O
pyrimidine B
part O
of O
the O
quinazoline B
core O
. O

Display O
of O
amino B
groups O
on O
substrate O
surfaces O
by O
simple O
dip O
- O
coating O
of O
methacrylate B
- O
based O
polymers O
and O
its O
application O
to O
DNA O
immobilization O
. O

Reactive O
functional O
groups O
( O
e O
. O
g O
. O
, O
an O
amino B
group O
and O
a O
hydroxyl B
group O
) O
are O
usually O
hydrophilic O
, O
which O
makes O
it O
difficult O
to O
display O
them O
on O
a O
dry O
polymer O
surface O
. O

We O
here O
propose O
a O
novel O
method O
for O
displaying O
amino B
groups O
on O
the O
surfaces O
of O
polymeric O
substrates O
through O
dip O
- O
coating O
of O
a O
methacrylate B
- O
based O
copolymer O
. O

We O
synthesized O
copolymers O
composed O
of O
methyl O
methacrylate O
and O
2 O
- O
aminoethyl O
methacrylate O
with O
different O
protecting O
groups O
or O
ion O
- O
complexes O
on O
their O
amino B
groups O
, O
then O
dip O
- O
coated O
the O
copolymers O
onto O
a O
poly B
( I
methyl I
methacrylate I
) I
( O
PMMA B
) O
substrate O
. O

Evaluation O
using O
a O
cleavable O
fluorescent O
compound O
, O
which O
was O
synthesized O
in O
the O
present O
study O
to O
quantify O
a O
small O
amount O
( O
pmol O
/ O
cm O
( O
2 O
) O
) O
of O
amino B
groups O
on O
a O
solid O
surface O
, O
revealed O
that O
the O
protection O
of O
amino B
groups O
affected O
their O
surface O
segregation O
in O
the O
copolymer O
coating O
. O

p O
- O
Toluenesulfonate O
ion O
- O
complex O
and O
tert O
- O
butoxycarbonyl O
( O
Boc O
) O
protection O
of O
amino B
groups O
were O
found O
to O
effectively O
display O
amino B
groups O
on O
the O
surface O
( O
more O
than O
70 O
pmol O
/ O
cm O
( O
2 O
) O
) O
. O

The O
density O
of O
amino B
groups O
displayed O
on O
a O
surface O
can O
be O
easily O
controlled O
by O
mixing O
the O
copolymer O
and O
PMMA B
before O
dip O
- O
coating O
. O

Dip O
- O
coating O
of O
the O
copolymer O
with O
Boc O
protection O
on O
various O
polymeric O
substrates O
also O
successfully O
displayed O
amino B
groups O
on O
their O
surfaces O
. O

Finally O
, O
we O
demonstrated O
that O
the O
amino B
groups O
displayed O
can O
be O
utilized O
for O
the O
immobilization O
of O
a O
DNA O
oligonucleotide O
on O
a O
substrate O
surface O
. O

Kinetics O
of O
the O
reaction O
of O
crystal O
violet O
with O
hydroxide B
ion O
in O
the O
critical O
solution O
of O
2 O
- O
butoxyethanol O
+ O
water O
. O

Further O
it O
seems O
to O
be O
involved O
in O
progesterone B
signalling O
and O
cytochrome O
P450 O
binding O
. O

PXR O
- O
mediated O
P O
- O
glycoprotein O
induction O
by O
small O
molecule O
tyrosine B
kinase O
inhibitors O
. O

The O
rapid O
development O
of O
drug O
resistance O
as O
a O
result O
of O
exposure O
to O
small O
molecule O
tyrosine B
kinase O
inhibitors O
( O
TKIs O
) O
is O
an O
important O
drawback O
to O
the O
successful O
use O
of O
these O
agents O
in O
the O
clinic O
. O

In O
addition O
, O
the O
involvement O
of O
the O
nuclear O
pregnane B
X O
receptor O
( O
PXR O
) O
, O
a O
known O
regulator O
of O
PGP O
expression O
, O
was O
determined O
. O

At O
least O
five O
out O
of O
the O
nine O
tested O
TKIs O
( O
erlotinib B
, O
gefitinib B
, O
nilotinib B
, O
sorafenib O
, O
vandetanib B
) O
were O
able O
to O
induce O
the O
expression O
of O
PGP O
within O
48 O
h O
in O
LS180 O
cells O
. O

Furthermore O
, O
we O
showed O
that O
the O
pregnane B
X O
receptor O
( O
PXR O
) O
, O
which O
is O
an O
important O
regulator O
of O
PGP O
induction O
, O
is O
involved O
in O
the O
upregulation O
of O
PGP O
protein O
expression O
following O
exposure O
to O
these O
TKIs O
. O

Therefore O
in O
this O
study O
we O
investigated O
the O
production O
of O
a O
PvdQ O
powder O
by O
spray O
- O
freeze O
drying O
using O
mannitol B
, O
trehalose O
and O
inulin O
as O
excipient O
. O

We O
found O
that O
the O
enzymatic O
activity O
of O
PvdQ O
is O
fully O
maintained O
during O
spray O
- O
freeze O
drying O
using O
mannitol B
, O
trehalose O
or O
inulin O
as O
excipient O
. O

However O
, O
mannitol B
was O
not O
able O
to O
stabilize O
the O
protein O
during O
storage O
, O
while O
PvdQ O
incorporated O
in O
trehalose O
or O
inulin O
was O
fully O
stabilized O
even O
during O
storage O
at O
55 O
degrees O
C O
for O
at O
least O
4 O
weeks O
. O

The O
poor O
stabilizing O
capacities O
of O
mannitol B
during O
storage O
could O
be O
related O
to O
its O
crystalline O
nature O
while O
the O
excellent O
stabilizing O
capacities O
of O
trehalose O
and O
inulin O
during O
storage O
could O
be O
related O
to O
their O
amorphous O
nature O
. O

The O
additional O
hydroxylation O
of O
EF O
- O
P O
at O
the O
same O
lysine B
residue O
by O
the O
YfcM O
protein O
has O
also O
recently O
been O
described O
. O

Biomarkers O
of O
toluene B
exposure O
in O
rats O
: O
mercapturic B
acids I
versus O
traditional O
indicators O
( O
urinary O
hippuric O
acid O
and O
o O
- O
cresol O
and O
blood O
toluene B
) O
. O

Toluene B
( O
TOL O
) O
is O
a O
neurotoxic O
, O
ototoxic O
and O
reprotoxic O
solvent O
which O
is O
metabolized O
via O
the O
glutathione B
pathway O
, O
producing O
benzylmercapturic O
, O
o O
- O
, O
m O
- O
and O
p O
- O
toluylmercapturic O
acids O
( O
MAs O
) O
. O

Treatment O
of O
estrogen B
receptor O
- O
positive O
breast O
cancer O
. O

Estrogen B
receptor O
( O
ER O
) O
expression O
is O
the O
main O
indicator O
of O
potential O
responses O
to O
endocrine O
therapy O
( O
ET O
) O
, O
and O
approximately O
70 O
% O
of O
human O
breast O
cancers O
( O
BCs O
) O
are O
hormone O
- O
dependent O
and O
ER O
- O
positive O
. O

Adjuvant O
ET O
currently O
consists O
of O
( O
i O
) O
ovarian O
suppression O
, O
( O
ii O
) O
selective O
estrogen B
receptor O
modulators O
( O
SERMs O
) O
and O
down O
- O
regulators O
, O
and O
( O
iii O
) O
aromatase O
inhibitors O
( O
AIs O
) O
. O

Tamoxifen B
is O
the O
best O
established O
SERM O
, O
has O
favorable O
effects O
on O
BC O
control O
and O
bone O
metabolism O
, O
but O
also O
has O
adverse O
effects O
due O
to O
its O
estrogenic O
activity O
in O
other O
tissues O
. O

Fulvestrant B
is O
an O
ER O
down O
- O
regulator O
with O
several O
potential O
advantages O
over O
SERMs O
, O
including O
a O
100 O
- O
fold O
increase O
in O
its O
affinity O
for O
ER O
compared O
with O
tamoxifen B
and O
no O
estrogen B
- O
like O
activity O
in O
the O
uterus O
. O

In O
postmenopausal O
patients O
with O
ER O
+ O
BC O
adjuvant O
treatment O
with O
AIs O
should O
be O
performed O
, O
either O
as O
sequential O
treatment O
after O
tamoxifen B
or O
as O
upfront O
therapy O
. O

Triple O
- O
negative O
breast O
cancer O
( O
TNBC O
) O
, O
that O
is O
breast O
cancer O
which O
stains O
negatively O
at O
immunohistochemistry O
for O
estrogen B
receptor O
( O
ER O
) O
, O
progesterone B
receptor O
( O
PR O
) O
and O
human O
epidermal O
growth O
factor O
2 O
( O
HER2 O
) O
, O
comprises O
a O
particularly O
aggressive O
subtype O
of O
breast O
cancer O
, O
with O
high O
rate O
of O
early O
local O
and O
distant O
relapse O
. O

Drugs O
under O
investigation O
can O
be O
broadly O
subdivided O
into O
four O
groups O
: O
( O
1 O
) O
Agents O
that O
create O
DNA O
damage O
( O
i O
. O
e O
. O
cisplatin B
, O
cyclophosphamide B
) O
; O
( O
2 O
) O
Agents O
that O
inhibit O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
; O
( O
3 O
) O
Tyrosin O
- O
kinase O
inhibitors O
and O
monoclonal O
antibodies O
; O
( O
4 O
) O
Agents O
that O
inhibit O
downstream O
signals O
. O

Identification O
of O
novel O
androgen B
receptor O
antagonists O
using O
structure O
- O
and O
ligand O
- O
based O
methods O
. O

Androgen B
receptor O
( O
AR O
) O
plays O
a O
critical O
role O
in O
the O
development O
and O
progression O
of O
prostate O
cancer O
( O
PCa O
) O
. O

The O
AR O
hormone O
- O
binding O
site O
( O
HBS O
) O
is O
intensively O
studied O
and O
represents O
the O
target O
area O
for O
current O
antiandrogens O
including O
Bicalutamide B
and O
structurally O
related O
Enzalutamide B
. O

Synthesis O
and O
biological O
activity O
against O
Trypanosoma O
cruzi O
of O
substituted O
1 B
, I
4 I
- I
naphthoquinones I
. O

New O
substituted O
1 B
, I
4 I
- I
naphthoquinones I
were O
synthesized O
and O
tested O
against O
the O
infective O
bloodstream O
form O
of O
Trypanosoma O
cruzi O
, O
the O
etiological O
agent O
of O
Chagas O
disease O
. O

For O
both O
flagellates O
, O
effects O
of O
TBA O
on O
algal O
growth O
, O
measured O
through O
cell O
density O
and O
carbon B
analysis O
, O
as O
well O
as O
on O
the O
photosynthetic O
activity O
are O
reported O
. O

Both O
flagellates O
increased O
cell O
carbon B
and O
nitrogen B
content O
in O
herbicide O
treatments O
compared O
to O
the O
control O
, O
except O
G O
. O
spinifera O
grown O
at O
15 O
degrees O
C O
. O

Chlorophyll B
- I
a I
production O
was O
increased O
only O
in O
G O
. O
spinifera O
exposed O
to O
5 O
mu O
g O
L O
( O
- O
1 O
) O
of O
TBA O
and O
the O
effect O
was O
enhanced O
with O
the O
increase O
of O
temperature O
. O

Herbicide O
- O
induced O
variations O
in O
cellular O
components O
determined O
changes O
in O
cellular O
carbon B
: O
nitrogen B
( O
C B
: O
N B
) O
and O
chlorophyll B
: O
carbon B
( O
Chl O
: O
C B
) O
ratios O
. O

The O
C B
: O
N B
ratio O
decreased O
in O
both O
species O
, O
while O
only O
G O
. O
spinifera O
showed O
an O
increase O
in O
the O
Chl O
: O
C B
ratio O
at O
all O
temperature O
conditions O
. O

Nitrate B
and O
phosphate B
uptake O
significantly O
increased O
in O
the O
presence O
of O
TBA O
and O
this O
response O
was O
enhanced O
at O
25 O
degrees O
C O
, O
while O
nitrate B
uptake O
increased O
in O
G O
. O
spinifera O
only O
when O
grown O
at O
25 O
degrees O
C O
. O

Our O
research O
addressed O
the O
question O
of O
whether O
or O
not O
dutasteride O
, O
a O
pharmaceutical O
used O
to O
treat O
benign O
prostatic O
hyperplasia O
, O
may O
cause O
adverse O
effects O
in O
a O
teleost O
fish O
, O
the O
fathead O
minnow O
( O
Pimephales O
promelas O
) O
, O
by O
inhibiting O
the O
activity O
of O
both O
isoforms O
of O
5 O
alpha O
- O
reductase O
( O
5 O
alpha O
R O
) O
, O
the O
enzyme O
that O
converts O
testosterone B
into O
dihydrotestosterone B
( O
DHT B
) O
. O

Evaluation O
of O
zebra O
mussels O
( O
Dreissena O
polymorpha O
) O
as O
biomonitors O
of O
mercury B
contamination O
in O
aquatic O
ecosystems O
. O

Zebra O
mussels O
have O
invaded O
many O
lakes O
in O
the O
United O
States O
and O
could O
be O
a O
useful O
tool O
for O
monitoring O
responses O
of O
aquatic O
biota O
to O
changes O
in O
mercury B
loading O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
evaluate O
zebra O
mussels O
for O
use O
as O
a O
biomonitor O
of O
mercury B
contamination O
by O
comparing O
zebra O
mussel O
mercury B
concentrations O
between O
a O
lake O
with O
only O
indirect O
atmospheric O
mercury B
contamination O
( O
Otisco O
Lake O
, O
NY O
, O
USA O
) O
and O
a O
lake O
that O
was O
directly O
contaminated O
by O
mercury B
discharges O
( O
Onondaga O
Lake O
, O
NY O
, O
USA O
) O
. O

Total O
mercury B
( O
THg O
) O
concentrations O
in O
zebra O
mussels O
were O
approximately O
seven O
times O
greater O
in O
Onondaga O
Lake O
than O
in O
Otisco O
Lake O
, O
and O
water O
column O
mercury B
concentrations O
differed O
by O
an O
order O
of O
magnitude O
between O
the O
two O
lakes O
. O

Mussel O
methylmercury B
concentrations O
averaged O
53 O
% O
of O
THg O
concentrations O
but O
were O
highly O
variable O
. O

Strong O
relationships O
between O
water O
column O
THg O
and O
zebra O
mussel O
THg O
suggest O
that O
zebra O
mussels O
are O
a O
good O
indicator O
of O
aquatic O
mercury B
concentrations O
and O
could O
be O
used O
as O
an O
effective O
biomonitor O
of O
mercury B
contamination O
in O
aquatic O
ecosystems O
. O

Sediments O
along O
the O
river O
Saale O
, O
one O
of O
the O
main O
tributaries O
of O
the O
river O
Elbe O
, O
were O
characterized O
with O
the O
yeast O
estrogen B
screen O
to O
elucidate O
possible O
sources O
of O
endocrine O
- O
disrupting O
compounds O
that O
might O
contribute O
to O
the O
downstream O
contamination O
of O
the O
river O
Elbe O
. O

At O
two O
sampling O
sites O
, O
elevated O
levels O
of O
estrogenic O
activity O
up O
to O
55 O
, O
000 O
ng O
ethinylestradiol B
equivalents O
per O
kilogram O
sediment O
dry O
weight O
were O
detected O
in O
the O
respective O
sediment O
extracts O
. O

The O
maximal O
concentrations O
of O
4 O
- O
iso O
- O
nonylphenol O
and O
estrone B
were O
115 O
mg O
/ O
kg O
dry O
weight O
and O
20 O
micro O
g O
/ O
kg O
dry O
weight O
at O
the O
sampling O
site O
Luppe O
, O
which O
showed O
in O
accordance O
the O
highest O
biological O
activity O
. O

Persistence O
of O
the O
tricyclic O
antidepressant O
drugs O
amitriptyline B
and O
nortriptyline B
in O
agriculture O
soils O
. O

Amitriptyline B
and O
nortriptyline B
are O
widely O
used O
tricyclic O
antidepressant O
drugs O
. O

In O
the O
absence O
of O
data O
on O
their O
fate O
in O
the O
environment O
, O
the O
persistence O
and O
dissipation O
pathways O
of O
radiolabeled O
amitriptyline B
were O
determined O
in O
three O
agriculture O
soils O
varying O
widely O
in O
texture O
and O
chemical O
properties O
( O
loam O
soil O
, O
clay O
loam O
soil O
, O
and O
sandy O
loam O
soil O
) O
. O

Tritiated O
amitriptyline O
was O
added O
to O
laboratory O
microcosms O
containing O
soils O
, O
and O
the O
metabolism O
of O
the O
extractable O
( B
3 I
) I
H I
was O
monitored O
during O
incubation O
at O
30 O
degrees O
C O
. O

Nortriptyline B
( O
N O
- O
desmethyl O
amitriptyline O
) O
and O
amitriptyline O
- O
N O
- O
oxide O
were O
identified O
as O
major O
transformation O
products O
in O
all O
three O
soils O
by O
high O
performance O
liquid O
chromatography O
with O
photodiode O
array O
detector O
and O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
HPLC O
- O
TOF O
- O
MS O
/ O
UV O
) O
. O

The O
addition O
of O
liquid O
municipal O
biosolids O
to O
the O
loam O
soil O
had O
no O
effect O
on O
the O
dissipation O
of O
amitriptyline B
. O

The O
persistence O
of O
nortriptyline B
was O
evaluated O
in O
the O
loam O
soil O
. O

The O
DT50 O
of O
nortriptyline B
was O
40 O
. O
5 O
+ O
/ O
- O
3 O
. O
2 O
d O
estimated O
with O
HPLC O
- O
TOF O
- O
MS O
/ O
UV O
. O

Approximately O
10 O
% O
of O
added O
nortriptyline B
was O
converted O
to O
hydroxylated O
products O
after O
50 O
d O
of O
incubation O
. O

In O
summary O
, O
amitriptyline B
persisted O
in O
agricultural O
soils O
with O
major O
dissipation O
mechanisms O
, O
including O
forming O
nonextractable O
residues O
and O
producing O
various O
transformation O
products O
including O
the O
psychoactive O
drug O
nortriptyline B
. O

Mercury B
in O
the O
seafood O
and O
human O
exposure O
in O
coastal O
area O
of O
Guangdong O
province O
, O
South O
China O
. O

Consumption O
of O
fish O
and O
aquatic O
products O
is O
considered O
to O
be O
the O
main O
pathway O
of O
human O
exposure O
to O
methylmercury B
( O
MeHg B
) O
. O

To O
assess O
human O
health O
risk O
through O
seafood O
consumption O
in O
a O
coastal O
area O
of O
Guangdong O
Province O
, O
South O
China O
, O
a O
total O
of O
518 O
seafood O
samples O
( O
including O
fish O
, O
shrimp O
, O
crabs O
, O
and O
mollusks O
) O
were O
collected O
from O
11 O
coastal O
cities O
for O
total O
mercury B
( O
THg O
) O
analysis O
. O

The O
median O
of O
probable O
daily O
intakes O
( O
PDIs O
) O
of O
MeHg B
via O
seafood O
consumption O
ranged O
from O
42 O
. O
6 O
to O
71 O
. O
4 O
ng O
/ O
g O
for O
different O
age O
groups O
, O
with O
fish O
contributing O
the O
major O
portion O
( O
84 O
% O
) O
. O

A O
carbon B
nanotube O
synapse O
with O
dynamic O
logic O
and O
learning O
. O

A O
carbon B
nanotube O
( O
CNT O
) O
synapse O
emulates O
a O
biological O
synapse O
with O
its O
dynamic O
logic O
, O
learning O
, O
and O
memory O
functions O
induced O
by O
the O
interactions O
between O
CNTs O
and O
hydrogen B
ions O
in O
an O
electrochemical O
cell O
. O

Tetracyclic O
BePI O
derivatives O
are O
characterized O
by O
a O
particular O
curved O
shape O
, O
and O
the O
presence O
of O
an O
oxo B
group O
on O
the O
pyridine B
ring O
was O
found O
to O
be O
required O
for O
aurora O
kinase O
B O
inhibition O
. O

Practical O
synthesis O
of O
( O
20S O
) O
- O
10 O
- O
( O
3 O
- O
aminopropyloxy O
) O
- O
7 O
- O
ethylcamptothecin O
, O
a O
water O
- O
soluble O
analogue O
of O
camptothecin B
. O

A O
robust O
, O
practical O
synthesis O
of O
( O
20S O
) O
- O
10 O
- O
( O
3 O
- O
aminopropyloxy O
) O
- O
7 O
- O
ethylcamptothecin O
( O
T O
- O
2513 O
, O
5 O
) O
, O
which O
is O
a O
water O
- O
soluble O
analogue O
of O
camptothecin B
, O
has O
been O
developed O
. O

It O
is O
found O
that O
the O
BolA O
- O
like O
dual O
ligands O
system O
exhibits O
significantly O
enhanced O
gene O
expression O
in O
both O
HeLa O
and O
293T O
cell O
lines O
, O
as O
compared O
with O
poly O
( O
ethylenimine O
) O
PEI B
. O

Chloroform B
- O
acetone B
extract O
of O
the O
aerial O
parts O
of O
Euphorbia O
aellenii O
Rech O
. O

This O
led O
to O
the O
isolation O
of O
two O
new O
and O
one O
known O
cyclomyrsinol O
- O
type O
diterpenes B
1 O
- O
3 O
. O

The O
structures O
were O
elucidated O
on O
the O
basis O
of O
1D O
and O
2D O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
techniques O
, O
and O
in O
vitro O
immunomodulatory O
activity O
was O
evaluated O
by O
standard O
proliferation O
of O
human O
peripheral O
blood O
lymphocytes O
. O

Here O
we O
report O
on O
the O
preparation O
of O
SBMs O
on O
silica B
surfaces O
via O
a O
similar O
process O
of O
" O
micelle O
fusion O
" O
from O
a O
cationic O
single O
- O
tail O
bolaamphiphile O
GLH O
- O
20 O
that O
forms O
spherical O
and O
elongated O
thread O
- O
like O
micelles O
in O
solution O
. O

The O
cationic O
charge O
of O
GLH O
- O
20 O
promotes O
the O
formation O
of O
a O
stable O
SBM O
through O
enhanced O
double O
- O
layer O
interactions O
with O
the O
negatively O
charged O
silica B
surface O
. O

Thyroid B
hormone I
replacement O
therapy O
attenuates O
the O
decline O
of O
renal O
function O
in O
chronic O
kidney O
disease O
patients O
with O
subclinical O
hypothyroidism O
. O

Even O
though O
previous O
studies O
have O
demonstrated O
that O
thyroid B
hormone I
replacement O
therapy O
( O
THRT O
) O
improved O
cardiac O
function O
and O
dyslipidemia O
in O
patients O
with O
subclinical O
hypothyroidism O
, O
it O
remains O
unclear O
as O
to O
whether O
THRT O
can O
improve O
renal O
function O
in O
CKD O
patients O
with O
SH O
. O

Serum O
albumin O
, O
calcium B
, O
phosphate B
, O
cholesterol B
, O
and O
triglyceride B
levels O
were O
also O
comparable O
after O
THRT O
. O

The O
rates O
of O
decline O
in O
eGFR O
were O
significantly O
attenuated O
by O
THRT O
[ O
- O
4 O
. O
31 O
( O
0 O
. O
51 O
) O
vs O
. O
- O
1 O
. O
08 O
( O
0 O
. O
36 O
) O
mL O
/ O
min O
/ O
year O
/ O
1 O
. O
73 O
m2 O
, O
P O
< O
0 O
. O
001 O
] O
even O
after O
adjustment O
for O
age O
, O
gender O
, O
diabetes O
, O
mean O
arterial O
pressure O
, O
serum O
albumin O
, O
cholesterol B
, O
and O
triglyceride B
concentrations O
( O
P O
< O
0 O
. O
001 O
) O
. O

Two O
[ O
4Fe B
- I
4S I
] O
clusters O
containing O
radical O
SAM O
enzyme O
SkfB O
catalyze O
thioether B
bond O
formation O
during O
the O
maturation O
of O
the O
sporulation O
killing O
factor O
. O

Like O
all O
sactipeptides O
, O
SKF O
contains O
a O
thioether B
bond O
, O
which O
links O
the O
cysteine B
residue O
Cys4 O
with O
the O
alpha B
- I
carbon I
of O
the O
methionine B
residue O
Met12 O
. O

In O
this O
study O
we O
demonstrate O
that O
this O
bond O
is O
generated O
by O
the O
two O
[ O
4Fe B
- I
4S I
] O
clusters O
containing O
radical O
SAM B
enzyme O
SkfB O
, O
which O
is O
encoded O
in O
the O
skf O
operon O
. O

Furthermore O
, O
we O
were O
able O
to O
show O
that O
thioether B
bond O
formation O
is O
specific O
toward O
hydrophobic O
amino B
acids I
at O
the O
acceptor O
site O
. O

Additionally O
we O
demonstrate O
that O
generation O
of O
the O
thioether B
linkage O
is O
leader O
- O
peptide O
- O
dependent O
, O
suggesting O
that O
this O
reaction O
is O
the O
first O
step O
in O
SKF O
maturation O
. O

Structure O
- O
based O
investigation O
of O
rat O
aldehyde B
oxidase O
inhibition O
by O
flavonoids B
. O

Flavonoids B
are O
a O
group O
of O
polyphenolic B
plant O
metabolites O
most O
commonly O
known O
for O
their O
antioxidant O
activities O
. O

Most O
notably O
, O
aldehyde B
oxidase O
( O
AO O
) O
, O
a O
member O
of O
this O
family O
, O
is O
responsible O
for O
metabolism O
of O
some O
therapeutic O
agents O
. O

As O
flavonoids B
are O
ubiquitous O
in O
human O
diet O
and O
have O
potential O
to O
interact O
with O
AO O
, O
it O
is O
important O
to O
investigate O
their O
effects O
at O
the O
molecular O
details O
. O

The O
inhibitory O
effects O
of O
15 O
flavonoids B
on O
the O
activity O
of O
rat O
liver O
AO O
were O
assessed O
. O

To O
further O
understand O
the O
mode O
of O
interaction O
between O
these O
flavonoids B
and O
AO O
, O
a O
homology O
model O
of O
the O
enzyme O
was O
built O
and O
flavonoids B
were O
docked O
into O
its O
active O
site O
. O

The O
most O
important O
amino B
acids I
involved O
in O
the O
interactions O
were O
identified O
. O

Quercetin B
, O
myricetin B
and O
genistein B
were O
the O
most O
potent O
inhibitors O
establishing O
favorable O
interactions O
with O
the O
enzyme O
. O

However O
, O
the O
glycosylated O
flavonoids O
showed O
relatively O
weaker O
inhibition O
which O
may O
be O
attributed O
to O
their O
hindered O
binding O
into O
the O
active O
site O
of O
AO O
by O
bulky O
sugar B
groups O
. O

Four O
new O
aaptamine O
derivatives O
( O
1 O
- O
4 O
) O
along O
with O
aaptamine O
( O
5 O
) O
and O
three O
related O
compounds O
( O
6 O
- O
8 O
) O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
sponge O
Aaptos O
suberitoides O
collected O
in O
Indonesia O
. O

Why O
is O
quercetin B
a O
better O
antioxidant O
than O
taxifolin O
? O

The O
stronger O
antioxidant O
capacity O
of O
the O
flavonoid O
quercetin B
( O
Q O
) O
compared O
with O
taxifolin O
( O
dihydroquercetin O
, O
T O
) O
has O
been O
the O
subject O
of O
previous O
experimental O
and O
theoretical O
studies O
. O

Theoretical O
work O
has O
focused O
on O
the O
analysis O
of O
hydrogen B
bond O
dissociation O
energies O
( O
BDE O
) O
of O
the O
OH B
phenolic B
groups O
, O
but O
consider O
mechanisms O
that O
only O
involve O
the O
transfer O
of O
one O
hydrogen B
atom O
. O

In O
the O
present O
work O
we O
consider O
other O
mechanisms O
involving O
a O
second O
hydrogen B
transfer O
in O
reactions O
with O
free O
radicals O
. O

The O
relative O
stability O
of O
the O
radicals O
formed O
after O
the O
first O
hydrogen B
transfer O
reaction O
is O
considered O
in O
discussing O
the O
antioxidant O
activity O
of O
Q O
and O
T O
. O

In O
terms O
of O
global O
and O
local O
theoretical O
reactivity O
descriptors O
, O
we O
propose O
that O
the O
radical O
arising O
from O
Q O
should O
be O
more O
persistent O
in O
the O
environment O
and O
with O
the O
capability O
to O
react O
with O
a O
second O
radical O
by O
hydrogen B
transfer O
, O
proton O
transfer O
and O
electron O
transfer O
mechanisms O
. O

As O
CEs O
hydrolyze O
clinically O
used O
drugs O
, O
the O
ability O
of O
tanshinones O
and O
S O
. O
miltiorrhiza O
root O
extracts O
to O
modulate O
the O
metabolism O
of O
the O
anticancer O
prodrug O
irinotecan B
( O
CPT O
- O
11 O
) O
was O
assessed O
. O

Multifunctional O
mesoporous O
nanocomposites O
with O
magnetic O
, O
optical O
, O
and O
sensing O
features O
: O
synthesis O
, O
characterization O
, O
and O
their O
oxygen B
- O
sensing O
performance O
. O

In O
this O
paper O
, O
the O
fabrication O
, O
characterization O
, O
and O
application O
in O
oxygen B
sensing O
are O
reported O
for O
a O
novel O
multifunctional O
nanomaterial O
of O
[ O
Ru O
( O
bpy O
) O
( O
2 O
) O
phen O
- O
MMS O
] O
( O
bpy B
, O
2 O
, O
2 O
' O
- O
bipyridyl O
; O
phen O
, O
phenathrolin O
) O
which O
was O
simply O
prepared O
by O
covalently O
grafting O
the O
ruthenium O
( O
II O
) O
polypyridyl O
compounds O
into O
the O
channels O
of O
magnetic O
mesoporous O
silica B
nanocomposites O
( O
MMS O
) O
. O

In O
addition O
, O
the O
obtained O
nanocomposites O
give O
high O
performance O
in O
oxygen B
sensing O
with O
high O
sensitivity O
( O
I O
( O
0 O
) O
/ O
I O
( O
100 O
) O
= O
5 O
. O
2 O
) O
, O
good O
Stern O
- O
Volmer O
characteristics O
( O
R O
( O
2 O
) O
= O
0 O
. O
9995 O
) O
, O
and O
short O
response O
/ O
recovery O
times O
( O
t O
v O
= O
6 O
s O
and O
t O
^ O
= O
12 O
s O
) O
. O

The O
magnetic O
, O
mesoporous O
, O
luminescent O
, O
and O
oxygen B
- O
sensing O
properties O
of O
this O
multifunctional O
nanostructure O
make O
it O
hold O
great O
promise O
as O
a O
novel O
multifunctional O
oxygen B
- O
sensing O
system O
for O
chemical O
/ O
biosensor O
. O

Recently O
, O
it O
has O
been O
reported O
that O
reactive O
oxygen B
species O
( O
ROS O
) O
produced O
by O
contact O
allergens O
can O
affect O
dendritic O
cell O
migration O
and O
contact O
hypersensitivity O
. O

Inhibition O
of O
T O
- O
type O
calcium B
channels O
disrupts O
Akt O
signaling O
and O
promotes O
apoptosis O
in O
glioblastoma O
cells O
. O

T O
- O
type O
calcium B
channels O
are O
one O
type O
of O
low O
voltage O
- O
gated O
channel O
( O
LVCC O
) O
involved O
in O
embryonic O
cell O
proliferation O
and O
differentiation O
; O
however O
they O
are O
often O
over O
- O
expressed O
in O
tumors O
, O
including O
GBM O
. O

In O
this O
study O
, O
we O
found O
that O
inhibition O
of O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
GBM O
cells O
significantly O
reduced O
their O
survival O
and O
resistance O
to O
therapy O
. O

The O
apoptotic O
response O
was O
specific O
for O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
, O
as O
inhibition O
of O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
did O
not O
induce O
similar O
effects O
. O

Our O
results O
implicate O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
as O
distinct O
entities O
for O
survival O
signaling O
in O
GBM O
cells O
and O
suggest O
that O
they O
are O
a O
novel O
molecular O
target O
for O
tumor O
therapy O
. O

Cis O
- O
hinokiresinol O
, O
a O
naturally O
occurring O
phenylpropanoid B
, O
was O
previously O
reported O
to O
possess O
anti O
- O
oxidant O
, O
anti O
- O
inflammatory O
and O
estrogen B
- O
like O
activities O
. O

The O
ORAC O
and O
DPPH B
assays O
showed O
that O
two O
isomers O
had O
similar O
free O
radical O
scavenging O
activities O
. O

However O
, O
only O
trans O
- O
hinokiresinol O
significantly O
decreased O
neuronal O
injury O
in O
cultured O
cortical O
neurons O
exposed O
to O
oxygen B
- O
glucose B
deprivation O
( O
75 O
min O
) O
followed O
by O
re O
- O
oxygenation O
( O
9 O
h O
) O
. O

The O
differential O
neuroprotective O
effect O
could O
be O
due O
to O
the O
stereo O
- O
specific O
augmentation O
of O
Cu B
/ O
Zn B
- O
SOD O
activity O
by O
trans O
- O
hinokiresinol O
, O
when O
compared O
with O
cis O
- O
hinokiresinol O
. O

The O
N B
- O
terminus O
of O
CBPTI O
- O
1 O
was O
modified O
and O
not O
amenable O
to O
Edman O
degradation O
sequencing O
, O
however O
an O
internal O
partial O
sequence O
was O
found O
to O
be O
SGRCRGHLRRIYYNPDSNKC O
. O

The O
N B
- O
termini O
of O
CBPTI O
- O
2 O
and O
CBPTI O
- O
3 O
were O
unmodified O
and O
their O
partial O
sequences O
were O
established O
as O
HDRPTFCNLAPESGRCRAH O
and O
HDRPKFCYLPADPGECMAYI O
respectively O
. O

From O
cloning O
studies O
CBPTI O
- O
1 O
was O
found O
to O
consist O
of O
66 O
amino B
acid I
residues O
, O
while O
CBPTI O
- O
2 O
and O
CBPTI O
- O
3 O
precursors O
consist O
of O
60 O
amino B
acid I
residues O
, O
including O
6 O
cysteine B
residues O
. O

Alignment O
of O
cDNA O
sequences O
showed O
that O
CBPTI O
- O
3 O
exhibited O
similar O
sequence O
homology O
to O
CBPTI O
- O
4 O
cDNA O
except O
for O
an O
8 O
nucleotide B
deletion O
in O
the O
open O
- O
reading O
frame O
. O

Previous O
phytochemical O
studies O
have O
shown O
that O
the O
plants O
of O
the O
Albizia O
genus O
( O
Fabaceae O
) O
contain O
bioactive O
saponins B
, O
lignans B
, O
spermine O
alkaloids O
, O
flavonoids B
, O
glycosides O
phenols O
and O
pyridoxine B
derivatives O
. O

This O
result O
was O
remarkable O
because O
chemical O
modifications O
of O
the O
sugar B
moieties O
and O
nucleobases O
of O
antiparallel O
TFOs O
generally O
destabilize O
triplex O
structures O
. O

Emerging O
evidence O
suggests O
that O
the O
model O
alkylating O
agents O
methyl B
- O
and O
ethylmethanesulfonat O
and O
methylnitrosourea O
( O
MNU O
) O
and O
ethylnitrosourea O
observe O
a O
nonlinear O
dose O
- O
response O
with O
a O
no O
observed O
genotoxic O
effect O
level O
( O
NOGEL O
) O
. O

Here O
, O
we O
tested O
MNU O
at O
10 O
- O
fold O
lower O
concentrations O
than O
a O
previous O
study O
and O
report O
a O
NOGEL O
of O
0 O
. O
0075 O
micro O
g O
/ O
ml O
( O
72 O
. O
8nM O
) O
in O
human O
lymphoblastoid O
cells O
, O
quantified O
through O
the O
hypoxanthine B
( O
guanine B
) O
phosphoribosyltransf O
assay O
( O
OECD O
476 O
) O
. O

An O
animal O
model O
of O
marginal O
iodine B
deficiency O
during O
development O
: O
the O
thyroid O
axis O
and O
neurodevelopmental O
outcome O
. O

Thyroid O
hormones O
( O
THs O
) O
are O
essential O
for O
brain O
development O
, O
and O
iodine B
is O
required O
for O
TH O
synthesis O
. O

This O
study O
examined O
the O
dose O
- O
response O
characteristics O
of O
marginal O
iodine B
deficiency O
( O
ID O
) O
on O
parameters O
of O
thyroid O
function O
and O
neurodevelopment O
. O

Diets O
deficient O
in O
iodine B
were O
prepared O
by O
adding O
975 O
, O
200 O
, O
125 O
, O
25 O
, O
or O
0 O
micro O
g O
/ O
kg O
potassium O
iodate O
to O
the O
base O
casein O
diet O
to O
produce O
five O
nominal O
iodine B
levels O
ranging O
from O
ample O
( O
Diet O
1 O
: O
1000 O
mu O
g O
iodine B
/ O
kg O
chow O
, O
D1 O
) O
to O
deficient O
( O
Diet O
5 O
: O
25 O
micro O
g O
iodine B
/ O
kg O
chow O
, O
D5 O
) O
. O

Blood O
, O
thyroid O
gland O
, O
and O
brain O
were O
collected O
for O
analysis O
of O
iodine B
, O
TH O
, O
and O
TH O
precursors O
and O
metabolites O
. O

Serum O
and O
thyroid O
gland O
iodine B
and O
TH O
were O
reduced O
in O
animals O
receiving O
two O
diets O
that O
were O
most O
deficient O
in O
iodine B
. O

Neurobehavior O
, O
assessed O
by O
acoustic O
startle O
, O
water O
maze O
learning O
, O
and O
fear O
conditioning O
, O
was O
unchanged O
in O
adult O
offspring O
, O
but O
excitatory O
synaptic O
transmission O
was O
impaired O
in O
the O
dentate O
gyrus O
in O
animals O
receiving O
two O
diets O
that O
were O
most O
deficient O
in O
iodine B
. O

Sunitinib B
, O
a O
tyrosine B
kinase O
inhibitor O
, O
induces O
cytochrome O
P450 O
1A1 O
gene O
in O
human O
breast O
cancer O
MCF7 O
cells O
through O
ligand O
- O
independent O
aryl B
hydrocarbon I
receptor O
activation O
. O

Sunitinib B
( O
SUN O
) O
is O
a O
new O
multi O
- O
targeted O
oral O
tyrosine B
kinase O
inhibitor O
that O
has O
both O
anti O
- O
angiogenic O
and O
anti O
- O
tumor O
activities O
. O

The O
increase O
in O
CYP1A1 O
mRNA O
by O
SUN O
was O
completely O
blocked O
by O
the O
transcriptional O
inhibitor O
, O
actinomycin B
D I
; O
implying O
that O
SUN O
increased O
de O
novo O
RNA O
synthesis O
. O

Furthermore O
, O
the O
ability O
of O
SUN O
to O
increase O
luciferase O
reporter O
gene O
expression O
suggests O
an O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
dependent O
transcriptional O
control O
and O
excludes O
the O
possibility O
of O
any O
posttranscriptional O
mechanisms O
. O

Pharmacokinetic O
profile O
of O
artemisinin B
derivatives O
and O
companion O
drugs O
used O
in O
artemisinin B
- O
based O
combination O
therapies O
for O
the O
treatment O
of O
Plasmodium O
falciparum O
malaria O
in O
children O
. O

The O
objectives O
of O
this O
review O
are O
to O
summarize O
and O
evaluate O
published O
literature O
reporting O
the O
pharmacokinetic O
parameters O
of O
artemisinin B
- O
based O
combinations O
used O
to O
treat O
P O
. O
falciparum O
in O
paediatric O
populations O
and O
to O
identify O
and O
discuss O
controversies O
regarding O
pharmacokinetics O
of O
these O
agents O
in O
children O
. O

Our O
search O
produced O
30 O
articles O
, O
of O
which O
23 O
were O
included O
in O
the O
review O
: O
artemisinin B
compounds O
, O
12 O
articles O
; O
lumefantrine O
, O
four O
articles O
; O
amodiaquine B
, O
five O
articles O
; O
sulfadoxine O
, O
six O
articles O
; O
pyrimethamine O
, O
one O
article O
; O
mefloquine O
, O
three O
articles O
; O
and O
piperaquine O
, O
two O
articles O
. O

Regiospecificity O
and O
stereospecificity O
of O
human O
UDP B
- O
glucuronosyltransfer O
in O
the O
glucuronidation O
of O
estriol O
, O
16 O
- O
epiestriol O
, O
17 O
- O
epiestriol O
, O
and O
13 O
- O
epiestradiol O
. O

The O
glucuronidation O
of O
estriol O
, O
16 O
- O
epiestriol O
, O
and O
17 O
- O
epiestriol O
by O
the O
human O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
of O
subfamilies O
1A O
, O
2A O
, O
and O
2B O
was O
examined O
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 O
- O
OH O
in O
all O
these O
estriols O
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 O
- O
OH O
in O
estriol O
and O
16 O
- O
epiestriol O
, O
but O
the O
17 B
- I
OH I
in O
17 O
- O
epiestriol O
. O

Kinetic O
analyses O
indicated O
that O
the O
17 B
- I
OH I
configuration O
plays O
a O
major O
role O
in O
the O
affinity O
of O
UGT2B7 O
for O
estrogens B
. O

To O
this O
study O
on O
estriol O
glucuronidation O
we O
have O
added O
experiments O
with O
13 O
- O
epiestradiol O
, O
a O
synthetic O
estradiol B
in O
which O
the O
spatial O
arrangement O
of O
the O
methyl B
on O
C18 O
and O
the O
hydroxyl B
on O
C17 O
is O
significantly O
different O
than O
in O
other O
estrogens B
. O

In O
comparison O
with O
estradiol B
glucuronidation O
, O
the O
C13 O
configuration O
change O
decreases O
the O
turnover O
of O
UGTs O
that O
conjugate O
the O
3 O
- O
OH O
, O
but O
increases O
it O
in O
UGTs O
that O
primarily O
conjugate O
the O
17 B
- I
OH I
. O

Unexpectedly O
, O
UGT2B17 O
exhibited O
similar O
conjugation O
rates O
of O
both O
the O
17 B
- I
OH I
and O
3 O
- O
OH O
of O
13 O
- O
espiestradiol O
. O

The O
combined O
results O
reveal O
the O
strong O
preference O
of O
UGT1A10 O
for O
the O
3 O
- O
OH O
of O
physiologic O
estrogens B
and O
the O
equivalently O
strong O
preference O
of O
UGT2B7 O
and O
UGT2B17 O
for O
the O
hydroxyls B
on O
ring O
D O
of O
such O
steroid O
hormones O
. O

Induced O
expression O
of O
cytochrome O
P450 O
1A O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
determined O
at O
mRNA O
, O
protein O
, O
and O
enzyme O
activity O
levels O
in O
rats O
exposed O
to O
the O
carcinogenic O
azo B
dye O
1 O
- O
phenylazo O
- O
2 O
- O
naphthol O
( O
Sudan O
I O
) O
. O

Western O
blots O
using O
antibodies O
raised O
against O
various O
P450s O
, O
NADPH B
: O
P450 O
reductase O
, O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
showed O
that O
the O
expression O
of O
P450 O
1A1 O
and O
NQO1 O
was O
induced O
in O
the O
liver O
, O
kidney O
, O
and O
lung O
of O
rats O
treated O
with O
Sudan O
I O
. O

Because O
P450 O
1A1 O
is O
playing O
a O
major O
role O
in O
the O
bioactivation O
of O
Sudan O
I O
in O
rat O
and O
human O
systems O
, O
its O
induction O
by O
Sudan O
I O
may O
have O
a O
profound O
effect O
on O
cancer O
risk O
by O
this O
azo B
dye O
. O

A O
beta O
interacts O
with O
both O
the O
iron B
center O
and O
the O
porphyrin B
ring O
of O
heme B
: O
mechanism O
of O
heme B
' O
s O
action O
on O
A O
beta O
aggregation O
and O
disaggregation O
. O

Interestingly O
, O
heme B
has O
been O
found O
to O
inhibit O
A O
beta O
aggregation O
and O
even O
dismantle O
A O
beta O
aggregates O
. O

Recent O
research O
has O
shown O
that O
heme B
binds O
preferentially O
to O
the O
His B
( O
13 O
) O
residue O
of O
A O
beta O
with O
the O
iron B
center O
, O
while O
the O
hydrophobic O
domain O
of O
A O
beta O
is O
also O
able O
to O
bind O
to O
heme B
. O

Herein O
, O
absorption O
spectrometric O
, O
Thioflavin B
T I
fluorescence O
, O
and O
circular O
dichroism O
spectroscopic O
and O
transmission O
electron O
microscopic O
measurements O
revealed O
that O
the O
iron B
center O
is O
not O
required O
for O
the O
inhibition O
of O
A O
beta O
aggregation O
but O
do O
influence O
the O
binding O
affinity O
of O
heme B
toward O
A O
beta O
and O
the O
dismantlement O
rate O
and O
degree O
of O
the O
A O
beta O
aggregates O
. O

By O
studying O
the O
interaction O
of O
different O
truncated O
or O
mutated O
A O
beta O
peptides O
with O
heme B
or O
protoporphyrin O
, O
we O
further O
found O
that O
the O
porphyrin B
ring O
of O
heme B
is O
implicated O
to O
interact O
preferentially O
with O
the O
Phe B
( O
19 O
) O
residue O
, O
facilitating O
the O
binding O
of O
heme B
to O
A O
beta O
and O
disturbing O
the O
interstrand O
aromatic O
interaction O
between O
the O
Phe B
residues O
, O
which O
is O
crucial O
for O
A O
beta O
fibrillation O
. O

These O
findings O
open O
new O
avenues O
in O
the O
understanding O
of O
the O
interaction O
between O
the O
heme B
and O
A O
beta O
and O
the O
pathways O
for O
modulation O
of O
A O
beta O
aggregation O
and O
disaggregation O
, O
which O
would O
be O
helpful O
in O
designing O
therapeutic O
strategies O
against O
AD O
. O

The O
mushroom O
Agaricus O
brasiliensis O
( O
sun O
mushroom O
) O
, O
native O
from O
the O
southeast O
of O
Brazil O
, O
is O
well O
known O
by O
its O
medicinal O
properties O
that O
include O
effects O
on O
diabetes O
, O
cholesterol B
levels O
, O
and O
osteoporosis O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
effect O
of O
the O
A O
. O
brasiliensis O
extract O
prepared O
in O
two O
different O
temperatures O
, O
4 O
degrees O
C O
and O
25 O
degrees O
C O
, O
on O
the O
doxorubicin B
- O
induced O
DNA O
strand O
breaks O
and O
chromosomal O
aberrations O
( O
CAs O
) O
in O
human O
lymphocytes O
. O

A O
new O
strategy O
for O
intracellular O
delivery O
of O
enzyme O
using O
mesoporous O
silica B
nanoparticles O
: O
superoxide B
dismutase O
. O

We O
developed O
mesoporous O
silica B
nanoparticle O
( O
MSN O
) O
as O
a O
multifunctional O
vehicle O
for O
enzyme O
delivery O
. O

Enhanced O
transmembrane O
delivery O
of O
a O
superoxide B
dismutase O
( O
SOD O
) O
enzyme O
embedded O
in O
MSN O
was O
demonstrated O
. O

Conjugation O
of O
the O
cell O
- O
penetrating O
peptide O
derived O
from O
the O
human O
immunodeficiency O
virus O
1 O
( O
HIV O
) O
transactivator O
protein O
( O
TAT O
) O
to O
mesoporous O
silica B
nanoparticle O
is O
shown O
to O
be O
an O
effective O
way O
to O
enhance O
transmembrane O
delivery O
of O
nanoparticles O
for O
intracellular O
and O
molecular O
therapy O
. O

Cu B
, O
Zn B
- O
superoxide B
dismutase O
( O
SOD O
) O
is O
a O
key O
antioxidant O
enzyme O
that O
detoxifies O
intracellular O
reactive O
oxygen B
species O
, O
ROS O
, O
thereby O
protecting O
cells O
from O
oxidative O
damage O
. O

In O
this O
study O
, O
we O
fused O
a O
human O
Cu B
, O
Zn B
- O
SOD O
gene O
with O
TAT O
in O
a O
bacterial O
expression O
vector O
to O
produce O
a O
genetic O
in O
- O
frame O
His O
- O
tagged O
TAT O
- O
SOD O
fusion O
protein O
. O

The O
His O
- O
tagged O
TAT O
- O
SOD O
fusion O
protein O
was O
expressed O
in O
E O
. O
coli O
using O
IPTG O
induction O
and O
purified O
using O
FMSN O
- O
Ni B
- O
NTA O
. O

In O
this O
study O
, O
we O
analysed O
CB1 O
expression O
, O
binding O
and O
signalling O
in O
the O
hippocampus O
of O
conditional O
mutant O
mice O
, O
bearing O
CB1 O
deletion O
in O
GABAergic O
( O
GABA O
- O
CB1 O
- O
KO O
mice O
) O
or O
cortical O
glutamatergic O
neurons O
( O
Glu B
- O
CB1 O
- O
KO O
mice O
) O
. O

Compared O
to O
their O
wild O
- O
type O
littermates O
, O
Glu B
- O
CB1 O
- O
KO O
displayed O
a O
small O
decrease O
of O
CB1 O
mRNA O
amount O
, O
immunoreactivity O
and O
[ O
( O
3 O
) O
H O
] O
CP55 O
, O
940 O
binding O
. O

Conversely O
, O
GABA B
- O
CB1 O
- O
KO O
mice O
showed O
a O
drastic O
reduction O
of O
these O
parameters O
, O
confirming O
that O
CB1 O
is O
present O
at O
much O
higher O
density O
on O
hippocampal O
GABAergic O
interneurons O
than O
glutamatergic O
neurons O
. O

Surprisingly O
, O
however O
, O
saturation O
analysis O
of O
HU210 O
- O
stimulated O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
demonstrated O
that O
' O
glutamatergic O
' O
CB1 O
is O
more O
efficiently O
coupled O
to O
G O
protein O
signalling O
than O
' O
GABAergic O
' O
CB1 O
. O

Class O
III O
phosphatidylinositol B
3 O
- O
kinase O
and O
its O
catalytic O
product O
PtdIns3P O
in O
regulation O
of O
endocytic O
membrane O
traffic O
. O

Central O
in O
this O
context O
is O
class O
III O
phosphatidylinositol B
3 O
- O
kinase O
, O
an O
evolutionarily O
conserved O
enzyme O
complex O
that O
phosphorylates O
phosphatidylinositol B
into O
phosphatidylinositol O
3 O
- O
phosphate O
. O

Design O
, O
synthesis O
, O
characterization O
and O
biological O
evaluation O
of O
novel O
pyrazole B
integrated O
benzophenones B
. O

A O
series O
of O
novel O
pyrazole B
integrated O
benzophenones B
( O
9a O
- O
j O
) O
have O
been O
designed O
, O
synthesized O
from O
1 B
- I
methyl I
- I
5 I
- I
( I
2 I
, I
4 I
, I
6 I
- I
trimethoxy I
- I
phenyl I
) I
- I
1H I
- I
pyrazole I
6 O
. O

The O
structures O
of O
the O
regioisomers O
6 O
and O
7 O
were O
determined O
by O
2D O
( B
1 I
) I
H I
- O
( B
1 I
) I
H I
COSY O
, O
( B
1 I
) I
H I
- O
( B
13 I
) I
C I
HSQC O
and O
( B
1 I
) I
H I
- O
( B
13 I
) I
C I
HMBC O
experiments O
. O

Biophysical O
characterization O
of O
the O
drug O
- O
membrane O
interactions O
: O
The O
case O
of O
propranolol B
and O
acebutolol B
. O

The O
interaction O
of O
propranolol B
and O
acebutolol B
with O
biological O
membranes O
was O
assessed O
in O
the O
present O
work O
by O
using O
a O
range O
of O
biophysical O
techniques O
and O
liposomes O
, O
as O
membrane O
mimetic O
models O
. O

Moreover O
, O
small O
and O
wide O
angle O
X O
- O
ray O
scattering O
techniques O
were O
used O
to O
evaluate O
the O
beta O
- O
blockers O
effect O
on O
long O
range O
bilayer O
order O
and O
hydrocarbon B
chain O
packing O
. O

The O
gathered O
results O
highlighted O
the O
importance O
of O
electrostatic O
interactions O
between O
propranolol B
and O
acebutolol B
with O
membranes O
. O

In O
general O
, O
propranolol B
unveiled O
a O
more O
pronounced O
effect O
on O
membrane O
fluidity O
and O
structure O
than O
acebutolol B
. O

Cholinesterase O
and O
carboxylesterase O
inhibition O
in O
Planorbarius O
corneus O
exposed O
to O
binary O
mixtures O
of O
azinphos O
- O
methyl O
and O
chlorpyrifos B
. O

The O
present O
investigation O
was O
undertaken O
to O
explore O
the O
in O
vivo O
inhibition O
of O
the O
freshwater O
gastropod O
snail O
Planorbarius O
corneus O
cholinesterase O
( O
ChE O
) O
and O
carboxylesterases O
( O
CES O
) O
activities O
by O
the O
organophosphorus B
pesticides O
azinphos O
- O
methyl O
( O
AZM O
) O
and O
chlorpyrifos B
( O
CPF O
) O
. O

A O
range O
of O
metabolic O
pathways O
and O
responses O
associated O
with O
bioactivation O
or O
detoxification O
may O
play O
important O
roles O
in O
organophosphorus B
interactions O
. O

In O
vitro O
study O
of O
intestinal O
transport O
of O
fluoride B
using O
the O
Caco O
- O
2 O
cell O
line O
. O

Water O
and O
food O
are O
the O
main O
sources O
of O
fluoride B
exposure O
and O
therefore O
it O
is O
necessary O
to O
study O
intestinal O
absorption O
in O
order O
to O
make O
a O
correct O
evaluation O
of O
the O
risk O
/ O
benefit O
associated O
with O
exposure O
to O
fluoride B
. O

The O
present O
study O
characterizes O
intestinal O
transport O
of O
fluoride B
, O
using O
the O
Caco O
- O
2 O
cell O
line O
as O
a O
model O
of O
the O
intestinal O
epithelium O
, O
and O
evaluates O
the O
coefficients O
of O
apparent O
permeability O
and O
intracellular O
accumulation O
in O
various O
conditions O
( O
pH O
, O
temperature O
, O
opening O
of O
cell O
junctions O
, O
presence O
of O
anions O
) O
. O

The O
results O
indicate O
that O
fluoride B
is O
an O
element O
with O
moderate O
absorption O
( O
< O
70 O
% O
) O
in O
both O
directions O
( O
absorptive O
and O
secretory O
) O
. O

Absorption O
and O
secretion O
of O
fluoride B
increase O
at O
acid O
pH O
levels O
, O
possibly O
because O
of O
its O
non O
- O
ionized O
state O
at O
these O
pHs O
and O
/ O
or O
because O
of O
participation O
of O
a O
F B
( I
- I
) I
/ O
H B
( I
+ I
) I
cotransporter O
or O
a O
F B
( I
- I
) I
/ O
OH B
( I
- I
) I
antiporter O
. O

The O
results O
also O
suggest O
transcellular O
participation O
of O
mechanisms O
involved O
in O
transport O
of O
Cl B
( I
- I
) I
and O
of O
an O
active O
transport O
in O
the O
secretory O
direction O
. O

The O
present O
study O
extend O
the O
knowledge O
on O
the O
cellular O
transport O
of O
fluoride B
and O
provide O
the O
basis O
for O
future O
studies O
aimed O
at O
identifying O
potential O
transporters O
involved O
in O
human O
fluoride B
absorption O
. O

Bombesin B
receptor O
subtype O
- O
3 O
( O
BRS O
- O
3 O
) O
, O
a O
novel O
candidate O
as O
therapeutic O
molecular O
target O
in O
obesity O
and O
diabetes O
. O

BRS O
- O
3 O
KO O
- O
mice O
developed O
obesity O
and O
unbalanced O
glucose B
metabolism O
, O
suggesting O
an O
important O
role O
of O
BRS O
- O
3 O
receptor O
in O
glucose B
homeostasis O
. O

We O
explored O
BRS O
- O
3 O
expression O
in O
skeletal O
muscle O
from O
normal O
, O
obese O
or O
type O
- O
2 O
diabetic O
( O
T2D O
) O
patients O
, O
and O
the O
effect O
of O
[ O
D B
- I
Phe I
( O
6 O
) O
, O
beta O
- O
Ala O
( O
11 O
) O
, O
Phe B
( O
13 O
) O
, O
Nle B
( O
14 O
) O
] O
bombesin B
( O
6 O
- O
14 O
) O
- O
BRS O
- O
3 O
- O
agonist O
- O
peptide O
( O
BRS O
- O
3 O
- O
AP O
) O
- O
on O
glucose B
- O
related O
effects O
, O
before O
or O
after O
BRS O
- O
3 O
gene O
silencing O
. O

In O
normal O
, O
obese O
and O
T2D O
cells O
: O
A O
) O
BRS O
- O
3 O
- O
AP O
as O
insulin O
enhanced O
BRS O
- O
3 O
and O
GLUT O
- O
4 O
mRNA O
/ O
protein O
levels O
; O
improving O
glucotransporter O
translocation O
to O
plasma O
membrane O
, O
and O
B O
) O
BRS O
- O
3 O
- O
AP O
caused O
a O
concentration O
- O
related O
- O
stimulation O
of O
glucose B
transport O
, O
being O
obese O
and O
T2D O
myocytes O
more O
sensitive O
to O
the O
ligand O
than O
normal O
. O

Wortmannin B
and O
PD98059 B
, O
but O
not O
rapamycin B
, O
abolished O
the O
stimulatory O
action O
of O
BRS O
- O
3 O
- O
AP O
on O
glucose B
transport O
. O

BRS O
- O
3 O
plays O
an O
important O
role O
in O
glucose B
metabolism O
, O
and O
could O
be O
use O
as O
a O
molecular O
target O
, O
and O
/ O
or O
its O
ligand O
, O
as O
a O
therapeutic O
agent O
for O
obesity O
and O
diabetes O
treatments O
. O

Aryl B
hydrocarbon I
receptor O
activation O
attenuates O
Per1 O
gene O
induction O
and O
influences O
circadian O
clock O
resetting O
. O

Our O
previous O
studies O
indicate O
that O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
agonist O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
attenuates O
light O
- O
induced O
phase O
resetting O
in O
early O
night O
. O

In O
this O
study O
, O
we O
showed O
that O
another O
potent O
AhR O
agonist O
- O
beta B
- I
naphthoflavone I
( O
BNF B
) O
- O
significantly O
decreased O
light O
- O
induced O
phase O
shifts O
in O
wild O
- O
type O
( O
WT O
) O
mice O
, O
whereas O
AhR O
knockout O
mice O
had O
an O
enhanced O
response O
to O
light O
that O
was O
unaffected O
by O
BNF B
. O

Mechanistically O
, O
BNF B
blocked O
light O
induction O
of O
the O
Per1 O
transcript O
in O
suprachiasmatic O
nucleus O
and O
liver O
in O
WT O
mice O
, O
and O
BNF B
blocked O
forskolin B
( O
FSK O
) O
- O
induced O
Per1 O
transcripts O
in O
Hepa O
- O
1c1c7 O
( O
c7 O
) O
cells O
. O

An O
E O
- O
box O
decoy O
did O
not O
affect O
BNF B
inhibition O
of O
FSK O
- O
induced O
Per1 O
transcripts O
in O
c7 O
cells O
. O

cAMP B
- O
response O
element O
( O
CRE O
) O
- O
dependent O
induction O
of O
Per1 O
promoter O
activity O
in O
response O
to O
FSK O
in O
combination O
with O
phorbol O
12 O
- O
tetradecanoate O
13 O
- O
acetate O
was O
suppressed O
in O
cells O
that O
expressed O
high O
levels O
of O
AhR O
( O
c7 O
) O
compared O
with O
cells O
lacking O
functional O
AhR O
activity O
( O
c12 O
) O
. O

In O
addition O
, O
the O
inhibitory O
effect O
of O
BNF B
on O
FSK O
- O
induced O
Per1 O
was O
dependent O
on O
phosphorylation O
of O
JNK O
. O

Preparation O
, O
preliminary O
screening O
of O
new O
types O
of O
steroid B
conjugates O
and O
their O
activities O
on O
steroid B
receptors O
. O

There O
were O
synthesized O
new O
types O
of O
ribbon O
type O
steroidal O
dimers O
derived O
from O
three O
types O
of O
steroidal O
skeletons O
( O
cholic B
acid I
, O
etienic O
acid O
, O
estrone B
) O
using O
Cu B
( I
I I
) I
catalyzed O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
. O

Steroid B
parts O
of O
the O
molecular O
" O
ribbons O
" O
are O
linked O
by O
heterocyclic O
moiety O
, O
namely O
by O
2 O
, O
6 O
- O
bis O
( O
( O
1H O
- O
1 O
, O
2 O
, O
3 O
- O
triazol O
- O
1 O
- O
yl O
) O
- O
methyl O
) O
pyridine O
. O

Pregabalin B
abuse O
and O
dependence O
in O
Germany O
: O
results O
from O
a O
database O
query O
. O

PURPOSE O
: O
Pregabalin B
( O
PRG O
) O
is O
approved O
for O
the O
treatment O
of O
neuropathic O
pain O
, O
partial O
seizures O
and O
generalised O
anxiety O
disorder O
in O
many O
countries O
and O
currently O
under O
study O
for O
other O
indications O
. O

Marked O
decline O
in O
beta O
cell O
function O
during O
pregnancy O
leads O
to O
the O
development O
of O
glucose B
intolerance O
in O
Japanese O
women O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
glucose B
metabolism O
longitudinally O
during O
pregnancy O
to O
explore O
mechanisms O
underlying O
gestational O
diabetes O
mellitus O
( O
GDM O
) O
. O

We O
reviewed O
a O
total O
of O
62 O
pregnant O
Japanese O
women O
who O
underwent O
a O
75g O
oral O
glucose B
tolerance O
test O
( O
OGTT O
) O
twice O
during O
pregnancy O
( O
median O
: O
early O
, O
13 O
; O
late O
, O
28 O
weeks O
' O
gestation O
) O
because O
of O
positive O
GDM O
screening O
. O

Based O
on O
late O
OGTT O
, O
15 O
had O
GDM O
( O
late O
- O
onset O
GDM O
) O
and O
47 O
normal O
glucose B
tolerance O
( O
NGT O
) O
. O

In O
early O
pregnancy O
, O
there O
were O
no O
significant O
differences O
in O
insulin O
sensitivity O
( O
insulin O
sensitivity O
index O
derived O
from O
OGTT O
[ O
ISOGTT O
] O
and O
homeostasis O
model O
assessment O
for O
insulin O
resistance O
[ O
HOMA O
- O
IR O
] O
) O
and O
insulin O
secretion O
( O
a O
ratio O
of O
the O
total O
area O
- O
under O
- O
the O
- O
insulin O
- O
curve O
to O
the O
total O
area O
- O
under O
- O
the O
- O
glucose B
- O
curve O
[ O
AUCins O
/ O
glu O
] O
and O
insulinogenic O
index O
[ O
IGI O
] O
) O
between O
the O
NGT O
and O
late O
- O
onset O
GDM O
groups O
. O

In O
particular O
, O
introducing O
unnatural O
amino B
acids I
( O
UAAs O
) O
has O
enabled O
modifications O
that O
are O
not O
found O
in O
natural O
proteins O
. O

We O
show O
that O
UAAs O
inserted O
in O
the O
N B
- O
terminal O
domain O
of O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
( O
NMDARs O
) O
serve O
as O
photo O
- O
crosslinkers O
that O
lock O
the O
receptor O
in O
a O
discrete O
conformational O
state O
in O
response O
to O
UV O
photo O
treatment O
. O

Plasmon O
- O
Mediated O
Synthesis O
of O
Silver B
Cubes O
with O
Unusual O
Twinning O
Structures O
Using O
Short O
Wavelength O
Excitation O
. O

The O
plasmon O
- O
mediated O
synthesis O
of O
silver B
nanoparticles O
is O
a O
versatile O
synthetic O
method O
which O
leverages O
the O
localized O
surface O
plasmon O
resonance O
( O
LSPR O
) O
of O
nanoscale O
silver B
to O
generate O
particles O
with O
non O
- O
spherical O
shapes O
and O
control O
over O
dimensions O
. O

Herein O
, O
a O
method O
is O
reported O
for O
controlling O
the O
twinning O
structure O
of O
silver B
nanoparticles O
, O
and O
consequently O
their O
shape O
, O
via O
the O
plasmon O
- O
mediated O
synthesis O
, O
solely O
by O
varying O
the O
excitation O
wavelength O
between O
400 O
, O
450 O
, O
and O
500 O
nm O
, O
which O
modulates O
the O
rate O
of O
Ag B
( I
+ I
) I
reduction O
. O

With O
this O
method O
, O
silver B
cubes O
can O
be O
synthesized O
using O
450 O
nm O
excitation O
, O
which O
represents O
the O
first O
time O
this O
shape O
has O
been O
realized O
by O
a O
plasmon O
- O
mediated O
synthetic O
approach O
. O

Examination O
of O
three O
retinoid B
X O
receptor O
( O
RXR O
) O
agonists O
[ O
Targretin O
( O
TRG B
) O
, O
UAB30 O
, O
and O
4 O
- O
methyl O
- O
UAB30 O
( O
4 O
- O
Me O
- O
UAB30 O
) O
] O
showed O
that O
all O
inhibited O
mammary O
cancer O
in O
rodents O
and O
two O
( O
TRG B
and O
4 O
- O
Me O
- O
UAB30 O
) O
strikingly O
increased O
serum O
triglyceride B
levels O
. O

For O
proliferator O
- O
activated O
receptor O
alpha O
/ O
RXR O
- O
activated O
genes O
, O
the O
strongest O
response O
was O
TRG B
> O
4 O
- O
Me O
- O
UAB30 O
> O
UAB30 O
. O

Many O
liver O
X O
receptor O
/ O
RXR O
- O
related O
genes O
( O
e O
. O
g O
. O
, O
Scd O
- O
1 O
and O
Srebf1 O
, O
which O
are O
associated O
with O
increased O
triglycerides B
) O
were O
highly O
expressed O
in O
TRG B
and O
4 O
- O
Me O
- O
UAB30 O
- O
but O
not O
UAB30 O
- O
treated O
livers O
. O

Minimal O
expression O
changes O
were O
associated O
with O
retinoic B
acid I
receptor O
or O
vitamin B
D I
receptor O
heterodimers O
by O
any O
of O
the O
agonists O
. O

UAB30 O
unexpectedly O
and O
uniquely O
activated O
genes O
associated O
with O
the O
aryl B
hydrocarbon I
hydroxylase O
( O
Ah O
) O
receptor O
( O
Cyp1a1 O
, O
Cyp1a2 O
, O
Cyp1b1 O
, O
and O
Nqo1 O
) O
. O

Based O
on O
the O
Ah O
receptor O
activation O
, O
UAB30 O
was O
tested O
for O
its O
ability O
to O
prevent O
dimethylbenzanthrace O
( O
DMBA B
) O
- O
induced O
mammary O
cancers O
, O
presumably O
by O
inhibiting O
DMBA B
activation O
, O
and O
was O
highly O
effective O
. O

STK40 O
is O
a O
putative O
serine B
/ O
threonine B
kinase O
and O
was O
shown O
to O
induce O
extraembryonic O
endoderm O
differentiation O
from O
mouse O
embryonic O
stem O
cells O
. O

The O
authors O
evaluated O
effects O
of O
feeding O
ranch O
mink O
( O
Mustela O
vison O
) O
diets O
containing O
polychlorinated B
biphenyl I
( O
PCB B
) O
- O
contaminated O
fish O
from O
the O
upper O
Hudson O
River O
( O
New O
York O
, O
USA O
) O
on O
adult O
and O
offspring O
organ O
mass O
and O
pathology O
. O

Diets O
contained O
2 O
. O
5 O
to O
20 O
% O
Hudson O
River O
fish O
, O
providing O
0 O
. O
72 O
to O
6 O
. O
1 O
micro O
g O
Sigma O
PCBs B
/ O
g O
feed O
( O
4 O
. O
8 O
- O
38 O
pg O
toxic O
equivalents O
[ O
TEQWHO O
2005 O
] O
/ O
g O
feed O
) O
. O

Absolute O
thyroid O
and O
adrenal O
gland O
masses O
were O
increased O
in O
adult O
females O
and O
31 O
- O
week O
- O
old O
juveniles O
, O
respectively O
, O
and O
absolute O
liver O
and O
heart O
masses O
were O
decreased O
in O
six O
- O
week O
- O
old O
kits O
exposed O
to O
dietary O
PCBs B
. O

Dietary O
concentrations O
of O
0 O
. O
72 O
micro O
g O
Sigma O
PCBs B
/ O
g O
feed O
( O
4 O
. O
8 O
pg O
TEQWHO O
2005 O
/ O
g O
feed O
) O
and O
greater O
induced O
mandibular O
and O
maxillary O
squamous O
epithelial O
proliferation O
in O
adult O
animals O
. O

The O
dietary O
concentration O
of O
Sigma O
PCBs B
predicted O
to O
result O
in O
20 O
% O
incidence O
of O
the O
jaw O
lesion O
( O
EC20 O
) O
was O
2 O
. O
3 O
micro O
g O
Sigma O
PCBs B
/ O
g O
feed O
( O
15 O
pg O
TEQWHO O
2005 O
/ O
g O
feed O
) O
, O
and O
the O
hepatic O
concentration O
was O
2 O
. O
8 O
micro O
g O
Sigma O
PCBs B
/ O
g O
liver O
( O
89 O
pg O
TEQWHO O
2005 O
/ O
g O
liver O
) O
. O

The O
EC20 O
values O
were O
greater O
than O
the O
dietary O
and O
hepatic O
concentrations O
predicted O
to O
result O
in O
a O
20 O
% O
increase O
in O
kit O
mortality O
( O
LC20 O
) O
at O
six O
weeks O
of O
age O
( O
0 O
. O
34 O
micro O
g O
Sigma O
PCBs B
/ O
g O
feed O
or O
2 O
. O
6 O
pg O
TEQWHO O
2005 O
/ O
g O
feed O
and O
0 O
. O
80 O
micro O
g O
Sigma O
PCBs B
/ O
g O
liver O
or O
13 O
pg O
TEQWHO O
2005 O
/ O
g O
liver O
) O
. O

However O
, O
the O
EC20 O
values O
reflect O
exposure O
of O
adults O
to O
PCBs B
for O
approximately O
six O
months O
, O
and O
the O
LC20 O
values O
reflect O
exposure O
of O
offspring O
from O
conception O
onward O
. O

In O
this O
article O
, O
the O
genotoxic O
and O
antigenotoxic O
effects O
of O
methanol B
extract O
of O
Evernia O
prunastri O
( O
Huds O
. O
) O
Willd O
. O

According O
to O
the O
SCE O
test O
system O
, O
MEP O
reduced O
the O
genotoxic O
effects O
of O
aflatoxin B
. O

Cotreatments O
of O
5 O
, O
10 O
and O
20 O
micro O
g O
/ O
mL O
concentrations O
of O
MEP O
with O
aflatoxin B
B I
( I
1 I
) I
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde B
level O
and O
increased O
amount O
of O
superoxide B
dismutase O
, O
glutathione B
and O
glutathione B
peroxidase O
which O
were O
decreased O
by O
aflatoxin B
. O

This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O
N O
- O
methyl O
- O
N O
' O
- O
nitro O
- O
N O
- O
nitrosoguanidine O
, O
acridin O
and O
aflatoxin B
. O

The O
activities O
of O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
peroxidase O
, O
glutathione B
reductase O
and O
the O
levels O
of O
reduced B
glutathione I
, O
vitamins O
C O
and O
E O
in O
the O
liver O
and O
kidney O
of O
the O
animals O
decreased O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
contrast O
, O
malondialdehyde B
and O
lipid O
hydroperoxide B
of O
trona O
- O
treated O
animals O
increased O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
in O
liver O
and O
kidney O
. O

BOC O
, O
a O
known O
substrate O
for O
cytochrome O
P450 O
( O
P450 O
) O
CYP3A O
and O
aldo O
- O
ketoreductases O
, O
was O
a O
reversible O
time O
- O
dependent O
inhibitor O
( O
k O
( O
inact O
) O
= O
0 O
. O
12 O
minute O
( O
- O
1 O
) O
, O
K O
( O
I O
) O
= O
6 O
. O
1 O
micro O
M O
) O
of O
CYP3A4 O
/ O
5 O
but O
not O
an O
inhibitor O
of O
other O
major O
P450s O
, O
nor O
of O
UDP B
- O
glucuronosyltransfer O
1A1 O
and O
2B7 O
. O

In O
human O
hepatocytes O
, O
BOC O
inhibited O
CYP3A O
- O
mediated O
metabolism O
of O
midazolam O
, O
OATP1B O
- O
mediated O
hepatic O
uptake O
of O
pitavastatin O
, O
and O
both O
the O
uptake O
and O
metabolism O
of O
atorvastatin B
. O

The O
inhibitory O
potency O
of O
BOC O
was O
lower O
than O
known O
inhibitors O
of O
CYP3A O
( O
ketoconazole B
) O
, O
OATP1B O
( O
rifampin O
) O
, O
or O
both O
( O
telaprevir O
) O
. O

BOC O
was O
a O
substrate O
for O
Pgp O
and O
BCRP O
but O
not O
for O
OATP1B1 O
, O
OATP1B3 O
, O
OATP2B1 O
, O
organic O
cation O
transporter O
, O
or O
sodium B
/ O
taurocholate B
cotransporting O
peptide O
. O

The O
absolute O
configuration O
of O
1 O
was O
assigned O
by O
X O
- O
ray O
crystallography O
using O
Cu B
K O
alpha O
radiation O
, O
whereas O
those O
of O
the O
C O
- O
11 O
tertiary O
alcohols O
in O
2 O
and O
3 O
were O
deduced O
via O
the O
circular O
dichroism O
data O
of O
the O
in O
situ O
formed O
[ O
Rh O
( O
2 O
) O
( O
OCOCF O
( O
3 O
) O
) O
( O
4 O
) O
] O
complexes O
. O

Inhibitors O
of O
the O
Yersinia O
protein O
tyrosine B
phosphatase O
through O
high O
throughput O
and O
virtual O
screening O
approaches O
. O

The O
bacterial O
protein O
tyrosine B
phosphatase O
YopH O
is O
an O
essential O
virulence O
determinant O
in O
Yersinia O
pestis O
and O
a O
potential O
antibacterial O
drug O
target O
. O

S B
- I
nitrosoglutathione I
covalently O
modifies O
cysteine B
residues O
of O
human O
carbonyl B
reductase O
1 O
and O
affects O
its O
activity O
. O

Carbonyl B
reductase O
1 O
( O
CBR1 O
or O
SDR21C1 O
) O
is O
a O
ubiquitously O
- O
expressed O
, O
cytosolic O
, O
monomeric O
, O
and O
NADPH B
- O
dependent O
enzyme O
. O

S B
- I
Nitrosoglutathione I
( O
GSNO O
) O
represents O
the O
newest O
addition O
to O
its O
diverse O
substrate O
spectrum O
, O
which O
includes O
a O
wide O
range O
of O
xenobiotics O
and O
endogenous O
substances O
. O

The O
analysis O
confirmed O
GSNO O
concentration O
- O
dependent O
S O
- O
glutathionylation O
of O
cysteines B
at O
positions O
122 O
, O
150 O
, O
226 O
, O
227 O
which O
was O
2 O
- O
700 O
times O
higher O
compared O
to O
wild O
- O
type O
CBR1 O
( O
WT O
- O
CBR1 O
) O
. O

Moreover O
, O
a O
disulfide B
bond O
between O
neighboring O
Cys B
- O
226 O
and O
Cys B
- O
227 O
was O
detected O
. O

We O
suggest O
a O
role O
of O
these O
two O
cysteines B
as O
a O
redox O
- O
sensitive O
cysteine O
pair O
. O

GSNO O
treatment O
of O
CBR1 O
resulted O
in O
a O
2 O
- O
5 O
- O
fold O
decrease O
in O
kcat O
with O
menadione B
, O
4 O
- O
benzoylpyridine O
, O
2 O
, O
3 O
- O
hexanedione O
, O
daunorubicin O
and O
1 O
, O
4 O
- O
naphthoquinone O
. O

In O
contrast O
, O
the O
same O
treatment O
increased O
kcat O
for O
substrates O
containing O
a O
1 O
, O
2 O
- O
diketo O
group O
in O
a O
ring O
structure O
( O
1 O
, O
2 O
- O
naphthoquinone O
, O
9 O
, O
10 O
- O
phenanthrenequinone O
, O
isatin B
) O
. O

The O
findings O
indicate O
that O
GSNO O
- O
induced O
covalent O
modification O
of O
cysteine B
residues O
affects O
the O
kinetic O
mechanism O
of O
CBR1 O
both O
in O
terms O
of O
substrate O
binding O
and O
turnover O
rate O
, O
probably O
by O
covalent O
modification O
of O
Cys B
- O
226 O
and O
/ O
or O
Cys B
- O
227 O
. O

We O
investigated O
the O
influence O
of O
maternal O
airway O
exposure O
to O
nanoparticulate O
titanium B
dioxide I
( O
TiO2 B
, O
UV O
- O
Titan O
) O
and O
carbon B
black I
( O
CB O
, O
Printex90 O
) O
, O
on O
male O
reproductive O
function O
in O
the O
two O
following O
generations O
. O

Maternal O
particulate O
exposure O
did O
not O
affect O
DSP O
statistically O
significantly O
in O
the O
F1 O
generation O
, O
although O
TiO2 B
tended O
to O
reduce O
sperm O
counts O
. O

There O
was O
no O
effect O
on O
sperm O
production O
in O
the O
F2 O
generation O
originating O
after O
TiO2 B
exposure O
. O

SKF83959 O
( O
3 O
- O
methyl O
- O
6 O
- O
chloro O
- O
7 O
, O
8 O
- O
hydroxy O
- O
1 O
- O
[ O
3 O
- O
methylphenyl O
] O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrahydro O
- O
1H O
- O
3 O
- O
benzazepine O
) O
, O
an O
atypical O
dopamine B
receptor O
- O
1 O
( O
D O
( O
1 O
) O
receptor O
) O
agonist O
, O
has O
shown O
many O
D O
( O
1 O
) O
receptor O
- O
independent O
effects O
, O
such O
as O
neuroprotection O
, O
blockade O
of O
Na B
( I
+ I
) I
channel O
, O
and O
promotion O
of O
spontaneous O
glutamate B
release O
, O
which O
resemble O
the O
effects O
of O

The O
nuclear O
receptor O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
alpha O
is O
known O
primarily O
as O
a O
regulator O
of O
fatty B
acid I
metabolism O
, O
energy O
balance O
, O
and O
inflammation O
, O
but O
evidence O
suggests O
a O
wider O
role O
in O
regulating O
the O
biotransformation O
of O
drugs O
and O
other O
lipophilic O
chemicals O
. O

Furthermore O
, O
a O
humanized O
CYP3A4 O
/ O
3A7 O
mouse O
model O
showed O
in O
vivo O
induction O
of O
CYP3A4 O
mRNA O
and O
protein O
by O
[ O
4 O
- O
chloro O
- O
6 O
- O
( O
2 O
, O
3 O
- O
xylidino O
) O
- O
2 O
- O
pyrimidinylthio O
] O
acetic O
acid O
( O
WY14 B
, I
643 I
) O
in O
liver O
but O
not O
in O
intestine O
, O
whereas O
hepatic O
occupancy O
of O
PBRs O
by O
PPAR O
alpha O
was O
ligand O
independent O
. O

Using O
lentiviral O
gene O
knock O
- O
down O
and O
treatment O
with O
WY14 B
, I
643 I
in O
primary O
human O
hepatocytes O
, O
PPAR O
alpha O
was O
further O
shown O
to O
affect O
the O
expression O
of O
a O
distinct O
set O
of O
CYPs O
, O
including O
1A1 O
, O
1A2 O
, O
2B6 O
, O
2C8 O
, O
3A4 O
, O
and O
7A1 O
, O
but O
not O
2C9 O
, O
2C19 O
, O
2D6 O
, O
or O
2E1 O
. O

Interestingly O
, O
the O
common O
phospholipid O
1 O
- O
palmitoyl O
- O
2 O
- O
oleoyl O
- O
sn O
- O
glycerol O
- O
3 O
- O
phosphocholine O
( O
16 O
: O
0 O
/ O
18 O
: O
1 O
- O
PC O
) O
, O
previously O
proposed O
to O
reflect O
nutritional O
status O
and O
shown O
to O
be O
a O
specific O
endogenous O
ligand O
of O
PPAR O
alpha O
, O
induced O
CYP3A4 O
( O
up O
to O
4 O
- O
fold O
) O
and O
other O
biotransformation O
genes O
in O
hepatocytes O
with O
similar O
selectivity O
and O
potency O
as O
WY14 B
, I
643 I
. O

The O
purpose O
of O
this O
work O
was O
to O
improve O
the O
efficacy O
of O
triamcinolone B
acetonide I
( O
TA O
) O
in O
the O
treatment O
of O
endotoxin O
- O
induced O
uveitis O
( O
EIU O
) O
using O
a O
polymeric O
nanoparticulate O
drug O
delivery O
system O
. O

Poly O
( O
d O
, O
l O
- O
lactide O
- O
co O
- O
glycolide O
) O
( O
PLGA B
) O
nanoparticles O
were O
prepared O
using O
a O
modified O
emulsification O
/ O
solvent O
diffusion O
method O
. O

Inflammatory O
mediators O
such O
as O
NO B
, O
PGE2 B
, O
cell O
, O
and O
protein O
were O
measured O
quantitatively O
36h O
after O
intravitreal O
injection O
of O
endotoxin O
in O
aqueous O
humor O
, O
and O
the O
therapeutic O
effects O
were O
compared O
in O
different O
groups O
. O

Effect O
of O
A O
and O
B O
- O
site O
cations O
on O
surface O
exchange O
coefficient O
for O
ABO3 O
perovskite B
materials O
. O

A O
novel O
approach O
, O
called O
isothermal O
isotope O
exchange O
( O
IIE O
) O
, O
was O
applied O
to O
varying O
A O
- O
and O
B O
- O
site O
lanthanum O
manganites O
, O
ferrites O
, O
and O
cobaltites O
in O
the O
perovskite B
crystal O
structure O
in O
order O
to O
extract O
accurate O
surface O
exchange O
coefficients O
( O
k O
* O
) O
. O

MIEC O
materials O
have O
higher O
k O
* O
values O
than O
pure O
electronic O
conductors O
in O
the O
temperature O
range O
from O
500 O
- O
850 O
degrees O
C O
, O
demonstrating O
the O
importance O
of O
both O
electronic O
species O
and O
oxygen B
vacancies O
being O
present O
for O
surface O
exchange O
. O

The O
results O
have O
significant O
implications O
for O
the O
improvement O
of O
the O
oxygen B
reduction O
reaction O
for O
fuel O
cells O
, O
metal O
- O
air O
batteries O
, O
and O
numerous O
other O
energy O
technologies O
. O

Endocrine O
disrupting O
effects O
of O
ochratoxin B
A I
at O
the O
level O
of O
nuclear O
receptor O
activation O
and O
steroidogenesis O
. O

Ochratoxin B
A I
( O
OTA O
) O
is O
a O
mycotoxin O
and O
extrolite O
of O
fungi O
which O
has O
been O
reported O
in O
a O
range O
of O
foods O
. O

At O
the O
receptor O
level O
, O
OTA O
( O
within O
a O
concentration O
range O
of O
0 O
. O
25 O
- O
2500 O
ng O
/ O
ml O
) O
did O
not O
induce O
an O
agonistic O
response O
in O
an O
oestrogen B
, O
androgen B
, O
progestagen O
or O
glucocorticoid O
RGA O
. O

However O
, O
while O
there O
was O
no O
significant O
cytotoxic O
effect O
observed O
in O
the O
MTT B
( O
thiazolyl O
blue O
tetrazolium O
bromide O
) O
cell O
viability O
assay O
at O
this O
concentration O
, O
there O
was O
a O
corresponding O
change O
in O
cell O
morphology O
which O
may O
be O
related O
to O
the O
resulting O
antagonistic O
effect O
. O

Treatment O
of O
the O
cells O
with O
1000 O
ng O
/ O
ml O
OTA O
increased O
the O
production O
of O
estradiol B
( O
117 O
+ O
/ O
- O
14 O
ng O
/ O
ml O
) O
over O
3 O
times O
that O
of O
the O
solvent O
control O
( O
36 O
+ O
/ O
- O
9 O
pg O
/ O
ml O
) O
. O

This O
is O
the O
first O
study O
identifying O
the O
effect O
OTA O
may O
have O
on O
production O
of O
the O
steroid B
hormone O
estradiol B
. O

Comparison O
of O
tolerance O
to O
morphine B
- O
induced O
respiratory O
and O
analgesic O
effects O
in O
mice O
. O

Morphine B
is O
responsible O
for O
severe O
poisonings O
in O
chronically O
treated O
patients O
. O

We O
hypothesize O
that O
toxicity O
could O
be O
related O
to O
the O
development O
of O
weaker O
tolerance O
for O
morphine B
- O
induced O
deleterious O
respiratory O
effects O
in O
comparison O
to O
analgesic O
effects O
. O

Tolerance O
to O
morphine B
- O
induced O
analgesia O
and O
respiratory O
effects O
was O
assessed O
using O
hot O
plate O
response O
latencies O
and O
plethysmography O
, O
respectively O
. O

Morphine B
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
was O
responsible O
for O
analgesia O
with O
significant O
increase O
in O
inspiratory O
time O
. O

Acute O
tolerance O
to O
analgesia O
( O
p O
< O
0 O
. O
01 O
) O
and O
effects O
on O
respiratory O
frequency O
( O
p O
< O
0 O
. O
05 O
) O
was O
observed O
in O
mice O
pre O
- O
treated O
with O
100 O
mg O
/ O
kg O
morphine B
in O
comparison O
to O
saline O
. O

Following O
repetitive O
administration O
( O
2 O
. O
5 O
mg O
/ O
kg O
/ O
day O
during O
10 O
days O
) O
, O
we O
observed O
a O
13 O
- O
fold O
increase O
in O
the O
effective O
dose O
- O
50 O
% O
( O
ED O
5 O
0 O
) O
of O
morphine B
- O
induced O
analgesia O
in O
comparison O
to O
a O
2 O
- O
or O
4 O
- O
fold O
increase O
in O
the O
ED O
5 O
0 O
of O
its O
related O
increase O
in O
inspiratory O
time O
determined O
in O
air O
and O
4 O
% O
CO B
2 I
, O
respectively O
. O

No O
significant O
alteration O
in O
MOR O
expression O
was O
observed O
in O
either O
PAG O
or O
brainstem O
following O
repeated O
morphine B
administration O
. O

However O
, O
in O
PAG O
, O
in O
contrast O
to O
brainstem O
, O
superactivation O
of O
AC O
was O
observed O
in O
morphine B
- O
treated O
mice O
in O
comparison O
to O
controls O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
conclusion O
, O
tolerance O
to O
morphine B
- O
induced O
respiratory O
effects O
is O
much O
more O
limited O
than O
tolerance O
to O
its O
analgesic O
effects O
in O
repeatedly O
morphine B
- O
treated O
mice O
. O

The O
difference O
in O
morphine B
- O
induced O
AC O
activation O
between O
the O
brainstem O
and O
the O
PAG O
contributes O
to O
the O
observed O
difference O
in O
tolerance O
between O
both O
morphine B
effects O
. O

Membrane O
- O
initiated O
estradiol B
signaling O
in O
immortalized O
hypothalamic O
N O
- O
38 O
neurons O
. O

Regulation O
of O
sexual O
reproduction O
by O
estradiol B
involves O
the O
activation O
of O
estrogen B
receptors O
( O
ERs O
) O
in O
the O
hypothalamus O
. O

Using O
surface O
biotinylation O
, O
we O
observed O
that O
treatment O
of O
N O
- O
38 O
neurons O
with O
estradiol B
or O
with O
a O
membrane O
impermeant O
estradiol B
elevated O
plasma O
membrane O
ER O
alpha O
protein O
levels O
, O
indicating O
that O
membrane O
signaling O
increased O
receptor O
insertion O
into O
the O
cell O
membrane O
. O

Insertion O
of O
ER O
alpha O
was O
blocked O
by O
the O
ER O
antagonist O
ICI B
182 I
, I
780 I
or O
with O
the O
protein O
kinase O
C O
( O
PKC O
) O
pathway O
inhibitor O
bisindolylmaleimide O
( O
BIS O
) O
. O

Downstream O
membrane O
- O
initiated O
signaling O
was O
confirmed O
by O
estradiol B
activation O
of O
PKC O
- O
theta O
( O
PKC O
theta O
) O
and O
the O
release O
of O
intracellular O
calcium O
. O

These O
results O
indicate O
that O
membrane O
ER O
alpha O
levels O
in O
N O
- O
38 O
neurons O
are O
dynamically O
autoregulated O
by O
estradiol B
. O

The O
effect O
of O
remelting O
on O
the O
physical O
properties O
of O
borotellurite O
glass O
doped O
with O
manganese B
. O

A O
systematic O
set O
of O
borotellurite O
glasses O
doped O
with O
manganese B
( O
1 O
- O
x O
) O
[ O
( O
B O
( O
2 O
) O
O O
( O
3 O
) O
) O
( O
0 O
. O
3 O
) O
( O
TeO O
( O
2 O
) O
) O
( O
0 O
. O
7 O
) O
] O
- O
xMnO O
, O
with O
x O
= O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
0 O
. O
3 O
and O
0 O
. O
4 O
mol O
% O
, O
were O
successfully O
synthesized O
by O
using O
a O
conventional O
melt O
and O
quench O
- O
casting O
technique O
. O

The O
different O
physical O
behaviors O
of O
the O
studied O
glasses O
were O
closely O
related O
to O
the O
concentration O
of O
manganese B
in O
each O
phase O
. O

FTIR O
spectra O
revealed O
that O
the O
addition O
of O
manganese O
oxide O
contributes O
the O
transformation O
of O
TeO O
( O
4 O
) O
trigonal O
bipyramids O
with O
bridging O
oxygen B
( O
BO O
) O
to O
TeO O
( O
3 O
) O
trigonal O
pyramids O
with O
non O
- O
bridging O
oxygen B
( O
NBO O
) O
. O

Effect O
of O
Wine O
Polyphenol B
Resveratrol B
on O
the O
Contractions O
Elicited O
Electrically O
or O
by O
Norepinephrine B
in O
the O
Rat O
Portal O
Vein O
. O

We O
investigated O
the O
effects O
of O
resveratrol B
on O
rat O
portal O
vein O
( O
RPV O
) O
contractility O
without O
endothelium O
. O

Contractions O
were O
produced O
by O
electrical O
field O
stimulation O
of O
perivascular O
nerves O
( O
EFS O
) O
, O
norepinephrine B
( O
NE O
) O
, O
adenosine B
5 I
' I
- I
triphosphate I
( O
ATP B
) O
, O
high O
K B
( I
+ I
) I
solution O
and O
by O
calcium O
chloride O
( O
CaCl B
( I
2 I
) I
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
and O
high O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
- O
free O
solution O
. O

The O
EFS O
- O
evoked O
contractions O
were O
more O
sensitive O
to O
resveratrol B
and O
to O
NS1619 O
- O
selective O
openers O
of O
big O
calcium B
- O
sensitive O
( O
BK O
( O
Ca B
) O
) O
channels O
, O
than O
NE O
- O
evoked O
contractions O
. O

Effects O
of O
resveratrol B
on O
the O
ATP B
- O
evoked O
contractions O
were O
weak O
. O

Blockers O
of O
BK O
( O
Ca B
) O
channels O
partly O
inhibited O
the O
effect O
of O
resveratrol B
only O
in O
EFS O
- O
contracted O
preparations O
. O

Western O
blotting O
showed O
that O
RPV O
expressed O
K B
( O
Ca B
) O
1 O
. O
1 O
protein O
. O

Inhibitors O
of O
ATP B
- O
and O
voltage O
- O
sensitive O
K B
( I
+ I
) I
channels O
did O
not O
modify O
the O
effects O
of O
resveratrol B
. O

None O
of O
the O
antagonists O
of O
K B
( I
+ I
) I
channels O
affected O
the O
resveratrol B
inhibition O
of O
NE O
- O
evoked O
contractions O
and O
effect O
of O
high O
concentrations O
of O
resveratrol B
on O
the O
EFS O
- O
evoked O
contractions O
. O

Resveratrol B
more O
potently O
inhibited O
CaCl B
( I
2 I
) I
than O
potassium O
chloride O
contractions O
of O
RPV O
. O

Thus O
, O
BK O
( O
Ca B
) O
channels O
partly O
mediate O
the O
inhibitory O
effect O
of O
resveratrol B
on O
the O
neurogenic O
contractions O
of O
RPV O
. O

The O
smooth O
muscle O
Ca B
( I
2 I
+ I
) I
channels O
and O
/ O
or O
Ca B
( I
2 I
+ I
) I
mobilizing O
through O
cells O
might O
be O
involved O
in O
the O
effects O
of O
resveratrol B
on O
the O
contractility O
of O
RPV O
. O

Our O
results O
are O
important O
for O
better O
understanding O
the O
impact O
of O
resveratrol B
on O
the O
portal O
circulation O
. O

The O
antinociceptive O
effect O
of O
milnacipran B
in O
the O
monosodium O
iodoacetate O
model O
of O
osteoarthritis O
pain O
and O
its O
relation O
to O
changes O
in O
descending O
inhibition O
. O

These O
studies O
used O
monoamine B
receptor O
agents O
combined O
with O
behavioral O
studies O
and O
single O
- O
unit O
dorsal O
horn O
recordings O
to O
examine O
whether O
descending O
noradrenergic O
and O
serotonergic O
inhibitions O
are O
altered O
in O
the O
monosodium O
iodoacetate O
model O
of O
OA O
pain O
, O
and O
whether O
increasing O
these O
inhibitions O
with O
the O
serotonin B
/ O
noradrenaline B
reuptake O
inhibitor O
milnacipran B
can O
attenuate O
the O
attendant O
hypersensitivity O
. O

Early O
and O
late O
in O
the O
course O
of O
this O
model O
, O
milnacipran B
( O
s O
. O
c O
. O
) O
reduced O
behavioral O
hypersensitivity O
, O
and O
inhibited O
evoked O
responses O
from O
sensitized O
dorsal O
horn O
neurons O
. O

Blocking O
spinal O
5 B
- I
hydroxytryptamine I
- O
7 O
receptors O
with O
( O
2R O
) O
- O
1 O
- O
[ O
( O
3 O
- O
hydroxyphenyl O
) O
sulfonyl O
] O
- O
2 O
- O
[ O
2 O
- O
( O
4 O
- O
methyl O
- O
1 O
- O
piperidinyl O
) O
ethyl O
] O
pyrrolidine O
hydrochloride O
suggested O
that O
the O
effects O
of O
milnacipran B
in O
the O
late O
phase O
were O
partly O
mediated O
by O
these O
receptors O
, O
and O
that O
descending O
serotonergic O
inhibition O
was O
increased O
in O
this O
phase O
. O

An O
opioidergic O
mechanism O
behind O
the O
effects O
of O
milnacipran B
was O
indicated O
by O
a O
partial O
reversal O
of O
these O
effects O
with O
naloxone B
. O

These O
studies O
demonstrate O
antinociceptive O
effects O
for O
milnacipran B
in O
a O
model O
of O
OA O
pain O
, O
whose O
effects O
come O
via O
descending O
serotonergic O
and O
noradrenergic O
, O
as O
well O
as O
opioidergic O
, O
pathways O
. O

Variations O
in O
the O
activity O
of O
these O
pathways O
over O
the O
course O
of O
this O
model O
may O
contribute O
to O
the O
presence O
of O
behavioral O
hypersensitivity O
and O
determine O
through O
which O
endogenous O
systems O
milnacipran B
exerts O
its O
effects O
. O

Sources O
of O
mercury B
in O
a O
contaminated O
stream O
- O
implications O
for O
the O
timescale O
of O
recovery O
. O

Mercury B
contamination O
in O
East O
Fork O
Poplar O
Creek O
in O
Tennessee O
arises O
from O
dissolved O
mercury B
exiting O
a O
headwater O
industrial O
complex O
and O
residual O
mercury B
in O
the O
streambed O
and O
soil O
throughout O
the O
watershed O
downstream O
. O

The O
headwater O
inputs O
generate O
chronic O
base O
flow O
concentrations O
of O
total O
mercury B
of O
about O
1 O
, O
000 O
ng O
/ O
L O
, O
but O
most O
of O
the O
annual O
export O
of O
mercury B
from O
the O
system O
appears O
to O
originate O
farther O
downstream O
. O

Effective O
targeting O
of O
remedial O
efforts O
requires O
determining O
how O
long O
downstream O
sources O
might O
continue O
to O
contaminate O
the O
system O
following O
elimination O
of O
the O
headwater O
mercury B
inputs O
. O

The O
authors O
calculations O
suggest O
that O
( O
1 O
) O
contaminated O
soils O
and O
sediments O
account O
for O
> O
80 O
% O
of O
the O
annual O
mercury B
export O
from O
the O
entire O
watershed O
, O
with O
most O
export O
occurring O
during O
wet O
weather O
events O
; O
( O
2 O
) O
bank O
erosion O
and O
resuspension O
of O
streambed O
particulates O
are O
the O
major O
mercury B
sources O
maintaining O
high O
annual O
mercury B
export O
rates O
; O
and O
( O
3 O
) O
the O
inventory O
of O
particle O
- O
associated O
mercury B
in O
the O
streambed O
was O
not O
large O
enough O
to O
sustain O
the O
estimated O
export O
rates O
for O
more O
than O
a O
few O
years O
. O

The O
authors O
findings O
imply O
that O
to O
prevent O
waterborne O
mercury B
contamination O
in O
this O
system O
from O
continuing O
for O
decades O
, O
remedial O
actions O
will O
have O
to O
control O
the O
headwater O
mercury B
source O
that O
sustains O
day O
- O
to O
- O
day O
base O
flow O
mercury B
concentrations O
and O
the O
riparian O
stream O
- O
bank O
sources O
that O
generate O
most O
of O
the O
mercury B
export O
from O
the O
system O
. O

Effect O
of O
major O
cations O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
and O
anions O
( O
SO O
42 O
- O
, O
Cl B
( I
- I
) I
, O
NO B
3 I
- I
) O
on O
Ni B
accumulation O
and O
toxicity O
in O
aquatic O
plant O
( O
Lemna O
minor O
L O
. O
) O
: O
implications O
For O
Ni B
risk O
assessment O
. O

The O
effect O
of O
major O
cation O
activity O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
on O
Ni B
toxicity O
, O
with O
dose O
expressed O
as O
exposure O
( O
total O
dissolved O
Ni B
concentration O
NiTot O
) O
or O
free O
Ni B
ion O
activity O
( O
in O
solution O
Ni B
( I
2 I
+ I
) I
) O
, O
or O
as O
tissue O
residue O
( O
Ni B
concentration O
in O
plant O
tissue O
NiTiss O
) O
to O
the O
aquatic O
plant O
Lemna O
minor O
L O
. O
was O
examined O
. O

In O
addition O
, O
Ni B
accumulation O
kinetics O
was O
explored O
to O
provide O
mechanistic O
insight O
into O
current O
approaches O
of O
toxicity O
modeling O
, O
such O
as O
the O
tissue O
residue O
approach O
and O
the O
biotic O
ligand O
model O
( O
BLM O
) O
, O
and O
the O
implications O
for O
plant O
Ni B
risk O
assessment O
. O

Major O
cations O
did O
not O
inhibit O
Ni B
accumulation O
via O
competitive O
inhibition O
as O
expected O
by O
the O
BLM O
framework O
. O

For O
example O
, O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
( O
sulfate B
as O
counter O
- O
anion O
) O
had O
an O
anticompetitive O
effect O
on O
Ni B
accumulation O
, O
suggesting O
that O
Ca B
or O
Mg B
forms O
a O
ternary O
complex O
with O
Ni B
- O
biotic O
ligand O
. O

The O
counter O
- O
anion O
of O
the O
added O
Ca B
( O
sulfate B
, O
chloride B
, O
or O
nitrate B
) O
affected O
plant O
response O
( O
percentage O
of O
root O
growth O
inhibition O
) O
to O
Ni B
. O

Generally O
, O
sulfate B
and O
chloride B
influenced O
plant O
response O
while O
nitrate B
did O
not O
, O
even O
when O
compared O
within O
the O
same O
range O
of O
Ca B
( I
2 I
+ I
) I
, O
which O
suggests O
that O
the O
anion O
dominated O
the O
observed O
plant O
response O
. O

Overall O
, O
although O
an O
effect O
of O
major O
cations O
on O
Ni B
toxicity O
to O
L O
. O
minor O
L O
. O
was O
observed O
at O
a O
physiological O
level O
, O
Ni B
( I
2 I
+ I
) I
or O
NiTot O
alone O
modeled O
plant O
response O
, O
generally O
within O
a O
span O
of O
twofold O
, O
over O
a O
wide O
range O
of O
water O
chemistry O
. O

Thus O
, O
consideration O
of O
major O
cation O
competition O
for O
improving O
Ni B
toxicity O
predictions O
in O
risk O
assessment O
for O
aquatic O
plants O
may O
not O
be O
necessary O
. O

The O
analysis O
of O
medium O
polarity O
constituents O
led O
to O
the O
isolation O
of O
several O
glycosides O
, O
such O
as O
flavonoids B
, O
i O
. O
e O
. O
scutellarein B
derivatives O
; O
phenylethanoids O
, O
i O
. O
e O
. O
verbascoside B
; O
and O
iridoids B
, O
i O
. O
e O
. O
melittoside O
and O
5 O
- O
allosyloxy O
- O
aucubin O
, O
besides O
the O
diterpene O
siderol O
. O

The O
data O
reported O
have O
chemotaxonomic O
relevance O
, O
since O
they O
are O
in O
contrast O
with O
the O
hypothesis O
that O
in O
Lamiaceae O
the O
species O
producing O
iridoids B
do O
not O
usually O
have O
relevant O
essential O
oil O
production O
and O
vice O
versa O
. O

In O
this O
study O
, O
the O
effect O
of O
chronic O
consumption O
of O
two O
garlic O
fractions O
was O
tested O
: O
one O
soluble O
in O
water O
( O
aqueous O
solution O
obtained O
by O
grinding O
and O
centrifugation O
) O
and O
the O
other O
one O
precipitated O
by O
ethanol B
( O
alcoholic O
precipitate O
obtained O
by O
precipitation O
of O
the O
aqueous O
solution O
) O
, O
on O
different O
variables O
of O
male O
rats O
' O
reproductive O
functions O
. O

In O
addition O
, O
garlic O
fractions O
induced O
apoptosis O
of O
testicular O
germ O
cells O
( O
TdT O
- O
mediated O
dUTP B
- O
X O
nick O
- O
end O
labeling O
[ O
TUNEL O
] O
approach O
) O
and O
a O
decrease O
of O
serum O
testosterone B
levels O
and O
seminiferous O
tubule O
DNA O
concentrations O
. O

In O
summary O
, O
our O
histological O
and O
molecular O
results O
suggest O
that O
one O
or O
several O
substances O
, O
soluble O
in O
water O
and O
precipitated O
by O
alcohol B
, O
impaired O
spermatogenesis O
. O

The O
oils O
were O
particularly O
rich O
in O
phenolic O
monoterpenes O
: O
they O
had O
a O
high O
thymol B
( O
64 O
. O
7 O
- O
92 O
. O
0 O
% O
) O
or O
carvacrol B
( O
93 O
. O
4 O
% O
) O
content O
, O
whereas O
in O
one O
of O
the O
oils O
considerable O
amount O
of O
both O
compounds O
was O
found O
( O
thymol B
61 O
. O
6 O
% O
and O
carvacrol B
26 O
. O
4 O
% O
) O
. O

Tunable O
morphology O
and O
mesophase O
formation O
by O
naphthalene B
- O
containing O
poly O
( O
aryl O
ether O
) O
dendron O
- O
based O
low O
- O
molecular O
- O
weight O
fluorescent O
gels O
. O

Novel O
poly O
( O
aryl O
ether O
) O
dendron O
- O
based O
low O
- O
molecular O
- O
weight O
organogelaters O
( O
LMWG O
) O
containing O
naphthalene B
units O
at O
the O
core O
have O
been O
synthesized O
, O
and O
the O
self O
- O
assembly O
of O
the O
system O
has O
been O
examined O
in O
a O
variety O
of O
solvents O
and O
solvent O
mixtures O
. O

In O
addition O
to O
the O
remarkable O
properties O
of O
the O
previously O
reported O
anthracene B
and O
pyrene B
analogues O
( O
Rajamalli O
, O
P O
. O
; O
Prasad O
, O
E O
. O
Org O
. O
Lett O
. O
2011 O
, O
13 O
, O
3714 O
and O
Rajamalli O
, O
P O
. O
; O
Prasad O
, O
E O
. O
Soft O
Matter2012 O
, O
8 O
, O
8896 O
) O
, O
the O
self O
- O
assembled O
systems O
exhibit O
distinctly O
different O
structure O
- O
property O
relationships O
. O

The O
unique O
properties O
of O
the O
self O
- O
assembled O
systems O
, O
which O
were O
analyzed O
through O
electron O
microscopic O
( O
SEM O
, O
TEM O
, O
AFM O
) O
and O
spectroscopic O
techniques O
( O
POM O
, O
fluorescence O
) O
, O
are O
attributed O
to O
the O
replacement O
of O
anthracene B
/ O
pyrene B
units O
by O
naphthalene B
units O
. O

Mechanism O
of O
solid O
state O
amorphization O
of O
glucose B
upon O
milling O
. O

Silver B
nanoparticles O
in O
cancer O
: O
therapeutic O
efficacy O
and O
toxicity O
. O

In O
particular O
, O
silver B
nanoparticles O
( O
AgNPs O
) O
are O
increasingly O
being O
investigated O
as O
tools O
for O
novel O
cancer O
therapeutics O
, O
capitalizing O
on O
their O
unique O
properties O
to O
enhance O
potential O
therapeutic O
efficacy O
. O

Gln8 O
in O
PR O
( O
R8Q O
) O
replaced O
the O
ionic O
interactions O
of O
wild O
type O
Arg8 O
with O
hydrogen B
bond O
interactions O
without O
changing O
the O
inhibition O
significantly O
. O

The O
carbonyl B
oxygen B
of O
Gly48 O
showed O
two O
alternative O
conformations O
in O
all O
structures O
likely O
due O
to O
the O
snug O
fit O
of O
the O
large O
tris O
- O
THF O
group O
in O
the O
S2 O
subsite O
in O
agreement O
with O
high O
antiviral O
efficacy O
of O
1 O
on O
resistant O
virus O
. O

The O
method O
consists O
of O
antisolvent O
co O
- O
precipitation O
from O
an O
aqueous O
solution O
containing O
both O
an O
amino B
acid I
core O
material O
( O
e O
. O
g O
. O
D O
, O
L O
- O
valine O
) O
, O
and O
either O
bovine O
serum O
albumin O
( O
BSA O
) O
or O
lysozyme O
( O
Lys O
) O
as O
model O
proteins O
. O

Synthesis O
, O
characterization O
and O
targeting O
potential O
of O
zidovudine B
loaded O
sialic B
acid I
conjugated O
- O
mannosylated O
poly O
( O
propyleneimine O
) O
dendrimers O
. O

The O
present O
investigation O
was O
aimed O
at O
exploring O
dual O
targeting O
of O
anti O
- O
HIV O
drug O
, O
zidovudine B
( O
ZDV O
) O
via O
sialic B
acid I
conjugated O
- O
mannosylated O
poly O
( O
propyleneimine O
) O
( O
PPI O
) O
dendritic O
nano O
- O
constructs O
. O

Fourth O
generation O
PPI O
dendrimers O
, O
sialic B
acid I
conjugated O
PPI O
dendrimers O
( O
SPPI O
) O
, O
mannose B
conjugated O
PPI O
dendrimers O
( O
MPPI O
) O
and O
dual O
ligand O
system O
i O
. O
e O
. O
sialic B
acid I
conjugated O
- O
mannosylated O
PPI O
dendrimers O
( O
SMPPI O
) O
were O
synthesized O
and O
characterized O
by O
FT O
- O
IR O
and O
( B
1 I
) I
H I
NMR O
spectroscopies O
and O
were O
further O
confirmed O
by O
size O
exclusion O
chromatography O
and O
differential O
scanning O
calorimetry O
. O

The O
in O
vivo O
blood O
level O
and O
tissue O
distribution O
studies O
in O
albino O
rats O
also O
demonstrated O
potential O
of O
dual O
targeted O
system O
towards O
sialoadhesin O
and O
carbohydrate B
receptors O
. O

PAMPA O
was O
performed O
with O
an O
acceptor O
solution O
simulating O
the O
binding O
of O
serum O
proteins O
, O
an O
artificial O
membrane O
impregnated O
with O
egg O
lecithin O
/ O
cholesterol B
and O
a O
gradient O
of O
pH O
between O
donor O
and O
acceptor O
solutions O
. O

Biodegradable O
core O
- O
shell O
nanoassemblies O
for O
the O
delivery O
of O
docetaxel B
and O
Zn B
( I
II I
) I
- O
phthalocyanine B
inspired O
by O
combination O
therapy O
for O
cancer O
. O

In O
this O
work O
, O
we O
develop O
multifunctional O
nanoparticles O
( O
NPs O
) O
for O
co O
- O
delivery O
of O
the O
conventional O
anticancer O
drug O
docetaxel B
( O
DTX O
) O
and O
the O
second O
generation O
photosensitizer O
zinc B
- O
phthalocyanine B
( O
ZnPc O
) O
as O
potential O
dual O
carrier O
system O
for O
the O
combination O
of O
chemotherapy O
and O
photodynamic O
therapy O
( O
PDT O
) O
. O

Biodegradable O
and O
amphiphilic O
block O
copolymers O
based O
on O
poly O
( O
epsilon O
- O
caprolactone O
) O
( O
PCL B
= O
B O
) O
and O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
= O
A O
) O
, O
with O
AB O
and O
ABA O
architectures O
, O
were O
assembled O
in O
" O
core O
- O
shell O
" O
NPs O
and O
loaded O
with O
both O
DTX O
and O
ZnPc O
employing O
the O
melting O
/ O
sonication O
method O
. O

Singlet O
oxygen B
generation O
was O
observed O
when O
ZnPc O
- O
loaded O
NPs O
were O
irradiated O
at O
610nm O
within O
a O
45min O
time O
range O
, O
despite O
that O
ZnPc O
was O
not O
released O
in O
the O
medium O
. O

Superior O
antitumor O
activity O
of O
ZnPc O
/ O
DTX O
- O
loaded O
NPs O
as O
compared O
to O
DTX O
- O
loaded O
NPs O
was O
confirmed O
in O
an O
animal O
model O
of O
orthotopic O
amelanotic O
melanoma O
, O
thus O
pointing O
to O
the O
application O
of O
PEO B
- O
PCL B
NPs O
in O
the O
combined O
chemo O
- O
photodynamic O
therapy O
of O
cancer O
. O

Polyethylenimine B
combined O
with O
liposomes O
and O
with O
decreased O
numbers O
of O
primary B
amine I
residues O
strongly O
enhanced O
therapeutic O
antiviral O
efficiency O
against O
herpes O
simplex O
virus O
type O
2 O
in O
a O
mouse O
model O
. O

We O
reported O
previously O
that O
topical O
application O
of O
branched O
3610 O
- O
Da O
polyethylenimine B
( O
PEI B
) O
exhibited O
preventative O
antiviral O
activity O
. O

In O
this O
study O
, O
to O
develop O
therapeutic O
anti O
- O
HSV O
- O
2 O
agents O
, O
the O
most O
potent O
PEI B
combined O
with O
~ O
200 O
nm O
- O
sized O
liposomes O
with O
or O
without O
oleic B
acid I
( O
liposomes O
/ O
PEI B
) O
was O
selected O
in O
vitro O
and O
further O
evaluated O
using O
in O
vivo O
studies O
. O

The O
mechanism O
of O
action O
in O
vivo O
was O
elucidated O
using O
PEIs B
with O
decreased O
numbers O
of O
primary B
amine I
residues O
, O
resulting O
from O
ethylene O
carbonate O
treatment O
, O
and O
polyallylamine B
, O
a O
linear O
polyamine B
consisting O
of O
primary B
amines I
. O

Cytotoxicity O
and O
antiviral O
activity O
in O
vitro O
, O
and O
the O
appearance O
of O
acute O
herpetic O
disease O
and O
virus O
yields O
in O
mice O
intravaginally O
administered O
with O
liposomes O
/ O
PEI B
were O
evaluated O
in O
cell O
culture O
assays O
and O
a O
mouse O
genital O
herpes O
model O
, O
respectively O
. O

In O
addition O
, O
the O
cellular O
association O
of O
liposome O
/ O
PEI B
was O
examined O
by O
flow O
cytometry O
and O
confocal O
microscopy O
. O

PEI B
showed O
higher O
antiviral O
activity O
postinfection O
than O
preinfection O
in O
vivo O
. O

Liposome O
/ O
PEI B
and O
PEI B
with O
decreased O
numbers O
of O
primary B
amine I
residues O
at O
a O
dose O
of O
0 O
. O
2 O
mg O
PEI B
/ O
mouse O
exhibited O
more O
potent O
therapeutic O
antiviral O
activity O
than O
acyclovir B
and O
PEI B
alone O
without O
acute O
lesion O
appearance O
or O
toxicity O
pre O
- O
or O
postinfection O
, O
but O
polyallylamine B
was O
moderately O
effective O
only O
preinfection O
. O

Liposome O
concentrations O
were O
important O
for O
the O
effectiveness O
of O
liposome O
/ O
PEI B
. O

This O
finding O
suggests O
that O
PEI B
combined O
with O
liposomes O
and O
with O
slightly O
decreased O
numbers O
of O
primary B
amines I
may O
be O
an O
effective O
vaginally O
administrated O
antiviral O
drug O
, O
and O
secondary O
and O
tertiary O
amine O
residues O
of O
PEI B
may O
contribute O
to O
the O
inhibitory O
efficiency O
against O
viral O
infection O
. O

The O
present O
study O
was O
conducted O
to O
examine O
the O
feasibility O
of O
nimodipine O
- O
loaded O
PLGA B
microparticles O
suspended O
in O
Tisseel O
( O
TM O
) O
fibrin O
sealant O
as O
an O
in O
situ O
forming O
depot O
system O
. O

Induction O
of O
HO O
- O
1 O
through O
p38 O
MAPK O
/ O
Nrf2 O
signaling O
pathway O
by O
ethanol B
extract O
of O
Inula O
helenium O
L O
. O
reduces O
inflammation O
in O
LPS O
- O
activated O
RAW O
264 O
. O
7 O
cells O
and O
CLP O
- O
induced O
septic O
mice O
. O

We O
recently O
proposed O
that O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
negatively O
regulates O
HMGB1 O
in O
inflammatory O
conditions O
. O

We O
investigated O
whether O
ethanol B
extract O
of O
Inula O
helenium O
L O
. O

The O
induction O
of O
HO O
- O
1 O
by O
EIH O
was O
inhibited O
by O
SB203580 B
but O
not O
by O
SP600125 B
, O
PD98059 B
, O
nor O
LY294002 B
. O

Most O
importantly O
, O
administration O
of O
EIH O
significantly O
reduced O
not O
only O
increase O
in O
blood O
HMGB1 O
, O
ALT O
, O
AST O
, O
BUN O
, O
creatinine B
levels O
but O
also O
decrease O
macrophage O
infiltrate O
in O
the O
liver O
of O
septic O
mice O
, O
which O
were O
reversed O
by O
ZnPPIX O
, O
a O
HO O
- O
1 O
inhibitor O
. O

Evaluation O
of O
insulin O
- O
like O
growth O
factor O
acid O
- O
labile O
subunit O
as O
a O
potential O
biomarker O
of O
effect O
for O
deoxynivalenol B
- O
induced O
proinflammatory O
cytokine O
expression O
. O

Consumption O
of O
the O
trichothecene O
deoxynivalenol B
( O
DON B
) O
suppresses O
growth O
in O
experimental O
animals O
- O
an O
adverse O
effect O
that O
was O
used O
to O
establish O
the O
tolerable O
daily O
intake O
for O
this O
toxin O
. O

DON B
ingestion O
has O
been O
recently O
found O
to O
suppress O
plasma O
insulin O
- O
like O
growth O
factor O
acid O
- O
labile O
subunit O
( O
IGFALS O
) O
, O
a O
protein O
essential O
for O
growth O
. O

Studies O
were O
conducted O
to O
explore O
the O
feasibility O
of O
using O
plasma O
IGFALS O
as O
a O
biomarker O
of O
effect O
for O
DON B
. O

In O
the O
first O
study O
, O
weanling O
mice O
were O
fed O
0 O
, O
1 O
, O
2 O
. O
5 O
, O
5 O
and O
10 O
ppm O
DON B
and O
weight O
and O
plasma O
IGFALS O
determined O
at O
intervals O
over O
9 O
wk O
. O

Benchmark O
dose O
modeling O
revealed O
the O
BMDL O
and O
BMD O
for O
plasma O
IGFALS O
reduction O
were O
1 O
. O
1 O
and O
3 O
. O
0 O
ppm O
DON B
and O
for O
weight O
reduction O
were O
2 O
. O
1 O
and O
4 O
. O
5 O
ppm O
DON B
. O

In O
the O
second O
study O
, O
it O
was O
demonstrated O
that O
mice O
fed O
15 O
ppm O
DON B
diet O
had O
significantly O
less O
plasma O
IGFALS O
than O
mice O
fed O
identical O
amounts O
of O
control O
diet O
. O

Thus O
DON B
' O
s O
influence O
on O
IGFALS O
likely O
reflects O
the O
combined O
effects O
of O
reduced O
food O
intake O
as O
well O
as O
its O
physiological O
action O
involving O
suppressors O
of O
cytokine O
signaling O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
plasma O
IGFALS O
might O
be O
a O
useful O
biomarker O
for O
DON B
' O
s O
adverse O
effects O
on O
growth O
. O

Locally O
administered O
prostaglandin B
E2 I
prevents O
aeroallergen O
- O
induced O
airway O
sensitization O
in O
mice O
through O
immunomodulatory O
mechanisms O
. O

Prostaglandin B
E2 I
attenuates O
airway O
pathology O
in O
asthmatic O
patients O
and O
exerts O
a O
protective O
effect O
in O
antigen O
- O
sensitized O
mice O
when O
administered O
systemically O
. O

We O
aimed O
to O
establish O
the O
consequences O
of O
intranasal O
PGE2 B
administration O
on O
airway O
reactivity O
to O
aeroallergens O
in O
mice O
and O
reveal O
the O
underlying O
immunoinflammatory O
mechanisms O
. O

PGE2 B
was O
administered O
either O
daily O
during O
a O
10 O
- O
day O
exposure O
to O
house O
dust O
mite O
( O
HDM O
) O
extracts O
or O
for O
limited O
intervals O
. O

Airway O
hyperreactivity O
was O
sustainably O
reduced O
only O
when O
PGE2 B
administration O
was O
restricted O
to O
the O
initial O
5 O
days O
of O
exposure O
to O
HDM O
. O

Lung O
inflammation O
, O
IL O
- O
4 O
production O
, O
and O
airway O
mast O
cell O
activity O
were O
also O
prevented O
under O
this O
early O
short O
- O
term O
treatment O
with O
PGE2 B
. O

Local O
PGE2 B
administration O
prevented O
the O
increase O
of O
airway O
IL O
- O
13 O
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O

These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 B
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O
mechanisms O
, O
and O
possibly O
a O
shift O
in O
the O
balance O
of O
dendritic O
cells O
towards O
a O
tolerogenic O
profile O
. O

Optimization O
of O
benzyloxazoles O
as O
non O
- O
nucleoside B
inhibitors O
of O
HIV O
- O
1 O
reverse O
transcriptase O
to O
enhance O
Y181C O
potency O
. O

Design O
of O
non O
- O
nucleoside B
inhibitors O
of O
HIV O
- O
1 O
reverse O
transcriptase O
with O
improved O
activity O
towards O
Tyr181Cys O
containing O
variants O
was O
pursued O
with O
the O
assistance O
of O
free O
energy O
perturbation O
( O
FEP O
) O
calculations O
. O

Optimization O
of O
the O
4 O
- O
R O
substituent O
in O
1 O
led O
to O
ethyl B
and O
isopropyl B
analogs O
1e O
and O
1f O
with O
1 O
- O
7 O
nM O
potency O
towards O
both O
the O
wild O
- O
type O
virus O
and O
a O
Tyr181C O
variant O
. O

Methadone O
N B
- O
demethylation O
by O
the O
common O
CYP2B6 O
allelic O
variant O
CYP2B6 O
. O
6 O
. O

Methadone O
metabolism O
clinically O
occurs O
primarily O
by O
N B
- O
demethylation O
to O
2 O
- O
ethyl O
- O
1 O
, O
5 O
- O
dimethyl O
- O
3 O
, O
3 O
- O
diphenylpyrrolidine O
( O
EDDP O
) O
, O
catalyzed O
predominantly O
by O
CYP2B6 O
. O

This O
investigation O
compared O
methadone O
N B
- O
demethylation O
by O
CYP2B6 O
. O
6 O
with O
that O
by O
wild O
- O
type O
CYP2B6 O
. O
1 O
. O

Methadone O
enantiomer O
and O
racemate O
N B
- O
demethylation O
by O
recombinant O
- O
expressed O
CYP2B6 O
. O
6 O
and O
CYP2B6 O
. O
1 O
was O
determined O
. O

At O
substrate O
concentrations O
( O
0 O
. O
25 O
- O
2 O
micro O
M O
) O
approximating O
plasma O
concentrations O
occurring O
clinically O
, O
rates O
of O
methadone O
enantiomer O
N B
- O
demethylation O
by O
CYP2B6 O
. O
6 O
, O
incubated O
individually O
or O
as O
the O
racemate O
, O
were O
one O
- O
third O
to O
one O
- O
fourth O
those O
by O
CYP2B6 O
. O
1 O
. O

Human O
liver O
microsomes O
with O
diminished O
CYP2B6 O
content O
due O
to O
a O
CYP2B6 O
* O
6 O
allele O
had O
lower O
rates O
of O
methadone O
N B
- O
demethylation O
. O

Results O
show O
that O
methadone O
N B
- O
demethylation O
catalyzed O
by O
CYP2B6 O
. O
6 O
, O
the O
CYP2B6 O
variant O
encoded O
by O
the O
CYP2B6 O
* O
6 O
polymorphism O
, O
is O
catalytically O
deficient O
compared O
with O
wild O
- O
type O
CYP2B6 O
. O
1 O
. O

Diminished O
methadone O
N B
- O
demethylation O
by O
CYP2B6 O
. O
6 O
may O
provide O
a O
mechanistic O
explanation O
for O
clinical O
observations O
of O
altered O
methadone O
disposition O
in O
individuals O
carrying O
the O
CYP2B6 O
* O
6 O
polymorphism O
. O

The O
nuclear O
receptors O
constitutive O
androstane B
receptor O
( O
CAR O
) O
, O
pregnane B
X O
receptor O
( O
PXR O
) O
and O
vitamin B
D I
receptor O
( O
VDR O
) O
control O
a O
large O
array O
of O
genes O
that O
code O
for O
important O
proteins O
in O
humans O
including O
metabolic O
enzymes O
and O
transporters O
. O

Subacute O
oral O
toxicity O
of O
combinations O
of O
selected O
synthetic O
pyrethroids B
, O
piperonyl B
butoxide I
, O
and O
tetramethrin O
in O
rats O
. O

Different O
combinations O
of O
insecticides O
were O
administered O
daily O
to O
the O
experimental O
groups O
( O
group O
1 O
: O
cypermethrin B
+ O
piperonyl B
butoxide I
( O
PBO O
) O
; O
group O
2 O
: O
alphacypermethrin O
+ O
PBO O
; O
group O
3 O
: O
deltamethrin B
+ O
PBO O
; O
group O
4 O
: O
cypermethrin B
+ O
PBO O
+ O
tetramethrin O
; O
group O
5 O
: O
alphacypermethrin O
+ O
PBO O
+ O
tetramethrin O
; O
and O
group O
6 O
: O
deltamethrin B
+ O
PBO O
+ O
tetramethrin O
) O
for O
28 O
days O
. O

Red O
blood O
cells O
, O
white O
blood O
cells O
, O
and O
hemoglobin O
levels O
, O
especially O
in O
cypermethrin B
and O
alphacypermethrin O
groups O
( O
groups O
1 O
, O
2 O
, O
and O
4 O
) O
, O
were O
found O
to O
be O
higher O
than O
the O
control O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

Relative O
liver O
and O
kidney O
weights O
of O
the O
male O
animals O
increased O
in O
the O
cypermethrin B
and O
alphacypermethrin O
groups O
( O
p O
< O
0 O
. O
05 O
) O
. O

It O
was O
concluded O
that O
although O
clinical O
symptoms O
were O
not O
observed O
, O
synthetic O
pyrethroid B
, O
synergist O
, O
and O
knockdown O
agent O
combinations O
might O
cause O
serious O
abnormalities O
when O
administered O
in O
certain O
doses O
in O
mammalians O
. O

A O
Serum O
- O
Tolerant O
Hydroxyl B
- O
Modified O
Polyethylenimine B
as O
Versatile O
Carriers O
of O
pDNA O
/ O
siRNA O
. O

The O
polyethylenimine B
( O
PEI B
) O
derivatives O
( O
PTn O
) O
are O
prepared O
by O
treating O
PEI25k O
with O
Tris O
( O
hydroxymethyl O
) O
acrylamidomethane O
via O
the O
Michael O
addition O
. O

Diagnosis O
of O
GDM O
was O
made O
at O
2nd O
trimester O
, O
based O
on O
a O
75 O
- O
g O
oral O
glucose B
tolerance O
test O
( O
International O
Association O
of O
Diabetes O
and O
Pregnancy O
Study O
Group O
criteria O
) O
. O

Insulin O
was O
measured O
( O
ELISA O
; O
Luminex O
) O
to O
estimate O
homeostasis O
model O
assessment O
of O
insulin O
resistance O
( O
HOMA O
- O
IR O
) O
, O
beta O
- O
cell O
function O
( O
HOMA O
- O
B O
) O
, O
insulin O
sensitivity O
( O
Matsuda O
index O
) O
, O
insulin O
secretion O
( O
AUC O
( O
insulin O
/ O
glucose B
) O
) O
, O
and O
beta O
- O
cell O
compensation O
( O
insulin O
secretion O
sensitivity O
index O
- O
2 O
) O
. O

Women O
who O
developed O
GDM O
had O
lower O
1st O
- O
trimester O
adiponectin O
levels O
( O
9 O
. O
67 O
+ O
/ O
- O
3 O
. O
84 O
vs O
. O
11 O
. O
92 O
+ O
/ O
- O
4 O
. O
59 O
micro O
g O
/ O
mL O
in O
women O
with O
normal O
glucose B
tolerance O
) O
. O

After O
adjustment O
for O
confounding O
factors O
, O
we O
found O
no O
significant O
association O
with O
HOMA O
- O
B O
and O
AUC O
( O
insulin O
/ O
glucose B
) O
. O
CONCLUSIONSPregnant O
women O
with O
lower O
adiponectin O
levels O
at O
1st O
trimester O
have O
higher O
levels O
of O
insulin O
resistance O
and O
are O
more O
likely O
to O
develop O
GDM O
independently O
of O
adiposity O
or O
glycemic O
measurements O
. O

The O
results O
are O
corroborated O
with O
adsorption O
to O
simple O
model O
supported O
lipid O
bilayers O
using O
a O
quartz B
crystal O
microbalance O
. O

Aminoalkyl O
derivatives O
of O
guanidine B
diaromatic O
minor O
groove O
binders O
with O
antiprotozoal O
activity O
. O

The O
O B
- O
linked O
derivatives O
13c O
and O
14c O
showed O
100 O
nM O
activities O
against O
P O
. O
falciparum O
, O
whereas O
for O
T O
. O

Phenyl B
linker O
- O
induced O
dense O
PEG B
conformation O
improves O
the O
efficacy O
of O
C B
- O
terminally O
monoPEGylated O
staphylokinase O
. O

Here O
, O
staphylokinase O
( O
SAK O
) O
, O
a O
thrombolysis O
agent O
for O
therapy O
of O
myocardial O
infarction O
, O
was O
mono O
- O
PEGylated O
at O
the O
C B
- O
terminus O
of O
SAK O
far O
from O
its O
bioactive O
domain O
. O

Phenyl B
, O
propyl B
, O
and O
amyl O
moieties O
were O
used O
as O
linkers O
between O
SAK O
and O
polyethylene B
glycol I
( O
PEG B
) O
, O
respectively O
. O

Flexible O
propyl B
and O
amyl O
linkers O
lead O
to O
loose O
conformation O
. O

In O
contrast O
, O
rigid O
and O
hydrophobic O
phenyl B
linker O
induces O
dense O
PEG B
conformation O
that O
can O
extensively O
shield O
most O
domains O
adjacent O
to O
C B
- O
terminus O
( O
e O
. O
g O
. O
, O
the O
antigen O
epitopes O
and O
proteolytic O
sites O
) O
of O
SAK O
and O
inefficiently O
shield O
its O
bioactive O
domain O
. O

As O
compared O
with O
loose O
PEG B
conformation O
, O
dense O
PEG B
conformation O
is O
more O
efficient O
to O
maintain O
the O
bioactivity O
, O
increase O
the O
plasma O
half O
- O
life O
, O
and O
decrease O
the O
proteolytic O
sensitivity O
and O
immunogenicity O
of O
the O
PEGylated O
SAK O
. O

Optical O
probing O
of O
the O
electronic O
interaction O
between O
graphene B
and O
hexagonal O
boron O
nitride O
. O

Although O
the O
electronic O
structure O
of O
graphene B
has O
been O
predicted O
to O
be O
modified O
by O
the O
vdW O
interaction O
with O
other O
materials O
, O
its O
optical O
characterization O
has O
not O
been O
successful O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
Raman O
spectroscopy O
can O
be O
utilized O
to O
detect O
a O
few O
percent O
decrease O
in O
the O
Fermi O
velocity O
( O
v O
( O
F O
) O
) O
of O
graphene B
caused O
by O
the O
vdW O
interaction O
with O
underlying O
hexagonal O
boron O
nitride O
( O
hBN O
) O
. O

The O
analysis O
reveals O
that O
spectral O
features O
of O
graphene B
on O
hBN O
are O
mainly O
affected O
by O
change O
in O
v O
( O
F O
) O
and O
mechanical O
strain O
but O
not O
by O
charge O
doping O
, O
unlike O
graphene B
supported O
on O
SiO B
2 I
substrates O
. O

Graphene B
on O
hBN O
was O
also O
found O
to O
be O
less O
susceptible O
to O
thermally O
induced O
hole O
doping O
. O

Eight O
new O
compounds O
, O
including O
two O
cyclopenta O
[ O
b O
] O
benzopyran O
derivatives O
( O
1 O
, O
2 O
) O
, O
two O
cyclopenta O
[ O
b O
] O
benzofuran O
derivatives O
( O
3 O
, O
4 O
) O
, O
three O
cycloartane O
triterpenoids O
( O
5 O
- O
7 O
) O
, O
and O
an O
apocarotenoid O
( O
8 O
) O
, O
together O
with O
16 O
known O
compounds O
, O
were O
isolated O
from O
the O
chloroform B
- O
soluble O
partitions O
of O
separate O
methanol B
extracts O
of O
a O
combination O
of O
the O
fruits O
, O
leaves O
, O
and O
twigs O
and O
of O
the O
roots O
of O
Aglaia O

The O
Mosher O
ester O
method O
was O
employed O
to O
determine O
the O
absolute O
configurations O
of O
5 O
- O
7 O
, O
and O
the O
absolute O
configuration O
of O
the O
9 O
, O
10 O
- O
diol B
unit O
of O
compound O
8 O
was O
established O
by O
a O
dimolybdenum O
tetraacetate O
[ O
Mo2 O
( O
AcO O
) O
4 O
] O
induced O
circular O
dichroism O
procedure O
. O

In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
( O
2 O
) O
, O
three O
known O
rocaglate O
derivatives O
( O
9 O
, O
11 O
, O
12 O
) O
, O
and O
a O
known O
sesquiterpene B
, O
2 O
- O
oxaisodauc O
- O
5 O
- O
en O
- O
12 O
- O
al O
( O
17 O
) O
, O
showed O
significant O
NF O
- O
kappa O
B O
( O
p65 O
) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

A O
powerful O
aluminum B
catalyst O
for O
the O
synthesis O
of O
highly O
functional O
organic O
carbonates O
. O

An O
aluminum B
complex O
based O
on O
an O
amino O
triphenolate O
ligand O
scaffold O
shows O
unprecedented O
high O
activity O
( O
initial O
TOFs O
up O
to O
36 O
, O
000 O
h O
( O
- O
1 O
) O
) O
, O
broad O
substrate O
scope O
, O
and O
functional O
group O
tolerance O
in O
the O
formation O
of O
highly O
functional O
organic O
carbonates O
prepared O
from O
epoxides O
and O
CO B
( I
2 I
) I
. O

We O
used O
a O
sensitive O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
and O
LC O
/ O
MS O
/ O
MS O
method O
to O
show O
that O
L O
- O
tyrosine O
( O
Tyr B
) O
, O
an O
amino B
acid I
with O
a O
highly O
reactive O
hydroxyl B
group O
, O
readily O
reacts O
with O
cigarette O
smoke O
extract O
( O
CSE O
) O
at O
body O
temperature O
( O
37 O
degrees O
C O
) O
to O
form O
various O
Tyr B
derivatives O
. O

Among O
these O
derivatives O
were O
N O
- O
( O
3 O
- O
oxobutyl O
) O
- O
Tyr O
and O
two O
acetylated O
compounds O
, O
N O
- O
acetyl O
- O
Tyr O
and O
O O
- O
acetyl O
- O
Tyr O
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr B
with O
methyl O
vinyl O
ketone O
and O
acetic O
anhydride O
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

These O
results O
indicate O
that O
Tyr B
can O
easily O
react O
with O
active O
ingredients O
in O
CSE O
. O

EPR O
spin O
Hamiltonian O
parameters O
of O
encapsulated O
spin O
- O
labels O
: O
impact O
of O
the O
hydrogen B
bonding O
topology O
. O

We O
focus O
on O
the O
dependence O
of O
the O
EPR O
properties O
of O
encapsulated O
spin O
- O
labels O
on O
the O
hydrogen B
bonding O
topologies O
that O
occur O
upon O
encapsulation O
, O
and O
quantize O
various O
contributions O
to O
these O
parameters O
according O
to O
specific O
hydrogen B
bonding O
patterns O
. O

The O
obtained O
results O
provide O
refined O
insight O
into O
the O
role O
of O
the O
hydrogen B
bonding O
induced O
encapsulation O
shifts O
of O
EPR O
spin O
Hamiltonian O
parameters O
in O
solvated O
" O
spin O
- O
label O
@ O
host O
compound O
" O
complexes O
. O

Lactobacillus O
johnsonii O
inhibits O
indoleamine B
2 O
, O
3 O
- O
dioxygenase O
and O
alters O
tryptophan B
metabolite O
levels O
in O
BioBreeding O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
host O
pathways O
affected O
by O
L O
. O
johnsonii O
, O
with O
specific O
focus O
on O
the O
rate O
- O
limiting O
enzyme O
of O
tryptophan B
catabolism O
, O
indoleamine B
2 O
, O
3 O
- O
dioxygenase O
( O
IDO O
) O
. O

Tissue O
IDO O
was O
investigated O
using O
quantitative O
RT O
- O
PCR O
and O
Western O
blot O
, O
whereas O
tryptophan B
, O
kynurenine O
, O
and O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
concentrations O
were O
quantified O
by O
HPLC O
and O
ELISA O
. O

L O
. O
johnsonii O
feeding O
resulted O
in O
a O
17 O
% O
reduction O
in O
serum O
kynurenine O
compared O
with O
that O
in O
vehicle O
- O
fed O
controls O
, O
correlating O
with O
a O
1 O
. O
4 O
- O
fold O
elevation O
in O
5 B
- I
HT I
levels O
. O

H2O2 B
produced O
by O
L O
. O
johnsonii O
abolished O
IDO O
activity O
in O
vitro O
, O
and O
L O
. O
johnsonii O
feeding O
resulted O
in O
a O
3 O
. O
9 O
- O
fold O
increase O
in O
ileum O
lumen O
H2O2 B
. O

These O
data O
support O
the O
role O
of O
H2O2 B
in O
commensal O
bacteria O
- O
host O
interactions O
and O
highlight O
the O
influence O
of O
commensal O
bacteria O
- O
derived O
H2O2 B
on O
host O
physiology O
. O
- O
Valladares O
, O
R O
. O
, O
Bojilova O
, O
L O
. O
, O
Potts O
, O
A O
. O

Lactobacillus O
johnsonii O
inhibits O
indoleamine B
2 O
, O
3 O
- O
dioxygenase O
and O
alters O
tryptophan B
metabolite O
levels O
in O
BioBreeding O
rats O
. O

Roughening O
of O
Pt B
nanoparticles O
induced O
by O
surface O
- O
oxide B
formation O
. O

Using O
density O
functional O
theory O
( O
DFT O
) O
and O
thermodynamic O
considerations O
we O
studied O
the O
equilibrium O
shape O
of O
Pt B
nanoparticles O
( O
NPs O
) O
under O
electrochemical O
conditions O
. O

We O
found O
that O
at O
very O
high O
oxygen B
coverage O
, O
obtained O
at O
high O
electrode O
potentials O
, O
the O
experimentally O
- O
observed O
tetrahexahedral O
( O
THH O
) O
NPs O
consist O
of O
high O
- O
index O
( O
520 O
) O
faces O
. O

Enhancing O
catalytic O
selectivity O
of O
supported O
metal O
nanoparticles O
with O
capping O
ligands O
is O
demonstrated O
using O
an O
Au B
/ O
SiO B
( I
2 I
) I
catalyst O
in O
liquid O
phase O
aerobic O
oxidation O
of O
benzyl B
alcohol I
. O

Chemisorption O
of O
an O
appropriate O
amount O
of O
polyvinylpyrrolidone B
on O
the O
Au B
/ O
SiO B
( I
2 I
) I
catalyst O
greatly O
enhances O
the O
benzaldehyde O
selectivity O
from O
43 O
% O
to O
~ O
100 O
% O
and O
its O
yield O
from O
4 O
. O
9 O
% O
to O
7 O
. O
2 O
% O
. O

Halogen B
bonding O
: O
an O
interim O
discussion O
. O

Halogen B
bonding O
is O
a O
noncovalent O
interaction O
that O
is O
receiving O
rapidly O
increasing O
attention O
because O
of O
its O
significance O
in O
biological O
systems O
and O
its O
importance O
in O
the O
design O
of O
new O
materials O
in O
a O
variety O
of O
areas O
, O
for O
example O
, O
electronics O
, O
nonlinear O
optical O
activity O
, O
and O
pharmaceuticals O
. O

The O
interactions O
can O
be O
understood O
in O
terms O
of O
electrostatics O
/ O
polarization O
and O
dispersion O
; O
they O
involve O
a O
region O
of O
positive O
electrostatic O
potential O
on O
a O
covalently O
bonded O
halogen B
and O
a O
negative O
site O
, O
such O
as O
the O
lone O
pair O
of O
a O
Lewis O
base O
. O

The O
positive O
potential O
, O
labeled O
a O
sigma O
hole O
, O
is O
on O
the O
extension O
of O
the O
covalent O
bond O
to O
the O
halogen B
, O
which O
accounts O
for O
the O
characteristic O
near O
- O
linearity O
of O
halogen B
bonding O
. O

In O
many O
instances O
, O
the O
lateral O
sides O
of O
the O
halogen B
have O
negative O
electrostatic O
potentials O
, O
allowing O
it O
to O
also O
interact O
favorably O
with O
positive O
sites O
. O

In O
this O
discussion O
, O
after O
looking O
at O
some O
of O
the O
experimental O
observations O
of O
halogen B
bonding O
, O
we O
address O
the O
origins O
of O
sigma O
holes O
, O
the O
factors O
that O
govern O
the O
magnitudes O
of O
their O
electrostatic O
potentials O
, O
and O
the O
properties O
of O
the O
resulting O
complexes O
with O
negative O
sites O
. O

The O
relationship O
of O
halogen B
and O
hydrogen B
bonding O
is O
examined O
. O

We O
also O
point O
out O
that O
sigma O
- O
hole O
interactions O
are O
not O
limited O
to O
halogens B
, O
but O
can O
also O
involve O
covalently O
bonded O
atoms O
of O
Groups O
IV O
- O
VI O
. O

Examples O
of O
applications O
in O
biological O
/ O
medicinal O
chemistry O
and O
in O
crystal O
engineering O
are O
mentioned O
, O
taking O
note O
that O
halogen B
bonding O
can O
be O
" O
tuned O
" O
to O
fit O
various O
requirements O
, O
that O
is O
, O
strength O
of O
interaction O
, O
steric O
factors O
, O
and O
so O
forth O
. O

Cyclophilin O
A O
( O
CYPA O
) O
, O
a O
peptidyl O
- O
prolyl B
cis O
- O
trans O
isomerase O
, O
was O
among O
these O
upregulated O
host O
proteins O
. O

We O
describe O
a O
new O
class O
of O
fluorescent O
reporter O
and O
its O
employment O
to O
visualize O
the O
biotin B
/ O
avidin O
binding O
interaction O
. O

Derivatives O
of O
the O
azamacrocycle O
cyclam O
that O
contain O
a O
pendant O
naphthalimide B
dye O
are O
inherently O
fluorescent O
when O
zinc B
( I
II I
) I
is O
coordinated O
. O

Introducing O
a O
second O
pendant O
group O
- O
- O
biotin B
- O
- O
affords O
an O
unsymmetrical O
bis O
- O
triazole O
- O
scorpionand O
ligand O
that O
interacts O
specifically O
with O
avidin O
. O

This O
ligand O
has O
been O
assembled O
by O
using O
a O
one O
- O
pot O
" O
double O
- O
click O
" O
strategy O
and O
complexed O
with O
copper B
( I
II I
) I
and O
zinc B
( I
II I
) I
. O

The O
zinc B
( I
II I
) I
complex O
is O
fluorescent O
, O
and O
its O
fluorescence O
output O
changes O
in O
the O
presence O
of O
avidin O
. O

The O
observed O
change O
might O
arise O
from O
a O
specific O
quenching O
effect O
in O
the O
biotin B
binding O
pocket O
or O
from O
a O
binding O
- O
induced O
change O
in O
the O
coordination O
geometry O
of O
the O
complex O
. O

Promiscuous O
catalysis O
of O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
to O
beta O
- O
nitrostyrene O
by O
the O
proline B
- O
based O
enzyme O
4 O
- O
oxalocrotonate O
tautomerase O
. O

Exploiting O
catalytic O
promiscuity O
: O
The O
proline B
- O
based O
enzyme O
4 O
- O
oxalocrotonate O
tautomerase O
( O
4 O
- O
OT O
) O
promiscuously O
catalyzes O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
- O
- O
ranging O
from O
acetaldehyde B
to O
octanal B
- O
- O
to O
trans O
- O
beta O
- O
nitrostyrene O
in O
aqueous O
solvent O
. O

Successful O
application O
of O
an O
ionic O
liquid O
carrying O
the O
fluoride B
counter O
- O
ion O
in O
biomacromolecular O
chemistry O
: O
microwave O
- O
assisted O
acylation O
of O
cellulose O
in O
the O
presence O
of O
1 O
- O
allyl O
- O
3 O
- O
methylimidazolium O
fluoride O
/ O
DMSO B
mixtures O
. O

The O
use O
of O
ionic O
liquids O
with O
fluoride B
anion O
( O
IL O
- O
F O
) O
is O
challenging O
because O
of O
side O
reactions O
. O

The O
results O
are O
disappointing O
due O
to O
side O
reactions O
in O
the O
IL O
proper O
, O
and O
F B
( I
- I
) I
- O
mediated O
hydrolysis O
of O
the O
produced O
ester B
. O

A O
dramatic O
improvement O
is O
observed O
, O
when O
AlMeImF O
/ O
DMSO B
mixture O
is O
employed O
. O

The O
new O
approach O
( O
use O
of O
IL O
- O
F O
/ O
DMSO B
) O
is O
attractive O
because O
of O
its O
efficiency O
, O
low O
cost O
, O
and O
applicability O
to O
the O
derivatization O
of O
any O
polymer O
. O

Semisynthesis O
and O
myocardial O
activity O
of O
thaliporphine O
N B
- O
homologues O
. O

The O
N B
- O
homologues O
and O
optical O
isomers O
of O
thaliporphine O
( O
5a O
) O
, O
a O
potent O
antiarrhythmic O
agent O
, O
were O
prepared O
starting O
from O
laurolitsine O
( O
1 O
) O
, O
an O
abundant O
aporphine O
present O
in O
Phoebe O
formosana O
. O

( B
1 I
) I
H I
NMR O
spectroscopic O
analysis O
was O
applied O
successfully O
to O
monitor O
the O
optical O
purity O
of O
the O
crystalline O
salt O
while O
undertaking O
optical O
resolution O
. O

Thaliporphine O
( O
5a O
) O
was O
demonstrated O
to O
possess O
better O
positive O
inotropic O
and O
less O
negative O
chronotropic O
effects O
than O
the O
left O
- O
hand O
optical O
isomer O
and O
showed O
the O
best O
activity O
on O
rat O
cardiac O
tissue O
among O
the O
N B
- O
homologues O
prepared O
. O

To O
overcome O
this O
issue O
, O
Bioglass O
is O
used O
to O
form O
a O
composite O
scaffold O
with O
poly B
( I
D I
, I
L I
- I
lactide I
) I
( O
PDLLA O
) O
, O
a O
biodegradable O
polymer O
. O

The O
polymer O
network O
slows O
down O
the O
Na B
( I
+ I
) I
/ O
H B
( I
+ I
) I
exchange O
between O
Bioglass O
and O
water O
used O
to O
leach O
salt O
particles O
to O
create O
pores O
within O
the O
scaffold O
. O

Launching O
of O
the O
excitation O
is O
done O
by O
exciting O
a O
localized O
surface O
plasmon O
mode O
of O
a O
40 O
nm O
silver B
nanoparticle O
by O
800 O
nm O
femtosecond O
laser O
pulses O
via O
two O
- O
photon O
absorption O
. O

Three O
new O
phenolic B
compounds O
from O
the O
roots O
of O
Glycyrrhiza O
yunnanensis O
. O

Three O
new O
phenolic B
compounds O
( O
1 O
- O
3 O
) O
, O
together O
with O
16 O
known O
compounds O
( O
4 O
- O
19 O
) O
, O
were O
isolated O
from O
the O
roots O
of O
Glycyrrhiza O
yunnanensis O
Cheng O
f O
. O

Compounds O
1 O
, O
3 O
, O
5 O
, O
12 O
, O
14 O
, O
15 O
and O
16 O
showed O
antioxidant O
activity O
by O
an O
ABTS B
- O
based O
assay O
. O

Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK O
- O
2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane B
, O
tert B
- I
butylhydroquinone I
, O
cinnamic O
aldehyde O
, O
and O
hydrogen B
peroxide I
) O
showed O
that O
the O
aldo O
- O
keto O
reductase O
( O
AKR O
) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O

The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane B
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O

Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane B
- O
inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2 O
- O
silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O

Both O
compounds O
affected O
a O
number O
of O
mitochondrial O
functions O
in O
HCT O
- O
116 O
cells O
namely O
increasing O
the O
intracellular O
concentrations O
of O
reactive O
oxygen B
species O
, O
inhibiting O
oxygen B
consumption O
and O
decreasing O
the O
mitochondrial O
membrane O
potential O
. O

Both O
compounds O
reacted O
with O
glutathione B
in O
the O
presence O
of O
glutathione B
S B
- O
transferase O
pi O
and O
hence O
they O
may O
be O
classified O
as O
thiol B
alkylators O
. O

Preparation O
of O
apigenin B
nanocrystals O
using O
supercritical O
antisolvent O
process O
for O
dissolution O
and O
bioavailability O
enhancement O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
potential O
of O
nanocrystals O
to O
enhance O
the O
oral O
bioavailability O
of O
apigenin B
( O
AP O
) O
, O
a O
bioactive O
flavonoid B
with O
various O
pharmacological O
activities O
but O
poor O
aqueous O
solubility O
. O

Effects O
of O
tris B
( I
1 I
, I
3 I
- I
dichloro I
- I
2 I
- I
propyl I
) I
phosphate I
and O
triphenyl O
phosphate O
on O
receptor O
- O
associated O
mRNA O
expression O
in O
zebrafish O
embryos O
/ O
larvae O
. O

Tris B
( I
1 I
, I
3 I
- I
dichloro I
- I
2 I
- I
propyl I
) I
phosphate I
( O
TDCPP B
) O
and O
triphenyl O
phosphate O
( O
TPP B
) O
are O
frequently O
detected O
in O
biota O
, O
including O
fish O
. O

In O
the O
present O
study O
, O
an O
in O
vivo O
screening O
approach O
was O
developed O
to O
evaluate O
effects O
of O
TDCPP B
and O
TPP B
on O
developmental O
endpoints O
and O
receptor O
- O
associated O
expression O
of O
mRNA O
in O
zebrafish O
embryos O
/ O
larvae O
. O

Exposure O
to O
TDCPP B
or O
TPP B
resulted O
in O
significantly O
smaller O
rates O
of O
hatching O
and O
survival O
, O
in O
dose O
- O
and O
time O
- O
dependent O
manners O
. O

The O
median O
lethal O
concentration O
( O
LC O
( O
50 O
) O
) O
was O
7 O
. O
0 O
mg O
/ O
L O
for O
TDCPP B
and O
29 O
. O
6 O
mg O
/ O
L O
for O
TPP B
at O
120 O
hour O
post O
- O
fertilization O
( O
hpf O
) O
. O

Real O
- O
time O
PCR O
revealed O
alterations O
in O
expression O
of O
mRNAs O
involved O
in O
aryl B
hydrocarbon I
receptors O
( O
AhRs O
) O
- O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
( O
PPAR O
alpha O
) O
- O
, O
estrogenic O
receptors O
( O
ERs O
) O
- O
, O
thyroid B
hormone I
receptor O
alpha O
( O
TR O
alpha O
) O
- O
, O
glucocorticoid O
receptor O
( O
GR O
) O
- O
, O
and O
mineralocorticoid O
receptor O
( O
MR O
) O
- O
centered O
gene O
networks O
. O

Exposure O
to O
TDCPP B
altered O
transcriptional O
profiles O
in O
all O
six O
receptor O
- O
centered O
gene O
networks O
, O
thus O
exerting O
multiple O
toxic O
effects O
. O

TPP B
was O
easily O
metabolized O
and O
its O
potency O
to O
change O
expression O
of O
mRNA O
involved O
in O
receptor O
- O
centered O
gene O
networks O
was O
weaker O
than O
that O
of O
TDCPP B
. O

The O
PPAR O
alpha O
- O
and O
TR O
alpha O
- O
centered O
gene O
networks O
might O
be O
the O
primary O
pathways O
affected O
by O
TPP B
. O

Taken O
together O
, O
these O
results O
demonstrated O
that O
TDCPP B
and O
TPP B
could O
alter O
mRNA O
expression O
of O
genes O
involved O
in O
the O
six O
receptor O
- O
centered O
gene O
networks O
in O
zebrafish O
embryos O
/ O
larvae O
, O
and O
TDCPP B
seemed O
to O
have O
higher O
potency O
in O
changing O
the O
mRNA O
expression O
of O
these O
genes O
. O

Lipid O
composition O
of O
Chlorella O
vulgaris O
( O
Trebouxiophyceae O
) O
as O
a O
function O
of O
different O
cadmium B
and O
phosphate B
concentrations O
. O

Fatty B
acids I
are O
the O
fundamental O
structural O
components O
of O
membrane O
lipids O
, O
and O
the O
degree O
of O
saturation O
of O
the O
long O
hydrocarbon B
chains O
in O
microalgae O
contributes O
to O
regulation O
of O
growth O
, O
biomass O
production O
and O
reproduction O
of O
aquatic O
consumers O
. O

This O
research O
aimed O
at O
evaluating O
the O
effects O
of O
cadmium B
( O
2 O
x O
10 O
( O
- O
8 O
) O
; O
10 O
( O
- O
7 O
) O
mol O
L O
( O
- O
1 O
) O
Cd B
) O
on O
lipid O
class O
and O
fatty B
acid I
composition O
of O
the O
microalga O
Chlorella O
vulgaris O
under O
varying O
phosphate B
( O
PO O
( O
4 O
) O
( O
3 O
- O
) O
) O
concentrations O
( O
6 O
. O
0 O
x O
10 O
( O
- O
7 O
) O
to O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
) O
. O

Under O
PO O
( O
4 O
) O
( O
3 O
- O
) O
limitation O
and O
Cd B
stress O
, O
the O
storage O
lipid O
class O
triacylglycerol B
( O
TAG B
) O
was O
the O
most O
accumulated O
among O
the O
lipid O
classes O
. O

Fatty B
acid I
composition O
revealed O
that O
the O
degree O
of O
saturation O
increased O
with O
increasing O
Cd B
stress O
and O
PO O
( O
4 O
) O
( O
3 O
- O
) O
limitation O
. O

Decreasing O
PO O
( O
4 O
) O
( O
3 O
- O
) O
and O
increasing O
Cd B
concentrations O
resulted O
in O
higher O
saturated O
fatty O
acid O
( O
SAFA O
) O
and O
monounsaturated O
FA O
( O
MUFA B
) O
concentrations O
. O

Total O
polyunsaturated O
FA O
( O
PUFA B
) O
and O
omega B
3 I
PUFA I
, O
and O
PUFA B
: O
SAFA O
ratios O
were O
higher O
in O
the O
control O
( O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
PO O
( O
4 O
) O
( O
3 O
- O
) O
) O
cells O
than O
in O
either O
PO O
( O
4 O
) O
( O
3 O
- O
) O
limitation O
or O
Cd B
stress O
, O
or O
in O
the O
combination O
of O
both O
stresses O
. O

Contrasting O
with O
all O
the O
other O
PUFAs B
, O
18 O
: O
2n O
- O
6 O
increased O
as O
PO O
( O
4 O
) O
( O
3 O
- O
) O
limitation O
increased O
. O

A O
significant O
positive O
relationship O
of O
PUFAs B
, O
acetone B
mobile O
polar O
lipids O
( O
AMPL O
) O
and O
phospholipids O
( O
PL O
) O
with O
phosphate B
concentration O
in O
the O
culture O
media O
was O
obtained O
, O
while O
TAG B
concentrations O
had O
a O
positive O
association O
with O
total O
MUFA B
and O
SAFA O
. O

Total O
SAFA O
, O
14 O
: O
0 O
, O
18 O
: O
1n O
- O
9 O
and O
18 O
: O
2n O
- O
6 O
were O
positively O
correlated O
with O
Cd B
and O
negatively O
with O
PO O
( O
4 O
) O
( O
3 O
- O
) O
concentrations O
. O

The O
microalga O
responded O
to O
combined O
PO O
( O
4 O
) O
( O
3 O
- O
) O
limitation O
and O
Cd B
exposure O
by O
increasing O
its O
total O
lipid O
production O
and O
significantly O
altering O
its O
lipid O
composition O
. O

The O
FA O
18 O
: O
2n O
- O
6 O
may O
be O
considered O
a O
stress O
biomarker O
for O
PO O
( O
4 O
) O
( O
3 O
- O
) O
limitation O
and O
Cd B
stress O
in O
C O
. O
vulgaris O
. O

Mitochondrial O
complex O
I O
couples O
electron O
transfer O
between O
matrix O
NADH B
and O
inner O
- O
membrane O
ubiquinone O
to O
the O
pumping O
of O
protons O
against O
a O
proton O
motive O
force O
. O

The O
accepted O
proton O
pumping O
stoichiometry O
was O
4 O
protons O
per O
2 O
electrons O
transferred O
( O
4H O
( O
+ O
) O
/ O
2e O
( O
- O
) O
) O
but O
it O
has O
been O
suggested O
that O
stoichiometry O
may O
be O
3H B
( I
+ I
) I
/ O
2e O
( O
- O
) O
based O
on O
the O
identification O
of O
only O
3 O
proton O
pumping O
units O
in O
the O
crystal O
structure O
and O
a O
revision O
of O
the O
previous O
experimental O
data O
. O

Measurement O
of O
proton O
pumping O
stoichiometry O
is O
challenging O
because O
, O
even O
in O
isolated O
mitochondria O
, O
it O
is O
difficult O
to O
measure O
the O
proton O
motive O
force O
while O
simultaneously O
measuring O
the O
redox O
potentials O
of O
the O
NADH B
/ O
NAD B
( I
+ I
) I
and O
ubiquinol O
/ O
ubiquinone O
pools O
. O

The O
hepatoprotection O
of O
caffeic B
acid I
and O
rosmarinic B
acid I
, O
major O
compounds O
of O
Perilla O
frutescens O
, O
against O
t O
- O
BHP O
- O
induced O
oxidative O
liver O
damage O
. O

In O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
effects O
of O
caffeic B
acid I
( O
CA O
) O
, O
rosmarinic B
acid I
( O
RA O
) O
, O
and O
their O
combination O
. O

CA O
remarkably O
reduced O
the O
oxidative O
damage O
than O
rosmarinic B
acid I
in O
an O
in O
vitro O
study O
. O

Oral O
intubation O
with O
CA O
or O
RA O
alone O
for O
five O
days O
was O
conducted O
prior O
to O
treatment O
with O
a O
single O
dose O
of O
tert B
- I
butyl I
hydroperoxide I
( O
0 O
. O
5mmol O
/ O
kg O
b O
. O
w O
. O
, O
i O
. O
p O
. O
) O
, O
which O
led O
to O
a O
significant O
reduction O
of O
indicators O
of O
hepatic O
toxicity O
, O
such O
as O
aspartate B
aminotransferase O
, O
alanine B
aminotransferase O
, O
oxidized B
glutathione I
, O
lipid O
peroxidation O
and O
enzyme O
activities O
related O
to O
antioxidant O
such O
as O
catalase O
, O
glutathione B
peroxidase O
and O
superoxide O

These O
results O
suggest O
that O
CA O
from O
perilla O
leaves O
plays O
a O
role O
in O
the O
increased O
hepatic O
GSH B
concentration O
, O
and O
shows O
an O
additive O
hepatic O
protection O
with O
RA O
against O
oxidative O
hepatic O
damage O
. O

Effects O
of O
silicon B
on O
osteoblast O
activity O
and O
bone O
mineralization O
of O
MC3T3 O
- O
E1 O
cells O
. O

Previous O
studies O
have O
reported O
that O
dietary O
silicon B
( O
Si B
) O
intake O
is O
positively O
associated O
with O
bone O
health O
including O
bone O
mineral O
density O
. O

Although O
the O
amount O
of O
Si B
intake O
is O
high O
among O
trace O
elements O
in O
humans O
, O
how O
dietary O
Si B
affects O
bone O
formation O
at O
the O
cellular O
level O
is O
not O
well O
addressed O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
Si B
in O
osteoblast O
activity O
and O
bone O
mineralization O
. O

MC3T3 O
- O
E1 O
was O
cultured O
as O
mature O
osteoblasts O
and O
treated O
with O
sodium O
metasilicate O
( O
0 O
, O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
as O
a O
source O
of O
Si B
. O

In O
light O
of O
the O
results O
, O
we O
conclude O
that O
Si B
has O
a O
positive O
effect O
on O
bone O
metabolism O
by O
enhancing O
osteoblast O
mineralization O
activity O
. O

Ruxolitinib B
: O
a O
new O
treatment O
option O
for O
myelofibrosis O
. O

Ruxolitinib B
is O
a O
small O
- O
molecule O
inhibitor O
of O
JAK1 O
and O
JAK2 O
and O
recently O
became O
the O
first O
drug O
approved O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
symptomatic O
intermediate O
- O
or O
high O
- O
risk O
myelofibrosis O
. O

In O
clinical O
trials O
, O
ruxolitinib B
demonstrated O
promising O
efficacy O
in O
reducing O
splenomegaly O
and O
myelofibrosis O
- O
related O
symptoms O
. O

However O
, O
ruxolitinib B
did O
not O
demonstrate O
disease O
- O
modifying O
potential O
and O
is O
not O
considered O
a O
curative O
therapeutic O
option O
. O

Adverse O
events O
associated O
with O
ruxolitinib B
are O
primarily O
hematologic O
, O
with O
thrombocytopenia O
and O
anemia O
being O
the O
most O
common O
toxicologic O
events O
identified O
. O

Future O
research O
will O
shed O
light O
on O
whether O
ruxolitinib B
in O
combination O
with O
other O
treatments O
will O
further O
enhance O
outcomes O
in O
myelofibrosis O
. O

Tuning O
optical O
properties O
of O
Si B
quantum O
dots O
by O
pi O
- O
conjugated O
capping O
molecules O
. O

The O
absorption O
and O
photoluminescence O
( O
PL O
) O
properties O
of O
silicon B
quantum O
dots O
( O
QDs O
) O
are O
greatly O
influenced O
by O
their O
size O
and O
surface O
chemistry O
. O

Herein O
, O
we O
examined O
the O
optical O
properties O
of O
three O
Si B
QDs O
with O
increasing O
sigma O
- O
pi O
conjugation O
length O
: O
octyl O
- O
, O
( O
trimethylsilyl O
) O
vinyl O
- O
, O
and O
2 O
- O
phenylvinyl O
- O
capped O
Si B
QDs O
. O

The O
PL O
photon O
energy O
obtained O
from O
as O
- O
prepared O
samples O
decreased O
by O
0 O
. O
1 O
- O
0 O
. O
3 O
eV O
, O
while O
the O
PL O
excitation O
( O
PLE O
) O
extended O
from O
360 O
nm O
( O
octyl O
- O
capped O
Si B
QDs O
) O
to O
400 O
nm O
( O
2 O
- O
phenylvinyl O
- O
capped O
Si B
QDs O
) O
. O

A O
similar O
high O
- O
energy O
peak O
was O
observed O
with O
the O
bare O
Si B
QD O
sample O
. O

The O
changes O
in O
the O
optical O
properties O
of O
Si B
QDs O
were O
mainly O
explained O
by O
the O
formation O
of O
additional O
states O
arising O
from O
the O
strong O
sigma O
- O
pi O
conjugation O
and O
QD O
oxidation O
. O

O O
( O
6 O
) O
- O
Alkylguanine O
- O
DNA O
alkyltransferase O
( O
AGT O
) O
is O
a O
DNA O
repair O
protein O
which O
removes O
alkyl O
groups O
from O
the O
O O
- O
6 O
position O
of O
guanine B
, O
thereby O
providing O
strong O
resistance O
to O
anticancer O
agents O
which O
alkylate O
this O
position O
. O

( B
13 I
) I
C I
NMR O
spectra O
, O
DLS O
, O
and O
circular O
dichroism O
spectra O
were O
employed O
to O
study O
the O
mechanism O
of O
the O
sol O
- O
gel O
phase O
transition O
. O

The O
presence O
of O
alkynyl O
side O
groups O
in O
the O
PEG O
- O
PPLG O
copolymers O
allowed O
convenient O
further O
functionalization O
with O
azide B
- O
modified O
bioactive O
molecules O
, O
such O
as O
biotin B
and O
galactose B
. O

The O
biofunctionalized O
PEG B
- O
polypeptide O
block O
copolymers O
showed O
sol O
- O
gel O
phase O
transitions O
similar O
to O
the O
parent O
copolymers O
. O

Interestingly O
, O
the O
incorporation O
of O
galactose B
groups O
into O
the O
hydrogels O
was O
found O
to O
improve O
cell O
adhesion O
, O
likely O
due O
to O
the O
adsorption O
of O
fibronectin O
( O
FN O
) O
in O
cell O
- O
extracellular O
matrix O
( O
ECM O
) O
. O

Surface O
and O
tribological O
behaviors O
of O
the O
bioinspired O
polydopamine B
thin O
films O
under O
dry O
and O
wet O
conditions O
. O

Dopamine B
is O
a O
" O
sticky O
" O
biomolecule O
containing O
the O
typical O
functional O
groups O
of O
mussel O
adhesive O
proteins O
. O

We O
investigated O
the O
surface O
, O
adhesion O
, O
friction O
, O
and O
cracking O
properties O
of O
polydopamine B
( O
PDA O
) O
thin O
films O
for O
their O
effective O
transfer O
to O
functional O
devices O
and O
biocompatible O
coatings O
. O

A O
series O
of O
surface O
characterizations O
and O
mechanical O
tests O
were O
performed O
to O
reveal O
the O
static O
and O
dynamic O
properties O
of O
PDA O
films O
coated O
on O
glass O
, O
polydimethylsiloxane B
( O
PDMS B
) O
, O
and O
epoxy B
. O

Unlike O
generic O
superoleophobic O
surfaces O
, O
our O
oil O
- O
repellent O
surface O
exhibited O
strong O
repellency O
to O
the O
lateral O
flow O
of O
low O
- O
surface O
- O
tension O
liquids O
such O
as O
hexadecane B
and O
dodecane O
. O

Evaluation O
of O
Coumarin B
and O
Neoflavone O
Derivatives O
as O
HCV O
NS5B O
Polymerase O
Inhibitors O
. O

Coumarins B
and O
coumestans O
represent O
an O
important O
family O
of O
compounds O
with O
diverse O
pharmacological O
properties O
. O

As O
the O
coumarins B
are O
structurally O
related O
to O
coumestans O
by O
virtue O
of O
their O
common O
A O
- O
and O
B O
- O
rings O
, O
we O
postulated O
them O
to O
also O
exhibit O
similar O
binding O
interaction O
with O
NS5B O
and O
inhibit O
its O
polymerase O
function O
. O

We O
therefore O
investigated O
24 O
coumarin B
and O
neoflavone O
derivatives O
as O
candidate O
NS5B O
inhibitors O
and O
identified O
14 O
compounds O
inhibiting O
NS5B O
polymerase O
activity O
with O
IC50 O
values O
between O
17 O
and O
63 O
mu O
m O
. O

We O
demonstrate O
that O
two O
flavin B
mono O
- O
oxygenase O
family O
members O
, O
FMO1 O
and O
FMO3 O
, O
oxidize O
trimethylamine O
( O
TMA B
) O
, O
derived O
from O
gut O
flora O
metabolism O
of O
choline B
, O
to O
TMAO O
. O

In O
mice O
, O
this O
reduction O
in O
FMO3 O
expression O
is O
due O
primarily O
to O
downregulation O
by O
androgens B
. O

FMO3 O
expression O
is O
induced O
by O
dietary O
bile B
acids I
by O
a O
mechanism O
that O
involves O
the O
farnesoid O
X O
receptor O
( O
FXR O
) O
, O
a O
bile B
acid I
- O
activated O
nuclear O
receptor O
. O

Identification O
of O
N O
- O
acyl O
4 O
- O
( O
5 O
- O
pyrimidine O
- O
2 O
, O
4 O
- O
dionyl O
) O
phenylalanine O
derivatives O
and O
their O
orally O
active O
prodrug O
esters B
as O
dual O
- O
acting O
alpha4 O
- O
beta1 O
and O
alpha4 O
- O
beta7 O
receptor O
antagonists O
. O

Tricycloalternarenes O
F O
- O
H O
: O
three O
new O
mixed O
terpenoids B
produced O
by O
an O
endolichenic O
fungus O
Ulocladium O
sp O
. O
using O
OSMAC O
method O
. O

Three O
new O
mixed O
terpenoids B
, O
tricycloalternarenes O
( O
TCAs O
) O
F O
- O
H O
( O
1 O
- O
3 O
) O
, O
together O
with O
ten O
known O
tricycloalternarenes O
( O
4 O
- O
13 O
) O
, O
were O
isolated O
from O
the O
Czapek O
' O
s O
culture O
of O
an O
endophytic O
fungus O
Ulocladium O
sp O
. O

What O
are O
the O
physiological O
estrogens B
? O

Estradiol B
( O
E2 O
) O
is O
the O
principal O
physiological O
estrogen O
in O
mammals O
. O

E2 O
and O
its O
active O
metabolites O
, O
estrone B
and O
estriol O
have O
a O
characteristic O
phenolic O
A O
ring O
, O
unlike O
progesterone B
, O
testosterone B
, O
cortisol B
and O
aldosterone B
, O
which O
have O
an O
A O
ring O
containing O
a O
C3 O
- O
ketone B
, O
a O
Delta O
( O
4 O
) O
bond O
and O
a O
C19 O
methyl B
group O
. O

Crystal O
structures O
of O
E2 O
in O
the O
estrogen B
receptor O
( O
ER O
) O
confirm O
the O
importance O
of O
the O
A O
ring O
in O
stabilizing O
E2 O
in O
the O
ER O
. O

However O
, O
other O
steroids B
, O
including O
Delta O
( O
5 O
) O
- O
androstenediol O
, O
5 O
alpha O
- O
androstanediol O
and O
27 B
- I
hydroxycholesterol I
, O
which O
have O
a O
saturated O
A O
ring O
containing O
a O
3 O
beta O
- O
hydroxyl O
and O
a O
C19 O
methyl B
group O
, O
also O
mediate O
physiological O
responses O
through O
binding O
to O
estrogen B
receptor O
- O
alpha O
( O
ER O
alpha O
) O
and O
ER O
beta O
. O

Moreover O
, O
selective O
estrogen B
response O
modulators O
( O
SERMs O
) O
with O
diverse O
structures O
also O
regulate O
transcription O
of O
ER O
alpha O
and O
ER O
beta O
. O

Our O
understanding O
of O
the O
physiological O
responses O
mediated O
by O
these O
" O
alternative O
" O
estrogens B
is O
in O
its O
infancy O
. O

Further O
studies O
of O
the O
role O
of O
these O
steroids B
and O
SERMs O
in O
regulating O
responses O
mediated O
by O
ER O
alpha O
and O
ER O
beta O
a O
variety O
of O
tissues O
, O
during O
different O
stages O
of O
development O
, O
are O
likely O
to O
uncover O
additional O
estrogenic O
activities O
. O

Perturbation O
of O
male O
sexual O
behavior O
in O
mice O
( O
Mus O
musculus O
) O
within O
a O
discrete O
range O
of O
perinatal O
bisphenol B
- I
A I
doses O
in O
the O
context O
of O
a O
high O
- O
or O
low O
- O
phytoestrogen O
diet O
. O

Differentiation O
of O
masculine O
and O
feminine O
behavior O
in O
mammals O
depends O
on O
perinatal O
sex O
steroids B
. O

As O
bisphenol B
- I
A I
( O
BPA B
) O
can O
be O
estrogenic O
and O
anti O
- O
androgenic O
, O
we O
examined O
impacts O
of O
perinatal O
exposure O
upon O
adult O
sexual O
behavior O
and O
morphology O
of O
male O
mice O
. O

In O
Experiment O
1 O
, O
dams O
were O
fed O
either O
a O
high O
- O
or O
low O
- O
phytoestrogen O
diet O
and O
received O
daily O
oral O
doses O
of O
0 O
, O
0 O
. O
175 O
, O
1 O
. O
75 O
, O
or O
17 O
. O
5 O
mu O
g O
BPA B
from O
gestation O
day O
10 O
through O
post O
- O
partum O
day O
9 O
. O

Male O
offspring O
from O
the O
high O
- O
phytoestrogen O
plus O
17 O
. O
5 O
mu O
g O
BPA B
condition O
showed O
reduced O
mass O
of O
vesicular O
- O
coagulating O
but O
not O
other O
male O
glands O
, O
and O
showed O
increased O
latency O
to O
insemination O
when O
paired O
with O
females O
. O

In O
Experiment O
2 O
, O
these O
procedures O
were O
replicated O
but O
with O
all O
animals O
fed O
the O
high O
- O
phytoestrogen O
diet O
and O
perinatal O
BPA B
doses O
of O
0 O
, O
17 O
. O
5 O
, O
175 O
, O
or O
1750 O
mu O
g O
/ O
day O
. O

Adult O
masses O
of O
testes O
and O
male O
- O
accessory O
glands O
and O
levels O
of O
urinary O
steroids B
were O
not O
significantly O
affected O
. O

Perinatal O
BPA B
dosages O
thus O
influenced O
male O
sexual O
behavior O
non O
- O
monotonically O
, O
with O
impairment O
evident O
in O
a O
discrete O
dose O
range O
among O
males O
on O
a O
high O
- O
phytoestrogen O
diet O
. O

Mouse O
model O
for O
brain O
injury O
showed O
reactive O
astrocytes O
with O
increased O
glial O
fibrillary O
acidic O
protein O
, O
and O
formation O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
. O

The O
former O
comprised O
exhaled O
nitric B
oxide I
( O
NOE O
) O
and O
' O
enhanced O
pause O
' O
( O
Penh O
) O
both O
measured O
in O
spontaneous O
breathing O
conscious O
rats O
. O

( O
- O
) O
- O
Xanthatin O
up O
- O
regulation O
of O
the O
GADD45 O
gamma O
tumor O
suppressor O
gene O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
: O
role O
of O
topoisomerase O
II O
alpha O
inhibition O
and O
reactive O
oxygen B
species O
. O

In O
addition O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
were O
elevated O
in O
cells O
treated O
with O
this O
agent O
. O

Mechanistically O
, O
it O
was O
determined O
that O
the O
induced O
levels O
of O
GADD45 O
gamma O
mRNA O
resulting O
from O
( O
- O
) O
- O
xanthatin O
exposures O
were O
stabilized O
by O
coordinately O
produced O
ROS O
, O
and O
that O
the O
consequent O
induction O
of O
GADD45 O
gamma O
mRNA O
, O
GADD45 O
gamma O
protein O
and O
ROS O
generation O
were O
abrogated O
by O
co O
- O
treatment O
with O
N B
- I
acetyl I
- I
l I
- I
cysteine I
. O

The O
pigments O
responsible O
for O
its O
attractive O
color O
belong O
to O
the O
class O
of O
anthocyanins B
. O

The O
objectives O
of O
this O
study O
were O
to O
characterize O
and O
measure O
the O
concentration O
of O
anthocyanins B
in O
pigmented O
potatoes O
and O
to O
evaluate O
their O
antioxidant O
and O
antimicrobial O
activities O
and O
their O
anti O
- O
proliferative O
effects O
in O
solid O
and O
hematological O
cancer O
cell O
lines O
. O

Anthocyanins B
exert O
anti O
- O
bacterial O
activity O
against O
different O
bacterial O
strains O
and O
a O
slight O
activity O
against O
three O
fungal O
strains O
. O

Antioxidant O
activities O
were O
evaluated O
by O
DPPH B
and O
FRAP O
methods O
; O
the O
extract O
showed O
a O
higher O
reducing O
capability O
than O
anti O
- O
radical O
activity O
. O

Moreover O
, O
we O
found O
that O
in O
different O
cancer O
cell O
models O
the O
anthocyanins B
cause O
inhibition O
of O
proliferation O
and O
apoptosis O
in O
a O
dose O
dependent O
manner O
. O

A O
divergent O
synthesis O
was O
used O
, O
with O
all O
compounds O
being O
elaborated O
from O
a O
single O
chiral O
aldehyde B
derived O
from O
ethyl O
lactate O
. O

Cross O
- O
linking O
time O
was O
5 O
h O
and O
glutaraldehyde B
3 O
. O
5 O
% O
( O
v O
/ O
v O
) O
was O
used O
as O
cross O
- O
linker O
. O

Bacitracin O
and O
sodium B
taurocholate I
were O
incorporated O
in O
the O
formulations O
as O
proteolytic O
enzyme O
inhibitor O
and O
absorption O
enhancer O
, O
respectively O
. O

In O
vitro O
insulin O
release O
studies O
were O
performed O
in O
phosphate B
buffer O
pH O
7 O
. O
4 O
and O
also O
in O
HCl B
pH O
2 O
with O
and O
without O
trypsin O
. O

Effects O
of O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c O
- O
fos O
, O
c O
- O
jun O
and O
p16 O
in O
rat O
stomachs O
. O

2 B
- I
Amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
is O
one O
of O
the O
most O
abundant O
heterocyclic B
amines I
( O
HCAs B
) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O

To O
understand O
the O
possible O
mechanism O
of O
PhIP B
- O
associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP B
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c O
- O
fos O
, O
c O
- O
jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O

The O
results O
showed O
that O
( O
1 O
) O
15mg O
/ O
kg O
body O
weight O
PhIP B
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa O
; O
( O
2 O
) O
PhIP B
( O
10 O
and O
/ O
or O
15mg O
/ O
kg O
) O
significantly O
decreased O
superoxide B
dismutase O
( O
SOD O
) O
and O
glutathioneperoxidas O
( O
GPx O
) O
activities O
, O
while O
increased O
catalase O
( O
CAT O
) O
activity O
compared O
with O
the O
control O
. O

With O
the O
elevated O
doses O
of O
PhIP B
, O
malondialdehyde B
( O
MDA B
) O
contents O
, O
protein O
carbonyl B
( O
PCO O
) O
contents O
and O
DNA O
- O
protein O
crosslinks O
( O
DPC O
) O
coefficients O
were O
significantly O
raised O
in O
a O
dose O
- O
dependent O
manner O
; O
( O
3 O
) O
PhIP B
at O
the O
doses O
of O
10mg O
/ O
kg O
and O
/ O
or O
15mg O
/ O
kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c O
- O
fos O
and O
c O
- O
jun O
expression O
relative O
to O
control O
. O

The O
data O
indicated O
that O
PhIP B
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c O
- O
fos O
and O
c O
- O
jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP B
- O
associated O
stomach O
cancer O
. O

Diminutive O
effect O
on O
T O
and O
B O
- O
cell O
proliferation O
of O
non O
- O
cytotoxic O
alpha O
- O
santonin O
derived O
1 B
, I
2 I
, I
3 I
- I
triazoles I
: O
a O
report O
. O

alpha O
- O
Santonin O
derived O
new O
series O
of O
1 B
, I
2 I
, I
3 I
- I
triazoles I
synthesized O
through O
Azide B
- I
Alkyne I
Huisgen O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
between O
substituted O
aryl B
azide I
and O
a O
propargylated O
alpha O
- O
desmotrosantonin O
were O
bio O
- O
evaluated O
for O
their O
diminutive O
effect O
on O
ConA O
induced O
T O
- O
cell O
and O
LPS O
induced O
B O
- O
cell O
proliferation O
. O

Triazole B
derivatives O
9 O
, O
10 O
, O
17 O
, O
18 O
, O
29 O
, O
and O
30 O
displayed O
significant O
diminutive O
effect O
on O
cell O
proliferation O
. O

The O
present O
study O
resulted O
in O
identification O
of O
several O
triazole B
derivatives O
as O
effective O
immunosuppressive O
agents O
. O

Tributyltin B
exposure O
influences O
predatory O
behavior O
, O
neurotransmitter O
content O
and O
receptor O
expression O
in O
Sebastiscus O
marmoratus O
. O

Tributyltin B
( O
TBT O
) O
is O
a O
ubiquitous O
marine O
contaminant O
due O
to O
its O
extensive O
use O
as O
a O
biocide O
, O
fungicide O
and O
antifouling O
agent O
. O

Dopamine B
levels O
in O
the O
fish O
brains O
increased O
in O
a O
dose O
- O
dependent O
manner O
, O
while O
5 B
- I
hydroxytryptamine I
and O
norepinephrine B
levels O
decreased O
significantly O
in O
the O
TBT O
exposure O
group O
compared O
to O
the O
control O
. O

The O
mRNA O
levels O
of O
dopamine B
receptors O
, O
which O
have O
functions O
such O
as O
cognition O
, O
motor O
activity O
, O
motivation O
and O
reward O
, O
mood O
, O
attention O
and O
learning O
, O
were O
significantly O
down O
- O
regulated O
by O
TBT O
exposure O
. O

Although O
the O
levels O
of O
amino B
acid I
neurotransmitters O
, O
including O
glutamate B
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
, O
a O
- O
amino O
- O
3 O
- O
hydroxy O
- O
5 O
- O
methylisoxazole O
- O
4 O
- O
propionic O
acid O
receptor O
, O
calmodulin O
, O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic O
adenosine O
monophosphate O
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT O
exposure O

Electrical O
field O
stimulation O
( O
EFS O
) O
- O
induced O
relaxations O
turn O
into O
contractions O
upon O
removal O
of O
extracellular O
calcium B
in O
rat O
mesenteric O
artery O
. O

In O
the O
present O
study O
, O
we O
aimed O
to O
examine O
the O
effect O
of O
blockade O
of O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
( O
LTCC O
) O
and O
in O
addition O
the O
removal O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
, O
on O
EFS O
- O
induced O
relaxations O
in O
rings O
of O
rat O
mesenteric O
artery O
. O

EFS O
applied O
to O
the O
tissues O
precontracted O
with O
phenylephrine B
caused O
relaxations O
which O
were O
markedly O
inhibited O
by O
nifedipine B
( O
10 O
( O
- O
7 O
) O
M O
) O
and O
tetraethylammonium B
( O
TEA B
) O
( O
1mM O
) O
. O

Upon O
removal O
of O
Ca B
( I
2 I
+ I
) I
, O
EFS O
with O
the O
same O
stimulation O
parameters O
produced O
frequency O
- O
dependent O
transient O
contractions O
. O

Tetrodotoxin B
( O
10 O
( O
- O
6 O
) O
M O
) O
, O
capsaicin B
( O
10 O
( O
- O
5 O
) O
M O
) O
and O
removal O
of O
endothelium O
did O
not O
alter O
these O
contractions O
suggesting O
that O
they O
were O
not O
neural O
in O
origin O
and O
endothelium O
- O
derived O
contracting O
factors O
were O
unlikely O
to O
be O
involved O
. O

However O
, O
they O
were O
increased O
by O
nearly O
40 O
% O
in O
response O
to O
BAY O
K O
8644 O
( O
10 O
( O
- O
7 O
) O
M O
) O
and O
were O
inhibited O
by O
nifedipine B
( O
10 O
( O
- O
7 O
) O
M O
) O
, O
indicating O
that O
activation O
of O
the O
LTCCs O
was O
essential O
. O

Inositol O
triphosphate O
( O
InsP3 O
) O
receptor O
antagonist O
2 B
- I
APB I
( O
10 O
( O
- O
4 O
) O
M O
) O
significantly O
reduced O
, O
and O
high O
concentration O
of O
caffeine B
( O
20mM O
) O
almost O
totally O
suppressed O
the O
contractions O
. O

These O
results O
suggest O
that O
in O
the O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
EFS O
through O
membrane O
depolarization O
, O
evokes O
the O
opening O
of O
the O
LTCCs O
which O
subsequently O
leads O
to O
the O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
internal O
stores O
via O
InsP3 O
receptors O
, O
a O
phenomenon O
known O
as O
Ca B
( I
2 I
+ I
) I
channel O
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
( O
CCICR O
) O
, O
to O
trigger O
vasoconstriction O
. O

That O
activation O
of O
LTCCs O
causes O
arterial O
relaxation O
or O
contraction O
depending O
on O
the O
Ca B
( I
2 I
+ I
) I
status O
apparently O
exemplifies O
how O
the O
same O
messenger O
fulfils O
opposing O
physiological O
functions O
in O
a O
given O
cell O
. O

OBJECTIVE O
: O
Pentachlorophenol O
( O
PCP B
) O
is O
characterized O
as O
likely O
carcinogen O
of O
lymphoma O
and O
hematopoietic O
neoplasm O
. O

A O
systematic O
review O
was O
conducted O
to O
explore O
two O
kinds O
of O
associations O
, O
one O
was O
between O
the O
workers O
exposed O
to O
PCP B
with O
lymphoma O
and O
hematopoietic O
neoplasm O
, O
the O
other O
was O
between O
childhood O
lymphoma O
and O
leukemia O
with O
their O
parents O
exposed O
to O
PCP B
. O

RESULTS O
: O
The O
meta O
- O
analysis O
suggested O
a O
significant O
association O
between O
lymphoma O
and O
workers O
' O
occupational O
exposing O
to O
PCP B
, O
for O
the O
pooled O
odds O
ratio O
= O
2 O
. O
57 O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
= O
1 O
. O
52 O
- O
4 O
. O
35 O
) O
. O

For O
the O
relationship O
of O
childhood O
leukemia O
and O
parental O
exposure O
to O
PCP B
, O
three O
published O
studies O
suggested O
an O
increased O
risk O
of O
childhood O
leukemia O
because O
of O
their O
parental O
exposure O
to O
PCP B
at O
the O
preconception O
period O
. O

CONCLUSION O
: O
Our O
review O
provided O
the O
evidence O
that O
occupational O
exposure O
of O
workers O
to O
PCP B
might O
increase O
the O
risk O
of O
lymphoma O
and O
hematopoietic O
neoplasm O
in O
themselves O
and O
in O
their O
children O
. O

Silica B
nanoparticles O
- O
induced O
cytotoxicity O
, O
oxidative O
stress O
and O
apoptosis O
in O
cultured O
A431 O
and O
A549 O
cells O
. O

In O
medicine O
, O
the O
use O
of O
silica B
nanoparticles O
( O
SiO B
( I
2 I
) I
NPs O
) O
offers O
new O
perspectives O
in O
biosensor O
, O
drug O
delivery O
and O
cancer O
therapy O
. O

However O
, O
questions O
about O
potential O
toxic O
and O
deleterious O
effects O
of O
SiO B
( I
2 I
) I
NPs O
have O
also O
been O
raised O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
induction O
of O
cytotoxicity O
, O
oxidative O
stress O
and O
apoptosis O
by O
SiO B
( I
2 I
) I
NPs O
( O
size O
15 O
nm O
) O
in O
human O
skin O
epithelial O
( O
A431 O
) O
and O
human O
lung O
epithelial O
( O
A549 O
) O
cells O
. O

SiO B
( I
2 I
) I
NPs O
( O
concentration O
range O
25 O
- O
200 O
micro O
g O
/ O
ml O
) O
induced O
dose O
- O
dependent O
cytotoxicity O
in O
both O
types O
of O
cells O
, O
which O
was O
demonstrated O
by O
cell O
viability O
( O
3 O
- O
( O
4 O
, O
5 O
- O
dimethylthiazol O
- O
2 O
- O
yl O
) O
- O
2 O
, O
5 O
- O
diphenyltetrazoliumb O
) O
and O
lactate B
dehydrogenase O
leakage O
assays O
. O

SiO B
( I
2 I
) I
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose O
- O
dependent O
manner O
, O
indicated O
by O
depletion O
of O
glutathione B
and O
induction O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
and O
lipid O
peroxidation O
. O

Quantitative O
real O
- O
time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO B
( I
2 I
) I
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
( O
caspase O
- O
3 O
and O
caspase O
- O
9 O
) O
were O
upregulated O
in O
a O
dose O
- O
dependent O
manner O
. O

Moreover O
, O
activities O
of O
caspase O
- O
3 O
and O
caspase O
- O
9 O
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO B
( I
2 I
) I
NPs O
. O

This O
study O
suggested O
that O
SiO B
( I
2 I
) I
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

Complex O
II O
of O
the O
mitochondrial O
respiratory O
chain O
is O
the O
key O
mediator O
of O
divalent O
manganese O
- O
induced O
hydrogen B
peroxide I
production O
in O
microglia O
. O

Exposure O
to O
excessive O
levels O
of O
manganese B
( O
Mn B
) O
is O
associated O
with O
the O
development O
of O
movement O
disorders O
, O
with O
symptoms O
overlapping O
with O
Parkinson O
' O
s O
disease O
. O

Oxidative O
damage O
has O
been O
implicated O
as O
a O
key O
contributor O
to O
Mn B
- O
induced O
neurotoxicity O
. O

We O
have O
recently O
reported O
that O
divalent O
Mn O
( O
Mn B
( I
2 I
+ I
) I
) O
stimulates O
brain O
microglia O
to O
produce O
and O
release O
hydrogen B
peroxide I
( O
H2O2 B
) O
, O
and O
microglial O
- O
free O
radical O
generation O
facilitates O
Mn B
( I
2 I
+ I
) I
- O
induced O
dopaminergic O
neurotoxicity O
. O

The O
goal O
of O
this O
study O
was O
to O
elucidate O
the O
underlying O
mechanism O
of O
the O
Mn B
( I
2 I
+ I
) I
- O
induced O
H2O2 B
production O
in O
microglia O
. O

Exposure O
to O
low O
micromolar O
concentrations O
of O
Mn B
( I
2 I
+ I
) I
, O
but O
not O
divalent O
copper O
, O
cadmium O
, O
nickel O
, O
cobalt O
, O
zinc O
, O
and O
iron O
, O
induced O
a O
significant O
production O
of O
H2O2 B
from O
rat O
microglial O
but O
not O
astroglial O
cells O
. O

Subcellular O
fractionation O
studies O
revealed O
that O
Mn B
( I
2 I
+ I
) I
was O
capable O
of O
inducing O
significant O
H2O2 B
production O
in O
the O
mitochondrial O
but O
not O
the O
cytosolic O
or O
nuclear O
fraction O
prepared O
from O
microglia O
. O

Analysis O
of O
the O
relative O
contribution O
of O
mitochondrial O
respiratory O
chain O
complexes O
indicated O
that O
Mn B
( I
2 I
+ I
) I
- O
induced O
mitochondrial O
H2O2 B
production O
required O
the O
presence O
of O
complex O
II O
substrate O
succinate B
. O

In O
contrast O
, O
complex O
I O
substrates O
malate B
and O
glutamate B
failed O
to O
support O
H2O2 B
production O
in O
the O
presence O
of O
Mn B
( I
2 I
+ I
) I
. O

Furthermore O
, O
the O
succinate B
- O
supported O
Mn B
( I
2 I
+ I
) I
- O
induced O
mitochondrial O
H2O2 B
production O
was O
abolished O
by O
pharmacological O
inhibition O
of O
complex O
II O
but O
not O
that O
of O
complexes O
I O
and O
III O
, O
suggesting O
that O
mitochondrial O
complex O
II O
is O
a O
key O
mediator O
in O
Mn B
( I
2 I
+ I
) I
- O
induced O
H2O2 B
production O
. O

These O
findings O
advance O
our O
knowledge O
on O
the O
mechanisms O
by O
which O
Mn B
induces O
oxidative O
stress O
and O
the O
potential O
contribution O
to O
Mn O
neurotoxicity O
. O

Human O
embryonic O
stem O
cell O
- O
derived O
cardiomyocytes O
( O
hESC O
- O
CMs O
) O
and O
the O
rat O
myoblastic O
H9c2 O
cell O
lines O
were O
used O
to O
phenotypically O
profile O
a O
panel O
of O
structural O
cardiotoxins O
by O
live O
- O
cell O
fluorescent O
imaging O
of O
mitochondrial O
membrane O
potential O
, O
endoplasmic O
reticulum O
integrity O
, O
Ca B
( I
2 I
+ I
) I
mobilization O
, O
and O
membrane O
permeability O
combined O
with O
an O
assessment O
of O
cell O
viability O
( O
ATP B
depletion O
) O
. O

Classification O
of O
structural O
cardiotoxins O
into O
mechanistic O
themes O
revealed O
mitochondria O
and O
calcium B
mobilization O
to O
be O
major O
distal O
targets O
, O
with O
only O
4 O
out O
of O
15 O
compounds O
affecting O
contractile O
function O
in O
freshly O
isolated O
canine O
cardiomyocytes O
at O
therapeutically O
relevant O
concentrations O
. O

The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic B
acid I
( O
AA O
) O
, O
linoleic B
acid I
( O
LA O
) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O

Each O
recombinant O
protein O
metabolized O
AA O
and O
LA O
to O
epoxides O
and O
hydroxy B
derivatives O
. O

Innovation O
and O
originality O
in O
the O
strategies O
developed O
by O
bacteria O
to O
get O
access O
to O
iron B
. O

The O
c O
- O
abl O
proto O
- O
oncogene O
encodes O
a O
unique O
protein O
- O
tyrosine B
kinase O
( O
Abl O
) O
distinct O
from O
c O
- O
Src O
, O
c O
- O
Fes O
, O
and O
other O
cytoplasmic O
tyrosine B
kinases O
. O

Selective O
inhibitors O
of O
Bcr O
- O
Abl O
, O
of O
which O
imatinib B
is O
the O
prototype O
, O
have O
had O
a O
tremendous O
impact O
on O
clinical O
outcomes O
in O
chronic O
myelogenous O
leukemia O
and O
revolutionized O
the O
field O
of O
targeted O
cancer O
therapy O
. O

In O
this O
study O
, O
supercritical O
fluid O
extraction O
( O
SFE O
) O
with O
CO B
( I
2 I
) I
and O
hydrodistillation O
( O
HD O
) O
were O
compared O
as O
methods O
to O
isolate O
the O
essential O
oil O
from O
Cupressus O
sempervirens O
. O

Targeting O
adenosine B
signaling O
to O
treatment O
of O
diabetic O
nephropathy O
. O

Interestingly O
, O
in O
the O
last O
years O
it O
has O
been O
documented O
that O
DN O
progresses O
with O
growing O
levels O
of O
the O
nucleoside O
adenosine B
. O

This O
finding O
increased O
the O
interest O
in O
the O
events O
controlling O
the O
extracellular O
levels O
of O
the O
nucleoside B
. O

While O
the O
metabolism O
of O
extracellular O
ATP B
and O
cyclic B
AMP I
are O
well O
recognized O
sources O
, O
evidences O
regarding O
the O
role O
of O
the O
equilibrative O
nucleoside B
transporters O
in O
controlling O
adenosine B
availability O
and O
promoting O
diabetic O
glomerulopathy O
have O
recently O
acquired O
a O
pivotal O
role O
. O

The O
physiological O
effects O
of O
nucleoside B
are O
mediated O
by O
the O
P1 O
family O
of O
adenosine B
receptors O
. O

This O
review O
highlights O
these O
findings O
that O
correlate O
the O
activity O
of O
a O
low O
affinity O
adenosine B
receptor O
with O
an O
increase O
in O
the O
ligand O
availability O
in O
the O
pathological O
state O
. O

In O
addition O
, O
we O
discuss O
the O
possible O
therapeutic O
interventions O
of O
adenosine B
signaling O
with O
regards O
to O
DN O
treatment O
. O

MMP O
inhibitors O
including O
endogenous O
tissue O
inhibitors O
( O
TIMPs O
) O
and O
pharmacological O
inhibitors O
such O
as O
zinc B
chelators O
, O
doxycycline B
, O
batimastat O
and O
marimastat O
, O
have O
been O
used O
as O
diagnostic O
and O
therapeutic O
tools O
in O
cancer O
, O
autoimmune O
and O
cardiovascular O
disease O
. O

Synthesis O
and O
biological O
evaluation O
as O
microtubule O
- O
active O
agents O
of O
several O
tetrahydrofuran B
and O
spiroacetal O
derivatives O
. O

The O
stereoselective O
preparation O
of O
several O
molecules O
containing O
structural O
fragments O
of O
the O
tetrahydrofuran B
and O
spiroacetal O
type O
is O
described O
. O

It O
has O
been O
confirmed O
that O
the O
tetrahydrofuran B
derivatives O
are O
cytotoxic O
but O
, O
in O
contrast O
to O
previous O
reports O
, O
it O
has O
been O
found O
that O
the O
cytoxicity O
is O
not O
due O
to O
interactions O
with O
the O
microtubule O
network O
. O

The O
oxygen B
therapy O
. O

Oxygen B
( O
O B
( I
2 I
) I
) O
is O
a O
vital O
element O
. O

Shortage O
of O
O B
( I
2 I
) I
results O
in O
deranged O
metabolism O
and O
important O
changes O
in O
vascular O
tone O
with O
opposite O
effects O
on O
the O
systemic O
and O
pulmonary O
circulation O
. O

However O
, O
O B
( I
2 I
) I
therapy O
remains O
the O
most O
common O
therapy O
of O
hypoxemia O
, O
but O
it O
must O
be O
carefully O
tailored O
to O
relieve O
hypoxemia O
without O
provoking O
hyperoxia O
or O
hypercarbia O
. O

Then O
, O
the O
individual O
response O
to O
O B
( I
2 I
) I
as O
well O
as O
changing O
needs O
of O
O B
( I
2 I
) I
during O
sleep O
or O
exercise O
must O
be O
evaluated O
to O
provide O
the O
best O
O B
( I
2 I
) I
therapy O
. O

A O
thorough O
knowledge O
of O
the O
pathophysiological O
bases O
of O
hypoxemia O
and O
O B
( I
2 I
) I
storage O
and O
delivery O
devices O
is O
then O
mandatory O
to O
administer O
O B
( I
2 I
) I
therapy O
guaranteeing O
for O
optimal O
correction O
of O
hypoxemia O
and O
minimizing O
the O
risk O
of O
hyperoxia O
. O

Consistent O
with O
this O
aim O
also O
is O
a O
careful O
scrutiny O
of O
instruments O
and O
procedures O
for O
monitoring O
the O
individual O
response O
to O
O B
( I
2 I
) I
over O
time O
. O

Thus O
, O
at O
variance O
from O
classical O
pharmacological O
therapy O
, O
performing O
O B
( I
2 I
) I
therapy O
requires O
a O
vast O
array O
of O
clinical O
and O
technical O
competences O
. O

The O
optimal O
integration O
of O
these O
competences O
is O
needed O
to O
optimize O
O B
( I
2 I
) I
therapy O
on O
individual O
bases O
. O

Recent O
Developments O
of O
p38 O
alpha O
MAP O
Kinase O
Inhibitors O
as O
Antiinflammatory O
Agents O
Based O
on O
the O
Imidazole B
Scaffolds O
. O

The O
imidazole B
derivatives O
are O
known O
as O
competitive O
inhibitors O
at O
the O
ATP B
binding O
site O
of O
the O
p38 O
alpha O
MAP O
kinase O
. O

Modifications O
on O
the O
imidazole B
scaffold O
have O
led O
to O
a O
large O
amount O
of O
potent O
p38 O
alpha O
MAP O
kinase O
inhibitors O
. O

This O
review O
will O
summarize O
the O
developments O
of O
small O
molecule O
p38 O
alpha O
MAP O
kinase O
inhibitors O
based O
on O
the O
imidazole B
core O
scaffolds O
in O
recent O
10 O
years O
. O

Variations O
at O
the O
N1 O
, O
C2 O
, O
C4 O
and O
C5 O
positions O
of O
imidazole B
were O
introduced O
, O
and O
the O
structure O
- O
activity O
relationships O
of O
these O
imidazole B
inhibitors O
were O
also O
discussed O
. O

What O
happens O
to O
the O
thiolates B
created O
by O
reductively O
desorbing O
SAMs O
? O

In O
situ O
examination O
of O
the O
reductive O
desorption O
process O
for O
Au B
microelectrodes O
modified O
with O
a O
thiol B
self O
- O
assembled O
monolayer O
( O
SAM O
) O
using O
fluorescence O
microscopy O
enabled O
the O
study O
of O
the O
fate O
of O
the O
desorbed O
thiolate O
species O
. O

The O
Bodipy O
labeled O
alkyl O
- O
thiol B
SAM O
, O
when O
adsorbed O
, O
is O
not O
fluorescent O
due O
to O
quenching O
by O
the O
Au B
surface O
. O

As O
the O
potential O
becomes O
more O
negative O
, O
the O
molecules O
move O
in O
an O
upward O
direction O
, O
with O
a O
speed O
that O
depends O
on O
the O
amount O
of O
dissolved O
H B
( I
2 I
) I
produced O
by O
water O
reduction O
. O

Shown O
is O
that O
this O
motion O
is O
controlled O
, O
in O
large O
part O
, O
by O
the O
change O
in O
the O
electrolyte O
density O
near O
the O
electrode O
due O
to O
dissolved O
H B
( I
2 I
) I
. O

The O
electrogenerated O
H B
( I
2 I
) I
was O
also O
shown O
to O
be O
able O
to O
reductively O
remove O
the O
thiol O
SAM O
from O
the O
Pt B
/ O
Ir B
particles O
that O
decorate O
the O
microelectrode O
glass O
sheath O
. O

The O
structure O
- O
activity O
relationship O
studies O
of O
a O
novel O
series O
of O
carboxylic B
acid I
derivatives O
of O
pyridine O
- O
carboxamides O
as O
DGAT O
- O
1 O
inhibitors O
is O
described O
. O

ErbB2 O
becomes O
phosphorylated O
at O
tyrosine B
877 O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
following O
exposure O
to O
X O
- O
rays O
, O
and O
activates O
downstream O
signaling O
cascades O
including O
PI3K O
/ O
Akt O
. O

Inhibition O
of O
these O
pathways O
, O
as O
well O
as O
inhibition O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
with O
antioxidants O
, O
prevents O
IR O
- O
induced O
invasion O
. O

Effects O
of O
celiac O
superior O
mesenteric O
ganglionectomy O
on O
glucose B
homeostasis O
and O
hormonal O
changes O
during O
oral O
glucose B
tolerance O
testing O
in O
rats O
. O

The O
liver O
plays O
an O
important O
role O
in O
maintaining O
glucose B
homeostasis O
in O
the O
body O
. O

In O
the O
prandial O
state O
, O
some O
of O
the O
glucose B
which O
is O
absorbed O
by O
the O
gastrointestinal O
tract O
is O
converted O
into O
glycogen O
and O
stored O
in O
the O
liver O
. O

In O
contrast O
, O
the O
liver O
produces O
glucose B
by O
glycogenolysis O
and O
gluconeogenesis O
while O
fasting O
. O

Thus O
, O
the O
liver O
contributes O
to O
maintaining O
blood O
glucose B
level O
within O
normoglycemic O
range O
. O

Glycogenesis O
and O
glycogenolysis O
are O
regulated O
by O
various O
mechanisms O
including O
hormones O
, O
the O
sympathetic O
and O
parasympathetic O
nervous O
systems O
and O
the O
hepatic O
glucose B
content O
. O

We O
attempted O
to O
elucidate O
how O
the O
celiac O
sympathetic O
nervous O
system O
is O
involved O
in O
regulating O
glucose B
homeostasis O
by O
assessing O
the O
effects O
of O
CSMG O
resection O
on O
glucose B
excursion O
during O
an O
oral O
glucose B
tolerance O
test O
, O
and O
by O
examining O
hepatic O
glycogen O
content O
and O
hepatic O
glycogen O
phosphorylase O
( O
GP O
) O
activity O
. O

On O
the O
oral O
glucose B
tolerance O
test O
, O
CSMG O
- O
resected O
rats O
demonstrated O
improved O
glucose B
tolerance O
and O
significantly O
increased O
GP O
activity O
compared O
with O
sham O
- O
operated O
rats O
, O
whereas O
there O
were O
no O
significant O
differences O
in O
insulin O
, O
glucagon O
or O
catecholamine B
levels O
between O
the O
2 O
groups O
. O

In O
conclusion O
, O
the O
examined O
rat O
model O
showed O
that O
the O
celiac O
sympathetic O
nervous O
system O
regulates O
hepatic O
glucose B
metabolism O
in O
conjunction O
with O
vagal O
nerve O
innervations O
and O
is O
a O
critical O
component O
in O
the O
maintenance O
of O
blood O
glucose B
homeostasis O
. O

Butein O
protects O
human O
dental O
pulp O
cells O
from O
hydrogen B
peroxide I
- O
induced O
oxidative O
toxicity O
via O
Nrf2 O
pathway O
- O
dependent O
heme O
oxygenase O
- O
1 O
expressions O
. O

Butein O
, O
a O
plant O
polyphenol B
, O
is O
one O
of O
the O
major O
active O
components O
of O
R O
. O
verniciflua O
. O

Reactive O
oxygen B
species O
( O
ROS O
) O
, O
produced O
via O
dental O
adhesive O
bleaching O
agents O
and O
pulpal O
disease O
, O
can O
cause O
oxidative O
stress O
. O

Here O
, O
we O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen B
peroxide I
( O
H2O2 B
) O
- O
induced O
dental O
cell O
death O
. O

H2O2 B
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
( O
HDP O
) O
cells O
. O

H2O2 B
- O
induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O

Butein O
also O
increased O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
protein O
expression O
and O
HO O
activity O
. O

In O
addition O
, O
butein O
- O
dependent O
HO O
- O
1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2 B
- O
induced O
cell O
death O
and O
ROS O
generation O
. O

Treatment O
of O
HDP O
cells O
with O
a O
c O
- O
Jun O
NH2 B
- O
terminal O
kinase O
( O
JNK O
) O
inhibitor O
also O
reduced O
butein O
- O
induced O
HO O
- O
1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O

Oxidative O
and O
nitrosative O
stress O
and O
apoptosis O
in O
oral O
mucosa O
cells O
after O
ex O
vivo O
exposure O
to O
lead O
and O
benzo B
[ I
a I
] I
pyrene I
. O

Exposure O
of O
human O
oral O
mucosa O
to O
lead O
( O
Pb B
) O
and O
benzo B
[ I
a I
] I
pyrene I
( O
BaP B
) O
by O
inhalation O
and O
ingestion O
can O
lead O
to O
pathological O
conditions O
via O
apoptosis O
and O
oxidative O
and O
nitrosative O
stress O
. O

However O
, O
few O
studies O
have O
investigated O
the O
effects O
of O
Pb B
and O
BaP B
on O
oral O
mucosa O
cells O
. O

Furthermore O
, O
previous O
studies O
focused O
on O
chronic O
Pb B
and O
BaP B
exposure O
. O

Therefore O
, O
we O
evaluated O
important O
markers O
of O
apoptosis O
and O
oxidative O
and O
nitrosative O
stress O
in O
oral O
mucosa O
cells O
by O
incubating O
the O
cells O
with O
Pb B
and O
BaP B
for O
5 O
- O
360 O
min O
. O

Ex O
vivo O
samples O
of O
human O
oral O
mucosa O
were O
exposed O
to O
Pb B
or O
BaP B
, O
and O
immunohistochemical O
staining O
was O
performed O
to O
evaluate O
active O
caspase O
- O
3 O
, O
8 O
- O
epi O
- O
prostaglandin O
F2 O
alpha O
( O
8 O
- O
epi O
- O
PGF2a O
) O
, O
and O
3 B
- I
nitrotyrosine I
( O
3 B
- I
NT I
) O
. O

Pb B
and O
BaP B
treatments O
significantly O
increased O
active O
caspase O
- O
3 O
levels O
in O
a O
time O
- O
dependent O
manner O
. O

Furthermore O
, O
the O
treatments O
induced O
an O
early O
increase O
in O
3 B
- I
NT I
level O
, O
which O
ceased O
with O
longer O
incubation O
times O
. O

8 O
- O
Epi O
- O
PGF2a O
level O
increased O
only O
after O
prolonged O
incubation O
with O
Pb B
, O
and O
this O
elevation O
was O
irrespective O
of O
BaP B
incubation O
duration O
. O

Thus O
, O
single O
, O
short O
- O
term O
exposure O
to O
Pb B
or O
BaP B
increases O
the O
levels O
of O
apoptosis O
markers O
and O
markers O
of O
oxidative O
and O
nitrosative O
stress O
. O

TAA O
increased O
the O
number O
and O
area O
of O
glutathione B
S B
- O
transferase O
placental O
form O
( O
GST O
- O
P O
) O
( O
+ O
) O
liver O
cell O
foci O
and O
the O
numbers O
of O
proliferating O
and O
apoptotic O
cells O
in O
randomly O
selected O
areas O
in O
liver O
sections O
. O

TAA O
also O
increased O
the O
numbers O
of O
ED2 O
( O
+ O
) O
, O
cyclooxygenase O
- O
2 O
( O
+ O
) O
, O
and O
heme B
oxygenase O
- O
1 O
( O
+ O
) O
liver O
cells O
, O
as O
well O
as O
the O
number O
of O
CD3 O
( O
+ O
) O
lymphocytes O
. O

EMIQ O
increased O
liver O
levels O
of O
thiobarbituric B
acid I
- O
reactive O
substance O
and O
8 B
- I
hydroxydeoxyguanosin I
, O
and O
TUNEL O
( O
+ O
) O
apoptotic O
cells O
, O
death O
receptor O
5 O
( O
DR5 O
) O
( O
+ O
) O
cells O
and O
4 O
- O
hydroxy O
- O
2 O
- O
nonenal O
( O
+ O
) O
cells O
within O
GST O
- O
P O
( O
+ O
) O
foci O
. O

Ciguatoxins O
are O
sodium B
channel O
activator O
toxins O
responsible O
for O
ciguatera O
fish O
poisoning O
. O

Mechanical O
characteristics O
of O
human O
red O
blood O
cell O
membrane O
change O
due O
to O
C60 B
nanoparticle O
infiltration O
. O

The O
mechanical O
characteristics O
of O
human O
red O
blood O
cell O
( O
RBC O
) O
membrane O
change O
due O
to O
C B
( I
60 I
) I
nanoparticle O
( O
NP O
) O
infiltration O
have O
been O
investigated O
in O
the O
present O
work O
. O

Using O
experimental O
approaches O
, O
including O
optical O
tweezer O
( O
OT O
) O
stretching O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
indentation O
, O
we O
found O
that O
RBCs O
in O
the O
presence O
of O
C B
( I
60 I
) I
NPs O
are O
softer O
than O
normal O
RBCs O
. O

The O
strain O
- O
stress O
relations O
of O
both O
normal O
and O
C B
( I
60 I
) I
infiltrated O
RBC O
membranes O
are O
extracted O
from O
the O
data O
of O
AFM O
indentation O
, O
from O
which O
we O
proved O
that O
C B
( I
60 I
) I
NP O
infiltration O
can O
affect O
the O
mechanical O
properties O
of O
RBC O
membrane O
and O
tend O
to O
weaken O
the O
tensile O
resistance O
of O
lipids O
bilayers O
. O

Based O
on O
this O
model O
, O
the O
strain O
- O
stress O
relations O
of O
both O
normal O
and O
C B
( I
60 I
) I
infiltrated O
lipid O
bilayers O
are O
calculated O
with O
consideration O
of O
intermolecular O
interactions O
. O

The O
influence O
of O
C B
( I
60 I
) I
NP O
concentration O
on O
the O
mechanical O
properties O
of O
RBC O
membrane O
is O
successfully O
predicted O
. O

Higher O
concentrations O
of O
C B
( I
60 I
) I
NPs O
in O
the O
lipid O
bilayers O
will O
lead O
to O
increased O
damage O
to O
the O
cell O
membrane O
, O
implying O
that O
the O
dosage O
of O
C B
( I
60 I
) I
NPs O
should O
be O
controlled O
in O
medical O
applications O
. O

We O
engineered O
specific O
microfluidic O
devices O
based O
on O
the O
pervaporation O
of O
water O
through O
a O
PDMS B
membrane O
, O
to O
formulate O
continuous O
and O
steady O
concentration O
gradients O
of O
a O
binary O
aqueous O
molecular O
mixture O
at O
the O
nanolitre O
scale O
. O

An O
N B
- O
terminal O
nuclear O
export O
signal O
regulates O
trafficking O
and O
aggregation O
of O
Huntingtin O
( O
Htt O
) O
protein O
exon O
1 O
. O

Huntington O
disease O
is O
a O
dominantly O
inherited O
neurodegenerative O
condition O
caused O
by O
polyglutamine O
expansion O
in O
the O
N B
terminus O
of O
the O
huntingtin O
protein O
( O
Htt O
) O
. O

The O
first O
17 O
amino B
acids I
( O
N17 O
) O
of O
Htt O
play O
a O
key O
role O
in O
regulating O
its O
toxicity O
and O
aggregation O
. O

We O
have O
defined O
amino B
acids I
within O
N17 O
that O
constitute O
the O
nuclear O
export O
sequence O
( O
NES O
) O
. O

Recently O
we O
discovered O
that O
for O
1 O
- O
dimensional O
( O
1D O
) O
nanocrystals O
( O
Au B
nanorods O
) O
, O
the O
catalytic O
activity O
is O
not O
constant O
along O
the O
same O
side O
facets O
of O
single O
nanorods O
but O
rather O
differs O
significantly O
and O
further O
shows O
a O
gradient O
along O
its O
length O
, O
which O
we O
attributed O
to O
an O
underlying O
gradient O
of O
surface O
defect O
density O
resulting O
from O
their O
linear O
decay O
in O
growth O
rate O
during O
synthesis O
( O
Nat O
. O
Nanotechnol O
. O
2012 O
, O
7 O
, O
237 O
- O
241 O
) O
. O

By O
using O
super O
- O
resolution O
fluorescence O
microscopy O
to O
map O
out O
the O
locations O
of O
catalytic O
events O
within O
individual O
triangular O
and O
hexagonal O
Au B
nanoplates O
in O
correlation O
with O
scanning O
electron O
microscopy O
, O
we O
find O
that O
the O
catalytic O
activity O
within O
the O
flat O
{ O
111 O
} O
surface O
facet O
of O
a O
Au B
nanoplate O
exhibits O
a O
2D O
radial O
gradient O
from O
the O
center O
toward O
the O
edges O
. O

In O
particular O
, O
we O
detected O
inter O
- O
monomer O
contacts O
between O
region O
I O
, O
and O
between O
region O
I O
and O
the O
C B
- O
terminal O
portion O
of O
region O
III O
. O

FosA O
is O
a O
manganese B
- O
dependent O
enzyme O
that O
utilizes O
a O
Mn B
( I
2 I
+ I
) I
ion O
to O
catalyze O
the O
inactivation O
of O
the O
fosfomycin O
antibiotic O
by O
glutathione B
( O
GSH B
) O
addition O
. O

According O
to O
quantum O
mechanics O
/ O
molecular O
mechanics O
( O
QM O
/ O
MM O
) O
calculations O
on O
the O
full O
solvated O
protein O
, O
the O
enzyme O
- O
catalyzed O
glutathione B
addition O
reaction O
involves O
two O
major O
chemical O
steps O
that O
both O
proceed O
in O
the O
sextet O
state O
: O
proton O
transfer O
from O
the O
GSH O
thiol O
group O
to O
the O
Tyr39 O
anion O
and O
nucleophilic O
attack O
by O
the O
GSH O
thiolate O
leading O
to O
epoxide B
ring O
- O
opening O
. O

The O
second O
step O
is O
rate O
- O
limiting O
and O
is O
facilitated O
by O
the O
presence O
of O
the O
high O
- O
spin O
Mn B
( I
2 I
+ I
) I
ion O
that O
functions O
as O
a O
Lewis B
acid I
and O
stabilizes O
the O
leaving O
oxyanion O
through O
direct O
coordination O
. O

Further O
QM O
/ O
MM O
calculations O
on O
the O
alternative O
water O
attack O
predict O
a O
concerted O
mechanism O
for O
this O
reaction O
, O
where O
the O
deprotonation O
of O
water O
, O
nucleophilic O
attack O
, O
and O
epoxide B
ring O
- O
opening O
take O
place O
via O
the O
same O
transition O
state O
. O

The O
calculated O
barrier O
is O
8 O
. O
3 O
kcal O
/ O
mol O
higher O
than O
that O
for O
GSH B
attack O
, O
in O
line O
with O
the O
observed O
chemoselectivity O
of O
the O
enzyme O
, O
which O
manages O
to O
catalyze O
the O
addition O
of O
GSH B
in O
the O
presence O
of O
water O
molecules O
around O
its O
active O
site O
. O

What O
is O
the O
contact O
angle O
of O
water O
on O
graphene B
? O

Although O
experimental O
and O
theoretical O
studies O
have O
addressed O
the O
question O
of O
the O
wetting O
properties O
of O
graphene B
, O
the O
actual O
value O
of O
the O
contact O
angle O
of O
water O
on O
an O
isolated O
graphene B
monolayer O
remains O
unknown O
. O

While O
recent O
experimental O
literature O
indicates O
that O
the O
contact O
angle O
of O
water O
on O
graphite B
is O
in O
the O
range O
90 O
- O
95 O
degrees O
, O
it O
has O
been O
suggested O
that O
the O
contact O
angle O
on O
graphene B
may O
either O
be O
as O
high O
as O
127 O
degrees O
or O
moderately O
enhanced O
in O
comparison O
with O
graphite B
. O

Our O
study O
establishes O
a O
connection O
between O
the O
variation O
of O
the O
work O
of O
adhesion O
of O
water O
on O
graphene B
- O
based O
surfaces O
and O
the O
interaction O
potential O
between O
individual O
water O
molecules O
and O
these O
surfaces O
. O

We O
show O
that O
a O
variation O
of O
the O
contact O
angle O
from O
90 O
degrees O
on O
graphite B
to O
127 O
degrees O
on O
graphene B
would O
imply O
that O
both O
of O
the O
first O
two O
carbon B
layers O
of O
graphite B
contribute O
approximately O
the O
same O
interaction O
energy O
with O
water O
. O

We O
also O
show O
that O
the O
interaction O
potential O
energy O
between O
water O
and O
the O
graphene B
- O
based O
substrates O
is O
the O
main O
contribution O
to O
the O
work O
of O
adhesion O
of O
water O
with O
a O
relative O
magnitude O
that O
is O
independent O
of O
the O
number O
of O
graphene B
layers O
. O

To O
directly O
compare O
the O
specificity O
and O
efficacy O
of O
different O
Cre O
lines O
in O
mediating O
adipocyte O
specific O
recombination O
, O
transgenic O
Cre O
lines O
driven O
by O
the O
adipocyte O
protein O
2 O
( O
aP2 O
) O
and O
adiponectin O
( O
Adipoq O
) O
gene O
promoters O
, O
as O
well O
as O
a O
tamoxifen B
- O
inducible O
Cre O
driven O
by O
the O
aP2 O
gene O
promoter O
( O
iaP2 O
) O
, O
were O
bred O
to O
the O
Rosa26R O
( O
R26R O
) O
reporter O
. O

Morphine B
and O
related O
micro O
- O
opioid O
receptor O
( O
MOR O
) O
agonists O
remain O
among O
the O
most O
effective O
drugs O
known O
for O
acute O
relief O
of O
severe O
pain O
. O

Evaluation O
of O
a O
Self O
- O
Administered O
Oral O
Glucose B
Tolerance O
Test O
. O

OBJECTIVETo O
assess O
the O
feasibility O
of O
using O
a O
disposable O
, O
self O
- O
administered O
, O
capillary O
blood O
sampling O
oral O
glucose B
tolerance O
test O
( O
OGTT O
) O
device O
in O
a O
community O
setting O
. O
RESEARCH O
DESIGN O
AND O
METHODSEighteen O
healthy O
and O
12 O
type O
2 O
diabetic O
volunteers O
underwent O
six O
75 O
- O
g O
OGTTs O
using O
a O
prototype O
device O
in O
the O
following O
three O
settings O
: O
unaided O
at O
home O
( O
twice O
) O
; O
unaided O
but O
observed O
in O
clinic O
( O
twice O
) O
; O
and O
performed O
by O
a O
nurse O
with O
simultaneous O
laboratory O
glucose B
assays O
of O
0 O
- O
and O
120 O
- O

A O
detachable O
data O
recorder O
returned O
to O
the O
clinic O
provided O
plasma O
- O
equivalent O
0 O
- O
and O
120 O
- O
min O
glucose B
values O
and O
key O
parameters O
, O
including O
test O
date O
, O
start O
and O
end O
times O
, O
and O
time O
taken O
to O
consume O
the O
glucose B
drink O
. O
RESULTSThe O
device O
was O
universally O
popular O
with O
participants O
, O
was O
perceived O
as O
easy O
to O
use O
, O
and O
the O
ability O
to O
test O
at O
home O
was O
well O
- O
liked O
. O

Device O
failures O
meant O
that O
0 O
- O
and O
120 O
- O
min O
glucose B
values O
were O
obtained O
for O
only O
141 O
( O
78 O
% O
) O
of O
the O
180 O
OGTTs O
performed O
, O
independent O
of O
setting O
. O

Device O
glucose B
measurements O
showed O
a O
mean O
bias O
compared O
with O
laboratory O
- O
measured O
values O
of O
+ O
0 O
. O
9 O
at O
5 O
. O
0 O
mmol O
/ O
L O
increasing O
to O
+ O
4 O
. O
4 O
at O
15 O
. O
0 O
mmol O
/ O
L O
. O

Paired O
device O
glucose B
values O
were O
equally O
reproducible O
across O
settings O
, O
with O
repeat O
testing O
showing O
no O
training O
effect O
regardless O
of O
setting O
order O
. O
CONCLUSIONSSelf O
- O
administered O
OGTTs O
can O
be O
performed O
successfully O
by O
untrained O
individuals O
in O
a O
community O
setting O
. O

With O
improved O
device O
reliability O
and O
appropriate O
calibration O
, O
this O
novel O
technology O
could O
be O
used O
in O
routine O
practice O
to O
screen O
people O
who O
might O
need O
a O
formal O
OGTT O
to O
confirm O
the O
presence O
of O
impaired O
glucose B
tolerance O
or O
diabetes O
. O

The O
minimum O
inhibitory O
concentration O
( O
MIC O
) O
of O
compound O
7p O
against O
Escherichia O
coli O
was O
0 O
. O
5 O
mu O
g O
/ O
mL O
, O
better O
than O
that O
of O
reference O
agent O
ciprofloxacin B
and O
amoxicillin B
. O

Since O
we O
recently O
reported O
a O
role O
for O
low O
density O
lipoprotein O
- O
related O
protein O
( O
LRP O
) O
- O
4 O
in O
monogenic O
disorders O
with O
bone O
overgrowth O
, O
we O
now O
wanted O
to O
evaluate O
whether O
genetic O
variation O
in O
the O
LRP4 O
gene O
has O
an O
effect O
on O
the O
susceptibility O
to O
osteoporosis O
in O
a O
population O
based O
cohort O
from O
the O
Odense O
Androgen B
Study O
. O

Cardioprotective O
potential O
of O
N O
, O
alpha O
- O
L O
- O
rhamnopyranosyl O
vincosamide O
, O
an O
indole B
alkaloid I
, O
isolated O
from O
the O
leaves O
of O
Moringa O
oleifera O
in O
isoproterenol B
induced O
cardiotoxic O
rats O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Hitherto O
unknown O
protective O
effect O
of O
N O
, O
alpha O
- O
L O
- O
rhamnopyranosyl O
vincosamide O
( O
VR O
) O
, O
isolated O
from O
Moringa O
oleifera O
leaves O
in O
isoproterenol B
( O
ISO B
) O
- O
induced O
cardiac O
toxicity O
was O
evaluated O
in O
rats O
. O

Oral O
administration O
of O
VR O
at O
40 O
mg O
/ O
kg O
for O
7 O
days O
markedly O
reduced O
the O
ISO B
- O
induced O
increase O
in O
the O
levels O
of O
serum O
cardiac O
markers O
such O
as O
troponin O
- O
T O
, O
creatine B
kinase O
- O
MB O
, O
lactate B
dehydrogenase O
and O
glutamate B
pyruvate B
transaminase O
as O
well O
as O
cardiac O
lipid O
peroxidation O
with O
a O
parallel O
increase O
in O
the O
cellular O
antioxidants O
suggesting O
its O
cardio O
- O
protective O
and O
free O
radical O
scavenging O
potential O
, O
which O
was O
latter O
confirmed O
by O
in O
vitro O
study O
. O

Rats O
treated O
with O
test O
compound O
also O
improved O
the O
ISO B
- O
induced O
abnormal O
changes O
in O
ECG O
as O
well O
as O
in O
cardiac O
histology O
. O

The O
potent O
topoisomerase O
II O
inhibitor O
indenoindolone O
derivatives O
exhibited O
good O
anticancer O
activities O
compared O
to O
etoposide B
and O
5 B
- I
fluorouracil I
, O
and O
relatively O
low O
toxicity O
to O
normal O
cells O
. O

The O
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
is O
highly O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
is O
associated O
with O
cognitive O
function O
as O
well O
as O
anxiety O
. O

Previously O
nicotine B
, O
which O
activates O
both O
alpha O
7 O
and O
non O
- O
alpha O
7 O
subtypes O
of O
nAChRs O
, O
has O
been O
shown O
to O
have O
an O
anxiogenic O
effect O
in O
behavioral O
tests O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
the O
alpha O
7 O
- O
selective O
agonist O
( O
PNU O
- O
282987 O
) O
and O
PAM O
( O
PNU B
- I
120596 I
) O
in O
a O
variety O
of O
behavioral O
tests O
in O
Sprague O
Dawley O
rats O
to O
look O
at O
their O
effects O
on O
learning O
and O
memory O
as O
well O
as O
anxiety O
. O

We O
found O
that O
neither O
PNU O
- O
282987 O
nor O
PNU B
- I
120596 I
improved O
spatial O
- O
learning O
or O
episodic O
memory O
by O
themselves O
. O

However O
when O
cognitive O
impairment O
was O
induced O
in O
the O
rats O
with O
scopolamine B
( O
1 O
mg O
/ O
kg O
) O
, O
both O
PNU B
- I
120596 I
and O
PNU O
- O
282987 O
were O
able O
to O
reverse O
this O
memory O
impairment O
and O
restore O
it O
back O
to O
normal O
levels O
. O

While O
PNU B
- I
120596 I
reversed O
the O
scopolamine O
- O
induced O
cognitive O
impairment O
, O
it O
did O
not O
have O
any O
adverse O
effect O
on O
anxiety O
. O

However O
the O
alpha O
7 O
receptor O
antagonist O
methyllycaconitine B
was O
unable O
to O
reverse O
these O
anxiety O
- O
like O
effects O
seen O
with O
PNU O
- O
282987 O
. O

There O
has O
been O
much O
recent O
interest O
in O
lysophosphatidic B
acid I
( O
LPA B
) O
signaling O
through O
one O
of O
its O
receptors O
, O
LPA1 O
, O
in O
fibrotic O
diseases O
, O
but O
the O
mechanisms O
by O
which O
LPA B
- O
LPA1 O
signaling O
promotes O
pathological O
fibrosis O
remain O
to O
be O
fully O
elucidated O
. O

Using O
a O
mouse O
peritoneal O
fibrosis O
model O
, O
we O
demonstrate O
central O
roles O
for O
LPA B
and O
LPA1 O
in O
fibroblast O
proliferation O
. O

LPA1 O
- O
induced O
cytoskeleton O
reorganization O
therefore O
makes O
a O
previously O
unrecognized O
but O
critically O
important O
contribution O
to O
the O
profibrotic O
activities O
of O
LPA B
by O
driving O
MRTF O
- O
dependent O
CTGF O
expression O
, O
which O
, O
in O
turn O
, O
drives O
fibroblast O
proliferation O
. O
- O
Sakai O
, O
N O
. O
, O
Chun O
, O
J O
. O
, O
Duffield O
, O
J O
. O

Pathophysiology O
in O
relation O
with O
the O
essential O
elements O
including O
copper B
, O
magnesium B
, O
zinc B
, O
manganese B
, O
chromium B
, O
and O
calcium B
has O
been O
reported O
in O
women O
with O
insulin O
resistance O
. O

In O
all O
women O
, O
basal O
levels O
of O
gonadotropins O
, O
prolactin O
, O
testosterone B
, O
insulin O
, O
glucose B
, O
and O
the O
six O
different O
elements O
were O
measured O
. O

Serum O
levels O
of O
testosterone B
( O
p O
< O
0 O
. O
001 O
) O
, O
luteinizing O
hormone O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
fasting O
insulin O
( O
p O
< O
0 O
. O
004 O
) O
were O
significantly O
higher O
in O
the O
PCOS O
population O
compared O
to O
controls O
as O
well O
as O
PCOS O
women O
without O
insulin O
resistance O
. O

Women O
with O
PCOS O
exhibited O
a O
significantly O
high O
calcium B
( O
p O
< O
0 O
. O
04 O
) O
and O
lower O
manganese B
levels O
( O
p O
< O
0 O
. O
002 O
) O
when O
compared O
to O
controls O
. O

However O
, O
the O
PCOS O
women O
with O
insulin O
resistance O
exhibited O
significantly O
lower O
serum O
levels O
of O
magnesium B
and O
chromium B
( O
p O
< O
0 O
. O
04 O
) O
, O
in O
addition O
to O
higher O
levels O
of O
zinc B
and O
copper B
( O
p O
< O
0 O
. O
04 O
) O
. O

The O
differences O
in O
calcium B
( O
p O
< O
0 O
. O
03 O
) O
and O
manganese B
levels O
( O
p O
< O
0 O
. O
0001 O
) O
became O
aggravated O
with O
the O
presence O
of O
insulin O
resistance O
when O
compared O
to O
control O
as O
well O
as O
PCOS O
women O
without O
insulin O
resistance O
. O

In O
PCOS O
- O
associated O
insulin O
resistance O
, O
circulating O
serum O
magnesium B
( O
r O
= O
- O
0 O
. O
31 O
; O
p O
< O
0 O
. O
03 O
) O
and O
chromium B
( O
r O
= O
- O
0 O
. O
38 O
; O
p O
< O
0 O
. O
006 O
) O
status O
significantly O
correlated O
with O
fasting O
insulin O
levels O
. O

We O
exposed O
wood O
frog O
tadpoles O
from O
15 O
populations O
to O
three O
acetylcholine B
esterase O
- O
inhibiting O
insecticides O
and O
found O
widespread O
variation O
in O
insecticide O
tolerance O
and O
evidence O
for O
cross O
- O
tolerance O
to O
these O
insecticides O
. O

The O
authors O
investigated O
the O
relationship O
between O
PFCs O
( O
including O
sum O
perfluorocarboxylate O
, O
sum O
perfluoroalkyl O
sulfonates O
, O
perfluorooctane B
sulfonate I
, O
perfluorooctanoic B
acid I
, O
and O
perfluorodecanoic O
acid O
) O
and O
the O
clinocopathologic O
and O
immune O
parameters O
in O
a O
highly O
exposed O
population O
( O
n O
= O
79 O
) O
of O
Atlantic O
bottlenose O
dolphins O
( O
mean O
sum O
PFCs O
= O
1970 O
ng O
/ O
ml O
; O
range O
574 O
- O
8670 O
ng O
/ O
ml O
) O
sampled O
from O
2003 O
to O
2005 O
near O
Charleston O
, O
South O
Carolina O

Several O
PFC O
analyte O
groups O
were O
also O
positively O
associated O
with O
serum O
alanine B
aminotransferase O
, O
gamma O
- O
glutamyltransferase O
, O
creatinine B
, O
phosphorus B
, O
amylase O
, O
and O
anion O
gap O
and O
negatively O
associated O
with O
cholesterol B
levels O
, O
creatinine B
phosphokinase O
, O
eosinophils O
, O
and O
monocytes O
. O

While O
conducting O
toxicity O
tests O
with O
nano O
titanium B
dioxide I
, O
the O
authors O
found O
that O
test O
suspensions O
were O
being O
contaminated O
with O
aluminum B
and O
titanium O
from O
tip O
erosion O
during O
direct O
sonication O
. O

Bioisosterism O
of O
alpha O
- O
amino O
acids O
is O
often O
accomplished O
by O
replacing O
the O
alpha O
- O
carboxylate O
with O
one O
of O
the O
many O
known O
carboxylic B
acid I
bioisosteres O
. O

However O
, O
bioisosterism O
of O
the O
whole O
alpha B
- I
amino I
acid I
moiety O
is O
accomplished O
with O
heterocyclic O
bioisosteres O
that O
often O
display O
an O
acidic O
function O
. O

The O
data O
collected O
here O
show O
the O
potential O
of O
this O
class O
of O
bioisosteres O
in O
the O
design O
of O
glutamate B
receptor O
ligands O
and O
beyond O
. O

Effects O
of O
antiresorptive O
therapies O
on O
glucose B
metabolism O
: O
Results O
from O
the O
FIT O
, O
HORIZON O
- O
PFT O
and O
FREEDOM O
trials O
. O

We O
tested O
whether O
antiresorptive O
therapies O
result O
in O
higher O
fasting O
glucose B
, O
increased O
weight O
, O
or O
greater O
diabetes O
incidence O
in O
post O
- O
hoc O
analyses O
of O
three O
randomized O
, O
placebo O
- O
controlled O
trials O
in O
postmenopausal O
women O
: O
Fracture O
Intervention O
Trial O
( O
FIT O
) O
( O
N O
= O
6151 O
) O
of O
alendronate B
( O
4 O
years O
) O
, O
Health O
Outcomes O
and O
Reduced O
Incidence O
with O
Zoledronic O
Acid O
Once O
Yearly O
Pivotal O
Fracture O
Trial O
( O
HORIZON O
- O
PFT O
) O
( O
N O
= O
7113 O
) O
of O
zoledronic O
acid O
( O

Fasting O
glucose B
was O
measured O
annually O
in O
FIT O
and O
HORIZON O
in O
a O
subset O
of O
women O
, O
and O
every O
6 O
months O
in O
FREEDOM O
on O
all O
participants O
. O

Incident O
diabetes O
was O
identified O
from O
adverse O
event O
reports O
, O
initiation O
of O
diabetes O
medication O
, O
or O
elevated O
fasting O
glucose B
. O

Differences O
in O
fasting O
glucose B
changes O
from O
randomization O
to O
trial O
conclusion O
between O
treatment O
and O
placebo O
groups O
were O
not O
statistically O
significant O
: O
- O
0 O
. O
47 O
mg O
/ O
dL O
in O
FIT O
, O
0 O
. O
20 O
mg O
/ O
dL O
in O
HORIZON O
- O
PFT O
and O
0 O
. O
09 O
mg O
/ O
dL O
in O
FREEDOM O
, O
all O
p O
> O
0 O
. O
6 O
. O

Antiresorptive O
therapy O
does O
not O
have O
a O
clinically O
important O
effect O
on O
fasting O
glucose B
, O
weight O
or O
diabetes O
risk O
in O
postmenopausal O
women O
. O

Contrary O
to O
predictions O
from O
mouse O
models O
, O
reduced O
bone O
turnover O
does O
not O
appear O
to O
play O
a O
significant O
role O
in O
glucose B
metabolism O
in O
humans O
. O

Single O
- O
walled O
carbon B
nanotube O
/ O
polyaniline B
/ O
n O
- O
silicon B
solar O
cells O
: O
fabrication O
, O
characterization O
, O
and O
performance O
measurements O
. O

Carbon B
nanotube O
- O
silicon B
solar O
cells O
are O
a O
recently O
investigated O
photovoltaic O
architecture O
with O
demonstrated O
high O
efficiencies O
. O

Silicon B
solar O
- O
cell O
devices O
fabricated O
with O
a O
thin O
film O
of O
conductive O
polymer O
( O
polyaniline B
) O
have O
been O
reported O
, O
but O
these O
devices O
can O
suffer O
from O
poor O
performance O
due O
to O
the O
limited O
lateral O
current O
- O
carrying O
capacity O
of O
thin O
polymer O
films O
. O

Herein O
, O
hybrid O
solar O
- O
cell O
devices O
of O
a O
thin O
film O
of O
polyaniline B
deposited O
on O
silicon B
and O
covered O
by O
a O
single O
- O
walled O
carbon B
nanotube O
film O
are O
fabricated O
and O
characterized O
. O

These O
hybrid O
devices O
combine O
the O
conformal O
coverage O
given O
by O
the O
polymer O
and O
the O
excellent O
electrical O
properties O
of O
single O
- O
walled O
carbon B
nanotube O
films O
and O
significantly O
outperform O
either O
of O
their O
component O
counterparts O
. O

Treatment O
of O
the O
silicon B
base O
and O
carbon B
nanotubes O
with O
hydrofluoric O
acid O
and O
a O
strong O
oxidizer O
( O
thionyl O
chloride O
) O
leads O
to O
a O
significant O
improvement O
in O
performance O
. O

Control O
of O
plasma O
cholesterol B
levels O
is O
a O
major O
therapeutic O
strategy O
for O
management O
of O
coronary O
artery O
disease O
( O
CAD O
) O
. O

Although O
reducing O
LDL O
cholesterol B
( O
LDL O
- O
c O
) O
levels O
decreases O
morbidity O
and O
mortality O
, O
this O
therapeutic O
intervention O
only O
translates O
into O
a O
25 O
- O
40 O
% O
reduction O
in O
cardiovascular O
events O
. O

Epidemiological O
studies O
have O
shown O
that O
a O
high O
LDL O
- O
c O
level O
is O
not O
the O
only O
risk O
factor O
for O
CAD O
; O
low O
HDL O
cholesterol B
( O
HDL O
- O
c O
) O
is O
an O
independent O
risk O
factor O
for O
CAD O
. O

Apolipoprotein O
A O
- O
I O
( O
ApoA O
- O
I O
) O
is O
the O
major O
protein O
component O
of O
HDL O
- O
c O
that O
mediates O
reverse O
cholesterol B
transport O
from O
tissues O
to O
the O
liver O
for O
excretion O
. O

Repression O
of O
farnesyltransferase O
( O
FNTA O
) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA O
- O
I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA O
- O
I O
and O
cholesterol B
ester I
transfer O
protein O
transgenes O
. O

Optimization O
of O
Non O
- O
ATP B
Competitive O
CDK O
/ O
Cyclin O
Groove O
Inhibitors O
through O
REPLACE O
- O
Mediated O
Fragment O
Assembly O
. O

In O
particular O
, O
these O
results O
shed O
light O
onto O
the O
key O
contributions O
of O
a O
H B
- O
bond O
observed O
in O
crystal O
structures O
of O
N B
- O
terminally O
capped O
peptides O
. O

Furthermore O
, O
the O
structure O
- O
activity O
relationship O
of O
a O
bis O
( O
aryl O
) O
ether O
C B
- O
terminal O
capping O
group O
mimicking O
dipeptide B
interactions O
was O
probed O
through O
ring O
substitutions O
, O
allowing O
increased O
complementarity O
with O
the O
primary O
hydrophobic O
pocket O
. O

- O
tetradehydro O
- O
4 O
- O
demethyl O
- O
4 O
- O
formaldehyde O
- O
3 O
, O
17 O
- O
epoxy O
- O
7 O
, O
20 O
( O
2H O
, O
19H O
) O
- O
cyclovobasan O
] O
, O
and O
M O
- O
4 O
[ O
1 O
, O
2 O
, O
4 O
, O
21 O
, O
18 O
, O
19 O
- O
hexadehydro O
- O
4 O
- O
demethyl O
- O
4 O
- O
oxy O
- O
3 O
, O
17 O
- O
epoxy O
- O
7 O
, O
20 O
( O
2H O
, O
19H O
) O
- O
cyclovobasan O
] O
were O
isolated O
from O
the O
chloroform B
extract O
of O
koumine O

A O
new O
flavonoid B
with O
6 O
- O
phenyl O
substituent O
from O
Selaginella O
uncinata O
. O

A O
new O
flavonoid B
, O
6 O
- O
( O
5 O
- O
acetyl O
- O
2 O
- O
methoxyphenyl O
) O
- O
apigenin O
( O
1 O
) O
, O
together O
with O
nine O
known O
compounds O
( O
2 O
- O
10 O
) O
, O
was O
isolated O
from O
Selaginella O
uncinata O
( O
Desv O
. O
) O
Spring O
. O

Controlled O
assembly O
and O
release O
of O
retinoic B
acid I
based O
on O
the O
layer O
- O
by O
- O
layer O
method O
. O

All B
- I
trans I
retinoic I
acid I
( O
RA O
) O
has O
been O
proved O
to O
play O
important O
roles O
in O
regulating O
cell O
growth O
in O
various O
types O
of O
cells O
. O

Phase O
separation O
induced O
by O
Au B
catalysts O
in O
ternary O
InGaAs O
nanowires O
. O

It O
has O
been O
found O
that O
for O
In O
( O
x O
) O
Ga O
( O
1 O
- O
x O
) O
As O
nanowires O
high O
precursor O
flow O
rates O
generate O
ternary O
In O
( O
x O
) O
Ga O
( O
1 O
- O
x O
) O
As O
cores O
with O
In O
- O
rich O
shells O
, O
while O
low O
precursor O
flow O
rates O
produce O
binary O
GaAs B
cores O
with O
ternary O
In O
( O
x O
) O
Ga O
( O
1 O
- O
x O
) O
As O
shells O
. O

First O
- O
principle O
calculations O
combined O
with O
thermodynamic O
considerations O
suggest O
that O
this O
phenomenon O
is O
due O
to O
competitive O
alloying O
of O
different O
group O
- O
III O
elements O
with O
Au B
catalysts O
, O
and O
variations O
in O
elemental O
concentrations O
of O
group O
- O
III O
materials O
in O
the O
catalyst O
under O
different O
precursor O
flow O
rates O
. O

This O
study O
shows O
that O
precursor O
flow O
rates O
are O
critical O
factors O
for O
manipulating O
Au B
catalysts O
to O
produce O
nanowires O
of O
desired O
composition O
. O

Hydrolysis O
of O
isocoumarin B
to O
keto O
acid O
( O
3 O
) O
followed O
by O
reduction O
and O
cyclodehydration O
of O
hydroxy O
acid O
analog O
( O
4 O
) O
afforded O
( O
+ O
/ O
- O
) O
- O
6 O
, O
8 O
- O
dimethoxy O
- O
3 O
- O
( O
4 O
- O
methoxyphenyl O
) O
- O
3 O
, O
4 O
- O
dihydroisocoumarin O
( O
5 O
) O
. O

Demethylation O
of O
the O
latter O
using O
anhydrous O
aluminum B
chloride I
/ O
ethane O
thiol O
furnished O
the O
title O
isocoumarin B
( O
6 O
) O
. O

Successful O
factorial O
design O
for O
the O
optimization O
of O
methylprednisolone B
encapsulation O
in O
biodegradable O
nanoparticles O
. O

Due O
to O
their O
crystalline O
nature O
, O
the O
encapsulation O
of O
hydrophobic O
corticosteroids B
within O
polymeric O
nanoparticles O
by O
o O
/ O
w O
solvent O
evaporation O
method O
is O
often O
difficult O
to O
achieve O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
both O
process O
and O
formulation O
parameters O
on O
the O
encapsulation O
of O
a O
model O
corticosteroid B
: O
methylprednisolone B
( O
MP O
) O
. O

The O
optimal O
nanoparticle O
formulation O
using O
0 O
. O
25 O
% O
( O
w O
/ O
v O
) O
of O
emulsifying O
agent O
( O
Polyvinyl B
- I
alcohol I
, O
PVA B
) O
and O
5 O
min O
of O
sonication O
was O
then O
characterized O
. O

The O
highest O
encapsulation O
was O
obtained O
with O
an O
organic O
phase O
consisting O
of O
acetone B
: O
dichloromethane B
( O
1 O
: O
1 O
) O
, O
polyD O
, O
L O
- O
lactide O
- O
co O
- O
glycolide O
( O
PLGA B
) O
50 O
: O
50 O
as O
polymer O
and O
an O
initial O
mass O
of O
6 O
. O
6 O
mg O
of O
methylprednisolone B
. O

Fasciospyrinadine O
, O
a O
novel O
sesquiterpene B
pyridine B
alkaloid I
from O
a O
Guangxi O
sponge O
Fasciospongia O
sp O
. O

Fasciospyrinadine O
( O
1 O
) O
, O
a O
novel O
sesquiterpene B
pyridine B
alkaloid I
with O
a O
previously O
unreported O
skeleton O
featuring O
a O
monocyclicfarnesane O
moiety O
attached O
to O
a O
3 O
- O
methylenepyridine O
residue O
, O
was O
isolated O
from O
the O
sponge O
Fasciospongia O
sp O
. O
from O
Weizhou O
Island O
, O
Guangxi O
Autonomous O
Region O
. O

Fundamental O
and O
Torsional O
Combination O
Bands O
of O
Two O
Isomers O
of O
the O
OCS O
- O
CO B
( I
2 I
) I
Complex O
in O
the O
CO B
( I
2 I
) I
nu O
( O
3 O
) O
Region O
. O

Spectra O
of O
two O
isomers O
of O
the O
weakly O
bound O
complex O
OCS O
- O
CO B
( I
2 I
) I
are O
observed O
in O
the O
region O
of O
the O
CO B
( I
2 I
) I
nu O
( O
3 O
) O
fundamental O
vibration O
( O
~ O
2349 O
cm O
( O
- O
1 O
) O
) O
, O
using O
an O
infrared O
tunable O
diode O
laser O
to O
probe O
a O
pulsed O
supersonic O
slit O
- O
jet O
expansion O
. O

Two O
bands O
are O
measured O
and O
analyzed O
for O
each O
isomer O
, O
the O
fundamental O
asymmetric O
stretch O
of O
the O
CO B
( I
2 I
) I
component O
and O
a O
combination O
band O
involving O
this O
fundamental O
plus O
the O
intermolecular O
out O
- O
of O
- O
plane O
torsional O
mode O
. O

The O
resulting O
torsional O
frequencies O
are O
found O
to O
be O
18 O
. O
8 O
and O
15 O
. O
9 O
cm O
( O
- O
1 O
) O
for O
isomers O
a O
and O
b O
of O
OCS O
- O
CO B
( I
2 I
) I
, O
respectively O
. O

The O
two O
epimers O
of O
1 O
were O
resolved O
through O
an O
acetonide O
reaction O
, O
and O
the O
absolute O
configurations O
of O
two O
derivatives O
were O
deduced O
by O
the O
analysis O
of O
their O
( B
13 I
) I
C I
NMR O
differences O
induced O
by O
gamma O
- O
gauche O
or O
steric O
effect O
. O

Based O
on O
it O
, O
the O
( B
13 I
) I
C I
NMR O
assignment O
of O
24R O
- O
1 O
and O
24S O
- O
1 O
was O
also O
established O
. O

Phthalazinone O
inhibitors O
of O
inosine B
- I
5 I
' I
- I
monophosphate I
dehydrogenase O
from O
Cryptosporidium O
parvum O
. O

This O
protozoan O
parasite O
relies O
on O
inosine B
5 I
' I
- I
monophosphate I
dehydrogenase O
( O
IMPDH O
) O
for O
the O
production O
of O
guanine O
nucleotides O
. O

Dietary O
composition O
of O
carbohydrates B
contributes O
to O
the O
development O
of O
experimental O
type O
2 O
diabetes O
. O

Body O
weight O
, O
blood O
glucose B
, O
glucose B
tolerance O
, O
and O
circulating O
cholesterol B
and O
triglyceride B
levels O
were O
measured O
for O
the O
duration O
of O
the O
study O
. O

We O
found O
that O
increasing O
the O
GI O
of O
a O
moderately O
HF O
diet O
induces O
severe O
hyperglycaemia O
and O
insulin O
resistance O
in O
C57BL O
/ O
6 O
mice O
, O
reflective O
of O
criteria O
for O
diagnosis O
of O
T2D O
, O
whilst O
littermates O
consuming O
an O
equivalent O
low O
GI O
diet O
maintain O
glucose B
homeostasis O
. O

This O
study O
demonstrates O
the O
significant O
contribution O
of O
both O
dietary O
carbohydrate B
and O
fat O
composition O
in O
the O
aetiopathogenesis O
of O
T2D O
. O

The O
high O
harm O
score O
of O
alcohol B
. O

The O
aim O
of O
this O
paper O
is O
to O
create O
awareness O
of O
the O
negative O
health O
impact O
and O
economic O
burden O
and O
benefits O
associated O
to O
alcohol B
consumption O
. O

Worldwide O
about O
two O
billion O
people O
consume O
alcohol B
. O

Low O
intake O
of O
alcohol B
has O
a O
minor O
protective O
cardiovascular O
effect O
. O

On O
the O
other O
hand O
, O
even O
moderate O
alcohol B
consumption O
appears O
to O
be O
weakly O
, O
but O
significantly O
, O
associated O
to O
a O
limited O
number O
of O
chronic O
diseases O
. O

Alcohol B
causes O
a O
considerable O
economic O
burden O
to O
society O
due O
to O
the O
high O
absolute O
number O
of O
alcohol B
consumers O
. O

As O
such O
, O
alcohol B
abuse O
is O
more O
harmful O
for O
public O
health O
and O
society O
than O
illicit O
drug O
use O
. O

Some O
3 O
. O
7 O
% O
of O
alcohol B
consumers O
( O
worldwide O
76 O
million O
people O
) O
have O
an O
alcohol B
use O
disorder O
leading O
to O
60 O
- O
70 O
% O
of O
the O
societal O
costs O
related O
to O
alcohol B
. O

Therefore O
, O
policy O
measures O
should O
, O
in O
addition O
to O
regulatory O
measures O
to O
reduce O
alcohol B
use O
, O
aim O
at O
closing O
the O
treatment O
gap O
and O
improving O
treatment O
effectiveness O
of O
people O
with O
an O
alcohol B
use O
disorder O
. O

The O
key O
message O
is O
that O
policy O
- O
makers O
unjustifiably O
focus O
on O
the O
harm O
of O
illicit O
drugs O
, O
whereas O
they O
underestimate O
the O
harm O
of O
alcohol B
use O
. O

Policy O
makers O
should O
therefore O
consider O
alcohol B
to O
be O
at O
least O
as O
harmful O
as O
illicit O
drugs O
and O
invest O
more O
in O
prevention O
and O
harm O
reduction O
strategies O
for O
alcohol B
abuse O
and O
dependence O
. O

Adjunctive O
aripiprazole O
therapy O
with O
escitalopram B
in O
patients O
with O
co O
- O
morbid O
major O
depressive O
disorder O
and O
alcohol B
dependence O
: O
clinical O
and O
neuroimaging O
evidence O
. O

The O
effective O
treatment O
of O
depression O
has O
been O
reported O
to O
reduce O
the O
severity O
of O
alcohol B
use O
, O
potentially O
reflecting O
improvements O
in O
common O
brain O
reward O
circuits O
. O

We O
hypothesized O
that O
augmentation O
therapy O
of O
escitalopram B
with O
aripiprazole O
would O
improve O
depressive O
symptoms O
as O
well O
as O
reduce O
craving O
for O
alcohol B
and O
cue O
- O
induced O
brain O
activity O
in O
patients O
with O
co O
- O
morbid O
alcohol B
dependence O
and O
major O
depressive O
disorder O
, O
compared O
with O
treatment O
with O
escitalopram B
alone O
. O

Thirty O
- O
five O
subjects O
with O
major O
depressive O
disorder O
and O
alcohol B
dependence O
were O
recruited O
and O
randomly O
assigned O
into O
17 O
aripiprazole O
+ O
escitalopram B
and O
18 O
escitalopram B
only O
groups O
. O

At O
baseline O
and O
following O
six O
weeks O
of O
treatment O
, O
symptoms O
of O
depression O
, O
craving O
for O
alcohol B
and O
brain O
activity O
were O
evaluated O
. O

During O
the O
six O
week O
treatment O
period O
, O
Beck O
Depression O
Inventory O
and O
clinical O
global O
index O
- O
severity O
( O
CGI O
- O
S O
) O
scores O
decreased O
in O
both O
the O
aripiprazole O
+ O
escitalopram B
and O
escitalopram B
only O
groups O
. O

In O
addition O
, O
following O
the O
treatment O
period O
, O
the O
Korean O
alcohol B
urge O
questionnaire O
scores O
in O
the O
aripiprazole O
+ O
escitalopram B
group O
were O
reduced O
from O
23 O
. O
3 O
+ O
/ O
- O
8 O
. O
4 O
to O
14 O
. O
3 O
+ O
/ O
- O
4 O
. O
9 O
, O
compared O
with O
those O
of O
the O
escitalopram B
group O
of O
from O
21 O
. O
6 O
+ O
/ O
- O
8 O
. O
4 O
to O
19 O
. O
3 O
+ O
/ O
- O
7 O
. O
1 O
( O
F O
= O
13 O
. O
1 O
, O
p O
< O
0 O
. O
01 O
) O
. O

The O
activity O
within O
the O
anterior O
cingulate O
was O
increased O
in O
response O
to O
the O
presentation O
of O
alcohol B
drinking O
scenes O
following O
treatment O
in O
the O
aripiprazole O
+ O
escitalopram B
group O
. O

The O
change O
of O
brain O
activity O
within O
the O
left O
anterior O
cingulate O
gyrus O
in O
all O
patients O
with O
co O
- O
morbid O
alcohol B
dependence O
and O
major O
depressive O
disorder O
was O
negatively O
correlated O
with O
the O
change O
in O
craving O
for O
alcohol B
. O

These O
findings O
suggest O
that O
the O
effects O
of O
aripiprazole O
on O
anterior O
cingulate O
cortex O
might O
mediate O
the O
successful O
treatment O
of O
alcohol B
dependence O
in O
patients O
with O
major O
depressive O
disorder O
. O

Activation O
of O
AMP B
- O
activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
beta O
Mediate O
Ursolic B
Acid I
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells O
. O

Despite O
the O
antitumour O
effect O
of O
ursolic B
acid I
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O

Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
( O
GSK3 O
beta O
) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O

Ursolic B
acid I
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub O
- O
G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase O
( O
TdT O
) O
mediated O
dUTP B
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O

Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly B
- I
ADP I
- I
ribose I
polymerase O
( O
PARP O
) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
( O
AEG1 O
) O
and O
survivin O
in O
HepG2 O
cells O
. O

Interestingly O
, O
ursolic B
acid I
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3 O
beta O
at O
inactive O
form O
serine B
9 O
, O
whereas O
ursolic B
acid I
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O

Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3 O
beta O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic B
acid I
in O
HepG2 O
cells O
. O

Furthermore O
, O
proteosomal O
inhibitor O
MG132 B
suppressed O
AMPK O
activation O
, O
GSK3 O
beta O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG O
- O
1 O
induced O
by O
ursolic B
acid I
in O
HepG2 O
cells O
. O

Overall O
, O
our O
findings O
suggest O
that O
ursolic B
acid I
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3 O
beta O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O

Binding O
mode O
analysis O
of O
potent O
inhibitors O
suggests O
that O
these O
compounds O
are O
well O
accommodated O
by O
the O
MAO O
- O
B O
active O
site O
through O
stable O
hydrophobic O
and O
hydrogen B
bonding O
interactions O
. O

RbgA O
, O
unlike O
many O
members O
of O
the O
Ras O
superfamily O
of O
GTPases O
, O
lacks O
a O
defined O
catalytic O
residue O
for O
carrying O
out O
guanosine O
triphosphate O
( O
GTP B
) O
hydrolysis O
. O

We O
identified O
a O
RNA O
- O
binding O
domain O
within O
the O
C B
- O
terminus O
of O
RbgA O
that O
is O
structurally O
similar O
to O
AmiR O
- O
NasR O
Transcription O
Anti O
- O
termination O
Regulator O
( O
ANTAR O
) O
domains O
, O
which O
are O
known O
to O
bind O
structured O
RNA O
. O

We O
identified O
a O
putative O
catalytic O
residue O
within O
a O
highly O
conserved O
region O
of O
RbgA O
, O
His9 O
, O
which O
is O
contained O
within O
a O
similar O
PGH O
motif O
found O
in O
elongation O
factor O
Tu O
( O
EF O
- O
Tu O
) O
that O
is O
required O
for O
GTP B
hydrolysis O
on O
interaction O
with O
the O
ribosome O
. O

Covalently O
functionalized O
double O
- O
walled O
carbon B
nanotubes O
combine O
high O
sensitivity O
and O
selectivity O
in O
the O
electrical O
detection O
of O
small O
molecules O
. O

Atom O
- O
thick O
materials O
such O
as O
single O
- O
walled O
carbon B
nanotubes O
( O
SWCNTs O
) O
and O
graphene B
exhibit O
ultrahigh O
sensitivity O
to O
chemical O
perturbation O
partly O
because O
all O
of O
the O
constituent O
atoms O
are O
surface O
atoms O
. O

Here O
, O
we O
demonstrated O
simultaneous O
attainment O
of O
high O
sensitivity O
and O
selectivity O
in O
thin O
- O
film O
field O
effect O
transistors O
( O
TFTs O
) O
based O
on O
outer O
- O
wall O
selectively O
functionalized O
double O
- O
walled O
carbon B
nanotubes O
( O
DWCNTs O
) O
. O

With O
carboxylic B
acid I
functionalized O
DWCNT O
TFTs O
, O
we O
obtained O
excellent O
gate O
modulation O
( O
on O
/ O
off O
ratio O
as O
high O
as O
4000 O
) O
with O
relatively O
high O
ON O
currents O
at O
a O
CNT O
areal O
density O
as O
low O
as O
35 O
ng O
/ O
cm O
( O
2 O
) O
. O

The O
devices O
displayed O
an O
NH B
( I
3 I
) I
sensitivity O
of O
60 O
nM O
( O
or O
~ O
1 O
ppb O
) O
, O
which O
is O
comparable O
to O
small O
molecule O
aqueous O
solution O
detection O
using O
state O
- O
of O
- O
the O
- O
art O
SWCNT O
TFT O
sensors O
while O
concomitantly O
achieving O
6000 O
times O
higher O
chemical O
selectivity O
toward O
a O
variety O
of O
amine B
- O
containing O
analyte O
molecules O
over O
that O
of O
other O
small O
molecules O
. O

These O
results O
highlight O
the O
potential O
of O
using O
covalently O
functionalized O
double O
- O
walled O
carbon B
nanotubes O
for O
simultaneous O
ultrahigh O
selective O
and O
sensitive O
detection O
of O
chemicals O
and O
illustrate O
some O
of O
the O
structural O
advantages O
of O
this O
double O
- O
wall O
materials O
strategy O
to O
nanoelectronics O
. O

High O
- O
contrast O
electrooptic O
modulation O
of O
a O
photonic O
crystal O
nanocavity O
by O
electrical O
gating O
of O
graphene B
. O

We O
demonstrate O
high O
- O
contrast O
electro O
- O
optic O
modulation O
of O
a O
photonic O
crystal O
nanocavity O
integrated O
with O
an O
electrically O
gated O
monolayer O
graphene B
. O

A O
silicon O
air O
- O
slot O
nanocavity O
provides O
strong O
overlap O
between O
the O
resonant O
optical O
field O
and O
graphene B
. O

Tuning O
the O
Fermi O
energy O
of O
the O
graphene B
layer O
to O
0 O
. O
85 O
eV O
enables O
strong O
control O
of O
its O
optical O
conductivity O
at O
telecom O
wavelengths O
, O
which O
allows O
modulation O
of O
cavity O
reflection O
in O
excess O
of O
10 O
dB O
for O
a O
swing O
voltage O
of O
only O
1 O
. O
5 O
V O
. O

These O
observations O
enable O
a O
cavity O
- O
enhanced O
determination O
of O
graphene B
' O
s O
complex O
optical O
sheet O
conductivity O
at O
different O
doping O
levels O
. O

Our O
simple O
device O
demonstrates O
the O
feasibility O
of O
high O
- O
contrast O
, O
low O
- O
power O
, O
and O
frequency O
- O
selective O
electro O
- O
optic O
modulators O
in O
graphene B
- O
integrated O
silicon B
photonic O
integrated O
circuits O
. O

Species O
- O
dependent O
metabolism O
of O
a O
novel O
selective O
alpha O
7 O
neuronal O
acetylcholine B
receptor O
agonist O
ABT O
- O
107 O
. O

Pathway O
1 O
, O
ABT O
- O
107 O
was O
oxidized O
at O
the O
nitrogen B
of O
quinuclidine O
moiety O
to O
form O
M1 O
. O

Pathway O
2 O
, O
oxidation O
occurred O
at O
indole B
- O
containing O
moiety O
to O
form O
M2 O
. O

Metabolism O
via O
N B
- O
oxidation O
was O
predominant O
in O
dog O
and O
rat O
, O
while O
in O
monkey O
and O
human O
, O
metabolism O
proceeded O
primarily O
via O
oxidation O
of O
indole B
- O
containing O
moiety O
. O

Our O
images O
reveal O
a O
sulfur B
abstraction O
and O
cyclization O
reaction O
that O
converts O
tetrathienoanthracen O
precursors O
into O
pentacene O
on O
the O
Ni O
( O
111 O
) O
surface O
. O

Correlation O
analyses O
revealed O
that O
the O
endometrial O
thickness O
was O
positively O
correlated O
with O
body O
mass O
index O
but O
was O
not O
correlated O
with O
age O
, O
serum O
androgens B
, O
or O
estradiol B
( O
E2 O
) O
levels O
. O

The O
anovulatory O
interval O
, O
follicle O
- O
stimulating O
hormone O
, O
luteinizing O
hormone O
, O
E2 O
and O
androgen B
levels O
were O
not O
significantly O
different O
between O
Groups O
A O
and O
B O
. O

We O
concluded O
that O
endometrial O
thickness O
in O
women O
with O
ovulatory O
dysfunction O
is O
positively O
correlated O
with O
body O
weight O
status O
but O
is O
not O
correlated O
with O
serum O
androgens B
or O
E2 O
levels O
. O

The O
macrocyclic O
peptide O
natural O
product O
CJ O
- O
15 O
, O
208 O
is O
orally O
active O
and O
prevents O
reinstatement O
of O
extinguished O
cocaine B
- O
seeking O
behavior O
. O

Orally O
administered O
CJ O
- O
15 O
, O
208 O
also O
prevented O
both O
cocaine B
- O
and O
stress O
- O
induced O
reinstatement O
of O
extinguished O
cocaine B
- O
seeking O
behavior O
in O
the O
conditioned O
place O
preference O
assay O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

TAFI O
suppresses O
fibrinolysis O
by O
removing O
carboxy B
- O
terminal O
lysine B
residues O
from O
partially O
degraded O
fibrin O
. O

Embelin B
accelerates O
cutaneous O
wound O
healing O
in O
diabetic O
rats O
. O

This O
study O
reports O
the O
effect O
of O
embelin B
( O
1 O
) O
on O
cutaneous O
wound O
in O
streptozotocin B
( O
STZ B
) O
- O
induced O
diabetic O
rats O
. O

In O
diabetic O
rats O
, O
topical O
application O
of O
embelin B
5 O
% O
( O
w O
/ O
w O
) O
ointment O
showed O
a O
significant O
increase O
in O
wound O
contraction O
and O
better O
epithelialization O
, O
thereby O
facilitating O
the O
healing O
. O

Embelin B
was O
also O
active O
by O
the O
oral O
route O
( O
25 O
and O
50 O
mg O
/ O
kg O
) O
in O
the O
incision O
and O
dead O
space O
wound O
models O
. O

In O
incision O
wound O
model O
, O
wound O
granulation O
tissues O
were O
removed O
on O
8th O
post O
- O
wounding O
day O
, O
and O
the O
hydroxyproline B
, O
hexosamine O
, O
total O
protein O
, O
and O
DNA O
contents O
were O
determined O
. O

In O
STZ B
diabetic O
rats O
, O
topical O
and O
oral O
applications O
of O
embelin B
showed O
an O
increase O
in O
hydroxyproline B
, O
hexosamine O
, O
total O
protein O
, O
and O
DNA O
contents O
. O

Embelin B
significantly O
increased O
granuloma O
tissue O
weight O
and O
breaking O
strength O
in O
dead O
space O
model O
. O

These O
results O
indicated O
that O
embelin B
accelerated O
wound O
healing O
in O
diabetic O
rat O
. O

Jatropholane O
- O
type O
diterpenes B
from O
Euphorbia O
sikkimensis O
. O

Four O
new O
jatropholane O
- O
type O
diterpenes B
( O
1 O
- O
4 O
) O
, O
named O
sikkimenoids O
A O
- O
D O
, O
were O
isolated O
from O
the O
aerial O
parts O
of O
Euphorbia O
sikkimensis O
. O

Mutations O
at O
the O
C B
- O
terminal O
domain O
led O
to O
variant O
proteins O
that O
aberrantly O
and O
stably O
translocate O
to O
the O
cytoplasm O
. O

We O
have O
previously O
shown O
that O
NPM1 O
C B
- O
terminal O
domain O
binds O
with O
high O
affinity O
G O
- O
quadruplex O
DNA O
. O

The O
findings O
presented O
show O
the O
complex O
inter O
- O
relationships O
between O
multiple O
regulators O
of O
drug O
metabolism O
and O
transport O
genes O
, O
such O
as O
estrogens B
, O
progesterone B
, O
and O
growth O
hormone O
, O
and O
their O
effects O
on O
enzyme O
and O
transporter O
expression O
in O
different O
tissues O
. O

Mithramycin O
( O
MTM B
) O
is O
a O
potent O
anti O
- O
cancer O
agent O
that O
has O
recently O
garnered O
renewed O
attention O
. O

Mithramycin O
SA O
shows O
decreased O
anti O
- O
cancer O
activity O
compared O
to O
mithramycin O
and O
has O
a O
shorter O
, O
two O
carbon B
aglycon O
side O
chain O
that O
is O
terminated O
in O
a O
carboxylic B
acid I
. O

The O
aglycon O
side O
chain O
is O
responsible O
for O
an O
interaction O
with O
the O
DNA O
- O
phosphate B
backbone O
as O
mithramycin O
interacts O
with O
its O
target O
DNA O
. O

It O
was O
therefore O
decided O
to O
further O
functionalize O
this O
side O
chain O
through O
reactions O
with O
the O
terminal O
carboxylic B
acid I
in O
an O
effort O
to O
enhance O
the O
interaction O
with O
the O
DNA O
phosphate B
backbone O
and O
improve O
the O
anti O
- O
cancer O
activity O
. O

Oxytocin B
in O
the O
central O
amygdaloid O
nucleus O
modulates O
the O
neuroendocrine O
responses O
induced O
by O
hypertonic O
volume O
expansion O
in O
the O
rat O
. O

The O
present O
study O
investigated O
the O
involvement O
of O
the O
oxytocinergic O
neurones O
that O
project O
into O
the O
central O
amygdala O
( O
CeA O
) O
in O
the O
control O
of O
electrolyte O
excretion O
and O
hormone O
secretion O
in O
unanaesthetised O
rats O
subjected O
to O
acute O
hypertonic O
blood O
volume O
expansion O
( O
BVE O
; O
0 O
. O
3 O
M O
NaCl B
, O
2 O
ml O
/ O
100 O
g O
of O
body O
weight O
over O
1 O
min O
) O
. O

Oxytocin B
and O
vasopressin O
mRNA O
expression O
in O
the O
paraventricular O
( O
Pa O
) O
and O
supraoptic O
nucleus O
( O
SON O
) O
of O
the O
hypothalamus O
were O
also O
determined O
using O
the O
real O
time O
- O
polymerase O
chain O
reaction O
and O
in O
situ O
hybridisation O
. O

Oxytocin B
( O
1 O
mu O
g O
/ O
0 O
. O
2 O
mu O
l O
) O
, O
vasotocin O
, O
an O
oxytocin B
antagonist O
( O
1 O
mu O
g O
/ O
0 O
. O
2 O
mu O
l O
) O
or O
vehicle O
was O
injected O
into O
the O
CeA O
20 O
min O
before O
the O
BVE O
. O

In O
rats O
treated O
with O
vehicle O
in O
the O
CeA O
, O
hypertonic O
BVE O
increased O
urinary O
volume O
, O
sodium O
excretion O
, O
plasma O
oxytocin B
( O
OT O
) O
, O
vasopressin O
( O
AVP O
) O
and O
atrial O
natriuretic O
peptide O
( O
ANP O
) O
levels O
and O
also O
increased O
the O
expression O
of O
OT O
and O
AVP O
mRNA O
in O
the O
Pa O
and O
SON O
. O

In O
rats O
pre O
- O
treated O
with O
OT O
in O
the O
CeA O
, O
previously O
to O
the O
hypertonic O
BVE O
, O
there O
were O
further O
significant O
increases O
in O
plasma O
AVP O
, O
OT O
and O
ANP O
levels O
, O
urinary O
sodium B
and O
urine O
output O
, O
as O
well O
as O
in O
gene O
expression O
( O
AVP O
and O
OT O
mRNA O
) O
in O
the O
Pa O
and O
SON O
compared O
to O
BVE O
alone O
. O

Vasotocin O
reduced O
sodium B
, O
urine O
output O
and O
ANP O
levels O
, O
although O
no O
changes O
were O
observed O
in O
plasma O
AVP O
and O
OT O
levels O
or O
in O
the O
expression O
of O
the O
AVP O
and O
OT O
genes O
in O
both O
hypothalamic O
nuclei O
. O

Testosterone B
deficiency O
induces O
markedly O
decreased O
serum O
triglycerides B
, O
increased O
small O
dense O
LDL O
, O
and O
hepatic O
steatosis O
mediated O
by O
dysregulation O
of O
lipid O
assembly O
and O
secretion O
in O
mice O
fed O
a O
high O
- O
fat O
diet O
. O

OBJECTIVE O
: O
Although O
low O
serum O
testosterone B
( O
T O
) O
is O
associated O
with O
metabolic O
disorders O
, O
the O
mechanism O
of O
this O
association O
is O
unclear O
. O

RESULTS O
: O
ORX O
mice O
fed O
HFD O
showed O
increased O
hepatic O
steatosis O
, O
markedly O
decreased O
serum O
triglyceride B
( O
TG O
) O
and O
TG O
- O
VLDL O
content O
, O
and O
increased O
serum O
very O
small O
- O
LDL O
content O
. O

Gene O
expression O
analysis O
revealed O
that O
ORX O
mice O
fed O
HFD O
showed O
significantly O
decreased O
expression O
of O
microsomal O
triglyceride B
transfer O
protein O
, O
lipin O
- O
1 O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
- O
alpha O
and O
PPAR O
- O
gamma O
coactivator O
1 O
- O
alpha O
, O
and O
significantly O
increased O
sterol B
regulatory O
element O
- O
binding O
protein O
- O
1 O
, O
diacylglycerol B
acyltransferase O
- O
2 O
and O
fatty B
acid I
synthase O
. O

Therefore O
the O
combination O
of O
aspirin B
and O
warfarin B
to O
improve O
prevention O
of O
atherothrombosis O
compared O
to O
antiplatelet O
therapy O
alone O
was O
studied O
but O
could O
not O
be O
established O
due O
to O
significantly O
increased O
risk O
of O
major O
bleeding O
compared O
to O
a O
nonsignificant O
reduction O
in O
ischemic O
events O
. O

The O
perception O
of O
aldosterone B
action O
to O
be O
restricted O
to O
regulation O
of O
fluid O
balance O
via O
sodium B
reabsorption O
and O
potassium B
excretion O
is O
incomplete O
; O
plenty O
of O
experimental O
and O
clinical O
studies O
have O
shown O
that O
aldosterone B
plays O
a O
pivotal O
role O
in O
a O
variety O
of O
( O
patho O
- O
) O
physiologic O
conditions O
within O
the O
cardiovascular O
continuum O
. O

Mineralocorticoid O
receptor O
antagonists O
( O
MRAs O
) O
, O
such O
as O
spironolactone B
and O
eplerenone O
, O
prevent O
some O
of O
these O
maladaptive O
effects O
on O
the O
cardiovascular O
system O
and O
have O
proven O
to O
be O
a O
highly O
efficacious O
pharmacological O
therapy O
. O

A O
series O
of O
tetrahydroisoquinoli B
were O
designed O
, O
synthesized O
and O
evaluated O
as O
the O
first O
non O
- O
natural O
product O
type O
of O
compounds O
with O
dual O
D O
( O
1 O
) O
receptor O
( O
D O
( O
1 O
) O
R O
) O
agonism O
and O
D O
( O
2 O
) O
receptor O
( O
D O
( O
2 O
) O
R O
) O
antagonism O
properties O
for O
treatment O
of O
schizophrenia O
. O

Mechanistically O
, O
RIF1 O
is O
recruited O
to O
DSBs O
via O
the O
N B
- O
terminal O
phospho B
- O
SQ O
/ O
TQ O
domain O
of O
53BP1 O
, O
and O
DSBs O
generated O
by O
ionizing O
radiation O
or O
during O
CSR O
are O
hyperresected O
in O
the O
absence O
of O
RIF1 O
. O

Mitochondrial O
electron O
transport O
is O
inhibited O
by O
disappearance O
of O
metallothionein O
in O
human O
bronchial O
epithelial O
cells O
following O
exposure O
to O
silver B
nitrate I
. O

Silver B
( O
Ag B
) O
possesses O
antibacterial O
activity O
and O
has O
been O
used O
in O
wound O
dressings O
and O
deodorant O
powders O
worldwide O
. O

However O
, O
the O
metabolic O
behavior O
and O
biological O
roles O
of O
Ag B
in O
mammals O
have O
not O
been O
well O
characterized O
. O

In O
the O
present O
study O
, O
we O
exposed O
human O
bronchial O
epithelial O
cells O
( O
BEAS O
- O
2B O
) O
to O
AgNO3 B
and O
investigated O
uptake O
and O
intracellular O
distribution O
of O
Ag B
, O
expression O
of O
metallothionein O
( O
MT O
) O
, O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
and O
changes O
in O
mitochondrial O
respiration O
. O

The O
culture O
medium O
concentration O
of O
Ag B
decreased O
with O
time O
and O
stabilized O
at O
12h O
. O

The O
concentration O
of O
both O
Ag B
and O
MT O
in O
the O
soluble O
cellular O
fraction O
increased O
up O
to O
3h O
and O
then O
decreased O
, O
indicating O
that O
cytosolic O
Ag B
relocated O
to O
the O
insoluble O
fraction O
of O
the O
cells O
. O

The O
levels O
of O
mRNAs O
for O
the O
major O
human O
MT O
isoforms O
MT O
- O
I O
and O
MT O
- O
II O
paralleled O
with O
the O
protein O
levels O
of O
Ag B
- O
MT O
. O

Ag B
decreased O
mitochondrial O
oxygen B
consumption O
in O
a O
dose O
- O
dependent O
manner O
and O
the O
activity O
of O
mitochondrial O
complex O
I O
- O
IV O
enzymes O
was O
significantly O
inhibited O
following O
exposure O
to O
Ag B
. O

In O
a O
separate O
experiment O
, O
we O
found O
that O
hydrogen B
peroxide I
( O
H2O2 B
) O
at O
concentrations O
as O
low O
as O
0 O
. O
001 O
% O
( O
equivalent O
to O
the O
concentration O
of O
H2O2 B
in O
Ag B
- O
exposed O
cells O
) O
removed O
Ag B
from O
MT O
. O

These O
results O
suggest O
MT O
was O
decomposed O
by O
cytosolic O
H2O2 B
, O
and O
then O
Ag B
released O
from O
MT O
relocated O
to O
insoluble O
cellular O
fractions O
and O
inhibited O
electron O
chain O
transfer O
of O
mitochondrial O
complexes O
, O
which O
eventually O
led O
to O
cell O
damage O
. O

Nitric B
oxide I
generated O
by O
the O
compound O
RuBPY O
promotes O
the O
vascular O
smooth O
cell O
membrane O
hyperpolarization O
. O

The O
cis O
- O
[ O
Ru O
( O
bpy O
) O
( O
2 O
) O
( O
py O
) O
NO O
( O
2 O
) O
] O
( O
PF O
( O
6 O
) O
) O
specie O
( O
RuBPY O
) O
has O
been O
used O
as O
nitric B
oxide I
( O
NO B
) O
delivery O
agent O
. O

It O
is O
an O
NO B
reservoir O
and O
it O
is O
thermodynamically O
stable O
in O
aqueous O
solution O
. O

This O
study O
aimed O
to O
evaluate O
the O
NO B
specie O
generated O
by O
RuBPY O
as O
compared O
to O
NO B
released O
from O
sodium B
nitroprusside I
( O
SNP B
) O
and O
to O
study O
the O
cellular O
mechanisms O
specially O
focusing O
the O
activation O
of O
soluble O
guanylyl O
- O
cyclase O
( O
sGC O
) O
, O
K B
( I
+ I
) I
channels O
and O
the O
cell O
membrane O
hyperpolarization O
, O
which O
are O
the O
main O
targets O
for O
NO B
- O
inducing O
vascular O
relaxation O
. O

NO B
generated O
by O
RuBPY O
and O
the O
vascular O
smooth O
muscle O
cell O
( O
VSMC O
) O
membrane O
potential O
were O
measured O
by O
confocal O
microscopy O
. O

The O
cellular O
mechanisms O
of O
aorta O
relaxation O
were O
investigated O
using O
K B
( I
+ I
) I
channel O
blockers O
and O
sGC O
inhibitor O
. O

NO B
released O
from O
RuBPY O
was O
higher O
than O
NO B
released O
from O
SNP B
. O

RuBPY O
released O
only O
radicalar O
NO O
( O
0 O
) O
and O
SNP B
released O
both O
NO B
( I
- I
) I
and O
NO B
( O
0 O
) O
. O

The O
concentration O
- O
effect O
curves O
for O
RuBPY O
- O
induced O
relaxation O
was O
shifted O
to O
the O
right O
by O
inhibition O
of O
sGC O
with O
ODQ B
and O
by O
the O
non O
- O
selective O
blockade O
of O
K B
( I
+ I
) I
channels O
with O
TEA B
. O

The O
simultaneous O
combination O
of O
ODQ B
and O
TEA B
abolished O
the O
vasorelaxation O
induced O
by O
RuBPY O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
large O
amount O
of O
NO B
( O
0 O
) O
specie O
generated O
by O
RuBPY O
induces O
vasorelaxation O
due O
to O
activation O
of O
sGC O
, O
K B
( I
+ I
) I
channels O
sensitive O
to O
TEA B
, O
and O
cell O
membrane O
hyperpolarization O
. O

These O
results O
indicate O
that O
NO B
( O
0 O
) O
generated O
from O
RuBPY O
can O
also O
directly O
activate O
the O
K B
( I
+ I
) I
channels O
in O
an O
independent O
way O
of O
sGC O
. O

The O
inhibition O
of O
HIF O
- O
2 O
alpha O
on O
the O
ATM O
/ O
Chk O
- O
2 O
pathway O
is O
involved O
in O
the O
promotion O
effect O
of O
arsenite B
on O
benzo B
( I
a I
) I
pyrene I
- O
induced O
cell O
transformation O
. O

Both O
arsenite B
and O
benzo B
( I
a I
) I
pyrene I
( O
BaP B
) O
are O
known O
human O
carcinogens O
. O

Studies O
on O
the O
mode O
- O
of O
- O
action O
of O
arsenite B
indicate O
that O
it O
can O
also O
act O
as O
co O
- O
carcinogen O
or O
as O
a O
cancer O
promoter O
, O
and O
that O
it O
can O
facilitate O
progression O
of O
cancers O
. O

Some O
studies O
on O
development O
of O
lung O
cancers O
have O
suggested O
a O
synergism O
between O
arsenite B
exposure O
and O
cigarette O
smoking O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effects O
of O
HIF O
- O
2 O
alpha O
on O
arsenite B
- O
and O
BaP B
- O
induced O
cell O
malignant O
transformation O
as O
well O
as O
on O
signal O
transduction O
pathways O
in O
human O
bronchial O
epithelial O
( O
HBE O
) O
cells O
. O

The O
results O
show O
that O
arsenite B
accelerates O
the O
neoplastic O
transformation O
and O
migration O
of O
cells O
and O
enhances O
chromosomal O
aberrations O
induced O
by O
BaP B
. O

HIF O
- O
2 O
alpha O
is O
involved O
in O
blocking O
the O
effects O
of O
arsenite B
in O
activating O
the O
ATM O
/ O
Chk O
- O
2 O
pathway O
and O
in O
repair O
of O
DNA O
damage O
induced O
by O
BaP B
. O

Moreover O
, O
blocking O
of O
HIF O
- O
2 O
alpha O
prevents O
the O
effects O
of O
arsenite B
on O
the O
neoplastic O
transformation O
, O
cell O
migration O
, O
and O
chromosomal O
aberrations O
caused O
by O
BaP B
. O

These O
results O
indicate O
that O
the O
repressive O
effect O
of O
HIF O
- O
2 O
alpha O
on O
the O
ATM O
/ O
Chk O
- O
2 O
pathway O
leads O
to O
genomic O
instability O
, O
which O
is O
involved O
in O
arsenite B
- O
accelerated O
, O
BaP B
- O
induced O
malignant O
transformation O
of O
HBE O
cells O
. O

Cryptotanshinone B
and O
dihydrotanshinone O
I O
exhibit O
strong O
inhibition O
towards O
human O
liver O
microsome O
( O
HLM O
) O
- O
catalyzed O
propofol B
glucuronidation O
. O

Evaluation O
of O
inhibition O
potential O
of O
danshen O
' O
s O
major O
ingredients O
towards O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
will O
be O
helpful O
for O
understanding O
detailed O
mechanisms O
for O
danshen O
- O
drugs O
interaction O
. O

Therefore O
, O
the O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
inhibitory O
situation O
of O
cryptotanshinone B
and O
dihydrotanshinone O
I O
towards O
UGT O
enzyme O
- O
catalyzed O
propofol B
glucuronidation O
. O

In O
vitro O
the O
human O
liver O
microsome O
( O
HLM O
) O
incubation O
system O
was O
used O
, O
and O
the O
results O
showed O
that O
cryptotanshinone B
and O
dihydrotanshinone O
I O
exhibited O
dose O
- O
dependent O
inhibition O
towards O
HLM O
- O
catalyzed O
propofol B
glucuronidation O
. O

Dixon O
plot O
and O
Lineweaver O
- O
Burk O
plot O
showed O
that O
the O
inhibition O
type O
was O
best O
fit O
to O
competitive O
inhibition O
type O
for O
both O
cryptotanshinone B
and O
dihydrotanshinone O
I O
. O

The O
second O
plot O
using O
the O
slopes O
from O
the O
Lineweaver O
- O
Burk O
plot O
versus O
the O
concentrations O
of O
cryptotanshinone B
or O
dihydrotanshinone O
I O
was O
employed O
to O
calculate O
the O
inhibition O
parameters O
( O
Ki O
) O
to O
be O
0 O
. O
4 O
and O
1 O
. O
7 O
mu O
M O
, O
respectively O
. O

Using O
the O
reported O
maximum O
plasma O
concentration O
( O
Cmax O
) O
, O
the O
altered O
in O
vivo O
exposure O
of O
propofol B
increased O
by O
10 O
% O
and O
8 O
. O
2 O
% O
for O
the O
co O
- O
administration O
of O
dihydrotanshinone O
I O
and O
cryptotanshinone B
, O
respectively O
. O

All O
these O
results O
indicated O
the O
possible O
danshen O
- O
propofol B
interaction O
due O
to O
the O
inhibition O
of O
dihydrotanshinone O
I O
and O
cryptotanshinone B
towards O
the O
glucuronidation O
reaction O
of O
propofol B
. O

Investigations O
of O
dipeptide B
structures O
containing O
pyrrolysine O
as O
N B
- O
terminal O
residues O
: O
a O
DFT O
study O
in O
gas O
and O
aqueous O
phase O
. O

A O
set O
of O
six O
dipeptides B
containing O
pyrrolysine O
invariably O
at O
their O
N B
- O
terminal O
positions O
is O
studied O
in O
gas O
and O
aqueous O
phase O
using O
a O
polarizable O
continuum O
model O
( O
PCM O
) O
. O

The O
molecular O
geometries O
of O
the O
dipeptides B
are O
fully O
optimized O
at O
B3LYP O
/ O
6 O
- O
31 O
+ O
+ O
G O
( O
d O
, O
p O
) O
level O
of O
theory O
and O
a O
second O
derivative O
( O
frequency O
) O
analysis O
confirms O
that O
all O
the O
optimized O
geometries O
are O
true O
minima O
. O

The O
effects O
of O
solvation O
and O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
on O
the O
energetics O
, O
structural O
features O
of O
the O
peptide O
planes O
, O
values O
of O
the O
psi O
and O
phi O
dihedrals O
, O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
and O
theoretically O
predicted O
vibrational O
spectra O
of O
the O
dipeptides B
are O
thoroughly O
analyzed O
. O

Solvation O
effects O
are O
found O
to O
modify O
the O
gas O
phase O
conformation O
of O
the O
dipeptides B
around O
psi O
dihedrals O
while O
the O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
affect O
the O
values O
of O
phi O
, O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
. O

The O
presence O
or O
absence O
of O
three O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
O B
. O
. O
. O
H O
- O
N O
, O
N B
. O
. O
. O
H O
- O
N O
and O
O B
. O
. O
. O
H O
- O
C O
that O
leave O
noticeable O
signatures O
in O
the O
IR O
spectra O
, O
play O
crucial O
roles O
in O
influencing O
the O
geometry O
of O
the O
peptide O
planes O
and O
in O
determining O
the O
energetics O
of O
the O
dipeptides B
. O

Electrochemical O
synthesis O
of O
CdTe B
/ O
SWNT O
hybrid O
nanostructures O
and O
their O
tunable O
electrical O
and O
optoelectrical O
properties O
. O

A O
facile O
electrodeposition O
technique O
was O
utilized O
to O
deposit O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
with O
cadmium B
telluride I
( O
CdTe B
) O
with O
well O
- O
controlled O
size O
, O
density O
, O
surface O
morphology O
, O
and O
composition O
. O

By O
controlling O
the O
applied O
charge O
, O
the O
morphology O
of O
these O
hybrid O
nanostructures O
was O
altered O
from O
CdTe B
nanoparticles O
on O
SWNTs O
to O
SWNT O
/ O
CdTe B
core O
/ O
shell O
nanostructures O
and O
the O
composition O
of O
the O
CdTe B
nanoparticles O
was O
altered O
from O
Te B
- O
rich O
( O
29 O
at O
% O
Cd B
) O
to O
Cd B
- O
rich O
( O
79 O
at O
% O
Cd B
) O
CdTe B
by O
adjusting O
the O
deposition O
potential O
. O

The O
electrical O
and O
optoelectrical O
properties O
of O
these O
hybrid O
nanostructures O
showed O
that O
photo O
- O
induced O
current O
can O
be O
tuned O
by O
tailoring O
the O
conductivity O
type O
( O
n O
- O
type O
or O
p O
- O
type O
) O
, O
morphology O
, O
and O
size O
of O
the O
CdTe B
nanostructures O
, O
with O
a O
maximum O
photosensitivity O
( O
Delta O
I O
/ O
I O
( O
0 O
) O
) O
of O
about O
30 O
% O
for O
SWNT O
/ O
Cd B
- O
rich O
CdTe B
( O
n O
- O
type O
) O
core O
/ O
shell O
nanostructures O
. O

Each O
was O
up O
- O
regulated O
at O
a O
different O
time O
following O
stimulation O
of O
the O
pepper O
leaves O
by O
Phytophthora O
capcisi O
and O
abiotic O
stresses O
including O
salicylic B
acid I
, O
methyl O
jasmonate O
, O
abscisic O
acid O
, O
wounding O
and O
cold O
treatment O
. O

Iron B
overload O
inhibits O
osteoblast O
biological O
activity O
through O
oxidative O
stress O
. O

Iron B
overload O
has O
recently O
been O
connected O
with O
bone O
mineral O
density O
in O
osteoporosis O
. O

However O
, O
to O
date O
, O
the O
effect O
of O
iron B
overload O
on O
osteoblasts O
remains O
poorly O
understood O
. O

The O
purpose O
of O
this O
study O
is O
to O
examine O
osteoblast O
biological O
activity O
under O
iron B
overload O
. O

The O
osteoblast O
cells O
( O
hFOB1 O
. O
19 O
) O
were O
cultured O
in O
a O
medium O
supplemented O
with O
different O
concentrations O
( O
50 O
, O
100 O
, O
and O
200 O
mu O
M O
) O
of O
ferric O
ammonium O
citrate O
as O
a O
donor O
of O
ferric B
ion O
. O

Intracellular O
iron B
was O
measured O
with O
a O
confocal O
laser O
scanning O
microscope O
. O

Reactive O
oxygen B
species O
( O
ROS O
) O
were O
detected O
by O
2 O
, O
7 O
- O
dichlorofluorescin O
diacetate O
fluorophotometry O
. O

Results O
indicated O
that O
iron B
overload O
could O
consequently O
increase O
intracellular O
iron B
concentration O
and O
intracellular O
ROS O
levels O
in O
a O
concentration O
- O
dependent O
manner O
. O

According O
to O
these O
results O
, O
it O
seems O
that O
iron B
overload O
probably O
inhibits O
osteoblast O
function O
through O
higher O
oxidative O
stress O
following O
increased O
intracellular O
iron B
concentrations O
. O

Chemopreventive O
effects O
of O
Ginkgo O
biloba O
extract O
in O
estrogen B
- O
negative O
human O
breast O
cancer O
cells O
. O

Excessive O
level O
of O
estrogen B
is O
considered O
as O
a O
main O
cause O
of O
breast O
cancer O
, O
therefore O
, O
many O
studies O
have O
focused O
on O
estrogen B
receptor O
( O
ER O
) O
- O
positive O
breast O
cancer O
, O
even O
though O
ER O
- O
negative O
cancer O
has O
a O
poor O
prognosis O
than O
ER O
- O
positive O
breast O
cancer O
. O

We O
evaluated O
the O
anti O
- O
cancer O
effects O
of O
Ginkgo O
biloba O
extract O
( O
GBE O
) O
in O
estrogen B
- O
independent O
breast O
cancer O
. O

Room O
- O
temperature O
ferromagnetism O
in O
ZnO B
- O
encapsulated O
1 O
. O
9 O
nm O
FePt3 O
nanoparticle O
- O
composite O
thin O
films O
with O
giant O
interfacial O
anisotropy O
. O

Coating O
those O
nanoparticles O
with O
ZnO B
renders O
them O
permanently O
ferromagnetic O
with O
coercivity O
field O
of O
650 O
Oe O
at O
room O
temperature O
. O

First O
- O
principles O
calculations O
indicate O
that O
giant O
interfacial O
anisotropy O
, O
induced O
by O
the O
strong O
spin O
- O
orbit O
interaction O
of O
enhanced O
orbit O
momentum O
of O
Fe B
, O
overcomes O
the O
superparamagnetic O
limit O
, O
leading O
to O
exceptional O
room O
- O
temperature O
permanent O
ferromagnetism O
. O

Fast O
, O
reversible O
, O
and O
general O
photomechanical O
motion O
in O
single O
crystals O
of O
various O
azo B
compounds O
using O
visible O
light O
. O

Studies O
of O
enantiomeric O
degradation O
of O
the O
triazole B
fungicide O
hexaconazole O
in O
tomato O
, O
cucumber O
, O
and O
field O
soil O
by O
chiral O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

Separation O
was O
by O
a O
reversed O
- O
phase O
Chiralcel O
OD O
- O
RH O
column O
, O
under O
isocratic O
conditions O
using O
a O
mixture O
of O
acetonitrile B
- O
2 O
mM O
ammonium B
acetate I
in O
water O
( O
60 O
/ O
40 O
, O
v O
/ O
v O
) O
as O
the O
mobile O
phase O
at O
a O
flow O
rate O
of O
0 O
. O
4 O
mL O
/ O
min O
. O

Electron O
transfer O
dissociation O
( O
ETD O
) O
: O
the O
mass O
spectrometric O
breakthrough O
essential O
for O
O O
- O
GlcNAc O
protein O
site O
assignments O
- O
a O
study O
of O
the O
O B
- O
GlcNAcylated O
protein O
host O
cell O
factor O
C1 O
. O

The O
field O
of O
intracellular O
O O
- O
GlcNAc O
( O
O B
- O
linked O
N B
- I
acetylglucosamine I
) O
signaling O
has O
especially O
advanced O
with O
the O
advent O
of O
ETD O
MS O
. O

Here O
, O
we O
discuss O
the O
advantages O
of O
using O
ETD O
, O
complimented O
with O
collisional O
- O
activation O
MS O
, O
in O
a O
study O
of O
the O
extensively O
O B
- O
GlcNAcylated O
protein O
Host O
Cell O
Factor O
C1 O
( O
HCF O
- O
1 O
) O
. O

These O
include O
19 O
sites O
of O
O B
- O
GlcNAcylation O
, O
two O
sites O
of O
phosphorylation O
, O
and O
two O
sites O
bearing O
dimethylarginine B
, O
and O
showcase O
the O
residue O
- O
specific O
, O
PTM O
complexity O
of O
this O
regulator O
of O
cell O
proliferation O
. O

ZnO B
is O
a O
CO B
( I
2 I
) I
- O
selective O
steam O
reforming O
catalyst O
. O

ZnO B
was O
tested O
as O
possible O
methanol B
and O
- O
since O
formaldehyde B
is O
one O
of O
the O
key O
intermediates O
in O
methanol B
conversion O
reactions O
- O
also O
as O
formaldehyde B
steam O
reforming O
catalyst O
. O

Catalytic O
experiments O
in O
a O
batch O
as O
well O
as O
a O
flow O
reactor O
resulted O
in O
highly O
selective O
steam O
reforming O
, O
though O
at O
low O
specific O
activities O
, O
of O
formaldehyde B
and O
methanol B
over O
ZnO B
toward O
CO B
( I
2 I
) I
( O
selectivity O
of O
95 O
- O
99 O
. O
6 O
% O
) O
. O

Comparison O
of O
the O
behavior O
of O
ZnPd O
near O
- O
surface O
intermetallic O
phases O
, O
unsupported O
intermetallic O
ZnPd O
and O
supported O
ZnPd O
/ O
ZnO B
catalysts O
reveals O
that O
formaldehyde B
is O
formed O
from O
methanol B
in O
parallel O
with O
CO B
( I
2 I
) I
on O
the O
former O
, O
while O
on O
unsupported O
intermetallic O
ZnPd O
and O
ZnO B
- O
supported O
ZnPd O
, O
it O
is O
efficiently O
reacted O
toward O
CO B
( I
2 I
) I
, O
thus O
, O
a O
beneficial O
role O
of O
ZnO B
in O
oxidizing O
formaldehyde B
- O
derived O
intermediates O
toward O

CO B
( I
2 I
) I
is O
evident O
. O

Nanoscale O
mapping O
of O
lithium B
- O
ion O
diffusion O
in O
a O
cathode O
within O
an O
all O
- O
solid O
- O
state O
lithium B
- O
ion O
battery O
by O
advanced O
scanning O
probe O
microscopy O
techniques O
. O

High O
- O
resolution O
real O
- O
space O
mapping O
of O
Li B
- O
ion O
diffusion O
in O
the O
LiNi O
( O
1 O
/ O
3 O
) O
Co O
( O
1 O
/ O
3 O
) O
Mn O
( O
1 O
/ O
3 O
) O
O O
2 O
cathode O
within O
an O
all O
- O
solid O
- O
state O
thin O
film O
Li B
- O
ion O
battery O
has O
been O
conducted O
using O
advanced O
scanning O
probe O
microscopy O
techniques O
, O
namely O
, O
band O
excitation O
electrochemical O
strain O
microscopy O
( O
BE O
- O
ESM O
) O
and O
conductive O
atomic O
force O
microscopy O
. O

The O
study O
on O
the O
relationships O
between O
the O
Li B
- O
ion O
redistribution O
and O
microstructure O
of O
the O
electrode O
materials O
within O
thin O
film O
Li B
- O
ion O
battery O
will O
provide O
further O
understanding O
of O
the O
electrochemical O
degradation O
mechanisms O
of O
Li B
- O
ion O
rechargeable O
batteries O
at O
the O
nanoscale O
. O

Polyphosphates B
inhibit O
extracellular O
matrix O
mineralization O
in O
MC3T3 O
- O
E1 O
osteoblast O
cultures O
. O

Studies O
on O
various O
compounds O
of O
inorganic O
phosphate B
, O
as O
well O
as O
on O
organic O
phosphate B
added O
by O
post O
- O
translational O
phosphorylation O
of O
proteins O
, O
all O
demonstrate O
a O
central O
role O
for O
phosphate B
in O
biomineralization O
processes O
. O

Inorganic O
polyphosphates B
are O
chains O
of O
orthophosphates O
linked O
by O
phosphoanhydride O
bonds O
that O
can O
be O
up O
to O
hundreds O
of O
orthophosphates O
in O
length O
. O

The O
role O
of O
polyphosphates B
in O
mammalian O
systems O
, O
where O
they O
are O
ubiquitous O
in O
cells O
, O
tissues O
and O
bodily O
fluids O
, O
and O
are O
at O
particularly O
high O
levels O
in O
osteoblasts O
, O
is O
not O
well O
understood O
. O

In O
cell O
- O
free O
systems O
, O
polyphosphates B
inhibit O
hydroxyapatite O
nucleation O
, O
crystal O
formation O
and O
growth O
, O
and O
solubility O
. O

Here O
we O
demonstrate O
in O
osteoblast O
cultures O
producing O
an O
abundant O
collagenous O
matrix O
that O
normally O
show O
robust O
mineralization O
, O
that O
two O
polyphosphates B
( O
PolyP5 O
and O
PolyP65 O
, O
polyphosphates B
of O
5 O
and O
65 O
phosphate B
residues O
in O
length O
) O
are O
potent O
mineralization O
inhibitors O
. O

Twelve O
- O
day O
MC3T3 O
- O
E1 O
osteoblast O
cultures O
with O
added O
ascorbic O
acid O
( O
for O
collagen O
matrix O
assembly O
) O
and O
beta O
- O
glycerophosphate O
( O
a O
source O
of O
phosphate B
for O
mineralization O
) O
were O
treated O
with O
either O
PolyP5 O
or O
PolyP65 O
. O

Von O
Kossa O
staining O
and O
calcium O
quantification O
revealed O
that O
mineralization O
was O
inhibited O
in O
a O
dose O
- O
dependent O
manner O
by O
both O
polyphosphates B
, O
with O
complete O
mineralization O
inhibition O
at O
10 O
mu O
M O
. O

This O
was O
confirmed O
by O
showing O
that O
PolyP5 O
and O
PolyP65 O
bound O
to O
synthetic O
hydroxyapatite B
in O
a O
concentration O
- O
dependent O
manner O
. O

Importantly O
, O
at O
the O
concentrations O
of O
polyphosphates B
used O
in O
this O
study O
which O
inhibited O
bone O
cell O
culture O
mineralization O
, O
the O
polyphosphates B
competitively O
saturated O
TNAP O
, O
thus O
potentially O
interfering O
with O
its O
ability O
to O
hydrolyze O
mineralization O
- O
inhibiting O
pyrophosphate B
( O
PPi O
) O
and O
mineralizing O
- O
promoting O
beta O
- O
glycerophosphate O
( O
in O
cell O
culture O
) O
. O

In O
the O
biological O
setting O
, O
polyphosphates B
may O
regulate O
mineralization O
by O
shielding O
the O
essential O
inhibitory O
substrate O
pyrophosphate B
from O
TNAP O
degradation O
, O
and O
in O
the O
same O
process O
, O
delay O
the O
release O
of O
phosphate B
from O
this O
source O
. O

In O
conclusion O
, O
the O
inhibition O
of O
mineralization O
by O
polyphosphates B
is O
shown O
to O
occur O
via O
direct O
binding O
to O
apatitic O
mineral O
and O
by O
mixed O
inhibition O
of O
TNAP O
. O

Sex O
differences O
in O
the O
antidepressant O
- O
like O
effects O
of O
ketamine B
. O

However O
, O
recent O
clinical O
studies O
have O
shown O
that O
a O
single O
low O
- O
dose O
injection O
of O
ketamine B
, O
an O
N B
- I
methyl I
d I
- I
aspartate I
receptor O
( O
NMDAR O
) O
antagonist O
, O
has O
rapid O
antidepressant O
effects O
that O
are O
observed O
within O
hours O
and O
are O
long O
lasting O
. O

Although O
major O
depression O
affects O
twice O
as O
many O
women O
as O
men O
, O
all O
studies O
examining O
the O
rapid O
antidepressant O
effects O
of O
ketamine B
have O
focused O
on O
male O
subjects O
. O

Thus O
, O
we O
have O
investigated O
the O
behavioral O
and O
molecular O
effects O
of O
ketamine B
in O
both O
male O
and O
female O
rats O
and O
demonstrated O
greater O
sensitivity O
in O
female O
rats O
at O
a O
low O
dose O
of O
ketamine B
, O
a O
dose O
does O
not O
have O
antidepressant O
- O
like O
effects O
in O
male O
rats O
. O

The O
antidepressant O
- O
like O
effects O
of O
this O
low O
dose O
of O
ketamine B
were O
completely O
abolished O
when O
female O
rats O
were O
ovariectomized O
( O
OVX O
) O
, O
and O
restored O
when O
physiological O
levels O
of O
estrogen B
and O
progesterone B
were O
supplemented O
, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant O
- O
like O
effects O
of O
ketamine B
in O
female O
rats O
. O

In O
preclinical O
studies O
, O
the O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic O
elongation O
factor O
( O
eEF2 O
) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine B
' O
s O
rapid O
antidepressant O
actions O
. O

In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine B
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR O
or O
eEF2 O
. O

Differential O
contribution O
of O
mesoaccumbens O
and O
mesohabenular O
dopamine B
to O
intracranial O
self O
- O
stimulation O
. O

The O
contribution O
of O
mesoaccumbens O
dopamine B
transmission O
to O
intracranial O
self O
- O
stimulation O
is O
well O
- O
established O
. O

Our O
first O
aim O
was O
to O
study O
the O
effects O
of O
d B
- I
amphetamine I
infusions O
into O
the O
shell O
and O
core O
in O
order O
to O
understand O
their O
relative O
importance O
to O
reward O
and O
operant O
responding O
. O

Our O
second O
aim O
was O
to O
examine O
the O
contribution O
of O
a O
lesser O
studied O
group O
of O
dopamine B
neurons O
, O
those O
within O
the O
mesohabenular O
pathway O
, O
to O
intracranial O
self O
- O
stimulation O
. O

Male O
Sprague O
- O
Dawley O
rats O
were O
implanted O
with O
bilateral O
cannulae O
in O
the O
nucleus O
accumbens O
shell O
, O
core O
or O
in O
the O
lateral O
habenula O
and O
a O
monopolar O
stimulation O
electrode O
in O
the O
posterior O
mesencephalon O
, O
a O
brain O
site O
that O
is O
sensitive O
to O
changes O
in O
dopamine B
transmission O
. O

Using O
curve O
- O
shift O
scaling O
, O
we O
measured O
the O
reward O
- O
and O
performance O
- O
enhancing O
effects O
of O
intra O
- O
accumbens O
( O
1 O
- O
20 O
mu O
g O
) O
and O
intra O
- O
habenular O
( O
10 O
- O
40 O
mu O
g O
) O
infusions O
of O
d B
- I
amphetamine I
or O
vehicle O
. O

Conversely O
, O
regardless O
of O
dose O
, O
intra O
- O
habenular O
d B
- I
amphetamine I
did O
not O
alter O
rewarding O
effectiveness O
or O
operant O
rate O
, O
highlighting O
the O
differential O
contribution O
of O
mesoaccumbens O
and O
mesohabenular O
dopamine B
pathways O
to O
intracranial O
self O
- O
stimulation O
. O

Osteoblasts O
survive O
the O
arsenic B
trioxide I
treatment O
by O
activation O
of O
ATM O
- O
mediated O
pathway O
. O

Arsenic B
trioxide I
( O
ATO B
) O
is O
widely O
used O
in O
tumor O
treatment O
, O
but O
excessive O
arsenic B
exposure O
can O
have O
adverse O
effects O
. O

We O
recently O
found O
that O
, O
in O
primary O
osteoblasts O
, O
ATO B
produces O
oxidative O
stress O
and O
causes O
DNA O
tailing O
, O
but O
does O
not O
induce O
apoptosis O
. O

We O
further O
examined O
the O
signaling O
pathway O
by O
which O
osteoblasts O
survive O
ATO B
treatment O
, O
and O
found O
that O
they O
were O
arrested O
at O
G2 O
/ O
M O
phase O
of O
the O
cell O
cycle O
at O
30h O
and O
overrode O
the O
G2 O
/ O
M O
boundary O
at O
48h O
. O

Additionally O
, O
these O
effects O
of O
ATO B
on O
gamma O
- O
H2AX O
, O
Chk1 O
, O
Chk2 O
, O
p53 O
, O
and O
p21 O
( O
waf1 O
/ O
cip1 O
) O
were O
reduced O
by O
an O
ATM O
inhibitor O
. O

Stabilization O
of O
glycogen O
synthase O
and O
beta O
- O
catenin O
, O
which O
are O
direct O
targets O
of O
GSK O
- O
3 O
, O
by O
compound O
1a O
was O
assessed O
in O
comparison O
with O
two O
other O
GSK O
- O
3 O
inhibitors O
: O
LiCl B
and O
SB O
- O
415286 O
. O

At O
first O
, O
the O
POM O
cluster O
bioconjugates O
were O
created O
by O
attaching O
the O
bioactive O
ligands O
on O
an O
amine B
grafted O
POM O
via O
simple O
amidation O
reaction O
. O

The O
use O
of O
reverse O
micellar O
medium O
not O
only O
enhanced O
the O
conversion O
rate O
, O
but O
also O
showed O
selectivity O
towards O
mono O
- O
coupled O
product O
in O
aryl O
chloride O
- O
aniline B
coupling O
reactions O
. O

Furthermore O
, O
the O
cytotoxicities O
of O
all O
the O
compounds O
against O
normal O
human O
liver O
cell O
line O
L02 O
were O
determined O
by O
an O
MTT B
method O
. O

Toxicity O
assessment O
on O
trophoblast O
cells O
for O
some O
environment O
polluting O
chemicals O
and O
17 B
beta I
- I
estradiol I
. O

Cells O
were O
exposed O
for O
24h O
to O
various O
concentrations O
( O
from O
0 O
. O
1 O
pM O
to O
1 O
mM O
) O
of O
atrazine B
( O
ATR B
) O
, O
diethylstilbestrol B
( O
DES B
) O
, O
para O
- O
nonylphenol O
( O
p O
- O
NP O
) O
, O
resveratrol B
( O
RES B
) O
and O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
and O
assayed O
for O
cell O
viability O
and O
human O
beta O
- O
Chorionic O
Gonadotropin O
( O
beta O
- O
hCG O
) O
secretion O
. O

A O
parallel O
decrease O
of O
beta O
- O
hCG O
secretion O
was O
observed O
in O
BeWo O
cells O
, O
at O
1 O
mu O
M O
- O
1 O
mM O
concentrations O
, O
with O
the O
only O
exception O
of O
ATR B
which O
caused O
an O
increase O
at O
concentrations O
up O
to O
1mM O
. O

beta O
- O
hCG O
release O
was O
also O
unexpectedly O
inhibited O
by O
ATR B
, O
DES B
, O
p O
- O
NP O
and O
RES B
at O
non O
- O
toxic O
( O
pM O
- O
nM O
) O
concentrations O
. O

Subcutaneous O
bortezomib B
: O
in O
multiple O
myeloma O
. O

A O
subcutaneous O
formulation O
of O
bortezomib B
is O
now O
indicated O
in O
the O
EU O
and O
the O
US O
for O
the O
treatment O
of O
patients O
with O
multiple O
myeloma O
. O

This O
article O
reviews O
pharmacological O
, O
therapeutic O
efficacy O
and O
tolerability O
data O
relevant O
to O
the O
utilization O
of O
subcutaneous O
bortezomib B
( O
Velcade O
( O
( O
R O
) O
) O
) O
in O
the O
treatment O
of O
patients O
with O
multiple O
myeloma O
. O

In O
a O
randomized O
, O
nonblind O
, O
phase O
III O
study O
, O
subcutaneous O
bortezomib B
was O
noninferior O
to O
intravenous O
bortezomib B
in O
the O
treatment O
of O
adults O
with O
relapsed O
multiple O
myeloma O
, O
as O
determined O
by O
the O
overall O
response O
rate O
after O
four O
cycles O
of O
therapy O
( O
primary O
endpoint O
) O
. O

No O
significant O
differences O
between O
the O
subcutaneous O
and O
intravenous O
bortezomib B
formulations O
were O
observed O
in O
the O
median O
time O
to O
first O
response O
, O
median O
progression O
- O
free O
survival O
, O
median O
time O
to O
progression O
and O
1 O
- O
year O
overall O
survival O
. O

Compared O
with O
intravenous O
bortezomib B
, O
subcutaneous O
bortezomib B
confers O
a O
significant O
advantage O
with O
respect O
to O
the O
incidence O
of O
peripheral O
neuropathy O
( O
all O
grades O
, O
grade O
> O
= O
2 O
and O
grade O
> O
= O
3 O
) O
. O

We O
demonstrate O
localized O
electrodeposition O
of O
anisotropic O
metal O
nanoobjects O
, O
namely O
Au B
nanorods O
( O
GNR O
) O
, O
on O
indium B
tin I
oxide I
( O
ITO B
) O
using O
scanning O
electrochemical O
microscopy O
( O
SECM O
) O
. O

A O
gold O
microelectrode O
was O
the O
source O
of O
the O
gold O
ions O
whereby O
double O
pulse O
chronoamperometry O
was O
employed O
to O
generate O
initially O
Au B
seeds O
which O
were O
further O
grown O
under O
controlled O
conditions O
. O

The O
distance O
between O
the O
microelectrode O
and O
the O
ITO B
surface O
as O
well O
as O
the O
different O
experimental O
parameters O
( O
electrodeposition O
regime O
, O
solution O
composition O
and O
temperature O
) O
were O
optimized O
to O
produce O
faceted O
gold O
seeds O
with O
the O
required O
characteristics O
( O
size O
and O
distribution O
) O
. O

Synthesis O
of O
long O
- O
circulating O
, O
backbone O
degradable O
HPMA B
copolymer O
- O
doxorubicin B
conjugates O
and O
evaluation O
of O
molecular O
- O
weight O
- O
dependent O
antitumor O
efficacy O
. O

Backbone O
degradable O
, O
linear O
, O
multiblock O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
- O
doxorubicin B
( O
DOX B
) O
conjugates O
are O
synthesized O
by O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
followed O
by O
chain O
extension O
via O
thiol B
- O
ene O
click O
reaction O
. O

The O
examination O
of O
molecular O
- O
weight O
- O
dependent O
antitumor O
activity O
toward O
human O
ovarian O
A2780 O
/ O
AD O
carcinoma O
in O
nude O
mice O
reveals O
enhanced O
activity O
of O
multiblock O
, O
second O
- O
generation O
, O
higher O
molecular O
weight O
conjugates O
when O
compared O
with O
traditional O
HPMA B
copolymer O
- O
DOX B
conjugates O
. O

Structure O
prediction O
of O
binary O
pernitride O
MN2 O
compounds O
( O
M O
= O
Ca B
, O
Sr B
, O
Ba O
, O
La B
, O
and O
Ti B
) O
. O

To O
investigate O
this O
issue O
, O
the O
energy O
landscapes O
of O
pernitrides O
of O
metals O
with O
different O
maximum O
valence O
( O
M O
= O
Ca B
, O
Sr B
, O
Ba O
, O
La B
, O
and O
Ti B
) O
were O
globally O
explored O
on O
the O
ab O
initio O
level O
at O
standard O
and O
high O
pressures O
, O
thereby O
yielding O
possible O
( O
meta O
) O
stable O
modifications O
in O
these O
systems O
together O
with O
information O
on O
how O
the O
landscape O
changed O
as O
function O
of O
the O
valence O
of O
the O
metal O
cation O
. O

Inhibition O
pathways O
of O
the O
potent O
organophosphate B
CBDP O
with O
cholinesterases O
revealed O
by O
X O
- O
ray O
crystallographic O
snapshots O
and O
mass O
spectrometry O
. O

X O
- O
ray O
crystallography O
and O
mass O
spectrometry O
show O
the O
formation O
of O
an O
aged O
end O
product O
formed O
in O
both O
AChE O
and O
BChE O
that O
cannot O
be O
reactivated O
by O
current O
oxime B
- O
based O
therapeutics O
. O

Additionally O
, O
we O
observe O
that O
the O
interaction O
of O
A O
beta O
species O
with O
the O
cell O
membrane O
is O
inhibited O
by O
the O
presence O
of O
ATP B
- O
independent O
molecular O
chaperones O
. O

Thyroid B
hormone I
levels O
within O
reference O
range O
are O
associated O
with O
heart O
rate O
, O
cardiac O
structure O
and O
function O
in O
middle O
- O
aged O
men O
and O
women O
. O

Background O
Triiodothyronine B
( O
T3 O
) O
has O
many O
effects O
on O
the O
heart O
and O
marked O
changes O
in O
cardiac O
function O
and O
structure O
occur O
in O
patients O
with O
( O
subclinical O
) O
thyroid O
disease O
. O

We O
investigated O
whether O
between O
- O
subject O
variation O
in O
thyroid B
hormone I
levels O
within O
the O
euthyroid O
range O
is O
also O
associated O
with O
heart O
rate O
and O
echocardiographic O
heart O
function O
and O
structure O
. O

Conclusion O
We O
have O
demonstrated O
a O
strong O
positive O
association O
between O
thyroid B
hormone I
levels O
within O
the O
euthyroid O
range O
and O
heart O
rate O
, O
and O
more O
subtle O
effects O
on O
cardiac O
function O
and O
structure O
. O

More O
specifically O
, O
we O
suggest O
smaller O
LV O
cavity O
size O
( O
with O
increased O
relative O
wall O
thickness O
) O
, O
an O
enhanced O
atrial O
and O
ventricular O
contraction O
and O
LV O
relaxation O
with O
higher O
circulating O
thyroid B
hormones I
. O

These O
results O
illustrate O
that O
variation O
of O
thyroid B
hormone I
levels O
even O
within O
the O
reference O
range O
exerts O
effects O
on O
the O
heart O
. O

Disorder O
imposed O
limits O
of O
mono O
- O
and O
bilayer O
graphene B
electronic O
modification O
using O
covalent O
chemistry O
. O

A O
central O
question O
in O
graphene B
chemistry O
is O
to O
what O
extent O
chemical O
modification O
can O
control O
an O
electronically O
accessible O
band O
gap O
in O
monolayer O
and O
bilayer O
graphene B
( O
MLG O
and O
BLG O
) O
. O

Density O
functional O
theory O
predicts O
gaps O
in O
covalently O
functionalized O
graphene B
as O
high O
as O
2 O
eV O
, O
while O
this O
approach O
neglects O
the O
fact O
that O
lattice O
symmetry O
breaking O
occurs O
over O
only O
a O
prescribed O
radius O
of O
nanometer O
dimension O
, O
which O
we O
label O
the O
S O
- O
region O
. O

For O
MLG O
, O
we O
find O
that O
band O
gap O
opening O
as O
measured O
during O
transport O
is O
linearly O
increased O
with O
respect O
to O
the O
I O
( O
D O
) O
/ O
I O
( O
G O
) O
ratio O
but O
remains O
below O
0 O
. O
1 O
meV O
in O
magnitude O
for O
SiO B
( I
2 I
) I
supported O
graphene B
. O

The O
largest O
transport O
band O
gap O
obtained O
in O
a O
suspended O
, O
highly O
functionalized O
( O
I O
( O
D O
) O
/ O
I O
( O
G O
) O
= O
4 O
. O
5 O
) O
graphene B
is O
about O
1 O
meV O
, O
lower O
than O
our O
theoretical O
predictions O
considering O
the O
quantum O
interference O
effect O
between O
two O
neighboring O
S O
- O
regions O
and O
attributed O
to O
its O
population O
with O
midgap O
states O
. O

These O
important O
observations O
set O
definitive O
limits O
on O
the O
extent O
to O
which O
chemical O
modification O
can O
control O
graphene B
electronically O
. O

The O
N B
- O
naphthoyl B
analogue O
3t O
had O
GI O
( O
50 O
) O
values O
of O
1 O
. O
30 O
and O
1 O
. O
91 O
mu O
M O
against O
HOP O
- O
92 O
non O
- O
small O
cell O
lung O
cancer O
and O
MDA O
- O
MB O
- O
435 O
melanoma O
cell O
lines O
, O
respectively O
. O

Interestingly O
, O
docking O
of O
the O
two O
active O
molecules O
3k O
and O
3w O
into O
the O
active O
site O
of O
COX O
- O
2 O
indicates O
that O
these O
compounds O
are O
COX O
- O
2 O
ligands O
with O
strong O
hydrophobic O
and O
hydrogen B
bonding O
interactions O
. O

This O
study O
evaluates O
the O
influence O
of O
cooking O
and O
handling O
conditions O
on O
the O
quantity O
of O
furanic O
compounds O
( O
furan B
, O
2 O
- O
furfural O
, O
furfuryl B
alcohol I
, O
2 O
- O
pentylfuran O
, O
5 B
- I
hydroxymethylfurfura I
) O
in O
breaded O
fish O
products O
. O

TF O
mimicked O
the O
gene O
transcription O
profile O
of O
the O
murine O
glucocorticoid O
corticosterone B
( O
Cort B
) O
. O

Cellular O
fractionation O
assays O
demonstrated O
that O
TF O
treatment O
promoted O
the O
activating O
serine B
phosphorylation O
of O
GR O
, O
augmenting O
its O
cytoplasmic O
- O
to O
- O
nuclear O
translocation O
as O
well O
as O
its O
enrichment O
at O
glucocorticoid O
response O
elements O
on O
the O
glucocorticoid O
- O
induced O
leucine B
zipper O
gene O
promoter O
. O

After O
acute O
treatment O
, O
Cort B
or O
TF O
promoted O
insulin O
receptor O
substrate O
- O
1 O
( O
IRS O
- O
1 O
) O
gene O
and O
protein O
expression O
. O

TF O
or O
Cort B
each O
increased O
insulin O
- O
stimulated O
lipogenesis O
, O
an O
effect O
resulting O
from O
increased O
lipogenic O
gene O
expression O
and O
enhanced O
insulin O
- O
stimulated O
dephosphorylation O
of O
acetyl O
- O
coenzyme O
A O
carboxylase O
. O

Albeit O
with O
less O
affinity O
than O
Cort B
, O
in O
silico O
analysis O
suggests O
that O
TF O
can O
interact O
with O
the O
ligand O
binding O
pocket O
of O
GR O
. O

Perfluoroalkylated O
compounds O
induce O
cell O
death O
and O
formation O
of O
reactive O
oxygen B
species O
in O
cultured O
cerebellar O
granule O
cells O
. O

The O
present O
communication O
investigates O
the O
effects O
of O
different O
perfluoroalkylated O
compounds O
( O
PFCs O
) O
on O
formation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
cell O
death O
in O
cultured O
cerebellar O
granule O
cells O
. O

This O
allows O
direct O
comparison O
with O
similar O
effects O
found O
for O
other O
environmental O
contaminants O
like O
polychlorinated B
biphenyls I
and O
brominated O
flame O
- O
retardants O
. O

The O
increase O
in O
ROS O
formation O
and O
cell O
death O
was O
assayed O
using O
the O
fluorescent O
probe O
2 O
, O
7 O
- O
dichlorofluorescin O
diacetate O
( O
DCFH B
- I
DA I
) O
and O
the O
trypan B
blue I
exclusion O
assay O
. O

Cell O
death O
was O
induced O
at O
relatively O
low O
concentrations O
by O
perfluorooctyl O
sulfonate O
( O
PFOS B
) O
, O
perfluorooctane O
sulfonylamide O
( O
PFOSA O
) O
and O
the O
fluorotelomer O
alcohol O
1H O
, O
1H O
, O
2H O
, O
2H O
- O
perfluorodecanol O
( O
FTOH O
8 O
: O
2 O
) O
with O
EC O
( O
50 O
) O
- O
values O
of O
62 O
+ O
/ O
- O
7 O
. O
6 O
, O
13 O
+ O
/ O
- O
1 O
. O
8 O
and O
15 O
+ O
/ O
- O
4 O
. O
2 O
mu O
M O
( O
mean O
+ O
/ O
- O
SD O
) O
respectively O
. O

PFOS B
, O
perfluorooctanoic B
acid I
( O
PFOA B
) O
and O
PFOSA O
induced O
a O
concentration O
dependent O
increase O
in O
ROS O
formation O
with O
EC O
( O
50 O
) O
- O
values O
of O
27 O
+ O
/ O
- O
9 O
. O
0 O
, O
25 O
+ O
/ O
- O
11 O
and O
57 O
+ O
/ O
- O
19 O
mu O
M O
respectively O
. O

Feasibility O
of O
this O
recombinant O
approach O
was O
explored O
with O
a O
focus O
on O
Drosophila O
bursicon O
, O
a O
heterodimeric O
cystine B
- O
knot O
protein O
that O
activates O
the O
G O
protein O
- O
coupled O
receptor O
rickets O
( O
rk O
) O
. O

We O
initially O
engineered O
two O
distinct O
MTL O
constructs O
, O
each O
composed O
of O
a O
type O
II O
transmembrane O
domain O
, O
a O
peptide O
linker O
, O
and O
a O
C B
terminal O
extracellular O
ligand O
that O
corresponded O
to O
either O
the O
alpha O
or O
beta O
bursicon O
subunit O
. O

Carboxy B
- O
terminal O
deletion O
of O
32 O
amino B
acids I
in O
the O
beta O
- O
alpha O
MTL O
construct O
resulted O
in O
loss O
of O
agonist O
activity O
. O

Eyeballs O
were O
collected O
24 O
h O
after O
irradiation O
, O
and O
corneas O
were O
stained O
with O
hematoxylin B
and O
eosin B
( O
H O
& O
amp O
; O
E O
) O
and O
terminal O
deoxynucleotidyl O
transferase O
dUTP B
nick O
end O
labeling O
( O
TUNEL O
) O
. O

HSP70 O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
, O
nuclear O
factor O
kappa O
- O
light O
- O
chain O
- O
enhancer O
of O
activated O
B O
cells O
( O
NF O
- O
kappa O
B O
) O
and O
protein O
kinase O
B O
( O
Akt O
) O
expression O
were O
also O
evaluated O
. O

NF O
- O
kappa O
B O
activation O
was O
reduced O
but O
phospho O
- O
( O
Ser B
/ O
Ther O
) O
Akt O
substrate O
expression O
was O
increased O
in O
corneas O
after O
irradiation O
when O
treated O
with O
GGA O
. O

The O
influence O
of O
changes O
in O
the O
chain O
conformation O
on O
the O
( B
13 I
) I
C I
sigma O
( O
ii O
) O
NMR O
shielding O
parameters O
is O
shown O
. O

Moreover O
, O
a O
comparison O
of O
the O
experimental O
( B
13 I
) I
C I
NMR O
spectra O
with O
the O
spectra O
calculated O
using O
the O
M1 O
- O
M4 O
models O
strongly O
supports O
the O
data O
for O
the O
M4 O
model O
. O

Photoelectron O
imaging O
of O
small O
aluminum B
clusters O
: O
quantifying O
s O
- O
p O
hybridization O
. O

The O
highest O
occupied O
molecular O
orbitals O
of O
these O
small O
aluminum B
clusters O
are O
found O
to O
contain O
varying O
degrees O
of O
s O
- O
p O
mixing O
, O
with O
Al B
( I
3 I
) I
( I
- I
) I
containing O
the O
" O
most O
hybridized O
" O
orbital O
and O
Al O
( O
4 O
) O
( O
- O
) O
containing O
the O
" O
least O
hybridized O
" O
orbital O
. O

A O
" O
clickable O
" O
MTX B
reagent O
as O
a O
practical O
tool O
for O
profiling O
small O
- O
molecule O
- O
intracellular O
target O
interactions O
via O
MASPIT O
. O

We O
present O
a O
scalable O
synthesis O
of O
a O
versatile O
MTX B
reagent O
with O
an O
azide B
ligation O
handle O
that O
allows O
rapid O
gamma O
- O
selective O
conjugation O
to O
yield O
MTX B
fusion O
compounds O
( O
MFCs O
) O
appropriate O
for O
MASPIT O
, O
a O
three O
- O
hybrid O
system O
that O
enables O
the O
identification O
of O
mammalian O
cytosolic O
proteins O
that O
interact O
with O
a O
small O
molecule O
of O
interest O
. O

We O
selected O
three O
structurally O
diverse O
pharmacologically O
active O
compounds O
( O
tamoxifen B
, O
reversine O
, O
and O
FK506 B
) O
as O
model O
baits O
. O

After O
acetylene B
functionalization O
of O
these O
baits O
, O
MFCs O
were O
synthesized O
via O
a O
CuAAC O
reaction O
, O
demonstrating O
the O
general O
applicability O
of O
the O
MTX B
reagent O
. O

Furthermore O
, O
we O
demonstrate O
that O
the O
sensitivity O
obtained O
with O
the O
new O
MTX B
reagent O
was O
significantly O
stronger O
than O
that O
of O
a O
previously O
used O
non O
- O
regiomeric O
conjugate O
mixture O
. O

Finally O
, O
the O
FK506 B
MFC O
was O
explored O
in O
a O
cellular O
array O
screen O
for O
targets O
of O
FK506 B
. O

Out O
of O
a O
pilot O
collection O
of O
nearly O
2000 O
full O
- O
length O
human O
ORF O
preys O
, O
FKBP12 O
, O
the O
established O
target O
of O
FK506 B
, O
emerged O
as O
the O
prey O
protein O
that O
gave O
the O
highest O
increase O
in O
luciferase O
activity O
. O

The O
role O
of O
silver B
and O
vanadium B
release O
in O
the O
toxicity O
of O
silver O
vanadate O
nanowires O
toward O
Daphnia O
similis O
. O

Recently O
, O
a O
new O
type O
of O
silver O
vanadate O
nanowire O
decorated O
with O
silver B
nanoparticles O
( O
SVSN O
- O
LQES1 O
) O
with O
promising O
antimicrobial O
activity O
against O
different O
pathogenic O
bacteria O
was O
described O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
evaluate O
the O
role O
of O
silver B
and O
vanadium B
release O
in O
the O
acute O
toxicity O
of O
this O
material O
using O
Daphnia O
similis O
. O

Total O
silver B
release O
to O
the O
testing O
media O
was O
determined O
using O
the O
method O
of O
inductively O
coupled O
plasma O
atomic O
emission O
spectroscopy O
( O
ICP O
- O
AES O
) O
. O

Silver O
vanadate O
nanowires O
decorated O
with O
silver B
nanoparticles O
( O
SVSN O
- O
LQES1 O
) O
are O
acutely O
toxic O
to O
D O
. O
similis O
. O

The O
release O
of O
silver B
from O
the O
nanomaterial O
trapped O
in O
the O
gut O
along O
with O
the O
silver B
released O
to O
the O
test O
media O
seems O
to O
be O
responsible O
for O
the O
observed O
toxicity O
. O

Although O
toxic O
to O
Daphnia O
, O
vanadium B
does O
not O
contribute O
to O
the O
toxicity O
of O
SVSN O
- O
LQES1 O
. O

In O
contrast O
, O
stressed O
mice O
lacking O
ghrelin O
receptors O
( O
GHSR O
KO O
mice O
) O
or O
C57BL O
mice O
receiving O
chronic O
intracerebroventricu O
delivery O
of O
the O
ghrelin O
receptor O
antagonist O
[ O
d O
- O
Lys B
( O
3 O
) O
] O
- O
GHRP O
- O
6 O
show O
attenuated O
weight O
gain O
and O
feeding O
responses O
under O
the O
same O
social O
stress O
paradigm O
. O

The O
composition O
of O
55 O
samples O
of O
essential O
oil O
isolated O
from O
the O
aerial O
parts O
of O
wild O
growing O
Myrtus O
communis O
L O
. O
harvested O
in O
16 O
locations O
from O
East O
to O
West O
Algeria O
were O
investigated O
by O
GC O
( O
determination O
of O
retention O
indices O
) O
and O
( B
13 I
) I
C I
- O
NMR O
analyses O
. O

The O
essential O
oils O
consisted O
mainly O
of O
monoterpenes O
, O
alpha B
- I
pinene I
( O
27 O
. O
4 O
- O
59 O
. O
2 O
% O
) O
and O
1 O
, O
8 O
- O
cineole O
( O
6 O
. O
1 O
- O
34 O
. O
3 O
% O
) O
being O
the O
major O
components O
. O

Groups O
I O
( O
78 O
% O
of O
the O
samples O
) O
and O
II O
were O
differentiated O
on O
the O
basis O
of O
the O
contents O
of O
alpha B
- I
pinene I
, O
linalool B
, O
and O
linalyl O
acetate O
. O

Subgroups O
IA O
and O
IB O
could O
be O
distinguished O
by O
their O
contents O
of O
alpha B
- I
pinene I
and O
1 O
, O
8 O
- O
cineole O
. O

Subgroups O
IIA O
and O
IIB O
differed O
substantially O
in O
their O
contents O
of O
1 O
, O
8 O
- O
cineole O
and O
limonene B
. O

Accumulation O
of O
dietary O
methylmercury B
and O
effects O
on O
growth O
and O
survival O
in O
two O
estuarine O
forage O
fish O
: O
Cyprinodon O
variegatus O
and O
Menidia O
beryllina O
. O

Dietary O
methylmercury B
( O
MeHg B
) O
uptake O
by O
fish O
in O
relation O
to O
life O
stage O
, O
species O
, O
and O
level O
of O
exposure O
is O
poorly O
understood O
in O
lower O
trophic O
levels O
, O
particularly O
in O
estuarine O
species O
. O

The O
authors O
compared O
accumulation O
of O
dietary O
MeHg B
as O
well O
as O
sensitivity O
( O
survival O
and O
growth O
) O
to O
dietary O
MeHg B
exposure O
in O
two O
species O
of O
estuarine O
forage O
fish O
, O
Cyprinodon O
variegatus O
and O
Menidia O
beryllina O
. O

Fish O
were O
fed O
one O
of O
five O
dietary O
MeHg B
concentrations O
( O
ranging O
from O
0 O
. O
04 O
to O
14 O
micro O
g O
/ O
g O
dry O
wt O
) O
over O
a O
period O
of O
70 O
d O
. O

Growth O
rate O
and O
the O
level O
of O
dietary O
exposure O
influenced O
MeHg B
tissue O
concentrations O
in O
both O
species O
. O

Mercury B
in O
the O
diet O
exhibited O
a O
strong O
linear O
relationship O
with O
fish O
Hg B
tissue O
concentrations O
. O

Additionally O
, O
the O
authors O
found O
that O
M O
. O
beryllina O
was O
more O
sensitive O
to O
dietary O
MeHg B
exposure O
than O
C O
. O
variegatus O
. O

Both O
species O
showed O
some O
decreases O
in O
growth O
related O
to O
MeHg B
exposure O
, O
although O
these O
patterns O
were O
not O
consistent O
among O
treatments O
. O

Overall O
, O
C O
. O
variegatus O
and O
M O
. O
beryllina O
were O
found O
to O
have O
a O
high O
tolerance O
for O
dietary O
MeHg B
exposure O
. O

If O
fish O
occupying O
low O
trophic O
levels O
are O
capable O
of O
surviving O
with O
high O
Hg B
body O
burdens O
, O
this O
tolerance O
has O
important O
implications O
for O
Hg B
exposure O
of O
organisms O
occupying O
higher O
trophic O
levels O
. O

N B
- O
terminal O
sequencing O
indicated O
that O
pro O
- O
BMP O
- O
2 O
was O
cleaved O
by O
FSAP O
at O
the O
canonical O
PC O
cleavage O
site O
, O
giving O
rise O
to O
mature O
BMP O
- O
2 O
( O
Arg O
( O
282 O
) O
v O
Gln B
( O
283 O
) O
) O
, O
as O
well O
as O
in O
the O
N B
- O
terminal O
heparin O
binding O
region O
of O
mature O
BMP O
- O
2 O
, O
generating O
a O
truncated O
mature O
BMP O
- O
2 O
peptide O
( O
Arg O
( O
289 O
) O
v O
Lys B
( O
290 O
) O
) O
. O

Similarly O
, O
mature O
BMP O
- O
2 O
was O
also O
cleaved O
to O
a O
truncated O
peptide O
within O
its O
N B
- O
terminal O
region O
( O
Arg O
( O
289 O
) O
v O
Lys B
( O
290 O
) O
) O
. O

To O
unravel O
the O
role O
of O
doping O
in O
iron B
- O
based O
superconductors O
, O
we O
investigated O
the O
in O
- O
plane O
resistivity O
of O
BaFe O
( O
2 O
) O
As O
( O
2 O
) O
doped O
at O
one O
of O
the O
three O
different O
lattice O
sites O
, O
Ba O
( O
Fe O
( O
1 O
- O
x O
) O
Co O
( O
x O
) O
) O
( O
2 O
) O
As O
( O
2 O
) O
, O
BaFe O
( O
2 O
) O
( O
As O
( O
1 O
- O
x O
) O
P O
( O
x O
) O
) O
( O
2 O
) O
, O
and O
Ba O
( O
1 O
- O
x O
) O
K O
( O
x O
) O
Fe O
( O
2 O
) O
As O
( O
2 O
) O
, O
focusing O
on O
the O
doping O
effect O
in O
the O
low O
- O
temperature O
antiferromagnetic O
/ O

Objective O
: O
We O
used O
this O
system O
to O
analyze O
suitable O
formulas O
for O
the O
production O
of O
orodispersible O
ibuprofen B
tablets O
. O

Results O
: O
The O
results O
indicated O
that O
production O
of O
ibuprofen B
tablets O
by O
DC O
would O
require O
improvements O
in O
the O
dimension O
and O
compressibility O
factors O
of O
the O
active O
pharmaceutical O
ingredient O
. O

The O
expert O
system O
analysis O
provided O
the O
specific O
percentage O
of O
disintegrant O
needed O
to O
blend O
with O
ibuprofen B
and O
a O
standardized O
formula O
of O
lubricants O
in O
order O
to O
obtain O
a O
powder O
mix O
that O
would O
successfully O
produce O
tablets O
by O
DC O
. O

Efficient O
two O
- O
electron O
reduction O
of O
dioxygen B
to O
hydrogen B
peroxide I
with O
one O
- O
electron O
reductants O
with O
a O
small O
overpotential O
catalyzed O
by O
a O
cobalt O
chlorin O
complex O
. O

A O
cobalt O
chlorin O
complex O
( O
Co O
( O
II O
) O
( O
Ch O
) O
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen B
( O
O B
( I
2 I
) I
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene B
derivatives O
) O
to O
produce O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
in O
the O
presence O
of O
perchloric O
acid O
( O
HClO O
( O
4 O
) O
) O
in O
benzonitrile B
( O
PhCN O
) O
at O
298 O
K O
. O

The O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
by O
1 O
, O
1 O
' O
- O
dibromoferrocene O
( O
Br O
( O
2 O
) O
Fc O
) O
was O
catalyzed O
by O
Co O
( O
II O
) O
( O
Ch O
) O
, O
whereas O
virtually O
no O
reduction O
of O
O B
( I
2 I
) I
occurred O
with O
Co O
( O
II O
) O
( O
OEP O
) O
. O

In O
addition O
, O
Co O
( O
II O
) O
( O
Ch O
) O
is O
more O
stable O
than O
Co O
( O
II O
) O
( O
OEP O
) O
, O
where O
the O
catalytic O
turnover O
number O
( O
TON O
) O
of O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
catalyzed O
by O
Co O
( O
II O
) O
( O
Ch O
) O
exceeded O
30000 O
. O

The O
detailed O
kinetic O
studies O
have O
revealed O
that O
the O
rate O
- O
determining O
step O
in O
the O
catalytic O
cycle O
is O
the O
proton O
- O
coupled O
electron O
transfer O
reduction O
of O
O B
( I
2 I
) I
with O
the O
protonated O
Co O
( O
II O
) O
( O
Ch O
) O
( O
[ O
Co O
( O
II O
) O
( O
ChH O
) O
] O
( O
+ O
) O
) O
that O
is O
produced O
by O
facile O
electron O
- O
transfer O
reduction O
of O
[ O
Co O
( O
III O
) O
( O
ChH O
) O
] O
( O
2 O
+ O
) O
by O
ferrocene B
derivative O
in O
the O
presence O
of O
HClO O
( O
4 O
) O
. O

Such O
a O
positive O
shift O
of O
[ O
Co O
( O
III O
) O
( O
Ch O
) O
] O
( O
+ O
) O
by O
protonation O
resulted O
in O
enhancement O
of O
the O
catalytic O
reactivity O
of O
[ O
Co O
( O
III O
) O
( O
ChH O
) O
] O
( O
2 O
+ O
) O
for O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
with O
a O
lower O
overpotential O
as O
compared O
with O
that O
of O
[ O
Co O
( O
III O
) O
( O
OEP O
) O
] O
( O
+ O
) O
. O

Binary O
diffusion O
coefficients O
for O
mixtures O
of O
ionic O
liquids O
[ O
EMIM O
] O
[ O
N O
( O
CN O
) O
2 O
] O
, O
[ O
EMIM O
] O
[ O
NTf2 O
] O
, O
and O
[ O
HMIM O
] O
[ O
NTf2 O
] O
with O
acetone B
and O
ethanol B
by O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

trifluoromethylsulfo O
) O
imide O
) O
with O
acetone O
and O
ethanol B
were O
studied O
in O
dependence O
on O
composition O
in O
the O
temperature O
range O
from O
283 O
. O
15 O
to O
323 O
. O
15 O
K O
, O
applying O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

Mutual O
diffusivities O
were O
found O
to O
be O
lower O
for O
the O
mixtures O
with O
ethanol B
than O
for O
those O
with O
acetone B
, O
which O
could O
be O
related O
to O
the O
formation O
of O
hydrogen B
bonds O
between O
ethanol B
and O
the O
ions O
. O

For O
the O
mixtures O
of O
[ O
EMIM O
] O
[ O
NTf2 O
] O
with O
ethanol B
, O
however O
, O
a O
minimum O
of O
the O
mutual O
diffusivities O
was O
found O
in O
the O
ethanol B
mole O
fraction O
range O
from O
0 O
. O
7 O
to O
0 O
. O
8 O
, O
which O
may O
hint O
at O
the O
vicinity O
of O
a O
critical O
demixing O
point O
. O

In O
the O
present O
review O
, O
marine O
algal O
compounds O
( O
phlorotannins B
, O
sulfated O
polysaccharides O
and O
tyrosinase O
inhibitors O
) O
have O
been O
discussed O
toward O
cosmeceutical O
application O
. O

Organic O
anion O
transporter O
3 O
interacts O
selectively O
with O
lipophilic O
beta B
- I
lactam I
antibiotics O
. O

Some O
beta B
- I
lactam I
antibiotics O
interact O
with O
Oat3 O
, O
and O
penicillin O
G O
exhibits O
a O
strong O
dependence O
on O
Oat3 O
for O
renal O
elimination O
. O

However O
, O
over O
80 O
beta B
- I
lactams I
exist O
, O
and O
many O
have O
not O
been O
assessed O
for O
an O
interaction O
with O
Oat3 O
. O

Moreover O
, O
beta B
- I
lactams I
continue O
to O
receive O
U O
. O
S O
. O

This O
study O
identified O
new O
beta B
- I
lactam I
- O
Oat3 O
interactions O
, O
provided O
a O
head O
- O
to O
- O
head O
comparison O
with O
Oat1 O
, O
and O
characterized O
the O
physicochemical O
determinants O
of O
affinity O
for O
Oat3 O
. O

Of O
26 O
beta B
- I
lactams I
tested O
, O
12 O
were O
clear O
inhibitors O
of O
Oat3 O
, O
and O
14 O
exhibited O
poor O
interactions O
. O

Oat1 O
demonstrated O
a O
poor O
interaction O
with O
most O
beta B
- I
lactams I
. O

That O
is O
, O
inhibitors O
had O
nearly O
40 O
% O
fewer O
hydrogen B
bond O
donors O
( O
P O
< O
0 O
. O
001 O
) O
, O
a O
lower O
total O
polar O
surface O
area O
( O
P O
< O
0 O
. O
05 O
) O
, O
and O
greater O
lipophilicity O
( O
LogP O
of O
inhibitors O
, O
+ O
1 O
. O
41 O
; O
noninhibitors O
, O
- O
1 O
. O
54 O
; O
P O
< O
0 O
. O
001 O
) O
. O

Pharmacophore O
mapping O
revealed O
a O
prohibitive O
hydrogen B
bond O
donor O
group O
in O
noninhibitors O
adjacent O
to O
a O
hydrophobic O
moiety O
that O
was O
important O
for O
binding O
to O
Oat3 O
. O

These O
findings O
indicate O
that O
Oat3 O
recognizes O
lipophilic O
beta B
- I
lactams I
more O
readily O
. O

Moreover O
, O
this O
study O
has O
potential O
implications O
for O
designing O
beta B
- I
lactams I
to O
avoid O
renal O
accumulation O
or O
brain O
efflux O
via O
Oat3 O
. O

Theoretical O
design O
and O
experimental O
implementation O
of O
Ag B
/ O
Au B
electrodes O
for O
the O
electrochemical O
reduction O
of O
nitrate B
. O

The O
current O
imbalance O
in O
the O
biogeochemical O
cycle O
of O
nitrogen B
is O
as O
serious O
as O
that O
of O
carbon B
. O

One O
way O
to O
mitigate O
this O
problem O
is O
through O
the O
electrochemical O
reduction O
of O
nitrates B
under O
mild O
conditions O
, O
which O
is O
an O
appealing O
though O
not O
fully O
understood O
process O
. O

Here O
we O
thoroughly O
analyse O
the O
adsorption O
energy O
of O
nitrate B
with O
DFT O
calculations O
on O
various O
surface O
facets O
of O
pure O
Au B
, O
Ag B
, O
and O
their O
near O
- O
surface O
and O
surface O
alloys O
, O
as O
the O
adsorption O
and O
subsequent O
reduction O
of O
nitrate B
are O
thought O
to O
be O
rate O
limiting O
in O
the O
electrocatalytic O
reaction O
. O

The O
observed O
systematic O
trends O
allow O
prediction O
of O
the O
surface O
with O
highest O
electrocatalytic O
activity O
for O
the O
reduction O
of O
nitrate B
. O

This O
prediction O
was O
verified O
experimentally O
by O
depositing O
sub O
- O
monolayer O
amounts O
of O
Ag B
on O
polycrystalline O
Au B
electrodes O
. O

We O
observe O
a O
well O
- O
defined O
volcano O
curve O
which O
correlates O
the O
amount O
of O
Ag B
deposited O
on O
the O
surface O
with O
the O
current O
density O
at O
a O
fixed O
potential O
, O
with O
the O
peak O
activity O
around O
2 O
/ O
3 O
ML O
Ag B
surface O
coverage O
. O

The O
electrocatalytic O
activity O
and O
stability O
of O
the O
bimetallic O
Ag B
- O
Au B
systems O
, O
found O
through O
the O
interplay O
of O
theoretical O
modelling O
and O
empirical O
observations O
, O
serve O
as O
a O
clear O
example O
for O
the O
rational O
design O
of O
novel O
catalytic O
materials O
and O
confirm O
the O
key O
role O
that O
the O
adsorption O
of O
nitrate B
plays O
in O
the O
overall O
nitrate B
reduction O
rate O
. O

The O
tissue O
- O
specific O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
in O
two O
predator O
fish O
species O
( O
redtail O
catfish O
and O
oscar O
fish O
) O
feeding O
on O
the O
same O
prey O
( O
tiger O
barb O
) O
that O
was O
exposed O
to O
technical O
pentabrominated O
diphenyl O
ether O
( O
DE O
- O
71 O
) O
in O
the O
laboratory O
were O
investigated O
. O

The O
trends O
in O
the O
wet O
- O
weight O
tissue O
concentration O
of O
PBDEs B
in O
two O
predatory O
fish O
species O
suggested O
that O
the O
tissue O
distribution O
of O
PBDEs B
occurs O
through O
a O
series O
of O
events O
involving O
passive O
diffusion O
to O
the O
lipid O
compartment O
. O

A O
comparison O
of O
the O
fugacities O
of O
PBDEs B
in O
various O
tissues O
and O
in O
the O
serum O
revealed O
that O
the O
liver O
, O
gill O
, O
and O
perivisceral O
adipose O
tissue O
readily O
achieved O
equilibrium O
with O
the O
serum O
, O
but O
the O
muscle O
, O
kidney O
, O
and O
intestine O
exhibited O
the O
potential O
to O
accumulate O
PBDEs B
. O

The O
lower O
fugacities O
of O
PBDEs B
in O
the O
intestine O
may O
have O
significance O
in O
the O
transportation O
of O
PBDEs B
from O
prey O
to O
predatory O
fish O
. O

No O
tissue O
- O
specific O
differences O
in O
PBDE B
congener O
profiles O
were O
found O
, O
while O
interspecies O
differences O
in O
PBDE B
profiles O
were O
evident O
. O

The O
difference O
in O
profiles O
between O
two O
species O
could O
be O
attributed O
to O
species O
- O
specific O
debromination O
of O
PBDE B
. O

No O
metabolic O
debromination O
of O
PBDE B
was O
observed O
in O
redtail O
catfish O
, O
but O
extensive O
debromination O
of O
PBDEs B
occurred O
in O
oscar O
fish O
. O

Several O
hydroxylated O
PBDEs O
( O
OH B
- I
PBDEs I
) O
were O
detected O
in O
serum O
samples O
from O
the O
two O
fish O
species O
, O
but O
no O
methoxylated O
PBDEs B
were O
found O
. O

The O
similarities O
in O
the O
OH B
- I
PBDE I
congener O
profile O
and O
the O
ratio O
of O
OH B
- I
PBDEs I
to O
total O
PBDEs B
between O
the O
two O
fish O
species O
indicated O
that O
the O
hydroxylation O
of O
PBDEs B
might O
not O
be O
species O
- O
specific O
. O

The O
initial O
fragment O
hits O
were O
thoroughly O
validated O
biophysically O
by O
isothermal O
titration O
calorimetry O
( O
ITC O
) O
and O
NMR O
techniques O
and O
observed O
by O
X O
- O
ray O
crystallography O
to O
bind O
in O
a O
shallow O
surface O
pocket O
that O
is O
occupied O
in O
the O
native O
complex O
by O
the O
side O
chain O
of O
a O
phenylalanine B
from O
the O
conserved O
FxxA O
interaction O
motif O
found O
in O
BRCA2 O
. O

Lead O
( O
Pb B
) O
is O
a O
highly O
toxic O
metal O
that O
can O
induce O
oxidative O
stress O
and O
affect O
the O
immune O
system O
by O
modifying O
the O
expression O
of O
immunomodulator O
- O
related O
genes O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
association O
between O
Pb B
exposure O
and O
the O
transcriptional O
profiles O
of O
some O
cytokines O
, O
as O
well O
as O
the O
relationship O
between O
Pb B
exposure O
and O
changes O
in O
oxidative O
stress O
biomarkers O
observed O
in O
the O
spleen O
of O
wild O
ungulates O
exposed O
to O
mining O
pollution O
. O

Red O
deer O
and O
wild O
boar O
from O
the O
mining O
area O
studied O
had O
higher O
spleen O
, O
liver O
, O
and O
bone O
Pb B
levels O
than O
controls O
, O
indicating O
a O
chronic O
exposure O
to O
Pb B
pollution O
. O

Such O
exposure O
caused O
a O
depletion O
of O
spleen O
glutathione B
levels O
in O
both O
species O
and O
disrupted O
the O
activity O
of O
antioxidant O
enzymes O
, O
suggesting O
the O
generation O
of O
oxidative O
stress O
conditions O
. O

These O
results O
indicate O
that O
environmental O
exposure O
to O
Pb B
may O
alter O
immune O
responses O
in O
wild O
ungulates O
exposed O
to O
mining O
pollution O
. O

However O
, O
evidence O
of O
direct O
relationships O
between O
Pb B
- O
mediated O
oxidative O
stress O
and O
the O
changes O
detected O
in O
immune O
responses O
were O
not O
found O
. O

Further O
research O
is O
needed O
to O
evaluate O
the O
immunotoxic O
potential O
of O
Pb B
pollution O
, O
also O
considering O
the O
prevalence O
of O
chronic O
infectious O
diseases O
in O
wildlife O
in O
environments O
affected O
by O
mining O
activities O
. O

Electrocatalytic O
hydrogenation O
and O
deoxygenation O
of O
glucose B
on O
solid O
metal O
electrodes O
. O

This O
Full O
Paper O
addresses O
the O
electrocatalytic O
hydrogenation O
of O
glucose B
to O
sorbitol B
or O
2 O
- O
deoxysorbitol O
on O
solid O
metal O
electrodes O
in O
neutral O
media O
. O

Three O
groups O
of O
catalysts O
clearly O
show O
affinities O
toward O
: O
( O
1 O
) O
hydrogen B
formation O
[ O
on O
early O
transition O
metals O
( O
Ti B
, O
V B
, O
Cr B
, O
Mn B
, O
Zr O
, O
Nb O
, O
Mo B
, O
Hf B
, O
Ta B
, O
We O
, O
and O
Re B
) O
and O
platinum B
group O
metals O
( O
Ru B
, O
Rh B
, O
Ir B
, O
and O
Pt B
) O
] O
, O
( O
2 O
) O
sorbitol B
formation O
[ O
on O
late O
transition O
metals O
( O
Fe B
, O
Co B
, O
Ni B
, O
Cu B
, O
Pd B
, O
Au B
, O
and O
Ag B
) O
and O
Al B
( O
sp O
metal O
) O
] O
, O
and O
( O
3 O
) O
sorbitol B
and O
2 O
- O

deoxysorbitol O
formation O
[ O
on O
post O
- O
transition O
metals O
( O
In B
, O
Sn B
, O
Sb O
, O
Pb B
, O
and O
Bi O
) O
, O
as O
well O
as O
Zn B
and O
Cd B
( O
d O
metals O
) O
] O
. O

Ni B
shows O
the O
lowest O
overpotential O
for O
the O
onset O
of O
sorbitol B
formation O
( O
- O
0 O
. O
25 O
V O
) O
whereas O
Pb B
generates O
sorbitol B
with O
the O
highest O
yield O
( O
< O
0 O
. O
7 O
mM O
cm O
( O
- O
2 O
) O
) O
. O

Different O
from O
a O
smooth O
Pt B
electrode O
, O
a O
large O
- O
surface O
- O
area O
Pt B
/ O
C B
electrode O
hydrogenates O
glucose B
to O
sorbitol B
from O
- O
0 O
. O
21 O
V O
with O
relatively O
low O
current O
. O

The O
mechanism O
to O
form O
2 O
- O
deoxysorbitol O
from O
glucose B
and O
/ O
or O
fructose B
is O
discussed O
according O
to O
the O
observed O
reaction O
products O
. O

NADPH B
oxidases O
transport O
electrons O
from O
cytosolic O
NADPH B
through O
biological O
membranes O
to O
generate O
reactive O
oxygen B
species O
. O

NADPH B
oxidase O
4 O
, O
broadly O
expressed O
in O
humans O
, O
is O
an O
interesting O
pharmacological O
target O
, O
since O
its O
activity O
is O
deregulated O
in O
several O
diseases O
, O
including O
pulmonary O
fibrosis O
, O
diabetic O
nephropathy O
, O
and O
cardiac O
hypertrophy O
. O

Whereas O
several O
candidate O
NADPH B
oxidase O
4 O
inhibitors O
were O
recently O
described O
, O
most O
of O
these O
compounds O
are O
either O
unspecific O
or O
toxic O
. O

Here O
we O
set O
out O
to O
identify O
new O
NADPH B
oxidase O
4 O
inhibitors O
from O
edible O
plants O
, O
in O
an O
attempt O
to O
decrease O
the O
number O
of O
hits O
with O
toxic O
side O
effects O
. O

We O
screened O
a O
compound O
library O
prepared O
from O
edible O
plants O
for O
new O
bioactives O
with O
the O
ability O
to O
inhibit O
the O
activity O
of O
NADPH B
oxidase O
4 O
. O

Using O
both O
cell O
- O
based O
and O
cell O
- O
free O
assays O
, O
we O
identified O
several O
compounds O
with O
significant O
inhibitory O
activity O
towards O
NADPH B
oxidase O
4 O
. O

For O
selected O
compounds O
, O
the O
activity O
profile O
towards O
NADPH B
oxidase O
2 O
and O
NADPH B
oxidase O
5 O
was O
established O
, O
and O
controls O
were O
carried O
out O
to O
exclude O
general O
reactive O
oxygen B
species O
scavengers O
. O

A O
number O
of O
promising O
NADPH B
oxidase O
4 O
inhibitors O
from O
edible O
plants O
was O
identified O
and O
characterised O
. O

Several O
new O
chemical O
entities O
are O
disclosed O
which O
act O
as O
NADPH B
oxidase O
4 O
inhibitors O
, O
and O
the O
efficacies O
of O
our O
best O
hits O
, O
in O
particular O
several O
diarylheptanoids O
and O
lignans B
, O
are O
comparable O
to O
the O
best O
available O
pharmacological O
NADPH B
oxidase O
4 O
inhibitors O
. O

These O
findings O
will O
provide O
valuable O
tools O
to O
study O
mechanisms O
of O
NADPH B
oxidase O
inhibition O
. O

Controlled O
synthesis O
of O
amino B
acid I
- O
based O
pH O
- O
responsive O
chiral O
polymers O
and O
self O
- O
assembly O
of O
their O
block O
copolymers O
. O

Leucine B
/ O
isoleucine B
side O
chain O
polymers O
are O
of O
interest O
due O
to O
their O
hydrophobicity O
and O
reported O
role O
in O
the O
formation O
of O
alpha O
- O
helical O
structures O
. O

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc O
- O
L O
- O
leucine O
methacryloyloxyethyl O
ester O
( O
Boc O
- O
L O
- O
Leu O
- O
HEMA O
, O
1a O
) O
, O
Boc O
- O
L O
- O
leucine O
acryloyloxyethyl O
ester O
( O
Boc O
- O
L O
- O
Leu O
- O
HEA O
, O
1b O
) O
, O
Boc O
- O
L O
- O
isoleucine O
methacryloyloxyethyl O
ester O
( O
Boc O
- O
L O
- O

Deprotection O
of O
Boc O
groups O
in O
the O
homopolymers O
and O
block O
copolymers O
under O
acidic O
conditions O
produced O
cationic O
, O
pH O
- O
responsive O
polymers O
with O
primary B
amine I
moieties O
at O
the O
side O
chains O
. O

The O
side O
chain O
amine B
functionality O
instills O
pH O
- O
responsive O
behavior O
, O
which O
makes O
these O
cationic O
polymers O
attractive O
candidates O
for O
drug O
delivery O
applications O
, O
as O
well O
as O
for O
conjugation O
of O
biomolecules O
. O

DFT O
calculations O
show O
that O
mercaptopropionic O
acid O
( O
MPA B
) O
and O
cysteine B
( O
Cys B
) O
exhibit O
characteristic O
binding O
configurations O
on O
TiO B
( I
2 I
) I
surfaces O
. O

This O
information O
is O
used O
to O
optimize O
the O
cell O
assembly O
process O
, O
yielding O
Cys B
- O
based O
cells O
that O
significantly O
outperform O
MPA B
cells O
, O
and O
reach O
power O
conversion O
efficiencies O
( O
PCE O
) O
as O
high O
as O
2 O
. O
7 O
% O
under O
AM O
1 O
. O
5 O
illumination O
. O

While O
no O
nonsynonymous O
substitutions O
were O
found O
in O
either O
alpha O
globin O
gene O
, O
three O
amino B
acid I
substitutions O
were O
observed O
in O
the O
beta O
( O
A O
) O
globin O
. O

This O
stepwise O
colonization O
pattern O
accompanied O
by O
polarized O
beta O
( O
A O
) O
globin O
amino B
acid I
replacements O
suggest O
that O
ruddy O
ducks O
first O
acclimatized O
or O
adapted O
to O
the O
Andean O
highlands O
and O
then O
again O
to O
the O
lowlands O
. O

Inositol O
hexanicotinate O
( O
IHN O
) O
is O
an O
ester O
of O
the O
anti O
- O
hyperlipidemic O
drug O
nicotinic B
acid I
( O
NA O
) O
. O

ATP B
- O
depletion O
, O
reducing O
skeletal O
junction O
phosphorylation O
in O
RBC O
cells O
, O
leads O
to O
membrane O
stiffening O
. O

Topography O
and O
mechanical O
mapping O
of O
single O
components O
at O
the O
cytoplasmic O
face O
reveal O
that O
, O
surprisingly O
, O
spectrin O
phosphorylation O
by O
ATP B
softens O
individual O
filaments O
. O

The O
percentage O
of O
patients O
with O
detectable O
bisphenol B
A I
( O
BPA B
) O
concentrations O
was O
significantly O
higher O
in O
the O
infertile O
patients O
compared O
with O
fertile O
subjects O
. O

No O
significant O
difference O
was O
found O
between O
the O
groups O
with O
regard O
to O
perfluorooctane B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctanoic B
acid I
( O
PFOA B
) O
, O
mono O
- O
ethylhexyl O
phthalate O
( O
MEHP B
) O
and O
di B
- I
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
concentrations O
. O

Among O
infertile O
women O
, O
the O
mean O
expression O
of O
estrogen B
receptor O
alpha O
( O
ER O
alpha O
) O
and O
beta O
( O
Er O
beta O
) O
, O
androgen B
receptor O
( O
AR O
) O
and O
pregnane B
X O
receptor O
( O
PXR O
) O
was O
significantly O
higher O
than O
fertile O
patients O
. O

The O
mean O
expression O
of O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
and O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
( O
PPAR O
gamma O
) O
did O
not O
show O
significant O
differences O
between O
two O
groups O
. O

Among O
them O
, O
deoxynivalenol B
( O
DON B
) O
and O
zearalenone B
( O
ZEN O
) O
are O
widespread O
worldwide O
contaminants O
of O
cereal O
commodities O
and O
are O
ranked O
as O
the O
most O
important O
chronic O
dietary O
risk O
factors O
. O

This O
study O
demonstrates O
for O
the O
first O
time O
that O
DON B
and O
ZEN O
are O
effectively O
deconjugated O
by O
the O
human O
colonic O
microbiota O
, O
releasing O
their O
toxic O
aglycones O
and O
generating O
yet O
unidentified O
catabolites O
. O

Anti O
- O
inflammatory O
diterpenoids B
from O
Croton O
tonkinensis O
. O

Phytochemical O
investigation O
of O
the O
methanolic O
extract O
of O
Croton O
tonkinensis O
afforded O
two O
known O
kauranes O
( O
1 O
, O
2 O
) O
, O
eight O
new O
ent O
- O
kauranes O
( O
3 O
- O
10 O
) O
, O
and O
16 O
known O
ent B
- I
kaurane I
- O
type O
diterpenoids B
( O
12 O
- O
27 O
) O
. O

Among O
the O
isolated O
compounds O
, O
ent O
- O
18 O
- O
acetoxykaur O
- O
16 O
- O
en O
- O
15 O
- O
one O
( O
20 O
) O
displayed O
the O
most O
significant O
inhibition O
of O
superoxide B
anion O
generation O
and O
elastase O
release O
. O

Quercetin B
ameliorate O
insulin O
resistance O
and O
up O
- O
regulates O
cellular O
antioxidants O
during O
oleic B
acid I
induced O
hepatic O
steatosis O
in O
HepG2 O
cells O
. O

Thus O
, O
we O
hypothesized O
that O
the O
hypolipidemic O
and O
antioxidant O
activity O
of O
quercetin B
would O
attenuate O
events O
leading O
to O
NAFLD O
. O

Addition O
of O
2 O
. O
0mM O
oleic B
acid I
( O
OA O
) O
into O
the O
culture O
media O
induced O
fatty O
liver O
condition O
in O
HepG2 O
cells O
by O
24h O
. O

It O
was O
marked O
by O
significant O
accumulation O
of O
lipid O
droplets O
as O
determined O
by O
Oil O
- O
Red O
- O
O O
( O
ORO O
) O
based O
colorimetric O
assay O
, O
increased O
triacylglycerol B
( O
TAG B
) O
and O
increased O
lipid O
peroxidation O
. O

OA O
induced O
insulin O
resistance O
which O
was O
evident O
by O
inhibition O
of O
glucose B
uptake O
and O
cell O
proliferation O
. O

Quercetin B
( O
10 O
mu O
M O
) O
increased O
cell O
proliferation O
by O
3 O
. O
05 O
folds O
with O
decreased O
TAG B
content O
( O
45 O
% O
) O
and O
was O
effective O
in O
increasing O
insulin O
mediated O
glucose B
uptake O
by O
2 O
. O
65 O
folds O
. O

The O
intracellular O
glutathione B
content O
was O
increased O
by O
2 O
. O
0 O
folds O
without O
substantial O
increase O
in O
GSSG B
content O
. O

Quercetin B
( O
10 O
mu O
M O
) O
decreased O
TNF O
- O
alpha O
and O
IL O
- O
8 O
by O
59 O
. O
74 O
% O
and O
41 O
. O
11 O
% O
respectively O
and O
inhibited O
generation O
of O
lipid O
peroxides B
by O
50 O
. O
5 O
% O
. O

In O
addition O
, O
RT O
- O
PCR O
results O
confirmed O
quercetin B
( O
10 O
mu O
M O
) O
inhibited O
TNF O
- O
alpha O
gene O
expression O
. O

Further O
, O
superoxide B
dismutase O
, O
catalase O
and O
glutathione B
peroxidase O
activities O
were O
increased O
by O
1 O
. O
68 O
, O
2 O
. O
19 O
and O
1 O
. O
71 O
folds O
respectively O
. O

Albumin O
and O
urea B
content O
was O
increased O
while O
the O
alanine B
aminotransferase O
( O
ALAT O
) O
activity O
was O
significantly O
decreased O
by O
quercetin B
. O

Hence O
, O
quercetin B
effectively O
reversed O
NAFLD O
symptoms O
by O
decreased O
triacyl O
glycerol O
accumulation O
, O
insulin O
resistance O
, O
inflammatory O
cytokine O
secretion O
and O
increased O
cellular O
antioxidants O
in O
OA O
induced O
hepatic O
steatosis O
in O
HepG2 O
cells O
. O

The O
male O
mammary O
gland O
: O
a O
target O
for O
the O
xenoestrogen O
bisphenol B
A I
. O

We O
also O
examined O
the O
effects O
of O
bisphenol B
A I
( O
BPA B
) O
, O
an O
estrogen B
mimic O
that O
alters O
development O
of O
the O
female O
mouse O
mammary O
gland O
. O

BPA B
was O
administered O
at O
a O
range O
of O
environmentally O
relevant O
doses O
( O
0 O
. O
25 O
- O
250 O
mu O
g O
/ O
kg O
/ O
day O
) O
to O
pregnant O
and O
lactating O
mice O
and O
then O
the O
mammary O
glands O
of O
male O
offspring O
were O
examined O
at O
several O
periods O
in O
adulthood O
. O

We O
observed O
age O
- O
and O
dose O
- O
specific O
effects O
on O
mammary O
gland O
morphology O
, O
indicating O
that O
perinatal O
BPA B
exposures O
alter O
the O
male O
mammary O
gland O
in O
adulthood O
. O

Prednisolone B
tablets O
were O
coated O
with O
a O
double O
- O
coating O
formulation O
by O
applying O
an O
inner O
layer O
composed O
of O
EUDRAGIT B
( O
R O
) O
S O
neutralised O
to O
pH O
8 O
. O
0 O
and O
a O
buffer O
salt O
( O
10 O
% O
KH O
( O
2 O
) O
PO O
( O
4 O
) O
) O
, O
which O
was O
overcoated O
with O
layer O
of O
standard O
EUDRAGIT B
( O
R O
) O
S O
organic O
solution O
. O

For O
comparison O
, O
a O
single O
coating O
system O
was O
produced O
by O
applying O
the O
same O
amount O
of O
EUDRAGIT B
( O
R O
) O
S O
organic O
solution O
on O
the O
tablet O
cores O
. O

Dissolution O
tests O
on O
the O
tablets O
were O
carried O
out O
using O
USP O
II O
apparatus O
in O
0 O
. O
1N O
HCl B
for O
2h O
and O
subsequently O
in O
pH O
7 O
. O
4 O
Krebs O
bicarbonate O
buffer O
. O

There O
was O
no O
drug O
release O
from O
the O
single O
- O
coated O
or O
double O
- O
coated O
tablets O
in O
0 O
. O
1N O
HCl B
for O
2h O
. O

The O
in O
vivo O
disintegration O
of O
the O
single O
- O
coated O
EUDRAGIT B
( O
R O
) O
S O
tablets O
in O
the O
large O
intestine O
was O
erratic O
. O

The O
accelerated O
in O
vivo O
disintegration O
of O
the O
double O
- O
coating O
EUDRAGIT B
( O
R O
) O
S O
system O
can O
overcome O
the O
limitations O
of O
conventional O
enteric O
coatings O
targeting O
the O
colon O
and O
avoid O
the O
pass O
- O
through O
of O
intact O
tablets O
. O

Moreover O
, O
Krebs O
bicarbonate B
buffer O
has O
the O
ability O
to O
discriminate O
between O
formulations O
designed O
to O
target O
the O
ileo O
- O
colonic O
region O
. O

Single O
isoflavones B
have O
been O
shown O
to O
affect O
adipocyte O
differentiation O
, O
but O
knowledge O
on O
the O
effect O
of O
dietary O
relevant O
mixtures O
of O
PEs O
, O
including O
for O
instance O
lignans O
, O
is O
lacking O
. O

In O
the O
current O
study O
dietary O
relevant O
mixtures O
of O
isoflavones B
and O
their O
metabolites O
, O
lignans B
and O
their O
metabolites O
, O
coumestrol O
, O
and O
a O
mixture O
containing O
all O
of O
them O
, O
were O
examined O
for O
effects O
on O
adipogenesis O
in O
3T3 O
- O
L1 O
adipocytes O
, O
as O
well O
as O
tested O
for O
their O
PPAR O
gamma O
activating O
abilities O
. O

The O
results O
showed O
that O
mixtures O
of O
isoflavonoid O
parent O
compounds O
and O
metabolites O
, O
respectively O
, O
a O
mixture O
of O
lignan B
metabolites O
, O
as O
well O
as O
coumestrol O
concentration O
- O
dependently O
inhibited O
adipocyte O
differentiation O
. O

A O
novel O
metabotropic O
glutamate B
receptor O
5 O
positive O
allosteric O
modulator O
acts O
at O
a O
unique O
site O
and O
confers O
stimulus O
bias O
to O
mGlu5 O
signaling O
. O

Metabotropic O
glutamate B
receptor O
5 O
( O
mGlu5 O
) O
is O
a O
target O
for O
the O
treatment O
of O
central O
nervous O
system O
( O
CNS O
) O
disorders O
, O
such O
as O
schizophrenia O
and O
Alzheimer O
' O
s O
disease O
. O

Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP B
( O
2 O
- O
Methyl O
- O
6 O
- O
( O
phenylethynyl O
) O
pyridine O
) O
binding O
site O
. O

Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
( O
LTD O
/ O
LTP O
) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP B
site O
PAMs O
. O

The O
stereoisomer O
( B
+ I
) I
- I
naloxone I
potentiates O
G O
- O
protein O
coupling O
and O
feeding O
associated O
with O
stimulation O
of O
mu O
opioid O
receptors O
in O
the O
parabrachial O
nucleus O
. O

Previous O
studies O
proposed O
that O
mu O
- O
opioid O
receptors O
can O
also O
stimulate O
adenylate B
cyclase O
due O
to O
an O
initial O
transient O
coupling O
to O
Gs O
- O
proteins O
. O

Treatment O
with O
ultra O
- O
low O
doses O
of O
the O
nonselective O
opioid O
antagonist O
( B
- I
) I
- I
naloxone I
or O
its O
inactive O
enantiomer O
( B
+ I
) I
- I
naloxone I
blocks O
this O
excitatory O
effect O
and O
enhances O
Gi O
- O
coupling O
. O

Pretreatment O
with O
( B
- I
) I
- I
naloxone I
blocks O
this O
effect O
. O

We O
used O
this O
parabrachial O
circuit O
as O
a O
model O
to O
assess O
cellular O
actions O
of O
ultra O
- O
low O
doses O
of O
( B
- I
) I
- I
naloxone I
and O
( B
+ I
) I
- I
naloxone I
in O
modifying O
the O
effects O
of O
DAMGO O
. O

Our O
results O
showed O
that O
an O
ultra O
- O
low O
concentration O
of O
( B
- I
) I
- I
naloxone I
( O
0 O
. O
001 O
nM O
) O
and O
several O
concentrations O
of O
( B
+ I
) I
- I
naloxone I
( O
0 O
. O
01 O
- O
10 O
nM O
) O
enhanced O
DAMGO O
- O
stimulated O
guanosine O
- O
5 O
' O
- O
0 O
- O
( O
gamma O
- O
thio O
) O
- O
triphosphate O
incorporation O
in O
parabrachial O
sections O
in O
vitro O
. O

In O
the O
present O
study O
, O
we O
show O
that O
( B
+ I
) I
- I
naloxone I
can O
potentiate O
DAMGO O
- O
induced O
feeding O
at O
doses O
at O
which O
( B
- I
) I
- I
naloxone I
was O
an O
antagonist O
. O

These O
results O
implicated O
( B
+ I
) I
- I
naloxone I
as O
a O
novel O
tool O
for O
studying O
mu O
- O
opioid O
receptor O
functions O
and O
suggest O
that O
( B
+ I
) I
- I
naloxone I
may O
have O
therapeutic O
value O
to O
enhance O
clinical O
actions O
of O
opiate O
drugs O
. O

An O
earlier O
study O
showed O
that O
CRBN O
negatively O
regulates O
the O
functional O
activity O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
in O
vitro O
by O
binding O
directly O
to O
the O
alpha O
1 O
subunit O
of O
the O
AMPK O
complex O
. O

Lineage O
- O
tracing O
studies O
using O
sequential O
administration O
of O
thymidine B
analogs O
, O
rat O
insulin O
2 O
promoter O
- O
driven O
cre O
- O
lox O
, O
and O
low O
- O
frequency O
ubiquitous O
cre O
- O
lox O
reveal O
that O
PDL O
does O
not O
convert O
progenitors O
to O
the O
beta O
- O
cell O
lineage O
. O

Obese O
LGALS3 O
( O
- O
/ O
- O
) O
mice O
have O
increased O
body O
weight O
, O
amount O
of O
total O
visceral O
adipose O
tissue O
, O
fasting O
blood O
glucose B
and O
insulin O
levels O
, O
HOMA O
- O
IR O
and O
markers O
of O
systemic O
inflammation O
compared O
to O
diet O
- O
matched O
WT O
animals O
. O

However O
, O
FaGHRKO O
mice O
have O
increases O
in O
all O
adipose O
depots O
with O
no O
improvements O
in O
measures O
of O
glucose B
homeostasis O
. O

However O
, O
removal O
of O
GHR O
in O
adipose O
tissue O
alone O
is O
not O
sufficient O
to O
increase O
levels O
of O
resistin O
or O
adiponectin O
and O
does O
not O
alter O
glucose B
metabolism O
. O

In O
the O
vasculature O
, O
insulin O
signaling O
plays O
a O
critical O
role O
in O
normal O
vascular O
function O
via O
endothelial O
cell O
nitric B
oxide I
production O
and O
modulation O
of O
Ca B
( I
2 I
+ I
) I
handling O
and O
sensitivity O
in O
vascular O
smooth O
muscle O
cells O
. O

In O
the O
overweight O
and O
obese O
individual O
, O
as O
well O
as O
in O
persons O
with O
hypertension O
, O
systemic O
and O
vascular O
insulin O
resistance O
often O
occur O
in O
concert O
with O
elevations O
in O
plasma O
aldosterone B
. O

Indeed O
, O
basic O
and O
clinical O
studies O
have O
demonstrated O
that O
elevated O
plasma O
aldosterone B
levels O
predict O
the O
development O
of O
insulin O
resistance O
and O
that O
aldosterone B
directly O
interferes O
with O
insulin O
signaling O
in O
vascular O
tissues O
. O

Furthermore O
, O
elevated O
plasma O
aldosterone B
levels O
are O
associated O
with O
increased O
heart O
attack O
and O
stroke O
risk O
. O

Conversely O
, O
renin O
- O
angiotensin O
- O
aldosterone B
system O
and O
mineralocorticoid O
receptor O
( O
MR O
) O
antagonism O
reduces O
cardiovascular O
risk O
in O
these O
patient O
populations O
. O

Recent O
and O
accumulating O
evidence O
in O
this O
area O
has O
implicated O
excessive O
Ser B
phosphorylation O
and O
proteosomal O
degradation O
of O
the O
docking O
protein O
, O
insulin O
receptor O
substrate O
, O
and O
enhanced O
signaling O
through O
hybrid O
insulin O
/ O
IGF O
- O
1 O
receptor O
as O
important O
mechanisms O
underlying O
aldosterone B
- O
mediated O
interruption O
of O
downstream O
vascular O
insulin O
signaling O
. O

Prevention O
or O
restoration O
of O
these O
changes O
via O
blockade O
of O
aldosterone B
action O
in O
the O
vascular O
wall O
with O
MR O
antagonists O
( O
i O
. O
e O
. O
, O
spironolactone B
, O
eplerenone O
) O
may O
therefore O
account O
for O
the O
clinical O
benefit O
of O
these O
compounds O
in O
obese O
and O
diabetic O
patients O
with O
cardiovascular O
disease O
. O

This O
review O
will O
highlight O
recent O
evidence O
supporting O
the O
hypothesis O
that O
aldosterone B
and O
MR O
signaling O
represent O
an O
ideal O
candidate O
pathway O
linking O
early O
promoters O
of O
diabetes O
, O
especially O
overnutrition O
and O
obesity O
, O
to O
vascular O
insulin O
resistance O
, O
dysfunction O
, O
and O
disease O
. O

Photocatalytic O
properties O
of O
graphdiyne O
and O
graphene B
modified O
TiO B
2 I
: O
from O
theory O
to O
experiment O
. O

The O
chemical O
structure O
and O
electronic O
properties O
of O
two O
- O
dimensional O
( O
2D O
) O
carbon B
- O
supported O
TiO B
2 I
, O
TiO O
2 O
- O
graphdiyne O
, O
and O
TiO O
2 O
- O
graphene O
composites O
have O
been O
studied O
by O
first O
- O
principles O
density O
functional O
theory O
. O

Calculation O
results O
show O
that O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne O
composites O
possess O
superior O
charge O
separation O
and O
oxidation O
properties O
, O
having O
the O
longest O
lifetimes O
of O
photoexcited O
carriers O
among O
all O
of O
the O
2D O
composites O
containing O
TiO B
2 I
of O
different O
facets O
. O

Our O
experimental O
results O
further O
proved O
that O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne O
composites O
could O
be O
a O
promising O
photocatalyst O
. O

For O
photocatalytic O
degradation O
of O
methylene B
blue I
, O
the O
rate O
constant O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne O
composite O
is O
1 O
. O
63 O
+ O
/ O
- O
0 O
. O
15 O
times O
that O
of O
the O
pure O
TiO B
2 I
( O
001 O
) O
and O
1 O
. O
27 O
+ O
/ O
- O
0 O
. O
12 O
times O
that O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphene B
composite O
. O

In O
vivo O
microdialysis O
for O
the O
evaluation O
of O
transfersomes O
as O
a O
novel O
transdermal O
delivery O
vehicle O
for O
cinnamic B
acid I
. O

Abstract O
In O
this O
study O
, O
cinnamic B
acid I
- O
loaded O
transfersomes O
were O
prepared O
and O
dermal O
microdialysis O
sampling O
was O
used O
in O
Sprague O
- O
Dawley O
rats O
to O
compare O
the O
amount O
of O
drug O
released O
into O
the O
skin O
using O
transfersomes O
as O
transdermal O
carriers O
with O
that O
released O
on O
using O
conventional O
liposomes O
. O

The O
formulation O
of O
cinnamic B
acid I
- O
loaded O
transfersomes O
was O
optimized O
by O
a O
uniform O
design O
through O
in O
vitro O
transdermal O
permeation O
studies O
. O

The O
fluxes O
of O
cinnamic B
acid I
from O
transfersomes O
were O
all O
higher O
than O
those O
from O
conventional O
liposomes O
, O
and O
the O
flux O
from O
the O
optimal O
transfersome O
formulation O
was O
3 O
. O
01 O
- O
fold O
higher O
than O
that O
from O
the O
conventional O
liposomes O
( O
p O
< O
0 O
. O
05 O
) O
. O

After O
the O
administration O
of O
drug O
- O
containing O
transfersomes O
and O
liposomes O
on O
abdominal O
skin O
regions O
of O
rats O
for O
a O
period O
of O
10 O
h O
, O
the O
C O
( O
max O
) O
of O
cinnamic B
acid I
from O
the O
compared O
liposomes O
was O
3 O
. O
21 O
+ O
/ O
- O
0 O
. O
25 O
mu O
g O
/ O
mL O
and O
that O
from O
the O
transfersomes O
was O
merely O
0 O
. O
59 O
+ O
/ O
- O
0 O
. O
02 O
mu O
g O
/ O
mL O
. O

The O
results O
suggest O
that O
transfersomes O
can O
be O
used O
as O
carriers O
to O
enhance O
the O
transdermal O
delivery O
of O
cinnamic B
acid I
, O
and O
that O
these O
vehicles O
may O
penetrate O
the O
skin O
in O
the O
complete O
form O
, O
given O
their O
significant O
deformability O
. O

Iontophoresis O
of O
amoxicillin B
and O
cefuroxime B
: O
rapid O
therapeutic O
concentrations O
in O
skin O
. O

Abstract O
Context O
: O
Amoxicillin B
( O
AMX O
) O
and O
cefuroxime B
( O
CFX O
) O
are O
antibiotics O
used O
often O
to O
treat O
skin O
bacterial O
infections O
. O

Methods O
: O
Iontophoresis O
was O
performed O
using O
a O
stainless O
steel O
electrode O
and O
a O
non O
- O
woven O
polypropylene B
pad O
. O

A O
well O
- O
trained O
support O
vector O
regression O
model O
based O
on O
mean O
impact O
value O
was O
used O
to O
identify O
lead O
active O
compounds O
on O
inhibiting O
the O
proliferation O
of O
the O
HeLa O
cells O
in O
curcuminoids B
from O
Curcuma O
longa O
L O
. O

Eight O
constituents O
possessing O
the O
high O
absolute O
mean O
impact O
value O
were O
identified O
to O
have O
significant O
cytotoxicity O
, O
and O
the O
cytotoxic O
effect O
of O
these O
constituents O
was O
partly O
confirmed O
by O
subsequent O
MTT B
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
) O
assays O
and O
previous O
reports O
. O

In O
the O
dosage O
range O
of O
0 O
. O
2 O
- O
211 O
. O
2 O
, O
0 O
. O
1 O
- O
140 O
. O
2 O
, O
0 O
. O
2 O
- O
149 O
. O
9 O
mu O
m O
, O
50 O
% O
inhibiting O
concentrations O
( O
IC50 O
) O
of O
curcumin B
, O
demethoxycurcumin O
, O
and O
bisdemethoxycurcumin O
were O
26 O
. O
99 O
+ O
/ O
- O
1 O
. O
11 O
, O
19 O
. O
90 O
+ O
/ O
- O
1 O
. O
22 O
, O
and O
35 O
. O
51 O
+ O
/ O
- O
7 O
. O
29 O
mu O
m O
, O
respectively O
. O

It O
was O
demonstrated O
that O
our O
method O
could O
successfully O
identify O
lead O
active O
compounds O
in O
curcuminoids B
from O
Curcuma O
longa O
L O
. O
prior O
to O
bioassay O
- O
guided O
separation O
. O

Visible O
light O
irradiation O
of O
a O
ruthenium B
( I
II I
) I
quinone B
- O
containing O
complex O
, O
[ O
( O
phen O
) O
( O
2 O
) O
Ru O
( O
phendione O
) O
] O
( O
2 O
+ O
) O
( O
1 O
( O
2 O
+ O
) O
) O
, O
where O
phendione O
= O
1 O
, O
10 O
- O
phenanthroline O
- O
5 O
, O
6 O
- O
dione O
, O
leads O
to O
DNA O
cleavage O
in O
an O
oxygen B
independent O
manner O
. O

A O
combination O
of O
NMR O
analyses O
, O
transient O
absorption O
spectroscopy O
, O
and O
fluorescence O
measurements O
in O
water O
and O
acetonitrile B
reveal O
that O
complex O
1 O
( O
2 O
+ O
) O
must O
be O
hydrated O
at O
the O
quinone B
functionality O
, O
giving O
[ O
( O
phen O
) O
( O
2 O
) O
Ru O
( O
phenH O
( O
2 O
) O
O O
) O
] O
( O
2 O
+ O
) O
( O
1H O
( O
2 O
) O
O O
( O
2 O
+ O
) O
, O
where O
phenH O
( O
2 O
) O
O O
= O
1 O
, O
10 O
- O
phenanthroline O
- O
6 O
- O
one O
- O
5 O
- O
diol O
) O
, O
in O
order O
to O
access O
a O
long O
- O
lived O
( O
3 O
) O

MLCT O
( O
hydrate O
) O
state O
( O
tau O
~ O
360 O
ns O
in O
H B
( I
2 I
) I
O I
) O
which O
is O
responsible O
for O
DNA O
cleavage O
. O

In O
effect O
, O
hydration O
at O
one O
of O
the O
carbonyl B
functions O
effectively O
eliminates O
the O
low O
- O
energy O
( O
3 O
) O
MLCT O
( O
SQ O
) O
state O
( O
Ru O
( O
III O
) O
phen O
- O
semiquinone O
radical O
anion O
) O
as O
the O
predominant O
nonradiative O
decay O
pathway O
. O

Whereas O
[ O
Ru O
( O
phen O
) O
( O
3 O
) O
] O
( O
2 O
+ O
) O
* O
does O
not O
show O
direct O
DNA O
cleavage O
, O
the O
deprotonated O
form O
of O
1H O
( O
2 O
) O
O O
( O
2 O
+ O
) O
* O
does O
via O
a O
proton O
- O
coupled O
electron O
transfer O
( O
PCET O
) O
mechanism O
where O
the O
peripheral O
basic O
oxygen B
sites O
act O
as O
the O
proton O
acceptor O
. O

Analysis O
of O
the O
small O
molecule O
byproducts O
of O
DNA O
scission O
supports O
the O
conclusion O
that O
cleavage O
occurs O
via O
H B
- O
atom O
abstraction O
from O
the O
sugar B
moieties O
, O
consistent O
with O
a O
PCET O
mechanism O
. O

Complex O
1 O
( O
2 O
+ O
) O
is O
a O
rare O
example O
of O
a O
ruthenium B
complex O
which O
' O
turns O
on O
' O
both O
reactivity O
and O
luminescence O
upon O
switching O
to O
a O
hydrated O
state O
. O

Increased O
protein O
sorption O
in O
poly B
( I
acrylic I
acid I
) I
- O
containing O
films O
through O
incorporation O
of O
comb O
- O
like O
polymers O
and O
film O
adsorption O
at O
low O
pH O
and O
high O
ionic O
strength O
. O

In O
the O
absence O
of O
added O
salt O
, O
alternating O
adsorption O
of O
5 O
bilayers O
of O
protonated O
poly O
( O
allylamine O
) O
( O
PAH B
) O
and O
comb O
- O
like O
poly O
( O
2 O
- O
hydroxyethyl O
methacrylate O
) O
- O
graft O
- O
poly O
( O
acrylic O
acid O
) O
( O
PHEMA O
- O
g O
- O
PAA O
) O
leads O
to O
~ O
2 O
- O
fold O
thicker O
coatings O
than O
adsorption O
of O
PAH B
and O
linear O
PAA B
, O
and O
the O
difference O
in O
the O
thicknesses O
of O
the O
two O
coatings O
increases O
with O
the O
number O
of O
bilayers O
. O

Moreover O
, O
the O
( O
PAH B
/ O
PHEMA O
- O
g O
- O
PAA O
) O
n O
films O
sorb O
2 O
- O
to O
4 O
- O
fold O
more O
protein O
than O
corresponding O
films O
prepared O
with O
linear O
PAA B
, O
and O
coatings O
deposited O
at O
pH O
3 O
. O
0 O
sorb O
more O
protein O
than O
coatings O
adsorbed O
at O
pH O
5 O
. O
0 O
, O
7 O
. O
0 O
, O
or O
9 O
. O
0 O
. O

In O
fact O
changes O
in O
deposition O
pH O
and O
addition O
of O
0 O
. O
5 O
M O
NaCl B
to O
polyelectrolyte O
adsorption O
solutions O
alter O
protein O
sorption O
more O
dramatically O
than O
variations O
in O
the O
constituent O
polymer O
architecture O
. O

When O
deposited O
from O
0 O
. O
5 O
M O
NaCl B
at O
pH O
3 O
. O
0 O
, O
both O
( O
PAH B
/ O
PHEMA O
- O
g O
- O
PAA O
) O
5 O
and O
( O
PAH B
/ O
PAA B
) O
5 O
films O
increase O
in O
thickness O
more O
than O
400 O
% O
upon O
adsorption O
of O
lysozyme O
. O

These O
films O
contain O
a O
high O
concentration O
of O
free O
- O
COOH B
groups O
, O
and O
subsequent O
deprotonation O
of O
these O
groups O
at O
neutral O
pH O
likely O
contributes O
to O
increased O
protein O
binding O
. O

Lysozyme O
sorption O
stabilizes O
these O
films O
, O
as O
without O
lysozyme O
films O
deposited O
at O
pH O
3 O
. O
0 O
from O
0 O
. O
5 O
M O
NaCl B
desorb O
at O
neutral O
pH O
. O

Films O
deposited O
at O
pH O
9 O
. O
0 O
from O
0 O
. O
5 O
M O
NaCl B
are O
more O
stable O
and O
also O
bind O
large O
amounts O
of O
lysozyme O
. O

Among O
the O
tested O
systems O
( O
barnase O
- O
barstar O
( O
BBS O
) O
, O
streptavidin O
- O
biotin B
, O
antibody O
- O
antigen O
, O
and O
protein O
A O
- O
immunoglobulin O
) O
, O
the O
BBS O
is O
notable O
due O
to O
the O
combination O
of O
its O
high O
resistance O
to O
severe O
chemical O
perturbation O
and O
unique O
advantages O
offered O
by O
genetic O
engineering O
of O
this O
entirely O
protein O
- O
based O
system O
. O

Cytotoxic O
constituents O
of O
ethyl B
acetate I
fraction O
from O
Dianthus O
superbus O
. O

The O
ethyl B
acetate I
fraction O
( O
EE O
- O
DS O
) O
from O
Dianthus O
superbus O
was O
found O
to O
possess O
the O
cytotoxic O
activity O
against O
cancer O
cells O
in O
previous O
study O
. O

Two O
dianthramides O
( O
1 O
and O
2 O
) O
, O
three O
flavonoids B
( O
3 O
- O
5 O
) O
, O
two O
coumarins B
( O
6 O
and O
7 O
) O
and O
three O
other O
compounds O
( O
8 O
- O
10 O
) O
were O
obtained O
. O

When O
the O
strain O
was O
grown O
in O
the O
presence O
of O
1 B
, I
4 I
- I
butanediol I
( O
BDO O
) O
as O
a O
4HB O
precursor O
, O
P4HB O
block O
was O
formed O
. O

Block O
copolymerization O
of O
P3HP O
and O
P4HB O
adds O
a O
new O
vision O
on O
PHA B
polymerization O
by O
generation O
of O
new O
polymers O
with O
superior O
properties O
. O

Neuroprotective O
effects O
of O
inhaled O
lavender O
oil O
on O
scopolamine B
- O
induced O
dementia O
via O
anti O
- O
oxidative O
activities O
in O
rats O
. O

The O
present O
study O
was O
undertaken O
in O
order O
to O
investigate O
the O
antioxidant O
and O
antiapoptotic O
activities O
of O
the O
lavender O
essential O
oils O
from O
Lavandula O
angustifolia O
ssp O
. O
angustifolia O
Mill O
. O
and O
Lavandula O
hybrida O
Rev O
. O
using O
superoxide B
dismutase O
( O
SOD O
) O
, O
glutathione B
peroxidase O
( O
GPX O
) O
and O
catalase O
( O
CAT O
) O
specific O
activities O
, O
total O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
, O
malondialdehyde B
( O
MDA B
) O
level O
( O
lipid O
peroxidation O
) O
and O
DNA O
fragmentation O

assays O
in O
male O
Wistar O
rats O
subjected O
to O
scopolamine B
- O
induced O
dementia O
rat O
model O
. O

In O
scopolamine B
- O
treated O
rats O
, O
lavender O
essential O
oils O
showed O
potent O
antioxidant O
and O
antiapoptotic O
activities O
. O

Subacute O
exposures O
( O
daily O
, O
for O
7 O
continuous O
days O
) O
to O
lavender O
oils O
significantly O
increased O
antioxidant O
enzyme O
activities O
( O
SOD O
, O
GPX O
and O
CAT O
) O
, O
total O
content O
of O
reduced O
GSH B
and O
reduced O
lipid O
peroxidation O
( O
MDA B
level O
) O
in O
rat O
temporal O
lobe O
homogenates O
, O
suggesting O
antioxidant O
potential O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
antioxidant O
and O
antiapoptotic O
activities O
of O
the O
lavender O
essential O
oils O
are O
the O
major O
mechanisms O
for O
their O
potent O
neuroprotective O
effects O
against O
scopolamine B
- O
induced O
oxidative O
stress O
in O
the O
rat O
brain O
. O

Protective O
effects O
of O
oral O
crocin B
against O
intracerebroventricu O
streptozotocin B
- O
induced O
spatial O
memory O
deficit O
and O
oxidative O
stress O
in O
rats O
. O

Intracerebroventricu O
( O
ICV O
) O
streptozotocin B
( O
STZ B
) O
has O
been O
shown O
to O
cause O
cognitive O
impairment O
, O
associated O
with O
free O
radical O
generation O
. O

In O
this O
study O
, O
we O
evaluated O
the O
effects O
of O
crocin B
on O
cognitive O
performance O
in O
ICV O
STZ B
- O
lesioned O
rats O
( O
3mg O
/ O
kg O
bilaterally O
, O
on O
day O
1 O
and O
3 O
) O
. O

Crocin B
( O
100mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
was O
administered O
for O
21 O
consecutive O
days O
, O
starting O
1h O
prior O
to O
the O
first O
dose O
of O
STZ B
. O

Cognitive O
performance O
was O
assessed O
using O
Morris O
water O
maze O
task O
while O
the O
parameters O
of O
oxidative O
stress O
assessed O
, O
were O
malondialdehyde B
( O
MDA B
) O
and O
total O
thiol B
levels O
besides O
glutathione B
peroxidase O
( O
GPx O
) O
activity O
. O

STZ B
- O
lesioned O
rats O
showed O
a O
severe O
deficit O
in O
memory O
associated O
with O
elevated O
MDA B
levels O
, O
reduced O
GPx O
activity O
and O
total O
thiol O
content O
. O

Crocin B
treatment O
improved O
cognitive O
performance O
and O
resulted O
in O
a O
significant O
reduction O
in O
MDA B
levels O
and O
elevation O
in O
total O
thiol B
content O
and O
GPx O
activity O
. O

This O
study O
demonstrates O
that O
crocin B
may O
have O
beneficial O
effects O
in O
the O
treatment O
of O
neurodegenerative O
disorders O
such O
as O
Alzheimer O
' O
s O
disease O
. O

New O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridines I
carrying O
active O
pharmacophores O
: O
synthesis O
and O
anticonvulsant O
studies O
. O

Five O
new O
series O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridines I
carrying O
biologically O
active O
pyrazoline O
( O
4a O
- O
e O
) O
, O
cyanopyridone O
( O
5a O
, O
b O
) O
, O
cyanopyridine O
( O
6a O
- O
f O
) O
, O
2 O
- O
aminopyrimidine O
( O
7a O
- O
f O
) O
and O
pyrimidine O
- O
2 O
- O
thione O
( O
8a O
- O
d O
) O
systems O
were O
designed O
and O
synthesized O
as O
prominent O
anticonvulsant O
agents O
. O

Enhanced O
activity O
profile O
was O
observed O
for O
new O
compounds O
in O
PTZ B
method O
over O
MES O
method O
. O

Sensitizing O
capacity O
and O
allergenicity O
of O
enzymatically O
cross O
- O
linked O
sodium B
caseinate O
in O
comparison O
to O
sodium B
caseinate O
in O
a O
mouse O
model O
for O
cow O
' O
s O
milk O
allergy O
. O

The O
sensitizing O
capacity O
and O
the O
allergenicity O
( O
the O
potency O
to O
induce O
an O
allergic O
effector O
response O
) O
of O
cross O
- O
linked O
sodium B
caseinate O
was O
investigated O
using O
a O
mouse O
model O
for O
cow O
' O
s O
milk O
allergy O
. O

These O
results O
indicate O
that O
in O
already O
caseinate O
- O
sensitized O
mice O
, O
cross O
- O
linked O
caseinate O
did O
not O
provoke O
more O
pronounced O
allergenic O
reactions O
compared O
to O
sodium B
caseinate O
. O

Thus O
, O
EO33SO14EO33 O
and O
EO38SO10EO38 O
polymeric O
micelles O
were O
tested O
regarding O
doxorubicin B
( O
DOXO O
) O
entrapment O
efficiency O
( O
solubilization O
test O
) O
, O
physical O
stability O
( O
DLS O
) O
, O
cytocompatibility O
( O
fibroblasts O
) O
, O
release O
profiles O
at O
various O
pHs O
( O
in O
vitro O
tests O
) O
, O
as O
well O
as O
P O
- O
gp O
inhibition O
and O
evasion O
and O
cytotoxicity O
of O
the O
DOXO O
- O
loaded O
micelles O
in O
an O
ovarian O
MDR O
NCI O
- O
ADR O
/ O
RES O
cell O

EO33SO14EO33 O
and O
EO38SO10EO38 O
formed O
spherical O
micelles O
( O
~ O
13nm O
) O
at O
lower O
concentration O
than O
other O
copolymers O
under O
clinical O
evaluation O
( O
e O
. O
g O
. O
Pluronic B
( O
R O
) O
) O
, O
exhibited O
0 O
. O
2 O
% O
to O
1 O
. O
8 O
% O
loading O
capacity O
, O
enhancing O
more O
than O
60 O
times O
drug O
apparent O
solubility O
, O
and O
retained O
the O
cargo O
for O
long O
time O
. O

Encapsulation O
of O
Nod1 O
and O
Nod2 O
receptor O
ligands O
into O
poly B
( I
lactic I
acid I
) I
nanoparticles O
potentiates O
their O
immune O
properties O
. O

As O
activation O
of O
intracytoplasmic O
NLRs O
is O
able O
to O
induce O
proinflammatory O
molecules O
, O
the O
added O
value O
of O
encapsulation O
of O
Nod1 O
and O
Nod2 O
receptor O
ligands O
into O
Poly B
( I
Lactic I
Acid I
) I
( O
PLA B
) O
biodegradable O
nanocarriers O
to O
modulate O
their O
immune O
properties O
on O
human O
dendritic O
cells O
( O
DCs O
) O
maturation O
has O
been O
evaluated O
. O

Nod O
ligands O
encapsulated O
into O
PLA B
NPs O
were O
efficiently O
taken O
up O
by O
DCs O
and O
subsequently O
induced O
a O
strong O
up O
- O
regulation O
of O
maturation O
markers O
and O
the O
enhancement O
of O
proinflammatory O
cytokine O
secretion O
by O
DCs O
. O

Furthermore O
, O
co O
- O
injection O
of O
encapsulated O
Nod O
- O
ligands O
with O
PLA B
particles O
carrying O
Gag O
p24 O
HIV O
- O
1 O
antigen O
allowed O
a O
100 O
fold O
increase O
in O
antibody O
responses O
in O
comparison O
to O
Alum O
. O

These O
results O
suggest O
that O
encapsulation O
of O
Nod O
ligands O
into O
PLA B
- O
NPs O
could O
be O
an O
effective O
way O
to O
improve O
vaccine O
efficiency O
. O

Differential O
regulation O
of O
drug O
transporter O
expression O
by O
all B
- I
trans I
retinoic I
acid I
in O
hepatoma O
HepaRG O
cells O
and O
human O
hepatocytes O
. O

All B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
is O
the O
active O
form O
of O
vitamin B
A I
, O
known O
to O
activate O
retinoid O
receptors O
, O
especially O
the O
heterodimer O
retinoid O
X O
receptor O
( O
RXR O
) O
: O
retinoic B
acid I
receptor O
( O
RAR O
) O
that O
otherwise O
may O
play O
a O
role O
in O
regulation O
of O
some O
drug O
transporters O
. O

The O
present O
study O
was O
designed O
to O
characterize O
the O
nature O
of O
human O
hepatic O
transporters O
that O
may O
be O
targeted O
by O
atRA B
and O
the O
heterodimer O
RXR O
: O
RAR O
. O

Exposure O
of O
human O
hepatoma O
HepaRG O
cells O
and O
primary O
human O
hepatocytes O
to O
5 O
mu O
M O
atRA B
down O
- O
regulated O
mRNA O
levels O
of O
various O
sinusoidal O
solute O
carrier O
( O
SLC O
) O
influx O
transporters O
, O
including O
organic O
anion O
transporting O
polypeptide O
( O
OATP O
) O
2B1 O
, O
OATP1B1 O
, O
organic O
cation O
transporter O
( O
OCT O
) O
1 O
and O
organic O
anion O
transporter O
( O
OAT O
) O
2 O
, O
and O
induced O
those O
of O
the O
canalicular O
breast O
cancer O
resistance O
protein O
( O
BCRP O
) O
. O

Some O
transporters O
such O
as O
OATP1B3 O
and O
the O
bile O
salt O
export O
pump O
( O
BSEP O
) O
were O
however O
down O
- O
regulated O
by O
atRA B
in O
primary O
human O
hepatocytes O
, O
but O
induced O
in O
HepaRG O
cells O
, O
thus O
pointing O
out O
discrepancies O
between O
these O
two O
liver O
cell O
models O
in O
terms O
of O
detoxifying O
protein O
regulation O
. O

atRA B
- O
mediated O
repressions O
of O
OATP2B1 O
, O
OATP1B1 O
, O
OAT2 O
and O
OCT1 O
mRNA O
expression O
were O
finally O
shown O
to O
be O
counteracted O
by O
knocking O
- O
down O
expression O
of O
RAR O
alpha O
and O
RXR O
alpha O
through O
siRNA O
transfection O
in O
HepaRG O
cells O
. O

atRA B
thus O
differentially O
regulated O
human O
hepatic O
drug O
transporters O
, O
mainly O
in O
a O
RXR O
: O
RAR O
- O
dependent O
manner O
, O
therefore O
establishing O
retinoids O
and O
retinoid O
receptors O
as O
modulators O
of O
liver O
drug O
transporter O
expression O
. O

1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
Penta I
- I
O I
- I
galloyl I
- I
beta I
- I
d I
- I
glucose I
, O
a O
bioactivity O
guided O
isolated O
compound O
from O
Mangifera O
indica O
inhibits O
11 O
beta O
- O
HSD O
- O
1 O
and O
ameliorates O
high O
fat O
diet O
- O
induced O
diabetes O
in O
C57BL O
/ O
6 O
mice O
. O

The O
EA O
- O
7 O
/ O
8 O
- O
9 O
/ O
10 O
- O
4 O
fraction O
was O
evolved O
as O
a O
most O
potent O
fraction O
among O
all O
the O
fractions O
and O
it O
was O
identified O
as O
well O
known O
gallotannin O
compound O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
d I
- I
glucose I
( O
PGG B
) O
by O
spectral O
analysis O
. O

Based O
on O
these O
results O
the O
PGG B
was O
further O
evaluated O
in O
ex O
vivo O
11 O
beta O
- O
HSD O
- O
1 O
inhibition O
assay O
and O
high O
fat O
diet O
( O
HFD O
) O
- O
induced O
diabetes O
in O
male O
C57BL O
/ O
6 O
mice O
. O

Single O
dose O
( O
10 O
, O
25 O
, O
50 O
and O
100mg O
/ O
kg O
) O
of O
PGG B
and O
carbenoxolone O
( O
CBX O
) O
have O
dose O
dependently O
inhibited O
the O
11 O
beta O
- O
HSD O
- O
1 O
activity O
in O
liver O
and O
adipose O
tissue O
. O

Furthermore O
, O
HFD O
appraisal O
to O
male O
C57BL O
/ O
6 O
mice O
caused O
severe O
hyperglycemia O
, O
hypertriglyceridemia O
, O
elevated O
levels O
of O
plasma O
corticosterone B
and O
insulin O
, O
increased O
liver O
and O
white O
adipose O
mass O
with O
increase O
in O
body O
weight O
was O
observed O
compare O
to O
normal O
control O
. O

Also O
, O
oral O
glucose B
tolerance O
was O
significantly O
impaired O
compare O
to O
normal O
control O
. O

Interestingly O
, O
post O
- O
treatment O
with O
PGG B
for O
21 O
days O
had O
alleviated O
the O
HFD O
- O
induced O
biochemical O
alterations O
and O
improved O
oral O
glucose B
tolerance O
compare O
to O
HFD O
- O
control O
. O

In O
conclusion O
, O
the O
PGG B
isolated O
from O
MEMI O
inhibits O
11 O
beta O
- O
HSD O
- O
1 O
activity O
and O
ameliorates O
HFD O
- O
induced O
diabetes O
in O
male O
C57BL O
/ O
6 O
mice O
. O

Labdane O
diterpenoids O
and O
lignans B
from O
Calocedrus O
macrolepis O
. O

Three O
new O
labdane O
diterpenoids O
, O
calomacrins O
A O
- O
C O
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
diaryl O
butyrolactone O
- O
type O
lignan B
, O
calomacrol O
A O
( O
8 O
) O
, O
as O
well O
as O
four O
known O
labdane O
diterpenoids O
and O
six O
known O
lignans B
, O
were O
isolated O
from O
the O
twigs O
and O
leaves O
of O
Calocedrus O
macrolepis O
. O

Tamoxifen B
magnifies O
therapeutic O
impact O
of O
ceramide O
in O
human O
colorectal O
cancer O
cells O
independent O
of O
p53 O
. O

Because O
intracellular O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
plays O
a O
role O
in O
catalyzing O
the O
conversion O
of O
ceramide O
to O
higher O
sphingolipids B
, O
we O
hypothesized O
that O
administration O
of O
P O
- O
gp O
antagonists O
with O
C6 O
- O
ceramide O
would O
magnify O
cell O
death O
cascades O
. O

The O
addition O
of O
either O
tamoxifen B
, O
VX O
- O
710 O
, O
verapamil B
, O
or O
cyclosporin O
A O
, O
antagonists O
of O
P O
- O
gp O
, O
enhanced O
C6 O
- O
ceramide O
cytotoxicity O
in O
all O
cell O
lines O
. O

In O
depth O
studies O
with O
C6 O
- O
ceramide O
and O
tamoxifen B
in O
LoVo O
cells O
showed O
the O
regimen O
induced O
PARP O
cleavage O
, O
caspase O
- O
dependent O
apoptosis O
, O
mitochondrial O
membrane O
permeabilization O
( O
MMP O
) O
, O
and O
cell O
cycle O
arrest O
at O
G1 O
and O
G2 O
. O

Nanoliposomal O
formulations O
of O
C6 O
- O
ceramide O
and O
tamoxifen B
were O
also O
effective O
, O
yielding O
synergistic O
cell O
kill O
. O

We O
conclude O
that O
tamoxifen B
is O
a O
favorable O
adjuvant O
for O
enhancing O
C6 O
- O
ceramide O
cytotoxicity O
in O
CRC O
, O
and O
demonstrates O
uniquely O
integrated O
effects O
. O

Transmethylation O
is O
an O
important O
reaction O
that O
transfers O
a O
methyl B
group O
in O
S B
- I
adenosylmethionine I
( O
SAM B
) O
to O
substrates O
such O
as O
DNA O
, O
RNA O
, O
and O
proteins O
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
transmethylation O
on O
tumorigenic O
responses O
and O
its O
regulatory O
mechanism O
using O
an O
upregulation O
strategy O
of O
adenosylhomocysteine B
( O
SAH O
) O
acting O
as O
a O
negative O
feedback O
inhibitor O
. O

Treatment O
with O
adenosine O
dialdehyde O
( O
AdOx O
) O
, O
an O
inhibitor O
of O
transmethylation O
- O
suppressive O
adenosylhomocysteine B
( O
SAH O
) O
hydrolase O
( O
SAHH O
) O
, O
enhanced O
the O
level O
of O
SAH O
and O
effectively O
blocked O
the O
proliferation O
, O
migration O
, O
and O
invasion O
of O
cancer O
cells O
; O
the O
treatment O
also O
induced O
the O
differentiation O
of O
C6 O
glioma O
cells O
and O
suppressed O
the O
neovascular O
genesis O
of O
eggs O
in O
a O
dose O
- O
dependent O
manner O
. O

Synthesis O
of O
derivatives O
of O
methyl B
rosmarinate I
and O
their O
inhibitory O
activities O
against O
matrix O
metalloproteinase O
- O
1 O
( O
MMP O
- O
1 O
) O
. O

A O
series O
of O
MMP O
- O
1 O
inhibitors O
have O
been O
identified O
based O
upon O
a O
methyl B
rosmarinate I
scaffold O
using O
structure O
- O
based O
drug O
design O
methods O
. O

A O
series O
of O
novel O
benzoxepins O
6 O
was O
designed O
and O
prepared O
as O
rigid O
- O
isoCA O
- O
4 O
analogs O
according O
to O
a O
convergent O
strategy O
using O
the O
coupling O
of O
N O
- O
tosylhydrazones O
with O
aryl O
iodides O
under O
palladium B
catalysis O
. O

Cytotoxicity O
of O
lapachol O
, O
beta O
- O
lapachone O
and O
related O
synthetic O
1 B
, I
4 I
- I
naphthoquinones I
against O
oesophageal O
cancer O
cells O
. O

Naphthoquinones B
have O
been O
found O
to O
have O
a O
wide O
range O
of O
biological O
activities O
, O
including O
cytotoxicity O
to O
cancer O
cells O
. O

The O
secondary O
metabolites O
lapachol O
, O
alpha O
- O
and O
beta O
- O
lapachone O
and O
a O
series O
of O
25 O
related O
synthetic O
1 B
, I
4 I
- I
naphthoquinones I
were O
screened O
against O
the O
oesophageal O
cancer O
cell O
line O
( O
WHCO1 O
) O
. O

Most O
of O
the O
compounds O
exhibited O
enhanced O
cytotoxicity O
( O
IC50 O
1 O
. O
6 O
- O
11 O
. O
7 O
mu O
M O
) O
compared O
to O
the O
current O
drug O
of O
choice O
cisplatin B
( O
IC50 O
= O
16 O
. O
5 O
mu O
M O
) O
. O

The O
synthesis O
of O
this O
enantiopure O
trifluoromethyl O
group O
containing O
tripeptide B
was O
performed O
through O
a O
peptide O
coupling O
reaction O
between O
the O
HCl O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 O
- O
( O
MIF O
- O
1 O
) O
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l O
- O
N O
( O
G O
) O
- O
nitroarginine O
ester O
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l O
- O
Arg O
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

Synthesis O
, O
characterization O
, O
cytotoxicity O
and O
antimicrobial O
studies O
on O
bis O
( O
N O
- O
furfuryl O
- O
N O
- O
( O
2 O
- O
phenylethyl O
) O
dithiocarbamato O
- O
S O
, O
S O
' O
) O
zinc O
( O
II O
) O
and O
its O
nitrogen B
donor O
adducts O
. O

[ O
Zn O
( O
fpedtc O
) O
2 O
] O
( O
1 O
) O
, O
[ O
Zn O
( O
fpedtc O
) O
2 O
( O
py O
) O
] O
( O
2 O
) O
, O
[ O
Zn O
( O
fpedtc O
) O
2 O
( O
1 O
, O
10 O
- O
phen O
) O
] O
( O
3 O
) O
and O
[ O
Zn O
( O
fpedtc O
) O
2 O
( O
2 O
, O
2 O
' O
- O
bipy O
) O
] O
( O
4 O
) O
( O
where O
fpedtc O
= O
N O
- O
furfuryl O
- O
N O
- O
( O
2 O
- O
phenylethyl O
) O
dithiocarbamate O
, O
py O
= O
pyridine B
, O
1 O
, O
10 O
- O
phen O
= O

1 B
, I
10 I
- I
phenanthroline I
and O
2 O
, O
2 O
' O
- O
bipy O
= O
2 B
, I
2 I
' I
- I
bipyridine I
) O
were O
synthesized O
. O

Characterization O
of O
the O
complexes O
were O
achieved O
by O
IR O
and O
NMR O
( O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
) O
spectra O
and O
in O
addition O
, O
for O
2 O
and O
3 O
, O
by O
X O
- O
ray O
crystallography O
. O

Zn B
- O
N B
distances O
in O
2 O
is O
shorter O
than O
that O
found O
in O
a O
six O
coordinate O
complex O
3 O
due O
to O
the O
change O
in O
coordination O
number O
. O

This O
communication O
describes O
the O
synthesis O
and O
inhibitory O
activities O
of O
thirty O
- O
seven O
novel O
C B
- O
terminal O
agmatine O
dipeptides O
used O
as O
screening O
compounds O
to O
study O
the O
structure O
- O
activity O
relationship O
between O
active O
- O
site O
peptidomimetics O
and O
the O
West O
Nile O
virus O
( O
WNV O
) O
NS2B O
/ O
NS3 O
serine B
protease O
. O

In O
addition O
, O
our O
study O
cleared O
the O
contention O
surrounding O
the O
previous O
X O
- O
ray O
co O
- O
crystallization O
study O
and O
an O
enzyme O
inhibition O
report O
on O
the O
binding O
conformation O
adopted O
by O
active O
- O
site O
peptide O
aldehydes B
. O

The O
structure O
activity O
relationship O
( O
SAR O
) O
revealed O
that O
the O
position O
and O
physicochemical O
character O
of O
the O
aromatic O
substituent O
proved O
to O
be O
critical O
for O
the O
levels O
of O
3 B
, I
4 I
- I
dihydroxyphenylaceti I
acid I
( O
DOPAC B
) O
in O
the O
brain O
of O
freely O
moving O
rats O
. O

Furthermore O
, O
the O
binding O
affinities O
to O
the O
dopamine B
D2 O
( O
DA O
D2 O
) O
receptor O
and O
monoamine B
oxidase O
A O
( O
MAO O
A O
) O
enzyme O
were O
determined O
for O
a O
chosen O
subset O
and O
QSAR O
models O
using O
the O
same O
descriptors O
as O
in O
the O
in O
vivo O
model O
were O
produced O
to O
investigate O
the O
mechanisms O
leading O
to O
the O
observed O
DOPAC B
response O
. O

These O
models O
, O
in O
combination O
with O
a O
strong O
correlation O
between O
the O
levels O
of O
striatal O
DOPAC B
and O
the O
affinities O
to O
DA O
D2 O
and O
MAO O
A O
, O
provides O
a O
comprehensive O
understanding O
of O
the O
biological O
response O
for O
compounds O
in O
this O
class O
. O

Here O
we O
describe O
polymersomes O
able O
to O
encapsulate O
up O
to O
6 O
% O
( O
w O
/ O
w O
) O
of O
doxorubicin B
( O
DOX B
) O
together O
with O
30 O
% O
( O
w O
/ O
w O
) O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
USPIO O
; O
gamma O
- O
Fe O
( O
2 O
) O
O O
( O
3 O
) O
) O
. O

Upon O
internalization O
in O
HeLa O
cells O
and O
when O
a O
high O
frequency O
AC O
magnetic O
field O
( O
14mT O
at O
750kHz O
) O
was O
applied O
, O
the O
developed O
delivery O
system O
elicited O
an O
18 O
% O
increase O
in O
cell O
toxicity O
, O
associated O
with O
augmented O
DOX B
release O
kinetics O
. O

In O
order O
to O
ensure O
that O
the O
observed O
cytotoxicity O
arose O
from O
the O
increased O
doxorubicin B
release O
and O
not O
from O
a O
pure O
magnetic O
hyperthermia O
effect O
, O
polymersomes O
loaded O
with O
magnetic O
nanoparticles O
alone O
were O
also O
tested O
. O

We O
observed O
that O
MYC O
drives O
the O
evasion O
of O
reactive O
- O
oxygen B
stress O
- O
induced O
melanocyte O
senescence O
, O
caused O
by O
activated O
receptor O
tyrosine B
kinase O
signaling O
. O

Both O
, O
MYC O
overexpression O
and O
Miz1 O
knockdown O
led O
to O
a O
strong O
reduction O
of O
endogenous O
reactive O
- O
oxygen B
species O
( O
ROS O
) O
, O
DNA O
damage O
and O
senescence O
. O

Importantly O
, O
pharmacological O
inhibition O
of O
CTH O
in O
human O
melanoma O
cells O
also O
reconstituted O
senescence O
in O
the O
majority O
of O
cell O
lines O
, O
and O
CTH O
knockdown O
reduced O
tumorigenic O
effects O
such O
as O
proliferation O
, O
H B
( I
2 I
) I
O I
( I
2 I
) I
resistance O
and O
soft O
agar O
growth O
. O

There O
are O
seemingly O
conflicting O
data O
in O
the O
literature O
regarding O
the O
role O
of O
serotonin B
( O
5 B
- I
HT I
) O
5 O
- O
HT2C O
receptors O
in O
the O
mouse O
head O
- O
twitch O
response O
( O
HTR O
) O
elicited O
by O
the O
hallucinogenic O
5 O
- O
HT2A O
/ O
2B O
/ O
2C O
receptor O
agonist O
2 O
, O
5 O
- O
dimethoxy O
- O
4 O
- O
iodoamphetamine O
( O
DOI B
) O
. O

The O
present O
experiments O
tested O
the O
hypothesis O
that O
both O
classes O
of O
5 O
- O
HT2C O
receptor O
compounds O
could O
attenuate O
the O
DOI B
- O
elicited O
- O
HTR O
in O
a O
single O
strain O
of O
mice O
, O
C57Bl O
/ O
6J O
. O

242084 O
) O
, O
and O
5 O
- O
HT2B O
/ O
2C O
( O
SB O
- O
206553 O
) O
receptors O
attenuated O
the O
DOI B
- O
elicited O
- O
HTR O
. O

In O
vitro O
molecular O
pharmacology O
studies O
showed O
that O
5 O
- O
HT2C O
agonists O
potent O
for O
attenuating O
the O
DOI B
- O
elicited O
- O
HTR O
also O
reduced O
the O
efficacy O
of O
DOI B
to O
activate O
mouse O
5 O
- O
HT2C O
receptor O
- O
mediated O
PLC O
signaling O
in O
HEK O
cells O
. O

Results O
indicate O
that O
5 O
- O
HT2C O
receptor O
agonists O
and O
antagonists O
attenuate O
the O
DOI B
- O
elicited O
- O
HTR O
in O
C57Bl O
/ O
6J O
mice O
, O
and O
suggest O
that O
structurally O
diverse O
5 O
- O
HT2C O
ligands O
result O
in O
different O
5 O
- O
HT2C O
receptor O
signaling O
outcomes O
compared O
to O
DOI B
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
if O
the O
increase O
in O
apparent O
solubility O
induced O
by O
liposomalization O
or O
micellization O
of O
the O
poorly O
soluble O
drug O
hydrocortisone B
( O
HC O
) O
would O
lead O
to O
an O
enhancement O
of O
its O
permeability O
through O
biological O
membranes O
. O

For O
this O
purpose O
phosphatidylcholine B
liposome O
formulations O
as O
well O
as O
d O
- O
alpha O
- O
tocopheryl O
polyethylene O
glycol O
1000 O
succinate O
( O
TPGS B
) O
micelle O
dispersions O
and O
polyvinylpyrrolidone B
( O
PVP B
) O
supersaturated O
solutions O
were O
prepared O
in O
order O
to O
increase O
the O
apparent O
solubility O
of O
HC O
. O

Both O
the O
apparent O
solubility O
of O
hydrocortisone B
( O
i O
. O
e O
. O
amount O
of O
drug O
entrapped O
plus O
non O
- O
entrapped O
in O
the O
carriers O
) O
as O
well O
as O
the O
concentration O
of O
molecularly O
dissolved O
drug O
( O
i O
. O
e O
. O
fraction O
non O
- O
entrapped O
into O
carriers O
, O
truly O
molecularly O
dissolved O
fraction O
) O
were O
characterized O
. O

Subsequently O
, O
the O
permeability O
of O
hydrocortisone B
was O
assessed O
for O
each O
type O
of O
formulation O
using O
the O
in O
vitro O
sheep O
nasal O
mucosa O
permeability O
assay O
. O

Several O
lines O
of O
evidence O
demonstrate O
that O
organochlorine B
and O
organophosphate B
pesticides O
can O
cause O
malignant O
transformation O
of O
cells O
in O
in O
vitro O
and O
in O
vivo O
models O
. O

Caffeine B
increases O
liking O
and O
consumption O
of O
novel O
- O
flavored O
yogurt O
. O

RATIONALE O
: O
Caffeine B
has O
been O
shown O
to O
increase O
preference O
for O
beverages O
with O
which O
it O
is O
paired O
; O
however O
, O
it O
is O
not O
known O
if O
caffeine B
alters O
liking O
for O
foods O
with O
which O
it O
is O
paired O
indirectly O
. O

We O
also O
tested O
the O
hypothesis O
that O
liking O
would O
increase O
more O
when O
caffeine B
was O
paired O
with O
high O
energy O
density O
yogurt O
. O

METHODS O
: O
Men O
and O
women O
( O
n O
= O
62 O
) O
were O
randomized O
to O
receive O
a O
beverage O
containing O
placebo O
( O
PLA O
) O
or O
caffeine B
( O
CAF B
) O
and O
to O
consume O
a O
low O
( O
LED O
) O
or O
high O
energy O
density O
( O
HED O
) O
, O
novel O
- O
flavored O
yogurt O
. O

Participants O
rated O
, O
ranked O
, O
and O
consumed O
seven O
novel O
- O
flavored O
yogurts O
and O
then O
had O
a O
target O
yogurt O
paired O
with O
either O
PLA O
or O
CAF B
over O
four O
consecutive O
days O
. O

RESULTS O
: O
In O
general O
, O
yogurt O
liking O
increased O
over O
time O
, O
the O
HED O
yogurt O
was O
liked O
more O
than O
the O
LED O
yogurt O
, O
and O
yogurt O
paired O
with O
caffeine B
was O
liked O
more O
than O
yogurt O
paired O
with O
placebo O
. O

Participants O
showed O
a O
significant O
increase O
in O
liking O
of O
LED O
yogurt O
paired O
with O
caffeine B
compared O
to O
those O
with O
LED O
yogurt O
paired O
with O
placebo O
. O

CONCLUSIONS O
: O
Caffeine B
administration O
may O
increase O
liking O
and O
consumption O
of O
novel O
- O
flavored O
foods O
, O
particularly O
if O
the O
food O
is O
not O
highly O
liked O
at O
baseline O
. O

This O
suggests O
that O
caffeine B
pairing O
may O
be O
a O
way O
to O
increase O
liking O
of O
LED O
foods O
, O
such O
as O
vegetables O
and O
fruit O
. O

Effects O
of O
repeated O
exposure O
to O
MDMA B
on O
5HT1a O
autoreceptor O
function O
: O
behavioral O
and O
neurochemical O
responses O
to O
8 O
- O
OHDPAT O
. O

A O
consistent O
effect O
of O
repeated O
exposure O
to O
3 B
, I
4 I
methylenedioxymetham I
( O
MDMA B
) O
is O
a O
decrease O
in O
the O
tissue O
levels O
of O
serotonin B
( O
5 B
- I
HT I
) O
. O

Tests O
were O
conducted O
2 O
weeks O
following O
MDMA B
exposure O
( O
four O
injections O
of O
10 O
. O
0 O
mg O
/ O
kg O
, O
IP O
, O
administered O
at O
2 O
- O
h O
intervals O
in O
a O
single O
day O
) O
. O

The O
8 O
- O
OHDPAT O
produced O
a O
dose O
- O
dependent O
increase O
in O
LLR O
and O
hypoactivity O
, O
but O
these O
effects O
were O
comparable O
for O
MDMA B
and O
saline O
pretreated O
groups O
. O

MDMA B
decreased O
tissue O
levels O
of O
5 B
- I
HT I
and O
the O
accumulation O
of O
5 O
- O
HTP O
, O
but O
these O
effects O
were O
not O
reflected O
in O
the O
changes O
in O
autoreceptor O
sensitivity O
. O

The O
data O
suggest O
that O
the O
decrease O
in O
tissue O
levels O
of O
5 B
- I
HT I
produced O
by O
MDMA B
is O
accompanied O
by O
a O
decrease O
in O
tryptophan B
hydroxylase O
activity O
but O
cannot O
be O
explained O
by O
supersensitivity O
of O
the O
5 O
- O
HT1a O
autoreceptor O
. O

After O
the O
brain O
samples O
were O
incinerated O
with O
nitric B
acid I
and O
perchloric O
acid O
, O
the O
element O
contents O
were O
determined O
by O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectrometry O
. O

It O
was O
found O
that O
both O
the O
Ca B
and O
Mg B
contents O
increased O
significantly O
in O
the O
amygdalae O
with O
aging O
, O
but O
the O
other O
five O
element O
contents O
( O
P B
, O
S B
, O
Zn B
, O
Fe B
, O
and O
Na B
) O
did O
not O
change O
significantly O
in O
the O
amygdalae O
with O
aging O
. O

Regarding O
the O
relationships O
among O
elements O
, O
very O
significant O
or O
significant O
direct O
correlations O
were O
found O
among O
the O
Ca B
, O
P B
, O
and O
Mg B
contents O
in O
the O
amygdalae O
. O

It O
was O
found O
that O
regarding O
the O
four O
elements O
of O
Ca B
, O
P B
, O
Mg B
, O
and O
Fe B
, O
a O
close O
relationship O
existed O
between O
the O
amygdala O
and O
hippocampus O
, O
globus O
pallidus O
, O
or O
mammillary O
body O
. O

The O
hope O
is O
to O
provide O
more O
options O
for O
glucose B
lowering O
and O
complication O
reduction O
with O
less O
risk O
for O
hypoglycemia O
and O
other O
adverse O
effects O
. O

These O
agents O
include O
newer O
incretin O
- O
based O
therapies O
and O
PPAR O
agonists O
, O
as O
well O
as O
new O
therapeutic O
classes O
such O
as O
sodium B
- O
coupled O
glucose B
cotransporter O
2 O
inhibitors O
, O
free O
fatty B
acid I
receptor O
agonists O
, O
11 B
- I
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
inhibitors O
, O
glucokinase O
activators O
, O
and O
several O
others O
that O
may O
enter O
clinical O
use O
over O
the O
next O
decade O
. O

Herein O
we O
review O
these O
agents O
that O
are O
advancing O
through O
clinical O
trials O
and O
describe O
the O
rationale O
behind O
their O
use O
, O
mechanisms O
of O
action O
, O
and O
potential O
for O
glucose B
lowering O
, O
as O
well O
as O
what O
is O
known O
of O
their O
limitations O
. O

beta B
- I
Asarone I
induces O
senescence O
in O
colorectal O
cancer O
cells O
by O
inducing O
lamin O
B1 O
expression O
. O

beta B
- I
Asarone I
( O
1 O
- O
propenyl O
- O
2 O
, O
4 O
, O
5 O
- O
methoxybenzol O
) O
is O
a O
compound O
from O
the O
traditional O
medical O
herb O
Acorus O
calamus O
Linn O
. O

This O
study O
tested O
the O
in O
vitro O
and O
in O
vivo O
effects O
of O
beta B
- I
asarone I
on O
colorectal O
cancer O
cells O
by O
testing O
cell O
viability O
using O
human O
colorectal O
cell O
lines O
HT29 O
and O
SW480 O
in O
MTT B
assays O
; O
tumorigenesis O
using O
xenografts O
in O
nude O
mice O
and O
a O
mouse O
model O
of O
colorectal O
cancer O
; O
cell O
senescence O
using O
senescence O
- O
associated O
beta O
- O
galactosidase O
activity O
; O
and O
expression O
of O
cancer O
and O
senescence O
- O
related O
proteins O
, O
specifically O
lamins O
, O
Oct O
- O
1 O
, O
p53 O
, O
p21 O
, O
and O
p15 O
, O
by O
Western O
blot O

beta B
- I
Asarone I
appeared O
to O
increase O
expression O
of O
lamin O
B1 O
, O
p53 O
, O
p21 O
, O
but O
not O
lamin O
A O
/ O
C O
. O

beta B
- I
Asarone I
regulates O
p15 O
expression O
by O
regulation O
of O
Oct O
- O
1 O
binding O
. O

Collectively O
, O
the O
results O
suggested O
that O
beta B
- I
asarone I
inhibits O
colon O
cancer O
formation O
in O
vivo O
and O
in O
vitro O
by O
inducing O
senescence O
. O

Since O
beta B
- I
asarone I
induced O
lamin O
B1 O
expression O
, O
a O
model O
is O
proposed O
in O
which O
beta B
- I
asarone I
inhibits O
colorectal O
cancer O
by O
inducing O
senescence O
through O
lamin O
B1 O
. O

Inhibitory O
effect O
on O
NO B
production O
of O
triterpenes B
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

Their O
anti O
- O
inflammatory O
activity O
was O
evaluated O
against O
LPS O
- O
induced O
NO B
production O
in O
macrophage O
RAW O
264 O
. O
7 O
cells O
. O

Furthermore O
, O
basal O
synaptic O
transmission O
in O
immature O
, O
but O
not O
mature O
, O
perirhinal O
cortex O
relies O
on O
persistent O
activity O
of O
metabotropic O
glutamate B
( O
mGlu O
) O
receptor O
, O
PI3Kinase O
and O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

To O
explore O
this O
potential O
, O
we O
conducted O
an O
RNA O
profiling O
study O
using O
the O
well O
- O
characterized O
acetaminophen B
overdose O
mouse O
model O
on O
liver O
and O
plasma O
with O
microarray O
and O
next O
- O
generation O
sequencing O
platforms O
, O
respectively O
. O

After O
drug O
treatment O
, O
the O
levels O
of O
a O
number O
of O
transcripts O
, O
both O
endogenous O
and O
exogenous O
RNAs O
, O
showed O
significant O
changes O
in O
plasma O
, O
reflecting O
not O
only O
the O
classical O
liver O
injury O
induced O
by O
acetaminophen B
overdose O
but O
also O
damage O
in O
tissues O
other O
than O
the O
liver O
. O

The O
changes O
in O
exogenous O
RNAs O
also O
reflect O
alteration O
on O
dieting O
behavior O
after O
acetaminophen B
overdose O
. O

Resistance O
to O
chemotherapy O
in O
cancer O
patients O
has O
been O
correlated O
to O
the O
overexpression O
of O
the O
ATP B
- O
binding O
cassette O
( O
ABC O
) O
drug O
transporters O
including O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
that O
actively O
efflux O
chemotherapeutic O
drugs O
from O
cancer O
cells O
. O

Didehydrostemofoline O
and O
eleven O
of O
its O
derivatives O
were O
synthesized O
and O
the O
cytotoxicity O
and O
their O
effect O
on O
doxorubicin B
, O
vinblastine B
and O
paclitaxel B
sensitivity O
in O
drug O
resistant O
( O
KB O
- O
V1 O
and O
K562 O
/ O
Adr O
) O
and O
drug O
sensitive O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
cell O
lines O
by O
a O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
were O
determined O
. O

We O
found O
that O
three O
out O
of O
the O
twelve O
stemofoline O
derivatives O
including O
OH O
- O
A1 O
, O
NH O
- O
B6 O
and O
NH O
- O
D6 O
showed O
commitment O
efficiency O
to O
increase O
sensitivity O
to O
doxorubicin B
, O
vinblastine B
and O
paclitaxel B
in O
KB O
- O
V1 O
cells O
and O
increase O
sensitivity O
to O
doxorubicin B
, O
and O
paclitaxel B
in O
K562 O
/ O
Adr O
cells O
whereas O
the O
effects O
have O
not O
been O
seen O
in O
their O
parental O
sensitive O
cancer O
cell O
lines O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
. O

In O
addition O
, O
the O
alpha O
- O
synuclein O
partial O
peptide O
modified O
with O
other O
small O
- O
molecule O
inhibitors O
, O
Baicalein B
and O
epigallocatechin B
gallate I
( O
EGCG B
) O
, O
prevented O
alpha O
- O
synuclein O
fibril O
formation O
. O

Currently O
reported O
quinone B
amyloid O
inhibitors O
do O
not O
have O
selectivity O
toward O
protein O
molecules O
. O

Therefore O
, O
our O
achievements O
provide O
a O
novel O
strategy O
for O
the O
development O
of O
targeted O
specific O
amyloid O
formation O
inhibitors O
: O
the O
combination O
of O
quinone B
compounds O
with O
specific O
peptide O
sequence O
from O
target O
proteins O
involved O
in O
amyloid O
formation O
. O

Synthesis O
and O
biological O
evaluation O
of O
xanthine B
derivatives O
on O
dipeptidyl O
peptidase O
4 O
. O

A O
series O
of O
xanthine B
derivatives O
in O
which O
a O
methylene B
was O
inserted O
at O
position O
8 O
of O
xanthine B
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl O
peptidase O
4 O
( O
DPP O
- O
4 O
) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

Variation O
in O
the O
alpha O
5 O
nicotinic O
acetylcholine B
receptor O
subunit O
gene O
predicts O
cigarette O
smoking O
intensity O
as O
a O
function O
of O
nicotine B
content O
. O

A O
single O
- O
nucleotide O
polymorphism O
( O
SNP O
) O
in O
the O
alpha O
5 O
nicotinic O
acetylcholine B
receptor O
subunit O
gene O
, O
rs16969968 O
, O
has O
been O
repeatedly O
associated O
with O
both O
smoking O
and O
respiratory O
health O
phenotypes O
. O

Preclinical O
studies O
suggest O
that O
alpha O
5 O
receptor O
subunit O
expression O
and O
function O
may O
have O
a O
direct O
role O
in O
nicotine B
titration O
during O
self O
administration O
. O

The O
present O
study O
investigated O
the O
association O
of O
CHRNA5 O
polymorphisms O
and O
smoking O
topography O
in O
66 O
smokers O
asked O
to O
smoke O
four O
nicotine B
- O
containing O
( O
nicotine B
yield O
= O
0 O
. O
60 O
mg O
) O
and O
four O
placebo O
( O
nicotine B
yield O
< O
0 O
. O
05 O
mg O
) O
cigarettes O
, O
during O
separate O
experimental O
sessions O
. O

Genotype O
at O
rs16969968 O
predicted O
nicotine B
titration O
, O
with O
homozygotes O
for O
the O
major O
allele O
( O
G O
: O
G O
) O
displaying O
significantly O
reduced O
puff O
volume O
in O
response O
to O
nicotine B
, O
whereas O
minor O
allele O
carriers O
( O
A O
: O
G O
or O
A O
: O
A O
) O
produced O
equivalent O
puff O
volumes O
for O
placebo O
and O
nicotine B
cigarettes O
. O

The O
present O
results O
suggest O
that O
puff O
volume O
may O
be O
a O
more O
powerful O
objective O
phenotype O
of O
smoking O
behavior O
than O
self O
- O
reported O
cigarettes O
per O
day O
and O
nicotine B
dependence O
. O

Dynamic O
pH O
mapping O
in O
microfluidic O
devices O
by O
integrating O
adaptive O
coatings O
based O
on O
polyaniline B
with O
colorimetric O
imaging O
techniques O
. O

In O
this O
paper O
we O
present O
a O
microfluidic O
device O
that O
has O
integrated O
pH O
optical O
sensing O
capabilities O
based O
on O
polyaniline B
. O

The O
optical O
properties O
of O
polyaniline B
coatings O
change O
in O
response O
to O
the O
pH O
of O
the O
solution O
that O
is O
flushed O
inside O
the O
microchannel O
offering O
the O
possibility O
of O
monitoring O
pH O
in O
continuous O
flow O
over O
a O
wide O
pH O
range O
throughout O
the O
entire O
channel O
length O
. O

Specifically O
, O
the O
use O
of O
a O
microfluidic O
channel O
coated O
with O
polyaniline B
is O
shown O
to O
respond O
colorimetrically O
to O
pH O
and O
that O
effect O
is O
detected O
by O
the O
detection O
system O
, O
even O
when O
pH O
gradients O
are O
induced O
within O
the O
channel O
. O

A O
TK O
/ O
TD O
model O
was O
developed O
that O
simulates O
the O
effect O
on O
growth O
of O
the O
green O
algae O
Scenedesmus O
vacuolatus O
continuously O
exposed O
to O
the O
model O
chemicals O
norflurazon O
, O
triclosan B
, O
and O
N O
- O
phenyl O
- O
2 O
- O
naphthylamine O
. O

Nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
is O
characterized O
by O
the O
accumulation O
of O
triglycerides B
in O
hepatocytes O
in O
the O
absence O
of O
excessive O
alcohol B
intake O
, O
ranging O
in O
severity O
from O
simple O
steatosis O
to O
nonalcoholic O
steatohepatitis O
( O
NASH O
) O
. O

PEG B
- O
Modified O
Macroporous O
Poly B
( I
Glycidyl I
Methacrylate I
) I
and O
Poly O
( O
2 O
- O
Hydroxyethyl O
Methacrylate O
) O
Microspheres O
to O
Reduce O
Non O
- O
Specific O
Protein O
Adsorption O
. O

To O
minimize O
non O
- O
specific O
protein O
adsorption O
on O
macroporous O
poly B
( I
glycidyl I
methacrylate I
) I
and O
poly O
( O
2 O
- O
hydroxyethyl O
methacrylate O
) O
microspheres O
containing O
amino B
and O
/ O
or O
carboxyl B
groups O
, O
the O
microspheres O
are O
coated O
with O
alpha O
, O
omega O
- O
bis O
- O
carboxy O
poly O
( O
ethylene O
glycol O
) O
and O
amino B
- O
terminated O
poly O
( O
ethylene O
glycol O
- O
co O
- O
propylene O
glycol O
) O
or O
alpha O
- O
methoxy O
- O
omega O
- O
amino O

The O
colloidal O
particles O
consist O
of O
a O
solid O
polystyrene B
core O
and O
a O
cross O
- O
linked O
poly B
- I
N I
- I
( I
isopropylacrylamide I
) I
shell O
with O
embedded O
crystalline O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
nanoparticles O
( O
d O
= O
6 O
+ O
/ O
- O
3 O
nm O
) O
. O

The O
TiO B
( I
2 I
) I
particles O
are O
generated O
in O
the O
carrier O
network O
by O
a O
sol O
- O
gel O
process O
at O
room O
temperature O
. O

The O
hybrid O
particles O
were O
imaged O
with O
photon O
energy O
steps O
of O
0 O
. O
1 O
eV O
in O
their O
hydrated O
environment O
with O
a O
cryo O
transmission O
X O
- O
ray O
microscope O
( O
TXM O
) O
at O
the O
Ti B
L O
( O
2 O
, O
3 O
) O
- O
edge O
. O

By O
analyzing O
the O
image O
stacks O
, O
the O
obtained O
near O
- O
edge O
X O
- O
ray O
absorption O
fine O
structure O
( O
NEXAFS O
) O
spectra O
of O
our O
individual O
hybrid O
particles O
show O
clearly O
that O
our O
synthesis O
generates O
TiO B
( I
2 I
) I
in O
the O
anastase O
phase O
. O

Additionally O
, O
our O
spectromicroscopy O
method O
permits O
the O
determination O
of O
the O
density O
distribution O
of O
TiO B
( I
2 I
) I
in O
single O
carrier O
particles O
. O

To O
explore O
the O
acceptor O
regioselectivity O
of O
OleD O
- O
catalyzed O
glucosylation O
, O
the O
products O
of O
OleD O
- O
catalyzed O
reactions O
with O
six O
structurally O
diverse O
acceptors O
flavones B
- O
( O
daidzein B
) O
, O
isoflavones B
( O
flavopiridol O
) O
, O
stilbenes B
( O
resveratrol B
) O
, O
indole B
alkaloids I
( O
10 O
- O
hydroxycamptothecin O
) O
, O
and O
steroids B
( O
2 O
- O
methoxyestradiol O
) O
- O
were O
determined O
. O

Epitaxial O
silicon B
dots O
self O
- O
assembled O
on O
aluminum O
nitride O
/ O
Si B
( I
111 I
) I
. O

Si B
nanoscale O
dots O
are O
synthesized O
on O
AlN B
/ O
Si B
( I
111 I
) I
by O
molecular O
beam O
epitaxy O
. O

A O
double O
Si B
coverage O
leads O
to O
a O
decrease O
in O
dot O
density O
and O
increase O
in O
dot O
size O
. O

The O
dot O
orientations O
are O
[ O
11 O
[ O
overline O
] O
0 O
] O
( O
Si B
) O
( O
or O
[ O
1 O
[ O
overline O
] O
10 O
] O
( O
Si B
) O
) O
/ O
/ O
[ O
112 O
[ O
overline O
] O
0 O
] O
( O
AlN B
) O
and O
( O
111 O
) O
( O
Si O
) O
/ O
/ O
( O
0001 O
) O
( O
AlN B
) O
, O
which O
are O
similar O
( O
or O
identical O
) O
to O
the O
orientation O
of O
AlN B
relative O
to O
the O
Si B
substrate O
. O

Among O
the O
commonly O
used O
triazoles B
, O
the O
recently O
released O
posaconazole O
is O
relatively O
less O
well O
investigated O
in O
terms O
of O
its O
safety O
. O

Mass O
transfer O
and O
adsorption O
equilibrium O
for O
low O
volatility O
alkanes B
in O
BPL O
activated O
carbon B
. O

We O
study O
mass O
transfer O
of O
alkanes B
in O
BPL O
activated O
carbon B
using O
the O
concentration O
- O
swing O
frequency O
response O
method O
, O
which O
can O
easily O
discriminate O
among O
mass O
transfer O
mechanisms O
. O

We O
measure O
concentration O
- O
dependent O
diffusion O
rates O
for O
n B
- I
hexane I
, O
n O
- O
octane O
, O
n O
- O
decane O
, O
2 O
, O
7 O
- O
dimethyloctane O
, O
and O
cyclodecane O
, O
which O
have O
different O
carbon B
numbers O
and O
geometries O
: O
straight O
chain O
, O
branched O
chain O
, O
and O
cyclic O
. O

In O
transmission O
electron O
microscopy O
, O
optimized O
thioflavin B
T I
and O
cell O
survival O
assays O
, O
CP O
- O
2 O
inhibits O
the O
formation O
of O
A O
beta O
aggregates O
, O
entirely O
disassembles O
preformed O
aggregated O
and O
fibrillar O
A O
beta O
, O
and O
protects O
rat O
pheochromocytoma O
PC12 O
cells O
from O
A O
beta O
toxicity O
, O
without O
inducing O
any O
toxicity O
by O
itself O
. O

Using O
various O
immunoassays O
, O
circular O
dichroism O
spectroscopy O
, O
photoinduced O
cross O
- O
linking O
of O
unmodified O
proteins O
( O
PICUP O
) O
combined O
with O
SDS B
/ O
PAGE O
, O
and O
NMR O
, O
we O
probed O
the O
mechanisms O
underlying O
CP O
- O
2 O
' O
s O
antiamyloidogenic O
activity O
. O

Anti O
- O
inflammatory O
effects O
of O
a O
special O
carbohydrate B
- O
whey O
protein O
cake O
after O
exhaustive O
cycling O
in O
humans O
. O

Thus O
, O
the O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
a O
special O
cake O
( O
consisting O
of O
carbohydrate B
to O
whey O
protein O
3 O
. O
5 O
: O
1 O
) O
vs O
. O
an O
isocaloric O
carbohydrate B
cake O
on O
inflammatory O
markers O
after O
exhaustive O
cycling O
in O
humans O
. O

X O
- O
ray O
absorption O
spectroscopy O
and O
energy O
storage O
of O
Ni B
- O
doped O
cobalt O
nitride O
, O
( O
Ni O
( O
0 O
. O
33 O
) O
Co O
( O
0 O
. O
67 O
) O
) O
N O
, O
prepared O
by O
a O
simple O
synthesis O
route O
. O

Metal O
nitride O
( O
Ni O
( O
0 O
. O
33 O
) O
Co O
( O
0 O
. O
67 O
) O
) O
N O
nanoparticles O
are O
prepared O
by O
nitridation O
using O
NiCo O
( O
2 O
) O
O O
( O
4 O
) O
as O
a O
precursor O
material O
by O
heating O
at O
335 O
degrees O
C O
for O
2 O
h O
in O
flowing O
NH B
( I
3 I
) I
+ O
N B
( I
2 I
) I
gas O
and O
characterized O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
field O
emission O
- O
scanning O
electron O
microscopy O
( O
FE O
- O
SEM O
) O
, O
high O
resolution O
- O
transmission O
electron O
microscopy O
( O
HR O
- O
TEM O
) O
, O
along O
with O
selective O
area O
electron O
diffraction O
( O
SAED O
) O
and O
X O

The O
X O
- O
ray O
absorption O
near O
edge O
structure O
( O
XANES O
) O
at O
the O
Co B
K O
- O
edge O
showed O
that O
the O
oxidation O
state O
of O
cobalt B
is O
close O
to O
3 O
+ O
. O

The O
( O
Ni O
( O
0 O
. O
33 O
) O
Co O
( O
0 O
. O
67 O
) O
) O
N O
showed O
a O
shift O
in O
edge O
energy O
towards O
lower O
values O
due O
to O
Ni B
- O
doping O
to O
cobalt O
site O
. O

The O
Li B
- O
storage O
behaviour O
of O
( O
Ni O
( O
0 O
. O
33 O
) O
Co O
( O
0 O
. O
67 O
) O
) O
N O
nanoparticles O
was O
evaluated O
by O
galvanostatic O
cycling O
and O
cyclic O
voltammetry O
in O
the O
cells O
with O
Li B
- O
metal O
as O
counter O
electrode O
in O
the O
voltage O
range O
of O
0 O
. O
005 O
- O
3 O
. O
0 O
V O
at O
ambient O
temperature O
. O

When O
cycled O
at O
250 O
mA O
g O
( O
- O
1 O
) O
, O
the O
first O
- O
cycle O
reversible O
capacity O
of O
700 O
( O
+ O
/ O
- O
5 O
) O
mA O
h O
g O
( O
- O
1 O
) O
( O
~ O
1 O
. O
9 O
moles O
of O
Li B
) O
is O
obtained O
. O

It O
showed O
an O
initial O
decrease O
in O
capacity O
until O
the O
10 O
( O
th O
) O
cycle O
and O
a O
stable O
capacity O
of O
400 O
( O
+ O
/ O
- O
5 O
) O
mA O
h O
g O
( O
- O
1 O
) O
( O
~ O
1 O
. O
09 O
moles O
of O
Li B
) O
is O
observed O
at O
the O
end O
of O
the O
50 O
( O
th O
) O
cycle O
. O

The O
materials O
showed O
excellent O
Li B
- O
ion O
insertion O
/ O
extraction O
, O
with O
the O
coulombic O
efficiency O
reaching O
almost O
99 O
% O
in O
the O
range O
of O
10 O
- O
50 O
cycles O
. O

Self O
- O
assembly O
of O
mesoporous O
CuO B
nanosheets O
- O
CNT O
3D O
- O
network O
composites O
for O
lithium B
- O
ion O
batteries O
. O

A O
facile O
, O
flexible O
and O
large O
- O
scale O
technique O
was O
proposed O
to O
prepare O
a O
CuO B
- O
CNT O
3D O
- O
network O
composite O
with O
the O
aid O
of O
electrostatic O
interactions O
in O
aqueous O
solution O
. O

At O
a O
rate O
of O
0 O
. O
1 O
C O
, O
the O
cycling O
discharge O
capacity O
of O
the O
optimal O
composite O
is O
more O
than O
2 O
. O
3 O
times O
of O
that O
of O
unmodified O
mesoporous O
CuO B
nanosheets O
as O
the O
active O
material O
in O
an O
anode O
after O
40 O
cycles O
. O

These O
include O
trials O
of O
administering O
dichloroacetate O
( O
an O
activator O
of O
pyruvate B
dehydrogenase O
complex O
) O
, O
arginine B
or O
citrulline B
( O
precursors O
of O
nitric B
oxide I
) O
, O
coenzyme O
Q10 O
( O
CoQ10 O
; O
part O
of O
the O
electron O
transport O
chain O
and O
an O
antioxidant O
) O
, O
idebenone O
( O
a O
synthetic O
analogue O
of O
CoQ10 O
) O
, O
EPI O
- O
743 O
( O
a O
novel O
oral O
potent O
2 O
- O
electron O
redox O
cycling O
agent O
) O
, O
creatine B
( O
a O
precursor O
of O
phosphocreatine O
) O
, O
combined O
administration O
( O
of O

creatine B
, O
alpha O
- O
lipoate O
, O
and O
CoQ10 O
) O
, O
and O
exercise O
training O
( O
to O
increase O
muscle O
mitochondria O
) O
. O

Of O
these O
only O
1 O
( O
treatment O
with O
creatine O
) O
showed O
a O
significant O
change O
in O
primary O
outcomes O
, O
but O
this O
was O
not O
reproduced O
in O
2 O
subsequent O
trials O
with O
creatine B
with O
different O
patients O
. O

The O
pathogenicity O
of O
the O
mutation O
, O
as O
indicated O
by O
the O
structure O
- O
based O
functional O
analyses O
, O
was O
further O
confirmed O
by O
abnormal O
monolysocardiolipin O
/ O
cardiolipin B
ratio O
in O
dry O
blood O
spots O
of O
the O
patients O
as O
well O
as O
the O
occurrence O
of O
this O
mutation O
in O
another O
reported O
BTHS O
proband O
. O

It O
can O
be O
hypothesised O
that O
impaired O
mt O
Delta O
Psi O
and O
mitochondrial O
ATP B
synthase O
activity O
may O
contribute O
to O
episodes O
of O
cardiac O
arrhythmia O
that O
occurred O
unexpectedly O
in O
BTHS O
patients O
. O

Facile O
solution O
synthesis O
of O
Ag B
@ O
Pt B
core O
- O
shell O
nanoparticles O
with O
dendritic O
Pt B
shells O
. O

Ag B
@ O
Pt B
nanoparticles O
with O
various O
dendritic O
Pt B
shells O
were O
successfully O
synthesized O
by O
using O
nonionic O
surfactants O
at O
room O
temperature O
. O

Our O
recent O
study O
demonstrated O
that O
the O
addition O
of O
nonionic O
surfactant O
plays O
an O
important O
key O
role O
in O
the O
synthesis O
of O
dendritic O
Pt B
nanostructures O
( O
J O
. O
Am O
. O
Chem O
. O
Soc O
. O
, O
2010 O
, O
132 O
, O
13636 O
) O
. O

Here O
we O
extend O
this O
synthetic O
concept O
to O
prepare O
various O
Ag B
@ O
Pt B
nanoarchitectures O
. O

The O
different O
nanostructured O
Pt B
shells O
on O
the O
Ag B
core O
were O
confirmed O
by O
ultraviolet O
- O
visible O
absorption O
spectroscopy O
and O
transmission O
electron O
microscopy O
. O

As O
a O
preliminary O
electrochemical O
application O
, O
the O
obtained O
Ag B
@ O
Pt B
nanostructures O
were O
applied O
in O
the O
methanol B
oxidation O
reaction O
( O
MOR O
) O
in O
0 O
. O
5 O
M O
H O
( O
2 O
) O
SO O
( O
4 O
) O
solution O
containing O
0 O
. O
5 O
M O
methanol B
. O

The O
Ag B
@ O
Pt B
nanoparticles O
with O
thin O
dendritic O
Pt B
shells O
show O
superior O
CO B
- O
tolerance O
performance O
with O
a O
I O
( O
f O
) O
/ O
I O
( O
b O
) O
value O
reaching O
3 O
. O
71 O
. O

Our O
Ag B
@ O
Pt B
nanostructures O
with O
good O
CO B
tolerant O
activity O
will O
be O
prominent O
catalysts O
for O
MOR O
. O

A O
mechanistic O
study O
of O
the O
electrochemical O
oxygen B
reduction O
on O
the O
model O
semiconductor O
n O
- O
Ge B
( O
100 O
) O
by O
ATR O
- O
IR O
and O
DFT O
. O

The O
electrochemical O
oxygen B
reduction O
reaction O
( O
ORR O
) O
on O
a O
n O
- O
Ge B
( O
100 O
) O
surface O
in O
0 O
. O
1 O
M O
HClO4 O
was O
investigated O
in O
situ O
and O
operando O
using O
a O
combination O
of O
attenuated O
total O
reflection O
infrared O
( O
ATR O
- O
IR O
) O
spectroscopy O
and O
density O
functional O
( O
DFT O
) O
calculations O
. O

The O
vibrational O
modes O
of O
the O
detected O
intermediates O
were O
assigned O
based O
on O
DFT O
calculations O
of O
solvated O
model O
clusters O
such O
as O
Ge B
- O
bound O
superoxides O
and O
peroxides B
. O

ATR O
- O
IR O
shows O
the O
Ge B
- O
bound O
superoxide B
with O
a O
transition O
dipole O
moment O
oriented O
at O
( O
28 O
+ O
/ O
- O
10 O
) O
degrees O
with O
respect O
to O
the O
surface O
normal O
. O

At O
slightly O
negative O
potentials O
, O
the O
surface O
- O
bound O
peroxide B
is O
identified O
by O
an O
OOH O
bending O
mode O
as O
a O
further O
intermediate O
, O
oriented O
at O
a O
similar O
angle O
. O

The O
reaction O
is O
furthermore O
coupled O
with O
the O
hydrogen B
evolution O
reaction O
( O
HER O
) O
. O

First O
, O
a O
multilayer O
polydimethylsiloxane B
( O
PDMS B
) O
- O
based O
spotting O
device O
was O
used O
to O
array O
siRNA O
molecules O
into O
96 O
microwells O
targeting O
markers O
of O
endocytosis O
, O
along O
with O
siRNA O
controls O
. O

By O
using O
a O
PDMS B
- O
based O
spotting O
device O
, O
we O
remove O
the O
need O
for O
a O
microarray O
printer O
necessary O
to O
perform O
previously O
described O
small O
scale O
( O
e O
. O
g O
. O
cellular O
microarrays O
) O
and O
microchip O
- O
based O
RNAi O
screening O
, O
while O
still O
minimizing O
reagent O
usage O
tenfold O
compared O
to O
conventional O
screening O
. O

Second O
, O
the O
siRNA O
spotted O
array O
was O
transferred O
to O
a O
reversibly O
sealed O
PDMS B
- O
based O
screening O
platform O
containing O
microchannels O
designed O
to O
enable O
efficient O
cell O
loading O
and O
transfection O
of O
mammalian O
cells O
while O
preventing O
cross O
- O
contamination O
between O
experimental O
conditions O
. O

Glucose B
is O
a O
primary O
fuel O
for O
generating O
energy O
in O
basic O
daily O
activities O
. O

Thus O
, O
glucose B
homeostasis O
is O
tightly O
regulated O
by O
counter O
- O
regulatory O
hormones O
such O
as O
glucagon O
, O
cortisol O
, O
and O
insulin O
, O
which O
affect O
key O
organs O
including O
liver O
, O
skeletal O
muscle O
, O
pancreas O
, O
and O
adipocytes O
. O

Among O
metabolic O
tissues O
, O
liver O
plays O
a O
critical O
role O
in O
controlling O
glucose B
production O
under O
various O
hormonal O
and O
metabolic O
cues O
. O

Under O
fasting O
, O
acute O
activation O
of O
both O
glycogenolysis O
and O
gluconeogenesis O
is O
achieved O
by O
post O
- O
translational O
modification O
or O
allosteric O
activation O
of O
key O
rate O
- O
limiting O
enzymes O
, O
thereby O
enabling O
enhanced O
glucose B
production O
from O
the O
liver O
to O
maintain O
glucose B
homeostasis O
. O

Methadone O
N B
- O
demethylation O
in O
vitro O
is O
catalyzed O
by O
hepatic O
cytochrome O
P4502B6 O
( O
CYP2B6 O
) O
and O
CYP3A4 O
, O
but O
clinical O
disposition O
is O
often O
attributed O
to O
CYP3A4 O
. O

This O
investigation O
tested O
the O
hypothesis O
that O
CYP2B6 O
is O
a O
prominent O
CYP O
isoform O
responsible O
for O
clinical O
methadone O
N B
- O
demethylation O
and O
clearance O
, O
using O
the O
in O
vivo O
mechanism O
- O
based O
CYP2B6 O
inhibitor O
ticlopidine O
, O
given O
orally O
for O
4 O
days O
. O

Subjects O
received O
intravenous O
plus O
oral O
( O
deuterium B
- O
labeled O
) O
racemic O
methadone O
before O
and O
after O
ticlopidine O
. O

Ticlopidine O
significantly O
and O
stereoselectively O
( O
S O
> O
R O
) O
inhibited O
methadone O
N B
- O
demethylation O
, O
decreasing O
plasma O
metabolite O
/ O
methadone O
area O
under O
the O
curve O
ratios O
and O
metabolite O
formation O
clearances O
. O

CYP2B6 O
inhibition O
reduces O
methadone O
N B
- O
demethylation O
and O
clearance O
, O
and O
alters O
methadone O
concentrations O
, O
demonstrating O
an O
important O
role O
for O
CYP2B6 O
in O
clinical O
methadone O
disposition O
. O

Carboxylic B
acid I
( O
bio O
) O
isosteres O
in O
drug O
design O
. O

The O
carboxylic B
acid I
functional O
group O
can O
be O
an O
important O
constituent O
of O
a O
pharmacophore O
, O
however O
, O
the O
presence O
of O
this O
moiety O
can O
also O
be O
responsible O
for O
significant O
drawbacks O
, O
including O
metabolic O
instability O
, O
toxicity O
, O
as O
well O
as O
limited O
passive O
diffusion O
across O
biological O
membranes O
. O

To O
avoid O
some O
of O
these O
shortcomings O
while O
retaining O
the O
desired O
attributes O
of O
the O
carboxylic B
acid I
moiety O
, O
medicinal O
chemists O
often O
investigate O
the O
use O
of O
carboxylic B
acid I
( O
bio O
) O
isosteres O
. O

Several O
carboxylic B
acid I
isosteres O
have O
been O
reported O
, O
however O
, O
the O
outcome O
of O
any O
isosteric O
replacement O
cannot O
be O
readily O
predicted O
as O
this O
strategy O
is O
generally O
found O
to O
be O
dependent O
upon O
the O
particular O
context O
( O
i O
. O
e O
. O
, O
the O
characteristic O
properties O
of O
the O
drug O
and O
the O
drug O
- O
target O
) O
. O

In O
this O
context O
, O
the O
discovery O
and O
development O
of O
novel O
carboxylic B
acid I
surrogates O
that O
could O
complement O
the O
existing O
palette O
of O
isosteres O
remains O
an O
important O
area O
of O
research O
. O

The O
goal O
of O
this O
Minireview O
is O
to O
provide O
an O
overview O
of O
the O
most O
commonly O
employed O
carboxylic B
acid I
( O
bio O
) O
isosteres O
and O
to O
present O
representative O
examples O
demonstrating O
the O
use O
and O
utility O
of O
each O
isostere O
in O
drug O
design O
. O

Tumor O
- O
induced O
osteomalacia O
( O
TIO O
) O
is O
a O
rare O
disorder O
of O
phosphate B
wasting O
due O
to O
fibroblast O
growth O
factor O
- O
23 O
( O
FGF23 O
) O
- O
secreting O
tumors O
that O
are O
often O
difficult O
to O
locate O
. O

Serum O
phosphorus B
returned O
to O
normal O
in O
all O
subjects O
within O
1 O
- O
5 O
days O
. O

C B
- O
terminal O
FGF23 O
( O
cFGF23 O
) O
decreased O
immediately O
but O
remained O
elevated O
, O
yielding O
a O
markedly O
elevated O
cFGF23 O
/ O
iFGF23 O
ratio O
. O

Serum O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 O
, O
25D O
) O
rose O
and O
exceeded O
the O
normal O
range O
. O

Graphene B
Oxide I
- O
Based O
Fluorescent O
Biosensor O
for O
Protein O
Detection O
via O
Terminal O
Protection O
of O
Small O
- O
Molecule O
- O
Linked O
DNA O
. O

A O
fluorescence O
method O
for O
protein O
detection O
is O
developed O
based O
on O
terminal O
protection O
of O
small O
- O
molecule O
- O
linked O
DNA O
by O
target O
protein O
and O
a O
graphene B
oxide I
- O
assisted O
DNA O
assay O
strategy O
. O

Vemurafenib B
potently O
induces O
endoplasmic O
reticulum O
stress O
- O
mediated O
apoptosis O
in O
BRAFV600E O
melanoma O
cells O
. O

Although O
the O
BRAFV600E O
kinase O
inhibitor O
vemurafenib B
has O
remarkable O
antitumor O
activity O
in O
patients O
with O
BRAFV600E O
- O
mutated O
melanoma O
, O
its O
effects O
are O
limited O
by O
the O
onset O
of O
drug O
resistance O
. O

We O
found O
that O
exposure O
of O
melanoma O
cell O
lines O
with O
the O
BRAFV600E O
mutation O
to O
vemurafenib B
decreased O
the O
abundance O
of O
antiapoptotic O
proteins O
and O
induced O
intrinsic O
mitochondrial O
apoptosis O
. O

Vemurafenib B
- O
treated O
melanoma O
cells O
showed O
increased O
cytosolic O
concentration O
of O
calcium B
, O
a O
potential O
trigger O
for O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
, O
which O
can O
lead O
to O
apoptosis O
. O

Consistent O
with O
an O
ER O
stress O
- O
induced O
response O
, O
vemurafenib B
decreased O
the O
abundance O
of O
the O
ER O
chaperone O
protein O
glucose B
- O
regulated O
protein O
78 O
, O
increased O
the O
abundance O
of O
the O
spliced O
isoform O
of O
the O
transcription O
factor O
X O
- O
box O
binding O
protein O
1 O
( O
XBP1 O
) O
( O
which O
transcriptionally O
activates O
genes O
involved O
in O
ER O
stress O
responses O
) O
, O
increased O
the O
phosphorylation O
of O
the O
translation O
initiation O
factor O
eIF2 O
alpha O
( O
which O
would O
be O
expected O
to O
inhibit O
protein O
synthesis O
) O
, O
and O
induced O
the O
expression O
of O
ER O
stress O
- O
related O
genes O
. O

Knockdown O
of O
the O
ER O
stress O
response O
protein O
activating O
transcription O
factor O
4 O
( O
ATF4 O
) O
significantly O
reduced O
vemurafenib B
- O
induced O
apoptosis O
. O

Moreover O
, O
the O
ER O
stress O
inducer O
thapsigargin B
prevented O
invasive O
growth O
of O
tumors O
formed O
from O
vemurafenib B
- O
sensitive O
melanoma O
cells O
in O
vivo O
. O

In O
melanoma O
cells O
with O
low O
sensitivity O
or O
resistance O
to O
vemurafenib B
, O
combination O
treatment O
with O
thapsigargin B
augmented O
or O
induced O
apoptosis O
. O

Thus O
, O
thapsigargin B
or O
other O
inducers O
of O
ER O
stress O
may O
be O
useful O
in O
combination O
therapies O
to O
overcome O
vemurafenib B
resistance O
. O

Transforming O
growth O
factor O
beta O
integrates O
Smad O
3 O
to O
mechanistic O
target O
of O
rapamycin B
complexes O
to O
arrest O
deptor O
abundance O
for O
glomerular O
mesangial O
cell O
hypertrophy O
. O

In O
many O
renal O
diseases O
, O
transforming O
growth O
factor O
beta O
( O
TGF O
beta O
) O
- O
stimulated O
canonical O
Smad O
3 O
and O
noncanonical O
mechanistic O
target O
of O
rapamycin B
( O
mTOR O
) O
promote O
increased O
protein O
synthesis O
and O
mesangial O
cell O
hypertrophy O
. O

Tuning O
the O
magnetic O
properties O
of O
metal B
oxide I
nanocrystal O
heterostructures O
by O
cation O
exchange O
. O

While O
the O
cation O
exchange O
procedure O
, O
performed O
in O
solution O
phase O
approach O
, O
was O
restricted O
so O
far O
to O
chalcogenide O
based O
semiconductor O
nanocrystals O
, O
here O
ferrite O
- O
based O
nanocrystals O
were O
subjected O
to O
a O
Fe B
( I
2 I
+ I
) I
to O
Co B
( I
2 I
+ I
) I
cation O
exchange O
procedure O
. O

For O
core O
/ O
shell O
nanoheterostructures O
a O
selective O
doping O
of O
either O
the O
shell O
or O
predominantly O
of O
the O
core O
with O
Co B
( I
2 I
+ I
) I
is O
demonstrated O
. O

Finally O
, O
an O
analysis O
of O
WS O
- O
PM O
fractions O
determined O
the O
presence O
of O
4 O
- O
5 O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
and O
preliminary O
work O
suggests O
a O
potential O
role O
for O
these O
PAHs B
to O
alter O
macrophage O
functions O
. O

The O
precursors O
were O
chosen O
to O
be O
elemental O
Se B
and O
iron O
acetylacetonate O
[ O
Fe O
( O
III O
) O
( O
C O
5 O
H O
8 O
O O
2 O
) O
3 O
] O
. O

The O
length O
of O
FeSe O
filling O
inside O
the O
carbon B
nanofibers O
could O
be O
varied O
by O
controlling O
the O
reaction O
conditions O
while O
the O
diameter O
of O
nanowires O
was O
dependent O
on O
the O
thickness O
of O
Au O
- O
Pd O
coating O
used O
as O
a O
catalyst O
. O

The O
presence O
of O
carbon B
nanofibers O
as O
a O
shell O
around O
the O
FeSe O
protected O
the O
FeSe O
nanowires O
from O
both O
atmospheric O
O B
2 I
and O
moisture O
attack O
, O
as O
was O
evident O
from O
the O
very O
long O
ambient O
condition O
shelf O
life O
of O
these O
nanocables O
, O
and O
also O
makes O
them O
more O
stable O
under O
e O
- O
beam O
irradiation O
. O

Genistein B
, O
a O
natural O
product O
derived O
from O
soybeans O
, O
ameliorates O
polyglutamine O
- O
mediated O
motor O
neuron O
disease O
. O

Spinal O
and O
bulbar O
muscular O
atrophy O
( O
SBMA O
) O
is O
an O
inherited O
motor O
neuron O
disease O
caused O
by O
the O
expansion O
of O
a O
polyglutamine O
( O
polyQ O
) O
tract O
within O
the O
androgen B
receptor O
( O
AR O
) O
gene O
. O

Here O
, O
we O
report O
that O
genistein B
, O
an O
isoflavone B
found O
in O
soy O
, O
disrupts O
the O
interaction O
between O
AR O
and O
ARA70 O
and O
promotes O
the O
degradation O
of O
mutant O
AR O
in O
neuronal O
cells O
and O
transgenic O
mouse O
models O
of O
SBMA O
. O

We O
also O
demonstrate O
that O
dietary O
genistein B
ameliorates O
behavioral O
abnormalities O
, O
improves O
spinal O
cord O
and O
muscle O
pathology O
, O
and O
decreases O
the O
amounts O
of O
monomeric O
AR O
and O
high O
- O
molecular O
- O
weight O
mutant O
AR O
protein O
aggregates O
in O
SBMA O
transgenic O
mice O
. O

Thus O
, O
genistein B
treatment O
may O
be O
a O
potential O
therapeutic O
approach O
for O
alleviating O
the O
symptoms O
of O
SBMA O
by O
disrupting O
the O
interactions O
between O
AR O
and O
ARA70 O
. O

The O
carbohydrate B
- O
based O
diol B
2 O
, O
4 O
: O
3 O
, O
5 O
- O
di O
- O
O O
- O
methylene O
- O
d O
- O
mannitol O
( O
Manx O
) O
has O
been O
used O
to O
obtain O
aliphatic O
polyesters O
. O

Manx O
is O
a O
symmetric O
bicyclic O
compound O
consisting O
of O
two O
fused O
1 O
, O
3 O
- O
dioxane O
rings O
and O
bearing O
two O
primary O
hydroxyl B
groups O
. O

The O
high O
thermal O
stability O
of O
PManxS O
, O
its O
relatively O
high O
glass O
transition O
temperature O
( O
Tg O
= O
68 O
degrees O
C O
) O
and O
elastic O
modulus O
, O
and O
its O
enhanced O
sensitivity O
to O
the O
action O
of O
lipases O
point O
to O
PManxS O
as O
a O
polyester B
of O
exceptional O
interest O
for O
those O
applications O
where O
biodegradability O
and O
molecular O
stiffness O
are O
priority O
requirements O
. O

In O
addition O
, O
random O
copolyesters O
( O
PBxManxyS O
) O
covering O
a O
broad O
range O
of O
compositions O
have O
been O
obtained O
using O
mixtures O
of O
Manx O
and O
1 B
, I
4 I
- I
butanediol I
in O
the O
reaction O
with O
dimethyl O
succinate O
. O

TCDD B
and O
corticosterone B
on O
testicular O
steroidogenesis O
and O
antioxidant O
system O
of O
epididymal O
sperm O
in O
rats O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachloro I
dibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
an O
endocrine O
- O
disrupting O
environmental O
pollutant O
, O
has O
been O
found O
to O
cause O
male O
reproductive O
toxicity O
. O

Glucocorticoids O
have O
been O
found O
to O
influence O
the O
metabolic O
pathway O
of O
TCDD B
. O

The O
present O
study O
was O
carried O
out O
to O
understand O
the O
effect O
of O
TCDD B
on O
testicular O
steroidogenesis O
and O
sperm O
antioxidant O
system O
under O
the O
influence O
of O
increased O
level O
of O
corticosterone B
in O
the O
body O
. O

Adult O
male O
rats O
were O
treated O
with O
either O
TCDD B
( O
100 O
ng O
/ O
kg O
bw O
/ O
day O
) O
or O
corticosterone B
( O
3 O
mg O
/ O
kg O
bw O
/ O
day O
) O
or O
both O
for O
15 O
days O
. O

Treatment O
with O
either O
TCDD B
or O
corticosterone O
was O
found O
to O
suppress O
the O
levels O
of O
steroidogenic O
acute O
regulatory O
protein O
and O
androgen O
- O
binding O
protein O
and O
reduce O
the O
activities O
of O
steroidogenic O
enzymes O
in O
testis O
while O
increasing O
oxidative O
stress O
in O
ventral O
prostate O
, O
seminal O
vesicles O
and O
epididymal O
sperm O
. O

In O
rats O
treated O
with O
both O
TCDD B
and O
corticosterone B
, O
the O
suppression O
of O
testicular O
steroidogenesis O
and O
increase O
in O
oxidative O
stress O
observed O
in O
ventral O
prostate O
, O
seminal O
vesicles O
and O
epididymal O
sperm O
were O
significant O
as O
compared O
to O
TCDD B
alone O
treated O
rats O
. O

The O
levels O
of O
Fas O
and O
FasL O
proteins O
were O
also O
increased O
in O
rats O
subjected O
to O
either O
TCDD B
or O
corticosterone B
treatment O
. O

In O
rats O
treated O
with O
both O
compounds O
, O
the O
increase O
observed O
in O
testicular O
levels O
of O
Fas O
and O
FasL O
was O
significant O
as O
compared O
to O
TCDD B
alone O
treated O
rats O
. O

Effect O
of O
TCDD B
on O
testicular O
steroidogenesis O
and O
antioxidant O
system O
of O
epididymal O
sperm O
may O
get O
enhanced O
under O
increased O
level O
of O
glucocorticoids O
in O
the O
body O
. O

Nowadays O
, O
tetrabenzoporphyrins O
occupy O
a O
prominent O
position O
in O
porphyrin B
chemistry O
, O
and O
this O
review O
is O
intended O
to O
cover O
the O
main O
synthetic O
methods O
and O
applications O
of O
these O
compounds O
. O

Using O
the O
transporter O
substrate O
atorvastatin B
as O
a O
test O
compound O
, O
incubations O
were O
performed O
and O
a O
mathematical O
model O
applied O
to O
describe O
metabolism O
, O
distribution O
, O
and O
binding O
at O
different O
hepatocyte O
concentrations O
. O

From O
these O
investigations O
it O
was O
evident O
that O
, O
since O
binding O
is O
more O
extensive O
intracellularly O
than O
in O
the O
medium O
, O
increased O
partitioning O
into O
the O
cellular O
volume O
, O
due O
to O
active O
uptake O
, O
increases O
the O
total O
amount O
of O
atorvastatin B
bound O
in O
the O
incubation O
. O

Investigation O
of O
the O
toxicokinetics O
of O
petroleum B
hydrocarbon I
distillates O
with O
the O
earthworm O
Eisenia O
andrei O
. O

The O
Canada O
- O
wide O
standards O
for O
petroleum B
hydrocarbons I
in O
soils O
regulate O
petroleum B
hydrocarbons I
based O
on O
four O
distillate O
ranges O
: O
F1 O
( O
C6 O
- O
C10 O
) O
, O
F2 O
( O
> O
C10 O
- O
C16 O
) O
, O
F3 O
( O
> O
C16 O
- O
C34 O
) O
, O
and O
F4 O
( O
> O
C34 O
) O
. O

Biota O
- O
soil O
accumulation O
factors O
were O
> O
1 O
for O
total O
F2 O
aliphatics O
and O
aromatics O
and O
F3a O
aromatics O
as O
well O
as O
for O
several O
individual O
polyaromatic B
hydrocarbons I
for O
each O
distillate O
. O

Cocoa O
polyphenols B
enhance O
positive O
mood O
states O
but O
not O
cognitive O
performance O
: O
a O
randomized O
, O
placebo O
- O
controlled O
trial O
. O

This O
study O
aimed O
to O
examine O
the O
acute O
and O
sub O
- O
chronic O
effects O
of O
cocoa O
polyphenols B
on O
cognition O
and O
mood O
. O

In O
a O
randomized O
, O
double O
- O
blind O
study O
, O
healthy O
middle O
- O
aged O
participants O
received O
a O
dark O
chocolate O
drink O
mix O
standardized O
to O
contain O
500 O
mg O
, O
250 O
mg O
or O
0 O
mg O
of O
polyphenols B
( O
placebo O
) O
in O
a O
parallel O
- O
groups O
design O
. O

This O
randomized O
controlled O
trial O
is O
perhaps O
the O
first O
to O
demonstrate O
the O
positive O
effects O
of O
cocoa O
polyphenols B
on O
mood O
in O
healthy O
participants O
. O

This O
provides O
a O
rationale O
for O
exploring O
whether O
cocoa O
polyphenols B
can O
ameliorate O
the O
symptoms O
associated O
with O
clinical O
anxiety O
or O
depression O
. O

Heroin B
addicts O
consume O
large O
quantities O
of O
refined O
sugars B
. O

Seven O
opiate O
users O
received O
methadone O
and O
seven O
buprenorphine B
maintenance O
. O

Sucrose B
recognition O
thresholds O
and O
measurements O
of O
pleasantness O
and O
intensity O
were O
determined O
before O
and O
four O
hours O
after O
1 O
) O
a O
single O
dose O
of O
methadone O
or O
buprenorphine B
or O
2 O
) O
naltrexone O
. O

Changes O
in O
taste O
perception O
may O
underlie O
altered O
consumption O
of O
refined O
sugars B
in O
opiate O
users O
. O

INTRODUCTION O
: O
Janus O
kinases O
( O
JAKs O
) O
comprise O
a O
family O
of O
four O
enzymes O
, O
JAK1 O
, O
JAK2 O
, O
JAK3 O
and O
tyrosine B
kinase O
2 O
( O
TYK2 O
) O
, O
centrally O
implicated O
in O
cell O
signaling O
processes O
important O
in O
cancer O
and O
immune O
- O
inflammatory O
diseases O
. O

Progression O
in O
the O
field O
has O
taken O
a O
recent O
step O
forward O
with O
the O
approval O
of O
ruxolitinib B
( O
Jakafi O
) O
, O
a O
selective O
inhibitor O
of O
JAK1 O
/ O
2 O
and O
very O
recently O
tofacitinib O
( O
Xeljanz O
) O
, O
a O
pan O
- O
JAK O
inhibitor O
. O

An O
overview O
is O
given O
on O
the O
diversity O
of O
core O
structures O
employed O
for O
inhibitor O
design O
showing O
that O
the O
vast O
majority O
of O
compounds O
are O
based O
on O
classic O
ATP B
- O
competitive O
kinase O
inhibitor O
heterocycles O
. O

EXPERT O
OPINION O
: O
JAK O
inhibitor O
therapy O
is O
entering O
a O
significant O
new O
era O
with O
the O
advent O
on O
the O
market O
of O
the O
JAK1 O
/ O
2 O
inhibitor O
ruxolitinib B
and O
the O
pan O
- O
JAK O
inhibitor O
tofacitinib O
, O
with O
unprecedented O
speed O
of O
development O
. O

Crystallization O
of O
glycine B
in O
the O
cylindrical O
nanopores O
of O
anodic O
aluminum B
oxide I
( O
AAO O
) O
revealed O
the O
formation O
of O
metastable O
beta O
- O
glycine O
in O
pores O
having O
diameters O
less O
than O
200 O
nm O
. O

The O
alpha O
- O
glycine O
nanocrystals O
were O
oriented O
with O
the O
[ O
010 O
] O
axis O
nearly O
perpendicular O
to O
the O
pore O
direction O
, O
reflecting O
a O
nearly O
90 O
degrees O
rotation O
of O
the O
glycine B
molecules O
during O
the O
transition O
. O

When O
the O
beta O
- O
glycine O
nanocrystals O
were O
formed O
in O
the O
AAO O
cylinders O
in O
the O
presence O
of O
small O
amounts O
of O
racemic O
hydrophobic O
amino B
acid I
auxiliaries O
, O
which O
are O
known O
to O
bind O
selectively O
to O
the O
( O
010 O
) O
and O
( O
010 O
) O
faces O
on O
the O
fast O
- O
growing O
end O
of O
beta O
- O
glycine O
enantiomorphs O
, O
the O
beta O
- O
- O
> O
alpha O
phase O
transition O
at O
90 O
% O
RH O
was O
suppressed O
. O

In O
contrast O
, O
beta O
- O
glycine O
nanocrystals O
grown O
in O
the O
presence O
of O
an O
enantiopure O
amino B
acid I
auxiliary O
, O
which O
binds O
to O
the O
fast O
- O
growing O
end O
of O
only O
one O
of O
the O
enantiomorphs O
, O
thus O
suppressing O
its O
formation O
and O
leaving O
the O
other O
enantiomorph O
unperturbed O
, O
transformed O
into O
the O
alpha O
polymorph O
under O
the O
same O
conditions O
. O

This O
observation O
confirms O
that O
binding O
of O
an O
amino B
acid I
to O
the O
{ O
010 O
} O
faces O
is O
stereoselective O
and O
that O
access O
of O
water O
to O
these O
faces O
is O
essential O
for O
the O
transition O
to O
the O
alpha O
polymorph O
. O

Two O
main O
barriers O
to O
its O
widespread O
use O
are O
the O
lack O
of O
( O
1 O
) O
fabrication O
protocols O
leading O
to O
tailored O
functionalization O
of O
the O
graphene B
sheet O
with O
oxygen B
- O
containing O
chemical O
groups O
, O
and O
( O
2 O
) O
understanding O
of O
the O
impact O
of O
such O
functional O
groups O
on O
the O
stability O
and O
on O
the O
optical O
and O
electronic O
properties O
of O
rGO O
. O

Our O
calculations O
indicate O
the O
metastable O
nature O
of O
carbonyl B
- O
rich O
rGO O
and O
its O
favorable O
transformation O
to O
hydroxyl B
- O
rich O
rGO O
at O
room O
temperature O
via O
carbonyl B
- O
to O
- O
hydroxyl B
conversion O
reactions O
near O
carbon B
vacancies O
and O
holes O
. O

We O
demonstrate O
a O
significant O
tunability O
in O
the O
work O
function O
of O
rGO O
up O
to O
2 O
. O
5 O
eV O
by O
altering O
the O
composition O
of O
oxygen B
- O
containing O
functional O
groups O
for O
a O
fixed O
oxygen B
concentration O
, O
and O
of O
the O
photoluminescence O
emission O
by O
modulating O
the O
fraction O
of O
epoxy B
and O
carbonyl B
groups O
. O

Not O
only O
are O
the O
iodido O
complexes O
more O
potent O
than O
the O
chlorido O
analogues O
, O
but O
they O
are O
not O
cross O
- O
resistant O
with O
the O
clinical O
platinum B
drugs O
cisplatin B
and O
oxaliplatin O
. O

They O
arrest O
cell O
growth O
in O
G1 O
phase O
in O
contrast O
to O
cisplatin B
( O
S O
phase O
) O
with O
a O
high O
incidence O
of O
late O
- O
stage O
apoptosis O
. O

In O
general O
, O
antiproliferative O
activity O
is O
greatly O
enhanced O
by O
low O
levels O
of O
the O
glutathione B
synthase O
inhibitor O
l O
- O
buthionine O
sulfoxime O
. O

Metastable O
Cu B
( I
I I
) I
- O
niobate O
semiconductor O
with O
a O
low O
- O
temperature O
, O
nanoparticle O
- O
mediated O
synthesis O
. O

A O
nanoparticle O
synthetic O
strategy O
for O
the O
preparation O
of O
a O
new O
metastable O
Cu B
( I
I I
) I
- O
niobate O
is O
described O
, O
and O
that O
involves O
multipored O
Li O
3 O
NbO O
4 O
nanoparticles O
as O
a O
precursor O
. O

These O
particles O
are O
subsequently O
used O
in O
a O
solvothermal O
copper B
( I
I I
) I
- O
exchange O
reaction O
with O
excess O
CuCl O
at O
150 O
degrees O
C O
. O

The O
compound O
thermally O
decomposes O
starting O
at O
~ O
250 O
degrees O
C O
and O
higher O
temperatures O
, O
depending O
on O
the O
particle O
sizes O
, O
owing O
to O
the O
loss O
of O
the O
weakly O
coordinated O
Cu B
( I
I I
) I
cations O
from O
the O
structure O
and O
a O
concurrent O
disproportionation O
reaction O
at O
its O
surfaces O
. O

Electronic O
structure O
calculations O
based O
on O
density O
functional O
theory O
show O
that O
the O
bandgap O
transition O
results O
from O
the O
excitation O
of O
electrons O
at O
the O
band O
edges O
between O
filled O
Cu B
( I
I I
) I
3d O
( O
1 O
) O
0 O
- O
orbitals O
and O
empty O
Nb O
( O
V O
) O
4d O
0 O
- O
orbitals O
, O
respectively O
. O

These O
results O
demonstrate O
the O
general O
utility O
of O
reactive O
nanoscale O
precursors O
in O
the O
synthetic O
discovery O
of O
new O
Cu B
( I
I I
) I
- O
based O
semiconducting O
oxides B
and O
which O
also O
show O
promise O
for O
use O
in O
solar O
energy O
conversion O
applications O
. O

Self O
- O
assembled O
structures O
of O
brush O
block O
copolymers O
( O
BrBCPs O
) O
with O
polylactide B
( O
PLA B
) O
and O
polystyrene B
( O
PS O
) O
side O
chains O
were O
studied O
. O

Oil O
droplets O
loaded O
with O
surfactant O
propel O
themselves O
with O
a O
velocity O
up O
to O
6 O
mm O
s O
( O
- O
1 O
) O
when O
they O
are O
placed O
in O
an O
aqueous O
phase O
of O
NaOH B
solution O
or O
buffer O
solution O
. O

Environmentally O
friendly O
poly O
( O
butylenesuccinate O
- O
co O
- O
butyleneazelate O
) O
( O
P O
( O
BS O
- O
co O
- O
BAz O
) O
s O
) O
aliphatic O
copolyesters O
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic B
acid I
( O
SuA O
) O
, O
1 B
, I
4 I
- I
butanediol I
( O
BDO O
) O
, O
and O
dimethylazelate O
( O
DMAz O
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

The O
molar O
SuA O
/ O
AzA B
ratio O
was O
varied O
from O
4 O
: O
1 O
to O
1 O
: O
4 O
, O
and O
the O
chemical O
structure O
and O
molecular O
characteristics O
of O
resulting O
( O
co O
) O
polyesters O
were O
characterized O
by O
NMR O
and O
SEC O
, O
whereas O
thermal O
properties O
and O
crystallinity O
were O
studied O
by O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
dynamic O
mechanical O
thermal O
analyses O
( O
DMTA O
) O
, O
and O
X O
- O
ray O
diffraction O
( O
XRD O
) O
. O

A O
good O
agreement O
between O
theoretical O
and O
experimental O
SuA O
/ O
AzA B
molar O
ratios O
in O
the O
copolyesters O
was O
achieved O
, O
together O
with O
the O
recovery O
of O
semicrystalline O
random O
copolymers O
of O
uniform O
composition O
along O
the O
chains O
. O

Abstract O
Context O
: O
Tri O
- O
layered O
floating O
tablets O
using O
only O
one O
grade O
of O
polyethylene B
oxide I
( O
PEO B
) O
would O
enable O
easy O
manufacturing O
, O
reproducibility O
and O
controlled O
release O
for O
highly O
soluble O
drugs O
. O

Objective O
: O
To O
evaluate O
the O
potential O
of O
PEO B
as O
a O
sole O
polymer O
for O
the O
controlled O
release O
and O
to O
study O
the O
effect O
of O
formulation O
variables O
on O
release O
and O
gastric O
retention O
of O
highly O
soluble O
Diltiazem O
hydrochloride O
( O
DTZ O
) O
. O

Design O
of O
formulation O
to O
obtain O
12 O
h O
, O
zero O
- O
order O
release O
and O
rapid O
floatation O
was O
done O
by O
varying O
the O
grades O
, O
quantity O
of O
PEO B
and O
sodium O
bicarbonate O
. O

Drug O
release O
was O
faster O
from O
low O
molecular O
weight O
( O
MW O
) O
PEO B
as O
compared O
to O
high O
MW O
. O

With O
an O
increase O
in O
the O
amount O
of O
sodium O
bicarbonate O
, O
faster O
buoyancy O
was O
achieved O
due O
to O
the O
increased O
CO B
( I
2 I
) I
gas O
formation O
. O

Currently O
, O
there O
are O
two O
NAI O
drugs O
which O
are O
licensed O
worldwide O
: O
oseltamivir O
and O
zanamivir B
, O
and O
two O
more O
drugs O
which O
have O
received O
recent O
approval O
in O
Japan O
: O
peramivir B
and O
laninamivir B
. O

They O
strongly O
exhibited O
the O
activity O
of O
NA O
in O
the O
low O
nanomolar O
range O
such O
as O
phosphonate B
congeners O
of O
zanamivir B
and O
oseltarmivir O
. O

Screening O
strategies O
based O
on O
the O
chemical O
diversity O
of O
natural O
products O
have O
revealed O
that O
flavonoids B
are O
the O
most O
prominent O
scaffolds O
possessing O
NA O
inhibitory O
activity O
. O

However O
, O
these O
substituted O
phenyl O
- O
benzopyrane O
compounds O
have O
been O
reported O
to O
exert O
a O
considerable O
quenching O
effect O
, O
causing O
false O
- O
positive O
results O
in O
the O
commonly O
used O
method O
of O
enzyme O
- O
based O
NA O
inhibition O
assays O
, O
and O
thus O
, O
reliability O
of O
the O
flavonoid B
- O
based O
NAIs O
reported O
in O
the O
literature O
. O

Liver O
, O
plasma O
and O
erythrocyte O
levels O
of O
thiamine B
and O
its O
phosphate O
esters O
in O
rats O
with O
acute O
ethanol B
intoxication O
: O
a O
comparison O
of O
thiamine B
and O
benfotiamine O
administration O
. O

Thiamine B
and O
benfotiamine O
are O
vitamin O
B1 O
and O
pro O
- O
vitamin O
B1 O
substances O
, O
respectively O
. O

This O
study O
presents O
new O
data O
about O
the O
effects O
of O
thiamine O
hydrochloride O
or O
benfotiamine O
treatment O
given O
to O
rats O
with O
acute O
alcohol B
intoxication O
, O
on O
the O
distribution O
of O
thiamine B
and O
its O
phosphate O
esters O
in O
liver O
, O
plasma O
and O
erythrocytes O
. O

The O
treatments O
were O
effective O
in O
increasing O
thiamine B
levels O
in O
plasma O
, O
erythrocytes O
and O
liver O
cells O
. O

The O
benfotiamine O
- O
treated O
group O
had O
its O
total O
plasma O
thiamine B
increased O
by O
100 O
% O
. O

In O
erythrocytes O
, O
thiamine B
levels O
were O
4 O
- O
and O
25 O
- O
fold O
higher O
in O
the O
groups O
treated O
with O
thiamine B
and O
benfotiamine O
, O
respectively O
, O
compared O
with O
the O
untreated O
groups O
. O

Liver O
thiamine B
was O
increased O
by O
60 O
% O
in O
the O
treated O
groups O
compared O
with O
the O
untreated O
groups O
. O

Thus O
, O
we O
verified O
the O
high O
bioavailability O
especially O
of O
benfotiamine O
within O
6h O
of O
ethanol B
administration O
. O

Short O
- O
term O
assessment O
of O
toxicological O
aspects O
, O
oxidative O
and O
inflammatory O
response O
to O
dietary O
melon O
superoxide B
dismutase O
in O
rats O
. O

The O
protective O
effects O
of O
SODB O
, O
a O
gastro O
- O
resistant O
encapsulated O
melon O
superoxide B
dismutase O
, O
on O
haematological O
and O
biochemical O
parameters O
and O
inflammatory O
and O
oxidative O
status O
, O
were O
evaluated O
in O
the O
blood O
and O
liver O
tissue O
. O

No O
marked O
change O
was O
recorded O
in O
biochemical O
parameters O
( O
plasma O
urea B
, O
creatinine B
, O
lipids O
, O
electrolytes O
, O
bilirubin B
, O
transaminases O
and O
gamma O
- O
glutamyl O
transferase O
) O
. O

The O
liver O
endogenous O
antioxidant O
enzymes O
( O
copper B
/ O
zinc B
and O
manganese O
superoxide O
dismutase O
) O
expressions O
were O
significantly O
increased O
in O
the O
rats O
receiving O
the O
highest O
dose O
of O
SODB O
( O
160USOD O
/ O
day O
) O
whatever O
the O
coating O
. O

Anti O
- O
oxidant O
and O
natural O
killer O
cell O
activity O
of O
Korean O
red O
ginseng O
( O
Panax O
ginseng O
) O
and O
urushiol B
( O
Rhus O
vernicifera O
Stokes O
) O
on O
non O
- O
alcoholic O
fatty O
liver O
disease O
of O
rat O
. O

Anti O
- O
oxidative O
and O
immunologic O
effects O
of O
the O
Korea O
red O
ginseng O
( O
KRG O
; O
Panax O
ginseng O
) O
and O
urushiol B
( O
Rhus O
vernicifera O
Stokes O
) O
on O
non O
- O
alcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
were O
evaluated O
. O

The O
OLETF O
rats O
were O
divided O
into O
the O
following O
four O
groups O
according O
to O
diet O
for O
2months O
: O
NAFLD O
( O
chew O
) O
, O
KRG O
( O
chew O
+ O
KRG O
[ O
200mg O
/ O
kg O
/ O
day O
] O
) O
, O
urushiol B
( O
chew O
+ O
urushiol B
[ O
0 O
. O
5mg O
/ O
kg O
/ O
day O
] O
) O
, O
and O
ursodeoxycholic O
acid O
( O
UDCA O
) O
( O
chew O
+ O
UDCA O
[ O
15mg O
/ O
kg O
/ O
day O
] O
) O
groups O
. O

In O
KRG O
and O
urushiol B
groups O
, O
the O
level O
of O
serum O
triglyceride B
( O
[ O
302 O
. O
0 O
+ O
/ O
- O
70 O
. O
4 O
and O
275 O
. O
2 O
+ O
/ O
- O
63 O
. O
8 O
] O
vs O
. O
527 O
. O
7 O
+ O
/ O
- O
153 O
. O
3mg O
/ O
dL O
) O
were O
lower O
compared O
with O
that O
of O
NAFLD O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
levels O
of O
HDL O
- O
cholesterol B
( O
liver O
tissue O
: O
[ O
4 O
. O
8 O
+ O
/ O
- O
0 O
. O
2 O
and O
4 O
. O
8 O
+ O
/ O
- O
0 O
. O
5 O
] O
vs O
. O
4 O
. O
2 O
+ O
/ O
- O
0 O
. O
2mg O
/ O
g O
) O
and O
NK O
cell O
activity O
( O
[ O
3485 O
+ O
/ O
- O
910 O
and O
3559 O
+ O
/ O
- O
910 O
] O
vs O
. O
2486 O
+ O
/ O
- O
619 O
counts O
) O
were O
significantly O
higher O
than O
those O
of O
the O
NAFLD O
group O
( O
p O
< O
0 O
. O
001 O
) O
. O

These O
results O
suggest O
that O
2months O
of O
oral O
KRG O
or O
urushiol B
administration O
improves O
lipid O
profiles O
and O
stimulates O
NK O
cell O
activity O
, O
while O
inhibiting O
steatohepatitis O
in O
OLEFT O
rats O
. O

The O
apoptosis O
was O
verified O
by O
staining O
with O
Annexin O
V O
- O
FITC B
and O
propidium B
iodide I
. O

Diastrophic O
dysplasia O
( O
DTD O
) O
is O
a O
chondrodysplasia O
caused O
by O
mutations O
in O
the O
SLC26A2 O
gene O
, O
leading O
to O
reduced O
intracellular O
sulfate B
pool O
in O
chondrocytes O
, O
osteoblasts O
and O
fibroblasts O
. O

Although O
the O
osteoclast O
number O
evaluated O
by O
histomorphometry O
was O
not O
different O
in O
dtd O
compared O
to O
wild O
- O
type O
mice O
, O
urine O
analysis O
of O
deoxypyridinoline B
cross O
- O
links O
and O
serum O
levels O
of O
type O
I O
collagen O
C B
- O
terminal O
telopeptides O
showed O
a O
higher O
resorption O
rate O
in O
dtd O
mice O
compared O
to O
wild O
- O
type O
littermates O
. O

Previously O
, O
we O
have O
showed O
that O
lead O
acetate O
( O
Pb B
) O
elicits O
EGFR O
activation O
to O
initiate O
the O
SFK O
/ O
PKC O
alpha O
/ O
Ras O
/ O
Raf O
- O
1 O
/ O
MKK1 O
/ O
2 O
/ O
ERK O
signaling O
cascade O
functioning O
against O
genotoxicity O
. O

Here O
, O
we O
explore O
whether O
APE1 O
and O
reactive O
oxygen B
species O
( O
ROS O
) O
affect O
ERK O
signaling O
and O
cell O
cycle O
progression O
following O
Pb B
exposure O
. O

We O
found O
that O
Pb B
induced O
APE1 O
expression O
and O
ROS O
generation O
in O
CL3 O
human O
lung O
cancer O
cells O
. O

The O
Pb B
- O
elicited O
ROS O
levels O
and O
cytotoxicity O
were O
further O
enhanced O
by O
introducing O
small O
interfering O
RNA O
specific O
for O
APE1 O
( O
siAPE1 O
) O
. O

E3330 O
, O
an O
inhibitor O
of O
APE1 O
redox O
activity O
, O
also O
augmented O
the O
ROS O
levels O
and O
cytotoxicity O
in O
Pb B
- O
treated O
cells O
. O

Intriguingly O
, O
the O
capability O
of O
Pb B
to O
activate O
ERK O
was O
abolished O
under O
siAPE1 O
or O
E3330 O
co O
- O
treatments O
; O
conversely O
, O
forced O
expression O
of O
APE1 O
up O
- O
regulated O
the O
ERK O
activation O
by O
Pb B
or O
serum O
in O
both O
Cys65 O
- O
redox O
activity O
dependent O
and O
independent O
manners O
. O

APE1 O
redox O
activity O
also O
facilitated O
the O
Cyclin O
D1 O
expression O
and O
G1 O
- O
to O
- O
S O
progression O
following O
Pb B
exposure O
. O

Synthesis O
, O
quantitative O
structure O
- O
activity O
relationship O
and O
biological O
evaluation O
of O
1 O
, O
3 O
, O
4 O
- O
oxadiazole O
derivatives O
possessing O
diphenylamine B
moiety O
as O
potential O
anticancer O
agents O
. O

All O
the O
synthesized O
derivatives O
were O
screened O
for O
anticancer O
activity O
against O
HT29 O
and O
MCF7 O
cancer O
cell O
lines O
using O
Sulfo O
- O
Rodamine O
B O
( O
SRB B
) O
standard O
method O
. O

Organosilicon B
compounds O
as O
adult O
T O
- O
cell O
leukemia O
cell O
proliferation O
inhibitors O
. O

Recently O
, O
we O
developed O
ATL O
cell O
- O
selective O
proliferation O
inhibitors O
based O
on O
a O
tetrahydrotetramethy O
( O
TMN O
) O
skeleton O
1 O
, O
and O
here O
we O
report O
the O
design O
and O
synthesis O
of O
silicon B
analogs O
of O
TMN O
derivatives O
. O

This O
result O
, O
as O
well O
as O
computational O
studies O
, O
suggests O
that O
sila O
- O
substitution O
( O
C B
/ O
Si B
exchange O
) O
is O
useful O
for O
structure O
optimization O
of O
these O
inhibitors O
. O

Silver B
clusters O
are O
sufficiently O
reactive O
to O
facilitate O
the O
study O
of O
the O
ambient O
temporal O
stability O
of O
magic O
- O
number O
metal O
clusters O
and O
to O
begin O
to O
understand O
their O
decay O
mechanisms O
. O

Here O
, O
the O
solution O
phase O
stability O
of O
a O
series O
of O
silver B
: O
glutathione B
( O
Ag B
: O
SG O
) O
clusters O
was O
studied O
as O
a O
function O
of O
size O
, O
pH O
and O
chemical O
environment O
. O

The O
decay O
mechanism O
was O
found O
to O
involve O
the O
loss O
of O
Ag B
( I
+ I
) I
ions O
and O
silver O
glutathionates O
. O

Clusters O
could O
be O
stabilized O
by O
the O
addition O
of O
Ag B
( I
+ I
) I
ions O
and O
destabilized O
by O
either O
the O
addition O
of O
glutathione B
or O
the O
removal O
of O
Ag B
( I
+ I
) I
ions O
. O

The O
role O
of O
cortisol B
and O
psychopathy O
in O
the O
cycle O
of O
violence O
. O

METHODS O
: O
Sixty O
- O
seven O
adult O
participants O
were O
given O
an O
acute O
dose O
of O
20 O
mg O
cortisol B
in O
a O
placebo O
- O
controlled O
, O
within O
- O
subject O
, O
counter O
- O
balanced O
dosing O
design O
. O

Salivary O
cortisol B
was O
measured O
at O
baseline O
and O
at O
regular O
intervals O
across O
a O
5 O
h O
testing O
period O
. O

RESULTS O
: O
Using O
multiple O
regression O
, O
a O
model O
including O
abuse O
/ O
neglect O
, O
psychopathy O
, O
impulsivity O
, O
and O
baseline O
cortisol B
explained O
58 O
% O
of O
the O
variance O
in O
trait O
aggression O
and O
26 O
% O
of O
the O
variance O
in O
state O
aggression O
. O

One O
- O
Pot O
Facile O
Synthesis O
of O
Double O
- O
Shelled O
SnO2 B
Yolk O
- O
Shell O
- O
Structured O
Powders O
by O
Continuous O
Process O
as O
Anode O
Materials O
for O
Li B
- O
ion O
Batteries O
. O

Double O
- O
shelled O
SnO2 B
yolk O
- O
shell O
- O
structured O
powders O
are O
prepared O
by O
applying O
a O
new O
facile O
one O
- O
pot O
process O
. O

Carbon B
- O
SnO2 B
composite O
powder O
particles O
are O
first O
formed O
as O
an O
intermediate O
product O
inside O
a O
tubular O
reactor O
. O

Step O
- O
by O
- O
step O
combustion O
of O
carbon B
from O
outside O
the O
composite O
powder O
particles O
forms O
the O
double O
- O
shelled O
SnO2 B
yolk O
- O
shell O
- O
structured O
powder O
particles O
. O

The O
SnO2 B
yolk O
- O
shell O
- O
structured O
powders O
show O
excellent O
electrochemical O
properties O
. O

The O
highly O
selective O
sensors O
, O
built O
from O
very O
small O
modified O
DNA O
oligomers O
containing O
the O
unnatural O
fluorescent O
base O
pyrene B
, O
and O
employing O
thymine B
as O
a O
quencher O
, O
were O
found O
to O
function O
in O
a O
variety O
of O
complex O
biological O
media O
. O

Manganese B
supplementation O
protects O
against O
diet O
- O
induced O
diabetes O
in O
wild O
type O
mice O
by O
enhancing O
insulin O
secretion O
. O

Mitochondrial O
manganese B
- O
superoxide B
dismutase O
( O
MnSOD O
) O
is O
a O
metalloenzyme O
that O
provides O
antioxidant O
protection O
. O

We O
have O
previously O
shown O
in O
a O
mouse O
model O
of O
hereditary O
iron O
overload O
that O
cytosolic O
iron B
levels O
affected O
mitochondrial O
manganese B
availability O
, O
MnSOD O
activity O
, O
and O
insulin O
secretion O
. O

To O
determine O
whether O
manganese O
supplementation O
offered O
glucose B
homeostasis O
under O
a O
situation O
of O
beta O
- O
cell O
stress O
, O
we O
challenged O
C57BL O
/ O
6J O
mice O
, O
which O
are O
more O
susceptible O
to O
diet O
- O
induced O
diabetes O
, O
with O
a O
high O
- O
fat O
diet O
for O
12 O
weeks O
. O

Manganese B
was O
supplemented O
or O
not O
for O
the O
final O
8 O
weeks O
on O
that O
diet O
, O
after O
which O
we O
examined O
glucose B
tolerance O
and O
the O
function O
of O
isolated O
islets O
. O

Liver O
mitochondria O
from O
manganese B
- O
injected O
C57BL O
/ O
6J O
mice O
had O
similar O
increases O
in O
MnSOD O
activity O
( O
81 O
% O
) O
and O
metallation O
as O
were O
seen O
in O
129 O
/ O
SvEVTac O
mice O
. O

The O
manganese B
- O
treated O
group O
fed O
high O
fat O
had O
improved O
glucose B
tolerance O
( O
24 O
% O
decrease O
in O
fasting O
glucose B
and O
41 O
% O
decrease O
in O
area O
under O
the O
glucose B
curve O
) O
, O
comparable O
with O
mice O
on O
normal O
chow O
and O
increased O
serum O
insulin O
levels O
. O

Isolated O
islets O
from O
the O
manganese B
- O
treated O
group O
exhibited O
improved O
insulin O
secretion O
, O
decreased O
lipid O
peroxidation O
, O
and O
improved O
mitochondrial O
function O
. O

In O
conclusion O
, O
MnSOD O
metallation O
and O
activity O
can O
be O
augmented O
with O
manganese B
supplementation O
in O
normal O
mice O
on O
normal O
chow O
, O
and O
manganese B
treatment O
can O
increase O
insulin O
secretion O
to O
improve O
glucose B
tolerance O
under O
conditions O
of O
dietary O
stress O
. O

Methods O
: O
The O
sample O
treatment O
included O
protein O
precipitation O
by O
cold O
acetonitrile B
, O
evaporation O
, O
reconstitution O
with O
methanol B
and O
filtration O
. O

The O
chromatography O
conditions O
included O
Xterra O
RP18 O
3 O
. O
5 O
micro O
m O
4 O
. O
6 O
x O
100 O
mm O
column O
at O
ambient O
temperature O
and O
mobile O
phase O
consisting O
of O
methanol B
/ O
water O
( O
93 O
/ O
7 O
, O
v O
/ O
v O
) O
at O
0 O
. O
5 O
mL O
/ O
min O
flow O
rate O
. O

Vitamin B
D I
( I
3 I
) I
and O
probucol B
were O
detected O
at O
265 O
nm O
and O
vitamin O
K O
( O
1 O
) O
at O
239 O
nm O
. O

Results O
: O
The O
calibration O
curves O
in O
rat O
plasma O
were O
linear O
up O
to O
5000 O
ng O
/ O
mL O
for O
both O
vitamins B
. O

The O
limit O
of O
quantification O
( O
LOQ O
) O
was O
20 O
ng O
/ O
mL O
for O
vitamin B
D I
( I
3 I
) I
and O
40 O
ng O
/ O
mL O
for O
K O
( O
1 O
) O
. O

The O
pharmacokinetic O
parameters O
of O
vitamin B
D I
( I
3 I
) I
following O
intravenous O
administration O
were O
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
11323 O
+ O
/ O
- O
1081 O
h O
x O
ng O
/ O
mL O
, O
V O
( O
d O
) O
= O
218 O
+ O
/ O
- O
80 O
mL O
/ O
kg O
, O
CL O
= O
8 O
. O
9 O
+ O
/ O
- O
0 O
. O
8 O
mL O
/ O
h O
/ O
kg O
, O
t O
( O
1 O
/ O
2 O
) O
= O
16 O
. O
8 O
+ O
/ O
- O
5 O
h O
; O
and O
of O
vitamin O
K O
( O
1 O
) O
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
2495 O
+ O
/ O
- O
297 O
h O
x O
ng O
/ O
mL O
, O

Emulsion O
- O
templated O
self O
- O
assembly O
of O
iron B
oxide I
nanoparticles O
into O
microparticles O
using O
oil O
- O
in O
- O
water O
emulsions O
was O
carried O
out O
using O
a O
modified O
Couette O
shear O
mixer O
with O
separate O
inlet O
ports O
for O
the O
oil O
and O
aqueous O
phases O
, O
enabling O
high O
throughput O
microparticle O
synthesis O
. O

Superparamagnetic O
microparticles O
with O
dimpled O
and O
crumpled O
morphologies O
were O
found O
to O
have O
higher O
specific O
binding O
capacities O
compared O
to O
spherical O
microparticles O
, O
while O
maintaining O
high O
magnetic O
field O
velocities O
due O
to O
their O
high O
iron B
oxide I
content O
. O

AtO B
( I
+ I
) I
is O
the O
dominant O
species O
existing O
under O
oxidizing O
and O
acidic O
pH O
conditions O
. O

The O
specificity O
of O
polymer O
conjugates O
based O
on O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
bearing O
cytostatic O
drugs O
for O
cancer O
cells O
could O
be O
significantly O
increased O
by O
the O
incorporation O
of O
a O
suitable O
targeting O
ligand O
, O
such O
as O
a O
monoclonal O
antibody O
( O
mAb O
) O
. O

Peptide O
E O
( O
( O
VAALEKE O
) O
4 O
) O
, O
which O
forms O
a O
stable O
coiled O
coil O
structure O
heterodimer O
with O
peptide O
K O
, O
was O
assembled O
with O
the O
HPMA B
copolymers O
bearing O
doxorubicin B
. O

Dopamine B
D2 O
receptor O
activation O
leads O
to O
an O
up O
- O
regulation O
of O
glial O
cell O
line O
- O
derived O
neurotrophic O
factor O
via O
G O
beta O
gamma O
- O
Erk1 O
/ O
2 O
- O
dependent O
induction O
of O
Zif268 O
. O

We O
found O
that O
treatment O
of O
both O
differentiated O
dopaminergic O
- O
like O
SH O
- O
SY5Y O
cells O
and O
rat O
midbrain O
slices O
with O
the O
dopamine B
D2 O
receptor O
( O
D2R O
) O
agonist O
, O
quinpirole B
, O
triggered O
an O
increase O
in O
the O
expression O
of O
GDNF O
that O
was O
temporally O
preceded O
by O
an O
increase O
in O
the O
levels O
of O
zinc B
- O
finger O
protein O
268 O
( O
Zif268 O
) O
, O
a O
DNA O
- O
binding O
transcription O
factor O
encoded O
by O
an O
immediate O
- O
early O
gene O
. O

Moreover O
, O
the O
D2R O
inhibitor O
raclopride B
blocked O
the O
increase O
of O
both O
GDNF O
and O
Zif268 O
expression O
following O
potassium B
- O
evoked O
dopamine B
release O
in O
SH O
- O
SY5Y O
cells O
. O

Fast O
protein O
motions O
are O
coupled O
to O
enzyme O
H B
- O
transfer O
reactions O
. O

Coupling O
of O
fast O
protein O
dynamics O
to O
enzyme O
chemistry O
is O
controversial O
and O
has O
ignited O
considerable O
debate O
, O
especially O
over O
the O
past O
15 O
years O
in O
relation O
to O
enzyme O
- O
catalyzed O
H B
- O
transfer O
. O

H B
- O
transfer O
can O
occur O
by O
quantum O
tunneling O
, O
and O
the O
temperature O
dependence O
of O
kinetic O
isotope O
effects O
( O
KIEs O
) O
has O
emerged O
as O
the O
" O
gold O
standard O
" O
descriptor O
of O
these O
reactions O
. O

The O
anomalous O
temperature O
dependence O
of O
KIEs O
is O
often O
rationalized O
by O
invoking O
fast O
motions O
to O
facilitate O
H B
- O
transfer O
, O
yet O
crucially O
, O
direct O
evidence O
for O
coupled O
motions O
is O
lacking O
. O

Here O
, O
we O
have O
perturbed O
vibrational O
motions O
in O
pentaerythritol O
tetranitrate O
reductase O
( O
PETNR O
) O
by O
isotopic O
substitution O
where O
all O
non O
- O
exchangeable O
atoms O
were O
replaced O
with O
the O
corresponding O
heavy O
isotope O
( O
( B
13 I
) I
C I
, O
( B
15 I
) I
N I
, O
and O
( B
2 I
) I
H I
) O
. O

Cis O
- O
trans O
isomerizations O
of O
proline B
residues O
are O
key O
to O
bradykinin O
conformations O
. O

A O
recent O
ion O
mobility O
- O
mass O
spectrometry O
( O
IM O
- O
MS O
) O
study O
of O
the O
nonapeptide O
bradykinin O
( O
BK O
, O
amino B
acid I
sequence O
Arg O
( O
1 O
) O
- O
Pro B
( O
2 O
) O
- O
Pro B
( O
3 O
) O
- O
Gly B
( O
4 O
) O
- O
Phe B
( O
5 O
) O
- O
Ser B
( O
6 O
) O
- O
Pro B
( O
7 O
) O
- O
Phe B
( O
8 O
) O
- O
Arg O
( O
9 O
) O
) O
found O
evidence O
for O
10 O
populations O
of O
conformations O
that O
depend O
upon O
the O
solution O
composition O
[ O
J O
. O
Am O
. O
Chem O
. O
Soc O
. O
2011 O
, O
133 O
, O
13810 O
] O
. O

Here O
, O
the O
role O
of O
the O
three O
proline B
residues O
( O
Pro B
( O
2 O
) O
, O
Pro B
( O
3 O
) O
, O
and O
Pro B
( O
7 O
) O
) O
in O
establishing O
these O
conformations O
is O
investigated O
using O
a O
series O
of O
seven O
analogue O
peptides O
in O
which O
combinations O
of O
alanine B
residues O
are O
substituted O
for O
prolines O
. O

IM O
- O
MS O
distributions O
of O
the O
analogue O
peptides O
, O
when O
compared O
to O
the O
distribution O
for O
BK O
, O
indicate O
the O
multiple O
structures O
are O
associated O
with O
different O
combinations O
of O
cis O
and O
trans O
forms O
of O
the O
three O
proline B
residues O
. O

METHODS O
: O
We O
conducted O
a O
retrospective O
review O
of O
patients O
undergoing O
total O
thyroidectomy O
for O
DTC O
and O
subsequent O
radioactive O
iodine B
( O
RAI O
) O
treatment O
. O

5 O
- O
Nitropyrimidine O
analogs O
with O
( O
2 O
- O
fluoro O
- O
4 O
- O
methylsulfonyl O
) O
phenylamino O
group O
( O
8 O
, O
10 O
, O
12 O
, O
14 O
) O
showed O
more O
potent O
GPR119 O
activation O
activities O
than O
the O
analogs O
without O
fluorine B
in O
all O
cases O
( O
7 O
, O
9 O
, O
11 O
, O
13 O
) O
. O

DNA O
- O
based O
aptamers O
that O
contain O
2 O
' O
- O
O O
, O
4 O
' O
- O
C O
- O
methylene O
- O
bridged O
/ O
linked O
bicyclic O
ribonucleotides O
( O
B O
/ O
L O
nucleotides B
) O
over O
the O
entire O
length O
were O
successfully O
obtained O
using O
a O
capillary O
electrophoresis O
systematic O
evolution O
of O
ligands O
by O
exponential O
enrichment O
( O
CE O
- O
SELEX O
) O
method O
. O

Forty O
2 O
' O
- O
O O
, O
4 O
' O
- O
C O
- O
methylene B
bridged O
/ O
locked O
nucleic O
acid O
( O
2 O
' O
, O
4 O
' O
- O
BNA O
/ O
LNA O
) O
aptamers O
were O
isolated O
from O
an O
enriched O
pool O
and O
classified O
into O
six O
groups O
according O
to O
their O
sequence O
. O

The O
structure O
of O
the O
alkaloid O
was O
elucidated O
by O
extensive O
use O
of O
NMR O
spectroscopy O
and O
the O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
is O
reported O
. O

Of O
marsupials O
and O
men O
: O
" O
Backdoor O
" O
dihydrotestosterone B
synthesis O
in O
male O
sexual O
differentiation O
. O

Following O
development O
of O
the O
fetal O
bipotential O
gonad O
into O
a O
testis O
, O
male O
genital O
differentiation O
requires O
testicular O
androgens B
. O

Fetal O
Leydig O
cells O
produce O
testosterone B
that O
is O
converted O
to O
dihydrotestosterone B
in O
genital O
skin O
, O
resulting O
in O
labio O
- O
scrotal O
fusion O
. O

An O
alternative O
' O
backdoor O
' O
pathway O
of O
dihydrotestosterone B
synthesis O
that O
bypasses O
testosterone B
has O
been O
described O
in O
marsupials O
, O
but O
its O
relevance O
to O
human O
biology O
has O
been O
uncertain O
. O

These O
observations O
indicate O
that O
fetal O
dihydrotestosterone B
acts O
both O
as O
a O
hormone O
and O
as O
a O
paracrine O
factor O
, O
substantially O
revising O
the O
classic O
paradigm O
for O
fetal O
male O
sexual O
development O
. O

Long O
- O
range O
interactions O
in O
the O
alpha O
subunit O
of O
tryptophan B
synthase O
help O
to O
coordinate O
ligand O
binding O
, O
catalysis O
, O
and O
substrate O
channeling O
. O

The O
alpha O
- O
subunit O
of O
tryptophan B
synthase O
( O
alpha O
TS O
) O
catalyzes O
the O
conversion O
of O
indole O
- O
3 O
- O
glycerol O
phosphate O
to O
d O
- O
glyceraldehyde O
- O
3 O
- O
phosphate O
and O
indole B
. O

Understanding O
these O
long O
- O
range O
amino B
acid I
networks O
in O
alpha O
TS O
thus O
gives O
insight O
into O
the O
coordination O
of O
the O
two O
active O
sites O
within O
TS O
. O

In O
this O
study O
, O
we O
have O
used O
Ala B
residues O
as O
probes O
for O
structural O
and O
dynamic O
changes O
of O
alpha O
TS O
throughout O
its O
catalytic O
cycle O
, O
in O
the O
absence O
of O
the O
beta O
- O
subunit O
. O

Projection O
analysis O
of O
the O
chemical O
shift O
changes O
by O
site O
- O
specific O
amino B
acid I
substitutions O
and O
ligand O
titrations O
indicates O
that O
alpha O
TS O
has O
three O
important O
conformational O
states O
: O
ligand O
- O
free O
, O
glyceraldehyde O
- O
3 O
- O
phosphate O
- O
bound O
( O
like O
) O
, O
and O
the O
active O
states O
. O

The O
amino B
acid I
networks O
within O
these O
conformations O
are O
different O
, O
as O
suggested O
by O
chemical O
shift O
correlation O
analysis O
. O

Characterization O
of O
the O
mouse O
promoter O
region O
of O
the O
acyl B
- I
CoA I
synthetase O
4 O
gene O
: O
role O
of O
Sp1 O
and O
CREB O
. O

Acyl B
- I
CoA I
synthetase O
4 O
( O
Acsl4 O
) O
is O
involved O
in O
several O
cellular O
functions O
including O
steroidogenesis O
, O
synaptic O
development O
and O
cancer O
metastasis O
. O

We O
demonstrated O
hCG O
and O
cAMP B
regulation O
of O
Acsl4 O
mRNA O
in O
mouse O
steroidogenic O
MA O
- O
10 O
Leydig O
cells O
. O

Functional O
characterization O
revealed O
that O
the O
specificity O
protein O
/ O
Kr O
u O
ppel O
- O
like O
factor O
Sp1 O
binding O
site O
in O
the O
proximal O
promoter O
is O
involved O
in O
basal O
activity O
and O
that O
the O
cAMP B
response O
element O
- O
binding O
site O
is O
involved O
in O
cAMP B
stimulation O
of O
Acsl4 O
transcription O
. O

Influence O
of O
environmentally O
relevant O
concentrations O
of O
vinclozolin B
on O
quality O
, O
DNA O
integrity O
, O
and O
antioxidant O
responses O
of O
sterlet O
Acipenser O
ruthenus O
spermatozoa O
. O

The O
effects O
of O
vinclozolin B
( O
VIN O
) O
, O
an O
anti O
- O
androgenic O
fungicide O
, O
on O
quality O
, O
oxidative O
stress O
, O
DNA O
integrity O
, O
and O
ATP B
level O
of O
sterlet O
( O
Acipenser O
ruthenus O
) O
spermatozoa O
were O
investigated O
in O
vitro O
. O

Fish O
spermatozoa O
were O
incubated O
with O
different O
concentrations O
of O
vinclozolin B
( O
0 O
. O
5 O
, O
2 O
, O
10 O
, O
15 O
, O
20 O
and O
50 O
mu O
g O
/ O
l O
) O
for O
2h O
. O

After O
2h O
exposure O
at O
higher O
test O
concentrations O
( O
10 O
- O
50 O
mu O
g O
/ O
l O
) O
, O
oxidative O
stress O
was O
apparent O
, O
as O
reflected O
by O
significantly O
higher O
levels O
of O
protein O
and O
lipid O
oxidation O
and O
significantly O
greater O
superoxide B
dismutase O
activity O
. O

Intracellular O
ATP B
content O
of O
spermatozoa O
decreased O
with O
increasing O
concentrations O
of O
VIN O
. O

The O
results O
demonstrated O
that O
VIN O
can O
induce O
reactive O
oxygen B
species O
stress O
in O
fish O
spermatozoa O
, O
which O
could O
impair O
the O
sperm O
quality O
, O
DNA O
integrity O
, O
ATP B
content O
, O
and O
the O
antioxidant O
defense O
system O
. O

Reactive O
oxygen B
species O
are O
produced O
as O
side O
products O
of O
oxygen B
utilization O
and O
can O
lead O
to O
the O
oxidation O
of O
nucleic O
acids O
and O
their O
precursor O
nucleotides B
. O

Among O
the O
various O
oxidized O
bases O
, O
8 O
- O
oxo O
- O
7 O
, O
8 O
- O
dihydroguanine O
seems O
to O
be O
the O
most O
critical O
during O
the O
transfer O
of O
genetic O
information O
because O
it O
can O
pair O
with O
both O
cytosine B
and O
adenine B
. O

During O
the O
de O
novo O
synthesis O
of O
guanine O
nucleotides O
, O
GMP O
is O
formed O
first O
, O
and O
it O
is O
converted O
to O
GDP B
by O
guanylate B
kinase O
. O

Although O
the O
formation O
of O
8 O
- O
oxo O
- O
GDP O
from O
8 O
- O
oxo O
- O
GMP O
is O
thus O
prevented O
, O
8 O
- O
oxo O
- O
GDP O
itself O
may O
be O
produced O
by O
the O
oxidation O
of O
GDP B
by O
reactive O
oxygen B
species O
. O

The O
8 O
- O
oxo O
- O
GDP O
thus O
formed O
can O
be O
converted O
to O
8 O
- O
oxo O
- O
GTP O
because O
nucleoside B
- I
diphosphate I
kinase O
and O
adenylate B
kinase O
, O
both O
of O
which O
catalyze O
the O
conversion O
of O
GDP B
to O
GTP B
, O
do O
not O
discriminate O
8 O
- O
oxo O
- O
GDP O
from O
normal O
GDP B
. O

The O
8 O
- O
oxo O
- O
GTP O
produced O
in O
this O
way O
and O
by O
the O
oxidation O
of O
GTP B
can O
be O
used O
for O
RNA O
synthesis O
. O

When O
( O
14 O
) O
C O
- O
labeled O
8 O
- O
oxo O
- O
GTP O
was O
applied O
to O
CaCl2 B
- O
permeabilized O
cells O
of O
a O
mutT O
( O
- O
) O
mutant O
strain O
, O
it O
could O
be O
incorporated O
into O
RNA O
at O
4 O
% O
of O
the O
rate O
for O
GTP B
. O

Bradykinin O
modulates O
spontaneous O
nerve O
growth O
factor O
production O
and O
stretch O
- O
induced O
ATP B
release O
in O
human O
urothelium O
. O

The O
urothelium O
plays O
a O
crucial O
role O
in O
integrating O
urinary O
bladder O
sensory O
outputs O
, O
responding O
to O
mechanical O
stress O
and O
chemical O
stimulation O
by O
producing O
several O
diffusible O
mediators O
, O
including O
ATP B
and O
, O
possibly O
, O
neurotrophin O
nerve O
growth O
factor O
( O
NGF O
) O
. O

Bradykinin O
- O
induced O
( O
100nM O
) O
B2 O
receptor O
activation O
markedly O
increased O
( O
192 O
+ O
/ O
- O
13 O
% O
of O
control O
levels O
) O
stretch O
- O
induced O
ATP B
release O
from O
UROtsa O
in O
hypotonic O
medium O
, O
the O
effect O
being O
dependent O
on O
intracellular O
calcium O
elevations O
. O

In O
conclusion O
, O
we O
show O
that O
bradykinin O
represents O
a O
versatile O
modulator O
of O
human O
urothelial O
phenotype O
, O
accelerating O
stretch O
- O
induced O
ATP B
release O
, O
spontaneous O
release O
of O
NGF O
, O
as O
well O
as O
expression O
of O
sensory O
ion O
channel O
TRPV1 O
. O

3 O
, O
3 O
' O
- O
Diindolymethane O
ameliorates O
adriamycin B
- O
induced O
cardiac O
fibrosis O
via O
activation O
of O
a O
BRCA1 O
- O
dependent O
anti O
- O
oxidant O
pathway O
. O

The O
cardiotoxicity O
of O
adriamycin B
greatly O
limits O
its O
application O
in O
the O
treatment O
of O
cancer O
. O

Heart O
failure O
that O
is O
caused O
by O
adriamycin B
- O
treatment O
induced O
cardiac O
fibrosis O
is O
a O
major O
cause O
of O
death O
in O
patients O
who O
are O
treated O
with O
this O
medication O
. O

The O
severe O
oxidative O
stress O
that O
is O
induced O
by O
adriamycin B
is O
considered O
to O
be O
one O
of O
the O
primary O
mechanisms O
by O
which O
fibrogenesis O
of O
cardiac O
tissue O
occurs O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
3 O
, O
3 O
' O
- O
diindolymethane O
( O
DIM O
) O
exhibits O
a O
significant O
anti O
- O
fibrosis O
effect O
on O
cardiac O
tissue O
in O
an O
animal O
model O
of O
adriamycin B
- O
induced O
cardiac O
fibrosis O
( O
AICF O
) O
. O

Because O
DIM O
is O
a O
safe O
food O
additive O
that O
has O
been O
used O
for O
decades O
, O
our O
findings O
suggest O
that O
there O
is O
a O
great O
potential O
for O
this O
chemical O
to O
be O
developed O
into O
a O
clinical O
medication O
for O
the O
treatment O
of O
adriamycin B
- O
induced O
heart O
failure O
during O
cancer O
therapy O
. O

LY294002 B
, O
a O
specific O
PI3K O
/ O
AKT O
inhibitor O
, O
selectively O
activated O
the O
p38 O
MAPK O
kinase O
pathway O
and O
enhanced O
c O
- O
Jun O
phosphorylation O
, O
but O
did O
not O
activate O
JNK O
. O

The O
pharmacological O
inhibitors O
SB203580 B
( O
p38 O
inhibitor O
) O
and O
SP600125 B
( O
a O
JNK O
inhibitor O
) O
protected O
primary O
cultures O
of O
rat O
CGCs O
from O
LY294002 B
- O
induced O
apoptosis O
. O

Gender O
and O
strain O
contributions O
to O
the O
variability O
of O
buprenorphine B
- O
related O
respiratory O
toxicity O
in O
mice O
. O

While O
most O
deaths O
from O
asphyxia O
related O
to O
buprenorphine B
( O
BUP O
) O
overdose O
have O
been O
reported O
in O
males O
, O
higher O
plasma O
concentrations O
of O
BUP O
and O
its O
toxic O
metabolite O
norbuprenorphine O
( O
NBUP O
) O
have O
been O
observed O
in O
females O
. O

Changes O
in O
skeletal O
muscle O
proteolytic O
gene O
expression O
after O
prophylactic O
supplementation O
of O
EGCG B
and O
NAC B
and O
eccentric O
damage O
. O

PURPOSE O
: O
The O
impact O
of O
prophylactic O
supplementation O
of O
N B
- I
acetyl I
- I
cysteine I
( O
NAC B
) O
and O
epigallocatechin B
gallate I
( O
EGCG B
) O
on O
intramuscular O
expression O
of O
proteolytic O
genes O
after O
unaccustomed O
eccentric O
muscle O
contractions O
was O
investigated O
. O

METHODS O
: O
Thirty O
apparently O
healthy O
males O
( O
mean O
+ O
/ O
- O
SD O
: O
20 O
. O
0 O
+ O
/ O
- O
1 O
. O
8years O
, O
175 O
+ O
/ O
- O
7 O
. O
1cm O
, O
76 O
. O
1 O
+ O
/ O
- O
16 O
. O
9kg O
) O
ingested O
daily O
either O
1800mg O
of O
NAC B
or O
1800mg O
of O
EGCG B
( O
98 O
% O
total O
polyphenols B
, O
80 O
% O
total O
catechins B
, O
and O
50 O
% O
EGCG B
) O
, O
or O
1000mg O
of O
a O
glucomannan O
placebo O
( O
PLA O
) O
in O
a O
double O
blind O
, O
prophylactic O
fashion O
for O
14days O
. O

CONCLUSIONS O
: O
Prophylactic O
supplementation O
of O
NAC B
and O
EGCG B
did O
not O
impact O
acute O
changes O
in O
skeletal O
muscle O
proteolytic O
gene O
expression O
following O
eccentric O
exercise O
. O

Lead O
( O
Pb B
) O
is O
known O
to O
increase O
MHC O
- O
II O
surface O
expression O
on O
murine O
peritoneal O
macrophages O
ex O
vivo O
at O
concentrations O
exceeding O
25 O
mu O
M O
. O

To O
address O
this O
deficit O
, O
we O
examined O
the O
effects O
of O
Pb B
on O
MHC O
- O
II O
surface O
expression O
, O
secondary O
T O
- O
cell O
activation O
markers O
( O
CD80 O
, O
CD86 O
, O
CD40 O
) O
, O
cell O
viability O
, O
cellular O
metabolic O
activity O
, O
and O
beta O
- O
hexosaminidase O
activity O
in O
RAW O
267 O
. O
4 O
macrophage O
cell O
lines O
, O
with O
changes O
in O
cell O
ultrastructure O
evaluated O
by O
electron O
and O
confocal O
microscopy O
. O

Pb B
induced O
an O
increase O
in O
MHC O
- O
II O
, O
CD86 O
, O
and O
lysosome O
- O
associated O
LAMP O
- O
1 O
and O
LAMP O
- O
2 O
surface O
mean O
expression O
during O
one O
doubling O
cycle O
( O
17 O
h O
) O
, O
which O
was O
mirrored O
by O
increased O
beta O
- O
hexosaminidase O
activity O
. O

Electron O
microscopy O
revealed O
evidence O
of O
lipid O
vacuolization O
, O
macroautophagy O
and O
myelin O
figure O
formation O
in O
cells O
cultured O
with O
either O
Pb B
or O
LPS O
. O

Collectively O
, O
these O
data O
suggest O
that O
2 O
. O
5 O
- O
5 O
. O
0 O
mu O
M O
Pb B
increased O
MHC O
- O
II O
surface O
expression O
by O
inhibiting O
metabolic O
activity O
, O
inducing O
autophagy O
, O
and O
increasing O
MHC O
- O
II O
trafficking O
in O
a O
macrophage O
cell O
line O
. O

The O
number O
of O
live O
fetuses O
, O
percent O
of O
post O
- O
implantation O
loss O
and O
of O
resorptions O
, O
fetal O
sex O
, O
and O
fetal O
body O
weights O
were O
not O
affected O
by O
either O
phthalate B
. O

Optimal O
dosing O
of O
warfarin B
and O
other O
coumarin B
anticoagulants O
: O
the O
role O
of O
genetic O
polymorphisms O
. O

Coumarin B
anticoagulants O
, O
which O
include O
warfarin B
, O
acenocoumarol O
and O
phenprocoumon O
, O
are O
among O
the O
most O
widely O
prescribed O
drugs O
worldwide O
. O

There O
is O
now O
a O
large O
body O
of O
published O
data O
showing O
that O
genotype O
for O
certain O
common O
polymorphisms O
in O
the O
genes O
encoding O
the O
target O
vitamin O
K O
epoxide O
reductase O
( O
G O
- O
1639A O
/ O
C1173T O
) O
and O
the O
main O
metabolizing O
enzyme O
CYP2C9 O
( O
CYP2C9 O
* O
2 O
and O
* O
3 O
alleles O
) O
are O
important O
determinants O
of O
the O
individual O
coumarin B
anticoagulant O
dose O
requirement O
. O

Various O
algorithms O
for O
dose O
calculation O
, O
which O
also O
take O
patient O
age O
and O
other O
characteristics O
into O
consideration O
, O
have O
been O
developed O
for O
all O
three O
widely O
used O
coumarin B
anticoagulants O
and O
are O
now O
being O
tested O
in O
ongoing O
large O
randomised O
clinical O
trials O
. O

One O
recently O
completed O
study O
has O
provided O
encouraging O
results O
suggesting O
that O
calculation O
of O
warfarin B
dose O
on O
the O
basis O
of O
individual O
patient O
genotype O
leads O
to O
few O
adverse O
events O
and O
a O
higher O
proportion O
of O
time O
within O
the O
therapeutic O
coagulation O
rate O
window O
, O
but O
these O
findings O
still O
need O
confirmation O
. O

Effects O
of O
caffeine B
and O
alcohol B
on O
mood O
and O
performance O
changes O
following O
consumption O
of O
lager O
. O

RATIONALE O
: O
The O
present O
study O
examined O
whether O
caffeine B
would O
modify O
the O
behavioural O
effects O
of O
alcohol B
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
caffeine B
modifies O
the O
effects O
of O
alcohol B
on O
mood O
and O
psychomotor O
performance O
and O
to O
identify O
possible O
dose O
- O
response O
and O
temporal O
relationships O
. O

Participants O
carried O
out O
a O
baseline O
session O
and O
were O
then O
randomly O
assigned O
to O
one O
of O
six O
conditions O
formed O
by O
combining O
three O
different O
doses O
of O
caffeine B
( O
0 O
, O
62 O
. O
5 O
and O
125 O
mg O
per O
drink O
) O
with O
either O
no O
alcohol B
or O
4 O
. O
3 O
% O
alcohol B
. O

RESULTS O
: O
Alcohol B
was O
associated O
with O
higher O
hedonic O
tone O
( O
p O
< O
0 O
. O
005 O
) O
, O
reduced O
anxiety O
( O
p O
< O
0 O
. O
05 O
) O
and O
reduced O
alertness O
( O
p O
< O
0 O
. O
005 O
) O
. O

Caffeine B
had O
no O
modifying O
effect O
on O
hedonic O
tone O
or O
anxiety O
. O

However O
, O
the O
highest O
dose O
of O
caffeine B
did O
remove O
the O
effect O
of O
alcohol B
on O
alertness O
( O
p O
< O
0 O
. O
05 O
) O
. O

Effects O
of O
alcohol B
and O
caffeine B
were O
found O
on O
the O
performance O
tasks O
( O
all O
p O
values O
< O
0 O
. O
05 O
) O
but O
these O
were O
independent O
effects O
. O

CONCLUSIONS O
: O
The O
results O
from O
the O
present O
study O
confirm O
that O
caffeine B
does O
not O
remove O
the O
negative O
effects O
of O
alcohol B
on O
performance O
although O
high O
doses O
counteract O
the O
drop O
in O
subjective O
alertness O
produced O
by O
alcohol B
. O

The O
organotypic O
cultures O
were O
maintained O
for O
3 O
weeks O
and O
assessed O
for O
( O
1 O
) O
liver O
specific O
functions O
, O
including O
phase O
I O
enzyme O
and O
transporter O
activities O
, O
( O
2 O
) O
expression O
of O
liver O
- O
specific O
proteins O
, O
and O
( O
3 O
) O
responses O
to O
three O
drugs O
( O
acetaminophen B
, O
troglitazone B
, O
and O
rosiglitazone B
) O
. O

Accordingly O
, O
the O
production O
rates O
of O
albumin O
and O
glucose B
, O
as O
well O
as O
CYP2E1 O
activity O
, O
were O
significantly O
higher O
in O
the O
3D O
versus O
the O
2D O
cultures O
. O

Toxicity O
studies O
show O
that O
the O
organotypic O
cultures O
are O
more O
sensitive O
to O
acetaminophen B
- O
and O
rosiglitazone B
- O
induced O
toxicity O
but O
less O
sensitive O
to O
troglitazone B
- O
induced O
toxicity O
than O
the O
2D O
cultures O
. O

Furthermore O
, O
the O
EC50 O
value O
( O
2 O
. O
7mM O
) O
for O
acetaminophen B
on O
the O
3D O
cultures O
was O
similar O
to O
in O
vivo O
toxicity O
. O

The O
angiopoietin O
( O
Angpt O
) O
/ O
Tie2 O
system O
consists O
of O
the O
transmembrane O
endothelial O
tyrosine B
kinase O
Tie2 O
and O
its O
circulating O
ligands O
( O
Angpt O
- O
1 O
, O
- O
2 O
, O
and O
- O
3 O
/ O
4 O
) O
. O

Glycosylphosphatidyl O
( O
GPI O
) O
enriches O
GPI O
- O
anchored O
proteins O
( O
GPI O
- O
AP O
) O
in O
lipid O
rafts O
by O
intimate O
interaction O
of O
its O
lipid O
moiety O
with O
sphingolipids B
and O
cholesterol B
. O

Here O
, O
we O
report O
that O
GPI O
- O
APs O
that O
have O
not O
undergone O
fatty B
acid I
remodeling O
exhibit O
reduced O
immunoreactivities O
in O
Western O
blotting O
, O
similar O
to O
delipidated O
proteins O
, O
compared O
with O
normal O
remodeled O
GPI O
- O
APs O
. O

Thus O
, O
this O
study O
clarifies O
the O
significance O
of O
GPI O
fatty B
acid I
remodeling O
in O
oligomerization O
of O
GPI O
- O
APs O
and O
provides O
useful O
information O
for O
technical O
studies O
of O
these O
cell O
components O
. O

The O
M O
( O
5 O
) O
muscarinic O
acetylcholine B
receptor O
is O
suggested O
to O
be O
a O
potential O
pharmacotherapeutic O
target O
for O
the O
treatment O
of O
drug O
abuse O
. O

Small O
molecule O
antivirulents O
targeting O
the O
iron B
- O
regulated O
heme B
oxygenase O
( O
HemO O
) O
of O
P O
. O
aeruginosa O
. O

Bacteria O
require O
iron B
for O
survival O
and O
virulence O
and O
employ O
several O
mechanisms O
including O
utilization O
of O
the O
host O
heme B
containing O
proteins O
. O

The O
final O
step O
in O
releasing O
iron B
is O
the O
oxidative O
cleavage O
of O
heme B
by O
HemO O
. O

Herein O
we O
report O
the O
near O
complete O
HN O
, O
N B
, O
CO B
, O
C O
alpha O
, O
and O
C O
beta O
chemical O
shift O
assignment O
of O
the O
P O
. O
aeruginosa O
HemO O
in O
the O
absence O
and O
presence O
of O
inhibitors O
( O
E O
) O
- O
3 O
- O
( O
4 O
- O
( O
phenylamino O
) O
phenylcarbamoyl O
) O
acrylic O
acid O
( O
3 O
) O
and O
( O
E O
) O
- O
N O
' O
- O
( O
4 O
- O
( O
dimethylamino O
) O
benzylidene O
) O
diazenecarboximidhyd O
( O
5 O
) O
. O

The O
NMR O
data O
confirm O
that O
the O
inhibitors O
bind O
within O
the O
heme B
pocket O
of O
HemO O
consistent O
with O
in O
silico O
molecular O
dynamic O
simulations O
. O

Both O
inhibitors O
and O
the O
phenoxy B
derivative O
of O
3 O
have O
activity O
against O
P O
. O
aeruginosa O
clinical O
isolates O
. O

Bifunctional O
inhibition O
of O
HIV O
- O
1 O
reverse O
transcriptase O
: O
a O
first O
step O
in O
designing O
a O
bifunctional O
triphosphate B
. O

Developing O
single O
molecular O
agents O
concurrently O
occupying O
the O
nucleoside B
and O
nonnucleoside O
binding O
sites O
in O
RT O
is O
an O
intriguing O
idea O
but O
the O
proof O
of O
concept O
has O
so O
far O
been O
elusive O
. O

As O
a O
first O
step O
, O
we O
describe O
molecular O
modeling O
to O
guide O
focused O
chemical O
syntheses O
of O
conjugates O
having O
nucleoside B
( O
d4T O
) O
and O
nonnucleoside O
( O
TIBO O
) O
moieties O
tethered O
by O
a O
flexible O
polyethylene B
glycol I
( O
PEG B
) O
linker O
. O

A O
triphosphate B
of O
d4T O
- O
6PEG O
- O
TIBO O
conjugate O
was O
successfully O
synthesized O
that O
is O
recognized O
as O
a O
substrate O
by O
HIV O
- O
1 O
RT O
and O
incorporated O
into O
a O
double O
- O
stranded O
DNA O
. O

After O
adjusting O
for O
age O
, O
sex O
, O
total O
cholesterol B
, O
HDL O
- O
cholesterol O
and O
triglyceride B
, O
max O
- O
IMT O
was O
significantly O
increased O
in O
the O
highest O
tertile O
of O
serum O
PCSK9 O
( O
0 O
. O
969 O
+ O
/ O
- O
0 O
. O
033 O
vs O
0 O
. O
959 O
+ O
/ O
- O
0 O
. O
033 O
vs O
1 O
. O
077 O
+ O
/ O
- O
0 O
. O
033mm O
, O
respectively O
; O
P O
= O
0 O
. O
026 O
) O
. O

Impairing O
effect O
of O
amphetamine B
and O
concomitant O
ionotropic O
glutamate B
receptors O
blockade O
in O
the O
ventral O
striatum O
on O
spatial O
learning O
in O
mice O
. O

The O
multiple O
cortical O
glutamatergic O
and O
mesolimbic O
dopaminergic O
( O
DAergic O
) O
afferences O
on O
the O
same O
neurons O
in O
the O
ventral O
striatum O
provide O
the O
neuroanatomical O
substrate O
for O
glutamate B
and O
dopamine B
functional O
interaction O
. O

OBJECTIVE O
: O
First O
, O
we O
evaluated O
the O
effect O
of O
intra O
- O
VS O
bilateral O
infusion O
of O
different O
doses O
of O
amphetamine B
( O
0 O
. O
3 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mu O
g O
/ O
side O
) O
on O
the O
ability O
to O
detect O
spatial O
novelty O
in O
mice O
. O

Next O
, O
we O
examined O
the O
impact O
produced O
on O
the O
same O
abilities O
by O
intra O
- O
VS O
infusion O
of O
ineffective O
doses O
of O
amphetamine B
( O
0 O
. O
3 O
mu O
g O
/ O
side O
) O
in O
association O
with O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
( O
3 O
. O
125 O
ng O
/ O
side O
) O
or O
alpha O
- O
amino O
- O
3 O
- O
hydroxy O
- O
5 O
- O
methylisoxazole O
- O
4 O
- O
propionic O
acid O
( O
AMPA B
) O
( O
0 O
. O
25 O
ng O
/ O
side O
) O
receptor O
antagonist O
. O

RESULTS O
: O
The O
results O
show O
that O
infusion O
of O
amphetamine B
impairs O
detection O
of O
spatial O
novelty O
, O
affecting O
also O
exploratory O
activity O
and O
marginally O
the O
detection O
of O
nonspatial O
novelty O
. O

In O
contrast O
, O
an O
association O
of O
subthreshold O
doses O
of O
amphetamine B
with O
NMDA B
or O
AMPA B
receptor O
antagonists O
exerted O
a O
selective O
effect O
on O
reactivity O
to O
a O
spatial O
change O
. O

CONCLUSIONS O
: O
These O
findings O
demonstrate O
that O
enhanced O
DAergic O
activity O
in O
the O
VS O
enhances O
glutamate B
receptor O
antagonist O
- O
induced O
impairment O
in O
learning O
and O
memory O
. O

Protein O
phosphatase O
2A O
is O
one O
of O
four O
major O
classes O
of O
serine B
/ O
threonine B
phosphatases O
. O

We O
have O
reported O
that O
B O
beta O
2 O
clones O
are O
sensitive O
to O
reactive O
oxygen B
species O
( O
ROS O
) O
treatment O
by O
inducing O
autophagic O
cell O
death O
. O

The O
pharmacological O
inhibitor O
, O
Bafilomycin B
A1 I
, O
rescued O
the O
cell O
death O
while O
suppressing O
autophagy O
. O

On O
the O
other O
hand O
, O
to O
assess O
how O
cells O
respond O
to O
ER O
stress O
, O
the O
cells O
were O
treated O
with O
0 O
. O
1 O
mu O
M O
of O
N B
- O
glycosylation O
inhibitor O
, O
tunicamycin B
( O
TM O
) O
. O

The O
autophagy O
inhibitor O
, O
3 B
- I
methyladenine I
, O
salvaged O
the O
final O
apoptosis O
. O

A O
review O
of O
fabrication O
and O
applications O
of O
carbon B
nanotube O
film O
- O
based O
flexible O
electronics O
. O

Carbon B
nanotubes O
( O
CNTs O
) O
are O
a O
promising O
material O
for O
flexible O
electronics O
, O
both O
as O
the O
channel O
material O
in O
field O
- O
effect O
transistors O
( O
FETs O
) O
and O
as O
transparent O
electrodes O
, O
due O
to O
their O
high O
intrinsic O
carrier O
mobility O
, O
conductivity O
, O
and O
mechanical O
flexibility O
. O

To O
employ O
CNTs O
as O
the O
channel O
material O
in O
FETs O
, O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
are O
used O
. O

In O
using O
carbon B
nanotubes O
as O
transparent O
electrodes O
( O
TEs O
) O
, O
two O
main O
strategies O
have O
been O
implemented O
to O
fabricate O
highly O
conductive O
, O
transparent O
, O
and O
mechanically O
compliant O
films O
- O
superaligned O
films O
of O
CNTs O
drawn O
from O
vertically O
grown O
CNT O
forests O
using O
the O
" O
dry O
- O
drawing O
" O
technique O
and O
the O
deposition O
or O
embedding O
of O
CNTs O
onto O
flexible O
or O
stretchable O
substrates O
. O

A O
Serum O
- O
Resistant O
Low O
- O
Generation O
Polyamidoamine B
with O
PEI O
423 O
Outer O
Layer O
for O
Gene O
Delivery O
Vector O
. O

A O
new O
derivative O
of O
polyamidoamine B
and O
polyethylenimine B
, O
G2 O
. O
5 O
- O
PEI O
423 O
or O
G1 O
. O
5 O
- O
PEI O
423 O
, O
is O
prepared O
by O
an O
amidation O
reaction O
of O
PAMAM B
G2 O
. O
5 O
or O
PAMAM B
G1 O
. O
5 O
using O
PEI O
423 O
. O

The O
G2 O
. O
5 O
- O
PEI O
423 O
complexes O
display O
much O
higher O
transfection O
efficiencies O
than O
PAMAM B
G5 O
and O
Lipo O
- O
2k O
, O
and O
the O
G1 O
. O
5 O
- O
PEI O
423 O
complexes O
display O
higher O
transfection O
efficiencies O
than O
PAMAM B
G4 O
and O
PEI B
- O
25k O
. O

Population O
pharmacokinetics O
of O
atorvastatin B
and O
its O
active O
metabolites O
in O
children O
and O
adolescents O
with O
heterozygous O
familial O
hypercholesterolemia O
: O
selective O
use O
of O
informative O
prior O
distributions O
from O
adults O
. O

The O
population O
pharmacokinetics O
( O
PPK O
) O
of O
atorvastatin B
and O
its O
principal O
active O
metabolite O
, O
o O
- O
hydroxyatorvastatin O
, O
were O
described O
in O
6 O
- O
17 O
years O
old O
pediatric O
hypercholesterolemia O
patients O
with O
a O
2 O
- O
compartment O
model O
for O
both O
parent O
and O
metabolite O
. O

Atorvastatin B
apparent O
oral O
clearance O
( O
CL O
/ O
F O
) O
was O
described O
as O
a O
function O
of O
body O
weight O
using O
an O
allometric O
equation O
. O

Variability O
in O
atorvastatin B
PK O
was O
primarily O
affected O
by O
weight O
. O

Different O
effects O
of O
clopidogrel B
and O
clarithromycin B
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine B
and O
its O
active O
metabolites O
in O
healthy O
subjects O
. O

In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel B
and O
clarithromycin B
, O
known O
CYP2B6 O
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O

Sibutramine B
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R O
- O
enantiomers O
. O

Clopidogrel B
and O
clarithromycin B
significantly O
increased O
the O
sibutramine B
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers O
; O
a O
2 O
. O
2 O
- O
fold O
versus O
4 O
. O
1 O
- O
fold O
increase O
in O
the O
AUC O
in O
S O
- O
enantiomer O
and O
1 O
. O
8 O
- O
fold O
versus O
2 O
. O
0 O
- O
fold O
for O
the O
R O
- O
enantiomer O
, O
respectively O
. O

The O
AUCs O
of O
S O
- O
and O
R O
- O
desmethyl O
metabolites O
changed O
significantly O
during O
the O
clopidogrel B
phase O
( O
P O
< O
. O
001 O
and O
P O
< O
. O
001 O
, O
respectively O
) O
but O
not O
during O
the O
clarithromycin B
phase O
( O
P O
= O
. O
099 O
and O
P O
= O
. O
090 O
, O
respectively O
) O
. O

Exposure O
to O
sibutramine B
was O
higher O
in O
subjects O
with O
the O
CYP2B6 O
* O
6 O
/ O
* O
6 O
genotype O
, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 O
genotypes O
. O

These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine B
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 O
and O
CYP3A O
activity O
in O
vivo O
. O

Absence O
of O
edge O
States O
in O
covalently O
bonded O
zigzag O
edges O
of O
graphene B
on O
ir O
( O
111 O
) O
. O

The O
zigzag O
edges O
of O
graphene B
on O
Ir O
( O
111 O
) O
are O
studied O
by O
ab O
initio O
simulations O
and O
low O
- O
temperature O
scanning O
tunneling O
spectroscopy O
, O
providing O
information O
about O
their O
structural O
, O
electronic O
, O
and O
magnetic O
properties O
. O

No O
edge O
state O
is O
found O
to O
exist O
, O
which O
is O
explained O
in O
terms O
of O
the O
interplay O
between O
a O
strong O
geometrical O
relaxation O
at O
the O
edge O
and O
a O
hybridization O
of O
the O
d O
orbitals O
of O
Ir O
atoms O
with O
the O
graphene B
orbitals O
at O
the O
edge O
. O

Characterization O
of O
efflux O
transporters O
involved O
in O
distribution O
and O
disposition O
of O
apixaban B
. O

The O
studies O
reported O
here O
were O
conducted O
to O
investigate O
the O
transport O
characteristics O
of O
apixaban B
( O
1 O
- O
( O
4 O
- O
methoxyphenyl O
) O
- O
7 O
- O
oxo O
- O
6 O
- O
( O
4 O
- O
( O
2 O
- O
oxopiperidin O
- O
1 O
- O
yl O
) O
phenyl O
) O
- O
4 O
, O
5 O
, O
6 O
, O
7 O
- O
tetrahydro O
- O
1H O
- O
pyrazolo O
[ O
3 O
, O
4 O
- O
c O
] O
pyridine O
- O
3 O
- O
carboxamide O
) O
and O
to O
understand O
the O
impact O
of O
transporters O
on O
apixaban O
distribution O
and O
disposition O
. O

In O
human O
permeability O
glycoprotein O
( O
P O
- O
gp O
) O
- O
and O
breast O
cancer O
resistance O
protein O
( O
BCRP O
) O
- O
cDNA O
- O
transfected O
cell O
monolayers O
as O
well O
as O
Caco O
- O
2 O
cell O
monolayers O
, O
the O
apparent O
efflux O
ratio O
of O
basolateral O
- O
to O
- O
apical O
( O
PcB O
- O
A O
) O
versus O
apical O
- O
to O
- O
basolateral O
permeability O
( O
PcA O
- O
B O
) O
of O
apixaban B
was O
> O
10 O
. O

The O
P O
- O
gp O
- O
and O
BCRP O
- O
facilitated O
transport O
of O
apixaban B
was O
concentration O
- O
and O
time O
- O
dependent O
and O
did O
not O
show O
saturation O
over O
a O
wide O
range O
of O
concentrations O
( O
1 O
- O
100 O
mu O
M O
) O
. O

The O
efflux O
transport O
of O
apixaban B
was O
also O
demonstrated O
by O
the O
lower O
mucosal O
- O
to O
- O
serosal O
permeability O
than O
that O
of O
the O
serosal O
- O
to O
- O
mucosal O
direction O
in O
isolated O
rat O
jejunum O
segments O
. O

Apixaban B
did O
not O
inhibit O
digoxin O
transport O
in O
Caco O
- O
2 O
cells O
. O

Ketoconazole B
decreased O
the O
P O
- O
gp O
- O
mediated O
apixaban O
efflux O
in O
Caco O
- O
2 O
and O
the O
P O
- O
gp O
- O
cDNA O
- O
transfected O
cell O
monolayers O
, O
but O
did O
not O
affect O
the O
apixaban B
efflux O
to O
a O
meaningful O
extent O
in O
the O
BCRP O
- O
cDNA O
- O
transfected O
cell O
monolayers O
. O

Coincubation O
of O
a O
P O
- O
gp O
inhibitor O
( O
ketoconazole B
or O
cyclosporin O
A O
) O
and O
a O
BCRP O
inhibitor O
( O
Ko134 O
) O
provided O
more O
complete O
inhibition O
of O
apixaban O
efflux O
in O
Caco O
- O
2 O
cells O
than O
separate O
inhibition O
by O
individual O
inhibitors O
. O

Naproxen B
inhibited O
apixaban B
efflux O
in O
Caco O
- O
2 O
cells O
but O
showed O
only O
a O
minimal O
effect O
on O
apixaban B
transport O
in O
the O
BCRP O
- O
transfected O
cells O
. O

Naproxen B
was O
the O
first O
nonsteroidal O
antiinflammatory O
drug O
that O
was O
demonstrated O
as O
a O
weak O
P O
- O
gp O
inhibitor O
. O

These O
results O
demonstrate O
that O
apixaban B
is O
a O
substrate O
for O
efflux O
transporters O
P O
- O
gp O
and O
BCRP O
, O
which O
can O
help O
explain O
its O
low O
brain O
penetration O
, O
and O
low O
fetal O
exposures O
and O
high O
milk O
excretion O
in O
rats O
. O

High O
- O
relaxivity O
and O
luminescent O
silica B
nanoparticles O
as O
multimodal O
agents O
for O
molecular O
imaging O
. O

Tunable O
- O
sized O
silica B
nanoparticles O
were O
synthesized O
by O
a O
microemulsion O
- O
mediated O
pathway O
and O
used O
as O
carriers O
for O
paramagnetic O
and O
luminescent O
probes O
. O

The O
near O
- O
infrared O
luminescent O
agent O
was O
a O
ruthenium B
complex O
that O
was O
directly O
entrapped O
in O
the O
silica B
shell O
to O
provide O
photoluminescence O
enhancement O
and O
to O
make O
it O
highly O
photostable O
as O
it O
was O
protected O
from O
the O
surrounding O
environment O
. O

The O
paramagnetic O
activity O
came O
from O
a O
Gd O
- O
DTPA O
derivative O
that O
was O
grafted O
on O
the O
silica B
surface O
. O

Polyethylene B
glycol I
was O
also O
grafted O
at O
the O
nanoparticle O
surface O
to O
enhance O
the O
nanoparticle O
residence O
time O
in O
the O
bloodstream O
. O

There O
are O
no O
data O
supporting O
an O
association O
between O
congenital O
anomalies O
in O
the O
fetus O
and O
propylthiouracil O
( O
PTU B
) O
. O

Hepatotoxicity O
, O
cytopenias O
- O
especially O
agranulocytosis O
and O
quite O
rarely O
, O
angioedema O
, O
may O
be O
seen O
as O
side O
effects O
of O
PTU B
. O

This O
intervention O
was O
assisted O
by O
the O
use O
of O
plasmapheresis O
to O
obtain O
rapid O
normalization O
of O
serum O
thyroid B
hormone I
levels O
. O

This O
study O
reports O
that O
mitochondrial O
dysfunctions O
may O
play O
an O
important O
role O
in O
liver O
injury O
and O
apoptosis O
induced O
by O
this O
retinoid B
. O

Acitretin O
( O
5 O
- O
20 O
mu O
M O
) O
impaired O
mitochondrial O
phosphorylation O
efficiency O
as O
demonstrated O
by O
the O
decrease O
in O
the O
state O
3 O
respiration O
and O
ATP B
levels O
, O
and O
by O
the O
increase O
in O
the O
lag O
phase O
of O
ADP B
phosphorylation O
cycle O
, O
without O
affecting O
the O
membrane O
potential O
. O

Acitretin O
induced O
Ca B
( I
2 I
+ I
) I
- O
mediated O
mitochondrial O
permeability O
transition O
( O
MPT O
) O
and O
decreased O
the O
adenine B
nucleotide I
translocase O
( O
ANT O
) O
content O
. O

Acitretin O
- O
induced O
MPT O
was O
not O
prevented O
by O
thiol B
group O
protecting O
and O
antioxidant O
agents O
, O
excluding O
the O
involvement O
of O
oxidative O
stress O
mechanisms O
. O

However O
, O
MPT O
was O
prevented O
by O
ANT O
ligands O
ATP B
, O
ADP B
, O
tamoxifen B
and O
4 B
- I
hydroxytamoxifen I
, O
implying O
that O
the O
MPT O
induction O
by O
acitretin O
is O
mediated O
by O
the O
ANT O
. O

ANT O
plays O
a O
major O
role O
in O
promoting O
apoptosis O
and O
ATP B
synthesis O
, O
and O
it O
is O
still O
considered O
as O
a O
structural O
component O
of O
the O
pore O
with O
a O
regulatory O
role O
in O
MPT O
formation O
. O

Therefore O
, O
our O
results O
, O
including O
the O
decrease O
in O
the O
state O
3 O
respiration O
and O
the O
increase O
in O
the O
lag O
phase O
of O
phosphorylation O
cycle O
, O
the O
ATP B
depletion O
and O
the O
induction O
of O
Ca B
( I
2 I
+ I
) I
- O
mediated O
MPT O
, O
indicate O
that O
acitretin O
- O
associated O
liver O
toxicity O
and O
apoptosis O
is O
possibly O
related O
with O
mitochondrial O
dysfunctions O
due O
to O
interactions O
with O
the O
ANT O
. O

Glucocorticoids O
can O
cause O
steroid B
- O
induced O
diabetes O
or O
accelerate O
the O
progression O
to O
diabetes O
by O
creating O
systemic O
insulin O
resistance O
and O
decreasing O
functional O
beta O
- O
cell O
mass O
, O
which O
is O
influenced O
by O
changes O
in O
beta O
- O
cell O
function O
, O
growth O
, O
and O
death O
. O

The O
synthetic O
glucocorticoid O
agonist O
dexamethasone B
( O
Dex B
) O
is O
deleterious O
to O
functional O
beta O
- O
cell O
mass O
by O
decreasing O
beta O
- O
cell O
function O
, O
survival O
, O
and O
proliferation O
. O

However O
, O
the O
mechanism O
by O
which O
Dex B
decreases O
beta O
- O
cell O
proliferation O
is O
unknown O
. O

Interestingly O
, O
Dex B
induces O
the O
transcription O
of O
an O
antiproliferative O
factor O
and O
negative O
regulator O
of O
epidermal O
growth O
factor O
receptor O
signaling O
, O
Mig6 O
( O
also O
known O
as O
gene O
33 O
, O
RALT O
, O
and O
Errfi1 O
) O
. O

We O
, O
therefore O
, O
hypothesized O
that O
Dex B
impairs O
beta O
- O
cell O
proliferation O
by O
increasing O
the O
expression O
of O
Mig6 O
and O
thereby O
decreasing O
downstream O
signaling O
of O
epidermal O
growth O
factor O
receptor O
. O

We O
found O
that O
Dex B
induced O
Mig6 O
and O
decreased O
[ B
( I
3 I
) I
H I
] I
thymidine I
incorporation O
, O
an O
index O
of O
cellular O
replication O
, O
in O
mouse O
, O
rat O
, O
and O
human O
islets O
. O

Using O
adenovirally O
delivered O
small O
interfering O
RNA O
targeted O
to O
Mig6 O
in O
rat O
islets O
, O
we O
were O
able O
to O
limit O
the O
induction O
of O
Mig6 O
upon O
exposure O
to O
Dex B
, O
compared O
with O
islets O
treated O
with O
a O
control O
virus O
, O
and O
completely O
rescued O
the O
Dex B
- O
mediated O
impairment O
in O
replication O
. O

We O
demonstrated O
that O
both O
Dex B
and O
overexpression O
of O
Mig6 O
attenuated O
the O
phosphorylation O
of O
ERK1 O
/ O
2 O
and O
blocked O
the O
G O
( O
1 O
) O
/ O
S O
transition O
of O
the O
cell O
cycle O
. O

Characterization O
of O
cytosolic O
glutathione B
peroxidase O
and O
phospholipid O
- O
hydroperoxide B
glutathione B
peroxidase O
genes O
in O
rainbow O
trout O
( O
Oncorhynchus O
mykiss O
) O
and O
their O
modulation O
by O
in O
vitro O
selenium B
exposure O
. O

Selenium B
( O
Se B
) O
is O
an O
oligonutrient O
with O
both O
essential O
biological O
functions O
and O
recognized O
harmful O
effects O
. O

As O
the O
selenocysteine B
( O
SeCys B
) O
amino B
acid I
, O
selenium B
is O
integrated O
in O
several O
Se B
- O
containing O
proteins O
( O
selenoproteins O
) O
, O
many O
of O
which O
are O
fundamental O
for O
cell O
homeostasis O
. O

Nevertheless O
, O
selenium O
may O
exert O
toxic O
effects O
at O
levels O
marginally O
above O
those O
required O
, O
mainly O
through O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

The O
selenium B
chemical O
speciation O
can O
strongly O
affect O
the O
bioavailability O
of O
this O
metal O
and O
its O
impact O
on O
metabolism O
, O
dictating O
the O
levels O
that O
can O
be O
beneficial O
or O
detrimental O
towards O
an O
organism O
. O

Glutathione B
peroxidase O
( O
GPxs O
) O
is O
the O
largest O
and O
the O
most O
studied O
selenoprotein O
family O
. O

Cytosolic O
glutathione B
peroxidase O
( O
cGPx O
, O
GPx1 O
) O
and O
phospholipid O
hydroperoxide B
glutathione B
peroxidase O
( O
PHGPx O
, O
GPx4 O
) O
are O
widely O
distributed O
throughout O
tissues O
, O
and O
play O
a O
pivotal O
role O
in O
regulating O
the O
oxidative O
status O
in O
the O
cell O
. O

An O
inorganic O
( O
sodium B
selenite I
, O
Na2SeO3 O
) O
and O
organic O
( O
selenocysteine B
, O
Cys O
- O
Se O
- O
Se O
- O
Cys O
) O
selenocompound O
have O
been O
used O
as O
Se B
sources O
. O

To O
understand O
if O
the O
results O
obtained O
from O
the O
transcript O
expression O
analysis O
were O
due O
to O
Se B
bioavailability O
or O
generation O
of O
ROS O
, O
the O
cytoxicity O
of O
the O
two O
selenocompounds O
was O
tested O
by O
measuring O
the O
impact O
of O
Se B
on O
cell O
membrane O
integrity O
. O

Lastly O
, O
Se B
availability O
was O
quantified O
by O
mass O
spectrophotometry O
to O
determine O
the O
amount O
of O
Se B
in O
the O
cell O
culture O
media O
, O
the O
Se B
background O
due O
to O
the O
foetal O
calf O
serum O
supplement O
and O
the O
contribution O
from O
the O
two O
selenocompounds O
used O
in O
the O
treatments O
. O

Transcripts O
of O
GPx4 O
genes O
were O
more O
highly O
expressed O
in O
most O
tissues O
examined O
in O
vivo O
( O
except O
blood O
, O
head O
kidney O
and O
spleen O
) O
, O
whereas O
those O
of O
the O
GPx1 O
genes O
were O
more O
responsive O
to O
selenium B
exposure O
in O
vitro O
, O
especially O
to O
the O
organic O
form O
. O

Interestingly O
, O
GPx1a O
was O
the O
most O
sensitive O
to O
selenium B
availability O
in O
non O
stressful O
conditions O
, O
whereas O
GPx1b1 O
and O
GPx1b2 O
were O
highly O
induced O
by O
exposure O
to O
selenium B
levels O
that O
had O
some O
toxic O
effects O
on O
the O
cells O
. O

Our O
results O
lead O
us O
to O
conclude O
that O
trout O
GPx1 O
transcripts O
expression O
level O
may O
represent O
a O
sensitive O
biomarker O
for O
selenium B
intake O
, O
helping O
to O
evaluate O
if O
selenium B
concentration O
and O
chemical O
speciation O
impact O
on O
cell O
homeostasis O
. O

Application O
of O
activated O
nucleoside B
analogs O
for O
the O
treatment O
of O
drug O
- O
resistant O
tumors O
by O
oral O
delivery O
of O
nanogel O
- O
drug O
conjugates O
. O

Here O
, O
we O
describe O
successful O
applications O
of O
innovative O
polymeric O
nanogels O
in O
the O
form O
of O
conjugates O
with O
activated O
nucleoside B
analogs O
for O
oral O
administration O
in O
cancer O
chemotherapy O
. O

Previously O
, O
we O
reported O
the O
synthesis O
of O
amphiphilic O
polyvinyl B
alcohol I
and O
dextrin O
- O
based O
nanogel O
conjugates O
with O
the O
phosphorylated O
5 O
- O
FU O
nucleoside O
Floxuridine O
and O
demonstrated O
their O
enhanced O
activity O
against O
regular O
and O
drug O
- O
resistant O
cancers O
( O
T O
. O
H O
. O
Senanayake O
, O
G O
. O
Warren O
, O
S O
. O
V O
. O
Vinogradov O
, O
Novel O
anticancer O
polymeric O
conjugates O
of O
activated O
nucleoside B
analogs O
, O
Bioconjug O
. O
Chem O
. O
22 O
( O
2011 O
) O
1983 O
- O
1993 O
) O
. O

In O
this O
study O
, O
we O
synthesized O
and O
evaluated O
oral O
applications O
of O
nanogel O
conjugates O
of O
a O
protected O
Gemcitabine B
, O
the O
drug O
never O
used O
in O
oral O
therapies O
. O

Gemcitabine B
conjugates O
demonstrated O
up O
to O
127 O
times O
higher O
in O
vitro O
efficacy O
than O
the O
free O
drug O
against O
various O
cancer O
cells O
, O
including O
the O
lines O
resistant O
to O
nucleoside B
analogs O
. O

In O
tumor O
xenograft O
models O
of O
several O
drug O
- O
resistant O
human O
cancers O
, O
we O
observed O
an O
efficient O
inhibition O
of O
tumor O
growth O
and O
extended O
the O
life O
- O
span O
of O
the O
animals O
by O
3 O
times O
that O
of O
the O
control O
with O
orally O
treated O
Gemcitabine B
- O
or O
Floxuridine O
- O
nanogel O
conjugates O
. O

Thus O
, O
we O
have O
demonstrated O
a O
potential O
of O
therapeutic O
nanogel O
conjugates O
with O
the O
activated O
and O
stabilized O
Gemcitabine B
as O
a O
successful O
oral O
drug O
form O
against O
Gemcitabine B
- O
resistant O
and O
other O
drug O
- O
resistant O
tumors O
. O

Design O
and O
synthesis O
of O
imidazole B
and O
triazole B
derivatives O
as O
Lp O
- O
PLA O
2 O
inhibitors O
and O
the O
unexpected O
discovery O
of O
highly O
potent O
quaternary O
ammonium O
salts O
. O

New O
Lp O
- O
PLA O
( O
2 O
) O
inhibitors O
were O
synthesized O
by O
the O
bioisosteric O
replacement O
of O
the O
amide B
group O
of O
Darapladib O
with O
an O
imidazole B
or O
a O
triazole B
. O

Synthesis O
and O
antibacterial O
activities O
of O
new O
piperidine B
substituted O
( O
5R O
) O
- O
[ O
1 O
, O
2 O
, O
3 O
] O
triazolylmethyl O
and O
( O
5R O
) O
- O
[ O
( O
4 O
- O
F O
- O
[ O
1 O
, O
2 O
, O
3 O
] O
triazolyl O
) O
methyl O
] O
oxazolidinones O
. O

A O
novel O
series O
of O
5 O
( O
R O
) O
- O
[ O
1 O
, O
2 O
, O
3 O
] O
triazolylmethyl O
and O
( O
5R O
) O
- O
[ O
( O
4 O
- O
F O
- O
[ O
1 O
, O
2 O
, O
3 O
] O
triazolyl O
) O
methyl O
] O
oxazolidinones O
having O
various O
piperidine B
group O
were O
synthesized O
and O
evaluated O
antibacterial O
activity O
against O
clinically O
isolated O
resistant O
strains O
of O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacteria O
. O

The O
compound O
12a O
having O
exo O
- O
cyanoethylidene O
group O
in O
the O
4 O
- O
position O
of O
piperidine B
ring O
was O
found O
to O
be O
two O
to O
threefold O
more O
potent O
than O
the O
linezolid B
against O
penicillin B
- O
resistant O
Staphylococcus O
pneumonia O
and O
Staphylococcus O
agalactiae O
, O
and O
also O
exhibited O
reduced O
MAO O
- O
B O
inhibitory O
activity O
. O

Integrated O
analysis O
of O
transcriptomics O
and O
metabonomics O
profiles O
in O
aflatoxin B
B1 I
- O
induced O
hepatotoxicity O
in O
rat O
. O

The O
aim O
of O
this O
work O
was O
to O
identify O
mechanisms O
and O
potential O
biomarkers O
for O
predicting O
the O
development O
and O
progression O
of O
aflatoxin B
B1 I
( O
AFB1 O
) O
- O
induced O
acute O
hepatotoxicity O
. O

Vibrational O
spectroscopic O
experiments O
started O
to O
shed O
light O
on O
the O
structural O
changes O
, O
that O
occur O
during O
the O
photocycle O
, O
especially O
in O
the O
hydrogen B
- O
bonded O
network O
surrounding O
the O
protonated O
D156 O
and O
C128 O
- O
the O
DC O
gate O
. O

In O
this O
article O
, O
we O
show O
that O
in O
combination O
with O
a O
recent O
reparametrization O
, O
the O
approximate O
DFT O
method O
, O
DFTB O
, O
is O
able O
to O
describe O
the O
effects O
of O
hydrogen B
bonding O
on O
the O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
stretch O
vibration O
in O
carboxylic B
acids I
reliably O
and O
agrees O
well O
with O
full O
DFT O
results O
. O

Doxazosin O
mesylate O
( O
DXM B
) O
sustained O
release O
pellets O
were O
prepared O
by O
an O
extrusion O
- O
spheronization O
and O
fluid O
- O
bed O
coating O
technique O
. O

The O
core O
pellets O
containing O
DXM B
were O
prepared O
by O
extrusion O
- O
spheronization O
technique O
, O
and O
coated O
by O
a O
fluid O
- O
bed O
coater O
to O
control O
the O
release O
of O
DXM B
. O

Polymethacrylate O
derivatives O
( O
Eudragit B
( O
R O
) O
RS O
PO O
and O
RL O
PO O
) O
were O
used O
for O
coating O
agents O
, O
and O
polyethylene O
glycol O
6000 O
( O
PEG O
6000 O
) O
, O
triethyl B
citrate I
( O
TEC O
) O
and O
castor O
oil O
were O
as O
plasticizers O
. O

Eudragit B
( O
R O
) O
RS O
PO O
had O
more O
marked O
sustaining O
effect O
on O
the O
dissolution O
rate O
than O
Eudragit B
( O
R O
) O
RL O
PO O
, O
and O
the O
effect O
was O
more O
pronounced O
with O
the O
increased O
coating O
level O
. O

PEG O
6000 O
was O
an O
appropriate O
plasticizer O
for O
DXM B
pellets O
, O
and O
increasing O
the O
content O
of O
PEG O
6000 O
, O
was O
also O
slightly O
decreasing O
the O
dissolution O
rate O
. O

Nocapyrone O
H O
( O
1 O
) O
reduced O
the O
pro O
- O
inflammatory O
factor O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
. O

Moreover O
, O
nocapyrone O
H O
showed O
5 O
. O
82 O
% O
stronger O
inhibitory O
effect O
on O
NO B
production O
than O
chrysin O
at O
a O
concentration O
of O
10 O
micro O
m O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
BV O
- O
2 O
microglial O
cells O
. O

In O
vitro O
- O
in O
vivo O
correlation O
of O
the O
inhibition O
potency O
of O
sodium B
- O
glucose B
cotransporter O
inhibitors O
in O
rat O
: O
a O
pharmacokinetic O
and O
pharmacodynamic O
modeling O
approach O
. O

To O
evaluate O
the O
relationship O
between O
the O
in O
vitro O
and O
in O
vivo O
potency O
of O
sodium B
- O
glucose B
cotransporter O
( O
SGLT O
) O
inhibitors O
, O
a O
pharmacokinetic O
and O
pharmacodynamic O
( O
PK O
- O
PD O
) O
study O
was O
performed O
using O
normal O
rats O
. O

A O
highly O
selective O
SGLT2 O
inhibitor O
, O
tofogliflozin O
, O
and O
four O
other O
inhibitors O
with O
different O
in O
vitro O
inhibition O
potency O
to O
SGLT2 O
and O
selectivity O
toward O
SGLT2 O
, O
versus O
SGLT1 O
were O
used O
as O
test O
compounds O
, O
and O
the O
time O
courses O
for O
urinary O
glucose B
excretion O
( O
UGE O
) O
and O
the O
plasma O
glucose B
and O
compound O
concentrations O
were O
monitored O
after O
administration O
of O
the O
compounds O
. O

A O
PK O
- O
PD O
analysis O
of O
the O
UGE O
caused O
by O
SGLT O
inhibition O
was O
performed O
on O
the O
basis O
of O
a O
nonlinear O
parallel O
tube O
model O
that O
took O
into O
consideration O
the O
consecutive O
reabsorption O
by O
different O
glucose B
transport O
properties O
of O
SGLT2 O
and O
SGLT1 O
. O

Furthermore O
, O
the O
complementary O
role O
of O
SGLT1 O
to O
SGLT2 O
and O
how O
selectivity O
toward O
SGLT2 O
affects O
the O
inhibitory O
potency O
for O
renal O
glucose B
reabsorption O
were O
discussed O
using O
the O
PK O
- O
PD O
model O
. O

SnO B
( I
2 I
) I
- O
Based O
Nanomaterials O
: O
Synthesis O
and O
Application O
in O
Lithium B
- O
Ion O
Batteries O
. O

The O
development O
of O
new O
electrode O
materials O
for O
lithium B
- O
ion O
batteries O
( O
LIBs O
) O
has O
always O
been O
a O
focal O
area O
of O
materials O
science O
, O
as O
the O
current O
technology O
may O
not O
be O
able O
to O
meet O
the O
high O
energy O
demands O
for O
electronic O
devices O
with O
better O
performance O
. O

Among O
all O
the O
metal B
oxides I
, O
tin O
dioxide O
( O
SnO B
( I
2 I
) I
) O
is O
regarded O
as O
a O
promising O
candidate O
to O
serve O
as O
the O
anode O
material O
for O
LIBs O
due O
to O
its O
high O
theoretical O
capacity O
. O

Here O
, O
a O
thorough O
survey O
is O
provided O
of O
the O
synthesis O
of O
SnO B
( I
2 I
) I
- O
based O
nanomaterials O
with O
various O
structures O
and O
chemical O
compositions O
, O
and O
their O
application O
as O
negative O
electrodes O
for O
LIBs O
. O

It O
covers O
SnO B
( I
2 I
) I
with O
different O
morphologies O
ranging O
from O
1D O
nanorods O
/ O
nanowires O
/ O
nanotubes O
, O
to O
2D O
nanosheets O
, O
to O
3D O
hollow O
nanostructures O
. O

Nanocomposites O
consisting O
of O
SnO B
( I
2 I
) I
and O
different O
carbonaceous O
supports O
, O
e O
. O
g O
. O
, O
amorphous O
carbon B
, O
carbon B
nanotubes O
, O
graphene B
, O
are O
also O
investigated O
. O

The O
use O
of O
Sn B
- O
based O
nanomaterials O
as O
the O
anode O
material O
for O
LIBs O
will O
be O
briefly O
discussed O
as O
well O
. O

The O
aim O
of O
this O
review O
is O
to O
provide O
an O
in O
- O
depth O
and O
rational O
understanding O
such O
that O
the O
electrochemical O
properties O
of O
SnO B
( I
2 I
) I
- O
based O
anodes O
can O
be O
effectively O
enhanced O
by O
making O
proper O
nanostructures O
with O
optimized O
chemical O
composition O
. O

By O
focusing O
on O
SnO B
( I
2 I
) I
, O
the O
hope O
is O
that O
such O
concepts O
and O
strategies O
can O
be O
extended O
to O
other O
potential O
metal B
oxides I
, O
such O
as O
titanium B
dioxide I
or O
iron O
oxides O
, O
thus O
shedding O
some O
light O
on O
the O
future O
development O
of O
high O
- O
performance O
metal B
- I
oxide I
based O
negative O
electrodes O
for O
LIBs O
. O

Add O
- O
on O
therapy O
with O
the O
DPP O
- O
4 O
inhibitor O
sitagliptin B
improves O
glycemic O
control O
in O
insulin O
- O
treated O
Japanese O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O

The O
effect O
of O
add O
- O
on O
therapy O
with O
sitagliptin B
on O
glycemic O
control O
was O
prospectively O
investigated O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
receiving O
insulin O
alone O
or O
insulin O
combined O
with O
oral O
antidiabetic O
drugs O
. O

Concomitant O
oral O
drugs O
included O
sulfonylureas B
, O
alpha O
- O
glucosidase O
inhibitors O
and O
metformin B
. O

The O
hemoglobin O
A1c O
( O
HbA1c O
) O
of O
all O
patients O
improved O
significantly O
from O
8 O
. O
1 O
+ O
/ O
- O
1 O
. O
2 O
% O
to O
7 O
. O
6 O
+ O
/ O
- O
1 O
. O
1 O
% O
after O
12 O
weeks O
of O
add O
- O
on O
therapy O
with O
sitagliptin B
( O
p O
< O
0 O
. O
01 O
) O
, O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27 O
. O
3 O
+ O
/ O
- O
15 O
. O
8 O
U O
/ O
day O
to O
24 O
. O
5 O
+ O
/ O
- O
16 O
. O
5 O
U O
/ O
day O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
baseline O
HbA1c O
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add O
- O
on O
therapy O
with O
sitagliptin B
. O

These O
findings O
suggest O
that O
add O
- O
on O
therapy O
with O
sitagliptin B
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O
patient O
' O
s O
demographic O
profile O
. O

Stratified O
analysis O
based O
on O
the O
insulin O
regimen O
revealed O
a O
stronger O
antidiabetic O
effect O
and O
a O
high O
efficacy O
of O
sitagliptin B
when O
it O
was O
added O
to O
basal O
insulin O
therapy O
. O

The O
results O
of O
this O
investigation O
confirmed O
that O
add O
- O
on O
therapy O
with O
sitagliptin B
to O
various O
insulin O
regimens O
could O
improve O
glycemic O
control O
without O
severe O
hypoglycemia O
and O
/ O
or O
weight O
gain O
. O

Androgen B
levels O
were O
determined O
at O
baseline O
by O
appropriate O
methodology O
in O
the O
follicular O
phase O
. O

PCOS O
women O
with O
17 B
- I
hydroxyprogesterone I
( O
17OHP O
) O
basal O
values O
> O
2 O
ng O
/ O
ml O
and O
/ O
or O
post O
- O
ACTH O
> O
10 O
ng O
/ O
ml O
were O
excluded O
. O

Moreover O
, O
17 B
- I
hydroxyprogesterone I
values O
of O
< O
10 O
ng O
/ O
ml O
post O
- O
ACTH O
exclude O
homozygosity O
of O
CYP21A2 O
mutations O
. O

Carboxylesterases O
hydrolyze O
esters B
, O
amides B
, O
and O
thioesters B
to O
produce O
carboxylic B
acids I
and O
resulting O
alcohols B
, O
amines B
, O
and O
thiols B
, O
respectively O
. O

Uridine O
5 O
' O
- O
diphosphate O
- O
glucuronosyltransfer O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic B
acids I
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters B
, O
also O
interact O
with O
carboxylesterases O
. O

Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
( O
100 O
mM O
potassium B
phosphate I
, O
pH O
7 O
. O
4 O
, O
37 O
degrees O
C O
) O
were O
investigated O
. O

Hepatic O
effects O
of O
ketamine B
administration O
for O
2 O
weeks O
in O
rats O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
long O
- O
term O
and O
high O
- O
dose O
application O
of O
ketamine B
on O
the O
liver O
by O
employing O
histologic O
and O
biochemical O
methods O
. O

Saline O
for O
control O
group O
and O
different O
doses O
of O
ketamine B
for O
four O
treatment O
groups O
( O
40 O
, O
60 O
, O
80 O
and O
100 O
mg O
kg O
( O
- O
1 O
) O
) O
were O
administered O
intraperitoneal O
twice O
a O
day O
for O
2 O
weeks O
. O

Prolonged O
use O
of O
ketamine B
caused O
hepatocellualar O
toxicity O
and O
histological O
changes O
in O
hepatocytes O
in O
a O
dose O
- O
dependent O
manner O
in O
all O
experimental O
groups O
. O

The O
hexane B
fraction O
from O
leaves O
( O
HL O
) O
and O
ethyl B
acetate I
( O
EAR O
) O
, O
chloroform B
( O
CR O
) O
and O
hydromethanolic O
( O
HMR O
) O
fractions O
from O
roots O
were O
the O
most O
active O
fractions O
against O
K O
- O
562 O
with O
GI O
( O
50 O
) O
values O
being O
lower O
than O
1 O
mu O
g O
mL O
( O
- O
1 O
) O
. O

The O
phytochemical O
study O
of O
the O
CR O
fraction O
allowed O
identifying O
the O
known O
iridoids B
secoxyloganin O
, O
sweroside B
and O
loganin O
. O

Photoelectron O
and O
electron O
momentum O
spectroscopy O
of O
tetrahydrofuran B
from O
a O
molecular O
dynamical O
perspective O
. O

The O
results O
of O
experimental O
studies O
of O
the O
valence O
electronic O
structure O
of O
tetrahydrofuran B
employing O
He B
I O
photoelectron O
spectroscopy O
as O
well O
as O
Electron O
Momentum O
Spectroscopy O
( O
EMS O
) O
have O
been O
reinterpreted O
on O
the O
basis O
of O
Molecular O
Dynamical O
simulations O
employing O
the O
classical O
MM3 O
force O
field O
and O
large O
- O
scale O
quantum O
mechanical O
simulations O
employing O
Born O
- O
Oppenheimer O
Molecular O
Dynamics O
in O
conjunction O
with O
the O
dispersion O
corrected O
omega O
B97XD O
exchange O
- O
correlation O
functional O
. O

These O
deviations O
are O
found O
to O
have O
a O
significant O
influence O
on O
several O
outer O
- O
valence O
electron O
momentum O
distributions O
, O
as O
well O
as O
on O
the O
He B
I O
photoelectron O
spectrum O
. O

The O
effects O
induced O
by O
AZA O
- O
1 O
were O
similar O
to O
those O
elicited O
by O
chlorpromazine B
and O
other O
agents O
preventing O
proper O
maturation O
of O
lysosomal O
enzymes O
, O
indicating O
that O
the O
inhibition O
of O
endocytic O
transfer O
of O
proforms O
to O
late O
endosomes O
/ O
lysosomess O
is O
responsible O
for O
the O
effect O
induced O
by O
the O
toxin O
. O

The O
data O
we O
obtained O
corroborated O
our O
hypothesis O
and O
provide O
a O
unified O
molecular O
frame O
for O
the O
mode O
of O
action O
of O
AZAs B
in O
animal O
models O
, O
involving O
a O
primary O
alteration O
of O
endocytic O
processes O
. O

Controlled O
fabrication O
of O
hexagonally O
close O
- O
packed O
Langmuir O
- O
Blodgett O
silica B
particulate O
monolayers O
from O
binary O
surfactant O
and O
solvent O
systems O
. O

We O
describe O
a O
controllable O
method O
to O
fabricate O
hexagonally O
close O
- O
packed O
Langmuir O
- O
Blodgett O
( O
LB O
) O
monolayers O
with O
stearic B
acid I
( O
SA O
) O
as O
co O
- O
surfactant O
and O
methanol B
as O
co O
- O
solvent O
. O

The O
optimal O
SA O
concentrations O
and O
volume O
ratios O
of O
chloroform B
to O
methanol B
are O
0 O
. O
8 O
mg O
/ O
mL O
and O
3 O
: O
1 O
for O
particles O
of O
140 O
nm O
, O
0 O
. O
50 O
mg O
/ O
mL O
and O
4 O
: O
1 O
for O
particles O
of O
300 O
nm O
, O
and O
0 O
. O
05 O
mg O
/ O
mL O
and O
5 O
: O
1 O
for O
particles O
of O
550 O
nm O
, O
respectively O
. O

The O
experimental O
results O
indicate O
that O
the O
interparticle O
repulsions O
and O
particle O
- O
water O
interactions O
can O
be O
enhanced O
without O
decreasing O
the O
particle O
hydrophobicity O
by O
adding O
SA O
and O
methanol B
; O
thus O
, O
particulate O
monolayers O
with O
large O
hexagonally O
close O
- O
packed O
domains O
composed O
of O
small O
silica B
particles O
can O
be O
successfully O
fabricated O
using O
LB O
technique O
. O

We O
propose O
that O
the O
enhanced O
interparticle O
repulsion O
is O
attributed O
to O
the O
Columbic O
repulsion O
resulting O
from O
the O
attachment O
of O
SA O
molecules O
to O
the O
CTAB B
modified O
particles O
around O
the O
three O
phase O
contact O
line O
. O

Sesquiterpenes B
from O
the O
rhizomes O
of O
Curcuma O
heyneana O
. O

Four O
new O
germacranes O
[ O
heyneanones O
A O
- O
D O
( O
1 O
- O
4 O
) O
] O
, O
three O
new O
guaianes O
[ O
4 O
, O
10 O
- O
epizedoarondiol O
( O
5 O
) O
, O
15 O
- O
hydroxyprocurcumenol O
( O
6 O
) O
, O
12 O
- O
hydroxycurcumenol O
( O
7 O
) O
] O
, O
and O
two O
new O
spirolactones O
[ O
curcumanolides O
C O
( O
8 O
) O
and O
D O
( O
9 O
) O
] O
were O
isolated O
from O
the O
rhizomes O
of O
Curcuma O
heyneana O
together O
with O
13 O
known O
sesquiterpenes B
and O

two O
known O
labdane O
- O
type O
diterpenes B
. O

Among O
the O
isolated O
compounds O
, O
heyneanone O
A O
( O
1 O
) O
, O
heyneanone O
C O
( O
3 O
) O
, O
4 O
, O
10 O
- O
epizedoarondiol O
( O
5 O
) O
, O
procurcumenol O
( O
16 O
) O
, O
aerugidiol O
( O
17 O
) O
, O
zerumin O
A O
( O
23 O
) O
, O
and O
( O
E O
) O
- O
15 O
, O
16 O
- O
bisnorlabda O
- O
8 O
( O
17 O
) O
, O
11 O
- O
dien O
- O
13 O
- O
one O
( O
24 O
) O
inhibited O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

The O
amphiphilic O
diblock O
copolymer O
poly O
( O
epsilon O
- O
caprolactone O
) O
- O
b O
- O
poly O
( O
ethylene O
oxide O
) O
( O
PCL O
- O
b O
- O
PEO O
) O
was O
first O
conjugated O
with O
the O
cyclic O
( O
Arginine O
- O
Glycine O
- O
Aspartic O
acid O
- O
d O
- O
Phenylalanine O
- O
Lysine O
) O
( O
c O
( O
RGDfK O
) O
) O
and O
fluorescein O
isothiocyannate O
( O
FITC B
) O
via O
the O
functional O
terminal O
groups O
of O
hydrophilic O
block O
, O
and O
then O
assembled O
into O
micelles O
. O

The O
c O
( O
RGDfK O
) O
on O
the O
surface O
of O
the O
micelle O
was O
confirmed O
by O
( B
1 I
) I
H I
NMR O
analysis O
and O
cell O
affinity O
with O
human O
glioblastoma O
- O
astrocytoma O
cells O
( O
U87MG O
) O
. O

The O
cell O
viability O
of O
bladder O
cancer O
cells O
( O
T O
- O
24 O
cells O
) O
after O
incubation O
with O
doxorubicin B
( O
DOX B
) O
loaded O
polymeric O
micelles O
was O
evaluated O
by O
in O
vitro O
cytotoxicity O
assay O
. O

The O
results O
revealed O
that O
c O
( O
RGDfK O
) O
modified O
micelles O
showed O
strong O
affinity O
to O
T O
- O
24 O
cells O
and O
strong O
inhibitory O
effect O
on O
the O
proliferation O
of O
T O
- O
24 O
cells O
when O
doxorubicin B
drug O
was O
loaded O
, O
indicating O
the O
high O
affinity O
of O
c O
( O
RGDfK O
) O
to O
bladder O
cancer O
cells O
. O

Prolyl B
- O
hydroxylase O
inhibition O
preserves O
endothelial O
cell O
function O
in O
a O
rat O
model O
of O
vascular O
ischemia O
reperfusion O
injury O
. O

Hypoxia O
elicits O
a O
variety O
of O
complex O
cellular O
responses O
by O
altering O
the O
activity O
of O
many O
signaling O
pathways O
, O
such O
as O
the O
oxygen B
- O
dependent O
prolyl B
- O
hyroxylase O
domain O
- O
containing O
enzyme O
( O
PHD O
) O
. O

VSMCs O
were O
incubated O
in O
NaCl B
or O
DMOG O
solution O
at O
4 O
degrees O
C O
for O
24 O
hours O
after O
the O
medium O
was O
changed O
for O
a O
supplied O
standard O
medium O
at O
37 O
degrees O
C O
for O
6 O
hours O
. O

Cold O
ischemic O
preservation O
and O
NaOCl O
induced O
severe O
endothelial O
dysfunction O
, O
which O
was O
significantly O
improved O
by O
DMOG O
supplementation O
( O
maximal O
relaxation O
of O
aortic O
segments O
to O
acetylcholine B
: O
control O
95 O
% O
+ O
/ O
- O
1 O
% O
versus O
NaOCl O
44 O
% O
+ O
/ O
- O
4 O
% O
versus O
DMOG O
68 O
% O
+ O
/ O
- O
5 O
% O
) O
. O

Inducible O
heme B
- O
oxygenase O
1 O
mRNA O
expressions O
were O
significantly O
higher O
in O
the O
DMOG O
group O
. O

Pharmacological O
modulation O
of O
oxygen B
sensing O
system O
by O
DMOG O
in O
an O
in O
vitro O
model O
of O
vascular O
IR O
effectively O
preserved O
endothelial O
function O
. O

Transport O
of O
A1 O
adenosine B
receptor O
agonist O
tecadenoson O
by O
human O
and O
mouse O
nucleoside B
transporters O
: O
evidence O
for O
blood O
- O
brain O
barrier O
transport O
by O
murine O
equilibrative O
nucleoside B
transporter O
1 O
mENT1 O
. O

The O
high O
density O
of O
A1 O
adenosine B
receptors O
in O
the O
brain O
results O
in O
significant O
potential O
for O
central O
nervous O
system O
( O
CNS O
) O
- O
related O
adverse O
effects O
with O
A1 O
agonists O
. O

Tecadenoson O
is O
a O
selective O
A1 O
adenosine B
receptor O
agonist O
with O
close O
similarity O
to O
adenosine B
. O

We O
studied O
the O
binding O
and O
transmembrane O
transport O
of O
tecadenoson O
by O
recombinant O
human O
equilibrative O
nucleoside B
transporters O
( O
hENTs O
) O
hENT1 O
and O
hENT2 O
, O
and O
human O
concentrative O
nucleoside B
transporters O
( O
hCNTs O
) O
hCNT1 O
, O
hCNT2 O
, O
and O
hCNT3 O
in O
vitro O
and O
by O
mouse O
mENT1 O
in O
vivo O
. O

Binding O
affinities O
of O
the O
five O
recombinant O
human O
nucleoside B
transporters O
for O
tecadenoson O
differed O
( O
hENT1 O
> O
hCNT1 O
> O
hCNT3 O
> O
hENT2 O
> O
hCNT2 O
) O
, O
and O
tecadenoson O
was O
transported O
largely O
by O
hENT1 O
. O

The O
herein O
presented O
complete O
structure O
of O
the O
core O
oligosaccharide O
of O
lipopolysaccharide O
( O
LPS O
) O
P O
. O
shigelloides O
Polish O
Collection O
of O
Microorganisms O
( O
PCM O
) O
2231 O
( O
serotype O
O17 O
) O
was O
investigated O
by O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
NMR O
spectroscopy O
, O
mass O
spectrometry O
, O
chemical O
analyses O
and O
serological O
methods O
. O

This O
structure O
is O
similar O
to O
that O
of O
the O
core O
oligosaccharide O
of O
P O
. O
shigelloides O
strains O
302 O
- O
73 O
( O
serotype O
O1 O
) O
and O
7 O
- O
63 O
( O
serotype O
O17 O
) O
and O
differs O
from O
these O
only O
by O
one O
sugar B
residue O
. O

All O
compounds O
were O
evaluated O
for O
their O
cytotoxicity O
against O
selected O
cancer O
cell O
lines O
and O
the O
inhibition O
of O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
nitric B
oxide I
( O
NO B
) O
production O
in O
mouse O
peritoneal O
macrophages O
. O

A O
series O
of O
iron B
oxide I
nanoparticles O
with O
varying O
stabilizing O
ligand O
brush O
lengths O
were O
synthesized O
. O

Comparison O
of O
toxicity O
between O
the O
different O
- O
type O
TiO B
( I
2 I
) I
nanowires O
in O
vivo O
and O
in O
vitro O
. O

In O
this O
study O
, O
we O
compared O
their O
toxicity O
in O
vivo O
and O
in O
vitro O
based O
on O
the O
physicochemical O
properties O
of O
three O
different O
types O
of O
TiO B
( I
2 I
) I
nanowires O
, O
H O
( O
2 O
) O
Ti O
( O
3 O
) O
O O
( O
7 O
) O
nanowires O
( O
1HTO O
) O
, O
hydrothermal O
treatment O
( O
2HTO O
) O
, O
and O
calcination O
( O
3HTO O
) O
of O
1HTO O
. O

In O
vitro O
, O
three O
TiO B
( I
2 I
) I
nanowires O
( O
10 O
mu O
g O
/ O
ml O
) O
commonly O
induced O
the O
generation O
of O
cell O
debris O
in O
eight O
cell O
lines O
which O
may O
be O
the O
potential O
target O
organ O
of O
nanoparticles O
, O
especially O
by O
2HTO O
. O

In O
further O
study O
using O
BEAS O
- O
2B O
cells O
originated O
from O
the O
lung O
, O
the O
protein O
amount O
from O
cells O
exposed O
to O
2HTO O
decreased O
more O
clearly O
although O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
was O
less O
compared O
to O
1HTO O
and O
3HTO O
. O

Based O
on O
these O
results O
, O
we O
suggest O
that O
surface O
area O
may O
act O
as O
an O
important O
factor O
depends O
on O
the O
biological O
response O
by O
TiO B
( I
2 I
) I
nanowires O
. O

The O
effects O
of O
BMY O
- O
14802 O
against O
L O
- O
DOPA O
- O
and O
dopamine B
agonist O
- O
induced O
dyskinesia O
in O
the O
hemiparkinsonian O
rat O
. O

OBJECTIVE O
: O
In O
the O
present O
study O
, O
we O
extend O
these O
findings O
by O
examining O
the O
anti O
- O
dyskinetic O
potential O
of O
BMY O
- O
14802 O
against O
L O
- O
DOPA O
, O
the O
D O
( O
1 O
) O
receptor O
agonist O
SKF81297 O
and O
the O
D O
( O
2 O
) O
receptor O
agonist O
, O
quinpirole B
, O
in O
the O
hemi O
- O
parkinsonian O
rat O
model O
. O

In O
addition O
, O
the O
receptor O
specificity O
of O
BMY O
- O
14802 O
' O
s O
effects O
was O
evaluated O
using O
WAY B
- I
100635 I
, O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
antagonist O
. O

Additionally O
, O
BMY O
- O
14802 O
' O
s O
anti O
- O
dyskinetic O
effects O
against O
L O
- O
DOPA O
, O
but O
not O
SKF81297 O
or O
quinpirole B
, O
were O
reversed O
by O
WAY B
- I
100635 I
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
. O

High O
K B
( I
+ I
) I
, O
noradrenaline B
( O
NA O
) O
, O
or O
acetylcholine B
( O
ACh B
) O
was O
applied O
with O
and O
without O
various O
antagonists O
and O
/ O
or O
inhibitors O
to O
examine O
the O
contractile O
signaling O
pathways O
. O

Both O
NA O
and O
ACh B
produced O
large O
contractions O
in O
ventral O
and O
dorsal O
rings O
, O
whereas O
only O
small O
contractions O
were O
elicited O
in O
lateral O
and O
anterior O
rings O
. O

Combination O
of O
alpha O
- O
1 O
and O
muscarinic O
antagonists O
suppressed O
K B
( I
+ I
) I
depolarization O
- O
induced O
contraction O
potently O
in O
ventral O
rings O
, O
but O
slightly O
in O
anterior O
rings O
. O

Blocking O
of O
either O
Ca B
( I
2 I
+ I
) I
- O
release O
or O
Ca B
( I
2 I
+ I
) I
- O
influx O
reduced O
agonist O
- O
induced O
contraction O
of O
ventral O
rings O
, O
however O
, O
a O
considerable O
amount O
of O
contractility O
remained O
even O
with O
both O
blockers O
. O

Inhibitors O
of O
ROCK O
and O
PKC O
partially O
inhibited O
NA O
- O
induced O
contractions O
, O
whereas O
a O
combination O
of O
Ca B
( I
2 I
+ I
) I
- O
blockers O
and O
Ca B
( I
2 I
+ I
) I
- O
sensitization O
inhibitors O
strongly O
suppressed O
the O
contraction O
. O

In O
ventral O
prostate O
smooth O
muscle O
, O
Ca B
( I
2 I
+ I
) I
- O
release O
, O
Ca B
( I
2 I
+ I
) I
- O
influx O
, O
and O
ROCK O
- O
and O
PKC O
- O
mediated O
Ca B
( I
2 I
+ I
) I
- O
sensitizations O
are O
all O
involved O
in O
NA O
- O
induced O
contractions O
. O

Inflammatory O
lesions O
were O
associated O
with O
an O
increase O
in O
the O
Ki O
- O
67 O
proliferative O
index O
, O
and O
diminished O
Nkx3 O
. O
1 O
and O
androgen B
receptor O
( O
AR O
) O
production O
. O

Using O
a O
glucocorticoid O
response O
element O
( O
GRE O
) O
luciferase O
reporter O
transfected O
into O
human O
airway O
epithelial O
cells O
[ O
both O
bronchial O
epithelium O
+ O
adenovirus O
12 O
- O
SV40 O
hybrid O
( O
BEAS O
- O
2B O
) O
cells O
and O
primary O
cultures O
] O
, O
roflumilast O
enhanced O
fluticasone B
propionate I
- O
induced O
GRE O
- O
dependent O
transcription O
. O

FOXO1 O
binds O
to O
the O
TAU5 O
motif O
and O
inhibits O
constitutively O
active O
androgen B
receptor O
splice O
variants O
. O

BACKGROUND O
: O
Aberrant O
activation O
of O
the O
androgen B
receptor O
( O
AR O
) O
is O
a O
major O
factor O
highly O
relevant O
to O
castration O
- O
resistant O
progression O
of O
prostate O
cancer O
( O
PCa O
) O
. O

FOXO1 O
, O
a O
key O
downstream O
effector O
of O
PTEN O
, O
inhibits O
androgen B
- O
independent O
activation O
of O
the O
AR O
. O

RESULTS O
: O
We O
found O
that O
a O
putative O
transcription O
repression O
domain O
in O
the O
NH2 B
- O
terminus O
of O
FOXO1 O
is O
dispensable O
for O
FOXO1 O
inhibition O
of O
the O
AR O
. O

In O
vitro O
protein O
binding O
assays O
showed O
that O
FOXO1 O
binds O
to O
the O
transcription O
activation O
unit O
5 O
( O
TAU5 O
) O
motif O
in O
the O
AR O
NH2 B
- O
terminal O
domain O
( O
NTD O
) O
, O
a O
region O
required O
for O
recruitment O
of O
p160 O
activators O
including O
SRC O
- O
1 O
. O

While O
SMN2 O
encodes O
a O
protein O
identical O
to O
SMN1 O
, O
a O
single O
nucleotide B
difference O
in O
exon O
7 O
causes O
most O
of O
the O
SMN2 O
- O
derived O
transcripts O
to O
be O
alternatively O
spliced O
resulting O
in O
a O
truncated O
and O
unstable O
protein O
( O
SMN O
Delta O
7 O
) O
. O

We O
report O
the O
acquisition O
and O
interpretation O
of O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
J O
- O
spectra O
at O
zero O
magnetic O
field O
for O
a O
series O
of O
benzene B
derivatives O
, O
demonstrating O
the O
analytical O
capabilities O
of O
zero O
- O
field O
NMR O
. O

Here O
we O
examine O
how O
changes O
in O
bulk O
solvent O
( O
water O
, O
methanol B
, O
or O
DMF O
) O
or O
applied O
pressure O
( O
up O
to O
150 O
MPa O
) O
affect O
the O
rotational O
dynamics O
of O
encapsulated O
benzyl O
phosphonium O
guests O
, O
as O
a O
way O
to O
probe O
changes O
in O
host O
cavity O
size O
or O
flexibility O
. O

At O
5 O
min O
after O
i O
. O
v O
. O
administration O
of O
the O
( B
14 I
) I
C I
compound O
, O
high O
levels O
of O
radioactivity O
were O
observed O
in O
the O
fundus O
of O
the O
stomach O
compared O
to O
blood O
and O
plasma O
and O
the O
rest O
of O
the O
stomach O
, O
indicating O
an O
active O
secretion O
of O
( B
14 I
) I
C I
material O
into O
the O
stomach O
. O

The O
MO O
was O
determined O
using O
the O
National O
Cholesterol B
Education O
Program O
- O
Adult O
Treatment O
Panel O
III O
classification O
with O
Korean O
- O
specific O
cutoffs O
for O
abdominal O
obesity O
. O

Quasiclassical O
trajectory O
and O
statistical O
quantum O
calculations O
for O
the O
C B
+ O
OH B
- O
- O
> O
CO B
+ O
H B
reaction O
on O
the O
first O
excited O
1 O
( O
2 O
) O
A O
' O
' O
potential O
energy O
surface O
. O

We O
report O
quasiclassical O
trajectory O
dynamical O
calculations O
for O
the O
C B
( O
( O
3 O
) O
P O
) O
+ O
OH B
( O
X O
( O
2 O
) O
Pi O
) O
- O
- O
> O
CO B
( O
a O
( O
3 O
) O
Pi O
) O
+ O
H B
( O
( O
2 O
) O
S O
) O
using O
a O
recently O
developed O
ab O
initio O
potential O
energy O
surface O
for O
the O
first O
electronic O
state O
of O
HCO B
of O
1 O
( O
2 O
) O
A O
' O
' O
symmetry O
. O

Twenty O
- O
five O
metabolites O
were O
tentatively O
identified O
for O
irgarol O
, O
terbutryn O
, O
tramadol O
, O
and O
venlafaxine B
in O
G O
. O
pulex O
( O
21 O
via O
oxidation O
and O
4 O
via O
conjugation O
reactions O
) O
and O
11 O
metabolites O
in O
D O
. O
magna O
( O
7 O
via O
oxidation O
and O
4 O
via O
conjugation O
reactions O
) O
, O
while O
no O
evidence O
of O
metabolites O
for O
clarithromycin B
and O
valsartan O
was O
found O
. O

Observed O
oxidative O
reactions O
included O
N B
- O
and O
O B
- O
demethylation O
, O
hydroxylation O
, O
and O
N B
- O
oxidation O
. O

Glutathione B
conjugation O
of O
selected O
biocides O
followed O
by O
subsequent O
reactions O
forming O
cysteine B
conjugates O
was O
described O
for O
the O
first O
time O
in O
freshwater O
invertebrates O
. O

Cloning O
, O
Characterization O
, O
and O
Sulfonamide B
and O
Thiol B
Inhibition O
Studies O
of O
an O
alpha O
- O
Carbonic O
Anhydrase O
from O
Trypanosoma O
cruzi O
, O
the O
Causative O
Agent O
of O
Chagas O
Disease O
. O

The O
enzyme O
( O
TcCA O
) O
has O
a O
very O
high O
catalytic O
activity O
for O
the O
CO B
( I
2 I
) I
hydration O
reaction O
, O
being O
similar O
kinetically O
to O
the O
human O
( O
h O
) O
isoform O
hCA O
II O
, O
although O
it O
is O
devoid O
of O
the O
His64 O
proton O
shuttle O
. O

The O
thiols B
were O
the O
most O
potent O
in O
vitro O
inhibitors O
( O
K O
( O
I O
) O
values O
of O
21 O
. O
1 O
- O
79 O
. O
0 O
nM O
) O
, O
and O
some O
of O
them O
also O
inhibited O
the O
epimastigotes O
growth O
of O
two O
T O
. O
cruzi O
strains O
in O
vivo O
. O

The O
present O
study O
evaluated O
the O
preclinical O
toxicity O
( O
acute O
and O
subchronic O
) O
, O
as O
well O
as O
the O
toxicokinetic O
and O
gastroprotective O
effects O
of O
BS O
against O
ethanol B
lesions O
. O

Synthesis O
of O
Li B
- O
Mn B
- O
O B
mesocrystals O
with O
controlled O
crystal O
phases O
through O
topotactic O
transformation O
of O
MnCO O
3 O
. O

Mesocrystals O
of O
Li B
- O
Mn B
- O
O B
compounds O
, O
such O
as O
LiMn2O4 O
, O
Li2MnO3 O
, O
and O
LiMnO2 O
- O
Li2MnO3 O
, O
consisting O
of O
oriented O
nanoscale O
units O
were O
selectively O
produced O
under O
hydrothermal O
conditions O
from O
biomimetically O
prepared O
MnCO3 B
mesocrystals O
. O

Topotactic O
transformation O
through O
the O
intermediate O
phase O
of O
Mn5O8 O
inheriting O
a O
hierarchical O
structure O
of O
the O
MnCO3 B
precursor O
was O
essential O
for O
the O
formation O
of O
the O
mesocrystal O
compounds O
. O

The O
Li B
- O
Mn B
- O
O B
mesocrystals O
have O
considerable O
potential O
as O
cathodes O
of O
Li B
- O
ion O
batteries O
. O

Ventral O
tegmental O
area O
GABA B
neurons O
and O
opiate O
motivation O
. O

RATIONALE O
: O
Past O
research O
has O
demonstrated O
that O
when O
an O
animal O
changes O
from O
a O
previously O
drug O
- O
naive O
to O
an O
opiate O
- O
dependent O
and O
withdrawn O
state O
, O
morphine B
' O
s O
motivational O
effects O
are O
switched O
from O
a O
tegmental O
pedunculopontine O
nucleus O
( O
TPP O
) O
- O
dependent O
to O
a O
dopamine B
- O
dependent O
pathway O
. O

Interestingly O
, O
a O
corresponding O
change O
is O
observed O
in O
ventral O
tegmental O
area O
( O
VTA O
) O
GABA B
( O
A O
) O
receptors O
, O
which O
change O
from O
mediating O
hyperpolarization O
of O
VTA O
GABA B
neurons O
to O
mediating O
depolarization O
. O

OBJECTIVES O
: O
The O
present O
study O
investigated O
whether O
pharmacological O
manipulation O
of O
VTA O
GABA B
( O
A O
) O
receptor O
activity O
could O
directly O
influence O
the O
mechanisms O
underlying O
opiate O
motivation O
. O

RESULTS O
: O
Using O
an O
unbiased O
place O
conditioning O
procedure O
, O
we O
demonstrated O
that O
in O
Wistar O
rats O
, O
intra O
- O
VTA O
administration O
of O
furosemide B
, O
a O
Cl B
( I
- I
) I
cotransporter O
inhibitor O
, O
was O
able O
to O
promote O
a O
switch O
in O
the O
mechanisms O
underlying O
morphine B
' O
s O
motivational O
properties O
, O
one O
which O
is O
normally O
observed O
only O
after O
chronic O
opiate O
exposure O
. O

This O
behavioral O
switch O
was O
prevented O
by O
intra O
- O
VTA O
administration O
of O
acetazolamide O
, O
an O
inhibitor O
of O
the O
bicarbonate B
ion O
- O
producing O
carbonic O
anhydrase O
enzyme O
. O

Electrophysiological O
recordings O
of O
mouse O
VTA O
showed O
that O
furosemide B
reduced O
the O
sensitivity O
of O
VTA O
GABA B
neurons O
to O
inhibition O
by O
the O
GABA B
( O
A O
) O
receptor O
agonist O
muscimol B
, O
instead O
increasing O
the O
firing O
rate O
of O
a O
significant O
subset O
of O
these O
GABA B
neurons O
. O

CONCLUSIONS O
: O
Our O
results O
suggest O
that O
the O
carbonic O
anhydrase O
enzyme O
may O
constitute O
part O
of O
a O
common O
VTA O
GABA B
neuron O
- O
based O
biological O
pathway O
responsible O
for O
controlling O
the O
mechanisms O
underlying O
opiate O
motivation O
, O
supporting O
the O
hypothesis O
that O
VTA O
GABA B
( O
A O
) O
receptor O
hyperpolarization O
or O
depolarization O
is O
responsible O
for O
selecting O
TPP O
- O
or O
dopamine B
- O
dependent O
motivational O
outputs O
, O
respectively O
. O

Effects O
of O
monocarboxylate B
transporter O
inhibition O
on O
the O
oral O
toxicokinetics O
/ O
toxicodynamics O
of O
gamma B
- I
hydroxybutyrate I
and O
gamma B
- I
butyrolactone I
. O

Respiratory O
depression O
and O
death O
secondary O
to O
respiratory O
arrest O
have O
occurred O
after O
oral O
overdoses O
of O
gamma B
- I
hydroxybutyrate I
( O
GHB B
) O
and O
its O
precursor O
gamma B
- I
butyrolactone I
( O
GBL B
) O
. O

GHB B
is O
a O
substrate O
for O
monocarboxylate B
transporters O
( O
MCTs O
) O
, O
and O
increasing O
GHB B
renal O
clearance O
or O
decreasing O
GHB B
absorption O
via O
MCT O
inhibition O
represents O
a O
potential O
treatment O
strategy O
for O
GHB B
/ O
GBL B
overdose O
. O

In O
these O
studies O
, O
GHB B
and O
GBL B
were O
administered O
in O
doses O
of O
1 O
. O
92 O
, O
5 O
. O
77 O
, O
and O
14 O
. O
4 O
mmol O
/ O
kg O
orally O
with O
and O
without O
MCT O
inhibition O
to O
determine O
effects O
of O
this O
treatment O
strategy O
on O
the O
oral O
toxicokinetics O
and O
toxicodynamics O
of O
GHB B
and O
GBL B
. O

The O
competitive O
MCT O
inhibitor O
l O
- O
lactate O
was O
administered O
by O
intravenous O
infusion O
starting O
1 O
hour O
after O
GHB B
and O
GBL B
administration O
. O

Intravenous O
l O
- O
lactate O
, O
but O
not O
oral O
treatments O
, O
significantly O
increased O
GHB B
renal O
and O
/ O
or O
oral O
clearances O
. O

At O
the O
low O
dose O
of O
GHB B
and O
GBL B
, O
i O
. O
v O
. O
l O
- O
lactate O
increased O
GHB B
renal O
clearance O
. O

At O
the O
highest O
GHB B
dose O
, O
oral O
clearance O
was O
increased O
without O
a O
significant O
change O
in O
renal O
clearance O
. O

The O
lack O
of O
effect O
of O
i O
. O
v O
. O
l O
- O
lactate O
on O
renal O
clearance O
after O
a O
high O
oral O
GHB B
dose O
suggests O
possible O
effects O
of O
i O
. O
v O
. O
l O
- O
lactate O
on O
MCT O
- O
mediated O
absorption O
. O

Intravenous O
l O
- O
lactate O
also O
reduced O
mortality O
with O
the O
high O
GBL B
dose O
. O

These O
data O
indicate O
i O
. O
v O
. O
l O
- O
lactate O
represents O
a O
potential O
treatment O
strategy O
in O
oral O
overdose O
of O
GHB B
and O
GBL B
. O

Antidepressant O
treatment O
and O
emotional O
processing O
: O
can O
we O
dissociate O
the O
roles O
of O
serotonin B
and O
noradrenaline B
? O

In O
particular O
, O
while O
the O
vast O
majority O
of O
antidepressant O
treatments O
affect O
either O
serotonin B
or O
noradrenaline B
or O
a O
combination O
of O
these O
two O
neurotransmitters O
, O
it O
is O
not O
known O
whether O
there O
are O
particular O
patients O
or O
symptom O
profiles O
which O
respond O
preferentially O
to O
the O
potentiation O
of O
serotonin B
over O
noradrenaline B
or O
vice O
versa O
. O

Here O
, O
we O
therefore O
review O
evidence O
from O
studies O
examining O
the O
effects O
of O
drugs O
which O
potentiate O
serotonin B
, O
noradrenaline B
or O
a O
combination O
of O
both O
neurotransmitters O
on O
emotional O
processing O
. O

These O
results O
suggest O
that O
antidepressants O
targeting O
serotonin B
and O
noradrenaline B
may O
have O
some O
specific O
actions O
on O
emotion O
and O
reward O
processing O
which O
could O
be O
used O
to O
improve O
tailoring O
of O
treatment O
or O
to O
understand O
the O
effects O
of O
dual O
- O
reuptake O
inhibition O
. O

Specifically O
, O
serotonin B
may O
be O
particularly O
important O
in O
alleviating O
distress O
symptoms O
, O
while O
noradrenaline B
may O
be O
especially O
relevant O
to O
anhedonia O
. O

The O
data O
reviewed O
here O
also O
suggest O
that O
noradrenergic O
- O
based O
treatments O
may O
have O
earlier O
effects O
on O
emotional O
memory O
that O
those O
which O
affect O
serotonin B
. O

cAMP B
response O
element O
- O
binding O
protein O
( O
CREB O
) O
has O
been O
implicated O
in O
the O
regulation O
of O
FSH O
beta O
gene O
expression O
, O
but O
the O
molecular O
mechanisms O
by O
which O
pulsatile O
GnRH O
regulates O
CREB O
activation O
remain O
poorly O
understood O
. O

Only O
a O
weak O
correlation O
was O
observed O
between O
the O
presence O
of O
subclinical O
myocardial O
necrosis O
and O
either O
glycemic O
control O
( O
r O
= O
0 O
. O
06 O
; O
P O
= O
0 O
. O
044 O
for O
hemoglobin O
A1c O
versus O
cTnI O
) O
or O
insulin O
resistance O
( O
r O
= O
0 O
. O
04 O
; O
P O
= O
0 O
. O
094 O
for O
glucose B
- O
to O
- O
insulin O
ratio O
versus O
cTnI O
) O
. O

clamp O
before O
and O
after O
pylorus O
- O
preserving O
pancreatoduodenectom O
for O
ampulloma O
. O
RESULTSAll O
patients O
experienced O
a O
reduction O
in O
insulin O
( O
P O
= O
0 O
. O
002 O
) O
, O
C O
- O
peptide O
( O
P O
= O
0 O
. O
0002 O
) O
, O
and O
gastric O
inhibitory O
peptide O
( O
GIP O
) O
secretion O
( O
P O
= O
0 O
. O
0004 O
) O
, O
while O
both O
fasting O
and O
postprandial O
glucose B
levels O
increased O
( O
P O
= O
0 O
. O
0001 O
) O
; O
GLP O
- O
1 O
and O
glucagon O
responses O
to O
the O
mixed O
meal O
increased O
significantly O
after O
surgery O
( O
P O
= O
0 O
. O
02 O
and O

While O
changes O
in O
GIP O
levels O
did O
not O
correlate O
with O
insulin O
, O
glucagon O
, O
and O
glucose B
levels O
, O
the O
increase O
in O
GLP O
- O
1 O
secretion O
was O
inversely O
related O
to O
the O
postsurgery O
decrease O
in O
insulin O
secretion O
( O
R O
( O
2 O
) O
= O
0 O
. O
56 O
; O
P O
= O
0 O
. O
012 O
) O
but O
not O
to O
the O
increased O
glucagon O
secretion O
, O
which O
correlated O
inversely O
with O
the O
reduction O
of O
insulin O
( O
R O
( O
2 O
) O
= O
0 O
. O
46 O
; O
P O
= O
0 O
. O
03 O
) O
and O
C O
- O
peptide O
( O
R O
( O
2 O
) O
= O
0 O
. O
37 O
; O
P O
= O
0 O
. O
04 O
) O
. O

Pharmacokinetic O
Interactions O
between O
Monoamine B
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5 O
- O
Methoxy O
- O
N O
, O
N O
- O
Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status O
. O

Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine B
oxidase O
A O
( O
MAO O
- O
A O
) O
inhibitor O
harmaline O
( O
5 O
mg O
/ O
kg O
) O
increases O
systemic O
exposure O
to O
5 O
- O
MeO O
- O
DMT O
( O
2 O
mg O
/ O
kg O
) O
and O
active O
metabolite O
bufotenine O
. O

This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5 O
- O
MeO O
- O
DMT O
pharmacokinetic O
( O
PK O
) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5 O
- O
MeO O
- O
DMT O
O B
- O
demethylation O
to O
produce O
bufotenine O
. O

Hyperbranched O
Polyester B
Hydrogels O
with O
Controlled O
Drug O
Release O
and O
Cell O
Adhesion O
Properties O
. O

The O
functionalization O
of O
HPE O
with O
photocrosslinkable O
acrylate B
moieties O
renders O
the O
formation O
of O
hydrogels O
with O
a O
highly O
porous O
interconnected O
structure O
and O
mechanically O
tough O
network O
. O

Stable O
aqueous O
dispersions O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
were O
synthesized O
in O
one O
step O
in O
the O
presence O
of O
a O
zwitterionic O
siloxane O
as O
the O
stabilizing O
/ O
capping O
/ O
solubilizing O
ligand O
. O

Four O
novel O
diterpenoids B
, O
including O
three O
tetracyclic O
diterpenes O
with O
isomerized O
isospongian O
skeletons O
, O
kravanhins O
A O
- O
C O
( O
1 O
- O
3 O
) O
, O
and O
kravanhin O
D O
( O
4 O
) O
, O
and O
three O
new O
labdane O
diterpenes O
( O
5 O
- O
7 O
) O
were O
isolated O
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Compound O
2 O
showed O
inhibitory O
activity O
on O
nitric B
oxide I
production O
in O
lipopolysaccharide O
- O
induced O
RAW264 O
. O
7 O
macrophages O
with O
an O
IC O
( O
50 O
) O
value O
of O
36 O
. O
2 O
mu O
M O
. O

Methotrexate B
pharmacogenetics O
in O
rheumatoid O
arthritis O
: O
a O
status O
report O
. O

Methotrexate B
( O
MTX B
) O
, O
an O
antifolate O
drug O
, O
is O
the O
first O
- O
line O
disease O
- O
modifying O
agent O
for O
the O
treatment O
of O
rheumatoid O
arthritis O
( O
RA O
) O
worldwide O
. O

MTX B
has O
excellent O
long O
- O
term O
efficacy O
, O
tolerability O
and O
safety O
. O

Early O
initiation O
of O
MTX B
in O
patients O
with O
RA O
controls O
joint O
destruction O
and O
slows O
progression O
of O
disease O
. O

However O
, O
the O
clinical O
response O
to O
MTX B
and O
frequency O
of O
adverse O
effects O
from O
the O
drug O
exhibit O
marked O
interpatient O
variability O
. O

Over O
the O
past O
decade O
, O
there O
has O
been O
a O
quest O
to O
identify O
genetic O
markers O
that O
reliably O
predict O
MTX B
efficacy O
and O
toxicity O
and O
help O
optimize O
MTX B
therapy O
in O
RA O
; O
that O
is O
, O
the O
field O
of O
MTX B
pharmacogenetics O
. O

This O
review O
will O
summarize O
key O
pharmacogenetic O
studies O
examining O
SNPs O
in O
the O
genes O
encoding O
enzymes O
in O
the O
MTX B
cellular O
pathway O
and O
their O
association O
with O
MTX B
response O
in O
RA O
. O

As O
evident O
from O
this O
review O
, O
MTX B
pharmacogenetics O
in O
RA O
remains O
a O
muddled O
field O
, O
mostly O
due O
to O
inconsistent O
results O
from O
several O
small O
underpowered O
studies O
. O

Reversible O
sol O
- O
to O
- O
gel O
transformation O
of O
uracil B
gelators O
: O
specific O
colorimetric O
and O
fluorimetric O
sensor O
for O
fluoride B
ions O
. O

A O
new O
type O
of O
anthracene B
organogelator O
based O
on O
uracil B
was O
obtained O
using O
organic O
aromatic O
solvents O
, O
cyclohexane B
, O
DMSO B
, O
ethanol B
, O
and O
ethyl B
acetate I
. O

Spectroscopic O
study O
and O
( B
1 I
) I
H I
NMR O
titration O
experiment O
revealed O
that O
the O
deprotonation O
of O
the O
hydrogen B
atom O
on O
the O
N B
position O
of O
uracil B
moiety O
by O
fluoride B
ions O
is O
responsible O
for O
the O
recognition O
events O
, O
evidenced O
by O
immediate O
transformation O
from O
the O
sol O
phase O
to O
the O
gel O
state O
upon O
adding O
a O
small O
amount O
of O
a O
proton O
solvent O
, O
methanol B
. O

The O
standards O
of O
medical O
care O
in O
diabetes O
recommend O
that O
statin O
therapy O
is O
added O
to O
lifestyle O
therapy O
for O
diabetic O
patients O
with O
overt O
cardiovascular O
disease O
( O
LDL O
cholesterol B
goal O
< O
70 O
mg O
/ O
dl O
) O
, O
or O
without O
cardiovascular O
disease O
who O
are O
over O
the O
age O
of O
40 O
years O
and O
who O
have O
one O
or O
more O
other O
cardiovascular O
disease O
risk O
factors O
( O
LDL O
cholesterol B
goal O
< O
100 O
mg O
/ O
dl O
) O
. O

Thymidylate O
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine B
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine B
5 I
' I
- I
monophosphate I
( O
dTMP O
) O
in O
the O
presence O
of O
ATP B
and O
Mg B
( I
2 I
+ I
) I
to O
form O
thymidine O
5 O
' O
- O
diphosphate O
( O
dTDP O
) O
, O
which O
is O
then O
converted O
to O
thymidine O
5 O
' O
- O
triphosphate O
( O
dTTP O
) O
by O
nucleoside B
- I
diphosphate I
kinase O
( O
NDK O
) O
. O

TMPK O
is O
well O
recognized O
as O
a O
potential O
drug O
target O
, O
with O
the O
most O
notable O
function O
being O
in O
the O
activation O
of O
anti O
- O
HIV O
nucleoside B
prodrugs O
. O

In O
addition O
, O
inhibition O
of O
human O
TMPK O
increases O
the O
potential O
of O
anticancer O
agent O
doxorubicin B
toward O
colon O
cancer O
cells O
regardless O
of O
p53 O
status O
. O

Growth O
of O
highly O
fluorescent O
polyethylene B
glycol I
- O
and O
zwitterion O
- O
functionalized O
gold O
nanoclusters O
. O

We O
have O
prepared O
and O
characterized O
a O
new O
set O
of O
highly O
fluorescent O
gold O
nanoclusters O
( O
AuNCs O
) O
using O
one O
- O
step O
aqueous O
reduction O
of O
a O
gold O
precursor O
in O
the O
presence O
of O
bidentate O
ligands O
made O
of O
lipoic B
acid I
anchoring O
groups O
, O
appended O
with O
either O
a O
poly B
( I
ethylene I
glycol I
) I
short O
chain O
or O
a O
zwitterion O
group O
. O

Dispersions O
of O
these O
AuNCs O
exhibit O
great O
long O
- O
term O
colloidal O
stability O
, O
over O
a O
wide O
range O
of O
pHs O
( O
2 O
- O
13 O
) O
and O
in O
the O
presence O
of O
high O
electrolyte O
concentrations O
, O
and O
a O
strong O
resistance O
to O
reducing O
agents O
such O
as O
glutathione B
. O

The O
growth O
strategy O
further O
permitted O
the O
controlled O
, O
in O
situ O
functionalization O
of O
the O
NCs O
with O
reactive O
groups O
( O
e O
. O
g O
. O
, O
carboxylic B
acid I
or O
amine B
) O
, O
making O
these O
nanoclusters O
compatible O
with O
common O
and O
simple O
- O
to O
- O
implement O
coupling O
strategies O
, O
such O
as O
carbodiimide O
chemistry O
. O

Correlating O
superlattice O
polymorphs O
to O
internanoparticle O
distance O
, O
packing O
density O
, O
and O
surface O
lattice O
in O
assemblies O
of O
PbS B
nanoparticles O
. O

Assemblies O
of O
3 O
. O
5 O
nm O
PbS B
nanoparticles O
( O
NPs O
) O
nucleate O
in O
three O
dominant O
superlattice O
polymorphs O
: O
amorphous O
, O
body O
- O
centered O
- O
cubic O
( O
bcc O
) O
and O
face O
- O
centered O
- O
cubic O
( O
fcc O
) O
phase O
. O

Linking O
molecule O
- O
NP O
interactions O
with O
a O
series O
of O
changes O
of O
packing O
density O
and O
surface O
lattice O
spacings O
of O
NPs O
allows O
for O
an O
interpretation O
of O
principles O
governing O
the O
nucleation O
, O
structure O
stability O
, O
and O
transformation O
of O
PbS B
NP O
- O
assembled O
supercrystals O
. O

Gut O
microbiota O
regulates O
bile B
acid I
metabolism O
by O
reducing O
the O
levels O
of O
tauro O
- O
beta O
- O
muricholic O
acid O
, O
a O
naturally O
occurring O
FXR O
antagonist O
. O

Bile B
acids I
are O
synthesized O
from O
cholesterol B
in O
the O
liver O
and O
further O
metabolized O
by O
the O
gut O
microbiota O
into O
secondary O
bile B
acids I
. O

Bile B
acid I
synthesis O
is O
under O
negative O
feedback O
control O
through O
activation O
of O
the O
nuclear O
receptor O
farnesoid O
X O
receptor O
( O
FXR O
) O
in O
the O
ileum O
and O
liver O
. O

Here O
we O
profiled O
the O
bile B
acid I
composition O
throughout O
the O
enterohepatic O
system O
in O
germ O
- O
free O
( O
GF O
) O
and O
conventionally O
raised O
( O
CONV O
- O
R O
) O
mice O
. O

We O
confirmed O
a O
dramatic O
reduction O
in O
muricholic O
acid O
, O
but O
not O
cholic B
acid I
, O
levels O
in O
CONV O
- O
R O
mice O
. O

Rederivation O
of O
Fxr O
- O
deficient O
mice O
as O
GF O
demonstrated O
that O
the O
gut O
microbiota O
regulated O
expression O
of O
fibroblast O
growth O
factor O
15 O
in O
the O
ileum O
and O
cholesterol B
7 O
alpha O
- O
hydroxylase O
( O
CYP7A1 O
) O
in O
the O
liver O
by O
FXR O
- O
dependent O
mechanisms O
. O

These O
studies O
suggest O
that O
the O
gut O
microbiota O
not O
only O
regulates O
secondary O
bile B
acid I
metabolism O
but O
also O
inhibits O
bile B
acid I
synthesis O
in O
the O
liver O
by O
alleviating O
FXR O
inhibition O
in O
the O
ileum O
. O

Tmem64 O
modulates O
calcium B
signaling O
during O
RANKL O
- O
mediated O
osteoclast O
differentiation O
. O

Osteoclast O
maturation O
and O
function O
primarily O
depend O
on O
receptor O
activator O
of O
NF O
- O
kappa O
B O
ligand O
( O
RANKL O
) O
- O
mediated O
induction O
of O
nuclear O
factor O
of O
activated O
T O
cells O
c1 O
( O
NFATc1 O
) O
, O
which O
is O
further O
activated O
via O
increased O
intracellular O
calcium B
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
) O
oscillation O
. O

However O
, O
the O
coordination O
mechanism O
that O
mediates O
Ca B
( I
2 I
+ I
) I
oscillation O
during O
osteoclastogenesis O
remains O
ill O
defined O
. O

Here O
, O
we O
identified O
transmembrane O
protein O
64 O
( O
Tmem64 O
) O
as O
a O
regulator O
of O
Ca B
( I
2 I
+ I
) I
oscillation O
during O
osteoclastogenesis O
. O

Using O
in O
vitro O
osteoclast O
culture O
systems O
, O
we O
show O
here O
that O
Tmem64 O
interacts O
with O
sarcoplasmic O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
ATPase O
2 O
( O
SERCA2 O
) O
and O
modulates O
its O
activity O
. O

Consequently O
, O
Tmem64 O
deficiency O
significantly O
diminishes O
RANKL O
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
oscillation O
, O
which O
results O
in O
reduced O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
( O
CaMK O
) O
IV O
and O
mitochondrial O
ROS O
, O
both O
of O
which O
contribute O
to O
achieving O
the O
CREB O
activity O
necessary O
for O
osteoclast O
formation O
. O

These O
data O
demonstrate O
that O
Tmem64 O
is O
a O
positive O
modulator O
of O
osteoclast O
differentiation O
via O
SERCA2 O
- O
dependent O
Ca B
( I
2 I
+ I
) I
signaling O
. O

HRG1 O
is O
essential O
for O
heme B
transport O
from O
the O
phagolysosome O
of O
macrophages O
during O
erythrophagocytosis O
. O

Despite O
the O
central O
role O
for O
EP O
in O
mammalian O
iron B
metabolism O
, O
the O
molecules O
and O
pathways O
responsible O
for O
heme B
trafficking O
during O
EP O
remain O
unknown O
. O

Here O
, O
we O
show O
that O
the O
mammalian O
homolog O
of O
HRG1 O
, O
a O
transmembrane O
heme B
permease O
in O
C O
. O
elegans O
, O
is O
essential O
for O
macrophage O
iron B
homeostasis O
and O
transports O
heme B
from O
the O
phagolysosome O
to O
the O
cytoplasm O
during O
EP O
. O

Depletion O
of O
Hrg1 O
in O
mouse O
macrophages O
causes O
attenuation O
of O
heme B
transport O
from O
the O
phagolysosomal O
compartment O
. O

Importantly O
, O
missense O
polymorphisms O
in O
human O
HRG1 O
are O
defective O
in O
heme B
transport O
. O

Our O
results O
reveal O
HRG1 O
as O
the O
long O
- O
sought O
heme B
transporter O
for O
heme B
- O
iron B
recycling O
in O
macrophages O
and O
suggest O
that O
genetic O
variations O
in O
HRG1 O
could O
be O
modifiers O
of O
human O
iron B
metabolism O
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl O
2 O
- O
methylbutanoate O
, O
butyl O
acetate O
, O
1 B
- I
butanol I
, O
ethyl O
hexanoate O
, O
1 O
- O
hexanol O
, O
butanoic O
acid O
, O
beta O
- O
damascenone O
, O
hexanoic O
acid O
, O
and O
octanoic B
acid I
. O

Biomedical O
applications O
of O
bisphosphonates B
. O

Since O
their O
discovery O
over O
100 O
years O
ago O
, O
bisphosphonates B
have O
been O
used O
industrially O
as O
corrosion O
inhibitors O
and O
complexing O
agents O
. O

With O
the O
discovery O
of O
their O
pharmacological O
activity O
in O
the O
late O
1960s O
, O
implicating O
their O
high O
affinity O
for O
hydroxyapatite B
, O
bisphosphonates B
have O
been O
employed O
in O
the O
treatment O
of O
bone O
diseases O
and O
as O
targeting O
agents O
for O
colloids O
and O
drugs O
. O

Beyond O
their O
important O
pharmacological O
role O
, O
the O
medical O
applications O
of O
bisphosphonates B
are O
numerous O
. O

In O
this O
contribution O
, O
we O
review O
the O
pharmacological O
and O
clinical O
uses O
of O
bisphosphonates B
and O
highlight O
their O
novel O
applications O
in O
the O
pharmaceutical O
and O
biomedical O
fields O
. O

In O
the O
work O
presented O
here O
, O
primary O
hepatocytes O
were O
isolated O
from O
specific O
pathogen O
- O
free O
male O
SD O
rats O
and O
incubated O
with O
200 O
mu O
mol O
/ O
L O
oleic B
acid I
for O
24h O
to O
induce O
steatotic O
model O
, O
then O
treated O
with O
sophocarpine O
for O
72 O
h O
. O

Methods O
for O
oxysterol B
analysis O
: O
Past O
, O
present O
and O
future O
. O

Oxysterols B
are O
oxidised O
forms O
of O
cholesterol B
or O
its O
precursors O
. O

Oxidation O
may O
be O
catalysed O
by O
endogenous O
enzymes O
or O
through O
reactive O
oxygen B
species O
forming O
a O
myriad O
of O
potential O
products O
. O

A O
number O
of O
these O
products O
are O
biologically O
active O
, O
and O
oxysterols B
may O
have O
roles O
in O
cholesterol B
homeostasis O
, O
neurogenesis O
, O
protein O
prenylation O
and O
in O
the O
immune O
system O
. O

Oxysterols B
are O
also O
implicated O
in O
aetiology O
of O
disease O
states O
including O
atherosclerosis O
, O
neurodegenerative O
and O
inflammatory O
diseases O
. O

Reports O
indicating O
the O
levels O
of O
oxysterols B
in O
plasma O
, O
cerebrospinal O
fluid O
and O
various O
tissues O
are O
in O
many O
cases O
unrealistic O
owing O
to O
a O
lack O
of O
attention O
to O
the O
possibility O
of O
autoxidation O
, O
a O
process O
by O
which O
oxysterols B
are O
formed O
from O
cholesterol B
by O
oxygen B
in O
air O
. O

This O
article O
comprises O
a O
critical O
assessment O
of O
the O
technical O
difficulties O
of O
oxysterol B
analysis O
, O
highlights O
methodologies O
utilising O
best O
practise O
and O
discusses O
newer O
procedures O
. O

Prolactin O
regulates O
transcription O
of O
the O
ion O
uptake O
Na B
+ I
/ O
Cl B
- I
cotransporter O
( O
ncc O
) O
gene O
in O
zebrafish O
gill O
. O

Ion O
- O
poor O
conditions O
led O
to O
increases O
in O
the O
expression O
of O
PRL O
receptor O
( O
prlra O
) O
, O
Na B
( I
+ I
) I
/ O
Cl B
( I
- I
) I
cotransporter O
( O
ncc O
; O
slc12a10 O
. O
2 O
) O
, O
Na B
( I
+ I
) I
/ O
H B
( I
+ I
) I
exchanger O
( O
nhe3b O
; O
slc9a3 O
. O
2 O
) O
, O
and O
epithelial O
Ca B
( I
2 I
+ I
) I
channel O
( O
ecac O
; O
trpv6 O
) O
transcripts O
within O
the O
gill O
. O

These O
results O
suggest O
that O
PRL O
signaling O
through O
PRL O
receptors O
in O
the O
gill O
regulates O
the O
expression O
of O
ncc O
, O
thereby O
linking O
this O
pituitary O
hormone O
with O
an O
effector O
of O
Cl B
( I
- I
) I
uptake O
in O
zebrafish O
for O
the O
first O
time O
. O

Here O
we O
designed O
a O
fusion O
protein O
named O
APP O
- O
IP O
- O
TIMP O
- O
2 O
, O
in O
which O
the O
ten O
amino B
acid I
residue O
sequence O
of O
APP O
- O
derived O
MMP O
- O
2 O
selective O
inhibitory O
peptide O
( O
APP O
- O
IP O
) O
is O
added O
to O
the O
N B
terminus O
of O
TIMP O
- O
2 O
. O

On O
the O
other O
hand O
, O
studies O
on O
the O
inhibitory O
effect O
of O
these O
compounds O
on O
SOD O
enzymes O
showed O
that O
while O
the O
inhibition O
of O
the O
Fe B
- O
SOD O
enzyme O
of O
the O
promastigote O
forms O
of O
the O
parasites O
is O
remarkable O
, O
the O
inhibition O
of O
human O
CuZn O
- O
SOD O
and O
Mn B
- O
SOD O
from O
Escherichia O
coli O
is O
negligible O
. O

The O
modifications O
observed O
by O
( B
1 I
) I
H I
NMR O
, O
and O
the O
amounts O
of O
catabolites O
excreted O
by O
the O
parasites O
after O
treatment O
with O
the O
compounds O
, O
suggested O
that O
the O
catabolic O
mechanism O
could O
depend O
on O
the O
structure O
of O
the O
side O
chains O
linked O
to O
the O
aza B
- O
scorpiand O
macrocycles O
. O

Alcohol B
modulates O
expression O
of O
DNA O
methyltranferases O
and O
methyl O
CpG O
- O
/ O
CpG B
domain O
- O
binding O
proteins O
in O
murine O
embryonic O
fibroblasts O
. O

Fetal O
alcohol B
syndrome O
( O
FAS O
) O
, O
presenting O
with O
a O
constellation O
of O
neuro O
- O
/ O
psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol B
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1 O
- O
3 O
per O
1000 O
livebirths O
. O

The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol B
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
( O
DNMTs O
) O
and O
various O
methyl O
CpG O
- O
binding O
proteins O
. O

Murine O
embryonic O
fibroblasts O
( O
MEFs O
) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
~ O
5 O
% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol B
. O

In O
addition O
, O
ethanol B
induced O
degradation O
of O
DNA O
methyltransferases O
( O
DNMT O
- O
1 O
, O
DNMT O
- O
3a O
, O
and O
DNMT O
- O
3b O
) O
, O
as O
well O
as O
the O
methyl O
CpG O
- O
binding O
proteins O
( O
MeCP O
- O
2 O
, O
MBD O
- O
2 O
and O
MBD O
- O
3 O
) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O

Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG B
- I
132 I
. O

Mouse O
hepatocytes O
cultured O
either O
in O
monolayer O
or O
sandwich O
configurations O
were O
finally O
shown O
to O
exhibit O
up O
- O
regulation O
of O
referent O
transporters O
in O
response O
to O
exposure O
to O
prototypical O
activators O
of O
the O
drug O
sensing O
receptors O
pregnane B
X O
receptor O
, O
aryl B
hydrocarbon I
receptor O
or O
constitutive O
androstane B
receptor O
. O

Co O
- O
exposure O
to O
environmental O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
and O
interleukin O
( O
IL O
) O
- O
1 O
beta O
induces O
expression O
of O
the O
tumor O
- O
promoting O
cytokine O
IL O
- O
6 O
in O
cancer O
cells O
. O

The O
present O
study O
was O
designed O
to O
determine O
whether O
such O
an O
IL O
- O
6 O
up O
- O
regulation O
also O
occurs O
in O
response O
to O
co O
- O
treatment O
by O
PAHs B
and O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
, O
an O
inflammatory O
cytokine O
commonly O
found O
in O
tumor O
microenvironment O
. O

Co O
- O
exposure O
to O
the O
prototypical O
PAH B
benzanthracene O
( O
BZA O
) O
and O
TNF O
- O
alpha O
was O
found O
to O
markedly O
induce O
mRNA O
expression O
and O
secretion O
of O
IL O
- O
6 O
in O
human O
breast O
cancer O
cells O
MCF O
- O
7 O
, O
whereas O
exposure O
to O
either O
BZA O
or O
TNF O
- O
alpha O
alone O
was O
without O
significant O
effect O
. O

BZA O
/ O
TNF O
- O
alpha O
- O
mediated O
IL O
- O
6 O
induction O
in O
MCF O
- O
7 O
cells O
was O
counteracted O
by O
silencing O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
known O
to O
mediates O
most O
of O
PAH B
effects O
. O

This O
regulation O
of O
IL O
- O
6 O
by O
environmental O
PAHs B
, O
that O
is O
dependent O
of O
inflammatory O
cytokine O
microenvironment O
, O
may O
contribute O
to O
the O
well O
- O
known O
carcinogenic O
properties O
of O
these O
organic O
pollutants O
. O

Quercetin B
prevents O
protein O
nitration O
and O
glycolytic O
block O
of O
proliferation O
in O
hydrogen B
peroxide I
insulted O
cultured O
neuronal O
precursor O
cells O
( O
NPCs O
) O
: O
Implications O
on O
CNS O
regeneration O
. O

Therefore O
, O
this O
study O
was O
aimed O
at O
the O
identification O
of O
the O
potent O
targets O
of O
oxidative O
damage O
to O
the O
neuronal O
precursors O
and O
its O
effective O
prevention O
by O
a O
natural O
flavonoid O
, O
Quercetin B
. O

These O
cells O
were O
challenged O
with O
a O
single O
dose O
of O
H2O2 B
( O
50 O
mu O
M O
) O
and O
/ O
or O
pre O
- O
treated O
with O
different O
concentrations O
of O
Quercetin B
. O

H2O2 B
severely O
limited O
the O
cellular O
viability O
and O
expansion O
of O
the O
neurospheres O
. O

Cellular O
- O
oxidation O
studies O
revealed O
reduction O
in O
glutathione B
dependent O
redox O
buffering O
along O
with O
depletion O
of O
enzymatic O
cellular O
antioxidants O
that O
might O
potentiate O
the O
nitrite B
( O
NO2 B
( I
- I
) I
) O
and O
superoxide B
anion O
( O
O2 B
( I
- I
) I
) O
mediated O
peroxynitrite B
( O
ONOO B
( I
- I
) I
) O
formation O
and O
irreversible O
protein O
nitration O
. O

We O
identified O
depleted O
PK O
- O
M2 O
( O
M2 O
isoform O
of O
pyruvate B
kinase O
) O
activity O
and O
apoptosis O
of O
NPCs O
revealed O
by O
the O
genomic O
DNA O
fragmentation O
and O
elevated O
PARP O
( O
poly B
ADP I
ribose I
polymerase O
) O
activity O
along O
with O
increased O
Caspase O
activity O
initiated O
by O
severely O
depolarised O
mitochondrial O
membranes O
. O

However O
, O
the O
pre O
- O
treatment O
of O
Quercetin B
in O
a O
dose O
- O
response O
manner O
prevented O
these O
changes O
and O
restored O
the O
expansion O
of O
neurospheres O
preferably O
by O
neutralizing O
the O
oxidative O
conditions O
and O
thereby O
reducing O
peroxynitrite B
formation O
, O
protein O
nitration O
and O
PK O
- O
M2 O
depletion O
. O

Our O
results O
unravel O
the O
potential O
interactions O
of O
oxidative O
environment O
and O
respiration O
in O
the O
survival O
and O
activation O
of O
precursors O
and O
offer O
a O
promise O
shown O
by O
a O
natural O
flavonoid B
in O
the O
protective O
strategy O
for O
neuronal O
precursors O
of O
adult O
brain O
. O

We O
recently O
showed O
that O
non O
- O
muscle O
myosin O
IIA O
( O
NMIIA O
) O
binds O
to O
the O
cytoplasmic O
tail O
of O
Core O
2 O
N B
- O
acetylglucosaminyltr O
mucus O
- O
type O
( O
C2GnT O
- O
M O
) O
and O
transports O
it O
to O
the O
endoplasmic O
reticulum O
for O
recycling O
. O

Here O
, O
we O
report O
that O
Golgi O
fragmentation O
induced O
by O
brefeldin B
A I
( O
BFA B
) O
or O
coatomer O
protein O
( O
beta O
- O
COP O
) O
knockdown O
( O
KD O
) O
in O
Panc1 O
- O
bC2GnT O
- O
M O
( O
c O
- O
Myc O
) O
cells O
is O
accompanied O
by O
the O
increased O
association O
of O
NMIIA O
with O
C2GnT O
- O
M O
and O
its O
degradation O
by O
proteasomes O
. O

Using O
multiple O
approaches O
, O
we O
have O
shown O
that O
the O
speed O
of O
BFA B
- O
induced O
Golgi O
fragmentation O
is O
positively O
correlated O
with O
the O
levels O
of O
this O
enzyme O
in O
the O
Golgi O
. O

The O
KD O
of O
both O
enzymes O
or O
the O
prevention O
of O
Golgi O
glycosyltransferases O
from O
exiting O
endoplasmic O
reticulum O
reduced O
Golgi O
- O
associated O
NMIIA O
and O
decreased O
the O
BFA B
- O
induced O
fragmentation O
. O

We O
conclude O
that O
NMIIA O
interacts O
with O
Golgi O
residential O
but O
not O
matrix O
proteins O
, O
and O
this O
interaction O
is O
responsible O
for O
Golgi O
fragmentation O
induced O
by O
beta O
- O
COP O
KD O
or O
BFA B
treatment O
. O

Atomic O
layer O
deposition O
of O
a O
submonolayer O
catalyst O
for O
the O
enhanced O
photoelectrochemical O
performance O
of O
water O
oxidation O
with O
hematite B
. O

Hematite B
photoanodes O
were O
coated O
with O
an O
ultrathin O
cobalt B
oxide I
layer O
by O
atomic O
layer O
deposition O
( O
ALD O
) O
. O

The O
optimal O
coating O
- O
1 O
ALD O
cycle O
, O
which O
amounts O
to O
< O
1 O
monolayer O
of O
Co O
( O
OH O
) O
2 O
/ O
Co3O4 B
- O
resulted O
in O
significantly O
enhanced O
photoelectrochemical O
water O
oxidation O
performance O
. O

A O
stable O
, O
100 O
- O
200 O
mV O
cathodic O
shift O
in O
the O
photocurrent O
onset O
potential O
was O
observed O
that O
is O
correlated O
to O
an O
order O
of O
magnitude O
reduction O
in O
the O
resistance O
to O
charge O
transfer O
at O
the O
Fe2O3 B
/ O
H2O B
interface O
. O

Furthermore O
, O
the O
optical O
transparency O
of O
the O
ultrathin O
Co O
( O
OH O
) O
2 O
/ O
Co3O4 B
coating O
establishes O
it O
as O
a O
particularly O
advantageous O
treatment O
for O
nanostructured O
water O
oxidation O
photoanodes O
. O

The O
photocurrent O
of O
catalyst O
- O
coated O
nanostructured O
inverse O
opal O
scaffold O
hematite B
photoanodes O
reached O
0 O
. O
81 O
and O
2 O
. O
1 O
mA O
/ O
cm O
( O
2 O
) O
at O
1 O
. O
23 O
and O
1 O
. O
53 O
V O
, O
respectively O
. O

For O
the O
case O
of O
one O
water O
molecule O
, O
most O
of O
the O
energy O
in O
the O
reactants O
region O
of O
the O
IRC O
is O
used O
for O
structural O
changes O
, O
while O
the O
transition O
state O
region O
encompasses O
the O
majority O
of O
electron O
activity O
, O
except O
for O
the O
formation O
of O
the O
C B
- I
O I
bond O
, O
which O
extends O
well O
into O
the O
products O
region O
. O

All O
- O
atom O
molecular O
dynamics O
simulations O
of O
the O
system O
SDS B
/ O
water O
and O
CTAB B
/ O
water O
have O
been O
applied O
in O
order O
to O
retrieve O
representative O
micelle O
structures O
for O
further O
analysis O
with O
COSMOmic O
. O

For O
the O
system O
CTAB B
/ O
water O
, O
different O
surfactant O
concentrations O
were O
considered O
, O
which O
results O
in O
different O
micelle O
sizes O
. O

Further O
, O
the O
partitioning O
in O
lipid O
bilayer O
systems O
containing O
different O
hydrophobic O
tail O
groups O
( O
DOPC B
( O
1 B
, I
2 I
- I
dioleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
SOPC O
( O
stearoyl O
- O
oleoylphosphatidylch O
) O
, O
DMPC B
( O
1 O
, O
2 O
- O
dimyristoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
) O
, O
and O
POPC B
( O
1 O
- O
palmitoyl O
- O
2 O
- O
oleoyl O
- O
sn O
- O

To O
determine O
the O
influence O
of O
cholesterol O
as O
an O
important O
component O
of O
cellular O
membranes O
, O
free O
energy O
profiles O
in O
the O
presence O
of O
cholesterol B
were O
calculated O
and O
shown O
to O
be O
in O
good O
agreement O
with O
experimental O
data O
. O

Probing O
adsorption O
of O
polyacrylamide B
- O
based O
polymers O
on O
anisotropic O
Basal O
planes O
of O
kaolinite B
using O
quartz B
crystal O
microbalance O
. O

Quartz B
crystal O
microbalance O
with O
dissipation O
( O
QCM O
- O
D O
) O
was O
applied O
to O
investigate O
the O
adsorption O
characteristics O
of O
polyacrylamide B
- O
based O
polymers O
( O
PAMs O
) O
on O
anisotropic O
basal O
planes O
of O
kaolinite B
. O

Kaolinite B
basal O
planes O
were O
differentiated O
by O
depositing O
kaolinite B
nanoparticles O
( O
KNPs O
) O
on O
silica B
and O
alumina B
sensors O
in O
solutions O
of O
controlled O
pH O
values O
. O

Adsorption O
of O
an O
in O
- O
house O
synthesized O
organic O
- O
inorganic O
Al O
( O
OH O
) O
3 O
- O
PAM O
( O
Al O
- O
PAM O
) O
as O
an O
example O
of O
cationic O
hybrid O
PAM O
and O
a O
commercially O
available O
partially O
hydrolyzed O
polyacrylamide B
( O
MF1011 O
) O
as O
an O
example O
of O
anionic O
PAM O
was O
studied O
. O

Cationic O
Al O
- O
PAM O
was O
found O
to O
adsorb O
irreversibly O
and O
preferentially O
on O
tetrahedral O
silica B
basal O
planes O
of O
kaolinite B
. O

In O
contrast O
, O
anionic O
MF1011 O
adsorbed O
strongly O
on O
aluminum O
- O
hydroxy O
basal O
planes O
, O
while O
its O
adsorption O
on O
tetrahedral O
silica B
basal O
planes O
was O
weak O
and O
reversible O
. O

Adsorption O
study O
revealed O
that O
both O
electrostatic O
attraction O
and O
hydrogen B
- O
bonding O
mechanisms O
contribute O
to O
adsorption O
of O
PAMs O
on O
kaolinite B
. O

The O
adsorbed O
Al O
- O
PAM O
layer O
was O
able O
to O
release O
trapped O
water O
overtime O
and O
became O
more O
compact O
, O
while O
MF1011 O
film O
became O
more O
dissipative O
as O
backbones O
stretched O
out O
from O
kaolinite B
surface O
with O
minimal O
overlapping O
. O

Strong O
effects O
of O
cluster O
size O
and O
air O
exposure O
on O
oxygen B
reduction O
and O
carbon B
oxidation O
electrocatalysis O
by O
size O
- O
selected O
Pt O
( O
n O
) O
( O
n O
< O
= O
11 O
) O
on O
glassy B
carbon I
electrodes O
. O

Model O
Pt O
( O
n O
) O
/ O
glassy B
carbon I
electrodes O
( O
Pt O
( O
n O
) O
/ O
GCE O
) O
were O
prepared O
by O
deposition O
of O
mass O
- O
selected O
Pt O
( O
n O
) O
( O
+ O
) O
( O
n O
< O
= O
11 O
) O
on O
GCE O
substrates O
in O
ultrahigh O
vacuum O
. O

Electrocatalysis O
under O
conditions O
appropriate O
for O
the O
oxygen B
reduction O
reaction O
( O
ORR O
) O
was O
studied O
, O
for O
samples O
both O
in O
situ O
with O
no O
exposure O
to O
laboratory O
air O
and O
with O
air O
exposure O
prior O
to O
electrochemical O
measurements O
. O

Of O
the O
small O
clusters O
, O
only O
a O
few O
cluster O
sizes O
show O
the O
expected O
ORR O
activity O
, O
and O
in O
those O
cases O
, O
the O
activity O
per O
Pt B
atom O
is O
similar O
to O
that O
seen O
under O
identical O
conditions O
with O
a O
conventionally O
prepared O
electrode O
with O
Pt B
nanoparticles O
grown O
on O
a O
GCE O
. O

For O
other O
small O
Pt O
( O
n O
) O
on O
GCE O
, O
any O
ORR O
signal O
is O
overwhelmed O
by O
large O
oxidative O
currents O
attributed O
to O
catalysis O
of O
carbon B
oxidation O
by O
water O
. O

If O
the O
samples O
are O
exposed O
to O
air O
prior O
to O
electrochemistry O
, O
both O
ORR O
and O
carbon B
oxidation O
signals O
are O
absent O
, O
and O
instead O
only O
small O
capacitive O
currents O
or O
currents O
attributed O
to O
redox O
chemistry O
of O
adventitious O
organic O
adsorbates O
are O
observed O
, O
indicating O
that O
air O
exposure O
results O
in O
passivation O
of O
the O
small O
Pt B
clusters O
. O

Effects O
of O
chronic O
dietary O
selenomethionine B
exposure O
on O
repeat O
swimming O
performance O
, O
aerobic O
metabolism O
and O
methionine B
catabolism O
in O
adult O
zebrafish O
( O
Danio O
rerio O
) O
. O

In O
a O
previous O
study O
we O
reported O
impaired O
swimming O
performance O
and O
greater O
stored O
energy O
in O
adult O
zebrafish O
( O
Danio O
rerio O
) O
after O
chronic O
dietary O
exposure O
to O
selenomethionine B
( O
SeMet B
) O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
further O
investigate O
effects O
of O
chronic O
exposure O
to O
dietary O
SeMet B
on O
repeat O
swimming O
performance O
, O
oxygen B
consumption O
( O
MO2 O
) O
, O
metabolic O
capacities O
( O
standard O
metabolic O
rate O
[ O
SMR O
] O
, O
active O
metabolic O
rate O
[ O
AMR O
] O
, O
factorial O
aerobic O
scope O
[ O
F O
- O
AS O
] O
and O
cost O
of O
transport O
[ O
COT O
] O
) O
and O
gene O
expression O
of O
energy O
metabolism O
and O
methionine B
catabolism O
enzymes O
in O
adult O
zebrafish O
. O

Fish O
were O
fed O
SeMet B
at O
measured O
concentrations O
of O
1 O
. O
3 O
, O
3 O
. O
4 O
, O
9 O
. O
8 O
or O
27 O
. O
5 O
mu O
g O
Se B
/ O
g O
dry O
mass O
( O
d O
. O
m O
. O
) O
for O
90 O
d O
. O

Fish O
from O
the O
no O
swim O
group O
were O
euthanized O
immediately O
at O
90 O
d O
and O
whole O
body O
triglycerides B
, O
glycogen O
and O
lactate B
, O
and O
gene O
expression O
of O
energy O
metabolism O
and O
methionine B
catabolism O
enzymes O
were O
determined O
. O

After O
both O
Ucrit O
and O
MO2 O
analyses O
, O
fish O
were O
euthanized O
and O
whole O
body O
energy O
stores O
and O
lactate B
were O
determined O
. O

Similarly O
, O
individual O
fish O
from O
the O
repeat O
swim O
group O
were O
subjected O
to O
two O
U O
( O
crit O
) O
tests O
( O
U O
( O
crit O
- O
1 O
) O
and O
U O
( O
crit O
- O
2 O
) O
) O
performed O
with O
a O
60 O
min O
recovery O
period O
between O
tests O
, O
followed O
by O
determination O
of O
energy O
stores O
and O
lactate B
. O

Impaired O
swim O
performance O
was O
observed O
in O
fish O
fed O
SeMet B
at O
concentrations O
greater O
than O
3 O
mu O
g O
Se B
/ O
g O
in O
the O
diet O
. O

However O
, O
within O
each O
dietary O
Se B
treatment O
group O
, O
no O
significant O
differences O
between O
single O
and O
repeat O
U O
( O
crits O
) O
were O
observed O
. O

Oxygen B
consumption O
, O
SMR O
and O
COT O
were O
significantly O
greater O
, O
and O
F O
- O
AS O
was O
significantly O
lesser O
, O
in O
fish O
fed O
SeMet B
. O

Whole O
body O
triglycerides B
were O
proportional O
to O
the O
concentration O
of O
SeMet B
in O
the O
diet O
. O

While O
swimming O
resulted O
in O
lesser O
concentrations O
of O
glycogen O
in O
the O
body O
, O
exposure O
to O
SeMet B
in O
the O
diet O
had O
no O
significant O
effect O
on O
glycogen O
content O
. O

Exposure O
to O
SeMet B
significantly O
down O
- O
regulated O
mRNA O
abundance O
of O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP O
1B O
) O
in O
muscle O
, O
and O
beta O
- O
hydroxyacyl O
coenzyme O
A O
dehydrogenase O
( O
HOAD O
) O
, O
sterol B
regulatory O
element O
binding O
protein O
1 O
( O
SREBP O
1 O
) O
and O
methionine B
adenosyltransferase O
1 O
alpha O
( O
MAT O
1A O
) O
in O
liver O
of O
adult O
zebrafish O
. O

Overall O
the O
results O
of O
this O
study O
suggest O
chronic O
exposure O
of O
adult O
zebrafish O
to O
SeMet B
in O
the O
diet O
can O
cause O
both O
cellular O
and O
organismal O
effects O
that O
could O
affect O
fitness O
and O
survivability O
of O
fish O
. O

Previous O
DEA O
studies O
on O
dialanine O
have O
shown O
that O
( O
M O
- O
H O
) O
( O
- O
) O
formation O
proceeds O
through O
abstraction O
of O
a O
hydrogen B
atom O
from O
the O
carboxyl B
and O
amide B
groups O
, O
contributing O
to O
two O
distinct O
resonances O
at O
0 O
. O
81 O
and O
1 O
. O
17 O
eV O
, O
respectively O
[ O
D O
. O
Gschliesser O
, O
V O
. O
Vizcaino O
, O
M O
. O
Probst O
, O
P O
. O
Scheier O
and O
S O
. O
Denifl O
, O
Chem O
. O
- O
Eur O
. O
J O
. O
, O
2012 O
, O
18 O
, O
4613 O
- O
4619 O
] O
. O

Here O
we O
show O
that O
by O
methylation O
of O
the O
carboxyl B
group O
, O
all O
( O
calculated O
) O
thresholds O
for O
H B
- O
loss O
from O
the O
different O
sites O
in O
the O
dialanine O
molecule O
are O
shifted O
up O
to O
a O
maximum O
of O
1 O
. O
4 O
eV O
. O

The O
lowest O
lying O
resonance O
observed O
experimentally O
for O
( O
M O
- O
H O
) O
( O
- O
) O
remains O
operative O
from O
the O
amide B
group O
at O
the O
electron O
energy O
of O
2 O
. O
4 O
eV O
due O
to O
the O
methylation O
. O

Probing O
the O
dielectric O
response O
of O
graphene B
via O
dual O
- O
band O
plasmonic O
nanoresonators O
. O

In O
this O
article O
, O
we O
use O
optical O
transmission O
spectroscopy O
to O
measure O
the O
changes O
in O
the O
resonance O
features O
of O
a O
Au B
plasmonic O
nanoresonator O
array O
consisting O
of O
concentric O
ring O
/ O
disc O
cavity O
elements O
, O
when O
graphene O
is O
introduced O
as O
an O
encapsulating O
medium O
. O

We O
show O
that O
by O
using O
finite O
element O
modelling O
to O
best O
reproduce O
our O
experimental O
results O
the O
dielectric O
response O
of O
the O
graphene B
film O
can O
be O
determined O
. O

The O
authors O
hypothesized O
that O
ester B
taggants O
added O
to O
vaginal O
gels O
would O
generate O
exhaled O
alcohol B
and O
ketone B
metabolites O
and O
provide O
a O
" O
breath O
test O
" O
for O
vaginal O
gel O
use O
. O

On O
8 O
visits O
, O
healthy O
women O
( O
n O
= O
8 O
) O
received O
intravaginal O
taggant O
( O
2 O
- O
butyl O
acetate O
, O
2 O
- O
pentyl O
acetate O
, O
isopropyl O
butyrate O
, O
or O
2 O
- O
pentyl O
butyrate O
; O
30 O
mg O
) O
formulated O
in O
hydroxyethylcellulos O
or O
tenofovir B
placebo O
gel O
. O

Samples O
were O
measured O
using O
a O
miniature O
gas O
chromatograph O
and O
/ O
or O
gas O
chromatography O
- O
mass O
spectroscopy O
for O
ester O
taggant O
, O
alcohol B
, O
and O
ketone B
concentrations O
. O

Arsenic B
geochemistry O
in O
a O
biostimulated O
aquifer O
: O
An O
aqueous O
speciation O
study O
. O

Bioreduction O
also O
changed O
the O
redox O
chemistry O
of O
site O
groundwater O
, O
altering O
the O
mobility O
of O
several O
other O
redox O
- O
sensitive O
elements O
present O
in O
the O
subsurface O
, O
including O
iron B
, O
sulfur B
, O
and O
arsenic B
. O

Following O
acetate B
amendment O
at O
the O
site O
, O
elevated O
concentrations O
of O
arsenic B
in O
the O
groundwater O
were O
observed O
. O

Ion O
chromatography O
- O
inductively O
coupled O
plasma O
- O
mass O
spectrometry O
was O
used O
to O
determine O
the O
aqueous O
arsenic B
speciation O
. O

Upgradient O
samples O
, O
unexposed O
to O
acetate B
, O
showed O
low O
levels O
of O
arsenic B
( O
= O
~ O
1 O
mu O
M O
) O
, O
with O
greater O
than O
90 O
% O
as O
arsenate B
( O
As B
[ I
V I
] I
) O
and O
a O
small O
amount O
of O
arsenite B
( O
As B
[ I
III I
] I
) O
. O

Downgradient O
acetate B
- O
stimulated O
water O
samples O
had O
much O
higher O
levels O
of O
arsenic B
( O
up O
to O
8 O
mu O
M O
) O
, O
and O
4 O
additional O
thioarsenic O
species O
were O
present O
under O
sulfate B
- O
reducing O
conditions O
. O

These O
thioarsenic O
species O
demonstrate O
a O
strong O
correlation O
between O
arsenic B
release O
and O
sulfide B
concentrations O
in O
groundwater O
, O
and O
their O
formation O
may O
explain O
the O
elevated O
total O
arsenic B
concentrations O
. O

An O
alternative O
remediation O
approach O
, O
enhanced O
flushing O
of O
uranium B
, O
was O
accomplished O
by O
addition O
of O
bicarbonate B
and O
did O
not O
result O
in O
highly O
elevated O
arsenic B
concentrations O
. O

The O
Lignan B
( B
- I
) I
- I
Cubebin I
Inhibits O
Vascular O
Contraction O
and O
Induces O
Relaxation O
Via O
Nitric B
Oxide I
Activation O
in O
Isolated O
Rat O
Aorta O
. O

Cubebin B
, O
the O
most O
abundant O
lignan B
in O
Piper O
cubeba O
, O
has O
been O
described O
as O
having O
several O
effects O
as O
trypanocidal O
, O
antimycobacterial O
, O
antispasmodic O
, O
antimicrobial O
, O
anti O
- O
inflammatory O
, O
and O
analgesic O
. O

This O
study O
investigated O
the O
vasorelaxant O
effect O
produced O
by O
( B
- I
) I
- I
cubebin I
in O
isolated O
rat O
aortic O
rings O
pre O
- O
contracted O
with O
phenylephrine B
( O
Phe B
) O
, O
and O
the O
possible O
mechanism O
involved O
in O
this O
event O
was O
evaluated O
. O

Endothelium O
- O
dependent O
relaxation O
was O
evoked O
by O
acetylcholine B
and O
( B
- I
) I
- I
cubebin I
in O
intact O
aortic O
rings O
, O
while O
endothelium O
- O
independent O
vasorelaxation O
was O
elicited O
by O
sodium B
nitroprusside I
and O
( B
- I
) I
- I
cubebin I
in O
denuded O
rings O
. O

Cumulative O
concentration O
- O
response O
curves O
for O
Phe B
( O
10 O
( O
- O
10 O
) O
- O
10 O
( O
- O
5 O
) O
M O
) O
were O
determined O
for O
endothelium O
- O
intact O
and O
endothelium O
- O
denuded O
aortic O
rings O
in O
either O
the O
presence O
or O
absence O
of O
( B
- I
) I
- I
cubebin I
. O

Dose O
- O
response O
curves O
were O
also O
constructed O
for O
pre O
- O
incubation O
of O
vascular O
rings O
with O
N O
omega O
- O
nitro O
- O
L O
- O
arginine O
methyl O
ester O
( O
L B
- I
NAME I
) O
( O
a O
non O
- O
specific O
nitric B
oxide I
synthase O
inhibitor O
) O
, O
indomethacin B
( O
an O
unspecific O
cyclooxygenase O
inhibitor O
) O
, O
and O
1H O
- O
[ O
1 O
, O
2 O
, O
4 O
] O
oxadiazolo O
[ O
4 O
, O
3 O
- O
a O
] O
quinoxalin O
- O
1 O
- O
one O
( O
ODQ B
) O
( O
a O
guanylyl O
cyclase O

( B
- I
) I
- I
Cubebin I
was O
found O
to O
exert O
a O
vasorelaxant O
effect O
irrespective O
of O
the O
presence O
of O
endothelium O
, O
which O
was O
abolished O
by O
pretreatment O
with O
L B
- I
NAME I
and O
ODQ B
, O
but O
not O
with O
indomethacin B
. O

In O
addition O
, O
( B
- I
) I
- I
cubebin I
was O
able O
to O
reduce O
Phe B
contraction O
in O
the O
case O
of O
intact O
rings O
. O

These O
results O
suggest O
that O
( B
- I
) I
- I
cubebin I
promotes O
vasorelaxation O
via O
NO B
/ O
cGMP B
pathway O
in O
rat O
aorta O
, O
without O
prostacyclin B
involvement O
. O

[ B
6 I
] I
- I
Shogaol I
Attenuates O
Neuronal O
Apoptosis O
in O
Hydrogen B
Peroxide I
- O
Treated O
Astrocytes O
Through O
the O
Up O
- O
Regulation O
of O
Neurotrophic O
Factors O
. O

[ B
6 I
] I
- I
shogaol I
, O
a O
bio O
- O
active O
compound O
in O
ginger O
, O
possesses O
potent O
anti O
- O
inflammatory O
actions O
and O
has O
recently O
emerged O
as O
a O
potential O
therapeutic O
agent O
for O
neurodegenerative O
disorders O
. O

However O
, O
the O
effects O
of O
[ B
6 I
] I
- I
shogaol I
on O
astroglial O
apoptosis O
following O
exogenously O
induced O
oxidative O
stress O
has O
not O
yet O
been O
investigated O
. O

Here O
, O
we O
show O
that O
the O
anti O
- O
apoptotic O
activity O
of O
[ B
6 I
] I
- I
shogaol I
in O
astrocytes O
following O
exposure O
to O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
involves O
a O
marked O
up O
- O
regulation O
of O
neurotrophic O
factors O
such O
as O
nerve O
growth O
factor O
, O
glial O
cell O
line O
- O
derived O
neurotrophic O
factor O
, O
and O
brain O
- O
derived O
neurotrophic O
factor O
. O

Astrocytes O
co O
- O
treated O
with O
[ B
6 I
] I
- I
shogaol I
and O
H B
( I
2 I
) I
O I
( I
2 I
) I
for O
1 O
h O
showed O
decrease O
in O
reactive O
oxygen B
species O
production O
compared O
with O
those O
only O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
. O

Moreover O
, O
[ B
6 I
] I
- I
shogaol I
counteracted O
the O
reduced O
expression O
of O
ERK1 O
/ O
2 O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
treated O
astrocytes O
and O
protected O
these O
cells O
from O
oxidative O
stress O
and O
apoptosis O
by O
attenuating O
the O
impairment O
of O
mitochondrial O
function O
proteins O
such O
as O
Bcl O
- O
2 O
and O
Bcl O
- O
xL O
. O

Additionally O
, O
[ B
6 I
] I
- I
shogaol I
inhibits O
the O
expression O
of O
the O
apoptotic O
proteins O
Bax O
and O
caspase O
- O
3 O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
treated O
astrocytes O
. O

This O
data O
suggest O
that O
following O
oxidative O
stress O
, O
[ B
6 I
] I
- I
shogaol I
protects O
astrocytes O
from O
oxidative O
damage O
through O
the O
up O
- O
regulating O
levels O
of O
neurotrophic O
factors O
. O

These O
findings O
provide O
further O
support O
for O
the O
use O
of O
[ B
6 I
] I
- I
shogaol I
as O
a O
therapeutic O
agent O
in O
neurodegenerative O
disorders O
. O

In O
an O
ongoing O
search O
for O
effective O
, O
safe O
and O
cheap O
antimalarial O
agents O
from O
plants O
, O
the O
80 O
% O
methanol B
leaf O
extract O
O O
. O
integrifolia O
was O
tested O
for O
its O
in O
vivo O
antimalarial O
activity O
, O
in O
a O
4 O
- O
day O
suppressive O
assay O
against O
Plasmodium O
berghei O
. O

Exploring O
the O
Interplay O
Between O
Ligand O
Derivatisation O
and O
Cation O
Type O
in O
the O
Assembly O
of O
Hybrid O
Polyoxometalate O
Mn B
- O
Andersons O
. O

Herein O
a O
library O
of O
hybrid O
Mn B
- O
Anderson O
polyoxometalates B
anions O
are O
presented O
: O
1 O
, O
[ O
( O
MnMo O
( O
6 O
) O
O O
( O
18 O
) O
) O
( O
( O
OCH O
( O
2 O
) O
) O
( O
3 O
) O
- O
C O
- O
( O
CH O
( O
2 O
) O
) O
( O
7 O
) O
CHCH O
( O
2 O
) O
) O
( O
2 O
) O
] O
( O
3 O
- O
) O
; O
compound O
2 O
, O
[ O
( O
MnMo O
( O
6 O
) O
O O
( O
18 O
) O
) O
( O
( O
OCH O
( O
2 O
) O
) O
( O
3 O
) O
C O
- O
NHCH O
( O
2 O
) O
C O
( O
16 O
) O
H O
( O
9 O
) O
) O
( O
2 O
) O
] O
( O
3 O
- O

Additionally O
, O
on O
day O
11 O
of O
both O
study O
periods O
, O
150 O
mg O
caffeine B
( O
CYP1A2 O
) O
, O
125 O
mg O
tolbutamide B
( O
CYP2C9 O
) O
, O
20 O
mg O
omeprazole B
( O
CYP2C19 O
) O
, O
30 O
mg O
dextromethorphan O
- O
HBr O
( O
CYP2D6 O
) O
, O
and O
2 O
mg O
midazolam B
( O
CYP3A4 O
) O
were O
administered O
orally O
. O

Mean O
ratios O
for O
all O
omeprazole B
- O
derived O
metrics O
were O
close O
to O
unity O
. O

The O
90 O
% O
CI O
for O
the O
AUC0 O
- O
t O
ratio O
of O
omeprazole B
but O
not O
for O
omeprazole B
/ O
5 O
- O
OH O
- O
omeprazole O
plasma O
ratio O
3 O
hours O
post O
- O
dose O
or O
omeprazole B
/ O
5 O
- O
OH O
- O
omeprazole O
AUC0 O
- O
t O
ratio O
( O
secondary O
CYP2C19 O
metrics O
) O
was O
above O
the O
predefined O
threshold O
of O
1 O
. O
43 O
, O
probably O
caused O
by O
the O
inherent O
high O
variability O
of O
omeprazole B
pharmacokinetics O
. O

Poly O
( O
lactic O
acid O
) O
- O
block O
- O
poly O
( O
ethylene O
glycol O
) O
copolymers O
( O
PLA O
- O
b O
- O
PEG O
) O
featuring O
varying O
tacticities O
( O
atactic O
, O
heterotactic O
, O
isotactic O
) O
in O
the O
PLA B
block O
were O
synthesized O
and O
investigated O
for O
their O
micellar O
stability O
, O
degradation O
, O
and O
thermal O
properties O
. O

The O
critical O
micelle O
concentration O
, O
which O
reflects O
the O
micellar O
stability O
, O
was O
probed O
using O
a O
fluorescence O
spectroscopic O
method O
with O
pyrene B
as O
the O
probe O
. O

The O
copolymers O
were O
degraded O
in O
a O
methanolic O
solution O
of O
1 O
, O
5 O
, O
7 O
- O
triaza O
- O
bicyclo O
[ O
4 O
. O
4 O
. O
0 O
] O
dec O
- O
5 O
- O
ene O
and O
the O
degradation O
was O
measured O
by O
( B
1 I
) I
H I
NMR O
spectroscopic O
and O
gel O
permeation O
chromatographic O
analyses O
. O

Atactic O
and O
heterotactic O
microstructures O
in O
the O
PLA B
block O
resulted O
in O
lower O
micellar O
stability O
, O
as O
well O
as O
faster O
degradation O
and O
shorter O
erosion O
time O
compared O
to O
polymers O
with O
high O
isotactic O
enchainment O
( O
Pm O
) O
. O

Interestingly O
, O
while O
tin O
( O
II O
) O
bis O
( O
2 O
- O
ethylhexanoate O
) O
and O
aluminum O
salan O
- O
catalyzed O
PLA O
- O
b O
- O
PEG O
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum O
salen O
- O
catalyzed O
PLA O
- O
b O
- O
PEG O
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene B
probe O
. O

Vitamin B
B12 I
and O
homocysteine B
status O
during O
pregnancy O
in O
the O
metformin B
in O
gestational O
diabetes O
trial O
: O
responses O
to O
maternal O
metformin B
compared O
with O
insulin O
treatment O
( O
+ O
) O

AIM O
: O
The O
aim O
of O
the O
study O
is O
to O
compare O
the O
effects O
of O
metformin B
and O
insulin O
treatment O
for O
gestational O
diabetes O
mellitus O
( O
GDM O
) O
on O
vitamin B
B12 I
and O
homocysteine B
( O
Hcy O
) O
status O
. O

METHODS O
: O
Women O
with O
GDM O
, O
who O
met O
criteria O
for O
insulin O
treatment O
, O
were O
randomly O
assigned O
to O
metformin B
( O
n O
= O
89 O
) O
or O
insulin O
( O
n O
= O
91 O
) O
in O
the O
Adelaide O
cohort O
of O
the O
metformin B
in O
gestational O
diabetes O
( O
MiG O
) O
trial O
. O

Fasting O
serum O
total O
vitamin B
B12 I
( O
TB12 O
) O
, O
holotranscobalamin O
( O
HoloTC O
) O
, O
a O
marker O
of O
functional O
B12 O
status O
and O
plasma O
Hcy O
concentrations O
were O
measured O
at O
20 O
- O
34 O
weeks O
( O
at O
randomization O
) O
and O
36 O
weeks O
gestation O
, O
then O
at O
6 O
- O
8 O
weeks O
postpartum O
. O

Women O
who O
were O
taking O
dietary O
folate B
supplements O
at O
randomization O
had O
higher O
serum O
TB12 O
and O
HoloTC O
at O
randomization O
than O
those O
not O
taking O
folate B
. O

Overall O
, O
serum O
TB12 O
fell O
more O
between O
randomization O
and O
36 O
weeks O
gestation O
in O
the O
metformin B
group O
than O
in O
the O
insulin O
group O
( O
metformin B
: O
- O
19 O
. O
7 O
+ O
/ O
- O
4 O
. O
7 O
pmol O
/ O
l O
, O
insulin O
: O
- O
6 O
. O
4 O
+ O
/ O
- O
3 O
. O
6 O
pmol O
/ O
l O
, O
p O
= O
0 O
. O
004 O
) O
. O

The O
decrease O
in O
serum O
TB12 O
during O
treatment O
was O
greater O
with O
increasing O
treatment O
duration O
in O
metformin B
- O
treated O
( O
p O
< O
0 O
. O
001 O
) O
, O
but O
not O
in O
insulin O
- O
treated O
women O
. O

CONCLUSIONS O
: O
Total O
, O
but O
not O
bioavailable O
, O
vitamin B
B12 I
stores O
were O
depleted O
during O
pregnancy O
to O
a O
greater O
extent O
in O
metformin B
- O
treated O
than O
in O
insulin O
- O
treated O
women O
with O
GDM O
, O
but O
neither O
analyte O
differed O
between O
groups O
at O
any O
stage O
. O

This O
adds O
further O
evidence O
supporting O
metformin B
as O
a O
safe O
alternative O
treatment O
to O
insulin O
in O
GDM O
. O

Further O
investigation O
is O
needed O
to O
evaluate O
whether O
women O
treated O
with O
metformin B
for O
longer O
periods O
in O
pregnancy O
require O
additional O
B12 O
or O
other O
supplementation O
. O

We O
developed O
a O
model O
for O
hole O
migration O
along O
relatively O
short O
DNA O
hairpins O
with O
fewer O
that O
seven O
adenine B
( O
A O
) O
: O
thymine B
( O
T O
) O
base O
pairs O
. O

We O
studied O
well O
- O
characterized O
boehmite O
engineered O
NP O
[ O
aluminum O
oxide O
hydroxide O
, O
AlO B
( I
OH I
) I
] O
. O

HMG O
- O
CoA B
- O
Reductase O
inhibitors O
, O
also O
known O
as O
statins O
, O
are O
currently O
the O
most O
powerful O
cholesterol B
- O
lowering O
drugs O
available O
on O
the O
market O
. O

Inhibition O
of O
mitochondrial O
carnitine B
/ O
acylcarnitine B
transporter O
by O
H2O2 B
: O
Molecular O
mechanism O
and O
possible O
implication O
in O
pathophysiology O
. O

H2O2 B
inhibits O
the O
[ O
( O
3 O
) O
H O
] O
carnitine O
/ O
carnitine B
antiport O
catalysed O
by O
the O
mitochondrial O
carnitine B
/ O
acylcarnitine B
transporter O
reconstituted O
in O
proteoliposomes O
. O

The O
inhibition O
was O
reversed O
by O
dithioerythritol O
, O
N B
- I
acetylcysteine I
and O
l O
- O
cysteine O
. O

Inhibition O
was O
tested O
on O
mutants O
in O
which O
one O
or O
more O
of O
the O
six O
Cys B
residues O
had O
been O
substituted O
with O
Ser B
or O
with O
Val B
. O

Mutants O
C23V O
/ O
C58V O
/ O
C155V O
/ O
C89S O
/ O
C283S O
and O
C23V O
/ O
C58V O
/ O
C136V O
/ O
C89S O
/ O
C283S O
containing O
only O
C136 O
or O
C155 O
, O
respectively O
, O
were O
inhibited O
at O
a O
much O
lower O
extent O
respect O
to O
the O
wild O
- O
type O
, O
while O
the O
mutant O
C136S O
/ O
C155S O
in O
which O
the O
two O
Cys B
were O
substituted O
and O
the O
C O
- O
less O
protein O
were O
virtually O
insensitive O
to O
inhibition O
. O

DTE O
reversed O
the O
inhibition O
of O
the O
H2O2 B
sensitive O
proteins O
except O
that O
in O
the O
case O
of O
the O
mutants O
containing O
only O
C136 O
or O
C155 O
after O
long O
time O
of O
incubation O
with O
H2O2 B
. O

The O
IC50 O
values O
obtained O
by O
dose O
- O
response O
curves O
of O
H2O2 B
inhibition O
were O
0 O
. O
17mM O
for O
the O
wild O
- O
type O
, O
0 O
. O
39mM O
for O
the O
four O
replacement O
mutant O
containing O
C136 O
and O
C155 O
, O
2 O
. O
23 O
or O
1 O
. O
8mM O
in O
the O
five O
replacement O
mutants O
containing O
the O
single O
C136 O
or O
C155 O
, O
respectively O
. O

Carnitine B
and O
acetylcarnitine O
protected O
the O
protein O
from O
the O
inhibition O
by O
H2O2 B
. O

Inhibition O
kinetics O
showed O
a O
competitive O
behaviour O
of O
H2O2 B
respect O
to O
carnitine B
. O

All O
the O
data O
concur O
to O
demonstrate O
that O
H2O2 B
interacts O
with O
C136 O
and O
C155 O
and O
completely O
inactivates O
the O
transporter O
by O
inducing O
the O
formation O
of O
a O
disulphide B
. O

Hematologic O
and O
hepatic O
responses O
of O
the O
freshwater O
fish O
Hoplias O
malabaricus O
after O
saxitoxin B
exposure O
. O

The O
animal O
' O
s O
liver O
was O
assessed O
using O
biomarkers O
as O
activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
glutathione B
S O
- O
transferase O
( O
GST O
) O
, O
and O
glutathione B
peroxidase O
( O
GPx O
) O
, O
and O
concentrations O
of O
reduced B
glutathione I
( O
GSH B
) O
and O
lipoperoxidation O
( O
LPO O
) O
and O
protein O
carbonylation O
( O
PCO O
) O
. O

The O
results O
suggested O
the O
generation O
of O
reactive O
oxygen B
species O
, O
with O
increased O
activity O
of O
GPx O
and O
concentrations O
of O
LPO O
and O
GSH B
; O
whereas O
the O
specific O
activity O
of O
SOD O
decreased O
. O

Elemental O
composition O
of O
dog O
foods O
using O
nitric B
acid I
and O
simulated O
gastric O
digestions O
. O

Eighteen O
dry O
dog O
foods O
obtained O
commercially O
in O
the O
United O
States O
were O
digested O
using O
microwave O
assisted O
nitric B
acid I
digestion O
and O
a O
simulated O
gastric O
digestion O
. O

Data O
, O
expressed O
as O
dry O
matter O
concentrations O
, O
were O
compared O
to O
published O
nitric B
acid I
digestion O
results O
. O

Nitric B
acid I
data O
obtained O
in O
the O
present O
study O
were O
not O
statistically O
different O
from O
published O
data O
, O
with O
the O
exception O
of O
Mo B
, O
Sn B
, O
Sb O
, O
Tl B
and O
Th O
. O

Much O
lower O
bioavailability O
was O
observed O
for O
Al B
, O
Ba O
and O
Pb B
. O

Evaluation O
against O
Reference O
Doses O
( O
RfDs O
) O
showed O
concentrations O
for O
many O
elements O
obtained O
by O
nitric B
acid I
digestion O
to O
be O
above O
RfD O
levels O
. O

Substances O
testing O
positive O
included O
reference O
chemicals O
: O
quinacrine B
( O
peak O
response O
, O
51 O
x O
) O
and O
etoposide B
( O
33 O
x O
) O
; O
flavonoids B
: O
EGCG B
( O
19 O
x O
) O
, O
curcumin B
( O
12 O
x O
) O
, O
apigenin B
( O
9 O
x O
) O
, O
and O
quercetin B
( O
7 O
x O
) O
; O
beverages O
: O
chamomile O
( O
11 O
x O
) O
, O
green O
( O
21 O
x O
) O
, O
and O
black O
tea O
( O
26 O
x O
) O
and O
coffee O
( O
3 O
- O
29 O
x O
) O
; O
and O
liquid O
smoke O
( O
4 O
- O
28 O
x O
) O
. O

Damage O
occurred O
at O
dietary O
concentrations O
: O
etoposide B
near O
5 O
mu O
g O
/ O
ml O
produced O
responses O
similar O
to O
a O
1 O
: O
1000 O
dilution O
of O
liquid O
smoke O
, O
a O
1 O
: O
20 O
dilution O
of O
coffee O
, O
and O
a O
1 O
: O
5 O
dilution O
of O
tea O
. O

Pyrogallol O
- O
related O
chemicals O
and O
tannins B
are O
present O
in O
dietary O
sources O
and O
individually O
produced O
strong O
activity O
: O
pyrogallol O
( O
30 O
x O
) O
, O
3 O
- O
methoxycatechol O
( O
25 O
x O
) O
, O
gallic B
acid I
( O
21 O
x O
) O
, O
and O
1 O
, O
2 O
, O
4 O
- O
benzenetriol O
( O
21 O
x O
) O
. O

From O
structure O
- O
activity O
relationships O
, O
high O
activities O
depended O
on O
specific O
orientations O
of O
hydroxyls B
on O
the O
benzene B
ring O
. O

The O
synthesis O
and O
SAR O
of O
calcitonin O
gene O
- O
related O
peptide O
( O
CGRP O
) O
receptor O
antagonists O
derived O
from O
tyrosine B
surrogates O
. O

Various O
substituted O
indazole B
and O
benzoxazolone O
amino B
acids I
were O
investigated O
as O
d O
- O
tyrosine O
surrogates O
in O
highly O
potent O
CGRP O
receptor O
antagonists O
. O

Compound O
3 O
, O
derived O
from O
the O
7 O
- O
methylindazole O
core O
, O
afforded O
a O
30 O
- O
fold O
increase O
in O
CGRP O
binding O
potency O
compared O
with O
its O
unsubstituted O
indazole B
analog O
1 O
. O

Formulations O
contained O
either O
microcrystalline O
cellulose O
( O
MCC O
) O
or O
dicalcium O
phosphate O
( O
DCP O
) O
as O
diluent O
, O
hydroxypropyl O
methylcellulose O
( O
HPMC O
) O
, O
lactose B
, O
and O
water O
. O

Extrudates O
were O
characterized O
for O
their O
tensile O
strength O
, O
Young O
' O
s O
modulus O
of O
elasticity O
, O
water O
absorption O
, O
gel O
forming O
capacity O
, O
and O
release O
of O
two O
model O
drugs O
, O
coumarin B
( O
COU O
) O
and O
propranolol O
hydrochloride O
( O
PRO B
) O
. O

In O
this O
study O
, O
the O
stabilization O
effects O
of O
three O
polymers O
on O
four O
model O
drugs O
( O
felodipine O
, O
fenofibrate B
, O
carbamazepine B
, O
and O
celecoxib B
) O
under O
saturated O
humidity O
were O
investigated O
. O

Amongst O
the O
polymers O
tested O
in O
this O
study O
, O
EUDRAGIT O
E O
PO O
was O
found O
to O
have O
the O
greatest O
inhibitory O
effect O
on O
crystallization O
, O
whilst O
PVP B
K30 I
was O
found O
to O
have O
the O
least O
protective O
effect O
; O
presumably O
because O
of O
its O
hygroscopic O
nature O
. O

Triethylenetetramine O
prevents O
insulin O
aggregation O
and O
fragmentation O
during O
copper B
catalyzed O
oxidation O
. O

Metal O
catalyzed O
oxidation O
via O
the O
oxidative O
system O
Cu B
( I
2 I
+ I
) I
/ O
ascorbate B
is O
known O
to O
induce O
aggregation O
of O
therapeutic O
proteins O
, O
resulting O
in O
enhanced O
immunogenicity O
. O

In O
this O
study O
, O
using O
recombinant O
human O
insulin O
( O
insulin O
) O
as O
a O
model O
, O
we O
investigated O
the O
ability O
of O
several O
excipients O
, O
in O
particular O
triethylenetetramine O
( O
TETA O
) O
, O
reduced B
glutathione I
( O
GSH B
) O
and O
ethylenediamine O
tetraacetic O
acid O
( O
EDTA B
) O
, O
for O
their O
ability O
to O
prevent O
protein O
oxidation O
, O
aggregation O
, O
and O
fragmentation O
. O

Insulin O
( O
1mg O
/ O
ml O
) O
was O
oxidized O
with O
40 O
mu O
M O
Cu B
( I
2 I
+ I
) I
and O
4mM O
ascorbic B
acid I
in O
absence O
or O
presence O
of O
excipients O
. O

Among O
the O
excipients O
studied O
, O
1mM O
of O
TETA O
, O
EDTA B
, O
or O
GSH B
prevented O
insulin O
aggregation O
upon O
metal O
catalyzed O
oxidation O
( O
MCO O
) O
for O
3h O
at O
room O
temperature O
, O
based O
on O
size O
exclusion O
chromatography O
( O
SEC O
) O
. O

In O
contrast O
, O
GSH B
had O
a O
slight O
pro O
- O
oxidant O
effect O
, O
as O
demonstrated O
by O
the O
higher O
percentage O
of O
aggregates O
and O
a O
more O
severe O
structural O
damage O
, O
whereas O
EDTA B
offered O
substantially O
less O
protection O
. O

Synthesis O
and O
Nrf2 O
- O
inducing O
activity O
of O
the O
isothiocyanates B
iberverin O
, O
iberin O
and O
cheirolin O
. O

Numerous O
studies O
have O
reported O
a O
potent O
induction O
of O
Nuclear O
factor O
( O
erythroid O
- O
derived O
2 O
) O
- O
like O
2 O
( O
Nrf2 O
) O
- O
dependent O
gene O
expression O
by O
the O
isothiocyanate O
sulforaphane B
. O

However O
, O
little O
is O
known O
regarding O
the O
Nrf2 O
- O
inducing O
activities O
of O
the O
lower O
structure O
- O
related O
sulforaphane B
homologues O
, O
such O
as O
iberverin O
, O
iberin O
and O
cheirolin O
, O
which O
exhibit O
different O
sulfur O
oxidation O
states O
. O

Therefore O
, O
in O
this O
study O
we O
synthesized O
the O
isothiocyanates B
iberverin O
, O
iberin O
and O
cheirolin O
with O
a O
high O
yield O
and O
purity O
and O
determined O
their O
Nrf2 O
- O
inducing O
activity O
in O
NIH3T3 O
fibroblasts O
. O

The O
increase O
in O
nuclear O
Nrf2 O
levels O
was O
accompanied O
by O
a O
significant O
increase O
in O
heme O
oxygenase O
1 O
( O
HO O
- O
1 O
) O
and O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
GCS O
) O
mRNA O
and O
protein O
levels O
. O

Overall O
, O
iberverin O
, O
iberin O
and O
cheirolin O
exhibited O
a O
similar O
potency O
to O
sulforaphane B
in O
inducing O
Nrf2 O
- O
dependent O
gene O
- O
expression O
. O

The O
food O
contaminant O
deoxynivalenol B
activates O
the O
mitogen O
activated O
protein O
kinases O
in O
the O
intestine O
: O
interest O
of O
ex O
vivo O
models O
as O
an O
alternative O
to O
in O
vivo O
experiments O
. O

Trichothecenes B
induce O
changes O
in O
the O
intestinal O
barrier O
function O
through O
decreased O
expression O
of O
cell O
junction O
proteins O
and O
apoptosis O
of O
enterocytes O
. O

Using O
ex O
vivo O
and O
in O
vivo O
approaches O
, O
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
ability O
of O
low O
doses O
of O
DON B
to O
induce O
histological O
changes O
in O
the O
intestine O
and O
to O
activate O
the O
MAPK O
ERK O
1 O
/ O
2 O
, O
p38 O
and O
JNK O
. O

Twelve O
weaning O
piglets O
received O
during O
four O
weeks O
a O
control O
diet O
or O
a O
DON B
- O
contaminated O
diet O
( O
2 O
. O
3 O
mg O
DON B
/ O
kg O
feed O
) O
. O

Explants O
were O
exposed O
during O
4 O
h O
to O
vehicle O
, O
5 O
or O
10 O
mu O
M O
DON B
. O

Pigs O
fed O
a O
DON B
- O
diet O
and O
explants O
exposed O
to O
DON B
showed O
a O
significant O
decrease O
in O
the O
jejunal O
score O
. O

Taken O
together O
these O
results O
indicate O
that O
in O
vivo O
or O
ex O
vivo O
exposure O
of O
intestinal O
tissue O
to O
DON B
lead O
to O
similar O
intestinal O
lesions O
and O
activation O
of O
MAPK O
. O

Antofine O
, O
a O
phenanthroindolizidi B
alkaloid I
derived O
from O
Cryptocaryachinensis O
and O
Ficusseptica O
in O
the O
Asclepiadaceae O
milkweed O
family O
, O
is O
cytotoxic O
for O
various O
cancer O
cell O
lines O
. O

Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co O
- O
treatment O
with O
antofine O
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl O
or O
MG132 B
, O
partially O
inhibited O
the O
antofine O
- O
induced O
decrease O
in O
Cx43 O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine O
- O
induced O
inhibition O
of O
GJIC O
. O

After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
concentration O
and O
activation O
of O
protein O
kinase O
C O
( O
PKC O
) O
alpha O
/ O
beta O
II O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O

Co O
- O
treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
chelator O
BAPTA B
- I
AM I
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O

Specifically O
, O
ritonavir B
- O
boosted O
lopinavir O
- O
and O
atazanavir O
- O
based O
regimens O
are O
preferred O
in O
pregnancy O
, O
while O
ritonavir B
- O
boosted O
darunavir B
- O
and O
saquinavir B
- O
based O
therapies O
are O
reasonable O
alternatives O
. O

RESULTS O
Sex O
, O
age O
, O
HbA1c O
, O
years O
after O
diagnosis O
, O
BMI O
, O
systolic O
blood O
pressure O
, O
non O
- O
HDL O
cholesterol B
, O
albumin O
- O
to O
- O
creatinine B
ratio O
, O
atrial O
fibrillation O
, O
current O
smoker O
, O
and O
leisure O
- O
time O
physical O
activity O
were O
risk O
factors O
for O
macro O
- O
and O
microvascular O
complications O
and O
were O
incorporated O
into O
the O
risk O
engine O
. O

VEGF O
- O
D O
is O
an O
angiogenic O
and O
lymphangiogenic O
glycoprotein O
that O
can O
be O
proteolytically O
processed O
generating O
various O
forms O
differing O
in O
subunit O
composition O
due O
to O
the O
presence O
or O
absence O
of O
N B
- O
and O
C B
- O
terminal O
propeptides O
. O

We O
report O
for O
the O
first O
time O
that O
VEGF O
- O
D O
binds O
heparin O
, O
and O
that O
the O
C B
- O
terminal O
propeptide O
significantly O
enhances O
this O
interaction O
( O
removal O
of O
this O
propeptide O
from O
full O
- O
length O
VEGF O
- O
D O
completely O
prevents O
heparin O
binding O
) O
. O

We O
also O
show O
that O
removal O
of O
either O
the O
N B
- O
or O
C B
- O
terminal O
propeptide O
is O
required O
for O
VEGF O
- O
D O
to O
drive O
formation O
of O
VEGFR O
- O
2 O
/ O
VEGFR O
- O
3 O
heterodimers O
which O
have O
recently O
been O
shown O
to O
positively O
regulate O
angiogenic O
sprouting O
. O

In O
a O
mouse O
tumor O
model O
, O
removal O
of O
only O
the O
C B
- O
terminal O
propeptide O
from O
full O
- O
length O
VEGF O
- O
D O
was O
sufficient O
to O
enhance O
angiogenesis O
and O
tumor O
growth O
. O

Increased O
immunoreactive O
11 B
- I
ketotestosterone I
concentrations O
in O
sheep O
feces O
after O
acth O
challenge O
. O

11 O
- O
Oxoetiocholanolone O
and O
related O
substances O
are O
important O
metabolites O
of O
cortisol B
and O
are O
excreted O
via O
feces O
in O
ruminants O
. O

To O
investigate O
whether O
11 B
- I
ketotestosterone I
( O
11 B
- I
KT I
) O
or O
its O
immunoreactive O
metabolites O
are O
formed O
and O
excreted O
in O
ruminant O
feces O
, O
an O
enzyme O
immunoassay O
( O
EIA O
) O
was O
developed O
and O
validated O
. O

Samples O
( O
0 O
. O
5 O
g O
) O
were O
extracted O
using O
80 O
% O
methanol B
and O
immunoreactive O
metabolites O
measured O
using O
the O
11 B
- I
KT I
EIA O
and O
an O
already O
established O
11 O
, O
17 O
- O
dioxoandrostane O
( O
11 O
, O
17 O
- O
DOA O
) O
EIA O
. O

High O
- O
performance O
liquid O
chromatography O
separation O
revealed O
no O
peak O
in O
the O
same O
elution O
position O
as O
authentic O
11 B
- I
KT I
; O
therefore O
, O
reacting O
substances O
were O
referred O
to O
as O
11 B
- I
KT I
equivalents O
. O

In O
the O
case O
of O
11 B
- I
KT I
immunoreactive O
substances O
, O
the O
values O
increased O
from O
baseline O
( O
median O
, O
136 O
ng O
/ O
g O
feces O
) O
to O
a O
peak O
concentration O
( O
median O
, O
424 O
ng O
/ O
g O
) O
10 O
to O
14 O
h O
after O
Synacthen O
injection O
and O
declined O
afterwards O
. O

From O
this O
data O
, O
the O
authors O
conclude O
that O
11 B
- I
KT I
- O
like O
substances O
, O
specifically O
C19 O
O3 O
- O
androgens O
with O
a O
17 O
beta O
- O
hydroxy O
group O
, O
were O
present O
in O
the O
feces O
. O

These O
substances O
originate O
from O
the O
adrenals O
and O
are O
most O
likely O
cortisol B
metabolites O
. O

Fractionation O
of O
organosolv O
lignin O
from O
olive O
tree O
clippings O
and O
its O
valorization O
to O
simple O
phenolic B
compounds O
. O

It O
involves O
ultrafiltration O
as O
a O
fractionation O
process O
to O
separate O
different O
molecular O
weight O
lignin O
fractions O
followed O
by O
a O
hydrogen B
- O
free O
, O
mild O
, O
hydrogenolytic O
, O
heterogeneously O
catalyzed O
methodology O
assisted O
by O
microwave O
irradiation O
to O
obtain O
simple O
phenolic B
, O
monomeric O
products O
by O
depolymerization O
using O
a O
nickel O
- O
based O
catalyst O
. O

The O
main O
products O
obtained O
were O
desaspidinol O
, O
syringaldehyde B
, O
and O
syringol O
; O
this O
proves O
the O
efficiency O
of O
the O
depolymerization O
conditions O
applied O
. O

The O
applied O
depolymerization O
conditions O
, O
which O
take O
advantage O
of O
the O
use O
of O
formic B
acid I
as O
a O
hydrogen B
- O
donating O
solvent O
, O
did O
not O
generate O
any O
biochar O
in O
the O
systems O
. O

Finding O
microRNA O
targets O
in O
the O
coding O
region O
is O
difficult O
due O
to O
the O
overwhelming O
signal O
encoding O
the O
amino B
acid I
sequence O
. O

Here O
, O
we O
introduce O
an O
algorithm O
( O
called O
PACCMIT O
- O
CDS O
) O
that O
finds O
potential O
microRNA O
targets O
within O
coding O
sequences O
by O
searching O
for O
conserved O
motifs O
that O
are O
complementary O
to O
the O
microRNA O
seed O
region O
and O
also O
overrepresented O
in O
comparison O
with O
a O
background O
model O
preserving O
both O
codon O
usage O
and O
amino B
acid I
sequence O
. O

Enzymatic O
characterization O
showed O
1 O
to O
be O
extremely O
specific O
, O
as O
the O
highly O
homologous O
human O
N B
- O
acetylgalactosaminyl O
( O
GTA O
) O
is O
not O
inhibited O
. O

The O
binding O
epitope O
of O
1 O
demonstrates O
a O
high O
involvement O
of O
the O
arabinityl O
linker O
, O
whereas O
the O
galactose B
residue O
is O
only O
making O
contact O
to O
the O
protein O
via O
its O
C O
- O
2 O
site O
, O
which O
is O
very O
important O
for O
the O
discrimination O
between O
galactose B
and O
N B
- I
acetylgalactosamine I
, O
the O
substrate O
transferred O
by O
GTA O
. O

To O
test O
this O
hypothesis O
, O
constructs O
were O
evaluated O
consisting O
of O
an O
immunophilin O
: O
human O
FK B
- I
506 I
binding O
protein O
12 O
( O
FKBP O
) O
attached O
to O
an O
ELP O
. O

Electric O
degradation O
only O
occurs O
when O
the O
device O
is O
in O
the O
charge O
- O
storage O
state O
, O
which O
provides O
a O
nanoscale O
dielectrophoretic O
force O
directing O
H2O B
to O
internal O
field O
centers O
( O
sites O
of O
trapped O
charge O
) O
to O
enable O
bond O
rupture O
and O
charged O
hydroxyl B
formation O
. O

Evaluation O
of O
oxidant O
- O
antioxidant O
status O
in O
oral O
toxicity O
of O
fish O
oil O
methyl B
esters I
and O
diesel O
fuel O
in O
male O
rats O
. O

At O
the O
end O
of O
the O
study O
, O
malondialdehyde B
( O
MDA B
) O
and O
reduced B
glutathione I
( O
GSH B
) O
levels O
were O
measured O
in O
the O
whole O
blood O
; O
catalase O
( O
CAT O
) O
activity O
level O
was O
measured O
in O
erythrocytes O
; O
and O
nitrite B
( O
NO B
( I
2 I
) I
) O
and O
nitrate B
( O
NO B
( I
3 I
) I
) O
levels O
were O
measured O
in O
the O
serum O
. O

It O
was O
observed O
that O
the O
whole O
blood O
MDA B
levels O
of O
the O
diesel O
groups O
were O
considerably O
different O
from O
those O
in O
the O
control O
and O
fish O
oil O
biodiesel O
groups O
( O
p O
< O
0 O
. O
001 O
) O
. O

GSH B
levels O
in O
the O
control O
group O
were O
observed O
to O
be O
considerably O
different O
from O
those O
in O
all O
other O
groups O
( O
p O
< O
0 O
. O
001 O
) O
. O

Serum O
NO B
( I
3 I
) I
concentrations O
in O
the O
diesel O
groups O
were O
found O
to O
be O
considerably O
different O
from O
those O
in O
the O
control O
and O
biodiesel O
groups O
. O

Serum O
NO B
( I
2 I
) I
concentrations O
in O
one O
of O
the O
diesel O
groups O
were O
significantly O
different O
from O
those O
in O
the O
control O
and O
biodiesel O
groups O
( O
p O
< O
0 O
. O
01 O
and O
p O
< O
0 O
. O
05 O
, O
respectively O
) O
. O

Effect O
of O
tocopherol B
on O
biochemical O
blood O
parameters O
in O
pleuritis O
- O
induced O
rats O
treated O
with O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
tocopherol B
on O
pleuritis O
- O
induced O
rats O
exposed O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

Rats O
were O
treated O
with O
a O
single O
TCDD B
dose O
of O
5 O
mu O
g O
/ O
kg O
body O
weight O
( O
b O
. O
w O
. O
) O
and O
then O
for O
3 O
weeks O
they O
were O
daily O
supplemented O
with O
tocopherol B
at O
a O
dose O
of O
30 O
mg O
/ O
kg O
b O
. O
w O
. O

Changes O
in O
biochemical O
blood O
parameters O
were O
measured O
three O
times O
at O
the O
24th O
, O
72nd O
and O
120th O
hour O
of O
pleuritis O
and O
the O
blood O
was O
collected O
from O
20 O
animals O
of O
each O
group O
of O
rats O
( O
group O
with O
the O
control O
inflammation O
; O
group O
treated O
with O
TCDD B
and O
with O
control O
inflammation O
; O
group O
treated O
with O
TCDD B
, O
supplemented O
with O
tocopherol O
and O
with O
the O
inflammation O
) O
. O

The O
following O
biochemical O
parameters O
were O
measured O
: O
tumor O
necrosis O
factor O
( O
TNF O
) O
, O
interleukin O
- O
1 O
( O
IL O
- O
1 O
) O
, O
IL O
- O
2 O
, O
IL O
- O
4 O
, O
IL O
- O
6 O
, O
procollagen O
, O
telopeptide O
, O
fibrinogen O
, O
cholesterol B
, O
urea B
, O
creatinine B
, O
aspartate B
aminotransferase O
( O
AspAT O
) O
and O
alanine B
aminotransferase O
( O
AlAT O
) O
. O

Daily O
supplementation O
of O
tocopherol B
caused O
significant O
changes O
in O
the O
level O
of O
TNF O
, O
IL O
- O
1 O
, O
IL O
- O
4 O
, O
IL O
- O
6 O
, O
urea B
, O
creatinine B
, O
AspAT O
and O
AlAT O
. O

According O
to O
the O
results O
of O
these O
studies O
, O
we O
suggest O
that O
tocopherol B
supplementation O
in O
high O
doses O
could O
act O
as O
a O
protective O
treatment O
to O
improve O
liver O
metabolism O
. O

In O
brine O
shrimp O
toxicology O
assays O
, O
profound O
cytotoxicity O
was O
displayed O
by O
ethyl B
acetate I
( O
LD O
( O
50 O
) O
8 O
. O
3 O
mu O
g O
/ O
ml O
) O
and O
chloroform B
( O
LD O
( O
50 O
) O
8 O
. O
8 O
mu O
g O
/ O
ml O
) O
fractions O
, O
followed O
by O
relatively O
weak O
crude O
methanolic O
extract O
of O
H O
. O
strigosum O
( O
LD O
( O
50 O
) O
909 O
mu O
g O
/ O
ml O
) O
and O
n B
- I
hexane I
fraction O
( O
LD O
( O
50 O
) O
1000 O
mu O
g O
/ O
ml O
) O
. O

In O
case O
of O
phytotoxicity O
activity O
against O
Lemna O
acquinoctialis O
, O
highest O
phytotoxic O
effect O
was O
showed O
by O
ethyl B
acetate I
fraction O
( O
LD O
( O
50 O
) O
91 O
. O
0 O
mu O
g O
/ O
ml O
) O
, O
while O
chloroform B
fraction O
, O
plant O
crude O
extract O
and O
n B
- I
hexane I
, O
respectively O
, O
caused O
50 O
% O
, O
30 O
. O
76 O
+ O
/ O
- O
1 O
. O
1 O
% O
and O
30 O
. O
7 O
+ O
/ O
- O
1 O
. O
1 O
% O
inhibitory O
action O
at O
maximum O
concentration O
used O
, O
that O
is O
, O
1000 O
mu O
g O
/ O
ml O
. O

The O
ethyl B
acetate I
and O
chloroform B
fractions O
were O
more O
potent O
for O
the O
evaluated O
toxicity O
effects O
, O
thus O
recommended O
for O
isolation O
and O
identification O
of O
the O
active O
compounds O
. O

Two O
ruthenium O
( O
ii O
) O
polypyridyl O
complexes O
[ O
Ru O
( O
phen O
) O
2 O
( O
4idip O
) O
] O
( O
ClO4 O
) O
2 O
( O
) O
and O
[ O
Ru O
( O
bpy O
) O
2 O
( O
4idip O
) O
] O
( O
ClO4 O
) O
2 O
( O
) O
( O
phen O
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip O
= O
4 O
- O
indoleimidazo O
[ O
4 O
, O
5 O
- O
f O
] O
[ O
1 O
, O
10 O
] O
phenanthroline O
) O
designed O
as O
telomeric O

Furthermore O
, O
both O
ruthenium B
complexes O
led O
to O
the O
inhibition O
of O
the O
enzyme O
telomerase O
, O
and O
complex O
was O
the O
significantly O
better O
inhibitor O
. O

RATIONALE O
: O
The O
head O
- O
twitch O
response O
( O
HTR O
) O
is O
a O
rapid O
side O
- O
to O
- O
side O
rotational O
head O
movement O
that O
occurs O
in O
rats O
and O
mice O
after O
administration O
of O
serotonergic O
hallucinogens O
and O
other O
5 B
- I
HT I
( O
2A O
) O
agonists O
. O

The O
HTR O
is O
widely O
used O
as O
a O
behavioral O
assay O
for O
5 B
- I
HT I
( O
2A O
) O
activation O
and O
to O
probe O
for O
interactions O
between O
the O
5 B
- I
HT I
( O
2A O
) O
receptor O
and O
other O
transmitter O
systems O
. O

The O
magnetometer O
coil O
detected O
the O
HTR O
induced O
by O
the O
serotonergic O
hallucinogens O
2 O
, O
5 O
- O
dimethoxy O
- O
4 O
- O
iodoamphetamine O
( O
DOI B
; O
0 O
. O
25 O
, O
0 O
. O
5 O
, O
and O
1 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lysergic O
acid O
diethylamide O
( O
LSD O
; O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
and O
0 O
. O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
with O
extremely O
high O
sensitivity O
and O
specificity O
. O

Magnetometer O
coil O
recordings O
demonstrated O
that O
the O
non O
- O
hallucinogenic O
compounds O
( B
+ I
) I
- I
amphetamine I
( O
2 O
. O
5 O
and O
5 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lisuride O
( O
0 O
. O
8 O
, O
1 O
. O
6 O
, O
and O
3 O
. O
2 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
did O
not O
induce O
the O
HTR O
. O

Faecal O
Excretion O
Dynamic O
during O
Subacute O
Oral O
Exposure O
to O
Different O
Pb B
Species O
in O
Rattus O
norvegicus O
. O

Faecal O
excretion O
is O
a O
basic O
means O
of O
detoxification O
upon O
ingestion O
of O
Pb B
- O
contaminated O
feed O
. O

In O
order O
to O
determine O
a O
time O
course O
of O
Pb B
elimination O
after O
oral O
exposure O
to O
two O
different O
forms O
of O
this O
heavy O
metal O
( O
lead O
acetate O
vs O
. O
phyto O
- O
bound O
Pb B
) O
, O
a O
feeding O
study O
was O
carried O
out O
in O
experimental O
rats O
using O
the O
Pb B
phyto O
- O
hyperaccumulator O
Pistia O
stratiotes O
as O
a O
model O
diet O
. O

The O
effect O
of O
starvation O
on O
Pb B
excretion O
was O
further O
studied O
in O
rats O
that O
were O
fed O
plant O
material O
. O

Twelve O
Pb B
doses O
( O
7 O
mu O
g O
Pb B
/ O
1 O
g O
BW O
) O
were O
administered O
orally O
over O
a O
5 O
- O
week O
period O
. O

Up O
to O
53 O
% O
of O
ingested O
Pb B
was O
rapidly O
eliminated O
from O
the O
exposed O
rats O
via O
faeces O
within O
24 O
h O
after O
exposure O
. O

Fasting O
before O
exposure O
reduced O
Pb B
excretion O
by O
up O
to O
50 O
% O
. O

Faecal O
excretions O
of O
both O
examined O
Pb B
forms O
exhibited O
almost O
identical O
patterns O
. O

Considerable O
differences O
were O
revealed O
concerning O
total O
excretion O
levels O
; O
lead O
acetate O
was O
excreted O
in O
amount O
greater O
extent O
than O
those O
of O
phytobound O
Pb B
. O

Results O
of O
our O
study O
suggest O
that O
Pb B
forms O
occurring O
in O
the O
P O
. O
stratiotes O
tissues O
are O
absorbed O
through O
the O
gastrointestinal O
tract O
to O
a O
greater O
extent O
than O
Pb B
from O
lead O
acetate O
. O

Therefore O
, O
higher O
portions O
of O
ingested O
Pb B
can O
be O
available O
for O
potential O
accumulation O
in O
tissues O
of O
exposed O
subjects O
. O

Echinacea O
sanguinea O
and O
Echinacea O
pallida O
extracts O
stimulate O
glucuronidation O
and O
basolateral O
transfer O
of O
Bauer O
alkamides O
8 O
and O
10 O
and O
ketone B
24 O
and O
inhibit O
P O
- O
glycoprotein O
transporter O
in O
Caco O
- O
2 O
cells O
. O

We O
hypothesized O
that O
Bauer O
alkamides O
8 O
, O
10 O
, O
and O
11 O
and O
ketone B
24 O
were O
absorbed O
similarly O
either O
as O
pure O
compounds O
or O
from O
Echinacea O
sanguinea O
and O
Echinacea O
pallida O
ethanol B
extracts O
, O
and O
that O
these O
Echinacea O
extracts O
could O
inhibit O
the O
P O
- O
glycoprotein O
transporter O
in O
Caco O
- O
2 O
human O
intestinal O
epithelial O
cells O
. O

Both O
Echinacea O
ethanol B
extracts O
stimulated O
apparent O
glucuronidation O
and O
basolateral O
efflux O
of O
glucuronides O
of O
alkamides O
8 O
and O
10 O
but O
not O
alkamide O
11 O
. O

Bauer O
ketone B
24 O
was O
totally O
metabolized O
to O
more O
hydrophilic O
metabolites O
when O
administered O
as O
a O
single O
compound O
, O
but O
was O
also O
glucuronidated O
when O
present O
in O
Echinacea O
extracts O
. O

Bauer O
alkamides O
8 O
, O
10 O
, O
and O
11 O
( O
175 O
- O
230 O
micro O
M O
) O
and O
ethanol B
extracts O
of O
E O
. O
sanguinea O
( O
1 O
mg O
/ O
mL O
, O
containing O
~ O
90 O
micro O
M O
total O
alkamides O
) O
and O
E O
. O
pallida O
( O
5 O
mg O
/ O
mL O
, O
containing O
285 O
micro O
M O
total O
alkamides O
) O
decreased O
the O
efflux O
of O
the O
P O
- O
glycoprotein O
transporter O
probe O
calcein O
- O
AM O
from O
Caco O
- O
2 O
cells O
. O

These O
results O
suggest O
that O
other O
constituents O
in O
these O
Echinacea O
extracts O
facilitated O
the O
metabolism O
and O
efflux O
of O
alkamides O
and O
ketones B
, O
which O
might O
improve O
therapeutic O
benefits O
. O

In O
2007 O
, O
the O
authors O
measured O
serum O
concentrations O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
in O
Laizhou O
Bay O
residents O
. O

To O
assess O
the O
PBDE B
concentration O
trend O
, O
and O
determine O
the O
concentrations O
of O
the O
emerging O
flame O
retardants O
Dechlorane B
Plus I
( O
DP O
) O
and O
bis O
( O
2 O
- O
ethylhexyl O
) O
- O
3 O
, O
4 O
, O
5 O
, O
6 O
- O
tetrabromophthalate O
( O
TBPH O
) O
, O
the O
authors O
measured O
the O
concentrations O
of O
8 O
PBDE B
congeners O
, O
2 O
DP O
isomers O
, O
and O
TBPH O
in O
10 O
composite O
samples O
, O
which O
were O
pooled O
from O
the O
serum O
collected O
from O
305 O
Laizhou O
Bay O
residents O
in O
October O
2011 O
. O

The O
average O
concentration O
of O
the O
total O
PBDE B
( O
sum O
8 O
PBDE B
) O
concentration O
in O
all O
serum O
pools O
was O
240 O
ng O
/ O
g O
lipid O
weight O
, O
and O
the O
highest O
serum O
pool O
concentration O
( O
in O
the O
30 O
- O
to O
39 O
- O
yr O
- O
old O
male O
group O
) O
was O
780 O
ng O
/ O
g O
lipid O
weight O
. O

Brominated O
diphenyl O
ether O
- O
209 O
was O
the O
dominant O
congener O
, O
accounting O
for O
87 O
% O
of O
sum O
8 O
PBDE B
. O

Compared O
with O
a O
previous O
study O
, O
sum O
8 O
PBDE B
serum O
concentrations O
in O
the O
present O
study O
showed O
no O
change O
in O
order O
of O
magnitude O
, O
but O
the O
relative O
contribution O
of O
BDE O
- O
209 O
to O
sum O
8 O
PBDE B
was O
higher O
. O

Versatile O
functionalization O
of O
the O
chromone B
nucleus O
allows O
attaining O
of O
a O
chemical O
diversity O
suitable O
to O
perform O
structure O
- O
activity O
relationships O
in O
drug O
discovery O
and O
development O
programs O
. O

We O
examined O
a O
number O
of O
anti O
- O
resorptive O
treatments O
to O
either O
block O
osteoclast O
activity O
, O
including O
the O
potent O
bisphosphonates B
zoledronic O
acid O
( O
ZA O
) O
and O
clodronate O
( O
CLOD O
) O
, O
which O
work O
via O
differing O
mechanisms O
, O
or O
antagonize O
osteoclastogenesis O
with O
recombinant O
OPG O
( O
HuOPG O
- O
Fc O
) O
, O
comparing O
these O
directly O
to O
an O
inhibitor O
of O
matrix O
metalloproteinase O
( O
MMP O
) O
activity O
( O
MMI270 O
) O
. O

Bisphosphonates B
and O
risk O
of O
subtrochanteric O
, O
femoral O
shaft O
, O
and O
atypical O
femur O
fracture O
: O
A O
systematic O
review O
and O
meta O
- O
analysis O
. O

While O
there O
is O
strong O
evidence O
that O
bisphosphonates B
prevent O
certain O
types O
of O
osteoporotic O
fractures O
, O
there O
are O
concerns O
that O
these O
medications O
may O
be O
associated O
with O
rare O
atypical O
femoral O
fractures O
( O
AFF O
) O
. O

We O
conducted O
a O
systematic O
review O
and O
meta O
- O
analysis O
of O
published O
studies O
examining O
the O
association O
of O
bisphosphonates B
with O
subtrochanteric O
, O
femoral O
shaft O
, O
and O
AFF O
. O

Subgroup O
analysis O
was O
performed O
by O
study O
design O
, O
for O
studies O
that O
used O
validated O
outcome O
definitions O
for O
AFF O
, O
and O
for O
studies O
reporting O
on O
duration O
of O
bisphosphonate B
use O
. O

Bisphosphonate B
exposure O
was O
associated O
with O
an O
increased O
risk O
of O
subtrochanteric O
, O
femoral O
shaft O
, O
and O
AFF O
with O
adjusted O
RR O
of O
1 O
. O
70 O
( O
95 O
% O
CI O
1 O
. O
22 O
- O
2 O
. O
37 O
) O
. O

Subgroup O
analysis O
of O
studies O
using O
the O
ASBMR O
- O
criteria O
to O
define O
AFF O
suggests O
a O
higher O
risk O
of O
AFF O
with O
bisphosphonate B
use O
with O
RR O
of O
11 O
. O
78 O
( O
95 O
% O
CI O
0 O
. O
39 O
- O
359 O
. O
69 O
) O
as O
compared O
to O
studies O
using O
mainly O
diagnosis O
codes O
( O
RR O
1 O
. O
62 O
, O
95 O
% O
CI O
1 O
. O
18 O
- O
2 O
. O
22 O
) O
, O
although O
there O
is O
a O
wide O
confidence O
interval O
and O
severe O
heterogeneity O
( O
I O
( O
2 O
) O
= O
96 O
. O
15 O
% O
) O
in O
this O
subgroup O
analysis O
. O

Subgroup O
analysis O
of O
studies O
examining O
at O
least O
5 O
years O
of O
bisphosphonate B
use O
showed O
adjusted O
RR O
of O
1 O
. O
62 O
( O
95 O
% O
CI O
1 O
. O
29 O
- O
2 O
. O
04 O
) O
. O

This O
meta O
- O
analysis O
suggests O
there O
is O
an O
increased O
risk O
of O
subtrochanteric O
, O
femoral O
shaft O
, O
and O
AFF O
among O
bisphosphonate B
users O
. O

Further O
research O
examining O
the O
risk O
of O
AFF O
with O
long O
- O
term O
use O
of O
bisphosphonates B
is O
indicated O
as O
there O
was O
limited O
data O
in O
this O
subgroup O
. O

Novel O
inhibition O
of O
archaeal O
family O
- O
D O
DNA O
polymerase O
by O
uracil B
. O

Archaeal O
family O
- O
D O
DNA O
polymerase O
is O
inhibited O
by O
the O
presence O
of O
uracil B
in O
DNA O
template O
strands O
. O

When O
the O
enzyme O
encounters O
uracil B
, O
following O
three O
parameters O
change O
: O
DNA O
binding O
increases O
roughly O
2 O
- O
fold O
, O
the O
rate O
of O
polymerization O
slows O
by O
a O
factor O
of O
~ O
5 O
and O
3 O
' O
- O
5 O
' O
proof O
- O
reading O
exonuclease O
activity O
is O
stimulated O
by O
a O
factor O
of O
~ O
2 O
. O

Pol O
D O
appears O
to O
interact O
with O
template O
strand O
uracil B
irrespective O
of O
its O
distance O
ahead O
of O
the O
replication O
fork O
. O

Polymerization O
does O
not O
stop O
at O
a O
defined O
location O
relative O
to O
uracil B
, O
rather O
a O
general O
decrease O
in O
DNA O
synthesis O
is O
observed O
. O

' O
Trans O
' O
inhibition O
, O
the O
slowing O
of O
Pol O
D O
by O
uracil B
on O
a O
DNA O
strand O
not O
being O
replicated O
is O
also O
observed O
. O

It O
is O
proposed O
that O
Pol O
D O
is O
able O
to O
interact O
with O
uracil B
by O
looping O
out O
the O
single O
- O
stranded O
template O
, O
allowing O
simultaneous O
contact O
of O
both O
the O
base O
and O
the O
primer O
- O
template O
junction O
to O
give O
a O
polymerase O
- O
DNA O
complex O
with O
diminished O
extension O
ability O
. O

MDSCs O
have O
unique O
ways O
of O
abrogatingan O
immune O
response O
in O
addition O
to O
those O
utilised O
by O
other O
immune O
- O
suppressive O
cell O
types O
, O
for O
example O
via O
the O
induction O
of O
arginase O
- O
1 O
and O
consequent O
upregulation O
in O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
. O

Fibroblast O
growth O
factor O
receptor O
- O
4 O
( O
FGFR4 O
) O
is O
a O
tyrosine B
kinase O
with O
a O
range O
of O
important O
physiological O
functions O
. O

Combination O
with O
ICS O
( O
fluticasone O
/ O
salmeterol O
, O
budesonide B
/ O
formoterol O
, O
beclomethasone O
/ O
formoterol O
) O
appears O
to O
provide O
an O
additional O
benefit O
over O
the O
monocomponent O
therapy O
, O
although O
the O
extent O
of O
this O
benefit O
is O
variable O
and O
often O
not O
clinically O
significant O
in O
all O
the O
endpoints O
assessed O
. O

The O
therapeutic O
potential O
of O
allosteric O
ligands O
for O
free O
fatty B
acid I
sensitive O
GPCRs O
. O

The O
present O
review O
will O
consider O
the O
advantages O
and O
challenges O
associated O
with O
allosteric O
GPCR O
ligands O
, O
and O
examine O
how O
the O
particular O
properties O
of O
these O
ligands O
may O
be O
exploited O
to O
uncover O
the O
therapeutic O
potential O
for O
free O
fatty B
acid I
sensitive O
GPCRs O
. O

DNA O
polymerases O
replicate O
DNA O
by O
catalyzing O
the O
template O
- O
directed O
polymerization O
of O
deoxynucleoside O
triphosphate O
( O
dNTP B
) O
substrates O
onto O
the O
3 O
' O
end O
of O
a O
growing O
DNA O
primer O
strand O
. O

Many O
DNA O
polymerases O
also O
possess O
a O
separate O
3 O
' O
- O
5 O
' O
exonuclease O
activity O
that O
is O
used O
to O
remove O
misincorporated O
nucleotides B
from O
the O
nascent O
DNA O
( O
proofreading O
) O
. O

Unexpectedly O
, O
a O
mispaired O
primer O
terminus O
accesses O
the O
exo O
site O
more O
frequently O
when O
dNTP B
substrates O
are O
also O
present O
in O
solution O
, O
which O
is O
expected O
to O
enhance O
proofreading O
. O

The O
basic O
generic O
claim O
of O
the O
patent O
covers O
pyrazole B
derivatives O
, O
different O
permutations O
on O
the O
core O
pyrazole B
ring O
are O
covered O
in O
the O
subsidiary O
claims O
. O

Methoxy B
- O
or O
hydroxyl B
- O
containing O
groups O
were O
the O
more O
potent O
indazole B
C4 O
substituents O
. O

N1 O
meta O
- O
substituted O
benzyl B
groups O
possessing O
an O
alpha O
- O
amino O
- O
3 O
- O
[ O
( O
methylamino O
) O
acyl O
] O
- O
group O
were O
the O
most O
potent O
N1 O
- O
substituents O
. O

Strongly O
basic O
amino B
groups O
had O
low O
oral O
absorption O
in O
vivo O
. O

Acute O
arsenic B
treatment O
alters O
cytochrome O
P450 O
expression O
and O
arachidonic B
acid I
metabolism O
in O
lung O
, O
liver O
and O
kidney O
of O
C57Bl O
/ O
6 O
mice O
. O

Abstract O
1 O
. O
Arsenic B
( O
As B
( I
III I
) I
) O
toxicity O
has O
received O
increasing O
attention O
as O
human O
exposure O
to O
arsenic B
is O
associated O
with O
pulmonary O
, O
hepatic O
and O
renal O
toxicities O
. O

Therefore O
, O
in O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
acute O
As B
( I
III I
) I
treatment O
on O
pulmonary O
, O
hepatic O
and O
renal O
cytochrome O
( O
CYP O
) O
P450 O
- O
mediated O
arachidonic B
acid I
metabolism O
. O

2 O
. O
Our O
results O
demonstrated O
that O
acute O
As B
( I
III I
) I
treatment O
( O
12 O
. O
5 O
mg O
/ O
kg O
) O
altered O
CYP O
epoxygenases O
, O
CYP O
omega O
- O
hydroxylases O
and O
EPHX2 O
mRNA O
levels O
that O
were O
isozyme O
and O
tissue O
specific O
. O

3 O
. O
Furthermore O
, O
As B
( I
III I
) I
increased O
the O
formation O
of O
epoxyeicosatrienoic B
acids I
( O
EETs B
) O
in O
the O
kidney O
without O
affecting O
their O
levels O
in O
the O
lung O
or O
liver O
. O

In O
addition O
, O
acute O
As B
( I
III I
) I
treatment O
increased O
dihydroxyeicosatrien O
acid O
( O
DHETs O
) O
formation O
in O
the O
lung O
, O
while O
it O
did O
not O
affect O
liver O
DHETs O
formation O
and O
decreased O
kidney O
DHETs O
formation O
. O

4 O
. O
As B
( I
III I
) I
also O
increased O
total O
epoxygenases O
activity O
in O
the O
lung O
while O
it O
decreased O
its O
levels O
in O
the O
kidney O
and O
had O
no O
effect O
on O
the O
liver O
. O

Furthermore O
, O
As B
( I
III I
) I
increased O
20 O
- O
hydroxyeicosatetraen O
acid O
formation O
in O
the O
liver O
while O
it O
decreased O
its O
formation O
in O
the O
kidney O
. O

5 O
. O
Lastly O
, O
As B
( I
III I
) I
increased O
soluble O
epoxide B
hydrolase O
activity O
in O
the O
lung O
, O
while O
it O
decreased O
its O
levels O
in O
the O
kidney O
and O
had O
no O
effect O
on O
the O
liver O
. O

In O
conclusion O
, O
this O
is O
the O
first O
demonstration O
that O
As B
( I
III I
) I
alters O
arachidonic B
acid I
metabolism O
in O
a O
tissue O
specific O
manner O
. O

Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 B
, O
resulted O
in O
the O
only O
PI3K O
vascular O
- O
targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
, O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O

Injectable O
superparamagnets O
: O
highly O
elastic O
and O
degradable O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
superparamagnetic O
iron B
oxide I
nanoparticle O
( O
SPION O
) O
composite O
hydrogels O
. O

Injectable O
, O
in O
situ O
- O
gelling O
magnetic O
composite O
materials O
have O
been O
fabricated O
by O
using O
aldehyde B
- O
functionalized O
dextran O
to O
cross O
- O
link O
superparamagnetic O
nanoparticles O
surface O
- O
functionalized O
with O
hydrazide O
- O
functionalized O
poly B
( I
N I
- I
isopropylacrylamide I
) I
( O
pNIPAM O
) O
. O

The O
composites O
hydrolytically O
degrade O
via O
slow O
hydrolysis O
of O
the O
hydrazone B
cross O
- O
link O
at O
physiological O
temperature O
and O
pH O
into O
degradation O
products O
that O
show O
no O
significant O
cytotoxicity O
. O

Evidence O
indicates O
that O
cysteine B
protease O
falcipain O
- O
2 O
plays O
essential O
role O
in O
malaria O
parasites O
; O
therefore O
the O
potent O
and O
selective O
inhibitors O
of O
falcipain O
- O
2 O
may O
be O
therapeutically O
useful O
drugs O
for O
treatment O
of O
various O
forms O
of O
malaria O
parasite O
plasmodium O
. O

The O
combination O
of O
docking O
analysis O
and O
MD O
simulation O
shows O
that O
Gly83 O
, O
Trp43 O
and O
Ala175 B
which O
formed O
several O
H B
- O
bonds O
are O
crucial O
for O
falcipain O
- O
2 O
inhibitors O
. O

Since O
two O
of O
the O
presently O
approved O
drugs O
for O
AD O
are O
based O
on O
natural O
products O
( O
galantamine B
and O
the O
physostigmine B
- O
derivative O
rivastigmine B
) O
, O
many O
plants O
are O
now O
under O
investigation O
as O
a O
potential O
source O
of O
new O
drugs O
. O

This O
review O
is O
limited O
to O
plant O
chemicals O
having O
different O
targets O
with O
actual O
( O
galantamine B
) O
or O
promising O
( O
drugs O
from O
Crocus O
sativus O
, O
Ginkgo O
biloba O
, O
Salvia O
species O
, O
and O
Huperzia O
serrata O
) O
clinical O
evidence O
in O
people O
with O
dementia O
or O
AD O
. O

We O
performed O
genome O
- O
wide O
DNA O
methylation O
analysis O
in O
male O
and O
female O
mouse O
primordial O
germ O
cells O
at O
embryonic O
days O
10 O
. O
5 O
, O
13 O
. O
5 O
, O
and O
16 O
. O
5 O
by O
whole O
- O
genome O
shotgun O
bisulfite B
sequencing O
. O

Our O
high O
- O
resolution O
DNA O
methylome O
maps O
demonstrated O
gender O
- O
specific O
differences O
in O
CpG B
methylation O
at O
genome O
- O
wide O
and O
gene O
- O
specific O
levels O
during O
fetal O
germline O
progression O
. O

Following O
global O
demethylation O
and O
sex O
determination O
, O
CpG B
sites O
switched O
to O
de O
novo O
methylation O
in O
males O
, O
but O
the O
X O
- O
linked O
genes O
appeared O
resistant O
to O
the O
wave O
of O
de O
novo O
methylation O
. O

Significant O
differential O
methylation O
at O
a O
subset O
of O
imprinted O
loci O
was O
identified O
in O
both O
genders O
, O
and O
non O
- O
CpG B
methylation O
occurred O
only O
in O
male O
gonocytes O
. O

A O
novel O
fluorogenic O
substrate O
for O
dinuclear O
Zn B
( I
II I
) I
- O
containing O
metallo O
- O
beta O
- O
lactamases O
. O

Saturated B
fatty I
acids I
( O
FA O
) O
were O
grafted O
using O
tyrosine B
as O
a O
spacer O
group O
to O
the O
cyclotriphosphazene O
ring O
along O
with O
equimolar O
hydrophilic O
methoxy O
poly O
( O
ethylene O
glycol O
) O
( O
MPEG B
) O
in O
cis O
- O
nongeminal O
way O
. O

Seven O
new O
cyclotriphosphazene O
amphiphiles O
were O
prepared O
from O
combinations O
of O
hydrophilic O
MPEGs O
with O
different O
molecular O
weights O
of O
350 O
, O
550 O
, O
750 O
and O
1000 O
and O
four O
different O
fatty B
acids I
of O
different O
hydrophobicity O
including O
lauric O
, O
myristic O
, O
palmitic O
and O
stearic O
acids O
. O

These O
steric O
amphiphiles O
bearing O
fatty B
acids I
as O
a O
hydrophobic O
group O
were O
found O
to O
form O
more O
stable O
micelles O
with O
very O
low O
critical O
micelle O
concentrations O
( O
CMC O
) O
( O
2 O
. O
95 O
- O
7 O
. O
80mg O
/ O
L O
) O
compared O
with O
oligopeptide O
analogues O
, O
and O
their O
highly O
hydrophobic O
core O
environment O
is O
unique O
and O
potentially O
useful O
for O
various O
biomedical O
applications O
. O

Electrochemical O
determination O
of O
Sudan O
I O
in O
food O
samples O
at O
graphene B
modified O
glassy O
carbon B
electrode O
based O
on O
the O
enhancement O
effect O
of O
sodium O
dodecyl O
sulphonate O
. O

This O
paper O
describes O
a O
novel O
electrochemical O
method O
for O
the O
determination O
of O
Sudan O
I O
in O
food O
samples O
based O
on O
the O
electrochemical O
catalytic O
activity O
of O
graphene B
modified O
glassy O
carbon B
electrode O
( O
GMGCE O
) O
and O
the O
enhancement O
effect O
of O
an O
anionic O
surfactant O
: O
sodium O
dodecyl O
sulphonate O
( O
SDS B
) O
. O

Using O
pH O
6 O
. O
0 O
phosphate B
buffer O
solution O
( O
PBS O
) O
as O
supporting O
electrolyte O
and O
in O
the O
presence O
of O
1 O
. O
5 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
SDS B
, O
Sudan O
I O
yielded O
a O
well O
- O
defined O
and O
sensitive O
oxidation O
peak O
at O
a O
GMGCE O
. O

The O
oxidation O
peak O
current O
of O
Sudan O
I O
remarkably O
increased O
in O
the O
presence O
of O
SDS B
. O

The O
experimental O
parameters O
, O
such O
as O
supporting O
electrolyte O
, O
concentration O
of O
SDS B
, O
and O
accumulation O
time O
, O
were O
optimised O
for O
Sudan O
I O
determination O
. O

Pterostilbene B
inhibits O
dimethylnitrosamine B
- O
induced O
liver O
fibrosis O
in O
rats O
. O

Pterostilbene B
, O
found O
in O
grapes O
and O
berries O
, O
exhibits O
pleiotropic O
effects O
, O
including O
anti O
- O
inflammatory O
, O
antioxidant O
, O
and O
anti O
- O
proliferative O
activities O
. O

This O
study O
was O
conducted O
to O
investigate O
the O
effect O
of O
pterostilbene B
on O
liver O
fibrosis O
and O
the O
potential O
underlying O
mechanism O
for O
such O
effect O
. O

Sprague O
- O
Dawley O
rats O
were O
intraperitoneally O
given O
dimethyl O
n O
- O
nitrosamine O
( O
DMN B
) O
( O
10mg O
/ O
kg O
) O
3 O
days O
per O
week O
for O
4 O
weeks O
. O

Pterostilbene B
( O
10 O
or O
20mg O
/ O
kg O
) O
was O
administered O
by O
oral O
gavage O
daily O
. O

Pterostilbene B
supplementation O
alleviated O
the O
DMN B
- O
induced O
changes O
in O
the O
serum O
levels O
of O
alanine O
transaminase O
and O
aspartate O
transaminase O
( O
p O
< O
0 O
. O
05 O
) O
. O

Fibrotic O
status O
and O
the O
activation O
of O
hepatic O
stellate O
cells O
were O
improved O
upon O
pterostilbene B
supplementation O
as O
evidenced O
by O
histopathological O
examination O
as O
well O
as O
the O
expression O
of O
alpha O
- O
smooth O
muscle O
actin O
( O
alpha O
- O
SMA O
) O
, O
transforming O
growth O
factor O
- O
beta O
1 O
( O
TGF O
- O
beta O
1 O
) O
, O
and O
matrix O
metalloproteinase O
2 O
( O
MMP2 O
) O
. O

These O
data O
demonstrated O
that O
pterostilbene B
exhibited O
hepatoprotective O
effects O
on O
experimental O
fibrosis O
, O
potentially O
by O
inhibiting O
the O
TGF O
- O
beta O
1 O
/ O
Smad O
signaling O
. O

Kale O
( O
Brassica O
oleracea O
var O
. O
sabellica O
) O
reveals O
a O
great O
diversity O
of O
flavonoids B
, O
which O
have O
been O
shown O
to O
be O
good O
antioxidants O
. O

As O
Brassica O
vegetables O
are O
mainly O
consumed O
cooked O
, O
the O
influence O
of O
boiling O
on O
kale O
' O
s O
flavonoids B
and O
their O
antioxidant O
activity O
was O
investigated O
. O

Using O
the O
HPLC O
- O
UV O
/ O
Vis O
- O
online O
- O
TEAC O
approach O
, O
distinct O
changes O
in O
composition O
and O
antioxidant O
activity O
of O
the O
flavonoids B
were O
detectable O
. O

Dispersive O
liquid O
- O
liquid O
microextraction O
combined O
with O
field O
- O
amplified O
sample O
stacking O
in O
capillary O
electrophoresis O
for O
the O
determination O
of O
non O
- O
steroidal B
anti O
- O
inflammatory O
drugs O
in O
milk O
and O
dairy O
products O
. O

Dispersive O
liquid O
- O
liquid O
microextraction O
( O
DLLME O
) O
was O
coupled O
with O
field O
- O
amplified O
sample O
stacking O
in O
capillary O
electrophoresis O
( O
FASS O
) O
for O
the O
determination O
of O
five O
non O
- O
steroidal B
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
in O
bovine O
milk O
and O
dairy O
products O
. O

Antioxidant O
activities O
of O
the O
synthesized O
thiol B
- O
contained O
peptides O
derived O
from O
computer O
- O
aided O
pepsin O
hydrolysis O
of O
yam O
tuber O
storage O
protein O
, O
dioscorin O
. O

In O
this O
study O
, O
the O
thiol B
- O
containing O
peptides O
derived O
from O
computer O
- O
aided O
simulation O
of O
pepsin O
hydrolysis O
of O
dioscorin O
, O
namely O
, O
KTCGNGME O
( O
diotide1 O
) O
, O
PPCSE O
( O
diotide2 O
) O
, O
CDDRVIRTPLT O
( O
diotide3 O
) O
, O
KTCGY O
( O
diotide4 O
) O
, O
and O
PPCTE O
( O
diotide5 O
) O
were O
synthesized O
to O
compare O
their O
antioxidant O
activities O
with O
GSH B
and O
/ O
or O
carnosine B
by O
examining O
hydroxyl B
radical O
scavenging O
activity O
by O
electron O
spin O
resonance O

spectrometry O
, O
anti O
- O
low O
- O
density O
lipoprotein O
peroxidation O
, O
anti O
- O
AAPH B
- O
induced O
hemolysis O
, O
and O
oxygen B
radical O
absorbance O
capacity O
activity O
. O

Moreover O
, O
all O
diotides O
( O
100 O
mu O
M O
) O
showed O
protective O
effects O
against O
methylglyoxal B
- O
induced O
human O
umbilical O
vein O
endothelial O
cell O
death O
. O

These O
results O
suggest O
that O
thiol B
- O
containing O
diotides O
derived O
from O
dioscorin O
hydrolysis O
exhibit O
antioxidant O
activities O
and O
reveal O
the O
benefits O
of O
yam O
tuber O
as O
an O
antioxidant O
- O
rich O
food O
. O

The O
flavone B
, O
tricin O
( O
5 O
, O
7 O
, O
4 O
' O
- O
trihydroxy O
- O
3 O
' O
, O
5 O
' O
- O
dimethoxyflavone O
) O
has O
great O
potential O
as O
an O
anticancer O
agent O
, O
due O
to O
its O
specific O
chemopreventive O
activity O
. O

In O
general O
, O
C6 B
compounds O
, O
alcohols B
, O
terpenes B
, O
phenols B
and O
C13 O
- O
norisoprenoids O
in O
Syrah O
showed O
a O
decrease O
and O
in O
Chardonnay O
an O
increase O
. O

1H B
NMR O
- O
based O
metabolic O
fingerprinting O
of O
urine O
metabolites O
after O
consumption O
of O
lingonberries O
( O
Vaccinium O
vitis O
- O
idaea O
) O
with O
a O
high O
- O
fat O
meal O
. O

Urine O
samples O
were O
analysed O
by O
( B
1 I
) I
H I
NMR O
, O
and O
untargeted O
multivariate O
analysis O
was O
applied O
to O
the O
data O
for O
comprehensive O
fingerprinting O
. O

Significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
levels O
of O
polyphenol B
metabolites O
, O
hippuric O
acid O
and O
4 O
- O
hydroxyhippuric O
acid O
, O
and O
decreased O
creatinine B
and O
dimethylamine B
levels O
were O
the O
major O
explanations O
for O
the O
grouping O
of O
the O
postprandial O
samples O
after O
the O
different O
meals O
. O

Thus O
, O
inclusion O
of O
polyphenol B
- O
rich O
lingonberry O
powder O
in O
a O
rapeseed O
oil O
- O
rich O
meal O
modifies O
the O
metabolic O
profile O
of O
urine O
which O
may O
be O
used O
to O
reveal O
both O
consumption O
of O
berries O
and O
health O
- O
promoting O
changes O
in O
the O
common O
metabolism O
. O

A O
simple O
and O
sensitive O
spectrophotometric O
method O
to O
the O
simultaneous O
determination O
of O
Mn B
( I
2 I
+ I
) I
and O
Fe B
( I
3 I
+ I
) I
in O
foods O
, O
vegetable O
and O
water O
sample O
with O
the O
aid O
of O
artificial O
neural O
networks O
( O
ANNs O
) O
is O
described O
. O

The O
analytical O
data O
show O
that O
the O
ratio O
of O
ligand O
to O
metal O
in O
metal O
complexes O
is O
1 O
: O
1 O
and O
1 O
: O
2 O
for O
Fe B
( I
3 I
+ I
) I
and O
Mn B
( I
2 I
+ I
) I
, O
respectively O
. O

The O
results O
showed O
that O
Mn B
( I
2 I
+ I
) I
and O
Fe B
( I
3 I
+ I
) I
could O
be O
determined O
simultaneously O
in O
the O
range O
of O
0 O
. O
20 O
- O
7 O
. O
5 O
and O
0 O
. O
30 O
- O
9 O
. O
0 O
mgl O
( O
- O
1 O
) O
, O
respectively O
. O

Regarding O
the O
effect O
of O
ion O
exchange O
on O
organoleptic O
characteristics O
and O
the O
quality O
of O
the O
obtained O
wines O
, O
a O
slight O
decrease O
in O
both O
anthocyanin B
and O
tannin O
contents O
was O
observed O
along O
with O
a O
small O
drop O
in O
the O
aromatic O
content O
. O

Multidisciplinary O
analytical O
investigation O
of O
phospholipids O
and O
triglycerides B
in O
offshore O
farmed O
gilthead O
sea O
bream O
( O
Sparus O
aurata O
) O
fed O
commercial O
diets O
. O

In O
this O
work O
, O
a O
quantitative O
characterisation O
of O
lipid O
( O
both O
triglycerides B
and O
phospholipids O
) O
rearrangements O
in O
the O
muscle O
of O
offshore O
- O
raised O
gilthead O
sea O
bream O
was O
carried O
out O
as O
a O
function O
of O
fish O
growth O
between O
April O
and O
September O
. O

Relative O
percentages O
of O
lipid O
classes O
and O
fatty B
acids I
/ O
acyls O
composition O
of O
the O
commercial O
feeds O
and O
fish O
dorsal O
muscles O
were O
assessed O
by O
means O
of O
an O
interdisciplinary O
analytical O
approach O
. O

While O
defined O
effects O
of O
feed O
composition O
on O
fatty B
acid I
profiles O
of O
fillets O
were O
ascertained O
, O
the O
relative O
increase O
of O
fatty O
acyls O
in O
triglycerides B
and O
phospholipids O
were O
also O
estimated O
enabling O
detailed O
evaluation O
of O
TAG O
: O
PL O
ratio O
in O
adult O
offshore O
- O
farmed O
gilthead O
sea O
bream O
. O

NMR O
was O
also O
used O
to O
quantify O
PUFA B
regiospecific O
distribution O
in O
TAG B
and O
PL O
. O

GTase O
can O
act O
on O
sucrose B
and O
catalyze O
trehalulose O
formation O
without O
isomaltose O
, O
isomaltulose O
, O
or O
isomelezitose O
, O
releasing O
small O
amounts O
of O
glucose B
and O
fructose B
as O
byproducts O
. O

In O
the O
first O
step O
, O
GTase O
catalyzed O
trehalulose O
formation O
using O
a O
20 O
% O
sucrose B
substrate O
. O

Miscellaneous O
sugars B
were O
then O
rapidly O
removed O
, O
while O
trehalulose O
was O
completely O
preserved O
by O
Saccharomyces O
cerevisiae O
cells O
. O

Ascorbic B
acid I
and O
chlorogenic B
acid I
contents O
were O
determined O
by O
HPLC O
- O
DAD O
, O
total O
anthocyanin B
content O
by O
pH O
- O
differential O
spectrophotometry O
, O
glycoalkaloid O
, O
alpha O
- O
chaconine O
and O
alpha O
- O
solanine O
contents O
by O
HPLC O
- O
ESI O
/ O
MS O
/ O
MS O
. O

All O
cooking O
treatments O
reduced O
ascorbic O
and O
chlorogenic B
acid I
contents O
, O
total O
glycoalkaloids O
, O
alpha O
- O
chaconine O
and O
alpha O
- O
solanine O
with O
the O
exception O
of O
total O
anthocyanins B
. O

The O
losses O
of O
ascorbic O
and O
chlorogenic O
acids O
were O
minimised O
with O
boiling O
and O
total O
anthocyanin B
levels O
retained O
the O
highest O
. O

Moreover O
, O
due O
to O
higher O
initial O
levels O
, O
red O
- O
and O
purple O
- O
fleshed O
cultivars O
retained O
higher O
amounts O
of O
antioxidants O
( O
ascorbic B
acid I
, O
chlorogenic B
acid I
and O
total O
anthocyanin B
) O
after O
boiling O
and O
may O
be O
healthier O
as O
compared O
with O
white O
or O
yellow O
cultivars O
. O

The O
rice O
samples O
were O
initially O
extracted O
with O
acetonitrile B
( O
MeCN O
) O
, O
and O
the O
targeted O
pesticides O
were O
purified O
following O
the O
dispersive O
solid O
phase O
extraction O
( O
d O
- O
SPE O
) O
cleanup O
method O
and O
detected O
by O
gas O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
GC O
- O
MS O
/ O
MS O
) O
. O

The O
efficiency O
of O
citrate B
- O
buffered O
and O
unbuffered O
method O
in O
liquid O
extraction O
procedure O
was O
compared O
; O
the O
amount O
of O
primary B
secondary I
amine I
( O
PSA O
) O
was O
optimised O
. O

Antioxidant O
activity O
of O
phytosteryl B
phenolates I
in O
different O
model O
systems O
. O

As O
part O
of O
a O
comprehensive O
study O
of O
the O
physiochemical O
and O
biological O
properties O
of O
phytosteryl B
phenolates I
, O
successfully O
synthesized O
chemoenzymatically O
in O
our O
lab O
, O
their O
antioxidant O
activity O
was O
evaluated O
using O
three O
different O
in O
vitro O
model O
systems O
, O
namely O
bulk O
oil O
model O
system O
, O
beta B
- I
carotene I
- O
linoleate O
model O
system O
and O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
oxidation O
assay O
. O

In O
the O
bulk O
oil O
system O
, O
phytosteryl B
phenolates I
showed O
similar O
or O
lower O
antioxidant O
activity O
compared O
with O
those O
of O
phenolic B
acids I
. O

However O
, O
in O
beta B
- I
carotene I
- O
linoleate O
assay O
, O
an O
emulsion O
model O
system O
, O
phytosteryl B
phenolates I
showed O
enhanced O
antioxidant O
activity O
except O
phytosteryl O
ferulates O
. O

Moderate O
inhibitory O
effect O
of O
LDL O
- O
C O
oxidation O
by O
phytosteryl B
phenolates I
was O
observed O
. O

These O
findings O
demonstrate O
that O
use O
of O
multidimensional O
antioxidant O
activity O
determinations O
with O
differing O
reaction O
mechanisms O
is O
necessary O
to O
provide O
an O
overall O
understanding O
of O
the O
mechanisms O
of O
antioxidant O
action O
of O
phytosteryl B
phenolates I
. O

The O
method O
is O
based O
on O
the O
catalytic O
effect O
of O
silver B
nanoparticle O
( O
AgNPs O
) O
on O
the O
oxidation O
reaction O
of O
tartrazine O
by O
potassium O
iodate O
in O
the O
acetate B
buffer O
medium O
. O

Root O
tubers O
of O
Lactuca O
tuberosa O
as O
a O
source O
of O
antioxidant O
phenolic B
compounds O
and O
new O
furofuran O
lignans O
. O

From O
the O
root O
tubers O
of O
Lactuca O
tuberosa O
, O
a O
wild O
edible O
plant O
species O
, O
nine O
phenolic B
compounds O
were O
isolated O
, O
including O
two O
new O
furofuran O
lignan O
glucosides O
, O
named O
lactuberin O
A O
and O
lactuberin O
B O
. O

The O
total O
phenolic O
content O
of O
the O
root O
tuber O
extract O
was O
evaluated O
and O
its O
major O
phenolic B
constituents O
, O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
3 B
, I
5 I
dicaffeoylquinic I
acid I
, O
known O
to O
possess O
antioxidant O
activity O
, O
were O
quantified O
. O

Additionally O
, O
the O
root O
tuber O
extract O
showed O
DPPH B
radical O
scavenging O
activity O
implying O
its O
potential O
as O
functional O
food O
. O

Compositional O
characterisation O
of O
soluble O
apple O
polysaccharides O
, O
and O
their O
antioxidant O
and O
hepatoprotective O
effects O
on O
acute O
CCl4 B
- O
caused O
liver O
damage O
in O
mice O
. O

Water O
- O
soluble O
apple O
peel O
polysaccharides O
( O
APP O
) O
and O
apple O
flesh O
polysaccharides O
( O
AFP O
) O
were O
isolated O
from O
Pink O
Lady O
fruits O
, O
and O
their O
in O
vitro O
antioxidant O
capacities O
were O
characterised O
by O
DPPH B
( O
) O
, O
HO O
( O
) O
, O
and O
O B
( I
2 I
) I
( I
- I
) I
systems O
, O
and O
ferric B
- O
reducing O
antioxidant O
power O
assay O
. O

Oral O
administration O
of O
APP O
at O
250 O
and O
500 O
mg O
/ O
kg O
bw O
in O
mice O
was O
shown O
to O
be O
as O
effective O
as O
AFP O
in O
lowering O
the O
CCl B
( I
4 I
) I
- O
caused O
increases O
of O
serum O
alanine B
aminotransferase O
, O
aspartate B
aminotransferase O
and O
lactic O
dehydrogenase O
activities O
, O
and O
hepatic O
malondialdehyde B
level O
, O
and O
antagonising O
the O
decreases O
in O
antioxidant O
superoxide B
dismutase O
and O
glutathione B
peroxidase O
activities O
caused O
by O
CCl B
( I
4 I
) I
( O
p O
< O
0 O
. O
05 O
) O
. O

Histopathological O
examinations O
further O
confirmed O
that O
both O
APP O
and O
AFP O
could O
protect O
the O
liver O
from O
CCl B
( I
4 I
) I
- O
induced O
histological O
alteration O
. O

HPLC O
analysis O
also O
showed O
similar O
profiles O
of O
monosaccharide O
composition O
for O
APP O
and O
AFP O
with O
arabinose B
, O
galactose B
and O
galacturonic B
acid I
being O
main O
component O
monosaccharides O
. O

Modelling O
the O
interactions O
between O
free O
phenols B
, O
L B
- I
ascorbic I
acid I
, O
apple O
polyphenoloxidase O
and O
oxygen B
during O
a O
thermal O
treatment O
. O

The O
kinetics O
of O
degradation O
of O
chlorogenic B
acid I
( O
CG O
) O
, O
( B
- I
) I
epicatechin I
( O
EPI O
) O
, O
L B
- I
ascorbic I
acid I
( O
AA O
) O
and O
polyphenoloxidase O
( O
PPO O
) O
activity O
from O
Marie O
- O
M O
e O
nard O
apple O
in O
pH O
3 O
. O
8 O
solutions O
at O
20 O
and O
50 O
degrees O
C O
were O
investigated O
to O
provide O
information O
on O
the O
impact O
of O
the O
presence O
of O
CG O
, O
EPI O
and O
/ O
or O
AA O
on O
PPO O
thermostability O
. O

Losses O
of O
PPO O
activity O
were O
favoured O
by O
the O
presence O
of O
EPI O
in O
model O
solutions O
, O
compared O
with O
CG O
, O
due O
to O
the O
formation O
of O
o B
- I
quinones I
of O
EPI O
( O
QEPI O
) O
lowering O
PPO O
stability O
. O

Temperature O
quickened O
both O
enzymatic O
phenol B
oxidations O
before O
PPO O
deteriorated O
and O
the O
whole O
set O
of O
the O
chemical O
reactions O
, O
including O
the O
production O
of O
secondary O
oxidation O
products O
and O
CG O
or O
EPI O
regeneration O
. O

Results O
also O
confirmed O
that O
AA O
in O
excess O
induced O
a O
fast O
regeneration O
of O
CG O
and O
EPI O
from O
the O
corresponding O
o B
- I
quinones I
formed O
enzymatically O
via O
redox O
chemical O
reactions O
. O

The O
antioxidant O
activities O
correlated O
positively O
to O
the O
total O
polyphenols B
content O
, O
which O
was O
higher O
in O
the O
ethanolic O
extract O
( O
81 O
. O
6 O
mg O
GAE O
/ O
g O
DW O
) O
compared O
to O
the O
water O
extract O
( O
46 O
. O
3mg O
GAE O
/ O
g O
DW O
) O
, O
suggesting O
polyphenols B
play O
an O
important O
role O
. O

Quantitative O
data O
from O
UHPLC O
and O
qualitative O
studies O
using O
HPLC O
- O
DAD O
- O
MS O
showed O
that O
in O
addition O
to O
commonly O
found O
phenolic B
acids I
, O
flavonoids B
and O
anthocyanins B
, O
R O
. O
hirta O
fruit O
contained O
a O
novel O
group O
of O
unique O
anthocyanins B
with O
aglycones O
( O
anthocyanidins B
) O
at O
449 O
, O
419 O
and O
433 O
Da O
. O

Relationships O
between O
the O
evolution O
of O
the O
percentage O
in O
weight O
of O
polar O
compounds O
and O
that O
of O
the O
molar O
percentage O
of O
acyl B
groups O
of O
edible O
oils O
submitted O
to O
frying O
temperature O
. O

The O
evolution O
of O
the O
molar O
percentage O
of O
several O
kinds O
of O
acyl B
groups O
of O
extra O
virgin O
olive O
, O
sunflower O
and O
virgin O
linseed O
oils O
was O
monitored O
throughout O
heating O
at O
frying O
temperature O
by O
means O
of O
( B
1 I
) I
H I
nuclear O
magnetic O
resonance O
. O

An O
equation O
which O
is O
able O
to O
accurately O
predict O
the O
percentage O
in O
weight O
of O
the O
polar O
compounds O
, O
throughout O
the O
heating O
at O
frying O
temperature O
, O
of O
any O
one O
of O
these O
three O
oils O
, O
from O
the O
molar O
percentage O
of O
triunsaturated O
, O
diunsaturated O
and O
monounsaturated O
acyl B
groups O
, O
was O
obtained O
. O

In O
this O
way O
both O
molar O
percentage O
of O
acyl B
groups O
and O
percentage O
in O
weight O
of O
polar O
compounds O
can O
be O
obtained O
in O
a O
few O
minutes O
that O
registration O
of O
the O
( B
1 I
) I
H I
NMR O
spectrum O
of O
the O
oil O
takes O
, O
in O
addition O
to O
the O
rest O
of O
information O
provided O
by O
this O
technique O
. O

The O
study O
reveals O
the O
close O
relationships O
between O
percentage O
in O
weight O
of O
polar O
compounds O
and O
the O
composition O
expressed O
in O
terms O
of O
molar O
percentages O
of O
acyl B
groups O
in O
edible O
oils O
heated O
at O
frying O
temperature O
. O

The O
chromogenic O
array O
used O
eight O
sensing O
materials O
( O
based O
on O
aluminium B
oxide I
and O
silica B
gel I
) O
containing O
pH O
indicators O
, O
Lewis O
acids O
and O
an O
oxidation O
- O
reduction O
indicator O
. O

Determination O
of O
moisture O
content O
, O
pH O
, O
total O
volatile O
basic O
nitrogen B
( O
TVB O
- O
N B
) O
, O
drip O
loss O
, O
ATP B
- O
related O
compounds O
and O
K O
( O
1 O
) O
- O
value O
and O
microbial O
( O
mesophilic O
bacteria O
and O
Enterobacteriaceae O
) O
analyses O
were O
carried O
out O
on O
the O
same O
days O
. O

A O
water O
- O
alcohol B
extract O
of O
Citrus O
grandis O
whole O
fruits O
has O
beneficial O
metabolic O
effects O
in O
the O
obese O
Zucker O
rats O
fed O
with O
high O
fat O
/ O
high O
cholesterol B
diet O
. O

Epidemiological O
studies O
suggest O
that O
citrus O
fruits O
and O
compounds O
such O
as O
flavonoids B
, O
limonoids O
and O
pectins O
have O
health O
promoting O
effects O
. O

A O
whole O
fruit O
powder O
from O
dry O
water O
and O
alcohol B
extracts O
of O
C O
. O
grandis O
containing O
19 O
% O
naringin B
flavonoid O
was O
prepared O
. O

The O
cholesterol B
and O
glucose B
levels O
were O
somewhat O
but O
not O
systematically O
improved O
in O
the O
HFD O
fed O
rats O
. O

After O
baking O
the O
total O
flavonoid B
content O
was O
lowered O
and O
ranged O
from O
308 O
to O
389 O
mu O
g O
CE O
/ O
g O
. O

Piceatannol O
, O
a O
potent O
bioactive O
stilbene B
, O
as O
major O
phenolic B
component O
in O
Rhodomyrtus O
tomentosa O
. O

Using O
HPLC O
- O
ESI O
- O
HR O
- O
MS O
, O
19 O
phenolic B
compounds O
( O
PCs O
) O
were O
tentatively O
characterised O
and O
included O
stilbenes B
and O
ellagitannins O
as O
major O
components O
, O
followed O
by O
anthocyanins B
, O
flavonols B
, O
and O
gallic B
acid I
. O

Piceatannol O
, O
a O
promising O
health O
- O
promoting O
stilbene B
component O
, O
was O
the O
major O
PC O
in O
the O
fruit O
with O
a O
concentration O
of O
2 O
. O
3mg O
/ O
g O
dry O
weight O
at O
full O
maturity O
stage O
. O

This O
concentration O
is O
1000 O
- O
2000 O
times O
higher O
than O
that O
of O
red O
grapes O
, O
a O
major O
source O
of O
stilbene B
in O
the O
human O
diet O
. O

During O
maturation O
, O
the O
contents O
in O
piceatannol O
and O
other O
stilbenes B
, O
ellagitannins O
, O
and O
flavonols B
decreased O
while O
the O
anthocyanin B
content O
increased O
. O

The O
hypocholesterolemic O
and O
antioxidant O
activities O
of O
various O
extracts O
( O
water O
, O
methanol B
, O
ethyl B
acetate I
, O
hexane B
, O
dichloro O
- O
methane O
) O
of O
fenugreek O
seeds O
were O
investigated O
in O
cholesterol B
- O
fed O
rats O
. O

Only O
the O
ethyl B
acetate I
extract O
reduced O
total O
cholesterol B
, O
triglycerides B
, O
and O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
and O
increased O
high O
- O
density O
lipoprotein O
cholesterol B
( O
HDL O
- O
C O
) O
compared O
with O
those O
of O
rats O
fed O
a O
cholesterol B
- O
rich O
diet O
( O
HCD O
) O
. O

Furthermore O
, O
the O
content O
of O
thiobarbituric B
acid I
- O
reactive O
substances O
( O
TBARS O
) O
, O
and O
catalase O
and O
superoxide B
dismutase O
( O
SOD O
) O
in O
liver O
, O
heart O
and O
kidney O
decreased O
significantly O
after O
oral O
administration O
of O
the O
ethyl B
acetate I
extract O
, O
compared O
with O
those O
of O
HCD O
- O
fed O
rats O
. O

The O
phenolic B
and O
flavono O
i O
d O
contents O
were O
highest O
in O
the O
methanol B
and O
the O
ethyl B
acetate I
extracts O
. O

These O
results O
showed O
that O
the O
ethyl B
acetate I
extract O
of O
the O
fenugreek O
seeds O
had O
a O
significant O
hypocholesterolemic O
effect O
and O
antioxidant O
activity O
in O
cholesterol B
- O
fed O
rats O
, O
whether O
this O
is O
partly O
due O
to O
the O
presence O
of O
flavono O
i O
ds O
in O
the O
extract O
needs O
further O
study O
. O

The O
antioxidant O
assays O
showed O
that O
BIWS O
- O
4b O
exhibited O
good O
activities O
, O
including O
free O
radicals O
scavenging O
effects O
, O
ferrous B
ion O
- O
chelating O
ability O
and O
reducing O
power O
. O

Effects O
of O
different O
freezing O
treatments O
on O
the O
biogenic O
amine B
and O
quality O
changes O
of O
bighead O
carp O
( O
Aristichthys O
nobilis O
) O
heads O
during O
ice O
storage O
. O

The O
effects O
of O
different O
freezing O
treatments O
on O
the O
quality O
changes O
of O
bighead O
carp O
heads O
were O
evaluated O
in O
terms O
of O
pH O
value O
, O
TBARS O
, O
TVB O
- O
N O
, O
K O
- O
value O
, O
biogenic O
amine B
, O
total O
aerobic O
counts O
( O
TACs O
) O
, O
drip O
loss O
, O
cooking O
loss O
and O
electrical O
conductivity O
( O
EC O
) O
during O
ice O
storage O
. O

Significant O
lower O
value O
of O
spermine B
and O
spermidine B
were O
observed O
in O
T1 O
, O
T2 O
and O
T3 O
than O
those O
of O
control O
group O
( O
fresh O
) O
from O
9th O
to O
18th O
day O
( O
p O
< O
0 O
. O
05 O
) O
. O

Isomerisation O
of O
carrot O
beta B
- I
carotene I
in O
presence O
of O
oil O
during O
thermal O
and O
combined O
thermal O
/ O
high O
pressure O
processing O
. O

The O
effect O
of O
thermal O
processing O
( O
85 O
- O
130 O
degrees O
C O
) O
and O
combined O
thermal O
/ O
high O
pressure O
processing O
( O
100 O
degrees O
C O
combined O
with O
0 O
. O
1 O
to O
700 O
MPa O
and O
700 O
MPa O
combined O
with O
85 O
- O
115 O
degrees O
C O
) O
on O
beta B
- I
carotene I
isomerisation O
in O
an O
olive O
oil O
/ O
carrot O
emulsion O
and O
pure O
olive O
oil O
phase O
enriched O
with O
carrot O
beta B
- I
carotene I
was O
investigated O
. O

In O
the O
oil O
/ O
carrot O
emulsion O
, O
less O
beta B
- I
carotene I
isomerisation O
was O
observed O
during O
combined O
thermal O
/ O
high O
pressure O
processing O
compared O
to O
thermal O
processing O
. O

This O
effect O
was O
attributed O
to O
strengthening O
of O
the O
carrot O
cell O
walls O
under O
high O
pressure O
, O
thereby O
hindering O
the O
transfer O
of O
beta B
- I
carotene I
to O
the O
oil O
phase O
and O
lowering O
its O
susceptibility O
to O
isomerisation O
. O

In O
an O
oil O
phase O
enriched O
with O
beta B
- I
carotene I
, O
beta B
- I
carotene I
isomerisation O
was O
not O
influenced O
by O
the O
applied O
pressure O
at O
100 O
degrees O
C O
and O
became O
almost O
temperature O
insensitive O
at O
700 O
MPa O
. O

Inhibitory O
activity O
of O
Filipendula O
ulmaria O
constituents O
on O
recombinant O
human O
histidine B
decarboxylase O
. O

Histidine B
decarboxylase O
( O
HDC O
) O
catalyses O
the O
formation O
of O
histamine B
, O
a O
bioactive O
amine B
. O

Agents O
that O
control O
HDC O
activity O
are O
beneficial O
for O
treating O
histamine B
- O
mediated O
symptoms O
, O
such O
as O
allergies O
and O
stomach O
ulceration O
. O

We O
searched O
for O
inhibitors O
of O
HDC O
from O
the O
ethyl B
acetate I
extract O
of O
the O
petal O
of O
Filipendula O
ulmaria O
, O
also O
called O
meadowsweet O
. O

Total O
phenolics B
, O
radical O
scavenging O
activity O
( O
RSA O
) O
on O
DPPH B
, O
ascorbic B
acid I
content O
and O
chelating O
activity O
on O
Fe B
( I
2 I
+ I
) I
of O
Pleurotus O
citrinopileatus O
, O
Pleurotus O
djamor O
, O
Pleurotus O
eryngii O
, O
Pleurotus O
flabellatus O
, O
Pleurotus O
florida O
, O
Pleurotus O
ostreatus O
, O
Pleurotus O
sajor O
- O
caju O
and O
Hypsizygus O
ulmarius O
have O
been O
evaluated O
. O

The O
assayed O
mushrooms O
contained O
3 O
. O
94 O
- O
21 O
. O
67 O
mg O
TAE O
of O
phenolics B
, O
13 O
. O
63 O
- O
69 O
. O
67 O
% O
DPPH B
scavenging O
activity O
, O
3 O
. O
76 O
- O
6 O
. O
76 O
mg O
ascorbic B
acid I
and O
60 O
. O
25 O
- O
82 O
. O
7 O
% O
chelating O
activity O
. O

Principal O
Component O
Analysis O
( O
PCA O
) O
revealed O
that O
significantly O
higher O
total O
phenolics B
, O
RSA O
on O
DPPH B
and O
growth O
/ O
day O
was O
present O
in O
P O
. O
eryngii O
whereas O
P O
. O
citrinopileatus O
showed O
higher O
ascorbic B
acid I
and O
chelating O
activity O
. O

Interaction O
between O
lysozyme O
and O
procyanidin B
: O
multilevel O
structural O
nature O
and O
effect O
of O
carbohydrates B
. O

The O
interaction O
of O
procyanidins B
with O
proteins O
has O
aroused O
extensive O
attention O
due O
to O
its O
important O
relationship O
with O
the O
bioavailability O
and O
astringent O
property O
of O
polyphenols B
. O

In O
the O
present O
work O
, O
we O
have O
investigated O
the O
interactions O
of O
lysozyme O
with O
procyanidin B
dimer O
( O
B3 O
) O
using O
various O
biophysical O
approaches O
, O
which O
aims O
to O
provide O
insights O
into O
the O
mechanism O
of O
protein O
/ O
polyphenol B
aggregation O
. O

The O
influences O
of O
two O
carbohydrates B
( O
gum O
arabic O
and O
sucrose B
) O
on O
lysozyme O
/ O
B3 O
aggregation O
were O
also O
studied O
. O

These O
results O
proposed O
two O
probable O
mechanisms O
by O
which O
these O
two O
carbohydrates B
inhibit O
protein O
/ O
polyphenol B
aggregation O
. O

The O
levels O
of O
disulphide B
- O
linked O
whey O
proteins O
were O
higher O
in O
SM O
- O
ME O
than O
in O
SM O
. O

This O
suggested O
that O
there O
may O
be O
higher O
levels O
of O
initiators O
for O
thiol B
- O
disulphide B
exchange O
reactions O
, O
resulting O
in O
an O
increase O
in O
the O
rate O
of O
the O
reactions O
and O
the O
formation O
of O
greater O
numbers O
of O
small O
aggregates O
, O
in O
SM O
- O
ME O
than O
in O
SM O
. O

A O
novel O
colloidal O
gold O
- O
based O
lateral O
flow O
immunoassay O
for O
rapid O
simultaneous O
detection O
of O
cyromazine O
and O
melamine B
in O
foods O
of O
animal O
origin O
. O

A O
rapid O
and O
sensitive O
lateral O
flow O
immunoassay O
( O
LFIA O
) O
based O
on O
competitive O
format O
was O
developed O
and O
validated O
for O
simultaneous O
detection O
of O
cyromazine O
( O
CA O
) O
and O
melamine B
( O
MA O
) O
in O
foods O
of O
animal O
origin O
. O

Total O
amino B
acid I
profiles O
of O
heat O
- O
processed O
fresh O
Elaeis O
guineensis O
and O
Raphia O
hookeri O
wines O
. O

Total O
amino B
acid I
( O
AA O
) O
profiles O
of O
heat O
- O
processed O
fresh O
Elaeis O
guineensis O
and O
Raphia O
hookeri O
wines O
were O
studied O
. O

Heating O
their O
fresh O
wines O
to O
85 O
degrees O
C O
, O
cooling O
and O
diluting O
to O
original O
volumes O
distilled O
off O
ethanol B
, O
but O
did O
not O
change O
their O
moisture O
and O
nitrogen B
contents O
. O

R O
. O
hookeri O
wine O
contained O
more O
( O
p O
< O
0 O
. O
05 O
) O
Phe B
, O
Val B
, O
Ala B
, O
Gly B
, O
Pro B
, O
Asp B
, O
Asn B
, O
His B
and O
Lys B
than O
E O
. O
guineensis O
wine O
which O
contained O
more O
( O
p O
< O
0 O
. O
05 O
) O
Met B
, O
Cys B
, O
Glu B
, O
Gln B
, O
Ser B
and O
Arg O
. O

Tyrosine B
, O
Leu B
, O
Ile B
and O
Thr B
contents O
did O
not O
vary O
( O
p O
> O
0 O
. O
05 O
) O
. O

Glycine B
and O
Pro B
contents O
were O
low O
suggesting O
high O
globular O
protein O
concentrations O
. O

Essential O
AA O
scores O
suggested O
Leu B
as O
their O
limiting O
AA O
. O

In O
conclusion O
, O
the O
wines O
can O
adequately O
meet O
daily O
nitrogen B
and O
essential O
AA O
needs O
when O
a O
70 O
kg O
adult O
drinks O
1425 O
. O
45 O
ml O
. O

OS O
contained O
mastication O
- O
extractable O
quercetin B
( O
4 O
. O
6 O
mg O
/ O
g O
) O
. O

Quercetin B
from O
OS O
was O
highly O
bioaccessible O
during O
in O
vitro O
conditions O
, O
but O
only O
approximately O
4 O
% O
of O
quercetin B
released O
during O
simulated O
digestion O
was O
bioavailable O
in O
vitro O
. O

Determination O
of O
total O
iron B
in O
food O
samples O
after O
flow O
injection O
preconcentration O
on O
polyurethane B
foam O
functionalized O
with O
N O
, O
N O
- O
bis O
( O
salicylidene O
) O
- O
1 O
, O
3 O
- O
propanediamine O
. O

A O
highly O
selective O
flow O
injection O
sorption O
system O
was O
developed O
for O
the O
fast O
determination O
of O
total O
iron B
in O
food O
samples O
. O

Iron O
( O
III O
) O
was O
reduced O
to O
iron B
( I
II I
) I
by O
ascorbic B
acid I
and O
preconcentrated O
on O
a O
mini O
- O
column O
packed O
with O
polyurethane B
foam O
( O
PUF O
) O
functionalized O
with O
N O
, O
N O
- O
bis O
( O
salicylidene O
) O
- O
1 O
, O
3 O
- O
propanediamine O
( O
SPDA O
) O
. O

The O
retained O
Fe B
( I
II I
) I
was O
eluted O
with O
hydrochloric O
acid O
and O
subsequently O
reacted O
to O
2 O
, O
4 O
, O
6 O
- O
tri O
( O
2 O
' O
- O
pyridyl O
) O
- O
1 O
, O
3 O
, O
5 O
- O
triazine O
( O
TPTZ O
) O
then O
measured O
at O
593 O
nm O
. O

The O
precision O
( O
RSD O
) O
was O
found O
to O
be O
5 O
. O
7 O
% O
and O
3 O
. O
1 O
% O
at O
concentration O
levels O
0 O
. O
1 O
and O
5 O
. O
0 O
mu O
g O
mL O
( O
- O
1 O
) O
iron B
( I
II I
) I
, O
respectively O
. O

Finally O
, O
the O
method O
was O
successfully O
applied O
to O
determination O
of O
total O
iron B
in O
reference O
material O
and O
food O
samples O
. O

Effects O
of O
blanching O
on O
polyphenol B
stability O
of O
innovative O
paste O
- O
like O
parsley O
( O
Petroselinum O
crispum O
( O
Mill O
. O
) O
Nym O
ex O
A O
. O
W O
. O
Hill O
) O
and O
marjoram O
( O
Origanum O
majorana O
L O
. O
) O
products O
. O

For O
the O
first O
time O
, O
phenolic B
compounds O
of O
unheated O
marjoram O
were O
characterised O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
. O

Hereby O
, O
10 O
phenolics B
were O
detected O
. O

Among O
them O
, O
apigenin O
- O
glucuronide O
, O
lucenin O
- O
2 O
and O
lithospermic B
acid I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

In O
unheated O
parsley O
, O
apart O
from O
the O
major O
compound O
apiin O
, O
10 O
further O
phenolics B
were O
characterised O
including O
several O
p B
- I
coumaric I
acid I
derivatives O
which O
were O
newly O
detected O
. O

Except O
for O
apiin O
, O
short O
- O
time O
steam O
- O
and O
water O
- O
blanching O
( O
1 O
min O
) O
, O
respectively O
, O
did O
not O
cause O
significant O
losses O
of O
phenolic B
compounds O
, O
and O
thus O
proved O
to O
be O
the O
most O
suitable O
measures O
to O
ensure O
polyphenol B
retention O
. O

Phenolic B
compounds O
and O
antioxidant O
activities O
of O
selected O
species O
of O
seaweeds O
from O
Danish O
coast O
. O

Water O
and O
ethanolic O
extracts O
of O
16 O
species O
of O
seaweeds O
collected O
along O
the O
Danish O
coasts O
were O
screened O
for O
antioxidant O
activities O
using O
four O
in O
vitro O
antioxidant O
assays O
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
activity O
, O
reducing O
power O
, O
ferrous B
ion O
- O
chelating O
and O
liposome O
model O
system O
) O
. O

Ethanol B
was O
more O
efficient O
for O
polyphenol B
extraction O
than O
water O
. O

In O
general O
, O
the O
various O
antioxidative O
assays O
correlated O
well O
with O
the O
total O
phenolic O
content O
, O
indicating O
that O
algal O
polyphenols B
are O
active O
components O
in O
these O
extracts O
. O

However O
, O
in O
some O
of O
the O
antioxidative O
assays O
some O
species O
with O
low O
total O
phenolic O
content O
also O
showed O
good O
antioxidative O
effects O
indicating O
that O
some O
other O
co O
- O
extracted O
active O
compounds O
such O
as O
pigments O
and O
tocopherols B
in O
ethanolic O
extracts O
and O
sulphated O
polysaccharides O
, O
proteins O
or O
peptides O
in O
water O
extracts O
may O
also O
contribute O
to O
the O
overall O
antioxidant O
properties O
and O
this O
needs O
further O
investigation O
. O

The O
study O
aimed O
to O
quantify O
the O
effects O
of O
grape O
maturity O
on O
wine O
alcohol O
, O
phenolics B
, O
flavour O
compounds O
and O
polysaccharides O
in O
Vitis O
vinifera O
L O
. O

Grapes O
were O
harvested O
at O
juice O
soluble O
solids O
from O
20 O
to O
26 O
degrees O
Brix O
which O
corresponded O
to O
a O
range O
of O
wine O
ethanol B
concentrations O
between O
12 O
% O
and O
15 O
. O
5 O
% O
. O

Grape O
anthocyanin B
and O
skin O
tannin O
concentration O
increased O
as O
ripening O
progressed O
, O
while O
seed O
tannin O
declined O
. O

In O
the O
corresponding O
wines O
, O
monomeric O
anthocyanin B
and O
wine O
tannin O
concentration O
increased O
with O
harvest O
date O
, O
consistent O
with O
an O
enhanced O
extraction O
of O
skin O
- O
derived O
phenolics B
. O

In O
wines O
, O
there O
was O
an O
observed O
increase O
in O
yeast O
- O
derived O
metabolites O
, O
including O
volatile O
esters B
, O
dimethyl O
sulfide O
, O
glycerol B
and O
mannoproteins O
with O
harvest O
date O
. O

Wine O
volatiles O
which O
were O
significantly O
influenced O
by O
harvest O
date O
were O
isobutyl O
methoxypyrazine O
, O
C O
( O
6 O
) O
alcohols B
and O
hexyl O
acetate O
, O
all O
of O
which O
decreased O
as O
ripening O
progressed O
. O

D B
/ O
H B
exchange O
in O
C B
- I
H I
bonds O
of O
fatty B
acids I
: O
implication O
for O
geographical O
discrimination O
of O
food O
materials O
. O

The O
stable O
isotope O
analysis O
of O
non O
- O
exchangeable O
hydrogen B
in O
food O
materials O
has O
been O
believed O
as O
a O
powerful O
tool O
for O
tracing O
geographical O
origins O
and O
delivery O
of O
the O
materials O
. O

However O
, O
little O
information O
is O
available O
for O
the O
D B
/ O
H B
exchanges O
even O
in O
hydrophobic O
molecules O
, O
which O
leads O
to O
potential O
uncertainty O
on O
the O
observed O
results O
. O

To O
further O
evaluate O
the O
reliability O
of O
hydrogen B
isotopes O
of O
organic O
molecules O
, O
we O
examined O
the O
isotope O
exchangeability O
in O
fatty B
acids I
within O
phospholipid O
bilayers O
exposed O
to O
D O
( O
2 O
) O
O O
for O
12h O
. O

The O
results O
indicate O
that O
the O
isotope O
ratio O
is O
clearly O
increased O
during O
all O
examines O
( O
e O
. O
g O
. O
, O
93 O
- O
328 O
/ O
1000 O
in O
50 O
% O
D O
( O
2 O
) O
O O
) O
, O
in O
which O
its O
magnitude O
depends O
on O
type O
of O
fatty B
acids I
and O
state O
of O
bilayers O
. O

However O
, O
these O
results O
also O
indicate O
very O
clearly O
that O
the O
observed O
exchange O
rate O
is O
negligible O
if O
samples O
are O
exposed O
to O
natural O
abundance O
of O
deuterium B
( O
0 O
. O
0156 O
% O
) O
in O
natural O
and O
laboratory O
environments O
before O
/ O
during O
analysis O
. O

The O
potential O
to O
intensify O
sulforaphane B
formation O
in O
cooked O
broccoli O
( O
Brassica O
oleracea O
var O
. O
italica O
) O
using O
mustard O
seeds O
( O
Sinapis O
alba O
) O
. O

Sulforaphane B
, O
a O
naturally O
occurring O
cancer O
chemopreventive O
, O
is O
the O
hydrolysis O
product O
of O
glucoraphanin O
, O
the O
main O
glucosinolate O
in O
broccoli O
. O

In O
this O
study O
, O
the O
effect O
of O
adding O
mustard O
seeds O
, O
which O
contain O
a O
more O
resilient O
isoform O
of O
myrosinase O
, O
to O
processed O
broccoli O
was O
investigated O
with O
a O
view O
to O
intensify O
the O
formation O
of O
sulforaphane B
. O

Thermal O
degradation O
of O
broccoli O
glucoraphanin O
was O
investigated O
in O
addition O
to O
the O
effects O
of O
thermal O
processing O
on O
the O
formation O
of O
sulforaphane B
and O
sulforaphane O
nitrile O
. O

Boiling O
broccoli O
in O
water O
prevented O
the O
formation O
of O
any O
significant O
levels O
of O
sulforaphane B
due O
to O
inactivated O
myrosinase O
. O

However O
, O
addition O
of O
powdered O
mustard O
seeds O
to O
the O
heat O
processed O
broccoli O
significantly O
increased O
the O
formation O
of O
sulforaphane B
. O

Effect O
of O
thermal O
heating O
on O
some O
lignans B
in O
flax O
seeds O
, O
sesame O
seeds O
and O
rye O
. O

Consumption O
of O
lignan B
rich O
food O
is O
presumed O
to O
have O
positive O
effects O
on O
human O
health O
. O

As O
numerous O
foods O
are O
consumed O
mainly O
in O
processed O
form O
it O
is O
important O
to O
investigate O
the O
changes O
of O
the O
lignan B
content O
during O
processing O
. O

To O
this O
end O
, O
unheated O
and O
heated O
sesame O
seeds O
, O
sesame O
products O
, O
rye O
grains O
, O
rye O
flour O
, O
rye O
bread O
and O
flax O
seeds O
were O
extracted O
by O
sonication O
with O
ethanol B
/ O
water O
( O
70 O
: O
30 O
, O
v O
: O
v O
) O
or O
sodium B
methoxide I
. O

In O
contrast O
, O
heating O
was O
responsible O
for O
the O
better O
extractability O
of O
the O
lignans B
. O

If O
samples O
with O
high O
moisture O
content O
were O
heated O
, O
the O
degradation O
of O
the O
lignans B
in O
sesame O
seeds O
and O
rye O
was O
observed O
already O
at O
100 O
degrees O
C O
. O

Previous O
studies O
from O
our O
lab O
showed O
that O
increase O
in O
AngII O
in O
H9c2 O
cells O
causes O
elevated O
IGFII O
and O
IGFIIR O
through O
MEK O
and O
JNK O
, O
leading O
to O
rise O
in O
intracellular O
calcium B
, O
calcineurin O
activation O
by O
PLC O
- O
beta O
3 O
via O
G O
alpha O
q O
, O
insertion O
into O
mitochondrial O
membranes O
of O
Bad O
, O
and O
apoptosis O
via O
caspases O
9 O
and O
3 O
. O

The O
purpose O
of O
our O
study O
is O
to O
investigate O
if O
C O
. O
pilosula O
attenuates O
AngII O
plus O
Leu B
( O
27 O
) O
- O
IGFII O
- O
induced O
calcium B
influx O
and O
apoptosis O
in O
H9c2 O
cardiomyoblasts O
. O

Leu B
( O
27 O
) O
- O
IGFII O
was O
applied O
to O
enhance O
the O
AngII O
effect O
. O

C O
. O
pilosula O
also O
reversed O
Ca B
( I
2 I
+ I
) I
influx O
, O
MOMP O
and O
apoptosis O
increased O
by O
AngII O
plus O
Leu B
( O
27 O
) O
- O
IGFII O
. O

Therefore O
, O
C O
. O
pilosula O
suppresses O
AngII O
plus O
Leu B
( O
27 O
) O
- O
IGFII O
- O
induced O
IGFII O
/ O
IGFIIR O
pathway O
in O
myocardial O
cells O
. O

The O
samples O
were O
first O
washed O
with O
water O
, O
and O
then O
the O
residues O
were O
extracted O
with O
alcohol B
. O

Effect O
of O
ferrous B
sulfate I
fortification O
in O
germinated O
brown O
rice O
on O
seed O
iron B
concentration O
and O
bioavailability O
. O

The O
present O
study O
evaluated O
the O
effectiveness O
of O
germination O
and O
iron B
fortification O
on O
iron B
concentration O
and O
bioavailability O
of O
brown O
rice O
. O

Iron B
fortification O
during O
germination O
process O
with O
0 O
. O
05 O
- O
2 O
g O
/ O
L O
ferrous B
sulfate I
increased O
the O
iron B
concentration O
in O
germinated O
brown O
rice O
from O
1 O
. O
1 O
to O
15 O
. O
6 O
times O
than O
those O
in O
raw O
brown O
rice O
. O

Based O
on O
the O
recommended O
dietary O
allowance O
of O
iron B
, O
maximum O
germination O
rate O
and O
gamma B
- I
aminobutyric I
acid I
, O
we O
recommend O
the O
brown O
rice O
fortified O
with O
0 O
. O
25 O
g O
/ O
L O
FeSO O
( O
4 O
) O
as O
a O
suitable O
fortification O
level O
to O
use O
in O
germination O
process O
. O

Iron B
fortification O
during O
the O
germination O
process O
has O
a O
positive O
effect O
on O
iron B
concentration O
and O
bioavailability O
. O

A O
significant O
difference O
was O
observed O
among O
the O
cultivars O
in O
respect O
to O
the O
capacity O
for O
iron B
accumulation O
and O
bioavailability O
. O

Germination O
alone O
could O
improve O
in O
vitro O
iron B
solubility O
, O
but O
had O
no O
effect O
on O
iron B
bioavailability O
in O
Caco O
- O
2 O
cell O
, O
the O
additional O
fortification O
process O
should O
be O
combined O
to O
get O
high O
amount O
of O
bioavailable O
iron B
from O
the O
brown O
rice O
. O

Apoptosis O
of O
human O
breast O
cancer O
cells O
induced O
by O
microencapsulated O
betulinic B
acid I
from O
sour O
jujube O
fruits O
through O
the O
mitochondria O
transduction O
pathway O
. O

Betulinic B
acid I
( O
BA O
) O
, O
a O
natural O
pentacyclic O
triterpenoid O
, O
was O
isolated O
from O
sour O
jujube O
fruits O
for O
the O
first O
time O
. O

An O
inclusion O
complex O
comprising O
BA O
and O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
was O
formed O
to O
improve O
the O
dissolution O
of O
BA O
, O
but O
little O
is O
known O
about O
its O
anticancer O
effect O
. O

High O
serum O
vitamin B
D I
levels O
reduce O
the O
risk O
for O
nonalcoholic O
fatty O
liver O
disease O
in O
healthy O
men O
independent O
of O
metabolic O
syndrome O
. O

Recent O
studies O
suggest O
an O
association O
of O
vitamin B
D I
with O
obesity O
, O
diabetes O
and O
cardiovascular O
diseases O
. O

We O
analyzed O
the O
association O
of O
serum O
vitamin B
D I
level O
assessed O
by O
25 O
- O
hydroxyvitamin O
D O
( O
3 O
) O
{ O
25 O
( O
OH O
) O
D O
( O
3 O
) O
} O
with O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
in O
apparently O
healthy O
men O
. O

Age O
, O
serum O
calcium B
, O
and O
aspartate B
aminotransferase O
levels O
showed O
weak O
but O
significant O
positive O
correlations O
with O
25 O
( O
OH O
) O
D O
( O
3 O
) O
level O
; O
total O
cholesterol B
, O
triglycerides B
, O
low O
- O
density O
lipoprotein O
cholesterol B
and O
fasting O
insulin O
level O
showed O
weak O
but O
significant O
negative O
correlations O
with O
25 O
( O
OH O
) O
D O
( O
3 O
) O
level O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
examine O
the O
social O
influences O
on O
cocaine B
self O
- O
administration O
in O
isolated O
and O
socially O
housed O
rats O
, O
under O
conditions O
where O
the O
socially O
housed O
rats O
were O
tested O
simultaneously O
with O
their O
partner O
in O
the O
same O
chamber O
. O

Rats O
were O
then O
implanted O
with O
intravenous O
catheters O
and O
cocaine B
self O
- O
administration O
was O
examined O
in O
custom O
- O
built O
operant O
conditioning O
chambers O
that O
allowed O
two O
rats O
to O
be O
tested O
simultaneously O
. O

For O
some O
socially O
housed O
subjects O
, O
both O
rats O
had O
simultaneous O
access O
to O
cocaine B
; O
for O
others O
, O
only O
one O
rat O
of O
the O
pair O
had O
access O
to O
cocaine B
. O

An O
econometric O
analysis O
was O
applied O
to O
the O
data O
, O
and O
the O
reinforcing O
strength O
of O
cocaine B
was O
measured O
by O
examining O
consumption O
( O
i O
. O
e O
. O
quantity O
demanded O
) O
and O
elasticity O
of O
demand O
as O
a O
function O
of O
price O
, O
which O
was O
manipulated O
by O
varying O
the O
dose O
and O
ratio O
requirements O
on O
a O
fixed O
ratio O
schedule O
of O
reinforcement O
. O

Cocaine B
consumption O
decreased O
as O
a O
function O
of O
price O
in O
all O
groups O
. O

Elasticity O
of O
demand O
did O
not O
vary O
across O
groups O
, O
but O
consumption O
was O
significantly O
lower O
in O
socially O
housed O
rats O
paired O
with O
a O
rat O
without O
access O
to O
cocaine B
. O

These O
data O
suggest O
that O
the O
presence O
of O
an O
abstaining O
peer O
decreases O
the O
reinforcing O
strength O
of O
cocaine B
, O
thus O
supporting O
the O
development O
of O
social O
interventions O
in O
drug O
abuse O
prevention O
and O
treatment O
programs O
. O

Inhibition O
of O
G O
beta O
gamma O
- O
subunit O
signaling O
potentiates O
morphine B
- O
induced O
antinociception O
but O
not O
respiratory O
depression O
, O
constipation O
, O
locomotion O
, O
and O
reward O
. O

Inhibition O
of O
G O
beta O
gamma O
- O
subunit O
signaling O
to O
phospholipase O
C O
beta O
3 O
has O
been O
shown O
to O
potentiate O
morphine B
- O
mediated O
antinociception O
while O
attenuating O
the O
development O
of O
tolerance O
and O
dependence O
in O
mice O
. O

The O
G O
beta O
gamma O
- O
subunit O
inhibitor O
, O
gallein O
, O
was O
administered O
to O
C57BL O
/ O
6J O
mice O
by O
intraperitoneal O
injection O
before O
morphine B
, O
and O
data O
were O
compared O
with O
mice O
treated O
with O
vehicle O
, O
morphine B
, O
or O
gallein O
alone O
. O

Morphine B
- O
induced O
antinociception O
was O
measured O
using O
the O
55 O
degrees O
C O
warm O
- O
water O
tail O
- O
withdrawal O
test O
. O

Pretreatment O
with O
gallein O
produced O
a O
dose O
- O
dependent O
potentiation O
of O
morphine B
- O
mediated O
antinociception O
, O
producing O
up O
to O
a O
10 O
- O
fold O
leftward O
shift O
in O
the O
morphine B
dose O
- O
response O
curve O
and O
extending O
the O
duration O
of O
antinociception O
induced O
by O
a O
single O
dose O
of O
morphine B
. O

Gallein O
pretreatment O
also O
prevented O
acute O
antinociceptive O
tolerance O
induced O
by O
morphine B
. O

In O
contrast O
, O
the O
dose O
- O
dependent O
respiratory O
depression O
and O
hyperlocomotion O
induced O
by O
morphine B
were O
not O
potentiated O
by O
gallein O
pretreatment O
. O

Similarly O
, O
gallein O
pretreatment O
did O
not O
potentiate O
morphine B
- O
conditioned O
place O
preference O
responses O
or O
morphine B
- O
induced O
constipation O
, O
as O
measured O
as O
a O
reduction O
in O
excreta O
. O

Cyclodextrin O
alleviates O
neuronal O
storage O
of O
cholesterol B
in O
Niemann O
- O
Pick O
C O
disease O
without O
evidence O
of O
detectable O
blood O
- O
brain O
barrier O
permeability O
. O

Niemann O
- O
Pick O
type O
C O
disease O
is O
an O
inherited O
autosomal O
recessive O
neurodegenerative O
disorder O
characterised O
by O
the O
accumulation O
of O
unesterified O
cholesterol B
and O
sphingolipids B
within O
the O
endosomal O
/ O
lysosomal O
compartments O
. O

It O
has O
been O
observed O
that O
the O
administration O
of O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HPBCD O
) O
delays O
onset O
of O
clinical O
symptoms O
and O
reduces O
accumulation O
of O
cholesterol B
and O
gangliosides O
within O
neuronal O
cells O
. O

It O
was O
assumed O
that O
HPBCD O
exerts O
its O
action O
by O
readily O
entering O
the O
CNS O
and O
directly O
interacting O
with O
neurones O
and O
other O
brain O
cells O
to O
facilitate O
removal O
of O
stored O
cholesterol B
from O
the O
late O
endosomal O
/ O
lysosomal O
compartment O
. O

In O
fact O
, O
it O
is O
nearly O
three O
times O
larger O
than O
that O
for O
sucrose B
( O
0 O
. O
039 O
+ O
/ O
- O
0 O
. O
006 O
ml O
/ O
g O
) O
. O

We O
propose O
that O
this O
indicates O
cell O
surface O
binding O
of O
HPBCD O
to O
the O
endothelium O
of O
the O
cerebral O
vasculature O
and O
may O
provide O
a O
mechanism O
for O
the O
mobilisation O
and O
clearance O
of O
cholesterol B
from O
the O
CNS O
. O

In O
our O
previous O
study O
, O
we O
identified O
the O
estrogen B
receptor O
alpha O
( O
ER O
alpha O
) O
as O
a O
relevant O
enhancer O
of O
leptin O
- O
induced O
signal O
transduction O
leading O
to O
transactivation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
Stat3 O
) O
. O

Phosphorus B
- O
doped O
silicon B
nanocrystals O
exhibiting O
mid O
- O
infrared O
localized O
surface O
plasmon O
resonance O
. O

Despite O
silicon B
' O
s O
importance O
for O
electronic O
and O
photonic O
applications O
, O
no O
LSPRs O
have O
been O
reported O
for O
doped O
silicon B
nanocrystals O
. O

Here O
we O
demonstrate O
doped O
silicon B
nanocrystals O
synthesized O
via O
a O
nonthermal O
plasma O
technique O
that O
exhibits O
tunable O
LSPRs O
in O
the O
energy O
range O
of O
0 O
. O
07 O
- O
0 O
. O
3 O
eV O
or O
mid O
- O
infrared O
wavenumbers O
of O
600 O
- O
2500 O
cm O
( O
- O
1 O
) O
. O

Developing O
the O
potential O
ophthalmic O
applications O
of O
pilocarpine B
entrapped O
into O
polyvinylpyrrolidone B
- O
poly B
( I
acrylic I
acid I
) I
nanogel O
dispersions O
prepared O
by O
gamma O
radiation O
. O

The O
aim O
of O
this O
study O
was O
to O
improve O
the O
stability O
and O
bioavailability O
of O
pilocarpine B
in O
order O
to O
maintain O
an O
adequate O
concentration O
of O
the O
pilocarpine B
at O
the O
site O
of O
action O
for O
prolonged O
period O
of O
time O
. O

Thus O
, O
pH O
- O
sensitive O
polyvinylpyrrolidone B
- O
poly B
( I
acrylic I
acid I
) I
( O
PVP B
/ O
PAAc O
) O
nanogels O
prepared O
by O
gamma O
radiation O
- O
induced O
polymerization O
of O
acrylic B
acid I
( O
AAc O
) O
in O
an O
aqueous O
solution O
of O
polyvinylpyrrolidone B
( O
PVP B
) O
as O
a O
template O
polymer O
were O
used O
to O
encapsulate O
pilocarpine B
. O

The O
PVP B
/ O
PAAc O
nanogel O
particles O
were O
characterized O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
, O
zeta O
potential O
, O
Fourier O
transform O
infrared O
spectroscopy O
( O
FTIR O
) O
, O
and O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
and O
their O
size O
can O
be O
controlled O
by O
the O
feed O
composition O
and O
concentration O
as O
well O
as O
the O
irradiation O
dose O
. O

Pilocarpine B
was O
loaded O
into O
the O
nanogel O
particles O
through O
electrostatic O
interactions O
where O
the O
AAc O
- O
rich O
nanogels O
exhibited O
the O
highest O
loading O
efficiency O
. O

The O
in O
vitro O
release O
study O
conducted O
in O
simulated O
tear O
fluid O
showed O
a O
relatively O
long O
sustained O
release O
of O
pilocarpine B
from O
the O
prepared O
PVP B
/ O
PAAc O
nanogel O
particles O
if O
compared O
with O
pilocarpine B
in O
solution O
. O

High O
- O
Performance O
Surface O
Acoustic O
Wave O
Immunosensing O
System O
on O
a O
PEG B
/ O
Aptamer O
Hybridized O
Surface O
. O

PEG B
is O
well O
- O
known O
as O
a O
blocking O
agent O
for O
the O
prevention O
of O
the O
adsorption O
of O
nonspecific O
binding O
materials O
when O
coimmobilized O
with O
ligands O
for O
targets O
such O
as O
antibodies O
and O
oligonucleotides O
. O

The O
construction O
strategy O
for O
PEG B
/ O
ligand O
coimmobilized O
surfaces O
is O
an O
important O
point O
in O
the O
preparation O
of O
a O
high O
- O
performance O
assays O
because O
the O
physiological O
condition O
of O
the O
ligand O
depends O
strongly O
on O
its O
interaction O
with O
the O
PEG B
chain O
. O

In O
this O
report O
, O
we O
investigate O
the O
interaction O
between O
thrombin O
and O
a O
thrombin O
- O
binding O
aptamer O
( O
TBA O
) O
on O
a O
PEG B
/ O
TBA O
coimmobilized O
surface O
by O
using O
a O
shear O
horizontal O
surface O
acoustic O
wave O
( O
SAW O
) O
sensor O
. O

The O
thrombin O
- O
TBA O
binding O
property O
shows O
remarkable O
differences O
with O
changes O
in O
the O
PEG B
density O
and O
the O
distance O
from O
the O
gold O
surface O
to O
the O
aptamer O
. O

Aiming O
at O
the O
design O
of O
specific O
melanocortin O
- O
1 O
receptor O
( O
MC1R O
) O
targeted O
imaging O
probes O
, O
we O
report O
on O
the O
effect O
of O
different O
azolyl O
- O
ring O
substitution O
patterns O
( O
carboxylate B
at O
the O
4 O
- O
position O
and O
/ O
or O
methyl B
groups O
at O
the O
3 O
, O
5 O
positions O
) O
of O
pyrazolyl O
- O
diamine O
bifunctional O
chelators O
( O
Pz O
( O
2 O
) O
- O
Pz O
( O
4 O
) O
) O
on O
the O
pharmacokinetic O
profile O
of O
the O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- O
labeled O
lactam B
bridge O
- O
cyclized O
alpha O
- O

The O
introduction O
of O
a O
carboxylate B
group O
in O
the O
azolyl O
- O
ring O
leads O
to O
a O
remarkable O
reduction O
of O
the O
kidney O
( O
> O
89 O
% O
) O
and O
liver O
( O
> O
91 O
% O
) O
accumulation O
for O
( O
99m O
) O
Tc O
( O
CO O
) O
3 O
- O
Pz O
( O
3 O
) O
- O
beta O
AlaNleCycMSH O
( O
hex O
) O
and O
( O
99m O
) O
Tc O
( O
CO O
) O
3 O
- O
Pz O
( O
4 O
) O
- O
beta O
AlaNleCycMSH O
( O
hex O
) O
when O
compared O
to O
the O
radiopeptide O
( O
99m O
) O
Tc O
( O
CO O
) O
3 O
- O
Pz O
( O
1 O
) O

Vegfrecine O
, O
an O
Inhibitor O
of O
VEGF O
Receptor O
Tyrosine B
Kinases O
Isolated O
from O
the O
Culture O
Broth O
of O
Streptomyces O
sp O
. O

A O
new O
inhibitor O
of O
VEGF O
receptor O
tyrosine B
kinases O
, O
vegfrecine O
( O
1 O
) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
Streptomyces O
sp O
. O

Reduction O
of O
dimethylarsinic B
acid I
to O
the O
highly O
toxic O
dimethylarsinous B
acid I
by O
rats O
and O
rat O
liver O
cytosol O
. O

Dimethylarsinic B
acid I
( O
DMAs O
( O
V O
) O
) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic B
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous B
acid I
( O
DMAs O
( O
III O
) O
) O
, O
is O
highly O
toxic O
. O

Although O
glutathione B
S B
- O
transferase O
omega O
1 O
( O
GSTO1 O
) O
and O
arsenic B
methyltransferase O
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs O
( O
V O
) O
reduction O
, O
their O
role O
in O
DMAs O
( O
V O
) O
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O

Pretreatment O
of O
rats O
with O
glutathione B
( O
GSH B
) O
depletors O
( O
phorone O
or O
BSO B
) O
delayed O
the O
elimination O
of O
DMAs O
( O
V O
) O
and O
the O
accumulation O
of O
RBC O
- O
bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate O
- O
oxidized O
adenosine B
was O
without O
effect O
. O

Assessment O
of O
DMAs O
( O
V O
) O
- O
reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs O
( O
V O
) O
required O
cytosolic O
protein O
and O
GSH B
and O
was O
inhibited O
by O
thiol B
reagents O
, O
GSSG B
and O
dehydroascorbate O
. O

Although O
thioredoxin O
reductase O
( O
TRR O
) O
inhibitors O
( O
aurothioglucose O
and O
Sb O
( O
III O
) O
) O
inhibited O
cytosolic O
DMAs O
( O
V O
) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH B
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs O
( O
V O
) O
reduction O
. O

On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH B
. O

In O
summary O
, O
reduction O
of O
DMAs O
( O
V O
) O
to O
the O
highly O
toxic O
DMAs O
( O
III O
) O
in O
rats O
and O
rat O
liver O
cytosol O
is O
a O
GSH B
- O
dependent O
enzymatic O
process O
, O
yet O
its O
mechanism O
remains O
uncertain O
. O

Large O
- O
scale O
spinning O
assembly O
of O
neat O
, O
morphology O
- O
defined O
, O
graphene B
- O
based O
hollow O
fibers O
. O

Large O
- O
scale O
assembly O
of O
graphenes B
in O
a O
well O
- O
controlled O
macroscopic O
fashion O
is O
important O
for O
practical O
applications O
. O

We O
have O
developed O
a O
facile O
and O
straightforward O
approach O
for O
continuous O
fabrication O
of O
neat O
, O
morphology O
- O
defined O
, O
graphene B
- O
based O
hollow O
fibers O
( O
HFs O
) O
via O
a O
coaxial O
two O
- O
capillary O
spinning O
strategy O
. O

With O
a O
high O
throughput O
, O
HFs O
and O
necklace O
- O
like O
HFs O
of O
graphene B
oxide I
have O
been O
well O
- O
controlled O
produced O
with O
the O
ease O
of O
functionalization O
and O
conversion O
to O
graphene B
HFs O
via O
simply O
thermal O
or O
chemical O
reduction O
. O

This O
work O
paves O
the O
way O
toward O
the O
mass O
production O
of O
graphene B
- O
based O
HFs O
with O
desirable O
functionalities O
and O
morphologies O
for O
many O
of O
important O
applications O
in O
fluidics O
, O
catalysis O
, O
purification O
, O
separation O
, O
and O
sensing O
. O

5 O
- O
Sulfonyl O
tetrazole O
easily O
accepted O
nucleophilic O
attack O
of O
thiol B
groups O
, O
while O
5 O
- O
sulfinyl O
tetrazole O
did O
not O
. O

Cyclosporine B
A I
, O
an O
immunosuppressant O
produced O
by O
a O
microbe O
, O
was O
derivatized O
to O
possess O
5 O
- O
sulfonyl O
tetrazole O
and O
a O
tag O
group O
, O
which O
enabled O
chemical O
tagging O
of O
cyclophilin O
A O
, O
the O
cellular O
receptor O
of O
cyclosporine B
A I
. O

Cyclosporine B
A I
derivative O
possessing O
5 O
- O
sulfinyl O
tetrazole O
could O
not O
tag O
cyclophilin O
A O
. O

This O
enzyme O
shows O
a O
good O
catalytic O
activity O
for O
the O
CO2 B
hydration O
reaction O
, O
comparable O
to O
that O
of O
the O
human O
( O
h O
) O
isoform O
hCA O
I O
. O

Inorganic O
anions O
such O
as O
cyanate O
, O
cyanide B
, O
hydrogen B
sulfide I
, O
hydrogen O
sulfite O
, O
and O
trithiocarbonate O
were O
effective O
VchCA O
inhibitors O
with O
inhibition O
constants O
in O
the O
range O
of O
33 O
- O
88 O
mu O
M O
. O

Halides O
( O
bromide B
, O
iodide B
) O
, O
bicarbonate B
and O
carbonate B
were O
much O
less O
effective O
VchCA O
inhibitors O
, O
with O
KIs O
in O
the O
range O
of O
4 O
. O
64 O
- O
28 O
. O
0mM O
. O

The O
resistance O
of O
VchCA O
to O
bicarbonate B
inhibition O
may O
represent O
an O
evolutionary O
adaptation O
of O
this O
enzyme O
to O
living O
in O
an O
environment O
rich O
in O
this O
ion O
, O
such O
as O
the O
gastrointestinal O
tract O
, O
as O
bicarbonate B
is O
a O
virulence O
enhancer O
of O
this O
bacterium O
. O

This O
work O
is O
focused O
on O
the O
design O
of O
new O
antimicrobial O
drugs O
and O
on O
the O
development O
of O
lipophilic O
inhibitors O
of O
the O
DXR O
, O
the O
second O
enzyme O
of O
the O
MEP O
pathway O
for O
the O
biosynthesis O
of O
isoprene O
units O
in O
most O
bacteria O
, O
by O
replacing O
the O
phosphonate B
group O
of O
fosmidomycin O
derivatives O
by O
a O
tetrazoyl O
moiety O
capable O
of O
multiple O
hydrogen B
bonding O
. O

The O
N B
- O
and O
C B
- O
substituted O
tetrazole B
analogues O
of O
phosphonohydroxamate O
inhibitors O
were O
synthesized O
and O
tested O
on O
the O
DXR O
of O
Escherichia O
coli O
. O

This O
work O
points O
out O
the O
hypothesis O
that O
the O
phosphonate B
/ O
phosphate B
recognition O
site O
might O
be O
too O
rigid O
to O
accommodate O
other O
functional O
groups O
. O

Stability O
of O
black O
cohosh O
triterpene O
glycosides O
and O
polyphenols B
: O
Potential O
clinical O
relevance O
. O

Analytical O
results O
showed O
that O
the O
major O
constituents O
, O
both O
triterpene O
glycosides O
and O
polyphenols B
, O
were O
stable O
over O
the O
3 O
- O
year O
period O
of O
testing O
. O

Profenofos O
is O
a O
direct O
acting O
phosphorothioate O
organophosphorus B
( O
OP O
) O
pesticide O
capable O
of O
inhibiting O
beta O
- O
esterases O
such O
as O
acetylcholinesterase O
, O
butyrylcholinesteras O
, O
and O
carboxylesterase O
. O

A O
pilot O
study O
conducted O
in O
Egyptian O
agriculture O
workers O
, O
demonstrated O
that O
urinary O
BCP O
levels O
prior O
to O
application O
( O
3 O
. O
3 O
- O
30 O
. O
0 O
mu O
g O
/ O
g O
creatinine B
) O
were O
elevated O
to O
34 O
. O
5 O
- O
3566 O
mu O
g O
/ O
g O
creatinine B
during O
the O
time O
workers O
were O
applying O
profenofos O
to O
cotton O
fields O
. O

Follicle O
- O
stimulating O
hormone O
( O
FSH O
) O
activates O
FSH O
receptors O
( O
FSHR O
) O
in O
granulosa O
cells O
to O
induce O
follicle O
differentiation O
, O
growth O
and O
estradiol B
production O
. O

In O
this O
study O
, O
we O
present O
the O
signaling O
mechanisms O
of O
a O
newly O
developed O
LMW O
dihydropyridine B
agonist O
of O
the O
FSHR O
, O
Org O
214444 O
- O
0 O
. O

When O
co O
- O
incubated O
with O
FSH O
, O
Org O
214444 O
- O
0 O
augments O
FSH O
' O
s O
potency O
in O
binding O
( O
6 O
. O
5 O
- O
fold O
) O
and O
adenylyl O
cyclase O
/ O
cAMP B
activation O
( O
3 O
. O
5 O
- O
fold O
) O
in O
a O
concentration O
- O
dependent O
manner O
. O

Moreover O
, O
Org O
214444 O
- O
0 O
stimulates O
cAMP B
and O
estradiol B
production O
in O
human O
granulosa O
cells O
in O
culture O
and O
supports O
the O
follicular O
phase O
in O
mature O
female O
rats O
. O

A O
high O
- O
throughput O
- O
compatible O
, O
fluorescence O
anisotropy O
- O
based O
assay O
for O
ATP B
- O
dependent O
supercoiled O
DNA O
relaxation O
by O
human O
topoisomerase O
II O
alpha O
. O

A O
novel O
, O
high O
- O
throughput O
- O
compatible O
assay O
for O
the O
ATP B
- O
dependent O
supercoiled O
DNA O
relaxing O
activity O
of O
human O
topoisomerase O
II O
alpha O
( O
hTopoII O
alpha O
) O
is O
described O
. O

The O
principle O
of O
detection O
is O
the O
preferential O
binding O
of O
the O
oligodeoxyribonucleo O
BODIPY B
- O
TMR O
- O
5 O
' O
- O
TTCTTCTTCT O
- O
3 O
' O
to O
relaxed O
double O
- O
stranded O
plasmid O
containing O
the O
triplex O
forming O
sequence O
( O
TTC O
) O
9 O
versus O
the O
supercoiled O
plasmid O
. O

Binding O
of O
the O
oligonucleotide O
to O
the O
plasmid O
increases O
the O
fluorescence O
anisotropy O
of O
the O
BODIPY B
- O
TMR O
label O
. O

An O
X O
- O
ray O
crystal O
structure O
of O
optimized O
compound O
9b O
bound O
in O
the O
active O
site O
of O
FVIIa O
showed O
that O
the O
bicyclic O
scaffold O
provides O
5 O
hydrogen B
bonding O
interactions O
in O
addition O
to O
projecting O
groups O
for O
interactions O
within O
the O
S1 O
, O
S2 O
and O
S3 O
pockets O
. O

In O
this O
report O
, O
an O
efficient O
method O
for O
the O
synthesis O
of O
anacardic O
acid O
derivatives O
was O
explored O
, O
and O
a O
small O
set O
of O
salicylic B
acid I
variants O
synthesised O
retaining O
a O
constant O
hydrophobic O
element O
( O
a O
naphthyl B
tail O
) O
. O

The O
naphthyl B
side O
chain O
was O
introduced O
via O
Wittig O
reaction O
and O
the O
aldehyde B
installed O
using O
directed O
ortho O
- O
metalation O
reaction O
of O
the O
substituted O
o O
- O
anisic O
acids O
. O

The O
failure O
of O
ortho O
- O
metalation O
using O
unprotected O
carboxylic B
acid I
group O
compelled O
us O
to O
use O
directed O
ortho O
- O
metalation O
in O
which O
a O
tertiary O
amide O
was O
used O
as O
a O
strong O
ortho O
- O
directing O
group O
. O

The O
Wittig O
reaction O
with O
protected O
carboxylic B
group O
( O
methyl O
ester O
) O
resulted O
in O
side O
- O
products O
whereas O
using O
sodium B
salt O
resulted O
in O
higher O
yields O
. O

While O
HIF O
- O
1 O
alpha O
in O
hypoxia O
translocates O
to O
the O
nucleus O
where O
it O
transcribes O
the O
target O
genes O
including O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
, O
HIF O
- O
1 O
alpha O
is O
degraded O
under O
normoxia O
, O
which O
involves O
its O
proline B
hydroxylation O
and O
subsequent O
binding O
to O
the O
von O
Hippel O
- O
Lindau O
protein O
- O
Elongin O
B O
- O
Elogin O
C O
( O
VBC O
) O
complex O
. O

The O
alpha O
3 O
beta O
4 O
* O
nicotinic O
acetylcholine B
receptor O
subtype O
mediates O
nicotine B
reward O
and O
physical O
nicotine B
withdrawal O
signs O
independently O
of O
the O
alpha O
5 O
subunit O
in O
the O
mouse O
. O

The O
15q25 O
gene O
cluster O
contains O
genes O
that O
code O
for O
the O
alpha O
5 O
, O
alpha O
3 O
, O
and O
beta O
4 O
nicotinic O
acetylcholine B
receptor O
( O
nAChRs O
) O
subunits O
, O
and O
in O
human O
genetic O
studies O
, O
has O
shown O
the O
most O
robust O
association O
with O
smoking O
behavior O
and O
nicotine B
dependence O
to O
date O
. O

The O
limited O
available O
animal O
studies O
implicate O
a O
role O
for O
the O
alpha O
5 O
and O
beta O
4 O
nAChR O
subunits O
in O
nicotine B
dependence O
and O
withdrawal O
; O
however O
studies O
focusing O
on O
the O
behavioral O
role O
of O
the O
alpha O
3 O
beta O
4 O
* O
nAChR O
receptor O
subtype O
in O
nicotine B
dependence O
are O
lacking O
. O

Because O
of O
the O
apparent O
role O
of O
the O
alpha O
3 O
beta O
4 O
* O
nAChR O
subtype O
in O
nicotine B
dependence O
, O
the O
goal O
of O
the O
current O
study O
was O
to O
better O
evaluate O
the O
involvement O
of O
this O
subtype O
in O
nicotine B
mediated O
behavioral O
responses O
. O

Using O
the O
selective O
alpha O
3 O
beta O
4 O
* O
nAChR O
antagonist O
, O
alpha O
- O
conotoxin O
AuIB O
, O
we O
assessed O
the O
role O
of O
alpha O
3 O
beta O
4 O
* O
nAChRs O
in O
acute O
nicotine B
, O
nicotine B
reward O
, O
and O
physical O
and O
affective O
nicotine B
withdrawal O
. O

Because O
alpha O
5 O
has O
also O
been O
implicated O
in O
nicotine B
dependence O
behaviors O
in O
mice O
and O
can O
form O
functional O
receptors O
with O
alpha O
3 O
beta O
4 O
* O
, O
we O
also O
evaluated O
the O
role O
of O
the O
alpha O
3 O
beta O
4 O
alpha O
5 O
* O
nAChR O
subtype O
in O
nicotine B
reward O
and O
somatic O
nicotine B
withdrawal O
signs O
by O
blocking O
the O
alpha O
3 O
beta O
4 O
* O
nAChR O
subtype O
in O
alpha O
5 O
nAChR O
knockout O
mice O
with O
AuIB O
. O

AuIB O
had O
no O
significant O
effect O
on O
acute O
nicotine B
behaviors O
, O
but O
dose O
- O
dependently O
attenuated O
nicotine B
reward O
and O
physical O
withdrawal O
signs O
, O
with O
no O
significant O
effect O
in O
affective O
withdrawal O
measures O
. O

Interestingly O
, O
AuIB O
also O
attenuated O
nicotine B
reward O
and O
somatic O
signs O
in O
alpha O
5 O
nAChR O
knockout O
mice O
. O

This O
study O
shows O
that O
alpha O
3 O
beta O
4 O
* O
nAChRs O
mediate O
nicotine B
reward O
and O
physical O
nicotine B
withdrawal O
, O
but O
not O
acute O
nicotine B
behaviors O
or O
affective O
nicotine B
withdrawal O
signs O
in O
mice O
. O

Our O
findings O
suggest O
an O
important O
role O
for O
the O
alpha O
3 O
beta O
4 O
* O
nAChR O
subtype O
in O
nicotine B
reward O
and O
physical O
aspects O
of O
the O
nicotine B
withdrawal O
syndrome O
. O

The O
crystal O
structure O
of O
HSA O
complexed O
with O
fatty B
acid I
and O
acetyldiflunisal O
revealed O
that O
acetyldiflunisal O
binds O
to O
the O
IIA O
subdomain O
and O
that O
upon O
binding O
, O
it O
acetylates O
lysine B
199 O
. O

In O
addition O
, O
SCPP11 O
( O
at O
50mg O
/ O
kg O
) O
could O
also O
increased O
in O
thymus O
indexes O
as O
well O
as O
IL O
- O
2 O
and O
TNF O
- O
alpha O
levels O
in O
serum O
in O
vivo O
and O
significantly O
enhance O
the O
phagocytosis O
activity O
and O
the O
productions O
of O
NO B
of O
RAW264 O
. O
7 O
in O
vitro O
. O

This O
study O
aimed O
to O
demonstrate O
protective O
activities O
of O
the O
narirutin O
fraction O
from O
peels O
of O
Citrus O
unshiu O
against O
ethanol B
- O
induced O
hepatic O
damage O
through O
an O
animal O
study O
. O

ICR O
mice O
were O
divided O
into O
four O
groups O
; O
normaldiet O
control O
, O
ethanol B
control O
( O
6 O
. O
5g O
ethanol B
/ O
kg O
) O
, O
low O
- O
CNF O
( O
ethanol B
+ O
150mg O
CNF O
/ O
kg O
) O
and O
high O
- O
CNF O
( O
ethanol B
+ O
300mg O
CNF O
/ O
kg O
) O
groups O
. O

Consumption O
of O
alcohol B
for O
8weeks O
induced O
severe O
liver O
damage O
with O
increases O
in O
prognostic O
indicators O
such O
as O
aspartate B
transaminase O
, O
alanine O
transaminase O
in O
serum O
whereas O
co O
- O
administration O
of O
CNF O
suppressed O
their O
increases O
. O

Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol B
control O
group O
were O
also O
suppressed O
by O
co O
- O
administration O
of O
CNF O
. O

Co O
- O
administration O
of O
CNF O
maintained O
SOD O
activity O
, O
GSH B
and O
malondialdehyde B
levels O
close O
to O
those O
of O
the O
normal O
diet O
group O
. O

Chronic O
consumption O
of O
alcohol B
also O
stimulated O
abrupt O
increases O
in O
pro O
- O
inflammatory O
cytokines O
such O
as O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
, O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
and O
interleukin O
( O
IL O
) O
- O
1 O
beta O
in O
liver O
otherwise O
co O
- O
administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines O
dose O
- O
dependently O
. O

These O
results O
indicate O
that O
co O
- O
administration O
of O
CNF O
with O
alcohol B
can O
alleviate O
alcohol B
induced O
liver O
damage O
through O
preventing O
lipid O
formation O
, O
protecting O
antioxidant O
system O
and O
suppressing O
productions O
of O
pro O
- O
inflammatory O
cytokines O
. O

For O
example O
, O
organophosphates B
, O
which O
inhibit O
acetylcholinesterase O
as O
do O
the O
drugs O
used O
in O
treating O
AD O
symptoms O
, O
have O
also O
been O
shown O
to O
lead O
to O
microtubule O
derangements O
and O
tau O
hyperphosphorylation O
, O
a O
hallmark O
of O
AD O
. O

Mutagenicity O
of O
the O
cysteine B
S B
- O
conjugate O
sulfoxides O
of O
trichloroethylene O
and O
tetrachloroethylene O
in O
the O
Ames O
test O
. O

The O
nephrotoxicity O
and O
nephrocarcinogenicit O
of O
trichloroethylene O
( O
TCE O
) O
and O
tetrachloroethylene O
( O
PCE O
) O
are O
believed O
to O
be O
mediated O
primarily O
through O
the O
cysteine B
S B
- O
conjugate O
beta O
- O
lyase O
- O
dependent O
bioactivation O
of O
the O
corresponding O
cysteine B
S B
- O
conjugate O
metabolites O
S O
- O
( O
1 O
, O
2 O
- O
dichlorovinyl O
) O
- O
l O
- O
cysteine O
( O
DCVC O
) O
and O
S O
- O
( O
1 O
, O
2 O
, O
2 O
- O
trichlorovinyl O
) O
- O
l O
- O

The O
synthesis O
of O
indeno O
[ O
2 O
, O
1 O
- O
e O
] O
pyrazolo O
[ O
3 O
, O
4 O
- O
b O
] O
pyrazin O
- O
5 O
- O
one O
was O
achieved O
by O
intramolecular O
Friedel O
- O
Crafts O
reaction O
of O
the O
acid O
chloride O
3 O
- O
methyl O
- O
1 O
, O
6 O
- O
diphenyl O
- O
1H O
- O
pyrazolo O
[ O
3 O
, O
4 O
- O
b O
] O
pyrazine O
- O
5 O
- O
carboxylic O
acid O
chloride O
( O
4 O
) O
using O
AlCl3 B
in O
boiling O
CS2 B
. O

Effects O
of O
nanoparticles O
of O
TiO2 B
on O
food O
depletion O
and O
life O
- O
history O
responses O
of O
Daphnia O
magna O
. O

The O
extent O
to O
which O
different O
forms O
of O
nanoparticles O
of O
titanium B
dioxide I
( O
nano O
- O
TiO2 B
) O
aggregated O
with O
microalgae O
, O
decreased O
food O
levels O
and O
hence O
impaired O
growth O
, O
reproduction O
and O
fitness O
of O
Daphnia O
magna O
individuals O
were O
studied O
. O

Treatments O
included O
three O
different O
types O
of O
nano O
- O
TiO2 B
differing O
in O
their O
coating O
or O
crystalline O
structure O
but O
of O
similar O
primary O
size O
( O
20 O
nm O
) O
plus O
a O
micron O
- O
sized O
bulk O
material O
, O
two O
exposure O
levels O
( O
1 O
, O
10mg O
/ O
l O
) O
and O
two O
food O
ration O
levels O
of O
the O
microalgae O
Chlorella O
vulgaris O
that O
included O
a O
non O
limiting O
( O
1 O
. O
5 O
mu O
gC O
/ O
ml O
) O
and O
a O
limiting O
one O
( O
0 O
. O
3 O
mu O
gC O
/ O
ml O
) O
. O

Large O
TiO2 B
- O
algae O
agglomerates O
settled O
readily O
dramatically O
depleting O
the O
concentration O
of O
available O
food O
for O
D O
. O
magna O
. O

At O
high O
food O
rations O
effects O
were O
only O
observed O
for O
one O
of O
the O
nano O
- O
TiO2 B
, O
P O
- O
25 O
, O
at O
high O
exposure O
levels O
( O
10 O
mg O
/ O
l O
) O
under O
both O
semi O
- O
static O
and O
particle O
re O
- O
suspension O
conditions O
, O
which O
suggest O
that O
P O
- O
25 O
effects O
were O
mediated O
by O
clogging O
the O
gut O
and O
hence O
diminishing O
food O
acquisition O
. O

These O
results O
indicate O
that O
nano O
- O
TiO2 B
may O
affect O
the O
transfer O
of O
energy O
throughout O
the O
planktonic O
aquatic O
food O
webs O
increasing O
the O
settlement O
of O
edible O
particles O
from O
the O
water O
column O
. O

Previous O
laboratory O
based O
studies O
have O
shown O
that O
oil O
sands O
process O
- O
affected O
waters O
( O
OSPWs O
) O
containing O
high O
concentrations O
of O
naphthenic B
acids I
( O
> O
25 O
mg O
/ O
l O
) O
have O
adverse O
effects O
on O
the O
reproductive O
physiology O
of O
fish O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
reproductive O
development O
and O
health O
of O
a O
wild O
population O
of O
fathead O
minnows O
( O
Pimephales O
promelas O
) O
inhabiting O
an O
OSPW O
pond O
that O
has O
moderate O
concentrations O
of O
naphthenic B
acids I
( O
~ O
10 O
mg O
/ O
l O
) O
. O

Condition O
factor O
, O
gill O
histopathology O
, O
gonadosomatic O
indices O
, O
liver O
somatic O
indices O
, O
male O
secondary O
sexual O
characteristics O
, O
and O
plasma O
sex O
steroids B
were O
examined O
. O

In O
comparison O
to O
reference O
fish O
, O
lower O
concentrations O
of O
11 B
- I
ketotestosterone I
were O
measured O
in O
the O
plasma O
of O
male O
fathead O
minnows O
collected O
from O
Demonstration O
Pond O
in O
June O
2006 O
and O
July O
2007 O
. O

Improving O
correlated O
SERS O
measurements O
with O
scanning O
electron O
microscopy O
: O
an O
assessment O
of O
the O
problem O
arising O
from O
the O
deposition O
of O
amorphous O
carbon B
. O

However O
, O
the O
deposition O
of O
carbon B
resulting O
from O
e O
- O
beam O
exposure O
during O
SEM O
imaging O
contaminates O
the O
surface O
of O
nanoparticles O
, O
potentially O
preventing O
their O
further O
functionalization O
with O
Raman O
probe O
molecules O
. O

In O
addition O
, O
the O
deposited O
carbon B
leads O
to O
unwanted O
background O
SERS O
signals O
. O

In O
this O
study O
, O
we O
systematically O
investigated O
the O
deposition O
of O
carbon B
during O
SEM O
imaging O
and O
examined O
how O
it O
affects O
the O
functionalization O
of O
nanoparticles O
with O
probe O
molecules O
and O
impacts O
the O
detection O
of O
SERS O
signals O
. O

Significantly O
, O
we O
found O
that O
the O
carbon B
could O
be O
removed O
or O
replaced O
from O
the O
surface O
of O
Ag B
nanoparticles O
through O
chemical O
or O
physical O
means O
, O
rendering O
the O
nanoparticles O
the O
capability O
for O
correlated O
SEM O
/ O
SERS O
studies O
. O

SDS B
- O
PAGE O
indicated O
12 O
distinct O
bands O
in O
the O
venom O
ranged O
between O
7 O
and O
250 O
kDa O
. O

An O
evaluation O
of O
the O
serotonin B
system O
and O
perseverative O
, O
compulsive O
, O
stereotypical O
, O
and O
hyperactive O
behaviors O
in O
dopamine B
transporter O
( O
DAT O
) O
knockout O
mice O
. O

RATIONALE O
: O
Mice O
lacking O
the O
dopamine B
transporter O
( O
DAT O
) O
display O
major O
behavioral O
alterations O
that O
include O
hyperactivity O
, O
perseverative O
locomotor O
patterns O
, O
and O
reduced O
prepulse O
inhibition O
of O
the O
acoustic O
startle O
reflex O
. O

OBJECTIVES O
: O
The O
objectives O
of O
this O
study O
were O
to O
investigate O
perseverative O
, O
compulsive O
, O
stereotypical O
, O
and O
hyperactive O
behaviors O
, O
as O
well O
as O
serotonin B
and O
its O
involvement O
with O
these O
behaviors O
, O
in O
DAT O
gene O
- O
altered O
mice O
. O

Following O
administration O
of O
the O
5 B
- I
HT I
( O
1A O
/ O
7 O
) O
agonist O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
stereotypical O
head O
weaving O
and O
forepaw O
treading O
were O
increased O
more O
in O
DAT O
- O
KO O
mice O
than O
in O
DAT O
- O
WT O
or O
- O
HET O
mice O
. O

By O
contrast O
, O
head O
twitches O
induced O
by O
treatment O
with O
the O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
agonist O
( O
+ O
/ O
- O
) O
- O
2 O
, O
5 O
- O
dimethoxy O
- O
4 O
- O
iodophenyl O
- O
2 O
- O
aminopropane O
( O
DOI B
) O
were O
similar O
in O
mice O
of O
all O
three O
DAT O
genotypes O
. O

5 B
- I
HT I
( O
1A O
) O
autoreceptor O
function O
was O
intact O
in O
DAT O
- O
KO O
mice O
. O

Compared O
to O
DAT O
- O
WT O
mice O
, O
serotonin B
levels O
were O
increased O
in O
DAT O
- O
HET O
and O
- O
KO O
mice O
in O
frontal O
cortex O
and O
hippocampus O
, O
respectively O
, O
and O
serotonin O
turnover O
rates O
were O
increased O
~ O
30 O
% O
in O
the O
striatum O
of O
DAT O
- O
KO O
mice O
. O

Hyperactivity O
, O
stereotypy O
, O
and O
perseverative O
behaviors O
are O
increased O
in O
these O
mice O
, O
with O
brain O
- O
area O
specific O
increases O
in O
serotonin B
levels O
and O
serotonin B
turnover O
, O
and O
marked O
increases O
in O
postsynaptic O
5 B
- I
HT I
( O
1A O
) O
receptor O
- O
mediated O
stereotypic O
responses O
. O

Quantum O
dots O
exhibit O
less O
bioaccumulation O
than O
free O
cadmium B
and O
selenium B
in O
the O
earthworm O
Eisenia O
andrei O
. O

Earthworms O
were O
exposed O
to O
quantum O
dot O
- O
treated O
soil O
for O
up O
to O
4 O
wk O
and O
analyzed O
for O
cadmium B
and O
selenium B
concentration O
using O
inductively O
coupled O
plasma O
mass O
spectrometry O
. O

Earthworms O
exposed O
to O
quantum O
dots O
showed O
significant O
bioaccumulation O
of O
cadmium B
and O
selenium B
( O
5 O
. O
3 O
- O
and O
1 O
. O
5 O
- O
fold O
higher O
concentration O
over O
negative O
controls O
, O
respectively O
) O
after O
4 O
wk O
. O

Over O
the O
same O
4 O
wk O
, O
positive O
control O
earthworms O
accumulated O
9 O
. O
2 O
- O
and O
2 O
. O
2 O
- O
fold O
higher O
cadmium B
and O
selenium B
, O
respectively O
, O
than O
negative O
controls O
for O
a O
much O
more O
substantial O
final O
body O
burden O
of O
the O
2 O
elements O
. O

The O
concentrations O
also O
increased O
with O
exposure O
time O
; O
cadmium B
concentrations O
increased O
from O
3600 O
+ O
/ O
- O
310 O
ng O
/ O
g O
to O
8080 O
+ O
/ O
- O
660 O
ng O
/ O
g O
, O
from O
1 O
to O
4 O
wk O
, O
suggesting O
that O
further O
bioaccumulation O
may O
take O
place O
with O
even O
longer O
exposure O
time O
. O

The O
molar O
ratio O
of O
cadmium B
to O
selenium B
in O
the O
quantum O
dot O
- O
exposed O
worms O
( O
6 O
. O
2 O
) O
is O
closer O
to O
the O
ratios O
seen O
in O
positive O
control O
worms O
( O
7 O
. O
2 O
) O
than O
to O
the O
pure O
quantum O
dots O
( O
1 O
. O
8 O
) O
, O
which O
implies O
that O
quantum O
dots O
are O
taken O
up O
predominantly O
in O
the O
degraded O
form O
. O

Recent O
advances O
in O
molecular O
organic O
photovoltaics O
( O
OPVs O
) O
have O
shown O
10 O
% O
power O
conversion O
efficiency O
( O
PCE O
) O
for O
single O
- O
junction O
cells O
, O
which O
put O
them O
in O
direct O
competition O
with O
PVs O
based O
on O
amorphous O
silicon B
. O

Tuning O
the O
Stability O
of O
Graphene B
Layers O
by O
Phthalocyanine B
- O
Based O
oPPV O
Oligomers O
Towards O
Photo O
- O
and O
Redoxactive O
Materials O
. O

In O
contrast O
to O
pristine O
zinc B
phthalocyanine I
( O
1 O
) O
, O
zinc B
phthalocyanine I
based O
oPPV O
- O
oligomers O
( O
2 O
- O
4 O
) O
of O
different O
chain O
lengths O
interact O
tightly O
and O
reversibly O
with O
graphite B
, O
affording O
stable O
and O
finely O
dispersed O
suspensions O
of O
mono O
- O
to O
few O
- O
layer O
graphene B
- O
nanographene O
( O
NG O
) O
- O
that O
are O
photoactive O
. O

The O
p O
- O
type O
character O
of O
the O
oPPV O
backbones O
and O
the O
increasing O
length O
of O
the O
oPPV O
backbones O
facilitate O
the O
overall O
pi O
- O
pi O
interactions O
with O
the O
graphene B
layers O
. O

Superhydrophobic O
and O
Superoleophilic O
PVDF B
Membranes O
for O
Effective O
Separation O
of O
Water O
- O
in O
- O
Oil O
Emulsions O
with O
High O
Flux O
. O

Ultralight O
and O
highly O
compressible O
graphene B
aerogels O
. O

Chemically O
converted O
graphene B
aerogels O
with O
ultralight O
density O
and O
high O
compressibility O
are O
prepared O
by O
diamine O
- O
mediated O
functionalization O
and O
assembly O
, O
followed O
by O
microwave O
irradiation O
. O

The O
resulting O
graphene B
aerogels O
with O
density O
as O
low O
as O
3 O
mg O
cm O
( O
- O
3 O
) O
show O
excellent O
resilience O
and O
can O
completely O
recover O
after O
more O
than O
90 O
% O
compression O
. O

The O
ultralight O
graphene B
aerogels O
possessing O
high O
elasticity O
are O
promising O
as O
compliant O
and O
energy O
- O
absorbing O
materials O
. O

We O
found O
it O
rich O
in O
Aloe O
- O
emodin B
, O
a O
hydroxylanthraquinon O
with O
known O
antitumoral O
activity O
and O
in O
several O
compounds O
with O
anti O
- O
oxidant O
properties O
. O

These O
results O
suggested O
that O
acylation O
of O
the O
19 O
- O
OH B
group O
of O
kaurane O
- O
and O
beyerane O
- O
type O
diterpenoids B
might O
be O
useful O
for O
enhancement O
of O
their O
cytotoxicities O
with O
apoptosis O
- O
inducing O
activity O
. O

The O
root O
essential O
oil O
was O
distinguished O
by O
its O
high O
content O
in O
acetylenes O
( O
matricaria O
ester O
, O
4 O
; O
74 O
. O
3 O
% O
) O
, O
while O
those O
from O
flower O
heads O
and O
leaves O
were O
dominated O
by O
oxygenated O
sesquiterpenes B
( O
61 O
. O
1 O
and O
50 O
. O
3 O
% O
, O
resp O
. O
) O
. O

Nicotinamide B
N B
- O
oxidation O
by O
CYP2E1 O
in O
human O
liver O
microsomes O
. O

Excess O
nicotinamide B
, O
a O
form O
of O
vitamin O
B O
( O
3 O
) O
, O
is O
metabolized O
through O
two O
enzymatic O
systems O
and O
eventually O
excreted O
from O
the O
body O
. O

The O
first O
system O
starts O
with O
the O
methylation O
of O
nicotinamide B
by O
nicotinamide B
N B
- O
methyltransferase O
, O
which O
can O
subsequently O
be O
oxidized O
by O
aldehyde B
oxidase O
. O

The O
second O
enzymatic O
system O
oxidizes O
nicotinamide B
to O
nicotinamide O
N O
- O
oxide O
. O

Optical O
response O
of O
individual O
Au O
- O
Ag O
@ O
SiO B
2 I
heterodimers O
. O

The O
optical O
extinction O
response O
of O
individual O
Au O
- O
Ag O
@ O
SiO2 B
heterodimers O
whose O
individual O
morphologies O
are O
determined O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
is O
investigated O
using O
spatial O
modulation O
spectroscopy O
. O

The O
extinction O
spectra O
show O
two O
resonances O
spectrally O
close O
to O
the O
surface O
plasmon O
resonances O
of O
the O
constituting O
Au B
and O
Ag B
@ O
SiO2 B
core O
- O
shell O
particles O
. O

The O
interparticle O
electromagnetic O
coupling O
is O
demonstrated O
to O
induce O
a O
large O
increase O
of O
the O
optical O
extinction O
of O
the O
dimer O
around O
its O
Au B
- O
like O
surface O
plasmon O
resonance O
for O
light O
polarized O
along O
its O
axis O
, O
as O
compared O
to O
that O
for O
perpendicular O
polarization O
and O
to O
that O
of O
an O
isolated O
Au B
nanoparticle O
. O

A O
polar O
copper B
- O
boron B
one O
- O
electron O
sigma O
- O
bond O
. O

Examples O
of O
sigma O
- O
bonds O
made O
of O
a O
single O
electron O
delocalized O
over O
two O
neighboring O
atoms O
were O
until O
recently O
found O
only O
in O
gas O
- O
phase O
cations O
such O
as O
H2 B
( I
+ I
) I
and O
Li2 O
( O
+ O
) O
and O
in O
highly O
unstable O
species O
generated O
in O
solid O
matrices O
. O

Beyond O
H B
( I
2 I
) I
S I
and O
NO B
Interplay O
: O
Hydrogen B
Sulfide I
and O
Nitroprusside O
React O
Directly O
to O
Give O
Nitroxyl B
( O
HNO O
) O
. O

Hydrogen B
sulfide I
( O
H B
( I
2 I
) I
S I
) O
has O
been O
increasingly O
recognized O
as O
an O
important O
signaling O
molecule O
that O
regulates O
both O
blood O
pressure O
and O
neuronal O
activity O
. O

Attention O
has O
been O
drawn O
to O
its O
interactions O
with O
another O
gasotransmitter O
, O
nitric B
oxide I
( O
NO B
) O
. O

Here O
, O
we O
provide O
evidence O
that O
the O
physiological O
effects O
observed O
upon O
the O
application O
of O
sodium B
nitroprusside I
( O
SNP B
) O
and O
H B
( I
2 I
) I
S I
can O
be O
ascribed O
to O
the O
generation O
of O
nitroxyl B
( O
HNO O
) O
, O
which O
is O
a O
direct O
product O
of O
the O
reaction O
between O
SNP B
and O
H B
( I
2 I
) I
S I
, O
not O
a O
consequence O
of O
released O
NO B
subsequently O
reacting O
with O
H B
( I
2 I
) I
S I
. O

Unlike O
with O
other O
thiols B
, O
SNP B
reacts O
with O
H B
( I
2 I
) I
S I
in O
the O
same O
way O
as O
rhodanese O
, O
i O
. O
e O
. O
, O
the O
cyanide B
transforms O
into O
a O
thiocyanate O
. O

These O
findings O
shed O
new O
light O
on O
how O
H B
( I
2 I
) I
S I
is O
understood O
to O
interact O
with O
nitroprusside O
. O

A O
star O
- O
shaped O
molecule O
with O
three O
butadiyne O
moieties O
attached O
to O
a O
central O
phenyl B
core O
was O
self O
- O
assembled O
via O
organogel O
formation O
in O
different O
solvents O
and O
subjected O
to O
UV O
irradiation O
in O
its O
xerogels O
form O
to O
give O
a O
soluble O
conjugated O
1D O
nanowire O
made O
of O
three O
connected O
polydiacetylene O
( O
PDA O
) O
chains O
. O

The O
protein O
chimera O
exerts O
higher O
stimulatory O
activity O
to O
drive O
expansion O
of O
purified O
CFSE B
- O
labeled O
OT O
- O
I O
CD8 O
( O
+ O
) O
T O
cells O
activated O
by O
an O
injection O
of O
a O
low O
dose O
of O
SIINFEKL O
peptide O
than O
IL O
- O
2 O
/ O
S4B6 O
mAb O
immunocomplexes O
in O
vivo O
. O

The O
content O
of O
reactive O
carbonyl B
derivates O
did O
not O
change O
with O
exercise O
, O
suggesting O
that O
the O
increased O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
were O
well O
tolerated O
in O
this O
experimental O
model O
. O

The O
neurobehavioral O
impact O
of O
manganese B
: O
Results O
and O
challenges O
obtained O
by O
a O
meta O
- O
analysis O
of O
individual O
participant O
data O
. O

Performance O
on O
a O
single O
test O
was O
significantly O
related O
to O
the O
biomarker O
manganese B
in O
blood O
. O

The O
lack O
of O
dose O
- O
response O
relationships O
was O
related O
to O
features O
of O
the O
biomarker O
: O
it O
does O
not O
reflect O
the O
Mn B
in O
brain O
responsible O
for O
changes O
in O
performances O
. O

We O
hypothesize O
that O
the O
key O
element O
in O
the O
cascade O
of O
events O
leading O
to O
failure O
of O
the O
largest O
and O
strongest O
bone O
in O
the O
human O
body O
is O
long O
- O
term O
suppression O
of O
normal O
bone O
turnover O
caused O
by O
exposure O
to O
potent O
anti O
- O
remodeling O
agents O
, O
most O
notably O
the O
bisphosphonates B
( O
BPs B
) O
. O

Further O
, O
the O
targeted O
repair O
of O
cracks O
by O
newly O
activated O
BMUs O
appears O
to O
be O
preferentially O
suppressed O
by O
BPs B
. O

Although O
terbinafine B
has O
been O
acknowledged O
to O
be O
the O
most O
effective O
antifungal O
agent O
against O
T O
. O
rubrum O
, O
its O
antifungal O
efficacy O
was O
improved O
by O
its O
incorporation O
into O
an O
optimal O
formulation O
. O

Charge O
affects O
the O
oral O
toxicity O
of O
poly B
( I
amidoamine I
) I
dendrimers O
. O

Poly B
( I
amidoamine I
) I
( O
PAMAM B
) O
dendrimers O
have O
been O
evaluated O
for O
the O
influence O
of O
surface O
functionality O
and O
size O
on O
the O
epithelial O
barrier O
of O
the O
gut O
with O
the O
goal O
of O
identifying O
safe O
carriers O
that O
can O
be O
used O
for O
oral O
drug O
delivery O
. O

Limited O
studies O
are O
conducted O
to O
date O
, O
however O
, O
to O
assess O
the O
toxicity O
of O
PAMAM B
dendrimers O
in O
vivo O
when O
administered O
by O
the O
oral O
route O
. O

The O
goal O
of O
this O
research O
was O
to O
conduct O
an O
oral O
acute O
toxicity O
study O
of O
PAMAM B
dendrimers O
as O
a O
function O
of O
size O
and O
charge O
in O
immune O
competent O
CD O
- O
1 O
mice O
. O

Maximum O
tolerated O
doses O
( O
MTD O
) O
of O
PAMAM B
dendrimers O
as O
a O
function O
of O
size O
and O
surface O
functionality O
were O
established O
and O
clinical O
signs O
of O
toxicity O
monitored O
. O

Severe O
signs O
of O
toxicity O
observed O
for O
large O
( O
G7 O
) O
cationic O
amine B
- O
or O
hydroxyl B
- O
terminated O
dendrimers O
include O
hemobilia O
and O
spleenomegaly O
. O

Anionic O
G6 O
. O
5 O
or O
smaller O
molecular O
weight O
carboxyl B
- O
, O
amine B
- O
, O
or O
hydroxyl B
- O
terminated O
dendrimers O
( O
G3 O
. O
5 O
- O
COOH B
, O
G4 O
- O
NH2 B
, O
G4 O
- O
OH B
) O
on O
the O
other O
hand O
were O
tolerated O
at O
doses O
of O
up O
to O
500mg O
/ O
kg O
( O
300mg O
/ O
kg O
in O
some O
cases O
) O
with O
minimal O
or O
no O
signs O
of O
toxicity O
. O

Establishing O
the O
MTD O
of O
orally O
delivered O
PAMAM B
dendrimers O
and O
the O
influence O
of O
surface O
functionality O
and O
size O
on O
toxicity O
aids O
in O
the O
rational O
design O
of O
PAMAM B
- O
drug O
conjugates O
for O
oral O
drug O
delivery O
applications O
. O

Modulation O
of O
mitochondrial O
glutathione B
status O
and O
cellular O
energetics O
in O
primary O
cultures O
of O
proximal O
tubular O
cells O
from O
remnant O
kidney O
of O
uninephrectomized O
rats O
. O

Our O
previous O
studies O
showed O
that O
overexpression O
of O
two O
mitochondrial O
anion O
transporters O
, O
the O
dicarboxylate O
( O
DIC O
, O
Slc25a10 O
) O
and O
oxoglutarate O
( O
OGC O
, O
Slc25a11 O
) O
carriers O
, O
in O
NRK O
- O
52E O
cells O
resulted O
in O
increased O
mitochondrial O
uptake O
of O
glutathione B
( O
GSH B
) O
and O
protection O
from O
chemically O
induced O
apoptosis O
. O

PT O
cells O
from O
NPX O
rats O
that O
were O
first O
preincubated O
with O
GSH B
were O
protected O
from O
cytotoxicity O
due O
to O
the O
mitochondrial O
inhibitor O
antimycin O
A O
by O
overexpression O
of O
either O
of O
the O
two O
mitochondrial O
GSH B
transporters O
. O

Our O
present O
results O
provide O
further O
evidence O
that O
compensatory O
renal O
hypertrophy O
is O
associated O
primarily O
with O
mitochondrial O
hypertrophy O
and O
hyperpolarization O
and O
that O
manipulation O
of O
mitochondrial O
GSH B
transporters O
in O
PT O
cells O
of O
hypertrophied O
kidney O
can O
alter O
susceptibility O
to O
chemically O
induced O
injury O
under O
appropriate O
conditions O
and O
may O
be O
a O
suitable O
therapeutic O
approach O
. O

Screening O
of O
transition O
and O
post O
- O
transition O
metals O
to O
incorporate O
into O
copper B
oxide I
and O
copper O
bismuth O
oxide O
for O
photoelectrochemical O
hydrogen B
evolution O
. O

A O
new O
dispenser O
and O
scanner O
system O
is O
used O
to O
create O
and O
screen O
Bi O
- O
M O
- O
Cu B
oxide B
arrays O
for O
cathodic O
photoactivity O
, O
where O
M O
represents O
1 O
of O
22 O
different O
transition O
and O
post O
- O
transition O
metals O
. O

Over O
3000 O
unique O
Bi O
: O
M O
: O
Cu B
atomic O
ratios O
are O
screened O
. O

Of O
the O
22 O
metals O
tested O
, O
10 O
show O
a O
M O
- O
Cu O
oxide O
with O
higher O
photoactivity O
than O
CuO B
and O
10 O
show O
a O
Bi O
- O
M O
- O
Cu B
oxide B
with O
higher O
photoactivity O
than O
CuBi2O4 O
. O

Cd B
, O
Zn B
, O
Sn B
, O
and O
Co B
produce O
the O
most O
photoactive O
M O
- O
Cu B
oxides B
, O
all O
showing O
a O
200 O
- O
300 O
% O
improvement O
in O
photocurrent O
over O
CuO B
. O

Ag B
, O
Cd B
, O
and O
Zn B
produce O
the O
highest O
photoactivity O
Bi O
- O
M O
- O
Cu B
oxides B
with O
a O
200 O
- O
400 O
% O
improvement O
over O
CuBi2O4 O
. O

Most O
notable O
is O
a O
Bi O
- O
Ag O
- O
Cu O
oxide O
( O
Bi O
: O
Ag B
: O
Cu B
atomic O
ratio O
of O
22 O
: O
3 O
: O
11 O
) O
which O
shows O
4 O
times O
higher O
photocurrent O
than O
CuBi2O4 O
. O

This O
material O
is O
capable O
of O
evolving O
hydrogen B
under O
illumination O
in O
neutral O
electrolyte O
solutions O
at O
0 O
. O
6 O
V O
vs O
. O
RHE O
when O
Pt B
is O
added O
to O
the O
surface O
as O
an O
electrocatalyst O
. O

Succinyl O
- O
CoA O
: O
3 O
- O
ketoacid O
CoA O
transferase O
( O
SCOT O
) O
deficiency O
is O
a O
rare O
inherited O
metabolic O
disorder O
of O
ketone B
metabolism O
, O
characterized O
by O
ketoacidotic O
episodes O
and O
often O
permanent O
ketosis O
. O

SCOT O
catalyzes O
the O
first O
, O
rate O
- O
limiting O
step O
of O
ketone B
body O
utilization O
in O
peripheral O
tissues O
, O
by O
transferring O
a O
CoA B
moiety O
from O
succinyl O
- O
CoA O
to O
form O
acetoacetyl O
- O
CoA O
, O
for O
entry O
into O
the O
tricarboxylic B
acid I
cycle O
for O
energy O
production O
. O

Gelatin O
- O
Methacrylamide B
Hydrogels O
as O
Potential O
Biomaterials O
for O
Fabrication O
of O
Tissue O
- O
Engineered O
Cartilage O
Constructs O
. O

Gelatin O
- O
methacrylamide B
( O
gelMA O
) O
hydrogels O
are O
shown O
to O
support O
chondrocyte O
viability O
and O
differentiation O
and O
give O
wide O
ranging O
mechanical O
properties O
depending O
on O
several O
cross O
- O
linking O
parameters O
. O

GNSs O
present O
a O
sheltered O
hydrophobic O
inner O
cavity O
formed O
by O
the O
carbonated O
tails O
, O
surrounded O
by O
PEG B
and O
lactose O
moieties O
. O

The O
amphiphilic O
character O
of O
GNSs O
allows O
the O
water O
solubility O
of O
insoluble O
hydrophobic O
cargos O
such O
as O
a O
perylene B
- I
bisimide I
derivative O
, O
[ O
60 O
] O
fullerene O
, O
or O
the O
anti O
- O
carcinogenic O
drug O
camptothecin B
( O
CPT B
) O
. O

GNS O
/ O
C60 B
inclusion O
complexes O
are O
able O
to O
establish O
specific O
interactions O
between O
peanut O
agglutinin O
( O
PNA O
) O
lectin O
and O
the O
lactose O
moiety O
surrounding O
the O
complexes O
, O
while O
CPT B
solubilized O
by O
GNS O
shows O
higher O
cytotoxicity O
toward O
MCF7 O
- O
type O
breast O
cancer O
cells O
than O
CPT B
alone O
. O

We O
focus O
on O
one O
materials O
pair O
, O
GaP O
/ O
Si B
, O
for O
which O
we O
use O
a O
wide O
range O
of O
growth O
parameters O
. O

We O
show O
that O
pure O
Si B
nanowires O
can O
be O
made O
to O
exhibit O
the O
same O
kinks O
and O
defects O
by O
changing O
their O
droplet O
volume O
. O

Reversal O
effect O
of O
rosmarinic B
acid I
on O
multidrug O
resistance O
in O
SGC7901 O
/ O
Adr O
cell O
. O

In O
this O
study O
, O
the O
aim O
was O
to O
explore O
the O
reversal O
effect O
and O
its O
potential O
mechanism O
of O
rosmarinic B
acid I
( O
RA O
) O
on O
SGC7901 O
/ O
Adr O
cells O
. O

3 O
- O
( O
4 O
, O
5 O
- O
Dimethylthiazol O
) O
- O
2 O
, O
5 O
- O
diphenyl O
tetrazolium O
bromide O
( O
MTT B
) O
assay O
was O
used O
to O
investigate O
the O
reversal O
index O
of O
RA O
in O
SGC7901 O
/ O
Adr O
cell O
line O
. O

The O
intracellular O
accumulation O
of O
adriamycin B
, O
rhodamine123 B
( O
Rh123 O
) O
, O
and O
the O
expression O
of O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
were O
assayed O
by O
flow O
cytometry O
. O

Two O
new O
piperidine B
alkaloids I
from O
Streptomyces O
sp O
. O

Two O
new O
piperidine B
alkaloids I
, O
streptazones O
E O
( O
1 O
) O
and O
F O
( O
2 O
) O
, O
were O
isolated O
from O
Streptomyces O
sp O
. O

Considering O
that O
many O
lead O
leishmanicidal O
compounds O
contain O
a O
quinoidal O
scaffold O
and O
the O
thiazole B
heterocyclic O
ring O
is O
found O
in O
a O
number O
of O
antimicrobial O
drugs O
, O
we O
proposed O
a O
hybridization O
approach O
to O
generate O
a O
diverse O
set O
of O
semi O
- O
synthetic O
heterocycles O
with O
antileishmanial O
activity O
. O

Two O
new O
sesquiterpenes B
from O
cultures O
of O
the O
basidiomycete O
Agaricus O
arvensis O
. O

Two O
new O
drimane O
sesquiterpenoids B
, O
11 O
, O
12 O
- O
dihydroxy O
- O
15 O
- O
drimeneoic O
acid O
( O
1 O
) O
and O
3 O
alpha O
, O
11 O
, O
15 O
- O
trihydroxydrimene O
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
basidiomycete O
Agaricus O
arvensis O
, O
together O
with O
one O
known O
compound O
3 O
beta O
, O
11 O
, O
12 O
- O
trihydroxydrimene O
( O
3 O
) O
. O

Calmodulin O
as O
a O
potential O
target O
by O
which O
berberine B
induce O
cell O
cycle O
arrest O
in O
human O
hepatoma O
Bel7402 O
cells O
. O

Berberine B
is O
an O
isoquinoline B
alkaloid I
that O
has O
drawn O
extensive O
attention O
since O
it O
possesses O
various O
biological O
activities O
. O

Several O
mechanisms O
have O
been O
proposed O
to O
interpret O
the O
anticancer O
activity O
of O
berberine B
. O

However O
, O
these O
explanations O
are O
mostly O
based O
on O
its O
downstream O
- O
regulated O
genes O
or O
proteins O
, O
information O
on O
the O
direct O
target O
proteins O
that O
mediate O
the O
antiproliferative O
action O
of O
berberine B
remain O
unclear O
. O

In O
the O
present O
study O
, O
a O
computational O
pipeline O
based O
on O
a O
ligand O
- O
protein O
inverse O
docking O
program O
and O
mining O
of O
the O
" O
Connectivity O
MAP O
" O
data O
was O
adopted O
to O
explore O
the O
potential O
target O
proteins O
for O
berberine B
. O

The O
results O
showed O
that O
four O
proteins O
, O
i O
. O
e O
. O
, O
calmodulin O
, O
cytochrome O
P450 O
3A4 O
, O
sex O
hormone O
- O
binding O
globulin O
and O
carbonic O
anhydrase O
II O
, O
were O
suggested O
to O
be O
the O
potential O
targets O
of O
berberine B
. O

The O
anti O
- O
calmodulin O
property O
of O
berberine B
was O
demonstrated O
with O
an O
in O
vitro O
phosphodiesterase O
activity O
assay O
. O

Flow O
cytometric O
analysis O
found O
that O
G1 O
cell O
cycle O
arrest O
induced O
by O
berberine B
in O
Bel7402 O
cells O
was O
enhanced O
by O
cotreatment O
with O
calmodulin O
inhibitors O
. O

Western O
blotting O
results O
indicated O
that O
berberine B
treatment O
decreased O
phosphorylation O
of O
calmodulin O
kinase O
II O
and O
blocked O
subsequent O
MEK1 O
activation O
as O
well O
as O
p27 O
protein O
degradation O
. O

These O
results O
suggested O
that O
calmodulin O
might O
play O
crucial O
roles O
in O
berberine B
- O
induced O
cell O
cycle O
arrest O
in O
cancer O
cells O
. O

Two O
new O
sesquiterpenoids B
from O
the O
fungus O
Ceriporia O
alachuana O
. O

Two O
new O
sesquiterpenoids B
, O
tremulenolide O
D O
( O
1 O
) O
and O
muurolane O
- O
10 O
beta O
, O
15 O
- O
diol O
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids B
, O
tremulenediol O
A O
( O
3 O
) O
, O
2 O
beta O
- O
hydroxy O
- O
alpha O
- O
candinol O
( O
4 O
) O
, O
epicubenol O
( O
5 O
) O
, O
and O
3 O
beta O
- O
hydroxy O
- O
delta O
- O
candinol O
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

Structurally O
, O
compounds O
1 O
and O
3 O
are O
tremulane O
- O
type O
sesquiterpenoids B
with O
an O
unusual O
perhydroazulene O
carbon B
skeleton O
. O

We O
have O
investigated O
the O
adsorption O
and O
organization O
at O
the O
air O
/ O
water O
interface O
of O
catanionic O
molecules O
released O
from O
a O
dispersion O
of O
solid O
- O
like O
catanionic O
vesicles O
composed O
of O
myristic B
acid I
and O
cetyl O
trimethylammonium O
chloride O
at O
the O
2 O
: O
1 O
ratio O
. O

Two O
new O
coumarin O
glycosides O
, O
namely O
nitensosides O
A O
- O
B O
( O
1 O
- O
2 O
) O
, O
together O
with O
six O
known O
compounds O
, O
scopolin B
( O
3 O
) O
, O
5 O
, O
6 O
, O
7 O
- O
trimethoxycoumarin O
( O
4 O
) O
, O
d O
- O
calycanthine O
( O
5 O
) O
, O
calycanthoside O
( O
6 O
) O
, O
xeroboside O
( O
7 O
) O
, O
and O
scopoletin B
( O
8 O
) O
, O
were O
isolated O
from O
Chimonanthus O
nitens O
. O

Comparisons O
are O
made O
to O
the O
known O
electronic O
states O
of O
CuF O
, O
CuCl O
, O
CuBr O
, O
and O
CuI O
, O
and O
it O
is O
argued O
that O
like O
these O
molecules O
, O
the O
CuCCH O
molecule O
is O
essentially O
ionic O
in O
both O
the O
ground O
and O
excited O
states O
, O
with O
the O
ground O
state O
correlating O
diabatically O
to O
Cu B
( I
+ I
) I
( O
3d O
( O
10 O
) O
, O
( O
1 O
) O
S O
) O
+ O
CCH O
( O
- O
) O
( O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
) O
and O
the O
excited O
states O
correlating O
diabatically O
to O
Cu B
( I
+ I
) I
( O
3d O
( O
9 O
) O
4s O

Measurements O
were O
carried O
out O
for O
pH O
3 O
. O
5 O
and O
an O
ionic O
strength O
range O
of O
10 O
( O
- O
3 O
) O
to O
0 O
. O
15 O
M O
NaCl B
. O

It O
was O
revealed O
that O
cyclic O
variations O
in O
NaCl B
concentration O
between O
10 O
( O
- O
3 O
) O
and O
0 O
. O
15 O
M O
induced O
no O
changes O
in O
the O
latex O
electrophoretic O
mobility O
, O
suggesting O
that O
there O
were O
no O
irreversible O
molecule O
orientation O
changes O
in O
the O
monolayers O
. O

A O
new O
type O
of O
protective O
surface O
layer O
for O
high O
- O
capacity O
Ni B
- O
based O
cathode O
materials O
: O
nanoscaled O
surface O
pillaring O
layer O
. O

A O
solid O
solution O
series O
of O
lithium O
nickel O
metal O
oxides O
, O
Li O
[ O
Ni O
( O
1 O
- O
x O
) O
M O
( O
x O
) O
] O
O2 O
( O
with O
M O
= O
Co B
, O
Mn B
, O
and O
Al B
) O
have O
been O
investigated O
intensively O
to O
enhance O
the O
inherent O
structural O
instability O
of O
LiNiO2 O
. O

However O
, O
when O
a O
voltage O
range O
of O
Ni B
- O
based O
cathode O
materials O
was O
increased O
up O
to O
> O
4 O
. O
5 O
V O
, O
phase O
transitions O
occurring O
above O
4 O
. O
3 O
V O
resulted O
in O
accelerated O
formation O
of O
the O
trigonal O
phase O
( O
P3m1 O
) O
and O
NiO B
phases O
, O
leading O
to O
and O
pulverization O
of O
the O
cathode O
during O
cycling O
at O
60 O
degrees O
C O
. O

In O
an O
attempt O
to O
overcome O
these O
problems O
, O
LiNi0 O
. O
62Co0 O
. O
14Mn0 O
. O
24O2 O
cathode O
material O
with O
pillar O
layers O
in O
which O
Ni B
( I
2 I
+ I
) I
ions O
were O
resided O
in O
Li B
slabs O
near O
the O
surface O
having O
a O
thickness O
of O
~ O
10 O
nm O
was O
prepared O
using O
a O
polyvinylpyrrolidone B
( O
PVP B
) O
functionalized O
Mn B
precursor O
coating O
on O
Ni0 O
. O
7Co0 O
. O
15Mn0 O
. O
15 O
( O
OH O
) O
2 O
. O

Bioactive O
phenolics B
from O
Seriphidium O
stenocephalum O
. O

Chromatographic O
separation O
of O
the O
ethyl B
acetate I
soluble O
part O
of O
the O
methanolic O
extract O
from O
Seriphidium O
stenocephalum O
yielded O
three O
new O
compounds O
: O
stenocepflavone O
( O
1 O
) O
, O
stenocepflavan O
( O
2 O
) O
, O
and O
stenocephol O
( O
3 O
) O
, O
together O
with O
cirsimaritin B
( O
4 O
) O
, O
5 O
, O
7 O
, O
5 O
' O
- O
trihydroxy O
- O
3 O
' O
, O
4 O
' O
, O
6 O
- O
trimethoxyflavone O
( O
5 O
) O
, O
5 O
, O
6 O
, O
7 O
, O
5 O
' O
- O
tetrahydroxy O

Most O
of O
the O
studies O
collected O
in O
the O
literature O
are O
on O
deoxynivalenol B
and O
zearalenone B
mycotoxins O
. O

The O
biomolecules O
identified O
so O
far O
participate O
in O
many O
metabolic O
pathways O
, O
including O
energy O
metabolism O
( O
glucose B
and O
lipid O
metabolism O
) O
, O
protein O
metabolic O
processes O
and O
protein O
folding O
, O
cytoskeleton O
structure O
, O
immune O
response O
, O
inflammation O
and O
iron O
metabolism O
, O
fibrinolysis O
and O
thrombosis O
, O
oxidative O
stress O
and O
intracellular O
calcium B
metabolism O
. O

Antioxidative O
polyphenols B
from O
Nigerian O
mistletoe O
Loranthus O
micranthus O
( O
Linn O
. O
) O
parasitizing O
on O
Hevea O
brasiliensis O
. O

Two O
new O
phenolic B
glycosides I
, O
linamarin O
gallate O
( O
1 O
) O
and O
walsuraside O
B O
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin O
3 O
- O
O O
- O
( O
3 O
- O
O O
- O
methyl O
) O
gallate O
( O
6 O
) O
, O
epicatechin O
3 O
- O
O O
- O
( O
3 O
, O
5 O
- O
O O
- O
dimethyl O
) O
gallate O
( O
7 O
) O
, O
epicatechin O
3 O
- O
O O
- O
( O
3 O
, O
4 O
, O
5 O
- O
O O
- O
trimethyl O

) O
gallate O
( O
8 O
) O
, O
quercetin O
3 O
- O
O O
- O
beta O
- O
d O
- O
glucopyranoside O
( O
9 O
) O
, O
rutin B
( O
10 O
) O
, O
and O
peltatoside O
( O
11 O
) O
, O
were O
isolated O
from O
the O
leafy O
twigs O
of O
Nigerian O
mistletoe O
Loranthus O
micranthus O
( O
Linn O
. O
) O
parasitic O
on O
Hevea O
brasiliensis O
. O

The O
structures O
of O
the O
new O
compounds O
were O
unambiguously O
elucidated O
by O
1D O
( O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
) O
, O
2D O
NMR O
( O
COSY O
, O
HSQC O
, O
and O
HMBC O
) O
and O
by O
mass O
spectroscopy O
. O

The O
antioxidant O
activities O
of O
the O
isolated O
compounds O
( O
1 O
- O
11 O
) O
were O
evaluated O
using O
the O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
) O
assay O
. O

The O
neuroprotector O
kynurenic B
acid I
increases O
neuronal O
cell O
survival O
through O
neprilysin O
induction O
. O

Kynurenic B
acid I
( O
KYNA B
) O
, O
one O
of O
the O
main O
product O
of O
the O
kynurenine O
pathway O
originating O
from O
tryptophan B
, O
is O
considered O
to O
be O
neuroprotective O
. O

Dysregulation O
of O
KYNA B
activity O
is O
thought O
to O
be O
involved O
in O
neurodegenerative O
diseases O
, O
the O
physiopathology O
of O
which O
evokes O
excitotoxicity O
, O
oxidative O
stress O
and O
/ O
or O
protein O
aggregation O
. O

The O
neuroprotective O
effect O
of O
KYNA B
is O
generally O
attributed O
to O
its O
antagonistic O
action O
on O
NMDA B
receptors O
. O

However O
, O
this O
single O
target O
action O
appears O
insufficient O
to O
support O
KYNA B
beneficial O
effects O
against O
complex O
neurodegenerative O
processes O
including O
neuroinflammation O
, O
beta O
- O
amyloid O
peptide O
( O
A O
beta O
) O
toxicity O
and O
apoptosis O
. O

Novel O
insights O
are O
therefore O
required O
to O
elucidate O
KYNA B
neuroprotective O
mechanisms O
. O

Here O
, O
we O
combined O
cellular O
, O
biochemical O
, O
molecular O
and O
pharmacological O
approaches O
to O
demonstrate O
that O
low O
micromolar O
concentrations O
of O
KYNA B
strongly O
induce O
neprilysin O
( O
NEP O
) O
gene O
expression O
, O
protein O
level O
and O
enzymatic O
activity O
increase O
in O
human O
neuroblastoma O
SH O
- O
SY5Y O
cells O
. O

Furthermore O
, O
our O
studies O
revealed O
that O
KYNA B
exerts O
a O
protective O
effect O
on O
SH O
- O
SY5Y O
cells O
by O
increasing O
their O
viability O
through O
a O
mechanism O
independent O
from O
NMDA B
receptors O
. O

Interestingly O
, O
KYNA B
also O
induced O
NEP O
activity O
and O
neuroprotection O
in O
mouse O
cortical O
neuron O
cultures O
the O
viability O
of O
which O
was O
more O
promoted O
than O
SH O
- O
SY5Y O
cell O
survival O
under O
KYNA B
treatment O
. O

KYNA B
- O
evoked O
neuroprotection O
disappeared O
in O
the O
presence O
of O
thiorphan O
, O
an O
inhibitor O
of O
NEP O
activity O
. O

Therefore O
, O
our O
results O
suggest O
that O
a O
part O
of O
the O
neuroprotective O
role O
of O
KYNA B
may O
depend O
on O
its O
ability O
to O
induce O
the O
expression O
and O
/ O
or O
activity O
of O
the O
amyloid O
- O
degrading O
enzyme O
NEP O
in O
nerve O
cells O
. O

We O
now O
show O
that O
lysine B
- O
specific O
molecular O
tweezers O
bind O
to O
a O
14 O
- O
3 O
- O
3 O
adapter O
protein O
and O
modulate O
its O
interaction O
with O
partner O
proteins O
. O

Protein O
crystallography O
shows O
that O
this O
effect O
arises O
from O
the O
binding O
of O
the O
tweezers O
to O
a O
single O
surface O
- O
exposed O
lysine B
( O
Lys214 O
) O
of O
the O
14 O
- O
3 O
- O
3 O
protein O
in O
the O
proximity O
of O
its O
central O
channel O
, O
which O
normally O
binds O
the O
partner O
proteins O
. O

SIRT1 O
inhibits O
NADPH B
oxidase O
activation O
and O
protects O
endothelial O
function O
in O
the O
rat O
aorta O
: O
Implications O
for O
vascular O
aging O
. O

Vascular O
aging O
is O
characterized O
by O
up O
- O
regulation O
of O
NADPH B
oxidase O
, O
oxidative O
stress O
and O
endothelial O
dysfunction O
. O

Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD B
( I
+ I
) I
- O
dependent O
deacetylase O
SIRT1 O
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti O
- O
aging O
cardiovascular O
effects O
. O

To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH B
oxidase O
- O
dependent O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
( O
nicotinamide B
, O
sirtinol O
, O
EX527 O
) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O

Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium O
- O
dependent O
vasodilators O
acetylcholine B
and O
the O
calcium B
ionophore O
A23187 O
. O

Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH B
oxidase O
inhibitor O
apocynin B
or O
superoxide B
dismutase O
. O

Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide B
production O
, O
enhanced O
NADPH B
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22 O
( O
phox O
) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol B
. O

Peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
( O
PPAR O
alpha O
) O
activation O
mimicked O
the O
effects O
of O
resveratrol B
while O
PPAR O
alpha O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O

SIRT1 O
co O
- O
precipitated O
with O
PPAR O
alpha O
and O
nicotinamide B
increased O
the O
acetylation O
of O
the O
PPAR O
alpha O
coactivator O
PGC O
- O
1 O
alpha O
, O
which O
was O
suppressed O
by O
resveratrol B
. O

In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up O
- O
regulates O
NADPH B
oxidase O
- O
derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O

Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O
a O
decreased O
PGC O
- O
1 O
alpha O
acetylation O
and O
the O
subsequent O
PPAR O
alpha O
activation O
, O
resulting O
in O
both O
decreased O
NADPH B
oxidase O
- O
driven O
ROS O
production O
and O
NO B
inactivation O
. O

A O
block O
/ O
homo O
- O
mixed O
polyplex O
micelle O
, O
comprising O
of O
cationic O
homo O
polymer O
: O
poly O
{ O
N O
' O
- O
[ O
N O
- O
( O
2 O
- O
aminoethyl O
) O
- O
2 O
- O
aminoethyl O
] O
aspartamide O
} O
P O
[ O
Asp O
( O
DET O
) O
] O
and O
block O
copolymer O
: O
polyethylene B
glycol I
( O
PEG O
) O
- O
b O
- O
P O
[ O
Asp O
( O
DET O
) O
] O
, O
has O
been O
reported O
to O
exhibit O
the O
efficient O
transgene O
expression O
in O
vivo O
by O
intratracheal O
and O
systemic O
administration O
. O

High O
- O
glucose B
environment O
enhanced O
oxidative O
stress O
and O
increased O
interleukin O
- O
8 O
secretion O
from O
keratinocytes O
: O
New O
insights O
on O
impaired O
diabetic O
wound O
healing O
. O

Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high O
- O
glucose B
environment O
enhanced O
IL O
- O
8 O
production O
via O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
- O
extracelluar O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
pathway O
in O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
- O
dependent O
manner O
in O
keratinocytes O
. O

In O
conclusion O
, O
IL O
- O
8 O
production O
and O
neutrophil O
infiltration O
are O
increased O
in O
high O
- O
glucose B
environment O
due O
to O
elevated O
ROS O
level O
and O
contributed O
to O
impaired O
wound O
healing O
in O
diabetic O
skin O
. O

The O
influence O
of O
salinity O
on O
acute O
nickel B
toxicity O
to O
the O
two O
euryhaline O
fish O
species O
, O
Fundulus O
heteroclitus O
and O
Kryptolebias O
marmoratus O
. O

Nickel B
( O
Ni B
) O
is O
a O
common O
pollutant O
found O
in O
aquatic O
environments O
and O
may O
be O
harmful O
at O
elevated O
concentrations O
. O

In O
the O
present O
study O
, O
acute O
Ni B
toxicity O
experiments O
( O
96 O
- O
h O
) O
were O
conducted O
at O
various O
salinities O
( O
0 O
- O
36 O
ppt O
) O
to O
determine O
the O
effects O
of O
salinity O
on O
Ni B
toxicity O
to O
2 O
euryhaline O
fish O
species O
, O
Kryptolebias O
marmoratus O
and O
Fundulus O
heteroclitus O
. O

Nickel B
concentrations O
causing O
lethality O
to O
50 O
% O
of O
the O
fish O
ranged O
from O
2 O
mg O
/ O
L O
in O
moderately O
hard O
freshwater O
to O
66 O
. O
6 O
mg O
/ O
L O
in O
36 O
ppt O
saltwater O
. O

Nickel B
toxicity O
to O
F O
. O
heteroclitus O
decreased O
linearly O
with O
increasing O
salinity O
; O
however O
, O
Ni B
toxicity O
to O
K O
. O
marmoratus O
was O
only O
lowered O
by O
salinities O
above O
6 O
ppt O
, O
demonstrating O
potential O
physiological O
differences O
between O
the O
2 O
species O
when O
they O
are O
functioning O
as O
freshwater O
fish O
. O

Furthermore O
, O
the O
authors O
investigated O
the O
influence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
and O
Cl B
( I
- I
) I
on O
Ni B
toxicity O
to O
F O
. O
heteroclitus O
. O

Freshwater O
with O
up O
to O
120 O
mg O
/ O
L O
Ca B
( I
2 I
+ I
) I
as O
CaSO4 B
, O
250 O
mg O
/ O
L O
Mg B
( I
2 I
+ I
) I
as O
MgSO4 O
, O
or O
250 O
mg O
/ O
L O
Na B
( I
+ I
) I
as O
NaHCO3 O
did O
not O
provide O
protection O
against O
Ni B
toxicity O
. O

Alternatively O
, O
250 O
mg O
/ O
L O
Na B
( I
+ I
) I
, O
as O
NaCl B
, O
was O
protective O
against O
Ni B
toxicity O
; O
and O
the O
extent O
of O
protection O
was O
similar O
to O
that O
demonstrated O
from O
salt O
water O
with O
the O
same O
Cl B
( I
- I
) I
concentration O
. O

These O
results O
suggest O
that O
Cl B
( I
- I
) I
is O
the O
predominant O
ion O
responsible O
for O
reducing O
Ni B
toxicity O
to O
K O
. O
marmoratus O
and O
F O
. O
heteroclitus O
in O
higher O
salinity O
waters O
. O

Evaluation O
of O
phytotoxicity O
and O
genotoxicity O
of O
nitrobenzene B
with O
A O
battery O
of O
Vicia O
Faba O
assay O
system O
. O

Nitrobenzene B
( O
NB O
) O
is O
an O
important O
organic O
compound O
intermediate O
that O
is O
used O
widely O
in O
industry O
. O

The O
results O
showed O
that O
OciBest O
( O
TM O
) O
( O
7 O
. O
9 O
- O
2500 O
. O
0 O
micro O
g O
/ O
mL O
) O
did O
not O
increase O
the O
number O
of O
histidine B
revertant O
colonies O
in O
Salmonella O
typhimurium O
strains O
( O
TA98 O
and O
TAMix O
) O
with O
and O
without O
exogenous O
metabolic O
activation O
( O
S9 O
) O
. O

N B
- I
Acetylcysteine I
prevents O
doxorubucine O
- O
induced O
cardiotoxicity O
in O
rats O
. O

This O
study O
is O
designed O
to O
observe O
the O
effects O
of O
N B
- I
acetylcysteine I
( O
NAC B
) O
on O
doxorubucine O
- O
induced O
cardiac O
toxicity O
in O
rats O
both O
histologically O
and O
biochemically O
. O

The O
first O
group O
received O
only O
200 O
mg O
/ O
kg O
NAC B
intraperitoneal O
( O
i O
. O
p O
. O
) O
once O
every O
24 O
h O
for O
5 O
days O
( O
group O
1 O
) O
; O
the O
second O
group O
received O
20 O
mg O
/ O
kg O
doxorubucine O
( O
DOX B
) O
i O
. O
p O
. O
single O
dose O
plus O
NAC B
200 O
mg O
/ O
kg O
i O
. O
p O
. O
once O
every O
24 O
h O
for O
5 O
days O
( O
group O
2 O
) O
; O
the O
third O
group O
received O
DOX B
20 O
mg O
/ O
kg O
DOX B
i O
. O
p O
. O
single O
dose O
( O
group O
3 O
) O
and O
the O
fourth O
group O
, O
which O
is O
also O
the O
control O
group O
, O
received O
saline O
( O
group O
4 O
) O
. O

Tissue O
thiobarbituric B
acid I
reactive O
substance O
( O
TBARS O
) O
and O
nitric B
oxide I
( O
NO B
) O
levels O
were O
highest O
in O
the O
DOX B
group O
. O

In O
the O
DOX B
- O
treated O
rats O
, O
serum O
TBARS O
, O
NO B
, O
aspartate B
transaminase O
, O
lactate B
dehydrogenase O
and O
creatine B
kinase O
levels O
were O
highest O
when O
compared O
with O
other O
groups O
. O

Except O
for O
serum O
superoxide B
dismutase O
levels O
, O
all O
other O
parameters O
differed O
significantly O
between O
the O
DOX B
plus O
NAC B
group O
and O
the O
DOX B
group O
. O

In O
the O
DOX B
plus O
NAC B
group O
, O
general O
architecture O
was O
preserved O
better O
than O
the O
DOX B
group O
and O
myofibril O
loss O
was O
minimal O
compared O
with O
the O
DOX B
group O
. O

NAC B
demonstrated O
, O
both O
biochemically O
and O
histologically O
, O
to O
be O
effective O
in O
the O
prevention O
of O
DOX B
- O
induced O
cardiotoxicity O
in O
rat O
models O
. O

Evaluation O
of O
NAC B
' O
s O
effect O
on O
DOX B
toxicity O
warrants O
further O
clinical O
trials O
on O
cancer O
patients O
. O

Synergistic O
GABA B
- O
Enhancing O
Therapy O
against O
Seizures O
in O
a O
Mouse O
Model O
of O
Dravet O
Syndrome O
. O

An O
extreme O
example O
is O
Dravet O
syndrome O
( O
DS O
) O
, O
an O
infantile O
- O
onset O
severe O
epilepsy O
caused O
by O
heterozygous O
loss O
of O
function O
mutations O
in O
SCN1A O
, O
the O
gene O
encoding O
the O
brain O
type O
- O
I O
voltage O
- O
gated O
sodium B
channel O
NaV1 O
. O
1 O
. O

Studies O
in O
Scn1a O
heterozygous O
knockout O
mice O
demonstrate O
reduced O
excitability O
of O
GABAergic O
interneurons O
, O
suggesting O
that O
enhancement O
of O
GABA B
signaling O
may O
improve O
seizure O
control O
and O
comorbidities O
. O

We O
studied O
the O
efficacy O
of O
two O
GABA B
- O
enhancing O
drugs O
, O
clonazepam B
and O
tiagabine B
, O
alone O
and O
in O
combination O
, O
against O
thermally O
evoked O
myoclonic O
and O
generalized O
tonic O
- O
clonic O
seizures O
. O

Clonazepam B
, O
a O
positive O
allosteric O
modulator O
of O
GABA B
- O
A O
receptors O
, O
protected O
against O
myoclonic O
and O
generalized O
tonic O
- O
clonic O
seizures O
. O

Tiagabine B
, O
a O
presynaptic O
GABA B
reuptake O
inhibitor O
, O
was O
protective O
against O
generalized O
tonic O
- O
clonic O
seizures O
but O
only O
minimally O
protective O
against O
myoclonic O
seizures O
and O
enhanced O
myoclonic O
seizure O
susceptibility O
at O
high O
doses O
. O

Combined O
therapy O
with O
clonazepam B
and O
tiagabine B
was O
synergistic O
against O
generalized O
tonic O
- O
clonic O
seizures O
but O
was O
additive O
against O
myoclonic O
seizures O
. O

The O
synergistic O
actions O
of O
clonazepam B
and O
tiagabine B
gave O
enhanced O
seizure O
protection O
and O
reduced O
toxicity O
, O
suggesting O
that O
combination O
therapy O
may O
be O
well O
tolerated O
and O
effective O
for O
seizures O
in O
DS O
. O

Binding O
of O
glyco O
- O
acridine B
derivatives O
to O
lysozyme O
leads O
to O
inhibition O
of O
amyloid O
fibrillization O
. O

The O
semiempirical O
quantum O
PM6 O
- O
DH O
+ O
method O
provided O
a O
good O
correlation O
pointing O
to O
the O
importance O
of O
quantum O
effects O
on O
the O
binding O
of O
glyco O
- O
acridine B
derivatives O
to O
lysozyme O
. O

The O
most O
abundant O
components O
in O
the O
stems O
oil O
included O
carvacrol B
( O
60 O
. O
8 O
% O
) O
, O
alpha B
- I
terpineol I
( O
4 O
. O
7 O
% O
) O
and O
p O
- O
cymene O
( O
2 O
. O
4 O
% O
) O
, O
while O
carvacrol B
( O
33 O
% O
) O
, O
p O
- O
cymene O
( O
25 O
. O
3 O
% O
) O
and O
alpha B
- I
pinene I
( O
11 O
. O
6 O
% O
) O
were O
the O
main O
components O
in O
the O
leaves O
. O

In O
the O
inflorescences O
, O
carvacrol B
( O
84 O
. O
9 O
% O
) O
is O
the O
major O
component O
. O

Quantum O
mechanics O
/ O
molecular O
mechanics O
modeling O
of O
fatty B
acid I
amide I
hydrolase O
reactivation O
distinguishes O
substrate O
from O
irreversible O
covalent O
inhibitors O
. O

Carbamate B
and O
urea B
derivatives O
are O
important O
classes O
of O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
inhibitors O
that O
carbamoylate O
the O
active O
- O
site O
nucleophile O
Ser241 O
. O

The O
potential O
energy O
surfaces O
for O
decarbamoylation O
of O
FAAH O
covalent O
adducts O
, O
derived O
from O
the O
O B
- O
aryl O
carbamate O
URB597 O
and O
from O
the O
N B
- O
piperazinylurea O
JNJ1661610 O
, O
were O
calculated O
and O
compared O
to O
that O
for O
deacylation O
of O
FAAH O
acylated O
by O
the O
substrate O
oleamide O
. O

Isoelectric O
focusing O
, O
SDS B
- O
PAGE O
, O
native O
PAGE O
and O
2D O
electrophoresis O
( O
2D O
- O
PAGE O
) O
have O
been O
frequently O
applied O
for O
this O
purpose O
. O

Supplementary O
techniques O
are O
fluorophore O
- O
assisted O
carbohydrate B
electrophoresis O
and O
sarcosyl O
- O
PAGE O
. O

Reagent O
array O
analysis O
combined O
with O
SDS B
- O
PAGE O
and O
western O
blotting O
proved O
especially O
useful O
for O
this O
purpose O
. O

Silver B
- O
zwitterion O
organic O
- O
inorganic O
nanocomposite O
with O
antimicrobial O
and O
antiadhesive O
capabilities O
. O

In O
this O
work O
, O
we O
demonstrate O
a O
convenient O
, O
efficient O
, O
and O
environmentally O
benign O
strategy O
to O
achieving O
antimicrobial O
and O
antiadhesive O
purposes O
using O
a O
silver B
- O
zwitterion O
nanocomposite O
. O

The O
synthesis O
of O
the O
nanocomposite O
relies O
on O
loading O
zwitterionic O
polymer O
brushes O
with O
Ag B
( I
+ I
) I
precursor O
ions O
, O
followed O
by O
their O
in O
situ O
reduction O
to O
Ag B
nanoparticle O
by O
ultraviolet O
( O
UV O
) O
irradiation O
. O

Both O
poly O
( O
sulfobetaine O
methacrylate O
) O
( O
pSBMA O
) O
and O
poly O
( O
carboxybetaine O
methacrylate O
) O
( O
pCBMA O
) O
have O
been O
studied O
as O
matrices O
for O
the O
embedding O
of O
silver B
. O

Well O
- O
dispersed O
silver B
nanoparticles O
are O
embedded O
into O
pCBMA O
matrices O
. O

The O
obtained O
pCBMA O
- O
silver B
hybrid O
( O
CB O
- O
Ag B
) O
is O
capable O
of O
killing O
bacteria O
upon O
contact O
and O
releasing O
dead O
bacteria O
under O
wet O
conditions O
. O

benzimidazol O
- O
2 O
( O
10H O
) O
- O
one O
13 O
, O
as O
well O
as O
the O
in O
vitro O
evaluation O
of O
their O
inhibitory O
activity O
on O
human O
platelet O
aggregation O
induced O
in O
platelet O
- O
rich O
plasma O
by O
ADP O
, O
collagen O
or O
the O
Ca B
( I
2 I
+ I
) I
ionophore O
A23187 O
were O
here O
described O
. O

Multiple O
- O
quantum O
( B
1 I
) I
H I
NMR O
spectroscopy O
has O
been O
finding O
a O
renewed O
interest O
for O
its O
possible O
applications O
in O
the O
analysis O
of O
mixtures O
of O
small O
molecules O
, O
due O
to O
its O
simplification O
properties O
. O

Cerebral O
involvement O
was O
confirmed O
by O
magnetic O
resonance O
imaging O
and O
histologic O
examination O
of O
brain O
sections O
after O
hematoxylin B
- O
eosin B
- O
safran O
or O
silver B
staining O
. O

Modeling O
toxic O
stress O
by O
atrazine B
in O
a O
marine O
consumer O
- O
resource O
system O
. O

The O
present O
study O
combines O
short O
- O
term O
experiments O
with O
food O
chain O
modeling O
to O
explore O
the O
long O
- O
term O
effects O
of O
the O
herbicide O
atrazine B
on O
consumer O
- O
resource O
dynamics O
in O
a O
marine O
intertidal O
ecosystem O
. O

Short O
- O
term O
( O
28 O
d O
) O
lab O
experiments O
indicated O
that O
the O
intrinsic O
rate O
of O
increase O
( O
r O
) O
and O
carrying O
capacity O
( O
K O
) O
of O
the O
marine O
diatom O
Seminavis O
robusta O
decreased O
with O
increasing O
atrazine B
exposure O
. O

These O
experimentally O
observed O
atrazine B
- O
induced O
decreases O
of O
r O
and O
K O
were O
used O
to O
parameterize O
a O
Rosenzweig O
- O
MacArthur O
model O
representing O
a O
simple O
food O
chain O
including O
the O
tested O
diatom O
and O
its O
grazer O
, O
the O
harpacticoid O
copepod O
Delavalia O
palustris O
var O
. O
palustris O
. O

Stable O
oscillation O
zoo O
- O
phytobenthos O
systems O
were O
produced O
at O
diatom O
exposures O
of O
0 O
, O
100 O
, O
and O
150 O
micro O
g O
/ O
L O
atrazine B
. O

An O
atrazine B
concentration O
of O
150 O
micro O
g O
/ O
L O
contributed O
to O
a O
15 O
% O
increase O
of O
the O
oscillation O
periods O
of O
both O
diatoms O
and O
copepods O
as O
well O
as O
a O
52 O
% O
reduction O
of O
oscillation O
amplitudes O
compared O
with O
the O
control O
situation O
. O

Although O
the O
amplitudes O
of O
copepods O
increased O
only O
7 O
% O
at O
150 O
micro O
g O
/ O
L O
atrazine B
, O
the O
maximum O
and O
minimum O
copepod O
densities O
at O
that O
concentration O
were O
reduced O
61 O
and O
63 O
% O
, O
respectively O
. O

The O
effects O
of O
atrazine B
on O
periodicity O
and O
amplitudes O
were O
robust O
to O
20 O
% O
changes O
in O
the O
food O
- O
chain O
model O
parameters O
that O
represented O
allometric O
relationships O
. O

Comparison O
of O
the O
anti O
- O
dopamine B
D2 O
and O
anti O
- O
serotonin B
5 O
- O
HT2A O
activities O
of O
chlorpromazine B
, O
bromperidol O
, O
haloperidol B
and O
second O
- O
generation O
antipsychotics O
parent O
compounds O
and O
metabolites O
thereof O
. O

Second O
- O
generation O
antipsychotics O
, O
which O
have O
become O
the O
standard O
drug O
therapies O
for O
schizophrenia O
, O
are O
known O
to O
have O
a O
serotonin B
5 O
- O
HT2A O
receptor O
blocking O
effect O
in O
addition O
to O
a O
dopamine B
D2 O
receptor O
blocking O
effect O
. O

However O
, O
although O
chlorpromazine B
( O
CPZ B
) O
has O
a O
5 O
- O
HT2A O
receptor O
blocking O
effect O
and O
has O
the O
profile O
of O
a O
second O
- O
generation O
antipsychotic O
in O
vitro O
, O
it O
loses O
this O
pharmacological O
profile O
in O
vivo O
. O

In O
order O
to O
elucidate O
the O
differences O
between O
the O
in O
vivo O
and O
in O
vitro O
pharmacological O
characteristics O
of O
CPZ B
, O
we O
used O
a O
radioreceptor O
assay O
to O
measure O
the O
anti O
- O
D2 O
activity O
and O
the O
anti O
- O
5 O
- O
HT2A O
activity O
of O
CPZ B
and O
five O
major O
metabolites O
of O
CPZ B
, O
and O
compared O
the O
results O
to O
the O
anti O
- O
D2 O
activity O
and O
anti O
- O
5 O
- O
HT2A O
activity O
of O
risperidone B
, O
zotepine O
, O
perospirone O
, O
the O
major O
metabolites O
of O
each O
of O
these O
drugs O
, O
and O
olanzapine B
, O

bromperidol O
, O
and O
haloperidol B
. O

The O
results O
revealed O
that O
CPZ B
exhibited O
little O
anti O
- O
5 O
- O
HT2A O
activity O
, O
regardless O
of O
the O
anti O
- O
D2 O
activity O
level O
, O
and O
that O
none O
of O
the O
metabolites O
possessed O
anti O
- O
5 O
- O
HT2A O
activity O
. O

This O
clarified O
that O
, O
unlike O
second O
- O
generation O
antipsychotics O
, O
the O
reason O
CPZ B
loses O
its O
second O
- O
generation O
antipsychotic O
profiles O
in O
vivo O
is O
because O
it O
does O
not O
have O
any O
metabolites O
that O
possess O
anti O
- O
5 O
- O
HT2A O
activity O
. O

Vapor O
- O
solid O
growth O
of O
high O
optical O
quality O
MoS B
2 I
monolayers O
with O
near O
- O
unity O
valley O
polarization O
. O

For O
example O
, O
Dirac O
valley O
polarization O
has O
been O
demonstrated O
in O
mechanically O
exfoliated O
monolayer O
MoS2 B
samples O
by O
polarization O
- O
resolved O
photoluminescence O
, O
although O
polarization O
has O
rarely O
been O
seen O
at O
room O
temperature O
. O

Here O
we O
report O
a O
new O
method O
for O
synthesizing O
high O
optical O
quality O
monolayer O
MoS2 B
single O
crystals O
up O
to O
25 O
mu O
m O
in O
size O
on O
a O
variety O
of O
standard O
insulating O
substrates O
( O
SiO2 B
, O
sapphire O
, O
and O
glass O
) O
using O
a O
catalyst O
- O
free O
vapor O
- O
solid O
growth O
mechanism O
. O

2 O
- O
Arylpyrazolo O
[ O
4 O
, O
3 O
- O
d O
] O
pyrimidin O
- O
7 O
- O
amino O
derivatives O
as O
new O
potent O
and O
selective O
human O
A3 O
Adenosine B
receptor O
antagonists O
. O

On O
the O
basis O
of O
our O
previously O
reported O
2 O
- O
arylpyrazolo O
[ O
4 O
, O
3 O
- O
d O
] O
pyrimidin O
- O
7 O
- O
ones O
, O
a O
set O
of O
2 O
- O
arylpyrazolo O
[ O
4 O
, O
3 O
- O
d O
] O
pyrimidin O
- O
7 O
- O
amines O
were O
designed O
as O
new O
human O
( O
h O
) O
A3 O
adenosine B
receptor O
( O
AR O
) O
antagonists O
. O

Lipophilic O
groups O
with O
different O
steric O
bulk O
were O
introduced O
at O
the O
5 O
- O
position O
of O
the O
bicyclic O
scaffold O
( O
R5 O
= O
Me B
, O
Ph B
, O
CH2Ph O
) O
, O
and O
different O
acyl B
and O
carbamoyl O
moieties O
( O
R7 O
) O
were O
appended O
on O
the O
7 O
- O
amino O
group O
, O
as O
well O
as O
a O
para O
- O
methoxy O
group O
inserted O
on O
the O
2 O
- O
phenyl O
ring O
. O

The O
presence O
of O
acyl B
groups O
turned O
out O
to O
be O
of O
paramount O
importance O
for O
an O
efficient O
and O
selective O
binding O
at O
the O
hA3 O
AR O
. O

Evaluation O
of O
difluoromethyl O
ketones O
as O
agonists O
of O
the O
gamma B
- I
aminobutyric I
acid I
type O
B O
( O
GABAB O
) O
receptor O
. O

The O
design O
, O
synthesis O
, O
biological O
evaluation O
, O
and O
in O
vivo O
studies O
of O
difluoromethyl O
ketones O
as O
GABAB O
agonists O
that O
are O
not O
structurally O
analogous O
to O
known O
GABAB O
agonists O
, O
such O
as O
baclofen B
or O
3 O
- O
aminopropyl O
phosphinic O
acid O
, O
are O
presented O
. O

Following O
evaluation O
at O
clinically O
relevant O
GABA B
receptors O
, O
we O
have O
identified O
a O
difluoromethyl O
ketone O
that O
is O
a O
potent O
GABAB O
agonist O
, O
obtained O
its O
X O
- O
ray O
structure O
, O
and O
presented O
preliminary O
in O
vivo O
data O
in O
alcohol B
- O
preferring O
mice O
. O

Resolution O
of O
the O
individual O
enantiomers O
of O
the O
difluoromethyl O
ketone O
provided O
a O
compound O
with O
full O
biological O
activity O
at O
concentrations O
less O
than O
an O
order O
of O
magnitude O
greater O
than O
the O
pharmaceutical O
, O
baclofen B
. O

Platinum B
- O
modulated O
cobalt B
nanocatalysts O
for O
low O
- O
temperature O
aqueous O
- O
phase O
Fischer O
- O
Tropsch O
synthesis O
. O

Fischer O
- O
Tropsch O
synthesis O
( O
FTS O
) O
is O
an O
important O
catalytic O
process O
for O
liquid O
fuel O
generation O
, O
which O
converts O
coal O
/ O
shale O
gas O
/ O
biomass O
- O
derived O
syngas O
( O
a O
mixture O
of O
CO B
and O
H2 B
) O
to O
oil O
. O

Coupling O
with O
atomic O
- O
resolution O
scanning O
transmission O
electron O
microscopy O
( O
STEM O
) O
and O
theoretical O
calculations O
, O
the O
outstanding O
activity O
is O
rationalized O
by O
the O
formation O
of O
Co B
overlayer O
structures O
on O
Pt B
NPs O
or O
Pt O
- O
Co O
alloy O
NPs O
. O

Cardiac O
hypertrophy O
, O
structural O
remodeling O
, O
and O
expression O
of O
the O
genes O
associated O
with O
fatty B
acid I
metabolism O
were O
examined O
in O
rats O
treated O
with O
triiodothyronine B
( O
T3 O
) O
alone O
( O
8 O
mu O
g O
/ O
100 O
g O
body O
weight O
( O
BW O
) O
, O
i O
. O
p O
. O
) O
for O
15 O
days O
or O
along O
with O
a O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
agonist O
bezafibrate O
( O
Bzf O
; O
30 O
mu O
g O
/ O
100 O
g O
BW O
, O
oral O
) O
and O
were O
found O
to O
improve O
in O
the O
Bzf O
co O
- O
treated O
condition O
. O

Hyperthyroidism O
- O
induced O
oxidative O
stress O
, O
reduction O
in O
cytochrome O
c O
oxidase O
activity O
, O
and O
myocardial O
ATP B
concentration O
were O
also O
significantly O
checked O
by O
Bzf O
. O

Plant O
polyphenols B
are O
reported O
to O
inhibit O
adipogenesis O
in O
cell O
and O
animal O
models O
of O
obesity O
. O

The O
total O
polyphenol B
content O
of O
unfermented O
C O
. O
subternata O
, O
unfermented O
C O
. O
maculata O
and O
fermented O
C O
. O
maculata O
extracts O
was O
25 O
. O
6 O
, O
22 O
. O
4 O
and O
10 O
. O
8g O
GAE O
/ O
100g O
, O
respectively O
. O

The O
major O
compounds O
present O
in O
the O
extracts O
were O
: O
the O
flavonoid B
, O
phloretin O
- O
3 O
' O
, O
5 O
' O
- O
di O
- O
C O
- O
glucoside O
in O
C O
. O
subternata O
, O
the O
xanthone O
, O
mangiferin O
in O
unfermented O
C O
. O
maculata O
and O
the O
flavanone O
, O
hesperidin O
in O
fermented O
C O
. O
maculata O
. O

All O
of O
the O
plant O
extracts O
inhibited O
intracellular O
triglyceride B
and O
fat O
accumulation O
, O
and O
decreased O
PPAR O
gamma O
2 O
expression O
. O

Both O
fermented O
and O
unfermented O
C O
. O
maculata O
, O
at O
concentrations O
greater O
than O
100 O
mu O
g O
/ O
ml O
, O
decreased O
cellular O
ATP B
content O
. O

Unraveling O
the O
mode O
of O
action O
of O
an O
obesogen O
: O
Mechanistic O
analysis O
of O
the O
model O
obesogen O
tributyltin B
in O
the O
3T3 O
- O
L1 O
cell O
line O
. O

The O
effects O
of O
cannabidiol B
on O
the O
antigen O
- O
induced O
contraction O
of O
airways O
smooth O
muscle O
in O
the O
guinea O
- O
pig O
. O

( B
- I
) I
- I
Delta I
( I
9 I
) I
- I
Tetrahydrocannabinol I
has O
been O
demonstrated O
to O
have O
beneficial O
effects O
in O
the O
airways O
, O
but O
its O
psychoactive O
effects O
preclude O
its O
therapeutic O
use O
for O
the O
treatment O
of O
airways O
diseases O
. O

In O
the O
present O
study O
we O
have O
investigated O
the O
effects O
of O
( B
- I
) I
- I
cannabidiol I
, O
a O
non O
- O
psychoactive O
component O
of O
cannabis O
for O
its O
actions O
on O
bronchial O
smooth O
muscle O
in O
vitro O
and O
in O
vivo O
. O

In O
addition O
, O
contractile O
responses O
of O
bronchial O
smooth O
muscle O
from O
ovalbumin O
- O
sensitized O
guinea O
- O
pigs O
were O
investigated O
in O
the O
absence O
or O
presence O
of O
( B
- I
) I
- I
cannabidiol I
. O

Furthermore O
, O
the O
effect O
of O
( B
- I
) I
- I
cannabidiol I
against O
ovalbumin O
- O
induced O
airway O
obstruction O
was O
investigated O
in O
vivo O
in O
ovalbumin O
- O
sensitized O
guinea O
- O
pigs O
. O

( B
- I
) I
- I
Cannabidiol I
did O
not O
influence O
the O
bronchial O
smooth O
muscle O
contraction O
induced O
by O
carbachol B
, O
histamine B
or O
neurokinin O
A O
. O

In O
contrast O
, O
( B
- I
) I
- I
cannabidiol I
inhibited O
anandamide B
- O
and O
virodhamine O
- O
induced O
responses O
of O
isolated O
bronchi O
. O

A O
fatty B
acid I
amide I
hydrolase O
inhibitor O
, O
phenylmethanesulfony O
fluoride O
reversed O
the O
inhibitory O
effect O
of O
( B
- I
) I
- I
cannabidiol I
on O
anandamide B
- O
induced O
contractions O
. O

In O
addition O
, O
( B
- I
) I
- I
cannabidiol I
inhibited O
the O
contractile O
response O
of O
bronchi O
obtained O
from O
allergic O
guinea O
- O
pigs O
induced O
by O
ovalbumin O
. O

In O
vivo O
, O
( B
- I
) I
- I
cannabidiol I
reduced O
ovalbumin O
- O
induced O
airway O
obstruction O
. O

In O
conclusion O
, O
our O
results O
suggest O
that O
cannabidiol B
can O
influence O
antigen O
- O
induced O
airway O
smooth O
muscle O
tone O
suggesting O
that O
this O
molecule O
may O
have O
beneficial O
effects O
in O
the O
treatment O
of O
obstructive O
airway O
disorders O
. O

Serial O
infusions O
of O
low O
- O
dose O
ketamine B
for O
major O
depression O
. O

Background O
: O
Single O
infusions O
of O
ketamine B
have O
been O
used O
successfully O
to O
achieve O
improvement O
in O
depressed O
patients O
. O

Methods O
: O
Ten O
depressed O
patients O
were O
treated O
with O
twice O
weekly O
ketamine B
infusions O
of O
ketamine B
0 O
. O
5 O
mg O
/ O
kg O
administered O
over O
100 O
min O
until O
either O
remission O
was O
achieved O
or O
four O
infusions O
were O
given O
. O

Conclusions O
: O
Ketamine B
infusions O
at O
a O
lower O
rate O
than O
previously O
reported O
have O
demonstrated O
similar O
efficacy O
and O
excellent O
tolerability O
and O
may O
be O
more O
practically O
available O
for O
routine O
clinical O
care O
. O

Serial O
ketamine B
infusions O
appear O
to O
be O
more O
effective O
than O
a O
single O
infusion O
. O

Further O
research O
to O
test O
relapse O
prevention O
strategies O
with O
continuation O
ketamine B
infusions O
is O
indicated O
. O

Nephroprotective O
effect O
of O
calcium B
channel O
blockers O
against O
toxicity O
of O
lead O
exposure O
in O
mice O
. O

Exposure O
to O
lead O
( O
Pb B
) O
can O
induce O
kidney O
damage O
, O
which O
is O
related O
to O
induction O
of O
oxidative O
damage O
and O
disturbance O
of O
intracellular O
calcium B
homeostasis O
. O

Pb B
can O
readily O
permeate O
through O
dihydropyridine O
- O
sensitive O
L O
- O
type O
calcium B
channels O
and O
accumulate O
within O
cells O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
protective O
effects O
of O
calcium B
channel O
blockers O
( O
CCBs O
) O
verapamil B
and O
nimodipine O
on O
nephrotoxicity O
induced O
by O
Pb O
acetate O
in O
mice O
. O

One O
hundred O
and O
twenty O
male O
mice O
were O
randomly O
divided O
into O
6 O
groups O
: O
control O
, O
Pb B
, O
low O
- O
dose O
verapamil B
, O
high O
- O
dose O
verapamil B
, O
low O
- O
dose O
nimodipine O
and O
high O
- O
dose O
nimodipine O
( O
n O
= O
20 O
per O
group O
) O
. O

Pb O
acetate O
was O
injected O
intraperitoneally O
( O
i O
. O
p O
. O
) O
at O
40 O
mg O
/ O
kg O
body O
weight O
/ O
day O
for O
10 O
days O
to O
establish O
the O
Pb B
toxicity O
model O
. O

While O
control O
mice O
received O
saline O
, O
mice O
of O
the O
treated O
groups O
simultaneously O
received O
i O
. O
p O
. O
injections O
of O
verapamil B
or O
nimodipine O
daily O
for O
10 O
days O
. O

Both O
verapamil B
and O
nimodipine O
showed O
protection O
against O
Pb B
- O
induced O
kidney O
injury O
, O
including O
alleviation O
of O
renal O
pathological O
damage O
and O
decreasing O
the O
level O
of O
Pb B
in O
kidney O
homogenate O
and O
extent O
of O
apoptosis O
in O
nephrocytes O
. O

Moreover O
, O
verapamil B
and O
nimodipine O
significantly O
down O
- O
regulated O
levels O
of O
blood O
urea B
nitrogen B
and O
creatinine B
in O
the O
serum O
. O

In O
addition O
, O
verapamil B
and O
nimodipine O
administration O
decreased O
malondialdehyde B
content O
and O
increased O
activities O
of O
super O
oxide O
dismutase O
activity O
and O
glutathione B
peroxidase O
in O
the O
kidney O
homogenate O
. O

The O
findings O
in O
the O
present O
study O
implicate O
the O
therapeutic O
potential O
of O
CCBs O
for O
Pb B
- O
induced O
nephrotoxicity O
, O
which O
were O
at O
least O
partly O
due O
to O
the O
decrease O
of O
Pb B
uptake O
and O
inhibition O
of O
lipid O
peroxidation O
. O

Therefore O
, O
to O
reveal O
the O
existence O
of O
more O
permanent O
alterations O
of O
DNA O
structure O
after O
genotoxic O
stress O
, O
the O
RTG O
- O
2 O
rainbow O
trout O
cell O
line O
was O
exposed O
for O
3days O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
, O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
and O
ethyl O
methanesulfonate O
( O
EMS B
, O
0 O
. O
1 O
- O
1mM O
) O
followed O
by O
3days O
of O
recovery O
period O
. O

Significant O
induction O
in O
DNA O
damage O
measured O
by O
the O
Comet O
assay O
was O
noticed O
after O
B B
[ I
a I
] I
P I
treatment O
at O
all O
concentrations O
but O
values O
returned O
to O
the O
control O
level O
after O
recovery O
. O

Four O
extracts O
were O
spiked O
with O
different O
doses O
of O
the O
sensitizers O
citral B
, O
cinnamic O
aldehyde O
and O
isoeugenol B
. O

Reversible O
effect O
of O
developmental O
exposure O
to O
chlorpyrifos B
on O
late O
- O
stage O
neurogenesis O
in O
the O
hippocampal O
dentate O
gyrus O
in O
mouse O
offspring O
. O

The O
effect O
of O
developmental O
exposure O
to O
chlorpyrifos B
( O
CPF O
) O
on O
hippocampal O
neurogenesis O
was O
examined O
in O
male O
mice O
after O
maternal O
dietary O
exposure O
to O
CPF O
at O
0 O
, O
4 O
, O
20 O
, O
or O
100ppm O
from O
gestation O
day O
10 O
to O
postnatal O
day O
( O
PND O
) O
21 O
. O

There O
were O
no O
differences O
in O
the O
numbers O
of O
progenitor O
populations O
expressing O
Tbr2 O
or O
M1 O
muscarinic O
acetylcholine B
receptors O
. O

The O
pro O
- O
apoptotic O
BCL O
- O
2 O
family O
member O
BOK O
is O
widely O
expressed O
and O
resembles O
the O
multi O
- O
BH O
domain O
proteins O
BAX O
and O
BAK O
based O
on O
its O
amino B
acid I
sequence O
. O

The O
C B
- O
terminal O
transmembrane O
domain O
of O
BOK O
thereby O
constitutes O
a O
' O
tail O
- O
anchor O
' O
specific O
for O
targeting O
to O
the O
Golgi O
and O
ER O
. O

A O
role O
for O
BOK O
on O
the O
Golgi O
apparatus O
and O
the O
ER O
is O
supported O
by O
an O
abnormal O
response O
of O
Bok O
- O
deficient O
cells O
to O
the O
Golgi O
/ O
ER O
stressor O
brefeldin B
A I
. O

Cyclic O
stretch O
induces O
inducible O
nitric B
oxide I
synthase O
and O
soluble O
guanylate B
cyclase O
in O
pulmonary O
artery O
smooth O
muscle O
cells O
. O

Nitric B
oxide I
is O
a O
potent O
regulator O
of O
soluble O
guanylate B
cyclase O
( O
sGC O
) O
, O
which O
drives O
cGMP B
production O
, O
causing O
vasorelaxation O
. O

Pulmonary O
artery O
smooth O
muscle O
cells O
( O
PASMCs O
) O
express O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
and O
while O
iNOS O
expression O
increases O
during O
late O
gestation O
, O
little O
is O
known O
about O
how O
cyclic O
stretch O
impacts O
this O
pathway O
. O

Cyclic O
stretch O
also O
increased O
sGC O
beta O
protein O
expression O
( O
2 O
. O
5 O
+ O
/ O
- O
0 O
. O
9 O
- O
fold O
) O
, O
sGC O
activity O
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
2 O
- O
fold O
) O
and O
cGMP B
levels O
( O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
2 O
- O
fold O
) O
, O
as O
well O
as O
iNOS O
mRNA O
and O
protein O
expression O
( O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
9 O
and O
2 O
. O
6 O
+ O
/ O
- O
0 O
. O
7 O
- O
fold O
, O
respectively O
) O
relative O
to O
control O
cells O
. O

An O
antioxidant O
, O
recombinant O
human O
superoxide B
dismutase O
( O
rhSOD O
) O
, O
significantly O
decreased O
stretch O
- O
induced O
cytosolic O
oxidative O
stress O
, O
but O
did O
not O
block O
stretch O
- O
induced O
sGC O
activity O
. O

A O
computational O
investigation O
was O
carried O
out O
to O
understand O
the O
aggregation O
of O
nanoscale O
graphene B
with O
two O
typical O
pathways O
of O
stacking O
assembly O
and O
sliding O
assembly O
in O
water O
. O

By O
means O
of O
potential O
mean O
forces O
( O
PMFs O
) O
calculation O
, O
no O
energy O
barrier O
was O
observed O
during O
the O
sliding O
assembly O
of O
two O
graphene B
nanosheets O
, O
while O
the O
PMF O
profiles O
could O
be O
impacted O
by O
the O
contact O
forms O
of O
nanographene O
and O
the O
MWF O
within O
the O
interplate O
of O
two O
graphene B
nanosheets O
. O

To O
explore O
the O
potential O
physical O
basis O
of O
the O
" O
hindering O
role O
" O
of O
self O
- O
organized O
interfacial O
water O
, O
the O
dynamical O
and O
structural O
properties O
as O
well O
as O
the O
status O
of O
hydrogen B
bonds O
( O
H B
- O
bonds O
) O
for O
interfacial O
water O
were O
investigated O
. O

We O
found O
that O
the O
compact O
, O
ordered O
structure O
and O
abundant O
H B
- O
bonds O
of O
the O
MWF O
could O
be O
taken O
as O
the O
fundamental O
aspects O
of O
the O
" O
hindering O
role O
" O
of O
interfacial O
water O
for O
the O
hydrophobic O
assembly O
of O
nanographene O
. O

TCDD B
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus O
. O

In O
mice O
, O
in O
utero O
exposure O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O

The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD B
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O

In O
support O
of O
the O
hypothesis O
that O
TCDD B
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD B
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD B
on O
prostatic O
bud O
formation O
: O
( O
1 O
) O
expression O
of O
R O
- O
spondins O
( O
Rspo2 O
and O
Rspo3 O
) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced O
; O
( O
2 O
) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased O
; O
( O
3 O
) O
expression O
of O
Lgr5 O
, O

a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced O
; O
and O
( O
4 O
) O
expression O
of O
Dickkopfs O
( O
Dkks O
) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD B
. O

Thus O
, O
the O
TCDD B
- O
induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
( O
Rspo2 O
and O
Rspo3 O
) O
rather O
than O
an O
increase O
in O
inhibitors O
( O
Dkk1 O
and O
Dkk2 O
) O
of O
the O
pathway O
. O

This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD B
- O
exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and O
/ O
or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD B
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD B
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

As O
the O
seminiferous O
epithelium O
operates O
on O
the O
verge O
of O
hypoxia O
, O
oxygen B
deficit O
can O
lead O
to O
secondary O
impairment O
of O
testicular O
function O
. O

They O
have O
reduced O
blood O
oxygen B
content O
that O
goes O
in O
parallel O
with O
impairment O
of O
testicular O
function O
and O
this O
effect O
remains O
for O
some O
time O
in O
spite O
of O
a O
compensatory O
polycythaemia O
. O

Similar O
findings O
are O
described O
for O
experimental O
animals O
exposed O
to O
hypobaric O
oxygen B
/ O
high O
altitude O
. O

In O
addition O
, O
testicular O
function O
is O
affected O
in O
severe O
diseases O
in O
humans O
associated O
with O
systemic O
oxygen B
deficit O
like O
chronic O
obstructive O
pulmonary O
disease O
, O
sickle O
cell O
disease O
or O
beta O
- O
thalassaemia O
as O
well O
as O
in O
transgenic O
animals O
simulating O
haemolytic O
anaemia O
or O
sickle O
cell O
disease O
. O

The O
problem O
of O
insufficient O
oxygen B
supply O
as O
the O
underlying O
cause O
for O
testicular O
impairment O
has O
received O
relatively O
little O
attention O
in O
toxicology O
, O
mainly O
because O
blood O
oxygen B
content O
is O
generally O
not O
measured O
in O
these O
animal O
experiments O
. O

The O
difficulties O
associated O
with O
the O
decision O
whether O
testicular O
toxicity O
is O
primary O
or O
secondary O
to O
hypoxia O
are O
exemplified O
by O
the O
results O
of O
inhalation O
studies O
with O
nickel O
subsulphide O
and O
gallium O
arsenide O
( O
GaAs B
) O
. O

Both O
of O
these O
particulate O
substances O
lead O
to O
severe O
lung O
toxicity O
that O
might O
impair O
oxygen B
uptake O
, O
but O
testicular O
toxicity O
is O
only O
observed O
with O
GaAs B
. O

This O
may O
first O
be O
explained O
by O
different O
effects O
on O
the O
blood O
: O
nickel O
subsulphide O
inhalation O
leads O
to O
a O
compensatory O
erythropoiesis O
that O
may O
mitigate O
pulmonary O
lack O
of O
oxygen B
uptake O
. O

In O
contrast O
, O
GaAs B
exposure O
is O
associated O
with O
microcytic O
haemolytic O
anaemia O
thereby O
aggravating O
any O
possible O
oxygen B
undersupply O
. O

Furthermore O
, O
the O
predominant O
pulmonary O
effect O
caused O
by O
GaAs B
( O
but O
not O
by O
nickel O
subsulphide O
) O
is O
alveolar O
proteinosis O
. O

Therefore O
, O
we O
conclude O
that O
the O
testicular O
effects O
observed O
after O
GaAs B
are O
secondary O
to O
hypoxaemia O
caused O
by O
the O
combination O
of O
pulmonary O
proteinosis O
and O
haemolytic O
anaemia O
. O

This O
publication O
tries O
to O
raise O
awareness O
to O
the O
severe O
consequences O
of O
hypoxaemia O
on O
testicular O
function O
that O
may O
already O
be O
caused O
by O
reduced O
oxygen B
pressure O
at O
high O
altitude O
without O
any O
chemical O
exposure O
. O

Exogenous O
sodium B
nitroprusside I
alleviates O
arsenic B
- O
induced O
oxidative O
stress O
in O
wheat O
( O
Triticum O
aestivum O
L O
. O
) O
seedlings O
by O
enhancing O
antioxidant O
defense O
and O
glyoxalase O
system O
. O

The O
present O
study O
investigates O
the O
possible O
regulatory O
role O
of O
exogenous O
nitric B
oxide I
( O
NO B
) O
in O
mitigating O
oxidative O
stress O
in O
wheat O
seedlings O
exposed O
to O
arsenic B
( O
As B
) O
. O

Seedlings O
were O
treated O
with O
NO B
donor O
( O
0 O
. O
25 O
mM O
sodium B
nitroprusside I
, O
SNP B
) O
and O
As B
( O
0 O
. O
25 O
and O
0 O
. O
5 O
mM O
Na2HAsO4 O
. O
7H2O O
) O
separately O
and O
/ O
or O
in O
combination O
and O
grown O
for O
72 O
h O
. O

Relative O
water O
content O
( O
RWC O
) O
and O
chlorophyll B
( O
chl O
) O
content O
were O
decreased O
by O
As B
treatment O
but O
proline B
( O
Pro B
) O
content O
was O
increased O
. O

The O
ascorbate B
( O
AsA B
) O
content O
was O
decreased O
significantly O
with O
increased O
As B
concentration O
. O

The O
imposition O
of O
As B
caused O
marked O
increase O
in O
the O
MDA B
and O
H2O2 B
content O
. O

The O
amount O
of O
reduced O
glutathione B
( O
GSH B
) O
and O
glutathione B
disulfide I
( O
GSSG B
) O
significantly O
increased O
with O
an O
increase O
in O
the O
level O
of O
As B
( O
both O
0 O
. O
25 O
and O
0 O
. O
5 O
mM O
) O
, O
while O
the O
GSH B
/ O
GSSG B
ratio O
decreased O
at O
higher O
concentration O
( O
0 O
. O
5 O
mM O
) O
. O

The O
ascorbate B
peroxidase O
and O
glutathione B
S B
- O
transferase O
activities O
consistently O
increased O
with O
an O
increase O
in O
the O
As B
concentration O
, O
while O
glutathione B
reductase O
( O
GR O
) O
activities O
increased O
only O
at O
0 O
. O
25 O
mM O
. O

The O
monodehydroascorbate O
reductase O
( O
MDHAR O
) O
and O
catalase O
( O
CAT O
) O
activities O
were O
not O
changed O
upon O
exposure O
to O
As B
. O

The O
activities O
of O
dehydroascorbate O
reductase O
( O
DHAR O
) O
and O
glyoxalase O
I O
( O
Gly O
I O
) O
decreased O
at O
any O
levels O
of O
As B
, O
while O
glutathione B
peroxidase O
( O
GPX O
) O
and O
glyoxalase O
II O
( O
Gly O
II O
) O
activities O
decreased O
only O
upon O
0 O
. O
5 O
mM O
As B
. O

Exogenous O
NO B
alone O
had O
little O
influence O
on O
the O
non O
- O
enzymatic O
and O
enzymatic O
components O
compared O
to O
the O
control O
seedlings O
. O

These O
inhibitory O
effects O
of O
As B
were O
markedly O
recovered O
by O
supplementation O
with O
SNP B
; O
that O
is O
, O
the O
treatment O
with O
SNP B
increased O
the O
RWC O
, O
chl O
and O
Pro B
contents O
; O
AsA B
and O
GSH B
contents O
and O
the O
GSH B
/ O
GSSG B
ratio O
as O
well O
as O
the O
activities O
of O
MDHAR O
, O
DHAR O
, O
GR O
, O
GPX O
, O
CAT O
, O
Gly O
I O
and O
Gly O
II O
in O
the O
seedlings O
subjected O
to O
As B
stress O
. O

These O
results O
suggest O
that O
the O
exogenous O
application O
of O
NO B
rendered O
the O
plants O
more O
tolerant O
to O
As B
- O
induced O
oxidative O
damage O
by O
enhancing O
their O
antioxidant O
defense O
and O
glyoxalase O
system O
. O

Recent O
studies O
demonstrate O
that O
Ca2 B
+ I
signal O
is O
essential O
for O
fibroblast O
proliferation O
, O
differentiation O
, O
and O
ECM O
- O
protein O
production O
. O

This O
review O
focuses O
on O
the O
recent O
advances O
in O
understanding O
molecular O
mechanisms O
of O
Ca2 B
+ I
signaling O
in O
cardiac O
fibrogenesis O
, O
and O
potential O
role O
of O
Ca2 B
+ I
- O
permeable O
channels O
, O
in O
particular O
, O
the O
transient O
potential O
( O
TRP O
) O
channels O
in O
fibrotic O
heart O
disease O
. O

Thus O
, O
the O
Ca2 B
+ I
- O
permeable O
TRP O
channels O
may O
serve O
as O
potential O
novel O
targets O
for O
developing O
anti O
- O
fibrotic O
drugs O
. O

Multiple O
TRP O
subtypes O
are O
expressed O
in O
vascular O
smooth O
muscle O
cells O
and O
endothelial O
cells O
, O
where O
they O
form O
diverse O
non O
- O
selective O
cation O
channels O
permeable O
to O
Ca2 B
+ I
. O

These O
channels O
mediate O
Ca2 B
+ I
entry O
following O
receptor O
stimulation O
, O
Ca2 B
+ I
store O
depletion O
and O
mechanical O
stimulation O
of O
vascular O
myocytes O
and O
endothelial O
cells O
. O

Strong O
correlations O
between O
structural O
( O
O O
- O
O O
and O
Mn B
. O
. O
. O
N O
( O
py O
, O
quin O
) O
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O O
- O
O O
) O
- O
- O
> O
Mn B
CT O
band O
) O
, O
nu O
( O
O O
- O
O O
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O O
- O
O O
bond O
cleavage O
. O

Control O
over O
the O
oxidation O
state O
and O
crystalline O
phase O
of O
thin O
- O
film O
iron O
oxides O
was O
achieved O
by O
low O
- O
temperature O
atomic O
layer O
deposition O
( O
ALD O
) O
, O
utilizing O
a O
novel O
iron B
precursor O
, O
bis O
( O
2 O
, O
4 O
- O
methylpentadienyl O
) O
iron O
. O

This O
low O
- O
temperature O
( O
T O
= O
120 O
degrees O
C O
) O
route O
to O
conformal O
deposition O
of O
crystalline O
Fe3O4 B
or O
alpha O
- O
Fe2O3 O
thin O
films O
is O
determined O
by O
the O
choice O
of O
oxygen B
source O
selected O
for O
the O
second O
surface O
half O
- O
reaction O
. O

The O
approach O
employs O
ozone O
to O
produce O
fully O
oxidized O
alpha O
- O
Fe2O3 O
or O
a O
milder O
oxidant O
, O
H2O2 B
, O
to O
generate O
the O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
spinel O
, O
Fe3O4 B
. O

We O
utilized O
this O
process O
to O
prepare O
conformal O
iron B
oxide I
thin O
films O
on O
a O
porous O
framework O
, O
for O
which O
alpha O
- O
Fe2O3 O
is O
active O
for O
photocatalytic O
water O
splitting O
. O

Studies O
on O
an O
( O
S O
) O
- O
2 O
- O
amino O
- O
3 O
- O
( O
3 O
- O
hydroxy O
- O
5 O
- O
methyl O
- O
4 O
- O
isoxazolyl O
) O
propionic O
acid O
( O
AMPA B
) O
receptor O
antagonist O
IKM O
- O
159 O
: O
asymmetric O
synthesis O
, O
neuroactivity O
, O
and O
structural O
characterization O
. O

IKM O
- O
159 O
was O
developed O
and O
identified O
as O
a O
member O
of O
a O
new O
class O
of O
heterotricyclic O
glutamate B
analogues O
that O
act O
as O
AMPA B
receptor O
- O
selective O
antagonists O
. O

A O
new O
member O
of O
5 O
alpha O
H O
, O
6 O
beta O
H O
, O
7 O
alpha O
H O
, O
11 O
alpha O
H O
- O
guaian O
- O
12 O
, O
6 O
alpha O
- O
olides O
, O
11 O
- O
epi O
- O
8 O
alpha O
- O
hydroxyarborescin O
, O
together O
with O
a O
mixture O
of O
( O
24R O
) O
- O
and O
( O
24S O
) O
- O
cycloart O
- O
25 O
- O
en O
- O
3b O
, O
24 O
- O
diols O
, O
palmitic B
acid I
and O
1 O
- O
octacosanol O
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

SNAIL O
Induces O
Epithelial O
- O
to O
- O
Mesenchymal O
Transition O
and O
Cancer O
Stem O
Cell O
- O
like O
Properties O
in O
Aldehyde B
Dehydroghenase O
- O
Negative O
Thyroid O
Cancer O
Cells O
. O

CSC O
properties O
were O
analyzed O
with O
assays O
for O
cell O
proliferation O
, O
chemosensitivity O
, O
in O
vitro O
and O
in O
vivo O
tumor O
formation O
ability O
, O
cell O
surface O
antigens O
and O
intracellular O
aldehyde B
dehydrogenase O
( O
ALDH O
; O
a O
known O
CSC O
marker O
) O
activities O
. O

Metabolic O
Activation O
of O
Polycyclic B
Aromatic I
Hydrocarbons I
and O
Aryl O
and O
Heterocyclic O
Amines O
by O
Human O
Cytochromes O
P450 O
2A13 O
and O
2A6 O
. O

Human O
cytochrome O
P450 O
( O
P450 O
) O
2A13 O
was O
found O
to O
interact O
with O
several O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
to O
produce O
Type O
I O
binding O
spectra O
, O
including O
acenaphthene O
, O
acenaphthylene O
, O
benzo O
[ O
c O
] O
phenanthrene O
, O
fluoranthene B
, O
fluoranthene O
- O
2 O
, O
3 O
- O
diol O
, O
and O
1 O
- O
nitropyrene O
. O

P450 O
2A6 O
also O
interacted O
with O
acenaphthene O
and O
acenaphthylene O
, O
but O
not O
with O
fluoranthene B
, O
fluoranthene O
- O
2 O
, O
3 O
- O
diol O
, O
or O
1 O
- O
nitropyrene O
. O

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs B
, O
and O
we O
found O
that O
several O
PAHs B
( O
i O
. O
e O
. O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
, O
7 O
, O
12 O
- O
dimethylbenz O
[ O
a O
] O
anthracene O
- O
5 O
, O
6 O
- O
diol O
, O
benzo O
[ O
c O
] O
phenanthrene O
, O
fluoranthene B
, O
fluoranthene O
- O
2 O
, O
3 O
- O
diol O
, O
5 O
- O
methylchrysene O
, O
benz O
[ O
a O
] O
pyrene O
- O
4 O
, O
5 O
- O

Metabolic O
activation O
of O
PAHs B
and O
aryl O
- O
and O
heterocyclic O
amines O
to O
genotoxic O
products O
was O
examined O
in O
Salmonella O
typhimurium O
NM2009 O
, O
and O
we O
found O
that O
P450 O
2A13 O
and O
2A6 O
( O
as O
well O
as O
P450 O
1B1 O
) O
were O
able O
to O
activate O
several O
of O
these O
procarcinogens O
. O

These O
results O
suggest O
that O
P450 O
2A O
enzymes O
, O
as O
well O
as O
P450 O
Family O
1 O
enzymes O
including O
P450 O
1B1 O
, O
are O
major O
enzymes O
involved O
in O
activating O
PAHs B
and O
aryl O
- O
and O
heterocyclic O
amines O
, O
as O
well O
as O
tobacco O
- O
related O
nitrosamines B
. O

Immunomodulatory O
properties O
of O
farnesoids O
: O
the O
new O
steroids B
? O

Recent O
advances O
in O
carbon B
nanotubes O
as O
delivery O
systems O
for O
anticancer O
drugs O
. O

A O
wide O
range O
of O
materials O
, O
including O
liposomes O
, O
microspheres O
, O
polymers O
and O
recently O
, O
carbon B
nanotubes O
( O
CNTs O
) O
, O
have O
been O
investigated O
for O
delivering O
anticancer O
drugs O
on O
the O
purpose O
of O
reducing O
the O
number O
of O
necessary O
administrations O
, O
providing O
more O
localized O
and O
better O
use O
of O
the O
active O
agents O
, O
and O
increasing O
patient O
compliance O
. O

Carbon B
nanotubes O
( O
CNTs O
) O
have O
attracted O
particular O
attention O
as O
carriers O
of O
biologically O
relevant O
molecules O
due O
to O
their O
unique O
physical O
, O
chemical O
and O
physiological O
properties O
. O

The O
exact O
relationship O
between O
the O
physical O
- O
chemical O
properties O
of O
carbon B
nanotubes O
, O
their O
cell O
to O
- O
cell O
interactions O
, O
reactivity O
, O
and O
biological O
/ O
systemic O
consequences O
are O
relevant O
issues O
and O
it O
is O
important O
to O
know O
suchinter O
- O
relationships O
beforehand O
to O
employ O
the O
benefits O
of O
these O
nanomaterials O
without O
the O
hazardous O
consequences O
. O

The O
purpose O
of O
this O
review O
is O
to O
present O
highlight O
of O
recent O
developments O
in O
the O
application O
of O
carbon B
nanotubes O
as O
cargoes O
for O
anti O
cancer O
drugs O
and O
in O
the O
diagnosis O
of O
cancer O
diseases O
. O

Camptothecin B
Resistance O
in O
Cancer O
: O
Insights O
into O
the O
Molecular O
Mechanisms O
of O
a O
DNA O
- O
Damaging O
Drug O
. O

Experimental O
models O
including O
yeast O
and O
mammalian O
cell O
cultures O
suggest O
three O
general O
mechanisms O
of O
camptothecin B
resistance O
: O
i O
) O
reduced O
cellular O
accumulation O
of O
drugs O
, O
ii O
) O
alteration O
in O
the O
structure O
/ O
expression O
of O
topoisomerase O
I O
, O
and O
iii O
) O
alterations O
in O
the O
cellular O
response O
to O
camptothecin B
- O
DNA O
- O
ternary O
complex O
formation O
. O

Some O
lines O
of O
evidence O
have O
also O
suggested O
links O
between O
cellular O
camptothecin B
resistance O
, O
the O
existence O
of O
a O
subset O
of O
tumor O
- O
initiating O
cells O
and O
miRNA O
deregulation O
. O

In O
this O
regard O
, O
a O
better O
definition O
of O
the O
molecular O
events O
clarifying O
the O
regulation O
of O
tumorigenesis O
and O
gene O
expression O
might O
contribute O
to O
gain O
insight O
into O
the O
molecular O
mechanisms O
on O
the O
basis O
of O
camptothecin B
resistance O
of O
tumors O
and O
to O
identify O
new O
molecular O
tools O
for O
targeting O
cancer O
cells O
. O

Full O
agonists O
to O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
gamma O
, O
such O
as O
Rosiglitazone B
, O
have O
been O
associated O
with O
a O
series O
of O
undesired O
side O
effects O
, O
such O
as O
weight O
gain O
, O
fluid O
retention O
, O
cardiac O
hypertrophy O
, O
and O
hepatotoxicity O
. O

Nevertheless O
, O
PPAR O
gamma O
is O
involved O
in O
the O
expression O
of O
genes O
that O
control O
glucose B
and O
lipid O
metabolism O
and O
is O
an O
important O
target O
for O
drugs O
against O
type O
2 O
diabetes O
, O
dyslipidemia O
, O
atherosclerosis O
, O
and O
cardiovascular O
disease O
. O

In O
- O
depth O
analysis O
of O
operando O
X O
- O
ray O
pair O
distribution O
function O
( O
PDF O
) O
data O
is O
combined O
with O
Li B
NMR O
spectroscopy O
to O
gain O
comprehensive O
insights O
into O
the O
electrochemical O
reaction O
mechanism O
of O
high O
- O
performance O
iron O
oxyfluoride O
electrodes O
. O

Bond O
valence O
sum O
analysis O
, O
based O
on O
the O
precise O
structural O
parameters O
( O
bond O
lengths O
and O
coordination O
number O
) O
extracted O
from O
the O
in O
situ O
PDF O
data O
, O
suggests O
that O
anion O
partitioning O
occurs O
during O
the O
electrochemical O
reaction O
, O
with O
the O
rutile O
phase O
being O
F B
- O
rich O
and O
the O
rock O
salt O
phase O
being O
O B
- O
rich O
. O

The O
F B
- O
and O
O B
- O
rich O
phases O
react O
sequentially O
; O
Fe B
in O
a O
F B
- O
rich O
environment O
reacts O
preferentially O
during O
both O
discharge O
and O
charge O
. O

The O
role O
of O
omega O
- O
3 O
derived O
resolvins B
in O
arthritis O
. O

Omega O
- O
3 O
polyunsaturated O
fatty O
acids O
( O
PUFAs B
) O
are O
known O
to O
alleviate O
joint O
stiffness O
and O
pain O
in O
rheumatoid O
arthritis O
patients O
. O

Herein O
we O
discuss O
a O
novel O
class O
of O
bioactive O
lipid O
mediators O
, O
which O
are O
enzymatically O
biosynthesized O
in O
vivo O
from O
omega O
- O
3 O
eicosapentaenoic O
acid O
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
, O
termed O
resolvins B
. O

We O
also O
highlight O
that O
formation O
of O
pro O
- O
resolving O
mediators O
can O
be O
enhanced O
by O
widely O
used O
anti O
- O
inflammatory O
and O
cardioprotective O
drugs O
( O
aspirin B
and O
statins O
) O
via O
the O
modification O
of O
cyclooxygenase O
- O
2 O
enzymatic O
activity O
. O

A O
library O
of O
novel O
5 O
- O
amino O
- O
2 O
, O
7 O
- O
diaryl O
- O
2 O
, O
3 O
- O
dihydrobenzo O
[ O
b O
] O
thiophene O
- O
4 O
, O
6 O
- O
dicarbonitriles O
have O
been O
synthesized O
regioselectively O
in O
good O
yields O
through O
the O
one O
- O
pot O
domino O
reactions O
of O
5 O
- O
aryldihydro O
- O
3 O
( O
2H O
) O
- O
thiophenones O
, O
malononitrile B
and O
aromatic B
aldehydes I
in O
the O
presence O
of O
morpholine B
. O

Pyridine B
to O
aniline B
: O
an O
exceptional O
biologically O
driven O
rearrangement O
. O

Synthesis O
and O
cytotoxicity O
evaluation O
of O
oleanolic B
acid I
derivatives O
. O

Twelve O
derivatives O
of O
oleanolic B
acid I
( O
1 O
) O
have O
been O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
activities O
against O
the O
growth O
of O
prostate O
PC3 O
, O
breast O
MCF O
- O
7 O
, O
lung O
A549 O
, O
and O
gastric O
BGC O
- O
823 O
cancer O
cells O
by O
MTT B
assays O
. O

SAR O
analysis O
indicates O
that O
H B
- O
donor O
substitution O
at O
C O
- O
3 O
position O
of O
oleanolic B
acid I
may O
be O
advantageous O
for O
improvement O
of O
cytotoxicity O
against O
PC3 O
, O
A549 O
and O
MCF O
- O
7 O
cell O
lines O
. O

Coenzyme O
Q10 O
protects O
Pc12 O
cells O
from O
cisplatin B
- O
induced O
DNA O
damage O
and O
neurotoxicity O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
neuroprotective O
effect O
of O
a O
water O
- O
soluble O
formulation O
of O
coenzyme O
Q10 O
( O
WS O
- O
CoQ10 O
) O
in O
PC12 O
cells O
exposed O
to O
cisplatin B
, O
a O
chemotherapeutic O
agent O
with O
a O
dose O
- O
limiting O
factor O
due O
to O
neurotoxicity O
. O

In O
the O
cytokinesis O
- O
block O
micronucleus O
cytome O
assay O
( O
CBMN O
Cyt O
) O
, O
WS O
- O
CoQ10 O
( O
at O
concentrations O
of O
0 O
. O
1 O
, O
0 O
. O
5 O
and O
1 O
. O
0 O
mu O
gmL O
( O
- O
1 O
) O
) O
protected O
PC12 O
cells O
from O
cisplatin B
- O
induced O
DNA O
damage O
( O
0 O
. O
1 O
mu O
gmL O
( O
- O
1 O
) O
) O
, O
reducing O
the O
frequency O
of O
micronuclei O
( O
MNi O
) O
and O
nuclear O
buds O
( O
NBUDs O
) O
. O

WS O
- O
CoQ10 O
did O
not O
alter O
the O
mRNA O
expression O
levels O
of O
Tp53 O
( O
at O
a O
concentration O
of O
1 O
. O
0 O
mu O
gmL O
( O
- O
1 O
) O
) O
and O
exhibited O
neuroprotective O
activity O
by O
stimulating O
cisplatin B
- O
inhibited O
neurite O
outgrowth O
in O
nerve O
growth O
factor O
( O
NGF O
) O
- O
differentiated O
PC12 O
cells O
( O
at O
a O
concentration O
of O
0 O
. O
1 O
mu O
gmL O
( O
- O
1 O
) O
) O
. O

In O
conclusion O
, O
WS O
- O
CoQ10 O
protected O
the O
PC12 O
cells O
from O
cisplatin B
- O
induced O
DNA O
damage O
and O
neurotoxicity O
. O

A O
rapid O
sensitive O
and O
selective O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
for O
determination O
of O
timosaponin O
AIII O
( O
TA O
- O
III O
) O
in O
rat O
plasma O
, O
using O
ginsenoside B
Re I
as O
an O
internal O
standard O
( O
IS O
) O
. O

Osteopontin O
( O
OPN O
) O
, O
an O
extracellular O
matrix O
protein O
, O
has O
a O
functional O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
domain O
for O
binding O
to O
integrin O
. O

OPN O
increased O
the O
mRNA O
and O
protein O
expression O
of O
p O
- O
glycoprotein O
( O
P O
- O
gp O
) O
, O
a O
subfamily O
of O
ATP B
- O
binding O
cassette O
transporter O
in O
a O
concentration O
- O
and O
time O
- O
dependent O
manner O
. O

Daunomycin B
( O
DUN O
) O
, O
a O
chemotherapeutic O
agent O
with O
autofluorescence O
, O
was O
used O
to O
evaluate O
the O
pump O
activity O
, O
and O
OPN O
increased O
the O
drug O
pumping O
- O
out O
activity O
. O

Furthermore O
, O
knockdown O
of O
OPN O
enhanced O
cell O
death O
caused O
by O
other O
drugs O
, O
including O
paclitaxel B
, O
doxorubicin B
, O
actinomycin B
- I
D I
, O
and O
rapamycin B
, O
which O
are O
also O
P O
- O
gp O
substrates O
. O

Moreover O
, O
asperolide O
A O
significantly O
activated O
MAP O
kinases O
( O
ERK1 O
/ O
2 O
, O
JNK O
and O
p38 O
MAP O
kinase O
) O
by O
phosphorylation O
, O
and O
only O
the O
inhibition O
of O
ERK O
activation O
by O
PD98059 B
reversed O
downregulation O
of O
G2 O
/ O
M O
regulatory O
proteins O
CDC2 O
, O
and O
suppressed O
upregulation O
of O
p21 O
and O
p O
- O
p53 O
levels O
. O

An O
in O
vivo O
study O
with O
asperolide O
A O
illustrated O
a O
marked O
inhibition O
of O
tumor O
growth O
, O
and O
little O
toxcity O
compared O
to O
Cisplatin B
therapy O
. O

The O
lipid O
A O
moiety O
of O
Escherichia O
coli O
lipopolysaccharide O
is O
a O
hexaacylated O
disaccharide O
of O
glucosamine B
phosphorylated O
at O
the O
1 O
- O
and O
4 O
' O
- O
positions O
. O

We O
produced O
hazard O
ratios O
( O
HRs O
) O
for O
mortality O
and O
compared O
rates O
of O
blood O
pressure O
testing O
, O
cholesterol B
monitoring O
, O
and O
use O
of O
aspirin B
, O
statins O
, O
and O
antihypertensive O
drugs O
. O
RESULTSPeople O
with O
type O
2 O
diabetes O
, O
compared O
with O
people O
without O
diabetes O
, O
had O
a O
twofold O
increased O
risk O
of O
all O
- O
cause O
mortality O
( O
HR O
2 O
. O
07 O
[ O
95 O
% O
CI O
1 O
. O
95 O
- O
2 O
. O
20 O
] O
, O
adjusted O
for O
smoking O
) O
and O
a O
threefold O
increased O
risk O
of O
cardiovascular O
mortality O
( O
3 O
. O
25 O
[ O
2 O
. O
87 O
- O
3 O
. O
68 O
] O
, O
adjusted O
for O
smoking O
) O
. O

This O
study O
investigated O
the O
effect O
of O
a O
structured O
self O
- O
monitoring O
of O
blood O
glucose B
( O
SMBG O
) O
protocol O
and O
the O
resulting O
improvements O
in O
glycemic O
control O
on O
changes O
in O
high O
- O
sensitivity O
C O
- O
reactive O
protein O
( O
hs O
- O
CRP O
) O
in O
insulin O
- O
na O
i O
ve O
patients O
with O
type O
2 O
diabetes O
. O
RESEARCH O
DESIGN O
AND O
METHODSThe O
Structured O
Testing O
Program O
( O
STeP O
) O
study O
was O
a O
prospective O
, O
cluster O
- O
randomized O
, O
multicenter O
trial O
in O
which O
483 O
poorly O
controlled O
, O
insulin O
- O
na O
i O
ve O
patients O
with O
type O
2 O
diabetes O
were O
randomized O
to O
active O
control O
( O
ACG O
) O
or O
structured O

It O
displays O
serine B
protease O
- O
like O
activity O
with O
procoagulant O
effect O
, O
and O
also O
induces O
cytokine O
secretion O
and O
antiapoptotic O
pathways O
in O
human O
cultured O
endothelial O
cells O
. O

It O
was O
considered O
different O
patterns O
of O
amino B
acid I
substitution O
related O
to O
the O
lipocalins O
' O
motif O
2 O
, O
which O
was O
recently O
shown O
to O
modulate O
cell O
survival O
. O

Changes O
in O
morphometry O
and O
association O
between O
whole O
- O
body O
fatty B
acids I
and O
steroid B
hormone O
profiles O
in O
relation O
to O
bioaccumulation O
patterns O
in O
salmon O
larvae O
exposed O
to O
perfluorooctane O
sulfonic O
or O
perfluorooctane O
carboxylic O
acids O
. O

In O
the O
present O
study O
, O
we O
have O
used O
salmon O
embryos O
whose O
continuous O
exposure O
to O
waterborne O
PFOA B
or O
PFOS B
at O
100 O
mu O
g O
/ O
L O
started O
as O
freshly O
fertilized O
eggs O
, O
and O
lasted O
for O
a O
total O
of O
52 O
days O
. O

PFOS B
and O
PFOA B
were O
dissolved O
in O
methanol B
( O
carrier O
vehicle O
) O
whose O
concentration O
never O
exceeded O
0 O
. O
01 O
% O
of O
total O
tank O
volume O
. O

Tissue O
bioaccumulations O
were O
determined O
by O
HPLC O
/ O
MS O
/ O
MS O
, O
steroid B
hormones O
, O
fatty B
acids I
( O
FAs B
) O
and O
lipids O
were O
determined O
by O
GC O
- O
MS O
, O
while O
mRNA O
expression O
levels O
of O
genes O
were O
determined O
by O
qPCR O
in O
whole O
body O
homogenate O
. O

We O
observed O
that O
PFOS B
and O
PFOA B
showed O
a O
steady O
increase O
in O
whole O
body O
burden O
during O
the O
exposure O
period O
, O
with O
a O
slight O
decrease O
after O
the O
recovery O
period O
. O

Calculated O
somatic O
indexes O
showed O
that O
PFOA B
produced O
increases O
in O
heart O
- O
, O
thymus O
- O
, O
liver O
- O
and O
kidney O
somatic O
indexes O
( O
HSI O
, O
TSI O
, O
LSI O
and O
KSI O
) O
. O

PFOA B
and O
PFOS B
exposure O
produced O
significant O
decreases O
in O
whole O
body O
dehydroepiandrostero B
( O
DHEA B
) O
, O
estrone O
and O
testosterone B
at O
sampling O
day O
21 O
and O
a O
strong O
increase O
of O
cortisol B
and O
cholesterol B
at O
the O
end O
of O
recovery O
period O
( O
day O
56 O
) O
. O

PFOA B
and O
PFOS B
effects O
differed O
with O
DHEA B
and O
estrone B
. O

While O
PFOS B
decreased O
DHEA B
levels O
, O
PFOA B
produced O
an O
increase O
at O
day O
49 O
, O
and O
while O
PFOS B
decreased O
estrone B
, O
PFOA B
produced O
a O
slight O
increase O
at O
day O
56 O
. O

We O
observed O
changes O
in O
FA O
composition O
that O
predominantly O
involved O
increases O
in O
FA O
methyl O
esters O
( O
FAMEs O
) O
, O
mono O
- O
and O
poly O
- O
unsaturated O
FA O
( O
MUFA B
and O
PUFA B
) O
and O
a O
decrease O
in O
n O
- O
3 O
/ O
n O
- O
6 O
PUFA B
ratio O
by O
both O
PFOA B
and O
PFOS B
. O

Particularly O
, O
an O
increase O
in O
- O
pentadecenoic O
MUFA O
( O
15 O
: O
1 O
) O
, O
two O
n O
- O
3 O
PUFAs B
alpha O
- O
linolenic O
acid O
[ O
ALA B
: O
18 O
: O
3 O
n3 O
] O
and O
eicosapentaenoic B
acid I
[ O
EPA B
: O
20 O
: O
5 O
n O
- O
3 O
] O
and O
n O
- O
6 O
PUFA B
: O
arachidonic B
acid I
[ O
ARA B
: O
20 O
: O
4 O
n6 O
] O
, O
docosapentaenoic O
acid O
( O
DPA O
) O
by O
PFOA B
and O
PFOS B
were O
observed O
. O

In O
summary O
, O
the O
changes O
in O
hormonal O
and O
FA O
profiles O
may O
represent O
cellular O
and O
/ O
or O
physiological O
adaptation O
to O
continuous O
PFOS B
and O
PFOA B
exposure O
by O
increasing O
membrane O
fluidity O
, O
and O
/ O
or O
overt O
developmental O
effects O
. O

Ferredoxin O
1 O
( O
FDX1 O
; O
adrenodoxin O
) O
is O
an O
iron B
- O
sulfur B
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O

Knockdown O
of O
FDX1 O
attenuated O
progesterone B
production O
in O
KGN O
cells O
. O

These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP B
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O
ovarian O
granulosa O
cells O
. O

Attenuation O
by O
statins B
of O
membrane O
raft O
- O
redox O
signaling O
in O
coronary O
arterial O
endothelium O
. O

Membrane O
raft O
( O
MR O
) O
- O
redox O
signaling O
platforms O
associated O
with O
NADPH B
oxidase O
are O
involved O
in O
coronary O
endothelial O
dysfunction O
. O

Here O
, O
we O
studied O
whether O
statins B
interfere O
with O
the O
formation O
of O
MR O
- O
redox O
signaling O
platforms O
to O
protect O
the O
coronary O
arterial O
endothelium O
from O
oxidized O
low O
- O
density O
lipoprotein O
( O
OxLDL O
) O
- O
induced O
injury O
and O
from O
acute O
hypercholesterolemia O
. O

In O
cultured O
human O
coronary O
arterial O
endothelial O
cells O
, O
confocal O
microscopy O
detected O
the O
formation O
of O
an O
MRs O
clustering O
when O
they O
were O
exposed O
to O
OxLDL O
, O
and O
such O
MR O
platform O
formation O
was O
inhibited O
markedly O
by O
statins B
, O
including O
pravastatin B
and O
simvastatin B
. O

In O
these O
MR O
clusters O
, O
NADPH B
oxidase O
subunits O
gp91 O
( O
phox O
) O
and O
p47 O
( O
phox O
) O
were O
aggregated O
and O
were O
markedly O
blocked O
by O
both O
statins B
. O

In O
addition O
, O
colocalization O
of O
acid O
sphingomyelinase O
( O
ASM O
) O
and O
ceramide O
was O
induced O
by O
OxLDL O
, O
which O
was O
blocked O
by O
statins B
. O

Electron O
spin O
resonance O
spectrometry O
showed O
that O
OxLDL O
- O
induced O
superoxide B
( O
O2 B
( I
. I
- I
) I
) O
production O
in O
the O
MR O
fractions O
was O
substantially O
reduced O
by O
statins B
. O

Such O
colocalization O
was O
rarely O
observed O
in O
the O
arteries O
of O
normal O
mice O
or O
significantly O
reduced O
by O
pretreatment O
of O
hypercholesterolemic O
mice O
with O
statins B
. O

Furthermore O
, O
O2 B
( I
. I
- I
) I
production O
in O
situ O
was O
3 O
- O
fold O
higher O
in O
the O
coronary O
arteries O
from O
hypercholesterolemic O
mice O
than O
in O
those O
from O
normal O
mice O
, O
and O
such O
increase O
was O
inhibited O
by O
statins B
. O

Our O
results O
indicate O
that O
blockade O
of O
MR O
- O
redox O
signaling O
platform O
formation O
in O
endothelial O
cell O
membrane O
may O
be O
another O
important O
therapeutic O
mechanism O
of O
statins B
in O
preventing O
endothelial O
injury O
and O
atherosclerosis O
and O
may O
be O
associated O
with O
their O
direct O
action O
on O
membrane O
cholesterol B
structure O
and O
function O
. O

Pharmacogenomics O
of O
acetylsalicylic B
acid I
and O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
: O
clinical O
implications O
. O

Aspirin B
and O
other O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
are O
among O
the O
most O
commonly O
prescribed O
medications O
with O
well O
- O
documented O
variation O
in O
patient O
response O
in O
terms O
of O
efficacy O
and O
safety O
. O

However O
, O
further O
research O
efforts O
are O
needed O
before O
knowledge O
on O
the O
pharmacogenomics O
of O
aspirin B
and O
NSAIDs O
can O
be O
implemented O
in O
clinical O
practice O
. O

Surface O
- O
enhanced O
Raman O
scattering O
( O
SERS O
) O
spectra O
of O
4 O
- O
mercaptobenzoic O
acid O
( O
4 O
- O
MBA O
) O
have O
been O
investigated O
on O
the O
surface O
of O
Cu2O B
nanospheres O
. O

The O
coupling O
between O
the O
adsorbates O
and O
the O
semiconductor O
, O
evidenced O
by O
the O
shift O
in O
absorption O
spectrum O
of O
modified O
Cu2O B
and O
the O
enhancement O
of O
non O
- O
totally O
symmetric O
modes O
of O
the O
4 O
- O
MBA O
and O
4 O
- O
mercaptopyridine O
( O
4 O
- O
MPY O
) O
molecules O
, O
were O
invoked O
to O
explain O
the O
experimental O
results O
. O

Density O
functional O
theory O
( O
DFT O
) O
calculations O
suggested O
a O
charge O
transfer O
( O
CT O
) O
transition O
process O
between O
the O
molecules O
and O
the O
Cu2O B
nanospheres O
. O

Three O
- O
dimensional O
finite O
- O
difference O
time O
domain O
( O
3D O
- O
FDTD O
) O
simulations O
were O
conducted O
to O
map O
out O
the O
electromagnetic O
field O
around O
the O
Cu2O B
nanospheres O
. O

The O
experimental O
and O
simulation O
results O
have O
revealed O
the O
promise O
of O
the O
Cu2O B
nanospheres O
as O
a O
good O
SERS O
substrate O
and O
the O
prospect O
of O
using O
the O
SERS O
substrate O
as O
a O
valuable O
tool O
for O
in O
situ O
investigation O
and O
assay O
of O
the O
adsorption O
behavior O
on O
semiconductor O
surfaces O
. O

The O
characteristics O
of O
genistin B
- O
induced O
inhibitory O
effects O
on O
intestinal O
motility O
. O

Genistin B
belongs O
to O
isoflavones B
. O

Based O
on O
the O
facts O
that O
genistin B
exerts O
inhibitory O
effects O
on O
the O
contractility O
of O
vascular O
smooth O
muscle O
, O
the O
present O
study O
was O
designed O
to O
characterize O
the O
effects O
of O
genistin B
on O
intestinal O
contractility O
and O
evaluate O
its O
potential O
clinical O
implication O
. O

The O
results O
indicated O
that O
genistin B
( O
5 O
- O
80 O
mu O
mol O
/ O
L O
) O
inhibited O
the O
contraction O
of O
IJS O
in O
a O
dose O
- O
dependent O
manner O
and O
inhibited O
the O
increased O
- O
contractility O
of O
IJS O
induced O
by O
acetylcholine B
( O
ACh B
) O
, O
histamine B
, O
high O
Ca B
( I
2 I
+ I
) I
, O
and O
erythromycin B
, O
respectively O
. O

The O
inhibitory O
effects O
of O
genistin B
were O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol B
respectively O
. O

No O
further O
inhibitory O
effects O
of O
genistin B
were O
observed O
in O
the O
presence O
of O
verapamil B
or O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
condition O
, O
indicating O
genistin B
- O
induced O
inhibitory O
effects O
are O
Ca B
( I
2 I
+ I
) I
- O
dependent O
. O

Genistin B
decreased O
myosin O
light O
chain O
kinase O
( O
MLCK O
) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg B
( I
2 I
+ I
) I
- O
ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin B
- O
induced O
inhibitory O
effects O
. O

The O
study O
suggests O
the O
potential O
clinical O
implications O
of O
genistin B
in O
relieving O
intestinal O
hypercontractility O
. O

The O
emerging O
role O
of O
hepatic O
transporters O
in O
regulating O
the O
movement O
of O
endogenous O
and O
exogenous O
chemicals O
( O
e O
. O
g O
. O
, O
bile B
acids I
and O
drugs O
) O
across O
cellular O
and O
tissue O
membranes O
is O
critical O
in O
determining O
the O
pathophysiology O
of O
liver O
disease O
as O
well O
as O
drug O
toxicity O
and O
efficacy O
. O

Effect O
of O
excipients O
on O
acetaminophen B
metabolism O
and O
its O
implications O
for O
prevention O
of O
liver O
injury O
. O

Acetaminophen B
poisoning O
is O
the O
most O
frequent O
cause O
of O
acute O
hepatic O
failure O
in O
the O
US O
. O

Toxicity O
requires O
reductive O
metabolism O
of O
acetaminophen B
, O
primarily O
via O
CYP2E1 O
. O

Liquid O
acetaminophen B
preparations O
contain O
propylene B
glycol I
, O
a O
common O
excipient O
that O
has O
been O
shown O
to O
reduce O
hepatocellular O
injury O
in O
vitro O
and O
in O
rodents O
. O

Children O
are O
less O
susceptible O
to O
acetaminophen B
toxicity O
for O
unclear O
reasons O
. O

We O
conducted O
a O
pharmacokinetic O
single O
- O
blinded O
crossover O
study O
of O
15 O
healthy O
adult O
volunteers O
comparing O
the O
CYP2E1 O
and O
conjugative O
metabolism O
of O
a O
15 O
mg O
/ O
kg O
dose O
of O
liquid O
versus O
solid O
preparations O
of O
acetaminophen B
. O

Propylene B
glycol I
, O
an O
established O
CYP2E1 O
competitive O
antagonist O
, O
was O
detected O
in O
the O
liquid O
formulation O
but O
not O
solid O
formulation O
arm O
. O

Since O
children O
tend O
to O
ingest O
liquid O
preparations O
, O
the O
protective O
effect O
of O
this O
excipient O
could O
explain O
their O
decreased O
susceptibility O
to O
acetaminophen B
toxicity O
. O

A O
less O
hepatotoxic O
formulation O
of O
acetaminophen B
could O
potentially O
be O
developed O
if O
co O
- O
formulated O
with O
a O
CYP2E1 O
inhibitor O
. O

This O
meta O
- O
analysis O
was O
performed O
to O
compare O
the O
risk O
of O
cardiac O
events O
and O
restenosis O
between O
triple O
antiplatelet O
therapy O
( O
TAT O
, O
addition O
of O
cilostazol O
to O
aspirin B
and O
clopidogrel B
) O
and O
conventional O
dual O
antiplatelet O
therapy O
( O
DAT O
, O
aspirin B
and O
clopidogrel B
) O
in O
drug O
- O
eluting O
stents O
( O
DES O
) O
implantation O
patients O
. O

The O
systolic O
and O
diastolic O
BPs O
, O
body O
mass O
index O
and O
blood O
levels O
of O
aspartate B
transaminase O
, O
alanine B
transaminase O
, O
alkaline O
phosphatase O
, O
creatinine B
and O
blood O
urea B
nitrogen B
were O
determined O
at O
baseline O
and O
endpoint O
. O

Readily O
accessible O
fluorescent O
probes O
for O
sensitive O
biological O
imaging O
of O
hydrogen B
peroxide I
. O

Hydrogen B
peroxide I
is O
a O
major O
component O
of O
oxygen B
metabolism O
in O
biological O
systems O
that O
, O
when O
present O
in O
high O
concentrations O
, O
can O
lead O
to O
oxidative O
stress O
in O
cells O
. O

Noninvasive O
molecular O
imaging O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
using O
fluorogenic O
systems O
represents O
an O
effective O
way O
to O
detect O
and O
measure O
the O
accumulation O
of O
this O
metabolite O
. O

Herein O
, O
we O
detail O
the O
development O
of O
robust O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
sensitive O
fluorescent O
probes O
using O
a O
boronic O
ester O
trigger O
appended O
to O
the O
fluorophore O
through O
a O
benzyl O
ether O
linkage O
. O

The O
sensitivity O
of O
the O
probes O
was O
evaluated O
in O
simulated O
physiological O
conditions O
, O
showing O
micromolar O
sensitivity O
to O
H B
( I
2 I
) I
O I
( I
2 I
) I
. O

The O
probes O
were O
tested O
in O
biological O
model O
systems O
, O
demonstrating O
effective O
imaging O
of O
unstimulated O
, O
endogenous O
H B
( I
2 I
) I
O I
( I
2 I
) I
levels O
in O
RAW O
264 O
. O
7 O
cells O
and O
murine O
brain O
tissue O
. O

Mifepristone B
for O
management O
of O
Cushing O
' O
s O
syndrome O
. O

Mifepristone B
( O
RU O
486 O
) O
, O
a O
first O
- O
in O
- O
class O
glucocorticoid O
receptor O
antagonist O
, O
was O
approved O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
in O
2012 O
for O
use O
in O
Cushing O
' O
s O
syndrome O
to O
control O
hyperglycemia O
in O
patients O
who O
are O
not O
surgical O
candidates O
or O
have O
not O
achieved O
remission O
from O
surgery O
. O

In O
its O
pivotal O
trial O
, O
60 O
% O
of O
patients O
responded O
to O
mifepristone B
with O
significant O
improvements O
in O
glycemic O
control O
and O
38 O
% O
had O
a O
reduction O
in O
diastolic O
blood O
pressure O
. O

The O
recommended O
starting O
dosage O
of O
mifepristone B
is O
300 O
mg O
/ O
day O
. O

Significant O
drug O
- O
drug O
interactions O
exist O
due O
to O
mifepristone B
' O
s O
effects O
on O
a O
number O
of O
cytochrome O
P450 O
enzymes O
. O

Despite O
its O
limitations O
, O
mifepristone B
is O
a O
welcome O
addition O
and O
an O
appropriate O
alternative O
to O
the O
available O
drug O
therapy O
for O
Cushing O
' O
s O
syndrome O
. O

UV O
/ O
Vis O
spectra O
of O
subporphyrazines O
and O
subphthalocyanines O
with O
aluminum B
and O
gallium B
: O
a O
time O
- O
dependent O
DFT O
study O
. O

The O
UV O
/ O
Vis O
spectra O
of O
selected O
substituted O
subporphyrazines O
( O
SubPz O
) O
and O
subphthalocyanines O
( O
SubPc O
) O
with O
aluminum B
and O
gallium B
as O
central O
atoms O
are O
analyzed O
through O
time O
- O
dependent O
DFT O
calculations O
in O
chloroform B
. O

The O
results O
are O
compared O
with O
previous O
results O
with O
boron B
as O
the O
central O
atom O
to O
analyze O
the O
photochemical O
properties O
of O
these O
two O
families O
of O
compounds O
on O
varying O
the O
metal O
along O
the O
same O
group O
. O

The O
absorptions O
of O
SubPz O
( O
Al B
, O
Ga B
) O
are O
redshifted O
or O
blueshifted O
with O
respect O
to O
SubPz O
( O
B O
) O
depending O
on O
the O
nature O
of O
the O
R O
substituents O
of O
the O
molecule O
, O
whereas O
the O
absorptions O
of O
SubPc O
( O
Al B
, O
Ga B
) O
structures O
are O
redshifted O
and O
with O
smaller O
energy O
gaps O
with O
respect O
to O
SubPc O
( O
B O
) O
for O
all O
kinds O
of O
R O
substituents O
. O

Looking O
at O
their O
absorption O
spectra O
, O
these O
systems O
with O
aluminum B
and O
gallium B
may O
also O
have O
, O
as O
in O
the O
case O
of O
boron B
, O
promising O
photochemical O
properties O
. O

Pu O
- O
erh O
tea O
hot O
- O
water O
extract O
activates O
Akt O
and O
induces O
insulin O
- O
independent O
glucose B
transport O
in O
rat O
skeletal O
muscle O
. O

Skeletal O
muscle O
is O
a O
major O
organ O
that O
is O
important O
for O
whole O
- O
body O
glucose B
metabolism O
. O

This O
activation O
was O
associated O
with O
an O
increase O
in O
Ser B
( O
473 O
) O
phosphorylation O
of O
Akt O
, O
a O
signaling O
intermediary O
leading O
to O
insulin O
- O
dependent O
glucose B
transport O
, O
but O
not O
Tyr B
( O
458 O
) O
phosphorylation O
of O
phosphoinositide O
3 O
- O
kinase O
p85 O
, O
an O
upstream O
molecule O
of O
Akt O
. O

PTE O
- O
stimulated O
3MG O
transport O
was O
also O
not O
accompanied O
by O
Thr B
( O
172 O
) O
phosphorylation O
of O
the O
catalytic O
alpha O
- O
subunit O
of O
5 O
' O
- O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
. O

Gallic B
acid I
, O
a O
water O
- O
soluble O
ingredient O
in O
Pu O
- O
erh O
tea O
, O
stimulated O
Akt O
phosphorylation O
, O
but O
not O
AMPK O
phosphorylation O
. O

These O
results O
suggest O
that O
Pu O
- O
erh O
tea O
potentially O
promotes O
skeletal O
muscle O
glucose B
transport O
at O
least O
in O
part O
by O
activating O
Akt O
. O

Discovery O
, O
biological O
evaluation O
, O
and O
structure O
- O
activity O
and O
- O
selectivity O
relationships O
of O
6 O
' O
- O
substituted O
( O
E O
) O
- O
2 O
- O
( O
benzofuran O
- O
3 O
( O
2H O
) O
- O
ylidene O
) O
- O
N O
- O
methylacetamides O
, O
a O
novel O
class O
of O
potent O
and O
selective O
monoamine B
oxidase O
inhibitors O
. O

The O
use O
of O
selective O
inhibitors O
of O
monoamine B
oxidase O
A O
( O
MAO O
- O
A O
) O
and O
B O
( O
MAO O
- O
B O
) O
holds O
a O
therapeutic O
relevance O
in O
the O
treatment O
of O
depressive O
disorders O
and O
Parkinson O
' O
s O
disease O
( O
PD O
) O
, O
respectively O
. O

Here O
, O
the O
discovery O
of O
a O
new O
class O
of O
compounds O
acting O
as O
monoamine B
oxidase O
inhibitors O
( O
MAO O
- O
Is O
) O
and O
bearing O
a O
6 O
' O
- O
substituted O
( O
E O
) O
- O
2 O
- O
( O
benzofuran O
- O
3 O
( O
2H O
) O
- O
ylidene O
) O
- O
N O
- O
alkylacetamide O
skeleton O
is O
reported O
. O

This O
protein O
, O
named O
MlatA1 O
, O
possesses O
61 O
amino B
acids I
with O
8 O
conserved O
cysteine B
residues O
, O
sharing O
30 O
- O
91 O
% O
sequence O
identity O
with O
other O
fully O
sequenced O
Micrurus O
toxins O
. O

MlatA1 O
( O
LD50i O
. O
v O
. O
= O
0 O
. O
064 O
mg O
/ O
kg O
) O
antagonizes O
with O
both O
fetal O
and O
adult O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
as O
well O
as O
alpha O
- O
7 O
neuronal O
nAChR O
in O
a O
dose O
- O
dependent O
way O
. O

Does O
Microsecond O
Sugar B
Ring O
Flexing O
Encode O
3D O
- O
Shape O
and O
Bioactivity O
in O
the O
Heparanome O
? O

The O
biological O
information O
encoded O
in O
carbohydrate B
sequences O
dwarfs O
that O
of O
proteins O
and O
nucleic O
acids O
. O

Deciphering O
structure O
- O
function O
relationships O
in O
heparin O
and O
heparan O
sulfate B
( O
the O
heparanome O
) O
is O
further O
compounded O
by O
extreme O
sequence O
diversity O
, O
experimental O
difficulties O
, O
and O
the O
computational O
cost O
of O
rigorous O
modeling O
. O

Furthermore O
, O
in O
coarse O
- O
grained O
simulations O
, O
inclusion O
of O
puckering O
was O
essential O
to O
predict O
macroscopic O
hydrodynamic O
properties O
of O
heparan O
sulfate B
chains O
containing O
hundreds O
of O
monosaccharaides O
. O

Definition O
of O
formulation O
design O
space O
, O
in O
vitro O
bioactivity O
and O
in O
vivo O
biodistribution O
for O
hydrophilic O
drug O
loaded O
PLGA B
/ O
PEO O
- O
PPO O
- O
PEO O
nanoparticles O
using O
OFAT O
experiments O
. O

Modified O
nanoprecipitation O
method O
was O
used O
for O
improved O
incorporation O
of O
hydrophilic O
drug O
( O
irinotecan O
hydrochloride O
) O
into O
the O
PLGA B
/ O
PEO O
- O
PPO O
- O
PEO O
blended O
and O
blended O
/ O
adsorbed O
nanoparticles O
. O

One O
factor O
at O
a O
time O
( O
OFAT O
) O
variation O
experiments O
were O
conducted O
in O
order O
to O
determine O
key O
formulation O
factors O
( O
concentration O
and O
volume O
of O
drug O
solution O
, O
evaporation O
rate O
and O
PLGA B
/ O
PEO O
- O
PPO O
- O
PEO O
ratio O
) O
influencing O
nanoparticle O
properties O
( O
particle O
size O
and O
size O
distribution O
, O
encapsulation O
efficiency O
, O
drug O
content O
, O
zeta O
potential O
, O
drug O
dissolution O
rate O
, O
as O
well O
as O
protein O
binding O
capacity O
) O
. O

The O
mean O
particle O
size O
, O
mainly O
dependent O
upon O
PLGA B
/ O
PEO O
- O
PPO O
- O
PEO O
ratio O
, O
was O
in O
the O
range O
of O
112 O
- O
125nm O
, O
with O
narrow O
unimodal O
distribution O
( O
PDI O
~ O
0 O
. O
1 O
) O
. O

Encapsulation O
efficiency O
( O
32 O
- O
63 O
% O
) O
was O
impacted O
by O
evaporation O
rate O
and O
PLGA B
/ O
PEO O
- O
PPO O
- O
PEO O
ratio O
. O

Zeta O
potential O
values O
indicated O
that O
presence O
of O
PEO O
- O
PPO O
- O
PEO O
in O
the O
formulations O
shielded O
the O
high O
surface O
negative O
charge O
of O
PLGA B
. O

PEO O
- O
PPO O
- O
PEO O
surface O
coverage O
of O
PLGA B
/ O
PEO O
- O
PPO O
- O
PEO O
blended O
as O
well O
as O
blended O
/ O
adsorbed O
nanoparticles O
depended O
upon O
amount O
of O
used O
PEO O
- O
PPO O
- O
PEO O
during O
preparation O
procedure O
and O
was O
related O
to O
the O
protein O
resistant O
characteristics O
of O
nanoparticles O
. O

Potential O
for O
preventive O
effects O
of O
cocoa O
and O
cocoa O
polyphenols B
in O
cancer O
. O

Prevention O
of O
cancer O
through O
the O
diet O
is O
receiving O
increasing O
interest O
, O
and O
cocoa O
because O
of O
its O
polyphenolic B
compounds O
has O
become O
an O
important O
potential O
chemopreventive O
and O
therapeutic O
natural O
agent O
. O

Cocoa O
and O
its O
main O
polyphenols B
have O
been O
reported O
to O
interfere O
at O
the O
initiation O
, O
promotion O
and O
progression O
of O
cancer O
. O

Cocoa O
flavonoids B
have O
been O
demonstrated O
to O
influence O
several O
important O
biological O
functions O
in O
vitro O
and O
in O
vivo O
by O
their O
free O
radical O
scavenging O
ability O
or O
through O
the O
regulation O
of O
signal O
transduction O
pathways O
to O
stimulate O
apoptosis O
and O
to O
inhibit O
inflammation O
, O
cellular O
proliferation O
, O
apoptosis O
, O
angiogenesis O
and O
metastasis O
. O

The O
aim O
of O
this O
review O
is O
to O
provide O
insights O
into O
the O
molecular O
basis O
of O
the O
potential O
chemopreventive O
activity O
of O
cocoa O
and O
its O
polyphenolic B
components O
by O
summarizing O
cell O
culture O
and O
animal O
models O
studies O
, O
as O
well O
as O
interventional O
and O
epidemiological O
studies O
on O
humans O
. O

Biosafety O
and O
antioxidant O
effects O
of O
a O
beverage O
containing O
silymarin O
and O
arginine B
. O

The O
study O
objective O
was O
to O
investigate O
the O
potential O
of O
a O
beverage O
containing O
silymarin O
and O
l B
- I
arginine I
to O
alter O
basic O
physiological O
and O
urodynamic O
parameters O
in O
22 O
normal O
healthy O
men O
aged O
38 O
- O
59years O
. O

The O
volunteers O
drank O
500ml O
/ O
day O
beverage O
without O
silymarin O
and O
l B
- I
arginine I
for O
10days O
followed O
, O
after O
a O
7 O
- O
day O
washout O
period O
, O
by O
the O
beverage O
with O
400mg O
silymarin O
and O
295mg O
l B
- I
arginine I
for O
10days O
. O

Total O
antioxidant O
capacity O
, O
total O
level O
of O
antioxidants O
, O
lipoperoxidation O
products O
( O
malondialdehyde B
) O
, O
advanced O
oxidation O
products O
of O
proteins O
in O
plasma O
and O
glutathione B
, O
glutathione B
peroxidase O
, O
glutathione B
reductase O
, O
superoxide B
dismutase O
and O
catalase O
levels O
in O
erythrocytes O
were O
not O
influenced O
. O

Serum O
gamma O
- O
glutamyl O
transferase O
, O
malondialdehyde B
level O
and O
activity O
of O
glutathione B
S B
- O
transferase O
in O
erythrocytes O
were O
lowered O
at O
day O
27 O
and O
the O
concentration O
of O
total O
plasma O
SH B
- O
groups O
was O
higher O
on O
day O
10 O
. O

Using O
an O
ex O
vivo O
system O
, O
we O
found O
that O
silymarin O
/ O
silybin B
at O
10 O
- O
100 O
mu O
M O
is O
able O
to O
adsorb O
onto O
human O
erythrocytes O
and O
the O
complexes O
displayed O
antioxidant O
properties O
as O
studied O
using O
ex O
situ O
square O
- O
wave O
voltammetry O
. O

Ghrelin O
inhibits O
sodium B
metabisulfite I
induced O
oxidative O
stress O
and O
apoptosis O
in O
rat O
gastric O
mucosa O
. O

This O
study O
aimed O
to O
investigate O
the O
effect O
of O
ghrelin O
administration O
on O
sulfite B
induced O
oxidative O
and O
apoptotic O
changes O
in O
rat O
gastric O
mucosa O
. O

Forty O
male O
albino O
Wistar O
rats O
were O
randomized O
into O
control O
( O
C O
) O
, O
sodium B
metabisulfite I
( O
Na2S2O5 O
) O
treated O
( O
S O
) O
, O
ghrelin O
treated O
( O
G O
) O
and O
, O
Na2S2O5 O
+ O
ghrelin O
treated O
( O
SG O
) O
groups O
. O

Sodium B
metabisulfite I
( O
100mg O
/ O
kg O
/ O
day O
) O
was O
given O
by O
gastric O
gavage O
and O
, O
ghrelin O
( O
20 O
mu O
g O
/ O
kg O
/ O
day O
) O
was O
given O
intraperitoneally O
for O
5weeks O
. O

Plasma O
- O
S B
- O
sulfonate B
level O
was O
increased O
in O
S O
and O
SG O
groups O
. O

Vitamin B
A I
and O
retinoid B
signaling O
: O
genomic O
and O
non O
- O
genomic O
effects O
. O

Vitamin B
A I
or O
retinol B
is O
arguably O
the O
most O
multifunctional O
vitamin O
in O
the O
human O
body O
as O
it O
is O
essential O
from O
embryogenesis O
to O
adulthood O
. O

The O
pleiotropic O
effects O
of O
vitamin B
A I
are O
exerted O
mainly O
by O
one O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
which O
regulates O
the O
expression O
of O
a O
battery O
of O
target O
genes O
through O
several O
families O
of O
nuclear O
receptors O
( O
RARs O
, O
RXRs O
and O
PPAR O
beta O
/ O
delta O
) O
, O
polymorphic O
retinoic B
acid I
( O
RA O
) O
response O
elements O
and O
multiple O
coregulators O
. O

However O
, O
vitamin B
A I
itself O
proved O
recently O
to O
be O
active O
and O
RARs O
to O
be O
present O
in O
the O
cytosol O
to O
regulate O
translation O
and O
cell O
plasticity O
. O

All O
these O
new O
concepts O
expand O
the O
scope O
of O
the O
biologic O
functions O
of O
vitamin B
A I
and O
RA O
. O

Synthesis O
and O
antiproliferative O
activity O
evaluation O
of O
imidazole B
- O
based O
indeno O
[ O
1 O
, O
2 O
- O
b O
] O
quinoline O
- O
9 O
, O
11 O
- O
dione O
derivatives O
. O

A O
series O
of O
new O
imidazole B
substituted O
indeno O
[ O
1 O
, O
2 O
- O
b O
] O
quinoline O
- O
9 O
, O
11 O
- O
dione O
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
effects O
on O
HeLa O
, O
LS180 O
, O
MCF O
- O
7 O
and O
Jurkat O
human O
cancer O
cell O
lines O
. O

Antiproliferative O
effects O
were O
evaluated O
using O
MTT B
assay O
. O

Moreover O
; O
it O
was O
found O
that O
some O
of O
the O
tested O
compounds O
bearing O
imidazole O
- O
2 O
- O
yl O
moiety O
on O
the O
C11 O
- O
position O
of O
dihydropyridine B
ring O
exhibited O
superior O
antiproliferative O
activity O
in O
comparison O
to O
cis O
- O
platin O
especially O
in O
Jurkat O
cell O
line O
( O
compounds O
29 O
, O
31 O
, O
and O
33 O
) O
. O

It O
seemed O
that O
the O
introduction O
of O
electron O
- O
withdrawing O
groups O
on O
the O
imidazole B
ring O
enhanced O
the O
antiproliferative O
potential O
of O
these O
compounds O
( O
compounds O
27 O
, O
29 O
and O
31 O
) O
. O

The O
results O
of O
this O
study O
proposed O
that O
some O
of O
the O
imidazole B
substituted O
indeno O
[ O
1 O
, O
2 O
- O
b O
] O
quinoline O
- O
9 O
, O
11 O
- O
dione O
compounds O
may O
act O
as O
efficient O
anticancer O
agents O
in O
vitro O
, O
emphasizing O
their O
potential O
role O
as O
a O
source O
for O
rational O
design O
of O
potent O
antiproliferative O
agents O
. O

Accumulating O
evidence O
indicates O
that O
HIFs O
also O
regulate O
cell O
survival O
, O
glucose B
metabolism O
, O
microenvironmental O
remodeling O
, O
cancer O
metastasis O
, O
and O
tumor O
progression O
, O
and O
thus O
, O
HIFs O
are O
viewed O
as O
therapeutic O
targets O
in O
many O
diseases O
. O

Mussel O
- O
inspired O
histidine B
- O
based O
transient O
network O
metal O
coordination O
hydrogels O
. O

Transient O
network O
hydrogels O
cross O
- O
linked O
through O
histidine B
- O
divalent O
cation O
coordination O
bonds O
were O
studied O
by O
conventional O
rheologic O
methods O
using O
histidine B
- O
modified O
star O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
polymers O
. O

These O
materials O
were O
inspired O
by O
the O
mussel O
, O
which O
is O
thought O
to O
use O
histidine B
- O
metal O
coordination O
bonds O
to O
impart O
self O
- O
healing O
properties O
in O
the O
mussel O
byssal O
thread O
. O

The O
equilibrium O
metal O
- O
binding O
constants O
were O
determined O
by O
dilute O
solution O
potentiometric O
titration O
of O
monofunctional O
histidine B
- O
modified O
methoxy O
- O
PEG O
and O
were O
found O
to O
be O
consistent O
with O
binding O
constants O
of O
small O
molecule O
analogs O
previously O
studied O
. O

pH O
- O
dependent O
speciation O
curves O
were O
then O
calculated O
using O
the O
equilibrium O
constants O
determined O
by O
potentiometric O
titration O
, O
providing O
insight O
into O
the O
pH O
dependence O
of O
histidine B
- O
metal O
ion O
coordination O
and O
guiding O
the O
design O
of O
metal O
coordination O
hydrogels O
. O

Natural O
product O
drug O
discovery O
programs O
often O
rely O
on O
the O
use O
of O
silica B
( O
Si B
) O
gel O
, O
reversed O
- O
phase O
media O
, O
or O
size O
- O
exclusion O
resins O
( O
e O
. O
g O
. O
, O
RP O
- O
C O
( O
18 O
) O
, O
Sephadex O
LH O
- O
20 O
) O
for O
compound O
purification O
. O

The O
synthetic O
polymer O
- O
based O
sorbent O
Diaion O
HP20SS O
( O
cross O
- O
linked O
polystyrene B
matrix O
) O
is O
used O
as O
an O
alternative O
to O
prepare O
purified O
natural O
product O
libraries O
. O

Curcuma O
longa O
, O
Saururus O
cernuus O
, O
and O
Citrus O
reticulata O
extracts O
showed O
decreased O
HIF O
- O
1 O
inhibitory O
activity O
after O
elution O
through O
Si B
gel O
. O

An O
additional O
nonpolar O
column O
wash O
of O
HP20SS O
with O
EtOAc B
retained O
considerable O
bioactivities O
of O
active O
extracts O
. O

In O
general O
, O
Si B
gel O
produced O
the O
greatest O
loss O
of O
bioactivity O
. O

The O
known O
compounds O
were O
characterised O
as O
n O
- O
tetracosane O
, O
beta O
- O
sitosteryl O
stearate O
, O
eicosanoic O
acid O
, O
stigmasterol B
, O
beta B
- I
sitosterol I
, O
racemosol O
, O
octacosyl O
ferulate O
, O
de O
- O
O O
- O
methyl O
racemosol O
, O
lupeol B
and O
1 O
, O
7 O
, O
8 O
, O
12b O
- O
tetrahydro O
- O
2 O
, O
2 O
, O
4 O
- O
trimethyl O
- O
2H O
- O
benzo O
[ O
6 O
, O
7 O
] O
cyclohepta O
[ O
1 O
, O
2 O
, O
3 O
- O
de O
] O
[ O
1 O
] O

The O
formation O
of O
the O
well O
- O
known O
product O
Br3 O
( O
- O
) O
, O
observed O
in O
the O
steady O
- O
state O
radiolysis O
of O
highly O
concentrated O
Br B
( I
- I
) I
aqueous O
solutions O
, O
has O
now O
been O
directly O
observed O
at O
ultrashort O
times O
corresponding O
to O
the O
relaxation O
of O
the O
spur O
. O

The O
transient O
absorption O
induced O
by O
picosecond O
pulse O
radiolysis O
of O
6 O
M O
Br B
( I
- I
) I
aqueous O
solution O
was O
probed O
simultaneously O
at O
260 O
nm O
with O
the O
third O
harmonic O
laser O
wave O
and O
from O
350 O
to O
750 O
nm O
with O
a O
supercontinuum O
generated O
by O
the O
fundamental O
laser O
wave O
. O

In O
highly O
concentrated O
Br B
( I
- I
) I
solutions O
, O
the O
OH B
( I
* I
) I
radical O
is O
fully O
replaced O
by O
Br2 O
( O
* O
- O
) O
, O
and O
the O
spur O
kinetics O
of O
OH B
( I
* I
) I
radical O
in O
pure O
water O
is O
comparable O
with O
that O
of O
Br2 O
( O
- O
* O
) O
. O

Model O
calculations O
indicate O
that O
the O
main O
OH B
( I
* I
) I
radical O
combination O
product O
H2O2 B
in O
pure O
water O
has O
formation O
kinetics O
similar O
to O
that O
of O
Br3 O
( O
- O
) O
in O
6 O
M O
Br B
( I
- I
) I
solutions O
. O

Moreover O
, O
they O
point O
out O
that O
oxidation O
of O
Br B
( I
- I
) I
occurs O
within O
the O
electron O
pulse O
both O
by O
direct O
energy O
absorption O
and O
by O
scavenging O
of O
the O
water O
radical O
cation O
, O
H2O B
( I
* I
+ I
) I
. O

Knowing O
the O
dynamic O
mechanical O
response O
of O
tissue O
, O
cells O
, O
membranes O
, O
proteins O
, O
nucleic O
acids O
, O
and O
carbohydrates B
to O
external O
perturbations O
is O
important O
to O
understand O
various O
biological O
and O
biotechnological O
problems O
. O

Developing O
one O
that O
is O
a O
small O
molecule O
kinase O
inhibitor O
that O
binds O
competitively O
with O
respect O
to O
ATP B
with O
superb O
selectivity O
is O
even O
more O
difficult O
, O
which O
makes O
the O
design O
and O
optimization O
work O
described O
by O
Jimenez O
et O
al O
. O

Palytoxin O
( O
PLTX O
) O
is O
the O
reference O
compound O
for O
a O
group O
of O
potent O
marine O
biotoxins O
, O
for O
which O
the O
molecular O
target O
is O
Na B
+ I
/ O
K B
+ I
- O
ATPase O
. O

Indeed O
, O
ouabain B
( O
OUA O
) O
, O
a O
potent O
blocker O
of O
the O
pump O
, O
is O
used O
to O
inhibit O
some O
PLTX O
effects O
in O
vitro O
. O

However O
, O
in O
an O
effort O
to O
explain O
incomplete O
inhibition O
of O
PLTX O
cytotoxicity O
, O
some O
studies O
suggest O
the O
possibility O
of O
two O
different O
binding O
sites O
on O
Na B
+ I
/ O
K B
+ I
- O
ATPase O
. O

Correlation O
of O
photobleaching O
, O
oxidation O
and O
metal O
induced O
fluorescence O
quenching O
of O
DNA O
- O
templated O
silver B
nanoclusters O
. O

DNA O
- O
templated O
silver B
nanoclusters O
( O
AgNCs O
) O
are O
of O
particular O
interest O
as O
different O
emission O
colors O
can O
be O
obtained O
by O
changing O
the O
DNA O
sequence O
. O

A O
popular O
analytical O
application O
is O
fluorescence O
quenching O
by O
Hg B
( I
2 I
+ I
) I
, O
where O
d O
( O
10 O
) O
- O
d O
( O
10 O
) O
metallophilic O
interaction O
has O
often O
been O
proposed O
for O
associating O
Hg B
( I
2 I
+ I
) I
with O
nanoclusters O
. O

However O
, O
it O
cannot O
explain O
the O
lack O
of O
response O
to O
other O
d O
( O
10 O
) O
ions O
such O
as O
Zn B
( I
2 I
+ I
) I
and O
Cd B
( I
2 I
+ I
) I
. O

In O
our O
effort O
to O
elucidate O
the O
quenching O
mechanism O
, O
we O
studied O
a O
total O
of O
eight O
AgNCs O
prepared O
by O
different O
hairpin O
DNA O
sequences O
; O
they O
showed O
different O
sensitivity O
to O
Hg B
( I
2 I
+ I
) I
, O
and O
DNA O
with O
a O
larger O
cytosine B
loop O
size O
produced O
more O
sensitive O
AgNCs O
. O

In O
all O
the O
cases O
, O
samples O
strongly O
quenched O
by O
Hg B
( I
2 I
+ I
) I
were O
also O
more O
easily O
photobleached O
. O

Light O
of O
shorter O
wavelengths O
bleached O
AgNCs O
more O
potently O
, O
and O
photobleached O
samples O
can O
be O
recovered O
by O
NaBH4 B
. O

Strong O
fluorescence O
quenching O
was O
also O
observed O
with O
high O
redox O
potential O
metal O
ions O
such O
as O
Ag B
( I
+ I
) I
, O
Au O
( O
3 O
+ O
) O
, O
Cu B
( I
2 I
+ I
) I
and O
Hg B
( I
2 I
+ I
) I
, O
but O
not O
with O
low O
redox O
potential O
ions O
. O

Such O
metal O
induced O
quenching O
cannot O
be O
recovered O
by O
NaBH4 B
. O

On O
the O
accuracy O
of O
explicitly O
correlated O
methods O
to O
generate O
potential O
energy O
surfaces O
for O
scattering O
calculations O
and O
clustering O
: O
application O
to O
the O
HCl B
- O
He B
complex O
. O

This O
work O
is O
performed O
on O
the O
benchmark O
rare O
gas O
- O
hydrogen O
halide O
interaction O
( O
HCl B
- O
He B
) O
system O
. O

Eugenol B
alters O
the O
integrity O
of O
cell O
membrane O
and O
acts O
against O
the O
nosocomial O
pathogen O
Proteus O
mirabilis O
. O

Eugenol B
, O
a O
member O
of O
the O
phenylpropanoids O
class O
of O
chemical O
compounds O
, O
is O
a O
clear O
to O
pale O
yellow O
oily O
liquid O
extracted O
from O
certain O
essential O
oils O
especially O
from O
clove O
oil O
, O
nutmeg O
, O
cinnamon O
, O
and O
bay O
leaf O
. O

The O
antibacterial O
activity O
of O
eugenol B
and O
its O
mechanism O
of O
bactericidal O
action O
against O
Proteus O
mirabilis O
were O
evaluated O
. O

Treatment O
with O
eugenol B
at O
their O
minimum O
inhibitory O
concentration O
[ O
0 O
. O
125 O
% O
( O
v O
/ O
v O
) O
] O
and O
minimum O
bactericidal O
concentration O
[ O
0 O
. O
25 O
% O
( O
v O
/ O
v O
) O
] O
reduced O
the O
viability O
and O
resulted O
in O
complete O
inhibition O
of O
P O
. O
mirabilis O
. O

A O
strong O
bactericidal O
effect O
on O
P O
. O
mirabilis O
was O
also O
evident O
, O
as O
eugenol B
inactivated O
the O
bacterial O
population O
within O
30 O
min O
exposure O
. O

Chemo O
- O
attractant O
property O
and O
the O
observance O
of O
highest O
antibacterial O
activity O
at O
alkaline O
pH O
suggest O
that O
eugenol B
can O
work O
more O
effectively O
when O
given O
in O
vivo O
. O

Eugenol B
inhibits O
the O
virulence O
factors O
produced O
by O
P O
. O
mirabilis O
as O
observed O
by O
swimming O
motility O
, O
swarming O
behavior O
and O
urease O
activity O
. O

SDS B
- O
polyacrylamide B
gel O
, O
scanning O
electron O
microscopy O
and O
Fourier O
transform O
infrared O
analysis O
further O
proves O
the O
disruptive O
action O
of O
eugenol B
on O
the O
plasma O
membrane O
of O
P O
. O
mirabilis O
. O

The O
findings O
reveal O
that O
eugenol B
shows O
an O
excellent O
bactericidal O
activity O
against O
P O
. O
mirabilis O
by O
altering O
the O
integrity O
of O
cell O
membrane O
. O

Phenolic B
constituents O
from O
Parakmeria O
yunnanensis O
and O
their O
anti O
- O
HIV O
- O
1 O
activity O
. O

Three O
new O
phenolic B
compounds O
, O
yunnanensins O
A O
- O
C O
( O
1 O
- O
3 O
) O
, O
together O
with O
fourteen O
known O
ones O
( O
4 O
- O
17 O
) O
, O
were O
isolated O
from O
the O
leaves O
and O
stems O
of O
Parakmeria O
yunnanensis O
. O

Selective O
inhibition O
of O
an O
apicoplastic O
aminoacyl B
- O
tRNA O
synthetase O
from O
Plasmodium O
falciparum O
. O

Aminoacyl B
- O
tRNA O
synthetases O
( O
ARSs O
) O
are O
essential O
enzymes O
and O
well O
- O
established O
antibacterial O
targets O
and O
so O
constitute O
a O
promising O
set O
of O
targets O
for O
the O
development O
of O
new O
antimalarials O
. O

Here O
we O
demonstrate O
that O
selective O
inhibition O
of O
apicoplastic O
ARSs O
is O
feasible O
and O
describe O
new O
compounds O
that O
that O
specifically O
inhibit O
Plasmodium O
apicoplastic O
lysyl B
- O
tRNA O
synthetase O
and O
show O
antimalarial O
activities O
in O
the O
micromolar O
range O
. O

The O
neonicotinoid O
imidacloprid B
shows O
high O
chronic O
toxicity O
to O
mayfly O
nymphs O
. O

The O
present O
study O
evaluated O
the O
acute O
and O
chronic O
toxicity O
of O
imidacloprid B
to O
a O
range O
of O
freshwater O
arthropods O
. O

Mayfly O
and O
caddisfly O
species O
were O
most O
sensitive O
to O
short O
- O
term O
imidacloprid B
exposures O
( O
10 O
tests O
) O
, O
whereas O
the O
mayflies O
showed O
by O
far O
the O
most O
sensitive O
response O
to O
long O
- O
term O
exposure O
of O
all O
seven O
arthropod O
species O
tested O
( O
28 O
- O
d O
EC10 O
values O
of O
approximately O
0 O
. O
03 O
micro O
g O
/ O
L O
) O
. O

The O
results O
indicated O
a O
high O
aquatic O
risk O
of O
chronic O
exposure O
of O
imidacloprid B
to O
mayflies O
. O

Pharmacokinetics O
of O
modified O
- O
release O
prednisone B
tablets O
in O
healthy O
subjects O
and O
patients O
with O
rheumatoid O
arthritis O
. O

Modified O
- O
release O
prednisone B
tablets O
were O
developed O
to O
allow O
administration O
at O
bedtime O
for O
programmed O
delivery O
of O
glucocorticoid O
during O
the O
night O
. O

Single O
- O
center O
crossover O
studies O
were O
conducted O
, O
each O
in O
< O
= O
24 O
healthy O
subjects O
, O
to O
compare O
the O
pharmacokinetics O
of O
a O
single O
5 O
- O
mg O
oral O
dose O
of O
modified O
- O
release O
prednisone B
and O
conventional O
prednisone B
, O
as O
well O
as O
the O
effect O
of O
food O
on O
bioavailability O
. O

Pharmacokinetic O
evaluation O
in O
9 O
patients O
with O
RA O
confirmed O
that O
modified O
- O
release O
prednisone B
tablets O
taken O
at O
bedtime O
( O
around O
22 O
: O
00 O
h O
) O
with O
or O
after O
an O
evening O
meal O
result O
in O
programmed O
release O
of O
glucocorticoid O
4 O
to O
6 O
hours O
after O
intake O
. O

Modification O
of O
the O
Catalytic O
Function O
of O
Human O
Hydroxysteroid B
Sulfotransferase O
hSULT2A1 O
by O
Formation O
of O
Disulfide B
Bonds O
. O

The O
human O
cytosolic O
sulfotransferase O
hSULT2A1 O
catalyzes O
the O
sulfation O
of O
a O
broad O
range O
of O
xenobiotics O
, O
as O
well O
as O
endogenous O
hydroxysteroids O
and O
bile B
acids I
. O

We O
have O
examined O
the O
hypothesis O
that O
the O
formation O
of O
disulfide B
bonds O
in O
hSULT2A1 O
can O
reversibly O
regulate O
the O
catalytic O
function O
of O
the O
enzyme O
. O

Three O
thiol B
oxidants O
were O
used O
as O
model O
compounds O
to O
investigate O
their O
effects O
on O
homogeneous O
preparations O
of O
hSULT2A1 O
: O
glutathione B
disulfide I
, O
5 B
, I
5 I
' I
- I
dithiobis I
( I
2 I
- I
nitrobenzoic I
acid I
) I
, O
and O
1 O
, O
1 O
' O
- O
azobis O
( O
N O
, O
N O
- O
dimethylformamide O
) O
( O
diamide O
) O
. O

Examination O
of O
the O
effects O
of O
disulfide B
bond O
formation O
with O
these O
agents O
indicated O
that O
the O
activity O
of O
the O
enzyme O
is O
reversibly O
altered O
. O

Studies O
on O
the O
kinetics O
of O
the O
hSULT2A1 O
- O
catalyzed O
sulfation O
of O
dehydroepiandrostero B
( O
DHEA B
) O
showed O
the O
effects O
of O
disulfide B
bond O
formation O
on O
the O
substrate O
inhibition O
characteristics O
of O
the O
enzyme O
. O

Our O
results O
indicate O
that O
conformational O
changes O
at O
cysteines B
near O
the O
nucleotide B
binding O
site O
affect O
the O
binding O
of O
both O
the O
nucleotide B
and O
DHEA B
to O
the O
enzyme O
, O
with O
the O
specific O
effects O
dependent O
on O
the O
structure O
of O
the O
resulting O
disulfide B
. O

Thus O
, O
the O
formation O
of O
disulfide B
bonds O
in O
hSULT2A1 O
is O
a O
potentially O
important O
reversible O
mechanism O
for O
alterations O
in O
the O
rates O
of O
sulfation O
of O
both O
endogenous O
and O
xenobiotic O
substrates O
. O

Vancomycin B
staining O
identified O
the O
overall O
septum O
morphology O
in O
living O
cells O
. O

Characterization O
, O
pharmacokinetics O
, O
tissue O
distribution O
and O
antitumor O
activity O
of O
honokiol B
submicron O
lipid O
emulsions O
in O
tumor O
- O
burdened O
mice O
. O

Honokiol B
, O
isolated O
from O
the O
Chinese O
traditional O
herb O
magnolia O
, O
is O
a O
poorly O
water O
- O
soluble O
component O
and O
has O
been O
found O
to O
have O
anti O
- O
tumor O
properties O
. O

In O
the O
current O
study O
, O
honokiol B
submicron O
lipid O
emulsions O
( O
HK O
- O
SLEs O
) O
were O
prepared O
by O
high O
pressure O
homogenization O
technology O
. O

After O
HK O
- O
SLEs O
were O
physically O
characterized O
, O
their O
pharmacokinetics O
, O
tissue O
distribution O
and O
antitumor O
activity O
after O
intravenous O
( O
i O
. O
v O
. O
) O
administration O
to O
tumor O
- O
burdened O
mice O
were O
examined O
, O
using O
honokiol B
solution O
( O
HK O
- O
SOL O
) O
as O
the O
control O
. O

These O
results O
suggest O
that O
HK O
- O
SLEs O
might O
be O
an O
effective O
parenteral O
carrier O
for O
honokiol B
delivery O
in O
cancer O
treatment O
. O

Ypc1p O
can O
catalyze O
the O
reverse O
reaction O
, O
i O
. O
e O
. O
the O
condensation O
of O
free O
fatty B
acids I
with O
phytosphingosine B
or O
dihydrosphingosine O
and O
overexpression O
of O
YPC1 O
or O
YDC1 O
can O
provide O
enough O
ceramide O
synthesis O
as O
to O
rescue O
the O
viability O
of O
cells O
lacking O
the O
normal O
acyl B
- I
CoA I
- O
dependent O
ceramide O
synthases O
. O

To O
better O
understand O
the O
coexistence O
of O
acyl B
- I
CoA I
dependent O
ceramide O
synthases O
and O
ceramidases O
in O
the O
ER O
we O
investigated O
the O
membrane O
topology O
of O
Ypc1p O
by O
probing O
cysteine B
accessibility O
of O
natural O
and O
substituted O
cysteines B
with O
membrane O
non O
- O
permeating O
mass O
- O
tagged O
probes O
. O

The O
N B
- O
and O
C B
- O
terminal O
ends O
of O
Ypc1p O
are O
oriented O
towards O
the O
lumen O
and O
cytosol O
, O
respectively O
. O

Two O
of O
the O
5 O
natural O
cysteines B
, O
Cys27 O
and O
Cys219 O
, O
are O
essential O
for O
enzymatic O
activity O
and O
form O
a O
disulfide B
bridge O
. O

The O
data O
allow O
inferring O
that O
all O
amino B
acids I
of O
Ypc1p O
that O
are O
conserved O
in O
the O
pfam O
PF05875 O
ceramidase O
motif O
and O
the O
CREST O
superfamily O
are O
located O
in O
or O
near O
the O
ER O
lumen O
. O

Microsomal O
assays O
using O
a O
lysine B
- O
specific O
reagent O
show O
that O
the O
reverse O
ceramidase O
activity O
can O
only O
be O
blocked O
when O
the O
reagent O
has O
access O
to O
Ypc1p O
from O
the O
lumenal O
side O
. O

Functionalizing O
the O
pi O
- O
cores O
with O
" O
alkyl B
chains O
" O
is O
a O
common O
strategy O
in O
the O
molecular O
design O
that O
can O
give O
the O
system O
desirable O
properties O
, O
such O
as O
good O
solubility O
in O
organic O
solvents O
for O
solution O
processing O
. O

However O
, O
while O
some O
general O
rules O
have O
been O
revealed O
, O
a O
comprehensive O
understanding O
of O
the O
function O
played O
by O
the O
attached O
alkyl B
chains O
is O
still O
lacking O
, O
and O
current O
methodology O
is O
system O
- O
specific O
in O
many O
cases O
. O

Here O
, O
based O
on O
recent O
efforts O
toward O
this O
goal O
, O
we O
show O
the O
power O
of O
the O
alkyl B
chains O
in O
controlling O
the O
self O
- O
assembly O
of O
soft O
molecular O
materials O
and O
their O
resulting O
optoelectronic O
properties O
. O

Some O
other O
closely O
related O
systems O
composed O
of O
alkyl B
chains O
and O
pi O
- O
units O
are O
also O
reviewed O
to O
indicate O
the O
universality O
of O
the O
methodology O
. O

The O
removal O
of O
bisphenol O
AP O
( O
BPAP O
) O
by O
a O
multiwalled O
carbon B
nanotube O
( O
MWCNT O
) O
was O
investigated O
. O

The O
hydrogen B
bond O
, O
hydrophobic O
, O
and O
pi O
- O
pi O
stacking O
interactions O
were O
dominant O
factors O
for O
the O
strong O
adsorption O
of O
BPAP O
, O
instead O
of O
the O
pH O
ionic O
strength O
and O
other O
ionic O
species O
in O
contaminated O
water O
. O

The O
MWCNT O
has O
higher O
stability O
within O
8 O
removal O
- O
regeneration O
recycles O
, O
and O
up O
to O
95 O
% O
of O
recovery O
could O
be O
obtained O
by O
eluting O
the O
adsorbed O
BPAP O
on O
MWCNT O
adsorbent O
using O
ethanol B
/ O
sodium O
hydrate O
solution O
. O

In O
general O
rates O
of O
hypoglycaemia O
in O
these O
trials O
were O
low O
, O
glucose B
control O
was O
comparable O
to O
currently O
available O
basal O
insulin O
analogs O
, O
and O
rates O
of O
nocturnal O
hypoglycaemia O
were O
significantly O
and O
substantially O
lower O
. O

Direct O
observation O
of O
a O
bent O
carbonyl B
ligand O
in O
a O
19 O
- O
electron O
transition B
metal I
complex O
. O

The O
photochemistry O
of O
[ O
CpRu O
( O
CO O
) O
2 O
] O
2 O
in O
P O
( O
OMe O
) O
3 O
/ O
CH2Cl2 B
solution O
has O
been O
studied O
using O
picosecond O
time O
- O
resolved O
infrared O
( O
TRIR O
) O
spectroscopy O
. O

The O
TRIR O
spectra O
of O
this O
adduct O
display O
an O
unusually O
low O
CO B
stretching O
frequency O
for O
the O
antisymmetric O
CO B
stretching O
mode O
, O
suggesting O
that O
one O
carbonyl B
ligand O
adopts O
a O
bent O
configuration O
to O
avoid O
a O
19 O
- O
electron O
count O
at O
the O
metal O
center O
. O

The O
DFT O
results O
predict O
a O
bent O
CO B
ligand O
in O
CpRu O
( O
CO O
) O
2P O
( O
OMe O
) O
3 O
( O
* O
) O
, O
whereas O
approximately O
linear O
Fe O
- O
C O
- O
O O
bond O
angles O
are O
predicted O
for O
CpFe O
( O
CO O
) O
2P O
( O
OMe O
) O
3 O
( O
* O
) O
. O

The O
observation O
of O
a O
bent O
CO B
ligand O
in O
the O
19 O
- O
electron O
ruthenium B
adduct O
is O
a O
surprising O
result O
, O
and O
it O
provides O
new O
insight O
into O
the O
solution O
- O
phase O
behavior O
of O
19 O
- O
electron O
complexes O
. O

TRIR O
spectra O
were O
also O
collected O
for O
[ O
CpRu O
( O
CO O
) O
2 O
] O
2 O
in O
neat O
CH2Cl2 B
, O
and O
it O
is O
interesting O
to O
note O
that O
no O
singly O
bridged O
[ O
CpRu O
( O
CO O
) O
] O
2 O
( O
mu O
- O
CO O
) O
photoproduct O
was O
observed O
to O
form O
following O
400 O
- O
or O
267 O
- O
nm O
excitation O
, O
despite O
previous O
observations O
of O
this O
species O
on O
longer O
time O
scales O
. O

Formulation O
, O
optimization O
, O
in O
vivo O
pharmacokinetic O
, O
behavioral O
and O
biochemical O
estimations O
of O
minocycline B
loaded O
chitosan O
nanoparticles O
for O
enhanced O
brain O
uptake O
. O

MH O
loaded O
nanoparticles O
( O
MHNP O
) O
were O
coated O
with O
tween B
80 I
( O
cMHNP O
) O
to O
improve O
its O
brain O
uptake O
followed O
by O
their O
optimization O
employing O
two O
factor O
- O
three O
level O
( O
3 O
( O
2 O
) O
) O
central O
composite O
design O
( O
CCD O
) O
in O
order O
to O
minimize O
particle O
size O
and O
maximize O
drug O
entrapment O
efficiency O
( O
DEE O
) O
and O
validated O
. O

The O
pharmacodynamic O
study O
was O
carried O
out O
using O
elevated O
plus O
maze O
( O
EPM O
) O
and O
Morris O
water O
maze O
( O
MWM O
) O
behavioral O
models O
for O
nootropic O
activity O
in O
swiss O
albino O
mice O
; O
and O
biochemical O
estimations O
( O
acetylcholine B
esterase O
, O
reduced B
glutathione I
, O
malondialdehyde B
and O
brain O
nitrite B
level O
) O
. O

Although O
cMHNP O
did O
not O
produce O
significant O
change O
in O
brain O
acetylcholinesterase O
, O
but O
, O
significantly O
increased O
reduced B
glutathione I
, O
malondialdehyde B
and O
reduced O
brain O
nitrite B
level O
as O
compared O
to O
saline O
, O
MH O
solution O
and O
MHNP O
treated O
groups O
. O

The O
introduction O
of O
a O
methoxy B
group O
to O
the O
benzothiazole B
ring O
in O
1 O
and O
the O
break O
up O
of O
the O
planarity O
between O
the O
imidazole B
ring O
and O
the O
thiazole B
ring O
improved O
the O
solubility O
in O
the O
lotion O
base O
of O
11 O
. O

Self O
- O
organizing O
map O
analysis O
using O
multivariate O
data O
from O
theophylline B
tablets O
predicted O
by O
a O
thin O
- O
plate O
spline O
interpolation O
. O

As O
a O
model O
pharmaceutical O
product O
, O
theophylline B
tablets O
were O
prepared O
based O
on O
a O
standard O
formulation O
. O

The O
results O
of O
this O
study O
suggest O
that O
increasing O
the O
proportion O
of O
microcrystalline O
cellulose O
( O
MCC O
) O
improved O
the O
tensile O
strength O
and O
the O
stability O
of O
tensile O
strength O
of O
these O
theophylline B
tablets O
. O

This O
technique O
provides O
a O
better O
understanding O
of O
the O
relationships O
between O
causal O
factors O
and O
pharmaceutical O
responses O
in O
theophylline B
tablet O
formulations O
. O

The O
asymmetric O
synthesis O
of O
( O
R O
) O
- O
dihydro O
- O
beta O
- O
ionol O
, O
one O
of O
the O
most O
valuable O
raw O
materials O
for O
fragrance O
and O
flavor O
, O
was O
performed O
from O
inexpensive O
beta B
- I
ionone I
via O
lipase O
- O
catalyzed O
dynamic O
kinetic O
resolution O
followed O
by O
reduction O
. O

Three O
new O
orcinol O
- O
conjugated O
hydrolysable O
tannins B
from O
the O
leaves O
of O
Cleyera O
japonica O
. O

Three O
new O
orcinol O
( O
3 O
- O
hydroxy O
- O
5 O
- O
methylphenol O
) O
- O
conjugated O
hydrolysable O
tannins B
, O
together O
with O
two O
known O
compounds O
were O
isolated O
from O
the O
leaves O
of O
Cleyera O
japonica O
( O
CJ O
) O
, O
and O
have O
been O
tentatively O
named O
cleyeratannin O
A O
( O
1 O
) O
, O
cleyeratannin O
B O
( O
2 O
) O
and O
cleyeratannin O
C O
( O
3 O
) O
. O

To O
evaluate O
their O
anti O
- O
oxidative O
activities O
, O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
/ O
free O
radical O
scavenging O
activity O
and O
nitroblue B
tetrazolium I
( O
NBT O
) O
/ O
superoxide B
anion O
scavenging O
activity O
were O
determined O
. O

ARF O
represses O
androgen B
receptor O
transactivation O
in O
prostate O
cancer O
. O

Androgen B
receptor O
( O
AR O
) O
signaling O
is O
essential O
for O
prostate O
cancer O
( O
PCa O
) O
development O
in O
humans O
. O

Here O
, O
we O
provide O
evidence O
that O
p14ARF O
physically O
interacts O
with O
AR O
and O
functions O
as O
an O
AR O
corespressor O
in O
both O
an O
androgen B
- O
dependent O
and O
androgen B
- O
independent O
manner O
. O

Overexpression O
of O
p14ARF O
in O
PCa O
cells O
significantly O
attenuates O
the O
activities O
of O
androgen B
response O
region O
( O
ARR2 O
) O
- O
probasin O
and O
prostate O
- O
specific O
antigen O
( O
PSA O
) O
promoters O
. O

Furthermore O
, O
we O
demonstrated O
that O
p14ARF O
binds O
to O
both O
the O
N B
- O
terminal O
domain O
and O
the O
ligand O
- O
binding O
domain O
of O
AR O
, O
and O
the O
human O
double O
minute O
2 O
( O
HDM2 O
) O
- O
binding O
motif O
of O
p14ARF O
is O
required O
for O
the O
interaction O
of O
p14ARF O
and O
AR O
proteins O
. O

p14ARF O
perturbs O
the O
androgen B
- O
induced O
interaction O
between O
the O
N B
terminus O
and O
C B
terminus O
of O
AR O
. O

Ceramide O
phosphoethanolamine O
biosynthesis O
in O
Drosophila O
is O
mediated O
by O
a O
unique O
ethanolamine B
phosphotransferase O
in O
the O
Golgi O
lumen O
. O

Sphingomyelin B
( O
SM O
) O
is O
a O
vital O
component O
of O
mammalian O
membranes O
, O
providing O
mechanical O
stability O
and O
a O
structural O
framework O
for O
plasma O
membrane O
organization O
. O

Its O
production O
involves O
the O
transfer O
of O
phosphocholine O
from O
phosphatidylcholine B
onto O
ceramide O
, O
a O
reaction O
catalyzed O
by O
SM O
synthase O
in O
the O
Golgi O
lumen O
. O

Drosophila O
lacks O
SM O
and O
instead O
synthesizes O
the O
SM O
analogue O
ceramide O
phosphoethanolamine O
( O
CPE O
) O
as O
the O
principal O
membrane O
sphingolipid B
. O

Using O
a O
functional O
cloning O
strategy O
, O
we O
here O
identified O
a O
CDP O
- O
ethanolamine B
: O
ceramide O
ethanolamine B
phosphotransferase O
as O
the O
enzyme O
responsible O
for O
CPE O
production O
in O
Drosophila O
. O

CPE O
synthase O
constitutes O
a O
new O
branch O
within O
the O
CDP O
- O
alcohol B
phosphotransferase O
superfamily O
with O
homologues O
in O
Arthropoda O
( O
insects O
, O
spiders O
, O
mites O
, O
scorpions O
) O
, O
Cnidaria O
( O
Hydra O
, O
sea O
anemones O
) O
, O
and O
Mollusca O
( O
oysters O
) O
but O
not O
in O
most O
other O
animal O
phyla O
. O

The O
enzyme O
resides O
in O
the O
Golgi O
complex O
with O
its O
active O
site O
facing O
the O
lumen O
, O
contrary O
to O
the O
membrane O
topology O
of O
other O
CDP O
- O
alcohol B
phosphotransferases O
. O

The O
gas O
- O
phase O
reaction O
of O
methane O
sulfonic O
acid O
with O
the O
hydroxyl B
radical O
without O
and O
with O
water O
vapor O
. O

The O
gas O
phase O
reaction O
between O
methane O
sulfonic O
acid O
( O
CH3SO3H O
; O
MSA O
) O
and O
the O
hydroxyl B
radical O
( O
HO O
) O
, O
without O
and O
with O
a O
water O
molecule O
, O
was O
investigated O
with O
DFT O
- O
B3LYP O
and O
CCSD O
( O
T O
) O
- O
F12 O
methods O
. O

For O
the O
bare O
reaction O
we O
have O
found O
two O
reaction O
mechanisms O
, O
involving O
proton O
coupled O
electron O
transfer O
and O
hydrogen B
atom O
transfer O
processes O
that O
produce O
CH3SO3 O
and O
H2O B
. O

The O
presence O
of O
a O
single O
water O
molecule O
makes O
the O
reaction O
between O
CH3SO3H O
and O
HO O
much O
more O
complex O
, O
introducing O
a O
new O
reaction O
that O
consists O
in O
the O
interchange O
of O
H2O B
between O
HO O
and O
CH3SO3H O
. O

Our O
kinetic O
calculations O
show O
that O
99 O
. O
5 O
% O
of O
the O
reaction O
involves O
this O
interchange O
of O
the O
water O
molecule O
and O
, O
consequently O
, O
water O
vapor O
does O
not O
play O
any O
role O
in O
the O
oxidation O
reaction O
of O
methane O
sulfonic O
acid O
by O
the O
hydroxyl B
radical O
. O

However O
, O
the O
overwhelming O
majority O
of O
previously O
reported O
temperature O
- O
responsive O
polymers O
are O
based O
on O
poly B
( I
N I
- I
isopropylacrylamide I
) I
( O
PNIPAM O
) O
, O
despite O
the O
fact O
that O
a O
wide O
range O
of O
other O
thermoresponsive O
polymers O
have O
demonstrated O
similar O
promise O
for O
the O
preparation O
of O
adaptive O
materials O
. O

Bacteriopheophytin O
a O
in O
the O
active O
branch O
of O
the O
reaction O
center O
of O
rhodobacter O
sphaeroides O
is O
not O
disturbed O
by O
the O
protein O
matrix O
as O
shown O
by O
13C B
photo O
- O
CIDNP O
MAS O
NMR O
. O

By O
using O
various O
isotope O
labeling O
systems O
, O
introduced O
by O
adding O
different O
( B
13 I
) I
C I
selectively O
labeled O
delta B
- I
aminolevulinic I
acid I
precursors O
in O
the O
growing O
medium O
of O
R O
. O
sphaeroides O
wild O
type O
( O
WT O
) O
, O
we O
were O
able O
to O
extract O
light O
- O
induced O
( B
13 I
) I
C I
NMR O
signals O
originating O
from O
the O
primary O
electron O
acceptor O
. O

1 B
, I
3 I
, I
4 I
- I
thiadiazole I
and O
its O
derivatives O
: O
a O
review O
on O
recent O
progress O
in O
biological O
activities O
. O

The O
1 B
, I
3 I
, I
4 I
- I
thiadiazole I
nucleus O
is O
one O
of O
the O
most O
important O
and O
well O
- O
known O
heterocyclic O
nuclei O
, O
which O
is O
a O
common O
and O
integral O
feature O
of O
a O
variety O
of O
natural O
products O
and O
medicinal O
agents O
. O

Introduction O
: O
The O
mGlu2 O
receptor O
, O
which O
belongs O
to O
the O
group O
II O
subfamily O
of O
metabotropic O
glutamate B
receptors O
( O
mGlu O
) O
along O
with O
the O
mGlu3 O
receptor O
, O
has O
proven O
to O
be O
of O
particular O
importance O
in O
neuropharmacology O
. O

Preferentially O
expressed O
on O
presynaptic O
nerve O
terminals O
, O
the O
mGlu2 O
receptor O
negatively O
modulates O
glutamate B
and O
GABA B
release O
and O
is O
widely O
distributed O
in O
the O
brain O
. O

High O
levels O
of O
mGlu2 O
receptors O
are O
seen O
in O
brain O
areas O
such O
as O
prefrontal O
cortex O
, O
hippocampus O
and O
amygdala O
where O
glutamate B
hyperfunction O
may O
be O
implicated O
in O
disorders O
and O
diseases O
such O
as O
anxiety O
and O
schizophrenia O
. O

Characterization O
of O
a O
pre O
- O
export O
enzyme O
- O
chaperone O
complex O
on O
the O
twin O
- O
arginine B
transport O
pathway O
. O

The O
Tat O
( O
twin O
- O
arginine B
translocation O
) O
system O
is O
a O
protein O
targeting O
pathway O
utilized O
by O
prokaryotes O
and O
chloroplasts O
. O

Tat O
substrates O
are O
produced O
with O
distinctive O
N B
- O
terminal O
signal O
peptides O
and O
are O
translocated O
as O
fully O
folded O
proteins O
. O

Further O
characterization O
suggested O
that O
the O
C B
- O
terminal O
' O
Domain O
IV O
' O
of O
TorA O
remained O
solvent O
- O
exposed O
in O
the O
cofactor O
- O
free O
pre O
- O
export O
TorAD O
complex O
. O

In O
this O
study O
, O
we O
use O
( B
13 I
) I
C I
and O
( B
31 I
) I
P I
solid O
- O
state O
NMR O
and O
wide O
angle O
X O
- O
ray O
diffraction O
( O
WAXD O
) O
as O
tools O
to O
elucidate O
molecular O
protein O
structure O
of O
caddisfly O
larval O
silk O
from O
the O
species O
Hesperophylax O
consimilis O
. O

Caddisfly O
larval O
silk O
is O
a O
fibroin O
protein O
based O
biopolymer O
containing O
mostly O
repetitive O
amino B
acid I
motifs O
. O

NMR O
and O
X O
- O
ray O
results O
provide O
strong O
supporting O
evidence O
for O
a O
structural O
model O
in O
which O
phosphorylated O
serine O
repeats O
( O
pSX O
) O
4 O
complex O
with O
divalent O
cations O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
to O
form O
rigid O
nanocrystalline O
beta O
- O
sheet O
structures O
in O
caddisfly O
silk O
. O

( B
13 I
) I
C I
NMR O
data O
suggests O
that O
both O
phosphorylated O
serine O
and O
neighboring O
valine B
residues O
exist O
in O
a O
beta O
- O
sheet O
conformation O
while O
glycine B
and O
leucine B
residues O
common O
in O
GGX O
repeats O
likely O
reside O
in O
random O
coil O
conformations O
. O

Additionally O
, O
( B
31 I
) I
P I
chemical O
shift O
anisotropy O
( O
CSA O
) O
analysis O
indicates O
that O
the O
phosphates B
on O
phosphoserine O
residues O
are O
doubly O
ionized O
, O
and O
are O
charge O
- O
stabilized O
by O
divalent O
cations O
. O

Positively O
charged O
arginine B
side O
chains O
also O
likely O
play O
a O
role O
in O
charge O
stabilization O
. O

Hydrocarbons B
( O
jet O
fuel O
JP O
- O
8 O
) O
induce O
epigenetic O
transgenerational O
inheritance O
of O
obesity O
, O
reproductive O
disease O
and O
sperm O
epimutations O
. O

The O
current O
study O
was O
designed O
to O
determine O
if O
a O
hydrocarbon B
mixture O
involving O
jet O
fuel O
( O
JP O
- O
8 O
) O
promotes O
epigenetic O
transgenerational O
inheritance O
of O
disease O
. O

Observations O
demonstrate O
hydrocarbons B
can O
promote O
epigenetic O
transgenerational O
inheritance O
of O
disease O
and O
sperm O
epimutations O
, O
potential O
biomarkers O
for O
ancestral O
exposures O
. O

Synthesis O
and O
evaluation O
of O
nicotinamide B
derivative O
as O
anti O
- O
angiogenic O
agents O
. O

Previously O
, O
we O
have O
found O
that O
BRN O
- O
103 O
, O
a O
nicotinamide B
derivative O
, O
inhibits O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
- O
mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O

During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti O
- O
angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide B
derivatives O
and O
evaluated O
their O
anti O
- O
angiogenic O
effects O
. O

Furthermore O
, O
BRN O
- O
250 O
inhibited O
the O
VEGF O
- O
induced O
phosphorylation O
and O
intracellular O
tyrosine B
kinase O
activity O
of O
VEGF O
receptor O
2 O
( O
VEGFR2 O
) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O

Plant O
- O
derived O
non O
- O
essential O
fatty B
acids I
are O
important O
dietary O
nutrients O
, O
and O
some O
are O
purported O
to O
have O
chemopreventive O
properties O
against O
various O
cancers O
, O
including O
that O
of O
the O
prostate O
. O

These O
fatty B
acids I
included O
jacaric O
and O
punicic O
acid O
found O
in O
jacaranda O
and O
pomegranate O
seed O
oil O
, O
respectively O
, O
three O
octadecatrienoic O
geometric O
isomers O
( O
alpha O
- O
and O
beta O
- O
calendic O
and O
catalpic O
acid O
) O
and O
two O
mono O
- O
unsaturated O
C O
- O
18 O
fatty O
acids O
( O
trans O
- O
and O
cis O
- O
vaccenic O
acid O
) O
. O

The O
spatial O
conformation O
cis O
, O
trans O
, O
cis O
of O
jacaric O
and O
punicic O
acid O
was O
shown O
to O
play O
a O
key O
role O
in O
the O
increased O
potency O
and O
efficacy O
of O
these O
two O
fatty B
acids I
in O
comparison O
to O
the O
five O
other O
C O
- O
18 O
fatty O
acids O
tested O
. O

This O
3 O
- O
D O
analysis O
of O
structural O
similarity O
enabled O
us O
to O
rank O
geoisomeric O
fatty B
acids I
according O
to O
cytotoxic O
potency O
, O
whereas O
a O
2 O
- O
D O
positional O
assessment O
of O
cis O
/ O
trans O
structure O
did O
not O
. O

Our O
findings O
provide O
mechanistic O
evidence O
that O
nutrition O
- O
derived O
non O
- O
essential O
fatty B
acids I
have O
chemopreventive O
biological O
activities O
and O
Exhibit O
3 O
- O
D O
structure O
- O
activity O
relationships O
that O
could O
be O
exploited O
to O
develop O
new O
strategies O
for O
the O
prevention O
or O
treatment O
of O
prostate O
cancer O
regardless O
of O
hormone O
dependency O
. O

Activated O
organophosphate B
( O
OP O
) O
insecticides O
and O
chemical O
agents O
inhibit O
acetylcholinesterase O
( O
AChE O
) O
to O
form O
OP O
- O
AChE O
adducts O
. O

The O
beta O
- O
fluoroethoxy O
methylphosphonate O
analog O
( O
R O
= O
Me O
, O
Z O
= O
F O
, O
n O
= O
2 O
) O
was O
the O
most O
potent O
anti O
- O
AChE O
compound O
comparable O
( O
ki O
~ O
6 O
x O
10 O
( O
6 O
) O
M O
( O
- O
1 O
) O
min O
( O
- O
1 O
) O
) O
to O
paraoxon B
against O
EEAChE O
. O

Novel O
N O
- O
alkyldeoxynojirimyci O
( O
NADNJs O
) O
with O
two O
hydrophobic O
groups O
attached O
to O
a O
nitrogen O
linker O
on O
the O
alkyl B
chain O
were O
designed O
. O

In O
particular O
, O
substituents O
with O
a O
tertiary O
amine O
linked O
via O
a O
two O
carbon B
chain O
show O
improved O
inhibitory O
potency O
for O
both O
enzyme O
isoforms O
. O

This O
potency O
improvement O
can O
be O
rationalized O
by O
X O
- O
ray O
crystallography O
, O
which O
shows O
a O
water O
- O
mediated O
contact O
between O
the O
basic O
nitrogen B
and O
the O
carboxylic B
acid I
side O
chain O
of O
Asp200 O
, O
which O
is O
situated O
at O
the O
mouth O
of O
the O
active O
site O
pocket O
of O
arginase O
II O
( O
Asp181 O
in O
arginase O
I O
) O
. O

Memantine B
- O
sulfur B
containing O
antioxidant O
conjugates O
as O
potential O
prodrugs O
to O
improve O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

The O
approved O
treatments O
for O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
exploit O
mainly O
a O
symptomatic O
approach O
based O
on O
the O
use O
of O
cholinesterase O
inhibitors O
or O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonists O
. O

In O
the O
present O
work O
, O
GSH B
( O
1 O
) O
or O
( O
R O
) O
- O
alpha O
- O
lipoic O
acid O
( O
LA O
) O
( O
2 O
) O
have O
been O
covalently O
linked O
with O
the O
NMDA B
receptor O
antagonists O
memantine B
( O
MEM O
) O
. O

The O
new O
conjugates O
, O
proposed O
as O
potential O
antialzheimer O
drugs O
, O
should O
act O
both O
as O
glutamate B
receptor O
antagonists O
and O
radical O
scavenging O
agents O
. O

Toxins O
of O
Escherichia O
coli O
( O
STEC O
) O
causing O
Uremic O
Hemolytic O
Syndrome O
( O
UHS O
) O
generate O
oxidative O
stress O
in O
human O
blood O
with O
more O
production O
of O
nitric B
oxide I
( O
NO B
) O
than O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Shiga O
toxin O
( O
Stx O
) O
together O
with O
the O
hemolysin O
( O
Hly O
) O
increased O
lipid O
oxidation O
, O
as O
evaluated O
by O
malondialdehyde B
MDA B
and O
oxidation O
of O
proteins O
. O

The O
addition O
of O
Ziziphus O
mistol O
Griseb O
extracts O
decreased O
NO B
, O
ROS O
, O
MDA B
and O
simultaneously O
caused O
an O
increase O
in O
the O
degradation O
of O
oxidized O
proteins O
to O
advanced O
oxidation O
protein O
products O
( O
AOPPs O
) O
in O
controls O
and O
samples O
with O
toxins O
. O

Z O
. O
mistol O
Griseb O
extracts O
exhibited O
a O
high O
proportion O
of O
polyphenols B
and O
flavonoids B
, O
with O
evident O
correlation O
with O
ferrous B
reduction O
antioxidant O
potential O
( O
FRAP O
) O
. O

The O
plasma O
of O
eight O
children O
with O
UHS O
showed O
oxidative O
stress O
and O
NO B
stimulus O
, O
comparable O
to O
the O
effect O
of O
toxins O
during O
the O
assays O
in O
vitro O
. O

Rotigotine O
is O
a O
non O
- O
ergoline O
D3 O
/ O
D2 O
/ O
D1 O
dopamine B
agonist O
for O
treating O
PD O
. O

As O
a O
new O
treatment O
option O
for O
CDS O
, O
rotigotine O
- O
loaded O
microspheres O
( O
RoMS O
) O
, O
a O
long O
- O
acting O
sustained O
- O
release O
microspheres O
for O
injection O
with O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
as O
drug O
carrier O
, O
are O
now O
being O
evaluated O
in O
clinical O
trial O
. O

The O
major O
toxicological O
effects O
were O
associated O
with O
the O
dopamine B
agonist O
- O
related O
pharmacodynamic O
properties O
of O
rotigotine O
( O
e O
. O
g O
. O
hyperactivity O
and O
stereotype O
, O
enlarged O
ovary O
, O
sporadic O
gastric O
mucous O
membrane O
lesions O
, O
decreased O
body O
weight O
, O
food O
consumption O
and O
prolactin O
, O
and O
increased O
mononuclear O
cell O
, O
neutrophil O
granulocyte O
, O
aspartate B
aminotransferase O
and O
alanine B
aminotransferase O
) O
and O
foreign O
body O
removal O
reaction O
induced O
by O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
and O

carboxymethycellulos O
sodium B
. O

A O
cell O
- O
penetrating O
peptide O
suppresses O
the O
hypoxia O
inducible O
factor O
- O
1 O
function O
by O
binding O
to O
the O
helix O
- O
loop O
- O
helix O
domain O
of O
the O
aryl B
hydrocarbon I
receptor O
nuclear O
translocator O
. O

The O
heterodimeric O
hypoxia O
inducible O
factor O
- O
1 O
( O
HIF O
- O
1 O
) O
complex O
is O
composed O
of O
the O
hypoxia O
inducible O
factor O
- O
1 O
alpha O
( O
HIF O
- O
1 O
alpha O
) O
and O
the O
aryl B
hydrocarbon I
receptor O
nuclear O
translocator O
( O
ARNT O
) O
. O

At O
2 O
mu O
M O
concentration O
, O
6His O
- O
TAT O
- O
Ainp1 O
is O
not O
cytotoxic O
in O
HeLa O
cells O
but O
suppresses O
the O
cobalt B
chloride I
- O
activated O
, O
hypoxia O
responsive O
enhancer O
- O
driven O
luciferase O
expression O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
addition O
, O
it O
decreases O
the O
cobalt B
chloride I
- O
dependent O
induction O
of O
the O
HIF O
- O
1 O
target O
genes O
at O
both O
the O
message O
( O
vascular O
endothelial O
growth O
factor O
and O
aldolase O
C O
) O
and O
protein O
( O
carbonic O
anhydrase O
IX O
and O
glucose B
transporter O
1 O
) O
levels O
. O

Genotoxicity O
assessment O
of O
vaccine O
adjuvant O
squalene B
. O

The O
genotoxic O
potential O
of O
the O
vaccine O
adjuvant O
Squalene B
was O
assessed O
by O
the O
chromosomal O
aberrations O
( O
CAs O
) O
, O
sister O
chromatid O
exchanges O
( O
SCEs O
) O
and O
micronucleus O
( O
MNs O
) O
tests O
in O
human O
lymphocytes O
and O
comet O
assay O
in O
both O
human O
and O
rat O
lymphocytes O
. O

Five O
different O
concentrations O
of O
squalene B
( O
1250 O
- O
20 O
, O
000 O
mu O
g O
/ O
ml O
for O
human O
lymphocytes O
and O
0 O
. O
07 O
- O
1 O
. O
12mg O
/ O
kg O
for O
rat O
lymphocytes O
) O
were O
studied O
. O

Squalene B
did O
not O
affect O
the O
CAs O
and O
MN O
frequency O
, O
in O
all O
treatments O
in O
vitro O
. O

Squalene B
did O
not O
affect O
significantly O
the O
comet O
tail O
length O
( O
CTL O
) O
( O
except O
2500 O
mu O
g O
/ O
ml O
) O
and O
comet O
tail O
intensity O
( O
CTI O
) O
at O
all O
treatments O
in O
vitro O
. O

In O
rats O
, O
squalene B
significantly O
increased O
and O
decreased O
CTL O
and O
CTI O
in O
some O
doses O
. O

Although O
there O
are O
increasing O
and O
reduction O
in O
the O
effect O
, O
squalene B
cannot O
be O
regarded O
as O
genotoxic O
in O
human O
lymphocytes O
. O

Virus O
- O
sized O
particulate O
adjuvants O
such O
as O
ISCOMs O
, O
polystyrene B
nanoparticles O
and O
virus O
- O
like O
particles O
have O
been O
shown O
to O
target O
dendritic O
cells O
, O
resulting O
in O
the O
activation O
of O
T O
and O
B O
cells O
in O
vivo O
. O

Glyphosate B
, O
a O
post O
emergent O
herbicide O
, O
has O
become O
the O
backbone O
of O
no O
- O
till O
agriculture O
and O
is O
considered O
safe O
for O
animals O
. O

However O
, O
the O
impact O
of O
glyphosate B
on O
non O
- O
target O
organisms O
, O
especially O
on O
amphibians O
, O
is O
the O
subject O
of O
major O
concern O
and O
debate O
in O
recent O
times O
. O

We O
examined O
the O
toxic O
and O
genotoxic O
effects O
of O
Roundup O
, O
a O
commercial O
formulation O
of O
glyphosate B
, O
in O
the O
tadpoles O
of O
the O
Indian O
skittering O
frog O
( O
Euflictis O
cyanophlyctis O
) O
. O

Synthesis O
and O
biochemical O
activities O
of O
antiproliferative O
amino B
acid I
and O
phosphate B
derivatives O
of O
microtubule O
- O
disrupting O
beta O
- O
lactam O
combretastatins O
. O

The O
synthesis O
and O
biochemical O
activities O
of O
novel O
water O
- O
soluble O
beta B
- I
lactam I
analogues O
of O
combretastatin O
A O
- O
4 O
are O
described O
. O

This O
indicates O
that O
the O
beta O
- O
lactam O
amides O
did O
not O
require O
metabolic O
activation O
to O
have O
antiproliferative O
effects O
, O
in O
contrast O
to O
the O
phosphate B
series O
. O

Molecular O
modelling O
studies O
indicated O
potential O
binding O
conformations O
for O
the O
beta O
- O
lactam O
amino O
acid O
amides O
10k O
and O
11l O
in O
the O
colchicine B
- O
binding O
site O
of O
tubulin O
. O

Synthesis O
, O
evaluation O
and O
absolute O
configuration O
assignment O
of O
novel O
dihydropyrimidin O
- O
2 O
- O
ones O
as O
picomolar O
sodium B
iodide I
symporter O
inhibitors O
. O

A O
small O
library O
of O
dihydropyrimidin O
- O
2 O
- O
ones O
( O
DHPMs O
) O
was O
synthesized O
and O
evaluated O
for O
their O
potency O
to O
block O
iodide B
entrapment O
in O
rat O
thyroid O
cells O
. O

Twelve O
compounds O
were O
tested O
for O
the O
inhibition O
of O
sodium B
iodide I
symporter O
( O
NIS O
) O
in O
a O
cell O
- O
based O
assay O
. O

This O
study O
provides O
new O
insights O
for O
the O
development O
of O
anti O
- O
thyroid O
drugs O
, O
as O
well O
as O
for O
the O
synthesis O
of O
novel O
pharmacological O
tools O
designed O
to O
investigate O
iodide B
transport O
mechanisms O
at O
cellular O
and O
molecular O
levels O
. O

Effect O
of O
chronic O
heroin B
and O
cocaine B
administration O
on O
global O
DNA O
methylation O
in O
brain O
and O
liver O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
examine O
the O
effect O
of O
chronic O
cocaine B
and O
heroin B
administration O
on O
global O
DNA O
methylation O
in O
brain O
and O
liver O
. O

Male O
, O
8 O
week O
old O
, O
C57BL O
/ O
6J O
mice O
received O
heroin B
in O
a O
chronic O
' O
intermittent O
' O
escalating O
dose O
paradigm O
, O
or O
cocaine B
in O
a O
chronic O
escalating O
dose O
' O
binge O
' O
paradigm O
, O
which O
mimic O
the O
human O
pattern O
of O
opioid O
or O
cocaine B
abuse O
respectively O
. O

There O
were O
no O
differences O
between O
the O
control O
animals O
and O
the O
cocaine B
or O
heroin B
treated O
animals O
in O
neither O
of O
the O
tissues O
examined O
, O
which O
is O
surprising O
since O
cocaine B
administration O
induced O
gross O
morphological O
changes O
in O
the O
liver O
. O

Moreover O
, O
there O
was O
no O
difference O
in O
the O
% O
5 O
- O
methyl O
- O
2 O
' O
- O
deoxycytidine O
content O
of O
DNA O
between O
the O
cocaine B
and O
the O
heroin B
treated O
animals O
. O

The O
global O
DNA O
methylation O
status O
in O
the O
brain O
and O
liver O
of O
mice O
chronically O
treated O
with O
cocaine B
or O
heroin B
remains O
unaffected O
, O
but O
this O
finding O
cannot O
exclude O
the O
existence O
of O
anatomical O
region O
or O
gene O
- O
specific O
methylation O
differences O
. O

This O
is O
the O
first O
time O
that O
global O
DNA O
methylation O
in O
the O
liver O
and O
whole O
brain O
has O
been O
studied O
following O
chronic O
cocaine B
or O
heroin B
treatment O
. O

A O
variety O
of O
2 O
- O
alkoxy O
- O
4 O
- O
aryl O
- O
6 O
- O
( O
1H O
- O
benzimidazol O
- O
2 O
- O
yl O
) O
- O
3 O
- O
pyridinecarbonitrile O
4a O
- O
r O
were O
prepared O
via O
either O
regioselective O
reaction O
of O
3 O
- O
aryl O
- O
1 O
- O
( O
1H O
- O
benzimidazol O
- O
2 O
- O
yl O
) O
- O
2 O
- O
propen O
- O
1 O
- O
ones O
3 O
with O
malononitrile B
or O
ylidenemalononitrile O
6 O
with O
2 O
- O
acetyl O
- O
1H O
- O
benzimidazoles O
1 O
in O

the O
presence O
of O
sodium O
alkoxide O
in O
the O
corresponding O
alcohol B
. O

Compounds O
25 O
, O
28 O
, O
33 O
, O
35 O
and O
36 O
showed O
broad O
spectrum O
antimicrobial O
activity O
comparable O
to O
the O
known O
antibiotic O
gentamicin B
. O

Molecular O
modeling O
studies O
concluded O
that O
recognition O
with O
key O
amino B
acid I
Arg38 O
and O
Lys31 O
are O
essential O
for O
binding O
and O
biological O
activities O
. O

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha O
- O
zearalenol O
, O
beta O
- O
zearalenol O
, O
T O
- O
2 O
- O
toxin O
, O
HT O
- O
2 O
- O
toxin O
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol O
- O
3 O
- O
glucoside O
, O
zearalenone O
- O
4 O
- O
glucoside O
, O
alpha O
- O

According O
to O
a O
probabilistic O
exposure O
analysis O
, O
the O
mean O
( O
and O
P95 O
) O
mycotoxin O
intake O
for O
the O
sum O
of O
the O
deoxynivalenol B
- O
equivalents O
, O
zearalenone B
- O
equivalents O
, O
and O
the O
sum O
of O
HT O
- O
2 O
- O
and O
T O
- O
2 O
- O
toxin O
for O
all O
cereal O
- O
based O
foods O
was O
0 O
. O
1162 O
( O
0 O
. O
4047 O
, O
P95 O
) O
, O
0 O
. O
0447 O
( O
0 O
. O
1568 O
, O
P95 O
) O
and O
0 O
. O
0258 O
( O
0 O
. O
0924 O
, O
P95 O
) O
mu O
g O
kg O
( O
- O
1 O
) O
body O
weight O
day O

These O
values O
were O
below O
the O
tolerable O
daily O
intake O
( O
TDI O
) O
levels O
for O
deoxynivalenol B
, O
zearalenone B
and O
the O
sum O
of O
T O
- O
2 O
and O
HT O
- O
2 O
toxin O
( O
1 O
. O
0 O
, O
0 O
. O
25 O
and O
0 O
. O
1 O
mu O
g O
kg O
( O
- O
1 O
) O
body O
weight O
day O
( O
- O
1 O
) O
, O
respectively O
) O
. O

Two O
new O
triterpenoids B
, O
( O
24R O
/ O
S O
) O
- O
24 O
- O
hydroxy O
- O
3 O
alpha O
10 O
alpha O
- O
epoxy O
- O
9 O
- O
eip O
- O
cucurbita O
- O
25 O
- O
ene O
( O
1a O
, O
b O
) O
, O
as O
well O
as O
six O
known O
compounds O
( O
3 O
- O
8 O
) O
, O
were O
isolated O
from O
the O
extraction O
of O
Fructus O
Viticis O
Negundo O
. O

In O
vitro O
nanotoxicity O
of O
single O
- O
walled O
carbon B
nanotube O
- O
dendrimer O
nanocomplexes O
against O
murine O
myoblast O
cells O
. O

Single O
- O
wall O
carbon B
nanotubes O
( O
SWCNTs O
) O
and O
polyamidoamine B
dendrimers O
( O
PAMAM O
) O
have O
been O
proposed O
for O
a O
variety O
of O
biomedical O
applications O
. O

Evaluation O
of O
the O
adjuvant O
effect O
of O
silver B
nanoparticles O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
immunological O
adjuvant O
effect O
of O
silver B
nanoparticles O
( O
AgNPs O
) O
was O
investigated O
both O
in O
vitro O
and O
in O
vivo O
. O

Six O
new O
platinum O
( O
II O
) O
complexes O
with O
mono O
- O
aminophosphonate O
ester O
were O
synthesized O
and O
characterized O
by O
elemental O
analysis O
, O
( B
1 I
) I
H I
NMR O
, O
ESI O
- O
MS O
as O
well O
as O
single O
crystal O
X O
- O
ray O
diffraction O
analysis O
. O

In O
all O
the O
crystal O
structures O
of O
complexes O
1 O
- O
6 O
, O
the O
platinum B
centre O
adopts O
an O
approximately O
square O
- O
planar O
geometry O
, O
which O
were O
found O
to O
possess O
excellent O
solubility O
in O
both O
organic O
solvents O
and O
water O
and O
exhibit O
considerable O
cytotoxicity O
against O
MG O
- O
63 O
, O
SK O
- O
OV O
- O
3 O
and O
HepG2 O
cell O
lines O
, O
but O
low O
cytotoxicity O
towards O
normal O
human O
liver O
cell O
HL O
- O
7702 O
. O

In O
contrast O
to O
cisplatin B
, O
their O
antitumour O
activities O
are O
achieved O
through O
the O
induction O
of O
cell O
apoptosis O
by O
G1 O
cell O
- O
cycle O
arrest O
. O

Activation O
of O
Both O
Protein O
Kinase O
A O
( O
PKA O
) O
Type O
I O
and O
PKA O
Type O
II O
Isozymes O
Is O
Required O
for O
Retinoid B
- O
Induced O
Maturation O
of O
Acute O
Promyelocytic O
Leukemia O
Cells O
. O

In O
most O
cases O
, O
this O
defect O
can O
be O
overcome O
by O
treatment O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
, O
leading O
to O
complete O
clinical O
remission O
. O

Cyclic B
AMP I
signaling O
has O
a O
key O
role O
in O
retinoid B
treatment O
efficacy O
: O
it O
enhances O
ATRA B
- O
induced O
maturation O
in O
ATRA B
- O
sensitive O
APL O
cells O
( O
including O
NB4 O
cells O
) O
and O
restores O
it O
in O
some O
ATRA B
- O
resistant O
cells O
( O
including O
NB4 O
- O
LR1 O
cells O
) O
. O

We O
show O
that O
the O
two O
cell O
types O
express O
identical O
levels O
of O
the O
C O
alpha O
catalytic O
subunit O
and O
comparable O
global O
cAMP B
- O
dependent O
protein O
kinase O
A O
( O
PKA O
) O
enzyme O
activity O
. O

Furthermore O
, O
the O
PKA O
regulatory O
subunit O
II O
exists O
mainly O
in O
the O
less O
cAMP B
- O
responsive O
nonautophosphorylate O
state O
in O
the O
NB4 O
- O
LR1 O
cells O
. O

By O
the O
use O
of O
isozyme O
- O
specific O
cAMP B
analog O
pairs O
, O
we O
show O
that O
both O
PKA O
- O
I O
and O
PKA O
- O
II O
must O
be O
activated O
to O
achieve O
maturation O
in O
NB4 O
- O
LR1 O
as O
well O
as O
NB4 O
cells O
. O

Therefore O
, O
special O
attention O
should O
be O
paid O
to O
activating O
not O
only O
PKA O
- O
I O
but O
also O
PKA O
- O
II O
in O
attempts O
to O
enhance O
ATRA B
- O
induced O
APL O
maturation O
in O
a O
clinical O
setting O
. O

METHODS O
: O
Overnight O
- O
deprived O
smokers O
( O
n O
= O
24 O
) O
and O
nonsmokers O
( O
n O
= O
20 O
) O
completed O
six O
neuroimaging O
assessments O
on O
different O
days O
both O
in O
the O
absence O
of O
, O
and O
following O
, O
varenicline O
and O
/ O
or O
nicotine B
administration O
. O

Higher O
alexithymia O
also O
predicted O
more O
severe O
tobacco O
craving O
during O
nicotine B
withdrawal O
. O

Acute O
behavioural O
effects O
of O
bupropion B
and O
naltrexone O
, O
alone O
and O
in O
combination O
, O
in O
non O
- O
deprived O
male O
rats O
presented O
with O
palatable O
mash O
. O

Although O
bupropion B
and O
naltrexone O
( O
alone O
and O
in O
combination O
) O
reduce O
food O
consumption O
in O
rodents O
and O
humans O
, O
their O
effects O
on O
behaviour O
during O
feeding O
tests O
have O
not O
been O
thoroughly O
investigated O
. O

OBJECTIVES O
: O
This O
study O
aimed O
to O
assess O
the O
behavioural O
specificity O
of O
anorectic O
responses O
to O
bupropion B
, O
naltrexone O
and O
their O
combination O
. O

METHODS O
: O
Video O
analysis O
was O
employed O
to O
characterise O
the O
behavioural O
effects O
of O
acute O
systemic O
treatment O
with O
bupropion B
( O
10 O
. O
0 O
- O
40 O
. O
0 O
mg O
/ O
kg O
) O
, O
naltrexone O
( O
0 O
. O
1 O
- O
3 O
. O
0 O
mg O
/ O
kg O
) O
and O
combined O
bupropion B
( O
20 O
mg O
/ O
kg O
) O
plus O
naltrexone O
( O
0 O
. O
1 O
- O
1 O
. O
0 O
mg O
/ O
kg O
) O
in O
non O
- O
deprived O
male O
rats O
exposed O
for O
1 O
h O
to O
palatable O
mash O
. O

RESULTS O
: O
In O
experiment O
1 O
, O
the O
anorectic O
response O
to O
40 O
mg O
/ O
kg O
bupropion B
was O
associated O
with O
significant O
psychomotor O
stimulation O
and O
a O
complete O
disruption O
of O
the O
BSS O
. O

In O
experiment O
3 O
, O
the O
co O
- O
administration O
of O
20 O
mg O
/ O
kg O
bupropion B
and O
naltrexone O
( O
0 O
. O
1 O
and O
1 O
. O
0 O
mg O
/ O
kg O
) O
not O
only O
produced O
an O
additive O
anorectic O
profile O
( O
including O
a O
reduced O
rate O
of O
eating O
) O
, O
but O
the O
addition O
of O
the O
opioid O
receptor O
antagonist O
also O
concurrently O
attenuated O
the O
psychomotor O
stimulant O
response O
to O
the O
atypical O
antidepressant O
. O

CONCLUSIONS O
: O
Low O
- O
dose O
co O
- O
treatment O
with O
naltrexone O
and O
bupropion B
produces O
a O
stronger O
suppression O
of O
appetite O
than O
that O
seen O
with O
either O
agent O
alone O
and O
has O
the O
additional O
advantage O
of O
reducing O
some O
of O
the O
unwanted O
effects O
of O
bupropion B
. O

To O
evaluate O
the O
vegetative O
periodic O
effect O
of O
rhizosphere O
on O
the O
patterns O
of O
metal O
bioaccumulation O
, O
the O
concentrations O
of O
Mg B
, O
K B
, O
Ca B
, O
Mn B
, O
Zn B
, O
Fe B
, O
Cu B
, O
Cr B
, O
Ni B
, O
Cd B
and O
Pb B
in O
the O
corresponding O
rhizosphere O
soil O
and O
tissues O
of O
Phragmites O
australis O
growing O
in O
the O
Sun O
Island O
wetland O
( O
Harbin O
, O
China O
) O
were O
compared O
. O

The O
concentrations O
of O
Zn B
, O
Fe B
, O
Cu B
, O
Cr B
, O
Ni B
, O
Cd B
and O
Pb B
in O
roots O
were O
higher O
than O
in O
shoots O
, O
suggesting O
that O
roots O
are O
the O
primary O
accumulation O
organs O
for O
these O
metals O
and O
there O
exists O
an O
exclusion O
strategy O
for O
metal O
tolerance O
. O

Harvesting O
would O
particularly O
be O
an O
effective O
method O
to O
remove O
Mn B
from O
the O
environment O
. O

The O
rhizospheric O
microbial O
characteristics O
were O
significantly O
related O
to O
the O
concentrations O
of O
Mg B
, O
K B
, O
Zn B
, O
Fe B
and O
Cu B
, O
suggesting O
that O
microbial O
influence O
on O
metal O
accumulation O
is O
specific O
and O
selective O
, O
not O
eurytopic O
. O

Dietary O
soy O
and O
soy O
isoflavones B
are O
neuroprotective O
in O
experimental O
cerebral O
ischemia O
. O

Because O
these O
isoflavones B
have O
estrogenic O
properties O
, O
we O
hypothesized O
that O
, O
like O
estrogens B
, O
they O
would O
inhibit O
acute O
vascular O
injury O
and O
the O
detrimental O
acute O
increase O
in O
hypoxia O
- O
induced O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
that O
leads O
to O
cerebral O
edema O
after O
stroke O
. O

Similar O
to O
estrogens B
, O
dietary O
soy O
significantly O
reduced O
cerebral O
edema O
and O
vascular O
apoptosis O
24 O
hours O
after O
stroke O
. O

These O
data O
suggest O
that O
soy O
isoflavones B
target O
events O
early O
in O
the O
ischemic O
cascade O
as O
part O
of O
their O
neuroprotective O
actions O
and O
counterbalance O
some O
of O
the O
detrimental O
effects O
of O
the O
endogenous O
response O
to O
cerebral O
injury O
. O

Genotoxic O
, O
antigenotoxic O
and O
antioxidant O
properties O
of O
methanol B
extracts O
obtained O
from O
Peltigera O
horizontalis O
and O
Peltigera O
praetextata O
. O

With O
this O
respect O
, O
the O
mutagenic O
and O
antimutagenic O
properties O
of O
methanol B
extracts O
of O
the O
lichens O
were O
determined O
by O
the O
bacterial O
reverse O
mutation O
and O
sister O
chromatid O
exchange O
assays O
. O

Furthermore O
, O
the O
malondialdehyde B
level O
, O
superoxide B
dismutase O
, O
glutathione B
and O
glutathione B
peroxidase O
activities O
against O
aflatoxin B
B1 I
were O
determined O
for O
understanding O
the O
ways O
in O
which O
the O
lichens O
showed O
their O
genotoxic O
properties O
. O

Higher O
levels O
of O
serum O
25 B
- I
hydroxyvitamin I
D I
predicted O
decreases O
in O
trabecular O
network O
heterogeneity O
. O

New O
flavonol B
and O
diterpenoids B
from O
the O
endophytic O
fungus O
Aspergillus O
sp O
. O

One O
new O
flavonol B
, O
chlorflavonin O
A O
( O
1 O
) O
, O
four O
new O
diterpenoids B
, O
aspergiloids O
E O
- O
H O
( O
3 O
, O
5 O
- O
7 O
) O
, O
together O
with O
eight O
known O
compounds O
( O
2 O
, O
4 O
, O
8 O
- O
13 O
) O
were O
isolated O
from O
solid O
fermentation O
of O
Aspergillus O
sp O
. O

Unique O
role O
of O
self O
- O
assembled O
monolayers O
in O
carbon B
nanomaterial O
- O
based O
field O
- O
effect O
transistors O
. O

Carbon B
nanomaterials O
, O
especially O
single O
- O
walled O
carbon B
nanotubes O
and O
graphene B
, O
have O
attracted O
intense O
interest O
in O
recent O
years O
due O
to O
their O
remarkable O
physicochemical O
properties O
. O

The O
combination O
of O
the O
advantages O
of O
both O
SAMs O
and O
carbon B
nanomaterials O
has O
been O
opening O
up O
a O
thriving O
research O
field O
. O

In O
this O
Review O
article O
, O
the O
unique O
role O
of O
SAMs O
acting O
as O
either O
active O
or O
auxiliary O
layers O
in O
carbon B
nanomaterials O
- O
based O
field O
- O
effect O
transistors O
is O
highlighted O
for O
tuning O
the O
substrate O
effect O
, O
controlling O
the O
carrier O
type O
and O
density O
in O
the O
conducting O
channel O
, O
and O
even O
installing O
new O
functionalities O
. O

Synthesis O
of O
Isoidide O
through O
Epimerization O
of O
Isosorbide O
using O
Ruthenium B
on O
Carbon B
. O

A O
highly O
efficient O
procedure O
for O
obtaining O
resin O
- O
grade O
isoidide O
through O
catalytic O
epimerization O
of O
isosorbide O
using O
a O
ruthenium B
- O
on O
- O
carbon B
( O
Ru B
/ O
C B
) O
catalyst O
is O
reported O
. O

A O
comprehensive O
reaction O
- O
parameter O
variation O
study O
involving O
substrate O
concentration O
, O
catalyst O
( O
type O
of O
metal O
, O
support O
, O
and O
loading O
) O
, O
initial O
pH O
value O
, O
hydrogen B
pressure O
, O
solvent O
, O
and O
reaction O
temperature O
demonstrates O
that O
superior O
performance O
and O
high O
selectivity O
can O
be O
achieved O
. O

Epimerization O
of O
isosorbide O
in O
water O
( O
pH O
8 O
) O
at O
220 O
degrees O
C O
, O
under O
40 O
bar O
of O
hydrogen B
, O
and O
using O
a O
Ru B
/ O
C B
catalyst O
( O
5 O
% O
Ru B
) O
for O
2 O
h O
results O
in O
a O
thermodynamic O
equilibrium O
mixture O
containing O
55 O
% O
isoidide O
, O
40 O
% O
isosorbide O
, O
and O
5 O
% O
isomannide O
. O

In O
comparison O
with O
previously O
reported O
nickel B
- O
based O
catalysts O
, O
the O
Ru B
/ O
C B
catalyst O
is O
advantageous O
because O
it O
is O
highly O
active O
( O
as O
low O
as O
360 O
ppm O
Ru B
) O
and O
recyclable O
. O

Delay O
and O
impairment O
in O
brain O
development O
and O
function O
in O
rat O
offspring O
after O
maternal O
exposure O
to O
methylmercury B
. O

Maternal O
exposure O
to O
the O
neurotoxin O
methylmercury B
( O
MeHg B
) O
has O
been O
shown O
to O
have O
adverse O
effects O
on O
neural O
development O
of O
the O
offspring O
in O
man O
. O

Little O
is O
known O
about O
the O
underlying O
mechanisms O
by O
which O
MeHg B
affects O
the O
developing O
brain O
. O

To O
explore O
the O
neurodevelopmental O
defects O
and O
the O
underlying O
mechanism O
associated O
with O
MeHg B
exposure O
, O
the O
cerebellum O
and O
cerebrum O
of O
Wistar O
rat O
pups O
were O
analyzed O
by O
[ B
( I
18 I
) I
F I
] I
FDG I
PET O
functional O
imaging O
, O
field O
potential O
analysis O
, O
and O
microarray O
gene O
expression O
profiling O
. O

Female O
rat O
pups O
were O
exposed O
to O
MeHg B
via O
maternal O
diet O
during O
intrauterinal O
and O
lactational O
period O
( O
from O
gestational O
day O
6 O
to O
postnatal O
day O
( O
PND O
) O
10 O
) O
, O
and O
their O
brain O
tissues O
were O
sampled O
for O
the O
analysis O
at O
weaning O
( O
PND18 O
- O
21 O
) O
and O
adulthood O
( O
PND61 O
- O
70 O
) O
. O

The O
[ B
( I
18 I
) I
F I
] I
FDG I
PET O
imaging O
and O
field O
potential O
analysis O
suggested O
a O
delay O
in O
brain O
activity O
and O
impaired O
neural O
function O
by O
MeHg B
. O

Thioflavin B
T I
and O
its O
photoirradiative O
derivatives O
: O
exploring O
their O
spectroscopic O
properties O
in O
the O
absence O
and O
presence O
of O
amyloid O
fibrils O
. O

These O
techniques O
, O
which O
are O
useful O
for O
in O
vitro O
studies O
, O
will O
be O
particularly O
advantageous O
where O
investigators O
seek O
deeper O
understanding O
of O
diseases O
where O
mismetabolism O
of O
metals O
, O
either O
physiological O
important O
( O
i O
. O
e O
. O
Cu B
, O
Zn B
) O
or O
outright O
toxic O
( O
i O
. O
e O
. O
Pb B
) O
, O
underlies O
pathogenesis O
. O

In O
particular O
, O
biodegradable O
nanoparticles O
formulated O
from O
poly O
( O
D O
, O
L O
- O
lactide O
- O
co O
- O
glycolide O
) O
( O
PLGA B
) O
have O
been O
extensively O
investigated O
for O
sustained O
and O
targeted O
delivery O
of O
different O
agents O
, O
including O
recombinant O
proteins O
, O
plasmid O
DNA O
, O
and O
low O
molecular O
weight O
compounds O
. O

PLGA B
NPs O
present O
some O
very O
attractive O
properties O
such O
as O
biodegradability O
and O
biocompatibility O
, O
protection O
of O
drug O
from O
degradation O
, O
possibility O
of O
sustained O
release O
, O
and O
the O
possibility O
to O
modify O
surface O
properties O
to O
target O
nanoparticles O
to O
specific O
organs O
or O
cells O
. O

Moreover O
, O
PLGA B
NPs O
have O
received O
the O
FDA O
and O
European O
Medicine O
Agency O
approval O
in O
drug O
delivery O
systems O
for O
parenteral O
administration O
, O
thus O
reducing O
the O
time O
for O
human O
clinical O
applications O
. O

This O
review O
in O
particular O
deals O
on O
surface O
modification O
of O
PLGA B
NPs O
and O
their O
possibility O
of O
clinical O
applications O
, O
including O
treatment O
for O
brain O
pathologies O
such O
as O
brain O
tumors O
and O
Lysosomal O
Storage O
Disorders O
with O
neurological O
involvement O
. O

Since O
a O
great O
number O
of O
pharmacologically O
active O
molecules O
are O
not O
able O
to O
cross O
the O
Blood O
- O
Brain O
Barrier O
( O
BBB O
) O
and O
reach O
the O
Central O
Nervous O
System O
( O
CNS O
) O
, O
new O
brain O
targeted O
polymeric O
PLGA B
NPs O
modified O
with O
glycopeptides O
( O
g7 O
- O
NPs O
) O
have O
been O
recently O
produced O
. O

Crotonaldehyde B
- O
exposed O
macrophages O
induce O
IL O
- O
8 O
release O
from O
airway O
epithelial O
cells O
through O
NF O
- O
kappa O
B O
and O
AP O
- O
1 O
pathways O
. O

Crotonaldehyde B
, O
a O
highly O
toxic O
alpha B
, I
beta I
- I
unsaturated I
aldehyde I
, O
is O
a O
major O
component O
of O
cigarette O
smoke O
and O
a O
ubiquitous O
environmental O
pollutant O
. O

Crotonaldehyde B
exposure O
is O
known O
to O
have O
adverse O
effects O
on O
respiratory O
health O
, O
but O
the O
underlying O
mechanisms O
remain O
obscure O
. O

To O
examine O
the O
interaction O
between O
macrophages O
and O
airway O
epithelial O
cells O
after O
exposure O
to O
crotonaldehyde B
, O
BEAS O
- O
2B O
and O
A549 O
cells O
were O
treated O
with O
conditioned O
media O
from O
a O
human O
monocytic O
leukemia O
cell O
line O
( O
THP O
- O
1 O
) O
cells O
stimulated O
with O
crotonaldehyde B
. O

We O
demonstrate O
that O
conditioned O
media O
from O
THP O
- O
1 O
cells O
stimulated O
with O
crotonaldehyde B
increased O
interleukin O
( O
IL O
) O
- O
8 O
production O
, O
enhanced O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
and O
AP O
- O
1 O
DNA O
- O
binding O
activity O
in O
BEAS O
- O
2B O
and O
A549 O
cells O
. O

Furthermore O
, O
BEAS O
- O
2B O
and O
A549 O
cells O
directly O
treated O
with O
crotonaldehyde B
induced O
increase O
in O
IL O
- O
8 O
production O
. O

These O
data O
suggest O
that O
crotonaldehyde B
is O
capable O
of O
directly O
stimulating O
the O
production O
of O
IL O
- O
8 O
in O
both O
macrophages O
and O
airway O
epithelial O
cells O
. O

Crotonaldehyde B
- O
stimulated O
macrophages O
also O
amplify O
the O
inflammatory O
response O
by O
enhancing O
IL O
- O
8 O
release O
from O
airway O
epithelial O
cells O
mediated O
by O
NF O
- O
kappa O
B O
and O
AP O
- O
1 O
pathways O
through O
a O
mechanism O
involving O
TNF O
- O
alpha O
and O
IL O
- O
1 O
beta O
. O

These O
findings O
indicate O
that O
crotonaldehyde B
can O
cause O
lung O
inflammatory O
response O
via O
multiple O
mechanisms O
, O
and O
may O
contribute O
to O
chronic O
airway O
inflammation O
in O
smokers O
. O

Exposure O
of O
mice O
to O
perfluorooctanoate O
( O
PFOA B
) O
evokes O
pronounced O
hepatomegaly O
along O
with O
significant O
alterations O
in O
both O
the O
histological O
structure O
and O
immune O
status O
of O
the O
liver O
. O

In O
this O
connection O
, O
the O
influence O
of O
both O
sub O
- O
acute O
( O
10 O
days O
) O
, O
moderate O
- O
dose O
( O
0 O
. O
002 O
% O
w O
/ O
w O
= O
3 O
+ O
/ O
- O
0 O
. O
7mg O
/ O
kg O
body O
weight O
/ O
day O
) O
and O
short O
- O
term O
( O
28 O
days O
) O
, O
low O
- O
dose O
( O
0 O
. O
00005 O
% O
w O
/ O
w O
= O
70 O
+ O
/ O
- O
2 O
mu O
g O
/ O
kg O
body O
weight O
/ O
day O
) O
dietary O
pretreatment O
with O
PFOA B
on O
the O
development O
of O
concanavalin O
A O
( O
Con O
A O
) O
- O
induced O
liver O
damage O
in O
mice O
was O
examined O
. O

With O
sub O
- O
acute O
, O
moderate O
, O
but O
not O
short O
- O
term O
, O
low O
- O
dose O
exposure O
, O
PFOA B
aggravated O
the O
acute O
liver O
damage O
caused O
by O
Con O
A O
, O
i O
. O
e O
. O
, O
elevated O
serum O
levels O
of O
transaminases O
and O
led O
to O
more O
pronounced O
damage O
of O
hepatic O
tissue O
. O

Our O
findings O
imply O
that O
exposure O
to O
PFOA B
may O
sensitize O
hepatic O
parenchymal O
cells O
to O
other O
toxicants O
that O
activate O
the O
hepatic O
immune O
system O
and O
thereby O
aggravate O
liver O
injury O
during O
acute O
inflammation O
. O

Zinc B
oxide I
nanoparticle O
induced O
autophagic O
cell O
death O
and O
mitochondrial O
damage O
via O
reactive O
oxygen B
species O
generation O
. O

Zinc B
oxide I
nanoparticles O
( O
ZnO B
- O
np O
) O
are O
used O
in O
an O
increasing O
number O
of O
industrial O
products O
such O
as O
paint O
, O
coating O
and O
cosmetics O
, O
and O
in O
other O
biological O
applications O
. O

There O
have O
been O
many O
suggestions O
of O
a O
ZnO B
- O
np O
toxicity O
paradigm O
but O
the O
underlying O
molecular O
mechanisms O
about O
the O
toxicity O
of O
ZnO B
- O
np O
remain O
unclear O
. O

This O
study O
was O
done O
to O
determine O
the O
potential O
toxicity O
of O
ZnO B
- O
np O
and O
to O
assess O
the O
toxicity O
mechanism O
in O
normal O
skin O
cells O
. O

Synthesized O
ZnO B
- O
np O
generated O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
as O
determined O
by O
electron O
spin O
resonance O
. O

After O
uptake O
into O
cells O
, O
ZnO B
- O
np O
induced O
ROS O
in O
a O
concentration O
- O
and O
time O
- O
dependent O
manner O
. O

To O
demonstrate O
ZnO B
- O
np O
toxicity O
mechanism O
related O
to O
ROS O
, O
we O
detected O
abnormal O
autophagic O
vacuoles O
accumulation O
and O
mitochondria O
dysfunction O
after O
ZnO B
- O
np O
treatment O
. O

Furthermore O
mitochondria O
membrane O
potential O
and O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
production O
are O
decreased O
for O
culture O
with O
ZnO B
- O
np O
. O

We O
conclude O
that O
ZnO B
- O
np O
leads O
to O
cell O
death O
through O
autophagic O
vacuole O
accumulation O
and O
mitochondria O
damage O
in O
normal O
skin O
cells O
via O
ROS O
induction O
. O

Accordingly O
, O
ZnO B
- O
np O
may O
cause O
toxicity O
and O
the O
results O
highlight O
and O
need O
for O
careful O
regulation O
of O
ZnO B
- O
np O
production O
and O
use O
. O

In O
vitro O
and O
in O
vivo O
evaluation O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
coated O
by O
bisphosphonates B
: O
The O
effects O
of O
electrical O
charge O
and O
molecule O
length O
. O

Physicochemical O
coating O
properties O
are O
often O
considered O
to O
be O
determining O
factors O
for O
in O
vivo O
characteristics O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
, O
used O
as O
contrast O
agent O
in O
Magnetic O
Resonance O
Imaging O
( O
MRI O
) O
. O

To O
investigate O
the O
electrical O
charge O
( O
modified O
by O
zero O
, O
one O
or O
two O
ammonium O
groups O
) O
and O
the O
molecule O
length O
( O
3 O
, O
5 O
or O
7 O
methylene B
chains O
) O
effects O
of O
bisphosphonate B
- O
type O
coatings O
, O
we O
assessed O
the O
complement O
activation O
, O
in O
vivo O
plasma O
and O
tissue O
relaxation O
time O
alterations O
of O
intravenously O
injected O
small O
iron B
oxide I
nanoparticles O
( O
< O
25nm O
) O
on O
male O
healthy O
Wistar O
rats O
. O

Polyethylene B
oxide I
( O
PEO B
) O
is O
used O
as O
a O
carrier O
polymer O
in O
a O
chemically O
cross O
- O
linking O
poly B
( I
ethylene I
glycol I
) I
- O
high O
molecular O
weight O
heparin O
( O
PEG B
- O
HMWH O
) O
hydrogel O
. O

An O
equilibrated O
, O
cross O
- O
linked O
hydrogel O
is O
then O
spun O
and O
the O
PEO B
is O
dissolved O
. O

In O
vivo O
binding O
of O
the O
dopamine B
- O
1 O
receptor O
PET O
tracers O
[ O
( O
11 O
) O
C O
] O
NNC112 O
and O
[ O
( O
11 O
) O
C O
] O
SCH23390 O
: O
a O
comparison O
study O
in O
individuals O
with O
schizophrenia O
. O

RATIONALE O
: O
A O
deficit O
in O
dopamine B
- O
1 O
( O
D1 O
) O
receptor O
function O
in O
the O
prefrontal O
cortex O
is O
suggested O
to O
play O
a O
role O
in O
the O
cognitive O
dysfunction O
observed O
in O
patients O
with O
schizophrenia O
. O

Furthermore O
, O
only O
dermatan O
sulfate B
influenced O
IFN O
- O
gamma O
signaling O
by O
significantly O
increasing O
CXCL O
- O
10 O
expression O
in O
contrast O
to O
decorin O
protein O
core O
alone O
. O

When O
its O
ability O
to O
release O
[ B
( I
3 I
) I
H I
] I
- I
dopamine I
from O
striatal O
slices O
was O
tested O
in O
a O
functional O
assay O
, O
compound O
1 O
behaved O
as O
a O
partial O
agonist O
with O
an O
EC50 O
of O
5 O
. O
8 O
mu O
M O
and O
an O
Emax O
that O
was O
43 O
% O
that O
of O
nicotine B
. O

When O
incubated O
with O
nicotine B
in O
the O
same O
assay O
, O
1 O
prevented O
a O
maximal O
effect O
from O
being O
reached O
. O

Rhodamine B
B I
( O
Rh O
B O
) O
and O
fluorescein B
isothiocyanate I
( O
FITC B
) O
as O
model O
hydrophilic O
and O
hydrophobic O
small O
/ O
medium O
- O
size O
molecules O
, O
respectively O
, O
were O
encapsulated O
in O
poly B
lactic I
- I
co I
- I
glycolic I
acid I
( O
PLGA B
) O
nanoparticles O
( O
NPs O
) O
and O
delivered O
through O
full O
thickness O
porcine O
skin O
pretreated O
with O
MN O
array O
. O

Correlation O
between O
aflatoxin O
M1 O
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
aflatoxin B
B1 I
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
Ogun O
State O
, O
Nigeria O
. O

Preclinical O
Assessment O
of O
Ketamine B
. O

BACKGROUND O
: O
Ketamine B
is O
used O
as O
a O
general O
anesthetic O
, O
and O
recent O
data O
suggest O
that O
anesthetics O
can O
cause O
neurodegeneration O
and O
/ O
or O
neuroprotection O
. O

AIMS O
: O
This O
review O
is O
to O
examine O
the O
work O
on O
ketamine B
and O
to O
address O
how O
developmental O
biology O
may O
be O
utilized O
when O
combined O
with O
biochemical O
, O
pathological O
, O
and O
pharmacokinetic O
assessments O
to O
produce O
a O
bridging O
model O
that O
may O
decrease O
the O
uncertainty O
in O
extrapolating O
preclinical O
data O
to O
human O
conditions O
. O

RESULTS O
: O
Advantages O
of O
using O
preclinical O
models O
to O
study O
critical O
issues O
related O
to O
ketamine B
anesthesia O
have O
been O
described O
. O

These O
include O
the O
relationships O
between O
ketamine B
- O
induced O
neurotoxicity O
/ O
protection O
and O
the O
preclinical O
models O
/ O
approaches O
in O
elucidating O
mechanisms O
associated O
with O
ketamine B
exposure O
. O

CONCLUSIONS O
: O
The O
discussions O
focus O
on O
the O
following O
: O
( O
1 O
) O
the O
doses O
and O
time O
- O
course O
over O
which O
ketamine B
is O
associated O
with O
damage O
to O
, O
or O
protection O
of O
, O
neural O
cells O
, O
( O
2 O
) O
how O
ketamine B
directs O
or O
signals O
neural O
cells O
to O
undergo O
apoptosis O
or O
necrosis O
, O
( O
3 O
) O
how O
such O
exposures O
can O
trigger O
mitochondrial O
dysfunction O
, O
( O
4 O
) O
how O
antioxidants O
and O
knockdowns O
of O
specific O
transcription O
modulators O
or O
receptors O
affect O
neurotoxicity O
induced O
by O
ketamine B
, O
and O
( O
5 O
) O
whether O
the O
potential O
neural O
damage O
can O
be O
monitored O
after O
ketamine O

Boron B
Neutron O
Capture O
Therapy O
( O
BNCT O
) O
involves O
the O
selective O
accumulation O
of O
boron O
carriers O
in O
tumor O
tissue O
followed O
by O
irradiation O
with O
a O
thermal O
or O
epithermal O
neutron O
beam O
. O

Human O
normal O
melanocytes O
and O
melanoma O
cells O
were O
treated O
with O
BNCT O
at O
different O
boronophenylalanine B
concentrations O
for O
signaling O
pathways O
analysis O
. O

Carrier O
free O
rapamycin B
loaded O
drug O
eluting O
stent O
: O
In O
vitro O
and O
in O
vivo O
evaluation O
. O

In O
this O
work O
, O
carrier O
free O
- O
rapamycin B
( O
RM O
) O
coated O
DES O
has O
been O
prepared O
, O
and O
evaluated O
by O
in O
vitro O
and O
in O
vivo O
procedures O
necessary O
for O
clinical O
development O
. O

In O
vitro O
drug O
release O
from O
the O
developed O
stents O
was O
carried O
in O
different O
release O
media O
, O
normal O
saline O
- O
isopropanol O
( O
NS O
- O
IP O
) O
, O
phosphate B
buffer O
( O
PB O
) O
, O
phosphate B
buffer O
saline O
( O
PBS O
) O
and O
in O
human O
plasma O
. O

A O
series O
of O
PACA O
- O
hydrogel O
hybrid O
systems O
with O
increasing O
PACA O
side O
chain O
hydrophobicity O
was O
prepared O
using O
physically O
crosslinked O
alginate O
films O
and O
hydrophilic O
diclofenac B
sodium I
as O
model O
hydrogel O
/ O
drug O
system O
. O

At O
the O
same O
time O
, O
the O
diclofenac B
release O
from O
the O
hybrid O
systems O
was O
substantially O
sustained O
from O
~ O
1day O
for O
unmodified O
hydrogels O
up O
to O
> O
14days O
depending O
on O
the O
type O
of O
PACA O
employed O
as O
diffusion O
barrier O
. O

In O
agreement O
, O
the O
acute O
dose O
- O
dependent O
glucose B
- O
lowering O
and O
insulinotropic O
actions O
of O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
were O
significantly O
enhanced O
by O
concurrent O
administration O
of O
[ O
D O
- O
Leu O
- O
4 O
] O
- O
OB3 O
. O

Twice O
daily O
injection O
of O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
alone O
and O
in O
combination O
with O
[ O
D O
- O
Leu O
- O
4 O
] O
- O
OB3 O
in O
high O
- O
fat O
- O
fed O
mice O
for O
18 O
days O
decreased O
body O
weight O
( O
p O
< O
0 O
. O
05 O
to O
p O
< O
0 O
. O
001 O
) O
, O
energy O
intake O
( O
p O
< O
0 O
. O
01 O
) O
, O
circulating O
triacylglycerol B
( O
p O
< O
0 O
. O
01 O
) O
, O
non O
- O
fasting O
glucose O
( O
p O
< O
0 O
. O
05 O
to O
p O
< O
0 O
. O
001 O
) O
and O
triacylglycerol B
deposition O
in O
liver O
and O
adipose O
tissue O
( O
p O
< O

All O
treatment O
regimens O
improved O
glucose B
tolerance O
( O
p O
< O
0 O
. O
05 O
to O
p O
< O
0 O
. O
001 O
) O
and O
insulin O
sensitivity O
( O
p O
< O
0 O
. O
001 O
) O
. O

Combined O
treatment O
with O
( O
pGlu O
- O
Gln O
) O
- O
CCK O
- O
8 O
and O
[ O
D O
- O
Leu O
- O
4 O
] O
- O
OB3 O
resulted O
in O
significantly O
lowered O
plasma O
insulin O
levels O
, O
normalisation O
of O
circulating O
LDL O
- O
cholesterol B
and O
decreased O
triacylglycerol B
deposition O
in O
muscle O
. O

Effect O
of O
surface O
morphology O
on O
friction O
of O
graphene B
on O
various O
substrates O
. O

The O
friction O
of O
graphene B
on O
various O
substrates O
, O
such O
as O
SiO2 B
, O
h O
- O
BN O
, O
bulk O
- O
like O
graphene B
, O
and O
mica O
, O
was O
investigated O
to O
characterize O
the O
adhesion O
level O
between O
graphene B
and O
the O
underlying O
surface O
. O

The O
friction O
of O
graphene B
on O
SiO2 B
decreased O
with O
increasing O
thickness O
and O
converged O
around O
the O
penta O
- O
layers O
due O
to O
incomplete O
contact O
between O
the O
two O
surfaces O
. O

However O
, O
the O
friction O
of O
graphene B
on O
an O
atomically O
flat O
substrate O
, O
such O
as O
h O
- O
BN O
or O
bulk O
- O
like O
graphene B
, O
was O
low O
and O
comparable O
to O
that O
of O
bulk O
- O
like O
graphene B
. O

In O
contrast O
, O
the O
friction O
of O
graphene B
folded O
onto O
bulk O
- O
like O
graphene B
was O
indistinguishable O
from O
that O
of O
mono O
- O
layer O
graphene B
on O
SiO2 B
despite O
the O
ultra O
- O
smoothness O
of O
bulk O
- O
like O
graphene B
. O

The O
characterization O
of O
the O
graphene B
' O
s O
roughness O
before O
and O
after O
folding O
showed O
that O
the O
corrugation O
of O
graphene B
induced O
by O
SiO2 B
morphology O
was O
preserved O
even O
after O
it O
was O
folded O
onto O
an O
atomically O
flat O
substrate O
. O

In O
addition O
, O
graphene B
deposited O
on O
mica O
, O
when O
folded O
, O
preserved O
the O
same O
corrugation O
level O
as O
before O
the O
folding O
event O
. O

Our O
friction O
measurements O
revealed O
that O
graphene B
, O
once O
exfoliated O
from O
the O
bulk O
crystal O
, O
tends O
to O
maintain O
its O
corrugation O
level O
even O
after O
it O
is O
folded O
onto O
an O
atomically O
flat O
substrate O
and O
that O
ultra O
- O
flatness O
in O
both O
graphene B
and O
the O
substrate O
is O
required O
to O
achieve O
the O
intimate O
contact O
necessary O
for O
strong O
adhesion O
. O

Anticancer O
drugs O
directed O
against O
the O
microtubule O
, O
including O
taxanes B
and O
vinca O
alkaloids O
, O
have O
been O
the O
backbone O
of O
many O
chemotherapy O
regimes O
for O
decades O
. O

Furthermore O
, O
the O
limitations O
of O
taxanes B
, O
including O
hypersensitivity O
reactions O
, O
neurotoxicity O
, O
drug O
resistance O
and O
lack O
of O
validated O
biomarkers O
to O
guide O
therapy O
will O
be O
discussed O
, O
all O
of O
which O
have O
driven O
the O
development O
of O
novel O
agents O
. O

Agents O
demonstrating O
utility O
in O
Phase O
III O
clinical O
trials O
, O
including O
eribulin O
, O
ixabepilone O
, O
cabazitaxel O
and O
trastuzumab O
- O
DM1 B
will O
be O
highlighted O
, O
as O
well O
as O
novel O
agents O
currently O
in O
development O
and O
future O
directions O
for O
MTAs O
. O

By O
comparing O
the O
lubricant O
loss O
, O
contact O
angle O
hysteresis O
, O
and O
sliding O
angles O
for O
water O
and O
ethanol B
droplets O
on O
flat O
, O
microscale O
, O
nanoscale O
, O
and O
hierarchically O
textured O
surfaces O
subjected O
to O
various O
spinning O
rates O
( O
from O
100 O
to O
10 O
000 O
rpm O
) O
, O
we O
show O
that O
lubricant O
- O
infused O
textured O
surfaces O
with O
uniform O
nanofeatures O
provide O
the O
most O
shear O
- O
tolerant O
liquid O
- O
repellent O
behavior O
, O
unlike O
lotus O
leaf O
- O
inspired O
superhydrophobic O
surfaces O
, O
which O
generally O
favor O
hierarchical O
structures O
for O
improved O
pressure O
stability O
and O
low O
contact O
angle O
hysteresis O
. O

Serum O
creatinine B
( O
Scr O
) O
and O
blood O
urea O
nitrogen B
( O
BUN O
) O
levels O
were O
detected O
. O

Uncinataflavone O
, O
a O
new O
flavonoid B
with O
a O
methyl O
benzoate O
substituent O
from O
Selaginella O
uncinata O
. O

Uncinataflavone O
( O
1 O
) O
, O
a O
new O
flavonoid B
, O
together O
with O
four O
known O
compounds O
( O
2 O
- O
5 O
) O
, O
was O
isolated O
from O
Selaginella O
uncinata O
( O
Desv O
. O
) O
Spring O
. O

These O
compounds O
( O
1 O
- O
5 O
) O
were O
evaluated O
for O
the O
antioxidant O
activity O
in O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
assay O
system O
. O

Two O
new O
tri O
- O
nor O
- O
eudesmane O
- O
type O
sesquiterpenoids B
were O
isolated O
from O
the O
roots O
of O
Inula O
racemosa O
, O
and O
their O
structures O
were O
elucidated O
as O
8 O
- O
oxo O
- O
tri O
- O
nor O
- O
eudesm O
- O
6 O
- O
en O
- O
5 O
alpha O
- O
ol O
( O
1 O
) O
and O
tri O
- O
nor O
- O
eudesm O
- O
5 O
- O
en O
- O
7 O
beta O
, O
8 O
beta O
- O
diol O
( O
2 O
) O
. O

Spectral O
Phonon O
Scattering O
from O
Sub O
- O
10 O
nm O
Surface O
Roughness O
Wavelengths O
in O
Metal O
- O
Assisted O
Chemically O
Etched O
Si B
Nanowires O
. O

We O
report O
low O
- O
temperature O
dependence O
of O
thermal O
conductivity O
in O
silicon B
nanowires O
fabricated O
using O
a O
two O
- O
step O
, O
metal O
- O
assisted O
chemical O
etch O
. O

A O
5 O
- O
10 O
nm O
roughness O
correlation O
length O
is O
typical O
in O
metal O
- O
assisted O
chemical O
etching O
and O
resonantly O
scatters O
dominant O
phonons O
in O
silicon B
, O
leading O
to O
the O
observed O
~ O
T O
( O
1 O
. O
6 O
- O
2 O
. O
4 O
) O
behavior O
. O

Compound O
1 O
displayed O
the O
protective O
effect O
against O
d B
- I
galactosamine I
- O
induced O
HepG2 O
damage O
and O
reduced O
the O
damage O
from O
58 O
. O
64 O
% O
to O
22 O
. O
26 O
% O
. O

Progress O
, O
challenges O
, O
and O
opportunities O
in O
two O
- O
dimensional O
materials O
beyond O
graphene B
. O

Graphene B
' O
s O
success O
has O
shown O
that O
it O
is O
possible O
to O
create O
stable O
, O
single O
and O
few O
- O
atom O
- O
thick O
layers O
of O
van O
der O
Waals O
materials O
, O
and O
also O
that O
these O
materials O
can O
exhibit O
fascinating O
and O
technologically O
useful O
properties O
. O

Here O
we O
review O
the O
state O
- O
of O
- O
the O
- O
art O
of O
2D O
materials O
beyond O
graphene B
. O

Thioacetamide O
( O
TA O
) O
has O
long O
been O
known O
as O
a O
hepatotoxicant O
whose O
bioactivation O
requires O
S B
- O
oxidation O
to O
thioacetamide O
S O
- O
oxide O
( O
TASO O
) O
and O
then O
to O
the O
very O
reactive O
S O
, O
S O
- O
dioxide O
( O
TASO2 O
) O
. O

The O
latter O
can O
tautomerize O
to O
form O
acylating O
species O
capable O
of O
covalently O
modifying O
cellular O
nucleophiles O
including O
phosphatidylethanola B
( O
PE O
) O
lipids O
and O
protein O
lysine B
side O
chains O
. O

The O
formation O
of O
both O
amide B
- O
and O
amidine B
- O
type O
adducts O
to O
protein O
lysine B
side O
chains O
is O
in O
contrast O
to O
the O
exclusive O
formation O
of O
amidine B
- O
type O
adducts O
with O
PE O
phospholipids O
. O

Thiobenzamide O
( O
TB O
) O
undergoes O
the O
same O
two O
- O
step O
oxidative O
bioactivation O
as O
TA O
, O
and O
it O
also O
gives O
rise O
to O
both O
amide B
and O
amidine B
adducts O
on O
protein O
lysine B
side O
chains O
but O
only O
amidine B
adducts O
to O
PE O
lipids O
. O

PF O
- O
04859989 O
as O
a O
template O
for O
structure O
- O
based O
drug O
design O
: O
identification O
of O
new O
pyrazole B
series O
of O
irreversible O
KAT O
II O
inhibitors O
with O
improved O
lipophilic O
efficiency O
. O

The O
structure O
- O
based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole B
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O

Compound O
20 O
is O
the O
most O
potent O
and O
lipophilically O
efficient O
of O
these O
new O
pyrazole B
analogs O
, O
with O
a O
k O
( O
inact O
) O
/ O
K O
( O
i O
) O
value O
of O
112 O
, O
000 O
M O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
and O
lipophilic O
efficiency O
( O
LipE O
) O
of O
8 O
. O
53 O
. O

Design O
, O
synthesis O
and O
antithrombotic O
evaluation O
of O
novel O
dabigatran B
prodrugs O
containing O
methyl O
ferulate O
. O

A O
novel O
series O
of O
prodrugs O
containing O
dabigatran B
and O
methyl O
( O
E O
) O
- O
3 O
- O
( O
4 O
- O
hydroxy O
- O
2 O
- O
methoxyphenyl O
) O
propenoate O
( O
methyl O
ferulate O
) O
were O
synthesized O
. O

In O
addition O
, O
in O
vivo O
experiment O
shows O
that O
one O
of O
the O
target O
compounds O
, O
X O
- O
2 O
( O
ED50 O
= O
3 O
. O
7 O
+ O
/ O
- O
1 O
. O
0 O
mu O
mol O
/ O
kg O
) O
possesses O
a O
more O
potent O
activity O
for O
inhibiting O
venous O
thrombosis O
than O
that O
of O
dabigatran B
etexilate I
( O
ED50 O
= O
7 O
. O
8 O
+ O
/ O
- O
1 O
. O
5 O
mu O
mol O
/ O
kg O
) O
. O

Several O
members O
of O
a O
new O
family O
of O
non O
- O
sugar B
- O
type O
alpha O
- O
glycosidase O
inhibitors O
, O
bearing O
a O
5 O
- O
( O
p O
- O
toluenesulfonylamino O
) O
phthalimide O
moiety O
and O
various O
substituent O
at O
the O
N2 O
position O
, O
were O
synthesized O
and O
their O
activities O
were O
investigated O
. O

A O
series O
of O
3 O
- O
S O
- O
beta O
- O
d O
- O
glucosides O
- O
4 O
- O
arylideneamino O
- O
5 O
- O
aryl O
- O
1 O
, O
2 O
, O
4 O
- O
triazoles O
were O
rationally O
designed O
and O
synthesized O
according O
to O
the O
principle O
of O
superposition O
of O
bioactive O
substructures O
by O
the O
combination O
of O
1 O
, O
2 O
, O
4 O
- O
triazole O
, O
Schiff B
base I
and O
glucosides O
. O

The O
structures O
of O
the O
target O
compounds O
have O
been O
characterized O
by O
( B
1 I
) I
H I
NMR O
, O
( B
13 I
) I
C I
NMR O
, O
IR O
, O
MS O
and O
HRMS O
. O

Important O
roles O
for O
norepinephrine B
in O
this O
region O
have O
been O
documented O
in O
a O
number O
of O
stress O
and O
reward O
related O
behaviors O
. O

This O
work O
has O
been O
paralleled O
over O
the O
last O
several O
years O
by O
efforts O
to O
understand O
the O
actions O
of O
norepinephrine B
on O
neuronal O
function O
in O
the O
region O
. O

Important O
functional O
interactions O
between O
the O
metabotropic O
glutamate B
2 O
( O
mGlu2 O
) O
and O
5 O
- O
hydroxytryptamine2A O
( O
5 O
- O
HT2A O
) O
neurotransmitter O
receptors O
have O
been O
established O
based O
on O
electrophysiological O
, O
biochemical O
and O
behavioral O
evidence O
. O

Reversal O
of O
P O
- O
glycoprotein O
- O
mediated O
multidrug O
resistance O
is O
induced O
by O
mollugin B
in O
MCF O
- O
7 O
/ O
adriamycin O
cells O
. O

In O
the O
present O
study O
, O
we O
investigated O
whether O
mollugin B
, O
purified O
from O
roots O
of O
Rubica O
cordifolia O
L O
. O
, O
down O
- O
regulated O
MDR1 O
expression O
in O
MCF O
- O
7 O
/ O
adriamycin B
( O
MCF O
- O
7 O
/ O
adr O
) O
cells O
, O
a O
human O
breast O
multidrug O
- O
resistant O
cancer O
cell O
line O
. O

Mollugin B
treatment O
significantly O
inhibited O
MDR1 O
expression O
by O
blocking O
MDR1 O
transcription O
. O

Mollugin B
treatment O
also O
significantly O
increased O
intracellular O
accumulation O
of O
the O
fluorescently O
- O
tagged O
P O
- O
gp O
substrate O
, O
rhodamine O
- O
123 O
. O

The O
suppression O
of O
MDR1 O
promoter O
activity O
and O
protein O
expression O
was O
mediated O
through O
mollugin B
- O
induced O
activation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
. O

Furthermore O
, O
mollugin B
inhibited O
MDR1 O
expression O
through O
the O
suppression O
of O
NF O
- O
kappa O
B O
and O
CREB O
activation O
. O

Interestingly O
, O
mollugin B
also O
inhibited O
COX O
- O
2 O
expression O
. O

These O
results O
suggest O
that O
mollugin B
treatment O
enhanced O
suppression O
of O
P O
- O
gp O
expression O
by O
inhibiting O
the O
NF O
- O
kappa O
B O
signaling O
pathway O
and O
COX O
- O
2 O
expression O
, O
as O
well O
as O
attenuating O
CRE O
transcriptional O
activity O
through O
AMPK O
activation O
. O

Membranar O
effects O
exerted O
in O
vitro O
by O
polyphenols B
- O
quercetin B
, O
epigallocatechin B
gallate I
and O
curcumin B
- O
on O
HUVEC O
and O
Jurkat O
cells O
, O
relevant O
for O
diabetes O
mellitus O
. O

Polyphenols B
are O
largely O
studied O
for O
their O
beneficial O
action O
in O
various O
pathologies O
, O
but O
the O
correlation O
with O
their O
effects O
on O
cell O
membranes O
is O
still O
elusive O
. O

In O
the O
present O
study O
we O
assessed O
the O
effects O
exerted O
in O
vitro O
by O
quercetin B
, O
epigallocatechin B
gallate I
and O
curcumin B
on O
membrane O
fluidity O
and O
transmembrane O
potential O
of O
human O
umbilical O
vein O
endothelial O
cells O
and O
Jurkat O
T O
lymphoblasts O
, O
in O
experimental O
conditions O
mimicking O
diabetes O
mellitus O
, O
i O
. O
e O
. O
high O
glucose B
conditions O
or O
increased O
concentration O
of O
advanced O
glycation O
end O
products O
. O

Results O
showed O
that O
the O
investigated O
polyphenols B
had O
beneficial O
effects O
on O
cell O
membranes O
altered O
in O
diabetic O
conditions O
, O
by O
restoring O
transmembrane O
potential O
and O
by O
membrane O
" O
stiffening O
" O
. O

Apparently O
, O
the O
inhibitory O
action O
of O
polyphenols B
on O
lipid O
peroxidation O
was O
associated O
with O
a O
decrease O
of O
membrane O
fluidity O
. O

Concluding O
, O
our O
in O
vitro O
study O
highlighted O
the O
potential O
beneficial O
action O
of O
polyphenols B
mainly O
in O
the O
late O
stages O
of O
diabetes O
, O
exerted O
at O
the O
level O
of O
membrane O
fluidity O
and O
transmembrane O
potential O
, O
accompanied O
by O
an O
anti O
- O
inflammatory O
effect O
on O
endothelial O
and O
immune O
cells O
. O

miR O
- O
21 O
confers O
cisplatin B
resistance O
in O
gastric O
cancer O
cells O
by O
regulating O
PTEN O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
miR O
- O
21 O
mediated O
resistance O
of O
the O
gastric O
cancer O
cell O
line O
SGC7901 O
to O
the O
chemotherapeutic O
agent O
cisplatin B
( O
DDP O
) O
. O

Our O
study O
found O
that O
the O
expression O
of O
miR O
- O
21 O
upregulated O
in O
the O
cisplatin B
resistant O
cell O
line O
SGC7901 O
/ O
DDP O
compared O
to O
its O
parental O
line O
SGC7901 O
. O

Moreover O
, O
over O
- O
expression O
of O
miR O
- O
21 O
significantly O
decreased O
antiproliferative O
effects O
and O
apoptosis O
induced O
by O
cisplatin B
, O
while O
knockdown O
of O
miR O
- O
21 O
dramatically O
increased O
antiproliferative O
effects O
and O
apoptosis O
induction O
by O
cisplatin B
. O

In O
addition O
, O
miR O
- O
21 O
induced O
cell O
survival O
and O
cisplatin B
resistance O
through O
downregulating O
the O
expression O
of O
phosphatase O
and O
tension O
homolog O
deleted O
on O
chromosome O
10 O
( O
PTEN O
) O
and O
activation O
of O
Akt O
pathway O
. O

These O
results O
suggest O
that O
miR O
- O
21 O
may O
provide O
a O
novel O
mechanism O
for O
understanding O
cisplatin B
resistance O
in O
gastric O
cancer O
by O
modulating O
PTEN O
/ O
PI3K O
/ O
Akt O
pathway O
. O

Our O
previous O
study O
has O
revealed O
that O
p O
- O
cresol O
increased O
intracellular O
calcium B
levels O
and O
activated O
protein O
kinase O
C O
alpha O
( O
PKC O
alpha O
) O
by O
phosphorylation O
. O

This O
PKC O
alpha O
activation O
also O
led O
to O
the O
serine B
dephosphorylation O
of O
p120ctn O
and O
caused O
the O
dissociation O
of O
p120ctn O
from O
N O
- O
cadherin O
. O

ZEB2 O
zinc B
- O
finger O
missense O
mutations O
lead O
to O
hypomorphic O
alleles O
and O
a O
mild O
Mowat O
- O
Wilson O
syndrome O
. O

In O
this O
study O
, O
we O
report O
and O
analyze O
the O
functional O
consequences O
of O
three O
novel O
missense O
mutations O
, O
p O
. O
Tyr1055Cys O
, O
p O
. O
Ser1071Pro O
and O
p O
. O
His1045Arg O
, O
identified O
in O
the O
highly O
conserved O
C O
- O
zinc B
- O
finger O
( O
C O
- O
ZF O
) O
domain O
of O
ZEB2 O
. O

Compound O
2 O
was O
then O
converted O
to O
the O
corresponding O
acetate B
derivative O
, O
ent O
- O
16 O
beta O
- O
acetoxybeyeran O
- O
19 O
- O
oic O
acid O
( O
3 O
) O
. O

Compound O
4 O
exerted O
vasorelaxant O
activity O
at O
particularly O
low O
concentration O
and O
the O
vasorelaxant O
profile O
reached O
maximum O
at O
relatively O
low O
concentration O
, O
especially O
when O
compared O
with O
acetylcholine B
, O
the O
positive O
control O
. O

A O
novel O
insulin O
mimetic O
vanadium O
- O
flavonol O
complex O
: O
Synthesis O
, O
characterization O
and O
in O
vivo O
evaluation O
in O
STZ B
- O
induced O
rats O
. O

Since O
1985 O
, O
when O
Heyliger O
et O
al O
. O
, O
first O
demonstrated O
a O
serendipitous O
discovery O
that O
oral O
administration O
of O
0 O
. O
8 O
mg O
/ O
ml O
of O
sodium O
orthovanadate O
in O
drinking O
water O
to O
streptozotocin B
- O
induced O
diabetic O
rats O
resulted O
in O
normoglycemia O
, O
numerous O
extensive O
studies O
have O
been O
pursued O
on O
the O
anti O
- O
diabetic O
and O
insulinomimetic O
actions O
of O
vanadium B
. O

The O
acceptance O
of O
vanadium B
compounds O
as O
promising O
therapeutic O
antidiabetic O
agents O
has O
been O
slowed O
due O
to O
the O
concern O
for O
chronic O
toxicity O
associated O
with O
vanadium B
accumulation O
. O

In O
order O
to O
circumvent O
the O
toxic O
effects O
of O
vanadium B
, O
we O
have O
taken O
up O
a O
combinational O
approach O
wherein O
a O
novel O
vanadium O
- O
flavonol O
complex O
was O
synthesized O
, O
characterized O
and O
its O
toxic O
as O
well O
as O
insulin O
mimetic O
potential O
was O
evaluated O
in O
STZ B
- O
induced O
experimental O
diabetes O
in O
rats O
. O

GPER O
: O
A O
novel O
target O
for O
non O
- O
genomic O
estrogen B
action O
in O
the O
cardiovascular O
system O
. O

A O
key O
to O
harnessing O
the O
enormous O
therapeutic O
potential O
of O
estrogens B
is O
understanding O
the O
diversity O
of O
estrogen B
receptors O
and O
their O
signaling O
mechanisms O
. O

In O
addition O
to O
the O
classic O
nuclear O
estrogen B
receptors O
( O
i O
. O
e O
. O
, O
ER O
alpha O
and O
ER O
beta O
) O
, O
over O
the O
past O
decade O
a O
novel O
G O
- O
protein O
- O
coupled O
estrogen B
receptor O
( O
GPER O
) O
has O
been O
discovered O
in O
cancer O
and O
other O
cell O
types O
. O

More O
recently O
, O
this O
non O
- O
genomic O
signaling O
mechanism O
has O
been O
found O
in O
blood O
vessels O
, O
and O
mediates O
vasodilatory O
responses O
to O
estrogen B
and O
estrogen B
- O
like O
agents O
; O
however O
, O
downstream O
signaling O
events O
involved O
acute O
estrogen B
action O
remain O
unclear O
. O

The O
purpose O
of O
this O
review O
is O
to O
discuss O
the O
latest O
knowledge O
concerning O
GPER O
modulation O
of O
cardiovascular O
function O
, O
with O
a O
particular O
emphasis O
upon O
how O
activation O
of O
this O
receptor O
could O
mediate O
acute O
estrogen B
effects O
in O
the O
heart O
and O
blood O
vessels O
( O
i O
. O
e O
. O
, O
vascular O
tone O
, O
cell O
growth O
and O
differentiation O
, O
apoptosis O
, O
endothelial O
function O
, O
myocardial O
protection O
) O
. O

Understanding O
the O
role O
of O
GPER O
in O
estrogen B
signaling O
may O
help O
resolve O
some O
of O
the O
controversies O
associated O
with O
estrogen B
and O
cardiovascular O
function O
. O

Moreover O
, O
a O
more O
thorough O
understanding O
of O
GPER O
function O
could O
also O
open O
significant O
opportunities O
for O
the O
development O
of O
new O
pharmacological O
strategies O
that O
would O
provide O
the O
cardiovascular O
benefits O
of O
estrogen B
while O
limiting O
the O
potentially O
dangerous O
side O
effects O
. O

Monitoring O
abacavir B
bioactivation O
in O
humans O
: O
Screening O
for O
an O
aldehyde B
metabolite O
. O

The O
anti O
- O
HIV O
drug O
abacavir B
is O
associated O
with O
idiosyncratic O
hypersensitivity O
reactions O
and O
cardiotoxicity O
. O

Although O
the O
mechanism O
underlying O
abacavir B
- O
toxicity O
is O
not O
fully O
understood O
, O
drug O
bioactivation O
to O
reactive O
metabolites O
may O
be O
involved O
. O

This O
work O
was O
aimed O
at O
identifying O
abacavir B
- O
protein O
adducts O
in O
the O
hemoglobin O
of O
HIV O
patients O
as O
biomarkers O
of O
abacavir B
bioactivation O
and O
protein O
modification O
. O

Abacavir B
- O
derived O
Edman O
adducts O
with O
the O
N B
- O
terminal O
valine B
of O
hemoglobin O
were O
analyzed O
by O
an O
established O
liquid O
chromatography O
- O
electrospray O
ionization O
- O
tandem O
mass O
spectrometry O
method O
. O

Abacavir B
- O
valine B
adducts O
were O
detected O
in O
three O
out O
of O
ten O
patients O
. O

This O
work O
represents O
the O
first O
evidence O
of O
abacavir B
- O
protein O
adduct O
formation O
in O
humans O
. O

The O
data O
confirm O
the O
ability O
of O
abacavir B
to O
modify O
self O
- O
proteins O
and O
suggest O
that O
the O
molecular O
mechanism O
( O
s O
) O
of O
some O
abacavir B
- O
induced O
adverse O
reactions O
may O
require O
bioactivation O
. O

Family O
history O
of O
alcoholism O
interacts O
with O
alcohol B
to O
affect O
brain O
regions O
involved O
in O
behavioral O
inhibition O
. O

RATIONALE O
: O
Impulsive O
behavior O
is O
associated O
with O
both O
alcohol B
use O
disorders O
and O
a O
family O
history O
of O
alcoholism O
( O
FHA O
) O
. O

OBJECTIVE O
: O
Employ O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
to O
study O
right O
frontal O
responses O
to O
stop O
signals O
in O
heavy O
drinking O
subjects O
with O
and O
without O
FHA O
, O
and O
as O
a O
function O
of O
alcohol B
exposure O
. O

METHODS O
: O
Twenty O
- O
two O
family O
history O
- O
positive O
( O
FHP O
; O
age O
= O
22 O
. O
7 O
years O
, O
SD O
= O
1 O
. O
9 O
) O
and O
18 O
family O
history O
- O
negative O
( O
FHN O
; O
age O
= O
23 O
. O
7 O
, O
SD O
= O
1 O
. O
8 O
) O
subjects O
performed O
the O
SST O
in O
fMRI O
in O
two O
randomized O
visits O
: O
once O
during O
intravenous O
infusion O
of O
alcohol B
, O
clamped O
at O
a O
steady O
- O
state O
breath O
alcohol B
( O
BrAC O
) O
concentration O
of O
60 O
mg O
/ O
dL O
, O
and O
once O
during O
infusion O
of O
placebo O
saline O
. O

RESULTS O
: O
FHA O
interacted O
with O
alcohol B
exposure O
in O
right O
prefrontal O
cortex O
, O
where O
alcohol B
reduced O
[ O
Inh O
> O
Go O
] O
activation O
in O
FHN O
subjects O
but O
not O
in O
FHP O
subjects O
. O

CONCLUSIONS O
: O
The O
results O
are O
consistent O
with O
the O
low O
level O
of O
response O
theory O
( O
Schuckit O
, O
J O
Stud O
Alcohol B
55 O
: O
149 O
- O
158 O
, O
1980 O
; O
Quinn O
and O
Fromme O
, O
Alcohol B
Clin O
Exp O
Res O
35 O
: O
1759 O
- O
1770 O
, O
2011 O
) O
, O
with O
FHP O
being O
less O
sensitive O
to O
alcohol B
' O
s O
effects O
. O

3 O
- O
Hydroxyazetidine O
carboxylic O
acids O
: O
non O
- O
proteinogenic O
amino B
acids I
for O
medicinal O
chemists O
. O

The O
formation O
from O
D B
- I
glucose I
of O
both O
enantiomers O
of O
2 O
, O
4 O
- O
dideoxy O
- O
2 O
, O
4 O
- O
iminoribonic O
acid O
is O
the O
first O
chemical O
synthesis O
of O
unprotected O
3 O
- O
hydroxyazetidine O
carboxylic O
acids O
. O

The O
long O
- O
term O
stability O
of O
3 O
- O
hydroxyazetidine O
amides O
is O
established O
at O
acidic O
and O
neutral O
pH O
and O
implies O
their O
value O
as O
non O
- O
proteinogenic O
amino B
acid I
components O
of O
peptides O
, O
providing O
medicinal O
chemists O
with O
a O
new O
class O
of O
peptide O
isosteres O
. O

An O
N O
- O
methylazetidine O
amide O
derivative O
is O
a O
specific O
inhibitor O
of O
beta O
- O
hexosaminidases O
at O
the O
micromolar O
level O
, O
and O
is O
only O
the O
second O
example O
of O
potent O
inhibition O
of O
any O
glycosidase O
by O
an O
amide B
of O
a O
sugar O
amino O
acid O
related O
to O
an O
iminosugar O
. O

The O
Role O
of O
Surface O
Chemistry O
on O
the O
Toxicity O
of O
Ag B
Nanoparticles O
. O

The O
role O
of O
surface O
chemistry O
on O
the O
toxicity O
of O
Ag B
nanoparticles O
is O
investigated O
using O
Saccharomyces O
cerevisiae O
yeast O
as O
a O
platform O
for O
evaluation O
. O

Combining O
the O
shape O
- O
controlled O
synthesis O
of O
Ag B
nanoparticles O
with O
a O
comprehensive O
characterization O
of O
their O
physicochemical O
properties O
, O
an O
understanding O
is O
formed O
of O
the O
correlation O
between O
the O
physicochemical O
parameters O
of O
nanoparticles O
and O
the O
inhibition O
growth O
of O
yeast O
cells O
upon O
the O
introduction O
of O
nanoparticles O
into O
the O
cell O
culture O
system O
. O

Capping O
agents O
, O
surface O
facets O
, O
and O
sample O
stability O
- O
the O
three O
experimental O
parameters O
that O
are O
inherent O
from O
the O
wet O
- O
chemical O
synthesis O
of O
Ag B
nanoparticles O
- O
have O
a O
strong O
impact O
on O
toxicity O
evaluation O
. O

Hence O
, O
it O
is O
important O
to O
characterize O
surface O
properties O
of O
Ag B
nanoparticles O
in O
the O
nature O
of O
biological O
media O
and O
to O
understand O
the O
role O
that O
surface O
chemistry O
may O
interplay O
to O
correlate O
the O
physicochemical O
properties O
of O
nanoparticles O
with O
their O
biological O
response O
upon O
exposure O
. O

This O
work O
demonstrates O
the O
great O
importance O
of O
surface O
chemistry O
in O
designing O
experiments O
for O
reliable O
toxicity O
evaluation O
and O
in O
mitigating O
the O
toxicity O
of O
Ag B
nanoparticles O
for O
their O
safe O
use O
in O
future O
commercialization O
. O

Hybridization O
of O
Phenylthiolate O
- O
and O
Methylthiolate O
- O
Adatom O
Species O
at O
Low O
Coverage O
on O
the O
Au B
( I
111 I
) I
Surface O
. O

Using O
scanning O
tunneling O
microscopy O
we O
observed O
reaction O
products O
of O
two O
chemisorbed O
thiolate O
species O
, O
methylthiolate O
and O
phenylthiolate O
, O
on O
the O
Au B
( I
111 I
) I
surface O
. O

Despite O
the O
apparent O
stability O
, O
organometallic B
complexes O
of O
methylthiolate O
and O
phenylthiolate O
with O
the O
gold O
- O
adatom O
( O
RS O
- O
Au O
- O
SR O
, O
with O
R O
- O
the O
hydrocarbon B
group O
) O
undergo O
a O
stoichiometric O
exchange O
reaction O
, O
forming O
hybridized O
CH3S O
- O
Au O
- O
SPh O
complexes O
. O

Targeted O
d4 O
dopamine B
receptors O
: O
implications O
for O
drug O
discovery O
and O
therapeutic O
development O
. O

A O
wealth O
of O
preclinical O
and O
clinical O
literature O
has O
established O
functional O
associations O
of O
CNS O
dopamine B
( O
DA O
) O
and O
its O
multiple O
G O
protein O
- O
coupled O
receptor O
( O
GPCR O
) O
types O
in O
the O
integration O
of O
key O
neurological O
processes O
linked O
to O
complex O
behavioral O
activities O
. O

Polyclonal O
Antibody O
to O
Soman B
- O
Tyrosine B
. O

Soman B
forms O
a O
stable O
, O
covalent O
bond O
with O
tyrosine B
411 O
of O
human O
albumin O
, O
with O
tyrosines O
257 O
and O
593 O
in O
human O
transferrin O
, O
and O
with O
tyrosine B
in O
many O
other O
proteins O
. O

The O
pinacolyl O
group O
of O
soman B
is O
retained O
, O
suggesting O
that O
pinacolyl O
methylphosphonate O
bound O
to O
tyrosine B
could O
generate O
specific O
antibodies O
. O

Tyrosine B
in O
the O
pentapeptide B
RYGRK O
was O
covalently O
modified O
with O
soman B
simply O
by O
adding O
soman B
to O
the O
peptide O
. O

The O
polyclonal O
antiserum O
recognized O
soman B
- O
labeled O
human O
albumin O
, O
soman B
- O
mouse O
albumin O
, O
and O
soman B
human O
transferrin O
but O
not O
nonphosphonylated O
control O
proteins O
. O

The O
soman B
- O
labeled O
tyrosines O
in O
these O
proteins O
are O
surrounded O
by O
different O
amino B
acid I
sequences O
, O
suggesting O
that O
the O
polyclonal O
recognizes O
soman B
- O
tyrosine B
independent O
of O
the O
amino B
acid I
sequence O
. O

The O
limit O
of O
detection O
on O
Western O
blots O
was O
0 O
. O
01 O
mu O
g O
( O
15 O
picomoles O
) O
of O
soman B
- O
labeled O
albumin O
. O

In O
conclusion O
, O
a O
high O
- O
affinity O
, O
polyclonal O
antibody O
that O
specifically O
recognizes O
soman B
adducts O
on O
tyrosine B
in O
a O
variety O
of O
proteins O
has O
been O
produced O
. O

Such O
an O
antibody O
could O
be O
useful O
for O
identifying O
secondary O
targets O
of O
soman B
toxicity O
. O

Biocompatible O
, O
functional O
spheres O
based O
on O
oxidative O
coupling O
assembly O
of O
green O
tea O
polyphenols B
. O

Green O
luminescent O
, O
monodisperse O
, O
smooth O
, O
porous O
and O
hollow O
spheres O
were O
simply O
prepared O
by O
Cu B
( I
2 I
+ I
) I
and O
temperature O
mediated O
oxidative O
coupling O
assembly O
of O
green O
tea O
polyphenols B
in O
water O
. O

These O
polymeric O
tea O
polyphenol B
spheres O
are O
GSH B
responsive O
, O
acid O
resistant O
but O
alkali O
- O
responsive O
, O
ideally O
used O
as O
platform O
for O
controlled O
delivery O
of O
functional O
guests O
. O

Here O
, O
we O
report O
on O
the O
vapor O
- O
deposited O
growth O
of O
rubrene O
films O
on O
the O
substrates O
made O
of O
cadmium O
arachidate O
( O
CdA O
) O
multilayers O
deposited O
onto O
SiO2 B
/ O
Si B
( O
100 O
) O
via O
the O
Langmuir O
- O
Blodgett O
technique O
. O

The O
CdA O
films O
, O
containing O
2n O
+ O
1 O
layers O
, O
with O
integer O
n O
ranging O
from O
0 O
to O
4 O
, O
are O
surface O
- O
terminated O
identically O
by O
the O
methyl B
group O
but O
exhibit O
the O
thickness O
- O
dependent O
morphology O
. O

Optimizing O
Small O
Molecule O
Inhibitors O
of O
Calcium B
- O
Dependent O
Protein O
Kinase O
1 O
to O
Prevent O
Infection O
by O
Toxoplasma O
gondii O
. O

Toxoplasma O
gondii O
is O
sensitive O
to O
bulky O
pyrazolo O
[ O
3 O
, O
4 O
- O
d O
] O
pyrimidine O
( O
PP O
) O
inhibitors O
due O
to O
the O
presence O
of O
a O
Gly B
gatekeeper O
in O
the O
essential O
calcium B
dependent O
protein O
kinase O
1 O
( O
CDPK1 O
) O
. O

A O
newly O
synthesized O
sinapic B
Acid I
derivative O
inhibits O
endothelial O
activation O
in O
vitro O
and O
in O
vivo O
. O

Sinapic B
acid I
( O
SA O
) O
, O
a O
phenylpropanoid B
compound O
, O
is O
found O
in O
natural O
herbs O
and O
high O
- O
bran O
cereals O
and O
has O
moderate O
antioxidant O
activity O
. O

Preliminary O
screening O
of O
the O
compounds O
involved O
scavenging O
hydroxyl B
radicals O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
( I
. I
) I
) O
, O
croton O
oil O
- O
induced O
ear O
edema O
in O
mice O
, O
and O
analysis O
of O
the O
mRNA O
expression O
of O
adhesion O
molecules O
in O
ECs O
. O

Measurement O
of O
Transport O
Activities O
of O
3 O
beta O
- O
Hydroxy O
- O
Delta O
( O
5 O
) O
- O
bile O
Acids O
in O
Bile B
Salt I
Export O
Pump O
and O
Multidrug O
Resistance O
- O
Associated O
Proteins O
Using O
LC O
- O
MS O
/ O
MS O
. O

Calibration O
curves O
for O
the O
bile B
acids I
were O
linear O
over O
the O
range O
of O
10 O
to O
2000 O
pmol O
/ O
mL O
, O
and O
the O
detection O
limit O
was O
less O
than O
1 O
pmol O
/ O
mL O
for O
3 O
beta O
- O
hydroxy O
- O
Delta O
( O
5 O
) O
- O
bile O
acids O
using O
selected O
reaction O
monitoring O
analysis O
. O

The O
analytical O
method O
was O
applied O
to O
measurements O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
human O
multidrug O
resistance O
- O
associated O
protein O
2 O
- O
, O
3 O
- O
, O
and O
human O
bile B
salt I
export O
pump O
- O
expressing O
Sf9 O
cells O
for O
conjugated O
3 O
beta O
- O
hydroxy O
- O
Delta O
( O
5 O
) O
- O
bile O
acids O
. O

The O
present O
study O
demonstrated O
that O
human O
multidrug O
resistance O
- O
associated O
protein O
3 O
vesicles O
accepted O
conjugated O
3 O
beta O
- O
hydroxy O
- O
Delta O
( O
5 O
) O
- O
bile O
acids O
along O
with O
common O
bile B
acids I
such O
as O
glycocholic O
acid O
and O
taurolithocholic O
acid O
3 O
- O
sulfate O
. O

Evaluation O
of O
the O
groups O
in O
terms O
of O
pre O
- O
and O
postphysiotherapy O
applications O
showed O
a O
significant O
increase O
in O
mixed O
venous O
oxygen B
saturation O
in O
both O
groups O
. O

On O
the O
basis O
of O
percent O
edema O
inhibition O
after O
3 O
h O
of O
carrageenin O
injection O
, O
n B
- I
butanol I
fraction O
showed O
promising O
activity O
through O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decrease O
in O
paw O
volume O
by O
85 O
. O
6 O
% O
from O
control O
using O
indomethacin B
as O
reference O
standard O
. O

Moreover O
, O
the O
n B
- I
butanol I
fraction O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
PGE2 B
and O
TNF O
- O
alpha O
in O
the O
exudates O
of O
rat O
paw O
edema O
. O

Chemical O
investigation O
of O
n B
- I
butanol I
fraction O
afforded O
alpha O
- O
amyrin O
3 O
- O
O O
- O
glucopyranoside O
( O
1 O
) O
, O
patuletin O
7 O
- O
O O
- O
glucopyranoside O
( O
2 O
) O
, O
myricitrin O
( O
3 O
) O
and O
a O
new O
oleanane O
triterpene O
saponin O
derivative O
( O
4 O
) O
, O
sophradiol O
3 O
- O
O O
- O
alpha O
- O
L O
- O
( O
1 O
) O
C4 O
- O
rhamnopyranosyl O
- O
( O
1 O
' O
' O
' O
- O
- O
> O
4 O
' O
' O
) O
- O
O O
- O
beta O
- O
D O
- O
( O
4 O
) O
C1 O
- O
galactopyranosyl O

Adenosine B
and O
dipyridamole O
are O
nonselective O
adenosine B
receptor O
agonists O
that O
have O
been O
associated O
with O
myocardial O
infarction O
( O
MI O
) O
during O
intravenous O
infusion O
. O

The O
Efficiency O
of O
the O
Metal O
Catalysts O
in O
the O
Nucleophilic O
Substitution O
of O
Alcohols B
is O
Dependent O
on O
the O
Nucleophile O
and O
Not O
on O
the O
Electrophile O
. O

In O
this O
study O
, O
we O
investigate O
the O
effect O
of O
the O
electrophiles O
and O
the O
nucleophiles O
for O
eight O
catalysts O
in O
the O
catalytic O
SN O
1 O
type O
substitution O
of O
alcohols B
with O
different O
degree O
of O
activation O
by O
sulfur B
- O
, O
carbon B
- O
, O
oxygen B
- O
, O
and O
nitrogen B
- O
centered O
nucleophiles O
. O

The O
catalysts O
do O
not O
show O
any O
general O
variance O
in O
efficiency O
or O
selectivity O
with O
respect O
to O
the O
alcohols B
and O
follow O
the O
trend O
of O
alcohol B
reactivity O
. O

Interestingly O
, O
the O
selectivity O
of O
the O
alcohols B
to O
produce O
the O
desired O
substitution O
products O
was O
found O
to O
be O
independent O
of O
the O
electrophilicity O
of O
the O
generated O
carbocations O
but O
highly O
dependent O
on O
the O
ease O
of O
formation O
of O
the O
cation O
. O

Catalysts O
based O
on O
iron O
( O
III O
) O
, O
bismuth O
( O
III O
) O
, O
and O
gold O
( O
III O
) O
show O
higher O
conversions O
for O
S B
- O
, O
C B
- O
, O
and O
N B
- O
centered O
nucleophiles O
, O
and O
Bi O
( O
III O
) O
was O
the O
most O
efficient O
catalyst O
in O
all O
combinations O
. O

Catalysts O
based O
on O
rhenium O
( O
I O
) O
or O
rhenium O
( O
VII O
) O
, O
palladium O
( O
II O
) O
, O
and O
lanthanum O
( O
III O
) O
were O
the O
most O
efficient O
in O
performing O
the O
nucleophilic O
substitution O
on O
the O
various O
alcohols B
with O
the O
O B
- O
centered O
nucleophiles O
. O

These O
catalysts O
generate O
the O
symmetrical O
ether O
as O
a O
by O
- O
product O
from O
the O
reactions O
of O
S B
- O
, O
C B
- O
, O
and O
N B
- O
centered O
nucleophiles O
as O
well O
, O
resulting O
in O
lower O
chemoselectivity O
. O

Ras O
/ O
cAMP B
- O
dependent O
Protein O
Kinase O
( O
PKA O
) O
Regulates O
Multiple O
Aspects O
of O
Cellular O
Events O
by O
Phosphorylating O
the O
Whi3 O
Cell O
Cycle O
Regulator O
in O
Budding O
Yeast O
. O

Here O
, O
we O
show O
that O
Whi3 O
is O
phosphorylated O
by O
the O
Ras O
/ O
cAMP B
- O
dependent O
protein O
kinase O
( O
PKA O
) O
and O
that O
phosphorylation O
of O
Ser B
- O
568 O
in O
Whi3 O
by O
PKA O
plays O
an O
inhibitory O
role O
in O
Whi3 O
function O
. O

In O
the O
second O
part O
of O
the O
study O
, O
the O
various O
x O
, O
y O
- O
ionenes O
( O
x O
, O
y O
are O
numbers O
of O
methylene B
groups O
between O
the O
adjacent O
charges O
) O
with O
fluoride B
, O
bromide B
, O
and O
iodide B
counterions O
are O
mixed O
with O
aqueous O
sodium O
sulfate O
solution O
. O

The O
theory O
predicts O
for O
the O
enthalpy O
of O
dilution O
to O
be O
exothermic O
and O
the O
enthalpy O
of O
mixing O
endothermic O
, O
while O
experiments O
show O
that O
signs O
of O
the O
heat O
effects O
depend O
on O
the O
nature O
of O
the O
counterion O
of O
the O
added O
salt O
, O
as O
also O
on O
the O
hydrophobicity O
( O
numbers O
x O
, O
y O
of O
methylene B
groups O
) O
of O
the O
ionene O
. O

We O
show O
that O
the O
salts O
when O
ordered O
by O
heat O
effects O
produced O
by O
mixing O
of O
NaF B
and O
NaBr O
with O
3 O
, O
3 O
- O
, O
6 O
, O
9 O
- O
, O
or O
6 O
, O
12 O
- O
ionene O
fluorides O
and O
bromides O
follow O
the O
opposite O
ordering O
than O
in O
the O
case O
when O
the O
same O
alkali O
halide O
salts O
are O
mixed O
with O
more O
hydrophobic O
12 O
, O
12 O
- O
ionene O
salts O
. O

We O
choose O
AOT B
/ O
Igepal O
- O
520 O
/ O
cyclohexane B
( O
Cy O
) O
mixed O
RM O
as O
a O
model O
system O
which O
exhibits O
synergistic O
water O
solubilization O
behavior O
as O
a O
function O
of O
interfacial O
stoichiometry O
. O

FTIR O
study O
in O
the O
3000 O
- O
3800 O
cm O
( O
- O
1 O
) O
region O
identifies O
that O
the O
relative O
population O
of O
the O
surface O
- O
bound O
water O
molecules O
is O
higher O
in O
AOT B
RM O
compared O
to O
that O
in O
Igepal O
RM O
, O
and O
in O
mixed O
systems O
it O
also O
follows O
a O
linear O
trend O
with O
XIgepal O
. O

Mechanistic O
studies O
revealed O
that O
the O
new O
PARP1 O
inhibitors O
significantly O
inhibited O
H2O2 B
- O
triggered O
PARylation O
in O
SKOV3 O
cells O
, O
induced O
cellular O
accumulation O
of O
DNA O
double O
- O
strand O
breaks O
, O
and O
impaired O
cell O
- O
cycle O
progression O
in O
BRCA2 O
- O
deficient O
cells O
. O

We O
report O
growth O
of O
various O
phase O
architectures O
of O
self O
- O
assembled O
BiFeO3 O
- O
CoFe2O4 O
( O
BFO O
- O
CFO O
) O
thin O
films O
on O
differently O
oriented O
SrTiO3 B
( O
STO O
) O
substrates O
. O

The O
results O
suggest O
a O
way O
to O
effectively O
control O
the O
magnetic O
anisotropy O
in O
patterned O
ferromagnetic O
oxide B
arrays O
with O
tunable O
shape O
, O
aspect O
ratio O
, O
and O
elastic O
strain O
conditions O
of O
the O
nanostructures O
. O

Biodistribution O
of O
different O
sized O
nanoparticles O
assessed O
by O
positron O
emission O
tomography O
: O
a O
general O
strategy O
for O
direct O
activation O
of O
metal B
oxide I
particles O
. O

We O
present O
a O
simple O
and O
straightforward O
method O
for O
the O
direct O
proton O
beam O
activation O
of O
synthetic O
or O
commercially O
available O
aluminum B
oxide I
NPs O
( O
Al2O3 B
NPs O
) O
via O
the O
( O
16 O
) O
O O
( O
p O
, O
alpha O
) O
( O
13 O
) O
N O
nuclear O
reaction O
in O
order O
to O
assess O
their O
biological O
fate O
using O
positron O
emission O
tomography O
( O
PET O
) O
. O

The O
incorporation O
of O
radioactive O
( O
13 O
) O
N O
atoms O
in O
the O
Al2O3 B
NPs O
allowed O
the O
study O
of O
the O
biodistribution O
of O
the O
metal B
oxide I
NPs O
in O
rats O
after O
intravenous O
administration O
via O
PET O
. O

This O
simple O
and O
robust O
activation O
strategy O
can O
be O
applied O
to O
any O
synthetic O
or O
commercially O
available O
metal B
oxide I
particle O
. O

Melanoma O
targeting O
property O
of O
a O
Lu O
- O
177 O
- O
labeled O
lactam B
bridge O
- O
cyclized O
alpha O
- O
MSH O
peptide O
. O

BCR O
- O
ABL O
tyrosine B
kinase O
inhibitor O
pharmacophore O
model O
derived O
from O
a O
series O
of O
phenylaminopyrimidin B
- O
based O
( O
PAP O
) O
derivatives O
. O

To O
reveal O
novel O
insights O
into O
the O
inhibition O
of O
BCR O
- O
ABL O
tyrosine B
kinase O
, O
pharmacophore O
mapping O
studies O
were O
performed O
for O
a O
series O
of O
phenylaminopyrimidin B
- O
based O
( O
PAP O
) O
derivatives O
, O
including O
imatinib B
( O
Gleevec O
) O
. O

A O
seven O
- O
point O
pharmacophore O
model O
with O
one O
hydrophobic O
group O
( O
H O
) O
, O
two O
hydrogen B
bond O
donors O
( O
D O
) O
and O
four O
aromatic O
rings O
( O
R O
) O
was O
developed O
using O
phase O
( O
pharmacophore O
alignment O
& O
scoring O
engine O
) O
. O

Time O
- O
dependent O
effects O
of O
corticosterone B
on O
reward O
- O
based O
decision O
- O
making O
in O
a O
rodent O
model O
of O
the O
Iowa O
Gambling O
Task O
. O

Here O
, O
we O
investigated O
whether O
reward O
- O
based O
decision O
- O
making O
, O
in O
a O
rat O
model O
of O
the O
Iowa O
Gambling O
Task O
( O
rIGT O
) O
, O
is O
also O
differently O
altered O
by O
rapid O
versus O
delayed O
actions O
of O
corticosterone B
. O

We O
targeted O
the O
rapid O
and O
delayed O
time O
domain O
by O
injecting O
corticosterone B
( O
CORT B
, O
1 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
at O
30 O
min O
( O
rapid O
) O
or O
180 O
min O
( O
delayed O
) O
respectively O
prior O
to O
behavioural O
testing O
, O
during O
the O
final O
3 O
days O
of O
the O
behavioural O
paradigm O
. O

In O
saline O
treated O
rats O
, O
the O
number O
of O
visits O
to O
the O
disadvantageous O
arm O
decreased O
over O
trial O
blocks O
, O
whilst O
this O
was O
attenuated O
when O
CORT B
was O
administered O
30 O
min O
before O
testing O
. O

Naturally O
occurring O
phosphonates B
such O
as O
phosphinothricin O
( O
Glufosinate O
, O
a O
commercially O
used O
herbicide O
) O
and O
fosfomycin O
( O
Monurol O
, O
a O
clinically O
used O
antibiotic O
) O
have O
proved O
to O
be O
potent O
and O
useful O
biocides O
. O

Here O
, O
we O
present O
an O
efficient O
mass O
- O
spectrometric O
method O
for O
the O
selective O
detection O
of O
natural O
products O
containing O
phosphonate B
and O
phosphinate O
functional O
groups O
. O

We O
have O
used O
this O
method O
to O
identify O
a O
new O
phosphonate B
metabolite O
, O
phosacetamycin O
, O
whose O
structure O
, O
biological O
activity O
, O
and O
biosynthetic O
gene O
cluster O
are O
reported O
. O

The O
present O
study O
determined O
the O
anti O
- O
Mycobacterium O
tuberculosis O
activities O
of O
supercritical O
CO2 B
extracts O
, O
neolignans B
eupomatenoid O
- O
5 O
( O
1 O
) O
, O
conocarpan O
( O
4 O
) O
and O
eupomatenoid O
- O
3 O
( O
7 O
) O
and O
their O
derivatives O
( O
2 O
, O
3 O
, O
5 O
, O
6 O
, O
and O
8 O
) O
from O
Piper O
regnellii O
, O
as O
well O
as O
their O
cytotoxicities O
. O

The O
supercritical O
CO2 B
extract O
from O
leaves O
was O
purified O
by O
chromatographic O
methods O
, O
yielding O
compounds O
( O
1 O
) O
, O
( O
4 O
) O
and O
( O
7 O
) O
, O
which O
were O
identified O
by O
( B
1 I
) I
H I
NMR O
and O
comparison O
with O
literature O
data O
. O

The O
cytotoxicity O
assay O
was O
carried O
out O
in O
macrophages O
J774G O
. O
8 O
by O
sulforhodamine B
B I
colorimetric O
assay O
. O

The O
supercritical O
CO2 B
extracts O
from O
leaves O
and O
stems O
, O
and O
compound O
( O
4 O
) O
showed O
activity O
against O
M O
. O
tuberculosis O
( O
MIC O
15 O
. O
6 O
mu O
g O
/ O
ml O
) O
. O

This O
is O
the O
first O
report O
, O
to O
our O
knowledge O
, O
to O
describe O
neolignans B
from O
P O
. O
regnellii O
with O
activity O
against O
M O
. O
tuberculosis O
, O
and O
compound O
( O
1 O
) O
is O
a O
potential O
candidate O
for O
future O
antituberculosis O
drugs O
. O

Prilling O
of O
fatty B
acids I
as O
a O
continuous O
process O
for O
the O
development O
of O
controlled O
release O
multiparticulate O
dosage O
forms O
. O

In O
this O
study O
, O
prilling O
was O
evaluated O
as O
a O
technique O
for O
the O
development O
of O
multiparticulate O
dosage O
forms O
using O
the O
fatty B
acids I
, O
stearic B
acid I
, O
and O
behenic B
acid I
as O
potential O
matrix O
formers O
to O
control O
the O
release O
of O
metoprolol O
tartrate O
( O
MPT O
) O
, O
a O
highly O
water O
soluble O
drug O
. O

The O
in O
vitro O
drug O
release O
was O
dependent O
on O
the O
drug O
load O
, O
type O
of O
fatty B
acid I
, O
and O
pH O
of O
the O
dissolution O
medium O
. O

Higher O
drug O
loads O
resulted O
in O
faster O
release O
with O
behenic B
acid I
releasing O
drug O
over O
longer O
periods O
relative O
to O
stearic B
acid I
. O

Due O
to O
ionization O
of O
the O
fatty B
acid I
at O
pH O
7 O
. O
4 O
, O
drug O
release O
was O
susceptible O
to O
the O
ionic O
strength O
at O
this O
pH O
value O
. O

Solid O
state O
characterization O
indicated O
that O
the O
crystalline O
state O
of O
the O
fatty B
acids I
was O
not O
affected O
by O
thermal O
processing O
via O
prilling O
, O
while O
the O
crystallinity O
of O
MPT O
was O
decreased O
. O

Drug O
release O
from O
behenic B
acid I
matrices O
was O
increased O
during O
storage O
at O
40 O
degrees O
C O
; O
however O
, O
no O
polymorphism O
of O
behenic B
acid I
was O
detected O
. O

The O
bioavailability O
of O
MPT O
, O
after O
oral O
administration O
to O
dogs O
as O
prills O
containing O
30 O
% O
and O
40 O
% O
MPT O
using O
behenic B
acid I
as O
matrix O
former O
, O
was O
not O
significantly O
different O
from O
a O
commercial O
sustained O
release O
reference O
formulation O
, O
although O
the O
40 O
% O
MPT O
prills O
showed O
a O
burst O
release O
. O

Synthesis O
of O
the O
target O
compounds O
was O
readily O
accomplished O
in O
good O
yields O
through O
a O
cyclisation O
reaction O
between O
indole O
- O
3 O
- O
carboxylic O
acid O
hydrazide O
and O
carbon B
disulfide I
under O
basic O
conditions O
, O
followed O
by O
S B
- O
benzylation O
. O

Sulfur B
- O
nitrogen B
co O
- O
doped O
three O
- O
dimensional O
carbon B
foams O
with O
hierarchical O
pore O
structures O
as O
efficient O
metal O
- O
free O
electrocatalysts O
for O
oxygen B
reduction O
reactions O
. O

Despite O
the O
good O
progress O
in O
developing O
doped O
carbon O
catalysts O
for O
oxygen B
- O
reduction O
reaction O
( O
ORR O
) O
, O
the O
current O
metal O
- O
free O
carbon B
catalysts O
are O
still O
far O
from O
satisfactory O
for O
large O
- O
scale O
applications O
of O
fuel O
cell O
. O

Developing O
new O
metal O
free O
doped O
carbon B
materials O
with O
abundance O
active O
sites O
as O
well O
as O
excellent O
electron O
transfer O
and O
reactant O
transport O
rate O
towards O
ORR O
may O
be O
a O
potential O
solution O
. O

Herein O
, O
we O
develop O
a O
novel O
three O
- O
dimensional O
( O
3D O
) O
sulfur O
- O
nitrogen O
co O
- O
doped O
carbon O
foams O
( O
S B
- O
N B
- O
CF O
) O
with O
hierarchical O
pore O
structures O
, O
using O
a O
convenient O
, O
economical O
, O
and O
scalable O
method O
. O

The O
experimental O
results O
have O
demonstrated O
that O
the O
obtained O
3D O
S B
- O
N B
- O
CF O
exhibited O
better O
catalytic O
activity O
, O
longer O
- O
term O
stability O
and O
higher O
methanol B
tolerance O
than O
a O
commercial O
Pt B
/ O
C B
catalyst O
. O

Such O
excellent O
performances O
may O
be O
attributed O
to O
the O
synergistic O
effect O
, O
which O
includes O
high O
catalytic O
sites O
for O
ORR O
provided O
by O
high O
S B
- O
N B
heteroatom O
loading O
, O
excellent O
reactant O
transport O
caused O
by O
hierarchical O
pore O
structures O
and O
high O
electron O
transfer O
rate O
provided O
by O
3D O
continuous O
networks O
. O

Our O
results O
not O
only O
develop O
a O
new O
type O
of O
catalysts O
with O
excellent O
electrocatalytic O
performance O
by O
a O
commercially O
valid O
route O
, O
but O
also O
provide O
useful O
information O
for O
further O
clarification O
of O
the O
relationship O
between O
the O
microstructures O
of O
metal O
- O
free O
carbon B
materials O
and O
catalyst O
properties O
for O
ORR O
. O

Biotransformation O
of O
Two O
beta O
- O
Secretase O
Inhibitors O
Including O
Ring O
Opening O
and O
Contraction O
of O
a O
Pyrimidine B
Ring O
. O

In O
vitro O
, O
CYP3A4 O
was O
the O
major O
responsible O
enzyme O
and O
metabolized O
both O
compounds O
to O
a O
large O
extent O
in O
the O
commonly O
shared O
pyridine B
and O
pyrimidine B
rings O
. O

The O
main O
proposed O
metabolic O
pathways O
in O
various O
in O
vitro O
systems O
were O
N B
- O
oxidation O
of O
the O
pyridine B
and O
/ O
or O
pyrimidine B
ring O
and O
conversion O
to O
4 O
- O
pyrimidone O
and O
pyrimidine O
- O
2 O
, O
4 O
- O
dione O
. O

Here O
, O
the O
main O
pathways O
were O
N B
- O
oxidation O
of O
the O
pyridine B
and O
/ O
or O
pyrimidine B
ring O
and O
a O
ring O
contraction O
of O
the O
pyrimidine B
ring O
into O
an O
imidazole B
ring O
. O

In O
conclusion O
, O
we O
discovered O
an O
unusual O
metabolic O
pathway O
of O
aryl O
- O
pyrimidine O
- O
containing O
compounds O
by O
a O
ring O
- O
opening O
reaction O
followed O
by O
elimination O
of O
a O
carbon B
atom O
and O
a O
ring O
closure O
to O
form O
an O
imidazole B
ring O
. O

More O
generally O
, O
we O
show O
that O
stability O
and O
electrohydrodynamics O
of O
viruses O
differ O
according O
to O
purification O
by O
( O
i O
) O
dialysis O
, O
( O
ii O
) O
isopycnic O
centrifugation O
in O
the O
cesium O
chloride O
gradient O
, O
and O
( O
iii O
) O
precipitation O
using O
polyethylene B
glycol I
( O
PEG B
) O
. O

In O
addition O
, O
VLPs O
prepared O
following O
methods O
( O
i O
) O
and O
( O
iii O
) O
aggregate O
only O
at O
the O
isoelectric O
point O
( O
pH O
~ O
3 O
- O
4 O
) O
in O
1 O
mM O
NaNO3 B
solution O
. O

RATIONALE O
: O
Several O
studies O
have O
suggested O
that O
modulation O
of O
the O
glutamatergic O
system O
via O
metabotropic O
glutamate B
receptors O
( O
mGlu O
) O
could O
be O
a O
new O
way O
to O
achieve O
antipsychotic O
- O
like O
activity O
. O

Apart O
from O
the O
above O
- O
mentioned O
models O
of O
negative O
and O
cognitive O
symptoms O
, O
MK B
- I
801 I
and O
amphetamine B
- O
induced O
hyperactivity O
tests O
, O
plus O
the O
DOI B
- O
induced O
head O
twitches O
in O
mice O
as O
models O
for O
positive O
symptoms O
of O
psychosis O
, O
were O
used O
in O
this O
part O
of O
the O
investigations O
. O

RESULTS O
: O
LSP1 O
- O
2111 O
( O
0 O
. O
5 O
, O
2 O
, O
and O
5 O
mg O
/ O
kg O
) O
dose O
- O
dependently O
inhibited O
MK B
- I
801 I
- O
induced O
deficits O
in O
social O
interaction O
and O
NOR O
tests O
. O

Practical O
synthesis O
of O
a O
chromene O
analog O
for O
use O
as O
a O
retinoic B
acid I
receptor O
alpha O
antagonist O
lead O
compound O
. O

Retinoic B
acid I
receptor O
alpha O
( O
RAR O
alpha O
) O
selective O
compounds O
may O
guide O
the O
design O
of O
drugs O
that O
can O
be O
used O
in O
conjunction O
with O
hormonal O
adjuvant O
therapy O
in O
the O
treatment O
of O
breast O
cancer O
. O

Synthesis O
of O
decacationic O
[ O
60 O
] O
fullerene O
decaiodides O
giving O
photoinduced O
production O
of O
superoxide B
radicals O
and O
effective O
PDT O
- O
mediation O
on O
antimicrobial O
photoinactivation O
. O

We O
report O
a O
novel O
class O
of O
highly O
water O
- O
soluble O
decacationic O
methano O
[ O
60 O
] O
fullerene O
decaiodides O
C60 O
[ O
> O
M O
( O
C3N6 O
( O
+ O
) O
C3 O
) O
2 O
] O
- O
( O
I O
( O
- O
) O
) O
10 O
[ O
1 O
- O
( O
I O
( O
- O
) O
) O
10 O
] O
capable O
of O
co O
- O
producing O
singlet O
oxygen B
( O
Type O
- O
II O
) O
and O
highly O
reactive O
hydroxyl B
radicals O
, O
formed O
from O
superoxide B
radicals O
in O
Type O
- O
I O
photosensitizing O
reactions O
, O
upon O
illumination O
at O
both O
UVA O
and O
white O
light O
wavelengths O
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( O
I O
( O
- O
) O
) O
10 O
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis O
( O
2 O
, O
4 O
- O
dinitrobenzenesulfon O
) O
tetrafluorofluoresce O
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( O
3 O
) O
C60 O
* O
[ O
> O
M O
( O
C3N6 O
( O
+ O
) O
C3 O
) O
2 O
] O
leading O
to O
C60 O
( O
- O
) O
. O
[ O
> O
M O
( O
C3N6 O
( O
+ O
) O
C3 O
) O
2 O
] O
. O

Incorporation O
of O
a O
defined O
number O
( O
ten O
) O
of O
quaternary O
ammonium O
cationic O
charges O
per O
C60 B
in O
1 O
was O
aimed O
to O
enhance O
its O
ability O
to O
target O
pathogenic O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacterial O
cells O
. O

We O
used O
the O
well O
- O
characterized O
malonato O
[ O
60 O
] O
fullerene O
diester O
monoadduct O
C60 O
[ O
> O
M O
( O
t O
- O
Bu O
) O
2 O
] O
as O
the O
starting O
fullerene B
derivative O
to O
provide O
a O
better O
synthetic O
route O
to O
C60 O
[ O
> O
M O
( O
C3N6 O
( O
+ O
) O
C3 O
) O
2 O
] O
via O
transesterification O
reaction O
under O
trifluoroacetic B
acid I
catalyzed O
conditions O
. O

New O
series O
of O
[ O
1 O
, O
3 O
, O
4 O
] O
thiadiazolo O
[ O
3 O
, O
2 O
- O
a O
] O
pyrimidines O
, O
benzo O
[ O
h O
] O
[ O
1 O
, O
3 O
, O
4 O
] O
thiadiazolo O
[ O
2 O
, O
3 O
- O
b O
] O
quinazolines O
, O
benzothiadiazolotria O
, O
and O
imidazo O
[ O
2 O
, O
1 O
- O
b O
] O
[ O
1 O
, O
3 O
, O
4 O
] O
thiadiazoles O
have O
been O
synthesized O
and O
characterized O
by O
analytical O
and O
spectrometrical O
methods O
( O
IR O
, O
MS O
, O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
) O
. O

Characterization O
of O
all O
compounds O
was O
performed O
using O
one O
- O
dimensional O
NMR O
techniques O
( O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
- O
APT O
) O
, O
IR O
spectra O
, O
elemental O
analyses O
and O
high O
- O
resolution O
electrospray O
ionization O
mass O
spectrometry O
( O
HR O
- O
ESI O
- O
MS O
) O
. O

Isoflavone B
supplementation O
influenced O
levels O
of O
triglyceride B
and O
luteunizing O
hormone O
in O
Korean O
postmenopausal O
women O
. O

We O
conducted O
a O
double O
- O
blind O
, O
randomized O
, O
placebo O
- O
controlled O
trial O
to O
evaluate O
the O
effects O
of O
soy O
- O
derived O
isoflavone B
on O
blood O
glucose B
, O
lipid O
profiles O
, O
and O
sex O
hormones O
related O
to O
cardiovascular O
disease O
in O
Korean O
postmenopausal O
women O
. O

Subjects O
received O
either O
70 O
mg O
isoflavone B
or O
placebo O
capsules O
daily O
for O
12 O
weeks O
. O

As O
a O
result O
, O
the O
values O
of O
fasting O
glucose B
, O
insulin O
and O
HOMA O
- O
IR O
, O
as O
well O
as O
those O
of O
TC O
, O
LDL O
- O
C O
, O
HDL O
- O
C O
and O
FFA O
, O
were O
not O
different O
between O
the O
groups O
after O
supplementation O
. O

However O
, O
triglyceride B
( O
TG O
) O
levels O
in O
the O
treatment O
group O
decreased O
significantly O
compared O
with O
those O
of O
the O
placebo O
group O
( O
p O
= O
0 O
. O
0215 O
) O
. O

The O
levels O
of O
luteinizing O
hormone O
( O
LH O
) O
significantly O
decreased O
in O
the O
treatment O
group O
( O
p O
= O
0 O
. O
027 O
) O
; O
however O
, O
the O
levels O
of O
FSH O
, O
estrone B
and O
estradiol B
were O
not O
changed O
after O
intervention O
. O

In O
conclusion O
, O
isoflavone B
supplement O
of O
70 O
mg O
/ O
day O
for O
12 O
weeks O
decreased O
blood O
levels O
of O
TG O
and O
LH O
in O
Korean O
postmenopausal O
women O
. O

Arsenic B
speciation O
and O
spatial O
and O
interspecies O
differences O
of O
metal O
concentrations O
in O
mollusks O
and O
crustaceans O
from O
a O
South O
China O
estuary O
. O

Arsenic B
speciation O
and O
concentrations O
were O
determined O
in O
mollusks O
and O
crustaceans O
in O
the O
intertidal O
zone O
from O
twelve O
locations O
in O
Zhanjiang O
estuary O
, O
South O
China O
. O

Metal O
concentrations O
( O
Ag B
, O
As B
, O
Cd B
, O
Cu B
, O
Hg B
, O
Ni B
, O
Pb B
, O
and O
Zn B
) O
were O
also O
concurrently O
determined O
in O
these O
species O
. O

Arsenic B
speciation O
analysis O
showed O
that O
the O
less O
- O
toxic O
arsenobetaine O
( O
AsB O
) O
constituted O
80 O
. O
6 O
- O
98 O
. O
8 O
% O
of O
all O
As O
compounds O
, O
and O
dimethylarsinic B
acid I
( O
DMA O
) O
constituted O
0 O
. O
47 O
- O
3 O
. O
44 O
% O
. O

Monomethylarsonic B
acid I
( O
MMA O
) O
and O
As B
( I
V I
) I
were O
only O
detected O
in O
the O
whelk O
Drupa O
fiscella O
and O
the O
crab O
Heteropilumnus O
ciliatus O
, O
respectively O
. O

Arsenite B
[ O
As B
( I
III I
) I
] O
was O
not O
detected O
in O
any O
of O
the O
sampled O
specimens O
, O
but O
there O
were O
also O
unidentified O
other O
As B
species O
. O

Furthermore O
, O
As B
, O
Cd B
, O
Cu B
, O
Hg B
, O
and O
Pb B
contents O
in O
mollusks O
and O
crustacean O
samples O
were O
below O
the O
Food O
and O
Agricultural O
Organization O
( O
FAO O
) O
safe O
concentrations O
, O
thus O
there O
was O
no O
obvious O
health O
risk O
from O
the O
intake O
of O
the O
metals O
through O
marine O
mollusks O
and O
crustaceans O
consumption O
. O

Pharmacological O
inhibition O
of O
Eph O
receptors O
enhances O
glucose B
- O
stimulated O
insulin O
secretion O
from O
mouse O
and O
human O
pancreatic O
islets O
. O

AIMS O
/ O
HYPOTHESIS O
: O
Type O
2 O
diabetes O
is O
characterised O
by O
impaired O
glucose B
- O
stimulated O
insulin O
secretion O
( O
GSIS O
) O
from O
pancreatic O
islets O
. O

Since O
erythropoietin O
- O
producing O
hepatoma O
( O
Eph O
) O
- O
ephrin O
bidirectional O
signalling O
fine O
- O
tunes O
GSIS O
from O
pancreatic O
beta O
cells O
, O
we O
investigated O
Eph O
receptor O
tyrosine B
kinases O
( O
RTK O
) O
as O
potential O
drug O
targets O
for O
selectively O
increasing O
GSIS O
. O

Furthermore O
, O
the O
most O
potent O
inhibitor O
was O
injected O
into O
mice O
to O
evaluate O
its O
effects O
on O
glucose B
tolerance O
and O
plasma O
insulin O
levels O
. O

Finally O
, O
pharmacological O
inhibition O
of O
Eph O
receptor O
signalling O
improved O
glucose B
tolerance O
in O
mice O
. O

CONCLUSIONS O
/ O
INTERPRETATION O
: O
We O
showed O
for O
the O
first O
time O
that O
Eph O
RTKs O
represent O
targets O
for O
small O
molecules O
to O
selectively O
increase O
GSIS O
and O
improve O
glucose B
tolerance O
. O

The O
collagen O
content O
of O
the O
chondrocytes O
, O
determined O
as O
hydroxyproline B
, O
was O
measured O
by O
a O
colorimetry O
method O
. O

Effect O
of O
nicotine B
pretreatment O
on O
arsenic B
- O
induced O
oxidative O
stress O
in O
male O
Wistar O
rats O
. O

Humans O
are O
commonly O
exposed O
to O
nicotine B
, O
one O
of O
the O
most O
important O
lifestyle O
chemicals O
. O

The O
occurrence O
of O
high O
levels O
of O
arsenic B
in O
the O
groundwater O
of O
the O
southeast O
region O
of O
Asia O
has O
received O
much O
attention O
in O
the O
past O
decade O
and O
has O
become O
a O
global O
health O
concern O
. O

Predominant O
occurrence O
of O
both O
these O
chemicals O
and O
ease O
of O
their O
human O
exposure O
led O
us O
to O
investigate O
the O
effect O
of O
nicotine B
, O
a O
major O
tobacco O
alkaloid O
, O
on O
arsenic B
toxicity O
. O

Adult O
male O
rats O
were O
pre O
- O
exposed O
to O
two O
different O
doses O
of O
nicotine B
( O
0 O
. O
75 O
and O
3 O
mg O
/ O
kg O
, O
intraperitoneally O
) O
for O
7 O
days O
followed O
by O
30 O
days O
of O
arsenic B
exposure O
( O
50 O
ppm O
sodium B
arsenite I
in O
drinking O
water O
) O
. O

Nicotine B
pre O
- O
exposure O
resulted O
in O
an O
increased O
brain O
arsenic B
accumulation O
and O
a O
decreased O
liver O
arsenic B
concentration O
. O

Arsenic B
also O
caused O
a O
significant O
oxidative O
stress O
in O
the O
blood O
, O
brain O
and O
liver O
of O
the O
exposed O
rats O
. O

Glutathione B
- O
S B
- O
transferase O
, O
a O
phase O
II O
enzyme O
, O
was O
inhibited O
by O
both O
arsenic B
and O
nicotine B
but O
no O
such O
inhibition O
was O
noted O
in O
arsenic B
- O
treated O
animals O
pre O
- O
exposed O
to O
nicotine B
. O

Upon O
nicotine B
pre O
- O
exposure O
, O
brain O
acetylcholinesterase O
increased O
, O
while O
monoamine O
oxidase O
( O
MAO O
) O
decreased O
. O

The O
toxic O
effects O
of O
MAO O
significantly O
attenuated O
with O
nicotine B
pre O
- O
exposure O
. O

The O
present O
study O
suggests O
that O
nicotine B
may O
not O
be O
the O
major O
contributing O
factor O
for O
the O
previously O
reported O
synergistic O
toxic O
interaction O
between O
tobacco O
and O
arsenic B
. O

Nicotine B
pre O
- O
exposure O
in O
arsenic B
- O
exposed O
animals O
revealed O
interesting O
toxicokinetics O
and O
oxidative O
stress O
modulating O
interactions O
in O
the O
brain O
and O
liver O
of O
rats O
, O
which O
requires O
further O
exploration O
. O

We O
developed O
a O
computational O
model O
of O
the O
hypothalamic O
- O
pituitary O
- O
gonadal O
( O
HPG O
) O
axis O
in O
female O
fathead O
minnows O
to O
predict O
dose O
- O
response O
and O
time O
- O
course O
( O
DRTC O
) O
behaviors O
for O
endocrine O
effects O
of O
the O
aromatase O
inhibitor O
, O
fadrozole B
( O
FAD B
) O
. O

For O
model O
development O
, O
we O
used O
plasma O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
concentrations O
and O
ovarian O
cytochrome O
P450 O
( O
CYP O
) O
19A O
aromatase O
mRNA O
data O
from O
two O
time O
- O
course O
experiments O
, O
each O
of O
which O
included O
both O
an O
exposure O
and O
a O
depuration O
phase O
, O
and O
plasma O
E2 O
data O
from O
a O
third O
4 O
- O
day O
study O
. O

Model O
parameters O
were O
estimated O
using O
E2 O
concentrations O
for O
0 O
, O
0 O
. O
5 O
, O
and O
3 O
micro O
g O
/ O
l O
FAD B
exposure O
concentrations O
, O
and O
good O
fits O
to O
these O
data O
were O
obtained O
. O

The O
model O
accurately O
predicted O
CYP19A O
mRNA O
fold O
changes O
for O
controls O
and O
three O
FAD B
doses O
( O
0 O
, O
0 O
. O
5 O
, O
and O
3 O
micro O
g O
/ O
l O
) O
and O
plasma O
E2 O
dose O
response O
from O
the O
4 O
- O
day O
study O
. O

A O
novel O
nontoxic O
inhibitor O
of O
the O
activation O
of O
NADPH B
oxidase O
reduces O
reactive O
oxygen B
species O
production O
in O
mouse O
lung O
. O

Prdx6 O
PLA2 O
activity O
is O
required O
for O
activation O
of O
NADPH B
oxidase O
2 O
and O
subsequent O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Modeling O
ring O
/ O
chain O
equilibrium O
in O
nanoconfined O
sulfur B
. O

The O
effect O
of O
nanoconfinement O
on O
the O
thermodynamics O
of O
free O
radical O
polymerization O
of O
sulfur B
is O
examined O
. O

We O
extend O
Tobolsky O
and O
Eisenberg O
' O
s O
model O
of O
bulk O
sulfur B
polymerization O
to O
nanopores O
accounting O
for O
the O
confinement O
entropy O
of O
the O
chains O
and O
ring O
using O
scaling O
reported O
in O
literature O
. O

The O
model O
quantitatively O
captures O
literature O
data O
from O
Yannopoulos O
and O
co O
- O
workers O
for O
the O
extent O
of O
polymerization O
versus O
temperature O
for O
bulk O
sulfur B
polymerization O
and O
for O
polymerization O
in O
20 O
, O
7 O
. O
5 O
, O
and O
2 O
. O
5 O
nm O
diameter O
Gelsil O
nanopores O
, O
assuming O
that O
the O
change O
of O
entropy O
of O
nanoconfined O
chains O
scales O
with O
molecular O
size O
to O
the O
second O
power O
and O
with O
nanopore O
diameter O
to O
either O
the O
- O
3 O
. O
0 O
or O
- O
3 O
. O
8 O
power O
, O
the O
former O
of O
which O
fits O
slightly O
better O
. O

The O
fruits O
are O
an O
excellent O
source O
of O
health O
- O
related O
compounds O
, O
such O
as O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
carotenoids O
( O
provitamin O
A O
) O
, O
tocopherols B
( O
vitamin B
E I
) O
, O
flavonoids B
, O
and O
capsaicinoids O
. O

DNA O
Adducts O
in O
Aldehyde B
Dehydrogenase O
- O
Positive O
Lung O
Stem O
Cells O
of O
A O
/ O
J O
Mice O
Treated O
with O
the O
Tobacco O
Specific O
Lung O
Carcinogen O
4 O
- O
( O
Methylnitrosamino O
) O
- O
1 O
- O
( O
3 O
- O
pyridyl O
) O
- O
1 O
- O
butanone O
( O
NNK O
) O
. O

Aldehyde B
dehydrogenase O
( O
ALDH O
) O
is O
a O
marker O
of O
stem O
cells O
. O

The O
primary O
efficacy O
parameter O
was O
urinary O
deoxypyridinoline B
( O
DPYR O
) O
levels O
, O
and O
serum O
osteocalcin O
( O
OSC O
) O
, O
bone O
- O
specific O
alkaline O
phosphatase O
( O
BALP O
) O
, O
urinary O
cross O
- O
linked O
C B
- O
telopeptide O
of O
type O
- O
1 O
collagen O
( O
CTx O
) O
, O
urinary O
cross O
- O
linked O
N B
- O
telopeptide O
of O
type O
- O
1 O
collagen O
( O
NTx O
) O
, O
calcium B
( O
Ca B
) O
, O
and O
phosphorus B
( O
P B
) O
levels O
, O
which O
were O
evaluated O
for O
comparison O
before O
and O
after O
administration O
of O

The O
values O
of O
blood O
OSC O
, O
BALP O
, O
serum O
Ca B
, O
and O
serum O
P B
from O
baseline O
to O
4 O
weeks O
of O
treatment O
were O
changed O
by O
- O
28 O
. O
44 O
% O
, O
14 O
. O
37 O
% O
, O
6 O
. O
11 O
% O
, O
and O
1 O
. O
42 O
% O
, O
respectively O
. O

Biomarkers O
of O
bone O
resorption O
: O
urinary O
DPYR O
, O
serum O
CTx O
, O
serum O
NTx O
, O
urinary O
Ca B
, O
and O
urinary O
P B
, O
at O
baseline O
after O
4 O
weeks O
of O
treatment O
were O
changed O
by O
- O
13 O
. O
40 O
% O
, O
6 O
. O
67 O
% O
, O
- O
5 O
. O
13 O
% O
, O
- O
22 O
. O
43 O
% O
, O
and O
- O
3 O
. O
04 O
% O
, O
respectively O
. O

A O
crystal O
structure O
of O
BMS O
- O
593214 O
bound O
to O
FVIIa O
highlights O
key O
contacts O
with O
Asp B
189 O
, O
Lys B
192 O
, O
and O
the O
S2 O
pocket O
. O

Rab12 O
regulates O
mTORC1 O
activity O
and O
autophagy O
through O
controlling O
the O
degradation O
of O
amino B
- I
acid I
transporter O
PAT4 O
. O

Here O
, O
we O
report O
small O
GTPase O
Rab12 O
as O
a O
new O
type O
of O
autophagic O
regulator O
that O
controls O
the O
degradation O
of O
an O
amino B
- I
acid I
transporter O
. O

Knockdown O
of O
Rab12 O
results O
in O
inhibition O
of O
autophagy O
and O
in O
increased O
activity O
of O
mTORC1 O
( O
mammalian O
/ O
mechanistic O
target O
of O
rapamycin B
complex O
1 O
) O
, O
an O
upstream O
regulator O
of O
autophagy O
. O

We O
also O
found O
that O
Rab12 O
promotes O
constitutive O
degradation O
of O
PAT4 O
( O
proton O
- O
coupled O
amino B
- I
acid I
transporter O
4 O
) O
, O
whose O
accumulation O
in O
Rab12 O
- O
knockdown O
cells O
modulates O
mTORC1 O
activity O
and O
autophagy O
. O

Benzoquinone B
Reveals O
a O
Cysteine B
- O
Dependent O
Desensitization O
Mechanism O
of O
TRPA1 O
. O

Electrophilic O
chemicals O
activate O
both O
insect O
and O
vertebrate O
TRPA1 O
via O
covalent O
modification O
of O
cysteine B
residues O
in O
the O
amino B
- O
terminal O
region O
. O

Although O
naturally O
occurring O
electrophilic O
plant O
compounds O
, O
such O
as O
mustard O
oil O
and O
cinnamaldehyde B
, O
are O
TRPA1 O
agonists O
, O
it O
is O
unknown O
whether O
arthropod O
- O
produced O
electrophiles O
activate O
mammalian O
TRPA1 O
. O

We O
used O
whole O
- O
cell O
recordings O
of O
human O
embryonic O
kidney O
cells O
heterologously O
expressing O
either O
wild O
- O
type O
TRPA1 O
or O
TRPA1 O
with O
three O
serine B
- O
substituted O
cysteines B
crucial O
for O
electrophile O
activation O
( O
C621S O
, O
C641S O
, O
C665S O
) O
. O

Activation O
by O
pBQN O
required O
reactivity O
with O
cysteine B
residues O
, O
but O
ones O
that O
are O
distinct O
from O
those O
previously O
reported O
to O
be O
the O
key O
targets O
of O
electrophiles O
. O

The O
cysteines B
required O
for O
desensitization O
are O
not O
accessible O
to O
all O
electrophiles O
as O
iodoacetamide O
and O
internally O
applied O
2 O
- O
( O
trimethylammonium O
) O
ethyl O
methanesulfonate O
failed O
to O
cause O
desensitization O
( O
despite O
large O
activation O
) O
. O

Interestingly O
, O
following O
pBQN O
desensitization O
, O
wild O
- O
type O
TRPA1 O
had O
dramatically O
reduced O
response O
to O
the O
nonelectrophile O
agonist O
carvacrol B
, O
whereas O
the O
triple O
cysteine B
mutant O
TRPA1 O
retained O
its O
full O
response O
. O

Our O
results O
suggest O
that O
modification O
of O
multiple O
cysteine B
residues O
by O
electrophilic O
compounds O
can O
generate O
both O
activation O
and O
desensitization O
of O
the O
TRPA1 O
channel O
. O

Furthermore O
, O
we O
examine O
the O
inhibitory O
effects O
of O
isopropyl B
- I
beta I
- I
d I
- I
thiogalactopyranosid I
( O
IPTG B
) O
on O
beta O
- O
galactosidase O
. O

A O
study O
of O
parabens B
and O
bisphenol B
A I
in O
surface O
water O
and O
fish O
brain O
tissue O
from O
the O
Greater O
Pittsburgh O
Area O
. O

BPA B
was O
detected O
between O
0 O
. O
6 O
and O
15 O
. O
4 O
ppt O
. O

Estrogenic O
potential O
of O
extracts O
from O
fish O
brain O
tissue O
was O
tested O
via O
Bromodeoxyuridine B
MCF O
- O
7 O
analysis O
and O
paired O
with O
HPLC O
- O
MS O
to O
investigate O
the O
presence O
of O
xenoestrogens O
. O

BPA B
was O
detected O
in O
44 O
of O
the O
58 O
samples O
, O
with O
a O
range O
from O
non O
- O
detectable O
to O
120 O
pg O
/ O
g O
. O

Results O
were O
statistically O
significant O
for O
location O
of O
capture O
( O
p O
< O
0 O
. O
05 O
) O
and O
correlation O
existed O
between O
estrogenicity O
and O
BPA B
. O

Sulfide B
induces O
apoptosis O
and O
Rho O
kinase O
- O
dependent O
cell O
blebbing O
in O
Jurkat O
cells O
. O

Hydrogen B
sulfide I
( O
H2S O
) O
is O
a O
toxic O
gaseous O
substance O
, O
and O
accidental O
exposure O
to O
high O
concentrations O
of O
H2S O
has O
been O
reported O
to O
be O
lethal O
to O
humans O
. O

In O
this O
study O
, O
we O
examined O
the O
cellular O
uptake O
and O
injury O
of O
sulfide B
- O
exposed O
human O
T O
lymphocytes O
( O
Jurkat O
) O
. O

Cells O
were O
exposed O
to O
a O
H2S O
donor O
, O
sodium O
hydroxysulfide O
( O
NaHS B
) O
, O
at O
pH O
6 O
. O
0 O
, O
7 O
. O
0 O
, O
or O
8 O
. O
0 O
for O
1 O
h O
at O
37 O
degrees O
C O
in O
a O
sealed O
conical O
tube O
to O
avoid O
the O
loss O
of O
dissolved O
H2S O
gas O
. O

Cytotoxicity O
and O
cellular O
sulfide B
concentrations O
increased O
dramatically O
as O
the O
pH O
of O
the O
NaHS B
solution O
decreased O
. O

Sulfide B
enhanced O
the O
cleavage O
of O
caspase O
- O
3 O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
induced O
early O
cellular O
apoptosis O
. O

A O
pan O
- O
caspase O
inhibitor O
reduced O
sulfide B
- O
induced O
apoptosis O
. O

These O
results O
indicate O
that O
sulfide B
induces O
pH O
- O
dependent O
and O
caspase O
- O
dependent O
apoptosis O
. O

We O
also O
found O
that O
blebbing O
of O
the O
plasma O
membrane O
occurred O
in O
sulfide B
- O
exposed O
cells O
. O

Both O
ROCK O
- O
1 O
and O
ROCK O
- O
2 O
( O
Rho O
kinases O
) O
were O
activated O
by O
sulfide B
, O
and O
sulfide B
- O
induced O
cell O
blebbing O
was O
suppressed O
by O
a O
ROCK O
inhibitor O
, O
suggesting O
that O
a O
Rho O
pathway O
is O
involved O
in O
sulfide B
- O
induced O
blebbing O
in O
lymphocytes O
. O

Association O
Between O
Lipids O
, O
Lipoproteins O
Composition O
of O
HDL O
Particles O
and O
Triglyceride B
- O
Rich O
Lipoproteins O
, O
and O
LCAT O
and O
CETP O
Activity O
in O
Post O
- O
renal O
Transplant O
Patients O
. O

High O
- O
density O
lipoprotein O
( O
HDL O
) O
remodeling O
within O
the O
plasma O
compartment O
and O
the O
association O
between O
lecithin O
- O
cholesterol B
acyltransferase O
( O
LCAT O
) O
and O
cholesterol B
ester I
transfer O
protein O
( O
CETP O
) O
activity O
, O
and O
lipid O
, O
lipoprotein O
concentrations O
and O
composition O
were O
investigated O
. O

Tx O
patients O
had O
moderate O
hypertriglyceridemia O
, O
hypercholesterolemia O
, O
and O
dyslipoproteinemia O
, O
disturbed O
triglyceride B
- O
rich O
lipoproteins O
( O
TRLs O
) O
and O
HDL O
composition O
, O
decreased O
LCAT O
, O
and O
slightly O
increased O
hsCRP O
but O
no O
CETP O
activity O
. O

Tx O
patients O
without O
statin B
and O
with O
lower O
triglycerides B
but O
higher O
HDL O
cholesterol B
concentration O
and O
disturbed O
lipoprotein O
composition O
of O
ApoAI O
and O
apoAII O
in O
HDL O
particle O
can O
decrease O
LCAT O
, O
increase O
LDL O
cholesterol B
, O
aggravate O
renal O
graft O
, O
and O
accelerate O
atherosclerosis O
and O
chronic O
heart O
diseases O
. O

Quercetin B
mitochondriotropic O
derivatives O
antagonize O
nitrate B
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

The O
natural O
flavonoid O
quercetin B
has O
been O
shown O
to O
counteract O
the O
development O
of O
glyceryl O
trinitrate O
tolerance O
in O
vitro O
. O

Two O
mitochondriotropic O
, O
4 O
- O
O O
- O
triphenylphosphonium O
derivatives O
of O
quercetin B
( O
QTA O
- O
3BTPI O
and O
Q O
- O
3BTPI O
) O
were O
compared O
to O
quercetin B
for O
protection O
against O
glyceryl O
trinitrate O
- O
induced O
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

Both O
QTA O
- O
3BTPI O
and O
Q O
- O
3BTPI O
significantly O
counteracted O
the O
reduced O
vascular O
responsiveness O
to O
both O
glyceryl O
trinitrate O
and O
acetylcholine B
caused O
by O
prolonged O
exposure O
of O
the O
vessel O
to O
glyceryl O
trinitrate O
itself O
, O
their O
potency O
being O
much O
greater O
than O
that O
of O
quercetin B
. O

Since O
Q O
- O
3BTPI O
antagonized O
in O
vitro O
nitrate B
tolerance O
and O
endothelial O
dysfunction O
of O
vessels O
, O
this O
encourages O
assessing O
whether O
this O
effect O
is O
displayed O
also O
in O
vivo O
during O
long O
- O
term O
glyceryl O
trinitrate O
treatment O
. O

Phytochemical O
investigation O
of O
the O
aerial O
parts O
of O
Prinsepia O
utilis O
Royle O
resulted O
in O
the O
isolation O
and O
identification O
of O
ten O
pentacyclic O
triterpenoids O
, O
including O
two O
new O
triterpenoids B
, O
2 O
alpha O
- O
O O
- O
trans O
- O
p O
- O
coumaroyl O
- O
3 O
beta O
, O
19 O
alpha O
- O
dihydroxy O
- O
urs O
- O
12 O
- O
en O
- O
28 O
- O
oic O
acid O
( O
1 O
) O
and O
2 O
alpha O
- O
O O
- O
cis O
- O
p O
- O
coumaroyl O
- O
3 O
beta O
, O
19 O
alpha O
- O
dihydroxy O
- O
urs O
- O
12 O
- O
en O
- O
28 O
- O

The O
main O
classes O
of O
phytoestrogens O
are O
flavonoids B
( O
flavonols B
, O
flavanones B
) O
, O
isoflavonoids B
( O
isoflavones B
, O
coumestans O
) O
, O
lignans B
, O
stilbenoids O
as O
well O
as O
miscellaneous O
chemical O
groups O
abundant O
in O
several O
edible O
and O
/ O
or O
medicinal O
plants O
, O
belonging O
mostly O
to O
the O
Leguminosae O
family O
. O

Novel O
- O
type O
serine B
- O
synthesizing O
enzymes O
, O
termed O
metal O
- O
independent O
phosphoserine O
phosphatases O
( O
iPSPs O
) O
, O
were O
recently O
identified O
and O
characterized O
from O
Hydrogenobacter O
thermophilus O
, O
a O
chemolithoautotrophi O
bacterium O
belonging O
to O
the O
order O
Aquificales O
. O

iPSPs O
are O
cofactor O
- O
dependent O
phosphoglycerate O
mutase O
( O
dPGM O
) O
- O
like O
phosphatases O
that O
have O
significant O
amino B
acid I
sequence O
similarity O
to O
dPGMs O
but O
lack O
phosphoglycerate O
mutase O
activity O
. O

Structural O
and O
biochemical O
characterization O
of O
iPSP1 O
revealed O
that O
the O
side O
chains O
of O
His B
( O
85 O
) O
and O
C B
- O
terminal O
region O
characteristic O
of O
iPSP1 O
are O
responsible O
for O
the O
PSP O
activity O
. O

We O
anticipate O
that O
our O
present O
findings O
will O
facilitate O
understanding O
of O
the O
serine B
biosynthesis O
pathways O
of O
organisms O
that O
lack O
gene O
( O
s O
) O
encoding O
conventional O
PSPs O
, O
as O
the O
structural O
information O
revealed O
here O
will O
help O
to O
identify O
iPSP O
from O
sequence O
databases O
. O

N O
- O
[ O
9 O
- O
( O
ortho O
- O
Fluorobenzyl O
) O
- O
2 O
- O
Phenyl O
- O
8 O
- O
Azapurin O
- O
6 O
- O
yl O
] O
- O
Amides O
as O
Potent O
and O
Selective O
Ligands O
for O
A1 O
Adenosine B
Receptors O
. O

A O
series O
of O
N O
- O
[ O
9 O
- O
( O
ortho O
- O
fluorobenzyl O
) O
- O
2 O
- O
phenyl O
- O
8 O
- O
azapurin O
- O
6 O
- O
yl O
] O
- O
amides O
were O
synthesised O
and O
tested O
for O
their O
affinity O
toward O
A1 O
, O
A2A O
and O
A3 O
adenosine B
receptor O
subtypes O
. O

Biological O
results O
demonstrated O
that O
the O
introduction O
of O
a O
fluorine B
atom O
at O
the O
ortho O
position O
of O
the O
9 O
- O
benzyl O
group O
generally O
enhanced O
affinity O
toward O
A1 O
subtype O
and O
did O
not O
significantly O
affect O
A2A O
and O
A3 O
affinity O
. O

Very O
interesting O
is O
the O
compound O
bearing O
a O
meta O
- O
fluorophenyl O
substituent O
on O
the O
carbonyl O
carbon O
of O
the O
amide B
group O
, O
which O
shows O
significantly O
high O
A1 O
/ O
A2A O
- O
A3 O
selectivity O
. O

Compounds O
of O
this O
new O
series O
, O
together O
with O
the O
previously O
published O
analogs O
without O
the O
fluorine B
atom O
on O
the O
9 O
- O
benzyl O
group O
, O
constituted O
the O
starting O
dataset O
for O
the O
development O
of O
QSAR O
models O
. O

The O
models O
obtained O
were O
able O
to O
rationally O
describe O
the O
affinity O
trends O
resulting O
from O
biological O
testing O
, O
and O
to O
enable O
investigation O
of O
the O
role O
of O
different O
substituents O
on O
the O
8 O
- O
azapurine O
scaffold O
, O
as O
well O
as O
the O
influence O
of O
the O
newly O
introduced O
fluorine B
atom O
on O
the O
benzyl B
moiety O
. O

The O
said O
QSAR O
models O
can O
also O
assist O
in O
the O
design O
of O
new O
compounds O
selectively O
active O
on O
A1 O
adenosine B
receptors O
. O

Furthermore O
, O
a O
molecular O
docking O
study O
was O
carried O
out O
in O
order O
to O
assess O
hypothetical O
binding O
mode O
of O
N O
- O
[ O
9 O
- O
( O
ortho O
- O
fluorobenzyl O
) O
- O
2 O
- O
phenyl O
- O
8 O
- O
azapurin O
- O
6 O
- O
yl O
] O
- O
amides O
to O
A1 O
adenosine B
receptors O
. O

Physicochemical O
Properties O
and O
Supernucleophilicity O
of O
Oxime B
- O
Functionalized O
Surfactants O
: O
Hydrolytic O
Catalysts O
toward O
Dephosphorylation O
of O
Di O
- O
and O
Triphosphate O
Esters O
. O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime B
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 O
- O
hydroxyiminomethyl O
- O
1 O
- O
alkylpyridinium O
bromide O
( O
alkyl B
= O
CnH2n O
+ O
1 O
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate O
esters O
, O
p O
- O
nitrophenyl O
diphenyl O
phosphate O
( O
PNPDPP O
) O
and O
bis O
( O
2 O
, O
4 O
- O
dinitrophenyl O
) O
phosphate O
( O

Acid O
dissociation O
constants O
( O
pKa O
) O
were O
determined O
, O
the O
effect O
of O
functional O
surfactant O
alkyl B
chain O
length O
and O
pH O
on O
the O
observed O
rate O
constant O
( O
kobs O
) O
for O
phosphate B
ester I
cleavage O
has O
been O
discussed O
, O
and O
the O
effect O
of O
substrate O
on O
the O
supernucleophiliciti O
of O
the O
studied O
oximes B
was O
monitored O
. O

Functionalized O
oxime B
- O
based O
surfactants O
were O
proved O
to O
be O
supernucleophiles O
to O
attack O
on O
the O
P B
= I
O I
center O
of O
tri O
- O
and O
diphosphate O
esters O
. O

Oximes B
with O
hexadecyl O
alkyl B
chain O
length O
( O
3 O
- O
C16 O
) O
showed O
maximum O
micellar O
effect O
on O
the O
rate O
constants O
toward O
PNPDPP O
. O

The O
approach O
is O
designed O
on O
the O
basis O
of O
the O
key O
regioselective O
Diels O
- O
Alder O
reaction O
of O
the O
properly O
substituted O
exo O
- O
2 O
- O
oxazolidinone O
diene O
3 O
with O
acrolein B
( O
4 O
) O
to O
give O
the O
corresponding O
adduct O
2 O
. O

The O
latter O
is O
converted O
to O
functionalised O
diarylamine O
8 O
, O
which O
is O
cyclised O
to O
the O
desired O
carbazole O
1 O
through O
a O
Pd B
- O
promoted O
or O
- O
catalysed O
double O
C B
- I
H I
bond O
activation O
process O
in O
a O
fairly O
good O
overall O
yield O
. O

Free O
fatty B
acid I
binding O
protein O
- O
4 O
and O
retinol B
binding O
protein O
- O
4 O
in O
polycystic O
ovary O
syndrome O
: O
response O
to O
simvastatin B
and O
metformin B
therapies O
. O

Abstract O
Free O
fatty B
acid I
binding O
protein O
- O
4 O
( O
FABP4 O
) O
and O
retinol B
binding O
protein O
- O
4 O
( O
RBP4 O
) O
contribute O
to O
metabolic O
syndrome O
. O

Sixty O
- O
two O
healthy O
, O
untreated O
women O
with O
PCOS O
( O
age O
25 O
. O
1 O
+ O
/ O
- O
3 O
. O
6 O
years O
, O
BMI O
: O
24 O
. O
0 O
+ O
/ O
- O
4 O
. O
7 O
kg O
/ O
m O
( O
2 O
) O
) O
were O
randomized O
to O
metformin B
( O
n O
= O
24 O
) O
, O
simvastatin B
( O
n O
= O
20 O
) O
or O
metformin B
plus O
simvastatin B
( O
n O
= O
18 O
) O
for O
3 O
months O
. O

Anthropometric O
measures O
, O
fasting O
blood O
tests O
and O
oral O
glucose B
tolerance O
tests O
( O
OGTT O
) O
were O
obtained O
at O
the O
baseline O
and O
the O
end O
. O

r O
= O
0 O
. O
23 O
, O
p O
= O
0 O
. O
03 O
; O
SHBG O
: O
r O
= O
- O
0 O
. O
28 O
, O
p O
= O
0 O
. O
03 O
) O
; O
while O
RBP4 O
correlated O
with O
total O
- O
cholesterol B
( O
r O
= O
0 O
. O
33 O
, O
p O
= O
0 O
. O
009 O
) O
. O

Multiple O
regression O
analysis O
indicated O
that O
t O
best O
predictors O
of O
serum O
FABP4 O
and O
RBP4 O
were O
BMI O
( O
beta O
= O
1 O
. O
02 O
, O
p O
= O
0 O
. O
0003 O
) O
and O
total O
cholesterol B
( O
beta O
= O
2326 O
, O
p O
= O
0 O
. O
01 O
) O
, O
respectively O
. O

Simvastatin B
, O
alone O
or O
with O
metformin B
did O
not O
affect O
serum O
FABP4 O
or O
RBP4 O
. O

Efficient O
MRI O
labeling O
of O
endothelial O
progenitor O
cells O
: O
Design O
of O
thiolated O
surface O
stabilized O
superparamagnetic O
iron B
oxide I
nanoparticles O
. O

The O
aim O
of O
this O
study O
was O
to O
design O
thiolated O
surface O
stabilized O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
TSS O
- O
SPIONs O
) O
for O
efficient O
internalization O
with O
high O
MRI O
sensitivity O
. O

TSS O
- O
SPIONs O
were O
developed O
by O
chelation O
between O
thiolated O
chitosan O
- O
thioglycolic O
acid O
( O
chitosan O
- O
TGA O
) O
hydrogel O
and O
iron B
ions O
( O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
) O
. O

Moreover O
, O
TSS O
- O
SPIONs O
were O
investigated O
regarding O
to O
their O
iron B
core O
size O
, O
hydrodynamic O
diameter O
, O
zeta O
potential O
, O
iron B
contents O
, O
molar O
relaxivities O
( O
r1 O
and O
r2 O
) O
, O
and O
cellular O
internalization O
. O

TSS O
- O
SPIONs O
demonstrated O
an O
iron B
oxide I
core O
diameter O
( O
crystallite O
size O
by O
XRD O
) O
of O
3 O
. O
1 O
+ O
/ O
- O
0 O
. O
02nm O
, O
a O
hydrodynamic O
diameter O
of O
94 O
+ O
/ O
- O
20nm O
, O
a O
zeta O
potential O
of O
+ O
21 O
+ O
/ O
- O
5mV O
, O
and O
an O
iron B
content O
of O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
9mg O
/ O
mL O
. O

With O
twofold O
lower O
incubation O
iron B
concentration O
of O
TSS O
- O
SPIONs O
, O
more O
than O
threefold O
higher O
internalization O
was O
achieved O
as O
compared O
to O
Resovist O
( O
R O
) O
. O

Dilysine O
motif O
recognition O
involves O
lysine B
side O
- O
chain O
interactions O
with O
two O
acidic O
patches O
. O

Surprisingly O
, O
however O
, O
KKxx O
and O
KxKxx O
motifs O
bind O
differently O
, O
with O
their O
lysine B
residues O
transposed O
at O
the O
binding O
patches O
. O

We O
derive O
rules O
for O
retrieval O
motif O
recognition O
from O
key O
structural O
features O
: O
the O
reversed O
binding O
modes O
, O
the O
recognition O
of O
the O
C B
- O
terminal O
carboxylate B
group O
which O
enforces O
lysine B
positional O
context O
, O
and O
the O
tolerance O
of O
the O
acidic O
patches O
for O
non O
- O
lysine B
residues O
. O

Generated O
toxicophore O
models O
showed O
four O
important O
features O
responsible O
for O
basal O
cytotoxicity O
: O
( O
i O
) O
two O
hydrophobic O
aliphatic O
groups O
( O
HYD O
Aliphatic O
) O
, O
( O
ii O
) O
ring O
aromatic O
group O
( O
RA O
) O
and O
( O
iii O
) O
hydrogen B
bond O
donor O
( O
HBD O
) O
. O

Testosterone B
modulates O
spatial O
recognition O
memory O
in O
male O
rats O
. O

A O
growing O
body O
of O
research O
indicates O
that O
testosterone B
influences O
spatial O
cognition O
in O
male O
rats O
; O
however O
, O
the O
overwhelming O
majority O
of O
studies O
have O
been O
conducted O
on O
tasks O
motivated O
by O
either O
food O
deprivation O
or O
water O
escape O
. O

The O
hippocampus O
- O
dependent O
version O
of O
the O
Y O
- O
maze O
task O
, O
which O
characterizes O
spatial O
recognition O
memory O
, O
capitalizes O
on O
the O
propensity O
of O
rats O
to O
gravitate O
toward O
novel O
spatial O
environments O
and O
is O
not O
contingent O
upon O
either O
appetite O
or O
the O
stress O
associated O
with O
water O
escape O
, O
two O
factors O
also O
affected O
by O
testosterone B
. O

Accordingly O
, O
the O
aim O
of O
the O
current O
study O
was O
to O
examine O
the O
effects O
of O
orchidectomy O
and O
subsequent O
testosterone B
treatment O
on O
spatial O
recognition O
memory O
. O

Alternatively O
, O
on O
the O
second O
Y O
- O
maze O
task O
, O
which O
featured O
a O
48 O
- O
h O
delay O
between O
trials O
, O
orchidectomy O
reduced O
, O
and O
treatments O
that O
produced O
higher O
levels O
of O
testosterone B
restored O
, O
preference O
for O
the O
arm O
associated O
with O
the O
novel O
spatial O
environment O
. O

Importantly O
, O
there O
were O
no O
differences O
in O
activity O
levels O
as O
a O
function O
of O
orchidectomy O
or O
testosterone B
treatment O
on O
either O
of O
the O
two O
tasks O
. O

Consistent O
with O
previous O
findings O
, O
orchidectomy O
attenuated O
, O
and O
testosterone B
treatment O
restored O
, O
both O
body O
weight O
gain O
and O
the O
relative O
weight O
of O
the O
androgen B
- O
sensitive O
ischiocavernosus O
muscle O
, O
which O
confirmed O
the O
efficacy O
of O
orchidectomy O
and O
testosterone B
treatments O
on O
physiological O
outcomes O
. O

Therefore O
, O
testosterone B
influenced O
spatial O
cognition O
on O
a O
task O
that O
minimized O
the O
influence O
of O
non O
- O
mnemonic O
factors O
and O
took O
advantage O
of O
the O
innate O
preference O
of O
rodents O
to O
seek O
out O
novel O
spatial O
environments O
. O

In O
vitro O
and O
in O
vivo O
, O
LIN28 O
preferentially O
bound O
single O
- O
stranded O
RNA O
containing O
a O
uridine B
- O
rich O
element O
and O
one O
or O
more O
flanking O
guanosines O
and O
appeared O
to O
be O
able O
to O
disrupt O
base O
- O
pairing O
to O
access O
these O
elements O
when O
embedded O
in O
predicted O
secondary O
structure O
. O

Novel O
tacrine B
- O
related O
drugs O
as O
potential O
candidates O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

A O
summary O
of O
the O
recently O
published O
efforts O
on O
tacrine B
derivatives O
as O
a O
renewed O
potential O
therapeutic O
approach O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
is O
presented O
. O

An O
unexpected O
trans O
- O
cis O
isomerization O
is O
observed O
during O
Hg B
/ O
Al B
reduction O
of O
the O
1 O
- O
pyrazoline O
NN O
bond O
. O

Glutamate B
receptor O
binding O
assays O
revealed O
that O
the O
azakaniod O
has O
a O
moderate O
affinity O
for O
unspecified O
glutamate B
receptors O
. O

Membrane O
depolarization O
of O
Aplysia O
neurons O
upon O
application O
of O
the O
azakainoid O
demonstrates O
that O
it O
is O
an O
ionotropic O
glutamate B
receptor O
agonist O
. O

Demonstration O
of O
a O
sucrose B
- O
derived O
contrast O
agent O
for O
magnetic O
resonance O
imaging O
of O
the O
GI O
tract O
. O

A O
scaffold O
bearing O
eight O
terminal O
alkyne B
groups O
was O
synthesized O
from O
sucrose B
, O
and O
copies O
of O
an O
azide B
- O
terminated O
Gd O
- O
DOTA O
complex O
were O
attached O
via O
copper B
( I
I I
) I
- O
catalyzed O
azide B
- I
alkyne I
cycloaddition O
. O

Cytotoxic O
and O
Anti O
- O
Inflammatory O
Eunicellin O
- O
Based O
Diterpenoids B
from O
the O
Soft O
Coral O
Cladiella O
krempfi O
. O

Five O
new O
eunicellin O
- O
based O
diterpenoids B
, O
krempfielins O
E O
- O
I O
( O
1 O
- O
5 O
) O
and O
seven O
known O
compounds O
( O
6 O
- O
12 O
) O
were O
isolated O
from O
the O
organic O
extract O
of O
a O
Taiwanese O
soft O
coral O
Cladiella O
krempfi O
. O

Sorafenib O
is O
an O
orally O
active O
tyrosine B
kinase O
inhibitor O
used O
in O
the O
treatment O
of O
renal O
and O
hepatocellular O
carcinoma O
. O

Hepatocyte O
uptake O
of O
[ O
( O
14 O
) O
C O
] O
sorafenib O
was O
not O
Na B
( I
+ I
) I
- O
dependent O
or O
influenced O
by O
the O
organic O
anion O
transporter O
2 O
( O
OAT2 O
) O
inhibitor O
ketoprofen B
. O

[ O
( O
14 O
) O
C O
] O
Sorafenib O
( O
0 O
. O
5 O
to O
5 O
mu O
M O
) O
uptake O
was O
significantly O
higher O
in O
hOCT1 O
- O
transfected O
CHO O
cells O
compared O
to O
mock O
cells O
, O
and O
inhibited O
by O
the O
general O
OCT O
inhibitor O
, O
MPP B
( I
+ I
) I
. O

Enhanced O
photovoltaic O
performance O
of O
a O
dye O
- O
sensitized O
solar O
cell O
using O
graphene B
- O
TiO2 B
photoanode O
prepared O
by O
a O
novel O
in O
situ O
simultaneous O
reduction O
- O
hydrolysis O
technique O
. O

Enhanced O
photovoltaic O
performance O
of O
a O
DSSC O
using O
graphene B
- O
TiO2 B
photoelectrodes O
prepared O
by O
our O
recent O
in O
situ O
simultaneous O
reduction O
- O
hydrolysis O
technique O
( O
Adv O
. O
Funct O
. O
Mater O
. O
, O
2012 O
, O
DOI O
: O
10 O
. O
1002 O
/ O
adfm O
. O
201202349 O
, O
in O
press O
) O
was O
achieved O
. O

The O
results O
prove O
that O
the O
promoting O
effect O
of O
graphene B
is O
strongly O
dependent O
on O
its O
content O
; O
namely O
, O
the O
efficiency O
of O
DSSCs O
increases O
and O
then O
decreases O
with O
increasing O
graphene B
content O
in O
TiO2 B
- O
graphene B
composites O
. O

Excessive O
graphene B
in O
the O
nanocomposite O
leads O
to O
a O
decrease O
of O
the O
light O
harvest O
of O
dye O
molecules O
and O
thus O
a O
negative O
effect O
on O
the O
power O
conversion O
efficiency O
of O
DSSCs O
. O

Effects O
of O
treatment O
with O
a O
carbon B
monoxide I
- O
releasing O
molecule O
and O
a O
heme O
oxygenase O
1 O
inducer O
in O
the O
antinociceptive O
effects O
of O
morphine B
in O
different O
models O
of O
acute O
and O
chronic O
pain O
in O
mice O
. O

RATIONALE O
: O
Treatment O
with O
a O
carbon B
monoxide I
- O
releasing O
molecule O
( O
tricarbonyldichloror O
( O
II O
) O
dimer O
, O
CORM O
- O
2 O
) O
or O
a O
classical O
heme O
oxygenase O
1 O
inducer O
( O
cobalt O
protoporphyrin O
IX O
, O
CoPP B
) O
has O
potent O
anti O
- O
inflammatory O
effects O
, O
but O
the O
role O
played O
by O
these O
treatments O
in O
the O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
chronic O
pain O
was O
not O
evaluated O
. O

OBJECTIVES O
: O
In O
wild O
type O
( O
WT O
) O
, O
neuronal O
( O
NOS1 O
- O
KO O
) O
, O
or O
inducible O
( O
NOS2 O
- O
KO O
) O
nitric B
oxide I
synthases O
knockout O
mice O
, O
we O
evaluated O
the O
effects O
of O
CORM O
- O
2 O
and O
CoPP B
treatments O
in O
the O
antinociceptive O
actions O
of O
morphine B
and O
their O
interaction O
with O
nitric B
oxide I
during O
acute O
, O
visceral O
, O
and O
chronic O
inflammatory O
or O
neuropathic O
pain O
. O

METHODS O
: O
Acute O
and O
visceral O
pain O
was O
assessed O
through O
formalin B
and O
acid O
acetic O
writhing O
tests O
. O

RESULTS O
: O
While O
nitric B
oxide I
, O
synthetized O
by O
NOS1 O
and O
/ O
or O
NOS2 O
, O
increased O
the O
local O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
chronic O
pain O
, O
it O
decreased O
the O
inhibitory O
effects O
of O
morphine B
after O
visceral O
pain O
. O

Moreover O
, O
while O
CORM O
- O
2 O
or O
CoPP B
treatments O
did O
not O
alter O
or O
reduced O
the O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
visceral O
pain O
, O
both O
treatments O
improved O
the O
local O
antiallodynic O
and O
antihyperalgesic O
effects O
of O
morphine B
after O
chronic O
inflammatory O
or O
neuropathic O
pain O
in O
WT O
, O
but O
not O
in O
KO O
mice O
. O

CONCLUSIONS O
: O
CORM O
- O
2 O
and O
CoPP B
treatments O
improved O
the O
local O
antinociceptive O
effects O
of O
morphine B
during O
chronic O
inflammatory O
and O
neuropathic O
pain O
by O
interaction O
with O
nitric B
oxide I
synthetized O
by O
NOS1 O
and O
NOS2 O
isoforms O
. O

Paclitaxel B
is O
an O
inhibitor O
and O
its O
boron O
dipyrromethene O
derivative O
is O
a O
fluorescent O
recognition O
agent O
for O
botulinum O
neurotoxin O
subtype O
a O
. O

Two O
new O
metabolites O
, O
embellicines O
A O
and O
B O
( O
1 O
and O
2 O
) O
, O
were O
isolated O
from O
the O
EtOAc B
extract O
of O
the O
fungus O
Embellisia O
eureka O
, O
an O
endophyte O
of O
the O
Moroccan O
plant O
Cladanthus O
arabicus O
( O
Asteraceae O
) O
. O

Tin O
- O
coated O
viral O
nanoforests O
as O
sodium B
- O
ion O
battery O
anodes O
. O

Designed O
as O
a O
high O
- O
capacity O
alloy O
host O
for O
Na B
- O
ion O
chemistry O
, O
a O
forest O
of O
Sn B
nanorods O
with O
a O
unique O
core O
- O
shell O
structure O
was O
synthesized O
on O
viral O
scaffolds O
, O
which O
were O
genetically O
engineered O
to O
ensure O
a O
nearly O
vertical O
alignment O
upon O
self O
- O
assembly O
onto O
a O
metal O
substrate O
. O

The O
interdigital O
spaces O
thus O
formed O
between O
individual O
rods O
effectively O
accommodated O
the O
volume O
expansion O
and O
contraction O
of O
the O
alloy O
upon O
sodiation O
/ O
desodiation O
, O
while O
additional O
carbon B
- O
coating O
engineered O
over O
these O
nanorods O
further O
suppressed O
Sn B
aggregation O
during O
extended O
electrochemical O
cycling O
. O

Due O
to O
the O
unique O
nanohierarchy O
of O
multiple O
functional O
layers O
, O
the O
resultant O
3D O
nanoforest O
of O
C B
/ O
Sn B
/ O
Ni B
/ O
TMV1cys O
, O
binder O
- O
free O
composite O
electrode O
already O
and O
evenly O
assembled O
on O
a O
stainless O
steel B
current O
collector O
, O
exhibited O
supreme O
capacity O
utilization O
and O
cycling O
stability O
toward O
Na B
- O
ion O
storage O
and O
release O
. O

An O
initial O
capacity O
of O
722 O
mA O
. O
h O
( O
g O
Sn B
) O
( O
- O
1 O
) O
along O
with O
405 O
mA O
. O
h O
( O
g O
Sn B
) O
( O
- O
1 O
) O
retained O
after O
150 O
deep O
cycles O
demonstrates O
the O
longest O
- O
cycling O
nano O
- O
Sn B
anode O
material O
for O
Na B
- O
ion O
batteries O
reported O
in O
the O
literature O
to O
date O
and O
marks O
a O
significant O
performance O
improvement O
for O
neat O
Sn B
material O
as O
alloy O
host O
for O
Na B
- O
ion O
chemistry O
. O

Direct O
modulation O
of O
microtubule O
stability O
contributes O
to O
anthracene B
general O
anesthesia O
. O

In O
vitro O
assays O
with O
aminoanthracene O
- O
cross O
- O
linked O
tubulin O
indicated O
inhibition O
of O
microtubule O
polymerization O
, O
similar O
to O
colchicine B
. O

Tandem O
mass O
spectrometry O
confirmed O
anthracene B
binding O
near O
the O
colchicine B
site O
. O

Epothilone O
D O
similarly O
mitigated O
the O
effects O
of O
a O
clinical O
neurosteroid O
general O
anesthetic O
, O
allopregnanolone B
, O
believed O
to O
occupy O
the O
colchicine B
site O
in O
tubulin O
. O

We O
conclude O
that O
neuronal O
microtubules O
are O
" O
on O
- O
pathway O
" O
targets O
for O
anthracene B
general O
anesthetics O
and O
may O
also O
represent O
functional O
targets O
for O
some O
neurosteroid O
general O
anesthetics O
. O

Hydrogenase O
enzymes O
are O
natural O
biocatalysts O
that O
might O
be O
harnessed O
to O
reduce O
the O
cost O
of O
hydrogen B
gas O
production O
. O

[ O
FeFe O
] O
- O
hydrogenases O
are O
the O
most O
effective O
of O
three O
such O
enzymes O
at O
catalyzing O
H B
( I
+ I
) I
reduction O
. O

Tetrodotoxin B
- O
sensitive O
spontaneous O
cholinergic O
neurotransmission O
was O
blocked O
> O
80 O
% O
by O
1 O
pM O
BoNT O
/ O
A O
despite O
cleaving O
< O
20 O
% O
of O
the O
SNAP O
- O
25 O
. O

Moreover O
, O
limited O
cleavage O
of O
SNAP O
- O
25 O
was O
conferred O
onto O
the O
protease O
from O
BoNT O
/ O
E O
when O
fused O
to O
the O
N B
- O
terminus O
of O
BoNT O
/ O
A O
. O

Polymethacrylates O
such O
as O
Eudragit B
( O
R O
) O
polymers O
are O
well O
established O
as O
drug O
delivery O
matrix O
. O

Three O
chemical O
modifications O
increased O
the O
glass O
transition O
temperature O
of O
the O
polymer O
: O
( O
a O
) O
substitution O
of O
n O
- O
butyl O
by O
t B
- I
butyl I
groups O
, O
( O
b O
) O
reduction O
of O
the O
dimethylaminoethyl B
methacrylate I
( O
DMAEMA B
) O
content O
, O
and O
( O
c O
) O
incorporation O
of O
a O
bulky O
isobornyl O
repeating O
unit O
. O

The O
presence O
of O
DMAEMA B
units O
proved O
to O
be O
crucial O
with O
respect O
to O
API O
/ O
polymer O
interaction O
( O
essential O
in O
creating O
glassy O
solid O
solutions O
) O
and O
drug O
release O
characteristics O
. O

Moreover O
, O
these O
chemical O
modifications O
accentuate O
the O
need O
for O
a O
more O
rational O
design O
of O
( O
methacrylate B
) O
polymer O
matrix O
excipients O
for O
drug O
formulation O
via O
hot O
melt O
extrusion O
and O
injection O
molding O
. O

Mercury B
in O
fishes O
from O
Augusta O
Bay O
( O
southern O
Italy O
) O
: O
Risk O
assessment O
and O
health O
implication O
. O

Our O
study O
reports O
on O
the O
total O
mercury B
( O
HgT O
) O
concentrations O
measured O
in O
the O
muscles O
and O
livers O
of O
several O
benthic O
, O
demersal O
and O
pelagic O
fish O
species O
caught O
inside O
and O
outside O
of O
Augusta O
Bay O
( O
southern O
Italy O
) O
, O
a O
semi O
- O
enclosed O
marine O
area O
, O
highly O
contaminated O
by O
the O
uncontrolled O
( O
since O
the O
1950s O
to O
1978s O
) O
discharge O
of O
the O
largest O
European O
petrochemical O
plant O
. O

Mercury B
levels O
in O
fish O
tissues O
are O
discussed O
with O
regard O
to O
specific O
habitat O
, O
size O
and O
/ O
or O
age O
of O
the O
specimens O
and O
HgT O
distribution O
in O
the O
bottom O
sediments O
. O

Results O
suggest O
a O
still O
active O
Hg B
release O
mechanism O
from O
the O
polluted O
sediments O
to O
the O
marine O
environment O
. O

Ionic O
liquid O
[ O
HMIM O
] O
HSO4 O
was O
found O
to O
be O
an O
efficient O
catalyst O
for O
the O
synthesis O
of O
N O
- O
substituted O
pyrroles O
through O
the O
reaction O
of O
2 O
, O
5 O
- O
hexanedione O
with O
amines B
under O
ultrasonic O
irradiation O
at O
room O
temperature O
. O

Platycodi O
Radix O
attenuates O
dimethylnitrosamine B
- O
induced O
liver O
fibrosis O
in O
rats O
by O
inducing O
Nrf2 O
- O
mediated O
antioxidant O
enzymes O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
anti O
- O
fibrotic O
effects O
of O
the O
aqueous O
extract O
of O
the O
Platycodi O
Radix O
root O
( O
Changkil O
: O
CK O
) O
on O
dimethylnitrosamine B
( O
DMN B
) O
- O
induced O
liver O
fibrosis O
in O
rats O
. O

DMN B
treatment O
for O
4weeks O
led O
to O
marked O
liver O
fibrosis O
as O
assessed O
by O
serum O
biochemistry O
, O
histopathological O
examination O
, O
and O
hepatic O
lipid O
peroxidation O
and O
collagen O
content O
. O

CK O
significantly O
inhibited O
DMN B
- O
induced O
increases O
in O
serum O
alanine B
aminotransferase O
( O
ALT O
) O
and O
aspartate B
aminotransferase O
( O
AST O
) O
activities O
, O
fibrosis O
score O
, O
and O
hepatic O
malondialdehyde B
and O
collagen O
content O
. O

CK O
also O
inhibited O
DMN B
- O
induced O
reductions O
in O
rat O
body O
and O
liver O
weights O
. O

Reverse O
transcription O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
and O
western O
blot O
analyses O
revealed O
that O
CK O
inhibited O
DMN B
- O
induced O
increases O
in O
matrix O
metalloproteinase O
- O
13 O
( O
MMP O
- O
13 O
) O
, O
tissue O
inhibitor O
of O
metalloproteinase O
- O
1 O
( O
TIMP O
- O
1 O
) O
, O
and O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
mRNA O
, O
and O
collagen O
type O
I O
and O
alpha O
- O
smooth O
muscle O
actin O
protein O
. O

DMN B
- O
induced O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
expression O
and O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
activation O
was O
reduced O
by O
CK O
treatment O
. O

Furthermore O
, O
CK O
induced O
activation O
of O
nuclear O
erythroid O
2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
- O
mediated O
antioxidant O
enzymes O
such O
as O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
NAD B
( I
P I
) I
H I
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
, O
and O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
in O
HepG2 O
cells O
. O

These O
results O
demonstrated O
that O
CK O
attenuates O
DMN B
- O
induced O
liver O
fibrosis O
through O
the O
activation O
of O
Nrf2 O
- O
mediated O
antioxidant O
enzymes O
. O

The O
migration O
values O
found O
for O
LAE O
were O
0 O
. O
94 O
+ O
/ O
- O
0 O
. O
14 O
and O
1 O
. O
62 O
+ O
/ O
- O
0 O
. O
70 O
mu O
g O
/ O
g O
in O
ethanol B
10 O
% O
v O
/ O
v O
( O
simulant O
A O
) O
and O
in O
ethanol B
95 O
% O
v O
/ O
v O
( O
simulant O
D O
) O
, O
respectively O
, O
and O
0 O
. O
93 O
+ O
/ O
- O
0 O
. O
17 O
mu O
g O
/ O
g O
in O
chicken O
. O

Cadmium B
telluride I
quantum O
dots O
cause O
oxidative O
stress O
leading O
to O
extrinsic O
and O
intrinsic O
apoptosis O
in O
hepatocellular O
carcinoma O
HepG2 O
cells O
. O

The O
mechanisms O
of O
toxicity O
related O
to O
human O
hepatocellular O
carcinoma O
HepG2 O
cell O
exposures O
to O
cadmium B
telluride I
quantum O
dots O
( O
CdTe B
- O
QDs O
) O
were O
investigated O
. O

CdTe B
- O
QDs O
caused O
cytotoxicity O
in O
HepG2 O
cells O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
. O

Treated O
cells O
showed O
an O
increase O
in O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Altered O
antioxidant O
levels O
were O
demonstrated O
by O
depletion O
of O
reduced B
glutathione I
( O
GSH B
) O
, O
a O
decreased O
ratio O
of O
reduced O
glutathione B
to O
oxidized B
glutathione I
( O
GSH B
/ O
GSSG B
) O
and O
an O
increased O
NF O
- O
E2 O
- O
related O
Factor O
2 O
( O
Nrf2 O
) O
activation O
. O

Enzyme O
assays O
showed O
that O
superoxide B
dismutase O
( O
SOD O
) O
activity O
was O
elevated O
whereas O
catalase O
( O
CAT O
) O
and O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
activities O
were O
depressed O
. O

Further O
analyses O
revealed O
that O
CdTe B
- O
QD O
exposure O
resulted O
in O
apoptosis O
, O
indicated O
by O
changes O
in O
levels O
of O
caspase O
- O
3 O
activity O
, O
poly B
ADP I
- I
ribose I
polymerase O
( O
PARP O
) O
cleavage O
and O
phosphatidylserine B
externalization O
. O

Extrinsic O
apoptotic O
pathway O
markers O
such O
as O
Fas O
levels O
and O
caspase O
- O
8 O
activity O
increased O
as O
a O
result O
of O
CdTe B
- O
QD O
exposure O
. O

Further O
, O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
such O
as O
c O
- O
Jun O
N B
- O
terminal O
kinases O
( O
JNK O
) O
, O
extracellular O
signal O
- O
regulated O
kinases O
( O
Erk1 O
/ O
2 O
) O
, O
and O
p38 O
were O
all O
activated O
. O

Our O
findings O
reveal O
that O
CdTe B
- O
QDs O
cause O
oxidative O
stress O
, O
interfere O
with O
antioxidant O
defenses O
and O
activate O
protein O
kinases O
, O
leading O
to O
apoptosis O
via O
both O
extrinsic O
and O
intrinsic O
pathways O
. O

Since O
the O
effects O
of O
CdTe B
- O
QDs O
on O
selected O
biomarkers O
were O
similar O
or O
greater O
compared O
to O
those O
of O
CdCl2 B
at O
equivalent O
concentrations O
of O
cadmium B
, O
the O
study O
suggests O
that O
the O
toxicity O
of O
CdTe B
- O
QDs O
arises O
from O
a O
combination O
of O
the O
effects O
of O
cadmium O
and O
ROS O
generated O
from O
the O
NPs O
. O

Multienzyme O
branched O
- O
chain O
alpha O
- O
ketoacid O
dehydrogenase O
complex O
( O
BCKDH O
) O
catalyzes O
the O
regulatory O
step O
of O
oxidative O
catabolism O
of O
indispensable O
branched O
- O
chain O
amino B
acids I
( O
BCAA O
) O
. O

Amitriptyline B
, O
clomipramine O
, O
doxepin O
, O
imipramine B
, O
and O
trimipramine O
are O
demethylated O
by O
CYP2C19 O
to O
pharmacologically O
active O
metabolites O
. O

These O
drugs O
and O
their O
metabolites O
, O
along O
with O
desipramine B
and O
nortriptyline B
, O
undergo O
hydroxylation O
by O
CYP2D6 O
to O
less O
active O
metabolites O
. O

It O
hydrolyzes O
lactose B
to O
galactose B
and O
glucose B
and O
catalyzes O
the O
intramolecular O
isomerization O
of O
lactose B
to O
allolactose O
, O
the O
lac O
operon O
inducer O
. O

beta O
- O
Galactosidase O
promotes O
the O
isomerization O
by O
means O
of O
an O
acceptor O
site O
that O
binds O
glucose B
after O
its O
cleavage O
from O
lactose B
and O
thus O
delays O
its O
exit O
from O
the O
site O
. O

However O
, O
because O
of O
its O
relatively O
low O
affinity O
for O
glucose B
, O
details O
of O
this O
site O
have O
remained O
elusive O
. O

We O
present O
structural O
data O
mapping O
the O
glucose B
site O
based O
on O
a O
substituted O
enzyme O
( O
G794A O
- O
beta O
- O
galactosidase O
) O
that O
traps O
allolactose O
. O

Various O
lines O
of O
evidence O
indicate O
that O
the O
glucose B
of O
the O
trapped O
allolactose O
is O
in O
the O
acceptor O
position O
. O

The O
site O
is O
composed O
of O
Asn B
- O
102 O
, O
His B
- O
418 O
, O
Lys B
- O
517 O
, O
Ser B
- O
796 O
, O
Glu B
- O
797 O
, O
and O
Trp B
- O
999 O
. O

Ser B
- O
796 O
and O
Glu B
- O
797 O
are O
part O
of O
a O
loop O
( O
residues O
795 O
- O
803 O
) O
that O
closes O
over O
the O
active O
site O
. O

This O
loop O
appears O
essential O
for O
the O
bifunctional O
nature O
of O
the O
enzyme O
because O
it O
helps O
form O
the O
glucose B
binding O
site O
. O

In O
addition O
, O
because O
the O
loop O
is O
mobile O
, O
glucose B
binding O
is O
transient O
, O
allowing O
the O
release O
of O
some O
glucose B
. O

Bioinformatics O
studies O
showed O
that O
the O
residues O
important O
for O
interacting O
with O
glucose B
are O
only O
conserved O
in O
a O
subset O
of O
related O
enzymes O
. O

This O
shows O
that O
the O
glucose B
binding O
site O
of O
beta O
- O
galactosidase O
played O
an O
important O
role O
in O
lac O
operon O
evolution O
. O

Eight O
ARBs O
are O
clinically O
available O
[ O
azilsartan O
, O
candesartan B
, O
eprosartan O
, O
irbesartan O
, O
losartan B
, O
olmesartan B
, O
telmisartan B
, O
valsartan O
] O
. O

Azilsartan O
( O
in O
some O
countries O
) O
, O
candesartan B
, O
and O
olmesartan B
are O
orally O
administered O
as O
prodrugs O
, O
whereas O
the O
blocking O
action O
of O
some O
is O
mediated O
through O
active O
metabolites O
. O

Although O
generally O
highly O
specific O
for O
angiotensin O
II O
type O
1 O
receptors O
, O
some O
ARBs O
, O
particularly O
telmisartan B
, O
are O
partial O
agonists O
at O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
. O

Heterogeneous O
OH B
oxidation O
of O
biomass O
burning O
organic O
aerosol O
surrogate O
compounds O
: O
assessment O
of O
volatilisation O
products O
and O
the O
role O
of O
OH B
concentration O
on O
the O
reactive O
uptake O
kinetics O
. O

The O
reactive O
uptake O
coefficients O
( O
gamma O
) O
of O
OH B
by O
levoglucosan B
, O
abietic B
acid I
, O
and O
nitroguaiacol O
serving O
as O
surrogate O
compounds O
for O
biomass O
burning O
aerosol O
have O
been O
determined O
employing O
a O
chemical O
ionisation O
mass O
spectrometer O
coupled O
to O
a O
rotating O
- O
wall O
flow O
- O
tube O
reactor O
over O
a O
wide O
range O
of O
[ O
OH B
] O
~ O
10 O
( O
7 O
) O
- O
10 O
( O
11 O
) O
molecule O
cm O
( O
- O
3 O
) O
. O

Volatilisation O
products O
of O
these O
organic O
substrates O
due O
to O
heterogeneous O
oxidation O
by O
OH B
have O
been O
determined O
at O
1 O
atm O
using O
a O
high O
resolution O
proton O
transfer O
reaction O
time O
- O
of O
- O
flight O
mass O
spectrometer O
( O
HR O
- O
PTR O
- O
ToF O
- O
MS O
) O
. O

gamma O
range O
within O
0 O
. O
05 O
- O
1 O
for O
[ O
OH B
] O
= O
2 O
. O
6 O
x O
10 O
( O
7 O
) O
- O
3 O
x O
10 O
( O
9 O
) O
molecule O
cm O
( O
- O
3 O
) O
for O
all O
investigated O
organic O
compounds O
, O
but O
decrease O
to O
0 O
. O
008 O
- O
0 O
. O
034 O
for O
[ O
OH B
] O
= O
4 O
. O
1 O
x O
10 O
( O
10 O
) O
- O
6 O
. O
7 O
x O
10 O
( O
10 O
) O
molecule O
cm O
( O
- O
3 O
) O
. O

gamma O
as O
a O
function O
of O
[ O
OH B
] O
can O
be O
described O
by O
a O
Langmuir O
- O
Hinshelwood O
model O
, O
neglecting O
bulk O
processes O
, O
suggesting O
that O
despite O
its O
strong O
reactivity O
, O
OH B
is O
mobile O
on O
surfaces O
prior O
to O
reaction O
. O

The O
best O
fit O
Langmuir O
- O
Hinshelwood O
parameters O
on O
average O
are O
K O
( O
OH B
) O
= O
3 O
. O
81 O
x O
10 O
( O
- O
10 O
) O
cm O
( O
3 O
) O
molecule O
( O
- O
1 O
) O
and O
k O
( O
s O
) O
= O
9 O
. O
71 O
x O
10 O
( O
- O
17 O
) O
cm O
( O
2 O
) O
molecule O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
for O
all O
of O
the O
investigated O
organic O
compounds O
. O

Amongst O
the O
common O
volatile O
organic O
compounds O
( O
VOCs O
) O
identified O
between O
levoglucosan B
, O
abietic B
acid I
, O
and O
nitroguaiacol O
were O
methanol B
, O
acetaldehyde B
, O
formic B
acid I
, O
and O
acetic B
acid I
. O

VOCs O
having O
the O
greatest O
enhancement O
over O
background O
were O
glucic O
acid O
from O
levoglucosan B
, O
glycolic O
acid O
from O
abietic B
acid I
, O
and O
methanol B
and O
nitric B
acid I
from O
nitroguaiacol O
. O

Reaction O
mechanisms O
leading O
to O
the O
formation O
of O
glucic O
acid O
, O
glycolic O
acid O
, O
methanol B
, O
and O
nitric B
acid I
are O
proposed O
. O

Estimated O
lower O
limits O
of O
atmospheric O
lifetimes O
of O
biomass O
burning O
aerosol O
particles O
, O
200 O
nm O
in O
diameter O
, O
by O
heterogeneous O
OH B
oxidation O
under O
fresh O
biomass O
burning O
plume O
conditions O
are O
~ O
2 O
days O
and O
up O
to O
~ O
2 O
weeks O
for O
atmospheric O
background O
conditions O
. O

However O
, O
estimated O
lifetimes O
depend O
crucially O
on O
[ O
OH B
] O
and O
corresponding O
gamma O
, O
emphasising O
the O
need O
to O
determine O
gamma O
under O
relevant O
conditions O
. O

METHODS O
: O
Pooled O
patient O
- O
level O
data O
from O
12 O
prospective O
, O
randomized O
, O
controlled O
studies O
that O
used O
insulin O
glargine O
in O
a O
treat O
- O
to O
- O
target O
titration O
regimen O
seeking O
fasting O
glucose B
levels O
< O
= O
5 O
. O
5 O
mmol O
/ O
l O
( O
100 O
mg O
/ O
dl O
) O
were O
analysed O
. O

Lower O
baseline O
HbA1c O
was O
the O
best O
clinical O
predictor O
of O
achieving O
HbA1c O
< O
= O
7 O
. O
0 O
% O
and O
also O
associated O
with O
higher O
risk O
of O
glucose B
- O
confirmed O
hypoglycaemia O
. O

Here O
, O
a O
main O
group O
seven O
- O
coordinated O
bismuth O
( O
III O
) O
complex O
[ O
Bi O
( O
L O
) O
( O
NO3 O
) O
2 O
( O
CH3CH2OH O
) O
] O
( O
1 O
) O
( O
HL O
= O
2 O
- O
acetylpyridine O
N O
( O
4 O
) O
- O
phenylthiosemicarbaz O
) O
has O
been O
synthesized O
and O
characterized O
by O
elemental O
analysis O
, O
IR O
, O
( B
1 I
) I
H I
NMR O
and O
single O
- O
crystal O
X O
- O
ray O
diffraction O
studies O
. O

Compound O
1 O
promotes O
a O
dose O
- O
dependent O
apoptosis O
in O
HepG2 O
cells O
and O
the O
apoptosis O
is O
associated O
with O
an O
increase O
in O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
reduction O
of O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
. O

On O
the O
singlet O
PES O
, O
the O
most O
important O
products O
include O
CF3OOOI O
, O
CF3OOIO O
, O
CF3OIO2 O
, O
and O
CF2O O
+ O
FIO2 O
, O
while O
other O
products O
such O
as O
CF2O O
+ O
FOIO O
, O
CF2O O
+ O
FOOI O
, O
CF3OOI O
+ O
O B
( O
( O
3 O
) O
P O
) O
, O
CF3OI O
+ O
O2 B
( O
( O
1 O
) O
Delta O
and O
( O
3 O
) O
Sigma O
) O
, O
and O
CF3O O
+ O
OIO O
are O
negligible O
due O
to O
high O
barriers O
or O
unstable O
formations O
. O

Moreover O
, O
a O
minor O
contribution O
relative O
to O
hydrogen B
is O
found O
in O
the O
CX3O2 O
+ O
IO O
( O
X O
= O
H B
and O
F B
) O
reactions O
. O

Multiple O
nicotine B
training O
doses O
in O
mice O
as O
a O
basis O
for O
differentiating O
the O
effects O
of O
smoking O
cessation O
aids O
. O

RATIONALE O
: O
Receptor O
mechanisms O
underlying O
the O
behavioral O
effects O
of O
clinically O
used O
nicotinic O
acetylcholine B
receptor O
agonists O
have O
not O
been O
fully O
established O
. O

METHODS O
: O
Separate O
groups O
of O
male O
C57BL O
/ O
6J O
mice O
discriminated O
0 O
. O
56 O
, O
1 O
, O
or O
1 O
. O
78 O
mg O
/ O
kg O
of O
nicotine B
base O
. O

Nicotine B
, O
varenicline O
, O
and O
cytisine O
were O
administered O
alone O
, O
in O
combination O
with O
each O
other O
, O
and O
in O
combination O
with O
mecamylamine B
and O
dihydro O
- O
beta O
- O
erythroidine O
( O
DH B
beta I
E I
) O
. O

Midazolam B
and O
morphine B
were O
tested O
to O
examine O
sensitivity O
to O
non O
- O
nicotinics O
. O

RESULTS O
: O
The O
ED50 O
value O
of O
nicotine B
to O
produce O
discriminative O
stimulus O
effects O
systematically O
increased O
as O
training O
dose O
increased O
. O

Varenicline O
and O
cytisine O
did O
not O
fully O
substitute O
for O
nicotine B
and O
, O
as O
compared O
with O
nicotine B
, O
their O
ED50 O
values O
varied O
less O
systematically O
as O
a O
function O
of O
nicotine B
training O
dose O
. O

Morphine B
did O
not O
substitute O
for O
nicotine B
, O
whereas O
midazolam B
substituted O
for O
the O
low O
and O
not O
the O
higher O
training O
doses O
of O
nicotine B
. O

As O
training O
dose O
increased O
, O
the O
dose O
of O
mecamylamine B
needed O
to O
produce O
a O
significant O
rightward O
shift O
in O
the O
nicotine O
dose O
- O
effect O
function O
also O
increased O
. O

DH B
beta I
E I
antagonized O
nicotine B
in O
animals O
discriminating O
the O
smallest O
dose O
of O
nicotine B
. O

Varenicline O
did O
not O
antagonize O
the O
effects O
of O
nicotine B
, O
whereas O
cytisine O
produced O
a O
modest O
though O
significant O
antagonism O
of O
nicotine B
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
differences O
in O
pharmacologic O
mechanism O
between O
nicotine B
, O
varenicline O
, O
and O
cytisine O
include O
not O
only O
differences O
in O
efficacy O
at O
a O
common O
subtype O
of O
nicotinic O
acetylcholine B
receptor O
, O
but O
also O
differential O
affinity O
and O
/ O
or O
efficacy O
at O
multiple O
receptor O
subtypes O
. O

Reinforcement O
enhancing O
effects O
of O
nicotine B
via O
smoking O
. O

RATIONALE O
: O
In O
animals O
, O
nicotine B
enhances O
reinforcement O
from O
stimuli O
unrelated O
to O
nicotine B
intake O
. O

Human O
research O
is O
suggestive O
but O
has O
not O
clearly O
shown O
a O
similar O
influence O
of O
nicotine B
. O

OBJECTIVES O
: O
We O
assessed O
acute O
effects O
of O
nicotine B
via O
smoking O
on O
enhancement O
of O
positive O
( O
money O
, O
music O
) O
or O
negative O
( O
termination O
of O
noise O
) O
reinforcers O
, O
or O
no O
" O
reward O
" O
( O
control O
) O
. O

These O
different O
rewards O
determined O
the O
generalizability O
of O
nicotine B
effects O
. O

Using O
a O
within O
- O
subjects O
design O
, O
sessions O
involved O
no O
smoking O
or O
smoking O
denicotinized O
( O
0 O
. O
05 O
mg O
) O
or O
nicotine B
( O
0 O
. O
6 O
mg O
) O
Quest O
( O
R O
) O
brand O
cigarettes O
. O

For O
comparison O
, O
a O
fourth O
session O
involved O
no O
abstinence O
prior O
to O
smoking O
one O
' O
s O
own O
brand O
to O
gauge O
responses O
under O
typical O
nicotine B
satiation O
. O

RESULTS O
: O
The O
reinforcing O
effect O
of O
music O
, O
but O
not O
other O
rewards O
, O
was O
greater O
due O
to O
the O
nicotine B
cigarette O
, O
compared O
to O
the O
denicotinized O
cigarette O
or O
no O
smoking O
. O

Reinforcement O
enhancing O
effects O
of O
nicotine B
did O
not O
differ O
between O
dependent O
and O
nondependent O
groups O
, O
indicating O
no O
influence O
of O
withdrawal O
relief O
. O

Responding O
due O
to O
acute O
nicotine B
after O
abstinence O
was O
very O
similar O
to O
responding O
to O
one O
' O
s O
own O
brand O
after O
no O
abstinence O
. O

CONCLUSIONS O
: O
Acute O
nicotine B
intake O
per O
se O
from O
smoking O
after O
abstinence O
enhances O
the O
reinforcing O
value O
of O
rewards O
unassociated O
with O
smoking O
, O
perhaps O
in O
a O
manner O
comparable O
to O
ad O
lib O
smoking O
after O
no O
abstinence O
. O

Nicotine B
' O
s O
reinforcement O
enhancing O
effects O
may O
be O
specific O
to O
certain O
rewards O
, O
perhaps O
those O
sensory O
in O
nature O
. O

Evaporation O
- O
Induced O
Coating O
of O
Hydrous O
Ruthenium O
Oxide O
on O
Mesoporous O
Silica B
Nanoparticles O
to O
Develop O
High O
- O
Performance O
Supercapacitors O
. O

An O
efficient O
evaporation O
- O
induced O
coating O
method O
combining O
microwave O
- O
assisted O
hydrothermal O
transformation O
and O
annealing O
is O
developed O
to O
fabricate O
an O
ideal O
electrode O
material O
from O
composites O
with O
a O
layer O
of O
hydrous O
RuO2 O
on O
mesoporous O
silica B
nanoparticles O
( O
MSNs O
) O
, O
for O
a O
high O
- O
performance O
supercapacitor O
. O

Furthermore O
, O
methylglyoxal B
, O
an O
antibacterial O
compound O
of O
manuka O
honey O
, O
was O
shown O
to O
be O
responsible O
for O
killing O
biofilm O
- O
embedded O
wound O
bacteria O
. O

Solution O
- O
processible O
highly O
conducting O
fullerenes B
. O

n O
- O
Doping O
of O
solution O
- O
processible O
organic O
semiconductors O
: O
highly O
conductive O
fullerenes B
are O
demonstrated O
through O
solution O
- O
processed O
fulleropyrrolidinium O
iodide O
( O
FPI O
) O
and O
FPI O
- O
doped O
PCBM B
to O
reach O
a O
high O
conductivity O
( O
3 O
. O
2 O
S O
/ O
m O
) O
. O

The O
n O
- O
doping O
proceeds O
via O
anion O
- O
induced O
electron O
transfer O
between O
the O
iodide B
on O
FPI O
and O
the O
fullerene B
in O
the O
solid O
state O
. O

Aluminium B
may O
have O
an O
important O
role O
in O
the O
aetiology O
/ O
pathogenesis O
/ O
precipitation O
of O
Alzheimer O
' O
s O
disease O
. O

Because O
green O
tea O
( O
Camellia O
sinensis O
L O
. O
) O
reportedly O
has O
health O
- O
promoting O
effects O
in O
the O
central O
nervous O
system O
, O
we O
evaluated O
the O
effects O
of O
green O
tea O
leaf O
extract O
( O
GTLE O
) O
on O
aluminium O
chloride O
( O
AlCl3 B
) O
neurotoxicity O
in O
rats O
. O

We O
measured O
the O
performance O
of O
active O
avoidance O
( O
AA O
) O
tasks O
, O
various O
enzyme O
activities O
and O
total O
glutathione B
content O
( O
TGC O
) O
in O
the O
forebrain O
cortex O
( O
FbC O
) O
, O
striatum O
, O
basal O
forebrain O
( O
BFb O
) O
, O
hippocampus O
, O
brain O
stem O
and O
cerebellum O
. O

AlCl3 B
markedly O
reduced O
AA O
performance O
and O
activities O
of O
cytochrome O
c O
oxidase O
( O
COX O
) O
and O
acetylcholinesterase O
( O
AChE O
) O
in O
all O
regions O
. O

It O
decreased O
TGC O
in O
the O
FbC O
, O
striatum O
, O
BFb O
, O
hippocampus O
, O
brain O
stem O
and O
cerebellum O
, O
and O
increased O
superoxide B
dismutase O
activity O
in O
the O
FbC O
, O
cerebellum O
and O
BFb O
. O

GTLE O
pretreatment O
completely O
reversed O
the O
damaging O
effects O
of O
AlCl3 B
on O
AA O
and O
superoxide B
dismutase O
activity O
, O
markedly O
corrected O
COX O
and O
AChE O
activities O
, O
and O
moderately O
improved O
TGC O
. O

GTLE O
reduces O
AlCl3 B
neurotoxicity O
probably O
via O
antioxidative O
effects O
and O
improves O
mitochondrial O
and O
cholinergic O
synaptic O
functions O
through O
the O
actions O
of O
( B
- I
) I
- I
epigallocatechin I
gallate I
and O
( B
- I
) I
- I
epicatechin I
, O
compounds O
most O
abundantly O
found O
in O
GTLE O
. O

Towards O
squalamine O
mimics O
: O
synthesis O
and O
antibacterial O
activities O
of O
head O
- O
to O
- O
tail O
dimeric O
sterol B
- O
polyamine B
conjugates O
. O

Four O
dimeric O
sterol B
- O
polyamine B
conjugates O
have O
been O
synthesized O
from O
the O
homo O
- O
and O
hetero O
- O
connection O
of O
monomeric O
sterol B
- O
polyamine B
analogs O
in O
a O
head O
- O
to O
- O
tail O
manner O
. O

Though O
no O
significant O
difference O
was O
observed O
in O
the O
activities O
of O
these O
conjugates O
, O
cholic B
acid I
- O
containing O
dimeric O
conjugates O
generally O
exhibit O
higher O
activities O
than O
the O
corresponding O
deoxycholic B
acid I
- O
derived O
analogs O
. O

This O
is O
in O
contrast O
to O
the O
finding O
that O
a O
monomeric O
deoxycholic B
acid I
- O
spermine B
conjugate O
was O
more O
active O
than O
the O
corresponding O
cholic B
acid I
- O
derived O
analog O
. O

4 O
- O
{ O
[ O
( O
4 O
- O
Cyanophenyl O
) O
( O
4H O
- O
1 O
, O
2 O
, O
4 O
- O
triazol O
- O
4 O
- O
yl O
) O
amino O
] O
methyl O
} O
phenyl O
sulfamate O
and O
its O
ortho O
- O
halogenated O
( O
F B
, O
Cl B
, O
Br B
) O
derivatives O
are O
first O
- O
generation O
dual O
aromatase O
and O
sulfatase O
inhibitors O
( O
DASIs O
) O
. O

Structure O
- O
activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen B
atom O
, O
introduction O
of O
more O
halogen B
atoms O
, O
replacement O
of O
the O
halogen B
with O
another O
group O
, O
replacement O
of O
the O
methylene B
linker O
with O
a O
difluoromethylene O
linker O
, O
replacement O
of O
the O
para O
- O
cyanophenyl O
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl O
group O
with O
an O
imidazolyl O
group O
. O

The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole B
derivative O
with O
IC50 O
values O
against O
aromatase O
and O
steroid B
sulfatase O
in O
a O
JEG O
- O
3 O
cell O
preparation O
of O
0 O
. O
2 O
and O
2 O
. O
5 O
nM O
, O
respectively O
. O

The O
parent O
phenol B
of O
this O
compound O
inhibits O
aromatase O
with O
an O
IC50 O
value O
of O
0 O
. O
028 O
nM O
in O
the O
same O
assay O
. O

P2X O
and O
P2Y O
nucleotide B
receptors O
as O
targets O
in O
cardiovascular O
disease O
. O

Endogenous O
nucleotides B
have O
widespread O
actions O
in O
the O
cardiovascular O
system O
, O
but O
it O
is O
only O
recently O
that O
the O
P2X O
and O
P2Y O
receptor O
subtypes O
, O
at O
which O
they O
act O
, O
have O
been O
identified O
and O
subtype O
- O
selective O
agonists O
and O
antagonists O
developed O
. O

The O
PU O
derivatives O
having O
amino B
groups O
( O
PU O
- O
Am O
) O
also O
showed O
UCST O
behavior O
. O

In O
this O
study O
, O
we O
modified O
the O
amino B
groups O
of O
the O
polymer O
with O
succinyl O
anhydride O
( O
PU O
- O
Su O
) O
or O
acetyl O
anhydride O
( O
PU O
- O
Ac O
) O
to O
determine O
the O
effects O
of O
these O
ionic O
groups O
on O
the O
UCST O
behavior O
and O
to O
control O
interactions O
between O
the O
PU O
derivatives O
and O
biocomponents O
such O
as O
proteins O
and O
cells O
. O

The O
block O
polypeptides O
comprise O
proline B
- O
rich O
poly O
( O
VPGXG O
) O
and O
glycine B
- O
rich O
poly O
( O
VGGVG O
) O
, O
both O
of O
which O
dehydrate O
at O
higher O
temperature O
but O
form O
distinct O
secondary O
structures O
, O
beta O
- O
turn O
and O
beta O
- O
sheet O
respectively O
. O

Extraction O
of O
the O
volatile O
oil O
from O
Carum O
carvi O
of O
Tunisia O
and O
Lithuania O
by O
supercritical O
carbon B
dioxide I
: O
chemical O
composition O
and O
antiulcerogenic O
activity O
. O

The O
chemical O
analysis O
revealed O
that O
the O
essential O
oils O
extracted O
under O
SFE O
conditions O
had O
high O
carvone B
and O
limonene B
contents O
. O

The O
antiulcerogenic O
activity O
was O
evaluated O
by O
the O
HCl B
/ O
ethanol B
method O
, O
which O
causes O
injury O
to O
the O
gastric O
mucosa O
. O

The O
reference O
group O
received O
omeprazole B
( O
30 O
mg O
/ O
kg O
) O
and O
the O
control O
group O
received O
NaCl B
. O

After O
30 O
min O
, O
all O
groups O
were O
treated O
with O
HCl B
/ O
EtOH B
for O
gastric O
ulcer O
induction O
. O

The O
results O
show O
C O
. O
carvi O
essential O
oil O
enhanced O
a O
significant O
inhibition O
of O
47 O
% O
, O
81 O
% O
and O
88 O
% O
, O
respectively O
, O
for O
three O
doses O
of O
essential O
oil O
used O
, O
which O
was O
similar O
to O
that O
induced O
by O
omeprazole B
( O
95 O
% O
) O
( O
p O
< O
0 O
. O
005 O
) O
. O

However O
, O
the O
cell O
patterning O
techniques O
often O
used O
are O
limited O
to O
creating O
2D O
functional O
surfaces O
on O
glass O
and O
silicon B
. O

Here O
, O
we O
show O
the O
formation O
of O
a O
living O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
layer O
that O
can O
be O
patterned O
with O
visible O
light O
on O
plastic O
surfaces O
. O

This O
new O
and O
simple O
method O
can O
be O
expanded O
to O
pattern O
multiple O
types O
of O
biomolecule O
on O
either O
a O
previously O
formed O
PEG B
layer O
or O
a O
plastic O
substrate O
. O

Using O
common O
plastic O
wares O
( O
i O
. O
e O
. O
, O
polyethylene B
films O
and O
polystyrene B
cell O
culture O
Petri O
- O
dishes O
) O
, O
we O
demonstrate O
that O
these O
PEG B
- O
modified O
surfaces O
have O
a O
high O
resistance O
to O
protein O
adsorption O
and O
cell O
adhesion O
, O
while O
at O
the O
same O
time O
, O
being O
capable O
of O
undergoing O
further O
molecular O
grafting O
with O
bioactive O
motifs O
. O

Both O
diastereomer O
complexes O
exist O
in O
different O
isomers O
, O
involving O
either O
direct O
addition O
of O
THIQM O
on O
ML O
with O
no O
structural O
rearrangement O
of O
the O
subunits O
or O
formation O
of O
very O
stable O
structures O
involving O
multiple O
intermolecular O
hydrogen B
bonds O
and O
extensive O
deformation O
of O
the O
subunits O
. O

It O
is O
shown O
that O
the O
most O
stable O
form O
of O
the O
chromophore O
( O
THIQMI O
with O
an O
OH B
. O
. O
. O
N B
hydrogen B
bond O
) O
prefers O
to O
directly O
stick O
to O
ML O
to O
form O
the O
addition O
complex O
whereas O
the O
second O
conformer O
( O
THIQMII O
with O
NH B
. O
. O
. O
O B
hydrogen B
bond O
) O
rearranges O
to O
form O
a O
strongly O
bound O
structure O
. O

In O
a O
series O
of O
papers O
we O
have O
reported O
on O
Langmuir O
monolayers O
with O
CF3 B
terminals O
of O
the O
polar O
heads O
, O
which O
show O
a O
negative O
surface O
dipole O
potential O
Delta O
V O
( O
Petrov O
, O
J O
. O
G O
. O
; O
Andreeva O
, O
T O
. O
D O
. O
; O
Kurt O
, O
D O
. O
K O
. O
; O
M O
o O
hwald O
, O
H O
. O
J O
. O
Phys O
. O
Chem O
. O
B O
2005 O
, O
109 O
, O
14102 O
) O
. O

The O
vibrational O
sum O
frequency O
spectra O
are O
recorded O
at O
the O
same O
film O
density O
of O
the O
S O
- O
phase O
of O
the O
EE O
and O
FEE O
monolayers O
and O
analyzed O
in O
the O
spectral O
regions O
of O
OH B
, O
COC O
, O
CH3 B
, O
and O
CF3 B
stretching O
vibrations O
because O
these O
functional O
groups O
could O
be O
responsible O
for O
the O
different O
dipole O
potentials O
. O

The O
results O
show O
that O
reversal O
of O
the O
Delta O
V O
sign O
caused O
by O
fluorination O
of O
the O
polar O
heads O
originates O
from O
the O
upward O
- O
oriented O
CF3 B
terminals O
of O
the O
FEE O
heads O
, O
whose O
negative O
normal O
dipole O
moment O
component O
determines O
the O
negative O
dipole O
potential O
of O
the O
FEE O
monolayer O
. O

Performances O
of O
CN O
- O
columns O
for O
the O
analysis O
of O
gamma B
- I
oryzanol I
and O
its O
p O
- O
coumarate O
and O
caffeate O
derivatives O
by O
normal O
phase O
HPLC O
and O
a O
validated O
method O
of O
quantitation O
. O

gamma B
- I
Oryzanol I
is O
an O
important O
phytochemical O
used O
in O
pharmaceutical O
, O
alimentary O
and O
cosmetic O
preparations O
. O

The O
present O
article O
, O
for O
the O
first O
time O
, O
discloses O
the O
performances O
of O
NP O
- O
HPLC O
in O
separating O
gamma B
- I
oryzanol I
components O
and O
develops O
a O
validated O
method O
for O
its O
routine O
quantification O
. O

The O
analysis O
is O
performed O
on O
a O
cyanopropyl O
bonded O
column O
using O
the O
hexane B
/ O
MTBE O
gradient O
elution O
and O
UV O
detection O
at O
325 O
nm O
. O

The O
method O
allows O
: O
the O
separation O
of O
steryl O
ferulate O
, O
p O
- O
coumarate O
and O
caffeate O
esters O
, O
the O
separation O
of O
cis O
- O
from O
trans O
- O
ferulate O
isomers O
, O
the O
splitting O
of O
steroid B
moieties O
into O
saturated O
and O
unsaturated O
at O
the O
side O
chain O
. O

The O
samples O
were O
characterised O
by O
high O
content O
of O
marine O
wax O
esters B
( O
55 O
- O
67 O
mol O
% O
of O
lipid O
classes O
) O
, O
of O
docosahexaenoic O
( O
22 O
: O
6 O
n O
- O
3 O
, O
25 O
w O
% O
) O
and O
oleic B
( O
18 O
: O
1 O
n O
- O
9 O
, O
19 O
w O
% O
) O
fatty B
acids I
. O

Cholesterol B
was O
detected O
as O
7 O
- O
9 O
w O
% O
of O
lipids O
. O

Free O
fatty B
acids I
, O
index O
of O
lipid O
hydrolysis O
, O
represented O
32 O
- O
39 O
mol O
% O
over O
total O
fatty B
acids I
. O

Among O
metabolites O
, O
nutrients O
as O
taurine B
, O
nicotinamide B
and O
beta O
- O
alanine O
, O
were O
found O
. O

The O
microflora O
comprised O
staphylococci O
, O
enterococci O
( O
2 O
. O
2 O
log O
( O
10 O
) O
CFU O
/ O
g O
) O
and O
lactic B
acid I
bacteria O
( O
3 O
log O
( O
10 O
) O
CFU O
/ O
g O
) O
. O

Theaflavins B
, O
dimeric O
catechins O
, O
inhibit O
peptide O
transport O
across O
Caco O
- O
2 O
cell O
monolayers O
via O
down O
- O
regulation O
of O
AMP B
- O
activated O
protein O
kinase O
- O
mediated O
peptide O
transporter O
PEPT1 O
. O

In O
this O
study O
, O
we O
investigated O
whether O
theaflavins B
( O
TFs O
) O
affect O
the O
absorption O
of O
small O
peptides O
in O
human O
intestinal O
Caco O
- O
2 O
cells O
, O
since O
TFs O
do O
not O
penetrate O
through O
the O
cells O
and O
might O
be O
involved O
in O
intestinal O
transport O
systems O
. O

In O
transport O
experiments O
, O
the O
transport O
of O
glycyl O
- O
sarcosine O
( O
Gly O
- O
Sar O
, O
a O
model O
molecule O
for O
PEPT1 O
transport O
) O
and O
other O
dipeptides B
( O
Val O
- O
Tyr O
and O
Ile O
- O
Phe O
) O
were O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
in O
TFs O
- O
pretreated O
cells O
. O

In O
TF O
3 O
' O
- O
O O
- O
gallate O
- O
pretreated O
cells O
, O
Western O
blot O
analysis O
revealed O
attenuated O
expression O
of O
PEPT1 O
transporter O
and O
Gly O
- O
Sar O
transport O
was O
completely O
ameliorated O
by O
10 O
mu O
M O
Compound O
C O
, O
an O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
. O

Analysing O
chemical O
composition O
of O
the O
extracted O
oil O
by O
GC O
- O
MS O
showed O
that O
the O
content O
of O
unsaturated B
fatty I
acids I
by O
this O
emerging O
method O
( O
91 O
. O
18 O
% O
) O
was O
similar O
to O
that O
by O
conventional O
organic O
solvent O
extraction O
( O
88 O
. O
76 O
% O
) O
. O

Monitoring O
the O
effect O
of O
high O
pressure O
and O
transglutaminase O
treatment O
of O
milk O
on O
the O
evolution O
of O
flavour O
compounds O
during O
lactic B
acid I
fermentation O
using O
PTR O
- O
ToF O
- O
MS O
. O

The O
presence O
of O
several O
tentatively O
identified O
volatile O
flavour O
compounds O
( O
VOCs O
) O
, O
both O
during O
the O
enzymatic O
treatment O
and O
the O
lactic B
acid I
fermentation O
of O
the O
milk O
base O
, O
were O
monitored O
using O
a O
proton O
transfer O
reaction O
time O
- O
of O
- O
flight O
mass O
spectrometer O
( O
PTR O
- O
ToF O
- O
MS O
) O
. O

The O
formation O
of O
the O
major O
flavour O
compounds O
( O
acetaldehyde B
, O
diacetyl B
, O
acetoin B
, O
and O
2 O
- O
butanone O
) O
followed O
a O
sigmoidal O
trend O
described O
by O
the O
modified O
Gompertz O
model O
. O

The O
HHP O
treatment O
of O
milk O
increased O
significantly O
the O
volatile O
compound O
formation O
rate O
whereas O
it O
did O
not O
affect O
the O
duration O
of O
the O
lag O
phase O
of O
formation O
, O
with O
the O
exception O
of O
acetaldehyde B
and O
diacetyl B
formation O
. O

Purification O
and O
characterisation O
of O
two O
enzymes O
related O
to O
endogenous O
formaldehyde B
in O
Lentinula O
edodes O
. O

We O
found O
that O
GGT O
together O
with O
C O
- O
S O
lyase O
caused O
the O
generation O
of O
endogenous O
formaldehyde B
in O
L O
. O
edodes O
. O

GGT O
was O
composed O
of O
a O
large O
subunit O
of O
41 O
kDa O
and O
a O
small O
subunit O
of O
25 O
kDa O
, O
and O
C O
- O
S O
lyase O
was O
composed O
of O
two O
identical O
subunits O
of O
46 O
kDa O
, O
as O
determined O
by O
SDS B
- O
PAGE O
. O

The O
present O
work O
supports O
the O
study O
of O
the O
mechanism O
of O
endogenous O
formaldehyde B
in O
L O
. O
edodes O
. O

Optimisation O
of O
synthesis O
of O
oligosaccharides O
derived O
from O
lactulose B
( O
fructosyl O
- O
galacto O
- O
oligosaccharides O
) O
with O
beta O
- O
galactosidases O
of O
different O
origin O
. O

Batch O
synthesis O
of O
fructosyl O
- O
galacto O
- O
oligosaccharides O
from O
lactulose B
was O
performed O
with O
commercial O
beta O
- O
galactosidase O
preparations O
from O
Aspergillus O
oryzae O
, O
Kluyveromyces O
lactis O
and O
Bacillus O
circulans O
. O

Optimization O
of O
fructosyl O
- O
galacto O
- O
oligosaccharides O
synthesis O
was O
carried O
out O
using O
response O
surface O
methodology O
, O
considering O
temperature O
and O
initial O
sugar B
concentration O
as O
variables O
and O
yield O
and O
specific O
productivity O
as O
response O
parameters O
. O

Maximum O
yield O
of O
0 O
. O
41 O
g O
g O
( O
- O
1 O
) O
fructosyl O
- O
galacto O
- O
oligosaccharides O
was O
obtained O
at O
70 O
degrees O
C O
and O
60 O
% O
w O
/ O
w O
lactulose B
concentration O
, O
while O
maximum O
specific O
productivity O
of O
1 O
. O
2 O
g O
h O
( O
- O
1 O
) O
mg O
( O
- O
1 O
) O
was O
obtained O
at O
70 O
degrees O
C O
and O
40 O
% O
w O
/ O
w O
lactulose B
concentration O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
interactions O
between O
ABCG2 O
and O
56 O
naturally O
- O
occurring O
phytochemicals O
including O
phenolic B
acids I
, O
flavonoids B
, O
triterpenes B
and O
other O
common O
dietary O
phytochemicals O
, O
as O
well O
as O
two O
non O
plant O
- O
based O
compounds O
( O
hippuric O
acid O
and O
propyl B
gallate I
) O
using O
cell O
- O
and O
membrane O
- O
based O
transport O
inhibition O
assays O
. O

Of O
the O
non O
- O
flavonoid B
phytochemicals O
tested O
, O
berberine B
, O
celastrol B
, O
ellagic B
acid I
, O
limonin O
, O
oleanolic B
acid I
, O
propyl B
gallate I
, O
sinapic B
acid I
and O
ursolic B
acid I
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Chrysoeriol B
, O
laricitrin O
, O
myricetin O
3 O
' O
, O
4 O
' O
, O
5 O
' O
- O
trimethylether O
, O
pinocembrin B
, O
quercitrin O
, O
tamarixetin O
, O
tricetin B
and O
tricetin O
3 O
' O
, O
4 O
' O
, O
5 O
' O
- O
trimethylether O
were O
also O
identified O
as O
novel O
flavonoid B
ABCG2 O
inhibitors O
. O

Thermal O
processing O
can O
promote O
reactions O
that O
change O
the O
structure O
of O
food O
constituents O
, O
often O
by O
unknown O
mechanisms O
, O
such O
as O
those O
occurring O
in O
arabinose B
residues O
of O
coffee O
arabinogalactan O
side O
chains O
. O

Also O
, O
products O
resulting O
from O
dehydration O
, O
oxidation O
, O
and O
cleavage O
of O
a O
carbon B
- O
carbon B
bond O
at O
the O
reducing O
end O
of O
the O
corresponding O
non O
- O
modified O
oligosaccharide O
were O
formed O
, O
probably O
promoting O
the O
release O
of O
formaldehyde B
, O
formic B
acid I
, O
glycolaldehyde O
, O
glyoxal B
, O
acetic B
acid I
, O
glycolic O
acid O
, O
glyceraldehyde B
, O
2 O
- O
hydroxypropanedialde O
and O
lactic O
acid O
. O

Changes O
in O
chemical O
composition O
( O
total O
and O
coagulable O
protein O
content O
, O
ash O
and O
minerals O
content O
and O
amino B
acid I
composition O
) O
, O
functional O
properties O
( O
protein O
solubility O
index O
, O
emulsifying O
activity O
and O
foaming O
capacity O
, O
water O
and O
oil O
absorption O
capacity O
) O
and O
phosphorus B
were O
determined O
. O

The O
PP O
- O
PPI O
at O
pH O
5 O
. O
2 O
was O
characterised O
by O
the O
highest O
content O
of O
all O
amino B
acids I
, O
whereas O
, O
PP O
- O
PPI O
under O
alkaline O
conditions O
( O
pH O
10 O
. O
5 O
) O
caused O
decrease O
in O
these O
compounds O
. O

The O
volatile O
oil O
was O
fractioned O
by O
silica B
gel I
column O
chromatography O
. O

Model O
experiments O
revealed O
that O
cis O
- O
2 O
, O
6 O
- O
dimethyl O
- O
1 O
, O
4 O
- O
cyclohexanedione O
was O
formed O
via O
thermal O
degradation O
of O
sugars B
, O
especially O
monosaccharides B
, O
under O
alkaline O
conditions O
. O

Further O
, O
we O
demonstrated O
that O
2 O
- O
hydroxy O
- O
3 O
- O
pentanone O
and O
1 O
- O
hydroxy O
- O
2 O
- O
propanone O
, O
thermal O
degradation O
products O
of O
monosaccharides B
, O
were O
closely O
related O
to O
the O
formation O
of O
cis O
- O
2 O
, O
6 O
- O
dimethyl O
- O
1 O
, O
4 O
- O
cyclohexanedione O
. O

Determination O
of O
major O
phlorotannins B
in O
Eisenia O
bicyclis O
using O
hydrophilic O
interaction O
chromatography O
: O
seasonal O
variation O
and O
extraction O
characteristics O
. O

In O
this O
study O
, O
a O
hydrophilic O
interaction O
chromatography O
( O
HILIC O
) O
condition O
was O
developed O
for O
the O
simultaneous O
determination O
of O
five O
major O
phlorotannins B
from O
an O
extract O
of O
Eisenia O
bicyclis O
( O
Kjellman O
) O
Setchell O
with O
good O
linearity O
( O
r O
( O
2 O
) O
> O
0 O
. O
999 O
) O
. O

Based O
on O
this O
method O
, O
the O
seasonal O
variations O
and O
extraction O
characteristics O
, O
in O
terms O
of O
total O
extraction O
yield O
and O
the O
content O
of O
the O
phlorotannins B
, O
were O
investigated O
under O
various O
extraction O
conditions O
. O

In O
results O
, O
the O
yields O
and O
phlorotannins B
were O
increased O
two O
- O
to O
- O
four O
times O
in O
summer O
( O
June O
- O
October O
) O
and O
then O
, O
were O
decreased O
to O
normal O
levels O
in O
winter O
( O
November O
- O
March O
) O
. O

In O
the O
extraction O
of O
E O
. O
bicyclis O
, O
ethanol B
percentage O
in O
water O
, O
extraction O
time O
and O
washing O
time O
significantly O
affected O
the O
yield O
of O
the O
extract O
and O
the O
phlorotannins B
, O
whereas O
the O
temperature O
and O
the O
sample O
/ O
solvent O
ratio O
impacted O
the O
extraction O
to O
a O
lesser O
degree O
. O

Effect O
of O
dietary O
carnosic O
acid O
on O
the O
fatty B
acid I
profile O
and O
flavour O
stability O
of O
meat O
from O
fattening O
lambs O
. O

Thirty O
- O
two O
lambs O
were O
fed O
with O
barley O
straw O
supplemented O
by O
a O
concentrate O
alone O
, O
or O
a O
concentrate O
enriched O
with O
either O
vitamin B
E I
( O
VITE006 O
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
or O
carnosic O
acid O
( O
CARN006 O
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
; O
or O
CARN012 O
: O
1 O
. O
2 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
. O

In O
order O
to O
elucidate O
the O
influence O
of O
the O
dietary O
supplementation O
of O
carnosic O
compared O
with O
a O
reference O
diet O
antioxidant O
( O
vitamin B
E I
) O
, O
the O
animals O
were O
slaughtered O
and O
the O
longissimus O
thoracis O
were O
lyophilised O
to O
determine O
the O
FAs B
profile O
and O
the O
phenolic B
compounds O
. O

Dietary O
carnosic O
acid O
did O
not O
modify O
the O
FAs B
profile O
, O
but O
had O
a O
clear O
effect O
on O
the O
production O
of O
volatile O
compounds O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

Innovative O
microwave O
- O
assisted O
hydrolysis O
of O
ellagitannins O
and O
quantification O
as O
ellagic B
acid I
equivalents O
. O

The O
health O
- O
promoting O
effects O
of O
ellagic B
acid I
and O
its O
intestinal O
degradation O
products O
are O
well O
- O
known O
. O

In O
plants O
, O
ellagic B
acid I
mainly O
appears O
in O
the O
form O
of O
its O
precursors O
, O
the O
so O
- O
called O
ellagitannins O
. O

Therefore O
, O
determination O
of O
total O
ellagic B
acid I
content O
has O
been O
accomplished O
by O
cleaving O
ellagitannins O
with O
high O
temperatures O
and O
strong O
acids O
. O

Thermal O
degradation O
kinetics O
of O
the O
major O
blood O
orange O
xanthophylls O
( O
cis O
- O
violaxanthin O
, O
lutein B
, O
beta B
- I
cryptoxanthin I
, O
zeaxanthin B
and O
cis O
- O
antheraxanthin O
) O
were O
investigated O
at O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
degrees O
C O
in O
real O
juice O
and O
three O
model O
systems O
formulated O
to O
evaluate O
the O
impact O
of O
xanthophyll O
form O
( O
esterified O
or O
free O
) O
and O
pH O
( O
acid O
or O
neutral O
) O
. O

In O
all O
acidic O
media O
, O
beta B
- I
cryptoxanthin I
exhibited O
the O
lowest O
degradation O
rates O
followed O
by O
lutein B
and O
zeaxanthin B
. O

In O
comparison O
, O
the O
epoxy B
carotenoids O
cis O
- O
violaxanthin O
and O
cis O
- O
antheraxanthin O
degraded O
around O
3 O
- O
fold O
faster O
in O
their O
esterified O
form O
. O

By O
contrast O
, O
in O
neutral O
medium O
, O
free O
epoxy B
- O
xanthophylls O
were O
about O
2 O
- O
fold O
more O
stable O
than O
were O
the O
free O
hydroxy B
xanthophylls O
lutein B
, O
zeaxanthin B
and O
beta B
- I
cryptoxanthin I
. O

Gender O
and O
body O
mass O
index O
modify O
the O
effect O
of O
increasing O
amounts O
of O
caffeinated O
coffee O
on O
postprandial O
glucose B
and O
insulin O
concentrations O
; O
a O
randomized O
, O
controlled O
, O
clinical O
trial O
. O

OBJECTIVE O
: O
To O
examine O
the O
effects O
of O
different O
coffee O
amounts O
on O
blood O
glucose B
and O
insulin O
concentrations O
of O
healthy O
volunteers O
, O
and O
to O
assess O
potential O
effect O
modification O
by O
sex O
and O
body O
mass O
index O
category O
. O

Iota O
n O
the O
morning O
of O
each O
experimental O
day O
volunteers O
received O
a O
standardized O
meal O
along O
with O
200mL O
of O
water O
or O
instant O
coffee O
containing O
either O
3 O
or O
6mg O
of O
caffeine B
/ O
kg O
body O
weight O
. O

Blood O
samples O
were O
obtained O
and O
analyzed O
for O
glucose B
and O
insulin O
concentrations O
in O
the O
fasting O
state O
, O
immediately O
after O
meal O
/ O
drink O
consumption O
and O
at O
standard O
time O
points O
for O
the O
next O
3h O
thereafter O
. O

RESULTS O
: O
Coffee O
delayed O
the O
rise O
of O
insulin O
in O
response O
to O
the O
standardized O
meal O
and O
the O
fall O
of O
glucose B
concentrations O
from O
its O
maximum O
levels O
in O
the O
entire O
study O
sample O
. O

Glucose B
incremental O
area O
under O
the O
curve O
( O
IAUC O
) O
was O
significantly O
different O
between O
interventions O
( O
P O
= O
. O
009 O
) O
with O
both O
coffee O
amounts O
inducing O
a O
greater O
area O
compared O
to O
water O
. O

CONCLUSIONS O
: O
Coffee O
exerts O
an O
acute O
effect O
on O
postprandial O
glucose B
and O
insulin O
concentrations O
. O

In O
further O
anti O
- O
inflammatory O
research O
, O
thienopyridine O
derivative O
1a O
showed O
potent O
inhibition O
of O
nitric B
oxide I
( O
NO B
) O
production O
. O

The O
structure O
- O
activity O
relationships O
( O
SARs O
) O
revealed O
that O
the O
most O
potent O
analogues O
1f O
and O
1o O
were O
identified O
as O
potent O
inhibitors O
of O
NO B
production O
with O
IC50 O
values O
of O
3 O
. O
30 O
and O
3 O
. O
24 O
mu O
M O
, O
respectively O
. O

In O
formalin B
- O
induced O
inflammatory O
pain O
we O
assessed O
the O
effect O
of O
opioid O
antagonists O
on O
antinociceptive O
activity O
of O
BTX O
- O
A O
. O

To O
investigate O
the O
effects O
of O
naltrexone O
and O
BTX O
- O
A O
on O
neuronal O
activation O
in O
spinal O
cord O
, O
c O
- O
Fos O
expression O
was O
immunohistochemicall O
examined O
in O
a O
model O
of O
formalin B
- O
induced O
pain O
. O

Antinociceptive O
effects O
of O
BTX O
- O
A O
in O
formalin B
and O
sciatic O
nerve O
transection O
- O
induced O
pain O
were O
prevented O
by O
non O
- O
selective O
opioid O
antagonist O
naltrexone O
. O

Construction O
of O
block O
copolymers O
for O
the O
coordinated O
delivery O
of O
doxorubicin B
and O
magnetite O
nanocubes O
. O

In O
this O
paper O
, O
we O
report O
the O
coordinated O
in O
vivo O
delivery O
of O
anti O
- O
cancer O
drugs O
and O
imaging O
agents O
by O
chemically O
loading O
doxorubicin B
and O
magnetite O
nanocubes O
( O
MNs O
) O
in O
the O
core O
of O
polymeric O
nanoparticles O
. O

Living O
polymerization O
, O
nitroxide B
- O
mediated O
radical O
polymerization O
( O
NMP O
) O
, O
was O
applied O
to O
construct O
the O
optimal O
polymers O
to O
co O
- O
deliver O
doxorubicin B
and O
MNs O
. O

The O
resulting O
diblock O
polymers O
consisted O
of O
one O
block O
with O
triethylene O
glycol O
brushes O
and O
another O
block O
with O
carboxylic B
acid I
groups O
to O
bind O
doxorubicin B
and O
Fe3O4 B
MNs O
. O

The O
optimal O
polymer O
has O
narrow O
polydispersity O
( O
PDI O
= O
1 O
. O
2 O
) O
and O
high O
doxorubicin B
/ O
MN O
loading O
( O
30wt O
. O
% O
/ O
28wt O
. O
% O
) O
. O

The O
doxorubicin B
and O
MNs O
loaded O
in O
this O
polymeric O
system O
showed O
highly O
coordinated O
bio O
- O
distribution O
in O
the O
balb O
/ O
C O
mice O
model O
. O

Oxidative O
stress O
responses O
in O
zebrafish O
Danio O
rerio O
after O
subchronic O
exposure O
to O
atrazine B
. O

Atrazine B
is O
one O
of O
the O
most O
used O
pesticides O
all O
over O
the O
world O
and O
it O
is O
frequently O
detected O
in O
surface O
water O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
if O
zebrafish O
exposure O
to O
atrazine B
could O
induce O
oxidative O
stress O
and O
changes O
in O
detoxifying O
system O
. O

The O
level O
of O
oxidized O
lipids O
increased O
in O
experimental O
groups O
exposed O
to O
atrazine B
at O
30 O
and O
90 O
mu O
gL O
( O
- O
1 O
) O
compared O
to O
control O
. O

Activity O
of O
glutathione B
S B
- O
transferase O
decreased O
in O
group O
with O
the O
highest O
concentration O
compared O
to O
control O
. O

Activity O
of O
superoxide B
dismutase O
increased O
only O
in O
experimental O
group O
exposed O
to O
atrazine B
at O
30 O
mu O
gL O
( O
- O
1 O
) O
compared O
to O
control O
. O

Activity O
of O
glutathione B
peroxidase O
and O
reductase O
( O
GR O
) O
increased O
in O
experimental O
groups O
exposed O
to O
atrazine B
at O
0 O
. O
3 O
( O
only O
for O
GR O
activity O
) O
and O
90 O
mu O
gL O
( O
- O
1 O
) O
compared O
to O
control O
. O

Our O
results O
showed O
that O
atrazine B
exposure O
had O
profound O
influence O
on O
the O
oxidative O
stress O
markers O
and O
detoxifying O
enzyme O
of O
the O
exposed O
zebrafish O
. O

The O
changes O
in O
antioxidant O
enzyme O
activities O
could O
be O
an O
adaptive O
response O
to O
protect O
the O
fish O
from O
the O
atrazine B
- O
induced O
toxicity O
. O

In O
our O
present O
study O
, O
QD705 O
- O
COOH O
and O
QD705 O
- O
PEG B
activated O
NF O
- O
kappa O
B O
and O
increased O
monocyte O
chemotactic O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
expression O
in O
macrophages O
RAW264 O
. O
7 O
via O
MyD88 O
dependent O
Toll O
- O
like O
receptor O
( O
TLR O
) O
signaling O
pathways O
. O

Co O
- O
treatment O
with O
a O
TLR4 O
inhibitor O
completely O
prevented O
MCP O
- O
1 O
induction O
by O
QD705 O
- O
PEG B
. O

Nevertheless O
, O
QD705 O
- O
COOH B
readily O
entered O
cells O
, O
and O
co O
- O
treatment O
with O
either O
inhibitors O
of O
endocytosis O
or O
intracellular O
TLRs O
prevented O
MCP O
- O
1 O
induction O
. O

The O
aim O
of O
the O
current O
investigations O
was O
to O
compare O
cytotoxicity O
of O
ticlopidine O
, O
clopidogrel B
, O
clopidogrel O
carboxylate O
and O
prasugrel O
for O
human O
neutrophil O
granulocytes O
with O
the O
toxicity O
for O
lymphocytes O
and O
to O
investigate O
underlying O
mechanisms O
. O

For O
granulocytes O
, O
clopidogrel B
, O
ticlopidine O
, O
clopidogrel O
carboxylate O
and O
prasugrel O
were O
concentration O
- O
dependently O
toxic O
starting O
at O
10 O
mu O
M O
. O

Cytotoxicity O
could O
be O
prevented O
by O
the O
myeloperoxidase O
inhibitor O
rutin B
, O
but O
not O
by O
the O
cytochrome O
P450 O
inhibitor O
ketoconazole B
. O

All O
compounds O
were O
also O
toxic O
for O
lymphocytes O
, O
but O
cytotoxicity O
started O
at O
100 O
mu O
M O
and O
could O
not O
be O
prevented O
by O
rutin B
or O
ketoconazole B
. O

Granulocytes O
metabolized O
ticlopidine O
, O
clopidogrel B
, O
clopidogrel O
carboxylate O
and O
prasugrel O
, O
and O
metabolization O
was O
inhibited O
by O
rutin B
, O
but O
not O
by O
ketoconazole B
. O

Metabolism O
of O
these O
compounds O
by O
lymphocytes O
was O
much O
slower O
and O
could O
not O
be O
inhibited O
by O
ketoconazole B
or O
rutin B
. O

All O
of O
these O
effects O
could O
be O
inhibited O
by O
rutin B
, O
but O
not O
by O
ketoconazole B
. O

Similar O
findings O
were O
obtained O
in O
lymphocytes O
; O
but O
compared O
to O
neutrophils O
, O
the O
effects O
were O
detectable O
only O
at O
higher O
concentrations O
and O
were O
not O
inhibited O
by O
rutin B
. O

In O
conclusion O
, O
ticlopidine O
, O
clopidogrel B
, O
clopidogrel O
carboxylate O
and O
prasugrel O
are O
toxic O
for O
both O
granulocytes O
and O
lymphocytes O
. O

Synthesis O
and O
antifungal O
activity O
of O
C O
- O
21 O
steroids B
with O
an O
aromatic O
D O
ring O
. O

Six O
analogues O
of O
salpichrolides O
with O
a O
simplified O
side O
chain O
( O
6 O
- O
11 O
) O
were O
synthesized O
using O
a O
new O
methodology O
to O
obtain O
steroids B
with O
an O
aromatic O
D O
- O
ring O
. O

Female O
C57BL O
/ O
6 O
mice O
were O
exposed O
to O
dextran O
sodium B
sulphate I
( O
DSS O
) O
and O
treated O
by O
intrarectal O
administration O
with O
either O
CD O
. O
siRNA O
TNF O
- O
alpha O
or O
a O
control O
solution O
. O

Structural O
Basis O
for O
the O
ATP B
- O
Induced O
Isomerization O
of O
Kinesin O
. O

Kinesin O
superfamily O
proteins O
( O
KIFs O
) O
are O
microtubule O
- O
based O
molecular O
motors O
driven O
by O
the O
energy O
derived O
from O
the O
hydrolysis O
of O
ATP B
. O

Previous O
studies O
have O
revealed O
that O
the O
ATP B
binding O
step O
is O
crucial O
both O
for O
the O
power O
stroke O
to O
produce O
motility O
and O
for O
the O
inter O
- O
domain O
regulation O
of O
ATPase O
activity O
to O
guarantee O
the O
processive O
movement O
of O
dimeric O
KIFs O
. O

Here O
, O
we O
report O
the O
first O
crystal O
structure O
of O
KIF4 O
complexed O
with O
the O
non O
- O
hydrolyzable O
ATP B
analog O
, O
AMPPNP O
( O
adenylyl O
imidodiphosphate O
) O
, O
at O
1 O
. O
7 O
A O
resolution O
. O

By O
combining O
our O
structure O
with O
previously O
solved O
KIF1A O
structures O
complexed O
with O
two O
ATP B
analogs O
, O
molecular O
snapshots O
during O
ATP B
binding O
reveal O
that O
the O
closure O
of O
the O
nucleotide B
- O
binding O
pocket O
during O
ATP B
binding O
is O
achieved O
by O
closure O
of O
the O
backdoor O
. O

Closure O
of O
the O
backdoor O
stabilizes O
two O
mobile O
regions O
, O
switch O
I O
and O
switch O
II O
, O
to O
generate O
the O
phosphate B
tube O
from O
which O
hydrolyzed O
phosphate B
is O
released O
. O

Oxysterols B
in O
cancer O
cell O
proliferation O
and O
death O
. O

Oxysterols B
have O
been O
shown O
to O
interfere O
with O
proliferation O
and O
cause O
the O
death O
of O
many O
cancer O
cell O
types O
, O
such O
as O
leukaemia O
, O
glioblastoma O
, O
colon O
, O
breast O
and O
prostate O
cancer O
cells O
, O
while O
they O
have O
little O
or O
no O
effect O
on O
senescent O
cells O
. O

The O
mechanisms O
by O
which O
oxysterols B
may O
influence O
proliferation O
are O
manifold O
: O
they O
control O
the O
transcription O
and O
the O
turnover O
of O
the O
key O
enzyme O
in O
cholesterol B
synthesis O
, O
3 O
- O
hydroxy O
- O
3 O
- O
methylglutaryl O
CoA O
reductase O
, O
by O
binding O
to O
Insig O
- O
1 O
, O
Insig O
- O
2 O
and O
liver O
X O
receptors O
. O

Oxysterols B
are O
thought O
to O
be O
generated O
in O
proportion O
to O
the O
rate O
of O
cholesterol B
synthesis O
. O

Although O
there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols B
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O

The O
25 O
- O
and O
the O
27 O
- O
cholesterol B
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O

Cholesterol B
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols B
. O

Oxysterols B
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O

When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols B
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O

Therefore O
, O
the O
two O
facets O
of O
oxysterol B
action O
that O
seem O
important O
for O
cancer O
treatment O
, O
cytostaticity O
and O
cytotoxicity O
, O
will O
be O
discussed O
. O

Intermediate O
- O
conductance O
calcium B
- O
activated O
K B
( I
+ I
) I
channels O
( O
KCa3 O
. O
1 O
channels O
) O
have O
important O
roles O
in O
cell O
proliferation O
. O

It O
was O
found O
that O
mRNA O
, O
protein O
, O
and O
current O
density O
of O
KCa3 O
. O
1 O
channels O
were O
greatly O
enhanced O
in O
cultured O
cardiac O
fibroblasts O
treated O
with O
1 O
mu O
M O
Ang O
II O
, O
and O
the O
effects O
were O
countered O
by O
the O
angiotensin O
type O
1 O
receptor O
( O
AT1R O
) O
blocker O
losartan O
, O
the O
p38 O
- O
MAPK O
inhibitor O
SB203580 B
, O
the O
ERK1 O
/ O
2 O
inhibitor O
PD98059 B
, O
and O
the O
PI3K O
/ O
Akt O
inhibitor O
LY294002 B
. O

Androgen B
and O
estrogen B
play O
an O
important O
role O
in O
the O
pathogenesis O
of O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
. O

Estrogen B
exerts O
its O
action O
through O
two O
distinct O
estrogen B
receptors O
( O
ERs O
) O
either O
ER O
- O
alpha O
or O
ER O
- O
beta O
. O

Thus O
, O
this O
study O
examined O
the O
protective O
effect O
of O
SIL O
against O
testosterone B
- O
induced O
BPH O
in O
rats O
. O

In O
an O
initial O
dose O
- O
response O
study O
, O
SIL O
in O
a O
dose O
of O
50mg O
/ O
kg O
was O
the O
most O
effective O
in O
preventing O
the O
rise O
in O
prostate O
weight O
, O
prostate O
weight O
/ O
body O
weight O
ratio O
and O
histopathologic O
changes O
induced O
by O
testosterone B
. O

Testosterone B
significantly O
decreased O
ER O
- O
beta O
and O
increased O
ER O
- O
alpha O
and O
AR O
expressions O
as O
compared O
to O
the O
control O
group O
and O
these O
effects O
were O
significantly O
ameliorated O
by O
SIL O
. O

Furthermore O
, O
SIL O
significantly O
protected O
against O
testosterone B
- O
provoked O
decline O
in O
mRNA O
expression O
of O
P21 O
( O
WAF1 O
/ O
Cip1 O
) O
and O
Bax O
/ O
Bcl O
- O
xl O
ratio O
as O
well O
as O
caspase O
- O
3 O
activity O
. O

SIL O
minimized O
the O
number O
of O
proliferating O
cell O
nuclear O
antigen O
( O
PCNA O
) O
positive O
cells O
as O
compared O
to O
testosterone B
- O
treated O
group O
. O

Collectively O
these O
findings O
elucidate O
the O
effectiveness O
of O
SIL O
in O
preventing O
testosterone B
- O
induced O
BPH O
in O
rats O
. O

Vanadium B
exposure O
- O
induced O
neurobehavioral O
alterations O
among O
Chinese O
workers O
. O

Vanadium B
- O
containing O
products O
are O
manufactured O
and O
widely O
used O
in O
the O
modern O
industry O
. O

Yet O
the O
neurobehavioral O
toxicity O
due O
to O
occupational O
exposure O
to O
vanadium B
remained O
elusive O
. O

This O
cross O
- O
sectional O
study O
was O
designed O
to O
examine O
the O
neurotoxic O
effects O
of O
occupational O
vanadium B
exposure O
. O

A O
total O
of O
463 O
vanadium B
- O
exposed O
workers O
( O
exposed O
group O
) O
and O
251 O
non O
- O
exposed O
workers O
( O
control O
group O
) O
were O
recruited O
from O
a O
Steel O
and O
Iron B
Group O
in O
Sichuan O
, O
China O
. O

Given O
the O
findings O
of O
our O
study O
and O
the O
limitations O
of O
neurobehavioral O
workplace O
testing O
, O
we O
found O
evidence O
of O
altered O
neurobehavioral O
outcomes O
by O
occupational O
exposure O
to O
vanadium B
. O

The O
lowest O
levels O
of O
peroxide B
value O
( O
PV O
) O
, O
thiobarbituric B
acid I
reactive O
substances O
( O
TBARs O
) O
, O
cholesterol B
oxidation O
products O
( O
COPs O
) O
and O
the O
highest O
level O
of O
polyunsaturated B
fatty I
acids I
( O
PUFAs B
) O
content O
, O
especially O
PUFA O
n O
- O
3 O
, O
were O
found O
in O
the O
untreated O
sardines O
( O
time O
zero O
) O
. O

After O
light O
exposure O
, O
PUFA B
dramatically O
dropped O
( O
up O
to O
a O
19 O
% O
decrease O
) O
and O
a O
marked O
increase O
of O
PV O
( O
11 O
. O
8meq O
O2 B
/ O
kg O
fat O
) O
, O
TBARs O
( O
3 O
. O
7mg O
MDA O
/ O
kg O
meat O
) O
and O
COPs O
( O
3 O
. O
7 O
mu O
g O
/ O
g O
muscle O
) O
was O
observed O
; O
under O
darkness O
, O
the O
values O
of O
the O
oxidation O
parameters O
were O
similar O
to O
those O
found O
in O
untreated O
sardines O
. O

Although O
cholesterol B
oxidation O
rate O
did O
not O
exceed O
0 O
. O
9 O
% O
, O
further O
research O
is O
required O
about O
toxicity O
levels O
of O
the O
single O
COPs O
, O
to O
better O
understand O
if O
the O
COPs O
levels O
found O
in O
untreated O
and O
photoxidized O
muscle O
( O
0 O
. O
62 O
- O
3 O
. O
72 O
mu O
g O
/ O
g O
of O
muscle O
) O
do O
not O
represent O
a O
risk O
for O
human O
health O
. O

Safety O
of O
purified O
decolorized O
( O
low O
anthraquinone B
) O
whole O
leaf O
Aloe O
vera O
( O
L O
) O
Burm O
. O

The O
test O
material O
contained O
total O
anthraquinones B
at O
< O
0 O
. O
1parts O
per O
million O
. O

Similar O
concentrations O
of O
non O
- O
decolorized O
( O
unpurified O
, O
high O
anthraquinone B
) O
Aloe O
vera O
extracts O
tested O
in O
other O
studies O
have O
resulted O
in O
an O
increased O
incidence O
and O
severity O
of O
diarrhea O
and O
colon O
adenomas O
and O
carcinomas O
. O

The O
results O
of O
this O
study O
supports O
the O
assertion O
that O
the O
high O
levels O
of O
anthraquinone B
present O
in O
orally O
administered O
, O
non O
- O
purified O
whole O
leaf O
Aloe O
vera O
extract O
may O
be O
responsible O
for O
the O
adverse O
effects O
observed O
on O
the O
colon O
. O

EROD O
activity O
induction O
in O
peripheral O
blood O
lymphocytes O
, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic B
aromatic I
hydrocarbons I
. O

Little O
is O
known O
in O
terms O
of O
multi O
- O
matrix O
cytochrome O
P450 O
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated O
and O
polycyclic O
aromatic O
hydrocarbons O
( O
PHH O
, O
PAH B
) O
. O

In O
the O
present O
study O
, O
60 O
rats O
were O
daily O
exposed O
, O
during O
28days O
, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene B
, O
pyrene B
and O
benzo B
( I
a I
) I
pyrene I
at O
0 O
, O
6 O
or O
600 O
mu O
g O
/ O
day O
. O

A O
series O
of O
novel O
2 O
- O
ferrocenyl O
- O
7 O
- O
hydroxy O
- O
5 O
- O
phenethyl O
- O
5 O
, O
6 O
, O
7 O
, O
8 O
- O
tetrahydro O
- O
4H O
- O
pyrazolo O
[ O
1 O
, O
5 O
- O
a O
] O
[ O
1 O
, O
4 O
] O
diazepin O
- O
4 O
- O
one O
derivatives O
with O
optical O
activity O
( O
2 O
) O
was O
synthesized O
in O
the O
microwave O
- O
assisted O
condition O
and O
characterized O
by O
means O
of O
IR O
, O
( B
1 I
) I
H I
NMR O
and O
mass O
spectroscopy O
, O
and O
furthermore O
confirmed O
by O
X O
- O
ray O
analysis O
of O
a O
representative O
compound O
( O
R O
) O
- O
2a O
. O

Besides O
, O
compounds O
showed O
higher O
activity O
of O
inhibiting O
AChE O
- O
induced O
amyloid O
- O
beta O
( O
A O
beta O
) O
aggregation O
than O
curcumin B
, O
higher O
anti O
- O
oxidative O
activity O
than O
Trolox B
, O
and O
could O
also O
be O
good O
metal O
chelators O
. O

mu O
- O
Opioid O
receptors O
in O
the O
stimulation O
of O
mesolimbic O
dopamine B
activity O
by O
ethanol B
and O
morphine B
in O
Long O
- O
Evans O
rats O
: O
a O
delayed O
effect O
of O
ethanol B
. O

RATIONALE O
: O
Naltrexone O
, O
a O
non O
- O
selective O
opioid O
antagonist O
, O
decreases O
the O
euphoria O
and O
positive O
subjective O
responses O
to O
alcohol B
in O
heavy O
drinkers O
. O

It O
has O
been O
proposed O
that O
the O
mu O
- O
opioid O
receptor O
plays O
a O
role O
in O
ethanol B
reinforcement O
through O
modulation O
of O
ethanol B
- O
stimulated O
mesolimbic O
dopamine B
release O
. O

OBJECTIVES O
: O
To O
investigate O
the O
ability O
of O
naltrexone O
and O
beta B
- I
funaltrexamine I
, O
an O
irreversible O
mu O
- O
opioid O
specific O
antagonist O
, O
to O
inhibit O
ethanol B
- O
stimulated O
and O
morphine B
- O
stimulated O
mesolimbic O
dopamine B
release O
, O
and O
to O
determine O
whether O
opioid O
receptors O
on O
mesolimbic O
neurons O
contribute O
to O
these O
mechanisms O
. O

METHODS O
: O
Ethanol B
- O
na O
i O
ve O
male O
Long O
Evans O
rats O
were O
given O
opioid O
receptor O
antagonists O
either O
intravenously O
, O
subcutaneously O
, O
or O
intracranially O
into O
the O
ventral O
tegmental O
area O
( O
VTA O
) O
, O
followed O
by O
intravenous O
administration O
of O
ethanol B
or O
morphine B
. O

We O
measured O
extracellular O
dopamine B
in O
vivo O
using O
microdialysis O
probes O
inserted O
into O
the O
nucleus O
accumbens O
shell O
( O
n O
= O
114 O
) O
. O

RESULTS O
: O
Administration O
of O
naltrexone O
( O
intravenously O
) O
and O
beta B
- I
funaltrexamine I
( O
subcutaneously O
) O
, O
as O
well O
as O
intracranial O
injection O
of O
naltrexone O
into O
the O
VTA O
did O
not O
prevent O
the O
initiation O
of O
dopamine B
release O
by O
intravenous O
ethanol B
administration O
, O
but O
prevented O
it O
from O
being O
as O
prolonged O
. O

In O
contrast O
, O
morphine B
- O
stimulated O
mesolimbic O
dopamine B
release O
was O
effectively O
suppressed O
. O

CONCLUSIONS O
: O
Our O
results O
provide O
novel O
evidence O
that O
there O
are O
two O
distinct O
mechanisms O
that O
mediate O
ethanol B
- O
stimulated O
mesolimbic O
dopamine B
release O
( O
an O
initial O
phase O
and O
a O
delayed O
phase O
) O
, O
and O
that O
opioid O
receptor O
activation O
is O
required O
to O
maintain O
the O
delayed O
- O
phase O
dopamine B
release O
. O

Moreover O
, O
mu O
- O
opioid O
receptors O
account O
for O
this O
delayed O
- O
phase O
dopamine B
response O
, O
and O
the O
VTA O
is O
potentially O
the O
site O
of O
action O
of O
this O
mechanism O
. O

We O
conclude O
that O
mu O
- O
opioid O
receptors O
play O
different O
roles O
in O
the O
mechanisms O
of O
stimulation O
of O
mesolimbic O
dopamine B
activity O
by O
ethanol B
and O
morphine B
. O

Differential O
antidepressant O
- O
like O
response O
to O
lithium B
treatment O
between O
mouse O
strains O
: O
effects O
of O
sex O
, O
maternal O
care O
, O
and O
mixed O
genetic O
background O
. O

BACKGROUND O
: O
Lithium B
is O
a O
mood O
stabilizer O
with O
both O
antidepressant O
and O
antimanic O
properties O
, O
however O
its O
mechanism O
of O
action O
is O
unclear O
. O

Identifying O
the O
genetic O
factors O
that O
influence O
lithium B
' O
s O
therapeutic O
actions O
will O
be O
an O
important O
step O
to O
assist O
in O
identifying O
such O
mechanisms O
. O

We O
previously O
reported O
that O
lithium B
treatment O
of O
male O
mice O
has O
antidepressant O
- O
like O
effects O
in O
the O
C57BL O
/ O
6J O
strain O
but O
that O
such O
effects O
were O
absent O
in O
the O
BALB O
/ O
cJ O
strain O
. O

OBJECTIVES O
: O
This O
study O
aimed O
to O
assess O
the O
roles O
of O
both O
genetic O
and O
non O
- O
genetic O
factors O
such O
as O
sex O
and O
non O
- O
shared O
environmental O
conditions O
that O
may O
mediate O
differential O
behavioral O
responses O
to O
lithium B
. O

METHODS O
: O
Mice O
were O
treated O
with O
lithium B
for O
10 O
days O
and O
then O
tested O
in O
the O
forced O
swim O
test O
followed O
by O
lithium B
discontinuation O
and O
retesting O
to O
assess O
effects O
of O
lithium B
withdrawal O
. O

We O
also O
assessed O
effects O
of O
sex O
and O
cross O
- O
fostering O
on O
lithium B
response O
between O
the O
C57BL O
/ O
6J O
and O
BALB O
/ O
cJ O
strains O
, O
and O
antidepressant O
- O
like O
effects O
of O
lithium B
in O
the O
hybrid O
CB6F1 O
/ O
J O
strain O
that O
is O
derived O
from O
C57BL O
/ O
6J O
and O
BALB O
/ O
cJ O
parental O
strains O
. O

RESULTS O
: O
Neither O
sex O
nor O
maternal O
care O
significantly O
influenced O
the O
differential O
antidepressant O
- O
like O
response O
to O
lithium B
. O

Withdrawal O
from O
lithium B
treatment O
reversed O
antidepressant O
- O
like O
effects O
in O
the O
C57BL O
/ O
6J O
strain O
but O
had O
no O
effects O
in O
BALB O
/ O
cJ O
mice O
. O

Lithium B
treatment O
did O
not O
result O
in O
antidepressant O
- O
like O
effects O
in O
the O
CB6F1 O
/ O
J O
strain O
. O

CONCLUSIONS O
: O
Genetic O
factors O
are O
likely O
primarily O
responsible O
for O
differential O
antidepressant O
- O
like O
effects O
of O
lithium B
in O
the O
C57BL O
/ O
6J O
and O
BALB O
/ O
cJ O
strains O
. O

Future O
studies O
identifying O
such O
genetic O
factors O
may O
help O
to O
elucidate O
the O
neurobiological O
mechanisms O
of O
lithium B
' O
s O
therapeutic O
actions O
. O

Alcohol B
dependent O
patients O
have O
weak O
negative O
rather O
than O
strong O
positive O
implicit O
alcohol B
associations O
. O

RATIONALE O
: O
Alcohol B
dependence O
is O
characterised O
by O
motivational O
conflict O
( O
or O
ambivalence O
) O
in O
controlled O
cognitive O
processes O
, O
but O
it O
is O
unclear O
if O
ambivalence O
also O
exists O
within O
automatic O
cognitive O
processes O
, O
and O
if O
ambivalence O
operates O
between O
controlled O
and O
automatic O
processes O
. O

OBJECTIVE O
: O
To O
investigate O
ambivalence O
operating O
within O
and O
between O
controlled O
and O
automatic O
processes O
in O
alcohol B
dependence O
. O

METHOD O
: O
Alcohol B
- O
dependent O
patients O
who O
had O
recently O
completed O
inpatient O
alcohol B
detoxification O
( O
N O
= O
47 O
) O
and O
social O
drinking O
controls O
( O
N O
= O
40 O
) O
completed O
unipolar O
implicit O
association O
tests O
and O
self O
- O
report O
measures O
of O
alcohol B
approach O
and O
avoidance O
motivation O
and O
alcohol B
outcome O
expectancies O
. O

RESULTS O
: O
As O
predicted O
, O
both O
positive O
and O
negative O
alcohol B
outcome O
expectancies O
were O
stronger O
in O
alcohol B
- O
dependent O
patients O
compared O
to O
controls O
, O
indicative O
of O
ambivalence O
. O

Groups O
did O
not O
differ O
on O
implicit O
alcohol B
- O
positive O
associations O
, O
but O
alcohol B
- O
dependent O
participants O
had O
significantly O
weaker O
alcohol B
- O
negative O
associations O
than O
controls O
. O

Regression O
analyses O
revealed O
that O
implicit O
negative O
associations O
accounted O
for O
unique O
variance O
in O
group O
membership O
after O
controlling O
for O
alcohol B
outcome O
expectancies O
. O

CONCLUSIONS O
: O
Our O
findings O
demonstrate O
that O
alcohol B
dependent O
patients O
possess O
weak O
automatic O
alcohol B
- O
negative O
associations O
but O
not O
strong O
automatic O
alcohol B
- O
positive O
associations O
, O
and O
they O
suggest O
the O
presence O
of O
conflict O
between O
controlled O
and O
automatic O
processes O
with O
regard O
to O
negative O
alcohol B
cognitions O
. O

Simultaneous O
effects O
of O
two O
fungicides O
( O
copper B
and O
dimethomorph O
) O
on O
their O
phytoremediation O
using O
Lemna O
minor O
. O

Effects O
of O
two O
fungicides O
, O
copper B
and O
dimethomorph O
( O
( O
E O
, O
Z O
) O
4 O
- O
[ O
3 O
- O
( O
4 O
- O
chlorophenyl O
) O
- O
3 O
- O
( O
3 O
- O
4dimethoxyphenyl O
) O
acryloyl O
] O
morpholine O
) O
on O
Lemna O
minor O
growth O
and O
phytoremediation O
were O
evaluated O
. O

The O
toxicity O
of O
copper B
and O
dimethomorph O
alone O
and O
in O
combination O
, O
was O
assessed O
by O
growth O
inhibition O
of O
L O
. O
minor O
cultures O
after O
96 O
and O
168 O
h O
. O

Copper B
had O
a O
severe O
impact O
on O
growth O
( O
max O
. O
inhibition O
: O
90 O
% O
at O
1 O
, O
000 O
mu O
g O
L O
( O
- O
1 O
) O
) O
while O
dimethomorph O
( O
as O
pure O
ingredient O
or O
formulated O
as O
Forum O
) O
did O
not O
( O
inhibition O
< O
45 O
% O
at O
1 O
, O
000 O
mu O
g O
L O
( O
- O
1 O
) O
) O
after O
168 O
h O
of O
treatment O
. O

When O
both O
chemicals O
were O
combined O
, O
synergism O
was O
observed O
after O
96 O
h O
of O
exposure O
to O
copper B
and O
Forum O
. O

Additivity O
was O
also O
observed O
when O
the O
pure O
active O
ingredient O
( O
dimethomorph O
) O
replaced O
Forum O
in O
the O
mixture O
of O
copper B
and O
dimethomorph O
at O
96 O
and O
168 O
h O
. O

L O
. O
minor O
showed O
an O
excellent O
performance O
in O
removing O
copper B
from O
the O
medium O
since O
after O
96 O
h O
, O
36 O
, O
60 O
, O
and O
76 O
% O
removal O
were O
reached O
for O
10 O
, O
20 O
, O
and O
30 O
mu O
g O
L O
( O
- O
1 O
) O
of O
Cu B
respectively O
. O

Copper B
accumulated O
in O
the O
plants O
. O

The O
removal O
of O
copper B
increased O
with O
Forum O
concentration O
. O

After O
96 O
h O
copper B
( O
10 O
mu O
g O
L O
( O
- O
1 O
) O
initial O
concentration O
) O
elimination O
increased O
from O
36 O
. O
39 O
+ O
/ O
- O
5 O
. O
86 O
- O
60 O
. O
70 O
+ O
/ O
- O
6 O
. O
06 O
% O
when O
Forum O
concentration O
increased O
from O
0 O
to O
500 O
mu O
g O
L O
( O
- O
1 O
) O
. O

Accumulation O
of O
copper B
in O
plants O
was O
also O
increased O
by O
Forum O
but O
not O
by O
the O
active O
ingredient O
alone O
. O

This O
depuration O
decreased O
in O
the O
presence O
of O
copper B
possibly O
due O
to O
the O
metal O
toxicity O
. O

Sorting O
out O
Semiconducting O
Single O
- O
Walled O
Carbon B
Nanotube O
Arrays O
by O
Washing O
off O
Metallic O
Tubes O
Using O
SDS B
Aqueous O
Solution O
. O

Semiconducting O
single O
- O
walled O
carbon B
nanotube O
( O
s O
- O
SWNT O
) O
arrays O
are O
produced O
via O
a O
procedure O
analogous O
to O
a O
surfactant O
- O
assisted O
decontamination O
process O
. O

Aligned O
individual O
SWNT O
arrays O
grow O
on O
a O
quartz B
surface O
as O
a O
mixture O
of O
metallic O
SWNTs O
( O
m O
- O
SWNTs O
) O
and O
s O
- O
SWNTs O
. O

They O
are O
immersed O
in O
a O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
solution O
, O
and O
the O
SDS B
molecules O
selectively O
adsorb O
onto O
m O
- O
SWNTs O
. O

This O
SDS B
coating O
minimizes O
the O
interaction O
between O
m O
- O
SWNTs O
and O
the O
substrate O
, O
thus O
the O
m O
- O
SWNTs O
are O
easily O
washed O
off O
during O
ultrasonication O
while O
the O
s O
- O
SWNT O
arrays O
remain O
on O
the O
substrate O
. O

Electrochemical O
Oxygen B
Reduction O
Behavior O
of O
Selectively O
Deposited O
Platinum B
Atoms O
on O
Gold O
Nanoparticles O
. O

Carbon B
- O
supported O
Pt B
@ O
Au B
" O
core O
- O
shell O
" O
nanoparticles O
with O
varying O
surface O
concentration O
of O
platinum B
atoms O
have O
been O
synthesized O
using O
a O
novel O
redox O
- O
mediated O
synthesis O
approach O
. O

The O
synthesis O
technique O
allows O
for O
a O
selective O
deposition O
of O
platinum B
atoms O
on O
the O
surface O
of O
prefabricated O
gold O
nanoparticles O
. O

Energy O
dispersive O
spectroscopic O
analyses O
in O
a O
scanning O
electron O
microscope O
reveal O
that O
the O
platinum B
to O
gold O
atomic O
ratios O
are O
close O
to O
the O
nominal O
values O
, O
validating O
the O
synthesis O
scheme O
. O

The O
platinum B
to O
gold O
surface O
atomic O
ratio O
determined O
from O
cyclic O
voltammetry O
and O
copper B
under O
- O
potential O
deposition O
experiments O
reveal O
good O
agreement O
with O
the O
calculated O
values O
at O
low O
platinum B
concentration O
. O

However O
, O
there O
is O
an O
increase O
in O
non O
- O
uniformity O
in O
the O
deposition O
process O
upon O
increasing O
the O
platinum B
concentration O
. O

Koutecky O
- O
Levich O
analysis O
of O
the O
samples O
indicates O
a O
transition O
of O
the O
total O
number O
of O
electrons O
transferred O
( O
n O
) O
in O
the O
electrochemical O
oxygen B
reduction O
reaction O
from O
two O
to O
four O
electrons O
upon O
increasing O
the O
surface O
concentration O
of O
platinum B
atoms O
. O

Furthermore O
, O
the O
data O
indicate O
that O
isolated O
platinum B
atoms O
can O
reduce O
molecular O
oxygen B
but O
via O
a O
two O
- O
electron O
route O
. O

Moreover O
, O
successful O
four O
- O
electron O
reduction O
of O
molecular O
oxygen B
requires O
clusters O
of O
platinum B
atoms O
. O

Synthesis O
of O
phenyleneethynylene B
- O
doped O
poly O
( O
pphenylenebutadiynyl O
) O
s O
for O
live O
cell O
imaging O
. O

The O
high O
purity O
, O
molecular O
weight O
and O
correct O
compositions O
of O
each O
new O
polypeptide O
have O
been O
confirmed O
via O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
, O
sodium O
dodecyl O
sulfate O
polyacrylamide O
gel O
electrophoresis O
( O
SDS B
- O
PAGE O
) O
, O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
mass O
spectrometry O
( O
MALDI O
- O
MS O
) O
, O
and O
amino B
acid I
analysis O
. O

Structural O
Basis O
for O
Enzyme O
I O
Inhibition O
by O
alpha B
- I
Ketoglutarate I
. O

Creating O
new O
bacterial O
strains O
in O
which O
carbon B
and O
nitrogen B
metabolism O
are O
uncoupled O
is O
potentially O
very O
useful O
for O
optimizing O
yields O
of O
microbial O
produced O
chemicals O
from O
renewable O
carbon B
sources O
. O

However O
, O
the O
mechanisms O
that O
balance O
carbon B
and O
nitrogen B
consumption O
in O
bacteria O
are O
poorly O
understood O
. O

Recently O
, O
alpha B
- I
ketoglutarate I
( O
alpha O
KG O
) O
, O
the O
carbon B
substrate O
for O
ammonia B
assimilation O
, O
has O
been O
observed O
to O
inhibit O
Escherichia O
coli O
enzyme O
I O
( O
EI O
) O
, O
the O
first O
component O
of O
the O
bacterial O
phosphotransferase O
system O
( O
PTS O
) O
, O
thereby O
providing O
a O
direct O
biochemical O
link O
between O
central O
carbon B
and O
nitrogen B
metabolism O
. O

An O
enriched O
fraction O
of O
n B
- I
butanol I
was O
obtained O
, O
after O
partition O
. O

Then O
, O
the O
chemical O
profile O
was O
determined O
using O
a O
C18 O
reversed O
column O
chromatography O
in O
a O
gradient O
solvent O
system O
with O
10 O
- O
40 O
% O
acetonitrile B
in O
0 O
. O
1 O
% O
formic B
acid I
, O
for O
60 O
min O
. O

The O
applicability O
of O
this O
protocol O
is O
demonstrated O
experimentally O
by O
assessing O
the O
performance O
of O
diamond B
- O
like O
carbon B
- O
coated O
and O
silicon B
- I
nitride I
- O
coated O
silicon B
probes O
scanned O
over O
ultrananocrystalline O
diamond B
substrates O
in O
repulsive O
mode O
AM O
- O
AFM O
. O

There O
is O
no O
sign O
of O
fracture O
or O
plastic O
deformation O
in O
the O
case O
of O
diamond B
- O
like O
carbon B
; O
wear O
could O
be O
characterized O
as O
a O
gradual O
atom O
- O
by O
- O
atom O
process O
. O

In O
contrast O
, O
silicon B
nitride I
wears O
through O
removal O
of O
the O
cluster O
of O
atoms O
and O
plastic O
deformation O
. O

Toward O
that O
, O
we O
present O
the O
functionalization O
of O
rigid O
native O
cellulose O
nanocrystals O
( O
CNCs O
) O
by O
esterification O
with O
a O
dense O
hydrocarbon B
chain O
brush O
containing O
cross O
- O
linkable O
double O
bonds O
. O

Composite O
films O
with O
0 O
- O
80 O
wt O
% O
of O
such O
modified O
CNCs O
( O
mCNCs O
) O
within O
a O
poly O
( O
butadiene O
) O
( O
PBD B
) O
rubber O
matrix O
were O
prepared O
via O
cross O
- O
linking O
by O
UV O
- O
light O
initiated O
thiol O
- O
ene O
click O
reaction O
. O

Transmission O
electron O
microscopy O
showed O
structures O
at O
two O
length O
scales O
, O
where O
the O
mCNCs O
and O
PBD B
form O
domains O
having O
internal O
aligned O
self O
- O
assemblies O
of O
alternating O
hard O
mCNCs O
and O
soft O
PBD B
with O
periodicity O
of O
ca O
. O

40 O
nm O
, O
and O
where O
additional O
PBD B
connects O
such O
domains O
. O

Increasing O
the O
weight O
fraction O
of O
mCNCs O
causes O
an O
uncommon O
abrupt O
transition O
from O
PBD B
- O
dominated O
soft O
materials O
to O
significantly O
reinforced O
mCNC O
- O
dominated O
mechanical O
properties O
, O
suggesting O
that O
the O
intercalated O
self O
- O
assembled O
mCNC O
/ O
PBD B
domains O
percolate O
in O
PBD B
upon O
passing O
30 O
- O
35 O
wt O
% O
of O
mCNCs O
. O

Cellulose O
nanowhiskers O
( O
CNWs O
, O
the O
crystalline O
portion O
of O
cellulose O
) O
, O
microcrystalline O
cellulose O
Avicel O
PH101 O
( O
partially O
crystalline O
cellulose O
) O
, O
and O
phosphoric B
acid I
swollen O
cellulose O
( O
PASC O
, O
amorphous O
cellulose O
) O
were O
used O
as O
representative O
models O
for O
cellulose O
to O
better O
understand O
the O
binding O
interactions O
between O
the O
CBMs O
and O
different O
regions O
of O
native O
cellulose O
. O

N2 B
adsorption O
and O
static O
light O
scattering O
( O
SLS O
) O
data O
were O
used O
to O
estimate O
the O
accessible O
surface O
area O
of O
cellulose O
which O
was O
then O
used O
for O
ITC O
data O
analysis O
. O

Cello O
- O
oligosaccharides O
less O
than O
two O
glucose B
units O
did O
not O
bind O
with O
CBMs O
, O
and O
improved O
binding O
affinities O
were O
observed O
for O
cello O
- O
oligosaccharides O
with O
longer O
glucose B
units O
. O

We O
also O
studied O
plasma O
levels O
of O
hydroperoxides O
( O
ROOHs O
) O
, O
alpha B
- I
tocopherol I
, O
glutathione B
and O
lipid O
profile O
as O
well O
as O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
erythrocyte O
activities O
. O

We O
found O
that O
alteration O
in O
MetHb O
, O
ROOHs O
, O
glutathione B
, O
alpha B
- I
tocopherol I
levels O
, O
SOD O
activity O
and O
plasma O
lipid O
profile O
, O
correlates O
with O
those O
expected O
if O
the O
alteration O
derived O
from O
hepatic O
damage O
. O

LC O
- O
MS O
/ O
MS O
Determination O
of O
Isoprostanes B
in O
Plasma O
Samples O
Collected O
from O
Mice O
Exposed O
to O
Doxorubicin B
or O
Tert B
- I
Butyl I
Hydroperoxide I
. O

Isoprostanes B
are O
stable O
products O
of O
arachidonic B
acid I
peroxidation O
and O
are O
regarded O
as O
the O
most O
reliable O
markers O
of O
oxidative O
stress O
in O
vivo O
. O

The O
four O
plasma O
isoprostanes B
are O
determined O
by O
LC O
- O
ESI O
- O
MS O
/ O
MS O
with O
deuterated O
8 O
- O
iso O
- O
PGF2 O
alpha O
- O
d4 O
as O
an O
internal O
standard O
( O
I O
. O
S O
. O
) O
. O

For O
plasma O
samples O
spiked O
with O
the O
isoprostanes B
at O
a O
level O
of O
200 O
pg O
/ O
mL O
each O
, O
the O
method O
imprecision O
has O
been O
below O
7 O
. O
1 O
% O
and O
mean O
inaccuracy O
equaled O
8 O
. O
7 O
% O
. O

The O
applicability O
of O
the O
proposed O
approach O
has O
been O
verified O
by O
the O
assessment O
of O
changes O
in O
isoprostane O
levels O
in O
plasma O
samples O
derived O
from O
mice O
exposed O
to O
tert B
- I
butyl I
hydroperoxide I
( O
TBHP O
) O
, O
a O
model O
inducer O
of O
oxidative O
stress O
, O
or O
to O
antitumor O
drug O
doxorubicin B
( O
DOX B
) O
known O
for O
potent O
stimulation O
of O
redox O
cycling O
. O

The O
greatest O
rise O
was O
observed O
in O
the O
case O
of O
15 O
( O
R O
) O
- O
prostaglandin O
F2 O
alpha O
, O
by O
about O
50 O
% O
and O
70 O
% O
in O
plasma O
samples O
derived O
from O
mice O
exposed O
to O
DOX B
and O
TBHP O
, O
respectively O
. O

Lysophosphatidic B
acid I
impairs O
glucose B
homeostasis O
and O
inhibits O
insulin O
secretion O
in O
high O
- O
fat O
diet O
obese O
mice O
. O

AIMS O
/ O
HYPOTHESIS O
: O
Lysophosphatidic B
acid I
( O
LPA B
) O
is O
a O
lipid O
mediator O
produced O
by O
adipocytes O
that O
acts O
via O
specific O
G O
- O
protein O
- O
coupled O
receptors O
; O
its O
synthesis O
is O
modulated O
in O
obesity O
. O

We O
previously O
reported O
that O
reducing O
adipocyte O
LPA B
production O
in O
high O
- O
fat O
diet O
( O
HFD O
) O
- O
fed O
obese O
mice O
is O
associated O
with O
improved O
glucose B
tolerance O
, O
suggesting O
a O
negative O
impact O
of O
LPA B
on O
glucose B
homeostasis O
. O

METHODS O
: O
First O
, O
glucose B
tolerance O
and O
plasma O
insulin O
were O
assessed O
after O
acute O
( O
30 O
min O
) O
injection O
of O
LPA B
( O
50 O
mg O
/ O
kg O
) O
or O
of O
the O
LPA1 O
/ O
LPA3 O
receptor O
antagonist O
Ki16425 O
( O
5 O
mg O
kg O
( O
- O
1 O
) O
day O
( O
- O
1 O
) O
, O
i O
. O
p O
. O
) O
in O
non O
- O
obese O
mice O
fed O
a O
normal O
diet O
( O
ND O
) O
and O
in O
obese O
/ O
prediabetic O
( O
defined O
as O
glucose B
- O
intolerant O
) O
HFD O
mice O
. O

Glucose B
and O
insulin O
tolerance O
, O
pancreas O
morphology O
, O
glycogen O
storage O
, O
glucose B
oxidation O
and O
glucose B
transport O
were O
then O
studied O
after O
chronic O
treatment O
( O
3 O
weeks O
) O
of O
HFD O
mice O
with O
Ki16425 O
. O

RESULTS O
: O
In O
ND O
and O
HFD O
mice O
, O
LPA B
acutely O
impaired O
glucose B
tolerance O
by O
inhibiting O
glucose B
- O
induced O
insulin O
secretion O
. O

Inhibition O
of O
glucose B
- O
induced O
insulin O
secretion O
by O
LPA B
also O
occurred O
in O
isolated O
mouse O
islets O
. O

Plasma O
LPA B
was O
higher O
in O
HFD O
mice O
than O
in O
ND O
mice O
and O
Ki16425 O
transiently O
improved O
glucose B
tolerance O
. O

Chronic O
treatment O
with O
Ki16425 O
also O
improved O
insulin O
tolerance O
and O
increased O
liver O
glycogen O
storage O
and O
basal O
glucose B
use O
in O
skeletal O
muscle O
. O

CONCLUSIONS O
/ O
INTERPRETATION O
: O
Exogenous O
and O
endogenous O
LPA B
exerts O
a O
deleterious O
effect O
on O
glucose B
disposal O
through O
a O
reduction O
of O
plasma O
insulin O
; O
pharmacological O
blockade O
of O
LPA B
receptors O
improves O
glucose B
homeostasis O
in O
obese O
/ O
prediabetic O
mice O
. O

Higher O
levels O
of O
trait O
impulsiveness O
and O
a O
less O
effective O
response O
inhibition O
are O
linked O
to O
more O
intense O
cue O
- O
elicited O
craving O
for O
alcohol B
in O
alcohol B
- O
dependent O
patients O
. O

RATIONALE O
: O
Cue O
- O
elicited O
craving O
is O
a O
well O
- O
researched O
phenomenon O
in O
alcohol B
literature O
. O

However O
, O
not O
all O
alcohol B
- O
dependent O
people O
display O
the O
same O
reactivity O
to O
alcohol B
cues O
. O

Nevertheless O
, O
there O
has O
been O
a O
scarcity O
of O
empirical O
studies O
testing O
this O
assumption O
in O
alcohol B
literature O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
response O
inhibition O
and O
trait O
impulsiveness O
on O
cue O
- O
elicited O
craving O
for O
alcohol B
in O
alcohol B
- O
dependent O
drinkers O
. O

Alcohol B
exposure O
took O
place O
in O
a O
real O
bar O
- O
restaurant O
close O
to O
the O
premises O
of O
the O
clinic O
, O
and O
participants O
were O
exposed O
to O
real O
alcohol B
cues O
. O

RESULTS O
: O
The O
cue O
exposure O
was O
successful O
as O
alcohol B
- O
dependent O
patients O
experienced O
higher O
craving O
for O
alcohol B
when O
exposed O
to O
alcohol B
rather O
than O
to O
neutral O
cues O
. O

Additionally O
, O
both O
response O
inhibition O
and O
trait O
impulsiveness O
predicted O
cue O
- O
elicited O
craving O
for O
alcohol B
. O

Trait O
impulsiveness O
predicted O
both O
the O
absolute O
craving O
in O
the O
bar O
- O
restaurant O
and O
the O
increase O
in O
cue O
- O
elicited O
craving O
during O
the O
whole O
alcohol B
cue O
exposure O
, O
while O
response O
inhibition O
predicted O
only O
the O
former O
. O

CONCLUSIONS O
: O
The O
results O
clearly O
implicate O
both O
trait O
impulsiveness O
and O
response O
inhibition O
in O
the O
modulation O
of O
cue O
- O
elicited O
craving O
in O
alcohol B
dependence O
. O

Theoretical O
and O
methodological O
issues O
in O
the O
findings O
and O
their O
clinical O
implications O
in O
alcohol B
treatment O
and O
relapse O
are O
discussed O
. O

Molecular O
Basis O
for O
Sialic B
Acid I
- O
dependent O
Receptor O
Recognition O
by O
the O
Plasmodium O
falciparum O
Invasion O
Protein O
Erythrocyte O
- O
binding O
Antigen O
- O
140 O
/ O
BAEBL O
. O

Plasmodium O
falciparum O
erythrocyte O
invasion O
is O
dependent O
on O
high O
affinity O
recognition O
of O
sialic B
acid I
on O
cell O
surface O
receptors O
. O

The O
erythrocyte O
binding O
- O
like O
( O
EBL O
) O
family O
of O
invasion O
ligands O
mediates O
recognition O
of O
sialic B
acid I
on O
erythrocyte O
glycoproteins O
. O

Erythrocyte O
- O
binding O
antigen O
- O
140 O
( O
PfEBA O
- O
140 O
/ O
BAEBL O
) O
is O
a O
critical O
EBL O
ligand O
that O
binds O
sialic B
acid I
on O
its O
receptor O
glycophorin O
C O
. O

We O
present O
here O
the O
crystal O
structure O
of O
the O
two O
- O
domain O
receptor O
- O
binding O
region O
of O
PfEBA O
- O
140 O
in O
complex O
with O
a O
glycan O
containing O
sialic B
acid I
. O

Specific O
molecular O
interactions O
that O
enable O
receptor O
engagement O
are O
identified O
and O
reveal O
that O
the O
glycan O
binding O
mode O
is O
distinct O
from O
that O
of O
apicomplexan O
and O
viral O
cell O
surface O
recognition O
ligands O
as O
well O
as O
host O
immune O
factors O
that O
bind O
sialic B
acid I
. O

The O
studies O
described O
here O
provide O
the O
first O
full O
description O
of O
sialic B
acid I
- O
dependent O
molecular O
interactions O
at O
the O
P O
. O
falciparum O
erythrocyte O
invasion O
interface O
and O
define O
a O
framework O
for O
development O
of O
PfEBA O
- O
140 O
- O
based O
therapeutics O
, O
vaccines O
, O
and O
diagnostics O
assessing O
vaccine O
efficacy O
and O
natural O
immunity O
to O
infection O
. O

Also O
blocking O
of O
CbpD O
using O
N B
- I
acetyl I
- I
glucosamine I
yielded O
a O
lower O
adhesion O
force O
( O
- O
4 O
. O
3 O
nN O
) O
with O
hyphae O
. O

24 O
% O
of O
the O
PDLLA O
core O
into O
lactic B
acid I
within O
5 O
d O
, O
as O
opposed O
to O
only O
ca O
. O

Therapeutic O
Nanocarriers O
with O
Hydrogen B
Peroxide I
- O
Triggered O
Drug O
Release O
for O
Cancer O
Treatment O
. O

In O
the O
present O
study O
, O
a O
reactive O
oxygen B
species O
- O
responsive O
nanocarrier O
has O
been O
successfully O
self O
- O
assembled O
from O
an O
amphiphilic O
hyperbranched O
polymer O
consisting O
of O
alternative O
hydrophobic O
selenide O
groups O
and O
hydrophilic O
phosphate B
segments O
in O
the O
dendritic O
backbone O
. O

The O
hydrophilic O
products O
of O
oxidation O
can O
be O
degraded O
into O
harmless O
small O
molecular O
species O
via O
the O
enzymatic O
digestion O
of O
the O
phosphate B
segments O
and O
then O
eliminated O
by O
renal O
excretion O
. O

Meanwhile O
, O
the O
reactive O
selenium B
- O
containing O
nanocarrier O
possesses O
a O
potent O
intrinsic O
anticancer O
effect O
since O
selenium B
compounds O
can O
produce O
antitumor O
metabolites O
which O
induce O
apoptosis O
of O
cancer O
cells O
efficiently O
. O

Carbonic O
anhydrase O
inhibitors O
: O
Inhibition O
of O
the O
beta O
- O
class O
enzyme O
from O
the O
pathogenic O
yeast O
Candida O
glabrata O
with O
sulfonamides B
, O
sulfamates O
and O
sulfamides O
. O

Here O
we O
report O
the O
first O
sulfonamides B
inhibition O
study O
of O
this O
enzyme O
. O

Simple O
sulfonamides B
showed O
weak O
or O
moderate O
CgNce103 O
inhibitory O
properties O
, O
whereas O
acetazolamide O
, O
and O
a O
series O
of O
4 O
- O
substituted O
ureido O
- O
benzene O
- O
sulfonamides O
, O
sulfamates O
and O
sulfamides O
showed O
effective O
CgNce103 O
inhibitory O
properties O
, O
with O
KIs O
in O
the O
range O
of O
4 O
. O
1 O
- O
115nM O
, O
being O
also O
ineffective O
as O
human O
CA O
II O
inhibitors O
. O

The O
resulting O
acoustic O
radiation O
force O
allowed O
us O
to O
locally O
trap O
particles O
/ O
cells O
, O
including O
15 O
mu O
m O
polystyrene B
beads O
and O
HeLa O
cells O
, O
around O
each O
bubble O
. O

A O
population O
pharmacokinetic O
study O
of O
ARS O
and O
dihydroartemisinin O
( O
DHA B
) O
was O
conducted O
from O
sparse O
sampling O
in O
70 O
Tanzanian O
children O
of O
ages O
6 O
months O
to O
11 O
years O
. O

A O
one O
- O
compartment O
disposition O
model O
accurately O
described O
first O
- O
dose O
population O
pharmacokinetics O
of O
ARS O
and O
DHA B
. O

Body O
weight O
significantly O
affected O
clearance O
and O
apparent O
volume O
of O
distribution O
( O
P O
< O
0 O
. O
001 O
) O
, O
resulting O
in O
lower O
ARS O
and O
DHA B
exposure O
levels O
in O
smaller O
children O
. O

A O
copper B
hyperaccumulation O
phenotype O
correlates O
with O
pathogenesis O
in O
Cryptococcus O
neoformans O
. O

Many O
factors O
contribute O
to O
the O
extraordinary O
survivability O
and O
pathogenicity O
of O
this O
fungus O
in O
humans O
, O
including O
copper B
homeostasis O
pathways O
. O

Previous O
work O
has O
shown O
that O
deletion O
of O
the O
copper B
- O
dependent O
regulator O
Cuf1 O
results O
in O
decreased O
virulence O
and O
dissemination O
in O
brain O
infection O
, O
suggesting O
that O
copper B
acquisition O
is O
important O
to O
the O
persistence O
of O
this O
pathogen O
. O

Here O
, O
we O
show O
that O
the O
minimal O
copper B
quota O
of O
C O
. O
neoformans O
is O
maintained O
at O
a O
high O
level O
even O
when O
grown O
under O
conditions O
of O
stringent O
copper B
limitation O
. O

Intriguingly O
, O
when O
this O
fungal O
pathogen O
is O
grown O
in O
standard O
and O
copper B
- O
enriched O
media O
, O
it O
sequesters O
even O
higher O
levels O
of O
this O
essential O
metal O
, O
achieving O
levels O
that O
are O
far O
higher O
than O
non O
- O
pathogenic O
S O
. O
cerevisiae O
. O

The O
hypothesis O
that O
copper B
acquisition O
plays O
an O
essential O
role O
in O
virulence O
is O
further O
corroborated O
by O
the O
findings O
that O
a O
hypovirulent O
CUF1 O
- O
deletant O
strain O
of O
C O
. O
neoformans O
retrieved O
from O
infected O
mice O
contains O
almost O
a O
6 O
- O
fold O
lower O
concentration O
of O
intracellular O
copper B
than O
the O
pathogenic O
wild O
- O
type O
strain O
. O

Under O
in O
vitro O
growth O
conditions O
, O
the O
size O
of O
the O
cuf1 O
Delta O
cells O
is O
normal O
and O
the O
hypertrophy O
phenotype O
is O
readily O
induced O
in O
vitro O
under O
conditions O
of O
copper B
starvation O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
acquisition O
of O
extraordinary O
levels O
of O
copper B
is O
an O
important O
factor O
in O
the O
survivability O
of O
the O
pathogen O
in O
the O
copper B
- O
deplete O
environment O
of O
infection O
, O
and O
effective O
copper B
concentration O
may O
play O
an O
important O
role O
in O
the O
pathogenesis O
of O
C O
. O
neoformans O
. O

Effect O
of O
voltage O
polarity O
and O
amplitude O
on O
electroforming O
of O
TiO2 B
based O
memristive O
devices O
. O

Pt B
/ O
TiO2 B
/ O
Pt B
/ O
Ti B
memristive O
devices O
were O
electrically O
formed O
to O
either O
the O
ON O
or O
OFF O
state O
using O
voltages O
of O
the O
same O
polarity O
but O
with O
different O
amplitudes O
. O

A O
qualitative O
model O
based O
on O
the O
creation O
and O
migration O
of O
oxygen B
vacancies O
was O
proposed O
to O
explain O
the O
experimental O
results O
. O

Is O
Artemisinin B
the O
Only O
Antiplasmodial O
Compound O
in O
the O
Artemisia O
annua O
Tea O
Infusion O
? O

In O
our O
ongoing O
investigation O
into O
Artemisia O
annua O
for O
the O
treatment O
of O
malaria O
, O
we O
decided O
to O
study O
the O
possibility O
that O
synergism O
might O
enhance O
the O
efficacy O
of O
artemisinin B
. O

Our O
main O
objective O
was O
to O
test O
tea O
infusions O
and O
nonpolar O
extracts O
prepared O
from O
different O
A O
. O
annua O
varieties O
against O
Plasmodium O
falciparum O
in O
vitro O
in O
order O
to O
determine O
if O
synergism O
will O
increase O
the O
effectiveness O
of O
artemisinin B
in O
the O
samples O
as O
compared O
to O
pure O
artemisinin B
. O

We O
found O
that O
the O
IC50 O
of O
artemisinin B
in O
the O
tea O
and O
nonpolar O
extracts O
was O
not O
significantly O
different O
to O
the O
IC50 O
of O
pure O
artemisinin B
. O

We O
could O
show O
that O
the O
year O
and O
country O
of O
harvest O
or O
storage O
conditions O
did O
not O
have O
any O
influence O
on O
the O
activity O
and O
that O
it O
narrowly O
followed O
the O
concentration O
of O
artemisinin B
in O
all O
the O
extracts O
. O

In O
conclusion O
, O
based O
on O
these O
in O
vitro O
results O
, O
artemisinin B
seems O
to O
be O
the O
only O
active O
antiplasmodial O
compound O
in O
A O
. O
annua O
. O

Despite O
preferentially O
activating O
estrogen B
receptor O
alpha O
, O
8 O
- O
PN O
is O
only O
slightly O
uterotrophic O
, O
but O
it O
also O
elucidates O
estrogenic O
effects O
on O
the O
mammary O
gland O
. O

Cardamonin O
Ameliorates O
Insulin O
Resistance O
Induced O
by O
High O
Insulin O
and O
High O
Glucose B
through O
the O
mTOR O
and O
Signal O
Pathway O
. O

The O
mammalian O
target O
of O
rapamycin B
is O
crucial O
in O
the O
regulation O
of O
cell O
growth O
and O
metabolism O
. O

Recent O
studies O
suggest O
that O
the O
mammalian O
target O
of O
rapamycin B
and O
its O
downstream O
70 O
- O
kDa O
ribosomal O
S6 O
kinase O
1 O
negatively O
modulate O
the O
insulin O
- O
signaling O
pathway O
, O
which O
is O
considered O
the O
main O
cause O
of O
insulin O
resistance O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
cardamonin O
, O
a O
potential O
inhibitor O
of O
the O
mammalian O
target O
of O
the O
rapamycin B
, O
on O
insulin O
- O
resistant O
vascular O
smooth O
muscle O
cells O
and O
the O
molecular O
mechanisms O
involved O
. O

Vascular O
smooth O
muscle O
cells O
were O
cultured O
with O
high O
glucose B
and O
high O
insulin O
to O
induce O
insulin O
resistance O
. O

The O
mammalian O
target O
of O
rapamycin B
was O
overstimulated O
in O
cells O
that O
were O
incubated O
with O
high O
glucose B
and O
high O
insulin O
, O
as O
reflected O
by O
the O
excessive O
activation O
of O
S6 O
kinase O
1 O
. O

Insulin O
- O
resistant O
vascular O
smooth O
muscle O
cells O
displayed O
hyperphosphorylation O
of O
insulin O
receptor O
substrate O
- O
1 O
at O
Ser B
residues O
636 O
/ O
639 O
, O
which O
decreased O
the O
activity O
of O
insulin O
receptor O
substrate O
- O
1 O
. O

Cardamonin O
increased O
the O
2 B
- I
deoxyglucose I
uptake O
and O
glycogen O
concentration O
, O
which O
was O
reduced O
by O
insulin O
resistance O
. O

As O
with O
rapamycin B
, O
cardamonin O
inhibited O
the O
activity O
of O
the O
mammalian O
target O
of O
rapamycin B
and O
S6 O
kinase O
1 O
, O
decreased O
the O
Ser B
636 O
/ O
639 O
phosphorylation O
of O
insulin O
receptor O
substrate O
- O
1 O
and O
increased O
the O
activation O
of O
protein O
kinase O
B O
. O

However O
, O
neither O
cardamonin O
nor O
rapamycin B
increased O
the O
expression O
of O
glucose B
transport O
4 O
which O
decreased O
in O
insulin O
- O
resistant O
vascular O
smooth O
muscle O
cells O
. O

This O
study O
suggests O
that O
cardamonin O
inhibited O
the O
activity O
of O
the O
mammalian O
target O
of O
rapamycin B
and O
eliminated O
the O
negative O
feedback O
of O
the O
mammalian O
target O
of O
rapamycin B
and O
S6 O
kinase O
1 O
on O
the O
insulin O
- O
signaling O
pathway O
. O

NAD B
( I
P I
) I
H I
: O
Quinone B
Oxidoreductase O
1 O
Inducer O
Activity O
of O
Some O
Saudi O
Arabian O
Medicinal O
Plants O
. O

One O
such O
multifunctional O
cytoprotective O
enzyme O
is O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
. O

In O
this O
study O
, O
we O
prepared O
extracts O
of O
27 O
Saudi O
Arabian O
medicinal O
plants O
which O
belong O
to O
18 O
different O
plant O
families O
and O
tested O
their O
ability O
to O
induce O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
in O
murine O
hepatoma O
cells O
grown O
in O
microtiter O
plate O
wells O
. O

In O
addition O
to O
the O
Brassicaceae O
, O
a O
known O
source O
of O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
inducer O
activity O
, O
we O
found O
substantial O
inducer O
activity O
in O
extracts O
from O
the O
Apiaceae O
, O
Apocynaceae O
, O
and O
the O
Asteraceae O
families O
. O

We O
further O
show O
that O
artemisinin B
, O
an O
agent O
which O
is O
used O
clinically O
for O
the O
treatment O
of O
malaria O
, O
contributes O
but O
does O
not O
fully O
account O
for O
the O
inducer O
activity O
of O
the O
extract O
of O
Artemisia O
monosperma O
. O

In O
contrast O
to O
artemisinin B
, O
deoxyartemisinin O
is O
inactive O
in O
this O
assay O
, O
demonstrating O
the O
critical O
role O
of O
the O
endoperoxide O
moiety O
of O
artemisinin B
for O
inducer O
activity O
. O

Thus O
, O
the O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
inducer O
activity O
of O
extracts O
of O
some O
Saudi O
Arabian O
medicinal O
plants O
indicates O
the O
presence O
of O
specific O
phytochemicals O
which O
have O
the O
potential O
to O
protect O
against O
chronic O
degenerative O
diseases O
. O

The O
protective O
effects O
of O
omega B
- I
3 I
fatty I
acids I
on O
doxorubicin B
- O
induced O
hepatotoxicity O
and O
nephrotoxicity O
in O
rats O
. O

This O
study O
aims O
to O
evaluate O
the O
protective O
effects O
of O
omega B
- I
3 I
fatty I
acids I
( O
FAs B
) O
on O
doxorubicin B
( O
DOX B
) O
- O
induced O
hepatotoxicity O
and O
nephrotoxicity O
in O
rats O
. O

DOX B
group O
received O
DOX B
at O
the O
dose O
of O
30 O
mg O
/ O
kg O
intraperitoneally O
on O
day O
28 O
. O

DOX O
- O
omega O
- O
3 O
FA O
group O
was O
given O
as O
omega O
- O
3 O
FAs O
at O
the O
dose O
of O
400 O
mg O
/ O
kg O
daily O
by O
intragastric O
gavage O
for O
30 O
days O
and O
received O
DOX B
at O
the O
dose O
of O
30 O
mg O
/ O
kg O
intraperitoneally O
on O
day O
28 O
. O

Glutathione B
( O
GSH B
) O
and O
malondialdehyde B
( O
MDA B
) O
levels O
in O
serum O
and O
GSH B
and O
MDA B
levels O
and O
superoxide B
dismutase O
( O
SOD O
) O
and O
glutathione B
peroxidase O
( O
GSH B
- O
Px O
) O
activities O
in O
liver O
and O
kidney O
tissues O
were O
measured O
spectrophotometrical O
. O

In O
our O
study O
, O
a O
significant O
increase O
in O
MDA B
levels O
was O
observed O
in O
rats O
when O
given O
a O
dose O
of O
DOX B
and O
a O
significant O
decrease O
in O
the O
levels O
of O
GSH B
, O
SOD O
and O
GSH B
- O
Px O
activities O
in O
serum O
, O
liver O
and O
kidney O
tissues O
was O
determined O
when O
compared O
with O
control O
group O
. O

In O
addition O
, O
a O
significant O
decrease O
in O
MDA B
levels O
was O
observed O
in O
rats O
when O
a O
dose O
of O
omega O
- O
3 O
FAs O
was O
given O
with O
DOX B
and O
a O
significant O
increase O
was O
determined O
in O
the O
levels O
of O
GSH B
, O
SOD O
and O
GSH B
- O
Px O
activities O
in O
serum O
, O
liver O
and O
kidney O
tissues O
, O
when O
compared O
with O
DOX B
group O
. O

The O
Tumor O
Suppressor O
Kruppel O
- O
Like O
Factor O
6 O
is O
a O
Novel O
Aryl B
Hydrocarbon I
Receptor O
DNA O
Binding O
Partner O
. O

The O
Aryl B
Hydrocarbon I
Receptor O
( O
AhR O
) O
is O
a O
ligand O
mediated O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
of O
Per O
/ O
Arnt O
/ O
Sim O
family O
that O
regulates O
adaptive O
and O
toxic O
responses O
to O
variety O
of O
chemical O
pollutants O
including O
polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
halogenated O
aromatic O
hydrocarbons O
, O
most O
notably O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

Characterization O
of O
one O
such O
target O
gene O
, O
the O
Plasminogen O
Activator O
Inhibitor O
1 O
( O
PAI O
- O
1 O
) O
identified O
a O
novel O
non O
- O
consensus O
XRE O
( O
NC O
- O
XRE O
) O
that O
confers O
TCDD B
responsiveness O
independently O
of O
the O
Arnt O
protein O
. O

Moreover O
, O
NC O
- O
XRE O
binding O
depends O
on O
the O
5 O
' O
basic O
region O
in O
KLF6 O
rather O
than O
the O
previously O
characterized O
zinc B
finger O
DNA O
binding O
domain O
. O

Epigallocatechin B
- I
3 I
- I
Gallate I
Inhibits O
Collagen O
Production O
of O
Nasal O
Polyp O
- O
Derived O
Fibroblasts O
. O

The O
major O
catechin B
from O
green O
tea O
is O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
( O
EGCG B
) O
, O
which O
has O
garnered O
attention O
for O
its O
potential O
to O
prevent O
oxidative O
stress O
- O
related O
diseases O
. O

The O
purpose O
of O
this O
study O
was O
twofold O
: O
( O
i O
) O
to O
determine O
the O
effect O
of O
EGCG B
on O
fibroblast O
differentiation O
into O
myofibroblasts O
and O
extracellular O
matrix O
accumulation O
in O
transforming O
growth O
factor O
( O
TGF O
) O
- O
beta O
1 O
- O
induced O
nasal O
polyp O
- O
derived O
fibroblasts O
( O
NPDFs O
) O
and O
( O
ii O
) O
to O
determine O
if O
the O
antioxidative O
effect O
of O
EGCG B
on O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
in O
TGF O
- O
beta O
1 O
- O
induced O
NPDFs O
is O
involved O
in O
the O
aforementioned O
processes O
. O

TGF O
- O
beta O
1 O
- O
induced O
NPDFs O
were O
treated O
with O
or O
without O
EGCG B
. O

ROS O
activity O
was O
measured O
by O
the O
nitroblue B
tetrazolium I
reduction O
assay O
and O
visualized O
by O
fluorescent O
microscopy O
. O

EGCG B
significantly O
inhibited O
expressions O
of O
alpha O
- O
SMA O
and O
collagen O
type O
I O
mRNA O
and O
reduced O
alpha O
- O
SMA O
and O
collagen O
protein O
levels O
at O
concentrations O
of O
10 O
- O
20 O
micro O
g O
/ O
mL O
. O

EGCG B
also O
inhibited O
TGF O
- O
beta O
1 O
- O
induced O
ROS O
production O
at O
the O
same O
concentrations O
. O

These O
results O
suggest O
the O
possibility O
that O
EGCG B
may O
be O
effective O
at O
inhibiting O
the O
development O
of O
nasal O
polyps O
through O
an O
anti O
- O
oxidant O
effect O
. O

Neuroprotective O
Effects O
of O
Puerarin B
on O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
induced O
Parkinson O
' O
s O
Disease O
Model O
in O
Mice O
. O

Puerarin B
, O
an O
active O
component O
of O
Pueraria O
montana O
var O
. O
lobata O
( O
Willd O
. O
) O
Sanjappa O
& O
Pradeep O
is O
well O
- O
known O
for O
its O
anti O
- O
oxidative O
and O
neuroprotective O
activities O
. O

Although O
anti O
- O
Parkinson O
' O
s O
disease O
activity O
of O
puerarin B
was O
reported O
in O
both O
of O
in O
vivo O
and O
in O
vitro O
model O
, O
detailed O
mechanisms O
are O
not O
clarified O
. O

In O
this O
study O
, O
we O
addressed O
that O
puerarin B
attenuated O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
- O
induced O
behavioral O
deficits O
, O
dopaminergic O
neuronal O
degeneration O
and O
dopamine B
depletion O
. O

Puerarin B
administration O
enhanced O
glutathione B
( O
GSH B
) O
activity O
, O
glial O
cell O
line O
- O
derived O
neurotrophic O
factor O
( O
GDNF O
) O
expression O
and O
PI3K O
/ O
Akt O
pathway O
activation O
, O
which O
might O
ameliorate O
MPTP B
injection O
- O
induced O
progressive O
elevation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
formation O
in O
mice O
. O

In O
addition O
to O
the O
effect O
on O
ROS O
, O
puerarin B
ameliorated O
MPTP B
- O
reduced O
lysosome O
- O
associated O
membrane O
protein O
type O
2A O
( O
Lamp O
2A O
) O
expression O
. O

Taken O
together O
, O
our O
data O
demonstrate O
that O
puerarin B
attenuates O
MPTP B
- O
induced O
dopaminergic O
neuronal O
degeneration O
via O
modulating O
GDNF O
expression O
, O
PI3K O
/ O
Akt O
pathway O
and O
GSH B
activation O
, O
which O
subsequently O
ameliorate O
MPTP B
- O
induced O
ROS O
formation O
and O
decrease O
of O
Lamp O
2A O
expression O
. O

Acetohydroxyacid O
synthases O
( O
AHASs O
) O
, O
which O
catalyze O
the O
first O
step O
in O
the O
biosynthesis O
of O
branched O
- O
chain O
amino B
acids I
, O
are O
composed O
of O
a O
catalytic O
subunit O
( O
CSU O
) O
and O
a O
regulatory O
subunit O
( O
RSU O
) O
. O

In O
this O
paper O
, O
C B
- O
terminal O
, O
N B
- O
terminal O
, O
and O
C B
- O
and O
N B
- O
terminal O
truncation O
mutants O
of O
ilvH O
were O
constructed O
. O

However O
, O
this O
peptide O
totally O
lost O
its O
ability O
for O
feedback O
regulation O
by O
valine B
, O
thus O
suggesting O
different O
elements O
for O
enzymatic O
activation O
and O
feedback O
regulation O
. O

The O
meso O
- O
tetra O
( O
2 O
, O
6 O
- O
dichloro O
- O
3 O
- O
sulfonatophenyl O
) O
porphyrinate O
of O
manganese O
( O
III O
) O
chloride O
[ O
Mn O
- O
( O
TDCPPS O
) O
Cl O
] O
biomimetic O
catalyst O
immobilized O
on O
spacer O
- O
functionalized O
kaolinite B
clay O
mineral O
was O
employed O
in O
the O
oxidative O
coupling O
reaction O
of O
a O
dissolved O
humic O
acid O
( O
HA O
) O
suprastructure O
with O
either O
chemical O
( O
H2O2 B
) O
or O
UV O
- O
light O
oxidation O
. O

The O
similarity O
between O
chemical O
and O
light O
- O
induced O
oxidation O
results O
suggests O
potential O
multiple O
applications O
of O
the O
kaolinite B
- O
supported O
heterogeneous O
catalyst O
in O
controlling O
the O
reactivity O
of O
natural O
organic O
matter O
within O
biogeochemical O
cycles O
and O
environmental O
reactions O
. O

The O
relative O
potencies O
of O
these O
piperidine B
alkaloids I
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptors O
had O
the O
rank O
order O
of O
gamma O
- O
coniceine O
> O
( O
- O
) O
- O
N O
- O
methylconiine O
> O
( O
+ O
/ O
- O
) O
- O
N O
- O
methylconiine O
> O
( O
+ O
) O
- O
N O
- O
methylconiine O
. O

Defect O
Chemistry O
of O
Oxide B
Nanomaterials O
with O
High O
Surface O
Area O
: O
Ordered O
Mesoporous O
Thin O
Films O
of O
the O
Oxygen B
Storage O
Catalyst O
CeO2 O
- O
ZrO2 O
. O

Samples O
over O
the O
whole O
range O
of O
composition O
, O
including O
bare O
CeO2 B
and O
ZrO2 O
, O
were O
fabricated O
by O
templating O
strategies O
using O
the O
large O
diblock O
copolymer O
KLE O
as O
the O
structure O
- O
directing O
agent O
. O

The O
total O
conductivity O
as O
a O
function O
of O
the O
film O
composition O
, O
temperature O
, O
and O
oxygen B
partial O
pressure O
was O
measured O
using O
impedance O
spectroscopy O
. O

The O
mesoporous O
solid O
solutions O
of O
CeO2 B
- O
ZrO2 O
prepared O
in O
this O
work O
showed O
a O
higher O
stability O
against O
thermal O
ripening O
than O
both O
binary O
oxides O
, O
making O
them O
ideal O
model O
systems O
to O
study O
both O
the O
charge O
transport O
properties O
and O
the O
oxygen O
storage O
at O
elevated O
temperatures O
. O

Colocalization O
of O
the O
Ganglioside O
GM1 O
and O
Cholesterol B
Detected O
by O
Secondary O
Ion O
Mass O
Spectrometry O
. O

We O
report O
here O
the O
use O
of O
secondary O
ion O
mass O
spectrometry O
( O
SIMS O
) O
to O
image O
the O
cholesterol B
- O
dependent O
cohesive O
phase O
separation O
of O
the O
ganglioside O
GM1 O
into O
nano O
- O
and O
microscale O
assemblies O
in O
a O
canonical O
lipid O
raft O
composition O
of O
lipids O
. O

This O
assembly O
of O
domains O
was O
interrogated O
in O
a O
model O
membrane O
system O
composed O
of O
palmitoyl O
sphingomyelin O
( O
PSM O
) O
, O
cholesterol B
, O
and O
an O
unsaturated O
lipid O
( O
dioleoylphosphatidyl O
, O
DOPC B
) O
. O

Images O
of O
this O
system O
provide O
the O
first O
direct O
, O
molecule O
specific O
, O
visual O
evidence O
for O
the O
colocalization O
of O
cholesterol B
and O
GM1 O
in O
supported O
lipid O
bilayers O
and O
further O
indicate O
the O
presence O
of O
three O
compositionally O
distinct O
phases O
: O
( O
1 O
) O
the O
interdomain O
region O
; O
( O
2 O
) O
micrometer O
- O
scale O
domains O
( O
d O
> O
3 O
mu O
m O
) O
; O
( O
3 O
) O
nanometer O
- O
scale O
domains O
( O
d O
= O
100 O
nm O
to O
1 O
mu O
m O
) O
localized O
within O
the O
micrometer O
- O
scale O
domains O
and O
the O
interdomain O
region O
. O

PSM O
- O
rich O
, O
nanometer O
- O
scale O
domains O
prefer O
to O
partition O
within O
the O
more O
ordered O
, O
cholesterol B
- O
rich O
/ O
DOPC B
- O
poor O
/ O
GM1 O
- O
rich O
micrometer O
- O
scale O
phase O
, O
while O
GM1 O
- O
rich O
, O
nanometer O
- O
scale O
domains O
prefer O
to O
partition O
within O
the O
surrounding O
, O
disordered O
, O
cholesterol B
- O
poor O
/ O
PSM O
- O
rich O
/ O
DOPC B
- O
rich O
interdomain O
phase O
. O

Due O
to O
the O
similarity O
between O
Pd B
and O
Pt B
, O
the O
complexes O
of O
palladium O
( O
II O
) O
can O
be O
considered O
as O
potential O
anticancer O
agents O
. O

Activity O
of O
six O
PdCl2 O
( O
X2Py O
) O
2 O
complexes O
( O
Py B
= O
pyridine B
, O
and O
X O
= O
CH3 B
or O
Cl B
) O
was O
measured O
by O
MTT B
test O
using O
MCF7 O
, O
CCRF O
- O
SB O
, O
PC3 O
and O
human O
B O
- O
lymphoblastoid O
cell O
lines O
. O

The O
Androgen B
Metabolite O
, O
5 O
alpha O
- O
Androstane O
- O
3 O
beta O
, O
17 O
beta O
- O
Diol O
( O
3 O
beta O
- O
Diol O
) O
, O
Activates O
the O
Oxytocin B
Promoter O
Through O
an O
Estrogen B
Receptor O
- O
beta O
Pathway O
. O

Testosterone B
has O
been O
shown O
to O
suppress O
the O
acute O
stress O
- O
induced O
activation O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
axis O
; O
however O
, O
the O
mechanisms O
underlying O
this O
response O
remain O
unclear O
. O

These O
neurons O
are O
devoid O
of O
androgen B
receptors O
( O
ARs O
) O
. O

Therefore O
, O
a O
possibility O
is O
that O
the O
PVN O
target O
neurons O
respond O
to O
a O
metabolite O
in O
the O
testosterone B
catabolic O
pathway O
via O
an O
AR O
- O
independent O
mechanism O
. O

The O
dihydrotestosterone B
metabolite O
, O
5 O
alpha O
- O
androstane O
- O
3 O
beta O
, O
17 O
beta O
- O
diol O
( O
3 O
beta O
- O
diol O
) O
, O
binds O
and O
activates O
estrogen B
receptor O
- O
beta O
( O
ER O
- O
beta O
) O
, O
the O
predominant O
ER O
in O
the O
PVN O
. O

In O
the O
PVN O
, O
ER O
- O
beta O
is O
coexpressed O
with O
oxytocin B
( O
OT O
) O
. O

The O
malondialdehyde B
( O
MDA B
) O
level O
, O
caspase O
- O
9 O
activity O
and O
the O
percentage O
of O
DNA O
fragmentation O
were O
significantly O
higher O
in O
placental O
tissue O
of O
PE O
than O
in O
control O
women O
. O

The O
serum O
level O
of O
MDA B
was O
significantly O
elevated O
in O
women O
with O
PE O
having O
delivery O
by O
cesarean O
section O
( O
CS O
) O
than O
in O
women O
with O
PE O
having O
vaginal O
delivery O
. O

In O
vitro O
study O
demonstrated O
that O
the O
addition O
of O
0 O
. O
5 O
mM O
Fe B
( I
2 I
+ I
) I
and O
0 O
. O
1 O
mM O
ascorbate B
caused O
increase O
in O
the O
production O
of O
MDA B
level O
in O
placental O
tissue O
with O
PE O
than O
normal O
placentas O
, O
and O
vitamin B
E I
( O
100 O
micro O
M O
) O
caused O
lower O
inhibition O
of O
in O
vitro O
lipid O
peroxidation O
in O
placental O
tissue O
with O
PE O
when O
compared O
with O
normal O
tissue O
. O

In O
conclusion O
, O
the O
elevations O
of O
MDA B
, O
caspase O
- O
9 O
activity O
and O
the O
percentage O
of O
DNA O
fragmentation O
in O
the O
placentas O
of O
women O
with O
PE O
implicate O
the O
involvement O
of O
lipid O
peroxidation O
and O
apoptosis O
in O
PE O
. O

The O
placenta O
represents O
a O
considerable O
source O
of O
the O
elevated O
circulating O
MDA B
in O
PE O
. O

Ca B
( I
2 I
+ I
) I
- O
dependent O
suicidal O
erythrocyte O
death O
following O
zearalenone B
exposure O
. O

Zearalenone B
, O
a O
cereal O
mycotoxin O
with O
mycoestrogen O
activity O
and O
effect O
on O
fertility O
, O
is O
known O
to O
trigger O
apoptosis O
of O
a O
variety O
of O
nucleated O
cell O
types O
including O
hematopoietic O
progenitor O
cells O
. O

The O
most O
important O
stimulator O
of O
eryptosis O
is O
an O
increase O
in O
cytosolic O
Ca B
( I
2 I
+ I
) I
activity O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

The O
present O
study O
explored O
whether O
zearalenone B
triggers O
eryptosis O
. O

Erythrocyte O
volume O
was O
estimated O
from O
forward O
scatter O
, O
phosphatidylserine O
exposure O
at O
the O
erythrocyte O
surface O
from O
annexin O
- O
V O
binding O
, O
hemolysis O
from O
hemoglobin O
release O
, O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
from O
Fluo3 O
fluorescence O
. O

A O
48 O
- O
h O
exposure O
to O
zearalenone B
( O
> O
= O
25 O
mu O
M O
) O
was O
followed O
by O
a O
significant O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
and O
annexin O
- O
V O
binding O
, O
and O
a O
significant O
decrease O
in O
forward O
scatter O
. O

The O
effect O
on O
annexin O
- O
V O
binding O
was O
significantly O
blunted O
in O
the O
nominal O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
. O

Zearalenone B
stimulates O
the O
suicidal O
erythrocyte O
death O
, O
an O
effect O
at O
least O
partially O
due O
to O
stimulation O
of O
Ca B
( I
2 I
+ I
) I
entry O
. O

Oxidative O
DNA O
damage O
is O
involved O
in O
ochratoxin B
A I
- O
induced O
G2 O
arrest O
through O
ataxia O
telangiectasia O
- O
mutated O
( O
ATM O
) O
pathways O
in O
human O
gastric O
epithelium O
GES O
- O
1 O
cells O
in O
vitro O
. O

Ochratoxin B
A I
( O
OTA O
) O
, O
one O
of O
the O
most O
abundant O
mycotoxin O
food O
contaminants O
, O
is O
classified O
as O
" O
possibly O
carcinogenic O
to O
humans O
. O
" O
Our O
previous O
study O
showed O
that O
OTA O
could O
induce O
a O
G2 O
arrest O
in O
immortalized O
human O
gastric O
epithelium O
cells O
( O
GES O
- O
1 O
) O
. O

To O
explore O
the O
putative O
roles O
of O
oxidative O
DNA O
damage O
and O
the O
ataxia O
telangiectasia O
- O
mutated O
( O
ATM O
) O
pathways O
on O
the O
OTA O
- O
induced O
G2 O
arrest O
, O
the O
current O
study O
systematically O
evaluated O
the O
roles O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
, O
DNA O
damage O
, O
and O
ATM O
- O
dependent O
pathway O
activation O
on O
the O
OTA O
- O
induced O
G2 O
phase O
arrest O
in O
GES O
- O
1 O
cells O
. O

The O
results O
showed O
that O
OTA O
exposure O
elevated O
intracellular O
ROS O
production O
, O
which O
directly O
induced O
DNA O
damage O
and O
increased O
the O
levels O
of O
8 B
- I
OHdG I
and O
DNA O
double O
- O
strand O
breaks O
( O
DSBs O
) O
. O

Finally O
, O
pretreatment O
with O
the O
antioxidant O
N B
- I
acetyl I
- I
L I
- I
cysteine I
( O
NAC B
) O
reduced O
the O
OTA O
- O
induced O
DNA O
DSBs O
, O
ATM O
phosphorylation O
, O
and O
G2 O
arrest O
. O

Effects O
of O
Gentamicin B
on O
the O
Proteomes O
of O
Aerobic O
and O
Oxygen B
- O
Limited O
Escherichia O
coli O
. O

In O
this O
study O
we O
have O
used O
proteomic O
techniques O
to O
establish O
the O
effects O
of O
gentamicin B
on O
the O
proteomes O
of O
aerobic O
and O
oxygen B
- O
limited O
Escherichia O
coli O
. O

Ribosomal O
proteins O
L1 O
, O
L9 O
, O
L10 O
, O
and O
S2 O
were O
found O
to O
be O
up O
- O
regulated O
in O
both O
conditions O
, O
and O
we O
postulate O
that O
these O
are O
candidate O
drug O
targets O
for O
the O
development O
of O
synergistic O
combinations O
with O
gentamicin B
. O

In O
this O
study O
, O
we O
investigated O
the O
expression O
of O
hepatic O
low O
- O
density O
lipoprotein O
receptor O
- O
related O
protein O
1 O
( O
LRP1 O
) O
, O
a O
receptor O
for O
remnant O
lipoproteins O
, O
in O
hypothyroidism O
and O
the O
effect O
of O
triiodothyronine B
( O
T3 O
) O
treatment O
on O
hepatic O
LRP1 O
expression O
. O

Methods O
: O
C57BL O
/ O
6 O
mice O
were O
fed O
a O
normal O
diet O
( O
control O
group O
) O
or O
a O
low O
iodine B
diet O
supplemented O
with O
0 O
. O
15 O
% O
propylthiouracil O
( O
PTU B
/ O
LI O
group O
) O
for O
4 O
weeks O
. O

Mice O
in O
PTU B
/ O
LI O
group O
were O
injected O
intraperitoneally O
with O
T3 O
( O
0 O
, O
30 O
, O
and O
150 O
mu O
g O
/ O
kg O
of O
body O
weight O
) O
for O
7 O
days O
. O

Results O
: O
Hypothyroidism O
was O
successfully O
induced O
in O
PTU B
/ O
LI O
group O
mice O
. O

Hepatic O
LRP1 O
protein O
expression O
was O
lower O
in O
the O
PTU B
/ O
LI O
group O
than O
the O
control O
group O
. O

T3 O
treatment O
up O
- O
regulated O
hepatic O
LRP1 O
protein O
expression O
in O
PTU B
/ O
LI O
group O
mice O
. O

Conclusions O
: O
Our O
data O
demonstrate O
that O
hepatic O
LRP1 O
expression O
and O
function O
decrease O
in O
hypothyroidism O
and O
are O
regulated O
by O
thyroid B
hormone I
. O

The O
solvent O
quality O
of O
an O
aqueous O
mixture O
of O
two O
good O
solvents O
, O
urea B
and O
guanidinium O
chloride O
( O
GdmCl O
) O
, O
for O
a O
hydrophobic O
polymer O
was O
investigated O
using O
atomistic O
molecular O
dynamics O
simulations O
. O

This O
cononsolvency O
of O
the O
polymer O
in O
the O
urea B
+ O
GdmCl O
mixture O
is O
found O
to O
be O
caused O
by O
the O
preferential O
adsorption O
of O
urea B
on O
the O
polymer O
. O

The O
polymer O
collapses O
as O
a O
result O
of O
indirect O
long O
- O
range O
interactions O
between O
monomers O
resulting O
from O
the O
presence O
of O
urea B
clouds O
surrounding O
them O
. O

Surprisingly O
, O
urea B
behaves O
as O
the O
better O
solvent O
in O
the O
mixture O
not O
because O
there O
exists O
a O
stronger O
affinity O
of O
the O
polymer O
for O
urea B
. O

We O
examined O
this O
hypothesis O
by O
using O
alginate O
and O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
modified O
with O
a O
controlled O
number O
of O
methacrylic O
groups O
as O
model O
inflexible O
and O
flexible O
cross O
- O
linkers O
, O
respectively O
. O

Interestingly O
, O
the O
polyacrylamide B
hydrogel O
cross O
- O
linked O
by O
the O
inflexible O
alginate O
methacrylates O
exhibited O
less O
dependency O
between O
the O
degree O
of O
swelling O
and O
the O
elastic O
modulus O
than O
the O
hydrogel O
cross O
- O
linked O
by O
flexible O
PAA B
methacrylates O
. O

This O
critical O
role O
of O
the O
cross O
- O
linker O
' O
s O
inflexibility O
was O
related O
to O
the O
difference O
of O
the O
degree O
of O
hydrophobic O
association O
between O
polymer O
cross O
- O
linkers O
, O
as O
confirmed O
with O
pyrene B
probes O
added O
in O
pregel O
solutions O
. O

In O
contrast O
, O
gels O
cross O
- O
linked O
with O
PAA B
methacrylates O
failed O
to O
modulate O
the O
cellular O
adhesion O
morphology O
due O
to O
a O
lower O
, O
and O
smaller O
, O
elastic O
modulus O
range O
to O
be O
controlled O
. O

The O
basic O
science O
and O
clinical O
use O
of O
morphine B
and O
other O
" O
opioid O
" O
drugs O
are O
based O
almost O
exclusively O
on O
the O
extracts O
or O
analogues O
of O
compounds O
isolated O
from O
a O
single O
source O
, O
the O
opium O
poppy O
( O
Papaver O
somniferum O
) O
. O

Specifically O
, O
at O
least O
two O
alkaloids O
isolated O
from O
the O
plant O
Mitragyna O
speciosa O
, O
mitragynine B
( O
( O
E O
) O
- O
2 O
- O
[ O
( O
2S O
, O
3S O
) O
- O
3 O
- O
ethyl O
- O
8 O
- O
methoxy O
- O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
7 O
, O
12 O
, O
12b O
- O
octahydroindolo O
[ O
3 O
, O
2 O
- O
h O
] O
quinolizin O
- O
2 O
- O
yl O
] O
- O
3 O
- O
methoxyprop O
- O
2 O
- O
enoic O
acid O
methyl O
ester O
; O
9 O
- O
methoxy O
coryantheidine O
; O
MG O
) O
and O

Several O
characteristics O
of O
these O
compounds O
suggest O
a O
classic O
" O
opioid O
" O
mechanism O
of O
action O
: O
nanomolar O
affinity O
for O
opioid O
receptors O
, O
competitive O
interaction O
with O
the O
opioid O
receptor O
antagonist O
naloxone B
, O
and O
two O
- O
way O
analgesic O
cross O
- O
tolerance O
with O
morphine B
. O

A O
novel O
series O
of O
compounds O
were O
synthesized O
by O
cyclic O
condensation O
reaction O
of O
substituted O
isothiocyanate B
( O
2a O
- O
c O
) O
with O
2 O
- O
thiophenecarboxylic O
acid O
hydrazide O
( O
1 O
) O
in O
the O
presence O
of O
ethyl O
alcohol O
, O
to O
obtain O
intermediate O
thiosemicarbazides B
( O
3a O
- O
c O
) O
, O
which O
were O
further O
treated O
with O
sodium B
hydroxide I
in O
the O
presence O
of O
ethanol B
to O
obtain O
triazole B
derivatives O
( O
4a O
- O
c O
) O
. O

The O
latter O
were O
refluxed O
with O
substituted O
secondary O
amines O
and O
formaldehyde B
for O
6 O
- O
10 O
h O
to O
afford O
Mannich B
bases I
( O
5a O
- O
k O
) O
. O

The O
synthesized O
compounds O
were O
characterized O
on O
the O
basis O
of O
their O
spectral O
( O
IR O
, O
( B
13 I
) I
C I
and O
( B
1 I
) I
H I
NMR O
) O
data O
and O
evaluated O
for O
biological O
activities O
. O

Design O
, O
modeling O
, O
synthesis O
and O
biological O
activity O
evaluation O
of O
camptothecin B
- O
linked O
platinum B
anticancer O
agents O
. O

The O
compounds O
showed O
growth O
inhibitory O
activity O
against O
a O
panel O
of O
human O
tumor O
cell O
lines O
, O
including O
sublines O
resistant O
to O
topotecan B
and O
platinum B
compounds O
. O

The O
derivatives O
were O
active O
in O
all O
the O
tested O
cell O
lines O
, O
and O
compound O
1b O
, O
the O
most O
active O
one O
, O
was O
able O
to O
overcome O
cisplatin B
resistance O
in O
the O
osteosarcoma O
U2OS O
/ O
Pt O
cell O
line O
. O

Platinum B
- O
containing O
camptothecins O
produced O
platinum B
- O
DNA O
adducts O
and O
topoisomerase O
I O
- O
mediated O
DNA O
damage O
with O
cleavage O
pattern O
and O
persistence O
similar O
to O
SN38 O
, O
the O
active O
principle O
of O
irinotecan B
. O

Compound O
1b O
exhibited O
an O
appreciable O
antitumor O
activity O
in O
vivo O
against O
human O
H460 O
tumor O
xenograft O
, O
comparable O
to O
that O
of O
irinotecan B
at O
lower O
well O
- O
tolerated O
dose O
levels O
and O
superior O
to O
cisplatin B
. O

The O
results O
support O
the O
interpretation O
that O
the O
diaminedichloro O
- O
platinum O
( O
II O
) O
complex O
conjugated O
via O
an O
oxyiminomethyl O
linker O
at O
the O
7 O
- O
position O
of O
the O
camptothecin B
resulted O
in O
a O
new O
class O
of O
effective O
antitumor O
compounds O
. O

Mesoporous O
silica B
- O
supported O
lipid O
bilayers O
( O
protocells O
) O
for O
DNA O
cargo O
delivery O
to O
the O
spinal O
cord O
. O

Amorphous O
mesoporous O
silica B
nanoparticles O
( O
' O
protocells O
' O
) O
that O
support O
surface O
lipid O
bilayers O
recently O
characterized O
in O
vitro O
as O
carrier O
constructs O
for O
small O
drug O
and O
DNA O
delivery O
are O
reported O
here O
as O
highly O
biocompatible O
both O
in O
vitro O
and O
in O
vivo O
, O
involving O
the O
brain O
and O
spinal O
cord O
following O
spinal O
delivery O
into O
the O
lumbosacral O
subarachnoid O
space O
( O
intrathecal O
; O
i O
. O
t O
. O
) O
. O

Specifically O
, O
positively O
charged O
, O
1 O
, O
2 O
- O
Dioleoyl O
- O
3 O
- O
Trimethylammonium O
- O
Propane O
( O
DOTAP B
) O
- O
cholesterol B
( O
DOTAP B
: O
Chol O
) O
liposome O
- O
formulated O
protocells O
revealed O
stable O
in O
vitro O
cargo O
release O
kinetics O
and O
cellular O
interleukin O
- O
10 O
( O
IL O
- O
10 O
) O
transgene O
transfection O
. O

We O
report O
here O
that O
i O
. O
t O
. O
delivery O
of O
protocells O
, O
with O
modified O
chemistry O
supporting O
a O
surface O
coating O
of O
DOTAP B
: O
Chol O
liposomes O
and O
containing O
the O
IL O
- O
10 O
transgene O
, O
results O
in O
functional O
suppression O
of O
pain O
- O
related O
behavior O
in O
rats O
for O
extended O
periods O
. O

Chemical O
characterization O
of O
domestic O
oral O
tobacco O
products O
: O
Total O
nicotine B
, O
pH O
, O
unprotonated O
nicotine B
and O
tobacco O
- O
specific O
N O
- O
nitrosamines O
. O

In O
this O
study O
, O
we O
measured O
pH O
, O
moisture O
, O
nicotine B
( O
total O
and O
unprotonated O
) O
, O
and O
tobacco O
- O
specific O
N O
- O
nitrosamines O
( O
TSNAs O
) O
for O
other O
established O
( O
twist O
, O
loose O
leaf O
, O
plug O
, O
and O
dry O
snuff O
without O
pouch O
) O
and O
emerging O
oral O
tobacco O
products O
( O
dry O
snuff O
pouch O
, O
US O
- O
made O
snus O
, O
and O
dissolvable O
tobacco O
) O
. O

Among O
the O
seven O
product O
categories O
, O
product O
pH O
ranged O
from O
4 O
. O
7 O
to O
7 O
. O
9 O
, O
and O
total O
nicotine B
concentration O
spanned O
from O
3 O
. O
9 O
to O
40 O
. O
1mg O
/ O
g O
. O

The O
most O
readily O
absorbable O
form O
of O
nicotine B
( O
unprotonated O
nicotine B
) O
varied O
more O
than O
350 O
- O
fold O
, O
ranging O
from O
0 O
. O
01 O
to O
3 O
. O
7mg O
/ O
g O
. O

While O
the O
highest O
total O
nicotine B
concentrations O
were O
observed O
in O
twist O
products O
, O
snus O
and O
dissolvable O
tobacco O
had O
the O
highest O
unprotonated O
nicotine B
levels O
. O

This O
study O
demonstrates O
the O
diversity O
among O
oral O
tobacco O
products O
and O
highlights O
the O
potential O
of O
these O
products O
to O
deliver O
a O
wide O
range O
of O
nicotine B
and O
carcinogenic O
TSNAs O
. O

Design O
, O
synthesis O
and O
structure O
- O
activity O
relationships O
of O
3 O
, O
5 O
- O
diaryl O
- O
1H O
- O
pyrazoles O
as O
inhibitors O
of O
arylamine O
N B
- O
acetyltransferase O
. O

The O
synthesis O
and O
inhibitory O
potencies O
of O
a O
novel O
series O
of O
3 O
, O
5 O
- O
diaryl O
- O
1H O
- O
pyrazoles O
as O
specific O
inhibitors O
of O
prokaryotic O
arylamine O
N B
- O
acetyltransferase O
enzymes O
is O
described O
. O

However O
, O
mutation O
of O
the O
highly O
conserved O
serine B
- O
994 O
to O
alanine B
in O
the O
ATP B
hydrolysis O
motif O
in O
the O
SMC6 O
C O
- O
terminal O
domain O
, O
resulted O
in O
mice O
with O
a O
surprisingly O
mild O
phenotype O
. O

When O
the O
neo O
gene O
was O
removed O
, O
the O
mice O
had O
normal O
size O
, O
but O
detailed O
phenotypic O
analysis O
revealed O
minor O
abnormalities O
in O
glucose B
tolerance O
, O
haematopoiesis O
, O
nociception O
and O
global O
gene O
expression O
patterns O
. O

Embryonic O
fibroblasts O
derived O
from O
the O
ser994 O
mutant O
mice O
were O
not O
sensitive O
to O
killing O
by O
a O
range O
of O
DNA O
damaging O
agents O
, O
but O
they O
were O
sensitive O
to O
the O
induction O
of O
sister O
chromatid O
exchanges O
induced O
by O
ultraviolet O
light O
or O
mitomycin B
C I
. O

Intermediate O
chain O
length O
( O
16 O
< O
= O
i O
< O
= O
50 O
) O
n B
- I
alkanes I
are O
known O
to O
surface O
freeze O
at O
temperatures O
that O
are O
up O
to O
three O
degrees O
higher O
than O
the O
equilibrium O
melting O
point O
[ O
B O
. O
M O
. O
Ocko O
et O
al O
. O
, O
Phys O
. O
Rev O
. O
E O
, O
1997 O
, O
55 O
, O
3164 O
- O
3182 O
] O
. O

Compared O
to O
the O
Au O
- O
Au O
homodimers O
, O
the O
Au O
- O
Ag O
dimers O
showed O
slightly O
broadened O
two O
- O
photon O
photoluminescence O
near O
the O
X O
symmetry O
point O
at O
the O
first O
Brillouin O
zone O
of O
Au B
, O
whilst O
that O
from O
the O
L O
symmetry O
point O
stayed O
the O
same O
. O

Pregnane B
X O
Receptor O
Mediates O
Dyslipidemia O
Induced O
by O
the O
HIV O
Protease O
Inhibitor O
Amprenavir O
in O
Mice O
. O

Several O
PIs O
have O
been O
implicated O
to O
activate O
the O
nuclear O
receptor O
pregnane B
X O
receptor O
( O
PXR O
) O
, O
which O
acts O
as O
a O
xenobiotic O
sensor O
to O
regulate O
xenobiotic O
metabolism O
in O
the O
liver O
and O
intestine O
. O

Short O
- O
term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol B
and O
atherogenic O
low O
- O
density O
lipoprotein O
cholesterol B
levels O
in O
wild O
- O
type O
mice O
, O
but O
not O
in O
PXR O
- O
deficient O
mice O
. O

Neuraminidases O
( O
sialidases O
) O
catalyze O
the O
removal O
of O
sialic B
acid I
residues O
from O
sialylated O
glycoconjugates O
. O

Insulin O
binding O
to O
its O
receptor O
rapidly O
induces O
interaction O
of O
the O
receptor O
with O
Neu1 O
, O
which O
hydrolyzes O
sialic B
acid I
residues O
in O
the O
glycan O
chains O
of O
the O
receptor O
and O
, O
consequently O
, O
induces O
its O
activation O
. O

Together O
, O
these O
studies O
identify O
Neu1 O
as O
a O
novel O
component O
of O
the O
signaling O
pathways O
of O
energy O
metabolism O
and O
glucose B
uptake O
. O

One O
exception O
is O
tranexamic O
acid O
( O
TXA O
) O
, O
which O
, O
as O
a O
lysine B
mimetic O
, O
inhibits O
binding O
of O
plasminogen O
to O
fibrin O
. O

Scutellarin B
from O
Scutellaria O
baicalensis O
Suppresses O
Adipogenesis O
by O
Upregulating O
PPAR O
alpha O
in O
3T3 O
- O
L1 O
Cells O
. O

This O
study O
investigated O
the O
antiadipogenic O
activity O
of O
scutellarin B
( O
1 O
) O
in O
3T3 O
- O
L1 O
preadipocytes O
as O
well O
as O
the O
underlying O
molecular O
mechanisms O
. O

Computational O
modeling O
indicated O
that O
1 O
can O
bind O
to O
PPAR O
alpha O
, O
gamma O
, O
and O
delta O
each O
in O
a O
distinct O
manner O
, O
while O
it O
can O
activate O
PPAR O
alpha O
only O
by O
forming O
a O
hydrogen B
bond O
with O
Y464 O
, O
thus O
stabilizing O
the O
AF O
- O
2 O
helix O
and O
activating O
PPAR O
alpha O
. O

The O
integration O
of O
a O
tripeptide B
derivative O
, O
which O
is O
a O
versatile O
self O
- O
assembly O
motif O
, O
with O
a O
ruthenium O
( O
II O
) O
tris O
( O
bipyridine O
) O
complex O
affords O
the O
first O
supramolecular O
metallo O
- O
hydrogelator O
that O
not O
only O
self O
assembles O
in O
water O
to O
form O
a O
hydrogel O
but O
also O
exhibits O
gel O
- O
sol O
transition O
upon O
oxidation O
of O
the O
metal O
center O
. O

Phellinus O
linteus O
mushroom O
protects O
against O
tacrine B
- O
induced O
mitochondrial O
impairment O
and O
oxidative O
stress O
in O
HepG2 O
cells O
. O

Tacrine B
( O
THA O
) O
was O
the O
first O
drug O
licensed O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

In O
our O
previous O
study O
, O
we O
found O
that O
PL O
could O
decrease O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
formation O
in O
HepG2 O
cells O
. O

Presently O
, O
protective O
effects O
of O
PL O
on O
tacrine B
- O
induced O
ROS O
formation O
and O
mitochondria O
dysfunction O
were O
evaluated O
. O

The O
results O
showed O
that O
PL O
significantly O
reduced O
tacrine B
- O
induced O
ROS O
production O
, O
disruption O
of O
Delta O
Psi O
m O
, O
8 B
- I
OHdG I
formation O
in O
mitochondrial O
DNA O
, O
and O
cytotoxicity O
in O
HepG2 O
cells O
. O

These O
data O
suggest O
that O
PL O
could O
attenuate O
the O
cytotoxicity O
and O
mitochondria O
dysfunction O
induced O
by O
tacrine B
in O
HepG2 O
cells O
. O

Consumption O
of O
PL O
may O
be O
a O
plausible O
way O
to O
prevent O
tacrine B
- O
induced O
hepatotoxicity O
. O

Poly B
- I
lactide I
- I
co I
- I
glycolide I
( O
PLGA B
) O
microparticles O
emerged O
as O
one O
of O
the O
most O
promising O
strategies O
to O
achieve O
site O
- O
specific O
drug O
delivery O
. O

The O
present O
work O
sought O
to O
explore O
PLGA B
microparticles O
as O
cardiac O
drug O
delivery O
systems O
. O

PLGA B
microparticles O
were O
prepared O
by O
Total O
Recirculation O
One O
- O
Machine O
System O
( O
TROMS O
) O
after O
the O
formation O
of O
a O
multiple O
emulsion O
. O

Next O
, O
the O
potential O
of O
PLGA B
microparticles O
for O
administration O
in O
the O
heart O
was O
assessed O
in O
a O
MI O
rat O
model O
. O

Taken O
together O
, O
these O
findings O
support O
the O
feasibility O
of O
the O
developed O
PLGA B
microparticles O
as O
vehicles O
for O
delivering O
growth O
factors O
in O
the O
infarcted O
myocardium O
. O

GLPG0492 O
, O
a O
novel O
selective O
androgen B
receptor O
modulator O
, O
improves O
muscle O
performance O
in O
the O
exercised O
- O
mdx O
mouse O
model O
of O
muscular O
dystrophy O
. O

Anabolic O
drugs O
may O
counteract O
muscle O
wasting O
and O
dysfunction O
in O
Duchenne O
muscular O
dystrophy O
( O
DMD O
) O
; O
however O
, O
steroids B
have O
unwanted O
side O
effects O
. O

We O
focused O
on O
GLPG0492 O
, O
a O
new O
non O
- O
steroidal O
selective O
androgen B
receptor O
modulator O
that O
is O
currently O
under O
development O
for O
musculo O
- O
skeletal O
diseases O
such O
as O
sarcopenia O
and O
cachexia O
. O

GLPG0492 O
was O
tested O
in O
the O
exercised O
mdx O
mouse O
model O
of O
DMD O
in O
a O
4 O
- O
week O
trial O
at O
a O
single O
high O
dose O
( O
30mg O
/ O
kg O
, O
6 O
day O
/ O
week O
s O
. O
c O
. O
) O
, O
and O
the O
results O
were O
compared O
with O
those O
from O
the O
administration O
of O
alpha O
- O
methylprednisolone O
( O
PDN O
; O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
nandrolone B
( O
NAND O
, O
5mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
. O

Screening O
of O
a O
small O
in O
- O
house O
library O
of O
1863 O
compounds O
identified O
29 O
compounds O
that O
protected O
Jurkat O
cells O
from O
hydrogen B
peroxide I
- O
induced O
cytotoxicity O
. O

From O
the O
cytoprotective O
compounds O
eleven O
proved O
to O
possess O
antioxidant O
activity O
( O
ABTS B
radical O
scavenger O
effect O
) O
and O
two O
were O
found O
to O
inhibit O
poly O
( O
ADP O
- O
ribosyl O
) O
ation O
( O
PARylation O
) O
, O
a O
cytotoxic O
pathway O
operating O
in O
severely O
injured O
cells O
. O

Four O
cytoprotective O
dibenzoylmethane O
( O
DBM O
) O
derivatives O
were O
investigated O
in O
more O
detail O
as O
they O
did O
not O
scavenge O
hydrogen B
peroxide I
nor O
did O
they O
inhibit O
PARylation O
. O

Hydrogen B
peroxide I
activated O
extracellular O
signal O
regulated O
kinase O
( O
ERK1 O
/ O
2 O
) O
and O
p38 O
MAP O
kinases O
but O
not O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
. O

In O
conclusion O
we O
identified O
DBM O
analogs O
as O
a O
novel O
class O
of O
cytoprotective O
compounds O
inhibiting O
ERK1 O
/ O
2 O
kinase O
and O
protecting O
from O
necrotic O
cell O
death O
by O
a O
mechanism O
independent O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
inhibition O
. O

Avermectin B
induces O
P O
- O
glycoprotein O
expression O
in O
S2 O
cells O
via O
the O
calcium B
/ O
calmodulin O
/ O
NF O
- O
kappa O
B O
pathway O
. O

Avermectin B
( O
AVM O
) O
is O
a O
macrocyclic O
lactone B
agent O
widely O
used O
as O
a O
nematicide O
, O
acaricide O
and O
insecticide O
in O
veterinary O
medicine O
and O
plant O
protection O
. O

P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
is O
an O
ATP B
- O
dependent O
drug O
efflux O
pump O
for O
xenobiotic O
compounds O
, O
and O
is O
involved O
in O
multidrug O
resistance O
. O

Furthermore O
, O
we O
observed O
that O
AVM O
- O
induced O
expression O
of O
P O
- O
gp O
was O
due O
to O
elevation O
of O
intracellular O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

This O
occurred O
both O
directly O
, O
by O
activating O
calcium B
ion O
channels O
, O
and O
indirectly O
, O
by O
activating O
chloride B
ion O
channels O
. O

These O
results O
are O
supported O
by O
our O
observations O
that O
verapamil B
, O
a O
Ca B
( I
2 I
+ I
) I
channel O
blocker O
, O
and O
niflumic O
acid O
, O
a O
chloride B
channel O
antagonist O
, O
significantly O
attenuated O
AVM O
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
elevation O
, O
thereby O
reducing O
P O
- O
gp O
expression O
. O

Inhibition O
of O
P O
- O
gp O
with O
anti O
- O
P O
- O
gp O
antibody O
or O
cyclosporine B
A I
( O
a O
P O
- O
gp O
inhibitor O
) O
reduced O
the O
AVM O
- O
induced O
elevation O
of O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
, O
implying O
that O
P O
- O
gp O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
regulate O
each O
other O
. O

Finally O
, O
we O
found O
that O
trifluoperazine B
, O
a O
calmodulin O
inhibitor O
, O
and O
pyrrolidine O
dithiocarbamic O
acid O
, O
an O
NF O
- O
kappa O
B O
inhibitor O
, O
attenuated O
the O
AVM O
- O
induced O
expression O
of O
P O
- O
gp O
, O
suggesting O
that O
AVM O
induces O
P O
- O
gp O
protein O
expression O
via O
the O
calmodulin O
/ O
Relish O
( O
NF O
- O
kappa O
B O
) O
signaling O
pathway O
. O

Evidence O
of O
securin O
- O
mediated O
resistance O
to O
gefitinib B
- O
induced O
apoptosis O
in O
human O
cancer O
cells O
. O

Gefitinib B
, O
a O
tyrosine B
kinase O
inhibitor O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
, O
has O
been O
used O
to O
treat O
numerous O
cancers O
; O
however O
, O
evidence O
has O
shown O
that O
cancer O
cells O
can O
become O
resistant O
to O
gefitinib B
during O
therapy O
. O

Gefitinib B
treatment O
decreases O
securin O
levels O
at O
the O
protein O
level O
by O
inducing O
protein O
instability O
but O
did O
not O
affect O
on O
the O
securin O
gene O
expression O
. O

Treatment O
with O
gefitinib B
induced O
cytotoxicity O
in O
various O
human O
cancer O
cell O
types O
, O
including O
RKO O
( O
colon O
cancer O
) O
, O
A549 O
( O
lung O
cancer O
) O
, O
BFTC905 O
( O
bladder O
cancer O
) O
, O
MCF7 O
( O
breast O
cancer O
) O
and O
A375 O
( O
skin O
cancer O
) O
. O

Moreover O
, O
following O
treatment O
with O
gefitinib B
, O
the O
securin O
- O
wild O
type O
cancer O
cells O
were O
more O
resistant O
to O
apoptotic O
induction O
than O
the O
securin O
- O
null O
cancer O
cells O
. O

Treatment O
with O
gefitinib B
induced O
mitochondrial O
dysfunction O
, O
cytochrome O
c O
release O
, O
caspase O
- O
3 O
activation O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
protein O
cleavage O
, O
indicating O
that O
apoptosis O
occurred O
in O
these O
cancer O
cells O
. O

The O
transfection O
of O
a O
GPF O
- O
securin O
expression O
vector O
increased O
both O
the O
proliferation O
rates O
and O
resistance O
to O
gefitinib B
- O
induced O
death O
in O
these O
cancer O
cells O
. O

Taken O
together O
, O
these O
findings O
demonstrate O
that O
the O
presence O
of O
securin O
promotes O
resistance O
to O
gefitinib B
- O
induced O
apoptosis O
via O
an O
EGFR O
- O
independent O
pathway O
in O
human O
cancer O
cells O
. O

Copper B
induces O
apoptotic O
cell O
death O
through O
reactive O
oxygen B
species O
- O
triggered O
oxidative O
stress O
in O
the O
intertidal O
copepod O
Tigriopus O
japonicus O
. O

To O
understand O
copper B
- O
induced O
cytotoxicity O
at O
the O
molecular O
level O
, O
we O
employed O
several O
cellular O
and O
biochemical O
assays O
after O
exposure O
to O
copper B
, O
and O
found O
a O
significant O
induction O
of O
enzyme O
activities O
of O
antioxidant O
proteins O
with O
increased O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
as O
well O
as O
an O
increase O
of O
TUNEL O
- O
positive O
cells O
, O
but O
a O
decrease O
of O
BrdU B
- O
positive O
cells O
. O

In O
addition O
, O
several O
important O
genes O
such O
as O
p38 O
MAPK O
, O
antioxidant O
- O
related O
genes O
, O
Hsps O
, O
and O
apoptosis O
- O
related O
genes O
were O
significantly O
modulated O
by O
copper B
exposure O
. O

Taken O
together O
, O
we O
suggest O
that O
copper B
- O
induced O
cytotoxicity O
is O
mediated O
by O
the O
formation O
of O
intracellular O
ROS O
and O
oxidative O
stress O
in O
T O
. O
japonicus O
. O

Whole O
body O
biochemical O
assays O
such O
as O
TUNEL O
- O
and O
BrdU B
- O
assay O
will O
provide O
a O
better O
understanding O
of O
cellular O
responses O
such O
as O
apoptosis O
and O
cell O
death O
upon O
cytotoxic O
exposure O
of O
copper B
in O
T O
. O
japonicus O
. O

The O
synthesis O
of O
22 O
structurally O
diverse O
urea B
, O
thiourea B
and O
acylthiourea O
derivatives O
containing O
the O
( O
R O
) O
- O
2 O
- O
amino O
- O
1 O
- O
butanol O
motif O
has O
been O
performed O
. O

For O
example O
, O
ABC O
transporters O
have O
been O
shown O
to O
protect O
against O
the O
harmful O
effects O
of O
hypoxia O
and O
oxidative O
stress O
through O
increased O
expression O
and O
efflux O
of O
oxysterols B
and O
glutathione B
conjugated O
xenobiotics O
. O

The O
addition O
of O
P188 B
to O
P407 B
gel O
formulations O
resulted O
in O
an O
increase O
in O
gelation O
temperature O
, O
decrease O
in O
viscosity O
at O
room O
temperature O
and O
faster O
gel O
dissolution O
. O

The O
liposomes O
were O
adsorbed O
to O
hydroxyapatite B
( O
HA O
) O
and O
human O
dental O
enamel O
using O
phosphate B
buffer O
and O
parotid O
saliva O
as O
adsorption O
media O
. O

In O
phosphate B
buffer O
the O
adsorption O
to O
HA O
of O
pectin O
coated O
liposomes O
was O
significantly O
lower O
than O
the O
negative O
liposomes O
. O

Effect O
of O
quercetin B
- O
rich O
onion O
peel O
extracts O
on O
arterial O
thrombosis O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
whether O
oral O
supplementation O
of O
quercetin B
- O
rich O
onion O
peel O
extract O
( O
OPE O
) O
influences O
blood O
coagulation O
and O
arterial O
thrombosis O
in O
Sprague O
- O
Dawley O
( O
SD O
) O
rats O
. O

The O
OPE O
did O
not O
affect O
blood O
cholesterol B
levels O
but O
significantly O
decreased O
blood O
triglyceride B
and O
glucose B
levels O
. O

In O
addition O
, O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
and O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
signaling O
pathways O
activated O
by O
thrombin O
treatment O
were O
prevented O
by O
the O
OPE O
pre O
- O
treatment O
. O

All O
the O
patients O
received O
platinum B
- O
based O
chemotherapy O
, O
and O
the O
therapeutic O
effects O
were O
evaluated O
. O

Amelioration O
of O
iron B
overload O
- O
induced O
liver O
toxicity O
by O
a O
potent O
antioxidant O
and O
iron B
chelator O
, O
Emblica O
officinalis O
Gaertn O
. O

In O
liver O
, O
the O
major O
site O
of O
iron B
storage O
, O
iron B
overload O
is O
associated O
with O
oxidative O
damage O
of O
protein O
, O
lipid O
, O
and O
DNA O
and O
causes O
protein O
oxidation O
, O
lipid O
peroxidation O
, O
and O
rupture O
of O
hepatocytes O
, O
leading O
to O
cell O
death O
. O

Serum O
ferritin O
and O
liver O
iron B
content O
are O
the O
main O
forecasters O
of O
moderate O
to O
severe O
iron B
overload O
in O
the O
liver O
. O

The O
sequels O
of O
excess O
iron B
deposition O
in O
the O
liver O
are O
fibrosis O
and O
enhanced O
levels O
of O
serum O
enzymes O
and O
bilirubin B
markers O
. O

Emblica O
officinalis O
( O
EO O
) O
fruit O
extract O
was O
found O
efficient O
in O
lessening O
intraperitoneally O
injected O
iron B
dextran O
- O
induced O
liver O
toxicity O
in O
Swiss O
albino O
mice O
. O

Mice O
administered O
with O
different O
doses O
of O
70 O
% O
methanol B
extract O
of O
EO O
( O
50 O
, O
100 O
, O
and O
200 O
mg O
kg O
( O
- O
1 O
) O
body O
weight O
) O
showed O
significant O
decrease O
in O
liver O
iron B
, O
serum O
ferritin O
, O
and O
serum O
enzyme O
levels O
, O
along O
with O
the O
decrease O
in O
lipid O
peroxidation O
, O
protein O
oxidation O
, O
and O
collagen O
content O
. O

The O
activity O
was O
further O
supported O
by O
its O
considerable O
iron B
chelation O
with O
half O
- O
maximal O
inhibitory O
concentration O
of O
70 O
. O
24 O
+ O
/ O
- O
2 O
. O
74 O
mu O
g O
ml O
( O
- O
1 O
) O
and O
the O
protection O
on O
ferrous B
ion O
- O
mediated O
DNA O
breakdown O
with O
50 O
% O
protection O
( O
[ O
P O
] O
50 O
) O
of O
1 O
. O
04 O
+ O
/ O
- O
0 O
. O
01 O
mu O
g O
ml O
( O
- O
1 O
) O
. O

Simultaneously O
, O
the O
extract O
effectively O
induced O
the O
antioxidant O
enzyme O
levels O
and O
also O
exhibited O
the O
potential O
activity O
of O
reductive O
release O
of O
ferritin O
iron B
. O

These O
findings O
suggest O
that O
the O
EO O
extract O
may O
be O
used O
as O
a O
potent O
drug O
for O
the O
treatment O
of O
pathological O
sequences O
arisen O
in O
the O
iron B
overload O
- O
induced O
liver O
damage O
. O

Ophthalmic O
findings O
in O
acute O
mercury B
poisoning O
in O
adults O
: O
A O
case O
series O
study O
. O

The O
aim O
of O
this O
study O
is O
to O
report O
ophthalmic O
findings O
of O
acute O
mercury B
poisoning O
in O
48 O
adults O
referred O
to O
emergency O
department O
. O

There O
was O
no O
correlation O
between O
the O
ocular O
findings O
and O
the O
urine O
and O
blood O
mercury B
levels O
. O

Methyl B
mercury I
, O
held O
in O
the O
school O
laboratory O
for O
experimental O
purpose O
, O
may O
be O
a O
source O
of O
poisoning O
. O

In O
this O
case O
series O
, O
we O
showed O
that O
acute O
exposure O
to O
mercury B
had O
hazardous O
effect O
on O
the O
visual O
system O
, O
especially O
CV O
and O
VF O
. O

We O
propose O
that O
emphasizing O
the O
public O
education O
on O
the O
potential O
hazards O
of O
mercury B
is O
crucial O
for O
preventive O
community O
health O
. O

dNTP B
- O
dependent O
conformational O
transitions O
in O
the O
fingers O
subdomain O
of O
Klentaq1 O
DNA O
polymerase O
: O
insights O
into O
the O
role O
of O
the O
" O
nucleotide B
binding O
" O
state O
. O

In O
the O
absence O
of O
nucleotide B
, O
the O
enzyme O
is O
mostly O
open O
, O
whereas O
in O
the O
presence O
of O
DNA O
and O
a O
correctly O
base O
- O
pairing O
dNTP B
it O
re O
- O
equilibrates O
to O
a O
closed O
state O
. O

In O
the O
presence O
of O
a O
dNTP B
alone O
, O
with O
DNA O
and O
an O
incorrect O
dNTP B
, O
or O
in O
elevated O
MgCl2 B
concentrations O
, O
an O
intermediate O
state O
termed O
' O
' O
nucleotide B
binding O
' O
' O
state O
predominates O
. O

Photon O
distribution O
and O
hidden O
Markov O
analysis O
revealed O
fast O
dynamic O
and O
slow O
conformational O
processes O
occurring O
between O
all O
three O
states O
in O
a O
complex O
energy O
landscape O
suggesting O
a O
mechanism O
in O
which O
dNTP B
delivery O
is O
mediated O
by O
the O
' O
' O
nucleotide B
binding O
' O
' O
state O
: O
After O
nucleotide B
binding O
, O
correct O
dNTPs B
are O
transported O
to O
the O
closed O
state O
while O
incorrect O
dNTPs B
are O
delivered O
to O
the O
open O
state O
. O

One O
- O
pot O
formation O
of O
multifunctional O
Pt B
- O
conducting O
polymer O
intercalated O
nanostructures O
. O

A O
novel O
multifunctional O
Pt B
nanoparticle O
@ O
PPy O
nanofiber O
intercalated O
structure O
( O
Pt B
NP O
@ O
PPy O
NF O
) O
has O
been O
synthesized O
facilely O
in O
one O
- O
pot O
. O

Pt B
NPs O
, O
with O
size O
and O
facet O
control O
, O
were O
nicely O
assembled O
and O
embedded O
into O
the O
polymer O
nanofiber O
network O
. O

Polyvinylpyrrolidone B
( O
PVP B
) O
was O
used O
during O
the O
synthesis O
process O
which O
would O
assist O
the O
self O
- O
assembly O
of O
the O
metal O
nanoparticles O
and O
polymer O
backbones O
into O
the O
intercalated O
structure O
. O

Space O
- O
confined O
distribution O
of O
the O
Pt B
NPs O
was O
achieved O
within O
the O
large O
dimension O
PPy O
nanofiber O
network O
, O
which O
could O
enhance O
the O
interfacial O
electron O
transfer O
process O
as O
well O
as O
diminish O
the O
catalyst O
deformation O
. O

The O
as O
- O
formed O
Pt B
NPs O
have O
a O
cluster O
- O
like O
structure O
and O
are O
mainly O
composed O
of O
3 O
. O
5 O
nm O
primary O
Pt B
particles O
with O
( O
100 O
) O
surface O
atoms O
. O

Enhanced O
electrocatalytic O
properties O
were O
shown O
by O
the O
Pt B
NP O
@ O
PPy O
NF O
intercalated O
structure O
, O
with O
sufficiently O
high O
enzyme O
- O
less O
glucose B
biosensitivity O
and O
a O
long O
linear O
range O
from O
1 O
- O
30 O
mM O
( O
R O
= O
0 O
. O
9995 O
) O
. O

High O
electrochemical O
cycling O
stability O
, O
chloride B
( O
Cl B
( I
- I
) I
) O
tolerance O
and O
good O
selectivity O
are O
also O
obtained O
for O
the O
Pt B
NP O
@ O
PPy O
NF O
structure O
, O
as O
the O
electrode O
showed O
no O
obvious O
response O
to O
the O
common O
interfering O
agents O
, O
such O
as O
ascorbic B
acid I
( O
AA O
) O
, O
uric B
acid I
( O
UA O
) O
, O
and O
4 O
- O
acetamidophenol O
( O
AP O
) O
. O

Furthermore O
, O
the O
Pt B
NP O
@ O
PPy O
NF O
showed O
excellent O
catalytic O
activity O
for O
the O
methanol B
oxidation O
reaction O
( O
MOR O
) O
and O
oxygen B
reduction O
reaction O
( O
ORR O
) O
, O
which O
displayed O
sufficient O
CO B
tolerance O
, O
and O
higher O
activity O
compared O
to O
the O
commercial O
Pt B
/ O
C B
catalyst O
. O

This O
intrinsically O
multifunctional O
Pt B
NP O
@ O
PPy O
NF O
with O
well O
- O
controlled O
Pt B
facets O
thus O
could O
serve O
as O
an O
advanced O
electrocatalyst O
for O
biosensing O
and O
fuel O
cell O
applications O
, O
surpassing O
the O
performance O
of O
many O
existing O
materials O
. O

Free O
fatty B
acids I
induce O
Lhb O
mRNA O
but O
suppress O
Fshb O
mRNA O
in O
pituitary O
L O
beta O
T2 O
gonadotropes O
and O
diet O
- O
induced O
obesity O
reduces O
FSH O
levels O
in O
male O
mice O
and O
disrupts O
the O
proestrus O
LH O
/ O
FSH O
surge O
in O
female O
mice O
. O

We O
hypothesized O
that O
elevated O
free O
fatty B
acids I
( O
FFAs O
) O
might O
directly O
modulate O
pituitary O
gonadotropin O
production O
. O

Two O
obvious O
advantages O
of O
doped O
QDs O
, O
especially O
doped O
ZnS B
QDs O
, O
over O
typical O
CdSe B
@ O
ZnS B
and O
CdTe B
QDs O
are O
longer O
dopant O
emission O
lifetime O
and O
potentially O
lower O
cytotoxicity O
. O

The O
lifetime O
of O
dopant O
emission O
from O
transition O
- O
metal O
ion O
or O
lanthanide B
ion O
- O
doped O
QDs O
is O
generally O
longer O
than O
that O
of O
the O
bandgap O
or O
defect O
- O
related O
emission O
of O
host O
, O
and O
that O
of O
biological O
background O
fluorescence O
, O
providing O
great O
opportunities O
to O
eliminate O
background O
fluorescence O
for O
biosensing O
and O
bioimaging O
. O

Modelling O
the O
surface O
free O
energy O
parameters O
of O
polyurethane B
coats O
- O
part O
1 O
. O

Solvent O
- O
based O
coats O
obtained O
from O
linear O
polyurethane B
elastomers O
. O

Polyurethane B
elastomers O
coating O
were O
synthesised O
by O
using O
typical O
diisocyanates O
, O
polyether B
and O
polyester O
polyols O
and O
HO O
- O
tertiary B
amines I
or O
diols B
as O
a O
chain O
extenders O
. O

Mole O
fractions O
of O
structural O
fragments O
( O
kappa O
exp O
) O
responsible O
for O
the O
polar O
interactions O
within O
polyurethane B
chains O
were O
calculated O
by O
( B
1 I
) I
H I
NMR O
method O
. O

Obtained O
results O
were O
confronted O
with O
the O
analogous O
parameter O
values O
( O
kappa O
theor O
) O
calculated O
on O
the O
basis O
of O
process O
stoichiometry O
, O
considering O
the O
stage O
of O
the O
production O
of O
isocyanate O
prepolymers O
and O
reaction O
of O
their O
extension O
for O
polyurethanes B
. O

Based O
on O
achieved O
results O
, O
another O
empirical O
models O
, O
allowing O
for O
prediction O
the O
influence O
of O
the O
kind O
of O
polyurethane B
raw O
materials O
on O
SFE O
values O
of O
received O
coatings O
were O
determined O
. O

Biocomposites O
of O
pHEMA B
with O
HA O
/ O
beta O
- O
TCP O
( O
60 O
/ O
40 O
) O
for O
bone O
tissue O
engineering O
: O
Swelling O
, O
hydrolytic O
degradation O
, O
and O
in O
vitro O
behavior O
. O

We O
created O
hydrolytically O
degradable O
hydrogel O
/ O
bioceramic O
biocomposites O
, O
comprising O
poly O
( O
2 O
- O
hydroxyethyl O
methacrylate O
) O
( O
pHEMA B
) O
hydrogels O
and O
50 O
wt O
% O
biphasic O
hydroxyapatite B
/ O
beta O
- O
tricalcium O
phosphate O
( O
60 O
/ O
40 O
) O
through O
in O
situ O
polymerization O
. O

Swelling O
and O
degradation O
were O
examined O
in O
details O
at O
a O
phosphate B
buffered O
saline O
solution O
at O
37 O
degrees O
C O
over O
a O
12 O
- O
week O
period O
of O
time O
. O

To O
vary O
degradability O
, O
a O
co O
- O
monomer O
, O
acrylic B
acid I
( O
AA O
) O
or O
2 O
- O
hydroxypropyl O
methacrylamide O
( O
HPMA B
) O
, O
was O
introduced O
, O
coupled O
with O
altering O
the O
concentration O
of O
the O
cross O
- O
linker O
and O
of O
the O
bioceramic O
. O

The O
co O
- O
monomer O
HPMA B
was O
found O
to O
be O
more O
effective O
than O
AA O
in O
enhancing O
degradation O
, O
though O
AA O
led O
to O
greater O
swelling O
ratios O
. O

33 O
% O
of O
weight O
loss O
was O
achieved O
in O
some O
of O
the O
biocomposites O
containing O
HPMA B
. O

Porous O
structures O
were O
developed O
during O
swelling O
and O
degradation O
in O
biocomposites O
with O
AA O
but O
not O
in O
those O
containing O
HPMA B
, O
suggesting O
different O
degradation O
mechanisms O
: O
bulk O
erosion O
vs O
. O
bulk O
degradation O
. O

Nicotinic B
Acid I
and O
Nicotinamide B
: O
A O
Review O
of O
Their O
Use O
for O
Hyperphosphatemia O
in O
Dialysis O
Patients O
. O

Phosphate B
binders O
have O
traditionally O
been O
used O
to O
treat O
hyperphosphatemia O
, O
a O
common O
complication O
in O
patients O
with O
end O
stage O
renal O
disease O
( O
ESRD O
) O
. O

New O
evidence O
suggests O
that O
nicotinic B
acid I
and O
its O
metabolites O
may O
effectively O
decrease O
phosphorus B
absorption O
in O
the O
gastrointestinal O
tract O
, O
thereby O
reducing O
serum O
phosphorus B
concentrations O
. O

We O
conducted O
a O
literature O
search O
to O
identify O
studies O
of O
patients O
with O
ESRD O
on O
dialysis O
that O
evaluated O
the O
role O
of O
niacin O
and O
related O
compounds O
in O
decreasing O
serum O
phosphorus B
levels O
. O

We O
searched O
PubMed O
using O
the O
search O
terms O
niacin O
, O
nicotinic B
acid I
, O
niacinamide O
, O
nicotinamide B
and O
hyperphosphatemia O
. O

Among O
the O
seven O
studies O
that O
met O
our O
exclusion O
criteria O
, O
three O
used O
nicotinic B
acid I
as O
the O
therapeutic O
intervention O
and O
four O
used O
nicotinamide B
. O

Both O
nicotinic B
acid I
and O
nicotinamide B
were O
effective O
in O
significantly O
reducing O
serum O
phosphorus B
concentrations O
in O
patients O
with O
ESRD O
on O
either O
hemodialysis O
or O
peritoneal O
dialysis O
. O

Eight O
phytoestrogens O
, O
including O
resveratrol B
, O
coumestrol O
, O
kaempferol B
, O
genistein B
, O
daidzein B
, O
apigenin B
, O
isoliquirtigenin O
and O
glycitin O
, O
were O
tested O
for O
their O
ability O
to O
induce O
MnSOD O
expression O
in O
mouse O
C2C12 O
and O
primary O
myoblasts O
. O

Five O
of O
these O
, O
resveratrol B
, O
coumestrol O
, O
kaempferol B
, O
genistein B
and O
daidzein B
, O
significantly O
increased O
MnSOD O
expression O
, O
slowed O
proliferative O
growth O
and O
enhanced O
stress O
resistance O
( O
hydrogen B
peroxide I
LD50 O
) O
. O

When O
siRNA O
was O
used O
to O
prevent O
the O
MnSOD O
induction O
by O
genistein B
, O
coumestrol O
or O
daidzein B
, O
none O
of O
these O
compounds O
exerted O
any O
effect O
on O
proliferative O
growth O
, O
and O
only O
the O
effect O
of O
coumestrol O
on O
stress O
resistance O
persisted O
. O

The O
estrogen B
antagonist O
ICI182780 O
prevented O
the O
increased O
MnSOD O
expression O
and O
also O
the O
changes O
in O
cell O
growth O
and O
stress O
resistance O
, O
indicating O
that O
these O
effects O
are O
mediated O
by O
estrogen B
receptors O
( O
ER O
) O
. O

The O
absence O
of O
effects O
of O
resveratrol B
or O
coumestrol O
, O
but O
not O
genistein B
, O
in O
ER O
beta O
- O
null O
cells O
further O
indicated O
that O
this O
ER O
in O
particular O
is O
important O
in O
mediating O
these O
effects O
. O

IPI O
- O
926 O
is O
not O
a O
potent O
reversible O
inhibitor O
of O
CYP1A2 O
, O
2C8 O
, O
2C9 O
or O
3A4 O
( O
testosterone B
) O
. O

IPI O
- O
926 O
is O
a O
moderate O
inhibitor O
of O
CYP2C19 O
, O
2D6 O
and O
3A4 O
( O
midazolam B
) O
with O
KI O
values O
of O
19 O
, O
16 O
and O
4 O
. O
5 O
micro O
M O
, O
respectively O
. O

Thiolactone O
Sulfoxides O
as O
New O
Reactive O
Metabolites O
Acting O
as O
Bis O
- O
Electrophiles O
: O
Implication O
in O
Clopidogrel B
and O
Prasugrel O
Bioactivation O
. O

The O
antithrombotics O
of O
the O
tetrahydrothienopyri O
series O
, O
clopidogrel B
and O
prasugrel O
, O
are O
prodrugs O
that O
must O
be O
metabolized O
in O
two O
steps O
to O
become O
pharmacologically O
active O
. O

The O
second O
step O
is O
a O
cytochrome O
P450 O
( O
P450 O
) O
- O
dependent O
oxidation O
of O
this O
thiolactone O
resulting O
in O
the O
formation O
of O
a O
sulfenic O
acid O
that O
is O
eventually O
reduced O
into O
the O
corresponding O
active O
thiol B
. O

The O
data O
described O
in O
the O
present O
article O
are O
in O
complete O
agreement O
with O
this O
proposition O
as O
they O
show O
that O
it O
was O
possible O
to O
trap O
these O
thiolactone O
sulfoxides O
by O
a O
series O
of O
nucleophiles O
such O
as O
amines B
, O
thiols B
, O
or O
cyclopentane O
- O
1 O
, O
3 O
- O
dione O
( O
CPDH O
) O
, O
an O
equivalent O
of O
dimedone O
that O
is O
used O
as O
a O
sulfenic O
acid O
trapping O
agent O
. O

One O
of O
them O
that O
resulted O
from O
the O
oxidation O
of O
2 O
- O
oxo O
- O
prasugrel O
by O
human O
liver O
microsomes O
in O
the O
presence O
of O
ethanolamine B
and O
CPDH O
was O
isolated O
and O
completely O
characterized O
by O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectroscopy O
in O
addition O
to O
MS O
and O
MS O
( O
2 O
) O
spectrometry O
. O

All O
metabolites O
derived O
from O
an O
attack O
of O
H2O B
or O
an O
amine B
at O
the O
CO B
carbon B
of O
the O
intermediate O
thiolactone O
sulfoxide O
existed O
as O
a O
mixture O
of O
two O
diastereomers O
having O
a O
cis O
configuration O
of O
the O
double O
bond O
, O
whereas O
those O
formed O
in O
the O
presence O
of O
thiols B
appeared O
as O
a O
mixture O
of O
four O
diastereomers O
with O
a O
cis O
or O
trans O
configuration O
of O
the O
double O
bond O
. O

This O
led O
us O
to O
propose O
tentative O
mechanisms O
for O
the O
previously O
reported O
formation O
of O
trans O
isomers O
of O
the O
active O
thiol B
metabolite O
of O
clopidogrel B
upon O
microsomal O
metabolism O
of O
this O
antithrombotic O
in O
the O
presence O
of O
thiols B
. O

The O
results O
described O
in O
this O
article O
showed O
that O
thiolactone O
sulfoxides O
are O
formed O
as O
reactive O
metabolites O
during O
the O
metabolism O
of O
clopidogrel B
and O
prasugrel O
and O
are O
able O
to O
react O
as O
bis O
- O
electrophiles O
with O
a O
variety O
of O
nucleophiles O
. O

Tensile O
Lattice O
Strain O
Accelerates O
Oxygen B
Surface O
Exchange O
and O
Diffusion O
in O
La1 O
- O
xSrxCoO3 O
- O
delta O
Thin O
Films O
. O

The O
influence O
of O
lattice O
strain O
on O
the O
oxygen B
exchange O
kinetics O
and O
diffusion O
in O
oxides B
was O
investigated O
on O
( O
100 O
) O
epitaxial O
La1 O
- O
xSrxCoO3 O
- O
delta O
( O
LSC O
) O
thin O
films O
grown O
by O
pulsed O
laser O
deposition O
. O

Planar O
tensile O
and O
compressively O
strained O
LSC O
films O
were O
obtained O
on O
single O
- O
crystalline O
SrTiO3 B
and O
LaAlO3 B
. O

The O
temperature O
dependence O
of O
k O
* O
and O
D O
* O
is O
discussed O
with O
respect O
to O
the O
contributions O
of O
strain O
states O
, O
formation O
enthalpy O
of O
oxygen B
vacancies O
, O
and O
vacancy O
mobility O
at O
different O
temperatures O
. O

Our O
findings O
point O
toward O
the O
control O
of O
oxygen B
surface O
exchange O
and O
diffusion O
kinetics O
by O
means O
of O
lattice O
strain O
in O
existing O
mixed O
conducting O
oxides B
for O
energy O
conversion O
applications O
. O

Arylpiperazines B
as O
fatty B
acid I
transport O
protein O
1 O
( O
FATP1 O
) O
inhibitors O
with O
improved O
potency O
and O
pharmacokinetic O
properties O
. O

Through O
the O
derivatization O
process O
, O
arylpiperazine B
derivatives O
5k O
and O
12a O
were O
identified O
as O
possessing O
potent O
in O
vitro O
activity O
against O
human O
and O
mouse O
FATP1s O
as O
well O
as O
excellent O
pharmacokinetic O
properties O
. O

In O
vivo O
evaluation O
of O
triglyceride B
accumulation O
in O
the O
liver O
, O
white O
gastrocnemius O
muscle O
and O
soleus O
is O
also O
described O
. O

Molecular O
design O
, O
synthesis O
and O
biological O
evaluation O
of O
cyclic O
imides O
bearing O
benzenesulfonamide B
fragment O
as O
potential O
COX O
- O
2 O
inhibitors O
. O

In O
vitro O
COX O
- O
1 O
/ O
COX O
- O
2 O
inhibition O
structure O
- O
activity O
studies O
identified O
compound O
8a O
as O
a O
highly O
potent O
( O
IC50 O
= O
0 O
. O
1 O
mu O
M O
) O
, O
and O
an O
extremely O
selective O
[ O
COX O
- O
2 O
( O
SI O
) O
> O
1000 O
] O
comparable O
to O
celecoxib B
[ O
COX O
- O
2 O
( O
SI O
) O
> O
384 O
] O
, O
COX O
- O
2 O
inhibitor O
that O
showed O
superior O
anti O
- O
inflammatory O
activity O
( O
ED50 O
= O
72 O
. O
4mg O
/ O
kg O
) O
relative O
to O
diclofenac B
( O
ED50 O
= O
114mg O
/ O
kg O
) O
. O

The O
study O
showed O
that O
the O
homosulfonamide O
fragment O
of O
8a O
inserted O
deep O
inside O
the O
2 O
degrees O
- O
pocket O
of O
the O
COX O
- O
2 O
active O
site O
, O
where O
the O
SO2NH2 O
group O
underwent O
H B
- O
bonding O
interaction O
with O
Gln B
( O
192 O
) O
( O
2 O
. O
95 O
A O
) O
, O
Phe B
( O
518 O
) O
( O
2 O
. O
82 O
A O
) O
and O
Arg O
( O
513 O
) O
( O
2 O
. O
63 O
and O
2 O
. O
73 O
A O
) O
. O

Glycyrrhizic O
acid O
( O
GA O
, O
also O
known O
as O
Glycyrrhizin B
) O
, O
a O
triterpenoid O
saponin O
glycoside O
, O
is O
considered O
to O
be O
a O
bioactive O
component O
in O
Licorice O
and O
is O
beneficial O
to O
diabetic O
vascular O
complications O
. O

The O
superoxide B
dismutase O
( O
SOD O
) O
activity O
and O
malondialdehyde B
( O
MDA B
) O
level O
in O
cell O
supernatant O
were O
detected O
by O
kits O
while O
the O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
was O
determined O
by O
2 O
, O
7 O
- O
dichlorodihydrofluor O
diacetate O
( O
DCFH B
- I
DA I
) O
kit O
. O

GA O
significantly O
increased O
antioxidant O
enzyme O
SOD O
activity O
and O
decreased O
peroxide O
degradation O
product O
MDA B
level O
in O
a O
dose O
- O
dependent O
manner O
. O

Complement O
activation O
by O
PEGylated O
liposomes O
containing O
prednisolone B
. O

Previously O
it O
has O
been O
shown O
that O
these O
reactions O
can O
be O
caused O
by O
activation O
of O
the O
complement O
( O
C O
) O
system O
by O
a O
negative O
charge O
on O
the O
anchor O
molecule O
of O
PEG B
at O
the O
liposomal O
surface O
. O

In O
this O
study O
it O
is O
tested O
whether O
the O
activation O
of O
the O
C O
system O
by O
PEG B
- O
liposomes O
could O
be O
significantly O
reduced O
to O
values O
comparable O
to O
nonreactive O
liposomal O
formulations O
, O
by O
changing O
the O
PEGylation O
- O
profile O
on O
the O
liposomal O
surface O
. O

Therefore O
, O
the O
formation O
of O
C O
activation O
markers O
SC5b O
- O
9 O
, O
C3a O
, O
C4d O
and O
Bb O
in O
normal O
human O
serum O
by O
both O
prednisolone B
loaded O
and O
empty O
liposomes O
with O
a O
variation O
of O
PEG B
chain O
length O
, O
PEG B
surface O
concentration O
, O
PEG B
anchor O
molecule O
and O
liposomal O
size O
was O
determined O
using O
in O
vitro O
assays O
. O

The O
tested O
liposomes O
caused O
no O
or O
only O
mild O
( O
30 O
% O
) O
activation O
of O
C O
except O
for O
one O
formulation O
wherein O
the O
PEG2000 O
was O
anchored O
to O
cholesterol B
( O
CHOL O
- O
PEG2000 O
) O
. O

The O
polyene B
antibiotic O
nystatin O
may O
be O
an O
optimal O
choice O
for O
active O
agent O
, O
incorporated O
in O
a O
bioadhesive O
multiparticulate O
system O
. O

Oral O
everolimus O
( O
Afinitor O
( O
( O
R O
) O
) O
) O
in O
combination O
with O
exemestane O
is O
indicated O
for O
the O
treatment O
of O
hormone O
receptor O
- O
positive O
, O
human O
epidermal O
growth O
factor O
receptor O
( O
HER O
) O
2 O
- O
negative O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
after O
failure O
of O
treatment O
with O
letrozole O
or O
anastrozole B
( O
in O
the O
USA O
) O
or O
after O
recurrence O
of O
progression O
following O
a O
nonsteroidal O
aromatase O
inhibitor O
( O
AI O
) O
in O
women O
without O
symptomatic O
visceral O
disease O
( O
in O
the O
EU O
) O
. O

Everolimus O
, O
a O
selective O
inhibitor O
of O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
, O
inhibits O
the O
downstream O
signalling O
events O
of O
the O
mTOR O
pathway O
. O

This O
review O
summarizes O
the O
pharmacology O
of O
everolimus O
and O
reviews O
its O
efficacy O
and O
tolerability O
when O
administered O
in O
combination O
with O
exemestane O
in O
postmenopausal O
women O
with O
oestrogen B
receptor O
- O
positive O
, O
HER2 O
- O
negative O
advanced O
breast O
cancer O
refractory O
to O
nonsteroidal O
AIs O
. O

Oral O
lorcaserin O
( O
BELVIQ B
( O
( O
R O
) O
) O
) O
, O
a O
selective O
serotonin B
5 O
- O
HT2C O
receptor O
agonist O
, O
is O
indicated O
in O
the O
US O
as O
an O
adjunct O
to O
diet O
and O
exercise O
in O
the O
chronic O
weight O
management O
of O
obese O
adults O
, O
or O
overweight O
adults O
with O
at O
least O
one O
weight O
- O
related O
comorbidity O
( O
e O
. O
g O
. O
dyslipidaemia O
, O
hypertension O
, O
type O
2 O
diabetes O
) O
. O

Broadband O
Light O
- O
Trapping O
Enhancement O
in O
an O
Ultrathin O
Film O
a O
- O
Si B
Absorber O
Using O
Whispering O
Gallery O
Modes O
and O
Guided O
Wave O
Modes O
with O
Dielectric O
Surface O
- O
Textured O
Structures O
. O

An O
embedded O
nanosphere O
dielectric O
structure O
on O
an O
a O
- O
Si B
ultrathin O
film O
improves O
weighted O
absorption O
from O
23 O
. O
8 O
% O
to O
39 O
. O
9 O
% O
. O

The O
PMMA B
embedding O
layer O
offers O
a O
guided O
wave O
mode O
as O
well O
as O
mechanical O
robustness O
, O
in O
addition O
to O
the O
resonant O
whispering O
gallery O
modes O
coupling O
. O

Besides O
its O
role O
in O
the O
control O
of O
ventilation O
, O
the O
CB O
has O
been O
proposed O
as O
a O
glucose B
sensor O
being O
implicated O
in O
the O
control O
of O
energy O
homeostasis O
. O

Universal O
rule O
on O
chirality O
- O
dependent O
bandgaps O
in O
graphene B
antidot O
lattices O
. O

Graphene B
with O
periodically O
patterned O
antidots O
has O
attracted O
intense O
research O
attention O
as O
it O
represents O
a O
facile O
route O
to O
open O
a O
bandgap O
for O
graphene B
electronics O
. O

However O
, O
not O
all O
graphene B
antidot O
lattices O
( O
GALs O
) O
can O
open O
a O
bandgap O
and O
a O
guiding O
rule O
is O
missing O
. O

Here O
, O
through O
systematic O
first O
- O
principles O
calculations O
, O
it O
is O
found O
that O
bandgaps O
in O
triangular O
GALs O
are O
surprisingly O
well O
defined O
by O
a O
chirality O
vector O
R O
= O
n O
a1 O
+ O
ma2 O
connecting O
two O
neighboring O
antidots O
, O
where O
a1 O
and O
a2 O
are O
the O
basis O
vectors O
of O
graphene B
. O

The O
bandgap O
opens O
in O
the O
GALs O
with O
( O
n O
- O
m O
) O
mod3 O
= O
0 O
but O
remains O
closed O
in O
those O
with O
( O
n O
- O
m O
) O
mod3 O
= O
+ O
/ O
- O
1 O
, O
reminiscent O
of O
the O
gap O
- O
chirality O
rule O
in O
carbon B
nanotubes O
. O

This O
chirality O
- O
dependent O
bandgap O
is O
further O
shown O
to O
be O
a O
generic O
behavior O
in O
any O
parallelogram O
GAL O
and O
thus O
serves O
as O
an O
essential O
stepping O
stone O
for O
experimenters O
to O
realize O
graphene B
devices O
by O
antidot O
engineering O
. O

Circulating O
Vitamin B
D I
Metabolites O
and O
Subclinical O
Atherosclerosis O
in O
Type O
1 O
Diabetes O
. O

Existing O
evidence O
suggests O
that O
impaired O
vitamin B
D I
metabolism O
may O
contribute O
to O
the O
development O
of O
atherosclerosis O
. O

We O
tested O
associations O
of O
circulating O
vitamin B
D I
metabolite O
concentrations O
with O
subclinical O
atherosclerosis O
among O
1 O
, O
193 O
participants O
with O
type O
1 O
diabetes O
in O
the O
DCCT O
/ O
EDIC O
study O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
plasma O
concentrations O
of O
25 B
- I
hydroxyvitamin I
D I
[ O
25 O
( O
OH O
) O
D O
] O
, O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
, O
and O
24 O
, O
25 O
- O
dihydroxyvitamin O
D O
by O
mass O
spectrometry O
at O
the O
end O
of O
the O
DCCT O
. O

In O
a O
staggered O
cross O
- O
sectional O
design O
, O
we O
tested O
associations O
with O
coronary O
artery O
calcium B
( O
CAC O
) O
, O
measured O
by O
computed O
tomography O
a O
median O
of O
10 O
years O
later O
, O
and O
with O
common O
and O
internal O
carotid O
intima O
- O
media O
thickness O
( O
IMT O
) O
, O
measured O
by O
B O
- O
mode O
ultrasonography O
on O
two O
occasions O
a O
median O
of O
4 O
years O
later O
and O
a O
median O
of O
10 O
years O
later O
. O

We O
hypothesized O
that O
lower O
concentrations O
of O
each O
vitamin B
D I
metabolite O
would O
be O
associated O
with O
increased O
risk O
of O
CAC O
and O
greater O
carotid O
IMT O
. O
RESULTSAt O
the O
time O
metabolites O
were O
measured O
, O
mean O
age O
was O
32 O
. O
4 O
years O
and O
mean O
duration O
of O
diabetes O
was O
7 O
. O
5 O
years O
. O

The O
prevalence O
and O
severity O
of O
CAC O
tended O
to O
be O
lower O
- O
not O
higher O
- O
with O
lower O
concentrations O
of O
each O
vitamin B
D I
metabolite O
. O

For O
instance O
, O
in O
a O
fully O
adjusted O
multinomial O
logistic O
model O
, O
a O
25 O
nmol O
/ O
L O
lower O
25 B
- I
hydroxyvitamin I
D I
was O
associated O
with O
a O
0 O
. O
8 O
- O
fold O
decrease O
in O
the O
odds O
of O
having O
higher O
CAC O
( O
95 O
% O
CI O
0 O
. O
68 O
- O
0 O
. O
96 O
, O
P O
= O
0 O
. O
01 O
) O
. O

No O
vitamin B
D I
metabolite O
was O
associated O
with O
either O
common O
or O
internal O
mean O
IMT O
. O
CONCLUSIONSWe O
did O
not O
find O
evidence O
linking O
impaired O
vitamin B
D I
metabolism O
with O
increased O
subclinical O
atherosclerosis O
in O
type O
1 O
diabetes O
. O

Regulation O
of O
the O
Bone O
- O
restricted O
ifitm O
- O
like O
( O
Bril O
) O
gene O
transcription O
by O
Sp O
and O
Gli O
family O
members O
and O
CpG B
methylation O
. O

Second O
, O
CpG B
methylation O
of O
the O
promoter O
region O
correlated O
with O
an O
inactive O
state O
, O
and O
prevented O
Sp1 O
activation O
. O

Silicone O
sheets O
are O
first O
plasma O
treated O
and O
then O
functionalized O
by O
grafting O
sequentially O
under O
stretching O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
chains O
and O
biotin B
or O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
peptides O
. O

Under O
a O
mechanical O
deformation O
, O
the O
surface O
becomes O
specifically O
interactive O
to O
streptavidin O
, O
biotin B
antibodies O
, O
or O
adherent O
for O
cells O
, O
the O
interactions O
both O
for O
proteins O
and O
cells O
being O
fully O
reversible O
by O
stretching O
/ O
unstretching O
, O
revealing O
a O
reversible O
exposure O
process O
of O
the O
ligands O
. O

Nickel O
( O
II O
) O
Dithiocarbamate O
Complexes O
Containing O
Sulforhodamine B
B I
as O
Fluorescent O
Probes O
for O
Selective O
Detection O
of O
Nitrogen B
Dioxide I
. O

We O
synthesized O
complexes O
of O
Ni B
( I
II I
) I
with O
dithiocarbamate B
ligands O
derived O
from O
the O
ortho O
and O
para O
isomers O
of O
sulforhodamine B
B I
fluorophores O
and O
demonstrated O
they O
are O
highly O
selective O
in O
reactions O
with O
nitrogen B
dioxide I
( O
NO2 B
) O
. O

Compared O
with O
the O
para O
isomer O
, O
the O
ortho O
isomer O
showed O
a O
much O
greater O
fluorescence O
increase O
upon O
reaction O
with O
NO2 B
, O
which O
led O
to O
oxidation O
and O
decomplexation O
of O
the O
dithiocarbamate B
ligand O
from O
Ni B
( I
II I
) I
. O

We O
applied O
this O
probe O
for O
visual O
detection O
of O
1 O
ppm O
NO2 B
in O
the O
gas O
phase O
and O
fluorescence O
imaging O
of O
NO2 B
in O
macrophage O
cells O
treated O
with O
a O
nitrogen B
dioxide I
donor O
. O

From O
the O
combination O
of O
magnetic O
and O
structural O
studies O
by O
means O
of O
Fe O
K O
- O
edge O
X O
- O
ray O
absorption O
near O
edge O
structure O
( O
XANES O
) O
and O
high O
- O
resolution O
transmission O
electron O
microscopy O
we O
have O
identified O
and O
quantified O
two O
phases O
of O
Fe B
( O
ferrihydrite B
and O
magnetite O
) O
involved O
in O
the O
biomineralization O
process O
, O
confirming O
the O
role O
of O
ferrihydrite B
as O
the O
source O
of O
Fe B
ions O
for O
magnetite O
biomineralization O
in O
M O
. O
gryphiswaldense O
. O

We O
have O
distinguished O
two O
steps O
in O
the O
biomineralization O
process O
: O
the O
first O
, O
in O
which O
Fe B
is O
accumulated O
in O
the O
form O
of O
ferrihydrite B
, O
and O
the O
second O
, O
in O
which O
the O
magnetite O
is O
rapidly O
biomineralized O
from O
ferrihydrite B
. O

Finally O
, O
the O
XANES O
analysis O
suggests O
that O
the O
origin O
of O
the O
ferrihydrite B
could O
be O
at O
bacterial O
ferritin O
cores O
, O
characterized O
by O
a O
poorly O
crystalline O
structure O
and O
high O
phosphorus B
content O
. O

Exploiting O
the O
Unique O
ATP B
- O
Binding O
Pocket O
of O
Toxoplasma O
Calcium B
- O
Dependent O
Protein O
Kinase O
1 O
To O
Identify O
Its O
Substrates O
. O

Apicomplexan O
parasites O
rely O
on O
calcium B
as O
a O
second O
messenger O
to O
regulate O
a O
variety O
of O
essential O
cellular O
processes O
. O

Calcium B
- O
dependent O
protein O
kinases O
( O
CDPK O
) O
, O
which O
transduce O
these O
signals O
, O
are O
conserved O
among O
apicomplexans O
but O
absent O
from O
mammalian O
hosts O
, O
making O
them O
attractive O
targets O
for O
therapeutic O
intervention O
. O

In O
Toxoplasma O
gondii O
, O
CDPK1 O
is O
required O
for O
calcium B
- O
regulated O
secretion O
from O
micronemes O
, O
thereby O
controlling O
motility O
, O
invasion O
, O
and O
egress O
from O
host O
cells O
. O

CDPK1 O
is O
unique O
among O
parasite O
and O
mammalian O
kinases O
in O
containing O
glycine B
at O
the O
key O
" O
gatekeeper O
" O
residue O
, O
which O
results O
in O
an O
expanded O
ATP B
- O
binding O
pocket O
. O

In O
the O
present O
study O
, O
we O
use O
a O
synthetic O
ATP O
gamma O
S O
analogue O
that O
displays O
steric O
complementarity O
to O
the O
ATP B
- O
binding O
pocket O
and O
hence O
allows O
identification O
of O
protein O
substrates O
based O
on O
selective O
thiophosphorylation O
. O

( B
1 I
) I
H I
NMR O
spectral O
analysis O
was O
used O
to O
determine O
the O
structures O
and O
content O
of O
ricinoleic O
acid O
containing O
oligomeric O
chains O
present O
in O
the O
degraded O
polymer O
. O

The O
polymer O
degrades O
into O
ester O
oligomers O
of O
2 O
- O
4 O
ricinoleic O
acid O
units O
which O
further O
degrade O
to O
ricinoleic O
acid O
, O
a O
natural O
fatty B
acid I
. O

Multipart O
Copolyelectrolyte O
Adhesive O
of O
the O
Sandcastle O
Worm O
, O
Phragmatopoma O
californica O
( O
Fewkes O
) O
: O
Catechol B
Oxidase O
Catalyzed O
Curing O
through O
Peptidyl O
- O
DOPA B
. O

Both O
types O
of O
granules O
contain O
catechol B
oxidase O
that O
catalyzes O
oxidative O
cross O
- O
linking O
of O
L O
- O
DOPA O
. O

Co O
- O
secretion O
of O
catechol B
oxidase O
guarantees O
rapid O
and O
spatially O
homogeneous O
curing O
with O
limited O
mixing O
of O
the O
preassembled O
adhesive O
packets O
. O

Catechol B
oxidase O
remains O
active O
long O
after O
the O
glue O
is O
fully O
cured O
, O
perhaps O
providing O
an O
active O
cue O
for O
conspecific O
larval O
settlement O
. O

AIM O
: O
To O
compare O
' O
progression O
to O
insulin O
' O
for O
three O
cohorts O
on O
oral O
antidiabetic O
medication O
combinations O
: O
metformin B
/ O
sulphonylurea O
( O
Met B
/ O
SU O
) O
, O
metformin B
/ O
thiazolidinedione B
( O
Met B
/ O
TZD B
) O
and O
sulphonylurea O
/ O
thiazolidinedione B
( O
SU O
/ O
TZD B
) O
. O

RESULTS O
: O
By O
the O
end O
of O
the O
2 O
- O
to O
6 O
- O
year O
follow O
- O
up O
period O
, O
14 O
. O
3 O
% O
of O
the O
Met B
/ O
TZD B
cohort O
, O
23 O
. O
6 O
% O
of O
the O
Met B
/ O
SU O
cohort O
and O
28 O
. O
2 O
% O
of O
the O
SU O
/ O
TZD B
cohort O
had O
insulin O
added O
to O
their O
regimen O
. O

Those O
in O
the O
Met B
/ O
SU O
cohort O
had O
a O
1 O
. O
8 O
times O
higher O
probability O
of O
progression O
to O
insulin O
than O
those O
in O
the O
Met B
/ O
TZD B
cohort O
[ O
odds O
ratio O
( O
OR O
) O
= O
1 O
. O
80 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
= O
1 O
. O
51 O
- O
2 O
. O
14 O
) O
, O
and O
those O
in O
the O
SU O
/ O
TZD B
cohort O
had O
a O
2 O
. O
5 O
times O
higher O
probability O
of O
progression O
to O
insulin O
than O
those O
in O
the O
Met B
/ O
TZD B
cohort O
( O
OR O
= O
2 O
. O
51 O
, O
95 O
% O
CI O
= O
2 O
. O
04 O
- O
3 O
. O
08 O
) O
. O

CONCLUSION O
: O
When O
sensitizers O
were O
paired O
( O
Met B
/ O
TZD B
) O
, O
a O
lower O
percentage O
of O
patients O
progressed O
to O
insulin O
during O
the O
study O
period O
, O
as O
opposed O
to O
patients O
who O
used O
a O
combination O
of O
a O
secretagogue O
with O
a O
sensitizer O
( O
SU O
/ O
TZD B
or O
Met B
/ O
SU O
) O
. O

The O
Protective O
Effects O
of O
alpha B
- I
Lipoic I
Acid I
on O
Kidneys O
in O
Type O
2 O
Diabetic O
Goto O
- O
Kakisaki O
Rats O
via O
Reducing O
Oxidative O
Stress O
. O

To O
evaluate O
the O
protective O
effects O
of O
alpha B
- I
lipoic I
acid I
on O
the O
kidneys O
of O
Goto O
- O
Kakisaki O
( O
GK O
) O
diabetic O
rats O
, O
ten O
GK O
diabetic O
rats O
were O
randomly O
divided O
into O
a O
diabetic O
control O
group O
and O
a O
lipoic B
acid I
- O
treated O
diabetic O
group O
with O
alpha B
- I
lipoic I
acid I
35 O
mg O
. O
Kg O
- O
1 O
intraperitoneal O
injections O
. O

Malonaldehyde B
( O
MDA B
) O
, O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
vitamin B
E I
, O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
levels O
in O
renal O
homogenate O
, O
and O
urine O
protein O
excretion O
were O
measured O
. O

The O
expression O
of O
mRNA O
for O
NF O
- O
kappa O
B O
, O
NADPH B
oxidase O
subunits O
p22phox O
and O
p47phox O
in O
renal O
tissue O
was O
examined O
by O
realtime O
PCR O
. O

There O
were O
significant O
increases O
in O
urine O
protein O
excretion O
, O
MDA B
levels O
and O
the O
expression O
of O
mRNA O
of O
NF O
- O
kappa O
B O
, O
p22phox O
and O
p47phox O
, O
and O
significant O
decreases O
in O
GSH B
, O
SOD O
, O
vitamin B
C I
and O
vitamin B
E I
levels O
in O
the O
diabetic O
control O
group O
compared O
with O
the O
normal O
control O
group O
. O

All O
the O
parameters O
above O
were O
improved O
in O
the O
alpha B
- I
lipoic I
acid I
- O
treated O
diabetic O
group O
. O

alpha B
- I
lipoic I
acid I
can O
protect O
renal O
function O
in O
diabetic O
rats O
via O
its O
antioxidant O
activity O
. O

Effect O
of O
oxygen B
concentration O
and O
selected O
protocol O
factors O
on O
viability O
and O
gene O
expression O
of O
mouse O
liver O
slices O
. O

Slices O
were O
cultured O
for O
24h O
under O
different O
concentrations O
of O
serum O
, O
glucose B
, O
insulin O
, O
and O
oxygen B
. O

Transcriptome O
analysis O
was O
performed O
to O
identify O
changes O
introduced O
by O
culture O
at O
different O
oxygen B
concentrations O
( O
20 O
% O
, O
40 O
% O
, O
60 O
% O
, O
and O
80 O
% O
of O
oxygen B
) O
. O

Although O
metabolic O
competence O
was O
unaffected O
by O
oxygen B
concentrations O
, O
culturing O
at O
80 O
% O
of O
oxygen B
yielded O
slices O
with O
the O
best O
biochemical O
characteristics O
. O

Moreover O
, O
80 O
% O
of O
oxygen B
was O
the O
most O
favorable O
condition O
with O
respect O
to O
maintenance O
of O
expression O
of O
genes O
involved O
in O
drug O
and O
energy O
metabolism O
. O

The O
outcome O
of O
this O
study O
indicates O
that O
mouse O
PCLS O
are O
a O
valuable O
tool O
in O
research O
on O
hepatic O
functions O
and O
toxicity O
, O
particularly O
if O
they O
are O
cultured O
under O
a O
controlled O
oxygen B
concentration O
of O
80 O
% O
. O

The O
noncellular O
reduction O
of O
MTT O
tetrazolium O
salt O
by O
TiO2 B
nanoparticles O
and O
its O
implications O
for O
cytotoxicity O
assays O
. O

We O
report O
results O
of O
noncellular O
tests O
, O
revealing O
the O
occurrence O
of O
photocatalytic O
interactions O
between O
titanium B
dioxide I
( O
TiO2 B
, O
titania O
) O
nanoparticles O
and O
the O
MTT B
[ O
3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
- I
bromide I
] O
cytotoxicity O
indicator O
. O

These O
interactions O
induce O
the O
reduction O
of O
MTT B
and O
formation O
of O
purple O
formazan O
under O
biologically O
relevant O
conditions O
. O

Classical O
MTT B
assays O
have O
been O
performed O
to O
evaluate O
the O
production O
of O
formazan O
in O
DMEM O
- O
F12 O
and O
RPMI O
- O
1640 O
cell O
culture O
media O
( O
containing O
10 O
% O
fetal O
bovine O
serum O
- O
FBS O
) O
treated O
with O
Degussa O
- O
P25 O
TiO2 O
nanoparticles O
, O
in O
the O
absence O
of O
cells O
. O

The O
colorimetric O
determinations O
revealed O
the O
noncellular O
MTT B
to O
formazan O
transformation O
induced O
by O
TiO2 B
nanoparticles O
, O
under O
conditions O
commonly O
used O
for O
in O
vitro O
cytotoxicity O
testing O
of O
nanomaterials O
. O

The O
formazan O
precipitation O
was O
found O
to O
be O
proportional O
to O
the O
TiO2 B
concentration O
, O
being O
enhanced O
under O
laboratory O
daylight O
exposure O
. O

The O
results O
show O
false O
viability O
increases O
with O
up O
to O
14 O
% O
( O
for O
TiO2 B
concentrations O
generally O
higher O
than O
50 O
mu O
g O
/ O
ml O
) O
, O
induced O
by O
the O
TiO2 B
- O
MTT B
reaction O
. O

Analysis O
of O
visible O
- O
light O
- O
active O
Sn O
( O
ii O
) O
- O
TiO2 B
photocatalysts O
. O

The O
influence O
of O
Sn O
( O
ii O
) O
species O
on O
TiO2 B
is O
investigated O
. O

This O
prominent O
red O
- O
shift O
is O
attributed O
to O
the O
interaction O
of O
Sn O
( O
ii O
) O
5s O
orbitals O
with O
the O
TiO2 B
decreasing O
the O
band O
gap O
of O
TiO2 B
by O
raising O
its O
valence O
band O
. O

These O
materials O
are O
active O
for O
sacrificial O
photo O
- O
generation O
of O
hydrogen B
in O
visible O
light O
. O

This O
study O
describes O
the O
use O
of O
the O
pyrrolidinium O
nitrate O
( O
[ O
Pyrr O
] O
[ O
NO3 O
] O
) O
protic O
ionic O
liquid O
( O
PIL O
) O
in O
a O
mixture O
with O
gamma B
butyrolactone I
( O
gamma O
- O
BL O
) O
as O
an O
electrolyte O
for O
carbon B
- O
based O
supercapacitors O
with O
an O
operating O
voltage O
of O
2 O
. O
0 O
V O
and O
at O
very O
low O
temperature O
. O

Electrochemical O
characterization O
of O
this O
electrolyte O
demonstrated O
, O
at O
first O
, O
a O
passivation O
on O
the O
aluminum B
collector O
, O
secondly O
good O
cycling O
performances O
with O
an O
activated O
carbon B
electrode O
from O
50 O
degrees O
C O
to O
- O
40 O
degrees O
C O
with O
capacitance O
up O
to O
132 O
F O
g O
( O
- O
1 O
) O
at O
room O
temperature O
and O
a O
wide O
voltage O
window O
( O
2 O
. O
0 O
V O
) O
. O

We O
analysed O
the O
influence O
of O
immunosuppressants O
on O
the O
proliferation O
of O
transplanted O
alpha O
and O
beta O
cells O
after O
syngeneic O
islet O
transplantation O
in O
streptozotocin B
- O
induced O
diabetic O
mice O
. O

METHODS O
: O
C57BL O
/ O
6 O
diabetic O
mice O
were O
transplanted O
with O
syngeneic O
islets O
in O
the O
liver O
and O
simultaneously O
abdominally O
implanted O
with O
a O
mini O
- O
osmotic O
pump O
delivering O
BrdU O
alone O
or O
together O
with O
an O
immunosuppressant O
( O
tacrolimus B
, O
sirolimus B
, O
everolimus O
or O
mycophenolate B
mofetil I
[ O
MMF B
] O
) O
. O

Insulinaemia O
was O
significantly O
lower O
in O
mice O
treated O
with O
everolimus O
, O
tacrolimus B
and O
sirolimus B
. O

MMF B
was O
the O
only O
immunosuppressant O
that O
did O
not O
significantly O
reduce O
beta O
cell O
area O
or O
proliferation O
, O
albeit O
its O
levels O
were O
in O
a O
lower O
range O
than O
those O
used O
in O
clinical O
settings O
. O

In O
contrast O
to O
other O
immunosuppressants O
, O
MMF B
neither O
impaired O
beta O
cell O
proliferation O
nor O
adversely O
affected O
the O
fractional O
beta O
cell O
area O
. O

Although O
human O
beta O
cells O
are O
less O
prone O
to O
proliferate O
compared O
with O
rodent O
beta O
cells O
, O
the O
use O
of O
MMF B
may O
improve O
the O
long O
- O
term O
outcome O
of O
islet O
transplantation O
. O

We O
aimed O
to O
document O
the O
capability O
( O
response O
) O
of O
adrenal O
gland O
to O
secrete O
cortisol B
and O
DHEA B
- O
S O
during O
hyperthyroidism O
compared O
to O
euthyroidism O
, O
and O
to O
describe O
factors O
associated O
with O
these O
responses O
. O

Baseline O
cortisol B
( O
Cor0 O
) O
, O
DHEA B
- O
S O
( O
DHEA B
- O
S0 O
) O
, O
cortisol B
binding O
globulin O
( O
CBG O
) O
, O
ACTH O
, O
calculated O
free O
cortisol B
( O
by O
Coolen O
' O
s O
equation O
= O
CFC O
) O
, O
free O
cortisol B
index O
( O
FCI O
) O
, O
60 O
- O
min O
cortisol B
( O
Cor60 O
) O
, O
and O
DHEA B
- O
S O
( O
DHEA B
- O
S60 O
) O
, O
delta O
cortisol O
( O
Delta O
Cor O
) O
, O
delta O
DHEA O
- O
S O
( O
Delta O
DHEA O
- O
S O
) O
responses O

Forty O
- O
one O
patients O
[ O
22 O
females O
, O
49 O
. O
5 O
+ O
/ O
- O
15 O
. O
2 O
years O
old O
, O
32 O
Graves O
disease O
, O
nine O
toxic O
nodular O
goiter O
] O
had O
similar O
Cor0 O
, O
DHEA B
- O
S0 O
, O
CFC O
, O
FCI O
, O
and O
DHEA B
- O
S60 O
in O
hyperthyroid O
and O
euthyroid O
states O
. O

In O
four O
( O
10 O
% O
) O
patients O
the O
peak O
ACTH O
- O
stimulated O
cortisol B
values O
were O
lower O
than O
18 O
mu O
g O
/ O
dL O
. O

When O
the O
test O
repeated O
after O
attainment O
of O
euthyroidism O
, O
all O
of O
the O
patients O
had O
normal O
cortisol B
response O
. O

However O
, O
the O
predictors O
of O
CFC O
, O
FCI O
, O
and O
DHEA B
- O
S O
levels O
were O
serum O
creatinine B
levels O
in O
hyperthyroidism O
, O
and O
both O
creatinine B
and O
transaminase O
levels O
in O
euthyroidism O
. O

ACTH O
- O
stimulated O
peak O
cortisol B
, O
delta O
cortisol O
, O
and O
delta O
DHEA O
- O
S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O

Tryptophan B
residue O
at O
active O
- O
site O
tunnel O
entrance O
of O
Trichoderma O
reesei O
cellobiohydrolase O
Cel7A O
is O
important O
to O
initiate O
degradation O
of O
crystalline O
cellulose O
. O

Our O
previous O
high O
- O
speed O
AFM O
studies O
showed O
that O
mutation O
of O
tryptophan B
residue O
( O
Trp40 O
; O
W40 O
) O
at O
the O
entrance O
of O
the O
catalytic O
tunnel O
drastically O
decreases O
the O
ability O
to O
degrade O
crystalline O
cellulose O
. O

Here O
, O
we O
examined O
the O
activities O
of O
the O
wild O
- O
type O
( O
WT O
) O
enzyme O
and O
tryptophan B
to O
alanine B
mutant O
( O
W40A O
) O
enzyme O
, O
with O
and O
without O
the O
CBD O
, O
towards O
various O
substrates O
. O

This O
idea O
was O
supported O
by O
molecular O
dynamics O
simulation O
study O
, O
i O
. O
e O
. O
, O
the O
reducing O
- O
end O
glucose B
unit O
was O
effectively O
loaded O
into O
the O
active O
site O
of O
WTcat O
, O
but O
not O
into O
that O
of O
W40Acat O
. O
when O
the O
simulation O
was O
started O
from O
subsite O
- O
7 O
. O

The O
filamentous O
fungi O
in O
the O
genus O
Aspergillus O
are O
opportunistic O
plant O
and O
animal O
pathogens O
that O
can O
adapt O
to O
their O
environment O
by O
producing O
various O
secondary O
metabolites O
including O
lovastatin O
, O
penicillin B
, O
and O
aflatoxin B
. O

Although O
the O
amino B
acid I
sequence O
of O
LaeA O
contains O
the O
motifs O
characteristic O
of O
seven O
- O
beta O
- O
strand O
methyltransferases O
, O
a O
methyl B
- O
accepting O
substrate O
of O
LaeA O
has O
not O
been O
identified O
. O

In O
this O
work O
, O
we O
did O
not O
find O
a O
methyl B
- O
accepting O
substrate O
in O
A O
. O
nidulans O
with O
various O
assays O
including O
in O
vivo O
S O
- O
adenosyl O
- O
[ O
methyl O
- O
( O
3 O
) O
H O
] O
methionine O
labeling O
, O
targeted O
in O
vitro O
methylation O
experiments O
using O
putative O
protein O
substrates O
, O
or O
in O
vitro O
methylation O
assays O
using O
whole O
cell O
extracts O
grown O
under O
different O
conditions O
. O

Amino B
acid I
hydrolysis O
of O
radioactively O
- O
labeled O
LaeA O
followed O
by O
cation O
exchange O
and O
reverse O
phase O
chromatography O
identified O
methionine B
as O
the O
modified O
residue O
. O

Point O
mutations O
show O
that O
the O
major O
site O
of O
modification O
of O
LaeA O
is O
on O
methionine B
- O
207 O
. O

However O
, O
in O
vivo O
complementation O
showed O
that O
methionine B
- O
207 O
is O
not O
required O
for O
the O
biological O
function O
of O
LaeA O
. O

LaeA O
is O
the O
first O
protein O
to O
exhibit O
automethylation O
at O
a O
methionine B
residue O
. O

These O
findings O
not O
only O
indicate O
LaeA O
may O
perform O
novel O
chemistry O
with O
S B
- I
adenosylmethionine I
, O
but O
also O
provide O
new O
insights O
into O
the O
physiological O
function O
of O
LaeA O
. O

Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil B
- O
Based O
Fluorescein B
Conjugates O
as O
GluN1 O
/ O
GluN2B O
N B
- I
Methyl I
- I
D I
- I
aspartate I
Receptor O
Antagonists O
. O

GluN2B O
- O
containing O
NMDA B
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O

Ifenprodil B
, O
known O
as O
the O
GluNR2B O
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O

We O
had O
previously O
reported O
a O
fluorescein B
conjugate O
that O
was O
shown O
( O
by O
confocal O
microscopy O
imaging O
of O
DS O
- O
red O
- O
labelled O
cortical O
neurons O
) O
to O
bind O
specifically O
to O
GluN2B O
. O

To O
elaborate O
this O
probe O
, O
we O
explored O
the O
influence O
of O
both O
the O
nature O
and O
the O
attachment O
point O
of O
the O
spacer O
between O
the O
fluorophore O
and O
the O
parent O
compound O
, O
ifenprodil B
. O

We O
performed O
chemical O
modifications O
of O
ifenprodil B
at O
the O
benzylic B
position O
and O
on O
the O
phenol B
ring O
by O
introducing O
secondary O
amine O
or O
amide O
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary B
amide I
functions O
as O
spacers O
. O

The O
previously O
developed O
probe O
was O
found O
to O
display O
the O
greatest O
activity O
in O
the O
inhibition O
of O
NMDA B
- O
induced O
Ca B
( I
2 I
+ I
) I
influx O
by O
calcium B
imaging O
experiments O
on O
HEK293 O
cells O
transfected O
with O
the O
cDNA O
encoding O
for O
GluN1 O
- O
1A O
and O
GluN2B O
. O

Further O
investigations O
revealed O
that O
this O
probe O
had O
a O
neuroprotective O
effect O
equivalent O
to O
that O
of O
ifenprodil B
in O
a O
standard O
test O
for O
neurotoxicity O
. O

Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil B
, O
we O
demonstrated O
that O
they O
displaced O
[ O
( O
3 O
) O
H O
] O
ifenprodil O
in O
mouse O
brain O
slices O
in O
a O
similar O
manner O
. O

Extended O
h O
u O
ckel O
theory O
for O
carbon B
nanotubes O
: O
band O
structure O
and O
transport O
properties O
. O

In O
this O
article O
, O
we O
present O
a O
set O
of O
extended O
H O
u O
ckel O
parameters O
for O
carbon B
nanotubes O
( O
CNTs O
) O
, O
obtained O
by O
fitting O
the O
ab O
initio O
band O
structure O
of O
the O
( O
6 O
, O
0 O
) O
CNT O
. O

Analogues O
14h O
and O
20l O
exhibited O
potential O
antimalarial O
activity O
against O
chloroquine B
- O
sensitive O
D6 O
strain O
with O
IC O
( O
50 O
) O
1 O
. O
25 O
and O
0 O
. O
88 O
mu O
M O
and O
chloroquine B
- O
resistant O
W2 O
strain O
with O
IC O
( O
50 O
) O
1 O
. O
64 O
and O
1 O
. O
07 O
mu O
M O
, O
respectively O
. O

Analogue O
20l O
having O
pentyl O
and O
methyl B
substituents O
on O
tricycle O
showed O
promising O
activities O
against O
all O
pathogens O
. O

Pickering O
- O
Emulsion O
- O
Polymerized O
Polystyrene B
/ O
Fe2O3 B
Composite O
Particles O
and O
Their O
Magnetoresponsive O
Characteristics O
. O

Core O
- O
shell O
- O
structured O
magnetic O
polystyrene B
( O
PS O
) O
/ O
inorganic O
particles O
were O
fabricated O
by O
Pickering O
emulsion O
polymerization O
using O
nanosized O
Fe2O3 B
particles O
as O
a O
solid O
stabilizer O
. O

Scanning O
electron O
microscopy O
and O
transmission O
electron O
microscopy O
confirmed O
the O
synthesized O
PS O
/ O
Fe2O3 B
particles O
to O
be O
comprised O
of O
a O
PS O
surface O
coated O
with O
Fe2O3 B
nanoparticles O
. O

In O
this O
study O
, O
conductive O
polydimethylsiloxane B
( O
PDMS B
) O
templates O
with O
different O
micropatterns O
were O
fabricated O
by O
combining O
photolithography O
, O
silicon B
wet O
etching O
, O
and O
PDMS B
molding O
techniques O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
pyripyropene O
A O
derivatives O
as O
potent O
and O
selective O
acyl B
- I
CoA I
: O
cholesterol B
acyltransferase O
2 O
( O
ACAT2 O
) O
inhibitors O
: O
Part O
2 O
. O

Disruption O
of O
AtWNK8 O
Enhances O
Tolerance O
of O
Arabidopsis O
to O
Salt O
and O
Osmotic O
Stresses O
via O
Modulating O
Proline B
Content O
and O
Activities O
of O
Catalase O
and O
Peroxidase O
. O

With O
no O
lysine B
kinases O
( O
WNKs O
) O
play O
important O
roles O
in O
plant O
growth O
and O
development O
. O

Here O
, O
we O
report O
that O
AtWNK8 O
is O
mainly O
expressed O
in O
primary O
root O
, O
hypocotyl O
, O
stamen O
and O
pistil O
and O
is O
induced O
by O
NaCl B
and O
sorbitol B
treatment O
. O

Compared O
to O
the O
wild O
- O
type O
, O
the O
T O
- O
DNA O
knock O
- O
out O
wnk8 O
mutant O
was O
more O
tolerant O
to O
severe O
salinity O
and O
osmotic O
stresses O
, O
as O
indicated O
by O
27 O
% O
and O
198 O
% O
more O
fresh O
weight O
in O
the O
NaCl B
and O
sorbitol B
treatment O
, O
respectively O
. O

The O
wnk8 O
mutant O
also O
accumulated O
1 O
. O
43 O
- O
fold O
more O
proline B
than O
the O
wild O
- O
type O
in O
the O
sorbitol B
treatment O
. O

Under O
NaCl B
and O
sorbitol B
stresses O
, O
catalase O
( O
CAT O
) O
activity O
in O
wnk8 O
mutant O
was O
1 O
. O
92 O
- O
and O
3 O
. O
7 O
- O
times O
of O
that O
in O
Col O
- O
0 O
, O
respectively O
. O

Taken O
together O
, O
we O
revealed O
that O
maintaining O
higher O
CAT O
and O
POD O
activities O
might O
be O
one O
of O
the O
reasons O
that O
the O
disruption O
of O
AtWNK8 O
enhances O
the O
tolerance O
to O
salt O
stress O
, O
and O
accumulating O
more O
proline B
and O
higher O
activities O
of O
CAT O
and O
POD O
might O
result O
in O
the O
higher O
tolerance O
of O
WNK8 O
to O
osmotic O
stress O
. O

A O
comparative O
study O
of O
the O
lipid O
status O
( O
i O
. O
e O
. O
, O
the O
total O
lipid O
and O
phospholipid O
concentrations O
and O
the O
percentage O
of O
fatty B
acids I
of O
the O
total O
lipids O
) O
of O
adult O
specimens O
of O
daubed O
shanny O
( O
Leptoclinus O
maculatus O
) O
from O
Svalbard O
waters O
( O
Isfjord O
) O
and O
slender O
eel O
blenny O
( O
Lumpenus O
fabricii O
) O
from O
the O
White O
Sea O
( O
Onega O
Bay O
and O
Tersky O
shore O
) O
was O
performed O
to O
study O
the O
metabolism O
and O
functions O
of O
lipids O
of O
these O
fishes O
in O
ontogeny O
and O
under O
various O
ecological O
conditions O
. O

Slender O
eel O
blenny O
from O
both O
areas O
of O
the O
White O
Sea O
were O
distinguished O
by O
a O
high O
level O
of O
sphingomyelin B
compared O
with O
the O
daubed O
shanny O
from O
Svalbard O
, O
and O
the O
amount O
of O
total O
phospholipids O
was O
higher O
in O
slender O
eel O
blenny O
from O
Onega O
Bay O
than O
in O
slender O
eel O
blenny O
from O
the O
Tersky O
shore O
. O

Further O
evidence O
for O
involvement O
of O
the O
dorsal O
hippocampus O
serotonergic O
and O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
ergic O
pathways O
in O
the O
expression O
of O
contextual O
fear O
conditioning O
in O
rats O
. O

Intra O
- O
dorsal O
hippocampus O
( O
DH O
) O
injections O
of O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
a O
serotonin B
- O
1A O
( O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
- O
1A O
) O
receptor O
agonist O
, O
were O
previously O
shown O
to O
inhibit O
the O
expression O
of O
contextual O
fear O
when O
administered O
six O
hours O
after O
conditioning O
. O

Thus O
, O
the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
role O
of O
DH O
serotonergic O
and O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
ergic O
mechanisms O
in O
the O
expression O
of O
contextual O
fear O
24 O
h O
after O
conditioning O
, O
reflected O
by O
fear O
- O
potentiated O
startle O
( O
FPS O
) O
and O
freezing O
behavior O
. O

Although O
intra O
- O
DH O
injections O
of O
8 B
- I
OH I
- I
DPAT I
did O
not O
produce O
behavioral O
changes O
, O
muscimol O
reduced O
both O
FPS O
and O
the O
freezing O
response O
. O

Fos O
protein O
immunoreactivity O
revealed O
that O
contextual O
fear O
promoted O
wide O
activation O
of O
the O
mPFC O
, O
which O
was O
significantly O
reduced O
after O
intra O
- O
DH O
infusions O
of O
muscimol B
. O

The O
present O
findings O
, O
together O
with O
previous O
data O
, O
indicate O
that O
in O
contrast O
to O
5 B
- I
HT I
, O
which O
appears O
to O
play O
a O
role O
during O
the O
early O
phases O
of O
contextual O
aversive O
memory O
consolidation O
, O
longer O
- O
lasting O
GABA B
- O
mediated O
mechanisms O
are O
recruited O
during O
the O
expression O
of O
contextual O
fear O
memories O
. O

Risk O
of O
ischemic O
stroke O
with O
the O
use O
of O
risperidone B
, O
quetiapine B
and O
olanzapine B
in O
elderly O
patients O
: O
a O
population O
- O
based O
, O
case O
- O
crossover O
study O
. O

We O
conducted O
a O
case O
- O
crossover O
study O
to O
evaluate O
the O
comparative O
risk O
of O
ischemic O
stroke O
associated O
with O
the O
use O
of O
risperidone B
, O
quetiapine B
and O
olanzapine B
in O
geriatric O
patients O
using O
the O
Korean O
Health O
Insurance O
Review O
and O
Assessment O
Service O
database O
. O

Exposures O
to O
risperidone B
, O
quetiapine B
and O
olanzapine B
were O
assessed O
during O
the O
30 O
days O
prior O
to O
the O
stroke O
episode O
. O

An O
increased O
risk O
of O
ischemic O
stroke O
was O
associated O
with O
the O
use O
of O
risperidone B
( O
aOR O
= O
3 O
. O
5 O
, O
95 O
% O
CI O
3 O
. O
3 O
- O
4 O
. O
6 O
) O
and O
quetiapine B
( O
aOR O
= O
2 O
. O
7 O
, O
95 O
% O
CI O
2 O
. O
0 O
- O
3 O
. O
6 O
) O
during O
the O
30 O
days O
prior O
to O
stroke O
: O
however O
, O
no O
significant O
risk O
was O
observed O
with O
olanzapine B
( O
aOR O
= O
1 O
. O
2 O
, O
95 O
% O
CI O
0 O
. O
7 O
- O
2 O
. O
0 O
) O
. O

The O
increased O
stroke O
risk O
in O
demented O
patients O
, O
assessed O
within O
30 O
days O
after O
exposure O
, O
was O
also O
observed O
with O
olanzapine B
. O

However O
, O
the O
sample O
of O
olanzapine B
users O
was O
small O
and O
underpowered O
. O

Evaluation O
of O
Perturbations O
in O
Serum O
Thyroid O
Hormones O
During O
Human O
Pregnancy O
Due O
to O
Dietary O
Iodide B
and O
Perchlorate O
Exposure O
Using O
a O
Biologically O
Based O
Dose O
- O
Response O
Model O
. O

This O
model O
was O
calibrated O
to O
predict O
serum O
levels O
of O
iodide B
, O
total O
thyroxine B
( O
T4 O
) O
, O
free O
thyroxine B
( O
fT4 O
) O
, O
and O
total O
triiodothyronine B
( O
T3 O
) O
in O
the O
mother O
and O
fetus O
for O
a O
range O
of O
dietary O
iodide B
intake O
. O

The O
model O
was O
extended O
to O
describe O
perchlorate O
, O
an O
environmental O
and O
food O
contaminant O
, O
that O
competes O
with O
the O
sodium B
iodide I
symporter O
protein O
for O
thyroidal O
uptake O
of O
iodide B
. O

Using O
this O
mode O
- O
of O
- O
action O
framework O
, O
simulations O
were O
performed O
to O
determine O
the O
daily O
ingestion O
rates O
of O
perchlorate O
that O
would O
be O
associated O
with O
hypothyroxinemia O
or O
onset O
of O
hypothyroidism O
for O
varying O
iodide B
intake O
. O

Model O
simulations O
suggested O
that O
a O
maternal O
iodide B
intake O
of O
75 O
to O
250 O
micro O
g O
/ O
day O
and O
an O
environmentally O
relevant O
exposure O
of O
perchlorate O
( O
~ O
0 O
. O
1 O
micro O
g O
/ O
kg O
/ O
day O
) O
did O
not O
result O
in O
hypothyroxinemia O
or O
hypothyroidism O
. O

For O
a O
daily O
iodide B
- O
sufficient O
intake O
of O
200 O
micro O
g O
/ O
day O
, O
the O
dose O
of O
perchlorate O
required O
to O
reduce O
maternal O
fT4 O
levels O
to O
a O
hypothyroxinemic O
state O
was O
estimated O
at O
32 O
. O
2 O
micro O
g O
/ O
kg O
/ O
day O
. O

As O
iodide B
intake O
was O
lowered O
to O
75 O
micro O
g O
/ O
day O
, O
the O
model O
simulated O
daily O
perchlorate O
dose O
required O
to O
cause O
hypothyroxinemia O
was O
reduced O
by O
eightfold O
. O

Similarly O
, O
the O
perchlorate O
intake O
rates O
associated O
with O
the O
onset O
of O
subclinical O
hypothyroidism O
ranged O
from O
54 O
. O
8 O
to O
21 O
. O
5 O
micro O
g O
/ O
kg O
/ O
day O
for O
daily O
iodide B
intake O
of O
250 O
- O
75 O
micro O
g O
/ O
day O
. O

Interferon O
- O
gamma O
Promoter O
Is O
Hypermethylated O
in O
Blood O
DNA O
from O
Workers O
with O
Confirmed O
Diisocyanate B
Asthma O
. O

Risk O
factors O
have O
not O
been O
identified O
that O
determine O
susceptibility O
for O
development O
of O
diisocyanate B
- O
induced O
occupational O
asthma O
( O
DA O
) O
. O

We O
hypothesized O
that O
diisocyanate B
( O
DI O
) O
exposure O
could O
modify O
gene O
promoter O
regions O
regulating O
transcription O
of O
cytokine O
mediators O
and O
thereby O
influence O
expression O
of O
DA O
. O

Results O
showed O
that O
relative O
methylation O
of O
IFN O
- O
gamma O
promoter O
was O
significantly O
increased O
in O
DA O
+ O
in O
comparison O
with O
both O
comparator O
groups O
( O
DA O
- O
and O
AW O
) O
, O
and O
it O
exhibited O
good O
sensitivity O
( O
77 O
. O
5 O
% O
) O
and O
specificity O
( O
80 O
% O
) O
for O
identifying O
DA O
workers O
in O
a O
multivariate O
predictive O
model O
after O
adjusting O
for O
type O
of O
DI O
exposure O
, O
smoking O
status O
, O
methacholine B
PC20 O
, O
and O
gender O
. O

The O
50 O
kDa O
fraction O
contains O
56 O
% O
of O
proteins O
, O
3 O
% O
of O
lipids O
and O
6 O
% O
of O
minerals O
on O
a O
dry O
weight O
basis O
and O
the O
lowest O
levels O
detected O
of O
taurine B
and O
methionine B
and O
highest O
levels O
of O
threonine B
, O
proline B
and O
glycine B
amino B
acids I
. O

This O
study O
aimed O
to O
evaluate O
the O
relationship O
between O
blood O
lead O
and O
serum O
creatinine B
and O
blood O
lead O
and O
serum O
urea B
nitrogen B
levels O
as O
biomarkers O
of O
lead O
exposure O
from O
subjects O
living O
in O
a O
historic O
polymetallic O
mining O
area O
in O
China O
. O

Elevated O
levels O
were O
found O
for O
blood O
lead O
, O
serum O
creatinine B
, O
and O
serum O
urea B
nitrogen B
in O
the O
mining O
area O
with O
mean O
values O
at O
245 O
. O
65 O
mu O
g O
/ O
l O
, O
74 O
. O
16 O
mu O
mol O
/ O
l O
, O
and O
12 O
. O
79 O
mmol O
/ O
l O
, O
which O
were O
significantly O
higher O
than O
those O
in O
the O
control O
area O
, O
respectively O
. O

Moreover O
, O
the O
coefficients O
between O
paired O
results O
for O
blood O
lead O
and O
serum O
creatinine B
and O
blood O
lead O
and O
serum O
urea B
nitrogen B
were O
positively O
statistically O
significant O
( O
serum O
creatinine B
vs O
. O
blood O
lead O
, O
r O
= O
0 O
. O
35 O
, O
p O
< O
0 O
. O
05 O
; O
serum O
urea B
nitrogen B
vs O
. O
blood O
lead O
, O
r O
= O
0 O
. O
48 O
, O
p O
< O
0 O
. O
05 O
) O
. O

With O
respect O
to O
the O
effects O
of O
sex O
and O
age O
on O
the O
blood O
lead O
, O
serum O
creatinine B
, O
and O
serum O
urea B
nitrogen B
levels O
, O
data O
analysis O
revealed O
there O
was O
a O
tendency O
for O
higher O
blood O
lead O
, O
serum O
creatinine B
, O
and O
serum O
urea B
nitrogen B
levels O
in O
females O
than O
in O
males O
, O
and O
the O
levels O
of O
blood O
lead O
, O
serum O
creatinine B
, O
and O
serum O
urea B
nitrogen B
increased O
among O
older O
residents O
. O

Blood O
lead O
, O
serum O
creatinine B
, O
and O
serum O
urea B
nitrogen B
can O
be O
useful O
biomarkers O
of O
lead O
exposure O
among O
populations O
under O
environmental O
stress O
. O

Terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP B
nick O
- O
end O
labeling O
( O
TUNLEL O
) O
staining O
revealed O
an O
increase O
in O
the O
RGC O
layer O
in O
OLETF O
compared O
with O
LETO O
rats O
( O
P O
< O
0 O
. O
05 O
) O
, O
and O
cilostazol O
treatment O
reduced O
the O
number O
of O
TUNEL O
- O
positive O
cells O
in O
OLETF O
rats O
( O
P O
< O
0 O
. O
05 O
) O
. O

Chrysin B
Ameliorates O
Chemically O
Induced O
Colitis O
in O
the O
Mouse O
Through O
Modulation O
of O
a O
PXR O
/ O
NF O
- O
kappa O
B O
Signaling O
Pathway O
. O

Chrysin B
is O
a O
naturally O
occurring O
flavonoid B
with O
anti O
- O
inflammation O
activity O
. O

The O
current O
study O
investigated O
the O
role O
of O
chrysin B
as O
a O
putative O
mouse O
PXR O
agonist O
in O
preventing O
experimental O
colitis O
. O

Pre O
- O
administration O
of O
chrysin B
ameliorated O
inflammatory O
symptoms O
in O
mouse O
models O
of O
colitis O
( O
DSS O
- O
and O
TNBS O
- O
induced O
) O
and O
resulted O
in O
down O
- O
regulation O
of O
NF O
- O
kappa O
B O
target O
genes O
( O
iNOS O
, O
ICAM O
- O
1 O
, O
MCP O
- O
1 O
, O
Cox2 O
, O
TNF O
- O
alpha O
and O
IL O
- O
6 O
) O
in O
the O
colon O
mucosa O
. O

Chrysin B
inhibited O
the O
phosphorylation O
/ O
degradation O
of O
I O
kappa O
B O
alpha O
, O
which O
correlated O
with O
the O
decline O
in O
the O
activity O
of O
myeloperoxidase O
( O
MPO O
) O
and O
the O
levels O
of O
TNF O
- O
alpha O
and O
IL O
- O
6 O
in O
the O
colon O
. O

Consistent O
with O
the O
in O
vivo O
results O
, O
chrysin B
blocked O
LPS O
- O
stimulated O
nuclear O
translocation O
of O
NF O
- O
kappa O
B O
p65 O
in O
mouse O
macrophage O
RAW264 O
. O
7 O
. O

Furthermore O
, O
chrysin B
dose O
- O
dependently O
activated O
human O
/ O
mouse O
PXR O
in O
reporter O
gene O
assays O
and O
up O
- O
regulated O
xenobiotic O
detoxification O
genes O
in O
the O
colon O
mucosa O
, O
but O
not O
in O
the O
liver O
. O

Silencing O
of O
PXR O
by O
RNAi O
demonstrated O
necessity O
of O
PXR O
in O
mediating O
chrysin B
' O
s O
ability O
to O
induce O
xenobiotic O
detoxification O
genes O
and O
NF O
- O
kappa O
B O
inactivation O
. O

The O
repression O
of O
NF O
- O
kappa O
B O
transcription O
activity O
by O
chrysin B
was O
confirmed O
by O
in O
vitro O
PXR O
transduction O
. O

These O
findings O
suggest O
the O
effect O
of O
chrysin B
in O
preventing O
chemically O
induced O
colitis O
is O
mediated O
in O
large O
part O
by O
a O
PXR O
/ O
NF O
- O
kappa O
B O
pathway O
. O

The O
data O
also O
suggest O
that O
chrysin B
or O
chrysin B
- O
like O
flavonoids B
could O
be O
further O
developed O
as O
intestine O
- O
specific O
PXR O
activators O
. O

The O
protective O
effects O
of O
taurine B
on O
experimental O
acute O
pancreatitis O
in O
a O
rat O
model O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effects O
of O
taurine B
( O
Tau O
) O
on O
experimental O
acute O
pancreatitis O
( O
AP O
) O
in O
a O
rat O
model O
by O
measuring O
cytokines O
and O
oxidant O
stress O
markers O
. O
Forty O
rats O
were O
randomly O
divided O
into O
four O
groups O
: O
sham O
, O
AP O
, O
Tau O
and O
AP O
+ O
Tau O
. O

AP O
was O
induced O
with O
sodium B
taurocholate I
. O

Pancreatic O
tissues O
of O
rats O
and O
blood O
samples O
were O
obtained O
. O
Tau O
treatment O
significantly O
decreased O
serum O
amylase O
activity O
( O
p O
< O
0 O
. O
001 O
) O
, O
total O
injury O
score O
( O
p O
< O
0 O
. O
001 O
) O
, O
malondialdehyde B
levels O
( O
p O
< O
0 O
. O
001 O
) O
and O
myeloperoxidase O
( O
MPO O
) O
activity O
( O
p O
< O
0 O
. O
001 O
) O
. O

Histopathologic O
scores O
in O
the O
AP O
+ O
Tau O
and O
Tau O
groups O
were O
significantly O
lower O
compared O
with O
the O
AP O
group O
( O
both O
p O
< O
0 O
. O
001 O
) O
. O
These O
results O
showed O
that O
Tau O
reduces O
lipid O
peroxidation O
, O
amylase O
and O
MPO O
activities O
and O
the O
concentrations O
of O
proinflammatory O
cytokines O
secondary O
to O
AP O
and O
also O
increases O
superoxide B
dismutase O
and O
glutathione B
peroxidase O
activities O
in O
rats O
with O
sodium B
taurocholate I
- O
induced O
AP O
. O

It O
has O
been O
hypothesized O
that O
oils O
containing O
high O
levels O
of O
omega O
- O
3 O
polyunsaturated O
fatty O
acids O
, O
such O
as O
canola O
and O
fish O
oil O
, O
could O
counteract O
some O
of O
the O
adverse O
effects O
induced O
by O
phthalates B
. O

DBP O
exposure O
lowered O
intratesticular O
testosterone B
levels O
and O
anogenital O
distance O
, O
regardless O
of O
the O
vehicle O
used O
. O

Lipid O
profile O
indicated O
that O
administration O
of O
canola O
and O
fish O
oil O
can O
increase O
the O
content O
of O
omega B
- I
3 I
fatty I
acids I
in O
rat O
testis O
. O

Resveratrol B
inhibits O
proliferation O
, O
angiogenesis O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
: O
Calorie O
restriction O
is O
the O
force O
to O
the O
cytotoxicity O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
antitumour O
activity O
of O
resveratrol B
in O
human O
colorectal O
cancer O
cell O
lines O
( O
HCT116 O
and O
Caco2 O
) O
and O
to O
explore O
its O
mechanism O
of O
action O
assuming O
that O
it O
is O
by O
calorie O
- O
restriction O
effect O
. O

Resveratrol B
inhibited O
the O
proliferation O
of O
colon O
cancer O
cells O
with O
half O
maximal O
inhibitory O
concentration O
( O
IC50 O
) O
equal O
to O
50 O
and O
130 O
mu O
M O
for O
HCT116 O
and O
Caco2 O
, O
respectively O
. O

Resveratrol B
( O
100 O
mu O
M O
) O
significantly O
decreased O
the O
glycolytic O
enzymes O
( O
pyruvate O
kinase O
and O
lactate O
dehydrogenase O
) O
in O
Caco2 O
cells O
, O
while O
an O
increase O
in O
citrate B
synthase O
activity O
and O
a O
decrease O
in O
glucose B
consumption O
were O
observed O
in O
both O
cell O
lines O
. O

Moreover O
, O
resveratrol B
downregulated O
the O
expressions O
of O
leptin O
and O
c O
- O
Myc O
, O
and O
decreased O
the O
content O
of O
vascular O
endothelial O
growth O
factor O
. O

The O
study O
suggested O
a O
promising O
anticancer O
activity O
of O
resveratrol B
, O
calorie O
- O
restriction O
pathway O
may O
be O
one O
of O
the O
driving O
forces O
for O
this O
activity O
. O

Differential O
effects O
of O
organic O
and O
inorganic O
selenium B
compounds O
on O
adenosine B
deaminase O
activity O
and O
scavenger O
capacity O
in O
cerebral O
cortex O
slices O
of O
young O
rats O
. O

Selenium B
( O
Se B
) O
has O
anti O
- O
inflammatory O
and O
antioxidant O
properties O
and O
is O
necessary O
for O
the O
development O
and O
normal O
function O
of O
the O
central O
nervous O
system O
. O

This O
study O
was O
aimed O
to O
compare O
the O
in O
vitro O
effects O
of O
3 O
- O
methyl O
- O
1 O
- O
phenyl O
- O
2 O
- O
( O
phenylseleno O
) O
oct O
- O
2 O
- O
en O
- O
1 O
- O
one O
( O
C21H2HOSe O
; O
organoselenium O
) O
and O
sodium O
selenate O
( O
inorganic O
Se B
) O
on O
adenosine B
deaminase O
( O
ADA O
) O
activity O
, O
cell O
viability O
, O
lipid O
peroxidation O
, O
scavenger O
of O
nitric B
oxide I
( O
NO B
) O
and O
nonprotein O
thiols B
( O
NP O
- O
SH B
) O
content O
in O
the O
cerebral O
cortex O

The O
same O
compound O
showed O
higher O
scavenger O
capacity O
of O
NO B
than O
the O
inorganic O
compound O
. O

Inorganic O
Se B
was O
able O
to O
protect O
against O
sodium B
nitroprusside I
- O
induced O
oxidative O
damage O
and O
increased O
the O
NP O
- O
SH B
content O
. O

Comparison O
of O
the O
Relative O
Propensities O
of O
Isoamyl O
Nitrite O
and O
Sodium B
Nitrite I
to O
Ameliorate O
Acute O
Cyanide B
Poisoning O
in O
Mice O
and O
a O
Novel O
Antidotal O
Effect O
Arising O
from O
Anesthetics O
. O

Isoamyl O
nitrite O
has O
previously O
been O
considered O
acceptable O
as O
an O
inhaled O
cyanide B
antidote O
; O
therefore O
, O
the O
antidotal O
utility O
of O
this O
organic O
nitrite B
compared O
with O
sodium B
nitrite I
was O
investigated O
. O

To O
facilitate O
a O
quantitative O
comparison O
, O
doses O
of O
both O
sodium B
nitrite I
and O
isoamyl O
nitrite O
were O
given O
intraperitoneally O
in O
equimolar O
amounts O
to O
sublethally O
cyanide B
- O
challenged O
mice O
. O

Righting O
recovery O
from O
the O
knockdown O
state O
was O
clearly O
compromised O
in O
the O
isoamyl O
nitrite O
- O
treated O
animals O
, O
the O
effect O
being O
attributable O
to O
the O
toxicity O
of O
the O
isoamyl O
alchol O
produced O
during O
hydrolysis O
of O
the O
isoamyl O
nitrite O
to O
release O
nitrite B
anion O
. O

Subsequently O
, O
inhaled O
aqueous O
sodium B
nitrite I
aerosol O
was O
demonstrated O
to O
ameliorate O
sublethal O
cyanide B
toxicity O
, O
when O
provided O
to O
mice O
after O
the O
toxic O
dose O
, O
by O
the O
more O
rapid O
recovery O
of O
righting O
ability O
compared O
to O
that O
of O
the O
control O
animals O
given O
only O
the O
toxicant O
. O

Aerosolized O
sodium B
nitrite I
has O
thus O
been O
shown O
by O
these O
experiments O
to O
have O
promise O
as O
a O
better O
alternative O
to O
organic O
nitrites O
for O
development O
as O
an O
inhaled O
cyanide B
antidote O
. O

The O
inhaled O
sodium B
nitrite I
led O
to O
the O
production O
of O
NO B
in O
the O
bloodstream O
as O
determined O
by O
the O
appearance O
of O
EPR O
signals O
attributable O
to O
nitrosylhemoglobin O
and O
methemoglobin O
. O

It O
is O
argued O
that O
administration O
of O
an O
effective O
inhaled O
aqueous O
sodium B
nitrite I
dose O
in O
humans O
is O
possible O
, O
though O
just O
beyond O
the O
capability O
of O
current O
individual O
metered O
- O
dose O
inhaler O
designs O
, O
such O
as O
those O
used O
for O
asthma O
. O

Finally O
, O
working O
at O
slightly O
greater O
than O
LD50 O
NaCN O
doses O
, O
it O
was O
fortuitously O
discovered O
that O
( O
i O
) O
anesthesia O
leads O
to O
significantly O
prolonged O
survival O
compared O
to O
that O
of O
unanesthetized O
animals O
and O
that O
( O
ii O
) O
the O
antidotal O
activity O
of O
nitrite B
anion O
was O
completely O
abolished O
under O
anesthesia O
. O

Plausible O
explanations O
for O
these O
effects O
in O
mice O
and O
their O
practical O
consequences O
in O
relation O
to O
testing O
putative O
cyanide B
antidotes O
are O
discussed O
. O

Biotransformation O
of O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
Ether I
( O
BDE B
- I
47 I
) O
by O
Human O
Liver O
Microsomes O
: O
Identification O
of O
Cytochrome O
P450 O
2B6 O
as O
the O
Major O
Enzyme O
Involved O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
were O
widely O
used O
flame O
retardants O
that O
have O
become O
persistent O
environmental O
pollutants O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
in O
vitro O
oxidative O
metabolism O
of O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
a O
major O
PBDE B
detected O
in O
human O
tissue O
and O
environmental O
samples O
. O

Biotransformation O
of O
BDE B
- I
47 I
by O
pooled O
and O
individual O
human O
liver O
microsomes O
and O
by O
human O
recombinant O
cytochrome O
P450 O
( O
P450 O
) O
enzymes O
was O
assessed O
using O
a O
liquid O
chromatography O
/ O
tandem O
mass O
spectrometry O
- O
based O
method O
. O

Of O
the O
nine O
hydroxylated O
metabolites O
of O
BDE B
- I
47 I
produced O
by O
human O
liver O
microsomes O
, O
seven O
metabolites O
were O
identified O
using O
authentic O
standards O
. O

A O
monohydroxy O
- O
tetrabrominated O
and O
a O
dihydroxy B
- O
tetrabrominated O
metabolite O
remain O
unidentified O
. O

Among O
the O
human O
recombinant O
P450 O
enzymes O
tested O
, O
P450 O
2B6 O
was O
the O
most O
active O
enzyme O
in O
the O
formation O
of O
the O
hydroxylated O
metabolites O
of O
BDE B
- I
47 I
. O

Moreover O
, O
the O
formation O
of O
all O
metabolites O
of O
BDE B
- I
47 I
by O
pooled O
human O
liver O
microsomes O
was O
inhibited O
by O
a O
P450 O
2B6 O
- O
specific O
antibody O
and O
was O
highly O
correlated O
with O
P450 O
2B6 O
- O
mediated O
activity O
in O
single O
donor O
liver O
microsomes O
indicating O
that O
P450 O
2B6 O
was O
the O
major O
P450 O
responsible O
for O
the O
biotransformation O
of O
BDE B
- I
47 I
. O

Additional O
experiments O
involving O
the O
incubation O
of O
liver O
microsomes O
with O
individual O
monohydroxy O
- O
tetrabrominated O
metabolites O
in O
place O
of O
BDE B
- I
47 I
demonstrated O
that O
2 O
, O
4 O
- O
dibromophenol O
was O
a O
product O
of O
BDE B
- I
47 I
and O
several O
primary O
metabolites O
, O
but O
the O
dihydroxy B
- O
tetrabrominated O
metabolite O
was O
not O
formed O
by O
sequential O
hydroxylation O
of O
any O
of O
the O
monohydroxy O
- O
tetrabrominated O
metabolites O
tested O
. O

The O
present O
study O
provides O
a O
comprehensive O
characterization O
of O
the O
oxidative O
metabolism O
of O
BDE B
- I
47 I
by O
human O
liver O
microsomes O
and O
P450 O
2B6 O
. O

Flavonoids B
of O
Dikamali O
: O
A O
phytochemical O
reinvestigation O
. O

Eleven O
known O
flavonoids B
( O
1 O
- O
11 O
) O
were O
isolated O
from O
Dikamali O
, O
the O
gum O
resin O
of O
Gardenia O
lucida O
. O

A O
new O
triterpene O
saponin O
( O
1 O
) O
was O
isolated O
from O
a O
methanol B
extract O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
, O
together O
with O
the O
flavonoids B
mauritianin O
( O
2 O
) O
, O
kaempferol B
( O
3 O
) O
and O
the O
triterpene O
saponin O
beta O
- O
D O
- O
glucopyranosyl O
3 O
beta O
- O
hydroxy O
- O
olean O
- O
12 O
- O
en O
- O
28 O
- O
oate O
( O
4 O
) O
. O

These O
compounds O
were O
characterised O
on O
the O
basis O
of O
their O
spectral O
data O
, O
mainly O
one O
- O
dimension O
( O
1D O
; O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
, O
APT O
) O
and O
two O
- O
dimension O
( O
2D O
; O
( B
1 I
) I
H I
- O
( B
1 I
) I
H I
- O
COSY O
, O
HMQC O
and O
HMBC O
) O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
and O
HR O
- O
ESI O
- O
MS O
, O
and O
comparison O
with O
values O
in O
the O
literature O
. O

Measurements O
of O
Rate O
Constants O
for O
the O
OH B
Reactions O
with O
Bromoform O
( O
CHBr3 B
) O
, O
CHBr2Cl O
, O
CHBrCl2 O
, O
and O
Epichlorohydrin B
( O
C3H5ClO O
) O
. O

Measurements O
of O
the O
rate O
constants O
for O
the O
gas O
phase O
reactions O
of O
OH B
radicals O
with O
bromoform O
( O
CHBr3 B
) O
and O
epichlorohydrin B
( O
C3H5ClO O
) O
were O
performed O
using O
a O
flash O
photolysis O
resonance O
- O
fluorescence O
technique O
over O
the O
temperature O
range O
230 O
- O
370 O
K O
. O

Rate O
constants O
for O
the O
reactions O
of O
OH B
with O
CHCl2Br O
and O
CHClBr2 O
were O
measured O
between O
230 O
and O
330 O
K O
. O

The O
atmospheric O
lifetimes O
due O
to O
reactions O
with O
tropospheric O
OH B
were O
estimated O
to O
be O
57 O
, O
39 O
, O
72 O
, O
and O
96 O
days O
, O
respectively O
. O

The O
total O
atmospheric O
lifetimes O
of O
the O
Br B
- O
containing O
methanes O
due O
to O
both O
reaction O
with O
OH B
and O
photolysis O
were O
calculated O
to O
be O
22 O
, O
50 O
, O
and O
67 O
days O
for O
CHBr3 B
, O
CHClBr2 O
, O
and O
CHCl2Br O
, O
respectively O
. O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH O
- O
PAHs O
( O
1 B
- I
naphthol I
, O
9 O
- O
phenantrol O
, O
9 O
- O
fluorenol O
, O
1 O
- O
pyrenol O
, O
1OH O
- O
BaP O
and O
3OH O
- O
BaP O
) O
and O
alkylphenols O
( O
4 O
- O
n O
- O
nonylphenol O
( O
4 O
- O
n O
- O
NP O
) O
and O
4 O
- O
tertoctylphenol O
( O
4 O
- O
tert O
- O
OP O
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

The O
nutraceutical O
potential O
of O
Chenopodium O
quinoa O
Leaves O
( O
ChL O
) O
was O
assessed O
through O
analyses O
of O
their O
phenolic B
content O
, O
elucidation O
of O
the O
effect O
of O
ChL O
phenolic B
compounds O
on O
cancer O
cell O
properties O
and O
estimation O
of O
their O
antioxidative O
activity O
, O
bioaccessibility O
and O
bioavailability O
in O
vitro O
. O

Considerable O
amounts O
of O
ferulic O
, O
sinapinic O
and O
gallic O
acids O
, O
kaempferol B
, O
isorhamnetin B
and O
rutin B
were O
observed O
in O
the O
chemical O
ChL O
extract O
and O
were O
linked O
with O
its O
inhibitory O
effect O
on O
prostate O
cancer O
cell O
proliferation O
, O
motility O
and O
cellular O
competence O
for O
gap O
junctional O
communication O
. O

These O
observations O
indicate O
that O
phenolic B
ChL O
compounds O
may O
exert O
a O
chemopreventive O
and O
anticarcinogenic O
effect O
on O
oxidative O
stress O
and O
ROS O
- O
dependent O
intracellular O
signaling O
via O
synergic O
effects O
. O

An O
ultra O
- O
low O
dose O
of O
tetrahydrocannabinol B
provides O
cardioprotection O
. O

Tetrahydrocannabinol B
( O
THC B
) O
, O
the O
major O
psychoactive O
component O
of O
marijuana O
, O
is O
a O
cannabinoid O
agonist O
that O
exerts O
its O
effects O
by O
activating O
at O
least O
two O
specific O
receptors O
( O
CB1 O
and O
CB2 O
) O
that O
belong O
to O
the O
seven O
transmembrane O
G O
- O
protein O
coupled O
receptor O
( O
GPCR O
) O
family O
. O

THC B
treatment O
was O
beneficial O
against O
hypoxia O
in O
neonatal O
cardiomyocytes O
in O
vitro O
. O

We O
also O
observed O
a O
neuroprotective O
effect O
of O
an O
ultra O
low O
dose O
of O
THC B
when O
applied O
to O
mice O
before O
brain O
insults O
. O

The O
present O
study O
was O
aimed O
to O
test O
and O
characterize O
the O
cardioprotective O
effects O
of O
a O
very O
low O
dose O
( O
0 O
. O
002mg O
/ O
kg O
) O
of O
THC B
which O
is O
3 O
- O
4 O
orders O
of O
magnitude O
lower O
than O
the O
conventional O
doses O
, O
administered O
before O
myocardial O
infarction O
in O
mice O
in O
vivo O
. O

Three O
regimens O
of O
THC B
administration O
were O
tested O
: O
single O
THC B
application O
2h O
or O
48h O
before O
the O
induction O
of O
infarct O
, O
or O
3 O
weeks O
continuous O
treatment O
before O
MI O
. O

All O
protocols O
of O
THC B
administration O
were O
found O
to O
be O
beneficial O
. O

In O
the O
case O
of O
THC B
treatment O
2h O
before O
MI O
, O
fractional O
shortening O
was O
elevated O
( O
37 O
+ O
/ O
- O
4 O
% O
vs O
. O
42 O
+ O
/ O
- O
1 O
% O
, O
p O
< O
0 O
. O
04 O
) O
, O
troponin O
T O
leakage O
to O
the O
blood O
was O
reduced O
( O
14 O
+ O
/ O
- O
3ng O
/ O
ml O
vs O
. O
10 O
+ O
/ O
- O
4ng O
/ O
ml O
, O
p O
< O
0 O
. O
008 O
) O
, O
infarct O
size O
decreased O
( O
29 O
+ O
/ O
- O
4 O
% O
vs O
. O
23 O
+ O
/ O
- O
4 O
% O
, O
p O
< O
0 O
. O
02 O
) O
, O
and O
the O
accumulation O
of O
neutrophils O
to O
the O
infarct O
area O

declined O
( O
36 O
+ O
/ O
- O
10cells O
/ O
field O
vs O
. O
19 O
+ O
/ O
- O
4cells O
/ O
field O
, O
p O
< O
0 O
. O
007 O
) O
in O
THC B
- O
compared O
to O
vehicle O
- O
pretreated O
mice O
, O
24h O
after O
MI O
. O

ERK1 O
/ O
2 O
phosphorylation O
following O
infarct O
was O
also O
inhibited O
by O
pre O
- O
treatment O
with O
THC B
( O
p O
< O
0 O
. O
01 O
) O
. O

CONCLUSION O
: O
A O
single O
ultra O
low O
dose O
of O
THC B
before O
ischemia O
is O
a O
safe O
and O
effective O
treatment O
that O
reduces O
myocardial O
ischemic O
damage O
. O

The O
identified O
Treg O
- O
promoting O
drugs O
include O
those O
previously O
known O
to O
induce O
Treg O
( O
rapamycin B
and O
retinoic B
acid I
) I
, O
statins O
, O
glucocorticoids O
and O
drugs O
in O
many O
other O
categories O
. O

In O
this O
study O
we O
investigated O
the O
relationship O
between O
several O
selected O
commercially O
available O
essential O
oils O
and O
beta B
- I
lactam I
antibiotics O
on O
their O
antibacterial O
effect O
against O
multidrug O
resistant O
bacteria O
. O

The O
combined O
effects O
between O
essential O
oils O
of O
cinnamon O
bark O
, O
lavender O
, O
marjoram O
, O
tea O
tree O
, O
peppermint O
and O
ampicillin B
, O
piperacillin O
, O
cefazolin O
, O
cefuroxime B
, O
carbenicillin O
, O
ceftazidime B
, O
meropenem O
, O
were O
evaluated O
by O
means O
of O
the O
checkerboard O
method O
against O
beta O
- O
lactamase O
- O
producing O
Escherichia O
coli O
. O

Reduced O
usage O
of O
antibiotics O
could O
be O
employed O
as O
a O
treatment O
strategy O
to O
decrease O
the O
adverse O
effects O
and O
possibly O
to O
reverse O
the O
beta B
- I
lactam I
antibiotic O
resistance O
. O

Two O
new O
tryptophan B
derivatives O
from O
the O
seed O
kernels O
of O
Entada O
rheedei O
: O
Effects O
on O
cell O
viability O
and O
HIV O
infectivity O
. O

Two O
new O
tryptophan B
derivatives O
, O
N O
- O
sulfonyl O
- O
L O
- O
tryptophan O
( O
tryptorheedei O
A O
) O
( O
1 O
) O
and O
3 O
- O
( O
N O
- O
sulfonylindolyl O
) O
- O
D O
- O
lactic O
acid O
( O
tryptorheedei O
B O
) O
( O
2 O
) O
together O
with O
the O
known O
5 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O
2 O
- O
hydroxyphenylacetic O
acid O
( O
3 O
) O
, O
1 O
- O
O O
- O
methylglucopyranosid O
, O
entadamide O
A O
, O
homogentisic O
acid O
and O
3 O
- O
O O

Both O
compounds O
1 O
and O
2 O
were O
found O
to O
promote O
early O
infection O
events O
in O
HIV O
, O
likely O
by O
inhibiting O
the O
enzyme O
indolamine O
2 O
, O
3 O
- O
dioxygenase O
( O
IDO O
) O
and O
preventing O
tryptophan B
depletion O
. O

IDO O
is O
also O
the O
gatekeeper O
enzyme O
for O
kynurenine O
metabolism O
, O
a O
pathway O
involved O
in O
serotonin B
and O
melatonin O
biosynthesis O
and O
the O
regulation O
of O
glutamate B
and O
dopamine B
levels O
in O
the O
brain O
. O

MC O
- O
RR O
differs O
from O
MC O
- O
LR O
, O
the O
most O
studied O
congener O
only O
for O
one O
residue O
( O
arginine B
vs O
leucine B
) O
, O
resulting O
in O
a O
ten O
- O
fold O
difference O
in O
the O
acute O
toxicity O
in O
mice O
. O

The O
accepted O
pathway O
for O
MC O
detoxication O
is O
GSH B
conjugation O
: O
here O
the O
MC O
- O
RR O
conjugation O
with O
GSH B
catalyzed O
by O
5 O
recombinant O
human O
GSTs O
and O
human O
liver O
cytosol O
( O
HLC O
) O
has O
been O
characterized O
and O
appeared O
to O
be O
more O
efficient O
than O
MC O
- O
LR O
conjugation O
. O

In O
HLC O
the O
spontaneous O
reaction O
is O
favored O
vs O
the O
enzymatic O
one O
( O
ratio O
3 O
: O
1 O
) O
at O
physiological O
GSH B
content O
. O

However O
, O
at O
low O
MC O
- O
RR O
concentrations O
, O
representative O
of O
repeated O
oral O
exposure O
, O
and O
low O
GSH B
content O
( O
down O
to O
0 O
. O
05mM O
) O
, O
possibly O
associated O
to O
exposure O
to O
drugs O
or O
in O
patients O
affected O
by O
several O
pathologies O
, O
the O
relevance O
of O
the O
enzymatic O
reaction O
progressively O
increases O
, O
providing O
the O
predominant O
contribution O
to O
MC O
- O
RR O
detoxication O
. O

Activating O
glucocorticoid O
receptor O
- O
ERK O
signaling O
pathway O
contributes O
to O
ginsenoside B
Rg1 I
protection O
against O
beta O
- O
amyloid O
peptide O
- O
induced O
human O
endothelial O
cells O
apoptosis O
. O

Ginsenoside B
Rg1 I
( O
Rg1 O
) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O

Rg1 O
attenuated O
the O
A O
beta O
25 O
- O
35 O
- O
associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF O
- O
1 O
alpha O
expression O
followed O
by O
intracellular O
reactive O
nitrogen B
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O

These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
( O
GR O
) O
antagonist O
RU486 B
or O
p O
- O
ERK O
inhibitor O
U0126 B
rather O
than O
estrogen B
receptor O
alpha O
antagonist O
ICI O
82 O
, O
780 O
. O

Exposure O
to O
2 B
, I
4 I
- I
dichlorophenoxyaceti I
acid I
alters O
glucose B
metabolism O
in O
immature O
rat O
Sertoli O
cells O
. O

SCs O
exposed O
to O
10 O
mu O
M O
and O
1mM O
of O
2 O
, O
4 O
- O
D O
presented O
lower O
intracellular O
glucose B
and O
lactate B
content O
. O

Exposure O
to O
10 O
mu O
M O
of O
2 O
, O
4 O
- O
D O
induced O
a O
significant O
decrease O
in O
glucose B
transporter O
- O
3 O
mRNA O
levels O
and O
phosphofructokinase O
- O
1 O
mRNA O
levels O
decreased O
in O
cells O
exposed O
to O
100nM O
and O
10 O
mu O
M O
of O
2 O
, O
4 O
- O
D O
. O

Exposure O
to O
100nM O
and O
10 O
mu O
M O
also O
induced O
a O
decrease O
in O
lactate B
dehydrogenase O
( O
LDH O
) O
mRNA O
levels O
while O
the O
LDH O
protein O
levels O
were O
only O
decreased O
in O
cells O
exposed O
to O
1mM O
of O
2 O
, O
4 O
- O
D O
. O

Exposure O
to O
2 O
, O
4 O
- O
D O
altered O
glucose B
uptake O
and O
metabolization O
in O
SCs O
, O
as O
well O
as O
lactate B
metabolism O
and O
export O
that O
may O
result O
in O
impaired O
spermatogenesis O
. O

The O
design O
of O
synthetic O
molecules O
based O
on O
DNA O
- O
interchelating O
properties O
by O
hydrogen B
bond O
formation O
. O

Biological O
screening O
revealed O
varying O
cytotoxic O
potencies O
of O
the O
tested O
molecules O
compared O
with O
Doxorubicin B
as O
a O
reference O
drug O
. O

Cadmium B
Tolerance O
and O
Removal O
from O
Cunninghamella O
elegans O
Related O
to O
the O
Polyphosphate O
Metabolism O
. O

The O
aim O
of O
the O
present O
work O
was O
to O
study O
the O
cadmium B
effects O
on O
growth O
, O
ultrastructure O
and O
polyphosphate O
metabolism O
, O
as O
well O
as O
to O
evaluate O
the O
metal O
removal O
and O
accumulation O
by O
Cunninghamella O
elegans O
( O
IFM O
46109 O
) O
growing O
in O
culture O
medium O
. O

The O
presence O
of O
cadmium B
reduced O
growth O
, O
and O
a O
longer O
lag O
phase O
was O
observed O
. O

However O
, O
the O
phosphate B
uptake O
from O
the O
culture O
medium O
increased O
15 O
% O
when O
compared O
to O
the O
control O
. O

Moreover O
, O
C O
. O
elegans O
removed O
70 O
% O
- O
81 O
% O
of O
the O
cadmium B
added O
to O
the O
culture O
medium O
during O
its O
growth O
. O

The O
C O
. O
elegans O
mycelia O
showed O
a O
removal O
efficiency O
of O
280 O
mg O
/ O
g O
at O
a O
cadmium B
concentration O
of O
22 O
. O
10 O
mg O
/ O
L O
, O
and O
the O
removal O
velocity O
of O
cadmium B
was O
0 O
. O
107 O
mg O
/ O
h O
. O

Additionally O
, O
it O
was O
observed O
that O
cadmium B
induced O
vacuolization O
, O
the O
presence O
of O
electron O
dense O
deposits O
in O
vacuoles O
, O
cytoplasm O
and O
cell O
membranes O
, O
as O
well O
as O
the O
distinct O
behavior O
of O
polyphosphate O
fractions O
. O

The O
results O
obtained O
with O
C O
. O
elegans O
suggest O
that O
precipitation O
, O
vacuolization O
and O
polyphosphate O
fractions O
were O
associated O
to O
cadmium B
tolerance O
, O
and O
this O
species O
demonstrated O
a O
higher O
potential O
for O
bioremediation O
of O
heavy O
metals O
. O

Chemical O
Stability O
of O
the O
Lipid O
Phase O
in O
Concentrated O
Beverage O
Emulsions O
Colored O
with O
Natural O
beta B
- I
Carotene I
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
oxidation O
of O
selected O
plant O
oils O
in O
concentrated O
beverage O
emulsions O
colored O
with O
natural O
beta B
- I
carotene I
. O

Carotenoid O
/ O
lipid O
hydro O
peroxide O
( O
LOOH O
) O
concentration O
was O
evaluated O
using O
two O
different O
methods O
: O
LOOH O
+ O
Fe B
( I
2 I
+ I
) I
reaction O
connected O
with O
a O
colored O
complex O
of O
ammonium O
thiocyanate O
determined O
with O
the O
help O
of O
a O
spectrophotometer O
, O
and O
LOOH O
determined O
with O
the O
help O
of O
a O
chemiluminometer O
. O

The O
Relationship O
Between O
Serum O
Calcium B
Level O
, O
Blood O
Lipids O
, O
and O
Blood O
Pressure O
in O
Hypertensive O
and O
Normotensive O
Subjects O
who O
Come O
from O
a O
Normal O
University O
in O
East O
of O
China O
. O

Previous O
studies O
revealed O
that O
low O
calcium B
intake O
is O
related O
to O
high O
prevalence O
of O
cardiovascular O
diseases O
such O
as O
hypertension O
. O

However O
, O
the O
relationship O
between O
serum O
calcium B
and O
blood O
pressure O
was O
unclear O
. O

Thus O
, O
the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
serum O
calcium B
level O
between O
hypertensive O
and O
normotensive O
groups O
and O
to O
investigate O
the O
correlation O
between O
serum O
calcium B
, O
blood O
pressure O
, O
and O
blood O
lipid O
parameters O
. O

Our O
results O
indicate O
a O
significant O
trend O
for O
men O
( O
60 O
years O
old O
or O
older O
) O
in O
the O
direction O
of O
decreasing O
blood O
pressure O
with O
increasing O
serum O
calcium B
level O
, O
but O
no O
trend O
for O
women O
was O
indicated O
. O

In O
the O
normotensive O
group O
, O
a O
significant O
positive O
correlation O
was O
found O
between O
DBP O
and O
total O
cholesterol B
( O
P O
< O
0 O
. O
01 O
) O
and O
triglyceride B
( O
P O
< O
0 O
. O
01 O
) O
, O
Likewise O
, O
triglyceride B
was O
positively O
correlated O
with O
SBP O
( O
P O
< O
0 O
. O
01 O
) O
. O

Overall O
, O
these O
data O
suggest O
that O
serum O
calcium B
may O
have O
an O
influence O
in O
the O
blood O
pressure O
of O
older O
male O
subjects O
with O
hypertension O
and O
in O
blood O
lipid O
profiles O
of O
normotensive O
subjects O
. O

Using O
a O
combination O
of O
flow O
cytometry O
and O
microscopy O
, O
we O
found O
that O
zantrin O
Z1 O
, O
cinnamaldehyde B
, O
totarol O
, O
sanguinarine O
, O
and O
viriditoxin O
decreased O
the O
B O
. O
subtilis O
transmembrane O
potential O
or O
perturbed O
membrane O
permeability O
, O
and O
influenced O
the O
localization O
of O
the O
membrane O
- O
associated O
, O
division O
protein O
MinD O
. O

Here O
, O
lipid O
transfers O
to O
HDL O
, O
an O
important O
step O
for O
HDL O
intravascular O
metabolism O
and O
for O
HDL O
role O
in O
reverse O
cholesterol B
transport O
( O
RCT O
) O
were O
investigated O
in O
FH O
patients O
. O

METHODS O
: O
Seventy O
- O
one O
FH O
patients O
( O
39 O
+ O
/ O
- O
15years O
, O
LDL O
- O
cholesterol B
= O
274 O
+ O
/ O
- O
101 O
; O
HDL O
- O
cholesterol B
= O
50 O
+ O
/ O
- O
14mg O
/ O
dl O
) O
and O
66 O
normolipidemic O
subjects O
( O
NL O
) O
( O
38 O
+ O
/ O
- O
11years O
, O
LDL O
- O
cholesterol B
= O
105 O
+ O
/ O
- O
27 O
; O
HDL O
- O
cholesterol B
= O
52 O
+ O
/ O
- O
12mg O
/ O
dl O
) O
were O
studied O
. O

In O
vitro O
, O
lipid O
transfers O
were O
evaluated O
by O
incubation O
of O
plasma O
samples O
( O
37 O
degrees O
C O
, O
1h O
) O
with O
a O
donor O
lipid O
nanoemulsion O
labeled O
with O
3H O
- O
triglycerides O
( O
TG O
) O
and O
14C B
- O
unesterified O
cholesterol B
( O
UC O
) O
or O
with O
3H O
- O
cholesteryl O
ester O
( O
EC O
) O
and O
14C B
- O
phospholipids O
( O
PL O
) O
. O

By O
multivariate O
analysis O
, O
transfers O
of O
all O
four O
lipids O
correlated O
with O
HDL O
- O
cholesterol B
and O
with O
apo O
A O
- O
I O
. O

Design O
, O
synthesis O
and O
biological O
activity O
of O
multifunctional O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
scaffolds O
for O
Alzheimer O
' O
s O
disease O
. O

A O
series O
of O
compounds O
containing O
an O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
moiety O
, O
such O
as O
chalcones B
and O
coumarins B
were O
designed O
, O
synthesized O
and O
tested O
in O
a O
variety O
of O
assays O
to O
assess O
their O
potential O
as O
anti O
- O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
agents O
. O

Based O
on O
the O
results O
, O
the O
long O
- O
chain O
coumarin B
scaffold O
appears O
to O
be O
a O
promising O
structural O
template O
for O
further O
AD O
drug O
development O
. O

Novel O
Pyridinone O
Derivatives O
As O
Non O
- O
Nucleoside B
Reverse O
Transcriptase O
Inhibitors O
( O
NNRTIs O
) O
with O
High O
Potency O
against O
NNRTI O
- O
Resistant O
HIV O
- O
1 O
Strains O
. O

Novel O
6 O
- O
substituted O
- O
4 O
- O
cycloalkyloxy O
- O
pyridin O
- O
2 O
( O
1H O
) O
- O
ones O
were O
synthesized O
as O
non O
- O
nucleoside B
reverse O
transcriptase O
inhibitors O
( O
NNRTIs O
) O
, O
and O
their O
biological O
activity O
was O
evaluated O
. O

Systemic O
administration O
of O
1 O
reduced O
acetic B
acid I
- O
induced O
writhing O
, O
the O
inflammatory O
phase O
of O
formalin B
- O
induced O
pain O
, O
and O
capsaicin B
- O
induced O
mechanical O
allodynia O
. O

The O
topical O
administration O
of O
1 O
also O
reduced O
the O
inflammatory O
phase O
of O
the O
formalin B
test O
, O
indicating O
that O
at O
least O
some O
of O
its O
effects O
are O
mediated O
peripherally O
. O

T O
- O
Cells O
from O
HLA O
- O
B O
* O
57 O
: O
01 O
+ O
Human O
Subjects O
Are O
Activated O
with O
Abacavir B
through O
Two O
Independent O
Pathways O
and O
Induce O
Cell O
Death O
by O
Multiple O
Mechanisms O
. O

The O
objectives O
of O
this O
study O
were O
to O
characterize O
the O
functionality O
of O
drug O
- O
responsive O
CD8 O
+ O
T O
- O
cell O
clones O
generated O
from O
HLA O
- O
B O
* O
57 O
: O
01 O
+ O
drug O
- O
naive O
subjects O
and O
to O
explore O
the O
relationship O
between O
abacavir B
accumulation O
in O
antigen O
presenting O
cells O
and O
the O
T O
- O
cell O
response O
. O

Seventy O
- O
four O
CD8 O
+ O
clones O
expressing O
different O
V O
beta O
receptors O
were O
shown O
to O
proliferate O
and O
kill O
target O
cells O
via O
different O
mechanisms O
when O
exposed O
to O
abacavir B
. O

Certain O
clones O
were O
activated O
with O
abacavir B
in O
the O
absence O
of O
antigen O
presenting O
cells O
. O

Overnight O
incubation O
of O
antigen O
presenting O
cells O
with O
abacavir B
, O
followed O
by O
repeated O
washing O
to O
remove O
soluble O
drug O
, O
activated O
approximately O
50 O
% O
of O
the O
clones O
, O
and O
the O
response O
was O
blocked O
by O
glutaraldehyde B
fixation O
. O

Accumulation O
of O
abacavir B
in O
antigen O
presenting O
cells O
was O
rapid O
( O
less O
than O
1 O
h O
) O
, O
and O
the O
intracellular O
concentrations O
were O
maintained O
for O
16 O
h O
. O

However O
, O
intracellular O
abacavir B
was O
not O
detectable O
by O
mass O
spectrometry O
after O
pulsing O
. O

These O
data O
suggest O
that O
T O
- O
cells O
can O
be O
activated O
by O
abacavir B
through O
a O
direct O
interaction O
with O
surface O
and O
intracellular O
major O
histocompatibility O
complex O
( O
MHC O
) O
molecules O
. O

With O
the O
former O
, O
abacavir B
seemingly O
participates O
in O
the O
MHC O
T O
- O
cell O
receptor O
binding O
interaction O
. O

In O
contrast O
, O
the O
latter O
pathway O
likely O
involves O
MHC O
binding O
peptides O
displayed O
as O
a O
consequence O
of O
abacavir B
exposure O
, O
but O
not O
abacavir B
itself O
. O

Cigarette O
smoke O
, O
diesel O
exhaust O
, O
and O
other O
combustion O
- O
derived O
particles O
activate O
the O
calcium B
channel O
transient O
receptor O
potential O
ankyrin O
- O
1 O
( O
TRPA1 O
) O
, O
causing O
irritation O
and O
inflammation O
in O
the O
respiratory O
tract O
. O

TRPA1 O
activation O
was O
assessed O
using O
calcium B
imaging O
assays O
in O
TRPA1 O
- O
overexpressing O
HEK O
- O
293 O
cells O
, O
mouse O
primary O
trigeminal O
neurons O
, O
and O
human O
adenocarcinoma O
( O
A549 O
) O
lung O
cells O
. O

Particles O
from O
pine O
and O
mesquite O
smoke O
were O
less O
potent O
agonists O
of O
TRPA1 O
than O
an O
equivalent O
mass O
concentration O
of O
an O
ethanol B
extract O
of O
diesel O
exhaust O
particles O
; O
pine O
particles O
were O
comparable O
in O
potency O
to O
cigarette O
smoke O
condensate O
, O
and O
mesquite O
particles O
were O
the O
least O
potent O
. O

The O
fine O
particulate O
( O
PM O
< O
2 O
. O
5 O
mu O
m O
) O
of O
wood O
smoke O
were O
the O
most O
potent O
TRPA1 O
agonists O
and O
several O
chemical O
constituents O
of O
wood O
smoke O
particulate O
, O
3 O
, O
5 O
- O
ditert O
- O
butylphenol O
, O
coniferaldehyde O
, O
formaldehyde B
, O
perinaphthenone O
, O
agathic O
acid O
, O
and O
isocupressic O
acid O
, O
were O
TRPA1 O
agonists O
. O

Pine O
particulate O
activated O
TRPA1 O
in O
mouse O
trigeminal O
neurons O
and O
A549 O
cells O
in O
a O
concentration O
- O
dependent O
manner O
, O
which O
was O
inhibited O
by O
the O
TRPA1 O
antagonist O
HC B
- I
030031 I
. O

TRPA1 O
activation O
by O
wood O
smoke O
particles O
occurred O
through O
the O
electrophile O
/ O
oxidant O
- O
sensing O
domain O
( O
i O
. O
e O
. O
, O
C621 O
/ O
C641 O
/ O
C665 O
/ O
K710 O
) O
, O
based O
on O
the O
inhibition O
of O
cellular O
responses O
when O
the O
particles O
were O
pretreated O
with O
glutathione B
; O
a O
role O
for O
the O
menthol B
- O
binding O
site O
of O
TRPA1 O
( O
S873 O
/ O
T874 O
) O
was O
demonstrated O
for O
3 O
, O
5 O
- O
ditert O
- O
butylphenol O
. O

Effects O
of O
exposure O
to O
amitraz O
on O
noradrenaline B
, O
serotonin B
and O
dopamine B
levels O
in O
brain O
regions O
of O
30 O
and O
60 O
days O
old O
male O
rats O
. O

The O
effects O
of O
amitraz O
oral O
exposure O
( O
20 O
, O
50 O
and O
80mg O
/ O
kg O
bw O
, O
5 O
days O
) O
on O
brain O
region O
monoamine B
levels O
of O
male O
rats O
at O
30 O
and O
60 O
days O
of O
age O
were O
examined O
. O

After O
the O
last O
dose O
of O
amitraz O
, O
NE O
, O
DA O
and O
5 B
- I
HT I
and O
its O
metabolites O
levels O
were O
determined O
in O
the O
brain O
regions O
hypothalamus O
, O
midbrain O
, O
prefrontal O
cortex O
, O
striatum O
and O
hippocampus O
by O
HPLC O
. O

Amitraz O
caused O
changes O
in O
the O
NE O
, O
DA O
and O
5 B
- I
HT I
and O
their O
metabolite O
levels O
in O
a O
brain O
regional O
- O
, O
dose O
- O
and O
age O
- O
related O
manner O
. O

In O
the O
brain O
regions O
studied O
, O
amitraz O
induced O
a O
statistically O
significant O
increase O
in O
5 B
- I
HT I
, O
NE O
and O
DA O
content O
with O
age O
interaction O
, O
but O
the O
NE O
increases O
in O
prefrontal O
cortex O
and O
hippocampus O
was O
without O
age O
interaction O
. O

Moreover O
, O
in O
the O
brain O
regions O
studied O
, O
amitraz O
induced O
a O
statistically O
significant O
decrease O
in O
the O
metabolite O
5 B
- I
HIAA I
, O
MHPG O
, O
DOPAC B
and O
HVA B
levels O
displaying O
an O
age O
interaction O
, O
excepting O
the O
5 B
- I
HIAA I
decrease O
in O
midbrain O
and O
the O
DOPAC B
decrease O
in O
hypothalamus O
and O
striatum O
which O
were O
without O
age O
interaction O
. O

Furthermore O
, O
amitraz O
evoked O
a O
statistically O
significant O
decrease O
in O
5 B
- I
HT I
, O
NE O
and O
DA O
turnover O
in O
the O
brain O
regions O
studied O
. O

Development O
of O
PVP B
/ O
PEG B
mixtures O
as O
appropriate O
carriers O
for O
the O
preparation O
of O
drug O
solid O
dispersions O
by O
melt O
mixing O
technique O
and O
optimization O
of O
dissolution O
using O
artificial O
neural O
networks O
. O

The O
effect O
of O
plasticizer O
' O
s O
( O
PEG B
) O
molecular O
weight O
( O
MW O
) O
on O
PVP B
based O
solid O
dispersions O
( O
SDs O
) O
, O
prepared O
by O
melt O
mixing O
, O
was O
evaluated O
in O
the O
present O
study O
using O
Tibolone O
as O
a O
poorly O
water O
soluble O
model O
drug O
. O

PEGs B
with O
MW O
of O
400 O
, O
600 O
, O
and O
2000g O
/ O
mol O
were O
tested O
, O
and O
the O
effect O
of O
drug O
content O
, O
time O
and O
temperature O
of O
melt O
mixing O
on O
the O
physical O
state O
of O
Tibolone O
, O
and O
the O
dissolution O
characteristics O
from O
SDs O
was O
investigated O
. O

PVP B
blends O
with O
PEG400 O
and O
PEG600 O
were O
completely O
miscible O
, O
while O
blends O
were O
heterogeneous O
. O

Furthermore O
, O
a O
single O
Tg O
recorded O
in O
all O
samples O
, O
indicating O
that O
Tibolone O
was O
dispersed O
in O
a O
molecular O
lever O
( O
or O
in O
the O
form O
of O
nanodispersions O
) O
, O
varied O
with O
varying O
PEG B
' O
s O
molecular O
weight O
, O
melt O
mixing O
temperature O
, O
and O
drug O
content O
, O
while O
FTIR O
analysis O
indicated O
significant O
interactions O
between O
Tibolone O
and O
PVP B
/ O
PEG B
matrices O
. O

Synthesis O
and O
biological O
evaluation O
of O
Foscan B
( O
( O
R O
) O
) O
bile B
acid I
conjugates O
to O
target O
esophageal O
cancer O
cells O
. O

Porphyrins B
and O
chlorins O
such O
as O
Foscan B
( O
R O
) O
have O
a O
natural O
proclivity O
to O
accumulate O
in O
cancer O
cells O
. O

Bile B
acids I
which O
are O
known O
to O
selectively O
bind O
to O
, O
or O
be O
readily O
taken O
up O
by O
cancer O
cells O
were O
chosen O
as O
targeting O
moieties O
. O

Synthesis O
of O
the O
conjugates O
was O
achieved O
via O
selective O
nucleophilic O
monofunctionalizatio O
of O
5 O
, O
10 O
, O
15 O
, O
20 O
- O
tetrahydroxyphenylpo O
with O
propargyl O
bromide O
followed O
by O
Cu B
( I
I I
) I
mediated O
cycloaddition O
with O
bile O
acid O
azides O
in O
good O
yields O
. O

A O
diazen O
- O
1 O
- O
ium O
- O
1 O
, O
2 O
- O
diolate O
analog O
of O
7 O
- O
azabenzobicyclo O
[ O
2 O
. O
2 O
. O
1 O
] O
heptane O
: O
Synthesis O
, O
nitric B
oxide I
and O
nitroxyl B
release O
, O
in O
vitro O
hemodynamic O
, O
and O
anti O
- O
hypertensive O
studies O
. O

1 O
- O
( O
7 O
- O
Azabenzobicyclo O
[ O
2 O
. O
2 O
. O
1 O
] O
heptane O
) O
diazen O
- O
1 O
- O
ium O
- O
1 O
, O
2 O
- O
diolate O
( O
16 O
) O
was O
designed O
with O
the O
expectation O
that O
it O
would O
act O
as O
a O
dual O
nitric B
oxide I
( O
NO B
) O
and O
nitroxyl B
( O
HNO O
) O
donor O
that O
is O
not O
carcinogenic O
or O
genotoxic O
. O

Compound O
16 O
, O
with O
a O
suitable O
half O
- O
life O
( O
17 O
. O
8min O
) O
in O
PBS O
at O
pH O
7 O
, O
released O
NO B
( O
19 O
% O
) O
and O
HNO O
( O
22 O
% O
) O
during O
a O
2h O
incubation O
in O
PBS O
at O
pH O
7 O
. O

PEG B
mediated O
synthesis O
and O
pharmacological O
evaluation O
of O
some O
fluoro O
substituted O
pyrazoline O
derivatives O
as O
antiinflammatory O
and O
analgesic O
agents O
. O

A O
new O
series O
of O
fluoro O
substituted O
pyrazoline O
derivatives O
5a O
- O
g O
and O
6a O
- O
g O
were O
synthesized O
in O
good O
to O
excellent O
yield O
from O
the O
corresponding O
pyrazole O
chalcones O
, O
4a O
- O
g O
, O
by O
using O
polyethylene O
glycol O
- O
400 O
( O
PEG B
- I
400 I
) O
as O
an O
alternative O
reaction O
medium O
. O

Compounds O
5g O
and O
6g O
were O
found O
to O
be O
more O
potent O
than O
standard O
drug O
Diclofenac B
and O
six O
other O
compounds O
5b O
, O
5c O
, O
5f O
, O
6b O
, O
6c O
and O
6f O
showed O
significant O
antiinflammatory O
activity O
as O
compared O
to O
standard O
drug O
. O

Identification O
of O
metal O
ion O
binding O
peptides O
containing O
unnatural O
amino B
acids I
by O
phage O
display O
. O

The O
bidentate O
metal O
binding O
amino B
acid I
bipyridylalanine O
( O
BpyAla O
) O
was O
incorporated O
into O
a O
disulfide B
linked O
cyclic O
peptide O
phage O
displayed O
library O
to O
identify O
metal O
ion O
binding O
peptides O
. O

Selection O
against O
Ni B
( I
2 I
+ I
) I
- O
nitrilotriacetic O
acid O
( O
NTA O
) O
enriched O
for O
sequences O
containing O
histidine B
and O
BpyAla O
. O

BpyAla O
predominated O
when O
selections O
were O
carried O
out O
at O
lower O
pH O
, O
consistent O
with O
the O
differential O
pKa O
' O
s O
of O
histidine B
and O
BpyAla O
. O

Two O
peptides O
containing O
BpyAla O
were O
synthesized O
and O
found O
to O
bind O
Ni B
( I
2 I
+ I
) I
with O
low O
micromolar O
dissociation O
constants O
. O

Incorporation O
of O
BpyAla O
and O
other O
metal O
binding O
amino B
acids I
into O
peptide O
and O
protein O
libraries O
should O
enable O
the O
evolution O
of O
novel O
binding O
and O
catalytic O
activities O
. O

A O
custom O
- O
designed O
bench O
- O
top O
framework O
comprising O
a O
model O
of O
a O
single O
drug O
- O
eluting O
stent O
strut O
and O
a O
poly B
- I
vinyl I
alcohol I
- O
based O
hydrogel O
as O
a O
model O
tissue O
bed O
simulated O
fluid O
flow O
and O
drug O
transport O
under O
fully O
apposed O
strut O
settings O
. O

Antagonists O
reversibly O
reverse O
chemical O
LTD O
induced O
by O
group O
I O
, O
group O
II O
and O
group O
III O
metabotropic O
glutamate B
receptors O
. O

Metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
are O
implicated O
in O
many O
neurological O
and O
psychiatric O
diseases O
and O
are O
the O
targets O
of O
therapeutic O
agents O
currently O
in O
clinical O
development O
. O

We O
previously O
reported O
that O
the O
brief O
exposure O
of O
hippocampal O
slices O
to O
dihydroxyphenylglyci O
( O
DHPG B
) O
can O
result O
in O
a O
long O
- O
term O
depression O
( O
LTD O
) O
of O
excitatory O
synaptic O
transmission O
. O

Here O
, O
15 O
years O
after O
the O
discovery O
of O
DHPG B
- O
LTD O
and O
its O
reversible O
reversibility O
, O
we O
summarise O
these O
initial O
findings O
. O

We O
then O
present O
new O
data O
on O
DHPG B
- O
LTD O
, O
which O
demonstrates O
that O
evoked O
epileptiform O
activity O
triggered O
by O
activation O
of O
group O
I O
mGlu O
receptors O
can O
also O
be O
reversibly O
reversed O
by O
mGlu O
receptor O
antagonists O
. O

Arsenic B
trioxide I
depletes O
cancer O
stem O
- O
like O
cells O
and O
inhibits O
repopulation O
of O
neurosphere O
derived O
from O
glioblastoma O
by O
downregulation O
of O
Notch O
pathway O
. O

We O
have O
recently O
demonstrated O
the O
inhibitory O
effect O
of O
arsenic B
trioxide I
( O
ATO B
) O
on O
CSLCs O
in O
glioblastoma O
cell O
lines O
. O

In O
this O
study O
we O
used O
neurosphere O
recovery O
assay O
that O
measured O
neurosphere O
formation O
at O
three O
time O
points O
to O
assess O
the O
capacity O
of O
the O
culture O
to O
repopulate O
after O
ATO B
treatment O
. O

Our O
results O
provided O
strong O
evidence O
that O
ATO B
depleted O
CSLCs O
in O
GBM O
, O
and O
inhibited O
neurosphere O
recovery O
and O
secondary O
neurosphere O
formation O
. O

ATO B
inhibited O
the O
phosphorylation O
and O
activation O
of O
AKT O
and O
STAT3 O
through O
Notch O
signaling O
blockade O
. O

These O
data O
show O
that O
the O
ATO B
is O
a O
promising O
new O
approach O
to O
decrease O
glioblastoma O
proliferation O
and O
recurrence O
by O
downregulation O
of O
Notch O
pathway O
. O

To O
further O
investigate O
the O
structure O
- O
activity O
relationship O
( O
SAR O
) O
of O
the O
5 B
- I
hydroxytryptamine I
type O
6 O
( O
5 O
- O
HT6 O
) O
receptor O
agonist O
5 O
- O
chloro O
- O
2 O
- O
methyl O
- O
3 O
- O
( O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridin O
- O
4 O
- O
yl O
) O
- O
1H O
- O
indole O
( O
EMD386088 O
, O
6 O
) O
, O
a O
series O
of O
2 O
- O
methyl O
- O
3 O
- O
( O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridin O
- O
4 O
- O
yl O
) O
- O
1H O
- O
indoles O

In O
order O
for O
a O
compound O
to O
demonstrate O
potent O
5 O
- O
HT6 O
receptor O
agonist O
properties O
, O
the O
indole B
N O
( O
1 O
) O
should O
be O
unsubstituted O
, O
an O
alkyl B
group O
such O
as O
2 O
- O
methyl O
is O
needed O
and O
finally O
halogen B
substituents O
in O
the O
indole B
5 O
- O
position O
( O
fluoro O
, O
chloro B
or O
, O
bromo O
) O
were O
essential O
requirements O
. O

A O
few O
compounds O
within O
the O
2 O
- O
methyl O
- O
3 O
- O
( O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridin O
- O
4 O
- O
yl O
) O
- O
1H O
- O
indoles O
were O
also O
screened O
for O
off O
- O
targets O
and O
generally O
they O
displayed O
low O
affinity O
for O
other O
5 B
- I
HT I
subtypes O
and O
serotonin B
transporter O
protein O
( O
SERT O
) O
. O

Sesquiterpene B
lactones I
( O
SLs O
) O
are O
natural O
products O
with O
a O
variety O
of O
biological O
activities O
. O

Purified O
preparations O
of O
gpL O
and O
several O
homologues O
all O
displayed O
a O
distinct O
reddish O
color O
, O
suggesting O
the O
binding O
of O
iron B
by O
these O
proteins O
. O

The O
C B
- O
terminal O
domain O
was O
demonstrated O
to O
coordinate O
an O
iron O
- O
sulfur O
cluster O
, O
providing O
the O
first O
example O
of O
a O
viral O
structural O
protein O
binding O
to O
this O
type O
of O
metal O
group O
. O

We O
characterized O
the O
iron O
- O
sulfur O
cluster O
using O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectroscopy O
, O
absorbance O
spectroscopy O
, O
and O
electron O
paramagnetic O
resonance O
spectroscopy O
and O
found O
that O
it O
is O
an O
oxygen B
- O
sensitive O
[ O
4Fe O
- O
4S O
] O
( O
2 O
+ O
) O
cluster O
. O

Four O
highly O
conserved O
cysteine B
residues O
were O
shown O
to O
be O
required O
for O
coordinating O
the O
iron O
- O
sulfur O
cluster O
, O
and O
substitution O
of O
any O
of O
these O
Cys B
residues O
with O
Ser B
or O
Ala B
within O
the O
context O
of O
lambda O
gpL O
abolished O
biological O
activity O
. O

The O
presence O
of O
four O
conserved O
Cys B
residues O
in O
the O
C B
- O
terminal O
regions O
of O
very O
diverse O
gpL O
homologues O
suggest O
that O
utilization O
of O
an O
iron O
- O
sulfur O
cluster O
is O
a O
widespread O
feature O
of O
non O
- O
contractile O
tailed O
phages O
that O
infect O
Gram O
- O
negative O
bacteria O
. O

Although O
the O
nanosuspension O
appeared O
to O
exhibit O
slower O
clearance O
from O
the O
injection O
site O
after O
i O
. O
m O
. O
injection O
, O
compared O
to O
microsuspension O
( O
~ O
5 O
mu O
m O
) O
, O
a O
significantly O
higher O
maximum O
plasma O
curcumin B
concentration O
( O
69 O
. O
0ng O
/ O
ml O
) O
was O
observed O
for O
the O
former O
than O
that O
for O
the O
latter O
( O
18 O
. O
5ng O
/ O
ml O
) O
. O

In O
addition O
, O
the O
nanosuspension O
provided O
significant O
higher O
plasma O
curcumin B
concentrations O
and O
brain O
CurDD O
contents O
for O
at O
least O
15days O
than O
the O
microsuspension O
, O
except O
for O
the O
initial O
times O
. O

A O
single O
i O
. O
m O
. O
injection O
of O
nanosuspension O
appeared O
to O
achieve O
reversal O
effect O
on O
reserpine B
- O
induced O
hypothermia O
for O
at O
least O
13days O
. O

This O
study O
demonstrates O
that O
CurDD O
nanosuspension O
may O
act O
as O
a O
long O
- O
acting O
i O
. O
m O
. O
injectable O
for O
sustained O
delivery O
of O
curcumin B
, O
potentially O
applicable O
to O
elicit O
a O
long O
- O
lasting O
antidepressant O
effect O
. O

Nanoparticles O
of O
poly O
( O
d O
, O
l O
- O
lactide O
- O
co O
- O
glycolide O
) O
, O
poly B
( I
d I
, I
l I
- I
lactide I
) I
and O
polyethylene O
glycol O
- O
block O
- O
poly O
( O
d O
, O
l O
- O
lactide O
) O
were O
developed O
to O
encapsulate O
chloroaluminium O
phthalocyanine O
( O
AlClPc O
) O
, O
a O
new O
hydrophobic O
photosensitiser O
used O
in O
photodynamic O
therapy O
( O
PDT O
) O
. O

Arsenic B
trioxide I
induces O
cardiac O
fibroblast O
apoptosis O
in O
vitro O
and O
in O
vivo O
by O
up O
- O
regulating O
TGF O
- O
beta O
1 O
expression O
. O

Arsenic B
trioxide I
( O
As2O3 O
; O
ATO B
) O
is O
clinically O
effective O
in O
treating O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
; O
however O
, O
it O
frequently O
causes O
cardiotoxic O
effects O
. O

This O
study O
was O
designed O
to O
investigate O
whether O
ATO B
could O
induce O
apoptosis O
of O
cardiac O
fibroblasts O
( O
CFs O
) O
that O
play O
very O
important O
roles O
in O
maintaining O
the O
structure O
integrity O
and O
function O
of O
the O
heart O
. O

Cardiac O
fibroblasts O
from O
guinea O
pigs O
administered O
with O
ATO B
( O
1mg O
/ O
kgbw O
) O
were O
used O
to O
test O
the O
pro O
- O
apoptotic O
role O
of O
ATO B
in O
vivo O
. O

The O
current O
study O
demonstrated O
that O
ATO B
induced O
morphological O
characteristics O
of O
apoptosis O
and O
Caspase O
- O
3 O
activation O
in O
CFs O
of O
guinea O
pigs O
along O
with O
a O
significant O
up O
- O
regulation O
in O
TGF O
- O
beta O
1 O
protein O
expression O
, O
Bax O
/ O
Bcl O
- O
2 O
ratio O
and O
ERK1 O
/ O
2 O
phosphorylation O
. O

In O
vitro O
MTT B
assay O
showed O
that O
ATO B
remarkably O
reduced O
the O
viability O
of O
cultured O
cardiac O
fibroblasts O
( O
NRCFs O
) O
from O
neonatal O
rat O
in O
a O
concentration O
- O
and O
time O
- O
dependent O
manner O
. O

Consistent O
with O
the O
notions O
in O
vivo O
, O
ATO B
significantly O
induced O
the O
apoptosis O
in O
NRCFs O
, O
dramatically O
up O
- O
regulated O
TGF O
- O
beta O
1 O
protein O
level O
and O
Bax O
/ O
Bcl O
- O
2 O
ratio O
in O
a O
time O
- O
dependent O
fashion O
and O
activated O
Caspase O
- O
3 O
and O
ERK1 O
/ O
2 O
. O

We O
therefore O
conclude O
that O
TGF O
- O
beta O
is O
functionally O
linked O
to O
ERK1 O
/ O
2 O
and O
that O
TGF O
- O
beta O
signaling O
is O
responsible O
for O
ATO B
- O
induced O
CFs O
apoptosis O
, O
which O
provides O
a O
novel O
mechanism O
of O
ATO B
related O
cardiac O
toxicology O
. O

In O
utero O
phthalate B
effects O
in O
the O
female O
rat O
: O
A O
model O
for O
MRKH O
syndrome O
. O

Reproductive O
toxicity O
of O
phthalate B
esters I
( O
PEs O
) O
occurs O
in O
rat O
offspring O
exposed O
in O
utero O
, O
a O
phenomenon O
that O
is O
better O
studied O
in O
male O
offspring O
than O
females O
. O

Overall O
, O
this O
study O
provides O
valuable O
information O
regarding O
female O
vulnerability O
to O
in O
utero O
phthalate B
exposure O
and O
further O
characterizes O
a O
potential O
model O
for O
the O
human O
MRKH O
syndrome O
. O

Those O
exposed O
to O
DEPs O
showed O
significantly O
higher O
oxidative O
stress O
than O
the O
untreated O
group O
, O
as O
indicated O
by O
the O
glutathione B
( O
GSH B
) O
and O
malondialdehyde B
( O
MDA B
) O
levels O
, O
and O
the O
glutathione B
peroxidase O
and O
glutathione B
reductase O
activities O
. O

The O
ethylene O
bis O
- O
dithiocarbamate O
fungicide O
Mancozeb O
activates O
voltage O
- O
gated O
KCNQ2 O
potassium B
channel O
. O

Further O
examination O
showed O
that O
manganese B
but O
not O
zinc O
ethylene O
bis O
- O
dithiocarbamate O
is O
the O
active O
component O
for O
the O
positive O
modulation O
effects O
. O

In O
addition O
, O
the O
compounds O
are O
effective O
when O
the O
metal O
ions O
are O
substituted O
by O
iron B
but O
lack O
potentiation O
activity O
when O
the O
metal O
ions O
are O
substituted O
by O
sodium B
, O
signifying O
the O
importance O
of O
the O
metal O
ion O
. O

However O
, O
the O
iron B
( O
Fe B
( I
3 I
+ I
) I
) O
alone O
, O
organic O
ligands O
alone O
or O
the O
mixture O
of O
iron B
with O
the O
organic O
ligand O
did O
not O
show O
any O
potentiation O
effect O
, O
suggesting O
as O
the O
active O
ingredient O
is O
a O
specific O
complex O
rather O
than O
two O
separate O
additive O
or O
synergistic O
components O
. O

Our O
study O
suggests O
that O
potentiation O
on O
KCNQ2 O
potassium B
channels O
might O
be O
the O
possible O
mechanism O
of O
Mancozeb O
toxicity O
in O
the O
nervous O
system O
. O

To O
date O
, O
few O
studies O
have O
examined O
the O
aberrant O
DNA O
methylation O
patterns O
in O
coke O
oven O
workers O
, O
who O
are O
highly O
at O
risk O
of O
lung O
cancer O
by O
occupational O
exposure O
to O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
. O

We O
recruited O
82 O
PAH B
- O
exposed O
workers O
and O
62 O
unexposed O
controls O
, O
assessed O
exposure O
levels O
by O
urinary O
1 B
- I
hydroxypyrene I
, O
and O
measured O
genetic O
damages O
by O
comet O
assay O
, O
bleomycin B
sensitivity O
, O
and O
micronucleus O
assay O
. O

The O
PAHs B
in O
coke O
oven O
emissions O
( O
COE O
) O
were O
estimated O
based O
on O
toxic O
equivalency O
factors O
. O

We O
used O
bisulfite B
- O
PCR O
pyrosequencing O
to O
quantitate O
DNA O
methylation O
in O
long O
interspersed O
nuclear O
element O
- O
1 O
( O
LINE O
- O
1 O
) O
and O
O O
( O
6 O
) O
- O
methylguanine O
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

We O
found O
there O
are O
higher O
levels O
of O
PAHs B
in O
COE O
. O

Among O
PAH B
- O
exposed O
workers O
, O
LINE O
- O
1 O
and O
MGMT O
methylation O
levels O
( O
with O
CpG B
site O
specificity O
) O
were O
significantly O
lowered O
. O

LINE O
- O
1 O
, O
MGMT O
, O
and O
its O
hot O
CpG B
site O
- O
specific O
methylation O
were O
negatively O
correlated O
with O
urinary O
1 B
- I
hydroxypyrene I
levels O
( O
r O
= O
- O
0 O
. O
329 O
, O
p O
< O
0 O
. O
001 O
; O
r O
= O
- O
0 O
. O
164 O
, O
p O
= O
0 O
. O
049 O
and O
r O
= O
- O
0 O
. O
176 O
, O
p O
= O
0 O
. O
034 O
, O
respectively O
) O
. O

These O
findings O
suggest O
hypomethylation O
of O
LINE O
- O
1 O
and O
MGMT O
promoter O
could O
be O
used O
as O
markers O
for O
PAHs B
exposure O
and O
merit O
further O
investigation O
. O

After O
treatment O
, O
the O
levels O
of O
serum O
creatine B
kinase O
isozyme O
MB O
( O
CK O
- O
MB O
) O
, O
creatine B
kinase O
, O
creatinine B
, O
glutamate B
- O
oxalacetate O
transaminase O
( O
AST O
) O
, O
glutamate B
- O
pyruvate B
transaminase O
( O
ALT O
) O
, O
APACHE O
II O
score O
on O
the O
1st O
, O
2nd O
, O
and O
7th O
day O
in O
both O
the O
treatment O
groups O
were O
lower O
than O
that O
before O
the O
treatment O
( O
P O
< O
0 O
. O
05 O
) O
. O

We O
previously O
reported O
that O
oroxylin O
A O
, O
a O
gamma B
- I
aminobutyric I
acid I
A O
( O
GABAA O
) O
receptor O
antagonist O
, O
ameliorates O
drugs O
- O
induced O
memory O
impairments O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
effect O
of O
a O
novel O
oroxylin O
A O
derivative O
, O
5 O
, O
7 O
- O
dihydroxy O
- O
6 O
- O
methoxy O
- O
2 O
( O
4 O
- O
phenoxyphenyl O
) O
- O
4H O
- O
chromene O
- O
4 O
- O
one O
( O
DMPC B
) O
, O
on O
pharmacological O
models O
of O
schizophrenia O
, O
which O
exhibit O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
. O

Memory O
impairment O
was O
induced O
by O
scopolamine B
, O
a O
muscarinic O
receptor O
antagonist O
, O
or O
MK B
- I
801 I
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
antagonist O
. O

Sensorimotor O
gating O
deficits O
were O
induced O
by O
MK B
- I
801 I
and O
measured O
by O
prepulse O
inhibition O
( O
PPI O
) O
of O
the O
acoustic O
startle O
response O
task O
. O

DMPC B
treatment O
( O
20 O
mg O
/ O
kg O
) O
significantly O
attenuated O
scopolamine B
- O
or O
MK B
- I
801 I
- O
induced O
memory O
impairment O
and O
it O
even O
enhanced O
cognitive O
performance O
of O
normal O
animals O
. O

Furthermore O
, O
DMPC B
significantly O
ameliorated O
MK B
- I
801 I
- O
induced O
PPI O
deficits O
in O
the O
acoustic O
startle O
response O
task O
. O

In O
an O
in O
vitro O
study O
, O
DMPC B
( O
20 O
mu O
M O
) O
inhibited O
intracellular O
Cl B
( I
- I
) I
influx O
induced O
by O
muscimol B
, O
a O
selective O
GABAA O
receptor O
agonist O
. O

These O
results O
suggest O
that O
DMPC B
would O
be O
a O
potential O
candidate O
for O
alleviating O
cognitive O
dysfunction O
and O
sensorimotor O
gating O
deficits O
in O
schizophrenia O
, O
and O
that O
its O
effects O
may O
be O
mediated O
, O
in O
part O
, O
via O
blockade O
of O
the O
GABAergic O
neurotransmitter O
system O
. O

Tryptanthrin O
showed O
a O
variety O
of O
intriguing O
biological O
properties O
such O
as O
antibacterial O
, O
antifungal O
, O
antiprotozoal O
, O
and O
antiparasitic O
activities O
, O
inhibitory O
activities O
against O
COX O
- O
2 O
, O
5 O
- O
LOX O
, O
NO B
synthase O
and O
PGE B
( I
2 I
) I
expression O
, O
as O
well O
as O
cytotoxic O
and O
antitumor O
activities O
. O

Design O
, O
synthesis O
, O
in O
vitro O
cytotoxicity O
evaluation O
and O
structure O
- O
activity O
relationship O
of O
Goniothalamin B
analogs O
. O

Structure O
- O
activity O
relationship O
study O
indicates O
that O
introducing O
substituent O
in O
phenyl O
ring O
or O
replacing O
phenyl B
ring O
by O
pyridine B
/ O
naphthalene B
, O
or O
decreasing O
the O
ring O
size O
of O
lactones B
( O
from O
six O
to O
five O
member O
) O
do O
not O
increase O
the O
cytotoxicity O
. O

Loss O
of O
Calcium B
/ O
Calmodulin O
- O
Dependent O
Protein O
Kinase O
II O
Activity O
in O
Cortical O
Astrocytes O
Decreases O
Glutamate B
Uptake O
and O
Induces O
Neurotoxic O
Release O
of O
ATP B
. O

The O
extent O
of O
calcium B
/ O
calmodulin O
- O
dependent O
protein O
kinase O
II O
( O
CaMKII O
) O
inactivation O
in O
the O
brain O
following O
ischemia O
correlates O
with O
the O
extent O
of O
damage O
. O

We O
have O
previously O
shown O
that O
a O
loss O
of O
CaMKII O
activity O
in O
neurons O
is O
detrimental O
to O
neuronal O
viability O
by O
inducing O
excitotoxic O
glutamate B
release O
. O

In O
the O
current O
study O
, O
we O
extend O
these O
findings O
to O
show O
that O
the O
ability O
of O
astrocytes O
to O
buffer O
extracellular O
glutamate B
is O
reduced O
when O
CaMKII O
is O
inhibited O
. O

Furthermore O
, O
CaMKII O
inhibition O
in O
astrocytes O
is O
associated O
with O
the O
rapid O
onset O
of O
intracellular O
calcium B
oscillations O
. O

Surprisingly O
, O
this O
rapid O
calcium B
influx O
is O
blocked O
by O
the O
N B
- O
type O
calcium B
channel O
antagonist O
, O
omega O
- O
conotoxin O
. O

While O
the O
function O
of O
N B
- O
type O
calcium B
channels O
within O
astrocytes O
is O
controversial O
, O
these O
voltage O
- O
gated O
calcium B
channels O
have O
been O
linked O
to O
calcium B
- O
dependent O
vesicular O
gliotransmitter O
release O
. O

When O
extracellular O
glutamate B
and O
ATP B
levels O
are O
measured O
following O
CaMKII O
inhibition O
within O
our O
enriched O
astrocyte O
cultures O
, O
no O
alterations O
in O
glutamate B
levels O
are O
observed O
, O
whereas O
ATP B
levels O
in O
the O
extracellular O
environment O
significantly O
increase O
. O

Extracellular O
ATP B
accumulation O
associated O
with O
CaMKII O
inhibition O
contributes O
both O
to O
calcium B
oscillations O
within O
astrocytes O
and O
ultimately O
cortical O
neuron O
toxicity O
. O

Thus O
, O
a O
loss O
of O
CaMKII O
signaling O
within O
astrocytes O
dysregulates O
glutamate B
uptake O
and O
supports O
ATP B
release O
, O
two O
processes O
that O
would O
compromise O
neuronal O
survival O
following O
ischemic O
/ O
excitotoxic O
insults O
. O

Mass O
and O
Ion O
Transport O
in O
Ketones B
and O
Ketone B
Electrolytes O
: O
Comparison O
with O
Acetate B
Systems O
. O

The O
data O
for O
the O
pure O
ketones B
and O
ketone B
- O
based O
electrolytes O
are O
compared O
with O
analogous O
data O
for O
pure O
n O
- O
alkyl O
acetates O
and O
n O
- O
alkyl O
acetate O
- O
based O
electrolytes O
. O

Some O
of O
these O
compounds O
displayed O
significant O
activity O
in O
vitro O
as O
positive O
allosteric O
modulators O
of O
the O
GABAB O
receptor O
by O
potentiating O
GTP O
gamma O
S O
stimulation O
induced O
by O
GABA B
at O
2 O
. O
5 O
and O
25 O
mu O
M O
while O
failing O
to O
exhibit O
intrinsic O
agonist O
activity O
. O

Compounds O
were O
also O
found O
to O
be O
effective O
in O
vivo O
, O
potentiating O
baclofen B
- O
induced O
sedation O
/ O
hypnosis O
in O
DBA O
mice O
when O
administered O
either O
intraperitoneally O
or O
intragastrically O
. O

Although O
displaying O
a O
lower O
potency O
in O
vitro O
than O
the O
reference O
compound O
GS39783 O
, O
the O
new O
compounds O
6 O
, O
10 O
, O
and O
11 O
exhibited O
a O
higher O
efficacy O
in O
vivo O
: O
combination O
of O
these O
compounds O
with O
a O
per O
se O
nonsedative O
dose O
of O
baclofen B
resulted O
in O
shorter O
onset O
and O
longer O
duration O
of O
the O
loss O
of O
righting O
reflex O
in O
mice O
. O

Test O
compounds O
showed O
cytotoxic O
effects O
at O
concentrations O
comparable O
to O
or O
higher O
than O
those O
of O
GS39783 O
or O
BHF177 B
. O

Transition B
metal I
- O
catalyzed O
efficient O
and O
green O
transformations O
of O
p O
( O
o O
) O
- O
h O
compounds O
to O
functional O
organophosphorus B
compounds O
. O

Organophosphorus B
compounds O
are O
of O
high O
importance O
in O
organic O
synthesis O
, O
catalysis O
, O
biochemistry O
, O
pharmaceuticals O
, O
and O
material O
science O
. O

In O
this O
mini O
review O
, O
we O
summarize O
our O
recent O
studies O
on O
transition B
metal I
- O
catalyzed O
green O
and O
atom O
efficient O
transformations O
of O
P O
( O
O O
) O
- O
H O
bonds O
to O
various O
versatile O
organophosphorus B
compounds O
, O
including O
the O
highly O
regio O
- O
and O
stereoselective O
P O
( O
O O
) O
- O
H O
additions O
to O
carbon B
- O
carbon B
unsaturated O
compounds O
, O
asymmetric O
hydrophosphorylation O
reactions O
, O
and O
dehydrogenative O
coupling O
reactions O
of O
P O
( O
O O
) O
- O
H O
compounds O
with O
carbon B
- O
H B
and O
heteroatom O
- O
H B
compounds O
. O

These O
new O
reactions O
provide O
efficient O
, O
general O
and O
practical O
ways O
for O
the O
preparation O
of O
a O
variety O
of O
well O
- O
defined O
functional O
organophosphorus B
compounds O
. O

Organic O
selenium B
resin O
in O
solid O
phase O
synthesis O
and O
its O
application O
in O
constructing O
medicinally O
relevant O
small O
organic O
molecules O
. O

In O
this O
mini O
review O
, O
we O
summarize O
the O
construction O
of O
heterocyclic O
compounds O
libraries O
such O
as O
isoxazoles O
, O
oxadiazoles O
, O
triazoles B
, O
pyrimidines B
, O
pyrrolines O
, O
indolines O
, O
benzopyrans O
, O
furans O
etc O
. O
using O
organoselenium O
resins O
. O

The O
effective O
partition O
coefficient O
keff O
( O
= O
CS O
/ O
C0 O
) O
was O
investigated O
for O
pure O
polystyrene B
and O
polystyrene B
dyed O
with O
fluorescent O
particles O
by O
changing O
the O
ratio O
of O
particle O
diameters O
dimp O
/ O
dcryst O
and O
growth O
rate O
V O
. O

At O
each O
size O
ratio O
for O
the O
polystyrene B
impurity O
, O
keff O
was O
less O
than O
unity O
and O
increased O
to O
unity O
with O
increasing O
V O
, O
whereas O
at O
a O
given O
growth O
rate O
, O
keff O
increased O
to O
unity O
as O
dimp O
/ O
dcryst O
approached O
unity O
. O

In O
contrast O
, O
while O
the O
fluorescent O
particles O
also O
followed O
the O
BPS O
model O
, O
they O
showed O
higher O
k0 O
values O
than O
those O
of O
the O
same O
size O
of O
polystyrene B
particles O
. O

The O
method O
utilizes O
information O
- O
based O
virtual O
transformation O
of O
library O
carboxylates B
to O
hydroxamic B
acids I
prior O
to O
docking O
, O
followed O
by O
compound O
acquisition O
, O
one O
- O
pot O
( O
two O
steps O
) O
chemical O
synthesis O
and O
in O
vitro O
screening O
. O

The O
aqueous O
root O
extracts O
of O
Pentanisia O
prunelloides O
combined O
( O
1 O
: O
1 O
) O
with O
Elephantorrhiza O
elephantina O
displayed O
synergistic O
interactions O
( O
Esh O
FIC O
values O
0 O
. O
31 O
- O
0 O
. O
38 O
) O
against O
Staphylococcus O
aureus O
, O
gentamycin O
- O
methicillin B
resistant O
Staphylococcus O
aureus O
, O
Staphylococcus O
epidermidis O
and O
Candida O
albicans O
. O

Stable O
and O
high O
- O
rate O
overcharge O
protection O
for O
rechargeable O
lithium B
batteries O
. O

Rechargeable O
lithium B
or O
lithium B
- O
ion O
cells O
can O
be O
overcharge O
- O
protected O
by O
an O
electroactive O
polymer O
composite O
separator O
. O

For O
the O
first O
time O
, O
stable O
overcharge O
protection O
for O
hundreds O
of O
cycles O
was O
demonstrated O
in O
several O
cell O
chemistries O
, O
including O
LiNi1 O
/ O
3Co1 O
/ O
3Mn1 O
/ O
3O2 O
, O
LiFePO4 B
, O
and O
spinel O
Li1 O
. O
05Mn1 O
. O
95O4 O
half O
- O
cells O
. O

The O
metabolic O
profile O
of O
mitoxantrone B
and O
its O
relation O
with O
mitoxantrone B
- O
induced O
cardiotoxicity O
. O

Mitoxantrone B
( O
MTX B
) O
is O
an O
antitumor O
agent O
that O
causes O
cardiotoxicity O
in O
18 O
% O
patients O
. O

The O
metabolic O
profile O
of O
MTX B
was O
assessed O
after O
incubation O
of O
100 O
mu O
M O
MTX B
with O
hepatic O
S9 O
fraction O
isolated O
from O
rats O
. O

The O
presence O
of O
MTX B
and O
its O
metabolites O
was O
also O
assessed O
in O
vivo O
through O
the O
analysis O
of O
liver O
and O
heart O
extracts O
of O
MTX B
- O
treated O
rats O
. O

The O
cytotoxic O
effects O
of O
MTX B
and O
MTX B
metabolites O
were O
evaluated O
in O
the O
H9c2 O
cells O
after O
24 O
- O
h O
incubation O
with O
MTX B
alone O
and O
MTX B
+ O
metabolites O
. O

The O
influence O
of O
CYP450 O
- O
and O
CYP2E1 O
- O
mediated O
metabolism O
for O
the O
cytotoxicity O
of O
MTX B
was O
assessed O
after O
96 O
- O
h O
incubation O
with O
MTX B
( O
100 O
nM O
and O
1 O
mu O
M O
) O
in O
the O
presence O
/ O
absence O
of O
CYP450 O
or O
CYP2E1 O
inhibitors O
. O

After O
4 O
- O
h O
incubation O
in O
supplemented O
S9 O
fraction O
, O
the O
MTX B
content O
was O
35 O
% O
lower O
and O
5 O
metabolites O
were O
identified O
: O
an O
acetoxy O
ester O
derivative O
( O
never O
described O
before O
) O
, O
two O
glutathione B
conjugates O
, O
a O
monocarboxylic B
acid I
derivative O
, O
and O
the O
naphtoquinoxaline O
, O
the O
later O
commonly O
related O
to O
MTX B
pharmacological O
effects O
. O

The O
presence O
of O
MTX B
and O
naphtoquinoxaline O
metabolite O
was O
evidenced O
in O
vivo O
in O
liver O
and O
heart O
of O
MTX B
- O
treated O
rats O
. O

The O
cytotoxicity O
caused O
by O
MTX B
+ O
metabolites O
was O
higher O
than O
that O
observed O
in O
the O
H9c2 O
cells O
incubated O
with O
non O
- O
metabolized O
MTX B
group O
. O

The O
co O
- O
incubation O
of O
MTX B
with O
CYP450 O
and O
CYP2E1 O
inhibitors O
partially O
prevented O
the O
cytotoxicity O
observed O
in O
the O
MTX B
groups O
incubated O
with O
H9c2 O
cells O
, O
highlighting O
that O
the O
metabolism O
of O
MTX B
is O
relevant O
for O
its O
undesirable O
effects O
. O

It O
was O
demonstrated O
that O
MTX B
P450 O
- O
mediated O
metabolism O
contributed O
to O
MTX B
toxicity O
. O

Hepatoprotective O
potential O
of O
Lavandula O
coronopifolia O
extracts O
against O
ethanol B
induced O
oxidative O
stress O
- O
mediated O
cytotoxicity O
in O
HepG2 O
cells O
. O

The O
present O
investigations O
were O
carried O
out O
to O
study O
the O
protective O
potential O
of O
four O
extracts O
( O
namely O
petroleum B
ether I
extract O
( O
LCR O
) O
, O
chloroform B
extract O
( O
LCM O
) O
, O
ethyl B
acetate I
extract O
( O
LCE O
) O
, O
and O
alcoholic O
extract O
( O
LCL O
) O
) O
of O
Lavandula O
coronopifolia O
on O
oxidative O
stress O
- O
mediated O
cell O
death O
induced O
by O
ethanol B
, O
a O
known O
hepatotoxin O
in O
human O
hapatocellular O
carcinoma O
( O
HepG2 O
) O
cells O
. O

Cells O
were O
pretreated O
with O
LCR O
, O
LCM O
, O
LCE O
, O
and O
LCL O
extracts O
( O
10 O
- O
50 O
mu O
g O
/ O
ml O
) O
of O
L O
. O
coronopifolia O
for O
24 O
h O
and O
then O
ethanol B
was O
added O
and O
incubated O
further O
for O
24 O
h O
. O

After O
the O
exposure O
, O
cell O
viability O
using O
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
) O
and O
neutral B
red I
uptake O
assays O
and O
morphological O
changes O
in O
HepG2 O
cells O
were O
studied O
. O

Pretreatment O
with O
various O
extracts O
of O
L O
. O
coronpifolia O
was O
found O
to O
be O
significantly O
effective O
in O
countering O
the O
cytotoxic O
responses O
of O
ethanol B
. O

Antioxidant O
properties O
of O
these O
L O
. O
coronopifolia O
extracts O
against O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
, O
lipid O
peroxidation O
( O
LPO O
) O
, O
and O
glutathione B
( O
GSH B
) O
levels O
induced O
by O
ethanol B
were O
investigated O
. O

Results O
show O
that O
pretreatment O
with O
these O
extracts O
for O
24 O
h O
significantly O
inhibited O
ROS O
generation O
and O
LPO O
induced O
and O
increased O
the O
GSH B
levels O
reduced O
by O
ethanol B
. O

The O
data O
from O
the O
study O
suggests O
that O
LCR O
, O
LCM O
, O
LCE O
, O
and O
LCL O
extracts O
of O
L O
. O
coronopifolia O
showed O
hepatoprotective O
activity O
against O
ethanol B
- O
induced O
damage O
in O
HepG2 O
cells O
. O

Differential O
propensity O
of O
citrate B
- O
and O
polyethylene B
glycol I
- O
coated O
silver B
nanoparticles O
to O
bovine O
hemoglobin O
. O

Propensity O
of O
two O
different O
silver B
nanoparticles O
( O
Ag B
- O
NPs O
) O
to O
bovine O
hemoglobin O
( O
BHb O
) O
was O
investigated O
by O
means O
of O
spectroscopic O
methods O
. O

We O
have O
combined O
spectrophotometric O
and O
calorimetric O
methods O
to O
show O
that O
there O
is O
no O
significant O
interaction O
between O
citrate B
- O
coated O
Ag B
- O
NPs O
and O
BHb O
at O
physiological O
pH O
and O
20 O
degrees O
C O
. O

However O
, O
our O
previous O
results O
show O
that O
polyethylene B
glycol I
- O
coated O
Ag B
- O
NPs O
strongly O
bind O
to O
Hb O
and O
effect O
on O
the O
secondary O
and O
tertiary O
structures O
of O
BHb O
. O

Excess O
androgens B
in O
utero O
alters O
fetal O
testis O
development O
. O

We O
therefore O
investigated O
whether O
increased O
prenatal O
androgen B
exposure O
also O
altered O
testicular O
development O
using O
ovine O
animal O
models O
. O

Biweekly O
maternal O
testosterone B
propionate I
( O
TP O
; O
100 O
mg O
) O
from O
day O
62 O
to O
day O
70 O
/ O
day O
90 O
of O
gestation O
altered O
male O
developmental O
trajectory O
. O

To O
examine O
the O
contribution O
of O
estrogens B
, O
fetuses O
were O
injected O
with O
TP O
( O
20 O
mg O
) O
, O
the O
potent O
estrogen B
agonist O
, O
diethylstilbestrol B
( O
DES B
; O
20 O
mg O
) O
, O
or O
vehicle O
control O
at O
day O
62 O
and O
day O
82 O
and O
assessed O
at O
day O
90 O
. O

The O
effects O
of O
fetal O
( O
direct O
) O
TP O
treatment O
, O
but O
not O
DES B
, O
paralleled O
maternal O
( O
indirect O
) O
TP O
exposure O
, O
supporting O
a O
direct O
androgen B
effect O
. O

Earlier O
maternal O
androgen B
exposure O
from O
day O
30 O
similarly O
influenced O
Leydig O
cell O
development O
at O
day O
90 O
but O
additionally O
affected O
the O
expression O
of O
Sertoli O
and O
germ O
cell O
markers O
. O

We O
show O
in O
this O
study O
that O
increased O
prenatal O
androgen O
exposure O
alters O
development O
and O
function O
of O
Leydig O
cells O
at O
a O
time O
when O
androgen B
production O
is O
paramount O
for O
male O
development O
. O

Budesonide B
/ O
cyclodextrin O
complex O
- O
loaded O
lyophilized O
microparticles O
for O
intranasal O
application O
. O

Abstract O
Objective O
: O
Lyophilized O
microparticles O
composed O
of O
budesonide B
( O
BDS O
) O
, O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
and O
hydroxypropylmethylc O
( O
HPMC O
) O
or O
sodium B
carboxymethylcellulo O
( O
CMC O
- O
Na B
) O
were O
developed O
for O
intranasal O
delivery O
and O
their O
characteristics O
were O
evaluated O
. O

Results O
and O
discussion O
: O
Lyophilized O
microparticles O
exhibited O
vanishment O
of O
crystallinity O
of O
drug O
in O
XRPD O
analysis O
, O
the O
enfeeblement O
of O
carbonyl B
( O
C B
= I
O I
) O
stretching O
bands O
of O
carboxyl B
group O
in O
BDS O
in O
FT O
- O
IR O
spectra O
and O
the O
disappearance O
of O
endothermic O
peak O
of O
drug O
in O
the O
results O
of O
DSC O
study O
. O

CD O
complexation O
enhanced O
drug O
solubility O
and O
release O
rate O
, O
and O
HPMC O
or O
CMC O
- O
Na B
also O
improved O
drug O
dissolution O
rates O
. O

Serotonin B
( O
5 B
- I
HT I
) O
in O
the O
Regulation O
of O
Depression O
- O
Related O
Emotionality O
: O
Insight O
from O
5 B
- I
HT I
Transporter O
and O
Tryptophan B
Hydroxylase O
- O
2 O
Knockout O
Mouse O
Models O
. O

Accumulating O
evidence O
suggests O
involvement O
of O
serotonin B
( O
5 B
- I
HT I
) O
in O
the O
regulation O
of O
emotion O
. O

Over O
the O
last O
decade O
, O
research O
on O
mice O
with O
a O
targeted O
inactivation O
of O
the O
5 B
- I
HT I
transporter O
( O
5 O
- O
Htt O
, O
Sert O
, O
Slc6a4 O
) O
has O
considerably O
advanced O
our O
knowledge O
about O
functions O
that O
the O
5 O
- O
HTT O
plays O
in O
the O
context O
of O
emotion O
related O
to O
depression O
. O

Moreover O
, O
the O
recent O
advent O
of O
knockout O
( O
KO O
) O
mice O
for O
tryptophan B
hydroxylase O
2 O
( O
Tph2 O
KO O
) O
, O
which O
lacks O
the O
rate O
- O
limiting O
enzyme O
for O
5 B
- I
HT I
synthesis O
in O
the O
brain O
, O
has O
further O
provided O
insight O
to O
the O
brain O
serotonergic O
system O
and O
its O
role O
in O
emotion O
dysregulation O
. O

Here O
, O
we O
first O
highlight O
basic O
characteristics O
of O
the O
serotonergic O
system O
including O
the O
biosynthesis O
of O
5 B
- I
HT I
as O
well O
as O
the O
anatomy O
and O
firing O
activity O
of O
serotonergic O
neurons O
. O

Controllable O
Hydrogen B
Sulfide I
Donors O
and O
Their O
Activity O
against O
Myocardial O
Ischemia O
- O
Reperfusion O
Injury O
. O

Hydrogen B
sulfide I
( O
H2S O
) O
, O
known O
as O
an O
important O
cellular O
signaling O
molecule O
, O
plays O
critical O
roles O
in O
many O
physiological O
and O
/ O
or O
pathological O
processes O
. O

H2S O
release O
mechanism O
from O
these O
donors O
was O
studied O
and O
proved O
to O
be O
thiol B
- O
dependent O
. O

Polycyclic O
Hybrid O
Isoprenoids B
from O
a O
Reed O
Rhizosphere O
Soil O
Derived O
Streptomyces O
sp O
. O

Two O
new O
hybrid O
isoprenoids B
, O
named O
indotertine O
B O
( O
2 O
) O
and O
drimentine O
H O
( O
3 O
) O
, O
along O
with O
the O
known O
analogue O
drimentine O
C O
( O
4 O
) O
, O
were O
isolated O
from O
the O
reed O
rhizosphere O
soil O
derived O
actinomycete O
Streptomyces O
sp O
. O

The O
results O
demonstrated O
the O
evolutionary O
importance O
of O
the O
fatty B
acid I
syntheses O
and O
the O
photosynthetic O
system O
in O
algae O
. O

A O
Coupling O
of O
Benzamides O
and O
Donor O
/ O
Acceptor O
Diazo O
Compounds O
To O
Form O
gamma O
- O
Lactams O
via O
Rh O
( O
III O
) O
- O
Catalyzed O
C B
- I
H I
Activation O
. O

Mechanistic O
experiments O
suggested O
that O
C B
- I
H I
activation O
is O
turnover O
- O
limiting O
and O
irreversible O
and O
that O
insertion O
of O
the O
diazo O
compound O
favors O
electron O
- O
deficient O
substrates O
. O

1 O
. O
Pazopanib O
( O
Votrient O
) O
is O
an O
oral O
tyrosine B
kinase O
inhibitor O
that O
was O
recently O
approved O
for O
the O
treatment O
of O
renal O
cell O
carcinoma O
and O
soft O
tissue O
sarcoma O
. O

Two O
metabolites O
derived O
from O
hydroxylation O
and O
one O
from O
N B
- O
demethylation O
were O
also O
circulating O
, O
but O
were O
minor O
, O
each O
accounting O
for O
< O
5 O
% O
of O
plasma O
radioactivity O
. O

Aqueous O
extract O
of O
Artemisia O
capillaris O
exerts O
hepatoprotective O
action O
in O
alcohol O
- O
pyrazole B
- O
fed O
rat O
model O
. O

MATERIALS O
AND O
METHODS O
: O
Liver O
injury O
was O
induced O
by O
oral O
administration O
of O
30 O
% O
alcohol O
( O
10mL O
/ O
kg O
, O
twice O
per O
day O
) O
plus O
pyrazole B
( O
PRZ O
, O
30mg O
/ O
kg O
) O
with O
/ O
without O
WAC O
( O
50 O
, O
100mg O
/ O
kg O
, O
orally O
once O
per O
day O
) O
or O
silymarin O
( O
50mg O
/ O
kg O
) O
for O
10 O
days O
. O

RESULTS O
: O
Alcohol O
- O
PRZ O
treatment O
drastically O
increased O
the O
serum O
levels O
of O
aspartate B
transaminase O
( O
AST O
) O
, O
alanine B
transaminase O
( O
ALT O
) O
, O
and O
malondialdehyde B
( O
MDA B
) O
levels O
in O
serum O
and O
liver O
tissues O
while O
these O
changes O
were O
significantly O
ameliorated O
by O
WAC O
administration O
( O
p O
< O
0 O
. O
05 O
or O
0 O
. O
01 O
) O
. O

Moreover O
, O
the O
alcohol O
- O
PRZ O
treatment O
- O
induced O
depletions O
of O
the O
antioxidant O
components O
including O
glutathione B
content O
, O
total O
antioxidant O
capacity O
( O
TAC O
) O
, O
activities O
of O
glutathione B
peroxidase O
( O
GSH O
- O
Px O
) O
, O
reductase O
( O
GSH O
- O
Rd O
) O
, O
catalase O
, O
and O
superoxide B
dismutase O
( O
SOD O
) O
were O
significantly O
ameliorated O
by O
WAC O
administration O
( O
p O
< O
0 O
. O
05 O
, O
except O
GSH O
- O
Rd O
) O
. O

In O
addition O
, O
WAC O
administration O
significantly O
attenuated O
the O
alterations O
of O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
level O
in O
serum O
and O
hepatic O
gene O
expressions O
of O
ALDH O
and O
alcohol O
dehydrogenase O
( O
ADH O
) O
. O

Novel O
quinolone B
substituted O
thiazolidin O
- O
4 O
- O
ones O
as O
anti O
- O
inflammatory O
, O
anticancer O
agents O
: O
Design O
, O
synthesis O
and O
biological O
screening O
. O

A O
library O
of O
quinolone B
substituted O
thiazolidin O
- O
4 O
- O
ones O
was O
docked O
into O
the O
active O
site O
of O
NF O
- O
kappa O
B O
and O
the O
top O
- O
ranked O
31 O
compounds O
were O
synthesized O
and O
evaluated O
for O
anti O
- O
inflammatory O
and O
anticancer O
activity O
. O

A O
central O
role O
for O
thiols B
in O
plant O
tolerance O
to O
abiotic O
stress O
. O

First O
, O
the O
roles O
of O
the O
amino O
acids O
cysteine B
and O
methionine B
, O
are O
discussed O
, O
followed O
by O
an O
extensive O
discussion O
of O
the O
low O
- O
molecular O
- O
weight O
tripeptide B
, O
thiol O
glutathione O
, O
which O
plays O
a O
central O
part O
in O
plant O
stress O
response O
and O
oxidative O
signalling O
and O
of O
glutathione B
- O
related O
enzymes O
, O
including O
those O
involved O
in O
the O
biosynthesis O
of O
non O
- O
protein O
thiol B
compounds O
. O

Special O
attention O
is O
given O
to O
the O
glutathione B
redox O
state O
, O
to O
phytochelatins O
and O
to O
the O
role O
of O
glutathione B
in O
the O
regulation O
of O
the O
cell O
cycle O
. O

The O
protein O
thiol B
section O
focuses O
on O
glutaredoxins O
and O
thioredoxins O
, O
proteins O
with O
oxidoreductase O
activity O
, O
which O
are O
involved O
in O
protein O
glutathionylation O
. O

The O
review O
concludes O
with O
a O
brief O
overview O
of O
and O
future O
perspectives O
for O
the O
involvement O
of O
plant O
thiols B
in O
abiotic O
stress O
tolerance O
. O

Effects O
of O
exogenous O
thiocyanate O
on O
mineral O
nutrients O
, O
antioxidative O
responses O
and O
free O
amino B
acids I
in O
rice O
seedlings O
. O

The O
effects O
of O
exogenous O
thiocyanate O
( O
SCN O
( O
- O
) O
) O
on O
amino B
acids I
composition O
, O
content O
of O
mineral O
nutrients O
and O
antioxidative O
systems O
in O
plants O
were O
investigated O
. O

Activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
, O
peroxidase O
( O
POD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
ascorbate B
peroxidase O
( O
APX O
) O
in O
plant O
materials O
were O
analyzed O
in O
vivo O
. O

Mineral O
nutrients O
and O
free O
amino B
acids I
in O
rice O
seedlings O
were O
also O
measured O
to O
determine O
metabolic O
responses O
to O
SCN O
( O
- O
) O
exposure O
. O

A O
significant O
reduction O
in O
transpiration O
and O
relative O
growth O
was O
recorded O
with O
all O
treatments O
( O
p O
< O
0 O
. O
05 O
) O
, O
while O
changes O
of O
total O
chlorophyll B
content O
in O
leaves O
was O
negligible O
( O
p O
> O
0 O
. O
05 O
) O
. O

Although O
the O
change O
of O
total O
free O
amino B
acids I
in O
shoots O
of O
SCN O
- O
exposed O
seedlings O
was O
negligible O
( O
p O
> O
0 O
. O
05 O
) O
, O
responses O
of O
different O
amino B
acids I
to O
SCN O
( O
- O
) O
application O
were O
quite O
different O
. O

Among O
fifteen O
free O
amino B
acids I
detected O
, O
serine B
( O
Ser B
) O
, O
proline B
( O
Pro B
) O
, O
and O
methionine B
( O
Met B
) O
increased O
, O
while O
asparagine B
( O
Asp B
) O
decreased O
with O
an O
increase O
of O
the O
doses O
of O
SCN O
( O
- O
) O
supplied O
. O

Recently O
, O
Chinese O
researchers O
have O
discovered O
that O
two O
anthraquinones B
isolated O
from O
a O
water O
extract O
of O
H O
. O
diffusa O
Willd O
showed O
apoptosis O
- O
inducing O
effects O
against O
cancer O
cells O
. O

Furthermore O
, O
PD98059 B
( O
ERK1 O
/ O
2 O
inhibitor O
) O
significantly O
enhanced O
2 O
- O
hydroxy O
- O
3 O
- O
methylanthraquinone O
- O
induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase O
- O
3 O
inhibitor O
or O
SB203580 B
( O
p O
- O
p38MAPK O
inhibitor O
) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O

Curcumin B
is O
a O
biologically O
active O
component O
of O
curry O
powder O
. O

IC50 O
values O
for O
an O
expanded O
set O
of O
curcumin B
analogues O
established O
a O
rank O
order O
of O
potencies O
, O
and O
analyses O
of O
IKK O
beta O
and O
AKT2 O
enzyme O
kinetics O
for O
4 O
revealed O
a O
mixed O
inhibition O
model O
, O
ATP B
competition O
dominating O
. O

Our O
curcumin B
mimetics O
are O
generally O
selective O
for O
Ser B
/ O
Thr B
kinases O
. O

Cytotoxic O
, O
Antitopoisomerase O
II O
alpha O
, O
and O
Anti O
- O
HIV O
- O
1 O
Activities O
of O
Triterpenoids B
Isolated O
from O
Leaves O
and O
Twigs O
of O
Gardenia O
carinata O
. O

A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7 O
- O
hydroxy O
- O
4 O
- O
trifluoromethylcouma O
by O
recombinant O
human O
UDP B
- O
glucuronosyltransfer O
and O
liver O
microsomes O
. O

Abstract O
1 O
. O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O

UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP B
- O
glucuronic B
acid I
than O
the O
other O
UGTs O
. O

The O
aqueous O
phase O
contains O
alkali O
- O
metal O
chlorides O
, O
including O
LiCl B
, O
NaCl B
, O
RbCl O
, O
or O
CsCl O
, O
and O
the O
organic O
phase O
is O
a O
1 O
, O
2 O
- O
dichloroethane O
solution O
of O
bis O
( O
triphenylphosphor O
anylidene O
) O
ammonium O
tetrakis O
( O
pentafluorophenyl O
) O
borate O
( O
BTPPATPFB O
) O
. O

Selected O
data O
for O
a O
subset O
of O
electric O
potential O
differences O
are O
analyzed O
to O
determine O
the O
potentials O
of O
mean O
force O
for O
Li B
( I
+ I
) I
, O
Rb B
( I
+ I
) I
, O
Cs B
( I
+ I
) I
, O
BTPPA O
( O
+ O
) O
, O
and O
TPFB O
( O
- O
) O
. O

Comparison O
of O
X O
- O
ray O
reflectivity O
data O
for O
strongly O
hydrated O
alkali O
- O
metal O
ions O
( O
Li B
( I
+ I
) I
and O
Na B
( I
+ I
) I
) O
, O
for O
which O
ion O
pairing O
to O
TPFB O
( O
- O
) O
ions O
across O
the O
interface O
is O
not O
expected O
, O
to O
data O
for O
weakly O
hydrated O
alkali O
- O
metal O
ions O
( O
Rb B
( I
+ I
) I
and O
Cs B
( I
+ I
) I
) O
indicates O
that O
the O
Gibbs O
energy O
of O
adsorption O
due O
to O
ion O
pairing O
at O
the O
interface O
must O
be O
small O
( O
< O
1 O
kBT O
per O
ion O
pair O
) O
for O
both O
the O
CsCl O
and O
RbCl O
samples O
. O

Here O
we O
demonstrate O
that O
the O
boron O
nitride O
nanomesh O
, O
a O
corrugated O
single O
layer O
of O
hexagonal O
boron O
nitride O
( O
h O
- O
BN O
) O
with O
a O
3 O
. O
2 O
nm O
honeycomb O
superstructure O
formed O
on O
a O
Rh O
( O
111 O
) O
surface O
, O
can O
trap O
individual O
argon B
atoms O
at O
distinct O
subsurface O
sites O
at O
room O
temperature O
. O

A O
kinetic O
energy O
window O
for O
implantation O
is O
identified O
where O
the O
argon B
ions O
can O
penetrate O
the O
h O
- O
BN O
layer O
but O
not O
enter O
the O
Rh B
lattice O
. O

Scanning O
tunneling O
microscopy O
and O
photoemission O
data O
show O
the O
presence O
of O
argon B
atoms O
at O
two O
distinct O
sites O
within O
the O
nanomesh O
unit O
cell O
, O
confirmed O
also O
by O
density O
functional O
theory O
calculations O
. O

We O
explain O
this O
" O
can O
- O
opener O
" O
effect O
by O
the O
presence O
of O
a O
vacancy O
defect O
, O
generated O
during O
the O
penetration O
of O
the O
Ar B
ion O
through O
the O
h O
- O
BN O
lattice O
, O
and O
propagating O
along O
the O
rim O
of O
a O
nanomesh O
pore O
where O
the O
h O
- O
BN O
lattice O
is O
highly O
bent O
. O

The O
reported O
effects O
are O
also O
observed O
in O
graphene B
on O
ruthenium B
and O
for O
neon O
atoms O
. O

Low O
- O
Dose O
Dexamethasone B
Treatment O
Promotes O
Pro O
- O
Survival O
Signalling O
Pathway O
In O
Adult O
Rat O
Prefrontal O
Cortex O
. O

Synthetic O
glucocorticoid O
dexamethasone B
( O
DEX B
) O
, O
a O
highly O
potent O
anti O
- O
inflammatory O
and O
immunosuppressive O
agent O
, O
is O
widely O
used O
in O
treatments O
of O
brain O
cancer O
, O
inflammatory O
and O
autoimmune O
diseases O
. O

The O
objective O
of O
the O
current O
study O
was O
to O
determine O
whether O
a O
low O
- O
dose O
subchronic O
DEX B
treatment O
( O
100 O
mu O
g O
/ O
kg O
for O
8 O
consecutive O
days O
) O
exerts O
long O
- O
term O
effects O
on O
apoptosis O
in O
the O
adult O
rat O
prefrontal O
cortex O
( O
PFC O
) O
by O
examining O
the O
expression O
of O
cell O
death O
- O
promoting O
molecules O
( O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax O
) O
and O
cell O
- O
survival O
molecules O
( O
AKT O
, O
Bcl O
- O
2 O
) O
. O

Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone B
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX B
injection O
. O

In O
PFC O
, O
DEX B
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro O
- O
survival O
Bcl O
- O
2 O
protein O
and O
enhanced O
Bcl O
- O
2 O
/ O
Bax O
protein O
ratio O
, O
as O
well O
Bcl O
- O
2 O
translocation O
to O
mitochondria O
. O

Results O
of O
RT O
- O
PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl O
- O
2 O
and O
Bax O
mRNA O
expressions O
in O
DEX B
- O
treated O
rats O
. O

Our O
findings O
support O
the O
concept O
that O
a O
low O
- O
dose O
DEX B
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX B
treatment O
activates O
pro O
- O
survival O
signalling O
pathway O
but O
does O
not O
change O
apoptotic O
markers O
in O
rat O
PFC O
. O

This O
mechanism O
might O
be O
relevant O
for O
DEX B
- O
induced O
apoptosis O
resistance O
observed O
during O
and O
after O
chemotherapy O
of O
patients O
with O
brain O
tumours O
. O

Histological O
, O
ultrastructural O
and O
immunohistochemical O
studies O
on O
the O
protective O
effect O
of O
ginger O
extract O
against O
cisplatin B
- O
induced O
nephrotoxicity O
in O
male O
rats O
. O

Cisplatin B
( O
CP O
) O
is O
a O
widely O
used O
anticancer O
drug O
; O
however O
, O
it O
has O
several O
side O
effects O
such O
as O
nephrotoxicity O
. O

CP O
group O
displayed O
a O
marked O
renal O
failure O
characterized O
by O
a O
significant O
increase O
in O
serum O
creatinine B
and O
blood O
urea B
nitrogen B
( O
BUN O
) O
levels O
in O
addition O
to O
severe O
histopathological O
and O
ultrastructural O
renal O
alterations O
. O

In O
contrast O
, O
GE O
+ O
CP O
group O
showed O
significant O
decrease O
in O
the O
elevated O
serum O
creatinine B
and O
BUN O
levels O
and O
an O
improvement O
in O
the O
histopathological O
and O
ultrastructural O
renal O
injury O
induced O
by O
CP O
. O

Of O
the O
tested O
extracts O
, O
the O
ethyl B
acetate I
fraction O
was O
the O
most O
potent O
( O
half O
- O
maximal O
inhibitory O
concentration O
( O
IC50 O
) O
: O
97 O
micro O
g O
/ O
mL O
) O
followed O
by O
aqueous O
fraction O
IC50 O
: O
109 O
micro O
g O
/ O
mL O
) O
. O

Regarding O
urease O
inhibition O
, O
n B
- I
butanol I
was O
the O
most O
potent O
fraction O
( O
IC50 O
: O
97 O
micro O
g O
/ O
mL O
) O
. O

In O
the O
preliminary O
phytochemical O
tests O
, O
the O
aerial O
parts O
of O
the O
plant O
showed O
the O
presence O
of O
saponins B
, O
alkaloids O
, O
flavonoids B
, O
phenols B
, O
tannins B
and O
terpenoids B
. O

In O
kidney O
tissue O
, O
the O
concentration O
differences O
of O
calcium B
, O
sodium B
, O
and O
zinc B
( O
Zn B
) O
were O
found O
between O
diesel O
and O
biodiesel O
groups O
. O

In O
lung O
tissue O
, O
the O
concentration O
differences O
of O
cadmium B
, O
lithium B
, O
magnesium B
, O
manganese B
, O
and O
Zn B
were O
found O
between O
diesel O
and O
biodiesel O
groups O
. O

Among O
the O
significant O
findings O
, O
Zn B
concentration O
in O
serum O
and O
liver O
tissue O
of O
diesel O
and O
biodiesel O
were O
different O
from O
control O
( O
p O
< O
0 O
. O
05 O
) O
. O

S96 O
group O
) O
, O
or O
0 O
. O
9 O
% O
sodium B
chloride I
( O
control O
group O
) O
. O

Synthesis O
and O
characterization O
of O
naphthalenediimide O
- O
functionalized O
flavin B
derivatives O
. O

Two O
acceptor O
- O
acceptor O
dyads O
have O
been O
synthesized O
featuring O
a O
flavin B
moiety O
and O
a O
naphthalenediimide O
( O
NDI O
) O
unit O
. O

The O
NDI O
unit O
is O
linked O
to O
the O
flavin B
through O
a O
short O
spacer O
group O
via O
either O
the O
N O
( O
3 O
) O
or O
N O
( O
10 O
) O
positions O
of O
the O
flavin B
. O

Fluorescence O
spectroscopy O
measurements O
have O
revealed O
that O
their O
emission O
properties O
are O
dominated O
by O
the O
flavin B
unit O
. O

The O
vibrational O
( O
hyper O
) O
polarizabilities O
of O
some O
selected O
Xe B
derivatives O
are O
studied O
in O
the O
context O
of O
Bishop O
- O
Kirtman O
perturbation O
theory O
( O
BKPT O
) O
and O
numerical O
finite O
field O
methodology O
. O

A O
limited O
study O
of O
the O
effect O
of O
Xe B
insertion O
to O
the O
nr O
vibrational O
properties O
is O
also O
reported O
. O

Assessment O
of O
the O
results O
revealed O
that O
Xe B
insertion O
has O
a O
remarkable O
effect O
on O
the O
nr O
( O
hyper O
) O
polarizabilities O
. O

Once O
- O
weekly O
exenatide O
, O
an O
extended O
- O
duration O
glucagon O
- O
like O
peptide O
- O
1 O
( O
GLP O
- O
1 O
) O
agonist O
, O
provides O
an O
option O
for O
patients O
to O
take O
a O
drug O
weekly O
, O
with O
pharmacotherapeutic O
effects O
that O
are O
superior O
to O
twice O
- O
daily O
exenatide O
and O
sitagliptin B
and O
comparable O
to O
insulin O
glargine O
. O

Specific O
antiretrovirals O
such O
as O
tenofovir B
may O
cause O
a O
greater O
loss O
of O
bone O
mineral O
density O
compared O
with O
other O
agents O
and O
have O
recently O
been O
linked O
to O
an O
increased O
risk O
for O
fracture O
. O

As O
a O
result O
, O
recent O
treatment O
guidelines O
suggest O
that O
clinicians O
consider O
avoiding O
tenofovir B
as O
initial O
therapy O
in O
postmenopausal O
women O
. O

Evaluating O
bone O
mineral O
density O
and O
vitamin B
D I
status O
in O
persons O
with O
HIV O
may O
be O
important O
steps O
in O
identifying O
those O
requiring O
pharmacotherapy O
; O
however O
, O
the O
appropriate O
timing O
for O
bone O
mineral O
density O
and O
vitamin B
D I
screening O
is O
uncertain O
, O
as O
is O
the O
appropriate O
method O
of O
replacing O
vitamin B
D I
in O
HIV O
- O
positive O
patients O
who O
are O
deficient O
. O

Further O
study O
is O
necessary O
to O
definitively O
determine O
the O
approach O
to O
evaluating O
bone O
health O
and O
managing O
low O
bone O
mineral O
density O
and O
vitamin B
D I
deficiency O
in O
patients O
with O
HIV O
infection O
. O

Package O
- O
Free O
Flexible O
Organic O
Solar O
Cells O
with O
Graphene B
top O
Electrodes O
. O

Package O
- O
free O
flexible O
organic O
solar O
cells O
were O
fabricated O
with O
multilayer O
graphene B
as O
top O
transparent O
electrodes O
, O
which O
show O
the O
highest O
power O
conversion O
efficiency O
of O
about O
3 O
. O
2 O
% O
and O
excellent O
flexibility O
and O
bending O
stability O
. O

The O
devices O
also O
show O
good O
air O
stability O
, O
indicating O
that O
multilayer O
graphene B
is O
a O
promising O
environmental O
barrier O
that O
can O
protect O
the O
organic O
solar O
cells O
from O
air O
contamination O
. O

Importantly O
, O
this O
bone O
loss O
was O
not O
associated O
with O
reduced O
locomotor O
activity O
or O
metabolic O
abnormalities O
, O
was O
accompanied O
with O
molecular O
signs O
of O
increased O
sympathetic O
outflow O
, O
and O
could O
be O
prevented O
by O
the O
beta O
- O
blocker O
propranolol B
. O

The O
Glucuronidation O
of O
R O
- O
and O
S O
- O
Lorazepam O
: O
Human O
Liver O
Microsomal O
Kinetics O
, O
UDP B
- O
Glucuronosyltransfer O
Enzyme O
Selectivity O
, O
and O
Inhibition O
by O
Drugs O
. O

The O
widely O
used O
hypnosedative O
- O
anxiolytic O
agent O
R O
, O
S O
- O
lorazepam O
is O
cleared O
predominantly O
by O
conjugation O
with O
glucuronic B
acid I
in O
humans O
, O
but O
the O
enantioselective O
glucuronidation O
of O
lorazepam B
has O
received O
little O
attention O
. O

The O
present O
study O
characterized O
the O
kinetics O
of O
the O
separate O
R O
- O
and O
S O
- O
enantiomers O
of O
lorazepam B
by O
human O
liver O
microsomes O
( O
HLM O
) O
and O
by O
a O
panel O
of O
recombinant O
human O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
enzymes O
. O

However O
, O
the O
possible O
contribution O
of O
other O
enzymes O
and O
the O
low O
activities O
observed O
in O
vitro O
indicate O
that O
the O
lorazepam B
enantiomers O
are O
of O
limited O
use O
as O
substrate O
probes O
for O
UGT2B15 O
. O

In O
order O
to O
identify O
potential O
drug O
- O
drug O
interactions O
, O
codeine O
, O
fluconazole B
, O
ketamine B
, O
ketoconazole B
, O
methadone O
, O
morphine B
, O
valproic B
acid I
, O
and O
zidovudine B
were O
screened O
as O
inhibitors O
of O
R O
- O
and O
S O
- O
lorazepam O
glucuronidation O
by O
HLM O
. O

Of O
these O
drugs O
, O
in O
vitro O
- O
in O
vivo O
extrapolation O
suggested O
that O
only O
ketoconazole B
had O
the O
potential O
to O
inhibit O
lorazepam B
clearance O
to O
a O
clinically O
significant O
extent O
. O

A O
liquid O
chromatography O
/ O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
to O
determine O
concentrations O
of O
posaconazole O
in O
human O
plasma O
precipitated O
by O
acetonitrile B
including O
internal O
standard O
. O

Rapid O
chromatographic O
separation O
was O
achieved O
in O
the O
mobile O
phase O
composition O
of O
acetonitrile B
, O
water O
and O
formic B
acid I
( O
v O
/ O
v O
/ O
v O
, O
55 O
: O
45 O
: O
0 O
. O
1 O
) O
with O
a O
flow O
rate O
of O
0 O
. O
25 O
ml O
/ O
min O
. O

Interspecies O
difference O
of O
luteolin B
and O
apigenin B
after O
oral O
administration O
of O
Chrysanthemum O
morifolium O
extract O
and O
prediction O
of O
human O
pharmacokinetics O
. O

The O
aims O
of O
the O
present O
study O
were O
to O
study O
the O
interspecies O
difference O
in O
the O
pharmacokinetics O
of O
luteolin B
and O
apigenin B
occurring O
in O
Chrysanthemum O
morifolium O
extract O
( O
CME O
) O
among O
rats O
, O
beagle O
dogs O
, O
mini O
- O
pigs O
, O
and O
humans O
, O
and O
compared O
the O
human O
pharmacokinetic O
parameters O
with O
the O
data O
predicted O
from O
the O
above O
three O
animals O
. O

The O
plasma O
concentrations O
of O
luteolin B
and O
apigenin B
were O
determined O
with O
a O
RP O
- O
HPLC O
method O
. O

An O
interspecies O
difference O
of O
pharmacokinetics O
was O
found O
, O
especially O
between O
rats O
and O
other O
species O
, O
the O
plasma O
concentration O
of O
luteolin B
was O
much O
lower O
than O
that O
of O
apigenin B
in O
rats O
, O
although O
the O
content O
of O
luteolin B
in O
CME O
was O
higherthan O
that O
of O
apigenin B
, O
whereas O
the O
plasma O
concentration O
of O
luteolin B
was O
much O
higher O
than O
that O
of O
apigenin B
in O
dogs O
, O
mini O
- O
pigs O
and O
humans O
. O

Animal O
scale O
- O
up O
of O
some O
pharmacokinetic O
parameters O
of O
luteolin B
and O
apigenin B
were O
also O
performed O
after O
rats O
, O
beagle O
dogs O
, O
mini O
- O
pigs O
and O
humans O
were O
orally O
given O
CME O
at O
dosages O
of O
400 O
mg O
/ O
kg O
, O
102 O
mg O
/ O
kg O
, O
90 O
mg O
/ O
kg O
, O
and O
20 O
mg O
/ O
kg O
, O
respectively O
. O

The O
corresponding O
allometric O
equations O
were O
MRT O
= O
9 O
. O
382W O
( O
0 O
. O
1711 O
) O
( O
R2 O
= O
0 O
. O
9999 O
) O
and O
t1 O
/ O
2 O
= O
4 O
. O
811W O
( O
0 O
. O
1093 O
) O
( O
R2 O
= O
0 O
. O
9013 O
) O
for O
luteolin B
, O
MRT O
= O
12 O
. O
53W O
( O
0 O
. O
0356 O
) O
( O
R2 O
= O
0 O
. O
9980 O
) O
and O
t1 O
/ O
2 O
= O
7 O
. O
940W O
( O
0 O
. O
0294 O
) O
( O
R2 O
= O
0 O
. O
9258 O
) O
for O
apigenin B
, O
respectively O
. O

The O
predicted O
human O
pharmacokinetic O
parameters O
( O
MRT O
and O
t1 O
/ O
2 O
) O
by O
an O
allometric O
approach O
were O
18 O
. O
6 O
h O
and O
7 O
. O
46 O
h O
for O
luteolin B
, O
14 O
. O
3 O
h O
and O
8 O
. O
95 O
h O
for O
apigenin B
, O
respectively O
, O
which O
were O
close O
to O
the O
values O
obtained O
from O
humans O
( O
20 O
mg O
CME O
/ O
kg O
) O
in O
the O
present O
study O
. O

The O
study O
has O
demonstrated O
the O
possibility O
to O
extrapolate O
the O
pharmacokinetic O
behavior O
of O
flavonoids B
from O
animals O
to O
humans O
. O

Interactions O
of O
PAMAM B
Dendrimers O
with O
SDS B
at O
the O
Solid O
- O
Liquid O
Interface O
. O

This O
work O
addresses O
structural O
and O
nonequilibrium O
effects O
of O
the O
interactions O
between O
well O
- O
defined O
cationic O
poly B
( I
amidoamine I
) I
PAMAM B
dendrimers O
of O
generations O
4 O
and O
8 O
and O
the O
anionic O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
at O
the O
hydrophilic O
silica B
- O
water O
interface O
. O

PAMAM B
dendrimers O
of O
both O
generations O
adsorb O
to O
hydrophilic O
silica B
as O
a O
compact O
monolayer O
, O
and O
the O
adsorption O
is O
irreversible O
upon O
rinsing O
with O
salt O
solution O
. O

SDS B
adsorbs O
on O
the O
dendrimer O
layer O
and O
at O
low O
bulk O
concentrations O
causes O
the O
expansion O
of O
the O
dendrimer O
layers O
on O
the O
surface O
. O

When O
the O
bulk O
concentration O
of O
SDS B
is O
increased O
, O
the O
surfactant O
layer O
consists O
of O
aggregates O
or O
bilayer O
- O
like O
structures O
. O

The O
adsorption O
of O
surfactant O
is O
reversible O
upon O
rinsing O
, O
but O
slight O
changes O
of O
the O
structure O
of O
the O
preadsorbed O
PAMAM B
monolayer O
were O
observed O
. O

A O
critical O
examination O
of O
the O
pathway O
of O
adsorption O
for O
the O
interactions O
of O
SDS B
with O
preadsorbed O
PAMAM B
monolayers O
and O
premixed O
PAMAM B
/ O
SDS B
solutions O
with O
hydrophilic O
silica B
revealed O
that O
nonequilibrium O
effects O
are O
important O
only O
in O
the O
latter O
case O
, O
and O
the O
application O
of O
a O
thermodynamic O
model O
to O
such O
experimental O
data O
would O
be O
inappropriate O
. O

The O
following O
surfactants O
were O
used O
in O
the O
experiments O
: O
cationic O
dodecyltrimethylammo O
bromide O
( O
DTAB O
) O
, O
anionic O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
anionic O
Pantene O
shampoo O
which O
primarily O
contains O
sodium B
lauryl I
sulfate I
, O
nonionic O
tetraethylene O
glycol O
monooctyl O
ether O
( O
C8E4 O
) O
, O
and O
nonionic O
Pluronic O
( O
P O
- O
123 O
) O
surfactants O
at O
different O
concentrations O
. O

Chemical O
force O
microscopy O
performed O
with O
atomic O
force O
microscope O
tips O
decorated O
with O
functional O
groups O
commonly O
found O
in O
urinary O
constituents O
that O
likely O
mediate O
aggregation O
and O
attachment O
( O
e O
. O
g O
. O
, O
COOH B
, O
NH2 B
, O
SH B
, O
CH3 B
, O
OH B
) O
revealed O
signatures O
that O
reflect O
differences O
in O
the O
chemical O
affinity O
of O
these O
groups O
for O
the O
( O
001 O
) O
and O
{ O
100 O
} O
faces O
of O
the O
naturally O
occurring O
hexagonal O
form O
of O
l O
- O
cystine O
single O
crystals O
and O
the O
{ O
110 O
} O
faces O
of O
the O
non O
- O
native O
tetragonal O
form O
. O

These O
signatures O
can O
be O
explained O
by O
the O
different O
chemical O
compositions O
of O
the O
crystal O
faces O
, O
and O
they O
reveal O
a O
remarkable O
binding O
specificity O
of O
the O
thiol O
group O
for O
the O
sulfur B
- O
rich O
{ O
100 O
} O
and O
{ O
110 O
} O
faces O
of O
the O
hexagonal O
and O
tetragonal O
forms O
, O
respectively O
. O

Global O
gene O
expression O
analysis O
reveals O
pathway O
differences O
between O
teratogenic O
and O
non O
- O
teratogenic O
exposure O
concentrations O
of O
bisphenol B
A I
and O
17 B
beta I
- I
estradiol I
in O
embryonic O
zebrafish O
. O

Transient O
developmental O
exposure O
to O
0 O
. O
1 O
mu O
M O
bisphenol B
A I
( O
BPA B
) O
results O
in O
larval O
zebrafish O
hyperactivity O
and O
learning O
impairments O
in O
the O
adult O
, O
while O
exposure O
to O
80 O
mu O
M O
BPA B
results O
in O
teratogenic O
responses O
, O
including O
craniofacial O
abnormalities O
and O
edema O
. O

We O
used O
global O
gene O
expression O
analysis O
to O
identify O
candidate O
genes O
and O
signaling O
pathways O
that O
mediate O
BPA B
' O
s O
developmental O
toxicity O
in O
zebrafish O
. O

Exposure O
concentrations O
were O
selected O
and O
anchored O
to O
the O
positive O
control O
, O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
, O
based O
on O
previously O
determined O
behavioral O
or O
teratogenic O
phenotypes O
. O

Functional O
analysis O
of O
differentially O
expressed O
genes O
revealed O
distinct O
expression O
profiles O
at O
24h O
post O
fertilization O
for O
0 O
. O
1 O
mu O
M O
versus O
80 O
mu O
M O
BPA B
and O
0 O
. O
1 O
mu O
M O
versus O
15 O
mu O
M O
E2 O
exposure O
, O
identification O
of O
prothrombin O
activation O
as O
a O
top O
canonical O
pathway O
impacted O
by O
both O
0 O
. O
1 O
mu O
M O
BPA B
and O
0 O
. O
1 O
mu O
M O
E2 O
exposure O
, O
and O
suppressed O
expression O
of O
several O
genes O
involved O
in O
nervous O
system O
development O
and O
function O
following O
0 O
. O
1 O
mu O
M O
BPA B
exposure O
. O

Environmental O
pesticide O
exposure O
modulates O
cytokines O
, O
arginase O
and O
ornithine B
decarboxylase O
expression O
in O
human O
placenta O
. O

To O
evaluate O
the O
cytokine O
balance O
and O
enzymatic O
alterations O
induced O
by O
environmental O
pesticide O
exposure O
during O
pregnancy O
, O
this O
transversal O
study O
explored O
placentas O
derived O
from O
non O
- O
exposed O
women O
( O
control O
group O
- O
CG O
) O
, O
and O
from O
women O
living O
in O
a O
rural O
area O
( O
rural O
group O
- O
RG O
) O
, O
collected O
during O
intensive O
organophosphate B
( O
OP O
) O
pesticide O
spraying O
season O
( O
RG O
- O
SS O
) O
and O
during O
non O
- O
spraying O
season O
( O
RG O
- O
NSS O
) O
. O

Arginase O
and O
ornithine B
decarboxylase O
( O
ODC O
) O
enzymes O
were O
induced O
in O
syncytiotrophoblast O
and O
endothelial O
cells O
. O

Deflazacort O
( O
DFZ O
) O
, O
a O
derivate O
of O
prednisolone B
, O
is O
a O
poorly O
soluble O
drug O
which O
has O
been O
proposed O
to O
have O
major O
advantages O
over O
other O
corticosteroids B
. O

In O
this O
study O
, O
DFZ O
was O
investigated O
in O
terms O
of O
its O
antisolvent O
crystallization O
in O
different O
solvents O
and O
under O
various O
preparation O
conditions O
( O
methanol B
/ O
water O
ratio O
, O
stirring O
and O
evaporation O
rate O
, O
etc O
. O
) O
, O
in O
order O
to O
compare O
the O
physicochemical O
properties O
between O
crystallized O
samples O
and O
raw O
materials O
available O
on O
the O
Brazilian O
market O
with O
and O
without O
micronization O
. O

Trichostatin B
A I
protects O
against O
cisplatin B
- O
induced O
ototoxicity O
by O
regulating O
expression O
of O
genes O
related O
to O
apoptosis O
and O
synaptic O
function O
. O

OBJECTIVE O
: O
Although O
inhibition O
of O
histone O
deacetylases O
( O
HDACs O
) O
has O
been O
shown O
to O
protect O
against O
cisplatin B
- O
induced O
hearing O
loss O
, O
the O
underlying O
mechanism O
is O
still O
poorly O
understood O
. O

In O
the O
present O
study O
, O
we O
aim O
to O
investigate O
the O
protective O
effect O
of O
trichostatin B
A I
( O
TSA B
) O
, O
a O
specific O
inhibitor O
of O
HDACs O
, O
on O
cisplatin B
- O
induced O
ototoxicity O
and O
to O
determine O
the O
differentially O
expressed O
genes O
involved O
in O
this O
process O
. O

Organotypic O
cultures O
were O
treated O
with O
150 O
mu O
M O
cisplatin B
or O
200nM O
TSA B
. O

For O
combination O
treatment O
, O
cells O
were O
pre O
- O
incubated O
with O
TSA B
for O
1h O
, O
followed O
by O
TSA B
plus O
cisplatin B
treatment O
. O

Rhodamine B
- O
phalloidin B
staining O
was O
used O
to O
label O
hair O
cells O
, O
and O
immunocytochemistry O
with O
an O
anti O
- O
neurofilament O
- O
200 O
antibody O
was O
applied O
to O
label O
spiral O
ganglion O
neurons O
( O
SGNs O
) O
. O

RESULTS O
: O
Severe O
loss O
of O
hair O
cells O
and O
SGNs O
occurred O
after O
48h O
of O
cisplatin B
incubation O
, O
while O
TSA B
significantly O
increased O
the O
number O
of O
hair O
cells O
and O
SGNs O
in O
the O
combination O
treatment O
group O
( O
P O
< O
0 O
. O
05 O
) O
. O

Compared O
with O
control O
, O
expression O
of O
71 O
genes O
were O
up O
- O
regulated O
and O
383 O
genes O
were O
down O
- O
regulated O
upon O
cisplatin B
treatment O
. O

Addition O
of O
TSA B
induced O
the O
up O
- O
regulation O
of O
1387 O
genes O
and O
down O
- O
regulation O
of O
1226 O
genes O
as O
compared O
with O
cisplatin B
administration O
alone O
. O

After O
cisplatin B
treatment O
, O
we O
observed O
significant O
down O
- O
regulation O
of O
mRNA O
for O
several O
genes O
related O
to O
synaptic O
function O
genes O
, O
including O
Camk2a O
, O
Camk2b O
, O
Vglut1 O
, O
Snap25 O
and O
Rab3b O
, O
whereas O
pretreatment O
with O
TSA B
elevated O
mRNA O
levels O
of O
these O
genes O
. O

TSA B
greatly O
decreased O
expression O
of O
genes O
related O
to O
the O
calcium B
signaling O
pathway O
( O
Capn1 O
and O
Capn2 O
) O
and O
apoptosis O
signaling O
pathway O
( O
Tnfrsf1a O
and O
Tp53 O
) O
, O
while O
addition O
of O
TSA B
significantly O
reduced O
levels O
of O
Tnfrsf1a O
and O
Tp53 O
compared O
with O
cisplatin B
alone O
( O
P O
< O
0 O
. O
01 O
) O
. O

CONCLUSIONS O
: O
Our O
results O
suggested O
that O
TSA B
might O
protect O
against O
cisplatin B
- O
induced O
ototoxicity O
via O
mediating O
expression O
of O
genes O
responsible O
for O
regulating O
apoptosis O
, O
intracellular O
calcium B
homeostasis O
, O
neurotransmitter O
synthesis O
and O
release O
, O
and O
synaptic O
plasticity O
. O

A O
novel O
series O
of O
histamine B
H4 O
receptor O
antagonists O
based O
on O
the O
pyrido O
[ O
3 O
, O
2 O
- O
d O
] O
pyrimidine O
scaffold O
: O
Comparison O
of O
hERG O
binding O
and O
target O
residence O
time O
with O
PF O
- O
3893787 O
. O

In O
this O
work O
we O
describe O
the O
optimization O
of O
a O
lead O
compound O
based O
on O
the O
quinazoline B
template O
to O
give O
a O
new O
series O
of O
potent O
pyrido O
[ O
3 O
, O
2 O
- O
d O
] O
pyrimidines O
as O
histamine B
H4 O
receptor O
antagonists O
. O

The O
pyrido O
[ O
3 O
, O
2 O
- O
d O
] O
pyrimidine O
ligands O
have O
significantly O
reduced O
hERG O
binding O
compared O
to O
clinical O
stage O
compound O
PF O
- O
3893787 O
while O
showing O
good O
affinities O
at O
the O
human O
and O
rodent O
histamine B
receptors O
. O

Rat O
liver O
epithelial O
cells O
( O
WB O
- O
F344 O
) O
were O
stained O
with O
the O
fluorescent O
dye O
Calcein B
AM I
( O
acetoxymethyl O
) O
and O
exposed O
to O
TPM O
from O
the O
Kentucky O
Reference O
Cigarette O
2R4F O
( O
a O
blend O
of O
Bright O
and O
Burley O
tobaccos O
) O
and O
from O
two O
single O
- O
tobacco O
cigarettes O
( O
Bright O
and O
Burley O
) O
for O
3h O
. O

Phorbol B
- I
12 I
- I
myristate I
- I
13 I
- I
acetate I
( O
TPA B
) O
was O
used O
as O
positive O
control O
and O
0 O
. O
5 O
% O
dimethyl B
sulfoxide I
( O
DMSO B
) O
as O
solvent O
control O
. O

The O
half O
- O
maximal O
effective O
concentration O
values O
were O
0 O
. O
34ng O
/ O
ml O
for O
TPA B
, O
0 O
. O
050mg O
/ O
ml O
for O
the O
2R4F O
, O
0 O
. O
044mg O
/ O
ml O
for O
the O
Bright O
cigarette O
, O
and O
0 O
. O
060mg O
/ O
ml O
for O
the O
Burley O
cigarette O
. O

Vinclozolin B
: O
A O
case O
study O
on O
the O
identification O
of O
endocrine O
active O
substances O
in O
the O
past O
and O
a O
future O
perspective O
. O

In O
the O
late O
1980s O
vinclozolin B
was O
tested O
for O
prenatal O
developmental O
toxicity O
in O
rats O
for O
registration O
purposes O
in O
USA O
. O

AA O
effects O
of O
vinclozolin B
are O
mediated O
by O
two O
metabolites O
, O
which O
have O
an O
antagonistic O
effect O
on O
the O
androgen O
receptor O
. O

Steroid O
synthesis O
in O
H295R O
cells O
( O
1 O
) O
, O
androgen B
- O
receptor O
binding O
in O
modified O
yeast O
( O
2 O
) O
and O
metabolomics O
( O
3 O
) O
. O

Using O
vinclozolin B
as O
a O
case O
study O
, O
results O
indicate O
: O
( O
1 O
) O
an O
effect O
on O
steroid B
synthesis O
in O
vitro O
, O
( O
2 O
) O
an O
antagonistic O
effect O
on O
the O
androgen B
receptor O
and O
( O
3 O
) O
that O
the O
metabolome O
profile O
of O
vinclozolin B
is O
similar O
to O
that O
of O
other O
receptor O
mediated O
anti O
- O
androgens B
( O
e O
. O
g O
. O
flutamide B
) O
. O

Norepinephrine B
and O
impulsivity O
: O
effects O
of O
acute O
yohimbine B
. O

RATIONALE O
: O
Rapid O
- O
response O
impulsivity O
, O
characterized O
by O
inability O
to O
withhold O
response O
to O
a O
stimulus O
until O
it O
is O
adequately O
appraised O
, O
is O
associated O
with O
risky O
behavior O
and O
may O
be O
increased O
in O
a O
state O
- O
dependent O
manner O
by O
norepinephrine B
. O

OBJECTIVE O
: O
We O
assessed O
effects O
of O
yohimbine B
, O
which O
increases O
norepinephrine B
release O
by O
blocking O
alpha O
- O
2 O
noradrenergic O
receptors O
, O
on O
plasma O
catecholamine B
metabolites O
, O
blood O
pressure O
, O
subjective O
symptoms O
, O
and O
laboratory O
- O
measured O
rapid O
- O
response O
impulsivity O
. O

Blood O
pressure O
, O
pulse O
, O
and O
behavioral O
measures O
were O
obtained O
before O
and O
periodically O
after O
0 O
. O
4 O
mg O
/ O
kg O
oral O
yohimbine B
or O
placebo O
in O
a O
randomized O
, O
counterbalanced O
design O
. O

Metabolites O
of O
norepinephrine B
[ O
3 O
- O
methoxy O
- O
4 O
- O
hydroxyphenylglycol O
( O
MHPG O
) O
and O
vanillylmandelic O
acid O
( O
VMA O
) O
] O
and O
dopamine B
[ O
homovanillic B
acid I
( O
HVA B
) O
] O
were O
measured O
by O
high O
- O
pressure O
liquid O
chromatography O
with O
electrochemical O
detection O
. O

RESULTS O
: O
Yohimbine B
increased O
plasma O
MHPG O
and O
VMA O
but O
not O
HVA B
. O

Yohimbine B
increased O
systolic O
and O
diastolic O
blood O
pressure O
and O
pulse O
rate O
. O

On O
the O
IMT O
, O
yohimbine B
increased O
impulsive O
errors O
and O
impulsive O
response O
bias O
and O
accelerated O
reaction O
times O
. O

Yohimbine B
- O
associated O
increase O
in O
plasma O
MHPG O
correlated O
with O
increased O
impulsive O
response O
rates O
. O

Labile O
noradrenergic O
responses O
, O
or O
increased O
sensitivity O
to O
norepinephrine B
, O
may O
increase O
risk O
for O
impulsive O
behavior O
. O

Using O
waste O
Li B
ion O
batteries O
as O
cathodes O
in O
rechargeable O
Li B
- O
liquid O
batteries O
. O

The O
rechargeable O
Li B
- O
liquid O
battery O
was O
developed O
using O
waste O
Li B
ion O
battery O
materials O
immersed O
in O
water O
and O
used O
as O
the O
liquid O
cathode O
. O

Either O
the O
Li B
metal O
or O
Li B
ions O
( O
by O
the O
formation O
LixC6 O
or O
Li4 O
+ O
xTi5O12 O
) O
was O
harvested O
from O
waste O
Li B
ion O
source O
materials O
such O
as O
a O
waste O
anode O
( O
LixC6 O
) O
, O
cathode O
( O
LixFePO4 O
) O
, O
and O
electrolyte O
( O
LiPF6 O
in O
EC O
: O
DEC O
) O
by O
charging O
the O
cell O
, O
which O
then O
discharged O
with O
the O
waste O
products O
in O
the O
liquid O
cathode O
solution O
to O
produce O
electric O
energy O
. O

Storable O
sunshine O
, O
reusable O
rays O
: O
A O
solar O
rechargeable O
redox O
flow O
battery O
is O
proposed O
based O
on O
the O
photoregeneration O
of O
I3 O
( O
- O
) O
/ O
I B
( I
- I
) I
and O
[ O
Fe O
( O
C10 O
H15 O
) O
2 O
] O
( O
+ O
) O
/ O
Fe O
( O
C10 O
H15 O
) O
2 O
soluble O
redox O
couples O
, O
which O
can O
be O
regenerated O
by O
flowing O
from O
a O
discharged O
redox O
flow O
battery O
( O
RFB O
) O
into O
a O
dye O
- O
sensitized O
solar O
cell O
( O
DSSC O
) O
and O
then O
stored O
in O
tanks O
for O
subsequent O
RFB O
applications O
This O
technology O
enables O
effective O
solar O
- O
to O
- O
chemical O
energy O
conversion O
. O

The O
star O
copolymers O
( O
HCP O
- O
star O
- O
PDMAEMAs O
) O
with O
different O
poly O
( O
2 O
- O
( O
dimethylamino O
) O
ethyl O
methacrylate O
) O
( O
PDMAEMA B
) O
chain O
lengths O
were O
synthesized O
from O
the O
hyperbranched O
conjugated O
polymer O
( O
HCP O
) O
macroinitiator O
by O
atom O
transfer O
radical O
polymerization O
( O
ATRP O
) O
. O

Above O
the O
LCST O
, O
the O
emission O
of O
HCP O
- O
star O
- O
PDMAEMAs O
was O
enhanced O
greatly O
through O
restriction O
of O
intermolecular O
aggregation O
of O
conjugated O
polymer O
cores O
by O
the O
collapse O
of O
PDMAEMA B
arms O
. O

By O
changing O
the O
PDMAEMA B
length O
, O
the O
emission O
performance O
of O
HCP O
- O
star O
- O
PDMAEMAs O
could O
be O
readily O
adjusted O
. O

Due O
to O
the O
existence O
of O
a O
hyperbranched O
conjugated O
core O
and O
many O
thermo O
- O
responsive O
PDMAEMA B
arms O
, O
the O
detection O
limit O
of O
E O
. O
coli O
could O
reach O
10 O
( O
2 O
) O
cfu O
mL O
( O
- O
1 O
) O
. O

Poly B
( I
vinyl I
alcohol I
) I
Physical O
Hydrogel O
Nanoparticles O
, O
Not O
Polymer O
Solutions O
, O
Exert O
Inhibition O
of O
Nitric B
Oxide I
Synthesis O
in O
Cultured O
Macrophages O
. O

In O
this O
work O
, O
we O
investigate O
assembly O
of O
HNP O
based O
on O
a O
polymer O
with O
decades O
of O
prominence O
in O
the O
biomedical O
field O
, O
poly B
( I
vinyl I
alcohol I
) I
, O
PVA B
. O

We O
develop O
a O
novel O
method O
for O
production O
of O
PVA B
HNP O
through O
nanoprecipitation O
- O
based O
assembly O
of O
polymer O
nanoparticles O
and O
subsequent O
physical O
hydrogelation O
of O
the O
polymer O
. O

Interaction O
of O
PVA B
HNP O
with O
mammalian O
cells O
was O
investigated O
using O
flow O
cytometry O
, O
viability O
screening O
, O
and O
measurements O
of O
nitric B
oxide I
production O
by O
cultured O
macrophages O
. O

The O
latter O
analyses O
revealed O
that O
PVA B
administered O
as O
a O
polymer O
solution O
or O
in O
the O
form O
of O
HNP O
resulted O
in O
no O
measurable O
increase O
in O
production O
of O
the O
inflammation O
marker O
. O

Unexpectedly O
, O
PVA B
HNP O
exerted O
a O
pronounced O
inhibition O
of O
NO B
synthesis O
by O
stimulated O
macrophages O
, O
that O
is O
, O
had O
an O
anti O
- O
inflammatory O
activity O
. O

This O
effect O
was O
accomplished O
with O
a O
negligible O
change O
in O
the O
cell O
viability O
and O
was O
not O
observed O
when O
PVA B
was O
administered O
as O
a O
polymer O
solution O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
observation O
of O
inhibition O
of O
NO B
synthesis O
in O
macrophages O
by O
administered O
nanoparticles O
and O
specifically O
hydrogel O
nanoparticles O
. O

Taken O
together O
, O
our O
results O
present O
PVA B
HNP O
as O
promising O
colloidal O
hydrogel O
nanocarriers O
for O
biomedical O
applications O
, O
specifically O
drug O
delivery O
and O
assembly O
of O
intracellular O
biosensors O
. O

Enhancing O
Raman O
Scattering O
without O
Plasmons O
: O
Unprecedented O
Sensitivity O
Achieved O
by O
TiO2 B
Shell O
- O
Based O
Resonators O
. O

A O
remarkable O
enhancement O
of O
Raman O
scattering O
is O
achieved O
by O
TiO2 B
shell O
- O
based O
spherical O
resonators O
in O
the O
absence O
of O
plasmonic O
enhancers O
. O

Graphene B
MEMS O
: O
AFM O
Probe O
Performance O
Improvement O
. O

We O
explore O
the O
feasibility O
of O
growing O
a O
continuous O
layer O
of O
graphene B
in O
prepatterned O
substrates O
, O
like O
an O
engineered O
silicon B
wafer O
, O
and O
we O
apply O
this O
as O
a O
mold O
for O
the O
fabrication O
of O
AFM O
probes O
. O

This O
fabrication O
method O
proves O
the O
fabrication O
of O
SU O
- O
8 O
devices O
coated O
with O
graphene B
in O
a O
full O
- O
wafer O
parallel O
technology O
and O
with O
high O
yield O
. O

It O
also O
demonstrates O
that O
graphene B
coating O
enhances O
the O
functionality O
of O
SU O
- O
8 O
probes O
, O
turning O
them O
conductive O
and O
more O
resistant O
to O
wear O
. O

Furthermore O
, O
it O
opens O
new O
experimental O
possibilities O
such O
as O
studying O
graphene B
- O
graphene B
interaction O
at O
the O
nanoscale O
with O
the O
precision O
of O
an O
AFM O
or O
the O
exploration O
of O
properties O
in O
nonplanar O
graphene B
layers O
. O

In O
this O
article O
, O
third O
- O
order O
response O
functions O
of O
a O
model O
QD O
resembling O
CdSe B
are O
calculated O
. O

Peptide O
- O
Directed O
Preparation O
and O
X O
- O
ray O
Structural O
Study O
of O
Au B
Nanoparticles O
on O
Titanium O
Surfaces O
. O

We O
report O
the O
peptide O
- O
directed O
preparation O
and O
X O
- O
ray O
structural O
study O
of O
biofunctionalized O
Au B
nanoparticles O
( O
NPs O
) O
deposited O
on O
Ti B
surfaces O
. O

Au B
NPs O
were O
prepared O
by O
reduction O
of O
Au O
( O
3 O
+ O
) O
compound O
onto O
HCl B
- O
refreshed O
Ti B
in O
the O
presence O
of O
thiol B
- O
functionalized O
small O
peptides O
. O

A O
modified O
extended O
X O
- O
ray O
absorption O
fine O
- O
structure O
( O
EXAFS O
) O
technique O
, O
equipped O
with O
a O
rotating O
- O
stage O
and O
glancing O
- O
angle O
setup O
, O
was O
able O
to O
more O
sensitively O
detect O
the O
structure O
and O
bonding O
of O
Au B
NPs O
on O
Ti B
with O
low O
surface O
coverage O
. O

It O
was O
found O
that O
the O
use O
of O
the O
tripeptide O
glutathione B
( O
GSH B
) O
results O
in O
smaller O
NP O
size O
when O
compared O
to O
N O
- O
( O
2 O
- O
mercapto O
- O
propionyl O
) O
glycine O
( O
MPG O
) O
, O
a O
pseudodipeptide O
, O
over O
a O
wide O
range O
of O
Au B
/ O
peptide O
molar O
ratios O
( O
20 O
: O
1 O
, O
10 O
: O
1 O
, O
5 O
: O
1 O
, O
and O
2 O
: O
1 O
) O
. O

By O
varying O
the O
ligand O
concentration O
, O
the O
Au B
NP O
structure O
in O
both O
systems O
can O
be O
controlled O
, O
generating O
nanocrystals O
, O
nanoclusters O
, O
and O
Au B
- O
thiolate O
polymer O
, O
which O
is O
unique O
for O
substrate O
- O
supported O
NP O
synthesis O
. O

This O
work O
presents O
a O
facile O
preparation O
of O
Au B
- O
peptide O
nanoparticles O
on O
biocompatible O
surfaces O
, O
and O
illustrates O
the O
high O
sensitivity O
of O
this O
modified O
EXAFS O
technique O
for O
structural O
studies O
of O
substrate O
- O
supported O
nanoparticles O
with O
low O
coverage O
. O

In O
this O
study O
, O
rapeseed O
cake O
( O
RSC O
) O
was O
used O
as O
a O
source O
of O
pectins O
due O
to O
its O
high O
carbohydrate B
content O
. O

The O
treatments O
chosen O
for O
combination O
were O
a O
fat O
removal O
process O
( O
FRP O
) O
( O
solvent O
extraction O
using O
an O
alcohol B
- O
benzene B
mixture O
) O
, O
a O
chemical O
treatment O
( O
CT O
) O
( O
hydrolysis O
using O
1 O
% O
hydrochloric O
acid O
) O
, O
and O
an O
enzymatic O
hydrolysis O
( O
EH O
) O
. O

After O
the O
combined O
processes O
, O
pectins O
were O
extracted O
by O
isopropanol O
/ O
ethanol B
precipitation O
and O
the O
residues O
were O
analysed O
by O
HPLC O
or O
an O
elemental O
analyser O
. O

The O
pectin O
yields O
and O
galacturonic B
acid I
contents O
were O
increased O
by O
FRP O
because O
72 O
. O
13 O
% O
of O
the O
total O
fat O
was O
removed O
; O
additionally O
, O
EH O
had O
a O
similar O
effect O
. O

However O
, O
CT O
decreased O
the O
yields O
because O
the O
treatment O
was O
too O
harsh O
and O
the O
galacturonic B
acid I
broke O
down O
. O

Pectin O
yields O
and O
galacturonic B
acid I
contents O
were O
highest O
in O
the O
combination O
process O
FRP O
/ O
EH O
( O
6 O
. O
23 O
% O
and O
64 O
. O
23 O
% O
, O
respectively O
) O
. O

The O
kinetic O
parameters O
including O
rate O
constant O
( O
K O
) O
, O
time O
( O
tau O
50 O
) O
in O
which O
50 O
% O
of O
isoflavone B
deglycosylation O
was O
reached O
, O
and O
time O
( O
tau O
complete O
) O
required O
to O
achieve O
complete O
isoflavone B
deglycosylation O
, O
were0 O
. O
16 O
+ O
/ O
- O
0 O
. O
02min O
( O
- O
1 O
) O
, O
4 O
. O
54 O
+ O
/ O
- O
0 O
. O
32min O
, O
60min O
for O
daidzin O
and O
0 O
. O
16 O
+ O
/ O
- O
0 O
. O
02min O
( O
- O
1 O
) O
, O
2 O
. O
28 O
+ O
/ O
- O
0 O
. O
11min O
, O
60min O
for O
genistin B
, O
respectively O
. O

Antioxidant O
activity O
- O
guided O
separation O
of O
coumarins B
and O
lignan B
from O
Melicope O
glabra O
( O
Rutaceae O
) O
. O

The O
ethyl B
acetate I
and O
methanol B
bark O
extracts O
of O
Melicope O
glabra O
were O
evaluated O
for O
their O
antioxidant O
capacities O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
free O
radical O
scavenging O
activity O
and O
beta B
- I
carotene I
bleaching O
/ O
linoleic B
acid I
system O
. O

Both O
extracts O
exhibited O
strong O
inhibition O
against O
the O
DPPH B
radical O
( O
IC50 O
values O
of O
24 O
. O
81 O
and O
13 O
. O
01 O
mu O
gml O
( O
- O
1 O
) O
, O
respectively O
) O
and O
strong O
antioxidant O
activity O
in O
beta B
- I
carotene I
bleaching O
assay O
. O

Antioxidant O
TLC O
assay O
- O
guided O
isolation O
on O
the O
methanol B
extract O
led O
to O
the O
isolation O
of O
a O
new O
pyranocoumarin O
, O
glabranin O
( O
1 O
) O
, O
umbelliferone B
( O
2 O
) O
, O
scopoletin B
( O
3 O
) O
and O
sesamin O
( O
4 O
) O
, O
and O
their O
structures O
were O
determined O
by O
spectroscopy O
. O

Compounds O
( O
1 O
- O
3 O
) O
showed O
significant O
activities O
on O
DPPH B
free O
radical O
with O
the O
IC50 O
of O
240 O
. O
20 O
, O
810 O
. O
02 O
and O
413 O
. O
19 O
mu O
gml O
( O
- O
1 O
) O
, O
respectively O
. O

However O
, O
in O
beta B
- I
carotene I
bleaching O
assay O
, O
sesamin O
( O
4 O
) O
showed O
higher O
inhibitory O
activity O
( O
1mgml O
( O
- O
1 O
) O
, O
95 O
% O
) O
than O
glabranin O
( O
1 O
) O
( O
1mgml O
( O
- O
1 O
) O
, O
74 O
% O
) O
, O
whilst O
umbelliferone B
( O
2 O
) O
and O
scopoletin B
( O
3 O
) O
were O
slightly O
pro O
- O
oxidant O
. O

Free O
phenolics B
and O
polyphenol B
oxidase O
( O
PPO O
) O
: O
The O
factors O
affecting O
post O
- O
cut O
browning O
in O
eggplant O
( O
Solanum O
melongena O
) O
. O

Polyphenol B
oxidase O
( O
PPO O
) O
catalyses O
oxidation O
of O
phenolics B
, O
which O
results O
in O
instant O
but O
differential O
browning O
in O
many O
cut O
fruits O
and O
vegetables O
, O
including O
eggplant O
. O

Eight O
cultivars O
of O
eggplant O
were O
characterised O
by O
their O
PPO O
specific O
activity O
, O
phenolic B
content O
, O
browning O
index O
, O
and O
PPO O
polymorphism O
. O

In O
fresh O
eggplant O
, O
browning O
was O
found O
to O
be O
dependent O
on O
both O
the O
phenolic B
content O
and O
PPO O
specific O
activity O
, O
whereas O
, O
total O
phenolic B
content O
played O
a O
major O
role O
in O
browning O
of O
stored O
fruits O
. O

Phenolic B
level O
was O
found O
to O
increase O
in O
all O
these O
cultivars O
during O
storage O
. O

Although O
a O
significant O
level O
of O
homology O
was O
observed O
in O
PPO O
nucleotide B
and O
conceptually O
translated O
protein O
sequence O
, O
two O
cultivars O
, O
which O
displayed O
highest O
PPO O
specific O
activity O
, O
differed O
in O
the O
38 O
amino B
acid I
stretch O
in O
the O
peptide O
region O
301 O
- O
338 O
. O

Another O
objective O
was O
to O
establish O
which O
of O
the O
two O
extracting O
agents O
, O
ethanol B
or O
methanol B
, O
is O
more O
effective O
. O

The O
seeds O
of O
the O
cultivars O
belonging O
to O
the O
species O
C O
. O
maxima O
are O
characterised O
by O
a O
higher O
content O
of O
fatty B
acids I
than O
are O
the O
cultivars O
of O
the O
species O
C O
. O
pepo O
. O

In O
the O
seed O
oil O
, O
unsaturated O
acids O
are O
dominant O
( O
oleic B
and O
linoleic B
) O
, O
and O
their O
proportion O
depends O
on O
the O
pumpkin O
variety O
. O

50 O
% O
ethanol B
is O
more O
efficient O
than O
80 O
% O
methanol B
when O
used O
as O
an O
extracting O
agent O
. O

The O
antioxidant O
activity O
values O
obtained O
with O
50 O
% O
ethanol B
are O
higher O
than O
those O
achieved O
with O
80 O
% O
methanol B
. O

Owing O
to O
the O
considerable O
differences O
in O
composition O
among O
the O
fatty B
acids I
examined O
, O
it O
is O
possible O
to O
choose O
the O
desired O
pumpkin O
variety O
for O
the O
intended O
use O
. O

Studies O
of O
isothermal O
crystallisation O
kinetics O
of O
sunflower O
hard O
stearin B
- O
based O
confectionery O
fats O
. O

Stop O
- O
and O
- O
return O
DSC O
studies O
showed O
that O
SHSs O
and O
CBEs O
exhibited O
different O
crystallisation O
mechanisms O
according O
to O
their O
triacylglycerol B
composition O
, O
with O
a O
quick O
formation O
of O
metastable O
crystals O
, O
followed O
by O
a O
polymorphic O
transition O
to O
the O
more O
stable O
beta O
or O
beta O
' O
forms O
. O

Simulated O
digestion O
of O
proanthocyanidins B
in O
grape O
skin O
and O
seed O
extracts O
and O
the O
effects O
of O
digestion O
on O
the O
angiotensin O
I O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitory O
activity O
. O

This O
study O
investigated O
the O
effect O
of O
in O
vitro O
gastrointestinal O
digestion O
on O
the O
stability O
and O
composition O
of O
flavan B
- I
3 I
- I
ols I
from O
red O
grape O
skin O
and O
seed O
extracts O
( O
raw O
and O
purified O
, O
which O
are O
high O
in O
proanthocyanidins B
( O
PAs O
) O
) O
. O

The O
extracts O
were O
digested O
with O
a O
mixture O
of O
pepsin O
- O
HCl B
for O
2h O
, O
followed O
by O
a O
2h O
incubation O
with O
pancreatin O
and O
bile B
salts I
including O
a O
cellulose O
dialysis O
tubing O
( O
molecular O
weight O
cut O
- O
off O
12kDa O
) O
at O
37 O
degrees O
C O
with O
shaking O
in O
the O
dark O
and O
under O
N2 O
. O

Purification O
and O
characterisation O
of O
sarcoplasmic O
calcium B
- O
binding O
protein O
, O
a O
novel O
allergen O
of O
red O
swamp O
crayfish O
( O
Procambarus O
clarkii O
) O
. O

Crayfish O
sarcoplasmic O
calcium B
- O
binding O
protein O
( O
SCP O
) O
was O
purified O
. O

Enzymatic O
modification O
enhances O
the O
protective O
activity O
of O
citrus O
flavonoids B
against O
alcohol B
- O
induced O
liver O
disease O
. O

Alcoholic O
liver O
disease O
( O
ALD O
) O
can O
be O
developed O
by O
a O
prolonged O
or O
large O
intake O
of O
alcohol B
in O
a O
short O
period O
of O
time O
. O

This O
study O
was O
aimed O
to O
investigate O
the O
effects O
of O
orally O
administrated O
citrus O
flavonoids B
( O
CFs O
) O
and O
their O
enzymatically O
modified O
ones O
( O
EM O
- O
CFs O
) O
to O
prevent O
ALD O
. O

Hesperidin B
and O
narirutin O
were O
extracted O
from O
peels O
of O
Citrus O
unshiu O
by O
ultra O
- O
sonication O
and O
purified O
further O
. O

CFs O
and O
EM O
- O
CFs O
were O
fed O
to O
ICR O
mouse O
along O
with O
ethanol B
for O
8weeks O
, O
and O
changes O
in O
lipid O
contents O
, O
lipid O
peroxidation O
, O
GSH B
, O
antioxidant O
enzymes O
activity O
and O
proinflammatory O
cytokines O
in O
hepatic O
tissues O
were O
observed O
. O

Administration O
of O
CFs O
and O
EM O
- O
CFs O
along O
with O
alcohol B
significantly O
suppressed O
increases O
in O
prognostic O
parameters O
of O
a O
hepatocellular O
injury O
. O

Especially O
, O
EM O
- O
CFs O
fed O
groups O
maintained O
malondialdehyde B
, O
GSH B
levels O
and O
catalase O
activity O
in O
hepatic O
tissues O
close O
to O
those O
of O
the O
normal O
diet O
fed O
group O
. O

Abrupt O
increases O
in O
proinflammatory O
cytokines O
such O
as O
I O
kappa O
B O
- O
alpha O
, O
TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
and O
IL O
- O
6 O
in O
hepatocytes O
due O
to O
a O
chronic O
alcohol B
uptake O
were O
significantly O
suppressed O
by O
co O
- O
administration O
of O
EM O
- O
CFs O
. O

Carbon B
nanotubes O
- O
reinforced O
hollow O
fibre O
solid O
- O
phase O
microextraction O
coupled O
with O
high O
performance O
liquid O
chromatography O
for O
the O
determination O
of O
carbamate B
pesticides O
in O
apples O
. O

An O
effective O
and O
sensitive O
method O
to O
determinate O
five O
carbamate B
pesticides O
in O
apples O
was O
developed O
by O
using O
carbon B
nanotubes O
- O
reinforced O
hollow O
fibre O
solid O
- O
phase O
microextraction O
( O
CNTs O
- O
HF O
- O
SPME O
) O
combined O
with O
high O
performance O
liquid O
chromatography O
- O
photodiode O
array O
detection O
( O
HPLC O
- O
DAD O
) O
. O

Therefore O
, O
the O
results O
demonstrated O
that O
this O
novel O
method O
was O
an O
efficient O
pretreatment O
and O
enrichment O
procedure O
for O
the O
determination O
of O
trace O
carbamate B
pesticides O
in O
apples O
. O

A O
new O
molecularly O
imprinted O
polymer O
( O
MIP O
) O
, O
selective O
for O
major O
metabolites O
of O
quinoxaline O
- O
1 O
, O
4 O
- O
dioxides O
, O
was O
prepared O
through O
bulk O
polymerisation O
using O
quinoxaline O
- O
2 O
- O
carboxylic O
acid O
( O
QCA O
) O
as O
template O
, O
diethylaminoethylmet O
as O
functional O
monomer O
and O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
in O
tetrahydrofuran B
. O

Synthesis O
of O
amino B
acid I
conjugates O
of O
tetrahydrocurcumin O
and O
evaluation O
of O
their O
antibacterial O
and O
anti O
- O
mutagenic O
properties O
. O

Tetrahydrocurcumin O
( O
THC B
) O
, O
the O
hydrogenated O
and O
stable O
form O
of O
curcumin B
, O
exhibits O
physiological O
and O
pharmacological O
activities O
similar O
to O
curcumin B
. O

A O
protocol O
has O
been O
developed O
for O
the O
synthesis O
of O
novel O
conjugates O
of O
THC B
with O
alanine B
( O
2a O
) O
, O
isoleucine B
( O
2b O
) O
, O
proline B
( O
2c O
) O
, O
valine B
( O
2d O
) O
, O
phenylalanine B
( O
2e O
) O
, O
glycine B
( O
2f O
) O
and O
leucine B
( O
2g O
) O
in O
high O
yields O
( O
43 O
- O
82 O
% O
) O
. O

All O
the O
derivatives O
of O
THC B
exhibited O
more O
potent O
anti O
- O
microbial O
activity O
than O
THC B
against O
Bacillus O
cereus O
, O
Staphylococcus O
aureus O
, O
Escherichia O
coli O
and O
Yersinia O
enterocolitica O
. O

The O
MIC O
values O
of O
the O
derivatives O
were O
24 O
- O
37 O
% O
of O
those O
for O
THC B
in O
case O
of O
both O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacteria O
. O

Derivatives O
2g O
and O
2d O
exhibited O
maximum O
anti O
- O
mutagenicity O
against O
Salmonella O
typhimurium O
TA O
98 O
and O
TA O
1538 O
, O
respectively O
at O
a O
low O
concentration O
of O
313 O
mu O
g O
/ O
plate O
, O
with O
comparable O
activity O
for O
THC B
evident O
only O
at O
3750 O
mu O
g O
/ O
plate O
. O

These O
results O
clearly O
demonstrated O
that O
the O
conjugation O
of O
THC B
at O
the O
phenolic B
position O
with O
amino B
acids I
led O
to O
significant O
improvement O
of O
its O
in O
vitro O
biological O
attributes O
. O

Influence O
of O
triterpenoids B
present O
in O
apple O
peel O
on O
inflammatory O
gene O
expression O
associated O
with O
inflammatory O
bowel O
disease O
( O
IBD O
) O
. O

After O
pretreatment O
with O
single O
triterpenoids B
, O
cells O
were O
stimulated O
with O
pro O
- O
inflammatory O
cytokines O
( O
TNF O
- O
alpha O
, O
INF O
- O
gamma O
, O
IL O
- O
1 O
beta O
) O
. O

Furthermore O
, O
the O
effects O
of O
ursolic B
acid I
( O
UA O
) O
and O
oleanolic B
acid I
( O
OA O
) O
on O
the O
synthesis O
of O
certain O
pro O
- O
inflammatory O
proteins O
were O
examined O
. O

The O
present O
study O
confirms O
that O
triterpenoids B
present O
in O
apple O
peel O
and O
beta O
- O
damascone O
may O
be O
implicated O
in O
the O
anti O
- O
inflammatory O
properties O
of O
apple O
constituents O
, O
suggesting O
that O
these O
substances O
might O
be O
helpful O
in O
the O
treatment O
of O
IBD O
as O
nutrient O
supplements O
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
antioxidant O
activities O
of O
water O
- O
soluble O
MRPs O
( O
Maillard O
reaction O
products O
) O
from O
the O
reactions O
between O
whey O
protein O
isolate O
( O
WPI O
) O
and O
xylose B
( O
X O
) O
, O
glucose B
( O
G O
) O
, O
fructose B
( O
F O
) O
, O
lactose B
( O
L O
) O
, O
maltose O
( O
M O
) O
and O
sucrose B
( O
S O
) O
at O
different O
initial O
pH O
values O
( O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
, O
8 O
and O
9 O
) O
. O

MRPs O
derived O
from O
the O
WPI O
- O
X O
system O
with O
increasing O
of O
pH O
rendered O
the O
highest O
browning O
, O
reducing O
power O
and O
DPPH B
radical O
- O
scavenging O
activity O
. O

SDS B
- O
PAGE O
analyses O
indicated O
formation O
of O
cross O
- O
linked O
proteins O
of O
large O
molecular O
mass O
produced O
from O
WPI O
- O
X O
systems O
. O

Results O
of O
FT O
- O
IR O
analysis O
indicated O
that O
the O
amide B
I O
, O
II O
and O
III O
bands O
of O
WPI O
from O
the O
WPI O
- O
X O
and O
WPI O
- O
G O
systems O
were O
changed O
by O
the O
Maillard O
reaction O
. O

Antioxidant O
assays O
demonstrated O
that O
ethanol B
extracts O
of O
A O
. O
paronychioides O
( O
EEAP O
) O
exhibited O
the O
highest O
antioxidant O
activity O
, O
which O
also O
had O
the O
highest O
phenolic B
and O
flavonoid B
contents O
. O

Two O
major O
polyphenolics O
, O
ferulic B
acid I
and O
quercetin B
, O
were O
identified O
from O
EEAP O
by O
HPLC O
- O
DAD O
. O

Effects O
of O
EEAP O
, O
ferulic B
acid I
and O
quercetin B
on O
high O
glucose O
( O
25mmol O
/ O
L O
) O
- O
induced O
pancreatic O
beta O
- O
cell O
apoptosis O
and O
dysfunction O
were O
further O
evaluated O
. O

Results O
showed O
that O
EEAP O
and O
quercetin B
but O
not O
ferulic B
acid I
protected O
beta O
- O
cells O
from O
glucotoxicity O
through O
several O
mechanisms O
, O
including O
: O
( O
1 O
) O
maintaining O
beta O
- O
cell O
viability O
; O
( O
2 O
) O
suppressing O
reactive O
oxygen B
species O
production O
; O
( O
3 O
) O
reducing O
characteristic O
features O
of O
apoptosis O
; O
( O
4 O
) O
inhibiting O
the O
activation O
of O
caspase O
- O
9 O
and O
caspase O
- O
3 O
and O
the O
cleavage O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
; O
( O
5 O
) O
upregulating O
pancreatic O
and O
duodenal O
homeobox O
1 O
gene O
expression O
and O
the O

Batsch O
, O
pulp O
extract O
on O
Ang O
II O
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
mobilization O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
signal O
transduction O
events O
in O
cultured O
vascular O
smooth O
muscle O
cells O
( O
VSMCs O
) O
was O
investigated O
. O

Pretreatment O
of O
peach O
ethyl B
acetate I
extract O
inhibited O
Ang O
II O
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
in O
VSMCs O
. O

Furthermore O
, O
Ang O
II O
- O
induced O
ROS O
generation O
, O
essential O
for O
signal O
transduction O
events O
, O
was O
diminished O
by O
the O
peach O
ethyl B
acetate I
extract O
. O

The O
peach O
ethyl B
acetate I
extract O
also O
attenuated O
the O
Ang O
II O
- O
induced O
phosphorylation O
of O
epidermal O
growth O
factor O
receptor O
and O
myosin O
phosphatase O
target O
subunit O
1 O
, O
both O
of O
which O
are O
associated O
with O
atherosclerosis O
and O
hypertension O
. O

These O
results O
suggest O
that O
peach O
ethyl B
acetate I
extract O
may O
have O
clinical O
potential O
for O
preventing O
cardiovascular O
diseases O
by O
interfering O
with O
Ang O
II O
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
, O
the O
generation O
of O
ROS O
, O
and O
then O
blocking O
signal O
transduction O
events O
. O

Free O
fatty B
acid I
profiles O
of O
emulsified O
lipids O
during O
in O
vitro O
digestion O
with O
pancreatic O
lipase O
. O

Individual O
free O
fatty B
acids I
released O
from O
milk O
protein O
- O
stabilized O
emulsions O
prepared O
with O
milk O
fat O
, O
soya O
bean O
oil O
or O
tuna O
fish O
oil O
during O
in O
vitro O
digestion O
with O
pancreatic O
lipase O
were O
monitored O
using O
gas O
chromatography O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 O
: O
0 O
and O
C18 O
: O
0 O
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 O
: O
1n9 O
, O
C18 O
: O
2n6 O
and O
C18 O
: O
3n3 O
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
confirm O
that O
the O
release O
behaviour O
of O
fatty B
acids I
from O
emulsions O
during O
digestion O
is O
related O
not O
only O
to O
the O
position O
of O
the O
fatty B
acids I
in O
the O
triglycerides B
in O
the O
fat O
/ O
oil O
, O
but O
also O
to O
the O
length O
of O
the O
carbon B
chain O
of O
the O
fatty B
acid I
. O

The O
rates O
and O
the O
extents O
of O
the O
digestion O
of O
lipids O
consisting O
of O
short O
chain O
fatty B
acids I
are O
higher O
than O
those O
of O
lipids O
consisting O
of O
long O
chain O
fatty B
acids I
. O

Muscles O
from O
Frigate O
mackerel O
had O
greater O
content O
of O
sodium B
chloride I
than O
had O
catfish O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
highest O
contents O
of O
iron B
, O
copper B
and O
selenium B
were O
found O
in O
Frigate O
mackerel O
dark O
muscle O
( O
p O
< O
0 O
. O
05 O
) O
. O

Most O
reported O
studies O
focused O
on O
specific O
oat O
extracts O
or O
particular O
oat O
components O
, O
such O
as O
beta O
- O
glucans O
, O
tocols O
( O
vitamin B
E I
) O
, O
or O
avenanthramides O
. O

All O
oat O
varieties O
had O
very O
similar O
oxygen B
radical O
absorption O
capacity O
compared O
with O
other O
whole O
grains O
. O

Assay O
of O
phenolic B
compounds O
from O
four O
species O
of O
ber O
( O
Ziziphus O
mauritiana O
L O
. O
) O
fruits O
: O
Comparison O
of O
three O
base O
hydrolysis O
procedure O
for O
quantification O
of O
total O
phenolic B
acids I
. O

The O
present O
study O
was O
undertaken O
to O
investigate O
the O
flavonoid B
profile O
in O
four O
species O
of O
ber O
( O
Ziziphus O
mauritiana O
Lamk O
. O
) O
fruit O
. O

The O
12 O
flavonoids B
identified O
were O
quercetin O
3 O
- O
O O
- O
robinobioside O
, O
quercetin O
3 O
- O
O O
- O
rutinoside O
, O
quercetin O
3 O
' O
- O
O O
- O
galactoside O
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin O
3 O
' O
- O
O O
- O
pentosylhexoside O
, O
quercetin O
3 O
- O
O O
- O
6 O
' O
malonylglucoside O
, O
quercetin O
3 O
' O
- O
O O
- O

This O
is O
the O
first O
report O
on O
extraction O
of O
nine O
additional O
flavonoids B
from O
the O
ber O
fruits O
. O

In O
addition O
, O
we O
also O
compared O
the O
impact O
of O
three O
different O
base O
hydrolysis O
techniques O
namely O
ultrasonic O
assisted O
base O
hydrolysis O
( O
UABH O
) O
, O
microwave O
assisted O
base O
hydrolysis O
( O
MWABH O
) O
, O
and O
pressurised O
liquid O
assisted O
base O
hydrolysis O
( O
PLABH O
) O
for O
the O
quantification O
of O
total O
phenolic B
acids I
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho O
- O
and O
para O
- O
coumaric O
acids O
, O
were O
identified O
and O
quantified O
. O

The O
three O
major O
phenolic B
acids I
identified O
in O
all O
four O
ber O
species O
were O
p B
- I
coumaric I
acid I
, O
vanillin B
and O
ferulic B
acids I
. O

Higher O
amounts O
( O
p O
< O
0 O
. O
05 O
) O
of O
total O
phenolic B
acids I
in O
all O
cultivars O
were O
obtained O
with O
the O
PLABH O
technique O
as O
compared O
to O
other O
two O
procedures O
( O
UABH O
and O
MWABH O
) O
. O

The O
physico O
- O
chemical O
and O
sensorial O
properties O
of O
the O
control O
( O
BCtr O
) O
, O
commercial O
wheat O
flour O
( O
CWF O
) O
bread O
substituted O
with O
10 O
% O
BPF O
( O
banana O
pseudo O
- O
stem O
flour O
) O
( O
B10BPF O
) O
and O
B10BPF O
with O
added O
0 O
. O
8 O
% O
w O
/ O
w O
( O
flour O
weight O
basis O
) O
xanthan O
gum O
( O
XG O
) O
or O
sodium B
carboxymethylcellulo O
( O
CMC O
) O
( O
B10BPFXG O
and O
B10BPFCMC O
, O
respectively O
) O
were O
examined O
. O

The O
proximate O
analyses O
revealed O
that O
the O
composite O
bread O
had O
significantly O
higher O
moisture O
, O
ash O
, O
crude O
fibre O
, O
soluble O
, O
insoluble O
and O
total O
dietary O
fibre O
contents O
but O
lower O
protein O
, O
fat O
and O
carbohydrate B
contents O
than O
the O
BCtr O
. O

All O
breads O
containing O
BPF O
had O
greater O
total O
phenolics B
, O
and O
antioxidant O
properties O
than O
the O
control O
bread O
. O

JG O
milk O
was O
associated O
with O
both O
favourable O
traits O
for O
human O
health O
, O
such O
as O
the O
higher O
total O
protein O
, O
total O
casein O
, O
alpha O
- O
casein O
, O
beta O
- O
casein O
, O
kappa O
- O
casein O
and O
alpha B
- I
tocopherol I
contents O
, O
and O
unfavourable O
traits O
, O
such O
as O
the O
higher O
concentrations O
of O
saturated O
fat O
, O
C12 O
: O
0 O
, O
C14 O
: O
0 O
and O
lower O
concentrations O
of O
monounsaturated B
fatty I
acids I
. O

Also O
, O
the O
relative O
increase O
in O
omega B
- I
3 I
fatty I
acids I
and O
alpha B
- I
tocopherol I
, O
from O
winter O
to O
summer O
, O
was O
greater O
in O
JG O
milk O
. O

Seasonality O
had O
a O
more O
marked O
impact O
on O
the O
fatty B
acid I
composition O
of O
JG O
milk O
than O
had O
NS O
milk O
, O
while O
the O
opposite O
was O
found O
for O
protein O
composition O
. O

( O
Du O
- O
zhong O
) O
leaves O
using O
HSCCC O
guided O
by O
DPPH B
- O
HPLC O
experiment O
. O

Seven O
antioxidants O
were O
purified O
from O
Eucommia O
ulmoides O
Oliv O
. O
leaves O
using O
HSCCC O
guided O
by O
DPPH B
- O
HPLC O
experiment O
. O

Ethyl B
acetate I
- O
n B
- I
butanol I
- O
water O
( O
1 O
: O
2 O
: O
3 O
, O
v O
/ O
v O
/ O
v O
) O
was O
selected O
as O
the O
optimum O
solvent O
system O
to O
purify O
geniposidic O
acid O
. O

Ethyl B
acetate I
- O
ethanol B
- O
water O
( O
4 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
) O
was O
used O
to O
isolate O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
ferulic B
acid I
. O

While O
three O
flavonoids B
, O
quercetin O
- O
3 O
- O
O O
- O
sambubioside O
, O
rutin B
and O
isoquercitrin O
were O
purified O
by O
petroleum B
ether I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
1 O
: O
5 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
. O

The O
results O
indicated O
that O
the O
combinative O
methods O
using O
DPPH B
- O
HPLC O
and O
HSCCC O
could O
be O
widely O
applied O
for O
screening O
and O
isolation O
of O
antioxidants O
from O
complex O
extracts O
. O

Ellagic B
acid I
derivatives O
, O
ellagitannins O
, O
proanthocyanidins B
and O
other O
phenolics B
, O
vitamin B
C I
and O
antioxidant O
capacity O
of O
two O
powder O
products O
from O
camu O
- O
camu O
fruit O
( O
Myrciaria O
dubia O
) O
. O

The O
aims O
of O
this O
study O
were O
the O
evaluation O
of O
polyphenols B
and O
vitamin B
C I
content O
, O
and O
antioxidant O
capacity O
of O
dehydrated O
pulp O
powder O
and O
the O
dried O
flour O
obtained O
from O
the O
skin O
and O
seeds O
residue O
remaining O
after O
pulp O
preparation O
from O
camu O
- O
camu O
( O
Myrciaria O
dudia O
) O
. O

Fifty O
- O
three O
different O
phenolics B
were O
characterised O
by O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
- O
MS O
and O
UPLC O
- O
HR O
- O
QTOF O
- O
MS O
- O
MS O
. O

In O
both O
products O
the O
flavonol B
myricetin B
and O
conjugates O
, O
ellagic B
acid I
and O
conjugates O
and O
ellagitannins O
were O
detected O
. O

Cyanidin O
3 O
- O
glucoside O
, O
and O
quercetin B
and O
its O
glycosides O
were O
only O
found O
in O
the O
pulp O
powder O
, O
while O
proanthocyanidins B
were O
only O
present O
in O
the O
flour O
( O
3 O
. O
5g O
/ O
100g O
, O
mean O
degree O
of O
polymerisation O
3 O
) O
. O

The O
vitamin B
C I
content O
was O
lower O
in O
pulp O
powder O
( O
3 O
. O
5 O
% O
) O
than O
in O
the O
flour O
( O
9 O
. O
1 O
% O
) O
. O

The O
radical O
- O
scavenging O
capacity O
of O
both O
powders O
was O
determined O
by O
the O
DPPH B
, O
ABTS B
and O
ORAC O
assays O
, O
and O
was O
higher O
for O
camu O
- O
camu O
flour O
as O
could O
be O
expected O
for O
its O
higher O
phenolics B
and O
vitamin B
C I
content O
. O

Analysis O
of O
fresh O
berries O
showed O
that O
ellagic B
acid I
derivatives O
and O
ellagitannins O
were O
mainly O
present O
in O
the O
seeds O
, O
while O
proanthocyanidins B
were O
present O
both O
in O
the O
seeds O
and O
skin O
. O

Five O
marinades O
were O
prepared O
with O
4 O
% O
( O
w O
/ O
v O
) O
sodium B
chloride I
and O
25 O
% O
( O
w O
/ O
v O
) O
soy O
sauce O
solutions O
( O
4 O
% O
salt O
concentration O
) O
and O
mixed O
with O
the O
ratios O
of O
100 O
: O
0 O
( O
S0 O
, O
pH O
6 O
. O
52 O
) O
, O
75 O
: O
25 O
( O
S25 O
, O
5 O
. O
40 O
) O
50 O
: O
50 O
( O
S50 O
, O
5 O
. O
24 O
) O
, O
25 O
: O
75 O
( O
S75 O
, O
5 O
. O
05 O
) O
, O
and O
0 O
: O
100 O
( O
S100 O
, O
4 O
. O
85 O
) O
, O
respectively O
. O

Reduction O
in O
intensity O
of O
few O
myofibrillar O
protein O
bands O
were O
observed O
for O
S100 O
treatment O
compared O
to O
control O
using O
SDS B
- O
PAGE O
. O

Effects O
of O
NaCl B
and O
pH O
on O
the O
structural O
conformations O
of O
kidney O
bean O
vicilin O
. O

The O
vicilin O
consisted O
of O
two O
polypeptide O
chains O
of O
about O
43 O
and O
45kDa O
in O
size O
when O
analysed O
under O
reducing O
SDS B
- O
PAGE O
. O

Amino B
acid I
analysis O
showed O
that O
the O
vicilin O
had O
high O
contents O
of O
acidic B
amino I
acids I
and O
a O
low O
lysine B
/ O
arginine B
ratio O
. O

Intrinsic O
fluorescence O
measurements O
were O
performed O
to O
measure O
exposure O
of O
tyrosine B
and O
tryptophan B
as O
a O
means O
of O
estimating O
protein O
conformational O
changes O
. O

Generally O
, O
the O
vicilin O
showed O
an O
unfolded O
structure O
at O
pH O
3 O
. O
0 O
, O
5 O
. O
0 O
, O
7 O
. O
0 O
, O
and O
9 O
. O
0 O
as O
evident O
by O
the O
extensive O
red O
shift O
( O
> O
350nm O
) O
of O
the O
wavelength O
of O
maximum O
tryptophan B
fluorescence O
intensity O
. O

At O
pH O
3 O
. O
0 O
and O
5 O
. O
0 O
, O
the O
fluorescence O
intensity O
( O
FI O
) O
was O
greater O
than O
values O
obtained O
at O
pH O
7 O
. O
0 O
and O
9 O
. O
0 O
, O
which O
suggests O
that O
the O
microenvironment O
of O
tryptophan B
was O
less O
hydrophilic O
at O
acidic O
pH O
. O

Addition O
of O
NaCl B
also O
led O
to O
increased O
FI O
, O
an O
indication O
of O
structural O
changes O
of O
tryptophan B
in O
response O
to O
the O
hydrophilic O
environment O
. O

These O
changes O
in O
FI O
were O
due O
mostly O
to O
tryptophan B
emission O
because O
tyrosine B
emission O
( O
at O
303nm O
) O
was O
suppressed O
. O

Addition O
of O
NaCl B
led O
to O
an O
increase O
in O
the O
tertiary O
structure O
conformation O
of O
vicilin O
as O
determined O
from O
the O
near O
- O
UV O
CD O
spectra O
. O

While O
putative O
disease O
- O
preventing O
lycopene B
metabolites O
are O
found O
in O
both O
tomato O
( O
Solanum O
lycopersicum O
) O
products O
and O
in O
their O
consumers O
, O
mammalian O
lycopene B
metabolism O
is O
poorly O
understood O
. O

To O
enhance O
the O
( B
13 I
) I
C I
- O
enrichment O
and O
yields O
of O
labelled O
lycopene B
from O
the O
hp O
- O
1 O
tomato O
cell O
line O
, O
cultures O
were O
first O
grown O
in O
( O
13 O
) O
C O
- O
glucose O
media O
for O
three O
serial O
batches O
and O
produced O
increasing O
proportions O
of O
uniformly O
labelled O
lycopene B
( O
14 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
% O
, O
39 O
. O
6 O
+ O
/ O
- O
0 O
. O
5 O
% O
, O
and O
48 O
. O
9 O
+ O
/ O
- O
1 O
. O
5 O
% O
) O
with O
consistent O
yields O
( O
from O
5 O
. O
8 O
to O
9mg O
/ O
L O
) O
. O

An O
optimised O
9 O
- O
day O
- O
long O
( B
13 I
) I
C I
- O
loading O
and O
18 O
- O
day O
- O
long O
labelling O
strategy O
developed O
based O
on O
glucose B
utilisation O
and O
lycopene B
yields O
, O
yielded O
( O
13 O
) O
C O
- O
lycopene O
with O
93 O
% O
( B
13 I
) I
C I
isotopic O
purity O
, O
and O
55 O
% O
of O
isotopomers O
were O
uniformly O
labelled O
. O

Furthermore O
, O
an O
optimised O
acetone B
and O
hexane B
extraction O
led O
to O
a O
fourfold O
increase O
in O
lycopene B
recovery O
from O
cultures O
compared O
to O
a O
standard O
extraction O
. O

The O
other O
two O
were O
prepared O
by O
initially O
recovering O
the O
oil O
bodies O
from O
the O
extract O
by O
centrifugation O
, O
either O
in O
the O
presence O
of O
sucrose B
or O
by O
applying O
isoelectric O
precipitation O
at O
pH O
5 O
. O
0 O
and O
then O
diluting O
the O
resulting O
oil O
body O
creams O
with O
deionized O
water O
. O

The O
green O
tea O
polyphenols B
seem O
to O
interact O
with O
the O
oil O
bodies O
leading O
to O
intensive O
dispersion O
destabilisation O
which O
, O
however O
, O
was O
halted O
following O
carrageenan O
addition O
at O
a O
relatively O
very O
low O
level O
. O

Effect O
of O
temperature O
on O
the O
release O
of O
intentionally O
and O
non O
- O
intentionally O
added O
substances O
from O
polyethylene B
terephthalate I
( O
PET B
) O
bottles O
into O
water O
: O
Chemical O
analysis O
and O
potential O
toxicity O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
temperature O
on O
the O
release O
of O
PET B
- O
bottle O
constituents O
into O
water O
and O
to O
assess O
the O
potential O
health O
hazard O
using O
in O
vitro O
bioassays O
with O
bacteria O
and O
human O
cell O
lines O
. O

Aldehydes B
, O
trace O
metals O
and O
other O
compounds O
found O
in O
plastic O
packaging O
were O
analysed O
in O
PET B
- O
bottled O
water O
stored O
at O
different O
temperatures O
: O
40 O
, O
50 O
, O
and O
60 O
degrees O
C O
. O

In O
this O
study O
, O
temperature O
and O
the O
presence O
of O
CO2 B
increased O
the O
release O
of O
formaldehyde B
, O
acetaldehyde B
and O
antimony O
( O
Sb O
) O
. O

As O
expected O
, O
and O
in O
accordance O
with O
the O
chemical O
formulations O
specified O
for O
PET B
bottles O
, O
neither O
phthalates B
nor O
UV O
stabilisers O
were O
present O
in O
the O
water O
extracts O
. O

However O
, O
2 O
, O
4 O
- O
di O
- O
tert O
- O
butylphenol O
, O
a O
degradation O
compound O
of O
phenolic B
antioxidants O
, O
was O
detected O
. O

In O
addition O
, O
an O
intermediary O
monomer O
, O
bis O
( O
2 O
- O
hydroxyethyl O
) O
terephthalate O
, O
was O
found O
but O
only O
in O
PET B
- O
bottled O
waters O
. O

However O
, O
the O
PET B
- O
bottled O
water O
extracts O
did O
not O
induce O
any O
cytotoxic O
, O
genotoxic O
or O
endocrine O
- O
disruption O
activity O
in O
the O
bioassays O
after O
exposure O
. O

Congeners O
in O
sugar B
cane O
spirits O
aged O
in O
casks O
of O
different O
woods O
. O

The O
profile O
of O
volatile O
compounds O
and O
aging O
markers O
in O
sugar B
cane O
spirits O
aged O
for O
36months O
in O
casks O
made O
of O
10 O
types O
of O
wood O
were O
studied O
. O

The O
ethanol B
content O
, O
volatile O
acidity O
, O
aldehydes B
, O
esters B
, O
higher O
alcohols B
, O
and O
methanol B
were O
determined O
. O

In O
addition O
, O
gallic O
, O
vanilic O
and O
syringic O
acids O
, O
siringaldehyde O
, O
coniferaldehyde O
, O
sinapaldehyde O
, O
vanillin B
, O
5 B
- I
hydroxymethylfurfura I
and O
furfural B
were O
identified O
and O
quantified O
. O

The O
Brazilian O
woods O
, O
similar O
to O
oak O
, O
were O
jequitib O
a O
rosa O
and O
cerejeira O
, O
which O
presented O
the O
highest O
contents O
of O
some O
maturation O
- O
related O
compounds O
, O
such O
as O
vanillin B
, O
vanilic O
acid O
, O
syringaldehyde B
and O
sinapaldehyde O
. O

Although O
oak O
wood O
conferred O
more O
chemical O
complexity O
to O
the O
beverage O
, O
Brazilian O
woods O
, O
singly O
or O
complementarily O
, O
present O
potential O
for O
spirit O
characterisation O
and O
for O
improving O
the O
quality O
of O
sugar B
cane O
spirits O
. O

Effects O
of O
fisetin B
supplementation O
on O
hepatic O
lipogenesis O
and O
glucose B
metabolism O
in O
Sprague O
- O
Dawley O
rats O
fed O
on O
a O
high O
fat O
diet O
. O

The O
modulatory O
effects O
of O
daily O
fisetin B
supplementation O
for O
8weeks O
on O
genes O
involved O
in O
hepatic O
lipogenesis O
and O
gluconeogenesis O
and O
hyperglycemia O
in O
rats O
fed O
a O
high O
fat O
( O
HF O
) O
diet O
were O
evaluated O
. O

Elevated O
levels O
of O
triglyceride B
( O
TG O
) O
, O
along O
with O
hepatic O
TG O
content O
and O
glucose B
concentrations O
in O
a O
high O
fat O
diet O
group O
were O
found O
to O
be O
reduced O
by O
fisetin B
supplementation O
. O

The O
high O
fat O
diet O
significantly O
increased O
hepatic O
mRNA O
expressions O
of O
PPAR O
gamma O
, O
SREBP1C O
and O
SCD O
- O
1 O
genes O
in O
comparison O
to O
the O
control O
diet O
, O
which O
was O
subsequently O
reversed O
by O
supplementation O
with O
fisetin B
. O

In O
addition O
, O
fisetin B
supplementation O
significantly O
reduced O
hepatic O
mRNA O
abundance O
of O
FAS O
, O
ATPCL O
and O
G6Pase O
compared O
to O
the O
control O
group O
. O

Finally O
, O
epididymal O
mRNA O
abundance O
of O
GLUT4 O
was O
significantly O
increased O
by O
fisetin B
supplementation O
, O
compared O
to O
levels O
in O
the O
control O
and O
HF O
groups O
. O

Enhancement O
of O
GLUT4 O
expression O
by O
fisetin B
was O
further O
confirmed O
in O
differentiated O
3T3 O
- O
L1 O
adipocytes O
. O

Fisetin B
supplementation O
decreases O
cardiovascular O
risks O
by O
ameliorating O
hepatic O
steatosis O
and O
lowering O
circulating O
glucose B
concentrations O
. O

Enrichment O
of O
polyphenol B
contents O
and O
antioxidant O
activities O
of O
Irish O
brown O
macroalgae O
using O
food O
- O
friendly O
techniques O
based O
on O
polarity O
and O
molecular O
size O
. O

An O
enhancement O
of O
the O
total O
phenolic O
content O
( O
TPC O
) O
, O
radical O
scavenging O
abilities O
( O
RSA O
) O
and O
ferric B
reducing O
antioxidant O
power O
( O
FRAP O
) O
in O
the O
HMW O
fractions O
of O
3 O
. O
5 O
- O
100kDa O
and O
/ O
or O
> O
100kDa O
from O
the O
cold O
water O
and O
aqueous O
ethanolic O
extracts O
was O
observed O
. O

Quadrupole O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
Q O
- O
Tof O
- O
MS O
) O
suggests O
that O
phlorotannins O
of O
varying O
degrees O
of O
phloroglucinol B
polymerisation O
are O
present O
in O
LMW O
fractions O
of O
the O
three O
brown O
macroalgal O
species O
. O

Characterisation O
of O
chlorophyll B
oxidation O
mediated O
by O
peroxidative O
activity O
in O
olives O
( O
Olea O
europaea O
L O
. O
) O
cv O
. O

The O
oxidation O
of O
chlorophyll B
a I
( O
chl B
a I
) O
catalysed O
by O
peroxidase O
( O
POD O
) O
from O
mesocarp O
of O
the O
olive O
fruit O
( O
Olea O
europaea O
L O
. O
, O
cv O
Hojiblanca O
) O
in O
the O
presence O
of O
H2O2 B
and O
2 O
, O
4 O
- O
dichlorophenol O
( O
2 O
, O
4 O
- O
DCP O
) O
, O
is O
characterised O
via O
the O
individualised O
quantification O
of O
the O
products O
of O
the O
enzymatic O
reaction O
using O
a O
new O
methodology O
of O
HPLC O
- O
UV O
spectrometry O
. O

This O
innovation O
has O
allowed O
the O
discovery O
that O
, O
in O
addition O
to O
13 O
( O
2 O
) O
OH O
chl O
a O
and O
15 O
( O
1 O
) O
OH O
lactone O
chl O
a O
, O
which O
are O
the O
first O
products O
of O
POD O
on O
chl B
a I
, O
the O
reaction O
process O
sequentially O
creates O
another O
series O
of O
oxidised O
chlorophyll B
derivatives O
which O
have O
not O
been O
previously O
described O
. O

Likewise O
, O
a O
study O
of O
the O
effect O
of O
the O
concentration O
of O
the O
various O
cosubstrates O
on O
the O
POD O
reaction O
rate O
demonstrated O
that O
the O
correct O
establishment O
of O
the O
relative O
concentrations O
of O
the O
same O
( O
[ O
H2O2 B
] O
/ O
[ O
2 O
, O
4 O
- O
DCP O
] O
/ O
[ O
Chl O
] O
= O
1 O
: O
3 O
: O
0 O
. O
02 O
) O
is O
crucial O
to O
explaining O
inhibition O
effects O
by O
substrates O
and O
carrying O
out O
optimum O
measurements O
. O

Therefore O
, O
new O
essential O
parameters O
for O
the O
determination O
of O
POD O
activity O
on O
a O
chlorophyll B
substrate O
are O
established O
. O

Oil O
composition O
and O
characterisation O
of O
phenolic B
compounds O
of O
Opuntia O
ficus O
- O
indica O
seeds O
. O

Seeds O
ground O
into O
a O
fine O
powder O
were O
first O
, O
subjected O
to O
oil O
extraction O
and O
fatty B
acids I
analysis O
. O

The O
phenolic B
compounds O
were O
then O
extracted O
from O
the O
defatted O
powder O
of O
seeds O
in O
order O
to O
be O
quantified O
and O
characterised O
by O
liquid O
chromatography O
coupled O
to O
mass O
spectrometry O
( O
LC O
- O
MS O
( O
n O
) O
) O
and O
to O
nuclear O
magnetic O
resonance O
( O
LC O
- O
NMR O
) O
approaches O
. O

Gas O
chromatography O
analysis O
of O
the O
seed O
oil O
showed O
high O
percentages O
of O
linoleic B
acid I
in O
the O
four O
varieties O
ranging O
from O
58 O
% O
to O
63 O
% O
. O

The O
effectiveness O
of O
the O
extract O
from O
fermented O
soybeans O
was O
studied O
in O
3 O
model O
foods O
with O
different O
complexities O
, O
i O
. O
e O
. O
, O
linoleic B
acid I
emulsion O
, O
sunflower O
oil O
emulsions O
and O
bulk O
sunflower O
oil O
. O

A O
crude O
antioxidant O
extract O
( O
5mg O
/ O
g O
) O
showed O
a O
comparable O
antioxidant O
activity O
to O
0 O
. O
26mg O
/ O
g O
of O
butylated B
hydroxytoluene I
( O
BHT B
) O
in O
the O
linoleic B
acid I
emulsions O
. O

The O
extract O
exhibited O
a O
better O
capability O
to O
retard O
primary O
products O
in O
the O
linoleic B
acid I
systems O
than O
the O
secondary O
products O
. O

A O
dipeptide B
and O
an O
amino B
acid I
present O
in O
whey O
protein O
hydrolysate O
increase O
translocation O
of O
GLUT O
- O
4 O
to O
the O
plasma O
membrane O
in O
Wistar O
rats O
. O

Whey O
protein O
hydrolysate O
( O
WPH O
) O
is O
capable O
of O
increasing O
muscle O
glycogen O
reserves O
and O
of O
concentrating O
the O
glucose B
transporter O
in O
the O
plasma O
membrane O
( O
PM O
) O
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
which O
WPH O
components O
could O
modulate O
translocation O
of O
the O
glucose B
transporter O
GLUT O
- O
4 O
to O
the O
PM O
of O
animal O
skeletal O
muscle O
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l O
- O
isoleucine O
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l O
- O
isoleucine O
; O
( O
f O
) O
l O
- O
isoleucyl O
- O
l O
- O
leucine O
dipeptide O
; O
( O
g O
) O
l O
- O
leucyl O
- O
l O
- O
isoleucine O
dipeptide O
. O

Additionally O
, O
glycogen O
, O
glycaemia O
, O
insulin O
and O
free O
amino B
acids I
were O
also O
determined O
by O
standard O
methods O
. O

Of O
the O
WPH O
components O
tested O
, O
the O
amino O
acid O
l O
- O
isoleucine O
and O
the O
peptide O
l O
- O
leucyl O
- O
l O
- O
isoleucine O
showed O
greater O
efficiency O
in O
translocating O
GLUT O
- O
4 O
to O
the O
PM O
and O
of O
increasing O
glucose B
capture O
by O
skeletal O
muscle O
. O

Antioxidant O
, O
free O
radical O
scavenging O
and O
liver O
protective O
effects O
of O
friedelin B
isolated O
from O
Azima O
tetracantha O
Lam O
. O
leaves O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
antioxidant O
, O
free O
radical O
scavenging O
and O
liver O
protective O
effects O
of O
friedelin B
isolated O
from O
Azima O
tetracantha O
Lam O
. O
leaves O
. O

In O
in O
vitro O
antioxidant O
study O
, O
the O
free O
radical O
scavenging O
effect O
of O
friedelin B
on O
2 O
, O
2 O
- O
diphenyl O
- O
picrylhydrazyl O
( O
DPPH B
) O
, O
hydroxyl B
, O
nitric B
oxide I
and O
superoxide B
radicals O
were O
evaluated O
. O

Friedelin B
showed O
very O
good O
scavenging O
effect O
on O
DPPH B
( O
IC50 O
21 O
. O
1mM O
) O
, O
hydroxyl B
( O
IC50 O
19 O
. O
8mM O
) O
, O
nitric B
oxide I
( O
IC50 O
22 O
. O
1mM O
) O
and O
superoxide B
( O
IC50 O
21 O
. O
9mM O
) O
radicals O
. O

Friedelin B
also O
showed O
strong O
suppressive O
effect O
on O
lipid O
peroxidation O
. O

In O
in O
vivo O
antioxidant O
study O
, O
CCl4 B
induced O
oxidative O
stress O
on O
rats O
produced O
significant O
increase O
in O
serum O
glutamate B
oxaloacetate O
transaminase O
( O
SGOT O
) O
, O
serum O
glutamate B
pyruvate B
transaminase O
( O
SGPT O
) O
and O
lactate B
dehydrogenase O
( O
LDH O
) O
levels O
along O
with O
reduction O
in O
liver O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
reduced B
glutathione I
( O
GSH B
) O
and O
glutathione B
peroxidase O
( O
GPx O
) O
levels O

Pre O
- O
treatment O
of O
rats O
with O
friedelin B
at O
40mg O
/ O
kg O
for O
7days O
restored O
these O
levels O
to O
normality O
and O
showed O
liver O
protection O
, O
comparable O
to O
the O
standard O
, O
silymarin O
( O
25mg O
/ O
kg O
) O
. O

These O
results O
clearly O
demonstrated O
that O
friedelin B
possessed O
marked O
antioxidant O
and O
liver O
protective O
effects O
. O

In O
vitro O
bioavailability O
of O
total O
selenium B
and O
selenium B
species O
from O
seafood O
. O

In O
vitro O
bioavailability O
of O
total O
selenium B
and O
selenium B
species O
from O
different O
raw O
seafood O
has O
been O
assessed O
by O
using O
a O
simulated O
gastric O
and O
intestinal O
digestion O
/ O
dialysis O
method O
. O

Inductively O
coupled O
plasma O
- O
mass O
spectrometry O
( O
ICP O
- O
MS O
) O
was O
used O
to O
assess O
total O
selenium B
contents O
after O
a O
microwave O
assisted O
acid O
digestion O
, O
and O
also O
to O
quantify O
total O
selenium B
in O
the O
dialyzable O
and O
non O
- O
dialyzable O
fractions O
. O

Selenium B
speciation O
in O
the O
dialyzates O
was O
assessed O
by O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
coupled O
with O
ICP O
- O
MS O
detection O
. O

Major O
Se B
species O
( O
selenium O
methionine O
and O
oxidized O
selenium O
methionine O
) O
from O
dialyzate O
were O
identified O
and O
characterized O
by O
HPLC O
coupled O
to O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
. O

Selenocystine O
was O
detected O
at O
low O
concentrations O
while O
Se B
- O
( O
Methyl O
) O
selenocysteine O
and O
inorganic O
selenium B
species O
( O
selenite O
and O
selenate B
) O
were O
not O
detected O
in O
the O
dialyzate O
. O

Low O
bioavailability O
percentages O
for O
total O
selenium B
( O
6 O
. O
69 O
+ O
/ O
- O
3 O
. O
39 O
and O
5 O
. O
45 O
+ O
/ O
- O
2 O
. O
44 O
% O
for O
fish O
and O
mollusk O
samples O
, O
respectively O
) O
were O
obtained O
. O

Similar O
bioavailability O
percentages O
was O
achieved O
for O
total O
selenium B
as O
a O
sum O
of O
selenium B
species O
( O
selenocystine O
plus O
oxidized O
selenium O
methionine O
and O
selenium O
methionine O
, O
mainly O
) O
. O

HPLC O
- O
MS O
data O
confirmed O
SeMet B
oxidation O
during O
the O
in O
vitro O
procedure O
. O

Oregon O
' O
Pinot O
noir O
' O
grape O
anthocyanin B
enhancement O
by O
early O
leaf O
removal O
. O

Fruit O
anthocyanin B
composition O
was O
examined O
at O
harvest O
for O
the O
last O
two O
vintages O
( O
2010 O
and O
2011 O
) O
and O
compared O
to O
a O
control O
- O
no O
cluster O
zone O
leaf O
removal O
. O

All O
clusters O
contained O
the O
five O
anthocyanins B
typically O
found O
in O
' O
Pinot O
noir O
' O
. O

Leaf O
removal O
at O
bloom O
and O
maintained O
until O
harvest O
produced O
maximum O
anthocyanin B
accumulation O
in O
' O
Pinot O
noir O
' O
grapes O
( O
site O
A O
= O
85 O
. O
24mg O
/ O
100g O
and O
site O
B O
= O
125 O
. O
06mg O
/ O
100g O
) O
, O
compared O
to O
no O
leaf O
removal O
( O
control O
; O
site O
A O
= O
57 O
. O
91mg O
/ O
100g O
and O
site O
B O
= O
97 O
. O
56mg O
/ O
100g O
) O
. O

Even O
leaf O
removal O
at O
bunch O
closure O
( O
last O
leaf O
removal O
initiation O
period O
) O
increased O
grape O
anthocyanin B
( O
site O
A O
= O
73 O
. O
22mg O
/ O
100g O
and O
site O
B O
= O
118 O
. O
93mg O
/ O
100g O
) O
compared O
to O
control O
, O
but O
total O
anthocyanins B
were O
lower O
than O
grapes O
from O
bloom O
leaf O
removal O
( O
first O
time O
period O
) O
. O

Inhibitory O
effects O
of O
myricetin B
on O
mammalian O
DNA O
polymerase O
, O
topoisomerase O
and O
human O
cancer O
cell O
proliferation O
. O

Myricetin B
( O
3 O
, O
3 O
' O
, O
4 O
' O
, O
5 O
, O
5 O
' O
, O
7 O
- O
hexahydroxyflavone O
) O
was O
the O
most O
potent O
inhibitor O
of O
pols O
amongst O
the O
compounds O
tested O
, O
with O
IC50 O
values O
of O
21 O
. O
3 O
- O
40 O
. O
9 O
mu O
M O
. O

Myricetin B
also O
inhibited O
human O
DNA O
topoisomerase O
II O
( O
topo O
II O
) O
activity O
with O
an O
IC50 O
value O
of O
27 O
. O
5 O
mu O
M O
, O
but O
did O
not O
inhibit O
the O
activities O
of O
other O
DNA O
metabolic O
enzymes O
tested O
. O

Myricetin B
also O
did O
not O
influence O
the O
direct O
binding O
to O
double O
stranded O
DNA O
as O
determined O
by O
thermal O
transition O
analysis O
. O

An O
experimental O
investigation O
was O
performed O
on O
blend O
extra O
virgin O
olive O
oils O
( O
EVOOs O
) O
from O
different O
cultivars O
and O
EVOO O
from O
different O
olive O
monovarieties O
( O
Coratina O
, O
Leccino O
, O
Maiatica O
, O
Ogliarola O
) O
with O
the O
aim O
to O
evaluate O
the O
possibility O
of O
estimating O
the O
perceived O
bitterness O
intensity O
by O
using O
chemical O
indices O
, O
such O
as O
the O
total O
phenol B
content O
and O
the O
compounds O
responsible O
for O
oil O
bitterness O
measured O
spectrophotometrical O
at O
225nm O
( O
K225 O
value O
) O
, O
as O
bitterness O
predictors O
in O
different O
EVOO O
. O

Polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
phenolic B
substances O
in O
meat O
products O
smoked O
with O
different O
types O
of O
wood O
and O
smoking O
spices O
. O

The O
contents O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
15 O
+ O
1 O
EU O
PAH B
) O
and O
phenolic B
substances O
( O
guaiacol O
, O
4 O
- O
methylguaiacol O
, O
syringol O
, O
eugenol B
, O
and O
trans O
- O
isoeugenol O
) O
were O
investigated O
in O
smouldering O
- O
smoked O
Frankfurters O
and O
mini O
- O
salamis O
. O

The O
use O
of O
poplar O
and O
hickory O
led O
to O
a O
decrease O
in O
the O
PAH B
contents O
in O
the O
range O
of O
35 O
- O
55 O
% O
compared O
to O
the O
commonly O
used O
beech O
wood O
. O

Higher O
PAH B
contents O
by O
using O
softwood O
were O
not O
observed O
. O

The O
use O
of O
the O
rapidly O
growing O
poplar O
seems O
to O
be O
a O
reasonable O
approach O
for O
reducing O
the O
PAH B
contents O
in O
smoked O
meat O
products O
. O

Furthermore O
, O
the O
sum O
contents O
of O
the O
five O
phenolic B
substances O
in O
sausages O
smoked O
with O
poplar O
were O
higher O
, O
or O
only O
slightly O
lower O
, O
when O
compared O
to O
the O
use O
of O
beech O
. O

Meanwhile O
, O
WFI O
also O
inhibited O
tyrosinase O
activity O
and O
NO B
generation O
in O
lipopolysaccharide O
( O
LPS O
) O
stimulated O
macrophages O
. O

High O
performance O
liquid O
chromatography O
analysis O
suggests O
that O
the O
major O
phenolic B
constituents O
in O
WFI O
are O
chlorogenic B
acid I
, O
rutin B
, O
quercetin B
, O
luteolin B
and O
kaempferol B
. O

The O
total O
water O
loss O
in O
83days O
was O
about O
62 O
% O
and O
the O
sugar B
concentration O
rose O
from O
225 O
to O
464g O
/ O
L O
. O

Within O
the O
free O
volatile O
compounds O
, O
isoamyl O
alcohols O
, O
benzaldehyde O
and O
guaiacol O
registered O
the O
largest O
increase O
above O
the O
concentration O
effect O
due O
to O
water O
loss O
; O
while O
within O
the O
bound O
volatile O
compounds O
were O
isoamyl O
alcohols O
, O
ethyl O
vanillate O
and O
benzoic B
acid I
. O

The O
aromatic O
profile O
of O
the O
raisins O
obtained O
were O
mainly O
caramelised O
, O
floral O
, O
phenolic B
and O
burned O
. O

Among O
10 O
compounds O
identified O
( O
saponins B
, O
flavonoids B
and O
sterols B
) O
five O
were O
reported O
for O
the O
first O
time O
in O
Z O
. O
album O
. O

Furthermore O
, O
novel O
biological O
activities O
of O
hexane B
, O
dichloromethane B
and O
methanolic O
extracts O
were O
assessed O
. O

Results O
showed O
that O
methanolic O
extract O
exhibit O
the O
highest O
antioxidant O
activity O
using O
in O
vitro O
ORAC O
test O
and O
anti O
- O
inflammatory O
activity O
, O
inhibiting O
by O
84 O
. O
8 O
% O
NO B
release O
in O
RAW264 O
. O
7 O
macrophages O
. O

However O
, O
dichloromethane B
extract O
proved O
the O
utmost O
antioxidant O
activity O
in O
cell O
( O
WS1 O
) O
based O
- O
assay O
( O
IC50 O
= O
57 O
mu O
g O
/ O
ml O
) O
and O
interesting O
anticancer O
capacity O
against O
human O
lung O
carcinoma O
( O
A O
- O
549 O
) O
and O
colon O
adenocarcinoma O
( O
DLD O
- O
1 O
) O
cells O
( O
IC50 O
= O
37 O
and O
48 O
mu O
g O
/ O
ml O
, O
respectively O
) O
. O

These O
findings O
can O
be O
attributed O
to O
the O
presence O
of O
triterpenes B
, O
flavonoids B
and O
sterols B
in O
Z O
. O
album O
, O
which O
are O
widely O
known O
as O
powerful O
antioxidants O
and O
used O
in O
various O
industrial O
fields O
. O

Degradation O
of O
complex O
carbohydrate B
: O
Immobilization O
of O
pectinase O
from O
Bacillus O
licheniformis O
KIBGE O
- O
IB21 O
using O
calcium B
alginate O
as O
a O
support O
. O

In O
current O
study O
, O
partially O
purified O
pectinase O
from O
Bacillus O
licheniformis O
KIBGE O
- O
IB21 O
was O
immobilized O
in O
calcium B
alginate O
beads O
. O

The O
effect O
of O
sodium B
alginate O
and O
calcium O
chloride O
concentration O
on O
immobilization O
was O
studied O
and O
it O
was O
found O
that O
the O
optimal O
sodium B
alginate O
and O
calcium O
chloride O
concentration O
was O
3 O
. O
0 O
% O
and O
0 O
. O
2M O
, O
respectively O
. O

In O
term O
of O
pectinase O
immobilization O
efficiency O
and O
stability O
, O
this O
calcium B
alginate O
beads O
approach O
seemed O
to O
permit O
good O
results O
and O
can O
be O
used O
to O
make O
a O
bioreactor O
for O
various O
applications O
in O
food O
industries O
. O

Influence O
of O
pH O
, O
metal O
chelator O
, O
free O
radical O
scavenger O
and O
interfacial O
characteristics O
on O
the O
oxidative O
stability O
of O
beta B
- I
carotene I
in O
conjugated O
whey O
protein O
- O
pectin O
stabilised O
emulsion O
. O

The O
influence O
of O
whey O
protein O
isolate O
( O
WPI O
) O
- O
beet O
pectin O
conjugates O
formed O
by O
dry O
- O
heating O
on O
the O
oxidative O
stability O
of O
beta B
- I
carotene I
in O
O O
/ O
W O
emulsions O
was O
studied O
. O

It O
was O
mainly O
focused O
on O
the O
influence O
of O
pH O
, O
metal O
chelator O
, O
free O
radical O
scavenger O
and O
interfacial O
characteristics O
on O
the O
degradation O
of O
beta B
- I
carotene I
in O
the O
emulsion O
stabilised O
by O
conjugate O
. O

The O
conjugate O
increased O
the O
oxidative O
stability O
of O
beta B
- I
carotene I
in O
the O
emulsion O
as O
compared O
to O
their O
unconjugated O
mixture O
at O
pH O
7 O
. O
0 O
. O

The O
desferoxamine O
retarded O
beta B
- I
carotene I
degradation O
at O
pH O
4 O
. O
0 O
more O
effectively O
than O
pH O
7 O
. O
0 O
and O
more O
effectively O
in O
the O
emulsion O
with O
the O
conjugate O
than O
the O
unconjugated O
mixture O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
addition O
of O
200mg O
/ O
kg O
alpha B
- I
tocopherol I
significantly O
improved O
the O
stability O
of O
beta B
- I
carotene I
in O
the O
conjugate O
stabilised O
emulsion O
. O

The O
emulsions O
were O
washed O
to O
remove O
conjugate O
not O
absorbed O
to O
the O
emulsion O
droplet O
interface O
, O
indicating O
that O
unabsorbed O
emulsifiers O
could O
protect O
beta B
- I
carotene I
. O

Phosphatidylcholine B
( O
PC O
) O
, O
phosphatidylethanola B
( O
PE O
) O
, O
phosphatidylinositol B
( O
PI O
) O
and O
their O
lyso O
forms O
are O
the O
major O
PLs O
in O
rice O
. O

A O
series O
of O
xanthans O
containing O
different O
levels O
of O
the O
charged O
group O
pyruvate B
has O
been O
examined O
. O

X O
- O
ray O
diffraction O
pattern O
identification O
software O
and O
an O
inorganic O
X O
- O
ray O
diffraction O
database O
showed O
the O
origin O
of O
the O
sharp O
peaks O
to O
be O
due O
to O
sodium B
sulphate I
polymorphs O
. O

Impact O
of O
pectin O
type O
on O
the O
storage O
stability O
of O
black O
currant O
( O
Ribes O
nigrum O
L O
. O
) O
anthocyanins B
in O
pectic O
model O
solutions O
. O

The O
effects O
of O
different O
pectins O
on O
the O
stabilisation O
of O
black O
currant O
anthocyanins B
in O
viscous O
model O
solutions O
at O
pH O
3 O
. O
0 O
were O
investigated O
. O

For O
this O
purpose O
, O
low O
esterified O
amidated O
( O
AM O
) O
, O
low O
( O
LM O
) O
and O
high O
( O
HM O
) O
methoxylated O
citrus O
and O
apple O
pectins O
and O
a O
sugar O
beet O
pectin O
were O
added O
to O
a O
purified O
anthocyanin B
extract O
( O
ACN B
- O
E O
) O
and O
to O
an O
extract O
containing O
anthocyanins B
and O
non O
- O
anthocyanin O
phenolics O
( O
PP O
- O
E O
) O
. O

Anthocyanin B
contents O
were O
monitored O
by O
HPLC O
analysis O
over O
a O
period O
of O
18weeks O
, O
and O
half O
- O
life O
and O
destruction O
values O
were O
calculated O
. O

In O
all O
pectic O
model O
solutions O
anthocyanin B
stability O
was O
significantly O
improved O
compared O
to O
stability O
of O
the O
extracts O
without O
added O
pectins O
( O
blank O
) O
. O

In O
model O
systems O
containing O
citrus O
pectins O
, O
anthocyanin B
stabilisation O
was O
better O
compared O
to O
that O
of O
apple O
pectins O
having O
similar O
degrees O
of O
esterification O
and O
amidation O
, O
respectively O
. O

This O
was O
primarily O
due O
to O
the O
strong O
interaction O
of O
delphinidin O
glycosides O
with O
the O
citrus O
pectins O
, O
whereas O
stabilisation O
of O
cyanidin B
derivatives O
was O
less O
important O
. O

Sugar O
beet O
pectin O
improved O
anthocyanin B
stability O
only O
to O
a O
limited O
extent O
. O

Addition O
of O
citrate O
to O
pectic O
systems O
accelerated O
anthocyanin B
decay O
. O

Stabilising O
effects O
of O
pectins O
were O
hardly O
noticeable O
when O
evaluating O
total O
phenolic B
content O
( O
TPC O
, O
Folin O
- O
Ciocalteu O
) O
and O
antioxidant O
capacity O
during O
storage O
. O

Conformational O
restriction O
approach O
to O
BACE1 O
inhibitors O
II O
: O
SAR O
study O
of O
the O
isocytosine O
derivatives O
fixed O
with O
a O
cis B
- I
cyclopropane I
ring O
. O

In O
the O
latter O
approach O
, O
another O
type O
of O
inhibitor O
17 O
bearing O
an O
ethylene B
spacer O
between O
two O
aromatic O
rings O
was O
found O
to O
exhibit O
good O
BACE1 O
inhibitory O
activity O
, O
while O
the O
corresponding O
conformationally O
unrestricted O
compound O
25 O
showed O
no O
activity O
. O

This O
result O
revealed O
an O
interesting O
effect O
of O
a O
conformational O
restriction O
with O
a O
cyclopropane B
ring O
. O

A O
multi O
- O
dimensional O
iterative O
parallel O
synthesis O
effort O
quickly O
explored O
isatin B
replacements O
and O
a O
number O
of O
southern O
heterobiaryl O
variations O
with O
no O
improvement O
over O
ML129 O
and O
ML172 O
. O

An O
HTS O
campaign O
identified O
several O
weak O
M5 O
PAMs O
( O
M5 O
EC50 O
> O
10 O
mu O
M O
) O
with O
a O
structurally O
related O
isatin B
core O
that O
possessed O
a O
southern O
phenethyl O
ether O
linkage O
. O

ACh B
CRC O
. O

In O
a O
rat O
glucagon O
challenge O
model O
, O
it O
was O
shown O
to O
reduce O
the O
glucagon O
- O
elicited O
glucose B
excursion O
in O
a O
dose O
- O
dependent O
manner O
and O
at O
a O
concentration O
consistent O
with O
its O
rat O
in O
vitro O
potency O
. O

Altered O
cholesterol B
homeostasis O
in O
aged O
macrophages O
linked O
to O
neovascular O
macular O
degeneration O
. O

( O
2013 O
) O
now O
demonstrate O
that O
in O
aged O
macrophages O
decreased O
ABCA1 O
expression O
, O
regulated O
by O
liver O
X O
receptor O
and O
miR O
- O
33 O
, O
impairs O
export O
of O
intracellular O
cholesterol B
, O
which O
promotes O
neovascular O
AMD O
. O

Lignans B
extracted O
from O
Vitex O
negundo O
possess O
cytotoxic O
activity O
by O
G2 O
/ O
M O
phase O
cell O
cycle O
arrest O
and O
apoptosis O
induction O
. O

Evn O
- O
50 O
is O
a O
lignan B
compounds O
mixture O
extracted O
from O
Vitex O
negundo O
, O
a O
widely O
used O
herb O
in O
traditional O
Chinese O
medicine O
. O

This O
study O
is O
aimed O
to O
define O
the O
spectrum O
of O
cytotoxic O
activity O
of O
EVn O
- O
50 O
, O
and O
also O
to O
investigate O
mechanisms O
underlying O
the O
anticancer O
actions O
via O
assessing O
the O
influence O
on O
cell O
cycle O
using O
EVn O
- O
50 O
, O
and O
the O
lignan B
compound O
VB1 O
purified O
from O
EVn O
- O
50 O
. O

Our O
data O
show O
that O
EVn O
- O
50 O
, O
lignan B
compounds O
extracted O
from O
Vitex O
negundo O
, O
possesses O
a O
broad O
spectrum O
cytotoxic O
effect O
via O
arresting O
cancer O
cells O
at O
G2 O
/ O
M O
phase O
cell O
cycle O
and O
subsequently O
inducing O
apoptosis O
. O

Transfer O
of O
metformin B
across O
the O
rat O
placenta O
is O
mediated O
by O
organic O
cation O
transporter O
3 O
( O
OCT3 O
/ O
SLC22A3 O
) O
and O
multidrug O
and O
toxin O
extrusion O
1 O
( O
MATE1 O
/ O
SLC47A1 O
) O
protein O
. O

Since O
metformin B
is O
a O
substrate O
of O
both O
OCT3 O
and O
MATE1 O
, O
in O
this O
study O
we O
used O
the O
model O
of O
dually O
perfused O
rat O
placenta O
to O
investigate O
the O
role O
of O
these O
transporters O
in O
metformin B
passage O
across O
the O
placenta O
. O

We O
observed O
concentration O
- O
dependent O
transplacental O
clearance O
of O
metformin B
in O
both O
maternal O
- O
to O
- O
fetal O
and O
fetal O
- O
to O
- O
maternal O
directions O
; O
in O
addition O
metformin B
crossed O
the O
placenta O
from O
the O
fetal O
to O
maternal O
compartment O
even O
against O
its O
concentration O
gradient O
. O

This O
transport O
was O
completely O
inhibited O
by O
MPP B
( I
+ I
) I
, O
a O
common O
OCT3 O
and O
MATE1 O
inhibitor O
. O

Furthermore O
, O
we O
observed O
that O
the O
oppositely O
directed O
H B
( I
+ I
) I
- O
gradient O
can O
drive O
the O
secretion O
of O
metformin B
from O
placenta O
to O
maternal O
circulation O
, O
confirming O
apical O
efflux O
of O
metformin B
from O
trophoblast O
by O
MATE1 O
. O

In O
conclusion O
, O
we O
suggest O
an O
important O
role O
of O
OCT3 O
and O
MATE1 O
in O
the O
transplacental O
transfer O
of O
metformin B
. O

In O
particular O
, O
triple O
negative O
breast O
cancers O
( O
TNBCs O
) O
, O
which O
do O
not O
express O
the O
genes O
for O
estrogen B
/ O
progesterone B
receptors O
( O
ER O
/ O
PR O
) O
and O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
, O
have O
been O
associated O
with O
poor O
prognosis O
and O
metastasis O
. O

Chalcones B
, O
the O
biosynthetic O
precursors O
of O
flavonoids B
present O
in O
edible O
plants O
, O
exert O
cytotoxic O
and O
chemopreventive O
activities O
. O

Although O
mounting O
evidence O
suggests O
the O
anticancer O
properties O
of O
chalcones B
, O
limited O
information O
is O
available O
regarding O
the O
inhibitory O
effects O
of O
chalcones B
on O
the O
aggressiveness O
of O
breast O
cancer O
cells O
. O

The O
present O
study O
aimed O
to O
investigate O
the O
effects O
of O
chalcone B
and O
its O
derivatives O
on O
the O
growth O
and O
the O
invasiveness O
of O
TNBC O
cells O
. O

Here O
, O
we O
showed O
that O
treatment O
with O
chalcone B
, O
2 O
- O
hydroxychalcone O
, O
and O
xanthohumol O
for O
24h O
inhibited O
the O
growth O
of O
MDA O
- O
MB O
- O
231cells O
with O
IC50 O
values O
of O
18 O
. O
1 O
, O
4 O
. O
6 O
, O
and O
6 O
. O
7 O
mu O
M O
, O
respectively O
. O

Similarly O
, O
Chalcone B
, O
2 O
- O
hydroxychalcone O
, O
and O
xanthohumol O
also O
exerted O
cytotoxicity O
in O
another O
TNBC O
cell O
line O
, O
Hs578T O
. O

Importantly O
, O
2 O
- O
hydroxychalcone O
and O
xanthohumol O
exerted O
more O
potent O
inhibitory O
effects O
on O
the O
proliferation O
, O
MMP O
- O
9 O
expression O
and O
invasive O
phenotype O
of O
MDA O
- O
MB O
- O
231 O
than O
chalcone B
. O

These O
results O
suggest O
a O
potential O
application O
of O
these O
chalcones B
as O
anticancer O
agents O
that O
can O
alleviate O
malignant O
progression O
of O
TNBC O
. O

Increased O
dissolution O
and O
oral O
absorption O
of O
itraconazole B
/ O
Soluplus B
extrudate O
compared O
with O
itraconazole B
nanosuspension O
. O

The O
purpose O
of O
this O
article O
was O
to O
compare O
the O
in O
vitro O
and O
in O
vivo O
profiles O
of O
itraconazole B
( O
ITZ B
) O
extrudates O
and O
nanosuspension O
separately O
prepared O
by O
two O
different O
methods O
. O

And O
it O
was O
proved O
truly O
to O
form O
nanocrystalline O
and O
amorphous O
ITZ B
characterized O
by O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
X O
- O
ray O
powder O
diffraction O
( O
XRD O
) O
analysis O
, O
Fourier O
transform O
infrared O
spectrum O
( O
FTIR O
) O
, O
transmission O
electron O
microscope O
( O
TEM O
) O
, O
and O
scanning O
electron O
microscope O
( O
SEM O
) O
. O

The O
release O
of O
ITZ B
/ O
Soluplus B
solid O
dispersions O
with O
amorphous O
ITZ B
was O
almost O
complete O
while O
only O
40 O
% O
release O
was O
obtained O
with O
ITZ B
nanocrystals O
. O

In O
the O
in O
vivo O
assay O
, O
the O
AUC O
( O
0 O
- O
t O
) O
and O
Cmax O
of O
ITZ B
/ O
Soluplus B
were O
6 O
. O
9 O
- O
and O
11 O
. O
6 O
- O
time O
higher O
than O
those O
of O
pure O
ITZ B
. O

The O
formulation O
of O
the O
extrudate O
had O
an O
AUC O
( O
0 O
- O
t O
) O
and O
Cmax O
similar O
to O
those O
of O
ITZ B
and O
also O
OH O
- O
ITZ O
compared O
with O
the O
commercial O
capsule O
( O
Sporanox O
( O
R O
) O
) O
. O

The O
results O
of O
this O
study O
showed O
increased O
dissolution O
and O
bioavailability O
of O
the O
solid O
dispersion O
of O
Soluplus B
- O
based O
carrier O
loading O
ITZ B
prepared O
by O
HME O
compared O
with O
the O
ITZ B
nanosuspension O
prepared O
by O
wet O
milling O
. O

In O
addition O
, O
AHS O
significantly O
increased O
the O
expression O
of O
plasticity O
- O
related O
proteins O
including O
postsynaptic O
density O
- O
95 O
, O
phosphor O
- O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptor O
1 O
, O
phospho B
- O
calcium B
- O
calmodulin O
dependent O
kinase O
II O
, O
phospho B
- O
protein O
kinase O
A O
Catalytic O
beta O
subunit O
, O
protein O
kinase O
C O
gamma O
subunit O
, O
phospho B
- O
CREB O
and O
brain O
derived O
neurotrophic O
factor O
. O

Furthermore O
, O
AHS O
increased O
the O
levels O
of O
acetylcholine B
( O
Ach B
) O
, O
but O
decreased O
cholinesterase O
( O
AchE O
) O
activity O
. O

These O
results O
demonstrated O
that O
AHS O
administration O
may O
prevent O
spatial O
learning O
and O
memory O
decline O
by O
scavenging O
free O
radicals O
, O
up O
- O
regulating O
the O
activity O
of O
antioxidant O
enzymes O
, O
decreasing O
the O
level O
of O
A O
beta O
, O
ameliorating O
dysfunction O
in O
synaptic O
plasticity O
, O
and O
reversing O
abnormal O
changes O
in O
Ach B
level O
and O
AchE O
activity O
. O

In O
the O
present O
study O
, O
we O
generated O
bioreducible O
cationic O
alginate O
- O
polyethylenimine B
( O
PEI B
) O
nanogels O
as O
a O
novel O
vaccine O
delivery O
system O
. O

Briefly O
, O
nanogels O
were O
prepared O
by O
the O
electrostatic O
interaction O
of O
negatively O
charged O
alginate O
sodium B
with O
branched O
PEI2k O
, O
followed O
by O
disulfide B
cross O
- O
linking O
to O
generate O
bioreducible O
nanogels O
( O
AP O
- O
SS O
) O
. O

Transcellular O
transport O
of O
aconitine B
across O
human O
intestinal O
Caco O
- O
2 O
cells O
. O

Aconitine B
( O
AC O
) O
is O
a O
highly O
toxic O
compound O
present O
in O
plants O
of O
the O
genus O
Aconitum O
. O

The O
influx O
of O
AC O
was O
temperature O
- O
, O
pH O
- O
and O
Na B
( I
+ I
) I
- O
dependent O
. O

Glucose B
markedly O
decreased O
the O
absorption O
of O
AC O
. O

However O
, O
the O
efflux O
of O
AC O
was O
temperature O
- O
and O
pH O
- O
dependent O
, O
but O
Na B
( I
+ I
) I
- O
independent O
. O

Cyclosporin O
A O
and O
verapamil B
, O
both O
inhibitors O
of O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
, O
significantly O
decreased O
the O
efflux O
of O
AC O
. O

A O
pH O
- O
dependent O
carrier O
- O
mediated O
transport O
system O
was O
the O
major O
absorption O
mechanism O
and O
a O
sodium B
- O
dependent O
glucose B
transporter O
may O
be O
involved O
. O

The O
wet O
masses O
of O
120 O
formulae O
were O
prepared O
taking O
microcrystalline O
celluloses O
as O
pelletization O
aid O
and O
lactose B
, O
hydroxypropyl B
methylcellulose O
grades O
, O
herbal O
medicines O
as O
model O
drugs O
. O

Functional O
studies O
did O
not O
reveal O
significant O
differences O
between O
the O
wild O
type O
and O
the O
Tyr135Phe O
allelic O
variants O
in O
their O
NPW O
mediated O
capacity O
to O
inhibit O
forskolin B
- O
induced O
cAMP B
production O
. O

Reference O
ranges O
for O
serum O
thyroid O
hormones O
free O
triiodothyronine B
( O
FT3 O
) O
, O
free O
thyroxine B
( O
FT4 O
) O
and O
thyroid O
stimulating O
hormone O
( O
TSH O
) O
in O
children O
were O
set O
using O
the O
assay O
kits O
currently O
used O
in O
clinical O
settings O
. O

Polybetaine O
modification O
of O
PDMS B
microfluidic O
devices O
to O
resist O
thrombus O
formation O
in O
whole O
blood O
. O

Assembled O
polydimethylsiloxane B
microfluidic O
devices O
were O
modified O
with O
a O
sulfobetaine O
polymer O
through O
continuous O
" O
tip O
- O
to O
- O
tip O
" O
modification O
, O
significantly O
reducing O
blood O
clotting O
and O
extending O
device O
patency O
under O
blood O
flow O
. O

Assessing O
triclosan B
- O
induced O
ecological O
and O
trans O
- O
generational O
effects O
in O
natural O
phytoplankton O
communities O
: O
a O
trait O
- O
based O
field O
method O
. O

We O
exposed O
replicated O
phytoplankton O
communities O
confined O
in O
semi O
- O
permeable O
membrane O
- O
based O
mesocosms O
to O
0 O
, O
0 O
. O
1 O
, O
1 O
and O
10 O
mu O
g O
L O
( O
- O
1 O
) O
triclosan B
( O
TCS B
) O
and O
placed O
them O
back O
in O
their O
original O
environment O
to O
investigate O
the O
occurrence O
of O
trans O
- O
generational O
responses O
at O
individual O
, O
population O
and O
community O
levels O
. O

TCS B
diffused O
out O
of O
mesocosms O
with O
a O
half O
- O
life O
of O
less O
than O
8 O
h O
, O
so O
that O
only O
the O
parental O
generation O
was O
directly O
stressed O
. O

We O
found O
significant O
changes O
in O
community O
functioning O
( O
increased O
productivity O
in O
terms O
of O
biovolume O
and O
total O
fluorescence O
) O
, O
with O
maximal O
effects O
at O
1 O
mu O
g O
L O
( O
- O
1 O
) O
TCS B
. O

Metabolic O
response O
demonstrated O
by O
18F B
- I
FDG I
- O
PET O
/ O
CT O
in O
metastatic O
medullary O
thyroid O
carcinoma O
under O
sorafenib O
therapy O
. O

The O
IC50 O
shifts O
ranged O
from O
9 O
- O
to O
> O
100 O
- O
fold O
, O
and O
the O
potency O
shifts O
collapsed O
in O
the O
presence O
of O
rifampicin B
, O
the O
inhibitor O
for O
OATPs O
. O

Expression O
of O
a O
novel O
mRNA O
transcript O
for O
human O
microsomal O
epoxide B
hydrolase O
( O
EPHX1 O
) O
is O
regulated O
by O
short O
open O
reading O
frames O
within O
its O
5 O
' O
- O
untranslated O
region O
. O

Microsomal O
epoxide B
hydrolase O
( O
mEH O
, O
EPHX1 O
) O
is O
a O
critical O
xenobiotic O
- O
metabolizing O
enzyme O
, O
catalyzing O
both O
detoxification O
and O
bioactivation O
reactions O
that O
direct O
the O
disposition O
of O
chemical O
epoxides O
, O
including O
the O
carcinogenic O
metabolites O
of O
several O
polycyclic B
aromatic I
hydrocarbons I
. O

Effects O
of O
Intraduodenal O
Glutamine B
on O
Incretin O
Hormone O
and O
Insulin O
Release O
, O
the O
Glycemic O
Response O
to O
an O
Intraduodenal O
Glucose B
Infusion O
, O
and O
Antropyloroduodenal O
Motility O
in O
Health O
and O
Type O
2 O
Diabetes O
. O

OBJECTIVEGlutamine O
reduces O
postprandial O
glycemia O
when O
given O
before O
oral O
glucose B
. O

We O
evaluated O
whether O
this O
is O
mediated O
by O
stimulation O
of O
insulin O
and O
/ O
or O
slowing O
of O
gastric O
emptying O
. O
RESEARCH O
DESIGN O
AND O
METHODSTen O
healthy O
subjects O
were O
studied O
during O
intraduodenal O
( O
ID O
) O
infusion O
of O
glutamine B
( O
7 O
. O
5 O
or O
15 O
g O
) O
or O
saline O
over O
30 O
min O
, O
followed O
by O
glucose B
( O
75 O
g O
over O
100 O
min O
) O
, O
while O
recording O
antropyloroduodenal O
pressures O
. O

Ten O
patients O
with O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
were O
also O
studied O
with O
15 O
g O
glutamine B
or O
saline O
. O
RESULTSID O
glutamine B
stimulated O
glucagon O
- O
like O
peptide O
1 O
( O
GLP O
- O
1 O
; O
healthy O
: O
P O
< O
0 O
. O
05 O
; O
T2DM O
: O
P O
< O
0 O
. O
05 O
) O
, O
glucose B
- O
dependent O
insulinotropic O
polypeptide O
( O
GIP O
; O
P O
= O
0 O
. O
098 O
; O
P O
< O
0 O
. O
05 O
) O
, O
glucagon O
( O
P O
< O
0 O
. O
01 O
; O
P O
< O
0 O
. O
001 O
) O
, O
insulin O
( O
P O
= O
0 O
. O

05 O
; O
P O
< O
0 O
. O
01 O
) O
, O
and O
phasic O
pyloric O
pressures O
( O
P O
< O
0 O
. O
05 O
; O
P O
< O
0 O
. O
05 O
) O
, O
but O
did O
not O
lower O
blood O
glucose B
( O
P O
= O
0 O
. O
077 O
; O
P O
= O
0 O
. O
5 O
) O
. O
CONCLUSIONSGlutamine O
does O
not O
lower O
glycemia O
after O
ID O
glucose B
, O
despite O
stimulating O
GLP O
- O
1 O
, O
GIP O
, O
and O
insulin O
, O
probably O
due O
to O
increased O
glucagon O
. O

Its O
capacity O
for O
pyloric O
stimulation O
suggests O
that O
delayed O
gastric O
emptying O
is O
a O
major O
mechanism O
for O
lowering O
glycemia O
when O
glutamine B
is O
given O
before O
oral O
glucose B
. O

Low O
- O
Carbohydrate B
Diet O
for O
the O
Treatment O
of O
Gestational O
Diabetes O
: O
A O
randomized O
controlled O
trial O
. O

OBJECTIVEMedical O
nutrition O
therapy O
based O
on O
the O
control O
of O
the O
amount O
and O
distribution O
of O
carbohydrates B
( O
CHO O
) O
is O
the O
initial O
treatment O
for O
gestational O
diabetes O
mellitus O
( O
GDM O
) O
, O
but O
there O
is O
a O
need O
for O
randomized O
controlled O
trials O
comparing O
different O
dietary O
strategies O
. O

OBJECTIVETo O
describe O
and O
make O
available O
an O
interactive O
, O
24 O
- O
variable O
homeostasis O
model O
assessment O
( O
iHOMA2 O
) O
that O
extends O
the O
HOMA2 O
model O
, O
enabling O
the O
modeling O
of O
physiology O
and O
treatment O
effects O
, O
to O
present O
equations O
of O
the O
HOMA2 O
and O
iHOMA2 O
models O
, O
and O
to O
exemplify O
iHOMA2 O
in O
two O
widely O
differing O
scenarios O
: O
changes O
in O
insulin O
sensitivity O
with O
thiazolidinediones B
and O
changes O
in O
renal O
threshold O
with O
sodium B
glucose B
transporter O
( O
SGLT2 O
) O
inhibition O
. O
RESEARCH O
DESIGN O
AND O

METHODSiHOMA2 O
enables O
a O
user O
of O
the O
available O
software O
to O
examine O
and O
modify O
the O
mathematical O
functions O
describing O
the O
organs O
and O
tissues O
involved O
in O
the O
glucose B
and O
hormonal O
compartments O
. O

We O
exemplify O
this O
with O
SGLT2 O
inhibition O
modeling O
( O
by O
changing O
the O
renal O
threshold O
parameters O
) O
using O
published O
data O
of O
renal O
effect O
, O
showing O
that O
the O
modeled O
effect O
is O
concordant O
with O
the O
effects O
on O
fasting O
glucose B
from O
independent O
data O
. O
RESULTSiHOMA2 O
modeling O
of O
thiazolidinediones B
effect O
suggested O
that O
changes O
in O
insulin O
sensitivity O
in O
the O
fasting O
state O
are O
predominantly O
hepatic O
. O

SGLT2 O
inhibition O
modeled O
by O
iHOMA2 O
resulted O
in O
a O
decrease O
in O
mean O
glucose B
of O
1 O
. O
1 O
mmol O
/ O
L O
. O

Observed O
data O
showed O
a O
decrease O
in O
glucose B
of O
0 O
. O
9 O
mmol O
/ O
L O
. O

Manipulation O
of O
iHOMA2s O
renal O
excretion O
threshold O
variable O
suggested O
that O
a O
decrease O
of O
17 O
% O
was O
required O
to O
obtain O
a O
0 O
. O
9 O
mmol O
/ O
L O
decrease O
in O
mean O
glucose B
. O
CONCLUSIONSiHOMA2 O
is O
an O
extended O
mathematical O
model O
for O
the O
assessment O
of O
insulin O
resistance O
and O
beta O
- O
cell O
function O
. O

The O
model O
can O
be O
used O
to O
evaluate O
therapeutic O
agents O
and O
predict O
effects O
on O
fasting O
glucose B
and O
insulin O
and O
on O
beta O
- O
cell O
function O
and O
insulin O
sensitivity O
. O

Interestingly O
, O
several O
classes O
of O
inhibitors O
notably O
the O
hydroxamates B
, O
display O
a O
large O
shift O
in O
potency O
between O
the O
two O
enzyme O
forms O
. O

LPS O
exacerbated O
the O
effects O
of O
ketoconazole B
and O
clozapine B
toxicity O
but O
not O
those O
of O
their O
non O
- O
IDILI O
- O
related O
comparators O
, O
voriconazole O
and O
olanzapine B
. O

However O
, O
the O
IDILI O
- O
related O
drugs O
diclofenac B
, O
carbamazepine B
, O
and O
troglitazone B
did O
not O
show O
synergistic O
toxicity O
with O
LPS O
after O
incubation O
for O
24 O
h O
. O

Co O
- O
incubation O
of O
ketoconazole B
and O
clozapine B
with O
LPS O
decreased O
the O
levels O
of O
glutathione B
in O
hPCLS O
, O
but O
this O
was O
not O
seen O
for O
the O
other O
drugs O
. O

All O
drugs O
affected O
LPS O
- O
induced O
cytokine O
release O
, O
but O
interestingly O
, O
only O
ketoconazole B
and O
clozapine B
increased O
the O
level O
of O
LPS O
- O
induced O
TNF O
release O
. O

Decreased O
levels O
of O
glutathione B
and O
cysteine B
conjugates O
of O
clozapine B
were O
detected O
in O
IDILI O
- O
responding O
livers O
following O
cotreatment O
with O
LPS O
. O

In O
conclusion O
, O
we O
identified O
ketoconazole B
and O
clozapine B
as O
drugs O
that O
exhibited O
synergistic O
toxicity O
with O
LPS O
, O
while O
glutathione B
and O
TNF O
were O
found O
to O
be O
potential O
biomarkers O
for O
IDILI O
- O
inducing O
drugs O
mediated O
by O
inflammatory O
stress O
. O

Controlling O
the O
Effective O
Surface O
Area O
and O
Pore O
Size O
Distribution O
of O
sp O
( O
2 O
) O
Carbon B
Materials O
and O
Their O
Impact O
on O
the O
Capacitance O
Performance O
of O
These O
Materials O
. O

A O
series O
of O
sp O
( O
2 O
) O
carbon B
materials O
with O
different O
specific O
surface O
area O
( O
SSA O
) O
and O
controlled O
pore O
size O
distribution O
( O
PSD O
) O
were O
synthesized O
at O
large O
scale O
through O
a O
facile O
and O
low O
- O
cost O
method O
. O

The O
SSA O
and O
PSD O
of O
these O
carbon B
materials O
were O
controlled O
by O
using O
different O
carbon B
sources O
and O
preparation O
methods O
. O

Based O
on O
these O
, O
a O
general O
model O
using O
the O
slit O
/ O
cylindrical O
NL O
- O
DFT O
approach O
is O
proposed O
for O
the O
estimation O
of O
the O
specific O
capacitance O
of O
sp O
( O
2 O
) O
carbon B
materials O
, O
which O
offers O
a O
simple O
but O
reliable O
method O
to O
predict O
the O
capacitance O
performance O
of O
these O
materials O
, O
thus O
speeding O
up O
the O
design O
and O
screening O
of O
the O
materials O
for O
high O
- O
performance O
supercapacitor O
and O
other O
surface O
area O
related O
devices O
. O

Approach O
to O
dark O
spin O
cooling O
in O
a O
diamond B
nanocrystal O
. O

Using O
a O
Hartman O
- O
Hahn O
protocol O
, O
we O
demonstrate O
spin O
polarization O
transfer O
from O
a O
single O
, O
optically O
polarized O
nitrogen B
- O
vacancy O
( O
NV O
) O
center O
to O
the O
ensemble O
of O
paramagnetic O
defects O
hosted O
by O
an O
individual O
diamond B
nanocrystal O
. O

The O
role O
of O
intracrine O
androgen B
metabolism O
, O
androgen B
receptor O
and O
apoptosis O
in O
the O
survival O
and O
recurrence O
of O
prostate O
cancer O
during O
androgen B
deprivation O
therapy O
. O

Almost O
all O
men O
present O
with O
advanced O
CaP O
and O
some O
men O
who O
fail O
potentially O
curative O
therapy O
are O
treated O
with O
androgen B
deprivation O
therapy O
( O
ADT O
) O
. O

The O
goal O
of O
this O
review O
is O
to O
apply O
our O
current O
understanding O
of O
CaP O
and O
castration O
- O
recurrent O
CaP O
( O
CR O
- O
CaP O
) O
to O
earlier O
studies O
that O
characterized O
ADT O
and O
the O
molecular O
mechanisms O
that O
facilitate O
the O
transition O
from O
androgen B
- O
stimulated O
CaP O
to O
CR O
- O
CaP O
. O

Multivalency O
is O
a O
key O
, O
ubiquitous O
phenomenon O
in O
nature O
characterized O
by O
a O
complex O
combination O
of O
binding O
mechanisms O
, O
with O
special O
relevance O
in O
carbohydrate B
- O
lectin O
recognition O
. O

Enhancing O
Catalytic O
Performance O
of O
Palladium B
in O
Gold O
and O
Palladium B
Alloy O
Nanoparticles O
for O
Organic O
Synthesis O
Reactions O
through O
Visible O
Light O
Irradiation O
at O
Ambient O
Temperatures O
. O

The O
intrinsic O
catalytic O
activity O
of O
palladium B
( O
Pd B
) O
is O
significantly O
enhanced O
in O
gold O
( O
Au B
) O
- O
Pd B
alloy O
nanoparticles O
( O
NPs O
) O
under O
visible O
light O
irradiation O
at O
ambient O
temperatures O
. O

The O
alloy O
NPs O
strongly O
absorb O
light O
and O
efficiently O
enhance O
the O
conversion O
of O
several O
reactions O
, O
including O
Suzuki O
- O
Miyaura O
cross O
coupling O
, O
oxidative O
addition O
of O
benzylamine O
, O
selective O
oxidation O
of O
aromatic O
alcohols O
to O
corresponding O
aldehydes B
and O
ketones B
, O
and O
phenol B
oxidation O
. O

The O
Au B
/ O
Pd B
molar O
ratio O
of O
the O
alloy O
NPs O
has O
an O
important O
impact O
on O
performance O
of O
the O
catalysts O
since O
it O
determines O
both O
the O
electronic O
heterogeneity O
and O
the O
distribution O
of O
Pd B
sites O
at O
the O
NP O
surface O
, O
with O
these O
two O
factors O
playing O
key O
roles O
in O
the O
catalytic O
activity O
. O

For O
example O
, O
the O
best O
conversion O
rate O
achieved O
thermally O
at O
30 O
degrees O
C O
for O
Suzuki O
- O
Miyaura O
cross O
coupling O
was O
37 O
% O
at O
a O
Au B
/ O
Pd B
ratio O
of O
1 O
: O
1 O
. O
86 O
, O
while O
under O
light O
illumination O
the O
yield O
increased O
to O
96 O
% O
under O
the O
same O
conditions O
. O

We O
believe O
that O
the O
conduction O
electrons O
of O
the O
NPs O
gain O
the O
light O
absorbed O
energy O
producing O
energetic O
electrons O
at O
the O
surface O
Pd B
sites O
, O
which O
enhances O
the O
sites O
' O
intrinsic O
catalytic O
ability O
. O

These O
findings O
provide O
useful O
guidelines O
for O
designing O
efficient O
catalysts O
composed O
of O
alloys O
of O
a O
plasmonic O
metal O
and O
a O
catalytically O
active O
transition B
metal I
for O
various O
organic O
syntheses O
driven O
by O
sunlight O
. O

Effects O
of O
Curcumin B
on O
Apoptosis O
and O
Oxidoinflammatory O
Regulation O
in O
a O
Rat O
Model O
of O
Acetic B
Acid I
- O
Induced O
Colitis O
: O
The O
Roles O
of O
c O
- O
Jun O
N B
- O
Terminal O
Kinase O
and O
p38 O
Mitogen O
- O
Activated O
Protein O
Kinase O
. O

Abstract O
The O
present O
study O
evaluated O
the O
effects O
of O
curcumin B
on O
epithelial O
cell O
apoptosis O
, O
the O
immunoreactivity O
of O
the O
phospho O
- O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
and O
phospho O
- O
p38 O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
in O
inflamed O
colon O
mucosa O
, O
and O
oxidative O
stress O
in O
a O
rat O
model O
of O
ulcerative O
colitis O
induced O
by O
acetic B
acid I
. O

Rats O
were O
randomly O
divided O
into O
three O
groups O
: O
control O
, O
acetic B
acid I
, O
and O
acetic B
acid I
+ O
curcumin B
. O

Curcumin B
( O
100 O
mg O
/ O
kg O
per O
day O
, O
intragastrically O
) O
was O
administered O
10 O
days O
before O
the O
induction O
of O
colitis O
and O
was O
continued O
for O
two O
additional O
days O
. O

Acetic B
acid I
- O
induced O
colitis O
caused O
a O
significant O
increase O
in O
the O
macroscopic O
and O
microscopic O
tissue O
ranking O
scores O
as O
well O
as O
an O
elevation O
in O
colonic O
myeloperoxidase O
( O
MPO O
) O
activity O
, O
malondialdehyde B
( O
MDA B
) O
levels O
, O
and O
the O
number O
of O
apoptotic O
epithelial O
cells O
in O
colon O
tissue O
compared O
to O
controls O
. O

Curcumin B
treatment O
was O
associated O
with O
amelioration O
of O
macroscopic O
and O
microscopic O
colitis O
sores O
, O
decreased O
MPO O
activity O
, O
and O
decreased O
MDA B
levels O
in O
acetic B
acid I
- O
induced O
colitis O
. O

Furthermore O
, O
oral O
curcumin B
supplementation O
clearly O
prevented O
programmed O
cell O
death O
and O
restored O
immunreactivity O
of O
MAPKs O
in O
the O
colons O
of O
colitic O
rats O
. O

The O
results O
of O
this O
study O
suggest O
that O
oral O
curcumin B
treatment O
decreases O
colon O
injury O
and O
is O
associated O
with O
decreased O
inflammatory O
reactions O
, O
lipid O
peroxidation O
, O
apoptotic O
cell O
death O
, O
and O
modulating O
p38 O
- O
and O
JNK O
- O
MAPK O
pathways O
. O

Oligonol O
supplementation O
attenuates O
body O
temperature O
and O
the O
circulating O
levels O
of O
prostaglandin B
e2 I
and O
cyclooxygenase O
- O
2 O
after O
heat O
stress O
in O
humans O
. O

Abstract O
Oligonol O
, O
a O
phenolic B
production O
from O
lychee O
, O
has O
been O
reported O
to O
exhibit O
anti O
- O
oxidative O
and O
anti O
- O
inflammatory O
effects O
. O

This O
study O
investigated O
the O
effect O
of O
Oligonol O
supplementation O
on O
circulating O
levels O
of O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
cyclooxygenase O
( O
COX O
) O
- O
2 O
, O
as O
well O
as O
body O
temperature O
, O
after O
heat O
stress O
in O
17 O
healthy O
human O
male O
volunteers O
( O
age O
, O
21 O
. O
6 O
+ O
/ O
- O
2 O
. O
1 O
years O
) O
. O

Serum O
concentrations O
of O
PGE2 B
and O
COX O
- O
2 O
were O
analyzed O
before O
, O
immediately O
after O
, O
and O
60 O
min O
after O
immersion O
. O

Oligonol O
intake O
significantly O
prevented O
elevation O
of O
tympanic O
( O
temperature O
difference O
: O
0 O
. O
17 O
degrees O
C O
at O
Post O
, O
P O
< O
. O
05 O
; O
0 O
. O
17 O
degrees O
C O
at O
Re O
- O
60 O
, O
P O
< O
. O
05 O
) O
and O
mean O
body O
temperatures O
( O
temperature O
difference O
: O
0 O
. O
18 O
degrees O
C O
at O
Post O
, O
P O
< O
. O
05 O
; O
0 O
. O
15 O
degrees O
C O
at O
Re O
- O
60 O
, O
P O
< O
. O
05 O
) O
, O
and O
lowered O
concentrations O
of O
serum O
PGE2 B
( O
increased O
by O
13 O
. O
3 O
% O
vs O
. O
29 O
. O
6 O
% O
at O
Post O
, O
P O
< O
. O
05 O
) O
and O
COX O
- O
2 O
( O
increased O
by O
15 O
. O
6 O
% O
vs O
. O
21 O

Our O
result O
suggests O
that O
Oligonol O
has O
the O
potential O
to O
suppress O
increases O
in O
body O
temperature O
under O
heat O
stress O
, O
and O
this O
is O
associated O
with O
decreases O
in O
serum O
levels O
of O
PGE2 B
and O
COX O
- O
2 O
. O

Abstract O
Enterolactone O
and O
enterodiol O
, O
mammalian O
lignans B
derived O
from O
dietary O
sources O
such O
as O
flaxseed O
, O
sesame O
seeds O
, O
kale O
, O
broccoli O
, O
and O
apricots O
, O
may O
impede O
tumor O
proliferation O
by O
inhibiting O
activation O
of O
nuclear O
factor O
kappa O
B O
( O
NF O
kappa O
B O
) O
and O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
. O

After O
supplementation O
, O
we O
observed O
significant O
correlations O
between O
intakes O
of O
plant O
lignan B
and O
urinary O
concentrations O
of O
total O
enterolignans O
( O
rho O
= O
0 O
. O
677 O
, O
P O
< O
. O
0001 O
) O
, O
enterolactone O
( O
rho O
= O
0 O
. O
676 O
, O
P O
< O
. O
0001 O
) O
, O
and O
enterodiol O
( O
rho O
= O
0 O
. O
628 O
, O
P O
< O
. O
0001 O
) O
. O

A O
novel O
series O
of O
amide B
derivatives O
of O
lomefloxacin O
were O
synthesized O
and O
evaluated O
for O
their O
topoisomerase O
I O
and O
II O
inhibitory O
activity O
as O
well O
as O
cytotoxicity O
against O
a O
panel O
of O
five O
human O
cancer O
cell O
lines O
. O

Tomatidine O
reduces O
the O
mRNA O
level O
of O
matrix O
metalloproteinase O
- O
2 O
( O
MMP O
- O
2 O
) O
, O
MMP O
- O
9 O
and O
increases O
the O
expression O
of O
reversion O
- O
inducing O
cysteine B
- O
rich O
protein O
with O
kazal O
motifs O
( O
RECK O
) O
, O
as O
well O
as O
tissue O
inhibitor O
of O
metalloproteinase O
- O
1 O
( O
TIMP O
- O
1 O
) O
. O

Furthermore O
, O
the O
treatment O
of O
inhibitors O
specific O
for O
PI3K O
/ O
Akt O
( O
LY294002 B
) O
, O
ERK O
( O
U0126 B
) O
, O
or O
NF O
- O
kappa O
B O
( O
pyrrolidine B
dithiocarbamate I
) O
to O
A549 O
cells O
reduced O
cell O
invasion O
and O
MMP O
- O
2 O
/ O
9 O
expression O
. O

The O
influence O
of O
Bauhinia O
forficata O
Link O
subsp O
. O
pruinosa O
tea O
on O
lipid O
peroxidation O
and O
non O
- O
protein O
SH B
groups O
in O
human O
erythrocytes O
exposed O
to O
high O
glucose B
concentrations O
. O

MATERIALS O
AND O
METHODS O
: O
Human O
erythrocytes O
were O
incubated O
with O
high O
glucose B
concentrations O
or O
glucose B
and O
BF O
tea O
for O
24h O
and O
48h O
. O

After O
incubation O
lipid O
peroxidation O
and O
non O
- O
protein O
SH B
levels O
were O
analyzed O
. O

Moreover O
, O
quantification O
of O
polyphenols B
and O
flavonoids B
, O
iron B
chelating O
property O
, O
scavenging O
of O
DPPH B
, O
and O
prevention O
of O
lipid O
peroxidation O
in O
isolated O
lipids O
were O
also O
assessed O
. O

RESULTS O
: O
A O
significant O
amount O
of O
polyphenols B
and O
flavonoids B
was O
observed O
. O

Moreover O
, O
BF O
tea O
was O
effective O
to O
increase O
non O
- O
protein O
SH B
levels O
and O
reduce O
lipid O
peroxidation O
induced O
by O
high O
glucose B
concentrations O
in O
human O
erythrocytes O
. O

CONCLUSION O
: O
The O
antioxidant O
effects O
of O
BF O
tea O
could O
be O
related O
to O
the O
presence O
of O
different O
phenolic B
and O
flavonoids B
components O
. O

We O
believe O
that O
these O
components O
can O
be O
responsible O
to O
protect O
human O
erythrocytes O
exposed O
to O
high O
glucose B
concentrations O
against O
oxidative O
damage O
. O

Therefore O
, O
this O
study O
was O
aimed O
to O
evaluate O
the O
anti O
- O
diabetic O
activity O
of O
the O
plant O
ethanol B
extract O
. O

After O
that O
, O
acute O
effect O
of O
the O
extract O
was O
executed O
in O
normal O
and O
streptozotocin B
- O
induced O
( O
60mg O
/ O
kg O
) O
diabetic O
mice O
. O

Oral O
glucose B
tolerance O
test O
and O
biochemical O
parameters O
were O
estimated O
at O
the O
end O
of O
the O
study O
. O

And O
also O
the O
extract O
displayed O
anti O
- O
hyperglycemic O
activity O
, O
improved O
antioxidant O
capacity O
, O
ameliorated O
the O
hyperlipidemia O
and O
carbohydrate B
metabolism O
in O
diabetic O
mice O
. O

AIM O
OF O
THE O
STUDY O
: O
The O
present O
studies O
aimed O
at O
evaluating O
the O
toxicological O
properties O
of O
the O
standardized O
ethanol B
extract O
of O
C O
. O
edulis O
root O
bark O
in O
rats O
, O
in O
order O
to O
determine O
its O
safety O
and O
to O
complement O
earlier O
efficacy O
studies O
on O
this O
widely O
used O
medicinal O
plant O
. O

The O
HPLC O
fingerprint O
of O
the O
extract O
shows O
a O
spectrum O
profile O
characteristic O
of O
C O
. O
edulis O
, O
while O
the O
preliminary O
phytochemical O
screening O
revealed O
the O
presence O
of O
saponins B
, O
flavonoids B
, O
tannins B
, O
anthraquinones B
and O
cardiac O
glycosides O
. O

CONCLUSION O
: O
Our O
results O
provided O
evidence O
that O
short O
- O
term O
administration O
of O
the O
standardized O
ethanol B
extract O
of O
C O
. O
edulis O
root O
bark O
at O
doses O
lower O
than O
1000mg O
/ O
kg O
is O
safe O
in O
rats O
and O
may O
not O
exert O
severe O
toxic O
effects O
. O

Identification O
of O
microcystins O
in O
a O
Lake O
Victoria O
cyanobacterial O
bloom O
using O
LC O
- O
MS O
with O
thiol B
derivatization O
. O

Thiol B
derivatization O
of O
the O
alpha O
, O
beta O
- O
unsaturated O
amide O
present O
in O
most O
microcystins O
was O
recently O
shown O
to O
simplify O
analysis O
of O
LC O
- O
MS O
chromatograms O
of O
a O
Microcystis O
culture O
, O
making O
it O
easier O
to O
identify O
peaks O
corresponding O
to O
microcystins O
in O
complex O
mixtures O
. O

Intra O
- O
articular O
drug O
delivery O
from O
an O
optimized O
topical O
patch O
containing O
teriflunomide B
and O
lornoxicam O
for O
rheumatoid O
arthritis O
treatment O
: O
Does O
the O
topical O
patch O
really O
enhance O
a O
local O
treatment O
? O

The O
aim O
of O
this O
work O
is O
to O
develop O
a O
compound O
transdermal O
patch O
containing O
teriflunomide B
( O
TEF O
) O
and O
lornoxicam O
( O
LOX O
) O
to O
transport O
these O
drugs O
across O
the O
skin O
with O
the O
isochronous O
permeation O
rates O
for O
RA O
therapy O
and O
investigate O
intra O
- O
articular O
delivery O
of O
TEF O
and O
LOX O
following O
transdermal O
patches O
applied O
topically O
. O

The O
salts O
of O
TEF O
and O
LOX O
with O
organic O
amines O
diethylamine O
( O
DEtA O
) O
, O
triethylamine B
( O
TEtA O
) O
, O
diethanolamine O
( O
DEA O
) O
, O
triethanolamine B
( O
TEA B
) O
and O
N O
- O
( O
2 O
' O
- O
hydroxy O
- O
ethanol O
) O
- O
piperdine O
( O
NP O
) O
were O
prepared O
to O
improve O
the O
skin O
permeation O
of O
the O
parent O
drug O
. O

Anti O
- O
inflammatory O
and O
analgesic O
effects O
of O
the O
optimized O
compound O
patch O
were O
evaluated O
using O
the O
adjuvant O
arthritis O
model O
and O
the O
pain O
model O
induced O
by O
acetic B
acid I
, O
respectively O
. O

The O
extract O
was O
applied O
topically O
, O
30min O
before O
each O
UVB O
exposure O
, O
in O
a O
dose O
of O
4mg O
total O
polyphenols B
/ O
cm O
( O
2 O
) O
. O

BM O
remarkably O
inhibited O
UVB O
- O
induced O
activation O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
therefore O
generation O
of O
nitric B
oxide I
( O
NO B
) O
and O
nitrotyrosine O
, O
in O
a O
UVB O
single O
dose O
regimen O
. O

In O
multiple O
UVB O
irradiations O
, O
BM O
increased O
NO B
formation O
and O
total O
ERK O
1 O
/ O
2 O
activity O
and O
reduced O
iNOS O
activity O
and O
nitrotyrosine O
levels O
, O
inhibited O
cell O
proliferation O
, O
diminished O
p53 O
and O
caspase O
- O
3 O
immunoreactivities O
and O
increased O
the O
percentage O
of O
Bcl O
- O
2 O
positive O
cells O
. O

Neonatal O
exposure O
to O
lipopolysaccharide O
enhances O
accumulation O
of O
alpha O
- O
synuclein O
aggregation O
and O
dopamine B
transporter O
protein O
expression O
in O
the O
substantia O
nigra O
in O
responses O
to O
rotenone B
challenge O
in O
later O
life O
. O

Our O
previous O
studies O
show O
that O
perinatal O
lipopolysaccharide O
( O
LPS O
) O
exposure O
enhances O
adult O
susceptibility O
to O
rotenone B
- O
induced O
injury O
to O
the O
dopaminergic O
system O
in O
the O
substantia O
nigra O
( O
SN O
) O
of O
the O
adult O
rat O
brain O
. O

To O
further O
investigate O
the O
enhanced O
adult O
susceptibility O
by O
neonatal O
LPS O
exposure O
to O
rotenone B
neurotoxicity O
, O
we O
used O
our O
neonatal O
rat O
model O
of O
LPS O
exposure O
( O
1mg O
/ O
kg O
, O
intracerebral O
injection O
in O
postnatal O
day O
5 O
, O
P5 O
, O
neonatal O
rats O
) O
to O
examine O
the O
protein O
levels O
of O
alpha O
- O
synuclein O
and O
dopamine B
transporters O
( O
DAT O
) O
in O
the O
adult O
rat O
. O

By O
P70 O
, O
rats O
from O
the O
saline O
- O
or O
LPS O
- O
exposed O
group O
were O
challenged O
with O
rotenone B
, O
a O
commonly O
used O
pesticide O
, O
through O
subcutaneous O
mini O
- O
pump O
infusion O
at O
a O
dose O
of O
1 O
. O
25mg O
/ O
kg O
/ O
day O
for O
14 O
days O
. O

Neonatal O
LPS O
exposure O
enhanced O
rotenone B
- O
stimulated O
accumulation O
of O
alpha O
- O
synuclein O
aggregation O
and O
increment O
in O
DAT O
protein O
expression O
in O
the O
cytoplasmic O
compartment O
of O
the O
SN O
, O
and O
in O
the O
synaptosomal O
compartment O
of O
the O
striatum O
of O
adult O
rats O
. O

Rotenone B
treatment O
also O
resulted O
in O
reduction O
of O
[ B
( I
3 I
) I
H I
] I
dopamine I
uptake O
and O
mitochondrial O
complex O
I O
activity O
in O
the O
striatum O
of O
rats O
with O
neonatal O
LPS O
exposure O
, O
but O
not O
in O
those O
without O
this O
exposure O
. O

Aqueous O
sugar B
formulations O
containing O
DLPC O
( O
0 O
. O
01mg O
/ O
ml O
) O
were O
lyophilized O
, O
and O
DLPC O
degradation O
was O
monitored O
using O
HPLC O
/ O
UV O
and O
GC O
/ O
MS O
methods O
. O

The O
effect O
of O
ferrous B
ion O
and O
sucrose B
concentration O
, O
as O
well O
as O
lyophilization O
stage O
promoting O
lipid O
degradation O
, O
was O
investigated O
. O

DLPC O
degradation O
increased O
with O
higher O
levels O
of O
ferrous B
ion O
. O

After O
lyophilization O
, O
103 O
. O
1 O
+ O
/ O
- O
1 O
. O
1 O
% O
, O
66 O
. O
9 O
+ O
/ O
- O
0 O
. O
8 O
% O
, O
and O
28 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
% O
DLPC O
remained O
in O
the O
sucrose B
samples O
spiked O
with O
0 O
. O
0ppm O
, O
0 O
. O
2ppm O
, O
and O
1 O
. O
0ppm O
ferrous B
ion O
, O
respectively O
. O

Sugar B
concentration O
and O
buffer O
ionic O
strength O
also O
influence O
the O
extent O
of O
lipid O
degradation O
, O
and O
DLPC O
loss O
correlated O
with O
degradation O
product O
formation O
. O

In O
addition O
, O
we O
demonstrate O
that O
metal O
contaminants O
in O
sugars B
can O
become O
highly O
active O
when O
lyophilized O
in O
the O
presence O
of O
a O
reducing O
agent O
. O

The O
cyclin O
D1 O
( O
CCND1 O
) O
rs9344 O
G O
> O
A O
polymorphism O
predicts O
clinical O
outcome O
in O
colon O
cancer O
patients O
treated O
with O
adjuvant O
5 B
- I
FU I
- O
based O
chemotherapy O
. O

Patients O
treated O
with O
5 B
- I
fluorouracil I
- O
based O
chemotherapy O
, O
carrying O
the O
CCND1 O
rs9344 O
A O
/ O
A O
genotype O
had O
significantly O
decreased O
time O
- O
to O
- O
tumor O
recurrence O
( O
TTR O
) O
in O
univariate O
analysis O
and O
multivariate O
analysis O
( O
hazard O
ratio O
( O
HR O
) O
2 O
. O
47 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
1 O
. O
16 O
- O
5 O
. O
29 O
; O
P O
= O
0 O
. O
019 O
) O
. O

DNA O
- O
binding O
, O
photocleavage O
, O
cytotoxicity O
in O
vitro O
, O
apoptosis O
and O
cell O
cycle O
arrest O
studies O
of O
symmetric O
ruthenium B
( I
II I
) I
complexes O
. O

Two O
novel O
ruthenium B
( I
II I
) I
complexes O
[ O
Ru O
( O
dmb O
) O
2 O
( O
addppn O
) O
] O
( O
ClO4 O
) O
2 O
( O
1 O
) O
and O
[ O
Ru O
( O
bpy O
) O
2 O
( O
addppn O
) O
] O
( O
ClO4 O
) O
2 O
( O
2 O
) O
were O
synthesized O
. O

The O
cytotoxicity O
in O
vitro O
of O
the O
complexes O
toward O
BEL O
- O
7402 O
, O
HeLa O
, O
MG O
- O
63 O
and O
SKBR O
- O
3 O
cells O
was O
assessed O
by O
MTT B
assay O
. O

The O
apoptosis O
was O
carried O
out O
with O
Hoechst B
33258 I
staining O
method O
and O
flow O
cytometry O
. O

propanehydrazide O
( O
JL418 O
) O
, O
throughout O
the O
assessment O
of O
their O
antioxidative O
potential O
using O
different O
antioxidant O
assays O
such O
as O
DPPH B
, O
lipid O
peroxidation O
in O
the O
APPH O
, O
or O
the O
DMSO B
method O
. O

We O
conclude O
that O
these O
compounds O
are O
convenient O
templates O
for O
the O
design O
of O
useful O
drugs O
in O
to O
treat O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
, O
a O
pathology O
characterized O
by O
extensive O
oxidative O
stress O
and O
inflammation O
, O
thus O
essentially O
affected O
by O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Most O
of O
them O
are O
potent O
hydroxyl B
radical O
scavengers O
and O
inhibit O
in O
vitro O
lipid O
peroxidation O
. O

None O
of O
the O
compounds O
showed O
significant O
cytotoxicity O
on O
human O
C3A O
hepatocytes O
in O
a O
neutral B
red I
dye O
uptake O
assay O
and O
no O
genotoxicity O
or O
mutagenicity O
was O
observed O
as O
demonstrated O
by O
a O
VITOTOX O
( O
TM O
) O
test O
and O
confirmed O
with O
a O
comet O
assay O
. O

Thin O
films O
: O
organic O
vapor O
passivation O
of O
silicon B
at O
room O
temperature O
( O
adv O
. O
Mater O
. O
14 O
/ O
2013 O
) O
. O

Initiated O
chemical O
vapor O
deposition O
is O
used O
to O
achieve O
air O
- O
stable O
organic O
passivation O
of O
silicon B
, O
as O
reported O
by O
Karen O
K O
. O
Gleason O
and O
co O
- O
workers O
on O
page O
2078 O
. O

Resistively O
heated O
wires O
produce O
reactive O
gas O
phase O
species O
, O
including O
methyl B
radicals O
, O
while O
the O
silicon B
surface O
below O
remains O
near O
room O
temperature O
. O

Cyclic B
AMP I
responsive O
element O
binding O
protein O
- O
a O
vital O
link O
in O
embryonic O
hormonal O
adaptation O
. O

The O
transcription O
factor O
cyclic B
AMP I
responsive O
element O
binding O
protein O
( O
CREB O
) O
and O
activating O
transcription O
factors O
( O
ATFs O
) O
are O
downstream O
components O
of O
the O
insulin O
/ O
IGF O
cascade O
, O
playing O
crucial O
roles O
in O
maintaining O
cell O
viability O
and O
embryo O
survival O
. O

Lack O
of O
insulin O
is O
compensated O
by O
a O
CREB O
- O
mediated O
adiponectin O
expression O
which O
may O
maintain O
glucose B
uptake O
in O
blastocysts O
grown O
in O
diabetic O
mothers O
. O

Highly O
Stretchable O
Patterned O
Gold O
Electrodes O
Made O
of O
Au B
Nanosheets O
. O

Multilayered O
Au B
nanosheets O
are O
suggested O
as O
a O
novel O
class O
of O
material O
for O
fabricating O
stretchable O
electrodes O
suitable O
for O
organic O
- O
based O
electronic O
devices O
. O

Effect O
of O
Topical O
Application O
of O
Chlorogenic B
Acid I
on O
Excision O
Wound O
Healing O
in O
Rats O
. O

This O
study O
was O
undertaken O
to O
evaluate O
the O
therapeutic O
effects O
of O
topical O
chlorogenic B
acid I
on O
excision O
wounds O
in O
Wistar O
rats O
. O

A O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic B
acid I
or O
silver O
sulfadiazine O
ointment O
was O
applied O
topically O
once O
a O
day O
for O
15 O
days O
on O
full O
- O
thickness O
excision O
wounds O
created O
on O
rats O
. O

The O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic B
acid I
ointment O
had O
potent O
wound O
healing O
capacity O
as O
evident O
from O
the O
wound O
contraction O
on O
the O
15th O
post O
- O
surgery O
day O
, O
which O
was O
similar O
to O
that O
produced O
by O
1 O
% O
( O
w O
/ O
w O
) O
silver O
sulfadiazine O
ointment O
. O

It O
also O
improved O
cellular O
proliferation O
, O
increased O
tumor O
necrosis O
factor O
- O
alpha O
levels O
during O
the O
inflammatory O
phase O
( O
12 O
h O
, O
24 O
h O
, O
48 O
h O
, O
and O
72 O
h O
post O
- O
wounding O
) O
of O
wound O
healing O
, O
upregulated O
transforming O
growth O
factor O
- O
beta O
1 O
and O
elevated O
collagen O
IV O
synthesis O
in O
the O
chlorogenic B
acid I
- O
treated O
group O
. O

The O
results O
also O
indicated O
that O
chlorogenic B
acid I
possesses O
potent O
antioxidant O
activity O
by O
increasing O
superoxide B
dismutase O
, O
catalase O
, O
and O
glutathione B
, O
and O
decreasing O
lipid O
peroxidation O
. O

In O
conclusion O
, O
these O
results O
demonstrate O
that O
topical O
application O
of O
chlorogenic B
acid I
can O
accelerate O
the O
process O
of O
excision O
wound O
healing O
by O
its O
ability O
to O
increase O
collagen O
synthesis O
through O
upregulation O
of O
key O
players O
such O
as O
tumor O
necrosis O
factor O
- O
alpha O
and O
transforming O
growth O
factor O
- O
beta O
1 O
in O
different O
phases O
of O
wound O
healing O
as O
well O
as O
by O
its O
antioxidant O
potential O
. O

The O
N B
- O
end O
rule O
pathway O
contributes O
significantly O
to O
accelerated O
muscle O
proteolysis O
mediated O
by O
the O
ubiquitin O
- O
proteasome O
pathway O
in O
various O
catabolic O
conditions O
. O

UBR2 O
( O
aka O
E3 O
alpha O
- O
II O
) O
is O
the O
only O
known O
E3 O
ubiquitin O
ligase O
of O
the O
N B
- O
end O
rule O
pathway O
that O
is O
up O
- O
regulated O
by O
cachectic O
stimuli O
including O
proinflammatory O
cytokines O
and O
tumors O
. O

UBR2 O
expression O
in O
C2C12 O
myotubes O
was O
up O
- O
regulated O
by O
conditioned O
medium O
from O
Lewis O
lung O
carcinoma O
cells O
or O
C26 O
colon O
adenocarcinoma O
cells O
, O
which O
was O
blocked O
by O
a O
pharmacological O
inhibitor O
of O
p38 O
alpha O
/ O
beta O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
, O
SB202190 B
. O

Similarly O
, O
SB202190 B
administration O
( O
i O
. O
p O
. O
) O
abolished O
UBR2 O
up O
- O
regulation O
in O
the O
tibialis O
anterior O
of O
LLC O
tumor O
- O
bearing O
mice O
. O

In O
addition O
, O
UBR2 O
up O
- O
regulation O
required O
p38 O
beta O
- O
mediated O
phosphorylation O
of O
CCAAT O
/ O
enhancer O
binding O
protein O
( O
C O
/ O
EBP O
) O
- O
beta O
Thr B
- O
188 O
, O
which O
was O
critical O
to O
C O
/ O
EBP O
beta O
binding O
to O
the O
UBR2 O
promoter O
. O

The O
two O
potentially O
most O
consequential O
changes O
were O
upregulation O
of O
intestinal O
carboxylesterase O
in O
Mdr1a O
- O
knockouts O
and O
catechol B
- O
O B
- O
methyltransferase O
in O
all O
tissues O
of O
Bcrp O
- O
knockout O
rats O
. O

However O
, O
until O
future O
studies O
elucidate O
the O
magnitude O
of O
functional O
change O
, O
caution O
is O
warranted O
in O
rare O
instances O
of O
extensive O
metabolism O
by O
catechol B
- O
O B
- O
methyltransferase O
in O
Bcrp O
- O
knockouts O
and O
intestinal O
carboxylesterase O
in O
Mdr1a O
- O
knockout O
rats O
, O
specifically O
for O
molecules O
with O
free O
catechol B
groups O
and O
esters O
subject O
to O
gut O
wall O
hydrolysis O
. O

Saccharomyces O
cerevisiae O
tau O
55 O
, O
a O
subunit O
of O
the O
RNA O
polymerase O
III O
- O
specific O
general O
transcription O
factor O
TFIIIC O
, O
comprises O
an O
N B
- O
terminal O
histidine B
phosphatase O
domain O
( O
tau O
55 O
- O
HPD O
) O
whose O
catalytic O
activity O
and O
cellular O
function O
is O
poorly O
understood O
. O

A O
comparative O
phospho B
- O
proteomic O
study O
identified O
additional O
phosphopeptides O
as O
possible O
targets O
, O
which O
show O
the O
involvement O
of O
these O
two O
phosphatases O
in O
the O
regulation O
of O
a O
variety O
of O
cellular O
functions O
. O

Adenine B
- O
DNA O
Adducts O
Derived O
from O
the O
Highly O
Tumorigenic O
Dibenzo O
[ O
a O
, O
l O
] O
pyrene O
Are O
Resistant O
to O
Nucleotide B
Excision O
Repair O
while O
Guanine B
Adducts O
Are O
Not O
. O

The O
structural O
origins O
of O
differences O
in O
susceptibilities O
of O
various O
DNA O
lesions O
to O
nucleotide B
excision O
repair O
( O
NER O
) O
are O
poorly O
understood O
. O

Here O
we O
compared O
, O
in O
the O
same O
sequence O
context O
, O
the O
relative O
NER O
dual O
incision O
efficiencies O
elicited O
by O
two O
stereochemically O
distinct O
pairs O
of O
guanine B
( O
N O
( O
2 O
) O
- O
dG O
) O
and O
adenine B
( O
N O
( O
6 O
) O
- O
dA O
) O
DNA O
lesions O
, O
derived O
from O
enantiomeric O
genotoxic O
diol O
epoxides O
of O
the O
highly O
tumorigenic O
fjord O
region O
polycyclic O
aromatic O
hydrocarbon O
dibenzo O
[ O
a O
, O
l O
] O
pyrene O
( O
DB O
[ O
a O
, O
l O
] O
P O
) O
. O

Remarkably O
, O
in O
cell O
- O
free O
HeLa O
cell O
extracts O
, O
the O
guanine B
adduct O
with O
R O
absolute O
chemistry O
at O
the O
N O
( O
2 O
) O
- O
dG O
linkage O
site O
is O
~ O
35 O
times O
more O
susceptible O
to O
NER O
dual O
incisions O
than O
the O
stereochemically O
identical O
N O
( O
6 O
) O
- O
dA O
adduct O
. O

For O
the O
guanine B
and O
adenine B
adducts O
with O
S O
stereochemistry O
, O
a O
similar O
but O
somewhat O
smaller O
effect O
( O
factor O
of O
~ O
15 O
) O
is O
observed O
. O

Our O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
high O
genotoxic O
activity O
of O
DB O
[ O
a O
, O
l O
] O
P O
is O
related O
to O
the O
formation O
of O
NER O
- O
resistant O
and O
persistent O
DB O
[ O
a O
, O
l O
] O
P O
- O
derived O
adenine B
adducts O
in O
cellular O
DNA O
. O

They O
include O
radical O
isomerization O
and O
dissociation O
, O
radical O
+ O
radical O
association O
, O
and O
unimolecular O
reactions O
of O
peroxy B
radicals O
. O

Some O
reactions O
of O
methylene B
in O
its O
lowest O
singlet O
state O
are O
also O
considered O
. O

Ion O
impacts O
on O
graphene B
/ O
ir O
( O
111 O
) O
: O
interface O
channeling O
, O
vacancy O
funnels O
, O
and O
a O
nanomesh O
. O

By O
combining O
ion O
beam O
experiments O
and O
atomistic O
simulations O
we O
study O
the O
production O
of O
defects O
in O
graphene B
on O
Ir O
( O
111 O
) O
under O
grazing O
incidence O
of O
low O
energy O
Xe B
ions O
. O

We O
demonstrate O
that O
the O
ions O
are O
channeled O
in O
between O
graphene B
and O
the O
substrate O
, O
giving O
rise O
to O
chains O
of O
vacancy O
clusters O
with O
their O
edges O
bending O
down O
toward O
the O
substrate O
. O

These O
clusters O
self O
- O
organize O
to O
a O
graphene B
nanomesh O
via O
thermally O
activated O
diffusion O
as O
their O
formation O
energy O
varies O
within O
the O
graphene B
moir O
e O
supercell O
. O

A O
facile O
strategy O
to O
design O
zeolite B
L I
crystals O
with O
tunable O
morphology O
and O
surface O
architecture O
. O

Here O
we O
discuss O
a O
method O
to O
selectively O
control O
the O
growth O
of O
zeolite B
crystals O
, O
which O
are O
used O
extensively O
in O
a O
wide O
range O
of O
industrial O
applications O
. O

We O
examined O
over O
30 O
molecules O
as O
potential O
zeolite B
growth O
modifiers O
( O
ZGMs O
) O
of O
zeolite B
L I
( O
LTL O
type O
) O
crystallization O
. O

We O
demonstrate O
an O
ability O
to O
tailor O
properties O
critical O
to O
zeolite B
performance O
, O
such O
as O
external O
porous O
surface O
area O
, O
crystal O
shape O
, O
and O
pore O
length O
, O
which O
can O
enhance O
sorbate O
accessibility O
to O
LTL O
pores O
, O
tune O
the O
supramolecular O
organization O
of O
guest O
- O
host O
composites O
, O
and O
minimize O
the O
diffusion O
path O
length O
, O
respectively O
. O

Silver B
Nanoparticles O
Induced O
RNA O
Polymerase O
- O
Silver B
Binding O
and O
RNA O
Transcription O
Inhibition O
in O
Erythroid O
Progenitor O
Cells O
. O

Silver B
( O
Ag B
) O
ions O
certainly O
play O
a O
crucial O
role O
, O
and O
the O
form O
of O
nanoparticles O
can O
change O
the O
dissolution O
rate O
, O
bioavailability O
, O
biodistribution O
, O
and O
cellular O
uptake O
of O
Ag B
. O

Here O
we O
demonstrated O
that O
nAg O
exhibited O
a O
robust O
inhibition O
on O
RNA O
polymerase O
activity O
and O
overall O
RNA O
transcription O
through O
direct O
Ag B
binding O
to O
RNA O
polymerase O
, O
which O
is O
separated O
from O
the O
cytotoxicity O
pathway O
induced O
by O
Ag B
ions O
. O

To O
date O
, O
there O
is O
no O
conclusive O
answer O
to O
the O
sources O
of O
nAg O
- O
mediated O
toxicity O
: O
Ag B
ions O
or O
" O
particle O
- O
specific O
" O
effects O
, O
or O
both O
. O

We O
here O
demonstrated O
that O
both O
Ag B
ions O
and O
nAg O
particles O
simultaneously O
existed O
inside O
cells O
, O
demonstrating O
the O
" O
Trojan O
horse O
" O
effects O
of O
nAg O
particles O
in O
posing O
biological O
impacts O
on O
erythroid O
cells O
. O

In O
light O
of O
the O
evidence O
suggesting O
a O
genetic O
effect O
of O
lithium B
reponse O
in O
BD O
, O
we O
focused O
particularly O
on O
the O
pharmacogenomic O
literature O
relevant O
to O
this O
trait O
. O

Adsorption O
of O
small O
organic O
molecules O
on O
graphene B
. O

We O
present O
a O
combined O
experimental O
and O
theoretical O
quantification O
of O
the O
adsorption O
enthalpies O
of O
seven O
organic O
molecules O
( O
acetone B
, O
acetonitrile B
, O
dichloromethane B
, O
ethanol B
, O
ethyl B
acetate I
, O
hexane B
, O
and O
toluene B
) O
on O
graphene B
. O

Adsorption O
enthalpies O
were O
measured O
by O
inverse O
gas O
chromatography O
and O
ranged O
from O
- O
5 O
. O
9 O
kcal O
/ O
mol O
for O
dichloromethane B
to O
- O
13 O
. O
5 O
kcal O
/ O
mol O
for O
toluene B
. O

The O
strength O
of O
interaction O
between O
graphene B
and O
the O
organic O
molecules O
was O
estimated O
by O
density O
functional O
theory O
( O
PBE O
, O
B97D O
, O
M06 O
- O
2X O
, O
and O
optB88 O
- O
vdW O
) O
, O
wave O
function O
theory O
( O
MP2 O
, O
SCS O
( O
MI O
) O
- O
MP2 O
, O
MP2 O
. O
5 O
, O
MP2 O
. O
X O
, O
and O
CCSD O
( O
T O
) O
) O
, O
and O
empirical O
calculations O
( O
OPLS O
- O
AA O
) O
using O
two O
graphene B
models O
: O
coronene O
and O
infinite O
graphene B
. O

Adsorption O
enthalpies O
obtained O
from O
ab O
initio O
molecular O
dynamics O
employing O
non O
- O
local O
optB88 O
- O
vdW O
functional O
were O
in O
excellent O
agreement O
with O
the O
experimental O
data O
, O
indicating O
that O
the O
functional O
can O
cover O
physical O
phenomena O
behind O
adsorption O
of O
organic O
molecules O
on O
graphene B
sufficiently O
well O
. O

We O
used O
formaldehyde B
- O
assisted O
isolation O
of O
regulatory O
elements O
followed O
by O
next O
- O
generation O
sequencing O
( O
FAIRE O
- O
seq O
) O
to O
map O
regions O
of O
open O
chromatin O
in O
three O
primary O
human O
blood O
cells O
of O
the O
myeloid O
lineage O
. O

Structure O
- O
activity O
relationship O
of O
potent O
antimicrobial O
peptide O
analogs O
of O
Ixosin O
- O
B O
amide B
. O

A O
series O
of O
overlapped O
peptide O
fragments O
of O
Ixosin O
- O
B O
, O
an O
antimicrobial O
peptide O
with O
amino B
acid I
sequence O
of O
QLKVDLWGTRSGIQPEQHSS O
, O
was O
designed O
, O
synthesized O
and O
examined O
for O
their O
antimicrobial O
activities O
against O
Escherichia O
coli O
, O
Staphylococcus O
aureus O
, O
and O
Pseudomonas O
aeruginosa O
. O

A O
potent O
11 O
- O
mer O
peptide O
TSG O
- O
8 O
- O
1 O
, O
WWSYVRRWRSR O
- O
amide B
, O
was O
developed O
, O
which O
exhibited O
antimicrobial O
activity O
against O
E O
. O
coli O
and O
S O
. O
aureus O
while O
very O
little O
hemolytic O
activity O
in O
human O
erythrocytes O
was O
observed O
at O
high O
dose O
level O
. O

Pyranocycloartobilox O
A O
, O
a O
novel O
gastroprotective O
compound O
from O
Artocarpus O
obtusus O
Jarret O
, O
against O
ethanol B
- O
induced O
acute O
gastric O
ulcer O
in O
vivo O
. O

In O
this O
study O
, O
the O
efficacy O
of O
PA O
as O
a O
gastroprotective O
compound O
was O
examined O
against O
ethanol B
- O
induced O
ulcer O
model O
in O
rats O
. O

The O
rats O
were O
pretreated O
with O
PA O
and O
subsequently O
exposed O
to O
acute O
gastric O
lesions O
induced O
by O
absolute O
ethanol B
. O

The O
ulcer O
index O
, O
gastric O
juice O
acidity O
, O
mucus O
content O
, O
histological O
analysis O
, O
glutathione B
( O
GSH B
) O
levels O
, O
malondialdehyde B
level O
( O
MDA B
) O
, O
nitric B
oxide I
( O
NO B
) O
and O
non O
- O
protein O
sulfhydryl B
group O
( O
NP O
- O
SH B
) O
contents O
were O
evaluated O
in O
vivo O
. O

The O
results O
showed O
that O
the O
oral O
administration O
of O
PA O
protects O
gastric O
mucosa O
from O
ethanol B
- O
induced O
gastric O
lesions O
. O

PA O
pretreatment O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
restored O
the O
depleted O
GSH B
, O
NP O
- O
SH B
and O
NO B
levels O
in O
the O
gastric O
homogenate O
. O

Moreover O
, O
PA O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
reduced O
the O
elevated O
MDA B
level O
due O
to O
ethanol B
administration O
. O

Plant O
High O
- O
Affinity O
Potassium B
( O
HKT O
) O
Transporters O
Involved O
in O
Salinity O
Tolerance O
: O
Structural O
Insights O
to O
Probe O
Differences O
in O
Ion O
Selectivity O
. O

High O
- O
affinity O
Potassium B
Transporters O
( O
HKTs O
) O
belong O
to O
an O
important O
class O
of O
integral O
membrane O
proteins O
( O
IMPs O
) O
that O
facilitate O
cation O
transport O
across O
the O
plasma O
membranes O
of O
plant O
cells O
. O

Some O
members O
of O
the O
HKT O
protein O
family O
have O
been O
shown O
to O
be O
critical O
for O
salinity O
tolerance O
in O
commercially O
important O
crop O
species O
, O
particularly O
in O
grains O
, O
through O
exclusion O
of O
Na B
+ I
ions O
from O
sensitive O
shoot O
tissues O
in O
plants O
. O

Sphingomyelin B
in O
high O
- O
density O
lipoproteins O
: O
structural O
role O
and O
biological O
function O
. O

High O
- O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
an O
inverse O
risk O
factor O
for O
cardiovascular O
diseases O
, O
and O
sphingomyelin B
( O
SM O
) O
is O
the O
second O
most O
abundant O
phospholipid O
component O
and O
the O
major O
sphingolipid B
in O
HDL O
. O

Considering O
the O
marked O
presence O
of O
SM O
, O
the O
present O
review O
has O
focused O
on O
the O
current O
knowledge O
about O
this O
phospholipid O
by O
addressing O
its O
variable O
distribution O
among O
HDL O
lipoparticles O
, O
how O
they O
acquire O
this O
phospholipid O
, O
and O
the O
important O
role O
that O
SM O
plays O
in O
regulating O
their O
fluidity O
and O
cholesterol B
efflux O
from O
different O
cells O
. O

In O
addition O
, O
plasma O
enzymes O
involved O
in O
HDL O
metabolism O
such O
as O
lecithin O
- O
cholesterol B
acyltransferase O
or O
phospholipid O
transfer O
protein O
are O
inhibited O
by O
HDL O
SM O
content O
. O

Bioinspired O
design O
and O
macroscopic O
assembly O
of O
poly B
( I
vinyl I
alcohol I
) I
- O
coated O
graphene B
into O
kilometers O
- O
long O
fibers O
. O

Here O
, O
we O
prepared O
sandwich O
- O
like O
building O
blocks O
of O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
- O
coated O
graphene B
, O
and O
achieved O
high O
- O
nanofiller O
- O
content O
kilometers O
- O
long O
fibers O
by O
continuous O
wet O
- O
spinning O
assembly O
technology O
. O

The O
fibers O
have O
a O
strict O
" O
brick O
and O
mortar O
" O
layered O
structure O
, O
with O
graphene B
sheet O
as O
rigid O
brick O
and O
PVA B
as O
soft O
mortar O
. O

The O
mortar O
thickness O
can O
be O
precisely O
tuned O
from O
2 O
. O
01 O
to O
3 O
. O
31 O
nm O
by O
the O
weight O
feed O
ratio O
of O
PVA O
to O
graphene B
, O
as O
demonstrated O
by O
both O
atomic O
force O
microscopy O
and O
X O
- O
ray O
diffraction O
measurements O
. O

The O
mechanical O
strength O
of O
the O
nacre O
- O
mimicking O
fibers O
increases O
with O
increasing O
the O
content O
of O
PVA B
, O
and O
it O
rises O
gradually O
from O
81 O
MPa O
for O
the O
fiber O
with O
53 O
. O
1 O
wt O
% O
PVA B
to O
161 O
MPa O
for O
the O
fiber O
with O
65 O
. O
8 O
wt O
% O
PVA B
. O

The O
mechanical O
performance O
of O
our O
fibers O
was O
independent O
of O
the O
molecular O
weight O
( O
MW O
) O
of O
PVA B
in O
the O
wide O
range O
of O
2 O
- O
100 O
kDa O
, O
indicating O
that O
low O
MW O
polymers O
can O
also O
be O
used O
to O
make O
strong O
nanocomposites O
. O

The O
tensile O
stress O
of O
fibers O
immersed O
in O
PVA B
5 O
wt O
% O
solution O
reached O
ca O
. O

It O
relies O
on O
the O
formation O
of O
a O
temporary O
parallel O
triplex O
, O
using O
a O
triple O
helix O
forming O
oligonucleotide O
containing O
locked O
nucleic O
acid O
nucleotides B
. O

E O
- O
cadherin O
is O
a O
transmembrane O
glycoprotein O
that O
mediates O
calcium B
- O
dependent O
interactions O
between O
adjacent O
epithelial O
cells O
. O

Walter O
on O
antioxidant O
enzyme O
activities O
such O
as O
peroxidases O
( O
PODs O
) O
, O
super O
oxide O
dismutases O
( O
SODs O
) O
and O
catalase O
( O
CAT O
) O
and O
on O
total O
protein O
contents O
( O
TPC O
) O
, O
cellular O
injury O
( O
CI O
) O
, O
and O
malondialdehyde B
( O
MDA B
) O
in O
the O
germinating O
seeds O
of O
Brassica O
napus O
L O
. O

A O
linear O
increase O
in O
the O
activity O
of O
CAT O
, O
CI O
, O
and O
MDA B
contents O
was O
found O
in O
both O
the O
test O
seeds O
with O
the O
increasing O
concentrations O
of O
CMEA O
and O
CMER O
, O
while O
TPC O
of O
the O
germinating O
seeds O
was O
found O
decreased O
. O

Ameliorative O
effect O
of O
lycopene B
against O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
pdioxin O
- O
induced O
rat O
liver O
microsomal O
toxicity O
: O
An O
in O
vitro O
study O
. O

The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
potential O
oxidative O
damage O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
in O
hepatic O
microsomal O
fractions O
in O
vitro O
and O
to O
further O
elucidate O
the O
potential O
modulatory O
effect O
of O
lycopene B
. O

Group O
I O
served O
as O
a O
control O
and O
is O
incubated O
with O
vehicle O
( O
toluene B
) O
. O

Groups O
II O
and O
IV O
were O
incubated O
with O
20 O
micro O
M O
lycopene B
for O
1 O
h O
before O
further O
incubating O
; O
groups O
III O
and O
IV O
with O
15 O
nM O
of O
TCDD B
for O
further O
1 O
h O
. O

Hydrogen B
peroxide I
( O
H2O2 B
) O
production O
, O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
carbonyl B
content O
and O
activities O
of O
uridine O
5 O
' O
- O
diphospho O
- O
glucuronyltransferas O
( O
UDPGT O
) O
and O
P450 O
were O
significantly O
increased O
. O

Moreover O
, O
the O
activity O
of O
antioxidant O
enzymes O
superoxide O
dismutase O
, O
glutathione B
peroxidase O
, O
catalse O
, O
glutathione B
- O
S B
- O
transferase O
and O
glutathione B
reductase O
as O
well O
as O
the O
microsomal O
thiol O
content O
were O
significantly O
decreased O
. O

Incubation O
with O
lycopene B
( O
group O
IV O
) O
maintained O
near O
normal O
activities O
of O
the O
enzymes O
, O
normalized O
thiol B
and O
carbonyl B
content O
and O
significantly O
reduced O
LPO O
and O
H2O2 B
production O
. O

In O
conclusion O
, O
the O
findings O
of O
the O
study O
indicate O
that O
TCDD B
induces O
a O
significant O
oxidative O
stress O
in O
liver O
microsomes O
as O
manifested O
by O
increased O
LPO O
, O
H2O2 B
production O
, O
protein O
carbonyl B
content O
and O
activities O
of O
UDPGT O
and O
P450 O
and O
decreased O
antioxidant O
enzymes O
activities O
and O
thiol B
content O
. O

By O
the O
reversal O
of O
biochemical O
and O
oxidative O
markers O
toward O
normalcy O
, O
the O
protective O
role O
of O
lycopene B
is O
illuminated O
in O
rat O
liver O
microsomal O
toxicity O
. O

We O
aimed O
to O
investigate O
circulating O
levels O
of O
some O
major O
components O
of O
the O
system O
that O
regulates O
energy O
stores O
, O
glucose B
, O
and O
fat O
metabolism O
, O
during O
thyrotoxicosis O
compared O
to O
euthyroidism O
. O

Fasting O
serum O
ghrelin O
, O
leptin O
, O
adiponectin O
, O
insulin O
, O
glucagon O
, O
glucose B
, O
as O
well O
as O
body O
fat O
composition O
were O
analyzed O
during O
thyrotoxicosis O
in O
40 O
hyperthyroid O
patients O
( O
50 O
. O
5 O
+ O
/ O
- O
15 O
. O
2 O
years O
old O
, O
22 O
females O
, O
31 O
with O
Graves O
disease O
, O
and O
9 O
with O
toxic O
nodular O
goiter O
) O
. O

Fasting O
serum O
glucose B
tended O
to O
be O
higher O
during O
thyrotoxicosis O
. O

Clinical O
strategies O
to O
enhance O
the O
efficacy O
of O
nicotine B
replacement O
therapy O
for O
smoking O
cessation O
: O
a O
review O
of O
the O
literature O
. O

Among O
existing O
medications O
, O
nicotine B
replacement O
therapy O
( O
NRT O
) O
has O
been O
available O
the O
longest O
, O
has O
the O
largest O
literature O
base O
in O
support O
, O
and O
is O
the O
only O
option O
for O
over O
- O
the O
- O
counter O
access O
. O

We O
conclude O
with O
a O
brief O
discussion O
of O
emergent O
NRT O
products O
( O
e O
. O
g O
. O
, O
oral O
nicotine B
spray O
, O
among O
others O
) O
, O
which O
may O
ultimately O
offer O
greater O
efficacy O
than O
current O
formulations O
. O

While O
high O
- O
dose O
interleukin O
( O
IL O
) O
- O
2 O
remains O
an O
option O
for O
highly O
selected O
good O
and O
intermediate O
risk O
patients O
with O
clear O
- O
cell O
histology O
because O
of O
durable O
complete O
responses O
in O
a O
small O
fraction O
of O
patients O
, O
cytokine O
- O
based O
therapy O
including O
interferon O
( O
IFN O
) O
has O
been O
supplanted O
by O
vascular O
- O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
inhibitors O
. O

For O
good O
and O
intermediate O
risk O
disease O
, O
pazopanib O
, O
sunitinib B
or O
the O
combination O
of O
bevacizumab O
plus O
IFN O
are O
considered O
. O

Notably O
, O
recent O
data O
suggest O
non O
- O
inferiority O
for O
the O
efficacy O
of O
pazopanib O
compared O
to O
sunitinib B
coupled O
with O
a O
better O
toxicity O
profile O
. O

Following O
first O
- O
line O
VEGF O
inhibitors O
, O
second O
- O
line O
therapy O
with O
everolimus O
and O
axitinib B
have O
demonstrated O
benefits O
in O
progression O
- O
free O
survival O
( O
PFS O
) O
. O

One O
phase O
III O
trial O
comparing O
sorafenib O
and O
temsirolimus O
in O
the O
post O
- O
sunitinib B
setting O
showed O
no O
difference O
in O
PFS O
, O
the O
primary O
endpoint O
, O
but O
did O
show O
a O
superior O
overall O
survival O
for O
sorafenib O
. O

Sorafenib O
, O
pazopanib O
and O
axitinib B
have O
all O
demonstrated O
clinical O
benefit O
following O
cytokines O
. O

Finally O
, O
optimal O
therapy O
for O
non O
- O
clear O
cell O
RCC O
remains O
to O
be O
delineated O
, O
although O
sunitinib B
, O
everolimus O
and O
other O
VEGFR O
- O
TKI O
or O
mTOR O
inhibitors O
have O
all O
demonstrated O
modest O
benefit O
. O

A O
preactivation O
step O
followed O
, O
mediated O
by O
6 O
, O
6 O
' O
dithionicotinamide O
, O
thiol B
groups O
were O
modified O
by O
disulfide B
bonds O
formation O
. O

Due O
to O
the O
preactivation O
, O
approximately O
60 O
% O
of O
thiol O
groups O
were O
modified O
by O
formation O
of O
disulfide B
bonds O
. O

Organic O
Solvent O
- O
Based O
Graphene B
Oxide I
Liquid O
Crystals O
: O
A O
Facile O
Route O
toward O
the O
Next O
Generation O
of O
Self O
- O
Assembled O
Layer O
- O
by O
- O
Layer O
Multifunctional O
3D O
Architectures O
. O

We O
introduce O
soft O
self O
- O
assembly O
of O
ultralarge O
liquid O
crystalline O
( O
LC O
) O
graphene B
oxide I
( O
GO O
) O
sheets O
in O
a O
wide O
range O
of O
organic O
solvents O
overcoming O
the O
practical O
limitations O
imposed O
on O
LC O
GO O
processing O
in O
water O
. O

This O
expands O
the O
number O
of O
known O
solvents O
which O
can O
support O
amphiphilic O
self O
- O
assembly O
to O
ethanol B
, O
acetone B
, O
tetrahydrofuran B
, O
N O
- O
dimethylformamide O
, O
N O
- O
cyclohexyl O
- O
2 O
- O
pyrrolidone O
, O
and O
a O
number O
of O
other O
organic O
solvents O
, O
many O
of O
which O
were O
not O
known O
to O
afford O
solvophobic O
self O
- O
assembly O
prior O
to O
this O
report O
. O

The O
LC O
behavior O
of O
the O
as O
- O
prepared O
GO O
sheets O
in O
organic O
solvents O
has O
enabled O
us O
to O
disperse O
and O
organize O
substantial O
amounts O
of O
aggregate O
- O
free O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
, O
up O
to O
10 O
wt O
% O
) O
without O
compromise O
in O
LC O
properties O
. O

Screening O
and O
Structural O
Analysis O
of O
Flavones B
Inhibiting O
Tankyrases O
. O

Flavonoids B
are O
known O
for O
their O
beneficial O
effects O
on O
human O
health O
, O
and O
therefore O
the O
therapeutic O
potential O
of O
these O
compounds O
have O
been O
extensively O
studied O
. O

Flavone B
has O
been O
previously O
identified O
as O
a O
tankyrase O
inhibitor O
, O
and O
to O
further O
elucidate O
whether O
tankyrases O
would O
be O
inhibited O
by O
other O
flavonoids B
, O
we O
performed O
a O
systematic O
screening O
of O
tankyrase O
2 O
inhibitory O
activity O
using O
500 O
natural O
and O
naturally O
derived O
flavonoids B
covering O
nine O
different O
flavonoid B
classes O
. O

All O
identified O
tankyrase O
inhibitors O
were O
flavones B
. O

Flavone B
derivatives O
in O
all O
10 O
crystal O
structures O
bind O
to O
the O
nicotinamide B
binding O
site O
of O
tankyrase O
2 O
. O

Potencies O
of O
the O
active O
flavones B
toward O
tankyrases O
vary O
between O
50 O
nM O
and O
1 O
. O
1 O
mu O
M O
, O
and O
flavones B
show O
up O
to O
200 O
- O
fold O
selectivity O
for O
tankyrases O
over O
ARTD1 O
. O

The O
molecular O
details O
of O
the O
interactions O
revealed O
by O
cocrystal O
structures O
efficiently O
describe O
the O
properties O
of O
potent O
flavone B
derivatives O
inhibiting O
tankyrases O
. O

Water O
- O
Mediated O
Interactions O
Influence O
the O
Binding O
of O
Thapsigargin B
to O
Sarco O
/ O
Endoplasmic O
Reticulum O
Calcium B
Adenosinetriphosphat O
. O

A O
crystal O
structure O
suggests O
four O
water O
molecules O
are O
present O
in O
the O
binding O
cavity O
of O
thapsigargin B
in O
sarco O
/ O
endoplasmic O
reticulum O
calcium B
ATPase O
( O
SERCA O
) O
. O

Computational O
chemistry O
indicates O
that O
three O
of O
these O
water O
molecules O
mediate O
an O
extensive O
hydrogen B
- O
bonding O
network O
between O
thapsigargin B
and O
the O
backbone O
of O
SERCA O
. O

The O
orientation O
of O
the O
thapsigargin B
molecule O
in O
SERCA O
is O
crucially O
dependent O
on O
these O
interactions O
. O

The O
hypothesis O
has O
been O
verified O
by O
measuring O
the O
affinity O
of O
newly O
synthesized O
model O
compounds O
, O
which O
are O
prevented O
from O
participating O
in O
such O
water O
- O
mediated O
interactions O
as O
hydrogen B
- O
bond O
donors O
. O

Water O
- O
Soluble O
Polymer O
Exfoliated O
Graphene B
: O
As O
Catalyst O
Support O
and O
Sensor O
. O

In O
this O
paper O
, O
we O
obtained O
various O
water O
- O
soluble O
polymer O
functionalized O
graphene B
in O
dimethyl B
sulfoxide I
under O
ultrasonication O
. O

Such O
polymer O
/ O
graphene B
exhibits O
high O
conductivity O
and O
tunable O
surface O
property O
, O
as O
confirmed O
by O
the O
selected O
area O
electron O
diffraction O
and O
Raman O
and O
electrochemical O
impedance O
spectroscopy O
. O

As O
a O
result O
, O
a O
catalyst O
based O
on O
polyvinyl B
pyrrolidone I
( O
PVP B
) O
/ O
graphene B
shows O
better O
methanol B
oxidation O
performance O
than O
that O
based O
on O
PVP B
/ O
reduced O
graphene B
oxide I
. O

By O
changing O
to O
another O
polymer O
, O
poly O
( O
4 O
- O
vinylpyridine O
) O
/ O
graphene B
shows O
a O
stable O
and O
reversible O
response O
to O
pH O
, O
and O
demonstrates O
its O
potential O
for O
sensor O
application O
. O

Detection O
of O
Nitrogen B
- O
Protonated O
Nitrous O
Oxide O
( O
HNNO O
( O
+ O
) O
) O
by O
Rotational O
Spectroscopy O
. O

The O
rotational O
spectrum O
of O
nitrogen B
- O
protonated O
nitrous O
oxide O
( O
HNNO O
( O
+ O
) O
) O
, O
an O
isomer O
whose O
existence O
was O
first O
inferred O
from O
kinetic O
studies O
more O
than O
30 O
years O
ago O
, O
has O
now O
been O
detected O
by O
Fourier O
transform O
microwave O
spectroscopy O
, O
guided O
by O
new O
high O
- O
level O
coupled O
- O
cluster O
calculations O
of O
its O
molecular O
structure O
. O

From O
high O
- O
resolution O
measurements O
of O
the O
hyperfine O
splitting O
in O
its O
fundamental O
rotational O
transition O
, O
the O
rotational O
constant O
( O
B O
+ O
C O
) O
/ O
2 O
and O
the O
quadrupole O
tensor O
element O
chi O
aa O
( O
N B
) O
for O
both O
nitrogen B
atoms O
have O
been O
precisely O
determined O
. O

The O
chi O
aa O
( O
N B
) O
values O
for O
the O
two O
isomers O
of O
protonated O
nitrous O
oxide O
are O
qualitatively O
consistent O
with O
the O
valence O
bond O
description O
of O
H O
- O
N O
= O
N O
( O
+ O
) O
= O
O O
for O
the O
electronic O
structure O
of O
the O
nitrogen B
- O
protonated O
form O
and O
N O
= O
N O
( O
+ O
) O
- O
O O
- O
H O
for O
the O
oxygen B
- O
protonated O
form O
. O

Desloratadine O
is O
highly O
selective O
for O
histamine B
H1 O
- O
receptors O
, O
does O
not O
cross O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
, O
and O
has O
minimal O
adverse O
events O
( O
very O
low O
sedation O
rate O
) O
, O
with O
a O
better O
safety O
and O
tolerability O
than O
first O
- O
generation O
antihistamines O
. O

Subclinical O
Cushing O
' O
s O
syndrome O
( O
SCS O
) O
associated O
with O
adrenal O
incidentaloma O
is O
usually O
characterized O
by O
autonomous O
cortisol B
secretion O
without O
overt O
symptoms O
of O
Cushing O
' O
s O
syndrome O
( O
CS O
) O
. O

Although O
the O
diagnostic O
criteria O
for O
SCS O
differ O
among O
countries O
, O
the O
1 O
mg O
dexamethasone B
suppression O
test O
( O
DST O
) O
is O
essential O
to O
confirm O
the O
presence O
and O
the O
extent O
of O
cortisol B
overproduction O
. O

Since O
1995 O
, O
SCS O
has O
been O
diagnosed O
in O
Japan O
based O
on O
serum O
cortisol B
levels O
> O
= O
3 O
mu O
g O
/ O
dl O
( O
measured O
by O
radioimmunoassay O
[ O
RIA O
] O
) O
after O
a O
1 O
mg O
DST O
. O

However O
, O
the O
increasing O
use O
of O
enzyme O
immunoassays O
( O
EIA O
) O
instead O
of O
RIA O
has O
hindered O
the O
diagnosis O
of O
SCS O
because O
of O
the O
differing O
sensitivities O
of O
commercially O
available O
assays O
, O
particularly O
for O
serum O
cortisol B
levels O
of O
around O
3 O
mu O
g O
/ O
dl O
. O

One O
way O
to O
overcome O
this O
problem O
is O
to O
lower O
the O
cortisol B
threshold O
level O
after O
a O
1 O
mg O
DST O
. O

In O
the O
present O
study O
, O
we O
examined O
the O
clinical O
applicability O
of O
lowering O
the O
cortisol B
threshold O
to O
1 O
. O
8 O
mu O
g O
/ O
dl O
, O
similar O
to O
the O
American O
Endocrine O
Society O
' O
s O
guidelines O
for O
CS O
, O
by O
reanalyzing O
119 O
patients O
with O
adrenal O
incidentaloma O
. O

Our O
findings O
indicate O
that O
serum O
cortisol B
levels O
> O
= O
1 O
. O
8 O
mu O
g O
/ O
dl O
after O
1 O
mg O
DST O
are O
useful O
to O
confirm O
the O
diagnosis O
of O
SCS O
if O
both O
of O
the O
following O
criteria O
are O
met O
: O
( O
1 O
) O
basal O
ACTH O
level O
< O
10 O
pg O
/ O
ml O
( O
or O
poor O
plasma O
ACTH O
response O
to O
corticotrophin O
- O
releasing O
hormone O
) O
and O
( O
2 O
) O
serum O
cortisol B
> O
= O
5 O
mu O
g O
/ O
dl O
at O
21 O
: O
00 O
to O
23 O
: O
00 O
h O
. O

If O
only O
one O
of O
( O
1 O
) O
and O
( O
2 O
) O
are O
met O
, O
we O
recommend O
that O
other O
clinical O
features O
are O
considered O
in O
the O
diagnosis O
of O
SCS O
, O
including O
serum O
dehydroepiandrostero B
sulfate I
levels O
, O
urine O
free O
cortisol B
levels O
, O
adrenal O
scintigraphy O
, O
and O
clinical O
manifestation O
. O

Synthesis O
, O
Antidepressant O
Evaluation O
and O
Docking O
Studies O
of O
Long O
- O
Chain O
Alkylnitroquipazines O
as O
Serotonin B
Transporter O
Inhibitors O
. O

Twelve O
alkyl B
analogues O
( O
1 O
- O
12 O
) O
of O
the O
high O
- O
affinity O
serotonin B
transporter O
( O
SERT O
) O
inhibitor O
6 O
- O
nitroquipazine O
( O
6 O
- O
NQ O
) O
were O
synthesized O
and O
studied O
using O
in O
vitro O
radioligand O
competition O
binding O
assays O
to O
determine O
their O
binding O
affinity O
( O
Ki O
) O
. O

Our O
results O
showed O
that O
several O
of O
the O
6 O
- O
NQ O
analogues O
are O
high O
- O
affinity O
SERT O
inhibitors O
and O
indicated O
that O
the O
octyl O
( O
8 O
) O
, O
decyl O
( O
10 O
) O
and O
dodecyl B
( O
12 O
) O
6 O
- O
NQ O
analogues O
exhibit O
moderate O
antidepressant O
activity O
. O

TCE O
exposure O
resulted O
in O
a O
decrease O
in O
urine O
of O
metabolites O
involved O
in O
fatty B
acid I
metabolism O
, O
resulting O
from O
altered O
expression O
of O
PPAR O
alpha O
target O
genes O
. O

TCE O
treatment O
also O
induced O
altered O
phospholipid O
homeostasis O
in O
serum O
, O
as O
revealed O
by O
increased O
serum O
lysophosphatidylchol O
18 O
: O
0 O
and O
18 O
: O
1 O
, O
and O
phosphatidylcholine B
metabolites O
. O

Boron B
Enhances O
Odontogenic O
and O
Osteogenic O
Differentiation O
of O
Human O
Tooth O
Germ O
Stem O
Cells O
( O
hTGSCs O
) O
In O
Vitro O
. O

Although O
some O
boron B
derivatives O
have O
been O
reported O
to O
promote O
bone O
and O
teeth O
growth O
in O
vivo O
, O
the O
molecular O
mechanism O
of O
bone O
formation O
has O
not O
been O
elucidated O
yet O
. O

The O
odontogenic O
, O
osteogenic O
differentiation O
and O
biomineralization O
of O
human O
tooth O
germ O
stem O
cells O
( O
hTGSCs O
) O
were O
evaluated O
by O
analyzing O
the O
mRNA O
expression O
levels O
, O
odontogenic O
and O
osteogenic O
protein O
expressions O
, O
alkaline O
phosphatase O
( O
ALP O
) O
activity O
, O
mineralization O
, O
and O
calcium B
deposits O
. O

Important O
strides O
have O
been O
made O
in O
an O
attempt O
to O
decrease O
the O
burden O
of O
disease O
, O
particularly O
the O
development O
of O
the O
lateral O
flow O
assay O
cryptococcal O
antigen O
( O
LFA O
CrAg O
) O
as O
a O
diagnostic O
tool O
in O
resource O
- O
limited O
settings O
, O
coupled O
with O
the O
introduction O
of O
pre O
- O
emptive O
treatment O
with O
fluconazole B
for O
HIV O
- O
positive O
patients O
at O
risk O
for O
cryptococcosis O
with O
a O
positive O
LFA O
CrAg O
. O

Saliva O
level O
oxidative O
stress O
parameters O
such O
as O
total O
antioxidant O
capacity O
( O
TAC O
) O
, O
glutathione B
peroxidase O
( O
GPx O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
superoxide B
dismutase O
( O
SOD O
) O
were O
estimated O
before O
and O
after O
consumption O
of O
GT O
in O
these O
workers O
. O

Emodinol O
, O
as O
a O
major O
triterpene B
compound O
in O
E O
. O
pungens O
, O
has O
been O
seldom O
reported O
to O
have O
an O
effect O
on O
gouty O
arthritis O
. O

Simultaneous O
two O
and O
three O
photon O
resonant O
enhancement O
of O
third O
- O
order O
NLO O
susceptibility O
in O
an O
azo B
- O
dye O
functionalized O
polymer O
film O
. O

We O
report O
the O
observation O
of O
simultaneous O
two O
and O
three O
photon O
resonances O
, O
enhancing O
the O
third O
- O
order O
NLO O
susceptibility O
in O
a O
thin O
film O
of O
an O
azo B
- O
dye O
polymer O
. O

This O
improves O
the O
applications O
of O
azo B
- O
polymers O
in O
all O
optical O
signal O
processing O
as O
well O
as O
in O
nonlinear O
optical O
imaging O
. O

The O
PIM O
Family O
of O
Serine B
/ O
Threonine B
Kinases O
in O
Cancer O
. O

The O
proviral O
insertion O
site O
in O
Moloney O
murine O
leukemia O
virus O
, O
or O
PIM O
proteins O
, O
are O
a O
family O
of O
serine B
/ O
threonine B
kinases O
composed O
of O
three O
different O
isoforms O
( O
PIM1 O
, O
PIM2 O
, O
and O
PIM3 O
) O
that O
are O
highly O
evolutionarily O
conserved O
. O

Configurational O
Assignment O
of O
Secondary O
Hydroxyl B
Groups O
and O
Methyl B
Branches O
in O
Polyketide O
Natural O
Products O
through O
Bioinformatic O
Analysis O
of O
the O
Ketoreductase O
Domain O
. O

The O
specific O
molecular O
interactions O
of O
the O
WHWTYYW O
peptide O
with O
cellohexaose B
were O
examined O
using O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
. O

The O
MM O
and O
NMR O
experiments O
indicate O
that O
the O
WHWTYYW O
peptide O
exhibits O
a O
bent O
structure O
when O
bound O
, O
allowing O
the O
Y5 O
amino B
acid I
to O
form O
a O
CH B
/ O
pi O
stacking O
interaction O
and O
H B
- O
bond O
with O
the O
glucose B
ring O
of O
cellulose O
. O

Probing O
the O
Mechanism O
of O
TBAF O
- O
Catalyzed O
Deacylation O
of O
Cellulose O
Esters B
. O

Additional O
studies O
suggest O
the O
possibility O
that O
TBAF O
chelation O
by O
neighboring O
acyl B
groups O
may O
account O
for O
the O
unexpected O
regioselectivity O
at O
the O
secondary O
alcohol O
esters O
that O
is O
observed O
in O
the O
TBAF O
deacylation O
of O
cellulose O
esters B
. O

The O
thermodynamic O
behavior O
of O
the O
system O
H2O B
/ O
BSA O
was O
studied O
at O
25 O
degrees O
C O
within O
the O
entire O
composition O
range O
: O
vapor O
pressure O
measurements O
via O
head O
space O
sampling O
gas O
chromatography O
demonstrate O
that O
the O
attainment O
of O
equilibria O
takes O
more O
than O
one O
week O
. O

Natural O
Products O
Containing O
a O
Nitrogen B
- O
Nitrogen B
Bond O
. O

As O
of O
early O
2013 O
, O
over O
200 O
natural O
products O
are O
known O
to O
contain O
a O
nitrogen B
- O
nitrogen B
( O
N O
- O
N O
) O
bond O
. O

The O
synthesis O
of O
the O
amphiphilic O
homoglycopolypeptide O
was O
carried O
out O
by O
a O
combination O
of O
NCA O
polymerization O
and O
click O
chemistry O
to O
yield O
a O
well O
- O
defined O
polypeptide O
having O
an O
amphiphilic O
carbohydrate B
on O
its O
side O
chain O
. O

The O
amphiphilicity O
of O
the O
carbohydrate B
was O
achieved O
by O
incorporation O
of O
an O
alkyl B
chain O
at O
the O
C O
- O
6 O
position O
of O
the O
carbohydrate B
thus O
also O
rendering O
the O
homoglycopolypeptide O
amphiphilic O
. O

It O
is O
proposed O
that O
hydrophobic O
interactions O
of O
the O
aliphatic O
chains O
at O
the O
6 O
- O
position O
of O
the O
sugar B
moieties O
drives O
the O
assembly O
of O
these O
rod O
- O
like O
homoglycopolypeptide O
into O
large O
spherical O
aggregates O
. O

Finally O
, O
amphiphilic O
random O
polypeptides O
containing O
10 O
% O
and O
20 O
% O
alpha O
- O
d O
- O
mannose O
in O
addition O
to O
glucose B
containing O
a O
hydrophobic O
alkyl B
chain O
at O
its O
6 O
position O
were O
synthesized O
by O
our O
methodology O
, O
and O
these O
polymers O
were O
also O
found O
to O
assemble O
into O
spherical O
nanostructures O
. O

The O
spherical O
assemblies O
of O
amphiphilic O
random O
glycopolypeptides O
containing O
10 O
% O
and O
20 O
% O
mannose B
were O
found O
to O
be O
surface O
bioactive O
and O
were O
found O
to O
interact O
with O
the O
lectin O
Con O
- O
A O
. O

The O
time O
point O
of O
beta O
- O
catenin O
knockout O
in O
hepatocytes O
determines O
their O
response O
to O
xenobiotic O
activation O
of O
the O
constitutive O
androstane B
receptor O
. O

The O
constitutive O
androstane B
receptor O
( O
CAR O
) O
controls O
the O
expression O
of O
drug O
- O
metabolizing O
enzymes O
and O
regulates O
hepatocyte O
proliferation O
. O

Glutathione B
conjugation O
attenuates O
biological O
activities O
of O
6 O
- O
dehydroshogaol O
from O
ginger O
. O

6 O
- O
Dehydroshogaol O
( O
6 O
- O
DHSG O
) O
is O
a O
bioactive O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compound O
isolated O
from O
fresh O
ginger O
with O
anti O
- O
inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities O
. O

Here O
we O
describe O
the O
glutathione B
( O
GSH B
) O
- O
dependent O
metabolism O
and O
the O
effect O
of O
this O
metabolic O
transformation O
on O
the O
biological O
activities O
of O
6 O
- O
DHSG O
. O

Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6 B
- I
gingerol I
and O
6 B
- I
shogaol I
, O
6 O
- O
DHSG O
showed O
the O
most O
potent O
anti O
- O
inflammatory O
effect O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
RAW O
264 O
. O
7 O
cells O
. O

The O
biological O
activities O
of O
6 O
- O
DHSG O
were O
attenuated O
by O
sulfhydryl B
antioxidants O
such O
as O
glutathione B
( O
GSH B
) O
or O
N B
- I
acetyl I
cysteine I
( O
NAC B
) O
, O
but O
not O
ascorbic B
acid I
( O
ASC O
) O
. O

6 O
- O
DHSG O
was O
metabolised O
by O
GSH B
to O
form O
a O
GSH B
conjugate O
( O
GS O
- O
6 O
- O
DHSG O
) O
in O
RAW O
264 O
. O
7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
. O

Together O
, O
these O
results O
indicate O
that O
GSH B
conjugation O
attenuates O
the O
biological O
activities O
of O
6 O
- O
DHSG O
and O
other O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compounds O
. O

Polyphenols B
in O
noni O
juice O
( O
NJ O
) O
are O
mainly O
composed O
of O
phenolic B
acids I
, O
mainly O
gentisic O
, O
p O
- O
hydroxybenoic O
, O
and O
chlorogenic O
acids O
. O

NJ O
also O
decreased O
( O
p O
< O
0 O
. O
05 O
) O
serum O
/ O
liver O
lipids O
but O
enhanced O
( O
p O
< O
0 O
. O
05 O
) O
daily O
faecal O
lipid O
/ O
bile B
acid I
outputs O
in O
the O
high O
- O
fat O
dietary O
hamsters O
. O

The O
addition O
of O
sodium O
sulphite O
or O
sodium B
dodecyl I
sulphate I
also O
inhibited O
precipitate O
formation O
after O
freeze O
- O
thawing O
, O
resulting O
in O
no O
fractionation O
. O

These O
results O
suggest O
that O
the O
fractionation O
is O
due O
to O
selective O
precipitation O
of O
aggregates O
of O
11S O
globulins O
and O
/ O
or O
11S O
globulins O
and O
lipid O
complexes O
, O
in O
which O
the O
protein O
molecules O
interact O
through O
disulphide B
bonds O
and O
/ O
or O
hydrophobic O
interactions O
. O

Novel O
water O
- O
resistant O
UV O
- O
activated O
oxygen B
indicator O
for O
intelligent O
food O
packaging O
. O

For O
the O
first O
time O
, O
alginate O
polymer O
has O
been O
applied O
to O
prevent O
dyes O
from O
leaching O
out O
of O
colorimetric O
oxygen B
indicator O
films O
, O
which O
enable O
people O
to O
notice O
the O
presence O
of O
oxygen B
in O
the O
package O
in O
an O
economic O
and O
simple O
manner O
. O

The O
dye O
- O
based O
oxygen B
indicator O
film O
suffers O
from O
dye O
leaching O
upon O
contact O
with O
water O
. O

In O
this O
work O
, O
UV O
- O
activated O
visual O
oxygen B
indicator O
films O
were O
fabricated O
using O
thionine O
, O
glycerol B
, O
P25 O
TiO2 O
, O
and O
zein O
as O
a O
redox O
dye O
, O
a O
sacrificial O
electron O
donor O
, O
UV O
- O
absorbing O
semiconducting O
photocatalyst O
, O
and O
an O
encapsulation O
polymer O
, O
respectively O
. O

This O
novel O
water O
- O
resistant O
UV O
- O
activated O
oxygen B
indicator O
was O
also O
successfully O
photo O
- O
bleached O
and O
regained O
colour O
fast O
in O
the O
presence O
of O
oxygen B
. O

Influence O
of O
phenolic B
compounds O
on O
the O
sensorial O
perception O
and O
volatility O
of O
red O
wine O
esters B
in O
model O
solution O
: O
An O
insight O
at O
the O
molecular O
level O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl O
acetate O
, O
ethyl O
isobutyrate O
, O
ethyl O
butyrate O
and O
ethyl O
octanoate O
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Catechin B
significantly O
altered O
the O
sensory O
perception O
of O
most O
esters B
( O
ethyl O
isobutyrate O
, O
ethyl O
butyrate O
and O
ethyl O
octanoate O
) O
while O
gallic B
acid I
displayed O
no O
impact O
. O

Ethyl O
butyrate O
and O
ethyl O
octanoate O
odour O
thresholds O
doubled O
or O
tripled O
in O
the O
presence O
of O
catechin B
, O
underlining O
a O
retention O
impact O
of O
phenolic B
compounds O
in O
liquid O
matrix O
. O

The O
headspace O
analyses O
displayed O
a O
decrease O
only O
in O
ethyl O
octanoate O
volatility O
in O
presence O
of O
catechin B
, O
whereas O
no O
significant O
difference O
in O
other O
esters B
concentrations O
was O
observed O
. O

This O
study O
indicated O
that O
phenolic B
compounds O
have O
a O
variable O
impact O
on O
aroma O
compounds O
' O
volatility O
and O
their O
sensory O
perception O
. O

The O
polarity O
of O
phenolic B
and O
volatile O
compounds O
as O
well O
as O
their O
spatial O
conformation O
also O
appeared O
to O
influence O
the O
interaction O
strength O
. O

Fast O
determination O
of O
sulfonamides B
from O
egg O
samples O
using O
magnetic O
multiwalled O
carbon B
nanotubes O
as O
adsorbents O
followed O
by O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

A O
simple O
and O
effective O
method O
based O
on O
magnetic O
separation O
has O
been O
developed O
for O
the O
extraction O
of O
sulfonamides B
( O
SAs O
) O
from O
egg O
samples O
using O
magnetic O
multiwalled O
carbon B
nanotubes O
( O
MMWCNTs O
) O
as O
an O
adsorbent O
. O

The O
MMWCNTs O
were O
simply O
prepared O
by O
depositing O
Fe3O4 B
onto O
MWCNTs O
that O
had O
been O
previously O
oxidised O
. O

Grain O
tocopherol B
as O
well O
as O
flag O
leaf O
vitamin B
E I
levels O
were O
also O
investigated O
for O
comparison O
. O

T3 O
precursors O
such O
as O
homogentisate O
and O
geranylgeranyl B
pyrophosphate I
decreased O
during O
maturation O
. O

Amino B
acid I
profiles O
and O
quantitative O
structure O
- O
property O
relationship O
models O
as O
markers O
for O
Merlot O
and O
Torront O
e O
s O
wines O
. O

Dragon O
theoretical O
descriptors O
were O
derived O
for O
a O
set O
of O
optimized O
amino B
acid I
structures O
with O
the O
purpose O
of O
establishing O
QSPR O
models O
. O

Predicted O
QSPR O
results O
were O
in O
good O
agreement O
with O
experimental O
amino B
acid I
profiles O
. O

The O
developed O
QSPR O
approach O
showed O
to O
be O
of O
practical O
value O
for O
distinguishing O
each O
wine O
varietal O
, O
and O
for O
calculating O
experimentally O
non O
- O
available O
amino B
acid I
concentrations O
of O
Torront O
e O
s O
and O
Merlot O
wines O
. O

Prooxidative O
and O
antioxidative O
properties O
of O
beta B
- I
carotene I
in O
chlorophyll B
and O
riboflavin O
photosensitized O
oil O
- O
in O
- O
water O
emulsions O
. O

Effects O
of O
beta B
- I
carotene I
on O
the O
oxidative O
stability O
of O
chlorophyll B
or O
riboflavin O
photosensitized O
oil O
- O
in O
- O
water O
( O
O O
/ O
W O
) O
emulsions O
were O
determined O
by O
analysing O
the O
depleted O
headspace O
oxygen B
content O
, O
lipid O
hydroperoxides O
, O
fluorescence O
intensity O
, O
and O
headspace O
volatiles O
. O

As O
the O
concentration O
of O
beta B
- I
carotene I
increased O
from O
0 O
to O
10 O
, O
100 O
, O
and O
1000 O
mu O
M O
, O
the O
oxidative O
stability O
of O
samples O
containing O
chlorophylls B
decreased O
in O
a O
concentration O
- O
dependent O
manner O
under O
light O
, O
indicating O
that O
beta B
- I
carotene I
acted O
as O
a O
prooxidant O
. O

However O
, O
in O
riboflavin O
photosensitized O
O O
/ O
W O
emulsions O
, O
100 O
and O
1000 O
mu O
M O
beta B
- I
carotene I
inhibited O
lipid O
oxidation O
. O

Although O
beta B
- I
carotene I
protected O
both O
photosensitisers O
in O
O O
/ O
W O
emulsions O
, O
beta B
- I
carotene I
displayed O
antioxidative O
or O
prooxidative O
properties O
, O
which O
depended O
on O
the O
polarity O
of O
the O
photosensitisers O
. O

The O
development O
of O
t O
- O
2 O
- O
heptenal O
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
greatly O
in O
chlorophyll B
sensitised O
O O
/ O
W O
emulsions O
with O
an O
increase O
in O
beta B
- I
carotene I
concentration O
, O
implying O
that O
more O
singlet O
oxygen B
oxidation O
occurred O
due O
to O
the O
higher O
levels O
of O
remaining O
chlorophylls B
. O

However O
, O
the O
content O
of O
t O
- O
2 O
- O
heptenal O
and O
1 B
- I
octen I
- I
3 I
- I
ol I
in O
the O
riboflavin O
sensitised O
O O
/ O
W O
emulsions O
was O
not O
significantly O
correlated O
with O
the O
beta B
- I
carotene I
concentration O
, O
which O
indicates O
that O
beta B
- I
carotene I
in O
the O
lipid O
particles O
effectively O
quenched O
singlet O
oxygen B
. O

Conjugated O
linoleic B
acid I
and O
calcium B
co O
- O
supplementation O
improves O
bone O
health O
in O
ovariectomised O
mice O
. O

Osteoporosis O
is O
a O
significant O
health O
concern O
for O
the O
elderly O
; O
conjugated O
linoleic B
acid I
( O
CLA O
) O
has O
been O
shown O
to O
improve O
overall O
bone O
mass O
when O
calcium B
is O
included O
as O
a O
co O
- O
supplement O
. O

However O
, O
potential O
effects O
of O
CLA O
and O
calcium B
on O
bone O
mass O
during O
a O
period O
of O
bone O
loss O
have O
not O
been O
reported O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
how O
dietary O
calcium B
modulates O
the O
effects O
of O
conjugated O
linoleic B
acid I
( O
CLA O
) O
in O
preventing O
bone O
loss O
, O
using O
an O
ovariectomised O
mouse O
model O
. O

CLA O
treatment O
increased O
serum O
parathyroid O
hormone O
( O
PTH O
) O
significantly O
( O
p O
= O
0 O
. O
0172 O
) O
, O
while O
serum O
1 B
, I
25 I
- I
dihydroxyvitamin I
D3 I
concentration O
was O
not O
changed O
by O
CLA O
. O

The O
data O
suggest O
that O
CLA O
, O
along O
with O
dietary O
calcium B
, O
has O
great O
potential O
to O
be O
used O
to O
prevent O
bone O
loss O
and O
weight O
gain O
associated O
with O
menopause O
. O

Twenty O
- O
six O
compounds O
were O
isolated O
and O
classified O
as O
10 O
skeletons O
, O
including O
two O
unusual O
new O
dihydrobenzofuroisoc O
, O
( O
+ O
) O
- O
platyphyllarin O
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
one O
new O
butanoate O
, O
ethyltributanoate O
( O
3 O
) O
, O
and O
two O
new O
homoisoflavanones O
, O
( O
- O
) O
- O
liriopein O
A O
( O
4 O
) O
and O
B O
( O
5 O
) O
, O
along O
with O
21 O
known O
compounds O
, O
including O
six O
homoisoflavonoids O
, O
one O
chalcone B
, O
six O
amides B
, O
one O
lignan B
, O
one O
fatty O
acid O

derivative O
, O
one O
alkaloid O
, O
three O
benzenoids O
, O
and O
two O
steroids B
. O

The O
study O
investigated O
the O
role O
of O
Spirulina O
platensis O
in O
reversing O
sodium B
fluoride I
- O
induced O
thyroid O
, O
neurodevelopment O
and O
oxidative O
alterations O
in O
offspring O
of O
pregnant O
rats O
. O

The O
total O
antioxidant O
activity O
, O
phycocyanins O
, O
and O
beta B
carotene I
content O
were O
quantified O
in O
Spirulina O
. O

Treatment O
groups O
included O
control O
, O
Spirulina O
alone O
, O
sodium B
fluoride I
( O
20mg O
/ O
kg O
) O
alone O
, O
and O
sodium B
fluoride I
along O
with O
Spirulina O
( O
250 O
and O
500mg O
/ O
kg O
) O
. O

Serum O
fluoride B
levels O
were O
determined O
on O
ED O
20 O
and O
PND O
11 O
. O

Fluoride B
- O
induced O
alterations O
in O
thyroid O
hormones O
, O
behaviour O
and O
increased O
oxidative O
stress O
. O

Spirulina O
augmented O
the O
displacement O
of O
fluoride B
, O
facilitated O
antioxidant O
formation O
, O
improved O
behaviour O
and O
protected O
Purkinje O
cells O
. O

Supplementing O
Spirulina O
during O
pregnancy O
could O
reduce O
the O
risk O
of O
fluoride B
toxicity O
in O
offspring O
. O

Impact O
of O
blanching O
on O
polyphenol B
stability O
and O
antioxidant O
capacity O
of O
innovative O
coriander O
( O
Coriandrum O
sativum O
L O
. O
) O
pastes O
. O

Among O
the O
11 O
phenolics B
characterised O
in O
leaves O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
mass O
spectrometric O
detection O
, O
several O
caffeic B
acid I
derivatives O
, O
5 O
- O
feruloylquinic O
and O
5 O
- O
p O
- O
coumaroylquinic O
acids O
were O
tentatively O
identified O
for O
the O
first O
time O
. O

In O
fruits O
, O
10 O
phenolics B
were O
detected O
, O
whereas O
rutin B
, O
a O
dicaffeic O
acid O
derivative O
and O
two O
feruloylquinic O
and O
caffeoylquinic O
acid O
isomers O
were O
newly O
detected O
. O

Upon O
steam O
- O
blanching O
for O
1min O
, O
phenolic B
contents O
and O
antioxidant O
capacities O
remained O
virtually O
unchanged O
. O

Part O
6 O
: O
Indole O
- O
5 O
- O
cycloalkyl O
methylamines O
as O
selective O
serotonin B
reuptake O
inhibitors O
. O

Racemic O
5 O
- O
( O
trans O
- O
2 O
- O
aminomethylcycloprop O
) O
indoles O
, O
5 O
- O
( O
trans O
- O
2 O
- O
aminomethylcyclopent O
) O
indoles O
, O
and O
5 O
- O
( O
cis O
- O
2 O
- O
aminomethylcyclopent O
) O
indoles O
were O
synthesized O
and O
evaluated O
as O
selective O
serotonin B
reuptake O
inhibitors O
. O

In O
this O
study O
we O
have O
demonstrated O
the O
use O
of O
poly O
( O
lactic O
acid O
- O
co O
- O
glycolic O
acid O
) O
( O
PLGA B
) O
/ O
collagen O
biodegradable O
microparticles O
formed O
using O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
/ O
O O
/ O
W O
) O
double O
emulsion O
method O
, O
as O
a O
neurotrophic O
factor O
delivery O
vehicle O
. O

Monoacylglycerol B
lipase O
inhibition O
- O
induced O
changes O
in O
plasma O
corticosterone B
levels O
, O
anxiety O
and O
locomotor O
activity O
in O
male O
CD1 O
mice O
. O

The O
specific O
impact O
of O
enhanced O
2 B
- I
arachidonoylglycerol I
signaling O
on O
corticosterone B
plasma O
levels O
, O
however O
, O
was O
not O
investigated O
so O
far O
. O

Here O
we O
studied O
the O
effects O
of O
the O
recently O
developed O
monoacylglycerol B
lipase O
inhibitor O
JZL184 B
on O
basal O
and O
stress O
- O
induced O
corticosterone B
levels O
in O
male O
CD1 O
mice O
, O
and O
found O
that O
this O
compound O
dramatically O
increased O
basal O
levels O
without O
affecting O
stress O
responses O
. O

Since O
acute O
changes O
in O
corticosterone B
levels O
can O
affect O
behavior O
, O
JZL184 B
was O
administered O
concurrently O
with O
the O
corticosterone B
synthesis O
inhibitor O
metyrapone O
, O
to O
investigate O
whether O
the O
previously O
shown O
behavioral O
effects O
of O
JZL184 B
are O
dependent O
on O
corticosterone B
. O

We O
found O
that O
in O
the O
elevated O
plus O
- O
maze O
, O
the O
effects O
of O
JZL184 B
on O
" O
classical O
" O
anxiety O
- O
related O
measures O
were O
abolished O
by O
corticosterone B
synthesis O
blockade O
. O

These O
findings O
show O
that O
monoacylglycerol B
lipase O
inhibition O
dramatically O
increases O
basal O
levels O
of O
corticosterone B
. O

This O
endocrine O
effect O
partly O
affects O
the O
anxiolytic O
, O
but O
not O
the O
locomotion O
- O
enhancing O
effects O
of O
monoacylglycerol B
lipase O
blockade O
. O

Effect O
of O
N B
- I
acetyl I
cysteine I
( O
NAC B
) O
, O
an O
organosulfur O
compound O
from O
Allium O
plants O
, O
on O
experimentally O
induced O
hepatic O
prefibrogenic O
events O
in O
wistar O
rat O
. O

Aim O
of O
present O
study O
was O
to O
investigate O
the O
effect O
of O
NAC B
on O
experimental O
chronic O
hepatotoxicity O
models O
induced O
by O
carbon B
tetrachloride I
( O
CCl4 B
) O
and O
thioacetamide O
( O
TAA O
) O
. O

CCl4 O
toxicity O
was O
induced O
by O
administering O
200 O
mu O
l O
CCl4 B
( O
diluted O
2 O
: O
3 O
in O
coconut O
oil O
) O
/ O
100g O
body O
weight O
, O
p O
. O
o O
. O
, O
twice O
weekly O
for O
8 O
weeks O
. O

NAC B
treatment O
was O
started O
along O
with O
toxicants O
( O
CCl4 B
and O
TAA O
) O
for O
8 O
weeks O
and O
continued O
for O
further O
4 O
weeks O
. O

Alanine B
aminotransferase O
( O
ALT O
) O
, O
Aspartate B
aminotransferase O
( O
AST O
) O
, O
Alkaline O
phosphatase O
( O
ALP O
) O
, O
Bilirubin B
were O
measured O
in O
serum O
. O

Hydroxyproline B
( O
HP O
) O
, O
lipid O
peroxidation O
( O
LPO O
) O
, O
catalase O
( O
CAT O
) O
, O
Glutathione B
peroxidase O
( O
GPx O
) O
and O
Glutathione B
( O
GSH B
) O
were O
determined O
in O
liver O
samples O
by O
colorimetric O
methods O
. O

Cytochrome O
P450 O
2E1 O
( O
CYP O
450 O
2E1 O
) O
, O
activity O
was O
determined O
as O
hydroxylation O
of O
aniline B
in O
liver O
microsomes O
. O

Serum O
markers O
of O
liver O
damage O
( O
AST O
, O
ALT O
, O
ALP O
and O
Bilirubin B
) O
were O
increased O
by O
CCl4 B
and O
TAA O
intoxication O
( O
p O
< O
0 O
. O
001 O
) O
, O
whereas O
co O
- O
treatment O
with O
NAC B
reversed O
such O
changes O
( O
p O
< O
0 O
. O
001 O
) O
. O

HP O
was O
enhanced O
in O
toxicant O
groups O
( O
p O
< O
0 O
. O
001 O
in O
CCl4 B
and O
TAA O
) O
, O
but O
inhibited O
by O
NAC B
( O
p O
< O
0 O
. O
001 O
) O
. O

LPO O
was O
increased O
while O
as O
GSH B
, O
CAT O
and O
GPx O
decreased O
by O
the O
administration O
of O
CCl4 O
and O
TAA O
( O
p O
< O
0 O
. O
001 O
) O
; O
co O
- O
administration O
of O
NAC B
restored O
these O
liver O
markers O
to O
normal O
levels O
( O
p O
< O
0 O
. O
001 O
) O
. O

Keeping O
in O
view O
the O
biochemical O
and O
histopathological O
studies O
, O
it O
was O
concluded O
that O
CCl4 B
and O
TAA O
are O
strong O
hepatotoxic O
agents O
that O
produce O
liver O
fibrosis O
with O
close O
proximity O
to O
human O
etiology O
( O
micronodular O
cirrhosis O
) O
and O
NAC B
has O
a O
significant O
protective O
activity O
against O
CCl4 B
and O
TAA O
. O

NAC B
has O
also O
been O
validated O
as O
a O
model O
against O
oxidative O
burden O
in O
chronic O
liver O
pathology O
. O

Incretin O
hormone O
action O
on O
beta O
- O
cells O
stimulates O
in O
parallel O
two O
different O
intracellular O
cyclic B
AMP I
- O
dependent O
signaling O
branches O
mediated O
by O
PKA O
and O
EPAC2A O
. O

Both O
pathways O
contribute O
towards O
potentiation O
of O
glucose B
- O
stimulated O
insulin O
secretion O
( O
GSIS O
) O
. O

However O
, O
the O
overall O
functional O
role O
of O
EPAC2A O
in O
beta O
- O
cells O
as O
it O
relates O
to O
in O
vivo O
glucose B
homeostasis O
remains O
incompletely O
understood O
. O

Additionally O
, O
we O
have O
conducted O
in O
vitro O
studies O
of O
GSIS O
and O
calcium B
dynamics O
in O
isolated O
EPAC2A O
- O
deficient O
islets O
. O

EPAC2A O
deficiency O
does O
not O
impact O
glucose B
- O
stimulated O
insulin O
secretion O
in O
mice O
under O
basal O
conditions O
. O

However O
, O
when O
mice O
are O
exposed O
to O
diet O
- O
induced O
insulin O
resistance O
, O
pharmacologic O
secretagogue O
stimulation O
of O
beta O
- O
cells O
with O
an O
incretin O
hormone O
glucagon O
- O
like O
peptide O
- O
1 O
analogue O
or O
with O
a O
Fatty B
Acid I
Receptor O
1 O
/ O
GPR40 O
selective O
activator O
, O
EPAC2A O
is O
required O
for O
the O
increased O
beta O
- O
cell O
response O
to O
secretory O
demand O
. O

Under O
these O
circumstances O
, O
EPAC2A O
is O
required O
for O
potentiating O
the O
early O
dynamic O
increase O
in O
islet O
calcium B
levels O
after O
glucose B
stimulation O
, O
which O
is O
reflected O
in O
potentiated O
first O
phase O
insulin O
secretion O
. O

Salicylic B
acid I
alleviates O
copper B
toxicity O
in O
rice O
( O
Oryza O
sativa O
L O
. O
) O
seedlings O
by O
up O
- O
regulating O
antioxidative O
and O
glyoxalase O
systems O
. O

The O
present O
study O
investigated O
the O
effect O
of O
salicylic B
acid I
( O
SA O
) O
on O
toxic O
symptoms O
, O
lipid O
peroxidation O
, O
reactive O
oxygen B
species O
generation O
and O
responses O
of O
antioxidative O
and O
glyoxalase O
systems O
in O
rice O
seedlings O
grown O
hydroponically O
under O
copper B
( O
Cu B
) O
stress O
for O
48 O
h O
. O

Exposures O
of O
75 O
and O
150 O
mu O
M O
Cu B
( I
2 I
+ I
) I
caused O
toxicity O
symptoms O
( O
chlorosis O
, O
necrosis O
and O
rolling O
in O
leaves O
) O
, O
sharp O
increases O
in O
malondialdehyde B
( O
MDA B
) O
, O
hydrogen B
peroxide I
( O
H2O2 B
) O
contents O
and O
lipoxygenase O
( O
LOX O
) O
activity O
with O
concomitant O
reductions O
of O
chlorophyll O
( O
Chl O
) O
and O
relative O
water O
content O
( O
RWC O
) O
. O

Both O
levels O
of O
Cu B
decreased O
ascorbic B
acid I
( O
AsA B
) O
, O
glutathione B
( O
GSH B
) O
, O
non O
- O
protein O
thiol B
( O
NPT O
) O
and O
proline B
contents O
in O
roots O
but O
rather O
increased O
in O
leaves O
except O
that O
AsA B
decreased O
in O
leaves O
too O
. O

These O
results O
together O
with O
overaccumulation O
of O
superoxide B
( O
O B
2 I
( I
* I
- I
) I
) O
and O
H2O2 B
in O
leaves O
revealed O
that O
Cu B
exposures O
induced O
oxidative O
stress O
. O

Contrary O
, O
SA O
- O
pretreatment O
( O
100 O
mu O
M O
for O
24 O
h O
) O
reduced O
toxicity O
symptoms O
and O
diminished O
Cu B
- O
induced O
increases O
in O
LOX O
activity O
, O
H2O2 B
, O
MDA B
and O
proline B
contents O
while O
the O
levels O
of O
RWC O
, O
Chl O
, O
AsA B
and O
redox O
ratios O
were O
elevated O
. O

Higher O
levels O
of O
GSH B
and O
NPT O
were O
also O
observed O
in O
roots O
of O
SA O
- O
pretreated O
Cu B
- O
exposed O
seedlings O
. O

SA O
- O
pretreatment O
also O
exerted O
its O
beneficial O
role O
by O
inhibiting O
the O
Cu B
upward O
process O
. O

Studies O
on O
antioxidant O
enzymes O
showed O
that O
SA O
further O
enhanced O
the O
activities O
of O
superoxide B
dismutase O
, O
ascorbate B
peroxidase O
, O
glutathione B
reductase O
and O
glutathione B
peroxidase O
, O
and O
also O
elevated O
the O
depressed O
activities O
of O
catalase O
, O
dehydroascorbate O
reductase O
and O
glutathione B
S B
- O
transferase O
particularly O
at O
150 O
mu O
M O
Cu B
( I
2 I
+ I
) I
stress O
. O

In O
addition O
, O
the O
activity O
of O
glyoxalase O
system O
( O
glyoxalase O
I O
and O
II O
) O
was O
further O
elevated O
by O
SA O
pretreatment O
in O
the O
Cu B
- O
exposed O
seedlings O
. O

These O
results O
concluded O
that O
SA O
- O
mediated O
retention O
of O
Cu B
in O
roots O
and O
enhanced O
capacity O
of O
both O
antioxidative O
and O
glyoxalase O
systems O
might O
be O
associated O
with O
the O
alleviation O
of O
Cu B
- O
toxicity O
in O
rice O
seedlings O
. O

Endowing O
carbon B
nanotubes O
with O
superparamagnetic O
properties O
: O
applications O
for O
cell O
labeling O
, O
MRI O
cell O
tracking O
and O
magnetic O
manipulations O
. O

Coating O
of O
carbon B
nanotubes O
( O
CNTs O
) O
with O
magnetic O
nanoparticles O
( O
NPs O
) O
imparts O
novel O
magnetic O
, O
optical O
, O
and O
thermal O
properties O
with O
potential O
applications O
in O
the O
biomedical O
domain O
. O

Multi O
- O
walled O
CNTs O
have O
been O
decorated O
with O
iron B
oxide I
superparamagnetic O
NPs O
. O

Diagnoses O
and O
evaluations O
were O
made O
with O
SCID O
based O
on O
DSM O
- O
IV O
, O
National O
Cholesterol B
Education O
Program O
Adult O
Treatment O
Panel O
III O
criteria O
, O
and O
the O
Hamilton O
Depression O
Rating O
Scale O
. O

The O
efficacy O
of O
metformin B
in O
pregnant O
women O
with O
polycystic O
ovary O
syndrome O
: O
a O
meta O
- O
analysis O
of O
clinical O
trials O
. O

Objectives O
: O
The O
role O
of O
metformin B
in O
the O
treatment O
of O
pregnant O
women O
with O
polycystic O
ovary O
syndrome O
is O
controversial O
. O

Therefore O
, O
we O
evaluated O
whether O
the O
use O
of O
metformin B
during O
pregnancy O
in O
women O
with O
polycystic O
ovary O
syndrome O
could O
reduce O
pregnancy O
- O
related O
complications O
. O

The O
pooled O
ORs O
( O
95 O
% O
CIs O
) O
of O
outcome O
for O
pregnant O
women O
with O
polycystic O
ovary O
syndrome O
prescribed O
metformin B
were O
0 O
. O
32 O
( O
0 O
. O
19 O
- O
0 O
. O
55 O
) O
for O
early O
pregnancy O
loss O
, O
0 O
. O
37 O
( O
0 O
. O
25 O
- O
0 O
. O
56 O
) O
for O
gestational O
diabetes O
, O
0 O
. O
53 O
( O
0 O
. O
30 O
- O
0 O
. O
95 O
) O
for O
preeclampsia O
and O
0 O
. O
30 O
( O
0 O
. O
13 O
- O
0 O
. O
68 O
) O
for O
preterm O
delivery O
. O

Conclusions O
: O
Metformin B
therapy O
throughout O
pregnancy O
decreased O
the O
ORs O
of O
early O
pregnancy O
loss O
, O
gestational O
diabetes O
, O
preeclampsia O
and O
preterm O
delivery O
in O
pregnant O
PCOS O
women O
with O
no O
serious O
detrimental O
sideeffects O
. O

Application O
of O
Ultra O
- O
Performance O
Liquid O
Chromatography O
/ O
Mass O
Spectrometry O
- O
Based O
Metabonomic O
Techniques O
to O
Analyze O
the O
Joint O
Toxic O
Action O
of O
Long O
- O
Term O
Low O
- O
Level O
Exposure O
to O
a O
Mixture O
of O
Organophosphate B
Pesticides O
on O
Rat O
Urine O
Profile O
. O

In O
previously O
published O
articles O
, O
we O
evaluated O
the O
toxicity O
of O
four O
organophosphate B
( O
OP O
) O
pesticides O
( O
dichlorvos B
, O
dimethoate O
, O
acephate O
and O
phorate O
) O
to O
rats O
using O
metabonomic O
technology O
at O
their O
corresponding O
no O
observed O
adverse O
effect O
level O
( O
NOAEL O
) O
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 O
- O
methylguanine O
, O
ribothymidine O
, O
cholic B
acid I
, O
4 O
- O
pyridoxic O
acid O
, O
kynurenine O
and O
indoxyl O
sulfate O
levels O
, O
as O
well O
as O
decreased O
hippuric O
acid O
, O
creatinine B
, O
uric B
acid I
, O
gentisic O
acid O
, O
C18 O
- O
dihydrosphingosine O
, O
phytosphingosine B
, O
suberic O
acid O
and O
citric B
acid I
. O

The O
results O
indicated O
that O
a O
mixture O
of O
OP O
pesticides O
induced O
DNA O
damage O
, O
oxidative O
stress O
, O
disturbed O
the O
metabolism O
of O
lipids O
as O
well O
as O
interfered O
with O
the O
tricarboxylic B
acid I
cycle O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
anti O
- O
ulcerative O
colitis O
( O
UC O
) O
activity O
of O
the O
total O
alcohol B
extracts O
of O
Euphorbia O
granuleta O
Forssk O
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic B
compounds O
( O
kampferol O
, O
kampferol O
- O
3 O
- O
glucoside O
and O
kampferol O
- O
3 O
- O
galactoside O
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 O
- O
ethoxypentacosane O
, O
heptacosan O
- O
1 O
- O
ol O
and O
beta B
- I
sitosterol I
) O
. O

Three O
compounds O
( O
heptacosan O
- O
1 O
- O
ol O
, O
beta B
- I
sitosterol I
and O
kampferol O
- O
3 O
- O
galactoside O
) O
were O
found O
to O
be O
responsible O
for O
the O
anti O
- O
UC O
activity O
of O
E O
. O
granuleta O
extract O
. O

The O
anti O
- O
UC O
activity O
of O
these O
compounds O
may O
be O
explained O
by O
reducing O
the O
pro O
- O
inflammatory O
cytokine O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
in O
addition O
to O
reduction O
of O
colonic O
malondialdehyde B
( O
MDA B
) O
contents O
. O

The O
active O
compounds O
reduced O
both O
serum O
TNF O
- O
alpha O
and O
mucosal O
MDA B
levels O
. O

The O
peptidyl O
- O
prolyl B
cis O
/ O
trans O
isomerase O
Pin1 O
is O
overexpressed O
in O
a O
wide O
variety O
of O
cancer O
cells O
and O
thus O
considered O
as O
an O
important O
target O
molecule O
for O
cancer O
therapy O
. O

Platelet O
- O
induced O
COX O
- O
2 O
- O
dependent O
PGE2 B
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21 O
( O
WAF1 O
/ O
CIP1 O
) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib O
( O
a O
selective O
COX O
- O
2 O
inhibitor O
) O
and O
rescued O
by O
exogenous O
PGE2 B
. O

Determining O
the O
spatial O
and O
temporal O
expression O
of O
genes O
involved O
in O
the O
ovulatory O
pathway O
is O
critical O
for O
the O
understanding O
of O
the O
role O
of O
each O
estrogen B
receptor O
in O
the O
modulation O
of O
folliculogenesis O
and O
ovulation O
. O

Estrogen B
receptor O
( O
ER O
) O
beta O
is O
highly O
expressed O
in O
ovarian O
granulosa O
cells O
and O
mice O
lacking O
ER O
beta O
( O
beta O
ERKO O
) O
are O
subfertile O
due O
to O
inefficient O
ovulation O
. O

Further O
, O
we O
demonstrated O
that O
caspase O
- O
14 O
mRNA O
level O
is O
decreased O
by O
40 O
% O
in O
placental O
BeWo O
cells O
treated O
with O
forskolin B
( O
FSK O
) O
. O

Because O
GCM1 O
is O
stabilized O
by O
acetylation O
, O
we O
subsequently O
showed O
that O
caspase O
- O
14 O
impedes O
the O
interaction O
between O
GCM1 O
and O
cAMP B
response O
element O
- O
binding O
protein O
( O
CREB O
) O
- O
binding O
protein O
( O
CBP O
) O
to O
suppress O
CBP O
- O
mediated O
acetylation O
and O
transcriptional O
coactivation O
of O
GCM1 O
. O

Patchy O
surfaces O
stabilize O
dextran O
- O
polyethylene B
glycol I
aqueous O
two O
- O
phase O
system O
liquid O
patterns O
. O

This O
paper O
analyzes O
surface O
chemistry O
effects O
to O
stably O
pattern O
aqueous O
two O
- O
phase O
system O
( O
ATPS O
) O
droplets O
on O
chemically O
modified O
poly B
( I
dimethylsiloxane I
) I
( O
PDMS B
) O
. O

Polyethylene B
glycol I
( O
PEG B
) O
and O
dextran O
( O
DEX O
) O
are O
used O
as O
phase O
- O
forming O
polymers O
for O
the O
ATPS O
. O

PDMS B
surface O
modifications O
studied O
include O
primary B
amine I
groups O
, O
carboxylic B
acid I
groups O
, O
and O
neutral O
polymer O
surfaces O
. O

The O
PDMS B
surfaces O
were O
characterized O
by O
fluorescent O
measurement O
, O
water O
and O
DEX O
contact O
angle O
measurements O
, O
and O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
analysis O
to O
confirm O
surface O
properties O
. O

A O
Butterfly O
- O
Shaped O
Pyrene B
Derivative O
of O
Cholesterol B
and O
Its O
Uses O
as O
a O
Fluorescent O
Probe O
. O

A O
butterfly O
- O
shaped O
pyrene O
derivative O
of O
cholesterol B
, O
namely O
, O
N O
, O
N O
' O
- O
( O
ethane O
- O
1 O
, O
2 O
- O
diyl O
) O
- O
bis O
( O
N O
- O
( O
2 O
- O
( O
chol O
- O
amino O
) O
ethyl O
) O
pyrene O
- O
1 O
- O
sulfonamide O
) O
( O
ECPS O
) O
, O
has O
been O
designed O
and O
synthesized O
. O

Solvent O
effect O
studies O
revealed O
that O
in O
good O
solvents O
such O
as O
n B
- I
hexane I
, O
benzene B
, O
and O
1 O
, O
4 O
- O
dioxane O
, O
the O
profile O
of O
the O
fluorescence O
emission O
of O
the O
compound O
is O
characterized O
by O
pyrene B
monomer O
emission O
, O
but O
in O
poor O
solvent O
such O
as O
water O
, O
the O
emission O
is O
dominated O
by O
pyrene O
excimer O
emission O
. O

Quantitatively O
speaking O
, O
the O
ratio O
of O
the O
excimer O
emission O
to O
monomer O
emission O
changes O
from O
50 O
to O
0 O
when O
ECPS O
is O
dissolved O
in O
water O
and O
n B
- I
hexane I
, O
respectively O
. O

In O
contrast O
, O
for O
a O
commonly O
used O
polarity O
probe O
pyrene B
, O
the O
ratio O
of O
I3 O
/ O
I1 O
varies O
only O
from O
~ O
0 O
. O
6 O
to O
~ O
1 O
. O
7 O
, O
where O
I3 O
and O
I1 O
stand O
for O
the O
intensities O
of O
the O
fluorescence O
emission O
at O
peak O
3 O
and O
peak O
1 O
, O
respectively O
. O

Furthermore O
, O
unlike O
the O
main O
components O
of O
the O
compound O
, O
pyrene B
and O
cholesterol B
, O
its O
main O
chain O
is O
composed O
of O
multiple O
hydrophilic O
structures O
, O
and O
it O
is O
this O
structure O
that O
makes O
the O
emission O
of O
the O
compound O
in O
organic O
solvents O
sensitive O
to O
the O
presence O
of O
water O
. O

As O
expected O
, O
the O
detection O
limit O
of O
the O
compound O
toward O
water O
in O
acetonitrile B
reaches O
7 O
ppm O
, O
a O
result O
never O
reached O
before O
. O

Enhanced O
Optical O
Second O
- O
Harmonic O
Generation O
from O
the O
Current O
- O
Biased O
Graphene B
/ O
SiO2 B
/ O
Si B
( O
001 O
) O
Structure O
. O

We O
find O
that O
optical O
second O
- O
harmonic O
generation O
( O
SHG O
) O
in O
reflection O
from O
a O
chemical O
- O
vapor O
- O
deposition O
graphene B
monolayer O
transferred O
onto O
a O
SiO2 B
/ O
Si B
( O
001 O
) O
substrate O
is O
enhanced O
about O
3 O
times O
by O
the O
flow O
of O
direct O
current O
electric O
current O
in O
graphene B
. O

Measurements O
of O
rotational O
- O
anisotropy O
SHG O
revealed O
that O
the O
current O
- O
induced O
SHG O
from O
the O
current O
- O
biased O
graphene B
/ O
SiO2 B
/ O
Si B
( O
001 O
) O
structure O
undergoes O
a O
phase O
inversion O
as O
the O
measurement O
location O
on O
graphene B
is O
shifted O
laterally O
along O
the O
current O
flow O
direction O
. O

The O
enhancement O
is O
due O
to O
current O
- O
associated O
charge O
trapping O
at O
the O
graphene B
/ O
SiO2 B
interface O
, O
which O
introduces O
a O
vertical O
electric O
field O
across O
the O
SiO2 B
/ O
Si B
interface O
that O
produces O
electric O
field O
- O
induced O
SHG O
. O

The O
phase O
inversion O
is O
due O
to O
the O
positive O
- O
to O
- O
negative O
polarity O
switch O
in O
the O
current O
direction O
of O
the O
trapped O
charges O
at O
the O
current O
- O
biased O
graphene B
/ O
SiO2 B
interface O
. O

Exciplex O
Formation O
in O
Blended O
Spin O
- O
Cast O
Films O
of O
Fluorene B
- O
Linked O
Dyes O
and O
Bisphthalimide O
Quenchers O
. O

The O
plasmid O
- O
oligomer O
conjugate O
was O
transformed O
into O
condensates O
by O
treating O
them O
with O
spermidine B
. O

The O
efficiency O
of O
strand O
cleavage O
action O
of O
ApeI O
enzyme O
on O
the O
abasic O
sites O
was O
determined O
by O
denaturing O
PAGE O
after O
timed O
incubation O
of O
the O
oligomer O
duplex O
and O
the O
oligomer O
- O
plasmid O
conjugate O
in O
presence O
and O
absence O
of O
spermidine B
. O

In O
addition O
, O
we O
found O
that O
presence O
of O
a O
polyamine B
such O
as O
spermidine B
has O
no O
notable O
effect O
in O
the O
incision O
activity O
of O
ApeI O
enzyme O
in O
linear O
oligomer O
DNA O
duplexes O
in O
our O
experimental O
concentration O
. O

Synthesis O
and O
antitumor O
activity O
of O
1 O
, O
3 O
, O
4 O
- O
oxadiazole O
possessing O
1 O
, O
4 O
- O
benzodioxan O
moiety O
as O
a O
novel O
class O
of O
potent O
methionine B
aminopeptidase O
type O
II O
inhibitors O
. O

The O
anti O
- O
diabetic O
effects O
and O
pharmacokinetic O
profiles O
of O
berberine B
in O
mice O
treated O
with O
Jiao O
- O
Tai O
- O
Wan O
and O
its O
compatibility O
. O

To O
investigate O
the O
comparative O
evaluations O
on O
anti O
- O
diabetic O
effects O
and O
pharmacokinetics O
of O
the O
active O
ingredient O
berberine B
in O
mice O
treated O
with O
JTW O
in O
various O
combinations O
of O
its O
constituent O
herbs O
. O

In O
our O
study O
, O
the O
anti O
- O
diabetic O
study O
was O
carried O
out O
in O
diabetic O
mice O
induced O
by O
intraperitoneal O
injection O
of O
streptozotocin B
. O

The O
level O
of O
plasma O
glucose B
, O
lipid O
profile O
and O
parameters O
related O
to O
oxidative O
stress O
were O
determined O
. O

The O
concentrations O
of O
berberine B
in O
non O
- O
diabetic O
mice O
plasma O
were O
determined O
using O
HPLC O
, O
and O
main O
pharmacokinetic O
parameters O
were O
investigated O
. O

The O
results O
indicated O
that O
the O
compatibility O
effects O
of O
ingredients O
present O
in O
Cinnamomum O
cassia O
could O
affect O
the O
anti O
- O
diabetic O
ability O
and O
pharmacokinetics O
of O
berberine B
in O
JTW O
. O

Quercetin B
suppressed O
CYP2E1 O
- O
dependent O
ethanol B
hepatotoxicity O
via O
depleting O
heme O
pool O
and O
releasing O
CO B
. O

Naturally O
occuring O
quercetin B
protects O
hepatocytes O
from O
ethanol B
- O
induced O
oxidative O
stress O
, O
and O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
induction O
and O
carbon B
monoxide I
( O
CO B
) O
metabolite O
may O
be O
implicated O
in O
the O
beneficial O
effect O
. O

However O
, O
the O
precise O
mechanism O
by O
which O
quercetin B
counteracts O
CYP2E1 O
- O
mediated O
ethanol B
hepatotoxicity O
through O
HO O
- O
1 O
system O
is O
still O
remained O
unclear O
. O

To O
explore O
the O
potential O
mechanism O
, O
herein O
, O
ethanol B
( O
4 O
. O
0g O
/ O
kg O
. O
bw O
. O
) O
was O
administrated O
to O
rats O
for O
90 O
days O
. O

Our O
data O
showed O
that O
chronic O
ethanol B
over O
- O
activated O
CYP2E1 O
but O
suppressed O
HO O
- O
1 O
with O
concurrent O
hepatic O
oxidative O
damage O
, O
which O
was O
partially O
normalized O
by O
quercetin B
( O
100mg O
/ O
kg O
. O
bw O
. O
) O
. O

Quercetin B
( O
100 O
mu O
M O
) O
induced O
HO O
- O
1 O
and O
depleted O
heme O
pool O
when O
incubated O
to O
human O
hepatocytes O
. O

Ethanol B
- O
stimulated O
( O
100mM O
) O
CYP2E1 O
upregulation O
was O
suppressed O
by O
quercetin B
but O
further O
enhanced O
by O
HO O
- O
1 O
inhibition O
with O
resultant O
heme B
accumulation O
. O

CO B
scavenging O
blocked O
the O
suppression O
of O
quercetin B
only O
on O
CYP2E1 O
activity O
. O

CO B
donor O
dose O
- O
dependently O
inactivated O
CYP2E1 O
of O
ethanol B
- O
incubated O
microsome O
, O
which O
was O
mimicked O
by O
HO O
- O
1 O
substrate O
but O
abolished O
by O
CO B
scavenger O
. O

Thus O
, O
CYP2E1 O
- O
mediated O
ethanol B
hepatotoxicity O
was O
alleviated O
by O
quercetin B
through O
HO O
- O
1 O
induction O
. O

Depleted O
heme O
pool O
and O
CO B
releasing O
limited O
protein O
synthesis O
and O
inhibited O
enzymatic O
activity O
of O
CYP2E1 O
, O
respectively O
. O

Quinone B
compounds O
regulate O
the O
level O
of O
ROS O
production O
by O
the O
NADPH B
oxidase O
Nox4 O
. O

NADPH B
oxidase O
Nox4 O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen B
species O
( O
ROS O
) O
as O
intracellular O
messengers O
. O

Nox4 O
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level O
; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone B
derivatives O
could O
modulate O
this O
activity O
. O

In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone B
derivatives O
( O
AA O
- O
861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone O
) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T O
- O
REx O
( O
TM O
) O
, O
and O
chondrocyte O
cell O
lines O
. O

Furthermore O
, O
we O
showed O
that O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
( O
NQO1 O
) O
may O
participate O
in O
this O
stimulation O
. O

Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide B
bridge O
( O
Cys226 O
, O
Cys270 O
) O
located O
in O
the O
extracellular O
E O
- O
loop O
of O
Nox4 O
. O

Such O
model O
of O
Nox4 O
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i O
. O
e O
. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones B
and O
Nox4 O
are O
implicated O
. O

Phenolic B
compounds O
present O
in O
Sardinian O
wine O
extracts O
protect O
against O
the O
production O
of O
inflammatory O
cytokines O
induced O
by O
oxysterols B
in O
CaCo O
- O
2 O
human O
enterocyte O
- O
like O
cells O
. O

Cholesterol B
auto O
- O
oxidation O
products O
, O
namely O
oxysterols B
, O
are O
widely O
present O
in O
cholesterol B
- O
rich O
foods O
. O

This O
report O
concerns O
the O
marked O
up O
- O
regulation O
in O
differentiated O
CaCo O
- O
2 O
colonic O
epithelial O
cells O
of O
two O
key O
inflammatory O
interleukins O
, O
IL O
- O
6 O
and O
IL O
- O
8 O
, O
caused O
by O
a O
mixture O
of O
oxysterols B
representative O
of O
a O
high O
cholesterol B
diet O
. O

This O
strong O
pro O
- O
inflammatory O
effect O
appeared O
to O
be O
dependent O
on O
the O
net O
imbalance O
of O
red O
- O
ox O
equilibrium O
with O
the O
production O
of O
excessive O
levels O
of O
reactive O
oxygen B
species O
through O
the O
colonic O
NADPH B
- O
oxidase O
NOX1 O
activation O
. O

Oxysterol B
- O
dependent O
NOX1 O
activation O
, O
as O
well O
as O
interleukin O
synthesis O
, O
were O
completely O
prevented O
by O
Cannonau O
red O
wine O
extract O
that O
contains O
an O
abundant O
phenolic O
fraction O
, O
in O
particular O
phenolic B
acids I
and O
flavonoids B
. O

Conversely O
, O
cell O
pre O
- O
treatment O
with O
Vermentino O
white O
wine O
extract O
with O
smaller O
phenolic O
fraction O
showed O
only O
a O
partial O
NOX1 O
down O
- O
regulation O
and O
was O
ineffective O
in O
interleukin O
synthesis O
induced O
by O
dietary O
oxysterols B
. O

It O
is O
thus O
likely O
that O
the O
effects O
of O
Sardinian O
wine O
extracts O
against O
intestinal O
inflammation O
induced O
by O
dietary O
oxysterols B
are O
mainly O
due O
to O
their O
high O
phenolic O
content O
: O
low O
doses O
of O
phenolics B
would O
be O
responsible O
only O
for O
direct O
scavenging O
oxysterol B
- O
dependent O
ROS O
production O
. O

Besides O
this O
direct O
activity O
, O
an O
excess O
of O
phenolic B
compounds O
detectable O
in O
red O
wine O
, O
may O
exert O
an O
additional O
indirect O
action O
by O
blocking O
oxysterol B
- O
related O
NOX1 O
induction O
, O
thus O
totally O
preventing O
the O
pro O
- O
oxidant O
and O
pro O
- O
inflammatory O
events O
triggered O
by O
dietary O
oxysterols B
. O

Two O
new O
sesqui O
- O
neolignans O
with O
novel O
conjugation O
way O
, O
simonol O
A O
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 O
, O
5 O
- O
dihydro O
- O
pyran O
with O
a O
hemiketal O
carbon O
, O
while O
simonol O
B O
( O
2 O
) O
possessing O
two O
dihydronfuran O
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

The O
two O
isolates O
were O
evaluated O
for O
their O
inhibitory O
activities O
against O
the O
growth O
of O
four O
lines O
of O
human O
cancer O
cells O
( O
NCI O
- O
H460 O
, O
SMMC O
- O
7721 O
, O
MCF O
- O
7 O
, O
BGC O
- O
823 O
) O
: O
1 O
showed O
strong O
activities O
comparable O
to O
5 B
- I
Fluorouracil I
, O
and O
2 O
to O
a O
less O
content O
. O

A O
comprehensive O
machine O
- O
readable O
view O
of O
the O
mammalian O
cholesterol B
biosynthesis O
pathway O
. O

Cholesterol B
biosynthesis O
serves O
as O
a O
central O
metabolic O
hub O
for O
numerous O
biological O
processes O
in O
health O
and O
disease O
. O

A O
detailed O
, O
integrative O
single O
- O
view O
description O
of O
how O
the O
cholesterol B
pathway O
is O
structured O
and O
how O
it O
interacts O
with O
other O
pathway O
systems O
is O
lacking O
in O
the O
existing O
literature O
. O

Here O
we O
provide O
a O
systematic O
review O
of O
the O
existing O
literature O
and O
present O
a O
detailed O
pathway O
diagram O
that O
describes O
the O
cholesterol B
biosynthesis O
pathway O
( O
the O
mevalonate O
, O
the O
Kandutch O
- O
Russell O
and O
the O
Bloch O
pathway O
) O
and O
shunt O
pathway O
that O
leads O
to O
24 O
( O
S O
) O
, O
25 O
- O
epoxycholesterol O
synthesis O
. O

Interdependency O
of O
protein O
- O
release O
completeness O
and O
polymer O
degradation O
in O
PLGA B
- O
based O
implants O
. O

Release O
of O
BSA O
( O
model O
protein O
) O
from O
hot O
- O
melt O
extruded O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
- O
based O
implants O
was O
incomplete O
. O

A O
residual O
mass O
of O
covalent O
BSA O
- O
PLGA B
adducts O
was O
still O
present O
after O
6months O
. O

BSA O
reduced O
the O
PLGA B
degradation O
and O
erosion O
rate O
as O
well O
as O
the O
extent O
of O
erosion O
. O

An O
increased O
uptake O
of O
release O
medium O
in O
the O
presence O
of O
BSA O
in O
addition O
to O
the O
early O
outflux O
of O
PLGA B
oligomers O
resulted O
in O
a O
reduction O
of O
the O
matrix O
acidity O
and O
thus O
reduction O
of O
autocatalysis O
effects O
. O

PLGA B
mass O
loss O
was O
incomplete O
at O
60 O
% O
and O
80 O
% O
for O
10 O
% O
and O
25 O
% O
BSA O
- O
containing O
implants O
. O

The O
extent O
of O
PLGA B
mass O
loss O
was O
correlated O
with O
the O
total O
releasable O
protein O
. O

The O
same O
release O
was O
obtained O
from O
implants O
prepared O
with O
pre O
- O
degraded O
PLGA B
suggesting O
that O
the O
induction O
phase O
did O
not O
affect O
the O
release O
completeness O
. O

Accordingly O
, O
the O
BSA O
release O
completeness O
could O
be O
improved O
by O
enhancing O
the O
outflux O
of O
soluble O
PLGA B
degradation O
products O
. O

Agonistic O
activity O
of O
ICI B
182 I
780 I
on O
activation O
of O
GSK O
3 O
beta O
/ O
AKT O
pathway O
in O
the O
rat O
uterus O
during O
the O
estrous O
cycle O
. O

We O
examined O
the O
ability O
of O
ICI B
182 I
, I
780 I
( O
ICI O
) O
to O
block O
uterine O
cell O
proliferation O
via O
protein O
kinase O
b O
/ O
AKT O
pathway O
in O
the O
uterus O
of O
the O
rat O
during O
the O
estrous O
cycle O
. O

Estradiol B
( O
E2 O
) O
and O
progesterone B
( O
P4 O
) O
plasma O
levels O
were O
measured O
by O
radioimmunoassay O
. O

Both O
ICI O
treatments O
, O
induced O
a O
significant O
decrease O
( O
p O
< O
0 O
. O
01 O
) O
in O
uterine O
estrogen B
receptor O
alpha O
( O
ER O
alpha O
) O
content O
, O
had O
no O
effect O
on O
uterine O
progesterone B
receptor O
( O
PR O
) O
protein O
expression O
and O
caused O
marked O
nuclear O
localization O
of O
cyclin O
D1 O
, O
in O
both O
luminal O
and O
glandular O
uterine O
epithelium O
, O
as O
compared O
to O
vehicle O
- O
treated O
animals O
. O

We O
observed O
that O
the O
administration O
of O
ICI O
at O
08 O
: O
00h O
on O
proestrus O
day O
produced O
a O
15 O
% O
inhibition O
of O
luminal O
epithelial O
cell O
proliferation O
, O
reduced O
uterine O
wet O
weight O
by O
21 O
% O
and O
caused O
reduction O
of O
Akt O
phosphorylation O
at O
Ser B
473 O
as O
compared O
to O
vehicle O
- O
treated O
animals O
, O
whereas O
ICI O
treatment O
at O
00 O
: O
00h O
on O
estrus O
day O
had O
no O
effect O
on O
these O
parameters O
. O

MATERIALS O
AND O
METHODS O
: O
In O
this O
study O
, O
we O
examined O
the O
proposed O
penetration O
enhancing O
properties O
of O
spilanthol O
, O
an O
N O
- O
alkylamide O
abundantly O
present O
in O
several O
Asteraceae O
plants O
like O
Spilanthes O
acmella O
L O
. O
, O
on O
three O
model O
drugs O
( O
caffeine B
, O
testosterone B
and O
ibuprofen B
) O
. O

Moreover O
, O
as O
plants O
are O
frequently O
contaminated O
with O
toxic O
environmental O
substances O
, O
the O
mutual O
influence O
on O
the O
transdermal O
behavior O
between O
spilanthol O
and O
six O
model O
mycotoxins O
( O
aflatoxin B
B1 I
, O
ochratoxin B
A I
, O
fumonisin B
B1 I
, O
citrinin O
, O
zearalenone B
, O
T O
- O
2 O
toxin O
) O
was O
investigated O
. O

No O
significant O
penetration O
enhancing O
effect O
for O
ibuprofen B
has O
been O
observed O
, O
but O
with O
increasing O
spilanthol O
concentration O
( O
from O
0 O
up O
to O
1w O
/ O
V O
% O
) O
, O
the O
permeability O
of O
caffeine B
increased O
, O
resulting O
in O
an O
enhancing O
ratio O
( O
ER O
) O
of O
4 O
. O
60 O
. O

For O
testosterone B
, O
a O
maximal O
penetration O
enhancing O
concentration O
of O
0 O
. O
5 O
% O
spilanthol O
was O
found O
( O
ER O
= O
4 O
. O
13 O
) O
. O

Dietary O
nimodipine O
delays O
the O
onset O
of O
methylmercury B
neurotoxicity O
in O
mice O
. O

One O
mechanism O
by O
which O
chronic O
MeHg B
may O
exert O
its O
neurotoxicity O
is O
via O
sustained O
disruption O
of O
intracellular O
calcium B
homeostasis O
, O
with O
a O
consequent O
increase O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
ions O
in O
vulnerable O
neurons O
. O

A O
biochemically O
heterogeneous O
group O
of O
compounds O
, O
calcium B
channel O
blockers O
, O
have O
been O
shown O
in O
vitro O
to O
attenuate O
MeHg B
' O
s O
toxicity O
. O

To O
evaluate O
the O
role O
of O
calcium B
antagonism O
in O
MeHg B
toxicity O
in O
vivo O
, O
adult O
BALB O
/ O
c O
mice O
were O
exposed O
chronically O
to O
0 O
or O
15ppm O
of O
Hg B
( O
as O
MeHg B
) O
via O
drinking O
water O
and O
to O
nimodipine O
, O
a O
dihydropryidine O
, O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channel O
blocker O
with O
action O
in O
the O
CNS O
. O

An O
incremental O
repeated O
acquisition O
( O
IRA O
) O
of O
response O
chains O
procedure O
was O
used O
to O
detect O
MeHg B
- O
induced O
deficits O
in O
learning O
or O
motoric O
function O
and O
to O
evaluate O
possible O
neuroprotection O
by O
nimodipine O
. O

MeHg B
impaired O
performance O
on O
the O
IRA O
task O
, O
and O
this O
was O
partially O
or O
completely O
blocked O
by O
dietary O
nimodipine O
, O
depending O
on O
dose O
. O

Nimodipine O
delayed O
or O
prevented O
the O
behavioral O
toxicity O
of O
MeHg B
exposure O
as O
evidenced O
by O
IRA O
performance O
; O
effects O
on O
learning O
seemed O
secondary O
to O
response O
rate O
decreases O
. O

Compared O
to O
TP O
, O
TP O
- O
PM O
significantly O
increased O
the O
ACP O
activity O
of O
the O
testis O
and O
decreased O
the O
MDA B
level O
in O
serum O
. O

Anti O
- O
inflammatory O
activity O
of O
Cymbopogon O
citratus O
leaves O
infusion O
via O
proteasome O
and O
nuclear O
factor O
- O
kappa O
B O
pathway O
inhibition O
: O
Contribution O
of O
chlorogenic B
acid I
. O

MATERIALS O
AND O
METHODS O
: O
An O
essential O
oil O
- O
free O
infusion O
of O
Cy O
was O
prepared O
and O
polyphenol B
- O
rich O
fractions O
( O
PFs O
) O
were O
obtained O
from O
it O
by O
column O
chromatography O
. O

Chlorogenic B
acid I
was O
identified O
, O
by O
HPLC O
/ O
PDA O
/ O
ESI O
- O
MS O
( O
n O
) O
. O

RESULTS O
: O
Cymbopogon O
citratus O
extract O
and O
its O
polyphenols B
inhibited O
the O
cytokine O
production O
on O
human O
macrophages O
. O

This O
supports O
the O
anti O
- O
inflammatory O
activity O
of O
Cy O
polyphenols B
in O
physiologically O
relevant O
cells O
. O

Chlorogenic B
acid I
was O
identified O
, O
by O
HPLC O
/ O
PDA O
/ O
ESI O
- O
MS O
( O
n O
) O
, O
as O
the O
main O
phenolic B
acid I
of O
the O
Cy O
infusion O
, O
and O
it O
demonstrated O
to O
be O
, O
at O
least O
in O
part O
, O
responsible O
by O
that O
effect O
. O

Additionally O
, O
Cy O
polyphenols B
, O
in O
particular O
chlorogenic B
acid I
, O
were O
highlighted O
as O
bio O
- O
active O
compounds O
. O

MTS B
assay O
, O
enzyme O
- O
linked O
immunosorbent O
assay O
and O
western O
blotting O
were O
then O
used O
to O
further O
investigate O
the O
molecular O
mechanisms O
. O

Moreover O
by O
the O
mean O
of O
an O
endothelial O
cell O
tube O
formation O
in O
vitro O
model O
2f O
tartaric B
acid I
salt O
proved O
to O
block O
angiogenesis O
of O
HUVEC O
at O
mu O
M O
level O
. O

Therefore O
, O
we O
aimed O
to O
investigate O
the O
effect O
of O
meclofenamic O
acid O
( O
MFA B
) O
on O
retinal O
pigment O
epithelium O
( O
RPE O
) O
. O

Materials O
and O
methods O
: O
In O
our O
study O
, O
we O
applied O
image O
analysis O
and O
whole O
- O
cell O
patch O
clamp O
recording O
to O
directly O
measure O
the O
effect O
of O
MFA B
on O
the O
gap O
junctional O
coupling O
between O
RPE O
cells O
. O

Importantly O
, O
MFA B
largely O
inhibited O
the O
gap O
junction O
conductance O
and O
induced O
the O
uncoupling O
of O
RPE O
cells O
. O
Other O
NSAIDs O
, O
like O
aspirin B
and O
flufenamic B
acid I
( O
FFA O
) O
, O
had O
the O
same O
effect O
. O

Conclusion O
: O
The O
gap O
junction O
functionally O
existed O
in O
RPE O
cells O
, O
which O
can O
be O
blocked O
by O
MFA B
. O

In O
this O
issue O
of O
Diabetologia O
, O
Berkelaar O
et O
al O
( O
DOI O
: O
10 O
. O
1007 O
/ O
s00125 O
- O
013 O
- O
2848 O
- O
6 O
) O
examined O
the O
effects O
of O
euglycaemic O
, O
and O
hyperglycaemic O
clamp O
with O
the O
addition O
of O
glucagon O
- O
like O
- O
peptide O
- O
1 O
( O
GLP O
- O
1 O
) O
and O
arginine B
, O
on O
cardiac O
vagal O
control O
in O
a O
large O
number O
of O
healthy O
subjects O
. O

Photocytotoxicity O
of O
copper B
( I
II I
) I
complexes O
of O
curcumin B
and O
N O
- O
ferrocenylmethyl O
- O
l O
- O
amino O
acids O
. O

Copper B
( I
II I
) I
complexes O
[ O
Cu O
( O
Fc O
- O
aa O
) O
( O
cur O
) O
] O
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur O
) O
and O
N O
- O
ferrocenylmethyl O
- O
l O
- O
amino O
acids O
( O
Fc O
- O
aa O
) O
, O
viz O
. O
, O
ferrocenylmethyl O
- O
l O
- O
tyrosine O
( O
Fc O
- O
TyrH O
) O
, O
ferrocenylmethyl O
- O
l O
- O
tryptophan O
( O
Fc O
- O
TrpH O
) O
and O
ferrocenylmethyl O
- O
l O
- O
methionine O

Acetylacetonate B
( O
acac O
) O
complexes O
[ O
Cu O
( O
Fc O
- O
aa O
) O
( O
acac O
) O
] O
( O
4 O
- O
6 O
) O
were O
prepared O
and O
used O
as O
controls O
. O

Diamond B
- O
Lipid O
Hybrids O
Enhance O
Chemotherapeutic O
Tolerance O
and O
Mediate O
Tumor O
Regression O
. O

Alkane O
Oxidation O
by O
an O
Immobilized O
Nickel B
Complex O
Catalyst O
: O
Structural O
and O
Reactivity O
Differences O
Induced O
by O
Surface O
- O
Ligand O
Density O
on O
Mesoporous O
Silica B
. O

Immobilized O
nickel B
catalysts O
SBA O
* O
- O
L O
- O
x O
/ O
Ni B
( O
L O
= O
bis O
( O
2 O
- O
pyridylmethyl O
) O
( O
1H O
- O
1 O
, O
2 O
, O
3 O
- O
triazol O
- O
4 O
- O
ylmethyl O
) O
amine O
) O
with O
various O
ligand O
densities O
( O
L O
content O
( O
x O
) O
= O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
mol O
% O
Si B
) O
have O
been O
prepared O
from O
azidopropyl O
- O
functionalized O
mesoporous O
silicas B
SBA O
- O
N3 O
- O
x O
. O

Related O
homogeneous O
ligand O
L O
( O
t O
) O
( O
Bu O
) O
and O
its O
Ni B
( I
II I
) I
complexes O
, O
[ O
Ni O
( O
L O
( O
t O
) O
( O
Bu O
) O
) O
( O
OAc O
) O
2 O
( O
H2 O
O O
) O
] O
( O
L O
( O
t O
) O
( O
Bu O
) O
/ O
Ni O
) O
and O
[ O
Ni O
( O
L O
( O
t O
) O
( O
Bu O
) O
) O
2 O
] O
BF4 O
( O
2 O
L O
( O
t O
) O
( O
Bu O
) O
/ O
Ni O
) O
, O
have O
been O
synthesized O
. O

The O
L O
/ O
Ni B
ratio O
( O
0 O
. O
9 O
- O
1 O
. O
7 O
: O
1 O
) O
in O
SBA O
* O
- O
L O
- O
x O
/ O
Ni B
suggests O
the O
formation O
of O
an O
inert O
[ O
NiL2 O
] O
site O
on O
the O
surface O
at O
higher O
ligand O
loadings O
. O

SBA O
* O
- O
L O
- O
x O
/ O
Ni B
has O
been O
applied O
to O
the O
catalytic O
oxidation O
of O
cyclohexane B
with O
m O
- O
chloroperbenzoic O
acid O
( O
mCPBA O
) O
. O

The O
catalyst O
with O
the O
lowest O
loading O
shows O
high O
activity O
in O
its O
initial O
use O
as O
the O
homogeneous O
L O
( O
t O
) O
( O
Bu O
) O
/ O
Ni B
catalyst O
, O
with O
some O
metal O
leaching O
. O

As O
the O
ligand O
loading O
increases O
, O
the O
activity O
and O
Ni B
leaching O
are O
suppressed O
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
develop O
a O
discrete O
- O
time O
simulation O
model O
for O
people O
with O
type O
1 O
diabetes O
mellitus O
, O
to O
estimate O
and O
compare O
mean O
life O
expectancy O
and O
quality O
- O
adjusted O
life O
- O
years O
( O
QALYs O
) O
over O
a O
lifetime O
between O
intensive O
and O
conventional O
blood O
glucose B
treatment O
groups O
. O

We O
examine O
the O
degree O
and O
source O
of O
parameter O
uncertainty O
and O
illustrate O
an O
application O
of O
the O
model O
in O
estimating O
lifetime O
outcomes O
of O
using O
intensive O
and O
conventional O
treatments O
for O
blood O
glucose B
control O
. O

The O
model O
produced O
estimates O
of O
the O
lifetime O
benefits O
of O
intensive O
treatment O
for O
blood O
glucose B
from O
the O
DCCT O
of O
4 O
. O
0 O
( O
95 O
% O
CI O
1 O
. O
2 O
- O
6 O
. O
8 O
) O
QALYs O
for O
women O
and O
4 O
. O
6 O
( O
95 O
% O
CI O
2 O
. O
7 O
- O
6 O
. O
9 O
) O
QALYs O
for O
men O
. O

tert B
- I
Butylhydroquinone I
reduces O
lipid O
accumulation O
in O
C57BL O
/ O
6 O
mice O
with O
lower O
body O
weight O
gain O
. O

tert B
- I
Butylhydroquinone I
( O
tBHQ B
) O
is O
a O
commonly O
used O
antioxidant O
additive O
that O
is O
approved O
for O
human O
use O
by O
both O
the O
Food O
and O
Agriculture O
Organization O
and O
the O
World O
Health O
Organization O
( O
FAO O
/ O
WHO O
) O
. O

In O
this O
study O
, O
we O
examined O
the O
effect O
of O
tBHQ B
on O
body O
weight O
gain O
and O
found O
that O
food O
supplementation O
with O
0 O
. O
001 O
% O
( O
w O
/ O
w O
) O
tBHQ B
inhibited O
61 O
. O
4 O
% O
( O
P O
< O
0 O
. O
01 O
) O
of O
body O
weight O
gain O
in O
high O
- O
fat O
diet O
( O
HFD O
) O
- O
induced O
C57BL O
/ O
6 O
mice O
, O
and O
the O
oral O
administration O
of O
tBHQ B
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
reduced O
47 O
. O
5 O
% O
( O
P O
< O
0 O
. O
05 O
) O
of O
body O
weight O
gain O
in O
normal O
diet O
fed O
db O
/ O
db O
mice O
. O

The O
HFD O
increased O
lipid O
deposit O
in O
adipocytes O
, O
but O
these O
were O
reduced O
significantly O
by O
tBHQ B
treatment O
in O
C57BL O
/ O
6 O
mice O
. O

tBHQ B
supplementation O
significantly O
lowered O
the O
plasma O
triglyceride B
and O
total O
cholesterol B
, O
with O
reduced O
size O
of O
accumulated O
fat O
mass O
. O

The O
rate O
limiting O
enzyme O
of O
beta O
- O
oxidation O
( O
ACOX1 O
) O
was O
significantly O
over O
- O
expressed O
in O
the O
liver O
with O
tBHQ B
treatment O
. O

These O
results O
indicate O
that O
tBHQ B
suppresses O
body O
weight O
gain O
in O
mice O
, O
possibly O
at O
least O
related O
to O
the O
up O
- O
regulation O
of O
ACOX1 O
gene O
expression O
. O

Tandem O
Assays O
of O
Protein O
and O
Glucose B
with O
Functionalized O
Core O
/ O
Shell O
Particles O
Based O
on O
Magnetic O
Separation O
and O
Surface O
- O
Enhanced O
Raman O
Scattering O
. O

Tandem O
assays O
of O
protein O
and O
glucose B
in O
combination O
with O
mannose B
- O
functionalized O
Fe3 O
O4 O
@ O
SiO2 B
and O
Ag B
@ O
SiO2 B
tag O
particles O
have O
promising O
potential O
in O
effective O
magnetic O
separation O
and O
highly O
sensitive O
and O
selective O
SERS O
assays O
of O
biomaterials O
. O

It O
is O
for O
the O
first O
time O
that O
tandem O
assay O
of O
glucose B
is O
developed O
using O
SERS O
based O
on O
the O
Con O
A O
- O
sandwiched O
microstructures O
between O
the O
functionalized O
magnetic O
and O
tag O
particles O
. O

Quantitative O
Determination O
of O
Lateral O
Concentration O
and O
Depth O
Profile O
of O
Histidine B
- O
Tagged O
Recombinant O
Proteins O
Probed O
by O
Grazing O
Incidence O
X O
- O
ray O
Fluorescence O
. O

We O
have O
demonstrated O
that O
the O
complementary O
combination O
of O
grazing O
incidence O
X O
- O
ray O
fluorescence O
( O
GIXF O
) O
with O
specular O
X O
- O
ray O
reflectivity O
( O
XRR O
) O
can O
be O
used O
to O
quantitatively O
determine O
the O
density O
profiles O
of O
Ni B
( I
2 I
) I
( I
+ I
) I
ions O
complexed O
with O
chelator O
headgroups O
as O
well O
as O
S B
atoms O
in O
recombinant O
proteins O
anchored O
to O
lipid O
monolayers O
at O
the O
air O
/ O
water O
interface O
. O

The O
fine O
- O
structures O
perpendicular O
to O
the O
global O
plane O
of O
monolayers O
were O
characterized O
by O
XRR O
in O
the O
presence O
of O
Ni B
( I
2 I
) I
( I
+ I
) I
ions O
, O
yielding O
the O
thickness O
, O
roughness O
, O
and O
electron O
density O
of O
the O
stratified O
lipid O
monolayers O
. O

X O
- O
ray O
fluorescence O
intensities O
from O
Ni B
K O
alpha O
core O
levels O
recorded O
at O
the O
incidence O
angles O
below O
and O
above O
the O
critical O
angle O
of O
total O
reflection O
allow O
for O
the O
determination O
of O
the O
position O
and O
lateral O
density O
of O
Ni B
( I
2 I
) I
( I
+ I
) I
ions O
associated O
with O
chelator O
headgroups O
with O
a O
high O
spatial O
accuracy O
( O
+ O
/ O
- O
5 O
A O
) O
. O

The O
coupling O
of O
histidine B
- O
tagged O
Xenopus O
cadherin O
11 O
( O
Xcad O
- O
11 O
) O
can O
also O
be O
identified O
by O
changes O
in O
the O
fines O
- O
structures O
using O
XRR O
. O

Although O
fluorescence O
intensities O
from O
S B
K O
alpha O
level O
were O
much O
weaker O
than O
Ni B
K O
alpha O
signals O
, O
we O
could O
detect O
the O
location O
of O
S B
atoms O
in O
recombinant O
Xcad O
- O
11 O
proteins O
. O

Ligand O
Based O
Approach O
to O
L O
- O
Type O
Calcium B
Channel O
by O
Imidazo O
[ O
2 O
, O
1 O
- O
b O
] O
thiazole O
- O
1 O
, O
4 O
- O
Dihydropyridines O
: O
from O
Heart O
Activity O
to O
Brain O
Affinity O
. O

To O
define O
the O
calcium B
blocker O
nature O
of O
the O
imidazo O
[ O
2 O
, O
1 O
- O
b O
] O
thiazole O
- O
1 O
, O
4 O
- O
DHPs O
and O
their O
selectivity O
on O
Cav1 O
. O
2 O
and O
Cav1 O
. O
3 O
isoforms O
we O
performed O
binding O
studies O
on O
guinea O
pig O
atrial O
and O
ventricular O
membranes O
, O
on O
intact O
cells O
expressing O
the O
cloned O
Cav1 O
. O
2a O
subunit O
and O
on O
rat O
brain O
cortex O
. O

Efficient O
and O
cost O
- O
effective O
conversion O
of O
solar O
energy O
to O
useful O
chemicals O
and O
fuels O
could O
lead O
to O
a O
significant O
reduction O
in O
fossil O
hydrocarbon B
use O
. O

Here O
we O
report O
a O
stable O
, O
scalable O
design O
and O
molecular O
level O
fabrication O
strategy O
to O
create O
photoelectrochemical O
active O
heterostructure O
( O
PAH O
) O
units O
consisting O
of O
an O
efficient O
semiconductor O
light O
absorber O
in O
contact O
with O
oxidation O
and O
reduction O
electrocatalysts O
and O
otherwise O
protected O
by O
alumina B
. O

The O
functional O
heterostructures O
are O
fabricated O
by O
layer O
- O
by O
- O
layer O
, O
template O
- O
directed O
, O
electrochemical O
synthesis O
in O
porous O
anodic O
aluminum B
oxide I
membranes O
to O
produce O
high O
density O
arrays O
of O
electronically O
autonomous O
, O
nanostructured O
, O
corrosion O
resistant O
, O
photoactive O
units O
( O
~ O
10 O
( O
9 O
) O
- O
10 O
( O
10 O
) O
PAHs O
per O
cm O
( O
2 O
) O
) O
. O

Each O
PAH O
unit O
is O
isolated O
from O
its O
neighbor O
by O
the O
transparent O
electrically O
insulating O
oxide B
cellular O
enclosure O
that O
makes O
the O
overall O
assembly O
fault O
tolerant O
. O

When O
illuminated O
with O
visible O
light O
, O
the O
free O
floating O
devices O
have O
been O
demonstrated O
to O
produce O
hydrogen B
at O
a O
stable O
rate O
for O
over O
24 O
h O
in O
corrosive O
hydroiodic O
acid O
electrolyte O
with O
light O
as O
the O
only O
input O
. O

The O
quantum O
efficiency O
( O
averaged O
over O
the O
solar O
spectrum O
) O
for O
absorbed O
photons O
- O
to O
- O
hydrogen B
conversion O
was O
7 O
. O
4 O
% O
and O
solar O
- O
to O
- O
hydrogen B
energy O
efficiency O
of O
incident O
light O
was O
0 O
. O
9 O
% O
. O

The O
role O
of O
external O
defects O
in O
chemical O
sensing O
of O
graphene B
field O
- O
effect O
transistors O
. O

A O
fundamental O
understanding O
of O
chemical O
sensing O
mechanisms O
in O
graphene B
- O
based O
chemical O
field O
- O
effect O
transistors O
( O
chemFETs O
) O
is O
essential O
for O
the O
development O
of O
next O
generation O
chemical O
sensors O
. O

Here O
we O
explore O
the O
hidden O
sensing O
modalities O
responsible O
for O
tailoring O
the O
gas O
detection O
ability O
of O
pristine O
graphene O
sensors O
by O
exposing O
graphene B
chemFETs O
to O
electron O
donor O
and O
acceptor O
trace O
gas O
vapors O
. O

We O
uncover O
that O
the O
sensitivity O
( O
in O
terms O
of O
modulation O
in O
electrical O
conductivity O
) O
of O
pristine O
graphene O
chemFETs O
is O
not O
necessarily O
intrinsic O
to O
graphene B
, O
but O
rather O
it O
is O
facilitated O
by O
external O
defects O
in O
the O
insulating O
substrate O
, O
which O
can O
modulate O
the O
electronic O
properties O
of O
graphene B
. O

We O
disclose O
a O
mixing O
effect O
caused O
by O
partial O
overlap O
of O
the O
highest O
occupied O
molecular O
orbital O
( O
HOMO O
) O
and O
lowest O
unoccupied O
molecular O
orbital O
( O
LUMO O
) O
of O
adsorbed O
gas O
molecules O
to O
explain O
graphene B
' O
s O
ability O
to O
detect O
adsorbed O
molecules O
. O

Our O
results O
open O
a O
new O
design O
space O
, O
suggesting O
that O
control O
of O
external O
defects O
in O
supporting O
substrates O
can O
lead O
to O
tunable O
graphene O
chemical O
sensors O
, O
which O
could O
be O
developed O
without O
compromising O
the O
intrinsic O
electrical O
and O
structural O
properties O
of O
graphene B
. O

Study O
of O
the O
microcharacter O
of O
ultrastable O
aqueous O
foam O
stabilized O
by O
a O
kind O
of O
flexible O
connecting O
bipolar O
- O
headed O
surfactant O
with O
existence O
of O
magnesium B
ion O
. O

In O
this O
paper O
, O
ultrastable O
aqueous O
foam O
stabilized O
by O
a O
kind O
of O
flexible O
connecting O
bipolar O
- O
headed O
surfactant O
alkyl O
polyoxyethylene O
sulfate O
( O
AE3S O
) O
with O
coexisting O
Mg B
( I
2 I
+ I
) I
was O
reported O
. O

Detailed O
molecular O
behaviors O
of O
AE3S O
in O
foam O
film O
with O
coexisting O
divalent O
cationic O
Ca B
( I
2 I
+ I
) I
or O
Mg B
( I
2 I
+ I
) I
were O
investigated O
by O
molecular O
dynamic O
simulation O
, O
comparing O
with O
the O
traditional O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
to O
find O
out O
how O
the O
microcharacter O
and O
array O
behavior O
of O
molecules O
in O
the O
foam O
film O
determined O
by O
molecular O
interaction O
effect O
the O
foam O
stability O
. O

It O
was O
found O
that O
the O
ultrastable O
foam O
film O
obtained O
by O
the O
cooperation O
of O
magnesium B
ions O
and O
AE3S O
was O
driven O
from O
two O
aspects O
: O
one O
is O
the O
favorable O
arrangement O
of O
surfactant O
molecules O
, O
and O
the O
other O
is O
the O
increase O
of O
capacity O
of O
foam O
films O
for O
resolutely O
holding O
water O
molecules O
deduced O
by O
a O
dipolar O
pair O
formed O
by O
the O
flexible O
connecting O
head O
groups O
of O
AE3S O
and O
hydrated O
Mg O
( O
2 O
+ O
) O
via O
intermolecular O
coactions O
, O
both O
related O
to O
the O
presence O
of O
magnesium B
ions O
. O

Fourier O
transform O
infrared O
( O
FT O
- O
IR O
) O
was O
used O
to O
detect O
the O
composition O
variation O
of O
foam O
film O
in O
the O
drainage O
process O
; O
the O
vibration O
peak O
of O
OH B
for O
water O
molecule O
shifted O
from O
the O
3390 O
cm O
( O
- O
1 O
) O
( O
being O
assigned O
to O
the O
bulk O
water O
integrated O
by O
hydrogen B
bonds O
) O
to O
3685 O
cm O
( O
- O
1 O
) O
( O
being O
assigned O
to O
the O
vibration O
of O
isolated O
water O
molecules O
) O
for O
the O
ultrastable O
foam O
film O
after O
complete O
drainage O
, O
which O
agreed O
very O
well O
with O
the O
molecular O
simulation O
results O
. O

Quinoline B
Drug O
- O
Heme B
Interactions O
and O
Implications O
for O
Antimalarial O
Cytostatic O
versus O
Cytocidal O
Activities O
. O

Heme B
released O
from O
catabolized O
host O
red O
blood O
cell O
hemoglobin O
is O
toxic O
, O
so O
malarial O
parasites O
crystallize O
heme B
to O
nontoxic O
hemozoin O
. O

For O
years O
it O
has O
been O
accepted O
that O
a O
number O
of O
effective O
quinoline B
antimalarial O
drugs O
( O
e O
. O
g O
. O
, O
chloroquine B
, O
quinine B
, O
amodiaquine B
) O
function O
by O
preventing O
hemozoin O
crystallization O
. O

However O
, O
recent O
studies O
over O
the O
past O
decade O
have O
revealed O
a O
surprising O
molecular O
diversity O
in O
quinoline B
- O
heme B
molecular O
interactions O
. O

This O
diversity O
shows O
that O
even O
closely O
related O
quinoline B
drugs O
may O
have O
quite O
different O
molecular O
pharmacology O
. O

This O
paper O
reviews O
the O
molecular O
diversity O
and O
highlights O
important O
implications O
for O
understanding O
quinoline B
antimalarial O
drug O
resistance O
and O
for O
future O
drug O
design O
. O

During O
acid O
hydrolysis O
of O
1 O
, O
the O
isomerization O
of O
the O
valine B
residue O
was O
observed O
and O
also O
studied O
in O
different O
conditions O
. O

The O
accumulated O
analogues O
from O
the O
Delta O
fosK O
and O
Delta O
fosM O
mutant O
strains O
possessed O
a O
malonyl O
ester O
moiety O
that O
suggested O
that O
all O
the O
post O
- O
PKS O
modification O
steps O
in O
FST O
biosynthesis O
occur O
with O
the O
polyketide O
chain O
bearing O
a O
malonyl O
ester O
at O
the O
C O
- O
3 O
position O
, O
with O
formation O
of O
the O
unsaturated O
six O
- O
membered O
lactone B
as O
the O
last O
step O
in O
FST O
biosynthesis O
. O

We O
used O
hydrophilic O
polystyrene B
colloids O
with O
four O
different O
shapes O
( O
spheres O
, O
barrels O
, O
rods O
, O
and O
oblong O
disks O
) O
, O
but O
otherwise O
identical O
surface O
properties O
. O

The O
nonspherical O
shapes O
were O
created O
by O
stretching O
spherical O
microspheres O
on O
a O
film O
of O
polyvinyl B
alcohol I
( O
PVA B
) O
. O

Here O
, O
we O
demonstrate O
that O
carbonated O
apatite O
present O
in O
collagen O
matrices O
derived O
from O
fish O
scale O
and O
bovine O
bone O
may O
be O
replaced O
by O
amorphous O
silica B
, O
using O
an O
approach O
that O
simulates O
what O
is O
utilized O
by O
phylogenetically O
ancient O
glass O
sponges O
. O

The O
structural O
hierarchy O
of O
these O
collagen O
- O
based O
biomaterials O
is O
replicated O
by O
the O
infiltration O
and O
condensation O
of O
fluidic O
polymer O
- O
stabilized O
silicic B
acid I
precursors O
within O
the O
intrafibrillar O
milieu O
of O
type O
I O
collagen O
fibrils O
. O

This O
facile O
biomimetic O
silicification O
strategy O
may O
be O
used O
for O
fabricating O
silica B
- O
based O
, O
three O
- O
dimensional O
functional O
materials O
with O
specific O
morphological O
and O
hierarchical O
requirements O
. O

Nocardiamides O
A O
and O
B O
, O
Two O
Cyclohexapeptides B
from O
the O
Marine O
- O
Derived O
Actinomycete O
Nocardiopsis O
sp O
. O

Duroquinone O
( O
derivative O
of O
1 B
, I
4 I
- I
benzoquinone I
) O
is O
a O
xenobiotic O
compound O
widespread O
in O
the O
environment O
. O

Spermatozoa O
motility O
, O
velocity O
, O
and O
ATP B
content O
were O
significantly O
decreased O
with O
exposure O
to O
duroquinone O
. O

Oxidative O
stress O
indices O
( O
lipid O
peroxidation O
and O
content O
of O
carbonyl B
proteins O
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
activity O
increased O
significantly O
with O
increasing O
concentrations O
of O
duroquinone O
. O

Spermatozoa O
motility O
, O
content O
of O
carbonyl B
proteins O
, O
and O
SOD O
activity O
were O
shown O
to O
be O
sensitive O
biomarkers O
, O
exhibiting O
strong O
responses O
to O
low O
concentrations O
of O
the O
xenobiotic O
. O

Kappa O
opioid O
receptors O
in O
the O
central O
amygdala O
regulate O
ethanol B
actions O
at O
presynaptic O
GABAergic O
sites O
. O

Human O
and O
animal O
studies O
indicate O
that O
kappa O
opioid O
receptor O
( O
KOR O
) O
systems O
are O
involved O
in O
ethanol B
drinking O
and O
dependence O
( O
Xuei O
et O
al O
. O
, O
2006 O
; O
Walker O
and O
Koob O
, O
2008 O
; O
Walker O
et O
al O
. O
, O
2011 O
) O
. O

The O
central O
amygdala O
( O
CeA O
) O
is O
a O
critical O
brain O
region O
mediating O
anxiety O
- O
related O
behavior O
and O
drug O
reward O
and O
is O
a O
likely O
site O
for O
the O
interaction O
of O
the O
KOR O
system O
and O
ethanol B
, O
although O
few O
studies O
have O
explored O
this O
interaction O
. O

Using O
in O
vitro O
single O
- O
cell O
recording O
techniques O
in O
mouse O
brain O
slices O
, O
we O
examined O
the O
physiological O
effects O
of O
KOR O
activation O
in O
CeA O
on O
GABAergic O
neurotransmission O
and O
its O
interaction O
with O
acute O
ethanol B
. O

In O
addition O
, O
the O
enhancement O
by O
acute O
ethanol B
of O
GABAergic O
IPSC O
amplitudes O
in O
the O
CeA O
was O
further O
augmented O
by O
pharmacological O
blockade O
of O
KORs O
, O
from O
14 O
% O
( O
n O
= O
36 O
) O
to O
27 O
% O
( O
n O
= O
26 O
; O
p O
< O
0 O
. O
01 O
) O
, O
or O
by O
genetic O
deletion O
of O
KORs O
, O
from O
14 O
% O
in O
WT O
mice O
( O
n O
= O
19 O
) O
to O
34 O
% O
in O
KOR O
knockout O
( O
KO O
) O
mice O
( O
n O
= O
13 O
, O
p O
< O
0 O
. O
01 O
) O
, O
suggesting O
that O
the O
KOR O
system O
regulates O
acute O
ethanol B
actions O
in O
the O
CeA O
. O

Subsequent O
experiments O
using O
tetrodotoxin O
to O
block O
activity O
- O
dependent O
neurotransmission O
suggest O
that O
KORs O
regulate O
GABA B
release O
at O
presynaptic O
sites O
. O

Thus O
, O
KOR O
activation O
modulates O
GABAergic O
neurotransmission O
and O
ethanol B
effects O
in O
CeA O
in O
a O
manner O
similar O
to O
other O
subtypes O
of O
opioid O
receptors O
, O
i O
. O
e O
. O
, O
mu O
and O
delta O
opioid O
receptors O
( O
Kang O
- O
Park O
et O
al O
. O
, O
2007 O
; O
Kang O
- O
Park O
et O
al O
. O
, O
2009 O
) O
. O

Our O
data O
support O
the O
idea O
that O
KORs O
modulate O
GABAergic O
synaptic O
responses O
and O
ethanol B
effects O
as O
one O
of O
multiple O
opioid O
system O
- O
dependent O
actions O
of O
ethanol B
in O
the O
CeA O
, O
possibly O
in O
a O
circuit O
- O
specific O
manner O
. O

Application O
of O
the O
combinative O
particle O
size O
reduction O
technology O
H O
42 O
to O
produce O
fast O
dissolving O
glibenclamide B
tablets O
. O

For O
untreated O
, O
micronized O
glibenclamide B
, O
the O
particle O
size O
analysis O
revealed O
a O
mean O
particle O
size O
of O
772nm O
and O
volume O
- O
based O
size O
distribution O
values O
of O
2 O
. O
686 O
mu O
m O
( O
d50 O
% O
) O
and O
14 O
. O
423 O
mu O
m O
( O
d90 O
% O
) O
. O

The O
use O
of O
pre O
- O
treated O
material O
( O
10 O
: O
1 O
glibenclamide B
/ O
docusate O
sodium O
salt O
ratio O
spray O
- O
dried O
as O
ethanolic O
solution O
) O
resulted O
in O
a O
mean O
particle O
size O
of O
236nm O
and O
volume O
- O
based O
size O
distribution O
values O
of O
0 O
. O
131 O
mu O
m O
( O
d50 O
% O
) O
and O
0 O
. O
285 O
mu O
m O
( O
d90 O
% O
) O
. O

The O
best O
drug O
release O
( O
90 O
% O
within O
10min O
) O
was O
obtained O
for O
tablets O
produced O
with O
spray O
- O
dried O
nanosuspension O
containing O
2 O
% O
mannitol B
as O
matrix O
former O
. O

In O
comparison O
, O
the O
tablets O
processed O
with O
micronized O
glibenclamide B
showed O
a O
drug O
release O
of O
only O
26 O
% O
after O
10min O
. O

Regulation O
of O
connexin O
hemichannel O
activity O
by O
membrane O
potential O
and O
the O
extracellular O
calcium B
in O
health O
and O
disease O
. O

Here O
, O
we O
present O
a O
comprehensive O
overview O
of O
how O
hemichannel O
activity O
is O
tightly O
regulated O
by O
membrane O
potential O
and O
the O
external O
calcium B
concentration O
. O

Cyp1a O
reporter O
zebrafish O
reveals O
target O
tissues O
for O
dioxin B
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
is O
the O
unintentional O
byproduct O
of O
various O
industrial O
processes O
, O
is O
classified O
as O
human O
carcinogen O
and O
could O
disrupt O
reproductive O
, O
developmental O
and O
endocrine O
systems O
. O

Induction O
of O
cyp1a1 O
is O
used O
as O
an O
indicator O
of O
TCDD B
exposure O
. O

We O
sought O
to O
determine O
tissues O
that O
are O
vulnerable O
to O
TCDD B
toxicity O
using O
a O
transgenic O
zebrafish O
( O
Danio O
rerio O
) O
model O
. O

The O
resulting O
recombineered O
fosmid O
was O
then O
used O
to O
generate O
cyp1a O
reporter O
zebrafish O
, O
embryos O
of O
which O
were O
exposed O
to O
TCDD B
. O

In O
addition O
, O
exposure O
of O
the O
embryos O
to O
TCDD B
at O
as O
low O
as O
10pM O
for O
72h O
, O
which O
does O
not O
elicit O
morphological O
abnormalities O
of O
embryos O
, O
markedly O
increased O
GFP O
expression O
. O

Exposure O
of O
the O
embryos O
to O
TCDD B
revealed O
previously O
reported O
( O
the O
cardiovascular O
system O
, O
liver O
, O
pancreas O
, O
kidney O
, O
swim O
bladder O
and O
skin O
) O
and O
unreported O
target O
tissues O
( O
retinal O
bipolar O
cells O
, O
otic O
vesicle O
, O
lateral O
line O
, O
cloaca O
and O
pectoral O
fin O
bud O
) O
for O
TCDD B
. O

Transgenic O
cyp1a O
reporter O
zebrafish O
we O
have O
developed O
can O
further O
understanding O
of O
ecotoxicological O
relevance O
and O
human O
health O
risks O
by O
TCDD B
. O

In O
addition O
, O
they O
could O
be O
used O
to O
identify O
agonists O
of O
AhR O
and O
antidotes O
to O
TCDD B
toxicity O
. O

MATERIALS O
AND O
METHODS O
: O
Methanol B
and O
aqueous O
extracts O
of O
six O
plant O
mixtures O
were O
screened O
for O
antibacterial O
properties O
against O
two O
Gram O
- O
negative O
and O
two O
Gram O
- O
positive O
bacteria O
using O
the O
minimum O
inhibitory O
microdilution O
method O
. O

Thereafter O
, O
chloroform B
: O
methanol B
( O
1 O
: O
1 O
; O
v O
/ O
v O
) O
extracts O
, O
essential O
oils O
and O
aqueous O
extracts O
of O
Agathosma O
crenulata O
, O
Dodonaea O
viscosa O
and O
Eucalyptus O
globulus O
were O
assayed O
for O
antimicrobial O
activity O
independently O
and O
in O
various O
combinations O
. O

RESULTS O
: O
From O
the O
six O
plant O
mixtures O
prepared O
by O
herbalists O
, O
a O
methanol B
extract O
derived O
from O
combining O
Agathosma O
crenulata O
, O
Dodonaea O
viscosa O
and O
Eucalyptus O
globulus O
showed O
the O
best O
antibacterial O
activity O
. O

The O
most O
noteworthy O
synergistic O
( O
Sigma O
FIC O
value O
0 O
. O
07 O
) O
1 O
: O
1 O
combinations O
were O
observed O
for O
the O
chloroform B
: O
methanol B
extracts O
of O
Agathosma O
crenulata O
mixed O
with O
Eucalyptus O
globulus O
against O
Klebsiella O
pneumoniae O
, O
Staphylococcus O
aureus O
and O
Bacillus O
subtilis O
. O

Dose O
- O
related O
nephrotoxicity O
, O
assessed O
by O
hematoxylin B
and O
eosin B
staining O
, O
was O
greater O
in O
males O
compared O
to O
female O
rats O
, O
as O
was O
cellular O
proliferation O
, O
assessed O
by O
bromodeoxyuridine B
staining O
. O

The O
fraction O
of O
proximal O
renal O
cells O
with O
elevated O
8 O
- O
oxodeoxyguanosine O
( O
8 B
- I
OH I
- I
dG I
) O
was O
only O
increased O
at O
the O
high O
dose O
and O
did O
not O
differ O
by O
sex O
. O

Elevated O
simvastatin B
AUC O
in O
virtual O
rheumatoid O
arthritis O
patients O
, O
following O
100 O
pg O
/ O
mL O
of O
IL O
- O
6 O
was O
comparable O
to O
observed O
clinical O
data O
( O
59 O
% O
versus O
58 O
% O
) O
. O

In O
virtual O
bone O
marrow O
transplant O
( O
BMT O
) O
patients O
, O
500 O
pg O
/ O
ml O
of O
IL O
- O
6 O
resulted O
in O
increase O
in O
cyclosporine B
AUC O
that O
was O
in O
good O
agreement O
with O
the O
observed O
data O
( O
45 O
% O
versus O
39 O
% O
) O
. O

In O
a O
different O
group O
of O
BMT O
patients O
treated O
with O
cyclosporine B
, O
the O
magnitude O
of O
interaction O
with O
IL O
- O
6 O
was O
under O
predicted O
~ O
3 O
- O
fold O
. O

The O
Fer O
tyrosine B
kinase O
is O
important O
for O
platelet O
- O
derived O
growth O
factor O
- O
BB O
- O
induced O
Stat3 O
phosphorylation O
, O
colony O
formation O
in O
soft O
agar O
and O
tumor O
growth O
in O
vivo O
. O

Fer O
is O
a O
cytoplasmic O
tyrosine B
kinase O
that O
is O
activated O
in O
response O
to O
platelet O
- O
derived O
growth O
factor O
( O
PDGF O
) O
stimulation O
. O

Exposure O
to O
mercury B
among O
dental O
health O
workers O
in O
Turkey O
: O
Correlation O
with O
amalgam O
work O
and O
own O
fillings O
. O

PURPOSE O
: O
To O
investigate O
the O
current O
status O
of O
exposure O
to O
mercury B
( O
Hg B
) O
among O
dental O
health O
workers O
in O
Turkey O
. O

RESULTS O
: O
Plasma O
Hg B
levels O
were O
found O
to O
be O
3 O
. O
76 O
+ O
/ O
- O
1 O
. O
84 O
, O
3 O
. O
54 O
+ O
/ O
- O
1 O
. O
83 O
, O
and O
2 O
. O
69 O
+ O
/ O
- O
0 O
. O
97 O
micro O
g O
/ O
L O
in O
groups O
1 O
, O
2 O
, O
and O
3 O
, O
respectively O
. O

Hg B
concentrations O
in O
group O
1 O
were O
significantly O
higher O
than O
the O
control O
group O
. O

The O
number O
of O
amalgam O
fillings O
made O
by O
the O
dentists O
in O
the O
previous O
year O
correlated O
significantly O
with O
plasma O
Hg B
levels O
( O
r O
= O
0 O
. O
378 O
, O
p O
< O
0 O
. O
01 O
) O
. O

There O
was O
no O
significant O
correlation O
between O
the O
own O
amalgam O
fillings O
in O
the O
teeth O
of O
the O
subjects O
and O
Hg B
levels O
. O

CONCLUSION O
: O
Preventive O
measures O
for O
protection O
from O
exposure O
to O
Hg B
are O
necessary O
for O
occupational O
health O
in O
dentistry O
and O
proper O
industrial O
hygiene O
rules O
should O
be O
emphasized O
to O
avoid O
contamination O
during O
work O
. O

Amelioration O
of O
hepatotoxicity O
induced O
by O
aflatoxin B
using O
citrus O
fruit O
oil O
in O
broilers O
( O
Gallus O
domesticus O
) O
. O

This O
study O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
citrus O
fruit O
oil O
( O
CFO O
; O
2 O
. O
5 O
g O
kg O
( O
- O
) O
( O
1 O
) O
) O
on O
the O
clinicopathological O
changes O
in O
broilers O
fed O
with O
diets O
containing O
1 O
ppm O
of O
aflatoxin B
( O
AF O
) O
. O

Monoamine B
oxidase O
( O
MAO O
) O
is O
an O
important O
drug O
target O
for O
the O
treatment O
of O
neurological O
disorders O
. O

5 O
- O
Nitro O
- O
2 O
- O
( O
4 O
- O
methoxyphenyl O
) O
benzofuran O
( O
8 O
) O
is O
the O
most O
active O
compound O
of O
the O
benzofuran B
series O
, O
presenting O
MAO O
- O
B O
selectivity O
and O
reversible O
inhibition O
( O
IC50 O
= O
140 O
nM O
) O
. O

3 O
- O
( O
4 O
' O
- O
Methoxyphenyl O
) O
- O
6 O
- O
nitrocoumarin O
( O
15 O
) O
, O
with O
the O
same O
substitution O
pattern O
as O
that O
of O
compound O
8 O
, O
was O
found O
to O
be O
the O
most O
active O
MAO O
- O
B O
inhibitor O
of O
the O
coumarin B
series O
( O
IC50 O
= O
3 O
nM O
) O
. O

Direct O
Laser O
- O
Patterned O
Micro O
- O
Supercapacitors O
from O
Paintable O
MoS2 B
Films O
. O

Here O
, O
a O
new O
approach O
to O
large O
- O
scale O
fabrication O
of O
high O
- O
capacitance O
, O
two O
- O
dimensional O
MoS2 B
film O
- O
based O
micro O
- O
supercapacitors O
is O
demonstrated O
via O
simple O
and O
low O
- O
cost O
spray O
painting O
of O
MoS2 B
nanosheets O
on O
Si B
/ O
SiO2 B
chip O
and O
subsequent O
laser O
patterning O
. O

The O
optimum O
MoS2 B
- O
based O
micro O
- O
supercapacitor O
exhibits O
excellent O
electrochemical O
performance O
for O
energy O
storage O
with O
aqueous O
electrolytes O
, O
with O
a O
high O
area O
capacitance O
of O
8 O
mF O
cm O
( O
- O
2 O
) O
( O
volumetric O
capacitance O
of O
178 O
F O
cm O
( O
- O
3 O
) O
) O
and O
excellent O
cyclic O
performance O
, O
superior O
to O
reported O
graphene B
- O
based O
micro O
- O
supercapacitors O
. O

Insulin O
is O
an O
amyloid O
- O
forming O
polypeptide O
built O
of O
two O
disulfide B
- O
linked O
chains O
( O
A O
and O
B O
) O
, O
both O
themselves O
amyloidogenic O
. O

Our O
study O
shows O
that O
only O
the O
B O
chain O
in O
the O
presence O
of O
TCEP O
is O
converted O
into O
aggregates O
with O
morphology O
( O
according O
to O
atomic O
force O
microscopy O
) O
and O
optical O
activity O
( O
manifested O
as O
an O
extrinsic O
Cotton O
effect O
induced O
in O
bound O
thioflavin B
T I
) O
characteristic O
of O
amyloid O
superstructures O
that O
are O
normally O
formed O
by O
insulin O
in O
the O
absence O
of O
TCEP O
. O

Determination O
of O
urinary O
6 B
- I
mercaptopurine I
and O
three O
of O
its O
metabolites O
by O
HPLC O
- O
UV O
coupled O
with O
the O
iodine B
- O
azide B
reaction O
. O

Background O
: O
The O
presented O
method O
is O
able O
to O
determine O
6 B
- I
mercaptopurine I
( O
6 O
- O
MP O
) O
, O
6 O
- O
thioguanine O
, O
6 O
- O
mercaptopurine O
riboside O
and O
6 O
- O
thioguanine O
riboside O
in O
urine O
, O
and O
is O
thereby O
dedicated O
to O
control O
of O
thiopurine O
therapy O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

Good O
separation O
of O
the O
mentioned O
compounds O
was O
achieved O
on O
a O
C18 O
stationary O
phase O
with O
a O
sodium B
azide I
and O
sodium O
heptane O
sulfonate O
solution O
, O
acetonitrile B
and O
water O
at O
ratio O
of O
50 O
: O
1 O
: O
49 O
( O
v O
/ O
v O
/ O
v O
) O
. O

Polyelectrolyte O
- O
Surfactant O
Complexes O
of O
Poly O
[ O
3 O
, O
5 O
- O
bis O
( O
dimethylaminomethyl O
) O
- O
4 O
- O
hydroxystyrene O
] O
- O
block O
- O
poly O
( O
ethylene O
oxide O
) O
and O
Sodium B
Dodecyl I
Sulfate I
: O
Anomalous O
Self O
- O
Assembly O
Behavior O
. O

Polyelectrolyte O
- O
surfactant O
complexes O
( O
PE O
- O
S O
) O
formed O
by O
double O
hydrophilic O
cationic O
polyelectrolyte O
poly O
[ O
3 O
, O
5 O
- O
bis O
( O
dimethylaminomethyl O
) O
- O
4 O
- O
hydroxystyrene O
] O
- O
block O
- O
poly O
( O
ethylene O
oxide O
) O
( O
NPHOS O
- O
PEO O
) O
and O
anionic O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
in O
acidic O
aqueous O
solutions O
were O
studied O
by O
light O
scattering O
, O
SAXS O
, O
and O
scanning O
transmission O
electron O
microcopy O
in O
the O
environmental O
mode O
( O

The O
obtained O
results O
show O
that O
the O
NPHOS O
- O
PEO O
/ O
SDS B
system O
behaves O
differently O
from O
other O
systems O
of O
double O
hydrophilic O
block O
polyelectrolyte O
and O
oppositely O
charged O
ionic O
surfactant O
because O
it O
forms O
water O
- O
insoluble O
PE O
- O
S O
for O
compositions O
close O
to O
the O
zero O
net O
charge O
of O
the O
complex O
. O

SAXS O
measurements O
indicate O
that O
although O
the O
NPHOS O
- O
PEO O
/ O
SDS B
system O
does O
not O
form O
the O
core O
- O
shell O
particles O
with O
the O
NPHOS O
/ O
SDS B
core O
and O
the O
PEO B
shell O
as O
other O
PE O
- O
S O
of O
double O
hydrophilic O
polyelectrolytes O
, O
the O
aggregates O
contain O
domains O
of O
closely O
packed O
surfactant O
micelles O
which O
bind O
to O
both O
NPHOS O
polyelectrolyte O
blocks O
and O
PEO B
blocks O
. O

Micellar O
nanoparticles O
were O
assembled O
from O
amphiphilic O
diblock O
copolymers O
composed O
of O
an O
ampholytic O
core O
- O
forming O
block O
and O
a O
redesigned O
polycationic O
corona O
block O
doped O
with O
thiol B
- O
reactive O
pyridyl O
disulfide O
groups O
to O
enable O
dual O
- O
delivery O
of O
antigens O
and O
immunostimulatory O
CpG B
oligodeoxynucleotide O
( O
CpG B
ODN O
) O
adjuvants O
. O

Polymers O
assembled O
into O
23 O
nm O
particles O
with O
simultaneous O
packaging O
of O
CpG B
ODN O
and O
a O
thiolated O
protein O
antigen O
, O
ovalbumin O
( O
ova O
) O
. O

Significantly O
, O
immunization O
with O
ova O
- O
nanoparticle O
conjugates O
electrostatically O
complexed O
with O
CpG B
ODN O
( O
dual O
- O
delivery O
) O
enhanced O
CD8 O
( O
+ O
) O
T O
cell O
responses O
( O
3 O
. O
4 O
% O
IFN O
- O
gamma O
( O
+ O
) O
of O
CD8 O
( O
+ O
) O
) O
7 O
- O
, O
18 O
- O
, O
and O
8 O
- O
fold O
relative O
to O
immunization O
with O
conjugates O
, O
ova O
administered O
with O
free O
CpG B
, O
or O
a O
formulation O
containing O
free O
ova O
and O
CpG B
complexed O
to O
micelles O
, O
respectively O
. O

This O
work O
demonstrates O
the O
ability O
of O
pH O
- O
responsive O
, O
endosomolytic O
nanoparticles O
to O
actively O
promote O
antigen O
cross O
- O
presentation O
and O
augment O
cellular O
and O
humoral O
immune O
responses O
via O
dual O
- O
delivery O
of O
protein O
antigens O
and O
CpG B
ODN O
. O

Improved O
Carrier O
Mobility O
in O
Few O
- O
Layer O
MoS2 B
Field O
- O
Effect O
Transistors O
with O
Ionic O
- O
Liquid O
Gating O
. O

We O
report O
the O
fabrication O
of O
ionic O
liquid O
( O
IL O
) O
- O
gated O
field O
- O
effect O
transistors O
( O
FETs O
) O
consisting O
of O
bilayer O
and O
few O
- O
layer O
MoS2 B
. O

Sodium B
salts O
of O
maleamic O
acid O
derivatives O
of O
lauryl O
ester O
of O
tyrosine B
( O
MTNa O
) O
and O
phenyl O
alanine O
( O
MPNa O
) O
in O
water O
exhibited O
strong O
pH O
- O
responsive O
behaviors O
of O
viscosity O
and O
specific O
conductivity O
that O
originate O
from O
the O
concentration O
and O
pH O
dependence O
of O
their O
aggregation O
states O
. O

Discovery O
of O
aryl O
ureas O
and O
aryl O
amides O
as O
potent O
and O
selective O
histamine B
H3 O
receptor O
antagonists O
for O
the O
treatment O
of O
obesity O
( O
Part O
I O
) O
. O

A O
series O
of O
structurally O
novel O
aryl O
ureas O
was O
derived O
from O
optimization O
of O
the O
HTS O
lead O
as O
selective O
histamine B
H3 O
receptor O
( O
H3R O
) O
antagonists O
. O

Phenanthroimidazole B
- O
based O
thiobenzamide O
as O
an O
effective O
sensor O
for O
highly O
selective O
detection O
of O
mercury B
( I
II I
) I
. O

Based O
on O
highly O
selective O
and O
irreversible O
Hg B
( I
2 I
+ I
) I
- O
promoted O
desulfurization O
reaction O
, O
a O
new O
and O
simple O
phenanthroimidazole B
- O
type O
sensor O
was O
prepared O
and O
exhibited O
high O
selectivity O
towards O
Hg B
( I
2 I
+ I
) I
ion O
over O
other O
metal O
ions O
, O
accompanied O
by O
transformation O
of O
a O
weakly O
fluorescent O
thioamide O
moiety O
( O
colorless O
) O
to O
a O
highly O
fluorescent O
amide B
one O
( O
blue O
) O
, O
with O
a O
136 O
- O
fold O
increase O
in O
fluorescent O
intensity O
in O
aqueous O
solution O
with O
a O
pH O
span O
2 O
. O
57 O
- O
9 O
. O
12 O
. O

The O
induced O
' O
ischemic O
depression O
' O
was O
lasting O
and O
sensitive O
to O
an O
acute O
administration O
of O
brain O
- O
derived O
neurotrophic O
factor O
or O
bryostatin B
- I
1 I
, O
a O
relatively O
selective O
activator O
of O
protein O
kinase O
C O
epsilon O
, O
during O
the O
induction O
phase O
. O

Chronic O
treatment O
with O
bryostatin B
- I
1 I
( O
5 O
weeks O
) O
after O
the O
induction O
of O
depressive O
behavior O
reversed O
the O
depressive O
immobility O
and O
produced O
a O
lasting O
therapeutic O
effect O
, O
which O
remained O
effective O
3 O
weeks O
after O
discontinuation O
of O
the O
treatment O
. O

Similar O
treatment O
with O
alaproclate O
, O
a O
selective O
serotonin B
reuptake O
inhibitor O
, O
in O
contrast O
, O
produced O
temporary O
relief O
from O
the O
depressive O
symptoms O
, O
with O
the O
therapeutic O
effect O
disappearing O
soon O
after O
the O
end O
of O
the O
treatment O
. O

The O
results O
strongly O
suggest O
that O
cerebral O
ischemia O
has O
a O
direct O
role O
in O
shaping O
the O
sensitivity O
of O
an O
individual O
to O
depressogenic O
events O
and O
that O
bryostatin B
- I
1 I
- O
like O
agents O
may O
be O
developed O
as O
therapeutics O
for O
treating O
ischemic O
depression O
in O
humans O
. O

Structure O
and O
energetics O
of O
gas O
phase O
halogen B
- O
bonding O
in O
mono O
- O
, O
bi O
- O
, O
and O
tri O
- O
dentate O
anion O
receptors O
as O
studied O
by O
BIRD O
. O

Complexes O
of O
mono O
- O
, O
bi O
- O
( O
RB O
) O
, O
and O
tridentate O
( O
RT O
) O
receptors O
with O
a O
range O
of O
anions O
( O
Cl B
( I
- I
) I
, O
Br B
( I
- I
) I
, O
I B
( I
- I
) I
, O
NO3 B
( I
- I
) I
, O
H2PO4 O
( O
- O
) O
, O
HSO4 O
( O
- O
) O
, O
and O
tosylate O
( O
TsO O
( O
- O
) O
) O
) O
have O
been O
studied O
in O
the O
gas O
phase O
by O
both O
experimental O
and O
theoretical O
methods O
. O

Temperature O
dependent O
blackbody O
infrared O
radiative O
dissociation O
( O
BIRD O
) O
experiments O
were O
performed O
on O
complexes O
of O
C8F17I O
with O
Br B
( I
- I
) I
and O
I B
( I
- I
) I
, O
RB O
with O
I B
( I
- I
) I
, O
NO3 B
( I
- I
) I
, O
HSO4 O
( O
- O
) O
, O
H2PO4 O
( O
- O
) O
, O
and O
TsO O
( O
- O
) O
, O
and O
RT O
with O
I B
( I
- I
) I
, O
HSO4 O
( O
- O
) O
and O
TsO O
( O
- O
) O
and O
the O
observed O
Arrhenius O
parameters O
are O
reported O
here O
. O

Results O
were O
examined O
in O
terms O
of O
the O
binding O
order O
of O
various O
anions O
as O
well O
as O
the O
added O
binding O
strength O
from O
additional O
halogen B
bonding O
( O
XB O
) O
interactions O
. O

An O
increase O
in O
the O
energy O
required O
to O
remove O
the O
same O
anion O
from O
the O
tridentate O
receptor O
when O
compared O
to O
the O
bidentate O
and O
monodentate O
receptors O
is O
explained O
as O
being O
due O
to O
the O
increase O
in O
halogen B
bonding O
interactions O
. O

The O
possibility O
of O
mixed O
halogen B
and O
hydrogen B
bonded O
complexes O
were O
considered O
. O

Effects O
of O
Selenium B
Intervention O
on O
Chronic O
Fluorosis O
- O
Induced O
Renal O
Cell O
Apoptosis O
in O
Rats O
. O

This O
study O
aims O
to O
explore O
the O
effect O
of O
selenium B
in O
fluoride B
- O
induced O
renal O
cell O
apoptosis O
in O
rats O
and O
determine O
the O
optimal O
level O
of O
selenium B
in O
drinking O
water O
to O
prevent O
fluorosis O
. O

Experimental O
animals O
were O
divided O
into O
a O
control O
group O
, O
a O
sodium B
fluoride I
- O
treated O
group O
( O
NaF B
, O
50 O
mg O
/ O
L O
) O
, O
three O
sodium B
selenite I
- O
treated O
groups O
( O
Na2SeO3 O
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
) O
, O
and O
three O
selenium B
+ O
NaF B
- O
treated O
groups O
( O
Na2SeO3 O
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
; O
NaF B
, O
50 O
mg O
/ O
L O
) O
. O

Apoptosis O
was O
detected O
by O
terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP B
nick O
- O
end O
labeling O
assay O
and O
the O
expressions O
of O
Bcl O
- O
2 O
and O
Bax O
proteins O
were O
detected O
by O
immunohistochemical O
methods O
. O

The O
results O
showed O
that O
Bcl O
- O
2 O
, O
Bax O
, O
and O
Bax O
/ O
Bcl O
- O
2 O
protein O
expressions O
in O
the O
fluoride B
and O
high O
selenium B
groups O
were O
highly O
elevated O
compared O
with O
the O
control O
group O
( O
P O
< O
0 O
. O
01 O
) O
. O

Bax O
expression O
in O
the O
low O
selenium B
group O
and O
Bcl O
- O
2 O
, O
Bax O
, O
and O
Bax O
/ O
Bcl O
- O
2 O
protein O
expressions O
in O
the O
moderate O
selenium B
groups O
were O
observably O
elevated O
( O
P O
< O
0 O
. O
05 O
) O
. O

Bax O
and O
Bax O
/ O
Bcl O
- O
2 O
expressions O
in O
the O
fluoride B
group O
and O
Bax O
mRNA O
expression O
in O
the O
high O
selenium B
group O
were O
highly O
elevated O
( O
P O
< O
0 O
. O
01 O
) O
. O

Bax O
/ O
Bcl O
- O
2 O
mRNA O
expression O
in O
the O
high O
selenium B
group O
was O
also O
highly O
elevated O
( O
P O
< O
0 O
. O
05 O
) O
. O

Compared O
with O
the O
fluoride B
group O
, O
the O
group O
treated O
with O
low O
selenium B
has O
Bax O
protein O
expression O
that O
was O
observably O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
; O
the O
group O
treated O
with O
moderate O
selenium B
has O
Bcl O
- O
2 O
protein O
expression O
that O
was O
observably O
elevated O
( O
P O
< O
0 O
. O
05 O
) O
, O
Bax O
protein O
expression O
that O
was O
highly O
reduced O
( O
P O
< O
0 O
. O
01 O
) O
, O
and O
Bax O
/ O
Bcl O
- O
2 O
protein O
expression O
that O
was O
observably O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
; O
the O
group O
treated O
with O
high O
selenium B
has O
Bcl O
- O
2 O

protein O
expression O
that O
was O
highly O
elevated O
( O
P O
< O
0 O
. O
01 O
) O
, O
Bax O
protein O
expression O
that O
was O
highly O
elevated O
( O
P O
< O
0 O
. O
01 O
) O
, O
and O
Bax O
/ O
Bcl O
- O
2 O
protein O
expression O
that O
was O
highly O
reduced O
( O
P O
< O
0 O
. O
01 O
) O
; O
the O
groups O
treated O
with O
moderate O
selenium B
and O
high O
selenium B
have O
Bax O
mRNA O
expression O
that O
was O
highly O
reduced O
( O
P O
< O
0 O
. O
01 O
) O
, O
and O
the O
groups O
treated O
with O
high O
selenium B
have O
Bax O
/ O
Bcl O
- O
2 O
mRNA O
expression O
that O
was O
observably O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
. O

Selenium B
may O
inhibit O
the O
apoptosis O
of O
renal O
cells O
in O
fluorosis O
rats O
by O
regulating O
the O
expressions O
of O
Bcl O
- O
2 O
and O
Bax O
. O

The O
optimal O
dose O
of O
Na2SeO3 O
to O
protect O
against O
fluoride B
- O
induced O
renal O
cell O
apoptosis O
was O
determined O
to O
be O
1 O
. O
5 O
mg O
/ O
L O
. O

Melatonin B
and O
its O
analogue O
5 O
- O
MCA O
- O
NAT O
potentiate O
adrenergic O
receptor O
- O
mediated O
ocular O
hypotensive O
effects O
in O
rabbits O
: O
Significance O
for O
combination O
therapy O
in O
glaucoma O
. O

Melatonin B
is O
currently O
considered O
as O
a O
promising O
drug O
for O
glaucoma O
treatment O
due O
to O
its O
ocular O
hypotensive O
and O
neuroprotective O
effects O
. O

We O
have O
investigated O
the O
effect O
of O
melatonin B
and O
its O
analogue O
5 O
- O
methoxycarbonylamino O
- O
N O
- O
acetyltryptamine O
, O
5 O
- O
MCA O
- O
NAT O
, O
on O
beta O
2 O
/ O
alpha O
2A O
- O
adrenergic O
receptor O
mRNA O
as O
well O
as O
protein O
expression O
in O
cultured O
rabbit O
non O
- O
pigmented O
ciliary O
epithelial O
cells O
. O

In O
addition O
, O
we O
have O
studied O
the O
effect O
of O
these O
drugs O
upon O
the O
ocular O
hypotensive O
action O
of O
a O
non O
- O
selective O
beta O
- O
adrenergic O
receptor O
( O
timolol B
) O
and O
a O
selective O
alpha O
2 O
- O
adrenergic O
receptor O
agonist O
( O
brimonidine O
) O
in O
normotensive O
rabbits O
. O

IOP O
experiments O
showed O
that O
the O
administration O
of O
timolol B
in O
rabbits O
pre O
- O
treated O
with O
melatonin B
or O
5 O
- O
MCA O
- O
NAT O
evoked O
an O
additional O
IOP O
reduction O
of O
14 O
. O
02 O
+ O
/ O
- O
5 O
. O
8 O
% O
or O
16 O
. O
75 O
+ O
/ O
- O
5 O
. O
48 O
% O
( O
p O
< O
0 O
. O
01 O
) O
in O
comparison O
with O
rabbits O
treated O
with O
timolol B
alone O
for O
24 O
hours O
. O

Concerning O
brimonidine O
hypotensive O
action O
, O
an O
additional O
IOP O
reduction O
of O
29 O
. O
26 O
+ O
/ O
- O
5 O
. O
21 O
% O
or O
39 O
. O
07 O
+ O
/ O
- O
5 O
. O
81 O
% O
( O
p O
< O
0 O
. O
001 O
) O
was O
observed O
in O
rabbits O
pretreated O
with O
melatonin B
or O
5 O
- O
MCA O
- O
NAT O
when O
compared O
with O
animals O
treated O
with O
brimonidine O
alone O
for O
24 O
hours O
. O

The O
defects O
arising O
from O
SMAD4 O
depletion O
could O
not O
be O
rescued O
by O
intra O
- O
ovarian O
mediators O
of O
LH O
actions O
, O
such O
as O
EGF O
- O
like O
factors O
and O
prostaglandin B
E2 I
. O

Charge O
- O
Transfer O
Interaction O
between O
Few O
- O
Layer O
MoS2 B
and O
Tetrathiafulvalene O
. O

Graphene B
look O
- O
alike O
: O
MoS2 B
has O
a O
layered O
structure O
similar O
to O
graphene B
. O

Tetrathiafulvalene O
( O
TTF O
) O
interacts O
with O
thin O
, O
few O
- O
layer O
MoS2 B
material O
by O
donating O
an O
electron O
, O
resulting O
in O
the O
formation O
of O
TTF O
radical O
cation O
and O
n O
- O
type O
doping O
of O
MoS2 B
. O

Electron O
- O
withdrawing O
tetracyanoethylene O
, O
in O
contrast O
, O
does O
not O
cause O
p O
- O
type O
doping O
in O
MoS2 B
. O

Wogonin O
is O
a O
flavonoid B
compound O
which O
exhibits O
antioxidation O
, O
anti O
- O
inflammation O
, O
neuroprotection O
, O
and O
antitumorgenesis O
functions O
. O

Although O
wogonin O
expressed O
only O
weak O
inhibitory O
effect O
on O
LPS O
- O
/ O
INF O
- O
gamma O
- O
induced O
phosphorylation O
of O
Janus O
kinase O
- O
2 O
( O
Jak O
- O
2 O
) O
and O
tyrosine B
kinase O
( O
Tyk O
) O
- O
2 O
, O
it O
significantly O
attenuated O
the O
phosphorylation O
of O
Jak O
- O
1 O
and O
Jak O
- O
3 O
. O

Structural O
mechanism O
of O
ring O
opening O
reaction O
of O
glucose B
by O
human O
serum O
albumin O
. O

Glucose B
reacts O
with O
proteins O
non O
- O
enzymatically O
under O
physiological O
conditions O
. O

Such O
glycation O
is O
exacerbated O
in O
diabetic O
patients O
with O
high O
level O
of O
blood O
sugar B
, O
and O
induces O
various O
complications O
. O

Human O
albumin O
serum O
( O
HSA O
) O
is O
the O
most O
abundant O
protein O
in O
plasma O
and O
is O
glycated O
by O
glucose B
. O

Here O
, O
we O
report O
two O
protein O
crystal O
structures O
of O
HSA O
in O
complex O
with O
either O
glucose B
or O
fructose B
. O

These O
crystal O
structures O
reveal O
that O
the O
presence O
of O
linear O
forms O
of O
sugar B
for O
both O
monosaccharides B
. O

The O
linear O
form O
of O
glucose B
forms O
a O
covalent O
bond O
to O
Lys195 O
of O
HSA O
, O
but O
not O
the O
case O
for O
fructose B
. O

Based O
on O
these O
structures O
, O
we O
propose O
a O
mechanism O
for O
glucose B
ring O
opening O
involving O
both O
residues O
Lys195 O
and O
Lys199 O
. O

These O
results O
provide O
mechanistic O
insights O
to O
understand O
the O
glucose B
ring O
opening O
reaction O
and O
the O
glycation O
of O
proteins O
by O
monosaccharides B
. O

The O
discovery O
that O
rapamycin B
extends O
the O
life O
span O
of O
diverse O
organisms O
has O
triggered O
many O
studies O
aimed O
at O
identifying O
the O
underlying O
molecular O
mechanisms O
. O

Mammalian O
target O
of O
rapamycin B
complex O
1 O
( O
mTORC1 O
) O
regulates O
cell O
growth O
and O
may O
regulate O
organismal O
aging O
by O
controlling O
mRNA O
translation O
. O

Conversely O
, O
rapamycin B
treatment O
restored O
the O
quality O
of O
newly O
synthesized O
polypeptides O
mainly O
by O
slowing O
the O
rate O
of O
ribosomal O
elongation O
. O

Loss O
of O
S6 O
kinases O
, O
but O
not O
4E O
- O
BP O
family O
proteins O
, O
which O
are O
both O
involved O
in O
regulation O
of O
translation O
, O
attenuated O
the O
effects O
of O
rapamycin B
on O
the O
quality O
of O
newly O
translated O
proteins O
. O

In O
this O
paper O
, O
the O
surface O
structures O
of O
two O
very O
different O
bioglass O
compositions O
, O
namely O
45S5 O
( O
46 O
. O
1 O
SiO2 B
, O
24 O
. O
4 O
Na2O O
, O
26 O
. O
9 O
CaO B
, O
and O
2 O
. O
6 O
P2O5 O
mol O
% O
) O
and O
77S O
( O
80 O
. O
0 O
SiO2 B
, O
16 O
. O
0 O
CaO B
, O
and O
4 O
. O
0 O
P2O5 O
mol O
% O
) O
, O
have O
been O
investigated O
by O
means O
of O
periodic O
DFT O
calculations O
based O
on O
a O
PBE O
functional O
and O
localized O
Gaussian O
basis O
set O
as O
encoded O
in O
the O
CRYSTAL O
code O
. O

Formation O
Mechanism O
of O
TiO B
2 I
Nanotubes O
and O
Their O
Applications O
in O
Photoelectrochemical O
Water O
Splitting O
and O
Supercapacitors O
. O

Structural O
observations O
of O
the O
transition O
of O
TiO B
2 I
nanopores O
into O
nanotubes O
by O
increasing O
the O
OH B
( I
- I
) I
concentration O
in O
the O
electrolyte O
challenge O
the O
validity O
of O
existing O
formation O
mechanisms O
of O
anodic O
TiO B
2 I
nanotubes O
. O

Based O
on O
this O
understanding O
, O
bamboo O
- O
type O
TiO B
2 I
nanotubes O
with O
large O
surface O
area O
and O
excellent O
interconnectivity O
are O
achieved O
by O
cycling O
high O
and O
low O
applied O
potentials O
. O

After O
thermal O
treatment O
in O
a O
H B
2 I
atmosphere O
, O
the O
bamboo O
- O
type O
TiO B
2 I
nanotubes O
show O
large O
photoelectrochemical O
water O
splitting O
efficiency O
and O
supercapacitors O
performace O
. O

These O
organoclays O
are O
produced O
via O
alkylammonium O
cation O
exchange O
with O
colloidally O
dispersed O
montmorillonite B
clay O
sheets O
followed O
by O
solvent O
casting O
. O

Matrix O
Isolation O
Spectroscopy O
and O
Nuclear O
Spin O
Conversion O
of O
NH3 B
and O
ND3 O
in O
Solid O
Parahydrogen O
. O

We O
present O
matrix O
isolation O
infrared O
absorption O
spectra O
of O
NH3 B
and O
ND3 O
trapped O
in O
solid O
parahydrogen O
( O
pH2 O
) O
at O
temperatures O
around O
1 O
. O
8 O
K O
. O

We O
used O
the O
relatively O
slow O
nuclear O
spin O
conversion O
( O
NSC O
) O
of O
NH3 B
and O
ND3 O
in O
freshly O
deposited O
pH2 O
samples O
as O
a O
tool O
to O
assign O
the O
sparse O
vibration O
- O
inversion O
- O
rotation O
( O
VIR O
) O
spectra O
of O
NH3 B
in O
the O
regions O
of O
the O
nu O
2 O
, O
nu O
4 O
, O
2 O
nu O
4 O
, O
nu O
1 O
, O
and O
nu O
3 O
bands O
and O
ND3 O
in O
the O
regions O
of O
the O
nu O
2 O
, O
nu O
4 O
, O
nu O
1 O
, O
and O
nu O
3 O
fundamentals O
. O

Partial O
assignments O
are O
also O
presented O
for O
various O
combination O
bands O
of O
NH3 B
. O

Detailed O
analysis O
of O
the O
nu O
2 O
bands O
of O
NH3 B
and O
ND3 O
indicates O
that O
both O
isotopomers O
are O
nearly O
free O
rotors O
; O
that O
the O
vibrational O
energy O
is O
blue O
- O
shifted O
by O
1 O
- O
2 O
% O
; O
and O
that O
the O
rotational O
constants O
and O
inversion O
tunneling O
splitting O
are O
91 O
- O
94 O
% O
and O
67 O
- O
75 O
% O
, O
respectively O
, O
of O
the O
gas O
- O
phase O
values O
. O

We O
report O
and O
assign O
a O
number O
of O
NH3 B
- O
induced O
infrared O
absorption O
features O
of O
the O
pH2 O
host O
near O
4150 O
cm O
( O
- O
1 O
) O
, O
along O
with O
a O
cooperative O
transition O
that O
involves O
simultaneous O
vibrational O
excitation O
of O
a O
pH2 O
molecule O
and O
rotation O
- O
inversion O
excitation O
of O
NH3 B
. O

The O
NSCs O
of O
NH3 B
and O
ND3 O
were O
found O
to O
follow O
first O
- O
order O
kinetics O
with O
rate O
constants O
at O
1 O
. O
8 O
K O
of O
k O
= O
1 O
. O
88 O
( O
16 O
) O
x O
10 O
( O
- O
3 O
) O
s O
( O
- O
1 O
) O
and O
k O
= O
1 O
. O
08 O
( O
8 O
) O
x O
10 O
( O
- O
3 O
) O
s O
( O
- O
1 O
) O
, O
respectively O
. O

These O
measured O
rate O
constants O
are O
compared O
to O
previous O
measurements O
for O
NH3 B
in O
an O
Ar O
matrix O
and O
with O
the O
rate O
constants O
measured O
for O
other O
dopant O
molecules O
isolated O
in O
solid O
pH2 O
. O

Development O
and O
validation O
of O
NIR O
- O
chemometric O
methods O
for O
chemical O
and O
pharmaceutical O
characterization O
of O
meloxicam B
tablets O
. O

Objective O
: O
The O
aim O
of O
this O
research O
work O
was O
to O
develop O
and O
validate O
NIR O
- O
chemometric O
methods O
not O
only O
for O
the O
determination O
of O
active O
pharmaceutical O
ingredients O
content O
but O
also O
pharmaceutical O
properties O
( O
crushing O
strength O
, O
disintegration O
time O
) O
of O
meloxicam B
tablets O
. O

Materials O
and O
methods O
: O
The O
development O
of O
the O
method O
for O
active O
content O
assay O
was O
performed O
on O
samples O
corresponding O
to O
80 O
% O
, O
90 O
% O
, O
100 O
% O
, O
110 O
% O
and O
120 O
% O
of O
meloxicam B
content O
and O
the O
development O
of O
the O
methods O
for O
pharmaceutical O
characterization O
was O
performed O
on O
samples O
prepared O
at O
seven O
different O
compression O
forces O
( O
ranging O
from O
7 O
to O
45 O
kN O
) O
using O
NIR O
transmission O
spectra O
of O
intact O
tablets O
and O
PLS O
as O
a O
regression O
method O
. O

Results O
: O
The O
results O
show O
that O
the O
developed O
methods O
have O
good O
trueness O
, O
precision O
and O
accuracy O
and O
are O
appropriate O
for O
direct O
active O
content O
assay O
in O
tablets O
( O
ranging O
from O
12 O
to O
18 O
mg O
/ O
tablet O
) O
and O
also O
for O
predicting O
crushing O
strength O
and O
disintegration O
time O
of O
intact O
meloxicam B
tablets O
. O

Discussion O
: O
The O
comparative O
data O
show O
that O
the O
proposed O
methods O
are O
in O
good O
agreement O
with O
the O
reference O
methods O
currently O
used O
for O
the O
characterization O
of O
meloxicam B
tablets O
( O
HPLC O
- O
UV O
methods O
for O
the O
assay O
and O
European O
Pharmacopeia O
methods O
for O
determining O
the O
crushing O
strength O
and O
disintegration O
time O
) O
. O

Conclusion O
: O
The O
results O
show O
the O
possibility O
to O
predict O
both O
chemical O
properties O
( O
active O
content O
) O
and O
physical O
/ O
pharmaceutical O
properties O
( O
crushing O
strength O
and O
disintegration O
time O
) O
directly O
, O
without O
any O
sample O
preparation O
, O
from O
the O
same O
NIR O
transmission O
spectrum O
of O
meloxicam B
tablets O
. O

Abstract O
Phyllanthin O
is O
a O
major O
bioactive O
lignan B
component O
of O
Phyllanthus O
amarus O
, O
with O
several O
known O
biological O
activities O
. O

UV O
, O
IR O
, O
MS O
, O
( B
1 I
) I
H I
NMR O
and O
( B
13 I
) I
C I
NMR O
spectra O
were O
employed O
to O
identify O
phyllanthin O
. O

Three O
kinds O
of O
phyllanthin O
crystals O
, O
recrystallized O
by O
petroleum B
ether I
, O
absolute O
ethanol B
and O
25 O
% O
ethanol B
solution O
, O
showed O
only O
one O
polymorph O
and O
no O
polymorphic O
impurity O
. O

Genistein O
- O
Modified O
Poly B
( I
ethylene I
oxide I
) I
/ O
Poly B
( I
d I
, I
l I
- I
lactic I
acid I
) I
Electrospun O
Mats O
with O
Improved O
Antioxidant O
and O
Anti O
- O
inflammatory O
Properties O
. O

Genistein B
is O
a O
phytochemical O
with O
a O
broad O
range O
of O
desirable O
biological O
activity O
for O
wound O
healing O
. O

However O
, O
its O
poor O
bioavailability O
requires O
developing O
a O
new O
method O
for O
fabricating O
an O
appropriate O
carrier O
vehicle O
to O
deliver O
genistein B
in O
a O
sustained O
manner O
. O

Based O
on O
the O
guidance O
afforded O
by O
the O
ternary O
phase O
diagram O
of O
poly B
( I
d I
, I
l I
- I
lactic I
acid I
) I
( O
PDLLA O
) O
, O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
) O
, O
and O
genistein B
blends O
, O
certain O
selective O
compositions O
were O
electrospun O
. O

We O
obtained O
a O
uniformly O
smooth O
surface O
morphology O
in O
unmodified O
and O
genistein B
- O
modified O
PEO B
/ O
PDLLA O
fibers O
, O
documented O
by O
scanning O
electron O
microscopy O
. O

Moreover O
, O
wide O
- O
angle O
X O
- O
ray O
diffraction O
and O
( B
1 I
) I
H I
NMR O
studies O
revealed O
that O
the O
genistein B
molecules O
, O
successfully O
incorporated O
in O
the O
blends O
, O
remained O
chemically O
stable O
after O
electrospinning O
. O

Besides O
surface O
wettability O
and O
dimensional O
stability O
of O
the O
electrospun O
mats O
, O
the O
released O
genistein B
amount O
has O
been O
evaluated O
as O
a O
function O
of O
PEO B
concentration O
. O

Our O
biocompatibility O
investigations O
suggest O
that O
genistein B
- O
modified O
PEO B
/ O
PDLLA O
electrospun O
mats O
exhibit O
strong O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
which O
indicate O
they O
have O
potential O
applications O
for O
wound O
dressings O
. O

Selective O
Permeation O
of O
Hydrogen B
Gas O
Using O
Cellulose O
Nanofibril O
Film O
. O

Biobased O
membranes O
that O
can O
selectively O
permeate O
hydrogen B
gas O
have O
been O
developed O
from O
aqueous O
dispersions O
of O
2 B
, I
2 I
, I
6 I
, I
6 I
- I
tetramethylpiperidin I
- I
1 I
- I
oxyl I
( O
TEMPO B
) O
- O
oxidized O
cellulose O
nanofibrils O
( O
TOCN O
) O
prepared O
from O
wood O
cellulose O
: O
TOCN O
- O
coated O
plastic O
films O
and O
self O
- O
standing O
TOCN O
films O
. O

Compared O
with O
TOCNs O
with O
sodium B
, O
lithium B
, O
potassium B
, O
and O
cesium O
carboxylate B
groups O
, O
TOCN O
with O
free O
carboxyl B
groups O
( O
TOCN O
- O
COOH B
) O
had O
much O
high O
and O
selective O
H2 B
gas O
permeation O
performance O
. O

Because O
permeabilities O
of O
H2 B
, O
N2 B
, O
O2 B
, O
and O
CO2 B
gases O
through O
the O
membranes O
primarily O
depended O
on O
their O
kinetic O
diameters O
, O
the O
gas O
permeation O
behavior O
of O
the O
various O
TOCNs O
can O
be O
explained O
in O
terms O
of O
a O
diffusion O
mechanism O
. O

Thus O
, O
the O
selective O
H2 B
gas O
permeability O
for O
TOCN O
- O
COOH B
was O
probably O
due O
to O
a O
larger O
average O
size O
in O
free O
volume O
holes O
present O
between O
nanofibrils O
in O
the O
layer O
and O
film O
than O
those O
of O
other O
TOCNs O
with O
metal O
carboxylate O
groups O
. O

The O
obtained O
results O
indicate O
that O
TOCN O
- O
COOH B
membranes O
are O
applicable O
as O
biobased O
H2 B
gas O
separation O
membranes O
in O
fuel O
cell O
electric O
power O
generation O
systems O
. O

It O
showed O
a O
significant O
antimalarial O
activity O
, O
with O
a O
50 O
% O
inhibitory O
concentration O
( O
IC50 O
) O
of O
0 O
. O
53 O
+ O
/ O
- O
0 O
. O
2 O
mu O
M O
against O
a O
chloroquine B
- O
resistant O
strain O
of O
Plasmodium O
falciparum O
. O

Unraveling O
the O
Reaction O
Mechanisms O
Governing O
Methanol B
- O
to O
- O
Olefins B
Catalysis O
by O
Theory O
and O
Experiment O
. O

The O
conversion O
of O
methanol B
to O
olefins B
( O
MTO O
) O
over O
a O
heterogeneous O
nanoporous O
catalyst O
material O
is O
a O
highly O
complex O
process O
involving O
a O
cascade O
of O
elementary O
reactions O
. O

Special O
emphasis O
is O
given O
to O
theoretical O
developments O
that O
open O
new O
perspectives O
and O
possibilities O
that O
aid O
to O
unravel O
a O
process O
as O
complex O
as O
methanol B
conversion O
over O
an O
acidic O
porous O
material O
. O

Metabolism O
and O
pathways O
for O
denitration O
of O
organic O
nitrates B
in O
the O
human O
liver O
. O

Liver O
first O
- O
pass O
metabolism O
differs O
considerably O
among O
organic O
nitrates B
but O
little O
information O
exists O
on O
the O
mechanism O
of O
denitration O
of O
these O
compounds O
in O
hepatic O
tissue O
. O

The O
metabolism O
of O
nitrooxybutyl O
- O
esters O
of O
flurbiprofen O
and O
ferulic B
- I
acid I
, O
a O
class O
of O
organic O
nitrates B
with O
potential O
therapeutic O
implication O
in O
variety O
of O
different O
conditions O
, O
was O
investigated O
in O
comparison O
with O
glyceryl O
trinitrate O
( O
GTN O
) O
in O
human O
liver O
by O
a O
multiple O
approach O
, O
using O
a O
spontaneous O
metabolism O
- O
independent O
NO B
donor O
( O
NOC O
- O
5 O
) O
as O
a O
reference O
tool O
. O

Nitrooxybutyl O
- O
esters O
were O
rapidly O
and O
quantitatively O
metabolized O
to O
their O
respective O
parent O
compounds O
and O
the O
organic O
nitrate B
moiety O
nitrooxybutyl O
- O
alcohol O
( O
NOBA O
) O
. O

Differently O
from O
GTN O
which O
was O
rapidly O
and O
completely O
metabolized O
to O
nitrite B
, O
NOBA O
was O
slowly O
metabolized O
to O
nitrate B
. O

In O
contrast O
to O
the O
spontaneous O
NO B
donor O
NOC O
- O
5 O
, O
NOBA O
and O
GTN O
did O
not O
generate O
detectable O
NO B
and O
failed O
to O
suppress O
the O
activity O
of O
cytochromeP450 O
; O
an O
enzyme O
known O
to O
be O
inhibited O
by O
NO B
. O

The O
direct O
identification O
of O
NOBA O
following O
liver O
metabolism O
targets O
this O
compound O
as O
the O
functional O
organic O
nitrate B
metabolite O
of O
nitrooxybutyl O
- O
esters O
. O

Moreover O
the O
investigation O
of O
the O
pathways O
for O
denitration O
of O
NOBA O
and O
GTN O
suggests O
that O
organic O
nitrates B
are O
not O
primarily O
metabolized O
to O
NO B
in O
the O
liver O
but O
to O
different O
extents O
of O
nitrite B
or O
nitrate B
depending O
from O
their O
different O
chemical O
structure O
. O

It O
follows O
that O
cytochromeP450 O
- O
dependent O
metabolism O
of O
concomitant O
drugs O
is O
not O
likely O
to O
be O
affected O
by O
oral O
co O
- O
administration O
of O
organic O
nitrates B
. O

However O
the O
first O
- O
pass O
may O
differently O
affect O
the O
pharmacological O
profile O
of O
organic O
nitrates B
in O
connection O
with O
the O
different O
extent O
of O
denitration O
and O
the O
distinct O
bioactive O
species O
generated O
and O
exported O
from O
the O
liver O
( O
nitrate B
or O
nitrite B
) O
. O

From O
a O
Multipotent O
Stilbene B
to O
Soluble O
Epoxide B
Hydrolase O
Inhibitors O
with O
Antiproliferative O
Properties O
. O

Inspired O
by O
nature O
: O
Natural O
product O
isopropylstilbene O
was O
identified O
as O
an O
inhibitor O
of O
soluble O
epoxide B
hydrolase O
exhibiting O
antiproliferative O
properties O
. O

Organophosphates B
( O
OPs O
) O
are O
among O
the O
most O
used O
pesticides O
. O

At O
PN10 O
, O
the O
effects O
were O
restricted O
to O
females O
and O
to O
the O
cholinergic O
system O
: O
Methamidophos O
promoted O
increased O
choline B
transporter O
binding O
in O
the O
brainstem O
. O

At O
PN63 O
, O
in O
the O
brainstem O
, O
there O
was O
a O
decrease O
in O
choline B
transporter O
, O
a O
female O
- O
only O
decrease O
in O
5HT1A O
and O
a O
male O
- O
only O
increase O
in O
5HT2 O
receptor O
binding O
. O

In O
the O
cortex O
, O
choline B
acetyltransferase O
activity O
was O
decreased O
and O
5HT2 O
receptor O
binding O
was O
increased O
both O
in O
males O
and O
females O
. O

Enhanced O
Triboelectric O
Nanogenerators O
and O
Triboelectric O
Nanosensor O
Using O
Chemically O
Modified O
TiO2 B
Nanomaterials O
. O

In O
this O
study O
, O
we O
developed O
a O
rationally O
designed O
triboelectric O
nanogenerator O
( O
TENG O
) O
by O
utilizing O
the O
contact O
electrification O
between O
a O
polytetrafluoroethyl B
( O
PTFE B
) O
thin O
film O
and O
a O
layer O
of O
TiO2 B
nanomaterial O
( O
nanowire O
and O
nanosheet O
) O
array O
. O

The O
as O
- O
developed O
TENG O
was O
systematically O
studied O
and O
demonstrated O
as O
a O
self O
- O
powered O
nanosensor O
toward O
catechin B
detection O
. O

The O
high O
sensitivity O
( O
detection O
limit O
of O
5 O
mu O
M O
) O
and O
selectivity O
are O
achieved O
through O
a O
strong O
interaction O
between O
Ti B
atoms O
of O
TiO2 B
nanomaterial O
and O
enediol O
group O
of O
catechin B
. O

The O
output O
voltage O
and O
current O
density O
were O
increased O
by O
a O
factor O
of O
5 O
. O
0 O
and O
2 O
. O
9 O
, O
respectively O
, O
when O
adsorbed O
with O
catechin B
of O
a O
saturated O
concentration O
, O
because O
of O
the O
charge O
transfer O
from O
catechin B
to O
TiO2 B
. O

Magnetic O
- O
Nanoparticle O
- O
Decorated O
Polypyrrole B
Microvessels O
: O
Toward O
Encapsulation O
of O
mRNA O
Cap O
Analogues O
. O

Many O
phosphorylated O
nucleoside B
derivatives O
have O
therapeutic O
potential O
, O
but O
their O
application O
is O
limited O
by O
problems O
with O
membrane O
permeability O
and O
with O
intracellular O
delivery O
. O

Here O
, O
we O
prepared O
polypyrrole B
microvessel O
structures O
modified O
with O
superparamagnetic O
nanoparticles O
for O
use O
as O
potential O
carriers O
of O
nucleotides B
. O

To O
demonstrate O
the O
encapsulation O
of O
drug O
molecules O
, O
two O
labeled O
mRNA O
cap O
analogues O
, O
nucleotide B
- O
derived O
potential O
anticancer O
agents O
, O
were O
used O
. O

This O
finding O
provides O
a O
foundation O
for O
the O
future O
development O
of O
anticancer O
therapies O
and O
for O
the O
delivery O
of O
nucleotide B
- O
based O
therapeutics O
. O

Enantioselective O
thiourea B
- O
catalyzed O
intramolecular O
cope O
- O
type O
hydroamination O
. O

Comparative O
study O
on O
effects O
of O
two O
different O
types O
of O
titanium B
dioxide I
nanoparticles O
on O
human O
neuronal O
cells O
. O

Titanium B
dioxide I
( O
TiO2 B
) O
are O
among O
most O
frequently O
used O
nanoparticles O
( O
NPs O
) O
. O

Therefore O
, O
the O
main O
objective O
of O
this O
work O
was O
to O
investigate O
the O
effects O
of O
two O
types O
of O
TiO2 B
NPs O
, O
with O
different O
crystalline O
structure O
, O
on O
human O
SHSY5Y O
neuronal O
cells O
. O

After O
NPs O
characterization O
, O
a O
battery O
of O
assays O
was O
performed O
to O
evaluate O
the O
viability O
, O
cytotoxicity O
, O
genotoxicity O
and O
oxidative O
damage O
in O
TiO2 B
NP O
- O
exposed O
SHSY5Y O
cells O
. O

Anandamide B
deficiency O
and O
heightened O
neuropathic O
pain O
in O
aged O
mice O
. O

R O
- O
flurbiprofen O
was O
used O
because O
it O
is O
able O
to O
reduce O
neuropathic O
pain O
in O
young O
mice O
in O
part O
by O
increasing O
anandamide B
. O

This O
was O
associated O
with O
low O
anandamide B
levels O
in O
the O
dorsal O
root O
ganglia O
, O
spinal O
cord O
, O
thalamus O
and O
cortex O
, O
which O
further O
decreased O
after O
nerve O
injury O
. O

In O
aged O
mice O
, O
R O
- O
flurbiprofen O
had O
only O
weak O
antinociceptive O
efficacy O
and O
it O
failed O
to O
restore O
normal O
anandamide B
levels O
after O
nerve O
injury O
. O

In O
terms O
of O
the O
mechanisms O
, O
we O
found O
that O
fatty B
acid I
amide B
hydrolase O
( O
FAAH O
) O
which O
degrades O
anandamide B
, O
was O
upregulated O
after O
nerve O
injury O
at O
both O
ages O
, O
so O
that O
this O
upregulation O
likely O
did O
not O
account O
for O
the O
age O
- O
dependent O
differences O
. O

However O
, O
enzymes O
contributing O
to O
oxidative O
metabolism O
of O
anandamide B
, O
namely O
cyclooxygenase O
- O
1 O
and O
Cyp2D6 O
, O
were O
increased O
in O
the O
brain O
of O
aged O
mice O
, O
possibly O
enhancing O
the O
oxidative O
breakdown O
of O
anandamide B
. O

This O
may O
overwhelm O
the O
capacity O
of O
R O
- O
flurbiprofen O
to O
restore O
anandamide B
homeostasis O
and O
may O
contribute O
to O
the O
heightened O
risk O
for O
neuropathic O
pain O
at O
old O
age O
. O

The O
novel O
recreational O
drug O
3 B
, I
4 I
- I
methylenedioxypyrova I
( O
MDPV B
) O
is O
a O
potent O
psychomotor O
stimulant O
: O
Self O
- O
administration O
and O
locomotor O
activity O
in O
rats O
. O

Recreational O
use O
of O
the O
cathinone O
derivative O
3 B
, I
4 I
- I
methylenedioxypyrova I
( O
MDPV B
; O
" O
bath O
salts O
" O
) O
has O
increased O
worldwide O
in O
past O
years O
, O
accompanied O
by O
accounts O
of O
health O
and O
legal O
problems O
in O
the O
popular O
media O
and O
efforts O
to O
criminalize O
possession O
in O
numerous O
jurisdictions O
. O

Minimal O
information O
exists O
on O
the O
effects O
of O
MDPV B
in O
laboratory O
models O
. O

This O
study O
determined O
the O
effects O
of O
MDPV B
, O
alongside O
those O
of O
the O
better O
studied O
stimulant O
d O
- O
methamphetamine O
( O
METH B
) O
, O
using O
rodent O
models O
of O
intravenous O
self O
- O
administration O
( O
IVSA O
) O
, O
thermoregulation O
and O
locomotor O
activity O
. O

Male O
Wistar O
rats O
were O
trained O
to O
self O
- O
administer O
MDPV B
or O
METH B
( O
0 O
. O
05 O
mg O
/ O
kg O
/ O
infusion O
, O
i O
. O
v O
. O
) O
or O
were O
prepared O
with O
radiotelemetry O
implants O
for O
the O
assessment O
of O
body O
temperature O
and O
activity O
responses O
to O
MDPV B
or O
METH B
( O
0 O
- O
5 O
. O
6 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O

METH B
and O
MDPV B
were O
consistently O
self O
- O
administered O
within O
10 O
training O
sessions O
( O
mg O
/ O
kg O
/ O
h O
; O
METH B
Mean O
= O
0 O
. O
4 O
and O
Max O
= O
1 O
. O
15 O
; O
MDPV B
Mean O
= O
0 O
. O
9 O
and O
Max O
= O
5 O
. O
8 O
) O
. O

Dose O
- O
substitution O
studies O
demonstrated O
that O
behavior O
was O
sensitive O
to O
dose O
for O
both O
drugs O
, O
but O
MDPV B
( O
0 O
. O
01 O
- O
0 O
. O
50 O
mg O
/ O
kg O
/ O
inf O
) O
showed O
greater O
potency O
and O
efficacy O
than O
METH B
( O
0 O
. O
1 O
- O
0 O
. O
25 O
mg O
/ O
kg O
/ O
inf O
) O
. O

In O
addition O
, O
both O
MDPV B
and O
METH B
increased O
locomotor O
activity O
at O
lower O
doses O
( O
0 O
. O
5 O
- O
1 O
. O
0 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
and O
transiently O
decreased O
activity O
at O
the O
highest O
dose O
( O
5 O
. O
6 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
. O

Body O
temperature O
increased O
monotonically O
with O
increasing O
doses O
of O
METH B
but O
MDPV B
had O
a O
negligible O
effect O
on O
temperature O
. O

Stereotypy O
was O
associated O
with O
relatively O
high O
self O
- O
administered O
cumulative O
doses O
of O
MDPV B
( O
~ O
1 O
. O
5 O
mg O
/ O
kg O
/ O
h O
) O
as O
well O
as O
with O
non O
- O
contingent O
MDPV B
administration O
wherein O
the O
intensity O
and O
duration O
of O
stereotypy O
increased O
as O
MDPV B
dose O
increased O
. O

Thus O
, O
MDPV B
poses O
a O
substantial O
threat O
for O
compulsive O
use O
that O
is O
potentially O
greater O
than O
that O
for O
METH B
. O

These O
newly O
designed O
PDE2 O
inhibitors O
bind O
to O
the O
PDE2 O
enzyme O
in O
a O
cGMP B
- O
like O
binding O
mode O
orthogonal O
to O
the O
cAMP B
- O
like O
binding O
mode O
found O
in O
PDE4 O
. O

The O
mechanisms O
by O
which O
early O
chronic O
lead O
( O
Pb B
) O
exposure O
alter O
brain O
development O
have O
not O
been O
identified O
. O

We O
examined O
neuroimmune O
system O
effects O
in O
C57BL O
/ O
6J O
mice O
with O
Pb B
exposure O
, O
including O
levels O
that O
may O
be O
common O
among O
children O
in O
lower O
socioeconomic O
income O
environments O
. O

Pups O
were O
exposed O
via O
dams O
' O
drinking O
water O
from O
birth O
to O
post O
- O
natal O
day O
28 O
to O
low O
, O
high O
or O
no O
Pb B
conditions O
. O

Blood O
Pb B
levels O
in O
exposed O
animals O
at O
sacrifice O
( O
post O
- O
natal O
day O
28 O
) O
ranged O
from O
2 O
. O
66 O
to O
20 O
. O
31 O
mu O
g O
/ O
dL O
. O

Instead O
, O
early O
chronic O
exposure O
to O
Pb B
disrupted O
microglia O
via O
damage O
to O
, O
loss O
of O
, O
or O
lack O
of O
proliferation O
of O
microglia O
in O
the O
developing O
brains O
of O
Pb B
- O
exposed O
animals O
. O

Rescue O
of O
platinum B
- O
damaged O
oocytes O
from O
programmed O
cell O
death O
through O
inactivation O
of O
the O
p53 O
family O
signaling O
network O
. O

Recently O
, O
the O
c O
- O
Abl O
kinase O
inhibitor O
imatinib O
mesylate O
( O
imatinib B
) O
has O
become O
the O
focus O
of O
research O
as O
a O
fertoprotective O
drug O
against O
cisplatin B
. O

However O
, O
the O
mechanism O
by O
which O
imatinib B
protects O
oocytes O
is O
not O
fully O
understood O
, O
and O
reports O
of O
the O
drug O
' O
s O
efficacy O
have O
been O
contradictory O
. O

Using O
in O
vitro O
culture O
and O
subrenal O
grafting O
of O
mouse O
ovaries O
, O
we O
demonstrated O
that O
imatinib B
inhibits O
the O
cisplatin B
- O
induced O
apoptosis O
of O
oocytes O
within O
primordial O
follicles O
. O

We O
found O
that O
, O
before O
apoptosis O
, O
cisplatin B
induces O
c O
- O
Abl O
and O
TAp73 O
expression O
in O
the O
oocyte O
. O

While O
imatinib B
was O
unable O
to O
block O
cisplatin B
- O
induced O
DNA O
damage O
and O
damage O
response O
, O
such O
as O
the O
upregulation O
of O
p53 O
, O
imatinib B
inhibited O
the O
cisplatin B
- O
induced O
nuclear O
accumulation O
of O
c O
- O
Abl O
/ O
TAp73 O
and O
the O
subsequent O
downregulation O
of O
TAp63 O
and O
upregulation O
of O
Bax O
, O
thereby O
abrogating O
oocyte O
cell O
death O
. O

Surprisingly O
, O
the O
conditional O
deletion O
of O
Trp63 O
, O
but O
not O
Delta O
Np63 O
, O
in O
oocytes O
inhibited O
apoptosis O
, O
as O
well O
as O
the O
accumulation O
of O
c O
- O
Abl O
and O
TAp73 O
caused O
by O
cisplatin B
. O

These O
data O
suggest O
that O
TAp63 O
is O
the O
master O
regulator O
of O
cisplatin B
- O
induced O
oocyte O
death O
. O

The O
expression O
kinetics O
of O
TAp63 O
, O
c O
- O
Abl O
and O
TAp73 O
suggest O
that O
cisplatin B
activates O
TAp63 O
- O
dependent O
expression O
of O
c O
- O
Abl O
and O
TAp73 O
and O
, O
in O
turn O
, O
the O
activation O
of O
TAp73 O
by O
c O
- O
Abl O
- O
induced O
BAX O
expression O
. O

Our O
findings O
indicate O
that O
imatinib B
protects O
oocytes O
from O
cisplatin B
- O
induced O
cell O
death O
by O
inhibiting O
c O
- O
Abl O
kinase O
, O
which O
would O
otherwise O
activate O
TAp73 O
- O
BAX O
- O
mediated O
apoptosis O
. O

Thus O
, O
imatinib B
and O
other O
c O
- O
Abl O
kinase O
inhibitors O
provide O
an O
intriguing O
new O
way O
to O
halt O
cisplatin B
- O
induced O
oocyte O
death O
in O
early O
follicles O
and O
perhaps O
conserve O
the O
endocrine O
function O
of O
the O
ovary O
against O
chemotherapy O
. O
Cell O
Death O
and O
Differentiation O
advance O
online O
publication O
, O
19 O
April O
2013 O
; O
doi O
: O
10 O
. O
1038 O
/ O
cdd O
. O
2013 O
. O
31 O
. O

Use O
of O
' O
split O
waves O
' O
for O
the O
measurement O
of O
electrocatalytic O
kinetics O
: O
methyl B
viologen I
mediated O
oxygen B
reduction O
on O
a O
boron B
- O
doped O
diamond B
electrode O
. O

The O
mediated O
reduction O
of O
oxygen B
via O
the O
reduced O
form O
of O
methyl B
viologen I
is O
studied O
voltammetrically O
. O

The O
investigation O
is O
facilitated O
through O
the O
use O
of O
a O
boron B
- O
doped O
diamond B
electrode O
, O
allowing O
the O
catalytic O
response O
to O
be O
clearly O
delineated O
from O
that O
of O
the O
direct O
oxygen B
reduction O
process O
at O
the O
electrode O
surface O
. O

From O
simulation O
a O
high O
homogeneous O
electron O
transfer O
rate O
( O
6 O
x O
10 O
( O
9 O
) O
M O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
) O
is O
found O
for O
the O
one O
- O
electron O
reduction O
of O
oxygen B
to O
superoxide B
. O

Reaction O
kinetics O
of O
CO2 B
absorption O
in O
to O
phosphonium O
based O
anion O
- O
functionalized O
ionic O
liquids O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl O
( O
tetradecyl O
) O
phosphonium O
( O
[ O
P66614 O
] O
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate O
( O
[ B
Pro I
] I
) O
, O
2 O
- O
cyanopyrrolide O
( O
[ O
2 O
- O
CNpyr O
] O
) O
, O
and O
3 O
- O
( O
trifluoromethyl O
) O
pyrazolide O
( O
[ O
3 O
- O
CF3pyra O
] O
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

The O
absorption O
of O
CO2 B
is O
carried O
out O
in O
a O
stirred O
reactor O
under O
pseudo O
first O
order O
conditions O
. O

Physical O
solubility O
of O
CO2 B
in O
the O
mixtures O
is O
calculated O
using O
correlations O
developed O
from O
CO2 B
solubility O
measurements O
in O
tetraglyme O
and O
the O
N2O O
- O
analogy O
for O
ILs O
and O
dilute O
IL O
solutions O
. O

The O
diffusivity O
of O
CO2 B
is O
estimated O
from O
viscosity O
- O
dependent O
correlations O
chosen O
after O
a O
thorough O
literature O
review O
. O

High O
reaction O
rates O
and O
tunable O
capacity O
make O
ILs O
, O
and O
AHA O
ILs O
in O
particular O
, O
attractive O
solvents O
for O
CO2 B
separations O
. O

P300 O
during O
response O
inhibition O
is O
associated O
with O
ad O
- O
lib O
alcohol B
consumption O
in O
social O
drinkers O
. O

Reduced O
amplitude O
of O
the O
cortical O
P300 O
event O
- O
related O
potential O
( O
ERP O
) O
component O
during O
response O
inhibition O
is O
associated O
with O
vulnerability O
to O
alcohol B
use O
disorders O
. O

In O
the O
current O
study O
, O
we O
investigated O
the O
effect O
of O
an O
experimental O
manipulation O
of O
response O
conflict O
on O
the O
amplitude O
of O
the O
P300 O
component O
during O
response O
inhibition O
, O
and O
examined O
whether O
individual O
differences O
in O
the O
amplitude O
of O
this O
P300 O
component O
would O
predict O
voluntary O
ad O
- O
lib O
alcohol B
consumption O
, O
in O
social O
drinkers O
. O

Most O
importantly O
, O
individual O
differences O
in O
the O
amplitude O
of O
P300 O
subcomponents O
during O
response O
inhibition O
were O
negatively O
correlated O
with O
ad O
- O
lib O
alcohol B
consumption O
. O

Results O
provide O
the O
first O
experimental O
support O
for O
theoretical O
models O
that O
posit O
that O
reduced O
amplitude O
of O
the O
P300 O
during O
response O
inhibition O
is O
associated O
with O
alcohol B
- O
seeking O
behaviour O
in O
humans O
. O

Npas4 O
is O
activated O
by O
melatonin B
, O
and O
drives O
the O
clock O
gene O
Cry1 O
in O
the O
ovine O
pars O
tuberalis O
. O

Seasonal O
mammals O
integrate O
changes O
in O
the O
duration O
of O
nocturnal O
melatonin B
secretion O
to O
drive O
annual O
physiological O
cycles O
. O

Melatonin B
receptors O
within O
the O
proximal O
pituitary O
region O
, O
the O
pars O
tuberalis O
( O
PT O
) O
, O
are O
essential O
in O
regulating O
seasonal O
neuroendocrine O
responses O
. O

In O
the O
ovine O
PT O
, O
melatonin B
is O
known O
to O
influence O
acute O
changes O
in O
transcriptional O
dynamics O
coupled O
to O
the O
onset O
( O
dusk O
) O
and O
offset O
( O
dawn O
) O
of O
melatonin B
secretion O
, O
leading O
to O
a O
potential O
interval O
- O
timing O
mechanism O
capable O
of O
decoding O
changes O
in O
day O
- O
length O
( O
photoperiod O
) O
. O

Melatonin B
offset O
at O
dawn O
is O
linked O
to O
cAMP B
accumulation O
, O
which O
directly O
induces O
transcription O
of O
the O
clock O
gene O
Per1 O
. O

The O
rise O
of O
melatonin B
at O
dusk O
induces O
a O
separate O
and O
distinct O
cohort O
, O
including O
the O
clock O
- O
regulated O
genes O
Cry1 O
and O
Nampt O
, O
but O
little O
is O
known O
of O
the O
up O
- O
stream O
mechanisms O
involved O
. O

Here O
, O
we O
used O
next O
generation O
sequencing O
of O
the O
ovine O
PT O
transcriptome O
at O
melatonin B
onset O
, O
and O
identified O
Npas4 O
as O
a O
rapidly O
induced O
bHLH O
- O
PAS O
domain O
transcription O
factor O
. O

In O
vivo O
we O
show O
nuclear O
localisation O
of O
NPAS4 O
protein O
in O
presumptive O
melatonin B
target O
cells O
of O
the O
PT O
( O
alpha O
GSU O
- O
expressing O
cells O
) O
, O
while O
in O
situ O
hybridisation O
studies O
identified O
acute O
and O
transient O
expression O
in O
the O
PT O
of O
Npas4 O
in O
response O
to O
melatonin B
. O

Our O
data O
thus O
reveal O
NPAS4 O
as O
a O
candidate O
immediate O
early O
- O
response O
gene O
in O
the O
ovine O
PT O
, O
driving O
molecular O
responses O
to O
melatonin B
. O

Phytochemical O
investigation O
of O
ethanol B
extract O
from O
the O
flowers O
of O
Trollius O
chinensis O
Bunge O
resulted O
in O
the O
isolation O
of O
two O
new O
flavone O
C O
- O
glycosides O
( O
1 O
- O
2 O
) O
, O
along O
with O
10 O
known O
compounds O
( O
3 O
- O
12 O
) O
. O

Bioassay O
showed O
that O
eight O
flavonoids B
inhibited O
complement O
activation O
on O
the O
classic O
pathway O
in O
vitro O
, O
with O
their O
IC50 O
values O
ranging O
from O
0 O
. O
88 O
to O
4 O
. O
02 O
mM O
, O
which O
may O
contribute O
to O
the O
applications O
of O
the O
herb O
in O
treatment O
of O
acute O
respiratory O
distress O
syndrome O
, O
etc O
. O

The O
recombinant O
C B
- O
terminal O
fragment O
of O
AFP O
( O
AFP O
- O
3BC O
, O
which O
consists O
of O
amino B
acid I
residues O
473 O
- O
596 O
) O
was O
obtained O
by O
the O
expression O
in O
Escherichia O
coli O
. O

A O
conjugate O
of O
synthesised O
AFP O
- O
3BC O
with O
the O
antitumour O
antibiotic O
doxorubicin B
( O
DOX B
- O
AFP O
- O
3BC O
) O
demonstrated O
high O
antitumour O
activity O
in O
vitro O
. O

To O
discover O
highly O
potent O
and O
selective O
inhibitors O
of O
P450s O
1A1 O
, O
1A2 O
, O
and O
1B1 O
, O
as O
well O
as O
to O
investigate O
active O
site O
cavities O
of O
these O
enzymes O
, O
14 O
novel O
flavone B
derivatives O
were O
prepared O
as O
chemical O
probes O
. O

alpha O
- O
Naphthoflavone O
- O
like O
and O
5 O
- O
hydroxyflavone O
derivatives O
preferentially O
inhibited O
P450 O
1A2 O
, O
while O
beta B
- I
naphthoflavone I
- O
like O
flavone B
derivatives O
showed O
selective O
inhibition O
of O
P450 O
1A1 O
. O

Trans B
fatty I
acids I
in O
a O
range O
of O
UK O
processed O
foods O
. O

Sixty O
two O
composite O
samples O
, O
made O
up O
of O
between O
5 O
and O
12 O
sub O
- O
samples O
, O
were O
collected O
in O
2010 O
and O
were O
analysed O
for O
fatty B
acids I
, O
and O
a O
range O
of O
nutrients O
. O

Levels O
of O
trans B
fatty I
acids I
were O
reduced O
considerably O
compared O
with O
previous O
UK O
analyses O
of O
similar O
foods O
where O
comparisons O
are O
possible O
. O

The O
top O
five O
ethnic O
foods O
containing O
highest O
levels O
of O
selected O
nutrients O
were O
lamb O
balti O
( O
3mg O
/ O
100g O
iron B
) O
, O
lamb O
kebab O
( O
3 O
. O
2mg O
/ O
100g O
zinc B
) O
, O
mixed O
dhal O
( O
62 O
mu O
g O
/ O
100g O
folate B
) O
, O
fish O
curry O
( O
1 O
. O
4 O
mu O
g O
/ O
100g O
vitamin B
D I
) O
, O
ghee O
( O
968 O
mu O
g O
/ O
100g O
retinol B
) O
and O
toor O
dhal O
( O
9 O
. O
1g O
/ O
100g O
dietary O
fibre O
) O
. O

The O
100g O
cooked O
shoulder O
, O
loin O
and O
leg O
cuts O
provide O
on O
average O
40 O
. O
11 O
% O
protein O
, O
5 O
. O
19 O
% O
magnesium B
, O
3 O
. O
37 O
% O
calcium B
, O
24 O
. O
29 O
% O
phosphorus B
, O
18 O
. O
22 O
% O
zinc B
, O
22 O
. O
33 O
% O
iron B
and O
22 O
. O
50 O
% O
vitamin O
B1 O
, O
2 O
. O
57 O
% O
vitamin O
B2 O
and O
42 O
. O
6 O
% O
vitamin O
B3 O
of O
Recommended O
Daily O
Allowances O
for O
males O
, O
age O
25 O
- O
50 O
. O

To O
conclude O
, O
the O
pork O
cuts O
are O
undoubtedly O
a O
good O
source O
of O
nutrients O
that O
is O
required O
for O
good O
health O
because O
it O
is O
high O
in O
protein O
, O
have O
a O
low O
fat O
content O
and O
are O
a O
nutrient O
- O
packed O
choice O
for O
the O
family O
and O
compares O
favourably O
with O
the O
fat O
, O
energy O
, O
and O
cholesterol B
content O
of O
many O
other O
meats O
and O
poultry O
. O

Pork O
meat O
is O
generally O
recognised O
as O
a O
food O
with O
relevant O
nutritional O
properties O
because O
of O
its O
content O
in O
high O
biological O
value O
proteins O
, O
group O
B O
vitamins O
, O
minerals O
especially O
heme B
iron B
, O
trace O
elements O
and O
other O
bioactive O
compounds O
. O

But O
pork O
meat O
also O
contributes O
to O
the O
intake O
of O
fat O
, O
saturated B
fatty I
acids I
, O
cholesterol B
, O
and O
other O
substances O
that O
, O
in O
inappropriate O
amounts O
, O
may O
result O
in O
negative O
physiologically O
effects O
. O

So O
, O
genetics O
, O
age O
and O
even O
type O
of O
muscle O
have O
a O
relevant O
influence O
on O
the O
amount O
of O
fat O
and O
the O
contents O
in O
heme B
iron B
. O

Also O
the O
composition O
in O
fatty B
acids I
of O
triacylglycerols B
is O
very O
sensitive O
to O
the O
contents O
of O
cereals O
in O
the O
feed O
; O
for O
instance O
, O
polyunsaturated B
fatty I
acids I
may O
range O
from O
10 O
% O
to O
22 O
% O
in O
pork O
meat O
. O

Some O
bioactive O
substances O
like O
coenzyme O
Q10 O
, O
taurine B
, O
glutamine B
, O
creatine B
, O
creatinine B
, O
carnosine B
and O
anserine O
show O
a O
large O
dependence O
on O
the O
type O
of O
muscle O
. O

Codex O
dietary O
fibre O
definition O
- O
Justification O
for O
inclusion O
of O
carbohydrates B
from O
3 O
to O
9 O
degrees O
of O
polymerisation O
. O

The O
main O
controversy O
about O
the O
DF O
definition O
, O
adopted O
by O
the O
commission O
of O
Codex O
Alimentarius O
, O
refers O
to O
the O
inclusion O
of O
carbohydrates B
of O
3 O
- O
9 O
degrees O
of O
polymerisation O
( O
DP O
) O
, O
decision O
which O
may O
be O
made O
individually O
by O
the O
authorities O
of O
each O
country O
. O

Due O
to O
the O
possibility O
of O
having O
two O
definitions O
and O
the O
negative O
impact O
it O
would O
cause O
over O
the O
harmonisation O
of O
nutritional O
information O
, O
a O
bibliographic O
review O
was O
carried O
, O
from O
2009 O
to O
2011 O
, O
aiming O
to O
gather O
justifications O
for O
the O
inclusion O
of O
carbohydrates B
of O
3 O
- O
9 O
DP O
in O
the O
definition O
. O

The O
decision O
of O
including O
unavailable O
carbohydrates B
of O
3 O
- O
9 O
DP O
in O
the O
definition O
of O
DF O
may O
cause O
effective O
global O
harmonisation O
in O
the O
nutritional O
labelling O
, O
considering O
that O
the O
main O
goal O
is O
to O
help O
consumers O
choose O
healthy O
foods O
. O

Biogenic O
amines B
content O
as O
a O
measure O
of O
the O
quality O
of O
wines O
of O
Abruzzo O
( O
Italy O
) O
. O

Aim O
of O
this O
research O
was O
to O
study O
the O
effect O
of O
some O
agronomic O
and O
oenological O
factors O
on O
the O
content O
of O
biogenic O
amines B
as O
quality O
index O
of O
sixty O
- O
five O
Abruzzo O
wines O
. O

Sum O
of O
amines B
was O
found O
to O
be O
decreasing O
in O
the O
order O
: O
red O
( O
19 O
. O
3 O
+ O
/ O
- O
12 O
. O
8mgL O
( O
- O
1 O
) O
) O
, O
ros O
e O
( O
9 O
. O
20 O
+ O
/ O
- O
6 O
. O
34mgL O
( O
- O
1 O
) O
) O
, O
white O
( O
7 O
. O
67 O
+ O
/ O
- O
3 O
. O
84mgL O
( O
- O
1 O
) O
) O
wine O
. O

Significant O
differences O
in O
relationship O
among O
amines B
levels O
and O
chemical O
and O
chemico O
- O
physical O
characteristics O
of O
red O
, O
white O
and O
ros O
e O
wine O
are O
due O
to O
their O
different O
biotechnological O
process O
and O
winemaking O
. O

The O
single O
amines B
significantly O
correlated O
with O
their O
sum O
were O
putrescine B
, O
histamine B
and O
tyramine B
, O
even O
if O
reached O
levels O
were O
below O
toxicity O
threshold O
, O
demonstrating O
a O
good O
quality O
of O
the O
wines O
of O
Abruzzo O
whose O
consumption O
is O
no O
risk O
to O
the O
health O
of O
the O
consumer O
following O
the O
rules O
of O
proper O
nutrition O
. O

Laboratories O
achieving O
satisfactory O
analytical O
results O
( O
z O
- O
score O
> O
= O
2 O
) O
were O
for O
lipid O
, O
82 O
% O
; O
protein O
, O
85 O
% O
; O
Na B
, O
82 O
% O
; O
Ca B
, O
62 O
% O
; O
Fe B
, O
81 O
% O
; O
ash O
, O
70 O
% O
; O
and O
moisture O
, O
62 O
% O
. O

Furthermore O
, O
we O
report O
that O
this O
flavonoid B
inhibits O
a O
single O
step O
in O
the O
sumoylation O
cascade O
: O
the O
transfer O
of O
SUMO O
from O
the O
E2 O
enzyme O
( O
Ubc9 O
) O
thioester O
conjugate O
to O
the O
substrate O
. O

Cell O
- O
based O
studies O
showed O
that O
the O
flavonoid O
inhibits O
the O
sumoylation O
of O
topoisomerase O
- O
I O
in O
response O
to O
camptothecin B
treatment O
in O
two O
different O
breast O
cancer O
cell O
lines O
, O
while O
isomeric O
analogs O
are O
inactive O
. O

In O
the O
present O
work O
we O
show O
that O
reduction O
sensitive O
and O
SDS B
- O
stable O
heteromers O
can O
be O
reconstituted O
in O
vitro O
by O
mixing O
proMMP O
- O
9 O
with O
either O
serglycin O
, O
versican O
or O
CSPGs O
isolated O
from O
various O
monocytic O
cell O
lines O
. O

In O
addition O
, O
a O
strong O
but O
SDS B
- O
soluble O
proMMP O
- O
9 O
. O
CSPG O
heteromer O
was O
formed O
. O

The O
two O
macromolecules O
in O
the O
SDS B
- O
stable O
reduction O
sensitive O
heteromers O
were O
not O
linked O
together O
by O
disulphide B
bonds O
. O

As O
for O
the O
heteromer O
isolated O
from O
THP O
- O
1 O
cells O
, O
the O
in O
vitro O
reconstituted O
SDS B
- O
stable O
and O
SDS B
- O
soluble O
heteromers O
had O
a O
weaker O
binding O
to O
gelatin O
than O
the O
proMMP O
- O
9 O
monomer O
. O

However O
, O
the O
presence O
of O
TIMP O
- O
1 O
inhibited O
the O
formation O
of O
the O
SDS B
- O
soluble O
heteromer O
, O
but O
not O
the O
SDS B
- O
stable O
reduction O
sensitive O
heteromer O
. O

CTRC O
stimulates O
trypsinogen O
autoactivation O
by O
processing O
the O
activation O
peptide O
to O
a O
shorter O
form O
but O
also O
promotes O
degradation O
by O
cleaving O
the O
calcium B
binding O
loop O
in O
trypsinogen O
. O

The O
tetra O
- O
aspartate B
motif O
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium B
( O
KD O
~ O
1 O
. O
6 O
mM O
) O
, O
which O
stimulates O
autoactivation O
. O

Unexpectedly O
, O
calcium B
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations O
. O

Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G O
and O
K23 O
_ O
I24insIDK O
was O
not O
stimulated O
by O
calcium B
. O

Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol B
esterase O
. O

A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol B
esterase O
( O
CEase O
) O
and O
acetylcholinesterase O
( O
AChE O
) O
. O

The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids B
. O

The O
structure O
- O
activity O
relationships O
revealed O
that O
the O
free O
hydroxyl B
group O
at O
position O
5 O
and O
phosphate B
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O

In O
a O
wide O
range O
of O
animals O
, O
uncontrollable O
stressful O
events O
can O
induce O
a O
condition O
called O
" O
learned O
helplessness O
. O
" O
In O
mammals O
it O
is O
associated O
with O
low O
general O
activity O
, O
poor O
learning O
, O
disorders O
of O
sleep O
and O
feeding O
, O
ulcers O
, O
and O
reduced O
immune O
status O
, O
as O
well O
as O
with O
increased O
serotonin B
in O
parts O
of O
the O
brain O
. O

Like O
Artemis O
, O
Metnase O
efficiently O
trimmed O
overhangs O
terminated O
in O
3 O
' O
- O
phosphoglycolates O
( O
PGs B
) O
, O
and O
in O
some O
cases O
the O
presence O
of O
3 O
' O
- O
PG O
stimulated O
cleavage O
and O
altered O
its O
specificity O
. O

Synergistic O
enhancement O
of O
cancer O
therapy O
using O
a O
combination O
of O
heat O
shock O
protein O
targeted O
HPMA B
copolymer O
- O
drug O
conjugates O
and O
gold O
nanorod O
induced O
hyperthermia O
. O

In O
this O
study O
, O
tumor O
hyperthermia O
was O
utilized O
as O
a O
means O
to O
increase O
the O
active O
delivery O
of O
heat O
shock O
protein O
( O
HSP O
) O
targeted O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
- O
drug O
conjugates O
. O

Following O
hyperthermia O
, O
induced O
expression O
of O
cell O
surface O
heat O
shock O
protein O
( O
HSP O
) O
glucose B
regulated O
protein O
78kDa O
( O
GRP78 O
) O
was O
utilized O
for O
targeted O
drug O
therapy O
. O

Conjugates O
bearing O
the O
anticancer O
agents O
aminohexylgeldanamyc O
( O
AHGDM O
) O
, O
docetaxel B
( O
DOC O
) O
, O
or O
cisplatin B
and O
the O
GRP78 O
targeting O
peptide O
WDLAWMFRLPVG O
were O
synthesized O
and O
characterized O
. O

In O
DU145 O
tumor O
bearing O
mice O
, O
a O
single O
treatment O
of O
tumor O
hyperthermia O
, O
induced O
via O
gold O
nanorod O
mediated O
plasmonic O
photothermal O
therapy O
, O
and O
intravenous O
administration O
of O
HSP O
targeted O
HPMA B
copolymer O
- O
docetaxel B
at O
10mg O
/ O
kg O
resulted O
in O
maintained O
tumor O
regression O
for O
a O
period O
of O
30days O
. O

Activation O
of O
CB1 O
increases O
expression O
of O
neuronal O
trophic O
factors O
and O
inhibits O
neurotransmitter O
release O
from O
GABA B
- O
ergic O
striatal O
neurons O
. O

Importantly O
, O
cannabinoid O
treatment O
improved O
ATP B
production O
, O
increased O
the O
expression O
of O
the O
trophic O
factor O
BDNF O
- O
2 O
, O
and O
the O
mitochondrial O
regulator O
PGC1 O
alpha O
, O
and O
reduced O
spontaneous O
GABA B
release O
, O
in O
HD O
cells O
. O

Chronic O
social O
stress O
during O
adolescence O
: O
Interplay O
of O
paroxetine B
treatment O
and O
ageing O
. O

The O
same O
holds O
true O
for O
the O
treatment O
with O
selective O
serotonin B
reuptake O
inhibitors O
( O
SSRIs O
) O
, O
which O
have O
been O
shown O
to O
prevent O
or O
reverse O
some O
stress O
- O
induced O
effects O
. O

Here O
, O
we O
studied O
the O
direct O
and O
long O
- O
lasting O
impact O
of O
chronic O
social O
stress O
during O
adolescence O
and O
the O
impact O
of O
chronic O
treatment O
with O
the O
SSRI O
paroxetine B
in O
adulthood O
and O
aged O
animals O
. O

Treatment O
with O
paroxetine B
was O
performed O
per O
os O
with O
a O
dosage O
of O
20 O
mg O
/ O
g O
BW O
. O

Several O
chromatographic O
systems O
( O
three O
systems O
of O
high O
- O
performance O
liquid O
chromatography O
and O
two O
micellar O
electrokinetic O
chromatography O
systems O
) O
besides O
the O
reference O
octanol B
- O
water O
partition O
system O
are O
evaluated O
by O
a O
systematic O
procedure O
previously O
proposed O
in O
order O
to O
know O
their O
ability O
to O
model O
human O
skin O
permeation O
. O

Superparamagnetic O
iron B
oxide I
nanoparticles O
( O
SPIONs O
) O
show O
a O
great O
promise O
for O
a O
wide O
specter O
of O
bioapplications O
, O
due O
to O
their O
characteristic O
magnetic O
properties O
exhibited O
only O
in O
the O
presence O
of O
magnetic O
field O
. O

Their O
advantages O
in O
the O
fields O
of O
magnetic O
drug O
targeting O
and O
imaging O
are O
well O
established O
and O
their O
safety O
is O
assumed O
, O
since O
iron B
oxide I
nanoparticles O
have O
already O
been O
approved O
for O
in O
vivo O
application O
, O
however O
, O
according O
to O
many O
literature O
reports O
the O
bare O
metal O
oxide O
nanoparticles O
may O
cause O
toxic O
effects O
on O
treated O
cells O
. O

In O
the O
current O
research O
ricinoleic O
acid O
coated O
maghemite B
nanoparticles O
were O
successfully O
synthesized O
, O
characterized O
and O
incorporated O
in O
the O
polymeric O
matrix O
, O
resulting O
in O
nanosized O
magnetic O
polymeric O
particles O
. O

The O
tumoural O
radioactivity O
uptake O
was O
most O
often O
high O
and O
specific O
even O
at O
early O
time O
points O
( O
12 O
. O
1 O
- O
18 O
. O
3 O
% O
ID O
/ O
g O
at O
3 O
h O
p O
. O
i O
. O
for O
[ O
( B
125 I
) I
I I
] O
39 O
- O
42 O
) O
and O
a O
fast O
clearance O
from O
the O
non O
- O
target O
organs O
was O
observed O
. O

Also O
, O
calculated O
effective O
doses O
that O
could O
be O
delivered O
to O
tumours O
when O
using O
corresponding O
[ O
( B
131 I
) I
I I
] O
- O
labelled O
analogues O
were O
generally O
higher O
than O
100 O
cGy O
/ O
MBq O
injected O
( O
98 O
. O
9 O
- O
150 O
. O
5 O
cGy O
/ O
MBq O
for O
[ O
( B
131 I
) I
I I
] O
39 O
- O
42 O
) O
. O

This O
review O
article O
is O
an O
effort O
to O
summarize O
medicinal O
chemistry O
investigations O
over O
the O
last O
decade O
, O
in O
search O
for O
new O
N B
- O
bridged O
heterocycles O
which O
can O
be O
a O
rich O
source O
of O
promising O
biological O
activities O
. O

The O
Fusarium O
toxin O
deoxynivalenol B
( O
DON B
) O
modulates O
the O
LPS O
induced O
acute O
phase O
reaction O
in O
pigs O
. O

The O
systemic O
effects O
of O
the O
Fusarium O
toxin O
deoxynivalenol B
( O
DON B
) O
and O
of O
bacterial O
lipopolysaccharides O
( O
LPS O
) O
were O
studied O
in O
male O
castrated O
pigs O
( O
40 O
. O
4 O
+ O
/ O
- O
3 O
. O
7kg O
) O
infused O
intravenously O
with O
either O
DON B
or O
LPS O
alone O
( O
100 O
mu O
gDON O
/ O
kg O
/ O
h O
, O
7 O
. O
5 O
mu O
g O
/ O
LPS O
/ O
kg O
/ O
h O
) O
, O
or O
together O
( O
100 O
mu O
gDON O
plus O
7 O
. O
5 O
mu O
g O
/ O
LPS O
/ O
kg O
/ O
h O
) O
. O

An O
additional O
DON B
infusion O
did O
not O
exacerbate O
the O
clinical O
signs O
observed O
in O
LPS O
- O
infused O
pigs O
. O

For O
example O
, O
rectal O
temperature O
climaxed O
after O
4h O
( O
40 O
. O
4 O
+ O
/ O
- O
0 O
. O
2 O
degrees O
C O
) O
and O
5h O
( O
40 O
. O
1 O
+ O
/ O
- O
0 O
. O
3 O
degrees O
C O
) O
, O
in O
the O
LPS O
and O
LPS O
+ O
DON B
groups O
, O
respectively O
. O

Saline O
and O
DON B
alone O
did O
not O
induce O
an O
acute O
phase O
reaction O
as O
indicated O
by O
unaltered O
plasma O
levels O
of O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
while O
LPS O
caused O
a O
significant O
rise O
of O
both O
cytokines O
. O

TNF O
- O
alpha O
plasma O
peak O
concentrations O
were O
significantly O
higher O
in O
the O
LPS O
compared O
to O
the O
DON B
+ O
LPS O
group O
( O
94 O
. O
3 O
+ O
/ O
- O
17 O
. O
2ng O
/ O
mL O
vs O
. O
79 O
. O
2 O
+ O
/ O
- O
15 O
. O
7ng O
/ O
mL O
) O
while O
IL O
- O
6 O
climaxed O
earlier O
in O
the O
latter O
group O
( O
3h O
p O
. O
i O
. O
vs O
. O
2h O
p O
. O
i O
. O
) O
. O

From O
the O
tested O
clinical O
- O
chemical O
plasma O
characteristics O
the O
total O
bilirubin B
concentration O
and O
the O
ASAT O
activity O
were O
strongly O
elevated O
by O
the O
LPS O
infusion O
and O
additionally O
increased O
and O
decreased O
by O
DON B
, O
respectively O
. O

In O
conclusion O
, O
the O
LPS O
- O
induced O
effects O
were O
only O
marginally O
modified O
by O
DON B
. O

Thermal O
inactivation O
reaction O
rates O
for O
ricin O
are O
influenced O
by O
pH O
and O
carbohydrates B
. O

We O
found O
that O
galactose B
and O
high O
molecular O
weight O
exopolysaccharides O
present O
in O
various O
dairy O
products O
contributed O
to O
the O
thermal O
stability O
of O
ricin O
. O

Short O
- O
term O
toxicity O
of O
hexavalent B
- I
chromium I
to O
epipsammic O
diatoms O
of O
a O
microtidal O
estuary O
( O
R O
i O
o O
de O
la O
Plata O
) O
: O
Responses O
from O
the O
individual O
cell O
to O
the O
community O
structure O
. O

The O
aim O
of O
this O
work O
was O
to O
study O
the O
environment O
- O
reflecting O
short O
- O
term O
responses O
at O
different O
levels O
of O
organization O
of O
epipsammic O
diatoms O
from O
the O
R O
i O
o O
de O
la O
Plata O
estuary O
, O
Argentina O
that O
had O
been O
exposed O
to O
hexavalent B
chromium I
within O
experimental O
microcosms O
. O

The O
epipsammic O
biofilms O
were O
exposed O
for O
96h O
to O
chromium B
at O
a O
concentration O
similar O
to O
that O
measured O
in O
highly O
impacted O
sites O
along O
the O
coast O
( O
80 O
mu O
gL O
( O
- O
1 O
) O
) O
. O

Chromium B
pollution O
, O
at O
this O
concentration O
and O
short O
exposure O
time O
did O
not O
affect O
the O
algal O
biomass O
and O
density O
of O
these O
mature O
biofilms O
. O

The O
most O
notable O
shifts O
related O
to O
chromium B
exposure O
were O
a O
decrease O
in O
the O
relative O
abundance O
of O
H O
. O
hungarica O
and O
a O
significant O
increase O
in O
the O
proportion O
of O
N O
. O
palea O
. O

MATERIALS O
AND O
METHODS O
: O
The O
effects O
of O
HEGG O
were O
assessed O
in O
melanin O
content O
assays O
in O
B16F10 O
melanoma O
cells O
compared O
with O
the O
reference O
drug O
kojic B
acid I
( O
500mM O
) O
. O

Anion O
exchange O
chromatography O
, O
DEAE B
Sepharose O
Fast O
Flow O
, O
and O
gel O
filtration O
chromatography O
, O
Superdex200 O
had O
been O
employed O
to O
isolate O
hemolytic O
proteins O
from O
the O
nematocyst O
venom O
of O
jellyfish O
S O
. O
meleagris O
. O

Native O
- O
PAGE O
profile O
displayed O
one O
protein O
band O
in O
the O
purified O
hemolytic O
protein O
( O
SmTX O
) O
; O
however O
, O
two O
protein O
bands O
with O
apparent O
molecular O
weights O
of O
~ O
45kDa O
and O
52kDa O
were O
observed O
in O
the O
reducing O
SDS B
- O
PAGE O
analysis O
. O

Murine O
N2A O
and O
human O
SK O
- O
N O
- O
AS O
neuroblastoma O
cells O
and O
murine O
preadipocyte O
fibroblasts O
( O
3T3 O
- O
L1 O
) O
were O
exposed O
to O
tributyltin B
( O
TBT O
) O
, O
diethylstilbestrol B
( O
DES B
) O
, O
bisphenol B
A I
( O
BPA B
) O
, O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
[ I
p I
] I
- I
dioxin I
( O
TCDD B
) O
, O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
, O
5 O
' O
- O

hexachlorobiphenyl O
( O
PCB O
- O
153 O
) O
, O
hexachlorobenzene O
( O
HCB O
) O
, O
hexabromocyclododeca B
( O
HBCD O
) O
, O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
- O
tetrabrominated O
diphenyl O
ether O
( O
BDE B
- I
47 I
) O
, O
perfluorinated O
octyl O
acid O
( O
PFOA B
) O
and O
perfluorinated O
octyl O
sulfonate O
( O
PFOS B
) O
. O

A O
modest O
decrease O
in O
global O
DNA O
methylation O
was O
observed O
in O
N2A O
cells O
exposed O
to O
10 O
mu O
M O
DES B
, O
BPA B
, O
TCDD B
, O
BDE B
- I
47 I
, O
PCB O
- O
153 O
and O
1 O
mu O
M O
HCB O
, O
but O
no O
changes O
were O
found O
in O
the O
human O
SK O
- O
N O
- O
AS O
cells O
. O

We O
reveal O
for O
the O
first O
time O
that O
BDE B
- I
47 I
increases O
adipocyte O
differentiation O
in O
a O
dose O
- O
dependent O
manner O
( O
2 O
. O
5 O
- O
25 O
mu O
M O
) O
. O

Adipocyte O
differentiation O
was O
also O
enhanced O
by O
TBT O
( O
< O
= O
10nM O
) O
and O
BPA B
( O
> O
10 O
mu O
M O
) O
and O
inhibited O
by O
TCDD B
( O
< O
= O
0 O
. O
1nM O
) O
. O

The O
other O
chemicals O
showed O
either O
modest O
or O
no O
effects O
on O
adipocyte O
differentiation O
at O
the O
concentrations O
tested O
( O
PFOA B
, O
PFOS B
and O
HBCD O
at O
10 O
mu O
M O
; O
PCB O
- O
153 O
, O
3 O
. O
4 O
mu O
M O
and O
HCB O
, O
1 O
mu O
M O
) O
. O

AMS O
- O
induced O
cardiovascular O
response O
was O
then O
evaluated O
in O
adult O
MS O
mice O
treated O
with O
Boophone O
disticha O
as O
compared O
to O
vehicle O
and O
diazepam B
. O

Boophone O
disticha O
treatment O
significantly O
reduced O
AMS O
- O
induced O
BP O
response O
in O
BALB O
/ O
c O
MS O
as O
compared O
to O
vehicle O
and O
diazepam B
treatments O
. O

Multiple O
treatments O
with O
liposomal O
doxorubicin B
and O
ultrasound O
- O
induced O
disruption O
of O
blood O
- O
tumor O
and O
blood O
- O
brain O
barriers O
improve O
outcomes O
in O
a O
rat O
glioma O
model O
. O

Here O
, O
we O
tested O
the O
impact O
of O
three O
weekly O
sessions O
of O
FUS O
and O
liposomal O
doxorubicin B
( O
DOX B
) O
in O
9L O
rat O
glioma O
tumors O
. O

Animals O
that O
received O
FUS O
+ O
DOX B
( O
N O
= O
8 O
) O
had O
a O
median O
survival O
time O
that O
was O
increased O
significantly O
( O
P O
< O
0 O
. O
001 O
) O
compared O
to O
animals O
who O
received O
DOX B
only O
( O
N O
= O
6 O
) O
, O
FUS O
only O
( O
N O
= O
8 O
) O
, O
or O
no O
treatment O
( O
N O
= O
7 O
) O
. O

Median O
survival O
for O
animals O
that O
received O
FUS O
+ O
DOX B
was O
increased O
by O
100 O
% O
relative O
to O
untreated O
controls O
, O
whereas O
animals O
who O
received O
DOX B
alone O
had O
only O
a O
16 O
% O
improvement O
. O

No O
tumor O
cells O
were O
found O
in O
histology O
in O
4 O
/ O
8 O
animals O
in O
the O
FUS O
+ O
DOX B
group O
, O
and O
in O
two O
animals O
, O
only O
a O
few O
tumor O
cells O
were O
detected O
. O

These O
events O
are O
largely O
consistent O
with O
known O
side O
effects O
of O
doxorubicin B
and O
with O
an O
extensive O
tumor O
burden O
. O

Overall O
this O
work O
demonstrates O
that O
multiple O
sessions O
using O
this O
FUS O
technique O
to O
enhance O
the O
delivery O
of O
liposomal O
doxorubicin B
have O
a O
pronounced O
therapeutic O
effect O
in O
this O
rat O
glioma O
model O
. O

Prediabetes O
Prevalence O
Defined O
by O
Hemoglobin O
A1c O
and O
Fasting O
Plasma O
Glucose B
: O
National O
Health O
and O
Nutrition O
Examination O
Surveys O
, O
1999 O
- O
2010 O
. O

We O
defined O
prediabetes O
as O
hemoglobin O
A1c O
5 O
. O
7 O
to O
< O
6 O
. O
5 O
% O
( O
39 O
to O
< O
48 O
mmol O
/ O
mol O
, O
A1C5 O
. O
7 O
) O
or O
fasting O
plasma O
glucose B
( O
FPG O
) O
100 O
to O
< O
126 O
mg O
/ O
dL O
( O
impaired O
fasting O
glucose B
[ O
IFG O
] O
) O
. O

The O
electrical O
( O
sigma O
) O
and O
thermal O
( O
k O
) O
conductivities O
of O
the O
Au B
film O
are O
found O
to O
be O
reduced O
dramatically O
from O
their O
bulk O
counterparts O
by O
93 O
. O
7 O
% O
( O
sigma O
) O
and O
80 O
. O
5 O
% O
( O
k O
) O
. O

The O
relationship O
between O
cocaine B
self O
- O
administration O
and O
actigraphy O
- O
based O
measures O
of O
sleep O
in O
adult O
rhesus O
monkeys O
. O

RATIONALE O
: O
Clinical O
trials O
show O
that O
chronic O
cocaine B
users O
suffer O
from O
sleep O
disturbances O
and O
preclinical O
research O
has O
shown O
that O
acute O
sleep O
deprivation O
increases O
the O
rate O
of O
cocaine B
self O
- O
administration O
in O
rats O
. O

OBJECTIVE O
: O
This O
study O
examined O
the O
effect O
of O
cocaine B
self O
- O
administration O
on O
behavioral O
indices O
of O
sleep O
and O
alternatively O
the O
effect O
of O
sleep O
disruption O
on O
cocaine B
- O
maintained O
responding O
by O
rhesus O
monkeys O
. O

METHODS O
: O
Seven O
adult O
rhesus O
monkeys O
, O
fitted O
with O
Actical O
( O
R O
) O
activity O
monitors O
, O
were O
trained O
to O
respond O
under O
a O
concurrent O
choice O
paradigm O
with O
food O
( O
three O
1 O
. O
0 O
- O
g O
pellets O
) O
and O
cocaine B
( O
0 O
. O
003 O
- O
0 O
. O
3 O
mg O
/ O
kg O
) O
or O
saline O
presentation O
. O

For O
each O
monkey O
, O
the O
lowest O
preferred O
dose O
of O
cocaine B
( O
> O
80 O
% O
cocaine B
choice O
) O
was O
determined O
. O

Subsequently O
, O
the O
monkeys O
' O
sleep O
was O
disrupted O
( O
every O
hour O
during O
lights O
- O
out O
period O
) O
the O
night O
prior O
to O
food O
- O
cocaine B
choice O
sessions O
. O

RESULTS O
: O
Self O
- O
administration O
of O
the O
preferred O
dose O
of O
cocaine B
resulted O
in O
a O
significant O
decrease O
in O
sleep O
efficiency O
, O
with O
a O
significant O
increase O
in O
total O
lights O
- O
out O
activity O
. O

Sleep O
disruption O
significantly O
altered O
behavioral O
indices O
of O
sleep O
, O
similar O
to O
those O
seen O
following O
cocaine B
self O
- O
administration O
. O

However O
, O
sleep O
disruption O
did O
not O
affect O
cocaine B
self O
- O
administration O
under O
concurrent O
choice O
conditions O
. O

CONCLUSIONS O
: O
Based O
on O
these O
findings O
, O
cocaine B
self O
- O
administration O
does O
appear O
to O
disrupt O
behavioral O
indices O
of O
sleep O
, O
although O
it O
remains O
to O
be O
determined O
if O
treatments O
that O
improve O
sleep O
measures O
can O
affect O
future O
cocaine B
taking O
. O

In O
the O
present O
study O
, O
the O
anti O
- O
inflammatory O
effect O
of O
salicylideneamino O
- O
2 O
- O
thiophenol O
( O
SAL O
- O
2 O
) O
, O
a O
derivative O
of O
salicylate B
, O
on O
a O
potent O
oxidant O
4 B
- I
hydroxynonenal I
( O
HNE O
) O
- O
induced O
oxidative O
stress O
was O
investigated O
using O
rat O
prostate O
endothelial O
( O
YPEN O
- O
1 O
) O
cells O
. O

We O
found O
that O
SAL O
- O
2 O
effectively O
inhibited O
HNE O
- O
induced O
reactive O
species O
generation O
, O
while O
upregulated O
GSH B
/ O
GSSG B
ratio O
. O

Prostagrandin O
( O
PG O
) O
E2 O
production O
stimulated O
by O
arachidonic B
acid I
was O
suppressed O
by O
SAL O
- O
2 O
. O

SAL O
- O
2 O
also O
downregulated O
COX O
- O
2 O
and O
iNOS O
expression O
induced O
by O
HNE O
, O
but O
salicylate B
did O
not O
. O

Collectively O
, O
SAL O
- O
2 O
inhibited O
COX O
- O
2 O
and O
iNOS O
gene O
expression O
through O
suppression O
of O
NF O
- O
kappa O
B O
leading O
to O
the O
inhibition O
of O
PGE2 B
synthesis O
. O

As O
part O
of O
our O
ongoing O
search O
for O
natural O
sources O
of O
therapeutic O
and O
preventive O
agents O
for O
diabetic O
complications O
, O
we O
evaluated O
the O
inhibitory O
effects O
of O
components O
of O
the O
fruit O
of O
Xanthium O
strumarium O
( O
X O
. O
strumarium O
) O
on O
aldose B
reductase O
( O
AR O
) O
and O
galactitol O
formation O
in O
rat O
lenses O
with O
high O
levels O
of O
glucose B
. O

To O
identify O
the O
bioactive O
components O
of O
X O
. O
strumarium O
, O
7 O
caffeoylquinic O
acids O
and O
3 O
phenolic B
compounds O
were O
isolated O
and O
their O
chemical O
structures O
were O
elucidated O
on O
the O
basis O
of O
spectroscopic O
evidence O
and O
comparison O
with O
published O
data O
. O

Furthermore O
, O
methyl O
- O
3 O
, O
5 O
- O
di O
- O
O O
- O
caffeoylquinate O
inhibited O
galactitol O
formation O
in O
the O
rat O
lens O
and O
in O
erythrocytes O
incubated O
with O
a O
high O
concentration O
of O
glucose B
, O
indicating O
that O
this O
compound O
may O
be O
effective O
in O
preventing O
diabetic O
complications O
. O

FBP O
suppressed O
the O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
but O
did O
not O
affect O
cyclooxygenase O
- O
2 O
expression O
and O
prostaglandin B
E2 I
production O
in O
endothelial O
cells O
stimulated O
with O
LPS O
. O

The O
regulation O
of O
epidermal O
melanogenesis O
via O
cAMP B
and O
/ O
or O
PKC O
signaling O
pathways O
: O
insights O
for O
the O
development O
of O
hypopigmenting O
agents O
. O

cAMP B
and O
PKC O
are O
critical O
factors O
of O
important O
transduction O
pathways O
and O
cross O
- O
talk O
between O
them O
could O
amplify O
the O
melanogenic O
effect O
. O

Here O
, O
factors O
involved O
in O
melanogenesis O
regulation O
via O
cAMP B
and O
/ O
or O
PKC O
pathways O
are O
reviewed O
with O
their O
action O
mechanisms O
. O

In O
this O
study O
, O
30 O
Wistar O
rats O
were O
randomly O
divided O
into O
three O
groups O
: O
a O
control O
group O
, O
a O
sodium B
fluoride I
( O
NaF B
) O
+ O
EGb O
group O
, O
and O
a O
NaF B
group O
. O

The O
rats O
were O
administered O
0 O
. O
5 O
ml O
water O
containing O
NaF B
( O
100 O
mg O
/ O
l O
) O
and O
EGb O
( O
120 O
mg O
/ O
kg O
) O
per O
day O
via O
gavage O
. O

Superoxide B
dismutase O
( O
SOD O
) O
activity O
and O
the O
levels O
of O
glutathione B
peroxidase O
( O
GSH B
- O
Px O
) O
and O
malondialdehyde B
( O
MDA B
) O
were O
measured O
. O

The O
results O
showed O
that O
EGb O
could O
improve O
learning O
and O
memory O
abilities O
, O
enhance O
the O
activities O
of O
SOD O
and O
GSH B
- O
Px O
, O
attenuate O
the O
level O
of O
MDA O
, O
upregulate O
the O
ratio O
of O
Bcl O
- O
2 O
/ O
Bax O
, O
and O
downregulate O
the O
level O
of O
cleaved O
Caspase3 O
. O

Effects O
of O
High O
Iron B
and O
Glucose B
Concentrations O
over O
the O
Relative O
Expression O
of O
Bcl2 O
, O
Bax O
, O
and O
Mfn2 O
in O
MIN6 O
Cells O
. O

The O
purpose O
of O
this O
study O
was O
to O
describe O
the O
effect O
of O
different O
iron B
and O
/ O
or O
glucose B
concentrations O
over O
Mfn2 O
, O
Bax O
, O
and O
Bcl2 O
expressions O
in O
a O
beta O
- O
pancreatic O
cell O
line O
( O
MIN6 O
cells O
) O
. O

MIN6 O
cells O
were O
pre O
- O
incubated O
with O
different O
iron B
and O
/ O
or O
glucose B
concentrations O
, O
and O
the O
relative O
mRNA O
abundance O
of O
the O
Bcl2 O
/ O
Bax O
ratio O
and O
of O
Mfn2 O
genes O
was O
measured O
by O
qRT O
- O
PCR O
. O

Heme O
oxygenase O
( O
HO O
) O
activity O
, O
iron B
uptake O
, O
superoxide B
dismutase O
activity O
, O
and O
glutathione B
content O
were O
also O
determined O
. O

The O
Bcl2 O
/ O
Bax O
ratio O
increased O
and O
Mfn2 O
expression O
decreased O
in O
MIN6 O
cells O
after O
glucose B
stimulation O
. O

These O
effects O
were O
higher O
when O
glucose B
and O
iron B
were O
incubated O
together O
. O

Additionally O
, O
treatment O
with O
glucose B
/ O
iron B
showed O
a O
higher O
HO O
activity O
. O

Our O
study O
revealed O
that O
high O
glucose B
/ O
Fe B
concentrations O
in O
MIN6 O
cells O
induced O
an O
increase O
of O
the O
Bcl2 O
/ O
Bax O
ratio O
, O
an O
indicator O
of O
increased O
cell O
apoptosis O
. O

Ospemifene O
( O
Osphena O
( O
TM O
) O
) O
is O
an O
oral O
selective O
estrogen B
receptor O
modulator O
( O
SERM O
) O
, O
with O
tissue O
- O
specific O
estrogenic O
agonist O
/ O
antagonist O
effects O
. O

Ospemifene O
is O
the O
first O
non O
- O
estrogen B
treatment O
approved O
for O
moderate O
to O
severe O
dyspareunia O
in O
women O
with O
menopause O
- O
related O
vulvar O
and O
vaginal O
atrophy O
. O

Pasireotide O
( O
Signifor O
( O
( O
R O
) O
) O
) O
is O
a O
new O
subcutaneous O
somatostatin B
analogue O
that O
acts O
via O
somatostatin B
receptors O
to O
inhibit O
the O
secretion O
of O
corticotropin O
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing O
' O
s O
disease O
. O

Pasireotide O
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin B
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin B
receptor O
subtype O
5 O
, O
which O
is O
strongly O
over O
expressed O
in O
corticotroph O
adenoma O
cells O
. O

In O
a O
phase O
III O
clinical O
trial O
in O
patients O
with O
Cushing O
' O
s O
disease O
, O
twice O
- O
daily O
pasireotide O
600 O
or O
900 O
mu O
g O
for O
6 O
months O
led O
to O
normalization O
of O
urinary O
free O
cortisol B
( O
UFC O
) O
levels O
in O
up O
to O
a O
quarter O
of O
all O
patients O
( O
primary O
endpoint O
) O
and O
significantly O
reduced O
mean O
UFC O
levels O
. O

Decreases O
in O
UFC O
levels O
achieved O
during O
pasireotide O
treatment O
are O
accompanied O
by O
decreases O
in O
serum O
and O
salivary O
cortisol B
levels O
, O
as O
well O
as O
improvements O
in O
clinical O
signs O
and O
symptoms O
, O
including O
body O
weight O
, O
blood O
pressure O
and O
health O
- O
related O
quality O
- O
of O
- O
life O
. O

Pasireotide O
has O
a O
generally O
similar O
tolerability O
profile O
to O
that O
of O
other O
somatostatin B
analogues O
, O
but O
is O
associated O
with O
a O
relatively O
high O
incidence O
of O
hyperglycaemia O
, O
requiring O
the O
addition O
or O
intensification O
of O
glucose B
- O
lowering O
medication O
in O
a O
substantial O
proportion O
of O
patients O
. O

One O
potential O
mechanism O
for O
its O
activity O
is O
the O
covalent O
modification O
of O
cellular O
proteins O
, O
via O
a O
reactive O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
group O
in O
its O
cyclopentenone O
ring O
, O
which O
in O
turn O
alters O
protein O
function O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
The O
primary O
outcome O
was O
development O
of O
renal O
dysfunction O
, O
defined O
as O
an O
increase O
in O
serum O
creatinine B
of O
50 O
% O
or O
more O
during O
therapy O
or O
the O
initiation O
of O
renal O
replacement O
therapy O
( O
RRT O
) O
, O
in O
patients O
who O
received O
at O
least O
one O
dose O
of O
colistin O
and O
were O
not O
already O
on O
RRT O
. O

Thermal O
and O
Electrical O
Transport O
in O
Ultralow O
Density O
Single O
- O
Walled O
Carbon B
Nanotube O
Networks O
. O

The O
thermal O
, O
electrical O
, O
and O
thermoelectric O
properties O
of O
aerogels O
of O
single O
- O
walled O
carbon B
nanotubes O
are O
characterized O
. O

A O
Dual O
Enzyme O
Microgel O
with O
High O
Antioxidant O
Ability O
Based O
on O
Engineered O
Seleno O
- O
Ferritin O
and O
Artificial O
Superoxide B
Dismutase O
. O

An O
antioxidant O
microgel O
with O
both O
glutathione B
peroxidase O
( O
GPx O
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
activities O
is O
reported O
. O

The O
resulting O
seleno O
- O
ferritin O
( O
Se B
- O
Fn O
) O
monomers O
can O
self O
- O
assemble O
into O
nanocomposites O
that O
exhibit O
remarkable O
GPx O
activity O
due O
to O
the O
well O
organized O
multi O
- O
GPx O
catalytic O
centers O
. O

Subsequently O
, O
a O
porphyrin B
derivative O
is O
synthesized O
as O
an O
SOD O
mimic O
, O
and O
is O
employed O
to O
construct O
a O
synergistic O
dual O
enzyme O
system O
by O
crosslinking O
Se B
- O
Fn O
nanocomposites O
into O
a O
microgel O
. O

A O
Model O
- O
Based O
Approach O
to O
Predict O
Longitudinal O
HbA1c O
, O
Using O
Early O
Phase O
Glucose B
Data O
From O
Type O
2 O
Diabetes O
Mellitus O
Patients O
After O
Anti O
- O
Diabetic O
Treatment O
. O

In O
this O
paper O
, O
we O
present O
a O
model O
- O
based O
approach O
for O
predicting O
glycosylated O
hemoglobin O
( O
HbA1c O
) O
in O
late O
phase O
using O
glucose B
and O
insulin O
concentrations O
from O
an O
early O
- O
phase O
study O
, O
investigating O
an O
anti O
- O
diabetic O
treatment O
. O

Two O
previously O
published O
models O
were O
used O
; O
an O
integrated O
glucose B
and O
insulin O
( O
IGI O
) O
model O
for O
meal O
tolerance O
tests O
and O
an O
integrated O
glucose B
- O
red O
blood O
cell O
- O
HbA1c O
( O
IGRH O
) O
model O
predicting O
the O
formation O
of O
HbA1c O
from O
the O
average O
glucose B
concentration O
( O
Cg O
, O
av O
) O
. O

We O
have O
shown O
that O
this O
approach O
well O
predicts O
the O
longitudinal O
HbA1c O
response O
in O
a O
12 O
- O
week O
study O
using O
only O
information O
from O
a O
1 O
- O
week O
study O
where O
glucose B
and O
insulin O
concentrations O
were O
measured O
. O

Transient O
, O
Biocompatible O
Electronics O
and O
Energy O
Harvesters O
Based O
on O
ZnO B
. O

The O
combined O
use O
of O
ZnO B
, O
Mg B
, O
MgO B
, O
and O
silk O
provides O
routes O
to O
classes O
of O
thin O
- O
film O
transistors O
and O
mechanical O
energy O
harvesters O
that O
are O
soluble O
in O
water O
and O
biofluids O
. O

Because O
of O
its O
biocompatibility O
, O
high O
bioresorbability O
, O
and O
responsiveness O
to O
pH O
changes O
, O
synthetic O
biomimetic O
nanocrystalline O
apatites B
are O
used O
as O
nanocarriers O
to O
produce O
multifunctional O
nanoparticles O
, O
by O
coupling O
them O
with O
the O
chemotherapeutic O
drug O
doxorubicin B
( O
DOXO O
) O
and O
the O
DO O
- O
24 O
monoclonal O
antibody O
( O
mAb O
) O
directed O
against O
the O
Met O
/ O
Hepatocyte O
Growth O
Factor O
receptor O
( O
Met O
/ O
HGFR O
) O
, O
which O
is O
over O
- O

Moreover O
they O
discharge O
DOXO O
in O
the O
targeted O
GTL O
- O
16 O
cells O
that O
reach O
the O
nucleus O
and O
display O
cytotoxicity O
as O
assessed O
in O
an O
MTT B
assay O
. O

Moreover O
, O
this O
work O
opens O
new O
perspectives O
in O
the O
use O
of O
nanocrystalline O
apatites B
as O
a O
new O
platform O
for O
theranostic O
applications O
in O
nanomedicine O
. O

Facile O
Preparation O
of O
Ordered O
Porous O
Graphene B
- O
Metal B
Oxide I
@ O
C O
Binder O
- O
Free O
Electrodes O
with O
High O
Li B
Storage O
Performance O
. O

A O
facile O
and O
general O
method O
is O
reported O
to O
prepare O
ordered O
porous O
graphene B
- O
based O
binder O
- O
free O
electrodes O
on O
a O
large O
scale O
. O

Such O
ordered O
porous O
electrodes O
demonstrate O
superior O
Li B
storage O
properties O
; O
for O
example O
, O
graphene B
- O
Fe3 O
O4 O
@ O
C O
depicts O
high O
capacities O
of O
1123 O
. O
8 O
and O
505 O
mAh O
g O
( O
- O
1 O
) O
at O
current O
densities O
of O
0 O
. O
5 O
and O
10 O
A O
g O
( O
- O
1 O
) O
, O
respectively O
. O

We O
report O
on O
a O
novel O
experimental O
study O
of O
a O
pH O
- O
responsive O
polyelectrolyte O
brush O
at O
the O
silicon B
/ O
D2O B
interface O
. O

A O
poly O
[ O
2 O
- O
( O
diethylamino O
) O
ethyl O
methacrylate O
] O
brush O
was O
grown O
on O
a O
large O
silicon B
crystal O
which O
acted O
as O
both O
a O
substrate O
for O
a O
neutron O
reflectivity O
solid O
/ O
liquid O
experiment O
but O
also O
as O
an O
FTIR O
- O
ATR O
spectroscopy O
crystal O
. O

The O
chosen O
polybase O
brush O
shows O
strong O
IR O
bands O
which O
can O
be O
assigned O
to O
the O
N O
- O
D O
( O
+ O
) O
stretch O
, O
D2O B
, O
and O
a O
carbonyl B
group O
. O

From O
such O
FTIR O
data O
, O
we O
are O
able O
to O
closely O
monitor O
the O
degree O
of O
protonation O
along O
the O
polymer O
chain O
as O
well O
as O
revealing O
information O
concerning O
the O
D2O B
concentration O
at O
the O
interface O
. O

3 O
- O
Hydroxy O
- O
3 O
- O
methylglutaryl O
coenzyme O
A O
reductase O
inhibitors O
( O
statins O
) O
exert O
pleiotropic O
effects O
on O
the O
cardiovascular O
system O
, O
in O
part O
through O
a O
decrease O
in O
reactive O
oxygen B
species O
( O
ROS O
) O
formation O
and O
reduction O
of O
vascular O
inflammation O
. O

Immune O
complex O
kinase O
assay O
of O
protein O
extracts O
from O
HAECs O
treated O
with O
atorvastatin B
revealed O
increased O
ERK5 O
activity O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

In O
addition O
, O
pretreatment O
with O
atorvastatin B
inhibited O
TNF O
- O
alpha O
- O
induced O
ROS O
production O
and O
VCAM O
- O
1 O
and O
ICAM O
- O
1 O
expression O
. O

Protective O
effect O
of O
ethyl B
acetate I
fraction O
of O
Acacia O
ferruginea O
DC O
. O
against O
ethanol B
- O
induced O
gastric O
ulcer O
in O
rats O
. O

MATERIALS O
AND O
METHODS O
: O
Acetone B
extract O
and O
its O
sub O
- O
fractions O
of O
Acacia O
ferruginea O
stem O
bark O
were O
subjected O
to O
assess O
their O
antioxidant O
potential O
using O
various O
in O
vitro O
systems O
such O
as O
DPPH B
( I
* I
) I
, O
ABTS B
( I
* I
+ I
) I
scavenging O
, O
FRAP O
and O
phosphomolybdenum O
reduction O
activities O
. O

Based O
on O
the O
antioxidant O
potential O
, O
the O
ethyl O
acetate O
fraction O
was O
used O
to O
evaluate O
the O
protective O
effect O
of O
ethanol B
- O
induced O
gastric O
damage O
in O
rat O
model O
. O

Enzyme O
activities O
such O
as O
superoxide B
dismutase O
, O
glutathione B
, O
catalase O
and O
lipid O
peroxidation O
were O
also O
determined O
in O
the O
stomach O
tissues O
. O

RESULTS O
: O
Ethyl B
acetate I
fraction O
( O
AFE O
) O
of O
Acacia O
ferruginea O
stem O
bark O
registered O
higher O
antioxidant O
and O
free O
radical O
scavenging O
activities O
than O
the O
crude O
acetone B
extract O
and O
other O
fractions O
. O

In O
addition O
, O
AFE O
exhibited O
that O
the O
IC50 O
values O
of O
DPPH B
( O
2 O
. O
5 O
micro O
g O
/ O
ml O
) O
and O
ABTS B
( O
1 O
. O
8 O
micro O
g O
/ O
ml O
) O
were O
lower O
when O
compared O
to O
the O
standard O
quercetin B
( O
12 O
. O
4 O
micro O
g O
/ O
ml O
and O
4 O
. O
7 O
micro O
g O
/ O
ml O
, O
respectively O
) O
. O

In O
ethanol B
induced O
gastric O
ulcer O
, O
administration O
of O
AFE O
at O
doses O
of O
10mg O
/ O
kg O
, O
50mg O
/ O
kg O
and O
100mg O
/ O
kg O
body O
weight O
prior O
to O
ethanol B
ingestion O
significantly O
protected O
the O
stomach O
ulceration O
. O

Consequently O
significant O
changes O
were O
observed O
in O
enzyme O
activities O
such O
as O
SOD O
, O
CAT O
, O
GSH B
and O
LPO O
in O
the O
stomach O
tissues O
when O
compared O
with O
ethanol B
control O
group O
. O

CONCLUSION O
: O
It O
is O
concluded O
that O
the O
ethyl B
acetate I
fraction O
of O
Acacia O
ferruginea O
stem O
bark O
possessed O
higher O
antioxidant O
and O
anti O
- O
ulcerogenic O
activities O
. O

Based O
on O
the O
results O
we O
suggest O
that O
Acacia O
ferruginea O
stem O
bark O
has O
potential O
to O
provide O
a O
therapeutic O
approach O
to O
ethanol B
mediated O
ulcer O
as O
an O
effective O
anti O
- O
ulcer O
agent O
. O

The O
phytochemical O
investigations O
showed O
the O
presence O
of O
cyclopeptid O
alkaloids O
, O
flavonoids B
( O
e O
. O
g O
. O
, O
( B
- I
) I
- I
epicatechin I
, O
quercetin B
, O
kaempferol B
, O
kaempferol O
- O
3 O
- O
O O
- O
beta O
- O
d O
- O
( O
6 O
' O
' O
- O
E O
- O
p O
- O
coumaryl O
) O
- O
glucopyranoside O
) O
, O
tannins B
, O
sterols B
, O
terpenes B
, O
saponins B
, O
anthraquinones B
. O

beta O
- O
estradiol O
17 O
- O
valerate O
( O
EV O
) O
is O
a O
synthetic O
estrogen B
widely O
used O
in O
combination O
with O
other O
steroid O
hormones O
in O
hormone O
replacement O
therapy O
drugs O
and O
is O
detected O
in O
natural O
waters O
. O

Quantitative O
real O
- O
time O
RT O
- O
PCR O
showed O
that O
mRNA O
levels O
of O
estrogen B
receptor O
alpha O
( O
ER O
- O
alpha O
) O
and O
vitellogenin O
- O
I O
( O
VTG O
- O
I O
) O
in O
the O
liver O
of O
females O
were O
significantly O
down O
- O
regulated O
, O
while O
those O
of O
vitellogenin O
- O
I O
( O
VTG O
- O
I O
) O
in O
the O
liver O
of O
males O
were O
significantly O
up O
- O
regulated O
at O
all O
concentrations O
. O

Estradiol B
replacement O
enhances O
cocaine B
- O
stimulated O
locomotion O
in O
female O
C57BL O
/ O
6 O
mice O
through O
estrogen B
receptor O
alpha O
. O

Estradiol B
increases O
behavioral O
responses O
to O
psychostimulants O
in O
women O
and O
female O
rats O
, O
although O
the O
underlying O
mechanism O
is O
unknown O
. O

This O
study O
utilized O
mice O
to O
investigate O
the O
time O
frame O
and O
receptor O
mediation O
of O
estradiol B
' O
s O
enhancement O
of O
cocaine B
- O
induced O
behavior O
as O
mice O
enable O
parallel O
use O
of O
genetic O
, O
surgical O
and O
pharmacological O
methods O
. O

The O
spontaneous O
behavior O
of O
Sham O
and O
Ovariectomized O
( O
Ovx O
) O
female O
wildtype O
( O
WT O
) O
mice O
was O
determined O
during O
habituation O
to O
a O
novel O
environment O
and O
after O
cocaine B
administration O
. O

Ovx O
mice O
were O
replaced O
with O
vehicle O
( O
sesame O
oil O
) O
or O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
for O
2 O
days O
or O
30 O
min O
prior O
to O
a O
cocaine B
challenge O
to O
investigate O
the O
time O
course O
of O
E2 O
' O
s O
effects O
. O

To O
examine O
receptor O
mediation O
of O
estradiol B
effects O
, O
Ovx O
mice O
replaced O
for O
2 O
days O
with O
either O
the O
ER O
alpha O
- O
selective O
agonist O
PPT B
or O
the O
ER O
beta O
- O
selective O
agonist O
DPN B
were O
compared O
to O
Sham O
mice O
, O
and O
mice O
lacking O
either O
ER O
alpha O
( O
alpha O
ERKO O
) O
or O
ER O
beta O
( O
beta O
ERKO O
) O
were O
compared O
to O
WT O
littermates O
. O

Cocaine B
- O
induced O
increases O
in O
behavioral O
ratings O
were O
greater O
in O
Sham O
than O
in O
Ovx O
mice O
. O

Two O
days O
but O
not O
30 O
min O
of O
E2 O
replacement O
in O
Ovx O
mice O
increased O
cocaine B
responses O
to O
Sham O
levels O
. O

PPT B
replacement O
also O
increased O
the O
cocaine B
response O
relative O
to O
vehicle O
- O
or O
DPN B
- O
treated O
Ovx O
mice O
. O

alpha O
ERKO O
mice O
displayed O
modestly O
attenuated O
behavioral O
responses O
to O
novelty O
and O
cocaine B
compared O
to O
alpha O
WT O
littermates O
, O
but O
no O
behavioral O
differences O
were O
found O
between O
beta O
ERKO O
and O
beta O
WT O
mice O
. O

These O
results O
suggest O
that O
E2 O
enhances O
cocaine B
- O
stimulated O
locomotion O
in O
mice O
predominantly O
through O
ER O
alpha O
. O

Discovery O
of O
natural O
estrogen B
receptor O
modulators O
with O
structure O
- O
based O
virtual O
screening O
. O

Eleven O
compounds O
were O
identified O
as O
estrogen B
receptor O
modulators O
from O
an O
in O
- O
house O
natural O
product O
database O
( O
NPD O
) O
by O
structure O
- O
based O
virtual O
screening O
for O
ER O
alpha O
and O
ER O
beta O
. O

Phytoestrogenic O
Potential O
of O
Cyclopia O
Extracts O
and O
Polyphenols B
. O

This O
minireview O
presents O
an O
overview O
of O
polyphenols B
found O
in O
Cyclopia O
and O
focusses O
on O
the O
phytoestrogenic O
potential O
of O
selected O
polyphenols B
and O
of O
extracts O
prepared O
from O
the O
plant O
. O

Resumption O
of O
menstruation O
and O
pituitary O
response O
to O
gonadotropin O
- O
releasing O
hormone O
in O
functional O
hypothalamic O
amenorrhea O
undertaking O
estrogen B
replacement O
therapy O
. O

Amphiphilic O
Polypeptides O
as O
a O
Bifunctional O
Template O
in O
the O
Mineralization O
of O
Calcium B
Carbonate I
at O
the O
Air O
/ O
Water O
Interface O
. O

The O
observations O
from O
SEM O
and O
TEM O
suggest O
that O
PGlu22 O
- O
b O
- O
PAla8 O
initiates O
the O
amorphous O
precursor O
phase O
and O
heterogeneous O
nucleation O
of O
CaCO3 O
at O
the O
air O
/ O
water O
interface O
, O
while O
temporarily O
stabilizes O
the O
gelatinous O
precursors O
as O
a O
process O
- O
directing O
agent O
; O
nevertheless O
, O
the O
initial O
concentration O
of O
Ca B
( I
2 I
+ I
) I
controls O
the O
procedure O
of O
crystallization O
and O
the O
final O
morphology O
of O
CaCO3 O
particles O
. O

Frequently O
sampled O
intravenous O
glucose B
tolerance O
tests O
were O
performed O
before O
and O
after O
interventions O
. O

Insulin O
sensitivity O
, O
acute O
insulin O
secretion O
after O
intravenous O
glucose B
administration O
and O
beta O
- O
cell O
function O
as O
determined O
by O
disposition O
index O
improved O
to O
a O
similar O
extent O
in O
both O
groups O
. O

Likewise O
, O
changes O
in O
fasting O
glucose B
and O
fructosamine B
levels O
were O
similar O
. O

Central O
Pulse O
Pressure O
and O
Its O
Hemodynamic O
Determinants O
in O
Middle O
- O
Aged O
Adults O
With O
Impaired O
Fasting O
Glucose B
and O
Diabetes O
: O
The O
Asklepios O
study O
. O

Little O
is O
known O
about O
the O
hemodynamic O
determinants O
of O
central O
PP O
in O
type O
2 O
diabetes O
or O
whether O
abnormalities O
in O
central O
pulsatile O
hemodynamics O
are O
already O
present O
in O
individuals O
with O
impaired O
fasting O
glucose B
( O
IFG O
) O
. O

In O
a O
population O
- O
based O
study O
, O
we O
aimed O
to O
compare O
central O
PP O
and O
its O
hemodynamic O
determinants O
among O
adults O
with O
normal O
fasting O
glucose B
( O
n O
= O
1654 O
) O
, O
IFG O
( O
n O
= O
240 O
) O
, O
and O
type O
2 O
diabetes O
( O
n O
= O
33 O
) O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
carotid O
pressure O
, O
left O
ventricular O
outflow O
, O
aortic O
root O
diameter O
, O
carotid O
artery O
flow O
, O
and O
distension O
in O
order O
to O
measure O
various O
structural O
and O
hemodynamic O
arterial O
parameters O
. O
RESULTSIFG O
was O
associated O
with O
a O

Aldosterone B
plays O
a O
major O
role O
in O
regulating O
sodium B
and O
potassium B
homeostasis O
, O
and O
blood O
pressure O
. O

More O
recently O
aldosterone B
has O
emerged O
as O
a O
key O
hormone O
in O
mediating O
end O
organ O
damage O
. O

In O
extreme O
cases O
, O
dysregulated O
aldosterone B
production O
leads O
to O
primary O
aldosteronism O
, O
the O
most O
common O
form O
of O
secondary O
hypertension O
. O

However O
, O
even O
within O
the O
physiological O
range O
, O
high O
levels O
of O
aldosterone B
are O
associated O
with O
an O
increased O
risk O
of O
developing O
hypertension O
over O
time O
. O

Although O
genetic O
causes O
underlying O
glucocorticoid O
remediable O
aldosteronism O
, O
one O
of O
the O
three O
Mendelian O
forms O
of O
primary O
aldosteronism O
, O
were O
established O
some O
time O
ago O
, O
somatic O
and O
inherited O
mutations O
in O
the O
potassium B
channel O
GIRK4 O
have O
only O
recently O
been O
implicated O
in O
the O
formation O
of O
aldosterone B
producing O
adenoma O
and O
in O
familial O
hyperaldosteronism O
type O
3 O
. O

Moreover O
, O
recent O
findings O
have O
identified O
somatic O
mutations O
in O
two O
additional O
genes O
, O
involved O
in O
maintaining O
intracellular O
ionic O
homeostasis O
and O
cell O
membrane O
potential O
, O
in O
a O
subset O
of O
aldosterone B
producing O
adenoma O
. O
This O
review O
summarizes O
our O
current O
knowledge O
on O
the O
genetic O
determinants O
that O
contribute O
to O
variations O
in O
plasma O
aldosterone B
and O
renin O
levels O
in O
the O
general O
population O
, O
and O
the O
genetics O
of O
familial O
and O
sporadic O
primary O
aldosteronism O
. O

Various O
animal O
models O
that O
have O
significantly O
improved O
our O
understanding O
of O
the O
pathophysiology O
of O
excess O
aldosterone B
production O
will O
also O
be O
discussed O
. O

The O
poly O
( O
benzyl O
1 O
, O
2 O
- O
glycerol O
carbonate O
) O
s O
were O
obtained O
via O
the O
ring O
- O
opening O
copolymerization O
of O
rac O
- O
/ O
( O
R O
) O
- O
benzyl O
glycidyl O
ether O
with O
CO2 B
using O
[ O
SalcyCo O
( O
III O
) O
X O
] O
complexes O
with O
high O
carbonate B
linkage O
selectivity O
and O
polymer O
/ O
cyclic O
carbonate B
selectivity O
( O
> O
99 O
% O
) O
. O

Deprotection O
of O
the O
resultant O
polymers O
afforded O
poly O
( O
1 O
, O
2 O
- O
glycerol O
carbonate O
) O
s O
with O
a O
functionalizable O
pendant O
primary B
hydroxyl I
group O
. O

These O
polymers O
fulfill O
an O
unmet O
need O
for O
a O
readily O
degradable O
biocompatible O
polycarbonate B
. O

A O
New O
Face O
for O
Old O
Antibiotics O
: O
Tetracyclines B
in O
Treatment O
of O
Amyloidoses O
. O

The O
use O
of O
tetracyclines B
has O
declined O
because O
of O
the O
appearance O
of O
resistant O
bacterial O
strains O
. O

About O
10 O
years O
ago O
we O
first O
reported O
that O
tetracyclines B
inhibited O
the O
aggregation O
of O
prion O
protein O
fragments O
and O
Alzheimer O
' O
s O
beta O
peptides O
, O
destabilizing O
their O
aggregates O
and O
promoting O
their O
degradation O
by O
proteases O
. O

On O
the O
basis O
of O
these O
observations O
, O
the O
antiamyloidogenic O
effects O
of O
tetracyclines B
on O
a O
variety O
of O
amyloidogenic O
proteins O
were O
studied O
and O
confirmed O
by O
independent O
research O
groups O
. O

Physicochemical O
characterization O
of O
nimodipine O
- O
polyethylene B
glycol I
solid O
dispersion O
systems O
. O

Abstract O
This O
study O
investigates O
the O
solid O
- O
solid O
interactions O
between O
nimodipine O
( O
NIM O
) O
and O
polyethylene B
glycol I
( O
PEG B
) O
of O
different O
mean O
molecular O
weights O
( O
PEG O
2000 O
, O
4000 O
and O
6000 O
) O
, O
in O
solid O
dispersion O
systems O
, O
applying O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
Fourier O
- O
Transform O
infrared O
spectroscopy O
, O
powder O
X O
- O
ray O
diffraction O
( O
PXRD O
) O
, O
hot O
stage O
microscopy O
( O
HSM O
) O
and O
theoretical O
modeling O
by O
the O
Flory O
- O
Huggins O
( O
FH O
) O
solution O
theory O
. O

When O
chi O
is O
considered O
a O
constant O
number O
( O
chi O
= O
alpha O
, O
alpha O
! O
= O
0 O
) O
, O
formation O
of O
a O
eutectic O
mixture O
is O
predicted O
in O
the O
70 O
- O
80 O
% O
w O
/ O
w O
PEG B
concentration O
region O
, O
while O
when O
chi O
was O
considered O
as O
a O
function O
of O
concentration O
and O
temperature O
( O
chi O
= O
f O
( O
phi O
, O
Tau O
) O
) O
, O
the O
model O
predicts O
the O
formation O
of O
monotectic O
systems O
. O

Studies O
on O
NIM O
' O
s O
re O
- O
crystallization O
process O
in O
the O
solid O
dispersions O
revealed O
a O
strong O
dependence O
of O
the O
crystallization O
rate O
, O
as O
well O
as O
the O
resulting O
crystal O
form O
, O
on O
the O
mean O
molecular O
weight O
and O
concentration O
of O
PEG B
: O
NIM O
crystallization O
rates O
decrease O
as O
PEG B
' O
s O
MW O
increases O
, O
while O
NIM O
mod O
II O
crystals O
predominate O
in O
dispersions O
prepared O
at O
temperatures O
above O
NIM O
' O
s O
liquidus O
and O
growth O
of O
NIM O
mod O
I O
prevailing O
in O
PEG B
- O
rich O
samples O
. O

Moreover O
, O
activation O
of O
Th1 O
type O
and O
suppression O
of O
Th2 O
type O
immune O
responses O
and O
induction O
in O
nitric B
oxide I
generation O
proved O
that O
8a O
and O
8g O
induce O
murine O
macrophages O
to O
prevent O
survival O
of O
parasites O
. O

A O
series O
of O
quinolone B
derivatives O
, O
containing O
different O
heterocyclic B
amines I
were O
prepared O
. O

Changes O
in O
the O
capacity O
of O
different O
depots O
to O
store O
and O
release O
fatty B
acids I
and O
to O
produce O
adipocytokines O
are O
important O
determinants O
of O
fat O
distribution O
and O
its O
metabolic O
consequences O
. O

Furthermore O
, O
from O
the O
native O
HE800 O
EPS O
, O
a O
low O
- O
molecular O
weight O
sulfated O
derivative O
( O
HE800 O
DROS O
) O
displaying O
chemical O
analogy O
with O
heparan O
- O
sulfate B
, O
was O
designed O
. O

Thus O
, O
it O
was O
demonstrated O
that O
HE800 O
DROS O
mimics O
some O
properties O
of O
heparan O
- O
sulfate B
, O
such O
as O
promotion O
of O
fibroblast O
proliferation O
and O
inhibition O
of O
matrix O
metalloproteinase O
( O
MMP O
) O
secretion O
. O

MATERIALS O
AND O
METHODS O
: O
The O
aqueous O
and O
80 O
% O
MeOH B
extracts O
, O
and O
a O
series O
of O
fractions O
and O
subfractions O
from O
the O
leaves O
, O
stem O
and O
root O
bark O
of O
Alstonia O
congensis O
were O
tested O
in O
vitro O
for O
their O
antiprotozoal O
activity O
against O
Trypanosoma O
brucei O
brucei O
, O
Trypanosoma O
cruzi O
, O
Lesihamania O
infantum O
and O
the O
chloroquine B
and O
pyrimethamine O
- O
resitant O
K1 O
strain O
of O
Plasmodium O
falciparum O
. O

RESULTS O
: O
The O
aqueous O
and O
80 O
% O
MeOH B
extracts O
and O
a O
series O
of O
subfractions O
of O
each O
plant O
part O
exhibited O
pronounced O
antiprotozoal O
activity O
against O
the O
K1 O
strain O
of O
Plasmodium O
falciparum O
with O
IC50 O
values O
ranging O
from O
2 O
to O
5 O
micro O
g O
/ O
ml O
, O
and O
good O
activity O
against O
Trypanosoma O
brucei O
brucei O
and O
Trypanosoma O
cruzi O
with O
IC50 O
values O
ranging O
between O
5 O
and O
10 O
micro O
g O
/ O
ml O
. O

The O
residual O
80 O
% O
MeOH B
extract O
from O
the O
leaves O
, O
and O
the O
total O
alkaloid O
extract O
from O
stem O
and O
root O
bark O
were O
the O
only O
subfractions O
active O
against O
Leishmania O
infantum O
with O
IC50 O
values O
< O
10 O
micro O
g O
/ O
ml O
. O

Structure O
of O
hydrated O
cobalt B
ions O
confined O
in O
the O
nanospace O
of O
single O
- O
walled O
carbon B
nanotubes O
. O

The O
structure O
of O
hydrated O
Co B
ions O
confined O
in O
the O
nanospace O
of O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
has O
been O
studied O
using O
the O
X O
- O
ray O
absorption O
fine O
structure O
( O
XAFS O
) O
technique O
. O

Water O
adsorption O
isotherms O
on O
Co B
- O
impregnated O
SWNTs O
indicate O
a O
high O
affinity O
of O
Co B
ions O
to O
water O
molecules O
. O

The O
results O
of O
XAFS O
analysis O
provided O
the O
information O
on O
the O
proportion O
of O
dissolved O
species O
in O
nanospaces O
against O
the O
total O
amount O
of O
cobalt B
ions O
adsorbed O
on O
the O
open O
- O
pored O
SWNT O
. O

The O
structural O
information O
of O
the O
first O
shell O
around O
a O
Co B
ion O
was O
expressed O
in O
terms O
of O
the O
hydration O
number O
, O
Co O
- O
O O
distance O
and O
Debye O
- O
Waller O
factor O
. O

The O
actual O
coordination O
number O
and O
the O
interatomic O
distance O
of O
Co O
- O
O O
for O
the O
dissolved O
species O
were O
remarkably O
reduced O
compared O
to O
the O
bulk O
aqueous O
solution O
indicating O
the O
dehydration O
of O
water O
molecules O
from O
Co B
ions O
and O
a O
compact O
hydrated O
structure O
in O
the O
micropore O
of O
SWNTs O
. O

A O
molecular O
mechanism O
for O
therapeutic O
effects O
of O
cGMP B
- O
elevating O
agents O
in O
pulmonary O
arterial O
hypertension O
. O

Here O
we O
show O
that O
BMP O
signaling O
via O
Smad1 O
/ O
5 O
/ O
8 O
requires O
cGMP B
- O
dependent O
protein O
kinase O
isotype O
I O
( O
PKGI O
) O
to O
maintain O
PASMCs O
in O
a O
differentiated O
, O
low O
- O
proliferative O
state O
. O

BMP O
cooperation O
with O
cGMP B
/ O
PKGI O
was O
crucial O
for O
transcription O
of O
contractile O
genes O
, O
and O
suppression O
of O
pro O
- O
proliferative O
and O
anti O
- O
apoptotic O
genes O
. O

Conversely O
, O
cGMP B
stimulation O
of O
PKGI O
restored O
defective O
BMP O
signaling O
in O
rats O
with O
hypoxia O
- O
induced O
PAH O
, O
consistent O
with O
cGMP B
- O
elevating O
agents O
reversing O
vascular O
remodeling O
in O
this O
PAH O
model O
. O

Our O
results O
provide O
a O
mechanism O
for O
the O
therapeutic O
effects O
of O
cGMP B
- O
elevating O
agents O
in O
PAH O
, O
and O
suggest O
that O
combining O
them O
with O
BMP O
mimetics O
may O
provide O
a O
novel O
, O
disease O
- O
modifying O
approach O
to O
PAH O
therapy O
. O

The O
in O
vivo O
TRPV6 O
protein O
starts O
at O
a O
non O
- O
AUG O
triplet O
decoded O
as O
methionine B
upstream O
the O
canonical O
initiation O
at O
AUG O
. O

TRPV6 O
channels O
function O
as O
epithelial O
Ca2 B
+ I
entry O
pathways O
in O
the O
epididymis O
, O
prostate O
and O
placenta O
. O

We O
show O
that O
in O
vivo O
the O
TRPV6 O
protein O
has O
an O
extended O
N B
- O
terminus O
. O

Translation O
initiates O
at O
a O
non O
- O
AUG O
codon O
, O
at O
ACG O
, O
which O
is O
decoded O
by O
methionine B
and O
which O
is O
upstream O
of O
the O
annotated O
AUG O
which O
is O
not O
used O
for O
initiation O
. O

The O
in O
vitro O
properties O
of O
channels O
formed O
by O
the O
extended O
full O
length O
TRPV6 O
proteins O
and O
the O
so O
far O
annotated O
and O
shorter O
TRPV6 O
are O
similar O
, O
but O
the O
extended O
N B
- O
terminus O
increases O
trafficking O
to O
the O
plasma O
membrane O
and O
represents O
an O
additional O
scaffold O
for O
channel O
assembly O
. O

The O
increased O
translation O
of O
the O
shorter O
TRPV6 O
cDNA O
version O
may O
overestimate O
the O
in O
vivo O
situation O
where O
translation O
efficiency O
may O
represent O
an O
additional O
mechanism O
to O
tightly O
control O
the O
TRPV6 O
- O
mediated O
Ca2 B
+ I
entry O
in O
order O
to O
prevent O
deleterious O
Ca2 B
+ I
overload O
. O

One O
- O
Pot O
in O
Situ O
Mixed O
Film O
Formation O
by O
Azo B
Coupling O
and O
Diazonium O
Salt O
Electrografting O
. O

So O
simple O
: O
The O
in O
situ O
synthesis O
of O
an O
aryldiazonium O
salt O
and O
an O
azo O
- O
aryldiazonium O
salt O
by O
azo B
coupling O
from O
sulfanilic O
acid O
and O
aniline B
is O
reported O
. O

Concentrations O
of O
the O
chosen O
elements O
( O
Zn B
, O
Cu B
, O
Fe B
, O
Mg B
, O
Ni B
, O
and O
Cd B
) O
in O
mycelium O
samples O
were O
measured O
by O
means O
of O
atomic O
absorption O
spectrometry O
. O

Fe B
concentration O
in O
the O
analyzed O
mushroom O
materials O
was O
in O
the O
range O
215 O
. O
4 O
- O
680 O
. O
3 O
mu O
g O
/ O
g O
dry O
weight O
. O

Mean O
values O
of O
Mg B
were O
respectively O
( O
in O
micrograms O
per O
gram O
dry O
weight O
) O
541 O
. O
8 O
for O
mycelium O
of O
C O
. O
cibarius O
cultured O
in O
vitro O
and O
1 O
, O
004 O
. O
1 O
for O
C O
. O
cibarius O
fruiting O
bodies O
and O
928 O
. O
9 O
for O
the O
mycelium O
of O
B O
. O
badius O
cultured O
in O
vitro O
and O
906 O
. O
4 O
for O
B O
. O
badius O
fruiting O
bodies O
. O

The O
mean O
concentrations O
of O
Zn B
were O
442 O
. O
7 O
mu O
g O
/ O
g O
dry O
weight O
in O
mycelium O
from O
in O
vitro O
cultures O
of O
B O
. O
badius O
and O
172 O
. O
1 O
in O
B O
. O
badius O
fruiting O
bodies O
and O
131 O
. O
9 O
in O
the O
case O
of O
C O
. O
cibarius O
in O
mycelium O
from O
in O
vitro O
cultures O
and O
95 O
. O
5 O
for O
the O
C O
. O
cibarius O
fruiting O
bodies O
. O

Cu B
exhibited O
a O
reversal O
tendency O
, O
i O
. O
e O
. O
, O
the O
element O
concentrations O
in O
naturally O
grown O
mushrooms O
were O
significantly O
higher O
( O
43 O
. O
57 O
mu O
g O
/ O
g O
dry O
weight O
for O
C O
. O
cibarius O
and O
43 O
. O
54 O
mu O
g O
/ O
g O
for O
B O
. O
badius O
) O
than O
in O
cultured O
in O
vitro O
mycelium O
( O
12 O
. O
47 O
mu O
g O
/ O
g O
for O
C O
. O
cibarius O
and O
4 O
. O
17 O
mu O
g O
/ O
g O
for O
B O
. O
badius O
) O
. O

Ni B
was O
found O
in O
lowest O
concentrations O
ranging O
from O
0 O
. O
33 O
to O
1 O
. O
88 O
mu O
g O
/ O
g O
dry O
weight O
. O

Toxic O
metal O
Cd B
was O
found O
in O
relatively O
high O
concentrations O
in O
naturally O
grown O
species O
( O
0 O
. O
79 O
mu O
g O
/ O
g O
dry O
weight O
- O
1 O
. O
02 O
) O
. O

The O
lowest O
was O
the O
concentration O
of O
Cd B
in O
C O
. O
cibarius O
mycelium O
from O
in O
vitro O
culture O
- O
0 O
. O
06 O
mu O
g O
/ O
g O
dry O
weight O
- O
a O
bit O
higher O
than O
it O
was O
in O
the O
B O
. O
badius O
mycelium O
( O
0 O
. O
21 O
mu O
g O
/ O
g O
) O
. O

In O
this O
work O
, O
the O
design O
and O
synthesis O
of O
biodegradable O
PSQ O
particles O
with O
extremely O
high O
payloads O
of O
paramagnetic O
Gd B
( I
III I
) I
centers O
is O
explored O
, O
for O
use O
as O
efficient O
contrast O
agents O
for O
magnetic O
resonance O
imaging O
( O
MRI O
) O
. O

Two O
new O
bis O
( O
trialkoxysilyl O
) O
derivatives O
of O
Gd O
( O
III O
) O
diethylenetriamine O
pentaacetate O
( O
Gd O
- O
DTPA O
) O
containing O
disulfide B
linkages O
are O
synthesized O
and O
used O
to O
form O
biodegradable O
Gd O
- O
PSQ O
particles O
by O
base O
- O
catalyzed O
condensation O
reactions O
in O
reverse O
microemulsions O
. O

The O
Gd O
- O
PSQ O
particles O
are O
readily O
degradable O
to O
release O
the O
constituent O
Gd B
( I
III I
) I
chelates O
in O
the O
presence O
of O
endogenous O
reducing O
agents O
such O
as O
cysteine B
and O
glutathione B
. O

The O
MR O
relaxivities O
of O
the O
Gd O
- O
PSQ O
particles O
are O
determined O
using O
a O
3T O
MR O
scanner O
, O
with O
r1 O
values O
ranging O
from O
5 O
. O
9 O
to O
17 O
. O
8 O
mMs O
( O
- O
1 O
) O
on O
a O
per O
- O
Gd B
basis O
. O

The O
enhanced O
efficiency O
of O
the O
anisamide O
- O
functionalized O
PSQ O
- O
2 O
particles O
as O
a O
contrast O
agent O
is O
corroborated O
by O
both O
confocal O
laser O
scanning O
microscopy O
imaging O
and O
ICP O
- O
MS O
analysis O
of O
Gd B
content O
in O
vitro O
. O

A O
solid O
phase O
extraction O
method O
for O
enrichment O
- O
separation O
and O
the O
determination O
of O
cobalt B
( O
Co B
( I
2 I
+ I
) I
) O
, O
copper B
( O
Cu B
( I
2 I
+ I
) I
) O
, O
nickel B
( O
Ni B
( I
2 I
+ I
) I
) O
, O
zinc B
( O
Zn B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
in O
real O
samples O
has O
been O
proposed O
. O

Growth O
factor O
receptor O
- O
bound O
protein O
10 O
( O
Grb10 O
) O
is O
a O
Src O
homology O
2 O
( O
SH2 O
) O
domain O
- O
containing O
protein O
and O
one O
of O
the O
binding O
partners O
for O
several O
trans O
- O
membrane O
tyrosine B
- O
kinase O
receptors O
, O
including O
insulin O
receptor O
( O
IR O
) O
and O
insulin O
- O
like O
growth O
factor O
- O
1 O
receptor O
( O
IGF1 O
- O
R O
) O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid O
glycoside O
from O
Isodon O
japonica O
var O
. O
glaucocalyx O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid O
glycoside O
( O
1 O
) O
, O
named O
glaucocalyxin O
G O
, O
has O
been O
isolated O
from O
the O
n B
- I
butanol I
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside O
( O
2 O
) O
and O
kaempferol O
- O
3 O
- O
O O
- O
rutinoside O
( O
3 O
) O
. O

The O
structures O
of O
the O
isolated O
compounds O
were O
assigned O
on O
the O
basis O
of O
their O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
including O
two O
- O
dimensional O
NMR O
techniques O
such O
as O
HMQC O
, O
HMBC O
, O
and O
NOESY O
experiments O
and O
comparison O
with O
the O
literature O
data O
. O

Distribution O
of O
CYP2D6 O
in O
brain O
and O
its O
role O
in O
serotonin B
metabolism O
suggest O
that O
CYP2D6 O
may O
have O
a O
function O
in O
the O
central O
nervous O
system O
. O

The O
abundance O
of O
serotonin B
and O
5 B
- I
hydroxyindoleacetic I
acid I
in O
brain O
of O
Tg O
- O
2D6 O
is O
higher O
than O
in O
WT O
mice O
, O
either O
basal O
levels O
or O
after O
harmaline O
induction O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl O
- O
L O
- O
carnitine O
, O
pantothenic O
acid O
, O
2 O
' O
- O
deoxycytidine O
diphosphate O
( O
dCDP O
) O
, O
anandamide B
, O
N O
- O
acetylglucosaminylam O
and O
a O
down O
- O
regulation O
of O
stearoyl O
- O
L O
- O
carnitine O
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Two O
Substrate O
- O
Confined O
Sol O
- O
Gel O
Coassembled O
Ordered O
Macroporous O
Silica B
Structures O
with O
an O
Open O
Surface O
. O

In O
this O
method O
, O
a O
sol O
- O
gel O
silicate B
precursor O
was O
cooperatively O
assembled O
into O
the O
interstitial O
spaces O
of O
microspheres O
at O
the O
same O
time O
when O
polystyrene O
templates O
formed O
in O
between O
two O
desired O
substrates O
. O

Silica B
inverse O
opals O
with O
a O
three O
- O
dimensional O
ordered O
macroporous O
( O
3DOM O
) O
structure O
were O
obtained O
after O
selective O
removing O
the O
colloidal O
templates O
by O
calcination O
. O

Optical O
transmission O
spectra O
reveals O
the O
existence O
of O
considerable O
deep O
band O
gaps O
of O
up O
to O
70 O
% O
and O
steep O
band O
edges O
of O
up O
to O
6 O
% O
/ O
nm O
in O
the O
[ O
111 O
] O
directions O
of O
the O
3DOM O
silica B
samples O
. O

All O
the O
results O
prove O
that O
the O
sol O
- O
gel O
coassembly O
method O
with O
two O
substrates O
confinement O
is O
a O
simple O
, O
low O
cost O
, O
convenient O
and O
versatile O
method O
for O
the O
fabrication O
of O
silica B
inverse O
opals O
without O
overlayers O
in O
large O
domains O
. O

This O
study O
thus O
aimed O
at O
assessing O
the O
hematological O
effects O
alteration O
of O
pyrethroid B
insecticide O
exposure O
using O
the O
experimental O
animal O
model O
. O

Objective O
: O
A O
commonly O
available O
Electric O
Mosquito O
- O
Repellent O
Liquid O
pyrethroid B
insecticide O
containing O
prallethrin O
1 O
. O
6 O
% O
w O
/ O
w O
is O
widely O
used O
for O
mosquito O
control O
in O
Saudi O
Arabia O
. O

Total O
blood O
count O
, O
blood O
indices O
of O
creatine B
kinase O
( O
CK O
) O
, O
gamma O
- O
glutamyltranspeptida O
( O
gamma O
- O
GT O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
nitric B
oxide I
( O
NO B
) O
, O
malondialdehyde B
( O
MDA B
) O
, O
interleukin O
( O
IL O
) O
- O
2 O
, O
tumor O
necrosis O
factors O
( O
TNF O
) O
alpha O
, O
alpha O
- O
fetoprotein O
( O
AFP O
) O
, O
carbohydrate B
antigen O
( O
CA O
) O
19 O
. O
9 O
and O
carcinoembrionic O
antigen O
( O
CEA O
) O
were O
assayed O

Significant O
increases O
in O
the O
levels O
of O
CK O
, O
gamma O
- O
GT O
, O
SOD O
, O
NO B
, O
MDA B
, O
AFP O
, O
IL O
- O
2 O
, O
and O
TNF O
alpha O
were O
recorded O
. O

It O
is O
also O
concluded O
that O
pyrethroid B
group O
of O
insecticide O
may O
cause O
hematological O
, O
biochemical O
, O
cytokine O
disturbances O
and O
possible O
mutagenic O
damage O
to O
the O
tissues O
. O

Vitamin B
C I
forestalls O
cigarette O
smoke O
induced O
NF O
- O
kappa O
B O
activation O
in O
alveolar O
epithelial O
cells O
. O

It O
is O
possible O
that O
vitamin B
C I
, O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
( O
CS O
) O
- O
induced O
NF O
- O
kappa O
B O
activation O
that O
involves O
degradation O
of O
I O
- O
kappa O
B O
epsilon O
and O
nuclear O
translocation O
of O
c O
- O
Rel O
/ O
p50 O
in O
alveolar O
epithelial O
cells O
. O

Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin B
C I
on O
CS O
- O
induced O
expression O
of O
NF O
- O
kappa O
B O
driven O
luciferase O
reporter O
and O
NF O
- O
kappa O
B O
binding O
at O
its O
target O
DNA O
by O
EMSA O
in O
alveolar O
epithelial O
A549 O
cells O
. O

We O
also O
examined O
the O
level O
of O
I O
- O
kappa O
B O
epsilon O
and O
sub O
- O
cellular O
distribution O
of O
c O
- O
Rel O
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE O
- O
treated O
A549 O
cells O
with O
or O
without O
vitamin B
C I
pretreatment O
. O

We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF O
- O
kappa O
B O
DNA O
binding O
, O
I O
- O
kappa O
B O
epsilon O
degradation O
and O
c O
- O
Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin B
C I
. O

To O
further O
validate O
the O
result O
, O
we O
examined O
sub O
- O
cellular O
distribution O
of O
c O
- O
Rel O
in O
lungs O
of O
CS O
- O
exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin B
C I
. O

Result O
showed O
that O
vitamin B
C I
treatment O
resulted O
in O
markedly O
reduced O
c O
- O
Rel O
nuclear O
translocation O
. O

All O
these O
results O
demonstrate O
that O
vitamin B
C I
prevents O
CS O
( O
E O
) O
- O
induced O
NF O
- O
kappa O
B O
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS O
- O
induced O
inflammatory O
diseases O
. O

Screening O
for O
polyphenols B
, O
antioxidant O
and O
antimicrobial O
activitiesof O
extracts O
from O
eleven O
Helianthemum O
taxa O
( O
Cistaceae O
) O
used O
in O
folk O
medicine O
in O
south O
- O
eastern O
Spain O
. O

Furthermore O
, O
HPLC O
analysis O
was O
performed O
for O
the O
estimation O
of O
gallic B
acid I
, O
ellagic B
acid I
, O
tannins B
and O
flavonols B
as O
marker O
compounds O
. O

The O
antioxidant O
activity O
was O
measured O
by O
employing O
the O
scavenging O
activity O
on O
DPPH B
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
) O
and O
ABTS B
( O
2 O
, O
2 O
' O
- O
azinobis O
- O
3 O
- O
ethylbenzothiazoline O
- O
6 O
- O
sulfonate O
) O
radicals O
. O

Whereas O
Helianthemum O
alypoides O
, O
Helianthemum O
cinereum O
subsp O
. O
rotundifolium O
, O
Helianthemum O
hirtum O
, O
Helianthemum O
asperum O
, O
and O
Helianthemum O
marifolium O
subsp O
. O
marifolium O
were O
characterized O
by O
the O
presence O
of O
gallic B
acid I
, O
egallic O
derivatives O
and O
ellagitannins O
; O
the O
polyphenolic O
profile O
of O
Helianthemum O
apenninum O
subsp O
. O
cavanillesianum O
, O
Helianthemum O
syriacum O
and O
Helianthemum O
polygonoides O
was O
mostly O
based O
on O

flavonoids B
. O

Helianthemum O
cinereum O
, O
Helianthemum O
alypoides O
and O
Helianthemum O
marifolium O
consistently O
presented O
the O
strongest O
radical O
scavenging O
activity O
( O
in O
water O
extracts O
EC50 O
ranges O
from O
29 O
. O
88 O
to O
38 O
. O
1 O
against O
DPPH B
and O
from O
8 O
. O
11 O
to O
20 O
. O
8 O
against O
ABTS B
, O
and O
in O
80 O
% O
MeOH B
extracts O
from O
25 O
. O
3 O
to O
31 O
. O
8 O
against O
DPPH B
and O
from O
6 O
. O
15 O
to O
8 O
. O
6 O
against O
ABTS B
) O
, O
total O
phenol O
content O
( O
> O
117mg O
GAE O
/ O
l O
) O
and O
antimicrobial O
activities O
. O

Caffeic B
Acid I
Phenethyl I
Ester I
Suppresses O
Proliferation O
and O
Survival O
of O
TW2 O
. O
6 O
Human O
Oral O
Cancer O
Cells O
via O
Inhibition O
of O
Akt O
Signaling O
. O

Caffeic B
acid I
phenethyl I
ester I
( O
CAPE B
) O
is O
a O
bioactive O
component O
extracted O
from O
honeybee O
hive O
propolis O
. O

Our O
observations O
indicated O
that O
CAPE B
treatment O
suppressed O
cell O
proliferation O
and O
colony O
formation O
of O
TW2 O
. O
6 O
human O
oral O
squamous O
cell O
carcinoma O
( O
OSCC O
) O
cells O
dose O
- O
dependently O
. O

CAPE B
treatment O
decreased O
G1 O
phase O
cell O
population O
, O
increased O
G2 O
/ O
M O
phase O
cell O
population O
, O
and O
induced O
apoptosis O
in O
TW2 O
. O
6 O
cells O
. O

Treatment O
with O
CAPE B
decreased O
protein O
abundance O
of O
Akt O
, O
Akt1 O
, O
Akt2 O
, O
Akt3 O
, O
phospho B
- O
Akt O
Ser473 O
, O
phospho B
- O
Akt O
Thr O
308 O
, O
GSK3 O
beta O
, O
FOXO1 O
, O
FOXO3a O
, O
phospho B
- O
FOXO1 O
Thr24 O
, O
phospho B
- O
FoxO3a O
Thr32 O
, O
NF O
- O
kappa O
B O
, O
phospho B
- O
NF O
- O
kappa O
B O
Ser536 O
, O
Rb O
, O
phospho B
- O
Rb O
Ser807 O
/ O

Overexpression O
of O
Akt1 O
or O
Akt2 O
in O
TW2 O
. O
6 O
cells O
rescued O
growth O
inhibition O
caused O
by O
CAPE B
treatment O
. O

Co O
- O
treating O
TW2 O
. O
6 O
cells O
with O
CAPE B
and O
5 B
- I
fluorouracil I
, O
a O
commonly O
used O
chemotherapeutic O
drug O
for O
oral O
cancers O
, O
exhibited O
additive O
cell O
proliferation O
inhibition O
. O

Our O
study O
suggested O
that O
administration O
of O
CAPE B
is O
a O
potential O
adjuvant O
therapy O
for O
patients O
with O
OSCC O
oral O
cancer O
. O

The O
halophilic O
and O
highly O
halotolerant O
bacterium O
Chromohalobacter O
salexigens O
is O
able O
to O
grow O
up O
to O
3 O
M O
NaCl B
in O
a O
minimal O
medium O
due O
to O
the O
de O
novo O
synthesis O
of O
ectoines O
. O

Metabolism O
of O
C O
. O
salexigens O
is O
more O
efficient O
at O
high O
salinity O
than O
at O
low O
salinity O
, O
as O
reflected O
by O
lower O
glucose B
consumption O
, O
lower O
metabolite O
overflow O
and O
higher O
biomass O
yield O
. O

At O
low O
salinity O
, O
by O
- O
products O
( O
mainly O
gluconate B
, O
pyruvate B
and O
acetate B
) O
accumulate O
extracellularly O
. O

Using O
[ O
1 O
- O
13C O
] O
- O
, O
[ O
2 O
- O
13C O
] O
- O
, O
[ O
6 O
- O
13C O
] O
- O
and O
[ O
U O
- O
13C6 O
] O
- O
glucose O
as O
carbon B
sources O
, O
we O
were O
able O
to O
determine O
the O
main O
central O
metabolic O
pathways O
involved O
in O
ectoines O
biosynthesis O
from O
glucose B
. O

C O
. O
salexigens O
uses O
the O
Entner O
- O
Doudoroff O
pathway O
rather O
than O
the O
standard O
glycolytic O
pathway O
for O
glucose B
catabolism O
, O
and O
anaplerotic O
activity O
is O
high O
to O
replenish O
the O
TCA O
cycle O
with O
the O
intermediaries O
withdrawn O
for O
ectoines O
biosynthesis O
. O

Potent O
and O
selective O
: O
The O
unique O
nature O
of O
the O
ATP B
binding O
pocket O
structure O
of O
Pim O
family O
protein O
kinases O
( O
PKs O
) O
was O
used O
for O
the O
development O
of O
bisubstrate O
inhibitors O
and O
a O
fluorescent O
probe O
with O
sub O
- O
nanomolar O
affinity O
. O

Conjugates O
of O
arginine B
- O
rich O
peptides O
with O
two O
ATP B
mimetic O
scaffolds O
were O
synthesized O
and O
tested O
as O
inhibitors O
of O
Pim O
- O
1 O
. O

In O
Vitro O
Activity O
of O
Paclitaxel B
- O
Loaded O
Polymeric O
Expansile O
Nanoparticles O
in O
Breast O
Cancer O
Cells O
. O

Through O
a O
series O
of O
in O
vitro O
studies O
, O
the O
essential O
steps O
for O
intracellular O
drug O
delivery O
of O
paclitaxel B
using O
a O
pH O
- O
responsive O
nanoparticle O
system O
have O
been O
investigated O
in O
breast O
cancer O
cells O
. O

We O
successfully O
encapsulated O
paclitaxel B
within O
polymeric O
expansile O
nanoparticles O
( O
Pax O
- O
eNPs O
) O
at O
5 O
% O
loading O
via O
a O
miniemulsion O
polymerization O
procedure O
. O

The O
ability O
of O
the O
encapsulated O
paclitaxel B
to O
reach O
the O
cytoplasm O
was O
also O
observed O
using O
confocal O
microscopy O
and O
fluorescently O
labeled O
paclitaxel B
. O

Though O
the O
alpha O
- O
LNA O
substituent O
has O
been O
proposed O
to O
mimic O
deoxyribose O
sugar B
in O
its O
conformational O
properties O
, O
the O
fully O
modified O
duplex O
was O
found O
to O
exhibit O
unique O
structural O
and O
dynamic O
properties O
with O
respect O
to O
the O
other O
three O
nucleic O
acid O
structures O
. O

M O
Frederick O
Hawthorne O
is O
a O
world O
- O
renowned O
scientist O
in O
the O
field O
of O
molecular O
medicine O
and O
a O
pioneer O
in O
boron B
chemistry O
. O

Hawthorne O
spoke O
to O
Future O
Medicinal O
Chemistry O
on O
how O
he O
became O
involved O
in O
the O
field O
, O
the O
future O
of O
boron B
neutron O
capture O
therapy O
, O
and O
provides O
his O
advice O
for O
the O
next O
generation O
of O
boron B
scientists O
. O

Boron B
chemicals O
in O
diagnosis O
and O
therapeutics O
. O

Advances O
in O
the O
field O
of O
boron B
chemistry O
have O
expanded O
the O
application O
of O
boron B
from O
material O
use O
to O
medicine O
. O

Boron B
- O
based O
drugs O
represent O
a O
new O
class O
of O
molecules O
that O
possess O
several O
biomedical O
applications O
including O
use O
as O
imaging O
agents O
for O
both O
optical O
and O
nuclear O
imaging O
as O
well O
as O
therapeutic O
agents O
with O
anticancer O
, O
antiviral O
, O
antibacterial O
, O
antifungal O
and O
other O
disease O
- O
specific O
activities O
. O

For O
example O
, O
bortezomib B
( O
Velcade O
( O
( O
R O
) O
) O
) O
, O
the O
only O
drug O
in O
clinical O
use O
with O
boron B
as O
an O
active O
element O
, O
was O
approved O
in O
2003 O
as O
a O
proteasome O
inhibitor O
for O
the O
treatment O
of O
multiple O
myeloma O
and O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Several O
other O
boron B
- O
based O
compounds O
are O
in O
various O
phases O
of O
clinical O
trials O
, O
which O
illustrates O
the O
promise O
of O
this O
approach O
for O
medicinal O
chemists O
working O
in O
the O
area O
of O
boron B
chemistry O
. O

It O
is O
expected O
that O
in O
the O
near O
future O
, O
several O
boron B
- O
containing O
drugs O
should O
become O
available O
in O
the O
market O
with O
better O
efficacy O
and O
potency O
than O
existing O
drugs O
. O

This O
article O
discusses O
the O
current O
status O
of O
the O
development O
of O
boron B
- O
based O
compounds O
as O
diagnostic O
and O
therapeutic O
agents O
in O
humans O
. O

Boronated O
carbohydrate O
derivatives O
as O
potential O
boron B
neutron O
capture O
therapy O
reagents O
. O

Boron B
neutron O
capture O
therapy O
is O
a O
binary O
approach O
for O
cancer O
treatment O
that O
is O
particularly O
attractive O
in O
treating O
high O
- O
grade O
gliomas O
and O
metastatic O
brain O
tumors O
. O

Among O
the O
types O
of O
boron B
- O
containing O
molecules O
used O
as O
boron B
neutron O
capture O
therapy O
agents O
, O
boronated O
carbohydrate O
derivatives O
have O
received O
significant O
attention O
because O
of O
their O
preferential O
uptake O
by O
growing O
tumor O
cells O
. O

This O
review O
provides O
a O
summary O
of O
the O
recent O
developments O
in O
the O
chemistry O
of O
carborane B
- O
containing O
carbohydrates B
. O

We O
recently O
reported O
that O
dispersing O
citrate B
- O
capped O
gold O
nanoparticles O
( O
AuNPs O
) O
in O
polymers O
such O
as O
polyethylene B
glycol I
( O
PEG B
) O
can O
achieve O
such O
a O
goal O
due O
to O
contributions O
from O
depletion O
stabilization O
. O

Since O
AuNPs O
can O
weakly O
adsorb O
PEG B
to O
exert O
steric O
stabilization O
and O
the O
remaining O
citrate B
can O
impart O
charge O
stabilization O
, O
the O
extent O
of O
the O
contribution O
of O
depletion O
stabilization O
is O
unclear O
. O

This O
is O
achieved O
by O
coating O
AuNPs O
with O
a O
layer O
of O
thiolated O
compound O
, O
which O
inhibits O
the O
adsorption O
of O
PEG B
and O
also O
allows O
the O
control O
of O
surface O
charge O
. O

The O
size O
of O
both O
AuNPs O
and O
PEG B
was O
systematically O
varied O
and O
the O
trend O
was O
compared O
with O
theoretical O
calculations O
. O

In O
this O
work O
we O
used O
RcLPS O
( O
consisting O
of O
lipid O
A O
plus O
the O
first O
seven O
sugars B
of O
the O
core O
polysaccharide O
) O
from O
a O
rough O
strain O
of O
E O
. O
coli O
to O
form O
stable O
monolayers O
of O
LPS O
at O
the O
air O
- O
liquid O
interface O
. O

It O
was O
found O
that O
RcLPS O
monolayers O
at O
surface O
pressures O
of O
20 O
mN O
m O
( O
- O
1 O
) O
and O
above O
are O
resolved O
as O
hydrocarbon B
tails O
, O
an O
inner O
headgroup O
and O
an O
outer O
headgroup O
of O
polysaccharide O
with O
increasing O
solvation O
from O
tails O
to O
outer O
headgroups O
. O

The O
lateral O
organization O
of O
the O
hydrocarbon B
lipid O
chains O
displays O
an O
oblique O
hexagonal O
unit O
cell O
at O
all O
surface O
pressures O
, O
with O
only O
the O
chain O
tilt O
angle O
changing O
with O
surface O
pressure O
. O

Probing O
the O
Role O
of O
the O
Vancomycin B
E O
- O
Ring O
Aryl O
Chloride O
: O
Selective O
Divergent O
Synthesis O
and O
Evaluation O
of O
Alternatively O
Substituted O
E O
- O
Ring O
Analogues O
. O

The O
selective O
functionalization O
of O
a O
vancomycin B
aglycon O
derivative O
through O
direct O
conversion O
of O
the O
E O
- O
ring O
aryl O
chloride O
to O
a O
reactive O
boronic O
acid O
, O
and O
its O
use O
in O
the O
synthesis O
of O
a O
systematic O
series O
of O
vancomycin B
E O
- O
ring O
analogues O
are O
described O
. O

The O
series O
of O
analogues O
was O
used O
to O
examine O
the O
impact O
of O
the O
E O
- O
ring O
chloride O
in O
binding O
D B
- I
Ala I
- I
D I
- I
Ala I
and O
on O
antimicrobial O
activity O
. O

In O
contrast O
to O
the O
reduced O
activity O
of O
the O
unsubstituted O
E O
- O
ring O
derivatives O
, O
hydrophobic O
and O
relatively O
non O
- O
polar O
substituents O
approach O
or O
match O
the O
chloro O
substituted O
vancomycin O
and O
was O
insensitive O
to O
the O
electronic O
character O
of O
the O
substituent O
( O
e O
. O
g O
. O
Cl B
vs O
CN O
or O
OMe O
) O
, O
whereas O
highly O
polar O
substituents O
fail O
to O
provide O
the O
enhancements O
. O

Moreover O
, O
the O
active O
permethylated O
vancomycin B
aglycon O
derivatives O
examined O
exhibit O
VanB O
VRE O
antimicrobial O
activity O
at O
levels O
that O
approach O
( O
typically O
within O
2 O
- O
fold O
) O
their O
activity O
against O
sensitive O
bacteria O
. O

The O
robust O
borylation O
reaction O
also O
enabled O
the O
selective O
functionalization O
of O
a O
minimally O
protected O
vancomycin B
aglycon O
( O
N O
- O
Boc O
vancomycin B
aglycon O
) O
, O
and O
provides O
a O
direct O
method O
for O
the O
preparation O
of O
previously O
inaccessible O
analogues O
. O

Expression O
of O
WWOX O
and O
FHIT O
is O
downregulated O
by O
exposure O
to O
arsenite B
in O
human O
uroepithelial O
cells O
. O

Ecological O
studies O
in O
Taiwan O
, O
Chile O
, O
Argentina O
, O
Bangladesh O
, O
and O
Mexico O
have O
confirmed O
significant O
dose O
- O
dependent O
associations O
between O
ingestion O
of O
arsenic B
- O
contaminated O
drinking O
water O
and O
the O
risk O
of O
various O
human O
malignancies O
. O

However O
, O
the O
effect O
of O
arsenite B
on O
the O
expressions O
and O
molecular O
mechanisms O
of O
these O
markers O
is O
still O
unclear O
. O

The O
aims O
of O
this O
study O
were O
( O
i O
) O
to O
observe O
the O
expression O
of O
ATR O
, O
WWOX O
and O
FHIT O
proteins O
in O
urothelial O
carcinoma O
( O
UC O
) O
between O
endemic O
and O
non O
- O
endemic O
areas O
of O
blackfoot O
disease O
( O
BFD O
) O
by O
immunohistochemical O
analyses O
; O
( O
ii O
) O
to O
compare O
expression O
of O
these O
genes O
between O
arsenite B
- O
treated O
SV O
- O
HUC O
- O
1 O
human O
epithelial O
cells O
and O
rat O
uroepithelial O
cells O
; O
and O
( O
iii O
) O
to O
determine O
the O
role O
of O
DNMT O
and O
MEK O
inhibitors O
on O
expressions O
of O
WWOX O
and O
FHIT O

in O
response O
to O
arsenite B
in O
SV O
- O
HUC O
- O
1 O
. O

In O
fact O
, O
the O
results O
for O
the O
arsenite B
- O
treated O
groups O
showed O
that O
ATR O
, O
WWOX O
and O
FHIT O
are O
downregulated O
by O
arsenite B
in O
SV O
- O
HUC O
- O
1 O
. O

However O
, O
the O
inhibitors O
suppressed O
the O
effects O
of O
arsenite B
on O
WWOX O
and O
FHIT O
proteins O
and O
mRNA O
expression O
. O

These O
findings O
confirm O
that O
dysregulations O
of O
these O
markers O
may O
contribute O
to O
arsenite B
- O
induced O
carcinogenesis O
. O

Nicotine B
does O
not O
account O
for O
the O
CSE O
stimulation O
of O
VEGF O
in O
HFL O
- O
1 O
. O

TCDD B
exposure O
has O
various O
toxic O
effects O
on O
in O
the O
human O
nervous O
system O
resulting O
in O
various O
developmental O
and O
behavioral O
deficits O
. O

However O
the O
underlying O
molecular O
mechanism O
of O
TCDD B
- O
induced O
adverse O
effects O
on O
the O
CNS O
and O
associated O
signaling O
pathways O
remains O
largely O
unknown O
. O

Herein O
we O
analyzed O
acute O
TCDD B
exposure O
in O
the O
rat O
brain O
cortex O
to O
investigate O
whether O
misregulation O
of O
the O
Wnt O
/ O
beta O
- O
catenin O
signaling O
pathway O
plays O
a O
role O
in O
neurotoxicity O
. O

Western O
blot O
and O
immunohistochemical O
experiments O
revealed O
a O
significant O
down O
- O
regulation O
of O
beta O
- O
catenin O
and O
phospho O
- O
glycogen O
synthase O
kinase O
- O
3 O
beta O
( O
pSer9 O
- O
GSK O
- O
3 O
beta O
) O
after O
TCDD B
exposure O
. O

TUNEL O
assay O
results O
showed O
apoptosis O
occurs O
mainly O
at O
day O
7 O
after O
TCDD B
treatment O
. O

Immunofluorescent O
labeling O
indicated O
that O
beta O
- O
catenin O
was O
localized O
mainly O
in O
the O
neurons O
; O
co O
- O
localization O
of O
beta O
- O
catenin O
and O
active O
caspase O
- O
3 O
was O
found O
following O
TCDD B
exposure O
. O

Further O
, O
TCDD B
exposure O
decreased O
the O
level O
of O
pSer9 O
- O
GSK O
- O
3 O
beta O
and O
beta O
- O
catenin O
, O
and O
increased O
apoptosis O
in O
the O
PC12 O
neuronal O
cell O
line O
in O
a O
dose O
- O
dependent O
manner O
. O

Interestingly O
the O
application O
of O
lithium O
chloride O
, O
a O
GSK O
- O
3 O
beta O
inhibitor O
, O
reversed O
the O
suppressive O
effect O
of O
TCDD B
on O
beta O
- O
catenin O
in O
PC12 O
cells O
and O
primary O
cortical O
neurons O
restoring O
cell O
viability O
and O
protecting O
cells O
from O
apoptosis O
as O
compared O
to O
untreated O
controls O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
the O
canonical O
Wnt O
/ O
beta O
- O
catenin O
signaling O
pathway O
may O
play O
an O
important O
role O
in O
TCDD B
- O
induced O
neurotoxicity O
and O
neuronal O
apoptosis O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
explore O
the O
effectiveness O
and O
the O
material O
basis O
of O
XXD O
in O
trinitrobenzene B
sulfonic I
acid I
( O
TNBS O
) O
- O
induced O
UC O
rats O
. O

Efficacy O
of O
XXD O
was O
positively O
related O
with O
AUC O
of O
five O
plasma O
compounds O
( O
baicalin B
, O
berberine B
, O
wogonoside O
, O
wogonin O
, O
and O
rhein O
) O
and O
concentrations O
of O
six O
colon O
tissue O
compounds O
( O
coptisine O
, O
jatrorrhizine O
, O
palmatine B
, O
berberine B
, O
baicalein B
and O
emodin B
) O
, O
respectively O
. O

RESULTS O
: O
MTT B
and O
colony O
formation O
assays O
showed O
that O
AC O
induced O
a O
dose O
- O
dependent O
reduction O
in O
SKOV O
- O
3 O
cell O
growth O
. O

Immunoblot O
analysis O
demonstrated O
that O
HER O
- O
2 O
/ O
neu O
activity O
and O
tyrosine B
phosphorylation O
were O
significantly O
inhibited O
by O
AC O
. O

An O
increase O
in O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
was O
observed O
in O
AC O
- O
treated O
cells O
, O
whereas O
the O
antioxidant O
N B
- I
acetylcysteine I
( O
NAC B
) O
prevented O
AC O
- O
induced O
cell O
death O
, O
HER O
- O
2 O
/ O
neu O
depletion O
, O
PI3K O
/ O
Akt O
inactivation O
, O
and O
Bcl O
- O
2 O
/ O
Bax O
dysregulation O
, O
indicating O
that O
AC O
- O
induced O
cell O
death O
was O
mediated O
by O
ROS O
generation O
. O

Comparative O
effectiveness O
of O
dabigatran B
, O
rivaroxaban B
, O
apixaban B
and O
warfarin B
in O
the O
management O
of O
patients O
with O
non O
- O
valvular O
atrial O
fibrillation O
. O

Alternative O
anticoagulants O
to O
warfarin B
( O
dabigatran B
, O
rivaroxaban B
and O
apixaban B
) O
are O
becoming O
available O
for O
the O
prevention O
of O
thromboembolic O
stroke O
in O
atrial O
fibrillation O
, O
but O
there O
is O
a O
lack O
of O
information O
on O
their O
comparative O
effectiveness O
. O

Over O
a O
lifetime O
, O
apixaban B
, O
dabigatran B
and O
rivaroxaban B
accrued O
0 O
. O
130 O
( O
95 O
% O
central O
range O
[ O
CR O
] O
- O
0 O
. O
030 O
to O
0 O
. O
264 O
) O
, O
0 O
. O
106 O
( O
95 O
% O
CR O
- O
0 O
. O
048 O
to O
0 O
. O
248 O
) O
and O
0 O
. O
095 O
( O
95 O
% O
CR O
- O
0 O
. O
052 O
to O
0 O
. O
242 O
) O
more O
quality O
- O
adjusted O
life O
- O
years O
than O
warfarin B
, O
respectively O
, O
with O
apixaban B
having O
a O
55 O
% O
probability O
of O
accruing O
the O
highest O
total O
lifetime O
QALYs O
. O

In O
the O
absence O
of O
a O
definitive O
trial O
, O
and O
acknowledging O
the O
limitations O
of O
an O
indirect O
comparison O
, O
the O
available O
evidence O
suggests O
apixaban B
to O
be O
the O
more O
effective O
anticoagulant O
. O
Clinical O
Pharmacology O
& O
Therapeutics O
( O
2013 O
) O
; O
accepted O
article O
preview O
online O
25 O
April O
2013 O
; O
doi O
: O
10 O
. O
1038 O
/ O
clpt O
. O
2013 O
. O
83 O
. O

Tandutinib O
( O
MLN518 O
/ O
CT53518 O
) O
targeted O
to O
stem O
- O
like O
cells O
by O
inhibiting O
the O
function O
of O
ATP B
- O
binding O
cassette O
subfamily O
G O
member O
2 O
. O

Tandutinib O
is O
a O
novel O
inhibitor O
of O
tyrosine B
kinases O
FLT3 O
, O
PDGFR O
and O
KIT O
. O

Tandutinib O
reversed O
ABCG2 O
- O
mediated O
drug O
resistance O
in O
ABCG2 O
- O
482 O
- O
R2 O
, O
ABCG2 O
- O
482 O
- O
G2 O
, O
ABCG2 O
- O
482 O
- O
T7 O
and O
S1 O
- O
M1 O
- O
80 O
cells O
and O
increased O
the O
accumulation O
of O
doxorubicin B
, O
rhodamine O
123 O
and O
[ O
H O
( O
3 O
) O
] O
mitoxantrone O
in O
ABCG2 O
- O
overexpressing O
cells O
. O

Importantly O
, O
tandutinib O
selectively O
sensitized O
side O
population O
cells O
to O
mitoxantrone B
. O

Rapamycin B
allosterically O
inhibits O
the O
proteasome O
. O

Rapamycin B
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro O
- O
apoptotic O
activities O
. O

We O
found O
that O
in O
vitro O
rapamycin B
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin O
- O
proteasome O
pathway O
. O

Rapamycin B
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O

A O
treatment O
with O
rapamycin B
affects O
conformational O
dynamics O
of O
the O
proteasomal O
gate O
, O
a O
centrally O
positioned O
within O
the O
alpha O
face O
and O
allosterically O
regulated O
element O
responsible O
for O
the O
intake O
of O
substrates O
. O

Interestingly O
, O
we O
showed O
that O
rapamycin B
shares O
all O
the O
proteasome O
targeting O
properties O
not O
only O
with O
other O
two O
- O
domain O
, O
closed O
- O
ring O
analogs O
( O
rapalogs O
) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco O
- O
rapamycin O
. O

The O
latter O
is O
the O
first O
in O
vivo O
open O
- O
ring O
metabolite O
of O
rapamycin B
that O
does O
not O
affect O
mTOR O
. O

We O
hypothesize O
that O
the O
rapamycin B
and O
related O
compounds O
bind O
to O
the O
alpha O
face O
and O
allosterically O
impact O
the O
proteasome O
function O
. O

The O
implications O
of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin B
and O
for O
design O
of O
novel O
allosteric O
drugs O
targeting O
the O
proteasome O
are O
discussed O
. O

Insulin O
- O
like O
growth O
factor O
1 O
( O
IGF O
- O
1 O
) O
expression O
is O
up O
- O
regulated O
in O
lymphoblastoid O
cell O
lines O
of O
lithium B
responsive O
bipolar O
disorder O
patients O
. O

Among O
mood O
stabilizers O
, O
lithium B
is O
the O
mainstay O
for O
the O
treatment O
of O
BD O
, O
with O
approximately O
one O
- O
third O
of O
patients O
showing O
remission O
from O
episode O
recurrence O
. O

While O
there O
is O
evidence O
suggesting O
genetic O
load O
for O
lithium B
response O
in O
BD O
, O
its O
molecular O
underpinnings O
are O
still O
not O
completely O
understood O
. O

To O
identify O
genes O
potentially O
involved O
in O
( O
or O
correlated O
with O
) O
lithium B
response O
, O
we O
carried O
out O
a O
genome O
- O
wide O
expression O
analysis O
on O
lymphoblastoid O
cell O
lines O
( O
LCLs O
) O
from O
10 O
BD O
patients O
responders O
( O
R O
) O
and O
10 O
non O
- O
responders O
( O
NR O
) O
to O
lithium B
. O

We O
compared O
expression O
levels O
of O
the O
two O
groups O
and O
tested O
whether O
in O
vitro O
lithium B
treatment O
had O
different O
effects O
in O
LCLs O
of O
R O
compared O
to O
NR O
. O

At O
basal O
, O
2060 O
genes O
were O
differentially O
expressed O
between O
R O
and O
NR O
while O
no O
genes O
were O
differentially O
regulated O
by O
lithium B
in O
the O
two O
groups O
. O

Our O
findings O
suggest O
that O
IGF O
- O
1 O
may O
be O
involved O
in O
lithium B
response O
, O
supporting O
further O
investigation O
on O
its O
potential O
as O
a O
biomarker O
. O

Polymorphism O
in O
porphyrin B
monolayers O
: O
the O
relation O
between O
adsorption O
configuration O
and O
molecular O
conformation O
. O

Self O
- O
assembled O
monolayers O
of O
meso O
- O
5 O
, O
10 O
, O
15 O
, O
20 O
- O
tetrakis O
( O
undecyl O
) O
porphyrin O
copper O
( O
ii O
) O
on O
a O
graphite B
/ O
1 O
- O
octanoic O
acid O
interface O
have O
been O
studied O
by O
Scanning O
Tunnelling O
Microscopy O
. O

The O
monolayers O
are O
not O
commensurate O
, O
but O
coincident O
with O
the O
underlying O
graphite B
substrate O
. O

The O
seamless O
transition O
between O
the O
polymorphs O
is O
proposed O
to O
be O
the O
result O
of O
an O
adaptation O
of O
the O
molecular O
conformations O
in O
the O
polymorphs O
and O
at O
the O
boundaries O
, O
which O
is O
enabled O
by O
the O
conformational O
freedom O
of O
the O
alkyl B
tails O
of O
these O
molecules O
. O

Chip O
- O
scale O
Mid O
- O
Infrared O
chemical O
sensors O
using O
air O
- O
clad O
pedestal O
silicon B
waveguides O
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon B
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C B
- I
H I
, O
N B
- I
H I
, O
O B
- I
H I
, O
C B
- I
C I
, O
N O
- O
O O
, O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
, O
and O
C B
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N B
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

To O
extend O
light O
transmission O
beyond O
lambda O
= O
3 O
. O
7 O
mu O
m O
, O
a O
spectral O
region O
where O
a O
typical O
silicon O
dioxide O
under O
- O
clad O
is O
absorbing O
, O
we O
fabricate O
a O
unique O
air O
- O
clad O
silicon B
pedestal O
waveguide O
. O

For O
instance O
, O
we O
show O
that O
when O
testing O
at O
lambda O
= O
3 O
. O
55 O
mu O
m O
, O
the O
Mid O
- O
IR O
sensor O
can O
distinguish O
hexane B
from O
the O
rest O
of O
the O
tested O
analytes O
( O
methanol B
, O
toluene B
, O
carbon B
tetrachloride I
, O
ethanol B
and O
acetone B
) O
, O
since O
hexane B
has O
a O
strong O
absorption O
from O
the O
aliphatic O
C B
- I
H I
stretch O
at O
lambda O
= O
3 O
. O
55 O
mu O
m O
. O

Analogously O
, O
applying O
the O
same O
technique O
at O
lambda O
= O
3 O
. O
3 O
mu O
m O
, O
the O
Mid O
- O
IR O
sensor O
is O
able O
to O
determine O
the O
concentration O
of O
toluene B
dissolved O
in O
carbon B
tetrachloride I
, O
because O
toluene B
has O
a O
strong O
absorption O
at O
lambda O
= O
3 O
. O
3 O
mu O
m O
from O
the O
aromatic O
C B
- I
H I
stretch O
. O

With O
our O
demonstration O
of O
an O
air O
- O
clad O
silicon B
pedestal O
waveguide O
sensor O
, O
we O
move O
closer O
towards O
the O
ultimate O
goal O
of O
an O
ultra O
- O
compact O
portable O
spectrometer O
- O
on O
- O
a O
- O
chip O
. O

METHODS O
: O
Adult O
gerbils O
were O
treated O
with O
MNU O
alone O
or O
associated O
with O
testosterone B
for O
3 O
or O
6 O
months O
of O
treatment O
. O

Lesions O
clearly O
progressed O
from O
a O
premalignant O
to O
a O
malignant O
phenotype O
over O
time O
and O
tumor O
latency O
was O
decreased O
by O
MNU O
+ O
testosterone B
administration O
. O

The O
Effect O
of O
BCRP O
, O
MDR1 O
and O
OATP1B3 O
on O
the O
Antitumor O
Efficacy O
of O
the O
Lipophilic O
Camptothecin B
AR O
- O
67 O
In O
Vitro O
. O

AR O
- O
67 O
is O
a O
lipophilic O
camptothecin B
analogue O
, O
currently O
under O
early O
stage O
clinical O
trials O
. O

Using O
cell O
lines O
expressing O
the O
aforementioned O
transporters O
, O
we O
showed O
that O
the O
lipophilic O
AR O
- O
67 O
lactone B
form O
is O
a O
substrate O
for O
efflux O
transporters O
BCRP O
and O
MDR1 O
. O

Additionally O
, O
OATP1B1 O
and O
OATP1B3 O
facilitated O
the O
uptake O
of O
AR O
- O
67 O
carboxylate B
in O
SLCO1B1 O
and O
SLCO1B3 O
- O
transfected O
cell O
systems O
compared O
to O
the O
mock O
- O
transfected O
ones O
. O

Notably O
, O
both O
BCRPand O
MDR1 O
, O
conferred O
resistance O
to O
AR O
- O
67 O
lactone B
. O

Prompted O
by O
recent O
studies O
showing O
increased O
OATP1B3 O
expression O
in O
certain O
cancer O
types O
, O
we O
investigated O
the O
effect O
of O
OATP1B3 O
expression O
on O
cell O
viability O
after O
exposure O
to O
AR O
- O
67 O
carboxylate B
. O

OATP1B3 O
expressing O
cells O
had O
increased O
carboxylate B
uptake O
as O
compared O
to O
mock O
transfected O
cells O
, O
but O
were O
not O
sensitized O
because O
the O
intracellular O
amount O
of O
lactone B
was O
fifty O
- O
fold O
higher O
than O
that O
of O
carboxylate B
and O
comparable O
between O
OATP1B3 O
expressing O
and O
non O
- O
expressing O
cells O
. O

In O
conclusion O
, O
BCRP O
- O
and O
MDR1 O
- O
mediated O
efflux O
of O
AR O
- O
67 O
lactone B
confers O
resistance O
to O
AR O
- O
67 O
, O
but O
OATP1B3 O
- O
mediated O
uptake O
of O
the O
AR O
- O
67 O
carboxylate B
does O
not O
sensitize O
OATP1B3 O
expressing O
tumor O
cells O
. O

Fetal O
renal O
excretion O
of O
sodium B
was O
increased O
while O
urine O
volume O
decreased O
in O
HSD O
group O
. O

Fetal O
blood O
urea B
nitrogen B
was O
increased O
, O
while O
kidney O
/ O
body O
weight O
ratio O
decreased O
in O
HSD O
group O
. O

Magnetic O
Porous O
Sugar B
- O
Functionalized O
PEG B
Microgels O
for O
Efficient O
Isolation O
and O
Removal O
of O
Bacteria O
from O
Solution O
. O

We O
apply O
highly O
porous O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
microparticles O
and O
functionalize O
them O
introducing O
both O
sugar B
ligands O
for O
specific O
bacteria O
targeting O
and O
cationic O
moieties O
for O
electrostatic O
loading O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
. O

The O
resulting O
magnetic O
, O
porous O
, O
sugar O
- O
functionalized O
( O
MaPoS O
) O
PEG B
microgels O
are O
able O
to O
selectively O
bind O
and O
discriminate O
between O
different O
strains O
of O
bacteria O
Escherichia O
coli O
. O

Such O
incretin O
- O
based O
therapies O
offer O
some O
advantages O
over O
other O
glucose B
- O
lowering O
agents O
, O
but O
might O
be O
associated O
with O
an O
increased O
risk O
of O
acute O
pancreatitis O
. O

Areas O
covered O
: O
An O
extensive O
literature O
search O
was O
performed O
to O
analyze O
clinical O
cases O
of O
acute O
pancreatitis O
reported O
in O
the O
literature O
or O
to O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
, O
in O
randomized O
clinical O
trials O
, O
and O
in O
observational O
studies O
with O
five O
DPP O
- O
4 O
inhibitors O
: O
sitagliptin B
, O
vildagliptin B
, O
saxagliptin O
, O
alogliptin B
, O
and O
linagliptin O
. O

Several O
anecdotal O
clinical O
cases O
of O
pancreatitis O
have O
been O
reported O
with O
sitagliptin B
and O
vildagliptin B
and O
an O
increased O
relative O
risk O
reported O
to O
the O
FDA O
with O
sitagliptin B
versus O
other O
comparators O
, O
but O
reporting O
bias O
cannot O
be O
excluded O
. O

In O
rather O
short O
- O
term O
clinical O
trials O
with O
well O
- O
selected O
diabetic O
patients O
, O
no O
increased O
risk O
of O
acute O
pancreatitis O
has O
been O
observed O
with O
any O
of O
the O
five O
commercialized O
DPP O
- O
4 O
inhibitors O
: O
sitagliptin B
, O
vildagliptin B
, O
saxagliptin O
, O
alogliptin B
, O
and O
linagliptin O
. O

Similarly O
, O
real O
- O
life O
cohort O
studies O
showed O
no O
increased O
incidence O
of O
pancreatitis O
with O
gliptins O
compared O
with O
other O
glucose B
- O
lowering O
agents O
, O
a O
finding O
recently O
challenged O
by O
a O
case O
- O
control O
study O
. O

Insertion O
of O
CO2 B
and O
COS O
into O
Bi O
- O
C O
Bonds O
: O
Reactivity O
of O
a O
Bismuth O
NCN O
Pincer O
Complex O
of O
an O
Oxyaryl O
Dianionic O
Ligand O
, O
[ O
2 O
, O
6 O
- O
( O
Me2NCH2 O
) O
2C6H3 O
] O
Bi O
( O
C6H2tBu2O O
) O
. O

The O
first O
insertion O
reactions O
of O
CO2 B
and O
COS O
into O
Bi O
- O
C O
bonds O
are O
observed O
with O
this O
oxyaryl O
dianionic O
ligand O
complex O
. O

Silyl O
halides O
and O
pseudohalides O
, O
R3SiX O
( O
X O
= O
Cl B
, O
CN O
, O
N3 B
; O
R O
= O
Me B
, O
Ph B
) O
, O
react O
with O
1 O
by O
attaching O
X O
to O
bismuth B
and O
R3Si O
to O
the O
oxyaryl O
oxygen B
to O
form O
Ar O
' O
Bi O
( O
X O
) O
( O
C6H2tBu2 O
- O
3 O
, O
5 O
- O
OSiR3 O
- O
4 O
) O
complexes O
, O
a O
formal O
addition O
across O
five O
bonds O
. O

The O
reaction O
of O
1 O
with O
I2 O
forms O
Ar O
' O
BiI2 O
and O
the O
coupled O
quinone B
, O
3 O
, O
3 O
' O
, O
5 O
, O
5 O
' O
- O
tetra O
- O
tert O
- O
butyl O
- O
4 O
, O
4 O
' O
- O
diphenoquinone O
, O
by O
oxidative O
coupling O
. O

High O
- O
Accuracy O
Estimates O
for O
the O
Vinylidene O
- O
Acetylene B
Isomerization O
Energy O
and O
the O
Ground O
State O
Rotational O
Constants O
of O
: O
C O
= O
CH2 O
. O

Highly O
accurate O
calculations O
are O
reported O
for O
properties O
of O
vinylidene O
( O
H2C O
= O
C O
: O
) O
, O
specically O
the O
position O
of O
its O
zero O
- O
point O
vibrational O
level O
relative O
to O
that O
of O
acetylene B
and O
its O
equilibrium O
structure O
and O
ground O
state O
rotational O
constants O
. O

In O
addition O
, O
the O
thermochemical O
calculations O
presented O
here O
also O
allow O
a O
determination O
of O
the O
: O
C O
= O
CH2 O
bond O
energy O
of O
the O
vinyl B
radical O
at O
the O
HEAT O
- O
345 O
( O
Q O
) O
level O
of O
theory O
, O
which O
is O
77 O
. O
70 O
. O
3 O
kcal O
mol1 O
. O

Atomic O
- O
Scale O
Interfacial O
Band O
Mapping O
across O
Vertically O
Phased O
- O
Separated O
Polymer O
/ O
Fullerene B
Hybrid O
Solar O
Cells O
. O

Using O
cross O
- O
sectional O
scanning O
tunneling O
microscope O
( O
XSTM O
) O
with O
samples O
cleaved O
in O
situ O
in O
an O
ultrahigh O
vacuum O
( O
UHV O
) O
chamber O
, O
this O
study O
demonstrates O
the O
direct O
visualization O
of O
high O
- O
resolution O
interfacial O
band O
mapping O
images O
across O
the O
film O
thickness O
in O
an O
optimized O
bulk O
heterojunction O
polymer O
solar O
cell O
consisting O
of O
nanoscale O
phase O
segregated O
blends O
of O
poly B
( I
3 I
- I
hexylthiophene I
) I
( O
P3HT B
) O
and O
[ O
6 O
, O
6 O
] O
- O
phenyl O
C61 O
butyric O
acid O
methyl O
ester O
( O
PCBM B
) O
. O

We O
were O
able O
to O
achieve O
the O
direct O
observation O
of O
the O
interfacial O
band O
alignments O
at O
the O
donor O
( O
P3HT B
) O
- O
acceptor O
( O
PCBM B
) O
interfaces O
and O
at O
the O
interfaces O
between O
the O
photoactive O
P3HT B
: O
PCBM B
blends O
and O
the O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
poly O
( O
styrenesulfonate O
) O
( O
PEDOT B
: O
PSS O
) O
anode O
modification O
layer O
with O
an O
atomic O
- O
scale O
spatial O
resolution O
. O

The O
unique O
advantage O
of O
using O
XSTM O
to O
characterize O
polymer O
: O
fullerene B
bulk O
heterojunction O
solar O
cells O
allows O
us O
to O
explore O
simultaneously O
the O
quantitative O
link O
between O
the O
vertical O
morphologies O
and O
their O
corresponding O
local O
electronic O
properties O
. O

Hydrazides B
/ O
Hydrazones O
as O
antimicrobial O
and O
anticancer O
agents O
in O
the O
new O
millennium O
. O

Hydrazide O
/ O
hydrazone B
derivatives O
are O
of O
quite O
interest O
for O
medicinal O
chemists O
because O
of O
their O
vast O
spectrum O
of O
biological O
activity O
. O

The O
aim O
of O
the O
present O
work O
is O
to O
collect O
literature O
reports O
focusing O
the O
antimicrobial O
and O
anticancer O
study O
of O
different O
hydrazide O
/ O
hydrazone B
derivatives O
carried O
out O
during O
the O
past O
decade O
which O
will O
serve O
as O
a O
valuable O
source O
of O
information O
for O
the O
researchers O
working O
in O
the O
field O
of O
antimicrobial O
and O
anticancer O
research O
. O

Abstract O
The O
conservative O
single O
- O
layered O
wound O
dressing O
system O
is O
decomposed O
when O
mixed O
in O
polyvinyl B
alcohol I
( O
PVA B
) O
solution O
, O
which O
means O
it O
cannot O
be O
used O
with O
a O
temperature O
- O
sensitive O
drug O
. O

The O
double O
- O
layered O
wound O
dressing O
was O
developed O
with O
PVA B
/ O
sodium O
alginate O
using O
a O
freeze O
- O
melting O
technique O
; O
one O
layer O
was O
PVA B
layer O
and O
the O
other O
was O
the O
drug O
- O
loaded O
sodium O
alginate O
layer O
. O

The O
double O
- O
layered O
wound O
dressing O
gave O
a O
similar O
gel O
fraction O
and O
Young O
' O
s O
module O
as O
single O
- O
layered O
wound O
bandages O
developed O
with O
only O
PVA B
, O
and O
a O
similar O
inflammation O
ability O
and O
WVTR O
as O
single O
- O
layered O
wound O
dressings O
developed O
with O
PVA B
and O
sodium O
alginate O
. O

Compared O
to O
the O
commercial O
product O
, O
the O
double O
- O
layered O
wound O
dressing O
comprising O
6 O
. O
7 O
% O
PVA B
, O
0 O
. O
5 O
% O
sodium O
alginate O
and O
0 O
. O
01 O
% O
AME O
significantly O
enhanced O
the O
wound O
- O
healing O
effect O
in O
the O
wound O
- O
healing O
test O
. O

Triterpenes B
from O
the O
Aerial O
Parts O
of O
Cimicifuga O
yunnanensis O
and O
Their O
Antiproliferative O
Effects O
on O
p53 O
( O
N236S O
) O
Mouse O
Embryonic O
Fibroblasts O
. O

Nine O
new O
triterpene B
derivatives O
, O
yunnanterpenes O
A O
- O
F O
( O
1 O
- O
6 O
) O
, O
15 O
, O
16 O
- O
seco O
- O
cimiterpenes O
A O
and O
B O
( O
7 O
, O
8 O
) O
, O
and O
cimilactone O
C O
( O
9 O
) O
, O
and O
15 O
known O
analogues O
( O
10 O
- O
24 O
) O
were O
isolated O
from O
the O
aerial O
parts O
of O
Cimicifuga O
yunnanensis O
. O

Two O
new O
daphnane O
- O
type O
diterpene O
esters O
, O
daphneresiniferins O
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
along O
with O
seven O
known O
diterpenes B
, O
yuanhuacine O
( O
3 O
) O
, O
yuanhuadine O
( O
4 O
) O
, O
yuanhuahine O
( O
5 O
) O
, O
genkwadaphnin O
( O
6 O
) O
, O
genkwanine O
A O
( O
7 O
) O
, O
genkwanine O
F O
( O
8 O
) O
, O
and O
genkwanine O
H O
( O
9 O
) O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
flower O
buds O
of O
Daphne O
genkwa O

Molecular O
and O
functional O
characterization O
of O
flavin B
- O
containing O
monooxygenases O
in O
cynomolgus O
macaque O
. O

Flavin B
- O
containing O
monooxygenases O
( O
FMOs O
) O
, O
drug O
- O
metabolizing O
enzymes O
essential O
for O
the O
metabolism O
of O
endogenous O
biochemicals O
and O
foreign O
compounds O
, O
have O
been O
characterized O
in O
human O
( O
including O
FMO1 O
- O
5 O
and O
FMO6P O
) O
, O
but O
remain O
to O
be O
investigated O
in O
cynomolgus O
macaque O
. O

Amino B
acid I
sequences O
of O
cynomolgus O
FMO1 O
- O
5 O
, O
respectively O
, O
shared O
high O
sequence O
identities O
( O
94 O
- O
98 O
% O
) O
and O
were O
closely O
clustered O
in O
a O
phylogenetic O
tree O
, O
with O
human O
FMO1 O
- O
5 O
. O

Cynomolgus O
FMO1 O
, O
FMO2 O
, O
FMO3 O
, O
and O
FMO5 O
metabolized O
benzydamine O
, O
and O
FMO1 O
/ O
FMO3 O
and O
FMO3 O
also O
metabolized O
methimazole B
and O
trimethylamine O
, O
respectively O
. O

Rates O
of O
benzydamine O
N B
- O
oxygenation O
( O
catalyzed O
by O
FMO3 O
) O
varied O
( O
approximately O
20 O
- O
fold O
) O
among O
the O
28 O
cynomolgus O
livers O
and O
were O
significantly O
correlated O
with O
FMO3 O
protein O
expression O
, O
indicating O
that O
the O
inter O
- O
animal O
variations O
in O
benzydamine O
N B
- O
oxygenation O
might O
be O
partly O
accounted O
for O
by O
the O
variable O
FMO3 O
expression O
. O

The O
action O
of O
piperine O
( O
the O
pungent O
component O
of O
pepper O
) O
and O
its O
derivative O
SCT O
- O
66 O
( O
( O
2E O
, O
4E O
) O
- O
5 O
- O
( O
1 O
, O
3 O
- O
benzodioxol O
- O
5 O
- O
yl O
) O
) O
- O
N O
, O
N O
- O
diisobutyl O
- O
2 O
, O
4 O
- O
pentadienamide O
) O
on O
different O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
type O
A O
( O
GABAA O
) O
receptors O
, O
transient O
- O
receptor O
- O
potential O
- O
vanilloid O
- O
1 O
( O
TRPV1 O
) O
receptors O
and O
behavioral O
effects O
were O
investigated O
. O

Modulation O
of O
GABA B
- O
induced O
chloride B
currents O
( O
IGABA O
) O
by O
piperine O
and O
SCT O
- O
66 O
and O
activation O
of O
TRPV1 O
was O
studied O
using O
the O
two O
- O
microelectrode O
- O
voltage O
- O
clamp O
technique O
and O
fast O
perfusion O
. O

Replacing O
the O
piperidine B
ring O
by O
a O
N O
- O
di O
- O
isobutyl O
residue O
( O
SCT O
- O
66 O
) O
prevents O
interactions O
with O
TRPV1 O
and O
simultaneously O
increases O
the O
potency O
and O
efficiency O
of O
GABAA O
receptor O
modulation O
. O

While O
older O
methods O
such O
as O
two O
- O
dimensional O
polyacrylamide B
electrophoresis O
continued O
to O
be O
used O
, O
a O
variety O
of O
more O
in O
- O
depth O
MS O
- O
based O
approaches O
including O
both O
label O
( O
ICAT O
, O
iTRAQ O
, O
TMT O
, O
SILAC O
, O
SILAM O
) O
, O
label O
- O
free O
( O
label O
- O
free O
, O
MRM O
, O
SWATH O
) O
and O
absolute O
quantification O
methods O
, O
are O
rapidly O
being O
applied O
to O
neurobiological O
investigations O
of O
normal O
and O
diseased O
brain O
tissue O
as O
well O
as O
of O
cerebrospinal O
fluid O
( O
CSF O
) O
. O

Maternal O
nicotine B
exposure O
during O
lactation O
alters O
hypothalamic O
neuropeptides O
expression O
in O
the O
adult O
rat O
progeny O
. O

Then O
, O
we O
evaluated O
the O
expression O
of O
pro O
- O
opiomelanocortin O
( O
POMC O
) O
, O
alpha O
- O
melanocyte O
stimulating O
hormone O
( O
alpha O
- O
MSH O
) O
, O
cocaine B
and O
amphetamine B
- O
regulated O
transcript O
( O
CART O
) O
, O
neuropeptide O
Y O
( O
NPY O
) O
, O
agouti O
- O
related O
peptide O
( O
AgRP O
) O
and O
others O
in O
different O
hypothalamic O
nuclei O
in O
order O
to O
better O
understand O
the O
mechanisms O
underlying O
the O
obese O
phenotype O
observed O
in O
these O
animals O
at O
adulthood O
. O

On O
the O
2nd O
postnatal O
day O
( O
P2 O
) O
, O
dams O
were O
subcutaneously O
implanted O
with O
osmotic O
minipumps O
releasing O
nicotine B
( O
NIC B
- O
6mg O
/ O
kg O
/ O
day O
) O
or O
saline O
for O
14days O
. O

Adult O
NIC B
offspring O
showed O
more O
intense O
NPY O
staining O
in O
the O
paraventricular O
nucleus O
( O
PVN O
) O
( O
+ O
21 O
% O
) O
and O
increased O
number O
of O
POMC O
- O
positive O
cells O
in O
the O
: O
arcuate O
nucleus O
( O
+ O
33 O
% O
) O
, O
as O
an O
increase O
in O
fiber O
density O
of O
alpha O
- O
MSH O
in O
PVN O
( O
+ O
85 O
% O
) O
. O

CRH O
staining O
was O
more O
intense O
in O
NIC B
offspring O
( O
+ O
136 O
% O
) O
. O

Thus O
, O
maternal O
nicotine B
exposure O
changes O
hypothalamic O
neuropeptides O
in O
the O
adult O
progeny O
that O
is O
partially O
compatible O
with O
leptin O
resistance O
. O

Developmental O
immunotoxicity O
in O
male O
rats O
after O
juvenile O
exposure O
to O
ethanol B
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
sensitivity O
of O
the O
developing O
immune O
system O
to O
ethanol B
( O
EtOH B
) O
after O
exposure O
from O
postnatal O
day O
( O
PND O
) O
10 O
onward O
. O

Adult O
Wistar O
dams O
and O
litters O
were O
exposed O
to O
EtOH B
via O
drinking O
water O
( O
0 O
, O
0 O
. O
25 O
, O
1 O
. O
5 O
, O
2 O
. O
75 O
, O
4 O
, O
5 O
. O
25 O
, O
or O
6 O
. O
5 O
% O
( O
w O
/ O
v O
) O
EtOH B
ad O
libitum O
) O
and O
drinking O
water O
exposure O
of O
the O
F1 O
was O
continued O
from O
weaning O
until O
sacrifice O
. O

EtOH B
exposure O
affected O
innate O
immune O
responses O
, O
such O
as O
LPS O
- O
induced O
NO B
- O
production O
by O
adherent O
splenocytes O
, O
as O
well O
as O
adaptive O
immune O
responses O
as O
represented O
by O
KLH O
- O
specific O
parameters O
. O

The O
most O
sensitive O
developmental O
parameters O
included O
effects O
on O
maternal O
and O
pup O
bodyweight O
with O
calculated O
BMDs O
of O
4 O
. O
0 O
% O
and O
4 O
. O
3 O
% O
EtOH B
, O
respectively O
. O

The O
most O
sensitive O
immune O
parameters O
were O
affected O
at O
dose O
levels O
lower O
than O
those O
affecting O
developmental O
parameters O
and O
included O
KLH O
- O
specific O
immune O
responses O
, O
LPS O
- O
induced O
NO B
production O
by O
adherent O
splenocytes O
, O
and O
IL O
- O
10 O
production O
by O
ConA O
stimulated O
splenocytes O
. O

Calculated O
BMDs O
for O
these O
parameters O
were O
between O
0 O
. O
01 O
% O
and O
0 O
. O
1 O
% O
EtOH B
. O

These O
findings O
demonstrate O
the O
relative O
sensitivity O
of O
the O
developing O
immune O
system O
for O
EtOH B
exposure O
, O
the O
additional O
value O
of O
assessing O
functional O
immune O
parameters O
, O
and O
the O
importance O
of O
the O
juvenile O
window O
in O
developmental O
immunotoxicity O
testing O
. O

Structural O
requirements O
within O
protoporphyrin B
IX I
in O
the O
inhibition O
of O
heat O
shock O
protein O
90 O
. O

Porphyrins B
are O
used O
for O
photodynamic O
therapy O
for O
their O
light O
- O
absorbing O
properties O
, O
and O
some O
of O
them O
were O
approved O
for O
the O
treatment O
of O
certain O
types O
of O
cancers O
. O

Porphyrins B
prevent O
activation O
of O
hypoxia O
inducible O
factor O
- O
1 O
alpha O
( O
HIF O
- O
1 O
alpha O
) O
by O
inhibiting O
heat O
shock O
protein O
90 O
( O
HSP90 O
) O
. O

This O
study O
investigated O
the O
structural O
requirements O
within O
protoporphyrin B
IX I
( O
PPIX B
) O
for O
the O
inhibition O
of O
HSP90 O
activity O
. O

In O
HCT116 O
, O
HT29 O
and O
DLD O
- O
1 O
cells O
, O
PPIX B
treatment O
directly O
hindered O
the O
binding O
between O
HSP90 O
and O
HIF O
- O
1 O
alpha O
; O
PPIX B
treatment O
inhibited O
the O
chaperone O
activity O
of O
HSP90 O
, O
accelerating O
protein O
degradation O
of O
HIF O
- O
1 O
alpha O
. O

In O
addition O
, O
PPIX B
treatment O
suppressed O
cancer O
cell O
migration O
, O
endothelial O
cell O
tube O
formation O
, O
and O
aortic O
ring O
sprouting O
, O
being O
consistent O
with O
its O
anti O
- O
tumor O
and O
anti O
- O
angiogenic O
activities O
. O

In O
silico O
analysis O
, O
molecular O
docking O
model O
indicated O
that O
a O
tetrapyrrole O
macrocycle O
and O
two O
propionate O
chains O
within O
PPIX B
are O
necessary O
for O
the O
binding O
to O
the O
adenosine B
triphosphate I
( O
ATP B
) O
- O
binding O
pocket O
of O
HSP90 O
. O

The O
predicted O
structural O
requirement O
was O
verified O
by O
the O
differential O
inhibitory O
effects O
of O
PPIX B
analogs O
, O
or O
the O
precursor O
of O
PPIX B
, O
on O
HIF O
- O
1 O
alpha O
; O
compounds O
lacking O
either O
the O
tetrapyrrole O
macrocycle O
or O
the O
propionate O
chains O
were O
inactive O
. O

Our O
results O
show O
that O
a O
tetrapyrrole O
macrocycle O
and O
two O
attached O
propionate O
chains O
in O
PPIX B
coordinately O
interact O
with O
the O
ATP B
- O
binding O
pocket O
of O
HSP90 O
, O
offering O
structural O
information O
on O
the O
inhibitory O
effect O
of O
porphyrins O
on O
angiogenesis O
. O

The O
PPI O
measurements O
were O
correlated O
with O
solution O
viscosity O
( O
measured O
by O
DLS O
using O
polystyrene B
nanospheres O
and O
ultrasonic O
shear O
rheology O
) O
as O
a O
function O
of O
pH O
( O
4 O
- O
9 O
) O
and O
ionic O
strength O
( O
10 O
, O
50 O
and O
150mM O
) O
. O

A O
factorial O
design O
was O
approached O
to O
assess O
the O
cytotoxicity O
of O
raw O
materials O
and O
nanoparticles O
by O
the O
metabolic O
test O
MTT B
. O

Liberation O
of O
drugs O
from O
multi O
- O
wall O
carbon B
nanotube O
carriers O
. O

This O
work O
reviews O
qualitative O
and O
quantitative O
analyses O
of O
Drug O
Delivery O
Systems O
( O
DDSs O
) O
based O
on O
multi O
- O
wall O
carbon B
nanotubes O
( O
MWCNTs O
) O
and O
their O
chemically O
modified O
analogues O
( O
mainly O
oxidised O
MWCNTs O
) O
. O

Oxidative O
damage O
induced O
by O
chlorpyrifos B
in O
the O
hepatic O
and O
renal O
tissue O
of O
Kunming O
mice O
and O
the O
antioxidant O
role O
of O
vitamin B
E I
. O

Chlorpyrifos B
is O
a O
broad O
- O
spectrum O
, O
chlorinated O
organophosphate O
pesticide O
employed O
for O
pest O
control O
in O
various O
agricultural O
and O
animal O
husbandries O
. O

We O
investigated O
neurotoxicity O
of O
CPF O
- O
treated O
mice O
, O
and O
evaluated O
the O
antioxidant O
effect O
of O
vitamin B
E I
against O
oxidative O
stress O
and O
histological O
changes O
in O
the O
livers O
and O
kidneys O
of O
CPF O
- O
treated O
mice O
. O

Kunming O
mice O
were O
divided O
randomly O
into O
five O
exposure O
groups O
of O
six O
: O
( O
A O
) O
peanut O
oil O
; O
( O
B O
) O
3mg O
/ O
kg O
CPF O
; O
( O
C O
) O
6mg O
/ O
kg O
CPF O
; O
( O
D O
) O
12mg O
/ O
kg O
CPF O
; O
( O
E O
) O
vitamin B
E I
( O
100mg O
/ O
kg O
) O
, O
3h O
after O
administration O
of O
CPF O
( O
12mg O
/ O
kg O
) O
and O
used O
as O
a O
post O
- O
treatment O
group O
. O

Oral O
administration O
of O
high O
- O
dose O
groups O
( O
12mg O
/ O
kg O
) O
CPF O
led O
to O
a O
significant O
increase O
in O
levels O
of O
reactive O
oxygen B
species O
, O
DNA O
- O
protein O
crosslinks O
, O
8 O
- O
hydroxy O
- O
2 O
- O
deoxyguanosine O
and O
malondialdehyde B
, O
decreases O
in O
acetylcholinesterase O
activity O
and O
glutathione B
level O
, O
as O
well O
as O
causing O
hepatic O
and O
renal O
histopathological O
change O
. O

Except O
for O
AChE O
activity O
levels O
, O
administration O
of O
vitamin B
E I
to O
CPF O
- O
treated O
mice O
restored O
these O
biochemical O
parameters O
to O
within O
normal O
levels O
, O
and O
resulted O
in O
overall O
improvement O
in O
damage O
to O
livers O
and O
kidneys O
. O

These O
data O
suggest O
that O
oxidative O
stress O
is O
involved O
in O
CPF O
- O
induced O
toxicity O
and O
that O
vitamin B
E I
can O
protect O
against O
the O
tissue O
damage O
induced O
by O
CPF O
. O

First O
sensors O
were O
fabricated O
using O
printed O
circuit O
board O
( O
PCB O
) O
technology O
and O
nickel B
and O
gold O
layers O
were O
electrodeposited O
onto O
the O
PCB O
sensors O
. O

Growth O
and O
potential O
damage O
of O
human O
bone O
- O
derived O
cells O
on O
fresh O
and O
aged O
fullerene B
c60 B
films O
. O

Fullerenes B
are O
nanoparticles O
composed O
of O
carbon B
atoms O
arranged O
in O
a O
spherical O
hollow O
cage O
- O
like O
structure O
. O

Numerous O
studies O
have O
evaluated O
the O
therapeutic O
potential O
of O
fullerene B
derivates O
against O
oxidative O
stress O
- O
associated O
conditions O
, O
including O
the O
prevention O
or O
treatment O
of O
arthritis O
. O

On O
the O
other O
hand O
, O
fullerenes B
are O
not O
only O
able O
to O
quench O
, O
but O
also O
to O
generate O
harmful O
reactive O
oxygen B
species O
. O

The O
reactivity O
of O
fullerenes B
may O
change O
in O
time O
due O
to O
the O
oxidation O
and O
polymerization O
of O
fullerenes B
in O
an O
air O
atmosphere O
. O

In O
this O
study O
, O
we O
therefore O
tested O
the O
dependence O
between O
the O
age O
of O
fullerene B
films O
( O
from O
one O
week O
to O
one O
year O
) O
and O
the O
proliferation O
, O
viability O
and O
metabolic O
activity O
of O
human O
osteosarcoma O
cells O
( O
lines O
MG O
- O
63 O
and O
U O
- O
2 O
OS O
) O
. O

The O
increasing O
age O
of O
the O
fullerene B
films O
did O
not O
cause O
enhancement O
of O
cytotoxicity O
. O

Therefore O
, O
fullerene B
films O
could O
be O
considered O
as O
a O
promising O
material O
with O
potential O
use O
as O
a O
bioactive O
coating O
of O
cell O
carriers O
for O
bone O
tissue O
engineering O
. O

High O
- O
affinity O
nicotinic O
acetylcholine B
receptor O
expression O
and O
trafficking O
abnormalities O
in O
psychiatric O
illness O
. O

RATIONALE O
: O
Nicotinic O
acetylcholine B
receptors O
( O
nAChRs O
) O
are O
a O
critical O
component O
of O
the O
cholinergic O
system O
of O
neurotransmission O
in O
the O
brain O
that O
modulates O
important O
physiological O
processes O
such O
as O
reward O
, O
cognition O
, O
and O
mood O
. O

There O
is O
significantly O
increased O
tobacco O
use O
, O
and O
therefore O
nicotine B
intake O
, O
in O
patient O
populations O
, O
and O
pharmacological O
agents O
that O
act O
on O
various O
nicotinic O
receptor O
subtypes O
ameliorate O
clinical O
features O
of O
these O
disorders O
. O

RESULTS O
: O
The O
objective O
of O
this O
review O
is O
to O
describe O
the O
multiple O
cellular O
pathways O
through O
which O
chronic O
nicotine B
exposure O
regulates O
nAChR O
expression O
, O
and O
to O
juxtapose O
these O
mechanisms O
with O
evidence O
for O
altered O
expression O
of O
high O
- O
affinity O
nAChRs O
in O
human O
psychiatric O
illness O
. O

Hyperphosphataemia O
can O
be O
induced O
by O
three O
main O
conditions O
: O
a O
massive O
acute O
phosphate B
load O
, O
a O
primary O
increase O
in O
renal O
phosphate B
reabsorption O
, O
and O
an O
impaired O
renal O
phosphate B
excretion O
due O
to O
acute O
or O
chronic O
renal O
insufficiency O
. O

Renal O
excretion O
is O
so O
efficient O
in O
normal O
subjects O
that O
balance O
can O
be O
maintained O
with O
only O
a O
minimal O
rise O
in O
serum O
phosphorus B
concentration O
even O
for O
a O
large O
phosphorus B
load O
. O

Lowering O
the O
phosphate B
load O
and O
maintaining O
serum O
phosphorus B
levels O
within O
the O
normal O
range O
are O
considered O
important O
therapeutic O
goals O
to O
improve O
clinical O
outcomes O
in O
CKD O
patients O
. O

Treatment O
consists O
of O
diminishing O
intestinal O
phosphate B
absorption O
by O
a O
low O
phosphate B
diet O
and O
phosphate B
binders O
. O

In O
CKD O
patients O
on O
dialysis O
an O
efficient O
dialysis O
removal O
of O
phosphate B
should O
be O
ensured O
. O

Dietary O
restriction O
of O
phosphorus B
while O
maintaining O
adequate O
protein O
intake O
is O
not O
sufficient O
to O
control O
serum O
phosphate B
levels O
in O
most O
CKD O
patients O
; O
therefore O
, O
the O
prescription O
of O
a O
phosphate B
binder O
is O
required O
. O

Aluminium B
- O
containing O
agents O
are O
efficient O
but O
no O
longer O
widely O
used O
because O
of O
their O
toxicity O
. O

Calcium B
- O
based O
salts O
are O
inexpensive O
, O
effective O
and O
most O
widely O
used O
, O
but O
there O
is O
now O
concern O
about O
their O
association O
with O
hypercalcaemia O
, O
parathyroid O
gland O
suppression O
, O
adynamic O
bone O
disease O
, O
and O
vascular O
and O
extraosseous O
calcification O
. O

The O
average O
daily O
dose O
of O
calcium O
acetate O
or O
carbonate O
prescribed O
in O
the O
randomised O
controlled O
trials O
to O
control O
hyperphosphataemia O
in O
dialysis O
patients O
ranges O
between O
1 O
. O
2 O
and O
2 O
. O
3 O
g O
of O
elemental O
calcium B
. O

Such O
doses O
are O
greater O
than O
the O
recommended O
dietary O
calcium B
intake O
and O
can O
lead O
to O
a O
positive O
calcium B
balance O
. O

Although O
large O
amounts O
of O
calcium B
salts O
should O
probably O
be O
avoided O
, O
modest O
doses O
( O
< O
1 O
g O
of O
elemental O
calcium B
) O
may O
represent O
a O
reasonable O
initial O
approach O
to O
reduced O
serum O
phosphorus O
levels O
. O

A O
non O
- O
calcium B
- O
based O
binder O
can O
then O
be O
added O
when O
large O
doses O
of O
binder O
are O
required O
. O

At O
present O
, O
there O
are O
three O
types O
of O
non O
- O
calcium B
- O
based O
phosphate O
binders O
available O
: O
sevelamer O
, O
lanthanum O
carbonate O
and O
magnesium B
salts O
. O

Each O
of O
these O
compounds O
is O
as O
effective O
as O
calcium B
salts O
in O
lowering O
serum O
phosphorus B
levels O
depending O
on O
an O
adequate O
prescribed O
dose O
and O
adherence O
of O
the O
patient O
to O
treatment O
. O

Sevelamer O
is O
the O
only O
non O
- O
calcium B
- O
containing O
phosphate B
binder O
that O
does O
not O
have O
potential O
for O
systemic O
accumulation O
and O
presents O
pleiotropic O
effects O
that O
may O
impact O
on O
cardiovascular O
disease O
. O

In O
contrast O
, O
lanthanum O
carbonate O
and O
magnesium B
salts O
are O
absorbed O
in O
the O
gut O
and O
their O
route O
of O
excretion O
is O
biliary O
for O
lanthanum O
and O
urinary O
for O
magnesium B
. O

There O
are O
insufficient O
data O
to O
establish O
the O
comparative O
superiority O
of O
non O
- O
calcium B
binding O
agents O
over O
calcium B
salts O
for O
such O
important O
patient O
- O
level O
outcomes O
as O
all O
- O
cause O
mortality O
and O
cardiovascular O
end O
points O
. O

Moreover O
, O
full O
adoption O
of O
sevelamer O
and O
lanthanum O
by O
government O
drug O
reimbursement O
agencies O
in O
place O
of O
calcium B
salts O
would O
lead O
to O
a O
large O
increase O
in O
health O
- O
care O
expenditure O
. O

Therefore O
, O
the O
choice O
of O
phosphate B
binder O
should O
be O
individualised O
, O
considering O
the O
clinical O
context O
, O
the O
costs O
, O
and O
the O
individual O
tolerability O
the O
concomitant O
effects O
on O
other O
parameters O
of O
mineral O
metabolism O
, O
such O
as O
serum O
calcium B
and O
parathyroid O
hormone O
, O
besides O
those O
on O
serum O
phosphorus B
. O

Our O
protocol O
is O
capable O
of O
reproducing O
the O
solvation O
pattern O
at O
the O
interface O
and O
recovers O
hydrogen B
- O
bonded O
water O
- O
mediated O
contacts O
in O
many O
of O
the O
benchmark O
cases O
. O

DESIGN O
: O
A O
decision O
- O
tree O
model O
was O
developed O
to O
compare O
the O
cost O
- O
effectiveness O
of O
oral O
direct O
FXaIs O
( O
rivaroxaban B
, O
apixaban B
, O
and O
edoxaban B
) O
to O
subcutaneous O
LMWHs O
( O
enoxaparin O
and O
dalteparin O
) O
, O
with O
separate O
models O
for O
THR O
and O
TKR O
. O

Mechanistic O
Aspects O
of O
hSOD1 O
Maturation O
from O
the O
Solution O
Structure O
of O
Cu B
( I
I I
) I
- O
Loaded O
hCCS O
Domain O
1 O
and O
Analysis O
of O
Disulfide B
- O
Free O
hSOD1 O
Mutants O
. O

Superoxide B
dismutase O
1 O
( O
SOD1 O
) O
maturation O
within O
the O
cell O
is O
mainly O
accomplished O
with O
the O
SOD1 O
- O
specific O
chaperone O
, O
CCS O
, O
a O
dimeric O
protein O
with O
three O
distinct O
domains O
in O
each O
monomer O
. O

We O
recently O
showed O
that O
the O
first O
domain O
of O
human O
CCS O
( O
hCCSD1 O
) O
is O
responsible O
for O
copper B
transfer O
to O
its O
protein O
partner O
, O
human O
SOD1 O
( O
hSOD1 O
) O
. O

The O
NMR O
solution O
structure O
of O
the O
copper B
( I
I I
) I
- O
loaded O
form O
of O
hCCSD1 O
reported O
here O
contributes O
further O
to O
characterization O
of O
the O
copper O
- O
transfer O
mechanism O
to O
hSOD1 O
. O

NMR O
spectroscopy O
was O
also O
used O
to O
examine O
the O
hSOD1 O
mutants O
C57A O
, O
C146A O
, O
and O
C57A O
/ O
C146A O
, O
which O
are O
unable O
to O
form O
the O
structurally O
conserved O
disulfide B
bond O
in O
SOD1 O
, O
in O
order O
to O
investigate O
the O
role O
of O
these O
cysteines B
during O
hSOD1 O
copper O
acquisition O
. O

Together O
, O
the O
information O
on O
both O
hCCS O
and O
hSOD1 O
, O
along O
with O
a O
sequence O
analysis O
of O
eukaryotic O
CCSD1 O
, O
allows O
us O
to O
propose O
important O
mechanistic O
aspects O
regarding O
the O
copper B
- O
transfer O
process O
from O
hCCS O
to O
hSOD1 O
. O

Metoprolol O
and O
diltiazem B
ameliorate O
ziprasidone B
- O
induced O
prolonged O
corrected O
QT O
interval O
in O
rats O
. O

Ziprasidone B
, O
an O
atypical O
antipsychotic O
agent O
, O
has O
been O
shown O
to O
increase O
the O
corrected O
QT O
( O
QTc O
) O
interval O
in O
some O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
reveal O
the O
effects O
of O
metoprolol O
and O
diltiazem B
on O
ziprasidone B
drug O
- O
induced O
prolonged O
QTc O
interval O
. O

A O
total O
of O
24 O
rats O
were O
equally O
divided O
into O
the O
following O
four O
groups O
: O
the O
first O
group O
was O
used O
as O
the O
control O
and O
received O
1 O
mL O
/ O
kg O
saline O
; O
3 O
mg O
/ O
kg O
ziprasidone B
and O
saline O
were O
administered O
to O
the O
second O
group O
; O
3 O
mg O
/ O
kg O
ziprasidone B
and O
1 O
mg O
/ O
kg O
metoprolol O
were O
administered O
to O
the O
third O
group O
and O
3 O
mg O
/ O
kg O
ziprasidone B
and O
2 O
mg O
/ O
kg O
diltiazem B
were O
administered O
to O
the O
fourth O
group O
. O

The O
study O
demonstrated O
the O
effectiveness O
of O
metoprolol O
and O
diltiazem B
in O
the O
prevention O
of O
ziprasidone B
- O
induced O
elongation O
in O
the O
QTc O
interval O
. O

Both O
metoprolol O
and O
diltiazem B
may O
be O
considered O
in O
the O
prophylactic O
therapy O
of O
high O
- O
risk O
patients O
who O
are O
using O
ziprasidone B
. O

Store O
- O
operated O
Ca2 B
+ I
Entry O
( O
SOCE O
) O
Induced O
by O
Protease O
- O
activated O
Receptor O
- O
1 O
mediates O
STIM1 O
Phosphorylation O
to O
inhibit O
SOCE O
in O
Endothelial O
Cells O
through O
AMP B
- O
activated O
Protein O
Kinase O
and O
p38beta O
Mitogen O
- O
activated O
Protein O
Kinase O
. O

The O
Ca2 B
+ I
sensor O
STIM1 O
is O
crucial O
for O
activation O
of O
store O
- O
operated O
Ca2 B
+ I
entry O
( O
SOCE O
) O
through O
TRPC O
and O
Orai O
channels O
. O

Here O
we O
show O
that O
SOCE O
activates O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
; O
its O
effector O
p38 O
beta O
mitogen O
- O
activated O
protein O
kinase O
( O
p38 O
beta O
MAPK O
) O
phosphorylates O
STIM1 O
, O
thus O
inhibiting O
SOCE O
in O
human O
lung O
microvascular O
endothelial O
cells O
( O
ECs O
) O
. O

Activation O
of O
AMPK O
using O
AICAR O
resulted O
in O
STIM1 O
phosphorylation O
on O
serine B
residues O
and O
prevented O
PAR O
- O
1 O
- O
induced O
Ca2 B
+ I
entry O
. O

Interestingly O
, O
SB203580 B
, O
a O
selective O
inhibitor O
of O
p38 O
MAPK O
, O
blocked O
STIM1 O
phosphorylation O
and O
led O
to O
sustained O
STIM1 O
- O
puncta O
formation O
and O
Ca2 B
+ I
entry O
. O

Novel O
pentablock O
copolymer O
( O
PLA B
- O
PCL B
- O
PEG B
- O
PCL B
- O
PLA B
) O
based O
nanoparticles O
for O
controlled O
drug O
delivery O
: O
Effect O
of O
copolymer O
compositions O
on O
the O
crystallinity O
of O
copolymers O
and O
in O
vitro O
drug O
release O
profile O
from O
nanoparticles O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
design O
novel O
pentablock O
copolymers O
( O
polylatide O
- O
polycaprolactone B
- O
polyethylene B
glycol I
- O
polycaprolactone B
- O
polylatide O
) O
( O
PLA B
- O
PCL B
- O
PEG B
- O
PCL B
- O
PLA B
) O
to O
prepare O
nanoparticle O
formulations O
which O
provide O
continuous O
delivery O
of O
steroids B
over O
a O
longer O
duration O
with O
minimal O
burst O
effect O
. O

Another O
purpose O
was O
to O
evaluate O
the O
effect O
of O
poly B
( I
L I
- I
lactide I
) I
( O
PLLA B
) O
or O
poly B
( I
D I
, I
L I
- I
lactide I
) I
( O
PDLLA O
) O
incorporation O
on O
crystallinity O
of O
pentablock O
copolymers O
and O
in O
vitro O
release O
profile O
of O
triamcinolone B
acetonide I
( O
selected O
as O
model O
drug O
) O
from O
nanoparticles O
. O

PLA B
- O
PCL B
- O
PEG B
- O
PCL B
- O
PLA B
copolymers O
with O
different O
block O
ratio O
of O
PCL B
/ O
PLA B
segment O
were O
synthesized O
. O

Release O
of O
triamcinolone B
acetonide I
from O
nanoparticles O
was O
significantly O
affected O
by O
crystallinity O
of O
the O
copolymers O
. O

Burst O
release O
of O
triamcinolone B
acetonide I
from O
nanoparticles O
was O
significantly O
minimized O
with O
incorporation O
of O
proper O
ratio O
of O
PDLLA O
in O
the O
existing O
triblock O
( O
PCL B
- O
PEG B
- O
PCL B
) O
copolymer O
. O

Moreover O
, O
pentablock O
copolymer O
based O
nanoparticles O
exhibited O
continuous O
release O
of O
triamcinolone B
acetonide I
. O

Synthesis O
and O
Structure O
Activity O
Relationship O
of O
Tetrahydroisoquinoli B
- O
based O
Potentiators O
of O
GluN2C O
and O
GluN2D O
Containing O
N B
- I
Methyl I
- I
D I
- I
Aspartate I
Receptors O
. O

We O
describe O
here O
the O
synthesis O
and O
evaluation O
of O
a O
series O
of O
tetrahydroisoquinoli B
that O
show O
subunit O
- O
selective O
potentiation O
of O
NMDA B
receptors O
containing O
the O
GluN2C O
or O
GluN2D O
subunits O
. O

Bischler O
- O
Napieralski O
conditions O
were O
employed O
in O
the O
key O
step O
for O
the O
conversion O
of O
acyclic O
amides O
to O
the O
corresponding O
tetrahydroisoquinoli B
containing O
analogs O
. O

Compounds O
were O
evaluated O
using O
both O
two O
electrode O
voltage O
clamp O
recordings O
from O
Xenopus O
laevis O
oocytes O
and O
imaging O
of O
mammalian O
BHK O
cells O
loaded O
with O
Ca B
( I
2 I
+ I
) I
- O
sensitive O
dyes O
. O

The O
most O
potent O
analogues O
had O
EC50 O
values O
of O
300 O
nM O
and O
showed O
over O
2 O
- O
fold O
potentiation O
of O
the O
response O
to O
maximally O
effective O
concentrations O
of O
glutamate B
and O
glycine B
, O
but O
had O
no O
effect O
on O
responses O
from O
NMDA B
receptors O
containing O
the O
GluN2A O
or O
GluN2B O
subunits O
, O
AMPA B
, O
kainate B
, O
GABA B
, O
or O
glycine B
receptors O
or O
a O
variety O
of O
other O
potential O
targets O
. O

These O
compounds O
represent O
a O
potent O
class O
of O
small O
molecule O
subunit O
- O
selective O
potentiators O
of O
NMDA B
receptors O
. O

We O
present O
CCSD O
( O
T O
) O
interaction O
energies O
and O
the O
bonding O
analysis O
for O
complexes O
of O
Cu B
, O
Ag B
, O
and O
Au B
with O
the O
lone O
- O
pair O
ligands O
, O
H2O B
, O
OF2 O
, O
OMe2 O
, O
NH3 B
, O
NF3 B
, O
NMe3 O
, O
H2S O
, O
SF2 B
, O
SMe2 O
, O
PH3 O
, O
PF3 O
, O
PCl3 O
, O
PMe3 O
( O
ML O
complexes O
) O
. O

Upon O
neglecting O
relativistic O
effects O
the O
Au B
- O
P B
bonds O
almost O
vanish O
aside O
from O
weak O
long O
- O
range O
van O
der O
Waals O
interactions O
. O

Highest O
binding O
energies O
are O
computed O
for O
complexes O
with O
Au B
, O
followed O
by O
Cu B
and O
Ag B
. O

Exceptional O
stability O
of O
gold O
complexes O
is O
due O
to O
large O
relativistic O
enhancement O
of O
the O
electron O
affinity O
of O
Au B
. O

Strong O
interaction O
with O
P B
containing O
ligands O
is O
attributed O
to O
their O
lower O
IP O
and O
the O
lone O
pair O
- O
- O
> O
metal O
electron O
donation O
accompanied O
with O
the O
back O
- O
donation O
characteristic O
for O
P B
containing O
ligand O
. O

In O
this O
work O
, O
we O
report O
over O
100 O
times O
modulation O
of O
light O
emission O
efficiency O
of O
these O
two O
- O
dimensional O
semiconductors O
by O
physical O
adsorption O
of O
O2 B
and O
/ O
or O
H2O B
molecules O
, O
while O
inert O
gases O
do O
not O
cause O
such O
effect O
. O

The O
O2 B
and O
/ O
or O
H2O B
pressure O
acts O
quantitatively O
as O
an O
instantaneously O
reversible O
" O
molecular O
gating O
" O
force O
, O
providing O
orders O
of O
magnitude O
broader O
control O
of O
carrier O
density O
and O
light O
emission O
than O
conventional O
electric O
field O
gating O
. O

Physi O
- O
sorbed O
O2 B
and O
/ O
or O
H2O B
molecules O
electronically O
deplete O
n O
- O
type O
materials O
such O
as O
MoS2 B
and O
MoSe2 O
, O
which O
weakens O
electrostatic O
screening O
that O
would O
otherwise O
destabilize O
excitons O
, O
leading O
to O
the O
drastic O
enhancement O
in O
photoluminescence O
. O

This O
issue O
is O
illustrated O
in O
the O
case O
of O
a O
fully O
epitaxial O
system O
: O
CoxNi1 O
- O
x O
nanowires O
in O
CeO2 B
/ O
SrTiO3 B
( O
001 O
) O
. O

The O
advantage O
brought O
by O
the O
ability O
to O
grow O
alloys O
is O
illustrated O
by O
the O
control O
of O
the O
magnetic O
anisotropy O
of O
the O
nanowires O
when O
passing O
from O
pure O
Ni B
wires O
to O
CoxNi1 O
- O
x O
alloys O
. O

The O
antiproliferative O
factor O
( O
APF O
) O
involved O
in O
interstitial O
cystitis O
is O
a O
glycosylated O
nonapeptide O
( O
TVPAAVVVA O
) O
containing O
a O
sialylated O
core O
alpha O
- O
O O
- O
disaccharide O
linked O
to O
the O
N B
- O
terminal O
threonine B
. O

The O
synthetic O
APF O
provided O
a O
platform O
to O
study O
amino B
acid I
modifications O
and O
their O
effect O
on O
APF O
activity O
, O
based O
on O
which O
a O
structure O
- O
activity O
relationship O
( O
SAR O
) O
for O
APF O
activity O
was O
previously O
proposed O
. O

The O
APF O
activity O
is O
found O
to O
be O
dictated O
by O
the O
close O
interplay O
between O
carbohydrate B
- O
peptide O
and O
peptide O
- O
peptide O
interactions O
. O

The O
former O
in O
- O
volves O
hydrogen B
bond O
and O
hydrophobic O
interactions O
and O
the O
latter O
is O
dominated O
by O
hydrophobic O
interac O
- O
tions O
. O

APF O
activity O
correlates O
with O
hydrophobic O
clustering O
associated O
with O
amino B
acids I
4A O
, O
6V O
and O
8V O
. O

Active O
Layer O
- O
Incorporated O
, O
Spectrally O
- O
Tuned O
Au B
/ O
SiO2 B
Core O
/ O
Shell O
Nanorod O
- O
Based O
Light O
Trapping O
for O
Organic O
Photovoltaics O
. O

We O
demonstrated O
that O
incorporation O
of O
octadecyltrimethoxys O
( O
OTMS O
) O
functionalized O
, O
spectrally O
tuned O
, O
gold O
/ O
silica B
( O
Au B
/ O
SiO2 B
) O
core O
/ O
shell O
nanospheres O
and O
nanorods O
into O
the O
active O
layer O
of O
an O
organic O
photovoltaic O
( O
OPV O
) O
device O
led O
to O
an O
in O
increase O
photo O
conversion O
efficiency O
( O
PCE O
) O
. O

A O
silica B
shell O
layer O
was O
added O
onto O
Au B
core O
nanospheres O
and O
nanorods O
in O
order O
to O
provide O
an O
electrically O
insulating O
surface O
that O
does O
not O
interfere O
with O
carrier O
generation O
and O
transport O
inside O
the O
active O
layer O
. O

Functionalization O
of O
the O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanoparticles O
with O
the O
OTMS O
organic O
ligand O
was O
then O
necessary O
in O
order O
to O
transfer O
the O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanoparticles O
from O
an O
ethanol B
solution O
into O
an O
OPV O
polymer O
- O
compatible O
solvent O
, O
such O
as O
dichlorobenzene O
( O
DCB O
) O
. O

The O
OTMS O
- O
functionalized O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanorods O
and O
nanospheres O
were O
then O
incorporated O
into O
the O
active O
layers O
of O
two O
OPV O
polymer O
systems O
: O
a O
poly B
( I
3 I
- I
hexylthiophene I
) I
: O
[ O
6 O
, O
6 O
] O
- O
phenyl O
- O
C61 O
- O
butyric O
acid O
methyl O
ester O
( O
P3HT B
: O
PCB60M O
) O
OPV O
device O
and O
a O
poly O
[ O
2 O
, O
6 O
- O
4 O
, O
8 O
- O
di O
( O
5 O
- O
ethylhexylthienyl O
) O
benzo O
[ O
1 O
, O
2 O
- O
b O
; O
3 O
, O
4 O

For O
the O
P3HT B
: O
PC60BM O
polymer O
with O
a O
band O
edge O
of O
~ O
700 O
nm O
, O
the O
addition O
of O
the O
core O
/ O
shell O
nanorods O
with O
an O
aspect O
ratio O
( O
AR O
) O
of O
~ O
2 O
. O
5 O
( O
extinction O
peak O
~ O
670 O
nm O
) O
resulted O
in O
a O
7 O
. O
1 O
% O
improvement O
in O
PCE O
, O
while O
for O
the O
PBDTT O
- O
DPP O
: O
PC60BM O
polymer O
with O
a O
band O
edge O
~ O
860 O
nm O
, O
the O
addition O
of O
core O
/ O
shell O
nanorods O
with O
an O
AR O
of O
~ O
4 O
( O
extinction O
peak O
~ O
830 O
nm O
) O
resulted O
in O
a O
14 O
. O
4 O
% O
improvement O
in O
PCE O
. O

The O
addition O
of O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanospheres O
to O
the O
P3HT B
: O
PC60BM O
- O
polymer O
resulted O
in O
a O
2 O
. O
7 O
% O
improvement O
in O
PCE O
, O
while O
their O
addition O
to O
a O
PBDTT O
- O
DPP O
: O
PC60BM O
polymer O
resulted O
in O
a O
9 O
. O
1 O
% O
improvement O
. O

The O
PCE O
and O
Jsc O
enhancements O
were O
consistent O
with O
external O
quantum O
efficiency O
( O
EQE O
) O
measurements O
and O
the O
EQE O
enhancements O
spectrally O
matched O
the O
extinction O
spectra O
of O
Au B
/ O
SiO2 B
nanospheres O
and O
nanorods O
in O
both O
OPV O
polymer O
systems O
. O

Interactions O
between O
solid O
surfaces O
with O
pre O
- O
adsorbed O
poly O
( O
ethylenimine O
) O
( O
PEI B
) O
layers O
: O
effect O
of O
unadsorbed O
free O
PEI B
chains O
. O

Poly O
( O
ethylenimine O
) O
( O
PEI B
) O
polyelectrolytes O
have O
been O
widely O
used O
to O
tune O
the O
stability O
, O
rheology O
, O
or O
adhesion O
properties O
of O
colloidal O
suspensions O
due O
to O
their O
strong O
tendency O
to O
adsorb O
to O
solid O
surfaces O
. O

They O
have O
also O
gained O
importance O
as O
gene O
carriers O
in O
biomedical O
applications O
, O
in O
which O
the O
anionic O
DNA O
chains O
are O
complexed O
and O
condensed O
to O
form O
PEI B
/ O
DNA O
polyplexes O
. O

Some O
reported O
literatures O
have O
recently O
shown O
that O
the O
overdosed O
PEI B
chains O
, O
which O
are O
free O
in O
the O
solution O
mixture O
, O
also O
play O
a O
vital O
role O
in O
promoting O
the O
gene O
transfection O
, O
but O
the O
reason O
is O
unclear O
. O

In O
this O
work O
, O
we O
present O
the O
results O
of O
using O
total O
internal O
reflection O
microscopy O
( O
TIRM O
) O
to O
measure O
the O
interaction O
forces O
between O
a O
Brownian O
colloidal O
sphere O
and O
a O
flat O
glass O
plate O
in O
the O
presence O
of O
overdosed O
free O
PEI B
cationic O
chains O
, O
when O
both O
surfaces O
were O
saturated O
adsorbed O
with O
the O
PEI B
chains O
. O

The O
colloidal O
sphere O
pre O
- O
adsorbed O
with O
PEI B
chains O
was O
chosen O
to O
mimic O
the O
PEI B
/ O
DNA O
polyplex O
. O

Results O
for O
the O
potential O
energy O
of O
interaction O
measured O
for O
model O
polyplex O
( O
e O
. O
g O
. O
, O
PEI B
- O
coated O
sphere O
) O
interacting O
with O
a O
PEI B
- O
coated O
glass O
surface O
in O
the O
presence O
of O
overdosed O
free O
PEI B
chains O
at O
various O
pH O
values O
and O
salt O
concentrations O
were O
presented O
. O

As O
can O
be O
shown O
by O
direct O
force O
measurements O
, O
the O
interaction O
potentials O
in O
NaCl B
salt O
solution O
are O
dominated O
by O
repulsive O
forces O
originating O
from O
diffuse O
layer O
overlap O
and O
gravitational O
attraction O
. O

However O
, O
the O
presence O
of O
free O
PEI B
chains O
in O
the O
solution O
mixture O
produces O
a O
long O
- O
ranged O
( O
> O
60 O
nm O
) O
attractive O
force O
between O
two O
PEI B
- O
coated O
surfaces O
with O
the O
range O
and O
magnitude O
tunable O
by O
pH O
value O
, O
PEI B
and O
salt O
concentrations O
. O

A O
better O
understanding O
of O
this O
free O
PEI B
- O
induced O
attractive O
force O
will O
be O
useful O
in O
the O
development O
of O
improved O
PEI B
/ O
DNA O
polyplexes O
systems O
for O
biomedical O
applications O
. O

Results O
showed O
that O
PPF O
supported O
similar O
cell O
metabolic O
activities O
of O
hMSC O
, O
L929 O
, O
MC3T3 O
, O
and O
cMSC O
compared O
to O
the O
noncytotoxic O
control O
, O
high O
- O
density O
polyethylene B
( O
HDPE O
) O
and O
were O
statistically O
different O
than O
those O
cultured O
with O
the O
cytotoxic O
control O
, O
a O
polyurethane B
film O
containing O
0 O
. O
1 O
% O
zinc O
diethyldithiocarbama O
( O
ZCF O
) O
. O

Fas O
receptor O
- O
deficient O
lpr O
mice O
are O
protected O
against O
acetaminophen B
hepatotoxicity O
due O
to O
higher O
glutathione B
synthesis O
and O
enhanced O
detoxification O
of O
oxidant O
stress O
. O

Acetaminophen B
( O
APAP B
) O
overdose O
is O
a O
classical O
model O
of O
hepatocellular O
necrosis O
; O
however O
, O
the O
involvement O
of O
the O
Fas O
receptor O
in O
the O
pathophysiology O
remains O
controversial O
. O

Fas O
receptor O
- O
deficient O
( O
lpr O
) O
and O
C57BL O
/ O
6 O
mice O
were O
treated O
with O
APAP B
to O
compare O
the O
mechanisms O
of O
hepatotoxicity O
. O

Lpr O
mice O
were O
partially O
protected O
against O
APAP B
hepatotoxicity O
as O
indicated O
by O
reduced O
plasma O
ALT O
and O
GDH O
levels O
and O
liver O
necrosis O
. O

Hepatic O
Cyp2e1 O
protein O
, O
adduct O
formation O
and O
hepatic O
glutathione B
( O
GSH B
) O
depletion O
were O
similar O
, O
demonstrating O
equivalent O
reactive O
metabolite O
generation O
. O

Interestingly O
, O
hepatic O
GSH B
recovered O
faster O
in O
lpr O
mice O
than O
in O
wild O
type O
animals O
resulting O
in O
enhanced O
detoxification O
of O
reactive O
oxygen B
species O
. O

Driving O
the O
increased O
GSH B
levels O
, O
mRNA O
induction O
and O
protein O
expression O
of O
glutamate B
- O
cysteine B
ligase O
( O
gclc O
) O
were O
higher O
in O
lpr O
mice O
. O

Inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
mRNA O
and O
protein O
levels O
at O
6h O
were O
significantly O
lower O
in O
lpr O
mice O
, O
which O
correlated O
with O
reduced O
nitrotyrosine O
staining O
. O

Heat O
shock O
protein O
70 O
( O
Hsp70 O
) O
mRNA O
levels O
were O
substantially O
higher O
in O
lpr O
mice O
after O
APAP B
. O

Conclusion O
: O
Our O
data O
suggest O
that O
the O
faster O
recovery O
of O
hepatic O
GSH B
levels O
during O
oxidant O
stress O
and O
peroxynitrite B
formation O
, O
reduced O
iNOS O
expression O
and O
enhanced O
induction O
of O
Hsp70 O
attenuated O
the O
susceptibility O
to O
APAP B
- O
induced O
cell O
death O
in O
lpr O
mice O
. O

However O
, O
our O
results O
reveal O
also O
a O
more O
critical O
role O
of O
the O
amino B
- O
terminal O
GDAP1 O
domains O
, O
carrying O
most O
CMT O
- O
causing O
mutations O
, O
in O
the O
regulation O
of O
mitochondrial O
compared O
to O
peroxisomal O
fission O
. O

Down O
- O
regulation O
of O
LRRK2 O
in O
control O
and O
DAT O
transfected O
HEK O
cells O
increases O
manganese B
- O
induced O
oxidative O
stress O
and O
cell O
toxicity O
. O

Genes O
linked O
to O
early O
onset O
of O
Parkinsonism O
which O
includes O
ATP13A2 O
and O
parkin O
have O
already O
been O
suggested O
to O
promote O
development O
of O
Mn B
toxicity O
. O

In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock O
- O
down O
on O
Mn B
toxicity O
was O
examined O
in O
control O
and O
DAT O
transfected O
HEK293 O
cells O
. O

Results O
demonstrate O
that O
LRRK2 O
down O
- O
regulation O
potentiates O
Mn B
toxicity O
in O
both O
control O
and O
DAT O
- O
transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O

Combined O
treatment O
of O
Mn B
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK O
phosphorylation O
in O
LRRK2 O
deficient O
cells O
compared O
to O
controls O
. O

Our O
findings O
suggest O
that O
null O
mutations O
in O
LRRK2 O
which O
cause O
Parkinsonism O
potentiate O
Mn B
toxicity O
and O
increase O
susceptibility O
to O
develop O
manganism O
. O

Earlier O
, O
we O
reported O
that O
quinoa O
( O
Chenopodium O
quinoa O
Willd O
. O
) O
, O
a O
facultative O
C3 O
halophyte O
species O
, O
can O
efficiently O
control O
the O
activity O
of O
slow O
( O
SV O
) O
and O
fast O
( O
FV O
) O
tonoplast O
channels O
to O
match O
specific O
growth O
conditions O
by O
ensuring O
that O
most O
of O
accumulated O
Na B
+ I
is O
safely O
locked O
in O
the O
vacuole O
( O
Bonales O
- O
Alatorre O
et O
al O
. O
( O
2013 O
) O
Plant O
Physiology O
) O
. O

These O
include O
: O
( O
i O
) O
a O
higher O
rate O
of O
Na B
+ I
exclusion O
from O
leaf O
mesophyll O
; O
( O
ii O
) O
maintenance O
of O
low O
cytosolic O
Na B
+ I
levels O
; O
( O
iii O
) O
better O
K B
+ I
retention O
in O
the O
leaf O
mesophyll O
; O
( O
iv O
) O
a O
high O
rate O
of O
H B
+ I
pumping O
, O
which O
increases O
the O
ability O
of O
mesophyll O
cells O
to O
restore O
their O
membrane O
potential O
; O
and O
( O
v O
) O
the O
ability O
to O
reduce O
the O
activity O
of O
SV O
and O
FV O
channels O
under O
saline O
conditions O
. O

Basic O
evidence O
for O
epidermal O
H2O2 B
/ O
ONOO B
- O
- O
mediated O
oxidation O
/ O
nitration O
in O
segmental O
vitiligo O
is O
supported O
by O
repigmentation O
of O
skin O
and O
eyelashes O
after O
reduction O
of O
epidermal O
H2O2 B
with O
topical O
NB O
- O
UVB O
- O
activated O
pseudocatalase O
PC O
- O
KUS O
. O

The O
cause O
of O
the O
disease O
is O
still O
unknown O
despite O
accumulating O
in O
vivo O
and O
in O
vitro O
evidence O
of O
massive O
epidermal O
oxidative O
stress O
via O
H2O2 B
and O
peroxynitrite B
( O
ONOO B
( I
- I
) I
) O
in O
affected O
individuals O
. O

We O
here O
asked O
the O
question O
whether O
ROS O
and O
possibly O
ONOO B
( I
- I
) I
could O
be O
players O
in O
the O
pathogenesis O
of O
SSV O
. O

Moreover O
, O
we O
show O
epidermal O
ONOO B
( I
- I
) I
accumulation O
. O

In O
vivo O
FT O
- O
Raman O
spectroscopy O
reveals O
the O
presence O
of O
H2O2 B
, O
methionine O
sulfoxide O
, O
and O
tryptophan B
metabolites O
; O
i O
. O
e O
. O
, O
N B
- I
formylkynurenine I
and O
kynurenine O
, O
implying O
Fenton O
chemistry O
in O
the O
cascade O
( O
n O
= O
10 O
) O
. O

Validation O
of O
the O
basic O
data O
stems O
from O
successful O
repigmentation O
of O
skin O
and O
eyelashes O
in O
affected O
individuals O
, O
regardless O
of O
SSV O
or O
segmental O
vitiligo O
in O
association O
with O
NSV O
after O
reduction O
of O
epidermal O
H2O2 B
( O
n O
= O
5 O
) O
. O

Taken O
together O
, O
our O
contribution O
strongly O
supports O
H2O2 B
/ O
ONOO B
- I
mediated O
stress O
in O
the O
pathogenesis O
of O
SSV O
. O

Basic O
evidence O
for O
epidermal O
H2O2 B
/ O
ONOO B
( I
- I
) I
- O
mediated O
oxidation O
/ O
nitration O
in O
segmental O
vitiligo O
is O
supported O
by O
repigmentation O
of O
skin O
and O
eyelashes O
after O
reduction O
of O
epidermal O
H2O2 B
with O
topical O
NB O
- O
UVB O
- O
activated O
pseudocatalase O
PC O
- O
KUS O
. O

While O
CPNs O
cause O
no O
toxicity O
, O
decreased O
CPN O
uptake O
is O
observed O
from O
cancer O
cells O
pretreated O
with O
genistein B
, O
which O
is O
an O
inhibitor O
of O
caveolae O
- O
mediated O
endocytosis O
( O
CvME O
) O
. O

Identification O
of O
an O
Inhibitory O
Mechanism O
of O
Luteolin B
on O
the O
Insulin O
- O
Like O
Growth O
Factor O
- O
1 O
Ligand O
- O
Receptor O
Interaction O
. O

Using O
single O
- O
molecule O
force O
measurement O
and O
fluorescence O
imaging O
, O
we O
have O
demonstrated O
that O
luteolin B
has O
an O
inhibitory O
effect O
on O
IGF O
- O
1 O
ligand O
- O
receptor O
binding O
, O
the O
initial O
step O
in O
IGF O
- O
1 O
signaling O
. O

In O
a O
subset O
of O
287 O
normoglycemic O
individuals O
, O
acute O
insulin O
secretion O
was O
measured O
by O
an O
intravenous O
glucose B
tolerance O
test O
. O

Exhibiting O
unique O
properties O
over O
other O
MMPIs O
( O
e O
. O
g O
. O
, O
hydroxamates B
) O
, O
these O
newly O
reported O
compounds O
are O
capable O
of O
modulating O
activities O
of O
several O
MMPs O
in O
the O
low O
nanomolar O
range O
, O
including O
MMP O
- O
2 O
( O
~ O
2 O
to O
50 O
nM O
) O
, O
MMP O
- O
13 O
( O
~ O
2 O
to O
50 O
nM O
) O
, O
and O
MMP O
- O
14 O
( O
~ O
4 O
to O
60 O
nM O
) O
. O

Our O
previous O
work O
with O
the O
mercaptosulfide O
functionality O
attached O
to O
both O
cyclopentane B
and O
pyrrolidine O
frameworks O
demonstrated O
that O
the O
cis O
- O
( O
3S O
, O
4R O
) O
- O
stereochemistry O
was O
optimal O
for O
all O
of O
the O
MMPs O
tested O
. O

Design O
, O
Synthesis O
and O
Biological O
Evaluation O
of O
Aminoalkylindole O
Derivatives O
as O
Cannabinoid O
Receptor O
Ligands O
with O
Potential O
for O
Treatment O
of O
Alcohol B
Abuse O
. O

Attenuation O
of O
increased O
endocannabinoid O
signaling O
with O
a O
CB1R O
neutral O
antagonist O
might O
offer O
a O
new O
therapeutic O
direction O
for O
treatment O
of O
alcohol B
abuse O
. O

We O
have O
recently O
reported O
that O
a O
mono O
- O
hydroxylated O
metabolite O
of O
the O
synthetic O
aminoalkylindole O
cannabinoid O
JHW O
- O
073 O
( O
3 O
) O
exhibits O
neutral O
antagonist O
activity O
at O
CB1Rs O
and O
thus O
may O
serve O
as O
a O
promising O
lead O
for O
the O
development O
of O
novel O
alcohol B
abuse O
therapies O
. O

Similar O
to O
the O
CB1R O
antagonist O
/ O
inverse O
agonist O
rimonabant O
, O
analogues O
27 O
and O
30 O
decrease O
oral O
alcohol B
self O
- O
administration O
, O
without O
affecting O
total O
fluid O
intake O
and O
block O
the O
development O
of O
alcohol B
- O
conditioned O
place O
preference O
. O

Collectively O
, O
these O
initial O
findings O
suggest O
that O
design O
and O
systematic O
modification O
of O
aminoalkylindoles O
such O
as O
3 O
may O
lead O
to O
development O
of O
novel O
cannabinoid O
ligands O
with O
dual O
CB1R O
antagonist O
/ O
CB2R O
agonist O
activity O
with O
potential O
for O
use O
as O
treatments O
of O
alcohol B
abuse O
. O

For O
31 O
weeks O
, O
six O
- O
week O
- O
old O
male O
apoE O
( O
- O
/ O
- O
) O
mice O
received O
a O
diet O
that O
included O
one O
of O
the O
following O
: O
fermented O
milk O
containing O
both O
VPP O
and O
IPP O
; O
casein O
hydrolysate O
containing O
both O
of O
these O
peptides O
; O
synthesized O
VPP O
; O
synthesized O
IPP O
; O
enalapril O
; O
captopril B
; O
or O
control O
diet O
. O

The O
area O
ratio O
of O
intima O
to O
media O
in O
the O
aortic O
arch O
was O
significantly O
lower O
in O
the O
fermented O
milk O
, O
casein O
hydrolysate O
, O
synthesized O
VPP O
, O
enalapril O
, O
and O
captopril B
groups O
than O
in O
the O
control O
group O
. O

Abstract O
Pomegranates O
have O
health O
- O
promoting O
benefits O
because O
of O
their O
polyphenol B
constituents O
. O

Designed O
amphiphilic O
beta O
- O
sheet O
peptides O
as O
templates O
for O
paraoxon B
adsorption O
and O
detection O
. O

Amphiphilic O
peptides O
were O
designed O
to O
fold O
into O
a O
beta O
- O
sheet O
monolayer O
structure O
while O
presenting O
the O
catalytic O
triad O
residues O
of O
the O
enzyme O
, O
acetylcholinesterase O
( O
Glu B
, O
His B
and O
Ser B
) O
, O
to O
a O
solution O
containing O
the O
organophosphate B
, O
paraoxon B
. O

Three O
peptides O
, O
in O
which O
the O
catalytic O
triad O
residues O
were O
arranged O
in O
different O
orders O
along O
the O
strand O
, O
were O
generated O
to O
reveal O
potential O
differences O
in O
interactions O
with O
paraoxon B
as O
a O
function O
of O
the O
order O
of O
these O
amino B
acids I
. O

One O
additional O
peptide O
with O
amino B
acids I
introduced O
in O
random O
order O
was O
studied O
to O
highlight O
the O
contribution O
of O
the O
beta O
- O
sheet O
secondary O
structure O
to O
any O
interactions O
with O
paraoxon B
. O

Langmuir O
isotherms O
, O
Brewster O
angle O
microscope O
at O
interfaces O
and O
circular O
dichroism O
measurements O
in O
bulk O
showed O
that O
both O
the O
beta O
- O
sheet O
conformation O
and O
the O
order O
of O
the O
amino B
acids I
along O
the O
strand O
influenced O
the O
interactions O
of O
paraoxon B
with O
the O
peptides O
. O

Compression O
isotherm O
curves O
, O
as O
well O
as O
Brewster O
- O
angle O
microscopy O
images O
, O
provided O
evidence O
for O
enhanced O
adsorption O
of O
the O
paraoxon B
to O
the O
monolayers O
of O
peptides O
which O
present O
neighboring O
Glu B
and O
Ser B
residues O
along O
the O
hydrophilic O
face O
of O
the O
beta O
- O
strand O
. O

Circular O
dichroism O
revealed O
that O
the O
peptide O
most O
sensitive O
to O
interactions O
with O
paraoxon B
was O
that O
with O
the O
triad O
residues O
in O
the O
order O
Glu B
, O
Ser B
and O
His B
, O
which O
appears O
to O
be O
appropriate O
for O
supporting O
a O
catalytic O
mechanism O
similar O
to O
that O
in O
acetylcholinesterase O
enzyme O
. O

These O
rationally O
designed O
peptides O
may O
be O
further O
utilized O
for O
the O
development O
of O
technologies O
for O
organophosphate B
adsorption O
and O
detection O
. O

Four O
formulations O
and O
a O
control O
were O
examined O
in O
this O
study O
using O
cidofovir B
as O
the O
model O
drug O
. O

Among O
the O
formulations O
investigated O
, O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
- O
poly B
( I
ethylene I
glycol I
) I
- O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
triblock O
copolymer O
systems O
provided O
the O
longest O
sustained O
drug O
delivery O
, O
probably O
due O
to O
their O
rigid O
gel O
structures O
and O
/ O
or O
polymer O
- O
to O
- O
cidofovir B
interactions O
. O

Synthesis O
of O
Amylose O
- O
Polystyrene B
Inclusion O
Complexes O
by O
a O
Facile O
Preparation O
Route O
. O

The O
formation O
of O
amylose O
- O
polystyrene B
inclusion O
complexes O
via O
a O
novel O
two O
- O
step O
approach O
is O
described O
. O

The O
formation O
of O
polystyrene B
was O
confirmed O
by O
gel O
Permeation O
Chromatography O
( O
GPC O
) O
. O

The O
molecular O
weight O
of O
polystyrene B
can O
be O
varied O
by O
using O
amylose O
bearing O
different O
molar O
masses O
. O

Synthesis O
of O
Silver B
Octahedra O
with O
Controlled O
Sizes O
and O
Optical O
Properties O
via O
Seed O
- O
Mediated O
Growth O
. O

Silver B
octahedra O
with O
edge O
lengths O
controlled O
in O
the O
range O
of O
20 O
- O
72 O
nm O
were O
synthesized O
via O
seed O
- O
mediated O
growth O
. O

The O
key O
to O
the O
success O
of O
this O
synthesis O
is O
the O
use O
of O
single O
- O
crystal O
Ag B
seeds O
with O
uniform O
and O
precisely O
controlled O
sizes O
to O
direct O
the O
growth O
and O
the O
use O
of O
citrate B
as O
a O
selective O
capping O
agent O
for O
the O
{ O
111 O
} O
facets O
. O

Our O
mechanistic O
studies O
demonstrated O
that O
Ag B
seeds O
with O
both O
cubic O
and O
quasi O
- O
spherical O
shapes O
could O
evolve O
into O
octahedra O
. O

For O
the O
first O
time O
, O
we O
were O
able O
to O
precisely O
control O
the O
edge O
lengths O
of O
Ag B
octahedra O
below O
100 O
nm O
, O
and O
the O
lower O
limit O
of O
size O
could O
even O
be O
pushed O
down O
to O
20 O
nm O
. O

Using O
the O
as O
- O
obtained O
Ag B
octahedra O
as O
sacrificial O
templates O
, O
Au B
nanocages O
with O
an O
octahedral O
shape O
and O
precisely O
tunable O
optical O
properties O
were O
synthesized O
through O
a O
galvanic O
replacement O
reaction O
. O

Highly O
Enantioselective O
Zirconium B
- O
Catalyzed O
Cyclization O
of O
Aminoalkenes O
. O

Aminoalkenes O
are O
catalytically O
cyclized O
in O
the O
presence O
of O
cyclopentadienylbis O
( O
oxazolinyl O
) O
borato O
group O
4 O
complexes O
{ O
PhB O
( O
C5H4 O
) O
( O
Ox O
( O
R O
) O
) O
2 O
} O
M O
( O
NMe2 O
) O
2 O
( O
M O
= O
Ti B
, O
Zr O
, O
Hf B
; O
Ox O
( O
R O
) O
= O
4 O
, O
4 O
- O
dimethyl O
- O
2 O
- O
oxazoline O
, O
4S O
- O
isopropyl O
- O
5 O
, O
5 O
- O
dimethyl O
- O
2 O
- O
oxazoline O
, O
4S O
- O

Secondary O
aminopentene O
cyclizations O
require O
a O
primary B
amine I
( O
1 O
- O
2 O
equiv O
vs O
catalyst O
) O
. O

Primary O
kinetic O
isotope O
effects O
from O
substrate O
conversion O
measurements O
( O
k O
' O
obs O
( O
( O
H O
) O
) O
/ O
k O
' O
obs O
( O
( O
D O
) O
) O
= O
3 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
) O
and O
from O
initial O
rate O
analysis O
( O
k2 O
( O
( O
H O
) O
) O
/ O
k2 O
( O
( O
D O
) O
) O
= O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
4 O
) O
indicate O
that O
a O
N B
- I
H I
bond O
is O
broken O
in O
the O
turnover O
- O
limiting O
and O
irreversible O
step O
of O
the O
catalytic O
cycle O
. O

A O
six O
- O
centered O
, O
concerted O
transition O
state O
for O
C B
- I
N I
and O
C B
- I
H I
bond O
formation O
and O
N B
- I
H I
bond O
cleavage O
involving O
two O
amidoalkene O
ligands O
is O
proposed O
as O
most O
consistent O
with O
the O
current O
data O
. O

Elucidation O
of O
the O
biochemical O
basis O
for O
a O
clinical O
drug O
- O
drug O
interaction O
between O
atorvastatin B
and O
5 O
- O
( O
N O
- O
( O
4 O
- O
( O
( O
4 O
- O
ethylbenzyl O
) O
thio O
) O
phenyl O
) O
sulfamoyl O
) O
- O
2 O
- O
methyl O
benzoic O
acid O
( O
CP O
- O
778 O
875 O
) O
, O
a O
subtype O
selective O
agonist O
of O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
. O

Group O
A O
was O
designed O
to O
estimate O
the O
effects O
of O
multiple O
doses O
of O
CP O
- O
778 O
875 O
on O
the O
single O
dose O
pharmacokinetics O
of O
atorvastatin B
. O

Subjects O
in O
group O
A O
( O
n O
= O
26 O
) O
received O
atorvastatin B
( O
40 O
mg O
) O
on O
days O
1 O
and O
9 O
and O
CP O
- O
778 O
875 O
( O
1 O
. O
0 O
mg O
QD O
) O
on O
days O
5 O
- O
12 O
. O

Group O
B O
was O
designed O
to O
examine O
the O
effects O
of O
multiple O
doses O
of O
atorvastatin B
on O
the O
single O
dose O
pharmacokinetics O
of O
CP O
- O
778 O
875 O
. O

Subjects O
in O
group O
B O
( O
n O
= O
29 O
) O
received O
CP O
- O
778 O
875 O
( O
0 O
. O
3 O
mg O
) O
on O
days O
1 O
and O
9 O
and O
atorvastatin B
( O
40 O
mg O
QD O
) O
on O
days O
5 O
- O
12 O
. O

3 O
. O
Mean O
maximum O
serum O
concentration O
( O
Cmax O
) O
and O
area O
under O
the O
curve O
of O
atorvastatin B
were O
increased O
by O
45 O
% O
and O
20 O
% O
, O
respectively O
, O
upon O
co O
- O
administration O
with O
CP O
- O
778 O
875 O
. O

CP O
- O
778 O
875 O
pharmacokinetics O
, O
however O
, O
were O
not O
impacted O
upon O
concomitant O
dosing O
with O
atorvastatin B
. O

4 O
. O
Inhibition O
of O
organic O
anion O
transporting O
polypeptide O
1B1 O
by O
CP O
- O
778 O
875 O
( O
IC50 O
= O
2 O
. O
14 O
+ O
/ O
- O
0 O
. O
40 O
mu O
M O
) O
could O
be O
the O
dominant O
cause O
of O
the O
pharmacokinetic O
interaction O
as O
CP O
- O
778 O
875 O
did O
not O
exhibit O
significant O
inhibition O
of O
cytochrome O
P450 O
3A4 O
/ O
3A5 O
, O
multidrug O
resistant O
protein O
1 O
or O
breast O
cancer O
resistant O
protein O
, O
which O
are O
also O
involved O
in O
the O
hepatobiliary O
disposition O
of O
atorvastatin B
. O

Chromatographic O
separation O
was O
performed O
on O
an O
Acquity O
UPLC O
with O
Agela O
C18 O
column O
, O
and O
the O
solvents O
of O
5 O
mM O
ammonium B
acetate I
( O
pH O
7 O
. O
8 O
) O
- O
acetonitrile B
( O
65 O
: O
35 O
, O
v O
/ O
v O
) O
were O
used O
as O
mobile O
phase O
for O
elution O
. O

Spatial O
memory O
deficits O
in O
maternal O
iron B
deficiency O
paradigms O
are O
associated O
with O
altered O
glucocorticoid O
levels O
. O

" O
The O
goal O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
maternal O
iron B
deficiency O
on O
the O
developing O
hippocampus O
in O
order O
to O
define O
a O
developmental O
window O
for O
this O
effect O
, O
and O
to O
see O
whether O
iron B
deficiency O
causes O
changes O
in O
glucocorticoid O
levels O
. O

The O
study O
was O
carried O
out O
using O
pre O
- O
natal O
, O
post O
- O
natal O
, O
and O
pre O
+ O
post O
- O
natal O
iron B
deficiency O
paradigm O
. O

Iron B
deficient O
pregnant O
dams O
and O
their O
pups O
displayed O
elevated O
corticosterone B
which O
, O
in O
turn O
, O
differentially O
affected O
glucocorticoid O
receptor O
( O
GR O
) O
expression O
in O
the O
CA1 O
and O
the O
dentate O
gyrus O
. O

Brain O
Derived O
Neurotrophic O
Factor O
( O
BDNF O
) O
was O
reduced O
in O
the O
hippocampi O
of O
pups O
following O
elevated O
corticosterone B
levels O
. O

Reduced O
neurogenesis O
at O
P7 O
was O
seen O
in O
pups O
born O
to O
iron B
deficient O
mothers O
, O
and O
these O
pups O
had O
reduced O
numbers O
of O
hippocampal O
pyramidal O
and O
granule O
cells O
as O
adults O
. O

Pups O
from O
dams O
that O
were O
iron B
deficient O
throughout O
pregnancy O
and O
lactation O
displayed O
the O
complete O
spectrum O
of O
defects O
, O
while O
pups O
from O
dams O
that O
were O
iron B
deficient O
only O
during O
pregnancy O
or O
during O
lactation O
displayed O
subsets O
of O
defects O
. O

These O
findings O
show O
that O
maternal O
iron B
deficiency O
is O
associated O
with O
altered O
levels O
of O
corticosterone B
and O
GR O
expression O
, O
and O
with O
spatial O
memory O
deficits O
in O
their O
pups O
. O
" O

An O
investigation O
of O
the O
effect O
of O
thiamine O
pyrophosphate O
on O
cisplatin B
- O
induced O
oxidative O
stress O
and O
DNA O
damage O
in O
rat O
brain O
tissue O
compared O
with O
thiamine B
: O
Thiamine B
and O
thiamine O
pyrophosphate O
effects O
on O
cisplatin B
neurotoxicity O
. O

This O
study O
investigated O
the O
effects O
of O
thiamine O
pyrophosphate O
( O
TPP B
) O
at O
dosages O
of O
10 O
and O
20 O
mg O
/ O
kg O
on O
oxidative O
stress O
induced O
in O
rat O
brain O
tissue O
with O
cisplatin B
and O
compared O
this O
with O
thiamine B
. O

Cisplatin B
neurotoxicity O
represents O
one O
of O
the O
main O
restrictions O
on O
the O
drug O
being O
given O
in O
effective O
doses O
. O

Oxidative O
stress O
is O
considered O
responsible O
for O
cisplatin B
toxicity O
. O

Our O
results O
showed O
that O
cisplatin B
increased O
the O
levels O
of O
oxidant O
parameters O
such O
as O
lipid O
peroxidation O
( O
thio O
barbituric O
acid O
reactive O
substance O
( O
TBARS O
) O
) O
and O
myeloperoxidase O
( O
MPO O
) O
in O
brain O
tissue O
and O
suppressed O
the O
effects O
of O
antioxidants O
such O
as O
total O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
. O

TPP B
, O
especially O
at O
a O
dosage O
of O
20 O
mg O
/ O
kg O
, O
significantly O
reduced O
TBARS O
and O
MPO O
levels O
that O
increase O
with O
cisplatin B
administration O
compared O
with O
the O
thiamine B
group O
, O
while O
TPP B
significantly O
increases O
GSH B
and O
SOD O
levels O
. O

In O
addition O
, O
the O
level O
of O
8 O
- O
Gua O
( O
guanine B
) O
, O
a O
product O
of O
DNA O
damage O
, O
was O
1 O
. O
7 O
+ O
/ O
- O
0 O
. O
12 O
8 O
- O
hydroxyl O
guanine O
( O
8 O
- O
OH O
Gua O
) O
/ O
105 O
Gua B
in O
brain O
tissue O
in O
the O
control O
group O
receiving O
cisplatin B
, O
compared O
with O
0 O
. O
97 O
+ O
/ O
- O
0 O
. O
03 O
8 O
- O
OH O
Gua B
/ O
105 O
Gua B
in O
the O
thiamine O
pyrophosphate O
( O
20 O
mg O
/ O
kg O
) O
group O
and O
1 O
. O
55 O
+ O
/ O
- O
0 O
. O
11 O
8 O
- O
OH O
Gua O
/ O
105 O
Gua B
in O
the O

thiamine B
( O
20 O
mg O
/ O
kg O
) O
group O
. O

These O
results O
show O
that O
thiamine O
pyrophosphate O
significantly O
prevents O
oxidative O
damage O
induced O
by O
cisplatin B
in O
brain O
tissue O
, O
while O
the O
protective O
effect O
of O
thiamine B
is O
insignificant O
. O

Effect O
of O
subacute O
exposure O
to O
silver B
nanoparticle O
on O
some O
hematological O
and O
plasma O
biochemical O
indices O
in O
silver B
carp O
( O
Hypophthalmichthys O
molitrix O
) O
. O

The O
use O
of O
silver B
nanoparticles O
( O
Ag B
- O
NPs O
) O
is O
rapidly O
increasing O
, O
but O
there O
are O
limited O
data O
on O
their O
effects O
on O
the O
aquatic O
environment O
. O

The O
present O
study O
aimed O
to O
determine O
the O
acute O
toxicity O
and O
evaluate O
the O
effect O
of O
subacute O
concentrations O
of O
Ag B
- O
NPs O
( O
Nanocid O
( O
R O
) O
: O
average O
particle O
size O
of O
61 O
nm O
) O
on O
hematological O
and O
plasma O
biochemical O
indices O
of O
silver B
carp O
, O
Hypophthalmichthys O
molitrix O
, O
after O
3 O
, O
7 O
and O
14 O
days O
. O

The O
24 O
- O
, O
48 O
- O
, O
72 O
- O
and O
96 O
- O
h O
median O
lethal O
concentration O
( O
LC50 O
) O
values O
of O
Nanocid O
for O
silver B
carp O
were O
estimated O
at O
0 O
. O
810 O
, O
0 O
. O
648 O
, O
0 O
. O
383 O
and O
0 O
. O
202 O
mg O
/ O
L O
, O
respectively O
; O
20 O
% O
and O
10 O
% O
of O
the O
96 O
- O
h O
LC50 O
values O
( O
0 O
. O
04 O
and O
0 O
. O
02 O
mg O
/ O
L O
) O
were O
selected O
for O
subacute O
study O
. O

White O
blood O
cell O
( O
WBC O
) O
, O
mean O
corpuscular O
hemoglobin O
( O
MCH O
) O
, O
mean O
corpuscular O
hemoglobin O
concentration O
( O
MCHC O
) O
, O
cortisol B
and O
glucose B
levels O
in O
Nanocid O
- O
treated O
groups O
were O
significantly O
higher O
than O
the O
controlled O
group O
at O
experimental O
periods O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
conclusion O
, O
Ag B
- O
NPs O
intoxication O
resulted O
in O
erythrocyte O
reduction O
, O
hematological O
disturbances O
, O
leucocytosis O
and O
stress O
response O
in O
silver B
carp O
and O
offered O
a O
simple O
tool O
to O
evaluate O
toxicity O
- O
derived O
alterations O
. O

Affected O
individuals O
typically O
present O
due O
to O
signs O
and O
symptoms O
of O
androgen B
excess O
. O

Calcium B
pathways O
such O
as O
cAMP B
modulate O
clothianidin O
action O
through O
activation O
of O
alpha O
- O
bungarotoxin O
- O
sensitive O
and O
- O
insensitive O
nicotinic O
acetylcholine B
receptors O
. O

We O
have O
recently O
demonstrated O
that O
it O
was O
a O
full O
agonist O
of O
alpha O
- O
bungarotoxin O
- O
sensitive O
and O
- O
insensitive O
nicotinic O
acetylcholine B
receptors O
expressed O
in O
the O
cockroach O
dorsal O
unpaired O
median O
neurons O
. O

Clothianidin O
was O
able O
to O
act O
as O
an O
agonist O
of O
imidacloprid B
- O
insensitive O
nAChR2 O
receptor O
and O
internal O
regulation O
of O
cAMP B
concentration O
modulated O
nAChR2 O
sensitivity O
to O
clothianidin O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
cAMP B
modulated O
the O
agonist O
action O
of O
clothianidin O
via O
alpha O
- O
bungarotoxin O
- O
sensitive O
and O
insensitive O
receptors O
. O

At O
10 O
mu O
M O
clothianidin O
, O
increasing O
cAMP B
concentration O
induced O
a O
linear O
current O
- O
voltage O
curve O
. O

Clothianidin O
effects O
were O
blocked O
by O
0 O
. O
5 O
mu O
M O
alpha O
- O
bungarotoxin O
suggesting O
that O
cAMP B
modulation O
occurred O
through O
alpha O
- O
bungarotoxin O
- O
sensitive O
receptors O
. O

At O
1mM O
clothianidin O
, O
cAMP B
effects O
were O
associated O
to O
alpha O
- O
bungarotoxin O
- O
insensitive O
receptors O
because O
clothianidin O
- O
induced O
currents O
were O
blocked O
by O
5 O
mu O
M O
mecamylamine B
and O
20 O
mu O
M O
d O
- O
tubocurarine O
. O

In O
addition O
, O
we O
found O
that O
application O
of O
1mM O
clothianidin O
induced O
a O
strong O
increase O
of O
intracellular O
calcium B
concentration O
. O

These O
data O
reinforced O
the O
finding O
that O
calcium B
pathways O
including O
cAMP B
modulated O
clothianidin O
action O
on O
insect O
nicotinic O
acetylcholine B
receptors O
. O

We O
proposed O
that O
intracellular O
calcium B
pathways O
such O
as O
cAMP B
could O
be O
a O
target O
to O
modulate O
the O
mode O
of O
action O
of O
neonicotinoid O
insecticides O
. O

A O
total O
of O
60 O
mice O
were O
randomly O
assigned O
to O
six O
experimental O
groups O
: O
control O
, O
model O
, O
dexamethasone B
( O
2mg O
/ O
kg O
) O
and O
GA O
( O
10mg O
/ O
kg O
, O
20mg O
/ O
kg O
, O
40mg O
/ O
kg O
) O
. O

Airway O
resistance O
( O
Raw O
) O
were O
measured O
by O
the O
forced O
oscillation O
technique O
, O
histological O
studies O
were O
evaluated O
by O
The O
hematoxylin B
and O
eosin B
( O
HE O
) O
staining O
, O
Th1 O
/ O
Th2 O
and O
Th17 O
cytokines O
were O
evaluated O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
and O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
Foxp3 O
( O
+ O
) O
regulatory O
T O
cells O
( O
Tregs O
) O
was O
evaluated O
by O
Flow O
Cytometry O
( O
FCM O
) O
, O
the O
forkhead O
/ O
winged O
helix O
transcription O
factor O
( O
Foxp3 O

Electronic O
structure O
analysis O
of O
multistate O
reactivity O
in O
transition O
metal O
catalyzed O
reactions O
: O
the O
case O
of O
C B
- I
H I
bond O
activation O
by O
non O
- O
heme O
iron O
( O
iv O
) O
- O
oxo O
cores O
. O

These O
concepts O
are O
then O
used O
to O
analyze O
the O
electronic O
structure O
changes O
occurring O
in O
the O
reaction O
of O
C B
- I
H I
bond O
oxidation O
by O
Fe O
( O
IV O
) O
oxo O
species O
. O

The O
electronic O
reorganization O
of O
the O
Fe O
( O
IV O
) O
oxo O
species O
during O
the O
reaction O
is O
thoroughly O
analyzed O
and O
it O
is O
shown O
that O
the O
Fe O
( O
IV O
) O
oxo O
reactant O
develops O
oxyl O
radical O
character O
, O
which O
interacts O
effectively O
with O
the O
sigma O
CH B
orbital O
of O
the O
alkane O
. O

First O
principles O
intensity O
calculations O
of O
the O
methane B
rovibrational O
spectra O
in O
the O
infrared O
up O
to O
9300 O
cm O
( O
- O
1 O
. O
) O

We O
report O
global O
calculations O
of O
rovibrational O
spectra O
and O
dipole O
transition O
intensities O
of O
methane B
using O
our O
recent O
ab O
initio O
dipole O
moment O
and O
potential O
surfaces O
[ O
Nikitin O
et O
al O
. O
, O
Chem O
. O
Phys O
. O
Lett O
. O
, O
2011 O
, O
501 O
, O
179 O
; O
2013 O
, O
565 O
, O
5 O
] O
. O

Comparisons O
of O
theoretical O
predictions O
up O
to O
J O
= O
25 O
for O
various O
complex O
polyads O
of O
methane B
involving O
strongly O
coupled O
vibration O
- O
rotation O
bands O
support O
the O
validity O
of O
this O
new O
approach O
. O

The O
theoretical O
predictions O
also O
correctly O
describe O
the O
isotopic O
effects O
in O
line O
positions O
and O
intensities O
due O
to O
the O
CH4 B
- O
- O
> O
CD4 O
substitution O
which O
is O
considered O
as O
the O
test O
for O
the O
method O
. O

This O
work O
is O
a O
first O
step O
toward O
the O
theoretical O
interpretation O
of O
numerous O
methane B
bands O
which O
remain O
still O
unassigned O
and O
detailed O
line O
- O
by O
- O
line O
absorption O
/ O
emission O
spectra O
analyses O
for O
atmospheric O
and O
planetological O
applications O
. O

A O
Structural O
Snapshot O
of O
Cytochrome O
P450 O
2B4 O
in O
Complex O
with O
Paroxetine B
Provides O
Insights O
into O
Ligand O
Binding O
and O
Clusters O
of O
Conformational O
States O
. O

An O
X O
- O
ray O
crystal O
structure O
of O
cytochrome O
P450 O
2B4 O
in O
complex O
with O
the O
drug O
paroxetine B
was O
solved O
at O
2 O
. O
14 O
A O
resolution O
. O

The O
2B4 O
- O
paroxetine B
structure O
is O
nearly O
superimposable O
on O
a O
previously O
solved O
closed O
structure O
in O
a O
ligand O
free O
state O
. O

Despite O
the O
overall O
conformational O
similarity O
among O
multiple O
closed O
structures O
, O
the O
active O
site O
cavity O
volume O
of O
the O
paroxetine B
complex O
is O
enlarged O
. O

Pyridinylquinazoline O
Selectively O
Inhibit O
Human O
Methionine B
Aminopeptidase O
- O
1 O
in O
Cells O
. O

Methionine B
aminopeptidases O
( O
MetAPs O
) O
, O
which O
remove O
the O
initiator O
methionine B
from O
nascent O
peptides O
, O
are O
essential O
in O
all O
organisms O
. O

Using O
Mn B
( I
II I
) I
or O
Zn B
( I
II I
) I
to O
activate O
HsMetAP1 O
, O
we O
found O
that O
1 O
- O
4 O
could O
only O
effectively O
inhibit O
purified O
HsMetAP1 O
in O
the O
presence O
of O
physiologically O
unachievable O
concentrations O
of O
Co B
( I
II I
) I
. O

In O
an O
effort O
to O
seek O
Co B
( I
II I
) I
- O
independent O
inhibitors O
, O
a O
novel O
structural O
class O
containing O
a O
2 O
- O
( O
pyridin O
- O
2 O
- O
yl O
) O
quinazoline O
core O
has O
been O
discovered O
. O

Many O
compounds O
in O
this O
class O
potently O
and O
selectively O
inhibited O
HsMetAP1 O
without O
Co B
( I
II I
) I
. O

We O
present O
single O
- O
ion O
- O
channel O
recordings O
performed O
with O
biomimetic O
lipid O
membranes O
which O
are O
directly O
attached O
to O
the O
surface O
of O
a O
complementary O
metal B
- I
oxide I
- O
semiconductor O
( O
CMOS O
) O
preamplifier O
chip O
. O

Indazole B
- O
based O
Potent O
and O
Cell O
- O
Active O
Mps1 O
Kinase O
Inhibitors O
: O
Rational O
Design O
from O
Pan O
- O
Kinase O
Inhibitor O
Anthrapyrazolone O
( O
SP600125 B
) O
. O

To O
design O
novel O
Mps1 O
inhibitors O
, O
we O
utilized O
the O
pan O
- O
kinase O
inhibitor O
anthrapyrazolone O
( O
4 O
, O
SP600125 B
) O
and O
its O
crystal O
structure O
bound O
to O
JNK1 O
. O

Our O
design O
efforts O
led O
to O
the O
identification O
of O
indazole B
- O
based O
lead O
6 O
with O
an O
Mps1 O
IC50 O
value O
of O
498 O
nM O
. O

Optimization O
of O
the O
3 O
- O
and O
6 O
- O
positions O
on O
the O
indazole B
core O
of O
6 O
resulted O
in O
23c O
with O
improved O
Mps1 O
activity O
( O
IC50 O
= O
3 O
. O
06 O
nM O
) O
. O

As O
a O
proof O
of O
concept O
, O
we O
generated O
a O
bionic O
ear O
via O
3D O
printing O
of O
a O
cell O
- O
seeded O
hydrogel O
matrix O
in O
the O
anatomic O
geometry O
of O
a O
human O
ear O
, O
along O
with O
an O
intertwined O
conducting O
polymer O
consisting O
of O
infused O
silver B
nanoparticles O
. O

Cigarette O
craving O
and O
withdrawal O
symptoms O
during O
temporary O
abstinence O
and O
the O
effect O
of O
nicotine B
gum O
. O

RATIONALE O
: O
It O
is O
widely O
believed O
that O
nicotine B
withdrawal O
symptoms O
appear O
within O
a O
few O
hours O
of O
stopping O
smoking O
, O
but O
few O
data O
exist O
documenting O
their O
emergence O
in O
naturalistic O
settings O
. O

In O
several O
countries O
, O
nicotine B
replacement O
products O
are O
licensed O
for O
relief O
of O
withdrawal O
symptoms O
during O
temporary O
abstinence O
, O
but O
again O
, O
there O
are O
no O
data O
supporting O
this O
from O
naturalistic O
settings O
. O

OBJECTIVES O
: O
To O
examine O
the O
emergence O
of O
cigarette O
craving O
and O
withdrawal O
symptoms O
during O
temporary O
abstinence O
in O
a O
naturalistic O
setting O
while O
using O
either O
nicotine B
or O
placebo O
gum O
. O

METHODS O
: O
Double O
- O
blind O
, O
randomised O
, O
placebo O
- O
controlled O
study O
in O
which O
132 O
dependent O
smokers O
abstained O
for O
6 O
h O
with O
the O
assistance O
of O
either O
nicotine B
( O
2 O
mg O
, O
n O
= O
42 O
or O
4 O
mg O
, O
n O
= O
24 O
) O
or O
placebo O
( O
n O
= O
66 O
) O
gum O
while O
travelling O
on O
a O
non O
- O
smoking O
train O
. O

Nicotine B
gum O
may O
not O
have O
an O
acute O
effect O
on O
the O
development O
of O
these O
symptoms O
. O

Enhanced O
beta O
cell O
function O
and O
anti O
- O
inflammatory O
effect O
after O
chronic O
treatment O
with O
the O
dipeptidyl O
peptidase O
- O
4 O
inhibitor O
vildagliptin B
in O
an O
advanced O
- O
aged O
diet O
- O
induced O
obesity O
mouse O
model O
. O

METHODS O
: O
After O
1 O
month O
of O
HFD O
alone O
, O
the O
mice O
were O
given O
the O
DPP4 O
inhibitor O
vildagliptin B
for O
a O
further O
11 O
months O
. O

RESULTS O
: O
Beta O
cell O
function O
and O
glucose B
tolerance O
were O
significantly O
improved O
by O
vildagliptin B
with O
both O
diets O
. O

In O
contrast O
, O
in O
spite O
of O
the O
long O
treatment O
period O
, O
beta O
cell O
area O
was O
not O
significantly O
different O
between O
vildagliptin B
- O
treated O
mice O
and O
controls O
. O

Mice O
of O
advanced O
age O
chronically O
fed O
an O
HFD O
displayed O
clear O
and O
extensive O
pancreatic O
inflammation O
and O
peri O
- O
insulitis O
, O
mainly O
formed O
by O
CD3 O
- O
positive O
T O
cells O
, O
which O
were O
completely O
prevented O
by O
vildagliptin B
treatment O
. O

Chronic O
vildagliptin B
treatment O
also O
improved O
survival O
rates O
for O
HFD O
- O
fed O
mice O
. O

The O
improved O
survival O
rates O
for O
obese O
mice O
chronically O
treated O
with O
vildagliptin B
suggest O
that O
chronic O
DPP4 O
inhibition O
potentially O
results O
in O
additional O
quality O
- O
adjusted O
life O
- O
years O
for O
individuals O
with O
type O
2 O
diabetes O
, O
which O
is O
the O
primary O
goal O
of O
any O
diabetes O
therapy O
. O

PT O
- O
ACRAMTU O
, O
A O
Platinum B
- O
Acridine B
Anticancer O
Agent O
, O
Lengthens O
and O
Aggregates O
, O
but O
does O
not O
Stiffen O
or O
Soften O
DNA O
. O

PT O
- O
ACRAMTU O
is O
the O
parent O
drug O
of O
a O
family O
of O
non O
- O
classical O
platinum B
- O
based O
agents O
that O
show O
potent O
activity O
in O
non O
- O
small O
cell O
lung O
cancer O
in O
vitro O
and O
in O
vivo O
. O

Its O
acridine B
moiety O
intercalates O
between O
DNA O
bases O
, O
while O
the O
platinum B
group O
forms O
mono O
- O
adducts O
with O
DNA O
bases O
. O

In O
the O
AG O
+ O
GG O
group O
, O
males O
with O
HDL O
cholesterol B
levels O
< O
40 O
mg O
/ O
dL O
are O
less O
frequent O
( O
P O
= O
0 O
. O
05 O
) O
and O
obesity O
tends O
to O
be O
less O
prevalent O
( O
P O
= O
0 O
. O
07 O
) O
. O

Charge O
transfer O
and O
Penning O
ionization O
of O
dopants O
in O
or O
on O
helium B
nanodroplets O
exposed O
to O
EUV O
radiation O
. O

Helium B
nanodroplets O
are O
widely O
used O
as O
a O
cold O
, O
weakly O
interacting O
matrix O
for O
spectroscopy O
of O
embedded O
species O
. O

In O
this O
work O
we O
excite O
or O
ionize O
doped O
He B
droplets O
using O
synchrotron O
radiation O
and O
study O
the O
effect O
onto O
the O
dopant O
atoms O
depending O
on O
their O
location O
inside O
the O
droplets O
( O
rare O
gases O
) O
or O
outside O
at O
the O
droplet O
surface O
( O
alkali O
metals O
) O
. O

Herein O
, O
we O
investigated O
the O
effect O
of O
a O
natural O
neuroprotective O
flavonoid O
, O
calycopterin O
, O
on O
H2O2 B
- O
induced O
disruption O
of O
phase O
II O
detoxifying O
enzyme O
system O
and O
cAMP B
response O
element O
binding O
protein O
( O
CREB O
) O
phosphorylation O
. O

METHODS O
: O
PC12 O
cells O
were O
treated O
with O
25 O
, O
50 O
and O
100 O
mu O
M O
of O
calycopterin O
for O
3h O
, O
followed O
by O
adding O
H2O2 B
( O
150 O
mu O
M O
) O
for O
24h O
. O

The O
concentration O
of O
glutathione B
( O
GSH B
) O
was O
determined O
in O
whole O
cell O
lysate O
using O
dithionitrobenzoic O
acid O
method O
. O

We O
found O
that O
H2O2 B
decreased O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
, O
while O
, O
calycopterin O
prevented O
this O
decrease O
in O
MMP O
in O
presence O
of O
H2O2 B
. O

In O
H2O2 B
- O
treated O
cells O
, O
calycopterin O
also O
suppressed O
cytochrome O
C O
release O
to O
cytosol O
that O
is O
necessary O
for O
maintaining O
mitochondrial O
homeostasis O
in O
survived O
cells O
. O

Moreover O
, O
calycopterin O
, O
in O
presence O
of O
H2O2 B
inhibited O
the O
decrease O
caused O
by O
oxidative O
stress O
in O
stress O
- O
sensing O
transcription O
factors O
, O
CREB O
and O
Nrf2 O
, O
which O
play O
an O
important O
role O
in O
antioxidant O
capacity O
of O
the O
cell O
. O

In O
the O
presence O
of O
H2O2 B
, O
calycopterin O
inhibited O
decrease O
in O
GSH B
level O
and O
SOD O
activity O
. O

CONCLUSION O
: O
We O
provided O
documentation O
of O
neuroprotective O
effect O
of O
a O
natural O
flavone O
, O
calycopterin O
, O
against O
H2O2 B
- O
induced O
oxidative O
stress O
in O
differentiated O
PC12 O
cells O
by O
modulating O
the O
level O
of O
CREB O
phosphorylation O
and O
Nrf2 O
pathway O
. O

Monitoring O
Conformational O
Changes O
in O
Peroxisome O
Proliferator O
- O
Activated O
Receptor O
alpha O
by O
a O
Genetically O
Encoded O
Photo O
- O
Amino B
Acid I
, O
Cross O
- O
Linking O
, O
and O
Mass O
Spectrometry O
. O

Using O
E O
. O
coli O
cells O
with O
a O
special O
tRNA O
/ O
aminoacyl O
- O
tRNA O
synthetase O
pair O
, O
two O
PPAR O
alpha O
variants O
were O
prepared O
, O
in O
which O
Leu B
- O
258 O
or O
Phe B
- O
273 O
were O
site O
- O
specifically O
replaced O
by O
the O
genetically O
encoded O
photo O
- O
reactive O
amino B
acid I
para O
- O
benzoylphenylalanine O
( O
Bpa B
) O
. O

At O
the O
highest O
dose O
, O
cyfluthrin O
increased O
renal O
and O
hepatic O
O B
- O
deethylation O
of O
ethoxyresorufin B
and O
O B
- O
demethylation O
of O
methoxyresorufin O
, O
metabolism O
mediated O
by O
the O
CYP1A O
subfamily O
. O

Liver O
and O
kidney O
were O
susceptible O
to O
cyfluthrin O
- O
dependent O
induction O
of O
12 O
- O
and O
11 O
- O
hydroxylation O
of O
lauric B
acid I
, O
suggesting O
CYP4A O
subfamily O
induction O
. O

Also O
cyfluthrin O
increased O
the O
beta O
- O
oxidation O
of O
palmitoyl B
- O
coenzyme O
A O
and O
carnitine B
acetyltransferase O
activity O
, O
supporting O
cyfluthrin O
as O
a O
peroxisome O
proliferator O
. O

I3S O
increased O
expression O
of O
ROR O
gamma O
t O
, O
the O
master O
transcription O
factor O
for O
Th17 O
differentiation O
, O
and O
stimulated O
Th17 O
differentiation O
, O
in O
a O
comparative O
manner O
as O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
a O
prototypical O
AhR O
ligand O
. O

Activation O
of O
STAT3 O
, O
which O
is O
phosphorylated O
by O
the O
IL O
- O
6 O
signaling O
pathways O
and O
thus O
is O
necessary O
for O
Th17 O
differentiation O
, O
was O
strongly O
stimulated O
by O
I3S O
and O
TCDD B
. O

Phosphorylation O
of O
c O
- O
Src O
, O
which O
was O
shown O
to O
be O
activated O
by O
AhR O
ligands O
, O
was O
also O
increased O
by O
I3S O
and O
TCDD B
, O
and O
blocking O
of O
c O
- O
Src O
activity O
by O
4 O
- O
amino O
- O
5 O
- O
( O
4 O
- O
chlorophenyl O
) O
- O
7 O
- O
( O
t O
- O
butyl O
) O
pyrazolo O
[ O
3 O
, O
4 O
- O
d O
] O
pyrimidine O
( O
PP2 O
) O
inhibited O
phosphorylation O
of O
both O
c O
- O
Src O
and O
STAT3 O
, O
raising O
a O
possibility O
that O
stimulatory O
activities O
of O
I3S O
and O
TCDD O

Canna O
indica O
L O
. O
attenuates O
high O
- O
glucose B
- O
and O
lipopolysaccharide O
- O
induced O
inflammatory O
mediators O
in O
monocyte O
/ O
macrophage O
. O

MATERIALS O
AND O
METHODS O
: O
The O
present O
study O
aimed O
to O
investigate O
the O
effect O
of O
CI O
ethanolic O
extract O
( O
CIE O
) O
on O
productions O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
RAW264 O
. O
7 O
macrophages O
. O

In O
addition O
, O
the O
effects O
of O
CIE O
in O
high O
glucose B
( O
HG O
) O
- O
induced O
U937 O
monocytes O
on O
mRNA O
expressions O
of O
IL O
- O
8 O
and O
monocyte O
chemoattractant O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
, O
and O
regulation O
of O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
pathways O
were O
also O
identified O
. O

RESULTS O
: O
CIE O
was O
found O
to O
inhibit O
the O
production O
of O
inflammatory O
mediators O
including O
NO B
, O
IL O
- O
1 O
beta O
, O
and O
PGE2 B
from O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
. O

Nedd4 O
is O
a O
specific O
E3 O
ubiquitin O
ligase O
for O
the O
NMDA B
receptor O
subunit O
GluN2D O
. O

NMDA B
receptors O
are O
a O
family O
of O
glutamate B
- O
gated O
ion O
channels O
that O
regulate O
various O
CNS O
functions O
such O
as O
synaptic O
plasticity O
and O
learning O
. O

However O
hypo O
- O
or O
hyper O
- O
activation O
of O
NMDA B
receptors O
is O
critically O
involved O
in O
many O
neurological O
and O
psychiatric O
conditions O
such O
as O
pain O
, O
stroke O
, O
epilepsy O
, O
neurodegeneration O
, O
schizophrenia O
, O
and O
depression O
. O

Thus O
, O
it O
is O
important O
to O
identify O
mechanisms O
( O
such O
as O
by O
targeted O
ubiquitination O
) O
that O
regulate O
the O
levels O
of O
individual O
subtypes O
of O
NMDA B
receptors O
. O

In O
this O
study O
, O
we O
used O
a O
series O
of O
tagged O
, O
carboxy B
terminal O
constructs O
of O
GluN2D O
to O
identify O
associating O
proteins O
from O
rat O
brain O
. O

Of O
seven O
different O
GluN2D O
C B
- O
terminal O
fragments O
used O
as O
bait O
, O
only O
the O
construct O
containing O
amino B
acids I
983 O
- O
1097 O
associated O
with O
an O
E3 O
ligase O
, O
Nedd4 O
. O

This O
association O
is O
mediated O
by O
an O
interaction O
between O
GluN2D O
' O
s O
C B
- O
terminal O
PPXY O
motif O
and O
the O
2nd O
and O
3rd O
WW O
domains O
of O
Nedd4 O
. O

Nedd4 O
coexpression O
with O
GluN2D O
enhances O
GluN2D O
ubiquitination O
and O
reduces O
GluN1 O
/ O
GluN2D O
NMDA B
receptor O
responses O
. O

These O
results O
identify O
Nedd4 O
as O
a O
novel O
binding O
partner O
for O
GluN2D O
and O
suggest O
a O
mechanism O
for O
the O
regulation O
of O
NMDA B
receptors O
that O
contains O
GluN2D O
subunit O
through O
ubiquitination O
- O
dependent O
downregulation O
. O

A O
dihydrochalcone O
and O
several O
homoisoflavonoids O
from O
Polygonatum O
odoratum O
are O
activators O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
. O

Adenosine B
monophosphate I
( O
AMP B
) O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
is O
a O
major O
cellular O
energy O
sensor O
and O
master O
regulator O
of O
metabolic O
homeostasis O
; O
thus O
, O
AMPK O
plays O
a O
central O
role O
in O
studies O
on O
diabetes O
and O
related O
metabolic O
diseases O
. O

The O
amount O
of O
active O
phosphorylated O
AMPK O
and O
acetyl B
- I
CoA I
carboxylase O
in O
rat O
liver O
epithelial O
IAR O
- O
20 O
cells O
increased O
when O
the O
cells O
were O
incubated O
with O
the O
aforementioned O
compounds O
. O

Two O
new O
photosensitizers O
based O
on O
the O
BODIPY B
scaffold O
have O
been O
synthesized O
, O
of O
which O
one O
bears O
an O
NLS O
peptide O
, O
which O
is O
linked O
to O
the O
BODIPY O
' O
s O
core O
using O
the O
copper B
catalysed O
azide B
- O
alkyne B
click O
reaction O
. O

The O
phototoxicities O
of O
these O
BODIPY B
based O
photosensitizers O
have O
been O
determined O
, O
as O
well O
as O
their O
dark O
toxicities O
. O

Although O
the O
conjugation O
of O
a O
single O
NLS O
peptide O
to O
the O
BODIPY B
did O
not O
lead O
to O
any O
observable O
nuclear O
localization O
, O
the O
photosensitizer O
did O
exhibit O
a O
superior O
photoxicity O
. O

Cellular O
co O
- O
localization O
experiments O
revealed O
a O
localization O
of O
both O
dyes O
in O
the O
lysosomes O
, O
as O
well O
as O
a O
partial O
localization O
within O
the O
ER O
( O
for O
the O
peptide O
- O
bearing O
BODIPY B
) O
. O

Valeriana O
officinalis O
attenuates O
the O
rotenone B
- O
induced O
toxicity O
in O
Drosophila O
melanogaster O
. O

In O
this O
study O
, O
we O
investigated O
the O
potential O
protective O
effects O
of O
Valeriana O
officinalis O
( O
V O
. O
officinalis O
) O
against O
the O
toxicity O
induced O
by O
rotenone B
in O
Drosophila O
melanogaster O
( O
D O
. O
melanogaster O
) O
. O

Adult O
wild O
- O
type O
flies O
were O
concomitantly O
exposed O
to O
rotenone B
( O
500 O
mu O
M O
) O
and O
V O
. O
officinalis O
aqueous O
extract O
( O
10mg O
/ O
mL O
) O
in O
the O
food O
during O
7 O
days O
. O

Rotenone B
- O
fed O
flies O
had O
a O
worse O
performance O
in O
the O
negative O
geotaxis O
assay O
( O
i O
. O
e O
. O
climbing O
capability O
) O
and O
open O
- O
field O
test O
( O
i O
. O
e O
. O
mobility O
time O
) O
as O
well O
as O
a O
higher O
incidence O
of O
mortality O
when O
compared O
to O
control O
group O
. O

V O
. O
officinalis O
treatment O
offered O
protection O
against O
these O
detrimental O
effects O
of O
rotenone B
. O

In O
contrast O
, O
the O
decreased O
number O
of O
crossings O
observed O
in O
the O
flies O
exposed O
to O
rotenone B
was O
not O
modified O
by O
V O
. O
officinalis O
. O

Rotenone B
toxicity O
was O
also O
associated O
with O
a O
marked O
decrease O
on O
the O
total O
- O
thiol B
content O
in O
the O
homogenates O
and O
cell O
viability O
of O
flies O
, O
which O
were O
reduced O
by O
V O
. O
officinalis O
treatment O
. O

Indeed O
, O
rotenone B
exposure O
caused O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
antioxidant O
enzymes O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
and O
also O
in O
the O
tyrosine B
hydroxylase O
gene O
( O
TH O
) O
. O

Our O
results O
suggest O
that O
V O
. O
officinalis O
extract O
was O
effective O
in O
reducing O
the O
toxicity O
induced O
by O
rotenone B
in O
D O
. O
melonogaster O
as O
well O
as O
confirm O
the O
utility O
of O
this O
model O
to O
investigate O
potential O
therapeutic O
strategies O
on O
movement O
disorders O
, O
including O
Parkinson O
disease O
( O
PD O
) O
. O

Direct O
methods O
for O
detection O
of O
protein O
S B
- O
nitrosylation O
. O

S B
- O
nitrosylation O
of O
protein O
cysteine B
residues O
is O
known O
to O
be O
an O
important O
mechanism O
for O
nitric B
oxide I
signaling O
. O

However O
, O
the O
detection O
of O
protein O
S B
- O
nitrosylation O
is O
still O
challenging O
due O
to O
technical O
limitations O
of O
current O
methods O
. O

This O
chapter O
provides O
a O
brief O
review O
on O
recent O
developments O
of O
methods O
, O
which O
directly O
target O
S B
- O
nitroso B
moieties O
for O
detection O
. O

We O
also O
describe O
in O
detail O
the O
protocol O
of O
an O
organophosphine O
- O
based O
biotin B
labeling O
of O
protein O
S B
- O
nitroso B
moieties O
. O

Mechanism O
of O
BDE209 O
- O
induced O
impaired O
glucose B
homeostasis O
based O
on O
gene O
microarray O
analysis O
of O
adult O
rat O
liver O
. O

2 O
, O
2 O
' O
, O
3 O
, O
3 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
, O
5 O
' O
, O
6 O
, O
6 O
' O
- O
decabromodiphenyl O
ether O
( O
BDE209 O
) O
is O
commercially O
most O
important O
both O
in O
the O
production O
and O
in O
the O
use O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
. O

It O
might O
bioaccumulate O
in O
wildlife O
and O
human O
and O
is O
the O
only O
PBDEs B
mixture O
still O
used O
today O
. O

In O
the O
present O
study O
, O
male O
adult O
rats O
treated O
with O
BDE209 O
( O
0 O
, O
0 O
. O
05 O
, O
1 O
, O
and O
20 O
mg O
/ O
kg O
) O
for O
8 O
weeks O
were O
used O
to O
explore O
the O
effects O
of O
BDE209 O
on O
glucose B
homeostasis O
and O
possible O
mechanisms O
; O
0 O
. O
05 O
mg O
/ O
kg O
of O
BDE209 O
induced O
dose O
- O
related O
hyperglycemia O
. O

Additionally O
, O
reduced B
glutathione I
and O
superoxide B
dismutase O
in O
plasma O
indicated O
that O
oxidative O
damage O
might O
partly O
contribute O
to O
BDE209 O
- O
induced O
hyperglycemia O
. O

This O
work O
demonstrates O
a O
novel O
multifunctional O
nanofibrous O
mat O
for O
photocatalytic O
applications O
based O
on O
TiO2 B
nanocables O
functionalized O
by O
Ag B
nanoparticles O
and O
coated O
with O
a O
thin O
( O
~ O
2 O
nm O
) O
graphitic O
shell O
. O

In O
this O
mat O
, O
which O
was O
realized O
by O
an O
electrospinning O
technique O
, O
each O
component O
serves O
a O
unique O
function O
: O
the O
carbon B
coating O
acts O
as O
both O
an O
adsorption O
material O
for O
capturing O
pollutants O
and O
as O
a O
charge O
- O
transfer O
material O
, O
the O
Ag B
nanoparticles O
act O
as O
a O
visible O
- O
light O
sensitizing O
agent O
and O
also O
as O
a O
charge O
- O
transfer O
material O
, O
finally O
the O
TiO2 B
nanocable O
mat O
acts O
as O
a O
UV O
sensitive O
photocatalytic O
matrix O
and O
as O
the O
flexible O
substrate O
for O
the O
other O
functional O
components O
. O

This O
multicomponent O
nanocable O
mat O
exhibits O
excellent O
photocatalytic O
activity O
under O
simulated O
solar O
irradiation O
for O
the O
degradation O
of O
model O
pollutants O
including O
RhB O
and O
phenol B
. O

In O
addition O
, O
the O
porous O
carbon B
coating O
infiltrated O
into O
the O
nanocable O
matrix O
endows O
the O
mat O
with O
excellent O
flexibility O
and O
enables O
robust O
, O
large O
- O
area O
( O
10 O
x O
10 O
cm O
) O
fabrication O
, O
representing O
a O
significant O
advantage O
over O
previous O
brittle O
ceramic O
nanofibrous O
mat O
photocatalyst O
substrates O
. O

Proline B
- O
rich O
tyrosine B
kinase O
2 O
( O
Pyk2 O
) O
is O
activated O
by O
various O
agonists O
in O
platelets O
. O

It O
has O
been O
shown O
that O
ADP B
- O
, O
but O
not O
thrombin O
- O
, O
induced O
thromboxane O
( O
TxA2 O
) O
generation O
depends O
on O
integrin O
signaling O
. O

Unlike O
ADP B
, O
thrombin O
activates O
G12 O
/ O
13 O
pathways O
, O
and O
G12 O
/ O
13 O
pathways O
can O
substitute O
for O
integrin O
signaling O
for O
TxA2 O
generation O
. O

Background O
: O
Antibody O
- O
drug O
conjugates O
( O
ADCs O
) O
such O
as O
Kadcyla O
( O
TM O
) O
( O
ado O
- O
trastuzumab O
emtansine O
[ O
T O
- O
DM1 B
] O
) O
present O
covalently O
bound O
cytotoxic O
drugs O
, O
which O
may O
influence O
their O
immunogenicity O
potential O
compared O
with O
antibody O
therapies O
. O

Results O
: O
The O
immunogenicity O
strategy O
for O
T O
- O
DM1 B
used O
a O
risk O
- O
based O
, O
tiered O
approach O
that O
included O
screening O
and O
titration O
to O
detect O
antitherapeutic O
antibodies O
; O
confirmation O
of O
positive O
responses O
; O
and O
characterization O
to O
assess O
whether O
the O
immune O
response O
is O
primarily O
to O
the O
antibody O
or O
to O
the O
linker O
- O
drug O
and O
/ O
or O
new O
epitopes O
in O
trastuzumab O
resulting O
from O
conjugation O
. O

Conclusion O
: O
The O
tiered O
immunogenicity O
assay O
strategy O
for O
T O
- O
DM1 B
allowed O
detection O
of O
antitherapeutic O
antibodies O
to O
all O
components O
of O
the O
ADC O
in O
multiple O
nonclinical O
and O
clinical O
studies O
. O

Results O
: O
This O
method O
involves O
collection O
of O
blood O
into O
a O
plastic O
- O
wrapped O
, O
EDTA B
- O
coated O
capillary O
tube O
, O
containing O
a O
small O
amount O
of O
a O
thixotropic O
gel O
and O
a O
porous O
plug O
. O

Solution O
pH O
and O
Oligoamine O
Molecular O
Weight O
Dependence O
of O
the O
Transition O
from O
Monolayer O
to O
Multilayer O
Adsorption O
at O
the O
Air O
- O
Water O
Interface O
from O
Sodium B
Dodecyl I
Sulfate I
/ O
Oligoamine O
Mixtures O
. O

Neutron O
reflectivity O
and O
surface O
tension O
have O
been O
used O
to O
investigate O
the O
solution O
pH O
and O
oligoamine O
molecular O
weight O
dependence O
of O
the O
adsorption O
of O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
/ O
oligoamine O
mixtures O
at O
the O
air O
- O
water O
interface O
. O

For O
diethylenetriamine O
, O
triamine O
, O
or O
triethylenetetramine O
, O
tetramine O
mixed O
with O
SDS B
, O
there O
is O
monolayer O
adsorption O
at O
pH O
7 O
and O
10 O
, O
and O
multilayer O
adsorption O
at O
pH O
3 O
. O

For O
the O
slightly O
higher O
molecular O
weight O
tetraethylenepentami B
, O
pentamine O
, O
and O
pentaethylenehexamin O
, O
hexamine O
, O
the O
adsorption O
is O
in O
the O
form O
of O
a O
monolayer O
at O
pH O
3 O
and O
multilayers O
at O
pH O
7 O
and O
10 O
. O

This O
results O
from O
the O
relative O
balance O
between O
the O
electrostatic O
attraction O
between O
the O
SDS B
and O
amine O
nitrogen O
group O
which O
decreases O
as O
the O
charge O
density O
decreases O
with O
increasing O
pH O
, O
the O
ion O
- O
dipole O
interaction O
between O
the O
amine O
nitrogen O
and O
SDS O
sulfate O
group O
which O
is O
dominant O
at O
higher O
pH O
, O
and O
the O
hydrophobic O
interalkyl O
chain O
interaction O
between O
bound O
SDS B
molecules O
which O
changes O
with O
oligoamine O
molecular O
weight O
. O

Ethylene O
sulfide O
( O
ES O
) O
, O
propargyl O
carbonylimidazole O
( O
PPC O
) O
and O
azidoethyl O
carbonylimidazole O
( O
AEC O
) O
reacted O
with O
amine B
and O
/ O
or O
hydroxyl B
groups O
in O
BC O
to O
introduce O
the O
corresponding O
thiol B
, O
alkyne B
and O
azide B
groups O
on O
SS O
surfaces O
( O
SS O
- O
thiol B
, O
SS O
- O
alkyne B
and O
SS O
- O
azide B
, O
respectively O
) O
. O

Antifouling O
zwitterionic O
SS O
- O
PMPC O
surface O
was O
prepared O
by O
thiol B
- O
ene O
photopolymerization O
of O
2 O
- O
methacryloyloxyethyl O
phosphorylcholine O
( O
MPC O
) O
from O
the O
SS O
- O
thiol B
surface O
. O

Protein O
- O
resistant O
SS O
- O
PPEGMA O
and O
protein O
- O
adsorbing O
SS O
- O
PPFS O
surfaces O
were O
prepared O
by O
coupling O
of O
the O
respective O
azide B
- O
functionalized O
poly O
( O
poly O
( O
ethylene O
glycol O
) O
methyl O
ether O
methacrylate O
) O
( O
azido O
- O
PPEGMA O
) O
and O
poly O
( O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
- O
pentafluorostyrene O
) O
( O
azido O
- O
PPFS O
) O
polymer O
brushes O
in O
azide B
- O
alkyne B
' O
click O
' O
reaction O
. O

Antifouling O
alkyne B
- O
functionalized O
poly O
( O
N O
- O
hydroxyethyl O
acrylamide O
) O
( O
alkynyl O
- O
PHEAA O
) O
and O
antibacterial O
alkyne B
- O
functionalized O
poly O
( O
2 O
- O
( O
methacryloyloxy O
) O
ethyl O
trimethylammonium O
chloride O
) O
( O
alkynyl O
- O
PMETA O
) O
polymer O
brushes O
were O
clicked O
on O
the O
SS O
- O
azide B
surface O
. O

Revisiting O
the O
Mechanism O
of O
Neutral O
Hydrolysis O
of O
Esters B
: O
Water O
Autoionization O
Mechanisms O
with O
Acid O
or O
Base O
Initiation O
Pathways O
. O

The O
mechanism O
of O
neutral O
hydrolysis O
of O
ester B
has O
long O
been O
explored O
by O
theoretical O
studies O
. O

An O
important O
advance O
was O
recently O
reported O
by O
Gunaydin O
and O
Houk O
, O
suggesting O
that O
ions O
are O
involved O
in O
the O
mechanism O
and O
the O
process O
initiates O
by O
water O
autoionization O
followed O
by O
protonation O
of O
the O
ester B
( O
WAIA O
mechanism O
) O
. O

However O
, O
this O
mechanism O
does O
not O
explain O
the O
hydrolysis O
of O
activated O
esters B
. O

In O
this O
work O
, O
we O
have O
used O
ab O
initio O
calculations O
, O
continuum O
solvation O
models O
and O
ab O
initio O
classical O
trajectory O
to O
support O
the O
WAIA O
mechanism O
for O
normal O
ester B
. O

In O
the O
case O
of O
activated O
esters O
, O
the O
process O
can O
also O
be O
viewed O
as O
water O
autoionization O
with O
formation O
of O
hydroxide B
ion O
aided O
by O
a O
second O
water O
moleculeacting O
as O
a O
general O
base O
( O
WAIB O
mechanism O
) O
. O

The O
approach O
used O
in O
this O
paper O
allows O
the O
calculation O
of O
the O
free O
energy O
profile O
and O
enable O
us O
to O
explain O
the O
mechanism O
and O
kinetics O
of O
the O
neutral O
hydrolysis O
of O
normal O
( O
methyl O
acetate O
) O
and O
activated O
( O
methyl O
trifluoroacetate O
) O
esters B
. O

This O
work O
describes O
a O
technique O
for O
forming O
high O
- O
density O
arrays O
and O
patterns O
of O
membrane O
- O
bound O
proteins O
through O
binding O
to O
a O
curvature O
- O
organized O
compositional O
pattern O
of O
metal O
- O
chelating O
lipids O
( O
Cu B
( I
2 I
+ I
) I
- O
DOIDA O
or O
Cu B
( I
2 I
+ I
) I
- O
DSIDA O
) O
. O

This O
curvature O
pattern O
sorts O
Cu B
( I
2 I
+ I
) I
- O
DOIDA O
to O
the O
200 O
nm O
hemispherical O
lattice O
sites O
of O
a O
600 O
nm O
X O
600 O
nm O
unit O
cell O
in O
Ld O
- O
Lo O
phase O
separated O
lipid O
multibilayers O
. O

In O
comparison O
, O
the O
negative O
pixel O
pattern O
is O
created O
by O
sorting O
Cu B
( I
2 I
+ I
) I
- O
DSIDA O
in O
Ld O
- O
L O
beta O
' O
phase O
separated O
lipid O
multibilayers O
to O
the O
flat O
grid O
between O
the O
lattice O
sites O
followed O
by O
binding O
to O
His O
- O
GFP O
. O

Ag B
nanoparticles O
of O
~ O
20 O
nm O
size O
and O
rather O
uniform O
size O
distribution O
were O
synthesized O
in O
polyelectrolyte O
multilayers O
( O
PEMs O
) O
via O
an O
ion O
- O
exchange O
/ O
reduction O
process O
in O
two O
stages O
( O
seeding O
and O
growth O
) O
, O
which O
were O
used O
as O
sacrificial O
templates O
to O
fabricate O
Ag O
- O
Au O
bimetallic O
hollow O
nanoparticles O
via O
galvanic O
replacement O
reaction O
. O

UV O
- O
vis O
absorbance O
spectroscopy O
and O
TEM O
results O
indicated O
that O
both O
size O
and O
optical O
properties O
of O
the O
Ag B
nanoparticles O
in O
the O
PEM O
can O
be O
controlled O
by O
manipulating O
ion O
content O
in O
the O
PEM O
and O
the O
number O
of O
the O
ion O
- O
exchange O
/ O
reduction O
cycle O
, O
whereas O
that O
of O
Ag O
- O
Au O
bimetallic O
nanoparticles O
were O
dependent O
on O
size O
of O
the O
Ag B
templates O
and O
the O
replacement O
reaction O
kinetics O
. O

Vibrational O
dynamics O
of O
the O
T1u O
CO B
stretching O
mode O
of O
tungsten O
hexacarbonyl O
is O
explored O
when O
the O
molecule O
is O
embedded O
in O
a O
nitrogen B
matrix O
at O
low O
temperature O
. O

In O
Oh O
sites O
, O
the O
vibrational O
coherence O
is O
strongly O
temperature O
dependent O
, O
exhibiting O
a O
coupling O
with O
librational O
phonons O
of O
the O
nitrogen B
lattice O
. O

Dephasing O
time O
in O
Kr O
does O
not O
depend O
on O
temperature O
and O
remains O
in O
the O
hundreds O
of O
picosecond O
, O
highlighting O
the O
molecular O
origin O
of O
dephasing O
process O
in O
N2 B
. O

Base O
- O
Specific O
Ionization O
of O
Deprotonated O
Nucleotides B
by O
Resonance O
Enhanced O
Two O
- O
Photon O
Detachment O
. O

Here O
, O
a O
two O
- O
photon O
resonance O
- O
enhanced O
ionization O
scheme O
is O
presented O
that O
utilizes O
the O
1 O
pi O
pi O
* O
transition O
, O
localized O
on O
the O
DNA O
base O
, O
to O
elucidate O
the O
base O
- O
specific O
ionization O
in O
a O
deprotonated O
nucleotide B
. O

In O
contrast O
to O
previous O
reports O
, O
the O
scheme O
is O
insensitive O
to O
competing O
ionization O
channels O
arising O
from O
the O
sugar B
- O
phosphate B
backbone O
. O

Using O
this O
approach O
, O
we O
demonstrate O
that O
for O
all O
bases O
except O
guanine B
, O
the O
lowest O
electron O
detachment O
energy O
corresponds O
to O
detachment O
from O
the O
sugar B
- O
phosphate B
backbone O
and O
allows O
us O
to O
determine O
the O
lowest O
adiabatic O
ionization O
energy O
for O
the O
other O
three O
bases O
for O
the O
first O
time O
in O
an O
isolated O
nucleotide B
. O

The O
Pyrimidyn O
compounds O
: O
dual O
- O
action O
small O
molecule O
pyrimidine B
- O
based O
dynamin O
inhibitors O
. O

We O
have O
designed O
a O
series O
of O
novel O
pyrimidine B
- O
based O
' O
PyrimidynTM O
' O
compounds O
which O
inhibit O
the O
lipid O
stimulated O
GTPase O
activity O
of O
full O
length O
dynamin O
I O
and O
II O
with O
similar O
potency O
. O

The O
compound O
competitively O
inhibits O
both O
GTP B
and O
phospholipid O
interactions O
with O
dynamin O
I O
. O

Therefore O
, O
Pyrimidyn O
compounds O
block O
endocytosis O
by O
directly O
competing O
with O
GTP B
and O
lipid O
binding O
to O
dynamin O
, O
limiting O
both O
the O
recruitment O
of O
dynamin O
to O
membranes O
and O
its O
activation O
. O

Interactive O
effects O
of O
smoking O
and O
glutathione B
S B
- O
transferase O
polymorphisms O
on O
the O
development O
of O
non O
- O
alcoholic O
fatty O
liver O
disease O
. O

Glutathione B
S B
- O
transferases O
( O
GSTs O
) O
protect O
cells O
against O
exogenous O
and O
endogenous O
oxidative O
stress O
. O

Melamine B
activates O
NF O
kappa O
B O
/ O
COX O
- O
2 O
/ O
PGE2 O
pathway O
and O
increases O
NADPH B
oxidase O
- O
dependent O
ROS O
production O
in O
macrophages O
and O
human O
embryonic O
kidney O
cells O
. O

Melamine B
is O
a O
wildly O
used O
compound O
in O
manufactures O
of O
plastics O
and O
resins O
. O

A O
variety O
of O
toxic O
effects O
from O
melamine B
, O
including O
nephrolithiasis O
, O
chronic O
kidney O
inflammation O
, O
and O
bladder O
carcinoma O
, O
have O
been O
mentioned O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
melamine B
- O
induced O
oxidative O
stress O
and O
inflammation O
in O
macrophage O
- O
like O
cell O
line O
RAW O
264 O
. O
7 O
and O
human O
embryonic O
kidney O
cell O
line O
HEK293 O
. O

Results O
indicated O
melamine B
activated O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
through O
increasing O
I O
kappa O
B O
- O
alpha O
degradation O
and O
NF O
- O
kappa O
B O
p65 O
/ O
p50 O
DNA O
- O
binding O
activity O
. O

In O
addition O
, O
melamine B
significantly O
increased O
COX O
- O
2 O
expression O
and O
prostaglandin B
E2 I
( O
PGE2 B
) O
production O
. O

Moreover O
, O
melamine B
activated O
NADPH B
oxidase O
( O
NOX O
) O
, O
including O
NOX1 O
, O
2 O
and O
4 O
, O
accompanied O
with O
an O
increase O
in O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
. O

Furthermore O
, O
melamine B
- O
induced O
ROS O
production O
could O
be O
attenuated O
by O
apocynin B
, O
a O
NOX O
inhibitor O
. O

In O
conclusion O
, O
our O
findings O
suggest O
melamine B
increased O
inflammation O
and O
oxidative O
stress O
via O
activation O
of O
NF O
- O
kappa O
B O
/ O
COX O
- O
2 O
and O
NOX O
/ O
ROS O
pathway O
, O
and O
first O
revealed O
the O
critical O
role O
of O
NOX O
in O
melamine B
- O
induced O
ROS O
production O
, O
suggesting O
the O
potential O
of O
NOX O
inhibitor O
against O
melamine B
toxicity O
. O

Genetic O
Polymorphism O
at O
Val B
( O
80 O
) O
( O
rs700518 O
) O
of O
the O
CYP19A1 O
Gene O
is O
Associated O
with O
Aromatase O
Inhibitor O
Associated O
Bone O
Loss O
in O
Women O
with O
ER O
( O
+ O
) O
Breast O
Cancer O
. O

PURPOSE O
: O
Polymorphisms O
in O
the O
CYP19A1 O
( O
aromatase O
) O
gene O
have O
been O
reported O
to O
influence O
disease O
- O
free O
survival O
and O
the O
incidence O
of O
musculoskeletal O
complaints O
in O
patients O
taking O
aromatase O
inhibitors O
( O
AIs O
) O
for O
estrogen B
receptor O
positive O
( O
ER O
+ O
) O
breast O
cancer O
. O

Twenty O
- O
four O
hour O
urine O
N B
- O
telopeptide O
( O
NTX O
) O
was O
measured O
by O
Elisa O
and O
serum O
estradiol B
was O
measured O
by O
ultrasensitive O
radioimmunoassay O
at O
baseline O
, O
and O
at O
6 O
months O
. O

RESULTS O
: O
Women O
with O
the O
AA O
genotype O
for O
the O
rs700518 O
( O
G O
/ O
A O
at O
Val B
( O
80 O
) O
) O
developed O
significant O
bone O
loss O
at O
the O
lumbar O
spine O
and O
the O
total O
hip O
at O
12 O
months O
relative O
to O
patients O
carrying O
the O
G O
allele O
( O
GA O
/ O
GG O
) O
; O
both O
p O
= O
0 O
. O
03 O
. O

There O
was O
a O
borderline O
greater O
increase O
in O
urinary O
NTX O
in O
those O
with O
the O
AA O
genotype O
compared O
to O
patients O
with O
the O
G O
allele O
, O
p O
= O
0 O
. O
05 O
; O
but O
no O
significant O
difference O
in O
changes O
in O
estradiol B
levels O
among O
the O
genotypes O
. O

Acetylcholine B
has O
traditionally O
only O
been O
regarded O
as O
a O
neurotransmitter O
of O
the O
parasympathetic O
nervous O
system O
, O
causing O
bronchoconstriction O
and O
mucus O
secretion O
in O
asthma O
and O
COPD O
by O
muscarinic O
receptor O
activation O
on O
airway O
smooth O
muscle O
and O
mucus O
- O
producing O
cells O
. O

Recent O
studies O
in O
experimental O
models O
indicate O
that O
muscarinic O
receptor O
stimulation O
in O
the O
airways O
also O
induces O
pro O
- O
inflammatory O
, O
pro O
- O
proliferative O
and O
pro O
- O
fibrotic O
effects O
, O
which O
may O
involve O
activation O
of O
airway O
structural O
and O
inflammatory O
cells O
by O
neuronal O
as O
well O
as O
non O
- O
neuronal O
acetylcholine B
. O

To O
address O
this O
issue O
, O
we O
infused O
the O
GABAA O
receptor O
( O
GABAAR O
) O
antagonist O
bicuculline B
to O
temporarily O
activate O
the O
IL O
cortex O
. O

IL O
cortex O
inactivation O
with O
the O
AMPA B
receptor O
( O
AMPAR O
) O
antagonist O
CNQX O
produced O
opposite O
, O
anxiolytic O
effects O
. O

However O
, O
infusion O
of O
the O
NMDA B
receptor O
( O
NMDAR O
) O
antagonist O
AP5 O
into O
the O
IL O
cortex O
had O
no O
significant O
effect O
. O

Interestingly O
, O
we O
found O
parallel O
and O
corresponding O
electrophysiological O
changes O
in O
anxious O
mice O
; O
compared O
to O
mice O
with O
relatively O
low O
anxiety O
, O
the O
relatively O
high O
anxiety O
mice O
exhibited O
smaller O
evoked O
inhibitory O
postsynaptic O
currents O
( O
eIPSCs O
) O
and O
larger O
AMPA B
- O
mediated O
evoked O
excitatory O
postsynaptic O
currents O
( O
eEPSCs O
) O
in O
pyramidal O
neurons O
in O
the O
IL O
cortex O
. O

Haloperidol B
promotes O
mTORC1 O
- O
dependent O
phosphorylation O
of O
ribosomal O
protein O
S6 O
via O
dopamine B
- O
and O
cAMP B
- O
regulated O
phosphoprotein O
of O
32 O
kDa O
and O
inhibition O
of O
protein O
phosphatase O
- O
1 O
. O

Here O
, O
we O
examined O
the O
effects O
produced O
by O
haloperidol B
, O
a O
typical O
antipsychotic O
drug O
, O
on O
the O
phosphorylation O
of O
rpS6 O
at O
Ser240 O
/ O
244 O
in O
the O
striatum O
, O
a O
brain O
region O
involved O
in O
neurodegenerative O
and O
neuropsychiatric O
disorders O
. O

Administration O
of O
haloperidol B
increased O
Ser240 O
/ O
244 O
phosphorylation O
in O
a O
subpopulation O
of O
GABA B
- O
ergic O
medium O
spiny O
neurons O
( O
MSNs O
) O
, O
which O
express O
dopamine B
D2 O
receptors O
( O
D2Rs O
) O
. O

This O
effect O
was O
prevented O
by O
rapamycin B
, O
an O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin B
complex O
1 O
( O
mTORC1 O
) O
, O
or O
by O
PF470867 O
, O
a O
selective O
inhibitor O
of O
the O
p70 O
ribosomal O
S6 O
kinase O
1 O
( O
S6K1 O
) O
. O

We O
also O
found O
that O
the O
effect O
of O
haloperidol B
on O
Ser240 O
/ O
244 O
phosphorylation O
was O
prevented O
by O
functional O
inactivation O
of O
dopamine B
- O
and O
cAMP B
- O
regulated O
phosphoprotein O
of O
32 O
kDa O
( O
DARPP O
- O
32 O
) O
, O
an O
endogenous O
inhibitor O
of O
protein O
phosphatase O
- O
1 O
( O
PP O
- O
1 O
) O
. O

These O
results O
show O
that O
haloperidol B
promotes O
mTORC1 O
- O
and O
S6K1 O
- O
dependent O
phosphorylation O
of O
rpS6 O
at O
Ser240 O
/ O
244 O
, O
in O
a O
subpopulation O
of O
striatal O
MSNs O
expressing O
D2Rs O
. O

Arylpiperazine B
- O
mediated O
activation O
of O
Akt O
protects O
SH O
- O
SY5Y O
neuroblastoma O
cells O
from O
6 B
- I
hydroxydopamine I
- O
induced O
apoptotic O
and O
autophagic O
death O
. O

We O
investigated O
the O
ability O
of O
19 O
recently O
synthesized O
arylpiperazine B
compounds O
to O
protect O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
from O
the O
neurotoxin O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
. O

The O
compound O
with O
the O
most O
potent O
neuroprotective O
action O
was O
N O
- O
{ O
3 O
- O
[ O
2 O
- O
( O
4 O
- O
phenyl O
- O
piperazin O
- O
1 O
- O
yl O
) O
- O
ethyl O
] O
- O
phenyl O
} O
- O
picolinamide O
( O
6b O
) O
, O
which O
reduced O
6 B
- I
OHDA I
- O
induced O
apoptotic O
death O
through O
stabilization O
of O
mitochondrial O
membrane O
and O
subsequent O
prevention O
of O
superoxide B
production O
, O
caspase O
activation O
and O
DNA O
fragmentation O
. O

6 B
- I
OHDA I
- O
triggered O
autophagic O
response O
was O
also O
reduced O
by O
6b O
, O
which O
prevented O
inactivation O
of O
the O
main O
autophagy O
repressor O
mTOR O
, O
upregulation O
of O
pro O
- O
autophagic O
beclin O
- O
1 O
, O
conversion O
of O
microtubule O
- O
associated O
protein O
1 O
light O
chain O
3 O
( O
LC3 O
) O
- O
I O
to O
autophagosome O
- O
associated O
LC3 O
- O
II O
, O
as O
well O
as O
intracytoplasmic O
acidification O
induced O
by O
6 B
- I
OHDA I
. O

The O
inhibition O
of O
autophagy O
using O
LC3 O
beta O
gene O
silencing O
or O
pharmacological O
autophagy O
blockers O
3 B
- I
methyladenine I
or O
bafilomycin B
A1 I
, O
mimicked O
the O
cytoprotective O
effect O
of O
6b O
. O

While O
the O
treatment O
with O
6b O
had O
no O
effect O
on O
the O
phosphorylation O
of O
proapoptotic O
MAP O
kinases O
ERK O
and O
JNK O
, O
it O
markedly O
increased O
the O
phosphorylation O
of O
the O
prosurvival O
kinase O
Akt O
in O
6 B
- I
OHDA I
- O
treated O
cells O
. O

Akt O
inhibitor O
DEBC O
or O
RNA O
interference O
- O
mediated O
Akt O
silencing O
reduced O
the O
ability O
of O
6b O
to O
block O
6 B
- I
OHDA I
- O
triggered O
apoptotic O
and O
autophagic O
responses O
, O
thus O
confirming O
their O
dependency O
on O
Akt O
activation O
. O

The O
cytoprotective O
effect O
of O
6b O
was O
also O
observed O
in O
6 B
- I
OHDA I
- O
treated O
neuronal O
PC12 O
cells O
, O
but O
not O
in O
SH O
- O
SY5Y O
or O
PC12 O
cells O
exposed O
to O
1 O
- O
methyl O
- O
4 O
- O
phenylpyridinium O
, O
indicating O
that O
the O
observed O
neuroprotection O
was O
dependent O
on O
the O
cytotoxic O
stimulus O
. O

Because O
of O
the O
ability O
to O
prevent O
6 B
- I
OHDA I
induced O
apoptotic O
/ O
autophagic O
cell O
death O
through O
activation O
of O
Akt O
, O
the O
investigated O
arylpiperazines B
could O
be O
potential O
candidates O
for O
treatment O
of O
neurodegenerative O
diseases O
. O

The O
fatty B
acid I
amide I
hydrolase O
inhibitor O
, O
URB597 O
, O
promotes O
retinal O
ganglion O
cell O
neuroprotection O
in O
a O
rat O
model O
of O
optic O
nerve O
axotomy O
. O

The O
endocannabinoid O
, O
N O
- O
arachidonoylethanola O
( O
AEA B
) O
, O
is O
degraded O
by O
the O
enzyme O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
. O

Measurement O
of O
retinal O
endocannabinoid O
levels O
in O
URB597 O
- O
treated O
animals O
at O
2 O
weeks O
post O
- O
axotomy O
revealed O
a O
significant O
increase O
in O
AEA B
levels O
, O
accompanied O
by O
a O
decrease O
by O
a O
decrease O
in O
the O
AEA B
metabolite O
, O
N O
- O
arachidonoylglycine O
, O
in O
young O
animals O
but O
not O
aged O
animals O
. O

2 B
- I
arachidonoylglycerol I
levels O
were O
similar O
across O
all O
experimental O
groups O
. O

We O
found O
that O
application O
of O
Carbachol B
( O
CCh O
) O
and O
Norepinephrine B
( O
NE O
) O
both O
enhanced O
the O
spontaneous O
network O
dynamics O
by O
increasing O
( O
1 O
) O
the O
activity O
levels O
, O
( O
2 O
) O
the O
temporal O
complexity O
of O
the O
network O
activity O
, O
and O
( O
3 O
) O
the O
spatial O
complexity O
by O
decorrelating O
the O
network O
activity O
over O
a O
wide O
range O
of O
neuromodulator O
concentrations O
( O
1 O
mu O
M O
, O
10 O
mu O
M O
, O
50 O
mu O
M O
, O
and O
100 O
mu O
M O
) O
. O

Controlling O
the O
Physical O
form O
of O
Mannitol B
in O
Freeze O
- O
Dried O
Systems O
. O

A O
potential O
drawback O
with O
the O
use O
of O
mannitol B
as O
a O
bulking O
agent O
is O
its O
existence O
as O
mannitol O
hemihydrate O
( O
MHH O
; O
C6H14O6 O
( O
. O
) O
0 O
. O
5H2O O
) O
in O
the O
lyophile O
. O

We O
systematically O
identified O
the O
conditions O
under O
which O
anhydrous O
mannitol B
and O
MHH O
crystallized O
in O
frozen O
systems O
with O
the O
goal O
of O
preventing O
MHH O
formation O
during O
freeze O
- O
drying O
. O

When O
mannitol B
solutions O
were O
cooled O
, O
the O
temperature O
of O
solute O
crystallization O
was O
the O
determinant O
of O
the O
physical O
form O
of O
mannitol B
. O

Based O
on O
low O
temperature O
X O
- O
ray O
diffractometry O
( O
using O
both O
laboratory O
and O
synchrotron O
sources O
) O
, O
MHH O
formation O
was O
observed O
when O
solute O
crystallization O
occurred O
at O
temperatures O
> O
= O
- O
20 O
degrees O
C O
while O
anhydrous O
mannitol B
crystallized O
at O
temperatures O
< O
= O
- O
10 O
degrees O
C O
. O

The O
use O
of O
a O
freeze O
- O
dryer O
with O
controlled O
ice O
nucleation O
technology O
enabled O
anhydrous O
mannitol B
crystallization O
at O
~ O
- O
5 O
degrees O
C O
. O

During O
the O
1H B
nuclear O
magnetic O
resonance O
spectra O
( O
1H B
NMR O
) O
study O
, O
the O
chemical O
shift O
perturbation O
and O
spin O
- O
lattice O
relaxation O
times O
of O
different O
protons O
were O
further O
used O
to O
investigate O
the O
interaction O
of O
GV O
with O
BHb O
and O
the O
results O
indicated O
that O
GV O
bound O
orientationally O
to O
BHb O
. O

Alteration O
of O
prolyl B
oligopeptidase O
and O
activated O
alpha O
- O
2 O
- O
macroglobulin O
in O
multiple O
sclerosis O
subtypes O
and O
in O
the O
clinically O
isolated O
syndrome O
. O

Prolyl B
oligopeptidase O
( O
PREP O
) O
has O
been O
considered O
as O
a O
drug O
target O
for O
the O
treatment O
of O
neurodegenerative O
diseases O
. O

Protein O
kinase O
C O
( O
PKC O
) O
is O
a O
family O
of O
serine B
/ O
threonine B
phosphotransferases O
ubiquitously O
expressed O
and O
involved O
in O
multiple O
cellular O
functions O
, O
such O
as O
proliferation O
, O
apoptosis O
and O
differentiation O
. O

These O
effects O
were O
induced O
by O
a O
7 O
- O
minute O
HMI O
- O
1b11 O
treatment O
and O
specifically O
depended O
on O
PKC O
alpha O
activation O
, O
since O
pretreatment O
with O
the O
selective O
inhibitor O
G B
o I
6976 I
abolished O
the O
up O
- O
regulation O
of O
GAP O
- O
43 O
protein O
observed O
at O
12hours O
In O
parallel O
, O
we O
found O
that O
a O
7 O
- O
minute O
exposure O
to O
HMI O
- O
1b11 O
induced O
PKC O
alpha O
accumulation O
to O
the O
cytoskeleton O
, O
an O
effect O
that O
was O
again O
prevented O
by O
pretreatment O
with O
G B
o I
6976 I
. O

Discovery O
of O
highly O
potent O
triazole B
antifungal O
derivatives O
by O
heterocycle O
- O
benzene B
bioisosteric O
replacement O
. O

On O
the O
basis O
of O
our O
previously O
discovered O
triazole B
antifungal O
lead O
compounds O
, O
heterocycle O
- O
benzene B
bioisosteric O
replacement O
was O
used O
to O
improve O
their O
pharmacokinetic O
profile O
. O

The O
designed O
new O
triazole B
derivatives O
have O
good O
antifungal O
activity O
toward O
a O
wide O
range O
of O
pathogenic O
fungi O
. O

In O
contrast O
, O
NAcc O
and O
hypothalamic O
response O
to O
the O
calorie O
- O
paired O
flavor O
was O
unrelated O
to O
liking O
but O
was O
strongly O
associated O
with O
the O
changes O
in O
plasma O
glucose B
levels O
produced O
by O
ingestion O
of O
the O
beverage O
when O
consumed O
previously O
with O
calories O
. O

Importantly O
, O
because O
each O
participant O
ingested O
the O
same O
caloric O
dose O
, O
the O
change O
in O
plasma O
glucose B
depended O
upon O
individual O
differences O
in O
glucose B
metabolism O
. O

We O
conclude O
that O
glucose B
metabolism O
is O
a O
critical O
signal O
regulating O
NAcc O
and O
hypothalamic O
response O
to O
food O
cues O
, O
and O
that O
this O
process O
operates O
independently O
from O
the O
ability O
of O
calories O
to O
condition O
liking O
. O

Treatment O
with O
ClpP O
resulted O
in O
hypodiploid O
DNA O
contents O
, O
increased O
Bax O
/ O
Bcl O
- O
2 O
ratio O
and O
induction O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
. O

In O
addition O
, O
pretreatment O
with O
Z O
- O
Val O
- O
Ala O
- O
Asp O
- O
fluoromethylketone O
( O
Z B
- I
VAD I
- I
fmk I
) O
, O
a O
broad O
spectrum O
of O
caspase O
inhibitor O
, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP O
toxicity O
. O

In O
contrast O
, O
LXA4 O
from O
different O
sources O
neither O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
and O
extracellular O
- O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
phosphorylation O
, O
nor O
did O
it O
induce O
a O
decrease O
in O
cAMP B
levels O
or O
a O
translocation O
of O
beta O
- O
arrestin O
. O

To O
elucidate O
the O
pharmacophore O
of O
echinocystic O
acid O
( O
EA O
) O
, O
an O
oleanane B
- O
type O
triterpene B
displaying O
substantial O
inhibitory O
activity O
on O
HCV O
entry O
, O
two O
microbial O
strains O
, O
Rhizopus O
chinensis O
CICC O
3043 O
and O
Alternaria O
alternata O
AS O
3 O
. O
4578 O
, O
were O
utilized O
to O
modify O
the O
chemical O
structure O
of O
EA O
. O

Eight O
new O
metabolites O
with O
regio O
- O
and O
stereo O
- O
selective O
introduction O
of O
hydroxyl B
and O
lactone B
groups O
at O
various O
inert O
carbon B
positions O
were O
obtained O
. O

Introduction O
of O
a O
hydroxyl B
group O
at O
C O
- O
16 O
enhanced O
the O
triterpene B
potency O
. O

Bioassays O
were O
set O
up O
to O
compare O
the O
efficacy O
of O
our O
range O
of O
N B
- O
alkylated O
compounds O
against O
classic O
antifungal O
agents O
; O
Amphotericin B
B I
and O
Thiabendazole O
. O

In O
previous O
studies O
we O
described O
the O
development O
of O
novel O
spirocyclic O
HDAC O
inhibitors O
based O
on O
the O
combination O
of O
privileged O
structures O
with O
hydroxamic B
acid I
moieties O
as O
zinc B
binding O
group O
. O

In O
addition O
, O
the O
two O
benzoxazines O
were O
found O
to O
have O
a O
minor O
affinity O
for O
the O
hERG O
potassium B
channel O
compared O
to O
their O
corresponding O
ketone B
analogues O
. O

The O
Claisen O
- O
Schmidt O
reaction O
of O
22 O
beta O
- O
hydroxy O
- O
3 O
- O
oxoolean O
- O
12 O
- O
en O
- O
28 O
- O
oic O
acid O
( O
5 O
) O
with O
requisite O
aldehydes B
afforded O
2 O
- O
arylidene O
- O
22 O
beta O
- O
hydroxy O
- O
3 O
- O
oxoolean O
- O
12 O
- O
en O
- O
28 O
- O
oic O
acids O
( O
7 O
- O
16 O
) O
. O

The O
mean O
graph O
midpoint O
( O
MG O
_ O
MID O
) O
value O
of O
compound O
3 O
( O
MG O
_ O
MID O
- O
5 O
. O
69 O
) O
was O
higher O
than O
standard O
drug O
cisplatin B
( O
MG O
_ O
MID O
- O
5 O
. O
66 O
) O
while O
comparable O
in O
case O
of O
compound O
12 O
( O
MG O
_ O
MID O
- O
5 O
. O
52 O
) O
. O

These O
compounds O
resulted O
from O
our O
efforts O
to O
merge O
the O
pharmacophores O
of O
selective O
factor O
Xa O
inhibitor O
rivaroxaban B
with O
a O
mimic O
of O
the O
Arg B
- I
Gly I
- I
Asp I
( O
RGD O
) O
sequence O
of O
fibrinogen O
to O
obtain O
designed O
multiple O
ligands O
with O
potential O
antithrombotic O
activity O
. O

Among O
these O
compounds O
, O
6d O
, O
which O
possesses O
an O
ortho O
- O
nitro O
group O
at O
the O
benzene B
ring O
, O
exhibited O
potent O
inhibitory O
effect O
on O
the O
proliferation O
of O
HUVECs O
, O
A549 O
, O
K562 O
, O
PC O
- O
3 O
, O
HCT116 O
, O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
cells O
( O
IC50 O
= O
5 O
. O
34 O
, O
40 O
. O
53 O
, O
10 O
. O
81 O
, O
52 O
. O
52 O
, O
10 O
. O
19 O
, O
21 O
. O
37 O
and O
2 O
. O
81 O
mu O
M O
, O
respectively O
) O
. O

Steroidal B
glycosides I
from O
the O
bulbs O
of O
Easter O
lily O
( O
Lilium O
longiflorum O
Thunb O
. O
) O
promote O
dermal O
fibroblast O
migration O
in O
vitro O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
evaluate O
fractionated O
Easter O
lily O
bulb O
extracts O
and O
their O
steroidal B
glycosides I
( O
1 O
- O
5 O
) O
for O
the O
promotion O
of O
dermal O
fibroblast O
migration O
in O
vitro O
, O
as O
a O
model O
for O
the O
early O
events O
in O
wound O
healing O
. O

Cytotoxicity O
was O
evaluated O
with O
methyl O
thiazole O
tetrazolium O
( O
MTT B
) O
. O

To O
gain O
insight O
into O
the O
mode O
of O
action O
of O
the O
steroidal B
glycosides I
, O
nitric B
oxide I
( O
NO B
) O
production O
, O
and O
expression O
of O
genes O
for O
transforming O
growth O
factor O
beta O
- O
1 O
( O
TGF O
- O
beta O
) O
and O
its O
receptors O
were O
evaluated O
. O

RESULTS O
: O
Fractionated O
bulb O
extracts O
and O
the O
two O
isolated O
steroidal O
glycoalkaloids O
( O
1 O
) O
and O
( O
2 O
) O
induced O
NO B
production O
and O
TGF O
- O
beta O
receptor O
I O
mRNA O
expression O
in O
fibroblast O
cell O
culture O
. O

In O
a O
cytotoxicity O
assay O
, O
steroidal B
glycosides I
( O
1 O
) O
and O
( O
3 O
) O
had O
IC50 O
values O
of O
8 O
. O
2 O
and O
8 O
. O
7 O
micro O
M O
, O
but O
the O
natural O
acetylation O
of O
the O
C O
- O
6 O
' O
' O
' O
hydroxy B
of O
the O
terminal O
glucose B
unit O
in O
( O
2 O
) O
resulted O
in O
a O
3 O
- O
fold O
decrease O
in O
cell O
cytotoxicity O
when O
compared O
with O
( O
1 O
) O
. O

CONCLUSION O
: O
Collectively O
, O
our O
data O
demonstrate O
that O
the O
steroidal B
glycosides I
present O
in O
Easter O
lily O
bulbs O
induce O
, O
at O
least O
in O
part O
, O
the O
observed O
dermal O
fibroblast O
migration O
activity O
of O
the O
bulb O
extracts O
. O

This O
is O
the O
first O
evidence O
that O
steroidal B
glycosides I
from O
L O
. O
longiflorum O
may O
potentially O
play O
a O
role O
in O
the O
wound O
healing O
process O
and O
may O
provide O
a O
scientific O
basis O
for O
the O
historical O
use O
of O
lily O
bulbs O
for O
this O
purpose O
. O

Cortical O
excitability O
in O
smoking O
and O
not O
smoking O
individuals O
with O
and O
without O
nicotine B
. O

RATIONAL O
: O
Activation O
of O
nicotinic O
acetylcholine B
receptors O
has O
a O
major O
neuromodulatory O
impact O
on O
central O
nervous O
system O
function O
. O

Beyond O
acute O
activation O
, O
chronic O
nicotine B
intake O
has O
long O
- O
lasting O
effects O
on O
cortical O
excitability O
in O
animal O
experiments O
, O
caused O
by O
receptor O
up O
- O
or O
down O
- O
regulation O
. O

Knowledge O
about O
the O
impact O
of O
nicotine B
on O
cortical O
excitability O
in O
humans O
, O
however O
, O
is O
limited O
. O

OBJECTIVES O
: O
We O
therefore O
aimed O
to O
explore O
the O
effect O
of O
nicotine B
intake O
on O
cortical O
excitability O
in O
healthy O
human O
smokers O
and O
non O
- O
smokers O
. O

Corticospinal O
excitability O
and O
intracortical O
excitability O
were O
recorded O
before O
and O
after O
application O
of O
nicotine B
patch O
in O
both O
groups O
. O

RESULTS O
: O
The O
results O
show O
that O
smokers O
during O
nicotine B
withdrawal O
display O
increased O
corticospinal O
excitability O
with O
regard O
to O
the O
I O
/ O
O O
curve O
( O
TMS O
intensity O
150 O
% O
of O
resting O
motor O
threshold O
) O
compared O
to O
non O
- O
smokers O
and O
furthermore O
enhanced O
SAI O
and O
diminished O
ICF O
at O
the O
intracortical O
circuit O
level O
. O

After O
administration O
of O
nicotine B
, O
intracortical O
facilitation O
in O
smokers O
increased O
, O
while O
in O
non O
- O
smokers O
, O
inhibition O
( O
SICI O
, O
SAI O
) O
was O
enhanced O
. O

CONCLUSION O
: O
Our O
results O
show O
that O
chronic O
nicotine B
consumption O
in O
smokers O
alters O
cortical O
excitability O
independent O
from O
acute O
nicotine B
consumption O
and O
that O
acute O
nicotine B
has O
different O
effects O
on O
motor O
cortical O
excitability O
in O
both O
groups O
. O

Neuritogenic O
and O
Neuroprotective O
Effects O
of O
Polar O
Steroids B
from O
the O
Far O
East O
Starfishes O
Patiria O
pectinifera O
and O
Distolasterias O
nipon O
. O

The O
neuritogenic O
and O
neuroprotective O
activities O
of O
six O
starfish O
polar O
steroids B
, O
asterosaponin O
P O
1 O
, O
( O
25S O
) O
- O
5 O
alpha O
- O
cholestane O
- O
3 O
beta O
, O
4 O
beta O
, O
6 O
alpha O
, O
7 O
alpha O
, O
8 O
, O
15 O
alpha O
, O
16 O
beta O
, O
26 O
- O
octaol O
, O
and O
( O
25S O
) O
- O
5 O
alpha O
- O
cholestane O
- O
3 O
beta O
, O
6 O
alpha O
, O
7 O
alpha O
, O
8 O
, O
15 O
alpha O
, O
16 O
beta O
, O
26 O
- O
heptaol O
( O
1 O
- O
3 O
) O
from O
the O
starfish O
Patiria O
pectinifera O
and O

Using O
NB O
cells O
and O
OHSCs O
, O
it O
was O
shown O
for O
the O
first O
time O
that O
starfish O
steroids B
1 O
- O
6 O
act O
as O
neuroprotectors O
against O
oxygen B
- O
glucose B
deprivation O
( O
OGD O
) O
by O
increasing O
the O
number O
of O
surviving O
cells O
. O

Antagonistic O
Basic O
Helix O
- O
Loop O
- O
Helix O
/ O
bZIP O
Transcription O
Factors O
Form O
Transcriptional O
Modules O
That O
Integrate O
Light O
and O
Reactive O
Oxygen B
Species O
Signaling O
in O
Arabidopsis O
. O

The O
critical O
developmental O
switch O
from O
heterotrophic O
to O
autotrophic O
growth O
of O
plants O
involves O
light O
signaling O
transduction O
and O
the O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

We O
show O
that O
pif O
mutants O
release O
more O
singlet O
oxygen B
and O
exhibit O
more O
extensive O
cell O
death O
than O
the O
wild O
type O
during O
Arabidopsis O
thaliana O
deetiolation O
. O

Self O
- O
assembling O
doxorubicin B
silk O
hydrogels O
for O
the O
focal O
treatment O
of O
primary O
breast O
cancer O
. O

Systemic O
chemotherapy O
provides O
only O
low O
locoregional O
control O
of O
the O
disease O
; O
therefore O
, O
we O
describe O
self O
- O
assembling O
silk O
hydrogels O
that O
can O
retain O
and O
then O
deliver O
doxorubicin B
locally O
. O

Self O
- O
assembling O
silk O
hydrogels O
show O
no O
swelling O
, O
are O
readily O
loaded O
with O
doxorubicin B
under O
aqueous O
conditions O
and O
release O
drug O
over O
4 O
weeks O
in O
amounts O
that O
can O
be O
fine O
- O
tuned O
by O
varying O
the O
silk O
content O
. O

Following O
successful O
in O
vitro O
studies O
, O
locally O
injected O
silk O
hydrogels O
loaded O
with O
doxorubicin B
show O
excellent O
antitumor O
response O
in O
mice O
, O
outperforming O
the O
equivalent O
amount O
of O
doxorubicin B
delivered O
intravenously O
. O

In O
addition O
to O
reducing O
primary O
tumor O
growth O
, O
doxorubicin B
- O
loaded O
silk O
hydrogels O
reduce O
metastatic O
spread O
and O
are O
well O
tolerated O
in O
vivo O
. O

The O
literature O
is O
reviewed O
, O
with O
emphasis O
on O
acetylene B
results O
. O

Resonance O
attachment O
of O
low O
- O
energy O
electrons O
to O
xenobiotic O
molecules O
, O
2 B
, I
4 I
- I
dichlorophenoxyaceti I
acid I
( O
) O
, O
dichlorodiphenyltric B
( O
) O
and O
dichlorodiphenyldich B
( O
) O
, O
was O
investigated O
under O
gas O
- O
phase O
conditions O
by O
means O
of O
complementary O
experimental O
techniques O
. O

